PMID- 42934535 OWN - NLM STAT- MEDLINE DCOM- 20261027 LR - 20261028 IS - 1471-2334 (Electronic) IS - 1471-2334 (Linking) VI - 26 IP - 1 DP - 2026 Jul 30 TI - Epidemiology, vaccine effectiveness, and risk factors of pertussis in Xinjiang children: a retrospective study. LID - 10.1186/s12879-026-13984-2 [doi] LID - 1888 AB - BACKGROUND: Despite the high global vaccination coverage, the incidence of pertussis is rising in many countries. The epidemiological data on pertussis in children in the Xinjiang region are limited. This study aims to investigate the epidemiological characteristics of pertussis in this region, the protective effectiveness of vaccines, and the independent risk factors associated with the disease. METHODS: A retrospective study was conducted among 2,250 children with suspected pertussis who presented to the Pediatric Center of the First Affiliated Hospital of Xinjiang Medical University from March 2024 to June 2025. Children aged /= 3 months (eligible for vaccination), vaccine effectiveness (VE) against laboratory-confirmed pertussis was 47.1% (95% CI: 9.4-69.1%) for >/= 1 dose versus unvaccinated. Multivariate analysis showed that age, season, history of cough contact, and laboratory markers (lymphocytosis) were independent predictors of pertussis positivity. In the age-restricted multivariable analysis (>/= 3 months, n = 1,741 complete cases), summer was the strongest risk factor (adjusted odds ratio [aOR] = 5.25, 95% confidence intervals [CI]: 3.27-8.45). History of cough contact (aOR = 2.54) and lymphocytosis > 50% (aOR = 1.56) were significant risk factors. The age group of 1-2 years showed the strongest protective effect (aOR = 0.16, p = 0.006), reflecting a U-shaped age-risk curve. CONCLUSIONS: In this single-center retrospective study of suspected pertussis cases in Xinjiang, children who tested positive were more likely to present in summer, have paroxysmal cough, and report a history of cough contact. Despite 90.3% vaccination coverage, the overall positivity rate was 9.3%, with a U-shaped age distribution peaking in infants aged 0-5 months and children >/= 6 years. These findings highlight the potential value of maternal immunization strategies and timely booster vaccination, though multi-center prospective studies are needed to confirm these observations. TRIAL REGISTRATION: Not applicable. CI - (c) 2026. The Author(s). FAU - Ru, Liang AU - Ru L AD - Department of Pediatrics, The First Affiliated Hospital of Xinjiang Medical University, No. 137 Liyushan Road, Xinshi District, Urumqi, Xinjiang, 830054, China. FAU - Zhu, Hongtao AU - Zhu H AD - Department of Pediatrics, The First Affiliated Hospital of Xinjiang Medical University, No. 137 Liyushan Road, Xinshi District, Urumqi, Xinjiang, 830054, China. FAU - Ma, Xiangping AU - Ma X AD - Department of Pediatrics, The First Affiliated Hospital of Xinjiang Medical University, No. 137 Liyushan Road, Xinshi District, Urumqi, Xinjiang, 830054, China. FAU - Abuduhaer, Abulaiti AU - Abuduhaer A AD - Department of Pediatrics, The First Affiliated Hospital of Xinjiang Medical University, No. 137 Liyushan Road, Xinshi District, Urumqi, Xinjiang, 830054, China. FAU - Yan, Mei AU - Yan M AD - Department of Pediatrics, The First Affiliated Hospital of Xinjiang Medical University, No. 137 Liyushan Road, Xinshi District, Urumqi, Xinjiang, 830054, China. 13669901666@163.com. LA - eng GR - TSYC202301B003/The Tianshan Elite High-Level Medical Talent Development Program administered by the Health Commission of Xinjiang Uygur Autonomous Region/ GR - 2021-284/The Chinese Maternal and Child Health Association Multi-Center Study on the Application of Pertussis Nucleic Acid Testing in Maternal and Child Health/ PT - Journal Article DEP - 20260730 PL - England TA - BMC Infect Dis JT - BMC infectious diseases JID - 100968551 RN - 0 (Pertussis Vaccine) SB - IM MH - Humans MH - *Whooping Cough/epidemiology/prevention & control MH - Retrospective Studies MH - China/epidemiology MH - Female MH - Risk Factors MH - Male MH - Infant MH - Child, Preschool MH - *Vaccine Efficacy MH - Bordetella pertussis/genetics/immunology/isolation & purification MH - Child MH - *Pertussis Vaccine/immunology/administration & dosage MH - Adolescent MH - Vaccination/statistics & numerical data MH - Infant, Newborn MH - Incidence MH - Unvaccinated Persons MH - Seasons PMC - PMC13712070 OTO - NOTNLM OT - Bordetella pertussis OT - China OT - Epidemiology OT - Pertussis OT - Retrospective study OT - Risk factors OT - Vaccine effectiveness COIS- Declarations. Ethics approval and consent to participate: This study was approved by the Ethics Committee of the First Affiliated Hospital of Xinjiang Medical University (Approval number: K202405-07). As a retrospective study using de-identified medical records, the requirement for informed consent was waived by the ethics committee. All methods were performed in accordance with relevant guidelines and regulations and the ethical standards of the Declaration of Helsinki. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests. EDAT- 2026/10/27 05:29 MHDA- 2026/10/27 05:30 PMCR- 2026/07/30 CRDT- 2026/10/27 00:35 PHST- 2025/12/23 00:00 [received] PHST- 2026/07/06 00:00 [accepted] PHST- 2026/10/27 05:30 [medline] PHST- 2026/10/27 05:29 [pubmed] PHST- 2026/10/27 00:35 [entrez] PHST- 2026/07/30 00:00 [pmc-release] AID - 10.1186/s12879-026-13984-2 [pii] AID - 13984 [pii] AID - 10.1186/s12879-026-13984-2 [doi] PST - epublish SO - BMC Infect Dis. 2026 Jul 30;26(1):1888. doi: 10.1186/s12879-026-13984-2. PMID- 42928190 OWN - NLM STAT- MEDLINE DCOM- 20261026 LR - 20261028 IS - 1471-2431 (Electronic) IS - 1471-2431 (Linking) VI - 26 IP - 1 DP - 2026 Jul 28 TI - Moral distress in pediatric complex care coordinators: a reflexive thematic analysis. LID - 10.1186/s12887-026-07421-1 [doi] LID - 1059 AB - BACKGROUND: Moral distress can occur in situations where one wants to follow a desired course of action but experiences restraints from internal and external barriers. Unaddressed moral distress is associated with negative outcomes (e.g., burnout). Due to the nature of their work with medically and neurodevelopmentally complex children and their families, pediatrics complex care coordinators are at risk of experiencing moral distress. However, there is limited understanding of moral distress in this professional population. Study objectives were to: (1) understand how pediatric complex care coordinators at a tertiary pediatric hospital defined moral distress; (2) explore factors that influence and modulate moral distress in these care coordinators; and (3) explore the impacts of moral distress on care coordinators. METHODS: Semi-structured virtual interviews were conducted with twelve pediatric complex care coordinators from a pediatric tertiary care centre to explore experiences with moral distress. Interviews ranged from 25 to 60 min. Interview transcripts were examined by two researchers using inductive reflexive thematic analysis for each objective. The data were analyzed and coded and a 15-point checklist was utilized throughout each phase of the analysis process for consistency amongst coders. RESULTS: All participants reported experiencing moral distress using the seminal definition of moral distress. Care coordinators added additional context and depth to this definition. Factors influencing and modulating moral distress in care coordinators were identified: (1) restrictiveness of their scope and capacity; (2) individual experiences; (3) availability of coping mechanisms; (4) the nature of their interactions; and (5) resolution. Four themes on the impact of moral distress were also identified: (1) changes in perspective; (2) impacts on well-being; (3) need for internal and external change; and (4) influence on interpersonal relationships. CONCLUSION: An expanded definition of moral distress was co-created with care coordinators and identified factors that influenced moral distress and impacts of moral distress. This work is an important first step to developing a better understanding of moral distress in care coordinators and could inform future interventions to address moral distress in this population. CI - (c) 2026. The Author(s). FAU - Chahal, Simran AU - Chahal S AD - Alberta Children's Hospital Research Institute, University of Calgary, Calgary, AB, Canada. AD - Hotchkiss Brain Institute, University of Calgary, Calgary, AB, Canada. AD - Department of Pediatrics, Cumming School of Medicine, University of Calgary Alberta Children's Hospital, 28 Oki Drive NW, Calgary, AB, T3B 6A8, Canada. FAU - Currie, Genevieve AU - Currie G AD - School of Nursing and Midwifery, Mount Royal University, Calgary, AB, Canada. AD - Department of Pediatrics, Cumming School of Medicine, University of Calgary Alberta Children's Hospital, 28 Oki Drive NW, Calgary, AB, T3B 6A8, Canada. FAU - Ha, Seong Eon AU - Ha SE AD - Alberta Children's Hospital Research Institute, University of Calgary, Calgary, AB, Canada. AD - Hotchkiss Brain Institute, University of Calgary, Calgary, AB, Canada. AD - Department of Pediatrics, Cumming School of Medicine, University of Calgary Alberta Children's Hospital, 28 Oki Drive NW, Calgary, AB, T3B 6A8, Canada. FAU - Kaushik, Skanda AU - Kaushik S AD - Department of Pediatrics, Cumming School of Medicine, University of Calgary Alberta Children's Hospital, 28 Oki Drive NW, Calgary, AB, T3B 6A8, Canada. FAU - Nahal, Ishnoor AU - Nahal I AD - Alberta Children's Hospital Research Institute, University of Calgary, Calgary, AB, Canada. AD - Department of Pediatrics, Cumming School of Medicine, University of Calgary Alberta Children's Hospital, 28 Oki Drive NW, Calgary, AB, T3B 6A8, Canada. FAU - Estes, Myka AU - Estes M AD - Alberta Children's Hospital Research Institute, University of Calgary, Calgary, AB, Canada. AD - Department of Pediatrics, Cumming School of Medicine, University of Calgary Alberta Children's Hospital, 28 Oki Drive NW, Calgary, AB, T3B 6A8, Canada. FAU - Jaskela, Shannon AU - Jaskela S AD - Alberta Health Services, Edmonton, Alberta, Canada. FAU - Manhas, Kiran Pohar AU - Manhas KP AD - Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada. AD - Faculty of Nursing, University of Alberta, AB, Edmonton, Canada. AD - Partnerships & Innovation, Acute Care Alberta, Calgary, AB, Canada. FAU - Lauzon, Julie AU - Lauzon J AD - Department of Pediatrics, Cumming School of Medicine, University of Calgary Alberta Children's Hospital, 28 Oki Drive NW, Calgary, AB, T3B 6A8, Canada. FAU - Mitchell, Ian AU - Mitchell I AD - Department of Pediatrics, Cumming School of Medicine, University of Calgary Alberta Children's Hospital, 28 Oki Drive NW, Calgary, AB, T3B 6A8, Canada. FAU - Page, Stacey AU - Page S AD - Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada. FAU - Zwicker, Jennifer AU - Zwicker J AD - School of Public Policy, University of Calgary, Calgary, AB, Canada. FAU - Dewey, Deborah AU - Dewey D AD - Alberta Children's Hospital Research Institute, University of Calgary, Calgary, AB, Canada. AD - Hotchkiss Brain Institute, University of Calgary, Calgary, AB, Canada. AD - Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada. AD - Department of Pediatrics, Cumming School of Medicine, University of Calgary Alberta Children's Hospital, 28 Oki Drive NW, Calgary, AB, T3B 6A8, Canada. FAU - Gibbard, W Ben AU - Gibbard WB AD - Alberta Children's Hospital Research Institute, University of Calgary, Calgary, AB, Canada. AD - Department of Pediatrics, Cumming School of Medicine, University of Calgary Alberta Children's Hospital, 28 Oki Drive NW, Calgary, AB, T3B 6A8, Canada. FAU - MacEachern, Sarah J AU - MacEachern SJ AUID- ORCID: 0000-0001-8473-5650 AD - Alberta Children's Hospital Research Institute, University of Calgary, Calgary, AB, Canada. sarah.maceachern@ucalgary.ca. AD - Hotchkiss Brain Institute, University of Calgary, Calgary, AB, Canada. sarah.maceachern@ucalgary.ca. AD - Faculty of Nursing, University of Alberta, AB, Edmonton, Canada. sarah.maceachern@ucalgary.ca. AD - Department of Pediatrics, Cumming School of Medicine, University of Calgary Alberta Children's Hospital, 28 Oki Drive NW, Calgary, AB, T3B 6A8, Canada. sarah.maceachern@ucalgary.ca. LA - eng PT - Journal Article DEP - 20260728 PL - England TA - BMC Pediatr JT - BMC pediatrics JID - 100967804 SB - IM MH - Humans MH - *Ethical Dilemmas MH - Female MH - Male MH - *Pediatrics MH - Child MH - Interviews as Topic MH - Qualitative Research MH - Adult MH - *Burnout, Professional/psychology/etiology MH - Hospitals, Pediatric MH - Attitude of Health Personnel PMC - PMC13700320 OTO - NOTNLM OT - Care coordination OT - Care coordinator OT - Children with medical complexity OT - Moral distress COIS- Declarations. Ethics approval and consent to participate: for this study was obtained from the Conjoint Health and Research Ethics Board of the University of Calgary (REB21-0591) on July 21, 2021. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests. EDAT- 2026/10/26 05:30 MHDA- 2026/10/26 05:31 PMCR- 2026/07/28 CRDT- 2026/10/26 00:19 PHST- 2025/07/03 00:00 [received] PHST- 2026/07/24 00:00 [accepted] PHST- 2026/10/26 05:31 [medline] PHST- 2026/10/26 05:30 [pubmed] PHST- 2026/10/26 00:19 [entrez] PHST- 2026/07/28 00:00 [pmc-release] AID - 10.1186/s12887-026-07421-1 [pii] AID - 7421 [pii] AID - 10.1186/s12887-026-07421-1 [doi] PST - epublish SO - BMC Pediatr. 2026 Jul 28;26(1):1059. doi: 10.1186/s12887-026-07421-1. PMID- 42902060 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20261021 LR - 20261023 IS - 2191-1991 (Print) IS - 2191-1991 (Electronic) IS - 2191-1991 (Linking) VI - 16 IP - 1 DP - 2026 Jul 25 TI - Cost-effectiveness of prehospital high-sensitivity troponin i testing versus standard emergency department care in patients with suspected acute coronary syndrome in France. LID - 10.1186/s13561-026-00832-x [doi] LID - 121 AB - BACKGROUND: Prehospital point-of-care high-sensitivity cardiac troponin I (hs-cTnI) may support earlier triage of adults with suspected acute coronary syndrome (ACS). We assessed its short-term economic consequences compared with standard emergency department (ED)-based care in France. METHODS: We developed a decision-analytic, continuous-time semi-Markov model over a 24-hour horizon using individual patient data from the prospective, multicentre, double-blinded cohort study (VALIDATE) conducted across four French hospitals (July 2021-May 2024; n = 737). The reference analysis adopted a restricted prehospital-and-ED perspective covering measured medical and paramedical resources from first emergency medical service contact through ED disposition (states 1-3). A complementary database audit searched for patients recorded with less than 24 h of follow-up in an extended "prehospital, emergency department and hospital" setting. None were identified; inpatient, intensive care unit (ICU), coronary angiography, percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG) costs were therefore excluded from the reference-case totals. The initial hs-cTnI H0 sample was obtained before hospital arrival, whereas subsequent H1 or H3 samples, when required, were intended to be collected after arrival. Costs were reported in 2025 euros. Sampling uncertainty was assessed using 1,000 non-parametric bootstrap replications and scenario analyses examined clinically relevant subgroups (> 3 h since symptom onset; availability of a prehospital HEART score). RESULTS: Among 737 participants (mean age 65.4 years; 58.8% men), 77 (10.4%) had non-ST-segment elevation myocardial infarction. ED attendance was lower with hs-cTnI than with standard care (90.9% [95% CI 88.6-92.8] vs. 96.7% [95% CI 95.2-97.8]; absolute difference - 5.8% points [95% CI - 9.2 to - 2.4]; P < 0.001). Among ED attendees, mean ED length of stay was 1.63 h versus 2.76 h (P < 0.001). Mean prehospital-and-ED cost per patient was euro185.24 with hs-cTnI and euro268.55 with standard care, a saving of euro83.31 ([95% CI 70.81-96.60]; P < 0.001). CONCLUSIONS: Within the restricted 24-hour prehospital-and-ED perspective supported by the available patient-level data, a strategy beginning with prehospital hs-cTnI testing was associated with fewer ED attendances, shorter ED stays and lower costs. Longer-term evaluations are planned because these findings do not establish system-wide for inpatient, wider organisational, patient and societal costs. TRIAL REGISTRATION: The VALIDATE study is registered with ClinicalTrials.gov (NCT04950244). CI - (c) 2026. The Author(s). FAU - Maunoury, Franck AU - Maunoury F AUID- ORCID: 0000-0003-1045-4666 AD - STATESIA, Le Mans, France. franck.maunoury@univ-lemans.fr. AD - Le Mans University, GAINS Laboratory, IRA Institute, Le Mans, France. franck.maunoury@univ-lemans.fr. FAU - Couvreur, Raphael AU - Couvreur R AD - Emergency Department and Pre-Hospital Care, University Hospital of Poitiers, Poitiers, France. FAU - Hausfater, Pierre AU - Hausfater P AD - Point of Care in Emergency Room (POCER) Network, ANR-24-DIME-0003, University Hospital of Bordeaux, Bordeaux France, Biochemistry Laboratory - Hormone Testing, University Hospital of Nice, University of Nice Cote d'Azur, Pasteur 1, Nice, F-06000, France. FAU - Guenezan, Jeremy AU - Guenezan J AUID- ORCID: 0000-0002-4736-1490 AD - Emergency Department and Pre-Hospital Care, University Hospital of Poitiers, Poitiers, France. AD - School of Medicine and Pharmacy, University of Poitiers, Poitiers, France. AD - INSERM U1070, Pharmacology of Anti-Infective Drugs, Poitiers, France. LA - eng SI - ClinicalTrials.gov/NCT04950244 PT - Journal Article DEP - 20260725 PL - Germany TA - Health Econ Rev JT - Health economics review JID - 101583209 PMC - PMC13685092 OTO - NOTNLM OT - Acute coronary syndrome OT - Chest pain OT - Cost-effectiveness OT - High-sensitivity troponin OT - Prehospital care COIS- Declarations. Ethics approval and consent to participate: This analysis used fully anonymised individual patient-level data from the VALIDATE database managed by the University Hospital of Poitiers. In accordance with French data protection requirements for fully anonymised secondary data (CNIL committee no. 2014 - 190), formal ethical approval was not required. The institutional ethics committee reviewed the protocol and waived the requirement for informed consent. Consent for publication: Not applicable. Competing interests: "All authors have completed the Unified Competing Interest form at https://www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare that (1) [F.M.] is the CEO of STATESIA. A serviceagreement (contract) was arranged between The University Hospital of Poitiers and STATESIA (2) [R.C.] declared no competing interest; (3) [J.G.] declared that Siemens Healthcare provided the equipment for this study (devices + reagents); (4) [P.H.] declared that Siemens Healthcare provided provision of study materials." EDAT- 2026/10/21 05:32 MHDA- 2026/10/21 05:33 PMCR- 2026/07/25 CRDT- 2026/10/20 23:58 PHST- 2026/03/11 00:00 [received] PHST- 2026/07/20 00:00 [accepted] PHST- 2026/10/21 05:33 [medline] PHST- 2026/10/21 05:32 [pubmed] PHST- 2026/10/20 23:58 [entrez] PHST- 2026/07/25 00:00 [pmc-release] AID - 10.1186/s13561-026-00832-x [pii] AID - 832 [pii] AID - 10.1186/s13561-026-00832-x [doi] PST - epublish SO - Health Econ Rev. 2026 Jul 25;16(1):121. doi: 10.1186/s13561-026-00832-x. PMID- 42877783 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20261015 LR - 20261015 IS - 1176-6328 (Print) IS - 1178-2021 (Electronic) IS - 1176-6328 (Linking) VI - 22 DP - 2026 TI - Ketamine and Esketamine in Acute Suicidal Presentations: Evidence, Limits, and a Conceptual Recovery-Enabling Downstaging Framework. PG - 641718 LID - 10.2147/NDT.S641718 [doi] LID - 641718 AB - OBJECTIVE: To synthesize evidence for intravenous racemic ketamine and regulated intranasal esketamine in adults with acute suicidal presentations; distinguish the outcomes these interventions have and have not been shown to change; and place any rapid response within a complete emergency suicide-care pathway. METHODS: A narrative review of PubMed/MEDLINE-indexed literature was updated through July 16, 2026. Searches and study selection were performed by Wieslaw Jerzy Cubala and Anita Slupska. Priority was given to randomized trials, systematic reviews and meta-analyses, pivotal ASPIRE publications, current US and European product information, and studies of emergency-department safety planning, lethal-means counseling, and post-discharge care. No formal risk-of-bias assessment or pooled reanalysis was undertaken. RESULTS: Intravenous racemic ketamine has randomized and meta-analytic evidence for rapid, short-term reduction of suicidal ideation in selected adults, with important variation by population, comparator, measure, and follow-up. The evidence does not establish prevention of suicide attempts or deaths. In ASPIRE I and II, regulated intranasal esketamine added to hospitalization, a newly initiated or optimized oral antidepressant, and comprehensive standard care accelerated improvement in depressive symptoms; clinician-rated suicidality improved markedly in both groups and did not consistently separate from placebo plus standard care. Across both evidence streams, a post-dose score cannot substitute for dynamic risk formulation, level-of-care decisions, safety planning, lethal-means restriction, or a confirmed transition of care. CONCLUSIONS: Intravenous racemic ketamine may produce a rapid, short-term reduction in suicidal ideation in selected adults, whereas regulated intranasal esketamine has demonstrated accelerated improvement in depressive symptoms in hospitalized patients with major depressive disorder and acute suicidal ideation with intent, without a consistent treatment-specific effect on suicidality. Neither intervention has been shown to prevent suicide attempts or deaths. We propose a conceptual, non-validated recovery-enabling downstaging framework to describe a time-limited movement from high acuity toward a state in which collaboration and definitive treatment become more feasible. The framework is intended to complement, not replace, dynamic risk formulation, safety planning, and disposition assessment. CI - (c) 2026 Slupska et al. FAU - Slupska, Anita AU - Slupska A AUID- ORCID: 0000-0003-3116-8474 AD - Department of Psychiatry, Faculty of Medicine, Medical University of Gdansk, Gdansk, Poland. FAU - Cubala, Wieslaw Jerzy AU - Cubala WJ AUID- ORCID: 0000-0001-6343-8454 AD - Department of Psychiatry, Faculty of Medicine, Medical University of Gdansk, Gdansk, Poland. FAU - Swieczkowski, Damian AU - Swieczkowski D AD - Department of Exercise Physiology and Functional Anatomy, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Bydgoszcz, Poland. FAU - Szarmach, Joanna AU - Szarmach J AUID- ORCID: 0000-0002-7645-4821 AD - Department of Psychiatry, Faculty of Medicine, Medical University of Gdansk, Gdansk, Poland. FAU - Wlodarczyk, Adam AU - Wlodarczyk A AUID- ORCID: 0000-0001-8549-254X AD - Department of Psychiatry, Faculty of Medicine, Medical University of Gdansk, Gdansk, Poland. FAU - Slupski, Jakub AU - Slupski J AUID- ORCID: 0000-0002-4579-0208 AD - Department of Psychiatry, Faculty of Medicine, Medical University of Gdansk, Gdansk, Poland. LA - eng PT - Journal Article PT - Review DEP - 20261010 PL - New Zealand TA - Neuropsychiatr Dis Treat JT - Neuropsychiatric disease and treatment JID - 101240304 PMC - PMC13664684 OTO - NOTNLM OT - discharge OT - downstaging OT - esketamine OT - hospitalization OT - ketamine OT - lethal means OT - psychiatric emergency OT - safety planning OT - suicidal behavior OT - suicidal ideation COIS- WJC: Grants: Acadia, Alkermes, Allergan, Angelini, Auspex Pharmaceuticals, Beckley Psytech, BMS, Celon, Cephalon, Compass Pathways, Cortexyme, Ferrier, Forest Laboratories, GedeonRichter, GH Research, GWPharmaceuticals, Helus Pharma, HMNC Brain Health, IntraCellular Therapies, Janssen, KCR, Lilly, Lundbeck, MindMed (Definium), Minerva, MSD, NIH, Neumora, Novartis, Orion, Otsuka, Recognify Life Sciences, Sanofi, Seaport, Servier; Honoraria: Adamed, Angelini, AstraZeneca, BMS, Celon, GH Research, GSK, Janssen, KRKA, Lekam, Lundbeck, Minerva, NeuroCog, Novartis, Orion, Pfizer, Polfa Tarchomin, Sanofi, Servier, Zentiva;Advisory boards: Angelini, Celon (ended 2021), Douglas Pharmaceuticals, GH Research, Janssen, MSD, Novartis, Polpharma, Sanofi, Tasman Therapeutics; Consulting fees from Douglas Pharmaceuticals, outside the submitted work. JSz: Subinvestigator in clinical trials for Janssen, Novartis, GH Research, Celon, Compass Pathways, KCR, Lilly, MSD, Minerva, Neumora, Otsuka. AW: Subinvestigator in clinical trials for Janssen, Novartis, GH Research, Celon, Compass Pathways, KCR, Lilly, MSD, Minerva, Neumora, Otsuka. JSl: Subinvestigator in clinical trials for Janssen, Novartis, GH Research, Celon, Compass Pathways, KCR, Lilly, MSD, Minerva, Neumora, Otsuka. The authors report no other conflicts of interest in this work. EDAT- 2026/10/15 17:38 MHDA- 2026/10/15 17:39 PMCR- 2026/10/10 CRDT- 2026/10/15 16:14 PHST- 2026/07/18 00:00 [received] PHST- 2026/09/13 00:00 [accepted] PHST- 2026/10/15 17:39 [medline] PHST- 2026/10/15 17:38 [pubmed] PHST- 2026/10/15 16:14 [entrez] PHST- 2026/10/10 00:00 [pmc-release] AID - 641718 [pii] AID - 10.2147/NDT.S641718 [doi] PST - epublish SO - Neuropsychiatr Dis Treat. 2026 Oct 10;22:641718. doi: 10.2147/NDT.S641718. eCollection 2026. PMID- 42855719 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20261010 LR - 20261012 IS - 2162-3619 (Print) IS - 2162-3619 (Electronic) IS - 2162-3619 (Linking) VI - 15 IP - 1 DP - 2026 Oct 9 TI - Beyond MYD88-only testing: MYD88/CD79B profiling improves molecular detection and MCD genotyping in VRL and CNS lymphomas. LID - 10.1186/s40164-026-00836-7 [doi] LID - 103 AB - Diagnosing rare, aggressive immune-privileged (IP)-large B-cell lymphomas (LBCL), such as primary vitreoretinal lymphoma (VRL) and primary central nervous system lymphoma (CNSL), remains challenging due to the fragility of lymphoma cells within the vitreous or cerebrospinal fluid (CSF) and paucicellular yields, which preclude definitive cytological diagnosis. Clinical MYD88(L265P) testing has therefore been incorporated into many haematology diagnostic workflows. These gel-based AS-PCRs are limited by DNA input and quality, are restricted to predefined hotspot variants, and cannot detect CD79B ITAM domain variants, which are seen in IP-LBCLs with MYD88/CD79B (MCD) genotype. To address these limitations, we developed a low-input multiplex MYD88/CD79B PCR and Sanger sequencing workflow that detects canonical MYD88 mutations and additional TIR-domain variants, along with CD79B ITAM-domain mutations, and evaluated its clinical performance in 42 vitreous specimens and 4 CSF specimens. Paired validation with clinical VRL and known inflammatory biopsies (N = 46) showed higher sensitivity, specificity, and diagnostic accuracy of 81.8%,100%, and 94.7%, respectively, over the current standard of care MYD88(L265P) laboratory-developed test (LDT) whilst reducing the minimum DNA input from 1ng to 0.016 ng and maintaining diagnostic concordance with LDT, clinical findings, and whole-exome sequencing (WES). Mixed wild-type and mutant Sanger sequencing peak patterns also provided insight into mutational burden and tumour heterogeneity. Although WES remains more comprehensive, multiplex MYD88/CD79B PCR with sequencing represents a practical intermediate molecular strategy for molecular characterization, identification of the MYD88/CD79B-associated (MCD) genotype, and support for therapeutic and prognostic assessment. CI - (c) 2026. The Author(s). FAU - Wang, Mona M AU - Wang MM AUID- ORCID: 0000-0002-4019-0289 AD - Medical Immune Oncology Research Group (MIORG), Institute of Biomedicine, Faculty of Medicine, University of Turku, Turku, Finland. AD - InFLAMES Research Flagship, University of Turku, Turku, Finland. AD - Singapore National Eye Centre and Singapore Eye Research Institute, Singapore, Singapore. FAU - Li, Yuanhan AU - Li Y AD - Singapore National Eye Centre and Singapore Eye Research Institute, Singapore, Singapore. AD - Duke-NUS Medical School, Singapore, Singapore. FAU - How, Gee Fung AU - How GF AD - Department of Haematology, Singapore General Hospital, Singapore, Singapore. FAU - Ho, Candice E H AU - Ho CEH AD - Singapore National Eye Centre and Singapore Eye Research Institute, Singapore, Singapore. FAU - Somasundaram, Nagavalli DO AU - Somasundaram ND AD - National Cancer Centre Singapore, Singapore, Singapore. FAU - Chan, Jason Yongsheng AU - Chan JY AD - National Cancer Centre Singapore, Singapore, Singapore. FAU - Tay, Timothy Kwang Yong AU - Tay TKY AUID- ORCID: 0000-0001-8592-5018 AD - Duke-NUS Medical School, Singapore, Singapore. AD - Department of Anatomical Pathology , Singapore General Hospital, Singapore, Singapore. FAU - Hein, Than AU - Hein T AD - Department of Haematology, Singapore General Hospital, Singapore, Singapore. FAU - Chan, Anita Sook Yee AU - Chan ASY AD - Singapore National Eye Centre and Singapore Eye Research Institute, Singapore, Singapore. anita.chan.s.y@singhealth.com.sg. AD - Duke-NUS Medical School, Singapore, Singapore. anita.chan.s.y@singhealth.com.sg. AD - Department of Anatomical Pathology , Singapore General Hospital, Singapore, Singapore. anita.chan.s.y@singhealth.com.sg. LA - eng PT - Letter DEP - 20261009 PL - England TA - Exp Hematol Oncol JT - Experimental hematology & oncology JID - 101590676 PMC - PMC13653407 COIS- Declarations. Ethics approval and consent to participate: This study was conducted in accordance with the ethical principles outlined in the Declaration of Helsinki. Ethical approval was obtained from the SingHealth Centralized Institutional Review Board (IRB reference: 2021-2073). The study utilized residual clinical specimens collected as part of routine diagnostic procedures, including vitreous fluid and cerebrospinal fluid samples. Written informed consent was obtained from patients where applicable, or a waiver of consent was granted by the Institutional Review Board for the use of de-identified residual samples. All samples were handled and processed in accordance with institutional guidelines and regulations. Clinical data were anonymized prior to analysis to ensure patient confidentiality. No additional procedures or interventions were performed for research purposes beyond standard clinical care. Consent for publication: Consent was obtained from each patient to use their pathological specimens for research. Competing interests: A.S.Y.C. received VRL research funding from A. Menarini Biomarkers Singapore Pte Ltd (2016-2024). MMW and ASYC share a patent METHODS, ASSAYS AND COMPOSITIONS FOR MULTIPLEX DETECTION OF TARGET MYD88 AND CD79B MUTATIONS [10202602571T] 24 July 2026. Single-cell MYD88 work is based on a patent filed on 21 August 2018 (#10201807097T). All other authors declare no competing financial interests. EDAT- 2026/10/10 05:32 MHDA- 2026/10/10 05:33 PMCR- 2026/10/09 CRDT- 2026/10/09 23:58 PHST- 2026/05/26 00:00 [received] PHST- 2026/09/23 00:00 [accepted] PHST- 2026/10/10 05:33 [medline] PHST- 2026/10/10 05:32 [pubmed] PHST- 2026/10/09 23:58 [entrez] PHST- 2026/10/09 00:00 [pmc-release] AID - 10.1186/s40164-026-00836-7 [pii] AID - 836 [pii] AID - 10.1186/s40164-026-00836-7 [doi] PST - epublish SO - Exp Hematol Oncol. 2026 Oct 9;15(1):103. doi: 10.1186/s40164-026-00836-7. PMID- 42842245 OWN - NLM STAT- MEDLINE DCOM- 20261007 LR - 20261010 IS - 2574-3805 (Electronic) IS - 2574-3805 (Linking) VI - 9 IP - 10 DP - 2026 Oct 1 TI - Regulatory Policy Changes and Mifepristone Access Through Pharmacies in Australia. PG - e2637766 LID - 10.1001/jamanetworkopen.2026.37766 [doi] LID - e2637766 AB - IMPORTANCE: In an effort to improve access, the Australian Therapeutic Goods Administration lifted prescribing and dispensing restrictions on mifepristone in August 2023. Mifepristone is approved for medication abortion up to 63 days' gestation and is marketed in Australia in a combipack with misoprostol (hereinafter, mifepristone-misoprostol). The previous restrictions were similar to current restrictions on mifepristone imposed by the US Food and Drug Administration. OBJECTIVE: To assess whether the number and geographic distribution of pharmacies ordering mifepristone-misoprostol in Australia increased after prescribing and dispensing restrictions were lifted in August 2023. DESIGN, SETTING, AND PARTICIPANTS: This cohort study used an interrupted time-series (ITS) analysis of monthly pharmacy orders, based on sales data from the sole Australian distributor of mifepristone for the 24-month periods before (August 1, 2021, to July 31, 2023) and after (August 1, 2023, to July 31, 2025) the regulatory change. EXPOSURE: August 2023 removal of mifepristone prescribing and dispensing restrictions. MAIN OUTCOMES AND MEASURES: The primary outcome was the monthly count of unique pharmacies ordering mifepristone-misoprostol. The monthly proportion of postcodes with at least 1 ordering pharmacy was also assessed. RESULTS: Overall, 2228 pharmacies ordered mifepristone-misoprostol before the policy change and 4107 after. In August 2021, 419 (95% CI, 393-444) pharmacies ordered mifepristone-misoprostol. The number of ordering pharmacies increased by 10 (95% CI, 9-12) per month before the 2023 regulatory change. When restrictions lifted, there was an immediate increase of 86 (95% CI, 16-157) pharmacies, and the increasing trend accelerated by 15 (95% CI, 10-20) additional pharmacies per month. As of July 2025, there were 446 (95% CI, 306-581) more ordering pharmacies (48.6% increase; 95% CI, 29.2%-72.4%) than expected. In August 2021, 11.5% (95% CI, 11.1%-11.8%) of postcodes contained at least 1 ordering pharmacy, increasing by 0.2% (95% CI, 0.2%-0.2%) per month. After the August 2023 regulatory change, there was an immediate and sustained increase. By July 2025, 4.4% (95% CI, 2.4%-6.4%) more postcodes than expected had at least 1 ordering pharmacy, representing a 19.9% (95% CI, 9.9%-31.4%) increase, with the change most pronounced in major cities. CONCLUSIONS AND RELEVANCE: In this cohort study of pharmacy orders for mifepristone-misoprostol in Australia, the removal of prescribing and dispensing restrictions on mifepristone in August 2023 was associated with improved access through pharmacies. These findings support removing similar distribution restrictions on mifepristone in other countries, including the US. FAU - Edvardsson, Kristina AU - Edvardsson K AD - Judith Lumley Centre, School of Nursing and Midwifery, La Trobe University, Bundoora, Victoria, Australia. AD - SPHERE Centre of Research Excellence in Women's Sexual and Reproductive Health in Primary Care, Department of General Practice, School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia. FAU - Schummers, Laura AU - Schummers L AD - SPHERE Centre of Research Excellence in Women's Sexual and Reproductive Health in Primary Care, Department of General Practice, School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia. AD - Collaboration for Outcomes Research and Evaluation, Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia, Canada. FAU - Moulton, Jessica E AU - Moulton JE AD - Judith Lumley Centre, School of Nursing and Midwifery, La Trobe University, Bundoora, Victoria, Australia. AD - SPHERE Centre of Research Excellence in Women's Sexual and Reproductive Health in Primary Care, Department of General Practice, School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia. FAU - Li, Xia AU - Li X AD - Department of Research and Infrastructure, La Trobe University, Bundoora, Victoria, Australia. FAU - Cheng, Lucy AU - Cheng L AD - Collaboration for Outcomes Research and Evaluation, Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia, Canada. FAU - Mazza, Danielle AU - Mazza D AD - SPHERE Centre of Research Excellence in Women's Sexual and Reproductive Health in Primary Care, Department of General Practice, School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia. AD - Department of General Practice, School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia. FAU - Goldstone, Philip AU - Goldstone P AD - MSI Australia, Melbourne, Victoria, Australia. FAU - Grossman, Daniel AU - Grossman D AD - Advancing New Standards in Reproductive Health, Bixby Center for Global Reproductive Health, Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California San Francisco, Oakland. LA - eng PT - Journal Article DEP - 20261001 PL - United States TA - JAMA Netw Open JT - JAMA network open JID - 101729235 RN - 320T6RNW1F (Mifepristone) RN - 0E43V0BB57 (Misoprostol) SB - IM MH - *Mifepristone/supply & distribution/therapeutic use MH - Australia MH - Humans MH - *Pharmacies/statistics & numerical data/legislation & jurisprudence MH - Misoprostol/therapeutic use/supply & distribution MH - Female MH - *Health Services Accessibility MH - Interrupted Time Series Analysis MH - Cohort Studies PMC - PMC13647150 COIS- Conflict of Interest Disclosures: Dr Schummers reported receiving grants from the Canadian Institutes of Health Information, the Canadian Foundation for Innovation, and the British Columbia Ministry of Health, as well as personal fees from Canada's Drug Agency, the Canadian Pharmacy Education and Research Conference, and the University of Calgary O'Brien Institute for Public Health outside the submitted work. Dr Goldstone reported serving as the medical director of MSI Australia and MS Health Pty Ltd (the Australian sponsor of the mifepristone-misoprostol MS-2 Step combipack). Dr Grossman reported receiving personal fees from the Planned Parenthood Federation of America for serving as an expert witness in cases challenging abortion restrictions. No other disclosures were reported. EDAT- 2026/10/07 17:33 MHDA- 2026/10/07 17:34 PMCR- 2026/10/07 CRDT- 2026/10/07 12:31 PHST- 2026/10/07 17:34 [medline] PHST- 2026/10/07 17:33 [pubmed] PHST- 2026/10/07 12:31 [entrez] PHST- 2026/10/07 00:00 [pmc-release] AID - 2854929 [pii] AID - zoi261019 [pii] AID - 10.1001/jamanetworkopen.2026.37766 [doi] PST - epublish SO - JAMA Netw Open. 2026 Oct 1;9(10):e2637766. doi: 10.1001/jamanetworkopen.2026.37766. PMID- 42819087 OWN - NLM STAT- MEDLINE DCOM- 20261001 LR - 20261002 IS - 2296-2565 (Electronic) IS - 2296-2565 (Linking) VI - 14 DP - 2026 TI - Association of coexisting type 2 diabetes and DXA-defined low muscle mass with prevalent radiographic vertebral fracture in community-dwelling older adults: a cross-sectional study. PG - 1908757 LID - 10.3389/fpubh.2026.1908757 [doi] LID - 1908757 AB - BACKGROUND: Prevalent radiographic vertebral fracture is frequently clinically unrecognized in older adults, and areal bone mineral density does not fully characterize its distribution. Whether coexisting type 2 diabetes mellitus (T2DM) and objectively measured low muscle mass identify a subgroup in which this burden is concentrated remains unclear. METHODS: This community-based cross-sectional analysis included 1,642 adults aged 65 years or older recruited through 16 community health service centers covering 36 administrative communities in Changchun, China, between July 2021 and March 2023. Participants were classified into four mutually exclusive groups: neither condition, T2DM alone, dual-energy X-ray absorptiometry (DXA)-defined low muscle mass alone, or both conditions. The primary outcome was prevalent radiographic vertebral fracture (Genant grade >/= 1), with Genant grade >/= 2 fracture as the key secondary outcome. Modified Poisson models estimated prevalence ratios (PRs). The primary model included age and body mass index as restricted cubic splines, sex, and current smoking, with covariance estimation accounting for 36 community clusters. Missing covariates were handled using 50 datasets generated by multiple imputation by chained equations, and marginal standardization was used to estimate prevalence differences. RESULTS: The analytic cohort included 343 participants (20.9%) with prevalent radiographic vertebral fracture. The coexisting phenotype comprised 14.1% of the cohort but accounted for 31.5% of all Genant grade >/= 1 events and 35.2% of all Genant grade >/= 2 events. Observed prevalence was 11.5, 20.7, 24.2, and 46.6% in the neither-condition, T2DM-alone, low-muscle-mass-alone, and coexisting groups, respectively. Primary-model PRs versus neither condition were 1.66 (95% CI, 1.30-2.12), 1.92 (95% CI, 1.42-2.59), and 3.63 (95% CI, 2.81-4.68), respectively. The coexisting phenotype had a standardized prevalence of 44.1% (95% CI, 38.3-49.9%) and a prevalence difference of 31.9 percentage points (95% CI, 25.3-38.5) versus neither condition. Results were similar in the femoral-neck-BMD-context, complete-case, Genant grade >/= 2, and no-prior-fracture analyses. CONCLUSION: In this analytic sample, coexisting T2DM and DXA-defined low muscle mass defined a relatively small subgroup with a disproportionate share of prevalent radiographic vertebral fracture events and the highest fracture prevalence. These cross-sectional findings do not establish causality, future fracture prediction, screening performance, or an indication for vertebral imaging. CI - Copyright (c) 2026 Zhong, Wu, Gao, Zhou, Li, Hao, Xu, Li, Dong and Luo. FAU - Zhong, Xuanpu AU - Zhong X AD - School of Traditional Chinese Medicine, Changchun University of Chinese Medicine, Changchun, China. FAU - Wu, Hailong AU - Wu H AD - Department of Orthopedics, The Affiliated Hospital of Changchun University of Chinese Medicine, Changchun, China. FAU - Gao, Tianjiao AU - Gao T AD - The Affiliated Hospital of Changchun University of Chinese Medicine, Changchun, China. FAU - Zhou, Zhenwei AU - Zhou Z AD - Northeast Asia Research Institute of Traditional Chinese Medicine, Changchun University of Chinese Medicine, Changchun, China. FAU - Li, Luan AU - Li L AD - Rehabilitation Teaching and Research Section, Changchun Medical College, Changchun, China. FAU - Hao, Ling AU - Hao L AD - The Affiliated Hospital of Changchun University of Chinese Medicine, Changchun, China. FAU - Xu, Yitong AU - Xu Y AD - School of Traditional Chinese Medicine, Changchun University of Chinese Medicine, Changchun, China. FAU - Li, Pengcheng AU - Li P AD - School of Traditional Chinese Medicine, Changchun University of Chinese Medicine, Changchun, China. FAU - Dong, Haisi AU - Dong H AD - Northeast Asia Research Institute of Traditional Chinese Medicine, Changchun University of Chinese Medicine, Changchun, China. FAU - Luo, Zongjian AU - Luo Z AD - Department of Orthopedics, The Affiliated Hospital of Changchun University of Chinese Medicine, Changchun, China. LA - eng PT - Journal Article DEP - 20260916 PL - Switzerland TA - Front Public Health JT - Frontiers in public health JID - 101616579 SB - IM MH - Humans MH - Cross-Sectional Studies MH - *Diabetes Mellitus, Type 2/epidemiology/complications MH - Female MH - Aged MH - Absorptiometry, Photon MH - *Spinal Fractures/epidemiology/diagnostic imaging MH - Male MH - Independent Living/statistics & numerical data MH - China/epidemiology MH - Prevalence MH - Bone Density MH - Aged, 80 and over PMC - PMC13623588 OTO - NOTNLM OT - DXA-defined low muscle mass OT - community-dwelling older adults OT - cross-sectional study OT - healthy aging OT - prevalence ratio OT - radiographic vertebral fracture OT - type 2 diabetes mellitus COIS- The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2026/10/01 17:29 MHDA- 2026/10/01 17:30 PMCR- 2026/09/16 CRDT- 2026/10/01 13:27 PHST- 2026/06/14 00:00 [received] PHST- 2026/08/26 00:00 [revised] PHST- 2026/09/07 00:00 [accepted] PHST- 2026/10/01 17:30 [medline] PHST- 2026/10/01 17:29 [pubmed] PHST- 2026/10/01 13:27 [entrez] PHST- 2026/09/16 00:00 [pmc-release] AID - 10.3389/fpubh.2026.1908757 [doi] PST - epublish SO - Front Public Health. 2026 Sep 16;14:1908757. doi: 10.3389/fpubh.2026.1908757. eCollection 2026. PMID- 42809284 OWN - NLM STAT- MEDLINE DCOM- 20260929 LR - 20261002 IS - 2574-3805 (Electronic) IS - 2574-3805 (Linking) VI - 9 IP - 9 DP - 2026 Sep 1 TI - Prevalence of Overweight and Obesity Among Children Younger Than 5 Years in India. PG - e2636750 LID - 10.1001/jamanetworkopen.2026.36750 [doi] LID - e2636750 AB - IMPORTANCE: Evidence is lacking on long-term trends across Indian states and union territories (UTs) and on the attainability of the 2030 Global Nutrition Target (GNT) goals within these specific regions. OBJECTIVES: To estimate the trends in overweight and obesity among children younger than 5 years across 36 states and UTs in India between 2006 and 2024 and to assess the feasibility of achieving the GNT of restricting the overweight burden to 5% or less by 2030. DESIGN, SETTING, AND PARTICIPANTS: For this cross-sectional study, microdata and aggregate data were used from the 4 most recent waves of the National Family Health Survey (repeated cross-sectional surveys conducted between January 1, 2006, and December 31, 2024). The analysis included individual-level samples of 41 306 children in 2006, 225 002 in 2016, and 201 687 in 2021, alongside aggregate estimates of overweight from the 2024 wave. Data were analyzed in January and updated in July 2026. MAIN OUTCOMES AND MEASURES: Following World Health Organization definitions of overweight and obesity in children younger than 5 years (overweight is defined as weight for height >2 SDs above the World Health Organization median and obesity as >3 SDs), their prevalence and standardized annualized changes for 5 timeframes (2006-2016, 2016-2021, 2021-2024, 2006-2021, and 2006-2024) were computed. Additionally, the fractional logistic regression was used to model national and state-level overweight trajectories, forecasting probability of achieving the 5% or less 2030 GNT threshold. RESULTS: The final sample included 467 995 children (241 645 [51.6%] male, 226 350 [48.4%] female) aged 0 to 59 months from NFHSs conducted between 2006 and 2021. Mean (SD) child age remained consistent from 2006 to 2021: 30.1 (17.1) months in 2006, 30.1 (17.0) months in 2016, and 29.9 (17.2) months in 2021. Between 2006 and 2021, the prevalence of overweight increased from 1.55% to 3.42%, whereas obesity prevalence increased from 0.50% to 1.30% before overweight prevalence decreased to 1.3% in 2024. Although India was projected to sustain the 2030 overweight target nationally, 9 states and UTs (Arunachal Pradesh, Assam, Himachal Pradesh, Jammu and Kashmir, Kerala, Mizoram, Nagaland, Sikkim, and Tripura) maintained a low to moderate probability of adherence. CONCLUSIONS AND RELEVANCE: In this cross-sectional study of Indian children younger than 5 years from 2006 to 2024, a historical overweight increase reversed in 2024. However, profound subnational disparities remained, suggesting that targeted regional interventions are needed to achieve the 2030 GNT. FAU - Rai, Rajesh Kumar AU - Rai RK AD - Division of Global Health Management and Policy, School of Public Health, San Diego State University, San Diego, California. AD - Birbhum Population Project, Society for Health and Demographic Surveillance, Suri, West Bengal, India. AD - ImplactLoop Ltd, London, UK. AD - Human Nutrition Unit, Institute of Nutrition, Mahidol University, Phutthamonthon, Nakhon Pathom, Thailand. AD - Department of Global Health and Population, Harvard T.H. Chan School of Public Health, Boston, Massachusetts. FAU - Matsuzaki, Mika AU - Matsuzaki M AD - Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland. AD - Center for Human Nutrition, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland. AD - Community Nutrition Unit, Institute of Nutrition, Mahidol University, Phutthamonthon, Nakhon Pathom, Thailand. FAU - De Neve, Jan-Walter AU - De Neve JW AD - Division of Global Health Management and Policy, School of Public Health, San Diego State University, San Diego, California. AD - Heidelberg Institute of Global Health, Faculty of Medicine and University Hospital, University of Heidelberg, Heidelberg, Germany. FAU - Zafar, Sumaira AU - Zafar S AD - Community Nutrition Unit, Institute of Nutrition, Mahidol University, Phutthamonthon, Nakhon Pathom, Thailand. FAU - Bromage, Sabri AU - Bromage S AD - Community Nutrition Unit, Institute of Nutrition, Mahidol University, Phutthamonthon, Nakhon Pathom, Thailand. AD - Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, Massachusetts. FAU - Kim, Rockli AU - Kim R AD - Division of Health Policy and Management, College of Health Science, Korea University, Seoul, South Korea. AD - Interdisciplinary Program in Precision Public Health, Department of Public Health Sciences, Graduate School of Korea University, Seoul, South Korea. FAU - Subramanian, S V AU - Subramanian SV AD - Harvard Center for Population and Development Studies, Cambridge, Massachusetts. AD - Department of Social and Behavioral Sciences, Harvard T.H. Chan School of Public Health, Boston, Massachusetts. LA - eng PT - Journal Article DEP - 20260901 PL - United States TA - JAMA Netw Open JT - JAMA network open JID - 101729235 SB - IM MH - Humans MH - India/epidemiology MH - Child, Preschool MH - Male MH - Cross-Sectional Studies MH - Female MH - Prevalence MH - Infant MH - *Overweight/epidemiology MH - *Pediatric Obesity/epidemiology PMC - PMC13624874 COIS- Conflict of Interest Disclosures: None reported. EDAT- 2026/09/29 19:04 MHDA- 2026/09/29 19:05 PMCR- 2026/09/29 CRDT- 2026/09/29 11:32 PHST- 2026/09/29 19:05 [medline] PHST- 2026/09/29 19:04 [pubmed] PHST- 2026/09/29 11:32 [entrez] PHST- 2026/09/29 00:00 [pmc-release] AID - 2854611 [pii] AID - zoi260985 [pii] AID - 10.1001/jamanetworkopen.2026.36750 [doi] PST - epublish SO - JAMA Netw Open. 2026 Sep 1;9(9):e2636750. doi: 10.1001/jamanetworkopen.2026.36750. PMID- 42804378 OWN - NLM STAT- MEDLINE DCOM- 20260928 LR - 20260930 IS - 2054-1058 (Electronic) IS - 2054-1058 (Linking) VI - 13 IP - 9 DP - 2026 Sep TI - Operation Room Pre-Experience Service Willingness of Surgical Patients: A Mixed Method Research. PG - e70840 LID - 10.1002/nop2.70840 [doi] LID - e70840 AB - AIM: To investigate surgical patients' willingness to engage in these services, their specific needs and the factors that influence their willingness. DESIGN: An exploratory, sequential, mixed-method study employing semi-structured interviews and cross-sectional surveys. METHODS: Qualitative data were collected from 15 patients via semi-structured interviews from August to November 2021. Colaizzi's phenomenological analysis was used to analyse interview data. The study collected quantitative data using the general information questionnaire, the questionnaire on willingness to participate in pre-experience service in the operating room, the General Self-Efficacy Scale and the All Aspects of Health Literacy Scale, recruiting 600 patients from March to July 2022. Univariate and binary logistic regression analyses identified factors. RESULTS: Fifteen patients were interviewed, and 10 agreed to participate in this service, citing reasons including stress relief, knowledge enhancement, cognitive shifts, identifying needs and enriching experiences. Five patients declined the pre-experience service due to restricted mobility, increased anxiety, fear of complications and lack of motivation. A total of 562 valid questionnaires were collected, with a response rate of 93.7%. Of which, 393 expressed willingness to participate in the service. Binary logistic regression analysis identified that the willingness of patients to participate in the service was associated with several factors, including age, American Society of Anesthesiologists grades, social support, professional support, health literacy and self-efficacy. IMPLICATIONS FOR THE PROFESSION AND/OR PATIENT CARE: This study delineates the willingness characteristics and influencing factors of surgical patients regarding the operating room pre-experience service within the Chinese sociocultural context (e.g., unfamiliarity-induced anxiety and passive information acceptance). The findings suggest that operating room nurses should integrate pre-experience services into routine preoperative care, particularly by offering personalized options based on patients' preferences. Given the strong influence of social support, nurses are encouraged to involve family members and peer patients in promoting these services. IMPACT: The study addressed the gap in understanding surgical patients' willingness to participate in a novel 'operating room pre-experience service' and the influencing factors that willingness. The main findings showed that nearly 70% of surgical patients were willing to participate, with key influencing factors including age (< 60 years), lower ASA grades, higher health literacy and self-efficacy and stronger social and professional support. This research offers a China-oriented perspective on surgical patients' preoperative experience needs globally, contributing a valuable addition to the international literature on preoperative nursing and patient-centred service design. REPORTING METHOD: This study is reported using Good Reporting of a Mixed Methods Study (GRAMMS). PATIENT OR PUBLIC CONTRIBUTION: No patient or public contribution. CI - (c) 2026 The Author(s). Nursing Open published by John Wiley & Sons Ltd. FAU - Zhou, Yuling AU - Zhou Y AUID- ORCID: 0009-0003-7490-2744 AD - School of Nursing, Anhui Medical University, Hefei, Anhui, China. AD - Department of Operating Room, The First Affiliated Hospital of University of Science and Technology of China, Hefei, Anhui, China. FAU - Chen, Qingqing AU - Chen Q AUID- ORCID: 0009-0000-6860-348X AD - School of Nursing, Anhui Medical University, Hefei, Anhui, China. FAU - Wang, Ting AU - Wang T AD - School of Nursing, Anhui Medical University, Hefei, Anhui, China. FAU - Qin, Chuang AU - Qin C AUID- ORCID: 0009-0001-5147-8819 AD - School of Nursing, Anhui Medical University, Hefei, Anhui, China. FAU - Peng, Yuqi AU - Peng Y AD - School of Nursing, Anhui Medical University, Hefei, Anhui, China. FAU - Zhang, Dan AU - Zhang D AD - School of Nursing, Anhui Medical University, Hefei, Anhui, China. FAU - Chen, Rongzhu AU - Chen R AD - Department of Operating Room, The First Affiliated Hospital of University of Science and Technology of China, Hefei, Anhui, China. FAU - Qiu, Panpan AU - Qiu P AD - Department of Thoracic Surgery, The First Affiliated Hospital of University of Science and Technology of China, Hefei, Anhui, China. FAU - Xie, Mingran AU - Xie M AD - Department of Thoracic Surgery, The First Affiliated Hospital of University of Science and Technology of China, Hefei, Anhui, China. FAU - Song, Guiqi AU - Song G AD - Department of Education, The First Affiliated Hospital of University of Science and Technology of China, Hefei, Anhui, China. FAU - Xie, Lunfang AU - Xie L AUID- ORCID: 0009-0003-5551-421X AD - School of Nursing, Anhui Medical University, Hefei, Anhui, China. AD - Hospital Management Institute, Anhui Medical University, Hefei, Anhui, China. LA - eng GR - 2024gykjgx12/'Anhui Zhongji Guoyi Medical Technology Co. Ltd' Open Program of Hospital Management Institute, Anhui Medical University/ GR - 202004j07020017/the Key Research and Development Program of Population Health in Anhui Province/ GR - 202210366033/the National College Student Innovation and Entrepreneurship Training Program Project/ PT - Journal Article PL - United States TA - Nurs Open JT - Nursing open JID - 101675107 SB - IM MH - Humans MH - Female MH - Male MH - Middle Aged MH - Surveys and Questionnaires MH - Cross-Sectional Studies MH - Adult MH - *Operating Rooms/organization & administration MH - Qualitative Research MH - Aged MH - Self Efficacy PMC - PMC13618924 OTO - NOTNLM OT - influencing factors OT - operating room nursing OT - pre-experience service OT - surgery OT - willingness COIS- The authors declare no conflicts of interest. EDAT- 2026/09/28 17:31 MHDA- 2026/09/28 17:32 PMCR- 2026/09/28 CRDT- 2026/09/28 12:53 PHST- 2026/08/29 00:00 [revised] PHST- 2024/12/12 00:00 [received] PHST- 2026/09/03 00:00 [accepted] PHST- 2026/09/28 17:32 [medline] PHST- 2026/09/28 17:31 [pubmed] PHST- 2026/09/28 12:53 [entrez] PHST- 2026/09/28 00:00 [pmc-release] AID - NOP270840 [pii] AID - 10.1002/nop2.70840 [doi] PST - ppublish SO - Nurs Open. 2026 Sep;13(9):e70840. doi: 10.1002/nop2.70840. PMID- 42761095 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20260921 IS - 2196-2952 (Print) IS - 2196-2952 (Electronic) VI - 13 IP - 1 DP - 2026 TI - Regulatory Whack-a-mole: A Rapid Scoping Review of Gambling Marketing Restrictions and their (in)Effectiveness. PG - 85 LID - 10.1007/s40429-026-00793-5 [doi] LID - 85 AB - PURPOSE OF REVIEW: Gambling marketing increases participation, spending, and harm. Marketing restrictions represent the best regulatory response. Decades of tobacco and alcohol marketing regulation demonstrate a recurring pattern in which each restriction triggers industry adaptation through, e.g., channel substitution, alibi marketing, and the exploitation of regulatory gaps. However, no review has systematically assessed gambling operator adaptations to marketing restrictions. This review examines the effectiveness of gambling marketing restrictions implemented globally between 2010 and 2026, in light of these potential adaptations. RECENT FINDINGS: Fifty records spanning 13 jurisdictions were synthesised across six gambling marketing restriction categories. (1) Content, (2) Timing, and (3) Channel Restrictions were consistently undermined by poor operator compliance, redistribution of advertising to less regulated platforms, and narrow regulatory scopes leaving the majority of marketing exposure unregulated. (4) Inducement Restrictions yielded the strongest behavioural evidence, with sustained reductions in customer acquisition and money gambled, though operators restrategised by redirecting promotional effort towards retaining existing customers. (5) Platform-enforced measures curtailed on-platform content but not external gambling website traffic or underage exposure. (6) Comprehensive Bans were circumvented through alibi marketing, transitional exemptions, and reallocation of spend to unregulated, operator-owned media channels. SUMMARY: Regulatory displacement was evident across all six categories. Operators consistently migrated marketing activity to less regulated channels, formats, and strategies following each restriction, mirroring the established regulatory trajectories of tobacco and alcohol marketing. Effective gambling marketing regulation requires statutory, comprehensive, and future-proof frameworks rather than the voluntary, circumventable, and reactive approaches evaluated in this review. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at https://doi.org/10.1007/s40429-026-00793-5. CI - (c) The Author(s) 2026. FAU - Torrance, Jamie AU - Torrance J AUID- ORCID: 0000-0001-5001-4126 AD - School of Psychology, Swansea University, Singleton Campus, Swansea, SA28PP UK. ROR: https://ror.org/053fq8t95. GRID: grid.4827.9. ISNI: 0000 0001 0658 8800 FAU - Smith, Jessica AU - Smith J AD - School of Psychology, Swansea University, Singleton Campus, Swansea, SA28PP UK. ROR: https://ror.org/053fq8t95. GRID: grid.4827.9. ISNI: 0000 0001 0658 8800 FAU - Russell, Alex M T AU - Russell AMT AD - Experimental Gambling Research Laboratory, School of Health, Medical and Applied Sciences, Central Queensland University, Rockhampton, Australia. ROR: https://ror.org/023q4bk22. GRID: grid.1023.0. ISNI: 0000 0001 2193 0854 FAU - Wright, Simon AU - Wright S AD - School of Psychology, Swansea University, Singleton Campus, Swansea, SA28PP UK. ROR: https://ror.org/053fq8t95. GRID: grid.4827.9. ISNI: 0000 0001 0658 8800 FAU - Xiao, Leon Y AU - Xiao LY AD - School of Creative Media, City University of Hong Kong, Hong Kong, China. ROR: https://ror.org/03q8dnn23. GRID: grid.35030.35. ISNI: 0000 0004 1792 6846 FAU - Wyn-Davies, Elen AU - Wyn-Davies E AD - School of Psychology, Swansea University, Singleton Campus, Swansea, SA28PP UK. ROR: https://ror.org/053fq8t95. GRID: grid.4827.9. ISNI: 0000 0001 0658 8800 FAU - Heath, Conor AU - Heath C AD - School of Psychology, Swansea University, Singleton Campus, Swansea, SA28PP UK. ROR: https://ror.org/053fq8t95. GRID: grid.4827.9. ISNI: 0000 0001 0658 8800 FAU - Newall, Philip AU - Newall P AD - School of Psychological Science, University of Bristol, Bristol, UK. ROR: https://ror.org/0524sp257. GRID: grid.5337.2. ISNI: 0000 0004 1936 7603 LA - eng PT - Journal Article PT - Review DEP - 20260917 PL - Switzerland TA - Curr Addict Rep JT - Current addiction reports JID - 101623508 PMC - PMC13585857 OTO - NOTNLM OT - Advertising regulation OT - Consumer protection, Harm reduction OT - Gambling marketing OT - Public health OT - Scoping review COIS- Conflict of InterestThe authors declare no conflicts of interest. JT has received, in the last three years: (1) Open access publication funding from Gambling Research Exchange Ontario (GREO), (2) Conference travel and accommodation funding from the Academic Forum for the Study of Gambling (AFSG), (3) A minor exploratory research grant from the ASFG, 4) Seed Grant funding from the International Centre for Responsible Gambling (ICRG), (5) Studentship funding from the Economic and Social Research Council (ESRC), (6) Rapid evidence review (RER) funding from UK Research and Innovation (UKRI), (7) Policy Fellowship funding from UKRI, (8) Gambling Harms Research and Innovation Partnership funding from UKRI. JS has no disclosures. AR has received funding in the last three years from the Tasmanian Department of Treasury and Finance, the ACT Gambling and Racing Commission, NSW Liquor and Gaming, Queensland Department of Justice, NSW Office of Responsible Gambling, Victorian Department of Justice and Community Safety, Northern Territory Department of Industry, Tourism and Trade and the New Zealand Ministry of Health. He declares no conflicts in relation to this work.SW has no disclosures. L.Y.X. is supported by a Presidential Assistant Professors Scheme Start-Up Research Grant (9382009) awarded by the City University of Hong Kong [香港城市大學] (March 2025). L.Y.X. has provided paid consultancy and research services for (i) Public Group International Ltd (t/a PUBLIC) (Companies House number: 10608507), commissioned by the UK Department for Culture, Media and Sport (DCMS) to conduct independent research on understanding player experiences of loot box protections (October 2024 - May 2025); (ii) the Council of Europe International Cooperation Group on Drugs and Addiction (the Pompidou Group) on a project concerning the risks of online gambling and gaming to young people co-funded by the European Union via the Technical Support Instrument and implemented by the Council of Europe, in cooperation with the European Commission (December 2024 - May 2025); and (iii) the Institute of Public Health on a report concerning the advertising of harmful products to children funded by the Irish Department of Health and intended for its Online Health Taskforce (July 2025). L.Y.X. was supported by a PhD Fellowship funded by the IT University of Copenhagen [IT-Universitetet i Kobenhavn] (December 2021 - November 2024). L.Y.X. was employed by LiveMe, then a subsidiary of Cheetah Mobile (NYSE: CMCM), as an in-house counsel intern from July to August 2019 in Beijing, China. L.Y.X. was not involved with the monetisation of video games by Cheetah Mobile or its subsidiaries. L.Y.X. undertook a brief period of voluntary work experience at Wiggin LLP (Solicitors Regulation Authority number: 420659) in London, England, in August 2022. L.Y.X. has contributed to research projects enabled by data access provided by the video game industry, specifically Unity Technologies (NYSE:U) (October 2022 - August 2023). L.Y.X. has been invited to provide advice to the UK Department for Digital, Culture, Media and Sport and its successor (the Department for Culture, Media and Sport; DCMS) on the technical working group for loot boxes and the Video Games Research Framework. L.Y.X. was the (co-)recipient of three Academic Forum for the Study of Gambling (AFSG) postgraduate research support grants (March 2022, January 2023, and July 2024) and a minor exploratory research grant (May 2024) derived from 'regulatory settlements applied for socially responsible purposes' received by the UK Gambling Commission and administered by Gambling Research Exchange Ontario (GREO) and its successor (Greo Evidence Insights; Greo). L.Y.X. accepted funding to publish open-access academic papers from GREO and the AFSG that was received by the UK Gambling Commission as above (October, November, and December 2022, November 2023, and May 2024). L.Y.X. was the recipient of an Elite Research Travel Grant 2024 [EliteForsk-rejsestipendium 2024] awarded by the Agency for Higher Education and Science of the Danish Ministry of Higher Education and Science [Uddannelses-og Forskningsstyrelsen under Uddannelses-og Forskningsministeriet] (February 2024). L.Y.X. has accepted conference travel and attendance grants from the Socio-Legal Studies Association (February 2022 and February 2023); the Current Advances in Gambling Research Conference Organising Committee with support from GREO (February 2022); the International Relations Office of The Jagiellonian University (Uniwersytet Jagiellonski), the Polish National Agency for Academic Exchange (NAWA; Narodowa Agencja Wymiany Akademickiej), and the Republic of Poland (Rzeczpospolita Polska) with co-financing from the European Social Fund of the European Commission of the European Union under the Knowledge Education Development Operational Programme (May 2022); the Society for the Study of Addiction (November 2022, March 2023, and November 2024); the organisers of the 13th Nordic SNSUS (Stiftelsen Nordiska Sallskapet for Upplysning om Spelberoende; the Nordic Society Foundation for Information about Problem Gambling) Conference, which received gambling industry sponsorship (January 2023); the MiSK Foundation (Prince Mohammed bin Salman bin Abdulaziz Foundation) (November 2023); the UK Gambling Commission (March 2024); the Video Game and Art Research Center, Peking University (April 2026); and the Alberta Gambling Research Institute (May 2026). L.Y.X. has received honoraria from the Center for Ludomani for contributing parent guides about mobile games for Tjekspillet.dk, which was funded by the Danish Ministry of Health's gambling addiction pool (Sundhedsministeriets Ludomanipulje) (March and December 2023), the Fundacio Publica Tecnocampus Mataro-Maresme (TecnoCampus Mataro-Maresme Foundation) for a guest lecture (November 2023), the Young Men's Christian Association (YMCA) of Greater Toronto Youth Gambling Awareness Program for a presentation, which was funded by the Government of Ontario, Canada (March 2024), Lunds universitet (Lund University) for the right to translate parent guides about mobile games into Swedish for Kollaspelet.se, which was funded by Mediamyndigheten (the Swedish Agency for the Media) and Barnahus Stockholm (December 2024); Shenkar College of Engineering, Design and Art for a guest lecture (December 2024); and DiGRA Korea and the Game-n-Science Institute [게임과학연구원] under the Game Culture Foundation [게임문화재단] under the Ministry of Culture, Sports and Tourism of South Korea [문화체육관광부] for participating in an academic research survey (January 2025). L.Y.X. received royalties by virtue of the copyright subsisting in some of his publications from the Authors' Licensing and Collecting Society (ALCS) (Companies House number: 01310636) (March 2023, 2024, & 2025). A full gifts and hospitality register-equivalent for L.Y.X. is available at: https://www.leonxiao.com/about/gifts-and-hospitality-register. The up-to-date version of L.Y.X.'s conflict-of-interest statement is available at: https://www.leonxiao.com/about/conflict-of-interest. EW-D has no disclosures. CH has no disclosures.PN was a member of the Advisory Board for Safer Gambling from 2021 to 2025, which was an advisory group of the Gambling Commission in Great Britain. In the last three years, PN has been a named researcher on projects funded by the Academic Forum for the Study of Gambling, Alberta Gambling Research Institute, Arts and Humanities Research Council, BA/Leverhulme, Canadian Institute for Health Research, Clean Up Gambling, Gambling Research Australia, and the Victorian Responsible Gambling Foundation. PN has received honoraria for reviewing from the Academic Forum for the Study of Gambling and the Belgium Ministry of Justice, travel and accommodation funding from the Alberta Gambling Research Institute and the Economic and Social Research Institute, and open access fee funding from the Academic Forum for the Study of Gambling and Greo Evidence Insights.Competing InterestsThe authors declare no competing interests. EDAT- 2026/09/19 23:52 MHDA- 2026/09/19 23:53 PMCR- 2026/09/17 CRDT- 2026/09/19 05:02 PHST- 2026/06/15 00:00 [received] PHST- 2026/09/11 00:00 [accepted] PHST- 2026/09/19 23:53 [medline] PHST- 2026/09/19 23:52 [pubmed] PHST- 2026/09/19 05:02 [entrez] PHST- 2026/09/17 00:00 [pmc-release] AID - 793 [pii] AID - 10.1007/s40429-026-00793-5 [doi] PST - ppublish SO - Curr Addict Rep. 2026;13(1):85. doi: 10.1007/s40429-026-00793-5. Epub 2026 Sep 17. PMID- 42643948 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260826 LR - 20260827 IS - 2168-8184 (Print) IS - 2168-8184 (Electronic) IS - 2168-8184 (Linking) VI - 18 IP - 7 DP - 2026 Jul TI - Temporal Changes in Pediatric Influenza Test Positivity Across COVID-19 Public Health Policy Phases: A Five-Year Retrospective Cohort Study. PG - e113386 LID - 10.7759/cureus.113386 [doi] LID - e113386 AB - Background The COVID-19 pandemic coincided with substantial changes in respiratory virus circulation, healthcare utilization, and diagnostic testing. Although population-level influenza activity declined markedly in many settings during periods of stringent public health restrictions, patterns among children undergoing clinical testing remain less clearly understood. This study compared pediatric influenza test positivity across pre-pandemic, restriction-dominant pandemic, and post-restriction periods. Methods This retrospective cohort study included 18,035 children who underwent influenza A/B antigen testing at the Department of Pediatrics, Hisar Intercontinental Hospital, Istanbul, Turkiye, between January 2018 and May 2023. The study period was divided into the pre-pandemic (January 2018-February 2020), restriction-dominant pandemic (March 2020-June 2021), and post-restriction (July 2021-May 2023) periods. Influenza A and B antigens were detected in nasopharyngeal swab specimens using the GenBody Influenza A/B Ag rapid immunochromatographic assay. Tests performed for the same patient within 14 days were considered part of the same illness episode, and only the first eligible test was included. Influenza test positivity was compared across periods and according to age, sex, influenza type, and seasonality. Multivariable logistic regression was used to evaluate factors independently associated with influenza positivity. Results Of the 18,035 children, 6,691 were tested during the pre-pandemic period, 3,375 during the restriction-dominant period, and 7,969 during the post-restriction period. Influenza was detected in 1,699 (25.4%), 969 (28.7%), and 1,937 (24.3%) children, respectively (P<0.001). Although the proportion of positive tests was highest during the restriction-dominant period, both the testing volume and absolute number of detected cases were lower than before the pandemic. Influenza A positivity increased from 17.1% during the restriction-dominant period to 20.0% after restrictions were relaxed, whereas influenza B positivity declined from 11.6% to 4.4%. Seasonal positivity also varied substantially across the study periods. After adjustment for demographic characteristics, the epidemiological period remained independently associated with influenza test positivity. Conclusions Temporal changes in pediatric influenza test positivity coincided with changes in COVID-19 public health measures. The higher positivity among tested children during the restriction-dominant period occurred in the context of substantially reduced testing and should not be interpreted as increased population-level influenza circulation. Changes in healthcare utilization, testing behavior, and the composition of the tested population should be considered when interpreting these findings. CI - Copyright (c) 2026, Nas et al. FAU - Nas, Yunus AU - Nas Y AD - School of Health Sciences, Dogus University, Istanbul, TUR. FAU - Gozukucuk, Suveyda AU - Gozukucuk S AD - Department of Infectious Diseases and Clinical Microbiology, Hisar Hospital Intercontinental, Istanbul, TUR. FAU - Cakiroglu, Basri AU - Cakiroglu B AD - Department of Urology, Uskudar University, Istanbul, TUR. LA - eng PT - Journal Article DEP - 20260726 PL - United States TA - Cureus JT - Cureus JID - 101596737 PMC - PMC13504437 OTO - NOTNLM OT - children OT - covid-19 OT - epidemiology OT - influenza OT - non-pharmaceutical interventions OT - respiratory viruses OT - retrospective cohort COIS- Human subjects: Informed consent for treatment and open access publication was obtained or waived by all participants in this study. Hisar Hospital Intercontinental Clinical Research Ethics Committee issued approval Approval No: 23-46/2026. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work. EDAT- 2026/08/26 11:50 MHDA- 2026/08/26 11:51 PMCR- 2026/07/26 CRDT- 2026/08/26 06:32 PHST- 2026/07/26 00:00 [accepted] PHST- 2026/08/26 11:51 [medline] PHST- 2026/08/26 11:50 [pubmed] PHST- 2026/08/26 06:32 [entrez] PHST- 2026/07/26 00:00 [pmc-release] AID - 10.7759/cureus.113386 [doi] PST - epublish SO - Cureus. 2026 Jul 26;18(7):e113386. doi: 10.7759/cureus.113386. eCollection 2026 Jul. PMID- 42566083 OWN - NLM STAT- MEDLINE DCOM- 20260807 LR - 20261008 IS - 1863-2491 (Electronic) IS - 1863-2483 (Linking) VI - 20 IP - 1 DP - 2026 Aug 7 TI - Intracorporeal urinary diversion during robot-assisted radical cystectomy: a bibliometric and visualization analysis of research evolution, evidence landscape, learning curves, and clinical outcomes. LID - 806 [pii] LID - 10.1007/s11701-026-03743-5 [doi] AB - Intracorporeal urinary diversion (ICUD) represents an important technical milestone in the transition of robot-assisted radical cystectomy (RARC) toward a completely minimally invasive surgical pathway. However, the evolution of research activity, collaborative structure, and emerging themes within this area has not yet been fully delineated. Therefore, the present study aimed to map the knowledge landscape of ICUD during RARC. Relevant publications were identified from the Web of Science Core Collection, with all available editions selected, and the search was conducted on July 1, 2026. English-language Articles and Reviews officially published between 2010 and 2025 were independently screened to determine their thematic eligibility. Sensitivity analyses were conducted using an abbreviation-free search strategy and more restrictive visualization thresholds. Bibliometrix, VOSviewer, CiteSpace, and SCImago Graphica were used to characterize publication patterns, national and institutional contributions, author and journal profiles, influential references, and temporal changes in keyword-based research themes. Overall, 250 records were included in the final analysis, including 212 Articles and 38 Review Articles. The annual number of publications showed a general upward trend, rising from 2 publications in 2010 to 34 publications in 2025, with a peak of 36 in 2021. The United States maintained the leading cumulative publication trajectory and received the highest total citation count (2,139). Karolinska Institutet was the most productive institution (43 publications), Giuseppe Simone ranked as the leading author in terms of productivity (23 publications), and BJU International was identified as the leading source journal (25 publications). The co-citation and keyword analyses revealed an evolutionary shift from initial feasibility studies and technical descriptions toward research on diversion types, perioperative outcomes, enhanced recovery, learning curves, and comparative effectiveness. Recent burst terms, including "randomised controlled trial," "mortality," "survival," and "morbidity," suggested increasing attention to comparative evaluation and clinically meaningful outcomes, although burst-term findings reflect changes in keyword usage rather than direct evidence of improved study quality. Sensitivity analyses using an abbreviation-free search strategy and more restrictive visualization thresholds showed broadly consistent thematic and source-level patterns. Research on ICUD during RARC has expanded from technical exploration toward increasing attention to procedural standardization, learning curves, comparative evaluation, and clinically meaningful outcomes. Nevertheless, these bibliometric patterns should be interpreted as indicators of research attention rather than direct evidence that surgical standardization has been achieved or that clinical outcomes have improved. The evidence base remains heterogeneous and concentrated in experienced centers. Further multicenter prospective studies with standardized reporting and longer follow-up are needed to clarify the implementation strategy and long-term clinical value of ICUD. CI - (c) 2026. The Author(s), under exclusive licence to Springer-Verlag London Ltd., part of Springer Nature. FAU - Xu, Zhao AU - Xu Z AD - Department of Urology, The Affiliated Taian City Central Hospital of Qingdao University, Taian, 271000, China. FAU - Wang, Xingliang AU - Wang X AD - Department of Urology, The Affiliated Taian City Central Hospital of Qingdao University, Taian, 271000, China. mnwkyswxl@126.com. LA - eng GR - 2020NS157/the Tai'an Science and Technology Innovation Development Project (Policy-guided Program)/ PT - Journal Article PT - Review DEP - 20260807 PL - England TA - J Robot Surg JT - Journal of robotic surgery JID - 101300401 SB - IM MH - *Cystectomy/methods/education MH - *Robotic Surgical Procedures/methods MH - *Bibliometrics MH - *Urinary Diversion/methods MH - Humans MH - Learning Curve MH - Treatment Outcome MH - Urinary Bladder Neoplasms/surgery OTO - NOTNLM OT - Bibliometric analysis OT - Bladder cancer OT - Intracorporeal urinary diversion OT - Learning curve OT - Robot-assisted radical cystectomy COIS- Declarations. Competing interests: The authors declare that they have no financial or non-financial competing interests related to this study. Ethics approval and consent to participate: The present bibliometric analysis was conducted exclusively using publicly accessible bibliographic information and involved no human participants, animal experiments, or identifiable individual-level data. Accordingly, institutional ethics review and informed-consent procedures were not applicable. EDAT- 2026/08/07 12:39 MHDA- 2026/08/07 12:40 CRDT- 2026/08/07 11:17 PHST- 2026/07/10 00:00 [received] PHST- 2026/07/21 00:00 [accepted] PHST- 2026/08/07 12:40 [medline] PHST- 2026/08/07 12:39 [pubmed] PHST- 2026/08/07 11:17 [entrez] AID - 10.1007/s11701-026-03743-5 [pii] AID - 10.1007/s11701-026-03743-5 [doi] PST - epublish SO - J Robot Surg. 2026 Aug 7;20(1):806. doi: 10.1007/s11701-026-03743-5. PMID- 42541313 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260801 LR - 20260923 IS - 2589-5370 (Electronic) IS - 2589-5370 (Linking) VI - 98 DP - 2026 Aug TI - Multi-organ structural and functional deficits in association with long COVID: a population-based case-control study. PG - 104104 LID - 10.1016/j.eclinm.2026.104104 [doi] LID - 104104 AB - BACKGROUND: Multi-system impacts of long COVID remain unknown. We aimed to compare multi-system deficits between people with long COVID and controls. METHODS: We conducted a case-control study and recruited participants from two UK population-based cohorts: the Avon Longitudinal Study of Parents and Children (ALSPAC) and TwinsUK. Participants provided samples for SARS-CoV-2 serology between 2020 and 2021 and were asked about duration of COVID-19 symptoms between July and December 2021. Cases had long COVID (evidence of COVID-19 infection and persistent symptoms >/=4 weeks post infection); controls comprised 3 groups: acute COVID-19 only (symptoms reported for <4 weeks) and serological evidence of infection; self-reported long COVID-like symptoms but without wild-type SARS-CoV-2 virus antibodies; no symptoms or history of COVID-19 infection. People who were severely unwell or pregnant were excluded. Participants attended a clinic follow-up visit between 2021 and 2023 and underwent multi-system MRI, (cardiac, brain, lung, kidney), measurement of blood pressure and autonomic function, spirometry, renal function, exercise tests, strength and physical capability. Severity of deficit was then scored for each system as 0 (none) to 3 (severe). Primary outcome was a single composite multi-domain score summing each of nine domains: autonomic, brain, exercise capacity, heart, lungs, physical, renal, strength and vascular, with a maximum score of 27. FINDINGS: In total, 349 participants, 141 with long COVID (40%) and 208 (60%) controls were recruited. Overall deficit score in cases was 0.22 (95% CI -0.44, 0.88) units greater than controls, adjusted for age, sex, ethnicity, cohort membership and relatedness. This estimate was little changed (0.32 (-0.34, 0.98)) when additionally adjusted for educational status, index of multiple deprivation, physical activity, smoking and co-morbidity. Restricting cases to those reporting symptoms including fatigue (n = 46) increased the excess deficit score to 0.81 (-0.19, 1.81) units in the minimally adjusted model. A difference was only observed in the vascular domain, largely attributable to elevated blood pressure, showing a 1.76 (1.04, 2.97) multivariable adjusted odds ratio excess in cases, and 3.04 (1.36, 6.80) when restricted to cases with fatigue. INTERPRETATION: There was no evidence of marked residual subclinical deficits in most systems in people with long-COVID, although there was evidence of persistent deficits in the vascular system, largely related to elevated blood pressure. Mechanisms unrelated to organ dysfunction may contribute to symptoms. Blood pressure measurement and control should be included in clinical follow-up. FUNDING: Jointly funded by the National Institute for Health and Care Research and UK Research and Innovation (CONVALESCENCE, COV-LT-0009, MC_PC_20051). CI - (c) 2026 The Author(s). FAU - Fernandez-Sanles, Alba AU - Fernandez-Sanles A AD - Unit for Lifelong Health and Ageing, Institute of Cardiovascular Science, University College London, UK. FAU - Goudswaard, Lucy J AU - Goudswaard LJ AD - MRC Integrative Epidemiology Unit at the University of Bristol, UK. FAU - Williams, Dylan M AU - Williams DM AD - Unit for Lifelong Health and Ageing, Institute of Cardiovascular Science, University College London, UK. FAU - Raman, Betty AU - Raman B AD - Division of Cardiovascular Medicine, Radcliffe Department of Medicine, National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC), University of Oxford, UK. FAU - Thompson, Ellen J AU - Thompson EJ AD - Department of Twin Research and Genetic Epidemiology, School of Life Course & Population Sciences, King's College London, London, UK. AD - School of Psychology, Faculty of Science, Engineering and Medicine, University of Sussex, Falmer, UK. FAU - Orini, Michele AU - Orini M AD - Unit for Lifelong Health and Ageing, Institute of Cardiovascular Science, University College London, UK. AD - School of Biomedical Engineering & Imaging Sciences, King's College London, UK. FAU - Jones, Siana AU - Jones S AD - Unit for Lifelong Health and Ageing, Institute of Cardiovascular Science, University College London, UK. FAU - Jamieson, Alexandra AU - Jamieson A AD - Unit for Lifelong Health and Ageing, Institute of Cardiovascular Science, University College London, UK. FAU - Howes, Lee Hamill AU - Howes LH AD - Unit for Lifelong Health and Ageing, Institute of Cardiovascular Science, University College London, UK. FAU - Wong, Andrew AU - Wong A AD - Unit for Lifelong Health and Ageing, Institute of Cardiovascular Science, University College London, UK. FAU - Handa, Vedika AU - Handa V AD - Division of Cardiovascular Medicine, Radcliffe Department of Medicine, National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC), University of Oxford, UK. FAU - Sudre, Carole H AU - Sudre CH AD - Unit for Lifelong Health and Ageing, Institute of Cardiovascular Science, University College London, UK. AD - School of Biomedical Engineering & Imaging Sciences, King's College London, UK. AD - Department of Computer Science, Hawkes Institute, University College London, UK. FAU - Saunders, Laura C AU - Saunders LC AD - Department of Twin Research and Genetic Epidemiology, School of Life Course & Population Sciences, King's College London, London, UK. FAU - Cheetham, Nathan AU - Cheetham N AD - Department of Twin Research and Genetic Epidemiology, School of Life Course & Population Sciences, King's College London, London, UK. FAU - Whitmarsh, Alex AU - Whitmarsh A AD - MRC Integrative Epidemiology Unit at the University of Bristol, UK. FAU - Lochlainn, Mary Ni AU - Lochlainn MN AD - Department of Twin Research and Genetic Epidemiology, School of Life Course & Population Sciences, King's College London, London, UK. FAU - Wild, Jim AU - Wild J AD - Division of Clinical Medicine, School of Medicine & Population Health, University of Sheffield, UK. FAU - Smith, Stephen M AU - Smith SM AD - FMRIB, Nuffield Department of Clinical Neurosciences, Oxford University, Oxford, UK. FAU - Piechnik, Stefan AU - Piechnik S AD - Division of Cardiovascular Medicine, Radcliffe Department of Medicine, National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC), University of Oxford, UK. FAU - Neubauer, Stefan AU - Neubauer S AD - Division of Cardiovascular Medicine, Radcliffe Department of Medicine, National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC), University of Oxford, UK. FAU - Steves, Claire J AU - Steves CJ AD - Department of Twin Research and Genetic Epidemiology, School of Life Course & Population Sciences, King's College London, London, UK. FAU - Timpson, Nicholas J AU - Timpson NJ AD - MRC Integrative Epidemiology Unit at the University of Bristol, UK. FAU - Chaturvedi, Nish AU - Chaturvedi N AD - Unit for Lifelong Health and Ageing, Institute of Cardiovascular Science, University College London, UK. FAU - Hughes, Alun D AU - Hughes AD AD - Unit for Lifelong Health and Ageing, Institute of Cardiovascular Science, University College London, UK. CN - CONVALESCENCE study collaborativej CN - CONVALESCENCE study collaborative LA - eng PT - Journal Article DEP - 20260723 PL - England TA - EClinicalMedicine JT - EClinicalMedicine JID - 101733727 PMC - PMC13427505 OTO - NOTNLM OT - Autonomic OT - Brain OT - Cardiovascular OT - Exercise OT - Long-COVID-19 OT - Lung OT - Magnetic resonance imaging OT - Muscular COIS- This work is independent research jointly funded by the National Institute for Health and Care Research (NIHR) and UK Research and Innovation (UKRI) "Characterisation, determinants, mechanisms and consequences of the long-term effects of COVID-19: providing the evidence base for health care services (CONVALESCENCE), COV-LT-009". The views expressed in this publication are those of the author(s) and not necessarily those of NIHR, The Department of Health and Social Care or UKRI. AH and NC receive support from the British Heart Foundation, the National Institute for Health Research University College London Hospitals Biomedical Research Centre and the UK Medical Research Council. NC receives funds from AstraZeneca to participate in Data Safety and Monitoring Committees for clinical trials. AH additionally receives funds from the Wellcome Trust, Horizon 2020 and Horizon Europe Programmes of the European Union. MNL also received support from NIHR, the Chronic Disease Research Foundation, King's Population Health Institute and King's College London Climate and Sustainability Seed Fund, received a speaker fee from Nestle Ltd and holds a leadership or fiduciary role in the Irish Elderly Advice Network charity, the British Geriatric Society Research and Development Committee, the South London NIHR Research Delivery Network and the Vivensa Academy. BR received funding support from the NIHR Oxford Biomedical Research Centre Doctoral Fellowship, a British Heart Foundation Centre of Research Excellence Intermediate Clinical Transition Fellowship (RE/18/3/34214), a Wellcome Trust Career Development Award and received consulting fees from Imbria Pharmaceuticals. CS receives support from NIHR UCL Biomedical Research Centre and the BHF, and she participates on an Advisory Board for MONAI and Brain Key. DW receives support from Alzheimer's Research UK, University College London Hospital Biomedical Research Centre and Alzheimer's Society (UK). The BCCP received infrastructure support from the British Heart Foundation and the National Institute for Health Research University College London Hospitals Biomedical Research Centre. Alex Whitmarsh could not be contacted his disclosures are not known. No other authors declare interests. FIR - Al Saikhan, Lamia IR - Al Saikhan L FIR - Barkhof, Frederick IR - Barkhof F FIR - Captur, Gabriella IR - Captur G FIR - Carnemolla, Alisia IR - Carnemolla A FIR - Chaturvedi, Nish IR - Chaturvedi N FIR - Cheetham, Nathan IR - Cheetham N FIR - Dobson, Richard IR - Dobson R FIR - Fernandez-Sanles, Alba IR - Fernandez-Sanles A FIR - Goudswaard, Lucy J IR - Goudswaard LJ FIR - Green, Rebecca IR - Green R FIR - Howes, Lee Hamill IR - Howes LH FIR - Handa, Vedika IR - Handa V FIR - Hughes, Alun IR - Hughes A FIR - Jamieson, Alexandra IR - Jamieson A FIR - Jones, Siana IR - Jones S FIR - Lewis, Rebecca IR - Lewis R FIR - Muthurangu, Vivek IR - Muthurangu V FIR - Neubauer, Stefan IR - Neubauer S FIR - Lochlainn, Mary Ni IR - Lochlainn MN FIR - Orini, Michele IR - Orini M FIR - Park, Chloe IR - Park C FIR - Patalay, Praveetha IR - Patalay P FIR - Piechnik, Stefan IR - Piechnik S FIR - Popham, Maria IR - Popham M FIR - Raman, Betty IR - Raman B FIR - Rapala, Alicja IR - Rapala A FIR - Rojas, Natalia IR - Rojas N FIR - Saunders, Laura C IR - Saunders LC FIR - Shafran, Roz IR - Shafran R FIR - Smith, Stephen M IR - Smith SM FIR - Stephenson, Terence IR - Stephenson T FIR - Steves, Claire J IR - Steves CJ FIR - Sudre, Carole H IR - Sudre CH FIR - Thompson, Ellen J IR - Thompson EJ FIR - Timpson, Nicholas J IR - Timpson NJ FIR - Triebel, Thomas IR - Triebel T FIR - Whitmarsh, Alex IR - Whitmarsh A FIR - Wild, Jim IR - Wild J FIR - Williams, Dylan M IR - Williams DM FIR - Wong, Andrew IR - Wong A EDAT- 2026/08/02 00:30 MHDA- 2026/08/02 00:31 PMCR- 2026/07/23 CRDT- 2026/08/01 06:57 PHST- 2026/02/16 00:00 [received] PHST- 2026/07/03 00:00 [revised] PHST- 2026/07/07 00:00 [accepted] PHST- 2026/08/02 00:31 [medline] PHST- 2026/08/02 00:30 [pubmed] PHST- 2026/08/01 06:57 [entrez] PHST- 2026/07/23 00:00 [pmc-release] AID - S2589-5370(26)00357-3 [pii] AID - 104104 [pii] AID - 10.1016/j.eclinm.2026.104104 [doi] PST - epublish SO - EClinicalMedicine. 2026 Jul 23;98:104104. doi: 10.1016/j.eclinm.2026.104104. eCollection 2026 Aug. PMID- 42535123 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260731 LR - 20260923 IS - 2459-3087 (Electronic) IS - 2459-3087 (Linking) VI - 12 DP - 2026 TI - Barriers and facilitators to delivering tobacco cessation interventions at HIV care clinics in Sub-Saharan Africa: Qualitative application of the consolidated framework for implementation research. LID - 10.18332/tpc/221806 [doi] AB - INTRODUCTION: Tobacco use among people living with HIV (PLWH) in Sub-Saharan Africa (SSA) is prevalent, compounding health risks. Tobacco cessation interventions (TCIs) have shown promise but are not widely tested in HIV care settings. In this study, we applied the Consolidated Framework for Implementation Research (CFIR) to examine barriers and facilitators to implementing the adapted tobacco cessation intervention Quit4life+ for PLWH in Uganda and Zambia. METHODS: Guided by the CFIR determinant framework, Quit4life+ trial implementation challenges were evaluated across 16 HIV clinics in Uganda and Zambia between July 2021 and October 2025. Qualitative data were drawn from multiple sources, including 22 quarterly site visit reports, 4 health systems assessments completed by study coordinators and health facility personnel in-charge, key informant interviews with 14 clinic healthcare providers (nurses, nursing officers, and midwives), and focus group discussions with 55 PLWH (aged >/=18 years and receiving HIV care at participating clinics). Qualitative data were mapped to relevant domains and constructs. RESULTS: Within the innovation domain, evidence for TCIs, nicotine replacement therapy (NRT), and culturally adapted message libraries enhanced acceptability, while costs challenged adoption. Outer setting challenges, including seasonal labor demands, civil unrest, poor road access, and restrictive procurement and regulatory processes, influenced delivery. Inner setting barriers included overcrowded clinics, limited counseling space, inconsistent network connectivity, and staff turnover. Providers were motivated to support cessation but reported limited skills and faced intersecting stigma among patients. The implementation process relied on external resources, raising concerns about sustainability. CONCLUSIONS: Findings identify multilevel barriers and facilitators to delivering cessation support within HIV care clinics in Uganda and Zambia. Further research is needed to determine how determinants can be effectively addressed and to build the evidence base for the sustainable integration of services into HIV care across SSA. FAU - Guy, Kyra AU - Guy K AD - Department of Population and Public Health SciencesUniversity of Southern CaliforniaLos AngelesUnited States. FAU - Tsui, Jennifer AU - Tsui J AD - Department of Population and Public Health SciencesUniversity of Southern CaliforniaLos AngelesUnited States. FAU - Musasizi, Ezekiel AU - Musasizi E AD - School of Public HealthMakerere UniversityKampalaUganda. FAU - Kusolo, Ronald AU - Kusolo R AD - School of Public HealthMakerere UniversityKampalaUganda. FAU - Mukupa, Musawa AU - Mukupa M AD - Centre for Primary Care ResearchUniversity of ZambiaLusakaZambia. FAU - Arinaitwe, Jim AU - Arinaitwe J AD - School of Public HealthMakerere UniversityKampalaUganda. FAU - Goma, Fastone AU - Goma F AD - Centre for Primary Care ResearchUniversity of ZambiaLusakaZambia. FAU - Atuyambe, Lynn AU - Atuyambe L AD - School of Public HealthMakerere UniversityKampalaUganda. FAU - Guwatudde, David AU - Guwatudde D AD - School of Public HealthMakerere UniversityKampalaUganda. FAU - Phiri, Masauso M AU - Phiri MM AD - Centre for Primary Care ResearchUniversity of ZambiaLusakaZambia. FAU - Zyambo, Cosmas AU - Zyambo C AD - Centre for Primary Care ResearchUniversity of ZambiaLusakaZambia. FAU - Wipfli, Heather AU - Wipfli H AD - School of Public HealthUniversity of MarylandCollege ParkUnited States. LA - eng GR - U01 CA261624/CA/NCI NIH HHS/United States PT - Journal Article DEP - 20260729 PL - Greece TA - Tob Prev Cessat JT - Tobacco prevention & cessation JID - 101693412 PMC - PMC13422703 OTO - NOTNLM OT - cessation OT - global health OT - low/middle income countries OT - prevention OT - priority/special populations EDAT- 2026/07/31 12:39 MHDA- 2026/07/31 12:40 PMCR- 2026/07/30 CRDT- 2026/07/31 06:36 PHST- 2026/04/02 00:00 [received] PHST- 2026/05/11 00:00 [revised] PHST- 2026/05/13 00:00 [accepted] PHST- 2026/07/31 12:40 [medline] PHST- 2026/07/31 12:39 [pubmed] PHST- 2026/07/31 06:36 [entrez] PHST- 2026/07/30 00:00 [pmc-release] AID - 10.18332/TPC1389 [pii] AID - 10.18332/tpc/221806 [doi] PST - epublish SO - Tob Prev Cessat. 2026 Jul 29;12. doi: 10.18332/tpc/221806. eCollection 2026. PMID- 42504479 OWN - NLM STAT- MEDLINE DCOM- 20260727 LR - 20260824 IS - 1758-2652 (Electronic) IS - 1758-2652 (Linking) VI - 29 IP - 8 DP - 2026 Aug TI - The Impact of the Common Elements Treatment Approach on HIV Treatment Outcomes Among Women Experiencing Intimate Partner Violence in South Africa: A Randomized Trial. PG - e70172 LID - 10.1002/jia2.70172 [doi] LID - e70172 AB - INTRODUCTION: In South Africa, which has the world's highest prevalence of HIV, intimate partner violence (IPV) and common mental health conditions are barriers to retention in HIV treatment and achieving viral suppression. The Common Elements Treatment Approach (CETA), a cognitive-behavioural-therapy-based intervention designed for lay healthcare worker delivery, is effective in reducing mental and behavioural health problems but has not been trialled for effectiveness in improving HIV outcomes. We conducted a randomized control trial to evaluate the effectiveness of CETA in improving HIV treatment outcomes among women experiencing IPV in South Africa. METHODS: This was a single-blind trial conducted among women living with HIV on antiretroviral therapy (ART) who experienced sexual and/or physical IPV in the last 12 months and had either an unsuppressed viral load or were at risk for poor medication adherence in the past year (e.g. defaulted on treatment, late or missed clinic visit). Women were randomized 1:1 to receive either 8-12 CETA counselling sessions or weekly safety text messages. The primary outcome was viral suppression (101.5 g/L) and 0.677 for TG (cut-off >1.915 mmol/L). CONCLUSION: Relatively higher baseline Hb and TG levels are independently associated with increased AVF dysfunction risk, alongside anatomical and technical determinants. Individualized metabolic monitoring and optimized surgical selection are recommended to enhance fistula longevity. FAU - Liu, Jianwei AU - Liu J AUID- ORCID: 0009-0000-8897-1589 AD - Urology Department, Beijing You An Hospital, Capital Medical University, Beijing, China. FAU - Zhang, Yu AU - Zhang Y AD - Urology Department, Beijing You An Hospital, Capital Medical University, Beijing, China. FAU - Xie, Qingnan AU - Xie Q AD - Urology Department, Beijing You An Hospital, Capital Medical University, Beijing, China. FAU - Hu, Shaowen AU - Hu S AD - Urology Department, Beijing You An Hospital, Capital Medical University, Beijing, China. LA - eng PT - Journal Article DEP - 20260511 PL - United States TA - J Vasc Access JT - The journal of vascular access JID - 100940729 RN - 0 (Biomarkers) RN - 0 (Hemoglobins) SB - IM MH - Humans MH - *Arteriovenous Shunt, Surgical/adverse effects MH - *Renal Dialysis MH - *Vascular Patency MH - Risk Factors MH - Female MH - Retrospective Studies MH - Male MH - Time Factors MH - *Graft Occlusion, Vascular/physiopathology/etiology MH - Middle Aged MH - Aged MH - Risk Assessment MH - Treatment Outcome MH - *Kidney Failure, Chronic/therapy/diagnosis MH - Biomarkers/blood MH - Hemoglobins/metabolism MH - Thrombosis/physiopathology/etiology MH - Adult OTO - NOTNLM OT - Arteriovenous fistula OT - dysfunction OT - hemoglobin OT - patency rate OT - risk factors OT - triglycerides COIS- Declaration of conflicting interestsThe authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. EDAT- 2026/05/11 12:59 MHDA- 2026/09/07 11:37 CRDT- 2026/05/11 08:22 PHST- 2026/09/07 11:37 [medline] PHST- 2026/05/11 12:59 [pubmed] PHST- 2026/05/11 08:22 [entrez] AID - 10.1177/11297298261443398 [doi] PST - ppublish SO - J Vasc Access. 2026 Sep;27(5):2232-2245. doi: 10.1177/11297298261443398. Epub 2026 May 11. PMID- 42060363 OWN - NLM STAT- MEDLINE DCOM- 20260716 LR - 20260813 IS - 2063-5303 (Electronic) IS - 2062-5871 (Print) IS - 2062-5871 (Linking) VI - 15 IP - 2 DP - 2026 Jul 15 TI - A significant minority of Dutch gambling adverts on social media illegally targeted and likely reached under-24s: Assessing compliance using Meta's advertising repository mandated by the EU Digital Services Act. PG - 833-845 LID - 10.1556/2006.2026.00037 [doi] AB - BACKGROUND AND AIMS: Many countries have legalised gambling, negatively impacting public health. Stakeholders are particularly concerned about online gambling advertising harming young adults. The Netherlands has legalised offline and online gambling, but subsequently introduced restrictions on advertising. Specifically, advertisements must not target young adults aged between 18 and 23. The EU Digital Services Act requires major social media platforms to publish databases of all paid adverts shown and disclose which demographic groups were the intended targets and how many users were eventually reached. We assessed whether Dutch gambling ads on social media illegally targeted under-24s. METHODS: We systematically collected recent advertisements (N = 277) published by both online and offline Dutch gambling licensees and associated demographic targeting and reach data using Meta's Ad Library. We then assessed whether the age range of users targeted by those ads included prohibited targets. RESULTS: The compliance rate was 92.7% for online gambling licensee ads, but only 70.2% for offline licensee ads. DISCUSSION: A significant minority of gambling ads illegally targeted Dutch young adults under 24. Whilst compliance is relatively high, building some confidence, the regulator must robustly enforce the rule against all licensees. Meta should adopt platform-level changes to reduce compliance friction. CONCLUSIONS: Prohibiting gambling adverts from targeting vulnerable demographics using technology is a practicable policy. Legally mandated data access can facilitate public scrutiny of policy implementation, enhancing accountability. Other countries may benefit from emulating these Dutch gambling advertising restrictions and EU advertising transparency regulations, better protecting vulnerable consumer demographics and enabling local research. FAU - Xiao, Leon Y AU - Xiao LY AUID- ORCID: 0000-0003-0709-0777 AD - 1School of Creative Media, City University of Hong Kong, China. AD - 2School of Psychological Science, University of Bristol, UK. AD - 3beClaws.org, UK. FAU - Deery, Callum AU - Deery C AUID- ORCID: 0009-0000-2137-2952 AD - 1School of Creative Media, City University of Hong Kong, China. AD - 2School of Psychological Science, University of Bristol, UK. LA - eng PT - Journal Article DEP - 20260429 PL - Hungary TA - J Behav Addict JT - Journal of behavioral addictions JID - 101602037 SB - IM MH - Humans MH - *Gambling MH - Netherlands MH - *Advertising/legislation & jurisprudence/statistics & numerical data MH - *Social Media/statistics & numerical data/legislation & jurisprudence MH - Young Adult MH - Adolescent MH - European Union MH - Female MH - Male PMC - PMC13371776 OTO - NOTNLM OT - EU Digital Services Act OT - advertising regulation OT - data access OT - gambling law OT - policy compliance and implementation OT - social media OT - the Netherlands OT - transparency OT - youth protection COIS- Conflict of interests: L.Y.X. has provided paid consultancy and research services for (i) Public Group International Ltd (t/a PUBLIC) (Companies House number: 10608507), commissioned by the UK Department for Culture, Media and Sport (DCMS) to conduct independent research on understanding player experiences of loot box protections (October 2024 - May 2025); (ii) the Council of Europe International Cooperation Group on Drugs and Addiction (the Pompidou Group) on a project concerning the risks of online gambling and gaming to young people co-funded by the European Union via the Technical Support Instrument and implemented by the Council of Europe, in cooperation with the European Commission (December 2024 - May 2025); and (iii) the Institute of Public Health on a report concerning the advertising of harmful products to children funded by the Irish Department of Health and intended for its Online Health Taskforce (July 2025). L.Y.X. was supported by a PhD Fellowship funded by the IT University of Copenhagen [IT-Universitetet i Kobenhavn] (December 2021 - November 2024). L.Y.X. was employed by LiveMe, then a subsidiary of Cheetah Mobile (NYSE: CMCM), as an in-house counsel intern from July to August 2019 in Beijing, China. L.Y.X. was not involved with the monetisation of video games by Cheetah Mobile or its subsidiaries. L.Y.X. undertook a brief period of voluntary work experience at Wiggin LLP (Solicitors Regulation Authority number: 420659) in London, England, in August 2022. L.Y.X. has contributed to research projects enabled by data access provided by the video game industry, specifically Unity Technologies (NYSE:U) (October 2022 - August 2023). L.Y.X. has been invited to provide advice to the UK Department for Digital, Culture, Media and Sport and its successor (the Department for Culture, Media and Sport; DCMS) on the technical working group for loot boxes and the Video Games Research Framework. L.Y.X. was the (co-)recipient of three Academic Forum for the Study of Gambling (AFSG) postgraduate research support grants (March 2022, January 2023, and July 2024) and a minor exploratory research grant (May 2024) derived from 'regulatory settlements applied for socially responsible purposes' received by the UK Gambling Commission and administered by Gambling Research Exchange Ontario (GREO) and its successor (Greo Evidence Insights; Greo). L.Y.X. accepted funding to publish open-access academic papers from GREO and the AFSG that was received by the UK Gambling Commission as above (October, November, and December 2022, November 2023, and May 2024). L.Y.X. was the recipient of an Elite Research Travel Grant 2024 [EliteForsk-rejsestipendium 2024] awarded by the Agency for Higher Education and Science of the Danish Ministry of Higher Education and Science [Uddannelses-og Forskningsstyrelsen under Uddannelses-og Forskningsministeriet] (February 2024). L.Y.X. has accepted conference travel and attendance grants from the Socio-Legal Studies Association (February 2022 and February 2023); the Current Advances in Gambling Research Conference Organising Committee with support from GREO (February 2022); the International Relations Office of The Jagiellonian University (Uniwersytet Jagiellonski), the Polish National Agency for Academic Exchange (NAWA; Narodowa Agencja Wymiany Akademickiej), and the Republic of Poland (Rzeczpospolita Polska) with co-financing from the European Social Fund of the European Commission of the European Union under the Knowledge Education Development Operational Programme (May 2022); the Society for the Study of Addiction (November 2022, March 2023, and November 2024); the organisers of the 13th Nordic SNSUS (Stiftelsen Nordiska Sallskapet for Upplysning om Spelberoende; the Nordic Society Foundation for Information about Problem Gambling) Conference, which received gambling industry sponsorship (January 2023); the MiSK Foundation (Prince Mohammed bin Salman bin Abdulaziz Foundation) (November 2023); and the UK Gambling Commission (March 2024). L.Y.X. has received honoraria from the Center for Ludomani for contributing parent guides about mobile games for Tjekspillet.dk, which was funded by the Danish Ministry of Health's gambling addiction pool (Sundhedsministeriets Ludomanipulje) (March and December 2023), the Fundacio Publica Tecnocampus Mataro-Maresme (TecnoCampus Mataro-Maresme Foundation) for a guest lecture (November 2023), the Young Men's Christian Association (YMCA) of Greater Toronto Youth Gambling Awareness Program for a presentation, which was funded by the Government of Ontario, Canada (March 2024), Lunds universitet (Lund University) for the right to translate parent guides about mobile games into Swedish for Kollaspelet.se, which was funded by Mediamyndigheten (the Swedish Agency for the Media) and Barnahus Stockholm (December 2024); Shenkar College of Engineering, Design and Art for a guest lecture (December 2024); and DiGRA Korea and the Game-n-Science Institute [게임과학연구원] under the Game Culture Foundation [게임문화재단] under the Ministry of Culture, Sports and Tourism of South Korea [문화체육관광부] for participating in an academic research survey (January 2025). L.Y.X. received royalties by virtue of the copyright subsisting in some of his publications from the Authors' Licensing and Collecting Society (ALCS) (Companies House number: 01310636) (March 2023, 2024, & 2025). A full gifts and hospitality register-equivalent for L.Y.X. is available at: https://www.leonxiao.com/about/gifts-and-hospitality-register. The up-to-date version of L.Y.X.'s conflict-of-interest statement is available at: https://www.leonxiao.com/about/conflict-of-interest. C.D. was employed by the University of Bristol as a research assistant with research funding from the AFSG between October 2024 - April 2025. Copyright information about the figures in the article: The Open Access license of the article does not apply to the figures. EDAT- 2026/04/30 18:32 MHDA- 2026/07/16 18:45 PMCR- 2026/04/29 CRDT- 2026/04/30 12:03 PHST- 2026/01/23 00:00 [received] PHST- 2026/03/04 00:00 [revised] PHST- 2026/03/10 00:00 [accepted] PHST- 2026/07/16 18:45 [medline] PHST- 2026/04/30 18:32 [pubmed] PHST- 2026/04/30 12:03 [entrez] PHST- 2026/04/29 00:00 [pmc-release] AID - 2006.2026.00037 [pii] AID - 10.1556/2006.2026.00037 [doi] PST - epublish SO - J Behav Addict. 2026 Apr 29;15(2):833-845. doi: 10.1556/2006.2026.00037. Print 2026 Jul 15. PMID- 41965802 OWN - NLM STAT- MEDLINE DCOM- 20260715 LR - 20260813 IS - 1475-2875 (Electronic) IS - 1475-2875 (Linking) VI - 25 IP - 1 DP - 2026 Apr 11 TI - Combatting malaria together: key findings from a rapid formative assessment on Royal Thai Army malaria practices and military-civilian collaboration in Sisaket Province, Thailand. LID - 10.1186/s12936-026-05884-2 [doi] LID - 224 AB - BACKGROUND: In the Greater Mekong Subregion, militaries constitute a critical but often underserved malaria transmission reservoir, given their high mobility, deployment to endemic areas, and frequent exposure to vectors. In Thailand, the Royal Thai Army (RTA) is a key risk population, yet their malaria practices, perceptions, and the scale and scope of coordination with the Ministry of Public Health (MoPH) are not well understood. A joint military-civilian research team conducted a rapid formative assessment in Sisaket Province, a persistent transmission hotspot, to characterize the unique RTA risk profile and identify opportunities to strengthen RTA-MoPH coordination on malaria elimination efforts. METHODS: Using a mixed-methods design, the research team conducted a five-year (2016-2020) retrospective analysis of Sisaket's malaria case and program response data, alongside 16 focus group discussions (FGDs) and 17 key informant interviews (KIIs) with RTA and MoPH respondents across all military ranks and health system levels in the province's three highest-burden districts (Kantharalak, Khun Han, Phu Sing). Qualitative data were collected between December 2021-January 2022 and thematically analyzed using an inductive content analysis approach. Quantitative data were descriptively analyzed using statistical methods to characterize the RTA malaria risk profile and identify and compare recent trends in program response between military and non-military populations in Sisaket Province. RESULTS: 432 military malaria cases were reported in Sisaket between 2016 and 2020, accounting for 18% of the province's total 2425 cases (with the proportion ranging from 14 to 30% annually). All military malaria cases were male, with a median age of 28 years. 96% of military cases were diagnosed and treated at MoPH facilities, with 41% of cases classified as indigenous and 40% as imported from abroad. Qualitative data were collected from a total of 116 respondents (72 RTA, 44 MoPH) through 16 FGDs and 17 KIIs. Malaria prevention and treatment practices and perceptions among soldiers were largely consistent across the three study districts. RTA-MoPH coordination occurred at all levels through both formal and informal channels and was reported to be improving and expanding by some respondents. Though several areas could benefit from increased collaboration: patient follow-up, border control efforts, vector control, and further capacitation of military medics. The RTA and MoPH both expressed strong interest in strengthening military-civilian coordination; though to better enable this, several identified challenges may need to be addressed, including restricted MoPH access to military sites, lack of continuity in relationships due to frequent RTA rotations, communication constraints, and broader differences in military versus civilian operating procedures. CONCLUSION: Strengthening RTA-MoPH coordination towards successfully interrupting malaria transmission in Thailand may require formalizing and standardizing some joint operating procedures, increasing communication and military-civilian touchpoints, and further capacitating the RTA to carry out malaria prevention, diagnosis and treatment, and patient follow-up activities. For Thailand to achieve its goal of nationwide malaria elimination, it is crucial that the RTA as a high-risk population be fully engaged in the country's malaria control and response efforts. CI - (c) 2026. The Author(s). FAU - Dantzer, Emily AU - Dantzer E AD - Malaria Elimination Initiative, Institute for Global Health Sciences, University of California San Francisco (UCSF), 550 16th Street, San Francisco, CA, 94143, USA. emilydantzer@gmail.com. FAU - Tabprasit, Sutchana AU - Tabprasit S AD - Research Division, Armed Forces Research Institute of Medical Sciences (AFRIMS), Royal Thai Army, Bangkok, Thailand. FAU - Suwannarong, Kanokwan AU - Suwannarong K AD - SUPA71 Co., Ltd., Bangkok, Thailand. FAU - Jongsakul, Krisada AU - Jongsakul K AD - Department of Bacterial and Parasitic Diseases, Walter Reed Army Institute of Research - Armed Forces Research Institute of Medical Sciences (WRAIR-AFRIMS), Bangkok, Thailand. FAU - Kana, Khunakorn AU - Kana K AD - Research Division, Armed Forces Research Institute of Medical Sciences (AFRIMS), Royal Thai Army, Bangkok, Thailand. FAU - Dharmarak, Pratin AU - Dharmarak P AD - Freelance Consultant, Bangkok, Thailand. FAU - Feldman, Mitra AU - Feldman M AD - Independent Global Health Consultant, Silver Spring, MD, USA. FAU - Sudathip, Prayuth AU - Sudathip P AD - Division of Vector Borne Diseases, Department of Disease Control, Ministry of Public Health, Nonthaburi, Thailand. FAU - Chaiwan, Jintana AU - Chaiwan J AD - Malaria Elimination Initiative, Institute for Global Health Sciences, University of California San Francisco (UCSF), 550 16th Street, San Francisco, CA, 94143, USA. FAU - Yokani, Watcharee AU - Yokani W AD - Research Division, Armed Forces Research Institute of Medical Sciences (AFRIMS), Royal Thai Army, Bangkok, Thailand. FAU - Kramyoo, Min AU - Kramyoo M AD - Research Division, Armed Forces Research Institute of Medical Sciences (AFRIMS), Royal Thai Army, Bangkok, Thailand. FAU - Thammasutti, Kannika AU - Thammasutti K AD - SUPA71 Co., Ltd., Bangkok, Thailand. FAU - Cotter, Chris AU - Cotter C AD - Malaria Elimination Initiative, Institute for Global Health Sciences, University of California San Francisco (UCSF), 550 16th Street, San Francisco, CA, 94143, USA. AD - Department of Women's and Children's Health, Uppsala University, Uppsala, Sweden. LA - eng PT - Journal Article DEP - 20260411 PL - England TA - Malar J JT - Malaria journal JID - 101139802 SB - IM MH - Thailand/epidemiology MH - *Military Personnel/statistics & numerical data MH - Humans MH - *Malaria/prevention & control/epidemiology MH - Retrospective Studies MH - Male PMC - PMC13188233 OTO - NOTNLM OT - Greater Mekong Subregion OT - Malaria OT - Malaria elimination OT - Military OT - Military-civilian collaboration OT - Royal Thai Army OT - Thailand COIS- Declarations. Ethics approval and consent to participate: The research protocol (dated 21 July 2021) was reviewed and approved by the Committee on Human Research at the University of California, San Francisco (UCSF 20-32642), and the Royal Thai Army Medical Department Institutional Review Board (RTA FR 01 2563). The U.S. Army Medical Research and Development Command (USAMRDC), Office of Human and Animal Research Oversight (OHARO), and Office of Human Research Oversight (OHRO) approved the no greater than minimal risk study on 02 December 2021 (WRAIR #2904, OHRO Log Number E02893.1c.). Consent for publication: Not applicable. Competing interests: The authors declare no competing interests. EDAT- 2026/04/12 04:37 MHDA- 2026/05/21 06:31 PMCR- 2026/04/11 CRDT- 2026/04/11 23:21 PHST- 2025/12/16 00:00 [received] PHST- 2026/03/18 00:00 [accepted] PHST- 2026/05/21 06:31 [medline] PHST- 2026/04/12 04:37 [pubmed] PHST- 2026/04/11 23:21 [entrez] PHST- 2026/04/11 00:00 [pmc-release] AID - 10.1186/s12936-026-05884-2 [pii] AID - 5884 [pii] AID - 10.1186/s12936-026-05884-2 [doi] PST - epublish SO - Malar J. 2026 Apr 11;25(1):224. doi: 10.1186/s12936-026-05884-2. PMID- 41954737 OWN - NLM STAT- MEDLINE DCOM- 20261026 LR - 20261026 IS - 1432-1912 (Electronic) IS - 0028-1298 (Print) IS - 0028-1298 (Linking) VI - 399 IP - 9 DP - 2026 Jun TI - Changes in the consumption of immediate-release fentanyl between 2018 and 2022 in the province of Santa Cruz de Tenerife after the implementation of regulatory measures by health authorities. PG - 14091-14107 LID - 10.1007/s00210-026-05235-7 [doi] AB - In 2018, the Spanish Agency of Medicines and Medical Devices (AEMPS) issued a warning regarding the increasing use of immediate-release fentanyl (IRF) in Spain and recommended strict adherence to the approved indications. In April 2019, the regional government modified the electronic prescribing system to support this objective. In July 2021, the Ministry of Health implemented a restrictive prescribing and dispensing measure to further ensure compliance with the authorized indications. We analyzed trends in transmucosal IRF consumption in the province of Santa Cruz de Tenerife (SCTF) and across each of its constituent islands between 2018 and 2022. Additionally, we compared the evolution of IRF use in the province with national data for Spain. Data were obtained from pharmaceutical wholesalers supplying community pharmacies at the population level. IRF utilization was expressed as defined daily doses per 1000 inhabitants per day (DID). Linear regression models were applied to assess temporal trends. At baseline, IRF consumption in SCTF was approximately twice the national average. Marked heterogeneity in consumption patterns was observed across the different islands. Four distinct periods with differing trends were identified, three of which coincided with the implementation of new regulatory measures. Our findings indicate that annual IRF consumption in SCTF decreased by 54.76% between 2018 and 2022, representing a greater reduction than the national average. The 2018 warning had limited impact, whereas subsequent regional and national regulatory measures were associated with a substantial decline in IRF use. CI - (c) 2026. The Author(s). FAU - Pozuelo, Maria Rosario AU - Pozuelo MR AD - Departamento de Medicina Fisica y Farmacologia, Facultad de Farmacia, Universidad de La Laguna, Tenerife, Spain. FAU - Abdala-Kuri, Susana AU - Abdala-Kuri S AD - Departamento de Medicina Fisica y Farmacologia, Facultad de Farmacia, Universidad de La Laguna, Tenerife, Spain. sabdala@ull.edu.es. FAU - Oliva-Martin, Alexis AU - Oliva-Martin A AD - Departamento de Ingenieria Quimica y Tecnologia Farmaceutica, Facultad de Farmacia, Universidad de La Laguna, Tenerife, Spain. FAU - Pena-Vera, Adama AU - Pena-Vera A AD - Departamento de Medicina Fisica y Farmacologia, Facultad de Farmacia, Universidad de La Laguna, Tenerife, Spain. FAU - Morales-Marrero, Chaxiraxi AU - Morales-Marrero C AD - Departamento de Medicina Fisica y Farmacologia, Facultad de Farmacia, Universidad de La Laguna, Tenerife, Spain. FAU - Devora-Gutierrez, Sandra AU - Devora-Gutierrez S AD - Departamento de Medicina Fisica y Farmacologia, Facultad de Farmacia, Universidad de La Laguna, Tenerife, Spain. LA - eng PT - Journal Article DEP - 20260409 PL - Germany TA - Naunyn Schmiedebergs Arch Pharmacol JT - Naunyn-Schmiedeberg's archives of pharmacology JID - 0326264 RN - 0 (Analgesics, Opioid) RN - UF599785JZ (Fentanyl) SB - IM MH - Humans MH - *Analgesics, Opioid/administration & dosage/supply & distribution MH - *Drug and Narcotic Control/legislation & jurisprudence MH - Drug Prescriptions MH - *Drug Utilization/legislation & jurisprudence/statistics & numerical data MH - *Fentanyl/administration & dosage/supply & distribution MH - Spain PMC - PMC13357448 OTO - NOTNLM OT - AEMPS safety communication OT - Immediate-release fentanyl OT - Medication use OT - Prescription controlled system OT - Transmucosal fentanyl OT - Wholesaler COIS- Declarations. Ethics approval: Not applicable. Consent for publication: Not applicable. Conflicts of interest: The authors declare no competing interests. EDAT- 2026/04/09 12:45 MHDA- 2026/07/14 14:01 PMCR- 2026/04/09 CRDT- 2026/04/09 11:12 PHST- 2025/10/12 00:00 [received] PHST- 2026/03/16 00:00 [accepted] PHST- 2026/07/14 14:01 [medline] PHST- 2026/04/09 12:45 [pubmed] PHST- 2026/04/09 11:12 [entrez] PHST- 2026/04/09 00:00 [pmc-release] AID - 10.1007/s00210-026-05235-7 [pii] AID - 5235 [pii] AID - 10.1007/s00210-026-05235-7 [doi] PST - ppublish SO - Naunyn Schmiedebergs Arch Pharmacol. 2026 Jun;399(9):14091-14107. doi: 10.1007/s00210-026-05235-7. Epub 2026 Apr 9. PMID- 41952018 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260612 LR - 20260813 IS - 1750-0680 (Print) IS - 1750-0680 (Electronic) IS - 1750-0680 (Linking) VI - 21 IP - 1 DP - 2026 Apr 8 TI - Do carbon policy shocks move stocks? evidence from China's carbon market. LID - 10.1186/s13021-026-00424-6 [doi] LID - 85 AB - As carbon policies expand under net zero goals, policy news in carbon markets can send fast signals for equity prices. Using daily data for more than 1,600 listed firms from July 2021 to December 2025, we build carbon policy shocks from carbon price moves on 12 national ETS release days and estimate their link to stock returns. Carbon price changes on release days have a much stronger link to stock returns than changes on other days. Channel tests suggest the response is tied to shifts in short-run risk conditions and changes in trading conditions around release days. The effect is stronger when the carbon market is more mature and more active, and it differs by ETS coverage status, policy type and firm carbon exposure. The findings show how transition risk is priced in China and inform ETS communication and market depth. CI - (c) 2026. The Author(s). FAU - Peng, Jiachao AU - Peng J AD - School of Law and Business, Wuhan Institute of Technology, Wuhan, 430205, China. AD - Chinese Academy of International Trade and Economic Cooperation, Beijing, 100710, China. AD - School of Business Administration, Zhejiang Gongshang University, Hangzhou, 310018, China. FAU - Zeng, Yuxin AU - Zeng Y AD - School of Law and Business, Wuhan Institute of Technology, Wuhan, 430205, China. FAU - Fu, Shuke AU - Fu S AD - School of Law and Business, Wuhan Institute of Technology, Wuhan, 430205, China. FAU - Tian, Jiali AU - Tian J AD - School of Law and Business, Wuhan Institute of Technology, Wuhan, 430205, China. tjl@wit.edu.cn. LA - eng GR - 72303174/National Natrual Science Foundation of China/ PT - Journal Article DEP - 20260408 PL - England TA - Carbon Balance Manag JT - Carbon balance and management JID - 101271519 PMC - PMC13262435 OTO - NOTNLM OT - Carbon policy surprise OT - Carbon prices OT - China's national ETS OT - Stock returns OT - Transition risk pricing COIS- Declarations. Ethics approval and consent to participate: Not applicable. Consent for publication: Not applicable. Data availability: The data used in this study come from several publicly accessible and proprietary sources. Carbon price data are obtained from China's national carbon emissions trading market (CEA). Firm-level stock market data are collected from the Wind database, and firm-level carbon emission intensity data are compiled from companies' ESG reports. Policy event information is collected from official documents released by the Ministry of Ecology and Environment of the People's Republic of China.Due to licensing restrictions of the Wind database and firm-level ESG disclosures, the datasets generated and analyzed during the current study are available from the corresponding author upon reasonable request. Competing interests: The authors declare no competing interests. EDAT- 2026/04/09 00:34 MHDA- 2026/04/09 00:35 PMCR- 2026/04/08 CRDT- 2026/04/08 23:32 PHST- 2026/01/20 00:00 [received] PHST- 2026/02/27 00:00 [accepted] PHST- 2026/04/09 00:35 [medline] PHST- 2026/04/09 00:34 [pubmed] PHST- 2026/04/08 23:32 [entrez] PHST- 2026/04/08 00:00 [pmc-release] AID - 10.1186/s13021-026-00424-6 [pii] AID - 424 [pii] AID - 10.1186/s13021-026-00424-6 [doi] PST - epublish SO - Carbon Balance Manag. 2026 Apr 8;21(1):85. doi: 10.1186/s13021-026-00424-6. PMID- 41946424 OWN - NLM STAT- MEDLINE DCOM- 20260818 LR - 20260921 IS - 1873-2607 (Electronic) IS - 0749-3797 (Print) IS - 0749-3797 (Linking) VI - 71 IP - 3 DP - 2026 Sep TI - The Impact of the 2021 Child Tax Credit on Perinatal Health: Evidence From the Expansion and Postexpiration Periods. PG - 108360 LID - S0749-3797(26)00103-0 [pii] LID - 10.1016/j.amepre.2026.108360 [doi] AB - INTRODUCTION: The perinatal period is a pivotal life stage that profoundly influences lifelong health and well-being. In 2021, the U.S. temporarily expanded the Child Tax Credit, providing monthly payments during July-December 2021 and the remaining lump-sum payment during the 2022 tax season. This study examines the impact of the 2021 expansion on perinatal health among low-income families. METHODS: Data were drawn from national birth certificate data (January 2021-December 2022) and were restricted to women covered by Medicaid, who are likely to be low income. A quasi-experimental event-study design was used to compare perinatal outcomes over time between women with and without previous live births, who had different exposure patterns to the 2021 expansion (N=2,485,813). Analyses were conducted in January-May 2025. RESULTS: The Child Tax Credit expansion was associated with increased appropriate-for-gestational-age births and decreased small-for-gestational-age and large-for-gestational-age births. Effects were most pronounced immediately after expiration of monthly payments (1.17 percentage points; 95% CI=0.45, 1.88)-potentially reflecting the cumulative impact of 6 months of income support-and several months after the lump-sum distributions, waning by the end of 2022. For maternal outcomes, an increased likelihood of hypertensive disorders of pregnancy and a decreased likelihood of no/late prenatal care were observed during the monthly payments period and persisting through the end of 2022. Sensitivity analyses supported the robustness of the findings. CONCLUSIONS: These results suggest that the expanded Child Tax Credit had positive effects on certain perinatal outcomes among low-income families, highlighting the potential of income support policies to reduce health inequities during a critical life stage and informing policymaking. CI - Copyright (c) 2026 The Author(s). Published by Elsevier Inc. All rights reserved. FAU - Wang, Guangyi AU - Wang G AD - Institute for Health Policy Studies, University of California San Francisco, San Francisco, California; Department of Social and Behavioral Sciences, Harvard School of Public Health, Boston, Massachusetts. Electronic address: guangyi.wang@ucsf.edu. FAU - Jackson, Kaitlyn E AU - Jackson KE AD - Department of Social and Behavioral Sciences, Harvard School of Public Health, Boston, Massachusetts. FAU - Hamad, Rita AU - Hamad R AD - Department of Social and Behavioral Sciences, Harvard School of Public Health, Boston, Massachusetts. LA - eng GR - P30 DK092924/DK/NIDDK NIH HHS/United States GR - U24 AG076462/AG/NIA NIH HHS/United States PT - Journal Article DEP - 20260405 PL - Netherlands TA - Am J Prev Med JT - American journal of preventive medicine JID - 8704773 SB - IM MH - Humans MH - Female MH - United States MH - *Taxes MH - Pregnancy MH - *Poverty/statistics & numerical data MH - Infant, Newborn MH - Medicaid/economics/statistics & numerical data MH - Pregnancy Outcome/epidemiology PMC - PMC13181731 MID - NIHMS2165029 COIS- Declaration of Interest: The authors have no conflicts of interest relevant to this article to disclose. EDAT- 2026/04/08 00:30 MHDA- 2026/08/18 23:36 PMCR- 2026/05/19 CRDT- 2026/04/07 19:13 PHST- 2025/10/14 00:00 [received] PHST- 2026/03/30 00:00 [revised] PHST- 2026/04/02 00:00 [accepted] PHST- 2026/08/18 23:36 [medline] PHST- 2026/04/08 00:30 [pubmed] PHST- 2026/04/07 19:13 [entrez] PHST- 2026/05/19 00:00 [pmc-release] AID - S0749-3797(26)00103-0 [pii] AID - 10.1016/j.amepre.2026.108360 [doi] PST - ppublish SO - Am J Prev Med. 2026 Sep;71(3):108360. doi: 10.1016/j.amepre.2026.108360. Epub 2026 Apr 5. PMID- 41882694 OWN - NLM STAT- MEDLINE DCOM- 20260627 LR - 20260813 IS - 1471-2482 (Electronic) IS - 1471-2482 (Linking) VI - 26 IP - 1 DP - 2026 Mar 25 TI - Elevated central venous-intrabdominal pressure associated with higher incidence of acute kidney injury following cardiac surgery in pediatric patients: a prospective observational study. LID - 10.1186/s12893-026-03667-9 [doi] LID - 308 AB - OBJECTIVE: The occurrence and development of acute kidney injury (AKI) is closely related to renal hemodynamic dysfunction. The sum of central venous pressure (CVP) and intra-abdominal pressure (IAP) which named Central venous-intrabdominal pressure (CIP) in exploring the relationship with postoperative AKI in pediatric cardiac surgery has received limited exploration yet. Our study sought to investigate the association between CIP and AKI following pediatric cardiac surgery. METHODS: This single-center prospective observational study included pediatric patients who underwent open-heart surgery between 2020 and 2021. The subject was divided into two groups according to the median value of CIP which measured and recorded 12 h after admission to the ICU. Three Logistic regression models and restricted cubic spline (RCS) functions assessed the connections between the CIP and AKI. Propensity score matching (PSM) was applied to attenuate the confounding interference of the covariates. RESULTS: A total of 279 pediatric patients were enrolled in this study, among which 64 patients developed AKI (22.94%). The median of CIP was 17mmHg. The incidence of AKI in the group of CIP>17mmHg was significantly higher than those in the group of CIP<17mmHg (47/159 vs. 17/120, P = 0.003).CIP monitored in patients with AKI was significantly higher than those without AKI at 12 h in ICU (19.5 vs. 18.0, p<0.001). The odds ratio of the full adjusted model was 2.35[(1.19 ~ 4.83), p = 0.016]. The results showed the same trend after PSM. No apparent non-linear relationship were found using RCS analysis. CONCLUSIONS: This study offers preliminary evidence of an association between elevated CIP and higher risk of AKI following cardiac surgery in pediatric patients. CIP may serve as a potential and early risk factor for AKI after cardiac surgery. Given the observational design and potential for unmeasured confounding, these results should be considered hypothesis-generating. They are intended to inform the design of future prospective studies rather than to support immediate clinical intervention. TRIAL REGISTRATION: ClinicalTrials.gov Identifier ChiCTR2000034322 on July 2, 2020. FAU - Wang, Shouping AU - Wang S AD - Department of Intensive Care Unit, West China Hospital, Sichuan University, Chengdu, China. FAU - Niu, Wang AU - Niu W AD - Department of Anesthesiology, Chinese Academy of Medical Sciences, West China Hospital, Sichuan University and the Research Units of West China (2018RU012), Chengdu, China. FAU - Zeng, Jiarong AU - Zeng J AD - Department of Intensive Care Unit, West China Hospital, Sichuan University, Chengdu, China. FAU - Gao, Kui AU - Gao K AD - Department of Anesthesiology, The General Hospital of Western Theater Command, Chengdu, China. FAU - Deng, Lijing AU - Deng L AD - Department of Intensive Care Unit, West China Hospital, Sichuan University, Chengdu, China. denglijing@wchscu.cn. FAU - He, Min AU - He M AD - Department of Intensive Care Unit, West China Hospital, Sichuan University, Chengdu, China. hemin19910306@wchscu.cn. LA - eng GR - 2023ZYD0168/Sichuan Science and Technology Program/ GR - 2023ZD0502400/Noncommunicable Chronic Diseases-National Science and Technology Major Project/ PT - Journal Article PT - Observational Study DEP - 20260325 PL - England TA - BMC Surg JT - BMC surgery JID - 100968567 SB - IM MH - Humans MH - *Acute Kidney Injury/epidemiology/etiology/physiopathology MH - Prospective Studies MH - *Cardiac Surgical Procedures/adverse effects MH - Female MH - Incidence MH - Male MH - *Central Venous Pressure MH - Infant MH - *Postoperative Complications/epidemiology/etiology/physiopathology MH - Child, Preschool MH - Child MH - Risk Factors MH - *Intra-Abdominal Hypertension/complications PMC - PMC13137686 OTO - NOTNLM OT - Acute kidney injury OT - Central venous pressure OT - Intra-abdominal hypertension OT - Prognosis COIS- Declarations. Ethics approval and consent to participate: The study protocol was approved by The Biomedical Research Ethics Committee of West China Hospital of Sichuan University [Approval number: 2020(547)]. All legal guardians of pediatrics provided written informed consent before participation and they can withdraw from the study at any time. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests. EDAT- 2026/03/26 07:08 MHDA- 2026/06/28 00:38 PMCR- 2026/03/25 CRDT- 2026/03/26 00:51 PHST- 2025/12/06 00:00 [received] PHST- 2026/03/12 00:00 [accepted] PHST- 2026/06/28 00:38 [medline] PHST- 2026/03/26 07:08 [pubmed] PHST- 2026/03/26 00:51 [entrez] PHST- 2026/03/25 00:00 [pmc-release] AID - 10.1186/s12893-026-03667-9 [pii] AID - 3667 [pii] AID - 10.1186/s12893-026-03667-9 [doi] PST - epublish SO - BMC Surg. 2026 Mar 25;26(1):308. doi: 10.1186/s12893-026-03667-9. PMID- 41825914 OWN - NLM STAT- MEDLINE DCOM- 20260710 LR - 20260910 IS - 2059-7908 (Print) IS - 2059-7908 (Electronic) IS - 2059-7908 (Linking) VI - 11 IP - 3 DP - 2026 Mar 13 TI - Lingering sex and age disparities in dolutegravir uptake among adults with HIV: a multicountry observational cohort study. LID - 10.1136/bmjgh-2025-020159 [doi] LID - e020159 AB - INTRODUCTION: Since July 2019, the WHO has recommended dolutegravir (DTG)-based regimens as preferred first-line antiretroviral therapy (ART) for adults and adolescents living with HIV (DTG-for-All), a reversal of a 2018 safety alert on use of DTG-based regimens by women of reproductive age (WRA). We examined sex and age disparities in DTG uptake before and after DTG-for-All in the International epidemiology Databases to Evaluate AIDS. METHODS: We included patients >/=16 years on or initiating treatment between January 2017 and July 2021 in 14 low- and middle-income countries where initial guidelines on DTG-based regimens for first-line ART either restricted use by WRA or had no such restrictions. We estimated the cumulative incidence of DTG uptake (CI-DTG) by sex and age group (aged 16-49 years vs 50+ years), stratified by patient, clinic and setting characteristics. RESULTS: Among 177 706 patients on ART during the study period, 51% were females aged 16-49 years, with 25% males aged 16-49 and 13% and 11%, respectively, females and males aged 50+. At the time of DTG-for-All, overall CI-DTG was 29.6% (95% CI 29.4% to 29.8%); it was lower among females aged 16-49 (16.2%; 95% CI 16.0% to 16.5%) than males (41.1%; 95% CI 40.6% to 41.5%), with no sex disparities among patients aged 50+ (females: 46.0%; males: 47.0%). While DTG uptake subsequently increased among all groups, by July 2021, it remained substantially lower among females 16-49 (66.4%; 95% CI 66.1% to 66.7%), compared with males 16-49 and older females and males (75.8% to 77.5%). Concentrated in countries where initial guidelines on DTG restricted use by WRA, disparities in DTG uptake persisted at all health system levels and in both low-income and lower-middle-income countries. CONCLUSIONS: While sex-age differentials in DTG uptake narrowed after WHO's DTG-for-All recommendation, lingering disparities in uptake underscore the difficulty of policy de-implementation when new evidence emerges. CI - (c) Author(s) (or their employer(s)) 2026. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group. FAU - Brazier, Ellen AU - Brazier E AUID- ORCID: 0000-0002-8514-1958 AD - Institute for Implementation Science in Population Health, City University of New York, Graduate School of Public Health and Health Policy, New York, New York, USA Ellen.Brazier@sph.cuny.edu. FAU - Romo, Matthew L AU - Romo ML AD - Institute for Implementation Science in Population Health, City University of New York, Graduate School of Public Health and Health Policy, New York, New York, USA. FAU - Ciaranello, Andrea L AU - Ciaranello AL AD - Medical Practice Evaluation Center, Massachusetts General Hospital, Boston, Massachusetts, USA. AD - Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA. FAU - Odhiambo, Francesca AU - Odhiambo F AD - Centre for Microbiology Research, Kenya Medical Research Institute, Nairobi, Nairobi County, Kenya. FAU - Pujari, Sanjay AU - Pujari S AD - Institute of Infectious Diseases, Pune, India. FAU - Murenzi, Gad AU - Murenzi G AUID- ORCID: 0000-0002-5513-5522 AD - School of Public Health, College of Medicine and Health Sciences, University of Rwanda, Kigali, Rwanda. AD - Goodlife Access, Kigali, Rwanda. FAU - Kasozi, Charles AU - Kasozi C AD - Department of Public Health, Masaka Regional Referral Hospital, Masaka, Uganda. FAU - Kiertiburanakul, Sasisopin AU - Kiertiburanakul S AD - Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand. FAU - Nsonde, Dominique Mahambu AU - Nsonde DM AD - Centre de Traitement Ambulatoire Brazzaville, Brazzaville, Congo. FAU - Muyindike, Winnie AU - Muyindike W AD - Mbarara National Referral Hospital, Mbarara, Mbarara, Uganda. AD - Department of Medicine, Mbarara University of Science and Technology, Mbarara, Uganda. FAU - Khol, Vohith AU - Khol V AD - National Center for HIV/AIDS, Dermatology and STDs, Phnom Penh, Cambodia. FAU - Lelo, Patricia AU - Lelo P AD - Department of Infectious Diseases, Kalembelembe Pediatric Hospital, Kinshasa, Congo (the Democratic Republic of the). FAU - Lyamuya, Rita AU - Lyamuya R AD - Care and Treatment Centre, Morogoro Regional Hospital, Morogoro, Tanzania. FAU - Lee, Man Po AU - Lee MP AUID- ORCID: 0009-0000-8591-4773 AD - Queen Elizabeth Hospital, Hong Kong, SAR, China. FAU - Nash, Denis AU - Nash D AD - Institute for Implementation Science in Population Health, City University of New York, Graduate School of Public Health and Health Policy, New York, New York, USA. AD - City University of New York, Graduate School of Public Health and Health Policy, New York, New York, USA. LA - eng GR - R24 AI124872/AI/NIAID NIH HHS/United States GR - U01 AI069907/AI/NIAID NIH HHS/United States GR - U01 AI069911/AI/NIAID NIH HHS/United States GR - U01 AI096299/AI/NIAID NIH HHS/United States PT - Journal Article PT - Multicenter Study PT - Observational Study DEP - 20260313 PL - England TA - BMJ Glob Health JT - BMJ global health JID - 101685275 RN - 0 (Piperazines) RN - 0 (Heterocyclic Compounds, 3-Ring) RN - 0 (Pyridones) RN - DKO1W9H7M1 (Dolutegravir) RN - 0 (Oxazines) RN - 0 (HIV Integrase Inhibitors) SB - IM UOF - medRxiv. 2025 May 23:2025.05.23.25325682. doi: 10.1101/2025.05.23.25325682. PMID: 40661277 MH - Humans MH - Adult MH - Female MH - *Piperazines/therapeutic use MH - *Heterocyclic Compounds, 3-Ring/therapeutic use MH - *Pyridones/therapeutic use MH - Middle Aged MH - Dolutegravir MH - Adolescent MH - Male MH - *Oxazines/therapeutic use MH - *HIV Infections/drug therapy MH - Young Adult MH - Age Factors MH - Sex Factors MH - *HIV Integrase Inhibitors/therapeutic use MH - Cohort Studies PMC - PMC12993343 OTO - NOTNLM OT - Cohort study OT - HIV OT - Health services research OT - Treatment COIS- Competing interests: AC reports institutional grants from NIH and serves as US Department of Health and Human Services Perinatal HIV Guidelines Panel Member and Co-Chair. DN reports institutional funding from NIH, and from the New York State AIDS Institute and Pfizer for unrelated research, and honouraria from the NIH Centers for AIDS Research, Yale Center for Interdisciplinary Research on AIDS and George Washington University School of Public Health. All authors have declared that no competing interests exist. EDAT- 2026/03/14 00:31 MHDA- 2026/03/14 00:32 PMCR- 2026/03/13 CRDT- 2026/03/13 21:03 PHST- 2025/04/11 00:00 [received] PHST- 2026/02/03 00:00 [accepted] PHST- 2026/03/14 00:32 [medline] PHST- 2026/03/14 00:31 [pubmed] PHST- 2026/03/13 21:03 [entrez] PHST- 2026/03/13 00:00 [pmc-release] AID - bmjgh-2025-020159 [pii] AID - 10.1136/bmjgh-2025-020159 [doi] PST - epublish SO - BMJ Glob Health. 2026 Mar 13;11(3):e020159. doi: 10.1136/bmjgh-2025-020159. PMID- 41803706 OWN - NLM STAT- MEDLINE DCOM- 20260628 LR - 20260813 IS - 1129-2377 (Electronic) IS - 1129-2369 (Print) IS - 1129-2369 (Linking) VI - 27 IP - 1 DP - 2026 Mar 9 TI - Safety and efficacy of occipital nerve stimulation as treatment of chronic cluster headache: an investigator-initiated, double-blind, randomized, placebo-controlled study. LID - 10.1186/s10194-026-02312-3 [doi] LID - 77 AB - BACKGROUND: Occipital nerve stimulation has shown promising results in attack prevention in patients with chronic cluster headache, but evidence from controlled trials is scarce. Conventional (tonic) occipital nerve stimulation elicits paresthesia, hampering blinded comparison to placebo. Using paresthesia-free burst occipital nerve stimulation, we conducted a randomized, placebo-controlled trial. METHODS: The study is an investigator-initiated, double-blind, randomized, placebo-controlled clinical trial involving participants with chronic cluster headache. It comprised a four-week baseline, a 12-week trial with transcutaneous electrical nerve stimulation, occipital nerve stimulator implantation, a 12-week randomized, double-blind burst occipital nerve stimulation treatment period, and a 12-week open-label tonic occipital nerve stimulation treatment period. The primary outcomes were safety and the proportion of participants reporting a >/=30% reduction in attack frequency in the randomized and open-label trial phases. RESULTS: Participants were enrolled between August 2021 and October 2023. 116 chronic cluster headache patients were assessed for eligibility. Sixty-five were excluded, and 51 entered baseline observation. Before occipital nerve stimulator implantation and randomization, an additional 13 were excluded. Thirty-eight participants underwent occipital nerve stimulator implantation and were randomly assigned to burst occipital nerve stimulation (n = 19) or placebo (n = 19). After the randomized trial phase, the proportion of >/=30% responders was 18.81% (95%CI 0.28%-37.87%) in the burst occipital nerve stimulation group and 50.02% (95%CI 26.87%-73.09%) in the placebo group. The likelihood of reaching the primary endpoint was 31.20% (95%CI 1.29%-61.23%, p = 0.042) higher in the placebo group. After the open-label phase, 42.09% (95%CI 19.91%-64.34%) in the burst occipital nerve stimulation group and 51.11% (95%CI 27.32%-74.88%) in the placebo group had >/=30% frequency reduction. In total, 20 adverse events were registered; eight were treatment-related serious adverse events. The most common adverse event was temporary occipital dysesthesia in eight participants. DISCUSSION: Occipital nerve stimulation reduced attack frequency but was not superior to placebo. The treatment had an acceptable safety profile and was well-tolerated. The results call for attention to sufficient placebo control when planning further studies. TRIAL REGISTRATION: The trial is registered at clinicaltrials.gov (identifier NCT05023460).Study registration date: July 27th 2021. FAU - Fogh-Andersen, Ida Stisen AU - Fogh-Andersen IS AUID- ORCID: 0000-0002-5328-9907 AD - Department of Neurosurgery, Aarhus University Hospital, Aarhus, Denmark. AD - Center for Experimental Neuroscience (CENSE), Department of Clinical Medicine, Aarhus University, Aarhus, Denmark. FAU - Sorensen, Jens Christian Hedemann AU - Sorensen JCH AUID- ORCID: 0000-0001-5139-7405 AD - Department of Neurosurgery, Aarhus University Hospital, Aarhus, Denmark. AD - Center for Experimental Neuroscience (CENSE), Department of Clinical Medicine, Aarhus University, Aarhus, Denmark. FAU - Petersen, Anja Sofie AU - Petersen AS AUID- ORCID: 0000-0002-0125-6038 AD - Danish Headache Centre, Rigshospitalet-Glostrup, Copenhagen University Hospital, Copenhagen, Denmark. FAU - Jensen, Rigmor Hojland AU - Jensen RH AUID- ORCID: 0000-0001-6433-5887 AD - Danish Headache Centre, Rigshospitalet-Glostrup, Copenhagen University Hospital, Copenhagen, Denmark. AD - Institute of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark. FAU - Meier, Kaare AU - Meier K AUID- ORCID: 0000-0001-7677-406X AD - Department of Neurosurgery, Aarhus University Hospital, Aarhus, Denmark. kaamei@rm.dk. AD - Center for Experimental Neuroscience (CENSE), Department of Clinical Medicine, Aarhus University, Aarhus, Denmark. kaamei@rm.dk. AD - Department of Anesthesiology, Aarhus University Hospital, Aarhus, Denmark. kaamei@rm.dk. LA - eng SI - ClinicalTrials.gov/NCT05023460 PT - Journal Article PT - Randomized Controlled Trial DEP - 20260309 PL - England TA - J Headache Pain JT - The journal of headache and pain JID - 100940562 SB - IM MH - Humans MH - *Cluster Headache/therapy MH - Double-Blind Method MH - Female MH - Male MH - Adult MH - Middle Aged MH - Treatment Outcome MH - *Transcutaneous Electric Nerve Stimulation/methods MH - *Spinal Nerves MH - *Electric Stimulation Therapy/methods PMC - PMC12980930 COIS- Declarations. Ethics approval: The protocol was approved by the independent regional scientific ethics committee (permit number VEK: 1-10-72-36-21). The Central Denmark Region authorized the acquisition, storage, and analysis of data (permit number 1-16-02-577-20). All participants provided signed informed consent before enrolling in the study. Consent for publication: Not applicable. Competing interests: JCHS has received a restricted research grant (for the institution) from the Novo Nordisk Foundation. KM has received teaching fees from Medtronic and consulting fees from Salvia BioElectronics. KM and JCHS are co-owners and co-founders of the neuromodulation database company Neurizon. RJ received restricted research grants (for the institution) from Lundbeck Pharma and the Novo Nordisk Foundation. RJ has received personal fees for educational and teaching activities from Pfizer, Teva, Novartis, Abbvie, Lundbeck Pharma, and Eli-Lilly, and a fee (for the institution) for serving on the Lundbeck Pharma Advisory Board. RJ is the chair of the Master of Headache Disorders, Director of the Danish Headache Center, and unpaid activities as Director in Lifting the Burden. ASP has received a restricted research grant (for the institution), conference attendance from Lundbeck Pharma, and personal fees from Pfizer for teaching activities. ISFA has nothing to declare. EDAT- 2026/03/10 07:00 MHDA- 2026/06/28 06:35 PMCR- 2026/03/09 CRDT- 2026/03/10 00:44 PHST- 2025/11/29 00:00 [received] PHST- 2026/02/19 00:00 [accepted] PHST- 2026/06/28 06:35 [medline] PHST- 2026/03/10 07:00 [pubmed] PHST- 2026/03/10 00:44 [entrez] PHST- 2026/03/09 00:00 [pmc-release] AID - 10.1186/s10194-026-02312-3 [pii] AID - 2312 [pii] AID - 10.1186/s10194-026-02312-3 [doi] PST - epublish SO - J Headache Pain. 2026 Mar 9;27(1):77. doi: 10.1186/s10194-026-02312-3. PMID- 41785272 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260305 LR - 20260813 IS - 2767-3375 (Electronic) IS - 2767-3375 (Linking) VI - 6 IP - 3 DP - 2026 TI - Native American resilience to protect family nutrition during a pandemic: A qualitative analysis. PG - e0004822 LID - 10.1371/journal.pgph.0004822 [doi] LID - e0004822 AB - Native American (NA) communities have a history of being forced to adapt to adversity and leverage cultural strengths to cope with nutrition injustices. For generations, NA families in the United States (US) have experienced ongoing burdens from colonization-related disruptions to traditional foodways, resulting in disproportionately high prevalence of food and drinking water insecurity and related early childhood obesity. The COVID-19 pandemic further exacerbated these disparities. This study qualitatively explored NA families' experiences with food access, water access and early childhood feeding during the COVID-19 pandemic. We further sought to identify resilience factors and specific response strategies that families employed to deal with challenges brought about by the pandemic. A total of 53 in-depth interviews were conducted with NA mothers (mean age 21.2 years) of children 0-3 years old living in reservation-based Southwest communities in the US. Study participants were a sub-sample of mothers from a home visiting study that was disrupted by COVID-19 in 2020. Interviews were conducted between July, 2021 and February, 2022. Findings suggest that pandemic lockdowns and store restrictions magnified existing challenges and barriers to accessing food and water. Families leveraged resilience factors, including family support and practicing traditional foodways, to minimize negative impacts on child feeding practices. Understanding the social and cultural resilience factors used to cope with pandemic challenges from an NA perspective can inform future strategies to improve food and water access and support positive child feeding practices for NA families, especially during public health crises. CI - Copyright: (c) 2026 Vanegas et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. FAU - Vanegas, Sarah AU - Vanegas S AUID- ORCID: 0009-0005-1388-7901 AD - Department of International Health, Johns Hopkins University, Bloomberg School of Public Health, Baltimore, Maryland, United States of America. FAU - Cuddy, Reese AU - Cuddy R AUID- ORCID: 0009-0000-5531-5673 AD - Department of International Health, Johns Hopkins University, Bloomberg School of Public Health, Baltimore, Maryland, United States of America. FAU - Billey, Taylor AU - Billey T AD - Department of International Health, Johns Hopkins University, Bloomberg School of Public Health, Baltimore, Maryland, United States of America. FAU - Jones, Tanya AU - Jones T AD - Department of International Health, Johns Hopkins University, Bloomberg School of Public Health, Baltimore, Maryland, United States of America. FAU - Pablo, Karlita AU - Pablo K AD - Department of International Health, Johns Hopkins University, Bloomberg School of Public Health, Baltimore, Maryland, United States of America. FAU - Goklish, Novalene AU - Goklish N AD - Department of International Health, Johns Hopkins University, Bloomberg School of Public Health, Baltimore, Maryland, United States of America. FAU - Thacker, Ashley AU - Thacker A AUID- ORCID: 0009-0004-3349-7620 AD - Department of International Health, Johns Hopkins University, Bloomberg School of Public Health, Baltimore, Maryland, United States of America. FAU - Nelson, Leonela AU - Nelson L AD - Department of International Health, Johns Hopkins University, Bloomberg School of Public Health, Baltimore, Maryland, United States of America. FAU - Tessay, Robin AU - Tessay R AD - Department of International Health, Johns Hopkins University, Bloomberg School of Public Health, Baltimore, Maryland, United States of America. FAU - Neault, Nicole AU - Neault N AD - Department of International Health, Johns Hopkins University, Bloomberg School of Public Health, Baltimore, Maryland, United States of America. FAU - Nelson, Katie E AU - Nelson KE AUID- ORCID: 0000-0002-0264-7292 AD - Department of International Health, Johns Hopkins University, Bloomberg School of Public Health, Baltimore, Maryland, United States of America. FAU - Yazzie, Kimberlyn AU - Yazzie K AD - Department of International Health, Johns Hopkins University, Bloomberg School of Public Health, Baltimore, Maryland, United States of America. FAU - Barlow, Allison AU - Barlow A AD - Department of International Health, Johns Hopkins University, Bloomberg School of Public Health, Baltimore, Maryland, United States of America. LA - eng PT - Journal Article DEP - 20260305 PL - United States TA - PLOS Glob Public Health JT - PLOS global public health JID - 9918283779606676 PMC - PMC12962456 COIS- The authors have declared that no competing interests exist. EDAT- 2026/03/06 09:03 MHDA- 2026/03/06 09:04 PMCR- 2026/03/05 CRDT- 2026/03/05 13:43 PHST- 2025/06/13 00:00 [received] PHST- 2026/02/17 00:00 [accepted] PHST- 2026/03/06 09:04 [medline] PHST- 2026/03/06 09:03 [pubmed] PHST- 2026/03/05 13:43 [entrez] PHST- 2026/03/05 00:00 [pmc-release] AID - PGPH-D-25-01405 [pii] AID - 10.1371/journal.pgph.0004822 [doi] PST - epublish SO - PLOS Glob Public Health. 2026 Mar 5;6(3):e0004822. doi: 10.1371/journal.pgph.0004822. eCollection 2026. PMID- 41781141 OWN - NLM STAT- MEDLINE DCOM- 20260710 LR - 20260813 IS - 1750-2659 (Electronic) IS - 1750-2640 (Print) IS - 1750-2640 (Linking) VI - 20 IP - 3 DP - 2026 Mar TI - Global Epidemiology of Human Adenoviruses, 2016-2024: A Pre- and Post-COVID-19 Analysis of Circulation Patterns and Epidemic Timing. PG - e70236 LID - 10.1111/irv.70236 [doi] LID - e70236 AB - BACKGROUND: Human adenoviruses (HAdV) circulate globally, but their seasonal patterns remain poorly defined. We aimed to characterize the timing, amplitude, and duration of HAdV epidemics worldwide and to compare patterns before and after the COVID-19 pandemic. METHODS: Virological surveillance data on HAdV were obtained from the WHO FluNet database: data from 65 countries were analyzed to estimate epidemic peak timing, amplitude, and duration across the Northern and Southern Hemispheres and the intertropical belt, comparing prepandemic (2016-2019) with postpandemic (2021-2024) periods. To ensure robustness, analyses were restricted to country-seasons with >/= 30 reporting weeks. RESULTS: From 2016 to 2024, 65 countries reported roughly 148,000 HAdV detections across 335 country-seasons; 46% of seasons had >/= 50 detections. In the 20 countries with sufficient data for seasonality analyses, median epidemic duration was 31 weeks (range 5-42) and median peak amplitude 70% (40%-98%). Peak timing followed latitude: June-July in Southern Hemisphere, November-December in high-latitude Northern countries, March-April in lower latitude. After COVID-19, several countries showed marked timing shifts, with concurrent changes in amplitude. CONCLUSIONS: After the onset of the COVID-19 pandemic, the usual seasonal patterns of HAdV were altered, with pronounced shifts in peak timing across settings and latitudes. These results underscore the need for strong, ongoing, type-specific surveillance to guide public health strategies. CI - (c) 2026 The Author(s). Influenza and Other Respiratory Viruses published by John Wiley & Sons Ltd. FAU - Papini, Emma AU - Papini E AUID- ORCID: 0009-0004-6368-9316 AD - Department of Health Sciences, University of Florence, Florence, Italy. FAU - Bonaccorsi, Guglielmo AU - Bonaccorsi G AD - Department of Health Sciences, University of Florence, Florence, Italy. FAU - Bechini, Angela AU - Bechini A AD - Department of Health Sciences, University of Florence, Florence, Italy. FAU - Berti, Fabiola AU - Berti F AD - Department of Health Sciences, University of Florence, Florence, Italy. FAU - Boccalini, Sara AU - Boccalini S AD - Department of Health Sciences, University of Florence, Florence, Italy. FAU - Bonanni, Paolo AU - Bonanni P AD - Department of Health Sciences, University of Florence, Florence, Italy. FAU - Chiavarini, Manuela AU - Chiavarini M AUID- ORCID: 0000-0002-3551-7486 AD - Department of Health Sciences, University of Florence, Florence, Italy. FAU - Cosma, Claudia AU - Cosma C AD - Department of Health Sciences, University of Florence, Florence, Italy. FAU - Lorini, Chiara AU - Lorini C AD - Department of Health Sciences, University of Florence, Florence, Italy. FAU - Salvati, Cristina AU - Salvati C AUID- ORCID: 0009-0001-7652-3487 AD - Department of Health Sciences, University of Florence, Florence, Italy. FAU - Saviozzi, Valentina AU - Saviozzi V AD - Department of Health Sciences, University of Florence, Florence, Italy. FAU - Zanobini, Patrizio AU - Zanobini P AUID- ORCID: 0000-0002-8202-2937 AD - Department of Health Sciences, University of Florence, Florence, Italy. FAU - Caini, Saverio AU - Caini S AD - University of Florence, Florence, Italy. FAU - Del Riccio, Marco AU - Del Riccio M AD - Department of Health Sciences, University of Florence, Florence, Italy. LA - eng PT - Journal Article PL - England TA - Influenza Other Respir Viruses JT - Influenza and other respiratory viruses JID - 101304007 SB - IM MH - Humans MH - *COVID-19/epidemiology MH - *Adenoviruses, Human/isolation & purification MH - Seasons MH - *Adenovirus Infections, Human/epidemiology/virology MH - SARS-CoV-2 MH - Global Health/statistics & numerical data MH - Pandemics PMC - PMC12959972 OTO - NOTNLM OT - COVID-19 pandemic OT - Human adenovirus OT - respiratory viruses OT - seasonality OT - virological surveillance COIS- The authors declare no conflicts of interest. EDAT- 2026/03/05 00:39 MHDA- 2026/03/07 16:15 PMCR- 2026/03/04 CRDT- 2026/03/04 21:02 PHST- 2025/12/22 00:00 [revised] PHST- 2025/09/23 00:00 [received] PHST- 2026/02/02 00:00 [accepted] PHST- 2026/03/07 16:15 [medline] PHST- 2026/03/05 00:39 [pubmed] PHST- 2026/03/04 21:02 [entrez] PHST- 2026/03/04 00:00 [pmc-release] AID - IRV70236 [pii] AID - 10.1111/irv.70236 [doi] PST - ppublish SO - Influenza Other Respir Viruses. 2026 Mar;20(3):e70236. doi: 10.1111/irv.70236. PMID- 41730982 OWN - NLM STAT- MEDLINE DCOM- 20260627 LR - 20260813 IS - 2045-2322 (Electronic) IS - 2045-2322 (Linking) VI - 16 IP - 1 DP - 2026 Feb 23 TI - Physical fitness changes among school-aged children during the COVID-19 lockdown evaluated within the Hungarian National Student Fitness Test cohort. LID - 10.1038/s41598-026-41055-8 [doi] LID - 10254 AB - This cohort-based analysis aims to compare the health-related physical fitness levels of Hungarian youth before and one year after the first wave of the COVID-19 pandemic. We also aimed to analyze the impact of the school environment on students' physical fitness. A cohort study was conducted to evaluate various physical fitness components, including body mass index (BMI), body fat percentage (BF%), cardiorespiratory fitness, musculoskeletal fitness, and flexibility, measured via the Hungarian National Student Fitness Test (NETFIT(R)). The analysis included 285,465 students across the pre-pandemic (2018/2019) and post-pandemic (2021/2022) academic years. Generalized linear mixed-effects models were used to quantify differences. The findings indicated a decline in BMI, BF%, cardiorespiratory fitness, flexibility, and musculoskeletal fitness measured with push-up and curl-up tests. However, standing broad jump, trunk-lift, and handgrip strength increased during the COVID-19 pandemic. Moreover, significant variations in students' physical fitness across schools suggest that school-level factors play a crucial role in shaping students' physical performance. This study highlights a general decline in adolescents' physical fitness, likely linked to reduced physical activity due to COVID-19 pandemic related restrictions, which contributed to increased sedentary behavior and fewer outdoor activities. The extent of these changes varied across schools. FAU - Vincze, Ferenc AU - Vincze F AD - Department of Public Health and Epidemiology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary. vincze.ferenc@med.unideb.hu. FAU - Csanyi, Tamas AU - Csanyi T AD - Department of Physical Education Theory and Methodology, Hungarian University of Sports Science, Budapest, Hungary. AD - Hungarian School Sport Federation, Budapest, Hungary. FAU - Kaj, Monika AU - Kaj M AD - Hungarian School Sport Federation, Budapest, Hungary. FAU - Kalbli, Katalin AU - Kalbli K AD - Hungarian School Sport Federation, Budapest, Hungary. AD - Barczi Gusztav Faculty of Special Needs Education, Eotvos Lorand University, Budapest, Hungary. FAU - Nagy-Penzes, Gabriella AU - Nagy-Penzes G AD - Department of Public Health and Epidemiology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary. FAU - Pinczes, Tamas AU - Pinczes T AD - Department of Physical Education and Sport, Ferenc Kolcsey Teacher Training Institute, Debrecen Reformed Theological University, Debrecen, Hungary. FAU - Cselko, Alexandra AU - Cselko A AD - Hungarian School Sport Federation, Budapest, Hungary. FAU - Sandor, Janos AU - Sandor J AD - Department of Public Health and Epidemiology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary. LA - eng PT - Journal Article DEP - 20260223 PL - England TA - Sci Rep JT - Scientific reports JID - 101563288 SB - IM MH - Humans MH - *COVID-19/epidemiology MH - *Physical Fitness/physiology MH - Hungary/epidemiology MH - Adolescent MH - Male MH - Female MH - Schools MH - Students/statistics & numerical data MH - Body Mass Index MH - SARS-CoV-2/isolation & purification MH - Child MH - Cardiorespiratory Fitness MH - Cohort Studies MH - Exercise MH - Pandemics PMC - PMC13031300 OTO - NOTNLM OT - Adolescents OT - COVID-19 OT - Fitness monitoring OT - Physical fitness OT - School COIS- Declarations. Competing interests: The authors declare no competing interests. Ethical approval: Informed consent was not required for this study, as the collection and processing of students' fitness test data are mandated by law. According to the Hungarian Act CXC of 2011 on National Public Education (as amended on July 26, 2019, Sect. 44/B), the Hungarian National Student Fitness Test (NETFIT(R)) is operated by the Hungarian School Sport Federation, and students' personal data related to fitness assessments are processed under statutory authorization. Based on this legal framework, parental or legal guardian consent is not required for data collection. The NETFIT(R) data collection is a statutory requirement for all educational institutions in Hungary under Act CXC of 2011 on National Public Education. The data were processed in accordance with the General Data Protection Regulation (GDPR), the Official Statistical Act (Act CLV of 2016) and the Hungarian Information Act (Act CXII of 2011). Access to the anonymized dataset was provided for research purposes by the Hungarian School Sport Federation, ensuring that no individual student could be identified. The study was approved and supervised by the scientific board of HSSF, which is responsible for both the utilization of NETFIT(R) database and the protection of human rights in handling sensitive personal data (410IB23). EDAT- 2026/02/24 00:29 MHDA- 2026/06/27 06:46 PMCR- 2026/02/23 CRDT- 2026/02/23 23:21 PHST- 2025/08/13 00:00 [received] PHST- 2026/02/17 00:00 [accepted] PHST- 2026/06/27 06:46 [medline] PHST- 2026/02/24 00:29 [pubmed] PHST- 2026/02/23 23:21 [entrez] PHST- 2026/02/23 00:00 [pmc-release] AID - 10.1038/s41598-026-41055-8 [pii] AID - 41055 [pii] AID - 10.1038/s41598-026-41055-8 [doi] PST - epublish SO - Sci Rep. 2026 Feb 23;16(1):10254. doi: 10.1038/s41598-026-41055-8. PMID- 41721409 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260328 LR - 20260813 IS - 1752-1505 (Print) IS - 1752-1505 (Electronic) IS - 1752-1505 (Linking) VI - 20 IP - 1 DP - 2026 Feb 20 TI - The impact of political instability on HIV services in conflict-affected areas of Myanmar following the military coup: a qualitative study. LID - 10.1186/s13031-026-00759-4 [doi] LID - 32 AB - INTRODUCTION: People living with HIV (PLHIV) and individuals at risk require consistent access to comprehensive HIV services. Political instability exacerbates existing challenges in HIV care by disrupting health systems, leading to medicine shortages, depletion of the healthcare workforce, and damage to essential infrastructure. Since 2021 military coup in Myanmar, there has been a lack of updated information on the status of HIV services in conflict-affected areas. METHODS: A cross-sectional online qualitative study was conducted from July to December 2024 in conflict-affected regions (Sagaing, Magway and Bago regions) of Myanmar. In-depth interviews (IDIs) and key informant interviews (KIIs) were conducted via the Zoom platform with 18 healthcare providers from hospitals/clinics and health administrators, and 10 PLHIV from a trusted network. Participants were recruited through purposive sampling. Thematic analysis was applied, and triangulation was performed across different participant groups to enhance the validity of the findings. RESULTS: A total of 28 participants were included in the study. Since 2021, HIV prevention services have been severely constrained due to limited resources and ongoing conflict. While all pregnant women are screened for HIV during antenatal care, the availability of PMTCT (prevention of mother-to-child transmission) syrup for newborns remains extremely limited. Antiretroviral drugs for post-exposure prophylaxis (PEP) are available in only certain facilities, and in limited quantities. HIV testing services are available in most areas, primarily at health facilities, but confirmatory testing is restricted to a small number of general health centers. Early infant diagnosis is not universally available. Many PLHIV remain on waiting lists to start antiretroviral therapy (ART), with prioritization based on disease severity and local security conditions. Baseline investigations and medications for opportunistic infections are largely unavailable. Some PLHIV have been referred to the TeleRed HIV telemedicine clinic. ART interruption has been reported due to travel restrictions, internet and mobile service disruptions, and security threats. Many areas are affected by airstrikes, conflict, and a lack of essential medicines and supplies. CONCLUSIONS: This study highlights the impact of political instability on HIV services in conflict-affected areas of Myanmar. Key challenges include limited prevention services, ART shortages, and reduced accessibility to care. Without timely and comprehensive interventions to address these gaps, a rise in new HIV infections and advanced HIV disease is anticipated in the coming years. CI - (c) 2026. The Author(s). FAU - Mon, M M AU - Mon MM AUID- ORCID: 0000-0003-4337-9754 AD - Research & Development Unit, Ministry of Health, National Unity Government, Yangon, Myanmar. mmyomon@gmail.com. AD - National HIV & AIDS Program, Ministry of Health, National Unity Government, Yangon, Myanmar. mmyomon@gmail.com. FAU - Thant, Kyaw Soe AU - Thant KS AD - National HIV & AIDS Program, Ministry of Health, National Unity Government, Yangon, Myanmar. FAU - Khaing, H A AU - Khaing HA AD - National HIV & AIDS Program, Ministry of Health, National Unity Government, Yangon, Myanmar. FAU - Kyaw, P P AU - Kyaw PP AD - National HIV & AIDS Program, Ministry of Health, National Unity Government, Yangon, Myanmar. FAU - Lwin, T S AU - Lwin TS AD - National HIV & AIDS Program, Ministry of Health, National Unity Government, Yangon, Myanmar. FAU - Oo, Estella AU - Oo E AD - National HIV & AIDS Program, Ministry of Health, National Unity Government, Yangon, Myanmar. LA - eng PT - Journal Article DEP - 20260220 PL - England TA - Confl Health JT - Conflict and health JID - 101286573 PMC - PMC13032656 OTO - NOTNLM OT - Conflict OT - HIV services; myanmar; military coup OT - HIV/AIDS OT - Myanmar OT - Political instability OT - Qualitative COIS- Declarations. Ethics approval and consent to participate: Ethical approval was obtained from the Ethics Review Committee, the Ministry of Health, National Unity Government, Myanmar (Ethics/NUG-MOH/2024/02). Objectives of the assessment were explained and informed consent was taken from all the participants. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests. EDAT- 2026/02/21 00:40 MHDA- 2026/02/21 00:41 PMCR- 2026/02/20 CRDT- 2026/02/20 23:56 PHST- 2025/07/21 00:00 [received] PHST- 2026/01/21 00:00 [accepted] PHST- 2026/02/21 00:41 [medline] PHST- 2026/02/21 00:40 [pubmed] PHST- 2026/02/20 23:56 [entrez] PHST- 2026/02/20 00:00 [pmc-release] AID - 10.1186/s13031-026-00759-4 [pii] AID - 759 [pii] AID - 10.1186/s13031-026-00759-4 [doi] PST - epublish SO - Confl Health. 2026 Feb 20;20(1):32. doi: 10.1186/s13031-026-00759-4. PMID- 41717450 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260220 LR - 20260920 IS - 2399-3529 (Electronic) IS - 2399-3529 (Linking) VI - 2026 IP - 1 DP - 2026 TI - Telehealth cognitive behavioural therapy improves health-related quality of life and pain in endometriosis: the Healing Pelvic Pain Intervention (HaPPI)-a randomized controlled trial. PG - hoag006 LID - 10.1093/hropen/hoag006 [doi] LID - hoag006 AB - STUDY QUESTION: Is telehealth cognitive behavioural therapy (CBT) or yoga effective in improving health-related quality of life (HRQoL) and secondary outcomes for endometriosis? SUMMARY ANSWER: Endometriosis-tailored CBT is superior to education for improving HRQoL and pain. WHAT IS KNOWN ALREADY: Endometriosis is a burdensome disease that contributes to diminished quality of life. Current biomedical care including hormonal and analgesic treatment is associated with inconsistent efficacy. Interdisciplinary care is therefore needed to augment the well-being of people with endometriosis. Although studies have suggested that CBT and yoga are promising for relieving pain and other symptoms associated with endometriosis, the evidence remains limited because they are based on small pilot studies. STUDY DESIGN SIZE DURATION: In this parallel 8-week randomized controlled trial (RCT), 334 participants were randomized using a computer-generated sequence with allocation concealment between April 2021 and February 2024. Outcome assessors were blinded to the group. PARTICIPANTS/MATERIALS SETTING METHODS: Participants required a diagnosis of endometriosis with pain for at least 6 months, and access to internet. Participants were randomly allocated to: (i) CBT (8-week telehealth therapist-led group, n = 79); (ii) yoga (8-week telehealth therapist-led group, n = 83); or (iii) education materials via email (n = 84). Primary outcomes: endometriosis-specific HRQoL (Endometriosis Health Profile-30; EHP-30 Total and Pain); general HRQoL (EQ-5D-5L global health) at post-treatment (8 weeks). Secondary outcomes: pain (period pain, bowel pain, bladder pain, and sexual pain), pain catastrophizing, pain self-efficacy, psychological distress, sleep, fatigue, menstrual symptoms, and central sensitization. Mixed-effects models examined group by time differences. MAIN RESULTS AND THE ROLE OF CHANCE: The CBT group reported statistically significant improvements in endometriosis-specific HRQoL (EHP Pain beta = -0.58, 95% CI = -0.89, -0.26, P = 0.01), and general HRQoL (EQ-5D-5L global health beta = 0.52, 95% CI = 0.21, 0.84, P = 0.02) compared to the education control group. CBT was also superior to education for pelvic pain (menstrual pain, bowel pain, bladder pain, and sexual pain), pain self-efficacy, and pain catastrophizing. Effect sizes for CBT were generally medium to large (Cohen's D = -0.28 to -0.93). Yoga was superior to education for menstrual symptoms and sexual pain, with medium effect sizes (Cohen's D = -0.56 to -0.71). LIMITATIONS REASONS FOR CAUTION: Due to the presence of COVID-19 restrictions during data collection, CBT and yoga were delivered online. As a result, it is unclear whether CBT and yoga would have the same effects if delivered face-to-face, or whether online delivery would show comparable efficacy in a post-pandemic context. WIDER IMPLICATIONS OF THE FINDINGS: Our RCT is the first to test the efficacy of telehealth CBT or yoga for improving outcomes in people living with endometriosis compared to an active control. Telehealth CBT demonstrated efficacy for improving endometriosis-specific and general HRQoL in people with endometriosis, as well as pain outcomes. Yoga demonstrated efficacy for improving menstrual symptoms and pain during sex. We recommend endometriosis-tailored CBT as part of interdisciplinary management for people with endometriosis, including online delivery to address access and mobility barriers. Yoga may be helpful in augmenting pelvic health. STUDY FUNDING/COMPETING INTERESTS: This work is supported by the Australian Government, Canberra under the Medical Research Future Fund grant number MRFF1200214. The authors do not have any conflicts of interest in relation to the present study. TRIAL REGISTRATION NUMBER: ACTRN12620000756921 https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=379947&isReview=true. TRIAL REGISTRATION DATE: 22 July 2020. DATE OF FIRST PATIENT'S ENROLMENT: 23 April 2021. CI - (c) The Author(s) 2026. Published by Oxford University Press on behalf of European Society of Human Reproduction and Embryology. FAU - Evans, Subhadra AU - Evans S AUID- ORCID: 0000-0002-1898-0030 AD - School of Psychology, Deakin University, Geelong, VIC, Australia. FAU - Skvarc, David AU - Skvarc D AD - School of Psychology, Deakin University, Geelong, VIC, Australia. FAU - Esterman, Adrian AU - Esterman A AD - School of Public Health, College of Health, Adelaide University, Adelaide SA, Australia. FAU - Mackay, Matthew I AU - Mackay MI AUID- ORCID: 0000-0003-1821-4923 AD - School of Psychology, Deakin University, Geelong, VIC, Australia. FAU - O'Shea, Melissa AU - O'Shea M AD - School of Psychology, Deakin University, Geelong, VIC, Australia. FAU - Van Niekerk, Leesa AU - Van Niekerk L AUID- ORCID: 0000-0002-6641-5888 AD - School of Psychological Sciences, University of Tasmania, Hobart, TAS, Australia. FAU - Druitt, Marilla L AU - Druitt ML AD - Barwon Health (University Hospital), Geelong, VIC, Australia. AD - School of Medicine, Deakin University, Geelong, VIC, Australia. FAU - Tsaltas, Jim AU - Tsaltas J AD - Department of Gynaecology, Epworth Freemasons Hospital, Melbourne, VIC, Australia. AD - Department of Obstetrics and Gynaecology, Monash Health and Monash University, Melbourne, VIC, Australia. FAU - Knowles, Simon R AU - Knowles SR AD - Department of Psychological Sciences, Faculty of Health, Arts and Design, Swinburne University of Technology, Melbourne, VIC, Australia. FAU - Parigi, Elesha AU - Parigi E AD - School of Psychology, Deakin University, Geelong, VIC, Australia. FAU - Stanley, Katherine AU - Stanley K AD - School of Psychology, Deakin University, Geelong, VIC, Australia. FAU - Harris, Jill AU - Harris J AD - Kyo Yoga & Healing, Ocean Grove, VIC, Australia. FAU - Barber, Meg AU - Barber M AD - Barwon Health (University Hospital), Geelong, VIC, Australia. FAU - Dober, Madeleine AU - Dober M AD - The Royal Melbourne Hospital, Melbourne, VIC, Australia. FAU - Dowding, Charlotte AU - Dowding C AD - School of Psychology, Deakin University, Geelong, VIC, Australia. AD - Orange Health Service, Orange, NSW, Australia. FAU - Mikocka-Walus, Antonina AU - Mikocka-Walus A AD - School of Psychology, Deakin University, Geelong, VIC, Australia. LA - eng PT - Journal Article DEP - 20260122 PL - England TA - Hum Reprod Open JT - Human reproduction open JID - 101722764 EIN - Hum Reprod Open. 2026 Jun 27;2026(3):hoag059. doi: 10.1093/hropen/hoag059. PMID: 42375549 PMC - PMC12915575 OTO - NOTNLM OT - cognitive behavioural therapy OT - endometriosis OT - quality of life OT - randomized controlled trial OT - telehealth OT - yoga COIS- L.V.N. is a member of the Endometriosis Australia Clinical Advisory Committee and research chair (unfunded roles) and member of the National Endometriosis Clinical Trial Steering Committee (NECST) (unfunded role). EDAT- 2026/02/20 07:05 MHDA- 2026/02/20 07:06 PMCR- 2026/01/22 CRDT- 2026/02/20 04:58 PHST- 2025/08/03 00:00 [received] PHST- 2025/11/27 00:00 [revised] PHST- 2025/12/23 00:00 [accepted] PHST- 2026/02/20 07:06 [medline] PHST- 2026/02/20 07:05 [pubmed] PHST- 2026/02/20 04:58 [entrez] PHST- 2026/01/22 00:00 [pmc-release] AID - hoag006 [pii] AID - 10.1093/hropen/hoag006 [doi] PST - epublish SO - Hum Reprod Open. 2026 Jan 22;2026(1):hoag006. doi: 10.1093/hropen/hoag006. eCollection 2026. PMID- 41691344 OWN - NLM STAT- MEDLINE DCOM- 20260707 LR - 20260813 IS - 1749-799X (Electronic) IS - 1749-799X (Linking) VI - 21 IP - 1 DP - 2026 Feb 14 TI - Epidemiological changes in clavicle fractures during the COVID-19 pandemic: a six-year analysis from a large single-center cohort. LID - 10.1186/s13018-025-06634-x [doi] LID - 209 AB - OBJECTIVE: To evaluate the epidemiological characteristics of clavicle fractures in a high-volume trauma center over a six-year period and to compare trauma mechanisms and management patterns before and during the COVID-19 pandemic. METHODS: A retrospective review of 1500 consecutive clavicle fracture cases treated at a level-one trauma center between January 2016 and December 2021 was conducted. Demographic characteristics, fracture classification, trauma mechanisms, and treatment modalities were analyzed. Comparisons were made between the pre-pandemic period (2016-March 2020) and the pandemic period (March 2020-2021). RESULTS: The cohort consisted predominantly of young males (68.5%, median age: 21.7 years). Midshaft fractures were most common (79.3%). During the pandemic, trauma mechanisms changed significantly, with a marked decrease in sports-related injuries (34.3% to 13.4%) and an increase in simple falls (46.0% to 62.9%) and high-energy trauma (19.7% to 23.7%) (p < 0.001). Despite these epidemiological shifts, the proportion of surgically treated fractures remained unchanged (8.7% pre-pandemic vs. 8.1% during the pandemic, p > 0.05). No significant differences were observed in fracture type or associated injuries between periods. CONCLUSION: The COVID-19 pandemic was associated with substantial changes in the epidemiology of clavicle fractures, particularly in trauma mechanisms, but did not affect the rate of operative versus non-operative management. These findings suggest that while societal restrictions altered injury patterns, clinical decision-making for clavicle fracture treatment remained stable. LEVEL OF EVIDENCE: III (Retrospective comparative study). CI - (c) 2025. The Author(s). FAU - Ziroglu, Nezih AU - Ziroglu N AUID- ORCID: 0000-0002-2595-9459 AD - Vocational School of Health Services, Department of Orthopedic Prosthetics and Orthotics, Acibadem Mehmet Ali Aydinlar University, 34638, Istanbul, Turkey. nezih.ziroglu@acibadem.com. AD - Department of Orthopaedics and Traumatology, Acibadem University Atakent Hospital, 34307, Istanbul, Turkey. nezih.ziroglu@acibadem.com. FAU - Ciftci, Mehmet Utku AU - Ciftci MU AUID- ORCID: 0000-0001-5594-4138 AD - Department of Orthopaedics and Traumatology, Abdulhamid Han Training and Research Hospital, Sultan 2, 34668, Istanbul, Turkey. FAU - Duramaz, Altug AU - Duramaz A AUID- ORCID: 0000-0002-5012-2079 AD - Department of Orthopaedics and Traumatology, Bakirkoy Dr. Sadi Konuk Training and Research Hospital, 34147, Istanbul, Turkey. FAU - Kural, Cemal AU - Kural C AUID- ORCID: 0000-0001-7493-391X AD - Department of Orthopaedics and Traumatology, Bakirkoy Dr. Sadi Konuk Training and Research Hospital, 34147, Istanbul, Turkey. FAU - Koluman, Ali Can AU - Koluman AC AUID- ORCID: 0000-0002-0191-3229 AD - Department of Orthopaedics and Traumatology, Bakirkoy Dr. Sadi Konuk Training and Research Hospital, 34147, Istanbul, Turkey. md.alicankoluman@gmail.com. LA - eng PT - Journal Article DEP - 20260214 PL - England TA - J Orthop Surg Res JT - Journal of orthopaedic surgery and research JID - 101265112 SB - IM MH - Humans MH - *COVID-19/epidemiology MH - *Fractures, Bone/epidemiology/therapy/etiology MH - *Clavicle/injuries MH - Retrospective Studies MH - Male MH - Female MH - Young Adult MH - Adult MH - Adolescent MH - Middle Aged MH - Cohort Studies MH - Time Factors MH - Trauma Centers/trends MH - Pandemics MH - Aged PMC - PMC13011530 OTO - NOTNLM OT - COVID-19 OT - Clavicle fracture OT - Collarbone OT - Conservative treatment OT - Epidemiology OT - Lockdown OT - Operative treatment OT - Pandemic OT - Upper extremity COIS- Declarations. Ethics approval and consent to participate: This study was approved by the Clinical Research Ethics Committee of Bakirkoy Sadi Konuk Training and Research Hospital, Istanbul, Turkiye (Approval No: 2019-14-02; Date: July 22, 2019). As this was a retrospective chart review using anonymized data, the requirement for informed consent was waived by the ethics committee. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests. EDAT- 2026/02/15 00:31 MHDA- 2026/03/24 07:42 PMCR- 2026/02/14 CRDT- 2026/02/14 23:28 PHST- 2025/11/15 00:00 [received] PHST- 2025/12/20 00:00 [accepted] PHST- 2026/03/24 07:42 [medline] PHST- 2026/02/15 00:31 [pubmed] PHST- 2026/02/14 23:28 [entrez] PHST- 2026/02/14 00:00 [pmc-release] AID - 10.1186/s13018-025-06634-x [pii] AID - 6634 [pii] AID - 10.1186/s13018-025-06634-x [doi] PST - epublish SO - J Orthop Surg Res. 2026 Feb 14;21(1):209. doi: 10.1186/s13018-025-06634-x. PMID- 41575210 OWN - NLM STAT- MEDLINE DCOM- 20260630 LR - 20260813 IS - 2165-0497 (Electronic) IS - 2165-0497 (Linking) VI - 14 IP - 3 DP - 2026 Mar 3 TI - Genomic analysis reveals dynamics of SARS-CoV-2 during the initial phases of the COVID-19 outbreak in the Dominican Republic. PG - e0110525 LID - 10.1128/spectrum.01105-25 [doi] LID - e01105-25 AB - Genomic sequencing of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been widely instituted during the coronavirus disease 2019 (COVID-19) pandemic to track the emergence and spread of new lineages. While this powerful tool can influence public health decisions and therapeutic development, not all regions of the world have had equal access to sequencing capacity, affecting surveillance. One such underrepresented region is the Caribbean islands, including the Dominican Republic (DR). To determine retrospectively what lineages were circulating in the DR in the first year of the pandemic, when there were strict travel restrictions imposed, we sequenced SARS-CoV-2 from nasal swab and saliva samples collected between July 2020 and February 2021. We investigated whether COVID-19 outbreaks were seeded by single or multiple introductions and established epidemiological linkages to other countries. Using 98 newly sequenced samples, we identified 16 SARS-CoV-2 lineages in the DR, indicating many independent introductions from diverse geographic areas. Further, we show that analyzing both globally prevalent and globally rare lineages within the DR highlights different aspects of international disease transmission.IMPORTANCEThis study uses genome sequencing of severe acute respiratory syndrome coronavirus 2 samples collected in an undersampled region of the world-the Caribbean, specifically the Dominican Republic-to make novel inferences about the dynamics of disease spread during a period of the coronavirus disease 2019 pandemic when many diverse lineages were co-circulating globally. FAU - Kreitman, Allie AU - Kreitman A AUID- ORCID: 0000-0002-0390-5425 AD - Systems Genomics Section, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA. RINGGOLD: 35037. ROR: https://ror.org/043z4tv69 FAU - Mushegian, Alexandra AU - Mushegian A AD - Systems Genomics Section, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA. RINGGOLD: 35037. ROR: https://ror.org/043z4tv69 FAU - Nelson, Martha I AU - Nelson MI AD - Computational Biology Branch, National Center for Biotechnology Information, National Library of Medicine, NIH, Bethesda, Maryland, USA. RINGGOLD: 10952 FAU - Banakis, Stephanie AU - Banakis S AD - Systems Genomics Section, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA. RINGGOLD: 35037. ROR: https://ror.org/043z4tv69 FAU - Mederos, Christopher AU - Mederos C AD - Systems Genomics Section, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA. RINGGOLD: 35037. ROR: https://ror.org/043z4tv69 FAU - Chung, Matthew AU - Chung M AD - Systems Genomics Section, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA. RINGGOLD: 35037. ROR: https://ror.org/043z4tv69 FAU - Roder, Allison AU - Roder A AD - Systems Genomics Section, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA. RINGGOLD: 35037. ROR: https://ror.org/043z4tv69 FAU - Peguero, Armando AU - Peguero A AD - Instituto de Medicina Tropical & Salud Global, Universidad Iberoamericana (UNIBE), UNIBE Research Hub, Santo Domingo, Dominican Republic. RINGGOLD: 37542. ROR: https://ror.org/004xzjm20 FAU - Mueses, Sayira AU - Mueses S AD - Instituto de Medicina Tropical & Salud Global, Universidad Iberoamericana (UNIBE), UNIBE Research Hub, Santo Domingo, Dominican Republic. RINGGOLD: 37542. ROR: https://ror.org/004xzjm20 FAU - Cuevas, Paula AU - Cuevas P AD - Department of Applications, Bionuclear, Santo Domingo, Dominican Republic. RINGGOLD: 37542. ROR: https://ror.org/004xzjm20 FAU - Paulino-Ramirez, Robert AU - Paulino-Ramirez R AUID- ORCID: 0000-0002-3676-0357 AD - Instituto de Medicina Tropical & Salud Global, Universidad Iberoamericana (UNIBE), UNIBE Research Hub, Santo Domingo, Dominican Republic. RINGGOLD: 37542. ROR: https://ror.org/004xzjm20 FAU - Ghedin, Elodie AU - Ghedin E AUID- ORCID: 0000-0002-1515-725X AD - Systems Genomics Section, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA. RINGGOLD: 35037. ROR: https://ror.org/043z4tv69 LA - eng GR - AI001324/NIH Intramural Research Program/ PT - Journal Article DEP - 20260123 PL - United States TA - Microbiol Spectr JT - Microbiology spectrum JID - 101634614 SB - IM MH - Dominican Republic/epidemiology MH - Humans MH - *COVID-19/epidemiology/virology/transmission MH - *SARS-CoV-2/genetics/classification/isolation & purification MH - *Genome, Viral MH - Phylogeny MH - Disease Outbreaks MH - Genomics MH - Pandemics MH - Retrospective Studies PMC - PMC12955433 OTO - NOTNLM OT - COVID-19 pandemic OT - Dominican Republic OT - SARS-CoV-2 genomics OT - genomic epidemiology COIS- The authors declare no conflict of interest. EDAT- 2026/01/23 13:05 MHDA- 2026/03/07 01:37 PMCR- 2026/01/23 CRDT- 2026/01/23 09:03 PHST- 2026/03/07 01:37 [medline] PHST- 2026/01/23 13:05 [pubmed] PHST- 2026/01/23 09:03 [entrez] PHST- 2026/01/23 00:00 [pmc-release] AID - spectrum01105-25 [pii] AID - spectrum.01105-25 [pii] AID - 10.1128/spectrum.01105-25 [doi] PST - ppublish SO - Microbiol Spectr. 2026 Mar 3;14(3):e0110525. doi: 10.1128/spectrum.01105-25. Epub 2026 Jan 23. PMID- 41556063 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260120 LR - 20260122 IS - 3005-0774 (Print) IS - 3005-0774 (Electronic) IS - 3005-0774 (Linking) VI - 23 IP - 1 DP - 2026 TI - Adherence to mask wearing and social distancing and use of lateral flow tests during the COVID19 pandemic in England and Wales based on the virus watch community cohort study. PG - 47 LID - 10.1186/s12982-026-01375-6 [doi] LID - 47 AB - BACKGROUND: Personal protective behaviours (PPBs) played a crucial role in limiting infection spread during the COVID-19 pandemic, yet adherence varied across communities. Understanding the factors influencing adherence is important, as PPBs will remain critical in future pandemics. Using behavioural science, we investigated the influences on adherence to PPBs, focusing on face mask wearing, social distancing, and lateral flow testing (LFT). METHODS: Two online surveys were conducted in July and August 2021 in England and Wales (N = 20,488 (survey 1) and N = 26,613 (survey 2)). Survey questions were informed by the Capability, Opportunity, Motivation model of Behaviour (COM-B). Multivariate models examined associations between behavioural influences and adherence to PPBs. RESULTS: Most respondents reported wearing a face mask in public indoor places (88.5%) and maintaining a 1 + metre distance (86.8%) all or most of the time. After two doses of COVID-19 vaccine, adherence declined with 48.3% reporting meeting friends or family and 38.3% visiting indoor places more frequently. Motivation, Opportunity and Capability factors were significantly associated with increased odds of wearing a face mask and social distancing (p < .05). Among those using LFTs (68% of the sample), 50.4% engaged in routine testing, while 55.3% of non-users cited a perceived lack of necessity for testing. Routine testing was significantly associated with accurate interpretation of test results. CONCLUSIONS: Despite reduced restrictions and high vaccination rates, overall adherence to PPBs remained high. Behavioural influences played a significant role in PPB use. These findings can inform tailored public health interventions and support future community-level emergency preparedness. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12982-026-01375-6. CI - (c) The Author(s) 2026. FAU - Antonopoulou, Vivi AU - Antonopoulou V AUID- ORCID: 0000-0002-1002-4191 AD - Centre for Behaviour Change, Department of Clinical, Educational and Health Psychology, University College London, 1-19 Torrington Place, London, WC1E 7HB UK. ROR: https://ror.org/02jx3x895. GRID: grid.83440.3b. ISNI: 0000 0001 2190 1201 AD - National Institute for Health and Social Care Research Policy Research Unit in Behavioural and Social Sciences, Population Health Sciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle, UK. ROR: https://ror.org/01kj2bm70. GRID: grid.1006.7. ISNI: 0000 0001 0462 7212 FAU - Ong, Madeline AU - Ong M AUID- ORCID: 0000-0002-4092-2152 AD - Centre for Behaviour Change, Department of Clinical, Educational and Health Psychology, University College London, 1-19 Torrington Place, London, WC1E 7HB UK. ROR: https://ror.org/02jx3x895. GRID: grid.83440.3b. ISNI: 0000 0001 2190 1201 FAU - Meyer, Carly AU - Meyer C AUID- ORCID: 0000-0002-2268-3055 AD - Centre for Behaviour Change, Department of Clinical, Educational and Health Psychology, University College London, 1-19 Torrington Place, London, WC1E 7HB UK. ROR: https://ror.org/02jx3x895. GRID: grid.83440.3b. ISNI: 0000 0001 2190 1201 FAU - Beale, Sarah AU - Beale S AUID- ORCID: 0000-0002-4038-7460 AD - Centre for Public Health Data Science, Institute of Health Informatics, University College London, London, UK. ROR: https://ror.org/02jx3x895. GRID: grid.83440.3b. ISNI: 0000 0001 2190 1201 AD - Institute of Epidemiology and Health Care, University College London, London, UK. ROR: https://ror.org/02jx3x895. GRID: grid.83440.3b. ISNI: 0000 0001 2190 1201 FAU - Lorencatto, Fabiana AU - Lorencatto F AUID- ORCID: 0000-0003-4418-7957 AD - Centre for Behaviour Change, Department of Clinical, Educational and Health Psychology, University College London, 1-19 Torrington Place, London, WC1E 7HB UK. ROR: https://ror.org/02jx3x895. GRID: grid.83440.3b. ISNI: 0000 0001 2190 1201 AD - National Institute for Health and Social Care Research Policy Research Unit in Behavioural and Social Sciences, Population Health Sciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle, UK. ROR: https://ror.org/01kj2bm70. GRID: grid.1006.7. ISNI: 0000 0001 0462 7212 FAU - Michie, Susan AU - Michie S AUID- ORCID: 0000-0003-0063-6378 AD - Centre for Behaviour Change, Department of Clinical, Educational and Health Psychology, University College London, 1-19 Torrington Place, London, WC1E 7HB UK. ROR: https://ror.org/02jx3x895. GRID: grid.83440.3b. ISNI: 0000 0001 2190 1201 AD - National Institute for Health and Social Care Research Policy Research Unit in Behavioural and Social Sciences, Population Health Sciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle, UK. ROR: https://ror.org/01kj2bm70. GRID: grid.1006.7. ISNI: 0000 0001 0462 7212 FAU - Aldridge, Robert W AU - Aldridge RW AUID- ORCID: 0000-0003-0542-0816 AD - Centre for Public Health Data Science, Institute of Health Informatics, University College London, London, UK. ROR: https://ror.org/02jx3x895. GRID: grid.83440.3b. ISNI: 0000 0001 2190 1201 AD - Institute for Health Metrics and Evaluation, University of Washington, Seattle, USA. ROR: https://ror.org/00cvxb145. GRID: grid.34477.33. ISNI: 0000000122986657 FAU - Hayward, Andrew AU - Hayward A AUID- ORCID: 0000-0002-3549-6232 AD - Institute of Epidemiology and Health Care, University College London, London, UK. ROR: https://ror.org/02jx3x895. GRID: grid.83440.3b. ISNI: 0000 0001 2190 1201 LA - eng PT - Journal Article DEP - 20260117 PL - England TA - Discov Public Health JT - Discover public health JID - 9918863331406676 PMC - PMC12812096 OTO - NOTNLM OT - Behavioral science OT - Lateral flow device (LFD) OT - Pandemic OT - Personal protective behaviors OT - Public health interventions OT - Rapid lateral flow tests COIS- Competing interestsThe authors declare no competing interests. EDAT- 2026/01/20 07:43 MHDA- 2026/01/20 07:44 PMCR- 2026/01/17 CRDT- 2026/01/20 03:46 PHST- 2025/04/03 00:00 [received] PHST- 2026/01/09 00:00 [accepted] PHST- 2026/01/20 07:44 [medline] PHST- 2026/01/20 07:43 [pubmed] PHST- 2026/01/20 03:46 [entrez] PHST- 2026/01/17 00:00 [pmc-release] AID - 1375 [pii] AID - 10.1186/s12982-026-01375-6 [doi] PST - ppublish SO - Discov Public Health. 2026;23(1):47. doi: 10.1186/s12982-026-01375-6. Epub 2026 Jan 17. PMID- 41514198 OWN - NLM STAT- MEDLINE DCOM- 20260625 LR - 20260625 IS - 1471-2393 (Electronic) IS - 1471-2393 (Linking) VI - 26 IP - 1 DP - 2026 Jan 10 TI - Clinical features of non-criteria obstetric antiphospholipid syndrome: a retrospective cohort study on antibody-based risk classification and pregnancy outcomes. PG - 139 LID - 10.1186/s12884-025-08606-9 [doi] LID - 139 AB - OBJECTIVE: To characterize patients with non-criteria obstetric antiphospholipid syndrome (NOAPS) and to evaluate how distinct antiphospholipid antibody (aPL) profiles relate to adverse gestational outcomes. METHODS: We retrospectively analyzed 350 women diagnosed from November 2021 to July 2024. Collected information included demographic characteristics, aPL stratification, anticardiolipin antibodies (ACA), anti-beta2 glycoprotein I antibodies (abeta2-GPIs), lupus anticoagulant (LA), treatment regimens, therapy duration, and obstetric outcomes (such as recurrent miscarriage, hypertensive disorders, premature delivery, and intrauterine growth restriction). Participants were grouped into high-, medium-, and low-risk categories according to aPL stratification. Propensity score matching (PSM) was conducted in R software, and maternal-fetal outcomes were compared across the three strata. Logistic regression was applied to assess the impact of aPL profiles, and correlation analyses plus heatmaps were used to visualize associations. RESULTS: Recurrent miscarriage was most frequent in high-risk women (50.56% vs. 13.48% in low-risk, P < 0.001). The incidence of preeclampsia was 38.20% in the high-risk group compared with 16.85% and 20.23% in the medium- and low-risk groups (P = 0.002). Preterm birth (26.97%) and fetal growth restriction (23.60%) were also significantly more common in the high-risk cohort (both P < 0.01). Fetal distress occurred in 49.44% of high-risk patients, exceeding rates in the medium-risk (32.58%) and low-risk (15.73%) groups (both P < 0.01). Multivariable regression indicated that high-risk profiles were strongly linked to poor maternal and neonatal outcomes (Maternal: OR = 5.013, 95% CI 2.683-9.613; Neonatal: OR = 12.302, 95% CI 6.092-26.283). aPL stratification independently predicted placental abruption, miscarriage, preeclampsia, premature birth, growth restriction, and fetal distress (OR = 1.470-6.938). LA was identified as a predictor of maternal venous thrombosis (OR = 17.556, 95% CI 1.541-200.068), while ACA contributed to preeclampsia risk (OR = 1.778, 95% CI 1.283-2.465). Elevated ACA titers and positive abeta2-GPI results were significant for fetal distress (OR = 1.040 and 1.881). CONCLUSION: In NOAPS patients, risk stratification based on aPL antibody types, titers, and combination patterns can effectively predict adverse maternal-neonatal pregnancy outcomes. High-risk patients often need prompt, intensive anticoagulant therapy together with coordinated multidisciplinary surveillance. CI - (c) 2026. The Author(s). FAU - Fu, Wenjie AU - Fu W AD - Department of Obstetrics and Gynecology, Jinshan Branch of Shanghai Sixth People's Hospital, Shanghai, 201599, China. Biaogelhv51981@163.com. FAU - Li, Huaping AU - Li H AD - Department of Obstetrics and Gynecology, Jinshan Branch of Shanghai Sixth People's Hospital, Shanghai, 201599, China. AD - Department of Obstetrics and Gynecology, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, 200233, China. FAU - Yu, Yi AU - Yu Y AD - Department of Obstetrics and Gynecology, Jinshan Branch of Shanghai Sixth People's Hospital, Shanghai, 201599, China. LA - eng PT - Journal Article DEP - 20260110 PL - England TA - BMC Pregnancy Childbirth JT - BMC pregnancy and childbirth JID - 100967799 RN - 0 (Antibodies, Antiphospholipid) RN - 0 (Antibodies, Anticardiolipin) RN - 0 (beta 2-Glycoprotein I) RN - 0 (Lupus Coagulation Inhibitor) SB - IM MH - Humans MH - Female MH - Pregnancy MH - *Antiphospholipid Syndrome/immunology/blood/complications MH - Retrospective Studies MH - *Pregnancy Outcome/epidemiology MH - Adult MH - *Antibodies, Antiphospholipid/blood MH - Abortion, Habitual/epidemiology MH - Antibodies, Anticardiolipin/blood MH - Pre-Eclampsia/epidemiology MH - *Pregnancy Complications/immunology/blood/epidemiology MH - Fetal Growth Retardation/epidemiology MH - Premature Birth/epidemiology MH - beta 2-Glycoprotein I/immunology MH - Lupus Coagulation Inhibitor/blood MH - Risk Assessment MH - Risk Factors PMC - PMC12882253 OTO - NOTNLM OT - Antiphospholipid antibody risk stratification OT - Non-criteria obstetric antiphospholipid syndrome OT - Pregnancy outcomes OT - Propensity score matching COIS- Declarations. Ethics approval and consent to participate: The study was approved by the local ethics committee of the Jinshan Branch of Shanghai Sixth People's Hospital. All experiments were performed in accordance with relevant guidelines and regulations such as the Declaration of Helsinki and the patients signed the informed consent form and agreed to be published. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests. EDAT- 2026/01/10 00:34 MHDA- 2026/02/07 06:33 PMCR- 2026/01/10 CRDT- 2026/01/09 23:53 PHST- 2025/10/08 00:00 [received] PHST- 2025/12/18 00:00 [accepted] PHST- 2026/02/07 06:33 [medline] PHST- 2026/01/10 00:34 [pubmed] PHST- 2026/01/09 23:53 [entrez] PHST- 2026/01/10 00:00 [pmc-release] AID - 10.1186/s12884-025-08606-9 [pii] AID - 8606 [pii] AID - 10.1186/s12884-025-08606-9 [doi] PST - epublish SO - BMC Pregnancy Childbirth. 2026 Jan 10;26(1):139. doi: 10.1186/s12884-025-08606-9. PMID- 41495667 OWN - NLM STAT- MEDLINE DCOM- 20260627 LR - 20260702 IS - 1471-2369 (Electronic) IS - 1471-2369 (Linking) VI - 27 IP - 1 DP - 2026 Jan 6 TI - Living with haemodialysis in Sri Lanka: a qualitative study on patient adaptation and care perceptions. PG - 22 LID - 10.1186/s12882-025-04728-6 [doi] LID - 22 AB - BACKGROUND: The increasing prevalence of individuals undergoing haemodialysis (HD) compels the necessity of person-centred care to minimise treatment-related complications and improve the quality of life. Although the person-centred approach has been widely discussed, it remains underutilised in HD care, particularly in low- to middle-income countries. Understanding how patients perceive their care is crucial for developing tailored interventions and achieving desirable health outcomes. Therefore, this study was aimed to explore patients' experiences of HD care in three selected government hospital dialysis units in Colombo District, Sri Lanka. METHODS: One-to-one, semi-structured interviews were conducted with a purposive sample of twelve participants undergoing HD for more than six consecutive months and receiving at least one dialysis session per week. Interviews were conducted from April to December 2022 until data saturation was reached. All interviews were digitally recorded, transcribed verbatim and analysed using the qualitative content analysis proposed by Graneheim and Lundman. RESULTS: An overarching theme, 'Adapting to a Disrupted Life Trajectory' with four categories emerged: Burden of living with HD, Physical and psychological consequences of treatment, Coping and adjustment mechanisms, Healthcare system and service experiences. Daily life was often a burden for the participants due to physical and psychological challenges, numerous life restrictions and self-care burden. Despite these altered life routines, patients adapted coping mechanisms to regain a sense of control and maintain continuity of their treatment. Stigma associated with the terminal illness, famiy dynamics, and internal coping through spirituality shaped unique patient adaptation to the illness experience. Participants expressed a need for accessible HD care that is high in quality, safe, and delivered with compassion. CONCLUSION: A person-centred approach, including goals of care conversations, would help to address patients' concerns related to the multifaceted burden of HD treatment. Strengthening a well-coordinated, multidisciplinary team including nephrology, palliative care, and community-based services is essential to meet patients' complex needs and provide specialist support across physical, psychological, social, and spiritual domains during the illness trajectory in a more holistic and timely manner. FAU - Lasanthika, Chalani AU - Lasanthika C AD - Department of Nursing and Midwifery, Faculty of Allied Health Sciences, University of Sri Jayewardenepura, Gangodawila, Nugegoda, Sri Lanka. c.nimna@sjp.ac.lk. FAU - Wanigasuriya, Kamani AU - Wanigasuriya K AD - Center for Kidney Research, Faculty of Medical Sciences, University of Sri Jayewardenepura, Gangodawila, Nugegoda, Sri Lanka. FAU - Hettiaratchi, Usha AU - Hettiaratchi U AD - Department of Biochemistry, Faculty of Medical Sciences, University of Sri Jayewardenepura, Gangodawila, Nugegoda, Sri Lanka. FAU - Amarasekara, Thamara Dilhani AU - Amarasekara TD AD - Department of Nursing and Midwifery, Faculty of Allied Health Sciences, University of Sri Jayewardenepura, Gangodawila, Nugegoda, Sri Lanka. FAU - Goonewardena, Christine Sampatha Evangeline AU - Goonewardena CSE AD - Department of Community Medicine, Faculty of Medical Sciences, University of Sri Jayewardenepura, Gangodawila, Nugegoda, Sri Lanka. AD - Non Communicable Diseases Research Centre, University of Sri Jayewardenepura, Gangodawila, Nugegoda, Sri Lanka. LA - eng GR - ASP/ 01/RE/MED/2017/61/University Research Grant, University of Sri Jayewardenepura, Sri Lanka./ PT - Journal Article DEP - 20260106 PL - England TA - BMC Nephrol JT - BMC nephrology JID - 100967793 SB - IM MH - Humans MH - Sri Lanka MH - *Renal Dialysis/psychology MH - Female MH - Male MH - *Adaptation, Psychological MH - Qualitative Research MH - Middle Aged MH - Quality of Life MH - Aged MH - Adult MH - *Kidney Failure, Chronic/therapy/psychology MH - Patient-Centered Care PMC - PMC12784590 OTO - NOTNLM OT - Chronic kidney failure OT - Hospital haemodialysis units OT - Qualitative research OT - Renal dialysis OT - Sri Lanka COIS- Declarations. Ethics approval and consent to participate: The study was approved by the Research Ethics Committees of the Faculty of Medical Sciences, University of Sri Jayewardenepura (Application No.06/19), The National Hospital of Sri Lanka (AAJ/ETH/COM/2021/JULY) and Colombo South Teaching Hospital (Application No.994). The study involved human participants and was conducted in accordance with the Declaration of Helsinki. We confirm that all methods were performed in accordance with relevant guidelines regulations. All participants were informed about the aims and process of this study, signed written informed consent forms prior to being interviewed, they were free to withdraw from the research at any point of time, and participated in this study voluntarily. The transcriptions were anonymised using a number to ensure confidentiality. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests. EDAT- 2026/01/07 01:11 MHDA- 2026/06/27 00:52 PMCR- 2026/01/06 CRDT- 2026/01/06 23:44 PHST- 2025/09/19 00:00 [received] PHST- 2025/12/29 00:00 [accepted] PHST- 2026/06/27 00:52 [medline] PHST- 2026/01/07 01:11 [pubmed] PHST- 2026/01/06 23:44 [entrez] PHST- 2026/01/06 00:00 [pmc-release] AID - 10.1186/s12882-025-04728-6 [pii] AID - 4728 [pii] AID - 10.1186/s12882-025-04728-6 [doi] PST - epublish SO - BMC Nephrol. 2026 Jan 6;27(1):22. doi: 10.1186/s12882-025-04728-6. PMID- 41494163 OWN - NLM STAT- MEDLINE DCOM- 20260106 LR - 20260622 IS - 2564-1891 (Electronic) IS - 2564-1891 (Linking) VI - 6 DP - 2026 Jan 6 TI - Marketing Strategies and Factors Influencing the Popularity of Alcohol Videos from Official Brand Accounts on Douyin: Content Analysis Study. PG - e74221 LID - 10.2196/74221 [doi] LID - e74221 AB - BACKGROUND: Alcohol consumption in China poses significant public health challenges. Alcohol marketing has been shown to increase public alcohol consumption, with social media platforms such as Douyin (TikTok in Mainland China) being among the main channels for alcohol marketing. OBJECTIVE: This study aimed to analyze the thematic content of alcohol advertising on the Douyin platform and to explore the factors influencing the popularity of these types of advertising. METHODS: Using data from the JINGDONG platform and alcohol industry reports, we identified 40 popular alcohol brands. For each brand, we located their official Douyin accounts and selected the top 20 most-liked videos posted between November 1, 2020, and November 1, 2021. In total, 659 videos from 37 brands were collected for analysis. Two trained researchers independently coded each video using a predefined codebook, which consisted of 7 sections and 20 items. Binary logistic regression was conducted with the grouping of the number of likes as the dependent variable, and the marketing strategies and warning elements of each video as independent variables. RESULTS: Among the 659 videos analyzed, 320 (48.6%) garnered more than 1000 likes. A significant portion of the videos was direct advertisements (281/659, 42.6%) and short skits (255/659, 38.7%), with 56.0% (369/659) featuring characters engaging in drinking-related behaviors or directly consuming alcohol. Additionally, many videos highlighted brand elements (510/659, 77.4%) and extended features (161/659, 24.4%). Cultural themes were also common, with 23.2% (153/659) of the videos promoting the enjoyment of life and 6.8% (45/659) emphasizing balance in life. However, age restrictions were missing for 26.9% (177/659) of the videos, and only 1.2% (8/659) included a health warning stating that "Drinking is harmful to health." Certain marketing strategies were significantly associated with greater video popularity, including the use of short skits (odds ratio [OR] 2.77, 95% CI 1.42-5.41), highlighting brand elements (OR 2.96, 95% CI 1.59-5.51), and emphasizing life balance (OR 3.44, 95% CI 1.11-10.66). In contrast, the presence of age restrictions (OR 0.32, 95% CI 0.15-0.67) and explicit health warnings (OR 0.06, 95% CI 0.01-0.84) were associated with lower popularity. The period from July to September and November was the peak release period for alcohol advertisements on Douyin. CONCLUSIONS: Alcohol marketing strategies on Douyin leverage experiential, brand-driven, collaborative, and cultural marketing techniques to enhance video attractiveness and create alcogenic environments. Moreover, effective age restrictions and health warnings are largely absent. It is essential to legislate and enforce stricter alcohol marketing regulations to reduce the health risks associated with alcohol marketing. CI - (c) Yuchen Zhao, Lingyun Zhang, Chenyu Qian, Wenjie Guo, Weiyun Zhu, Pinpin Zheng. Originally published in JMIR Infodemiology (https://infodemiology.jmir.org). FAU - Zhao, Yuchen AU - Zhao Y AUID- ORCID: 0000-0002-1935-8147 AD - Department of Preventive Medicine and Health Education, School of Public Health, Institute of Health Communication, Fudan University, 138 Yixueyuan Road, Xuhui District, Shanghai, 200032, China, 86 13917249701. FAU - Zhang, Lingyun AU - Zhang L AUID- ORCID: 0000-0002-6237-8936 AD - Department of Preventive Medicine and Health Education, School of Public Health, Institute of Health Communication, Fudan University, 138 Yixueyuan Road, Xuhui District, Shanghai, 200032, China, 86 13917249701. AD - Party Committee Office, Zhongshan Hospital Affiliated with Fudan University, Shanghai, China. FAU - Qian, Chenyu AU - Qian C AUID- ORCID: 0009-0005-9902-150X AD - Department of Preventive Medicine and Health Education, School of Public Health, Institute of Health Communication, Fudan University, 138 Yixueyuan Road, Xuhui District, Shanghai, 200032, China, 86 13917249701. FAU - Guo, Wenjie AU - Guo W AUID- ORCID: 0009-0003-1700-3451 AD - Department of Preventive Medicine and Health Education, School of Public Health, Institute of Health Communication, Fudan University, 138 Yixueyuan Road, Xuhui District, Shanghai, 200032, China, 86 13917249701. FAU - Zhu, Weiyun AU - Zhu W AUID- ORCID: 0009-0007-4578-6800 AD - Department of Preventive Medicine and Health Education, School of Public Health, Institute of Health Communication, Fudan University, 138 Yixueyuan Road, Xuhui District, Shanghai, 200032, China, 86 13917249701. FAU - Zheng, Pinpin AU - Zheng P AUID- ORCID: 0000-0003-3902-2955 AD - Department of Preventive Medicine and Health Education, School of Public Health, Institute of Health Communication, Fudan University, 138 Yixueyuan Road, Xuhui District, Shanghai, 200032, China, 86 13917249701. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20260106 PL - Canada TA - JMIR Infodemiology JT - JMIR infodemiology JID - 9918249014806676 SB - IM MH - Humans MH - *Alcoholic Beverages/statistics & numerical data MH - *Social Media/statistics & numerical data MH - *Alcohol Drinking MH - *Marketing/methods/statistics & numerical data MH - *Advertising/statistics & numerical data/methods MH - China MH - *Video Recording/statistics & numerical data PMC - PMC12774395 OTO - NOTNLM OT - Douyin platform OT - advertisement OT - alcogenic environments OT - alcohol marketing OT - health warning COIS- Conflicts of Interest: None declared. EDAT- 2026/01/06 19:18 MHDA- 2026/01/06 19:19 PMCR- 2026/01/06 CRDT- 2026/01/06 16:33 PHST- 2025/03/20 00:00 [received] PHST- 2025/12/09 00:00 [accepted] PHST- 2026/01/06 19:19 [medline] PHST- 2026/01/06 19:18 [pubmed] PHST- 2026/01/06 16:33 [entrez] PHST- 2026/01/06 00:00 [pmc-release] AID - v6i1e74221 [pii] AID - 74221 [pii] AID - 10.2196/74221 [doi] PST - epublish SO - JMIR Infodemiology. 2026 Jan 6;6:e74221. doi: 10.2196/74221. PMID- 41489243 OWN - NLM STAT- In-Process LR - 20260105 IS - 2284-0729 (Electronic) IS - 1128-3602 (Linking) VI - 29 IP - 12 DP - 2025 Dec TI - Publisher Correction: Effects of effective antithyroid therapy on adiposity and skeletal muscle in patients with hyperthyroidism across gender and age groups. PG - 560-561 LID - 37563 [pii] LID - 10.26355/eurrev_202512_37563 [doi] AB - Eur Rev Med Pharmacol Sci 2023; 27 (13): 6170-6175 DOI: 10.26355/eurrev_202307_32973D-PMID: 37458673, published online on July 13, 2023. Following an editorial quality check, we have determined that incorrect references from another article were inadvertently inserted into the final PDF. The error was not detected by the authors prior to publication, and the PDF file was approved for publication. The erratum is issued to correct the whole list of references. The corrected list of references is provided below: Lai CL, Wu H, Ni GJ. [Traditional Chinese medicine Pericarpium Citri Reticulatae from Guangdong and Xinhui textual criticism]. Zhongguo Zhong Yao Za Zhi 2017; 42: 789-794. Moro T, Tinsley G, Bianco A, Marcolin G, Pacelli QF, Battaglia G, Palma A, Gentil P, Neri M, Paoli A. Effects of eight weeks of time-restricted feeding (16/8) on basal metabolism, maximal strength, body composition, inflammation, and cardiovascular risk factors in resistance-trained males. J Transl Med 2016; 14: 290. Hayashi A, Takano K, Kawakami Y, Hitomi M, Ohata Y, Suzuki A, Kamata Y, Shichiri M. Short-term Change in Resting Energy Expenditure and Body Compositions in Therapeutic Process for Graves' Disease. Intern Med 2020; 59: 1827-1833. New Medical Journal: Archives of Scientific and Practical Medicine. Buffalo Med Surg J 1872; 12: 154. Bande AR, Kalra P, Dharmalingam M, Selvan C, Suryanarayana KM. Serum Fibroblast Growth Factor 21 Levels in Patients with Hyperthyroidism and its Association with Body Fat Percentage. Indian J Endocrinol Metab 2019; 23: 557-562. Caixas A, Tirado R, Vendrell J, Gallart L, Megia A, Simon I, Llaurado G, Gonzalez-Clemente JM, Gimenez-Palop O. Plasma visfatin concentrations increase in both hyper and hypothyroid subjects after normalization of thyroid function and are not related to insulin resistance, anthropometric or inflammatory parameters. Clin Endocrinol (Oxf) 2009; 71: 733-738. Major E, Gyory F, Horvath D, Keller I, Tamas I, Uray K, Fulop P, Lontay B. Smoothelin-Like Protein 1 Regulates Development and Metabolic Transformation of Skeletal Muscle in Hyperthyroidism. Front Endocrinol (Lausanne) 2021; 12: 751488. Calonne J, Isacco L, Miles-Chan J, Arsenijevic D, Montani JP, Guillet C, Boirie Y, Dulloo AG. Reduced Skeletal Muscle Protein Turnover and Thyroid Hormone Metabolism in Adaptive Thermogenesis That Facilitates Body Fat Recovery During Weight Regain. Front Endocrinol (Lausanne) 2019; 10: 119. Peterson ME, Castellano CA, Rishniw M. Evaluation of Body Weight, Body Condition, and Muscle Condition in Cats with Hyperthyroidism. J Vet Intern Med 2016; 30: 1780-1789. Brunova J, Kasalicky P, Lanska V. [The assessment of body composition using DEXA in patients with thyroid dysfunction]. Cas Lek Cesk 2007; 146: 497-502. Acotto CG, Niepomniszcze H, Mautalen CA. Estimating body fat and lean tissue distribution in hyperthyroidism by dual-energy X-ray absorptiometry. J Clin Densitom 2002; 5: 305-311. Kim MJ, Cho SW, Choi S, Ju DL, Park DJ, Park YJ. Changes in Body Compositions and Basal Metabolic Rates during Treatment of Graves' Disease. Int J Endocrinol 2018; 2018: 9863050. Grove-Laugesen D, Cramon PK, Malmstroem S, Ebbehoj E, Watt T, Hansen KW, Rejnmark L. Effects of Supplemental Vitamin D on Muscle Performance and Quality of Life in Graves' Disease: A Randomized Clinical Trial. Thyroid 2020; 30: 661-671. Bloise FF, Cordeiro A, Ortiga-Carvalho TM. Role of thyroid hormone in skeletal muscle physiology. J Endocrinol 2018; 236: R57-R68. Ambrosio R, De Stefano MA, Di Girolamo D, Salvatore D. Thyroid hormone signaling and deiodinase actions in muscle stem/progenitor cells. Mol Cell Endocrinol 2017; 459: 79-83. Braclik M, Marcisz C, Giebel S, Orzel A. Serum leptin and ghrelin levels in premenopausal women with stable body mass index during treatment of thyroid dysfunction. Thyroid 2008; 18: 545-550. Zhou J, Parker DC, White JP, Lim A, Huffman KM, Ho JP, Yen PM, Kraus WE. Thyroid Hormone Status Regulates Skeletal Muscle Response to Chronic Motor Nerve Stimulation. Front Physiol 2019; 10: 1363. Szlejf C, Suemoto CK, Janovsky C, Barreto SM, Diniz M, Lotufo PA, Bensenor IM. Thyroid Function and Sarcopenia: Results from the ELSA-Brasil Study. J Am Geriatr Soc 2020; 68: 1545-1553. Jiang X, He P, Zhu D, Shi X, Meng Q. Different impacts of the zero-markup drug policy on county general and traditional Chinese medicine hospitals: evidence from Shandong province, China. Int J Equity Health 2020; 19: 219. Selivanova EK, Gaynullina DK, Tarasova OS. Thyroxine Induces Acute Relaxation of Rat Skeletal Muscle Arteries via Integrin alphavbeta3, ERK1/2 and Integrin-Linked Kinase. Front Physiol 2021; 12: 726354. Mitrou P, Raptis SA, Dimitriadis G. Insulin action in hyperthyroidism: a focus on muscle and adipose tissue. Endocr Rev 2010; 31: 663-679. Boj-Carceller D, Sanz-Paris A, Sanchez-Oriz E, Garcia-Foncillas Lopez R, Calmarza-Calmarza P, Blay-Cortes V, Abos-Olivares MD. TREATMENT OF SUBCLINICAL HYPERTHYROIDISM: EFFECT ON BODY COMPOSITION. Nutr Hosp 2015; 32: 2331-2337. Xie LJ, Zhou HJ, Li JF, Zhang F, Zeng FW, Qin LP, Chen Y, Yuan HJ, Cheng MH. Redistribution of body composition in patients with Graves' disease after iodine-131 treatment. Eur J Clin Nutr 2015; 69: 856-861. Tanski W, Kosiorowska J, Szymanska-Chabowska A. Osteoporosis - risk factors, pharmaceutical and non-pharmaceutical treatment. Eur Rev Med Pharmacol Sci 2021; 25: 3557-3566. Bousquet-Santos K, Vaisman M, Barreto ND, Cruz-Filho RA, Salvador BA, Frontera WR, Nobrega AC. Resistance training improves muscle function and body composition in patients with hyperthyroidism. Arch Phys Med Rehabil 2006; 87: 1123-1130. There are amendments to this paper. The Publisher apologizes for any inconvenience this may cause. https://www.europeanreview.org/article/32973. FAU - Zhou, H-Y AU - Zhou HY AD - Department of Endocrinology, Liuzhou People's Hospital, Liuzhou, China. FAU - Deng, S-S AU - Deng SS FAU - Wei, S-Y AU - Wei SY FAU - Chen, S-G AU - Chen SG FAU - Lai, L-H AU - Lai LH LA - eng PT - Published Erratum PL - United States TA - Eur Rev Med Pharmacol Sci JT - European review for medical and pharmacological sciences JID - 9717360 SB - IM EFR - Eur Rev Med Pharmacol Sci. 2023 Jul;27(13):6170-6175. doi: 10.26355/eurrev_202307_32973. PMID: 37458673 EDAT- 2026/01/05 12:47 MHDA- 2026/01/05 12:47 CRDT- 2026/01/05 07:33 PHST- 2026/01/05 12:47 [medline] PHST- 2026/01/05 12:47 [pubmed] PHST- 2026/01/05 07:33 [entrez] AID - 37563 [pii] AID - 10.26355/eurrev_202512_37563 [doi] PST - ppublish SO - Eur Rev Med Pharmacol Sci. 2025 Dec;29(12):560-561. doi: 10.26355/eurrev_202512_37563. PMID- 41466257 OWN - NLM STAT- MEDLINE DCOM- 20251230 LR - 20260101 IS - 1472-684X (Electronic) IS - 1472-684X (Linking) VI - 24 IP - 1 DP - 2025 Dec 29 TI - Cancer treatment shared decision-making and coping during the COVID-19 pandemic (CAN-DECIDE): a mixed-methods study. PG - 303 LID - 10.1186/s12904-025-01944-7 [doi] LID - 303 AB - BACKGROUND: We hypothesized that cancer patients, their family members, and cancer and palliative care practitioners were experiencing significant COVID-related stress and changes to cancer care and sought to characterize contributing factors. METHODS: We completed a mixed methods study to explore cancer care-related experiences during the COVID-19 pandemic of cancer patients, family members, and cancer and palliative care practitioners. Participants were recruited from an ongoing clinical trial. RESULTS: Patients were pursuing curative-intent surgeries for upper gastrointestinal cancers. Between October 2020 and July 2021, we collected 491 surveys from 181 cancer patients and 26 family caregivers and conducted 71 in-depth interviews with 48 cancer patients, 6 family caregivers, and 19 practitioners. Patient-reported quality-of-life measurements were not associated with a corresponding COVID surge. Patients and caregivers were generally satisfied with their care, trusted providers, and were often unaware of pandemic-related changes. In contrast, practitioners reported significant pandemic-related changes to cancer care delivery with associated practitioner anxiety, fatigue, and moral distress. All felt that visitor restrictions negatively impacted care. CONCLUSIONS: Our data suggest that cancer patients coped well overall despite pandemic-related disruptions whereas cancer care clinicians experienced significant stress. These findings can inform future disaster-preparedness planning and policy-setting in institutions providing cancer care. CI - (c) 2025. The Author(s). FAU - Aslakson, Rebecca A AU - Aslakson RA AD - Department of Anesthesiology, Larner College of Medicine at the University of Vermont, 111 Colchester Ave., West Pavilion 2-240, Burlington, VT, USA. Rebecca.Aslakson@uvmhealth.org. FAU - Siden, Rachel AU - Siden R AD - Department of Medicine, Stanford School of Medicine, Stanford, CA, USA. FAU - Holdsworth, Laura M AU - Holdsworth LM AD - Department of Medicine, Stanford School of Medicine, Stanford, CA, USA. FAU - Colborn, Kathryn AU - Colborn K AD - Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA. FAU - Verano, Mae AU - Verano M AD - Department of Medicine, Stanford School of Medicine, Stanford, CA, USA. FAU - Wong, Bonnie Odelia AU - Wong BO AD - Department of Surgery, Brigham and Women's Hospital, Boston, MA, USA. FAU - Johnston, Fabian AU - Johnston F AD - Department of Surgery, Johns Hopkins Medical Institutions Campus, Baltimore, MD, USA. FAU - Nudotor, Richard AU - Nudotor R AD - Department of Surgery, Johns Hopkins Medical Institutions Campus, Baltimore, MD, USA. FAU - Siddiqi, Amn AU - Siddiqi A AD - Department of Surgery, Johns Hopkins Medical Institutions Campus, Baltimore, MD, USA. FAU - Rickerson, Elizabeth AU - Rickerson E AD - Department of Psychosocial Oncology and Palliative Care, Dana-Farber Cancer Institute, Boston, MA, USA. AD - Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital, Boston, MA, USA. FAU - Hollahan, Caroline AU - Hollahan C AD - Department of Psychosocial Oncology and Palliative Care, Dana-Farber Cancer Institute, Boston, MA, USA. FAU - Fahy, Bridget AU - Fahy B AD - Department of Surgery, Divisions of Surgical Oncology and Palliative Medicine, University of New Mexico, Albuquerque, NM, USA. FAU - Lira, Isaac AU - Lira I AD - Clinical Research Department, University of New Mexico Comprehensive Cancer Center, Albuquerque, NM, USA. FAU - Waterman, Brittany AU - Waterman B AD - Department of Internal Medicine, Division of Palliative Medicine, Ohio State University Wexner Medical Center, Columbus, OH, USA. FAU - Johnson, Kemba AU - Johnson K AD - Clinical Research Center, Ohio State University Wexner Medical Center, Columbus, OH, USA. FAU - Nasso, Shelley Fuld AU - Nasso SF AD - National Coalition for Cancer Survivorship, Silver Spring, MD, USA. FAU - Tabor, Holly AU - Tabor H AD - Department of Medicine, Stanford School of Medicine, Stanford, CA, USA. FAU - Schapira, Lidia AU - Schapira L AD - Stanford Cancer Institute, Stanford, CA, USA. LA - eng GR - IHS 1609-36518/PCORI/Patient-Centered Outcomes Research Institute/United States PT - Journal Article DEP - 20251229 PL - England TA - BMC Palliat Care JT - BMC palliative care JID - 101088685 SB - IM MH - Humans MH - *COVID-19/psychology/epidemiology MH - Female MH - Male MH - Middle Aged MH - Aged MH - *Adaptation, Psychological MH - *Neoplasms/therapy/psychology MH - Adult MH - *Decision Making, Shared MH - Surveys and Questionnaires MH - Qualitative Research MH - Caregivers/psychology MH - Palliative Care/psychology MH - Pandemics MH - Quality of Life/psychology PMC - PMC12750573 OTO - NOTNLM OT - Burnout OT - COVID OT - COVID-19 OT - Cancer OT - Cancer care OT - Palliative care OT - Quality of life COIS- Declarations. Ethics approval and consent to participate: This research was conducted in accordance with federal and state regulations and ethical guidelines for biomedical research, adhering to the principles outlined in the Declaration of Helsinki and the Belmont Report. This study was reviewed and approved by the Institutional Review Board (IRB) at each study site: Stanford University IRB (protocols #45805 and #57590); Johns Hopkins Medicine IRB (protocol #00045052); Dana-Farber Cancer Institute IRB (protocol #18-219); and University of New Mexico IRB (protocol #18-670). Informed consent was obtained from all study participants. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests. EDAT- 2025/12/30 07:40 MHDA- 2025/12/30 13:09 PMCR- 2025/12/29 CRDT- 2025/12/30 02:36 PHST- 2025/04/10 00:00 [received] PHST- 2025/11/12 00:00 [accepted] PHST- 2025/12/30 13:09 [medline] PHST- 2025/12/30 07:40 [pubmed] PHST- 2025/12/30 02:36 [entrez] PHST- 2025/12/29 00:00 [pmc-release] AID - 10.1186/s12904-025-01944-7 [pii] AID - 1944 [pii] AID - 10.1186/s12904-025-01944-7 [doi] PST - epublish SO - BMC Palliat Care. 2025 Dec 29;24(1):303. doi: 10.1186/s12904-025-01944-7. PMID- 41458699 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20251229 LR - 20251231 IS - 2168-8184 (Print) IS - 2168-8184 (Electronic) IS - 2168-8184 (Linking) VI - 17 IP - 11 DP - 2025 Nov TI - Lactose Intolerance in Irritable Bowel Syndrome: Prevalence, Subtype Correlations, and Clinical Predictors in an Indian Cohort. PG - e97697 LID - 10.7759/cureus.97697 [doi] LID - e97697 AB - Irritable bowel syndrome (IBS) and lactose intolerance (LI) frequently coexist, complicating diagnosis and management due to overlapping abdominal pain, bloating, and altered bowel habits. This study aimed to quantify LI prevalence in IBS and delineate clinical predictors to inform targeted care. We conducted a single-center observational study (July 2021-December 2022) at a tertiary hospital in North India, enrolling 100 adults with Rome IV-defined IBS. Standardized hydrogen breath testing identified lactose malabsorption; demographic, dietary, and symptom data were collected, and associations were evaluated using chi-square tests and logistic regression with a prespecified alpha = 0.05. LI was present in 38 (38%) IBS patients in this study. The diarrhea-predominant (IBS-D) subtype showed the strongest association with LI (OR = 5.92; 95% CI 2.1-16.8; p < 0.001), whereas the constipation-predominant (IBS-C) subtype was least affected. Higher habitual lactose intake (>/=26 g/day) correlated with greater symptom frequency (p < 0.001). The cohort's mean age was 36.8 +/- 11.4 years, and most reported symptoms for >/=1 year, underscoring chronicity. No significant associations were observed with sex or BMI categories. These findings demonstrate that unrecognized LI contributes substantially to symptom burden in Indian IBS populations, particularly IBS-D. Incorporating structured dietary assessment and selective breath testing into diagnostic algorithms can reduce misclassification, avoid unnecessary pharmacotherapy, and enable individualized lactose restriction. The study provides population-specific evidence supporting diet-responsive, precision strategies for IBS care and highlights the value of simple, noninvasive diagnostics in resource-constrained settings. Prospective multicenter trials integrating microbiome and dietary interventions are warranted to refine subtype-specific, nutrition-based management. CI - Copyright (c) 2025, Chavhan et al. FAU - Chavhan, Praful Kumar B AU - Chavhan PKB AD - Gastroenterology, Aryavart Hospital, Meerut, IND. FAU - Sayeed, Mohmad Sejarali AU - Sayeed MS AD - Gastrointestinal Surgery, Aryavart Hospital, Meerut, IND. FAU - Saiyad, Sajidali S AU - Saiyad SS AD - Physiology, Pacific Medical College and Hospital, Pacific Medical University, Udaipur, IND. FAU - Shah, Mansi Nileshkumar AU - Shah MN AD - Medical Health, Community Health Centre, Udalpur, IND. FAU - Ekambaram, Gnanadesigan AU - Ekambaram G AD - Physiology, Nootan Medical College and Research Centre, Sankalchand Patel University, Visnagar, IND. FAU - Panchal, Hasmukh AU - Panchal H AD - Medicine, Pacific Medical College and Hospital, Pacific Medical University, Udaipur, IND. FAU - B H, Gayathri AU - B H G AD - Physiology, Pacific Medical College and Hospital, Pacific Medical University, Udaipur, IND. FAU - Js, Sravan AU - Js S AD - Forensic Medicine, Pacific Medical College and Hospital, Pacific Medical University, Udaipur, IND. AD - Forensic Medicine and Toxicology, All India Institute of Medical Sciences, Bhopal, IND. LA - eng PT - Journal Article DEP - 20251124 PL - United States TA - Cureus JT - Cureus JID - 101596737 PMC - PMC12740768 OTO - NOTNLM OT - diarrhea-predominant ibs OT - dietary management OT - gut microbiota OT - hydrogen breath test OT - ibs subtypes OT - irritable bowel syndrome OT - lactose intolerance OT - lactose malabsorption OT - rome iv criteria OT - visceral hypersensitivity COIS- Human subjects: Informed consent for treatment and open access publication was obtained or waived by all participants in this study. Artemis Health Sciences Institutional Ethics Committee issued approval AHS-IEC Reg. No.: ECR/53/Inst/HR/2013/RR-16. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work. EDAT- 2025/12/29 07:08 MHDA- 2025/12/29 07:09 PMCR- 2025/11/24 CRDT- 2025/12/29 05:14 PHST- 2025/11/24 00:00 [accepted] PHST- 2025/12/29 07:09 [medline] PHST- 2025/12/29 07:08 [pubmed] PHST- 2025/12/29 05:14 [entrez] PHST- 2025/11/24 00:00 [pmc-release] AID - 10.7759/cureus.97697 [doi] PST - epublish SO - Cureus. 2025 Nov 24;17(11):e97697. doi: 10.7759/cureus.97697. eCollection 2025 Nov. PMID- 41456735 OWN - NLM STAT- MEDLINE DCOM- 20260621 LR - 20260621 IS - 1531-5037 (Electronic) IS - 0022-3468 (Linking) VI - 61 IP - 7 DP - 2026 Jul TI - State legislation and surgical demand: Operative needs of Texas infants after early abortion ban. PG - 162888 LID - S0022-3468(25)00735-3 [pii] LID - 10.1016/j.jpedsurg.2025.162888 [doi] AB - BACKGROUND: The 2021 Texas Senate Bill 8 (SB8) restricts abortion after approximately six weeks' gestation. Prior statewide analyses have demonstrated increased congenital anomalies following SB8, but the operative implications of these changes remain unknown. PURPOSE: To evaluate changes in operative admissions, outcomes, and charges for infants with congenital anomalies in Texas before and after SB8 implementation. METHODS: We conducted a retrospective cohort study using the Texas Inpatient Public Use Data File. Inpatient admissions for infants younger than one year were analyzed a year before (July 1, 2020-June 30, 2021) and after (July 1, 2022-June 30, 2023) SB8. Operative admissions were identified using operating room charges. Primary outcomes included admission volume, mortality, length of stay, and hospital charges. Secondary outcomes included operative admissions by congenital anomaly organ system. RESULTS: Operative admissions increased by 1121 in the post-SB8 year, though the overall proportion decreased (22.5 % pre-SB8 vs 20.5 % post-SB8). Operative admissions with congenital anomalies increased by 1443 (21.7 %-23.2 %). Median charge per operative admission with congenital anomalies increased by $7,001, contributing to a nearly $1.1 billion rise in aggregate charges (P < 0.0001). Mortality and median length of stay remained stable. Organ system analyses demonstrated varied changes, with the largest increases in circulatory, urinary, and genital anomalies. CONCLUSIONS: The early abortion ban in Texas is associated with increased operative demand and higher inpatient charges for infants with congenital anomalies. These findings highlight the growing surgical and economic impact of abortion restrictions on pediatric healthcare systems. CI - Copyright (c) 2025. Published by Elsevier Inc. FAU - Guerra, Mary Elizabeth AU - Guerra ME AD - Michael E. DeBakey Department of Surgery, Baylor College of Medicine, 1 Baylor Plaza, Houston, TX 77030, USA. FAU - Larabee, Shannon M AU - Larabee SM AD - Department of Surgery, Division of Pediatric Surgery, Texas Children's Hospital, 6701 Fannin St., Houston, TX 77030, USA. FAU - Hosek, Kathleen E AU - Hosek KE AD - Department of Surgery, Division of Pediatric Surgery, Texas Children's Hospital, 6701 Fannin St., Houston, TX 77030, USA. FAU - Peiffer, Sarah E AU - Peiffer SE AD - Michael E. DeBakey Department of Surgery, Baylor College of Medicine, 1 Baylor Plaza, Houston, TX 77030, USA. FAU - Keswani, Sundeep G AU - Keswani SG AD - Michael E. DeBakey Department of Surgery, Baylor College of Medicine, 1 Baylor Plaza, Houston, TX 77030, USA; Department of Surgery, Division of Pediatric Surgery, Texas Children's Hospital, 6701 Fannin St., Houston, TX 77030, USA. FAU - Lee, Timothy C AU - Lee TC AD - Michael E. DeBakey Department of Surgery, Baylor College of Medicine, 1 Baylor Plaza, Houston, TX 77030, USA; Department of Surgery, Division of Pediatric Surgery, Texas Children's Hospital, 6701 Fannin St., Houston, TX 77030, USA. FAU - King, Alice AU - King A AD - Michael E. DeBakey Department of Surgery, Baylor College of Medicine, 1 Baylor Plaza, Houston, TX 77030, USA; Department of Surgery, Division of Pediatric Surgery, Texas Children's Hospital, 6701 Fannin St., Houston, TX 77030, USA. Electronic address: alice.king@bcm.edu. LA - eng PT - Journal Article DEP - 20251226 PL - United States TA - J Pediatr Surg JT - Journal of pediatric surgery JID - 0052631 SB - IM MH - Humans MH - Texas/epidemiology MH - Retrospective Studies MH - Female MH - *Congenital Abnormalities/surgery/epidemiology/economics MH - Infant MH - Length of Stay/statistics & numerical data MH - Infant, Newborn MH - Pregnancy MH - Hospital Charges/statistics & numerical data MH - *Health Services Needs and Demand/statistics & numerical data MH - *Abortion, Induced/legislation & jurisprudence OTO - NOTNLM OT - Abortion OT - Birth defects OT - Congenital anomalies OT - Cost OT - Healthcare utilization OT - Policy OT - Senate Bill 8 OT - Surgery COIS- Conflict of interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2025/12/29 00:24 MHDA- 2026/06/21 22:31 CRDT- 2025/12/28 19:34 PHST- 2025/12/12 00:00 [received] PHST- 2025/12/19 00:00 [accepted] PHST- 2026/06/21 22:31 [medline] PHST- 2025/12/29 00:24 [pubmed] PHST- 2025/12/28 19:34 [entrez] AID - S0022-3468(25)00735-3 [pii] AID - 10.1016/j.jpedsurg.2025.162888 [doi] PST - ppublish SO - J Pediatr Surg. 2026 Jul;61(7):162888. doi: 10.1016/j.jpedsurg.2025.162888. Epub 2025 Dec 26. PMID- 41445636 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260722 LR - 20260919 DP - 2025 Dec 18 TI - Cohort Profile: PRECISE-DYAD: a prospective cohort study linking maternal and infant health trajectories in sub-Saharan Africa. LID - 2025.12.17.25342279 [pii] LID - 10.64898/2025.12.17.25342279 [doi] AB - PURPOSE: The PRECISE-DYAD study is a prospective observational cohort, designed to investigate health outcomes among mother-child pairs (dyads), over the first three years of life in two contexts from sub-Saharan Africa. The primary objective of the study was to explore the effects of selected placenta-related complications, such as pregnancy hypertension, fetal growth restriction, and preterm birth, on 1) child health and development, and 2) women's health and well-being, including outcomes after stillbirth. PARTICIPANTS: The PRECISE-DYAD study enrolled women (and their children) originally recruited into the PRECISE regnancy cohort study in The Gambia and Kenya between July 2021 and April 2024. Participants were seen at 6 weeks to 6 months, 12 months, 24 months, and 36 months post-partum. Clinical and health data, including anthropometry and diet were collected for both mothers and children. Mother assessment included a cardiology assessment and collection of data about symptoms of COVID-19 infection. In a subset of participants, mothers were asked about their mental health, their health care costs during and after pregnancy, and experiences of care during labour and childbirth / delivery. Additonally, a personal environmental exposure assessement was performed for a subset of the cohort, by collecting air and water quality data alongside geographical, demographic, and behavioural factors. Child development was assessed using neurodevelopmental assessments, home environment evaluation, and quality of life measures. Biological samples were collected from mothers and children, processed promptly and biobanked locally. Sample data were entered into an OpenSpecimen database and linked to each individual, as well as to their corresponding social determinants and clinical data. FINDINGS TO DATE: A total of 2,980 women and 2,909 children completed at least one PRECISE-DYAD study visit. The biorepository contains 108,897 biological samples from mothers and children. Baseline descriptive analysis of the cohort are reported here. FUTURE PLANS: Analysis of data and samples will include biomarker studies, social determinants of health, and epidemiological investigations. These analyses will explore how placenta-related complications and environmental exposures, such as nutrition and air quality, interact to shape maternal health, mental well-being, subsequent pregnancies, and mother-child interaction, as well as child growth and neurodevelopment through early childhood. Additional work will examine the biological pathways linking these exposures to outcomes and the impacts of caring for children with moderate-to-severe disabilities on maternal well-being. Findings will be disseminated through scientific publications, conference presentations, engagement with local stakeholders, and continued community outreach. FAU - Volvert, Marie-Laure AU - Volvert ML AD - Department of Women and Children's Health, School of Life Course Sciences, Faculty of Life Sciences and Medicine, King's College London, London, UK. FAU - Wilson, Milly AU - Wilson M AD - Department of Women and Children's Health, School of Life Course Sciences, Faculty of Life Sciences and Medicine, King's College London, London, UK. FAU - Owino, Robin Okello AU - Owino RO AD - Centre of Excellence in Women & Child Health, East Africa, Aga Khan University, Nairobi, Kenya. FAU - Koech, Angela AU - Koech A AD - Centre of Excellence in Women & Child Health, East Africa, Aga Khan University, Nairobi, Kenya. FAU - Jah, Hawanatu AU - Jah H AD - Medical Research Council Unit The Gambia at the London School of Hygiene and Tropical Medicine, Fajara, The Gambia. FAU - Blencowe, Hannah AU - Blencowe H AD - Centre for Maternal Reproductive Adolescent and Child Health (MARCH), London School of Hygiene and Tropical Medicine, London, UK. FAU - Idris, Yahaya AU - Idris Y AD - Medical Research Council Unit The Gambia at the London School of Hygiene and Tropical Medicine, Fajara, The Gambia. FAU - Wanje, Onesmus AU - Wanje O AD - Centre of Excellence in Women & Child Health, East Africa, Aga Khan University, Nairobi, Kenya. FAU - Mwaniki, Isaak AU - Mwaniki I AD - Centre of Excellence in Women & Child Health, East Africa, Aga Khan University, Nairobi, Kenya. FAU - Mutunga, Joseph AU - Mutunga J AD - Centre of Excellence in Women & Child Health, East Africa, Aga Khan University, Nairobi, Kenya. FAU - Touray, Fatima AU - Touray F AD - Medical Research Council Unit The Gambia at the London School of Hygiene and Tropical Medicine, Fajara, The Gambia. FAU - Mwadime, Emily AU - Mwadime E AD - Centre of Excellence in Women & Child Health, East Africa, Aga Khan University, Nairobi, Kenya. FAU - Roca, Anna AU - Roca A AD - Medical Research Council Unit The Gambia at the London School of Hygiene and Tropical Medicine, Fajara, The Gambia. AD - ISGlobal, Hospital Clinic-Universitat de Barcelona, Barcelona, Spain. AD - ICREA, Barcelona, Spain. FAU - Omuse, Geoffrey AU - Omuse G AD - Department of Pathology, Aga Khan University, Nairobi, Kenya. FAU - Craik, Rachel AU - Craik R AD - Department of Women and Children's Health, School of Life Course Sciences, Faculty of Life Sciences and Medicine, King's College London, London, UK. FAU - Kongira, Fatoumata AU - Kongira F AD - Medical Research Council Unit The Gambia at the London School of Hygiene and Tropical Medicine, Fajara, The Gambia. FAU - Mukhanya, Moses AU - Mukhanya M AD - Centre of Excellence in Women & Child Health, East Africa, Aga Khan University, Nairobi, Kenya. FAU - Bojang, Kalilu AU - Bojang K AD - Medical Research Council Unit The Gambia at the London School of Hygiene and Tropical Medicine, Fajara, The Gambia. FAU - Njie, Baboucar AU - Njie B AD - Medical Research Council Unit The Gambia at the London School of Hygiene and Tropical Medicine, Fajara, The Gambia. FAU - Ochieng, Marvine AU - Ochieng M AD - Centre of Excellence in Women & Child Health, East Africa, Aga Khan University, Nairobi, Kenya. FAU - D'Alessandro, Umberto AU - D'Alessandro U AD - Medical Research Council Unit The Gambia at the London School of Hygiene and Tropical Medicine, Fajara, The Gambia. FAU - Mwashigadi, Grace AU - Mwashigadi G AD - Centre of Excellence in Women & Child Health, East Africa, Aga Khan University, Nairobi, Kenya. FAU - Mutua, Agnes M AU - Mutua AM AD - Centre of Excellence in Women & Child Health, East Africa, Aga Khan University, Nairobi, Kenya. FAU - Rerimoi, Anne AU - Rerimoi A AD - Department of Women and Children's Health, School of Life Course Sciences, Faculty of Life Sciences and Medicine, King's College London, London, UK. FAU - Temmerman, Marleen AU - Temmerman M AD - Centre of Excellence in Women & Child Health, East Africa, Aga Khan University, Nairobi, Kenya. FAU - Akuze, Joseph AU - Akuze J AD - Centre for Maternal Reproductive Adolescent and Child Health (MARCH), London School of Hygiene and Tropical Medicine, London, UK. FAU - Martinez-Alvarez, Melisa AU - Martinez-Alvarez M AD - Medical Research Council Unit The Gambia at the London School of Hygiene and Tropical Medicine, Fajara, The Gambia. FAU - Magai, Dorcas N AU - Magai DN AD - Department of Women's and Children's Health, Institute of Life Course and Medical Sciences, University of Liverpool, UK. FAU - Barratt, Benjamin AU - Barratt B AD - MRC Centre for Environment and Health, Imperial College London, SW7 2AZ London, UK. FAU - Li, Jing AU - Li J AD - Department of Obstetrics and Gynaecology and BC Children's Hospital Research Institute, University of British Columbia, Vancouver, Canada. FAU - Chandna, Jaya AU - Chandna J AD - Centre for Maternal Reproductive Adolescent and Child Health (MARCH), London School of Hygiene and Tropical Medicine, London, UK. FAU - Gladstone, Melissa J AU - Gladstone MJ AD - Department of Women's and Children's Health, Institute of Life Course and Medical Sciences, University of Liverpool, UK. FAU - Abubakar, Amina AU - Abubakar A AD - Institute for Human Development, Aga Khan University, Nairobi, Kenya. FAU - Tribe, Rachel M AU - Tribe RM AD - Department of Women and Children's Health, School of Life Course Sciences, Faculty of Life Sciences and Medicine, King's College London, London, UK. FAU - Khalil, Asma AU - Khalil A AD - Fetal Medicine Unit, Department of Obstetrics and Gynaecology, St. George's University Hospitals NHS Foundation Trust, Blackshaw Road, London SW17 0QT, UK. FAU - Vidler, Marianne AU - Vidler M AD - Department of Obstetrics and Gynaecology and BC Children's Hospital Research Institute, University of British Columbia, Vancouver, Canada. FAU - Makanga, Tatenda AU - Makanga T AD - Department of Surveying and Geomatics, Midlands State University, P. Bag 9055, Gweru, Zimbabwe. FAU - Salisbury, Tatiana Taylor AU - Salisbury TT AD - Health Service and Population Research Department, Institute of Psychiatry, Psychology and Neuroscience, King's College London, Denmark Hill, SE5 8AF, London, UK. FAU - Mistry, Hiten D AU - Mistry HD AD - Department of Women and Children's Health, School of Life Course Sciences, Faculty of Life Sciences and Medicine, King's College London, London, UK. AD - Divison of Public Health and Epidemiolgy, College of Life Sciences, Universty of Leicester, Leicester, UK. FAU - Moore, Sophie E AU - Moore SE AD - Department of Women and Children's Health, School of Life Course Sciences, Faculty of Life Sciences and Medicine, King's College London, London, UK. FAU - Nabwera, Helen AU - Nabwera H AD - Centre of Excellence in Women & Child Health, East Africa, Aga Khan University, Nairobi, Kenya. FAU - Filippi, Veronique AU - Filippi V AUID- ORCID: 0000-0003-1331-3391 AD - Centre for Maternal Reproductive Adolescent and Child Health (MARCH), London School of Hygiene and Tropical Medicine, London, UK. FAU - Magee, Laura A AU - Magee LA AD - Department of Women and Children's Health, School of Life Course Sciences, Faculty of Life Sciences and Medicine, King's College London, London, UK. AD - Department of Obstetrics and Gynaecology and BC Children's Hospital Research Institute, University of British Columbia, Vancouver, Canada. FAU - Makacha, Liberty AU - Makacha L AD - Department of Women and Children's Health, School of Life Course Sciences, Faculty of Life Sciences and Medicine, King's College London, London, UK. AD - Department of Obstetrics and Gynaecology and BC Children's Hospital Research Institute, University of British Columbia, Vancouver, Canada. FAU - Poston, Lucilla AU - Poston L AD - Department of Women and Children's Health, School of Life Course Sciences, Faculty of Life Sciences and Medicine, King's College London, London, UK. FAU - Sevene, Esperanca AU - Sevene E AD - Centro de Investigacao em Saude de Manhica, Manhica, Mozambique. FAU - von Dadelszen, Peter AU - von Dadelszen P AD - Department of Women and Children's Health, School of Life Course Sciences, Faculty of Life Sciences and Medicine, King's College London, London, UK. AD - Department of Obstetrics and Gynaecology and BC Children's Hospital Research Institute, University of British Columbia, Vancouver, Canada. LA - eng GR - WT_/Wellcome Trust/United Kingdom GR - U54 TW012089/TW/FIC NIH HHS/United States PT - Journal Article PT - Preprint DEP - 20251218 PL - United States TA - medRxiv JT - medRxiv : the preprint server for health sciences JID - 101767986 UIN - BMJ Open. 2026 Jul 17;16(7):e115586. doi: 10.1136/bmjopen-2025-115586. PMID: 42468953 PMC - PMC12723761 COIS- All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: no support from any organisation for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; and no other relationships or activities that could appear to have influenced the submitted work. EDAT- 2025/12/25 07:40 MHDA- 2025/12/25 07:41 PMCR- 2025/12/23 CRDT- 2025/12/25 04:49 PHST- 2025/12/25 07:40 [pubmed] PHST- 2025/12/25 07:41 [medline] PHST- 2025/12/25 04:49 [entrez] PHST- 2025/12/23 00:00 [pmc-release] AID - 2025.12.17.25342279 [pii] AID - 10.64898/2025.12.17.25342279 [doi] PST - epublish SO - medRxiv [Preprint]. 2025 Dec 18:2025.12.17.25342279. doi: 10.64898/2025.12.17.25342279. PMID- 41388543 OWN - NLM STAT- MEDLINE DCOM- 20260626 LR - 20260626 IS - 1476-511X (Electronic) IS - 1476-511X (Linking) VI - 24 IP - 1 DP - 2025 Dec 12 TI - Association between lipoprotein(a) levels, cumulative lipoprotein(a) burden, and cardiovascular outcomes in patients with acute myocardial infarction: a large-scale cohort study. PG - 383 LID - 10.1186/s12944-025-02800-6 [doi] LID - 383 AB - AIMS: To determine whether lipoprotein(a) [Lp(a)] and cumulative Lp(a) (CumLp(a)) are associated with adverse outcomes in patients with acute myocardial infarction (AMI). METHODS: This cohort study included 2,634 hospitalized patients diagnosed with AMI who underwent coronary angiography at Zhongda Hospital, Southeast University, from July 2013, to December 2021. The main outcome was major adverse cardiac and cerebrovascular events (MACCE), defined as cardiovascular (CV) death, non-fatal myocardial infarction, non-fatal stroke, or unplanned revascularization-occurring singly or in combination. We used Cox proportional hazards models, with subgroup and sensitivity analyses, restricted cubic spline (RCS) modeling, and threshold-effect assessment to evaluate the relationships between Lp(a), CumLp(a), and prognosis. RESULTS: Across a median 55.2-month follow-up, 907 participants (34.40%) experienced a MACCE, 342 (13.00%) patients had CV death, 177 (6.70%) patients had non-fatal MI, 202 (7.70%) patients had non-fatal stroke, 399 (15.10%) patients underwent unplanned revascularization, and all-cause death occurred in 547 (20.80%) patients. Multivariable Cox regression models demonstrated a significantly increased risk of MACCE, CV death, non-fatal MI, and non-fatal stroke in both the higher Lp(a) and higher CumLp(a) groups compared with the lower groups (HRs for Lp(a): 1.652, 2.157, 3.455, and 1.930; HRs for CumLp(a): 1.697, 1.675, 3.759, and 2.032), and every one-unit rise in CumLp(a), the risk of MACCE, CV death, non-fatal MI and non-fatal stroke increased by 1.3%, 1.4%, 1.9% and 1.2%, respectively. The majority of subgroup and sensitivity checks consistently supported a stable link between Lp(a)/CumLp(a) and the risks of MACCE, CV death, non-fatal MI, and stroke. Analyses using RCS and threshold models revealed that Log10(Lp(a)) had both nonlinear and threshold effects on the risks of MACCE and each single event other than unplanned revascularization, while log10-transformed CumLp(a) showed nonlinear and threshold associations only with MACCE, CV death, and non-fatal MI (nonlinearity P < 0.05). CONCLUSIONS: Higher levels of Lp(a) and CumLp(a) are linked to a greater risk of poor outcomes among patients with AMI as the index event, highlighting their potential value for risk stratification and guiding clinical decision-making. FAU - Wang, Zhenwei AU - Wang Z AD - Department of Cardiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, 450052, China. AD - Henan Province Key Laboratory of Cardiac Injury and Repair, Zhengzhou, Henan, 450052, China. AD - Henan Province Clinical Research Center for Cardiovascular Disease, Zhengzhou, Henan, 450052, China. AD - Henan Province Academy of Prevention and Treatment for Cardiovascular Disease, Zhengzhou, Henan, 450052, China. AD - Tianjian Laboratory of Advanced Biomedical Sciences, Academy of Medical Sciences, Zhengzhou University, Zhengzhou, Henan, 450052, China. AD - Department of Cardiology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, Jiangsu, 210009, China. FAU - Zhang, Jinying AU - Zhang J AD - Department of Cardiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, 450052, China. jyzhang@zzu.edu.cn. AD - Henan Province Key Laboratory of Cardiac Injury and Repair, Zhengzhou, Henan, 450052, China. jyzhang@zzu.edu.cn. AD - Henan Province Clinical Research Center for Cardiovascular Disease, Zhengzhou, Henan, 450052, China. jyzhang@zzu.edu.cn. AD - Henan Province Academy of Prevention and Treatment for Cardiovascular Disease, Zhengzhou, Henan, 450052, China. jyzhang@zzu.edu.cn. AD - Tianjian Laboratory of Advanced Biomedical Sciences, Academy of Medical Sciences, Zhengzhou University, Zhengzhou, Henan, 450052, China. jyzhang@zzu.edu.cn. FAU - Tang, Junnan AU - Tang J AD - Department of Cardiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, 450052, China. fcctangjn@zzu.edu.cn. AD - Henan Province Key Laboratory of Cardiac Injury and Repair, Zhengzhou, Henan, 450052, China. fcctangjn@zzu.edu.cn. AD - Henan Province Clinical Research Center for Cardiovascular Disease, Zhengzhou, Henan, 450052, China. fcctangjn@zzu.edu.cn. AD - Henan Province Academy of Prevention and Treatment for Cardiovascular Disease, Zhengzhou, Henan, 450052, China. fcctangjn@zzu.edu.cn. AD - Tianjian Laboratory of Advanced Biomedical Sciences, Academy of Medical Sciences, Zhengzhou University, Zhengzhou, Henan, 450052, China. fcctangjn@zzu.edu.cn. LA - eng GR - No. 252300420543/Natural Science Foundation of Henan Province/ GR - No. LHGJ20240195/Joint Construction Project of Henan Provincial Medical Science and Technology Research Program/ GR - No. 254000510006/Innovation Scientists and Technicians Troop Construction Projects of Henan Province/ GR - No. ZYCXTD2023008 and QNCXTD2023001/Funding for Scientific Research and Innovation Team of The First Affiliated Hospital of Zhengzhou University/ GR - No. SBGJ202101012/Henan Provincial Medical Science and Technology Research Program Provincial and Ministerial Joint Construction Project/ GR - No. 82222007, 82170281, U2004203/National Natural Science Foundation of China/ GR - No. 241111313300/Henan Province Key R&D Program/ GR - No. 222301420054/Henan Province Science and Technology Research Joint Project/ GR - No. HNCMS202418/Henan Provincial Clinical Medical Scientist Training Project/ GR - No. ZYYC202305ZD/Henan Zhongyuan Medical Science and Technology Innovation and Development Foundation Project/ PT - Journal Article DEP - 20251212 PL - England TA - Lipids Health Dis JT - Lipids in health and disease JID - 101147696 RN - 0 (Lipoprotein(a)) SB - IM MH - Humans MH - *Lipoprotein(a)/blood MH - *Myocardial Infarction/blood/mortality MH - Male MH - Female MH - Aged MH - Middle Aged MH - Prognosis MH - Proportional Hazards Models MH - Stroke/blood/mortality MH - Cohort Studies MH - Risk Factors PMC - PMC12699833 OTO - NOTNLM OT - Acute myocardial infarction OT - Cumulative exposure OT - Lipoprotein(a) OT - Major adverse cardiac and cerebrovascular events OT - Poor prognosis COIS- Declarations. Ethics approval and consent to participate: The study protocol was approved by the Clinical Research Ethics Committee of Zhongda Hospital affiliated to Southeast University (2021ZDSYLL152-P01) and complied with the basic principles of the Declaration of Helsinki, and informed consent was obtained from all enrolled patients. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests. EDAT- 2025/12/13 06:29 MHDA- 2026/06/27 00:54 PMCR- 2025/12/12 CRDT- 2025/12/13 01:14 PHST- 2025/09/19 00:00 [received] PHST- 2025/11/06 00:00 [accepted] PHST- 2026/06/27 00:54 [medline] PHST- 2025/12/13 06:29 [pubmed] PHST- 2025/12/13 01:14 [entrez] PHST- 2025/12/12 00:00 [pmc-release] AID - 10.1186/s12944-025-02800-6 [pii] AID - 2800 [pii] AID - 10.1186/s12944-025-02800-6 [doi] PST - epublish SO - Lipids Health Dis. 2025 Dec 12;24(1):383. doi: 10.1186/s12944-025-02800-6. PMID- 41387933 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260121 LR - 20260123 IS - 2050-2974 (Print) IS - 2050-2974 (Electronic) IS - 2050-2974 (Linking) VI - 14 IP - 1 DP - 2025 Dec 12 TI - Exploring markers of feasibility for a pragmatic study of biomarkers in adolescents with eating disorders: steps towards a precision psychiatry approach. PG - 17 LID - 10.1186/s40337-025-01490-w [doi] LID - 17 AB - OBJECTIVE: To examine markers of feasibility for a pragmatic interdisciplinary multi-axial study of biomarkers in adolescents with eating disorders (EDs). METHOD: The study included the collection of medical and clinical variables, psychometric measures, dietary logs, sensory and sleep assessments, and biological samples (i.e., blood and stool collection) for biomarker analyses. Adolescents between the ages of 11 to 17 diagnosed with a restrictive ED, along with control participants were enrolled between November 2021 to July 2024. Participants with EDs underwent concurrent treatment while enrolled in the study. Time points for low-weight patients included baseline, 4, 12, and 26 weeks, depending on the biological marker. Control subjects and patients over 90% treatment goal weight were assessed once. Feasibility was evaluated using clinical participant recruitment efficiency and uptake, adherence to the study protocol, rates of study completion, and self-reported ratings of acceptability. RESULTS: In total, 100 participants with an ED, and 52 controls participated. We observed high rates of clinical participant enrolment, high adherence with most protocol collection procedures, modest dropout for longitudinal clinical participants (17% at 12 weeks), and positive feedback returned on surveys. We observed higher dropout at the 26-week timepoint (33%). Food log and sleep assessments were hindered by several contributing factors, resulting in completion rates of 31-70% and 40-87%. DISCUSSION: Overall, results suggest acceptable feasibility for most variables assessed. Protocols requiring participation beyond 12 weeks, and utilizing dietary logs and sleep assessments, should be powered accordingly to account for lower completion rates. Further studies are needed to determine methods to optimize dietary and sleep assessments. This study provides valuable insights that can inform future precision psychiatry ED research strategies. CI - (c) 2025. The Author(s). FAU - Norris, Mark L AU - Norris ML AD - Division of Adolescent Medicine, Department of Pediatrics, Children's Hospital of Eastern Ontario, 401 Smyth Ave, Ottawa, ON, Canada. mnorris@cheo.on.ca. AD - Department of Pediatrics, Faculty of Medicine, University of Ottawa, Ottawa, Canada. mnorris@cheo.on.ca. AD - Children's Hospital of Eastern Ontario Research Institute (CHEO RI), Ottawa, Canada. mnorris@cheo.on.ca. FAU - Power, Krista A AU - Power KA AD - Department of Biochemistry, Microbiology and Immunology, Faculty of Medicine, University of Ottawa, Ottawa, Canada. AD - School of Nutrition Sciences, Faculty of Health Sciences, University of Ottawa, Ottawa, Canada. FAU - Spettigue, Wendy AU - Spettigue W AD - Children's Hospital of Eastern Ontario Research Institute (CHEO RI), Ottawa, Canada. AD - Department of Psychiatry, Faculty of Medicine, University of Ottawa, Ottawa, Canada. FAU - Lavallee, Niana AU - Lavallee N AD - Children's Hospital of Eastern Ontario Research Institute (CHEO RI), Ottawa, Canada. FAU - Gertler, Madeline J AU - Gertler MJ AD - Children's Hospital of Eastern Ontario Research Institute (CHEO RI), Ottawa, Canada. FAU - Livingston, Dawson B H AU - Livingston DBH AD - Children's Hospital of Eastern Ontario Research Institute (CHEO RI), Ottawa, Canada. AD - Department of Biochemistry, Microbiology and Immunology, Faculty of Medicine, University of Ottawa, Ottawa, Canada. FAU - Rodrigue, Alexane F AU - Rodrigue AF AD - Children's Hospital of Eastern Ontario Research Institute (CHEO RI), Ottawa, Canada. AD - Department of Biochemistry, Microbiology and Immunology, Faculty of Medicine, University of Ottawa, Ottawa, Canada. FAU - Porter, Janessa E AU - Porter JE AD - Children's Hospital of Eastern Ontario Research Institute (CHEO RI), Ottawa, Canada. FAU - Pope, Lori AU - Pope L AD - Children's Hospital of Eastern Ontario Research Institute (CHEO RI), Ottawa, Canada. FAU - Harrison, Megan AU - Harrison M AD - Division of Adolescent Medicine, Department of Pediatrics, Children's Hospital of Eastern Ontario, 401 Smyth Ave, Ottawa, ON, Canada. AD - Department of Pediatrics, Faculty of Medicine, University of Ottawa, Ottawa, Canada. AD - Children's Hospital of Eastern Ontario Research Institute (CHEO RI), Ottawa, Canada. FAU - Kanbur, Nuray AU - Kanbur N AD - Division of Adolescent Medicine, Department of Pediatrics, Children's Hospital of Eastern Ontario, 401 Smyth Ave, Ottawa, ON, Canada. AD - Department of Pediatrics, Faculty of Medicine, University of Ottawa, Ottawa, Canada. FAU - Goldfield, Gary S AU - Goldfield GS AD - Department of Pediatrics, Faculty of Medicine, University of Ottawa, Ottawa, Canada. AD - Children's Hospital of Eastern Ontario Research Institute (CHEO RI), Ottawa, Canada. FAU - Isserlin, Leanna AU - Isserlin L AD - Department of Psychiatry, Faculty of Medicine, University of Ottawa, Ottawa, Canada. FAU - Robinson, Amy AU - Robinson A AD - Division of Adolescent Medicine, Department of Pediatrics, Children's Hospital of Eastern Ontario, 401 Smyth Ave, Ottawa, ON, Canada. AD - Department of Pediatrics, Faculty of Medicine, University of Ottawa, Ottawa, Canada. FAU - Obeid, Nicole AU - Obeid N AD - Children's Hospital of Eastern Ontario Research Institute (CHEO RI), Ottawa, Canada. AD - Department of Psychiatry, Faculty of Medicine, University of Ottawa, Ottawa, Canada. LA - eng PT - Journal Article DEP - 20251212 PL - England TA - J Eat Disord JT - Journal of eating disorders JID - 101610672 PMC - PMC12821823 OAB - In this study, we report on the feasibility of collecting biomarker samples in adolescents with eating disorders (ED) to help inform a platform of precision psychiatry research. We included standardized questionnaires, dietary logs, sleep, sensory, and pharmacogenetic assessments, and collected blood and stool samples. Depending on the biomarker and grouping of participants, we collected data at 1, 3 or 4 timepoints. We evaluated feasibility using rates of recruitment, adherence to the protocol, timepoints and study completion, and overall acceptability. We recruited 100 participants with an ED and 52 controls. We observed high rates of clinical enrolment and adherence to most collection procedures, low rates of drop out over the first 12 weeks, and positive feedback returned on surveys. Dietary log completion and sleep assessments were the most challenging research tasks, with the highest rates of non-completion. Our results suggest that most participants followed longitudinally completed testing up to twelve weeks. Protocols requiring participation beyond this timeframe should account for substantial dropout. Further studies are required to investigate the optimal method to track nutritional intake and assess sleep characteristics for research purposes in adolescents with EDs. OABL- eng OTO - NOTNLM OT - Adolescents OT - Anorexia nervosa OT - Eating disorders OT - Feasibility OT - Precision psychiatry COIS- Declarations. Ethics approval and consent to participate: The study was approved but the Research Ethics Board at the Children's Hospital of Eastern Ontario (CHEOREB# 22/43X, 22/20X) and the University of Ottawa Research Ethics Board (REB # H-04-22-7917). Consent for publication: Consent to publish the de-identified study data was obtained by participants who consented to participate in the study. Competing interests: The authors declare no competing interests. EDAT- 2025/12/13 00:32 MHDA- 2025/12/13 00:33 PMCR- 2025/12/12 CRDT- 2025/12/12 23:40 PHST- 2025/05/16 00:00 [received] PHST- 2025/11/28 00:00 [accepted] PHST- 2025/12/13 00:33 [medline] PHST- 2025/12/13 00:32 [pubmed] PHST- 2025/12/12 23:40 [entrez] PHST- 2025/12/12 00:00 [pmc-release] AID - 10.1186/s40337-025-01490-w [pii] AID - 1490 [pii] AID - 10.1186/s40337-025-01490-w [doi] PST - epublish SO - J Eat Disord. 2025 Dec 12;14(1):17. doi: 10.1186/s40337-025-01490-w. PMID- 41329302 OWN - NLM STAT- MEDLINE DCOM- 20251202 LR - 20261009 IS - 1435-604X (Electronic) IS - 0268-8921 (Linking) VI - 40 IP - 1 DP - 2025 Dec 2 TI - Nd: YAG laser in the treatment of non-melanoma and melanoma skin cancers. PG - 506 LID - 10.1007/s10103-025-04750-y [doi] AB - Surgical excision remains the cornerstone treatment for skin cancer, considered the gold standard in clinical practice. However, alternative methods such as laser therapy are being explored for their potential to achieve tumor control while minimizing tissue damage and improving cosmetic outcomes. This review analyzes the existing literature on the use of Nd: YAG laser in the management of non-melanoma and melanoma skin cancer, with the aim of evaluating clearance and recurrence rates, as well as gaining deeper insights into the efficacy, safety, and potential side effects linked to this treatment approach. A systematic literature search was conducted using Embase, PubMed, Google Scholar, and Cochrane with the keywords: "Nd: YAG laser," "skin cancer," and "treatment." The search encompassed studies published from 1985 to July 2023 and included prospective, retrospective, double-blind randomized controlled trials, and non-blinded clinical trials in English. Studies were selected based on their focus on the use of Nd: YAG laser for non-melanoma including basal cell carcinoma and squamous cell carcinoma and melanoma skin cancer treatment, specifically excluding those that investigated the combination of ND: YAG laser with other therapies. Only studies reporting on the direct application of ND: YAG laser in treating various forms of skin cancer or premalignant skin lesions were considered for inclusion. Across all identified Nd: YAG laser studies from 1985 to 2023 (n = 12), a total of 7,358 histologically confirmed skin malignancies were reported, including 6,846 basal cell carcinomas (BCCs), 185 squamous cell carcinomas (SCCs), 323 malignant melanomas, and 4 cases of Bowen's disease. BCCs accounted for the vast majority of treated lesions (93.0%), followed by malignant melanoma (4.4%), SCC (2.5%), and Bowen's disease (0.05%). In calculating these totals, only lesions explicitly reported in each study were included. For instance, Brunner et al. (1985) described four patients with nevoid basal cell carcinoma syndrome as having "hundreds" of lesions; however, because the exact number was not provided, only the 200 histologically confirmed BCCs from this cohort were counted to avoid overestimation. No overlapping patients between studies were assumed unless explicitly noted. Moskalik et al. (2009) treated 188 recurrent limited BCCs alongside 3,346 primary BCCs, while Moskalik and Kozlow (2010) treated 172 recurrent limited BCCs within a cohort of 2,837 patients. El Tonsy et al. (2004) included patients with previously treated lesions, emphasizing the clearance of 37 BCCs, some of which were recurrent. Sharmazan et al. (1996) and later studies (Ortiz 2015/2018; Ahluwalia 2019; Markowitz & Bressler 2021; Kranz 2023) mostly treated primary BCCs but some non-facial and challenging anatomical locations likely included previously treated lesions. SCCs and melanomas were treated less frequently, usually in early-stage or thin lesions, and Bowen's disease appeared rarely. Taken together, these results indicate that Nd:YAG laser therapy has been applied predominantly to BCCs, reflecting both the high prevalence of this tumor type and the favorable safety and cosmetic outcomes reported. SCCs and melanomas were treated less frequently but showed encouraging clearance and cosmetic results in early-stage or low-thickness lesions, while Bowen's disease appeared only rarely in the literature. Nd:YAG laser therapy represents a promising, minimally invasive option for selected cases of non-melanoma skin cancers, offering good cosmetic outcomes and reduced morbidity compared to surgery. Its effectiveness in low-risk BCC and SCC, especially in cosmetically sensitive areas or for non-surgical candidates, is supported by current evidence. However, limitations such as lack of margin control and variable results restrict broader use, and its application in melanoma remains experimental. Continued research through standardized, long-term studies is needed to confirm its oncologic safety and define its future role in dermatologic oncology. CI - (c) 2025. The Author(s), under exclusive licence to Springer-Verlag London Ltd., part of Springer Nature. FAU - Abo Zaken, Ghufran AU - Abo Zaken G AD - Department of Public Health, Columbia Southern University, Orange Beach, Alabama, Orange Beach, Alabama, USA. Ghufranabozaken@gmail.com. AD - Department of Dermatology, Syrian Specialized Hospital for Dermatological Diseases in Dummar, Damascus, Syrian Arab Republic. Ghufranabozaken@gmail.com. AD - Dr. Philip Frost Department of Dermatology and Cutaneous Surgery, University of Miami, Miami, FL, USA. Ghufranabozaken@gmail.com. FAU - Moussa, Marah Mhna AU - Moussa MM AD - Department of Dermatology, Syrian Specialized Hospital for Dermatological Diseases in Dummar, Damascus, Syrian Arab Republic. FAU - Albeik, Muhammad Talaat Muhammad Nudar AU - Albeik MTMN AD - Department of Dermatology, Syrian Specialized Hospital for Dermatological Diseases in Dummar, Damascus, Syrian Arab Republic. FAU - Omar, Abdullah AU - Omar A AUID- ORCID: 0000-0002-2054-5011 AD - Department of Dermatology, Syrian Specialized Hospital for Dermatological Diseases in Dummar, Damascus, Syrian Arab Republic. FAU - Almahfoud, Samir AU - Almahfoud S AD - Department of Dermatology, Syrian Specialized Hospital for Dermatological Diseases in Dummar, Damascus, Syrian Arab Republic. LA - eng PT - Journal Article PT - Systematic Review DEP - 20251202 PL - England TA - Lasers Med Sci JT - Lasers in medical science JID - 8611515 SB - IM MH - Humans MH - *Skin Neoplasms/surgery/radiotherapy MH - *Lasers, Solid-State/therapeutic use/adverse effects MH - *Melanoma/surgery/radiotherapy MH - *Carcinoma, Squamous Cell/surgery/radiotherapy MH - *Basal Cell Carcinoma/surgery/radiotherapy MH - Neoplasm Recurrence, Local OTO - NOTNLM OT - Basal cell carcinoma OT - Laser therapy OT - Melanoma OT - Nd:YAG laser OT - Non-melanoma skin cancer OT - Skin cancer OT - Squamous cell carcinoma COIS- Declarations. Ethics approval: Not applicable, as this is a literature review and did not involve direct research on human participants. For referenced studies involving human subjects, ethical approval was obtained by the respective original investigators and their institutions. Consent to participate: Not applicable. No new human data was collected for this review. Competing interests: The authors declare no competing interests. Clinical trial number: not applicable. EDAT- 2025/12/02 12:56 MHDA- 2025/12/02 12:57 CRDT- 2025/12/02 11:05 PHST- 2025/07/26 00:00 [received] PHST- 2025/11/11 00:00 [accepted] PHST- 2025/12/02 12:57 [medline] PHST- 2025/12/02 12:56 [pubmed] PHST- 2025/12/02 11:05 [entrez] AID - 10.1007/s10103-025-04750-y [pii] AID - 10.1007/s10103-025-04750-y [doi] PST - epublish SO - Lasers Med Sci. 2025 Dec 2;40(1):506. doi: 10.1007/s10103-025-04750-y. PMID- 41318437 OWN - NLM STAT- MEDLINE DCOM- 20260626 LR - 20261014 IS - 1471-2318 (Electronic) IS - 1471-2318 (Linking) VI - 26 IP - 1 DP - 2025 Nov 29 TI - Association between serum copper concentration and type 2 diabetes mellitus in elderly people in Northeast China: a cross-sectional study. PG - 156 LID - 10.1186/s12877-025-06815-7 [doi] LID - 156 AB - BACKGROUND: Numerous studies have demonstrated a significant association between serum copper (Cu) levels and abnormal glucose metabolism. However, there is a notable lack of research specifically examining the relationship between serum Cu concentration and type 2 diabetes mellitus (T2DM) in the elderly population. Consequently, this study aims to investigate the potential association between serum Cu concentration and T2DM in elderly adults. METHODS: A total of 565 participants were recruited from the outpatient and inpatient geriatric departments of the First Hospital of Jilin University between July 2021 and July 2023. Logistic regression models were employed to explore the association between serum Cu concentration and the risk of diabetes mellitus, with odds ratios (ORs) and 95% confidence intervals (95% CIs) calculated. Additionally, both smooth curve fitting and restricted cubic splines were utilized to assess the dose-response relationship between serum Cu concentration and T2DM. RESULTS: The results showed that serum Cu concentrations were higher in the T2DM group (17.5 +/- 4.6mumol/L) than in the control group (16.6 +/- 4.0mumol/L) (P = 0.021). After adjusting for potential covariates, the ORs (95% CI) for higher serum Cu levels were 1.00 (reference value), 1.66 (1.08-2.55), 2.07 (1.32-3.26), and 2.06(1.26-3.38) for T2DM, respectively. Both smooth curve fitting and restricted cubic spline curves showed a potential linear relationship between serum Cu concentration and T2DM (P for non-linear = 0.231 and P = 0.08). CONCLUSION: This study suggests that T2DM in elderly adults is associated with increased serum Cu concentrations. Further prospective cohort studies in different populations are needed to validate our results. FAU - Li, Xiaonan AU - Li X AD - Department of Geriatrics, Jilin Geriatrics Clinical Research Center, The First Hospital of Jilin University, Changchun, China. FAU - Yang, Li AU - Yang L AD - The First Hospital of Jilin University, Changchun, China. FAU - Mu, Dongmei AU - Mu D AD - Division of Clinical Research, The First Hospital of Jilin University, Changchun City, China. FAU - Wang, Yuehui AU - Wang Y AD - Department of Geriatrics, Jilin Geriatrics Clinical Research Center, The First Hospital of Jilin University, Changchun, China. yuehuiwang300@jlu.edu.cn. LA - eng GR - No. 20240304164SF/Technology Development Plan of Jilin Province/ PT - Journal Article DEP - 20251129 PL - England TA - BMC Geriatr JT - BMC geriatrics JID - 100968548 RN - 789U1901C5 (Copper) RN - 0 (Biomarkers) SB - IM MH - Humans MH - *Copper/blood MH - *Diabetes Mellitus, Type 2/blood/epidemiology/diagnosis MH - Female MH - Cross-Sectional Studies MH - China/epidemiology MH - Aged MH - Male MH - Aged, 80 and over MH - Biomarkers/blood PMC - PMC12869914 OTO - NOTNLM OT - Elderly OT - Insulin Resistance OT - Serum copper OT - T2DM COIS- Declarations. Ethics approval and consent to participate: The study adhered to the medical ethics standards and was approved by the Ethics Committee of the First Hospital of Jilin University (NO.19K028-001). Our study was a retrospective study not a clinical study, so clinical trial number were not applicable. All patients involved in the study provided written informed consent to participate in the research. Consent for publication: All patients involved in the study provided written informed consent for the publication of the research materials without mentioning their names. Competing interests. Competing interests: The authors declare no competing interests. EDAT- 2025/11/30 00:30 MHDA- 2026/06/27 00:52 PMCR- 2025/11/29 CRDT- 2025/11/29 23:15 PHST- 2025/06/14 00:00 [received] PHST- 2025/11/18 00:00 [accepted] PHST- 2026/06/27 00:52 [medline] PHST- 2025/11/30 00:30 [pubmed] PHST- 2025/11/29 23:15 [entrez] PHST- 2025/11/29 00:00 [pmc-release] AID - 10.1186/s12877-025-06815-7 [pii] AID - 6815 [pii] AID - 10.1186/s12877-025-06815-7 [doi] PST - epublish SO - BMC Geriatr. 2025 Nov 29;26(1):156. doi: 10.1186/s12877-025-06815-7. PMID- 41298280 OWN - NLM STAT- MEDLINE DCOM- 20251126 LR - 20260903 IS - 1365-2060 (Electronic) IS - 0785-3890 (Print) IS - 0785-3890 (Linking) VI - 57 IP - 1 DP - 2025 Dec TI - Preschool children's eating behaviors and caregivers' feeding practices in relation to children's weight in China: a network analysis. PG - 2593729 LID - 10.1080/07853890.2025.2593729 [doi] LID - 2593729 AB - OBJECTIVE: This study aimed to characterize the interactions between preschool children's eating behaviors and their caregivers' feeding practices, and to compare these patterns across underweight, normal weight, and overweight/obesity groups using a network model. MATERIALS AND METHODS: A cross-sectional survey (January-July 2021) included 3-6-year-old preschool children and their primary caregivers from seven cities in Shaanxi Province, China. Children's eating behaviors and caregivers' feeding practices were measured using the Chinese Preschoolers' Eating Behavior Scale and the Chinese Preschoolers' Caregivers' Feeding Behavior Scale. Network centrality indices identified core and bridge behaviors, with stability assessed via case-dropping bootstrapping. RESULTS: The network had 14 nodes, 82 non-zero edges (90.11% of all possible edges), and all networks showed good stability (correlation stability coefficient > 0.5). Among subgroups, the overweight/obese group had the highest mean edge weight (0.048), while the underweight group had the lowest non-zero edge proportion (45.05%). Across all samples, the strongest edge was between Feeding Responsibility and Content-Restricted Feeding (0.47), and the strongest cross-domain link was Emotional Eating-Weight Concerns (0.22), both stably confirmed by bootstrap. Feeding Responsibility had the highest strength (1.74) across groups, and Weight Concerns had the highest overall bridge strength (0.58), identifying it as a key connector. Edge weight distribution differed significantly between normal-weight and overweight/obese groups (p = 0.02). CONCLUSIONS: Network analysis identified Feeding Responsibility as core behavior and Weight Concerns as a critical cross-domain bridge, highlighting caregivers' central role. These findings inform targeted interventions and nutritional strategies. FAU - Zhang, Haiyue AU - Zhang H AD - Department of Health Statistics, Ministry of Education Key Lab of Hazard Assessment and Control in Special Operational Environment, School of Public Health, Fourth Military Medical University, Xi'an, Shaanxi, China. FAU - Yang, Zhe AU - Yang Z AD - Department of Health Statistics, Ministry of Education Key Lab of Hazard Assessment and Control in Special Operational Environment, School of Public Health, Fourth Military Medical University, Xi'an, Shaanxi, China. FAU - Zhang, Hao AU - Zhang H AD - Transfusion Medicine Department, PLA 985th Hospital, Taiyuan, China. FAU - Yuan, Jing AU - Yuan J AD - Department of Medical Information, PLA 960th Hospital, Jinan, China. FAU - Yang, Xianjun AU - Yang X AD - No. 945 Hospital of Joint Logistics Support Force of PLA, China. FAU - Liang, Ying AU - Liang Y AD - Department of Health Statistics, Ministry of Education Key Lab of Hazard Assessment and Control in Special Operational Environment, School of Public Health, Fourth Military Medical University, Xi'an, Shaanxi, China. FAU - Tan, Zhijun AU - Tan Z AD - Department of Health Statistics, Ministry of Education Key Lab of Hazard Assessment and Control in Special Operational Environment, School of Public Health, Fourth Military Medical University, Xi'an, Shaanxi, China. FAU - Wang, Yue AU - Wang Y AD - Department of Health Statistics, Ministry of Education Key Lab of Hazard Assessment and Control in Special Operational Environment, School of Public Health, Fourth Military Medical University, Xi'an, Shaanxi, China. FAU - Zhang, Wei AU - Zhang W AD - Department of Health Statistics, Ministry of Education Key Lab of Hazard Assessment and Control in Special Operational Environment, School of Public Health, Fourth Military Medical University, Xi'an, Shaanxi, China. FAU - Zhang, Yuhai AU - Zhang Y AD - Department of Health Statistics, Ministry of Education Key Lab of Hazard Assessment and Control in Special Operational Environment, School of Public Health, Fourth Military Medical University, Xi'an, Shaanxi, China. FAU - Jiang, Xun AU - Jiang X AD - Department of Pediatrics, Tangdu Hospital, Fourth Military Medical University, Xi'an, China. FAU - Shang, Lei AU - Shang L AD - Department of Health Statistics, Ministry of Education Key Lab of Hazard Assessment and Control in Special Operational Environment, School of Public Health, Fourth Military Medical University, Xi'an, Shaanxi, China. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20251126 PL - England TA - Ann Med JT - Annals of medicine JID - 8906388 SB - IM MH - Humans MH - China/epidemiology MH - Child, Preschool MH - *Feeding Behavior/psychology MH - Female MH - Male MH - Cross-Sectional Studies MH - *Caregivers/psychology/statistics & numerical data MH - Child MH - *Pediatric Obesity/epidemiology/psychology MH - Thinness/epidemiology/psychology MH - Body Weight MH - Surveys and Questionnaires PMC - PMC12667339 OAB - Network analysis reveals that caregivers' Feeding Responsibility (as core behavior) and Weight Concerns (as cross-domain bridge) are key in preschoolers' feeding-eating network, emphasizing caregivers' central role.Weight-specific differences in the feeding-eating network structure indicate that tailored interventions are necessary for preschoolers with different weight statuses.The study's findings provide guidance for developing targeted nutritional strategies, with caregivers' Feeding Responsibility and Weight Concern identified as priority intervention targets. OABL- eng OTO - NOTNLM OT - Eating behaviors OT - feeding practices OT - network analysis OT - preschool children COIS- The authors declare that they have no competing interests. EDAT- 2025/11/27 00:27 MHDA- 2025/11/27 00:28 PMCR- 2025/11/26 CRDT- 2025/11/26 22:33 PHST- 2025/11/27 00:28 [medline] PHST- 2025/11/27 00:27 [pubmed] PHST- 2025/11/26 22:33 [entrez] PHST- 2025/11/26 00:00 [pmc-release] AID - 2593729 [pii] AID - 10.1080/07853890.2025.2593729 [doi] PST - ppublish SO - Ann Med. 2025 Dec;57(1):2593729. doi: 10.1080/07853890.2025.2593729. Epub 2025 Nov 26. PMID- 41272110 OWN - NLM STAT- Publisher LR - 20251121 IS - 1476-5373 (Electronic) IS - 0007-0610 (Linking) DP - 2025 Nov 21 TI - The impact of the COVID-19 pandemic on UK dental nurses' professional practice 2020-21: lessons for the future. LID - 10.1038/s41415-025-8914-x [doi] AB - Introduction The COVID-19 pandemic has reshaped dental care in the United Kingdom, particularly influencing dental nurses' practice. This study explored dental nurses' experiences during the phased return to work from June 2020, amid evolving infection prevention and control policies.Aim To explore dental nurses' experience during the phased return to work post-COVID-19 and draw conclusions for the future.Method: A sequential two-stage mixed-methods approach was used. In July 2021, a 34-item anonymous online survey was distributed via Facebook and analysed using SPSS software. In September 2021, seven interviews were conducted and analysed.Results This paper focuses on the online survey. A total of 121 dental nurses participated, predominantly white (66%), female (88%), and aged 30 years and over (76%). Most were registered dental nurses (84%), with 31% holding extended-duty qualifications. The main sources of infection prevention guidelines were from NHS standard operating procedures (SOPs) (51%), Public Health England (45%), employer SOPs (42%), government publications (40%), the World Health Organization (34%) and the General Dental Council (28%). Nurses expressed concerns about frequent updates to infection prevention policies, particularly regarding aerosol-generating procedures.Conclusion While the pandemic presented challenges, including lockdown restrictions and enhanced protective equipment requirements, dental nurses showed resilience and dedication. Despite financial, physical, and psychological strains, they adapted professionally, emphasising the need for clear communication and accessible support systems. CI - (c) 2025. The Author(s). FAU - Turkistani, Samia AU - Turkistani S AD - Research Associate, The University of Portsmouth Dental Academy, University of Portsmouth, Hampshire Terrace, Portsmouth, PO1 2QG, UK. samia.turkistani@port.ac.uk. FAU - Radford, David R AU - Radford DR AD - Visiting Professor, The University of Portsmouth Dental Academy, University of Portsmouth, Hampshire Terrace, Portsmouth, PO1 2QG, UK. FAU - Vargas, Carolina Machuca AU - Vargas CM AD - Senior Lecturer in Dental Public Health, The University of Portsmouth Dental Academy, University of Portsmouth, Hampshire Terrace, Portsmouth, PO1 2QG, UK. FAU - Wallis, Tracy AU - Wallis T AD - Associate Head (Student), The University of Portsmouth Dental Academy, University of Portsmouth, Hampshire Terrace, Portsmouth, PO1 2QG, UK. FAU - Louca, Chris AU - Louca C AD - Director, The University of Portsmouth Dental Academy, University of Portsmouth, Hampshire Terrace, Portsmouth, PO1 2QG, UK. LA - eng PT - Journal Article DEP - 20251121 PL - England TA - Br Dent J JT - British dental journal JID - 7513219 SB - IM COIS- Ethics declaration. The authors declare no conflicts of interest. The study received approval from the Ethics Committee of the Science and Health Faculty at the University of Portsmouth (SHFEC 2021-075). Informed consent was obtained via a checkbox on the survey. EDAT- 2025/11/22 00:28 MHDA- 2025/11/22 00:28 CRDT- 2025/11/21 23:51 PHST- 2025/02/21 00:00 [received] PHST- 2025/06/08 00:00 [accepted] PHST- 2025/05/23 00:00 [revised] PHST- 2025/11/22 00:28 [medline] PHST- 2025/11/22 00:28 [pubmed] PHST- 2025/11/21 23:51 [entrez] AID - 10.1038/s41415-025-8914-x [pii] AID - 10.1038/s41415-025-8914-x [doi] PST - aheadofprint SO - Br Dent J. 2025 Nov 21. doi: 10.1038/s41415-025-8914-x. PMID- 41264900 OWN - NLM STAT- MEDLINE DCOM- 20260211 LR - 20260214 IS - 1541-0048 (Electronic) IS - 0090-0036 (Print) IS - 0090-0036 (Linking) VI - 116 IP - 3 DP - 2026 Mar TI - Examining Post-Dobbs Changes in Abortion Use at 3 Southern Michigan Clinics, July 2021‒June 2023. PG - 351-358 LID - 10.2105/AJPH.2025.308305 [doi] AB - Objectives. To examine changes in abortion service delivery for the years before (July 2021‒June 2022) and after Dobbs v Jackson Women's Health (July 2022‒June 2023) at 3 Planned Parenthood clinics in southern Michigan, when several states enacted laws further restricting abortion access, and Michigan became a destination for individuals in restrictive states. Methods. We used monthly abortion data from 3 Michigan clinics to calculate the mean number of monthly abortions and changes in proportions for gestation, method, and patient state of residence for the 2 time periods. Results. Mean monthly abortions increased from 358 before Dobbs to 575 after Dobbs. Simultaneously, out-of-state patients increased from 383 before Dobbs to 1145 after Dobbs and received a larger share of total abortions. Methods shifted slightly, with medication abortions decreasing from 58% to 53% and procedural abortions at less than 14 weeks increasing from 31% to 36%. Most out-of-state patients came from Indiana and Ohio. Conclusions. The increasing number of out-of-state patients and increased provision of procedural abortions represent both increased need among patients from restrictive states and adaptability among providers in protective states such as Michigan-underscoring changes in care amid the rapidly evolving abortion landscape in the United States. (Am J Public Health. 2026;116(3):351-358. https://doi.org/10.2105/AJPH.2025.308305). FAU - Smith, Mikaela H AU - Smith MH AUID- ORCID: 0000-0001-5658-4808 AD - Mikaela H. Smith and Alison Norris are with the Division of Epidemiology, School of Public Health, The Ohio State University, Columbus. Caroline Sucher, Vanessa K. Dalton, and Sarah D. Compton are with the Department of Obstetrics and Gynecology, University of Michigan, Ann Arbor. FAU - Sucher, Caroline AU - Sucher C AUID- ORCID: 0009-0000-5048-3264 AD - Mikaela H. Smith and Alison Norris are with the Division of Epidemiology, School of Public Health, The Ohio State University, Columbus. Caroline Sucher, Vanessa K. Dalton, and Sarah D. Compton are with the Department of Obstetrics and Gynecology, University of Michigan, Ann Arbor. FAU - Norris, Alison AU - Norris A AD - Mikaela H. Smith and Alison Norris are with the Division of Epidemiology, School of Public Health, The Ohio State University, Columbus. Caroline Sucher, Vanessa K. Dalton, and Sarah D. Compton are with the Department of Obstetrics and Gynecology, University of Michigan, Ann Arbor. FAU - Dalton, Vanessa K AU - Dalton VK AD - Mikaela H. Smith and Alison Norris are with the Division of Epidemiology, School of Public Health, The Ohio State University, Columbus. Caroline Sucher, Vanessa K. Dalton, and Sarah D. Compton are with the Department of Obstetrics and Gynecology, University of Michigan, Ann Arbor. FAU - Compton, Sarah D AU - Compton SD AD - Mikaela H. Smith and Alison Norris are with the Division of Epidemiology, School of Public Health, The Ohio State University, Columbus. Caroline Sucher, Vanessa K. Dalton, and Sarah D. Compton are with the Department of Obstetrics and Gynecology, University of Michigan, Ann Arbor. LA - eng PT - Journal Article DEP - 20251120 PL - United States TA - Am J Public Health JT - American journal of public health JID - 1254074 SB - IM MH - Humans MH - Michigan MH - Female MH - Pregnancy MH - *Abortion, Induced/statistics & numerical data/trends/legislation & jurisprudence MH - Adult MH - *Health Services Accessibility/statistics & numerical data/legislation & jurisprudence MH - *International Planned Parenthood Federation MH - *Ambulatory Care Facilities/statistics & numerical data PMC - PMC12895881 EDAT- 2025/11/20 18:28 MHDA- 2026/02/11 18:59 PMCR- 2028/03/01 CRDT- 2025/11/20 16:02 PHST- 2026/02/11 18:59 [medline] PHST- 2025/11/20 18:28 [pubmed] PHST- 2025/11/20 16:02 [entrez] PHST- 2028/03/01 00:00 [pmc-release] AID - 202549211 [pii] AID - 10.2105/AJPH.2025.308305 [doi] PST - ppublish SO - Am J Public Health. 2026 Mar;116(3):351-358. doi: 10.2105/AJPH.2025.308305. Epub 2025 Nov 20. PMID- 41244205 OWN - NLM STAT- MEDLINE DCOM- 20251117 LR - 20261022 IS - 2167-8359 (Electronic) IS - 2167-8359 (Linking) VI - 13 DP - 2025 TI - The association of maternal pre-pregnancy body mass index with macrosomia: a birth cohort study from China. PG - e20332 LID - 10.7717/peerj.20332 [doi] LID - e20332 AB - OBJECTIVE: To investigate the association between pre-pregnancy body mass index (BMI) and the risk of macrosomia through a preconception-early pregnancy-birth cohort in China. METHODS: Among the 12,254 women initially recruited between July 2018 and December 2021, a total of 11,438 (drop out rate: 6.66%) mother-infant pairs were included in the final analysis after excluding participants with missing data on key variables or lost to follow-up. We collected basic demographic characteristics and lifestyle behavior information of the subjects through questionnaires and practical measurements, and conducted further follow-up for pregnancy outcomes. The study assessed the association between pre-pregnancy BMI-defined categories (underweight, normal weight, overweight, and obesity) and macrosomia using multivariable logistic regression models, adjusting for sociodemographic characteristics, lifestyle behaviors, and maternal clinical factors during pregnancy. A linear trend test was also conducted. Moreover, we utilized restricted cubic spline models with three knots (placed at the 10th, 50th, and 90th percentiles of BMI) and polynomial regression to investigate the non-linear relationship of pre-pregnancy BMI with macrosomia. RESULTS: A total of 11,438 subjects were included in this study, among whom 645 infants were diagnosed with macrosomia, resulting in a prevalence of 5.64%. The results indicated that, compared with the normal weight group, overweight women had a significantly higher risk of macrosomia (odds ratio (OR) = 1.66, 95% CI [1.35-2.01]), as did obese women (OR = 1.66, 95% CI [1.13-2.45]), while underweight women had a significantly lower risk (OR = 0.55, 95% CI [0.41-0.73]). A similar association pattern between pre-pregnancy BMI and grade 1 macrosomia was observed, consistent with that for overall macrosomia. The use of restricted cubic splines revealed that the prevalence of macrosomia/grade 1 macrosomia increased with rising pre-pregnancy BMI. Furthermore, when we stratified the data by covariates, the nonlinear relationship between pre-pregnancy BMI and macrosomia/grade 1 macrosomia persisted. The results of the polynomial regression showed a gradual increase in fetal birth weight with increasing pre-pregnancy BMI levels. CONCLUSIONS: Pre-pregnancy overweight and obesity were associated with higher risks of macrosomia. Therefore, these findings suggest that promoting healthy weight management before conception may be an effective public health strategy to reduce the risk of macrosomia and improve perinatal outcomes. CI - (c) 2025 Yan et al. FAU - Yan, Mingxin AU - Yan M AD - Institute for Hygiene of Ordnance Industry, Xi'an, China. AD - Department of Epidemiology and Biostatistics, School of Public Health, Xi'an Jiaotong University Health Science Center, Xi'an, Shaanxi, China. FAU - Zhang, Yunbo AU - Zhang Y AD - Department of Epidemiology and Biostatistics, School of Public Health, Xi'an Jiaotong University Health Science Center, Xi'an, Shaanxi, China. FAU - Zhao, Doudou AU - Zhao D AD - Translational Medicine Center Northwest Women's and Children's Hospital, Xi'an, Shaanxi, China. FAU - Zhao, Yan AU - Zhao Y AD - The First Affiliated Hospital of Xi'an Jiaotong University Dermatology, Xi'an, Shaanxi, China. FAU - Liu, Danmeng AU - Liu D AD - Translational Medicine Center Northwest Women's and Children's Hospital, Xi'an, Shaanxi, China. FAU - Shan, Li AU - Shan L AD - Translational Medicine Center Northwest Women's and Children's Hospital, Xi'an, Shaanxi, China. FAU - Mi, Yang AU - Mi Y AD - Translational Medicine Center Northwest Women's and Children's Hospital, Xi'an, Shaanxi, China. FAU - Pei, Leilei AU - Pei L AD - Department of Epidemiology and Biostatistics, School of Public Health, Xi'an Jiaotong University Health Science Center, Xi'an, Shaanxi, China. FAU - Qu, Pengfei AU - Qu P AD - Translational Medicine Center Northwest Women's and Children's Hospital, Xi'an, Shaanxi, China. AD - Central Laboratory, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing, China. LA - eng GR - National Natural Science Foundation of China/ PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20251110 PL - United States TA - PeerJ JT - PeerJ JID - 101603425 SB - IM MH - Humans MH - Female MH - *Fetal Macrosomia/epidemiology/etiology MH - China/epidemiology MH - *Body Mass Index MH - Pregnancy MH - Adult MH - Risk Factors MH - Overweight/epidemiology MH - Cohort Studies MH - Obesity/epidemiology/complications MH - Birth Cohort MH - Infant, Newborn MH - Prevalence PMC - PMC12614098 OTO - NOTNLM OT - Birth weight OT - Grade 1 macrosomia OT - Macrosomia OT - Obesity OT - Overweight OT - Pre-pregnancy BMI OT - Underweight COIS- The authors declare that they have no competing interests. EDAT- 2025/11/17 17:29 MHDA- 2025/11/17 17:30 PMCR- 2025/11/10 CRDT- 2025/11/17 06:06 PHST- 2025/04/28 00:00 [received] PHST- 2025/10/13 00:00 [accepted] PHST- 2025/11/17 17:30 [medline] PHST- 2025/11/17 17:29 [pubmed] PHST- 2025/11/17 06:06 [entrez] PHST- 2025/11/10 00:00 [pmc-release] AID - 20332 [pii] AID - 10.7717/peerj.20332 [doi] PST - epublish SO - PeerJ. 2025 Nov 10;13:e20332. doi: 10.7717/peerj.20332. eCollection 2025. PMID- 41199369 OWN - NLM STAT- MEDLINE DCOM- 20251107 LR - 20251208 IS - 1756-0500 (Electronic) IS - 1756-0500 (Linking) VI - 18 IP - 1 DP - 2025 Nov 7 TI - Early use of neutral Protamine Hagedorn (NPH) insulin in the management of diabetic ketoacidosis: an open-label randomized controlled trial in a resource-limited setting. PG - 471 LID - 10.1186/s13104-025-07508-5 [doi] LID - 471 AB - OBJECTIVE: Regular insulin infusion and intravenous fluids are the cornerstones of managing diabetic ketoacidosis (DKA). To shorten the time taken to resolve DKA in known diabetic patients, the concomitant administration of glargine with regular insulin infusion has been tried, with promising results. This study primarily aimed to assess whether the addition of Neutral Protamine Hagedorn (NPH) insulin to continuous insulin infusion (CII) hastens the resolution of DKA. The secondary objectives were to compare the time to rebound hyperglycemia, frequency of hypoglycemia and duration of hospital stay between the early NPH insulin and control groups. RESULTS: An open-label, randomised controlled trial (CTRI ref/2022/08/044760, dated August 8, 2022) of 50 adult participants with DKA was conducted from August 2022 to June 2023. In the intervention arm, 25 participants received 0.25 IU/kg subcutaneous NPH insulin in 2 divided doses, along with a continuous insulin infusion from the time of randomization until the primary outcome was achieved. The control arm (n = 25) received the standard of care. The time to resolution of DKA was significantly shorter in the intervention arm [Intervention (I): 20 (16-32) hours vs. Standard (S): 38.5 (27-48) hours] in those with severe DKA (p = 0.01). Rebound hyperglycemia was delayed in the intervention arm [I: 7.9 +/- 2.7 h vs. S: 5.9 +/- 2.2 h]. There was no significant difference in the duration of hospital stay or frequency of hypoglycemia. However, the small sample size restricts the generalizability of the results and, larger studies are needed for confirmation of these findings. TRIAL REGISTRATION: This trial was prospectively registered in the Clinical Trials Registry India (CTRI)-CTRI/2022/08/044760 on August 8, 2022. CI - (c) 2025. The Author(s). FAU - Baby, Naveen AU - Baby N AD - Department of Medicine, JIPMER, Puducherry, 605006, India. FAU - Wyawahare, Mukta AU - Wyawahare M AD - Department of Medicine, JIPMER, Puducherry, 605006, India. mukta.wyawahare@gmail.com. FAU - Naik, Dukhabandhu AU - Naik D AD - Department of Endocrinology, JIPMER, Puducherry, 605006, India. FAU - Ramasamy, Nishaant AU - Ramasamy N AD - Department of Preventive & Social Medicine, JIPMER, Puducherry, 605006, India. LA - eng GR - IMRF/JULY-SEPT 2022-23/Proposal no 3//Jawaharlal Institute Of Postgraduate Medical Education and Research/ PT - Journal Article PT - Randomized Controlled Trial DEP - 20251107 PL - England TA - BMC Res Notes JT - BMC research notes JID - 101462768 RN - 53027-39-7 (Insulin, Isophane) RN - 0 (Hypoglycemic Agents) RN - 0 (Blood Glucose) SB - IM MH - Humans MH - *Diabetic Ketoacidosis/drug therapy MH - *Insulin, Isophane/administration & dosage/therapeutic use MH - Male MH - Female MH - Adult MH - Middle Aged MH - *Hypoglycemic Agents/administration & dosage/therapeutic use MH - Blood Glucose MH - Length of Stay MH - Hypoglycemia/chemically induced MH - Treatment Outcome MH - Resource-Limited Settings PMC - PMC12593859 OTO - NOTNLM OT - Diabetic ketoacidosis OT - Metabolic acidosis OT - Neutral protamine hagedorn insulin OT - Rebound hyperglycemia COIS- Declarations. Ethics approval and consent to participate: This study was approved by the Institute Ethics Committee at Jawaharlal Institute of Postgraduate Medical Education and Research (Ref No JIP/IEC/2021/078). Written informed consent was obtained from the participants. Consent for publication: Written informed consent was obtained from the study participants. Competing interests: The authors declare that they have no competing interests. EDAT- 2025/11/07 00:27 MHDA- 2025/11/07 06:28 PMCR- 2025/11/07 CRDT- 2025/11/06 23:51 PHST- 2024/06/25 00:00 [received] PHST- 2025/09/21 00:00 [accepted] PHST- 2025/11/07 06:28 [medline] PHST- 2025/11/07 00:27 [pubmed] PHST- 2025/11/06 23:51 [entrez] PHST- 2025/11/07 00:00 [pmc-release] AID - 10.1186/s13104-025-07508-5 [pii] AID - 7508 [pii] AID - 10.1186/s13104-025-07508-5 [doi] PST - epublish SO - BMC Res Notes. 2025 Nov 7;18(1):471. doi: 10.1186/s13104-025-07508-5. PMID- 41174538 OWN - NLM STAT- MEDLINE DCOM- 20251101 LR - 20261013 IS - 1471-2318 (Electronic) IS - 1471-2318 (Linking) VI - 25 IP - 1 DP - 2025 Oct 31 TI - Association of hepatorenal function biomarkers with depression risk in geriatric psychiatry inpatient: a hospital-based cross-sectional study. PG - 829 LID - 10.1186/s12877-025-06536-x [doi] LID - 829 AB - BACKGROUND: Emerging evidences have suggested a potential link between hepatorenal dysfunction and depression. However, the association between hepatorenal function biomarkers and geriatric depression remains unclear. This study aimed to evaluate the contribution of hepatorenal function biomarkers to depression risk in elderly psychiatric inpatients and identify potential predictive biomarkers for geriatric depression. METHODS: This cross-sectional study analyzed electronic medical records of geriatric psychiatric inpatients (July 2021-December 2024) from a hospital in Eastern China. Multivariable logistic regression models were applied to examine associations between alanine aminotransferase (ALT)/aspartate aminotransferase (AST) ratio, blood urea nitrogen (BUN), BUN/creatinine (Cr) ratio and depression risk, with restricted cubic spline models assessing dose-response relationships. Progressive adjustments included demographic characteristics, metabolic indicators, inflammatory markers, and comorbidities. Subgroup analyses with interaction tests evaluated heterogeneity across predefined subgroups. RESULTS: Analysis of 1,783 participants (688 with depression) revealed that depressed patients exhibited a higher ALT/AST ratio (0.9 vs. 0.8; P < 0.001) with lower BUN (5.4 vs. 6.5 mmol/L; P < 0.001) and BUN/Cr ratio (19.4 vs. 21.2; P < 0.001). Adjusted models demonstrated that each 1-unit increase in ALT/AST ratio was associated with a 106% higher risk of depression (OR = 2.06, 95% CI: 1.41-3.01; P < 0.001), whereas each 1-unit increase in BUN and BUN/Cr ratio corresponded to 16% (OR = 0.84, 95% CI: 0.79-0.89) and 4% (OR = 0.96, 95% CI: 0.94-0.98) decreased risks, respectively (P < 0.001). Restricted cubic spline analyses identified linear dose-response relationships: ALT/AST ratio positively correlated with depression risk (P < 0.001), while lower levels of BUN (P < 0.001) and BUN/Cr ratio (P < 0.001) inversely associated with depression risk, with no significant heterogeneity across subgroups (interaction P > 0.05). CONCLUSION: Hepatorenal function biomarkers (ALT/AST ratio, BUN, BUN/Cr ratio) demonstrate independent associations with geriatric depression risk, suggesting potential involvement of liver-brain and kidney-brain axis in depressive pathophysiology. We recommend incorporating these biomarkers into depression risk stratification protocols for elderly inpatients and propose novel research avenues to elucidate multi-organ crosstalk mechanisms. CI - (c) 2025. The Author(s). FAU - Mao, Shijie AU - Mao S AD - Department of Pharmacy, Huzhou Third Municipal Hospital Affiliated to Huzhou University, Huzhou, 313000, China. FAU - Meng, Fanhao AU - Meng F AD - Department of Psychiatry, Huzhou Third Municipal Hospital Affiliated to Huzhou University, Huzhou, 313000, China. FAU - Shen, Jianchao AU - Shen J AD - Department of Urology, Huzhou Third Municipal Hospital Affiliated to Huzhou University, Huzhou, 313000, China. FAU - Cheng, Yu AU - Cheng Y AD - Department of Critical Care Medicine, Huzhou Third Municipal Hospital Affiliated to Huzhou University, Huzhou, 313000, China. FAU - Yan, Chao AU - Yan C AD - Department of Health Information Technology, Huzhou Third Municipal Hospital Affiliated to Huzhou University, Huzhou, 313000, China. FAU - Zhou, Weimin AU - Zhou W AD - Department of General Surgery, Huzhou Third Municipal Hospital Affiliated to Huzhou University, Huzhou, 313000, China. Weiminzhou2025@163.com. LA - eng GR - 2025KY1560/Medical and Health Technology Foundation of Zhejiang Provincial Health Commission/ PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20251031 PL - England TA - BMC Geriatr JT - BMC geriatrics JID - 100968548 RN - 0 (Biomarkers) RN - EC 2.6.1.2 (Alanine Transaminase) RN - EC 2.6.1.1 (Aspartate Aminotransferases) RN - AYI8EX34EU (Creatinine) SB - IM MH - Humans MH - Cross-Sectional Studies MH - Male MH - Female MH - Aged MH - Biomarkers/blood MH - *Depression/epidemiology/blood/diagnosis MH - Inpatients/psychology MH - Alanine Transaminase/blood MH - Blood Urea Nitrogen MH - Aspartate Aminotransferases/blood MH - Creatinine/blood MH - China/epidemiology MH - Aged, 80 and over MH - Risk Factors PMC - PMC12577328 OTO - NOTNLM OT - ALT/AST ratio OT - BUN OT - BUN/Cr ratio OT - Geriatric depression COIS- Declarations. Ethics approval and consent to participate: The ethics committee of Huzhou Third Municipal Hospital approved the data collection from the patients' medical records without their consent (the approval number: 2025-119). This retrospective study used de-identified data from hospital records. The ethics committee specifically waived the requirement for written informed consent in this study based on: 1) Article 32 of Ethical Review Measures for Life Sciences and Medical Research Involving Human Subjects in China, which permits waiver of consent for retrospective studies using fully anonymized data; 2) Minimal risk to participants, as confirmed by the Committee. We confirm that all methods were conducted in accordance with the relevant guidelines and regulations. All procedures adhered to the Declaration of Helsinki. Consent of publication: Not applicable. Competing interests: The authors declare no competing interests. EDAT- 2025/11/01 05:37 MHDA- 2025/11/01 06:29 PMCR- 2025/10/31 CRDT- 2025/11/01 01:06 PHST- 2025/06/25 00:00 [received] PHST- 2025/09/24 00:00 [accepted] PHST- 2025/11/01 06:29 [medline] PHST- 2025/11/01 05:37 [pubmed] PHST- 2025/11/01 01:06 [entrez] PHST- 2025/10/31 00:00 [pmc-release] AID - 10.1186/s12877-025-06536-x [pii] AID - 6536 [pii] AID - 10.1186/s12877-025-06536-x [doi] PST - epublish SO - BMC Geriatr. 2025 Oct 31;25(1):829. doi: 10.1186/s12877-025-06536-x. PMID- 41163021 OWN - NLM STAT- MEDLINE DCOM- 20251030 LR - 20251101 IS - 1742-4755 (Electronic) IS - 1742-4755 (Linking) VI - 22 IP - 1 DP - 2025 Oct 29 TI - Barriers to access and utilization of sexual and reproductive health services among young Rohingya refugees in Bangladesh. PG - 212 LID - 10.1186/s12978-025-02178-9 [doi] LID - 212 AB - BACKGROUND: Sexual and reproductive health (SRH) is a critical concern for young people in humanitarian settings, who face heightened vulnerability due to displacement and restricted access to care. This study examined barriers to SRH service access and utilization among young Rohingya refugees in Bangladesh, focusing on health system constraints and sociocultural norms. METHODS: A qualitative study was conducted between May and July 2021, consisting of in-depth interviews with 12 young Rohingya refugees and informal conversations with 7 service providers. The data were analyzed thematically using Atlas-ti qualitative analysis software. RESULTS: Young people reported relying on friends, cousins, and community health educators for SRH-related information and services. Young people said it was easier for married people to obtain SRH services than for sexually active unmarried people. Limited healthcare infrastructure, crowded facilities, and trust issues affected service quality, suggesting the need for resource improvements. Conservative social structures and stigma around sexual activity and SRH limited young people's efforts to seek out SRH services. Half of the participants raised concerns about the limited operating hours of health posts and distant field hospitals, especially at night or in the afternoon. Self-identified male participants exhibited reduced inclination for SRH services and information, and commonly held the belief that sexually transmitted infections could be managed easily without consulting service providers. Service providers also emphasized the low utilization of facility-based services by men and the prevalence of misconceptions regarding sexually transmitted infections. CONCLUSION: Substantial barriers limit SRH service access for young Rohingya refugees, especially unmarried individuals. Addressing these gaps requires services tailored to marital status, gender, age, and prevailing community norms. CI - (c) 2025. The Author(s). FAU - Alam Siddiquee, Noor Kutubul AU - Alam Siddiquee NK AD - Arizona State University, Tempe, AZ, USA. siddiquee.nka@gmail.com. LA - eng PT - Journal Article DEP - 20251029 PL - England TA - Reprod Health JT - Reproductive health JID - 101224380 SB - IM MH - Humans MH - *Refugees/psychology/statistics & numerical data MH - Bangladesh MH - *Health Services Accessibility/statistics & numerical data MH - Male MH - *Reproductive Health Services/statistics & numerical data MH - Female MH - Adolescent MH - Young Adult MH - Qualitative Research MH - *Reproductive Health MH - Adult MH - *Patient Acceptance of Health Care MH - *Sexual Health MH - Sexual Behavior MH - Health Knowledge, Attitudes, Practice PMC - PMC12573905 OAB - Young Rohingya people living in Cox's Bazar, Bangladesh, are one of the most vulnerable groups due to their limited access to various healthcare services, including sexual and reproductive health (SRH). A qualitative study was designed, consisting of in-depth interviews with 12 young Rohingya refugees and informal conversations with 7 service providers to explore why such challenges exist in terms of young people's access to and utilization of SRH services. The findings of the study indicated that the most common sources of relevant SRH information were friends, cousins, and elder siblings, in addition to health educators. Married people had easier access to both SRH information and services than unmarried people. At the same time, married males utilized fewer services and were reluctant to visit healthcare facilities than married females. Another key finding was the limited or no access to contraceptive methods for unmarried people, although there were services available. While unmarried young males could visit drug stores or other informal health service providers, for unmarried young females, it was impossible to do so in privacy. To summarize, the availability of services is merely one aspect of a strong healthcare system wherein individuals actively participate. Access and utilization of SRH services are heavily influenced by social, cultural, and gender norms, as well as the various identities individuals hold within society (e.g., a young, unmarried female with limited literacy). Therefore, it is crucial for SRH service provision to be sensitive to these factors and address them accordingly. OABL- eng OTO - NOTNLM OT - Access OT - Intersectionality OT - Refugee OT - Sexual and reproductive health OT - Utilization OT - Youth COIS- Declarations. Ethics approval and consent to participate: Verbal consent was obtained from each participant. Ethics approval for this study was obtained from the Joint Ethical Review Board (ERB) of UNU CPR, UNU IIGH, UNU Macau, and UNU WIDER (reference number 683/2015). Consent for publication: Not applicable. Competing interests: The authors declare no competing interests. EDAT- 2025/10/30 06:29 MHDA- 2025/10/30 06:30 PMCR- 2025/10/29 CRDT- 2025/10/30 00:51 PHST- 2023/06/01 00:00 [received] PHST- 2025/09/26 00:00 [accepted] PHST- 2025/10/30 06:30 [medline] PHST- 2025/10/30 06:29 [pubmed] PHST- 2025/10/30 00:51 [entrez] PHST- 2025/10/29 00:00 [pmc-release] AID - 10.1186/s12978-025-02178-9 [pii] AID - 2178 [pii] AID - 10.1186/s12978-025-02178-9 [doi] PST - epublish SO - Reprod Health. 2025 Oct 29;22(1):212. doi: 10.1186/s12978-025-02178-9. PMID- 41140457 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20251027 LR - 20251029 IS - 2589-5370 (Electronic) IS - 2589-5370 (Linking) VI - 89 DP - 2025 Nov TI - Novel avatar-based video-guided acupuncture imagery treatment for chronic low back pain: a randomised controlled trial in the USA. PG - 103538 LID - 10.1016/j.eclinm.2025.103538 [doi] LID - 103538 AB - BACKGROUND: Chronic low back pain (cLBP) imposes a significant public health burden. Digital health interventions are increasingly used for chronic pain management, yet effective home-based therapies remain limited. We aimed to evaluate a novel, remotely delivered avatar-based video-guided acupuncture imagery treatment (AB-VGAIT) for cLBP. METHODS: This parallel-group, randomised, controlled trial was performed at Massachusetts General Hospital (MA USA). Eligible participants, aged 18-75 years, had been experiencing cLBP for over six months and had at least 4/10 clinical pain on the low back pain numeric rating scale ranging from 0 to 10. Enrolled participants were randomly assigned (1:1) to either the AB-VGAIT or the avatar-based video-guided touch imagery treatment (AB-VGTIT; control) group. Participants underwent eight treatment sessions of either AB-VGAIT or AB-VGTIT over a 4-week period, wherein avatar-based, animated videos guided participants to imagine acupuncture (AB-VGAIT) or cotton stabs (AB-VGTIT) stimulation. Outcome evaluators and statisticians were blinded to group assignments, however participant blinding was not feasible due to the visual and interactive nature of the intervention. The primary outcome was the change from baseline in pain bothersomeness after 4 weeks of treatment. This study was registered with ClinicalTrials.gov, NCT03765879. FINDINGS: Between June 22, 2021 and July 27, 2024, 60 participants were enrolled (n = 30 per group). Five (8.33%) participants did not complete the study, two (6.67%) in the AB-VGAIT group and three (10%) in the AB-VGTIT group. Although both groups demonstrated significant reductions in pain bothersomeness from baseline (AB-VGAIT: -1.71 [-2.38 to -1.04], p < 0.001; AB-VGTIT: -1.24 [-1.92 to -0.55], p = 0.001), no between-group difference was observed between AB-VGAIT and AB-VGTIT (-0.47 [-1.43 to 0.49], p = 0.586). Subgroup analyses stratified by sex, age, and baseline pain severity were consistent with the overall between-group findings. No serious adverse events occurred. INTERPRETATION: Short duration, limited treatment frequency, and small sample size may restrict generalisability. No significant difference was observed between AB-VGAIT and AB-VGTIT; although both interventions yielded significant improvements in pain relief, suggesting each may offer a promising remote, self-administered digital intervention for cLBP. The scalable, non-invasive nature may help to bridge treatment gaps, particularly for individuals with limited access to in-person care. Future larger-scale trials are warranted to validate efficacy and generalisability. FUNDING: National Institutes of Health/National Center for Complementary and Integrative Health. CI - (c) 2025 The Author(s). FAU - Hodges, Sierra AU - Hodges S AD - Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA. FAU - Li, Yuanyuan AU - Li Y AD - Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA. FAU - Wu, Jiani AU - Wu J AD - Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA. FAU - Ma, Linting AU - Ma L AD - Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA. FAU - Liu, Yu AU - Liu Y AD - Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA. FAU - Reddy, Sveta AU - Reddy S AD - Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA. FAU - Sacca, Valeria AU - Sacca V AD - Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA. FAU - Walker, Kathryn M AU - Walker KM AD - Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA. FAU - Chen, Lucy AU - Chen L AD - Department of Anesthesia, Critical Care and Pain Medicine, MGH Center for Translational Pain Research, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA. FAU - Camprodon, Joan A AU - Camprodon JA AD - Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA. FAU - Orr, Scott P AU - Orr SP AD - Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA. FAU - Fregni, Felipe AU - Fregni F AD - Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA. FAU - Zhang, Yi AU - Zhang Y AD - Department of Anesthesia, Critical Care and Pain Medicine, MGH Center for Translational Pain Research, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA. FAU - Yao, Sean AU - Yao S AD - Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA. FAU - Vangel, Mark AU - Vangel M AD - Department of Biostatistics, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114, USA. FAU - Kong, Jian AU - Kong J AD - Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA. LA - eng SI - ClinicalTrials.gov/NCT03765879 PT - Journal Article DEP - 20251010 PL - England TA - EClinicalMedicine JT - EClinicalMedicine JID - 101733727 PMC - PMC12547178 OTO - NOTNLM OT - Avatar-based video-guided acupuncture imagery treatment OT - Chronic low back pain OT - Digital health intervention OT - Randomised controlled trial OT - Remote therapy COIS- JK has a disclosure to report, including equity ownership in startup companies (MNT, BTT) and involvement in a granted patent (applying ear vagus nerve stimulation [US 2018/0339148]) and several pending patents. All other authors declare no competing interests. EDAT- 2025/10/27 13:28 MHDA- 2025/10/27 13:29 PMCR- 2025/10/10 CRDT- 2025/10/27 06:56 PHST- 2025/06/24 00:00 [received] PHST- 2025/09/09 00:00 [revised] PHST- 2025/09/12 00:00 [accepted] PHST- 2025/10/27 13:29 [medline] PHST- 2025/10/27 13:28 [pubmed] PHST- 2025/10/27 06:56 [entrez] PHST- 2025/10/10 00:00 [pmc-release] AID - S2589-5370(25)00471-7 [pii] AID - 103538 [pii] AID - 10.1016/j.eclinm.2025.103538 [doi] PST - epublish SO - EClinicalMedicine. 2025 Oct 10;89:103538. doi: 10.1016/j.eclinm.2025.103538. eCollection 2025 Nov. PMID- 41100803 OWN - NLM STAT- MEDLINE DCOM- 20260211 LR - 20260825 IS - 1541-0048 (Electronic) IS - 0090-0036 (Print) IS - 0090-0036 (Linking) VI - 116 IP - 3 DP - 2026 Mar TI - Clinic Adaptations and Changes in Abortion Use After Dobbs in Illinois, July 2021-June 2023. PG - 359-367 LID - 10.2105/AJPH.2025.308273 [doi] AB - Objectives. To assess changes in abortion service delivery in Illinois after the Dobbs v Jackson Women's Health Organization decision. Methods. We used data from a monthly survey of 2 Illinois abortion providers that provide half of Illinois's abortions. We collected data from 2021 to 2023 on abortion counts, overall and stratified by method, gestation duration, and patient state. We compared pre- and post-Dobbs findings. Results. A total of 24 071 abortions took place from July 2021 to June 2022 and 32 579 from July 2022 to June 2023. This 35% increase was driven by a 191% increase in out-of-state patients. Medication abortions increased by 22%, procedural abortions by 53%, and abortions occurring at 12 weeks or later by 75%. Conclusions. After Dobbs, 2 large Illinois abortion providers increasingly offered care to out-of-state patients and patients presenting at later gestations while maintaining in-state abortion rates. Public Health Implications. Policymakers in states where abortion remains legal can anticipate increased demand for care when other states restrict abortion. By passing legislation to protect access to medication and procedural abortions and abortions later in pregnancy, they can support facilities in meeting patient needs. (Am J Public Health. 2026;116(3):359-367. https://doi.org/10.2105/AJPH.2025.308273). FAU - Smith, Mikaela H AU - Smith MH AUID- ORCID: 0000-0001-5658-4808 AD - Mikaela H. Smith and Alison H. Norris are with the Division of Epidemiology, College of Public Health, The Ohio State University, Columbus. At the time of the study, Danielle Young was with Planned Parenthood of Illinois, Chicago. Hanz Dismer and Valla Diskin are with Hope Clinic, Granite City, IL. Lee Hasselbacher and Katherine Rivlin are with the Department of Obstetrics & Gynecology, University of Chicago Medicine, Chicago, IL. Danielle Bessett is with the Sociology Department, University of Cincinnati, Cincinnati, OH. FAU - Young, Danielle AU - Young D AUID- ORCID: 0009-0005-8051-5892 AD - Mikaela H. Smith and Alison H. Norris are with the Division of Epidemiology, College of Public Health, The Ohio State University, Columbus. At the time of the study, Danielle Young was with Planned Parenthood of Illinois, Chicago. Hanz Dismer and Valla Diskin are with Hope Clinic, Granite City, IL. Lee Hasselbacher and Katherine Rivlin are with the Department of Obstetrics & Gynecology, University of Chicago Medicine, Chicago, IL. Danielle Bessett is with the Sociology Department, University of Cincinnati, Cincinnati, OH. FAU - Dismer, Hanz AU - Dismer H AUID- ORCID: 0009-0000-5089-6288 AD - Mikaela H. Smith and Alison H. Norris are with the Division of Epidemiology, College of Public Health, The Ohio State University, Columbus. At the time of the study, Danielle Young was with Planned Parenthood of Illinois, Chicago. Hanz Dismer and Valla Diskin are with Hope Clinic, Granite City, IL. Lee Hasselbacher and Katherine Rivlin are with the Department of Obstetrics & Gynecology, University of Chicago Medicine, Chicago, IL. Danielle Bessett is with the Sociology Department, University of Cincinnati, Cincinnati, OH. FAU - Diskin, Valla AU - Diskin V AD - Mikaela H. Smith and Alison H. Norris are with the Division of Epidemiology, College of Public Health, The Ohio State University, Columbus. At the time of the study, Danielle Young was with Planned Parenthood of Illinois, Chicago. Hanz Dismer and Valla Diskin are with Hope Clinic, Granite City, IL. Lee Hasselbacher and Katherine Rivlin are with the Department of Obstetrics & Gynecology, University of Chicago Medicine, Chicago, IL. Danielle Bessett is with the Sociology Department, University of Cincinnati, Cincinnati, OH. FAU - Hasselbacher, Lee AU - Hasselbacher L AD - Mikaela H. Smith and Alison H. Norris are with the Division of Epidemiology, College of Public Health, The Ohio State University, Columbus. At the time of the study, Danielle Young was with Planned Parenthood of Illinois, Chicago. Hanz Dismer and Valla Diskin are with Hope Clinic, Granite City, IL. Lee Hasselbacher and Katherine Rivlin are with the Department of Obstetrics & Gynecology, University of Chicago Medicine, Chicago, IL. Danielle Bessett is with the Sociology Department, University of Cincinnati, Cincinnati, OH. FAU - Rivlin, Katherine AU - Rivlin K AD - Mikaela H. Smith and Alison H. Norris are with the Division of Epidemiology, College of Public Health, The Ohio State University, Columbus. At the time of the study, Danielle Young was with Planned Parenthood of Illinois, Chicago. Hanz Dismer and Valla Diskin are with Hope Clinic, Granite City, IL. Lee Hasselbacher and Katherine Rivlin are with the Department of Obstetrics & Gynecology, University of Chicago Medicine, Chicago, IL. Danielle Bessett is with the Sociology Department, University of Cincinnati, Cincinnati, OH. FAU - Bessett, Danielle AU - Bessett D AD - Mikaela H. Smith and Alison H. Norris are with the Division of Epidemiology, College of Public Health, The Ohio State University, Columbus. At the time of the study, Danielle Young was with Planned Parenthood of Illinois, Chicago. Hanz Dismer and Valla Diskin are with Hope Clinic, Granite City, IL. Lee Hasselbacher and Katherine Rivlin are with the Department of Obstetrics & Gynecology, University of Chicago Medicine, Chicago, IL. Danielle Bessett is with the Sociology Department, University of Cincinnati, Cincinnati, OH. FAU - Norris, Alison H AU - Norris AH AD - Mikaela H. Smith and Alison H. Norris are with the Division of Epidemiology, College of Public Health, The Ohio State University, Columbus. At the time of the study, Danielle Young was with Planned Parenthood of Illinois, Chicago. Hanz Dismer and Valla Diskin are with Hope Clinic, Granite City, IL. Lee Hasselbacher and Katherine Rivlin are with the Department of Obstetrics & Gynecology, University of Chicago Medicine, Chicago, IL. Danielle Bessett is with the Sociology Department, University of Cincinnati, Cincinnati, OH. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20251016 PL - United States TA - Am J Public Health JT - American journal of public health JID - 1254074 SB - IM MH - Humans MH - Illinois MH - Female MH - Pregnancy MH - *Abortion, Induced/statistics & numerical data/trends MH - Adult MH - Health Services Accessibility MH - Surveys and Questionnaires PMC - PMC12895905 EDAT- 2025/10/16 18:35 MHDA- 2026/02/11 18:59 PMCR- 2028/03/01 CRDT- 2025/10/16 16:04 PHST- 2026/02/11 18:59 [medline] PHST- 2025/10/16 18:35 [pubmed] PHST- 2025/10/16 16:04 [entrez] PHST- 2028/03/01 00:00 [pmc-release] AID - 202548630 [pii] AID - 10.2105/AJPH.2025.308273 [doi] PST - ppublish SO - Am J Public Health. 2026 Mar;116(3):359-367. doi: 10.2105/AJPH.2025.308273. Epub 2025 Oct 16. PMID- 41092928 OWN - NLM STAT- MEDLINE DCOM- 20251018 LR - 20260923 IS - 1474-547X (Electronic) IS - 0140-6736 (Print) IS - 0140-6736 (Linking) VI - 406 IP - 10513 DP - 2025 Oct 18 TI - Global burden of 292 causes of death in 204 countries and territories and 660 subnational locations, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023. PG - 1811-1872 LID - S0140-6736(25)01917-8 [pii] LID - 10.1016/S0140-6736(25)01917-8 [doi] AB - BACKGROUND: Timely and comprehensive analyses of causes of death stratified by age, sex, and location are essential for shaping effective health policies aimed at reducing global mortality. The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2023 provides cause-specific mortality estimates measured in counts, rates, and years of life lost (YLLs). GBD 2023 aimed to enhance our understanding of the relationship between age and cause of death by quantifying the probability of dying before age 70 years (70q0) and the mean age at death by cause and sex. This study enables comparisons of the impact of causes of death over time, offering a deeper understanding of how these causes affect global populations. METHODS: GBD 2023 produced estimates for 292 causes of death disaggregated by age-sex-location-year in 204 countries and territories and 660 subnational locations for each year from 1990 until 2023. We used a modelling tool developed for GBD, the Cause of Death Ensemble model (CODEm), to estimate cause-specific death rates for most causes. We computed YLLs as the product of the number of deaths for each cause-age-sex-location-year and the standard life expectancy at each age. Probability of death was calculated as the chance of dying from a given cause in a specific age period, for a specific population. Mean age at death was calculated by first assigning the midpoint age of each age group for every death, followed by computing the mean of all midpoint ages across all deaths attributed to a given cause. We used GBD death estimates to calculate the observed mean age at death and to model the expected mean age across causes, sexes, years, and locations. The expected mean age reflects the expected mean age at death for individuals within a population, based on global mortality rates and the population's age structure. Comparatively, the observed mean age represents the actual mean age at death, influenced by all factors unique to a location-specific population, including its age structure. As part of the modelling process, uncertainty intervals (UIs) were generated using the 2.5th and 97.5th percentiles from a 250-draw distribution for each metric. Findings are reported as counts and age-standardised rates. Methodological improvements for cause-of-death estimates in GBD 2023 include a correction for the misclassification of deaths due to COVID-19, updates to the method used to estimate COVID-19, and updates to the CODEm modelling framework. This analysis used 55 761 data sources, including vital registration and verbal autopsy data as well as data from surveys, censuses, surveillance systems, and cancer registries, among others. For GBD 2023, there were 312 new country-years of vital registration cause-of-death data, 3 country-years of surveillance data, 51 country-years of verbal autopsy data, and 144 country-years of other data types that were added to those used in previous GBD rounds. FINDINGS: The initial years of the COVID-19 pandemic caused shifts in long-standing rankings of the leading causes of global deaths: it ranked as the number one age-standardised cause of death at Level 3 of the GBD cause classification hierarchy in 2021. By 2023, COVID-19 dropped to the 20th place among the leading global causes, returning the rankings of the leading two causes to those typical across the time series (ie, ischaemic heart disease and stroke). While ischaemic heart disease and stroke persist as leading causes of death, there has been progress in reducing their age-standardised mortality rates globally. Four other leading causes have also shown large declines in global age-standardised mortality rates across the study period: diarrhoeal diseases, tuberculosis, stomach cancer, and measles. Other causes of death showed disparate patterns between sexes, notably for deaths from conflict and terrorism in some locations. A large reduction in age-standardised rates of YLLs occurred for neonatal disorders. Despite this, neonatal disorders remained the leading cause of global YLLs over the period studied, except in 2021, when COVID-19 was temporarily the leading cause. Compared to 1990, there has been a considerable reduction in total YLLs in many vaccine-preventable diseases, most notably diphtheria, pertussis, tetanus, and measles. In addition, this study quantified the mean age at death for all-cause mortality and cause-specific mortality and found noticeable variation by sex and location. The global all-cause mean age at death increased from 46.8 years (95% UI 46.6-47.0) in 1990 to 63.4 years (63.1-63.7) in 2023. For males, mean age increased from 45.4 years (45.1-45.7) to 61.2 years (60.7-61.6), and for females it increased from 48.5 years (48.1-48.8) to 65.9 years (65.5-66.3), from 1990 to 2023. The highest all-cause mean age at death in 2023 was found in the high-income super-region, where the mean age for females reached 80.9 years (80.9-81.0) and for males 74.8 years (74.8-74.9). By comparison, the lowest all-cause mean age at death occurred in sub-Saharan Africa, where it was 38.0 years (37.5-38.4) for females and 35.6 years (35.2-35.9) for males in 2023. Lastly, our study found that all-cause 70q0 decreased across each GBD super-region and region from 2000 to 2023, although with large variability between them. For females, we found that 70q0 notably increased from drug use disorders and conflict and terrorism. Leading causes that increased 70q0 for males also included drug use disorders, as well as diabetes. In sub-Saharan Africa, there was an increase in 70q0 for many non-communicable diseases (NCDs). Additionally, the mean age at death from NCDs was lower than the expected mean age at death for this super-region. By comparison, there was an increase in 70q0 for drug use disorders in the high-income super-region, which also had an observed mean age at death lower than the expected value. INTERPRETATION: We examined global mortality patterns over the past three decades, highlighting-with enhanced estimation methods-the impacts of major events such as the COVID-19 pandemic, in addition to broader trends such as increasing NCDs in low-income regions that reflect ongoing shifts in the global epidemiological transition. This study also delves into premature mortality patterns, exploring the interplay between age and causes of death and deepening our understanding of where targeted resources could be applied to further reduce preventable sources of mortality. We provide essential insights into global and regional health disparities, identifying locations in need of targeted interventions to address both communicable and non-communicable diseases. There is an ever-present need for strengthened health-care systems that are resilient to future pandemics and the shifting burden of disease, particularly among ageing populations in regions with high mortality rates. Robust estimates of causes of death are increasingly essential to inform health priorities and guide efforts toward achieving global health equity. The need for global collaboration to reduce preventable mortality is more important than ever, as shifting burdens of disease are affecting all nations, albeit at different paces and scales. FUNDING: Gates Foundation. CI - Copyright (c) 2025 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. CN - GBD 2023 Causes of Death Collaborators LA - eng GR - P01 HD031921/HD/NICHD NIH HHS/United States GR - R01 AG044917/AG/NIA NIH HHS/United States GR - R01 AG030153/AG/NIA NIH HHS/United States GR - HHSN271201300071C/AG/NIA NIH HHS/United States GR - WT_/Wellcome Trust/United Kingdom GR - R03 AG043052/AG/NIA NIH HHS/United States GR - R01 AG034479/AG/NIA NIH HHS/United States GR - R01 AG018016/AG/NIA NIH HHS/United States GR - R21 AG032572/AG/NIA NIH HHS/United States GR - U01 AG009740/AG/NIA NIH HHS/United States GR - R01 AG031716/AG/NIA NIH HHS/United States GR - R21 AG034263/AG/NIA NIH HHS/United States PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20251012 PL - England TA - Lancet JT - Lancet (London, England) JID - 2985213R SB - IM MH - Humans MH - *Global Burden of Disease/trends MH - Cause of Death/trends MH - Male MH - Female MH - Aged MH - Middle Aged MH - Adult MH - Infant MH - Child MH - Child, Preschool MH - Adolescent MH - Life Expectancy/trends MH - Global Health/statistics & numerical data MH - Young Adult MH - Infant, Newborn MH - Aged, 80 and over MH - Risk Factors MH - Mortality/trends PMC - PMC12535838 COIS- Declaration of interests J Arnlov reports payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from AstraZeneca, Boehringer Ingelheim, and Novartis; participation on a Data Safety Monitoring Board or Advisory Board with AstraZeneca, Boehringer Ingelheim, and Astella; all outside the submitted work. D Abramov reports payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from AstraZeneca and Bayer; participation on a Data Safety Monitoring Board or Advisory Board with BridgeBio; all outside the submitted work. S Afzal reports support for the present manuscript from Institute of Public Health Lahore for study material, manuscripts, medical writings and library resources; grants or contracts from the Dean Institute of Public Health Lahore; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from the Dean Institute of Public Health Lahore; support for attending meetings and/or travel from the Dean Institute of Public Health Lahore; participation on a Data Safety Monitoring Board or Advisory Board with Pakistan National Bioethics Committee as a Member, Institutional Review Board of Fatima Jinnah Medical University as a Member, Ethical Review Board and Data Monitoring Board Institute of Public Health Lahore Pakistan as a Member, Clinical Research Organization King Edward Medical University, Annals of King Edward Medical University Advisory Board as a Member; leadership or fiduciary roles in other board, society, committee or advocacy group, paid or unpaid, with Pakistan Higher Education Commission Research Committee as a Member, Pakistan Medical and Dental Commission Research and Journals Committee as a Member, Pakistan National Bioethics Committee as a Member, Pakistan Society of Internal Medicine as a Member, Pakistan Association of Medical Editors as a Member, Medical Microbiology and Infectious Diseases Society as a Member, Leads International as a Fellow, Faculty of Public Health UK as a Fellow, College of Physicians and Surgeons Pakistan as a Fellow; receipt of equipment, materials, drugs, medical writing, gifts or other services from Bergen University Norway; other financial or non-financial interests with Dean Institute of Public Health Birdwood Lahore; all outside the submitted work. C A Sobrinho reports grants or contracts from Fundacao para a Ciencia e Tecnologia (FCT) via grant CEECINST/00093/2021/CP2815/CT0001, outside the submitted work. R Ancuceanu reports consulting fees from Abbvie and Merck Romania; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Abbvie, Laropharm, Reckitt, Merck Romania, and MagnaPharm; support for attending meetings and/or travel from Merck Romania and Reckitt; all outside the submitted work. O C Baltatu reports support for the present manuscript from the National Council for Scientific and Technological Development Fellowship (CNPq, 304224/2022-7), the Anima Institute (AI) Research Professor Fellowship, and Alfaisal University; leadership or fiduciary roles in other board, society, committee or advocacy group, paid or unpaid, with VividiWise Analytics as Managing Partner and Sao Jose dos Campos Tech Park-CITE as Biotech Advisory Board Member; all outside the submitted work. S Barteit reports support for attending meetings and/or travel from Wellcome Trust, September 2023+January 2025; stock or stock options in Climate Change and Health Evaluation and Response System (euro4,200 in shares); all outside the submitted work. A Beloukas reports grants or contracts from Gilead for a research grant and sponsorship to the University of West Attica, and from GSK/ViiV for a Research Sponsorship to the University of West Attica; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Gilead and GSK paid to the University of West Attica; support for attending meetings and/or travel from Gilead and GSK paid to the University of West Attica; receipt of equipment, materials, drugs, medical writing, gifts or other services from Cepheid in the form of FOC reagents for a research project; all outside the submitted work. P J G Bettencourt reports the following patents issued or pending: WO2020229805A1, BR112021022592A2, EP3965809A1, OA1202100511, US2023173050A1, EP4265271A2, EP4275700A2, EP4265271A3, EP4275700A3; all outside the submitted work. S Bhaskar reports grants or contracts from Japan Society for the Promotion of Science (JSPS), Japanese Ministry of Education, Culture, Sports, Science and Technology (MEXT), Grant-in-Aid for Scientific Research (KAKENHI; grant ID: 23KF0126), JSPS and the Australian Academy of Science, JSPS International Fellowship (grant ID P23712); leadership or fiduciary roles in other board, society, committee or advocacy group, paid or unpaid, with Rotary District 9675, Sydney, Australia as District Chair, Diversity, Equity, Inclusion & Belonging, with Global Health & Migration Hub Community, Global Health Hub Germany, Berlin, Germany as Chair, Founding Member and Manager, with PLOS One, BMC Neurology, Frontiers in Neurology, Frontiers in Stroke, Frontiers in Public Health, Journal of Aging Research, Neurology International, Diagnostics, & BMC Medical Research Methodology as an Editorial Board Member, with College of Reviewers, Canadian Institutes of Health Research (CIHR), Government of Canada as a Member, with World Headache Society, Bengaluru, India as Director of Research, with Cariplo Foundation, Milan, Italy as an Expert Adviser/Reviewer, with National Cerebral and Cardiovascular Center, Department of Neurology, Division of Cerebrovascular Medicine and Neurology, Suita, Osaka, Japan as Visiting Director, with Cardiff University Biobank, Cardiff, UK as a Member, Scientific Review Committee, with Rotary Reconciliation Action Plan as Chair, and with Japan Connect, Osaka, Japan as a Healthcare and Medical Adviser; all outside the submitted work. A Biswas reports consulting fees from LUPIN Pharmaceuticals Ltd, INTAS Pharmaceuticals Ltd, Alkem Laboratories Ltd, and Torrent Pharmaceuticals Ltd; all outside the submitted work. R Cairns reports grants or contracts from Reckitt for an untied educational grant to study poisoning; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from The Pharmacy Guild of Australia and Reckitt; all outside the submitted work. M C D de Carvalho reports other financial or non-financial interests with LAQV/REQUIMTE, University of Porto, Porto, Portugal, and from FCT/MCTES under the scope of the project UIDP/50006/2020 (DOI 10.54499/UIDP/50006/2020); all outside the submitted work. A L Catapano reports grants or contracts from Chiesi, Amarin, and Ultragenyx; consulting fees from Amarin, Amgen, AstraZeneca, Chiesi, Daiichi Sankyo, Eli Lilly, Esperion, Ionis Pharmaceutical, Medscape, Menarini, MSD, Novartis, NovoNordisk, Regeneron, Sanofi, Ultragenyx, and Viatris; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Amarin, Amgen, AstraZeneca, Chiesi, Daiichi Sankyo, Eli Lilly, Esperion, Ionis Pharmaceutical, Medscape, Menarini, MSD, Novartis, NovoNordisk, Regeneron, Sanofi, Ultragenyx, and Viatris; participation on a Data Safety Monitoring Board or Advisory Board with Amarin, Amgen, AstraZeneca, Chiesi, Daiichi Sankyo, Eli Lilly, Esperion, Ionis Pharmaceutical, Medscape, Menarini, MSD, Novartis, NovoNordisk, Regeneron, Sanofi, Ultragenyx, and Viatris; all outside the submitted work. H Christensen reports grants or contracts from Velux Foundation, Novo Foundation, Br Hartman Fonden, Tvaersfonden, and Lundbeck Foundation; participation on a Data Safety Monitoring Board or Advisory Board with Atricure: LEEAPS trial-DSMB; leadership or fiduciary roles in other board, society, committee or advocacy group, paid or unpaid, with Action Plan for Stroke in Europe as Past Chair; all outside the submitted work. F Cohen reports consulting fees from Abbvie and Pfizer; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Abbvie and Axsome; all outside the submitted work. J Conde reports grants or contracts from OncoNanoAI: Artificial intelligence to discover the next generation of personalised nanoparticles for triple-negative breast cancer therapy (2025-2027) (FCT grant LISBOA2030-FEDER-00862500-149983); patents issued or pending: "TRPV2 Antagonists" US Application (number US11273152B2), "Surfactant-based cellulose hydrogel methods and uses thereof" (PCT/IB2025/051694, 17/02/2025), "Self-immolative micelle, methods and uses thereof" (EP25165757, 24/03/2025); all outside the submitted work. S E Congly reports grants or contracts paid to their institution from AstraZeneca, Merck, Ipsen, Bausch Health, Oncoustics, Boehringer Ingelheim, and Gilead Sciences Canada; consulting fees paid to them from GSK and Boehringer Ingelheim; participation on a Data Safety Monitoring Board or Advisory Board with Boehringer Ingelheim, Gilead Sciences Canada, and AstraZeneca; leadership or fiduciary roles in other board, society, committee or advocacy group, paid or unpaid, with Canadian Association for the Study of the Liver as a Member of the Board of Directors and Alberta Society of Gastroenterology as Vice President; all outside the submitted work. N Conrad reports grants or contracts paid to their institution from Wellcome Trust Career Development Award (grant number 318034/Z/24/Z), Research Foundation Flanders (grant number 12ZU922N), and KU Leuven (internal funding); all outside the submitted work. S Cortese reports grants or contracts from the National Institute for Health and Care Research (NIHR) and the European Research Agency; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from the Association for Child and Adolescent Mental Health (ACAMH), the British Association of Psychopharmacology (BAP), Medice; support for attending meetings and/or travel from the Association for Child and Adolescent Mental Health (ACAMH), the British Association of Psychopharmacology (BAP), Medice; leadership or fiduciary roles in other board, society, committee or advocacy group, paid or unpaid, with the European ADHD Guideline Group (EAGG); all outside the submitted work. E C Dee reports support for the present manuscript from Prostate Cancer Foundation Young Investigator Award and through the Cancer Center Support grant from the US National Cancer Institute (P30 CA008748). A K Demetriades reports non-fiduciary leadership roles in other board, society, committee or advocacy group with EANS (European Association of Neurosurgical Societies) as a Board member, AO SPINE as a Steering Committee Member for Knowledge Forum Degenerative, Global Neuro Foundation as a Board Member, AO SPINE as a Steering Committee Member for Knowledge Forum Degenerative; all outside the submitted work. X Ding reports grants or contracts from American Heart Association for a 2-year predoctoral fellowship (DOI: 10.58275/AHA.25PRE1373497.pc.gr.227106); quarterly payments made to their institution; all outside the submitted work. L L M Ebraheim reports support for the present manuscript from the Gates Foundation, and royalties or licenses from the Institute for Health Metrics and Evaluation outside the submitted work. A Faro reports support for the present manuscript from National Council for Scientific and Technological Development (CNPq, Brazil) for a personal grant "Researcher at CNPq-Level 1B". A A Fomenkov reports support for the present manuscript from the Ministry of Science and Higher Education of the Russian Federation (theme number 122042600086-7). L M Force reports support for the present manuscript from Gates Foundation, St. Jude Children's Research Hospital; grants or contracts from St. Baldrick's Foundation, Conquer Cancer Foundation, NIH Loan Repayment Program; leadership or fiduciary roles in other board, society, committee or advocacy group, unpaid, with the Lancet Oncology International Advisory Board; all outside the submitted work. R C Franklin reports support for attending meetings and/or travel from ACTM-Annual Conference 2022-2024; leadership or fiduciary roles in other board, society, committee or advocacy group, paid or unpaid, with Australasian College of Tropical Medicine as President, Kidsafe Australia as President, Royal Life Saving Society Australia as a Board Member, and Auschem Training as a Board Member; all outside the submitted work. A Guha reports grants or contracts from American Heart Association and US Department of Defense; leadership or fiduciary roles in other board, society, committee or advocacy group, paid or unpaid, with ZERO Cancer health disparities working group; all outside the submitted work. A A Harris reports grants or contracts from the Gates Foundation and Gavi; all outside the submitted work. A Hassan reports consulting fees from Novartis, Sanofi Genzyme, Biologix, Astra Zeneca, Pfizer, Merz, Roche, Merck, Hikma Pharma, Janssen, Inspire Pharma, Future Pharma, and Elixir Pharma; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Novartis, Allergan, Abbvie, Merck, Biologix, Viatris, Pfizer, Eli Lilly, Janssen, Roche, Sanofi Genzyme, Bayer, AstraZeneca, Hikma Pharma, Al Andalus, Chemipharm, Lundbeck, Elixir, EvaPharma, Inspire Pharma, Future Pharma and Habib Scientific Office, and Everpharma; support for attending meetings and/or travel from Novartis, Allergan, Merz, Pfizer, Merck, Biologix, Roche, Sanofi Genzyme, Bayer, Hikma Pharma, Chemipharm, Al Andalus and Clavita Pharm; leadership or fiduciary roles in other board, society, committee or advocacy group, paid or unpaid, with MENA Headache Society as Vice President, Multiple Sclerosis Chapter of the Egyptian Society of Neurology as a Board Member, Headache Chapter of the Egyptian Society of Neurology as a Board Member, The International Headache Society (IHS) as a Member of the committee of education, the membership committee, and regional committee; all outside the submitted work. P J Hotez is a co-inventor on non-revenue generating patents for neglected tropical diseases owned by Baylor College of Medicine (BCM). He is also a co-inventor of a COVID-19 recombinant protein vaccine technology owned by BCM that was licensed by Baylor Ventures non-exclusively and with no patent restrictions to several companies committed to advance vaccines for low- and middle-income countries. The co-inventors have no involvement in license negotiations conducted by BCM. Similar to other research universities, a long-standing BCM policy provides its faculty and staff, who make discoveries and that result in a commercial license, a share of any royalty income. Any such distribution will be undertaken in accordance with BCM policy. P J Hotez is also the author of several books published by academic presses (ASM-Wiley) and Johns Hopkins University Press, and he receives modest royalty income from this activity. I M Ilic reports support for the present manuscript from Ministry of Science, Technological Development and Innovation of the Republic of Serbia; number 451-03-137/2025-03/200110. M D Ilic reports support for the present manuscript from Ministry of Science, Technological Development and Innovation of the Republic of Serbia number 451-03-47/2023-01/200111. N E Ismail reports leadership or fiduciary roles in other board, society, committee or advocacy group, unpaid, with Malaysian Academy of Pharmacy, Malaysia as the Bursar and Council Member and Malaysian Pharmacists Society Education Chapter Committee as a Committee Member; all outside the submitted work. I O Iyamu reports grants or contracts from Canadian Institutes for Health Research (CIHR) Health Systems Impact Fellowship (Funding Reference number IF8-196153), Michael Smith Health Research BC Trainee Award (award number HSIF-2024-04465), and CIHR Canadian HIV Trials Network (CTN+) post-doctoral fellowship; consulting fees from Excellence Community Education Welfare Scheme; support for attending meetings and/or travel from Pacific Public Health Foundation; leadership or fiduciary roles in other board, society, committee or advocacy group, paid or unpaid, with Public Health Association of British Columbia as Vice President; all outside the submitted work. V Jha reports consulting fees from Bayer, AstraZeneca, Boehringer Ingelheim, Baxter, Vera, Visterra, Otsuka, Novartis, Timberlyne, Biogen, Chinook, and Alpine; All payments to the George Institute; all outside the submitted work. T Joo reports support for the present manuscript from EU4Health Programme 2021-2027 under grant agreement 101126953 (The Joint Action on CARdiovascular diseases and DIabetes-JACARDI). The views and opinions expressed are those of the author(s) only and do not necessarily reflect those of the European Union or the European Health and Digital Executive Agency (HaDEA). Neither the European Union nor the granting authority can be held responsible for them; and National Research, Development and Innovation Office in Hungary (RRF-2.3.1-21-2022-00006, Data-Driven Health Division of National Laboratory for Health Security for funding of participation in the research project. J J Jozwiak reports payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Novartis, Adamed, Amgen, Boehringer Ingelheim, Servier, Novo Nordisk; all outside the submitted work. R Kalani reports grants or contracts from the National Institutes of Health (NIH) (USA) 1R01NS138297; all outside the submitted work. M Kivimaki reports grants or contracts paid to their university from the Wellcome Trust (221854/Z/20/Z), Medical Research Council (MR/Y014154/1), National Institute on Aging (R01AG056477, R01AG062553) and Research Council of Finland (350426); all outside the submitted work. J M Kocarnik reports support for the present manuscript from Institute for Health Metrics and Evaluation as an employee, the Gates Foundation for funding to his institution, and American Lebanese Syrian Associated Charities for funding to his institution. K Krishan reports other financial or non-financial interests with non-financial support from the UGC Centre of Advanced Study, CAS II, awarded to the Department of Anthropology, Panjab University, Chandigarh, India, outside the submitted work. T Lallukka reports support for the present manuscript from the Research Council of Finland (330527), payments made to their institution. M-C Li reports grants or contracts from the National Science and Technology Council, Taiwan (NSTC 113-2314-B-003-002) and the "Higher Education Sprout Project" of National Taiwan Normal University; leadership or fiduciary roles in other board, society, committee or advocacy group, paid or unpaid, with Journal of the American Heart Association as Technical Editor; all outside the submitted work. D Lindholm reports stock or stock options in AstraZeneca during time of employment (>2.5 years ago); other financial or non-financial interests with AstraZeneca as a former employee (>2.5 years ago); all outside the submitted work. H Liu reports other financial or non-financial interests as a mentor of National Medical Research Association (NMRA, U.K.), a member of British Society for Cardiovascular Research (BSCR, U.K.), and a member of and Cardiovascular Analytics Group (CVAG, HKSAR of China), all are not-for-profit organisations; all outside the submitted work. J Liu reports support for the present manuscript from the National Natural Science Foundation (72474005) and Beijing Natural Science Foundation (L222027, Z240004); grants of contracts the National Natural Science Foundation (72474005) and Beijing Natural Science Foundation (L222027, Z240004), outside the submitted work. V Lohner reports support for the present manuscript from Marga and Walter Boll Foundation, Kerpen, Germany. S Lorkowski reports grants or contracts paid to their institution from dsm-firmenich (formerly DSM Nutritional Products); consulting fees from Danone, Novartis Pharma, and Swedish Orphan Biovitrum (SOBI); payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from AMARIN Germany, Amedes Holding, AMGEN, Berlin-Chemie, Boehringer Ingelheim Pharma, Daiichi Sankyo Deutschland, Danone, Hubert Burda Media Holding, Janssen-Cilag, Lilly Deutschland, Novartis Pharma, Novo Nordisk Pharma, Roche Pharma, Sanofi-Aventis, Swedish Orphan Biovitrum (SOBI), SYNLAB Holding Deutschland; support for attending meetings and/or travel from AMGEN; participation on a Data Safety Monitoring Board or Advisory Board with AMGEN, Daiichi Sankyo Deutschland, Novartis Pharma, Sanofi-Aventis; all outside the submitted work. K S-K Ma reports grants or contracts from the International Team for Implantology outside the submitted work. P Maffia reports grants or contracts from British Heart Foundation, NextGenerationEU PNRR, Heart Research UK, Italian Ministry of University, BBSRC International Partnerships Funding, and Scottish Founding Council; leadership or fiduciary roles in other board, society, committee or advocacy group, paid or unpaid, with Translational Section for the International Union of Basic and Clinical Pharmacology (IUPHAR) as Vice-Chair, the Translational Research Medical Review Panel for Heart Research UK (HRUK) as Chair, the European Society of Cardiology (ESC) Working Group on Atherosclerosis & Vascular Biology and Cell Biology of the Heart as a Nucleus Member, the British Atherosclerosis Society (BAS) as an Executive Committee Member, Immunotherapy Committee of the International Union of Immunological Societies (IUIS) as a Member, and the Translational Clinical Studies (TCS) Grant Panel for the Chief Scientist Office (CSO) as a Member; all outside the submitted work. H R Marateb reports grants or contracts from Universitat Politecnica de Catalunya . Barcelona Tech-UPC; all outside the submitted work. S Masi reports grants or contracts from Servier for personal contracts for consulting activities, lectures, presentations, manuscript writing and educational events, Tuscany Region for grants for research projects in the field of arterial hypertension and management of SARS-CoV2 infection, and Italian Ministry of University and Research for grants for research projects in the field of heart failure; consulting fees from Servier (2022-Present); payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Servier (2018-Present); support for attending meetings and/or travel from Servier (2018-Present); participation on a Data Safety Monitoring Board or Advisory Board with Servier on advisory board for the lunch of new drugs (2024-Present); all outside the submitted work. R J Maude reports support for the present manuscript from Wellcome Trust. This research was supported in part by Wellcome Trust (grant number 220211) as it provides core funding for Mahidol Oxford Tropical Medicine Research and contributes to their salary. They are required by Wellcome to acknowledge this grant in all publications. S A Meo reports grants or contracts from the Ongoing Research Funding Program (ORF-2025-47), King Saud University, Riyadh, Saudi Arabia; all outside the submitted work. T R Miller reports grants or contracts from National Institute for Mental Health (USA), AB InBev Foundation, Santa Clara County Public Health Department (California); payment for expert testimony from lawyers representing state & local plaintiffs in opioid litigation; all outside the submitted work. H M Mohamed reports support for the present manuscript from Higher Colleges of Technology; participation on a Data Safety Monitoring Board or Advisory Board with FIP Technology Advisory Group as a Member; leadership or fiduciary roles in other board, society, committee or advocacy group, paid or unpaid, with ISPOR UAE chapter as Education Committee Member; all outside the submitted work. L Monasta reports support for the present manuscript from the Italian Ministry of Health (Ricerca Corrente 34/2017), payments made to the Institute for Maternal and Child Health IRCCS Burlo Garofolo. R da Silveira Moreira reports grants or contracts from CNPq (National Council for Scientific and Technological Development) for a CNPq Research Productivity Scholarship (scholarship registration number is 316607/2021-5); all outside the submitted work. J F Mosser reports support for the present manuscript from the Gates Foundation; grants or contracts from Gavi; honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Providence Medical Center for CME presentation; support for attending meetings and/or travel from the Gates Foundation; all outside the submitted work. F Mughal reports support for the present manuscript paid to their institution from the National Institute for Health and Care Research (NIHR) (USA) (300957). Views expressed in this manuscript are those of the authors and not of the NHS, NIHR, or DHSC. S Nomura reports support for the present manuscript from Ministry of Education, Culture, Sports, Science and Technology of Japan (24H00663) and the Japan Science and Technology Agency for Precursory Research for Embryonic Science and Technology (JPMJPR22R8). B OANCEA reports support for the present manuscript from Ministry of Research, Innovation and Digitalization through the Core Program of the National Research, Development and Innovation Plan 2022-2027, project number PN 23-02-0101, contract number 7N/2023; PNRR/2022/C9/MCID/I8 project 760096. R Olum reports grants or contracts from Gilead Sciences Inc. through the Gilead Research Scholars Program for Public Health; all outside the submitted work. S Onie reports support for the present manuscript from National Health and Medical Research Council, Australia for an Investigator Grant; consulting fees from WHO for the amount of USD$9000 from November 2023 to date; support for attending meetings and/or travel from Suicide Prevention Australia for travel and attendance fees for annual conference and International Association for Suicide Prevention for conference attendance fees; leadership or fiduciary roles in other board, society, committee or advocacy group, paid or unpaid, with International Association for Suicide Prevention as Vice President and Indonesian Association for Suicide Prevention as President; stock or stock options in Wellspring Indonesia, a local mental health clinic in Indonesia (not majority shareholder); all outside the submitted work. R Ornello reports consulting fees from Teva; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Novartis, Eli Lilly, Teva, AbbVie, Bayer, Pfizer, Lundbeck, Organon; support for attending meetings and/or travel from Teva and Novartis; participation on an Advisory Board with Eli Lilly and AbbVie; receipt of equipment, materials, drugs, medical writing, gifts or other services from Novartis; all outside the submitted work. A Ortiz reports grants or contracts from Sanofi paid to their institution The Fundacion Jimenez Diaz Health Research Institute (IIS-FJD UAM) and as Director of the Catedra AstraZeneca-UAM of chronic kidney disease and electrolytes paid to their institution Universidad Autonoma de Madrid (UAM); consulting fees from Astellas, AstraZeneca, Bioporto, Boehringer Ingelheim, Fresenius Medical Care, GSK, Bayer, Sanofi-Genzyme, Lilly, Chiesi, Otsuka, Novo-Nordisk, and Sysmex; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Astellas, AstraZeneca, Bioporto, Boehringer Ingelheim, Fresenius Medical Care, GSK, Bayer, Sanofi-Genzyme, Sobi, Menarini, Lilly, Chiesi, Otsuka, Novo-Nordisk, Sysmex and Vifor Fresenius Medical Care Renal Pharma and Spafarma; support for attending meetings and/or travel from Astellas, AstraZeneca, Fresenius Medical Care, Boehringer-Ingelheim, Bayer, Sanofi-Genzyme, Chiesi, Sobi, and Bayer; participation on a Data Safety Monitoring Board or Advisory Board with Astellas, AstraZeneca, Boehringer-Ingelheim, Fresenius Medical Care, Bayer, Sanofi-Genzyme, Chiesi, Otsuka, Novo Nordisk, and Sysmex; leadership or fiduciary roles in other board, society, committee or advocacy group, unpaid, with Council ERA. SOMANE; all outside the submitted work. P K Pal reports grants or contracts paid to their institution from Indian Council of Medical Research (ICMR), Department of Science & Technology(DST)-Science and Engineering Research Board, Department of Biotechnology (DBT), DST-Cognitive Science Research Initiative, Wellcome Trust UK-India Alliance DBT, PACE scheme of BIRAC, Michael J. Fox Foundation, SKAN (Scientific Knowledge for Ageing and Neurological ailments)-Research Trust; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from the International Parkinson and Movement Disorder Society, and Movement Disorder Societies of Korea, Taiwan and Bangladesh, Japanese Society of Neurology, Teva Pharmaceutical Industries and Elsevier Inc (payment of one-thirds of the honorarium to their institute); support for attending meetings and/or travel from the National Institute of Mental Health and Neurosciences (NIMHANS), International Parkinson and Movement Disorder Society, and Movement Disorder Societies of Korea, Taiwan and Bangladesh, Japanese Society of Neurology and Asian Oceanian Congress of Neurology.; leadership or fiduciary roles in other board, society, committee or advocacy group with Indian Academy of Neurology as Past President, Asian and Oceanian subsection of International Parkinson and Movement Disorder Society (MDS-AOS) as Past Secretary, Annals of Movement Disorders as Past Editor-in-Chief, the Parkinson Society of Karnataka as President, Infection Related Movement Disorders Study Group of MDS as Chair, Rare Movement Disorders Study Group of International Parkinson and Movement Disorder Society (IPMDS) as a Member, Education Committee of IAPRD as a Member, Rating Scales Education and Training Program Committee of IPMDS as a Member, Neurophysiology Study Group of IPMDS as a Member, Movement Disorders in Asia Study Group as a Member, Post-Stroke Movement Disorders as a Member, Ataxia Study Group of IPMDS as a Member, Ataxia Global Initiative as a Member, Movement Disorders Society of India as President, and the Education Committee of International Parkinson and Movement Disorder Society (IPMDS) as Chair-all unpaid posts except Annual Leadership stipend for 2023-2025, of which one-thirds to be paid to their institute; all outside the submitted work. S K Panda reports support for the present manuscript from Siksha 'O' Anusandhan (deemed to be university) in the form of a salary; grants or contracts from file number 17-59/2023-24/CCRH/Tech./Coll./ICMR-Diabetes/960 as co-investigator; all outside the submitted work. G D Panos reports support for attending meetings and/or travel (expenses covered without receiving direct payment) from Roche and Bayer AG; all outside the submitted work. R Passera reports participation on a Data Safety Monitoring Board or Advisory Board with the Data Safety Monitoring Board dello studio "Consolidation with ADCT-402 (loncastuximab tesirine) after immunochemotherapy: a phase II study in BTKi-treated/ineligible Relapse/Refractory Mantle Cell Lymphoma (MCL) patients"-FIL, Fondazione Italiana Linfomi, Alessandria (Italy), unpaid; leadership or fiduciary roles in other board, society, committee or advocacy group, paid or unpaid, with the EBMT Statistical Committee, European Society for Blood and Marrow Transplantation, Paris (France) as a member, and the IRB/IEC Comitato Etico AO SS. Antonio e Biagio Alessandria-ASL AL-VC (Italy) as a past Member (2020-2023); all outside the submitted work. A E Peden reports support for the present manuscript from the (Australian] National Health and Medical Research Council (grant number APP2009306). V C F Pepito reports grants or contracts from Sanofi Consumer Healthcare for study self-care in the Philippines, and Zuellig Family Foundation for health systems strengthening; all outside the submitted work. P Ionela-Roxana reports grants or contracts from the project 'Societal and Economic Resilience within multi-hazards environment in Romania' funded by European Union-NextgenerationEU and Romanian Government, under National Recovery and Resilience Plan for Romania, contract number 760050/ 23.05.2023, cod PNRR-C9-I8-CF 267/ 29.11.2022, through the Romanian Ministry of Research, Innovation and Digitalization, within Component 9, Investment I8; all outside the submitted work. L Ronfani reports support for the present manuscript from the Italian Ministry of Health (Ricerca Corrente 34/2017), payments made to the Institute for Maternal and Child Health IRCCS Burlo Garofolo. P S Sachdev reports grants or contracts from National Health and Medical Research Council of Australia, APP1169489 and National Institutes of Health, USA; grants 1RF1AG057531-01 and 2R01AG057531-02A1; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Alkem Labs for a lecture as part of the Frontiers of Psychiatry 2023 seminar, Mumbai, India, June 2023; participation on a Data Safety Monitoring Board or Advisory Board with Biogen Australia Medical Advisory committee in 2020 and 2021 Roche Australia Medical Advisory Committee in 2022, Eli Lilly, Expert Advisory Panel, 2025; leadership or fiduciary roles in other board, society, committee or advocacy group, unpaid, with International Neuropsychiatric Association as Executive Board Member and World Psychiatric Association as Planning Committee Member; all outside the submitted work. Y L Samodra reports grants or contracts from NSTC-NTU Institute of Epidemiology and Preventive Medicine, Taiwan for a post-doctoral fellow contract; leadership or fiduciary roles in other board, society, committee or advocacy group, paid or unpaid, with Benang Merah Research Center, Indonesia as Co-Founder; other financial or non-financial interests with Jago Beasiswa (idebeasiswa.com) as a scholarship mentor; all outside the submitted work. A E Schutte reports consulting fees from AstraZeneca, Medtronic, Sky Labs, Servier, and Roche; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from AstraZeneca, Medtronic, Sky Labs, Servier, Omron, and Aktiia; support for attending meetings and/or travel from Medtronic, Servier; all outside the submitted work. M Sekerija reports consulting fees from Roche; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Astellas; all outside the submitted work. V Sharma reports other financial or non-financial interests with DFSS (MHA)'s research project (DFSS28(1)2019/EMR/6) at Institute of Forensic Science & Criminology, Panjab University, Chandigarh, India, outside the submitted work. V Shivarov reports one patent issued or pending with the Bulgarian Patent Office; other financial or non-financial interests with ICON plc. in the form of a salary; all outside the submitted work. J P Silva reports support for the present manuscript from Portuguese Foundation for Science and Technology for payment of a salary (contract with reference 2021.01789.CEECIND/CP1662/CT0014). L M L R Da Silva reports grants or contracts from SPRINT, Sport Physical Activity and Health Research e Innovation Center, Polytechnic of Guarda, 6300-559 6 Guarda, Portugal; and collaborate with RISE-UBI, Health Sciences Research Centre, University of Beira Interior, 6201-506 Covilha, Portugal; all outside the submitted work. J A Singh reports consulting fees from ROMTech, Atheneum, Clearview healthcare partners, American College of Rheumatology, Yale, Hulio, Horizon Pharmaceuticals, DINORA, ANI/Exeltis, USA Inc., Frictionless Solutions, Schipher, Crealta/Horizon, Medisys, Fidia, PK Med, Two labs Inc., Adept Field Solutions, Clinical Care options, Putnam associates, Focus forward, Navigant consulting, Spherix, MedIQ, Jupiter Life Science, UBM LLC, Trio Health, Medscape, WebMD, and Practice Point communications; and the National Institutes of Health; Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Simply Speaking; Support for attending meetings and/or travel from Simply Speaking; Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid as a past steering committee member of the OMERACT, an international organisation that develops measures for clinical trials and receives arm's length funding from 12 pharmaceutical companies, and as a Chair of the Veterans Affairs Rheumatology Field Advisory Committee, and as editor and the Director of the UAB Cochrane Musculoskeletal Group Satellite Center on Network Meta-analysis; Stock or stock options in Atai life sciences, Kintara therapeutics, Intelligent Biosolutions, Acumen pharmaceutical, TPT Global Tech, Vaxart pharmaceuticals, Atyu biopharma, Adaptimmune Therapeutics, GeoVax Labs, Pieris Pharmaceuticals, Enzolytics Inc., Seres Therapeutics, Tonix Pharmaceuticals Holding Corp., Aebona Pharmaceuticals, and Charlotte's Web Holdings, Inc. and previously owned stock options in Amarin, Viking, and Moderna Pharmaceuticals; outside the submitted work. I N Soyiri reports leadership or fiduciary roles in board, society, committee or advocacy groups, unpaid as Trustee of the Citizens Advice Bureau for Hull & East Riding, United Kingdom; outside the submitted work. D J Stein reports consultancy honoraria from Discovery Vitality, Kanna, L'Oreal, Lundbeck, Orion, Servier, Seaport Therapeutics, Takeda, and Wellcome; all outside the submitted work. J Sundstrom reports direct or indirect stock ownership in companies (Anagram kommunikation AB, Sence Research AB, Symptoms Europe AB, MinForskning AB) providing services to companies and authorities in the health sector including Amgen, AstraZeneca, Bayer, Boehringer, Eli Lilly, Gilead, GSK, Goteborg University, Itrim, Ipsen, Janssen, Karolinska Institutet, LIF, Linkoping University, Novo Nordisk, Parexel, Pfizer, Region Stockholm, Region Uppsala, Sanofi, STRAMA, Takeda, TLV, Uppsala University, Vifor Pharma, WeMind; all outside the submitted work. R Tabares-Seisdedos reports grants or contracts from Valencian Regional Government's Ministry of Education (PROMETEO/CIPROM/2022/58) and the Spanish Ministry of Science, Innovation and Universities (PID2021-129099OB-I00). The funders were not involved in the design of the manuscript or decision to submit the manuscript for publication, nor will they be involved in any aspect of the study's conduct; all outside the submitted work. J H V Ticoalu reports leadership or fiduciary roles in other board, society, committee or advocacy group, paid or unpaid, with Benang Merah Research Center, Indonesia as Co-Founder; all outside the submitted work. D Trico reports payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from AstraZeneca, Eli Lilly, and Novo Nordisk; support for attending meetings and/or travel from AstraZeneca; participation on a Data Safety Monitoring Board or Advisory Board with Amarin, Boehringer Ingelheim, Novo Nordisk; leadership or fiduciary roles in other board, society, committee or advocacy group, paid or unpaid, with EASD Early Career Academy and EASD Committee on Clinical Affairs; receipt of equipment, materials, drugs, medical writing, gifts or other services from Abbott and PharmaNutra; all outside the submitted work. S J Tromans reports grants or contracts paid to University of Leicester, their institution, as part of the 2023/4 Adult Psychiatric Morbidity Survey team, collecting epidemiological data on community-based adults living in England (a contracted study from NHS Digital, via the Department of Health and Social Care. Contributions on chapters of the 2023/4 Adult Psychiatric Morbidity Survey report), as lead on a study funded by the National Institute for Health and Care Research Clinical Research Network, on optimising the survey design for people with learning disability and autism, as lead on a study from the National Institute for Health and Care Research related to reviewing a national training programme for health and social care professionals relating to learning disability and autism, and as Co-applicant on study funded by the National Institute for Health and Care Research related to Identification, recording, and reasonable adjustments for people with a learning disability and autistic people in NHS electronic clinical record systems; support for attending meetings and/or travel from the Royal College of Psychiatrists; leadership or fiduciary roles in board, society, committee or advocacy groups, paid or unpaid as Academic Secretary for the Neurodevelopmental Psychiatry Special Interest Group and Psychiatry of Intellectual Disability Faculty at the Royal College of Psychiatrists, as Editorial Board Member for Progress in Neurology and Psychiatry, Advances in Mental Health and Intellectual Disability, Advances in Autism, BMC Psychiatry, and BJPsych Open, and as Editor of Psychiatry of Intellectual Disability Across Cultures (Oxford University Press); outside the submitted work. V-S Tseriotis reports grants or contracts from the European Academy of Neurology, European Committee for Treatment and Research in Multiple Sclerosis; support for attending meetings and/or travel from Inovis, Genesis Pharma, and Novartis; all outside the submitted work. E Upadhyay reports patents issued or pending for "A system and method of reusable filters for anti-pollution mask" (Published); "A system and method for electricity generation through crop stubble by using microbial fuel cells" (Published); "A system for disposed personal protection equipment (PPE) into biofuel through pyrolysis and method" (Published); "A novel herbal pharmaceutical aid for formulation of gel and method thereof" (Published); "Herbal drug formulation for treating lung tissue degenerated by particulate matter exposure" (Published); "A method to transform cow dung into the wall paint by using natural materials and composition thereof" (Filed); "Biodegradable packaging composition and method of preparation thereof" (Filed); "Eco-friendly bio-shoe polish from banana and turmeric" (Filed); "Honey-based polyherbal syrup composition to treat air pollution-induced inflammation and preparation method thereof" (Filed); "Process for preparing a caffeine free, antioxidant and nutrient rich beverage" (Filed); leadership or fiduciary roles in other board, society, committee or advocacy group, paid or unpaid, with Meteorological Society, Jaipur (India) as Executive Council Member, Indian Chapter and DSTPURSE Program as member Secretary; all outside the submitted work. E Vounzoulaki reports grants or contracts from a National Institute for Health and Care Research (NIHR) Development and Skills Enhancement Award (DSE) until July 2026, outside the submitted work. Yichen Wang reports grants or contracts from Mayo Clinic Center for Digital Health and Mayo Clinic Office of Belonging (formerly the Office of Inclusion and Diversity) with support from Dalio Philanthropies, 2024 for an Artificial Intelligence-Machine Learning Award; support for attending meetings and/or travel from The International Foundation for Gastrointestinal Disorders and University of Kansas Health Center; a provisional patent, "A Method to Automate International Classification of Diseases Coding using Large Language Model"; all outside the submitted work. J W Ward reports grants or contracts from Abbott, Gilead, AbbVie, Merck, Siemens, GSK, Cepheid, Zydus Life, governmental agencies, and philanthropic organisations to the Task Force for Global Health for the general support of the Coalition for Global Hepatitis Elimination; all outside the submitted work. P Willeit reports consulting fees from Novartis Pharmaceuticals; outside the submitted work. J F Wu reports grants or contracts from the National Heart, Lung, and Blood Institute (R38HL167238) and prior funding from the American Society of Hematology Hematology Opportunities for the Next Generation of Research Scientists (HONORS) Award; all outside the submitted work. Y Yasufuku reports grants or contracts from Shionogi & Co, Ltd; their employment expenses are paid from the joint research fund provided by this pharmaceutical company to The University of Osaka, outside the submitted work. S Zadey reports payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Think Global Health, The Hindu, and Harvard Public Health Magazine; leadership or fiduciary roles in other board, society, committee or advocacy group, paid or unpaid, with Association for Socially Applicable Research (ASAR) as Cofounding Director, Asia Working Group, The G4 Alliance as Chair, Lancet Citizens' Commission as a Fellow, Duke GEMINI Research Center as Research Aide Sr., Maharashtra State Mental Health Policy as a Drafting Committee Member, and Dr D. Y. Patil University as Adjunct Research Faculty; all outside the submitted work. G Zamagni reports support for the present manuscript from the Italian Ministry of Health (Ricerca Corrente 34/2017), payments made to the Institute for Maternal and Child Health IRCCS Burlo Garofolo. M Zielinska reports other financial or non-financial interests with Alexion and AstraZeneca Rare Disease as an employee; all outside the submitted work. EDAT- 2025/10/16 05:32 MHDA- 2025/10/19 00:28 PMCR- 2025/10/18 CRDT- 2025/10/15 18:53 PHST- 2025/03/24 00:00 [received] PHST- 2025/07/14 00:00 [revised] PHST- 2025/09/19 00:00 [accepted] PHST- 2025/10/19 00:28 [medline] PHST- 2025/10/16 05:32 [pubmed] PHST- 2025/10/15 18:53 [entrez] PHST- 2025/10/18 00:00 [pmc-release] AID - S0140-6736(25)01917-8 [pii] AID - 10.1016/S0140-6736(25)01917-8 [doi] PST - ppublish SO - Lancet. 2025 Oct 18;406(10513):1811-1872. doi: 10.1016/S0140-6736(25)01917-8. Epub 2025 Oct 12. PMID- 41091464 OWN - NLM STAT- MEDLINE DCOM- 20251015 LR - 20260722 IS - 2574-3805 (Electronic) IS - 2574-3805 (Linking) VI - 8 IP - 10 DP - 2025 Oct 1 TI - Immunity to Streptococcus pyogenes and Common Respiratory Viruses at Age 0 to 4 Years After COVID-19 Restrictions. PG - e2537808 LID - 10.1001/jamanetworkopen.2025.37808 [doi] LID - e2537808 AB - IMPORTANCE: The upsurge in invasive disease caused by Streptococcus pyogenes among children reported in several European countries during 2022 to 2023 has not been fully explained. OBJECTIVE: To evaluate whether changes in the circulation of common respiratory pathogens associated with the introduction of nonpharmaceutical interventions (NPIs) during the COVID-19 pandemic were associated with acquisition of immunity to S pyogenes and common respiratory viruses. DESIGN, SETTING, AND PARTICIPANTS: This cross-sectional study recruited children with suspected infection and afebrile control participants at hospitals in 10 European countries. Data were collected before (September 2016 to March 2020) and after (April 2020 to July 2023) the introduction of NPIs. MAIN OUTCOMES AND MEASURES: Molecular detection of bacterial and viral pathogens on throat swabs and age-stratified total serum immunoglobin G (IgG) reactivity to S pyogenes cell wall extract from 2 strains, respiratory syncytial virus (RSV), 5 influenza viruses, 4 common cold coronaviruses, and SARS-CoV-2, measured by immunoassay. RESULTS: Throat swabs from 1942 children aged 0 to 4 years were tested for respiratory pathogens (1449 recruited before introduction of NPIs [median (IQR) age, 19.7 (8.2-38.1) months; 798 (55.1%) male]; 493 recruited after [median (IQR) age, 20.7 (9.7-38.1) months; 269 (54.7%) male]). A decrease in detection of S pyogenes, RSV, common cold coronaviruses, and influenza viruses was observed between March 2020 to July 2021, corresponding to the maximal period of NPIs. Antibodies to S pyogenes were measured in 252 children recruited before NPIs and 200 thereafter. Antibodies to viral antigens were measured in 230 children before NPIs and 92 thereafter. Total IgG to S pyogenes and RSV was significantly lower in children aged 3 to 4 years recruited after NPI introduction compared with those recruited before (S pyogenes emm1 strain: after, 67 participants; median [IQR] 0.13 [0.44-0.44] relative units [RU]; before, 87 participants; median [IQR] 0.35 [0.10-0.65] RU; P = .007. RSV: after, 30 participants; median [IQR] 49.6 [31.1-120.7] mesoscale units [MU]/1000; before, 76 participants; median [IQR] 141.8 [78.1-423.1] MU/1000; P < .001). No such differences were observed for children aged 0 to 2 years or for individual influenza viruses or SARS-CoV-2. CONCLUSIONS AND RELEVANCE: In this cross-sectional study, there was a significant reduction in serum antibodies to S pyogenes and RSV in children aged 3 to 4 years after introduction of NPIs. Equivalent to approximately a 1-year delay in acquisition of immunity, these data suggest a putative biological basis for the 2022 to 2023 upsurge in severe S pyogenes infections in this age group. FAU - Dokal, Kitt AU - Dokal K AD - Department of Infectious Disease, Imperial College London, London, United Kingdom. FAU - Channon-Wells, Samuel AU - Channon-Wells S AD - Department of Infectious Disease, Imperial College London, London, United Kingdom. AD - Centre for Paediatrics and Child Health, Imperial College London, London, United Kingdom. AD - UKRI Centre for Doctoral Training in AI for Healthcare, Imperial College London, London, United Kingdom. FAU - Davis, Catherine AU - Davis C AD - Micropathology Ltd, University of Warwick, Coventry, United Kingdom. FAU - Estrada-Rivadeneyra, Diego AU - Estrada-Rivadeneyra D AD - Department of Infectious Disease, Imperial College London, London, United Kingdom. AD - Centre for Paediatrics and Child Health, Imperial College London, London, United Kingdom. FAU - Huse, Kristin K AU - Huse KK AD - Department of Infectious Disease, Imperial College London, London, United Kingdom. AD - Centre for Bacterial Resistance Biology, Imperial College London, London, United Kingdom. FAU - Lias, Amelia AU - Lias A AD - Department of Infectious Disease, Imperial College London, London, United Kingdom. AD - Centre for Bacterial Resistance Biology, Imperial College London, London, United Kingdom. FAU - Hamilton, Shea AU - Hamilton S AD - Department of Infectious Disease, Imperial College London, London, United Kingdom. AD - Centre for Paediatrics and Child Health, Imperial College London, London, United Kingdom. FAU - Guy, Rebecca L AU - Guy RL AD - Antimicrobial Resistance & Healthcare-Associated Infection Division, UK Health Security Agency, London, United Kingdom. FAU - Lamagni, Theresa AU - Lamagni T AD - Antimicrobial Resistance & Healthcare-Associated Infection Division, UK Health Security Agency, London, United Kingdom. AD - NIHR Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance, Imperial College London and UK Health Security Agency, London, United Kingdom. FAU - Nichols, Sam AU - Nichols S AD - Department of Infectious Disease, Imperial College London, London, United Kingdom. AD - Centre for Paediatrics and Child Health, Imperial College London, London, United Kingdom. FAU - Taylor, Andrew AU - Taylor A AD - Micropathology Ltd, University of Warwick, Coventry, United Kingdom. FAU - Agyeman, Philipp K A AU - Agyeman PKA AD - Department of Pediatrics, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland. FAU - Anpananthar, Amutha AU - Anpananthar A AD - Barts Health NHS Trust, London, United Kingdom. FAU - Basmaci, Romain AU - Basmaci R AD - Service de Pediatrie-Urgences, AP-HP, Hopital Louis-Mourier, Colombes, France. AD - Universite Paris Cite, INSERM, IAME, Paris, France. FAU - Carrol, Enitan D AU - Carrol ED AD - Department of Clinical Infection, Microbiology and Immunology, Veterinary and Ecological Sciences, University of Liverpool Institute of Infection, Liverpool, United Kingdom. AD - Department of Infectious Diseases, Alder Hey Children's Hospital, Liverpool, United Kingdom. FAU - Carter, Michael J AU - Carter MJ AD - Evelina London Children's Hospital, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom. FAU - De, Tisham AU - De T AD - Department of Infectious Disease, Imperial College London, London, United Kingdom. AD - Centre for Paediatrics and Child Health, Imperial College London, London, United Kingdom. FAU - de Jonge, Marien I AU - de Jonge MI AD - Laboratory of Medical Immunology, Radboud Institute for Medical Innovation, Radboud UMC, Nijmegen, the Netherlands. AD - Radboud Community for Infectious Diseases, Radboud University Medical Center, Nijmegen, the Netherlands. FAU - Emonts, Marieke AU - Emonts M AD - Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom. AD - Great North Children's Hospital, Paediatric Immunology, Infectious Diseases & Allergy, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom. AD - NIHR Newcastle Biomedical Research Centre Based at Newcastle upon Tyne Hospitals NHS Trust and Newcastle University, Newcastle upon Tyne, United Kingdom. FAU - Elorrieta, Leire Estramiana AU - Elorrieta LE AD - Department of Infectious Disease, Imperial College London, London, United Kingdom. AD - Centre for Paediatrics and Child Health, Imperial College London, London, United Kingdom. FAU - Fidler, Katy AU - Fidler K AD - Brighton and Sussex Medical School, University of Sussex, East Sussex, United Kingdom. AD - Royal Alexandra Children's Hospital, Brighton, United Kingdom. FAU - Kolnik, Mojca AU - Kolnik M AD - University Childrens' Hospital, University Medical Centre Ljubljana, Ljubljana, Slovenia. FAU - Kuijpers, Taco W AU - Kuijpers TW AD - Department of Pediatric Immunology, Rheumatology and Infectious Diseases, Amsterdam University Medical Center (Amsterdam UMC), Academic Medical Center (AMC), University of Amsterdam, Amsterdam, the Netherlands. AD - Sanquin Research Institute & Landsteiner Laboratory at the AMC, University of Amsterdam, Amsterdam, the Netherlands. FAU - Martinon-Torres, Federico AU - Martinon-Torres F AD - Translational Pediatrics and Infectious Diseases, Pediatrics Department, Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain. AD - GENVIP Research Group, Instituto de Investigacion Sanitaria de Santiago, Universidad de Santiago de Compostela, Galicia, Spain. AD - CIBER of Respiratory Diseases (CIBERES), Instituto de Salud Carlos III, Madrid, Spain. FAU - Moll, Henriette AU - Moll H AD - Department of General Paediatrics, Erasmus MC-Sophia Children's Hospital, Rotterdam, the Netherlands. FAU - Mommert-Tripon, Marine AU - Mommert-Tripon M AD - Innovation & Partnerships, bioMerieux, Marcy l'Etoile, France. AD - Joint Research Unit Hospice Civils de Lyon-bioMerieux, Centre Hospitalier Lyon Sud, Pierre-Benite, France. AD - EA 7426 Pathophysiology of Injury-Induced Immunosuppression, Lyon 1 University, Hospices Civils de Lyon-bioMerieux, Hopital Edouard Herriot, Lyon, France. FAU - Neshat, Samira AU - Neshat S AD - Barts Health NHS Trust, London, United Kingdom. FAU - Nyirenda-Nyang'wa, Maggie AU - Nyirenda-Nyang'wa M AD - Lewisham and Greenwich NHS Trust, London, United Kingdom. FAU - O'Riordan, Sean AU - O'Riordan S AD - Leeds Children's Hospital, Leeds, United Kingdom. FAU - Owens, Daniel R AU - Owens DR AD - NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom. FAU - Pathan, Nazima AU - Pathan N AD - Department of Paediatrics, University of Cambridge, Addenbrookes Hospital, Cambridge, United Kingdom. FAU - Paulus, Stephane AU - Paulus S AD - Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, United Kingdom. AD - NIHR Oxford Biomedical Research Centre, Oxford, United Kingdom. FAU - Peters, Mark J AU - Peters MJ AD - Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom. FAU - Pokorn, Marko AU - Pokorn M AD - University Childrens' Hospital, University Medical Centre Ljubljana, Ljubljana, Slovenia. AD - Department of Infectious Diseases, University Medical Centre Ljubljana, Ljubljana, Slovenia. AD - Department of Paediatrics, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia. FAU - Pollard, Andrew J AU - Pollard AJ AD - Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, United Kingdom. AD - NIHR Oxford Biomedical Research Centre, Oxford, United Kingdom. FAU - Rivero-Calle, Irene AU - Rivero-Calle I AD - Translational Pediatrics and Infectious Diseases, Pediatrics Department, Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain. AD - GENVIP Research Group, Instituto de Investigacion Sanitaria de Santiago, Universidad de Santiago de Compostela, Galicia, Spain. FAU - Rojo, Pablo AU - Rojo P AD - Servicio Madrileno de Salud (SERMAS), Pediatric Infectious Diseases Unit, Department of Pediatrics, Hospital Universitario 12 de Octubre, Madrid, Spain. AD - Department of Pediatrics, Faculty of Medicine, Universidad Complutense de Madrid, Madrid, Spain. FAU - Romani, Lorenza AU - Romani L AD - Infectious Disease Unit, Academic Department of Pediatrics, Bambino Gesu Children's Hospital, IRCCS, Rome, Italy. FAU - Rughani, Prita AU - Rughani P AD - Barts Health NHS Trust, London, United Kingdom. FAU - Schlapbach, Luregn J AU - Schlapbach LJ AD - Department of Intensive Care and Neonatology, University Children's Hospital Zurich, University of Zurich, Zurich, Switzerland. AD - Child Health Research Centre, University of Queensland, Brisbane, Queensland, Australia. FAU - Schweintzger, Nina A AU - Schweintzger NA AD - Department of Pediatrics and Adolescent Medicine, Division of General Pediatrics, Medical University of Graz, Graz, Austria. FAU - Shen, Ching-Fen AU - Shen CF AD - Department of Pediatrics, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan City, Taiwan. FAU - Sulik, Artur AU - Sulik A AD - Department of Pediatric Infectious Diseases, Medical University of Bialystok, Bialystok, Poland. FAU - Tsolia, Maria AU - Tsolia M AD - National and Kapodistrian University of Athens, Second Department of Paediatrics, "P. and A. Kyriakou" Children's Hospital, Athina, Greece. FAU - Usuf, Effua AU - Usuf E AD - Medical Research Council Unit, The Gambia at LSHTM, Fajara, The Gambia. FAU - van der Flier, Michiel AU - van der Flier M AD - Wilhelmina Children's Hospital, University Medical Center Utrecht, Utrecht, the Netherlands. FAU - Vermont, Clementien AU - Vermont C AD - Department of Paediatric Infectious Diseases & Immunology, Erasmus MC-Sophia Children's Hospital, Rotterdam, the Netherlands. FAU - von Both, Ulrich AU - von Both U AD - Division of Paediatric Infectious Diseases, Hauner Children's Hospital, University Hospital, Ludwig Maximilians University, Munich, Germany. AD - German Center for Infection Research, Partner Site Munich, Munich, Germany. FAU - Wellman, Paul AU - Wellman P AD - Evelina London Children's Hospital, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom. FAU - Wright, Victoria J AU - Wright VJ AD - Department of Infectious Disease, Imperial College London, London, United Kingdom. AD - Centre for Paediatrics and Child Health, Imperial College London, London, United Kingdom. FAU - Yeung, Shunmay AU - Yeung S AD - Faculty of Infectious and Tropical Disease, London School of Hygiene and Tropical Medicine, London, United Kingdom. AD - Faculty of Public Health and Policy, London School of Hygiene and Tropical Medicine, London, United Kingdom. AD - Department of Paediatrics, St Mary's Hospital Imperial College Hospital, London, United Kingdom. FAU - Zavadska, Dace AU - Zavadska D AD - Riga Stradins University, Riga, Latvia. AD - Children Clinical University Hospital, Riga, Latvia. FAU - Cunnington, Aubrey J AU - Cunnington AJ AD - Department of Infectious Disease, Imperial College London, London, United Kingdom. AD - Centre for Paediatrics and Child Health, Imperial College London, London, United Kingdom. FAU - Fink, Colin AU - Fink C AD - Micropathology Ltd, University of Warwick, Coventry, United Kingdom. FAU - Herberg, Jethro AU - Herberg J AD - Department of Infectious Disease, Imperial College London, London, United Kingdom. AD - Centre for Paediatrics and Child Health, Imperial College London, London, United Kingdom. FAU - Kaforou, Myrsini AU - Kaforou M AD - Department of Infectious Disease, Imperial College London, London, United Kingdom. AD - Centre for Paediatrics and Child Health, Imperial College London, London, United Kingdom. FAU - Sriskandan, Shiranee AU - Sriskandan S AD - Department of Infectious Disease, Imperial College London, London, United Kingdom. AD - Centre for Bacterial Resistance Biology, Imperial College London, London, United Kingdom. AD - NIHR Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance, Imperial College London and UK Health Security Agency, London, United Kingdom. FAU - Levin, Michael AU - Levin M AD - Department of Infectious Disease, Imperial College London, London, United Kingdom. AD - Centre for Paediatrics and Child Health, Imperial College London, London, United Kingdom. FAU - Parks, Tom AU - Parks T AD - Department of Infectious Disease, Imperial College London, London, United Kingdom. AD - Centre for Human Genetics, University of Oxford, Oxford, United Kingdom. CN - PERFORM and DIAMONDS consortiums LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20251001 PL - United States TA - JAMA Netw Open JT - JAMA network open JID - 101729235 RN - 0 (Immunoglobulin G) RN - 0 (Antibodies, Viral) SB - IM MH - Humans MH - *Streptococcus pyogenes/immunology/isolation & purification MH - *COVID-19/prevention & control/epidemiology/immunology MH - Infant MH - Male MH - Female MH - Child, Preschool MH - Cross-Sectional Studies MH - *Streptococcal Infections/immunology/epidemiology MH - SARS-CoV-2/immunology MH - Europe/epidemiology MH - Infant, Newborn MH - Immunoglobulin G/blood MH - Antibodies, Viral/blood PMC - PMC12529189 COIS- Conflict of Interest Disclosures: Dr Agyeman reported receiving personal fees paid to the institution for providing expert testimony for and serving on the advisory board of Medtrix Group Switzerland and Sanofi outside the submitted work. Prof Basmaci reported receiving personal fees from Sanofi and MSD outside the submitted work. Prof Carrol reported serving on the scientific advisory boards of Thermofisher, bioMerieux, and Danaher, with grants paid to the institution, during the conduct of the study. Dr Carter reported receiving grants from the UK National Institute of Health Research (NIHR), the Rosetrees Trust, and BactiVac during the conduct of the study. Dr Martinon-Torres reported receiving grants to the institution from Sanofi-Astra Zeneca, GSK, and Pfizer as well as consulting fees from GSK Vaccines SRL, Pfizer Inc, Sanofi Pasteur, Janssen Pharmaceuticals, MSD, Seqirus, Biofabri, and AstraZeneca; being an unpaid member of The European Technical Advisory Group of Experts on Immunization (ETAGE-World Health Organization [WHO]) and coordinator of Spanish Pediatric Critical Trials Network and the WHO collaborating center for vaccine safety of Santiago de Compostela; and being a principal investigator in randomized clinical trials for Ablynx, Abbott, Seqirus, Sanofi Pasteur MSD, Sanofi Pasteur, Cubist, Wyeth, Merck, Pfizer, Roche, Regeneron, Jansen, Medimmune, Novavax, Novartis and GSK during the conduct of the study and receiving grants to the institution from GSK, Pfizer, Sanofi, AstraZeneca, Moderna, and MSD; receiving personal fees from GSK, Pfizer, Sanofi, AstraZeneca, Moderna, and MSD; and receiving trial fees paid to the institution from Sanofi, GSK, Pfizer, Moderna, MSD, and Seqirus outside the submitted work. Ms Mommert-Tripon reported being employed by bioMerieux during the conduct of the study. Dr Owens reported being an investigator on studies funded or sponsored by AstraZeneca, GSK, Janssen Pharmaceuticals, Medimmune, Merck, Pfizer, Sanofi, Iliad, Moderna, and Valneva during the conduct of the study, with payments to the institution, and receiving grants from Sanofi outside the submitted work. Mr Paulus reported receiving personal fees from Eumedica Pharma Advisory Board outside the submitted work. Prof Peters reported receiving grants to institution from the Engineering and Physical Sciences Research Council (UK) and UK National Institute of Health and Social Care and receiving personal fees from the Ministry of Justice (UK) during the conduct of the study. Mr Pokorn reported receiving an investigator-initiated grant from Pfizer as well as personal fees from Pfizer, MSD, and Sanofi outside the submitted work. Prof Pollard reported receiving grants from the European Commission and receiving personal fees from Shionogi and Moderna during the conduct of the study as well as receiving grants from Serum Institute of India, AstraZeneca, the Gates Foundation, the Wellcome Trust, the UK Medical Research Council (MRC), NIHR, Coalition for Epidemic Preparedness Innovations, and the European Commission outside the submitted work; in addition, Prof Pollard had a patent licensed to AstraZeneca and served as the chair of the UK Department of Health and Social Care's Joint Committee on Vaccination and Immunisation, a member of the WHO Strategic Advisory Group of Experts on Immunization, and chair of WHO Salmonella Technical Advisory Group during the conduct of the study. Dr Rivero-Calle reported receiving consulting fees from Pfizer, MSD, Sanofi, and GSK; receiving speaking fees from MSD, GSK, Sanofi, and Pfizer; receiving travel support from Pfizer, MSD, Sanofi, and GSK; serving on the board of directors of the Vaccine Advisory Committee of the Spanish Association of Pediatrics (AEP) since 2021, the board of directors of the Spanish Society for Pediatric Infectious Diseases (SEIP) since 2020, and the executive committee of the Pediatric Research Platform of the Spanish Association of Pediatrics (INVEST-AEP) since 2018; participating on the advisory board and serving as a subinvestigator in clinical trials of vaccines, with payments to the institution, for Ablynx, Abbott, Seqirus, Sanofi Pasteur MSD, Sanofi Pasteur, Cubist, Wyeth, Merck, Pfizer, Roche, Regeneron, Jansen, Medimmune, Novavax, Novartis, and GSK outside the submitted work. Prof Schlapbach reported receiving grants from the Swiss National Science Foundation, the NOMIS Foundation, the Thomas and Doris Ammann Foundation, the National Institutes of Health, Swiss Personalized Health Network, Personalized Health and Related Technologies, Medical Research Future Fund, and National Health and Medical Research Council during the conduct of the study. Dr Shen reported receiving grants from Ministry of Science and Technology, Taiwan, during the conduct of the study and receiving speaking fees from Sanofi Pasteur, Moderna, AstraZeneca, and Pfizer outside the submitted work. Prof Sulik reported receiving a grant from Medical University of Bialystok during the conduct of the study. Dr Tsolia reported receiving grants to the institution from MSD; serving as a scientific advisory board member for Pfizer (unpaid), MSD (unpaid), and Sanofi; serving as president and a board member of the Hellenic Society for Pediatric Infectious Diseases; and receiving personal fees from MSD and Sanofi during the conduct of the study. Dr von Both reported serving as the chair of the European Society for Paediatric Infectious Diseases (ESPID) committee for research and receiving personal travel support from ESPID during the conduct of the study and serving on the extended board of the German Society of Paediatric Infectious Diseases outside the submitted work. Dr Yeung reported being a conference speaker for CSL Behring and serving as a consultant in paediatric infectious disease. Prof Fink reported receiving payments to institution for laboratory work as part of the conduct of the study; serving as chairman of the Medical and Life Sciences Research Fund UK Charity during the conduct of the study, and receiving grants from the European Union during the conduct of the study and outside the submitted work. Dr Herberg reported receiving grant support from the Imperial College London Biomedical Research Centre. Dr Kaforou reported receiving grants to the institution from the Rosetrees Trust during the conduct of the study. Prof Sriskandan reported receiving nonfinancial support in the form of study management and patient recruitment from NIHR Imperial Biomedical Research Centre as well as grants from Leducq Foundation and the Wellcome Trust during the conduct of the study. Dr Parks reported receiving grants from the Leducq Foundation during the conduct of the study as well as receiving grants from the British Medical Association, the British Infection Association, the Leducq Foundation, and the MRC and receiving travel support other from Strep A Vaccine Global Consortium outside the submitted work. No other disclosures were reported. FIR - Levin, Michael IR - Levin M FIR - Cunnington, Aubrey IR - Cunnington A FIR - Herberg, Jethro IR - Herberg J FIR - Kaforou, Myrsini IR - Kaforou M FIR - Wright, Victoria J IR - Wright VJ FIR - Bellos, Evangelos IR - Bellos E FIR - Broderick, Claire IR - Broderick C FIR - Channon-Wells, Samuel IR - Channon-Wells S FIR - Cooray, Samantha IR - Cooray S FIR - De, Tisham IR - De T FIR - D'Souza, Giselle IR - D'Souza G FIR - Duret, Amedine IR - Duret A FIR - Duseja, Anikta IR - Duseja A FIR - Estamiana Ellorrieta, Leire IR - Estamiana Ellorrieta L FIR - Estrada-Rivadeneyra, Diego IR - Estrada-Rivadeneyra D FIR - Gallassini, Rachel IR - Gallassini R FIR - Habgood-Coote, Dominic IR - Habgood-Coote D FIR - Hamilton, Shea IR - Hamilton S FIR - Jackson, Heather IR - Jackson H FIR - Kavanagh, James IR - Kavanagh J FIR - Keren, Ilana IR - Keren I FIR - Moradi Marjeneh, Mahdi IR - Moradi Marjeneh M FIR - Menikou, Stephanie IR - Menikou S FIR - Nichols, Samuel IR - Nichols S FIR - Nijman, Ruud IR - Nijman R FIR - Patel, Harsita IR - Patel H FIR - Pennisi, Ivana IR - Pennisi I FIR - Powell, Oliver IR - Powell O FIR - Reid, Ruth IR - Reid R FIR - Shah, Priyen IR - Shah P FIR - Vito, Ortensia IR - Vito O FIR - Whittaker, Elizabeth IR - Whittaker E FIR - Wilson, Clare IR - Wilson C FIR - Womersley, Rebecca IR - Womersley R FIR - Abdulla, Amina IR - Abdulla A FIR - Darnell, Sarah IR - Darnell S FIR - Mustafa, Sobia IR - Mustafa S FIR - Georgiou, Pantelis IR - Georgiou P FIR - Rodriguez-Manzano, Jesus IR - Rodriguez-Manzano J FIR - Moser, Nicolas IR - Moser N FIR - Carter, Michael IR - Carter M FIR - Wellman, Paul IR - Wellman P FIR - Tibby, Shane IR - Tibby S FIR - Cohen, Jonathan IR - Cohen J FIR - Davis, Francesca IR - Davis F FIR - Kenny, Julia IR - Kenny J FIR - White, Marie IR - White M FIR - Fish, Matthew IR - Fish M FIR - Jennings, Aislinn IR - Jennings A FIR - Shankar-Hari, Manu IR - Shankar-Hari M FIR - Fidler, Katy IR - Fidler K FIR - Agranoff, Dan IR - Agranoff D FIR - Richmond, Viven IR - Richmond V FIR - Seal, Matthew IR - Seal M FIR - Faust, Saul IR - Faust S FIR - Owen, Dan IR - Owen D FIR - Ensom, Ruth IR - Ensom R FIR - McKay, Sarah IR - McKay S FIR - Mondo, Diana IR - Mondo D FIR - Shaji, Mariya IR - Shaji M FIR - Schranz, Rachel IR - Schranz R FIR - Rughani, Prita IR - Rughani P FIR - Anpananthar, Amutha IR - Anpananthar A FIR - Liebeschuetz, Susan IR - Liebeschuetz S FIR - Riddell, Anna IR - Riddell A FIR - Divakaran, Divya IR - Divakaran D FIR - Han, Louise IR - Han L FIR - Khalid, Nosheen IR - Khalid N FIR - Lancoma-Malcolm, Ivone IR - Lancoma-Malcolm I FIR - Schofield, Jessica IR - Schofield J FIR - Simagan, Teresa IR - Simagan T FIR - Peters, Mark IR - Peters M FIR - Bamford, Alasdair IR - Bamford A FIR - O'Neill, Lauran IR - O'Neill L FIR - Pathan, Nazima IR - Pathan N FIR - Daubney, Esther IR - Daubney E FIR - White, Deborah IR - White D FIR - Heightman, Melissa IR - Heightman M FIR - Eisen, Sarah IR - Eisen S FIR - Segal, Terry IR - Segal T FIR - Wellings, Lucy IR - Wellings L FIR - Drysdale, Simon B IR - Drysdale SB FIR - Branch, Nicole IR - Branch N FIR - Hamzah, Lisa IR - Hamzah L FIR - Jarman, Heather IR - Jarman H FIR - Nyirenda, Maggie IR - Nyirenda M FIR - Capozzi, Lisa IR - Capozzi L FIR - Gardiner, Emma IR - Gardiner E FIR - Moots, Robert IR - Moots R FIR - Nasher, Madga IR - Nasher M FIR - Hanson, Anita IR - Hanson A FIR - Linforth, Michelle IR - Linforth M FIR - O'Riordan, Sean IR - O'Riordan S FIR - Ellis, Donna IR - Ellis D FIR - Deep, Akash IR - Deep A FIR - Caro, Ivan IR - Caro I FIR - Shackley, Fiona IR - Shackley F FIR - Bellini, Arianna IR - Bellini A FIR - Gormley, Stuart IR - Gormley S FIR - Neshat, Samira IR - Neshat S FIR - Scholefield, Barnaby J IR - Scholefield BJ FIR - Robbins, Ceri IR - Robbins C FIR - Winmill, Helen IR - Winmill H FIR - Paulus, Stephane C IR - Paulus SC FIR - Pollard, Andrew J IR - Pollard AJ FIR - Anthony, Mark IR - Anthony M FIR - Hopton, Sarah IR - Hopton S FIR - Miller, Danielle IR - Miller D FIR - Oliver, Zoe IR - Oliver Z FIR - Beer, Sally IR - Beer S FIR - Ward, Bryony IR - Ward B FIR - Shrestha, Shrijana IR - Shrestha S FIR - Gurung, Meeru IR - Gurung M FIR - Amatya, Puja IR - Amatya P FIR - Pokhrel, Bhishma IR - Pokhrel B FIR - Bijukchhe, Sanjeev Man IR - Bijukchhe SM FIR - Gautam, Madhav Chandra IR - Gautam MC FIR - Kelly, Sarah IR - Kelly S FIR - O'Reilly, Peter IR - O'Reilly P FIR - Shrestha, Sonu IR - Shrestha S FIR - Martinon-Torres, Federico IR - Martinon-Torres F FIR - Salas, Antonio IR - Salas A FIR - Gonzalez, Fernando Alvez IR - Gonzalez FA FIR - Gomez, Sonia Ares IR - Gomez SA FIR - Bellos, Xabier IR - Bellos X FIR - Garcia, Mirian Ben IR - Garcia MB FIR - Vina, Fernando Caamano IR - Vina FC FIR - Carnota, Sandra IR - Carnota S FIR - Curras-Tuala, Maria Jose IR - Curras-Tuala MJ FIR - Urbieta, Ana Dacosta IR - Urbieta AD FIR - Suarez, Carlos Duran IR - Suarez CD FIR - Vidal, Isabel Ferreiros IR - Vidal IF FIR - Vicente, Luisa Garcia IR - Vicente LG FIR - Gomez-Carballa, Alberto IR - Gomez-Carballa A FIR - Gomez Rial, Jose IR - Gomez Rial J FIR - Leborans Iglesias, Pilar IR - Leborans Iglesias P FIR - Mallah, Narmeen IR - Mallah N FIR - Martinon-Torres, Nazareth IR - Martinon-Torres N FIR - Sanchez, Jose Maria Martinon IR - Sanchez JMM FIR - Perez, Belen Mosquera IR - Perez BM FIR - Pardo-Seco, Jacobo IR - Pardo-Seco J FIR - Pischedda, Sara IR - Pischedda S FIR - Vazquez, Sara Rey IR - Vazquez SR FIR - Calle, Irene Rivero IR - Calle IR FIR - Rodriguez-Tenreiro, Carmen IR - Rodriguez-Tenreiro C FIR - Redondo-Collazo, Lorenzo IR - Redondo-Collazo L FIR - Seren Fernandez, Sonia IR - Seren Fernandez S FIR - Iglesias, Marisol Vilas IR - Iglesias MV FIR - Carrol, Enitan D IR - Carrol ED FIR - Cocklin, Elizabeth IR - Cocklin E FIR - Beckley, Rebecca IR - Beckley R FIR - Bracken, Abbey IR - Bracken A FIR - Evans, Ceri IR - Evans C FIR - Khanijau, Aakash IR - Khanijau A FIR - Lenihan, Rebecca IR - Lenihan R FIR - Lewis-Burke, Nadia IR - Lewis-Burke N FIR - Newall, Karen IR - Newall K FIR - Romaine, Sam IR - Romaine S FIR - Whitbread, Jennifer IR - Whitbread J FIR - Tsolia, Maria IR - Tsolia M FIR - Eleftheriou, Irini IR - Eleftheriou I FIR - Spyridis, Nikos IR - Spyridis N FIR - Tambouratzi, Maria IR - Tambouratzi M FIR - Maritsi, Despoina IR - Maritsi D FIR - Marmarinos, Antonios IR - Marmarinos A FIR - Xagorari, Marietta IR - Xagorari M FIR - Panagiota, Lourida IR - Panagiota L FIR - Aggelos, Pefanis IR - Aggelos P FIR - Karolina, Akinosoglou IR - Karolina A FIR - Charalambos, Gogos IR - Charalambos G FIR - Markos, Maragos IR - Markos M FIR - Michalis, Voulgarelis IR - Michalis V FIR - Ioanna, Stergiou IR - Ioanna S FIR - Emonts, Marieke IR - Emonts M FIR - Lim, Emma IR - Lim E FIR - Isaacs, John IR - Isaacs J FIR - Bell, Kathryn IR - Bell K FIR - Crulley, Stephen IR - Crulley S FIR - Fabian, Daniel IR - Fabian D FIR - Thomson, Evelyn IR - Thomson E FIR - Wallia, Diane IR - Wallia D FIR - Miller, Caroline IR - Miller C FIR - Bell, Ashley IR - Bell A FIR - Van der Velden, Fabian J S IR - Van der Velden FJS FIR - Shenton, Geoff IR - Shenton G FIR - Price, Ashley IR - Price A FIR - Treloar, Owen IR - Treloar O FIR - Thomas, Daisy IR - Thomas D FIR - Rojo, Pablo IR - Rojo P FIR - Epalza, Cristina IR - Epalza C FIR - Villaverde, Serena IR - Villaverde S FIR - Marquez, Sonia IR - Marquez S FIR - Gijon, Manuel IR - Gijon M FIR - Varchetta, Romina IR - Varchetta R FIR - Machin, Fatima IR - Machin F FIR - Cabello, Laura IR - Cabello L FIR - Hernandez, Irene IR - Hernandez I FIR - Gutierrez, Lourdes IR - Gutierrez L FIR - Manzanares, Angela IR - Manzanares A FIR - Kuijpers, T W Taco IR - Kuijpers TWT FIR - Van de Kuip, M Martijn IR - Van de Kuip MM FIR - Van Furth, A M Marceline IR - Van Furth AMM FIR - Van den Berg, J M Merlijn IR - Van den Berg JMM FIR - Biesbroek, Giske IR - Biesbroek G FIR - Verkuil, Floris IR - Verkuil F FIR - Van der Zee, Carlijn C W IR - Van der Zee CCW FIR - Pajkrt, Dasja IR - Pajkrt D FIR - van Hensbroek, Michael Boele IR - van Hensbroek MB FIR - Schonenberg, Dieneke IR - Schonenberg D FIR - Gruppen, Mariken IR - Gruppen M FIR - Nagelkerke, Sietse IR - Nagelkerke S FIR - Jansen, Machiel H IR - Jansen MH FIR - Goetschalckx, Ines IR - Goetschalckx I FIR - Romani, Lorenza IR - Romani L FIR - De Luca, Maia IR - De Luca M FIR - Chiurchiu, Sara IR - Chiurchiu S FIR - Tripiciano, Costanza IR - Tripiciano C FIR - Mercadante, Stefania IR - Mercadante S FIR - Vermont, Clementien L IR - Vermont CL FIR - Moll, Henriette A IR - Moll HA FIR - Borensztajn, Dorine M IR - Borensztajn DM FIR - Hagedoorn, Nienke N IR - Hagedoorn NN FIR - Tan, Chantal IR - Tan C FIR - Zachariasse, Joany IR - Zachariasse J FIR - Dik, W IR - Dik W FIR - Shen, Ching-Fen IR - Shen CF FIR - Zavadska, Dace IR - Zavadska D FIR - Laivacuma, Sniedze IR - Laivacuma S FIR - Rudzate, Aleksandra IR - Rudzate A FIR - Stoldere, Diana IR - Stoldere D FIR - Barzdina, Arta IR - Barzdina A FIR - Barzdina, Elza IR - Barzdina E FIR - Madelane, Monta IR - Madelane M FIR - Gravele, Dagne IR - Gravele D FIR - Svile, Dace IR - Svile D FIR - Basmaci, Romain IR - Basmaci R FIR - Lachaume, Noemie IR - Lachaume N FIR - Bories, Pauline IR - Bories P FIR - Tkhayat, Raja Ben IR - Tkhayat RB FIR - Cheriaux, Laura IR - Cheriaux L FIR - Davoust, Jurate IR - Davoust J FIR - Ong, Kim-Thanh IR - Ong KT FIR - Cotillon, Marie IR - Cotillon M FIR - de Groc, Thibault IR - de Groc T FIR - Le, Sebastien IR - Le S FIR - Vergnault, Nathalie IR - Vergnault N FIR - See, Helene IR - See H FIR - Cohen, Laure IR - Cohen L FIR - Tugny, Alice de IR - Tugny A FIR - Danekova, Nevena IR - Danekova N FIR - Mommert-Tripon, Marine IR - Mommert-Tripon M FIR - Brengel-Pesce, Karen IR - Brengel-Pesce K FIR - Pokorn, Marko IR - Pokorn M FIR - Kolnik, Mojca IR - Kolnik M FIR - Avcin, Tadej IR - Avcin T FIR - Avramoska, Tanja IR - Avramoska T FIR - Bahovec, Natalija IR - Bahovec N FIR - Bogovic, Petra IR - Bogovic P FIR - Kitanovski, Lidija IR - Kitanovski L FIR - Nahtigal, Mirijam IR - Nahtigal M FIR - Papst, Lea IR - Papst L FIR - Srovin, Tina Plankar IR - Srovin TP FIR - Strle, Frac IR - Strle F FIR - Vincek, Katarina IR - Vincek K FIR - van der Flier, Michiel IR - van der Flier M FIR - Tissing, Wim J E IR - Tissing WJE FIR - Wosten-van Asperen, Rosalie M IR - Wosten-van Asperen RM FIR - Vastert, Sebastiaan J IR - Vastert SJ FIR - Vijlbrief, Daniel C IR - Vijlbrief DC FIR - Bont, Louis J IR - Bont LJ FIR - Beudeker, Coco R IR - Beudeker CR FIR - Agyeman, Philipp IR - Agyeman P FIR - Aebi, Christoph IR - Aebi C FIR - Schobi, Nina IR - Schobi N FIR - Usman, Mariama IR - Usman M FIR - Schluchter, Stefanie IR - Schluchter S FIR - Schlapbach, Luregn IR - Schlapbach L FIR - Hagmann, Cornelia IR - Hagmann C FIR - Zapf, Florian IR - Zapf F FIR - Baumann, Philipp IR - Baumann P FIR - Brotschi, Barbara IR - Brotschi B FIR - Zimmermann, Elisa IR - Zimmermann E FIR - Meier, Marion IR - Meier M FIR - Weber, Kathrin IR - Weber K FIR - Frink, Colin IR - Frink C FIR - Voice, Marie IR - Voice M FIR - Calvo-Bado, Leo IR - Calvo-Bado L FIR - Steele, Michael IR - Steele M FIR - Holden, Jennifer IR - Holden J FIR - Taylor, Andrew IR - Taylor A FIR - Calvez, Ronan IR - Calvez R FIR - Davies, Catherine IR - Davies C FIR - Evans, Benjamin IR - Evans B FIR - Stevens, Jake IR - Stevens J FIR - Matthews, Peter IR - Matthews P FIR - Billing, Kyle IR - Billing K FIR - Zenz, Werner IR - Zenz W FIR - Binder, Alexander IR - Binder A FIR - Kohlmaier, Benno IR - Kohlmaier B FIR - Kohlfurst, Daniela S IR - Kohlfurst DS FIR - Schweintzge, Nina A IR - Schweintzge NA FIR - Zurl, Christoph IR - Zurl C FIR - Hosele, Susanne IR - Hosele S FIR - Gampawar, Piyush G IR - Gampawar PG FIR - Kapo, Barbara IR - Kapo B FIR - Leitner, Manuel IR - Leitner M FIR - Polz, Lena IR - Polz L FIR - Rusu, Alexandra IR - Rusu A FIR - Rajic, Glorija IR - Rajic G FIR - Stoiser, Bianca IR - Stoiser B FIR - Strempfl, Martina IR - Strempfl M FIR - Sagmeister, Manfred G IR - Sagmeister MG FIR - Bauchinger, Sebastian IR - Bauchinger S FIR - Benesch, Martin IR - Benesch M FIR - Ceolotto, Astrid IR - Ceolotto A FIR - Eber, Ernst IR - Eber E FIR - Gallistl, Siegfried IR - Gallistl S FIR - Haidi, Harald IR - Haidi H FIR - Hauer, Almuthe IR - Hauer A FIR - Hude, Christa IR - Hude C FIR - Kapper, Andrea IR - Kapper A FIR - Keldorfer, Markus IR - Keldorfer M FIR - Loffler, Sabine IR - Loffler S FIR - Niedrist, Tobias IR - Niedrist T FIR - Pilch, Heidemarie IR - Pilch H FIR - Pfleger, Andreas IR - Pfleger A FIR - Pfurtscheller, Klaus IR - Pfurtscheller K FIR - Rodl, Siegfried IR - Rodl S FIR - Skrabi-Baumgartner, Andrea IR - Skrabi-Baumgartner A FIR - Strenger, Volker IR - Strenger V FIR - Wallner, Elmar IR - Wallner E FIR - Tauchert, Maike K IR - Tauchert MK FIR - von Both, Ulrich IR - von Both U FIR - Kolberg, Laura IR - Kolberg L FIR - Schmied, Patricia IR - Schmied P FIR - Mavridi, Ioanna IR - Mavridi I FIR - Alba-Alejandre, Irene IR - Alba-Alejandre I FIR - Danhauser, Katharina IR - Danhauser K FIR - Haas, Nikolaus IR - Haas N FIR - Griese, Matthias IR - Griese M FIR - Feuchtinger, Tobias IR - Feuchtinger T FIR - Juranek, Sabrina IR - Juranek S FIR - Kappler, Matthias IR - Kappler M FIR - Lurz, Eberhard IR - Lurz E FIR - Maier, Esther IR - Maier E FIR - Reiter, Karl IR - Reiter K FIR - Schoen, Carola IR - Schoen C FIR - Schroepf, Sebastian IR - Schroepf S FIR - Yeung, Shunmay IR - Yeung S FIR - Dewez, Manuel IR - Dewez M FIR - Bath, David IR - Bath D FIR - Fitchett, Elizabeth IR - Fitchett E FIR - Cresswell, Fiona IR - Cresswell F FIR - Usuf, Effua IR - Usuf E FIR - Bojang, Kalifa IR - Bojang K FIR - Roca, Anna IR - Roca A FIR - Sarr, Isatou IR - Sarr I FIR - Saidykhan, Momodou IR - Saidykhan M FIR - Ndure, Ebrahim IR - Ndure E FIR - Madrigal, Pedro IR - Madrigal P FIR - Fexova, Silvie IR - Fexova S FIR - Sulik, Artur IR - Sulik A FIR - Toczylowski, Kacper IR - Toczylowski K FIR - Lewandowski, Dawid IR - Lewandowski D FIR - Wright, Victoria IR - Wright V FIR - Baumard, Lucas IR - Baumard L FIR - Galassini, Rachel IR - Galassini R FIR - HabgoodCoote, Dominic IR - HabgoodCoote D FIR - Hoggart, Clive IR - Hoggart C FIR - Hourmat, Sara IR - Hourmat S FIR - Maconochie, Ian IR - Maconochie I FIR - Lin, Naomi IR - Lin N FIR - Pas, Ivonne Pena IR - Pas IP FIR - Shailes, Hannah IR - Shailes H FIR - Ali, Ladan IR - Ali L FIR - Jorgensen, Rikke IR - Jorgensen R FIR - Persand, Salina IR - Persand S FIR - Stevens, Molly IR - Stevens M FIR - Kim, Eunjung IR - Kim E FIR - Pierce, Benjamin IR - Pierce B FIR - Dudley, Julia IR - Dudley J FIR - Richmond, Vivien IR - Richmond V FIR - Tavliavini, Emma IR - Tavliavini E FIR - Liu, Ching-Chuang IR - Liu CC FIR - Wang, Shih-Min IR - Wang SM FIR - Farto, Cristina Balo IR - Farto CB FIR - Barral-Arca, Ruth IR - Barral-Arca R FIR - Castro, Maria Barreiro IR - Castro MB FIR - Bello, Xabier IR - Bello X FIR - Garcia, Mirian Ben IR - Garcia MB FIR - Cebey-Lopez, Miriam IR - Cebey-Lopez M FIR - Jose Curras-Tuala, Maria IR - Jose Curras-Tuala M FIR - Rodriguez, Lidia Pineiro IR - Rodriguez LP FIR - Rivero-Calle, Irene IR - Rivero-Calle I FIR - Sadiki Ora, Miguel IR - Sadiki Ora M FIR - Trasorras, Cristina Seren IR - Trasorras CS FIR - Zavadaska, Dace IR - Zavadaska D FIR - Balode, Anda IR - Balode A FIR - Barzdina, Arta IR - Barzdina A FIR - Deksne, Darta IR - Deksne D FIR - Gardovska, Dace IR - Gardovska D FIR - Gravele, Dagne IR - Gravele D FIR - Grope, Ilze IR - Grope I FIR - Meiere, Anija IR - Meiere A FIR - Nokalna, Ieva IR - Nokalna I FIR - Pavare, Jana IR - Pavare J FIR - Pucuka, Zanda IR - Pucuka Z FIR - Selecka, Katrina IR - Selecka K FIR - Sidorova, Aleksandra IR - Sidorova A FIR - Nora Urbane, Urzula IR - Nora Urbane U FIR - Zaman, Syed M A IR - Zaman SMA FIR - Secka, Fatou IR - Secka F FIR - Anderson, Suzanne IR - Anderson S FIR - Rocalsatou Sarr, Anna IR - Rocalsatou Sarr A FIR - Darboe, Saffiatou IR - Darboe S FIR - Ceesay, Samba IR - Ceesay S FIR - D'alessandro, Umberto IR - D'alessandro U FIR - Moll, Henriette A IR - Moll HA FIR - Vermont, Clementien L IR - Vermont CL FIR - Schlapbach, Luregn J IR - Schlapbach LJ FIR - Wyss, Verena IR - Wyss V FIR - Giannoni, Eric IR - Giannoni E FIR - Stocker, Martin IR - Stocker M FIR - Posfay-Barbe, Klara M IR - Posfay-Barbe KM FIR - Heininger, Ulrich IR - Heininger U FIR - Bernhard-Stirnemann, Sara Rey IR - Bernhard-Stirnemann SR FIR - Niederer-Loher, Anita IR - Niederer-Loher A FIR - Kahlert, Christian IR - Kahlert C FIR - Natalucci, Giancarlo IR - Natalucci G FIR - Relly, Christa IR - Relly C FIR - Riedel, Thomas IR - Riedel T FIR - Berger, Christoph IR - Berger C FIR - Carrol, Enitan D IR - Carrol ED FIR - Paulus, Stephane IR - Paulus S FIR - Jennings, Rebecca IR - Jennings R FIR - Johnston, Joanne IR - Johnston J FIR - Leigh, Simon IR - Leigh S FIR - Marmarinos, Antonis IR - Marmarinos A FIR - Syggelou, Kelly IR - Syggelou K FIR - Fink, Colin IR - Fink C FIR - Schweintzger, Nina A IR - Schweintzger NA FIR - Baumgart, Hinrich IR - Baumgart H FIR - Gores, Gunther IR - Gores G FIR - Haidl, Harald IR - Haidl H FIR - Krenn, Larissa IR - Krenn L FIR - Nordberg, Gudrun IR - Nordberg G FIR - Skrabl-Baumgartner, Andrea IR - Skrabl-Baumgartner A FIR - Sperl, Matthias IR - Sperl M FIR - Stampfer, Laura IR - Stampfer L FIR - Till, Holger IR - Till H FIR - Trobisch, Andreas IR - Trobisch A FIR - Emmanuel Dewez, Juan IR - Emmanuel Dewez J FIR - Hibbered, Martin IR - Hibbered M FIR - Miners, Alec IR - Miners A FIR - Wedderburn, Catherine IR - Wedderburn C FIR - Meierford, Anne IR - Meierford A FIR - Leurent, Baptiste IR - Leurent B FIR - de Groot, Ronald IR - de Groot R FIR - Van der Flier, Michiel IR - Van der Flier M FIR - de Jonge, Marien I IR - de Jonge MI FIR - van Aerde, Koen IR - van Aerde K FIR - Alkema, Wynard IR - Alkema W FIR - van den Broek, Bryan IR - van den Broek B FIR - Gloerich, Jolein IR - Gloerich J FIR - van Gool, Alain J IR - van Gool AJ FIR - Henriet, Stefanie IR - Henriet S FIR - Huijnen, Martijn IR - Huijnen M FIR - Philipsen, Ria IR - Philipsen R FIR - Willems, Esther IR - Willems E FIR - Gerrits, G P J M IR - Gerrits GPJM FIR - van Leur, M IR - van Leur M FIR - Heidema, J IR - Heidema J FIR - de Haan, L IR - de Haan L FIR - Miedema, C J IR - Miedema CJ FIR - Neeleman, C IR - Neeleman C FIR - Obihara, C C IR - Obihara CC FIR - Tramper-Stranders, G A IR - Tramper-Stranders GA FIR - Kandasamy, Rama IR - Kandasamy R FIR - Carter, Michael J IR - Carter MJ FIR - O'Connor, Daniel IR - O'Connor D FIR - Bibi, Sagida IR - Bibi S FIR - Kelly, Dominic F IR - Kelly DF FIR - Thorson, Stephen IR - Thorson S FIR - Ansari, Imran IR - Ansari I FIR - Murdoch, David R IR - Murdoch DR FIR - Valentine, Lucille IR - Valentine L FIR - Allen, Karen IR - Allen K FIR - Chan, Adora IR - Chan A FIR - Devine, Kirsty IR - Devine K FIR - King, Sharon IR - King S FIR - McAlinden, Paul IR - McAlinden P FIR - McDonald, Sam IR - McDonald S FIR - McDonnell, Anne IR - McDonnell A FIR - Pickering, Ailsa IR - Pickering A FIR - Wood, Amanda IR - Wood A FIR - Woodsford, Phil IR - Woodsford P FIR - Baxter, Frances IR - Baxter F FIR - Rhodes, Matthew IR - Rhodes M FIR - Agbeko, Rachel IR - Agbeko R FIR - Mackerness, Christine IR - Mackerness C FIR - Baas, Bryan IR - Baas B FIR - Kloosterhuis, Lieke IR - Kloosterhuis L FIR - Oosthoek, Wilma IR - Oosthoek W FIR - Arif, Tasnim IR - Arif T FIR - Bennet, Joshua IR - Bennet J FIR - Collings, Kalvin IR - Collings K FIR - van der Giessen, Ilona IR - van der Giessen I FIR - Martin, Alex IR - Martin A FIR - Rashid, Aqeela IR - Rashid A FIR - Rowlands, Emily IR - Rowlands E FIR - de Vries, Gabriella IR - de Vries G FIR - van der Velden, Fabian IR - van der Velden F FIR - Soon, Joshua IR - Soon J FIR - Zwerenz, Manuela IR - Zwerenz M FIR - Bruschbeck, Judith IR - Bruschbeck J FIR - Bidlingmaier, Christoph IR - Bidlingmaier C FIR - Binder, Vera IR - Binder V FIR - Keil, Julia IR - Keil J FIR - Muench, Georg IR - Muench G FIR - Mallet, Francois IR - Mallet F FIR - Pachot, Alexandre IR - Pachot A FIR - Mommert, Marine IR - Mommert M FIR - Prunk, Petra IR - Prunk P FIR - Osterman, Veronika IR - Osterman V FIR - Kuijpers, Taco IR - Kuijpers T FIR - Jongerius, Ilse IR - Jongerius I FIR - van den Berg, J M IR - van den Berg JM FIR - Schonenberg, D IR - Schonenberg D FIR - Barendregt, A M IR - Barendregt AM FIR - Pajkrt, D IR - Pajkrt D FIR - van der Kuip, M IR - van der Kuip M FIR - van Furth, A M IR - van Furth AM FIR - Sprenkeler, Evelien IR - Sprenkeler E FIR - Zandstra, Judith IR - Zandstra J FIR - van Mierlo, G IR - van Mierlo G FIR - Geissler, Judy IR - Geissler J EDAT- 2025/10/15 12:32 MHDA- 2025/10/15 18:28 PMCR- 2025/10/15 CRDT- 2025/10/15 11:33 PHST- 2025/10/15 18:28 [medline] PHST- 2025/10/15 12:32 [pubmed] PHST- 2025/10/15 11:33 [entrez] PHST- 2025/10/15 00:00 [pmc-release] AID - 2840134 [pii] AID - zoi251045 [pii] AID - 10.1001/jamanetworkopen.2025.37808 [doi] PST - epublish SO - JAMA Netw Open. 2025 Oct 1;8(10):e2537808. doi: 10.1001/jamanetworkopen.2025.37808. PMID- 41054436 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20251007 LR - 20260726 IS - 2589-5370 (Electronic) IS - 2589-5370 (Linking) VI - 87 DP - 2025 Sep TI - Osimertinib plus consolidative radiotherapy for advanced EGFR mutant non-small cell lung cancer: a multicentre, single-arm, phase 2 trial. PG - 103435 LID - 10.1016/j.eclinm.2025.103435 [doi] LID - 103435 AB - BACKGROUND: Despite high response rates to epidermal growth factor receptor (EGFR) inhibitors, patients with advanced EGFR mutant non-small cell lung cancer (NSCLC) generally experience disease progression within 2 years. We evaluated whether consolidative radiation therapy (RT) to residual sites of disease at the time of expected best response to EGFR inhibition prolongs disease control. METHODS: This multicentre, single-arm phase 2 trial was conducted at two sites in the USA. Eligible patients (aged >/=18 years) had advanced EGFR mutant (exon 19 or 21) NSCLC not restricted by number, site, or size of metastases; ECOG 0-2; and no prior treatment with EGFR or immune checkpoint inhibitors. Patients with stable or responding disease after 8 weeks of osimertinib 80 mg orally daily received radiation therapy (RT) to persisting lesions, followed by continued osimertinib until progression or intolerance. The primary endpoint was progression-free survival (PFS) in all participants who received at least one dose of osimertinib, assessed radiographically every 8 weeks. Secondary endpoints were toxicity, duration on osimertinib, and overall survival (OS). This trial is registered with Clinicaltrials.gov, NCT03667820. FINDINGS: Between Oct 15, 2018, and July 1, 2021, 42 patients (32 female, 10 male) were enrolled and initiated osimertinib, of whom 32 (76%) received consolidative RT, primarily stereotactic RT. The most common reasons RT was not administered were insufficient residual disease (10%) and inadequate response (5%). At a median follow-up of 35.7 months, median PFS was 32.3 months (95% CI, 21.9-51.7), median OS was 45 months (95% CI, 39.3-56.4), and median duration of osimertinib was 32.4 months. Osimertinib-related toxicities, including skin, nail, and gastrointestinal events, occurred at expected rates and were almost always grade 1-2. Two patients (5%) developed pneumonitis, including one grade 4 event. INTERPRETATION: These findings show osimertinib plus consolidative RT was well tolerated and demonstrates promising efficacy in patients with advanced EGFR mutant NSCLC. Because this approach may be less complex and less toxic than multi-agent targeted therapy regimens for this population, the results of ongoing randomised trials testing similar strategies are awaited. FUNDING: AstraZeneca and the Biostatistics Shared Resource, UT Southwestern Harold C. Simmons Comprehensive Cancer Center. CI - (c) 2025 The Authors. FAU - Sampath, Sagus AU - Sampath S AD - Department of Radiation Oncology, City of Hope National Medical Center, Duarte, CA, USA. FAU - Rashdan, Sawsan AU - Rashdan S AD - Division of Hematology-Oncology, University of Texas Southwestern Medical Center, Dallas, TX, USA. AD - Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX, USA. FAU - Iyengar, Puneeth AU - Iyengar P AD - Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX, USA. AD - Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, TX, USA. FAU - Mickel, Townes A AU - Mickel TA AD - Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, TX, USA. FAU - Zhang, Song AU - Zhang S AD - Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX, USA. AD - Peter O'Donnell Jr. School of Public Health, University of Texas Southwestern Medical Center, Dallas, TX, USA. FAU - Ahn, Chul AU - Ahn C AD - Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX, USA. AD - Peter O'Donnell Jr. School of Public Health, University of Texas Southwestern Medical Center, Dallas, TX, USA. FAU - Gao, Ang AU - Gao A AD - Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX, USA. AD - Peter O'Donnell Jr. School of Public Health, University of Texas Southwestern Medical Center, Dallas, TX, USA. FAU - Dowell, Jonathan E AU - Dowell JE AD - Division of Hematology-Oncology, University of Texas Southwestern Medical Center, Dallas, TX, USA. AD - Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX, USA. FAU - Zhang, Yuanyuan AU - Zhang Y AD - Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX, USA. AD - Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, TX, USA. FAU - Westover, Kenneth D AU - Westover KD AD - Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX, USA. AD - Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, TX, USA. FAU - Cole, Suzanne M AU - Cole SM AD - Division of Hematology-Oncology, University of Texas Southwestern Medical Center, Dallas, TX, USA. AD - Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX, USA. FAU - Amini, Arya AU - Amini A AD - Department of Radiation Oncology, City of Hope National Medical Center, Duarte, CA, USA. FAU - Rock, Adam AU - Rock A AD - Department of Medical Oncology, City of Hope National Medical Center, Duarte, CA, USA. FAU - Massarelli, Erminia AU - Massarelli E AD - Department of Medical Oncology, City of Hope National Medical Center, Duarte, CA, USA. FAU - Koczywas, Marianna AU - Koczywas M AD - Department of Medical Oncology, City of Hope National Medical Center, Duarte, CA, USA. FAU - Gerber, David E AU - Gerber DE AD - Division of Hematology-Oncology, University of Texas Southwestern Medical Center, Dallas, TX, USA. AD - Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX, USA. AD - Peter O'Donnell Jr. School of Public Health, University of Texas Southwestern Medical Center, Dallas, TX, USA. LA - eng SI - ClinicalTrials.gov/NCT03667820 GR - P30 CA142543/CA/NCI NIH HHS/United States PT - Journal Article DEP - 20250826 PL - England TA - EClinicalMedicine JT - EClinicalMedicine JID - 101733727 PMC - PMC12496182 OTO - NOTNLM OT - Consolidation OT - EGFR mutant non-small cell lung cancer OT - Pneumonitis OT - Stereotactic radiation therapy COIS- PI reports grants or contracts from Incyte (to institution); and consulting fees from Johnson & Johnson, AstraZeneca, Pfizer, and Novocure. JED reports leadership or fiduciary role in other board for Takeda, Catalyst, and Regeneron. YZ reports grants or contracts from the UT Lung Specialized Program of Research Excellence (SPORE), the UT Southwestern President Research Council, the UT Southwestern Clinical and Translational Science Award (NIH CTSA KL2 scholar award), American Society of Clinical Oncology, American Cancer Society, and AstraZeneca (all to institution). KDW reports grants or contracts from Elekta; consulting fees from AstraZeneca, Sanofi, and Amgen; patents planned, issued, or pending for KRAS inhibitors, SRC inhibitors, and stereotactic body frame; leadership or fiduciary role in other board for the National Comprehensive Cancer Network (lung cancer screening); stock or stock options in Vibliome, Vellorum, and Stabilix; and serving as co-founder of Stabilix. SMC reports grants or contracts from the U.S. Food and Drug Administration (FDA) and Merck (both to institution); and leadership or fiduciary role in other board for the American Society of Clinical Oncology (ASCO) and Eastern Cooperative Oncology Group-American College of Radiology Imaging Network (ECOG-ACRIN). AR reports payment or honoraria from Omni Oncology and Oncohost; and stock or stock options in Merck, Cigna, and Bristol Myers Squibb. EM reports consulting fees from Abbvie, Bristol Myers Squibb, Merck, AstraZeneca, Sanofi, Daiichi Sankyo, and Johnson & Johnson; support for attending meetings and/or travel from Johnson & Johnson; and participation on a data safety monitoring board for Abbvie, Bristol Myers Squibb, Merck, AstraZeneca, Sanofi, Daiichi Sankyo, and Johnson & Johnson. DEG reports grants or contracts from AstraZeneca, BerGenBio, Karyopharm, and Novocure (all to institution); royalties from Oxford University Press; consulting fees from Abbvie, AstraZeneca, Catalyst Pharmaceuticals, Daiichi Sankyo, Elevation Oncology, Janssen Scientific Affairs, Jazz Pharmaceuticals, Regeneron Pharmaceuticals, and Sanofi; U.S. patents planned, issued, or pending (11,747,345; 17/045,482, 18/504,868, 63/386,387, 63/382,972, and 63/382,257); participation on a data and safety monitoring board for Daiichi Sankyo; leadership or fiduciary role in other board for OncoSeer Diagnostics, Inc. (co-founder and Chief Medical Officer); and stock shares in Gilead. All other authors declare no competing interests. EDAT- 2025/10/07 11:59 MHDA- 2025/10/07 12:00 PMCR- 2025/08/26 CRDT- 2025/10/07 04:14 PHST- 2025/05/08 00:00 [received] PHST- 2025/07/30 00:00 [revised] PHST- 2025/08/01 00:00 [accepted] PHST- 2025/10/07 12:00 [medline] PHST- 2025/10/07 11:59 [pubmed] PHST- 2025/10/07 04:14 [entrez] PHST- 2025/08/26 00:00 [pmc-release] AID - S2589-5370(25)00367-0 [pii] AID - 103435 [pii] AID - 10.1016/j.eclinm.2025.103435 [doi] PST - epublish SO - EClinicalMedicine. 2025 Aug 26;87:103435. doi: 10.1016/j.eclinm.2025.103435. eCollection 2025 Sep. PMID- 41043537 OWN - NLM STAT- MEDLINE DCOM- 20251127 LR - 20251127 IS - 1879-0518 (Electronic) IS - 0010-7824 (Linking) VI - 153 DP - 2026 Jan TI - Preferred strategies for obtaining abortion care among pregnant Texans: A latent class analysis. PG - 111244 LID - S0010-7824(25)00435-4 [pii] LID - 10.1016/j.contraception.2025.111244 [doi] AB - OBJECTIVE: In September 2021, Texas implemented Senate Bill 8 (SB8)- a law prohibiting abortion after detection of embryonic cardiac activity and was poised to ban all abortions with few exemptions if the US Supreme Court ended federal protections for abortion. Given restricted options for in-state facility-based care, we evaluated pregnant Texans' preferences for other strategies to obtain abortion care and assessed social and economic factors associated with their interest. STUDY DESIGN: In June and July 2022, we recruited Texans >/= 18 years of age attending the mandatory consultation and ultrasound visit at 8 in-state facilities for a survey about their interest in strategies to obtain an abortion if they could not do so in Texas. We asked about five strategies: out-of-state facility-based care; abortion on a ship off Texas' coast; asynchronous non-US-based telehealth; synchronous US-based telehealth; or use of misoprostol from Mexico. We used 3-step latent class analysis to identify clusters (or classes) of abortion seekers with similar preferences and multinomial regression analysis to assess the relationship between resource constraints and class membership. RESULTS: Among 293 respondents with complete information, we identified four classes: amenable to most strategies (n = 209), amenable to in-person strategies (n = 39), amenable to at-home strategies (n = 20), and few strategies acceptable (n = 25). Class membership was related to care preferences, access to a reliable car, and concern about the legality and safety of abortion pills obtained online. CONCLUSIONS: Most respondents were interested in all strategies, while those with transportation barriers and abortion modality concerns found fewer strategies acceptable. IMPLICATIONS: Most Texans seeking abortion were interested in a variety of in-person and virtual strategies for obtaining abortion if they could not do so in Texas. Information about the safety and legality of options for abortion care and about financial and logistical-support resources could improve accessibility for those facing greater constraints. CI - Copyright (c) 2025 Elsevier Inc. All rights reserved. FAU - Nagle, Amanda AU - Nagle A AD - Population Research Center, The University of Texas at Austin, Austin, TX, United States; Department of Sociology, The University of Texas at Austin, Austin, TX, United States. Electronic address: anagle@utexas.edu. FAU - Beasley, Anitra AU - Beasley A AD - Baylor College of Medicine, Houston, TX, United States. FAU - Lerma, Klaira AU - Lerma K AD - Department of Obstetrics & Gynecology, University of Wisconsin School of Medicine and Public Health, Madison, WI, United States. FAU - Sierra, Gracia AU - Sierra G AD - Resound Research for Reproductive Health, Austin, TX, United States. FAU - Alvarez Perez, Gabriela AU - Alvarez Perez G AD - Resound Research for Reproductive Health, Austin, TX, United States. FAU - Grossman, Daniel AU - Grossman D AD - Advancing New Standards in Reproductive Health, Bixby Center for Global Reproductive Health, Department of Obstetrics, Gynecology and Reproductive Sciences, University of California San Francisco, Oakland, CA, United States. FAU - White, Kari AU - White K AD - Population Research Center, The University of Texas at Austin, Austin, TX, United States; Resound Research for Reproductive Health, Austin, TX, United States. LA - eng PT - Journal Article DEP - 20251001 PL - United States TA - Contraception JT - Contraception JID - 0234361 RN - 0E43V0BB57 (Misoprostol) SB - IM MH - Female MH - Humans MH - Texas MH - Pregnancy MH - Adult MH - *Abortion, Induced/psychology/legislation & jurisprudence/methods MH - Latent Class Analysis MH - Young Adult MH - Telemedicine MH - *Patient Preference/statistics & numerical data MH - Health Services Accessibility MH - Misoprostol MH - *Abortion, Legal MH - Adolescent MH - *Abortion Applicants/psychology MH - Surveys and Questionnaires OTO - NOTNLM OT - Abortion OT - Abortion bans OT - Latent class OT - Out-of-state travel OT - Telehealth EDAT- 2025/10/04 00:30 MHDA- 2025/11/28 00:26 CRDT- 2025/10/03 19:32 PHST- 2025/03/26 00:00 [received] PHST- 2025/09/24 00:00 [revised] PHST- 2025/09/30 00:00 [accepted] PHST- 2025/11/28 00:26 [medline] PHST- 2025/10/04 00:30 [pubmed] PHST- 2025/10/03 19:32 [entrez] AID - S0010-7824(25)00435-4 [pii] AID - 10.1016/j.contraception.2025.111244 [doi] PST - ppublish SO - Contraception. 2026 Jan;153:111244. doi: 10.1016/j.contraception.2025.111244. Epub 2025 Oct 1. PMID- 41036125 OWN - NLM STAT- MEDLINE DCOM- 20251002 LR - 20251114 IS - 2296-2565 (Electronic) IS - 2296-2565 (Linking) VI - 13 DP - 2025 TI - Association between hemoglobin-to-red cell distribution width ratio and depression in Chinese adults: a population-based cross-sectional study. PG - 1638290 LID - 10.3389/fpubh.2025.1638290 [doi] LID - 1638290 AB - OBJECTIVE: This study investigates the hemoglobin-to-red blood cell distribution width ratio (HRR) and its association with risk of elevated depressive symptoms in Chinese adults, addressing a gap in evidence for non-older populations and exploring potential effect modifiers. METHODS: In this cross-sectional analysis of 30,427 adults from routine health screenings (July 2020-June 2021), depression was assessed using the Self-Rating Depression Scale. HRR was calculated as hemoglobin (g/dL) divided by red cell distribution width (%). Multivariable logistic regression, restricted cubic splines (RCS), sensitivity analyses with alternative depression definitions, E-value analysis, and ROC curve comparisons with the RDW-to-albumin ratio (RAR) were conducted, adjusted for sociodemographic, lifestyle, and clinical confounders. RESULTS: In a population of 30,427 adults (46.3% female; mean age 44.9 +/- 10.7 years; 56.7% with college education or above) undergoing routine health screenings, a strong inverse graded statistical association was observed between hemoglobin-to-red cell distribution width ratio (HRR) and elevated depressive symptoms (SDS >/= 53). Each unit increase in HRR reduced elevated depressive symptoms (SDS >/= 53) by 39% in fully adjusted models (OR = 0.61, 95% CI: 0.51-0.72, p < 0.0001). After adjusting covariates, compared to the lowest quartile (Q1: HRR /=1.25) exhibited 10% (OR = 0.90, 95% CI: 0.84-0.98), 13% (OR = 0.87, 95% CI: 0.80-0.94), and 24% (OR = 0.76, 95% CI: 0.70-0.83,) reductions in elevated depressive symptoms (SDS >/= 53), respectively (p-trend<0.0001). RCS confirmed a linear association without threshold effects. Age modified the relationship (p-interaction = 0.004), with stronger protection in adults >/=45 years (OR = 0.40, 95% CI: 0.32-0.51) than younger individuals (OR = 0.64, 95% CI: 0.50-0.82). CONCLUSION: HRR may indicate an independent, linear inverse association with elevated depressive symptoms (SDS >/= 53) in Chinese adults, with strong effects in older populations. As a cost-effective hematological biomarker, HRR could support scalable elevated depressive symptoms (SDS >/= 53) stratification and prevention strategies to complement other risk factors for elevated depressive symptoms, particularly in aging groups, and these findings warrant validation in prospective studies. CI - Copyright (c) 2025 Xu, Zhang, Liu and Zhou. FAU - Xu, Yike AU - Xu Y AD - West China School of Medicine, West China Hospital, Sichuan University, Chengdu, China. FAU - Zhang, Shuwen AU - Zhang S AD - Medical Imaging Key Laboratory of Sichuan Province, North Sichuan Medical College, Nanchong, Sichuan, China. AD - Department of Cardiology and Laboratory of Cardiovascular Diseases, West China Hospital, Institute of Cardiovascular Diseases, Sichuan University, Chengdu, Sichuan, China. FAU - Liu, Yang AU - Liu Y AD - Division of Vascular Surgery, Department of General Surgery, and Laboratory of Cardiovascular Diseases, West China Hospital, Sichuan University, Chengdu, China. FAU - Zhou, Junteng AU - Zhou J AD - Health Management Center, General Practice Medical Center, West China Hospital, Sichuan University, Chengdu, China. LA - eng PT - Journal Article DEP - 20250916 PL - Switzerland TA - Front Public Health JT - Frontiers in public health JID - 101616579 RN - 0 (Hemoglobins) RN - Chinese people SB - IM MH - Humans MH - Cross-Sectional Studies MH - Female MH - Male MH - Adult MH - China/epidemiology MH - *Depression/epidemiology/blood MH - Middle Aged MH - *Hemoglobins/analysis MH - *Erythrocyte Indices MH - East Asian People PMC - PMC12479292 OTO - NOTNLM OT - Chinese population OT - cross-sectional study OT - depression OT - graded statistical association OT - hemoglobin-to-red cell distribution width ratio COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2025/10/02 06:28 MHDA- 2025/10/02 06:29 PMCR- 2025/09/16 CRDT- 2025/10/02 04:54 PHST- 2025/05/30 00:00 [received] PHST- 2025/09/02 00:00 [accepted] PHST- 2025/10/02 06:29 [medline] PHST- 2025/10/02 06:28 [pubmed] PHST- 2025/10/02 04:54 [entrez] PHST- 2025/09/16 00:00 [pmc-release] AID - 10.3389/fpubh.2025.1638290 [doi] PST - epublish SO - Front Public Health. 2025 Sep 16;13:1638290. doi: 10.3389/fpubh.2025.1638290. eCollection 2025. PMID- 41021918 OWN - NLM STAT- MEDLINE DCOM- 20250929 LR - 20260813 IS - 1929-0748 (Electronic) IS - 1929-0748 (Linking) VI - 14 DP - 2025 Sep 29 TI - Vascular and Cardiovascular Outcomes of Smoking Cessation and Switching to Electronic Cigarette Use: Protocol for a Systematic Review of Prospective Studies. PG - e74949 LID - 10.2196/74949 [doi] LID - e74949 AB - BACKGROUND: Despite the well-documented adverse health effects of tobacco smoking, it remains prevalent worldwide. Chronic tobacco smoking is associated with significant cardiovascular effects, including an increased risk of cardiovascular disease and vascular dysfunction. In recent years, the use of electronic cigarettes (ECs) has increased, with many former tobacco cigarette smokers switching to ECs to aid in smoking cessation. To date, no systematic review has synthesized prospective evidence on key vascular and cardiovascular outcomes among adult smokers who quit or switch to ECs, with the specific aim of identifying early and clinically meaningful indicators of vascular recovery. OBJECTIVE: This systematic review aims to summarize the current prospective studies on the vascular effects of switching to exclusive EC use and the overall effects of smoking cessation on regular tobacco cigarette smokers. The review will focus, in particular, on early indicators of vascular improvement, such as measures of vascular function, including arterial stiffness and endothelial function, as well as on heart rate, blood pressure, nonfatal myocardial infarction, nonfatal stroke, sudden cardiovascular death, and acute heart failure. METHODS: The review will be reported following the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines. A comprehensive search was performed in PubMed and Scopus on January 12, 2025, without restrictions on the publication date. Studies will be included if they focus on cardiovascular outcomes, with study designs, including clinical trials (randomized controlled trials, observational studies), prospective cohort studies, and case-control studies. Studies involving regular smokers, aged 18 years and older, and those reporting on smoking cessation or switching to ECs will be considered. Data will be extracted using a standardized form and synthesized qualitatively. Risk of bias will be assessed using Joanna Briggs Institute's critical appraisal tools, with results informing sensitivity analyses and interpretation. RESULTS: As of January 2025, the preliminary search retrieved 1479 records across PubMed and Scopus. At the time of this protocol's publication, the first manuscript on vascular function outcomes was completed in July 2025 and is currently under peer review. Each subsequent review will include an updated search before completion. CONCLUSIONS: This review will provide a comprehensive landscape of current literature on the long-term vascular effects of smoking cessation and switching to exclusive EC use. The findings will help identify early indicators of vascular damage reversal, gaps in the current evidence base, and inform future research directions. By disseminating the results through peer-reviewed journals, conferences, and digital platforms, the review aims to enhance the understanding of smoking cessation's impact on vascular health and support public health efforts in reducing tobacco-related harm. TRIAL REGISTRATION: PROSPERO CRD420251016878; https://www.crd.york.ac.uk/PROSPERO/view/CRD420251016878. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): PRR1-10.2196/74949. CI - (c)Giusy Rita Maria La Rosa, Jacqueline Yu, Giulio Geraci, Davide Capodanno, Takao Ohki, Jacob George, Riccardo Polosa. Originally published in JMIR Research Protocols (https://www.researchprotocols.org), 29.09.2025. FAU - La Rosa, Giusy Rita Maria AU - La Rosa GRM AUID- ORCID: 0000-0001-5127-5299 AD - Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy. FAU - Yu, Jacqueline AU - Yu J AUID- ORCID: 0009-0002-6239-751X AD - University of Dundee Medical School, Dundee, United Kingdom. FAU - Geraci, Giulio AU - Geraci G AUID- ORCID: 0000-0003-3806-1151 AD - Faculty of Medicine and Surgery, Kore University of Enna, Enna, Italy. FAU - Capodanno, Davide AU - Capodanno D AUID- ORCID: 0000-0002-5156-7723 AD - Azienda Ospedaliero-Universitaria Policlinico "Gaspare Rodolico-San Marco", University of Catania, Catania, Italy. FAU - Ohki, Takao AU - Ohki T AUID- ORCID: 0009-0008-3669-1508 AD - Department of Surgery, Jikei University Hospital, Tokyo, Japan. FAU - George, Jacob AU - George J AUID- ORCID: 0000-0001-8154-8278 AD - University of Dundee Medical School, Dundee, United Kingdom. FAU - Polosa, Riccardo AU - Polosa R AUID- ORCID: 0000-0002-8450-5721 AD - Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy. AD - Faculty of Medicine and Surgery, Kore University of Enna, Enna, Italy. AD - Center of Excellence for the Acceleration of Harm Reduction, University of Catania, Catania, Italy. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20250929 PL - Canada TA - JMIR Res Protoc JT - JMIR research protocols JID - 101599504 SB - IM MH - Humans MH - *Smoking Cessation/methods MH - Systematic Reviews as Topic MH - *Cardiovascular Diseases/etiology MH - Prospective Studies MH - *Electronic Nicotine Delivery Systems MH - Research Design MH - Adult PMC - PMC12519031 OTO - NOTNLM OT - cardiovascular disease OT - e-cigarettes OT - smoking cessation OT - stroke OT - vascular function COIS- Conflicts of Interest: GRMLR serves as Associate Editor for JMIR Research Protocols. However, she was not involved in any aspect of the editorial process for this manuscript, including its review, decision-making, or handling, which were managed independently according to the journal's policies. RP is professor of Medicine and Director of the Institute for Internal Medicine and Clinical Immunology at Catania University. He has received the grants: U-BIOPRED, AIR-PROM, IRIS, Ministero dell'Universita e della Ricerca (MUR) PNRR 3277/2021, PNRR 341/2022, and PNRR 411/2021 funded by NextGenerationEU of the European Commission. He has received investigator-initiated grants from Foundation for a Global Action to End Smoking (formerly known as Foundation for Smoke-Free World), Pfizer, GlaxoSmithKline, CV Therapeutics, NeuroSearch A/S, Sandoz, Merk Sharp & Dohme, Boehringer Ingelheim, Novartis, Arbi Group Srl., Duska Therapeutics, and Forest Laboratories. He is the founder of the Center for Tobacco Prevention and Treatment and of the Center of Excellence for the Acceleration of Harm Reduction at Catania University. He has been consulting for Pfizer, Boehringer Ingelheim, Duska Therapeutics, Forest Laboratories, CV Therapeutics, Sermo Inc., GRG Health, Clarivate Analytics, Guidepoint Expert Network, and GLG Group. He receives textbooks royalties from Elsevier and EDRA. He is Chair of the European Technical Committee for Standardization on Requirements and test methods for emissions of electronic cigarettes (CEN/TC 437; WG4) and scientific advisor at RIDE2Med. EDAT- 2025/09/29 22:46 MHDA- 2025/09/29 22:47 PMCR- 2025/09/29 CRDT- 2025/09/29 16:53 PHST- 2025/03/26 00:00 [received] PHST- 2025/06/02 00:00 [accepted] PHST- 2025/05/22 00:00 [revised] PHST- 2025/09/29 22:47 [medline] PHST- 2025/09/29 22:46 [pubmed] PHST- 2025/09/29 16:53 [entrez] PHST- 2025/09/29 00:00 [pmc-release] AID - v14i1e74949 [pii] AID - 10.2196/74949 [doi] PST - epublish SO - JMIR Res Protoc. 2025 Sep 29;14:e74949. doi: 10.2196/74949. PMID- 41004075 OWN - NLM STAT- MEDLINE DCOM- 20251101 LR - 20251104 IS - 1865-8652 (Electronic) IS - 0741-238X (Print) IS - 0741-238X (Linking) VI - 42 IP - 11 DP - 2025 Nov TI - The IMPACT Survey: The Humanistic Impact of Caring for an Individual with Osteogenesis Imperfecta. PG - 5811-5829 LID - 10.1007/s12325-025-03372-8 [doi] AB - INTRODUCTION: The IMPACT Survey ("IMPACT") investigated the humanistic, clinical, and economic impact of osteogenesis imperfecta (OI) on affected individuals, caregivers, and the broader community. Prior publications reported the methodology, initial findings, and economic and humanistic impacts on adults with OI. Here, data is presented on the humanistic impact of OI on caregivers to explore how caring for an individual with OI impacts their quality of life (QoL), and any drivers of impact. We hypothesise that caring for an individual with OI will impact the QoL of caregivers. METHODS: IMPACT, fielded July through September 2021 in eight languages, targeted adults and adolescents with OI, close relatives, and caregivers with or without OI. The survey covered demographics, socioeconomic factors, clinical characteristics, treatment patterns, QoL, and health economics. The impact of caring for an individual with OI was measured across QoL and worry domains. We performed descriptive analyses of the QoL of caregivers without OI and exploratory regression analyses to identify independent associations between caregiver and care recipient characteristics ("predictors"), and their QoL impact on caregivers. RESULTS: Of 528 caregivers without OI with one care recipient, across 10 areas and three domains (career and finances, social and relationships, and mental and physical well-being), 58-83% reported that caring for an individual with OI negatively impacted their QoL; 80% and 83% reported impacted mental health and time for leisure activities, respectively. Predictors of QoL impact included caregiver age, care recipient OI severity, age, and clinical signs, symptoms and events (SSEs). Additionally, 36-96% worried about their care recipients' future lives, medication access, and transition to adult care. CONCLUSION: Our results suggest that caring for individuals with OI might have considerable impacts on QoL and worries. The level of impact may be predicted by caregiver age and care recipient OI severity, age, and clinical SSEs. CI - (c) 2025. The Author(s). FAU - Westerheim, Ingunn AU - Westerheim I AD - Osteogenesis Imperfecta Federation Europe, Heffen, Belgium. FAU - Rauch, Frank AU - Rauch F AD - McGill University, Montreal, Canada. FAU - Hart, Tracy AU - Hart T AD - Osteogenesis Imperfecta Foundation, Gaithersburg, MD, USA. FAU - Wekre, Lena Lande AU - Wekre LL AD - TRS National Resource Center for Rare Disorders, Sunnaas Rehabilitation Hospital, Bjornemyr, Nesodden, Norway. FAU - van Welzenis, Taco AU - van Welzenis T AD - Osteogenesis Imperfecta Federation Europe, Heffen, Belgium. FAU - Raggio, Cathleen AU - Raggio C AD - Hospital for Special Surgery, New York, NY, USA. FAU - Mulhall, Heather AU - Mulhall H AD - Wickenstones Ltd, 1 & 3 Kings Meadow, Oxford, Oxfordshire, OX2 0DP, UK. FAU - Battersby, Alysia AU - Battersby A AD - Wickenstones Ltd, 1 & 3 Kings Meadow, Oxford, Oxfordshire, OX2 0DP, UK. alysia@wickenstones.com. FAU - Prince, Samantha AU - Prince S AD - Wickenstones Ltd, 1 & 3 Kings Meadow, Oxford, Oxfordshire, OX2 0DP, UK. FAU - Semler, Oliver AU - Semler O AD - University of Cologne, Cologne, Germany. LA - eng PT - Journal Article DEP - 20250926 PL - United States TA - Adv Ther JT - Advances in therapy JID - 8611864 SB - IM MH - Humans MH - *Osteogenesis Imperfecta/psychology/therapy/economics MH - *Quality of Life MH - *Caregivers/psychology MH - Male MH - Female MH - Adult MH - Middle Aged MH - Adolescent MH - Young Adult MH - *Humanism MH - Surveys and Questionnaires MH - Aged MH - Socioeconomic Factors MH - Cost of Illness PMC - PMC12579686 OAB - The IMPACT Survey looked at how osteogenesis imperfecta, a rare bone condition also known as brittle bone disease, affects people living with the condition and their caregivers. This report presents data on how caring for someone with osteogenesis imperfecta affects caregivers' quality of life. The Survey was done in 2021 and was open to caregivers (both with and without osteogenesis imperfecta), as well as people with osteogenesis imperfecta. It asked about health, daily life, treatments, emotional well-being, and caregiving costs. It included 528 caregivers who do not have osteogenesis imperfecta and who care for one person with the condition. Most caregivers (between 58% and 83%) said that caring for someone with osteogenesis imperfecta negatively affected their lives. They reported effects on their mental health, free time, work, social life, and finances. Many also said that they were very worried, especially about the future of their care recipients. For example, they were concerned about accessing medication and moving from child to adult healthcare. Some factors, like the caregiver's age and the care recipient's osteogenesis imperfecta severity, were linked to how much the caregiver's life was affected. This study shows that caring for someone with osteogenesis imperfecta can have a big impact on the caregiver's life-especially their mental health and personal time. OABL- eng OTO - NOTNLM OT - Caregiver OT - Humanistic burden OT - Osteogenesis imperfecta OT - Quality of life OT - Rare disease OT - Survey COIS- Declarations. Conflict of Interest: Heather Mulhall and Alysia Battersby are employees of Wickenstones Ltd, Oxford, UK. Samantha Prince is an employee of Mereo BioPharma Group London, UK. At the time of the survey design and development of this report, Samantha Prince was an employee of Wickenstones Ltd. Ingunn Westerheim, Tracy Hart, Taco van Welzenis, Lena Lande Wekre, Oliver Semler, Cathleen Raggio, and Frank Rauch have provided expert consulting to Mereo BioPharma Group London, UK. Tracy Hart serves as the Chief Executive Officer of the Osteogenesis Imperfecta Foundation who have received unrestricted educational grants from Mereo BioPharma Group London, UK and Ultragenyx Pharmaceuticals Inc, Novato, USA. Oliver Semler has participated in a national advisory board for Mereo BioPharma Group London, UK and has received study contracts for clinical studies from Ultragenyx Pharmaceuticals Inc, Novato, USA. Frank Rauch has received study contracts for experimental preclinical studies with Precithera Inc, Quebec, Canada, Mesentech Inc, Vancouver, Canada and Catabasis Pharmaceuticals Inc, Cambridge, USA. He has participated in advisory boards for Ultragenyx Pharmaceuticals Inc, Novato, USA, Sanofi S.A. Paris, France, Novartis International AG, Basel, Switzerland and Mereo BioPharma Group, London, UK. Frank Rauch has received a speaker fee from Ultragenyx Pharmaceuticals Inc, Novato, USA for a lecture and received a donation of experimental drugs for a preclinical study from Acceleron Pharma Inc, Cambridge, USA. Cathleen Raggio received an institutional grant from and has been a speaker for BioMarin Pharmaceuticals Inc, Novato, California, has participated in advisory boards for Ultragenyx Pharmaceuticals Inc, Novato, USA. She has received an institutional grant from and is a consultant for Nextcure, Beltville, MD, USA. Cathleen Raggio sits on the board of directors of the Osteogenesis Imperfecta Foundation. Cathleen Raggio has also participated in an advisory board for Mereo BioPharma Group, London, UK. Taco van Welzenis and Ingunn Westerheim hold leadership positions in the Osteogenesis Imperfecta Federation Europe, which has received grants from Mereo BioPharma Group, London, UK (unrestricted), Ultragenyx Pharmaceuticals Inc, Novato, USA (restricted grant for a conference), Quince Therapeutics Inc, San Francisco, CA, USA (donation for a conference), UCB (restricted grant to conference), Angitia Biopharmaceuticals Inc., Woodland Hills, CA, USA (donation to conference), Azafaros BV, Naarden, the Netherlands (donation to conference), Alexion Inc. Boston, MA, USA, (sponsorship of conference); Pega Medical Inc, Laval, Quebec, Canada (donation), PuREC, Shimane, Japan (sponsorship of conference) and Takeda, Tokyo, Japan (payment to Ingunn Westerheim as a panellist; donated to OIFE). Ethical Approval: The need for informed consent was waived, and an ethics approval exemption was granted for this study by Pearl IRB Indianapolis, IN, USA, (registered with OHRP and FDA; organisation number 0006471, registration number 00007772) according to FDA 21 CFR 56.104 and 45CFR46.104(b)(2): (2) Tests, Surveys, Interviews on 23 June 2021. The survey protocol is in line with the UK Research Integrity Office's guidance on good practice in internet-mediated research [29]. This online survey was anonymous and did not collect identifiable data on individuals. Participants were provided with a data privacy statement and consented for their responses to be analysed. Further, the study aligned with key principles of the EphMRA Code of Practice, including informing respondents in the survey landing page with a clear understanding of the purpose of the data collection, how it will be used (i.e. analysis and publication), anonymity, non-promotion, the right to withdraw, participation is voluntary, and data protection principles [30]. Additionally, the study aligns with the key principles of ESOMAR, including transparent information on what data will be collected, how it will be used and who it may be shared with; and ensuring data protection and ethical behaviour by researchers [31]. Participants were informed of the use of the data (as described above) prior to initiating the survey and indicated their consent by continuing to enter and complete the survey. Because the survey collected sensitive information about participants, all data were anonymised from data collection onwards. Participants did not provide names, email addresses or other identifiers, and internet protocol (IP) addresses were never captured within the survey platform. Provided data were handled in line with General Data Protection Regulation (GDPR) guidance [32]. EDAT- 2025/09/26 12:32 MHDA- 2025/11/01 21:21 PMCR- 2025/09/26 CRDT- 2025/09/26 11:24 PHST- 2025/05/15 00:00 [received] PHST- 2025/09/05 00:00 [accepted] PHST- 2025/11/01 21:21 [medline] PHST- 2025/09/26 12:32 [pubmed] PHST- 2025/09/26 11:24 [entrez] PHST- 2025/09/26 00:00 [pmc-release] AID - 10.1007/s12325-025-03372-8 [pii] AID - 3372 [pii] AID - 10.1007/s12325-025-03372-8 [doi] PST - ppublish SO - Adv Ther. 2025 Nov;42(11):5811-5829. doi: 10.1007/s12325-025-03372-8. Epub 2025 Sep 26. PMID- 40991296 OWN - NLM STAT- MEDLINE DCOM- 20251104 LR - 20260325 IS - 1538-3598 (Electronic) IS - 0098-7484 (Print) IS - 0098-7484 (Linking) VI - 334 IP - 17 DP - 2025 Nov 4 TI - Insurance Dynamics During Childhood in the Fragmented US Health System. PG - 1533-1540 LID - 10.1001/jama.2025.15488 [doi] AB - IMPORTANCE: US children's health insurance is fragmented across public and private sources, with wide state variation. However, the extent of children's interactions with Medicaid and Children's Health Insurance Program (CHIP) and their experience of uninsurance over 18 years of childhood remains unclear. Such estimates can provide a baseline for gauging the potential impact of upcoming Medicaid policy changes. OBJECTIVE: To estimate insurance dynamics in relation to Medicaid or CHIP and uninsurance over childhood under post-Affordable Care Act (ACA) prepandemic policy conditions. DESIGN, SETTING, AND PARTICIPANTS: Using a microsimulation model, we projected individual-level monthly insurance coverage (Medicaid or CHIP, Marketplace, employment-based, other, or uninsured) from birth until the 18th birthday for a simulated nationally representative cohort of 100 000 US children. National data were synthesized (2015-2019), including natality records, Medical Expenditure Panel Survey pooled 2-year panels, and 1 Survey of Income and Program Participation (SIPP) 3-year panel. Monthly insurance status was simulated by matching dynamically updated predictors to SIPP samples every 12 months. Predictors included annual family income as a percentage of the federal poverty level, insurance history, state, and age. The analysis was bootstrapped 1000 times to generate 95% uncertainty intervals (95% UI). EXPOSURES: Insurance status and state of residence at birth. MAIN OUTCOMES AND MEASURES: Cumulative insurance experience, overall and by subgroup. RESULTS: It was estimated that, by their 18th birthday, 61% (95% UI, 58%-63%) of US children were ever enrolled in Medicaid or CHIP and 42% (95% UI, 38%-46%) were ever uninsured. An estimated 26% (95% UI, 24%-29%) of children were continuously enrolled in employment-based or other insurance excluding Medicaid, CHIP, or Marketplace. Among children born with Medicaid or CHIP, the share ever uninsured was 59% (95% UI, 48%-66%) in ACA nonexpansion states vs 36% (95% UI, 30%-41%) in expansion states. Across alternative categorizations of policy restrictiveness, the highest share of ever uninsured among children born with Medicaid or CHIP was consistently estimated in states with the most restrictive Medicaid and CHIP eligibility criteria. CONCLUSIONS AND RELEVANCE: An estimated 3 of 4 US children relied on publicly subsidized insurance (Medicaid, CHIP, or Marketplace) or experienced a period without any insurance by their 18th birthday in the post-ACA, prepandemic policy environment. Substantial state heterogeneity in childhood uninsurance underscores the critical role of Medicaid policies. FAU - Shen, Ye AU - Shen Y AD - Interfaculty Initiative in Health Policy, Harvard University, Cambridge, Massachusetts. AD - Center for Health Decision Science, Harvard T.H. Chan School of Public Health, Boston, Massachusetts. FAU - Sommers, Benjamin D AU - Sommers BD AD - Department of Health Policy and Management, Harvard T.H. Chan School of Public Health, Boston, Massachusetts. AD - Department of Medicine, Harvard Medical School, Brigham & Women's Hospital, Boston, Massachusetts. FAU - Hatfield, Laura A AU - Hatfield LA AD - Statistics and Data Science, NORC at the University of Chicago, Chicago, Illinois. FAU - Hayes, Catherine AU - Hayes C AD - Department of Oral Health Policy & Epidemiology, Harvard School of Dental Medicine, Boston, Massachusetts. FAU - Pandya, Ankur AU - Pandya A AD - Center for Health Decision Science, Harvard T.H. Chan School of Public Health, Boston, Massachusetts. AD - Department of Health Policy and Management, Harvard T.H. Chan School of Public Health, Boston, Massachusetts. FAU - Menzies, Nicolas A AU - Menzies NA AD - Center for Health Decision Science, Harvard T.H. Chan School of Public Health, Boston, Massachusetts. AD - Department of Global Health and Population, Harvard T.H. Chan School of Public Health, Boston, Massachusetts. LA - eng PT - Journal Article PL - United States TA - JAMA JT - JAMA JID - 7501160 SB - IM CIN - JAMA. 2025 Nov 4;334(17):1517-1519. doi: 10.1001/jama.2025.18087. PMID: 40991244 MH - Adolescent MH - Child MH - Child, Preschool MH - Female MH - Humans MH - Infant MH - Infant, Newborn MH - Male MH - *Children's Health Insurance Program/economics/statistics & numerical data/trends MH - Health Policy/economics/trends MH - *Insurance Coverage/economics/statistics & numerical data/trends MH - *Insurance, Health/economics/statistics & numerical data/trends MH - *Medicaid/economics/statistics & numerical data/trends MH - *Medically Uninsured/statistics & numerical data MH - Patient Protection and Affordable Care Act/economics/statistics & numerical data/trends MH - United States PMC - PMC12461604 COIS- Conflict of Interest Disclosures: Dr Sommers reported receiving grants from the Commonwealth Fund, Episcopal Health Foundation, and United Hospital Fund; honoraria from Kinetix Group, Massachusetts Psychiatric Society, and American Medical Association; and travel support from the AcademyHealth outside the submitted work; and had been employed by the US Department of Health and Human Services from January 2021 to July 2023. No other disclosures were reported. EDAT- 2025/09/24 13:01 MHDA- 2025/11/04 12:28 PMCR- 2026/03/24 CRDT- 2025/09/24 11:34 PHST- 2025/11/04 12:28 [medline] PHST- 2025/09/24 13:01 [pubmed] PHST- 2025/09/24 11:34 [entrez] PHST- 2026/03/24 00:00 [pmc-release] AID - 2839299 [pii] AID - joi250069 [pii] AID - 10.1001/jama.2025.15488 [doi] PST - ppublish SO - JAMA. 2025 Nov 4;334(17):1533-1540. doi: 10.1001/jama.2025.15488. PMID- 40986854 OWN - NLM STAT- MEDLINE DCOM- 20250923 LR - 20250927 IS - 1438-8871 (Electronic) IS - 1439-4456 (Print) IS - 1438-8871 (Linking) VI - 27 DP - 2025 Sep 23 TI - Impact of Telemedicine on Health Expenditures During the COVID-19 Pandemic in Japan: Quasi-Experimental Study. PG - e72051 LID - 10.2196/72051 [doi] LID - e72051 AB - BACKGROUND: The effects of telemedicine on health expenditures and health outcomes are an important policy question. Many countries loosened regulations on the use of telemedicine during the COVID-19 pandemic, thereby offering an opportunity to evaluate these effects via a natural experiment. OBJECTIVE: This study aimed to assess the effect of greater telemedicine use on area-level health expenditures and health outcomes related to common chronic conditions in Japan during the COVID-19 pandemic. METHODS: We compared prefectures (area levels of government) with higher prepandemic telemedicine rates (fiscal year [FY] 2019) versus those with lower rates and conducted a difference-in-differences analysis of the change in prefecture-level health expenditures from FY2017 to FY2022 and health outcomes from FY2017 to FY2021. The participants were the total population in Japan from FY2017 to FY2022 (n=126 million), and the exposure was the increase in telemedicine use following the government's relaxation of restrictions on telemedicine use as an exceptional measure during the COVID-19 pandemic. Our main outcomes were the share of outpatient claims that were for telehealth services; total, inpatient, and outpatient annual prefecture-level health expenditures; all-cause mortality, glycated hemoglobin, systolic blood pressure, and low-density lipoprotein cholesterol. RESULTS: Treatment prefectures (n=15, population of 62 million) were defined as those with greater-than-median telemedicine use before the pandemic, while control prefectures (n=32, population of 64 million) were defined as those with less-than-median telemedicine use. Treatment and control prefectures shared similar demographic characteristics before the pandemic. The growth in telemedicine after 2020 as a share of outpatient claims increased among the treatment prefectures by 0.35 percentage points more than among control prefectures, which represented more than a threefold increase in telemedicine use compared to the prepandemic median. In difference-in-differences analyses, this difference was associated with a 1.0% relative decrease (95% CI 0.3%-1.8%) in total health expenditure (P=.006) and a 1.1% relative decrease (95% CI 0.2%-2.0%) in inpatient expenditure (P=.02). Outpatient expenditures showed no significant difference as a result of increased telemedicine adoption. Most health outcomes-all-cause mortality, glycated hemoglobin, systolic blood pressure, diastolic blood pressure, and low-density lipoprotein cholesterol-did not show any significant changes. CONCLUSIONS: Areas in Japan with greater expansion of telemedicine use during the pandemic experienced a significant decrease in both inpatient and total health care spending compared with areas with less telemedicine use, without harming health outcomes. CI - (c) Hikaru Aihara, Ichiro Kawachi, Benjamin D Sommers. Originally published in the Journal of Medical Internet Research (https://www.jmir.org). FAU - Aihara, Hikaru AU - Aihara H AUID- ORCID: 0009-0006-1628-4142 AD - Department of Health Policy and Management, Harvard T.H. Chan School of Public Health, Boston, MA, United States, 1 617 495 1000. AD - Department of Public Health and Health Policy, Graduate School of Medicine, The University of Tokyo, Bunkyo Hongo 7-3-1, Tokyo, 113-0033, Japan, 81 35841 3491. FAU - Kawachi, Ichiro AU - Kawachi I AUID- ORCID: 0000-0001-9339-2821 AD - Department of Social and Behavioral Sciences, Harvard T.H. Chan School of Public Health, Boston, MA, United States. FAU - Sommers, Benjamin D AU - Sommers BD AUID- ORCID: 0000-0001-6507-6047 AD - Department of Health Policy and Management, Harvard T.H. Chan School of Public Health, Boston, MA, United States, 1 617 495 1000. AD - Department of Medicine, Brigham and Women's Hospital, Boston, MA, United States. LA - eng PT - Journal Article DEP - 20250923 PL - Canada TA - J Med Internet Res JT - Journal of medical Internet research JID - 100959882 SB - IM MH - *COVID-19/epidemiology/economics MH - Humans MH - *Telemedicine/economics/statistics & numerical data MH - Japan/epidemiology MH - *Health Expenditures/statistics & numerical data MH - SARS-CoV-2 MH - Pandemics MH - Female MH - Male MH - Middle Aged PMC - PMC12456874 OTO - NOTNLM OT - COVID-19 OT - cost containment OT - health reform OT - health spending OT - telemedicine COIS- Conflicts of Interest: HA reports working for the Ministry of Health, Labour and Welfare in Japan from April 2015 to June 2024 and with McKinsey and Company in Japan since July 2024, but HA drafted this article as a researcher at Harvard University and the University of Tokyo, independent of the Ministry of Health, Labour and Welfare. The findings and views do not reflect their views. BDS reports grants from the Commonwealth Fund (2024), the Episcopal Health Foundation (2023), and the United Hospital Fund (2024); personal fees from the Kinetix Group (honorarium 2024), the Massachusetts Psychiatric Society (honorarium 2024), and the American Medical Association (honorarium, 2024); and nonfinancial support from AcademyHealth (conference travel, 2024), all outside the submitted work. BDS also worked in the US Department of Health and Human Services (HHS) from January 2021 to July 2023. The views expressed in this article do not necessarily reflect those of HHS. EDAT- 2025/09/23 18:28 MHDA- 2025/09/23 18:29 PMCR- 2025/09/23 CRDT- 2025/09/23 16:53 PHST- 2025/02/03 00:00 [received] PHST- 2025/07/27 00:00 [revised] PHST- 2025/07/30 00:00 [accepted] PHST- 2025/09/23 18:29 [medline] PHST- 2025/09/23 18:28 [pubmed] PHST- 2025/09/23 16:53 [entrez] PHST- 2025/09/23 00:00 [pmc-release] AID - v27i1e72051 [pii] AID - 72051 [pii] AID - 10.2196/72051 [doi] PST - epublish SO - J Med Internet Res. 2025 Sep 23;27:e72051. doi: 10.2196/72051. PMID- 40986183 OWN - NLM STAT- MEDLINE DCOM- 20251101 LR - 20251104 IS - 1865-8652 (Electronic) IS - 0741-238X (Print) IS - 0741-238X (Linking) VI - 42 IP - 11 DP - 2025 Nov TI - The IMPACT Survey: The Economic Impact of Caring for an Individual with Osteogenesis Imperfecta. PG - 5761-5780 LID - 10.1007/s12325-025-03373-7 [doi] AB - INTRODUCTION: The IMPACT Survey ("IMPACT") investigated the economic, clinical, and humanistic challenges of osteogenesis imperfecta (OI) on affected individuals, caregivers, and the broader community. Prior publications detail the methodology, initial findings, healthcare expenditures, and quality of life (QoL) impact on adults with OI. Here, data is presented on the productivity and finances of caregivers and any predictors of impact. We hypothesise that caring for an individual with OI will impact the productivity and finances of caregivers. METHODS: IMPACT, fielded July through September 2021 in eight languages, targeted adults and adolescents with OI, caregivers (with or without OI), and close relatives. Survey items covered demographics, socioeconomic factors, clinical characteristics, treatment patterns, QoL, and health economics. We performed descriptive analyses of caregivers' productivity and finances and exploratory regression analyses to identify independent associations between care recipient and caregiver characteristics ("predictors"), and their economic impact on caregivers. RESULTS: Of 528 caregivers (without OI) with one care recipient, 64% were in paid employment. Of these, 50% reported missing workdays in the preceding 4 weeks (mean 1.9 days). Caregivers reported impacted finances, spending a mean total of euro209 out of pocket (OOP) with the most spent on travel to medical appointments (mean euro83) and medicine (mean euro46) in the preceding 4 weeks. Caregiver spending varied across regions. Caregivers in the USA spent more in 4 weeks (mean euro334) than caregivers in EU4 (France, Germany, Italy, and Spain) and UK (mean euro163) or Nordic countries (mean euro33). Predictors of productivity and OOP spending included caregiver age, sex and employment status, care recipient age, and various signs, symptoms, and events. CONCLUSION: Our results suggest that caring for an individual with OI may impact caregivers' productivity and finances. The degree of impact may be predicted by caregiver and care recipient age, fracture frequency, and dental problems. CI - (c) 2025. The Author(s). FAU - Rauch, Frank AU - Rauch F AD - McGill University, Montreal, Canada. FAU - van Welzenis, Taco AU - van Welzenis T AD - Osteogenesis Imperfecta Federation Europe, Heffen, Belgium. FAU - Wekre, Lena Lande AU - Wekre LL AD - TRS National Resource Center for Rare Disorders, Sunnaas Rehabilitation Hospital, Bjornemyr, Nesodden, Norway. FAU - Raggio, Cathleen AU - Raggio C AD - Hospital for Special Surgery, New York, NY, USA. FAU - Semler, Oliver AU - Semler O AD - University of Cologne, Cologne, Germany. FAU - Westerheim, Ingunn AU - Westerheim I AD - Osteogenesis Imperfecta Federation Europe, Heffen, Belgium. FAU - Mulhall, Heather AU - Mulhall H AD - Wickenstones Ltd, 1 & 3 Kings Meadow, Oxford, Oxfordshire, OX2 0DP, UK. FAU - Anderson, Melanie AU - Anderson M AD - Wickenstones Ltd, 1 & 3 Kings Meadow, Oxford, Oxfordshire, OX2 0DP, UK. melanie@wickenstones.com. FAU - Prince, Samantha AU - Prince S AD - Wickenstones Ltd, 1 & 3 Kings Meadow, Oxford, Oxfordshire, OX2 0DP, UK. FAU - Hart, Tracy AU - Hart T AD - Osteogenesis Imperfecta Foundation, Gaithersburg, MD, USA. LA - eng PT - Journal Article DEP - 20250923 PL - United States TA - Adv Ther JT - Advances in therapy JID - 8611864 SB - IM MH - Humans MH - *Osteogenesis Imperfecta/economics/therapy MH - *Caregivers/economics/psychology MH - Female MH - Male MH - Adult MH - Quality of Life MH - Middle Aged MH - Adolescent MH - *Cost of Illness MH - *Health Expenditures/statistics & numerical data MH - Surveys and Questionnaires MH - Young Adult MH - Efficiency MH - Socioeconomic Factors MH - Aged PMC - PMC12579707 OAB - The IMPACT Survey looked at how caring for someone with osteogenesis imperfecta affects caregivers' work and finances. It aimed to understand the challenges caregivers face and what factors might make the experience of the caregivers worse. The survey was done in 2021 and was open to caregivers (both with and without osteogenesis imperfecta), as well as people with osteogenesis imperfecta. It asked about health, daily life, treatments, and the costs of care. The survey also looked at how often caregivers missed work and how much they spent on healthcare costs like travel and medication. Of 528 caregivers, 64% were employed. Half of them missed work in the last month, averaging 1.9 days off in 4 weeks. Caregivers reported spending an average of euro209 on healthcare in the previous 4 weeks, with the most spent on travel to medical appointments (euro83) and medicine (euro46). Caregiver spending varied by country, with those in the USA spending more (euro334) compared with Europe and Nordic countries (euro33-163). The survey found that factors like the caregiver's age, employment status, and the person they care for (e.g. their age and how often they fracture) impacted how much their work and finances were affected. The results show that caregiving for someone with osteogenesis imperfecta can impact both a caregiver's job and finances. OABL- eng OTO - NOTNLM OT - Caregiver OT - Costs OT - Economic burden OT - Osteogenesis imperfecta OT - Productivity loss OT - Rare disease OT - Survey COIS- Declarations. Conflict of Interest: Heather Mulhall and Melanie Anderson are employees of Wickenstones Ltd, Oxford, UK. Samantha Prince is an employee of Mereo BioPharma Group London, UK. At the time of the survey design and development of this research, Samantha Prince was an employee of Wickenstones Ltd. Ingunn Westerheim, Tracy Hart, Taco van Welzenis, Lena Lande Wekre, Oliver Semler, Cathleen Raggio, and Frank Rauch have provided expert consulting to Mereo BioPharma Group London, UK. Tracy Hart serves as the Chief Executive Officer of the Osteogenesis Imperfecta Foundation, who have received unrestricted educational grants from Mereo BioPharma Group London, UK and Ultragenyx Pharmaceuticals Inc, Novato, USA. Oliver Semler has participated in a national advisory board for Mereo BioPharma Group London, UK and has received study contracts for clinical studies from Ultragenyx Pharmaceuticals Inc, Novato, USA. Frank Rauch has received study contracts for experimental preclinical studies with Precithera Inc, Quebec, Canada, Mesentech Inc, Vancouver, Canada and Catabasis Pharmaceuticals Inc, Cambridge, USA. He has participated in advisory boards for Ultragenyx Pharmaceuticals Inc, Novato, USA, Sanofi S.A. Paris, France, Novartis International AG, Basel, Switzerland and Mereo BioPharma Group, London, UK. Frank Rauch has received a speaker fee from Ultragenyx Pharmaceuticals Inc, Novato, USA for a lecture and received a donation of experimental drugs for a preclinical study from Acceleron Pharma Inc, Cambridge, USA. Cathleen Raggio received an institutional grant from and has been a speaker for BioMarin Pharmaceuticals Inc, Novato, California, has participated in advisory boards for Ultragenyx Pharmaceuticals Inc, Novato, USA. She has received an institutional grant from and is a consultant for Nextcure, Beltville, MD, USA. Cathleen Raggio sits on the board of directors of the Osteogenesis Imperfecta Foundation. Cathleen Raggio has also participated in an advisory board for Mereo BioPharma Group, London, UK. Taco van Welzenis and Ingunn Westerheim hold leadership positions in the Osteogenesis Imperfecta Federation Europe, which has received grants from Mereo BioPharma Group, London, UK (unrestricted), Ultragenyx Pharmaceuticals Inc, Novato, USA (restricted grant for a conference), Quince Therapeutics Inc, San Francisco, CA, USA (donation for a conference), UCB (restricted grant to conference), Angitia Biopharmaceuticals Inc., Woodland Hills, CA, USA (donation to conference), Azafaros BV, Naarden, the Netherlands (donation to conference), Alexion Inc. Boston, MA, USA, (sponsorship of conference); Pega Medical Inc, Laval, Quebec, Canada (donation), PuREC, Shimane, Japan (sponsorship of conference) and Takeda, Tokyo, Japan (payment to Ingunn Westerheim as a panellist; donated to OIFE). Ethical Approval: The need for informed consent was waived, and an ethics approval exemption was granted for this study by Pearl IRB Indianapolis, IN, USA, (registered with OHRP and FDA; organisation number 0006471, registration number 00007772) according to FDA 21 CFR 56.104 and 45CFR46.104(b)(2): (2) Tests, Surveys, Interviews on 23 June 2021 [21]. The survey protocol is in line with the UK Research Integrity Office's guidance on good practice in internet-mediated research [22]. This online survey was anonymous and did not collect identifiable data on individuals. Participants were provided with a data privacy statement and consented for their responses to be analysed. Further, the study aligned with key principles of the European Pharmaceutical Market Research Association (EphMRA) Code of Practice, including informing respondents in the survey landing page with a clear understanding of the purpose of the data collection, how it will be used (i.e. analysis and publication), anonymity, non-promotion, the right to withdraw, participation is voluntary, and data protection principles [23]. Additionally, the study aligns with the key principles of the International Chamber of Commerce (ICC)/European Society for Opinion and Marketing Research (ESOMAR) International Code on Market, Opinion and Social Research and Data Analytics, including transparent information on what data will be collected, how it will be used and who it may be shared with; and ensuring data protection and ethical behaviour by researchers [24]. Participants were informed of the use of the data (as described above) prior to initiating the survey and indicated their consent by continuing to enter and complete the survey. Because the survey collected sensitive information about participants, all data were anonymised from data collection onwards. Participants did not provide names, email addresses or other identifiers, and internet protocol (IP) addresses were never captured within the survey platform. Provided data were handled in line with General Data Protection Regulation (GDPR) guidance [25]. EDAT- 2025/09/23 12:47 MHDA- 2025/11/01 21:22 PMCR- 2025/09/23 CRDT- 2025/09/23 11:20 PHST- 2025/05/15 00:00 [received] PHST- 2025/09/04 00:00 [accepted] PHST- 2025/11/01 21:22 [medline] PHST- 2025/09/23 12:47 [pubmed] PHST- 2025/09/23 11:20 [entrez] PHST- 2025/09/23 00:00 [pmc-release] AID - 10.1007/s12325-025-03373-7 [pii] AID - 3373 [pii] AID - 10.1007/s12325-025-03373-7 [doi] PST - ppublish SO - Adv Ther. 2025 Nov;42(11):5761-5780. doi: 10.1007/s12325-025-03373-7. Epub 2025 Sep 23. PMID- 40978169 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20250922 LR - 20250924 IS - 2772-8293 (Electronic) IS - 2772-8293 (Linking) VI - 4 IP - 4 DP - 2025 Nov TI - Mepolizumab for the management of chronic rhinosinusitis with nasal polyps across the United States: A retrospective study. PG - 100549 LID - 10.1016/j.jacig.2025.100549 [doi] LID - 100549 AB - BACKGROUND: Retrospective data are limited on the effectiveness of mepolizumab treatment that is reflective of real-world practice in patients with chronic rhinosinusitis with nasal polyps (CRSwNP). OBJECTIVE: We evaluated changes in administration of nasal polyp (NP)-related oral corticosteroids (OCS) and other treatments, exacerbations, sinus surgeries, NP-related health care resource utilization, and costs before and after mepolizumab initiation in patients with CRSwNP. METHODS: Retrospective cohort study using data from the Komodo Research database included adults with CRSwNP, without severe asthma, initiating mepolizumab therapy on or after July 29, 2021 (index date), with 12 months of continuous health care enrollment before index and >/=6 months after index. Treatment with reslizumab, benralizumab, or tezepelumab during the study period was excluded. Outcomes were compared pre- versus post-mepolizumab initiation for the overall population and on-label subgroup analysis. RESULTS: Mean number of NP-related OCS dispensings per patient per year (PPPY) (0.5 after vs 1.2 before therapy initiation), total mean OCS dose (119.1 vs 309.9 mg), mean daily OCS dose per period (0.3 vs 0.8 mg), and mean number of OCS bursts (0.3 vs 0.7) were significantly lower after versus before initiation, respectively (all P < .001). Numbers of patients requiring NP-related treatments significantly decreased (75.0% post vs 86.7% pre, P < .001). Mean number of NP-related exacerbations experienced by patients significantly reduced (1.6 PPPY pre vs 0.3 PPPY post). Mean number of sinus surgeries significantly reduced after initiation (annual rate ratio [95% confidence interval] 0.23 [0.13, 0.40], P < .001), as did rate of otolaryngologist visits PPPY, excluding mepolizumab administration visits (rate ratio 0.52 [95% confidence interval 0.43, 0.63], P < .001). CONCLUSION: In this first retrospective mepolizumab study for patients with CRSwNP without severe asthma, improvements in all outcomes were observed after mepolizumab initiation. CI - (c) 2025 The Authors. FAU - Cardet, Juan Carlos AU - Cardet JC AD - Department of Internal Medicine, Division of Allergy and Immunology, University of South Florida Morsani College of Medicine, Tampa, Fla. FAU - Silver, Jared AU - Silver J AD - US Medical Affairs-Respiratory, GSK, Durham, NC. FAU - Maldonado-Puebla, Martin AU - Maldonado-Puebla M AD - Department of Internal Medicine, Division of Allergy and Immunology, University of South Florida Morsani College of Medicine, Tampa, Fla. FAU - Laliberte, Francois AU - Laliberte F AD - Groupe d'analyse, Ltee, Montreal, Quebec, Canada. FAU - Gao, Chi AU - Gao C AD - Analysis Group Inc, Boston, Mass. FAU - Ramasubramanian, Ramya AU - Ramasubramanian R AD - Analysis Group Inc, Los Angeles, Calif. FAU - Hilts, Annalise AU - Hilts A AD - Groupe d'analyse, Ltee, Montreal, Quebec, Canada. FAU - Zhang, Kaixin AU - Zhang K AD - Groupe d'analyse, Ltee, Montreal, Quebec, Canada. FAU - Hwee, Jeremiah AU - Hwee J AD - Global Epidemiology, GSK, Mississauga, Ontario, Canada. FAU - Ahmed, Waseem AU - Ahmed W AD - Global Data Generation, GSK, London, United Kingdom. FAU - Edgecomb, Amy G AU - Edgecomb AG AD - Anti-Infectives and Respiratory Business, US Value, Evidence, and Outcomes, GSK, Philadelphia, Pa. LA - eng PT - Journal Article DEP - 20250731 PL - United States TA - J Allergy Clin Immunol Glob JT - The journal of allergy and clinical immunology. Global JID - 9918453488706676 PMC - PMC12444170 OTO - NOTNLM OT - Chronic rhinosinusitis with nasal polyps OT - claims-based data OT - costs OT - health care resource utilization OT - mepolizumab OT - nasal polyposis OT - nasal polyp-related treatments OT - oral corticosteroids OT - sinus surgery COIS- Funded by GSK (ID 218957). The sponsor was involved in study design and implementation, as well as data collection, analysis, interpretation, and writing and reviewing the study report. The sponsor did not place any restrictions on the authors' access to data or statements made in the report. All authors had full access to study data and had the final responsibility for the decision to submit for publication. Data-sharing statement: Data are owned by Komodo Research database and were accessed by GSK to address the prespecified research questions only. The data are available via Komodo data license. Disclosure of potential conflict of interest: J. C. Cardet reports receiving honoraria from Aiolosbio, Amgen, Apogee, 10.13039/100004325AstraZeneca, Chiesi, GSK, Genentech, and Sanofi for work on advisory boards and steering committees, and for educational lectures; and funding from the National Heart, Lung and Blood Institute (R21HL172124), the 10.13039/100002590American Lung Association/10.13039/100002567American Academy of Allergy, Asthma & Immunology Allergic Respiratory Diseases Award (AI-835475), a GSK investigator-initiated study grant, and the 10.13039/100001009Bristol Myers Squibb Foundation Winn Award. J. Silver was formerly employed by GSK and holds financial equities in GSK and is now employed by Amgen and holds financial equities in Amgen. F. Laliberte, C. Gao, R. Ramasubramanian, A. Hilts, and K. Zhang are employees of Analysis Group, a consulting company that received payment from GSK to conduct this study but did not receive payment for the report's development. J. Hwee, W. Ahmed, and A. G. Edgecomb are employed by GSK and hold financial equities in GSK. M. Maldonado-Puebla declares no relevant conflicts of interest. EDAT- 2025/09/22 12:47 MHDA- 2025/09/22 12:48 PMCR- 2025/07/31 CRDT- 2025/09/22 07:44 PHST- 2024/10/28 00:00 [received] PHST- 2025/05/28 00:00 [revised] PHST- 2025/06/09 00:00 [accepted] PHST- 2025/09/22 12:48 [medline] PHST- 2025/09/22 12:47 [pubmed] PHST- 2025/09/22 07:44 [entrez] PHST- 2025/07/31 00:00 [pmc-release] AID - S2772-8293(25)00150-X [pii] AID - 100549 [pii] AID - 10.1016/j.jacig.2025.100549 [doi] PST - epublish SO - J Allergy Clin Immunol Glob. 2025 Jul 31;4(4):100549. doi: 10.1016/j.jacig.2025.100549. eCollection 2025 Nov. PMID- 40975841 OWN - NLM STAT- MEDLINE DCOM- 20260110 LR - 20260508 IS - 1179-1896 (Electronic) IS - 1175-5652 (Print) IS - 1175-5652 (Linking) VI - 24 IP - 1 DP - 2026 Jan TI - Aligning Indigenous and Western Concepts of Health Resource Decision Making in a Western Canadian First Nations Context. PG - 163-179 LID - 10.1007/s40258-025-01004-4 [doi] AB - BACKGROUND: Western health economic evaluation tools often fail to reflect the relational, collective, and holistic perspectives that underpin Indigenous concepts of health. These limitations pose challenges when applying Western measures in Indigenous contexts. The individualistic foundation of the Western definition of health and the values that inform it are significantly different from the community-based values typically found in Canadian Indigenous communities. For health economics to effectively support Indigenous health decision making, a values-based approach should initially be undertaken to identify conceptual commonalities with Western perspectives. AIMS: This study aimed to develop a conceptual framework that identifies shared elements between Western and First Nations understandings of health resource decision making, with the goal of supporting the creation of culturally meaningful health outcome measures. METHODS: Through a Health Economics Technical Advisory Group (HE-TAG) in Alberta, Canada, co-led by Indigenous and non-Indigenous researchers, we conducted a conceptual exploration of health resource decision making. Fourteen HE-TAG sessions held between July 2021 and June 2023 were transcribed and analyzed using a hybrid approach-combining Q methodology, thematic analysis (Braun & Clarke), and Walker and Avant's concept analysis. DATA: Transcripts from 14 HE-TAG sessions provide the qualitative data upon which analysis was conducted. Sessions were held online using virtual meeting technology, and recordings were transcribed and analyzed. RESULTS: Indigenous and Western conceptual frameworks allow for a common understanding of health resourcing. Indigenous community and culture and Western economic evaluation and social determinants of health were the four main observed themes, each of which contained two subthemes which differentiated between concepts of 'health.' Five concepts were found to resonate between Indigenous and Western themes when exploring health resource thinking: values, holism, time, resources, and context. Concepts and themes were mapped to illustrate common approaches to understanding health resource decision making. CONCLUSIONS: This Indigenous-informed research aligns concepts of resource decision making by showing the thematic backgrounds of First Nations and Western thinking, which are linked by the common concepts of values, holism, time, resources, and context. Centering future community engagement on these shared concepts while grounding them in community-generated health value sets can advance the development of novel, culturally relevant health outcome measures. CI - (c) 2025. Crown. FAU - Neill, Aidan AU - Neill A AUID- ORCID: 0009-0009-2156-620X AD - School of Public Health, University of Alberta, Edmonton, Canada. aaneill@ualberta.ca. FAU - Montesanti, Stephanie AU - Montesanti S AUID- ORCID: 0000-0002-3284-5767 AD - School of Public Health, University of Alberta, Edmonton, Canada. AD - Collaborative Applied Research for Equity in Health Policy and Systems (CARE) Lab, School of Public Health, University of Alberta, Edmonton, Canada. FAU - Bill, Lea AU - Bill L AUID- ORCID: 0000-0002-5430-4902 AD - Alberta First Nations Information Governance Center, Calgary, Canada. FAU - Verstraeten, Barbara S E AU - Verstraeten BSE AUID- ORCID: 0000-0002-0539-8877 AD - School of Public Health, University of Alberta, Edmonton, Canada. AD - Collaborative Applied Research for Equity in Health Policy and Systems (CARE) Lab, School of Public Health, University of Alberta, Edmonton, Canada. FAU - Bell, Rhonda C AU - Bell RC AUID- ORCID: 0000-0002-4298-9641 AD - School of Public Health, University of Alberta, Edmonton, Canada. FAU - Oster, Richard T AU - Oster RT AUID- ORCID: 0000-0003-0657-9263 AD - Department of Agricultural, Food and Nutritional Sciences, University of Alberta, Edmonton, Canada. AD - Indigenous Wellness Core, Alberta Health Services, Edmonton, Canada. FAU - Ohinmaa, Arto AU - Ohinmaa A AUID- ORCID: 0000-0002-7094-1573 AD - School of Public Health, University of Alberta, Edmonton, Canada. FAU - Paulden, Mike AU - Paulden M AUID- ORCID: 0000-0002-0381-5980 AD - School of Public Health, University of Alberta, Edmonton, Canada. LA - eng GR - Team Grant: I-HeLTI Cohort Research Study/Canadian Institutes of Health Research (CA)/ PT - Journal Article DEP - 20250921 PL - New Zealand TA - Appl Health Econ Health Policy JT - Applied health economics and health policy JID - 101150314 SB - IM MH - Humans MH - Alberta MH - Canada MH - *Decision Making MH - *Health Resources MH - *Health Services, Indigenous MH - *Inuit MH - *Indigenous Canadians PMC - PMC12790536 COIS- Declarations. Data Availability Statement: The HE-TAG data that supports this study are available from the Collaborative Applied Research for Equity in Health Policy and Systems (CARE) Lab, but restrictions apply to the availability of these data. The data are, however, available from the authors upon reasonable request and with the permission of the CARE Lab. Conflicts of interest: The authors declare no conflicts of interest. Ethical approval: Ethics approval for Health Economics Technical Advisory Group under the I-HeLTI project is covered under Alberta Research Information Services (ARISE) ethics protocol number 97455, led by Principal Investigator Dr Stephanie Montesanti. The study is titled Restoring Healthy Family Systems in Indigenous Communities. This research was conducted in accordance with the Declaration of Helsinki [2] and Chapter 9 of the Tri-Council [3]. Consent to participate: Not applicable. Consent for publication: Not applicable. Code availability: Not applicable. Authors' contributions: This study was grounded in a community-based participatory research (CBPR) approach, co-developed with the Cree Nations of Maskwacis (CNM) and the five Cree and Dene Nations of the Regional Municipality of Wood Buffalo (CDNWB). Co-Principal Investigators Dr Stephanie Montesanti and Dr Richard Oster engaged regularly with these partner communities to guide the research process, ensuring that the work is informed by local priorities, Indigenous knowledge systems, and lived experience. The work was co-produced through iterative collaboration with members of the Canadian Institutes of Health Research (CIHR)-funded Indigenous Healthy Life Trajectories Initiative (I-HeLTI) Health Economics Technical Advisory Group (HE-TAG), established by Dr Montesanti, to support the development of culturally grounded economic evaluation methods for the CIHR-funded team cohort grant. Lea Bill, as a Co-Principal Investigator, guided the HE-TAG session discussions around topics of Indigenous knowledge based on her expertise as a Knowledge Keeper and speaker of the Cree language. Lea's perspective as recorded in session transcripts provided a rich source of cultural meaning. Dr Montesanti provided extensive conceptual framing, mentorship, critical review, and refinement of the manuscript. Dr Rhonda Bell, Dr Richard Oster, and Dr Barbara Verstraeten played active roles in HE-TAG sessions and the review of the manuscript. Dr Mike Paulden provided expertise as a senior health economist during all HE-TAG discussions. In his capacity as a senior health economist, Dr Arto Ohinmaa provided extensive editing of the manuscript and guidance, as a PhD supervisor to Dr Aidan Neill, who was a student at the time of this research. Dr Neill contributed knowledge of health economics during HE-TAG sessions. He also provided the overall vision for the data synthesis by conducting the conceptual and thematic analysis on the HE-TAG session transcripts. Dr Neill designed the framework, which is based upon the data. Authors' expertise: The strength of this work is grounded in the diverse and complementary expertise of the eight co-authors, whose leadership spans Indigenous health systems, health economics, community-based research, and policy development. Stephanie Montesanti is a nationally recognized expert in Indigenous health systems research, with specialized expertise in Indigenous research methodologies, systems thinking, health system integration, and intersectoral policy analysis. She is a Professor and Canada Research Chair in Health Systems Integration, leading the Collaborative Applied Research for Equity in Health Policy and Systems (CARE) Lab at the University of Alberta. As a Principal Investigator of the I-HeLTI Alberta team, Dr Montesanti provides strategic vision for advancing equity-centered and values-based approaches to health system transformation. Lea Bill is an Indigenous knowledge holder from the Cree Pelican Lake First Nation in Saskatchewan with thirty years of experience in community as a registered nurse. Lea is also Executive Director of the Alberta First Nations Information Governance Centre (AFNIGC) where she is also a project lead and research manager. Barbara S.E. Verstraeten holds a medical degree and a PhD in health sciences, with a focus on pregnancy, maternal, and child health, as well as the developmental origins of health and wellness. Barbara is a research associate in the CARE lab, supporting qualitative and quantitative data analysis for the I-HeLTI and other projects. Rhonda Bell is a professor of human nutrition in the Faculty of Agricultural, Life & Environmental Sciences at the University of Alberta. Rhonda is an expert in maternal and infant nutrition and health outcomes with a focus on the developmental origins of health and disease. Richard Oster is Scientific Director, Indigenous Wellness Core with the government of Alberta, and he has worked with and learned from Indigenous communities, particularly relating to engagement, collaboration, community-based participatory research, epidemiology, qualitative inquiry, intervention design, project management, knowledge translation, Indigenous ways of knowing, and Indigenous research ethics. Arto Ohinmaa is a professor of health economics at the University of Alberta with expertise in economic evaluation, health-related quality of life, health outcomes, cost-effectiveness analysis, and health services research. Mike Paulden has expertise in cost-effectiveness analysis and developing appropriate methods for the economic evaluation of health technologies. Mike is also interested in how social values can be integrated within the methods used for health economic evaluations. Aidan Neill is a recent PhD graduate in health services and policy research. Aidan is a resource professional and chartered professional accountant (CPA) who has worked in the Canadian federal policy space for over twenty years. EDAT- 2025/09/21 13:06 MHDA- 2026/01/10 22:40 PMCR- 2025/09/21 CRDT- 2025/09/21 11:02 PHST- 2025/03/01 00:00 [received] PHST- 2025/08/18 00:00 [accepted] PHST- 2026/01/10 22:40 [medline] PHST- 2025/09/21 13:06 [pubmed] PHST- 2025/09/21 11:02 [entrez] PHST- 2025/09/21 00:00 [pmc-release] AID - 10.1007/s40258-025-01004-4 [pii] AID - 1004 [pii] AID - 10.1007/s40258-025-01004-4 [doi] PST - ppublish SO - Appl Health Econ Health Policy. 2026 Jan;24(1):163-179. doi: 10.1007/s40258-025-01004-4. Epub 2025 Sep 21. PMID- 40975425 OWN - NLM STAT- MEDLINE DCOM- 20251211 LR - 20260331 IS - 1097-6833 (Electronic) IS - 0022-3476 (Linking) VI - 288 DP - 2026 Jan TI - Increase in Health Care Utilization of Texas Infants with Congenital Anomalies Following Senate Bill 8. PG - 114823 LID - S0022-3476(25)00364-6 [pii] LID - 10.1016/j.jpeds.2025.114823 [doi] AB - OBJECTIVE: To evaluate the impact of Texas Senate Bill 8 (SB8), which bans early abortion, on health care utilization of infants with congenital anomalies. STUDY DESIGN: The Texas Inpatient Public Use Data File was queried for inpatient encounters of Texas patients <1 year old between July 1, 2020, and June 30, 2023. Encounters were grouped as pre-SB8 (July 1, 2020-June 30, 2021) and post-SB8 (July 1, 2022-June 30, 2023). Descriptive statistics and bivariate analyses were used to compare rates of congenital anomaly admissions, mortality, length of stay, and hospital charges. RESULTS: Among 1 149 242 infant inpatient admissions, 204 580 were for patients with congenital anomalies. Post-SB8, the proportions of anomaly admissions increased from 17.1% to 19.0% (P < .0001). Mortality and length of stay of these admissions remained similar. However, total charges for congenital anomaly admissions increased by $1.89 billion to over $8.7 billion post-SB8 (P < .0001), accounting for 56.5% of all inpatient charges despite comprising a minority of admissions. CONCLUSIONS: Following SB8, inpatient admissions and charges for infants with congenital anomalies increased significantly. Although these patients represent a small proportion of admissions, their care accounts for a disproportionate share of hospital costs and increased by $1.89 billion following SB8. Future studies should explore outpatient costs and long-term outcomes following abortion restrictions. CI - Copyright (c) 2025 Elsevier Inc. All rights reserved. FAU - Peiffer, Sarah E AU - Peiffer SE AD - Department of Surgery, Baylor College of Medicine, Houston, TX. FAU - Guerra, Mary Elizabeth AU - Guerra ME AD - Department of Surgery, Baylor College of Medicine, Houston, TX. FAU - Hosek, Kathleen E AU - Hosek KE AD - Department of Quality Improvement, Texas Children's Hospital, Houston, TX. FAU - Larabee, Shannon M AU - Larabee SM AD - Department of Surgery, Baylor College of Medicine, Houston, TX; Division of Pediatric Surgery, Texas Children's Hospital, Houston, TX. FAU - Cheng, Lily S AU - Cheng LS AD - Department of Surgery, Division of Pediatric Surgery, University of Virginia Health, Charlottesville, VA. FAU - Keswani, Sundeep G AU - Keswani SG AD - Department of Surgery, Baylor College of Medicine, Houston, TX; Division of Pediatric Surgery, Texas Children's Hospital, Houston, TX. FAU - Lee, Timothy C AU - Lee TC AD - Department of Surgery, Baylor College of Medicine, Houston, TX; Division of Pediatric Surgery, Texas Children's Hospital, Houston, TX. FAU - King, Alice AU - King A AD - Department of Surgery, Baylor College of Medicine, Houston, TX; Division of Pediatric Surgery, Texas Children's Hospital, Houston, TX. Electronic address: alice.king@bcm.edu. LA - eng PT - Journal Article DEP - 20250918 PL - United States TA - J Pediatr JT - The Journal of pediatrics JID - 0375410 SB - IM MH - Humans MH - Texas/epidemiology MH - *Congenital Abnormalities/economics/therapy/epidemiology/mortality MH - Infant MH - Infant, Newborn MH - Female MH - Male MH - *Patient Acceptance of Health Care/statistics & numerical data MH - Length of Stay/statistics & numerical data MH - Retrospective Studies MH - Hospital Charges/statistics & numerical data MH - *Abortion, Legal/legislation & jurisprudence MH - Hospitalization/statistics & numerical data/economics OTO - NOTNLM OT - abortion OT - birth defects OT - cost OT - senate bill 8 COIS- Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2025/09/21 00:30 MHDA- 2025/12/11 07:42 CRDT- 2025/09/20 19:41 PHST- 2025/07/21 00:00 [received] PHST- 2025/08/28 00:00 [revised] PHST- 2025/09/11 00:00 [accepted] PHST- 2025/12/11 07:42 [medline] PHST- 2025/09/21 00:30 [pubmed] PHST- 2025/09/20 19:41 [entrez] AID - S0022-3476(25)00364-6 [pii] AID - 10.1016/j.jpeds.2025.114823 [doi] PST - ppublish SO - J Pediatr. 2026 Jan;288:114823. doi: 10.1016/j.jpeds.2025.114823. Epub 2025 Sep 18. PMID- 40961252 OWN - NLM STAT- MEDLINE DCOM- 20260707 LR - 20260707 IS - 2047-945X (Electronic) IS - 0260-1060 (Linking) VI - 32 IP - 4 DP - 2026 Jul TI - Intuitive eating and mindfulness during pre-pregnancy, pregnancy, and postpartum. PG - 1403-1408 LID - 10.1177/02601060251379529 [doi] AB - Background: The pre-gestational, gestational, and postpartum periods are marked by physiological, hormonal, and emotional changes that can significantly impact women's eating habits and behaviors. In this context, mindful eating and intuitive eating have emerged as promising strategies to promote a healthier relationship with food throughout these stages. Objectives: To investigate the practice of mindful eating and intuitive eating during the pre-gestational, gestational, and postpartum periods. Methodology: This longitudinal study was conducted with pregnant women receiving care in both the public and private healthcare systems in Lavras, Minas Gerais, Brazil. Data related to the pre-pregnancy period (retrospective) and pregnancy were collected in person between July 2019 and February 2020. Postpartum data were collected through telephone interviews from March 2020 to May 2021, due to social distancing measures imposed by the COVID-19 pandemic. Eating behavior was assessed using self-administered versions of the Mindful Eating Questionnaire (MEQ) and the Intuitive Eating Scale (IES). The MEQ was used to analyze mindful eating, and the IES was used to assess intuitive eating. Analysis of covariance was employed to compare the mean scores of eating behaviors across the different periods, followed by Bonferroni post hoc tests to identify significant differences. Data are presented as means and standard deviations. Results: The sample consisted of 103 participants (mean age 28.50 +/- 6.11 years). During pregnancy, women showed higher mean scores for intuitive eating (3.43 +/- 0.51) and mindful eating (2.69 +/- 0.35) compared to the pre-pregnancy period (3.36 +/- 0.55 and 2.59 +/- 0.34, respectively; p = 0.038 and p < 0.001). However, when comparing pregnancy to the postpartum period, a higher mean score for mindful eating was observed in the postpartum period (2.75 +/- 0.31; p < 0.001). Conclusion: Women showed greater engagement in intuitive and mindful eating during pregnancy compared to the pre-gestational period, and mindful eating behaviors were maintained postpartum. These findings suggest that maternal nutritional interventions can be enhanced by incorporating these approaches, fostering the development of self-regulation in eating and mind-body connection, which supports healthier and more sustainable food choices throughout the perinatal period. FAU - Ferreira Frois, Laudiceia AU - Ferreira Frois L AUID- ORCID: 0000-0002-8514-2600 AD - Postgraduate Program in Health and Nutrition (PPGSN), School of Nutrition, Federal University of Ouro Preto, Ouro Preto, Minas Gerais, Brazil. RINGGOLD: 495554 FAU - Lima de Oliveira, Joao Paulo AU - Lima de Oliveira JP AUID- ORCID: 0000-0002-9623-5474 AD - Faculty of Health Sciences, Department of Nutrition, Federal University of Lavras, Lavras, Minas Gerais, Brazil. FAU - Goncalves Teixeira, Lilian AU - Goncalves Teixeira L AUID- ORCID: 0000-0003-4682-8594 AD - Faculty of Health Sciences, Department of Nutrition, Federal University of Lavras, Lavras, Minas Gerais, Brazil. LA - eng PT - Journal Article DEP - 20250917 PL - England TA - Nutr Health JT - Nutrition and health JID - 8306569 SB - IM MH - Humans MH - Female MH - Pregnancy MH - Adult MH - *Postpartum Period/psychology MH - *Mindfulness MH - *Feeding Behavior/psychology MH - Longitudinal Studies MH - Brazil MH - Surveys and Questionnaires MH - Young Adult MH - Emotional Eating MH - COVID-19 OTO - NOTNLM OT - Eating behaviors OT - dietary restriction OT - emotional eating OT - hunger OT - maternal feeding OT - satiety COIS- Declaration of conflicting interestsThe authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. EDAT- 2025/09/17 18:31 MHDA- 2026/07/07 12:33 CRDT- 2025/09/17 14:23 PHST- 2026/07/07 12:33 [medline] PHST- 2025/09/17 18:31 [pubmed] PHST- 2025/09/17 14:23 [entrez] AID - 10.1177/02601060251379529 [doi] PST - ppublish SO - Nutr Health. 2026 Jul;32(4):1403-1408. doi: 10.1177/02601060251379529. Epub 2025 Sep 17. PMID- 40885974 OWN - NLM STAT- MEDLINE DCOM- 20250830 LR - 20250903 IS - 1471-2466 (Electronic) IS - 1471-2466 (Linking) VI - 25 IP - 1 DP - 2025 Aug 30 TI - Impact of COVID-19 and lockdown on outcomes of COPD patients in Turkey: lessons for the future. PG - 414 LID - 10.1186/s12890-025-03883-8 [doi] LID - 414 AB - BACKGROUND: The COVID-19 pandemic and related public health restrictions have substantially altered healthcare access and delivery, particularly for patients with chronic conditions such as chronic obstructive pulmonary disease (COPD). This study aimed to evaluate the impact of the COVID-19 pandemic and lockdown measures on COPD-related symptoms and hospital admissions, and to compare these outcomes with the pre-pandemic period. METHODS: This multicenter cross-sectional study was conducted between July 2021 and February 2022 across ten tertiary pulmonary outpatient clinics in Turkey. A total of 347 COPD patients were included. Data on demographics, spirometry, symptom progression, medication access, COVID-19 history, and hospital admissions were collected via structured questionnaire and medical records. Pandemic-related outcomes were compared with data from the pre-pandemic year (March 2019-March 2020). Additional multivariable regression analyses were performed to identify predictors of hospital admission and COVID-19-related hospitalization. RESULTS: The mean number of hospital admissions significantly decreased during the pandemic compared to the pre-pandemic period (p < 0.001), while patient-reported respiratory symptoms increased over time. Hospital admissions were lowest during the first pandemic period, when restrictions were most intense. Regression analyses showed that lower FEV(1), advanced GOLD stage, and inhaled corticosteroid (ICS) use were independently associated with increased hospital admissions. COVID-19 was diagnosed in 21.1% of patients. Lower FEV(1), GOLD stage, and smoking were significantly associated with COVID-19-related hospitalization. CONCLUSION: Although COPD-related hospital admissions decreased during the pandemic, respiratory symptoms progressively worsened. These findings reflect the complex interplay between public health measures, healthcare accessibility, and chronic disease management. Disease severity and airflow limitation were key determinants of adverse outcomes. Maintaining access to routine care and adopting personalized approaches in COPD management are essential during public health emergencies. CI - (c) 2025. The Author(s). FAU - Polat Yulug, Demet AU - Polat Yulug D AD - Faculty of Medicine, Department of Pulmonary Diseases, Mersin University, Mersin, Turkey. drdemetyulug@gmail.com. FAU - Sen, Elif AU - Sen E AD - Faculty of Medicine, Department of Pulmonary Diseases, Ankara University, Ankara, Turkey. FAU - Alpaydin, Aylin Ozgen AU - Alpaydin AO AD - Faculty of Medicine, Department of Pulmonary Diseases, Dokuz Eylul University, Izmir, Turkey. FAU - Nayci, Sibel AU - Nayci S AD - Faculty of Medicine, Department of Pulmonary Diseases, Mersin University, Mersin, Turkey. FAU - Ozgur, Eylem Sercan AU - Ozgur ES AD - Faculty of Medicine, Department of Pulmonary Diseases, Mersin University, Mersin, Turkey. FAU - Baydar Toprak, Oya AU - Baydar Toprak O AD - Faculty of Medicine, Department of Pulmonary Diseases, Cukurova University, Adana, Turkey. FAU - Sahin, Ahmet Melih AU - Sahin AM AD - Faculty of Medicine, Department of Pulmonary Diseases, Ankara University, Ankara, Turkey. FAU - Selcuk, Elif AU - Selcuk E AD - Faculty of Medicine, Department of Pulmonary Diseases, Ankara University, Ankara, Turkey. FAU - Yigit, Salih AU - Yigit S AD - Faculty of Medicine, Department of Pulmonary Diseases, Dokuz Eylul University, Izmir, Turkey. FAU - Elmas Uysal, Funda AU - Elmas Uysal F AD - Faculty of Medicine, Department of Pulmonary Diseases, Ege University, Izmir, Turkey. FAU - Gurgun, Alev AU - Gurgun A AD - Faculty of Medicine, Department of Pulmonary Diseases, Ege University, Izmir, Turkey. FAU - Kokturk, Nurdan AU - Kokturk N AD - Faculty of Medicine, Department of Pulmonary Diseases, Gazi University, Ankara, Turkey. FAU - Mammadova, Ayshan AU - Mammadova A AD - Faculty of Medicine, Department of Pulmonary Diseases Division of Critical Care Medicine, Gazi University, Ankara, Turkey. FAU - Varol, Yelda AU - Varol Y AD - Dr. Suat Seren Chest Diseases and Surgery Training, Research Hospital, Department of Pulmonary Diseases, University of Health Sciences, Izmir, Turkey. FAU - Baha, Ayse AU - Baha A AD - Department of Pulmonary Diseases, Near East University Hospital, Nicosia, Cyprus. FAU - Polatli, Mehmet AU - Polatli M AD - Faculty of Medicine, Department of Pulmonary Diseases, Adnan Menderes University, Aydin, Turkey. FAU - Yaz, Aybuke AU - Yaz A AD - Faculty of Medicine, Department of Pulmonary Diseases, Adnan Menderes University, Aydin, Turkey. FAU - Serifoglu Rahatli, Irem AU - Serifoglu Rahatli I AD - Department of Pulmonary Diseases, Ankara Bilkent City Hospital, Ankara, Turkey. FAU - Kocabas, Ali AU - Kocabas A AD - Faculty of Medicine, Department of Pulmonary Diseases, Cukurova University, Adana, Turkey. LA - eng PT - Journal Article PT - Multicenter Study DEP - 20250830 PL - England TA - BMC Pulm Med JT - BMC pulmonary medicine JID - 100968563 RN - 0 (Adrenal Cortex Hormones) SB - IM MH - Humans MH - *Pulmonary Disease, Chronic Obstructive/epidemiology/therapy/physiopathology MH - *COVID-19/epidemiology/prevention & control MH - Turkey/epidemiology MH - Male MH - Female MH - Cross-Sectional Studies MH - Middle Aged MH - Aged MH - *Hospitalization/statistics & numerical data/trends MH - SARS-CoV-2 MH - *Quarantine MH - Adrenal Cortex Hormones/therapeutic use PMC - PMC12398964 OTO - NOTNLM OT - Chronic obstructive pulmonary disease OT - Coronavirus disease 2019 OT - Hospital admission OT - Lockdown OT - Pandemic COIS- Declarations. Ethics approval and consent to participate: The study protocol was approved by the Ankara Faculty, Clinical Research Ethics Committee on 08.06.2021 with the decision number I5-362-21. All participating centers accepted this approval and provided official letters confirming their agreement to participate in the study. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests. EDAT- 2025/09/01 04:45 MHDA- 2025/09/01 04:46 PMCR- 2025/08/30 CRDT- 2025/08/30 23:36 PHST- 2025/05/11 00:00 [received] PHST- 2025/07/25 00:00 [accepted] PHST- 2025/09/01 04:46 [medline] PHST- 2025/09/01 04:45 [pubmed] PHST- 2025/08/30 23:36 [entrez] PHST- 2025/08/30 00:00 [pmc-release] AID - 10.1186/s12890-025-03883-8 [pii] AID - 3883 [pii] AID - 10.1186/s12890-025-03883-8 [doi] PST - epublish SO - BMC Pulm Med. 2025 Aug 30;25(1):414. doi: 10.1186/s12890-025-03883-8. PMID- 40828967 OWN - NLM STAT- MEDLINE DCOM- 20251001 LR - 20251001 IS - 2162-2906 (Electronic) IS - 1096-2247 (Linking) VI - 75 IP - 10 DP - 2025 Oct TI - Temporal dynamics between COVID-19 cases and particulate matter in Bangkok: Impact of lockdown policies on air quality and disease transmission. PG - 823-838 LID - 10.1080/10962247.2025.2547642 [doi] AB - This study investigates the relationship between COVID-19 transmission and ambient air pollution in Bangkok, Thailand, during multiple pandemic waves from January 2020 to January 2022. The objectives were to quantify correlations between COVID-19 cases and criteria air pollutants (PM(2.5), PM(10), CO, NO(2), O(3)) across pandemic phases, analyze relationship variations during different waves and control periods, delineate temporal and seasonal trends, and evaluate lockdown effects on disease transmission and air quality. We employed comprehensive time-series analysis using data from six air quality monitoring stations and daily COVID-19 case records. Air quality parameters were measured using reference-grade instrumentation including Beta-attenuation monitors for particulate matter, non-dispersive infrared spectroscopy for CO, chemiluminescence for NO(2), and ultraviolet photometry for O(3). Statistical analyses included Pearson correlation with Bonferroni correction, multiple linear regression with assumption verification, and Seasonal Autoregressive Integrated Moving Average (SARIMA) forecasting, stratified by seasonal variations, lockdown periods, and viral variant periods. During the first lockdown (March-June 2020), moderate positive correlations existed between COVID-19 cases and particulate matter (PM(2.5): r = 0.159; PM(10): r = 0.093), with both infection rates and pollution levels decreasing significantly (PM(2.5) declined 18.7%). During Delta variant prevalence (July-August 2021), correlations shifted negative (PM(2.5): r = -0.073; PM(10): r = -0.125), indicating variant dynamics superseded environmental influences. Multiple regression revealed nitrogen dioxide from vehicular sources as the primary PM(2.5) predictor (beta = 0.682, p < 0.001), explaining 72.4% of variation. Seasonal analysis showed particulate pollution peaked during winter months, with average PM(2.5) levels (36.54 +/- 18.73 mug/m(3)) exceeding WHO guidelines. This research demonstrates that Bangkok's air quality improvements during COVID-19 restrictions resulted primarily from reduced vehicular emissions rather than industrial changes, suggesting targeted traffic emission reduction strategies could substantially improve air quality while highlighting complex environmental-disease transmission relationships during pandemics.Implications: These findings argue for a multi‑faceted air‑quality strategy for Bangkok. Because vehicular emissions dominate, transportation measures should lead: accelerate electric‑vehicle adoption, expand high‑capacity public transit, and implement congestion pricing or low‑emission zones. Seasonal patterns justify tighter winter controls, when meteorology intensifies pollutant accumulation. The evolving association between air pollution and COVID‑19 highlights the need for integrated environmental‑health surveillance that adapts to shifting pandemic dynamics. Preparedness should explicitly incorporate environmental indicators during early outbreak phases, while acknowledging that their relative influence likely wanes as biological determinants-emerging variants, population immunity, and clinical management-become predominant over time and across successive epidemic waves. FAU - Prapassornpitaya, Phawichsak AU - Prapassornpitaya P AUID- ORCID: 0009-0003-4567-6880 AD - Department of Environmental Science, Chulalongkorn University, Bangkok, Thailand. FAU - Jinsart, Wanida AU - Jinsart W AUID- ORCID: 0000-0002-3415-6850 AD - Department of Environmental Science, Chulalongkorn University, Bangkok, Thailand. LA - eng PT - Journal Article DEP - 20250903 PL - United States TA - J Air Waste Manag Assoc JT - Journal of the Air & Waste Management Association (1995) JID - 9503111 RN - 0 (Particulate Matter) RN - 0 (Air Pollutants) SB - IM MH - *COVID-19/epidemiology/transmission MH - *Particulate Matter/analysis MH - Humans MH - *Air Pollution/analysis MH - Thailand/epidemiology MH - *Air Pollutants/analysis MH - Environmental Monitoring MH - *Quarantine MH - Seasons MH - SARS-CoV-2 EDAT- 2025/08/19 18:30 MHDA- 2025/10/01 12:30 CRDT- 2025/08/19 14:33 PHST- 2025/10/01 12:30 [medline] PHST- 2025/08/19 18:30 [pubmed] PHST- 2025/08/19 14:33 [entrez] AID - 10.1080/10962247.2025.2547642 [doi] PST - ppublish SO - J Air Waste Manag Assoc. 2025 Oct;75(10):823-838. doi: 10.1080/10962247.2025.2547642. Epub 2025 Sep 3. PMID- 40781305 OWN - NLM STAT- MEDLINE DCOM- 20250809 LR - 20250812 IS - 1472-6963 (Electronic) IS - 1472-6963 (Linking) VI - 25 IP - 1 DP - 2025 Aug 8 TI - How did health service utilization and delivery change during the COVID-19 pandemic? Frontline healthcare workers' perceptions from the Central African Republic, the Democratic Republic of Congo, and Bangladesh. PG - 1046 LID - 10.1186/s12913-025-13255-x [doi] LID - 1046 AB - BACKGROUND: Most countries experienced disruptions in essential health services since the beginning of the COVID-19 pandemic, with the risk and prioritization of COVID-19 leading to diversions of resources and health staff. Disruptions were particularly concerning in humanitarian and fragile settings due to pre-existing vulnerabilities. We investigated how healthcare workers (HCW) perceived changes in health service provision, and whether and how programmatic adaptations were introduced in three humanitarian settings. METHODS: Key informant interviews were conducted with 29, 39 and 54 frontline HCWs in the Central African Republic, the Democratic Republic of Congo, and Bangladesh, respectively. The interviews were coded by two authors using deductive and inductive coding. Data were organized in a framework, and thematic analysis was conducted to identify similarities and discrepancies across respondents and study sites. Data were collected between March and July 2021 in each country. RESULTS: HCWs' perceptions varied across services and countries. Most HCWs reported decreased consultations for maternal and newborn health, sexual reproductive health, communicable diseases, and community-based activities, with mixed perceptions across countries for vaccinations, nutrition, non-communicable diseases, and referrals. Reasons for reduced healthcare utilization included fear of contracting COVID-19 and receiving the COVID-19 vaccine, compliance with movement restrictions, financial barriers, and medication stockouts. Factors specific to humanitarian settings included insecurity, population displacement, presence of a technical partner, lack of medical equipment, and staff shortages. Infection prevention and control measures (i.e., patient triage, mask-wearing, physical distance, hand washing) were introduced in all countries. Other service adaptations included spaced out consultations, reduced group size, extended drug prescriptions, changes in nutrition protocols, telemedicine, and shift to COVID-19 focus during awareness activities. CONCLUSIONS: During the first year of the COVID-19 pandemic, HCWs reported varying healthcare utilization according to different services and contexts in three humanitarian settings. Program adaptations to address COVID-19 risks were introduced. Although guidance existed at the global level, contextual factors such as insecurity, displacement, and pre-existing capacity affected healthcare utilization and health service delivery more than the COVID-19 pandemic, especially in DRC and CAR, where the number of reported COVID-19 cases remained low for several months. CI - (c) 2025. The Author(s). FAU - Altare, Chiara AU - Altare C AD - Johns Hopkins Bloomberg School of Public Health, Baltimore, USA. chiara.altare@jhu.edu. AD - Johns Hopkins Center for Humanitarian Health, Baltimore, USA. chiara.altare@jhu.edu. FAU - Bates, Madison AU - Bates M AD - Johns Hopkins Bloomberg School of Public Health, Baltimore, USA. FAU - Crockett, Hannah AU - Crockett H AD - Johns Hopkins Bloomberg School of Public Health, Baltimore, USA. FAU - Gankpe, Gbetoho Fortune AU - Gankpe GF AD - Action contre la Faim, Bangui, Central African Republic. FAU - Hasan, Md Abul AU - Hasan MA AD - Action contre la Faim, Cox's Bazar, Bangladesh. FAU - Basadia, Linda Matadi AU - Basadia LM AD - Action contre la Faim, Kinshasa, Congo. FAU - Agbogan, Jogie Abucejo AU - Agbogan JA AD - Action contre la Faim, Cox's Bazar, Bangladesh. FAU - Petry, Marie AU - Petry M AD - Action contre la Faim, Kinshasa, Congo. FAU - Abaradine, Abdoul Azizi Almoustapha AU - Abaradine AAA AD - Action contre la Faim, Bangui, Central African Republic. FAU - Tonon, Brigitte AU - Tonon B AD - Action contre la Faim, Paris, France. FAU - Bruneau, Sophie AU - Bruneau S AD - Action contre la Faim, Paris, France. FAU - Antoine, Caroline AU - Antoine C AD - Action contre la Faim, Paris, France. FAU - Spiegel, Paul AU - Spiegel P AD - Johns Hopkins Bloomberg School of Public Health, Baltimore, USA. AD - Johns Hopkins Center for Humanitarian Health, Baltimore, USA. LA - eng GR - 720FDA20GR00228/United States Agency for International Development/ GR - 720FDA20GR00228/United States Agency for International Development/ GR - 720FDA20GR00228/United States Agency for International Development/ GR - 720FDA20GR00228/United States Agency for International Development/ GR - 720FDA20GR00228/United States Agency for International Development/ GR - 720FDA20GR00228/United States Agency for International Development/ GR - 720FDA20GR00228/United States Agency for International Development/ GR - 720FDA20GR00228/United States Agency for International Development/ GR - 720FDA20GR00228/United States Agency for International Development/ GR - 720FDA20GR00228/United States Agency for International Development/ GR - 720FDA20GR00228/United States Agency for International Development/ PT - Journal Article DEP - 20250808 PL - England TA - BMC Health Serv Res JT - BMC health services research JID - 101088677 SB - IM MH - Humans MH - *COVID-19/epidemiology MH - Democratic Republic of the Congo/epidemiology MH - Bangladesh/epidemiology MH - Female MH - *Health Personnel/psychology MH - Male MH - Adult MH - Central African Republic/epidemiology MH - SARS-CoV-2 MH - *Delivery of Health Care/organization & administration MH - *Attitude of Health Personnel MH - *Patient Acceptance of Health Care/statistics & numerical data MH - Middle Aged MH - Interviews as Topic MH - Qualitative Research MH - Pandemics PMC - PMC12335175 OTO - NOTNLM OT - Bangladesh OT - COVID-19 OT - Central African Republic OT - Democratic Republic of Congo OT - Health service delivery OT - Healthcare workers' perceptions OT - Humanitarian settings COIS- Declarations. Ethics approval and consent to participate: Ethical approval was obtained from the Johns Hopkins Bloomberg School of Public Health's Institutional Review Board. This work was determined non-human subject research (determination notice 14719) as qualitative interviews with HCWs were conducted in their professional capacity. National authorizations were obtained from the Ethical Committee of the School of Public Health of the University of Kinshasa (Letter ESP/CE/175/2020), Bangladesh's Medical Research Council (Ref: BMRC/NREC/2019-2022/125, dated March 4, 2021), and CAR's Ministry of Health and Population (Letter 065 MSP/DIRCAB/CTC-19/AA/20). Informed consent was obtained by each participant before the interview. No human participant or human tissue was used for this paper. All methods were carried out in accordance with relevant guidelines and regulations. Consent for publication: Not applicable, as no individual or identifiable information was used in the manuscript. Competing interests: The authors declare no competing interests. EDAT- 2025/08/09 13:48 MHDA- 2025/08/09 13:49 PMCR- 2025/08/08 CRDT- 2025/08/08 23:41 PHST- 2023/11/27 00:00 [received] PHST- 2025/07/19 00:00 [accepted] PHST- 2025/08/09 13:49 [medline] PHST- 2025/08/09 13:48 [pubmed] PHST- 2025/08/08 23:41 [entrez] PHST- 2025/08/08 00:00 [pmc-release] AID - 10.1186/s12913-025-13255-x [pii] AID - 13255 [pii] AID - 10.1186/s12913-025-13255-x [doi] PST - epublish SO - BMC Health Serv Res. 2025 Aug 8;25(1):1046. doi: 10.1186/s12913-025-13255-x. PMID- 40770626 OWN - NLM STAT- MEDLINE DCOM- 20250807 LR - 20250812 IS - 1471-2458 (Electronic) IS - 1471-2458 (Linking) VI - 25 IP - 1 DP - 2025 Aug 6 TI - One year on - the long-term impact of COVID-19 pandemic and government restrictions on the health-seeking behaviour, financial security and mental health of TB survivors. PG - 2660 LID - 10.1186/s12889-025-24006-2 [doi] LID - 2660 AB - BACKGROUND: People with tuberculosis (TB) may face long-term physical and psycho-social-economic disability related to TB treatment. The Corona Virus Disease 2019 (COVID-19) pandemic and government restrictions disrupted health care services. We describe health-seeking behaviour, perceived financial impact, and the mental health of TB survivors one year after the COVID-19 pandemic. We further explore factors associated with the perceived impact of COVID-19 and government restrictions on health-seeking behaviour. METHODS: This is a cross-sectional study nested in an ongoing observational TB Sequel cohort study. Adults (>/= 18yrs) who had completed treatment for drug-susceptible pulmonary TB in South Africa, the Gambia, and Mozambique before the start of the COVID-19 pandemic, completed a COVID-19 questionnaire which included the WHO tool for Behavioural Insights on COVID-19, the Kessler Psychological Distress Scale (K10) and Medical Outcomes Short Form Survey (SF-36) for health-related quality of life. Questionnaires were administered during scheduled TB Sequel follow-up study visits between 04/2021 and 10/2021. We used publicly available data on the number of COVID-19 cases and the start and end date of each wave to define country-specific COVID-19 "in-wave" and "out-of-wave" phases. We compared psycho-social and economic measures reported during these phases. In addition, we explored factors associated with poor health-seeking behaviour (comprised of moderate or serious impact) using logistic regression. RESULTS: Four hundred eighty seven TB survivors (69% male, median age 33 years IQR 25-42, median time since TB treatment completion 16 months IQR 13-27) completed the COVID-19 questionnaire. About a quarter of TB survivors reported that their financial status (n = 117; 24%) or their health-seeking behaviour for any health condition (n = 128; 26%) had been seriously impacted by COVID-19 and the governments' response. A third of patients (30.4%) reported using coping strategies. Logistic regression indicated that males, living with HIV and being on antiretroviral treatment (ART), being impacted financially during COVID-19, and experiencing social changes, were associated with poor health-seeking behaviour. CONCLUSION: Governments' response to COVID-19 affected TB survivors' healthcare-seeking behaviour, financial status and mental health. The long-term adverse effects on health-seeking behaviour are important for TB survivors who are at increased risk for recurrent disease and long-term disability in the first two years after treatment completion. TRIAL REGISTRATION: Clinical trial number: not applicable. CI - (c) 2025. The Author(s). FAU - Jinga, Nelly AU - Jinga N AD - Health Economics and Epidemiology Research Office, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. njinga@heroza.org. AD - School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. njinga@heroza.org. FAU - Hirasen, Kamban AU - Hirasen K AD - Health Economics and Epidemiology Research Office, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. AD - Health Economics Division, Faculty of Health Sciences, School of Public Health, University of Cape Town, Cape Town, South Africa. FAU - Ivanova, Olena AU - Ivanova O AD - Institute of Infectious Diseases and Tropical Medicine, LMU University Hospital, LMU Munich, Munich, Germany. FAU - Rachow, Andrea AU - Rachow A AD - Institute of Infectious Diseases and Tropical Medicine, LMU University Hospital, LMU Munich, Munich, Germany. AD - German Centre for Infection Research (DZIF), Partner Site Munich, Munich, Germany. AD - Unit Global Health, Helmholtz Zentrum Munchen, German Research Center for Environmental Health (HMGU), Neuherberg, Germany. FAU - Charalambous, Salome AU - Charalambous S AD - School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. AD - The Aurum Institute, Johannesburg, South Africa. FAU - Lonnroth, Knut AU - Lonnroth K AD - Department of Public Health Sciences, Karolinska Institute, Solna, Sweden. FAU - Moolla, Aneesa AU - Moolla A AD - Health Economics and Epidemiology Research Office, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. FAU - Rassool, Mohammed AU - Rassool M AD - Clinical HIV Research Unit, Department of Internal Medicine, School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. FAU - Evans, Denise AU - Evans D AD - Health Economics and Epidemiology Research Office, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. LA - eng PT - Journal Article PT - Observational Study DEP - 20250806 PL - England TA - BMC Public Health JT - BMC public health JID - 100968562 SB - IM MH - Humans MH - *COVID-19/epidemiology/psychology MH - Male MH - Female MH - Adult MH - Cross-Sectional Studies MH - *Patient Acceptance of Health Care/statistics & numerical data/psychology MH - Middle Aged MH - *Survivors/psychology/statistics & numerical data MH - *Mental Health/statistics & numerical data MH - Surveys and Questionnaires MH - *Tuberculosis/psychology MH - Pandemics PMC - PMC12326666 OTO - NOTNLM OT - COVID-19 OT - COVID-19 pandemic OT - Health-seeking behaviour OT - TB COIS- Declarations. Ethics approval and consent to participate: This study is performed in accordance with the study protocol, the Declaration of Helsinki (October 2013) and the WHO Handbook for Good Clinical Research Practice (July 2002) as well as other applicable national and other regulatory guidelines. This study was reviewed and approved by all respective Ethics Committees' at each study site as well as for coordinating institutions [17]. All participants enrolled in the TB Sequel study provided written informed consent. Participants were assigned a unique study identification number for identification purposes, and all electronic data extracted from the clinical data management system were de-identified. The surveys used in this analysis were conducted at visits where patients were reimbursed. Competing interests: The authors declare no competing interests. EDAT- 2025/08/07 06:27 MHDA- 2025/08/07 06:28 PMCR- 2025/08/06 CRDT- 2025/08/07 00:40 PHST- 2024/12/10 00:00 [received] PHST- 2025/07/15 00:00 [accepted] PHST- 2025/08/07 06:28 [medline] PHST- 2025/08/07 06:27 [pubmed] PHST- 2025/08/07 00:40 [entrez] PHST- 2025/08/06 00:00 [pmc-release] AID - 10.1186/s12889-025-24006-2 [pii] AID - 24006 [pii] AID - 10.1186/s12889-025-24006-2 [doi] PST - epublish SO - BMC Public Health. 2025 Aug 6;25(1):2660. doi: 10.1186/s12889-025-24006-2. PMID- 40759970 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250807 IS - 0778-7367 (Print) IS - 2049-3258 (Electronic) IS - 0778-7367 (Linking) VI - 83 IP - 1 DP - 2025 Aug 4 TI - Long-term impact of the COVID-19 pandemic on physical activity and estimated cardiorespiratory fitness in south American adults: a multi-country cross-sectional online survey. PG - 203 LID - 10.1186/s13690-025-01664-7 [doi] LID - 203 AB - BACKGROUND: Restriction measures during the COVID-19 pandemic may have reduced opportunities to engage in physical activity. This study explored the changes in self-reported physical activity level (PAL), risk factors, and estimated cardiorespiratory fitness (eCRF) among south American adults by comparing data reflecting the pre-pandemic period to data collected during the survey. METHODS: We conducted a cross-sectional online survey between July 2021 through March 2022 using validated questionnaires (e.g., GPAQ and WHO-STEPS) on a convenience sample of 1,934 adults (68.7% women) from Argentina (n = 484), Brazil (n = 405), Chile (n = 279), Colombia (n = 343) and Uruguay (n = 423). We compared self-reported PAL, risk factors, and eCRF before the pandemic period and at the time of the survey (mean 842 days from the first reported case in each country). Data were presented as medians (interquartile range [IQR]) or means (95% confidence interval [CI]) for continuous variables and percentages for categorical ones. Paired data analyses were conducted using paired t-tests, Wilcoxon Signed Rank test, and McNamar's tests, as applicable. RESULTS: We observed a decrease in PAL at work (median, 0 METs/min/week and interquartile range, [0-240] vs. 0 METs/min/week [0-30]; p = 0.032) and active transportation domains (0 METs/min/week [0-693] vs. 0 METs/min/week [0-594]; p = 0.008). In addition, the median sedentary time on weekdays increased by 60 min/day (360 [240-540] vs 420 [240-600]; p < 0.001). We also observed an increase in the proportion of participants with hypertension (12.9 vs. 16.5%), diabetes (6.8 vs. 9.8%), dyslipidemia (18.9 to 24%), depression symptoms (14.4 to 15.4%) and obesity (15.4 to 18.2%) compared with pre-pandemic levels (all p-values < 0.05). The eCRF was significantly lower at the survey time compared with pre-pandemic levels (mean difference, -1.17 mL/min/kg (or 3.34%): 95% CI, -1.03 to -1.30) even after adjusting for age (-0.50 mL/min/kg (or 1.45%): 95% CI -0.37 to -0.64). CONCLUSIONS: Across five countries in South America, social restriction policies to control the COVID-19 pandemic may have reduced physical activity and estimated cardiorespiratory fitness with no recovery until the survey time. CI - (c) 2025. The Author(s). FAU - Dourado, Victor Zuniga AU - Dourado VZ AD - Department of Human Movement Sciences, Federal University of Sao Paulo (UNIFESP), Santos, Sao Paulo, Brazil. victor.dourado@unifesp.br. AD - Lown Scholars in the Bernard Lown Scholars in Cardiovascular Health Program at Harvard T.H. Chan School of Public Health, Boston, MA, USA. victor.dourado@unifesp.br. FAU - Morais Pereira Simoes, Maria do Socorro AU - Morais Pereira Simoes MDS AD - Department of Human Movement Sciences, Federal University of Sao Paulo (UNIFESP), Santos, Sao Paulo, Brazil. FAU - Lauria, Vinicius Tonon AU - Lauria VT AD - Department of Human Movement Sciences, Federal University of Sao Paulo (UNIFESP), Santos, Sao Paulo, Brazil. FAU - Gulayin, Pablo AU - Gulayin P AD - Department of Research in Chronic Diseases, Institute for Clinical Effectiveness and Health Policy (IECS), Buenos Aires, Argentina. AD - Catedra de Salud Publica, Facultad de Ciencias Medicas, Universidad Nacional de La Plata, Buenos Aires, Argentina. AD - Lown Scholars in the Bernard Lown Scholars in Cardiovascular Health Program at Harvard T.H. Chan School of Public Health, Boston, MA, USA. FAU - Gutierrez, Laura AU - Gutierrez L AD - Department of Research in Chronic Diseases, Institute for Clinical Effectiveness and Health Policy (IECS), Buenos Aires, Argentina. FAU - Pena-Silva, Ricardo AU - Pena-Silva R AD - College of Medicine, Universidad de los Andes, Bogota, Colombia. AD - Lown Scholars in the Bernard Lown Scholars in Cardiovascular Health Program at Harvard T.H. Chan School of Public Health, Boston, MA, USA. FAU - Pereyra-Gonzalez, Isabel AU - Pereyra-Gonzalez I AD - Faculty of Health Sciences, Catholic University of Maule, Curico, Chile. AD - Lown Scholars in the Bernard Lown Scholars in Cardiovascular Health Program at Harvard T.H. Chan School of Public Health, Boston, MA, USA. FAU - Ortiz, Alfonsina AU - Ortiz A AD - Department of Wellness and Health, Catholic University of Uruguay, Montevideo, Uruguay. FAU - Lopez-Arana, Sandra AU - Lopez-Arana S AD - School of Nutrition and Dietetics, Faculty of Medicine, Finis Terrae University, Santiago, Chile. AD - Department of Nutrition, Faculty of Medicine, University of Chile, Santiago, Chile. AD - Lown Scholars in the Bernard Lown Scholars in Cardiovascular Health Program at Harvard T.H. Chan School of Public Health, Boston, MA, USA. FAU - Widyahening, Indah Suci AU - Widyahening IS AD - Department of Community Medicine, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia. AD - Lown Scholars in the Bernard Lown Scholars in Cardiovascular Health Program at Harvard T.H. Chan School of Public Health, Boston, MA, USA. FAU - Al-Shaar, Laila AU - Al-Shaar L AD - Department of Public Health Sciences, College of Medicine, Penn State University, Pennsylvania, PA, USA. AD - Lown Scholars in the Bernard Lown Scholars in Cardiovascular Health Program at Harvard T.H. Chan School of Public Health, Boston, MA, USA. FAU - Danaei, Goodarz AU - Danaei G AD - Department of Global Health, Harvard T.H. School of Public Health, Boston, MA, USA. AD - Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA. FAU - Poggio, Rosana AU - Poggio R AD - Department of Research in Chronic Diseases, Institute for Clinical Effectiveness and Health Policy (IECS), Buenos Aires, Argentina. AD - Lown Scholars in the Bernard Lown Scholars in Cardiovascular Health Program at Harvard T.H. Chan School of Public Health, Boston, MA, USA. CN - On behalf of Lown Scholars in Physical Activity and Fitness Network (PA&FIT) LA - eng GR - 2011/07282-6/Fundacao de Amparo a Pesquisa do Estado de Sao Paulo/ GR - 2011/07282-6/Fundacao de Amparo a Pesquisa do Estado de Sao Paulo/ GR - 2011/07282-6/Fundacao de Amparo a Pesquisa do Estado de Sao Paulo/ PT - Journal Article DEP - 20250804 PL - England TA - Arch Public Health JT - Archives of public health = Archives belges de sante publique JID - 9208826 PMC - PMC12323014 OTO - NOTNLM OT - V O2max OT - Cardiovascular risk OT - Coronavirus OT - Exercise OT - SARS-Cov-2 COIS- Declarations. Ethics approval and consent to participate: The present Multi-country Study was approved by all the local Ethics Committees: Comite de Etica em Pesquisa com Seres Humano da Universidade Federal de Sao Paulo (UNIFESP), Brazil (#5.453.598), Comitede Bioetica e Etica de la Investigacion de Catedra de Salud Publica, Facultad de Ciencias Medicas, Universidad Nacional de La Plata, Argentina (Ref. 116); Comite de Etica em Investigacion con Seres Humanos de la Universidad de Chile, Facultad de Medicina, Chile (#020-2022/053), Comite de Etica de la Investigaon de la Facultad de Medicina, de la Universidad de los Andes, Colombia (#20220703), and El Comite de Etica en Investigacion con Seres Humanos de la Universidad Catolica del Uruguay, Uruguay (#20/05/2022), following the Declaration of Helsinki. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests. EDAT- 2025/08/05 00:30 MHDA- 2025/08/05 00:31 PMCR- 2025/08/04 CRDT- 2025/08/04 23:35 PHST- 2025/03/17 00:00 [received] PHST- 2025/06/17 00:00 [accepted] PHST- 2025/08/05 00:31 [medline] PHST- 2025/08/05 00:30 [pubmed] PHST- 2025/08/04 23:35 [entrez] PHST- 2025/08/04 00:00 [pmc-release] AID - 10.1186/s13690-025-01664-7 [pii] AID - 1664 [pii] AID - 10.1186/s13690-025-01664-7 [doi] PST - epublish SO - Arch Public Health. 2025 Aug 4;83(1):203. doi: 10.1186/s13690-025-01664-7. PMID- 40716833 OWN - NLM STAT- MEDLINE DCOM- 20250729 LR - 20251208 IS - 1532-3390 (Electronic) IS - 1532-3382 (Linking) VI - 25 IP - 3 DP - 2025 Sep TI - THE ROLE OF OZONE THERAPY IN THE TREATMENT OF TEMPOROMANDIBULAR DISORDERS: A SYSTEMATIC REVIEW. PG - 102127 LID - S1532-3382(25)00042-9 [pii] LID - 10.1016/j.jebdp.2025.102127 [doi] AB - BACKGROUND: Temporomandibular disorders (TMD) refer to a range of conditions affecting the temporomandibular joints (TMJ), masticatory muscles, and related structures, bothering around 12% of the population. This systematic review aims to answer whether ozone therapy effectively reduces TMD-related symptoms. METHODS: A systematic electronic search of 6 databases was conducted on July 15th, 2021, and updated on November 17th, 2023. Only clinical trials published in Portuguese, English, or Spanish were selected, with no restriction to the year of publication. Animal studies, retrospective studies, case reports, review papers, meta-analysis, and ozone therapy applications outside the orofacial region were excluded. The risk of bias analysis was performed following the Cochrane Collaboration tool, RoB 2. RESULTS: Of the 315 articles identified in the search, only 7 studies were included in this review. Two studies were considered low risk of bias, 2 with some concerns, and 3 as high risk of bias. Ozone therapy, applied to both articular and muscular TMDs, has been shown to reduce pain intensity and palpatory pain, and improve pressure pain thresholds and mandibular range of motion. CONCLUSION: Ozone therapy emerges as a potential therapy for reducing TMD-related symptoms. However, the current evidence lacks robustness, and further high-quality randomized controlled trials are necessary to enhance the existing evidence base. CI - Copyright (c) 2025 Elsevier Inc. All rights reserved. FAU - Machado, Tassia T AU - Machado TT AD - Department of Functional and Structural Biology, Institute of Biology - Pain Studies Laboratory, State University of Campinas (UNICAMP), Campinas, Sao Paulo, Brazil; Egas Moniz Center for Interdisciplinary Research (CiiEM), Egas Moniz School of Health & Science, Caparica, Almada, Portugal. Electronic address: tassiatillemont@gmail.com. FAU - Machado, Ana Carolina S AU - Machado ACS AD - Department of Functional and Structural Biology, Institute of Biology - Pain Studies Laboratory, State University of Campinas (UNICAMP), Campinas, Sao Paulo, Brazil. FAU - Poluha, Rodrigo L AU - Poluha RL AD - Department of Dentistry, State University of Maringa, Maringa, Parana, Brazil. FAU - Proenca, Leilane S AU - Proenca LS AD - Department of Dentistry, Inga University Center - (UNINGA), Maringa, Parana, Brazil. FAU - Christidis, Nikolaos AU - Christidis N AD - Division of Oral Rehabilitation, Department of Dental Medicine, Karolinska Institutet, and the Scandinavian Network for Orofacial Neurosciences (SCON), Huddinge, Sweden. FAU - Parada, Carlos A AU - Parada CA AD - Department of Functional and Structural Biology, Institute of Biology - Pain Studies Laboratory, State University of Campinas (UNICAMP), Campinas, Sao Paulo, Brazil. FAU - Canales, Giancarlo De la Torre AU - Canales GT AD - Department of Dentistry, Inga University Center - (UNINGA), Maringa, Parana, Brazil; Egas Moniz Center for Interdisciplinary Research (CiiEM), Egas Moniz School of Health & Science, Caparica, Almada, Portugal; Division of Oral Rehabilitation, Department of Dental Medicine, Karolinska Institutet, and the Scandinavian Network for Orofacial Neurosciences (SCON), Huddinge, Sweden. FAU - Tambeli, Claudia H AU - Tambeli CH AD - Department of Functional and Structural Biology, Institute of Biology - Pain Studies Laboratory, State University of Campinas (UNICAMP), Campinas, Sao Paulo, Brazil. LA - eng PT - Journal Article PT - Systematic Review DEP - 20250222 PL - United States TA - J Evid Based Dent Pract JT - The journal of evidence-based dental practice JID - 101083101 RN - 66H7ZZK23N (Ozone) SB - IM MH - *Ozone/therapeutic use MH - Humans MH - *Temporomandibular Joint Disorders/therapy/drug therapy MH - Range of Motion, Articular OTO - NOTNLM OT - Myofascial pain syndrome OT - Ozone therapy OT - Systematic review OT - Temporomandibular disorders OT - Temporomandibular joint disorder EDAT- 2025/07/29 04:06 MHDA- 2025/07/29 18:32 CRDT- 2025/07/27 20:55 PHST- 2024/09/17 00:00 [received] PHST- 2025/01/20 00:00 [revised] PHST- 2025/02/18 00:00 [accepted] PHST- 2025/07/29 18:32 [medline] PHST- 2025/07/29 04:06 [pubmed] PHST- 2025/07/27 20:55 [entrez] AID - S1532-3382(25)00042-9 [pii] AID - 10.1016/j.jebdp.2025.102127 [doi] PST - ppublish SO - J Evid Based Dent Pract. 2025 Sep;25(3):102127. doi: 10.1016/j.jebdp.2025.102127. Epub 2025 Feb 22. PMID- 40711626 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260626 LR - 20260626 IS - 2194-7899 (Print) IS - 2194-7899 (Electronic) IS - 2194-7899 (Linking) VI - 13 IP - 1 DP - 2025 Jul 25 TI - Overdose education and naloxone distribution in jails: Examining the impact of the Communities That HEAL intervention in 4 states. PG - 47 LID - 10.1186/s40352-025-00353-5 [doi] LID - 47 AB - BACKGROUND: Opioid-related overdose is the leading cause of mortality among individuals recently released from incarceration in the U.S. Naloxone is an FDA-approved opioid antagonist medication designed to rapidly reverse opioid overdose. Despite evidence of its acceptability and effectiveness at reducing the risk of opioid overdose death after release from incarceration, only an estimated 25% of US jails provide naloxone upon release. This study examines the effectiveness of the HEALing Communities Study (HCS) Communities That HEAL (CTH) intervention on enhancing access to overdose education and naloxone distribution (OEND) in participating jails in Kentucky, New York, Massachusetts, and Ohio. METHODS: Communities were randomized to intervention (n = 34) or wait-list control (n = 33) arms stratified by state. Jail-based surveys (n = 59) were implemented at three time points during 2019 to 2022. Generalized linear mixed models (GLMM) with imputation captured intervention effects during the evaluation period (July 1, 2021-June 30, 2022). Interpretation of results was informed by the Practical, Robust Implementation and Sustainability Model framework. RESULTS: The CTH intervention was significantly associated with the hypothesized outcome, resulting in a greater number of jails providing overdose education (H1, relative riskAdj = 1.51 [95% CI: 1.09, 2.08], p = 0.013) and the number of jails providing naloxone upon release (H2, relative riskAdj = 1.49 [95% CI: 1.05, 2.13)], p = 0.027). External factors related to OEND implementation, such as correctional health care models, available resources, and state COVID restrictions, varied across communities. CONCLUSIONS: The CTH intervention engaging community coalitions to deploy evidence-based practices was effective in increasing OEND implementation in jails, helping address elevated overdose risks for individuals during and post-release from incarceration. Partnerships between state, community, and jail-based stakeholders are needed to assure expanded access to this lifesaving, evidence-based approach. FAU - Hunt, Timothy AU - Hunt T AD - Columbia University School of Social Work, New York, USA. th2258@columbia.edu. FAU - Oser, Carrie B AU - Oser CB AD - Department of Behavioral Science, Center on Drug & Alcohol Research, Center for Health, Engagement and Transformation, University of Kentucky, Lexington, USA. FAU - Friedmann, Peter D AU - Friedmann PD AD - Baystate Health and University of Massachusetts Chan Medical School- Baystate, Springfield, USA. FAU - Mack, Nicole AU - Mack N AD - RTI International, Durham, USA. FAU - Balvanz, Peter AU - Balvanz P AD - General Internal Medicine, Boston Medical Center, Boston, USA. FAU - Freisthler, Bridget AU - Freisthler B AD - Ohio State University, Columbus, USA. FAU - Chandler, Redonna K AU - Chandler RK AD - National Institutes of Health, Bethesda, USA. FAU - Hochstatter, Karli AU - Hochstatter K AD - Friends Research Institute, Baltimore, USA. FAU - Harris, Daniel R AU - Harris DR AD - College of Pharmacy, University of Kentucky, Lexington, USA. FAU - Glasgow, LaShawn AU - Glasgow L AD - RTI International, Durham, USA. FAU - D'Costa, Lauren AU - D'Costa L AD - RTI International, Durham, USA. FAU - Russo, Mary R AU - Russo MR AD - Columbia University School of Social Work, New York, USA. FAU - Eggleston, Barry AU - Eggleston B AD - RTI International, Durham, USA. FAU - Aldridge, Arnie AU - Aldridge A AD - RTI International, Durham, USA. FAU - Bellair, Paul AU - Bellair P AD - Ohio State University, Columbus, USA. FAU - Cogan, Allyson G AU - Cogan AG AD - General Internal Medicine, Boston Medical Center, Boston, USA. FAU - David, James L AU - David JL AD - Columbia University School of Social Work, New York, USA. FAU - El-Bassel, Nabila AU - El-Bassel N AD - Columbia University School of Social Work, New York, USA. FAU - Goddard-Eckrich, Dawn AU - Goddard-Eckrich D AD - Columbia University School of Social Work, New York, USA. FAU - Gomori, Steve AU - Gomori S AD - RTI International, Durham, USA. FAU - Hagan, Holly AU - Hagan H AD - New York University, New York, USA. FAU - Hanson, Steve AU - Hanson S AD - All Rise Treatment Court Institute, Alexandria, Virginia, USA. FAU - Holloway, JaNae AU - Holloway J AD - RTI International, Durham, USA. FAU - Kinnard, Elizabeth N AU - Kinnard EN AD - General Internal Medicine, Boston Medical Center, Boston, USA. FAU - Knott, Charlie AU - Knott C AD - RTI International, Durham, USA. FAU - Konstan, Michael W AU - Konstan MW AD - Case Western Reserve University, Cleveland, USA. FAU - Walsh, Sharon L AU - Walsh SL AD - Department of Behavioral Science, Center on Drug & Alcohol Research, Center for Health, Engagement and Transformation, University of Kentucky, Lexington, USA. FAU - LeBaron, Patricia A AU - LeBaron PA AD - RTI International, Durham, USA. FAU - Lyons, Michael S AU - Lyons MS AD - Ohio State University, Columbus, USA. FAU - McGladrey, Margaret AU - McGladrey M AD - Department of Behavioral Science, Center on Drug & Alcohol Research, Center for Health, Engagement and Transformation, University of Kentucky, Lexington, USA. FAU - Papp, Joan AU - Papp J AD - Case Western Reserve University, Cleveland, USA. FAU - Murphy, Sean M AU - Murphy SM AD - Weill Cornell Medical College, New York, USA. FAU - Springer, Sandra AU - Springer S AD - Yale School of Medicine, New Haven, USA. FAU - Oga, Emmanuel AU - Oga E AD - RTI International, Durham, USA. FAU - Staton, Michele AU - Staton M AD - Department of Behavioral Science, Center on Drug & Alcohol Research, Center for Health, Engagement and Transformation, University of Kentucky, Lexington, USA. FAU - Schady, Elizabeth AU - Schady E AD - Health Research, Inc., New York, USA. FAU - Montero, Fernando AU - Montero F AD - Columbia University School of Social Work, New York, USA. FAU - Surratt, Hilary L AU - Surratt HL AD - Department of Behavioral Science, Center on Drug & Alcohol Research, Center for Health, Engagement and Transformation, University of Kentucky, Lexington, USA. FAU - Stevens-Watkins, Danelle AU - Stevens-Watkins D AD - Department of Behavioral Science, Center on Drug & Alcohol Research, Center for Health, Engagement and Transformation, University of Kentucky, Lexington, USA. FAU - Winhusen, John AU - Winhusen J AD - University of Cincinnati College of Medicine, Cincinnati, USA. FAU - Zarkin, Gary A AU - Zarkin GA AD - RTI International, Durham, USA. FAU - Hamilton, Greer A AU - Hamilton GA AD - School of Social Work, University of Michigan, Ann Arbor, USA. FAU - Sprunger, Joel G AU - Sprunger JG AD - University of Cincinnati College of Medicine, Cincinnati, USA. LA - eng GR - UM1 DA049394/DA/NIDA NIH HHS/United States GR - UM1 DA049415/DA/NIDA NIH HHS/United States GR - UM1DA049394/DA/NIDA NIH HHS/United States GR - UM1DA049417/DA/NIDA NIH HHS/United States GR - UM1 DA049412/DA/NIDA NIH HHS/United States GR - UM1 DA049417/DA/NIDA NIH HHS/United States GR - UM1 DA049406/DA/NIDA NIH HHS/United States PT - Journal Article DEP - 20250725 PL - England TA - Health Justice JT - Health & justice JID - 101626355 PMC - PMC12296605 OTO - NOTNLM OT - Carceral settings OT - Jail OT - Naloxone distribution OT - Opioid epidemic OT - Overdose education COIS- Declarations. Ethics approval and consent to participate: This study protocol (Pro00038088) was approved by Advarra Inc., the HEALing Communities Study Single Institutional Review Board. Consent to participate was not required by the Advarra IRB for this project because it is an analysis of implementation at the community and agency level rather than at the individual human participant level. Consent for publication: Not applicable. Competing interests: Author Dr. Sandra Springer has provided paid scientific consultation to Alkermes Inc and has received in-kind study drug donations from Alkermes Inc and Indivior Pharmaceutical Company for NIH-funded research. EDAT- 2025/07/25 12:32 MHDA- 2025/07/25 12:33 PMCR- 2025/07/25 CRDT- 2025/07/25 11:18 PHST- 2024/12/24 00:00 [received] PHST- 2025/06/30 00:00 [accepted] PHST- 2025/07/25 12:33 [medline] PHST- 2025/07/25 12:32 [pubmed] PHST- 2025/07/25 11:18 [entrez] PHST- 2025/07/25 00:00 [pmc-release] AID - 10.1186/s40352-025-00353-5 [pii] AID - 353 [pii] AID - 10.1186/s40352-025-00353-5 [doi] PST - epublish SO - Health Justice. 2025 Jul 25;13(1):47. doi: 10.1186/s40352-025-00353-5. PMID- 40708108 OWN - NLM STAT- MEDLINE DCOM- 20250725 LR - 20260614 IS - 1742-6723 (Electronic) IS - 1742-6731 (Print) IS - 1742-6723 (Linking) VI - 37 IP - 4 DP - 2025 Aug TI - The Impact of the COVID-19 Pandemic on Cardiac Related Emergency Department Presentations in Queensland: A Retrospective Cohort Study. PG - e70096 LID - 10.1111/1742-6723.70096 [doi] LID - e70096 AB - OBJECTIVE: To (i) describe and compare rates, demographics, ED characteristics and outcomes for cardiac-related presentations to Queensland EDs before, during and after periods of government restrictions, (ii) determine if and which cardiac conditions were impacted by COVID-19 restrictions. METHODS: Retrospective cohort study of all adult presentations in 105 Queensland public EDs who were diagnosed with a cardiac condition or chest pain. Four periods were compared: 'pre-pandemic' (January 2018-March 2020), 'statewide restrictions' (11 March-30 June 2020), 'easing of restrictions' (1 July 2020-12 December 2021) and 'outbreak' (13 December 2021-30 June 2022). ED presentation rates (per 10,000 person-years) and incident rate ratios were calculated for chest pain, ischaemic heart disease, arrhythmias, heart failure, inflammatory conditions, cardiac arrest, and 'other' acute cardiac conditions. Proportions of presentations by demographic group, ED characteristics and outcomes were also compared. RESULTS: The study included 609,485 acute cardiac-related presentations. All-cause acute cardiac presentations decreased by 4% from 'pre-pandemic' to 'statewide restrictions', then increased by 20% and 25% in the 'easing of restrictions' and 'outbreak' periods, respectively. Ischaemic heart disease presentation rates decreased during 'statewide restrictions'. Weekly chest pain presentations dropped early during 'statewide restrictions' but increased in each consecutive period. Weekly heart failure presentations appeared to follow seasonal patterns. Compared to 'statewide restrictions', inflammatory presentations increased during 'easing of restrictions' and 'outbreak' periods. CONCLUSIONS: The COVID-19 pandemic impacted acute cardiac-related ED presentations in Queensland in various ways. Public health messaging for people to seek timely medical care for urgent conditions and symptoms should be emphasised in future pandemics. CI - (c) 2025 The Author(s). Emergency Medicine Australasia published by John Wiley & Sons Australia, Ltd on behalf of Australasian College for Emergency Medicine. FAU - Hall, Emma J AU - Hall EJ AUID- ORCID: 0000-0001-7827-5344 AD - School of Pharmacy and Medical Science, Griffith University, Gold Coast, Australia. AD - Department of Emergency Medicine, Gold Coast Hospital and Health Service, Southport, Australia. FAU - Keijzers, Gerben AU - Keijzers G AUID- ORCID: 0000-0003-1100-4552 AD - Department of Emergency Medicine, Gold Coast Hospital and Health Service, Southport, Australia. AD - Faculty of Health Sciences and Medicine, Bond University, Robina, Australia. AD - School of Medicine and Dentistry, Griffith University, Gold Coast, Australia. FAU - Ranse, Jamie AU - Ranse J AUID- ORCID: 0000-0002-5265-6365 AD - Department of Emergency Medicine, Gold Coast Hospital and Health Service, Southport, Australia. AD - School of Nursing and Midwifery, Griffith University, Gold Coast, Australia. FAU - Sweeny, Amy L AU - Sweeny AL AUID- ORCID: 0000-0001-8392-5612 AD - Department of Emergency Medicine, Gold Coast Hospital and Health Service, Southport, Australia. AD - Faculty of Health Sciences and Medicine, Bond University, Robina, Australia. AD - School of Medicine and Dentistry, Griffith University, Gold Coast, Australia. FAU - Crilly, Julia AU - Crilly J AUID- ORCID: 0000-0002-1455-8983 AD - Department of Emergency Medicine, Gold Coast Hospital and Health Service, Southport, Australia. AD - School of Nursing and Midwifery, Griffith University, Gold Coast, Australia. FAU - Covered-Covid Study Investigators AU - Covered-Covid Study Investigators CN - New Collective Author LA - eng GR - EMSF-008COV-2020-CRILLY/Emergency Medicine Foundation/ GR - Australian Government Research Training Program (RTP) Scholarship/ PT - Journal Article PL - Australia TA - Emerg Med Australas JT - Emergency medicine Australasia : EMA JID - 101199824 SB - IM MH - Humans MH - Queensland/epidemiology MH - *COVID-19/epidemiology/prevention & control MH - Retrospective Studies MH - *Emergency Service, Hospital/statistics & numerical data/organization & administration MH - Male MH - Female MH - Middle Aged MH - Aged MH - Adult MH - *Heart Diseases/epidemiology MH - Chest Pain/epidemiology MH - Pandemics MH - SARS-CoV-2 PMC - PMC12290241 OTO - NOTNLM OT - COVID-19 pandemic OT - chest pain OT - emergency service OT - heart disease OT - hospital COIS- The views and findings presented in this paper are those of the investigators and do not represent those of the collaborating organisations. Author Gerben Keijzers is an Editorial Board member of EMA. He had no involvement in editorial decisions relating to this manuscript. COVERED-COVID Study Investigator Jaimi Greenslade is an Editorial Board member of EMA and had no involvement in editorial decisions relating to this manuscript. FIR - Crilly, Julia IR - Crilly J FIR - Sweeny, Amy IR - Sweeny A FIR - Keijzers, Gerben IR - Keijzers G FIR - Gerrard, John IR - Gerrard J FIR - Palipana, Dinesh IR - Palipana D FIR - Ranse, Jamie IR - Ranse J FIR - Greenslade, Jaimi IR - Greenslade J FIR - Walters, Ben IR - Walters B FIR - Padowitz, Anthony IR - Padowitz A FIR - Green, David IR - Green D FIR - Marshall, Andrea IR - Marshall A FIR - Zhang, Ping IR - Zhang P FIR - Grant, Gary IR - Grant G FIR - Teng, Yang D IR - Teng YD FIR - Gerhardy, Ben IR - Gerhardy B FIR - Alcorn, Kylie IR - Alcorn K FIR - Hall, Emma IR - Hall E EDAT- 2025/07/25 06:38 MHDA- 2025/07/25 06:39 PMCR- 2025/07/25 CRDT- 2025/07/25 00:22 PHST- 2025/07/01 00:00 [revised] PHST- 2025/05/07 00:00 [received] PHST- 2025/07/03 00:00 [accepted] PHST- 2025/07/25 06:39 [medline] PHST- 2025/07/25 06:38 [pubmed] PHST- 2025/07/25 00:22 [entrez] PHST- 2025/07/25 00:00 [pmc-release] AID - EMM70096 [pii] AID - 10.1111/1742-6723.70096 [doi] PST - ppublish SO - Emerg Med Australas. 2025 Aug;37(4):e70096. doi: 10.1111/1742-6723.70096. PMID- 40698576 OWN - NLM STAT- MEDLINE DCOM- 20250723 LR - 20260813 IS - 1469-493X (Electronic) IS - 1361-6137 (Linking) VI - 7 IP - 7 DP - 2025 Jul 23 TI - Palivizumab for preventing severe respiratory syncytial virus (RSV) infection in children. PG - CD013757 LID - 10.1002/14651858.CD013757.pub3 [doi] LID - CD013757 AB - RATIONALE: Respiratory viruses are the leading cause of lower respiratory tract infection and hospitalisation in infants and young children. Respiratory syncytial virus (RSV) is the main infectious agent in this population. Palivizumab is administered intramuscularly every month for five months in the first RSV season to prevent serious RSV lower respiratory tract infection in children. Given its high cost, it is essential to know if palivizumab continues to be effective in preventing severe RSV disease in children. OBJECTIVES: To assess the effects of palivizumab in preventing severe RSV infection in children. SEARCH METHODS: We searched CENTRAL, MEDLINE, Embase, LILACS, CINAHL, Scopus, and two trials registers from the inception of each database to July 2024 with no language or publication status restrictions. ELIGIBILITY CRITERIA: We included randomised controlled trials (RCTs) and cluster-RCTs in children 0 to 24 months of age of any gender, regardless of RSV infection history, comparing palivizumab given at a dose of 15 mg/kg once a month (maximum five doses) with placebo, no intervention, or standard care. OUTCOMES: The critical outcomes were hospitalisation due to RSV infection, all-cause mortality, and adverse events. Important outcomes were hospitalisation due to respiratory-related illness, length of hospital stay, RSV infection, number of wheezing days, days of supplemental oxygen, intensive care unit length of stay, and mechanical ventilation days. RISK OF BIAS: We used Cochrane's RoB 2 tool to assess risk of bias. SYNTHESIS METHODS: We conducted meta-analyses using random-effects models to calculate risk ratios (RR) for dichotomous outcomes and mean differences (MD) for continuous outcomes, both with 95% confidence intervals (CI). We used GRADE to assess the certainty of evidence for each outcome. INCLUDED STUDIES: We included one new trial in this update, bringing the total number of RCTs to six studies with 3611 children. All studies were parallel RCTs assessing the effects of 15 mg/kg of palivizumab every month for up to five months, compared to placebo or no intervention in an outpatient setting, although one study also included hospitalised infants, and another study administered palivizumab intranasally. Most of the included studies were conducted in children with a high risk of severe RSV infection due to comorbidities like bronchopulmonary dysplasia or congenital heart disease. SYNTHESIS OF RESULTS: Systemic palivizumab reduces hospitalisation due to RSV infection at two years' follow-up (RR 0.44, 95% CI 0.30 to 0.64; I(2) = 23%; 5 studies, 3343 participants; high-certainty evidence). Based on 98 hospitalisations per 1000 participants in the placebo group, this corresponds to 43 (29 to 62) per 1000 participants in the palivizumab group. Intranasal palivizumab may increase hospitalisation due to RSV infection compared to placebo or no intervention at two years' follow-up (RR 2.33, 95% CI 0.64 to 8.48; 1 study, 94 participants; low-certainty evidence due to serious concerns about imprecision). Based on 64 hospitalisations per 1000 participants in the placebo group, this corresponds to 149 (41 to 541) per 1000 participants in the palivizumab group. Palivizumab probably results in little to no difference in mortality at two years' follow-up (RR 0.69, 95% CI 0.42 to 1.15; I(2) = 0%; 5 studies, 3343 participants; moderate-certainty evidence due to concerns about imprecision). Based on 23 deaths per 1000 participants in the placebo group, this corresponds to 16 (10 to 27) per 1000 participants in the palivizumab group. Palivizumab probably results in little to no difference in adverse events at 150 days' follow-up (RR 1.08, 95% CI 0.85 to 1.38; I(2) = 0%; 4 studies, 3099 participants; moderate-certainty evidence due to concerns about imprecision). Based on 78 cases per 1000 participants in the placebo group, this corresponds to 84 (66 to 107) per 1000 participants in the palivizumab group. Palivizumab probably results in a slight reduction in hospitalisation due to respiratory-related illness at two years' follow-up (RR 0.80, 95% CI 0.65 to 0.99; I(2) = 41%; 6 studies, 3437 participants; moderate-certainty evidence due to concerns about imprecision). Systemic palivizumab may result in a large reduction in RSV infection at two years' follow-up (RR 0.33, 95% CI 0.20 to 0.55; I(2) = 0%; 3 studies, 554 participants; low-certainty evidence due to serious concerns about imprecision). Intranasal palivizumab may increase RSV infection compared to placebo or no intervention at two years' follow-up (RR 1.64, 95% CI 0.87 to 3.08; 1 study, 94 participants; low-certainty evidence due to serious concerns about imprecision). Systemic palivizumab also reduces the number of wheezing days at one-year follow-up (RR 0.39, 95% CI 0.35 to 0.44; 1 study, 429 participants; high-certainty evidence). Intranasal palivizumab may result in little to no difference in the mean fraction of wheezing days (mean fraction of wheezing days of 0.94, 95% CI -1.9 to 3.5; 1 study, 93 participants; low-certainty evidence). The risk of bias in outcomes across all studies was similar and predominantly low. AUTHORS' CONCLUSIONS: Based on the available evidence, prophylaxis with systemic palivizumab reduces hospitalisation due to RSV infection and probably results in little to no difference in mortality. Intranasal palivizumab may increase hospitalisation due to RSV infection. Palivizumab probably results in little to no difference in adverse events. Moreover, palivizumab probably results in a slight reduction in hospitalisation due to respiratory-related illness. Systemic palivizumab may result in a large reduction in RSV infections, whilst intranasal palivizumab may increase RSV infection. Systemic palivizumab also reduces the number of wheezing days, whilst intranasal palivizumab may result in little to no difference in the mean fraction of wheezing days. These results may be applicable to children with a high risk of severe RSV infection due to comorbidities. Further research is needed to establish the effect of palivizumab in children with other comorbidities known as risk factors for severe RSV disease (e.g. immune deficiencies) and other social determinants of the disease, including children living in low- and middle-income countries, tropical regions, children lacking breastfeeding, living in poverty, or members of families in overcrowded situations. FUNDING: This Cochrane review had no dedicated funding. REGISTRATION: Protocol (2020): doi.org/10.1002/14651858.CD013757 First review version (2021): doi.org/10.1002/14651858.CD013757.pub2. CI - Copyright (c) 2025 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. FAU - Garegnani, Luis AU - Garegnani L AD - Associate Cochrane Centre, Universidad Hospital Italiano de Buenos Aires, Buenos Aires, Argentina. FAU - Roson Rodriguez, Pablo AU - Roson Rodriguez P AD - Associate Cochrane Centre, Universidad Hospital Italiano de Buenos Aires, Buenos Aires, Argentina. FAU - Escobar Liquitay, Camila Micaela AU - Escobar Liquitay CM AD - Associate Cochrane Centre, Universidad Hospital Italiano de Buenos Aires, Buenos Aires, Argentina. FAU - Esteban, Ignacio AU - Esteban I AD - Gavi, the Vaccine Alliance, Geneva, Switzerland. AD - Facultad de Ciencias Biomedicas, Universidad Austral, Pilar, Argentina. FAU - Franco, Juan Va AU - Franco JV AD - Institute of General Practice, Medical Faculty of the Heinrich-Heine-University Dusseldorf, Dusseldorf, Germany. LA - eng PT - Journal Article PT - Meta-Analysis PT - Systematic Review DEP - 20250723 PL - England TA - Cochrane Database Syst Rev JT - The Cochrane database of systematic reviews JID - 100909747 RN - DQ448MW7KS (Palivizumab) RN - 0 (Antiviral Agents) SB - IM UOF - Cochrane Database Syst Rev. 2021 Nov 16;11:CD013757. doi: 10.1002/14651858.CD013757.pub2. PMID: 34783356 MH - Humans MH - *Respiratory Syncytial Virus Infections/prevention & control/mortality MH - *Palivizumab/therapeutic use/adverse effects/administration & dosage MH - *Antiviral Agents/therapeutic use/adverse effects/administration & dosage MH - Randomized Controlled Trials as Topic MH - Infant MH - Hospitalization/statistics & numerical data MH - Infant, Newborn MH - Child, Preschool MH - Length of Stay/statistics & numerical data PMC - PMC12284916 COIS- LG: declared that they have no conflict of interest. PR: declared that they have no conflict of interest. CMEL: declared that they have no conflict of interest. IE: declared that they have no conflict of interest. JVAF: is the Contact Editor for the Cochrane Urology Review Group and the Managing Editor for the Cochrane Metabolic and Endocrine Disorders Group. He was not involved in the editorial process for this review. EDAT- 2025/07/23 12:30 MHDA- 2025/07/23 12:31 PMCR- 2026/07/23 CRDT- 2025/07/23 06:23 PHST- 2025/07/23 12:31 [medline] PHST- 2025/07/23 12:30 [pubmed] PHST- 2025/07/23 06:23 [entrez] PHST- 2026/07/23 00:00 [pmc-release] AID - CD013757.pub3 [pii] AID - 10.1002/14651858.CD013757.pub3 [doi] PST - epublish SO - Cochrane Database Syst Rev. 2025 Jul 23;7(7):CD013757. doi: 10.1002/14651858.CD013757.pub3. PMID- 40670372 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250720 IS - 2059-0105 (Electronic) IS - 2059-0105 (Linking) VI - 10 IP - 1 DP - 2025 Jul 16 TI - Surveillance and follow up outcomes of myocarditis after mRNA COVID-19 vaccination in Australia. PG - 155 LID - 10.1038/s41541-025-01206-w [doi] LID - 155 AB - Clinical progression and medium-long term morbidity from myocarditis following mRNA COVID-19 vaccinations remains an important but undefined public health concern. We conducted prospective follow-up of individuals with either confirmed or probable myocarditis following monovalent Pfizer-BioNTech BNT162b2 or Moderna mRNA-1273 vaccination between 21 April 2021 and 5 July 2022 in Australia. Of 256 individuals who consented to follow up, mostly males following a second dose, 60% (133/221) had ongoing symptoms at 3-6 months and 35% (81/231) at 12-18 months. Self-reported ongoing exercise restrictions, medication requirements, and hospital re-presentations were associated with ongoing symptoms, as was a lower self-reported health status and quality of life. Clinical severity remained mild, with low hospitalisation rates and no deaths in the follow-up period and health-related quality of life improved over time. These findings support ongoing use of mRNA COVID-19 vaccines in at-risk individuals to prevent disease caused by SARS-CoV-2 infection. CI - (c) 2025. Crown. FAU - Deng, Lucy AU - Deng L AD - National Centre for Immunisation Research and Surveillance, Children's Hospital at Westmead, Westmead, NSW, Australia. lucy.deng@health.nsw.gov.au. AD - The University of Sydney Children's Hospital Westmead Clinical School, Westmead, NSW, Australia. lucy.deng@health.nsw.gov.au. FAU - Van Eldik, Amanda AU - Van Eldik A AD - National Centre for Immunisation Research and Surveillance, Children's Hospital at Westmead, Westmead, NSW, Australia. FAU - O'Moore, Megan AU - O'Moore M AD - Therapeutic Goods Administration, Department of Health, Disability and Ageing, Canberra, ACT, Australia. FAU - Buttery, Jim AU - Buttery J AD - Murdoch Children's Research Institute, Parkville, Victoria, Australia. AD - Department of Paediatrics, University of Melbourne, Parkville, Victoria, Australia. FAU - Cheung, Abigail AU - Cheung A AD - Women's and Children's Health Network, Adelaide, South Australia, Australia. FAU - Cox, Nicholas AU - Cox N AD - Western Health, Victoria, Australia. AD - Royal Melbourne Hospital Clinical School, Department of Medicine, University of Melbourne, Melbourne, Victoria, Australia. FAU - Drake-Brockman, Carla AU - Drake-Brockman C AD - Perth Children's Hospital, Nedlands, Western Australia, Australia. FAU - Dwyer, Nathan AU - Dwyer N AD - Royal Hobart Hospital, Hobart, Tasmania, Australia. FAU - Effler, Paul AU - Effler P AD - Western Australia Department of Health, Perth, Western Australia, Australia. FAU - Gold, Michael AU - Gold M AD - Women's and Children's Health Network, Adelaide, South Australia, Australia. AD - School of Medicine, Adelaide University, Adelaide, South Australia, Australia. FAU - Hissaria, Pravin AU - Hissaria P AD - School of Medicine, Adelaide University, Adelaide, South Australia, Australia. AD - South Australia Pathology, Adelaide, South Australia, Australia. FAU - Kelly, Andrew AU - Kelly A AD - Women's and Children's Health Network, Adelaide, South Australia, Australia. FAU - Khanlari, Sarah AU - Khanlari S AD - New South Wales Ministry of Health, St Leonards, NSW, Australia. FAU - Larter, Claire AU - Larter C AD - Therapeutic Goods Administration, Department of Health, Disability and Ageing, Canberra, ACT, Australia. FAU - Melody, Shannon AU - Melody S AD - Public Health Services, Department of Health Tasmania, Hobart, Tasmania, Australia. FAU - Nissen, Michael AU - Nissen M AD - Queensland Adult Specialist Immunisation Service, The Prince Charles Hospital, Chermside, Queensland, Australia. FAU - Puranik, Rajesh AU - Puranik R AD - Royal Prince Alfred Hospital, Camperdown, NSW, Australia. FAU - Rankin, James AU - Rankin J AD - Fiona Stanley Hospital, Murdoch, Western Australia, Australia. FAU - Singleton, Sally AU - Singleton S AD - Australian Capital Territory Health Directorate, Canberra, ACT, Australia. FAU - Thomas, Liza AU - Thomas L AD - The University of Sydney's Westmead Clinical School, Westmead, NSW, Australia. AD - Westmead Hospital, Westmead, NSW, Australia. FAU - Wahi, Sudhir AU - Wahi S AD - Princess Alexandra Hospital, Brisbane, Queensland, Australia. FAU - Wheaton, Gavin AU - Wheaton G AD - Women's and Children's Health Network, Adelaide, South Australia, Australia. FAU - Zentner, Dominica AU - Zentner D AD - Royal Melbourne Hospital Clinical School, Department of Medicine, University of Melbourne, Melbourne, Victoria, Australia. AD - Royal Melbourne Hospital, Parkville, Victoria, Australia. FAU - Macartney, Kristine AU - Macartney K AD - National Centre for Immunisation Research and Surveillance, Children's Hospital at Westmead, Westmead, NSW, Australia. AD - The University of Sydney Children's Hospital Westmead Clinical School, Westmead, NSW, Australia. FAU - Chow, Clara K AU - Chow CK AD - Westmead Hospital, Westmead, NSW, Australia. AD - Westmead Applied Research Centre, Faculty of Medicine and Health, The University of Sydney, Westmead, NSW, Australia. FAU - Wood, Nicholas AU - Wood N AD - National Centre for Immunisation Research and Surveillance, Children's Hospital at Westmead, Westmead, NSW, Australia. AD - The University of Sydney Children's Hospital Westmead Clinical School, Westmead, NSW, Australia. LA - eng PT - Journal Article DEP - 20250716 PL - England TA - NPJ Vaccines JT - NPJ vaccines JID - 101699863 PMC - PMC12267834 COIS- Competing interests: The authors declare no competing interests. Ethics approval: This study was conducted as part of the AusVaxSafety Adverse Event of Special Interest Program of Research, approved by The Sydney Children's Hospital Network Human Research Ethics Committee (2021/ ETH11149). EDAT- 2025/07/17 04:42 MHDA- 2025/07/17 04:43 PMCR- 2025/07/16 CRDT- 2025/07/16 23:15 PHST- 2025/02/13 00:00 [received] PHST- 2025/06/23 00:00 [accepted] PHST- 2025/07/17 04:43 [medline] PHST- 2025/07/17 04:42 [pubmed] PHST- 2025/07/16 23:15 [entrez] PHST- 2025/07/16 00:00 [pmc-release] AID - 10.1038/s41541-025-01206-w [pii] AID - 1206 [pii] AID - 10.1038/s41541-025-01206-w [doi] PST - epublish SO - NPJ Vaccines. 2025 Jul 16;10(1):155. doi: 10.1038/s41541-025-01206-w. PMID- 40661277 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260317 LR - 20260619 DP - 2025 May 23 TI - Lingering sex and age disparities in dolutegravir uptake among adults with HIV: A multi-country observational cohort study. LID - 2025.05.23.25325682 [pii] LID - 10.1101/2025.05.23.25325682 [doi] AB - INTRODUCTION: Since July 2019, the World Health Organization (WHO) has recommended dolutegravir (DTG)-based regimens as preferred first-line antiretroviral therapy (ART) for adults and adolescents living with HIV (DTG-for-All), a reversal of a 2018 safety alert on use of DTG-based regimens by women of reproductive age (WRA). We examined sex and age disparities in DTG uptake before and after DTG-for-All in the International epidemiology Databases to Evaluate AIDS (IeDEA). METHODS: We included patients >/=16 years on or initiating treatment between January 2017 and July 2021 in 14 low- and middle-income countries where initial guidelines on DTG-based regimens for first-line ART either restricted use by WRA or had no such restrictions. We estimated the cumulative incidence of DTG uptake (CI-DTG) by sex and age group (aged 16-49 years vs. 50+ years), stratified by patient, clinic and setting characteristics. RESULTS: Among 177,706 patients on ART during the study period, 51% were females aged 16-49 years, with 25% males aged 16-49, and 13% and 11%, respectively, females and males aged 50+. At the time of DTG-for-All, overall CI-DTG was 29.6% (95%CI: 29.4, 29.8); it was lower among females aged 16-49 (16.2%; 95%CI: 16.0-16.5) than males (41.1%; 95%CI: 40.6, 41.5), with no sex disparities among patients aged 50+ (females: 46.0%; males: 47.0%). While DTG uptake subsequently increased among all groups, by July 2021, it remained substantially lower among females 16-49 (66.4%; 95%CI: 66.1, 66.7), compared with males 16-49 and older females and males (75.8% to 77.5%). Concentrated in countries where initial guidelines on DTG restricted use by WRA, disparities in DTG uptake persisted at all health system levels and in both low-income and lower-middle income countries. CONCLUSIONS: While sex-age differentials in DTG uptake narrowed after WHO's DTG-for-All recommendation, lingering disparities uptake underscore the challenges of policy de-implementation when new evidence emerges. FAU - Brazier, Ellen AU - Brazier E AUID- ORCID: 0000-0002-8514-1958 AD - Institute for Implementation Science in Population Health, City University of New York, New York, USA. FAU - Romo, Matthew L AU - Romo ML AD - Institute for Implementation Science in Population Health, City University of New York, New York, USA. FAU - Ciaranello, Andrea AU - Ciaranello A AD - Perinatal Infectious Disease Program and Medical Practice Evaluation Center, Massachusetts General Hospital, Boston, USA. FAU - Odhiambo, Francesca AU - Odhiambo F AD - Kenya Medical Research Institute, Centre for Microbiology Research, Nairobi, Kenya. FAU - Pujari, Sanjay AU - Pujari S AD - Institute of Infectious Diseases, Pune, India. FAU - Murenzi, Gad AU - Murenzi G AD - Einstein-Rwanda Research and Capacity Building Program, Research for Development (RD Rwanda), Kigali, Rwanda. AD - Rwanda Military Referral and Teaching Hospital, Kigali, Rwanda. FAU - Kasozi, Charles AU - Kasozi C AD - Department of Public Health, Masaka Regional Referral Hospital, Masaka Uganda. FAU - Kiertiburanakul, Sasisopin AU - Kiertiburanakul S AD - Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand. FAU - Nsonde, Dominique Mahambou AU - Nsonde DM AD - Centre de Traitement Ambulatoire, Brazzaville, Republic of Congo. FAU - Muyindike, Winnie R AU - Muyindike WR AD - Mbarara University of Science and Technology, Department of Medicine, Mbarara, Uganda. AD - Mbarara Regional Referral Hospital, Mbarara, Uganda. FAU - Khol, Vohith AU - Khol V AD - National Center for HIV/AIDS, Dermatology & STDs, Phnom Penh, Cambodia. FAU - Lelo, Patricia AU - Lelo P AD - Department of Infectious Diseases, Kalembelembe Pediatric Hospital, Democratic Republic of the Congo. FAU - Lyamuya, Rita AU - Lyamuya R AD - Morogoro Regional Hospital - CTC, Morogoro, Tanzania. FAU - Lee, Man Po AU - Lee MP AD - Queen Elizabeth Hospital, Hong Kong SAR. FAU - Nash, Denis AU - Nash D AD - Institute for Implementation Science in Population Health, City University of New York, New York, USA. AD - Graduate School of Public Health and Health Policy, City University of New York, New York, USA. LA - eng GR - U01 AI069907/AI/NIAID NIH HHS/United States GR - U01 AI069911/AI/NIAID NIH HHS/United States GR - U01 AI096299/AI/NIAID NIH HHS/United States PT - Journal Article PT - Preprint DEP - 20250523 PL - United States TA - medRxiv JT - medRxiv : the preprint server for health sciences JID - 101767986 UIN - BMJ Glob Health. 2026 Mar 13;11(3):e020159. doi: 10.1136/bmjgh-2025-020159. PMID: 41825914 PMC - PMC12258775 COIS- Competing Interests AC reports institutional grants from NIH and serves as US Department of Health and Human Services Perinatal HIV Guidelines Panel Member and Co-Chair. DN reports institutional funding from NIH, and from the New York State AIDS Institute and Pfizer Inc for unrelated research, and honoraria from the NIH Centers for AIDS Research, Yale Center for Interdisciplinary Research on AIDS, and George Washington University School of Public Health. All authors have declared that no competing interests exist. EDAT- 2025/07/15 06:28 MHDA- 2025/07/15 06:29 PMCR- 2025/07/14 CRDT- 2025/07/15 04:58 PHST- 2025/07/15 06:28 [pubmed] PHST- 2025/07/15 06:29 [medline] PHST- 2025/07/15 04:58 [entrez] PHST- 2025/07/14 00:00 [pmc-release] AID - 2025.05.23.25325682 [pii] AID - 10.1101/2025.05.23.25325682 [doi] PST - epublish SO - medRxiv [Preprint]. 2025 May 23:2025.05.23.25325682. doi: 10.1101/2025.05.23.25325682. PMID- 40659369 OWN - NLM STAT- MEDLINE DCOM- 20250714 LR - 20250717 IS - 2059-7908 (Print) IS - 2059-7908 (Electronic) IS - 2059-7908 (Linking) VI - 10 IP - 7 DP - 2025 Jul 13 TI - The influence of the expanded Global Gag Rule on Malawi's sexual and reproductive health and rights landscape: a qualitative study. LID - 10.1136/bmjgh-2023-013639 [doi] LID - e013639 AB - INTRODUCTION: The Global Gag Rule (GGR) prohibits non-governmental organisations receiving US international family planning funding from using these funds to provide or refer for abortion services or advocate for abortion law liberalisation. In 2017, President Trump renamed the policy Protecting Life in Global Health Assistance (PLGHA) and expanded it to all US global health assistance funding. On 28 January 2021, President Biden revoked PLGHA. Limited research explores the expanded GGR's influence when revoked in countries dependent on US global health assistance. We examined how PLGHA influenced the sexual and reproductive health and rights (SRHR) landscape of Malawi during its enforcement and since its revocation by President Biden in January 2021. METHODS: We conducted semi-structured qualitative interviews between July and August 2021 with 17 current and past recipients of US global health assistance and civil society organisations working in SRHR in Malawi. RESULTS: While PLGHA was in effect, participants observed the stalling of a liberalised abortion bill in Parliament, enhancement of anti-abortion attitudes and hindrance of national sovereignty in Malawi. In some cases, participants reported that over-implementation of the policy restricted legal access to post-abortion and contraceptive care. The Biden administration's revocation of PLGHA seemed to exemplify support of SRHR globally but did not reverse anti-abortion sentiment emboldened by prior enforcement of the policy. The threat of PLGHA being reinstated by a future US president was associated with hesitation among participants to invest in public health programmes and advocacy efforts. CONCLUSION: Participants felt that PLGHA's enforcement was associated with impaired abortion law reform, prevented organisations from providing safe post-abortion care and reinforced abortion stigma in Malawi. Participants felt these impacts endured even after the policy's revocation in January 2021. A permanent repeal of the GGR would allow organisations and the Malawi government to fully invest in public health interventions promoting SRHR. CI - (c) Author(s) (or their employer(s)) 2025. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group. FAU - Iyer, Aishwarya AU - Iyer A AUID- ORCID: 0000-0001-7488-1486 AD - University of Washington, Seattle, Washington, USA ashiyer7897@gmail.com. AD - Hubert Department of Global Health, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA. FAU - Luffy, Samantha M AU - Luffy SM AD - Fos Feminista, Washington, DC, USA. FAU - Newton-Levinson, Anna AU - Newton-Levinson A AD - Hubert Department of Global Health, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA. FAU - Rochat, Roger AU - Rochat R AD - Hubert Department of Global Health, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA. FAU - Cooper, Bergen AU - Cooper B AD - Fos Feminista, Washington, DC, USA. CN - Chaos Continues Research Team LA - eng PT - Journal Article DEP - 20250713 PL - England TA - BMJ Glob Health JT - BMJ global health JID - 101685275 SB - IM MH - Malawi MH - Humans MH - Qualitative Research MH - *Reproductive Health MH - Female MH - *Sexual Health MH - *Reproductive Rights/legislation & jurisprudence MH - *Abortion, Induced/legislation & jurisprudence MH - *International Cooperation/legislation & jurisprudence MH - Global Health MH - Pregnancy MH - Interviews as Topic MH - United States MH - Male MH - Adult PMC - PMC12258357 OTO - NOTNLM OT - Global Health OT - Health policy OT - Maternal health OT - Public Health OT - Qualitative study COIS- Competing interests: None declared. FIR - Cargile, Honora IR - Cargile H FIR - Miller, Savannah IR - Miller S FIR - Sheth, Anisha IR - Sheth A FIR - Switzer, Maggie IR - Switzer M FIR - Wynne, Allison IR - Wynne A EDAT- 2025/07/15 00:30 MHDA- 2025/07/15 00:31 PMCR- 2025/07/13 CRDT- 2025/07/14 20:42 PHST- 2023/08/06 00:00 [received] PHST- 2025/06/25 00:00 [accepted] PHST- 2025/07/15 00:31 [medline] PHST- 2025/07/15 00:30 [pubmed] PHST- 2025/07/14 20:42 [entrez] PHST- 2025/07/13 00:00 [pmc-release] AID - bmjgh-2023-013639 [pii] AID - 10.1136/bmjgh-2023-013639 [doi] PST - epublish SO - BMJ Glob Health. 2025 Jul 13;10(7):e013639. doi: 10.1136/bmjgh-2023-013639. PMID- 40612179 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250705 IS - 3050-2225 (Electronic) IS - 3050-2225 (Linking) VI - 12 DP - 2025 Jan-Dec TI - The Social Challenges of Stomas Faced by Families of Children With Anorectal Malformations in Uganda. PG - 30502225251338534 LID - 10.1177/30502225251338534 [doi] LID - 30502225251338534 AB - AIM: To evaluate the anorectal malformation-stoma social challenges experienced by families of children with anorectal malformation in southwestern Uganda. METHODS: Using a mixed-methods approach, a descriptive observational quantitative study with structured interview-based data collection was performed. The link between ARMs-stoma-related social challenges faced by families in southwestern Uganda from June 2021 to July 2023 was examined. RESULTS: 157 participants were enrolled, and 74.3% of caregivers reported social challenges. Among those surveyed about the specific nature of these social difficulties, 66.7% reported facing discrimination from the community. 17.9% of patients experienced abandonment by their relatives. 72.1% reported being unable to attend public functions, while 21.4% felt compelled to keep their children indoors. 27.6% reported experiencing social restrictions. CONCLUSION: Caregivers face social challenges and restrictions due to stomas related to anorectal malformations in their communities. Healthcare providers should tailor care to address the urgent needs associated with these stoma challenges. CI - (c) The Author(s) 2025. FAU - Oyania, Felix AU - Oyania F AUID- ORCID: 0000-0003-4773-7790 AD - Mbarara University of Science and Technology, Uganda. FAU - Eze, Anthony N AU - Eze AN AD - Duke University Medical Center, Durham, NC, USA. FAU - Ullrich, Sarah AU - Ullrich S AD - Cincinnati Children's Hospital Medical Center, OH, USA. FAU - Kotagal, Meera AU - Kotagal M AD - Cincinnati Children's Hospital Medical Center, OH, USA. FAU - Ozgediz, Doruk E AU - Ozgediz DE AD - University of California, San Francisco, CA, USA. LA - eng PT - Journal Article DEP - 20250529 PL - United States TA - Sage Open Pediatr JT - Sage open pediatrics JID - 9919052035406676 PMC - PMC12220878 OTO - NOTNLM OT - anorectal malformation OT - social challenges OT - southwestern Uganda OT - stomas COIS- The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. EDAT- 2025/07/04 06:27 MHDA- 2025/07/04 06:28 PMCR- 2025/05/29 CRDT- 2025/07/04 04:58 PHST- 2024/10/12 00:00 [received] PHST- 2025/07/04 06:28 [medline] PHST- 2025/07/04 06:27 [pubmed] PHST- 2025/07/04 04:58 [entrez] PHST- 2025/05/29 00:00 [pmc-release] AID - 10.1177_30502225251338534 [pii] AID - 10.1177/30502225251338534 [doi] PST - epublish SO - Sage Open Pediatr. 2025 May 29;12:30502225251338534. doi: 10.1177/30502225251338534. eCollection 2025 Jan-Dec. PMID- 40599225 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20260307 IS - 2211-4203 (Electronic) IS - 2211-419X (Print) IS - 2211-419X (Linking) VI - 15 IP - 3 DP - 2025 Sep TI - Characteristics and outcomes of children initiated on high flow nasal cannula and continuous positive airway pressure at the emergency centre of a district hospital in South Africa. PG - 100884 LID - 10.1016/j.afjem.2025.100884 [doi] LID - 100884 AB - INTRODUCTION: High-flow nasal cannula (HFNC) and continuous positive airway pressure delivered via a nasal interface (nCPAP) are increasingly used for paediatric emergency care in South Africa. In Cape Town, initiation of HFNC/nCPAP at a district hospital, in most instances, necessitates transfer to a paediatric high-care facility. We sought to describe the population of children initiated on HFNC/nCPAP and their short-term hospital outcomes post interfacility transfer. METHODS: The authors conducted a one-year retrospective observational study between August 1st 2021, to July 31st(,) 2022 of children initiated on HFNC or nCPAP in the emergency centre (EC) of Khayelitsha district Hospital and transferred by ambulance to Tygerberg Hospital paediatric emergency centre. Children were excluded from the study if they were <10 days or >13 years of age, if they had an advanced care plan that restricted the escalation of respiratory support or if their medical records were incomplete. RESULTS: At Khayelitsha Hospital, 117 patients were initiated on HFNC (n = 58) or nCPAP (n = 59). Participants had a median age of 6.8 months. There were no major adverse events reported during inter-facility transfer. Respiratory support was weaned to low flow oxygen or room air within 24 h of transfer in 23.9 % and escalated in 9.4 %. During hospital stay 14.5 % were admitted to intensive care, 6.0 % ultimately required mechanical ventilation, and the in-hospital mortality rate was 1.7 %. CONCLUSION: Roughly a quarter of patients were weaned from respiratory support within 24 h of transfer. Short term outcomes were good overall, demonstrating safe interfacility transfer and low mortality. Further research is needed to inform practice on best use of HFNC and nCPAP in the emergency care of children presenting with acute respiratory illness in South Africa. CI - (c) 2025 The Authors. Published by Elsevier B.V. on behalf of African Federation for Emergency Medicine. FAU - Head, Jessica AU - Head J AD - Department of Paediatrics, Khayelitsha Hospital, Cape Town, South Africa. AD - Department of Paediatrics & Child Health, Stellenbosch University, Cape Town, South Africa. FAU - Redfern, Andrew AU - Redfern A AD - Department of Paediatrics & Child Health, Stellenbosch University, Cape Town, South Africa. AD - Paediatric Emergency and Ambulatory Unit, Tygerberg Hospital, Cape Town, South Africa. FAU - Hoole, Jana AU - Hoole J AD - Department of Paediatrics, Khayelitsha Hospital, Cape Town, South Africa. FAU - Ulbrich, Liezl AU - Ulbrich L AD - Western Cape Government Emergency Medical Services, Cape Town, South Africa. FAU - More, Refilwe AU - More R AD - Department of Paediatrics & Child Health, Stellenbosch University, Cape Town, South Africa. AD - Human Sciences Research Council Internship Program, Cape Town, South Africa. FAU - van Hoving, Daniel J AU - van Hoving DJ AD - Division of Emergency Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa. FAU - McCollum, Eric D AU - McCollum ED AD - Health Systems Program, Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. AD - Global Program in Pediatric Respiratory Sciences, Eudowood Division of Pediatric Respiratory Sciences, Department of Pediatrics, Johns Hopkins School of Medicine, Baltimore, MD, USA. FAU - Hooli, Shubhada AU - Hooli S AD - Global Program in Pediatric Respiratory Sciences, Eudowood Division of Pediatric Respiratory Sciences, Department of Pediatrics, Johns Hopkins School of Medicine, Baltimore, MD, USA. AD - Department of Pediatrics, Division of Emergency Medicine, Baylor College of Medicine, Houston, TX, USA. LA - eng GR - K23 HL169901/HL/NHLBI NIH HHS/United States PT - Journal Article DEP - 20250616 PL - Netherlands TA - Afr J Emerg Med JT - African journal of emergency medicine : Revue africaine de la medecine d'urgence JID - 101572277 PMC - PMC12211819 OTO - NOTNLM OT - Child OT - Continuous positive airway pressure OT - High flow nasal cannula OT - Low- and middle-income countries OT - Pneumonia OT - South Africa COIS- The authors declare no conflict of interests. EDAT- 2025/07/02 06:29 MHDA- 2025/07/02 06:30 PMCR- 2025/06/16 CRDT- 2025/07/02 05:16 PHST- 2025/02/20 00:00 [received] PHST- 2025/05/21 00:00 [revised] PHST- 2025/05/23 00:00 [accepted] PHST- 2025/07/02 06:30 [medline] PHST- 2025/07/02 06:29 [pubmed] PHST- 2025/07/02 05:16 [entrez] PHST- 2025/06/16 00:00 [pmc-release] AID - S2211-419X(25)00024-2 [pii] AID - 100884 [pii] AID - 10.1016/j.afjem.2025.100884 [doi] PST - ppublish SO - Afr J Emerg Med. 2025 Sep;15(3):100884. doi: 10.1016/j.afjem.2025.100884. Epub 2025 Jun 16. PMID- 40591928 OWN - NLM STAT- MEDLINE DCOM- 20250701 LR - 20250703 IS - 1464-3685 (Electronic) IS - 0300-5771 (Print) IS - 0300-5771 (Linking) VI - 54 IP - 4 DP - 2025 Jun 11 TI - Impact of COVID-19 lockdown on outpatient care for non-communicable diseases in Nepal. LID - 10.1093/ije/dyaf100 [doi] LID - dyaf100 AB - BACKGROUND: The implementation of restriction and mitigation measures to contain COVID-19 infection led to a significant disruption in the delivery of essential health services. However, the ramifications of the immediate COVID-19 containment policies on healthcare service utilization for major non-communicable diseases (NCDs)-related cases, particularly in low- and middle-income countries, remains unknown. METHODS: We used an interrupted time series study design, fitted with quasi-Poisson regression models, to assess the impacts of the nationwide lockdown on hospital visits for NCDs, namely cardiovascular disease (CVD), chronic respiratory disease (CRD), chronic kidney disease (CKD), cancer, and hypertension (HTN)-related cases, in Nepal. A total of 33 months of nationwide outpatient department visits data for NCD cases between July 2018 and April 2021, 20 months before and 13 months after the enforcement of the nationwide lockdown, were included in the final analysis. RESULTS: Compared with the expected level, there was an estimated 73% [relative risk (RR) 0.269, 95% confidence interval (CI): 0.089-0.808] decrease in outpatient department visits for CVD and a 64% (RR 0.361, 95% CI: 0.175-0.745) decrease for cancer. Although an immediate reduction in outpatient department visits was observed, the evidence was not conclusive to determine the true effect of the COVID-19 pandemic on outpatient department visits for CRD (RR 0.89, 95% CI: 0.651-1.228), HTN (RR 1.004, 95% CI: 0.64-1.575), and kidney disease (RR 0.589, 95% CI: 0.231-1.501). CONCLUSION: We estimated that the nationwide lockdown implemented in response to the COVID-19 pandemic affected hospital visits for patients with CVD and cancer. However, the available evidence was not conclusive enough to determine the impact of COVID-19 on outpatient department visits for the other NCDs analysed, namely HTN, CRD, and CKD. CI - (c) The Author(s) 2025. Published by Oxford University Press on behalf of the International Epidemiological Association. FAU - Shakya, Rajina AU - Shakya R AD - Nepal Health Research Council, Kathmandu, Nepal. FAU - Dhimal, Meghnath AU - Dhimal M AD - Nepal Health Research Council, Kathmandu, Nepal. FAU - Joshi, Pramod AU - Joshi P AD - Nepal Health Research Council, Kathmandu, Nepal. FAU - Aryal, Umesh Raj AU - Aryal UR AD - School of Public Health and Community Health Sciences, Karnali Academy of Health Sciences, Jumla, Nepal. FAU - Gynawali, Pradip AU - Gynawali P AD - Nepal Health Research Council, Kathmandu, Nepal. FAU - Bhandari, Dinesh AU - Bhandari D AUID- ORCID: 0000-0002-0979-1406 AD - School of Nursing and Midwifery, Monash University, Melbourne, Victoria, Australia. AD - School of Public Health, University of Adelaide, Adelaide, Australia. LA - eng PT - Journal Article PL - England TA - Int J Epidemiol JT - International journal of epidemiology JID - 7802871 SB - IM MH - Humans MH - *COVID-19/epidemiology/prevention & control MH - Nepal/epidemiology MH - *Ambulatory Care/statistics & numerical data MH - *Noncommunicable Diseases/therapy/epidemiology MH - Interrupted Time Series Analysis MH - SARS-CoV-2 MH - Neoplasms/therapy/epidemiology MH - Male MH - Female MH - Cardiovascular Diseases/therapy/epidemiology MH - Middle Aged MH - Renal Insufficiency, Chronic/therapy/epidemiology MH - Adult MH - Hypertension/therapy/epidemiology PMC - PMC12212638 OTO - NOTNLM OT - COVID-19 OT - interrupted time series analysis OT - non-communicable diseases OT - outpatient care COIS- None declared. EDAT- 2025/07/01 21:17 MHDA- 2025/07/01 21:18 PMCR- 2025/07/01 CRDT- 2025/07/01 16:33 PHST- 2024/09/01 00:00 [received] PHST- 2025/05/30 00:00 [accepted] PHST- 2025/07/01 21:18 [medline] PHST- 2025/07/01 21:17 [pubmed] PHST- 2025/07/01 16:33 [entrez] PHST- 2025/07/01 00:00 [pmc-release] AID - 8180641 [pii] AID - dyaf100 [pii] AID - 10.1093/ije/dyaf100 [doi] PST - ppublish SO - Int J Epidemiol. 2025 Jun 11;54(4):dyaf100. doi: 10.1093/ije/dyaf100. PMID- 40585674 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250702 IS - 2168-8184 (Print) IS - 2168-8184 (Electronic) IS - 2168-8184 (Linking) VI - 17 IP - 5 DP - 2025 May TI - Lessons Learned From the Pandemic: A Retrospective Analysis of the Impact of COVID-19 in the Routine of a Reference Center for Spine Surgery. PG - e85032 LID - 10.7759/cureus.85032 [doi] LID - e85032 AB - INTRODUCTION: The COVID-19 pandemic significantly impacted the operating room schedules and reduced spine-related surgical activity around the world. With the widespread adoption of vaccination and the gradual easing of restrictions in Canada, the healthcare system has largely returned to its pre-pandemic operational capacity. METHODS: This retrospective study evaluated spine surgery activities at Centre Hospitalier de l'Universite de Montreal (CHUM), a tertiary academic hospital in Canada. Three continuous but distinct periods were analyzed: pre-pandemic (P1) extended from March 2018 to February 2020; pandemic period (P2), from March 2020 to June 2021; and post-vaccination period (P3), from July 2021 to September 2022. Data on surgical volume, type of surgery (scheduled vs. emergency), mean preoperative waiting time, complication rates, and 30-day mortality rates were compared across the three periods. RESULTS: A total of 1,775 surgeries were performed during the study period. The monthly surgical volume averaged 34.6 in P1 (820 in total), decreased to 33.8 in P2 (540 in total), and rebounded to 37.7 in P3 (415 in total). Emergency surgeries accounted for 31% of cases in P1, increased to 52% in P2, and decreased to 35% in P3 (p = 0.03) (256, 281, and 144, respectively). Complication rates declined from 10.1% in P1 to 5.6% in P2 and then rose to 10.6% in P3 (p < 0.01) (83, 30, and 44, respectively). The mean preoperative waiting times were 131.3 days in P1, 118.4 days in P2, and 178.8 days in P3 (p < 0.01). The 30-day mortality rate remained less than 1% across all periods. CONCLUSION: This work showed the steady volume of surgical activity during the pandemic in a tertiary center. This phenomenon happened largely due to the change in profile in surgical cases. Non-elective cases became more frequent, and elective patients were sparse, probably demonstrating the necessity to deal with cases that otherwise would be treated in community hospitals. Despite this fact, the complication rate decreased during the pandemic, and the mortality rate stayed stable. As the application of the vaccine in the Canadian population, elective spine surgery activity levels were successfully restored. CI - Copyright (c) 2025, Kamel et al. FAU - Kamel, Yousef AU - Kamel Y AD - Orthopedic Surgery, Centre Hospitalier de l'Universite de Montreal (CHUM), Montreal, CAN. FAU - Osman, Galil AU - Osman G AD - Orthopedic Surgery, Centre Hospitalier de l'Universite de Montreal (CHUM), Montreal, CAN. FAU - Al-Shakfa, Fidaa AU - Al-Shakfa F AD - Orthopedic Surgery, Centre Hospitalier de l'Universite de Montreal (CHUM), Montreal, CAN. FAU - Olijnyk, Leonardo AU - Olijnyk L AD - Orthopedic Surgery, Centre Hospitalier de l'Universite de Montreal (CHUM), Montreal, CAN. FAU - Shen, Jesse AU - Shen J AD - Orthopedic Surgery, Centre Hospitalier de l'Universite de Montreal (CHUM), Montreal, CAN. FAU - Zhang, Hao AU - Zhang H AD - Orthopedic Surgery, Centre Hospitalier de l'Universite de Montreal (CHUM), Montreal, CAN. FAU - Boule, Danielle AU - Boule D AD - Orthopedic Surgery, Centre Hospitalier de l'Universite de Montreal (CHUM), Montreal, CAN. FAU - Wang, Zhi AU - Wang Z AD - Orthopedic Surgery, Centre Hospitalier de l'Universite de Montreal (CHUM), Montreal, CAN. LA - eng PT - Journal Article DEP - 20250529 PL - United States TA - Cureus JT - Cureus JID - 101596737 PMC - PMC12205719 OTO - NOTNLM OT - covid-19 OT - elective spine surgery OT - orthopedic surgery OT - surgical case volume OT - trend analysis COIS- Human subjects: Consent for treatment and open access publication was obtained or waived by all participants in this study. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work. EDAT- 2025/07/01 04:06 MHDA- 2025/07/01 04:07 PMCR- 2025/05/29 CRDT- 2025/06/30 06:26 PHST- 2025/05/24 00:00 [accepted] PHST- 2025/07/01 04:07 [medline] PHST- 2025/07/01 04:06 [pubmed] PHST- 2025/06/30 06:26 [entrez] PHST- 2025/05/29 00:00 [pmc-release] AID - 10.7759/cureus.85032 [doi] PST - epublish SO - Cureus. 2025 May 29;17(5):e85032. doi: 10.7759/cureus.85032. eCollection 2025 May. PMID- 40483383 OWN - NLM STAT- MEDLINE DCOM- 20251027 LR - 20260622 IS - 1178-1661 (Electronic) IS - 1178-1653 (Print) IS - 1178-1653 (Linking) VI - 18 IP - 6 DP - 2025 Nov TI - Preferences for Telephone Cancer Information and Support in People with Cancer and Carers: Attribute and Level Selection for a Discrete Choice Experiment. PG - 645-660 LID - 10.1007/s40271-025-00746-6 [doi] AB - BACKGROUND AND OBJECTIVE: Telephone cancer information and support services (CISS) deliver essential evidence-based resources for people living with cancer. This research aimed to describe how attributes and levels were developed for a future discrete choice experiment to elicit preferences for operational characteristics of a CISS, focusing on Cancer Council Victoria's service. METHODS: Using a mixed-methods approach guided by the ISPOR checklist for conjoint analysis in healthcare, initial attributes were developed using an artificial intelligence framework to analyse CISS calls (January 2018-December 2021), focus groups with people with cancer and carers using the CISS (July-August 2022), and a systematic literature review of qualitative studies. A four-stage descriptive process guided attribute and level development. An expert panel of researchers (n = 10), a CISS staff member, a person with lived experience of cancer and a consumer-only panel (n = 7) met monthly to prioritise, refine and finalise attributes by consensus. RESULTS: Call data analysis (people with cancer n = 7701; carers n = 5500), six focus groups (people with cancer n = 10; carers n = 11) and a systematic literature review of qualitative studies generated 14 candidate attributes. The expert panels selected seven final attributes, each with three levels: follow-up call, operating hours, additional technology, operator type, operator consistency, call length and service fee. CONCLUSIONS: Transparent reporting of the discrete choice experiment design process is essential for credible interpretation. The four-stage approach enhanced the comprehensibility of the experiment, as multi-modal data ensured the selected attributes and levels accurately reflect CISS caller priorities, which may be applicable to other choice-based studies. CI - (c) 2025. The Author(s). FAU - Livingstone, Ann AU - Livingstone A AUID- ORCID: 0000-0002-6836-0382 AD - Institute for Health Transformation, Deakin Health Economics, School of Health and Social Development, Faculty of Health, Deakin University, Geelong, VIC, Australia. a.livingstone@deakin.edu.au. FAU - Engel, Lidia AU - Engel L AUID- ORCID: 0000-0002-7959-3149 AD - School of Public Health and Preventive Medicine, Health Economics Group, Monash University, Melbourne, VIC, Australia. FAU - White, Victoria AU - White V AUID- ORCID: 0000-0001-6619-8484 AD - School of Psychology, Faculty of Health, Deakin University, Geelong, VIC, Australia. FAU - De Silva, Daswin AU - De Silva D AUID- ORCID: 0000-0003-3878-5969 AD - Centre for Data Analytics and Cognition, La Trobe University, Bundoora, VIC, Australia. FAU - Bucholc, Jessica AU - Bucholc J AUID- ORCID: 0000-0003-0758-2704 AD - Institute for Health Transformation, Deakin Health Economics, School of Health and Social Development, Faculty of Health, Deakin University, Geelong, VIC, Australia. AD - Cancer Council Victoria, Melbourne, VIC, Australia. FAU - Murphy, April AU - Murphy A AUID- ORCID: 0000-0003-3717-4760 AD - Institute for Health Transformation, Deakin Health Economics, School of Health and Social Development, Faculty of Health, Deakin University, Geelong, VIC, Australia. AD - School of Social Sciences, Monash University, Clayton, VIC, Australia. FAU - Cook, Elaine AU - Cook E AD - Cancer Council Victoria, Melbourne, VIC, Australia. FAU - Mihalopoulos, Cathrine AU - Mihalopoulos C AD - School of Public Health and Preventive Medicine, Health Economics Group, Monash University, Melbourne, VIC, Australia. FAU - Orellana, Liliana AU - Orellana L AUID- ORCID: 0000-0003-3736-4337 AD - Biostatistics Unit, Faculty of Health, Deakin University, Geelong, VIC, Australia. FAU - Ratcliffe, Julie AU - Ratcliffe J AUID- ORCID: 0000-0001-7365-1988 AD - Flinders Health Economics Group, Flinders University, Repatriation General Hospital, Daw Park, SA, Australia. FAU - Spence, Danielle AU - Spence D AD - Cancer Council Victoria, Melbourne, VIC, Australia. FAU - McCaffrey, Nikki AU - McCaffrey N AUID- ORCID: 0000-0003-3684-3723 CN - 131120 Social Return on Investment (SROI) Project Team LA - eng GR - APP2005191/National Health and Medical Research Council/ GR - MCRF20049/Victorian Cancer Agency/ PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Systematic Review DEP - 20250607 PL - New Zealand TA - Patient JT - The patient JID - 101309314 SB - IM MH - Humans MH - *Caregivers/psychology MH - *Neoplasms/psychology/therapy MH - *Patient Preference MH - Focus Groups MH - Female MH - Choice Behavior MH - Male MH - *Telephone MH - Qualitative Research MH - Middle Aged MH - Adult MH - Aged PMC - PMC12559155 OAB - Worldwide cancer impacts more than one in five people, creating a significant need for reliable and easily accessible information. One approach to meet this need is through freely available telephone cancer services delivered by trained professionals. While these services provide valuable benefits, such as access to evidence-based information, they also have limitations for consumers. These may include restricted operating hours and costs incurred by the organisation to sustain the service. We reviewed existing research and engaged with people living with cancer and carers who have experience using telephone cancer services to identify what service features are important. These insights will inform a broader survey exploring people's preferences for telephone cancer services to determine which service features are most highly valued. The results will help the Cancer Council, governments, healthcare providers and other cancer charities running these services make decisions about the design of telephone support services to better meet the needs of people with cancer and their families. OABL- eng COIS- Declarations. Funding: The Australian Government's National Health and Medical Research Council Partnership Project grant (APP2005191) and contributions (financial and/or in-kind) from Cancer Council Victoria, Cancer Council Australia, Victorian Department of Health, Breast Cancer Network Australia, and Prostate Cancer Foundation Australia funded this research. Nikki McCaffrey holds a Victorian Government Mid-Career Research Fellowship through the Victorian Cancer Agency (MCRF20049). The funders had no role in identifying DCE attributes and levels. Conflicts of Interest: Ann Livingstone, Lidia Engel, Victoria White, Daswin De Silva, Jessica Bucholc, April Murphy, Elaine Cook, Cathrine Mihalopoulos, Liliana Orellana, Julie Ratcliffe, Danielle Spence and Nikki McCaffrey have no conflicts of interest that are directly relevant to the content of this article. Ethics Approval: The Cancer Council Victoria Human Research Ethics Committee (reference numbers HREC2107iii, HREC2107i and HREC2107) granted ethics approval, with research governance approved by the Deakin University Human Research Ethics Committee. Consent to Participate: All participants provided consent; the Declaration of Helsinki underpinned this study [27]. Consent for Publication: Not applicable. Availability of Data and Material: The de-identified data sets used and analysed during the current study may be available from the corresponding author if the request meets the project's ethics approval. Code Availability: Not applicable. Authors' Contributions: AL: methodology, investigation, formal analysis, data curation, resources, writing (original draft preparation); LE: conceptualisation, assistance with DCE methodology, writing, critical review/editing; VW: investigation, data curation, formal analysis, writing, critical review/editing; DDS: investigation, data curation, software, formal analysis, writing, critical review/editing; JB: participant recruitment, project administration, resources, writing, critical review/editing, AM: formal analysis, data curation, writing, critical review/editing; EC: writing, critical review/editing; CM: writing, critical review/editing; LO: writing, critical review/editing; JR: writing, critical review/editing; DS: writing, critical review/editing; NM: conceptualisation, resources, supervision, writing, critical review/editing. FIR - Aranda, Sanchia IR - Aranda S FIR - De Silva, Daswin IR - De Silva D FIR - Engel, Lidia IR - Engel L FIR - Fradgley, Elizabeth IR - Fradgley E FIR - Hutchinson, Alison IR - Hutchinson A FIR - Hutchinson, Claire IR - Hutchinson C FIR - Livingstone, Patricia IR - Livingstone P FIR - Mihalopoulos, Cathrine IR - Mihalopoulos C FIR - Orellana, Liliana IR - Orellana L FIR - Paul, Christine IR - Paul C FIR - Ratcliffe, Julie IR - Ratcliffe J FIR - Steiner, Anna IR - Steiner A FIR - White, Victoria IR - White V EDAT- 2025/06/08 03:37 MHDA- 2025/10/27 18:25 PMCR- 2025/06/07 CRDT- 2025/06/07 23:17 PHST- 2025/05/18 00:00 [accepted] PHST- 2025/10/27 18:25 [medline] PHST- 2025/06/08 03:37 [pubmed] PHST- 2025/06/07 23:17 [entrez] PHST- 2025/06/07 00:00 [pmc-release] AID - 10.1007/s40271-025-00746-6 [pii] AID - 746 [pii] AID - 10.1007/s40271-025-00746-6 [doi] PST - ppublish SO - Patient. 2025 Nov;18(6):645-660. doi: 10.1007/s40271-025-00746-6. Epub 2025 Jun 7. PMID- 40468506 OWN - NLM STAT- MEDLINE DCOM- 20250605 LR - 20250605 IS - 1001-9391 (Print) IS - 1001-9391 (Linking) VI - 43 IP - 5 DP - 2025 May 20 TI - [Analysis of pulmonary ventilation function and inflammatory indexes in workers exposed to different doses of chromate]. PG - 338-343 LID - 10.3760/cma.j.cn121094-20240903-00412 [doi] AB - Objective: To investigate the impact of chromate exposure on pulmonary function indices in occupational populations and explore the potential role of alterations in inflammatory indicators in this process. Methods: In July 2024, A cross-sectional analysis was conducted using occupational health examination data of 30875 workers from chromate-related enterprises in Jiangsu Province in 2020 and 2021. Based on the occupational positions and whether there is chromium acid salt exposure in the occupational hazards of the research subjects over the years, they are divided into chromium acid salt exposure group and non-exposure group. For those exposed to chromium acid salts, based on job position descriptions and duration of chromium acid salt exposure, they are further categorized into intermittent exposure group and continuous exposure group; among them, the actual exposure time in the intermittent exposure group is less than half of the working shift time, and the exposure duration is less than the total working life. Pulmonary function test indicators include forced vital capacity (forced vital capacity, FVC) %, first-second forced expiratory volume (forced expiratory volume in one second, FEV(1.0)) %, and the ratio of first-second forced expiratory volume to forced vital capacity (FEV(1.0)/FVC) %. Peripheral blood samples from the upper limbs of the research subjects were collected on an empty stomach for routine blood tests, selecting neutrophil count, platelet count, and lymphocyte count results, calculating the neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR). Quantitative data that meet normal distribution are expressed using Mean+/-SD, while variables that do not meet normal distribution are represented by M (Q(1), Q(3)). Categorical data are expressed using frequency or proportion (%). Linear variable comparisons between groups use t-tests. Generalized linear models were employed to assess the correlation between chromate exposure and pulmonary function indices, while mixed regression models were utilized to explore potential underlying effects. Results: Compared with the non-exposed group, the pulmonary function indices FVC (%), FEV(1.0)/FVC (%), and FEV(1.0) (%) in the chromate-exposed group showed a decreasing trend (P<0.01), indicating statistically significant differences. As the frequency of chromate exposure increased, the prevalence of pulmonary dysfunction rose. The prevalence rates of obstructive, restrictive, and mixed respiratory dysfunction among the chromate-exposed population (including intermittent exposure and continuous exposure groups) were 0.26%, 4.67%, and 0.12%, which were higher than those in the non-exposed group (0.09%, 0.84%, and 0.07%, respectively). All these differences were statistically significant (P<0.05). After stratification by gender, a negative correlation was observed between chromate exposure and the inflammatory indicator platelet-to-lymphocyte ratio (PLR) (P<0.05). Potential effect analysis revealed that PLR played a certain mediating role between chromate exposure and the decline in pulmonary function indices, with a mediating proportion of 2.2%. Conclusion: Chromate exposure in occupational populations may lead to a decline in pulmonary ventilatory function and alterations in peripheral blood inflammatory indicators. Inflammatory indicators may be involved in the pulmonary function decline caused by chromate exposure. FAU - Tian, K N AU - Tian KN AD - Department of Occupational Health Standards Research, National Institute of Occupational Health and Poison Control, Chinese Center for Disease Control Prevention, Beijing 100050, China. FAU - Zhu, Q H AU - Zhu QH AD - Department of Occupational Health Standards Research, National Institute of Occupational Health and Poison Control, Chinese Center for Disease Control Prevention, Beijing 100050, China. FAU - Liu, X AU - Liu X AD - Institute of Occupational Disease Prevention, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing 210009, China. FAU - Li, W J AU - Li WJ AD - Department of Occupational Health Standards Research, National Institute of Occupational Health and Poison Control, Chinese Center for Disease Control Prevention, Beijing 100050, China. FAU - Han, L AU - Han L AD - Institute of Occupational Disease Prevention, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing 210009, China. FAU - Chen, W H AU - Chen WH AD - Department of Occupational Health and Environmental Health, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Key Laboratory of Environment and Health of Ministry of Education, Wuhan 430030, China. LA - chi PT - English Abstract PT - Journal Article PL - China TA - Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi JT - Zhonghua lao dong wei sheng zhi ye bing za zhi = Zhonghua laodong weisheng zhiyebing zazhi = Chinese journal of industrial hygiene and occupational diseases JID - 8410840 RN - 0 (Chromates) SB - IM MH - Humans MH - *Occupational Exposure/adverse effects MH - Cross-Sectional Studies MH - *Chromates/adverse effects MH - Male MH - Respiratory Function Tests MH - Adult MH - *Pulmonary Ventilation MH - Female MH - Middle Aged MH - Inflammation MH - Vital Capacity MH - Forced Expiratory Volume OTO - NOTNLM OT - Chromates OT - Lung function OT - Occupational exposure OT - Occupational hazard EDAT- 2025/06/05 06:27 MHDA- 2025/06/05 06:28 CRDT- 2025/06/05 00:13 PHST- 2025/06/05 06:28 [medline] PHST- 2025/06/05 06:27 [pubmed] PHST- 2025/06/05 00:13 [entrez] AID - 10.3760/cma.j.cn121094-20240903-00412 [doi] PST - ppublish SO - Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi. 2025 May 20;43(5):338-343. doi: 10.3760/cma.j.cn121094-20240903-00412. PMID- 40452052 OWN - NLM STAT- MEDLINE DCOM- 20250601 LR - 20250630 IS - 1745-6215 (Electronic) IS - 1745-6215 (Linking) VI - 26 IP - 1 DP - 2025 Jun 2 TI - Digital vertigo therapy: study protocol for a confirmatory randomized controlled trial in patients with vestibular vertigo. PG - 184 LID - 10.1186/s13063-025-08775-0 [doi] LID - 184 AB - BACKGROUND: Vestibular vertigo is one of the leading causes of disability. The clinical standard of care for vestibular vertigo includes physical activity producing central vestibular compensation (CVC). Home exercises are considered an integral part of physical therapy. However, a reliable solution is still needed to support the regular and correct execution of home exercises. For this purpose, VH-90-D DiGA was developed, which is a digital therapeutic (DTx) for multimodular in-home therapeutic training. OBJECTIVE: The purpose of this study is to assess the clinical efficacy and safety of a vestibular health app for patients with vestibular vertigo. METHODS: A randomized group-controlled single-blinded clinical trial (RCT) has been designed. Patients will be randomly assigned to one of two treatment groups and the endpoints examined in a pre-determined order. The experimental group receives the DTx (around 15 min/daily for 90 days), and the control receives physiotherapy according to the German statutory health care plan (usually 6 x 20 min of live physiotherapy). The primary outcome will be vertigo intensity measured using the German version of the validated Vertigo Symptom Scale-short form VSS-sf-VER (0-32 score points). Evaluation is performed after 2, 6, and 12 weeks. Primary outcomes are determined by measuring the group differences of the VSS-sf-score point changes from baseline to week twelve. Including dropouts, the sample size has been determined to be 2 x 100. EXPECTED RESULTS: It is expected that therapy with the DTx will be statistically superior to physiotherapy in terms of effect size. DISCUSSION: This trial protocol marks a confirmatory RCT (GEVE II) to investigate the efficacy and safety of a digital vertigo treatment. The planned RCT is based on a series of primary and secondary efficacy variables. Examination of the endpoints in a pre-determined order ensures the rigor of confirmatory statistics and addresses the challenge of multiplicity. This sequential testing continues until significance is achieved. However, if a specific variable fails to reach significance, subsequent variables will be explored solely on a descriptive basis. TRIAL REGISTRATION: German National Registry of Clinical Studies (DRKS00028026), a WHO ICRTP registry. Registered on December 12, 2023. CI - (c) 2025. The Author(s). FAU - Wirth, Markus AU - Wirth M AUID- ORCID: 0000-0001-7240-5363 AD - Department of Otolaryngology, RWTH University Aachen, Aachen, Germany. mwirth@ukaachen.de. AD - Department of Otolaryngology, Technical University of Munich, Munich, Germany. mwirth@ukaachen.de. FAU - Pieper, Jannik AU - Pieper J AD - Chair of Economic and Social Policy, Otto Beisheim School of Management, Koblenz-Vallendar, Germany. FAU - Heller, Ulrike AU - Heller U AD - Tubingen Study Center, Clinic of Otolaryngology, Tubingen, Germany. FAU - Bulitta, Michael AU - Bulitta M AUID- ORCID: 0000-0002-1928-3886 AD - CRM Biometrics, Bornheim, Germany. FAU - Schmitz, Daniel AU - Schmitz D AD - CRM Biometrics, Bornheim, Germany. FAU - Wollenberg, Barbara AU - Wollenberg B AD - Department of Otolaryngology, Technical University of Munich, Munich, Germany. FAU - Lowenheim, Hubert AU - Lowenheim H AD - Department of Otolaryngology, University of Tubingen, Tubingen, Germany. FAU - Wolpert, Stephan AU - Wolpert S AD - Department of Otolaryngology, University of Tubingen, Tubingen, Germany. LA - eng PT - Clinical Trial Protocol PT - Journal Article DEP - 20250602 PL - England TA - Trials JT - Trials JID - 101263253 SB - IM MH - Humans MH - *Vertigo/therapy/physiopathology/diagnosis MH - Single-Blind Method MH - Randomized Controlled Trials as Topic MH - Treatment Outcome MH - *Mobile Applications MH - Germany MH - *Exercise Therapy/methods MH - Time Factors MH - *Physical Therapy Modalities PMC - PMC12128363 OTO - NOTNLM OT - DiGA OT - Digital health OT - Digital health application OT - Physiotherapy OT - Vestibulocochlear nerve diseases COIS- Declarations. Ethics approval and consent to participate: The study protocol was approved by the Ethics Committee of the German State of Baden-Wurttemberg Chamber of Physicians and Surgeons (F 2021-157). The study has been registered with the German National Registry of Clinical Studies (DRKS00028026). The first patient was enrolled July, 8, 2023. The last patient out is expected for May 15, 2025. The study may provide individual benefit for patients in both groups. Risk of AR realization is very low. After investigation and oral clarification by a doctor, patients sign the written declaration of informed consent. In addition, they receive written patient information including a description of the study and its purpose, possible AEs, name and address of the insurer, and explicit data protection information. Access to personal data is restricted to clinical investigators (physician and monitors) and patients. With the exception of the monitors authorized by the patients informed consent, data access by the sponsor is restricted to anonymous results. Statistics will be calculated on the basis of pseudonymized data. The study will be conducted in accordance with the ethical principles that have their origins in the Declaration of Helsinki and in compliance with Good Clinical Practices (GCP), including the archiving of essential documents. Protocol modifications will be communicated to relevant parties (IRB, investigators, ...) in advance and in accordance with local regulatory requirements. Consent for publication: The above mentioned informed consent includes the consent to publish anonymous data. The participant information materials and informed consent form are available from the corresponding authors on request. Competing interests: The authors declare that they have no competing interests. EDAT- 2025/06/02 03:18 MHDA- 2025/06/02 03:19 PMCR- 2025/06/02 CRDT- 2025/06/01 23:15 PHST- 2024/03/29 00:00 [received] PHST- 2025/02/14 00:00 [accepted] PHST- 2025/06/02 03:19 [medline] PHST- 2025/06/02 03:18 [pubmed] PHST- 2025/06/01 23:15 [entrez] PHST- 2025/06/02 00:00 [pmc-release] AID - 10.1186/s13063-025-08775-0 [pii] AID - 8775 [pii] AID - 10.1186/s13063-025-08775-0 [doi] PST - epublish SO - Trials. 2025 Jun 2;26(1):184. doi: 10.1186/s13063-025-08775-0. PMID- 40401059 OWN - NLM STAT- MEDLINE DCOM- 20250522 LR - 20250523 IS - 2296-2565 (Electronic) IS - 2296-2565 (Linking) VI - 13 DP - 2025 TI - U-shaped association between myeloperoxidase levels and anxiety risk: a cross-sectional study in a Chinese population. PG - 1596844 LID - 10.3389/fpubh.2025.1596844 [doi] LID - 1596844 AB - OBJECTIVE: This study investigates the association between myeloperoxidase (MPO) levels and anxiety risk in Chinese adults and explores potential effect modifiers, with implications for neuroinflammatory biomarker-guided anxiety prevention strategies. METHODS: Using cross-sectional data from 30,418 adults undergoing routine health examinations (July 2020-June 2021), anxiety severity was assessed via the Self-Rating Anxiety Scale (SAS; score >/= 50 as clinically relevant). Plasma MPO was quantified by ELISA. Multivariate logistic regression, restricted cubic splines (RCS), threshold effect analysis, and subgroup interactions were conducted to evaluate nonlinear associations. RESULTS: A U-shaped relationship between MPO and anxiety risk was identified. In fully adjusted models, participants in the lowest (Q1: /=47.3 ng/mL, OR = 1.17, 95% CI: 1.05-1.31, p = 0.004) exhibited significantly elevated anxiety risks compared to the reference quintile (Q2: 29.8-34.7 ng/mL). RCS analysis confirmed a nonlinear association (p for nonlinearity < 0.01), with an inflection point at 30 ng/mL: below this threshold, each 1 ng/mL MPO increase reduced anxiety risk (OR = 0.982, CI: 0.970-0.994), while levels above it heightened risk (OR = 1.004, CI: 1.001-1.008). Diabetes mellitus significantly modified this relationship (p-interaction = 0.028), with diabetic individuals showing amplified risks at higher plasma MPO (Q5 OR = 1.84 vs. non-diabetic Q5 OR = 1.15). CONCLUSION: Plasma MPO demonstrates a U-shaped association with anxiety risk independent of cardiometabolic confounders. Diabetic individuals exhibit heightened susceptibility to MPO-related anxiety, suggesting synergistic neuroinflammatory pathways. Monitoring MPO may aid in risk stratification and personalized interventions, particularly in populations with diabetes. CI - Copyright (c) 2025 Zhou, Kong, Liu and Huang. FAU - Zhou, Junteng AU - Zhou J AD - Health Management Center, General Practice Medical Center, West China Hospital, Sichuan University, Chengdu, China. FAU - Kong, Qihang AU - Kong Q AD - Laboratory of Cardiovascular Diseases, Regenerative Medicine Research Center, West China Hospital, Sichuan University, Chengdu, China. FAU - Liu, Xiaojing AU - Liu X AD - Laboratory of Cardiovascular Diseases, Regenerative Medicine Research Center, West China Hospital, Sichuan University, Chengdu, China. AD - Department of Cardiology, West China Hospital, Sichuan University, Chengdu, China. FAU - Huang, Yan AU - Huang Y AD - Health Management Center, General Practice Medical Center, West China Hospital, Sichuan University, Chengdu, China. AD - State Key Laboratory of Respiratory Health and Multimorbidity, West China Hospital, Sichuan University, Chengdu, China. AD - Research Laboratory for Prediction and Evaluation of Chronic Diseases in the Elderly, National Clinical Research Center for Geriatric Diseases, West China Hospital, Sichuan University, Chengdu, China. AD - General Practice Research Institute, West China Hospital, Sichuan University, Chengdu, China. LA - eng PT - Journal Article DEP - 20250507 PL - Switzerland TA - Front Public Health JT - Frontiers in public health JID - 101616579 RN - EC 1.11.1.7 (Peroxidase) RN - 0 (Biomarkers) RN - Chinese people SB - IM MH - Humans MH - *Peroxidase/blood MH - Cross-Sectional Studies MH - Female MH - Male MH - China/epidemiology MH - Middle Aged MH - *Anxiety/blood/epidemiology MH - Adult MH - Biomarkers/blood MH - Risk Factors MH - Aged MH - East Asian People PMC - PMC12092346 OTO - NOTNLM OT - U-shaped association OT - anxiety OT - cross-sectional study OT - diabetes mellitus OT - myeloperoxidase OT - neuroinflammation COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2025/05/22 06:28 MHDA- 2025/05/22 06:29 PMCR- 2025/05/07 CRDT- 2025/05/22 04:31 PHST- 2025/03/20 00:00 [received] PHST- 2025/04/18 00:00 [accepted] PHST- 2025/05/22 06:29 [medline] PHST- 2025/05/22 06:28 [pubmed] PHST- 2025/05/22 04:31 [entrez] PHST- 2025/05/07 00:00 [pmc-release] AID - 10.3389/fpubh.2025.1596844 [doi] PST - epublish SO - Front Public Health. 2025 May 7;13:1596844. doi: 10.3389/fpubh.2025.1596844. eCollection 2025. PMID- 40312836 OWN - NLM STAT- MEDLINE DCOM- 20250904 LR - 20260629 IS - 1476-6256 (Electronic) IS - 0002-9262 (Linking) VI - 194 IP - 9 DP - 2025 Sep 3 TI - Reproducibility and validity of low-carbohydrate diet and low-fat diet scores derived from 24-hour dietary recalls. PG - 2724-2732 LID - 10.1093/aje/kwaf087 [doi] AB - The reproducibility and validity of low-carbohydrate diets (LCD) and low-fat diets (LFD) from 24-hour dietary recall (24HDR) remain unclear. We evaluated the performance of 24HDR-based assessments of 6 dietary patterns (overall, healthful, and unhealthful LCD/LFD) to determine the optimum number of 24HDR in epidemiologic studies. Participants (n = 432, 185 men and 247 women) aged 18-84 years from the Anhui Lifestyle Validation Study (ALVS) completed 4 quarterly 3 consecutive 24HDRs (2 weekdays and 1 weekend day) during July 2021 to July 2022. Reproducibility was evaluated by intraclass correlation coefficient (ICC). Validity was evaluated by comparing the estimates against those from the average of 12 24HDRs using deattenuated Spearman correlation coefficient (rc). Reproducibility and validity increased with an escalating number of 24HDRs. Dietary pattern scores from 2 24HDRs showed moderate reproducibility (ICC: 0.40-0.47), except unhealthful LFD with the ICC of 0.37, while 4 24HDRs yielded a moderate reproducibility for all dietary patterns (ICC: 0.43-0.59). The validity of the 6 dietary patterns was moderate for 1 24HDR (rc: 0.44-0.58) and moderate or strong for >/=2 24HDRs (rc: 0.56-0.98). Two 24HDRs show reasonable performance in measuring most LCD/LFD scores, and 4 24HDRs are sufficient for all dietary patterns. CI - (c) The Author(s) 2025. Published by Oxford University Press on behalf of the Johns Hopkins Bloomberg School of Public Health. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site-for further information please contact journals.permissions@oup.com. FAU - Li, Meiling AU - Li M AUID- ORCID: 0009-0000-1052-8501 AD - Department of Nutrition, Center for Big Data and Population Health of IHM, School of Public Health, Anhui Medical University, Hefei, Anhui, China. AD - Key Laboratory of Population Health Across Life Cycle (Anhui Medical University), Ministry of Education of the People's Republic of China, Hefei, Anhui, China. AD - NHC Key Laboratory of Study on Abnormal Gametes and Reproductive Tract, National Health Commission of the People's Republic of China, Hefei, Anhui, China. AD - Anhui Provincial Key Laboratory of Population Health and Aristogenics/Key Laboratory of Environmental Toxicology of Anhui Higher Education Institutes, Anhui Medical University, Hefei, Anhui, China. FAU - Li, Xiude AU - Li X AUID- ORCID: 0000-0002-3475-7015 AD - Department of Clinical Nutrition, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China. FAU - Yin, Kewan AU - Yin K AUID- ORCID: 0009-0002-7918-6807 AD - Department of Nutrition, Center for Big Data and Population Health of IHM, School of Public Health, Anhui Medical University, Hefei, Anhui, China. FAU - Wang, Tingting AU - Wang T AUID- ORCID: 0009-0009-3521-2445 AD - Department of Nutrition, Center for Big Data and Population Health of IHM, School of Public Health, Anhui Medical University, Hefei, Anhui, China. FAU - Jiang, Chao AU - Jiang C AUID- ORCID: 0009-0004-6243-4565 AD - Department of Chronic Non-communicable Diseases Prevention and Control, Huoshan County Center for Disease Control and Prevention, Huoshan, Anhui, China. FAU - Cao, Hongjuan AU - Cao H AUID- ORCID: 0009-0004-1664-289X AD - Department of Chronic Non-communicable Diseases Prevention and Control, Lu'an Center for Disease Control and Prevention, Lu'an, Anhui, China. FAU - Zhang, Zhuang AU - Zhang Z AUID- ORCID: 0009-0004-1144-9740 AD - Department of Nutrition, Center for Big Data and Population Health of IHM, School of Public Health, Anhui Medical University, Hefei, Anhui, China. FAU - Sun, Jiangwei AU - Sun J AUID- ORCID: 0000-0003-2252-684X AD - Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden. FAU - Yang, Wanshui AU - Yang W AUID- ORCID: 0000-0002-7365-2689 AD - Department of Nutrition, Center for Big Data and Population Health of IHM, School of Public Health, Anhui Medical University, Hefei, Anhui, China. AD - Key Laboratory of Population Health Across Life Cycle (Anhui Medical University), Ministry of Education of the People's Republic of China, Hefei, Anhui, China. AD - NHC Key Laboratory of Study on Abnormal Gametes and Reproductive Tract, National Health Commission of the People's Republic of China, Hefei, Anhui, China. AD - Anhui Provincial Key Laboratory of Population Health and Aristogenics/Key Laboratory of Environmental Toxicology of Anhui Higher Education Institutes, Anhui Medical University, Hefei, Anhui, China. LA - eng GR - YJS20230150/Postgraduate Innovation Research and Practice Program of Anhui Medical University/ GR - YJS20230104/Postgraduate Innovation Research and Practice Program of Anhui Medical University/ GR - 2021xkjT007/Anhui Medical University/ GR - JKS2022018/Research Funds of Center for Big Data and Population Health of IHM/ GR - 82373673/National Natural Science Foundation of China/ GR - 2023YFA1800800/National Key Research and Development Program of China/ PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Validation Study PL - United States TA - Am J Epidemiol JT - American journal of epidemiology JID - 7910653 SB - IM MH - Humans MH - Middle Aged MH - Male MH - Female MH - Reproducibility of Results MH - Adult MH - Aged MH - *Diet, Carbohydrate-Restricted/statistics & numerical data MH - Aged, 80 and over MH - Adolescent MH - Young Adult MH - *Diet, Fat-Restricted/statistics & numerical data MH - *Mental Recall MH - *Diet Surveys OTO - NOTNLM OT - 24-hour dietary recall OT - low-carbohydrate diet OT - low-fat diet OT - reproducibility OT - validity EDAT- 2025/05/02 06:28 MHDA- 2025/09/04 06:37 CRDT- 2025/05/02 00:53 PHST- 2024/07/04 00:00 [received] PHST- 2025/04/08 00:00 [revised] PHST- 2025/04/15 00:00 [accepted] PHST- 2025/09/04 06:37 [medline] PHST- 2025/05/02 06:28 [pubmed] PHST- 2025/05/02 00:53 [entrez] AID - 8123640 [pii] AID - 10.1093/aje/kwaf087 [doi] PST - ppublish SO - Am J Epidemiol. 2025 Sep 3;194(9):2724-2732. doi: 10.1093/aje/kwaf087. PMID- 40305004 OWN - NLM STAT- MEDLINE DCOM- 20250523 LR - 20250525 IS - 1552-9924 (Electronic) IS - 0091-6765 (Print) IS - 0091-6765 (Linking) VI - 133 IP - 5 DP - 2025 May TI - Pavements to Longevity: The Influence of Neighborhood Walkability on Mortality in Taiwan. PG - 57018 LID - 10.1289/EHP15209 [doi] LID - 057018 AB - BACKGROUND: There is limited information on the association between walkability and health in Asian countries. OBJECTIVE: Our study aimed to investigate the association between neighborhood walkability and mortality in Taiwanese adults. METHODS: We selected 457,874 participants ( >/= 18 y of age) from Taiwan who joined a standard medical examination program between 1998 and 2016 and followed them until 31 July 2021. Three walkability measures were estimated within a walking distance of 640 m of participant's addresses: points of interest (POI), transit stations, and impedance (restrictions to walking due to absence of intersections and physical barriers). Walkability measures were applied as continuous and categorical (tertiles) variables in data analyses. Mortality data were obtained from the National Death Registry maintained by the Ministry of Health and Welfare in Taiwan. A time-varying Cox regression model was used to investigate the association of neighborhood walkability with deaths from natural causes and specific causes. RESULTS: This study identified 24,744 deaths over a median follow-up of 16.9 y. In comparison with participants living with the first tertile for numbers of POI and transit stations, those living with higher numbers of POI and transit stations were associated with a lower risk of natural-cause mortality, with hazard ratios (HRs) of 0.97 [95% confidence intervals (CIs): 0.94, 1.00] and 0.93 (95% CI: 0.90, 0.96) for second and third tertiles of numbers of POI, and 0.99 (95% CI: 0.96, 1.02) and 0.94 (95% CI: 0.92, 0.98) for second and third tertiles of numbers of transit stations, respectively. Each unit increase in POI and transit stations was associated with a 3% (HR = 0.97; 95% CI: 0.96, 0.99) and 2% (HR = 0.98; 95% CI: 0.97, 0.99) reduced risk of natural-cause mortality, respectively. In addition, in comparison with living in areas with the first tertile of impedance, living with the third tertile of impedance was associated a higher risk of natural-cause mortality, with HRs of 1.01 (95% CI: 1.00, 1.03). One unit increase in impedance was associated with a 1% (HR = 1.01; 95% CI: 1.00, 1.03) increased risk of natural-cause mortality. We also found significantly inverse associations between three walkability measures with deaths from cardiovascular diseases and between POI and death from chronic respiratory diseases. CONCLUSION: Our findings indicate that a higher level of neighborhood walkability was associated with a lower risk of mortality. Our data suggest that it is important to take into account neighborhood walkability in urban planning and health guideline development. https://doi.org/10.1289/EHP15209. FAU - Zeng, Yiqian AU - Zeng Y AD - Department of Biomedical Sciences, City University of Hong Kong, Hong Kong SAR, China. FAU - Rudge, Gavin AU - Rudge G AD - Institute of Applied Health Research, College of Medical and Dental Sciences, The University of Birmingham, Birmingham, UK. FAU - Yu, Tsung AU - Yu T AD - Department of Public Health, National Cheng Kung University, Tainan, Taiwan. FAU - Chen, Weiyi AU - Chen W AD - Department of Biomedical Sciences, City University of Hong Kong, Hong Kong SAR, China. FAU - Chong, Ka Chun AU - Chong KC AD - Jockey Club School of Public Health and Primary Care, the Chinese University of Hong Kong, Hong Kong SAR, China. FAU - Huang, Yu AU - Huang Y AD - Department of Biomedical Sciences, City University of Hong Kong, Hong Kong SAR, China. FAU - Thomas, G Neil AU - Thomas GN AD - Institute of Applied Health Research, College of Medical and Dental Sciences, The University of Birmingham, Birmingham, UK. FAU - Lao, Xiang Qian AU - Lao XQ AD - Department of Biomedical Sciences, City University of Hong Kong, Hong Kong SAR, China. LA - eng PT - Journal Article DEP - 20250523 PL - United States TA - Environ Health Perspect JT - Environmental health perspectives JID - 0330411 SB - IM MH - Humans MH - Taiwan/epidemiology MH - *Walking/statistics & numerical data MH - Female MH - Male MH - *Mortality MH - Middle Aged MH - *Neighborhood Characteristics/statistics & numerical data MH - *Longevity MH - Aged MH - Adult MH - *Residence Characteristics/statistics & numerical data MH - *Environment Design PMC - PMC12101571 EDAT- 2025/04/30 12:28 MHDA- 2025/05/23 18:39 PMCR- 2025/05/23 CRDT- 2025/04/30 11:25 PHST- 2025/05/23 18:39 [medline] PHST- 2025/04/30 12:28 [pubmed] PHST- 2025/04/30 11:25 [entrez] PHST- 2025/05/23 00:00 [pmc-release] AID - EHP15209 [pii] AID - 10.1289/EHP15209 [doi] PST - ppublish SO - Environ Health Perspect. 2025 May;133(5):57018. doi: 10.1289/EHP15209. Epub 2025 May 23. PMID- 40292491 OWN - NLM STAT- MEDLINE DCOM- 20260212 LR - 20260212 IS - 1753-4887 (Electronic) IS - 0029-6643 (Linking) VI - 84 IP - 3 DP - 2026 Mar 1 TI - Association Among Vitamin D Receptor Gene Polymorphisms, Metabolic Control, and Inflammatory Markers in Type 2 Diabetes: A Systematic Review and Meta-Analysis. PG - 540-550 LID - 10.1093/nutrit/nuaf055 [doi] AB - CONTEXT: Single-nucleotide polymorphisms (SNPs) in the vitamin D receptor (VDR) contribute to inadequate metabolic profiles in individuals with type 2 diabetes mellitus (T2DM). OBJECTIVE: We sought to elucidate the relationship among SNPs in the VDR and markers for glycemic control, lipid profile, and inflammation in individuals with T2DM. DATA SOURCES: We performed a systematic search in the MEDLINE (via PubMed), EMBASE, and SCOPUS databases in July 2021 and updated the search in October 2023. DATA EXTRACTION: 6 observational studies were selected from the databases, and 1 study was included after checking the reference list. Two authors independently completed the selection and data extraction of studies and population characteristics, the prevalence of SNPs in the VDR, genotyping methods, and laboratory findings, and performed summary statistics of the results. DATA ANALYSIS: The meta-analyses were performed on 5 studies including 1198 adults with T2DM. The duration of the diabetes diagnosis ranged from 5.0 to 14.7 years. A random-effects model was used to pool the results using a 2-tailed (P < .05). Effect sizes were reported as standardized mean differences (SMDs) and 95% confidence intervals (CIs). Four SNPs in the VDR were identified (Fokl, BsmI, Taql, and Apal) by using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). The Fokl SNP was identified in 5 studies and associated with a higher percentage of glycated hemoglobin (HbA1c%) (SMD, 0.41 [95% CI, 0.15-0.67]). The Bsml in 4 studies was associated with higher triacylglycerol (SMD, 0.21 [95% CI, 0.03-0.38]). The Taql SNP was identified in 2 studies and did not show any associations, and the Apal SNP was identified in only 1 study and was not analysed in the meta-analysis. CONCLUSIONS: Although the studies identified 4 SNPs in the VDR, the results of the meta-analysis allowed us to infer only the association of the SNPs Fokl and Bsml with increased %HbA1c and triacylglycerol levels, respectively, in individuals with T2DM. SYSTEMATIC REVIEW REGISTRATION: PROSPERO registration number CRD42021268152. CI - (c) The Author(s) 2025. Published by Oxford University Press on behalf of the International Life Sciences Institute. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site-for further information please contact journals.permissions@oup.com. FAU - Santos, Ramara Kadija Fonseca AU - Santos RKF AUID- ORCID: 0000-0002-2486-1900 AD - Health Sciences Post-Graduation Program, University Hospital, Federal University of Sergipe, Aracaju, Sergipe 49060-108, Brazil. AD - Nutrition Sciences Post-Graduation Program, Federal University of Sergipe, Sao Cristovao, Sergipe 49107-230, Brazil. FAU - Pereira, Raquel Oliveira AU - Pereira RO AUID- ORCID: 0000-0002-9785-4824 AD - Health Sciences Post-Graduation Program, University Hospital, Federal University of Sergipe, Aracaju, Sergipe 49060-108, Brazil. FAU - Brandao-Lima, Paula Nascimento AU - Brandao-Lima PN AUID- ORCID: 0000-0002-0949-361X AD - Department of Nutrition, School of Public Health, University of Sao Paulo, Sao Paulo 01246-904, Brazil. FAU - Martins-Filho, Paulo Ricardo AU - Martins-Filho PR AUID- ORCID: 0000-0001-8779-0727 AD - Health Sciences Post-Graduation Program, University Hospital, Federal University of Sergipe, Aracaju, Sergipe 49060-108, Brazil. FAU - Melo, Caroline Dos Santos AU - Melo CDS AUID- ORCID: 0000-0003-1629-9855 AD - Health Sciences Post-Graduation Program, University Hospital, Federal University of Sergipe, Aracaju, Sergipe 49060-108, Brazil. AD - Nutrition Sciences Post-Graduation Program, Federal University of Sergipe, Sao Cristovao, Sergipe 49107-230, Brazil. FAU - Pires, Liliane Viana AU - Pires LV AUID- ORCID: 0000-0003-1710-0836 AD - Nutrition Sciences Post-Graduation Program, Federal University of Sergipe, Sao Cristovao, Sergipe 49107-230, Brazil. AD - Nutritional Biochemistry Laboratory, Department of Nutrition, Center for Biological and Health Sciences, Federal University of Sergipe, Sao Cristovao, Sergipe 49107-230, Brazil. FAU - Silva, Ana Mara de Oliveira E AU - Silva AMOE AUID- ORCID: 0000-0003-0831-8833 AD - Health Sciences Post-Graduation Program, University Hospital, Federal University of Sergipe, Aracaju, Sergipe 49060-108, Brazil. AD - Nutrition Sciences Post-Graduation Program, Federal University of Sergipe, Sao Cristovao, Sergipe 49107-230, Brazil. LA - eng GR - Coordination for the Improvement of Higher Education Personnel/ GR - 2019/22934-1/Sao Paulo Research Foundation/ PT - Journal Article PT - Meta-Analysis PT - Systematic Review PL - United States TA - Nutr Rev JT - Nutrition reviews JID - 0376405 RN - 0 (Receptors, Calcitriol) RN - 0 (VDR protein, human) RN - 0 (Biomarkers) RN - 0 (Blood Glucose) SB - IM MH - Humans MH - *Diabetes Mellitus, Type 2/genetics/metabolism/blood MH - *Receptors, Calcitriol/genetics MH - *Polymorphism, Single Nucleotide MH - Biomarkers/blood MH - *Inflammation/genetics MH - Blood Glucose/metabolism OTO - NOTNLM OT - cholecalciferol OT - polymorphism OT - type 2 diabetes OT - vitamin D OT - vitamin D receptor EDAT- 2025/04/28 12:29 MHDA- 2026/02/12 12:49 CRDT- 2025/04/28 06:46 PHST- 2026/02/12 12:49 [medline] PHST- 2025/04/28 12:29 [pubmed] PHST- 2025/04/28 06:46 [entrez] AID - 8120902 [pii] AID - 10.1093/nutrit/nuaf055 [doi] PST - ppublish SO - Nutr Rev. 2026 Mar 1;84(3):540-550. doi: 10.1093/nutrit/nuaf055. PMID- 40263594 OWN - NLM STAT- MEDLINE DCOM- 20250423 LR - 20250425 IS - 2045-2322 (Electronic) IS - 2045-2322 (Linking) VI - 15 IP - 1 DP - 2025 Apr 22 TI - The acceptances and associated influences of body donation in Mainland China: a national cross-sectional study. PG - 13920 LID - 10.1038/s41598-025-98401-5 [doi] LID - 13920 AB - The inadequate body donors have restricted the development of medical sciences in some ways in mainland China. However, the investigation of potential donors may change the status quo of body donation. From July 10th to September 15th, 2021, we conducted a cross-sectional, multi-stage sampling study collected demographic data and individuals' willingness to accept body donation from 120 cities in mainland China. A stepwise linear regression analysis was adopted. 11,031 valid samples were collected for this survey. The willingness to donate body among Chinese residents averaged 53.66 points. To be specific, patients with a different number of children (1: beta=-0.05; 2: beta=-0.04; >/=3: beta= -0.03) are less willing to donate their organs while respondents who live in an urban area (beta = 0.03), have higher education level (high school or junior college: beta = 0.04, such as a bachelor degree or above: beta = 0.09), feel anxious (mild, moderate beta = 0.02), feel pressured (moderate: beta = 0.08; severe: beta = 0.09), have higher scores of the Short-Form Health Literacy Instrument (HLS-SF12) (beta = 0.30), Chronic Disease Self-Management Study Measures (CDSMS) (beta = 0.18) and EuroQol Visual Analogue Scale (EQ-VAS) (beta = 0.23), are more positive to donate. In this study, we discovered that Chinese residents' acceptance level of body donation is affected by age, gender, housing, educational levels, anxiety, pressure, social support, and health literacy, among which health literacy plays a key role in residents' attitudes towards body donation. This study firstly discusses the public acceptance of body donation through a nationwide sample around mainland China. CI - (c) 2025. The Author(s). FAU - Wu, Jian AU - Wu J AD - Department of Laboratory Medicine, Suzhou Municipal Hospital, Gusu School, The Affiliated Suzhou Hospital of Nanjing Medical University, Nanjing Medical University, 242 Guangji Road, Suzhou, 215008, Jiangsu, China. wujianglinxing@163.com. FAU - Zhang, Xinyue AU - Zhang X AD - School of Health Policy and Management, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. FAU - Xiang, Ze AU - Xiang Z AD - Zhejiang University School of Medicine, Hangzhou, 310011, Zhejiang, China. FAU - Li, Yiqi AU - Li Y AD - Zhejiang University School of Medicine, Hangzhou, 310011, Zhejiang, China. FAU - Hu, Zihao AU - Hu Z AD - Zhejiang University School of Medicine, Hangzhou, 310011, Zhejiang, China. FAU - Chen, Tianle AU - Chen T AD - School of Mathematical Sciences, Zhejiang University, Hangzhou, 310058, China. FAU - Zhou, Jianmin AU - Zhou J AD - Zhejiang University, 866 Yuhangtang Road, Xihu District, Hangzhou City, Zhejiang Province, China. FAU - Sun, Xinying AU - Sun X AD - School of Public Health, Peking University, 38 Xueyuan Road, Haidian District, Beijing, China. FAU - Wu, Yibo AU - Wu Y AD - School of Public Health, Peking University, 38 Xueyuan Road, Haidian District, Beijing, China. FAU - Yi, Yuyang AU - Yi Y AD - Department of Infectious Diseases and Public Health, City University of Hong Kong, Tat Chee Avenue, Kowloon, Hong Kong, China. yuyangyi2-c@my.cityu.edu.hk. FAU - Wang, Yinlin AU - Wang Y AD - School of Health Policy and Management, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. wyl1998@zju.edu.cn. AD - Stomatology Hospital, School of stomatology, Zhejiang Provincial Clinical Research Center for Oral Diseases, Key Laboratory of Oral Biomedical Research of Zhejiang Province, Zhejiang university of Medicine, Cancer Center of Zhejiang University, Hangzhou, 310006, China. wyl1998@zju.edu.cn. LA - eng PT - Journal Article DEP - 20250422 PL - England TA - Sci Rep JT - Scientific reports JID - 101563288 SB - IM MH - Humans MH - Female MH - China MH - Male MH - Cross-Sectional Studies MH - Adult MH - Middle Aged MH - *Tissue and Organ Procurement MH - Surveys and Questionnaires MH - *Tissue Donors/psychology MH - Young Adult MH - Aged MH - Adolescent PMC - PMC12015374 OTO - NOTNLM OT - Body donation OT - Cross-sectional study OT - Influencing factors OT - Mainland China OT - Public acceptance COIS- Declarations. Competing interests: The authors declare no competing interests. Ethical approval and consent to participate: All methods were carried out in accordance with relevant guidelines and regulations. The study passed the ethical review (JNUKY-2021-018) by the Institutional Review Committee of Ji'nan University, Guangzhou, China. The informed consent was obtained from all participants and/or their legal guardian(s), confirming their informed and voluntary approval. EDAT- 2025/04/23 00:31 MHDA- 2025/04/23 06:26 PMCR- 2025/04/22 CRDT- 2025/04/22 23:42 PHST- 2024/08/03 00:00 [received] PHST- 2025/04/11 00:00 [accepted] PHST- 2025/04/23 06:26 [medline] PHST- 2025/04/23 00:31 [pubmed] PHST- 2025/04/22 23:42 [entrez] PHST- 2025/04/22 00:00 [pmc-release] AID - 10.1038/s41598-025-98401-5 [pii] AID - 98401 [pii] AID - 10.1038/s41598-025-98401-5 [doi] PST - epublish SO - Sci Rep. 2025 Apr 22;15(1):13920. doi: 10.1038/s41598-025-98401-5. PMID- 40259241 OWN - NLM STAT- MEDLINE DCOM- 20250421 LR - 20250424 IS - 1471-230X (Electronic) IS - 1471-230X (Linking) VI - 25 IP - 1 DP - 2025 Apr 21 TI - Comparison of the predictive value of TyG index and METS-IR for OSA combined with NAFLD: a retrospective observational study based on a physical examination population. PG - 279 LID - 10.1186/s12876-025-03856-5 [doi] LID - 279 AB - BACKGROUND: Obstructive sleep apnoea (OSA), Non-alcoholic fatty liver disease (NAFLD) and insulin resistance (IR) are interlinked. The aim of our study was to investigate the predictive value of metabolic score for insulin resistance (METS-IR) and triglyceride-glucose(TyG) index in relation to OSA combined with NAFLD in physical examination population. METHODS: This is a retrospective observational study. 329 physical examiners who attended the healthcare centre of the First Affiliated Hospital of Wenzhou Medical University for polysomnography and abdominal ultrasonography (or CT abdominal scanning) from September 2021 to July 2024. Subjects were categorized into two groups according to the presence or absence of combined NAFLD. Logistic regression analysis and restricted cubic spline model (RCS) were used to evaluate the relationship between TyG index and METS-IR and NAFLD. The predictive value of TyG index and METS-IR for NAFLD was determined by receiver operating characteristic curves (ROC curves). RESULTS: A total of 329 subjects were analyzed. The prevalence of NAFLD increased with increasing TyG index (P for trend < 0.001), and METS-IR showed an increasing-decreasing-increasing trend with NAFLD risk (P for trend < 0.001). RCS analysis showed a dose-response relationship between NAFLD risk and METS-IR (p = 0.012) and a linear relationship with the TyG index (p = 0.078), with a significant increase in the risk of NAFLD when the METS-IR exceeded a threshold of 47.47 (OR = 1). Compared with TyG index (AUC = 0.775, 95% CI: 0.711-0.828), METS-IR (AUC = 0.778, 95% CI: 0.716-0.836) had a higher predictive value for NAFLD in the OSA physical examination population. CONCLUSIONS: In the OSA population, TyG index and METS-IR had predictive value for the development of NAFLD, with METS-IR being superior to TyG index. CI - (c) 2025. The Author(s). FAU - Li, Min AU - Li M AD - First Clinical School of Medicine (School of Information and Engineering), Wenzhou Medical University, Wenzhou, Zhejiang, 325000, China. AD - The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China. FAU - Wan, Yujing AU - Wan Y AD - First Clinical School of Medicine (School of Information and Engineering), Wenzhou Medical University, Wenzhou, Zhejiang, 325000, China. AD - The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China. FAU - Wei, Ziyue AU - Wei Z AD - First Clinical School of Medicine (School of Information and Engineering), Wenzhou Medical University, Wenzhou, Zhejiang, 325000, China. AD - The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China. FAU - Lin, Weihong AU - Lin W AD - Department of Healthcare Center, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China. ylbjzxlwh@163.com. AD - Wenzhou Key Laboratory of Intelligent Prevention and Active Health for Aging-Related Chronic Diseases, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, 325000, China. ylbjzxlwh@163.com. LA - eng GR - Y20210036/Wen Zhou Science Technology Bureau/ GR - Y20210036/Wen Zhou Science Technology Bureau/ GR - Y20210036/Wen Zhou Science Technology Bureau/ GR - Y20210036/Wen Zhou Science Technology Bureau/ PT - Comparative Study PT - Journal Article PT - Observational Study DEP - 20250421 PL - England TA - BMC Gastroenterol JT - BMC gastroenterology JID - 100968547 RN - 0 (Blood Glucose) RN - 0 (Triglycerides) SB - IM MH - Humans MH - *Non-alcoholic Fatty Liver Disease/complications/epidemiology/blood/diagnosis MH - Retrospective Studies MH - Male MH - Female MH - Middle Aged MH - *Sleep Apnea, Obstructive/complications/blood/epidemiology/diagnosis MH - Predictive Value of Tests MH - *Blood Glucose/analysis MH - Adult MH - *Insulin Resistance MH - *Triglycerides/blood MH - ROC Curve MH - *Metabolic Syndrome/diagnosis/complications/epidemiology MH - Physical Examination PMC - PMC12013029 OTO - NOTNLM OT - Insulin resistance OT - Metabolic score for insulin resistance OT - Non-alcoholic fatty liver disease OT - Obstructive sleep apnoea OT - Triglyceride-glucose index COIS- Declarations. Ethics approval and consent to participate: This study complied with the Declaration of Helsinki. This study was approved by the Ethical Review Committee of the First Affiliated Hospital of Wenzhou Medical University (KY2024 - 194). The data are anonymous, therefore the Ethics Committee of the First Affiliated Hospital of Wenzhou Medical University has waived the requirement of informed consent. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests. EDAT- 2025/04/22 00:26 MHDA- 2025/04/22 00:27 PMCR- 2025/04/21 CRDT- 2025/04/21 23:34 PHST- 2024/12/18 00:00 [received] PHST- 2025/04/04 00:00 [accepted] PHST- 2025/04/22 00:27 [medline] PHST- 2025/04/22 00:26 [pubmed] PHST- 2025/04/21 23:34 [entrez] PHST- 2025/04/21 00:00 [pmc-release] AID - 10.1186/s12876-025-03856-5 [pii] AID - 3856 [pii] AID - 10.1186/s12876-025-03856-5 [doi] PST - epublish SO - BMC Gastroenterol. 2025 Apr 21;25(1):279. doi: 10.1186/s12876-025-03856-5. PMID- 40225521 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250415 IS - 2168-8184 (Print) IS - 2168-8184 (Electronic) IS - 2168-8184 (Linking) VI - 17 IP - 3 DP - 2025 Mar TI - The Effect of COVID-19 on Attendance Rates in Pediatric Residency Training Educational Sessions. PG - e80443 LID - 10.7759/cureus.80443 [doi] LID - e80443 AB - INTRODUCTION: Residency education faced significant challenges during the COVID-19 pandemic. Programs had to adopt new methods to maintain high-quality education while adhering to social distancing restrictions. This necessity prompted medical training programs worldwide to change their learning routines dramatically. A notable shift occurred from traditional classroom lectures to online educational tools, with web-based learning becoming a key strategy to address these challenges. OBJECTIVE: This study aimed to evaluate the impact of the transition to virtual learning during the COVID-19 pandemic on attendance rates at scheduled educational sessions in a pediatric residency program. HYPOTHESIS: We postulated that the introduction of virtual lectures for residency training will increase the attendance of residents. METHODOLOGY: All pediatric residents exposed to in-person and virtual learning during the study period (October 2020) were included. Attendance records were reviewed, and data were stratified based on the year of expected graduation (Class of 2021 and Class of 2022). The attendance rate percent (ARP) was calculated as: (Number of educational sessions attended / Total number of sessions held) x 100. ARP during the prepandemic (traditional method; July-September 2019) period was compared with ARP during the pandemic period (virtual learning; July 2020-September 2020). Statistical analysis was done using chi-square analysis. RESULTS: A total of 23 residents were subjects in the study: 11 from the graduating class of 2021 and 12 from the graduating class of 2022. In July- October 2019, with 54 lectures, the total expected attendance was 1,242 (23 residents x 54 lectures). In July-October 2020, with 62 educational sessions, the total expected attendance was 1,426 (62 sessions x 23 residents). The actual attendance was 451 (36%) in 2019 compared to 722 (51%) in 2020, a 15% increase (p < 0.00001). This increase was associated with the shift to virtual learning for both classes (p < 0.001). CONCLUSION: Our results show a significant increase in educational session attendance rate among our resident group after the implementation of virtual learning, irrespective of their level of training. However, it is not a given that increased attendance is likely to result in increased knowledge and better clinical performance. Virtual learning should be considered a valuable educational tool for residency training. CI - Copyright (c) 2025, Sunderajan et al. FAU - Sunderajan, Trisha AU - Sunderajan T AD - Pediatric Critical Care Medicine, Loma Linda University Children's Hospital, Loma Linda, USA. FAU - Pierre, Louisdon AU - Pierre L AD - Pediatrics, The Brooklyn Hospital Center, Brooklyn, USA. FAU - Kondamudi, Noah AU - Kondamudi N AD - Pediatric Emergency Medicine, The Brooklyn Hospital Center, Brooklyn, USA. FAU - Adebayo, Adeyinka AU - Adebayo A AD - Pediatric Critical Care Medicine, The Brooklyn Hospital Center, Brooklyn, USA. LA - eng PT - Journal Article DEP - 20250311 PL - United States TA - Cureus JT - Cureus JID - 101596737 PMC - PMC11990663 OTO - NOTNLM OT - attendance rates OT - covid-19 impact OT - medical training OT - residency education OT - virtual learning COIS- Human subjects: Consent for treatment and open access publication was obtained or waived by all participants in this study. Institutional Review Board at the Brooklyn Hospital Center issued approval 1622184-1. This study was approved by the Institutional Review Board at the Brooklyn Hospital Center, IRB approval number 1622184-1. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work. EDAT- 2025/04/14 17:28 MHDA- 2025/04/14 17:29 PMCR- 2025/03/11 CRDT- 2025/04/14 07:11 PHST- 2025/03/11 00:00 [accepted] PHST- 2025/04/14 17:29 [medline] PHST- 2025/04/14 17:28 [pubmed] PHST- 2025/04/14 07:11 [entrez] PHST- 2025/03/11 00:00 [pmc-release] AID - 10.7759/cureus.80443 [doi] PST - epublish SO - Cureus. 2025 Mar 11;17(3):e80443. doi: 10.7759/cureus.80443. eCollection 2025 Mar. PMID- 40175907 OWN - NLM STAT- MEDLINE DCOM- 20250515 LR - 20260428 IS - 1471-2261 (Electronic) IS - 1471-2261 (Linking) VI - 25 IP - 1 DP - 2025 Apr 2 TI - High triglyceride-to-high-density lipoprotein cholesterol ratio predicts poor prognosis in new-onset heart failure: a retrospective study. PG - 251 LID - 10.1186/s12872-025-04706-8 [doi] LID - 251 AB - BACKGROUND: There is limited research on the relationship between the triglyceride-to-high-density lipoprotein cholesterol (TG/HDL-C) ratio and outcomes in new-onset heart failure (HF). Therefore, this study aimed to explore the association between TG/HDL-C ratio and clinical outcomes in these patients. METHODS: A retrospective cohort of 614 adults with new-onset HF hospitalized at The First Affiliated Hospital of Nanchang University between July 2021 and December 2022 was analyzed. The primary endpoint was major adverse cardiovascular events (MACE), defined as cardiovascular (CV) death and HF rehospitalizations within 12 months after discharge. Kaplan-Meier (K-M) curves, restricted cubic spline (RCS) analysis, and Cox regression evaluated the association between TG/HDL-C ratio and MACE risk. RESULTS: Patients were divided into four quartiles (Quartile 1, 2,3 and 4) based on their TG/HDL-C ratios. The mean age was 68.94 +/- 14.34 years, with 59.12% male. The mean left ventricular ejection fraction (LVEF) was 46.59 +/- 10.89%, with 45.11% having an LVEF 25 kg/m(2) (91%), and were taking anti-hypertensive medication (83%). Demographic and medical characteristics were similar across the randomised groups. 182 (98%) completed the trial. Over the 12-week intervention, the sodium density of groceries purchased by the intervention group compared to the control group was 204 mg/1000 kcal lower (95%CI, -352 to -56) (P = 0.01). The reduction in sodium density of purchases was apparent in weeks 1-4 and sustained through the end of the trial. 86% of participants in the intervention group made at least one switch to a lower sodium product. There were no detectable effects on blood pressure, spot urine sodium concentration, or other secondary outcomes across the 12-week study period. CONCLUSIONS: Online shopping platforms provide a novel opportunity to support purchases of lower sodium foods. While the reductions in sodium density of purchases were moderate in size, population health benefits could nonetheless be large if they were sustained over time and at scale, with large and growing numbers of online grocery shoppers and a high prevalence of elevated blood pressure amongst adults. TRIAL REGISTRATION: ACTRN12621000642886. CI - (c) 2024. The Author(s). FAU - Wu, Jason Hy AU - Wu JH AUID- ORCID: 0000-0003-2073-3562 AD - The George Institute for Global Health, University of New South Wales, Level 18, International Towers 3, 300 Barangaroo Ave, Sydney, NSW, 2000, Australia. JWu1@georgeinstitute.org.au. AD - School of Population Health, University of New South Wales, Samuels Building, Samuel Terry Ave, Kensington, NSW, 2052, Australia. JWu1@georgeinstitute.org.au. AD - , PO Box M201, Missenden Rd, Sydney, NSW, W2 1PG, Australia. JWu1@georgeinstitute.org.au. FAU - Maganja, Damian AU - Maganja D AD - The George Institute for Global Health, University of New South Wales, Level 18, International Towers 3, 300 Barangaroo Ave, Sydney, NSW, 2000, Australia. FAU - Huang, Liping AU - Huang L AD - The George Institute for Global Health, University of New South Wales, Level 18, International Towers 3, 300 Barangaroo Ave, Sydney, NSW, 2000, Australia. FAU - Trieu, Kathy AU - Trieu K AD - The George Institute for Global Health, University of New South Wales, Level 18, International Towers 3, 300 Barangaroo Ave, Sydney, NSW, 2000, Australia. FAU - Taylor, Fraser AU - Taylor F AD - The George Institute for Global Health, University of New South Wales, Level 18, International Towers 3, 300 Barangaroo Ave, Sydney, NSW, 2000, Australia. FAU - Barrett, Eden M AU - Barrett EM AD - The George Institute for Global Health, University of New South Wales, Level 18, International Towers 3, 300 Barangaroo Ave, Sydney, NSW, 2000, Australia. FAU - Arnott, Clare AU - Arnott C AD - The George Institute for Global Health, University of New South Wales, Level 18, International Towers 3, 300 Barangaroo Ave, Sydney, NSW, 2000, Australia. AD - Department of Cardiology, Royal Prince Alfred Hospital, 50 Missenden Rd, Camperdown, NSW, 2050, Australia. FAU - Feng, Xiaoqi AU - Feng X AD - The George Institute for Global Health, University of New South Wales, Level 18, International Towers 3, 300 Barangaroo Ave, Sydney, NSW, 2000, Australia. AD - School of Population Health, University of New South Wales, Samuels Building, Samuel Terry Ave, Kensington, NSW, 2052, Australia. FAU - Schutte, Aletta E AU - Schutte AE AD - The George Institute for Global Health, University of New South Wales, Level 18, International Towers 3, 300 Barangaroo Ave, Sydney, NSW, 2000, Australia. AD - School of Population Health, University of New South Wales, Samuels Building, Samuel Terry Ave, Kensington, NSW, 2052, Australia. FAU - Di Tanna, Gian Luca AU - Di Tanna GL AD - The George Institute for Global Health, University of New South Wales, Level 18, International Towers 3, 300 Barangaroo Ave, Sydney, NSW, 2000, Australia. AD - Department of Business Economics, Health & Social Care, University of Applied Sciences and Arts of Southern Switzerland, Stabile Piazzetta, Via Violino 11, Manno, 6928, Switzerland. FAU - Mhurchu, Cliona Ni AU - Mhurchu CN AD - The George Institute for Global Health, University of New South Wales, Level 18, International Towers 3, 300 Barangaroo Ave, Sydney, NSW, 2000, Australia. AD - Department of Epidemiology and Biostatistics, School of Population Health, University of Auckland, Building 507, 22-30 Park Avenue, Grafton, 1023, New Zealand. FAU - Cameron, Adrian J AU - Cameron AJ AD - Global Centre for Preventive Health and Nutrition, Institute for Health Transformation, Deakin University, 1 Gheringhap Street, Geelong, VIC, 3220, Australia. FAU - Huffman, Mark D AU - Huffman MD AD - The George Institute for Global Health, University of New South Wales, Level 18, International Towers 3, 300 Barangaroo Ave, Sydney, NSW, 2000, Australia. AD - Department of Medicine, Washington University in St Louis, 660 S. Euclid Ave, St. Louis, MO, 63110-1010, USA. FAU - Neal, Bruce AU - Neal B AD - The George Institute for Global Health, University of New South Wales, Level 18, International Towers 3, 300 Barangaroo Ave, Sydney, NSW, 2000, Australia. AD - Department of Epidemiology and Biostatistics, Imperial College London, Medical School Building, St Mary's Campus, Norfolk Place, London, W2 1PG, UK. LA - eng GR - MRF1200105/Australian Government Medical Research Future Fund/ PT - Journal Article PT - Randomized Controlled Trial PT - Research Support, Non-U.S. Gov't DEP - 20241230 PL - England TA - Int J Behav Nutr Phys Act JT - The international journal of behavioral nutrition and physical activity JID - 101217089 RN - 0 (Sodium Chloride, Dietary) SB - IM MH - Humans MH - Female MH - Male MH - *Hypertension/drug therapy MH - Middle Aged MH - *Consumer Behavior MH - Australia MH - *Sodium Chloride, Dietary MH - Aged MH - Diet, Sodium-Restricted/methods MH - Internet MH - Adult MH - Commerce MH - Food Preferences PMC - PMC11687014 OTO - NOTNLM OT - Hypertension OT - Nudge OT - Online shopping OT - Product labelling OT - Sodium COIS- Declarations. Ethics approval and consent to participate: The trial received ethics approval from the University of New South Wales Human Research Ethics Committee (HC200970). Consent for publication: Not applicable. Competing interests: JHYW is a member of the Editorial Board of International Journal of Behavioral Nutrition and Physical Activity. JHYW was not involved in the journal's peer review process of, or decisions related to, this manuscript. In the last 3 years, JHYW has received grant support from New South Wales (NSW) Health, Ian Potter Foundation, Hort Innovation, and Future Food System Cooperative Research Centre, as well as travel support by AusVeg, all outside of the present work. In the last 3 years, MDH has received travel support from the World Heart Federation. MDH has planned patents for combination therapy for the treatment of heart failure. AJC and CNM were academic partners on a healthy supermarket intervention trial that includes Australian local government and supermarket retail (IGA) collaborators, with funding from the Australian National Health and Medical Research Council (NHMRC), the Victorian Health Promotion Foundation (VicHealth) and Deakin University. The George Institute for Global Health has a patent, license, and has received investment funding with intent to commercialize fixed-dose combination therapy for hypertension through its social enterprise business, George Medicines. The George Institute has also previously received funding from Australian supermarket retailers to independently assess and provide advice on improving the healthiness of private label (home brand) product ranges. BN is supported by an Australian NHMRC fellowship. AES is supported by a NHMRC Investigator Grant (APP2017504), has received funding from the MRFF and NSW Health, and has also received speaker honoraria or sat on Advisory Boards for Servier, Medtronic, Sanofi, AstraZeneca, Omron, Aktiia, Skylabs, and Abbott. CA has received research funding from NHMRC, MRFF and NSW Health and has also received honoraria or sat on Advisory Boards for Novo Nordisk, Amgen and Astra Zeneca. EDAT- 2024/12/31 00:19 MHDA- 2024/12/31 11:04 PMCR- 2024/12/30 CRDT- 2024/12/30 23:51 PHST- 2024/09/30 00:00 [received] PHST- 2024/12/22 00:00 [accepted] PHST- 2024/12/31 11:04 [medline] PHST- 2024/12/31 00:19 [pubmed] PHST- 2024/12/30 23:51 [entrez] PHST- 2024/12/30 00:00 [pmc-release] AID - 10.1186/s12966-024-01700-9 [pii] AID - 1700 [pii] AID - 10.1186/s12966-024-01700-9 [doi] PST - epublish SO - Int J Behav Nutr Phys Act. 2024 Dec 30;21(1):148. doi: 10.1186/s12966-024-01700-9. PMID- 39722532 OWN - NLM STAT- MEDLINE DCOM- 20250429 LR - 20260726 IS - 1552-681X (Electronic) IS - 0272-989X (Print) IS - 0272-989X (Linking) VI - 45 IP - 2 DP - 2025 Feb TI - Changes in Risk Tolerance for Ovarian Cancer Prevention Strategies during the COVID-19 Pandemic: Results of a Discrete Choice Experiment. PG - 168-176 LID - 10.1177/0272989X241302829 [doi] AB - BACKGROUND: Prior to COVID-19, little was known about how risks associated with such a pandemic would compete with and influence patient decision making regarding cancer risk reducing medical decision making. We investigated how the pandemic affected preferences for medical risk-reducing strategies among women at elevated risk of breast or ovarian cancer. METHODS: We conducted a discrete choice experiment. Women about to undergo genetic testing and counseling at 2 medical centers participated. Enrollment occurred between 2019 and 2022, allowing us to investigate changes in preferences from before the pandemic to after the pandemic. Women chose from permuted scenarios that specified type of surgery, age of menopause, quality of menopausal symptoms, and risk of ovarian cancer, heart disease, or osteoporosis. RESULTS: A total of 355 women, with a median age of 36 y, participated. In 2019, women were less likely to choose prevention scenarios with higher ovarian cancer risk (odds ratio [OR] = 0.42 per 10-point increase in risk, 95% confidence interval [CI] 0.22-0.61). In June 2020, the effect of higher ovarian cancer risk scenarios on choice was attenuated (OR = 0.86, 95% CI 0.68-1.04), with the effect becoming more salient again by July 2021 (OR = 0.59, 95% CI 0.52-0.67) (P = 0.039 for test of temporal interaction). No other attribute demonstrated a temporal trend. CONCLUSION: The risks associated with the COVID-19 pandemic may have attenuated the impact of risk of ovarian cancer on choice of risk-reducing prevention strategies for ovarian cancer. The maximum attenuation occurred at the beginning of the pandemic when access to risk-reducing surgery was most restricted. Our findings highlight how individuals evaluate competing health risks and adjust their uptake of cancer prevention strategies when faced with a future pandemic or similar global crisis. HIGHLIGHTS: In this discrete choice experiment, women were much less likely to choose prevention scenarios that had higher ovarian cancer risk prior to the COVID-19 pandemic than after the pandemic.The attenuation of preferences may have persisted through 2022.COVID-19 may have altered the relative importance of factors that motivate women to undergo risk-reducing surgeries. FAU - Egleston, Brian L AU - Egleston BL AUID- ORCID: 0000-0002-1633-799X AD - Fox Chase Cancer Center, Temple University Health System, Philadelphia, PA, USA. FAU - Daly, Mary B AU - Daly MB AD - Fox Chase Cancer Center, Temple University Health System, Philadelphia, PA, USA. FAU - Lew, Kaitlyn AU - Lew K AD - Dana-Farber Cancer Institute, Boston, MA, USA. FAU - Bealin, Lisa AU - Bealin L AD - Fox Chase Cancer Center, Temple University Health System, Philadelphia, PA, USA. FAU - Husband, Alexander D AU - Husband AD AUID- ORCID: 0009-0000-6033-529X AD - Dana-Farber Cancer Institute, Boston, MA, USA. FAU - Stopfer, Jill E AU - Stopfer JE AD - Dana-Farber Cancer Institute, Boston, MA, USA. FAU - Przybysz, Pawel AU - Przybysz P AD - Fox Chase Cancer Center, Temple University Health System, Philadelphia, PA, USA. FAU - Tchuvatkina, Olga AU - Tchuvatkina O AD - Fox Chase Cancer Center, Temple University Health System, Philadelphia, PA, USA. FAU - Wong, Yu-Ning AU - Wong YN AD - Section of Hematology and Oncology, Department of Medicine, Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, USA. AD - Division of Hematology-Oncology, Perelman School of Medicine, University of Pennsylvania, USA. FAU - Garber, Judy E AU - Garber JE AD - Dana-Farber Cancer Institute, Boston, MA, USA. FAU - Rebbeck, Timothy R AU - Rebbeck TR AUID- ORCID: 0000-0002-4799-1900 AD - Dana-Farber Cancer Institute, Boston, MA, USA. AD - TH Chan School of Public Health, Harvard University, Boston, MA, USA. LA - eng GR - P30 CA006927/CA/NCI NIH HHS/United States GR - R01 CA207365/CA/NCI NIH HHS/United States GR - R01 CA236468/CA/NCI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural DEP - 20241225 PL - United States TA - Med Decis Making JT - Medical decision making : an international journal of the Society for Medical Decision Making JID - 8109073 SB - IM MH - Humans MH - Female MH - *COVID-19/epidemiology MH - *Ovarian Neoplasms/prevention & control/psychology MH - Adult MH - Middle Aged MH - *Choice Behavior MH - SARS-CoV-2 MH - *Patient Preference/psychology MH - Pandemics MH - Aged MH - Risk Assessment MH - Risk Factors PMC - PMC11881031 MID - NIHMS2035321 OTO - NOTNLM OT - COVID-19 OT - discrete choice experiment OT - high-risk women OT - ovarian cancer OT - preventive surgery COIS- The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by US National Institutes of Health/National Cancer Institute (NCI) grants P30CA006927 (Fox Chase Cancer Center Support Grant) and NCI R01 CA207365 (principal investigator: TRR). The funding agreement ensured the authors' independence in designing the study, interpreting the data, writing, and publishing the report. EDAT- 2024/12/26 06:20 MHDA- 2025/01/15 12:23 PMCR- 2025/03/05 CRDT- 2024/12/26 02:23 PHST- 2025/01/15 12:23 [medline] PHST- 2024/12/26 06:20 [pubmed] PHST- 2024/12/26 02:23 [entrez] PHST- 2025/03/05 00:00 [pmc-release] AID - 10.1177/0272989X241302829 [doi] PST - ppublish SO - Med Decis Making. 2025 Feb;45(2):168-176. doi: 10.1177/0272989X241302829. Epub 2024 Dec 25. PMID- 39709493 OWN - NLM STAT- MEDLINE DCOM- 20241221 LR - 20250905 IS - 1466-609X (Electronic) IS - 1364-8535 (Print) IS - 1364-8535 (Linking) VI - 28 IP - 1 DP - 2024 Dec 21 TI - Impact on fluid balance of an optimized restrictive strategy targeting non-resuscitative fluids in intensive care patients with septic shock: a single-blind, multicenter, randomized, controlled, pilot study. PG - 429 LID - 10.1186/s13054-024-05155-z [doi] LID - 429 AB - BACKGROUND: In septic shock, the classic fluid resuscitation strategy can lead to a potentially harmful positive fluid balance. This multicenter, randomized, single-blind, parallel, controlled pilot study assessed the effectiveness of a restrictive fluid strategy aiming to limit daily volume. METHODS: Patients 18-85 years' old admitted to the ICU department of three French hospitals were eligible for inclusion if they had septic shock and were in the first 24 h of vasopressor infusion. Exclusion criteria were acute kidney injury requiring renal replacement therapy, end stage chronic kidney disease, and severe malnutrition. Patients were electronically randomized 1:1 to either an optimized fluid restriction (reducing fluid intake as much as possible in terms of maintenance fluids and fluids for drug dilution during the first 7 days) or standard fluid strategy. The primary outcome was cumulative fluid balance (ml/kg) in the first 5 days. Patients and statisticians were blinded to group arm, but not clinicians. RESULTS: Between September 2021 and February 2023, 1201 patients were screened and 50 included, with two in the control group withdrawing, thus 48 patients were analyzed (24 in each group). In the first 5 days, the optimized restrictive strategy and control groups received 89.7 (IQR 35; 128.9) and 114.3 (IQR 78.8; 168.5) ml/kg of fluid, respectively (mean difference: 35.9 ml/kg [0.0; 71.8], p = 0.0506). After 5 days, the median cumulative fluid balance was 6.9 (IQR - 13.7; 52.1) and 35.0 (IQR - 7.9; 40.2) ml/kg in the optimized restrictive strategy and control groups, respectively (absolute difference 13.2 [95%CI - 15.2; 41.6], p = 0.42). After 28 days, mortality and the numbers of days alive without life support were similar between groups. The main adverse events were severe hypernatremia in 1 and 2 patients in the fluid restriction strategy and control groups, respectively, and acute kidney injury KDIGO 3 in 4 and 7 patients in the fluid restriction strategy and control groups, respectively. CONCLUSIONS: In ICU patients with septic shock, an optimized restrictive fluid strategy targeting hidden fluid intakes did not reduce the overall fluid balance at day 5. Trial registration ClinicalTrials.gov identifier NCT04947904, registered on 1 July 2021. CI - (c) 2024. The Author(s). FAU - Boulet, Nicolas AU - Boulet N AD - Division of Anesthesia, Critical Care, Pain and Emergency Medicine, UR‑UM103 IMAGINE, University of Montpellier, Nimes University Hospital, Nimes, France. AD - Division of Anesthesia, Critical Care, Pain and Emergency Medicine, Nimes University Hospital, University of Montpellier, Nimes, France. FAU - Quenot, Jean-Pierre AU - Quenot JP AD - Department of Intensive Care, Burgundy University Hospital, Dijon, France. AD - Lipness Team, INSERM Research Center LNC-UMR1231 and LabEx LipSTIC, University of Burgundy, Dijon, France. AD - INSERM CIC 1432, Clinical Epidemiology, University of Burgundy, Dijon, France. FAU - Serrand, Chris AU - Serrand C AD - Department of Biostatistics, Epidemiology, Public Health and Innovation in Methodology, Nimes University Hospital, University of Montpellier, Nimes, France. FAU - Antier, Nadiejda AU - Antier N AD - Division of Anesthesia, Critical Care, Pain and Emergency Medicine, Nimes University Hospital, University of Montpellier, Nimes, France. AD - Department of Intensive Care, Ales General Hospital, Ales, France. FAU - Garnier, Sylvain AU - Garnier S AD - Division of Anesthesia, Critical Care, Pain and Emergency Medicine, Nimes University Hospital, University of Montpellier, Nimes, France. FAU - Buzancais, Aurele AU - Buzancais A AD - Division of Anesthesia, Critical Care, Pain and Emergency Medicine, Nimes University Hospital, University of Montpellier, Nimes, France. FAU - Muller, Laurent AU - Muller L AD - Division of Anesthesia, Critical Care, Pain and Emergency Medicine, UR‑UM103 IMAGINE, University of Montpellier, Nimes University Hospital, Nimes, France. AD - Division of Anesthesia, Critical Care, Pain and Emergency Medicine, Nimes University Hospital, University of Montpellier, Nimes, France. FAU - Roger, Claire AU - Roger C AD - Division of Anesthesia, Critical Care, Pain and Emergency Medicine, UR‑UM103 IMAGINE, University of Montpellier, Nimes University Hospital, Nimes, France. AD - Division of Anesthesia, Critical Care, Pain and Emergency Medicine, Nimes University Hospital, University of Montpellier, Nimes, France. FAU - Lefrant, Jean-Yves AU - Lefrant JY AD - Division of Anesthesia, Critical Care, Pain and Emergency Medicine, UR‑UM103 IMAGINE, University of Montpellier, Nimes University Hospital, Nimes, France. FAU - Barbar, Saber Davide AU - Barbar SD AD - Division of Anesthesia, Critical Care, Pain and Emergency Medicine, UR‑UM103 IMAGINE, University of Montpellier, Nimes University Hospital, Nimes, France. saber.barbar@chu-nimes.fr. AD - Division of Anesthesia, Critical Care, Pain and Emergency Medicine, Nimes University Hospital, University of Montpellier, Nimes, France. saber.barbar@chu-nimes.fr. LA - eng SI - ClinicalTrials.gov/NCT04947904 PT - Journal Article PT - Multicenter Study PT - Randomized Controlled Trial PT - Research Support, Non-U.S. Gov't DEP - 20241221 PL - England TA - Crit Care JT - Critical care (London, England) JID - 9801902 SB - IM MH - Humans MH - Pilot Projects MH - Male MH - Female MH - Aged MH - *Shock, Septic/therapy/physiopathology MH - Middle Aged MH - *Fluid Therapy/methods/standards/statistics & numerical data MH - Single-Blind Method MH - Adult MH - Aged, 80 and over MH - Intensive Care Units/organization & administration/statistics & numerical data MH - Water-Electrolyte Balance/physiology MH - France PMC - PMC11663312 OTO - NOTNLM OT - Fluid balance OT - Intensive care unit OT - Restrictive strategy OT - Septic shock COIS- Declarations. Ethics approval and consent to participate: The study was approved by the Comite de Protection des Personnes Sud-Mediterranee II (Number 2020-A01952-37). Written informed consent was obtained from patients or their legal surrogates. Consent for publication: Written informed consent was obtained from patients or their legal surrogates either before randomization or as soon as possible thereafter. Competing interests: The authors declare no competing interests. EDAT- 2024/12/22 00:27 MHDA- 2024/12/22 00:28 PMCR- 2024/12/21 CRDT- 2024/12/21 23:21 PHST- 2024/09/10 00:00 [received] PHST- 2024/10/31 00:00 [accepted] PHST- 2024/12/22 00:28 [medline] PHST- 2024/12/22 00:27 [pubmed] PHST- 2024/12/21 23:21 [entrez] PHST- 2024/12/21 00:00 [pmc-release] AID - 10.1186/s13054-024-05155-z [pii] AID - 5155 [pii] AID - 10.1186/s13054-024-05155-z [doi] PST - epublish SO - Crit Care. 2024 Dec 21;28(1):429. doi: 10.1186/s13054-024-05155-z. PMID- 39639362 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20241208 IS - 2055-5784 (Print) IS - 2055-5784 (Electronic) IS - 2055-5784 (Linking) VI - 10 IP - 1 DP - 2024 Dec 5 TI - The feasibility of a self-regulation and mental imagery programme to enhance everyday functioning for people with Parkinson's disease: study protocol. PG - 148 LID - 10.1186/s40814-024-01578-1 [doi] LID - 148 AB - BACKGROUND: Less dopaminergic neurons in people with Parkinson's disease result in a reliance on a slow and energy-intensive control, restricting their ability to complete routine everyday activities. Self-regulation takes an active learning approach to rehabilitation by enhancing the person's self-awareness and encourages self-reflection to overcome problems. Mental imagery assists the person to focus attention on the requirements for the task, making it a goal-directed action and allowing for faster movements. There is a growing body of evidence to support the use of self-regulation and mental imagery in rehabilitation to maintain or improve the performance of everyday activities for people with a neurological condition. METHODS: A prospective pilot study using a single-group, pre-test and posttest design will test the feasibility and acceptability of a self-regulation and mental imagery programme to enhance performance of everyday activities and motor and cognitive function in people with Parkinson's disease. People who have a diagnosis of Parkinson's disease with mild-to-moderate severity and intact attention, comprehension and short-term memory will be recruited. The participants will receive a 6-week programme with one therapist-led session, a home programme and a telephone call each week. The programme uses self-regulation through a step-based problem-solving process and mental imagery to assist in movement planning. Appropriate rehabilitation strategies are used as solutions to tackle problems experienced, impacting performance in everyday activities. The attendance rate will be recorded to indicate the feasibility. A questionnaire will be administered post-intervention to collect feedback on programme acceptability. Patient outcomes will include Barthel index, Lawton Instrumental Activities of Daily Living Scale, Canadian Occupational Performance Measure and Timed Up and Go test. Trail Making Test and Montreal Cognitive Assessment will be collected pre- and post-intervention. DISCUSSION: The programme aims to combine the metacognitive strategies of self-regulation and mental imagery to enable individuals with Parkinson's disease to improve the performance of everyday activities. If feasible, the programme has the potential to be further tested in a randomised controlled trial and benefit people with Parkinson's disease by enhancing their performance required in independent community living. TRIAL REGISTRATION: Australian New Zealand Clinical Trials Registry ACTRN12621000903886, Registered on 12 July 2021 - retrospectively registered. CI - (c) 2024. The Author(s). FAU - Hill, Christine AU - Hill C AD - School of Health Sciences, Western Sydney University, Penrith, NSW, Australia. FAU - Pillay, Renai AU - Pillay R AD - Concord Hospital, Concord, NSW, Australia. FAU - Liu, Karen P Y AU - Liu KPY AUID- ORCID: 0000-0001-7397-5149 AD - School of Health Sciences, Western Sydney University, Penrith, NSW, Australia. karen.Liu@westernsydney.edu.au. AD - Department of Rehabilitation Sciences, The Hong Kong Polytechnic University, Kowloon, Hong Kong SAR. karen.Liu@westernsydney.edu.au. LA - eng PT - Journal Article DEP - 20241205 PL - England TA - Pilot Feasibility Stud JT - Pilot and feasibility studies JID - 101676536 PMC - PMC11619683 OTO - NOTNLM OT - Everyday activities OT - Mental imagery OT - Parkinson's disease OT - Rehabilitation OT - Self-regulation COIS- Declarations. Ethics approval and consent to participate: This study has attained ethical approval from Western Sydney University Human Research Ethics Committee (H13312) and Sydney Local Health District Human Research Ethics Committee (2020/PID03236). Consent for publication: Not applicable. Competing interests: The authors declare that they have no competing interests. EDAT- 2024/12/06 05:32 MHDA- 2024/12/06 05:33 PMCR- 2024/12/05 CRDT- 2024/12/05 23:56 PHST- 2021/07/21 00:00 [received] PHST- 2024/11/23 00:00 [accepted] PHST- 2024/12/06 05:33 [medline] PHST- 2024/12/06 05:32 [pubmed] PHST- 2024/12/05 23:56 [entrez] PHST- 2024/12/05 00:00 [pmc-release] AID - 10.1186/s40814-024-01578-1 [pii] AID - 1578 [pii] AID - 10.1186/s40814-024-01578-1 [doi] PST - epublish SO - Pilot Feasibility Stud. 2024 Dec 5;10(1):148. doi: 10.1186/s40814-024-01578-1. PMID- 39609757 OWN - NLM STAT- MEDLINE DCOM- 20241129 LR - 20241201 IS - 1471-2458 (Electronic) IS - 1471-2458 (Linking) VI - 24 IP - 1 DP - 2024 Nov 28 TI - The IMPACT Survey: the humanistic impact of osteogenesis imperfecta in adults. PG - 3318 LID - 10.1186/s12889-024-20555-0 [doi] LID - 3318 AB - BACKGROUND: The IMPACT Survey explored the humanistic, clinical, and economic burden of osteogenesis imperfecta (OI) on individuals with OI, their families, caregivers, and wider society. Two previous publications report research methodology, initial insights of the survey, and cost of illness of OI. Here, we present data on the impact of OI on the quality of life (QoL) of adults with OI and explore potential drivers of this impact. METHODS: The IMPACT Survey was an international mixed methods online survey in eight languages (fielded July-September 2021), aimed at adults (aged >/= 18 years) or adolescents (aged 12-17 years) with OI, caregivers (with or without OI) of individuals with OI, and other close relatives. Survey domains included demographics, socioeconomic factors, clinical characteristics, treatment patterns, QoL, and health economics. We conducted a descriptive analysis of the QoL data, as well as exploratory regression analyses to identify drivers of impact of OI on QoL (independent associations between patient characteristics and the impact on QoL). RESULTS: 1,440 adults with OI participated in the survey. The proportion who reported an impact of OI on their QoL across individual areas in the physical, socioeconomic, and mental well-being domains ranged between 49 and 84%. For instance, 84% of adults reported an impact of OI on the types of leisure activities they could do and 74% on the type of job they could do. More severe self-reported OI and higher fracture frequency were consistently identified as drivers of OI's impact on QoL. The proportion of adults who reported worrying about different aspects of their lives due to their OI, such as mobility loss, future fractures, and ageing, ranged between 31 and 97%. CONCLUSION: IMPACT provides insights into the humanistic burden of OI on adults, revealing that OI has a substantial impact on the QoL of adults. OI severity and fracture frequency were consistently identified as drivers of impact on QoL across all domains. Understanding these drivers may aid in identifying areas for targeted interventions, such as fracture prevention. CI - (c) 2024. The Author(s). FAU - van Welzenis, Taco AU - van Welzenis T AD - Osteogenesis Imperfecta Federation Europe, Heffen, Belgium. FAU - Westerheim, Ingunn AU - Westerheim I AD - Osteogenesis Imperfecta Federation Europe, Heffen, Belgium. FAU - Hart, Tracy AU - Hart T AD - Osteogenesis Imperfecta Foundation, Gaithersburg, MD, USA. FAU - Wekre, Lena Lande AU - Wekre LL AD - TRS National Resource Center for Rare Disorders, Sunnaas Rehabilitation Hospital, Nesodden, Norway. FAU - Semler, Oliver AU - Semler O AD - Faculty of Medicine and University Hospital Cologne, Department of Pediatrics, University of Cologne, Cologne, Germany. FAU - Rauch, Frank AU - Rauch F AD - McGill University, Montreal, Canada. FAU - Dewavrin, Laetitia AU - Dewavrin L AD - Wickenstones Ltd, Oxford, Oxfordshire, UK. laetitia@wickenstones.com. FAU - Dadzie, Ruby AU - Dadzie R AD - Wickenstones Ltd, Oxford, Oxfordshire, UK. FAU - Prince, Samantha AU - Prince S AD - Wickenstones Ltd, Oxford, Oxfordshire, UK. FAU - Raggio, Cathleen AU - Raggio C AD - Hospital for Special Surgery, New York, USA. LA - eng PT - Journal Article DEP - 20241128 PL - England TA - BMC Public Health JT - BMC public health JID - 100968562 SB - IM MH - Humans MH - *Osteogenesis Imperfecta/psychology MH - *Quality of Life/psychology MH - Male MH - Female MH - Adult MH - Adolescent MH - Young Adult MH - Middle Aged MH - Child MH - Surveys and Questionnaires MH - *Cost of Illness MH - Caregivers/psychology/statistics & numerical data MH - Aged MH - Socioeconomic Factors PMC - PMC11605868 OTO - NOTNLM OT - Burden of disease OT - Fatigue OT - Fractures OT - Health worries OT - Humanistic burden OT - Osteogenesis imperfecta OT - Pain OT - Patient-reported outcomes OT - Quality of life OT - Self-reported disease severity OT - Survey COIS- Declarations. Ethics approval and consent to participate: An ethics approval exemption was granted by Pearl IRB, Indianapolis, IN, USA on 23rd June 2021. The survey protocol is in line with the UK Research Integrity Office's guidance on good practice in internet-mediated research [79].This online survey was anonymous and did not collect any identifiable data on individuals. Participants were provided with a data privacy statement and consented for their responses to be analysed. Consent for publication: Not applicable. Competing interests: LD and RD are employees of Wickenstones Ltd, Oxford, United Kingdom. SP is an employee of Mereo BioPharma Group, London, United Kingdom. At the time of the survey design and development of this report, SP was an employee of Wickenstones Ltd. CR has received payments for their contributions to the present manuscript. TH serves as the Chief Executive Officer of the Osteogenesis Imperfecta Foundation, which has received unrestricted educational grants from Mereo BioPharma Group London, United Kingdom and Ultragenyx Pharmaceuticals Inc, Novato, USA. OS has participated in a national advisory board for Mereo BioPharma Group London, United Kingdom and has received study contracts for clinical studies from Ultragenyx Pharmaceuticals Inc, Novato, USA. FR has received study contracts for experimental preclinical studies with Precithera Inc, Quebec, Canada, Mesentech Inc, Vancouver, Canada and Catabasis Pharmaceuticals Inc, Cambridge, USA. He has participated in advisory boards for Ultragenyx Pharmaceuticals Inc, Novato, USA, Sanofi S.A. Paris, France, Novartis International AG, Basel, Switzerland and Mereo BioPharma Group, London, United Kingdom. FR has received a speaker fee from Ultragenyx Pharmaceuticals Inc, Novato, USA for a lecture and received a donation of experimental drugs for a preclinical study from Acceleron Pharma Inc, Cambridge, USA. CR received an institutional grant from and has been a speaker for BioMarin Pharmaceuticals Inc, Novato, California, has participated in advisory boards for Ultragenyx Pharmaceuticals Inc, Novato, USA. She has received an institutional grant from and is a consultant for Nextcure, Beltville, MD, USA. CR sits on the board of directors of the Osteogenesis Imperfecta Foundation. CR has also participated in an advisory board for Mereo BioPharma Group, London, United Kingdom. TW and IW hold leadership positions in the Osteogenesis Imperfecta Federation Europe, which has received grants from Mereo BioPharma Group, London, United Kingdom (unrestricted), Ultragenyx Pharmaceuticals Inc, Novato, USA (restricted grant for a conference), Quince Therapeutics Inc, San Francisco, CA, USA (donation for a conference), UCB (restricted grant to conference), Angitia Biopharmaceuticals Inc., Woodland Hills, CA, USA (donation to conference), Azafaros BV, Naarden, the Netherlands (donation to conference), Alexion Inc. Boston, MA, USA, (sponsorship of conference); Pega Medical Inc, Laval, Quebec, Canada (donation), PuREC, Shimane, Japan (sponsorship of conference), Takeda, Tokyo, Japan (payment to IW as a panellist; donated to OIFE). EDAT- 2024/11/29 05:20 MHDA- 2024/11/29 06:21 PMCR- 2024/11/28 CRDT- 2024/11/28 23:52 PHST- 2024/07/22 00:00 [received] PHST- 2024/10/29 00:00 [accepted] PHST- 2024/11/29 06:21 [medline] PHST- 2024/11/29 05:20 [pubmed] PHST- 2024/11/28 23:52 [entrez] PHST- 2024/11/28 00:00 [pmc-release] AID - 10.1186/s12889-024-20555-0 [pii] AID - 20555 [pii] AID - 10.1186/s12889-024-20555-0 [doi] PST - epublish SO - BMC Public Health. 2024 Nov 28;24(1):3318. doi: 10.1186/s12889-024-20555-0. PMID- 39581967 OWN - NLM STAT- MEDLINE DCOM- 20241124 LR - 20260923 IS - 1742-4755 (Electronic) IS - 1742-4755 (Linking) VI - 21 IP - 1 DP - 2024 Nov 24 TI - "I am putting my fear on them subconsciously": a qualitative study of contraceptive care in the context of abortion bans in the U.S. PG - 171 LID - 10.1186/s12978-024-01908-9 [doi] LID - 171 AB - BACKGROUND: Since the Dobbs vs. Jackson Women's Health Organization decision in June 2022, providers throughout the U.S. have been navigating the shifting legal landscape of abortion bans, which diminish the delivery of evidence-based healthcare. The Dobbs decision has had a detrimental impact on medical training, the physician-patient relationship, and provision of medical care. However, few studies have captured the effects on providers in adjacent fields, including contraceptive care. Our objective was to examine the impact of Dobbs on contraceptive care. METHODS: We conducted semi-structured in-depth interviews (August 2022-July 2024), with 41 contraceptive healthcare providers across the US, with the majority (63%) in abortion restrictive states. We utilized deductive thematic analysis to assess providers' practice changes and experiences related to contraceptive services. RESULTS: In reaction to the Dobbs decision, providers noted increased requests for contraception, especially for highly effective methods. Providers worried that certain methods, such as IUDs or emergency contraception, would become restricted, and mentioned advance provision of pills and other ways that they would try to ensure supplies. Providers also discussed that their patients were worried about threats to contraception, including for adolescents. Some expressed concern, however, that the abortion bans may prompt providers to overemphasize high-efficacy methods with directive counseling. Providers shared that it was stressful to practice in contexts of uncertainty, with shifting abortion policies affecting contraceptive care, including emergent needs such as providing contraceptive services to out-of-state patients before they go home. Several providers shared that they felt an increased importance of their role in their communities, and a deepened commitment to advocate for their patients. CONCLUSIONS: Abortion restrictions profoundly impact providers' contraceptive counseling and care. The effects of Dobbs on providers and their clinical practices underscore providers' legally precarious position in today's reproductive health landscape. Attention to contraceptive access and person-centered care has become a salient public health need across the U.S. The long-term impacts of limited reproductive rights may stretch an already under-resourced healthcare system and further emphasize moral pressures. CI - (c) 2024. The Author(s). FAU - Zia, Yasaman AU - Zia Y AD - Department of Obstetrics, Gynecology, and Reproductive Sciences, Bixby Center for Global Reproductive Health, University of California San Francsico, San Francisco, CA, USA. Yasaman.zia2@ucsf.edu. FAU - Somerson, Erica AU - Somerson E AD - Department of Obstetrics, Gynecology, and Reproductive Sciences, Bixby Center for Global Reproductive Health, University of California San Francsico, San Francisco, CA, USA. FAU - Folse, Connie AU - Folse C AD - Department of Obstetrics, Gynecology, and Reproductive Sciences, Bixby Center for Global Reproductive Health, University of California San Francsico, San Francisco, CA, USA. FAU - Alvarez, Alejandra AU - Alvarez A AD - Department of Obstetrics, Gynecology, and Reproductive Sciences, Bixby Center for Global Reproductive Health, University of California San Francsico, San Francisco, CA, USA. FAU - Albergate Davis, Kathryn AU - Albergate Davis K AD - Department of Obstetrics, Gynecology, and Reproductive Sciences, Bixby Center for Global Reproductive Health, University of California San Francsico, San Francisco, CA, USA. FAU - Comfort, Alison B AU - Comfort AB AD - Department of Obstetrics, Gynecology, and Reproductive Sciences, Bixby Center for Global Reproductive Health, University of California San Francsico, San Francisco, CA, USA. FAU - Brown, Katherine AU - Brown K AD - Department of Obstetrics, Gynecology, and Reproductive Sciences, Bixby Center for Global Reproductive Health, University of California San Francsico, San Francisco, CA, USA. FAU - Brandi, Kristyn AU - Brandi K AD - Ryan Residency Training Program, University of California San Francisco, San Francisco, CA, USA. FAU - Moayedi, Ghazaleh AU - Moayedi G AD - Pegasus Health Justice Center, Dallas, TX, USA. FAU - Harper, Cynthia C AU - Harper CC AD - Department of Obstetrics, Gynecology, and Reproductive Sciences, Bixby Center for Global Reproductive Health, University of California San Francsico, San Francisco, CA, USA. AD - Philip R. Lee Institute for Health Policy Studies, University of California, San Francisco, San Francisco, CA, USA. LA - eng GR - 2021-2688/JPB Foundation/ PT - Journal Article DEP - 20241124 PL - England TA - Reprod Health JT - Reproductive health JID - 101224380 SB - IM MH - Humans MH - Female MH - *Abortion, Induced/legislation & jurisprudence/psychology MH - *Qualitative Research MH - United States MH - *Contraception/psychology MH - Pregnancy MH - Adult MH - Family Planning Services/legislation & jurisprudence MH - Health Personnel/psychology MH - Health Services Accessibility MH - Fear MH - Male MH - Attitude of Health Personnel MH - Abortion, Legal/legislation & jurisprudence PMC - PMC11587542 OAB - Since the Dobbs vs. Jackson Women's Health Organization decision in June 2022, providers throughout the U.S. have been navigating the shifting legal landscape of abortion bans, which diminish the delivery of evidence-based healthcare. The Dobbs decision has had detrimental impacts on health care, including medical training, the physician-patient relationship, and how medical care is provided for patients. This study is focused on the impacts of the Dobbs decision on the clinic practices and experiences of providers in contraceptive care, where patients receive birth control counseling and methods. We conducted interviews with healthcare providers working in contraceptive care to assess their practice changes and personal reactions since the Dobbs decision. Providers noted changes in increased patient requests for certain contraceptive methods, uncertainty about abortion restrictions affecting contraceptive care, and feeling personally obligated to provide contraceptive care and medical advice around abortion despite the shifting legal landscape. Providers also expressed personal experiences of stress, or moral injury, around the high stakes impact of abortion restrictions on patients as well as confusion and uncertainty of how legal restraints impact their work. Nevertheless, they felt an increased emphasis on the importance of their roles in their communities. Abortion restrictions profoundly impact providers' contraceptive counseling and care. Providers' comments underscored a sense of moral injury, a feeling of urgency to help patients, and shifts in counseling approaches that may over-emphasize contraceptives in the context of limited abortion access. OABL- eng COIS- Declarations. Ethics approval and consent to participate: The Institutional Review Board at University of California, San Francisco approved the study (#12-10336). Consent for publication: All participants provided consent to participate in research. Competing interests: The authors declare no competing interests. EDAT- 2024/11/25 01:26 MHDA- 2024/11/25 01:27 PMCR- 2024/11/24 CRDT- 2024/11/24 23:13 PHST- 2024/06/03 00:00 [received] PHST- 2024/11/11 00:00 [accepted] PHST- 2024/11/25 01:27 [medline] PHST- 2024/11/25 01:26 [pubmed] PHST- 2024/11/24 23:13 [entrez] PHST- 2024/11/24 00:00 [pmc-release] AID - 10.1186/s12978-024-01908-9 [pii] AID - 1908 [pii] AID - 10.1186/s12978-024-01908-9 [doi] PST - epublish SO - Reprod Health. 2024 Nov 24;21(1):171. doi: 10.1186/s12978-024-01908-9. PMID- 39579379 OWN - NLM STAT- MEDLINE DCOM- 20250411 LR - 20250411 IS - 2050-439X (Electronic) IS - 2050-4381 (Linking) VI - 12 IP - 16 DP - 2024 Nov TI - Assessing the impact of COVID-19 on the physical activity of 10-11-year-old children and their parents: Active-6 a mixed-methods study. PG - 1-29 LID - 10.3310/WYHT5821 [doi] AB - BACKGROUND: Physical activity is essential for long-term health, yet data from before the COVID-19 pandemic showed only 41% of 10- to 11-year-olds met the UK government's physical activity recommendations. Children's physical activity was limited during the national COVID-19 lockdowns. It is important to measure children's physical activity in the recovery period to assess the short- and medium-term impact of the lockdowns. OBJECTIVES: To use mixed-methods to assess the impact of the COVID-19 pandemic on moderate-to-vigorous physical activity of year 6 children in the short-term (2021) and medium-term (2022) recovery periods by comparing these with data sampled from the same schools in 2017/18. METHODS: Quantitative and qualitative data were collected in two waves: wave 1 (May-December 2021), when lockdowns had finished but some COVID-19 mitigation policies were still in place, and wave 2 (January-July 2022), when most restrictions had been removed. These were compared with baseline data from similar year 6 children and parents/carers in the same schools collected between March 2017 and June 2018 (wave 0). RESULTS: In wave 1, average child accelerometer-measured weekday moderate-to-vigorous physical activity was 7-8 minutes lower than pre-pandemic while sedentary time was higher by almost 30 minutes. Child moderate-to-vigorous physical activity had recovered to pre-pandemic levels in wave 2, although sedentary time remained elevated. Across our studies, we found a new normal for child physical activity, characterised as more dependent on structured activities such as active clubs. Physical activity inequalities appear to be widening among girls and low socioeconomic position families, as they face unique barriers to participating in the new normal. LIMITATIONS: Our sample includes more households with higher educational qualifications and predominantly female parents. Undertaking this research in schools while COVID-19 disruptions were ongoing created challenges to data collection which may have limited schools' and families' participation. CONCLUSIONS: COVID-19 lockdowns negatively impacted child physical activity. It took almost a year of no restrictions for this to recover, and sedentary time remains high. Despite this recovery, 59% of children do not meet activity guidelines. There is a new normal to child physical activity that relies on structured activities, and some children and families may face challenges to taking part in the new normal. Strategies are needed to increase child physical activity for all. FUTURE WORK: Develop new ways to work in partnership with schools to design bespoke physical activity programmes that can be delivered at the school site. Develop new ways to help girls and children from lower-income households to be physically active. Find the most effective means of maximising existing school resources such as extended school provision (after-school clubs) and physical resources (equipment) to promote physical activity outside of curriculum time. FUNDING: This synopsis presents independent research funded by the National Institute for Health and Care Research (NIHR) Public Health Research as award number NIHR131847. FAU - Jago, Russell AU - Jago R AUID- ORCID: 0000-0002-3394-0176 AD - Centre for Exercise, Nutrition & Health Sciences, School for Policy Studies, University of Bristol, Bristol, UK. AD - Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK. AD - The National Institute for Health Research, Applied Research Collaboration West (NIHR ARC West), University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK. FAU - House, Danielle AU - House D AUID- ORCID: 0000-0001-6171-9922 AD - Centre for Exercise, Nutrition & Health Sciences, School for Policy Studies, University of Bristol, Bristol, UK. FAU - Salway, Ruth AU - Salway R AUID- ORCID: 0000-0002-3242-3951 AD - Centre for Exercise, Nutrition & Health Sciences, School for Policy Studies, University of Bristol, Bristol, UK. FAU - Walker, Robert AU - Walker R AUID- ORCID: 0000-0001-9901-5285 AD - Centre for Exercise, Nutrition & Health Sciences, School for Policy Studies, University of Bristol, Bristol, UK. FAU - Emm-Collison, Lydia AU - Emm-Collison L AUID- ORCID: 0000-0002-5493-3223 AD - Centre for Exercise, Nutrition & Health Sciences, School for Policy Studies, University of Bristol, Bristol, UK. FAU - Sansum, Kate AU - Sansum K AUID- ORCID: 0000-0003-3392-6750 AD - Centre for Exercise, Nutrition & Health Sciences, School for Policy Studies, University of Bristol, Bristol, UK. FAU - Breheny, Katie AU - Breheny K AUID- ORCID: 0000-0001-6886-4049 AD - Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK. AD - The National Institute for Health Research, Applied Research Collaboration West (NIHR ARC West), University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK. FAU - Churchward, Sarah AU - Churchward S AUID- ORCID: 0009-0007-7765-3682 AD - Independent Public Member of the Project Team. FAU - Williams, Joanna G AU - Williams JG AUID- ORCID: 0000-0002-4737-1760 AD - Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK. AD - Communities and Public Health, Bristol City Council, Bristol, UK. FAU - Hollingworth, William AU - Hollingworth W AUID- ORCID: 0000-0002-0840-6254 AD - Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK. AD - The National Institute for Health Research, Applied Research Collaboration West (NIHR ARC West), University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK. FAU - de Vocht, Frank AU - de Vocht F AUID- ORCID: 0000-0003-3631-627X AD - Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK. AD - The National Institute for Health Research, Applied Research Collaboration West (NIHR ARC West), University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK. LA - eng PT - Journal Article PL - England TA - Public Health Res (Southampt) JT - Public health research (Southampton, England) JID - 101653231 SB - IM MH - Humans MH - *COVID-19/epidemiology/prevention & control MH - Child MH - *Exercise MH - *Parents/psychology MH - Female MH - Male MH - United Kingdom/epidemiology MH - SARS-CoV-2 MH - Schools MH - Pandemics OAB - Physical activity can improve children's health, learning and quality of life, yet only 41% of year 6 children (aged 10-11 years) in the UK were meeting physical activity guidelines before the pandemic. COVID-19 lockdowns and restrictions meant children were unable to be active in their normal ways. We expected these restrictions to reduce children's activity while they were in place. The Active-6 project wanted to know whether any changes to children's activity lasted after the restrictions had gone. We used devices called accelerometers to measure Year 6 children's activity in 2021 and 2022. We compared this information with data collected in 2017/18 from year 6 children from the same schools. We also interviewed parents, children and school staff to find out about their experiences and why they felt any changes had happened. In 2021, children's activity was significantly lower than before the pandemic. The time children spent sedentary, not moving at all, was higher. By 2022, child activity returned to pre-COVID levels but their sedentary time remained high. We found that the ways in which children are active have changed since the COVID-19 lockdowns. Children spend less time doing active play and now rely more on structured activities like sports clubs. The gap in how active children are seems to be widening, with girls and low-income families being less active. It took almost a year with no restrictions for children's physical activity to recover, and sedentary time remains high. Despite this recovery, 59% of children do not meet activity guidelines. Children now rely more on clubs for their activity, and it is hard for some children and families to take part in these. Strategies are needed to increase child physical activity for all. OABL- eng OTO - NOTNLM OT - ACTIVE CLUBS OT - CROSS-SECTIONAL NATURAL EXPERIMENT OT - EXERCISE OT - HEALTH OT - LOCKDOWNS OT - MIXED METHODS STUDY OT - SCHOOLS EDAT- 2024/11/24 00:43 MHDA- 2025/04/11 12:28 CRDT- 2024/11/23 13:53 PHST- 2025/04/11 12:28 [medline] PHST- 2024/11/24 00:43 [pubmed] PHST- 2024/11/23 13:53 [entrez] AID - 10.3310/WYHT5821 [doi] PST - ppublish SO - Public Health Res (Southampt). 2024 Nov;12(16):1-29. doi: 10.3310/WYHT5821. PMID- 39577306 OWN - NLM STAT- MEDLINE DCOM- 20241228 LR - 20241228 IS - 1873-5134 (Electronic) IS - 0738-3991 (Linking) VI - 131 DP - 2025 Feb TI - Two sides of trust: How cancer survivors' communication with healthcare providers and on social media predicted healthy behaviors during COVID-19. PG - 108553 LID - S0738-3991(24)00420-8 [pii] LID - 10.1016/j.pec.2024.108553 [doi] AB - OBJECTIVES: COVID-19 exacerbated pre-existing social inequalities. Using three theories linking clinical and media contexts to patients' health outcomes, our study investigated (1) potential factors of cancer patients' trust in healthcare providers and social media; (2) how such trust may influence healthy lifestyles during COVID-19. METHODS: Using structural equation modeling, we investigated effects of key patient-provider communication variables and media factors on healthy behaviors among cancer survivors (N = 1130) using a nationally representative dataset (HINTS-SEER restricted use files, January-July 2021). RESULTS: More healthy behaviors since COVID-19 began were associated with more trust in healthcare providers, lower trust in social media about COVID-19, and more use of social media for health purposes. More trust in social media about COVID-19 was associated with more use of social media for health purposes (p < .01). More trust in healthcare providers about COVID-19 was associated with increased perceptions of patient-provider communication (p < .01). CONCLUSIONS: Findings can inform interventions to connect at-risk cancer patients (e.g., those younger and with lower educational background) with providers in trust-enhancing conversations during situations like COVID-19. PRACTICE IMPLICATIONS: Partnership building between providers and patients can be supplemented with scientific videos on popular social media sites like YouTube during public health crises and emergencies. CI - Copyright (c) 2024 Elsevier B.V. All rights reserved. FAU - Wu, Qiwei Luna AU - Wu QL AD - Department of Communication Studies, Texas Tech University, Lubbock, TX, USA. Electronic address: luna.wu@ttu.edu. FAU - Liao, Yue AU - Liao Y AD - Department of Kinesiology, University of Texas Arlington, Arlington, TX, USA. Electronic address: yue.liao@uta.edu. FAU - Brannon, Grace Ellen AU - Brannon GE AD - Department of Communication, University of Texas Arlington, Arlington, TX, USA. Electronic address: grace.brannon@uta.edu. LA - eng PT - Journal Article DEP - 20241117 PL - Ireland TA - Patient Educ Couns JT - Patient education and counseling JID - 8406280 SB - IM MH - Humans MH - *COVID-19/psychology MH - *Trust MH - *Social Media MH - Male MH - Female MH - *Cancer Survivors/psychology MH - Middle Aged MH - *Health Behavior MH - *Communication MH - Aged MH - Health Personnel/psychology MH - SARS-CoV-2 MH - Adult MH - Neoplasms/psychology MH - Professional-Patient Relations MH - Physician-Patient Relations OTO - NOTNLM OT - Cancer survivors OT - Misinformation OT - Patient trust OT - Patient-provider communication OT - Social media use COIS- Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2024/11/23 11:12 MHDA- 2024/12/29 00:20 CRDT- 2024/11/22 18:12 PHST- 2024/09/21 00:00 [received] PHST- 2024/10/25 00:00 [revised] PHST- 2024/11/12 00:00 [accepted] PHST- 2024/12/29 00:20 [medline] PHST- 2024/11/23 11:12 [pubmed] PHST- 2024/11/22 18:12 [entrez] AID - S0738-3991(24)00420-8 [pii] AID - 10.1016/j.pec.2024.108553 [doi] PST - ppublish SO - Patient Educ Couns. 2025 Feb;131:108553. doi: 10.1016/j.pec.2024.108553. Epub 2024 Nov 17. PMID- 39548457 OWN - NLM STAT- MEDLINE DCOM- 20241116 LR - 20241211 IS - 1472-6939 (Electronic) IS - 1472-6939 (Linking) VI - 25 IP - 1 DP - 2024 Nov 15 TI - Exploring barriers and ethical challenges to medical data sharing: perspectives from Chinese researchers. PG - 132 LID - 10.1186/s12910-024-01135-8 [doi] LID - 132 AB - BACKGROUND: The impetus for policies promoting medical data sharing in China has gained significant traction. Nonetheless, the present legal and ethical framework governing the research use of medical data in China, is characterized by a more restrictive rather than permissive approach. The proportion of Chinese medical data being leveraged for scientific research still has room for improvement at present, indicating a significant untapped potential for advancing medical knowledge and improving healthcare outcomes. Building upon this research, we aim to delve deeper into the challenges researchers encounter in the sharing of medical data through focus group interviews. METHODS: We conducted two focus group interviews study with researchers representing diverse disciplines to explore their perspectives on 21 June 2021 and 28 July 2021. A total of seventeen researchers willingly participated in this study, representing various professional backgrounds. Similar codes were merged. Research team discussions were also utilized to select interviewees' statements that were regarded as typical or representative. RESULTS: The respondents demonstrated a strong understanding that medical data should not be disseminated arbitrarily, recognizing the importance of sharing data in compliance with laws. Through the interview, we found that although respondents stressed the importance of careful consideration regarding if and when this information can be responsibly released, none of the respondents raised the issue of necessitating consent from data subjects for the research use of medical data. This observation sharply contrasts with the stringent separate consent provisions for secondary data use outlined in the PIPL. CONCLUSIONS: The findings from the focus group studies shed light on researchers' barriers and ethical challenges towards medical data sharing for scientific research, highlighting their deep concern for data security and cautious approach to sharing. The key objectives aimed at facilitating and enabling the reuse of medical data encompass enhancing interoperability, harmonizing data standards, improving data quality, safeguarding privacy, ensuring informed consent, incentivizing patients, and establishing explicit regulations pertaining to data access and utilization. CI - (c) 2024. The Author(s). FAU - Li, Xiaojie AU - Li X AD - Department of Situation and Policy, University of International Business and Economics, Beijing, China. FAU - Cong, Yali AU - Cong Y AD - Department of Medical Ethics and Law, Peking University Health Science Center, Beijing, China. ethics@bjmu.edu.cn. LA - eng GR - 23BZ095/National Social Science Fund of China/ PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20241115 PL - England TA - BMC Med Ethics JT - BMC medical ethics JID - 101088680 SB - IM MH - Humans MH - *Information Dissemination/ethics MH - China MH - *Research Personnel/ethics MH - *Focus Groups MH - Informed Consent/ethics MH - Confidentiality/ethics MH - Biomedical Research/ethics MH - Ethics, Research MH - Female MH - Male MH - East Asian People PMC - PMC11566659 OTO - NOTNLM OT - Benefits sharing OT - Data protection law OT - Data quality OT - Data sensitivity OT - Data sharing OT - Medical data COIS- Declarations Ethical approval and consent to participate This investigation was reviewed and approved by the Health Science Center of Peking University IRB (No IRB00001052-19013). To safeguard the privacy of the respondents, we proactively requested them to mask any identifying characteristics that could potentially lead to recognition. Moreover, all respondents provided informed consent, having received comprehensive written and oral information about the project. This information included details about the objectives and topics of the focus group interviews, the confidentiality measures in place to protect their data, the storage and use of the data for scientific papers and presentations, as well as the option to withdraw from the study at any point without providing a specific reason. Throughout the transcription process, careful consideration was given to protecting the identities of individuals, institutions, and locations involved in the study. Names were changed, and any information that posed a risk of identifying individuals was handled with utmost caution. Consent for publication Not applicable. Competing interests The authors declare no competing interests. EDAT- 2024/11/16 22:18 MHDA- 2024/11/16 22:19 PMCR- 2024/11/15 CRDT- 2024/11/16 00:05 PHST- 2023/10/25 00:00 [received] PHST- 2024/11/07 00:00 [accepted] PHST- 2024/11/16 22:19 [medline] PHST- 2024/11/16 22:18 [pubmed] PHST- 2024/11/16 00:05 [entrez] PHST- 2024/11/15 00:00 [pmc-release] AID - 10.1186/s12910-024-01135-8 [pii] AID - 1135 [pii] AID - 10.1186/s12910-024-01135-8 [doi] PST - epublish SO - BMC Med Ethics. 2024 Nov 15;25(1):132. doi: 10.1186/s12910-024-01135-8. PMID- 39544543 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20241116 IS - 2168-8184 (Print) IS - 2168-8184 (Electronic) IS - 2168-8184 (Linking) VI - 16 IP - 10 DP - 2024 Oct TI - The Impact of Family Relationship on Serum 25-Hydroxyvitamin D (25OHD) Concentrations in Individuals Residing in Pune, India. PG - e71513 LID - 10.7759/cureus.71513 [doi] LID - e71513 AB - INTRODUCTION: An understanding of the influence of family relationship on vitamin D concentrations could be useful in designing community-based strategies to improve vitamin D status. Hence, the aim of this study was to explore if family relationship had an impact on total serum 25-hydroxyvitamin D (25OHD) concentrations of individuals living in Pune, India. METHODS: This cross-sectional study included 104 families. Data collected included anthropometry (height and weight), body composition (bioelectric impedance), sunlight exposure (validated questionnaire), and blood samples for estimation of serum 25OHD(2) and 25OHD(3) by liquid chromatography-tandem mass spectrometry (LC-MS/MS) method. Total serum 25OHD was computed as the sum of the serum 25OHD(2) and 25OHD(3) concentrations. Linear mixed model analysis was employed to assess the impact of family on serum 25OHD(2) and total 25OHD concentrations. The strength of the family-level component was assessed by calculating the intra-family correlation for each model separately for children and adults. RESULTS: More than half (63%) of the participants of the participants (235 adults, 118 children) had poor daily sunlight exposure (< 30 minutes). Around one-third, both adults and children, were found to be vitamin D deficient. Intra-family correlation was found to be higher in children than in adults for serum 25OHD(2) (0.6 vs 0.4) and total serum 25OHD (0.5 vs 0.1) concentrations. CONCLUSIONS: Our findings indicate that the likelihood of having similar vitamin D concentrations is higher among children as compared to adults in a family. This suggests a role played by genetic factors or possibly shared habits among children in a family, thus resulting in stronger correlations. This can facilitate the adoption of early preventive measures for treatment or prevention of vitamin D deficiency, even if one child among siblings is vitamin D insufficient. CI - Copyright (c) 2024, Mandlik et al. FAU - Mandlik, Rubina AU - Mandlik R AD - Growth and Pediatric Endocrinology, Hirabai Cowasji Jehangir Medical Research Institute, Pune, IND. FAU - Deshpande, Swapna AU - Deshpande S AD - Health Sciences, Tampere University, Tampere, FIN. AD - Growth and Pediatric Endocrinology, Hirabai Cowasji Jehangir Medical Research Institute, Pune, IND. FAU - Khadilkar, Anuradha AU - Khadilkar A AD - Growth and Pediatric Endocrinology, Hirabai Cowasji Jehangir Medical Research Institute, Pune, IND. AD - Health Sciences, Savitribai Phule Pune University, Pune, IND. LA - eng PT - Journal Article DEP - 20241015 PL - United States TA - Cureus JT - Cureus JID - 101596737 PMC - PMC11561856 OTO - NOTNLM OT - 25ohd OT - 25ohd2 OT - adults OT - children OT - family OT - intra-family correlation OT - siblings OT - vitamin d COIS- Human subjects: Consent was obtained or waived by all participants in this study. Ethics Committee Biomedical and Health Research Ethics Committee, Jehangir Clinical Development Centre Pvt. Ltd. issued approval NA. The Ethics Committee Jehangir Clinical Development Centre Pvt. Ltd. provided ethics approval for the study on July 7, 2020. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: This study was supported by the Tata Trusts (TEDT/MUM/NUT/HCJMRI/2021- 2022/0152-MA/al dt. 27 December 2021). The funders had no involvement in the study procedures or restrictions regarding publication. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work. EDAT- 2024/11/15 11:00 MHDA- 2024/11/15 11:01 PMCR- 2024/10/15 CRDT- 2024/11/15 04:30 PHST- 2024/10/10 00:00 [accepted] PHST- 2024/11/15 11:01 [medline] PHST- 2024/11/15 11:00 [pubmed] PHST- 2024/11/15 04:30 [entrez] PHST- 2024/10/15 00:00 [pmc-release] AID - 10.7759/cureus.71513 [doi] PST - epublish SO - Cureus. 2024 Oct 15;16(10):e71513. doi: 10.7759/cureus.71513. eCollection 2024 Oct. PMID- 39513292 OWN - NLM STAT- MEDLINE DCOM- 20241108 LR - 20241116 IS - 2047-2986 (Electronic) IS - 2047-2978 (Print) IS - 2047-2978 (Linking) VI - 14 DP - 2024 Nov 8 TI - A rural ambulance service in Northern Togo improves access to emergency care for women with obstetric complications. PG - 04201 LID - 10.7189/jogh.14.04201 [doi] LID - 04201 AB - BACKGROUND: Maternal mortality remains high in sub-Saharan Africa, with little progress made in the last 20 years. The provision of emergency obstetric care has been shown to have the greatest effect in reducing maternal mortality in countries with high maternal mortality ratios, especially when paired with an emergency transport service. Integrate Health has partnered with the Togolese Ministry of Health to improve maternal and child health via the integration of a free ambulance service into a pre-existing primary care model. In this study, we aim to describe the implementation of this service and assess its effectiveness on access to emergency obstetric care by estimating its coverage of women with obstetric complications. METHODS: This is a retrospective cross-sectional study using routinely collected data from ambulance logbooks. The study was restricted to pregnant or postpartum woman in four districts of Northern Togo. For each patient transported, the variables collected included date of transport, destination, patient information, kilometres travelled, and reason for transport. Complicated obstetric cases were defined by reason for transport and included maternal haemorrhage, complicated birth, and signs of danger. Estimated coverage of major obstetric complications was calculated using population estimates per fiscal year, the birth rate (3.7%) in Togo, and the assumption that 15% of pregnant women will have a complication. RESULTS: Between July 2020 and June 2023, there were 2926 maternal patients transported by the ambulance service. Of these, 1030 were reported as complicated obstetric cases. Estimated coverage of obstetric complications increased over time and as the programme expanded, from 18% in 2020 to 35.7% in 2021, and 66.5% in 2022. CONCLUSIONS: Our findings demonstrate that implementing a rural ambulance service in a region with historically high maternal mortality rates may improve maternal access to emergency obstetric care. The success of our ambulance service was likely due to the fact that it is free, available 24/7, easily accessible, operated by trained staff and community members, and integrated into a pre-existing primary care programme with well-resourced health care centres. CI - Copyright (c) 2024 by the Journal of Global Health. All rights reserved. FAU - Fagan, Margaret AU - Fagan M AD - Department of Pediatrics, Albert Einstein College of Medicine, Bronx, New York, USA. FAU - Levano, Samantha AU - Levano S AD - Department of Pediatrics, Albert Einstein College of Medicine, Bronx, New York, USA. AD - Community Health Systems Lab, Integrate Health/Sante Integree, Kara, Togo. AD - Department of Family & Social Medicine, Albert Einstein College of Medicine, Bronx, New York, USA. FAU - Haughton, Jessica AU - Haughton J AD - Department of Pediatrics, Albert Einstein College of Medicine, Bronx, New York, USA. AD - Community Health Systems Lab, Integrate Health/Sante Integree, Kara, Togo. AD - Department of Family & Social Medicine, Albert Einstein College of Medicine, Bronx, New York, USA. FAU - Badohoun, Komivi AU - Badohoun K AD - Community Health Systems Lab, Integrate Health/Sante Integree, Kara, Togo. FAU - Dabla, Desire AU - Dabla D AD - Community Health Systems Lab, Integrate Health/Sante Integree, Kara, Togo. FAU - Kangni-Zovoin, Assiongbonvi AU - Kangni-Zovoin A AD - Ministry of Health, Public Hygiene, and Universal Access to Health Care, Kara, Togo. FAU - Midokpor, Messan AU - Midokpor M AD - Ministry of Health, Public Hygiene, and Universal Access to Health Care, Kara, Togo. FAU - Katchoou, Wiyao AU - Katchoou W AD - Ministry of Health, Public Hygiene, and Universal Access to Health Care, Kara, Togo. FAU - Agba, Ekla AU - Agba E AD - Ministry of Health, Public Hygiene, and Universal Access to Health Care, Kara, Togo. FAU - Fiori, Kevin P AU - Fiori KP AD - Department of Pediatrics, Albert Einstein College of Medicine, Bronx, New York, USA. AD - Community Health Systems Lab, Integrate Health/Sante Integree, Kara, Togo. AD - Department of Family & Social Medicine, Albert Einstein College of Medicine, Bronx, New York, USA. LA - eng PT - Journal Article DEP - 20241108 PL - Scotland TA - J Glob Health JT - Journal of global health JID - 101578780 SB - IM MH - Humans MH - Female MH - Pregnancy MH - *Ambulances MH - Retrospective Studies MH - Cross-Sectional Studies MH - Togo MH - *Health Services Accessibility MH - *Pregnancy Complications/mortality/epidemiology MH - *Emergency Medical Services MH - Adult MH - Rural Health Services/organization & administration MH - Maternal Mortality MH - Maternal Health Services/organization & administration MH - Rural Population PMC - PMC11551529 COIS- Disclosure of interest: The authors completed the ICMJE Disclosure of Interest Form (available upon request from the corresponding author) and disclose no relevant interests. EDAT- 2024/11/13 14:01 MHDA- 2024/11/13 14:02 PMCR- 2024/11/08 CRDT- 2024/11/08 05:13 PHST- 2024/11/13 14:02 [medline] PHST- 2024/11/13 14:01 [pubmed] PHST- 2024/11/08 05:13 [entrez] PHST- 2024/11/08 00:00 [pmc-release] AID - jogh-14-04201 [pii] AID - 10.7189/jogh.14.04201 [doi] PST - epublish SO - J Glob Health. 2024 Nov 8;14:04201. doi: 10.7189/jogh.14.04201. PMID- 39475067 OWN - NLM STAT- MEDLINE DCOM- 20250522 LR - 20260924 IS - 1469-994X (Electronic) IS - 1462-2203 (Print) IS - 1462-2203 (Linking) VI - 27 IP - 6 DP - 2025 May 22 TI - Do-It-Yourself Flavored Capsule Cigarettes: Exploiting Potential Regulatory Loopholes? PG - 1142-1146 LID - 10.1093/ntr/ntae258 [doi] AB - INTRODUCTION: Capsule cigarettes allow users to crush liquid-filled capsules to release flavors into cigarettes' filters. New devices are emerging across the globe that allow people who smoke to circumvent tobacco flavor restrictions via injectable capsules. This study examined TikTok videos marketing flavored capsule injector devices. METHODS: TikTok videos (n = 832) posted worldwide between July 6, 2021, and December 28, 2023, that used hashtags #injectorflavor, #flavourclickball, #flavorball, and #injectorballcigarette were collected using a TikTok application programing interface. A codebook was developed using a systematic iterative approach, identifying six codes: flavor capsules, promotes flavors (i.e., fruit, mint or menthol flavors, nonalcoholic drinks, alcoholic drinks), demonstrates how to use or refill large injector devices, demonstrates how to use small convenient devices, includes music (any or English language). Two independent coders annotated all videos. RESULTS: Overall, 88.3% (n = 735) of the videos displayed flavor capsules and had been viewed more than 72 million times. Half (51.6%) of the videos demonstrated how to use large box-shaped devices to inject capsules into the filter of a cigarette, and 15.0% of the videos showed how to do this with smaller, more convenient devices. Flavors including fruit (35.5%), menthol/mint (27.8%), nonalcoholic drinks (21.9%), and alcoholic drinks (11.6%) were used to promote these capsules. Most videos (85.6%) were uploaded by sellers on "TikTok shop." DISCUSSION: TikTok accounts are promoting injectable capsule devices that circumvent flavored tobacco sales restrictions. Policy makers, tobacco control advocates, and public health practitioners should be aware of such marketing to inform regulation and develop prevention strategies. IMPLICATIONS: Our findings identified an emerging product that can encourage circumvention of flavor restriction policies. Regulators, policy makers, public health practitioners, researchers, and advocates should be aware of such products to inform regulation and develop prevention strategies. Given the potential for these products to reduce the intended effects of flavored tobacco sales restrictions, policy makers must be poised to address materials that consumers use to create their own flavored tobacco products, including flavor capsules designed to be inserted into cigarettes. CI - (c) The Author(s) 2024. Published by Oxford University Press on behalf of the Society for Research on Nicotine and Tobacco. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site-for further information please contact journals.permissions@oup.com. FAU - Dobbs, Page D AU - Dobbs PD AUID- ORCID: 0000-0003-1913-6488 AD - Department of Health, Human Performance and Recreation, University of Arkansas, Fayetteville, AR, USA. AD - Department of Health, Human Performance and Recreation, Center for Public Health and Technology, University of Arkansas, Fayetteville, AR, USA. FAU - Soule, Eric K AU - Soule EK AUID- ORCID: 0000-0003-2740-5633 AD - Department of Health Education and Promotion, East Carolina University, Greenville, NC, USA. FAU - Mahoney, Margaret AU - Mahoney M AD - Public Health Policy Consultant, Minneapolis, MN, USA. FAU - Tabassum, Mufazzela AU - Tabassum M AD - Department of Health, Human Performance and Recreation, University of Arkansas, Fayetteville, AR, USA. FAU - Burgess, Nia AU - Burgess N AD - Department of Health Education and Promotion, East Carolina University, Greenville, NC, USA. FAU - Henriksen, Lisa AU - Henriksen L AUID- ORCID: 0000-0002-9288-3562 AD - Stanford Prevention Research Center, Stanford University School of Medicine, Palo Alto, CA, USA. LA - eng GR - P01 CA225597/CA/NCI NIH HHS/United States GR - P50MD017319/NH/NIH HHS/United States GR - P50 MD017319/MD/NIMHD NIH HHS/United States GR - NH/NIH HHS/United States GR - K01CA267967/US Food and Drug Administration/ GR - K01 CA267967/CA/NCI NIH HHS/United States GR - National Cancer Institute and the Center for Tobacco Products/ GR - DA/NIDA NIH HHS/United States GR - CA225597/the National Cancer Institute/ PT - Journal Article PL - England TA - Nicotine Tob Res JT - Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco JID - 9815751 RN - 0 (Flavoring Agents) RN - 0 (Capsules) SB - IM MH - Humans MH - *Flavoring Agents MH - *Tobacco Products/legislation & jurisprudence MH - Capsules MH - *Marketing PMC - PMC12095802 COIS- None declared. EDAT- 2024/10/30 13:20 MHDA- 2025/05/22 06:28 PMCR- 2025/10/30 CRDT- 2024/10/30 07:42 PHST- 2024/06/10 00:00 [received] PHST- 2024/10/21 00:00 [revised] PHST- 2024/10/26 00:00 [accepted] PHST- 2025/05/22 06:28 [medline] PHST- 2024/10/30 13:20 [pubmed] PHST- 2024/10/30 07:42 [entrez] PHST- 2025/10/30 00:00 [pmc-release] AID - 7849826 [pii] AID - ntae258 [pii] AID - 10.1093/ntr/ntae258 [doi] PST - ppublish SO - Nicotine Tob Res. 2025 May 22;27(6):1142-1146. doi: 10.1093/ntr/ntae258. PMID- 39468000 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250112 IS - 2509-4254 (Electronic) IS - 2509-4262 (Print) IS - 2509-4262 (Linking) VI - 9 IP - 1 DP - 2025 Jan TI - Mortality, Clinical Complications, and Healthcare Resource Utilization Associated with Managing Transfusion-Dependent beta-Thalassemia and Sickle Cell Disease with Recurrent Vaso-occlusive Crises in Italy. PG - 115-124 LID - 10.1007/s41669-024-00532-4 [doi] AB - OBJECTIVE: To examine the clinical burden and healthcare resource utilization (HCRU) among patients with transfusion-dependent beta-thalassemia (TDT) and patients with sickle cell disease (SCD) with recurrent vaso-occlusive crises (VOCs) in Italy. METHODS: Eligible patients were identified from an administrative claims database from 1 January 2010 and 1 February 2019. Patients with TDT had >/= 1 iron chelation treatment, >/= 8 red blood cell transfusions (RBCTs) during any 12-month period, and >/= 12 months of available data pre- and post-index (i.e., first RBCT claim). Patients with SCD with recurrent VOCs had >/= 2 VOCs/year in >/= 2 consecutive years and >/= 12 months of available data pre- and post-index (second VOC claim in the second of 2 consecutive years). Patients were propensity score matched to five controls by age, sex, geographic area, and index year. Clinical and HCRU outcomes were evaluated post-index. RESULTS: In total, 214 patients with TDT and 111 patients with SCD with recurrent VOCs were matched to 1070 and 555 controls, respectively. Both patient groups had substantially higher mortality rates than controls (TDT: 4.8 versus 0.8 deaths per 100 person-years; SCD: 1.6 versus 0.4 deaths per 100 person-years). Clinical complications were prevalent in both patient groups. Compared with controls, both patient groups had significantly higher mean rates of all-cause hospitalizations (TDT: 1.4 versus 0.1; SCD: 2.0 versus 0.1) and outpatient services (TDT: 21.9 versus 1.6; SCD: 6.2 versus 1.0) per patient per year (all: p < 0.05). CONCLUSIONS: Management of TDT and SCD in Italy is associated with significant clinical and health system burden, highlighting the need for new treatments that eliminate RBCTs and VOCs. CI - (c) 2024. The Author(s). FAU - Udeze, Chuka AU - Udeze C AUID- ORCID: 0009-0002-7840-6804 AD - Vertex Pharmaceuticals Incorporated, 50 Northern Avenue, Boston, MA, 02210, USA. chuka_udeze@vrtx.com. FAU - Dovizio, Melania AU - Dovizio M AD - CliCon S.r.l. Societa Benefit, Bologna, Italy. FAU - Veronesi, Chiara AU - Veronesi C AD - CliCon S.r.l. Societa Benefit, Bologna, Italy. FAU - Esposti, Luca Degli AU - Esposti LD AD - CliCon S.r.l. Societa Benefit, Bologna, Italy. FAU - Li, Nanxin AU - Li N AD - Vertex Pharmaceuticals Incorporated, 50 Northern Avenue, Boston, MA, 02210, USA. FAU - Dang, Thi Xuan Mai Patricia AU - Dang TXMP AD - Vertex Pharmaceuticals Incorporated, 50 Northern Avenue, Boston, MA, 02210, USA. FAU - Forni, Gian Luca AU - Forni GL AD - ForAnemia Foundation, Genoa, Italy. LA - eng PT - Journal Article DEP - 20241028 PL - Switzerland TA - Pharmacoecon Open JT - PharmacoEconomics - open JID - 101700780 PMC - PMC11718030 COIS- Declarations. Funding: This study was supported by Vertex Pharmaceuticals Incorporated. Clicon S.r.l. Societa Benefit is an independent company. The agreement signed by Clicon S.r.l. Societa Benefit and Vertex Pharmaceuticals Incorporated does not create any ownership, joint venture, or any similar relationship between parties. Neither CliCon S.r.l. Societa Benefit nor any of their representatives are employees of Vertex Pharmaceuticals Incorporated for any purpose. Conflicts of Interest: Chuka Udeze, Nanxin Li, and Thi Xuan Mai Patricia Dang are employees of Vertex Pharmaceuticals Incorporated and may hold stock or stock options in the company. Gian Luca Forni reports advisory board participation for Agios, Bristol Myers Squibb, and Vertex. Melania Dovizio, Chiara Veronesi, and Luca Degli Esposti do not have conflicts of interest to disclose. Availability of Data and Material: This study used data available from Clicon. Restrictions apply to the availability of these data, which were used under a licensing agreement. Ethics Approval: The Declaration of Helsinki is not applicable to this study. The study was conducted in accordance with ethical standards, submitted, and approved by the local ethics committees of the participating healthcare entities as follows: Authorization of the Ethics Committee "BAT (Barletta-Andria-Trani) Comitato etico interprovinciale Area I" (protocol number 68/CE/20, approval date 3 December 2020). Authorization of the Ethics Committee "Berica Comitato Etico per le Sperimentazioni Cliniche (CESC) della Provincia di Vicenza" (protocol number 1627, approval date 28 October 2020). Authorization of the Ethics Committee "Foggia Comitato etico interprovinciale Area I" (protocol number 63/CE/20, approval date 3 December 2020). Authorization of the Ethics Committee "Frosinone Comitato Etico Lazio 2" (protocol number 0179046/2020, approval date 28 October 2020). Authorization of the Ethics Committee "Genova Comitato Etico Regionale Liguria" (protocol number 0179046/2020, approval date 14 June 2021). Authorization of the Ethics Committee "Comitato Etico ASL Lecce" (protocol number 34, approval date 04 July 2019). Authorization of the Ethics Committee "Napoli 3 Comitato Etico Interaziendale Campania Sud" (protocol number 51, approval date 02 September 2020). Authorization of the Ethics Committee "Pedemontana Comitato Etico per le Sperimentazioni Cliniche (CESC) della Provincia di Vicenza" (protocol number 0036999, approval date 28 April 2021). Authorization of the Ethics Committee "Comitato Etico delle Province di Chieti e Pescara" (protocol number 07, approval date 18 March 2021). Authorization of the Ethics Committee "ASREM Azienda Sanitaria Regione Molise" (protocol number 101125, approval date 27 October 2020). Authorization of the Ethics Committee "Roma 4 Comitato Etico Lazio 1" (protocol number 1079/CE Lazio 1, approval date 23 September 2020). Authorization of the Ethics Committee "Roma 5 Comitato Etico Lazio 1" (protocol number 1166/CE Lazio 1, approval date 12 October 2020). Authorization of the Ethics Committee "Roma 6 Comitato Etico Lazio 2" (protocol number 0216084/2020, approval date 15 December 2020). Authorization of the Ethics Committee "Salerno Comitato Etico Inter-aziendale Campania Sud" (protocol number 64, approval date 03 November 2020). Authorization of the Ethics Committee "Serenissima Comitato Etico per la Sperimentazione Clinica della provincia di Venezia e IRCCS S. Camillo" (28/07/2020). Authorization of the Ethics Committee "Comitato Etico per le province di L'Aquila e Teramo" (protocol number 11, approval date 24 March 2021). Authorization of the Ethics Committee "Umbria 2 Comitato Etico Regionale Umbria" (protocol number 19414/20/ON, approval date 16 September 2020). Authorization of the Ethics Committee "Vercelli Comitato Etico Interaziendale A.O. SS. Antonio e Biagio e Cesare Arrigo - Alessandria" (protocol number 0008668, approval date 20 April 2021). Consent to Participate: Not applicable. Consent for Publication: Not applicable. Code Availability: Not applicable. Author Contributions: All authors contributed to the study conceptualization, design, and results interpretation. Initial data analysis was performed by Melania Dovizio, Chiara Veronesi, and Luca Degli Esposti in consultation with Chuka Udeze, Nanxin Li, Gian Luca Forni, and Thi Xuan Mai Patricia Dang, and all authors reviewed the results. All authors read and approved the final manuscript. EDAT- 2024/10/29 06:23 MHDA- 2024/10/29 06:24 PMCR- 2024/10/28 CRDT- 2024/10/29 00:28 PHST- 2024/09/24 00:00 [accepted] PHST- 2024/10/29 06:24 [medline] PHST- 2024/10/29 06:23 [pubmed] PHST- 2024/10/29 00:28 [entrez] PHST- 2024/10/28 00:00 [pmc-release] AID - 10.1007/s41669-024-00532-4 [pii] AID - 532 [pii] AID - 10.1007/s41669-024-00532-4 [doi] PST - ppublish SO - Pharmacoecon Open. 2025 Jan;9(1):115-124. doi: 10.1007/s41669-024-00532-4. Epub 2024 Oct 28. PMID- 39446431 OWN - NLM STAT- MEDLINE DCOM- 20241024 LR - 20250904 IS - 1438-8871 (Electronic) IS - 1439-4456 (Print) IS - 1438-8871 (Linking) VI - 26 DP - 2024 Oct 24 TI - Discussion of Heated Tobacco Products on Twitter Following IQOS's Modified-Risk Tobacco Product Authorization and US Import Ban: Content Analysis. PG - e53938 LID - 10.2196/53938 [doi] LID - e53938 AB - BACKGROUND: Understanding public opinions about emerging tobacco products is important to inform future interventions and regulatory decisions. Heated tobacco products (HTPs) are an emerging tobacco product category promoted by the tobacco industry as a "better alternative" to combustible cigarettes. Philip Morris International's IQOS is leading the global HTP market and recently has been subject to important policy events, including the US Food and Drug Administration's (FDA) modified-risk tobacco product (MRTP) authorization (July 2020) and the US import ban (November 2021). Although limited in their legal implications outside the United States, these policy events have been quoted in global news outlets and Philip Morris International's promotional communications, showing how they may potentially impact global tobacco regulation. Given the impending return of IQOS to the US market, understanding how the policy events were received through social media discourse will provide valuable insights to inform global tobacco control policy. OBJECTIVE: This study aims to examine HTP-related social media discourse around important policy events. METHODS: We analyzed HTP-related posts on Twitter during the time period that included IQOS's MRTP authorization in the United States and the US import ban, examining personal testimonial, news/information, and direct marketing/retail tweets separately. We also examined how the tweets discussed health and policy. A total of 10,454 public English tweets (posted from June 2020 to December 2021) were collected using HTP-related keywords. We randomly sampled 2796 (26.7%) tweets and conducted a content analysis. We used pairwise co-occurrence analyses to evaluate connections across themes. RESULTS: Tweet volumes peaked around IQOS-related policy events. Among all tweets, personal testimonials were the most common (1613/2796, 57.7%), followed by news/information (862/2796, 30.8%) and direct marketing/retail (321/2796, 11%). Among personal testimonials, more tweets were positive (495/1613, 30.7%) than negative (372/1613, 23.1%), often comparing the health risks of HTPs with cigarettes (402/1613, 24.9%) or vaping products (252/1613, 15.6%). Approximately 10% (31/321) of the direct marketing/retail tweets promoted international delivery, suggesting cross-border promotion. More than a quarter of tweets (809/2796, 28.9%) discussed US and global policy, including misinterpretation about IQOS being a "safer" tobacco product after the US FDA's MRTP authorization. Neutral testimonials mentioning the IQOS brand (634/1613, 39.3%) and discussing policy (378/1613, 23.4%) showed the largest pairwise co-occurrence. CONCLUSIONS: Results suggest the need for careful communication about the meaning of MRTP authorizations and relative risks of tobacco products. Many tweets expressed HTP-favorable opinions referring to reduced health risks, even though the US FDA has denied marketing of the HTP with reduced risk claims. The popularity of social media as an information source with global reach poses unique challenges in health communication and health policies. While many countries restrict tobacco marketing via the web, our results suggest that retailers may circumvent such regulations by operating overseas. CI - (c)Minji Kim, Julia Vassey, Dongmei Li, Artur Galimov, Eileen Han, Matthew G Kirkpatrick, Cassandra A Stanton, Jenny E Ozga, Sarah Lee, Jennifer B Unger. Originally published in the Journal of Medical Internet Research (https://www.jmir.org), 24.10.2024. FAU - Kim, Minji AU - Kim M AUID- ORCID: 0000-0002-7715-6826 AD - Department of Health Promotion, Education, and Behavior, Arnold School of Public Health, University of South Carolina, Columbia, SC, United States. FAU - Vassey, Julia AU - Vassey J AUID- ORCID: 0000-0003-3002-2000 AD - Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States. FAU - Li, Dongmei AU - Li D AUID- ORCID: 0000-0001-9140-2483 AD - Department of Clinical and Translational Research, University of Rochester Medical Center, Rochester, NY, United States. FAU - Galimov, Artur AU - Galimov A AUID- ORCID: 0000-0002-9718-439X AD - Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States. FAU - Han, Eileen AU - Han E AUID- ORCID: 0000-0002-3443-4240 AD - Center for Tobacco Control Research and Education, University of California, San Francisco, San Francisco, CA, United States. FAU - Kirkpatrick, Matthew G AU - Kirkpatrick MG AUID- ORCID: 0000-0003-2586-9514 AD - Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States. AD - Department of Psychology, University of Southern California, Los Angeles, CA, United States. FAU - Stanton, Cassandra A AU - Stanton CA AUID- ORCID: 0000-0001-5329-6261 AD - Behavioral Health and Health Policy Practice, Westat, Rockville, MD, United States. FAU - Ozga, Jenny E AU - Ozga JE AUID- ORCID: 0000-0003-2543-561X AD - Behavioral Health and Health Policy Practice, Westat, Rockville, MD, United States. FAU - Lee, Sarah AU - Lee S AUID- ORCID: 0009-0006-9962-0489 AD - Department of Clinical and Translational Research, University of Rochester Medical Center, Rochester, NY, United States. FAU - Unger, Jennifer B AU - Unger JB AUID- ORCID: 0000-0001-9064-6603 AD - Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States. LA - eng GR - U54 CA180905/CA/NCI NIH HHS/United States GR - U54 CA228110/CA/NCI NIH HHS/United States GR - U54 DA046060/DA/NIDA NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20241024 PL - Canada TA - J Med Internet Res JT - Journal of medical Internet research JID - 100959882 SB - IM MH - United States MH - *Tobacco Products/legislation & jurisprudence MH - *Social Media/statistics & numerical data MH - Humans MH - *Tobacco Industry/legislation & jurisprudence MH - United States Food and Drug Administration PMC - PMC11544331 OTO - NOTNLM OT - IQOS OT - MRTP authorization OT - Twitter OT - content analysis OT - heated tobacco products OT - import ban OT - modified-risk tobacco product authorization OT - observational study OT - public opinion OT - social media OT - tobacco control OT - tobacco regulatory science COIS- Conflicts of Interest: None declared. EDAT- 2024/10/24 12:32 MHDA- 2024/10/25 07:20 PMCR- 2024/10/24 CRDT- 2024/10/24 11:53 PHST- 2023/10/30 00:00 [received] PHST- 2024/08/14 00:00 [accepted] PHST- 2024/04/01 00:00 [revised] PHST- 2024/10/25 07:20 [medline] PHST- 2024/10/24 12:32 [pubmed] PHST- 2024/10/24 11:53 [entrez] PHST- 2024/10/24 00:00 [pmc-release] AID - v26i1e53938 [pii] AID - 10.2196/53938 [doi] PST - epublish SO - J Med Internet Res. 2024 Oct 24;26:e53938. doi: 10.2196/53938. PMID- 39445701 OWN - NLM STAT- MEDLINE DCOM- 20250612 LR - 20250614 IS - 1365-2648 (Electronic) IS - 0309-2402 (Print) IS - 0309-2402 (Linking) VI - 81 IP - 7 DP - 2025 Jul TI - No Backstage: The Relentless Emotional Management of Acute Nursing Through the COVID-19 Pandemic. PG - 4010-4022 LID - 10.1111/jan.16563 [doi] AB - AIM(S): To explore the impact of the COVID-19 pandemic on nurse's well-being, experiences of delivering healthcare within acute settings and their emotional management. DESIGN: Sequential mixed methods. METHODS: February to July 2021 an online well-being survey was disseminated to nurses working in acute settings within one Scottish health board. In-depth interviews with a purposive sample of respondents were conducted. Survey data were analysed descriptively, and interview data using Framework analysis and emotional management as the theoretical framework. RESULTS: Well-being was poor overall. Infection control measures impeded interactions, with loss of connection between patients, families and nurses. Emotional work was extended in caring for patients and families when visits were forbidden or restricted. Disconnect between colleagues was intensely felt. On COVID and non-COVID wards, nurses were caring for patients with a significantly reduced workforce and often outside their clinical speciality. Nurses masked their own anxieties, fears, moral distress and exhaustion on the ward. Communal 'backstage' spaces, were reduced to enable more infection-control space but reduced opportunity for collegial support. Formal psychological intervention required access after shift, and/or nurses feared they could not contain their emotions afterwards. CONCLUSION: Working during the pandemic was emotionally and physically demanding for those in COVID a.nd non-COVID wards. Unintended consequences of infection control measures significantly extended nurses' emotional management, by caring for isolated patients and families but impeding opportunities to care for each other, compounding their emotions. IMPLICATIONS FOR THE PROFESSION: There is a need to value emotional work in nursing to better support mental well-being. IMPACT: We advance the nursing emotional management literature by addressing the gap of exploration in challenging conditions. The importance of emotional management on nurses' mental well-being has been overlooked but focusing on this in the next crisis could improve nurse's well-being. PATIENT OR PUBLIC CONTRIBUTION: No patient or public contribution. REPORTING METHOD: GRAMMS. CI - (c) 2024 The Author(s). Journal of Advanced Nursing published by John Wiley & Sons Ltd. FAU - Grant, Aileen AU - Grant A AUID- ORCID: 0000-0001-6146-101X AD - School of Nursing Midwifery and Paramedic Practice, Robert Gordon University, Aberdeen, Scotland. FAU - O'Brien, Rosaleen AU - O'Brien R AD - Independent Scholar, Glasgow, UK. FAU - Douglas, Flora AU - Douglas F AUID- ORCID: 0000-0002-0333-6605 AD - School of Nursing Midwifery and Paramedic Practice, Robert Gordon University, Aberdeen, Scotland. FAU - Kennedy, Catriona AU - Kennedy C AUID- ORCID: 0000-0003-3510-9113 AD - School of Nursing Midwifery and Paramedic Practice, Robert Gordon University, Aberdeen, Scotland. FAU - Baldie, Debbie AU - Baldie D AD - NHS Grampian, Scotland. FAU - Torrance, Nicola AU - Torrance N AUID- ORCID: 0000-0002-7856-7408 AD - School of Nursing Midwifery and Paramedic Practice, Robert Gordon University, Aberdeen, Scotland. LA - eng PT - Journal Article DEP - 20241024 PL - England TA - J Adv Nurs JT - Journal of advanced nursing JID - 7609811 SB - IM MH - Humans MH - *COVID-19/nursing/epidemiology/psychology MH - Female MH - *Nursing Staff, Hospital/psychology MH - Male MH - Adult MH - SARS-CoV-2 MH - Middle Aged MH - Scotland/epidemiology MH - Pandemics MH - Surveys and Questionnaires MH - Emotions PMC - PMC12159377 OTO - NOTNLM OT - COVID-19 pandemic OT - burnout OT - compassion OT - emotional intelligence OT - nurse-patient interaction OT - organisational behaviour OT - pandemic OT - patient safety OT - teamwork OT - work organisation COIS- The authors declare no conflicts of interest. EDAT- 2024/10/24 16:21 MHDA- 2025/06/12 06:30 PMCR- 2025/06/12 CRDT- 2024/10/24 08:03 PHST- 2024/09/09 00:00 [revised] PHST- 2024/01/25 00:00 [received] PHST- 2024/10/08 00:00 [accepted] PHST- 2025/06/12 06:30 [medline] PHST- 2024/10/24 16:21 [pubmed] PHST- 2024/10/24 08:03 [entrez] PHST- 2025/06/12 00:00 [pmc-release] AID - JAN16563 [pii] AID - 10.1111/jan.16563 [doi] PST - ppublish SO - J Adv Nurs. 2025 Jul;81(7):4010-4022. doi: 10.1111/jan.16563. Epub 2024 Oct 24. PMID- 39438860 OWN - NLM STAT- MEDLINE DCOM- 20241023 LR - 20250205 IS - 1471-2458 (Electronic) IS - 1471-2458 (Linking) VI - 24 IP - 1 DP - 2024 Oct 23 TI - The long-term effect of the coronavirus pandemic on parkrun participation: an interrupted time series analysis. PG - 2931 LID - 10.1186/s12889-024-20420-0 [doi] LID - 2931 AB - BACKGROUND: The growth of parkrun between 2004 and 2019 has been heralded as a success story for public health as a result of its physical activity and wellbeing benefits for participants. However, parkrun was not immune from the COVID-19 pandemic - with events in mainland England cancelled from March 2020 to July 2021. This study explores the lasting impact of the pandemic on parkrun participation to February 2023, and its implications across the socioeconomic spectrum. METHODS: The study combines aggregated parkrun weekly finisher data from 32,470 Lower Layer Super Output Areas (LSOA) in England from January 2015 to February 2023 with Office of National Statistics (ONS) data on population and deprivation. Interrupted time series analysis using segmented Poisson regression models was used to estimate the immediate change in parkrun participation and the change in the rate of growth following the pandemic. Models were fitted for each Index of Multiple Deprivation (IMD) quintile separately to assess whether this effect differed by socioeconomic deprivation. RESULTS: Visualisation and interrupted time series analysis showed a significant and long-term decrease in parkrun participation following the reopening of parkrun events. This was consistent across all IMD quintiles, indicating that the inequalities in parkrun participation according to IMD observed prior to the pandemic remained after the pandemic. Between March 2020 and February 2023, almost 13 million fewer parkrun finishes are estimated to have occurred relative to what would have occurred in the absence of the pandemic. CONCLUSION: The reduction in parkrun participation during the pandemic and following the reopening of events is likely to have negatively impacted wellbeing in would-be participants. Going forwards, policymakers must make the difficult trade-off between the long-term health and social implications of restricting outdoor physical activity events against the benefits associated with a reduction in infectious disease transmission. CI - (c) 2024. The Author(s). FAU - Rousham, Oscar AU - Rousham O AUID- ORCID: 0009-0003-3464-6096 AD - Sheffield Centre for Health and Related Research (SCHARR), The University of Sheffield, Sheffield, S10 2TN, UK. ogrousham1@sheffield.ac.uk. FAU - Quirk, Helen AU - Quirk H AUID- ORCID: 0000-0003-2716-4681 AD - Sheffield Centre for Health and Related Research (SCHARR), The University of Sheffield, Sheffield, S10 2TN, UK. FAU - Goyder, Elizabeth AU - Goyder E AUID- ORCID: 0000-0003-3691-1888 AD - Sheffield Centre for Health and Related Research (SCHARR), The University of Sheffield, Sheffield, S10 2TN, UK. FAU - Smith, Robert A AU - Smith RA AUID- ORCID: 0000-0003-0245-3217 AD - Sheffield Centre for Health and Related Research (SCHARR), The University of Sheffield, Sheffield, S10 2TN, UK. LA - eng GR - WT_/Wellcome Trust/United Kingdom GR - 108903/WT_/Wellcome Trust/United Kingdom PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20241023 PL - England TA - BMC Public Health JT - BMC public health JID - 100968562 SB - IM MH - Humans MH - *Interrupted Time Series Analysis MH - *COVID-19/epidemiology/prevention & control MH - England/epidemiology MH - Parks, Recreational/statistics & numerical data MH - Pandemics MH - Exercise MH - Socioeconomic Factors MH - SARS-CoV-2 PMC - PMC11520146 OTO - NOTNLM OT - Ecological study OT - Interrupted time series OT - Parkrun OT - Physical activity OT - Socioeconomic deprivation COIS- H.Q. is Deputy Chair of the parkrun Research Board. EDAT- 2024/10/23 00:21 MHDA- 2024/10/23 10:18 PMCR- 2024/10/23 CRDT- 2024/10/22 23:58 PHST- 2024/04/26 00:00 [received] PHST- 2024/10/16 00:00 [accepted] PHST- 2024/10/23 10:18 [medline] PHST- 2024/10/23 00:21 [pubmed] PHST- 2024/10/22 23:58 [entrez] PHST- 2024/10/23 00:00 [pmc-release] AID - 10.1186/s12889-024-20420-0 [pii] AID - 20420 [pii] AID - 10.1186/s12889-024-20420-0 [doi] PST - epublish SO - BMC Public Health. 2024 Oct 23;24(1):2931. doi: 10.1186/s12889-024-20420-0. PMID- 39419608 OWN - NLM STAT- Publisher LR - 20260418 IS - 1468-3318 (Electronic) IS - 0964-4563 (Print) IS - 0964-4563 (Linking) DP - 2024 Oct 17 TI - Analysis of cigar marketing expenditures by product category, placement strategy and geolocation in the USA, from 2017 to 2022. LID - tc-2024-058812 [pii] LID - 10.1136/tc-2024-058812 [doi] AB - SIGNIFICANCE: The marketing of cigars, little cigars and cigarillos (CLCCs) and cigar wraps is under-regulated and understudied in the USA. To describe strategies CLCC manufacturers and vendors used to advertise their products across marketing channels, we systematically tracked CLCC marketing expenditures from January 2017 to July 2022. METHODS: Using the Kantar Media's Strategy (presently Vivvix) platform, we collected marketing expenditures for 624 CLCC products, vendors, venues, events and media outlets. Advertising data were collected from consumer magazines, B-to-B magazines, newspapers, television, radio, outdoor and internet media. Advertising expenditures were aggregated by month, designated market area, manufacturer and product category. RESULTS: Across the study period, cigarillo marketing comprised the largest proportion of CLCC product expenditures (49.5%), followed by little/filtered cigars (44.7%). Cigarillos dominated advertising expenditures in 2018 ($19.9M), declined to $1.4M by 2020 when little/filtered cigars emerged as the most promoted category ($10.4M); cigarillos re-surfaced as the top category in 2022. Radio advertising expenditures for CLCCs increased substantially in 2021. Outdoor CLCC vendor expenditures steadily increased during the period. Online marketing expenditures by CLCC vendors increased from 2020 to 2021, and newly reported mobile app expenditures occurred in 2021 ($22K). CONCLUSION: Advertising expenditures for little/filtered cigars declined following the April 2021 Food and Drug Administration (FDA) announcement of forthcoming flavoured cigar sale restrictions. As the FDA considers prohibiting flavoured cigars, it is essential to monitor CLCC marketing expenditures to inform policy design, promotion and implementation efforts. Surveillance of new digital marketing channels is critical as they can readily reach minoritised populations. CI - (c) Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. FAU - Carter, Chandler C AU - Carter CC AUID- ORCID: 0000-0001-8347-5201 AD - Public Health, NORC at the University of Chicago, Chicago, Illinois, USA carter-chandler@norc.org. FAU - Binns, Steven AU - Binns S AUID- ORCID: 0000-0001-8573-107X AD - Public Health, NORC at the University of Chicago, Chicago, Illinois, USA. FAU - Emery, Sherry L AU - Emery SL AUID- ORCID: 0000-0001-9278-9990 AD - Public Health, NORC at the University of Chicago, Chicago, Illinois, USA. FAU - Kostygina, Ganna AU - Kostygina G AUID- ORCID: 0000-0002-8416-6168 AD - Public Health, NORC at the University of Chicago, Chicago, Illinois, USA. LA - eng GR - R01 CA248871/CA/NCI NIH HHS/United States PT - Journal Article DEP - 20241017 PL - England TA - Tob Control JT - Tobacco control JID - 9209612 SB - IM PMC - PMC12003699 MID - NIHMS2029414 OTO - NOTNLM OT - Advertising and Promotion OT - Media OT - Tobacco industry COIS- Competing interests: No, there are no competing interests. EDAT- 2024/10/18 07:19 MHDA- 2024/10/18 07:19 PMCR- 2026/04/17 CRDT- 2024/10/17 21:23 PHST- 2024/05/20 00:00 [received] PHST- 2024/09/27 00:00 [accepted] PHST- 2024/10/18 07:19 [medline] PHST- 2024/10/18 07:19 [pubmed] PHST- 2024/10/17 21:23 [entrez] PHST- 2026/04/17 00:00 [pmc-release] AID - tc-2024-058812 [pii] AID - 10.1136/tc-2024-058812 [doi] PST - aheadofprint SO - Tob Control. 2024 Oct 17:tc-2024-058812. doi: 10.1136/tc-2024-058812. PMID- 39395978 OWN - NLM STAT- MEDLINE DCOM- 20241012 LR - 20261013 IS - 1471-2318 (Electronic) IS - 1471-2318 (Linking) VI - 24 IP - 1 DP - 2024 Oct 12 TI - The relationship between the Barthel Index and stroke-associated pneumonia in elderly patients and factors of SAP. PG - 829 LID - 10.1186/s12877-024-05400-8 [doi] LID - 829 AB - BACKGROUND: Stroke-associated pneumonia (SAP) is a common complication in stroke patients, and the Barthel Index (BI) is a well-established metric for assessing activities of daily living (ADL). However, the association between BI and SAP in acute ischemic stroke (AIS) patients remains unclear. This study aims to investigate the relationship between BI at admission and SAP, and explore the factors in AIS elderly patients. METHOD: Retrospective data were collected from ischemic stroke patients hospitalized at the Second Affiliated Hospital of Nanchang University between January 2018 and July 2021, including their basic demographic and laboratory test results. Restricted cubic spline regression, multivariate logistic regression analysis, and receiver operating characteristic (ROC) curve analysis were employed to investigate the relationship between BI and SAP. Additionally, the Shapley Additive exPlanations (SHAP) method was used to identify the factors influencing SAP. RESULTS: The study included 7,548 eligible stroke patients with a mean age of 75.1 +/- 7.6 years, among which 41.14% were female. The SAP group demonstrated significantly lower BI compared to the non-SAP group (50.86 +/- 35.60 vs. 75.27 +/- 26.33, P < 0.001). Additionally, a conspicuous trend of decreasing SAP risk across the Q1-4 groups was observed (P < 0.001). The RCS analysis further confirmed a gradual reduction in SAP risk with increasing BI. Based on the clinical model, both the BI (NRI = 0.014, P = 0.005; IDI = 0.04, P < 0.001) and the NIHSS score (NRI = 0.09, P = 0.03; IDI = 0.025, P < 0.001) demonstrated additional predictive value for SAP. Multivariate logistic regression and SHAP analysis identified WBC, CONUT, TG, UA, and RBC levels, as well as the type of health insurance (urban employee basic medical insurance), as important independent predictors of SAP. CONCLUSION: BI at admission constitutes a risk factor for the onset of SAP in elderly patients with AIS, Compared to the NIHSS and mRS score, BI may be a more reliable and practical predictor of SAP. CI - (c) 2024. The Author(s). FAU - Wu, Bin AU - Wu B AD - Department of Medical Big Data Research Centre, The Second Affiliated Hospital of Nanchang University, 1MinDe Road, Nanchang, 330006, People's Republic of China. AD - School of Public Health, Jiangxi Medical College, Nanchang University, Nanchang, People's Republic of China. FAU - Luo, Haowen AU - Luo H AD - Department of Medical Big Data Research Centre, The Second Affiliated Hospital of Nanchang University, 1MinDe Road, Nanchang, 330006, People's Republic of China. FAU - Li, Jingyi AU - Li J AD - Department of Medical Big Data Research Centre, The Second Affiliated Hospital of Nanchang University, 1MinDe Road, Nanchang, 330006, People's Republic of China. AD - School of Public Health, Jiangxi Medical College, Nanchang University, Nanchang, People's Republic of China. FAU - Chen, Yongsen AU - Chen Y AD - Department of Medical Big Data Research Centre, The Second Affiliated Hospital of Nanchang University, 1MinDe Road, Nanchang, 330006, People's Republic of China. AD - School of Public Health, Jiangxi Medical College, Nanchang University, Nanchang, People's Republic of China. FAU - Liu, Jianmo AU - Liu J AD - Department of Medical Big Data Research Centre, The Second Affiliated Hospital of Nanchang University, 1MinDe Road, Nanchang, 330006, People's Republic of China. FAU - Yu, Pengfei AU - Yu P AD - Department of Medical Big Data Research Centre, The Second Affiliated Hospital of Nanchang University, 1MinDe Road, Nanchang, 330006, People's Republic of China. FAU - Yan, Zhilang AU - Yan Z AD - Nanchang Medical College, Nanchang, People's Republic of China. FAU - Wang, Aiqin AU - Wang A AD - Nanchang Medical College, Nanchang, People's Republic of China. FAU - Xian, Hongfei AU - Xian H AD - Department of Medical Big Data Research Centre, The Second Affiliated Hospital of Nanchang University, 1MinDe Road, Nanchang, 330006, People's Republic of China. AD - School of Public Health, Jiangxi Medical College, Nanchang University, Nanchang, People's Republic of China. FAU - Ke, Jingyao AU - Ke J AD - Department of Medical Big Data Research Centre, The Second Affiliated Hospital of Nanchang University, 1MinDe Road, Nanchang, 330006, People's Republic of China. AD - School of Public Health, Jiangxi Medical College, Nanchang University, Nanchang, People's Republic of China. FAU - Cheng, Rui AU - Cheng R AD - Department of Medical Big Data Research Centre, The Second Affiliated Hospital of Nanchang University, 1MinDe Road, Nanchang, 330006, People's Republic of China. AD - School of Public Health, Jiangxi Medical College, Nanchang University, Nanchang, People's Republic of China. FAU - Wang, Xiaoman AU - Wang X AD - Department of Medical Big Data Research Centre, The Second Affiliated Hospital of Nanchang University, 1MinDe Road, Nanchang, 330006, People's Republic of China. AD - School of Public Health, Jiangxi Medical College, Nanchang University, Nanchang, People's Republic of China. FAU - Yi, Canwei AU - Yi C AD - Department of Medical Big Data Research Centre, The Second Affiliated Hospital of Nanchang University, 1MinDe Road, Nanchang, 330006, People's Republic of China. AD - School of Public Health, Jiangxi Medical College, Nanchang University, Nanchang, People's Republic of China. FAU - Han, Weijiang AU - Han W AD - Department of Medical Big Data Research Centre, The Second Affiliated Hospital of Nanchang University, 1MinDe Road, Nanchang, 330006, People's Republic of China. AD - School of Public Health, Jiangxi Medical College, Nanchang University, Nanchang, People's Republic of China. FAU - Liao, Huiming AU - Liao H AD - Department of Medical Big Data Research Centre, The Second Affiliated Hospital of Nanchang University, 1MinDe Road, Nanchang, 330006, People's Republic of China. AD - School of Public Health, Jiangxi Medical College, Nanchang University, Nanchang, People's Republic of China. FAU - Wu, Yifan AU - Wu Y AD - Department of Medical Big Data Research Centre, The Second Affiliated Hospital of Nanchang University, 1MinDe Road, Nanchang, 330006, People's Republic of China. AD - School of Public Health, Jiangxi Medical College, Nanchang University, Nanchang, People's Republic of China. FAU - Jia, Weijie AU - Jia W AD - Department of Medical Big Data Research Centre, The Second Affiliated Hospital of Nanchang University, 1MinDe Road, Nanchang, 330006, People's Republic of China. AD - School of Public Health, Jiangxi Medical College, Nanchang University, Nanchang, People's Republic of China. FAU - Han, Mengqi AU - Han M AD - Department of Medical Big Data Research Centre, The Second Affiliated Hospital of Nanchang University, 1MinDe Road, Nanchang, 330006, People's Republic of China. AD - School of Public Health, Jiangxi Medical College, Nanchang University, Nanchang, People's Republic of China. FAU - Yi, Yingping AU - Yi Y AD - Department of Medical Big Data Research Centre, The Second Affiliated Hospital of Nanchang University, 1MinDe Road, Nanchang, 330006, People's Republic of China. yyp66@126.com. LA - eng GR - 81960609/the National Natural Science Foundation of China/ GR - 81960609/the National Natural Science Foundation of China/ GR - 81960609/the National Natural Science Foundation of China/ GR - 81960609/the National Natural Science Foundation of China/ GR - 81960609/the National Natural Science Foundation of China/ GR - 81960609/the National Natural Science Foundation of China/ GR - 81960609/the National Natural Science Foundation of China/ GR - 81960609/the National Natural Science Foundation of China/ GR - 81960609/the National Natural Science Foundation of China/ GR - 81960609/the National Natural Science Foundation of China/ GR - 81960609/the National Natural Science Foundation of China/ GR - 81960609/the National Natural Science Foundation of China/ GR - 81960609/the National Natural Science Foundation of China/ GR - 81960609/the National Natural Science Foundation of China/ GR - 81960609/the National Natural Science Foundation of China/ GR - 81960609/the National Natural Science Foundation of China/ GR - 81960609/the National Natural Science Foundation of China/ GR - 2020YFC2002901/the National Key R&D Program of China/ GR - 2020YFC2002901/the National Key R&D Program of China/ GR - 2020YFC2002901/the National Key R&D Program of China/ GR - 2020YFC2002901/the National Key R&D Program of China/ GR - 2020YFC2002901/the National Key R&D Program of China/ GR - 2020YFC2002901/the National Key R&D Program of China/ GR - 2020YFC2002901/the National Key R&D Program of China/ GR - 2020YFC2002901/the National Key R&D Program of China/ GR - 2020YFC2002901/the National Key R&D Program of China/ GR - 2020YFC2002901/the National Key R&D Program of China/ GR - 2020YFC2002901/the National Key R&D Program of China/ GR - 2020YFC2002901/the National Key R&D Program of China/ GR - 2020YFC2002901/the National Key R&D Program of China/ GR - 2020YFC2002901/the National Key R&D Program of China/ GR - 2020YFC2002901/the National Key R&D Program of China/ PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20241012 PL - England TA - BMC Geriatr JT - BMC geriatrics JID - 100968548 SB - IM MH - Humans MH - Female MH - Male MH - Aged MH - Retrospective Studies MH - *Activities of Daily Living MH - Aged, 80 and over MH - *Pneumonia/epidemiology/diagnosis/complications MH - Risk Factors MH - Ischemic Stroke/epidemiology/diagnosis MH - Stroke/epidemiology/diagnosis/complications MH - China/epidemiology PMC - PMC11471020 OTO - NOTNLM OT - Activity of daily living OT - Barthel Index OT - Pneumonia OT - Stroke COIS- The authors declare no competing interests. EDAT- 2024/10/13 00:30 MHDA- 2024/10/13 00:31 PMCR- 2024/10/12 CRDT- 2024/10/12 23:15 PHST- 2023/07/03 00:00 [received] PHST- 2024/09/23 00:00 [accepted] PHST- 2024/10/13 00:31 [medline] PHST- 2024/10/13 00:30 [pubmed] PHST- 2024/10/12 23:15 [entrez] PHST- 2024/10/12 00:00 [pmc-release] AID - 10.1186/s12877-024-05400-8 [pii] AID - 5400 [pii] AID - 10.1186/s12877-024-05400-8 [doi] PST - epublish SO - BMC Geriatr. 2024 Oct 12;24(1):829. doi: 10.1186/s12877-024-05400-8. PMID- 39365879 OWN - NLM STAT- MEDLINE DCOM- 20250313 LR - 20250711 IS - 2768-3613 (Electronic) IS - 2768-3605 (Linking) VI - 31 IP - 3 DP - 2025 Mar TI - Use of Hypnosis in the Treatment of Orofacial Pain: A Systematic Review. PG - 224-232 LID - 10.1089/jicm.2024.0154 [doi] AB - Objectives: To conduct a systematic review on the use of hypnosis in the treatment of orofacial pain. Methods: The search was performed on February 2021 and updated in July 2024 in the following databases: MEDLINE via PUBMED, Virtual Health Library (VHL), Web of Science, Cochrane Library, Embase, Clinical Trials, ISRCTN Registry, Psycinfo, Open Grey, Google Scholar, and Brazilian Digital Library of Theses and Dissertations (BDTD). The descriptors referring to Orofacial Pain and hypnosis were used to select clinical trials on the use of hypnosis in the treatment of Orofacial Pain, in English, Spanish, Portuguese, French, and Italian, without restriction on date and place of publication. In a first stage, two independent, trained, and calibrated reviewers classified the abstracts and then the full texts. The data were extracted, and the risk of bias was assessed using the Cochrane RoB 2.0 tool. Results: Of the 642 references identified, 6 studies-published between 1986 and 2010-were included in the review, with 232 patients reported. Hypnosis was mainly used in cases of chronic pain associated with temporomandibular disorders (TMDs), compared with relaxation sessions, acupuncture, occlusal splint, minimal treatment, or no interference. Hypnotherapy was applied in different ways, either exclusively by professionals or by means of self-hypnosis in a complementary or exclusive manner. All studies showed statistical significance for the effect of the intervention (hypnotherapy). The overall RoB2 consisted of three studies with high risk of bias and three studies with some concern. Conclusions: Although there were clinical studies on the subject and they had methodological flaws, hypnotherapy (induction and/or self-hypnosis) appears to be a promising strategy for the treatment of orofacial pain, especially TMDs. There is, therefore, a need for new randomized clinical studies with adequate methodological standards to confirm the findings. FAU - Silva, Fabio Washington Da AU - Silva FWD AUID- ORCID: 0009-0004-4533-9953 AD - Department of Community and Preventive Dentistry, School of Dentistry, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil. FAU - Oliveira, Douglas Vaz de AU - Oliveira DV AD - Department of Community and Preventive Dentistry, School of Dentistry, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil. FAU - Zina, Livia Guimaraes AU - Zina LG AUID- ORCID: 0000-0003-1842-2300 AD - Department of Community and Preventive Dentistry, School of Dentistry, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil. FAU - Paula, Janice Simpson de AU - Paula JS AUID- ORCID: 0000-0002-5396-0959 AD - Department of Community and Preventive Dentistry, School of Dentistry, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil. LA - eng PT - Journal Article PT - Systematic Review DEP - 20241004 PL - United States TA - J Integr Complement Med JT - Journal of integrative and complementary medicine JID - 9918283075806676 SB - IM MH - Humans MH - *Facial Pain/therapy MH - *Hypnosis OTO - NOTNLM OT - dentistry OT - hypnosis OT - hypnotherapy OT - orofacial pain EDAT- 2024/10/04 22:18 MHDA- 2025/03/14 11:23 CRDT- 2024/10/04 14:13 PHST- 2025/03/14 11:23 [medline] PHST- 2024/10/04 22:18 [pubmed] PHST- 2024/10/04 14:13 [entrez] AID - 10.1089/jicm.2024.0154 [doi] PST - ppublish SO - J Integr Complement Med. 2025 Mar;31(3):224-232. doi: 10.1089/jicm.2024.0154. Epub 2024 Oct 4. PMID- 39357399 OWN - NLM STAT- MEDLINE DCOM- 20241104 LR - 20260716 IS - 1879-1379 (Electronic) IS - 0022-3956 (Linking) VI - 179 DP - 2024 Nov TI - The inflexible mind: A critical factor in understanding and addressing COVID-19 vaccine hesitancy. PG - 360-365 LID - S0022-3956(24)00549-1 [pii] LID - 10.1016/j.jpsychires.2024.09.028 [doi] AB - BACKGROUND: Vaccine hesitancy has gained heightened relevance amid the COVID-19 pandemic, underscoring the urgency of understanding its determinants. This study explores the association between Covid-19 vaccine hesitancy, mental health variables and inflexible thinking. METHODS: A convenience sample of 252 UK adults was assessed online between June 2021-July 2022 (when Covid-19 lockdown restrictions had finally eased). We assessed participants using the Oxford Covid Vaccine Hesitancy Scale (OCVHS), various aspects of mental health, using: the Obsessive-Compulsive Inventory-Revised (OCI-R), Compulsive Personality Assessment Scale (CPAS), Depression, Anxiety, and Stress scale (DASS-21), and finally, performance on a computerized version of the Wisconsin Card Sort Task (WCST). This study was preregistered at the Open Science Framework (https://osf.io/xd5wz). RESULTS: Multiple regression analyses showed that only cognitive inflexibility, and specifically the WCST item of perseverative errors, significantly predicted vaccine hesitancy. CONCLUSION: Our exploratory analysis provides the first evidence that cognitive inflexibility, measured using an objective task, is an independent risk-factor for vaccine hesitancy. Public health strategies should consider the impact of an inflexible thinking style on the decision-making of those most at risk of vaccine hesitancy and adapt interventions accordingly. CI - Copyright (c) 2024 Elsevier Ltd. All rights reserved. FAU - Pellegrini, L AU - Pellegrini L AD - School of Life and Medical Sciences, University of Hertfordshire, Hatfield, UK; Hertfordshire Partnership University NHS Foundation Trust, Welwyn Garden City, UK; Centre for Psychedelic Research, Imperial College London, London, UK. Electronic address: luca.pellegrini@nhs.net. FAU - Clarke, A AU - Clarke A AD - School of Life and Medical Sciences, University of Hertfordshire, Hatfield, UK. FAU - Fineberg, N A AU - Fineberg NA AD - School of Life and Medical Sciences, University of Hertfordshire, Hatfield, UK; Hertfordshire Partnership University NHS Foundation Trust, Welwyn Garden City, UK; University of Cambridge School of Clinical Medicine, Cambridge, UK. FAU - Laws, K R AU - Laws KR AD - School of Life and Medical Sciences, University of Hertfordshire, Hatfield, UK. LA - eng PT - Journal Article DEP - 20240923 PL - England TA - J Psychiatr Res JT - Journal of psychiatric research JID - 0376331 RN - 0 (COVID-19 Vaccines) SB - IM MH - Humans MH - Male MH - Female MH - Adult MH - *COVID-19 Vaccines/administration & dosage MH - *Vaccination Hesitancy/psychology/statistics & numerical data MH - Middle Aged MH - *COVID-19/prevention & control MH - Young Adult MH - Aged MH - United Kingdom MH - Adolescent OTO - NOTNLM OT - Cognitive flexibility OT - Cognitive rigidity OT - Covid OT - Pandemic OT - Perseveration COIS- Declaration of competing interest Prof. Naomi Fineberg reports in the past 3 years she has held research or networking grants from the UKNIHR, COST Action, Orchard; accepted travel and/or hospitality expenses from the BAP, ECNP, RCPsych, CINP, International Forum of Mood and Anxiety Disorders, World Psychiatric Association; received payment from Elsevier for editorial duties and the Mental Health Academy for lecturing. Previously, she has accepted paid speaking engagements in various industry supported symposia and recruited patients for various industry-sponsored studies in the field of OCD treatment. She leads an NHS treatment service for OCD. She holds Board membership for various registered charities linked to OCD. She gives expert advice on psychopharmacology to the UK MHRA. She has participated in a WHO working group focusing on diagnosis and classification of obsessive compulsive or related disorders for the ICD-11. Dr Luca Pellegrini reports a relationship with European Cooperation in Science and Technology, the University of Hertfordshire, Orchard, ECNP-OCRN International College of Obsessive-Compulsive Spectrum Disorders (ICOCS), that includes: funding grants. Professor Laws and Dr. Clarke report no interest. EDAT- 2024/10/03 04:22 MHDA- 2024/11/04 06:22 CRDT- 2024/10/02 18:10 PHST- 2024/05/03 00:00 [received] PHST- 2024/08/06 00:00 [revised] PHST- 2024/09/21 00:00 [accepted] PHST- 2024/11/04 06:22 [medline] PHST- 2024/10/03 04:22 [pubmed] PHST- 2024/10/02 18:10 [entrez] AID - S0022-3956(24)00549-1 [pii] AID - 10.1016/j.jpsychires.2024.09.028 [doi] PST - ppublish SO - J Psychiatr Res. 2024 Nov;179:360-365. doi: 10.1016/j.jpsychires.2024.09.028. Epub 2024 Sep 23. PMID- 39327859 OWN - NLM STAT- MEDLINE DCOM- 20250411 LR - 20250411 IS - 2050-439X (Electronic) IS - 2050-4381 (Linking) VI - 12 IP - 16 DP - 2024 Sep TI - Quality of life, capability well-being, financial strain and physical activity in the short- and medium-term COVID-19 post-lockdown phases in the UK: a repeated cross-sectional study. PG - 39-58 LID - 10.3310/LYJG6305 [doi] AB - BACKGROUND: The COVID-19 lockdowns had negative effects on children's and adults' mental and physical health. There is, however, a paucity of research that explores differences in health-related quality of life (HRQL) and well-being over time after the COVID-19 lockdowns had been lifted. Furlough during lockdowns, increases in unemployment, and the emerging cost-of-living crisis all put pressure on family finances, which could have a detrimental effect on HRQL and well-being. This study, part of the wider Active-6 study, explored how HRQL, capability well-being and family financial strain changed after the lockdowns, the relationship between these outcomes, and whether physical activity had any mediating effect on differences in HRQL and capability well-being. METHODS: Cross-sectional data were collected in May-December 2021 (Wave 1) and January-July 2022 (Wave 2). Children (aged 10-11) and their parent/carer were recruited from 23 to 27 schools in each wave, respectively, and completed validated questionnaires measuring HRQL (adults - EQ-5D-5L, children - CHU9D), capability well-being (adults - ICECAP-A) and family financial strain (adults - Family Economic Strain Scale, FESS). Children also completed questions on capability well-being. Weekday minutes of moderate-to-vigorous physical activity (MVPA) were measured using accelerometers. Mixed-effects regression models, adjusted for gender, age group (adults only), IMD and highest household education, were used to explore differences in HRQL and capability well-being between waves. In addition, the moderating effect of financial strain and the mediating effect of MVPA on HRQL and capability well-being were explored. RESULTS: Active-6 recruited 393 parent-child pairs in Wave 1 and 436 in Wave 2. There were no differences in HRQL (EQ-5D, CHU9D) and capability well-being (ICECAP-A) scores between waves, but financial strain was worse in Wave 2 compared to Wave 1 (FESS score difference 1.14 adjusted 95% CI 0.15 to 2.12). Increased financial strain was associated with lower (worse) EQ-5D-5L, CHU9D and ICECAP-A scores. There was no evidence of a mediating effect of MVPA. LIMITATIONS AND FUTURE WORK: Pre-COVID-19 data on HRQL were not collected, so analysis was limited to post-lockdown only. Participating parents were predominantly female and participation was lower among lower socio-economic groups, limiting our ability to explore inequalities. Intervention planning to increase physical activity and health and well-being during the COVID-19 recovery should consider the financial strain families are experiencing and the negative implications of financial strain on HRQL. CONCLUSIONS: There were no differences in HRQL and capability well-being in children and adults after lockdowns lifted in 2021 and a year later in 2022. The results indicate increasing financial strain, which could reflect the UK's 'cost of living crisis'. FUNDING: This article presents independent research funded by the National Institute for Health and Care Research (NIHR) Public Health Research programme as award number NIHR131847. FAU - Breheny, Katie AU - Breheny K AUID- ORCID: 0000-0001-6886-4049 AD - Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK. AD - The National Institute for Health Research, Applied Research Collaboration West (NIHR ARC West), University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK. FAU - Salway, Ruth AU - Salway R AUID- ORCID: 0000-0002-3242-3951 AD - Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK. AD - Centre for Exercise, Nutrition & Health Sciences, School for Policy Studies, University of Bristol, Bristol, UK. FAU - House, Danielle AU - House D AUID- ORCID: 0000-0001-6171-9922 AD - Centre for Exercise, Nutrition & Health Sciences, School for Policy Studies, University of Bristol, Bristol, UK. FAU - Walker, Robert AU - Walker R AUID- ORCID: 0000-0001-9901-5285 AD - Centre for Exercise, Nutrition & Health Sciences, School for Policy Studies, University of Bristol, Bristol, UK. FAU - Emm-Collison, Lydia AU - Emm-Collison L AUID- ORCID: 0000-0002-5493-3223 AD - Centre for Exercise, Nutrition & Health Sciences, School for Policy Studies, University of Bristol, Bristol, UK. FAU - Sansum, Kate AU - Sansum K AUID- ORCID: 0000-0003-3392-6750 AD - Centre for Exercise, Nutrition & Health Sciences, School for Policy Studies, University of Bristol, Bristol, UK. FAU - Williams, Joanna G AU - Williams JG AUID- ORCID: 0000-0002-4737-1760 AD - Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK. AD - Communities and Public Health, Bristol City Council, Bristol, UK. FAU - de Vocht, Frank AU - de Vocht F AUID- ORCID: 0000-0003-3631-627X AD - Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK. AD - The National Institute for Health Research, Applied Research Collaboration West (NIHR ARC West), University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK. FAU - Jago, Russell AU - Jago R AUID- ORCID: 0000-0002-3394-0176 AD - Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK. AD - The National Institute for Health Research, Applied Research Collaboration West (NIHR ARC West), University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK. AD - Centre for Exercise, Nutrition & Health Sciences, School for Policy Studies, University of Bristol, Bristol, UK. FAU - Hollingworth, William AU - Hollingworth W AUID- ORCID: 0000-0002-0840-6254 AD - Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK. AD - The National Institute for Health Research, Applied Research Collaboration West (NIHR ARC West), University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK. LA - eng PT - Journal Article PL - England TA - Public Health Res (Southampt) JT - Public health research (Southampton, England) JID - 101653231 SB - IM MH - Humans MH - Cross-Sectional Studies MH - *COVID-19/epidemiology/psychology MH - *Quality of Life/psychology MH - Male MH - Female MH - *Exercise/psychology MH - United Kingdom/epidemiology MH - Child MH - *Financial Stress/epidemiology/psychology MH - Adult MH - Surveys and Questionnaires MH - SARS-CoV-2 OAB - We know that the COVID-19 pandemic negatively affected people's mental and physical health. But we don't know how quality of life, well-being and pressure on family finances changed for people after the lockdowns were lifted and society reopened. We also wanted to know if these changes were related to how physically active people were. Children and a parent/carer answered questions about their quality of life, well-being and family budget pressures. Physical activity data were also collected using devices worn on their waists. We did this in 2021, when society started to reopen after lockdowns, and a year later in 2022 when all restrictions were gone. We explored differences in quality of life, well-being and pressure on family finances between 2021 and 2022. We then looked at whether any of these differences were because of changes in physical activity, and if financial strain was related to quality of life. We did not find any differences in quality of life or well-being between 2021 and 2022. Financial strain increased slightly. As financial strain increased, quality of life and well-being decreased. This was worse for those experiencing most financial difficulties. Physical activity did not seem to explain differences in quality of life. If family finances are stretched, it might be difficult for families to pay for activities that will help their children be more active. We have also found that family financial difficulties are related to quality of life and well-being. OABL- eng OTO - NOTNLM OT - COVID-19 OT - CROSS-SECTIONAL OT - ECONOMIC SHOCK OT - HEALTH ECONOMICS OT - OUTCOMES RESEARCH OT - PHYSICAL ACTIVITY OT - QUALITY OF LIFE OT - WELL-BEING EDAT- 2024/09/27 07:05 MHDA- 2025/04/11 12:28 CRDT- 2024/09/27 03:12 PHST- 2025/04/11 12:28 [medline] PHST- 2024/09/27 07:05 [pubmed] PHST- 2024/09/27 03:12 [entrez] AID - 10.3310/LYJG6305 [doi] PST - ppublish SO - Public Health Res (Southampt). 2024 Sep;12(16):39-58. doi: 10.3310/LYJG6305. PMID- 39289744 OWN - NLM STAT- MEDLINE DCOM- 20240918 LR - 20240921 IS - 1472-6963 (Electronic) IS - 1472-6963 (Linking) VI - 24 IP - 1 DP - 2024 Sep 17 TI - Lessons from the COVID-19 pandemic to strengthen NCD care and policy in humanitarian settings: a mixed methods study exploring humanitarian actors' experiences. PG - 1081 LID - 10.1186/s12913-024-11458-2 [doi] LID - 1081 AB - BACKGROUND: The COVID-19 pandemic and response severely impacted people living with non-communicable diseases (PLWNCDs) globally. It exacerbated pre-existing health inequalities, severely disrupted access to care, and worsened clinical outcomes for PLWNCDs, who were at higher risk of morbidity and mortality from the virus. The pandemic's effects were likely magnified in humanitarian settings, where there were pre-existing gaps in continuity of care for non-communicable diseases (NCDs). We sought to explore factors affecting implementation of NCD care in crisis settings during the COVID-19 pandemic and the adaptations made to support implementation. METHODS: Guided by the Consolidated Framework for Implementation Research, we undertook an online survey of 98 humanitarian actors from multiple regions and organization types (March-July 2021), followed by in-depth interviews with 13 purposively selected survey respondents (October-December 2021). Survey data were analysed using descriptive statistics, while interview data were analysed thematically, using both deductive and inductive approaches. RESULTS: Initially, humanitarian actors faced challenges influenced by external actors' priorities, such as de-prioritisation of NCD care by governments, travel restrictions and supply chain interruptions. With each infection wave and lockdown, humanitarian actors were better able to adapt and maintain NCD services. The availability of COVID-19 vaccines was a positive turning point, especially for the risk management of people with NCDs and protection of health workers. Key findings include that, despite pre-existing challenges, humanitarian actors largely continued NCD services during the crisis. Enabling factors that supported continuity of NCD services included the ability to quickly pivot to remote means of communication with PLWNCDs, flexibility in medicine dispensing, and successful advocacy to prioritize NCD management within health systems. Key lessons learned included the importance of partnerships and cooperation with other health actors, and the mobilisation or repurposing of community health workers/volunteer networks. CONCLUSIONS: The COVID-19 experience should prompt national and global health stakeholders to strengthen inclusion of NCDs in emergency preparedness, response, and resilience planning. Key lessons were learned around remote care provision, including adapting to NCD severity, integrating community health workers, providing context-adapted patient information, combating misinformation, and strengthening cross-sectoral partnerships. CI - (c) 2024. The Author(s). FAU - Ansbro, Eimhin AU - Ansbro E AD - Department of Epidemiology of Noncommunicable Diseases, Epidemiology & Population Health, London School of Hygiene & Tropical Medicine, London, UK. eimhin.ansbro@lshtm.ac.uk. AD - Centre for Global Chronic Conditions, London, School of Hygiene & Tropical Medicine , London, UK. eimhin.ansbro@lshtm.ac.uk. FAU - Heller, Olivia AU - Heller O AD - Service de Medecine Tropicale Et Humanitaire, Hopitaux Universitaires de Geneve, Geneva, Switzerland. FAU - Vijayasingham, Lavanya AU - Vijayasingham L AD - Department of Epidemiology of Noncommunicable Diseases, Epidemiology & Population Health, London School of Hygiene & Tropical Medicine, London, UK. AD - Centre for Global Chronic Conditions, London, School of Hygiene & Tropical Medicine , London, UK. FAU - Favas, Caroline AU - Favas C AD - Department of Epidemiology of Noncommunicable Diseases, Epidemiology & Population Health, London School of Hygiene & Tropical Medicine, London, UK. AD - Centre for Global Chronic Conditions, London, School of Hygiene & Tropical Medicine , London, UK. FAU - Rintjema, Jacqueline AU - Rintjema J AD - Centre for Global Chronic Conditions, London, School of Hygiene & Tropical Medicine , London, UK. AD - Faculty of Law, University of Toronto, Toronto, Canada. FAU - Chase-Vilchez, Alyssa AU - Chase-Vilchez A AD - Global Alliance for Chronic Diseases, Wellcome, London, UK. FAU - Stein, Claire AU - Stein C AD - Help Age International, Yangon, Myanmar. AD - Faculty of Economics and Business, University of Groningen, Groningen, The Netherlands. FAU - Issa, Rita AU - Issa R AD - School of Global Development, University of East Anglia, Norwich, UK. AD - T.H. Chan School of Public Health, FXB Center for Health and Human Rights, Harvard University, Boston, USA. FAU - Sanga, Leah AU - Sanga L AD - Department of Epidemiology of Noncommunicable Diseases, Epidemiology & Population Health, London School of Hygiene & Tropical Medicine, London, UK. AD - Centre for Global Chronic Conditions, London, School of Hygiene & Tropical Medicine , London, UK. FAU - Murphy, Adrianna AU - Murphy A AD - Centre for Global Chronic Conditions, London, School of Hygiene & Tropical Medicine , London, UK. AD - Department of Health Services Research and Policy, Public Health & Policy, London School of Hygiene & Tropical Medicine, London, UK. FAU - Perel, Pablo AU - Perel P AD - Department of Epidemiology of Noncommunicable Diseases, Epidemiology & Population Health, London School of Hygiene & Tropical Medicine, London, UK. AD - Centre for Global Chronic Conditions, London, School of Hygiene & Tropical Medicine , London, UK. LA - eng PT - Journal Article DEP - 20240917 PL - England TA - BMC Health Serv Res JT - BMC health services research JID - 101088677 SB - IM MH - Humans MH - *COVID-19/epidemiology MH - *Noncommunicable Diseases/therapy MH - Pandemics MH - Health Policy MH - SARS-CoV-2 MH - Altruism MH - Male MH - Female MH - Relief Work/organization & administration MH - Surveys and Questionnaires PMC - PMC11406764 OTO - NOTNLM OT - COVID-19 OT - Crisis OT - Diabetes OT - Disaster OT - Humanitarian OT - Hypertension OT - Implementation OT - Noncommunicable OT - Pandemic OT - Service delivery COIS- The authors declare no competing interests. EDAT- 2024/09/18 00:50 MHDA- 2024/09/18 06:42 PMCR- 2024/09/17 CRDT- 2024/09/17 23:48 PHST- 2024/03/29 00:00 [received] PHST- 2024/08/19 00:00 [accepted] PHST- 2024/09/18 06:42 [medline] PHST- 2024/09/18 00:50 [pubmed] PHST- 2024/09/17 23:48 [entrez] PHST- 2024/09/17 00:00 [pmc-release] AID - 10.1186/s12913-024-11458-2 [pii] AID - 11458 [pii] AID - 10.1186/s12913-024-11458-2 [doi] PST - epublish SO - BMC Health Serv Res. 2024 Sep 17;24(1):1081. doi: 10.1186/s12913-024-11458-2. PMID- 39259733 OWN - NLM STAT- MEDLINE DCOM- 20240911 LR - 20260923 IS - 1932-6203 (Electronic) IS - 1932-6203 (Linking) VI - 19 IP - 9 DP - 2024 TI - Knowledge and intentions to use fertility preservation among urban Chinese cancer patients: A study from Hong Kong. PG - e0307715 LID - 10.1371/journal.pone.0307715 [doi] LID - e0307715 AB - OBJECTIVE: To assess the knowledge levels and fertility preservation (FP) intentions of urban Chinese cancer patients. METHODS: A cross-sectional study was conducted on Hong Kong Chinese male and female cancer patients aged 18-54 years (N = 325) who were recruited by a local non-governmental organization for cancer patients between July 2020 to January 2021. Patients completed a self-administered questionnaire on knowledge, perceptions, and intentions to use FP services/seek FP-related information. Multivariable logistic regression was used to explore the correlates of intention to seek additional FP information and intention to undergo FP treatments. RESULTS: Although cancer patients demonstrated a good knowledge of the available FP treatment options, they were less knowledgeable about the legal restrictions of these procedures. Only one in seven cancer patients first became aware of FP through a health provider and the majority of cancer patients felt they did not have adequate knowledge about FP to make informed FP decisions at the current time. Yet, over one-third of cancer patients would consider FP options even if their cancer or cancer treatment had < 5% chance of causing infertility, and 13.4% of females and 14.6% of males would delay their cancer treatment by >/= 3 months to undergo FP procedures. However, for both sexes, the main perceived barrier to obtaining FP was its financial cost. Patients with older-aged spouses were less likely to seek FP treatments or seek more information about FP. CONCLUSION: There is an unmet need for more FP information and FP services for reproductive-aged cancer patients in East Asian populations. Greater integration of FP services into cancer treatment requires a reduction of cost barriers, greater provision of timely FP information, and improved referral systems. CI - Copyright: (c) 2024 Chan et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. FAU - Chan, Louis S AU - Chan LS AD - School of Public Health, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong SAR. FAU - Cochon, Kim L AU - Cochon KL AUID- ORCID: 0000-0002-0511-0407 AD - School of Public Health, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong SAR. AD - Institute of Clinical Epidemiology, National Institutes of Health, University of the Philippines - Manila, Manila, Philippines. FAU - Li, Tin C AU - Li TC AD - School of Public Health, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong SAR. FAU - Chung, Jacqueline P W AU - Chung JPW AD - School of Public Health, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong SAR. FAU - Kim, Jean H AU - Kim JH AUID- ORCID: 0000-0002-5799-5913 AD - School of Public Health, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong SAR. LA - eng PT - Journal Article DEP - 20240911 PL - United States TA - PLoS One JT - PloS one JID - 101285081 SB - IM MH - Humans MH - Female MH - Male MH - Adult MH - Hong Kong MH - Middle Aged MH - *Fertility Preservation/psychology MH - *Neoplasms/therapy/psychology MH - *Health Knowledge, Attitudes, Practice MH - Adolescent MH - Cross-Sectional Studies MH - Young Adult MH - Surveys and Questionnaires MH - Intention MH - Urban Population MH - East Asian People PMC - PMC11389933 COIS- The authors have declared that no competing interests exist. EDAT- 2024/09/11 20:42 MHDA- 2024/09/11 20:43 PMCR- 2024/09/11 CRDT- 2024/09/11 13:33 PHST- 2023/07/14 00:00 [received] PHST- 2024/07/03 00:00 [accepted] PHST- 2024/09/11 20:43 [medline] PHST- 2024/09/11 20:42 [pubmed] PHST- 2024/09/11 13:33 [entrez] PHST- 2024/09/11 00:00 [pmc-release] AID - PONE-D-23-18836 [pii] AID - 10.1371/journal.pone.0307715 [doi] PST - epublish SO - PLoS One. 2024 Sep 11;19(9):e0307715. doi: 10.1371/journal.pone.0307715. eCollection 2024. PMID- 39250801 OWN - NLM STAT- MEDLINE DCOM- 20241014 LR - 20260703 IS - 1539-3704 (Electronic) IS - 0003-4819 (Linking) VI - 177 IP - 10 DP - 2024 Oct TI - Association Between Hospital Type and Resilience During COVID-19 Caseload Stress : A Retrospective Cohort Study. PG - 1370-1380 LID - 10.7326/M24-0869 [doi] AB - BACKGROUND: Imbalances between hospital caseload and care resources that strained U.S. hospitals during the pandemic have persisted after the pandemic amid ongoing staff shortages. Understanding which hospital types were more resilient to pandemic overcrowding-related excess deaths may prioritize patient safety during future crises. OBJECTIVE: To determine whether hospital type classified by capabilities and resources (that is, extracorporeal membrane oxygenation [ECMO] capability, multiplicity of intensive care unit [ICU] types, and large or small hospital) influenced COVID-19 volume-outcome relationships during Delta wave surges. DESIGN: Retrospective cohort study. SETTING: 620 U.S. hospitals in the PINC AI Healthcare Database. PARTICIPANTS: Adult inpatients with COVID-19 admitted July to November 2021. MEASUREMENTS: Hospital-months were ranked by previously validated surge index (severity-weighted COVID-19 inpatient caseload relative to hospital bed capacity) percentiles. Hierarchical models were used to evaluate the effect of log-transformed surge index on the marginally adjusted probability of in-hospital mortality or discharge to hospice. Effect modification was assessed for by 4 mutually exclusive hospital types. RESULTS: Among 620 hospitals recording 223 380 inpatients with COVID-19 during the Delta wave, there were 208 ECMO-capable, 216 multi-ICU, 36 large (>/=200 beds) single-ICU, and 160 small (<200 beds) single-ICU hospitals. Overall, 50 752 (23%) patients required admission to the ICU, and 34 274 (15.3%) died. The marginally adjusted probability for mortality was 5.51% (95% CI, 4.53% to 6.50%) per unit increase in the log surge index (strain attributable mortality = 7375 [CI, 5936 to 8813] or 1 in 5 COVID-19 deaths). The test for interaction showed no difference (P = 0.32) in log surge index-mortality relationship across 4 hospital types. Results were consistent after excluding transferred patients, restricting to patients with acute respiratory failure and mechanical ventilation, and using alternative strain metrics. LIMITATION: Residual confounding. CONCLUSION: Comparably detrimental relationships between COVID-19 caseload and survival were seen across all hospital types, including highly advanced centers, and well beyond the pandemic's learning curve. These lessons from the pandemic heighten the need to minimize caseload surges and their effects across all hospital types during public health and staffing crises. PRIMARY FUNDING SOURCE: Intramural Research Program of the National Institutes of Health Clinical Center. FAU - Neupane, Maniraj AU - Neupane M AUID- ORCID: 0000-0002-0947-489X AD - Critical Care Medicine Department, National Institutes of Health Clinical Center, and National Heart, Lung, and Blood Institute, Bethesda, Maryland (M.N., S.W., A.M., J.S., C.Y., R.A., M.R., M.W., B.J.S., C.Y.D., S.S.K.). FAU - Warner, Sarah AU - Warner S AUID- ORCID: 0000-0002-4998-9257 AD - Critical Care Medicine Department, National Institutes of Health Clinical Center, and National Heart, Lung, and Blood Institute, Bethesda, Maryland (M.N., S.W., A.M., J.S., C.Y., R.A., M.R., M.W., B.J.S., C.Y.D., S.S.K.). FAU - Mancera, Alex AU - Mancera A AUID- ORCID: 0009-0007-6152-8350 AD - Critical Care Medicine Department, National Institutes of Health Clinical Center, and National Heart, Lung, and Blood Institute, Bethesda, Maryland (M.N., S.W., A.M., J.S., C.Y., R.A., M.R., M.W., B.J.S., C.Y.D., S.S.K.). FAU - Sun, Junfeng AU - Sun J AD - Critical Care Medicine Department, National Institutes of Health Clinical Center, and National Heart, Lung, and Blood Institute, Bethesda, Maryland (M.N., S.W., A.M., J.S., C.Y., R.A., M.R., M.W., B.J.S., C.Y.D., S.S.K.). FAU - Yek, Christina AU - Yek C AUID- ORCID: 0000-0001-8293-3901 AD - Critical Care Medicine Department, National Institutes of Health Clinical Center, and National Heart, Lung, and Blood Institute, Bethesda, Maryland (M.N., S.W., A.M., J.S., C.Y., R.A., M.R., M.W., B.J.S., C.Y.D., S.S.K.). FAU - Sarzynski, Sadia H AU - Sarzynski SH AD - Critical Care Medicine Department, National Institutes of Health Clinical Center, Bethesda, Maryland (S.H.S., E.C.). FAU - Amirahmadi, Roxana AU - Amirahmadi R AD - Critical Care Medicine Department, National Institutes of Health Clinical Center, and National Heart, Lung, and Blood Institute, Bethesda, Maryland (M.N., S.W., A.M., J.S., C.Y., R.A., M.R., M.W., B.J.S., C.Y.D., S.S.K.). FAU - Richert, Mary AU - Richert M AD - Critical Care Medicine Department, National Institutes of Health Clinical Center, and National Heart, Lung, and Blood Institute, Bethesda, Maryland (M.N., S.W., A.M., J.S., C.Y., R.A., M.R., M.W., B.J.S., C.Y.D., S.S.K.). FAU - Chishti, Emad AU - Chishti E AD - Critical Care Medicine Department, National Institutes of Health Clinical Center, Bethesda, Maryland (S.H.S., E.C.). FAU - Walker, Morgan AU - Walker M AD - Critical Care Medicine Department, National Institutes of Health Clinical Center, and National Heart, Lung, and Blood Institute, Bethesda, Maryland (M.N., S.W., A.M., J.S., C.Y., R.A., M.R., M.W., B.J.S., C.Y.D., S.S.K.). FAU - Swihart, Bruce J AU - Swihart BJ AUID- ORCID: 0000-0002-4216-9942 AD - Critical Care Medicine Department, National Institutes of Health Clinical Center, and National Heart, Lung, and Blood Institute, Bethesda, Maryland (M.N., S.W., A.M., J.S., C.Y., R.A., M.R., M.W., B.J.S., C.Y.D., S.S.K.). FAU - Mitchell, Steven H AU - Mitchell SH AUID- ORCID: 0000-0002-9779-2635 AD - Harborview Medical Center, Seattle, Washington (S.H.M.). FAU - Hick, John AU - Hick J AD - University of Minnesota and Hennepin Healthcare, Minneapolis, Minnesota (J.H.). FAU - Rochwerg, Bram AU - Rochwerg B AD - Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada (B.R.). FAU - Fan, Eddy AU - Fan E AD - Interdepartmental Division of Critical Care Medicine, University of Toronto, Toronto, Ontario, Canada (E.F.). FAU - Demirkale, Cumhur Y AU - Demirkale CY AD - Critical Care Medicine Department, National Institutes of Health Clinical Center, and National Heart, Lung, and Blood Institute, Bethesda, Maryland (M.N., S.W., A.M., J.S., C.Y., R.A., M.R., M.W., B.J.S., C.Y.D., S.S.K.). FAU - Kadri, Sameer S AU - Kadri SS AUID- ORCID: 0000-0002-4420-9004 AD - Critical Care Medicine Department, National Institutes of Health Clinical Center, and National Heart, Lung, and Blood Institute, Bethesda, Maryland (M.N., S.W., A.M., J.S., C.Y., R.A., M.R., M.W., B.J.S., C.Y.D., S.S.K.). LA - eng PT - Journal Article DEP - 20240910 PL - United States TA - Ann Intern Med JT - Annals of internal medicine JID - 0372351 SB - IM MH - Humans MH - *COVID-19/epidemiology/mortality MH - Retrospective Studies MH - *Hospital Mortality MH - Male MH - United States/epidemiology MH - Female MH - *SARS-CoV-2 MH - Middle Aged MH - *Intensive Care Units/statistics & numerical data MH - Extracorporeal Membrane Oxygenation/statistics & numerical data MH - Hospitals/statistics & numerical data MH - Pandemics MH - Aged MH - Workload MH - Adult MH - Hospital Bed Capacity/statistics & numerical data COIS- Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M24-0869. EDAT- 2024/09/09 18:42 MHDA- 2024/10/14 19:00 CRDT- 2024/09/09 17:02 PHST- 2024/10/14 19:00 [medline] PHST- 2024/09/09 18:42 [pubmed] PHST- 2024/09/09 17:02 [entrez] AID - 10.7326/M24-0869 [doi] PST - ppublish SO - Ann Intern Med. 2024 Oct;177(10):1370-1380. doi: 10.7326/M24-0869. Epub 2024 Sep 10. PMID- 39227674 OWN - NLM STAT- MEDLINE DCOM- 20241202 LR - 20250311 IS - 1745-655X (Electronic) IS - 0197-5897 (Print) IS - 0197-5897 (Linking) VI - 45 IP - 4 DP - 2024 Dec TI - Flavored electronic nicotine delivery system product use among adults in New York State post-statewide restriction implementation. PG - 687-699 LID - 10.1057/s41271-024-00515-z [doi] AB - In May 2020, New York State restricted the sale of flavored e-liquids, excluding tobacco flavor. We conducted a Web-based survey to assess support and changes in use behavior between July and October 2020 (n = 946), with a follow-up between April and June 2021 (n = 542). Most electronic nicotine delivery system (ENDS) users (n = 82/55) continued to use, with 39%/33% reporting continuing to purchase flavored e-liquids, 20%/32% reporting using tobacco flavor, 5%/6% reporting quitting ENDS and smoking cigarettes, and 8%/3% reporting quitting ENDS and not smoking cigarettes. In 2020, 65% of non-users, 53% of cigarette users, 34% of cigarette/ENDS users, and 18% of ENDS users supported this policy restriction on e-liquids. Similar results were observed in 2021. Many ENDS users continued purchasing flavored e-liquids, suggesting that compliance with the policy can be improved. Cigarette smoking did not appear to increase. Continued evaluation of how restrictions on sales of products influence use is critical to understanding the long-term impact on behavior. CI - (c) 2024. The Author(s), under exclusive licence to Springer Nature Limited. FAU - Fix, Brian V AU - Fix BV AUID- ORCID: 0000-0001-9135-4290 AD - Roswell Park Comprehensive Cancer Center Department of Health Behavior, Buffalo, NY, USA. brian.fix@roswellpark.org. FAU - Bansal-Travers, Maansi AU - Bansal-Travers M AD - Roswell Park Comprehensive Cancer Center Department of Health Behavior, Buffalo, NY, USA. FAU - Hyland, Andrew AU - Hyland A AD - Roswell Park Comprehensive Cancer Center Department of Health Behavior, Buffalo, NY, USA. FAU - Najm, Liane M AU - Najm LM AD - Roswell Park Comprehensive Cancer Center Department of Health Behavior, Buffalo, NY, USA. FAU - Diaz, Destiny AU - Diaz D AD - Rutgers University School of Public Health, New Brunswick, NJ, USA. FAU - Sharma, Akshika AU - Sharma A AD - Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA. FAU - Ossip, Deborah J AU - Ossip DJ AD - University of Rochester Medical Center, Rochester, NY, USA. FAU - O'Connor, Richard J AU - O'Connor RJ AD - Roswell Park Comprehensive Cancer Center Department of Health Behavior, Buffalo, NY, USA. LA - eng GR - P30 CA016056/CA/NCI NIH HHS/United States GR - U54 CA228110/CA/NCI NIH HHS/United States GR - P30 ES001247/ES/NIEHS NIH HHS/United States GR - U54CA228110/Center for Tobacco Products/ GR - P30CA016056/CA/NCI NIH HHS/United States PT - Journal Article DEP - 20240904 PL - England TA - J Public Health Policy JT - Journal of public health policy JID - 8006508 RN - 0 (Flavoring Agents) SB - IM EIN - J Public Health Policy. 2025 Mar;46(1):229-230. doi: 10.1057/s41271-024-00532-y. PMID: 39496846 MH - Humans MH - *Electronic Nicotine Delivery Systems/statistics & numerical data MH - New York MH - Adult MH - Male MH - Female MH - *Flavoring Agents/administration & dosage MH - Middle Aged MH - Surveys and Questionnaires MH - Young Adult MH - Adolescent PMC - PMC11639505 MID - NIHMS2037591 OTO - NOTNLM OT - Electronic nicotine delivery systems OT - Nicotine OT - Policy OT - Smoking COIS- Declarations. Conflicts of interest: The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results. EDAT- 2024/09/04 01:01 MHDA- 2024/12/02 06:27 PMCR- 2024/12/13 CRDT- 2024/09/03 23:38 PHST- 2024/08/10 00:00 [accepted] PHST- 2024/12/02 06:27 [medline] PHST- 2024/09/04 01:01 [pubmed] PHST- 2024/09/03 23:38 [entrez] PHST- 2024/12/13 00:00 [pmc-release] AID - 10.1057/s41271-024-00515-z [pii] AID - 10.1057/s41271-024-00515-z [doi] PST - ppublish SO - J Public Health Policy. 2024 Dec;45(4):687-699. doi: 10.1057/s41271-024-00515-z. Epub 2024 Sep 4. PMID- 39171311 OWN - NLM STAT- MEDLINE DCOM- 20240822 LR - 20261021 IS - 2296-2565 (Electronic) IS - 2296-2565 (Linking) VI - 12 DP - 2024 TI - Freedom for some, but not for Mum: the reproductive injustice associated with pandemic 'Freedom Day' for perinatal women in the United Kingdom. PG - 1389702 LID - 10.3389/fpubh.2024.1389702 [doi] LID - 1389702 AB - INTRODUCTION: Healthcare services for pregnant and postpartum ('perinatal') women were reconfigured significantly at the advent and for the duration of the SARS-CoV-2 pandemic, and despite the United Kingdom announcing 'Freedom Day' on 19 July 2021 (whereafter all legal lockdown-related restrictions were lifted), restrictions to maternity (antenatal, intrapartum, and postnatal) services remained. This study presents data from eight perinatal women about their experiences of psychosocial wellbeing and maternity care in the post-'Freedom Day' epoch. METHODS: Semi-structured interviews were conducted virtually, with data recorded, transcribed, and analysed by hand. Grounded theory analysis was employed with the final theory assessing the reproductive injustice of the pandemic 'Freedom Day'. RESULTS: Analysing iteratively and inductively led to four emergent themes: 'A Failing System, Failing Women'; 'Harm Caused by a State of Difference'; 'The Privileges (Not Rights) of Reproductive Autonomy, Agency, and Advocacy'; and 'Worried Women and Marginalised Mothers'. Together, these themes form the theory of 'Freedom for some, but not for Mum'. DISCUSSION: Women experienced a lack of high-quality reliable information about the pandemic, vaccination against the virus, and the changes to, and decision-making surrounding, their perinatal care. Women recognised healthcare professionals and maternity services were stretched and that maternity services were failing but often reported hostility from staff and abandonment at times when they were unsure about how to navigate their care. The most singular injustice was the disparity between women having to accept continuing restrictions to their freedom whilst receiving maternity care and the (reckless) freedom being enacted by the general public. CI - Copyright (c) 2024 Silverio, Harris, Jackson, Fallon, The PRaM Study Group, Easter, von Dadelszen, Jurkovic and Magee. FAU - Silverio, Sergio A AU - Silverio SA AD - Department of Psychology, University of Liverpool, Liverpool, United Kingdom. AD - Department of Women & Children's Health, King's College London, London, United Kingdom. FAU - Harris, Elizabeth J AU - Harris EJ AD - Department of Psychology, University of Liverpool, Liverpool, United Kingdom. FAU - Jackson, Leanne AU - Jackson L AD - Department of Psychology, University of Liverpool, Liverpool, United Kingdom. FAU - Fallon, Victoria AU - Fallon V AD - Department of Psychology, University of Liverpool, Liverpool, United Kingdom. CN - PRaM Study Group FAU - Easter, Abigail AU - Easter A AD - Department of Women & Children's Health, King's College London, London, United Kingdom. FAU - von Dadelszen, Peter AU - von Dadelszen P AD - Department of Women & Children's Health, King's College London, London, United Kingdom. FAU - Jurkovic, Davor AU - Jurkovic D AD - Gynaecology Diagnostic and Treatment Unit, University College London Hospitals NHS Foundation Trust, London, United Kingdom. FAU - Magee, Laura A AU - Magee LA AD - Department of Women & Children's Health, King's College London, London, United Kingdom. LA - eng GR - WT_/Wellcome Trust/United Kingdom PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20240807 PL - Switzerland TA - Front Public Health JT - Frontiers in public health JID - 101616579 SB - IM MH - Humans MH - Female MH - *COVID-19/psychology/epidemiology MH - United Kingdom MH - Pregnancy MH - Adult MH - Perinatal Care MH - SARS-CoV-2 MH - Maternal Health Services MH - Qualitative Research MH - Social Justice MH - Pandemics MH - Grounded Theory MH - Interviews as Topic PMC - PMC11338017 OTO - NOTNLM OT - COVID-19 OT - motherhood OT - perinatal period OT - postpartum period OT - pregnancy OT - reproductive justice OT - women's health COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. FIR - Soulsby, Laura K IR - Soulsby LK FIR - Christiansen, Paul IR - Christiansen P FIR - De Pascalis, Leonardo IR - De Pascalis L FIR - Harrold, Joanne A IR - Harrold JA EDAT- 2024/08/22 06:42 MHDA- 2024/08/22 06:43 PMCR- 2024/08/07 CRDT- 2024/08/22 04:51 PHST- 2024/02/26 00:00 [received] PHST- 2024/07/24 00:00 [accepted] PHST- 2024/08/22 06:43 [medline] PHST- 2024/08/22 06:42 [pubmed] PHST- 2024/08/22 04:51 [entrez] PHST- 2024/08/07 00:00 [pmc-release] AID - 10.3389/fpubh.2024.1389702 [doi] PST - epublish SO - Front Public Health. 2024 Aug 7;12:1389702. doi: 10.3389/fpubh.2024.1389702. eCollection 2024. PMID- 39152466 OWN - NLM STAT- MEDLINE DCOM- 20240817 LR - 20250131 IS - 2045-4015 (Electronic) IS - 2045-4015 (Linking) VI - 13 IP - 1 DP - 2024 Aug 16 TI - IQOS point-of-sale marketing: a comparison between Arab and Jewish neighborhoods in Israel. PG - 39 LID - 10.1186/s13584-024-00626-8 [doi] LID - 39 AB - BACKGROUND: Philip Morris International's IQOS, with its heatsticks (HEETS), is the heated tobacco product with the largest global market share. IQOS and/or electronic cigarettes use rate is higher among Arabs vs. Jews in Israel. This paper aims to compare IQOS point-of-sale marketing strategies, and regulatory compliance in Arab vs. Jewish neighborhoods in Israel. METHODS: We integrated data from two separate studies including a cross-sectional survey with IQOS retailers (December 2020-April 2021) and audits of points-of-sale that sold IQOS/HEETS (April 2021-July 2021) in 5 large cities in Israel, after marketing restrictions including a points-of-sale display ban and plain packaging became effective in Israel (January 2020). The survey included 69 points-of-sale (21 Arab, 48 Jewish neighborhoods) and the audits included 129 points-of-sale (48 Arab, 81 Jewish neighborhoods). Comparisons of IQOS marketing strategies between points-of-sale in Arab and Jewish neighborhoods were conducted using Chi-Square test, Fisher's exact test or Mann-Whitney test, as appropriate. Thematic analysis was used to analyze open-ended questions. RESULTS: The survey showed that most marketing strategies, such as promotions to customers, were uniform across points-of-sale in Arab and Jewish neighborhoods. The most noteworthy differences were that a higher proportion of retailers from Arab neighborhoods were invited to IQOS parties (47.6% vs. 21.7%, p < 0.05) and reported personal communication with a Philip Morris International's representative (80.0% vs. 51.2%, p < 0.05). Additionally, Philip Morris International's representatives assisted points-of-sale in both Arab and Jewish neighborhoods in implementing the display ban by providing free compliant cabinets and product placement instructions, and directly interacted with customers. The audits showed that points-of-sale in Arab neighborhoods were more compliant with the display ban (25.5% vs. 8.8%, p < 0.05), but less compliant with plain packaging (62.5% vs. 79.3%, p < 0.05). CONCLUSIONS: There were not many notable differences in IQOS marketing across points-of-sale in Arab vs. Jewish neighborhoods, but Philip Morris International utilized marketing elements of cultural significance, especially for points-of-sale in Arab neighborhoods, such as more personal communication and invitation to social events. Continuous surveillance of tobacco points-of-sale marketing and legislation compliance is needed, with a special focus on demographic/location-based differences. CI - (c) 2024. The Author(s). FAU - Khayat, Amal AU - Khayat A AUID- ORCID: 0000-0003-0525-4889 AD - Braun School of Public Health and Community Medicine, Faculty of Medicine, The Hebrew University of Jerusalem - Hadassah Medical Center, Ein Kerem, PO Box 12272, 911200, Jerusalem, Israel. amal.khayat@mail.huji.ac.il. FAU - Levine, Hagai AU - Levine H AUID- ORCID: 0000-0002-5597-4916 AD - Braun School of Public Health and Community Medicine, Faculty of Medicine, The Hebrew University of Jerusalem - Hadassah Medical Center, Ein Kerem, PO Box 12272, 911200, Jerusalem, Israel. FAU - Berg, Carla J AU - Berg CJ AUID- ORCID: 0000-0001-8931-1961 AD - Milken Institute School of Public Health, George Washington University, Washington, DC, USA. FAU - Abroms, Lorien C AU - Abroms LC AUID- ORCID: 0000-0001-6859-283X AD - Milken Institute School of Public Health, George Washington University, Washington, DC, USA. FAU - Duan, Zongshuan AU - Duan Z AD - Department of Population Health Sciences, School of Public Health, Georgia State University, Atlanta, GA, USA. FAU - Wang, Yan AU - Wang Y AD - Milken Institute School of Public Health, George Washington University, Washington, DC, USA. FAU - LoParco, Cassidy R AU - LoParco CR AD - Milken Institute School of Public Health, George Washington University, Washington, DC, USA. FAU - Elbaz, Daniel AU - Elbaz D AD - Braun School of Public Health and Community Medicine, Faculty of Medicine, The Hebrew University of Jerusalem - Hadassah Medical Center, Ein Kerem, PO Box 12272, 911200, Jerusalem, Israel. FAU - Cui, Yuxian AU - Cui Y AD - Milken Institute School of Public Health, George Washington University, Washington, DC, USA. FAU - Bar-Zeev, Yael AU - Bar-Zeev Y AUID- ORCID: 0000-0002-1916-836X AD - Braun School of Public Health and Community Medicine, Faculty of Medicine, The Hebrew University of Jerusalem - Hadassah Medical Center, Ein Kerem, PO Box 12272, 911200, Jerusalem, Israel. LA - eng GR - R01 CA239178/CA/NCI NIH HHS/United States GR - R01CA239178-01A1/CA/NCI NIH HHS/United States PT - Comparative Study PT - Journal Article DEP - 20240816 PL - England TA - Isr J Health Policy Res JT - Israel journal of health policy research JID - 101584158 SB - IM UOF - Res Sq. 2024 Mar 01:rs.3.rs-3953025. doi: 10.21203/rs.3.rs-3953025/v1. PMID: 38464035 MH - Israel MH - *Arabs/statistics & numerical data MH - *Jews/statistics & numerical data MH - Humans MH - *Marketing/statistics & numerical data/methods MH - Cross-Sectional Studies MH - Residence Characteristics/statistics & numerical data MH - Surveys and Questionnaires MH - Commerce/statistics & numerical data PMC - PMC11328467 OTO - NOTNLM OT - Heated tobacco products OT - IQOS OT - Marketing OT - Point-of-sale COIS- YBZ has received fees for lectures from Pfizer Ltd, Novartis NCH, and GSK Consumer Health (distributors of smoking cessation pharmacotherapy in Israel) in the past (2012-July 2019). LA receives royalties for the sale of Text2Quit and is a shareholder in Welltok, Inc. EDAT- 2024/08/17 15:42 MHDA- 2024/08/17 15:43 PMCR- 2024/08/16 CRDT- 2024/08/16 23:36 PHST- 2024/02/21 00:00 [received] PHST- 2024/08/03 00:00 [accepted] PHST- 2024/08/17 15:43 [medline] PHST- 2024/08/17 15:42 [pubmed] PHST- 2024/08/16 23:36 [entrez] PHST- 2024/08/16 00:00 [pmc-release] AID - 10.1186/s13584-024-00626-8 [pii] AID - 626 [pii] AID - 10.1186/s13584-024-00626-8 [doi] PST - epublish SO - Isr J Health Policy Res. 2024 Aug 16;13(1):39. doi: 10.1186/s13584-024-00626-8. PMID- 39102265 OWN - NLM STAT- MEDLINE DCOM- 20240805 LR - 20260518 IS - 2574-3805 (Electronic) IS - 2574-3805 (Linking) VI - 7 IP - 8 DP - 2024 Aug 1 TI - COVID-19 Pandemic School Disruptions and Acute Mental Health in Children and Adolescents. PG - e2425829 LID - 10.1001/jamanetworkopen.2024.25829 [doi] LID - e2425829 AB - IMPORTANCE: There are suggestions that school pressure may be stressful and a factor in child and adolescent mental health disturbances, but data about this association are scarce and inconclusive. OBJECTIVE: To assess whether varying degrees of school interruption were associated with changes in emergency department (ED) psychiatric visits of children and adolescents before and after the COVID-19 outbreak. DESIGN, SETTING, AND PARTICIPANTS: A cross-sectional observational study was conducted at 9 urban university hospitals in Italy. All ED visits from January 1, 2018, to December 31, 2021, for psychiatric reasons of patients younger than 18 years were examined for demographic characteristics and type of psychopathologic factors. Data analysis was conducted from July 1 to August 31, 2023. EXPOSURE: The disruption in the usual succession of school and holiday periods brought on by the COVID-19 pandemic at different times and with various degrees of intensity. MAIN OUTCOMES AND MEASURES: Total number of pediatric ED visits, psychiatric ED visits, and psychiatric ED visits categorized by specific reasons (eg, psychomotor agitation, suicide ideation [SI] or suicide attempt [SA], and eating disorders) on a weekly basis. RESULTS: A total of 13 014 psychiatric ED visits (1.3% of all pediatric ED visits) were recorded (63.2% females; mean [SD] age, 13.8 [3.8] years). The number of ED psychiatric visits increased over time (incidence rate ratio [IRR], 1.19; 95% CI, 1.16-1.22 for each year). Significant increases in ED visits were observed for eating disorders (294.8%), SI (297.8%), and SA (249.1%). School opening, but not social lockdown restriction, was associated with an increase in the number of ED psychiatric visits (IRR, 1.29; 95% CI, 1.23-1.34), which was evident for females and for SI with SA. Socioeconomic status was associated with an increase in psychiatric visits for males (IRR, 1.12; 95% CI, 1.04-1.20) but not females (IRR, 1.04; 95% CI, 0.98-1.10). CONCLUSIONS AND RELEVANCE: In this study, school opening was associated with an increased incidence of acute psychiatric emergencies among children and adolescents, suggesting that school can be a substantial source of stress with acute mental health implications. FAU - Davico, Chiara AU - Davico C AD - Department of Public Health and Pediatric Sciences, University of Turin/Regina Margherita Children's Hospital, Turin, Italy. FAU - Marcotulli, Daniele AU - Marcotulli D AD - Department of Public Health and Pediatric Sciences, University of Turin/Regina Margherita Children's Hospital, Turin, Italy. FAU - Abbracciavento, Giuseppe AU - Abbracciavento G AD - University of Trieste, B. Garofalo Hospital, Trieste, Italy. FAU - Anfosso, Thomas AU - Anfosso T AD - Department of Clinical and Experimental Science, University of Brescia, Brescia, Italy. FAU - Apicella, Massimo AU - Apicella M AD - Division of Child and Adolescent Psychiatry, Bambino Gesu Children's Hospital IRCCS, Rome, Italy. FAU - Averna, Roberto AU - Averna R AD - Division of Child and Adolescent Psychiatry, Bambino Gesu Children's Hospital IRCCS, Rome, Italy. FAU - Bazzoni, Marzia AU - Bazzoni M AD - Department of Biomedical Sciences, Section of Neuroscience & Clinical Pharmacology, University of Cagliari, Cagliari, Italy. FAU - Calderoni, Dario AU - Calderoni D AD - Department of Human Neurosciences, Sapienza University of Rome, Rome, Italy. FAU - Cammisa, Luca AU - Cammisa L AD - Department of Human Neurosciences, Sapienza University of Rome, Rome, Italy. FAU - Carta, Alessandra AU - Carta A AD - University Hospital of Sassari, Division of Child Neuropsychiatry, Sassari, Italy. FAU - Carucci, Sara AU - Carucci S AD - Department of Biomedical Sciences, Section of Neuroscience & Clinical Pharmacology, University of Cagliari, Cagliari, Italy. AD - Child & Adolescent Neuropsychiatry Unit, "A. Cao" Paediatric Hospital, ASL Cagliari, Italy. FAU - Cozzi, Giorgio AU - Cozzi G AD - University of Trieste, B. Garofalo Hospital, Trieste, Italy. FAU - Di Santo, Federica AU - Di Santo F AD - Department of Human Neurosciences, Sapienza University of Rome, Rome, Italy. FAU - Fazzi, Elisa AU - Fazzi E AD - Department of Clinical and Experimental Science, University of Brescia, Brescia, Italy. FAU - Lux, Caterina AU - Lux C AD - Department of Public Health and Pediatric Sciences, University of Turin/Regina Margherita Children's Hospital, Turin, Italy. FAU - Narducci, Chiara AU - Narducci C AD - Department of Biomedical Sciences, Section of Neuroscience & Clinical Pharmacology, University of Cagliari, Cagliari, Italy. AD - Child & Adolescent Neuropsychiatry Unit, "A. Cao" Paediatric Hospital, ASL Cagliari, Italy. FAU - Nobili, Lino AU - Nobili L AD - IRCCS Istituto G. Gaslini, University of Genoa, Genoa, Italy. AD - IRCCS Istituto G. Gaslini, Genoa, Italy. FAU - Onida, Ilaria AU - Onida I AD - University Hospital of Sassari, Division of Child Neuropsychiatry, Sassari, Italy. FAU - Pisano, Tiziana AU - Pisano T AD - Neuroscience Department, Meyer Children's Hospital IRCCS, Florence, Italy. FAU - Raucci, Umberto AU - Raucci U AD - Division of Child and Adolescent Psychiatry, Bambino Gesu Children's Hospital IRCCS, Rome, Italy. FAU - Sforzi, Idanna AU - Sforzi I AD - Emergency Department and Trauma Center Meyer Children's Hospital IRCCS, Florence, Italy. FAU - Siri, Laura AU - Siri L AD - IRCCS Istituto G. Gaslini, Genoa, Italy. FAU - Sotgiu, Stefano AU - Sotgiu S AD - University Hospital of Sassari, Division of Child Neuropsychiatry, Sassari, Italy. FAU - Tavano, Simone AU - Tavano S AD - Neuroscience Department, Meyer Children's Hospital IRCCS, Florence, Italy. FAU - Terrinoni, Arianna AU - Terrinoni A AD - Department of Human Neurosciences, Sapienza University of Rome, Rome, Italy. FAU - Uccella, Sara AU - Uccella S AD - IRCCS Istituto G. Gaslini, University of Genoa, Genoa, Italy. AD - IRCCS Istituto G. Gaslini, Genoa, Italy. FAU - Vicari, Stefano AU - Vicari S AD - Division of Child and Adolescent Psychiatry, Bambino Gesu Children's Hospital IRCCS, Rome, Italy. AD - Dipartimento di Scienze della Vita e Sanita Pubblica, Catholic University, Rome, Italy. FAU - Zanus, Caterina AU - Zanus C AD - University of Trieste, B. Garofalo Hospital, Trieste, Italy. FAU - Vitiello, Benedetto AU - Vitiello B AD - Department of Public Health and Pediatric Sciences, University of Turin/Regina Margherita Children's Hospital, Turin, Italy. CN - Italian Covid-Child and Adolescent Psychiatric Emergencies Study Group LA - eng PT - Journal Article PT - Observational Study PT - Research Support, Non-U.S. Gov't DEP - 20240801 PL - United States TA - JAMA Netw Open JT - JAMA network open JID - 101729235 SB - IM MH - Humans MH - *COVID-19/epidemiology/psychology MH - Female MH - Male MH - Child MH - Adolescent MH - Cross-Sectional Studies MH - *Schools MH - Italy/epidemiology MH - *Emergency Service, Hospital/statistics & numerical data MH - Mental Health/statistics & numerical data MH - Mental Disorders/epidemiology MH - SARS-CoV-2 MH - Pandemics MH - Suicidal Ideation PMC - PMC11301547 COIS- Conflict of Interest Disclosures: Dr Davico reported consultant fees from Lundbeck and personal fees from Roche outside the submitted work. Dr Marcotulli reported receiving consultant fees from Ethos Ltd outside the submitted work. Dr Carucci reported participation in a clinical trial sponsored by Janssen-Cilag outside the submitted work. Dr Vitiello reported receiving grants from the Italian Ministry of University and Research and Italian Autism Foundation, and personal fees from Menarini, Angelini, Medice, and Alkermes outside the submitted work. No other disclosures were reported. FIR - Davico, Chiara IR - Davico C FIR - Marcotulli, Daniele IR - Marcotulli D FIR - Lux, Caterina M IR - Lux CM FIR - Vitiello, Benedetto IR - Vitiello B FIR - Cudia, Valentina F IR - Cudia VF FIR - Amianto, Federico IR - Amianto F FIR - Borgogno, Marta IR - Borgogno M FIR - Ricci, Federica S IR - Ricci FS FIR - Defilippi, Giulia IR - Defilippi G FIR - Lonardelli, Elena IR - Lonardelli E FIR - Bondone, Claudia IR - Bondone C FIR - Abbracciavento, Giuseppe IR - Abbracciavento G FIR - Cozzi, Giorgio IR - Cozzi G FIR - Zanus, Caterina IR - Zanus C FIR - Anfosso, Thomas IR - Anfosso T FIR - Fazzi, Elisa IR - Fazzi E FIR - Apicella, Massimo IR - Apicella M FIR - Averna, Roberto IR - Averna R FIR - Raucci, Umberto IR - Raucci U FIR - Vicari, Stefano IR - Vicari S FIR - Bazzoni, Marzia IR - Bazzoni M FIR - Carucci, Sara IR - Carucci S FIR - Narducci, Chiara IR - Narducci C FIR - Zuddas, Alessandro IR - Zuddas A FIR - Calderoni, Dario IR - Calderoni D FIR - Cammisa, Luca IR - Cammisa L FIR - di Santo, Federica IR - di Santo F FIR - Terrinoni, Arianna IR - Terrinoni A FIR - Ferrara, Mauro IR - Ferrara M FIR - Carta, Alessandra IR - Carta A FIR - Onida, Ilaria IR - Onida I FIR - Sotgiu, Stefano IR - Sotgiu S FIR - Nobili, Lino IR - Nobili L FIR - Siri, Laura IR - Siri L FIR - Uccella, Sara IR - Uccella S FIR - Pisano, Tiziana IR - Pisano T FIR - Sforzi, Idanna IR - Sforzi I FIR - Tavano, Simone IR - Tavano S EDAT- 2024/08/05 12:42 MHDA- 2024/08/05 12:43 PMCR- 2024/08/05 CRDT- 2024/08/05 11:34 PHST- 2024/08/05 12:43 [medline] PHST- 2024/08/05 12:42 [pubmed] PHST- 2024/08/05 11:34 [entrez] PHST- 2024/08/05 00:00 [pmc-release] AID - 2821950 [pii] AID - zoi240804 [pii] AID - 10.1001/jamanetworkopen.2024.25829 [doi] PST - epublish SO - JAMA Netw Open. 2024 Aug 1;7(8):e2425829. doi: 10.1001/jamanetworkopen.2024.25829. PMID- 39088820 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240818 IS - 2561-326X (Electronic) IS - 2561-326X (Linking) VI - 8 DP - 2024 Aug 1 TI - Quality of Chronic Obstructive Pulmonary Disease Information on the Chinese Internet: Website Evaluation Study. PG - e56594 LID - 10.2196/56594 [doi] LID - e56594 AB - BACKGROUND: The development of internet technology has greatly increased the ability of patients with chronic obstructive pulmonary disease (COPD) to obtain health information, giving patients more initiative in the patient-physician decision-making process. However, concerns about the quality of website health information will affect the enthusiasm of patients' website search behavior. Therefore, it is necessary to evaluate the current situation of Chinese internet information on COPD. OBJECTIVE: This study aims to evaluate the quality of COPD treatment information on the Chinese internet. METHODS: Using the standard disease name "" ("chronic obstructive pulmonary disease" in Chinese) and the commonly used public search terms "" ("COPD") and "" ("emphysema") combined with the keyword "" ("treatment"), we searched the PC client web page of Baidu, Sogou, and 360 search engines and screened the first 50 links of the website from July to August 2021. The language was restricted to Chinese for all the websites. The DISCERN tool was used to evaluate the websites. RESULTS: A total of 96 websites were included and analyzed. The mean overall DISCERN score for all websites was 30.4 (SD 10.3; range 17.3-58.7; low quality), no website reached the maximum DISCERN score of 75, and the mean score for each item was 2.0 (SD 0.7; range 1.2-3.9). There were significant differences in mean DISCERN scores between terms, with "chronic obstructive pulmonary disease" having the highest mean score. CONCLUSIONS: The quality of COPD information on the Chinese internet is poor, which is mainly reflected in the low reliability and relevance of COPD treatment information, which can easily lead consumers to make inappropriate treatment choices. The term "chronic obstructive pulmonary disease" has the highest DISCERN score among commonly used disease search terms. It is recommended that consumers use standard disease names when searching for website information, as the information obtained is relatively reliable. CI - (c)Qinqin Wang, Lingjun Liu, Hong Li, Qiao Zhang, Qianli Ma. Originally published in JMIR Formative Research (https://formative.jmir.org), 01.08.2024. FAU - Wang, Qinqin AU - Wang Q AUID- ORCID: 0000-0002-5001-2531 AD - Chronic Respiratory Disease Management and Rehabilitation Center, SongShan General Hospital, Chongqing, China. FAU - Liu, Lingjun AU - Liu L AUID- ORCID: 0009-0009-5313-0566 AD - Chronic Respiratory Disease Management and Rehabilitation Center, SongShan General Hospital, Chongqing, China. FAU - Li, Hong AU - Li H AUID- ORCID: 0009-0008-7443-7412 AD - Chronic Respiratory Disease Management and Rehabilitation Center, SongShan General Hospital, Chongqing, China. FAU - Zhang, Qiao AU - Zhang Q AUID- ORCID: 0000-0002-5115-6529 AD - Chronic Respiratory Disease Management and Rehabilitation Center, SongShan General Hospital, Chongqing, China. FAU - Ma, Qianli AU - Ma Q AUID- ORCID: 0000-0003-4504-1933 AD - Chronic Respiratory Disease Management and Rehabilitation Center, SongShan General Hospital, Chongqing, China. LA - eng PT - Journal Article DEP - 20240801 PL - Canada TA - JMIR Form Res JT - JMIR formative research JID - 101726394 PMC - PMC11327628 OTO - NOTNLM OT - COPD OT - China OT - DISCERN OT - DISCERN instrument OT - chronic OT - chronic obstructive pulmonary disease OT - chronic pulmonary disease OT - cross-sectional study OT - evaluation OT - health information OT - information quality OT - internet OT - pulmonary OT - pulmonary disease OT - treatment OT - website information OT - websites COIS- Conflicts of Interest: None declared. EDAT- 2024/08/01 18:43 MHDA- 2024/08/01 18:44 PMCR- 2024/08/01 CRDT- 2024/08/01 16:53 PHST- 2024/01/21 00:00 [received] PHST- 2024/07/01 00:00 [accepted] PHST- 2024/03/31 00:00 [revised] PHST- 2024/08/01 18:44 [medline] PHST- 2024/08/01 18:43 [pubmed] PHST- 2024/08/01 16:53 [entrez] PHST- 2024/08/01 00:00 [pmc-release] AID - v8i1e56594 [pii] AID - 10.2196/56594 [doi] PST - epublish SO - JMIR Form Res. 2024 Aug 1;8:e56594. doi: 10.2196/56594. PMID- 39018312 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250723 IS - 2767-3375 (Electronic) IS - 2767-3375 (Linking) VI - 4 IP - 7 DP - 2024 TI - The impact of COVID-19 on sexual risk behaviour for HIV acquisition in east Zimbabwe: An observational study. PG - e0003194 LID - 10.1371/journal.pgph.0003194 [doi] LID - e0003194 AB - The Covid-19 pandemic and associated restrictions have the potential to alter sexual risk behaviours for HIV acquisition with important implications for HIV prevention programmes in sub-Saharan Africa. To date, no large-scale data have been published to substantiate hypothesised changes in sexual risk behaviours. We used longitudinal survey data to assess the impact of Covid-19 on sexual risk behaviours in east Zimbabwe. Data on sexual behaviours in HIV-negative adults aged 15-54 years were collected in two rounds of a general population open-cohort survey conducted in Manicaland, Zimbabwe shortly before (July 2018 to December 2019; N = 7316) and several months into the Covid-19 epidemic (February to July 2021; N = 6356). Descriptive statistics and logistic regression models of serial cross-sectional and prospective cohort data were used to assess changes in sexual risk behaviours. The proportion of females aged 15-19 years reporting sexual debut declined from 29.7% before Covid-19 to 20.3% during Covid-19 (adjusted odds ratio (AOR) = 0.49, 95% confidence interval (95% CI), 0.38-0.63). Fewer sexually-active females reported multiple sexual partners during Covid-19 (3.35% versus 6.07%; AOR = 0.55, 95% CI, 0.43-0.72). No population-level changes in male behaviour between survey rounds were recorded but the cohort analysis revealed a complex pattern of behaviour change with HIV risk behaviours increasing for some individuals and decreasing for others. Overall HIV risk behaviours remained high in a sub-Saharan African population with a generalised HIV epidemic over a period of Covid-19 lockdowns when movements and social contacts were restricted. CI - Copyright: (c) 2024 Morris et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. FAU - Morris, Rebekah AU - Morris R AUID- ORCID: 0000-0002-5740-6963 AD - Department of Infectious Disease Epidemiology and MRC Centre for Global Infectious Disease Analysis, School of Public Health, Imperial College London, London, United Kingdom. FAU - Gregson, Simon AU - Gregson S AUID- ORCID: 0000-0003-2707-0714 AD - Department of Infectious Disease Epidemiology and MRC Centre for Global Infectious Disease Analysis, School of Public Health, Imperial College London, London, United Kingdom. AD - Manicaland Centre for Public Health Research, Biomedical Research and Training Institute, Harare, Zimbabwe. FAU - Maswera, Rufurwokuda AU - Maswera R AD - Manicaland Centre for Public Health Research, Biomedical Research and Training Institute, Harare, Zimbabwe. FAU - Moorhouse, Louisa AU - Moorhouse L AD - Department of Infectious Disease Epidemiology and MRC Centre for Global Infectious Disease Analysis, School of Public Health, Imperial College London, London, United Kingdom. FAU - Dadirai, Tawanda AU - Dadirai T AD - Manicaland Centre for Public Health Research, Biomedical Research and Training Institute, Harare, Zimbabwe. FAU - Mandizvidza, Phyllis AU - Mandizvidza P AD - Manicaland Centre for Public Health Research, Biomedical Research and Training Institute, Harare, Zimbabwe. FAU - Moyo, Brian AU - Moyo B AD - AIDS and TB programme, Zimbabwe Ministry of Health and Child Care, Harare, Zimbabwe. FAU - Mugurungi, Owen AU - Mugurungi O AD - AIDS and TB programme, Zimbabwe Ministry of Health and Child Care, Harare, Zimbabwe. FAU - Nyamukapa, Constance AU - Nyamukapa C AD - Department of Infectious Disease Epidemiology and MRC Centre for Global Infectious Disease Analysis, School of Public Health, Imperial College London, London, United Kingdom. AD - Manicaland Centre for Public Health Research, Biomedical Research and Training Institute, Harare, Zimbabwe. LA - eng GR - INV-009999/GATES/Gates Foundation/United States GR - INV-023210/GATES/Gates Foundation/United States GR - R01 MH114562/MH/NIMH NIH HHS/United States PT - Journal Article DEP - 20240717 PL - United States TA - PLOS Glob Public Health JT - PLOS global public health JID - 9918283779606676 EIN - PLOS Glob Public Health. 2025 Jul 22;5(7):e0004970. doi: 10.1371/journal.pgph.0004970. PMID: 40694539 PMC - PMC11253984 COIS- The authors have declared that no competing interests exist. EDAT- 2024/07/17 18:42 MHDA- 2024/07/17 18:43 PMCR- 2024/07/17 CRDT- 2024/07/17 13:34 PHST- 2023/12/06 00:00 [received] PHST- 2024/05/29 00:00 [accepted] PHST- 2024/07/17 18:43 [medline] PHST- 2024/07/17 18:42 [pubmed] PHST- 2024/07/17 13:34 [entrez] PHST- 2024/07/17 00:00 [pmc-release] AID - PGPH-D-23-02077 [pii] AID - 10.1371/journal.pgph.0003194 [doi] PST - epublish SO - PLOS Glob Public Health. 2024 Jul 17;4(7):e0003194. doi: 10.1371/journal.pgph.0003194. eCollection 2024. PMID- 38958979 OWN - NLM STAT- MEDLINE DCOM- 20240703 LR - 20260922 IS - 2574-3805 (Electronic) IS - 2574-3805 (Linking) VI - 7 IP - 7 DP - 2024 Jul 1 TI - Cancer Survivorship Care in the United States at Facilities Accredited by the Commission on Cancer. PG - e2418736 LID - 10.1001/jamanetworkopen.2024.18736 [doi] LID - e2418736 AB - IMPORTANCE: Since 2021, American College of Surgeons Commission on Cancer (CoC) accreditation standards require providing a survivorship program for patients with adult-onset cancer treated with curative intent. Since more than 70% of all patients with cancer in the US are treated at CoC-accredited facilities, this presents an opportunity for a landscape analysis of survivorship care availability. OBJECTIVE: To determine the prevalence, types, and outcomes of cancer survivorship services at CoC-accredited facilities. DESIGN, SETTING, AND PARTICIPANTS: This survey study used an anonymous, online, cross-sectional survey conducted from May 4 to 25, 2023. Participants were CoC-accredited facilities in the US representing diverse CoC program categories, institutional characteristics, geographic regions, and practice types. Department of Veterans Affairs cancer programs were excluded due to data usage restrictions. Data were analyzed from July to October 2023. EXPOSURE: CoC Survivorship Standard 4.8 was released in October 2019 and programs were expected to adhere to the Standard beginning January 1, 2021. MAIN OUTCOMES AND MEASURES: Questions included self-reported survivorship program characteristics, availability of services aligned to CoC Survivorship Standard 4.8, and perceived program impacts. Response frequencies and proportions were determined in aggregate and by CoC program category. RESULTS: There were 1400 eligible programs, and 384 programs participated (27.4% response rate). All regions and eligible program categories were represented, and most had analytic caseloads of 500 to 4999 patients in 2021. Most survivorship program personnel included nurses (334 programs [87.0%]) and social workers (278 programs [72.4%]), while physical (180 programs [46.9%]) and occupational (87 programs [22.7%]) therapists were less common. Services most endorsed as available for all survivors were screening for new cancers (330 programs [87.5%]), nutritional counseling (325 programs [85.3%]), and referrals to specialists (320 programs [84.7%]), while treatment summaries (242 programs [64.7%]), and survivorship care plans (173 programs [43.0%]), sexual health (217 programs [57.3%]), and fertility (214 programs [56.9%]) were less common. Survivorship services were usually delivered by cancer treatment teams (243 programs [63.3%]) rather than specialized survivorship clinics (120 programs [31.3%]). For resources needed, additional advanced practice clinicians with dedicated survivorship effort (205 programs [53.4%]) and electronic health record enhancements (185 programs [48.2%]) were most endorsed. Lack of referrals and low patient awareness were endorsed as the primary barriers. A total of 335 programs (87.2%) agreed that Survivorship Standard 4.8 helped advance their programs. CONCLUSIONS AND RELEVANCE: These findings of this survey study of CoC-accredited programs establish a benchmark for survivorship care delivery in the US, identify gaps in specific services and opportunities for intervention, contribute to longitudinal reevaluation for tracking progress nationally, and suggest the value of survivorship care standards. FAU - Stal, Julia AU - Stal J AD - Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles. AD - Cancer Research Program, American College of Surgeons, Chicago, Illinois. FAU - Miller, Kimberly A AU - Miller KA AD - Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles. AD - Department of Dermatology, Keck School of Medicine, University of Southern California, Los Angeles. AD - USC Norris Comprehensive Cancer Center, Los Angeles, California. FAU - Mullett, Timothy W AU - Mullett TW AD - Markey Cancer Center, Cancer Prevention and Control Program, University of Kentucky, Lexington. AD - Department of Surgery, College of Medicine, University of Kentucky, Lexington. AD - Commission on Cancer, American College of Surgeons, Chicago, Illinois. FAU - Boughey, Judy C AU - Boughey JC AD - Cancer Research Program, American College of Surgeons, Chicago, Illinois. AD - Department of Surgery, Mayo Clinic, Rochester, Minnesota. FAU - Francescatti, Amanda B AU - Francescatti AB AD - Cancer Research Program, American College of Surgeons, Chicago, Illinois. FAU - Funk, Elizabeth AU - Funk E AD - Cancer Research Program, American College of Surgeons, Chicago, Illinois. FAU - Nelson, Heidi AU - Nelson H AD - Cancer Research Program, American College of Surgeons, Chicago, Illinois. AD - Commission on Cancer, American College of Surgeons, Chicago, Illinois. AD - Department of Surgery, Mayo Clinic, Rochester, Minnesota. FAU - Freyer, David R AU - Freyer DR AD - Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles. AD - USC Norris Comprehensive Cancer Center, Los Angeles, California. AD - Department of Pediatrics, Keck School of Medicine, University of Southern California, Los Angeles. AD - Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles. AD - Cancer and Blood Disease Institute, Children's Hospital Los Angeles, Los Angeles, California. LA - eng GR - F99 CA284291/CA/NCI NIH HHS/United States GR - P30 CA014089/CA/NCI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural DEP - 20240701 PL - United States TA - JAMA Netw Open JT - JAMA network open JID - 101729235 SB - IM CIN - JAMA Netw Open. 2024 Jul 1;7(7):e2418686. doi: 10.1001/jamanetworkopen.2024.18686. PMID: 38958982 MH - Humans MH - United States MH - Cross-Sectional Studies MH - *Survivorship MH - *Cancer Survivors/statistics & numerical data MH - *Neoplasms/therapy/mortality MH - *Accreditation/statistics & numerical data MH - Cancer Care Facilities/statistics & numerical data/standards MH - Surveys and Questionnaires MH - Female MH - Male PMC - PMC11222991 COIS- Conflict of Interest Disclosures: None reported. EDAT- 2024/07/03 13:43 MHDA- 2024/07/03 13:44 PMCR- 2024/07/03 CRDT- 2024/07/03 11:34 PHST- 2024/07/03 13:44 [medline] PHST- 2024/07/03 13:43 [pubmed] PHST- 2024/07/03 11:34 [entrez] PHST- 2024/07/03 00:00 [pmc-release] AID - 2820708 [pii] AID - zoi240613 [pii] AID - 10.1001/jamanetworkopen.2024.18736 [doi] PST - epublish SO - JAMA Netw Open. 2024 Jul 1;7(7):e2418736. doi: 10.1001/jamanetworkopen.2024.18736. PMID- 38943076 OWN - NLM STAT- MEDLINE DCOM- 20240629 LR - 20260901 IS - 2731-4553 (Electronic) IS - 2731-4553 (Linking) VI - 25 IP - 1 DP - 2024 Jun 28 TI - An exploratory randomised trial investigating feasibility, potential impact and cost effectiveness of link workers for people living with multimorbidity attending general practices in deprived urban communities. PG - 233 LID - 10.1186/s12875-024-02482-6 [doi] LID - 233 AB - BACKGROUND: Social prescribing link workers are non-health or social care professionals who connect people with psychosocial needs to non-clinical community supports. They are being implemented widely, but there is limited evidence for appropriate target populations or cost effectiveness. This study aimed to explore the feasibility, potential impact on health outcomes and cost effectiveness of practice-based link workers for people with multimorbidity living in deprived urban communities. METHODS: A pragmatic exploratory randomised trial with wait-list usual care control and blinding at analysis was conducted during the COVID 19 pandemic (July 2020 to January 2021). Participants had two or more ongoing health conditions, attended a general practitioner (GP) serving a deprived urban community who felt they may benefit from a one-month practice-based social prescribing link worker intervention.. Feasibility measures were recruitment and retention of participants, practices and link workers, and completion of outcome data. Primary outcomes at one month were health-related quality of life (EQ-5D-5L) and mental health (HADS). Potential cost effectiveness from the health service perspective was evaluated using quality adjusted life years (QALYs), based on conversion of the EQ-5D-5L and ICECAP-A capability index to utility scoring. RESULTS: From a target of 600, 251 patients were recruited across 13 general practices. Randomisation to intervention (n = 123) and control (n = 117) was after baseline data collection. Participant retention at one month was 80%. All practices and link workers (n = 10) were retained for the trial period. Data completion for primary outcomes was 75%. There were no significant differences identified using mixed effects regression analysis in EQ-5D-5L (MD 0.01, 95% CI -0.07 to 0.09) or HADS (MD 0.05, 95% CI -0.63 to 0.73), and no cost effectiveness advantages. A sensitivity analysis that considered link workers operating at full capacity in a non-pandemic setting, indicated the probability of effectiveness at the euro45,000 ICER threshold value for Ireland was 0.787 using the ICECAP-A capability index. CONCLUSIONS: While the trial under-recruited participants mainly due to COVID-19 restrictions, it demonstrates that robust evaluations and cost utility analyses are possible. Further evaluations are required to establish cost effectiveness and should consider using the ICE-CAP-A wellbeing measure for cost utility analysis. REGISTRATION: This trial is registered on ISRCTN. TITLE: Use of link workers to provide social prescribing and health and social care coordination for people with complex multimorbidity in socially deprived areas. TRIAL ID: ISRCTN10287737. Date registered 10/12/2019. Link: https://www.isrctn.com/ISRCTN10287737. CI - (c) 2024. The Author(s). FAU - Kiely, Bridget AU - Kiely B AUID- ORCID: 0000-0002-5752-0432 AD - Department of General Practice, Clinical Research Fellow, Royal College of Surgeons in Ireland University of Medicine and Health Sciences, 123 St Stephens Green, Dublin 2, Dublin, Ireland. bridgetkiely@rcsi.com. FAU - Hobbins, Anna AU - Hobbins A AD - Centre for Research in Medical Devices (CURAM, RC/2073_P2) and Health Economics and Policy Analysis Centre, University of Galway, SFI 13, Galway, Ireland. FAU - Boland, Fiona AU - Boland F AD - Data Science Centre, Royal College of Surgeons in Ireland University of Medicine and Health Sciences, 123 St Stephens Green, Dublin 2, Dublin, Ireland. FAU - Clyne, Barbara AU - Clyne B AD - Department of Public Health and Epidemiology, Royal College of Surgeons in Ireland University of Medicine and Health Sciences, 123 St Stephens Green, Dublin 2, Dublin, Ireland. FAU - Galvin, Emer AU - Galvin E AD - Royal College of Surgeons in Ireland University of Medicine and Health Sciences, 123 St Stephens Green, Dublin 2, Dublin, Ireland. FAU - Byers, Vivienne AU - Byers V AD - Environment Sustainability and Health Institute, Technological University Dublin, Dublin, Ireland. FAU - Loomba, Sonali AU - Loomba S AD - Royal College of Surgeons in Ireland University of Medicine and Health Sciences, 123 St Stephens Green, Dublin 2, Dublin, Ireland. FAU - O'Donnell, Patrick AU - O'Donnell P AD - Graduate Entry Medical School, University of Limerick, Limerick, Ireland. FAU - Connolly, Deirdre AU - Connolly D AD - Discipline of Occupational Therapy, Trinity College, Dublin, Ireland. FAU - Shea, Eamon O ' AU - Shea EO' AD - School of Business and Economics, University of Galway, Galway, Ireland. FAU - Smith, Susan M AU - Smith SM AD - Discipline of Public Health and Primary Care, Trinity College, Dublin, Ireland. LA - eng PT - Journal Article PT - Pragmatic Clinical Trial PT - Randomized Controlled Trial DEP - 20240628 PL - England TA - BMC Prim Care JT - BMC primary care JID - 9918300889006676 SB - IM MH - Humans MH - *Cost-Benefit Analysis MH - Male MH - Female MH - *Feasibility Studies MH - *COVID-19/epidemiology/economics MH - *Multimorbidity MH - Middle Aged MH - *General Practice/economics MH - Quality of Life MH - Urban Population MH - Aged MH - Quality-Adjusted Life Years MH - Adult MH - Cost-Effectiveness Analysis PMC - PMC11212363 OTO - NOTNLM OT - Cost analysis OT - General practice OT - Multimorbidity OT - Pragmatic clinical trial OT - Primary care OT - Social prescribing COIS- The authors declare no competing interests. EDAT- 2024/06/29 15:42 MHDA- 2024/06/29 15:43 PMCR- 2024/06/28 CRDT- 2024/06/29 00:04 PHST- 2023/07/28 00:00 [received] PHST- 2024/06/20 00:00 [accepted] PHST- 2024/06/29 15:43 [medline] PHST- 2024/06/29 15:42 [pubmed] PHST- 2024/06/29 00:04 [entrez] PHST- 2024/06/28 00:00 [pmc-release] AID - 10.1186/s12875-024-02482-6 [pii] AID - 2482 [pii] AID - 10.1186/s12875-024-02482-6 [doi] PST - epublish SO - BMC Prim Care. 2024 Jun 28;25(1):233. doi: 10.1186/s12875-024-02482-6. PMID- 38936011 OWN - NLM STAT- MEDLINE DCOM- 20240808 LR - 20260918 IS - 1879-1360 (Electronic) IS - 0022-3999 (Linking) VI - 184 DP - 2024 Sep TI - Association of COVID-19 vaccination and anxiety symptoms: A Scleroderma Patient-centered Intervention Network (SPIN) Cohort longitudinal study. PG - 111852 LID - S0022-3999(24)00264-2 [pii] LID - 10.1016/j.jpsychores.2024.111852 [doi] AB - OBJECTIVE: Symptoms of anxiety increased early in the COVID-19 pandemic among people with systemic sclerosis (SSc) then returned to pre-pandemic levels, but this was an aggregate finding and did not evaluate whether vaccination may have contributed to reduced anxiety symptom levels. We investigated whether being vaccinated for COVID-19 was associated with reduced anxiety symptoms among people with SSc. METHODS: The longitudinal Scleroderma Patient-centered Intervention Network (SPIN) COVID-19 Cohort was launched in April 2020 and included participants from the ongoing SPIN Cohort and external enrollees. Participants completed measures bi-weekly through July 2020, then every 4 weeks afterwards through August 2022 (32 assessments). We used linear mixed models to evaluate longitudinal trends of PROMIS Anxiety 4a v1.0 anxiety domain scores and their association with vaccination. RESULTS: Among 517 participants included in analyses, 489 (95%) were vaccinated by September 2021, and no participants were vaccinated subsequently. Except for briefly at the beginning, when few had received a vaccine, and end, when only 28 participants remained unvaccinated, anxiety symptom trajectories were largely overlapping. Participants who were never vaccinated had higher anxiety symptoms by August 2022, but there were no other differences, and receiving a vaccination did not appear to change anxiety symptom trajectories meaningfully. CONCLUSION: Vaccination did not appear to influence changes in anxiety symptoms among vulnerable people with SSc during the COVID-19 pandemic. This may be due to people restricting their behavior when they were unvaccinated and returning to more normal social engagement once vaccinated to maintain a steady level of anxiety symptoms. CI - Copyright (c) 2024 The Authors. Published by Elsevier Inc. All rights reserved. FAU - Virgili-Gervais, Gabrielle AU - Virgili-Gervais G AD - Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, Canada. FAU - Henry, Richard S AU - Henry RS AD - Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, Canada; Department of Psychiatry, McGill University, Montreal, Quebec, Canada. FAU - Kwakkenbos, Linda AU - Kwakkenbos L AD - Department of Clinical Psychology, Radboud University, Nijmegen, the Netherlands; Department of Medical Psychology, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, the Netherlands; IQ Healthcare, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, the Netherlands; Radboudumc Center for Mindfulness, Department of Psychiatry, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, the Netherlands. FAU - Carrier, Marie-Eve AU - Carrier ME AD - Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, Canada. FAU - Patten, Scott AU - Patten S AD - Department of Community Health Sciences, University of Calgary, Calgary, Alberta, Canada; Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada; O'Brien Institute for Public Health, University of Calgary, Calgary, Alberta, Canada. FAU - Bartlett, Susan J AU - Bartlett SJ AD - Department of Medicine, McGill University, Montreal, Quebec, Canada; Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada. FAU - Mouthon, Luc AU - Mouthon L AD - Service de Medecine Interne, Centre de Reference Maladies Autoimmunes Systemiques Rares d'Ile de France, Hopital Cochin, Assistance Publique - Hopitaux de Paris, Paris, France; Hopital Cochin, Paris, Universite de Paris, Paris, France. FAU - Varga, John AU - Varga J AD - Department of Medicine, Division of Rheumatology, University of Michigan, Ann Arbor, MI, USA. FAU - Benedetti, Andrea AU - Benedetti A AD - Department of Medicine, McGill University, Montreal, Quebec, Canada; Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, Quebec, Canada; Respiratory Epidemiology and Clinical Research Unit, McGill University Health Centre, Montreal, Quebec, Canada. FAU - Thombs, Brett D AU - Thombs BD AD - Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, Canada; Department of Psychiatry, McGill University, Montreal, Quebec, Canada; Department of Medicine, McGill University, Montreal, Quebec, Canada; Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, Quebec, Canada; Department of Psychology, McGill University, Montreal, Quebec, Canada; Biomedical Ethics Unit, McGill University, Montreal, Quebec, Canada. Electronic address: brett.thombs@mcgill.ca. CN - SPIN COVID-19 Patient Advisory Team CN - SPIN Investigators LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20240623 PL - England TA - J Psychosom Res JT - Journal of psychosomatic research JID - 0376333 RN - 0 (COVID-19 Vaccines) SB - IM MH - Humans MH - *COVID-19/prevention & control/psychology MH - Female MH - Male MH - *Scleroderma, Systemic/psychology MH - *Anxiety/psychology MH - Middle Aged MH - Longitudinal Studies MH - *COVID-19 Vaccines MH - *Vaccination/psychology MH - SARS-CoV-2 MH - Adult MH - Aged MH - Patient-Centered Care OTO - NOTNLM OT - Anxiety OT - COVID-19 OT - Scleroderma OT - Systemic sclerosis OT - Vaccination COIS- Declaration of competing interest The authors have competing interests to declare. EDAT- 2024/06/28 00:42 MHDA- 2024/08/09 00:43 CRDT- 2024/06/27 18:02 PHST- 2024/02/27 00:00 [received] PHST- 2024/05/18 00:00 [revised] PHST- 2024/06/22 00:00 [accepted] PHST- 2024/08/09 00:43 [medline] PHST- 2024/06/28 00:42 [pubmed] PHST- 2024/06/27 18:02 [entrez] AID - S0022-3999(24)00264-2 [pii] AID - 10.1016/j.jpsychores.2024.111852 [doi] PST - ppublish SO - J Psychosom Res. 2024 Sep;184:111852. doi: 10.1016/j.jpsychores.2024.111852. Epub 2024 Jun 23. PMID- 41000583 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20250926 LR - 20250928 IS - 2994-9726 (Electronic) IS - 2994-9726 (Linking) VI - 1 IP - 2 DP - 2024 Jun TI - Induced Abortion and Out-of-State Travel Among Insured Women Before and After the Dobbs v. Jackson Women's Health Organization Decision. PG - 16 LID - 10.1097/og9.0000000000000016 [doi] AB - OBJECTIVE: To quantify changes in abortion rates and out-of-state travel for abortion among insured women before and after the Dobbs v. Jackson decision. METHODS: This was a cross-sectional analysis of IQVIA's anonymized, patient-level preadjudicated medical claims on induced medication or procedural abortions among 43.1 million insured women of reproductive age (15-49 years) in the United States. We used information from the Guttmacher Institute to stratify states based on post-Dobbs abortion access policy: 1) legal with protections, 2) legal with restrictions, 3) partial ban, and 4) full ban. The main outcomes were 1) total number and rate of abortions per 100,000 women of reproductive age and 2) proportion of women with out-of-state abortions before (July-December 2021) and after (July-December 2022) Dobbs. RESULTS: Between January 2021 and December 2022, a total of 212,875 women of reproductive age (mean+/-SD age 28.1+/-6.5 years) had at least one induced abortion. In a comparison of the pre-Dobbs period with the post-Dobbs periods, there were increases in both the total number of women with at least one abortion (from 54,634 to 57,017) and the rate of abortions (from 121.7 to 137.7/100,000). Increases in abortion rates were driven primarily by states where abortion is legal with protections (from 278.5 to 328.5/100,000), whereas abortion rates declined slightly in states with partial (from 16.1 to 15.0/100,000) and full (from 7.2 to 6.8/100,000) abortion bans. Increases in the percentage of women traveling out of state to obtain an abortion were observed only in restrictive states and were greatest in states with full abortion bans (27.4% before Dobbs to 53.4% after Dobbs) (P<.001). CONCLUSION: There was a modest increase in abortion rates among insured women nationally after Dobbs, with modest increases in abortions among residents of states with protective abortion policies and increases in out-of-state abortions among residents of full- and partial-ban states. CI - (c) 2024 The Authors. Published by Wolters Kluwer Health, Inc. on behalf of the American College of Obstetricians and Gynecologists. FAU - Odouard, Ilina C AU - Odouard IC AD - Department of Health Policy and Management, the Center for Drug Safety and Effectiveness, and the Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, and the Division of General Internal Medicine, Johns Hopkins Medicine, Baltimore, Maryland; and the Division of Health Policy and Management, University of California, Berkeley School of Public Health, Berkeley, and the Program on Medicines and Public Health, Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences, and the Schaeffer Center for Health Policy & Economics, University of Southern California, Los Angeles, California. FAU - Guadamuz, Jenny S AU - Guadamuz JS AD - Department of Health Policy and Management, the Center for Drug Safety and Effectiveness, and the Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, and the Division of General Internal Medicine, Johns Hopkins Medicine, Baltimore, Maryland; and the Division of Health Policy and Management, University of California, Berkeley School of Public Health, Berkeley, and the Program on Medicines and Public Health, Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences, and the Schaeffer Center for Health Policy & Economics, University of Southern California, Los Angeles, California. FAU - Chakraborty, Apurba AU - Chakraborty A AD - Department of Health Policy and Management, the Center for Drug Safety and Effectiveness, and the Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, and the Division of General Internal Medicine, Johns Hopkins Medicine, Baltimore, Maryland; and the Division of Health Policy and Management, University of California, Berkeley School of Public Health, Berkeley, and the Program on Medicines and Public Health, Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences, and the Schaeffer Center for Health Policy & Economics, University of Southern California, Los Angeles, California. FAU - Alexander, G Caleb AU - Alexander GC AD - Department of Health Policy and Management, the Center for Drug Safety and Effectiveness, and the Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, and the Division of General Internal Medicine, Johns Hopkins Medicine, Baltimore, Maryland; and the Division of Health Policy and Management, University of California, Berkeley School of Public Health, Berkeley, and the Program on Medicines and Public Health, Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences, and the Schaeffer Center for Health Policy & Economics, University of Southern California, Los Angeles, California. FAU - Qato, Dima M AU - Qato DM AD - Department of Health Policy and Management, the Center for Drug Safety and Effectiveness, and the Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, and the Division of General Internal Medicine, Johns Hopkins Medicine, Baltimore, Maryland; and the Division of Health Policy and Management, University of California, Berkeley School of Public Health, Berkeley, and the Program on Medicines and Public Health, Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences, and the Schaeffer Center for Health Policy & Economics, University of Southern California, Los Angeles, California. LA - eng PT - Journal Article DEP - 20240627 PL - United States TA - O G Open JT - O&G open JID - 9918787579406676 PMC - PMC12456511 EDAT- 2024/06/27 00:00 MHDA- 2024/06/27 00:01 PMCR- 2024/06/27 CRDT- 2025/09/26 05:32 PHST- 2024/02/28 00:00 [received] PHST- 2024/04/15 00:00 [revised] PHST- 2024/04/18 00:00 [accepted] PHST- 2024/06/27 00:01 [medline] PHST- 2024/06/27 00:00 [pubmed] PHST- 2025/09/26 05:32 [entrez] PHST- 2024/06/27 00:00 [pmc-release] AID - OGO-24-19 [pii] AID - 10.1097/og9.0000000000000016 [doi] PST - epublish SO - O G Open. 2024 Jun 27;1(2):16. doi: 10.1097/og9.0000000000000016. eCollection 2024 Jun. PMID- 38926651 OWN - NLM STAT- MEDLINE DCOM- 20240627 LR - 20240626 IS - 2209-6051 (Electronic) IS - 2209-6051 (Linking) VI - 48 DP - 2024 Jun 24 TI - Epidemiology of respiratory syncytial virus in Central Queensland, Australia. LID - 10.33321/cdi.2024.48.45 [doi] AB - Respiratory syncytial virus (RSV) is the leading cause of bronchiolitis and pneumonia in infants. Little is known about the epidemiology, burden, and seasonality of RSV in subtropical regions of Australia like Central Queensland. This information is important to plan prevention strategies, including therapeutics, future vaccines, and health system preparedness. We collected data on laboratory-confirmed RSV cases and admissions in Central Queensland for the period 1 July 2021 to 31 December 2022. From July 2021, RSV was listed as a nationally notifiable condition on laboratory-confirmed diagnosis. During the study period, 1,142 laboratory-confirmed cases of RSV (50.0% female sex) were reported, with 169 cases (14.8%) requiring hospital admission, 12 of which (7.1%) required intensive care unit/high dependency unit admissions; two deaths occurred. Of cases requiring hospital admission, RSV was listed as the primary diagnosis in 113/169 cases (66.9%); 63/169 admitted cases (37.3%) had a major comorbidity. Of all cases, 55.4% were in children < 5 years of age (20.9% hospitalised); 35.7% in children < 2 years of age (24.3% hospitalised), and 19.1% in children < 12 months of age (27.5% hospitalised). Children under five years of age made up 78.1% of admissions, a rate of 9.0 admissions per 1,000 children over the 18-month study period, with an average age of 15.8 months (standard deviation, SD: 13.1 months) in this cohort. Indigenous children aged < 5 years were over-represented in cases (rate ratio, RR: 1.6; 95% confidence interval [95% CI]: 1.3-1.9) and admissions (RR: 1.6; 95% CI: 1.0-2.4). Antibiotics were prescribed to 48.5% of admitted cases under two years of age, despite documented bacterial infection in only 26.3% of these cases; antibiotic prescription was significantly higher in those who received a chest X-ray (p < 0.001). Of all cases, 33.5% occurred in July 2022 alone, with greater than 75.0% of cases occurring during June-August 2022. RSV showed year-round activity with a distinctive winter peak in 2022; however, this season was likely affected by coronavirus disease 2019 (COVID-19) restrictions and behaviours. Ongoing surveillance is required to better understand the epidemiology and seasonality of RSV in Central Queensland. CI - (c) Commonwealth of Australia CC BY-NC-ND. FAU - Gale, Emma AU - Gale E AD - Central Queensland Public Health Unit, Central Queensland Hospital and Health Service, Rockhampton, QLD 4700, Australia. FAU - Smoll, Nicolas AU - Smoll N AD - Sunshine Coast Public Health Unit, Sunshine Coast Hospital and Health Service, Maroochydore, QLD 4558, Australia. FAU - Al Imam, Mahmudul Hassan AU - Al Imam MH AD - Central Queensland Public Health Unit, Central Queensland Hospital and Health Service, Rockhampton, QLD 4700, Australia. AD - School of Health, Medical and Applied Sciences, Central Queensland University, Rockhampton, QLD 4701, Australia. FAU - Walker, Jacina AU - Walker J AD - Central Queensland Public Health Unit, Central Queensland Hospital and Health Service, Rockhampton, QLD 4700, Australia. FAU - Kirk, Michael AU - Kirk M AD - Rockhampton Business Unit, Central Queensland Hospital and Health Service, Rockhampton, QLD 4701, Australia. FAU - Pam, Sunday AU - Pam S AD - University of Queensland Rural Clinical School, Rockhampton, Queensland. AD - Department of Paediatrics, Central Queensland Hospital and Health Service, Rockhampton, QLD 4701, Australia. FAU - Menzies, Robert AU - Menzies R AD - Research Division, Sanofi, Macquarie Park, NSW 2193, Australia. FAU - Khandaker, Gulam AU - Khandaker G AD - Central Queensland Public Health Unit, Central Queensland Hospital and Health Service, Rockhampton, QLD 4700, Australia. AD - Research Division, Central Queensland University, Rockhampton, QLD 4701, Australia. AD - Discipline of Child and Adolescent Health, Sydney Medical School, The University of Sydney, Camperdown NSW 2006, Australia. LA - eng PT - Journal Article DEP - 20240624 PL - Australia TA - Commun Dis Intell (2018) JT - Communicable diseases intelligence (2018) JID - 101735394 SB - IM MH - Humans MH - *Respiratory Syncytial Virus Infections/epidemiology MH - Queensland/epidemiology MH - Female MH - Male MH - Infant MH - Child, Preschool MH - *Hospitalization/statistics & numerical data MH - *Respiratory Syncytial Virus, Human MH - Child MH - *Seasons MH - Adolescent MH - Infant, Newborn MH - Adult MH - Middle Aged OTO - NOTNLM OT - Australia OT - epidemiology OT - respiratory syncytial virus OT - seasonality OT - surveillance EDAT- 2024/06/27 00:42 MHDA- 2024/06/27 06:42 CRDT- 2024/06/26 23:42 PHST- 2024/06/27 06:42 [medline] PHST- 2024/06/27 00:42 [pubmed] PHST- 2024/06/26 23:42 [entrez] AID - 10.33321/cdi.2024.48.45 [doi] PST - epublish SO - Commun Dis Intell (2018). 2024 Jun 24;48. doi: 10.33321/cdi.2024.48.45. PMID- 38922616 OWN - NLM STAT- MEDLINE DCOM- 20240626 LR - 20250218 IS - 2574-3805 (Electronic) IS - 2574-3805 (Linking) VI - 7 IP - 6 DP - 2024 Jun 3 TI - Use of Oral and Emergency Contraceptives After the US Supreme Court's Dobbs Decision. PG - e2418620 LID - 10.1001/jamanetworkopen.2024.18620 [doi] LID - e2418620 AB - IMPORTANCE: The US Supreme Court Dobbs v Jackson Women's Health Organization decision allowed states to strengthen restrictions on abortion access, triggering the closure of family planning clinics and leading to confusion about the legality of emergency contraceptives (ECs). OBJECTIVES: To evaluate the association between the Dobbs decision and fills for oral and emergency contraceptives in states that enacted the most restrictive abortion policies after Dobbs. DESIGN, SETTING, AND PARTICIPANTS: This cohort study used data on contraceptive fills for women of reproductive age (15-49 years) in the US from IQVIA's National Prescription Audit PayerTrak and data from the Guttmacher Institute were used to categorize changes in abortion restrictions in each state. A difference-in-differences analysis compared changes in monthly fill rates for daily oral contraceptive pills (OCPs) and ECs in states that became most restrictive (implemented a full abortion ban after Dobbs) and comparison states (kept a medium level of abortion restrictions after Dobbs) before (March 2021 to November 2021) and after (July 2022 to October 2023) the Dobbs decision. EXPOSURE: State-level abortion restrictions. MAIN OUTCOMES AND MEASURES: Monthly fills of OCPs and ECs per 100 000 women of reproductive age. RESULTS: Between March 2021 and October 2023, 142.8 million prescriptions for OCPs and 904 269 prescriptions for ECs were dispensed at US retail pharmacies. Before Dobbs, trends in monthly fill rates were similar for OCPs and ECs between the most restrictive and comparison states. After the Dobbs decision, states that became the most restrictive experienced an additional 4.1% decline in OCP fills with 285.9 fewer fills per 100 000 (95% CI, -495.8 to -6.8; P = .04). In contrast to OCPs, fills for ECs increased during the first year after Dobbs (July 2022 to June 2023) in both groups of states. However, 1 year after Dobbs (July 2023 to October 2023), the most restrictive states experienced an additional 65% decrease in emergency contraceptive fills with 13.2 fewer fills per 100 000 (95% CI, -27.2 to -4.1; P = .01). CONCLUSIONS AND RELEVANCE: In this cohort study of prescriptions filled at US pharmacies, the Dobbs decision was associated with declines in oral contraceptives, particularly ECs, in states enacting the most restrictive abortion policies. Given the important role of OCPs and ECs in preventing pregnancy and the need for abortion, efforts to improve access may be needed, especially in states where legal abortion is no longer an option. FAU - Qato, Dima M AU - Qato DM AD - Program on Medicines and Public Health, Alfred Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California, Los Angeles. AD - Leonard D. Schaeffer Center for Health Policy and Economics, University of Southern California, Los Angeles. FAU - Myerson, Rebecca AU - Myerson R AD - Leonard D. Schaeffer Center for Health Policy and Economics, University of Southern California, Los Angeles. AD - Department of Population Health Sciences, University of Wisconsin, Madison. FAU - Shooshtari, Andrew AU - Shooshtari A AD - Program on Medicines and Public Health, Alfred Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California, Los Angeles. FAU - Guadamuz, Jenny S AU - Guadamuz JS AD - Division of Health Policy and Management, University of California at Berkeley School of Public Health, Berkeley. FAU - Alexander, G Caleb AU - Alexander GC AD - Department of Epidemiology at the Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland. AD - Center for Drug Safety and Effectiveness, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20240603 PL - United States TA - JAMA Netw Open JT - JAMA network open JID - 101729235 RN - 0 (Contraceptives, Postcoital) RN - 0 (Contraceptives, Oral) SB - IM EIN - JAMA Netw Open. 2024 Jul 1;7(7):e2429077. doi: 10.1001/jamanetworkopen.2024.29077. PMID: 39052299 MH - Humans MH - Female MH - United States MH - Adult MH - Adolescent MH - Young Adult MH - *Contraceptives, Postcoital/therapeutic use MH - Middle Aged MH - *Supreme Court Decisions MH - Contraceptives, Oral/therapeutic use MH - Abortion, Induced/legislation & jurisprudence/statistics & numerical data MH - Cohort Studies MH - Pregnancy MH - Contraception, Postcoital/statistics & numerical data PMC - PMC11208973 COIS- Conflict of Interest Disclosures: Dr Qato reported serving as consultant for the World Heath Organization Reproductive and Sexual Health Unit and the Public Citizen's Health Research Group. Dr Guadamuz reported previous employment with Flatiron Health Inc, an independent subsidiary of the Roche group, within the last 12 months; and reported receiving funding from the Robert Wood Johnson Foundation. Dr Alexander reported being past Chair of FDA's Peripheral and Central Nervous System Advisory Committee and a cofounding principal and equity holder in Stage Analytics. No other disclosures were reported. EDAT- 2024/06/26 12:42 MHDA- 2024/06/26 12:43 PMCR- 2024/06/26 CRDT- 2024/06/26 11:33 PHST- 2024/06/26 12:43 [medline] PHST- 2024/06/26 12:42 [pubmed] PHST- 2024/06/26 11:33 [entrez] PHST- 2024/06/26 00:00 [pmc-release] AID - 2820370 [pii] AID - zoi240610 [pii] AID - 10.1001/jamanetworkopen.2024.18620 [doi] PST - epublish SO - JAMA Netw Open. 2024 Jun 3;7(6):e2418620. doi: 10.1001/jamanetworkopen.2024.18620. PMID- 38913344 OWN - NLM STAT- MEDLINE DCOM- 20240805 LR - 20260911 IS - 2168-6211 (Electronic) IS - 2168-6203 (Print) IS - 2168-6203 (Linking) VI - 178 IP - 8 DP - 2024 Aug 1 TI - Infant Deaths After Texas' 2021 Ban on Abortion in Early Pregnancy. PG - 784-791 LID - 10.1001/jamapediatrics.2024.0885 [doi] AB - IMPORTANCE: Prior observational research has shown that infants born in states with more abortion restrictions are more likely to die during infancy. It is unclear how recent and more severe abortion bans in the US have impacted infant mortality. OBJECTIVE: To examine whether Texas Senate Bill 8 (SB8), which banned abortions after embryonic cardiac activity and did not allow exemptions for congenital anomalies, is associated with infant mortality in the state of Texas. DESIGN, SETTING, AND PARTICIPANTS: This population-based cohort study of all recorded infant deaths from the state of Texas and 28 comparison states used a comparative interrupted time series analysis with an augmented synthetic control approach and national birth certificate data from January 1, 2018, to December 31, 2022, to estimate the difference between the number of observed and expected infant and neonatal deaths and death rates among monthly cohorts exposed to Texas' SB8. EXPOSURE: Deaths in March 2022 were treated as the first cohort exposed to the Texas' SB8 abortion policy because these infants (if born full term) were approximately 10 to 14 weeks' gestation when SB8 went into effect on September 1, 2021. The exposure period was thus March through December 2022. MAIN OUTCOMES AND MEASURES: Our outcomes were monthly counts and rates of infant (aged <1 year) and neonatal (aged <28 days) deaths in the exposure period in Texas. In secondary analyses, annual changes in cause-specific infant deaths between 2021 and 2022 in Texas and the rest of the US were examined. RESULTS: Between 2018 and 2022, there were 102 391 infant deaths in the US, with 10 351 of these deaths occurring in the state of Texas. Between 2021 and 2022, infant deaths in Texas increased from 1985 to 2240, or 255 additional deaths. This corresponds to a 12.9% increase, whereas the rest of the US experienced a comparatively lower 1.8% increase. On the basis of the counterfactual analysis that used data from Texas and eligible comparison states, an excess of 216 infant deaths (95% CI, -122 to 554) was observed from March to December 2022, or a 12.7% increase above expectation. At the monthly level, significantly greater-than-expected counts were observed for 4 months between March and December 2022: April, July, September, and October. An analysis of neonatal deaths found somewhat similar patterns, with significantly greater-than-expected neonatal deaths in April and October 2022. Descriptive statistics by cause of death showed that infant deaths attributable to congenital anomalies in 2022 increased more for Texas (22.9% increase) but not the rest of the US (3.1% decrease). CONCLUSIONS AND RELEVANCE: This study found that Texas' 2021 ban on abortion in early pregnancy was associated with unexpected increases in infant and neonatal deaths in Texas between 2021 and 2022. Congenital anomalies, which are the leading cause of infant death, also increased in Texas but not the rest of the US. Although replication and further analyses are needed to understand the mechanisms behind these findings, the results suggest that restrictive abortion policies may have important unintended consequences in terms of trauma to families and medical cost as a result of increases in infant mortality. These findings are particularly relevant given the recent Dobbs v Jackson Women's Health Organization US Supreme Court decision and subsequent rollbacks of reproductive rights in many US states. FAU - Gemmill, Alison AU - Gemmill A AD - Department of Population, Family and Reproductive Health, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland. FAU - Margerison, Claire E AU - Margerison CE AD - Department of Epidemiology and Biostatistics, Michigan State University, East Lansing. FAU - Stuart, Elizabeth A AU - Stuart EA AD - Department of Mental Health, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland. FAU - Bell, Suzanne O AU - Bell SO AD - Department of Population, Family and Reproductive Health, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland. LA - eng GR - P2C HD042854/HD/NICHD NIH HHS/United States GR - R01 HD114292/HD/NICHD NIH HHS/United States PT - Journal Article PL - United States TA - JAMA Pediatr JT - JAMA pediatrics JID - 101589544 SB - IM CIN - JAMA Pediatr. 2024 Aug 1;178(8):748-750. doi: 10.1001/jamapediatrics.2024.1792. PMID: 38913338 MH - Humans MH - Texas/epidemiology MH - Female MH - Pregnancy MH - *Infant Mortality/trends MH - Infant MH - Infant, Newborn MH - Cohort Studies MH - Abortion, Legal/legislation & jurisprudence/statistics & numerical data MH - Abortion, Induced/legislation & jurisprudence/mortality/statistics & numerical data MH - Interrupted Time Series Analysis PMC - PMC11197445 COIS- Conflict of Interest Disclosures: Drs Gemmill, Margerison, Stuart, and Bell reported receiving grants from the National Institutes of Health outside the current study. No other disclosures were reported. EDAT- 2024/06/24 12:41 MHDA- 2024/08/05 12:42 PMCR- 2025/06/24 CRDT- 2024/06/24 11:33 PHST- 2024/08/05 12:42 [medline] PHST- 2024/06/24 12:41 [pubmed] PHST- 2024/06/24 11:33 [entrez] PHST- 2025/06/24 00:00 [pmc-release] AID - 2819785 [pii] AID - poi240019 [pii] AID - 10.1001/jamapediatrics.2024.0885 [doi] PST - ppublish SO - JAMA Pediatr. 2024 Aug 1;178(8):784-791. doi: 10.1001/jamapediatrics.2024.0885. PMID- 38901135 OWN - NLM STAT- MEDLINE DCOM- 20240915 LR - 20260814 IS - 1873-2054 (Electronic) IS - 1353-8292 (Linking) VI - 89 DP - 2024 Sep TI - Urban density, household overcrowding and the spread of COVID-19 in Australian cities. PG - 103298 LID - S1353-8292(24)00126-6 [pii] LID - 10.1016/j.healthplace.2024.103298 [doi] AB - The UN-Habitat World Cities Report 2020 highlighted that overcrowded housing, not urban density, is the major contributing factor to the spread of COVID-19. The relatively successful ability of densely populated cities such as Seoul, Singapore, Tokyo and New York City to manage virus spread supports this. We hypothesise that, given the complexity of the interaction between people and place, the relative contribution of density and crowding to the spread of infectious diseases may be contingent on local factors. To directly compare the role of urban density and household overcrowding, we examine each in relation to COVID-19 incidence in the three largest cities in Australia, Sydney, Melbourne and Brisbane, as the pandemic unfolded from July 2021 to January 2022. Using ecological models adjusted for spatial autocorrelation and area-level measures of age and socio-economic factors, we assess the association between population density, overcrowding in homes, and COVID-19 infections in local neighbourhoods. Challenging prevailing assumptions, we find evidence for an effect of both density and overcrowding on COVID-19 infections depending on the city and area within cities; that is, depending on the local context. For example, in the southwestern suburbs of Sydney, the case rate decreases by between 0.4 and 6.4 with every one-unit increase in gross density however the case rate increases by between 0.01 and 9.6 with every one-unit increase in total overcrowding. These findings have important implications for developing pandemic response strategies: public health measures that target either density (e.g., lockdowns and restricted range of travel) or overcrowding (e.g., restricting number of people relative to dwelling, mask-wearing indoors, vaccination prioritisation) must be cognisant of the geographically local contexts in which they are implemented. CI - Copyright (c) 2024 The Authors. Published by Elsevier Ltd.. All rights reserved. FAU - Herath, Shanaka AU - Herath S AD - School of Built Environment, Faculty of Design, Architecture & Building, University of Technology Sydney, Ultimo, NSW, 2007, Australia. Electronic address: shanaka.herath@uts.edu.au. FAU - Mansour, Adelle AU - Mansour A AD - Centre of Research Excellence in Healthy Housing, Melbourne School of Population and Global Health, The University of Melbourne, Parkville, 3010, Victoria, Australia. FAU - Bentley, Rebecca AU - Bentley R AD - Centre of Research Excellence in Healthy Housing, Melbourne School of Population and Global Health, The University of Melbourne, Parkville, 3010, Victoria, Australia. LA - eng PT - Journal Article DEP - 20240619 PL - England TA - Health Place JT - Health & place JID - 9510067 SB - IM MH - Humans MH - *COVID-19/epidemiology MH - *Crowding MH - *Cities/epidemiology MH - Australia/epidemiology MH - *Population Density MH - Adult MH - SARS-CoV-2 MH - Middle Aged MH - Female MH - Male MH - Family Characteristics MH - Incidence MH - Aged MH - Pandemics MH - Urban Population/statistics & numerical data EDAT- 2024/06/21 00:42 MHDA- 2024/09/16 00:42 CRDT- 2024/06/20 18:03 PHST- 2024/03/27 00:00 [received] PHST- 2024/05/27 00:00 [revised] PHST- 2024/06/15 00:00 [accepted] PHST- 2024/09/16 00:42 [medline] PHST- 2024/06/21 00:42 [pubmed] PHST- 2024/06/20 18:03 [entrez] AID - S1353-8292(24)00126-6 [pii] AID - 10.1016/j.healthplace.2024.103298 [doi] PST - ppublish SO - Health Place. 2024 Sep;89:103298. doi: 10.1016/j.healthplace.2024.103298. Epub 2024 Jun 19. PMID- 38887259 OWN - NLM STAT- MEDLINE DCOM- 20240618 LR - 20261019 IS - 2296-2565 (Electronic) IS - 2296-2565 (Linking) VI - 12 DP - 2024 TI - What was the impact of COVID-19 restrictions on unintentional injuries, in Canada and globally? A scoping review investigating how lockdown measures impacted the global burden of unintentional injury. PG - 1385452 LID - 10.3389/fpubh.2024.1385452 [doi] LID - 1385452 AB - BACKGROUND: Injuries are among the leading causes for hospitalizations and emergency department (ED) visits. COVID-19 restrictions ensured safety to Canadians, but also negatively impacted health outcomes, including increasing rates of certain injuries. These differences in trends have been reported internationally however the evidence is scattered and needs to be better understood to identify opportunities for public education and to prepare for future outbreaks. OBJECTIVE: A scoping review was conducted to synthesize evidence regarding the impact of COVID-19 restrictions on unintentional injuries in Canada, compared to other countries. METHODS: Studies investigating unintentional injuries among all ages during COVID-19 from any country, published in English between December 2019 and July 2021, were included. Intentional injuries and/or previous pandemics were excluded. Four databases were searched (MEDLINE, Embase, Web of Science, SPORTDiscus), and a gray literature search was also conducted. RESULTS: The search yielded 3,041 results, and 189 articles were selected for extraction. A total of 41 reports were included from the gray literature search. Final studies included research from: Europe (n = 85); North America (n = 44); Asia (n = 32); Oceania (n = 12); Africa (n = 8); South America (n = 4); and multi-country (n = 4). Most studies reported higher occurrence of injuries/trauma among males, and the average age across studies was 46 years. The following mechanisms of injury were reported on most frequently: motor vehicle collisions (MVCs; n = 134), falls (n = 104), sports/recreation (n = 65), non-motorized vehicle (n = 31), and occupational (n = 24). Injuries occurring at home (e.g., gardening, home improvement projects) increased, and injuries occurring at schools, workplaces, and public spaces decreased. Overall, decreases were observed in occupational injuries and those resulting from sport/recreation, pedestrian-related, and crush/trap incidents. Decreases were also seen in MVCs and burns, however the severity of injury from these causes increased during the pandemic period. Increases were observed in poisonings, non-motorized vehicle collisions, lacerations, drownings, trampoline injuries; and, foreign body ingestions. IMPLICATIONS: Findings from this review can inform interventions and policies to identify gaps in public education, promote safety within the home, and decrease the negative impact of future stay-at-home measures on unintentional injury among Canadians and populations worldwide. CI - Copyright (c) 2024 Karmali, Saxena, Richards, Thompson, McFaull and Pike. FAU - Karmali, Shazya AU - Karmali S AD - BC Injury Research and Prevention Unit, BC Children's Hospital Research Institute, Vancouver, BC, Canada. FAU - Saxena, Shikha AU - Saxena S AD - Public Health Agency of Canada, Ottawa, ON, Canada. FAU - Richards, Olivia AU - Richards O AD - Public Health Agency of Canada, Ottawa, ON, Canada. FAU - Thompson, Wendy AU - Thompson W AD - Public Health Agency of Canada, Ottawa, ON, Canada. FAU - McFaull, Steven R AU - McFaull SR AD - Public Health Agency of Canada, Ottawa, ON, Canada. FAU - Pike, Ian AU - Pike I AD - BC Injury Research and Prevention Unit, BC Children's Hospital Research Institute, Vancouver, BC, Canada. AD - Faculty of Medicine, Department of Pediatrics, University of British Columbia, Vancouver, BC, Canada. LA - eng PT - Journal Article PT - Scoping Review DEP - 20240603 PL - Switzerland TA - Front Public Health JT - Frontiers in public health JID - 101616579 SB - IM MH - Humans MH - *COVID-19/epidemiology/prevention & control MH - Canada/epidemiology MH - *Wounds and Injuries/epidemiology MH - Global Health/statistics & numerical data MH - SARS-CoV-2 MH - Quarantine/statistics & numerical data MH - Male MH - Child MH - Female MH - Middle Aged PMC - PMC11180821 OTO - NOTNLM OT - accident OT - lockdown OT - pandemic (COVID19) OT - public health measure OT - restriction COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2024/06/18 06:41 MHDA- 2024/06/18 23:42 PMCR- 2024/06/03 CRDT- 2024/06/18 03:53 PHST- 2024/02/12 00:00 [received] PHST- 2024/05/20 00:00 [accepted] PHST- 2024/06/18 06:41 [pubmed] PHST- 2024/06/18 23:42 [medline] PHST- 2024/06/18 03:53 [entrez] PHST- 2024/06/03 00:00 [pmc-release] AID - 10.3389/fpubh.2024.1385452 [doi] PST - epublish SO - Front Public Health. 2024 Jun 3;12:1385452. doi: 10.3389/fpubh.2024.1385452. eCollection 2024. PMID- 38865517 OWN - NLM STAT- MEDLINE DCOM- 20240612 LR - 20260922 IS - 2177-6709 (Electronic) IS - 2176-9451 (Print) IS - 2176-9451 (Linking) VI - 29 IP - 2 DP - 2024 TI - A bibliometric analysis of the 100 top-cited systematic review and meta-analysis in Orthodontics. PG - e242401 LID - S2176-94512024000200304 [pii] LID - 10.1590/2177-6709.29.2.e242401.oar [doi] LID - e242401 AB - OBJECTIVE: This bibliometric study aimed to analyze the citation metrics, journal and author characteristics, and subject domains of the 100 top-cited Systematic Reviews (SR) and Meta-Analysis (MA) in orthodontics. MATERIAL AND METHODS: An electronic database search was conducted for SR and MA in the Web of Science on 16th July 2023, without language and time restrictions. Of the 802 hits returned, the 100 top-cited orthodontic articles were shortlisted. They were analyzed for citation metrics, journal characteristics (journal, year of publication, impact factor-IF), author and affiliation characteristics (number, primary and corresponding author's affiliation, and country), study domain, and keywords. RESULTS: These articles were published from 1996 to 2021 in 20 journals, with an impact factor of 1.9 to 10.5, by 351 researchers affiliated with 104 universities. Their citations ranged from 45 to 344, and 34 poised to be classified as classic (>/= 100 citations). The maximum number of articles was published in the American Journal of Orthodontics and Dentofacial Orthopedics (n=38), the European Journal of Orthodontics (n=18), and the Angle Orthodontist (n=8). The authors for individual papers ranged from 1 to 10, with 5 being the most common (n=58). Europe had the highest contribution regarding the number of corresponding authors, institutions, and citations. Bone anchorage and orthodontic tooth movement/Biomechanics were the most frequently researched domains (n=11 each). The most common keyword used was Orthodontics (n=19), followed by Systematic Review (n=16) and Meta-analysis (n=9). CONCLUSION: In general, the top cited SR and MA were published in high-impact orthodontic journals, were multi-authored, and reflected the collaborative work from different universities. FAU - Selvaraj, Madhanraj AU - Selvaraj M AUID- ORCID: 0000-0002-2150-6022 AD - Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Department of Dentistry, Division of Orthodontics and Dentofacial Orthopedics (Puducherry, India). FAU - Nivethitha, Bhaskar AU - Nivethitha B AUID- ORCID: 0000-0002-3309-2007 AD - Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Department of Dentistry, Division of Orthodontics and Dentofacial Orthopedics (Puducherry, India). FAU - Varshitha, Piramanayagam AU - Varshitha P AUID- ORCID: 0009-0003-8445-9467 AD - Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Department of Dentistry, Division of Orthodontics and Dentofacial Orthopedics (Puducherry, India). FAU - Sangeetha, Ulaganathan AU - Sangeetha U AUID- ORCID: 0000-0002-1712-7150 AD - Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Department of Dentistry, Division of Orthodontics and Dentofacial Orthopedics (Puducherry, India). FAU - Madhan, Balasubramanian AU - Madhan B AUID- ORCID: 0000-0001-6088-3552 AD - Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Department of Dentistry, Division of Orthodontics and Dentofacial Orthopedics (Puducherry, India). LA - eng PT - Journal Article DEP - 20240610 PL - Brazil TA - Dental Press J Orthod JT - Dental press journal of orthodontics JID - 101532240 SB - IM MH - Humans MH - *Bibliometrics MH - Journal Impact Factor MH - Meta-Analysis as Topic MH - *Orthodontics MH - Periodicals as Topic/statistics & numerical data MH - *Systematic Reviews as Topic PMC - PMC11163958 COIS- The authors report no commercial, proprietary or financial interest in the products or companies described in this article. EDAT- 2024/06/12 18:42 MHDA- 2024/06/12 18:43 PMCR- 2024/06/10 CRDT- 2024/06/12 14:23 PHST- 2024/01/01 00:00 [received] PHST- 2024/03/13 00:00 [accepted] PHST- 2024/06/12 18:43 [medline] PHST- 2024/06/12 18:42 [pubmed] PHST- 2024/06/12 14:23 [entrez] PHST- 2024/06/10 00:00 [pmc-release] AID - S2176-94512024000200304 [pii] AID - 10.1590/2177-6709.29.2.e242401.oar [doi] PST - epublish SO - Dental Press J Orthod. 2024 Jun 10;29(2):e242401. doi: 10.1590/2177-6709.29.2.e242401.oar. eCollection 2024. PMID- 38839475 OWN - NLM STAT- MEDLINE DCOM- 20240701 LR - 20240701 IS - 1753-6405 (Electronic) IS - 1326-0200 (Linking) VI - 48 IP - 3 DP - 2024 Jun TI - Covert marketing of quick-service restaurants via news media in Australia: A content analysis. PG - 100150 LID - S1326-0200(24)00025-6 [pii] LID - 10.1016/j.anzjph.2024.100150 [doi] AB - OBJECTIVE: To determine the extent and nature of news media coverage generated from press releases made by top-selling quick-service restaurants in Australia. METHODS: We conducted a content analysis of press releases made between July 2021 and June 2022 by the five largest quick-service restaurant brands in Australia by brand share, including coding their main subject. We then conducted a content analysis of news media coverage related to the press releases, including coding its slant towards the brand. RESULTS: Among 52 press releases, new food products (27% of press releases; all unhealthy foods) and corporate social responsibility activities (25%) were the most promoted subjects. For 62% of press releases, at least one news media item was identified. Among the 86 identified news media items, most related to press releases promoting new food products (45% of news media items) or corporate social responsibility activities (21%). News media items overwhelmingly had a slant favourable to the relevant brand (93%). CONCLUSIONS: Press releases by top-selling quick-service restaurant brands in Australia commonly generate news media coverage that promotes such brands and their predominantly unhealthy products. IMPLICATIONS FOR PUBLIC HEALTH: Policies restricting unhealthy food marketing should consider brand-generated news media coverage. CI - Copyright (c) 2024 The Authors. Published by Elsevier B.V. All rights reserved. FAU - Brooks, Ruby AU - Brooks R AD - Sydney School of Public Health, University of Sydney, Australia; Global Centre for Preventive Health and Nutrition, Institute for Health Transformation, Deakin University, Australia. Electronic address: rubybrooks@live.com. FAU - Backholer, Kathryn AU - Backholer K AD - Global Centre for Preventive Health and Nutrition, Institute for Health Transformation, Deakin University, Australia. FAU - Kite, James AU - Kite J AD - Sydney School of Public Health, University of Sydney, Australia. LA - eng PT - Journal Article DEP - 20240604 PL - United States TA - Aust N Z J Public Health JT - Australian and New Zealand journal of public health JID - 9611095 SB - IM MH - *Restaurants/statistics & numerical data MH - Humans MH - Australia MH - *Mass Media MH - *Marketing/methods MH - Fast Foods OTO - NOTNLM OT - food OT - marketing OT - media OT - news COIS- Conflicts of interest The authors have no competing interests to declare. EDAT- 2024/06/06 01:15 MHDA- 2024/07/02 00:42 CRDT- 2024/06/05 21:59 PHST- 2023/08/12 00:00 [received] PHST- 2024/03/04 00:00 [revised] PHST- 2024/03/28 00:00 [accepted] PHST- 2024/07/02 00:42 [medline] PHST- 2024/06/06 01:15 [pubmed] PHST- 2024/06/05 21:59 [entrez] AID - S1326-0200(24)00025-6 [pii] AID - 10.1016/j.anzjph.2024.100150 [doi] PST - ppublish SO - Aust N Z J Public Health. 2024 Jun;48(3):100150. doi: 10.1016/j.anzjph.2024.100150. Epub 2024 Jun 4. PMID- 38824186 OWN - NLM STAT- MEDLINE DCOM- 20240628 LR - 20250520 IS - 1476-5446 (Electronic) IS - 1462-0049 (Print) IS - 1462-0049 (Linking) VI - 25 IP - 2 DP - 2024 Jun TI - Fluoride and children's IQ: evidence of causation lacking. PG - 95-97 LID - 10.1038/s41432-024-01022-6 [doi] AB - DATA SOURCES: Human, animal, and in vitro studies. Extensive literature search of multiple bibliographic databases, trial registries, major grey literature sources and bibliographies of identified studies. STUDY SELECTION: The authors aimed to identify studies which could be used to determine the maximum safe level for fluoride in drinking water. To identify new studies published since a 2016 Australian review, the search period was 2016 to July 2021. Studies which evaluated the association between either naturally or artificially fluoridated water (any concentration) and any health outcomes were included. No restrictions on study design or publication status. Articles published in a 'non-Latin language' were excluded. Screening of abstracts and full texts was in duplicate. For IQ and dental fluorosis, a top-up search was conducted between 2021 and Feb 2023. DATA EXTRACTION AND SYNTHESIS: Extensive data extraction. Risk of bias assessment using the OHAT tool. A narrative synthesis of the results was carried out. RESULTS: The review included 89 studies in humans, 199 in animals and 10 reviews of in vitro studies. Where there was consistent evidence of a positive association, in relation to a water fluoride concentration of <20 ppm (mg F/L), and where studies were judged to be acceptable or high quality, health effects were taken forwards for further examination of causality using Bradford Hill's 9 criteria. Of the 39 health outcomes reviewed, 4 were further assessed for causality. The authors reported 'strong' evidence of causality for dental fluorosis and reductions in children's IQ scores, 'moderate' strength evidence for thyroid dysfunction, 'weak' for kidney dysfunction, and 'limited' evidence for sex hormone disruption. CONCLUSIONS: The authors conclude that moderate dental fluorosis and reductions in children's IQ scores are the most appropriate health outcomes to use when setting an upper safe level of fluoride in drinking water. For reductions in children's IQ, the authors acknowledge a biological mechanism of action has not been elucidated, and the dose response curve is not clear at lower concentrations, limiting the ability to set an upper safe threshold. CI - (c) 2024. The Author(s). FAU - Moore, Deborah AU - Moore D AUID- ORCID: 0000-0001-9965-9371 AD - Senior Clinical Lecturer / Honorary Consultant in Dental Public Health, The University of Liverpool, Liverpool, UK. Deborah.moore@liverpool.ac.uk. FAU - Glenny, Anne-Marie AU - Glenny AM AD - Professor of Health Sciences Research, The University of Manchester, Manchester, UK. LA - eng PT - Journal Article DEP - 20240601 PL - England TA - Evid Based Dent JT - Evidence-based dentistry JID - 100883603 RN - 0 (Drinking Water) RN - Q80VPU408O (Fluorides) SB - IM MH - Animals MH - Child MH - Humans MH - Drinking Water MH - *Fluoridation/adverse effects MH - *Fluorides/adverse effects MH - *Fluorosis, Dental/etiology MH - *Intelligence/drug effects MH - Review Literature as Topic PMC - PMC11213703 COIS- The authors declare no competing interests. EDAT- 2024/06/02 00:43 MHDA- 2024/06/29 00:42 PMCR- 2024/06/01 CRDT- 2024/06/01 23:18 PHST- 2024/04/12 00:00 [received] PHST- 2024/04/15 00:00 [accepted] PHST- 2024/06/29 00:42 [medline] PHST- 2024/06/02 00:43 [pubmed] PHST- 2024/06/01 23:18 [entrez] PHST- 2024/06/01 00:00 [pmc-release] AID - 10.1038/s41432-024-01022-6 [pii] AID - 1022 [pii] AID - 10.1038/s41432-024-01022-6 [doi] PST - ppublish SO - Evid Based Dent. 2024 Jun;25(2):95-97. doi: 10.1038/s41432-024-01022-6. Epub 2024 Jun 1. PMID- 38817023 OWN - NLM STAT- MEDLINE DCOM- 20240531 LR - 20240618 IS - 1469-994X (Electronic) IS - 1462-2203 (Print) IS - 1462-2203 (Linking) VI - 26 IP - Supplement_2 DP - 2024 May 31 TI - Commercial Tobacco Retailers Need to Be Included in Research on Policies Restricting the Sale of Menthol Cigarettes. PG - S143-S146 LID - 10.1093/ntr/ntad252 [doi] AB - INTRODUCTION: Menthol cigarettes are disproportionately marketed and advertised in the commercial tobacco retail environment in Black communities across the United States, contributing to menthol cigarette-related disparities and lower likelihood of successful quitting among Black people who smoke. Policies restricting retail sales of menthol cigarettes are aimed at preventing initiation, promoting quitting, and reducing related disparities. METHODS: Structured phone interview surveys were conducted from January to July 2021 with commercial tobacco retailers in Los Angeles County, California, unincorporated communities with a high percentage of Black residents, eight months after a local policy restricting retail sales of menthol cigarettes and other flavored nicotine and commercial tobacco products became effective on May 20, 2020. Interviews examined menthol cigarette sales restrictions-related knowledge, attitudes, and practices. RESULTS: Among 22 retailers interviewed, most (86.4%) reported having knowledge of the local ban on menthol cigarettes, and more than half (54.5%) reported offering price promotions for menthol cigarettes. Additionally, more than half (54.5%) reported believing customers who buy menthol cigarettes would stop smoking altogether following the ban. CONCLUSIONS: Most retailers reported having knowledge of the menthol ban, yet half reported offering price promotions for menthol cigarettes. Findings suggest retail availability of menthol cigarettes in Los Angeles County unincorporated communities with a high percentage of Black residents, post ban. Public health and policy implications are discussed. CI - (c) The Author(s) 2024. Published by Oxford University Press on behalf of the Society for Research on Nicotine and Tobacco. FAU - Mei, Kellie Ann AU - Mei KA AD - Division of Health Promotion and Behavioral Science, School of Public Health, San Diego State University, San Diego, CA, USA. FAU - Shin, Heesung AU - Shin H AD - Division of Health Promotion and Behavioral Science, School of Public Health, San Diego State University, San Diego, CA, USA. FAU - Smiley, Sabrina L AU - Smiley SL AUID- ORCID: 0000-0003-3202-7534 AD - Division of Health Promotion and Behavioral Science, School of Public Health, San Diego State University, San Diego, CA, USA. LA - eng GR - DP1 DA058978/DA/NIDA NIH HHS/United States GR - University of California Tobacco-Related Disease Research Program/ PT - Journal Article PL - England TA - Nicotine Tob Res JT - Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco JID - 9815751 RN - 1490-04-6 (Menthol) SB - IM MH - Humans MH - *Menthol MH - *Tobacco Products/economics/legislation & jurisprudence MH - *Commerce/legislation & jurisprudence/statistics & numerical data MH - Female MH - Male MH - Adult MH - Black or African American/statistics & numerical data MH - California MH - Health Knowledge, Attitudes, Practice MH - Middle Aged MH - Smoking Cessation/methods/legislation & jurisprudence MH - Los Angeles MH - Surveys and Questionnaires PMC - PMC11140219 COIS- None declared. EDAT- 2024/05/31 06:42 MHDA- 2024/05/31 06:43 PMCR- 2024/05/31 CRDT- 2024/05/31 02:03 PHST- 2023/09/06 00:00 [received] PHST- 2023/11/21 00:00 [revised] PHST- 2023/12/14 00:00 [accepted] PHST- 2024/05/31 06:43 [medline] PHST- 2024/05/31 06:42 [pubmed] PHST- 2024/05/31 02:03 [entrez] PHST- 2024/05/31 00:00 [pmc-release] AID - 7685218 [pii] AID - ntad252 [pii] AID - 10.1093/ntr/ntad252 [doi] PST - ppublish SO - Nicotine Tob Res. 2024 May 31;26(Supplement_2):S143-S146. doi: 10.1093/ntr/ntad252. PMID- 38815050 OWN - NLM STAT- MEDLINE DCOM- 20240530 LR - 20260528 IS - 1545-1151 (Electronic) IS - 1545-1151 (Linking) VI - 21 DP - 2024 May 30 TI - Facilitators and Barriers to Passing Local Policies That Prohibit the Sale of Flavored Tobacco Products: Qualitative Analysis of Strategies Implemented by 36 Communities in California, 2017-2021. PG - E36 LID - 10.5888/pcd21.230283 [doi] LID - E36 AB - To reduce youth access to tobacco products, the California Tobacco Prevention Program funded local tobacco prevention programs from July 2017 through December 2021 to address its Communities of Excellence Indicator 3.2.9: "the number of jurisdictions with a policy eliminating or restricting the sale and/or distribution of any mentholated cigarettes and other flavored tobacco products, and paraphernalia." We examined the strategies by which community coalitions attempted to limit the number of stores selling flavored tobacco across California. Thirty-six final evaluation reports (FERs) were used for our analysis. We examined certain elements or factors as primary areas of interest because of their apparent link to successful outcomes in analyses of FERs in the past. Over half (19 of 36) of FERs reported successfully passing at least 1 policy to regulate the sale of flavored tobacco products. Urban communities passed more policies (16 of 18) compared with rural communities (3 of 18). Successful campaigns tended to involve youth, demonstrate illegal sales to minors and public support for a ban, and identify a champion. Barriers included the COVID-19 pandemic, California wildfires, staffing shortages, and conservative political climates. This evaluation offers insights into the successes and challenges faced by local coalitions seeking policy changes for tobacco use prevention, which can be different for urban and rural communities. The evaluation also indicates the necessity of adopting flexible tactical plans for overcoming environmental factors that affected intervention and evaluation activities. FAU - Hellesen, Sarah AU - Hellesen S AD - Public Health Sciences, School of Medicine, University of California, Davis, California. AD - Tobacco Control Evaluation Center, Department of Public Health Sciences, University of California, Davis, 1616 Da Vinci Court, Davis, CA 95618 (sehellesen@ucdavis.edu). FAU - Haun, Sue AU - Haun S AD - Public Health Sciences, School of Medicine, University of California, Davis, California. FAU - Dove, Melanie S AU - Dove MS AD - Public Health Sciences, School of Medicine, University of California, Davis, California. LA - eng PT - Journal Article DEP - 20240530 PL - United States TA - Prev Chronic Dis JT - Preventing chronic disease JID - 101205018 RN - 0 (Flavoring Agents) SB - IM MH - California MH - Humans MH - *Tobacco Products/legislation & jurisprudence MH - *Commerce/legislation & jurisprudence MH - *Flavoring Agents MH - Smoking Prevention/legislation & jurisprudence MH - COVID-19/prevention & control/epidemiology MH - Public Policy PMC - PMC11155685 EDAT- 2024/05/30 18:43 MHDA- 2024/05/30 18:44 PMCR- 2024/01/01 CRDT- 2024/05/30 14:03 PHST- 2024/05/30 18:44 [medline] PHST- 2024/05/30 18:43 [pubmed] PHST- 2024/05/30 14:03 [entrez] PHST- 2024/01/01 00:00 [pmc-release] AID - E36 [pii] AID - 23_0283 [pii] AID - 10.5888/pcd21.230283 [doi] PST - epublish SO - Prev Chronic Dis. 2024 May 30;21:E36. doi: 10.5888/pcd21.230283. PMID- 38781708 OWN - NLM STAT- MEDLINE DCOM- 20240609 LR - 20260809 IS - 1872-6054 (Electronic) IS - 0168-8510 (Linking) VI - 145 DP - 2024 Jul TI - Political determinants of COVID-19 restrictions and vaccine rollouts: The case of regional elections in Italy and Spain. PG - 105082 LID - S0168-8510(24)00092-7 [pii] LID - 10.1016/j.healthpol.2024.105082 [doi] AB - The COVID-19 pandemic is one of the most significant public health crises in modern history, with considerable impacts on the policy frameworks of national governments. In response to the pandemic, non-pharmaceutical interventions (NPIs) and mass vaccination campaigns have been employed to protect vulnerable groups. Through the lens of Political Budget Cycle (PBC) theory, this study explores the interplay between incumbent electoral concerns and political dynamics in influencing the implementation of NPIs and vaccination rollout within the administrative regions of Italy and Spain during the period spanning June 2020 to July 2021. The results reveal that incumbents up for the next scheduled election are 5.8 % more likely to increase the stringency of containment measures than those that face a term limit. The findings also demonstrate that the seats of the incumbent and coalition parties in parliament and the number of parties in the coalition have a negative effect on both the efficiency of the vaccination rollout and the stringency of NPIs. Additionally, the competitiveness of the election emerges as an important predictor of the strictness of NPIs. Therefore, our results suggest that incumbents may strategically manipulate COVID-19 policy measures to optimize electoral outcomes. The study underscores the substantive influence of political incentives, competitive electoral environments, and government coalitions on policy formulation during health emergencies. CI - Copyright (c) 2024 The Authors. Published by Elsevier B.V. All rights reserved. FAU - Arija Prieto, Pablo AU - Arija Prieto P AD - Department of Sociology and Business Law, University of Bologna, Bologna 40126, Italy. FAU - Antonini, Marcello AU - Antonini M AD - School of Medicine and Public Health, University of Newcastle, Callaghan, NSW 2308, Australia; Department of Health Policy, London School of Economics and Political Science, London, WC2A 2AE, UK. Electronic address: m.antonini1@lse.ac.uk. FAU - Ammi, Mehdi AU - Ammi M AD - School of Public Policy and Administration, Carleton University, Richcraft Hall, 1125 Colonel By Dr, Ottawa, ON, K1S 5B6, Canada. FAU - Genie, Mesfin AU - Genie M AD - Newcastle Business School, University of Newcastle, Newcastle, NSW, 2300, Australia; Health Economics Research Unit, Institute of Applied Health Sciences, University of Aberdeen, Aberdeen AB25 2ZD, UK; Department of Population Health Sciences, Duke University, 215 Morris Street, Durham, NC, 27701, USA. FAU - Paolucci, Francesco AU - Paolucci F AD - Department of Sociology and Business Law, University of Bologna, Bologna 40126, Italy; Newcastle Business School, University of Newcastle, Newcastle, NSW, 2300, Australia. LA - eng PT - Journal Article DEP - 20240516 PL - Ireland TA - Health Policy JT - Health policy (Amsterdam, Netherlands) JID - 8409431 RN - 0 (COVID-19 Vaccines) SB - IM MH - Humans MH - *COVID-19/prevention & control/epidemiology MH - Spain/epidemiology MH - Italy MH - *Politics MH - *COVID-19 Vaccines/supply & distribution MH - *Health Policy MH - SARS-CoV-2 MH - Mass Vaccination/organization & administration OTO - NOTNLM OT - COVID-19 policy responses OT - Electoral competitiveness OT - Italy OT - Non-pharmaceutical Interventions OT - Political budget cycle theory OT - Spain OT - Vaccine rollout COIS- Declaration of competing interest The authors declare that they have no known competing interests. EDAT- 2024/05/24 00:42 MHDA- 2024/06/10 00:42 CRDT- 2024/05/23 18:05 PHST- 2023/10/05 00:00 [received] PHST- 2024/03/15 00:00 [revised] PHST- 2024/05/12 00:00 [accepted] PHST- 2024/06/10 00:42 [medline] PHST- 2024/05/24 00:42 [pubmed] PHST- 2024/05/23 18:05 [entrez] AID - S0168-8510(24)00092-7 [pii] AID - 10.1016/j.healthpol.2024.105082 [doi] PST - ppublish SO - Health Policy. 2024 Jul;145:105082. doi: 10.1016/j.healthpol.2024.105082. Epub 2024 May 16. PMID- 38774160 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240523 IS - 2168-8184 (Print) IS - 2168-8184 (Electronic) IS - 2168-8184 (Linking) VI - 16 IP - 4 DP - 2024 Apr TI - Impact of Health Literacy on Patient-Reported Outcomes in Benign Gynecology: A Systematic Review. PG - e58661 LID - 10.7759/cureus.58661 [doi] LID - e58661 AB - The objective of this study was to systematically review the relationship between low health literacy and patient-reported outcomes in patients with benign gynecologic conditions. In this specific population, we also sought to determine the current reported prevalence of low health literacy, examine demographic characteristics that may be related to low health literacy, and collate any health literacy interventions described in the literature. A systematic search of MEDLINE (Medical Literature Analysis and Retrieval System Online), Embase, The Cochrane Library, Web of Science, PubMed, and clinicaltrials.gov was performed on July 12, 2021, and repeated on October 13, 2023, for terms related to health literacy, specific health literacy measures, and benign gynecologic conditions. There were language or publication period restrictions. Inclusion required primary literature to report associations between health literacy and patient-reported outcomes, using validated tools to quantitatively measure each, in adult women with benign gynecologic conditions. Title screening, abstract screening, and full-text review were conducted with Covidence software (Melbourne, Australia) assisting with the review process. Of the 18,701 studies returned using our search strategy, 25 were selected for full-text review. Of these, no studies met inclusion criteria and reported an association between health literacy and patient-reported outcomes. This study identified a large gap in the literature. Future work should be directed at evaluating the association between health literacy and patient-reported outcomes in benign gynecology to inform patient-centered interventions and care provision. CI - Copyright (c) 2024, Singh et al. FAU - Singh, Ashmita AU - Singh A AD - General Surgery, Northern Ontario School of Medicine, Sudbury, CAN. FAU - Skolnik, Emma AU - Skolnik E AD - Obstetrics and Gynecology, University of Toronto, Toronto, CAN. FAU - Miazga, Elizabeth AU - Miazga E AD - Obstetrics and Gynecology, Trillium Health Partners - Credit Valley Hospital, Mississauga, CAN. FAU - Nensi, Alysha AU - Nensi A AD - Obstetrics and Gynecology, St. Michael's Hospital, Toronto, CAN. LA - eng PT - Journal Article PT - Review DEP - 20240420 PL - United States TA - Cureus JT - Cureus JID - 101596737 PMC - PMC11105969 OTO - NOTNLM OT - benign gynecology OT - general gynecology OT - health literacy OT - healthcare outcomes OT - patient-reported outcome COIS- The authors have declared that no competing interests exist. EDAT- 2024/05/22 06:42 MHDA- 2024/05/22 06:43 PMCR- 2024/04/20 CRDT- 2024/05/22 03:37 PHST- 2024/04/20 00:00 [accepted] PHST- 2024/05/22 06:43 [medline] PHST- 2024/05/22 06:42 [pubmed] PHST- 2024/05/22 03:37 [entrez] PHST- 2024/04/20 00:00 [pmc-release] AID - 10.7759/cureus.58661 [doi] PST - epublish SO - Cureus. 2024 Apr 20;16(4):e58661. doi: 10.7759/cureus.58661. eCollection 2024 Apr. PMID- 38767993 OWN - NLM STAT- MEDLINE DCOM- 20240520 LR - 20241018 IS - 2578-7470 (Electronic) IS - 2578-7470 (Linking) VI - 25 IP - 1 DP - 2024 May 14 TI - The impact of COVID-19 on HIV treatment and care delivery in South and Southeast Asia: a qualitative study. PG - 2355763 AB - The COVID-19 pandemic has significantly impacted HIV treatment worldwide, but its effects on South and Southeast Asia, particularly in India, Indonesia, and Thailand, have been less evident. Our aim was to study the perceptions of providers and policymakers to understand how interventions were implemented as part of pandemic responses and how their effectiveness was viewed. We conducted a qualitative study with semi-structured interviews focusing on the shifts in HIV care in response to the pandemic. Between June and July 2021, 40 individuals were invited for interviews; 33 (83%) agreed. Participants included 25 (76%) providers and 8 (24%) policymakers, who were from India (10; 30%), Indonesia (10; 30%), and Thailand (10; 30%), along with 3 (9.1%) regional policymakers. Sixteen (48%) were female. Our findings revealed four major themes: (1) limitations in accessing HIV care due to movement restrictions and shutdowns, such as transportation issues; (2) diversion of healthcare resources away from HIV care to COVID-19 responses, leading to reallocation of providers and hospital space; (3) setbacks in HIV-related policy implementation as COVID-19 emergency responses took priority; (4) the expansion of HIV differentiated service delivery interventions, allowing longer gaps between visits and larger-volume prescription refills to delay returns to healthcare facilities. These changes have raised concerns about the long-term consequences on HIV epidemic control and future pandemic responses. However, they have also presented opportunities for innovative care delivery, which should be sustained to address these challenges effectively. FAU - Ahmad, Sophie AU - Ahmad S AUID- ORCID: 0009-0007-0656-2572 AD - Kirk Kerkorian School of Medicine, University of Nevada, Las Vegas, Las Vegas, NV, USA (current affiliation). AD - University of California, San Francisco, San Francisco, CA, USA. FAU - Fuller, Shannon AU - Fuller S AUID- ORCID: 0000-0001-6070-8172 AD - University of California, San Francisco, San Francisco, CA, USA. AD - Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA (current affiliation). FAU - Sohn, Annette H AU - Sohn AH AUID- ORCID: 0000-0002-0209-3285 AD - TREAT Asia, amfAR - the Foundation for AIDS Research, Bangkok, Thailand. LA - eng PT - Journal Article DEP - 20240520 PL - England TA - HIV Res Clin Pract JT - HIV research & clinical practice JID - 101738312 SB - IM MH - Humans MH - *HIV Infections/drug therapy/epidemiology MH - *COVID-19/epidemiology MH - Female MH - *Qualitative Research MH - Male MH - *SARS-CoV-2 MH - *Delivery of Health Care/statistics & numerical data MH - Asia, Southeastern/epidemiology MH - Health Services Accessibility/statistics & numerical data MH - Thailand/epidemiology MH - Adult MH - India/epidemiology MH - Indonesia/epidemiology OTO - NOTNLM OT - COVID-19 OT - Human immunodeficiency virus OT - South Asia OT - Southeast Asia OT - pandemic EDAT- 2024/05/20 18:43 MHDA- 2024/05/20 18:44 CRDT- 2024/05/20 12:22 PHST- 2024/05/20 18:44 [medline] PHST- 2024/05/20 18:43 [pubmed] PHST- 2024/05/20 12:22 [entrez] AID - 10.1080/25787489.2024.2355763 [pii] PST - ppublish SO - HIV Res Clin Pract. 2024 May 14;25(1):2355763. Epub 2024 May 20. PMID- 38750471 OWN - NLM STAT- MEDLINE DCOM- 20240516 LR - 20260203 IS - 1471-2393 (Electronic) IS - 1471-2393 (Linking) VI - 24 IP - 1 DP - 2024 May 15 TI - No role of the third-trimester inflammatory factors in the association of gestational diabetes mellitus with postpartum cardiometabolic indicators. PG - 361 LID - 10.1186/s12884-024-06563-3 [doi] LID - 361 AB - BACKGROUND: The influence of gestational diabetes mellitus (GDM) on postpartum cardiometabolic indicators is primarily restricted to glucose and lipid metabolism, however the indicators for liver and kidney function have been rarely explored, and the role of the third-trimester inflammatory factors in these associations has never been investigated. METHODS: Based on the Ma'anshan birth cohort (MABC), women with or without GDM history were selected and invited to participate in a 6-year postpartum follow-up. The fasting blood samples were collected to measure 16 comprehensive metabolic indicators during a 6-year postpartum follow-up: fasting plasma glucose (FPG), glycosylated hemoglobin (HbA1c), triglycerides (TG), total cholesterol (TC), uric acid (UA), blood urea nitrogen (BUN), serum creatinine (SCR), etc. Seven inflammatory factors, including TNF-alpha, IFN-gamma, IL-1beta, IL-6, IL-10, IL-12p70, and IL-17 A, were measured with serum samples collected during the third trimester of pregnancy. Linear regression models were used to analyze the associations between GDM and 6-year postpartum metabolic indicators, GDM and third-trimester inflammatory factors, and the third-trimester inflammatory factors and 6-year postpartum metabolic indicators. Mediating and moderating effect analyses were further performed to explore if the third-trimester inflammatory factors mediate or modify the association between GDM and postpartum cardiometabolic indicators. RESULTS: From July 2021 to August 2022, 307 participants have been followed up, with 99 women with a prior GDM history. Compared with those without GDM, individuals with a prior history of GDM had significantly elevated levels of FPG (beta = 0.40, 95% CI: 0.18 to 0.62, P(FDR) < 0.001), HbA1c (beta = 0.22, 95% CI: 0.09 to 0.34, P(FDR) = 0.009), TyG (beta = 0.22, 95% CI: 0.07 to 0.37, P(FDR) = 0.024) at 6 years postpartum, and the association between GDM and SCR (beta = 2.43, 95% CI: 0.02 to 4.85, P(FDR) = 0.144) reached nominal significance level. GDM history was associated with a decreased level of third-trimester IL-17 A (beta = -0.58, 95% CI: -0.99 to -0.18, P(FDR) = 0.035). No significant association between third-trimester inflammatory factors and 6-year postpartum metabolic indicators was observed. And no mediating or moderating effect of third-trimester inflammatory factors was observed in those associations. CONCLUSION: A prior history of GDM was significantly associated with elevated FPG, HbA1c, and TyG in women at 6 years postpartum, whereas third-trimester inflammatory factors had no role in mediating or moderating these associations. CI - (c) 2024. The Author(s). FAU - Yu, Xiayan AU - Yu X AD - Department of Maternal, Child and Adolescent Health, School of Public Health, Anhui Medical University, No 81 Meishan Road, Hefei, Anhui, 230032, China. AD - Key Laboratory of Population Health Across Life Cycle (Anhui Medical University), Ministry of Education of the People's Republic of China, No 81 Meishan Road, Hefei, Anhui, 230032, China. AD - Anhui Provincial Key Laboratory of Environment and Population Health across the Life Course, Anhui Medical University, No 81 Meishan Road, Hefei, Anhui, 230032, China. AD - NHC Key Laboratory of Study on Abnormal Gametes and Reproductive Tract, No 81 Meishan Road, Hefei, Anhui, 230032, China. FAU - Qiang, Wenjing AU - Qiang W AD - Department of Maternal, Child and Adolescent Health, School of Public Health, Anhui Medical University, No 81 Meishan Road, Hefei, Anhui, 230032, China. AD - Key Laboratory of Population Health Across Life Cycle (Anhui Medical University), Ministry of Education of the People's Republic of China, No 81 Meishan Road, Hefei, Anhui, 230032, China. AD - Anhui Provincial Key Laboratory of Environment and Population Health across the Life Course, Anhui Medical University, No 81 Meishan Road, Hefei, Anhui, 230032, China. AD - NHC Key Laboratory of Study on Abnormal Gametes and Reproductive Tract, No 81 Meishan Road, Hefei, Anhui, 230032, China. FAU - Gong, Kexin AU - Gong K AD - Department of Maternal, Child and Adolescent Health, School of Public Health, Anhui Medical University, No 81 Meishan Road, Hefei, Anhui, 230032, China. AD - Key Laboratory of Population Health Across Life Cycle (Anhui Medical University), Ministry of Education of the People's Republic of China, No 81 Meishan Road, Hefei, Anhui, 230032, China. AD - Anhui Provincial Key Laboratory of Environment and Population Health across the Life Course, Anhui Medical University, No 81 Meishan Road, Hefei, Anhui, 230032, China. AD - NHC Key Laboratory of Study on Abnormal Gametes and Reproductive Tract, No 81 Meishan Road, Hefei, Anhui, 230032, China. FAU - Cao, Yidan AU - Cao Y AD - Department of Maternal, Child and Adolescent Health, School of Public Health, Anhui Medical University, No 81 Meishan Road, Hefei, Anhui, 230032, China. AD - Key Laboratory of Population Health Across Life Cycle (Anhui Medical University), Ministry of Education of the People's Republic of China, No 81 Meishan Road, Hefei, Anhui, 230032, China. AD - Anhui Provincial Key Laboratory of Environment and Population Health across the Life Course, Anhui Medical University, No 81 Meishan Road, Hefei, Anhui, 230032, China. AD - NHC Key Laboratory of Study on Abnormal Gametes and Reproductive Tract, No 81 Meishan Road, Hefei, Anhui, 230032, China. FAU - Yan, Shuangqin AU - Yan S AD - Ma'anshan Maternal and Child Healthcare (MCH) Center, Ma'anshan, 243011, China. FAU - Gao, Guopeng AU - Gao G AD - Ma'anshan Maternal and Child Healthcare (MCH) Center, Ma'anshan, 243011, China. FAU - Tao, Fangbiao AU - Tao F AD - Department of Maternal, Child and Adolescent Health, School of Public Health, Anhui Medical University, No 81 Meishan Road, Hefei, Anhui, 230032, China. taofangbiao@126.com. AD - Key Laboratory of Population Health Across Life Cycle (Anhui Medical University), Ministry of Education of the People's Republic of China, No 81 Meishan Road, Hefei, Anhui, 230032, China. taofangbiao@126.com. AD - Anhui Provincial Key Laboratory of Environment and Population Health across the Life Course, Anhui Medical University, No 81 Meishan Road, Hefei, Anhui, 230032, China. taofangbiao@126.com. AD - NHC Key Laboratory of Study on Abnormal Gametes and Reproductive Tract, No 81 Meishan Road, Hefei, Anhui, 230032, China. taofangbiao@126.com. FAU - Zhu, Beibei AU - Zhu B AD - Department of Maternal, Child and Adolescent Health, School of Public Health, Anhui Medical University, No 81 Meishan Road, Hefei, Anhui, 230032, China. a513275541@126.com. AD - Key Laboratory of Population Health Across Life Cycle (Anhui Medical University), Ministry of Education of the People's Republic of China, No 81 Meishan Road, Hefei, Anhui, 230032, China. a513275541@126.com. AD - Anhui Provincial Key Laboratory of Environment and Population Health across the Life Course, Anhui Medical University, No 81 Meishan Road, Hefei, Anhui, 230032, China. a513275541@126.com. AD - NHC Key Laboratory of Study on Abnormal Gametes and Reproductive Tract, No 81 Meishan Road, Hefei, Anhui, 230032, China. a513275541@126.com. LA - eng GR - 2021004j07020034/the Key Research and Development Projects of Anhui Province/ GR - 82073564/National Natural Science Foundation of China/ PT - Journal Article DEP - 20240515 PL - England TA - BMC Pregnancy Childbirth JT - BMC pregnancy and childbirth JID - 100967799 RN - 0 (Glycated Hemoglobin) RN - 0 (Blood Glucose) RN - 268B43MJ25 (Uric Acid) RN - 0 (Triglycerides) RN - 97C5T2UQ7J (Cholesterol) RN - AYI8EX34EU (Creatinine) SB - IM MH - Humans MH - Female MH - Pregnancy MH - *Diabetes, Gestational/blood/epidemiology MH - *Pregnancy Trimester, Third/blood MH - Adult MH - *Postpartum Period/blood MH - *Glycated Hemoglobin/analysis MH - *Blood Glucose/analysis/metabolism MH - Inflammation/blood MH - Uric Acid/blood MH - Triglycerides/blood MH - Cholesterol/blood MH - Follow-Up Studies MH - Creatinine/blood MH - Blood Urea Nitrogen PMC - PMC11095010 OTO - NOTNLM OT - Cardiometabolic indicators OT - Cohort study OT - Gestational diabetes mellitus OT - Inflammatory factors COIS- The authors declare no competing interests. EDAT- 2024/05/16 00:43 MHDA- 2024/05/16 06:42 PMCR- 2024/05/15 CRDT- 2024/05/15 23:42 PHST- 2023/09/26 00:00 [received] PHST- 2024/05/03 00:00 [accepted] PHST- 2024/05/16 06:42 [medline] PHST- 2024/05/16 00:43 [pubmed] PHST- 2024/05/15 23:42 [entrez] PHST- 2024/05/15 00:00 [pmc-release] AID - 10.1186/s12884-024-06563-3 [pii] AID - 6563 [pii] AID - 10.1186/s12884-024-06563-3 [doi] PST - epublish SO - BMC Pregnancy Childbirth. 2024 May 15;24(1):361. doi: 10.1186/s12884-024-06563-3. PMID- 38742161 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240515 IS - 1188-4169 (Print) IS - 1481-8531 (Electronic) IS - 1188-4169 (Linking) VI - 50 IP - 3-4 DP - 2024 Apr 30 TI - Impact of the COVID-19 pandemic on inbound air travel to Canada. PG - 106-113 LID - 10.14745/ccdr.v50i34a04 [doi] AB - BACKGROUND: Commercial air travel can result in global dispersal of infectious diseases. During the coronavirus disease 2019 (COVID-19) pandemic, many countries implemented border measures, including restrictions on air travel, to reduce the importation risk of COVID-19. In the context of inbound air travel to Canada, this study aimed to: 1) characterize travel trends before and during the pandemic, and 2) statistically assess the association between travel volumes and travel restrictions during the pandemic. METHODS: Monthly commercial air travel volume data from March 2017 to February 2023 were obtained from the International Air Transport Association (IATA). National and airport-level travel trends to Canada were characterized by inbound travel volumes, the number of countries contributing travellers and the ranking of the top ten countries contributing travellers across the study period, by six year-length subperiod groupings (three pre-pandemic and three pandemic). Using seasonal autoregressive integrated moving average (SARIMA) models, interrupted time series (ITS) analyses assessed the association between major travel restrictions and travel volumes by including variables to represent changes to the level and slope of the time series. RESULTS: The pre-pandemic inbound travel volume increased by 3% to 7% between consecutive subperiods, with three seasonal peaks (July-August, December-January, March). At the onset of the pandemic, travel volume decreased by 90%, with the number of contributing countries declining from approximately 200 to 140, followed by a slow recovery in volume and seasonality. A disruption in the ranking of countries that contributed travellers was also noticeable during the pandemic. Results from the ITS analysis aligned with the timing of travel restrictions as follows: implementation in March 2020 coincided with a sharp reduction in volumes, while the easing of major restrictions, starting with the authorization of fully vaccinated travellers from the United States to enter Canada in August 2021, coincided with an increase in the slope of travel volumes. Descriptive and statistical results suggest a near-return of pre-pandemic travel patterns by the end of the study period. CONCLUSION: Study results suggest resilience in commercial air travel into Canada. Although the COVID-19 pandemic led to a disruption in travel trends, easing of travel restrictions appeared to enable pre-pandemic trends to re-emerge. Understanding trends in air travel volumes, as demonstrated here, can provide information that supports preparedness and response regarding importation risk of infectious pathogens. FAU - Gabriele-Rivet, Vanessa AU - Gabriele-Rivet V AD - National Microbiology Laboratory, Public Health Agency of Canada, St-Hyacinthe, QC. FAU - Rees, Erin AU - Rees E AD - National Microbiology Laboratory, Public Health Agency of Canada, St-Hyacinthe, QC. FAU - Rahman, Afnan AU - Rahman A AD - National Microbiology Laboratory, Public Health Agency of Canada, St-Hyacinthe, QC. FAU - Milwid, Rachael M AU - Milwid RM AD - National Microbiology Laboratory, Public Health Agency of Canada, St-Hyacinthe, QC. LA - eng PT - Journal Article DEP - 20240430 PL - Canada TA - Can Commun Dis Rep JT - Canada communicable disease report = Releve des maladies transmissibles au Canada JID - 9303729 PMC - PMC11090504 OTO - NOTNLM OT - COVID-19 OT - Canada OT - IATA OT - SARIMA OT - commercial air traffic OT - interrupted time series analysis OT - travel restrictions OT - travel volume COIS- Competing interests The authors declare no competing interests. EDAT- 2024/05/14 06:41 MHDA- 2024/05/14 06:42 PMCR- 2024/04/30 CRDT- 2024/05/14 03:45 PHST- 2024/05/14 06:42 [medline] PHST- 2024/05/14 06:41 [pubmed] PHST- 2024/05/14 03:45 [entrez] PHST- 2024/04/30 00:00 [pmc-release] AID - 503404 [pii] AID - 10.14745/ccdr.v50i34a04 [doi] PST - epublish SO - Can Commun Dis Rep. 2024 Apr 30;50(3-4):106-113. doi: 10.14745/ccdr.v50i34a04. eCollection 2024 Apr 30. PMID- 38735934 OWN - NLM STAT- MEDLINE DCOM- 20240512 LR - 20260610 IS - 1479-5868 (Electronic) IS - 1479-5868 (Linking) VI - 21 IP - 1 DP - 2024 May 13 TI - The impact of the world's first regulatory, multi-setting intervention on sedentary behaviour among children and adolescents (ENERGISE): a natural experiment evaluation. PG - 53 LID - 10.1186/s12966-024-01591-w [doi] LID - 53 AB - BACKGROUND: Regulatory actions are increasingly used to tackle issues such as excessive alcohol or sugar intake, but such actions to reduce sedentary behaviour remain scarce. World Health Organization (WHO) guidelines on sedentary behaviour call for system-wide policies. The Chinese government introduced the world's first nation-wide multi-setting regulation on multiple types of sedentary behaviour in children and adolescents in July 2021. This regulation restricts when (and for how long) online gaming businesses can provide access to pupils; the amount of homework teachers can assign to pupils according to their year groups; and when tutoring businesses can provide lessons to pupils. We evaluated the effect of this regulation on sedentary behaviour safeguarding pupils. METHODS: With a natural experiment evaluation design, we used representative surveillance data from 9- to 18-year-old pupils before and after the introduction of the regulation, for longitudinal (n = 7,054, matched individuals, primary analysis) and repeated cross-sectional (n = 99,947, exploratory analysis) analyses. We analysed pre-post differences for self-reported sedentary behaviour outcomes (total sedentary behaviour time, screen viewing time, electronic device use time, homework time, and out-of-campus learning time) using multilevel models, and explored differences by sex, education stage, residency, and baseline weight status. RESULTS: Longitudinal analyses indicated that pupils had reduced their mean total daily sedentary behaviour time by 13.8% (95% confidence interval [CI]: -15.9 to -11.7%, approximately 46 min) and were 1.20 times as likely to meet international daily screen time recommendations (95% CI: 1.01 to 1.32) one month after the introduction of the regulation compared to the reference group (before its introduction). They were on average 2.79 times as likely to meet the regulatory requirement on homework time (95% CI: 2.47 to 3.14) than the reference group and reduced their daily total screen-viewing time by 6.4% (95% CI: -9.6 to -3.3%, approximately 10 min). The positive effects were more pronounced among high-risk groups (secondary school and urban pupils who generally spend more time in sedentary behaviour) than in low-risk groups (primary school and rural pupils who generally spend less time in sedentary behaviour). The exploratory analyses showed comparable findings. CONCLUSIONS: This regulatory intervention has been effective in reducing total and specific types of sedentary behaviour among Chinese children and adolescents, with the potential to reduce health inequalities. International researchers and policy makers may explore the feasibility and acceptability of implementing regulatory interventions on sedentary behaviour elsewhere. CI - (c) 2024. The Author(s). FAU - Li, Bai AU - Li B AUID- ORCID: 0000-0003-2706-9799 AD - Centre for Exercise, Nutrition and Health Sciences, School for Policy Studies, University of Bristol, Bristol, UK. bai.li@bristol.ac.uk. FAU - Valerino-Perea, Selene AU - Valerino-Perea S AD - Public Health Wales, Cardiff, UK. FAU - Zhou, Weiwen AU - Zhou W AD - Department of Nutrition and School Health, Guangxi Center for Disease Control and Prevention, Nanning, Guangxi, China. FAU - Xie, Yihong AU - Xie Y AD - School of Public Health, Guangxi Medical University, Nanning, Guangxi, China. FAU - Syrett, Keith AU - Syrett K AD - Centre for Health, Law, and Society, School of Law, University of Bristol, Bristol, UK. FAU - Peters, Remco AU - Peters R AD - Centre for Exercise, Nutrition and Health Sciences, School for Policy Studies, University of Bristol, Bristol, UK. FAU - He, Zouyan AU - He Z AD - School of Public Health, Guangxi Medical University, Nanning, Guangxi, China. FAU - Zou, Yunfeng AU - Zou Y AD - School of Public Health, Guangxi Medical University, Nanning, Guangxi, China. FAU - de Vocht, Frank AU - de Vocht F AD - Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK. AD - NIHR Applied Research Collaboration West (ARC West), Bristol, UK. FAU - Foster, Charlie AU - Foster C AD - Centre for Exercise, Nutrition and Health Sciences, School for Policy Studies, University of Bristol, Bristol, UK. LA - eng GR - WT_/Wellcome Trust/United Kingdom GR - 204813/Z/16/Z/WT_/Wellcome Trust/United Kingdom PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20240513 PL - England TA - Int J Behav Nutr Phys Act JT - The international journal of behavioral nutrition and physical activity JID - 101217089 SB - IM EIN - Int J Behav Nutr Phys Act. 2024 Dec 12;21(1):139. doi: 10.1186/s12966-024-01695-3. PMID: 39668358 MH - Humans MH - *Sedentary Behavior MH - Adolescent MH - Male MH - Female MH - Child MH - China MH - Cross-Sectional Studies MH - Screen Time MH - Video Games MH - Health Promotion/methods MH - Adolescent Behavior MH - Longitudinal Studies MH - Exercise MH - Students MH - Child Behavior/psychology MH - Schools PMC - PMC11089804 OTO - NOTNLM OT - Child health OT - Health policy OT - Health promotion OT - Mental health OT - Natural experiment OT - Physical activity OT - Regulatory intervention OT - Screen time OT - Sedentary behaviour OT - Well-being COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential competing interest. EDAT- 2024/05/13 00:43 MHDA- 2024/05/13 00:44 PMCR- 2024/05/13 CRDT- 2024/05/12 23:14 PHST- 2023/12/20 00:00 [received] PHST- 2024/04/04 00:00 [accepted] PHST- 2024/05/13 00:44 [medline] PHST- 2024/05/13 00:43 [pubmed] PHST- 2024/05/12 23:14 [entrez] PHST- 2024/05/13 00:00 [pmc-release] AID - 10.1186/s12966-024-01591-w [pii] AID - 1591 [pii] AID - 10.1186/s12966-024-01591-w [doi] PST - epublish SO - Int J Behav Nutr Phys Act. 2024 May 13;21(1):53. doi: 10.1186/s12966-024-01591-w. PMID- 38703752 OWN - NLM STAT- MEDLINE DCOM- 20240608 LR - 20260630 IS - 1096-0457 (Electronic) IS - 0022-0965 (Linking) VI - 244 DP - 2024 Aug TI - Altered development of face recognition among infants born amid the COVID-19 pandemic. PG - 105942 LID - S0022-0965(24)00082-1 [pii] LID - 10.1016/j.jecp.2024.105942 [doi] AB - To effectively contain the spread of COVID-19, public health agencies mandated special regulations. Although they protected us from COVID-19, these restrictions have inevitably changed the environment around us. It remains unclear how these changes may have affected early cognitive development among infants born during the pandemic. Thus, this study examined how the COVID-19 restrictions have affected infants' face recognition ability, a hallmark of their cognitive capacities. Specifically, we used the familiarization and visual pair comparison paradigm to examine face recognition performance among infants aged 6 to 14 months amid the second wave of the pandemic (February to July 2021). Experiment 1 investigated the recognition of unmasked faces and found that only younger infants, but not older infants, recognized faces by showing a novelty preference. Experiment 2 examined the recognition of faces wearing masks and found that only older infants, but not younger ones, recognized faces by exhibiting a familiarity preference. These results suggest that with limited interactions during the pandemic, infants could have developed an overly specialized face processing ability that failed to recognize the faces of strangers. Moreover, infants could have obtained more information on masked faces during the pandemic and adapted to the current situation. In Expreiment 3, we further confirmed the restriction on infants' interpersonal experiences with a survey conducted both before and during the pandemic. Overall, these findings demonstrated how the pandemic altered early perceptual development and further confirmed that interpersonal experiences during infancy are critical in their cognitive development. CI - Copyright (c) 2024 The Author(s). Published by Elsevier Inc. All rights reserved. FAU - Kim, Kate Kyuri AU - Kim KK AD - Department of Psychology, Neuroscience & Behaviour, McMaster University, Hamilton, Ontario L8S 4L8, Canada. FAU - Fang, Wei AU - Fang W AD - Department of Psychology, Neuroscience & Behaviour, McMaster University, Hamilton, Ontario L8S 4L8, Canada. FAU - Liu, Anna Y AU - Liu AY AD - Department of Psychology, Neuroscience & Behaviour, McMaster University, Hamilton, Ontario L8S 4L8, Canada. FAU - Panesar, Darshan AU - Panesar D AD - Applied Psychology and Human Development, Ontario Institute for Studies in Education, Toronto, Ontario M5S 1V6, Canada. FAU - Xiao, Naiqi G AU - Xiao NG AD - Department of Psychology, Neuroscience & Behaviour, McMaster University, Hamilton, Ontario L8S 4L8, Canada. Electronic address: xiaon8@mcmaster.ca. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20240503 PL - United States TA - J Exp Child Psychol JT - Journal of experimental child psychology JID - 2985128R SB - IM MH - Humans MH - *COVID-19/psychology/prevention & control/epidemiology MH - Female MH - *Facial Recognition MH - Infant MH - Male MH - *Child Development MH - Recognition, Psychology MH - SARS-CoV-2 MH - Pandemics OTO - NOTNLM OT - COVID-19 OT - Face recognition OT - Infancy OT - Online study EDAT- 2024/05/05 07:47 MHDA- 2024/06/09 09:42 CRDT- 2024/05/04 18:15 PHST- 2023/10/09 00:00 [received] PHST- 2024/01/25 00:00 [revised] PHST- 2024/03/25 00:00 [accepted] PHST- 2024/06/09 09:42 [medline] PHST- 2024/05/05 07:47 [pubmed] PHST- 2024/05/04 18:15 [entrez] AID - S0022-0965(24)00082-1 [pii] AID - 10.1016/j.jecp.2024.105942 [doi] PST - ppublish SO - J Exp Child Psychol. 2024 Aug;244:105942. doi: 10.1016/j.jecp.2024.105942. Epub 2024 May 3. PMID- 38689272 OWN - NLM STAT- MEDLINE DCOM- 20240430 LR - 20241231 IS - 1471-2458 (Electronic) IS - 1471-2458 (Linking) VI - 24 IP - 1 DP - 2024 Apr 30 TI - School-aged children's movement behaviours and subjective health complaints in Japan: a cross-sectional study during COVID-19 pandemic-related school closures and after school reopenings. PG - 1204 LID - 10.1186/s12889-024-18712-6 [doi] LID - 1204 AB - BACKGROUND: Social restrictions associated with the COVID-19 pandemic have altered children's movement behaviours and impacted their mental health. However, the influence of social restrictions on subjective health complaints remains inadequately understood. This study compared adherence to 24-hour movement behaviour guidelines and the prevalence of subjective health complaints during school closure and one year after reopening. We also examined how combinations of adherence to movement behaviour recommendations relate to subjective health complaints. METHODS: A repeated cross-sectional survey was conducted at two points. The first survey in May 2020 included 1535 (766 boys and 769 girls) participants during school closures, while the second survey from May to July 2021 involved 1125 (583 boys and 542 girls) participants one year after school reopening. The questionnaire covered socio-demographics, physical activity, screen time, sleep, and subjective health complaints. Differences between periods were analysed using chi-square tests. Logistic regression models assessed the association between adherence to guidelines and subjective health complaints. RESULTS: During school closure, children were more likely to meet 'only sleep' recommendations and have irritability and lethargy symptoms. Irrespective of sex, those adhering to two or all three recommendations (excluding physical activity and screen time) had a lower risk of symptoms related to physical and mental pain, fatigue, irritability, and lethargy as compared to those who met none of the recommendations. CONCLUSIONS: Children should meet at least one physical activity or screen time recommendation in addition to sleep recommendations for subjective health. Strategies considering the priority of each movement behaviour are crucial, even during abnormal situations, such as pandemic-related social restrictions. This study offers insightful findings concerning children's mental health issues during unprecedented and massive disasters or crises. CI - (c) 2024. The Author(s). FAU - Kasai, Akane AU - Kasai A AD - Graduate School of Health and Sport Science, Nippon Sport Science University, Tokyo, Japan. FAU - Shikano, Akiko AU - Shikano A AD - Research Institute for Children's Physical Health, Nippon Sport Science University, Tokyo, Japan. FAU - Tanaka, Ryo AU - Tanaka R AD - School of Sport Sciences, Osaka University of Health and Sport Sciences, Osaka, Japan. FAU - Yoshinaga, Mari AU - Yoshinaga M AD - Faculty of Pharmaceutical Science, Showa Pharmaceutical University, Tokyo, Japan. FAU - Noi, Shingo AU - Noi S AD - Research Institute for Children's Physical Health, Nippon Sport Science University, Tokyo, Japan. nois@nittai.ac.jp. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20240430 PL - England TA - BMC Public Health JT - BMC public health JID - 100968562 SB - IM MH - Humans MH - *COVID-19/epidemiology/prevention & control/psychology MH - Cross-Sectional Studies MH - Male MH - Female MH - Japan/epidemiology MH - Child MH - *Schools MH - *Exercise/psychology MH - Screen Time MH - Pandemics MH - Sleep MH - Adolescent MH - Surveys and Questionnaires MH - Child Behavior/psychology MH - Diagnostic Self Evaluation PMC - PMC11061910 OTO - NOTNLM OT - 24-hour movement behaviour guidelines OT - Mental health OT - Physical activity OT - Psychosomatic symptoms OT - Screen time OT - Sleep COIS- The authors declare no competing interests. EDAT- 2024/05/01 01:49 MHDA- 2024/05/01 01:50 PMCR- 2024/04/30 CRDT- 2024/04/30 23:37 PHST- 2024/02/13 00:00 [received] PHST- 2024/04/24 00:00 [accepted] PHST- 2024/05/01 01:50 [medline] PHST- 2024/05/01 01:49 [pubmed] PHST- 2024/04/30 23:37 [entrez] PHST- 2024/04/30 00:00 [pmc-release] AID - 10.1186/s12889-024-18712-6 [pii] AID - 18712 [pii] AID - 10.1186/s12889-024-18712-6 [doi] PST - epublish SO - BMC Public Health. 2024 Apr 30;24(1):1204. doi: 10.1186/s12889-024-18712-6. PMID- 38682788 OWN - NLM STAT- MEDLINE DCOM- 20240429 LR - 20250711 IS - 1469-493X (Electronic) IS - 1361-6137 (Linking) VI - 4 IP - 4 DP - 2024 Apr 29 TI - Appendectomy versus antibiotic treatment for acute appendicitis. PG - CD015038 LID - 10.1002/14651858.CD015038.pub2 [doi] LID - CD015038 AB - BACKGROUND: Acute appendicitis is one of the most common emergency general surgical conditions worldwide. Uncomplicated/simple appendicitis can be treated with appendectomy or antibiotics. Some studies have suggested possible benefits with antibiotics with reduced complications, length of hospital stay, and the number of days off work. However, surgery may improve success of treatment as antibiotic treatment is associated with recurrence and future need for surgery. OBJECTIVES: To assess the effects of antibiotic treatment for uncomplicated/simple acute appendicitis compared with appendectomy for resolution of symptoms and complications. SEARCH METHODS: We searched CENTRAL, MEDLINE, Embase, and two trial registers (World Health Organization International Clinical Trials Registry Platform and ClinicalTrials.gov) on 19 July 2022. We also searched for unpublished studies in conference proceedings together with reference checking and citation search. There were no restrictions on date, publication status, or language of publication. SELECTION CRITERIA: We included parallel-group randomised controlled trials (RCTs) only. We included studies where most participants were adults with uncomplicated/simple appendicitis. Interventions included antibiotics (by any route) compared with appendectomy (open or laparoscopic). DATA COLLECTION AND ANALYSIS: We used standard methodology expected by Cochrane. We used GRADE to assess the certainty of evidence for each outcome. Primary outcomes included mortality and success of treatment, and secondary outcomes included number of participants requiring appendectomy in the antibiotic group, complications, pain, length of hospital stay, sick leave, malignancy in the antibiotic group, negative appendectomy rate, and quality of life. Success of treatment definitions were heterogeneous although mainly based on resolution of symptoms rather than incorporation of long-term recurrence or need for surgery in the antibiotic group. MAIN RESULTS: We included 13 studies in the review covering 1675 participants randomised to antibiotics and 1683 participants randomised to appendectomy. One study was unpublished. All were conducted in secondary care and two studies received pharmaceutical funding. All studies used broad-spectrum antibiotic regimens expected to cover gastrointestinal bacteria. Most studies used predominantly laparoscopic surgery, but some included mainly open procedures. Six studies included adults and children. Almost all studies aimed to exclude participants with complicated appendicitis prior to randomisation, although one study included 12% with perforation. The diagnostic technique was clinical assessment and imaging in most studies. Only one study limited inclusion by sex (male only). Follow-up ranged from hospital admission only to seven years. Certainty of evidence was mainly affected by risk of bias (due to lack of blinding and loss to follow-up) and imprecision. Primary outcomes It is uncertain whether there was any difference in mortality due to the very low-certainty evidence (Peto odds ratio (OR) 0.51, 95% confidence interval (CI) 0.05 to 4.95; 1 study, 492 participants). There may be 76 more people per 1000 having unsuccessful treatment in the antibiotic group compared with surgery, which did not reach our predefined level for clinical significance (risk ratio (RR) 0.91, 95% CI 0.87 to 0.96; I(2) = 69%; 7 studies, 2471 participants; low-certainty evidence). Secondary outcomes At one year, 30.7% (95% CI 24.0 to 37.8; I(2) = 80%; 9 studies, 1396 participants) of participants in the antibiotic group required appendectomy or, alternatively, more than two-thirds of antibiotic-treated participants avoided surgery in the first year, but the evidence is very uncertain. Regarding complications, it is uncertain whether there is any difference in episodes of Clostridium difficile diarrhoea due to very low-certainty evidence (Peto OR 0.97, 95% CI 0.24 to 3.89; 1 study, 1332 participants). There may be a clinically significant reduction in wound infections with antibiotics (RR 0.25, 95% CI 0.09 to 0.68; I(2) = 16%; 9 studies, 2606 participants; low-certainty evidence). It is uncertain whether antibiotics affect the incidence of intra-abdominal abscess or collection (RR 1.58, 95% CI 0.61 to 4.07; I(2) = 19%; 6 studies, 1831 participants), or reoperation (Peto OR 0.13, 95% CI 0.01 to 2.16; 1 study, 492 participants) due to very low-certainty evidence, mainly due to rare events causing imprecision and risk of bias. It is uncertain if antibiotics prolonged length of hospital stay by half a day due to the very low-certainty evidence (MD 0.54, 95% CI 0.06 to 1.01; I(2) = 97%; 11 studies, 3192 participants). The incidence of malignancy was 0.3% (95% CI 0 to 1.5; 5 studies, 403 participants) in the antibiotic group although follow-up was variable. Antibiotics probably increased the number of negative appendectomies at surgery (RR 3.16, 95% CI 1.54 to 6.49; I(2) = 17%; 5 studies, 707 participants; moderate-certainty evidence). AUTHORS' CONCLUSIONS: Antibiotics may be associated with higher rates of unsuccessful treatment for 76 per 1000 people, although differences may not be clinically significant. It is uncertain if antibiotics increase length of hospital stay by half a day. Antibiotics may reduce wound infections. A third of the participants initially treated with antibiotics required subsequent appendectomy or two-thirds avoided surgery within one year, but the evidence is very uncertain. There were too few data from the included studies to comment on major complications. CI - Copyright (c) 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. FAU - Doleman, Brett AU - Doleman B AD - Department of Surgery and Anaesthesia, Division of Medical Sciences and Graduate Entry Medicine, School of Medicine, University of Nottingham, Derby, UK. FAU - Fonnes, Siv AU - Fonnes S AD - Center for Perioperative Optimization, Department of Surgery, Herlev Hospital, Herlev, Denmark. FAU - Lund, Jon N AU - Lund JN AD - Division of Health Sciences, School of Medicine, University of Nottingham, Derby, UK. FAU - Boyd-Carson, Hannah AU - Boyd-Carson H AD - Department of Surgery, Division of Medical Sciences and Graduate Entry Medicine, School of Medicine, University of Nottingham, Derby, UK. FAU - Javanmard-Emamghissi, Hannah AU - Javanmard-Emamghissi H AD - Faculty of Medicine and Health Sciences, University of Nottingham, Nottinghamshire, UK. FAU - Moug, Susan AU - Moug S AD - Department of Surgery, Royal Alexandra Hospital, Paisley, UK. FAU - Hollyman, Marianne AU - Hollyman M AD - Department of General Surgery, Taunton and Somerset NHS Foundation Trust, Taunton, UK. FAU - Tierney, Gillian AU - Tierney G AD - Department of Surgery, Royal Derby Hospital, Derby, UK. FAU - Tou, Samson AU - Tou S AD - Department of Colorectal Surgery, Royal Derby Hospital, Derby, UK. FAU - Williams, John P AU - Williams JP AD - Department of Surgery and Anaesthesia, Division of Medical Sciences and Graduate Entry Medicine, School of Medicine, University of Nottingham, Derby, UK. LA - eng PT - Journal Article PT - Meta-Analysis PT - Research Support, Non-U.S. Gov't PT - Systematic Review DEP - 20240429 PL - England TA - Cochrane Database Syst Rev JT - The Cochrane database of systematic reviews JID - 100909747 RN - 0 (Anti-Bacterial Agents) SB - IM UOF - doi: 10.1002/14651858.CD015038 MH - *Appendicitis/surgery/drug therapy MH - Humans MH - *Appendectomy/adverse effects MH - *Anti-Bacterial Agents/therapeutic use MH - *Randomized Controlled Trials as Topic MH - *Length of Stay MH - Adult MH - Acute Disease MH - Bias MH - Quality of Life MH - Recurrence MH - Sick Leave/statistics & numerical data MH - Laparoscopy/adverse effects MH - Postoperative Complications MH - Male MH - Female PMC - PMC11057219 COIS- BD: collaborator on an acute appendicitis study in UK called COVIDHarem, which was not eligible for inclusion in the review (Javanmard-Emamghissi 2021). Has previously peer reviewed and received honorarium from Research Square. SF: Managing Editor at Cochrane Colorectal Group, but had no involvement in the editorial processes. JNL: collaborator on an acute appendicitis study in UK called COVIDHarem, which was not eligible for inclusion in the review (Javanmard-Emamghissi 2021). HBC: collaborator on an acute appendicitis study in UK called COVIDHarem, which was not eligible for inclusion in the review (Javanmard-Emamghissi 2021). HJE: collaborator on an acute appendicitis study in UK called COVIDHarem, which was not eligible for inclusion in the review (Javanmard-Emamghissi 2021). Has published two papers from an observational cohort study comparing operative and non-operative management of appendicitis. SM: collaborator on an acute appendicitis study in UK called COVIDHarem, which was not eligible for inclusion in the review. (Javanmard-Emamghissi 2021). MH: collaborator on an acute appendicitis study in UK called COVIDHarem, which was not eligible for inclusion in the review (Javanmard-Emamghissi 2021). GT: collaborator on an acute appendicitis study in UK called COVIDHarem, which is not eligible for inclusion in the review (Javanmard-Emamghissi 2021). Association of Surgeons of Great Britain and Ireland President. Often asked to comment in the press/social media/broadcast on behalf of the organisation. ST: Editor, Cochrane Colorectal Group, but had no involvement in the editorial processes. JPW: none. All review authors work as health professionals. EDAT- 2024/04/29 13:59 MHDA- 2024/04/29 14:00 PMCR- 2025/04/29 CRDT- 2024/04/29 07:45 PHST- 2024/04/29 14:00 [medline] PHST- 2024/04/29 13:59 [pubmed] PHST- 2024/04/29 07:45 [entrez] PHST- 2025/04/29 00:00 [pmc-release] AID - CD015038.pub2 [pii] AID - 10.1002/14651858.CD015038.pub2 [doi] PST - epublish SO - Cochrane Database Syst Rev. 2024 Apr 29;4(4):CD015038. doi: 10.1002/14651858.CD015038.pub2. PMID- 38586487 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240627 IS - 1205-7088 (Print) IS - 1918-1485 (Electronic) IS - 1205-7088 (Linking) VI - 29 IP - 2 DP - 2024 May TI - The acute care burden of asthma in children was profoundly reduced during the COVID-19 pandemic: A multi-centre Canadian retrospective study. PG - 98-103 LID - 10.1093/pch/pxad037 [doi] AB - OBJECTIVES: Asthma is a chronic lung condition that can be exacerbated when triggered by viruses. Pandemic public health restrictions aimed to reduce COVID-19 transmission indirectly effected other circulating viruses. This study assessed the impact of the pandemic and associated public health measures on acute paediatric asthma across four tertiary sites in three Canadian provinces. We queried whether pandemic-related changes would impair preventive care and delay presentation to care, increasing asthma exacerbation severity. METHODS: This retrospective study compared the frequency of acute care access and severity of presentation to emergency departments (ED) for acute asthma to four tertiary care children's hospitals during the COVID-19 pandemic (from March 17, 2020 to June 30, 2021) to a pre-lockdown control period (July 1, 2018 to March 16, 2020). Data was subjected to interrupted time series and Chi-square analysis. RESULTS: Our study included 26,316 acute asthma visits to ED. Sites experienced a 63% to 89% reduction in acute asthma visits during the pandemic, compared with pre-lockdown controls, and a 17% to 85% reduction in asthma, that is out of proportion as a fraction of all-cause ED visits. For asthma, there was no difference in severity measured by rate of ward admission or rate of Paediatric Intensive Care Unit (PICU) admission. CONCLUSIONS: Public health measures appear to have resulted in a specific protective association on acute asthma with reduced acute care utilization over and above the reduction in all-cause presentations, without an increase in severity upon presentation. Our study indicates an importance to antiviral public health and engineering strategies to reduce viral transmission and thereby asthma morbidity. CI - (c) The Author(s) 2023. Published by Oxford University Press on behalf of the Canadian Paediatric Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. FAU - McConnery, Jason R AU - McConnery JR AUID- ORCID: 0000-0002-5431-1010 AD - Division of Respiratory Medicine, The Hospital for Sick Children, 555 University Avenue, Toronto, Ontario. FAU - Bone, Jeffrey N AU - Bone JN AUID- ORCID: 0000-0001-7704-1677 AD - Department of Obstetrics and Gynecology, BC Children's Hospital, Vancouver. FAU - Goldman, Ran D AU - Goldman RD AD - Division of Emergency Medicine, Department of Pediatrics, University of British Columbia, BC Children's Hospital Research Institute, Vancouver, British Columbia. FAU - Hicks, Anne AU - Hicks A AUID- ORCID: 0000-0001-6553-3826 AD - Division of Pediatric Respiratory Medicine, Department of Pediatrics, University of Alberta, Edmonton, Alberta. FAU - Seaton, Claire AU - Seaton C AD - Division of Respirology, Department of Pediatrics, University of British Columbia and British Columbia Children's Hospital, Vancouver, British Columbia. FAU - Subbarao, Padmaja AU - Subbarao P AD - Division of Respiratory Medicine, The Hospital for Sick Children, 555 University Avenue, Toronto, Ontario. FAU - Moraes, Theo J AU - Moraes TJ AD - Division of Respiratory Medicine, The Hospital for Sick Children, 555 University Avenue, Toronto, Ontario. LA - eng PT - Journal Article DEP - 20230626 PL - England TA - Paediatr Child Health JT - Paediatrics & child health JID - 9815960 PMC - PMC10996573 OTO - NOTNLM OT - Acute care OT - Asthma OT - COVID-19 OT - Paediatrics OT - Pandemic COIS- JM reports a grant from the University of Toronto (Fellowship in Pediatric Respirology) and support from the Division of Respiratory Medicine to attend Canadian Respiratory Conference 2022. AH is a senior assistant editor for Paediatrics & Child Health. Another editor was assigned to oversee the editing and peer review of this manuscript. TJM reports grants from Canadian Institutes of Health Research (CIHR), PSI, CF Canada unrelated to this work, as well as payment received from CAMH, Covid Pharma, GSK, Sanofi (also unrelated to this work). PS holds a Tier 1 Canada Research Chair in Pediatric Asthma and Lung Health at the Hospital for Sick Children and the University of Toronto. These entities had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication. There are no other disclosures. EDAT- 2024/04/08 06:43 MHDA- 2024/04/08 06:44 PMCR- 2024/06/26 CRDT- 2024/04/08 04:47 PHST- 2023/01/03 00:00 [received] PHST- 2023/06/08 00:00 [accepted] PHST- 2024/04/08 06:44 [medline] PHST- 2024/04/08 06:43 [pubmed] PHST- 2024/04/08 04:47 [entrez] PHST- 2024/06/26 00:00 [pmc-release] AID - pxad037 [pii] AID - 10.1093/pch/pxad037 [doi] PST - epublish SO - Paediatr Child Health. 2023 Jun 26;29(2):98-103. doi: 10.1093/pch/pxad037. eCollection 2024 May. PMID- 38506817 OWN - NLM STAT- MEDLINE DCOM- 20240605 LR - 20260911 IS - 2168-6238 (Electronic) IS - 2168-622X (Print) IS - 2168-622X (Linking) VI - 81 IP - 6 DP - 2024 Jun 1 TI - Decoding Suicide Decedent Profiles and Signs of Suicidal Intent Using Latent Class Analysis. PG - 595-605 LID - 10.1001/jamapsychiatry.2024.0171 [doi] AB - IMPORTANCE: Suicide rates in the US increased by 35.6% from 2001 to 2021. Given that most individuals die on their first attempt, earlier detection and intervention are crucial. Understanding modifiable risk factors is key to effective prevention strategies. OBJECTIVE: To identify distinct suicide profiles or classes, associated signs of suicidal intent, and patterns of modifiable risks for targeted prevention efforts. DESIGN, SETTING, AND PARTICIPANTS: This cross-sectional study used data from the 2003-2020 National Violent Death Reporting System Restricted Access Database for 306 800 suicide decedents. Statistical analysis was performed from July 2022 to June 2023. EXPOSURES: Suicide decedent profiles were determined using latent class analyses of available data on suicide circumstances, toxicology, and methods. MAIN OUTCOMES AND MEASURES: Disclosure of recent intent, suicide note presence, and known psychotropic usage. RESULTS: Among 306 800 suicide decedents (mean [SD] age, 46.3 [18.4] years; 239 627 males [78.1%] and 67 108 females [21.9%]), 5 profiles or classes were identified. The largest class, class 4 (97 175 [31.7%]), predominantly faced physical health challenges, followed by polysubstance problems in class 5 (58 803 [19.2%]), and crisis, alcohol-related, and intimate partner problems in class 3 (55 367 [18.0%]), mental health problems (class 2, 53 928 [17.6%]), and comorbid mental health and substance use disorders (class 1, 41 527 [13.5%]). Class 4 had the lowest rates of disclosing suicidal intent (13 952 [14.4%]) and leaving a suicide note (24 351 [25.1%]). Adjusting for covariates, compared with class 1, class 4 had the highest odds of not disclosing suicide intent (odds ratio [OR], 2.58; 95% CI, 2.51-2.66) and not leaving a suicide note (OR, 1.45; 95% CI, 1.41-1.49). Class 4 also had the lowest rates of all known psychiatric illnesses and psychotropic medications among all suicide profiles. Class 4 had more older adults (23 794 were aged 55-70 years [24.5%]; 20 100 aged >/=71 years [20.7%]), veterans (22 220 [22.9%]), widows (8633 [8.9%]), individuals with less than high school education (15 690 [16.1%]), and rural residents (23 966 [24.7%]). CONCLUSIONS AND RELEVANCE: This study identified 5 distinct suicide profiles, highlighting a need for tailored prevention strategies. Improving the detection and treatment of coexisting mental health conditions, substance and alcohol use disorders, and physical illnesses is paramount. The implementation of means restriction strategies plays a vital role in reducing suicide risks across most of the profiles, reinforcing the need for a multifaceted approach to suicide prevention. FAU - Xiao, Yunyu AU - Xiao Y AD - Department of Population Health Sciences, Weill Cornell Medicine/NewYork-Presbyterian, New York. FAU - Bi, Kaiwen AU - Bi K AD - Department of Social Work and Social Administration, The University of Hong Kong, Hong Kong. FAU - Yip, Paul Siu-Fai AU - Yip PS AD - Department of Social Work and Social Administration, The University of Hong Kong, Hong Kong. AD - Hong Kong Jockey Club Centre for Suicide Research and Prevention, The University of Hong Kong, Hong Kong. FAU - Cerel, Julie AU - Cerel J AD - College of Social Work, University of Kentucky, Lexington. FAU - Brown, Timothy T AU - Brown TT AD - School of Public Health, University of California, Berkeley. FAU - Peng, Yifan AU - Peng Y AD - Department of Population Health Sciences, Weill Cornell Medicine/NewYork-Presbyterian, New York. FAU - Pathak, Jyotishman AU - Pathak J AD - Department of Population Health Sciences, Weill Cornell Medicine/NewYork-Presbyterian, New York. FAU - Mann, J John AU - Mann JJ AD - Department of Psychiatry, Columbia University Irving Medical Center, Columbia University, New York, New York. AD - Department of Radiology, Columbia University Irving Medical Center, Columbia University, New York, New York. AD - Division of Molecular Imaging and Neuropathology, New York State Psychiatric Institute, New York. LA - eng GR - RF1 MH134649/MH/NIMH NIH HHS/United States PT - Journal Article PL - United States TA - JAMA Psychiatry JT - JAMA psychiatry JID - 101589550 SB - IM MH - Humans MH - Male MH - Female MH - Middle Aged MH - Cross-Sectional Studies MH - Adult MH - *Latent Class Analysis MH - United States/epidemiology MH - Suicidal Ideation MH - Aged MH - Suicide, Attempted/statistics & numerical data/psychology MH - Young Adult MH - Suicide, Completed/statistics & numerical data/psychology MH - Risk Factors MH - Suicide/statistics & numerical data/psychology MH - Adolescent MH - Substance-Related Disorders/epidemiology/psychology PMC - PMC10955339 COIS- Conflict of Interest Disclosures: Dr Mann reported royalties for commercial use of the Columbia-Suicide Severity Rating Scale from the Research Foundation for Mental Hygiene. No other disclosures were reported. EDAT- 2024/03/20 12:43 MHDA- 2024/06/05 13:11 PMCR- 2024/03/20 CRDT- 2024/03/20 11:35 PHST- 2024/06/05 13:11 [medline] PHST- 2024/03/20 12:43 [pubmed] PHST- 2024/03/20 11:35 [entrez] PHST- 2024/03/20 00:00 [pmc-release] AID - 2816483 [pii] AID - yoi240006 [pii] AID - 10.1001/jamapsychiatry.2024.0171 [doi] PST - ppublish SO - JAMA Psychiatry. 2024 Jun 1;81(6):595-605. doi: 10.1001/jamapsychiatry.2024.0171. PMID- 38498510 OWN - NLM STAT- MEDLINE DCOM- 20240320 LR - 20260831 IS - 1932-6203 (Electronic) IS - 1932-6203 (Linking) VI - 19 IP - 3 DP - 2024 TI - Health-related quality of life during the COVID-19 pandemic: The impact of restrictive measures using data from two Dutch population-based cohort studies. PG - e0300324 LID - 10.1371/journal.pone.0300324 [doi] LID - e0300324 AB - OBJECTIVES: We describe health-related quality of life during the COVID-19 pandemic in the general Dutch population and correlations with restrictive measures. METHODS: Data were obtained from 18-85 year-old participants of two population-based cohort studies (February 2021-July 2022): PIENTER Corona (n = 8,019) and VASCO (n = 45,413). Per cohort, mean scores of mental and physical health and health utility from the SF-12 were calculated by age group, sex and presence of a medical risk condition. Spearman correlations with stringency of measures were calculated. RESULTS: Both cohorts showed comparable results. Participants <30 years had lowest health utility and mental health score, and highest physical health score. Health utility and mental health score increased with age (up to 79 years), while physical health score decreased with age. Women and participants with a medical risk condition scored lower than their counterparts. Fluctuations were small over time but most pronounced among participants <60 years, and correlated weakly, but mostly positively with measure stringency. CONCLUSIONS: During the Dutch COVID-19 epidemic, health utility and mental health scores were lower and fluctuated strongest among young adults compared to older adults. In our study population, age, sex and presence of a medical risk condition seemed to have more impact on health scores than stringency of COVID-19 non-pharmaceutical interventions. CI - Copyright: (c) 2024 van Hagen et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. FAU - van Hagen, Cheyenne C E AU - van Hagen CCE AUID- ORCID: 0009-0001-8235-232X AD - Centre for Infectious Disease Control, National Institute for Public Health and Environment (RIVM), Bilthoven, the Netherlands. FAU - Huiberts, Anne J AU - Huiberts AJ AUID- ORCID: 0000-0003-3206-9777 AD - Centre for Infectious Disease Control, National Institute for Public Health and Environment (RIVM), Bilthoven, the Netherlands. FAU - Mutubuki, Elizabeth N AU - Mutubuki EN AD - Centre for Infectious Disease Control, National Institute for Public Health and Environment (RIVM), Bilthoven, the Netherlands. FAU - de Melker, Hester E AU - de Melker HE AD - Centre for Infectious Disease Control, National Institute for Public Health and Environment (RIVM), Bilthoven, the Netherlands. FAU - Vos, Eric R A AU - Vos ERA AD - Centre for Infectious Disease Control, National Institute for Public Health and Environment (RIVM), Bilthoven, the Netherlands. FAU - van de Wijgert, Janneke H H M AU - van de Wijgert JHHM AD - Centre for Infectious Disease Control, National Institute for Public Health and Environment (RIVM), Bilthoven, the Netherlands. AD - Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht (UMCU), Utrecht, the Netherlands. FAU - van den Hof, Susan AU - van den Hof S AD - Centre for Infectious Disease Control, National Institute for Public Health and Environment (RIVM), Bilthoven, the Netherlands. FAU - Knol, Mirjam J AU - Knol MJ AD - Centre for Infectious Disease Control, National Institute for Public Health and Environment (RIVM), Bilthoven, the Netherlands. FAU - van Hoek, Albert Jan AU - van Hoek AJ AD - Centre for Infectious Disease Control, National Institute for Public Health and Environment (RIVM), Bilthoven, the Netherlands. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20240318 PL - United States TA - PLoS One JT - PloS one JID - 101285081 SB - IM MH - Young Adult MH - Humans MH - Female MH - Aged MH - Adolescent MH - Adult MH - Middle Aged MH - Aged, 80 and over MH - *Quality of Life/psychology MH - *COVID-19/epidemiology MH - Pandemics MH - Mental Health MH - Cohort Studies PMC - PMC10947685 COIS- The authors have declared that no competing interests exist. EDAT- 2024/03/19 00:42 MHDA- 2024/03/20 06:45 PMCR- 2024/03/18 CRDT- 2024/03/18 13:38 PHST- 2023/08/22 00:00 [received] PHST- 2024/02/23 00:00 [accepted] PHST- 2024/03/20 06:45 [medline] PHST- 2024/03/19 00:42 [pubmed] PHST- 2024/03/18 13:38 [entrez] PHST- 2024/03/18 00:00 [pmc-release] AID - PONE-D-23-26762 [pii] AID - 10.1371/journal.pone.0300324 [doi] PST - epublish SO - PLoS One. 2024 Mar 18;19(3):e0300324. doi: 10.1371/journal.pone.0300324. eCollection 2024. PMID- 38485068 OWN - NLM STAT- MEDLINE DCOM- 20240918 LR - 20261024 IS - 1532-8503 (Electronic) IS - 1051-2276 (Linking) VI - 34 IP - 5 DP - 2024 Sep TI - A Systematic Review of Online Resources for the Dietary Management of Hyperphosphatemia in People With Chronic Kidney Disease. PG - 410-417 LID - S1051-2276(24)00033-5 [pii] LID - 10.1053/j.jrn.2024.01.005 [doi] AB - OBJECTIVE: Internet search engines and social media websites are prominent and growing sources of dietary information for people with chronic kidney disease (CKD) and their healthcare providers. However, nutrition therapy for CKD is undergoing a paradigm shift, which may lead to inconsistent advice for managing hyperphosphatemia. The aim of this study was to summarize and evaluate online resources for phosphorus-specific nutrition therapy. DESIGN AND METHODS: Patient-facing resources were collected from Google, Yahoo, and Facebook in June-July 2021. Using nine independent search terms, the first 100 hits were reviewed. Dietary advice for food types, food groups, food subgroups, and individual food items was categorized as "restricted," "recommended," "mixed," and "not mentioned." Information on publication date, source, and author(s), phosphorus bioavailability, and demineralization were also collected. RESULTS: After removing duplicates, 199 resources from Google and Yahoo and 33 from Facebook were reviewed. Resources ranged from 2005 to 2021 and were primarily authored by registered dietitians and medical doctors (65% and 31%, respectively). Dietary advice mostly focuses on restricting high-phosphorus foods and phosphorus additive-based processed foods. Dietary restrictions were generally consistent with the traditional low-phosphorus diet, which targets whole grains, dairy, and plant-based protein foods, although major inconsistencies were noted. Phosphorus bioavailability and demineralization were rarely mentioned (16% and 8%, respectively). Similar findings were found on Facebook, but the limited number of resources limited meaningful comparisons. CONCLUSION: Results showed that online resources for phosphorus-specific nutrition therapy are highly restrictive of heart-healthy food items and contain significant inconsistencies. Given the widespread and increasing use of online resources by people with CKD and health care professionals to inform dietary choices, efforts are urgently needed to establish consensus for phosphorus-specific nutrition therapy. Until then, the findings of this study provide a basis for increasing awareness of the potential for confusion arising from online resources. CI - Copyright (c) 2024 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved. FAU - Begum, Most Murshida AU - Begum MM AD - Department of Nutrition, University of Nevada, Reno, Nevada. FAU - Biruete, Annabel AU - Biruete A AD - Department of Nutrition Science, Purdue University, West Lafayette, Indiana. FAU - Kistler, Brandon AU - Kistler B AD - Department of Nutrition Science, Purdue University, West Lafayette, Indiana. FAU - Meade, Anthony AU - Meade A AD - Central Northern Adelaide Renal and Transplantation Service Department, Royal Adelaide Hospital, Adelaide, South Australia, Australia. FAU - Westhoff, John AU - Westhoff J AD - Department of Internal Medicine, School of Medicine, University of Nevada, Reno, Nevada. FAU - St-Jules, David E AU - St-Jules DE AD - Department of Nutrition, University of Nevada, Reno, Nevada. Electronic address: stjules@unr.edu. LA - eng PT - Journal Article PT - Systematic Review DEP - 20240313 PL - United States TA - J Ren Nutr JT - Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation JID - 9112938 RN - 0 (Phosphorus, Dietary) SB - IM MH - Humans MH - *Hyperphosphatemia/diet therapy MH - *Renal Insufficiency, Chronic/diet therapy/therapy/complications MH - *Internet MH - Phosphorus, Dietary/administration & dosage MH - Nutrition Therapy/methods MH - Social Media OTO - NOTNLM OT - Chronic kidney disease OT - hyperphosphatemia OT - low-phosphorus diet OT - online resources EDAT- 2024/03/15 00:43 MHDA- 2024/09/19 00:55 CRDT- 2024/03/14 20:30 PHST- 2023/07/20 00:00 [received] PHST- 2024/01/22 00:00 [revised] PHST- 2024/01/28 00:00 [accepted] PHST- 2024/09/19 00:55 [medline] PHST- 2024/03/15 00:43 [pubmed] PHST- 2024/03/14 20:30 [entrez] AID - S1051-2276(24)00033-5 [pii] AID - 10.1053/j.jrn.2024.01.005 [doi] PST - ppublish SO - J Ren Nutr. 2024 Sep;34(5):410-417. doi: 10.1053/j.jrn.2024.01.005. Epub 2024 Mar 13. PMID- 38464035 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240820 IS - 2693-5015 (Electronic) IS - 2693-5015 (Linking) DP - 2024 Mar 1 TI - IQOS point-of-sale marketing: a comparison between Arab and Jewish neighborhoods in Israel. LID - rs.3.rs-3953025 [pii] LID - 10.21203/rs.3.rs-3953025/v1 [doi] AB - BACKGROUND: Philip Morris International's (PMI) IQOS, with its heatsticks (HEETS), is the heated tobacco product with the largest global market share. IQOS and/or electronic cigarettes use rate is higher among Arabs vs. Jews in Israel. This paper aims to compare IQOS point-of-sale (POS) marketing strategies, and regulatory compliance in Arab vs. Jewish neighborhoods in Israel. METHODS: We integrated data from two separate studies including a cross-sectional survey with IQOS retailers (December 2020-April 2021) and audits of POS that sold IQOS/HEETS (April 2021-July 2021) in 5 large cities in Israel, after marketing restrictions including a POS display ban and plain packaging became effective in Israel (January 2020). The survey included 69 POS (21 Arab, 48 Jewish neighborhoods) and the audits included 129 POS (48 Arab, 81 Jewish neighborhoods). Comparisons of IQOS marketing strategies between POS in Arab and Jewish neighborhoods were conducted using Chi-Square test, Fisher's exact test or Mann-Whitney test, as appropriate. Thematic analysis was used to analyze open-ended questions. RESULTS: Most marketing strategies, such as promotions to customers, were uniform across POS in Arab and Jewish neighborhoods. The most noteworthy differences were that a higher proportion of retailers from Arab neighborhoods were invited to IQOS parties (47.6% vs. 21.7%, p<0.05) and reported personal communication with a PMI representative (80.0% vs. 51.2%, p<0.05). Additionally, PMI representatives assisted POS in both Arab and Jewish neighborhoods in implementing the display ban by providing free compliant cabinets and product placement instructions, and directly interacted with customers. POS in Arab neighborhoods were more compliant with the display ban (25.5% vs. 8.8%, p<0.05), but less compliant with plain packaging (62.5% vs. 79.3%, p<0.05). CONCLUSIONS: There were not many notable differences in IQOS marketing across POS in Arab vs. Jewish neighborhoods, but PMI utilized marketing elements of cultural significance, especially for POS in Arab neighborhoods, such as more personal communication and invitation to social events. Continuous surveillance of tobacco POS marketing and legislation compliance is needed, with a special focus on demographic/location-based differences. FAU - Khayat, Amal AU - Khayat A AUID- ORCID: 0000-0003-0525-4889 AD - Hebrew University of Jerusalem Braun School of Public Health and Community Medicine. FAU - Levine, Hagai AU - Levine H AD - Hebrew University of Jerusalem Braun School of Public Health and Community Medicine. FAU - Berg, Carla J AU - Berg CJ AD - George Washington University School of Public Health and Health Services: The George Washington University Milken Institute of Public Health. FAU - Abroms, Lorien C AU - Abroms LC AD - George Washington University School of Public Health and Health Services: The George Washington University Milken Institute of Public Health. FAU - Duan, Zongshuan AU - Duan Z AD - Georgia State University School of Public Health. FAU - Wang, Yan AU - Wang Y AD - George Washington University School of Public Health and Health Services: The George Washington University Milken Institute of Public Health. FAU - LoParco, Cassidy R AU - LoParco CR AD - George Washington University School of Public Health and Health Services: The George Washington University Milken Institute of Public Health. FAU - Elbaz, Daniel AU - Elbaz D AD - Hebrew University of Jerusalem Faculty of Medicine. FAU - Cui, Yuxian AU - Cui Y AD - George Washington University School of Public Health and Health Services: The George Washington University Milken Institute of Public Health. FAU - Bar-Zeev, Yael AU - Bar-Zeev Y AD - Hebrew University of Jerusalem Braun School of Public Health and Community Medicine. LA - eng GR - R01 CA239178/CA/NCI NIH HHS/United States PT - Journal Article PT - Preprint DEP - 20240301 PL - United States TA - Res Sq JT - Research square JID - 101768035 UIN - Isr J Health Policy Res. 2024 Aug 16;13(1):39. doi: 10.1186/s13584-024-00626-8. PMID: 39152466 PMC - PMC10925470 OTO - NOTNLM OT - IQOS OT - heated tobacco products OT - marketing OT - point-of-sale COIS- Competing interests YBZ has received fees for lectures from Pfizer Ltd, Novartis NCH, and GSK Consumer Health (distributors of smoking cessation pharmacotherapy in Israel) in the past (2012- July 2019). LA receives royalties for the sale of Text2Quit and is a shareholder in Welltok, Inc. EDAT- 2024/03/11 06:42 MHDA- 2024/03/11 06:43 PMCR- 2024/03/10 CRDT- 2024/03/11 04:30 PHST- 2024/03/11 06:42 [pubmed] PHST- 2024/03/11 06:43 [medline] PHST- 2024/03/11 04:30 [entrez] PHST- 2024/03/10 00:00 [pmc-release] AID - rs.3.rs-3953025 [pii] AID - 10.21203/rs.3.rs-3953025/v1 [doi] PST - epublish SO - Res Sq [Preprint]. 2024 Mar 1:rs.3.rs-3953025. doi: 10.21203/rs.3.rs-3953025/v1. PMID- 38453517 OWN - NLM STAT- MEDLINE DCOM- 20240311 LR - 20250530 IS - 2059-7908 (Print) IS - 2059-7908 (Electronic) IS - 2059-7908 (Linking) VI - 9 IP - 3 DP - 2024 Mar 7 TI - The impact of policy and policy communication on COVID-19 vaccination inequalities among Venezuelan refugees and migrants in Colombia: a comparative cross-sectional interrupted time-series analysis. LID - 10.1136/bmjgh-2023-014464 [doi] LID - e014464 AB - INTRODUCTION: Equitable access to vaccines for migrants and refugees is necessary to ensure their right to health and to achieve public health goals of reducing vaccine-preventable illness. Public health policies require regulatory frameworks and communication to effect uptake of effective vaccines among the target population. In Colombia, the National COVID-19 Vaccination Plan implicitly included Venezuelan refugees and migrants; however, initial communication of the policy indicated that vaccine availability was restricted to people with regular migration status. We estimated the impact of a public announcement, which clarified access for refugees and migrants, on vaccination coverage among Venezuelans living in Colombia. METHODS: Between 30 July 2021 and 5 February 2022, 6221 adult Venezuelans participated in a cross-sectional, population-based health survey. We used a comparative cross-sectional time-series analysis to estimate the effect of the October 2021 announcement on the average biweekly change in COVID-19 vaccine coverage of Venezuelans with regular and irregular migration status. RESULTS: 71% of Venezuelans had an irregular status. The baseline (preannouncement) vaccine coverage was lower among people with an irregular status but increased at similar rates as those with a regular status. After the announcement, there was a level change of 14.49% (95% CI: 1.57 to 27.42, p=0.03) in vaccination rates among individuals with irregular migration status with a 4.61% increase in vaccination rate per biweekly period (95% CI: 1.71 to 7.51, p=0.004). By February 2022, there was a 26.2% relative increase in vaccinations among individuals with irregular migration status compared with what was expected without the announcement. CONCLUSION: While there was no policy change, communication clarifying the policy drastically reduced vaccination inequalities across migration status. Lessons can be translated from the COVID-19 pandemic into more effective global, regional and local public health emergency preparedness and response to displacement. CI - (c) Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. FAU - Gomez, Wilson AU - Gomez W AUID- ORCID: 0009-0008-3751-7907 AD - Center for Public Health and Human Rights, Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA. FAU - Fernandez-Nino, Julian A AU - Fernandez-Nino JA AD - Center for Humanitarian Health, Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA. FAU - Guillen, Jose Rafael AU - Guillen JR AD - Red Somos, Bogota, Colombia. FAU - Stevenson, Megan AU - Stevenson M AD - Center for Public Health and Human Rights, Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA. FAU - Ortiz, Jennifer AU - Ortiz J AD - Red Somos, Bogota, Colombia. FAU - Barriga Talero, Miguel Angel AU - Barriga Talero MA AD - Red Somos, Bogota, Colombia. FAU - Lopez, Jhon Jairo AU - Lopez JJ AD - Red Somos, Bogota, Colombia. FAU - Nunez, Ricardo Luque AU - Nunez RL AD - Government of Colombia Ministry of Health and Social Protection, Bogota, Colombia. FAU - Spiegel, Paul AU - Spiegel P AUID- ORCID: 0000-0002-6158-6661 AD - Center for Humanitarian Health, Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA. FAU - Page, Kathleen R AU - Page KR AD - Center for Public Health and Human Rights, Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA. AD - Center for Humanitarian Health, Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA. AD - Medicine, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA. FAU - Ramirez Correa, Jhon Fredy AU - Ramirez Correa JF AD - Red Somos, Bogota, Colombia. FAU - Porras, Damary Martinez AU - Porras DM AD - Red Somos, Bogota, Colombia. FAU - Wirtz, Andrea L AU - Wirtz AL AUID- ORCID: 0000-0002-2063-1534 AD - Center for Public Health and Human Rights, Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA awirtz1@jhu.edu. AD - Center for Humanitarian Health, Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA. LA - eng PT - Journal Article DEP - 20240307 PL - England TA - BMJ Glob Health JT - BMJ global health JID - 101685275 RN - 0 (COVID-19 Vaccines) RN - Venezuelan people SB - IM MH - Adult MH - Humans MH - Colombia/epidemiology MH - Communication MH - *COVID-19/prevention & control MH - *COVID-19 Vaccines MH - Cross-Sectional Studies MH - Health Policy MH - Pandemics MH - *Refugees MH - *South American People MH - *Transients and Migrants MH - Vaccination PMC - PMC10921509 OTO - NOTNLM OT - COVID-19 OT - Health policies and all other topics OT - Vaccines COIS- Competing interests: None declared. EDAT- 2024/03/08 00:43 MHDA- 2024/03/11 06:42 PMCR- 2024/03/07 CRDT- 2024/03/07 21:53 PHST- 2023/11/07 00:00 [received] PHST- 2024/01/06 00:00 [accepted] PHST- 2024/03/11 06:42 [medline] PHST- 2024/03/08 00:43 [pubmed] PHST- 2024/03/07 21:53 [entrez] PHST- 2024/03/07 00:00 [pmc-release] AID - bmjgh-2023-014464 [pii] AID - 10.1136/bmjgh-2023-014464 [doi] PST - epublish SO - BMJ Glob Health. 2024 Mar 7;9(3):e014464. doi: 10.1136/bmjgh-2023-014464. PMID- 38444235 OWN - NLM STAT- MEDLINE DCOM- 20240911 LR - 20241009 IS - 1724-6016 (Electronic) IS - 1120-6721 (Linking) VI - 34 IP - 5 DP - 2024 Sep TI - Euthyroid graves' ophthalmopathy in a Chinese population: A cross-sectional follow-up study. PG - 1432-1437 LID - 10.1177/11206721241229470 [doi] AB - OBJECTIVES: A subtype of patients with thyroid eye disease (TED) were found to be euthyroid without prior thyroid dysfunction or treatment, known as Euthyroid Graves' Ophthalmopathy (EGO). We report the prevalence, clinical and serological phenotypes of EGO in a Chinese population. METHODS: A cross-sectional follow-up study. Ethnic Chinese TED patients were managed at the Thyroid Eye Clinic(TEC), Prince of Wales Hospital and TEC, the Chinese University of Hong Kong between September 2007 and July 2021. RESULTS: A total of 66 (5%) patients among the 1266 ethnic Han Chinese TED cohort were diagnosed as EGO, and 6 (9%)of them become dysthyroid over an average of 74-month follow-up. EGO patients were associated with a longer duration between onset of the symptoms to our first consultation (P < 0.0001), a higher male-to-female ratio (P = 0.0045) and a higher age of disease onset (P = 0.0092). Family history of thyroid disease was more common in TED patients (P = 0.0216) than in EGO patients. EGO patients were more likely to present unilaterally (P < 0.0001), and they have a larger difference in MRD1 (P < 0.0001), and extraocular motility (P < 0.0001) between the 2 eyes when compared to the TED patients. Notably, the extraocular motility restriction of the worst eye was more affected in EGO patients (P = 0.0113). The percentages of patients who received IVMP, ORT and emergency or elective surgeries(decompression or squint operation) between EGO and TED were similar. CONCLUSIONS: Understanding the important clinical phenotypes of EGO may help the clinician to make the correct diagnosis. Further study to compare EGO and TED is warranted. FAU - Lai, Kenneth Kh AU - Lai KK AUID- ORCID: 0000-0001-9579-2060 AD - Department of Ophthalmology and Visual Sciences, Faculty of Medicine, The Chinese University of Hong Kong, HKSAR, China. RINGGOLD: 26451 AD - Department of Ophthalmology and Visual Sciences, Prince of Wales Hospital, HKSAR, China. RINGGOLD: 13621 FAU - Ali Abdulla Aljufairi, Fatema Mohamed AU - Ali Abdulla Aljufairi FM AD - Department of Ophthalmology and Visual Sciences, Faculty of Medicine, The Chinese University of Hong Kong, HKSAR, China. RINGGOLD: 26451 AD - Department of Ophthalmology and Visual Sciences, Prince of Wales Hospital, HKSAR, China. RINGGOLD: 13621 AD - Department of Ophthalmology, Salmaniya Medical Complex, Government Hospitals, Bahrain. FAU - Sebastian, Jake Uy AU - Sebastian JU AD - Department of Ophthalmology and Visual Sciences, Faculty of Medicine, The Chinese University of Hong Kong, HKSAR, China. RINGGOLD: 26451 AD - Department of Ophthalmology and Visual Sciences, Prince of Wales Hospital, HKSAR, China. RINGGOLD: 13621 AD - Department of Ophthalmology, Vicente Sotto Memorial Medical Center, Cebu City, Philippines. FAU - Chin, Joyce Ky AU - Chin JK AD - Department of Ophthalmology and Visual Sciences, Prince of Wales Hospital, HKSAR, China. RINGGOLD: 13621 FAU - Choy, Eric Kh AU - Choy EK AD - Department of Ophthalmology and Visual Sciences, Faculty of Medicine, The Chinese University of Hong Kong, HKSAR, China. RINGGOLD: 26451 FAU - Yiu, Annika Hl AU - Yiu AH AD - Department of Ophthalmology and Visual Sciences, Faculty of Medicine, The Chinese University of Hong Kong, HKSAR, China. RINGGOLD: 26451 FAU - Lee, Alan Ch AU - Lee AC AD - Division of Endocrinology and Metabolism, Department of Medicine, Queen Mary Hospital, HKSAR, China. RINGGOLD: 26473 FAU - Ng, C M AU - Ng CM AD - Department of Medicine, Queen Elizabeth Hospital, HKSAR, China. RINGGOLD: 156807 FAU - Yip, Wilson Wk AU - Yip WW AD - Department of Ophthalmology and Visual Sciences, Prince of Wales Hospital, HKSAR, China. RINGGOLD: 13621 FAU - Young, Alvin L AU - Young AL AD - Department of Ophthalmology and Visual Sciences, Prince of Wales Hospital, HKSAR, China. RINGGOLD: 13621 FAU - Yuen, Hunter Kl AU - Yuen HK AD - Department of Ophthalmology and Visual Sciences, Faculty of Medicine, The Chinese University of Hong Kong, HKSAR, China. RINGGOLD: 26451 AD - Hong Kong Eye Hospital, HKSAR, China. RINGGOLD: 71113 FAU - Tham, Clement Cy AU - Tham CC AD - Department of Ophthalmology and Visual Sciences, Faculty of Medicine, The Chinese University of Hong Kong, HKSAR, China. RINGGOLD: 26451 AD - Department of Ophthalmology and Visual Sciences, Prince of Wales Hospital, HKSAR, China. RINGGOLD: 13621 AD - Hong Kong Eye Hospital, HKSAR, China. RINGGOLD: 71113 FAU - Pang, Chi Pui AU - Pang CP AD - Department of Ophthalmology and Visual Sciences, Faculty of Medicine, The Chinese University of Hong Kong, HKSAR, China. RINGGOLD: 26451 FAU - Chong, Kelvin Kl AU - Chong KK AUID- ORCID: 0000-0003-2587-1323 AD - Department of Ophthalmology and Visual Sciences, Faculty of Medicine, The Chinese University of Hong Kong, HKSAR, China. RINGGOLD: 26451 AD - Department of Ophthalmology and Visual Sciences, Prince of Wales Hospital, HKSAR, China. RINGGOLD: 13621 AD - Hong Kong Eye Hospital, HKSAR, China. RINGGOLD: 71113 LA - eng PT - Journal Article DEP - 20240305 PL - United States TA - Eur J Ophthalmol JT - European journal of ophthalmology JID - 9110772 SB - IM MH - Adult MH - Aged MH - Female MH - Humans MH - Male MH - Middle Aged MH - China/epidemiology MH - Cross-Sectional Studies MH - Follow-Up Studies MH - *Graves Ophthalmopathy/ethnology/epidemiology MH - Hong Kong/epidemiology MH - Prevalence MH - East Asian People OTO - NOTNLM OT - Diseases of the ocular surface < CORNEA / EXTERNAL DISEASE OT - OCULOPLASTIC EYELID /LACRIMAL DISEASE OT - eyelid disease < OCULOPLASTIC EYELID /LACRIMAL DISEASE OT - thyroid eye disease < ORBITAL DISEASE OT - thyroid ophthalmopathy < STRABISMUS COIS- Declaration of conflicting interestsThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. EDAT- 2024/03/06 06:43 MHDA- 2024/09/11 12:45 CRDT- 2024/03/06 02:23 PHST- 2024/09/11 12:45 [medline] PHST- 2024/03/06 06:43 [pubmed] PHST- 2024/03/06 02:23 [entrez] AID - 10.1177/11206721241229470 [doi] PST - ppublish SO - Eur J Ophthalmol. 2024 Sep;34(5):1432-1437. doi: 10.1177/11206721241229470. Epub 2024 Mar 5. PMID- 38413968 OWN - NLM STAT- MEDLINE DCOM- 20240229 LR - 20240301 IS - 1472-6963 (Electronic) IS - 1472-6963 (Linking) VI - 24 IP - 1 DP - 2024 Feb 27 TI - Evaluating a peer-to-peer health education program in Australian public housing communities during the COVID-19 pandemic. PG - 250 LID - 10.1186/s12913-024-10627-7 [doi] LID - 250 AB - BACKGROUND: The cohealth Health Concierge program operated in Melbourne, Australia from July 2020 to 30 June 2022. It provided peer-to-peer support to culturally and linguistically diverse residents of high-rise public housing. During this time, the COVID-19 public health response changed frequently and included movement restriction, testing and vaccination. We conducted a mixed-methods evaluation to determine the Health Concierge program's impact on residents' engagement with health services and public health activities. METHODS: The evaluation, informed by a Project Reference Group, used the RE-AIM framework. We analysed data from 20,901 routinely collected forms describing interactions between Concierges and residents from August 2021 to May 2022. Additional evaluation-specific data were collected between March and May 2022 in four housing estates; we surveyed 301 residents and conducted 32 interviews with residents, Concierges and program stakeholders. RESULTS: Concierges promoted COVID-safe behaviours; linked residents with support, testing and vaccination services; and disseminated up-to-date information. Of the 20,901 recorded interactions, 8,872 (42%) included Concierges providing support around COVID-19 vaccination. Most surveyed residents (191/301, 63%) reported speaking with a Concierge in the previous six months. The self-reported two-dose COVID-19 vaccine uptake was 94% (283/301). Some residents described having meaningful, appreciated conversations with Concierges, and some described superficial interactions. While residents initially welcomed the program, many felt it failed to evolve. Poorly defined management and hiring criteria led to variable program implementation. A need for bicultural workers to continue linking residents with services was discussed. CONCLUSIONS: Concierges' impact on residents may have contributed to high community uptake of COVID-19 testing and vaccination, and had benefits beyond the COVID-19 remit. We recommend the program be revised and continued to inform further preparedness planning and support service access generally. Program models such as this have potential to inform and reassure high-risk communities during a pandemic. In addition, such programs can help overcome vaccine hesitancy and promote protective health behaviours, regardless of whether a pandemic is currently occurring. Ensuring these programs remain responsive to the changing needs of end-users needs over time is imperative. CI - (c) 2024. The Author(s). FAU - Oliver, Jane AU - Oliver J AD - Department of Infectious Diseases, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, 792 Elizabeth St, Melbourne, VIC, 3000, Australia. jane.oliver@unimelb.edu.au. AD - Murdoch Children's Research Institute, Melbourne, VIC, 3052, Australia. jane.oliver@unimelb.edu.au. FAU - Ferdinand, Angeline AU - Ferdinand A AD - Centre for Health Policy, Melbourne School of Population and Global Health, University of Melbourne, Melbourne, VIC, 3000, Australia. FAU - Hussein, Awil AU - Hussein A AD - North Melbourne Resident Action Group, Melbourne, VIC, 3052, Australia. FAU - Hussein, Ruqiyo AU - Hussein R AD - Department of Infectious Diseases, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, 792 Elizabeth St, Melbourne, VIC, 3000, Australia. FAU - Kaufman, Jessica AU - Kaufman J AD - Murdoch Children's Research Institute, Melbourne, VIC, 3052, Australia. FAU - Edler, Peta AU - Edler P AD - Department of Infectious Diseases, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, 792 Elizabeth St, Melbourne, VIC, 3000, Australia. FAU - Allard, Nicole AU - Allard N AD - Department of Infectious Diseases, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, 792 Elizabeth St, Melbourne, VIC, 3000, Australia. AD - cohealth, Melbourne, VIC, 3066, Australia. FAU - Danchin, Margie AU - Danchin M AD - Murdoch Children's Research Institute, Melbourne, VIC, 3052, Australia. AD - Department of Paediatrics, University of Melbourne, Melbourne, VIC, 3000, Australia. AD - Department of General Medicine, The Royal Childrens Hospital Melbourne, Melbourne, VIC, 3052, Australia. FAU - Gibney, Katherine B AU - Gibney KB AD - Department of Infectious Diseases, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, 792 Elizabeth St, Melbourne, VIC, 3000, Australia. LA - eng PT - Journal Article DEP - 20240227 PL - England TA - BMC Health Serv Res JT - BMC health services research JID - 101088677 RN - 0 (COVID-19 Vaccines) SB - IM MH - Humans MH - *COVID-19/epidemiology/prevention & control MH - Pandemics/prevention & control MH - COVID-19 Vaccines MH - COVID-19 Testing MH - Public Housing MH - Australia/epidemiology MH - Health Education PMC - PMC10900559 OTO - NOTNLM OT - COVID-19 OT - Community health worker OT - Health services OT - Pandemic COIS- The authors declare no competing interests. EDAT- 2024/02/28 00:43 MHDA- 2024/02/29 06:43 PMCR- 2024/02/27 CRDT- 2024/02/27 23:54 PHST- 2023/09/20 00:00 [received] PHST- 2024/01/23 00:00 [accepted] PHST- 2024/02/29 06:43 [medline] PHST- 2024/02/28 00:43 [pubmed] PHST- 2024/02/27 23:54 [entrez] PHST- 2024/02/27 00:00 [pmc-release] AID - 10.1186/s12913-024-10627-7 [pii] AID - 10627 [pii] AID - 10.1186/s12913-024-10627-7 [doi] PST - epublish SO - BMC Health Serv Res. 2024 Feb 27;24(1):250. doi: 10.1186/s12913-024-10627-7. PMID- 38382835 OWN - NLM STAT- MEDLINE DCOM- 20240510 LR - 20240516 IS - 1473-4893 (Electronic) IS - 1470-2118 (Print) IS - 1470-2118 (Linking) VI - 24 IP - 2 DP - 2024 Mar TI - Impact of penicillin allergy records on antimicrobial prescribing in hospitalised patients. PG - 100024 LID - S1470-2118(24)00012-5 [pii] LID - 10.1016/j.clinme.2024.100024 [doi] LID - 100024 AB - BACKGROUND: The overdiagnosis of penicillin allergy and misclassification of non-truly allergic reactions is a growing public health problem, associated with the overuse of broad-spectrum and restricted antimicrobials. We aimed to evaluate the impact of penicillin allergy status on antimicrobial prescribing. METHODS: A retrospective study of inpatients with a documented penicillin allergy receiving antimicrobials was conducted from 1 April to 1 July 2021. Antimicrobial prescribing and clinical characteristics were compared between patients with an active penicillin allergy label and those whose label was removed following antimicrobial stewardship team review. Antimicrobials were classified in two categories: i) 'Access' (recommended), ii) 'Watch and Reserve' (restricted) according to WHO AWaRe classification, a tool to guide appropriate antibiotic use. RESULTS: 437 patients with a documented penicillin allergy receiving antimicrobials were included. 353 patients with an active penicillin allergy label, more frequently received antimicrobials from the 'Watch and Reserve list' (283;80% vs 30;37%; p<0.001). In contrast, 84 patients who were de-labelled received more often antimicrobials from the 'Access list' (53;63% vs 64;18%; p<0.001). CONCLUSIONS: Penicillin allergy reviews and de-labelling strategies may reduce the use of restricted antimicrobials under the 'Watch and Reserve list'. This practice should be encouraged and reinforced in all hospitals. CI - Copyright (c) 2024. Published by Elsevier Ltd. FAU - Anton-Vazquez, Vanesa AU - Anton-Vazquez V AD - Medical Microbiology, Lewisham & Greenwich NHS Trust, London, UK. Electronic address: v.anton-vazquez@nhs.net. FAU - Ferretti, Francesca AU - Ferretti F AD - Medical Microbiology, Lewisham & Greenwich NHS Trust, London, UK. FAU - Kaya, Deniz AU - Kaya D AD - General Internal Medicine, Lewisham & Greenwich NHS Trust, London, UK. FAU - Mishra, Shashwat AU - Mishra S AD - General Internal Medicine, Lewisham & Greenwich NHS Trust, London, UK. FAU - Kerneis, Sven AU - Kerneis S AD - General Internal Medicine, Lewisham & Greenwich NHS Trust, London, UK. FAU - Eden, Charlotte AU - Eden C AD - General Internal Medicine, Lewisham & Greenwich NHS Trust, London, UK. FAU - Doan, Hong AU - Doan H AD - General Internal Medicine, Lewisham & Greenwich NHS Trust, London, UK. FAU - Leung, Hiu Fung AU - Leung HF AD - Antimicrobial pharmacy, Lewisham & Greenwich NHS Trust, London, UK. FAU - Baltazar, Jeanelli AU - Baltazar J AD - Antimicrobial pharmacy, Lewisham & Greenwich NHS Trust, London, UK. FAU - Starkey, Sarah AU - Starkey S AD - Medical Microbiology, Lewisham & Greenwich NHS Trust, London, UK. FAU - Uwagwu, Juliet AU - Uwagwu J AD - Medical Microbiology, Lewisham & Greenwich NHS Trust, London, UK. FAU - Dall'Antonia, Martino AU - Dall'Antonia M AD - Medical Microbiology, Lewisham & Greenwich NHS Trust, London, UK. FAU - Cepeda, Jorge AU - Cepeda J AD - Medical Microbiology, Lewisham & Greenwich NHS Trust, London, UK. LA - eng PT - Journal Article DEP - 20240220 PL - England TA - Clin Med (Lond) JT - Clinical medicine (London, England) JID - 101092853 RN - 0 (Penicillins) RN - 0 (Anti-Bacterial Agents) SB - IM MH - Humans MH - Retrospective Studies MH - *Penicillins/adverse effects/therapeutic use MH - Male MH - Female MH - *Drug Hypersensitivity MH - Middle Aged MH - Aged MH - *Anti-Bacterial Agents/therapeutic use/adverse effects MH - Antimicrobial Stewardship MH - Aged, 80 and over MH - Adult MH - Hospitalization/statistics & numerical data PMC - PMC11091395 OTO - NOTNLM OT - AWaRe OT - Access OT - Antibiotics OT - Antimicrobial prescribing OT - Antimicrobials OT - Penicillin allergy OT - Reserve OT - Stewardship OT - Watch COIS- None to declare. EDAT- 2024/02/22 00:43 MHDA- 2024/05/11 08:42 PMCR- 2024/02/20 CRDT- 2024/02/21 19:18 PHST- 2024/05/11 08:42 [medline] PHST- 2024/02/22 00:43 [pubmed] PHST- 2024/02/21 19:18 [entrez] PHST- 2024/02/20 00:00 [pmc-release] AID - S1470-2118(24)00012-5 [pii] AID - 100024 [pii] AID - 10.1016/j.clinme.2024.100024 [doi] PST - ppublish SO - Clin Med (Lond). 2024 Mar;24(2):100024. doi: 10.1016/j.clinme.2024.100024. Epub 2024 Feb 20. PMID- 38369711 OWN - NLM STAT- MEDLINE DCOM- 20250919 LR - 20251119 IS - 2204-2091 (Electronic) IS - 2204-2091 (Linking) VI - 34 IP - 2 DP - 2024 Jun 19 TI - Changes in systemic cancer therapy in Australia during the Delta and Omicron waves of the COVID-19 pandemic (2021-2022): a controlled interrupted time series analysis. LID - 34012402 [pii] LID - 10.17061/phrp34012402 [doi] AB - OBJECTIVES: Australian lockdowns in response to the initial coronavirus disease 2019 (COVID-19) outbreak in 2020 were associated with small and transient changes in the use of systemic cancer therapy. We aimed to investigate the impacts of the longer and more restrictive lockdowns in the Australian states of New South Wales (NSW) and Victoria during both the Delta subvariant lockdowns in mid-2021 and the Omicron subvariant outbreak in late 2021/early 2022. STUDY TYPE: Population-based, controlled interrupted time series analysis. METHODS: We conducted a national observational study using de-identified records of government-subsidised cancer medicines dispensed to a random 10% sample of Australians between July 2018 and July 2022. We used controlled interrupted time series analysis to investigate changes in the dispensing, initiation and discontinuation of all cancer medicines dispensed to residents of NSW and Victoria, using the rest of Australia as a control series. We used quasi-Poisson regression to model weekly counts and estimate incidence rate ratios (IRRs) for the effect of (each) the Delta phase lockdown and the Omicron outbreak on our systemic cancer therapy outcomes. RESULTS: Between July 2018 and July 2022, cancer medicines were dispensed 592 141 times to 33 198 people in NSW and Victoria. Overall, there were no changes to the rates of dispensing, initiation or discontinuation of antineoplastics during the Delta phase lockdowns. In both states during the Omicron outbreak, there were significant decreases in the dispensing of antineoplastics (NSW IRR 0.89; 95% confidence interval [CI] 0.84, 0.93. Victoria IRR 0.92; 95% CI 0.88, 0.96) and in the initiation of endocrine therapy (NSW IRR 0.85; 95% CI 0.74, 0.99. Victoria IRR 0.78; 95% CI 0.65, 0.94), and no changes in the discontinuation of any systemic cancer therapy. CONCLUSIONS: The 2021 lockdowns and 2021/2022 Omicron outbreaks in NSW and Victoria had significant impacts on the dispensing, initiation and discontinuation of systemic cancer therapies, however, the overall effects were minimal. The impacts of lockdowns were less significant than the Omicron outbreaks, suggesting COVID-19 infection, health system capacity, and patient and community concerns were important factors for treatment changes. FAU - Koch, Forrest C AU - Koch FC AD - Medicines Intelligence Research Group, School of Population Health, UNSW Sydney, Australia. FAU - Tang, Monica AU - Tang M AD - Medicines Intelligence Research Group, School of Population Health, UNSW Sydney, Australia; Nelune Comprehensive Cancer Centre, Prince of Wales Hospital, Sydney, NSW, Australia. FAU - Walpola, Ramesh AU - Walpola R AD - School of Health Sciences, UNSW Sydney, Australia. FAU - Aslam, Maria AU - Aslam M AD - Maitland Hospital, Metford, NSW, Australia; Hunter Medical Research Institute; University of Newcastle, NSW, Australia; School of Medicine and Public Health; College of Health, Medicine and Wellbeing; University of Newcastle; NSW, Australia. FAU - Pearson, Sallie-Anne AU - Pearson SA AD - University of New South Wales Medicines Intelligence Research Program, School of Population Health Sydney Australia. FAU - Daniels, Benjamin AU - Daniels B AD - Medicines Intelligence Research Group, School of Population Health, UNSW Sydney, Australia; b.daniels@unsw.edu.au. LA - eng PT - Journal Article PT - Observational Study DEP - 20240619 PL - Australia TA - Public Health Res Pract JT - Public health research & practice JID - 101648133 RN - 0 (Antineoplastic Agents) SB - IM MH - Humans MH - *COVID-19/epidemiology MH - Interrupted Time Series Analysis MH - *Neoplasms/drug therapy/epidemiology MH - Pandemics MH - New South Wales/epidemiology MH - SARS-CoV-2 MH - Australia/epidemiology MH - *Antineoplastic Agents/therapeutic use MH - Victoria/epidemiology MH - Male MH - Female COIS- FK has performed consulting work for BCAL Diagnostics within the past 3 years. BCAL Diagnostics did not have any knowledge of, or involvement in, the present study. SAP is a member of the Drug Utilisation Sub Committee of the Pharmaceutical Benefits Advisory Committee, an independent statutory body that advises the Australian Government on the PBS. The views expressed in this paper do not represent those of the Committee. All remaining authors have declared no conflicts of interest relevant to the submitted work. SAP is a member of the PHRP Editorial Board. She was not involved in reviewing, or in the decision to publish, this manuscript. EDAT- 2024/02/19 06:43 MHDA- 2025/09/19 18:31 CRDT- 2024/02/19 00:32 PHST- 2024/06/19 00:00 [aheadofprint] PHST- 2025/09/19 18:31 [medline] PHST- 2024/02/19 06:43 [pubmed] PHST- 2024/02/19 00:32 [entrez] AID - 34012402 [pii] AID - 10.17061/phrp34012402 [doi] PST - epublish SO - Public Health Res Pract. 2024 Jun 19;34(2):34012402. doi: 10.17061/phrp34012402. PMID- 38367631 OWN - NLM STAT- MEDLINE DCOM- 20240311 LR - 20260518 IS - 2468-1253 (Electronic) VI - 9 IP - 4 DP - 2024 Apr TI - Direct-acting antiviral therapies for hepatitis C infection: global registration, reimbursement, and restrictions. PG - 366-382 LID - S2468-1253(23)00335-7 [pii] LID - 10.1016/S2468-1253(23)00335-7 [doi] AB - Direct-acting antivirals (DAAs) for hepatitis C virus (HCV) infection have delivered high response rates (>95%) and simplified the management of HCV treatment, permitting non-specialists to manage patients without advanced liver disease. We collected and reviewed global data on the registration and reimbursement (government subsidised) of HCV therapies, including restrictions on reimbursement. Primary data collection occurred between Nov 15, 2021, and July 24, 2023, through the assistance of a global network of 166 HCV experts. We retrieved data for 160 (77%) of 209 countries and juristrictions. By mid-2023, 145 (91%) countries had registered at least one of the following DAA therapies: sofosbuvir-velpatasvir, sofosbuvir-velpatasvir-voxilaprevir, glecaprevir-pibrentasvir, sofosbuvir-daclatasvir, or sofosbuvir. 109 (68%) countries reimbursed at least one DAA therapy. Among 102 low-income and middle-income countries (LMICs), 89 (87%) had registered at least one HCV DAA therapy and 53 (52%) reimbursed at least one DAA therapy. Among all countries with DAA therapy reimbursement (n=109), 66 (61%) required specialist prescribing, eight (7%) had retreatment restrictions, seven (6%) had an illicit drug use restriction, five (5%) had an alcohol use restriction, and three (3%) had liver disease restrictions. Global access to DAA reimbursement remains uneven, with LMICs having comparatively low reimbursement compared with high-income countries. To meet WHO goals for HCV elimination, efforts should be made to assist countries, particularly LMICs, to increase access to DAA reimbursement and remove reimbursement restrictions-especially prescriber-type restrictions-to ensure universal access. CI - Copyright (c) 2024 Elsevier Ltd. All rights reserved. FAU - Marshall, Alison D AU - Marshall AD AD - Viral Hepatitis Clinical Research Program, The Kirby Institute, University of New South Wales, Sydney, NSW, Australia; Centre for Social Research in Health, University of New South Wales, Sydney, NSW, Australia. Electronic address: amarshall@kirby.unsw.edu.au. FAU - Willing, Alex R AU - Willing AR AD - Viral Hepatitis Clinical Research Program, The Kirby Institute, University of New South Wales, Sydney, NSW, Australia. FAU - Kairouz, Abe AU - Kairouz A AD - Viral Hepatitis Clinical Research Program, The Kirby Institute, University of New South Wales, Sydney, NSW, Australia. FAU - Cunningham, Evan B AU - Cunningham EB AD - Viral Hepatitis Clinical Research Program, The Kirby Institute, University of New South Wales, Sydney, NSW, Australia. FAU - Wheeler, Alice AU - Wheeler A AD - Viral Hepatitis Clinical Research Program, The Kirby Institute, University of New South Wales, Sydney, NSW, Australia. FAU - O'Brien, Nicholas AU - O'Brien N AD - Macquarie University, Sydney, NSW, Australia. FAU - Perera, Vidura AU - Perera V AD - Macquarie University, Sydney, NSW, Australia. FAU - Ward, John W AU - Ward JW AD - Coalition for Global Hepatitis Elimination, Task Force for Global Health, Decatur, GA, USA. FAU - Hiebert, Lindsey AU - Hiebert L AD - Coalition for Global Hepatitis Elimination, Task Force for Global Health, Decatur, GA, USA. FAU - Degenhardt, Louisa AU - Degenhardt L AD - National Drug and Alcohol Research Centre, University of New South Wales, Sydney, NSW, Australia. FAU - Hajarizadeh, Behzad AU - Hajarizadeh B AD - Viral Hepatitis Clinical Research Program, The Kirby Institute, University of New South Wales, Sydney, NSW, Australia. FAU - Colledge, Samantha AU - Colledge S AD - National Drug Research Institute, Curtin University, Perth, WA, Australia. FAU - Hickman, Matthew AU - Hickman M AD - Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK. FAU - Jawad, Danielle AU - Jawad D AD - Sydney School of Public Health, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia. FAU - Lazarus, Jeffrey V AU - Lazarus JV AD - Barcelona Institute for Global Health (IS Global), Hospital Clinic, University of Barcelona, Barcelona, Spain; CUNY Graduate School of Public Health and Health Policy, New York, NY, USA. FAU - Matthews, Gail V AU - Matthews GV AD - Therapeutic and Vaccine Research Program, The Kirby Institute, University of New South Wales, Sydney, NSW, Australia; St Vincent's Hospital, Darlinghurst, Sydney, NSW, Australia. FAU - Scheibe, Andrew AU - Scheibe A AD - TB HIV Care, Cape Town, South Africa; Community Orientated, Primary Care Research Unit, Department of Family Medicine, University of Pretoria, Pretoria, South Africa. FAU - Vickerman, Peter AU - Vickerman P AD - Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK. FAU - Dore, Gregory J AU - Dore GJ AD - Viral Hepatitis Clinical Research Program, The Kirby Institute, University of New South Wales, Sydney, NSW, Australia. FAU - Grebely, Jason AU - Grebely J AD - Viral Hepatitis Clinical Research Program, The Kirby Institute, University of New South Wales, Sydney, NSW, Australia. CN - Global HCV and HIV Treatment Restrictions Group LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review DEP - 20240215 PL - Netherlands TA - Lancet Gastroenterol Hepatol JT - The lancet. Gastroenterology & hepatology JID - 101690683 RN - WJ6CA3ZU8B (Sofosbuvir) RN - 0 (Antiviral Agents) RN - KCU0C7RS7Z (velpatasvir) RN - 0 (Benzimidazoles) RN - 0 (Benzopyrans) RN - 0 (Carbamates) RN - 0 (Heterocyclic Compounds, 4 or More Rings) SB - IM MH - Humans MH - Sofosbuvir/adverse effects MH - Antiviral Agents/adverse effects MH - *Hepatitis C, Chronic/drug therapy/epidemiology MH - *Hepatitis C/drug therapy/epidemiology MH - Hepacivirus/genetics MH - *Benzimidazoles MH - *Benzopyrans MH - *Carbamates MH - *Heterocyclic Compounds, 4 or More Rings COIS- Declaration of interests The Kirby Institute is funded by the Australian Government Department of Health and Aged Care. The views expressed in this publication do not necessarily represent the position of the Australian Government. GJD has received clinical trial grants from Gilead Sciences and AbbVie and has participated on a data safety monitoring board for a National Institutes of Health grant (unpaid). JG is supported by a National Health and Medical Research Council Investigator Grant (1176131); has received grants or contracts from AbbVie, bioLytical Laboratories, Camurus, Cepheid, Gilead Sciences, Hologic, Indivior, and Roche; and has received payment or honoraria from AbbVie, Cepheid, Gilead Sciences, and Roche. The Task Force for Global Health (JWW and LH) has received funds for the general support of the Coalition for Global Hepatitis Elimination from Abbott Laboratories, AbbVie, Cepheid, Gilead Sciences, John C Martin Foundation, Merck, Pharco, Roche, Siemens, the US Centers for Disease Control and Prevention, the US National Institutes of Health, VBI Vaccines, and Zydus-Cadila. All payments to the Task Force for Global Health were to directly support the general work of the Coalition. JVL (via the Barcelona Institute for Global Health) has received grants or contracts from AbbVie, FIND, Gilead Sciences, Merck Sharp and Dohme, and Roche Diagnostics. JVL has also received consulting fees from NovoVax and Roche Diagnostics; payment or honoraria from AbbVie, Echosens, Gilead Sciences, Intercept, Janssen, Moderna, and Novo Nordisk; has participated on a data safety monitoring board or advisory board for the QuickStart Study (unpaid); and is a member of the public health and policy committee of the European Association for the Study of the Liver (unpaid), an HIV Outcomes co-chair (unpaid), and coordinator for Healthy Livers, Healthy Lives (unpaid). All other authors declare no competing interests. FIR - Sargsyants, N IR - Sargsyants N FIR - Suleymanova, L IR - Suleymanova L FIR - Salkic, N IR - Salkic N FIR - Simonova, M IR - Simonova M FIR - Nemeth-Blazic, T IR - Nemeth-Blazic T FIR - Mravcik, V IR - Mravcik V FIR - Kivimets, K IR - Kivimets K FIR - Salupere, R IR - Salupere R FIR - Butsashvili, M IR - Butsashvili M FIR - Soselia, G IR - Soselia G FIR - Makara, M IR - Makara M FIR - Tolmane, I IR - Tolmane I FIR - Jancoriene, L IR - Jancoriene L FIR - Stratulat, S IR - Stratulat S FIR - Flisiak, R IR - Flisiak R FIR - Gheorghe, L IR - Gheorghe L FIR - Cernat, R IR - Cernat R FIR - Lakhov, A IR - Lakhov A FIR - Stanevich, O IR - Stanevich O FIR - Jarcuska, P IR - Jarcuska P FIR - Peck-Radosavljevic, M IR - Peck-Radosavljevic M FIR - Robaeys, G IR - Robaeys G FIR - Ovrehus, A IR - Ovrehus A FIR - Foster, G IR - Foster G FIR - Sutinen, J IR - Sutinen J FIR - Farkkila, M IR - Farkkila M FIR - Rautiainen, H IR - Rautiainen H FIR - Vuoti, S IR - Vuoti S FIR - Nikolova, D IR - Nikolova D FIR - Pawlotsky, J M IR - Pawlotsky JM FIR - Rockstroh, J IR - Rockstroh J FIR - Sypsa, V IR - Sypsa V FIR - Papatheodoridis, G IR - Papatheodoridis G FIR - Olafsson, S IR - Olafsson S FIR - Feeney, E IR - Feeney E FIR - Teti, E IR - Teti E FIR - Seguin-Devaux, C IR - Seguin-Devaux C FIR - Pocock, J IR - Pocock J FIR - Reiff, S IR - Reiff S FIR - McDougall, N IR - McDougall N FIR - Van der Valk, M IR - Van der Valk M FIR - Dalgard, O IR - Dalgard O FIR - Tato Marinho, R IR - Tato Marinho R FIR - Dillon, J IR - Dillon J FIR - Peters, E IR - Peters E FIR - Bojovic, K IR - Bojovic K FIR - Maticic, M IR - Maticic M FIR - Kaberg, M IR - Kaberg M FIR - Bruggmann, P IR - Bruggmann P FIR - Healy, B IR - Healy B FIR - Chong, V H IR - Chong VH FIR - Yi, S IR - Yi S FIR - Tucker, J IR - Tucker J FIR - Pasaribu, L R IR - Pasaribu LR FIR - Tanaka, J IR - Tanaka J FIR - Ashley, E A IR - Ashley EA FIR - Abu Hassan, M R IR - Abu Hassan MR FIR - Mohammed, N S IR - Mohammed NS FIR - Chan, H K IR - Chan HK FIR - Gidaagaya, S IR - Gidaagaya S FIR - Kyi, K P IR - Kyi KP FIR - Hyung Joon, K IR - Hyung Joon K FIR - Chin, B IR - Chin B FIR - Baladjay, P C IR - Baladjay PC FIR - Kao, J H IR - Kao JH FIR - Wansom, T IR - Wansom T FIR - da Cruz, B IR - da Cruz B FIR - Flower, B IR - Flower B FIR - Ehsan, E IR - Ehsan E FIR - Al Mahtab, M IR - Al Mahtab M FIR - Khandu, L IR - Khandu L FIR - Bhadoria, A S IR - Bhadoria AS FIR - Alavi, M IR - Alavi M FIR - Kc, P IR - Kc P FIR - Hamid, S IR - Hamid S FIR - Biryukov, S IR - Biryukov S FIR - Alymbaeva, D IR - Alymbaeva D FIR - Alaei, A IR - Alaei A FIR - Bakieva, S IR - Bakieva S FIR - Flichman, D IR - Flichman D FIR - Carmo, R F IR - Carmo RF FIR - Valdez, E IR - Valdez E FIR - Cortes, C P IR - Cortes CP FIR - Contreras, F IR - Contreras F FIR - Teran, E IR - Teran E FIR - Velez-Moller, P IR - Velez-Moller P FIR - Jagnarine, T IR - Jagnarine T FIR - Mills, M IR - Mills M FIR - Goodman-Meza, D IR - Goodman-Meza D FIR - Sanchez, J IR - Sanchez J FIR - Montenegro-Idrogo, J J IR - Montenegro-Idrogo JJ FIR - Lugo Canales, A M IR - Lugo Canales AM FIR - Davy, J IR - Davy J FIR - Alexander, A IR - Alexander A FIR - Gerona, S IR - Gerona S FIR - Perazzo, R IR - Perazzo R FIR - Balak, D IR - Balak D FIR - Kelly-Hanku, A IR - Kelly-Hanku A FIR - Fineanganofo, A IR - Fineanganofo A FIR - Gane, E IR - Gane E FIR - Raymond, N IR - Raymond N FIR - Debzi, N IR - Debzi N FIR - Sridharan, K IR - Sridharan K FIR - Waked, I IR - Waked I FIR - Turner, D IR - Turner D FIR - Shibolet, O IR - Shibolet O FIR - Al Muzaini, A IR - Al Muzaini A FIR - El Nakib, M IR - El Nakib M FIR - Sheriff, D S IR - Sheriff DS FIR - Brahni, T IR - Brahni T FIR - Essayagh, T IR - Essayagh T FIR - Essayagh, S IR - Essayagh S FIR - Hjaija, D IR - Hjaija D FIR - Al-Naamani, K IR - Al-Naamani K FIR - Sanai, F M IR - Sanai FM FIR - Pasquale, H IR - Pasquale H FIR - Bedri, S IR - Bedri S FIR - Chakroun, M IR - Chakroun M FIR - Ghrabi, A IR - Ghrabi A FIR - Akarca, U S IR - Akarca US FIR - Falcao, V IR - Falcao V FIR - Edmond Gbedo, S IR - Edmond Gbedo S FIR - Ouoba, S IR - Ouoba S FIR - Nyabenda, F IR - Nyabenda F FIR - Rocher Mbella, M IR - Rocher Mbella M FIR - Mahamat Moussa, A IR - Mahamat Moussa A FIR - Youssouf, T IR - Youssouf T FIR - Boniface, Y IR - Boniface Y FIR - Akilimali Shindano, T IR - Akilimali Shindano T FIR - Hamida, M E IR - Hamida ME FIR - Mongo, A IR - Mongo A FIR - Mapapa, C IR - Mapapa C FIR - Desalegn, H IR - Desalegn H FIR - Embinga, E L A IR - Embinga ELA FIR - Ndow, G IR - Ndow G FIR - Nartey, Y IR - Nartey Y FIR - Cisse, M IR - Cisse M FIR - Djalo, M A IR - Djalo MA FIR - Mugambi, M IR - Mugambi M FIR - Nyakowa, M IR - Nyakowa M FIR - Jeuronlon, M K IR - Jeuronlon MK FIR - Ngoma, J IR - Ngoma J FIR - Manitrala Ramanampamonjy, R IR - Manitrala Ramanampamonjy R FIR - Naik, K IR - Naik K FIR - Soyjaudah, M D IR - Soyjaudah MD FIR - Filipe, E IR - Filipe E FIR - Nnakelu, E IR - Nnakelu E FIR - Serumondo, J IR - Serumondo J FIR - Mbodj, M IR - Mbodj M FIR - Patino, M IR - Patino M FIR - Aalto, M K IR - Aalto MK FIR - Waweru, P IR - Waweru P FIR - Dagnra, A IR - Dagnra A FIR - Ocama, P IR - Ocama P FIR - Maghimbi, A IR - Maghimbi A FIR - Hamooya, B M IR - Hamooya BM FIR - Katsidzira, L IR - Katsidzira L FIR - Rios, C IR - Rios C FIR - Thormann, M IR - Thormann M FIR - Al Marzooqi, N IR - Al Marzooqi N FIR - Al Rand, H M IR - Al Rand HM FIR - Francois, K IR - Francois K FIR - Hamoudi, W IR - Hamoudi W FIR - Alkharty, M IR - Alkharty M FIR - Skripo, O IR - Skripo O FIR - Uka, T IR - Uka T EDAT- 2024/02/18 00:42 MHDA- 2024/03/11 06:43 CRDT- 2024/02/17 18:52 PHST- 2023/08/18 00:00 [received] PHST- 2023/09/25 00:00 [revised] PHST- 2023/10/02 00:00 [accepted] PHST- 2024/03/11 06:43 [medline] PHST- 2024/02/18 00:42 [pubmed] PHST- 2024/02/17 18:52 [entrez] AID - S2468-1253(23)00335-7 [pii] AID - 10.1016/S2468-1253(23)00335-7 [doi] PST - ppublish SO - Lancet Gastroenterol Hepatol. 2024 Apr;9(4):366-382. doi: 10.1016/S2468-1253(23)00335-7. Epub 2024 Feb 15. PMID- 38366865 OWN - NLM STAT- MEDLINE DCOM- 20240807 LR - 20260614 IS - 1740-7753 (Electronic) IS - 1740-7745 (Print) IS - 1740-7745 (Linking) VI - 21 IP - 4 DP - 2024 Aug TI - Rethinking the clinical research protocol: Lessons learned from the COVID-19 pandemic and recommendations for reducing noncompliance. PG - 491-499 LID - 10.1177/17407745241232430 [doi] AB - BACKGROUND/AIMS: Since the onset of the coronavirus disease 2019 (COVID-19) pandemic, 103.4 million cases and 1.1 million deaths have occurred nationally as of November 2023. Despite the benefit of mitigating measures, the pandemic's effect on participant safety is rarely documented. METHODS: This study assessed noncompliance occurring from July 2019 to August 2021 that were stratified by the date of noncompliance (before or after restrictions). Events were described by size, site, noncompliance type, primary category, subcategory, and cause. In addition, noncompliance associated with COVID-19 was analyzed to determine characteristics. RESULTS: In total, 323 noncompliance events occurred across 21,146 participants at risk in 35 protocols. The overall rate of noncompliance increased from 0.008 events per participant to 0.022 events per participant after the COVID-19 restrictions (p < 0.001). For onsite protocols, the median within protocol change in rates was 0.001 (interquartile range = 0.141) after the onset of COVID-19 restrictions (p = 0.54). For large-sized protocols (n >/= 100), the median within protocol change in rates was also 0.001 (interquartile range = 0.017) after COVID-19 restrictions (p = 0.15). For events related to COVID-19 restrictions, 160/162 (99%) were minor deviations, 161/162 (99%) were procedural noncompliance, and 124/162 (77%) were an incomplete study visit. CONCLUSION: These noncompliance events have implications for clinical trial methodology because nonadherence to trial design can lead to participant safety concerns and loss of trial data validity. Protocols should be written to better facilitate the capture of all safety and efficacy data. This recommendation should be considered when changes occur to the protocol environment that are outside of the study team's control. FAU - Gooden, Matthew J AU - Gooden MJ AUID- ORCID: 0000-0002-8430-3265 AD - Clinical Trials Unit, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA. FAU - Norato, Gina AU - Norato G AD - Clinical Trials Unit, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA. FAU - Landry, Katherine AU - Landry K AD - Clinical Trials Unit, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA. FAU - Martin, Sandra B AU - Martin SB AD - Clinical Trials Unit, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA. FAU - Nath, Avindra AU - Nath A AD - Section of Infections of the Nervous System, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA. FAU - Reoma, Lauren AU - Reoma L AUID- ORCID: 0000-0001-6305-7723 AD - Clinical Trials Unit, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA. AD - Section of Infections of the Nervous System, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA. LA - eng GR - R13 NS127635/NS/NINDS NIH HHS/United States GR - Z99 NS999999/ImNIH/Intramural NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, N.I.H., Intramural DEP - 20240217 PL - England TA - Clin Trials JT - Clinical trials (London, England) JID - 101197451 SB - IM MH - Humans MH - *COVID-19/prevention & control/epidemiology MH - SARS-CoV-2 MH - Clinical Protocols MH - Pandemics MH - Research Design MH - Patient Compliance/statistics & numerical data PMC - PMC11305973 MID - NIHMS1963233 OTO - NOTNLM OT - COVID-19 OT - electronic medical records OT - human subjects research OT - patient safety OT - risk reduction COIS- Declaration of conflicting interestsThe author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: L.R. is the incoming Vice Chair of the American Academy of Neurology's Section on Experimental Neurotherapeutics and is the Intramural NINDS Program Director for the NINDS-FDA Fellowship in Clinical Trial Methodology and Regulatory Science. EDAT- 2024/02/17 12:43 MHDA- 2024/08/07 06:41 PMCR- 2024/08/08 CRDT- 2024/02/17 05:29 PHST- 2024/08/07 06:41 [medline] PHST- 2024/02/17 12:43 [pubmed] PHST- 2024/02/17 05:29 [entrez] PHST- 2024/08/08 00:00 [pmc-release] AID - 10.1177/17407745241232430 [doi] PST - ppublish SO - Clin Trials. 2024 Aug;21(4):491-499. doi: 10.1177/17407745241232430. Epub 2024 Feb 17. PMID- 38363565 OWN - NLM STAT- MEDLINE DCOM- 20240219 LR - 20241023 IS - 2574-3805 (Electronic) IS - 2574-3805 (Linking) VI - 7 IP - 2 DP - 2024 Feb 5 TI - Health Economic Consequences Associated With COVID-19-Related Delay in Melanoma Diagnosis in Europe. PG - e2356479 LID - 10.1001/jamanetworkopen.2023.56479 [doi] LID - e2356479 AB - IMPORTANCE: The COVID-19 pandemic resulted in delayed access to medical care. Restrictions to health care specialists, staff shortages, and fear of SARS-CoV-2 infection led to interruptions in routine care, such as early melanoma detection; however, premature mortality and economic burden associated with this postponement have not been studied yet. OBJECTIVE: To determine the premature mortality and economic costs associated with suspended melanoma screenings during COVID-19 pandemic lockdowns by estimating the total burden of delayed melanoma diagnoses for Europe. DESIGN, SETTING, AND PARTICIPANTS: This multicenter economic evaluation used population-based data from patients aged at least 18 years with invasive primary cutaneous melanomas stages I to IV according to the American Joint Committee on Cancer (AJCC) seventh and eighth editions, including melanomas of unknown primary (T0). Data were collected from January 2017 to December 2021 in Switzerland and from January 2019 to December 2021 in Hungary. Data were used to develop an estimation of melanoma upstaging rates in AJCC stages, which was verified with peripandemic data. Years of life lost (YLL) were calculated and were, together with cost data, used for financial estimations. The total financial burden was assessed through direct and indirect treatment costs. Models were building using data from 50 072 patients aged 18 years and older with invasive primary cutaneous melanomas stages I to IV according to the AJCC seventh and eighth edition, including melanomas of unknown primary (T0) from 2 European tertiary centers. Data from European cancer registries included patient-based direct and indirect cost data, country-level economic indicators, melanoma incidence, and population rates per country. Data were analyzed from July 2021 to September 2022. EXPOSURE: COVID-19 lockdown-related delay of melanoma detection and consecutive public health and economic burden. As lockdown restrictions varied by country, lockdown scenario was defined as elimination of routine medical examinations and severely restricted access to follow-up examinations for at least 4 weeks. MAIN OUTCOMES AND MEASURES: Primary outcomes were the total burden of a delay in melanoma diagnosis during COVID-19 lockdown periods, measured using the direct (in US$) and indirect (calculated as YLL plus years lost due to disability [YLD] and disability-adjusted life-years [DALYs]) costs for Europe. Secondary outcomes included estimation of upstaging rate, estimated YLD, YLL, and DALY for each European country, absolute direct and indirect treatment costs per European country, proportion of the relative direct and indirect treatment costs for the countries, and European health expenditure. RESULTS: There were an estimated 111 464 (range, 52 454-295 051) YLL due to pandemic-associated delay in melanoma diagnosis in Europe, and estimated total additional costs were $7.65 (range, $3.60 to $20.25) billion. Indirect treatment costs were the main cost driver, accounting for 94.5% of total costs. Estimates for YLD in Europe resulted in 15 360 years for the 17% upstaging model, ranging from 7228 years (8% upstaging model) to 40 660 years (45% upstaging model). Together, YLL and YLD constitute the overall disease burden, ranging from 59 682 DALYs (8% upstaging model) to 335 711 DALYs (45% upstaging model), with 126 824 DALYs for the real-world 17% scenario. CONCLUSIONS AND RELEVANCE: This economic analysis emphasizes the importance of continuing secondary skin cancer prevention measures during pandemics. Beyond the personal outcomes of a delayed melanoma diagnosis, the additional economic and public health consequences are underscored, emphasizing the need to include indirect economic costs in future decision-making processes. These estimates on DALYs and the associated financial losses complement previous studies highlighting the cost-effectiveness of screening for melanoma. FAU - Maul, Lara V AU - Maul LV AD - Department of Dermatology, University Hospital of Basel, Basel, Switzerland. AD - Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland. AD - Faculty of Medicine, University of Zurich, Zurich, Switzerland. FAU - Jamiolkowski, Dagmar AU - Jamiolkowski D AD - Department of Dermatology, University Hospital of Basel, Basel, Switzerland. AD - Division of Pediatric Dermatology, Children's Hospital Auf der Bult, Hannover, Germany. FAU - Lapides, Rebecca A AU - Lapides RA AD - Robert Larner, MD, College of Medicine at the University of Vermont, Burlington, Vermont. AD - Cutaneous Biology Research Center, Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Charlestown. FAU - Mueller, Alina M AU - Mueller AM AD - Department of Dermatology, University Hospital of Basel, Basel, Switzerland. FAU - Hauschild, Axel AU - Hauschild A AD - Department of Dermatology, University Hospital of Schleswig-Holstein, Campus Kiel, Kiel, Germany. FAU - Garbe, Claus AU - Garbe C AD - Center for Dermatooncology, Department of Dermatology, Eberhard Karls University of Tuebingen, Tuebingen, Germany. FAU - Lorigan, Paul AU - Lorigan P AD - Division of Cancer Sciences, University of Manchester, Manchester, United Kingdom. AD - The Christie NHS Foundation Trust, Manchester, United Kingdom. FAU - Gershenwald, Jeffrey E AU - Gershenwald JE AD - Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston. FAU - Ascierto, Paolo Antonio AU - Ascierto PA AD - Istituto Nazionale Tumori, IRCCS, Fondazione G Pascale, Naples, Italy. FAU - Long, Georgina V AU - Long GV AD - Melanoma Institute Australia, The University of Sydney, Sydney, Australia. AD - Royal North Shore Hospital, Sydney, Australia. AD - Faculty of Medicine and Health, The University of Sydney, Sydney, Australia. AD - Charles Perkins Centre, The University of Sydney, Sydney, Australia. FAU - Wang-Evers, Michael AU - Wang-Evers M AD - Cutaneous Biology Research Center, Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Charlestown. FAU - Scolyer, Richard A AU - Scolyer RA AD - Melanoma Institute Australia, The University of Sydney, Sydney, Australia. AD - Royal Prince Alfred Hospital and NSW Health Pathology, Sydney, Australia. AD - Faculty of Medicine and Health, The University of Sydney, Sydney, Australia. AD - Charles Perkins Centre, The University of Sydney, Sydney, Australia. FAU - Saravi, Babak AU - Saravi B AD - Department of Orthopedics and Trauma Surgery, Medical Center-University of Freiburg, Germany. AD - Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. FAU - Augustin, Matthias AU - Augustin M AD - University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Navarini, Alexander A AU - Navarini AA AD - Department of Dermatology, University Hospital of Basel, Basel, Switzerland. FAU - Legge, Stefan AU - Legge S AD - Institute of Law and Economics, University of St Gallen, St Gallen, Switzerland. FAU - Nemeth, Istvan B AU - Nemeth IB AD - Department of Dermatology and Allergology, University of Szeged, Szent-Gyorgyi Albert Medical School, Szeged, Hungary. FAU - Janosi, Agnes J AU - Janosi AJ AD - Department of Dermatology and Allergology, University of Szeged, Szent-Gyorgyi Albert Medical School, Szeged, Hungary. FAU - Mocellin, Simone AU - Mocellin S AD - Soft-Tissue, Peritoneum and Melanoma Surgical Oncology Unit, Istituto Oncologico Veneto - IRCCS, Padua, Italy. AD - Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy. FAU - Feller, Anita AU - Feller A AD - National Agency for Cancer Registration, University of Zurich, Zurich, Switzerland. AD - Foundation National Institute for Cancer Epidemiology and Registration, University of Zurich, Zurich, Switzerland. FAU - Manstein, Dieter AU - Manstein D AD - Cutaneous Biology Research Center, Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Charlestown. FAU - Zink, Alexander AU - Zink A AD - Department of Dermatology and Allergy, TUM School of Medicine and Health, Technical University of Munich, Munich, Germany. FAU - Maul, Julia-Tatjana AU - Maul JT AD - Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland. AD - Faculty of Medicine, University of Zurich, Zurich, Switzerland. FAU - Buja, Alessandra AU - Buja A AD - Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova, Via Loredan, Padova, Italy. FAU - Adhikari, Kaustubh AU - Adhikari K AD - School of Mathematics and Statistics, Faculty of Science, Technology, Engineering and Mathematics, The Open University, Milton Keynes, United Kingdom. AD - Department of Genetics, Evolution and Environment, and UCL Genetics Institute, University College London, London, United Kingdom. FAU - Roider, Elisabeth AU - Roider E AD - Department of Dermatology, University Hospital of Basel, Basel, Switzerland. AD - Cutaneous Biology Research Center, Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Charlestown. LA - eng PT - Journal Article PT - Multicenter Study PT - Research Support, Non-U.S. Gov't DEP - 20240205 PL - United States TA - JAMA Netw Open JT - JAMA network open JID - 101729235 SB - IM MH - Humans MH - Adolescent MH - Adult MH - *Melanoma/diagnosis/epidemiology MH - Pandemics MH - *Neoplasms, Unknown Primary/epidemiology MH - *COVID-19/diagnosis/epidemiology MH - SARS-CoV-2 MH - Communicable Disease Control MH - Europe/epidemiology MH - Cost of Illness MH - *Skin Neoplasms/diagnosis/epidemiology MH - COVID-19 Testing PMC - PMC10873772 COIS- Conflict of Interest Disclosures: Dr L.V. Maul reported receiving personal fees from Almirall, Amgen, Eli Lilly, MSD, Novartis, Pierre Fabre, Roche, and Sanofi outside the submitted work and funding from the Research Foundation of the University Hospital Basel and the ProPatient Foundation. Dr Mueller reported receiving personal fees European Academy of Dermatology and Venereology outside the submitted work. Dr Garbe reported receiving personal fees from CeCaVa, MSD, NeraCare, and Philogen outside the submitted work and serving as President of the European Association of DermatoOncology. Dr Hauschild reported receiving grants from MSD/Merck, Philogen, Pierre Fabre, Regeneron, Roche, Sanofi-Genzyme, Novartis Pharma, and Eisai (paid to institution) and personal fees from MSD/Merck, Pierre Fabre, Regeneron, Roche, Sanofi-Genzyme, Novartis Pharma, Eisai, Immunocore, Replimune, and Seagen. Dr Lorigan reported receiving grants from Bristol Meyers Squibb and Pierre Fabre and personal fees from Bristol Meyers Squibb, Pierre Fabre, MSD, and Novartis. Dr Gershenwald reported receiving personal fees from Merck and UpToDate outside the submitted work. Dr Ascierto reported receiving grants from Bristol Meyers Squibb, Roche-Genentech, Pfizer, and Sanofi; personal fees from Bristol Myers Squibb, Roche-Genentech, Pfizer, Sanofi, MSD, Novartis, Merck Serono, Pierre Fabre, Sun Pharma, Sandoz, Immunocore, Italfarmaco, Boehringer Ingelheim, Regeneron, Nouscom, Lunaphore, Medicenna, Bio-Al Health, Replimmune, Bayer, Erasca, and Philogen; and serving as an unpaid consultant for ValoTx outside the submitted work. Dr Long reported receiving personal fees from Agenus, Amgen, Array Biopharma, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Evaxion, Hexal (Sandoz Company), Highlight Therapeutics, Innovent Biologics USA, MSD, Novartis, PHMR, Pierre Fabre, Provectus, Qbiotics, and Regeneron outside the submitted work. Dr Scolyer reported receiving grants from National Health and Medical Research Council of Australia during the conduct of the study; personal fees from MetaOptima Technology, F. Hoffmann-La Roche, Evaxion, Provectus Biopharmaceuticals Australia, Qbiotics, Novartis, MSD, NeraCare, Amgen, Bristol Myers Squibb, Myriad Genetics, and GSK outside the submitted work. Dr Augustin reported receiving personal fees from AbbVie, Almirall, Beiersdorf, Eli Lilly, Galderma, LEO, Pfizer, and Sanofi-Genzyme outside the submitted work. Dr Navarini reported receiving personal fees from AbbVie, Almirall, Amgen, Biomed, Bristol Meyers Squibb, Boehringer Ingelheim, Celgene, Eli Lilly, Galderma, GSK, LEO Pharma, Janssen-Cilag, MSD, Novartis, Pfizer, Pierre Fabre Pharma, Regeneron, Sandoz, Sanofi, and UCB outside the submitted work. Dr Manstein reported serving as a consultant for Avava and R2, receiving grants from Shiseido, and owning stock in Blossom Innovations and German Medical Engineering outside the submitted work. Dr Zink reported receiving personal fees from Novartis, Janssen, Eli Lilly, UCB, Bristol Meyers Squibb, and Almirall outside the submitted work. Dr J.-T. Maul reported serving as an advisor or receiving personal fees from AbbVie, Almirall, Amgen, Bristol Meyers Squibb, Celgene, Eli Lilly, LEO Pharma, Janssen-Cilag, MSD, Novartis, Pfizer, Pierre Fabre, Roche, Sanofi, and UCB. Dr Roider reported being a shareholder and founder of Maximon and its holding ventures, receiving grants from the Goldschmidt Jacobson Foundation and Swiss National Foundation, and receiving personal fees from Eli Lilly and Galderma. No other disclosures were reported. EDAT- 2024/02/16 12:46 MHDA- 2024/02/19 06:42 PMCR- 2024/02/16 CRDT- 2024/02/16 11:33 PHST- 2024/02/19 06:42 [medline] PHST- 2024/02/16 12:46 [pubmed] PHST- 2024/02/16 11:33 [entrez] PHST- 2024/02/16 00:00 [pmc-release] AID - 2815226 [pii] AID - zoi231665 [pii] AID - 10.1001/jamanetworkopen.2023.56479 [doi] PST - epublish SO - JAMA Netw Open. 2024 Feb 5;7(2):e2356479. doi: 10.1001/jamanetworkopen.2023.56479. PMID- 38345271 OWN - NLM STAT- MEDLINE DCOM- 20250411 LR - 20250411 IS - 2050-439X (Electronic) IS - 2050-4381 (Linking) VI - 12 IP - 16 DP - 2024 Feb TI - The impact of the COVID-19 pandemic on the physical activity environment in English primary schools: a multi-perspective qualitative analysis. PG - 59-104 LID - 10.3310/KLML4701 [doi] AB - BACKGROUND: The COVID-19 lockdowns and social distancing measures, including school closures, had a major impact on children's physical activity in England, with data showing an initial reduction in activity in the short-term post-lockdown phase of the pandemic followed by a recovery on average in the medium-term post-lockdown period. The school environment is an important context for child physical activity. The purpose of this study is to understand the changes that took place to school physical activity environments once schools reopened after lockdowns. This information will improve understanding of why changes to children's physical activity have occurred over the course of the pandemic and the implications for future promotion of physical activity in schools. METHODS: Interviews with parents (n = 43), school staff (n = 18) and focus groups with 10- to 11-year-old children (participant n = 92) were conducted at two time points: between September-December 2021 and February-July 2022. Interview and focus group guides covered the impact of the pandemic on child physical activity and changes to this over time. The framework method was used for analysis. RESULTS: Three themes and three subthemes were generated: (1) the return to school; (2) over-pressured staff and environment and (3) the uneven impact of the pandemic. Theme 3 consists of three subthemes: (a) retained pandemic policies, (b) impact on physical activity culture and (c) different children need different things. LIMITATIONS AND FUTURE WORK: Conducting this research in schools during ongoing COVID-19 disruptions was a challenge and may have limited school and participant participation, particularly school staff. The parent interview sample is predominantly female, active and of higher socioeconomic status, so the experiences of male, less active and lower socioeconomic parents are limited. This study suggests that the impact of COVID-19 on child physical activity is uneven, affecting some children more than others. Future work is therefore needed to explore the details of this potential diverging experience. CONCLUSION: The COVID-19 pandemic, school closures and post-lockdown school policies have impacted upon primary school physical activity environments. The post-lockdown school environment is highly pressured, impacting the extent to which schools can support and encourage child physical activity. Future research is needed to further explore the impact of post-lockdown changes on physical activity environments in schools, particularly over the longer term, as schools continue to adapt post lockdowns. Strategies required to support school physical activity environments must be context specific and sensitive to these changes, pressures and needs. FUNDING: This article presents independent research funded by the National Institute for Health and Care Research (NIHR) Public Health Research programme as award number NIHR131847. FAU - House, Danielle AU - House D AUID- ORCID: 0000-0001-6171-9922 AD - Centre for Exercise, Nutrition and Health Sciences, School for Policy Studies, University of Bristol, Bristol, UK. FAU - Walker, Robert AU - Walker R AUID- ORCID: 0000-0001-9901-5285 AD - Centre for Exercise, Nutrition and Health Sciences, School for Policy Studies, University of Bristol, Bristol, UK. FAU - Salway, Ruth AU - Salway R AUID- ORCID: 0000-0002-3242-3951 AD - Centre for Exercise, Nutrition and Health Sciences, School for Policy Studies, University of Bristol, Bristol, UK. FAU - Emm-Collison, Lydia AU - Emm-Collison L AUID- ORCID: 0000-0002-5493-3223 AD - Centre for Exercise, Nutrition and Health Sciences, School for Policy Studies, University of Bristol, Bristol, UK. FAU - Breheny, Katie AU - Breheny K AUID- ORCID: 0000-0001-6886-4049 AD - Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK. FAU - Sansum, Kate AU - Sansum K AUID- ORCID: 0000-0003-3392-6750 AD - Centre for Exercise, Nutrition and Health Sciences, School for Policy Studies, University of Bristol, Bristol, UK. FAU - Churchward, Sarah AU - Churchward S AUID- ORCID: 0009-0007-7765-3682 AD - Independent Public Member of the Project Team, Bristol, UK. FAU - Williams, Joanna G AU - Williams JG AUID- ORCID: 0000-0002-4737-1760 AD - Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK. AD - Communities and Public Health, Bristol City Council, Bristol, UK. FAU - de Vocht, Frank AU - de Vocht F AUID- ORCID: 0000-0003-3631-627X AD - Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK. AD - The National Institute for Health Research, Applied Research Collaboration West (NIHR ARC West), University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK. FAU - Jago, Russell AU - Jago R AUID- ORCID: 0000-0002-3394-0176 AD - Centre for Exercise, Nutrition and Health Sciences, School for Policy Studies, University of Bristol, Bristol, UK. AD - Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK. AD - The National Institute for Health Research, Applied Research Collaboration West (NIHR ARC West), University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK. AD - NIHR Bristol Biomedical Research Centre, University Hospitals Bristol and Weston NHS Foundation Trust and University of Bristol, Bristol, UK. LA - eng PT - Journal Article PL - England TA - Public Health Res (Southampt) JT - Public health research (Southampton, England) JID - 101653231 SB - IM MH - Humans MH - *COVID-19/epidemiology/prevention & control MH - *Exercise MH - *Schools/organization & administration MH - Child MH - England/epidemiology MH - Female MH - Male MH - Qualitative Research MH - Focus Groups MH - SARS-CoV-2 MH - Interviews as Topic MH - Pandemics MH - Parents/psychology MH - Physical Distancing OAB - Schools are important spaces for children's physical activity. Children can be active in physical education lessons, break times, after-school clubs and travelling to school. School closures and other COVID-19 restrictions affected children's physical activity. We wanted to know how physical activity in primary schools might have changed since the pandemic. We spoke to school staff, pupils and parents two times after schools reopened. We asked about children's physical activity, and if or how this had changed over the course of the pandemic. We asked school staff about school policies around physical activity. When children went back to school, schools needed a 'recovery' approach. Children's academic, social and physical skills had been affected. For this time schools prioritised physical activity, but this was short-lived. Since then, schools have been highly pressured. They have had to 'catch up' on missed learning, staff are overloaded and some pupils are still affected by the lockdowns. Physical activity policies in schools have changed, but in many different ways. Some have kept social distancing policies; others feel their school culture has changed. Additionally, pupil ability and needs are more polarised. These factors have shaped, but are also shaped by, the high pressure in schools. Supporting changing child needs in highly pressured schools is hard for state primary schools. Changes to school physical activity policies need to be understood and evaluated. Strategies to ease pressure in schools are needed to support physical activity. OABL- eng EDAT- 2024/02/12 15:43 MHDA- 2025/04/11 12:27 CRDT- 2024/02/12 08:13 PHST- 2025/04/11 12:27 [medline] PHST- 2024/02/12 15:43 [pubmed] PHST- 2024/02/12 08:13 [entrez] AID - 10.3310/KLML4701 [doi] PST - ppublish SO - Public Health Res (Southampt). 2024 Feb;12(16):59-104. doi: 10.3310/KLML4701. PMID- 38324540 OWN - NLM STAT- MEDLINE DCOM- 20240214 LR - 20260817 IS - 1932-6203 (Electronic) IS - 1932-6203 (Linking) VI - 19 IP - 2 DP - 2024 TI - Positive and negative emotions during the COVID-19 pandemic: A longitudinal survey study of the UK population. PG - e0297214 LID - 10.1371/journal.pone.0297214 [doi] LID - e0297214 AB - The COVID-19 pandemic has had a profound impact on society; it changed the way we work, learn, socialise, and move throughout the world. In the United Kingdom, policies such as business closures, travel restrictions, and social distance mandates were implemented to slow the spread of COVID-19 and implemented and relaxed intermittently throughout the response period. While negative emotions and feelings such as distress and anxiety during this time of crisis were to be expected, we also see the signs of human resilience, including positive feelings like determination, pride, and strength. A longitudinal study using online survey tools was conducted to assess people's changing moods during the pandemic in the UK. The Positive and Negative Affect Schedule (PANAS) was used to measure self-reported feelings and emotions throughout six periods (phases) of the study from March 2020 to July 2021. A total of 4,222 respondents participated in the survey, while a sub-group participated in each of the six study phases (n = 167). The results were analysed using a cross-sectional study design for the full group across each study phase, while prospective cohort analysis was used to assess the subset of participants who voluntarily answered the survey in each of the six study phases (n = 167). Gender, age and employment status were found to be most significant to PANAS score, with older people, retirees, and women generally reporting more positive moods, while young people and unemployed people generally reported lower positive scores and higher negative scores, indicating more negative emotions. Additionally, it was found that people generally reported higher positive feelings in the summer of 2021, which may be related to the relaxation of COVID-19-related policies in the UK as well as the introduction of vaccines for the general population. This study is an important investigation into what allows for positivity during a crisis and gives insights into periods or groups that may be vulnerable to increased negative states of emotions and feelings. CI - Copyright: (c) 2024 Li et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. FAU - Li, Lan AU - Li L AUID- ORCID: 0000-0002-5532-5764 AD - Centre for Digital Public Health in Emergencies, Institute for Risk and Disaster Reduction, University College London, London, United Kingdom. FAU - Sullivan, Ava AU - Sullivan A AD - Centre for Digital Public Health in Emergencies, Institute for Risk and Disaster Reduction, University College London, London, United Kingdom. AD - EcoHealth Alliance, New York, New York, United States of America. FAU - Musah, Anwar AU - Musah A AUID- ORCID: 0000-0001-7978-1871 AD - Centre for Digital Public Health in Emergencies, Institute for Risk and Disaster Reduction, University College London, London, United Kingdom. AD - Department of Geography, University College London, London, United Kingdom. FAU - Stavrianaki, Katerina AU - Stavrianaki K AUID- ORCID: 0000-0001-9413-1842 AD - Centre for Digital Public Health in Emergencies, Institute for Risk and Disaster Reduction, University College London, London, United Kingdom. AD - Department of Statistical Science, University College London, London, United Kingdom. FAU - Wood, Caroline E AU - Wood CE AD - Centre for Digital Public Health in Emergencies, Institute for Risk and Disaster Reduction, University College London, London, United Kingdom. FAU - Baker, Philip AU - Baker P AD - Centre for Digital Public Health in Emergencies, Institute for Risk and Disaster Reduction, University College London, London, United Kingdom. AD - Crisis Response, British Red Cross, London, United Kingdom. FAU - Kostkova, Patty AU - Kostkova P AD - Centre for Digital Public Health in Emergencies, Institute for Risk and Disaster Reduction, University College London, London, United Kingdom. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20240207 PL - United States TA - PLoS One JT - PloS one JID - 101285081 SB - IM MH - Humans MH - Female MH - Aged MH - Adolescent MH - Longitudinal Studies MH - *Pandemics MH - *COVID-19/epidemiology MH - Cross-Sectional Studies MH - Prospective Studies MH - Emotions MH - Self Report PMC - PMC10849398 COIS- The authors have declared that no competing interests exist. EDAT- 2024/02/07 18:41 MHDA- 2024/02/09 00:42 PMCR- 2024/02/07 CRDT- 2024/02/07 13:34 PHST- 2022/05/15 00:00 [received] PHST- 2023/12/29 00:00 [accepted] PHST- 2024/02/09 00:42 [medline] PHST- 2024/02/07 18:41 [pubmed] PHST- 2024/02/07 13:34 [entrez] PHST- 2024/02/07 00:00 [pmc-release] AID - PONE-D-22-14167 [pii] AID - 10.1371/journal.pone.0297214 [doi] PST - epublish SO - PLoS One. 2024 Feb 7;19(2):e0297214. doi: 10.1371/journal.pone.0297214. eCollection 2024. PMID- 38324379 OWN - NLM STAT- MEDLINE DCOM- 20240208 LR - 20250612 IS - 1438-8871 (Electronic) IS - 1439-4456 (Print) IS - 1438-8871 (Linking) VI - 26 DP - 2024 Feb 7 TI - Depression and Anxiety in Adolescents During the COVID-19 Pandemic in Relation to the Use of Digital Technologies: Longitudinal Cohort Study. PG - e45114 LID - 10.2196/45114 [doi] LID - e45114 AB - BACKGROUND: Adolescents are susceptible to mental illness and have experienced substantial disruption owing to the COVID-19 pandemic. The digital environment is increasingly important in the context of a pandemic when in-person social connection is restricted. OBJECTIVE: This study aims to estimate whether depression and anxiety had worsened compared with the prepandemic period and examine potential associations with sociodemographic characteristics and behavioral factors, particularly digital behaviors. METHODS: We analyzed cross-sectional and longitudinal data from a large, representative Greater London adolescent cohort study: the Study of Cognition, Adolescents and Mobile Phones (SCAMP). Participants completed surveys at T1 between November 2016 and July 2018 (N=4978; aged 13 to 15 years) and at T2 between July 2020 and June 2021 (N=1328; aged 16 to 18 years). Depression and anxiety were measured using the Patient Health Questionnaire and Generalized Anxiety Disorder scale, respectively. Information on the duration of total mobile phone use, social network site use, and video gaming was also collected using questionnaires. Multivariable logistic regression was used to assess the cross-sectional and longitudinal associations of sociodemographic characteristics, digital technology use, and sleep duration with clinically significant depression and anxiety. RESULTS: The proportion of adolescents who had clinical depression and anxiety significantly increased at T2 (depression: 140/421, 33.3%; anxiety: 125/425, 29.4%) compared with the proportion of adolescents at T1 (depression: 57/421, 13.5%; anxiety: 58/425, 13.6%; P for 2-proportion z test <.001 for both depression and anxiety). Depression and anxiety levels were similar between the summer holiday, school opening, and school closures. Female participants had higher odds of new incident depression (odds ratio [OR] 2.5, 95% CI 1.5-4.18) and anxiety (OR 2.11, 95% CI 1.23-3.61) at T2. A high level of total mobile phone use at T1 was associated with developing depression at T2 (OR 1.89, 95% CI 1.02-3.49). Social network site use was associated with depression and anxiety cross-sectionally at T1 and T2 but did not appear to be associated with developing depression or anxiety longitudinally. Insufficient sleep at T1 was associated with developing depression at T2 (OR 2.26, 95% CI 1.31-3.91). CONCLUSIONS: The mental health of this large sample of adolescents from London deteriorated during the pandemic without noticeable variations relating to public health measures. The deterioration was exacerbated in girls, those with preexisting high total mobile phone use, and those with preexisting disrupted sleep. Our findings suggest the necessity for allocating resources to address these modifiable factors and target high-risk groups. CI - (c)Chen Shen, Rachel B Smith, Joel Heller, Alexander D V Spiers, Rhiannon Thompson, Helen Ward, Jonathan P Roiser, Dasha Nicholls, Mireille B Toledano. Originally published in the Journal of Medical Internet Research (https://www.jmir.org), 07.02.2024. FAU - Shen, Chen AU - Shen C AUID- ORCID: 0000-0002-0119-4455 AD - MRC Centre for Environment and Health, School of Public Health, Imperial College London, London, United Kingdom. AD - National Institute for Health Research Health Protection Research Unit in Chemical and Radiation Threats and Hazards, Imperial College London, London, United Kingdom. FAU - Smith, Rachel B AU - Smith RB AUID- ORCID: 0000-0003-4000-2919 AD - MRC Centre for Environment and Health, School of Public Health, Imperial College London, London, United Kingdom. AD - National Institute for Health Research Health Protection Research Unit in Chemical and Radiation Threats and Hazards, Imperial College London, London, United Kingdom. AD - Mohn Centre for Children's Health and Wellbeing, School of Public Health, Imperial College London, London, United Kingdom. FAU - Heller, Joel AU - Heller J AUID- ORCID: 0009-0008-7569-0540 AD - MRC Centre for Environment and Health, School of Public Health, Imperial College London, London, United Kingdom. AD - National Institute for Health Research Health Protection Research Unit in Chemical and Radiation Threats and Hazards, Imperial College London, London, United Kingdom. FAU - Spiers, Alexander D V AU - Spiers ADV AUID- ORCID: 0000-0002-8874-085X AD - MRC Centre for Environment and Health, School of Public Health, Imperial College London, London, United Kingdom. AD - National Institute for Health Research Health Protection Research Unit in Chemical and Radiation Threats and Hazards, Imperial College London, London, United Kingdom. FAU - Thompson, Rhiannon AU - Thompson R AUID- ORCID: 0000-0002-8188-3460 AD - MRC Centre for Environment and Health, School of Public Health, Imperial College London, London, United Kingdom. AD - National Institute for Health Research Health Protection Research Unit in Chemical and Radiation Threats and Hazards, Imperial College London, London, United Kingdom. AD - National Institute for Health Research School for Public Health Research, Imperial College London, London, United Kingdom. FAU - Ward, Helen AU - Ward H AUID- ORCID: 0000-0001-8238-5036 AD - Patient Experience Research Centre, School of Public Health, Imperial College London, London, United Kingdom. FAU - Roiser, Jonathan P AU - Roiser JP AUID- ORCID: 0000-0001-8269-1228 AD - Institute of Cognitive Neuroscience, University College London, London, United Kingdom. FAU - Nicholls, Dasha AU - Nicholls D AUID- ORCID: 0000-0001-7257-6605 AD - Department of Brain Sciences, Division of Psychiatry, Imperial College London, London, United Kingdom. FAU - Toledano, Mireille B AU - Toledano MB AUID- ORCID: 0000-0001-5695-6210 AD - MRC Centre for Environment and Health, School of Public Health, Imperial College London, London, United Kingdom. AD - National Institute for Health Research Health Protection Research Unit in Chemical and Radiation Threats and Hazards, Imperial College London, London, United Kingdom. AD - Mohn Centre for Children's Health and Wellbeing, School of Public Health, Imperial College London, London, United Kingdom. LA - eng GR - MR/V004190/1/MRC_/Medical Research Council/United Kingdom GR - MR/V028472/1/MRC_/Medical Research Council/United Kingdom PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20240207 PL - Canada TA - J Med Internet Res JT - Journal of medical Internet research JID - 100959882 SB - IM MH - Adolescent MH - Female MH - Humans MH - Cohort Studies MH - Longitudinal Studies MH - *Digital Technology MH - Pandemics MH - Cross-Sectional Studies MH - Depression MH - *COVID-19 MH - Anxiety PMC - PMC10882466 OTO - NOTNLM OT - COVID-19 OT - adolescence OT - anxiety OT - depression OT - digital technology use OT - mobile phone OT - public health OT - sleep COIS- Conflicts of Interest: None declared. EDAT- 2024/02/07 12:44 MHDA- 2024/02/08 06:42 PMCR- 2024/02/07 CRDT- 2024/02/07 11:54 PHST- 2022/12/18 00:00 [received] PHST- 2024/01/19 00:00 [accepted] PHST- 2023/12/20 00:00 [revised] PHST- 2024/02/08 06:42 [medline] PHST- 2024/02/07 12:44 [pubmed] PHST- 2024/02/07 11:54 [entrez] PHST- 2024/02/07 00:00 [pmc-release] AID - v26i1e45114 [pii] AID - 10.2196/45114 [doi] PST - epublish SO - J Med Internet Res. 2024 Feb 7;26:e45114. doi: 10.2196/45114. PMID- 38320581 OWN - NLM STAT- MEDLINE DCOM- 20250710 LR - 20250710 IS - 1439-3824 (Electronic) IS - 0300-8630 (Linking) VI - 237 IP - 4 DP - 2025 Jul TI - Inpatient Rsv-Management 2016-2022: Epidemiology and Adherence to A Bronchiolitis Treatment Standard at a German University Children's Hospital. PG - 243-249 LID - 10.1055/a-2218-5171 [doi] AB - BACKGROUND: This study analyzes the RSV season 2021/2022 in a referral children's hospital, compares the epidemiology and illness severity with RSV-infected inpatients from 2016 to 2020 and audits the adherence to our internal therapy standard for RSV bronchiolitis. MATERIAL AND METHODS: Inpatients with rtPCR-confirmed RSV infection (Jan. 2016 to Jan. 2022). RESULTS: The audit comprises 306 RSV inpatients, on average 50 hospitalizations per year; in 03/2020, a rapid RSV Season-Offset was observed. In the winter season 2020/2021, no patient with RSV was hospitalized. Beginning in July, we noticed a rapid increase of RSV-admissions (most cases in Sept./Oct, duration until Dec. 2021; n=53). In 2021-2022, a significant larger share needed PICU admission (9.4% vs 3.2%, p=0.040). Adherence to the internal guidance was low; only 11.8% (n=36) of all patients received supportive treatment without inhalative or systemic medications, 37% of all patients received antibiotics. CONCLUSIONS: This audit confirms the strong impact of public preventive measures directed against SARS-CoV-2 transmission on RSV epidemiology. Few weeks after easing public COVID-19 restrictions (summer 2021), RSV inpatient cases rapidly increased, lasting until Dec. 2021. The audit of bronchiolitis management revealed surprisingly low adherence to the internal guidance, despite a face-to-face educational session with the attending pediatricians in Oct. 2021. Low adherence resulted in an unnecessary exposure of RSV patients to systemic medications of questionable benefit including antibiotics. CI - Thieme. All rights reserved. FAU - Heidtmann, Solvej AU - Heidtmann S AD - Pediatric Oncology and Hematology, TeleKasper Project, Saarland University Hospital, Homburg, Germany. FAU - Baltaci, Yeliz AU - Baltaci Y AD - Pediatric Oncology and Hematology, TeleKasper Project, Saarland University Hospital, Homburg, Germany. FAU - Meyer, Sascha AU - Meyer S AD - General Pediatrics and Neonatology, University Children̓s Hospital Homburg, Homburg, Germany. FAU - Zemlin, Michael AU - Zemlin M AUID- ORCID: 0000-0001-9528-7419 AD - General Pediatrics and Neonatology, University Children̓s Hospital Homburg, Homburg, Germany. FAU - Furtwangler, Rhoikos AU - Furtwangler R AD - Pediatric Haematology and Oncology, Saarland University Hospital, Homburg/Saar, Germany. FAU - Rissland, Juergen AU - Rissland J AD - Institute of Virology, Saarland University Medical Center, Homburg/Saar, Germany. FAU - Simon, Arne AU - Simon A AD - Pediatric Oncology and Hematology, Saarland University Hospital, Homburg, Germany. LA - eng PT - Journal Article TT - Stationar behandelte Patienten mit RSV-Infektion 2016-2022 und Adharenz zu einem klinikinternen Behandlungsstandard der RSV Bronchiolitis. DEP - 20240206 PL - Germany TA - Klin Padiatr JT - Klinische Padiatrie JID - 0326144 SB - IM MH - Humans MH - *Respiratory Syncytial Virus Infections/epidemiology/therapy MH - Germany/epidemiology MH - Infant MH - *Guideline Adherence/statistics & numerical data MH - Male MH - Female MH - *Hospitals, Pediatric/statistics & numerical data MH - Hospitalization/statistics & numerical data MH - Hospitals, University/statistics & numerical data MH - *Bronchiolitis, Viral/epidemiology/therapy MH - Child, Preschool MH - Bronchiolitis/epidemiology/therapy MH - COVID-19/epidemiology/prevention & control MH - Infant, Newborn MH - Seasons COIS- The authors declare that they have no conflict of interest. EDAT- 2024/02/07 00:42 MHDA- 2025/07/11 00:26 CRDT- 2024/02/06 19:02 PHST- 2025/07/11 00:26 [medline] PHST- 2024/02/07 00:42 [pubmed] PHST- 2024/02/06 19:02 [entrez] AID - 10.1055/a-2218-5171 [doi] PST - ppublish SO - Klin Padiatr. 2025 Jul;237(4):243-249. doi: 10.1055/a-2218-5171. Epub 2024 Feb 6. PMID- 38313091 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240206 IS - 1679-4435 (Print) IS - 2447-0147 (Electronic) IS - 1679-4435 (Linking) VI - 21 IP - 2 DP - 2023 Apr-Jun TI - Occupational cancer illness in Brazil: an integrative literature review. PG - e2022845 LID - 10.47626/1679-4435-2022-845 [doi] LID - e2022845 AB - The present study aimed to investigate data from the scientific literature on patterns of illness due to occupational cancer in Brazil. An integrative literature review was conducted in July 2020 and reviewed in June 2021, with no time restriction, using the Health Science Descriptors "Neoplasms," "Occupational Risks," "Occupational Cancer," and keywords related, which were searched on the following databases: Latin American Literature in Health Sciences, SciELO, PubMed, Scopus, Web of Science, and Cumulative Index to Nursing and Allied Health Literature. The search and selection flow followed that recommended by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Statement - 2020. Six manuscripts were selected, published from 1995 to 2019, which described occupational cancer affecting lung, oral cavity, pharynx and larynx, central nervous system, and skin. There was a time gap between the studies, and only the one involving lung cancer results on the most prevalent pattern of illness in the industrial sector, compared to the non-industrial. A shortage of scientific articles on patterns of illness was found. There was a predominance of scientific publications referring to occupational cancer illness related to the industrial sector compared to the number of publications directed to the primary and tertiary productive sectors. It is worth noting the constant need for research and epidemiological surveys to promote surveillance and protective actions aimed at occupational health. FAU - de Almeida, Thamyres Morgado AU - de Almeida TM AUID- ORCID: 0000-0002-0286-8159 AD - Faculdade de Enfermagem, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, RJ, Brazil. FAU - da Costa, Yasmin Albuquerque AU - da Costa YA AUID- ORCID: 0000-0001-6068-4852 AD - Faculdade de Enfermagem, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, RJ, Brazil. FAU - Faria, Magda Guimaraes de Araujo AU - Faria MGA AUID- ORCID: 0000-0001-9928-6392 AD - Faculdade de Enfermagem, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, RJ, Brazil. FAU - Gallasch, Cristiane Helena AU - Gallasch CH AUID- ORCID: 0000-0002-0823-0818 AD - Faculdade de Enfermagem, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, RJ, Brazil. LA - eng PT - Journal Article PT - Review DEP - 20230808 PL - Brazil TA - Rev Bras Med Trab JT - Revista brasileira de medicina do trabalho : publicacao oficial da Associacao Nacional de Medicina do Trabalho-ANAMT JID - 101214718 PMC - PMC10835392 OTO - NOTNLM OT - occupational cancer OT - occupational health OT - occupational risks COIS- Conflicts of interest: None EDAT- 2024/02/05 06:43 MHDA- 2024/02/05 06:44 PMCR- 2023/08/08 CRDT- 2024/02/05 04:31 PHST- 2021/07/09 00:00 [received] PHST- 2021/07/26 00:00 [accepted] PHST- 2024/02/05 06:44 [medline] PHST- 2024/02/05 06:43 [pubmed] PHST- 2024/02/05 04:31 [entrez] PHST- 2023/08/08 00:00 [pmc-release] AID - 10.47626/1679-4435-2022-845 [doi] PST - epublish SO - Rev Bras Med Trab. 2023 Aug 8;21(2):e2022845. doi: 10.47626/1679-4435-2022-845. eCollection 2023 Apr-Jun. PMID- 38268464 OWN - NLM STAT- MEDLINE DCOM- 20240701 LR - 20260805 IS - 1557-9700 (Electronic) IS - 1075-2730 (Linking) VI - 75 IP - 7 DP - 2024 Jul 1 TI - Addressing Mental Health Disability in Unsheltered Homelessness: Outpatient Conservatorship in Los Angeles. PG - 689-698 LID - 10.1176/appi.ps.20230235 [doi] AB - OBJECTIVE: The authors sought to describe a pilot program for gravely disabled individuals experiencing unsheltered homelessness in Los Angeles County that illustrates a promising public health framework to address mental health-related disability in homeless populations. METHODS: Homeless outreach teams implementing the outpatient conservatorship (OPC) pilot program adopted a population health approach, multisystem care coordination, and prioritization of the least restrictive environments. The program allowed initiation of a Lanterman-Petris-Short (LPS) conservatorship outside of a hospital, with the goal of serving highly vulnerable individuals in the least restrictive settings. Between August 2020 and July 2021, the OPC pilot program served 43 clients, corresponding to 2% of those served by the outreach teams during that period. Using observational program evaluation data, the authors examined the impact of the program on this sample of participants. RESULTS: At 12 months, 81% of OPC clients were no longer experiencing unsheltered homelessness; 65% accessed an LPS conservatorship. Although most OPC clients utilized a psychiatric hospital, 54% left locked settings earlier than would have been possible without the program. One-third of clients referred for LPS conservatorship used unlocked licensed residential facilities in the first year. Negative events, such as remaining in unsheltered homelessness, were more common among clients not referred for LPS conservatorship. CONCLUSIONS: Timely receipt of street-based services and coordination of care before, during, and after referral for LPS conservatorship reduced use of restrictive settings. The OPC program's components constitute a promising triadic framework for addressing mental health disability among unsheltered individuals that warrants further investigation. FAU - Bromley, Elizabeth AU - Bromley E AD - Department of Psychiatry and Biobehavioral Sciences, Jane and Terry Semel Institute for Neuroscience and Human Behavior, David Geffen School of Medicine, and Los Angeles County Department of Mental Health and University of California Los Angeles Public Mental Health Partnership, University of California Los Angeles, Los Angeles (Bromley, Rahmanian Koushkaki, Davis, McCoy, Sherin); Mental Illness Research, Education and Clinical Center, Greater Los Angeles Healthcare System, U.S. Department of Veterans Affairs, Los Angeles (Bromley, McCoy); Los Angeles County Department of Health Services, Los Angeles (Moon); Center for Community Health, Altman Clinical and Translational Research Institute, University of California San Diego, La Jolla (Resnick); Los Angeles County Department of Mental Health, Los Angeles (Bennett, Rab, Draxler, Jackson, Lovelace). FAU - Rahmanian Koushkaki, Sara AU - Rahmanian Koushkaki S AD - Department of Psychiatry and Biobehavioral Sciences, Jane and Terry Semel Institute for Neuroscience and Human Behavior, David Geffen School of Medicine, and Los Angeles County Department of Mental Health and University of California Los Angeles Public Mental Health Partnership, University of California Los Angeles, Los Angeles (Bromley, Rahmanian Koushkaki, Davis, McCoy, Sherin); Mental Illness Research, Education and Clinical Center, Greater Los Angeles Healthcare System, U.S. Department of Veterans Affairs, Los Angeles (Bromley, McCoy); Los Angeles County Department of Health Services, Los Angeles (Moon); Center for Community Health, Altman Clinical and Translational Research Institute, University of California San Diego, La Jolla (Resnick); Los Angeles County Department of Mental Health, Los Angeles (Bennett, Rab, Draxler, Jackson, Lovelace). FAU - Davis, Lisa G AU - Davis LG AD - Department of Psychiatry and Biobehavioral Sciences, Jane and Terry Semel Institute for Neuroscience and Human Behavior, David Geffen School of Medicine, and Los Angeles County Department of Mental Health and University of California Los Angeles Public Mental Health Partnership, University of California Los Angeles, Los Angeles (Bromley, Rahmanian Koushkaki, Davis, McCoy, Sherin); Mental Illness Research, Education and Clinical Center, Greater Los Angeles Healthcare System, U.S. Department of Veterans Affairs, Los Angeles (Bromley, McCoy); Los Angeles County Department of Health Services, Los Angeles (Moon); Center for Community Health, Altman Clinical and Translational Research Institute, University of California San Diego, La Jolla (Resnick); Los Angeles County Department of Mental Health, Los Angeles (Bennett, Rab, Draxler, Jackson, Lovelace). FAU - Moon, Stephanie AU - Moon S AD - Department of Psychiatry and Biobehavioral Sciences, Jane and Terry Semel Institute for Neuroscience and Human Behavior, David Geffen School of Medicine, and Los Angeles County Department of Mental Health and University of California Los Angeles Public Mental Health Partnership, University of California Los Angeles, Los Angeles (Bromley, Rahmanian Koushkaki, Davis, McCoy, Sherin); Mental Illness Research, Education and Clinical Center, Greater Los Angeles Healthcare System, U.S. Department of Veterans Affairs, Los Angeles (Bromley, McCoy); Los Angeles County Department of Health Services, Los Angeles (Moon); Center for Community Health, Altman Clinical and Translational Research Institute, University of California San Diego, La Jolla (Resnick); Los Angeles County Department of Mental Health, Los Angeles (Bennett, Rab, Draxler, Jackson, Lovelace). FAU - Resnick, Jaclyn AU - Resnick J AD - Department of Psychiatry and Biobehavioral Sciences, Jane and Terry Semel Institute for Neuroscience and Human Behavior, David Geffen School of Medicine, and Los Angeles County Department of Mental Health and University of California Los Angeles Public Mental Health Partnership, University of California Los Angeles, Los Angeles (Bromley, Rahmanian Koushkaki, Davis, McCoy, Sherin); Mental Illness Research, Education and Clinical Center, Greater Los Angeles Healthcare System, U.S. Department of Veterans Affairs, Los Angeles (Bromley, McCoy); Los Angeles County Department of Health Services, Los Angeles (Moon); Center for Community Health, Altman Clinical and Translational Research Institute, University of California San Diego, La Jolla (Resnick); Los Angeles County Department of Mental Health, Los Angeles (Bennett, Rab, Draxler, Jackson, Lovelace). FAU - McCoy, Matthew AU - McCoy M AD - Department of Psychiatry and Biobehavioral Sciences, Jane and Terry Semel Institute for Neuroscience and Human Behavior, David Geffen School of Medicine, and Los Angeles County Department of Mental Health and University of California Los Angeles Public Mental Health Partnership, University of California Los Angeles, Los Angeles (Bromley, Rahmanian Koushkaki, Davis, McCoy, Sherin); Mental Illness Research, Education and Clinical Center, Greater Los Angeles Healthcare System, U.S. Department of Veterans Affairs, Los Angeles (Bromley, McCoy); Los Angeles County Department of Health Services, Los Angeles (Moon); Center for Community Health, Altman Clinical and Translational Research Institute, University of California San Diego, La Jolla (Resnick); Los Angeles County Department of Mental Health, Los Angeles (Bennett, Rab, Draxler, Jackson, Lovelace). FAU - Bennett, Karla AU - Bennett K AD - Department of Psychiatry and Biobehavioral Sciences, Jane and Terry Semel Institute for Neuroscience and Human Behavior, David Geffen School of Medicine, and Los Angeles County Department of Mental Health and University of California Los Angeles Public Mental Health Partnership, University of California Los Angeles, Los Angeles (Bromley, Rahmanian Koushkaki, Davis, McCoy, Sherin); Mental Illness Research, Education and Clinical Center, Greater Los Angeles Healthcare System, U.S. Department of Veterans Affairs, Los Angeles (Bromley, McCoy); Los Angeles County Department of Health Services, Los Angeles (Moon); Center for Community Health, Altman Clinical and Translational Research Institute, University of California San Diego, La Jolla (Resnick); Los Angeles County Department of Mental Health, Los Angeles (Bennett, Rab, Draxler, Jackson, Lovelace). FAU - Rab, Shayan AU - Rab S AD - Department of Psychiatry and Biobehavioral Sciences, Jane and Terry Semel Institute for Neuroscience and Human Behavior, David Geffen School of Medicine, and Los Angeles County Department of Mental Health and University of California Los Angeles Public Mental Health Partnership, University of California Los Angeles, Los Angeles (Bromley, Rahmanian Koushkaki, Davis, McCoy, Sherin); Mental Illness Research, Education and Clinical Center, Greater Los Angeles Healthcare System, U.S. Department of Veterans Affairs, Los Angeles (Bromley, McCoy); Los Angeles County Department of Health Services, Los Angeles (Moon); Center for Community Health, Altman Clinical and Translational Research Institute, University of California San Diego, La Jolla (Resnick); Los Angeles County Department of Mental Health, Los Angeles (Bennett, Rab, Draxler, Jackson, Lovelace). FAU - Draxler, Connie D AU - Draxler CD AD - Department of Psychiatry and Biobehavioral Sciences, Jane and Terry Semel Institute for Neuroscience and Human Behavior, David Geffen School of Medicine, and Los Angeles County Department of Mental Health and University of California Los Angeles Public Mental Health Partnership, University of California Los Angeles, Los Angeles (Bromley, Rahmanian Koushkaki, Davis, McCoy, Sherin); Mental Illness Research, Education and Clinical Center, Greater Los Angeles Healthcare System, U.S. Department of Veterans Affairs, Los Angeles (Bromley, McCoy); Los Angeles County Department of Health Services, Los Angeles (Moon); Center for Community Health, Altman Clinical and Translational Research Institute, University of California San Diego, La Jolla (Resnick); Los Angeles County Department of Mental Health, Los Angeles (Bennett, Rab, Draxler, Jackson, Lovelace). FAU - Jackson, La Tina AU - Jackson T AD - Department of Psychiatry and Biobehavioral Sciences, Jane and Terry Semel Institute for Neuroscience and Human Behavior, David Geffen School of Medicine, and Los Angeles County Department of Mental Health and University of California Los Angeles Public Mental Health Partnership, University of California Los Angeles, Los Angeles (Bromley, Rahmanian Koushkaki, Davis, McCoy, Sherin); Mental Illness Research, Education and Clinical Center, Greater Los Angeles Healthcare System, U.S. Department of Veterans Affairs, Los Angeles (Bromley, McCoy); Los Angeles County Department of Health Services, Los Angeles (Moon); Center for Community Health, Altman Clinical and Translational Research Institute, University of California San Diego, La Jolla (Resnick); Los Angeles County Department of Mental Health, Los Angeles (Bennett, Rab, Draxler, Jackson, Lovelace). FAU - Lovelace, Aubree AU - Lovelace A AD - Department of Psychiatry and Biobehavioral Sciences, Jane and Terry Semel Institute for Neuroscience and Human Behavior, David Geffen School of Medicine, and Los Angeles County Department of Mental Health and University of California Los Angeles Public Mental Health Partnership, University of California Los Angeles, Los Angeles (Bromley, Rahmanian Koushkaki, Davis, McCoy, Sherin); Mental Illness Research, Education and Clinical Center, Greater Los Angeles Healthcare System, U.S. Department of Veterans Affairs, Los Angeles (Bromley, McCoy); Los Angeles County Department of Health Services, Los Angeles (Moon); Center for Community Health, Altman Clinical and Translational Research Institute, University of California San Diego, La Jolla (Resnick); Los Angeles County Department of Mental Health, Los Angeles (Bennett, Rab, Draxler, Jackson, Lovelace). FAU - Sherin, Jonathan AU - Sherin J AD - Department of Psychiatry and Biobehavioral Sciences, Jane and Terry Semel Institute for Neuroscience and Human Behavior, David Geffen School of Medicine, and Los Angeles County Department of Mental Health and University of California Los Angeles Public Mental Health Partnership, University of California Los Angeles, Los Angeles (Bromley, Rahmanian Koushkaki, Davis, McCoy, Sherin); Mental Illness Research, Education and Clinical Center, Greater Los Angeles Healthcare System, U.S. Department of Veterans Affairs, Los Angeles (Bromley, McCoy); Los Angeles County Department of Health Services, Los Angeles (Moon); Center for Community Health, Altman Clinical and Translational Research Institute, University of California San Diego, La Jolla (Resnick); Los Angeles County Department of Mental Health, Los Angeles (Bennett, Rab, Draxler, Jackson, Lovelace). LA - eng PT - Journal Article DEP - 20240125 PL - United States TA - Psychiatr Serv JT - Psychiatric services (Washington, D.C.) JID - 9502838 SB - IM MH - Humans MH - *Ill-Housed Persons/psychology/statistics & numerical data MH - Los Angeles MH - Male MH - Adult MH - Female MH - Pilot Projects MH - Middle Aged MH - *Mental Disorders/therapy MH - Program Evaluation MH - Mental Health Services/statistics & numerical data MH - Outpatients/statistics & numerical data OTO - NOTNLM OT - Involuntary commitment OT - LPS conservatorship OT - Mental health guardianship OT - Service delivery systems OT - Severe mental illness OT - Unsheltered homelessness COIS- The authors report no financial relationships with commercial interests. EDAT- 2024/01/25 06:43 MHDA- 2024/07/01 06:41 CRDT- 2024/01/25 03:54 PHST- 2024/07/01 06:41 [medline] PHST- 2024/01/25 06:43 [pubmed] PHST- 2024/01/25 03:54 [entrez] AID - 10.1176/appi.ps.20230235 [doi] PST - ppublish SO - Psychiatr Serv. 2024 Jul 1;75(7):689-698. doi: 10.1176/appi.ps.20230235. Epub 2024 Jan 25. PMID- 38263988 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20241023 IS - 2055-2238 (Electronic) IS - 2055-2238 (Linking) VI - 10 IP - 1 DP - 2024 Feb TI - Long-term effects of the COVID-19 pandemic on children's physical activity and sedentary behavior. PG - e710 LID - 10.1002/osp4.710 [doi] LID - e710 AB - BACKGROUND: During the early months of the COVID-19 pandemic, decreases in physical activity (PA) and increases in sedentary behavior (SB) were reported among children in the United States (U.S.). This follow-up analysis examines 13-month effects of the COVID-19 pandemic on children's PA and SB one year into the pandemic. METHODS: Parents of 5-13-year-old children in the U.S. (N = 71) reported on their child's PA and SB during the early COVID-19 period (April-May 2020) and again 12-14 months later (June-July 2021). RESULTS: Paired t-tests showed significant within-subject reductions in SB minutes per day (M (diff) = -86.20, t = 3.26, p < 0.01) but no changes in PA minutes per day. Separate mixed-model repeated-measures analysis of covariance procedures found that within-subject changes in PA and SB did not differ by child sex or age. CONCLUSION: As COVID-19 restrictions lessened, there were more opportunities for children to reduce SB, but there were still barriers to engage in PA. CI - (c) 2023 The Authors. Obesity Science & Practice published by World Obesity and The Obesity Society and John Wiley & Sons Ltd. FAU - Moore, Kristen N AU - Moore KN AUID- ORCID: 0000-0002-6977-3138 AD - Department of Population and Public Health Sciences University of Southern California Los Angeles California USA. FAU - Do, Bridgette AU - Do B AD - Department of Population and Public Health Sciences University of Southern California Los Angeles California USA. FAU - Wang, Shirlene D AU - Wang SD AD - Department of Population and Public Health Sciences University of Southern California Los Angeles California USA. FAU - McAlister, Kelsey AU - McAlister K AD - Department of Population and Public Health Sciences University of Southern California Los Angeles California USA. FAU - Chapman, Tiffany M AU - Chapman TM AD - Department of Population and Public Health Sciences University of Southern California Los Angeles California USA. FAU - Belcher, Britni R AU - Belcher BR AUID- ORCID: 0000-0001-7965-7520 AD - Department of Population and Public Health Sciences University of Southern California Los Angeles California USA. FAU - Dunton, Genevieve F AU - Dunton GF AD - Department of Population and Public Health Sciences University of Southern California Los Angeles California USA. AD - Department of Psychology University of Southern California Los Angeles California USA. LA - eng GR - R01 HL119255/HL/NHLBI NIH HHS/United States GR - U01 HL146327/HL/NHLBI NIH HHS/United States PT - Journal Article DEP - 20230906 PL - United States TA - Obes Sci Pract JT - Obesity science & practice JID - 101675151 PMC - PMC10804322 OTO - NOTNLM OT - coronavirus OT - health behaviors OT - parent reported OT - questionnaire COIS- The authors declare no conflicts of interest. EDAT- 2024/01/24 06:43 MHDA- 2024/01/24 06:44 PMCR- 2023/09/06 CRDT- 2024/01/24 03:44 PHST- 2023/05/22 00:00 [received] PHST- 2023/08/16 00:00 [revised] PHST- 2023/08/26 00:00 [accepted] PHST- 2024/01/24 06:44 [medline] PHST- 2024/01/24 06:43 [pubmed] PHST- 2024/01/24 03:44 [entrez] PHST- 2023/09/06 00:00 [pmc-release] AID - OSP4710 [pii] AID - 10.1002/osp4.710 [doi] PST - epublish SO - Obes Sci Pract. 2023 Sep 6;10(1):e710. doi: 10.1002/osp4.710. eCollection 2024 Feb. PMID- 38260162 OWN - NLM STAT- MEDLINE DCOM- 20240124 LR - 20241023 IS - 1664-2392 (Print) IS - 1664-2392 (Electronic) IS - 1664-2392 (Linking) VI - 14 DP - 2023 TI - Triglyceride-glucose index is a predictor of the risk of prostate cancer: a retrospective study based on a transprostatic aspiration biopsy population. PG - 1280221 LID - 10.3389/fendo.2023.1280221 [doi] LID - 1280221 AB - BACKGROUND: Current research suggests that prostate cancer (PCa), one of the most common cancers in men, may be linked to insulin resistance (IR).Triglyceride-glucose index (TyG index) was made for a marker of insulin resistance. We investigated the relationship between the TyG index and the risk of PCa. OBJECTIVE: To assess the correlation and dose-response relationship between TyG index and prostate cancer. METHOD: Retrospectively, 316 patients who required prostate biopsy puncture in the First Affiliated Hospital of Xinjiang Medical University from March 2017 to July 2021 were collected, and the relationship between factors such as the TyG index and prostate cancer was analyzed by Logistic regression model combined with a restricted cubic spline. RESULTS: (1) The differences in age, initial PSA and TyG index between the two groups were statistically significant; (2) Logistic regression results showed that the risk of prostate cancer in the highest quartile of the TyG index (Q4) was 3.387 times higher than that in the lowest quartile (Q1) (OR=3.387,95% CI [1.511,7.593], P=0.003); (3) The interaction results showed a significant interaction between the TyG index Q4 group and age with the risk of developing prostate cancer (P for interaction<0.001). (4) The results of the restricted cubic spline showed a linear dose-response relationship between the TyG index and the risk of prostate cancer; (5) The Receiver operating characteristic (ROC) curve results showed that the area under the curve (AUC) of the TyG index combined with initial PSA and age was 0.840, with a sensitivity and specificity of 62.5% and 93.3%, respectively. CONCLUSION: TyG index and age are risk factors for prostate cancer, and the interaction between the TyG index and different risk factors may increase the risk of prostate cancer. TyG index has some predictive value for the risk of prostate cancer, and the risk of prostate cancer can be reduced by controlling the levels of blood lipids and blood glucose. CI - Copyright (c) 2024 Zhou, Li, Muheiyati, Duan, Xiao, Gao, Tao and An. FAU - Zhou, Yijie AU - Zhou Y AD - School of Public Health, Xinjiang Medical University, Urumqi, Xinjiang, China. FAU - Li, Tianqi AU - Li T AD - School of Public Health, Xinjiang Medical University, Urumqi, Xinjiang, China. FAU - Muheiyati, Guliman AU - Muheiyati G AD - School of Public Health, Xinjiang Medical University, Urumqi, Xinjiang, China. FAU - Duan, Yajun AU - Duan Y AD - School of Public Health, Xinjiang Medical University, Urumqi, Xinjiang, China. FAU - Xiao, Songtao AU - Xiao S AD - School of Public Health, Xinjiang Medical University, Urumqi, Xinjiang, China. FAU - Gao, Yi AU - Gao Y AD - School of Traditional Chinese Medicine, Xinjiang Medical University, Urumqi, Xinjiang, China. FAU - Tao, Ning AU - Tao N AD - School of Public Health, Xinjiang Medical University, Urumqi, Xinjiang, China. AD - Department of Epidemiological Statistics, School of Public Health, Xinjiang Medical University, Urumqi, Xinjiang, China. FAU - An, Hengqing AU - An H AD - Department of Urology, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20240108 PL - Switzerland TA - Front Endocrinol (Lausanne) JT - Frontiers in endocrinology JID - 101555782 RN - IY9XDZ35W2 (Glucose) RN - 0 (Triglycerides) RN - EC 3.4.21.77 (Prostate-Specific Antigen) SB - IM MH - Male MH - Humans MH - Retrospective Studies MH - Glucose MH - Triglycerides MH - *Insulin Resistance MH - Prostate-Specific Antigen MH - Biopsy, Fine-Needle MH - *Prostatic Neoplasms/diagnosis PMC - PMC10801031 OTO - NOTNLM OT - endocrinology OT - insulin resistance OT - prostate cancer OT - triglyceride-glucose index OT - urology COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2024/01/23 12:44 MHDA- 2024/01/24 06:43 PMCR- 2023/01/01 CRDT- 2024/01/23 10:35 PHST- 2023/08/19 00:00 [received] PHST- 2023/12/15 00:00 [accepted] PHST- 2024/01/24 06:43 [medline] PHST- 2024/01/23 12:44 [pubmed] PHST- 2024/01/23 10:35 [entrez] PHST- 2023/01/01 00:00 [pmc-release] AID - 10.3389/fendo.2023.1280221 [doi] PST - epublish SO - Front Endocrinol (Lausanne). 2024 Jan 8;14:1280221. doi: 10.3389/fendo.2023.1280221. eCollection 2023. PMID- 38246091 OWN - NLM STAT- MEDLINE DCOM- 20240322 LR - 20240322 IS - 1618-0607 (Electronic) IS - 1438-4221 (Linking) VI - 314 DP - 2024 Mar TI - Impact of the COVID-19 pandemic on norovirus circulation in Germany. PG - 151600 LID - S1438-4221(24)00004-3 [pii] LID - 10.1016/j.ijmm.2024.151600 [doi] AB - Human norovirus is a major cause of viral gastroenteritis in all age groups. The virus is constantly and rapidly changing, allowing mutations and recombination events to create great diversity of circulating viruses. With the start of the COVID-19 pandemic in 2020, a wide range of public health measures were introduced worldwide to control human-to-human transmission of SARS-CoV-2. In Germany, control measures such as distance rules, contact restrictions, personal protection equipment as well as intensive hand hygiene were introduced. To better understand the effect of the measures to control the COVID-19 pandemic on incidence and the molecular epidemiological dynamics of norovirus outbreaks in Germany, we analyzed national notification data between July 2017 and December 2022 and characterized norovirus sequences circulating between January 2018 and December 2022. Compared to a reference period before the pandemic, the incidence of notified norovirus gastroenteritis decreased by 89.7% to 9.6 per 100,000 during the 2020/2021 norovirus season, corresponding to an incidence rate ratio (IRR) of 0.10. Samples from 539 outbreaks were genotyped in two regions of the viral genome from pre-pandemic (January 2018 to February 2020) and samples from 208 outbreaks during pandemic time period (March 2020 to December 2022). As expected, norovirus outbreaks were mainly found in child care facilities and nursing homes. In total, 36 genotypes were detected in the study period. A high proportion of recombinant strains (86%) was found in patients, the proportion of detected recombinant viruses did not vary between the pre-pandemic and pandemic phase. The proportion of the predominant recombinant strain GII.4 Sydney[P16] was unchanged before pandemic and during pandemic at 37.5%. The diversity of most common genotypes in nursing homes and child care facilities showed a different proportion of genotypes causing outbreaks. In nursing homes as well as in child care facilities GII.4 Sydney[P16] was predominant during the whole study period. Compared to the nursing homes, a greater variety of genotypes at the expense of GII.4 Sydney[P16] was detected in child care facilities. Furthermore, the overall proportion of recombinant strain GII.3[P12] increased during the pandemic, due to outbreaks in child care facilities. The COVID-19 pandemic had a high impact on the occurrence of sporadic cases and norovirus outbreaks in Germany, leading to a near suppression of the typical norovirus winter season following the start of the pandemic. The number of norovirus-associated outbreak samples sent to the Consultant Laboratory dropped by 63% during the pandemic. We could not identify a clear influence on circulating norovirus genotypes. The dominance of GII.4 Sydney recombinant strains was independent from the pandemic. Further studies are needed to follow up on the diversity of less predominant genotypes to see if the pandemic could have acted as a bottleneck to the spread of previously minoritized genotypes like GII.3[P12]. CI - Copyright (c) 2024 The Authors. Published by Elsevier GmbH.. All rights reserved. FAU - Jacobsen, Sonja AU - Jacobsen S AD - Consultant Laboratory for Norovirus, Department of Infectious Diseases, Robert Koch Institute, 13353 Berlin, Germany. FAU - Faber, Mirko AU - Faber M AD - Department of Infectious Disease Epidemiology, Robert Koch Institute, 13353 Berlin, Germany. FAU - Altmann, Britta AU - Altmann B AD - Department of Infectious Disease, Robert Koch Institute, 13353 Berlin, Germany. FAU - Mas Marques, Andreas AU - Mas Marques A AD - Consultant Laboratory for Norovirus, Department of Infectious Diseases, Robert Koch Institute, 13353 Berlin, Germany. FAU - Bock, C-Thomas AU - Bock CT AD - Department of Infectious Disease, Robert Koch Institute, 13353 Berlin, Germany. FAU - Niendorf, Sandra AU - Niendorf S AD - Consultant Laboratory for Norovirus, Department of Infectious Diseases, Robert Koch Institute, 13353 Berlin, Germany. Electronic address: NiendorfS@rki.de. LA - eng PT - Journal Article DEP - 20240118 PL - Germany TA - Int J Med Microbiol JT - International journal of medical microbiology : IJMM JID - 100898849 SB - IM MH - Humans MH - *Gastroenteritis/epidemiology MH - *Norovirus/genetics MH - Pandemics MH - *COVID-19/epidemiology MH - *Caliciviridae Infections/epidemiology MH - SARS-CoV-2/genetics MH - Genotype MH - Disease Outbreaks MH - Phylogeny OTO - NOTNLM OT - COVID-19 pandemic OT - Dual typing OT - Germany OT - Molecular epidemiology OT - Norovirus surveillance EDAT- 2024/01/22 00:41 MHDA- 2024/03/22 06:44 CRDT- 2024/01/21 18:09 PHST- 2023/10/31 00:00 [received] PHST- 2023/12/14 00:00 [revised] PHST- 2024/01/15 00:00 [accepted] PHST- 2024/03/22 06:44 [medline] PHST- 2024/01/22 00:41 [pubmed] PHST- 2024/01/21 18:09 [entrez] AID - S1438-4221(24)00004-3 [pii] AID - 10.1016/j.ijmm.2024.151600 [doi] PST - ppublish SO - Int J Med Microbiol. 2024 Mar;314:151600. doi: 10.1016/j.ijmm.2024.151600. Epub 2024 Jan 18. PMID- 38216233 OWN - NLM STAT- MEDLINE DCOM- 20240115 LR - 20250626 IS - 1878-1888 (Electronic) IS - 0005-7894 (Print) IS - 0005-7894 (Linking) VI - 55 IP - 1 DP - 2024 Jan TI - Availability of Internet-Based Cognitive-Behavioral Therapies for Depression: A Systematic Review. PG - 201-211 LID - S0005-7894(23)00068-0 [pii] LID - 10.1016/j.beth.2023.06.003 [doi] AB - We examined the availability and components of internet-based cognitive-behavioral therapies (iCBTs) for depression tested in randomized-controlled trials (RCTs). The objectives of this literature review were to determine the extent to which research-validated iCBTs were available to the public, as well as to determine their therapeutic content. A literature review of RCTs for iCBTs was conducted on July 30, 2021. For each iCBT, interventions were rated by content and compared to commercially available smartphone apps. Our search yielded 80 studies using 41 unique iCBTs. Of these, only 6 (15%) were completely available to the public, more than half were not publicly available (46%), and the remaining 39% were available to the public with some restrictions (e.g., those based on the user's geographical location). When comparing iCBTs evaluated in RCTs to commercially available smartphone apps, we found that iCBTs were more likely to contain psychoeducation, cognitive restructuring, behavioral activation, problem solving, and interpersonal communication components. iCBTs from RCTs contain evidence-based content but few are available to the public. Extending beyond efficacy, attention should be paid to the dissemination of iCBTs. CI - Copyright (c) 2023. Published by Elsevier Ltd. FAU - Buss, John F AU - Buss JF AD - Indiana University. FAU - Steinberg, Joshua S AU - Steinberg JS AD - Harvard University. FAU - Banks, Gregory AU - Banks G AD - Indiana University. FAU - Horani, Deena AU - Horani D AD - Indiana University. FAU - Rutter, Lauren A AU - Rutter LA AD - Indiana University. FAU - Wasil, Akash R AU - Wasil AR AD - University of Pennsylvania. FAU - Ramirez, Israel AU - Ramirez I AD - Indiana University. FAU - Lorenzo-Luaces, Lorenzo AU - Lorenzo-Luaces L AD - Indiana University. Electronic address: lolorenz@iu.edu. LA - eng GR - T32 MH103213/MH/NIMH NIH HHS/United States PT - Journal Article PT - Systematic Review DEP - 20230629 PL - England TA - Behav Ther JT - Behavior therapy JID - 1251640 SB - IM MH - Humans MH - Cognition MH - *Cognitive Behavioral Therapy MH - Depression/therapy MH - *Mobile Applications MH - Internet-Based Intervention PMC - PMC10787155 MID - NIHMS1931096 OTO - NOTNLM OT - cognitive-behavioral therapy (CBT) OT - depression OT - internet-based CBT (iCBT) OT - mental health apps COIS- The authors declare no conflicts of interest. EDAT- 2024/01/13 00:42 MHDA- 2024/01/15 12:43 PMCR- 2025/01/01 CRDT- 2024/01/12 20:57 PHST- 2022/08/01 00:00 [received] PHST- 2023/06/20 00:00 [revised] PHST- 2023/06/20 00:00 [accepted] PHST- 2024/01/15 12:43 [medline] PHST- 2024/01/13 00:42 [pubmed] PHST- 2024/01/12 20:57 [entrez] PHST- 2025/01/01 00:00 [pmc-release] AID - S0005-7894(23)00068-0 [pii] AID - 10.1016/j.beth.2023.06.003 [doi] PST - ppublish SO - Behav Ther. 2024 Jan;55(1):201-211. doi: 10.1016/j.beth.2023.06.003. Epub 2023 Jun 29. PMID- 38206033 OWN - NLM STAT- MEDLINE DCOM- 20240208 LR - 20260604 IS - 2165-0497 (Electronic) IS - 2165-0497 (Linking) VI - 12 IP - 2 DP - 2024 Feb 6 TI - Human carriage of ESBL/pAmpC-producing Escherichia coli and Klebsiella pneumoniae in relation to the consumption of raw or undercooked vegetables, fruits, and fresh herbs. PG - e0284923 LID - 10.1128/spectrum.02849-23 [doi] LID - e02849-23 AB - We investigated to what extent the consumption of raw or undercooked vegetables, fruits, and fresh herbs influences carriage rates of ESBL/pAmpC-producing Escherichia coli and Klebsiella pneumoniae (ESBL-E/K) in the general population. We assessed long-term carriage and changes in ESBL-E/K prevalence over time, by comparing the results to findings in the same population 5 years earlier. Between July and December 2021, participants sent in two fecal samples and questionnaires, 3 months apart. Food frequency questionnaires were sent on a monthly basis. Fecal samples were cultured and screened for ESBL-E/K, and phenotypically positive isolates were sequenced. Multivariable logistic regression models were established to assess the association between the consumption of fresh produce and ESBL-E/K carriage. The ESBL-E/K prevalence was 7.6% [41/537; 95% confidence interval (CI): 5.7-10.2] in the first sampling round and 7.0% (34/489; 95% CI: 5.0-9.6) in the second. Multivariable models did not result in statistical significance for any of the selected fruit and vegetable types. Trends for increased carriage rates were observed for the consumption of raspberry and blueberry in the summer period. ESBL-E/K prevalence was comparable with the prevalence in the same cohort 5 years earlier (7.5%; 95% CI: 5.6-10.1%). In six persons (1.2%) a genetically highly homologous ESBL-E/K was found. In conclusion, the contribution of the consumption of raw fruits, vegetables, and herbs to ESBL-E/K carriage in humans in the Netherlands is probably low. Despite COVID-19 containment measures (e.g., travel restrictions, social distancing, and hygiene) the ESBL-E/K prevalence was similar to 5 years earlier. Furthermore, indications for long-term carriage were found.IMPORTANCEESBL-producing bacteria are resistant against important classes of antibiotics, including penicillins and cephalosporines, which complicates treatment of infections. Food is one of the main routes of transmission for carriage of these bacteria in the general population. Although fruits, vegetables, and herbs are generally less frequently contaminated with ESBL-producing bacteria compared to meat, exposure might be higher since these products are often eaten raw or undercooked. This research showed that the contribution of the consumption of raw or undercooked fresh produce to ESBL-E/K carriage in the general Dutch population was low. No specific types of fruit or vegetables could be identified that gave a higher risk of carriage. In addition, we demonstrated the presence of genetically highly homologous ESBL-E/K in six persons after a period of 5 years, indicative for long-term carriage. FAU - Meijs, A P AU - Meijs AP AUID- ORCID: 0000-0001-5454-0350 AD - Centre for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, the Netherlands. FAU - Rozwandowicz, M AU - Rozwandowicz M AD - Centre for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, the Netherlands. FAU - Hengeveld, P D AU - Hengeveld PD AD - Centre for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, the Netherlands. FAU - Dierikx, C M AU - Dierikx CM AD - Centre for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, the Netherlands. FAU - de Greeff, S C AU - de Greeff SC AD - Centre for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, the Netherlands. FAU - van Duijkeren, E AU - van Duijkeren E AD - Centre for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, the Netherlands. FAU - van Dissel, J T AU - van Dissel JT AD - Centre for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, the Netherlands. AD - Department of Infectious Diseases and Internal Medicine, Leiden University Medical Center, Leiden, the Netherlands. LA - eng SI - Nucleotide/PRJEB63082 GR - Ministerie van Volksgezondheid, Welzijn en Sport (VWS)/ PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20240111 PL - United States TA - Microbiol Spectr JT - Microbiology spectrum JID - 101634614 RN - EC 3.5.2.6 (beta-Lactamases) RN - 0 (Anti-Bacterial Agents) SB - IM MH - Humans MH - *Klebsiella pneumoniae MH - Vegetables MH - Fruit MH - beta-Lactamases MH - Escherichia coli MH - *Escherichia coli Infections/microbiology MH - Anti-Bacterial Agents PMC - PMC10845978 OTO - NOTNLM OT - ESBL OT - Escherichia coli OT - Klebsiella pneumoniae OT - consumption OT - fruits OT - herbs OT - vegetables COIS- The authors declare no conflict of interest. EDAT- 2024/01/11 12:42 MHDA- 2024/02/08 06:43 PMCR- 2024/01/11 CRDT- 2024/01/11 09:04 PHST- 2024/02/08 06:43 [medline] PHST- 2024/01/11 12:42 [pubmed] PHST- 2024/01/11 09:04 [entrez] PHST- 2024/01/11 00:00 [pmc-release] AID - 02849-23 [pii] AID - spectrum.02849-23 [pii] AID - 10.1128/spectrum.02849-23 [doi] PST - ppublish SO - Microbiol Spectr. 2024 Feb 6;12(2):e0284923. doi: 10.1128/spectrum.02849-23. Epub 2024 Jan 11. PMID- 38167386 OWN - NLM STAT- MEDLINE DCOM- 20240126 LR - 20240204 IS - 1080-6059 (Electronic) IS - 1080-6040 (Print) IS - 1080-6040 (Linking) VI - 30 IP - 2 DP - 2024 Feb TI - Rebound of Gonorrhea after Lifting of COVID-19 Preventive Measures, England. PG - 329-332 LID - 10.3201/eid3002.231148 [doi] AB - After lifting of all COVID-19 preventive measures in England in July 2021, marked, widespread increases in gonorrhea diagnoses, but not testing numbers, were observed, particularly in persons 15-24 years of age. Continued close surveillance and public health messaging to young persons are needed to control and prevent gonorrhea transmission. FAU - Fountain, Holly AU - Fountain H FAU - Migchelsen, Stephanie J AU - Migchelsen SJ FAU - Charles, Hannah AU - Charles H FAU - Ram, Tika AU - Ram T FAU - Fifer, Helen AU - Fifer H FAU - Mohammed, Hamish AU - Mohammed H FAU - Sinka, Katy AU - Sinka K LA - eng PT - Journal Article DEP - 20240102 PL - United States TA - Emerg Infect Dis JT - Emerging infectious diseases JID - 9508155 SB - IM MH - Humans MH - *COVID-19/prevention & control MH - *Gonorrhea/epidemiology/prevention & control MH - SARS-CoV-2 MH - Public Health MH - England/epidemiology PMC - PMC10826777 OTO - NOTNLM OT - COVID-19 OT - COVID-19 preventive measures OT - COVID-19 restrictions OT - England OT - Neisseria gonorrhoeae OT - SARS OT - SARS-CoV-2 OT - United Kingdom OT - bacteria OT - coronavirus OT - coronavirus disease OT - gonorrhea OT - respiratory infections OT - severe acute respiratory syndrome coronavirus 2 OT - viruses OT - zoonoses EDAT- 2024/01/04 01:18 MHDA- 2024/01/26 06:43 PMCR- 2024/02/01 CRDT- 2024/01/03 09:47 PHST- 2024/01/26 06:43 [medline] PHST- 2024/01/04 01:18 [pubmed] PHST- 2024/01/03 09:47 [entrez] PHST- 2024/02/01 00:00 [pmc-release] AID - 23-1148 [pii] AID - 10.3201/eid3002.231148 [doi] PST - ppublish SO - Emerg Infect Dis. 2024 Feb;30(2):329-332. doi: 10.3201/eid3002.231148. Epub 2024 Jan 2. PMID- 38140623 OWN - NLM STAT- MEDLINE DCOM- 20231225 LR - 20240523 IS - 1999-4915 (Electronic) IS - 1999-4915 (Linking) VI - 15 IP - 12 DP - 2023 Dec 4 TI - Molecular Epidemiology of Respiratory Syncytial Virus during 2019-2022 and Surviving Genotypes after the COVID-19 Pandemic in Japan. LID - 10.3390/v15122382 [doi] LID - 2382 AB - To evaluate the changes in respiratory syncytial virus (RSV) collected between 2019 and 2022, we analyzed RSV-A and RSV-B strains from various prefectures in Japan before and after the COVID-19 pandemic. RT-PCR-positive samples collected from children with rapid test positivity at outpatient clinics in 11 prefectures in Japan were sequenced for the ectodomain of the G gene to determine the genotype. Time-aware phylogeographic analyses were performed using the second hypervariable region (HVR) of the G gene from 2012 to 2022. Of 967 samples, 739 (76.4%) were found to be RSV-positive using RT-PCR. RSV peaked in September 2019 but was not detected in 2020, except in Okinawa. Nationwide epidemics occurred with peaks in July 2021 and 2022. The genotype remained the same, ON1 for RSV-A and BA9 for RSV-B during 2019-2022. Phylogeographic analysis of HVR revealed that at least seven clusters of RSV-A had circulated previously but decreased to two clusters after the pandemic, whereas RSV-B had a single monophyletic cluster over the 10 years. Both RSV-A and RSV-B were transferred from Okinawa into other prefectures after the pandemic. The RSV epidemic was suppressed due to pandemic restrictions; however, pre-pandemic genotypes spread nationwide after the pandemic. FAU - Yoshioka, Sayaka AU - Yoshioka S AD - Division of International Health (Public Health), Graduate School of Medical and Dental Sciences, Niigata University, Niigata 951-8510, Japan. AD - Infectious Diseases Research Center of Niigata University (IDRC), Niigata University, Niigata 951-8510, Japan. FAU - Phyu, Wint Wint AU - Phyu WW AUID- ORCID: 0000-0002-7208-830X AD - Division of International Health (Public Health), Graduate School of Medical and Dental Sciences, Niigata University, Niigata 951-8510, Japan. AD - University of Medicine, Yangon, Myanmar. FAU - Wagatsuma, Keita AU - Wagatsuma K AD - Division of International Health (Public Health), Graduate School of Medical and Dental Sciences, Niigata University, Niigata 951-8510, Japan. FAU - Nagai, Takao AU - Nagai T AD - Nagai Pediatric Clinic, Takamatsu 760-0002, Japan. FAU - Sano, Yasuko AU - Sano Y AD - Sano Clinic, Niigata 950-0853, Japan. FAU - Taniguchi, Kiyosu AU - Taniguchi K AD - Mie National Hospital, Tsu 514-0125, Japan. FAU - Nagata, Nobuo AU - Nagata N AD - Hiraoka-Kouen Pediatric Clinic, Sapporo 004-0872, Japan. FAU - Tomimoto, Kazuhiko AU - Tomimoto K AD - Tomimoto Pediatric Clinic, Hachinohe 031-0823, Japan. FAU - Sato, Isamu AU - Sato I AD - Yoiko Pediatric Clinic Sato, Niigata 950-0983, Japan. FAU - Kaji, Harumi AU - Kaji H AD - Kaji Clinic, Hachioji 193-0816, Japan. FAU - Sugata, Ken AU - Sugata K AD - Mie National Hospital, Tsu 514-0125, Japan. FAU - Sugiura, Katsumi AU - Sugiura K AD - Mie National Hospital, Tsu 514-0125, Japan. FAU - Saito, Naruo AU - Saito N AD - Saito Pediatric Clinic, Moriyama 524-0022, Japan. FAU - Aoki, Satoshi AU - Aoki S AD - Aoki Pediatrics, Kitakatsuragi 636-0002, Japan. FAU - Suzuki, Eitaro AU - Suzuki E AD - Suzuki Pediatric Clinic, Ube 755-0151, Japan. FAU - Shimada, Yasushi AU - Shimada Y AD - Shimada Pediatrics, Kamiamakusa 869-3601, Japan. FAU - Hamabata, Hirotsune AU - Hamabata H AD - Awase Daiichi Clinic, Okinawa 904-2172, Japan. FAU - Chon, Irina AU - Chon I AUID- ORCID: 0000-0003-1829-0686 AD - Division of International Health (Public Health), Graduate School of Medical and Dental Sciences, Niigata University, Niigata 951-8510, Japan. FAU - Otoguro, Teruhime AU - Otoguro T AD - Infectious Diseases Research Center of Niigata University (IDRC), Niigata University, Niigata 951-8510, Japan. FAU - Watanabe, Hisami AU - Watanabe H AD - Infectious Diseases Research Center of Niigata University (IDRC), Niigata University, Niigata 951-8510, Japan. FAU - Saito, Reiko AU - Saito R AUID- ORCID: 0000-0002-1554-8226 AD - Division of International Health (Public Health), Graduate School of Medical and Dental Sciences, Niigata University, Niigata 951-8510, Japan. AD - Infectious Diseases Research Center of Niigata University (IDRC), Niigata University, Niigata 951-8510, Japan. LA - eng GR - not available/Ministry of Education, Culture, Sports, Science and Technology/ GR - 18K10043/Ministry of Education, Culture, Sports, Science and Technology/ GR - 21K10414/Ministry of Education, Culture, Sports, Science and Technology/ GR - 15fm0108009h0001-19fm0108009h005/Japan Agency for Medical Research and Development/ GR - 20wm0125005h001-23wm0125005h004/Japan Agency for Medical Research and Development/ GR - H24-Shinkou-Ippan-014/Ministry of Health, Labour and Welfare, and Sciences, Japan/ GR - H27- Shinkougyousei-Shitei-001/Ministry of Health, Labour and Welfare, and Sciences, Japan/ GR - H30-Shinkougyousei-Shitei-004/Ministry of Health, Labour and Welfare, and Sciences, Japan/ GR - not available/Niigata Prefectural Medical Association Grant/ PT - Journal Article DEP - 20231204 PL - Switzerland TA - Viruses JT - Viruses JID - 101509722 SB - IM MH - Child MH - Humans MH - Infant MH - *Respiratory Syncytial Virus Infections/epidemiology MH - Pandemics MH - Molecular Epidemiology MH - Japan/epidemiology MH - *COVID-19/epidemiology MH - Phylogeny MH - *Respiratory Syncytial Virus, Human/genetics MH - Genotype PMC - PMC10748361 OTO - NOTNLM OT - COVID-19 pandemic OT - G gene OT - molecular epidemiology OT - phylogeography OT - respiratory syncytial virus COIS- The authors declare no conflict of interest. EDAT- 2023/12/23 12:43 MHDA- 2023/12/25 06:43 PMCR- 2023/12/04 CRDT- 2023/12/23 01:29 PHST- 2023/11/17 00:00 [received] PHST- 2023/12/01 00:00 [revised] PHST- 2023/12/02 00:00 [accepted] PHST- 2023/12/25 06:43 [medline] PHST- 2023/12/23 12:43 [pubmed] PHST- 2023/12/23 01:29 [entrez] PHST- 2023/12/04 00:00 [pmc-release] AID - v15122382 [pii] AID - viruses-15-02382 [pii] AID - 10.3390/v15122382 [doi] PST - epublish SO - Viruses. 2023 Dec 4;15(12):2382. doi: 10.3390/v15122382. PMID- 38088154 OWN - NLM STAT- MEDLINE DCOM- 20240117 LR - 20240329 IS - 1941-7705 (Electronic) IS - 1941-7713 (Linking) VI - 17 IP - 1 DP - 2024 Jan TI - Daily Physical Activity Measured by Wearable Smartwatch for Patients Undergoing Transcatheter Aortic Valve Replacement: Insights From the SMART TAVR Study. PG - e010066 LID - 10.1161/CIRCOUTCOMES.123.010066 [doi] AB - BACKGROUND: This study aims to evaluate limited data about daily physical activity patterns, influential factors, and their association with 1-year mortality or rehospitalization after transcatheter aortic valve replacement (TAVR) through smartwatches. METHODS: Consecutive severe aortic stenosis patients undergoing elective transfemoral TAVR in a Chinese tertiary hospital were enrolled from July 2021 to May 2022 and received a Huawei smartwatch at least 1 day before TAVR. The primary outcome was a composite of all-cause mortality or hospital readmission within 1 year. Linear mixed-effects models were applied to determine influential factors of daily step counts, and Cox proportional hazard regression models were to estimate the association between baseline step counts within 1 month since discharge and composite outcome from months 2 to 12. The dose-response association was assessed using restricted cubic spline curves. RESULTS: A total of 222 participants and 59 469 valid monitoring person-day records were included (mean age, 72.7 years; 61% women). Step counts increased rapidly within the first 2 months (P<0.001), followed by a slower increase for those without composite outcomes (P=0.029) and a gradual decrease for those who developed composite outcomes (P<0.001). In multivariate linear mixed models, a 1-m increase in baseline 6-minute walk test and a 1-month delay after discharge were associated with 4 (95% CI, 1-7) and 170 (95% CI, 145-194) additional step counts, respectively. In restricted cubic spline analysis, the hazard ratio declined progressively until approximately 5000 steps per day, after which they leveled. Below 5000 steps, the adjusted hazard ratio of composite outcome associated with each 1000-step count increase was 0.67 (0.50-0.89; P=0.007). However, above 5000 steps, step counts were not significantly associated with the composite outcome (P=0.645), with a hazard ratio of 1.12 (0.70-1.79). CONCLUSIONS: Daily step counts rapidly increased within the first 2 months post-TAVR. Increased physical activity was associated with a lower risk of 1-year mortality or rehospitalization after TAVR for patients with daily step counts below 5000. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT04454177. FAU - Fan, Jiaqi AU - Fan J AUID- ORCID: 0000-0002-1909-9026 AD - Department of Cardiology (J.F., Q.L., Y.G., L.W., P.H., J.J., X. Lin, X. Liu, J.W.), Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, China. AD - Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA (J.F.). AD - State Key Laboratory of Transvascular Implantation Devices, Hangzhou, China (J.F., Q.L., X.L., J.W.). FAU - Liu, Qiong AU - Liu Q AD - Department of Cardiology (J.F., Q.L., Y.G., L.W., P.H., J.J., X. Lin, X. Liu, J.W.), Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, China. AD - State Key Laboratory of Transvascular Implantation Devices, Hangzhou, China (J.F., Q.L., X.L., J.W.). AD - Cardiovascular Key Laboratory of Zhejiang Province, Hangzhou, China (Q.L., J.W.). FAU - Dai, Hanyi AU - Dai H AUID- ORCID: 0000-0002-7782-891X AD - Zhejiang University School of Medicine, Hangzhou, China (H.D., D.Z.). FAU - Zhou, Dao AU - Zhou D AUID- ORCID: 0000-0001-7815-9490 AD - Zhejiang University School of Medicine, Hangzhou, China (H.D., D.Z.). FAU - Guo, Yuchao AU - Guo Y AUID- ORCID: 0000-0002-8206-6323 AD - Department of Cardiology (J.F., Q.L., Y.G., L.W., P.H., J.J., X. Lin, X. Liu, J.W.), Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, China. FAU - Xu, Jianguo AU - Xu J AD - Department of Electrocardiogram (J.X.), Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, China. FAU - Wang, Lihan AU - Wang L AD - Department of Cardiology (J.F., Q.L., Y.G., L.W., P.H., J.J., X. Lin, X. Liu, J.W.), Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, China. FAU - Hu, Po AU - Hu P AD - Department of Cardiology (J.F., Q.L., Y.G., L.W., P.H., J.J., X. Lin, X. Liu, J.W.), Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, China. FAU - Jiang, Jubo AU - Jiang J AD - Department of Cardiology (J.F., Q.L., Y.G., L.W., P.H., J.J., X. Lin, X. Liu, J.W.), Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, China. FAU - Lin, Xinping AU - Lin X AD - Department of Cardiology (J.F., Q.L., Y.G., L.W., P.H., J.J., X. Lin, X. Liu, J.W.), Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, China. AD - State Key Laboratory of Transvascular Implantation Devices, Hangzhou, China (J.F., Q.L., X.L., J.W.). FAU - Li, Cheng AU - Li C AD - Department of Nursing (C.L.), Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, China. FAU - Liu, Xianbao AU - Liu X AD - Department of Cardiology (J.F., Q.L., Y.G., L.W., P.H., J.J., X. Lin, X. Liu, J.W.), Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, China. FAU - Wang, Jian'an AU - Wang J AD - Department of Cardiology (J.F., Q.L., Y.G., L.W., P.H., J.J., X. Lin, X. Liu, J.W.), Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, China. AD - State Key Laboratory of Transvascular Implantation Devices, Hangzhou, China (J.F., Q.L., X.L., J.W.). AD - Cardiovascular Key Laboratory of Zhejiang Province, Hangzhou, China (Q.L., J.W.). AD - Research Center for Life Science and Human Health, Binjiang Institute of Zhejiang University, Hangzhou, China (J.W.). LA - eng SI - ClinicalTrials.gov/NCT04454177 PT - Journal Article DEP - 20231213 PL - United States TA - Circ Cardiovasc Qual Outcomes JT - Circulation. Cardiovascular quality and outcomes JID - 101489148 SB - IM MH - Humans MH - Female MH - Aged MH - Male MH - *Transcatheter Aortic Valve Replacement/adverse effects MH - *Aortic Valve Stenosis/diagnosis/surgery MH - Treatment Outcome MH - Exercise MH - *Wearable Electronic Devices MH - Aortic Valve/surgery MH - Risk Factors MH - Severity of Illness Index OTO - NOTNLM OT - aortic valve OT - humans OT - prognosis OT - quality of life OT - transcatheter aortic valve replacement COIS- Disclosures None. EDAT- 2023/12/13 06:42 MHDA- 2024/01/17 06:43 CRDT- 2023/12/13 05:26 PHST- 2024/01/17 06:43 [medline] PHST- 2023/12/13 06:42 [pubmed] PHST- 2023/12/13 05:26 [entrez] AID - 10.1161/CIRCOUTCOMES.123.010066 [doi] PST - ppublish SO - Circ Cardiovasc Qual Outcomes. 2024 Jan;17(1):e010066. doi: 10.1161/CIRCOUTCOMES.123.010066. Epub 2023 Dec 13. PMID- 38051326 OWN - NLM STAT- MEDLINE DCOM- 20231215 LR - 20260518 IS - 1538-3598 (Electronic) IS - 0098-7484 (Print) IS - 0098-7484 (Linking) VI - 330 IP - 21 DP - 2023 Dec 5 TI - Adenotonsillectomy for Snoring and Mild Sleep Apnea in Children: A Randomized Clinical Trial. PG - 2084-2095 LID - 10.1001/jama.2023.22114 [doi] AB - IMPORTANCE: The utility of adenotonsillectomy in children who have habitual snoring without frequent obstructive breathing events (mild sleep-disordered breathing [SDB]) is unknown. OBJECTIVES: To evaluate early adenotonsillectomy compared with watchful waiting and supportive care (watchful waiting) on neurodevelopmental, behavioral, health, and polysomnographic outcomes in children with mild SDB. DESIGN, SETTING, AND PARTICIPANTS: Randomized clinical trial enrolling 459 children aged 3 to 12.9 years with snoring and an obstructive apnea-hypopnea index (AHI) less than 3 enrolled at 7 US academic sleep centers from June 29, 2016, to February 1, 2021, and followed up for 12 months. INTERVENTION: Participants were randomized 1:1 to either early adenotonsillectomy (n = 231) or watchful waiting (n = 228). MAIN OUTCOMES AND MEASURES: The 2 primary outcomes were changes from baseline to 12 months for caregiver-reported Behavior Rating Inventory of Executive Function (BRIEF) Global Executive Composite (GEC) T score, a measure of executive function; and a computerized test of attention, the Go/No-go (GNG) test d-prime signal detection score, reflecting the probability of response to target vs nontarget stimuli. Twenty-two secondary outcomes included 12-month changes in neurodevelopmental, behavioral, quality of life, sleep, and health outcomes. RESULTS: Of the 458 participants in the analyzed sample (231 adenotonsillectomy and 237 watchful waiting; mean age, 6.1 years; 230 female [50%]; 123 Black/African American [26.9%]; 75 Hispanic [16.3%]; median AHI, 0.5 [IQR, 0.2-1.1]), 394 children (86%) completed 12-month follow-up visits. There were no statistically significant differences in change from baseline between the 2 groups in executive function (BRIEF GEC T-scores: -3.1 for adenotonsillectomy vs -1.9 for watchful waiting; difference, -0.96 [95% CI, -2.66 to 0.74]) or attention (GNG d-prime scores: 0.2 for adenotonsillectomy vs 0.1 for watchful waiting; difference, 0.05 [95% CI, -0.18 to 0.27]) at 12 months. Behavioral problems, sleepiness, symptoms, and quality of life each improved more with adenotonsillectomy than with watchful waiting. Adenotonsillectomy was associated with a greater 12-month decline in systolic and diastolic blood pressure percentile levels (difference in changes, -9.02 [97% CI, -15.49 to -2.54] and -6.52 [97% CI, -11.59 to -1.45], respectively) and less progression of the AHI to greater than 3 events/h (1.3% of children in the adenotonsillectomy group compared with 13.2% in the watchful waiting group; difference, -11.2% [97% CI, -17.5% to -4.9%]). Six children (2.7%) experienced a serious adverse event associated with adenotonsillectomy. CONCLUSIONS: In children with mild SDB, adenotonsillectomy, compared with watchful waiting, did not significantly improve executive function or attention at 12 months. However, children with adenotonsillectomy had improved secondary outcomes, including behavior, symptoms, and quality of life and decreased blood pressure, at 12-month follow-up. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02562040. FAU - Redline, Susan AU - Redline S AD - Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. FAU - Cook, Kaitlyn AU - Cook K AD - Program in Statistical and Data Sciences, Smith College, Northampton, Massachusetts. AD - Department of Population Medicine, Harvard Pilgrim Health Care Institute and Harvard Medical School, Boston, Massachusetts. FAU - Chervin, Ronald D AU - Chervin RD AD - Sleep Disorders Center and Department of Neurology, University of Michigan, Ann Arbor. FAU - Ishman, Stacey AU - Ishman S AD - Department of Otolaryngology, Head and Neck Surgery, University of Cincinnati College of Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio. FAU - Baldassari, Cristina M AU - Baldassari CM AD - Department of Otolaryngology, Eastern Virginia Medical School, Children's Hospital of The King's Daughters, Norfolk. FAU - Mitchell, Ron B AU - Mitchell RB AD - Departments of Otolaryngology-Head and Neck Surgery and Neurology Sleep Disorders Center, UT Southwestern Medical Center, Children's Medical Center, Dallas. FAU - Tapia, Ignacio E AU - Tapia IE AD - Department of Pediatrics, Children's Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania, Philadelphia. FAU - Amin, Raouf AU - Amin R AD - Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio. FAU - Hassan, Fauziya AU - Hassan F AD - Sleep Disorders Center and Department of Pediatrics and Communicable Diseases, University of Michigan, Ann Arbor. FAU - Ibrahim, Sally AU - Ibrahim S AD - Department of Pediatrics, University Hospitals Rainbow Babies & Children's Hospital, Cleveland, Ohio. FAU - Ross, Kristie AU - Ross K AD - Department of Pediatrics, University Hospitals Rainbow Babies & Children's Hospital, Cleveland, Ohio. FAU - Elden, Lisa M AU - Elden LM AD - Division of Pediatric Otolaryngology, Children's Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania, Philadelphia. FAU - Kirkham, Erin M AU - Kirkham EM AD - Department of Otolaryngology-Head and Neck Surgery, University of Michigan, Ann Arbor. FAU - Zopf, David AU - Zopf D AD - Department of Otolaryngology-Head and Neck Surgery, University of Michigan, Ann Arbor. FAU - Shah, Jay AU - Shah J AD - Department of Otolaryngology, University Hospitals Rainbow Babies. AD - University Hospitals Rainbow Babies & Children's Hospital, Case Western Reserve University, Cleveland, Ohio. FAU - Otteson, Todd AU - Otteson T AD - Department of Otolaryngology, University Hospitals Rainbow Babies. AD - University Hospitals Rainbow Babies & Children's Hospital, Case Western Reserve University, Cleveland, Ohio. FAU - Naqvi, Kamal AU - Naqvi K AD - Department of Pediatrics, UT Southwestern Medical Center, Dallas. FAU - Owens, Judith AU - Owens J AD - Department of Neurology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts. FAU - Young, Lisa AU - Young L AD - Department of Pediatrics, Children's Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania, Philadelphia. FAU - Furth, Susan AU - Furth S AD - Department of Pediatrics, Children's Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania, Philadelphia. FAU - Connolly, Heidi AU - Connolly H AD - Department of Pediatrics, University of Rochester, Rochester, New York. FAU - Clark, Caron A C AU - Clark CAC AD - Department of Educational Psychology, University of Nebraska-Lincoln. FAU - Bakker, Jessie P AU - Bakker JP AD - Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. FAU - Garetz, Susan AU - Garetz S AD - Department of Otolaryngology-Head and Neck Surgery and Department of Neurology-Sleep Disorders Center, University of Michigan, Ann Arbor. FAU - Radcliffe, Jerilynn AU - Radcliffe J AD - Department of Pediatrics, Children's Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania, Philadelphia. FAU - Taylor, H Gerry AU - Taylor HG AD - Abigail Wexner Research Institute at Nationwide Children's Hospital and The Ohio State University, Columbus. FAU - Rosen, Carol L AU - Rosen CL AD - Case Western Reserve University School of Medicine, Department of Pediatrics, Cleveland, Ohio. FAU - Wang, Rui AU - Wang R AD - Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. AD - Department of Population Medicine, Harvard Pilgrim Health Care Institute and Harvard Medical School, Boston, Massachusetts. AD - Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts. CN - Pediatric Adenotonsillectomy Trial for Snoring (PATS) Study Team LA - eng SI - ClinicalTrials.gov/NCT02562040 GR - K23 HL153897/HL/NHLBI NIH HHS/United States GR - U01 HL125295/HL/NHLBI NIH HHS/United States GR - U01 HL125307/HL/NHLBI NIH HHS/United States PT - Comparative Study PT - Journal Article PT - Randomized Controlled Trial PT - Research Support, N.I.H., Extramural PL - United States TA - JAMA JT - JAMA JID - 7501160 SB - IM CIN - JAMA. 2023 Dec 5;330(21):2057-2058. doi: 10.1001/jama.2023.22373. PMID: 38051336 CIN - JAMA Otolaryngol Head Neck Surg. 2024 Jun 1;150(6):528-529. doi: 10.1001/jamaoto.2024.0585. PMID: 38635260 MH - Child MH - Female MH - Humans MH - Polysomnography MH - Quality of Life MH - *Sleep Apnea Syndromes/diagnosis/etiology/surgery MH - Sleep Apnea, Obstructive/diagnosis/etiology/surgery MH - *Snoring/etiology/surgery MH - *Tonsillectomy/adverse effects/methods MH - Male MH - *Adenoidectomy/adverse effects/methods MH - *Watchful Waiting MH - Child, Preschool MH - Treatment Outcome MH - Follow-Up Studies PMC - PMC10698619 COIS- Conflict of Interest Disclosures: Dr Redline reported receiving personal fees from Jazz Pharma, Eli Lilly, and ApniMed and receiving grants to institution from the National Institutes of Health (NIH). Dr Chervin reported serving as a consultant for Eli Lilly through a contract between that company and University of Michigan Health; holding a patent for a copyrighted questionnaire about pediatric sleep-disordered breathing, with royalties paid (may receive royalties in future, depending on contract that University of Michigan Health may negotiate with a company); serving on the board of directors (unpaid) and as treasurer for the International Pediatric Sleep Association; and that he was a member of the American Academy of Sleep Medicine board of directors from July 2010 to June 2018 (the views expressed are his own and do not represent the view of the American Academy of Sleep Medicine). Dr Hassan reported serving as a consultant for Eli Lilly. Dr Ibrahim reported receiving research-related funding from Jazz Pharmaceuticals, Avadel Pharmaceuticals, and Harmony Biosciences. Dr Ross reported receiving grants to institution from AstraZeneca and from GlaxoSmithKline to conduct asthma clinical trials and receiving fees from AstraZeneca for advisory board participation related to asthma therapeutics. Dr Kirkham reported receiving grant K23 HL153897-01A1 from the NIH/National Heart, Lung, and Blood Institute (NHLBI) and that she is an author for UpToDate on Adenotonsillectomy for Obstructive Sleep Apnea in Children. Dr Shah reported receiving personal fees from AMBU. Dr Otteson reported receiving grants from NIH/NHLBI. Dr Young reported receiving grants from NIH/NHLBI; Dr Young reported receiving authorship payment from UpToDate Wolters Kluwer, payment from Boehringer Inghelheim for pediatric interstitial lung disease advisory board member roles, advisory fees from Genzyme Sanofi, consulting fees from Roche, and grants from the University of Pennsylvania. Dr Bakker reported receiving salary and shares from Philips, salary and restricted stock units from Signifier Medical Technologies, and personal fees from Koneksa Health, Apnimed, and Digital Medicine Society, a 501(c)(3) non-profit organization. Dr Taylor reported receiving grants from the Abigail Wexner Research Institute at Nationwide Children's Hospital. Dr Rosen reported serving as a board of directors member of the American Academy of Sleep Medicine from 2017 to 2023 (the views expressed are her own and do not represent the view of the American Academy of Sleep Medicine). Dr Wang reported grants to institution from NIH/NHLBI. No other disclosures were reported. FIR - Rueschman, Michael N IR - Rueschman MN FIR - Tully, Meg IR - Tully M FIR - Arnold, Jean IR - Arnold J FIR - Nicholson, Michelle IR - Nicholson M FIR - Kaplan, Emily IR - Kaplan E FIR - Mobley, Dan IR - Mobley D FIR - Morrical, Michael IR - Morrical M FIR - Karamessinis, Laurie IR - Karamessinis L FIR - Ward, Michelle IR - Ward M FIR - Cornaglia, Mary Ann IR - Cornaglia MA FIR - Bradford, Ruth IR - Bradford R FIR - Ciampaglia, Alyssa IR - Ciampaglia A FIR - Groubert, Hayley IR - Groubert H FIR - Denallo, Erica IR - Denallo E FIR - Rajashari, Rasal IR - Rajashari R FIR - Pyzoha, Morgan IR - Pyzoha M FIR - Rogers, Heather IR - Rogers H FIR - McKibben, Kieran IR - McKibben K FIR - Hicks, Suzie IR - Hicks S FIR - Carter, Belinda IR - Carter B FIR - Boh, Melodie IR - Boh M FIR - Swegheimer, Krista IR - Swegheimer K FIR - Niehaus, Stacey IR - Niehaus S FIR - Herresoff, Emily IR - Herresoff E FIR - Heffner, Marianne IR - Heffner M FIR - Fetterolf, Judy IR - Fetterolf J FIR - Geal, Bill IR - Geal B FIR - Brand, Sarah IR - Brand S FIR - DeWeese, Braden IR - DeWeese B FIR - Johnson, Libby IR - Johnson L FIR - Brierly, Kristin IR - Brierly K FIR - Jordan, Allison IR - Jordan A FIR - Pavelka, Kacee IR - Pavelka K FIR - Sands, Jay IR - Sands J FIR - Szpara, Ashley IR - Szpara A FIR - Chambers, Francesca IR - Chambers F FIR - Vargas, Laura IR - Vargas L FIR - Eshon, Constance IR - Eshon C FIR - George, Florence IR - George F FIR - Martin, Mary IR - Martin M FIR - Sparks, Vernell IR - Sparks V FIR - Young, Victoria IR - Young V FIR - Stone, Laura IR - Stone L FIR - Boykin, Amy IR - Boykin A FIR - Riggan, Emily IR - Riggan E FIR - Boswick, Thomas IR - Boswick T FIR - Bailey, Michael IR - Bailey M FIR - Stetler, Amanda IR - Stetler A FIR - Tham, Addy IR - Tham A EDAT- 2023/12/05 17:44 MHDA- 2023/12/07 12:42 PMCR- 2024/06/05 CRDT- 2023/12/05 11:04 PHST- 2023/12/07 12:42 [medline] PHST- 2023/12/05 17:44 [pubmed] PHST- 2023/12/05 11:04 [entrez] PHST- 2024/06/05 00:00 [pmc-release] AID - 2812479 [pii] AID - joi230132 [pii] AID - 10.1001/jama.2023.22114 [doi] PST - ppublish SO - JAMA. 2023 Dec 5;330(21):2084-2095. doi: 10.1001/jama.2023.22114. PMID- 38020794 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20231201 IS - 2050-3121 (Print) IS - 2050-3121 (Electronic) IS - 2050-3121 (Linking) VI - 11 DP - 2023 TI - Vitamin D and preeclampsia: A systematic review and meta-analysis. PG - 20503121231212093 LID - 10.1177/20503121231212093 [doi] LID - 20503121231212093 AB - OBJECTIVES: Preeclampsia is one of the most frequent pregnancy disorders, with a global incidence of 2%-8%. Serum 25-hydroxyvitamin D is an essential mineral for human health; some studies suggest link between 25-hydroxyvitamin D deficiency and preeclampsia, while others offer contradictory findings. Thus, the goal of this study is to evaluate the relationships between maternal 25- hydroxyvitamin D concentrations and the risk of preeclampsia. In addition to this, our study also evaluates the effects of 25- hydroxyvitamin D supplementation on the incidence of preeclampsia. Therefore, assessing 25- hydroxyvitamin D's potential as a possible intervention to lower the risk of preeclampsia. METHODS: The Medline database was queried from inception until July 2021 for randomized controlled trials and observational studies without any restrictions. The studies assessing the association between 25-hydroxyvitamin D deficiency and preeclampsia and the impact of 25-hydroxyvitamin D supplementation on the incidence of preeclampsia were incorporated. The results were reported using a random-effects meta-analysis and the Mantel-Haenszel odds ratio. A p-value of <0.05 was considered significant for the analysis. RESULTS: This analysis includes 34 papers, including 10 randomized controlled trials and 24 observational studies. According to our pooled analysis, 25-hydroxyvitamin D supplementation was significantly associated with a lower risk of preeclampsia in pregnant women (OR: 0.50; 95% CI: 0.40-0.63; p = 0.00001), while 25-hydroxyvitamin D deficiency was significantly associated with an increased risk of preeclampsia (OR: 4.30; 95 % CI: 2.57-7.18; p < 0.00001, OR: 1.71; 95 % Cl: 1.27-2.32; p = 0.0005, OR 1.61; 95 % Cl: 1.21-2.16; p = 0.001). CONCLUSION: Results suggest that 25-hydroxyvitamin D has a significant relationship with preeclampsia as confirmed by the findings that low maternal 25-hydroxyvitamin D concentrations cause increased risk of preeclampsia while 25-hydroxyvitamin D supplementation reduces the incidence of preeclampsia. Our findings indicate that 25-hydroxyvitamin D supplementation can be used as a possible intervention strategy in preventing one of the most common causes of maternal mortality around the world, preeclampsia. CI - (c) The Author(s) 2023. FAU - AlSubai, Abdulla AU - AlSubai A AD - Royal College of Surgeons in Ireland, Dublin, Ireland. FAU - Baqai, Muhammad Hadi AU - Baqai MH AUID- ORCID: 0000-0002-9351-4769 AD - Ziauddin Medical University, Karachi, Sindh, Pakistan. FAU - Agha, Hifza AU - Agha H AD - Shaheed Mohtarma Benazir Bhutto Medical College Lyari, Karachi, Pakistan. FAU - Shankarlal, Neha AU - Shankarlal N AD - Dow Medical College, Karachi, Sindh, Pakistan. FAU - Javaid, Syed Sarmad AU - Javaid SS AD - Jinnah Sindh Medical University, Karachi, Sindh, Pakistan. FAU - Jesrani, Eshika Kumari AU - Jesrani EK AD - Ziauddin Medical University, Karachi, Sindh, Pakistan. FAU - Golani, Shalni AU - Golani S AD - The Aga Khan University Medical College Pakistan, Karachi, Sindh, Pakistan. FAU - Akram, Abdullah AU - Akram A AD - Dow Medical College, Karachi, Sindh, Pakistan. FAU - Qureshi, Faiza AU - Qureshi F AD - The Aga Khan University Medical College Pakistan, Karachi, Sindh, Pakistan. FAU - Ahmed, Shaheer AU - Ahmed S AD - Dow Medical College, Karachi, Sindh, Pakistan. FAU - Saran, Simran AU - Saran S AD - University of Waterloo, Waterloo, ON, Canada. LA - eng PT - Journal Article DEP - 20231122 PL - England TA - SAGE Open Med JT - SAGE open medicine JID - 101624744 PMC - PMC10666722 OTO - NOTNLM OT - 25(OH)D OT - hypertension OT - incidence OT - meta-analysis OT - preeclampsia OT - pregnancy OT - treatment OT - vitamin D COIS- The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. EDAT- 2023/11/29 18:42 MHDA- 2023/11/29 18:43 PMCR- 2023/11/22 CRDT- 2023/11/29 14:51 PHST- 2023/07/05 00:00 [received] PHST- 2023/10/18 00:00 [accepted] PHST- 2023/11/29 18:43 [medline] PHST- 2023/11/29 18:42 [pubmed] PHST- 2023/11/29 14:51 [entrez] PHST- 2023/11/22 00:00 [pmc-release] AID - 10.1177_20503121231212093 [pii] AID - 10.1177/20503121231212093 [doi] PST - epublish SO - SAGE Open Med. 2023 Nov 22;11:20503121231212093. doi: 10.1177/20503121231212093. eCollection 2023. PMID- 38006343 OWN - NLM STAT- MEDLINE DCOM- 20231127 LR - 20251114 IS - 0971-5916 (Print) IS - 0975-9174 (Electronic) IS - 0971-5916 (Linking) VI - 158 IP - 4 DP - 2023 Oct 1 TI - Challenges in screening for sickle cell disease among newborns from the tribal region of Palghar, Maharashtra during the COVID-19 pandemic. PG - 378-383 LID - 10.4103/ijmr.ijmr_3220_21 [doi] AB - BACKGROUND OBJECTIVES: Despite several adversities imposed by the COVID-19 pandemic, it was crucial to sustain research having public health relevance such as investigations around sickle cell disease (SCD). Against this background, an ongoing ICMR-multicentric study for newborn screening of SCD in the tribal population at Model Rural Health Research Unit (MRHRU-Dahanu) in Palghar District, Maharashtra constituted the current study setting. This was a descriptive study wherein, certain measures were undertaken and strategies were developed in view of the challenges in newborn screening for SCD due to the COVID-19 pandemic during December 2019-September 2021 at Sub District Hospital, MRHRU-Dahanu. METHODS: During the onset of the pandemic, (December 2019-March 2020), the follow up was possible in 26.7 per cent (20/75) of the newborns. Subsequently, challenges such as travel restrictions, fear of COVID-19, shortage of staff were experienced with respect to enrolment and follow up visits. RESULTS: After implementing certain pragmatic strategies (ASHA involvement, usage of virtual platform and flexible visits), follow up rate increased to 47.5 per cent (66/139) between July 2020-April 2021 (post first lockdown) and to 66 per cent (65/98) during the second wave (May 2021-August 2021). INTERPRETATION CONCLUSIONS: The study emphasizes the importance of network building, use of virtual platform and engaging health workers in tribal settings. Such pragmatic approaches have the potential to pave a path for further implementation research involving specific interventions to improve health outcomes in tribal settings. CI - Copyright (c) 2023 Copyright: (c) 2023 Indian Journal of Medical Research. FAU - Surve, Suchitra AU - Surve S AD - Department of Child Health Research, ICMR-National Institute for Research in Reproductive & Child Health, Mumbai, India. FAU - Chauhan, Sanjay AU - Chauhan S AD - Department of Operational & Implementation Research, ICMR-National Institute for Research in Reproductive & Child Health, Mumbai, India. FAU - Kulkarni, Ragini AU - Kulkarni R AD - Department of Operational & Implementation Research, ICMR-National Institute for Research in Reproductive & Child Health, Mumbai, India. FAU - Salvi, Neha AU - Salvi N AD - Model Rural Health Research Unit, Dahanu, Maharashtra, India. FAU - Nadkarni, Anita AU - Nadkarni A AD - ICMR-National Institute for Immunohaematology, KEM Hospital Campus, Mumbai, India. FAU - Madkaikar, Manisha AU - Madkaikar M AD - ICMR-National Institute for Immunohaematology, KEM Hospital Campus, Mumbai, India. FAU - Chaudhary, Khushbu AU - Chaudhary K AD - Model Rural Health Research Unit, Dahanu, Maharashtra, India. FAU - Chavan, Abhijit AU - Chavan A AD - Sub District Hospital, Dahanu, Maharashtra, India. FAU - Suryavanshi, Dayanand AU - Suryavanshi D AD - District Health Officer, Palghar District, Maharashtra, India. FAU - Thorat, Anil AU - Thorat A AD - Civil Surgeon Office, Palghar District, Maharashtra, India. FAU - Kaur, Harpreet AU - Kaur H AD - Division of Epidemiology & Communicable Diseases, Indian Council of Medical Research, Ansari Nagar, New Delhi, India. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20230925 PL - United States TA - Indian J Med Res JT - The Indian journal of medical research JID - 0374701 SB - IM MH - Humans MH - Infant, Newborn MH - *COVID-19/epidemiology MH - Pandemics MH - Communicable Disease Control MH - India/epidemiology MH - *Anemia, Sickle Cell/diagnosis/epidemiology PMC - PMC10793820 COIS- None. EDAT- 2023/11/26 07:42 MHDA- 2023/11/27 16:18 PMCR- 2023/10/01 CRDT- 2023/11/25 09:03 PHST- 2021/11/03 00:00 [received] PHST- 2023/11/27 16:18 [medline] PHST- 2023/11/26 07:42 [pubmed] PHST- 2023/11/25 09:03 [entrez] PHST- 2023/10/01 00:00 [pmc-release] AID - 02223309-202310000-00009 [pii] AID - IJMR-158-378 [pii] AID - 10.4103/ijmr.ijmr_3220_21 [doi] PST - ppublish SO - Indian J Med Res. 2023 Oct 1;158(4):378-383. doi: 10.4103/ijmr.ijmr_3220_21. Epub 2023 Sep 25. PMID- 37906535 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240210 IS - 2767-3375 (Electronic) IS - 2767-3375 (Linking) VI - 3 IP - 10 DP - 2023 TI - Changes in mobility patterns during the COVID-19 pandemic in Zambia: Implications for the effectiveness of NPIs in Sub-Saharan Africa. PG - e0000892 LID - 10.1371/journal.pgph.0000892 [doi] LID - e0000892 AB - The COVID-19 pandemic has impacted many facets of human behavior, including human mobility partially driven by the implementation of non-pharmaceutical interventions (NPIs) such as stay at home orders, travel restrictions, and workplace and school closures. Given the importance of human mobility in the transmission of SARS-CoV-2, there have been an increase in analyses of mobility data to understand the COVID-19 pandemic to date. However, despite an abundance of these analyses, few have focused on Sub-Saharan Africa (SSA). Here, we use mobile phone calling data to provide a spatially refined analysis of sub-national human mobility patterns during the COVID-19 pandemic from March 2020-July 2021 in Zambia using transmission and mobility models. Overall, among highly trafficked intra-province routes, mobility decreased up to 52% during the time of the strictest NPIs (March-May 2020) compared to baseline. However, despite dips in mobility during the first wave of COVID-19 cases, mobility returned to baseline levels and did not drop again suggesting COVID-19 cases did not influence mobility in subsequent waves. CI - Copyright: (c) 2023 Loisate et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. FAU - Loisate, Stacie AU - Loisate S AD - Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America. FAU - Mutembo, Simon AU - Mutembo S AD - Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America. AD - Ministry of Health, Government of the Republic of Zambia, Lusaka, Zambia. FAU - Arambepola, Rohan AU - Arambepola R AUID- ORCID: 0000-0003-2833-8786 AD - Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America. FAU - Makungo, Kabondo AU - Makungo K AUID- ORCID: 0000-0003-3116-545X AD - Zamtel, Lusaka, Zambia. FAU - Kabalo, Elliot N AU - Kabalo EN AD - Zambia Information and Communications Technology Authority, Lusaka, Zambia. FAU - Sinyange, Nyambe B AU - Sinyange NB AD - Zambian National Public Health Institute, Lusaka, Zambia. FAU - Kapata, Nathan AU - Kapata N AD - Zambian National Public Health Institute, Lusaka, Zambia. FAU - Liwewe, Mazyanga AU - Liwewe M AD - Zambian National Public Health Institute, Lusaka, Zambia. FAU - Silumezi, Andrew AU - Silumezi A AD - Directorate of Public Health and Research, Lusaka, Zambia. FAU - Chongwe, Gershom AU - Chongwe G AD - Tropical Diseases Research Center, Ndola, Zambia. FAU - Kostandova, Natalya AU - Kostandova N AUID- ORCID: 0000-0002-6184-531X AD - Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America. FAU - Truelove, Shaun AU - Truelove S AD - Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America. AD - Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America. FAU - Wesolowski, Amy AU - Wesolowski A AUID- ORCID: 0000-0001-6320-3575 AD - Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America. LA - eng GR - DP2 LM013102/LM/NLM NIH HHS/United States GR - R01 AI160780/AI/NIAID NIH HHS/United States PT - Journal Article DEP - 20231031 PL - United States TA - PLOS Glob Public Health JT - PLOS global public health JID - 9918283779606676 PMC - PMC10617722 COIS- The authors have declared that no competing interests exist. EDAT- 2023/10/31 18:42 MHDA- 2023/10/31 18:43 PMCR- 2023/10/31 CRDT- 2023/10/31 13:23 PHST- 2022/07/18 00:00 [received] PHST- 2023/09/22 00:00 [accepted] PHST- 2023/10/31 18:43 [medline] PHST- 2023/10/31 18:42 [pubmed] PHST- 2023/10/31 13:23 [entrez] PHST- 2023/10/31 00:00 [pmc-release] AID - PGPH-D-22-01142 [pii] AID - 10.1371/journal.pgph.0000892 [doi] PST - epublish SO - PLOS Glob Public Health. 2023 Oct 31;3(10):e0000892. doi: 10.1371/journal.pgph.0000892. eCollection 2023. PMID- 37885976 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20231028 IS - 2476-4108 (Print) IS - 2476-3772 (Electronic) IS - 2476-3772 (Linking) VI - 21 IP - 8 DP - 2023 Aug TI - Association between anogenital distance as a noninvasive index in the diagnosis and prognosis of reproductive disorder: A systematic review. PG - 599-618 LID - 10.18502/ijrm.v21i8.14016 [doi] AB - BACKGROUND: There are 2 measures of anogenital distance (AGD) in men and women. AGD has been used as an indicator of fetal androgen dysfunction and an adverse outcome in adulthood. Some studies have shown the association of AGD as a predictor in the diagnosis and prognosis of diseases and disorders. OBJECTIVE: To systematically summarize the latest evidence for presenting AGD as a new approach for prognosis and early diagnosis of diseases. MATERIALS AND METHODS: A systematic review of the available literature was performed using Medline via PubMed, Scopus, and ISI Web of Knowledge up to July 2021, using search terms "anogenital distance" OR "anogenital index" OR "ano genital distance" OR "ano genital index". Language restrictions were not imposed. RESULTS: After reviewing the retrieved articles, 47 unique studies were included in this systematic review. Different outcomes, including endometriosis, prostate cancer, polycystic ovary syndrome, pelvic organ prolapse, hypospadias, cryptorchidism, fertility and semen parameters, maternal and birth development, and ovarian and gynecological-related disorders, have been studied in the included evidence. A negative association was observed between AGD and endometriosis and hypospadias and a positive association between AGD and prostate cancer, polycystic ovary syndrome, male fetal gender, and fertility parameters. CONCLUSION: Using quantitative indicators such as AGD may be a useful clinical tool for the diagnosis of diseases. Although many studies have shown an association between AGD and diseases, some factors, including different measurement methods, different measurement tools, age, and different definitions of AGD, can be involved in the variation of AGD. CI - Copyright (c) 2023 Zamani et al. FAU - Zamani, Parisa AU - Zamani P AD - Student Research Committee, School of Nursing and Midwifery, Shahroud University of Medical Sciences, Shahroud, Iran. FAU - Hemati, Zeinab AU - Hemati Z AD - Child Growth and Development Research Center, Research Institute for Primordial Prevention of Non-Communicable Disease, Isfahan University of Medical Sciences, Isfahan, Iran. FAU - Kelishadi, Roya AU - Kelishadi R AD - Child Growth and Development Research Center, Research Institute for Primordial Prevention of Non-Communicable Disease, Isfahan University of Medical Sciences, Isfahan, Iran. FAU - Kolahdozan, Sakineh AU - Kolahdozan S AD - Clinical Research Development Unit, Bahar Hospital, Shahroud University of Medical Sciences, Shahroud, Iran. FAU - Dianatinasab, Mostafa AU - Dianatinasab M AD - Department of Medical Sciences, School of Medical and Life Sciences, Sunway University, Malaysia. AD - Department of Complex Genetics and Epidemiology, School of Nutrition and Translational Research in Metabolism, Maastricht University, Maastricht, The Netherlands. FAU - Keikha, Mojtaba AU - Keikha M AUID- ORCID: 0000-0003-1464-0810 AD - Department of Biostatistics and Epidemiology, Faculty of Public Health, Kerman University of Medical Sciences, Kerman, Iran. LA - eng PT - Journal Article PT - Review DEP - 20230920 PL - Iran TA - Int J Reprod Biomed JT - International journal of reproductive biomedicine JID - 101679102 PMC - PMC10598470 OTO - NOTNLM OT - Early diagnosis OT - Prognosis OT - Reproductive health OT - Genitalia COIS- The authors declare that there is no conflict of interest. EDAT- 2023/10/27 06:42 MHDA- 2023/10/27 06:43 PMCR- 2023/09/20 CRDT- 2023/10/27 04:27 PHST- 2022/02/01 00:00 [received] PHST- 2023/01/03 00:00 [revised] PHST- 2023/06/07 00:00 [accepted] PHST- 2023/10/27 06:43 [medline] PHST- 2023/10/27 06:42 [pubmed] PHST- 2023/10/27 04:27 [entrez] PHST- 2023/09/20 00:00 [pmc-release] AID - 10.18502/ijrm.v21i8.14016 [doi] PST - epublish SO - Int J Reprod Biomed. 2023 Sep 20;21(8):599-618. doi: 10.18502/ijrm.v21i8.14016. eCollection 2023 Aug. PMID- 37853205 OWN - NLM STAT- MEDLINE DCOM- 20231023 LR - 20231110 IS - 1573-2959 (Electronic) IS - 0167-6369 (Linking) VI - 195 IP - 11 DP - 2023 Oct 18 TI - Effect of lockdown and associated mobility changes amid COVID-19 on air quality in the Kathmandu Valley, Nepal. PG - 1337 LID - 10.1007/s10661-023-11949-5 [doi] AB - The COVID-19 pandemic caused a setback for Nepal, leading to nationwide lockdowns. The study analyzed the impact of lockdown on air quality during the first and second waves of the COVID-19 pandemic in the Kathmandu Valley. We analyzed 5 years of ground-based air quality monitoring data (2017-2021) from March to July and April to June for the first and second wave lockdowns, respectively. A significant decrease in PM(2.5) (particulate matter with an aerodynamic diameter /=55 across the United States (mean age 71). Reflexive thematic analysis identified heightened sociopolitical tensions and complex community experiences since the pandemic's onset. Participants shared nuanced perceptions of greater physical and emotional distancing, siloed communities, politicized public health adherence, fears of gun violence, and experiences of racial discrimination in shared spaces. Hopeful efforts to re-engage in civic life involved cautious social activities post-vaccination, altered daily routines, and finding a "new normal." The novel results explore how a large sample of racially and socioeconomically diverse older adults perceive and experience American sociopolitical tensions anchored in shared everyday spaces. Results may inform practical opportunities for policymakers and community service providers to strengthen social infrastructure, support wellbeing, and bolster civic life. CI - Copyright (c) 2023 Elsevier Ltd. All rights reserved. FAU - Finlay, Jessica AU - Finlay J AD - Department of Geography, University of Colorado Boulder, Boulder, CO, USA; Institute of Behavioral Science, University of Colorado Boulder, Boulder, CO, USA; Social Environment and Health Program, Institute for Social Research, University of Michigan, Ann Arbor, USA. Electronic address: jessica.finlay@colorado.edu. FAU - Eastman, Marisa AU - Eastman M AD - Social Environment and Health Program, Institute for Social Research, University of Michigan, Ann Arbor, USA; Center for Social Epidemiology and Population Health, School of Public Health, University of Michigan, Ann Arbor, USA. Electronic address: meastma@umich.edu. FAU - Kobayashi, Lindsay AU - Kobayashi L AD - Social Environment and Health Program, Institute for Social Research, University of Michigan, Ann Arbor, USA; Center for Social Epidemiology and Population Health, School of Public Health, University of Michigan, Ann Arbor, USA. Electronic address: lkob@umich.edu. LA - eng GR - K99 AG075152/AG/NIA NIH HHS/United States GR - R00 AG075152/AG/NIA NIH HHS/United States PT - Journal Article DEP - 20231006 PL - England TA - Soc Sci Med JT - Social science & medicine (1982) JID - 8303205 SB - IM MH - Humans MH - United States/epidemiology MH - Aged MH - *COVID-19/epidemiology MH - Pandemics MH - Food Markets MH - Social Behavior MH - Life Style PMC - PMC10842428 MID - NIHMS1939898 OTO - NOTNLM OT - Aging in place OT - Bridging social capital OT - COVID-19 pandemic OT - Geographical gerontology OT - Natural neighborhood networks OT - Sociopolitical polarization EDAT- 2023/10/19 00:43 MHDA- 2023/11/06 06:42 PMCR- 2024/11/01 CRDT- 2023/10/18 18:02 PHST- 2023/02/05 00:00 [received] PHST- 2023/07/14 00:00 [revised] PHST- 2023/09/22 00:00 [accepted] PHST- 2023/11/06 06:42 [medline] PHST- 2023/10/19 00:43 [pubmed] PHST- 2023/10/18 18:02 [entrez] PHST- 2024/11/01 00:00 [pmc-release] AID - S0277-9536(23)00624-X [pii] AID - 10.1016/j.socscimed.2023.116267 [doi] PST - ppublish SO - Soc Sci Med. 2023 Nov;337:116267. doi: 10.1016/j.socscimed.2023.116267. Epub 2023 Oct 6. PMID- 37812788 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240106 IS - 1911-6470 (Print) IS - 1920-1214 (Electronic) IS - 1911-6470 (Linking) VI - 18 IP - 1 DP - 2024 Jan TI - Septic and febrile kidney stone presentations during the COVID-19 pandemic What is the effect of reduced access to care during pandemic restrictions? PG - E19-E25 LID - 10.5489/cuaj.8450 [doi] AB - INTRODUCTION: During the early stages of the COVID-19 pandemic, hospitals shifted their resources and focus toward COVID-19 care and non-deferrable conditions. Renal colic is one of the most common urologic presentations to the emergency department (ED ). In our study, we examined whether there was an increase in septic/febrile stone presentations to the ED requiring ureteral stent insertion after the public health restrictions during the COVID-19 pandemic. METHODS: We carried out a retrospective cohort study and reviewed charts of septic/febrile stone patients requiring ureteral stent insertion from January 1, 2019, to March 16, 2020 (pre-COVID) and July 1, 2020, to December 31, 2021 (intra-COVID) at the Queen Elizabeth II Health Sciences Centre in Halifax, NS. The incidence of septic/febrile stone presentation, baseline characteristics, and perioperative outcomes were captured. RESULTS: There were 54 patients in the pre-COVID group and 74 patients in the intra- COVID group. There were no statistically significant differences found in baseline or stone characteristics between the two groups (p>0.05). Patients in the intra-COVID group were found to have a longer presentation to operating room time when compared to the pre- COVID cohort (U=961.00, p=0.04). The intra-COVID group had 20 more cases of septic stone presentations compared to the pre-COVID group at the 15-month mark (pre-COVID, n=54; intra-COVID, n=74). CONCLUSIONS: We found increased time to operative intervention in the intra-COVID cohort compared to the pre-COVID cohort. The overall number of urgent and/or critically ill ureteric stone patients increased between cohorts but was not statistically significant. FAU - Spooner, Jesse AU - Spooner J AD - Department of Urology, Dalhousie University, Halifax, NS, Canada. FAU - Masoumi-Ravandi, Kaveh AU - Masoumi-Ravandi K AD - Department of Urology, Dalhousie University, Halifax, NS, Canada. FAU - MacNevin, Wyatt AU - MacNevin W AD - Department of Urology, Dalhousie University, Halifax, NS, Canada. FAU - Ilie, Gabriela AU - Ilie G AD - Department of Urology, Dalhousie University, Halifax, NS, Canada. AD - Department of Community and Health Epidemiology, Dalhousie University, Halifax, NS, Canada. AD - Department of Psychology and Neuroscience, Dalhousie University, Halifax, NS, Canada. AD - Department of Radiation Oncology, Dalhousie University, Halifax, NS, Canada. FAU - Skinner, Thomas AU - Skinner T AD - Department of Urology, Dalhousie University, Halifax, NS, Canada. FAU - Powers, Andrea Lantz AU - Powers AL AD - Department of Urology, Dalhousie University, Halifax, NS, Canada. LA - eng PT - Journal Article PL - Canada TA - Can Urol Assoc J JT - Canadian Urological Association journal = Journal de l'Association des urologues du Canada JID - 101312644 PMC - PMC10766334 COIS- COMPETING INTERESTS: The authors do not report any competing personal or financial interests related to this work. EDAT- 2023/10/09 18:42 MHDA- 2023/10/09 18:43 PMCR- 2024/01/01 CRDT- 2023/10/09 17:12 PHST- 2023/10/09 18:43 [medline] PHST- 2023/10/09 18:42 [pubmed] PHST- 2023/10/09 17:12 [entrez] PHST- 2024/01/01 00:00 [pmc-release] AID - cuaj.8450 [pii] AID - cuaj-1-e19 [pii] AID - 10.5489/cuaj.8450 [doi] PST - ppublish SO - Can Urol Assoc J. 2024 Jan;18(1):E19-E25. doi: 10.5489/cuaj.8450. PMID- 37803931 OWN - NLM STAT- MEDLINE DCOM- 20231101 LR - 20231101 IS - 1945-7243 (Electronic) IS - 0046-9580 (Print) IS - 0046-9580 (Linking) VI - 60 DP - 2023 Jan-Dec TI - Prevalence and Factors Associated With Compliance With COVID-19 Presidential Lockdown Measures: A Cross-Sectional Study. PG - 469580231201258 LID - 10.1177/00469580231201258 [doi] LID - 00469580231201258 AB - The coronavirus disease 2019 (COVID-19) is one of the most severe global health uncertainties to date. Although significant global effort has been put into implementing COVID-19 pandemic control measures such as lockdowns, travel restrictions, and hygiene precautions, the transmission is expected to resurface once these efforts are discontinued. We aimed to determine the prevalence and factors associated with compliance with presidential 53-day lockdown measures in June-July 2021 in northern Uganda. In this cross-sectional study, 587 adult participants (>/=18 years old) from northern Uganda were selected using a systematic sampling method. Data collection involved interviewer-administered questionnaires with an internal validity of Cronbach's alpha = .72. Socio-demographic characteristics of participants were described, and multivariable modified Poisson regressions were performed to assess prevalence ratios between dependent and selected independent variables, with respective P values at 95% confidence intervals. All analyses were conducted using Stata 17.0. Participants' compliance with the presidential lockdown directives was high at 88%(95% CI: 85%-90%). Compliance with the presidential directives was more likely among participants who agreed to the lockdown measures [adjusted Prevalence Ratio, aPR = 1.28 (95% CI: 1.10-1.49; P = .001)] compared to those who did not, and more likely among those who were afraid of death from COVID-19 [aPR = 1.08 (95% CI: 1.01-1.15; P = .023)] than those who did not. However, compliance was less likely among males [aPR = 0.91 (95% CI: 0.86-0.97; P = .002)] compared to females, those aged 35 to 44 years [aPR = 0.87 (95% CI: 0.79-0.97; P = .013)] compared to those less 25 years; and unmarried [aPR = 0.89 (95% CI: 0.82-0.97; P = .011)] compared to the married. Compliance with the COVID-19 presidential lockdown measures in northern Uganda was high. The factors associated with compliance were the fear of death and agreement with presidential lockdown measures. However, compliance was less likely among males, unmarried persons, and persons aged 35 to 44. The authors recommend more community engagements, participation, sensitization, mobilization, and simultaneous application of multiple public health approaches to improve compliance and control of COVID-19. FAU - Olal, Emmanuel AU - Olal E AD - Yotkom Medical Centre, Kitgum, Uganda. AD - Uganda Medical Association, Gulu City, Uganda. FAU - Mukunya, David AU - Mukunya D AD - Busitema University, Mbale, Uganda. AD - Nikao Medical Center, Kampala, Uganda. FAU - Oloya, Johnson Nyeko AU - Oloya JN AD - Uganda Medical Association, Gulu City, Uganda. AD - Moroto Regional Referral Hospital, Moroto, Uganda. FAU - Baguma, Steven AU - Baguma S AD - Uganda Medical Association, Gulu City, Uganda. AD - Gulu Regional Referral Hospital, Gulu City, Uganda. FAU - Okot, Christopher AU - Okot C AD - Uganda Medical Association, Gulu City, Uganda. AD - Gulu Regional Referral Hospital, Gulu City, Uganda. FAU - Alema, Nelson Onira AU - Alema NO AD - Gulu University, Gulu City, Uganda. FAU - Acullu, Denis AU - Acullu D AD - Uganda Medical Association, Gulu City, Uganda. AD - Aga Khan Hospital, Mombasa, Kenya. FAU - Ochula, Denish Omoya AU - Ochula DO AD - Uganda Medical Association, Gulu City, Uganda. AD - Lamwo District Local Government, District Health Office, Padibe, Uganda. FAU - Atim, Pamela Okot AU - Atim PO AD - Uganda Medical Association, Gulu City, Uganda. AD - St. Joseph's Hospital, Kitgum District, Uganda. FAU - Odong, Patrick Olwedo AU - Odong PO AD - Uganda Medical Association, Gulu City, Uganda. AD - Amuru District Local Government, District Health Office, Amuru, Uganda. FAU - Okot, Godfrey Smart AU - Okot GS AD - Uganda Medical Association, Gulu City, Uganda. AD - Dr. Ambrosoli Memorial Hospital, Kalongo, Uganda. FAU - Pebolo, Francis Pebalo AU - Pebolo FP AD - Gulu University, Gulu City, Uganda. FAU - Oyat, Freddy Wathum Drinkwater AU - Oyat FWD AD - Uganda Medical Association, Gulu City, Uganda. FAU - Ikoona, Eric Nzirakaindi AU - Ikoona EN AD - ICAP at Columbia University, Freetown, Sierra Leone. FAU - Aloyo, Judith AU - Aloyo J AD - Uganda Medical Association, Gulu City, Uganda. AD - Rhites-N, Acholi, Gulu City, Uganda. FAU - Kitara, David Lagoro AU - Kitara DL AUID- ORCID: 0000-0001-7282-5026 AD - Uganda Medical Association, Gulu City, Uganda. AD - Gulu University, Gulu City, Uganda. AD - Gulu Centre for Advanced Medical Diagnostics, Research, Trainings, and Innovations (GRUDI BIONTECH), Gulu, Uganda. LA - eng PT - Journal Article PL - United States TA - Inquiry JT - Inquiry : a journal of medical care organization, provision and financing JID - 0171671 SB - IM MH - Adult MH - Female MH - Male MH - Humans MH - Adolescent MH - Cross-Sectional Studies MH - *COVID-19/epidemiology MH - Communicable Disease Control MH - Pandemics MH - Prevalence PMC - PMC10559722 OTO - NOTNLM OT - COVID-19 lockdown measures OT - associated factors OT - compliance OT - prevalence COIS- Declaration of Conflicting InterestsThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. EDAT- 2023/10/07 11:42 MHDA- 2023/11/01 12:43 PMCR- 2023/10/06 CRDT- 2023/10/07 02:42 PHST- 2023/11/01 12:43 [medline] PHST- 2023/10/07 11:42 [pubmed] PHST- 2023/10/07 02:42 [entrez] PHST- 2023/10/06 00:00 [pmc-release] AID - 10.1177_00469580231201258 [pii] AID - 10.1177/00469580231201258 [doi] PST - ppublish SO - Inquiry. 2023 Jan-Dec;60:469580231201258. doi: 10.1177/00469580231201258. PMID- 37798577 OWN - NLM STAT- MEDLINE DCOM- 20231027 LR - 20240225 IS - 1525-1497 (Electronic) IS - 0884-8734 (Print) IS - 0884-8734 (Linking) VI - 38 IP - Suppl 4 DP - 2023 Oct TI - "Everything's so Role-Specific": VA Employee Perspectives' on Electronic Health Record (EHR) Transition Implications for Roles and Responsibilities. PG - 991-998 LID - 10.1007/s11606-023-08282-5 [doi] AB - BACKGROUND: Electronic health record (EHR) transitions are increasingly widespread and often highly disruptive. It is imperative we learn from past experiences to anticipate and mitigate such disruptions. Veterans Affairs (VA) is undergoing a large-scale transition from its homegrown EHR (CPRS/Vista) to a commercial EHR (Cerner), creating a unique opportunity of shedding light on large-scale EHR-to-EHR transition challenges. OBJECTIVE: To explore one facet of the organizational impact of VA's EHR transition: its implications for employees' roles and responsibilities at the first VA site to implement Cerner Millennium EHR. DESIGN: As part of a formative evaluation of frontline staff experiences with VA's EHR transition, we conducted brief (~ 15 min) and full-length interviews (~ 60 min) with clinicians and staff at Mann-Grandstaff VA Medical Center in Spokane, WA, before, during, and after transition (July 2020-November 2021). PARTICIPANTS: We conducted 111 interviews with 26 Spokane clinicians and staff, recruited via snowball sampling. APPROACH: We conducted audio interviews using a semi-structured guide with grounded prompts. We coded interview transcripts using a priori and emergent codes, followed by qualitative content analysis. KEY RESULTS: Unlike VA's previous EHR, Cerner imposes additional restrictions on access to its EHR functionality based upon "roles" assigned to users. Participants described a mismatch between established institutional duties and their EHR permissions, unanticipated changes in scope of duties brought upon by the transition, as well as impediments to communication and collaboration due to different role-based views. CONCLUSIONS: Health systems should anticipate substantive impacts on professional workflows when EHR role settings do not reflect prior workflows. Such changes may increase user error, dissatisfaction, and patient care disruptions. To mitigate employee dissatisfaction and safety risks, health systems should proactively plan for and communicate about expected modifications and monitor for unintended role-related consequences of EHR transitions, while vendors should ensure accurate role configuration and assignment. CI - (c) 2023. The Author(s). FAU - Ahlness, Ellen A AU - Ahlness EA AUID- ORCID: 0000-0002-3324-3135 AD - Center of Innovation for Veteran-Centered and Value-Driven Care, Seattle VA Medical Center, Seattle, WA, USA. Ellen.A.AhlnessAbdulmuminov@va.gov. FAU - Orlander, Jay AU - Orlander J AD - Medical Service, VA Boston Healthcare System, Boston, MA, USA. AD - Section of General Internal Medicine, Boston University Chobanian and Avedisian School of Medicine, Boston, MA, USA. FAU - Brunner, Julian AU - Brunner J AD - Center for the Study of Healthcare Innovation, Implementation & Policy, VA Greater Los Angeles Health Care, Los Angeles, CA, USA. FAU - Cutrona, Sarah L AU - Cutrona SL AD - Center for Healthcare Organization and Implementation Research, VA Bedford Healthcare System, Bedford, MA, USA. AD - Division of Health Informatics & Implementation Science, Department of Population and Quantitative Health Sciences, University of Massachusetts Chan Medical School, Worcester, MA, USA. FAU - Kim, Bo AU - Kim B AD - Center for Healthcare Organization and Implementation Research, VA Boston Health Care System, Boston, MA, USA. AD - Department of Psychiatry, Harvard Medical School, Boston, MA, USA. FAU - Molloy-Paolillo, Brianne K AU - Molloy-Paolillo BK AD - Center for Healthcare Organization and Implementation Research, VA Bedford Healthcare System, Bedford, MA, USA. FAU - Rinne, Seppo T AU - Rinne ST AD - Center for Healthcare Organization and Implementation Research, VA Bedford Healthcare System, Bedford, MA, USA. AD - Division of Pulmonary and Critical Care Medicine, Department of Medicine, Boston University Chobanian and Avedisian School of Medicine, Boston, MA, USA. FAU - Rucci, Justin AU - Rucci J AD - Center for Healthcare Organization and Implementation Research, VA Boston Health Care System, Boston, MA, USA. AD - Division of Pulmonary and Critical Care Medicine, Department of Medicine, Boston University Chobanian and Avedisian School of Medicine, Boston, MA, USA. FAU - Sayre, George AU - Sayre G AD - Center of Innovation for Veteran-Centered and Value-Driven Care, Seattle VA Medical Center, Seattle, WA, USA. AD - University of Washington School of Public Health, Seattle, WA, USA. FAU - Anderson, Ekaterina AU - Anderson E AD - Center for Healthcare Organization and Implementation Research, VA Bedford Healthcare System, Bedford, MA, USA. AD - Division of Health Informatics & Implementation Science, Department of Population and Quantitative Health Sciences, University of Massachusetts Chan Medical School, Worcester, MA, USA. LA - eng GR - T32 HL007035/HL/NHLBI NIH HHS/United States PT - Journal Article PT - Research Support, U.S. Gov't, Non-P.H.S. DEP - 20231005 PL - United States TA - J Gen Intern Med JT - Journal of general internal medicine JID - 8605834 SB - IM MH - Humans MH - United States MH - *Electronic Health Records MH - *United States Department of Veterans Affairs PMC - PMC10593626 OTO - NOTNLM OT - EHR OT - EHR transitions OT - United States Department of Veterans Affairs OT - care roles OT - interface OT - role scope OT - user experience OT - workflow EDAT- 2023/10/06 00:43 MHDA- 2023/10/27 06:42 PMCR- 2023/10/05 CRDT- 2023/10/05 23:36 PHST- 2022/12/02 00:00 [received] PHST- 2023/06/13 00:00 [accepted] PHST- 2023/10/27 06:42 [medline] PHST- 2023/10/06 00:43 [pubmed] PHST- 2023/10/05 23:36 [entrez] PHST- 2023/10/05 00:00 [pmc-release] AID - 10.1007/s11606-023-08282-5 [pii] AID - 8282 [pii] AID - 10.1007/s11606-023-08282-5 [doi] PST - ppublish SO - J Gen Intern Med. 2023 Oct;38(Suppl 4):991-998. doi: 10.1007/s11606-023-08282-5. Epub 2023 Oct 5. PMID- 37794878 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20231031 IS - 1664-2295 (Print) IS - 1664-2295 (Electronic) IS - 1664-2295 (Linking) VI - 14 DP - 2023 TI - Neurological telerehabilitation in the COVID-19 era - current perspectives through a bibliometric analysis. PG - 1227846 LID - 10.3389/fneur.2023.1227846 [doi] LID - 1227846 AB - OBJECTIVE: To identify bibliometric parameters and research trends regarding to telerehabilitation of patients with stroke in the COVID-19 era. METHODOLOGY: This is an integrative review carried out in the Scopus database, from June to July 2021, through the Biblioshiny graphical interface, provided by the Bibliometrix program. The search terms used were "Stroke," "COVID-19" and "Telerehabilitation." Results were filtered by publication date from 2019 onwards. No language restrictions were imposed. RESULTS: Twenty two articles were included in the study and the results were presented in the form of figures demonstrating that the journal Frontiers in Neurology was the one with the most relevant studies and the author with the highest number of citations. The Brazilian Academy of Neurology was the institution with the greatest number of studies and China ranked first as the country with the greatest scientific production. The authors used recent references in their work. A thematic map showed the centrality and density of the words presented and, finally, a three-field graph showed a strong intimacy between countries, keywords and authors. CONCLUSION: A greater interest in the subject was observed in China with greater relevance of journals and institutions focused on neurology. However, despite telerehabilitation being an effective alternative in the context of the pandemic, few studies have explored this modality. CI - Copyright (c) 2023 Lebioda, Pedroso, Santos, Pinto and Welling. FAU - Lebioda, Lucia Aparecida AU - Lebioda LA AD - Graduate Program in Health Sciences, Universidade Estadual de Ponta Grossa, Ponta Grossa, Brazil. FAU - Pedroso, Bruno AU - Pedroso B AD - Graduate Program in Health Sciences, Universidade Estadual de Ponta Grossa, Ponta Grossa, Brazil. FAU - Dos Santos, Marlon Estevam Camilo AU - Dos Santos MEC AD - Graduate Program in Health Sciences, Universidade Estadual de Ponta Grossa, Ponta Grossa, Brazil. FAU - Pinto, Guilherme Moreira Caetano AU - Pinto GMC AD - Graduate Program in Health Sciences, Universidade Estadual de Ponta Grossa, Ponta Grossa, Brazil. FAU - Welling, Leonardo Christiaan AU - Welling LC AD - Graduate Program in Health Sciences, Universidade Estadual de Ponta Grossa, Ponta Grossa, Brazil. LA - eng PT - Journal Article PT - Systematic Review DEP - 20230919 PL - Switzerland TA - Front Neurol JT - Frontiers in neurology JID - 101546899 PMC - PMC10546771 OTO - NOTNLM OT - COVID-19 OT - SARS-CoV OT - rehabilitation OT - stroke OT - telerehabilitation COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2023/10/05 06:43 MHDA- 2023/10/05 06:44 PMCR- 2023/09/19 CRDT- 2023/10/05 03:58 PHST- 2023/05/23 00:00 [received] PHST- 2023/08/10 00:00 [accepted] PHST- 2023/10/05 06:44 [medline] PHST- 2023/10/05 06:43 [pubmed] PHST- 2023/10/05 03:58 [entrez] PHST- 2023/09/19 00:00 [pmc-release] AID - 10.3389/fneur.2023.1227846 [doi] PST - epublish SO - Front Neurol. 2023 Sep 19;14:1227846. doi: 10.3389/fneur.2023.1227846. eCollection 2023. PMID- 37786814 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20231031 IS - 2054-3581 (Print) IS - 2054-3581 (Electronic) IS - 2054-3581 (Linking) VI - 10 DP - 2023 TI - Variability in Reporting eGFR at Dialysis Initiation in Canada: A Research Letter. PG - 20543581231203065 LID - 10.1177/20543581231203065 [doi] LID - 20543581231203065 AB - BACKGROUND: Estimated glomerular filtration rate (eGFR) at dialysis initiation is increasingly recognized as a key quality indicator (QI) for patients with end-stage kidney disease (ESKD). Specifically, guidelines recommend assessing deferral of dialysis initiation until symptoms arise or if the eGFR is /= 18 years. For our analyses, we made use of the data acquired between 2014-2017 (n = 100,285). A fifth of the participants completed the questionnaires during COVID-19 restrictive policies in July 2021 (n = 20,806). Seven spatial components were calculated for a 500m and 1650m Euclidean buffer per postal code area in GIS: population density, retail and service destination density, land use mix, street connectivity, green space density, sidewalk density, and public transport stops. Additionally, the walkability index (WI) of these seven components was calculated. Using multivariable linear regression analyses, we analyzed the association between the WI (and separate components) and the change in leisure walking minutes/week. Included demographic variables were age, gender, BMI, education, net income, occupation status, household composition and the season in which the questionnaire was filled in. RESULTS: The average leisure walking time strongly increased by 127 min/week upon COVID-19 restrictions. All seven spatial components of the WI were significantly associated with an increase in leisure walking time; a 10% higher score in the individual spatial component was associated with 5 to 8 more minutes of leisure walking/week. Green space density at the 500m Euclidean buffer and side-walk density at the 1650m Euclidean buffer were associated with the highest increase in leisure walking time/week. Subgroup analysis revealed that the built environment showed its strongest impact on leisure walking time in participants not engaging in leisure walking before the COVID-19 pandemic, compared to participants who already engaged in leisure walking before the COVID-19 pandemic. CONCLUSIONS: These results provide strong evidence that the built environment, corrected for individual-level characteristics, directly links to changes observed in leisure walking time during COVID-19 restrictions. Since this relation was strongest in those who did not engage in leisure walking before the COVID-19 pandemic, our results encourage new perspectives in health promotion and urban planning. CI - (c) 2023. BioMed Central Ltd., part of Springer Nature. FAU - Spoelder, Marcia AU - Spoelder M AUID- ORCID: 0000-0002-9217-0642 AD - Department of Physiology, Radboud Institute for Health Sciences, Radboud University Medical Center, Philips Van Leydenlaan 15, Nijmegen, 6525 EX, The Netherlands. marcia.spoelder-merkens@radboudumc.nl. AD - Present affiliation: Department of Primary and Community Care, Radboud Institute for Health Sciences, Radboud University Medical Center, Geert Grooteplein Noord 21, Nijmegen, 6525 EZ, The Netherlands. marcia.spoelder-merkens@radboudumc.nl. FAU - Schoofs, Merle C A AU - Schoofs MCA AD - Department of Physiology, Radboud Institute for Health Sciences, Radboud University Medical Center, Philips Van Leydenlaan 15, Nijmegen, 6525 EX, The Netherlands. FAU - Raaphorst, Kevin AU - Raaphorst K AD - Department of Geography, Planning and Environment, Institute for Management Research, Radboud University, Nijmegen, The Netherlands. FAU - Lakerveld, Jeroen AU - Lakerveld J AD - Amsterdam UMC, Department of Epidemiology and Data Science, Vrije Universiteit Amsterdam, Amsterdam Public Health Research Institute, Boelelaan 1089a, Amsterdam, 1081HV, The Netherlands. AD - Amsterdam Public Health, Health Behaviours and Chronic Diseases, Amsterdam, The Netherlands. AD - Upstream Team, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands. FAU - Wagtendonk, Alfred AU - Wagtendonk A AD - Amsterdam UMC, Department of Epidemiology and Data Science, Vrije Universiteit Amsterdam, Amsterdam Public Health Research Institute, Boelelaan 1089a, Amsterdam, 1081HV, The Netherlands. AD - Amsterdam Public Health, Health Behaviours and Chronic Diseases, Amsterdam, The Netherlands. AD - Upstream Team, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands. FAU - Hartman, Yvonne A W AU - Hartman YAW AD - Department of Physiology, Radboud Institute for Health Sciences, Radboud University Medical Center, Philips Van Leydenlaan 15, Nijmegen, 6525 EX, The Netherlands. FAU - van der Krabben, Erwin AU - van der Krabben E AD - Department of Geography, Planning and Environment, Institute for Management Research, Radboud University, Nijmegen, The Netherlands. FAU - Hopman, Maria T E AU - Hopman MTE AD - Department of Physiology, Radboud Institute for Health Sciences, Radboud University Medical Center, Philips Van Leydenlaan 15, Nijmegen, 6525 EX, The Netherlands. FAU - Thijssen, Dick H J AU - Thijssen DHJ AD - Department of Physiology, Radboud Institute for Health Sciences, Radboud University Medical Center, Philips Van Leydenlaan 15, Nijmegen, 6525 EX, The Netherlands. AD - Research Institute for Sports and Exercise Sciences, Liverpool John Moores University, Liverpool, UK. CN - Lifelines Corona Research Initiative LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20230926 PL - England TA - Int J Behav Nutr Phys Act JT - The international journal of behavioral nutrition and physical activity JID - 101217089 SB - IM MH - Adult MH - Humans MH - Cohort Studies MH - Longitudinal Studies MH - Prospective Studies MH - Cross-Sectional Studies MH - *Pandemics MH - *COVID-19/epidemiology MH - Communicable Disease Control MH - Walking PMC - PMC10521432 OTO - NOTNLM OT - Built environment OT - COVID-19 OT - Health OT - Physical activity OT - Walking COIS- The authors declare that they have no competing interests. EDAT- 2023/09/27 00:42 MHDA- 2023/09/28 06:42 PMCR- 2023/09/26 CRDT- 2023/09/26 23:48 PHST- 2023/04/24 00:00 [received] PHST- 2023/09/07 00:00 [accepted] PHST- 2023/09/28 06:42 [medline] PHST- 2023/09/27 00:42 [pubmed] PHST- 2023/09/26 23:48 [entrez] PHST- 2023/09/26 00:00 [pmc-release] AID - 10.1186/s12966-023-01512-3 [pii] AID - 1512 [pii] AID - 10.1186/s12966-023-01512-3 [doi] PST - epublish SO - Int J Behav Nutr Phys Act. 2023 Sep 26;20(1):116. doi: 10.1186/s12966-023-01512-3. PMID- 37697227 OWN - NLM STAT- MEDLINE DCOM- 20230913 LR - 20231121 IS - 1471-2334 (Electronic) IS - 1471-2334 (Linking) VI - 23 IP - 1 DP - 2023 Sep 11 TI - Impact of COVID-19 on the changing pattern of human orthopneumovirus (respiratory syncytial virus) infection in Iran. PG - 591 LID - 10.1186/s12879-023-08588-z [doi] LID - 591 AB - BACKGROUND: Human orthopneumovirus (HOPV) or respiratory syncytial virus (RSV) is one of the important causes of acute respiratory infections (ARIs) during the cold months of the year worldwide. Many countries have reported an absence of ARIs due to HOPV during the winter of 2020-2021 associated with preventive measures to reduce the spread of SARS-CoV2. However, with the reduction of COVID-19 public health restrictions and the absence of immunity in the community due to the lack of exposure in the previous season, many countries had a delayed HOPV outbreak. Here we reported the impact of COVID-19 on the changing pattern of HOPV infection in Iran. METHODS: Throat and nasopharyngeal swab samples were collected from patients (children and adults) with ARIs and sent to the Iran National Influenza Center. After RNA extraction, Real time RT-PCR was performed for HOPV detection. RESULTS: In 260 samples collected from patients with ARIs in three different groups, which included children in March 2021, pilgrims in July 2022, and outpatients during November and December 2022, no HOPV was detected in any group. CONCLUSIONS: The lack of HOPV activity in Iran during the winter of 2020-2021 and then the resurgence in spring 2022 and again the absence of activity in summer and autumn 2022 was extraordinary in the HOPV epidemiology, and probably due to the implementation of public health non-pharmaceutical interventions to reduce the spread of SARS-CoV2. Although it is not possible to keep such restrictions, similar methods can be taken to control outbreaks caused by respiratory viruses. CI - (c) 2023. BioMed Central Ltd., part of Springer Nature. FAU - Yavarian, Jila AU - Yavarian J AD - Virology Department, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran. AD - Research Center for Antibiotic Stewardship & Antimicrobial Resistance, Tehran University of Medical Sciences, Tehran, Iran. FAU - Shatizadeh Malekshahi, Somayeh AU - Shatizadeh Malekshahi S AD - Department of Virology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran. FAU - Faraji-Zonouz, Marziyeh AU - Faraji-Zonouz M AD - Virology Department, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran. FAU - Kalantari, Shirin AU - Kalantari S AD - Virology Department, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran. FAU - Zadheidar, Sevrin AU - Zadheidar S AD - Virology Department, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran. FAU - Saghafi, Sara AU - Saghafi S AD - Virology Department, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran. FAU - Tarpour, Faezeh AU - Tarpour F AD - Virology Department, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran. FAU - Letafati, Arash AU - Letafati A AD - Virology Department, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran. FAU - Ahmadi, Akram Sadat AU - Ahmadi AS AD - Virology Department, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran. FAU - Shafiei-Jandaghi, Nazanin-Zahra AU - Shafiei-Jandaghi NZ AD - Virology Department, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran. FAU - Mokhtari-Azad, Talat AU - Mokhtari-Azad T AUID- ORCID: 0000-0002-9289-021X AD - Virology Department, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran. mokhtari@tums.ac.ir. LA - eng PT - Journal Article DEP - 20230911 PL - England TA - BMC Infect Dis JT - BMC infectious diseases JID - 100968551 RN - 0 (RNA, Viral) SB - IM MH - Adult MH - Child MH - Humans MH - Iran/epidemiology MH - RNA, Viral MH - *COVID-19/epidemiology MH - SARS-CoV-2 MH - *Respiratory Syncytial Virus, Human/genetics MH - *Respiratory Tract Infections PMC - PMC10494416 OTO - NOTNLM OT - COVID-19, Iran OT - Human orthopneumovirus OT - Respiratory syncytial virus COIS- The authors declare no competing interests. EDAT- 2023/09/12 00:42 MHDA- 2023/09/13 06:41 PMCR- 2023/09/11 CRDT- 2023/09/11 23:48 PHST- 2023/04/24 00:00 [received] PHST- 2023/09/06 00:00 [accepted] PHST- 2023/09/13 06:41 [medline] PHST- 2023/09/12 00:42 [pubmed] PHST- 2023/09/11 23:48 [entrez] PHST- 2023/09/11 00:00 [pmc-release] AID - 10.1186/s12879-023-08588-z [pii] AID - 8588 [pii] AID - 10.1186/s12879-023-08588-z [doi] PST - epublish SO - BMC Infect Dis. 2023 Sep 11;23(1):591. doi: 10.1186/s12879-023-08588-z. PMID- 37681561 OWN - NLM STAT- MEDLINE DCOM- 20230911 LR - 20251017 IS - 1469-493X (Electronic) IS - 1361-6137 (Linking) VI - 9 IP - 9 DP - 2023 Sep 8 TI - Prognostic models for predicting clinical disease progression, worsening and activity in people with multiple sclerosis. PG - CD013606 LID - 10.1002/14651858.CD013606.pub2 [doi] LID - CD013606 AB - BACKGROUND: Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system that affects millions of people worldwide. The disease course varies greatly across individuals and many disease-modifying treatments with different safety and efficacy profiles have been developed recently. Prognostic models evaluated and shown to be valid in different settings have the potential to support people with MS and their physicians during the decision-making process for treatment or disease/life management, allow stratified and more precise interpretation of interventional trials, and provide insights into disease mechanisms. Many researchers have turned to prognostic models to help predict clinical outcomes in people with MS; however, to our knowledge, no widely accepted prognostic model for MS is being used in clinical practice yet. OBJECTIVES: To identify and summarise multivariable prognostic models, and their validation studies for quantifying the risk of clinical disease progression, worsening, and activity in adults with MS. SEARCH METHODS: We searched MEDLINE, Embase, and the Cochrane Database of Systematic Reviews from January 1996 until July 2021. We also screened the reference lists of included studies and relevant reviews, and references citing the included studies. SELECTION CRITERIA: We included all statistically developed multivariable prognostic models aiming to predict clinical disease progression, worsening, and activity, as measured by disability, relapse, conversion to definite MS, conversion to progressive MS, or a composite of these in adult individuals with MS. We also included any studies evaluating the performance of (i.e. validating) these models. There were no restrictions based on language, data source, timing of prognostication, or timing of outcome. DATA COLLECTION AND ANALYSIS: Pairs of review authors independently screened titles/abstracts and full texts, extracted data using a piloted form based on the Checklist for Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modelling Studies (CHARMS), assessed risk of bias using the Prediction Model Risk Of Bias Assessment Tool (PROBAST), and assessed reporting deficiencies based on the checklist items in Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis (TRIPOD). The characteristics of the included models and their validations are described narratively. We planned to meta-analyse the discrimination and calibration of models with at least three external validations outside the model development study but no model met this criterion. We summarised between-study heterogeneity narratively but again could not perform the planned meta-regression. MAIN RESULTS: We included 57 studies, from which we identified 75 model developments, 15 external validations corresponding to only 12 (16%) of the models, and six author-reported validations. Only two models were externally validated multiple times. None of the identified external validations were performed by researchers independent of those that developed the model. The outcome was related to disease progression in 39 (41%), relapses in 8 (8%), conversion to definite MS in 17 (18%), and conversion to progressive MS in 27 (28%) of the 96 models or validations. The disease and treatment-related characteristics of included participants, and definitions of considered predictors and outcome, were highly heterogeneous amongst the studies. Based on the publication year, we observed an increase in the percent of participants on treatment, diversification of the diagnostic criteria used, an increase in consideration of biomarkers or treatment as predictors, and increased use of machine learning methods over time. Usability and reproducibility All identified models contained at least one predictor requiring the skills of a medical specialist for measurement or assessment. Most of the models (44; 59%) contained predictors that require specialist equipment likely to be absent from primary care or standard hospital settings. Over half (52%) of the developed models were not accompanied by model coefficients, tools, or instructions, which hinders their application, independent validation or reproduction. The data used in model developments were made publicly available or reported to be available on request only in a few studies (two and six, respectively). Risk of bias We rated all but one of the model developments or validations as having high overall risk of bias. The main reason for this was the statistical methods used for the development or evaluation of prognostic models; we rated all but two of the included model developments or validations as having high risk of bias in the analysis domain. None of the model developments that were externally validated or these models' external validations had low risk of bias. There were concerns related to applicability of the models to our research question in over one-third (38%) of the models or their validations. Reporting deficiencies Reporting was poor overall and there was no observable increase in the quality of reporting over time. The items that were unclearly reported or not reported at all for most of the included models or validations were related to sample size justification, blinding of outcome assessors, details of the full model or how to obtain predictions from it, amount of missing data, and treatments received by the participants. Reporting of preferred model performance measures of discrimination and calibration was suboptimal. AUTHORS' CONCLUSIONS: The current evidence is not sufficient for recommending the use of any of the published prognostic prediction models for people with MS in clinical routine today due to lack of independent external validations. The MS prognostic research community should adhere to the current reporting and methodological guidelines and conduct many more state-of-the-art external validation studies for the existing or newly developed models. CI - Copyright (c) 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. FAU - Reeve, Kelly AU - Reeve K AD - Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland. FAU - On, Begum Irmak AU - On BI AD - Institute for Medical Information Processing, Biometry and Epidemiology, Ludwig-Maximilians-Universitat Munchen, Munich, Germany. FAU - Havla, Joachim AU - Havla J AD - lnstitute of Clinical Neuroimmunology, Ludwig-Maximilians-Universitat Munchen, Munich, Germany. FAU - Burns, Jacob AU - Burns J AD - Institute for Medical Information Processing, Biometry and Epidemiology, Ludwig-Maximilians-Universitat Munchen, Munich, Germany. AD - Pettenkofer School of Public Health, Munich, Germany. FAU - Gosteli-Peter, Martina A AU - Gosteli-Peter MA AD - University Library, University of Zurich, Zurich, Switzerland. FAU - Alabsawi, Albraa AU - Alabsawi A AD - Institute for Medical Information Processing, Biometry and Epidemiology, Ludwig-Maximilians-Universitat Munchen, Munich, Germany. FAU - Alayash, Zoheir AU - Alayash Z AD - Institute for Medical Information Processing, Biometry and Epidemiology, Ludwig-Maximilians-Universitat Munchen, Munich, Germany. AD - Institute of Health Services Research in Dentistry, University of Munster, Muenster, Germany. FAU - Gotschi, Andrea AU - Gotschi A AD - Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland. FAU - Seibold, Heidi AU - Seibold H AD - IGDORE, Munich, Germany. FAU - Mansmann, Ulrich AU - Mansmann U AD - Institute for Medical Information Processing, Biometry and Epidemiology, Ludwig-Maximilians-Universitat Munchen, Munich, Germany. AD - Pettenkofer School of Public Health, Munich, Germany. FAU - Held, Ulrike AU - Held U AD - Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review DEP - 20230908 PL - England TA - Cochrane Database Syst Rev JT - The Cochrane database of systematic reviews JID - 100909747 SB - IM UOF - doi: 10.1002/14651858.CD013606 MH - Adult MH - Humans MH - Prognosis MH - *Multiple Sclerosis MH - Reproducibility of Results MH - Systematic Reviews as Topic MH - Disease Progression PMC - PMC10486189 COIS- JH reports a grant for OCT research from the Friedrich-Baur-Stiftung and Merck, personal fees and non-financial support from Alexion, Bayer HealthCare Pharmaceuticals, Biogen, Celgene, F. Hoffman-La Roche, Janssen Biotech, Merck, Novartis, and Sanofi Genzyme and non-financial support from the Guthy-Jackson Charitable Foundation, all outside the submitted work. UH received financial compensation once for a lecture organised by CSL Behring, after submission of the manuscript, and outside the submitted work. BIO has provided consultancy to Roche once on a topic outside the submitted work. KAR, JB, MG, AA, ZA, AG, HS, UM: nothing to declare. EDAT- 2023/09/08 12:43 MHDA- 2023/09/11 06:43 PMCR- 2024/09/08 CRDT- 2023/09/08 07:23 PHST- 2023/09/11 06:43 [medline] PHST- 2023/09/08 12:43 [pubmed] PHST- 2023/09/08 07:23 [entrez] PHST- 2024/09/08 00:00 [pmc-release] AID - CD013606.pub2 [pii] AID - 10.1002/14651858.CD013606.pub2 [doi] PST - epublish SO - Cochrane Database Syst Rev. 2023 Sep 8;9(9):CD013606. doi: 10.1002/14651858.CD013606.pub2. PMID- 37674680 OWN - NLM STAT- MEDLINE DCOM- 20231011 LR - 20231011 IS - 2296-2565 (Electronic) IS - 2296-2565 (Linking) VI - 11 DP - 2023 TI - Perceptions of the health risk from hot days and the cooling effect of urban green spaces: a case study in Xi'an, China. PG - 1211164 LID - 10.3389/fpubh.2023.1211164 [doi] LID - 1211164 AB - BACKGROUND: Hot days are one of the typical threats to human health and sustainable cities. The exploration of residents' perceptions of thermal environment and its mitigation measures will support the health risk prevention. METHODS: A survey with a combination of closed-ended and open-ended questions was conducted in July 2021 among 13 urban parks in Xi'an City, China. With the help of ANOVA and ordinal logistic regression, this study investigated the influencing factors both on residents' health risk perception of hot days and their perception of the effect of urban ecological landscape on reducing the thermal risk. The relationship between health risk perception and residents' needs of urban ecological construction was also explored. RESULTS: According to 325 valid questionnaires, the male-female ratio of respondents was found to be 1:0.87, young people aged 18-29 (26.46%), the retirees (27.08%) and the ones with undergraduate education (33.23%) were, relatively, the largest groups. The results show that 92.31% of the respondents believed that their daily lives were under the influence of hot days. Housing types, occupation, cooling equipment at work, and outdoor working hours all had a significant impact on their high temperature perceptions. The proportion of respondents who were under a huge health risk and sought medical treatment due to hot days was 30.16% and 44.92%, respectively. Women were 18.52 and 2.33 times more likely to suffer health threats and experience discomforts than men. Furthermore, 73.23% of the respondents believed that the urban ecological landscapes in Xi'an had an enhanced cooling effect in recent years. Compared with the morphological characteristics, residents' recognition of the restriction of landscape's area on its cooling effect was higher, and the residence duration showed a significant influence. CONCLUSION: The cooling effect of green spaces and water effectively resisted urban thermal threats, and residents' needs of the urban ecological landscapes was associated with their health risk perceptions of hot days. In the future, it is necessary to promote the early warning of hot days, meanwhile, the optimization of landscape patterns of green infrastructures should be implemented in urban planning for the purposes of residents' health risk prevention. CI - Copyright (c) 2023 Zhang, Huang, Yang, Lin, Ma, Wang and Huang. FAU - Zhang, Tian AU - Zhang T AD - Northwest Land and Resource Research Center, Shaanxi Normal University, Xi'an, China. FAU - Huang, Rong AU - Huang R AD - School of Geography and Tourism, Shaanxi Normal University, Xi'an, China. FAU - Yang, Mei AU - Yang M AD - School of Geography and Tourism, Shaanxi Normal University, Xi'an, China. FAU - Lin, Guohua AU - Lin G AD - School of Geography and Tourism, Shaanxi Normal University, Xi'an, China. FAU - Ma, Xiaoyan AU - Ma X AD - School of Geography and Tourism, Shaanxi Normal University, Xi'an, China. FAU - Wang, Xuan AU - Wang X AD - School of Geography and Tourism, Shaanxi Normal University, Xi'an, China. FAU - Huang, Qian AU - Huang Q AD - School of Geography and Tourism, Shaanxi Normal University, Xi'an, China. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20230822 PL - Switzerland TA - Front Public Health JT - Frontiers in public health JID - 101616579 RN - 059QF0KO0R (Water) SB - IM MH - Female MH - Humans MH - Male MH - China MH - Cities MH - *Parks, Recreational MH - Water MH - *Hot Temperature PMC - PMC10477602 OTO - NOTNLM OT - Xi'an City OT - cooling effect OT - health risk perception OT - hot days OT - urban green spaces COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2023/09/07 06:42 MHDA- 2023/09/08 06:42 PMCR- 2023/08/22 CRDT- 2023/09/07 04:04 PHST- 2023/04/24 00:00 [received] PHST- 2023/08/08 00:00 [accepted] PHST- 2023/09/08 06:42 [medline] PHST- 2023/09/07 06:42 [pubmed] PHST- 2023/09/07 04:04 [entrez] PHST- 2023/08/22 00:00 [pmc-release] AID - 10.3389/fpubh.2023.1211164 [doi] PST - epublish SO - Front Public Health. 2023 Aug 22;11:1211164. doi: 10.3389/fpubh.2023.1211164. eCollection 2023. PMID- 37669838 OWN - NLM STAT- MEDLINE DCOM- 20230907 LR - 20230908 IS - 2044-6055 (Electronic) IS - 2044-6055 (Linking) VI - 13 IP - 9 DP - 2023 Sep 5 TI - Protocol for the Paediatric Otorrhoea Study (POSt): a multi-methods study to understand the burden of paediatric otorrhoea in the UK. PG - e078052 LID - 10.1136/bmjopen-2023-078052 [doi] LID - e078052 AB - INTRODUCTION: Paediatric otorrhoea (PO) refers to the leakage of fluid through a perforation in the ear drum, resulting from an infection of the middle ear of a child or young person (CYP). PO frequently results in hearing loss which may lead to developmental delay, restricted communication and reduced educational attainment.Epidemiological information for PO is largely derived from low-income countries. The aim of this study will be to establish the incidence of PO within the UK and to understand the impact of PO on CYP and their families' everyday lives. It will build the foundations for a randomised controlled trial investigating the best antibiotic treatment for PO. METHODS AND ANALYSIS: The study will consist of two work packages. (1) Data from the Clinical Practice Research Datalink (CPRD), January 2005 to July 2021, will be used to determine the incidence of patient presentations with PO to primary care in the UK. It will also explore the current antimicrobial prescribing practice for PO in primary care. (2) Thirty semi-structured interviews will be conducted from 13 July to 31 October 2023 with CYP and their parents/carers to help identify the impact of PO on everyday life, the patient journey and how service users define treatment success. Three medical professional focus groups will be used to understand the current management practice, how treatment success is measured and acceptability to randomise patients. Thematic analysis will be used. ETHICS AND DISSEMINATION: The Health Research Authority, The Health and Social Care Research Ethics Committee (23/NI/0082) and the CPRD's research data governance panel (22_002508) reviewed this study. Results will be disseminated at medical conferences, in peer-reviewed journals and via social media. The study will cocreate a webpage on healthtalk.org, with the Dipex Charity, about PO to ensure members of the public can learn more about the condition. TRIAL REGISTRATION NUMBER: ISRCTN46071200. CI - (c) Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. FAU - Heward, Elliot AU - Heward E AUID- ORCID: 0000-0002-9692-646X AD - Division of Infection, Immunity and Respiratory Medicine, School of Biological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK elliotheward@doctors.org.uk. FAU - Dempsey, James AU - Dempsey J AUID- ORCID: 0009-0007-1318-9358 AD - Royal Manchester Children's Hospital, Manchester University NHS Foundation Trust, Manchester, UK. FAU - Lunn, Judith AU - Lunn J AD - Lancaster University, Lancaster, UK. FAU - Molloy, John AU - Molloy J AD - Division of Infection, Immunity and Respiratory Medicine, School of Biological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK. AD - Royal Manchester Children's Hospital, Manchester University NHS Foundation Trust, Manchester, UK. FAU - Isba, Rachel AU - Isba R AUID- ORCID: 0000-0002-2896-4309 AD - Lancaster University, Lancaster, UK. AD - Alder Hey Children's NHS Foundation Trust, Liverpool, UK. FAU - Carr, Matthew AU - Carr M AD - Division of Pharmacy & Optometry, School of Health Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK. FAU - Ashcroft, Darren AU - Ashcroft D AD - Division of Pharmacy & Optometry, School of Health Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK. AD - NIHR Greater Manchester Patient Safety Research Collaboration (PSRC), The University of Manchester, Manchester, UK. FAU - Hay, Alastair D AU - Hay AD AD - Centre for Academic Primary Care, Bristol Medical School: Population Health Sciences, University of Bristol, Bristol, UK. FAU - Nichani, Jaya R AU - Nichani JR AD - Division of Infection, Immunity and Respiratory Medicine, School of Biological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK. AD - Royal Manchester Children's Hospital, Manchester University NHS Foundation Trust, Manchester, UK. FAU - Bruce, Iain A AU - Bruce IA AD - Division of Infection, Immunity and Respiratory Medicine, School of Biological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK. AD - Royal Manchester Children's Hospital, Manchester University NHS Foundation Trust, Manchester, UK. LA - eng SI - ISRCTN/ISRCTN46071200 GR - NIHR204036/DH_/Department of Health/United Kingdom PT - Clinical Trial Protocol PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20230905 PL - England TA - BMJ Open JT - BMJ open JID - 101552874 SB - IM MH - Humans MH - Child MH - Adolescent MH - *Deafness MH - *Academic Success MH - Charities MH - Communication MH - United Kingdom MH - Randomized Controlled Trials as Topic PMC - PMC10481712 OTO - NOTNLM OT - epidemiologic studies OT - paediatric otolaryngology OT - qualitative research COIS- Competing interests: None declared. EDAT- 2023/09/06 00:41 MHDA- 2023/09/07 06:42 PMCR- 2023/09/05 CRDT- 2023/09/05 21:03 PHST- 2023/09/07 06:42 [medline] PHST- 2023/09/06 00:41 [pubmed] PHST- 2023/09/05 21:03 [entrez] PHST- 2023/09/05 00:00 [pmc-release] AID - bmjopen-2023-078052 [pii] AID - 10.1136/bmjopen-2023-078052 [doi] PST - epublish SO - BMJ Open. 2023 Sep 5;13(9):e078052. doi: 10.1136/bmjopen-2023-078052. PMID- 37667922 OWN - NLM STAT- MEDLINE DCOM- 20230906 LR - 20231019 IS - 2284-0729 (Electronic) IS - 1128-3602 (Linking) VI - 27 IP - 16 DP - 2023 Aug TI - Assessment of hesitancy to COVID-19 vaccine in patients with rheumatic arthritis. PG - 7459-7469 LID - 33397 [pii] LID - 10.26355/eurrev_202308_33397 [doi] AB - OBJECTIVE: The COVID-19 pandemic caused by SARS-CoV-2 in 2019 has greatly impacted global health, leading to high morbidity and mortality rates. Rheumatoid arthritis (RA) patients have faced numerous challenges during the pandemic, including concerns about infection, limited medical resources, and shortages of medication. While vaccination is a crucial strategy against COVID-19, the reasons behind vaccine hesitancy (VH) among people with RA remain largely unexplored. SUBJECTS AND METHODS: We conducted a cross-sectional, single-arm study in China from July 18 to August 18, 2021. Using a self-administered questionnaire and a convenient sampling method, we investigated vaccine attitudes and VH among RA patients. The questionnaire developed by the investigators was validated by two public health experts and one senior rheumatologist. It covered sociodemographics, disease-related variables, vaccination attitudes, and willingness, etc. We employed Chi-squared and regression analyses to identify factors associated with VH toward COVID-19 vaccination. RESULTS: A total of 184 RA patients were enrolled in the survey, with 113 (61.41%) expressing unwillingness to be vaccinated. The Chi-squared test revealed significant differences in employment status and related systemic damage (p < 0.05). Among the unvaccinated RA patients, 71.68% believed COVID-19 vaccination might impact their disease. Binary and multicollinearity logistic regression analyses showed that the acute stage of RA (p < 0.001, OR = -3.165, 95% CI: 0.035 - 0.164) and fear of disease development caused by drug discontinuation during vaccination (p < 0.001, OR = -3.591, 95% CI: 0.005 - 0.157) were the restricting factors influencing the COVID-19 vaccine inoculation rate in RA patients. CONCLUSIONS: The COVID-19 vaccination rate among RA patients in China is low due to limited knowledge, misconceptions, and insufficient promotion. Boosting confidence and understanding of the vaccine's effectiveness and safety is crucial to improve vaccination success. FAU - Zeng, H-Q AU - Zeng HQ AD - Department of Rheumatology, Shenzhen Futian Hospital for Rheumatic Diseases, Shenzhen, China. 15986686048@139.com. FAU - Liu, H-J AU - Liu HJ FAU - Wang, S-B AU - Wang SB FAU - Yin, Z-H AU - Yin ZH LA - eng PT - Journal Article PL - United States TA - Eur Rev Med Pharmacol Sci JT - European review for medical and pharmacological sciences JID - 9717360 RN - 0 (COVID-19 Vaccines) SB - IM MH - Humans MH - *Rheumatic Fever MH - COVID-19 Vaccines/therapeutic use MH - Cross-Sectional Studies MH - Pandemics MH - *COVID-19/prevention & control MH - SARS-CoV-2 MH - *Arthritis, Rheumatoid EDAT- 2023/09/05 06:42 MHDA- 2023/09/06 06:42 CRDT- 2023/09/05 05:27 PHST- 2023/09/06 06:42 [medline] PHST- 2023/09/05 06:42 [pubmed] PHST- 2023/09/05 05:27 [entrez] AID - 33397 [pii] AID - 10.26355/eurrev_202308_33397 [doi] PST - ppublish SO - Eur Rev Med Pharmacol Sci. 2023 Aug;27(16):7459-7469. doi: 10.26355/eurrev_202308_33397. PMID- 37657124 OWN - NLM STAT- MEDLINE DCOM- 20260311 LR - 20260730 IS - 1873-5150 (Electronic) IS - 0887-8994 (Linking) VI - 148 DP - 2023 Nov TI - Utility of Brain Injury Biomarkers in Children With Congenital Heart Disease Undergoing Cardiac Surgery. PG - 44-53 LID - S0887-8994(23)00208-4 [pii] LID - 10.1016/j.pediatrneurol.2023.06.024 [doi] AB - BACKGROUND: Congenital heart disease (CHD) affects roughly 40,000 children annually. Despite advancements, children undergoing surgery for CHD are at an increased risk for adverse neurological outcomes. At present, there is no gold standard for the diagnosis of cerebral injury during the perioperative period. OBJECTIVE: To determine the utility of brain injury biomarkers in children undergoing cardiac surgery. METHODS: We searched PUBMED, EMBASE, LILACS, EBSCO, ClinicalTrials.gov, Cochrane Databases, and OVID interface to search MEDLINE through July 2021 and assessed the literature following the snowball method. The search terms used were "congenital heart disease," "cardiopulmonary bypass," "biomarkers," "diagnosis," "prognosis," and "children." No language or publication date restrictions were used. Papers studying inflammatory and imaging biomarkers were excluded. The risk of bias, strengths, and limitations of the study were reported. Study was registered in PROSPERO ID: CRD42021258385. RESULTS: A total of 1449 articles were retrieved, and 27 were included. Eight neurological biomarkers were examined. Outcomes assessed included prognosis of poor neurological outcome, mortality, readmission, and diagnosis of brain injury. Results from these studies support that significant perioperative elevations in brain injury biomarkers in cerebrospinal fluid and serum, including S100B, GFAP, NSE, and activin A, may be diagnostic of real-time brain injury and serve as an independent predictor of adverse neurological outcomes in patients with CHD undergoing cardiopulmonary bypass. CONCLUSIONS: There are limited homogeneous data in the field, limiting the generalizability and comparability of the results. Further large-scale longitudinal studies addressing neurological biomarkers in children undergoing CHD corrective surgery are required to support the routine use of neuronal biomarkers in this population. CI - Copyright (c) 2023 Elsevier Inc. All rights reserved. FAU - Kuhn, Jessica E AU - Kuhn JE AD - University of Miami Miller School of Medicine, Miami, Florida. FAU - Pareja Zabala, Maria C AU - Pareja Zabala MC AD - Department of Pediatrics Medical College of Wisconsin, Milwaukee, Wisconsin. FAU - Chavez, Maria Mateo AU - Chavez MM AD - Knowledge and Research Evaluation Unit, Mayo Clinic College of Medicine and Science, Rochester, Minnesota. FAU - Almodovar, Melvin AU - Almodovar M AD - Division of Pediatric Cardiology, Department of Pediatrics, University of Miami Miller School of Medicine, Miami, Florida. FAU - Mulinari, Leonardo A AU - Mulinari LA AD - Division of Pediatric Cardiothoracic Surgery, Department of Surgery, University of Miami Miller School of Medicine, Miami, Florida. FAU - Sainathan, Sandeep AU - Sainathan S AD - Division of Pediatric Cardiothoracic Surgery, Department of Surgery, University of Miami Miller School of Medicine, Miami, Florida. FAU - de Rivero Vaccari, Juan Pablo AU - de Rivero Vaccari JP AD - Department of Neurological Surgery and the Miami Project to Cure Paralysis, University of Miami Miller School of Medicine, Miami, Florida. FAU - Wang, Kevin K AU - Wang KK AD - Department of Emergency Medicine, Morehouse University, School of Medicine, Atlanta, Georgia; Center for Neurotrauma, Multiomics & Biomarkers (CNMB), Morehouse University, School of Medicine, Atlanta, Georgia. FAU - Munoz Pareja, Jennifer C AU - Munoz Pareja JC AD - Department of Neurological Surgery and the Miami Project to Cure Paralysis, University of Miami Miller School of Medicine, Miami, Florida; Division of Pediatric Critical Care, Department of Pediatrics, University of Miami Miller School of Medicine, Miami, Florida. Electronic address: jcm457@med.miami.edu. LA - eng PT - Journal Article PT - Systematic Review DEP - 20230706 PL - United States TA - Pediatr Neurol JT - Pediatric neurology JID - 8508183 RN - 0 (Biomarkers) SB - IM MH - Humans MH - *Heart Defects, Congenital/surgery MH - Biomarkers/blood MH - *Brain Injuries/diagnosis/etiology/blood MH - *Cardiac Surgical Procedures/adverse effects MH - Child MH - *Postoperative Complications/diagnosis/blood OTO - NOTNLM OT - Biomarkers OT - Brain injury OT - Cardiopulmonary bypass OT - Congenital heart disease OT - Neurodevelopmental outcome OT - Pediatrics EDAT- 2023/09/01 18:42 MHDA- 2026/03/11 13:21 CRDT- 2023/09/01 18:00 PHST- 2023/02/05 00:00 [received] PHST- 2023/06/26 00:00 [revised] PHST- 2023/06/30 00:00 [accepted] PHST- 2026/03/11 13:21 [medline] PHST- 2023/09/01 18:42 [pubmed] PHST- 2023/09/01 18:00 [entrez] AID - S0887-8994(23)00208-4 [pii] AID - 10.1016/j.pediatrneurol.2023.06.024 [doi] PST - ppublish SO - Pediatr Neurol. 2023 Nov;148:44-53. doi: 10.1016/j.pediatrneurol.2023.06.024. Epub 2023 Jul 6. PMID- 37655289 OWN - NLM STAT- MEDLINE DCOM- 20230904 LR - 20230911 IS - 2296-2565 (Electronic) IS - 2296-2565 (Linking) VI - 11 DP - 2023 TI - Experience of loss and grief among people from Germany who have lost their relatives during the pandemic: the impact of healthcare professionals' support. PG - 1230198 LID - 10.3389/fpubh.2023.1230198 [doi] LID - 1230198 AB - BACKGROUND: Due to public restrictions during the early stages of the COVID-19 pandemic, many people were unable to visit and bid a proper farewell to their dying loved ones. This study aimed to address the loss-oriented aspects of grief and bereavement of relatives and relate these to the support they may have received from their dying relative's caring professionals. MATERIALS AND METHODS: People from Germany who experienced bereavement during the COVID-19 pandemic were enrolled in a cross-sectional study between July 2021 and May 2022, using standardized questionnaires (i.e., ICG, Inventory of Complicated Grief; BGL, Burdened by Grief and Loss scale; WHO-5, WHO-Five Wellbeing Index; and 5NRS, perception of burden related to the pandemic). RESULTS: Most participants (n = 196) had the opportunity to visit their relatives before death (59%). When this was not possible, being burdened by grief and loss was significantly higher (Eta(2) = 0.153), while this had no significant influence on complicated grief or psychological wellbeing. Furthermore, 34% of participants felt well-supported by the treatment/care team. Their own support was moderately correlated with BGL scores (r = -0.38) and marginally with ICG scores (r = -15). Regression analyses showed that complicated grief symptoms as the dependent variable were predicted by (low) psychological wellbeing, relational status, and the perception of COVID-19-related burden (R(2) = 0.70). In contrast, BGL as the dependent variable can be best explained by the perception of emotional affections because of restricted visits shortly before their death, by the (short) duration of visits before death, and by the relational status (R(2) = 0.53). Although both were interconnected (r = 0.44), their predictor pattern was different. CONCLUSION: Being able to visit dying relatives was important for the mourning and bereavement processes. This emotional aspect was more relevant to the normal, non-pathological grief and loss processes than to complicated grief processes. Support from their dying relatives' treatment/care team was highly relevant to the mourning process, but the visiting relatives often lacked information about additional resources such as psychologists or pastoral care professionals or had limited access to them. CI - Copyright (c) 2023 Bussing and Baumann. FAU - Bussing, Arndt AU - Bussing A AD - Professorship Quality of Life, Spirituality and Coping, Faculty of Health, Witten/Herdecke University, Herdecke, Germany. FAU - Baumann, Klaus AU - Baumann K AD - Caritas Science and Christian Social Work, Faculty of Theology, Albert-Ludwig-University, Freiburg, Germany. LA - eng PT - Journal Article DEP - 20230816 PL - Switzerland TA - Front Public Health JT - Frontiers in public health JID - 101616579 SB - IM MH - Humans MH - Pandemics MH - Cross-Sectional Studies MH - *COVID-19/epidemiology MH - Grief MH - *Bereavement MH - Germany/epidemiology MH - Delivery of Health Care MH - World Health Organization PMC - PMC10467025 OTO - NOTNLM OT - bereavement OT - grief OT - health care provider OT - loss OT - pandemic OT - wellbeing COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2023/09/01 06:43 MHDA- 2023/09/04 06:43 PMCR- 2023/08/16 CRDT- 2023/09/01 04:11 PHST- 2023/05/28 00:00 [received] PHST- 2023/07/24 00:00 [accepted] PHST- 2023/09/04 06:43 [medline] PHST- 2023/09/01 06:43 [pubmed] PHST- 2023/09/01 04:11 [entrez] PHST- 2023/08/16 00:00 [pmc-release] AID - 10.3389/fpubh.2023.1230198 [doi] PST - epublish SO - Front Public Health. 2023 Aug 16;11:1230198. doi: 10.3389/fpubh.2023.1230198. eCollection 2023. PMID- 37653123 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240924 IS - 2193-8229 (Print) IS - 2193-6382 (Electronic) IS - 2193-6382 (Linking) VI - 12 IP - 8 DP - 2023 Aug TI - Safety and Clinical Benefits of Adacel((R)) and Adacel((R))-Polio Vaccination in Pregnancy: A Structured Literature Review. PG - 1955-2003 LID - 10.1007/s40121-023-00847-5 [doi] AB - Vaccination in pregnancy using a tetanus toxoid, reduced dose diphtheria toxoid, and reduced dose acellular pertussis (Tdap) vaccine is important for prevention of severe pertussis disease in young infants. The objectives of this systematic literature review were to search for original research studies evaluating the vaccine effectiveness, immunogenicity, and safety of Adacel((R))/Adacel-Polio((R)) used during pregnancy to prevent pertussis disease in young infants. Medical databases used included EMBASE, BIOSIS Previews, and Chemical Abstracts, with search terms related to pregnancy, vaccines/immunization, safety, pertussis, effectiveness/efficacy, and immune response; other potentially eligible reports were included where applicable. Search results were restricted to literature published from 1 January 1995 to 26 July 2021. A total of 2021 articles and 4 other reports were identified for primary review. A total of 49 publications qualified for inclusion after primary and secondary reviews. Effectiveness studies of Adacel or Adacel-Polio given in pregnancy consistently showed high levels of protection from pertussis disease in the newborn (vaccine effectiveness: 91-93%). In immunogenicity studies, the response in pregnant women was consistent with that of non-pregnant women. Infants of mothers vaccinated with Adacel or Adacel-Polio in pregnancy had higher anti-pertussis antibody levels at birth and at 2 months of age compared to infants born to women vaccinated with comparator vaccines, placebo, or those not vaccinated during pregnancy. There was evidence of a slightly decreased response to primary pertussis vaccination in infants of mothers vaccinated with Adacel or Adacel-Polio, but this was not thought to be clinically significant. In safety studies, Adacel or Adacel-Polio vaccination was well tolerated by pregnant woman and not associated with pregnancy, postpartum, or neonatal complications. In conclusion, Adacel or Adacel-Polio vaccination in pregnancy is highly effective in protecting young infants from pertussis disease, with a favorable safety profile for both pregnant women and their infants. CI - (c) 2023. The Author(s). FAU - Clark, Liana R AU - Clark LR AD - Global Medical, Sanofi, 1 Discovery Drive, Swiftwater, PA, 18370, USA. liana.clark@sanofi.com. FAU - Johnson, David R AU - Johnson DR AD - Global Medical, Sanofi, 1 Discovery Drive, Swiftwater, PA, 18370, USA. LA - eng PT - Journal Article PT - Review DEP - 20230901 PL - New Zealand TA - Infect Dis Ther JT - Infectious diseases and therapy JID - 101634499 PMC - PMC10505126 OTO - NOTNLM OT - Effectiveness OT - Immune response OT - Infant OT - Pertussis OT - Pregnancy OT - Safety OT - Tdap COIS- Liana R. Clark and David R. Johnson are employees of Sanofi. EDAT- 2023/09/01 00:41 MHDA- 2023/09/01 00:42 PMCR- 2023/09/01 CRDT- 2023/08/31 23:31 PHST- 2023/05/23 00:00 [received] PHST- 2023/07/03 00:00 [accepted] PHST- 2023/09/01 00:42 [medline] PHST- 2023/09/01 00:41 [pubmed] PHST- 2023/08/31 23:31 [entrez] PHST- 2023/09/01 00:00 [pmc-release] AID - 10.1007/s40121-023-00847-5 [pii] AID - 847 [pii] AID - 10.1007/s40121-023-00847-5 [doi] PST - ppublish SO - Infect Dis Ther. 2023 Aug;12(8):1955-2003. doi: 10.1007/s40121-023-00847-5. Epub 2023 Sep 1. PMID- 37647284 OWN - NLM STAT- MEDLINE DCOM- 20230901 LR - 20230905 IS - 1932-6203 (Electronic) IS - 1932-6203 (Linking) VI - 18 IP - 8 DP - 2023 TI - The effectiveness and decay of public health policy actions on infection-control behaviour in the general public: Evidence from a low-COVID prevalence jurisdiction. PG - e0283711 LID - 10.1371/journal.pone.0283711 [doi] LID - e0283711 AB - BACKGROUND: Public health policies designed to influence individuals' infection-control behaviour are a tool for governments to help prevent the spread of disease. Findings on the impacts of policies are mixed and there is limited information on the effects of removing restrictions and how policies impact behavioural trends. METHODS: We use low-acuity emergency department visits from 12 hospitals in New Brunswick, Canada, (January 2017 -October 2021) as a proxy for infection-control behaviour and provide insight into the effects of the COVID-19 virus on a population with a low prevalence of cases. Quasi-experimental techniques (event studies) are applied to estimate the magnitude and persistence of effects of specific events (e.g., policy changes), to control for COVID-19 cases and vaccines, and to explore how the effectiveness of policy changes during the pandemic as more policies are introduced. RESULTS: Initial tightening of restrictions on March 11, 2020 reduced low-acuity emergency department visits by around 60% and reached a minimum after 30 days. Relaxing policies on social gatherings and personal services gradually increased low-acuity emergency department visits by approximately 50% after 44 days. No effects were found from policies lifting all restrictions, and reinstating a state of emergency on July 31, 2021, and September 24, 2021. CONCLUSION: These results suggest that policy interventions are less likely to be effective at influencing infection control behaviour with time and more policies introduced, and that tracking and publicly reporting case numbers can influence infection control behaviour. CI - Copyright: (c) 2023 Ross, Dutton. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. FAU - Ross, Kent AU - Ross K AUID- ORCID: 0000-0003-3407-5927 AD - Community Health and Epidemiology, Dalhousie University, Saint John, New Brunswick, Canada. FAU - Dutton, Daniel J AU - Dutton DJ AD - Community Health and Epidemiology, Dalhousie University, Saint John, New Brunswick, Canada. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20230830 PL - United States TA - PLoS One JT - PloS one JID - 101285081 SB - IM MH - Humans MH - Prevalence MH - *COVID-19/epidemiology/prevention & control MH - Public Policy MH - Infection Control MH - Health Policy PMC - PMC10468032 COIS- The authors have declared that no competing interests exist. EDAT- 2023/08/30 18:42 MHDA- 2023/09/01 06:43 PMCR- 2023/08/30 CRDT- 2023/08/30 13:33 PHST- 2022/11/04 00:00 [received] PHST- 2023/03/15 00:00 [accepted] PHST- 2023/09/01 06:43 [medline] PHST- 2023/08/30 18:42 [pubmed] PHST- 2023/08/30 13:33 [entrez] PHST- 2023/08/30 00:00 [pmc-release] AID - PONE-D-22-29992 [pii] AID - 10.1371/journal.pone.0283711 [doi] PST - epublish SO - PLoS One. 2023 Aug 30;18(8):e0283711. doi: 10.1371/journal.pone.0283711. eCollection 2023. PMID- 37644838 OWN - NLM STAT- MEDLINE DCOM- 20230831 LR - 20230914 IS - 1471-2954 (Electronic) IS - 0962-8452 (Print) IS - 0962-8452 (Linking) VI - 290 IP - 2005 DP - 2023 Aug 30 TI - COVID-19 vaccine coverage targets to inform reopening plans in a low incidence setting. PG - 20231437 LID - 10.1098/rspb.2023.1437 [doi] LID - 20231437 AB - Since the emergence of SARS-CoV-2 in 2019 through to mid-2021, much of the Australian population lived in a COVID-19-free environment. This followed the broadly successful implementation of a strong suppression strategy, including international border closures. With the availability of COVID-19 vaccines in early 2021, the national government sought to transition from a state of minimal incidence and strong suppression activities to one of high vaccine coverage and reduced restrictions but with still-manageable transmission. This transition is articulated in the national 're-opening' plan released in July 2021. Here, we report on the dynamic modelling study that directly informed policies within the national re-opening plan including the identification of priority age groups for vaccination, target vaccine coverage thresholds and the anticipated requirements for continued public health measures-assuming circulation of the Delta SARS-CoV-2 variant. Our findings demonstrated that adult vaccine coverage needed to be at least 60% to minimize public health and clinical impacts following the establishment of community transmission. They also supported the need for continued application of test-trace-isolate-quarantine and social measures during the vaccine roll-out phase and beyond. FAU - Conway, Eamon AU - Conway E AD - Population Health and Immunity Division, WEHI, Parkville 3052, Vic, Australia. FAU - Walker, Camelia R AU - Walker CR AD - School of Mathematics and Statistics, The University of Melbourne, Melbourne, Victoria, Australia. FAU - Baker, Christopher AU - Baker C AD - School of Mathematics and Statistics, The University of Melbourne, Melbourne, Victoria, Australia. AD - Melbourne Centre for Data Science, The University of Melbourne, Melbourne, Victoria, Australia. AD - Centre of Excellence for Biosecurity Risk Analysis, The University of Melbourne, Melbourne, Victoria, Australia. FAU - Lydeamore, Michael J AU - Lydeamore MJ AD - Department of Econometrics and Business Statistics, Monash University, Clayton, Victoria, Australia. FAU - Ryan, Gerard E AU - Ryan GE AUID- ORCID: 0000-0003-0183-7630 AD - Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Victoria, Australia. AD - Infectious Disease Ecology and Modelling, Telethon Kids Institute, Perth, Western Australia, Australia. FAU - Campbell, Trish AU - Campbell T AD - Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Victoria, Australia. AD - Department of Infectious Diseases, The University of Melbourne, Melbourne, Victoria, Australia. FAU - Miller, Joel C AU - Miller JC AD - Department of Mathematics and Statistics, La Trobe University, Melbourne, Victoria, Australia. FAU - Rebuli, Nic AU - Rebuli N AD - School of Population Health, The University of New South Wales, Sydney, New South Wales, Australia. FAU - Yeung, Max AU - Yeung M AD - Quantium, Sydney, New South Wales, Australia. FAU - Kabashima, Greg AU - Kabashima G AD - Quantium, Sydney, New South Wales, Australia. FAU - Geard, Nicholas AU - Geard N AUID- ORCID: 0000-0003-0069-2281 AD - School of Computing and Information Systems, The University of Melbourne, Melbourne, Victoria, Australia. FAU - Wood, James AU - Wood J AD - School of Population Health, The University of New South Wales, Sydney, New South Wales, Australia. FAU - McCaw, James M AU - McCaw JM AUID- ORCID: 0000-0002-2452-3098 AD - School of Mathematics and Statistics, The University of Melbourne, Melbourne, Victoria, Australia. AD - Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Victoria, Australia. FAU - McVernon, Jodie AU - McVernon J AD - Victorian Infectious Diseases Reference Laboratory Epidemiology Unit at the Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, Victoria, Australia. AD - Department of Econometrics and Business Statistics, Monash University, Clayton, Victoria, Australia. FAU - Golding, Nick AU - Golding N AD - Infectious Disease Ecology and Modelling, Telethon Kids Institute, Perth, Western Australia, Australia. AD - Curtin School of Population Health, Curtin University, Perth, Western Australia, Australia. FAU - Price, David J AU - Price DJ AUID- ORCID: 0000-0003-0076-3123 AD - Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Victoria, Australia. AD - Department of Infectious Diseases, The University of Melbourne, Melbourne, Victoria, Australia. FAU - Shearer, Freya M AU - Shearer FM AUID- ORCID: 0000-0001-9600-3473 AD - Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Victoria, Australia. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20230830 PL - England TA - Proc Biol Sci JT - Proceedings. Biological sciences JID - 101245157 RN - 0 (COVID-19 Vaccines) RN - SARS-CoV-2 variants SB - IM MH - Adult MH - Humans MH - *COVID-19 Vaccines MH - SARS-CoV-2 MH - Incidence MH - *COVID-19/epidemiology/prevention & control MH - Australia/epidemiology PMC - PMC10465974 OTO - NOTNLM OT - COVID-19 OT - SARS-CoV-2 OT - mathematical modelling OT - pandemic response OT - public health policy OT - vaccination strategy COIS- We declare we have no competing interests. EDAT- 2023/08/30 06:47 MHDA- 2023/08/31 06:41 PMCR- 2023/08/30 CRDT- 2023/08/30 03:09 PHST- 2023/08/31 06:41 [medline] PHST- 2023/08/30 06:47 [pubmed] PHST- 2023/08/30 03:09 [entrez] PHST- 2023/08/30 00:00 [pmc-release] AID - rspb20231437 [pii] AID - 10.1098/rspb.2023.1437 [doi] PST - ppublish SO - Proc Biol Sci. 2023 Aug 30;290(2005):20231437. doi: 10.1098/rspb.2023.1437. Epub 2023 Aug 30. PMID- 37610805 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230909 IS - 2561-326X (Electronic) IS - 2561-326X (Linking) VI - 7 DP - 2023 Aug 23 TI - Developing Culturally Appropriate Content for a Child-Rearing App to Support Young Children's Socioemotional and Cognitive Development in Afghanistan: Co-Design Study. PG - e44267 LID - 10.2196/44267 [doi] LID - e44267 AB - BACKGROUND: Optimal child-rearing practices can help mitigate the consequences of detrimental social determinants of health in early childhood. Given the ubiquity of personal digital technologies worldwide, the direct delivery of evidence-based information about early childhood development holds great promise. However, to make the content of these novel systems effective, it is crucial to incorporate place-based cultural beliefs, traditions, circumstances, and value systems of end users. OBJECTIVE: This paper describes the iterative approach used to develop the Thrive by Five child-rearing app in collaboration with Afghan parents, caregivers (eg, grandparents, aunts, and nannies), and subject matter experts (SMEs). We outline how co-design methodologies informed the development and cultural contextualization of content to meet the specific needs of Afghan parents and the content was tested and refined in collaboration with key Afghan stakeholders. METHODS: The preliminary content was developed based on a comprehensive literature review of the historical and sociocultural contexts in Afghanistan, including factors that influence child-rearing practices and early childhood development. After an initial review and refinement based on feedback from SMEs, this content was populated into a beta app for testing. Overall, 8 co-design workshops were conducted in July and August 2021 and February 2022 with 39 Afghan parents and caregivers and 6 SMEs to collect their feedback on the app and its content. The workshops were audio recorded and transcribed; detailed field notes were taken by 2 scribes. A theoretical thematic analysis using semantic codes was conducted to inform the refinement of existing content and development of new content to fulfill the needs identified by participants. RESULTS: The following 4 primary themes were identified: child-rearing in the Afghan sociocultural context, safety concerns, emotion and behavior management, and physical health and nutrition. Overall, participants agreed that the app had the potential to deliver valuable information to Afghan parents; however, owing to the volatility in the country, participants recommended including more activities that could be safely done indoors, as mothers and children are required to spend most of their time at home. Additionally, restrictions on public engagement in music required the removal of activities referencing singing that might be performed outside the home. Further, activities to help parents reduce their children's screen time, promote empathy, manage emotions, regulate behavior, and improve physical health and nutrition were requested. CONCLUSIONS: Direct engagement with Afghan parents, caregivers, and SMEs through co-design workshops enabled the development and refinement of evidence-based, localized, and contextually relevant child-rearing activities promoting healthy social, emotional, and cognitive development during the first 5 years of children's lives. Importantly, the content was adapted for the ongoing conflict in Afghanistan with the aim of empowering Afghan parents and caregivers to support their children's developmental potential despite the security concerns and situational stressors. CI - (c)Haley M LaMonica, Jacob J Crouse, Yun J C Song, Mafruha Alam, Chloe E Wilson, Gabrielle Hindmarsh, Adam Yoon, Kelsie A Boulton, Mahalakshmi Ekambareshwar, Victoria Loblay, Jakelin Troy, Mujahid Torwali, Adam J Guastella, Richard B Banati, Ian B Hickie. Originally published in JMIR Formative Research (https://formative.jmir.org), 23.08.2023. FAU - LaMonica, Haley M AU - LaMonica HM AUID- ORCID: 0000-0002-6563-5467 AD - Youth Mental Health and Technology Team, Brain and Mind Centre, The University of Sydney, Sydney, Australia. FAU - Crouse, Jacob J AU - Crouse JJ AUID- ORCID: 0000-0002-3805-2936 AD - Youth Mental Health and Technology Team, Brain and Mind Centre, The University of Sydney, Sydney, Australia. FAU - Song, Yun J C AU - Song YJC AUID- ORCID: 0000-0001-8776-6305 AD - Youth Mental Health and Technology Team, Brain and Mind Centre, The University of Sydney, Sydney, Australia. FAU - Alam, Mafruha AU - Alam M AUID- ORCID: 0000-0001-7433-4220 AD - Youth Mental Health and Technology Team, Brain and Mind Centre, The University of Sydney, Sydney, Australia. FAU - Wilson, Chloe E AU - Wilson CE AUID- ORCID: 0000-0001-6539-423X AD - Youth Mental Health and Technology Team, Brain and Mind Centre, The University of Sydney, Sydney, Australia. FAU - Hindmarsh, Gabrielle AU - Hindmarsh G AUID- ORCID: 0000-0003-1822-3328 AD - Youth Mental Health and Technology Team, Brain and Mind Centre, The University of Sydney, Sydney, Australia. FAU - Yoon, Adam AU - Yoon A AUID- ORCID: 0000-0002-9960-954X AD - Youth Mental Health and Technology Team, Brain and Mind Centre, The University of Sydney, Sydney, Australia. FAU - Boulton, Kelsie A AU - Boulton KA AUID- ORCID: 0000-0002-9408-7367 AD - Clinic for Autism and Neurodevelopment Research, Brain and Mind Centre, The University of Sydney, Sydney, Australia. FAU - Ekambareshwar, Mahalakshmi AU - Ekambareshwar M AUID- ORCID: 0000-0003-1936-7120 AD - Youth Mental Health and Technology Team, Brain and Mind Centre, The University of Sydney, Sydney, Australia. FAU - Loblay, Victoria AU - Loblay V AUID- ORCID: 0000-0003-4094-9619 AD - Youth Mental Health and Technology Team, Brain and Mind Centre, The University of Sydney, Sydney, Australia. AD - The Australian Prevention Partnership Centre, Sydney, Australia. FAU - Troy, Jakelin AU - Troy J AUID- ORCID: 0000-0002-8044-1150 AD - Faculty of Arts and Social Sciences, The University of Sydney, Sydney, Australia. FAU - Torwali, Mujahid AU - Torwali M AUID- ORCID: 0000-0002-6960-8917 AD - Faculty of Arts and Social Sciences, The University of Sydney, Sydney, Australia. FAU - Guastella, Adam J AU - Guastella AJ AUID- ORCID: 0000-0001-8178-4625 AD - Clinic for Autism and Neurodevelopment Research, Brain and Mind Centre, The University of Sydney, Sydney, Australia. FAU - Banati, Richard B AU - Banati RB AUID- ORCID: 0000-0003-3558-597X AD - Medical Imaging Sciences, Faculty of Medicine and Health, Brain and Mind Centre, The University of Sydney, Sydney, Australia. AD - Australian Nuclear Science and Technology Organisation, Sydney, Australia. FAU - Hickie, Ian B AU - Hickie IB AUID- ORCID: 0000-0001-8832-9895 AD - Youth Mental Health and Technology Team, Brain and Mind Centre, The University of Sydney, Sydney, Australia. LA - eng PT - Journal Article DEP - 20230823 PL - Canada TA - JMIR Form Res JT - JMIR formative research JID - 101726394 PMC - PMC10483291 OTO - NOTNLM OT - Afghanistan OT - child development OT - co-design OT - digital technology OT - global health OT - mobile app OT - mobile phone OT - participatory research OT - smartphone OT - stakeholder participation COIS- Conflicts of Interest: IBH is the co-director, health and policy at the Brain and Mind Centre, University of Sydney. The Brain and Mind Centre operates an early-intervention youth service at Camperdown under contract to headspace. He is the chief scientific adviser to and a 3.2% equity shareholder in InnoWell Pty Ltd. InnoWell was formed by the University of Sydney (32% equity) and PricewaterhouseCoopers (Australia; 32% equity) to deliver the A$30 million (US $21.6 million) Australian government-funded Project Synergy (2017-2020; a 3-year program for the transformation of mental health services) and to lead the transformation of mental health services internationally through the use of innovative technologies. HML is a section editor for JMIR Aging, a sister journal to JMIR Pediatrics and Parenting. She does not receive any financial benefit for this role or undue advantage in the peer-review process. VL is a board member of Matana Foundation, a philanthropic organization that provides funding to programs for disadvantaged young people in Australia. She does not receive any financial benefit for this role. All other authors declare no competing interests. EDAT- 2023/08/23 12:42 MHDA- 2023/08/23 12:43 PMCR- 2023/08/23 CRDT- 2023/08/23 11:53 PHST- 2022/11/24 00:00 [received] PHST- 2023/07/23 00:00 [accepted] PHST- 2023/06/24 00:00 [revised] PHST- 2023/08/23 12:43 [medline] PHST- 2023/08/23 12:42 [pubmed] PHST- 2023/08/23 11:53 [entrez] PHST- 2023/08/23 00:00 [pmc-release] AID - v7i1e44267 [pii] AID - 10.2196/44267 [doi] PST - epublish SO - JMIR Form Res. 2023 Aug 23;7:e44267. doi: 10.2196/44267. PMID- 37600867 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230823 IS - 2691-3593 (Electronic) IS - 2691-3593 (Linking) VI - 4 IP - 1 DP - 2023 Mar TI - A Population-Based Analysis of the Impact of the COVID-19 Pandemic on Solid Organ Transplantation in Ontario, Canada: Policy Response and Changes in Volume and 90-Day Outcomes. PG - e230 LID - 10.1097/AS9.0000000000000230 [doi] LID - e230 AB - OBJECTIVES: To evaluate the impact of the COVID-19 pandemic on solid organ transplantation. BACKGROUND: COVID-19 caused unprecedented disruption to solid organ transplantation (kidney, liver, heart, lung). Concerns about safety and decreases in deceased donors due to pandemic lockdowns have been described as potential causes. METHODS: We report population-based rates of transplantation during the first 3 waves of COVID-19 in Ontario, Canada (March 1, 2020-July 3, 2021) versus a pre-COVID-19 baseline period (January 1, 2017-February 29, 2020). Poisson models were used to predict transplantation rates during COVID-19, based on pre-COVID-19 rates, and generate observed to expected rate ratios (RRs). Ninety-day transplant outcomes (mortality, retransplantation, transplant nephrectomy) were captured. RESULTS: A 34.4% decrease (RR, 0.656; 95% confidence interval [CI], 0.586-0.734) in transplant rates was observed, coinciding with wave 1 and the deployment of a provincial transplant triaging system. Transplants decreased by 14.6% in wave 2 (RR, 0.854; 95% CI, 0.770-0.947) and 23.1% in wave 3 (RR, 0.769; 95% CI, 0.690-0.857) despite the triaging system not being activated. Overall, there was a 24.3% decrease (RR, 0.757; 95% CI, 0.679-0.844) in transplant rates, equivalent to 409 fewer transplants. No sustained changes were observed in heart or liver but sustained and large decreases were seen for lung (RR, 0.664; 95% CI, 0.482-0.915) and kidney (RR, 0.721; 95% CI, 0.602-0.863) transplantation. A low prevalence (1.7%) of COVID-19 infection within 90 days of transplantation was seen. No differences were observed in other 90-day outcomes. CONCLUSIONS: Early safety concerns limited transplantation to immediate life-saving procedures; however, the reductions in kidney and lung transplants continued for the rest of the pandemic, where no restrictions were in place. CI - Copyright (c) 2022 The Author(s). Published by Wolters Kluwer Health, Inc. FAU - Gomez, David AU - Gomez D AD - From the Department of Surgery, Faculty of Medicine, University of Toronto, Toronto, ON, Canada. AD - Department of Surgery, St. Michael's Hospital, Unity Health Toronto, Toronto, ON, Canada. AD - ICES, Toronto, ON, Canada. AD - Institute of Health Policy, Management and Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada. FAU - Stukel, Therese A AU - Stukel TA AD - ICES, Toronto, ON, Canada. AD - Institute of Health Policy, Management and Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada. FAU - Baxter, Nancy N AU - Baxter NN AD - From the Department of Surgery, Faculty of Medicine, University of Toronto, Toronto, ON, Canada. AD - ICES, Toronto, ON, Canada. AD - Institute of Health Policy, Management and Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada. AD - Melbourne School of Population and Global Health, University of Melbourne, Melbourne, VIC, Australia. FAU - Acuna, Sergio A AU - Acuna SA AD - From the Department of Surgery, Faculty of Medicine, University of Toronto, Toronto, ON, Canada. FAU - Wilton, Andrew S AU - Wilton AS AD - ICES, Toronto, ON, Canada. FAU - Treleaven, Darin AU - Treleaven D AD - Department of Medicine, McMaster University, Hamilton, ON, Canada. AD - Trillium Gift of Life Network, Ontario Health, Toronto, ON, Canada. FAU - Ordon, Michael AU - Ordon M AD - From the Department of Surgery, Faculty of Medicine, University of Toronto, Toronto, ON, Canada. AD - Department of Surgery, St. Michael's Hospital, Unity Health Toronto, Toronto, ON, Canada. AD - ICES, Toronto, ON, Canada. FAU - Kim, S Joseph AU - Kim SJ AD - ICES, Toronto, ON, Canada. AD - Institute of Health Policy, Management and Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada. AD - Department of Medicine, University of Toronto and the Ajmera Transplant Centre, Toronto General Hospital, University Health Network, Toronto, ON, Canada. LA - eng PT - Journal Article DEP - 20230105 PL - United States TA - Ann Surg Open JT - Annals of surgery open : perspectives of surgical history, education, and clinical approaches JID - 101769928 PMC - PMC10431431 OTO - NOTNLM OT - COVID-19 OT - heart transplant OT - kidney transplant OT - liver transplant OT - lung transplant OT - solid organ transplantation EDAT- 2023/08/21 06:42 MHDA- 2023/08/21 06:43 PMCR- 2023/01/05 CRDT- 2023/08/21 04:51 PHST- 2022/04/28 00:00 [received] PHST- 2022/11/04 00:00 [accepted] PHST- 2023/08/21 06:43 [medline] PHST- 2023/08/21 06:42 [pubmed] PHST- 2023/08/21 04:51 [entrez] PHST- 2023/01/05 00:00 [pmc-release] AID - 10.1097/AS9.0000000000000230 [doi] PST - epublish SO - Ann Surg Open. 2023 Jan 5;4(1):e230. doi: 10.1097/AS9.0000000000000230. eCollection 2023 Mar. PMID- 37575901 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250530 IS - 2224-4344 (Print) IS - 2224-4344 (Electronic) IS - 2224-4336 (Linking) VI - 12 IP - 7 DP - 2023 Jul 31 TI - Network structure of emotional and behavioral problems, loneliness, and suicidal thoughts in adolescents at the school closure and reopening stage in China. PG - 1373-1385 LID - 10.21037/tp-23-33 [doi] AB - BACKGROUND: Public restriction and school closure policies during the pandemic may have long-term effects on adolescents' mental health, and adolescents' feelings and needs may change as the pandemic progresses. This study was conducted to explore the network structure and differences in emotional and behavioral problems (EBPs), loneliness, and suicidal thoughts in adolescents during different pandemic periods in China. METHODS: Based on two cross-sectional studies conducted in Taizhou, China, during school closure (April 16 to May 14, 2020) and reopening (May 25 to July 10, 2021) using online questionnaire, a total of 14,726 adolescents (school closure: 6,587, school reopening: 8,139) were recruited. EBPs were evaluated based on the student version of the Strengths and Difficulties Questionnaire (SDQ). Loneliness and suicidal thoughts were measured by item 20 and item 9 of the Chinese version of the Children's Depression Inventory (CDI), respectively. Network analysis was used to estimate the network connections and properties between EBPs, loneliness, and suicidal thoughts. RESULTS: The prevalence of psychosocial problems significantly increased at the school reopening compared with the school closure: EBPs: 36.8% vs. 31.6%; loneliness: 40.3% vs. 33.9%; suicidal thoughts: 40.8% vs. 15.4%. Suicidal thoughts showed the closest connections with being unhappy and lonely. Being bullied was strongly connected with conduct problems of lying and stealing. The links between hyperactivity symptoms and the other domains of EBPs were stronger after the school reopened. Being unhappy and showing the hyperactivity symptoms of "nonpersistent, distractible, and fidgety" presented high network and bridge (increasing transference from one symptom domain to another) centrality. Loneliness showed high expected influence and bridge centrality. CONCLUSIONS: This study highlighted the high prevalence of EBPs, loneliness, and suicidal thoughts in Chinese adolescents. It also presented the network structure of these psychological problems over different pandemic stages. It is recommended that psychological support should be provided for adolescents, especially focusing on the central and bridge symptoms highlighted in this study. CI - 2023 Translational Pediatrics. All rights reserved. FAU - Chen, Yun AU - Chen Y AD - School of Public Health, Key Laboratory of Public Health Safety, National Health Commission Key Laboratory of Health Technology Assessment, Fudan University, Shanghai, China. FAU - Wang, Jingyi AU - Wang J AD - School of Public Health, Key Laboratory of Public Health Safety, National Health Commission Key Laboratory of Health Technology Assessment, Fudan University, Shanghai, China. FAU - Lin, Haijiang AU - Lin H AD - Taizhou City Center of Disease Control and Prevention, Taizhou, China. FAU - Richards, Marcus AU - Richards M AD - Medical Research Council Unit for Lifelong Health and Ageing, Institute of Cardiovascular Science, University College London, London, UK. FAU - Yang, Xiulu AU - Yang X AD - School of Public Health, Key Laboratory of Public Health Safety, National Health Commission Key Laboratory of Health Technology Assessment, Fudan University, Shanghai, China. FAU - Wang, Tingting AU - Wang T AD - Taizhou City Center of Disease Control and Prevention, Taizhou, China. FAU - Chen, Xiaoxiao AU - Chen X AD - Taizhou City Center of Disease Control and Prevention, Taizhou, China. FAU - Fu, Chaowei AU - Fu C AD - School of Public Health, Key Laboratory of Public Health Safety, National Health Commission Key Laboratory of Health Technology Assessment, Fudan University, Shanghai, China. LA - eng GR - MC_UU_00019/1/MRC_/Medical Research Council/United Kingdom GR - MC_UU_00019/3/MRC_/Medical Research Council/United Kingdom PT - Journal Article DEP - 20230719 PL - China TA - Transl Pediatr JT - Translational pediatrics JID - 101649179 PMC - PMC10416125 OTO - NOTNLM OT - Network analysis OT - bullying OT - emotional and behavioral problems (EBPs) OT - loneliness OT - suicidal thoughts COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tp.amegroups.com/article/view/10.21037/tp-23-33/coif). The authors have no conflicts of interest to declare. EDAT- 2023/08/14 06:42 MHDA- 2023/08/14 06:43 PMCR- 2023/07/31 CRDT- 2023/08/14 04:35 PHST- 2023/01/14 00:00 [received] PHST- 2023/06/12 00:00 [accepted] PHST- 2023/08/14 06:43 [medline] PHST- 2023/08/14 06:42 [pubmed] PHST- 2023/08/14 04:35 [entrez] PHST- 2023/07/31 00:00 [pmc-release] AID - tp-12-07-1373 [pii] AID - 10.21037/tp-23-33 [doi] PST - ppublish SO - Transl Pediatr. 2023 Jul 31;12(7):1373-1385. doi: 10.21037/tp-23-33. Epub 2023 Jul 19. PMID- 37563302 OWN - NLM STAT- MEDLINE DCOM- 20231203 LR - 20251117 IS - 2397-3374 (Electronic) IS - 2397-3374 (Linking) VI - 7 IP - 10 DP - 2023 Oct TI - No evidence that Chinese playtime mandates reduced heavy gaming in one segment of the video games industry. PG - 1753-1766 LID - 10.1038/s41562-023-01669-8 [doi] AB - Governments around the world are considering regulatory measures to reduce young people's time spent on digital devices, particularly video games. This raises the question of whether proposed regulatory measures would be effective. Since the early 2000s, the Chinese government has been enacting regulations to directly restrict young people's playtime. In November 2019, it limited players aged under 18 to 1.5 hours of daily playtime and 3 hours on public holidays. Using telemetry data on over seven billion hours of playtime provided by a stakeholder from the video games industry, we found no credible evidence for overall reduction in the prevalence of heavy playtime following the implementation of regulations: individual accounts became 1.14 times more likely to play heavily in any given week (95% confidence interval 1.139-1.141). This falls below our preregistered smallest effect size of interest (2.0) and thus is not interpreted as a practically meaningful increase. Results remain robust across a variety of sensitivity analyses, including an analysis of more recent (2021) adjustments to playtime regulation. This casts doubt on the effectiveness of such state-controlled playtime mandates. CI - (c) 2023. The Author(s). FAU - Zendle, David AU - Zendle D AUID- ORCID: 0000-0003-0279-6439 AD - Department of Computer Science, University of York, York, UK. david.zendle@york.ac.uk. FAU - Flick, Catherine AU - Flick C AUID- ORCID: 0000-0001-5831-5257 AD - School of Computer Science and Informatics, De Montfort University, Leicester, UK. FAU - Gordon-Petrovskaya, Elena AU - Gordon-Petrovskaya E AUID- ORCID: 0000-0003-4276-6154 AD - Department of Computer Science, University of York, York, UK. FAU - Ballou, Nick AU - Ballou N AUID- ORCID: 0000-0003-4126-0696 AD - School of Electronic Engineering and Computer Science, Queen Mary University of London, London, UK. FAU - Xiao, Leon Y AU - Xiao LY AUID- ORCID: 0000-0003-0709-0777 AD - Center for Digital Play, IT University of Copenhagen, Copenhagen, Denmark. FAU - Drachen, Anders AU - Drachen A AUID- ORCID: 0000-0002-1002-0414 AD - Department of Computer Science, University of York, York, UK. AD - SDU Metaverse Lab, Maersk McKinney-Moeller Institute, University of Southern Denmark, Odense, Denmark. LA - eng GR - iGGi DTC/RCUK | Engineering and Physical Sciences Research Council (EPSRC)/ GR - EP/S022325/1/RCUK | Engineering and Physical Sciences Research Council (EPSRC)/ PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20230810 PL - England TA - Nat Hum Behav JT - Nature human behaviour JID - 101697750 SB - IM MH - Adolescent MH - Aged MH - Humans MH - Asian People MH - *Video Games MH - Time Factors PMC - PMC10593605 COIS- Data for this study were provided by Unity Technologies. Unity Technologies played no role in the design of the study, its reporting or its execution. No funds were disbursed to the research team for the work incorporated into this manuscript. This includes data access fees for the serverless data warehouse from which the data under analysis were accessed, which were paid by the lead author out of a research stipend he receives from his host institution. Access to the data used in this study was contingent on a data-sharing agreement between Unity Technologies and D.Z.'s host institution. Legal approval was sought from Unity for the sharing of the data in this paper before its submission for peer review. D.Z. has never received any form of funding from the games industry. He has worked as a paid consultant for governments seeking to understand the effects of video games and gambling. He has worked as an expert witness in cases relating to the video game industry, but has never represented the games industry legally or been formally affiliated with any games industry body in any way. D.Z. has been involved in brokering data-sharing agreements with industry stakeholders in the past. He acknowledges that such data-sharing agreements constitute a conflict of interest as important as financial awards and wishes to highlight that he has used such data brokerage in ways that are likely to give him indirect financial advantage: he has used them as evidence for excellence in promotion applications; he has used them as evidence in grant applications. No such applications have been funded at the time of writing this manuscript. D.Z. is a member of the Advisory Board for Safer Gambling, a statutory body whose remit is to provide independent advice to the UK Gambling Commission. D.Z. is the recipient of an Academic Forum for the Study of Gambling Major Exploratory Grant that is derived from 'regulatory settlements applied for socially responsible purposes' received by the UK Gambling Commission and administered by Gambling Research Exchange Ontario (GREO). He has no further conflicts to declare. C.F. has received funding from the Tides Foundation on the recommendation of the Unity Charitable Fund (grant number TF2201-105180) for a separate project. A.D. has previously worked in a paid capacity within the video games industry as a game analytics consultant. He has worked on multiple industry-focused projects with a focus on knowledge transfer. He has received funding from the Tides Foundation on the recommendation of the Unity Charitable Fund (grant number TF2201-105180) for a separate project. L.Y.X. was employed by LiveMe, then a subsidiary of Cheetah Mobile (NYSE:CMCM), as an in-house counsel intern from July 2019 to August 2019 in Beijing, People's Republic of China. L.Y.X. was not involved with the monetisation of video games by Cheetah Mobile or its subsidiaries. L.Y.X. undertook a brief period of voluntary work experience at Wiggin LLP (Solicitors Regulation Authority (SRA) number: 420659) in London, England in August 2022. L.Y.X. has contributed and continues to contribute to research projects that were enabled by data access provided by the video game industry, specifically Unity Technologies (NYSE:U) (October 2022 to Present). L.Y.X. was the recipient of two AFSG (Academic Forum for the Study of Gambling) Postgraduate Research Support Grants that were derived from 'regulatory settlements applied for socially responsible purposes' received by the UK Gambling Commission and administered by Gambling Research Exchange Ontario (GREO) (March 2022 & January 2023). L.Y.X. has accepted funding to publish academic papers open access from GREO that was received by the UK Gambling Commission as above (October, November, & December 2022). L.Y.X. has accepted conference travel and attendance grants from, inter alia, the organisers of the 13th Nordic SNSUS (Stiftelsen Nordiska Sallskapet for Upplysning om Spelberoende; the Nordic Society Foundation for Information about Problem Gambling) Conference, which received gambling industry sponsorship (January 2023). L.Y.X. has received an honorarium from the Center for Ludomani for contributing a parent guide about a mobile game for Tjekspillet.dk, which is funded by the Danish Ministry of Health's gambling addiction pool (Sundhedsministeriets Ludomanipulje) (March 2023). The up to date version of L.Y.X.'s conflict of interest statement is available via https://sites.google.com/view/leon-xiao/about/conflict-of-interest. EP has previously received funding from the Academic Forum for the Study of Gambling (AFSG) Postgraduate Research Support Grant that was derived from 'regulatory settlements applied for socially responsible purposes' received by the UK Gambling Commission and administered by Gambling Research Exchange Ontario (GREO). The remaining authors declare no competing interests. EDAT- 2023/08/11 00:42 MHDA- 2023/10/27 06:43 PMCR- 2023/08/10 CRDT- 2023/08/10 23:29 PHST- 2022/11/25 00:00 [received] PHST- 2023/06/27 00:00 [accepted] PHST- 2023/10/27 06:43 [medline] PHST- 2023/08/11 00:42 [pubmed] PHST- 2023/08/10 23:29 [entrez] PHST- 2023/08/10 00:00 [pmc-release] AID - 10.1038/s41562-023-01669-8 [pii] AID - 1669 [pii] AID - 10.1038/s41562-023-01669-8 [doi] PST - ppublish SO - Nat Hum Behav. 2023 Oct;7(10):1753-1766. doi: 10.1038/s41562-023-01669-8. Epub 2023 Aug 10. PMID- 37549543 OWN - NLM STAT- MEDLINE DCOM- 20230822 LR - 20240210 IS - 1879-0046 (Electronic) IS - 0376-8716 (Print) IS - 0376-8716 (Linking) VI - 250 DP - 2023 Sep 1 TI - Perceptions of cannabis use risk to mental health among youth in Canada, England and the United States from 2017 to 2021. PG - 110904 LID - S0376-8716(23)01142-0 [pii] LID - 10.1016/j.drugalcdep.2023.110904 [doi] AB - BACKGROUND: There is little research examining perceptions of cannabis use risk to mental health in countries with differing cannabis regulations. This study therefore examines such perceptions among youth between 2017 and 2021 in Canada (non-medical cannabis legalized in October 2018), England (highly-restricted medical cannabis legalized November 2018), and the US (non-medical cannabis legal in some states). METHODS: Seven repeat cross-sectional online surveys were conducted between July 2017 to August 2021 among youth aged 16-19 in Canada (N=29,420), England (N=28,155), and the US (N=32,974). Logistic regression models, stratified by country, were used to examine perceptions of cannabis use risk to mental health over time, adjusting for age group, sex, race/ethnicity, cannabis use and, for the US only, state-level cannabis legalization. RESULTS: Perceptions that cannabis use posed "no risk" to mental health decreased between July 2017 and August 2021 in Canada (6.1-4.4%; AOR=0.64, 95% CI=0.52-0.78) and the US (14.0-11.3%; AOR=0.74, 0.65-0.84) but not England (3.7-4.5%; AOR=1.21, 0.97-1.52). No significant changes were observed from immediately before (August 2018) to after (August 2019) legalization of non-medical cannabis in Canada (AOR=0.99, 0.83-1.20) or highly-restricted medical cannabis in England (AOR=0.90, 0.70-1.17). In the US, perceptions of "no risk" were more likely in states where cannabis use was illegal (15.0%) compared with legal non-medical (12.2%) (AOR=0.68, 0.63-0.74). CONCLUSION: There were modest decreases in perceptions that cannabis use poses no risk to mental health in Canada and the US between 2017 and 2021 but no clear association with cannabis legalization status. CI - Copyright (c) 2023 The Author(s). Published by Elsevier B.V. All rights reserved. FAU - Lemos, Maria K AU - Lemos MK AD - National Addiction Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK. FAU - Taylor, Eve AU - Taylor E AD - National Addiction Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK. FAU - Wadsworth, Elle AU - Wadsworth E AD - RAND Europe, Cambridge, UK; School of Public Health Sciences, Faculty of Health, University of Waterloo, Ontario, Canada. FAU - Reid, Jessica L AU - Reid JL AD - School of Public Health Sciences, Faculty of Health, University of Waterloo, Ontario, Canada. FAU - Hammond, David AU - Hammond D AD - School of Public Health Sciences, Faculty of Health, University of Waterloo, Ontario, Canada. FAU - East, Katherine AU - East K AD - National Addiction Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK; School of Public Health Sciences, Faculty of Health, University of Waterloo, Ontario, Canada. Electronic address: katherine.east@kcl.ac.uk. LA - eng GR - P01 CA200512/CA/NCI NIH HHS/United States GR - DH_/Department of Health/United Kingdom PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20230722 PL - Ireland TA - Drug Alcohol Depend JT - Drug and alcohol dependence JID - 7513587 RN - 0 (Medical Marijuana) RN - 0 (Hallucinogens) SB - IM MH - Humans MH - United States/epidemiology MH - Adolescent MH - *Cannabis MH - Cross-Sectional Studies MH - Mental Health MH - *Marijuana Smoking/psychology MH - *Medical Marijuana MH - Canada/epidemiology MH - *Hallucinogens MH - Legislation, Drug PMC - PMC10847957 MID - NIHMS1958150 OTO - NOTNLM OT - Adolescents OT - Cannabinoids OT - Policy COIS- Declaration of Competing Interest DH has served as a paid expert witness on behalf of governments and public health authorities in legal challenges against tobacco, vaping, and cannabis companies. All other authors have no potential conflicts of interest to disclose. EDAT- 2023/08/08 00:42 MHDA- 2023/08/22 06:42 PMCR- 2024/02/07 CRDT- 2023/08/07 18:05 PHST- 2023/03/27 00:00 [received] PHST- 2023/07/05 00:00 [revised] PHST- 2023/07/17 00:00 [accepted] PHST- 2023/08/22 06:42 [medline] PHST- 2023/08/08 00:42 [pubmed] PHST- 2023/08/07 18:05 [entrez] PHST- 2024/02/07 00:00 [pmc-release] AID - S0376-8716(23)01142-0 [pii] AID - 10.1016/j.drugalcdep.2023.110904 [doi] PST - ppublish SO - Drug Alcohol Depend. 2023 Sep 1;250:110904. doi: 10.1016/j.drugalcdep.2023.110904. Epub 2023 Jul 22. PMID- 37539609 OWN - NLM STAT- MEDLINE DCOM- 20230807 LR - 20230823 IS - 2531-6745 (Electronic) IS - 0392-4203 (Print) IS - 0392-4203 (Linking) VI - 94 IP - 4 DP - 2023 Aug 3 TI - Digital epidemiology and infodemiology of hand-foot-mouth disease (HFMD) in Italy. Disease trend assessment via Google and Wikipedia. PG - e2023107 LID - 10.23750/abm.v94i4.14184 [doi] LID - e2023107 AB - BACKGROUND AND AIM: The study aimed to evaluate the epidemiological trend of hand, foot and mouth disease (HFMD) in Italy using data on Internet search volume. METHODS: A cross-sectional study design was used. Data on Internet searches were obtained from Google Trends (GT) and Wikipedia. We used the following Italian search term: "Malattia mano-piede-bocca" (Hand-foot-mouth disease, in English). A monthly time-frame was extracted, partly overlapping, from July 2015 to December 2022. GT and Wikipedia were overlapped to perform a linear regression and correlation analyses. Statistical analyses were performed using the Spearman's rank correlation coefficient (rho). A linear regression analysis was performed considering Wikipedia and GT. RESULTS: Search peaks for both Wikipedia and GT occurred in the months November-December during the autumn-winter season and in June during the spring-summer season, except for the period from June 2020 to June 2021, probably due to the restrictions of the COVID19 pandemic. A temporal correlation was observed between GT and Wikipedia search trends. CONCLUSIONS: This is the first study in Italy that attempts to clarify the epidemiology of HFMD. Google search and Wikipedia can be valuable for public health surveillance; however, to date, digital epidemiology cannot replace the traditional surveillance system. FAU - Santangelo, Omar Enzo AU - Santangelo OE AD - Regional Health Care and Social Agency of Lodi, ASST Lodi. omarenzosantangelo@hotmail.it. FAU - Gianfredi, Vincenza AU - Gianfredi V AD - Department of Biomedical Sciences for Health, University of Milan. vincenza.gianfredi@unimi.it. FAU - Provenzano, Sandro AU - Provenzano S AD - 3Local Health Unit of Trapani, ASP Trapani, 91100 Trapani. provenzanosandro@hotmail.it. FAU - Cedrone, Fabrizio AU - Cedrone F AD - Hospital Management, Local Health Unit of Pescara, 65122 Pescara. cedronefab@gmail.com. LA - eng PT - Journal Article DEP - 20230803 PL - Italy TA - Acta Biomed JT - Acta bio-medica : Atenei Parmensis JID - 101295064 SB - IM MH - Humans MH - *Hand, Foot and Mouth Disease/epidemiology MH - Search Engine MH - Cross-Sectional Studies MH - Infodemiology MH - *COVID-19 PMC - PMC10440772 COIS- Each author declares that he or she has no commercial associations (e.g. consultancies, stock ownership, equity interest, patent/licensing arrangement etc.) that might pose a conflict of interest in connection with the submitted article. EDAT- 2023/08/04 06:43 MHDA- 2023/08/07 06:42 PMCR- 2023/01/01 CRDT- 2023/08/04 05:29 PHST- 2023/01/19 00:00 [received] PHST- 2023/02/17 00:00 [accepted] PHST- 2023/08/07 06:42 [medline] PHST- 2023/08/04 06:43 [pubmed] PHST- 2023/08/04 05:29 [entrez] PHST- 2023/01/01 00:00 [pmc-release] AID - ACTA-94-107 [pii] AID - 10.23750/abm.v94i4.14184 [doi] PST - epublish SO - Acta Biomed. 2023 Aug 3;94(4):e2023107. doi: 10.23750/abm.v94i4.14184. PMID- 37552787 STAT- Publisher PB - Agency for Healthcare Research and Quality (US) CTI - U.S. Preventive Services Task Force Evidence Syntheses, formerly Systematic Evidence Reviews DP - 2023 Aug BTI - Folic Acid Supplementation to Prevent Neural Tube Defects: A Limited Systematic Review Update for the U.S. Preventive Services Task Force AB - PURPOSE: To conduct a limited update of new evidence of the benefits and harms of folic acid supplementation for the prevention of neural tube defects (NTDs) in persons capable of becoming pregnant for the U.S. Preventive Services Task Force (USPSTF) to update its 2017 recommendation. DATA SOURCES: PubMed/MEDLINE, the Cochrane Library, Embase, and trial registries for publications from July 1, 2015, through July 2, 2021; reference lists of retrieved articles, with surveillance of the literature through February 10, 2023. STUDY SELECTION: Two investigators independently screened studies from the update search using a priori inclusion and exclusion criteria. We included English-language randomized studies and nonrandomized cohort studies with comparisons that focused on the use of folic acid supplementation (by itself or in multivitamin) for the prevention of NTD-affected pregnancies in persons capable of getting pregnant. We also evaluated studies investigating potential harms of folic acid supplementation such as maternal cancer and autism spectrum disorder. We excluded poor-quality studies, studies not conducted in very highly developed countries, and studies focusing solely on persons on antiseizure medications, persons with a history of NTDs in previous pregnancies, or persons not capable of getting pregnant. DATA EXTRACTION AND ANALYSIS: One investigator extracted data and a second checked accuracy. Two reviewers independently rated the methodological quality of the included studies based on predefined criteria. RESULTS: Twelve observational studies (reported in 13 publications) were eligible for this limited update (N=1,244,072 [from nonoverlapping cohorts]). Of these, three studies (N=990,372) reported on the effect of folic acid supplementation on NTDs. No studies reported on differences by race or ethnicity. For harms, nine studies were eligible; one randomized, controlled trial (N=431) reported on variations in twin delivery, seven observational studies (N=761,125) reported on the incidence of autism spectrum disorder, and one observational study (N=429,004) reported on maternal cancer. Regarding benefits of folic acid supplementation, two cohort studies and one case-control study in this update reported on the association between folic acid supplementation and NTDs (N=990,372). One cohort study reported a statistically significant reduced risk of NTDs associated with folic acid supplementation taken before pregnancy (adjusted relative risk [aRR]: 0.54 [95% confidence interval CI, 0.31 to 0.91]), during pregnancy (aRR, 0.62 [95% CI, 0.39 to 0.97]), and before and during pregnancy (aRR, 0.49 [95% CI, 0.29 to 0.83]), but for only the later of two periods studied (2006 to 2013 and not 1999 to 2005). No other statistically significant benefits were reported overall. No study reported statistically significant harms (multiple gestation, autism, and maternal cancer) associated with pregnancy-related folic acid exposure. LIMITATIONS: Interventions evaluated by included studies were restricted to folic acid supplementation and did not include interventions such as food fortification, counseling to increase dietary intake, or screening for NTDs. We did not evaluate the association between red blood cell folate concentrations and NTDs. We found limited information on differences in benefits and risks of folic acid supplementation by dose and timing. We found no information about variation in outcomes by duration of use or by race or ethnicity. Our review was designed to identify evidence that could result in a change in the 2017 USPSTF A recommendation; therefore, it focused only on studies published since 2015 and did not include the previously reviewed evidence. Ethical and logistical issues constrain the conduct of new randomized, controlled trials of folate supplementation versus placebo. All newly available evidence is observational and offers limited ability to control for confounding (including from mandatory food fortification), selection bias, recall bias, and attrition. As a result, included studies have inherent uncertainty regarding case ascertainment (for NTDs and harms) and degree of exposure (dose, timing, and duration) to folic acid supplementation. CONCLUSIONS: New evidence from observational studies provides continued evidence of benefit of folic acid supplementation for preventing NTDs and no evidence of harms related to multiple gestation, autism, or maternal cancer and is consistent with the previously reviewed evidence on this topic. The 2017 USPSTF recommendation supporting folic acid supplementation in pregnancy was based on previously reviewed evidence from a randomized, controlled trial and observational studies reporting reduced NTDs with supplementation and no consistent evidence of harms for multiple gestations, maternal adverse effects, or child respiratory illness. FAU - Viswanathan, Meera AU - Viswanathan M FAU - Urrutia, Rachel P AU - Urrutia RP FAU - Hudson, Kesha N AU - Hudson KN FAU - Middleton, Jennifer Cook AU - Middleton JC FAU - Kahwati, Leila C AU - Kahwati LC LA - eng PT - Review PT - Book PL - Rockville (MD) EDAT- 2023/08/01 00:00 CRDT- 2023/08/01 00:00 AID - NBK593614 [bookaccession] PMID- 37521757 OWN - NLM STAT- MEDLINE DCOM- 20230801 LR - 20230801 IS - 1937-8688 (Electronic) VI - 45 DP - 2023 TI - Seroprevalence of SARS-CoV-2 immunoglobulin G antibody during COVID-19 pandemic in Fayoum District, Egypt: a community-based pilot survey. PG - 22 LID - 10.11604/pamj.2023.45.22.36513 [doi] LID - 22 AB - INTRODUCTION: controlling the worldwide pandemic, coronavirus disease (COVID-19), could be impossible due to the hesitancy about the available vaccines and the difficulty to implement strict restrictions. Little information is available about herd immunity in the highly vulnerable region of North East Africa, Egypt. The objective of this study was to assess the seroprevalence of SARS-CoV-2 during the pandemic in one of the highly vulnerable populations in Egypt, the Fayoum district of Fayoum Governorate. Additionally, to assess the predictive value of symptoms and other associated risk factors towards a positive COVID-19 test. METHODS: in this cross-sectional community-based pilot study, immunoglobulin G (IgG) antibodies that are specific for the SARS-CoV-2 spike (S1-RBD) protein were tested during the period from February 2021 to July 2021. RESULTS: out of 155 participants, 60.6% were SARS-CoV-2 seropositive. Out of symptomatic and asymptomatic individuals, 76.5% and 56.2% were seropositive, respectively. Surprisingly, only one individual had received the COVID-19 vaccine. Previous history of COVID-19; such as symptoms and gender are statistically significant predictors of high seroconversion independent of age, comorbidities, and level of education. CONCLUSION: this study which disclosed unexpectedly high SARS-CoV-2 seroconversion among the Egyptians, might provide a clear insight into COVID-19 transmission patterns and state of immunity. Further study with a larger sample size on a large scale is required to represent the whole local population. CI - Copyright: Salwa Bakr et al. FAU - Bakr, Salwa AU - Bakr S AD - Department of Clinical Pathology/Hematology and Transfusion Medicine, Faculty of Medicine, Fayoum University, Fayoum, Egypt. FAU - Ezzat, Eman Mahmoud AU - Ezzat EM AD - Department of Internal Medicine, Faculty of Medicine, Fayoum University, Fayoum, Egypt. FAU - Salem, Karem Mohamed AU - Salem KM AD - Department of Internal Medicine, Faculty of Medicine, Fayoum University, Fayoum, Egypt. FAU - Masoud, Mohamed AU - Masoud M AD - Department of Public Health and Community Medicine, Faculty of Medicine, Fayoum University, Fayoum, Egypt. FAU - Abdelaziz, Hossam Eldin Mahmoud AU - Abdelaziz HEM AD - Department of Clinical Pathology/Hematology and Transfusion Medicine, Faculty of Medicine, Fayoum University, Fayoum, Egypt. LA - eng PT - Journal Article DEP - 20230505 PL - Uganda TA - Pan Afr Med J JT - The Pan African medical journal JID - 101517926 RN - 0 (Immunoglobulin G) RN - 0 (COVID-19 Vaccines) RN - 0 (Antibodies, Viral) SB - IM MH - Humans MH - *Immunoglobulin G MH - Pandemics MH - SARS-CoV-2 MH - Egypt/epidemiology MH - Seroepidemiologic Studies MH - COVID-19 Vaccines MH - Cross-Sectional Studies MH - Pilot Projects MH - *COVID-19/epidemiology MH - Antibodies, Viral PMC - PMC10386537 OTO - NOTNLM OT - COVID-19 OT - Coronavirus OT - Egypt OT - SARS-CoV-2 OT - seroconversion COIS- All authors declare no competing interests. EDAT- 2023/07/31 06:43 MHDA- 2023/08/01 06:44 PMCR- 2023/05/05 CRDT- 2023/07/31 05:12 PHST- 2022/07/26 00:00 [received] PHST- 2023/04/30 00:00 [accepted] PHST- 2023/08/01 06:44 [medline] PHST- 2023/07/31 06:43 [pubmed] PHST- 2023/07/31 05:12 [entrez] PHST- 2023/05/05 00:00 [pmc-release] AID - PAMJ-45-22 [pii] AID - 10.11604/pamj.2023.45.22.36513 [doi] PST - epublish SO - Pan Afr Med J. 2023 May 5;45:22. doi: 10.11604/pamj.2023.45.22.36513. eCollection 2023. PMID- 37496830 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230728 IS - 2468-0427 (Electronic) IS - 2468-2152 (Print) IS - 2468-0427 (Linking) VI - 8 IP - 3 DP - 2023 Sep TI - Improvement of the software for modeling the dynamics of epidemics and developing a user-friendly interface. PG - 806-821 LID - 10.1016/j.idm.2023.06.003 [doi] AB - The challenges humanity is facing due to the Covid-19 pandemic require timely and accurate forecasting of the dynamics of various epidemics to minimize the negative consequences for public health and the economy. One can use a variety of well-known and new mathematical models, taking into account a huge number of factors. However, complex models contain a large number of unknown parameters, the values of which must be determined using a limited number of observations, e.g., the daily datasets for the accumulated number of cases. Successful experience in modeling the COVID-19 pandemic has shown that it is possible to apply the simplest SIR model, which contains 4 unknown parameters. Application of the original algorithm of the model parameter identification for the first waves of the COVID-19 pandemic in China, South Korea, Austria, Italy, Germany, France, Spain has shown its high accuracy in predicting their duration and number of diseases. To simulate different epidemic waves and take into account the incompleteness of statistical data, the generalized SIR model and algorithms for determining the values of its parameters were proposed. The interference of the previous waves, changes in testing levels, quarantine or social behavior require constant monitoring of the epidemic dynamics and performing SIR simulations as often as possible with the use of a user-friendly interface. Such tool will allow predicting the dynamics of any epidemic using the data on the number of diseases over a limited period (e.g., 14 days). It will be possible to predict the daily number of new cases for the country as a whole or for its separate region, to estimate the number of carriers of the infection and the probability of facing such a carrier, as well as to estimate the number of deaths. Results of three SIR simulations of the COVID-19 epidemic wave in Japan in the summer of 2022 are presented and discussed. The predicted accumulated and daily numbers of cases agree with the results of observations, especially for the simulation based on the datasets corresponding to the period from July 3 to July 16, 2022. A user-friendly interface also has to ensure an opportunity to compare the epidemic dynamics in different countries/regions and in different years in order to estimate the impact of vaccination levels, quarantine restrictions, social behavior, etc. on the numbers of new infections, death, and mortality rates. As example, the comparison of the COVID-19 pandemic dynamics in Japan in the summer of 2020, 2021 and 2022 is presented. The high level of vaccinations achieved in the summer of 2022 did not save Japan from a powerful pandemic wave. The daily numbers of cases were about ten times higher than in the corresponding period of 2021. Nevertheless, the death per case ratio in 2022 was much lower than in 2020. CI - (c) 2023 The Authors. FAU - Nesteruk, Igor AU - Nesteruk I AD - Institute of Hydromechanics, National Academy of Sciences of Ukraine, Kyiv, Ukraine. AD - Igor Sikorsky Kyiv Polytechnic Institute, Kyiv, Ukraine. LA - eng PT - Journal Article DEP - 20230708 PL - China TA - Infect Dis Model JT - Infectious Disease Modelling JID - 101692406 PMC - PMC10366461 OTO - NOTNLM OT - COVID-19 pandemic OT - Epidemic dynamics in Japan OT - Epidemic waves OT - Mathematical modeling of infection diseases OT - Parameter identification OT - SIR model OT - Statistical methods COIS- The author states that there is no conflict of interest. There are no competing interests. The study was not supported by any funding.The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2023/07/27 06:42 MHDA- 2023/07/27 06:43 PMCR- 2023/07/08 CRDT- 2023/07/27 04:10 PHST- 2023/03/01 00:00 [received] PHST- 2023/06/20 00:00 [revised] PHST- 2023/06/22 00:00 [accepted] PHST- 2023/07/27 06:43 [medline] PHST- 2023/07/27 06:42 [pubmed] PHST- 2023/07/27 04:10 [entrez] PHST- 2023/07/08 00:00 [pmc-release] AID - S2468-0427(23)00057-X [pii] AID - 10.1016/j.idm.2023.06.003 [doi] PST - epublish SO - Infect Dis Model. 2023 Jul 8;8(3):806-821. doi: 10.1016/j.idm.2023.06.003. eCollection 2023 Sep. PMID- 37490397 OWN - NLM STAT- MEDLINE DCOM- 20260310 LR - 20260310 IS - 0265-539X (Print) IS - 0265-539X (Linking) VI - 40 IP - 3 DP - 2023 Aug 31 TI - The impact of restricted access on the need and demand for specialist dental services - A consideration for future needs assessments. PG - 139-145 LID - 10.1922/CDH_00122Keat07 [doi] AB - INTRODUCTION: The COVID-19 pandemic forced NHS Dental Services to adapt quickly and implement measures which would safeguard essential care provision, whilst mitigating COVID-19 transmission risks. However, these changes impacted on both dental access, and onward referrals for specialist care. BASIC RESEARCH DESIGN: A longitudinal study design is used to offer descriptive analysis of referrals sent across three referral groups (orthodontics, paediatric dentistry, suspected cancers) across three time-matched periods (1st July to 31st December in 2019, 2020 and 2021). Anonymised data, extracted from an electronic referral management system (eRMS), are considered. Number of referrals, reasons for referral, Indices of Multiple Deprivation for each referral are discussed. RESULTS: Referrals reduced from 2019 to 2020. Proportionally, the greatest reduction in onward referral was observed amongst individuals from the lowest socioeconomic positions, across all groups. Although mandated to conduct only 62.5% of the 2019 activity, the 2021 referrals exceeded 2019 figures. Proportions referred from the lowest socioeconomic position were still slightly lower across all three groups. CONCLUSIONS: Referrals from the lowest socioeconomic groups decreased in 2020, followed by a rebound in 2021, despite a reduction in mandated clinical activity. There are potential implications for future oral health needs assessments that should be considered when developing interventions to enhance access for vulnerable populations as we emerge from the COVID-19 pandemic. CI - Copyright(c) 2023 Dennis Barber Ltd. FAU - Keat, R AU - Keat R AD - Dental Health Unit, University of Manchester, UK. FAU - Pretty, I AU - Pretty I AD - Dental Health Unit, University of Manchester, UK. LA - eng PT - Journal Article DEP - 20230831 PL - England TA - Community Dent Health JT - Community dental health JID - 8411261 SB - IM MH - Humans MH - *COVID-19/epidemiology MH - *Health Services Accessibility/statistics & numerical data MH - Longitudinal Studies MH - *Referral and Consultation/statistics & numerical data MH - *Health Services Needs and Demand MH - *Needs Assessment MH - United Kingdom/epidemiology MH - Pandemics MH - *Dental Care OTO - NOTNLM OT - Access OT - Dental OT - Healthcare Public Health OT - Public Health Dentistry OT - Referral Management OT - Specialties EDAT- 2023/07/25 19:15 MHDA- 2026/03/10 18:36 CRDT- 2023/07/25 12:53 PHST- 2026/03/10 18:36 [medline] PHST- 2023/07/25 19:15 [pubmed] PHST- 2023/07/25 12:53 [entrez] AID - 10.1922/CDH_00122Keat07 [doi] PST - epublish SO - Community Dent Health. 2023 Aug 31;40(3):139-145. doi: 10.1922/CDH_00122Keat07. PMID- 37413848 OWN - NLM STAT- MEDLINE DCOM- 20230724 LR - 20230724 IS - 1873-5347 (Electronic) IS - 0277-9536 (Linking) VI - 330 DP - 2023 Aug TI - Mental health symptoms following the January 6th attack on the United States Capitol. PG - 116015 LID - S0277-9536(23)00372-6 [pii] LID - 10.1016/j.socscimed.2023.116015 [doi] AB - On January 6, 2021, rioters stormed the US Capitol to overturn the Congressional certification of Joseph Biden as the 46th president of the United States. In previous work, the symbolic dis/empowerment framework, as a result of sociopolitical context, has influenced health outcomes in certain sub-populations. We examine whether the Capitol Riot corresponds with an increase in mental health symptoms and explore whether this relation differs by individual political party affiliation and/or state electoral college victory. We utilize the Understanding America Study, a nationally representative panel of adults, between March 10, 2020-July 11, 2021. Using fixed effects linear regression, we find a modest increase above expected levels in mental health symptoms immediately following the Capitol Riot. This result holds for Democrats overall, Democrats in Biden states, and when restricting analyses to only states that voted for Biden (or separately, for Trump). Democrats show the greatest increase of mental health symptoms following the Capital Riot, supporting the symbolic dis/empowerment framework as well as notions of political polarization and allegiance. Social and political events of national importance may adversely affect mental health of specific subpopulations. CI - Copyright (c) 2023. Published by Elsevier Ltd. FAU - Das, Abhery AU - Das A AD - Program in Public Health, University of California, Irvine, USA; Center for Population, Inequality, and Policy, University of California, Irvine, USA. Electronic address: abheryd@uci.edu. FAU - Morey, Brittany N AU - Morey BN AD - Program in Public Health, University of California, Irvine, USA; Center for Population, Inequality, and Policy, University of California, Irvine, USA. FAU - Bruckner, Tim A AU - Bruckner TA AD - Program in Public Health, University of California, Irvine, USA; Center for Population, Inequality, and Policy, University of California, Irvine, USA. LA - eng PT - Journal Article DEP - 20230616 PL - England TA - Soc Sci Med JT - Social science & medicine (1982) JID - 8303205 SB - IM MH - Adult MH - Humans MH - United States/epidemiology MH - *Mental Health MH - *Mental Disorders MH - Politics MH - Universities OTO - NOTNLM OT - Capitol riot OT - Electoral college OT - Insurrection OT - January 6 OT - Mental health OT - Political party affiliation COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2023/07/07 01:05 MHDA- 2023/07/24 06:43 CRDT- 2023/07/06 18:06 PHST- 2022/10/29 00:00 [received] PHST- 2023/05/05 00:00 [revised] PHST- 2023/06/11 00:00 [accepted] PHST- 2023/07/24 06:43 [medline] PHST- 2023/07/07 01:05 [pubmed] PHST- 2023/07/06 18:06 [entrez] AID - S0277-9536(23)00372-6 [pii] AID - 10.1016/j.socscimed.2023.116015 [doi] PST - ppublish SO - Soc Sci Med. 2023 Aug;330:116015. doi: 10.1016/j.socscimed.2023.116015. Epub 2023 Jun 16. PMID- 37406049 OWN - NLM STAT- MEDLINE DCOM- 20230707 LR - 20240922 IS - 1537-6591 (Electronic) IS - 1058-4838 (Print) IS - 1058-4838 (Linking) VI - 77 IP - Suppl 1 DP - 2023 Jul 5 TI - Colonization With Antibiotic-Resistant Bacteria in a Hospital and Associated Communities in Guatemala: An Antibiotic Resistance in Communities and Hospitals (ARCH) Study. PG - S82-S88 LID - 10.1093/cid/ciad222 [doi] AB - BACKGROUND: We estimated the prevalence of colonization with extended-spectrum cephalosporin-resistant Enterobacterales (ESCrE) and carbapenem-resistant Enterobacterales (CRE) from a hospital and associated communities in western Guatemala. METHODS: Randomly selected infants, children, and adults (<1, 1-17, and >/=18 years, respectively) were enrolled from the hospital (n = 641) during the coronavirus disease 2019 (COVID-19) pandemic, March to September 2021. Community participants were enrolled using a 3-stage cluster design between November 2019 and March 2020 (phase 1, n = 381) and between July 2020 and May 2021 (phase 2, with COVID-19 pandemic restrictions, n = 538). Stool samples were streaked onto selective chromogenic agar, and a Vitek 2 instrument was used to verify ESCrE or CRE classification. Prevalence estimates were weighted to account for sampling design. RESULTS: The prevalence of colonization with ESCrE and CRE was higher among hospital patients compared to community participants (ESCrE: 67% vs 46%, P < .01; CRE: 37% vs 1%, P < .01). Hospital ESCrE colonization was higher for adults (72%) compared with children (65%) and infants (60%) (P < .05). Colonization was higher for adults (50%) than children (40%) in the community (P < .05). There was no difference in ESCrE colonization between phase 1 and 2 (45% and 47%, respectively, P > .05), although reported use of antibiotics among households declined (23% and 7%, respectively, P < .001). CONCLUSIONS: While hospitals remain foci for ESCrE and CRE colonization, consistent with the need for infection control programs, community prevalence of ESCrE in this study was high, potentially adding to colonization pressure and transmission in healthcare settings. Better understanding of transmission dynamics and age-related factors is needed. CI - (c) The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. FAU - Ramay, Brooke M AU - Ramay BM AD - Center for Health Studies, Universidad del Valle de Guatemala, Guatemala City, Guatemala Department, Republic of Guatemala. AD - Paul G. Allen School for Global Health, Washington State University, Pullman, Washington, USA. FAU - Castillo, Carmen AU - Castillo C AD - Center for Health Studies, Universidad del Valle de Guatemala, Guatemala City, Guatemala Department, Republic of Guatemala. FAU - Grajeda, Laura AU - Grajeda L AD - Center for Health Studies, Universidad del Valle de Guatemala, Guatemala City, Guatemala Department, Republic of Guatemala. FAU - Santos, Lucas F AU - Santos LF AD - Center for Health Studies, Universidad del Valle de Guatemala, Guatemala City, Guatemala Department, Republic of Guatemala. FAU - Romero, Juan Carlos AU - Romero JC AD - Center for Health Studies, Universidad del Valle de Guatemala, Guatemala City, Guatemala Department, Republic of Guatemala. FAU - Lopez, Maria Renee AU - Lopez MR AD - Center for Health Studies, Universidad del Valle de Guatemala, Guatemala City, Guatemala Department, Republic of Guatemala. FAU - Gomez, Andrea AU - Gomez A AD - Center for Health Studies, Universidad del Valle de Guatemala, Guatemala City, Guatemala Department, Republic of Guatemala. FAU - Caudell, Mark AU - Caudell M AD - Paul G. Allen School for Global Health, Washington State University, Pullman, Washington, USA. FAU - Smith, Rachel M AU - Smith RM AD - Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia, USA. FAU - Styczynski, Ashley AU - Styczynski A AD - Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia, USA. FAU - Herzig, Carolyn T A AU - Herzig CTA AD - Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia, USA. FAU - Bollinger, Susan AU - Bollinger S AD - Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia, USA. FAU - Ning, Mariangeli Freitas AU - Ning MF AD - Central America Regional Office, Centers for Disease Control and Prevention, Guatemala City, Guatemala Department, Republic of Guatemala. FAU - Horton, Jennifer AU - Horton J AD - Paul G. Allen School for Global Health, Washington State University, Pullman, Washington, USA. FAU - Omulo, Sylvia AU - Omulo S AD - Paul G. Allen School for Global Health, Washington State University, Pullman, Washington, USA. AD - Washington State University Global Health-Kenya, Nairobi, Nairobi County, Kenya. FAU - Palmer, Guy H AU - Palmer GH AD - Paul G. Allen School for Global Health, Washington State University, Pullman, Washington, USA. FAU - Cordon-Rosales, Celia AU - Cordon-Rosales C AD - Center for Health Studies, Universidad del Valle de Guatemala, Guatemala City, Guatemala Department, Republic of Guatemala. AD - Paul G. Allen School for Global Health, Washington State University, Pullman, Washington, USA. FAU - Call, Douglas R AU - Call DR AUID- ORCID: 0000-0001-6791-055X AD - Paul G. Allen School for Global Health, Washington State University, Pullman, Washington, USA. LA - eng GR - WT_/Wellcome Trust/United Kingdom GR - T32 GM008336/GM/NIGMS NIH HHS/United States GR - U01 GH002241/GH/CGH CDC HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't PL - United States TA - Clin Infect Dis JT - Clinical infectious diseases : an official publication of the Infectious Diseases Society of America JID - 9203213 RN - 0 (Anti-Bacterial Agents) RN - 0 (Carbapenems) SB - IM MH - Adult MH - Child MH - Humans MH - Infant MH - *Anti-Bacterial Agents/pharmacology/therapeutic use MH - Bacteria MH - Carbapenems MH - *COVID-19 MH - Drug Resistance, Microbial MH - Guatemala/epidemiology MH - Hospitals MH - Pandemics MH - Child, Preschool MH - Adolescent PMC - PMC10321699 OTO - NOTNLM OT - Guatemala OT - antimicrobial resistance OT - communities OT - hospitals OT - public health COIS- Potential conflicts of interest. The authors: No reported conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed. EDAT- 2023/07/05 19:12 MHDA- 2023/07/07 06:42 PMCR- 2023/07/05 CRDT- 2023/07/05 13:43 PHST- 2023/07/07 06:42 [medline] PHST- 2023/07/05 19:12 [pubmed] PHST- 2023/07/05 13:43 [entrez] PHST- 2023/07/05 00:00 [pmc-release] AID - 7219536 [pii] AID - ciad222 [pii] AID - 10.1093/cid/ciad222 [doi] PST - ppublish SO - Clin Infect Dis. 2023 Jul 5;77(Suppl 1):S82-S88. doi: 10.1093/cid/ciad222. PMID- 37399770 OWN - NLM STAT- MEDLINE DCOM- 20230821 LR - 20230824 IS - 1873-6750 (Electronic) IS - 0160-4120 (Linking) VI - 178 DP - 2023 Aug TI - Festivals following the easing of COVID-19 restrictions: Prevalence of new psychoactive substances and illicit drugs. PG - 108075 LID - S0160-4120(23)00348-3 [pii] LID - 10.1016/j.envint.2023.108075 [doi] AB - The market for illicit drugs and new psychoactive substances (NPS) has grown significantly and people attending festivals have been identified as being at high risk (high extent and frequency of substance use). Traditional public health surveillance data sources have limitations (high costs, long implementation times, and ethical issues) and wastewater-based epidemiology (WBE) can cost-effectively support surveillance efforts. Influent wastewater samples were analyzed for NPS and illicit drug consumption collected during New Year period (from 29-Dec-2021 to 4-Jan-2022) and a summer Festival (from 29-June-2022 to 12-July-2022) in a large city in Spain. Samples were analyzed for phenethylamines, cathinones, opioids, benzodiazepines, plant-based NPS, dissociatives, and the illicit drugs methamphetamine, MDA, MDMA, ketamine, heroin, cocaine, and pseudoephedrine by liquid chromatography mass spectrometry. High consumption rates of specific NPS and established illicit drugs were identified at the peak of each event. Furthermore, a dynamic change in NPS use (presence and absence of substances) was detected over a period of six months. Eleven NPS, including synthetic cathinones, benzodiazepines, plant-based NPS and dissociatives, and seven illicit drugs were found across both the New Year and summer Festival. Statistically significant differences (p < 0.05) were seen for 3-MMC (New Year vs summer Festival), eutylone (New Year vs summer Festival), cocaine (summer Festival vs normal week and summer Festival vs New Year), MDMA (New Year vs normal week and summer Festival vs normal week), heroin (summer Festival vs New Year) and pseudoephedrine (summer Festival vs New Year). This WBE study assessed the prevalence of NPS and illicit drugs at festivals following the reduction of the COVID-19 pandemic restrictions highlighting the high use of specific substances at the peak of each event. This approach identified in a cost-effective and timely manner without any ethical issues the most used drugs and changes in use patterns and, thus, can complement public health information. CI - Copyright (c) 2023 The Author(s). Published by Elsevier Ltd.. All rights reserved. FAU - Rousis, Nikolaos AU - Rousis N AD - Queensland Alliance for Environmental Health Sciences (QAEHS), The University of Queensland, 20 Cornwall Street, Woolloongabba, Queensland 4102, Australia; Laboratory of Analytical Chemistry, Department of Chemistry, National and Kapodistrian University of Athens, Panepistimiopolis Zografou, 15771 Athens, Greece. Electronic address: nrousis@chem.uoa.gr. FAU - Bade, Richard AU - Bade R AD - Queensland Alliance for Environmental Health Sciences (QAEHS), The University of Queensland, 20 Cornwall Street, Woolloongabba, Queensland 4102, Australia. Electronic address: r.bade@uq.edu.au. FAU - Romero-Sanchez, Ivan AU - Romero-Sanchez I AD - Department of Analytical Chemistry, Faculty of Chemistry, Complutense University of Madrid, Avenida Complutense s/n, 28040 Madrid, Spain. FAU - Mueller, Jochen F AU - Mueller JF AD - Queensland Alliance for Environmental Health Sciences (QAEHS), The University of Queensland, 20 Cornwall Street, Woolloongabba, Queensland 4102, Australia. FAU - Thomaidis, Nikolaos S AU - Thomaidis NS AD - Laboratory of Analytical Chemistry, Department of Chemistry, National and Kapodistrian University of Athens, Panepistimiopolis Zografou, 15771 Athens, Greece. FAU - Thomas, Kevin V AU - Thomas KV AD - Queensland Alliance for Environmental Health Sciences (QAEHS), The University of Queensland, 20 Cornwall Street, Woolloongabba, Queensland 4102, Australia. FAU - Gracia-Lor, Emma AU - Gracia-Lor E AD - Department of Analytical Chemistry, Faculty of Chemistry, Complutense University of Madrid, Avenida Complutense s/n, 28040 Madrid, Spain. Electronic address: emgracia@ucm.es. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20230629 PL - Netherlands TA - Environ Int JT - Environment international JID - 7807270 RN - 0 (Illicit Drugs) RN - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine) RN - 70D95007SX (Heroin) RN - 7CUC9DDI9F (Pseudoephedrine) RN - I5Y540LHVR (Cocaine) RN - 0 (Psychotropic Drugs) SB - IM MH - Humans MH - *Illicit Drugs MH - Holidays MH - *N-Methyl-3,4-methylenedioxyamphetamine MH - Prevalence MH - Heroin MH - Pandemics MH - Pseudoephedrine MH - *COVID-19/epidemiology MH - *Substance-Related Disorders/epidemiology MH - *Cocaine MH - Psychotropic Drugs OTO - NOTNLM OT - 2F-deschloroketamine (2F-DCK) OT - 3-chloromethcathinone (3-CMC) OT - N,N-dimethylpentylone OT - Substance abuse OT - Synthetic cathinones OT - Wastewater-based epidemiology COIS- Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2023/07/04 01:05 MHDA- 2023/08/21 06:42 CRDT- 2023/07/03 18:07 PHST- 2023/03/15 00:00 [received] PHST- 2023/05/15 00:00 [revised] PHST- 2023/06/29 00:00 [accepted] PHST- 2023/08/21 06:42 [medline] PHST- 2023/07/04 01:05 [pubmed] PHST- 2023/07/03 18:07 [entrez] AID - S0160-4120(23)00348-3 [pii] AID - 10.1016/j.envint.2023.108075 [doi] PST - ppublish SO - Environ Int. 2023 Aug;178:108075. doi: 10.1016/j.envint.2023.108075. Epub 2023 Jun 29. PMID- 37384481 OWN - NLM STAT- MEDLINE DCOM- 20241031 LR - 20241031 IS - 1942-969X (Electronic) IS - 1942-969X (Linking) VI - 16 IP - 8 DP - 2024 Nov TI - Revisiting the hidden wound: Impact of the COVID-19 pandemic on domestic violence and divorce in Taiwan (2020-2021). PG - 1382-1391 LID - 10.1037/tra0001539 [doi] AB - BACKGROUND: Data from some countries showed a worrisome increase in domestic violence but a paradoxical decrease in divorce during the early months of the COVID-19 pandemic. We investigated the impact of the pandemic on domestic violence and divorce in Taiwan in 2020-2021. METHOD: Data for reported domestic violence and divorce by month and county/city (2017-2021) were from Taiwan government's registries. We used random-effects negative binomial regression to estimate the rate ratios (RRs) and their 95% confidence intervals (CIs) between the observed numbers of domestic violence cases and divorces in 2020-2021 and the expected numbers based on prepandemic trends (2017-2019). We calculated RRs for the two outbreak periods (First: January-May 2020; Second: May-July 2021) and the two postoutbreak periods (First: June 2020-April 2021; Second: August-December 2021) and each month in 2020-2021. RESULTS: The number of overall domestic violence cases was greater than expected during the first COVID-19 outbreak-a 3% increase (95% CI [0.3%-6%])-and the two postoutbreak periods-a 9% increase ([6%-12%]) and a 12% increase ([8%-16%]), respectively. Intimate partner violence was the main contributor to the increases. The number of divorces was lower than expected throughout the pandemic (a 5%-24% decrease). CONCLUSION: Reported domestic violence cases were higher than expected during the pandemic, particularly during the postoutbreak periods when the outbreak control measures were relaxed and people's movement resumed. Tailored prevention and intervention measures may be needed to address the increased vulnerability to domestic violence and restricted access to support during the outbreaks. (PsycInfo Database Record (c) 2024 APA, all rights reserved). FAU - Chang, Yi-Han AU - Chang YH AUID- ORCID: 0000-0003-1005-163X AD - Institute of Health Policy and Management, College of Public Health, National Taiwan University. FAU - Chang, Shu-Sen AU - Chang SS AUID- ORCID: 0000-0001-5012-1132 AD - Institute of Health Behaviors and Community Sciences, College of Public Health, National Taiwan University. FAU - Jou, Susyan AU - Jou S AD - Psychiatric Research Center, Wan Fang Hospital, Taipei Medical University. FAU - Hsu, Chia-Yueh AU - Hsu CY AD - Psychiatric Research Center, Wan Fang Hospital, Taipei Medical University. FAU - Goh, Kah Kheng AU - Goh KK AUID- ORCID: 0000-0003-2677-3944 AD - Psychiatric Research Center, Wan Fang Hospital, Taipei Medical University. LA - eng GR - Taipei Medical University/ GR - Ministry of Education in Taiwan/ PT - Journal Article DEP - 20230629 PL - United States TA - Psychol Trauma JT - Psychological trauma : theory, research, practice and policy JID - 101495376 SB - IM MH - Humans MH - *COVID-19/epidemiology MH - Taiwan/epidemiology MH - *Domestic Violence/statistics & numerical data MH - *Divorce/statistics & numerical data MH - Female MH - Male MH - Adult EDAT- 2023/06/29 19:12 MHDA- 2024/10/31 12:29 CRDT- 2023/06/29 12:35 PHST- 2024/10/31 12:29 [medline] PHST- 2023/06/29 19:12 [pubmed] PHST- 2023/06/29 12:35 [entrez] AID - 2023-86311-001 [pii] AID - 10.1037/tra0001539 [doi] PST - ppublish SO - Psychol Trauma. 2024 Nov;16(8):1382-1391. doi: 10.1037/tra0001539. Epub 2023 Jun 29. PMID- 37365874 OWN - NLM STAT- MEDLINE DCOM- 20231204 LR - 20231217 IS - 2047-945X (Electronic) IS - 0260-1060 (Print) IS - 0260-1060 (Linking) VI - 29 IP - 4 DP - 2023 Dec TI - Food price and availability in Solomon Islands during COVID-19: A food environment survey. PG - 611-619 LID - 10.1177/02601060231183592 [doi] AB - Background: In Solomon Islands, the retail food environment is an important food source, for instance, the dominant source of fresh fruit and vegetables for urban consumers is open markets. The effects of COVID-19 mitigation measures (such as restriction of human movement and border closures) in early 2020 placed food security at risk in many parts of the community. Of particular concern was the risk of price gouging in an already price-sensitive market. Aims: The study aimed to provide rapid and policy-relevant information on the pricing of foods in the urban food environment in Solomon Islands in the context of the unfolding COVID-19 pandemic. Methods: A vendor survey was conducted in July to August 2020 and repeated in July 2021 using a survey tool that collected information on type, quantity, and price of food on offer. Findings: We found price reductions among the majority of fresh fruit and non-starchy vegetables available. A trend of rising prices was reported for some other commodities, such as fresh locally caught fish. Conclusion: Our findings highlight the impact of 'schocks to the system' on food prices as a potential barrier or enabler to consumption of fresh foods purchased from urban areas - an important finding in a price sensitive market. The survey design was successful in collecting pricing data from the retail food environment during a time of external 'shock to the system'. Our approach is applicable to other settings needing a rapid survey of the external food environment. FAU - Farrell, Penny AU - Farrell P AUID- ORCID: 0000-0002-1567-381X AD - Menzies Centre for Health Policy and Economics, Charles Perkins Centre (D17), Sydney School of Public Health, The University of Sydney, Sydney, NSW, Australia. RINGGOLD: 4334 FAU - Bogard, Jessica AU - Bogard J AD - Agriculture and Food, Commonwealth Scientific and Industrial Research Organisation, Brisbane, QLD, Australia. FAU - Thow, Anne Marie AU - Thow AM AD - Menzies Centre for Health Policy and Economics, Charles Perkins Centre (D17), Sydney School of Public Health, The University of Sydney, Sydney, NSW, Australia. RINGGOLD: 4334 FAU - Boylan, Sinead AU - Boylan S AD - Agriculture and Food, Commonwealth Scientific and Industrial Research Organisation, Eveleigh, NSW, Australia. FAU - Johnson, Ellen AU - Johnson E AD - Menzies Centre for Health Policy and Economics, Charles Perkins Centre (D17), Sydney School of Public Health, The University of Sydney, Sydney, NSW, Australia. RINGGOLD: 4334 FAU - Tutuo, Jillian AU - Tutuo J AD - WorldFish, Honiara, Solomon Islands. LA - eng PT - Journal Article DEP - 20230626 PL - England TA - Nutr Health JT - Nutrition and health JID - 8306569 SB - IM MH - Humans MH - *Pandemics MH - Food Supply MH - *COVID-19/epidemiology MH - Food MH - Fruit MH - Vegetables MH - Melanesia PMC - PMC10293874 OTO - NOTNLM OT - COVID-19 OT - Food prices OT - Pacific Island Countries and Territories OT - Solomon Islands OT - availability OT - food environment OT - food security COIS- Declaration of conflicting interestsThe authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. EDAT- 2023/06/27 06:42 MHDA- 2023/12/04 12:43 PMCR- 2023/12/03 CRDT- 2023/06/27 02:33 PHST- 2023/12/04 12:43 [medline] PHST- 2023/06/27 06:42 [pubmed] PHST- 2023/06/27 02:33 [entrez] PHST- 2023/12/03 00:00 [pmc-release] AID - 10.1177_02601060231183592 [pii] AID - 10.1177/02601060231183592 [doi] PST - ppublish SO - Nutr Health. 2023 Dec;29(4):611-619. doi: 10.1177/02601060231183592. Epub 2023 Jun 26. PMID- 37339859 OWN - NLM STAT- MEDLINE DCOM- 20231120 LR - 20241108 IS - 1468-2044 (Electronic) IS - 0003-9888 (Print) IS - 0003-9888 (Linking) VI - 108 IP - 12 DP - 2023 Dec TI - Effects of size at birth on health, growth and developmental outcomes in children up to age 18: an umbrella review. PG - 956-969 LID - 10.1136/archdischild-2022-324884 [doi] LID - e324884 AB - BACKGROUND: Size at birth, an indicator of intrauterine growth, has been studied extensively in relation to subsequent health, growth and developmental outcomes. Our umbrella review synthesises evidence from systematic reviews and meta-analyses on the effects of size at birth on subsequent health, growth and development in children and adolescents up to age 18, and identifies gaps. METHODS: We searched five databases from inception to mid-July 2021 to identify eligible systematic reviews and meta-analyses. For each meta-analysis, we extracted data on the exposures and outcomes measured and the strength of the association. FINDINGS: We screened 16 641 articles and identified 302 systematic reviews. The literature operationalised size at birth (birth weight and/or gestation) in 12 ways. There were 1041 meta-analyses of associations between size at birth and 67 outcomes. Thirteen outcomes had no meta-analysis.Small size at birth was examined for 50 outcomes and was associated with over half of these (32 of 50); continuous/post-term/large size at birth was examined for 35 outcomes and was consistently associated with 11 of the 35 outcomes. Seventy-three meta-analyses (in 11 reviews) compared risks by size for gestational age (GA), stratified by preterm and term. Prematurity mechanisms were the key aetiologies linked to mortality and cognitive development, while intrauterine growth restriction (IUGR), manifesting as small for GA, was primarily linked to underweight and stunting. INTERPRETATION: Future reviews should use methodologically sound comparators to further understand aetiological mechanisms linking IUGR and prematurity to subsequent outcomes. Future research should focus on understudied exposures (large size at birth and size at birth stratified by gestation), gaps in outcomes (specifically those without reviews or meta-analysis and stratified by age group of children) and neglected populations. PROSPERO REGISTRATION NUMBER: CRD42021268843. CI - (c) Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. FAU - Jamaluddine, Zeina AU - Jamaluddine Z AUID- ORCID: 0000-0003-2074-9329 AD - Faculty of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, London, UK zeina.jamaluddine@lshtm.ac.uk. AD - School of Tropical Medicine and Global Health, Nagasaki University, Nagasaki, Japan. FAU - Sharara, Eman AU - Sharara E AD - Center for Research On Population and Health, Faculty of Health Sciences, American University of Beirut, Beirut, Lebanon. FAU - Helou, Vanessa AU - Helou V AUID- ORCID: 0000-0003-4826-1659 AD - Faculty of Medicine, American University of Beirut, Beirut, Lebanon. FAU - El Rashidi, Nadine AU - El Rashidi N AD - Center for Research On Population and Health, Faculty of Health Sciences, American University of Beirut, Beirut, Lebanon. FAU - Safadi, Gloria AU - Safadi G AD - Center for Research On Population and Health, Faculty of Health Sciences, American University of Beirut, Beirut, Lebanon. FAU - El-Helou, Nehmat AU - El-Helou N AD - Center for Research On Population and Health, Faculty of Health Sciences, American University of Beirut, Beirut, Lebanon. FAU - Ghattas, Hala AU - Ghattas H AUID- ORCID: 0000-0001-8864-3374 AD - Center for Research On Population and Health, Faculty of Health Sciences, American University of Beirut, Beirut, Lebanon. AD - Arnold School of Public Health, University of South Carolina, Columbia, South Carolina, USA. FAU - Sato, Miho AU - Sato M AD - School of Tropical Medicine and Global Health, Nagasaki University, Nagasaki, Japan. FAU - Blencowe, Hannah AU - Blencowe H AD - Faculty of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, London, UK. FAU - Campbell, Oona M R AU - Campbell OMR AUID- ORCID: 0000-0002-9311-0115 AD - Faculty of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, London, UK. LA - eng PT - Journal Article PT - Meta-Analysis PT - Systematic Review DEP - 20230620 PL - England TA - Arch Dis Child JT - Archives of disease in childhood JID - 0372434 SB - IM MH - Infant, Newborn MH - Pregnancy MH - Female MH - Adolescent MH - Child MH - Humans MH - Birth Weight MH - *Pregnancy Outcome MH - *Fetal Growth Retardation/epidemiology/etiology MH - Infant, Small for Gestational Age MH - Growth Disorders PMC - PMC11474254 OTO - NOTNLM OT - Child Development OT - Child Health OT - Growth OT - Mental health OT - Mortality COIS- Competing interests: None declared. EDAT- 2023/06/21 01:07 MHDA- 2023/11/20 06:56 PMCR- 2024/10/15 CRDT- 2023/06/20 21:02 PHST- 2022/10/02 00:00 [received] PHST- 2023/05/04 00:00 [accepted] PHST- 2023/11/20 06:56 [medline] PHST- 2023/06/21 01:07 [pubmed] PHST- 2023/06/20 21:02 [entrez] PHST- 2024/10/15 00:00 [pmc-release] AID - archdischild-2022-324884 [pii] AID - 10.1136/archdischild-2022-324884 [doi] PST - ppublish SO - Arch Dis Child. 2023 Dec;108(12):956-969. doi: 10.1136/archdischild-2022-324884. Epub 2023 Jun 20. PMID- 37338742 OWN - NLM STAT- MEDLINE DCOM- 20230731 LR - 20230801 IS - 1996-9805 (Electronic) IS - 1818-6300 (Print) IS - 1818-6300 (Linking) VI - 24 IP - 4 DP - 2023 Aug TI - Is there any correlation between otitis media and dental malocclusion in children? A systematic review. PG - 441-449 LID - 10.1007/s40368-023-00807-0 [doi] AB - PURPOSE: This study aims to evaluate whether there is a correlation between otitis and dental malocclusions. METHODS: Electronic databases were searched for observational studies published until July 2021 without language or time restrictions. PROSPERO: CRD42021270760. Observational studies on children with and without OM and/or malocclusion were included. After removing duplicates and excluding not-eligible articles, two reviewers screened relevant articles independently. Two reviewers independently extracted data and assessed data quality and validity through the Newcastle-Ottawa Scale (NOS) quality assessment tool for non-randomized studies. RESULTS: Five studies met the selection inclusion criteria and were included in the studies for a total of 499 patients. Three studies investigated the relationship between malocclusion and otitis media, while the remaining two studies analyzed the inverse relationship and one of them considered eustachian tube dysfunction as a proxy of OM. An association between malocclusion and otitis media and vice versa emerged, although with relevant limitations. CONCLUSION: There is some evidence that there is an association between otitis and malocclusion; however, it is not yet possible to establish a definitive correlation. CI - (c) 2023. The Author(s). FAU - Bardellini, E AU - Bardellini E AUID- ORCID: 0000-0002-3955-4794 AD - Department of Medical and Surgery Specialties, Radiological Sciences and Public Health, School of Pediatric Dentistry, University of Brescia, Dental Clinic, P.le Spedali Civili N.1, 25133, Brescia, Italy. elena.bardellini@unibs.it. FAU - Amadori, F AU - Amadori F AD - Department of Medical and Surgery Specialties, Radiological Sciences and Public Health, School of Pediatric Dentistry, University of Brescia, Dental Clinic, P.le Spedali Civili N.1, 25133, Brescia, Italy. FAU - Garo, M L AU - Garo ML AD - Department of Medical and Surgery Specialties, Radiological Sciences and Public Health, School of Pediatric Dentistry, University of Brescia, Dental Clinic, P.le Spedali Civili N.1, 25133, Brescia, Italy. FAU - Majorana, A AU - Majorana A AD - Department of Medical and Surgery Specialties, Radiological Sciences and Public Health, School of Pediatric Dentistry, University of Brescia, Dental Clinic, P.le Spedali Civili N.1, 25133, Brescia, Italy. FAU - Conti, G AU - Conti G AD - University of Insubria, Varese, Italy. LA - eng PT - Journal Article PT - Systematic Review DEP - 20230620 PL - England TA - Eur Arch Paediatr Dent JT - European archives of paediatric dentistry : official journal of the European Academy of Paediatric Dentistry JID - 101277157 SB - IM MH - Humans MH - Child MH - *Otitis Media/complications MH - *Malocclusion/complications PMC - PMC10382365 OTO - NOTNLM OT - Children OT - Malocclusion OT - Occlusion OT - Otitis COIS- The authors have no relevant financial or non-financial interests to disclose. EDAT- 2023/06/20 13:09 MHDA- 2023/07/31 06:43 PMCR- 2023/06/20 CRDT- 2023/06/20 11:12 PHST- 2022/12/27 00:00 [received] PHST- 2023/05/15 00:00 [accepted] PHST- 2023/07/31 06:43 [medline] PHST- 2023/06/20 13:09 [pubmed] PHST- 2023/06/20 11:12 [entrez] PHST- 2023/06/20 00:00 [pmc-release] AID - 10.1007/s40368-023-00807-0 [pii] AID - 807 [pii] AID - 10.1007/s40368-023-00807-0 [doi] PST - ppublish SO - Eur Arch Paediatr Dent. 2023 Aug;24(4):441-449. doi: 10.1007/s40368-023-00807-0. Epub 2023 Jun 20. PMID- 37322091 OWN - NLM STAT- MEDLINE DCOM- 20230619 LR - 20241207 IS - 2041-1723 (Electronic) IS - 2041-1723 (Linking) VI - 14 IP - 1 DP - 2023 Jun 15 TI - Attributed causes of excess mortality during the COVID-19 pandemic in a south Indian city. PG - 3563 LID - 10.1038/s41467-023-39322-7 [doi] LID - 3563 AB - Globally, excess deaths during 2020-21 outnumbered documented COVID-19 deaths by 9.5 million, primarily driven by deaths in low- and middle-income countries (LMICs) with limited vital surveillance. Here we unravel the contributions of probable COVID-19 deaths from other changes in mortality related to pandemic control measures using medically-certified death registrations from Madurai, India-an urban center with well-functioning vital surveillance. Between March, 2020 and July, 2021, all-cause deaths in Madurai exceeded expected levels by 30% (95% confidence interval: 27-33%). Although driven by deaths attributed to cardiovascular or cerebrovascular conditions, diabetes, senility, and other uncategorized causes, increases in these attributions were restricted to medically-unsupervised deaths, and aligned with surges in confirmed or attributed COVID-19 mortality, likely reflecting mortality among unconfirmed COVID-19 cases. Implementation of lockdown measures was associated with a 7% (0-13%) reduction in all-cause mortality, driven by reductions in deaths attributed to injuries, infectious diseases and maternal conditions, and cirrhosis and other liver conditions, respectively, but offset by a doubling in cancer deaths. Our findings help to account for gaps between documented COVID-19 mortality and excess all-cause mortality during the pandemic in an LMIC setting. CI - (c) 2023. The Author(s). FAU - Lewnard, Joseph A AU - Lewnard JA AUID- ORCID: 0000-0002-8505-8839 AD - Division of Epidemiology, School of Public Health, University of California, Berkeley, Berkeley, CA, USA. jLewnard@berkeley.edu. AD - Division of Infectious Diseases & Vaccinology, School of Public Health, University of California, Berkeley, Berkeley, CA, USA. jLewnard@berkeley.edu. AD - Center for Computational Biology, College of Engineering, University of California, Berkeley, Berkeley, CA, USA. jLewnard@berkeley.edu. FAU - B, Chandra Mohan AU - B CM AD - Indian Administrative Service, Chennai, India. FAU - Kang, Gagandeep AU - Kang G AUID- ORCID: 0000-0002-3656-564X AD - Christian Medical College, Vellore, India. FAU - Laxminarayan, Ramanan AU - Laxminarayan R AD - One Health Trust, Bangalore, India. AD - Princeton University, Princeton, NJ, USA. LA - eng PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't PT - Research Support, U.S. Gov't, Non-P.H.S. DEP - 20230615 PL - England TA - Nat Commun JT - Nature communications JID - 101528555 SB - IM MH - Humans MH - *COVID-19/epidemiology MH - Pandemics MH - Cause of Death MH - India/epidemiology MH - Communicable Disease Control MH - Mortality PMC - PMC10272147 COIS- J.A.L. discloses receipt of grants and honoraria from Pfizer unrelated to this research. The remaining authors declare no competing interest. EDAT- 2023/06/16 01:08 MHDA- 2023/06/19 13:08 PMCR- 2023/06/15 CRDT- 2023/06/15 23:22 PHST- 2023/05/18 00:00 [received] PHST- 2023/06/07 00:00 [accepted] PHST- 2023/06/19 13:08 [medline] PHST- 2023/06/16 01:08 [pubmed] PHST- 2023/06/15 23:22 [entrez] PHST- 2023/06/15 00:00 [pmc-release] AID - 10.1038/s41467-023-39322-7 [pii] AID - 39322 [pii] AID - 10.1038/s41467-023-39322-7 [doi] PST - epublish SO - Nat Commun. 2023 Jun 15;14(1):3563. doi: 10.1038/s41467-023-39322-7. PMID- 37315103 OWN - NLM STAT- MEDLINE DCOM- 20230703 LR - 20250623 IS - 1549-1676 (Electronic) IS - 1549-1277 (Print) IS - 1549-1277 (Linking) VI - 20 IP - 6 DP - 2023 Jun TI - Major trauma presentations and patient outcomes in English hospitals during the COVID-19 pandemic: An observational cohort study. PG - e1004243 LID - 10.1371/journal.pmed.1004243 [doi] LID - e1004243 AB - BACKGROUND: Single-centre studies suggest that successive Coronavirus Disease 2019 (COVID-19)-related "lockdown" restrictions in England may have led to significant changes in the characteristics of major trauma patients. There is also evidence from other countries that diversion of intensive care capacity and other healthcare resources to treating patients with COVID-19 may have impacted on outcomes for major trauma patients. We aimed to assess the impact of the COVID-19 pandemic on the number, characteristics, care pathways, and outcomes of major trauma patients presenting to hospitals in England. METHODS AND FINDINGS: We completed an observational cohort study and interrupted time series analysis including all patients eligible for inclusion in England in the national clinical audit for major trauma presenting between 1 January 2017 and 31 of August 2021 (354,202 patients). Demographic characteristics (age, sex, physiology, and injury severity) and clinical pathways of major trauma patients in the first lockdown (17,510 patients) and second lockdown (38,262 patients) were compared to pre-COVID-19 periods in 2018 to 2019 (comparator period 1: 22,243 patients; comparator period 2: 18,099 patients). Discontinuities in trends for weekly estimated excess survival rate were estimated when lockdown measures were introduced using segmented linear regression. The first lockdown had a larger associated reduction in numbers of major trauma patients (-4,733 (21%)) compared to the pre-COVID period than the second lockdown (-2,754 (6.7%)). The largest reductions observed were in numbers of people injured in road traffic collisions excepting cyclists where numbers increased. During the second lockdown, there were increases in the numbers of people injured aged 65 and over (665 (3%)) and 85 and over (828 (9.3%)). In the second week of March 2020, there was a reduction in level of major trauma excess survival rate (-1.71%; 95% CI: -2.76% to -0.66%) associated with the first lockdown. This was followed by a weekly trend of improving survival until the lifting of restrictions in July 2020 (0.25; 95% CI: 0.14 to 0.35). Limitations include eligibility criteria for inclusion to the audit and COVID status of patients not being recorded. CONCLUSIONS: This national evaluation of the impact of COVID on major trauma presentations to English hospitals has observed important public health findings: The large reduction in overall numbers injured has been primarily driven by reductions in road traffic collisions, while numbers of older people injured at home increased over the second lockdown. Future research is needed to better understand the initial reduction in likelihood of survival after major trauma observed with the implementation of the first lockdown. CI - Copyright: (c) 2023 Marincowitz et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. FAU - Marincowitz, Carl AU - Marincowitz C AUID- ORCID: 0000-0003-3043-7564 AD - Centre for Urgent and Emergency Care Research (CURE), Health Services Research School of Health and Related Research, University of Sheffield, Sheffield, United Kingdom. FAU - Bouamra, Omar AU - Bouamra O AUID- ORCID: 0000-0002-3155-4634 AD - Trauma Audit Research Network, University of Manchester, Manchester, United Kingdom. FAU - Coats, Tim AU - Coats T AUID- ORCID: 0000-0003-2736-2784 AD - Emergency Medicine Academic Group, Department of Cardiovascular Sciences, University of Leicester, Leicester, United Kingdom. FAU - Surendra Kumar, Dhushy AU - Surendra Kumar D AD - Department of Critical Care, Anaesthesia and Pre-hospital Emergency Medicine, University Hospital Coventry, Coventry, United Kingdom. FAU - Lockey, David AU - Lockey D AUID- ORCID: 0000-0003-0180-9197 AD - London's Air Ambulance, Royal London Hospital, London, United Kingdom. AD - North Bristol NHS Trust, Bristol, United Kingdom. FAU - Mason, Lyndon AU - Mason L AD - Liverpool University Hospitals NHS Foundation Trust, University of Liverpool, Liverpool, United Kingdom. FAU - Newcombe, Virginia AU - Newcombe V AD - Division of Anaesthesia, University of Cambridge, Cambridge, United Kingdom. FAU - Thompson, Julian AU - Thompson J AD - Department of Anaesthesia and Intensive Care Medicine, Southmead Hospital Intensive Care Unit, Southmead Hospital, North Bristol NHS Trust, Bristol, United Kingdom. FAU - Edwards, Antoinette AU - Edwards A AUID- ORCID: 0000-0003-1427-0725 AD - Trauma Audit Research Network, University of Manchester, Manchester, United Kingdom. FAU - Lecky, Fiona AU - Lecky F AUID- ORCID: 0000-0001-6806-0921 AD - Centre for Urgent and Emergency Care Research (CURE), Health Services Research School of Health and Related Research, University of Sheffield, Sheffield, United Kingdom. AD - Trauma Audit Research Network, University of Manchester, Manchester, United Kingdom. LA - eng PT - Journal Article PT - Observational Study DEP - 20230614 PL - United States TA - PLoS Med JT - PLoS medicine JID - 101231360 SB - IM MH - Humans MH - Aged MH - *Pandemics MH - *COVID-19/epidemiology MH - Communicable Disease Control MH - Cohort Studies MH - Hospitals MH - Retrospective Studies PMC - PMC10309989 COIS- The authors have declared that no competing interests exist. EDAT- 2023/06/14 19:10 MHDA- 2023/07/03 06:42 PMCR- 2023/06/14 CRDT- 2023/06/14 13:53 PHST- 2022/10/25 00:00 [received] PHST- 2023/05/19 00:00 [accepted] PHST- 2023/06/29 00:00 [revised] PHST- 2023/07/03 06:42 [medline] PHST- 2023/06/14 19:10 [pubmed] PHST- 2023/06/14 13:53 [entrez] PHST- 2023/06/14 00:00 [pmc-release] AID - PMEDICINE-D-22-03493 [pii] AID - 10.1371/journal.pmed.1004243 [doi] PST - epublish SO - PLoS Med. 2023 Jun 14;20(6):e1004243. doi: 10.1371/journal.pmed.1004243. eCollection 2023 Jun. PMID- 37301830 OWN - NLM STAT- MEDLINE DCOM- 20230612 LR - 20230613 IS - 1471-2164 (Electronic) IS - 1471-2164 (Linking) VI - 24 IP - 1 DP - 2023 Jun 10 TI - Genomic surveillance of severe acute respiratory syndrome coronavirus 2 in Burundi, from May 2021 to January 2022. PG - 312 LID - 10.1186/s12864-023-09420-3 [doi] LID - 312 AB - BACKGROUND: The emergence and rapid spread of new severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) variants have challenged the control of the COVID-19 pandemic globally. Burundi was not spared by that pandemic, but the genetic diversity, evolution, and epidemiology of those variants in the country remained poorly understood. The present study sought to investigate the role of different SARS-COV-2 variants in the successive COVID-19 waves experienced in Burundi and the impact of their evolution on the course of that pandemic. We conducted a cross-sectional descriptive study using positive SARS-COV-2 samples for genomic sequencing. Subsequently, we performed statistical and bioinformatics analyses of the genome sequences in light of available metadata. RESULTS: In total, we documented 27 PANGO lineages of which BA.1, B.1.617.2, AY.46, AY.122, and BA.1.1, all VOCs, accounted for 83.15% of all the genomes isolated in Burundi from May 2021 to January 2022. Delta (B.1.617.2) and its descendants predominated the peak observed in July-October 2021. It replaced the previously predominant B.1.351 lineage. It was itself subsequently replaced by Omicron (B.1.1.529, BA.1, and BA.1.1). Furthermore, we identified amino acid mutations including E484K, D614G, and L452R known to increase infectivity and immune escape in the spike proteins of Delta and Omicron variants isolated in Burundi. The SARS-COV-2 genomes from imported and community-detected cases were genetically closely related. CONCLUSION: The global emergence of SARS-COV-2 VOCs and their subsequent introductions in Burundi was accompanied by new peaks (waves) of COVID-19. The relaxation of travel restrictions and the mutations occurring in the virus genome played an important role in the introduction and the spread of new SARS-COV-2 variants in the country. It is of utmost importance to strengthen the genomic surveillance of SARS-COV-2, enhance the protection by increasing the SARS-COV-2 vaccine coverage, and adjust the public health and social measures ahead of the emergence or introduction of new SARS-COV-2 VOCs in the country. CI - (c) 2023. The Author(s). FAU - Nduwimana, Cassien AU - Nduwimana C AD - National Reference Laboratory, National Institute of Public Health, Bujumbura, Burundi. cassimbare@gmail.com. FAU - Nzoyikorera, Nehemie AU - Nzoyikorera N AD - National Reference Laboratory, National Institute of Public Health, Bujumbura, Burundi. AD - Mohamed VI University of Health Sciences (UM6SS), Higher Institute of Biosciences and Biotechnology, Casablanca, Morocco. AD - Mohamed VI Center for Research & Innovation, Laboratory of Microbial Biotechnology and Infectiology Research, Mohamed VI University of Health Sciences (UM6SS), Rabat, Morocco. FAU - Ndihokubwayo, Armstrong AU - Ndihokubwayo A AD - National Reference Laboratory, National Institute of Public Health, Bujumbura, Burundi. FAU - Ihorimbere, Theogene AU - Ihorimbere T AD - National Reference Laboratory, National Institute of Public Health, Bujumbura, Burundi. FAU - Nibogora, Celestin AU - Nibogora C AD - National Reference Laboratory, National Institute of Public Health, Bujumbura, Burundi. FAU - Ndoreraho, Adolphe AU - Ndoreraho A AD - National Institute of Public Health, Ministry of Public Health and the Fight against AIDS, Bujumbura, Burundi. FAU - Hajayandi, Oscar AU - Hajayandi O AD - National Reference Laboratory, National Institute of Public Health, Bujumbura, Burundi. FAU - Bizimana, Jean Claude AU - Bizimana JC AD - Public Health Emergency Operation Center, Ministry of Public Health and the Fight against AIDS, Bujumbura, Burundi. FAU - Diawara, Idrissa AU - Diawara I AD - Mohamed VI University of Health Sciences (UM6SS), Higher Institute of Biosciences and Biotechnology, Casablanca, Morocco. AD - Mohamed VI Center for Research & Innovation, Laboratory of Microbial Biotechnology and Infectiology Research, Mohamed VI University of Health Sciences (UM6SS), Rabat, Morocco. FAU - Niyonizigiye, Dionis AU - Niyonizigiye D AD - National Institute of Public Health, Ministry of Public Health and the Fight against AIDS, Bujumbura, Burundi. FAU - Nyandwi, Joseph AU - Nyandwi J AD - National Institute of Public Health, Ministry of Public Health and the Fight against AIDS, Bujumbura, Burundi. AD - Faculte de Medecine, Universite du Burundi, Bujumbura, Burundi. LA - eng PT - Journal Article DEP - 20230610 PL - England TA - BMC Genomics JT - BMC genomics JID - 100965258 RN - 0 (COVID-19 Vaccines) RN - SARS-CoV-2 variants SB - IM MH - Humans MH - *SARS-CoV-2/genetics MH - COVID-19 Vaccines MH - Cross-Sectional Studies MH - Pandemics MH - *COVID-19/epidemiology MH - Genomics PMC - PMC10257533 OTO - NOTNLM OT - Amino acid change OT - COVID-19 OT - Genetic diversity OT - Lineage OT - SARS-COV-2 variants OT - Waves COIS- The authors declare no competing interests. EDAT- 2023/06/11 01:06 MHDA- 2023/06/12 06:42 PMCR- 2023/06/10 CRDT- 2023/06/10 23:14 PHST- 2023/01/25 00:00 [received] PHST- 2023/05/31 00:00 [accepted] PHST- 2023/06/12 06:42 [medline] PHST- 2023/06/11 01:06 [pubmed] PHST- 2023/06/10 23:14 [entrez] PHST- 2023/06/10 00:00 [pmc-release] AID - 10.1186/s12864-023-09420-3 [pii] AID - 9420 [pii] AID - 10.1186/s12864-023-09420-3 [doi] PST - epublish SO - BMC Genomics. 2023 Jun 10;24(1):312. doi: 10.1186/s12864-023-09420-3. PMID- 37293897 OWN - NLM STAT- MEDLINE DCOM- 20231030 LR - 20250801 IS - 1556-9519 (Electronic) IS - 1556-3650 (Linking) VI - 61 IP - 5 DP - 2023 May TI - Kidney outcomes after methanol and ethylene glycol poisoning: a systematic review and meta-analysis. PG - 326-335 LID - 10.1080/15563650.2023.2200547 [doi] AB - INTRODUCTION: Ingestions with methanol, ethylene glycol, diethylene glycol, propylene glycol, and isopropanol are rare yet exceedingly dangerous conditions that may require emergent management with kidney replacement therapy. Little is known regarding short- and long-term kidney outcomes post-ingestion. OBJECTIVES: To comprehensively synthesize existing evidence regarding short- and long-term kidney and other outcomes of adult patients following these poisonings. METHODS: We developed a search strategy in MEDLINE via OVID and then translated it into other databases including EMBASE (via OVID), PubMed, CENTRAL (via OVID). The databases were searched from their dates of inception to 29 July 2021. A grey literature search was conducted in the International Traditional Medicine Clinical Trial Registry and ClinicalTrials.gov. All interventional and observational studies and case series with >/= five participants that reported on the outcomes of toxic alcohol (methanol, ethylene glycol, diethylene glycol, propylene glycol and isopropanol) poisonings in adult patients >/=18 years old were included. Studies that reported mortality, kidney outcomes and/or complications attributed to toxic alcohol poisoning were eligible. RESULTS: The search strategy identified 1,221 citations. Sixty-seven studies (13 retrospective observational studies, one prospective observational study, 53 case series) met inclusion criteria (total N = 2,327 participants). No randomized controlled trials were identified per our prespecified criteria. Generally, included studies had small sample sizes (median of 27 participants) and were of low quality. Methanol and/or ethylene glycol poisoning made up 94.1% of included studies, whereas one study reported on isopropanol and none reported on propylene glycol. Results of the 13 observational studies of methanol and/or ethylene glycol poisoning were pooled for meta-analyses. The pooled in-hospital mortality estimates amongst patients with methanol and ethylene glycol poisoning were 24 and 11%, respectively. A more recent year of publication, female sex and mean age were associated with lower in-hospital mortality amongst individuals with ethylene glycol poisoning. Although hemodialysis was the most frequently employed kidney replacement therapy, the indications for initiation of this therapy were not reported in the majority of studies. At hospital discharge, kidney recovery occurred in 64.7-96.3% of patients with ethylene glycol poisoning. In studies of methanol and/or ethylene glycol poisoning, 2-3.7% of individuals required ongoing dialysis. Only one study reported post-discharge mortality. Furthermore, long-term toxic alcohol-mediated sequelae, such as visual and neurologic outcomes, were scarcely reported. DISCUSSION: Ingestions of methanol and ethylene glycol were associated with a significant short-term risk of mortality. Although a wealth of literature in the form of case reports and case series exists, high-quality evidence regarding kidney outcomes after these poisonings is lacking. We identified a paucity of standardized reporting in clinical presentations, therapeutics and outcomes amongst adults with toxic alcohol poisoning. Amongst the included studies, there was substantial heterogeneity encompassing study type, outcomes, duration of follow-up and treatment modalities. These sources of heterogeneity restricted our ability to perform comprehensive meta-analyses of all outcomes of interest. An additional limitation is the lack of studies pertaining to propylene glycol and the paucity of data on isopropanol. CONCLUSIONS: The indications for hemodialysis, long-term kidney recovery and long-term mortality risk vary widely in these poisonings and are inconsistently reported in the literature. This highlights the need for further research with standardized reporting of baseline kidney function, indications for initiation of kidney replacement therapy and short-term and long-term kidney outcomes. REGISTRATION: This systematic review protocol is registered at PROSPERO, CRD42018101955. FAU - Wang, Carol AU - Wang C AD - Division of Nephrology, Department of Medicine, Western University, London, ON, Canada. FAU - Hiremath, Swapnil AU - Hiremath S AD - Division of Nephrology, Department of Medicine, University of Ottawa, Ottawa, ON, Canada. FAU - Sikora, Lindsey AU - Sikora L AD - Health Sciences Library, University of Ottawa Library, University of Ottawa, Ottawa, ON, Canada. FAU - Kanji, Salmaan AU - Kanji S AD - Clinical Epidemiology Program, Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON, Canada. FAU - Bugeja, Ann AU - Bugeja A AD - Division of Nephrology, Department of Medicine, University of Ottawa, Ottawa, ON, Canada. FAU - Samaha, Daniel AU - Samaha D AD - Division of Nephrology, Department of Medicine, University of Ottawa, Ottawa, ON, Canada. FAU - Sood, Manish M AU - Sood MM AD - Division of Nephrology, Department of Medicine, University of Ottawa, Ottawa, ON, Canada. FAU - Kong, Jennifer W Y AU - Kong JWY AD - Division of Nephrology, Department of Medicine, University of Ottawa, Ottawa, ON, Canada. FAU - Clark, Edward G AU - Clark EG AUID- ORCID: 0000-0002-6767-1197 AD - Division of Nephrology, Department of Medicine, University of Ottawa, Ottawa, ON, Canada. LA - eng PT - Journal Article PT - Meta-Analysis PT - Systematic Review PL - England TA - Clin Toxicol (Phila) JT - Clinical toxicology (Philadelphia, Pa.) JID - 101241654 RN - ND2M416302 (2-Propanol) RN - 61BR964293 (diethylene glycol) RN - FC72KVT52F (Ethylene Glycol) RN - 0 (Ethylene Glycols) RN - Y4S76JWI15 (Methanol) RN - 6DC9Q167V3 (Propylene Glycol) SB - IM MH - Adolescent MH - Adult MH - Female MH - Humans MH - 2-Propanol MH - Aftercare MH - *Ethylene Glycol/poisoning MH - Ethylene Glycols MH - *Kidney MH - *Methanol/poisoning MH - Observational Studies as Topic MH - Patient Discharge MH - *Poisoning/therapy MH - Propylene Glycol MH - Retrospective Studies OTO - NOTNLM OT - Toxic alcohol OT - ethylene glycol OT - kidney replacement therapy OT - methanol OT - mortality OT - poisoning EDAT- 2023/06/09 13:41 MHDA- 2023/06/12 06:42 CRDT- 2023/06/09 06:43 PHST- 2023/06/12 06:42 [medline] PHST- 2023/06/09 13:41 [pubmed] PHST- 2023/06/09 06:43 [entrez] AID - 10.1080/15563650.2023.2200547 [doi] PST - ppublish SO - Clin Toxicol (Phila). 2023 May;61(5):326-335. doi: 10.1080/15563650.2023.2200547. PMID- 37287728 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240918 IS - 2578-0026 (Electronic) IS - 2578-0026 (Linking) VI - 6 IP - 1 DP - 2023 TI - Understanding Changes in Social Cannabis Use among Young Adults During the COVID-19 Pandemic: A Social Network Analysis. PG - 20-33 LID - 10.26828/cannabis/2023.01.003 [doi] AB - INTRODUCTION: As the COVID-19 pandemic has caused historic morbidity and mortality and disrupted young people's social relationships, little is known regarding change in young adults' social cannabis use following social distancing orders, or other factors associated with such changes before and during the pandemic. METHODS: 108 young adult cannabis users in Los Angeles reported on their personal (egocentric) social network characteristics, cannabis use, and pandemic-related variables before (July 2019 - March 2020) and during the COVID-19 pandemic (August 2020 - August 2021). Multinomial logistic regression identified factors associated with increasing or maintaining the number of network members (alters) participants used cannabis with before and during the pandemic. Multilevel modeling identified ego- and alter-level factors associated with dyadic cannabis use between each ego and alter during the pandemic. RESULTS: Most participants (61%) decreased the number of alters they used cannabis with, 14% maintained, and 25% increased. Larger networks were associated with a lower risk of increasing (vs. decreasing); more supportive cannabis-using alters was associated with a lower risk of maintaining (vs. decreasing); relationship duration was associated with a greater risk of maintaining and increasing (vs. decreasing). During the COVID-19 pandemic (August 2020 - August 2021), participants were more likely to use cannabis with alters they also used alcohol with and alters who were perceived to have more positive attitudes towards cannabis. CONCLUSIONS: The present study identifies significant factors associated with changes in young adults' social cannabis use following pandemic-related social distancing. These findings may inform social network interventions for young adults who use cannabis with their network members amid such social restrictions. CI - (c) 2023 Authors et al. FAU - DiGuiseppi, Graham T AU - DiGuiseppi GT AD - Suzanne Dworak-Peck School of Social Work, University of Southern California. FAU - Fedorova, Ekaterina V AU - Fedorova EV AD - Drexel University, Dornsife School of Public Health, Department of Community Health and Prevention. FAU - Conn, Bridgid AU - Conn B AD - Children's Hospital Los Angeles, Division of Adolescent and Young Adult Medicine. AD - University of Southern California, Keck School of Medicine, Department of Pediatrics. FAU - Lankenau, Stephen E AU - Lankenau SE AD - Drexel University, Dornsife School of Public Health, Department of Community Health and Prevention. FAU - Davis, Jordan P AU - Davis JP AD - Suzanne Dworak-Peck School of Social Work, University of Southern California. FAU - Ataiants, Janna AU - Ataiants J AD - Drexel University, Dornsife School of Public Health, Department of Community Health and Prevention. FAU - Wong, Carolyn F AU - Wong CF AD - Children's Hospital Los Angeles, Division of Adolescent and Young Adult Medicine. AD - University of Southern California, Keck School of Medicine, Department of Pediatrics. LA - eng PT - Journal Article DEP - 20230207 PL - United States TA - Cannabis JT - Cannabis (Albuquerque, N.M.) JID - 101722785 PMC - PMC10212261 OTO - NOTNLM OT - COVID-19 OT - cannabis OT - egocentric networks OT - social distancing OT - social network analysis OT - young adults EDAT- 2023/06/08 06:42 MHDA- 2023/06/08 06:43 PMCR- 2023/02/07 CRDT- 2023/06/08 04:22 PHST- 2023/06/08 06:43 [medline] PHST- 2023/06/08 06:42 [pubmed] PHST- 2023/06/08 04:22 [entrez] PHST- 2023/02/07 00:00 [pmc-release] AID - 2023.01.003 [pii] AID - 10.26828/cannabis/2023.01.003 [doi] PST - epublish SO - Cannabis. 2023 Feb 7;6(1):20-33. doi: 10.26828/cannabis/2023.01.003. eCollection 2023. PMID- 37279249 OWN - NLM STAT- MEDLINE DCOM- 20230608 LR - 20260921 IS - 1932-6203 (Electronic) IS - 1932-6203 (Linking) VI - 18 IP - 6 DP - 2023 TI - On the forms, contributions and impacts of community mobilisation involved with Kerala's COVID-19 response: Perspectives of health staff, Local Self Government institution and community leaders. PG - e0285999 LID - 10.1371/journal.pone.0285999 [doi] LID - e0285999 AB - BACKGROUND: Kerala, a south Indian state, has a long and strong history of mobilisation of people's participation with institutionalised mechanisms as part of decentralisation reforms introduced three decades ago. This history formed the backdrop of the state's COVID-19 response from 2020 onwards. As part of a larger health equity study, we carried out an analysis to understand the contributions of people's participation to the state's COVID-19 response, and what implications this may have for health reform as well as governance more broadly. METHODS: We employed in-depth interviews with participants from four districts of Kerala between July and October, 2021. Following written informed consent procedures, we carried out interviews of health staff from eight primary health care centres, elected Local Self Government (LSG, or Panchayat) representatives, and community leaders. Questions explored primary health care reforms, COVID responses, and populations left behind. Transliterated English transcripts were analysed by four research team members using a thematic analysis approach and ATLAS.ti 9 software. For this paper, we specifically analysed codes and themes related to experiences of community actors and processes for COVID mitigation activities. RESULTS: A key feature of the COVID-19 response was the formation of Rapid Response Teams (RRTs), groups of lay community volunteers, who were identified and convened by LSG leaders. In some cases, pre-pandemic 'Arogya sena' (health army) community volunteer groups were merged with RRTs. RRT members were trained and supported by the health departments at the local level to distribute medicine and essential items, provided support for transportation to health facilities, and assisted with funerary rites during lockdown and containment period. RRTs often comprised youth cadres of ruling and opposition political parties. Existing community networks like Kudumbashree (Self Help Groups) and field workers from other departments have supported and been supported by RRTs. As pandemic restrictions eased, however, there was concern about the sustainability of this arrangement as well. CONCLUSION: Participatory local governance in Kerala allowed for the creation of invited spaces for community participation in a variety of roles as part of the COVID 19 response, with manifest impact. However, the terms of engagement were not decided by communities, nor were they involved more deeply in planning and organising health policy or services. The sustainability and governance features of such involvement warrant further study. CI - Copyright: (c) 2023 Benny et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. FAU - Benny, Gloria AU - Benny G AUID- ORCID: 0000-0003-3263-0798 AD - The George Institute for Global Health, New Delhi, India. FAU - D, Hari Sankar AU - D HS AD - The George Institute for Global Health, New Delhi, India. FAU - Joseph, Jaison AU - Joseph J AD - The George Institute for Global Health, New Delhi, India. FAU - Surendran, Surya AU - Surendran S AD - The George Institute for Global Health, New Delhi, India. FAU - Nambiar, Devaki AU - Nambiar D AD - The George Institute for Global Health, New Delhi, India. AD - Faculty of Medicine, University of New South Wales, Kensington, Australia. AD - Prasanna School of Public Health, Manipal Academy of Higher Education, Manipal, India. LA - eng GR - WT_/Wellcome Trust/United Kingdom PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20230606 PL - United States TA - PLoS One JT - PloS one JID - 101285081 SB - IM MH - Humans MH - Adolescent MH - *Health Care Reform MH - *COVID-19/epidemiology MH - Communicable Disease Control MH - Health Facilities MH - Government PMC - PMC10243625 COIS- The authors have declared that no competing interests exist. EDAT- 2023/06/06 19:12 MHDA- 2023/06/08 06:42 PMCR- 2023/06/06 CRDT- 2023/06/06 13:43 PHST- 2022/10/27 00:00 [received] PHST- 2023/05/06 00:00 [accepted] PHST- 2023/06/08 06:42 [medline] PHST- 2023/06/06 19:12 [pubmed] PHST- 2023/06/06 13:43 [entrez] PHST- 2023/06/06 00:00 [pmc-release] AID - PONE-D-22-29723 [pii] AID - 10.1371/journal.pone.0285999 [doi] PST - epublish SO - PLoS One. 2023 Jun 6;18(6):e0285999. doi: 10.1371/journal.pone.0285999. eCollection 2023. PMID- 37275953 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230607 IS - 1658-3612 (Electronic) IS - 1658-3612 (Linking) VI - 18 IP - 6 DP - 2023 Dec TI - Molecular identification of Leishmania major species in phlebotomine sand flies from Al Ahsa, Eastern KSA. PG - 1268-1272 LID - 10.1016/j.jtumed.2023.05.007 [doi] AB - OBJECTIVES: Cutaneous leishmaniasis (CL) is considered an overlooked public health threat in KSA. CL is endemic to several Saudi regions, including Al Ahsa City, Eastern KSA. To our knowledge, no prior molecular identification of Leishmania parasites in vectors in Al Ahsa has been published. The aim of this study was to perform molecular identification of Leishmania species in sand flies collected from Al Ahsa. METHODS: This cross-sectional study was conducted in Al Ahsa from July 2020 to May 2021. Sand flies were collected from the three areas with the highest rates of CL cases and sand flies, according to data from the Vector Borne Diseases Prevention Center in Al Ahsa. CDC miniature light traps and sticky traps were used to collect sand flies. Pools of 3-10 female sand flies were subjected to genomic DNA extraction. The extracted DNA was then amplified with a protocol targeting the Leishmania genus and using species-specific primers. For Leishmania species identification, a PCR-restriction fragment length polymorphism (PCR-RFLP) method was used. RESULTS: Ten of 113 pools of samples tested positive for the Leishmania genus, according to our experimental protocol. Characterization of Leishmania species by PCR-RFLP established Leishmania major as the only species found in the collected sand flies. CONCLUSION: This is the first documentation of molecular identification of Leishmania species in phlebotomine sand flies in the Al Ahsa region. L. major was the only species identified in our study. Further comprehensive research investigating the vectors and reservoirs will be crucial to establish the dynamics of transmission of Leishmania in Al Ahsa. CI - (c) 2023 [The Author/The Authors]. FAU - Al Rashed, Abdullatif AU - Al Rashed A AD - Department of Microbiology, College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam, KSA. FAU - Al Jindan, Reem AU - Al Jindan R AD - Department of Microbiology, College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam, KSA. FAU - Al Jaroodi, Salma AU - Al Jaroodi S AD - Department of Microbiology, College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam, KSA. FAU - Al Mohanna, Ahmed AU - Al Mohanna A AD - Vector Control Department, Vector and Zoonotic Diseases Center, Ministery of Health, Al Ahsa, Saudi Arabia. FAU - El-Badry, Ayman A AU - El-Badry AA AD - Department of Microbiology, College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam, KSA. LA - eng PT - Journal Article DEP - 20230519 PL - Saudi Arabia TA - J Taibah Univ Med Sci JT - Journal of Taibah University Medical Sciences JID - 101621911 PMC - PMC10238839 OTO - NOTNLM OT - Al Ahsa OT - ITS1 PCR OT - KSA OT - Leishmania major OT - Molecular OT - Phlebotomine sand fly EDAT- 2023/06/05 19:10 MHDA- 2023/06/05 19:11 PMCR- 2023/05/19 CRDT- 2023/06/05 12:24 PHST- 2023/01/21 00:00 [received] PHST- 2023/04/01 00:00 [revised] PHST- 2023/05/09 00:00 [accepted] PHST- 2023/06/05 19:11 [medline] PHST- 2023/06/05 19:10 [pubmed] PHST- 2023/06/05 12:24 [entrez] PHST- 2023/05/19 00:00 [pmc-release] AID - S1658-3612(23)00074-4 [pii] AID - 10.1016/j.jtumed.2023.05.007 [doi] PST - epublish SO - J Taibah Univ Med Sci. 2023 May 19;18(6):1268-1272. doi: 10.1016/j.jtumed.2023.05.007. eCollection 2023 Dec. PMID- 37268874 OWN - NLM STAT- MEDLINE DCOM- 20230605 LR - 20230605 IS - 1471-2393 (Electronic) IS - 1471-2393 (Linking) VI - 23 IP - 1 DP - 2023 Jun 2 TI - Gender norms and access to sexual and reproductive health services among women in the Marrakech-Safi region of Morocco: a qualitative study. PG - 407 LID - 10.1186/s12884-023-05724-0 [doi] LID - 407 AB - INTRODUCTION: Improving access to sexual and reproductive health remains a public health challenge, especially for women, whose access is affected by several determinants, such as gender inequality, which is the underlying barrier to all other determinants. Many actions have been carried out, but much remains to be done before all women and girls can exercise their rights. This study aimed to explore how gender norms influence access to sexual and reproductive health services. METHOD: A qualitative study was conducted from November 2021 to July 2022. The inclusion criteria were women and men aged over 18 years old, living in the urban and rural areas of the Marrakech-Safi region in Morocco. A purposive sampling method was used to select participants. Data were obtained through semi-structured interviews and focus groups with selected participants. The data were coded and classified using thematic content analysis. RESULTS: The study highlighted inequitable, restrictive gender norms that lead to stigmatization and affect the sexual and reproductive healthcare-seeking behavior and access of girls and women in the Marrakech-Safi region. These most common gender norms for women include parental refusal, stigmatization, and social exclusion of girls from sexual and reproductive health education services; strong decision-making power of family members over contraceptive use and women's adherence to pregnancy monitoring and access to supervised delivery; and culturally constructed role allocation, assigning a reproductive role to women and making them responsible for the health of new-borns. CONCLUSION: Sexual and reproductive health projects must strive to be gender sensitive. Gender-blind projects are missed opportunities to improve health outcomes and advance gender equality. CI - (c) 2023. The Author(s). FAU - Ouahid, Hajar AU - Ouahid H AD - Bioscience and Health Research Laboratory, Faculty of Medicine and Pharmacy, Cadi Ayyad University, Marrakech, Morocco. ouahid.hajar.1@gmail.com. FAU - Mansouri, Adil AU - Mansouri A AD - Clinical Research Department, Mohammed VI University Hospital, Marrakech, Morocco. FAU - Sebbani, Majda AU - Sebbani M AD - Bioscience and Health Research Laboratory, Faculty of Medicine and Pharmacy, Cadi Ayyad University, Marrakech, Morocco. AD - Clinical Research Department, Mohammed VI University Hospital, Marrakech, Morocco. AD - Department of Public Health, Community Medicine and Epidemiology, Faculty of Medicine and Pharmacy, Cadi Ayyad University, Marrakech, Morocco. FAU - Nouari, Nadia AU - Nouari N AD - Bioscience and Health Research Laboratory, Faculty of Medicine and Pharmacy, Cadi Ayyad University, Marrakech, Morocco. FAU - Khachay, Fatima Ezzahra AU - Khachay FE AD - Bioscience and Health Research Laboratory, Faculty of Medicine and Pharmacy, Cadi Ayyad University, Marrakech, Morocco. FAU - Cherkaoui, Mohamed AU - Cherkaoui M AD - Laboratory of Pharmacology, Neurobiology, Anthropobiology, and Environment, Faculty of Sciences Semlalia, Cadi Ayyad University, Marrakech, Morocco. FAU - Amine, Mohamed AU - Amine M AD - Bioscience and Health Research Laboratory, Faculty of Medicine and Pharmacy, Cadi Ayyad University, Marrakech, Morocco. AD - Clinical Research Department, Mohammed VI University Hospital, Marrakech, Morocco. AD - Department of Public Health, Community Medicine and Epidemiology, Faculty of Medicine and Pharmacy, Cadi Ayyad University, Marrakech, Morocco. FAU - Adarmouch, Latifa AU - Adarmouch L AD - Bioscience and Health Research Laboratory, Faculty of Medicine and Pharmacy, Cadi Ayyad University, Marrakech, Morocco. AD - Clinical Research Department, Mohammed VI University Hospital, Marrakech, Morocco. AD - Department of Public Health, Community Medicine and Epidemiology, Faculty of Medicine and Pharmacy, Cadi Ayyad University, Marrakech, Morocco. LA - eng PT - Journal Article DEP - 20230602 PL - England TA - BMC Pregnancy Childbirth JT - BMC pregnancy and childbirth JID - 100967799 SB - IM MH - Male MH - Pregnancy MH - Humans MH - Female MH - Adult MH - Middle Aged MH - Morocco MH - *Sexual Behavior MH - Qualitative Research MH - Focus Groups MH - *Reproductive Health Services MH - Reproductive Health PMC - PMC10235828 OTO - NOTNLM OT - Gender norms OT - Gender roles OT - Healthcare Access OT - Morocco OT - Reproductive health OT - Sexual health COIS- The authors declare no competing interests. EDAT- 2023/06/03 11:42 MHDA- 2023/06/05 06:42 PMCR- 2023/06/02 CRDT- 2023/06/02 23:30 PHST- 2022/12/15 00:00 [received] PHST- 2023/05/20 00:00 [accepted] PHST- 2023/06/05 06:42 [medline] PHST- 2023/06/03 11:42 [pubmed] PHST- 2023/06/02 23:30 [entrez] PHST- 2023/06/02 00:00 [pmc-release] AID - 10.1186/s12884-023-05724-0 [pii] AID - 5724 [pii] AID - 10.1186/s12884-023-05724-0 [doi] PST - epublish SO - BMC Pregnancy Childbirth. 2023 Jun 2;23(1):407. doi: 10.1186/s12884-023-05724-0. PMID- 37228475 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20231101 IS - 2632-0886 (Electronic) IS - 2632-0886 (Linking) VI - 4 DP - 2022 TI - Self-perceived loneliness and depression during the Covid-19 pandemic: a two-wave replication study. PG - e051 LID - 10.14324/111.444/ucloe.000051 [doi] LID - e051 AB - The global Covid-19 pandemic has forced countries to impose strict lockdown restrictions and mandatory stay-at-home orders with varying impacts on individual's health. Combining a data-driven machine learning paradigm and a statistical approach, our previous paper documented a U-shaped pattern in levels of self-perceived loneliness in both the UK and Greek populations during the first lockdown (17 April to 17 July 2020). The current paper aimed to test the robustness of these results by focusing on data from the first and second lockdown waves in the UK. We tested a) the impact of the chosen model on the identification of the most time-sensitive variable in the period spent in lockdown. Two new machine learning models - namely, support vector regressor (SVR) and multiple linear regressor (MLR) were adopted to identify the most time-sensitive variable in the UK dataset from Wave 1 (n = 435). In the second part of the study, we tested b) whether the pattern of self-perceived loneliness found in the first UK national lockdown was generalisable to the second wave of the UK lockdown (17 October 2020 to 31 January 2021). To do so, data from Wave 2 of the UK lockdown (n = 263) was used to conduct a graphical inspection of the week-by-week distribution of self-perceived loneliness scores. In both SVR and MLR models, depressive symptoms resulted to be the most time-sensitive variable during the lockdown period. Statistical analysis of depressive symptoms by week of lockdown resulted in a U-shaped pattern between weeks 3 and 7 of Wave 1 of the UK national lockdown. Furthermore, although the sample size by week in Wave 2 was too small to have a meaningful statistical insight, a graphical U-shaped distribution between weeks 3 and 9 of lockdown was observed. Consistent with past studies, these preliminary results suggest that self-perceived loneliness and depressive symptoms may be two of the most relevant symptoms to address when imposing lockdown restrictions. CI - (c) 2022 The Authors. FAU - Carollo, Alessandro AU - Carollo A AUID- ORCID: 0000-0002-2737-0218 AD - Department of Psychology and Cognitive Science, University of Trento, Rovereto, Italy. FAU - Bizzego, Andrea AU - Bizzego A AUID- ORCID: 0000-0002-1586-8350 AD - Department of Psychology and Cognitive Science, University of Trento, Rovereto, Italy. FAU - Gabrieli, Giulio AU - Gabrieli G AUID- ORCID: 0000-0002-9846-5767 AD - School of Social Sciences, Nanyang Technological University, Singapore, Singapore. FAU - Wong, Keri Ka-Yee AU - Wong KK AUID- ORCID: 0000-0002-2962-8438 AD - Department of Psychology and Human Development, University College London, London, UK. FAU - Raine, Adrian AU - Raine A AUID- ORCID: 0000-0002-3756-4307 AD - Departments of Criminology, Psychiatry, and Psychology, University of Pennsylvania, Philadelphia, PA, USA. FAU - Esposito, Gianluca AU - Esposito G AUID- ORCID: 0000-0002-9442-0254 AD - Department of Psychology and Cognitive Science, University of Trento, Rovereto, Italy. LA - eng PT - Journal Article DEP - 20221103 PL - England TA - UCL Open Environ JT - UCL open. Environment JID - 101771734 PMC - PMC10171408 OTO - NOTNLM OT - Covid-19 OT - SARS-CoV-2 OT - depression OT - global study OT - lockdown OT - loneliness OT - machine learning COIS- Research ethics statementThis study was pre-registered (https://osf.io/4nj3g/) on 17 April 2020 and ethical approval for the COVID-19 Social Study was granted by the University College London Institute of Education Ethics and Review Committee in April 2020 (REC 1331; [24]). The study is GDPR compliant.Consent for publication statementThe authors declare that research participants' informed consent to publication of findings - including photos, videos and any personal or identifiable information - was secured prior to publication.Conflicts of interest statementThe author declares no conflict of interest with this work.The author declares no conflict of interest with this work. EDAT- 2023/05/25 19:12 MHDA- 2023/05/25 19:13 PMCR- 2022/11/03 CRDT- 2023/05/25 14:08 PHST- 2021/10/08 00:00 [received] PHST- 2022/09/23 00:00 [accepted] PHST- 2023/05/25 19:13 [medline] PHST- 2023/05/25 19:12 [pubmed] PHST- 2023/05/25 14:08 [entrez] PHST- 2022/11/03 00:00 [pmc-release] AID - 10.14324/111.444/ucloe.000051 [doi] PST - epublish SO - UCL Open Environ. 2022 Nov 3;4:e051. doi: 10.14324/111.444/ucloe.000051. eCollection 2022. PMID- 37226946 OWN - NLM STAT- MEDLINE DCOM- 20230601 LR - 20240502 IS - 1468-2877 (Electronic) IS - 0033-3549 (Print) IS - 0033-3549 (Linking) VI - 138 IP - 1_suppl DP - 2023 May-Jun TI - Patient-Centered Care Through Nurse Practitioner-Led Integrated Behavioral Health: A Case Study. PG - 36S-41S LID - 10.1177/00333549231152192 [doi] AB - Integrated behavioral health can improve primary care and mental health outcomes. Access to behavioral health and primary care services in Texas is in crisis because of high uninsurance rates, regulatory restrictions, and lack of workforce. To address gaps in access to care, a partnership formed among a large local mental health authority in central Texas, a federally designated rural health clinic, and the Texas A&M University School of Nursing to create an interprofessional team-based health care delivery model led by nurse practitioners in rural and medically underserved areas of central Texas. Academic-practice partners identified 5 clinics for an integrated behavioral health care delivery model. From July 1, 2020, through December 31, 2021, a total of 3183 patient visits were completed. Patients were predominantly female (n = 1719, 54%) and Hispanic (n = 1750, 55%); 1050 (33%) were living at or below the federal poverty level; and 1400 (44%) were uninsured. The purpose of this case study was to describe the first year of implementation of the integrated health care delivery model, barriers to implementation, challenges to sustainability, and successes. We analyzed data from multiple sources, including meeting minutes and agendas, grant reports, direct observations of clinic flow, and interviews with clinic staff, and identified common qualitative themes (eg, challenges to integration, sustainability of integration, outcome successes). Results revealed implementation challenges with the electronic health record, service integration, low staffing levels during a global pandemic, and effective communication. We also examined 2 patient cases to illustrate the success of integrated behavioral health and highlighted lessons learned from the implementation process, including the need for a robust electronic health record and organizational flexibility. FAU - Weston, Cindy AU - Weston C AUID- ORCID: 0000-0002-3385-6652 AD - School of Nursing, Texas A&M University, Bryan, TX, USA. FAU - Wells-Beede, Elizabeth AU - Wells-Beede E AD - School of Nursing, Texas A&M University, Bryan, TX, USA. FAU - Salazar, Alice AU - Salazar A AD - School of Nursing, Texas A&M University, Bryan, TX, USA. FAU - Poston, Doris AU - Poston D AD - School of Nursing, Texas A&M University, Bryan, TX, USA. FAU - Brown, Sandra AU - Brown S AD - School of Nursing, Texas A&M University, Bryan, TX, USA. FAU - Hare, Martha AU - Hare M AD - School of Nursing, Texas A&M University, Bryan, TX, USA. FAU - Page, Robin AU - Page R AUID- ORCID: 0000-0001-7223-412X AD - School of Nursing, Texas A&M University, Bryan, TX, USA. LA - eng PT - Journal Article PT - Research Support, U.S. Gov't, Non-P.H.S. PT - Research Support, U.S. Gov't, P.H.S. PL - United States TA - Public Health Rep JT - Public health reports (Washington, D.C. : 1974) JID - 9716844 SB - IM MH - Female MH - Humans MH - Male MH - Ambulatory Care Facilities MH - Electronic Health Records MH - *Hispanic or Latino MH - *Nurse Practitioners MH - *Patient-Centered Care MH - Mental Health MH - Rural Population MH - Medically Underserved Area MH - Texas MH - *Health Services Accessibility MH - *Community Mental Health Services MH - Medically Uninsured PMC - PMC10226064 OTO - NOTNLM OT - academic-practice partnership OT - integrated behavioral health OT - nurse practitioner COIS- The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. EDAT- 2023/05/25 13:06 MHDA- 2023/05/26 06:42 PMCR- 2024/05/01 CRDT- 2023/05/25 06:33 PHST- 2023/05/26 06:42 [medline] PHST- 2023/05/25 13:06 [pubmed] PHST- 2023/05/25 06:33 [entrez] PHST- 2024/05/01 00:00 [pmc-release] AID - 10.1177_00333549231152192 [pii] AID - 10.1177/00333549231152192 [doi] PST - ppublish SO - Public Health Rep. 2023 May-Jun;138(1_suppl):36S-41S. doi: 10.1177/00333549231152192. PMID- 37202028 OWN - NLM STAT- MEDLINE DCOM- 20230522 LR - 20230524 IS - 2214-109X (Electronic) IS - 2214-109X (Linking) VI - 11 IP - 6 DP - 2023 Jun TI - Tracking SARS-CoV-2 introductions in Mozambique using pandemic-scale phylogenies: a retrospective observational study. PG - e933-e941 LID - S2214-109X(23)00169-9 [pii] LID - 10.1016/S2214-109X(23)00169-9 [doi] AB - BACKGROUND: From the start of the SARS-CoV-2 outbreak, global sequencing efforts have generated an unprecedented amount of genomic data. Nonetheless, unequal sampling between high-income and low-income countries hinders the implementation of genomic surveillance systems at the global and local level. Filling the knowledge gaps of genomic information and understanding pandemic dynamics in low-income countries is essential for public health decision making and to prepare for future pandemics. In this context, we aimed to discover the timing and origin of SARS-CoV-2 variant introductions in Mozambique, taking advantage of pandemic-scale phylogenies. METHODS: We did a retrospective, observational study in southern Mozambique. Patients from Manhica presenting with respiratory symptoms were recruited, and those enrolled in clinical trials were excluded. Data were included from three sources: (1) a prospective hospital-based surveillance study (MozCOVID), recruiting patients living in Manhica, attending the Manhica district hospital, and fulfilling the criteria of suspected COVID-19 case according to WHO; (2) symptomatic and asymptomatic individuals with SARS-CoV-2 infection recruited by the National Surveillance system; and (3) sequences from SARS-CoV-2-infected Mozambican cases deposited on the Global Initiative on Sharing Avian Influenza Data database. Positive samples amenable for sequencing were analysed. We used Ultrafast Sample placement on Existing tRees to understand the dynamics of beta and delta waves, using available genomic data. This tool can reconstruct a phylogeny with millions of sequences by efficient sample placement in a tree. We reconstructed a phylogeny (~7.6 million sequences) adding new and publicly available beta and delta sequences. FINDINGS: A total of 5793 patients were recruited between Nov 1, 2020, and Aug 31, 2021. During this time, 133 328 COVID-19 cases were reported in Mozambique. 280 good quality new SARS-CoV-2 sequences were obtained after the inclusion criteria were applied and an additional 652 beta (B.1.351) and delta (B.1.617.2) public sequences were included from Mozambique. We evaluated 373 beta and 559 delta sequences. We identified 187 beta introductions (including 295 sequences), divided in 42 transmission groups and 145 unique introductions, mostly from South Africa, between August, 2020 and July, 2021. For delta, we identified 220 introductions (including 494 sequences), with 49 transmission groups and 171 unique introductions, mostly from the UK, India, and South Africa, between April and November, 2021. INTERPRETATION: The timing and origin of introductions suggests that movement restrictions effectively avoided introductions from non-African countries, but not from surrounding countries. Our results raise questions about the imbalance between the consequences of restrictions and health benefits. This new understanding of pandemic dynamics in Mozambique can be used to inform public health interventions to control the spread of new variants. FUNDING: European and Developing Countries Clinical Trials, European Research Council, Bill & Melinda Gates Foundation, and Agencia de Gestio d'Ajuts Universitaris i de Recerca. CI - Copyright (c) 2023 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved. FAU - Martinez-Martinez, Francisco Jose AU - Martinez-Martinez FJ AD - Tuberculosis Genomics Unit, Instituto de Biomedicina de Valencia, Consejo Superior de Investigaciones Cientificas, Valencia, Spain. FAU - Massinga, Arsenia J AU - Massinga AJ AD - Centro de Investigacao em Saude de Manhica, Maputo, Mozambique. FAU - De Jesus, Auria AU - De Jesus A AD - Centro de Investigacao em Saude de Manhica, Maputo, Mozambique. FAU - Ernesto, Rita M AU - Ernesto RM AD - Centro de Investigacao em Saude de Manhica, Maputo, Mozambique. FAU - Cano-Jimenez, Pablo AU - Cano-Jimenez P AD - Tuberculosis Genomics Unit, Instituto de Biomedicina de Valencia, Consejo Superior de Investigaciones Cientificas, Valencia, Spain. FAU - Chiner-Oms, Alvaro AU - Chiner-Oms A AD - Tuberculosis Genomics Unit, Instituto de Biomedicina de Valencia, Consejo Superior de Investigaciones Cientificas, Valencia, Spain. FAU - Gomez-Navarro, Inmaculada AU - Gomez-Navarro I AD - Tuberculosis Genomics Unit, Instituto de Biomedicina de Valencia, Consejo Superior de Investigaciones Cientificas, Valencia, Spain. FAU - Guillot-Fernandez, Marina AU - Guillot-Fernandez M AD - Tuberculosis Genomics Unit, Instituto de Biomedicina de Valencia, Consejo Superior de Investigaciones Cientificas, Valencia, Spain. FAU - Guinovart, Caterina AU - Guinovart C AD - ISGlobal, Hospital Clinic - Universitat de Barcelona, Barcelona, Spain. FAU - Sitoe, Antonio AU - Sitoe A AD - Centro de Investigacao em Saude de Manhica, Maputo, Mozambique. FAU - Vubil, Delfino AU - Vubil D AD - Centro de Investigacao em Saude de Manhica, Maputo, Mozambique. FAU - Bila, Rubao AU - Bila R AD - Hospital Distrital da Manhica, Marracuene, Mozambique. FAU - Gujamo, Rufino AU - Gujamo R AD - Instituto Nacional de Saude, Marracuene, Mozambique. FAU - Enosse, Sonia AU - Enosse S AD - Instituto Nacional de Saude, Marracuene, Mozambique. FAU - Jimenez-Serrano, Santiago AU - Jimenez-Serrano S AD - Tuberculosis Genomics Unit, Instituto de Biomedicina de Valencia, Consejo Superior de Investigaciones Cientificas, Valencia, Spain. FAU - Torres-Puente, Manuela AU - Torres-Puente M AD - Tuberculosis Genomics Unit, Instituto de Biomedicina de Valencia, Consejo Superior de Investigaciones Cientificas, Valencia, Spain. FAU - Comas, Inaki AU - Comas I AD - Tuberculosis Genomics Unit, Instituto de Biomedicina de Valencia, Consejo Superior de Investigaciones Cientificas, Valencia, Spain; Centro de Investigacion Biomedica en Red en Epidemiologia y Salud Publica (CIBERESP), Madrid, Spain. FAU - Mandomando, Inacio AU - Mandomando I AD - Centro de Investigacao em Saude de Manhica, Maputo, Mozambique; Instituto Nacional de Saude, Marracuene, Mozambique. FAU - Lopez, Mariana G AU - Lopez MG AD - Tuberculosis Genomics Unit, Instituto de Biomedicina de Valencia, Consejo Superior de Investigaciones Cientificas, Valencia, Spain. Electronic address: mglopez@ibv.csic.es. FAU - Mayor, Alfredo AU - Mayor A AD - Centro de Investigacao em Saude de Manhica, Maputo, Mozambique; ISGlobal, Hospital Clinic - Universitat de Barcelona, Barcelona, Spain; Centro de Investigacion Biomedica en Red en Epidemiologia y Salud Publica (CIBERESP), Madrid, Spain; Department of Physiologic Sciences, Faculty of Medicine, Universidade Eduardo Mondlane, Maputo, Mozambique. LA - eng PT - Journal Article PT - Observational Study PT - Research Support, Non-U.S. Gov't PL - England TA - Lancet Glob Health JT - The Lancet. Global health JID - 101613665 RN - SARS-CoV-2 variants SB - IM CIN - Lancet Glob Health. 2023 Jun;11(6):e815-e816. doi: 10.1016/S2214-109X(23)00197-3. PMID: 37202013 MH - Humans MH - *SARS-CoV-2/genetics MH - *COVID-19/epidemiology/prevention & control MH - Pandemics/prevention & control MH - Phylogeny MH - Mozambique/epidemiology MH - Retrospective Studies MH - Prospective Studies PMC - PMC10187989 COIS- Declaration of interests We declare no competing interests. EDAT- 2023/05/19 01:04 MHDA- 2023/05/22 06:43 PMCR- 2023/05/16 CRDT- 2023/05/18 20:58 PHST- 2022/09/26 00:00 [received] PHST- 2023/03/09 00:00 [revised] PHST- 2023/03/23 00:00 [accepted] PHST- 2023/05/22 06:43 [medline] PHST- 2023/05/19 01:04 [pubmed] PHST- 2023/05/18 20:58 [entrez] PHST- 2023/05/16 00:00 [pmc-release] AID - S2214-109X(23)00169-9 [pii] AID - 10.1016/S2214-109X(23)00169-9 [doi] PST - ppublish SO - Lancet Glob Health. 2023 Jun;11(6):e933-e941. doi: 10.1016/S2214-109X(23)00169-9. PMID- 37194840 OWN - NLM STAT- MEDLINE DCOM- 20230518 LR - 20250130 IS - 1984-0462 (Electronic) IS - 0103-0582 (Print) IS - 0103-0582 (Linking) VI - 41 DP - 2023 TI - Oral findings in children on liver transplantation programming: a scoping review. PG - e2022095 LID - S0103-05822023000100515 [pii] LID - 10.1590/1984-0462/2023/41/2022095 [doi] LID - e2022095 AB - OBJECTIVE: To identify oral characteristics found in children with liver disease in programming for liver transplantation. DATA SOURCE: The methodology was written according to PRISMA-ScR. We adopted the methodological framework and recommendations for this type of review by Arksey and O'Malley and the Joanna Briggs Institute. The protocol was registered in the Open Science Framework (https://doi.org/10.17605/OSF.IO/QCU4W). A systematic search (Medline/PubMed, Scopus, Web of Science, and ProQuest) was conducted to identify studies that met the inclusion criteria: systematic reviews; prospective clinical trials (parallel or crossover group designs); observational studies (cohort, case-control, and cross-sectional studies); clinical case series; and case reports evaluating children with liver disease in preparation for transplantation. The last search was conducted in July 2021, and no restrictions were imposed as to language or year of publication. Studies presenting mixed data with post-transplant evaluation, and studies evaluating not only liver transplantation but also other solid organs were excluded. Screening, inclusion, and data extraction were performed by two reviewers independently. A narrative synthesis was conducted to describe the findings of the study. DATA SYNTHESIS: The bibliographic search identified 830 references. A total of 21 articles were read in their entirety after the inclusion criteria assessment. Finally, after evaluating the exclusion criteria, only 3 studies were considered for the qualitative analysis. CONCLUSIONS: Children with liver disease in preparation for transplantation may present enamel defects, tooth pigmentation, caries, gingivitis, and opportunistic infections such as candidiasis. FAU - Santos, Catielma Nascimento AU - Santos CN AUID- ORCID: 0000-0003-3932-5550 AD - Universidade de Sao Paulo, Sao Paulo, SP, Brazil. AD - Universidade Federal de Sergipe, Lagarto, SE, Brazil. FAU - Gallegos, Claudia Jacqueline Lopez AU - Gallegos CJL AUID- ORCID: 0000-0002-7674-4909 AD - Universidade de Sao Paulo, Sao Paulo, SP, Brazil. FAU - Caminha, Raquel D'Aquino Garcia AU - Caminha RDG AUID- ORCID: 0000-0002-8361-3894 AD - Universidade de Sao Paulo, Bauru, SP, Brazil. FAU - Porta, Gilda AU - Porta G AUID- ORCID: 0000-0002-0274-6274 AD - Universidade de Sao Paulo, Sao Paulo, SP, Brazil. FAU - Soares Junior, Luiz Alberto Valente AU - Soares Junior LAV AUID- ORCID: 0000-0003-0717-7354 AD - Universidade de Sao Paulo, Sao Paulo, SP, Brazil. FAU - Bonecker, Marcelo AU - Bonecker M AUID- ORCID: 0000-0001-9786-6473 AD - Universidade de Sao Paulo, Sao Paulo, SP, Brazil. FAU - Santos, Paulo Sergio da Silva AU - Santos PSDS AUID- ORCID: 0000-0002-0674-3759 AD - Universidade de Sao Paulo, Bauru, SP, Brazil. LA - eng PT - Journal Article PT - Scoping Review DEP - 20230515 PL - Brazil TA - Rev Paul Pediatr JT - Revista paulista de pediatria : orgao oficial da Sociedade de Pediatria de Sao Paulo JID - 9109353 SB - IM MH - Child MH - Humans MH - Cross-Sectional Studies MH - *Liver Diseases MH - *Liver Transplantation MH - Prospective Studies PMC - PMC10184978 COIS- Conflict of interests The authors declare no conflict of interests. EDAT- 2023/05/17 13:10 MHDA- 2023/05/18 06:42 PMCR- 2023/05/15 CRDT- 2023/05/17 07:24 PHST- 2022/05/24 00:00 [received] PHST- 2022/10/23 00:00 [accepted] PHST- 2023/05/18 06:42 [medline] PHST- 2023/05/17 13:10 [pubmed] PHST- 2023/05/17 07:24 [entrez] PHST- 2023/05/15 00:00 [pmc-release] AID - S0103-05822023000100515 [pii] AID - 10.1590/1984-0462/2023/41/2022095 [doi] PST - epublish SO - Rev Paul Pediatr. 2023 May 15;41:e2022095. doi: 10.1590/1984-0462/2023/41/2022095. eCollection 2023. PMID- 37183510 OWN - NLM STAT- MEDLINE DCOM- 20230811 LR - 20250626 IS - 1743-1328 (Electronic) IS - 0161-6412 (Linking) VI - 45 IP - 9 DP - 2023 Sep TI - Effects of transcranial direct current stimulation on lower limb function, balance and quality of life after stroke: a systematic review and meta-analysis. PG - 843-853 LID - 10.1080/01616412.2023.2211457 [doi] AB - OBJECTIVE: This systematic review with meta-analysis aimed to evaluate the effectiveness of tDCS on lower limb function, balance and quality of life in stroke patients. METHODS: The search included PubMed, CENTRAL, PEDro, Web of Science, SCOPUS, PsycINFO Ovid, CINAHL EBSCO, EMBASE, ScienceDirect, reference lists of relevant reviews, clinical trials registries and academic google, in June and July 2021. Randomized controlled trials were selected, which present the effect of tDCS on lower limb motor function recovery in stroke patients, comparing any type of active tDCS versus sham; parallel or crossover study design; adult patients; stimulation on the primary motor cortex; articles published in any language; without restriction of publication period. RESULTS: Nineteen studies were included. The treatment with active tDCS did not improve motor function (Chi(2) = 32,87, I(2) = 76%, SMD = 0,36 e 95% CI -0,18-0,90). Subgroup analyzes showed a significant effect favorable to tDCS, in relation to motor function, in the acute and subacute post stroke phases. However, the quality of evidence for this outcome was very low. Regarding balance outcome, a meta-analysis showed a significant difference in favor of active tDCS, but the quality of the evidence was considered very low. As for the quality of life outcome, no statistically significant difference was found in favor of tDCS. DISCUSSION: There is a lack of evidence in recommending the use of tDCS in isolation in the treatment of patients after stroke, aiming at improving motor function, balance and quality of life. However, it is possible that tDCS can be beneficial when associated with other therapies or interventions. FAU - Lima, Eloise AU - Lima E AUID- ORCID: 0000-0002-7031-1969 AD - Aging and Neuroscience Laboratory, Federal University of Paraiba, Joao Pessoa, Brazil. FAU - de Souza Neto, Jose Mauricio Ramos AU - de Souza Neto JMR AD - Center for Alternative and Renewable Energies (CEAR), Federal University of Paraiba, Joao Pessoa, Brazil. FAU - Andrade, Suellen Marinho AU - Andrade SM AUID- ORCID: 0000-0002-6801-0462 AD - Aging and Neuroscience Laboratory, Federal University of Paraiba, Joao Pessoa, Brazil. LA - eng PT - Journal Article PT - Meta-Analysis PT - Systematic Review DEP - 20230514 PL - England TA - Neurol Res JT - Neurological research JID - 7905298 SB - IM MH - Adult MH - Humans MH - *Transcranial Direct Current Stimulation MH - Quality of Life MH - Cross-Over Studies MH - *Stroke/therapy/complications MH - *Stroke Rehabilitation MH - Lower Extremity OTO - NOTNLM OT - Transcranial direct current stimulation OT - lower extremity OT - meta-analysis OT - quality of life OT - stroke OT - systematic review EDAT- 2023/05/15 06:42 MHDA- 2023/08/11 06:42 CRDT- 2023/05/15 03:44 PHST- 2023/08/11 06:42 [medline] PHST- 2023/05/15 06:42 [pubmed] PHST- 2023/05/15 03:44 [entrez] AID - 10.1080/01616412.2023.2211457 [doi] PST - ppublish SO - Neurol Res. 2023 Sep;45(9):843-853. doi: 10.1080/01616412.2023.2211457. Epub 2023 May 14. PMID- 37172027 OWN - NLM STAT- MEDLINE DCOM- 20230526 LR - 20230601 IS - 1553-7358 (Electronic) IS - 1553-734X (Print) IS - 1553-734X (Linking) VI - 19 IP - 5 DP - 2023 May TI - Understanding the impact of mobility on COVID-19 spread: A hybrid gravity-metapopulation model of COVID-19. PG - e1011123 LID - 10.1371/journal.pcbi.1011123 [doi] LID - e1011123 AB - The outbreak of the severe acute respiratory syndrome coronavirus 2 started in Wuhan, China, towards the end of 2019 and spread worldwide. The rapid spread of the disease can be attributed to many factors including its high infectiousness and the high rate of human mobility around the world. Although travel/movement restrictions and other non-pharmaceutical interventions aimed at controlling the disease spread were put in place during the early stages of the pandemic, these interventions did not stop COVID-19 spread. To better understand the impact of human mobility on the spread of COVID-19 between regions, we propose a hybrid gravity-metapopulation model of COVID-19. Our modeling framework has the flexibility of determining mobility between regions based on the distances between the regions or using data from mobile devices. In addition, our model explicitly incorporates time-dependent human mobility into the disease transmission rate, and has the potential to incorporate other factors that affect disease transmission such as facemasks, physical distancing, contact rates, etc. An important feature of this modeling framework is its ability to independently assess the contribution of each factor to disease transmission. Using a Bayesian hierarchical modeling framework, we calibrate our model to the weekly reported cases of COVID-19 in thirteen local health areas in Metro Vancouver, British Columbia (BC), Canada, from July 2020 to January 2021. We consider two main scenarios in our model calibration: using a fixed distance matrix and time-dependent weekly mobility matrices. We found that the distance matrix provides a better fit to the data, whilst the mobility matrices have the ability to explain the variance in transmission between regions. This result shows that the mobility data provides more information in terms of disease transmission than the distances between the regions. CI - Copyright: (c) 2023 Iyaniwura et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. FAU - Iyaniwura, Sarafa A AU - Iyaniwura SA AUID- ORCID: 0000-0002-8854-2335 AD - British Columbia Centre for Disease Control, Vancouver, British Columbia, Canada. AD - Department of Mathematics and Institute of Applied Mathematics, University of British Columbia, Vancouver, British Columbia, Canada. FAU - Ringa, Notice AU - Ringa N AD - British Columbia Centre for Disease Control, Vancouver, British Columbia, Canada. AD - School of Population and Public Health, University of British Columbia, Vancouver, British Columbia, Canada. FAU - Adu, Prince A AU - Adu PA AD - British Columbia Centre for Disease Control, Vancouver, British Columbia, Canada. AD - School of Population and Public Health, University of British Columbia, Vancouver, British Columbia, Canada. FAU - Mak, Sunny AU - Mak S AD - British Columbia Centre for Disease Control, Vancouver, British Columbia, Canada. FAU - Janjua, Naveed Z AU - Janjua NZ AD - British Columbia Centre for Disease Control, Vancouver, British Columbia, Canada. AD - School of Population and Public Health, University of British Columbia, Vancouver, British Columbia, Canada. FAU - Irvine, Michael A AU - Irvine MA AD - British Columbia Centre for Disease Control, Vancouver, British Columbia, Canada. AD - Faculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia, Canada. FAU - Otterstatter, Michael AU - Otterstatter M AD - British Columbia Centre for Disease Control, Vancouver, British Columbia, Canada. AD - School of Population and Public Health, University of British Columbia, Vancouver, British Columbia, Canada. LA - eng GR - VR5-172683/CIHR/Canada PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20230512 PL - United States TA - PLoS Comput Biol JT - PLoS computational biology JID - 101238922 SB - IM MH - Humans MH - *COVID-19/epidemiology MH - Bayes Theorem MH - SARS-CoV-2 MH - Disease Outbreaks MH - British Columbia PMC - PMC10208486 COIS- The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2023/05/12 19:07 MHDA- 2023/05/26 06:42 PMCR- 2023/05/12 CRDT- 2023/05/12 13:33 PHST- 2022/12/18 00:00 [received] PHST- 2023/04/24 00:00 [accepted] PHST- 2023/05/24 00:00 [revised] PHST- 2023/05/26 06:42 [medline] PHST- 2023/05/12 19:07 [pubmed] PHST- 2023/05/12 13:33 [entrez] PHST- 2023/05/12 00:00 [pmc-release] AID - PCOMPBIOL-D-22-01857 [pii] AID - 10.1371/journal.pcbi.1011123 [doi] PST - epublish SO - PLoS Comput Biol. 2023 May 12;19(5):e1011123. doi: 10.1371/journal.pcbi.1011123. eCollection 2023 May. PMID- 37166166 OWN - NLM STAT- MEDLINE DCOM- 20230529 LR - 20230918 IS - 1538-7488 (Electronic) IS - 0002-936X (Linking) VI - 123 IP - 6 DP - 2023 Jun 1 TI - Original Research: The Impact of COVID-19 on Pain Care Among Older Adults. PG - 26-36 LID - 10.1097/01.NAJ.0000937180.48669.ae [doi] AB - PURPOSE: In this qualitative descriptive study, we sought to understand the professional experiences and perceptions of pain management nurses who cared for older adults in the United States during the height of the COVID-19 pandemic. METHODS: Data were collected between July 2020 and July 2021 through individual, semistructured interviews with a nonprobability sample of 18 pain management nurses. An inductive content analysis approach, in which categories were derived from a coding process based on a close reading of data extracts from the interview transcripts, was used to reveal the major theme related to the study aim. RESULTS: Notwithstanding the variable consequences of COVID-19 on patients' health, a single overarching theme was pronounced: "Pain management for older adults remained unchanged during the pandemic despite unpredictable survival, restrictions on human interactions, and communication challenges." This theme was supported by four categories that emerged from the data: unpredictable survival, restriction-induced isolation, perceived continuity and equality of pain management, and communication challenges. CONCLUSIONS: During the COVID-19 pandemic, pain management nurses stepped in and joined interdisciplinary teams providing general and specialized pain care to ensure that older adults, whether inpatient or outpatient, continued to receive quality care. These study findings highlight the many challenges pain management nurses faced during this unprecedented public health crisis, as well as opportunities to improve the health system and enhance nursing practice to meet the needs of older patients. CI - Copyright (c) 2023 Wolters Kluwer Health, Inc. All rights reserved. FAU - Booker, Staja Q AU - Booker SQ AD - Staja Q. Booker is an assistant professor at the University of Florida College of Nursing in Gainesville. Timothy Joseph Sowicz is an assistant professor at the University of Arizona College of Nursing in Tucson. Mitchell R. Knisely is an associate professor at the Duke University School of Nursing in Durham, NC. Anitha Saravanan is an assistant professor at Northern Illinois University School of Nursing and Health Studies in DeKalb. Jinbing Bai is an assistant professor at the Emory University Nell Hodgson Woodruff School of Nursing in Atlanta. Barbara St. Marie is an associate professor at the University of Iowa College of Nursing in Iowa City. Contact author: Staja Q. Booker, bookers@ufl.edu . The authors have disclosed no potential conflicts of interest, financial or otherwise. FAU - Sowicz, Timothy Joseph AU - Sowicz TJ FAU - Knisely, Mitchell R AU - Knisely MR FAU - Saravanan, Anitha AU - Saravanan A FAU - Bai, Jinbing AU - Bai J FAU - St Marie, Barbara AU - St Marie B LA - eng PT - Journal Article PL - United States TA - Am J Nurs JT - The American journal of nursing JID - 0372646 SB - IM MH - Humans MH - United States/epidemiology MH - Aged MH - *Pandemics MH - *COVID-19 MH - Pain MH - Pain Management MH - Qualitative Research EDAT- 2023/05/11 13:18 MHDA- 2023/05/29 06:42 CRDT- 2023/05/11 08:43 PHST- 2023/05/29 06:42 [medline] PHST- 2023/05/11 13:18 [pubmed] PHST- 2023/05/11 08:43 [entrez] AID - 00000446-202306000-00019 [pii] AID - 10.1097/01.NAJ.0000937180.48669.ae [doi] PST - ppublish SO - Am J Nurs. 2023 Jun 1;123(6):26-36. doi: 10.1097/01.NAJ.0000937180.48669.ae. PMID- 37153184 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230509 IS - 0361-1981 (Print) IS - 2169-4052 (Electronic) IS - 0361-1981 (Linking) VI - 2677 IP - 4 DP - 2023 Apr TI - Will We Fly Again? Modeling Air Travel Demand in light of COVID-19 through a London Case Study. PG - 105-117 LID - 10.1177/03611981211025287 [doi] AB - The COVID-19 pandemic and associated travel restrictions have created an unprecedented challenge for the air transport industry, which before the pandemic was facing almost the exact opposite set of problems. Instead of the growing demand and need for capacity expansion warring against environmental concerns, the sector is now facing a slump in demand and the continuing uncertainty about the impacts of the pandemic on people's willingness to fly. To shed light on consumer attitudes toward air travel during and post the pandemic, this study presents an analysis that draws on recently collected survey data (April-July 2020), including both revealed and stated preference components, of 388 respondents who traveled from one of the six London, U.K., airports in 2019. Several travel scenarios considering the circumstances and attitudes related to COVID-19 are explored. The data is analyzed using a hybrid choice model to integrate latent constructs related to attitudinal characteristics. The analysis confirms the impact of consumers' health concerns on their willingness to travel, as a function of travel characteristics, that is, cost and number of transfers. It also provides insights into preference heterogeneity as a function of sociodemographic characteristics. However, no significant effects are observed concerning perceptions of safety arising from wearing a mask, or concerns over the necessity to quarantine. Results also suggest that some respondents may perceive virtual substitutes for business travel, for example video calls and similar software, as only a temporary measure, and seek to return to traveling as soon as it is possible to do so safely. CI - (c) National Academy of Sciences: Transportation Research Board 2021. FAU - Manca, Francesco AU - Manca F AUID- ORCID: 0000-0001-6968-7654 AD - Urban Systems Lab, Centre for Transport Studies, Department of Civil and Environmental Engineering, Imperial College London, London, U.K. FAU - Sivakumar, Aruna AU - Sivakumar A AUID- ORCID: 0000-0003-2721-8299 AD - Urban Systems Lab, Centre for Transport Studies, Department of Civil and Environmental Engineering, Imperial College London, London, U.K. FAU - Pawlak, Jacek AU - Pawlak J AUID- ORCID: 0000-0002-3254-6257 AD - Urban Systems Lab, Centre for Transport Studies, Department of Civil and Environmental Engineering, Imperial College London, London, U.K. FAU - Brodzinski, Norbert J AU - Brodzinski NJ AD - Urban Systems Lab, Centre for Transport Studies, Department of Civil and Environmental Engineering, Imperial College London, London, U.K. LA - eng PT - Journal Article DEP - 20210714 PL - United States TA - Transp Res Rec JT - Transportation research record JID - 101481512 PMC - PMC10149510 COIS- The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. EDAT- 2023/05/08 06:41 MHDA- 2023/05/08 06:42 PMCR- 2021/07/14 CRDT- 2023/05/08 04:12 PHST- 2023/05/08 06:42 [medline] PHST- 2023/05/08 06:41 [pubmed] PHST- 2023/05/08 04:12 [entrez] PHST- 2021/07/14 00:00 [pmc-release] AID - 10.1177_03611981211025287 [pii] AID - 10.1177/03611981211025287 [doi] PST - ppublish SO - Transp Res Rec. 2023 Apr;2677(4):105-117. doi: 10.1177/03611981211025287. Epub 2021 Jul 14. PMID- 37133235 OWN - NLM STAT- MEDLINE DCOM- 20230505 LR - 20260917 IS - 1654-9880 (Electronic) IS - 1654-9716 (Print) IS - 1654-9880 (Linking) VI - 16 IP - 1 DP - 2023 Dec 31 TI - 'Condoms are hard to get by': access to HIV prevention methods during lockdown of the COVID-19 epidemic in eastern Zimbabwe. PG - 2206207 LID - 10.1080/16549716.2023.2206207 [doi] LID - 2206207 AB - BACKGROUND: In the early phase of the coronavirus disease 2019 (COVID-19) pandemic, health services were disrupted worldwide, including HIV prevention services. While some studies have begun to document the effects of COVID-19 on HIV prevention, little has been done to qualitatively examine how lockdown measures were experienced and perceived to affect access to HIV prevention methods in sub-Saharan Africa. OBJECTIVES: To explore how the COVID-19 pandemic was perceived to affect access to HIV prevention methods in eastern Zimbabwe. METHOD: This article draws on qualitative data from the first three data collection points (involving telephone interviews, group discussions, and photography) of a telephone and WhatsApp-enabled digital ethnography. Data were collected from 11 adolescent girls and young women and five men over a 5-month period (March-July 2021). The data were analysed thematically. RESULTS: Participants reported widespread interruption to their condom supply when beerhalls were shut down as part of a nationwide lockdown. Restrictions in movement meant that participants who could afford to buy condoms from larger supermarkets or pharmacies were unable to. Additionally, the police reportedly refused to issue letters granting permission to travel for the purpose of accessing HIV prevention services. The COVID-19 pandemic was also described to obstruct the demand (fear of COVID-19, movement restrictions) and supply (de-prioritised, stock-outs) for HIV prevention services. Nonetheless, under certain formal and informal circumstances, such as accessing other and more prioritised health services, or 'knowing the right people', some participants were able to access HIV prevention methods. CONCLUSION: People at risk of HIV experienced the COVID-19 epidemic in Zimbabwe as disruptive to access to HIV prevention methods. While the disruptions were temporary, they were long enough to catalyse local responses, and to highlight the need for future pandemic response capacities to circumvent a reversal of hard-won gains in HIV prevention. FAU - Skovdal, Morten AU - Skovdal M AD - Department of Public Health, University of Copenhagen, Copenhagen, Denmark. FAU - Maunzagona, Tanyaradzwa AU - Maunzagona T AD - Manicaland Centre for Public Health Research, Biomedical Research and Training Institute, Harare, Zimbabwe. FAU - Dzamatira, Freedom AU - Dzamatira F AD - Manicaland Centre for Public Health Research, Biomedical Research and Training Institute, Harare, Zimbabwe. FAU - Magoge-Mandizvidza, Phyllis AU - Magoge-Mandizvidza P AD - Manicaland Centre for Public Health Research, Biomedical Research and Training Institute, Harare, Zimbabwe. FAU - Maswera, Rufurwokuda AU - Maswera R AD - Manicaland Centre for Public Health Research, Biomedical Research and Training Institute, Harare, Zimbabwe. FAU - Moyo, Brian Kumbirai AU - Moyo BK AD - HIV and TB Unit, Ministry of Health and Child Care, Harare, Zimbabwe. FAU - Nyamukapa, Constance AU - Nyamukapa C AD - Manicaland Centre for Public Health Research, Biomedical Research and Training Institute, Harare, Zimbabwe. AD - Department of Infectious Disease Epidemiology, Imperial College London, London, UK. FAU - Gregson, Simon AU - Gregson S AD - Manicaland Centre for Public Health Research, Biomedical Research and Training Institute, Harare, Zimbabwe. AD - Department of Infectious Disease Epidemiology, Imperial College London, London, UK. LA - eng GR - INV-023210/Bill & Melinda Gates Foundation/United States GR - MR/R015600/1/MRC_/Medical Research Council/United Kingdom PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - Glob Health Action JT - Global health action JID - 101496665 SB - IM MH - Male MH - Adolescent MH - Female MH - Humans MH - Condoms MH - Zimbabwe/epidemiology MH - *HIV Infections/epidemiology/prevention & control MH - Pandemics/prevention & control MH - *COVID-19/epidemiology/prevention & control MH - Communicable Disease Control MH - *Acquired Immunodeficiency Syndrome/epidemiology PMC - PMC10158550 OTO - NOTNLM OT - COVID-19 OT - HIV prevention OT - Zimbabwe OT - condoms OT - pandemic response COIS- No potential conflict of interest was reported by the author(s). EDAT- 2023/05/03 12:42 MHDA- 2023/05/05 06:42 PMCR- 2023/05/03 CRDT- 2023/05/03 08:53 PHST- 2023/05/05 06:42 [medline] PHST- 2023/05/03 12:42 [pubmed] PHST- 2023/05/03 08:53 [entrez] PHST- 2023/05/03 00:00 [pmc-release] AID - 2206207 [pii] AID - 10.1080/16549716.2023.2206207 [doi] PST - ppublish SO - Glob Health Action. 2023 Dec 31;16(1):2206207. doi: 10.1080/16549716.2023.2206207. PMID- 37104337 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240917 IS - 2414-6366 (Electronic) IS - 2414-6366 (Linking) VI - 8 IP - 4 DP - 2023 Mar 31 TI - Wastewater Surveillance Can Function as an Early Warning System for COVID-19 in Low-Incidence Settings. LID - 10.3390/tropicalmed8040211 [doi] LID - 211 AB - INTRODUCTION: During the first two years of the COVID-19 pandemic, Australia implemented a series of international and interstate border restrictions. The state of Queensland experienced limited COVID-19 transmission and relied on lockdowns to stem any emerging COVID-19 outbreaks. However, early detection of new outbreaks was difficult. In this paper, we describe the wastewater surveillance program for SARS-CoV-2 in Queensland, Australia, and report two case studies in which we aimed to assess the potential for this program to provide early warning of new community transmission of COVID-19. Both case studies involved clusters of localised transmission, one originating in a Brisbane suburb (Brisbane Inner West) in July-August 2021, and the other originating in Cairns, North Queensland in February-March 2021. MATERIALS AND METHODS: Publicly available COVID-19 case data derived from the notifiable conditions (NoCs) registry from the Queensland Health data portal were cleaned and merged spatially with the wastewater surveillance data using statistical area 2 (SA2) codes. The positive predictive value and negative predictive value of wastewater detection for predicting the presence of COVID-19 reported cases were calculated for the two case study sites. RESULTS: Early warnings for local transmission of SARS-CoV-2 through wastewater surveillance were noted in both the Brisbane Inner West cluster and the Cairns cluster. The positive predictive value of wastewater detection for the presence of notified cases of COVID-19 in Brisbane Inner West and Cairns were 71.4% and 50%, respectively. The negative predictive value for Brisbane Inner West and Cairns were 94.7% and 100%, respectively. CONCLUSIONS: Our findings highlight the utility of wastewater surveillance as an early warning tool in low COVID-19 transmission settings. FAU - Assoum, Mohamad AU - Assoum M AUID- ORCID: 0000-0001-5857-4814 AD - School of Public Health, Faculty of Medicine, The University of Queensland, Brisbane, QLD 4006, Australia. FAU - Lau, Colleen L AU - Lau CL AUID- ORCID: 0000-0001-8288-4169 AD - School of Public Health, Faculty of Medicine, The University of Queensland, Brisbane, QLD 4006, Australia. FAU - Thai, Phong K AU - Thai PK AD - Queensland Alliance for Environmental Health Sciences (QAEHS), The University of Queensland, Woolloongabba, QLD 4102, Australia. FAU - Ahmed, Warish AU - Ahmed W AD - CSIRO Land and Water, Ecosciences Precinct, 41 Boggo Road, Dutton Park, QLD 4102, Australia. FAU - Mueller, Jochen F AU - Mueller JF AD - Queensland Alliance for Environmental Health Sciences (QAEHS), The University of Queensland, Woolloongabba, QLD 4102, Australia. FAU - Thomas, Kevin V AU - Thomas KV AUID- ORCID: 0000-0002-2155-100X AD - Queensland Alliance for Environmental Health Sciences (QAEHS), The University of Queensland, Woolloongabba, QLD 4102, Australia. FAU - Choi, Phil Min AU - Choi PM AD - Health Protection Branch, Queensland Health, Brisbane, QLD 4006, Australia. FAU - Jackson, Greg AU - Jackson G AUID- ORCID: 0000-0001-6748-8301 AD - Health Protection Branch, Queensland Health, Brisbane, QLD 4006, Australia. FAU - Selvey, Linda A AU - Selvey LA AUID- ORCID: 0000-0001-8493-0974 AD - School of Public Health, Faculty of Medicine, The University of Queensland, Brisbane, QLD 4006, Australia. LA - eng PT - Journal Article DEP - 20230331 PL - Switzerland TA - Trop Med Infect Dis JT - Tropical medicine and infectious disease JID - 101709042 PMC - PMC10143724 OTO - NOTNLM OT - SARS-CoV-2 OT - early warning OT - surveillance OT - wastewater surveillance COIS- The authors declare no conflict of interest. EDAT- 2023/04/27 18:41 MHDA- 2023/04/27 18:42 PMCR- 2023/03/31 CRDT- 2023/04/27 13:35 PHST- 2023/02/10 00:00 [received] PHST- 2023/03/07 00:00 [revised] PHST- 2023/03/28 00:00 [accepted] PHST- 2023/04/27 18:42 [medline] PHST- 2023/04/27 18:41 [pubmed] PHST- 2023/04/27 13:35 [entrez] PHST- 2023/03/31 00:00 [pmc-release] AID - tropicalmed8040211 [pii] AID - tropicalmed-08-00211 [pii] AID - 10.3390/tropicalmed8040211 [doi] PST - epublish SO - Trop Med Infect Dis. 2023 Mar 31;8(4):211. doi: 10.3390/tropicalmed8040211. PMID- 37104282 OWN - NLM STAT- MEDLINE DCOM- 20230501 LR - 20260912 IS - 1549-1676 (Electronic) IS - 1549-1277 (Print) IS - 1549-1277 (Linking) VI - 20 IP - 4 DP - 2023 Apr TI - Home working and social and mental wellbeing at different stages of the COVID-19 pandemic in the UK: Evidence from 7 longitudinal population surveys. PG - e1004214 LID - 10.1371/journal.pmed.1004214 [doi] LID - e1004214 AB - BACKGROUND: Home working has increased since the Coronavirus Disease 2019 (COVID-19) pandemic's onset with concerns that it may have adverse health implications. We assessed the association between home working and social and mental wellbeing among the employed population aged 16 to 66 through harmonised analyses of 7 UK longitudinal studies. METHODS AND FINDINGS: We estimated associations between home working and measures of psychological distress, low life satisfaction, poor self-rated health, low social contact, and loneliness across 3 different stages of the pandemic (T1 = April to June 2020 -first lockdown, T2 = July to October 2020 -eased restrictions, T3 = November 2020 to March 2021 -second lockdown) using modified Poisson regression and meta-analyses to pool results across studies. We successively adjusted the model for sociodemographic characteristics (e.g., age, sex), job characteristics (e.g., sector of activity, pre-pandemic home working propensities), and pre-pandemic health. Among respectively 10,367, 11,585, and 12,179 participants at T1, T2, and T3, we found higher rates of home working at T1 and T3 compared with T2, reflecting lockdown periods. Home working was not associated with psychological distress at T1 (RR = 0.92, 95% CI = 0.79 to 1.08) or T2 (RR = 0.99, 95% CI = 0.88 to 1.11), but a detrimental association was found with psychological distress at T3 (RR = 1.17, 95% CI = 1.05 to 1.30). Study limitations include the fact that pre-pandemic home working propensities were derived from external sources, no information was collected on home working dosage and possible reverse association between change in wellbeing and home working likelihood. CONCLUSIONS: No clear evidence of an association between home working and mental wellbeing was found, apart from greater risk of psychological distress during the second lockdown, but differences across subgroups (e.g., by sex or level of education) may exist. Longer term shifts to home working might not have adverse impacts on population wellbeing in the absence of pandemic restrictions but further monitoring of health inequalities is required. CI - Copyright: (c) 2023 Wels et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. FAU - Wels, Jacques AU - Wels J AUID- ORCID: 0000-0002-9292-917X AD - MRC Unit for Lifelong Health and Ageing, University College London, London, United Kingdom. AD - Centre Metices, Universite libre de Bruxelles, Brussels, Belgium. FAU - Wielgoszewska, Bozena AU - Wielgoszewska B AUID- ORCID: 0000-0003-1592-5236 AD - Centre for Longitudinal Studies (CLS), Social Research Institute, University College London, London, United Kingdom. FAU - Moltrecht, Bettina AU - Moltrecht B AUID- ORCID: 0000-0002-1838-428X AD - Centre for Longitudinal Studies (CLS), Social Research Institute, University College London, London, United Kingdom. FAU - Booth, Charlotte AU - Booth C AUID- ORCID: 0000-0001-7576-4070 AD - Centre for Longitudinal Studies (CLS), Social Research Institute, University College London, London, United Kingdom. FAU - Green, Michael J AU - Green MJ AUID- ORCID: 0000-0003-3193-2452 AD - MRC/CSO Social and Public Health Sciences Unit, School of Health and Wellbeing, University of Glasgow, Clarice Pears Building, Glasgow, United Kingdom. FAU - Hamilton, Olivia Kl AU - Hamilton OK AUID- ORCID: 0000-0002-5874-0058 AD - MRC/CSO Social and Public Health Sciences Unit, School of Health and Wellbeing, University of Glasgow, Clarice Pears Building, Glasgow, United Kingdom. FAU - Demou, Evangelia AU - Demou E AUID- ORCID: 0000-0001-8616-525X AD - MRC/CSO Social and Public Health Sciences Unit, School of Health and Wellbeing, University of Glasgow, Clarice Pears Building, Glasgow, United Kingdom. FAU - Di Gessa, Giorgio AU - Di Gessa G AUID- ORCID: 0000-0001-6154-1845 AD - Research Department of Epidemiology and Public Health, University College London, London, United Kingdom. FAU - Huggins, Charlotte AU - Huggins C AD - Centre for Genomic and Experimental Medicine, The University of Edinburgh Western General Hospital, Edinburgh, United Kingdom. FAU - Zhu, Jingmin AU - Zhu J AD - Research Department of Epidemiology and Public Health, University College London, London, United Kingdom. FAU - Santorelli, Gillian AU - Santorelli G AD - Bradford Teaching Hospitals NHS Foundation Trust, Bradford, United Kingdom. FAU - Silverwood, Richard J AU - Silverwood RJ AUID- ORCID: 0000-0002-2744-1194 AD - Centre for Longitudinal Studies (CLS), Social Research Institute, University College London, London, United Kingdom. FAU - Kopasker, Daniel AU - Kopasker D AUID- ORCID: 0000-0002-2636-8431 AD - MRC/CSO Social and Public Health Sciences Unit, School of Health and Wellbeing, University of Glasgow, Clarice Pears Building, Glasgow, United Kingdom. FAU - Shaw, Richard J AU - Shaw RJ AUID- ORCID: 0000-0002-7906-6066 AD - MRC/CSO Social and Public Health Sciences Unit, School of Health and Wellbeing, University of Glasgow, Clarice Pears Building, Glasgow, United Kingdom. FAU - Hughes, Alun AU - Hughes A AD - MRC Unit for Lifelong Health and Ageing, University College London, London, United Kingdom. FAU - Patalay, Praveetha AU - Patalay P AUID- ORCID: 0000-0002-5341-3461 AD - MRC Unit for Lifelong Health and Ageing, University College London, London, United Kingdom. AD - Centre for Longitudinal Studies (CLS), Social Research Institute, University College London, London, United Kingdom. FAU - Steves, Claire AU - Steves C AD - Twin Research & Genetic Epidemiology, King's College London, St Thomas' Hospital London, United Kingdom. FAU - Chaturvedi, Nishi AU - Chaturvedi N AD - MRC Unit for Lifelong Health and Ageing, University College London, London, United Kingdom. FAU - Porteous, David J AU - Porteous DJ AUID- ORCID: 0000-0003-1249-6106 AD - Centre for Genomic and Experimental Medicine, The University of Edinburgh Western General Hospital, Edinburgh, United Kingdom. FAU - Rhead, Rebecca AU - Rhead R AUID- ORCID: 0000-0002-5863-604X AD - Centre for Longitudinal Studies (CLS), Social Research Institute, University College London, London, United Kingdom. FAU - Katikireddi, Srinivasa Vittal AU - Katikireddi SV AUID- ORCID: 0000-0001-6593-9092 AD - MRC/CSO Social and Public Health Sciences Unit, School of Health and Wellbeing, University of Glasgow, Clarice Pears Building, Glasgow, United Kingdom. FAU - Ploubidis, George B AU - Ploubidis GB AUID- ORCID: 0000-0002-8198-5790 AD - Centre for Longitudinal Studies (CLS), Social Research Institute, University College London, London, United Kingdom. LA - eng GR - MR/S037527/1/MRC_/Medical Research Council/United Kingdom GR - 104036/Z/14/Z/WT_/Wellcome Trust/United Kingdom GR - MR/W021277/1/MRC_/Medical Research Council/United Kingdom GR - MR/N024397/1/MRC_/Medical Research Council/United Kingdom GR - CS/16/4/32482/BHF_/British Heart Foundation/United Kingdom GR - MC_PC_20030/MRC_/Medical Research Council/United Kingdom GR - SCAF/15/02/CSO_/Chief Scientist Office/United Kingdom GR - MC_UU_00022/2/MRC_/Medical Research Council/United Kingdom GR - MC_PC_20059/MRC_/Medical Research Council/United Kingdom GR - WT101597MA/WT_/Wellcome Trust/United Kingdom GR - MC_UU_00019/3/MRC_/Medical Research Council/United Kingdom GR - WT_/Wellcome Trust/United Kingdom GR - 216767/Z/19/Z/WT_/Wellcome Trust/United Kingdom PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20230427 PL - United States TA - PLoS Med JT - PLoS medicine JID - 101231360 SB - IM MH - Humans MH - *Pandemics MH - *COVID-19/epidemiology MH - Communicable Disease Control MH - Longitudinal Studies MH - United Kingdom/epidemiology PMC - PMC10138202 COIS- I have read the journal's policy and the authors of this manuscript have the following competing interests: SVK is a member of the Scientific Advisory Group on Emergencies, the other authors report no competing interests. EDAT- 2023/04/27 18:41 MHDA- 2023/05/01 06:42 PMCR- 2023/04/27 CRDT- 2023/04/27 13:34 PHST- 2022/11/25 00:00 [received] PHST- 2023/03/07 00:00 [accepted] PHST- 2023/05/01 06:42 [medline] PHST- 2023/04/27 18:41 [pubmed] PHST- 2023/04/27 13:34 [entrez] PHST- 2023/04/27 00:00 [pmc-release] AID - PMEDICINE-D-22-03828 [pii] AID - 10.1371/journal.pmed.1004214 [doi] PST - epublish SO - PLoS Med. 2023 Apr 27;20(4):e1004214. doi: 10.1371/journal.pmed.1004214. eCollection 2023 Apr. PMID- 37080275 OWN - NLM STAT- MEDLINE DCOM- 20230516 LR - 20241005 IS - 1096-0953 (Electronic) IS - 0013-9351 (Print) IS - 0013-9351 (Linking) VI - 228 DP - 2023 Jul 1 TI - Peculiar weather patterns effects on air pollution and COVID-19 spread in Tokyo metropolis. PG - 115907 LID - S0013-9351(23)00699-0 [pii] LID - 10.1016/j.envres.2023.115907 [doi] AB - As a pandemic hotspot in Japan, between March 1, 2020-October 1, 2022, Tokyo metropolis experienced seven COVID-19 waves. Motivated by the high rate of COVID-19 incidence and mortality during the seventh wave, and environmental/health challenges we conducted a time-series analysis to investigate the long-term interaction of air quality and climate variability with viral pandemic in Tokyo. Through daily time series geospatial and observational air pollution/climate data, and COVID-19 incidence and death cases, this study compared the environmental conditions during COVID-19 multiwaves. In spite of five State of Emergency (SOEs) restrictions associated with COVID-19 pandemic, during (2020-2022) period air quality recorded low improvements relative to (2015-2019) average annual values, namely: Aerosol Optical Depth increased by 9.13% in 2020 year, and declined by 6.64% in 2021, and 12.03% in 2022; particulate matter PM2.5 and PM10 decreased during 2020, 2021, and 2022 years by 10.22%, 62.26%, 0.39%, and respectively by 4.42%, 3.95%, 5.76%. For (2021-2022) period the average ratio of PM2.5/PM10 was (0.319 +/- 0.1640), showing a higher contribution to aerosol loading of traffic-related coarse particles in comparison with fine particles. The highest rates of the daily recorded COVID-19 incidence and death cases in Tokyo during the seventh COVID-19 wave (1 July 2022-1 October 2022) may be attributed to accumulation near the ground of high levels of air pollutants and viral pathogens due to: 1) peculiar persistent atmospheric anticyclonic circulation with strong positive anomalies of geopotential height at 500 hPa; 2) lower levels of Planetary Boundary Layer (PBL) heights; 3) high daily maximum air temperature and land surface temperature due to the prolonged heat waves (HWs) in summer 2022; 4) no imposed restrictions. Such findings can guide public decision-makers to design proper strategies to curb pandemics under persistent stable anticyclonic weather conditions and summer HWs in large metropolitan areas. CI - Copyright (c) 2023 National Institute of R&D for Optoelectronics INOE 2000. Published by Elsevier Inc. All rights reserved. FAU - Zoran, Maria A AU - Zoran MA AD - IT Department, National Institute of R&D for Optoelectronics, Atomistilor Street 409, MG5, Magurele-Bucharest, 077125, Romania. Electronic address: mzoran@inoe.ro. FAU - Savastru, Roxana S AU - Savastru RS AD - IT Department, National Institute of R&D for Optoelectronics, Atomistilor Street 409, MG5, Magurele-Bucharest, 077125, Romania. FAU - Savastru, Dan M AU - Savastru DM AD - IT Department, National Institute of R&D for Optoelectronics, Atomistilor Street 409, MG5, Magurele-Bucharest, 077125, Romania. FAU - Tautan, Marina N AU - Tautan MN AD - IT Department, National Institute of R&D for Optoelectronics, Atomistilor Street 409, MG5, Magurele-Bucharest, 077125, Romania. LA - eng PT - Journal Article PT - Observational Study PT - Research Support, Non-U.S. Gov't DEP - 20230418 PL - Netherlands TA - Environ Res JT - Environmental research JID - 0147621 RN - 0 (Air Pollutants) RN - 0 (Particulate Matter) SB - IM MH - Humans MH - *COVID-19/epidemiology MH - Tokyo/epidemiology MH - Pandemics MH - *Air Pollution/analysis MH - *Air Pollutants/analysis MH - Weather MH - Particulate Matter/analysis MH - Environmental Monitoring PMC - PMC10111861 OTO - NOTNLM OT - Aerosol Optical Depth OT - Air pollutants: PM2.5 OT - COVID-19 disease OT - Heat Waves OT - NO(2) OT - O(3) OT - PM10 OT - Synoptic meteorological circulation OT - Tokyo COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2023/04/21 00:42 MHDA- 2023/05/16 06:42 PMCR- 2023/04/18 CRDT- 2023/04/20 19:23 PHST- 2023/03/08 00:00 [received] PHST- 2023/04/11 00:00 [revised] PHST- 2023/04/12 00:00 [accepted] PHST- 2023/05/16 06:42 [medline] PHST- 2023/04/21 00:42 [pubmed] PHST- 2023/04/20 19:23 [entrez] PHST- 2023/04/18 00:00 [pmc-release] AID - S0013-9351(23)00699-0 [pii] AID - 115907 [pii] AID - 10.1016/j.envres.2023.115907 [doi] PST - ppublish SO - Environ Res. 2023 Jul 1;228:115907. doi: 10.1016/j.envres.2023.115907. Epub 2023 Apr 18. PMID- 37078882 OWN - NLM STAT- MEDLINE DCOM- 20230424 LR - 20230701 IS - 1560-7917 (Electronic) IS - 1025-496X (Print) IS - 1025-496X (Linking) VI - 28 IP - 16 DP - 2023 Apr TI - COVID-19 outbreaks among crew on commercial ships at the Port of Rotterdam, the Netherlands, 2020 to 2021. LID - 10.2807/1560-7917.ES.2023.28.16.2200525 [doi] LID - 2200525 AB - BackgroundDuring the COVID-19 pandemic, international shipping activity was disrupted as movement of people and goods was restricted. The Port of Rotterdam, the largest port in Europe, remained operational throughout.AimWe describe the burden of COVID-19 among crew on sea-going vessels at the port and recommend improvements in future infectious disease event notification and response at commercial ports.MethodsSuspected COVID-19 cases on sea-going vessels were notified to port authorities and public health (PH) authorities pre-arrival via the Maritime Declaration of Health. We linked data from port and PH information systems between 1 January 2020 and 31 July 2021, derived a notification rate (NR) of COVID-19 events per arrival, and an attack rate (AR) per vessel (confirmed cases). We compared AR by vessel type (workship/tanker/cargo/passenger), during wildtype-, alpha- and delta-dominant calendar periods.ResultsEighty-four COVID-19 events were notified on ships, involving 622 cases. The NR among 45,030 new arrivals was 173 per 100,000 impacting 1% of vessels. Events per week peaked in April 2021 and again in July 2021, when the AR was also highest. Half of all cases were notified on workships, events occurring earlier and more frequently than on other vessels.ConclusionNotification of COVID-19 events on ships occurred infrequently, although case under-ascertainment was likely. Pre-agreed protocols for data-sharing between stakeholders locally and across Europe would facilitate more efficient pandemic response. Public health access to specimens for sequencing and environmental sampling would give greater insight into viral spread on ships. FAU - Gebuis, Edward AU - Gebuis E AD - Public Health Service Rotterdam-Rijnmond, Rotterdam, the Netherlands. FAU - Vieyra, Bruno AU - Vieyra B AD - Public Health Service Rotterdam-Rijnmond, Rotterdam, the Netherlands. FAU - Slegtenhorst, Rob AU - Slegtenhorst R AD - Port of Rotterdam Authority, Port of Rotterdam, the Netherlands. FAU - Wiegmans, Saskia AU - Wiegmans S AD - Port of Rotterdam Authority, Port of Rotterdam, the Netherlands. FAU - van Dijk, Bas AU - van Dijk B AD - Port of Rotterdam Authority, Port of Rotterdam, the Netherlands. FAU - Veenstra, Thijs AU - Veenstra T AD - National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands. FAU - Tejland, Saskia AU - Tejland S AD - Public Health Service Rotterdam-Rijnmond, Rotterdam, the Netherlands. FAU - Fanoy, Ewout AU - Fanoy E AD - Public Health Service Rotterdam-Rijnmond, Rotterdam, the Netherlands. FAU - de Raad, Annemieke AU - de Raad A AD - Public Health Service Rotterdam-Rijnmond, Rotterdam, the Netherlands. FAU - Koopmans, Marion AU - Koopmans M AD - Department of Viroscience, Erasmus Medical Centre, Rotterdam, Netherlands/ Pandemic and Disaster Preparedness Center, Rotterdam/Delft, the Netherlands. FAU - de Vries, Rene AU - de Vries R AD - Port of Rotterdam Authority, Port of Rotterdam, the Netherlands. FAU - van Leeuwen-Voerman, Saskia AU - van Leeuwen-Voerman S AD - Public Health Service Rotterdam-Rijnmond, Rotterdam, the Netherlands. FAU - Whelan, Jane AU - Whelan J AD - Public Health Service Rotterdam-Rijnmond, Rotterdam, the Netherlands. LA - eng PT - Journal Article PL - Sweden TA - Euro Surveill JT - Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin JID - 100887452 SB - IM MH - Humans MH - *Ships MH - Netherlands/epidemiology MH - Pandemics MH - *COVID-19/epidemiology MH - Disease Outbreaks MH - Disease Notification PMC - PMC10283453 OTO - NOTNLM OT - COVID-19 Testing / statistics and numerical data OT - Disease Outbreaks OT - Naval Medicine/statistics and numerical data OT - Port health OT - Ships OT - Travel OT - disease prevention and control COIS- Conflict of interest: None declared. EDAT- 2023/04/20 13:41 MHDA- 2023/04/24 06:42 PMCR- 2023/04/20 CRDT- 2023/04/20 10:13 PHST- 2023/04/24 06:42 [medline] PHST- 2023/04/20 13:41 [pubmed] PHST- 2023/04/20 10:13 [entrez] PHST- 2023/04/20 00:00 [pmc-release] AID - 2200525 [pii] AID - 10.2807/1560-7917.ES.2023.28.16.2200525 [doi] PST - ppublish SO - Euro Surveill. 2023 Apr;28(16):2200525. doi: 10.2807/1560-7917.ES.2023.28.16.2200525. PMID- 37031080 OWN - NLM STAT- MEDLINE DCOM- 20230509 LR - 20240929 IS - 1878-0210 (Electronic) IS - 1751-9918 (Print) IS - 1878-0210 (Linking) VI - 17 IP - 3 DP - 2023 Jun TI - Metabolic control of diabetic patients assisted by private and public health care systems during the COVID-19 pandemic: A retrospective cohort study. PG - 242-249 LID - S1751-9918(23)00070-0 [pii] LID - 10.1016/j.pcd.2023.04.001 [doi] AB - AIMS: We sought to analyze the impacts of social restriction measures imposed by the pandemic COVID-19 on the control of metabolic parameters in diabetic patients. METHODS: We accessed the medical records of patients who underwent clinical follow-up in the public and private health systems between July 2019 and June 2021. The sample consisted of 288 patients (111 adults and 177 older individuals). A two-way ANOVA mixed model was used to test the effects of intra- (time: baseline and after 24 months) and inter-subject factors. Linear regression analysis was used to predict the difference in body weight considering age, sex, HbA1c, health care system and insulin use. RESULTS: Among adults, we observed an increase in body weight and LDL-c levels, especially for insulin users (p /=6 partners and group sex (class 2; 29.8%, n = 13,596), and the highest proportions of chemsex and sex work (class 3; 16.7% of visits, n = 7,603). Visits in classes 2 and 3 (vs. class 1) were significantly more often with individuals who were diagnosed with an STI, older (>/=36 vs. /=10, partners' participation in housework and parenting, and factors associated with having a partner-accompanied birth were examined using a multivariable Poisson regression model. The proportion of women who had partner-accompanied births was 65.7% between January 2019 and March 2020, dropping to 32.1% between April 2020 and August 2021. Partner-accompanied birth was not associated with a K6 score >/=10, but was significantly associated with the partner's daily housework and parenting (adjusted prevalence ratio 1.08, 95% CI 1.02-1.14). Partner-accompanied births have been substantially restricted since the beginning of the COVID-19 pandemic. The right to a birth partner should be protected, while addressing infection control. FAU - Uchida, Mai AU - Uchida M AD - Department of Psychiatry, Massachusetts General Hospital, Boston, MA 02114, USA. AD - Department of Psychiatry, Harvard Medical School, Boston, MA 02115, USA. FAU - Okawa, Sumiyo AU - Okawa S AUID- ORCID: 0000-0002-2197-7078 AD - Institute for Global Health Policy Research, Bureau of International Health Cooperation, National Center for Global Health and Medicine, Tokyo 162-8655, Japan. FAU - Hosokawa, Yoshihiko AU - Hosokawa Y AD - Department of Obstetrics and Gynecology, Faculty of Medicine, University of Tsukuba, Tsukuba 305-8577, Japan. FAU - Tabuchi, Takahiro AU - Tabuchi T AUID- ORCID: 0000-0002-1050-3125 AD - Cancer Control Center, Osaka International Cancer Institute, Osaka 541-8567, Japan. LA - eng GR - JP 21H04856/Japan Society for the Promotion of Science/ GR - JPMJSC21U6/Japan Science and Technology Agency/ GR - R3-2-2/Innovative Research Program on Suicide Countermeasures/ GR - 19K19452/Japan Society for the Promotion of Science Kakenhi/ PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20230303 PL - Switzerland TA - Int J Environ Res Public Health JT - International journal of environmental research and public health JID - 101238455 SB - IM MH - Humans MH - Female MH - Japan/epidemiology MH - Cross-Sectional Studies MH - *Pandemics MH - *COVID-19/epidemiology MH - Intention PMC - PMC10002132 OTO - NOTNLM OT - COVID-19 OT - birth partner OT - mental health OT - parenting COIS- The authors declare no conflict of interest. EDAT- 2023/03/12 06:00 MHDA- 2023/03/15 06:00 PMCR- 2023/03/03 CRDT- 2023/03/11 01:13 PHST- 2023/02/03 00:00 [received] PHST- 2023/02/27 00:00 [revised] PHST- 2023/03/02 00:00 [accepted] PHST- 2023/03/11 01:13 [entrez] PHST- 2023/03/12 06:00 [pubmed] PHST- 2023/03/15 06:00 [medline] PHST- 2023/03/03 00:00 [pmc-release] AID - ijerph20054546 [pii] AID - ijerph-20-04546 [pii] AID - 10.3390/ijerph20054546 [doi] PST - epublish SO - Int J Environ Res Public Health. 2023 Mar 3;20(5):4546. doi: 10.3390/ijerph20054546. PMID- 36895854 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240913 IS - 2054-2704 (Print) IS - 2054-2704 (Electronic) IS - 2054-2704 (Linking) VI - 14 IP - 3 DP - 2023 Mar TI - The impact of "freedom day" on COVID-19 health protective behaviour in England: An observational study of hand hygiene, face covering use and physical distancing in public spaces pre and post the relaxing of restrictions. PG - 20542704231153563 LID - 10.1177/20542704231153563 [doi] LID - 20542704231153563 AB - OBJECTIVES: To study the prevalence of COVID-19 health protective behaviours before and after rules eased in England on the 19(th) July 2021. DESIGN: Observational study pre (12(th)-18(th) July) and post (26(th) July-1(st) August) 19(th) July, and a cross-sectional online survey (26(th) to 27(th) July). SETTING: Observations occurred in supermarkets (n = 10), train stations (n = 10), bus stops (n = 10), a coach station (n = 1) and a London Underground station (n = 1). The survey recruited a nationally representative sample. PARTICIPANTS: All adults entering the observed locations during a one-hour period (n = 3819 pre- and n = 2948 post-19(th) July). In the online survey, 1472 respondents reported having been shopping for groceries/visited a pharmacy and 566 reported having used public transport or having been in a taxi/minicab in the last week. MAIN OUTCOME MEASURES: We observed whether people wore a face covering, maintained distance from others and cleaned their hands. We investigated self-reports of wearing a face covering while in shops or using public transport. RESULTS: In most locations observed, the proportion of people wearing face coverings, cleaning the hands and maintaining physical distance declined post 19th July. Pre 19(th) July, 70.2% (95% CI 68.7 to 71.7%) of people were observed to be wearing a face covering versus 55.8% (54.2 to 57.9%) post 19(th) July. Equivalent rates for physical distancing were 40.9% (39.0 to 42.8%) versus 29.5% (27.4 to 31.7%), and for hand hygiene were 4.4% (3.8 to 5.1%) versus 3.9% (3.2 to 4.6%). Self-reports of "always" wearing face coverings were broadly similar to observed rates. CONCLUSIONS: Adherence to protective behaviours was sub-optimal and declined during the relaxation of restrictions, despite appeals to exercise caution. Self-reports of "always" wearing a face covering in specific locations appear valid. CI - (c) 2023 The Author(s). FAU - Davies, Rachel AU - Davies R AUID- ORCID: 0000-0002-3498-172X AD - NIHR Health Protection Research Unit in Emergency Preparedness and Response, King's College London, London, United Kingdom of Great Britain and Northern Ireland. RINGGOLD: 4616 FAU - Martin, Alex F AU - Martin AF AUID- ORCID: 0000-0003-1097-1137 AD - NIHR Health Protection Research Unit in Emergency Preparedness and Response, King's College London, London, United Kingdom of Great Britain and Northern Ireland. RINGGOLD: 4616 FAU - Smith, Louise E AU - Smith LE AUID- ORCID: 0000-0002-1277-2564 AD - NIHR Health Protection Research Unit in Emergency Preparedness and Response, King's College London, London, United Kingdom of Great Britain and Northern Ireland. RINGGOLD: 4616 FAU - Mowbray, Fiona AU - Mowbray F AD - NIHR Health Protection Research Unit in Emergency Preparedness and Response, King's College London, London, United Kingdom of Great Britain and Northern Ireland. RINGGOLD: 4616 FAU - Woodland, Lisa AU - Woodland L AUID- ORCID: 0000-0003-2440-3210 AD - NIHR Health Protection Research Unit in Emergency Preparedness and Response, King's College London, London, United Kingdom of Great Britain and Northern Ireland. RINGGOLD: 4616 FAU - Amlot, Richard AU - Amlot R AD - NIHR Health Protection Research Unit in Emergency Preparedness and Response, King's College London, London, United Kingdom of Great Britain and Northern Ireland. RINGGOLD: 4616 AD - Behavioural Science and Insights Unit, UK Health Security Agency, London, United Kingdom of Great Britain and Northern Ireland. FAU - Rubin, G James AU - Rubin GJ AD - NIHR Health Protection Research Unit in Emergency Preparedness and Response, King's College London, London, United Kingdom of Great Britain and Northern Ireland. RINGGOLD: 4616 LA - eng PT - Journal Article DEP - 20230306 PL - England TA - JRSM Open JT - JRSM open JID - 101625786 PMC - PMC9989406 OTO - NOTNLM OT - health promotion OT - infectious diseases OT - other public health COIS- Declarations GJR, RA and LS participate in the UK's Scientific Advisory Group for Emergencies, or its subgroups. RA is an employee of the UK Health Security Agency. EDAT- 2023/03/11 06:00 MHDA- 2023/03/11 06:01 PMCR- 2023/03/06 CRDT- 2023/03/10 02:34 PHST- 2023/03/10 02:34 [entrez] PHST- 2023/03/11 06:00 [pubmed] PHST- 2023/03/11 06:01 [medline] PHST- 2023/03/06 00:00 [pmc-release] AID - 10.1177_20542704231153563 [pii] AID - 10.1177/20542704231153563 [doi] PST - epublish SO - JRSM Open. 2023 Mar 6;14(3):20542704231153563. doi: 10.1177/20542704231153563. eCollection 2023 Mar. PMID- 36866803 OWN - NLM STAT- MEDLINE DCOM- 20230322 LR - 20230322 IS - 2042-650X (Electronic) IS - 2042-6496 (Linking) VI - 14 IP - 6 DP - 2023 Mar 20 TI - Dose-response meta-analysis of ultra-processed food with the risk of cardiovascular events and all-cause mortality: evidence from prospective cohort studies. PG - 2586-2596 LID - 10.1039/d2fo02628g [doi] AB - Background: Previous meta-analyses included abundant cross-sectional studies, and/or only assessed high versus low categories of UPF consumption. We conducted this meta-analysis based on prospective cohort studies to estimate the dose-response associations of UPF consumption with the risk of cardiovascular events (CVEs) and all-cause mortality among general adults. Methods: PubMed, Embase, and Web of Science were searched for relevant articles published up to August 17, 2021, and newly published articles between August 17, 2021 and July 21, 2022 were re-searched. Random-effects models were used to estimate the summary relative risks (RRs) and confidence intervals (CIs). Generalized least squares regression was used to estimate the linear dose-response associations of each additional serving of UPF. Restricted cubic splines were used to model the possible nonlinear trends. Results: Eleven eligible papers (17 analyses) were finally identified. The pooled effect size for the highest versus lowest category of UPF consumption showed positive associations with the risk of CVEs (RR = 1.35, 95% CI, 1.18-1.54) and all-cause mortality (RR = 1.21, 95% CI, 1.15-1.27). For each additional daily serving of UPF, the risk increased by 4% (RR = 1.04, 95% CI, 1.02-1.06) for CVEs and 2% (RR = 1.02, 95% CI, 1.01-1.03) for all-cause mortality. With increasing UPF intake, the risk of CVEs reflected a linear upward trend (P(nonlinearity) = 0.095), while all-cause mortality reflected a nonlinear upward trend (P(nonlinearity) = 0.039). Conclusion: Our findings based on prospective cohorts suggested that any increased level of UPF consumption was linked to higher CVEs and mortality risk. Thus, the recommendation is to control the intake of UPF in daily diet. FAU - Yuan, Lijun AU - Yuan L AD - Department of General Practice, The Affiliated Luohu Hospital of Shenzhen University Medical School, Shenzhen, Guangdong, People's Republic of China. dongshenghu563@126.com. FAU - Hu, Huifang AU - Hu H AD - Department of General Practice, The Affiliated Luohu Hospital of Shenzhen University Medical School, Shenzhen, Guangdong, People's Republic of China. dongshenghu563@126.com. FAU - Li, Tianze AU - Li T AD - Department of Biostatistics and Epidemiology, School of Public Health, Shenzhen University Medical School, Shenzhen, Guangdong, People's Republic of China. FAU - Zhang, Jinli AU - Zhang J AD - Department of Biostatistics and Epidemiology, School of Public Health, Shenzhen University Medical School, Shenzhen, Guangdong, People's Republic of China. FAU - Feng, Yifei AU - Feng Y AD - Department of Epidemiology and Health Statistics, College of Public Health, Zhengzhou University, Zhengzhou, Henan, People's Republic of China. FAU - Yang, Xingjin AU - Yang X AD - Department of Epidemiology and Health Statistics, College of Public Health, Zhengzhou University, Zhengzhou, Henan, People's Republic of China. FAU - Li, Yang AU - Li Y AD - Department of Biostatistics and Epidemiology, School of Public Health, Shenzhen University Medical School, Shenzhen, Guangdong, People's Republic of China. FAU - Wu, Yuying AU - Wu Y AD - Department of General Practice, The Affiliated Luohu Hospital of Shenzhen University Medical School, Shenzhen, Guangdong, People's Republic of China. dongshenghu563@126.com. AD - Department of Biostatistics and Epidemiology, School of Public Health, Shenzhen University Medical School, Shenzhen, Guangdong, People's Republic of China. FAU - Li, Xi AU - Li X AD - Department of Epidemiology and Health Statistics, College of Public Health, Zhengzhou University, Zhengzhou, Henan, People's Republic of China. FAU - Huang, Hao AU - Huang H AD - Department of General Practice, The Affiliated Luohu Hospital of Shenzhen University Medical School, Shenzhen, Guangdong, People's Republic of China. dongshenghu563@126.com. AD - Department of Biostatistics and Epidemiology, School of Public Health, Shenzhen University Medical School, Shenzhen, Guangdong, People's Republic of China. FAU - Hu, Fulan AU - Hu F AD - Department of General Practice, The Affiliated Luohu Hospital of Shenzhen University Medical School, Shenzhen, Guangdong, People's Republic of China. dongshenghu563@126.com. AD - Department of Biostatistics and Epidemiology, School of Public Health, Shenzhen University Medical School, Shenzhen, Guangdong, People's Republic of China. FAU - Chen, Chuanqi AU - Chen C AD - Department of Endocrinology, Shenzhen Qianhai Shekou Free Trade Zone Hospital, Shenzhen, Guangdong, People's Republic of China. FAU - Zhang, Ming AU - Zhang M AD - Department of General Practice, The Affiliated Luohu Hospital of Shenzhen University Medical School, Shenzhen, Guangdong, People's Republic of China. dongshenghu563@126.com. AD - Department of Biostatistics and Epidemiology, School of Public Health, Shenzhen University Medical School, Shenzhen, Guangdong, People's Republic of China. FAU - Zhao, Yang AU - Zhao Y AD - Department of Epidemiology and Health Statistics, College of Public Health, Zhengzhou University, Zhengzhou, Henan, People's Republic of China. FAU - Hu, Dongsheng AU - Hu D AUID- ORCID: 0000-0002-9998-8041 AD - Department of General Practice, The Affiliated Luohu Hospital of Shenzhen University Medical School, Shenzhen, Guangdong, People's Republic of China. dongshenghu563@126.com. LA - eng PT - Journal Article PT - Meta-Analysis PT - Review DEP - 20230320 PL - England TA - Food Funct JT - Food & function JID - 101549033 SB - IM MH - Adult MH - Humans MH - Risk Factors MH - Prospective Studies MH - *Food, Processed MH - Cross-Sectional Studies MH - Diet MH - *Cardiovascular Diseases EDAT- 2023/03/04 06:00 MHDA- 2023/03/23 06:00 CRDT- 2023/03/03 06:33 PHST- 2023/03/04 06:00 [pubmed] PHST- 2023/03/23 06:00 [medline] PHST- 2023/03/03 06:33 [entrez] AID - 10.1039/d2fo02628g [doi] PST - epublish SO - Food Funct. 2023 Mar 20;14(6):2586-2596. doi: 10.1039/d2fo02628g. PMID- 36863349 OWN - NLM STAT- MEDLINE DCOM- 20230809 LR - 20230809 IS - 1439-1058 (Electronic) IS - 0937-2032 (Linking) VI - 73 IP - 8 DP - 2023 Aug TI - [Psychological Effects of the COVID-19 Pandemic on Freelance Professional Musicians]. PG - 321-327 LID - 10.1055/a-2017-5392 [doi] AB - With the onset of public life restrictions in the COVID 19 pandemic in March 2020, freelance professional musicians were exposed to significant pandemic-related restrictions in exercising their profession. Due to the particular working conditions, this professional group was already considered high at risk in terms of mental health before the pandemic. The present study investigates the level of mental distress among professional musicians during the pandemic in relation to basic mental health needs and help-seeking behaviour. In July and August 2021, psychological distress was measured in a nationwide sample of N=209 professional musicians using the ICD-10 Symptom Checklist (ISR). In addition, the extent to which the musicians' basic psychological needs are met and whether they would seek professional psychological help was determined. Compared to various control groups before and during the pandemic, professional musicians showed significantly higher levels of psychological symptoms than the general population before and during the pandemic. Regression analyses support the assumption that pandemic-related changes in the basic psychological needs of pleasure or displeasure avoidance, self-esteem enhancement or self-esteem protection and attachment have a significant influence on the expression of depression symptoms. The musicians' help-seeking behaviour, on the other hand, decreases with an increase in depression symptoms. Due to the high overall psychological stress among freelance musicians, there is a need for action, especially in the provision of specially adapted psychosocial support services. CI - Thieme. All rights reserved. FAU - Rosenbaum, Dirk AU - Rosenbaum D AD - Department Psychologie, PFH Private Hochschule Gottingen. FAU - Weibelzahl, Stephan AU - Weibelzahl S AD - Department Psychologie, PFH Private Hochschule Gottingen. LA - ger PT - English Abstract PT - Journal Article TT - Psychische Auswirkungen der COVID-19-Pandemie bei freiberuflichen Berufsmusiker*innen. DEP - 20230302 PL - Germany TA - Psychother Psychosom Med Psychol JT - Psychotherapie, Psychosomatik, medizinische Psychologie JID - 8002823 SB - IM MH - Humans MH - *COVID-19/epidemiology MH - Pandemics MH - Mental Health MH - Stress, Psychological/epidemiology MH - Psychosocial Support Systems COIS- Die Autorinnen/Autoren geben an, dass kein Interessenkonflikt besteht. EDAT- 2023/03/03 06:00 MHDA- 2023/08/09 06:43 CRDT- 2023/03/02 18:42 PHST- 2023/08/09 06:43 [medline] PHST- 2023/03/03 06:00 [pubmed] PHST- 2023/03/02 18:42 [entrez] AID - 10.1055/a-2017-5392 [doi] PST - ppublish SO - Psychother Psychosom Med Psychol. 2023 Aug;73(8):321-327. doi: 10.1055/a-2017-5392. Epub 2023 Mar 2. PMID- 36859179 OWN - NLM STAT- MEDLINE DCOM- 20230303 LR - 20230313 IS - 2731-4553 (Electronic) IS - 2731-4553 (Linking) VI - 24 IP - 1 DP - 2023 Mar 1 TI - Of primary health care reforms and pandemic responses: understanding perspectives of health system actors in Kerala before and during COVID-19. PG - 59 LID - 10.1186/s12875-023-02000-0 [doi] LID - 59 AB - BACKGROUND: In 2016, the Government of the southern Indian state of Kerala launched the Aardram mission, a set of reforms in the state's health sector with the support of Local Self Governments (LSG). Primary Health Centres (PHCs) were slated for transformation into Family Health Centres (FHCs), with extended hours of operation as well as improved quality and range of services. With the COVID-19 pandemic emerging soon after their introduction, we studied the outcomes of the transformation from PHC to FHC and how they related to primary healthcare service delivery during COVID-19. METHODS: A qualitative study was conducted using In-depth interviews with 80 health system actors (male n = 32, female n = 48) aged between 30-63 years in eight primary care facilities of four districts in Kerala from July to October 2021. Participants included LSG members, medical and public health staff, as well as community leaders. Questions about the need for primary healthcare reforms, their implementation, challenges, achievements, and the impact of COVID-19 on service delivery were asked. Written informed consent was obtained and interview transcripts - transliterated into English-were thematically analysed by a team of four researchers using ATLAS.ti 9 software. RESULTS: LSG members and health staff felt that the PHC was an institution that guarantees preventive, promotive, and curative care to the poorest section of society and can help in reducing the high cost of care. Post-transformation to FHCs, improved timings, additional human resources, new services, fully functioning laboratories, and well stocked pharmacies were observed and linked to improved service utilization and reduced cost of care. Challenges of geographical access remained, along with concerns about the lack of attention to public health functions, and sustainability in low-revenue LSGs. COVID-19 pandemic restrictions disrupted promotive services, awareness sessions and outreach activities; newly introduced services were stopped, and outpatient numbers were reduced drastically. Essential health delivery and COVID-19 management increased the workload of health workers and LSG members, as the emphasis was placed on managing the COVID-19 pandemic and delivering essential health services. CONCLUSION: Most of the health system actors expressed their belief in and commitment to primary health care reforms and noted positive impacts on the clinical side with remaining challenges of access, outreach, and sustainability. COVID-19 reduced service coverage and utilisation, but motivated greater efforts on the part of both health workers and community representatives. Primary health care is a shared priority now, with a need for greater focus on systems strengthening, collaboration, and primary prevention. CI - (c) 2023. The Author(s). FAU - Sankar D, Hari AU - Sankar D H AD - The George Institute for Global Health, India, 308, Third Floor, Elegance Tower, Plot No. 8, Jasola District Centre, New Delhi, 110025, India. vaidyarsankar@gmail.com. FAU - Joseph, Jaison AU - Joseph J AD - The George Institute for Global Health, India, 308, Third Floor, Elegance Tower, Plot No. 8, Jasola District Centre, New Delhi, 110025, India. FAU - Benny, Gloria AU - Benny G AD - The George Institute for Global Health, India, 308, Third Floor, Elegance Tower, Plot No. 8, Jasola District Centre, New Delhi, 110025, India. FAU - Nambiar, Devaki AU - Nambiar D AD - The George Institute for Global Health, India, 308, Third Floor, Elegance Tower, Plot No. 8, Jasola District Centre, New Delhi, 110025, India. AD - Faculty of Medicine, University of New South Wales, Sydney, Australia. AD - Prasanna School of Public Health, Manipal Academy of Higher Education, Manipal, India. LA - eng GR - IA/CPHI/16/1/502653/The Wellcome Trust DBT India Alliance/ PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20230301 PL - England TA - BMC Prim Care JT - BMC primary care JID - 9918300889006676 SB - IM MH - Humans MH - Female MH - Male MH - Animals MH - Adult MH - Middle Aged MH - Health Care Reform MH - Pandemics MH - *COVID-19 MH - Government Programs MH - *Lepidoptera PMC - PMC9975828 OTO - NOTNLM OT - Aardram OT - Family Health Centres OT - Kerala OT - Primary Care OT - Universal Health Coverage COIS- The authors declare no competing interests. EDAT- 2023/03/02 06:00 MHDA- 2023/03/04 06:00 PMCR- 2023/03/01 CRDT- 2023/03/01 23:34 PHST- 2022/08/24 00:00 [received] PHST- 2023/02/02 00:00 [accepted] PHST- 2023/03/01 23:34 [entrez] PHST- 2023/03/02 06:00 [pubmed] PHST- 2023/03/04 06:00 [medline] PHST- 2023/03/01 00:00 [pmc-release] AID - 10.1186/s12875-023-02000-0 [pii] AID - 2000 [pii] AID - 10.1186/s12875-023-02000-0 [doi] PST - epublish SO - BMC Prim Care. 2023 Mar 1;24(1):59. doi: 10.1186/s12875-023-02000-0. PMID- 40587628 STAT- Publisher PB - Patient-Centered Outcomes Research Institute (PCORI) CTI - PCORI Final Research Reports DP - 2023 Mar BTI - COVID-19 Testing, Infections, and Hospital Admissions among People Who Identify as Transgender AB - BACKGROUND: Transgender and gender-diverse (TGD) people may be disproportionately affected by the COVID-19 pandemic because they may face barriers to timely care and because they may be at higher risk for severe disease because of possible interaction between COVID-19 infection and gender-affirming hormone therapy. OBJECTIVES: In this analysis of data from the Study of Transition, Outcomes & Gender nested in Kaiser Permanente health plans in northern and southern California, we sought to characterize the potential impact of the COVID-19 pandemic among TGD people enrolled at participating sites by comparing rates of COVID-19 testing and diagnoses in transfeminine (TF) and transmasculine (TM) participants relative to cisgender referents. In addition, data on COVID-19 cases among TGD and cisgender study participants were analyzed to assess the likelihood of hospitalization in the 2 groups. METHODS: Electronic health records (EHRs) were used to identify and validate a cohort of 6774 TM and 4607 TF Kaiser Permanente members who were enrolled in the 2 participating plans from January 1, 2020, through July 31, 2021. Ten cisgender male (CM) and 10 cisgender female (CF) enrollees were matched to each TGD cohort member on year of birth, race or ethnicity, and study site. Rates of COVID-19 testing and diagnoses and hospitalizations within 30 days of diagnosis among TGD cohort members were ascertained from the EHR and compared with those in the reference cohorts via Cox regression models, with results expressed as hazard ratios (HRs) and 95% CIs. RESULTS: The rate of COVID-19 testing was 18% higher (HR, 1.18 [95% CI, 1.13-1.24]) among TF cohort members than among matched CF referents and 51% higher (HR, 1.51 [95% CI, 1.44-1.59]) when the reference group consisted of CM study participants. TM study participants also had significantly higher rates of COVID-19 testing, with HR estimates of 1.34 (95% CI, 1.29-1.40) relative to CF referents and 1.74 (95% CI, 1.68-1.81) relative to CM referents. The HR (95% CI) estimates for COVID-19 incidence rates comparing TF and CF and CM cohort members were 0.64 (0.56-0.73) and 0.71 (0.62-0.81), respectively. Similarly, TM participants were approximately 30% to 40% less likely to receive a COVID-19 diagnosis than cisgender referents, with all 95% CI estimates excluding unity. Although the unadjusted analyses suggested that hospitalization rates were higher among TF patients with COVID-19 than among cisgender referents, the association was attenuated and was not statistically significant after the results were controlled for covariates. More importantly, the association was no longer evident once the analyses were restricted to TF patients with evidence of gender-affirming hormone therapy receipt. The corresponding analyses for TM patients with COVID-19 produced essentially null results. CONCLUSIONS: In this analysis of the data from an EHR-based cohort nested within 2 large integrated health systems, there was no evidence that TGD people were disproportionately affected by the COVID-19 pandemic in terms of rates of testing and rates and severity of disease. LIMITATIONS: Though reassuring, the results of this study must be interpreted with caution because the data are limited to participants with adequate access to care and included few cases of COVID-19 that necessitated intensive care. Although COVID-19 testing and diagnoses from outside the system are documented in Kaiser Permanente records, the completeness of this documentation is not clear. CI - Copyright (c) 2023. Emory University. All Rights Reserved. FAU - Goodman, Michael AU - Goodman M AD - Department of Epidemiology, Emory University School of Public Health, Atlanta, Georgia LA - eng PT - Review PT - Book PL - Washington (DC) EDAT- 2023/03/01 00:00 CRDT- 2023/03/01 00:00 AID - NBK615679 [bookaccession] AID - 10.25302/03.3023.ADSS.4532-C19 [doi] PMID- 37440675 STAT- Publisher PB - Patient-Centered Outcomes Research Institute (PCORI) CTI - PCORI Final Research Reports DP - 2023 Mar BTI - Developing and Testing Models for COVID-19 Health Outcomes AB - BACKGROUND: Supporting decisions that patients who present at the emergency department with COVID-19 make requires accurate prognostication, but a highly dynamic pandemic poses special challenges for predicting patient outcomes. OBJECTIVES: We aimed to develop clinical prediction models (CPMs) to support shared decision-making for COVID-19 care. We also aimed to evaluate geographic transportability by assessing model performance across different data sets (from different countries) as well as temporal transportability by assessing model performance within the same data set across time periods. We convened focus groups with COVID-19 care providers, survivors, and surrogates to elicit feedback about care-related decision-making during the COVID-19 pandemic. METHODS: Clinical prediction models to predict the probability of (1) mortality, (2) whether a patient will require mechanical ventilation (MV) or intensive care unit (ICU) admission, (3) mortality if a patient is placed on MV, and (4) length of stay in the ICU were developed in each of 2 hospital systems using easily obtainable variables at the time of admission to the emergency department. The Northwell COVID-19 Survival (NOCOS) models were developed based on New York City (NYC) data, and the COVID-19 Outcome Prediction in the Emergency Department (COPE) models were developed based on data from the Netherlands, both using data from the first wave (March 2020 through August 2020). For temporal validation, all models were tested on second-wave data (September 2020 through December 2020) within the same set of hospitals as well as on both first- and second-wave data from the alternative country. Online focus groups and interviews were conducted among health care professionals, people who had had COVID-19, and surrogates in the United States and the Netherlands. Semistructured questions were used to explore experiences about clinical decision-making in COVID-19 care as well as facilitators and barriers for implementing CPMs. RESULTS: Twenty-eight-day mortality was considerably higher in the NYC first-wave data (19.8%) than the second-wave (9.6%) and Dutch data (first wave, 10.8%; second wave, 10.0%). The COPE mortality predictions discriminated well at temporal validation (area under the curve [AUC], 0.82), with excellent calibration (E statistic, 0.8%). At geographic validation restricted to the second wave, COPE mortality predictions had satisfactory discrimination (AUC, 0.77) but with moderate overprediction of mortality risk, particularly in higher-risk patients (E statistic, 2.9%). Although discrimination was adequate when NOCOS mortality predictions were evaluated against second-wave data in NYC (AUC, 0.76), NOCOS systematically overestimated the mortality risk (E statistic, 5.1%). Discrimination in the second-wave Dutch data was good (AUC, 0.81) but with overprediction of risk, particularly in lower-risk patients (E statistic, 4.0%). Recalibration of COPE and NOCOS led to negligible net benefit improvement in Dutch data but substantial net benefit improvement in NYC data. Predictions of the need for MV or ICU admission had a pattern of performance similar to mortality predictions, but models predicting outcomes among the subset of patients admitted to the ICU performed poorly. In the United States, we conducted 4 online focus groups with health care professionals (n = 9) and with people who had had COVID-19 and their surrogates (n = 12) between January 2021 and July 2021. In the Netherlands, we conducted 3 focus groups and 4 individual interviews with providers (n = 6) and with people who had had COVID-19 and their surrogates (n = 9) between May and July 2021. Clinicians expressed concern about data accuracy and validity as well as a belief that patients may interpret the data as absolutes rather than estimates. Health care professionals described CPMs as being useful for resource allocation, triaging, education, and research. Most people who had had COVID-19 and their surrogates were not given prognostic estimates but believed that this information would have supported and influenced their decision-making. CONCLUSIONS: The NOCOS performed moderately worse than the COPE on second-wave data, both at temporal and geographic validation, likely reflecting unique aspects of the early pandemic in NYC. Frequent updating of prognostic models is required to warrant transportability over time and space, particularly during a dynamic pandemic. Many health care professionals had reservations about using CPMs for people with COVID-19 because of concerns about data accuracy and patient-level data interpretation. Several people who had had COVID-19 and their surrogates, however, indicated that they would have found this information useful for decision-making. LIMITATIONS: The performance of these models, as measured in second-wave data, may not apply currently because the pandemic has continued to evolve. In particular, the widespread dissemination of vaccines may well affect clinical presentation, patient risk, and predictor effects. CI - Copyright (c) 2023. Tufts Medical Center. All Rights Reserved. FAU - Kent, David M AU - Kent DM AD - Predictive Analytics and Comparative Effectiveness Center, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, Massachusetts FAU - Zanos, Theodoros AU - Zanos T AD - Institute of Bioelectronic Medicine, Feinstein Institutes for Medical Research, Northwell Health, New York, New York FAU - Nelson, Jason AU - Nelson J AD - Predictive Analytics and Comparative Effectiveness Center, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, Massachusetts FAU - Levy, Todd AU - Levy T AD - Institute of Bioelectronic Medicine, Feinstein Institutes for Medical Research, Northwell Health, New York, New York FAU - Basile, Melissa AU - Basile M AD - Department of Medicine, Northwell Health, New York, New York FAU - Hajizadeh, Negin AU - Hajizadeh N AD - Department of Medicine, Northwell Health, New York, New York FAU - Lingsma, Hester AU - Lingsma H AD - Department of Public Health, Erasmus University Medical Center, Rotterdam, The Netherlands FAU - Park, Jinny G AU - Park JG AD - Predictive Analytics and Comparative Effectiveness Center, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, Massachusetts FAU - Helmrich, Isabel Retel AU - Helmrich IR AD - Department of Public Health, Erasmus University Medical Center, Rotterdam, The Netherlands FAU - Rietjens, Judith AU - Rietjens J AD - Department of Public Health, Erasmus University Medical Center, Rotterdam, The Netherlands FAU - van Klaveren, David AU - van Klaveren D AD - Predictive Analytics and Comparative Effectiveness Center, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, Massachusetts AD - Department of Public Health, Erasmus University Medical Center, Rotterdam, The Netherlands LA - eng PT - Review PT - Book PL - Washington (DC) EDAT- 2023/03/01 00:00 CRDT- 2023/03/01 00:00 AID - NBK592973 [bookaccession] AID - 10.25302/03.2023.ME.160635555-C19 [doi] PMID- 36807924 OWN - NLM STAT- MEDLINE DCOM- 20230811 LR - 20230811 IS - 1365-2648 (Electronic) IS - 0309-2402 (Linking) VI - 79 IP - 9 DP - 2023 Sep TI - Embedding nurse-led supportive care in an outpatient service for patients with Chronic Obstructive Pulmonary Disease. PG - 3274-3285 LID - 10.1111/jan.15605 [doi] AB - AIM: To describe a small multidisciplinary team's experience of the process of embedding nurse-led supportive care into an existing Chronic Obstructive Pulmonary Disease outpatient service. DESIGN: Case study methodology METHODS: Data were collected from multiple sources including key documents and semi-structured interviews with healthcare professionals (n = 6) conducted between June and July 2021. A purposive sampling strategy was used. Content analysis was applied to key documents. Interviews were transcribed verbatim and analysed using an inductive approach. RESULTS: Subcategories under the four-stage process were identified from the data. ASSESSMENT: evidence of needs of patients with Chronic Obstructive Pulmonary Disease; gaps in care and evidence of other models of supportive care. Planning: setting the supportive care service structure and intention; resources and funding; leadership, specialization and respiratory/palliative care roles. IMPLEMENTATION: relationships and trust; embedding supportive care and communication. EVALUATION: benefits and positive outcomes for staff and patients, and, improvements and future considerations for supportive care in the COPD service. CONCLUSION: A collaboration between respiratory and palliative care services resulted in successfully embedding nurse-led supportive care in a small outpatient service for patients with Chronic Obstructive Pulmonary Disease. Nurses are well placed to lead new models of care that aim to address unmet biopsychosocial-spiritual needs of patients. More research is needed to evaluate nurse-led supportive care in Chronic Obstructive Pulmonary Disease and other chronic illness settings; the effectiveness of nurse-led supportive care from the perspective of patients and caregivers and the impact of nurse-led supportive care on health service usage. PATIENT OR PUBLIC CONTRIBUTION: The development of the model of care is informed by ongoing discussions with patients with COPD and their caregivers. Data availability statement: Research data are not shared (due to ethical restrictions). IMPACT: Embedding nurse-led supportive care in an existing Chronic Obstructive Pulmonary Disease outpatient service is achievable. Nurses with clinical expertise can lead innovative models of care that address the unmet biopsychosocial-spiritual needs of patients with conditions such as Chronic Obstructive Pulmonary Disease. Nurse-led supportive care may have utility and relevance in other chronic disease contexts. CI - (c) 2023 John Wiley & Sons Ltd. FAU - Ora, Linda AU - Ora L AUID- ORCID: 0000-0002-6055-3470 AD - School of Nursing and Midwifery, Western Sydney University, Penrith, New South Wales, Australia. AD - Nepean Blue Mountains Local Health District, Penrith, New South Wales, Australia. FAU - Wilkes, Lesley AU - Wilkes L AUID- ORCID: 0000-0002-2986-4510 AD - School of Nursing and Midwifery, Western Sydney University, Penrith, New South Wales, Australia. FAU - Mannix, Judy AU - Mannix J AUID- ORCID: 0000-0002-5882-469X AD - School of Nursing and Midwifery, Western Sydney University, Penrith, New South Wales, Australia. FAU - Gregory, Linda AU - Gregory L AUID- ORCID: 0000-0001-5661-3357 AD - School of Nursing and Midwifery, Western Sydney University, Penrith, New South Wales, Australia. FAU - Luck, Lauretta AU - Luck L AUID- ORCID: 0000-0001-8446-1397 AD - School of Nursing and Midwifery, Western Sydney University, Penrith, New South Wales, Australia. LA - eng PT - Journal Article DEP - 20230221 PL - England TA - J Adv Nurs JT - Journal of advanced nursing JID - 7609811 SB - IM MH - Humans MH - *Nurse's Role MH - *Pulmonary Disease, Chronic Obstructive/therapy MH - Chronic Disease MH - Ambulatory Care MH - Caregivers OTO - NOTNLM OT - Chronic Obstructive Pulmonary Disease OT - model of care OT - nurse-led OT - palliative care OT - supportive care EDAT- 2023/02/23 06:00 MHDA- 2023/08/11 06:42 CRDT- 2023/02/22 12:19 PHST- 2023/01/13 00:00 [revised] PHST- 2021/11/13 00:00 [received] PHST- 2023/02/10 00:00 [accepted] PHST- 2023/08/11 06:42 [medline] PHST- 2023/02/23 06:00 [pubmed] PHST- 2023/02/22 12:19 [entrez] AID - 10.1111/jan.15605 [doi] PST - ppublish SO - J Adv Nurs. 2023 Sep;79(9):3274-3285. doi: 10.1111/jan.15605. Epub 2023 Feb 21. PMID- 36806221 OWN - NLM STAT- MEDLINE DCOM- 20230515 LR - 20230823 IS - 1537-4521 (Electronic) IS - 0148-5717 (Print) IS - 0148-5717 (Linking) VI - 50 IP - 6 DP - 2023 Jun 1 TI - Immediate and Ongoing Impact of COVID-19 on Chlamydia Treatment in Australia. PG - 363-369 LID - 10.1097/OLQ.0000000000001785 [doi] AB - BACKGROUND: The COVID-19 pandemic has impacted the sexual health and well-being of individuals, directly through risk of contracting COVID-19, and indirectly through government lockdowns. Government restrictions were especially strict and long-lasting in Australia, they also varied by state, offering an interesting opportunity to study the impacts of varying restrictions. This study compares the impact of the COVID-19 pandemic and resulting restrictions on chlamydia treatment prescriptions during 2020, through to July 2021 between different states and demographic groups in Australia. METHODS: The rate of prescriptions per 100,000 population filled each month from January 2017 to July 2021 from Australia's Pharmaceutical Benefits Scheme for Azithromycin with a restricted indication to treat Chlamydia trachomatis was used to measure chlamydia treatment. The impact of COVID-19 lockdowns was modeled using an interrupted time-series Poisson regression model. RESULTS: The data included 520,025 prescriptions to treat chlamydia, averaging 37.5 prescriptions per month per 100,000 population. Prescriptions declined 26% in April to May 2020 when initial COVID-19 lockdowns began in Australia; prescriptions increased in the following months but remained on average 21% below prepandemic (2017-2019) levels through to July 2021. Prescriptions declined the most in 1 Australian state, Victoria, both in the initial lockdown and the following period; generally, states with more COVID-19 cases saw bigger reductions in prescriptions. CONCLUSIONS: This is the first study to examine how treatment for chlamydia in Australia was impacted by the COVID-19 pandemic and restrictions not only in the immediate-term, but also ongoing up to July 2021, providing important information for planning for sexual health services in future pandemics. CI - Copyright (c) 2023 American Sexually Transmitted Diseases Association. All rights reserved. FAU - Engstrom, Teyl AU - Engstrom T AUID- ORCID: 0000-0002-1778-5006 AD - From the Centre for Health Services Research. FAU - Baliunas, Dolly AU - Baliunas D AUID- ORCID: 0000-0001-5685-0715 FAU - Smith, Angela AU - Smith A AD - Sexual Health and HIV Services, Metro North Hospital and Health Service, Queensland Health, Brisbane, QLD, Australia. FAU - Dean, Judith A AU - Dean JA AUID- ORCID: 0000-0002-2513-2013 AD - School of Public Health, Faculty of Medicine, The University of Queensland, Herston, QLD, Australia. FAU - Pole, Jason D AU - Pole JD AUID- ORCID: 0000-0002-0413-5434 LA - eng PT - Journal Article DEP - 20230220 PL - United States TA - Sex Transm Dis JT - Sexually transmitted diseases JID - 7705941 RN - 83905-01-5 (Azithromycin) SB - IM MH - Humans MH - *Pandemics MH - *COVID-19/epidemiology MH - Communicable Disease Control MH - Victoria MH - Azithromycin/therapeutic use PMC - PMC10184705 COIS- Conflict of Interest and Sources of Funding: None declared. EDAT- 2023/02/23 06:00 MHDA- 2023/05/15 06:42 PMCR- 2023/02/20 CRDT- 2023/02/22 10:29 PHST- 2023/05/15 06:42 [medline] PHST- 2023/02/23 06:00 [pubmed] PHST- 2023/02/22 10:29 [entrez] PHST- 2023/02/20 00:00 [pmc-release] AID - 00007435-202306000-00008 [pii] AID - STD_230446 [pii] AID - 10.1097/OLQ.0000000000001785 [doi] PST - ppublish SO - Sex Transm Dis. 2023 Jun 1;50(6):363-369. doi: 10.1097/OLQ.0000000000001785. Epub 2023 Feb 20. PMID- 36790805 OWN - NLM STAT- MEDLINE DCOM- 20230217 LR - 20260518 IS - 2574-3805 (Electronic) IS - 2574-3805 (Linking) VI - 6 IP - 2 DP - 2023 Feb 1 TI - Trends in Screen Time Use Among Children During the COVID-19 Pandemic, July 2019 Through August 2021. PG - e2256157 LID - 10.1001/jamanetworkopen.2022.56157 [doi] LID - e2256157 AB - IMPORTANCE: The COVID-19 pandemic led to widespread lockdowns and school closures that may have affected screen time among children. Although restrictions were strongest early in the pandemic, it is unclear how screen time changed as the pandemic progressed. OBJECTIVE: To evaluate change in children's screen time from before the pandemic to during the pandemic, from July 2019 through August 2021. DESIGN, SETTING, AND PARTICIPANTS: This is a longitudinal cohort study with repeated measures of screen time collected before the pandemic and during 2 pandemic periods. Children aged 4 to 12 years and their parent were enrolled in 3 pediatric cohorts across 3 states in the US participating in the Environmental Influences of Child Health Outcomes (ECHO) Program. Data analysis was performed from November 2021 to July 2022. EXPOSURES: COVID-19 pandemic period: prepandemic (July 2019 to March 2020), pandemic period 1 (December 2020 to April 2021), and pandemic period 2 (May 2021 to August 2021). MAIN OUTCOMES AND MEASURES: The primary outcomes were total, educational (not including remote school), and recreational screen time assessed via the ECHO Child Media Use questionnaire. Linear mixed-effects models were used for screen time adjusted for child's age, number of siblings, sex, race, ethnicity, and maternal education. RESULTS: The cohort included 228 children (prepandemic mean [SD] age, 7.0 [2.7] years; 100 female [43.9%]) with screen time measured during the prepandemic period and at least once during the pandemic period. Prepandemic mean (SD) total screen time was 4.4 (3.9) hours per day and increased 1.75 hours per day (95% CI, 1.18-2.31 hours per day) in the first pandemic period and 1.11 hours per day (95% CI, 0.49-1.72 hours per day) in the second pandemic period, in adjusted models. Prepandemic mean (SD) recreational screen time was 4.0 (3.5) hours per day and increased 0.89 hours per day (95% CI, 0.39-1.39 hours per day) in the first pandemic period and 0.70 hours per day (95% CI, 0.16-1.25 hours per day) in the second pandemic period. Prepandemic mean (SD) educational screen time was 0.5 (1.2) hours per day (median [IQR], 0.0 [0.0-0.4] hours per day) and increased 0.93 hours per day (95% CI, 0.67-1.19 hours per day) in the first pandemic period and 0.46 hours per day (95% CI, 0.18-0.74 hours per day) in the second pandemic period. CONCLUSIONS AND RELEVANCE: These findings suggest that screen time among children increased during the COVID-19 pandemic and remained elevated even after many public health precautions were lifted. The long-term association of increased screen time during the COVID-19 pandemic with children's health needs to be determined. FAU - Hedderson, Monique M AU - Hedderson MM AD - Kaiser Permanente Northern California Division of Research, Oakland. FAU - Bekelman, Traci A AU - Bekelman TA AD - Lifecourse Epidemiology of Adiposity and Diabetes (LEAD) Center, University of Colorado Anschutz Medical Campus, Aurora. FAU - Li, Mingyi AU - Li M AD - Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland. FAU - Knapp, Emily A AU - Knapp EA AD - Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland. FAU - Palmore, Meredith AU - Palmore M AD - Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland. FAU - Dong, Yanan AU - Dong Y AD - Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland. FAU - Elliott, Amy J AU - Elliott AJ AD - Avera Research Institute, Sioux Falls, South Dakota. AD - Department of Pediatrics, University of South Dakota School of Medicine, Sioux Falls. FAU - Friedman, Chloe AU - Friedman C AD - Lifecourse Epidemiology of Adiposity and Diabetes (LEAD) Center, University of Colorado Anschutz Medical Campus, Aurora. FAU - Galarce, Maren AU - Galarce M AD - Kaiser Permanente Northern California Division of Research, Oakland. FAU - Gilbert-Diamond, Diane AU - Gilbert-Diamond D AD - Department of Epidemiology, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire. AD - Department of Medicine, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire. AD - Department of Pediatrics, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire. FAU - Glueck, Deborah AU - Glueck D AD - Department of Pediatrics, University of Colorado School of Medicine, Aurora. FAU - Hockett, Christine W AU - Hockett CW AD - Avera Research Institute, Sioux Falls, South Dakota. AD - Department of Pediatrics, University of South Dakota School of Medicine, Sioux Falls. FAU - Lucchini, Maristella AU - Lucchini M AD - Department of Psychiatry, Columbia University Irving Medical Center, New York, New York. FAU - McDonald, Julia AU - McDonald J AD - Kaiser Permanente Northern California Division of Research, Oakland. FAU - Sauder, Katherine AU - Sauder K AD - Lifecourse Epidemiology of Adiposity and Diabetes (LEAD) Center, University of Colorado Anschutz Medical Campus, Aurora. FAU - Zhu, Yeyi AU - Zhu Y AD - Kaiser Permanente Northern California Division of Research, Oakland. FAU - Karagas, Margaret R AU - Karagas MR AD - Department of Epidemiology, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire. FAU - Dabelea, Dana AU - Dabelea D AD - Lifecourse Epidemiology of Adiposity and Diabetes (LEAD) Center, University of Colorado Anschutz Medical Campus, Aurora. FAU - Ferrara, Assiamira AU - Ferrara A AD - Kaiser Permanente Northern California Division of Research, Oakland. CN - Environmental Influences on Child Health Outcomes Program LA - eng GR - UH3 OD023248/OD/NIH HHS/United States GR - U24 OD023382/OD/NIH HHS/United States GR - UH3 OD023275/OD/NIH HHS/United States GR - UG3 OD023320/OD/NIH HHS/United States GR - UG3 OD023275/OD/NIH HHS/United States GR - UG3 OD023289/OD/NIH HHS/United States GR - UH3 OD023279/OD/NIH HHS/United States GR - U2C OD023375/OD/NIH HHS/United States GR - UH3 OD023320/OD/NIH HHS/United States GR - UH3 OD023289/OD/NIH HHS/United States GR - U24 OD023319/OD/NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural DEP - 20230201 PL - United States TA - JAMA Netw Open JT - JAMA network open JID - 101729235 SB - IM MH - Humans MH - Child MH - Female MH - *COVID-19/epidemiology MH - Communicable Disease Control MH - Longitudinal Studies MH - Pandemics MH - Screen Time PMC - PMC9932850 COIS- Conflict of Interest Disclosures: None reported. FIR - Smith, Brian P IR - Smith BP FIR - Newby, Kristen L IR - Newby KL FIR - Jacobson, Lisa P IR - Jacobson LP FIR - Parker, Corette B IR - Parker CB FIR - Gershon, Richard C IR - Gershon RC FIR - Cella, David IR - Cella D FIR - Alshawabkeh, Akram N IR - Alshawabkeh AN FIR - Aschner, Judy L IR - Aschner JL FIR - Merhar, Stephanie L IR - Merhar SL FIR - Pryhuber, Gloria S IR - Pryhuber GS FIR - Moore, Paul E IR - Moore PE FIR - Lampland, Andrea L IR - Lampland AL FIR - Wadhawan, Rajan IR - Wadhawan R FIR - Wagner, Carol L IR - Wagner CL FIR - Hudak, Mark L IR - Hudak ML FIR - Mayock, Dennis E IR - Mayock DE FIR - Washburn, Lisa K IR - Washburn LK FIR - Croen, Lisa A IR - Croen LA FIR - Karr, Caherine J IR - Karr CJ FIR - Mason, Alex IR - Mason A FIR - Lester, Barry M IR - Lester BM FIR - Carter, Brian S IR - Carter BS FIR - Marsit, Carmen J IR - Marsit CJ FIR - Pastyrnak, Steven L IR - Pastyrnak SL FIR - Neal, Charles IR - Neal C FIR - Smith, Lynne M IR - Smith LM FIR - Helderman, Jennifer B IR - Helderman JB FIR - McEvoy, Cindy IR - McEvoy C FIR - Tepper, Robert S IR - Tepper RS FIR - Kerver, Jean IR - Kerver J FIR - Barone, Charles IR - Barone C FIR - McKane, Patricia IR - McKane P FIR - Paneth, Nigel IR - Paneth N FIR - Elliott, Michael R IR - Elliott MR FIR - Trasande, Leonardo IR - Trasande L FIR - Sathyanarayana, Sheela IR - Sathyanarayana S FIR - Bush, Nicole IR - Bush N FIR - Nguyen, Ruby Hn IR - Nguyen RH FIR - Barrett, Emily S IR - Barrett ES EDAT- 2023/02/16 06:00 MHDA- 2023/02/18 06:00 PMCR- 2023/02/15 CRDT- 2023/02/15 11:34 PHST- 2023/02/15 11:34 [entrez] PHST- 2023/02/16 06:00 [pubmed] PHST- 2023/02/18 06:00 [medline] PHST- 2023/02/15 00:00 [pmc-release] AID - 2801457 [pii] AID - zoi221600 [pii] AID - 10.1001/jamanetworkopen.2022.56157 [doi] PST - epublish SO - JAMA Netw Open. 2023 Feb 1;6(2):e2256157. doi: 10.1001/jamanetworkopen.2022.56157. PMID- 36789381 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230221 IS - 2059-1381 (Electronic) IS - 2059-1381 (Linking) VI - 9 IP - 1 DP - 2023 TI - Changes in body composition of patients undergoing hemodialysis during the coronavirus disease 2019 pandemic: a retrospective longitudinal study. PG - 12 LID - 10.1186/s41100-023-00465-4 [doi] LID - 12 AB - BACKGROUND: The spread of coronavirus disease 2019 (COVID-19) has dramatically altered the lifestyles of many people worldwide. Several studies reported that body weight of young adults increased during the COVID-19 pandemic; however, weight loss has been observed in the elderly population. Therefore, trends in body composition due to the COVID-19 pandemic may vary depending on the characteristics of the population. This study aimed to investigate the changes in body mass index (BMI), muscle mass, and fat mass before and during the COVID-19 pandemic among patients undergoing hemodialysis. METHODS: In this retrospective longitudinal study, we enrolled 115 clinically stable outpatients (mean age: 65.7 +/- 11.2 years, 62.6% men) who underwent hemodialysis thrice a week. Baseline data were collected between April 2019 and March 2020, before the declaration of the COVID-19 emergency by the Japanese government. The follow-up measurements were performed between July 2020 and March 2021 during the COVID-19 pandemic. Patient characteristics, laboratory data, and BMI measurements were collected from the medical records. Muscle mass and fat mass were measured using bioelectrical impedance analysis. RESULTS: BMI and fat mass among the study participants were significantly higher during the COVID-19 pandemic than before the pandemic (p < 0.01), but no significant change in muscle mass was observed. A restricted cubic spline function showed that the increase in BMI appeared to correlate well with fat mass, but not with muscle mass. CONCLUSIONS: BMI and fat mass of patients on hemodialysis significantly increased due to preventive measures against the COVID-19 pandemic in Japan. These findings may provide useful information in making nutritional management decisions for patients undergoing hemodialysis during and after the COVID-19 pandemic. CI - (c) The Author(s) 2023. FAU - Fukuzaki, Narumi AU - Fukuzaki N AD - Department of Rehabilitation Sciences, Graduate School of Medical Sciences, Kitasato University, Sagamihara, Kanagawa Japan. GRID: grid.410786.c. ISNI: 0000 0000 9206 2938 FAU - Suzuki, Yuta AU - Suzuki Y AD - Center for Outcomes Research and Economic Evaluation for Health, National Institute of Public Health, Wako, Saitama Japan. GRID: grid.415776.6. ISNI: 0000 0001 2037 6433 FAU - Uchida, Juri AU - Uchida J AD - Department of Rehabilitation Sciences, Graduate School of Medical Sciences, Kitasato University, Sagamihara, Kanagawa Japan. GRID: grid.410786.c. ISNI: 0000 0000 9206 2938 FAU - Nakajima, Takuya AU - Nakajima T AD - Department of Rehabilitation Sciences, Graduate School of Medical Sciences, Kitasato University, Sagamihara, Kanagawa Japan. GRID: grid.410786.c. ISNI: 0000 0000 9206 2938 FAU - Yamamoto, Shohei AU - Yamamoto S AD - Department of Epidemiology and Prevention, Center for Clinical Sciences, National Center for Global Health and Medicine, Shinjuku, Tokyo Japan. GRID: grid.45203.30. ISNI: 0000 0004 0489 0290 FAU - Imamura, Keigo AU - Imamura K AD - Department of Rehabilitation Sciences, Graduate School of Medical Sciences, Kitasato University, Sagamihara, Kanagawa Japan. GRID: grid.410786.c. ISNI: 0000 0000 9206 2938 AD - Tokyo Metropolitan Institute of Gerontology, Itabashi, Tokyo Japan. GRID: grid.420122.7. ISNI: 0000 0000 9337 2516 FAU - Yoshikoshi, Shun AU - Yoshikoshi S AD - Department of Rehabilitation Sciences, Graduate School of Medical Sciences, Kitasato University, Sagamihara, Kanagawa Japan. GRID: grid.410786.c. ISNI: 0000 0000 9206 2938 AD - Department of Rehabilitation, Sagami Circulatory Organ Clinic, Sagamihara, Kanagawa Japan. FAU - Harada, Manae AU - Harada M AD - Department of Rehabilitation, Sagami Circulatory Organ Clinic, Sagamihara, Kanagawa Japan. FAU - Matsuzawa, Ryota AU - Matsuzawa R AD - Department of Physical Therapy, School of Rehabilitation, Hyogo Medical University, Kobe, Hyogo Japan. GRID: grid.272264.7. ISNI: 0000 0000 9142 153X FAU - Kamiya, Kentaro AU - Kamiya K AD - Department of Rehabilitation Sciences, Graduate School of Medical Sciences, Kitasato University, Sagamihara, Kanagawa Japan. GRID: grid.410786.c. ISNI: 0000 0000 9206 2938 FAU - Matsunaga, Atsuhiko AU - Matsunaga A AUID- ORCID: 0000-0003-0190-707X AD - Department of Rehabilitation Sciences, Graduate School of Medical Sciences, Kitasato University, Sagamihara, Kanagawa Japan. GRID: grid.410786.c. ISNI: 0000 0000 9206 2938 LA - eng PT - Journal Article DEP - 20230210 PL - England TA - Ren Replace Ther JT - Renal replacement therapy JID - 101698599 PMC - PMC9912208 OTO - NOTNLM OT - Body weight OT - COVID-19 OT - Fat mass OT - Hemodialysis OT - Muscle mass COIS- Competing interestsThe authors declare that they have no competing interests. EDAT- 2023/02/16 06:00 MHDA- 2023/02/16 06:01 PMCR- 2023/02/10 CRDT- 2023/02/15 02:12 PHST- 2022/02/18 00:00 [received] PHST- 2023/01/30 00:00 [accepted] PHST- 2023/02/15 02:12 [entrez] PHST- 2023/02/16 06:00 [pubmed] PHST- 2023/02/16 06:01 [medline] PHST- 2023/02/10 00:00 [pmc-release] AID - 465 [pii] AID - 10.1186/s41100-023-00465-4 [doi] PST - ppublish SO - Ren Replace Ther. 2023;9(1):12. doi: 10.1186/s41100-023-00465-4. Epub 2023 Feb 10. PMID- 36767117 OWN - NLM STAT- MEDLINE DCOM- 20230214 LR - 20240912 IS - 1660-4601 (Electronic) IS - 1661-7827 (Print) IS - 1660-4601 (Linking) VI - 20 IP - 3 DP - 2023 Jan 18 TI - Encouraging and Reinforcing Safe Breastfeeding Practices during the COVID-19 Pandemic. LID - 10.3390/ijerph20031756 [doi] LID - 1756 AB - AIM: Promote safe breastfeeding during the pandemic. METHODS: All participants were encouraged to request safe breastfeeding education from their prenatal provider. Pregnant mothers received appropriate breastfeeding and COVID-19 safe breastfeeding education in line with the CDC's COVID-19 breastfeeding guidelines. Data were obtained from 39 mothers attending Nashville General Hospital pediatric well-baby clinics (Group I: from December 2019 to June 2020) and 97 pregnant women attending prenatal clinics (Group II: from July 2020 to August 2021). RESULTS: The participants' ages ranged from 15 to 45 years, with a mean of 27.5 +/- 6.2. The women in both groups were similar in age, education, employment, and breastfeeding experience. They were equally unlikely to use face masks at home even while receiving guests or holding their babies. Although 121 (89.0%) women claimed face mask use while shopping, the rate for never doing so was 7 (18.0%) vs. 8 (8.3%) (p < 0.006) for Groups I and II, respectively. Safe practices included limited outing (66 (48.5%)), sanitized hands (62 (45.6%)), restricted visitors (44 (32.4%)), and limited baby outing (27 (19.9%)), and 8 (8.3%) in Group II received COVID-19 vaccinations. About half described fair and accurate COVID-19 safe breastfeeding knowledge, but 22 (30.1%) of them claimed they received no information. Breastfeeding contraindication awareness for Groups I and II were as follows: cocaine = 53.8% vs. 37.1%, p < 0.06; HIV = 35.9% vs. 12.4%, p < 0.002; breast cancer = 17.9% vs. 16.5%; and COVID-19 with symptoms = 28.2% vs. 5.2%, p < 0.001. The information source was similar, with family, friends, and media accounting for 77 (56.6%) of women while doctors, nurses, and the CLC was the source for 21 (15.4%) women. Exclusive breastfeeding one month postpartum for Groups I and II was 41.9% and 12.8% (p < 0.006), respectively. CONCLUSION: The mothers were not more knowledgeable regarding breastfeeding safely one year into the COVID-19 pandemic. Conflicting lay information can create healthy behavior ambivalence, which can be prevented by health professionals confidently advising mothers to wear face masks when breastfeeding, restricting visitors and outings, and accepting COVID-19 vaccination. This pandemic remains an open opportunity to promote and encourage breastfeeding to every mother as the default newborn feeding method. FAU - Ukoli, Flora AU - Ukoli F AD - Department of Surgery, Meharry Medical College, Nashville, TN 37208, USA. FAU - Leavell, Jacinta AU - Leavell J AD - Department of Dental Public Health, School of Dentistry, Meharry Medical College, Nashville, TN 37208, USA. FAU - Mayo, Amasyah AU - Mayo A AD - Meharry Medical College, Nashville, TN 37208, USA. FAU - Moore, Jayla AU - Moore J AD - Meharry Medical College, Nashville, TN 37208, USA. FAU - Nchami, Nia AU - Nchami N AD - Meharry Medical College, Nashville, TN 37208, USA. FAU - Britt, Allysceaeioun AU - Britt A AD - Division of Public Health Practice, School of Graduate Studies and Research, Meharry Medical College, Nashville, TN 37208, USA. LA - eng GR - U54 MD007586/MD/NIMHD NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural DEP - 20230118 PL - Switzerland TA - Int J Environ Res Public Health JT - International journal of environmental research and public health JID - 101238455 RN - 0 (COVID-19 Vaccines) SB - IM MH - Infant MH - Infant, Newborn MH - Child MH - Female MH - Humans MH - Pregnancy MH - Adolescent MH - Young Adult MH - Adult MH - Middle Aged MH - Male MH - *Breast Feeding MH - Pandemics MH - COVID-19 Vaccines MH - *COVID-19/epidemiology/prevention & control MH - Mothers PMC - PMC9914864 OTO - NOTNLM OT - African American OT - COVID-19 OT - breastfeeding OT - breastfeeding guidelines COIS- There are no conflicts of interest to declare for any of the authors. EDAT- 2023/02/12 06:00 MHDA- 2023/02/15 06:00 PMCR- 2023/01/18 CRDT- 2023/02/11 01:11 PHST- 2022/10/26 00:00 [received] PHST- 2022/12/29 00:00 [revised] PHST- 2023/01/03 00:00 [accepted] PHST- 2023/02/11 01:11 [entrez] PHST- 2023/02/12 06:00 [pubmed] PHST- 2023/02/15 06:00 [medline] PHST- 2023/01/18 00:00 [pmc-release] AID - ijerph20031756 [pii] AID - ijerph-20-01756 [pii] AID - 10.3390/ijerph20031756 [doi] PST - epublish SO - Int J Environ Res Public Health. 2023 Jan 18;20(3):1756. doi: 10.3390/ijerph20031756. PMID- 36734116 OWN - NLM STAT- MEDLINE DCOM- 20230217 LR - 20230228 IS - 1469-4409 (Electronic) IS - 0950-2688 (Print) IS - 0950-2688 (Linking) VI - 151 DP - 2023 Feb 3 TI - A SARS-CoV-2 outbreak associated with five air force bases and a nightclub following the lifting of COVID-19-related social restrictions, United Kingdom, July-to-September 2021. PG - e26 LID - 10.1017/S0950268823000134 [doi] LID - e26 AB - We describe the management of two linked severe acute respiratory coronavirus 2 (SARS-CoV-2) outbreaks, predominantly amongst 18-35-year-olds, in a UK county in July-to-September 2021, following the lifting of national coronavirus disease 2019 (COVID-19)-associated social restrictions. One was associated with a nightclub and one with five air force bases. On week beginning 2nd August 2021, air force contact tracing teams detected 68 cases across five bases within one county; 21 (30.9%) were associated with a night-time economy venue, 13 (19.1%) with night-time economy venues in the county's main town and at least one case per base (n = 6, 8.8%) with a particular nightclub in this town, which itself had been associated with 302 cases in the previous week (coinciding with its reopening following a national lockdown). In response, Public Health England/United Kingdom Health Security Agency, air force and local authority teams collaboratively implemented communication strategies and enhanced access to SARS-CoV-2 testing and vaccination. Key challenges included attempting to encourage behaviours that reduce likelihood of transmission to a population who may have considered themselves at low risk from severe COVID-19. This report may inform future preparation for, and management of, easing of potential future pandemic-related social restrictions, and how an outbreak in this context may be addressed. FAU - Taylor, Michael James AU - Taylor MJ AUID- ORCID: 0000-0002-2755-7314 AD - Health Protection Team, UK Health Security Agency East Midlands, Nottingham, UK. FAU - Kumbang, Jharna AU - Kumbang J AD - Health Protection Team, UK Health Security Agency East Midlands, Nottingham, UK. FAU - Bamford, Kate AU - Bamford K AD - Health Protection Team, UK Health Security Agency East Midlands, Nottingham, UK. FAU - Mohammed Jazuli Ismail, Hanouf AU - Mohammed Jazuli Ismail H AD - Health Protection Team, UK Health Security Agency East Midlands, Nottingham, UK. FAU - Huntley, Phil AU - Huntley P AD - Lincolnshire County Council, Lincoln, UK. FAU - Liddle, Natalie AU - Liddle N AD - Lincolnshire County Council, Lincoln, UK. FAU - Errington, Jim AU - Errington J AD - Royal Air Force, Sleaford, UK. FAU - Mair-Jenkins, John AU - Mair-Jenkins J AUID- ORCID: 0000-0003-1957-519X AD - Field Service Midlands, UK Health Security Agency, Nottingham, UK. LA - eng PT - Journal Article DEP - 20230203 PL - England TA - Epidemiol Infect JT - Epidemiology and infection JID - 8703737 SB - IM MH - Humans MH - *COVID-19/epidemiology MH - SARS-CoV-2 MH - COVID-19 Testing MH - Communicable Disease Control MH - Disease Outbreaks MH - United Kingdom/epidemiology PMC - PMC9947034 OTO - NOTNLM OT - COVID-19 OT - SARS-CoV-2 OT - outbreak management OT - outbreaks OT - prevention EDAT- 2023/02/04 06:00 MHDA- 2023/02/18 06:00 PMCR- 2023/02/03 CRDT- 2023/02/03 03:34 PHST- 2023/02/04 06:00 [pubmed] PHST- 2023/02/18 06:00 [medline] PHST- 2023/02/03 03:34 [entrez] PHST- 2023/02/03 00:00 [pmc-release] AID - S0950268823000134 [pii] AID - 10.1017/S0950268823000134 [doi] PST - epublish SO - Epidemiol Infect. 2023 Feb 3;151:e26. doi: 10.1017/S0950268823000134. PMID- 38603251 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240413 IS - 0265-4075 (Print) IS - 1460-3608 (Electronic) IS - 0265-4075 (Linking) VI - 40 IP - 1 DP - 2023 Feb TI - Impact of the COVID-19 Pandemic on Canadian Social Connections: A Thematic Analysis. PG - 76-101 LID - 10.1177/02654075221113365 [doi] AB - BACKGROUND: On March 11, 2020, the World Health Organization declared COVID-19 a worldwide pandemic. Responses to the pandemic response disrupted Canadian social connections in complex ways; because social connections are determinants of health and well-being, their disruption could adversely affect health and well-being. Moreover, understanding how pandemics and public health responses affect social connections could inform pandemic recovery strategy and public health approaches designed for future pandemics. The purpose of this study is to understand experiences of pandemic impact on social connections over the pandemic. METHODS: A sample of 343 Canadian adults was recruited through Athabasca University and social media. Participants were predominantly White (81%) and female (88%). After the pandemic onset, participants responded to open-ended questions about the impact of the pandemic on and any changes to social connections at three time points (baseline, and three- and 6 months from study entry). Responses were categorized into epochs by date (April-June 2020 [Spring]; July-August 2020 [Summer]; September 2020-January 2021 [Fall/Winter]). Qualitative thematic analysis was used to code themes for each epoch. RESULTS: Negative impact of the pandemic (37-45%), loss of social connections (32-36%), and alternative means of connection (26-32%) were prominent themes across the epochs. Restrictions to face-to-face connections were largest in spring (9%) and lowest in the Summer (4%). Conversely, participants increasingly reported limited contact or communication into the Fall and Winter (6-12%) as pandemic restrictions in Canada were reinstated. CONCLUSIONS: The COVID-19 pandemic threatens social connections, with negative impacts that fluctuated with COVID-19 case rates and subsequent pandemic restrictions. These findings could be used to identify targets for social supports during the pandemic recovery, and to adjust public health strategies for future pandemics that minimize impact on social connections. CI - (c) The Author(s) 2022. FAU - Lowe, Catherine AU - Lowe C AUID- ORCID: 0000-0003-1278-3906 AD - Athabasca University, Athabasca, AL, CA. RINGGOLD: 1349 AD - University of Calgary, Calgary, AL, CA. RINGGOLD: 2129 FAU - Rafiq, Maliha AU - Rafiq M AD - University of Calgary, Calgary, AL, CA. RINGGOLD: 2129 FAU - MacKay, Lyndsay Jerusha AU - MacKay LJ AD - University of Calgary, Calgary, AL, CA. RINGGOLD: 2129 FAU - Letourneau, Nicole AU - Letourneau N AUID- ORCID: 0000-0002-7468-915X AD - University of Calgary, Calgary, AL, CA. RINGGOLD: 2129 FAU - Ng, Cheuk Fan AU - Ng CF AUID- ORCID: 0000-0003-2043-575X AD - Athabasca University, Athabasca, AL, CA. RINGGOLD: 1349 FAU - Keown-Gerrard, Janine AU - Keown-Gerrard J AUID- ORCID: 0000-0001-6162-224X AD - Athabasca University, Athabasca, AL, CA. RINGGOLD: 1349 FAU - Gilbert, Trevor AU - Gilbert T AD - Athabasca University, Athabasca, AL, CA. RINGGOLD: 1349 FAU - Ross, Kharah M AU - Ross KM AD - Athabasca University, Athabasca, AL, CA. RINGGOLD: 1349 AD - University of Calgary, Calgary, AL, CA. RINGGOLD: 2129 LA - eng PT - Journal Article PL - England TA - J Soc Pers Relat JT - Journal of social and personal relationships JID - 8409448 PMC - PMC9272044 OTO - NOTNLM OT - COVID-19 OT - health psychology OT - pandemic impact OT - public health OT - social connection OT - thematic analysis COIS- The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. EDAT- 2023/02/01 00:00 MHDA- 2023/02/01 00:01 PMCR- 2023/02/01 CRDT- 2024/04/11 14:00 PHST- 2023/02/01 00:01 [medline] PHST- 2023/02/01 00:00 [pubmed] PHST- 2024/04/11 14:00 [entrez] PHST- 2023/02/01 00:00 [pmc-release] AID - 10.1177_02654075221113365 [pii] AID - 10.1177/02654075221113365 [doi] PST - ppublish SO - J Soc Pers Relat. 2023 Feb;40(1):76-101. doi: 10.1177/02654075221113365. PMID- 36703528 OWN - NLM STAT- MEDLINE DCOM- 20230509 LR - 20250319 IS - 1552-6518 (Electronic) IS - 0886-2605 (Print) IS - 0886-2605 (Linking) VI - 38 IP - 11-12 DP - 2023 Jun TI - Intimate Partner Violence During COVID-19 Restrictions: A Study of 30 Countries From the I-SHARE Consortium. PG - 7115-7142 LID - 10.1177/08862605221141865 [doi] AB - Intimate partner violence (IPV) causes substantial physical and psychological trauma. Restrictions introduced in response to the COVID-19 pandemic, including lockdowns and movement restrictions, may exacerbate IPV risk and reduce access to IPV support services. This cross-sectional study examines IPV during COVID-19 restrictions in 30 countries from the International Sexual HeAlth and REproductive Health (I-SHARE) study conducted from July 20th, 2020, to February, 15th, 2021. IPV was a primary outcome measure adapted from a World Health Organization multicountry survey. Mixed-effects modeling was used to determine IPV correlates among participants stratified by cohabitation status. The sample included 23,067 participants from 30 countries. A total of 1,070/15,336 (7.0%) participants stated that they experienced IPV during COVID-19 restrictions. A total of 1,486/15,336 (9.2%) participants stated that they had experienced either physical or sexual partner violence before the restrictions, which then decreased to 1,070 (7.0%) after the restrictions. In general, identifying as a sexual minority and experiencing greater economic vulnerability were associated with higher odds of experiencing IPV during COVID-19 restrictions, which were accentuated among participants who were living with their partners. Greater stringency of COVID-19 restrictions and living in urban or semi-urban areas were associated with lower odds of experiencing IPV in some settings. The I-SHARE data suggest a substantial burden of IPV during COVID-19 restrictions. However, the restrictions were correlated with reduced IPV in some settings. There is a need for investing in specific support systems for survivors of IPV during the implementation of restrictions designed to contain infectious disease outbreaks. FAU - Campbell, Linda AU - Campbell L AD - Center for Population, Family, and Health, University of Antwerp, Belgium. AD - Department of Public Health and Primary Care, Faculty of Medicine and Health Sciences, University of Ghent, Belgium. FAU - Tan, Rayner K J AU - Tan RKJ AUID- ORCID: 0000-0002-9188-3368 AD - Dermatology Hospital of Southern Medical University, Guangzhou, China. AD - University of North Carolina Project, Guangzhou, China. AD - Saw Swee Hock School of Public Health, National University of Singapore, Singapore. FAU - Uhlich, Maximiliane AU - Uhlich M AD - Department of Psychology, University of Basel, Switzerland. FAU - Francis, Joel M AU - Francis JM AUID- ORCID: 0000-0003-1902-2683 AD - Department of Family Medicine and Primary Care, School of Clinical Medicine, University of Witwatersrand, Johannesburg, South Africa. FAU - Mark, Kristen AU - Mark K AD - Institute for Sexual and Gender Health, University of Minnesota Medical School, Minneapolis, MN, USA. FAU - Miall, Naomi AU - Miall N AUID- ORCID: 0000-0002-7212-6273 AD - Clinical Research Department, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, UK. FAU - Eleuteri, Stefano AU - Eleuteri S AD - Faculty of Medicine and Psychology, Sapienza University of Rome, Rome, Italy. FAU - Gabster, Amanda AU - Gabster A AD - Department of Genomics and Proteomics, Gorgas Memorial Institute for Health Studies, Panama City, Panama. AD - National Research System, National Secretariat of Science, Technology and Innovation, Panama City, Panama. AD - Center of Population Sciences for Health Equity, Florida State University, Tallahassee, FL, USA. FAU - Shamu, Simukai AU - Shamu S AD - Health Systems Strengthening Division, Foundation for Professional Development, Pretoria, South Africa. AD - School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. FAU - Plasilova, Leona AU - Plasilova L AD - Department of Psychology and Life Sciences, Faculty of Humanities, Charles University, Prague, Czech Republic. AD - Laboratory of Evolutionary Sexology and Psychopathology, National Institute of Mental Health, Klecany, Czech Republic. FAU - Kemigisha, Elizabeth AU - Kemigisha E AD - Mbarara University of Science and Technology, Mbarara, Uganda. FAU - Olumide, Adesola AU - Olumide A AD - Institute of Child Health, College of Medicine, University of Ibadan and University College Hospital, Ibadan, Nigeria. FAU - Kosana, Priya AU - Kosana P AD - Institute of Global Health and Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. FAU - Hurtado-Murillo, Felipe AU - Hurtado-Murillo F AD - Center for Sexual and Reproductive Health, University Hospital Doctor Peset, Valencia, Spain. FAU - Larsson, Elin C AU - Larsson EC AD - Karolinska Institutet, Department of Global Health and Department of Women's and Children's Health, Stockholm, Sweden. FAU - Cleeve, Amanda AU - Cleeve A AD - Karolinska Institutet, Department of Global Health and Department of Women's and Children's Health, Stockholm, Sweden. AD - South General Hospital, Stockholm, Sweden. FAU - Calvo Gonzalez, Soraya AU - Calvo Gonzalez S AD - Department of Education Sciences, University of Oviedo, Oviedo, Spain. FAU - Perrotta, Gabriela AU - Perrotta G AUID- ORCID: 0000-0003-2472-1518 AD - Faculty of Psychology, University of Buenos Aires, Buenos Aires, Argentina. FAU - Fernandez Albamonte, Victoria AU - Fernandez Albamonte V AD - Faculty of Psychology, University of Buenos Aires, Buenos Aires, Argentina. FAU - Blanco, Lucia AU - Blanco L AD - Faculty of Psychology, University of Buenos Aires, Buenos Aires, Argentina. FAU - Schroder, Johanna AU - Schroder J AD - Institute for Sex Research, Sexual Medicine and Forensic Psychiatry, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Adebayo, Adedamola AU - Adebayo A AD - Institute of Child Health, University of Ibadan, Ibadan, Nigeria. FAU - Hendriks, Jacqueline AU - Hendriks J AD - Collaboration for Evidence, Research and Impact in Public Health, School of Population Health, Curtin University, Perth, Australia. FAU - Saltis, Hanna AU - Saltis H AD - Collaboration for Evidence, Research and Impact in Public Health, School of Population Health, Curtin University, Perth, Australia. FAU - Marks, Michael AU - Marks M AD - Clinical Research Department, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, UK. AD - Hospital for Tropical Diseases, University College London Hospital, London, UK. AD - Division of Infection and Immunity, University College London, London, UK. FAU - Wu, Dan AU - Wu D AUID- ORCID: 0000-0003-0415-5467 AD - Clinical Research Department, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, UK. FAU - Morroni, Chelsea AU - Morroni C AD - Centre for Reproductive Health, University of Edinburgh, Edinburgh, UK. AD - Botswana Sexual and Reproductive Health Initiative, Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana. FAU - Esho, Tammary AU - Esho T AD - Amref International University, Nairobi, Kenya. FAU - Briken, Peer AU - Briken P AD - Institute for Sex Research, Sexual Medicine and Forensic Psychiatry, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Hlatshwako, Takhona Grace AU - Hlatshwako TG AD - Institute of Global Health and Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. FAU - Ryan, Rebecca AU - Ryan R AD - Botswana Sexual and Reproductive Health Initiative, Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana. FAU - Farid, Nik Daliana Nik AU - Farid NDN AD - Department of Social and Preventive Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia. FAU - Gomez Bravo, Raquel AU - Gomez Bravo R AD - Institute for Health and Behaviour, Department of Behavioural and Cognitive Sciences, University of Luxembourg, Esch-sur-Alzette, Luxembourg. FAU - Van de Velde, Sarah AU - Van de Velde S AD - Center for Population, Family, and Health, University of Antwerp, Belgium. FAU - Tucker, Joseph D AU - Tucker JD AD - Clinical Research Department, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, UK. AD - Institute of Global Health and Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. CN - the ISHARE research consortium LA - eng GR - K24 AI143471/AI/NIAID NIH HHS/United States GR - UH3 HD096929/HD/NICHD NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural DEP - 20230126 PL - United States TA - J Interpers Violence JT - Journal of interpersonal violence JID - 8700910 SB - IM MH - Humans MH - *Sexual Health MH - Cross-Sectional Studies MH - Pandemics MH - Reproductive Health MH - *COVID-19/epidemiology/prevention & control MH - Communicable Disease Control MH - *Intimate Partner Violence/psychology MH - Sexual Partners/psychology MH - Risk Factors PMC - PMC9895276 OTO - NOTNLM OT - COVID-19 OT - IPV OT - Lockdown OT - global OT - physical violence OT - sexual assault OT - sexual coercion OT - sexual violence OT - social science COIS- The author(s) declared no potential conflicts of interest with respect to the authorship and/or publication of this article. EDAT- 2023/01/28 06:00 MHDA- 2023/05/09 10:16 PMCR- 2023/01/26 CRDT- 2023/01/27 01:24 PHST- 2023/05/09 10:16 [medline] PHST- 2023/01/28 06:00 [pubmed] PHST- 2023/01/27 01:24 [entrez] PHST- 2023/01/26 00:00 [pmc-release] AID - 10.1177_08862605221141865 [pii] AID - 10.1177/08862605221141865 [doi] PST - ppublish SO - J Interpers Violence. 2023 Jun;38(11-12):7115-7142. doi: 10.1177/08862605221141865. Epub 2023 Jan 26. PMID- 36701251 OWN - NLM STAT- MEDLINE DCOM- 20230710 LR - 20231119 IS - 1526-7598 (Electronic) IS - 0003-2999 (Linking) VI - 137 IP - 1 DP - 2023 Jul 1 TI - Evaluation of Anemia and Iron Deficiency in French Surgical Departments: The National Multicenter Observational PERIOPES Study. PG - 182-190 LID - 10.1213/ANE.0000000000006362 [doi] AB - BACKGROUND: Assessment of anemia and iron deficiency before surgery is pivotal for patient blood management (PBM), but few data on current practices are available in the French context. The objective of this study was to describe anemia and iron deficiency management and blood transfusion use in surgical departments in France. METHODS: This was a national multicenter cross-sectional study in 13 public hospitals and 3 private ones (all with an interest for PBM). Data of consecutive surgical patients from different specialties were retrieved from their chart between July 30, 2019, and December 31, 2021. Data included hemoglobin, iron workup, treatment with oral/intravenous iron or erythropoiesis-stimulating agent, and transfusions. RESULTS: Data from 2345 patients (median age, 68 years; women, 50.9%; American Society of Anesthesiologists [ASA] physical status III-IV, 35.4%) were obtained. Only 5 centers had a formalized PBM program. At preoperative anesthesia visit, hemoglobin (Hb) level was assessed in 2112 (90.1%) patients and anemia diagnosed in 722 of them (34.2%). Complete iron workup was performed in 715 (30.5%) of the 2345 patients. Iron deficiency anemia was present in 219 (30.3%) of the 722 anemic patients. Among patients with anemia, only 217 (30.1%) of them were treated. A total of 479 perioperative blood transfusions were reported in 315 patients. Restrictive transfusion was not applied in 50% of transfusion episodes, and the single-unit red blood cell transfusion was also not frequent (37.2%). CONCLUSIONS: Our observational study showed that preoperative anemia was frequent, but iron deficiency was often not assessed and few patients were treated. There is an urgent need for PBM implementation in these centers. CI - Copyright (c) 2023 International Anesthesia Research Society. FAU - Lasocki, Sigismond AU - Lasocki S AD - From the Departement Anesthesie Reanimation, CHU Angers, Angers, France. FAU - Belbachir, Anissa AU - Belbachir A AD - Department of Anesthesia and Critical Care Medicine, Cochin University Paris-Descartes Hospital, Paris, France. FAU - Mertes, Paul-Michel AU - Mertes PM AD - Department of Anesthesia and Intensive Care, Hopitaux Universitaires de Strasbourg, Nouvel Hopital Civil, INSERM U1255, FMTS de Strasbourg, Strasbourg, France. FAU - Pelley, Eric Le AU - Pelley EL AD - Departement Anesthesie Reanimation, Polyclinique de Poitiers, Poitiers, France. FAU - Capdevila, Xavier AU - Capdevila X AD - Department of Anesthesia and Critical Care Medicine, Lapeyronie University Hospital and Montpellier University, Montpellier, France. LA - eng PT - Journal Article PT - Multicenter Study PT - Observational Study PT - Research Support, Non-U.S. Gov't DEP - 20230616 PL - United States TA - Anesth Analg JT - Anesthesia and analgesia JID - 1310650 RN - E1UOL152H7 (Iron) RN - 0 (Hemoglobins) SB - IM MH - Humans MH - Female MH - Aged MH - Cross-Sectional Studies MH - *Anemia/diagnosis/epidemiology/therapy MH - Iron MH - Hemoglobins/analysis MH - *Iron Deficiencies COIS- Conflicts of Interest: See Disclosures at the end of the article. EDAT- 2023/01/27 06:00 MHDA- 2023/07/10 06:42 CRDT- 2023/01/26 13:12 PHST- 2023/07/10 06:42 [medline] PHST- 2023/01/27 06:00 [pubmed] PHST- 2023/01/26 13:12 [entrez] AID - 00000539-990000000-00508 [pii] AID - 10.1213/ANE.0000000000006362 [doi] PST - ppublish SO - Anesth Analg. 2023 Jul 1;137(1):182-190. doi: 10.1213/ANE.0000000000006362. Epub 2023 Jun 16. PMID- 36690579 OWN - NLM STAT- MEDLINE DCOM- 20230503 LR - 20230504 IS - 1099-1557 (Electronic) IS - 1053-8569 (Linking) VI - 32 IP - 6 DP - 2023 Jun TI - Outpatient fluoroquinolone use in relation to European Medicines Agency's recommendation: An Estonian nationwide drug utilization study. PG - 643-650 LID - 10.1002/pds.5593 [doi] AB - PURPOSE: To determine possible changes in prescribing of fluoroquinolones in relation to the European Medicines Agency's (EMA) recommendation in October 2018. METHODS: We conducted a nationwide time-series study on outpatient use of fluoroquinolones during January 2016-June 2021 in Estonia. Joinpoint regression was used to identify change points over time. Several subgroup analyses by prescriber specialty, indication group, risk factors for tendon injury, aortic aneurysm/dissection or heart valve regurgitation/incompetence and the prescribing of other antibiotics were performed. RESULTS: During the study period 236 989 prescriptions of fluoroquinolones were dispensed to 142 659 persons. The number of episodes per month declined from 3780 (2.9/1000 inhabitants) to 2570 (1.9/1000 inhabitants). We identified three change points with four different trend segments: from January 2016 to November 2018 monthly percent change (MPC) -0.4%, from November 2018 to June 2019 MPC -2.5%, from June 2019 to July 2020 MPC 1.7% and from July 2020 to June 2021 MPC -3.3%. Prescribing for indications which were removed or restricted by EMA's recommendation comprised a small proportion of all fluoroquinolone episodes -2.8% and 6.3%, respectively. The risk factors for tendon injury and for cardiac disorders (aortic aneurysm/dissection or heart valve regurgitation/incompetence) were present in 46.4% and 57.8% episodes of fluoroquinolone users, respectively. No changes in the trend of prescribing to users with risk factors was detected. CONCLUSIONS: The EMA's recommendation may have contributed to the greater decline in the use of fluoroquinolones. However, there is still a high proportion of users with predisposing factors for tendon injury and serious cardiac disorders. CI - (c) 2023 John Wiley & Sons Ltd. FAU - Kurvits, Katrin AU - Kurvits K AUID- ORCID: 0000-0002-8728-651X AD - Department of Post-authorisation Safety, State Agency of Medicines, Tartu, Estonia. AD - Institute of Family Medicine and Public Health, University of Tartu, Tartu, Estonia. FAU - Uuskula, Maia AU - Uuskula M AD - Department of Post-authorisation Safety, State Agency of Medicines, Tartu, Estonia. FAU - Vestman, Helve AU - Vestman H AD - Department of Post-authorisation Safety, State Agency of Medicines, Tartu, Estonia. FAU - Laius, Ott AU - Laius O AD - Department of Post-authorisation Safety, State Agency of Medicines, Tartu, Estonia. LA - eng PT - Journal Article DEP - 20230203 PL - England TA - Pharmacoepidemiol Drug Saf JT - Pharmacoepidemiology and drug safety JID - 9208369 RN - 0 (Fluoroquinolones) RN - 0 (Anti-Bacterial Agents) SB - IM MH - Humans MH - Fluoroquinolones/adverse effects MH - Estonia MH - Outpatients MH - Anti-Bacterial Agents/therapeutic use MH - Drug Utilization MH - *Tendon Injuries/chemically induced/drug therapy MH - *Heart Diseases/chemically induced/drug therapy MH - *Aortic Aneurysm OTO - NOTNLM OT - EMA recommendation OT - antibiotic OT - fluoroquinolone OT - pharmacoepidemiology OT - prescription data EDAT- 2023/01/24 06:00 MHDA- 2023/05/03 06:42 CRDT- 2023/01/23 22:03 PHST- 2022/11/24 00:00 [revised] PHST- 2022/09/09 00:00 [received] PHST- 2023/01/18 00:00 [accepted] PHST- 2023/05/03 06:42 [medline] PHST- 2023/01/24 06:00 [pubmed] PHST- 2023/01/23 22:03 [entrez] AID - 10.1002/pds.5593 [doi] PST - ppublish SO - Pharmacoepidemiol Drug Saf. 2023 Jun;32(6):643-650. doi: 10.1002/pds.5593. Epub 2023 Feb 3. PMID- 36645708 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230212 IS - 1929-0748 (Print) IS - 1929-0748 (Electronic) IS - 1929-0748 (Linking) VI - 12 DP - 2023 Jan 16 TI - Improving Self-management of Type 2 Diabetes in Latinx Patients: Protocol for a Sequential Multiple Assignment Randomized Trial Involving Community Health Workers, Registered Nurses, and Family Members. PG - e44793 LID - 10.2196/44793 [doi] LID - e44793 AB - BACKGROUND: The rate of Type 2 diabetes mellitus (T2DM) among Mexican American individuals is 16.3%, about twice that of non-Hispanic White individuals. While a number of education approaches have been developed and shown to improve diabetes self-management behaviors and glycemic control for Spanish-speaking Latinx patients with T2DM, there is little research to guide health practitioners regarding which interventions to apply and when so that resources are used efficiently, and treatment outcomes are maximized. OBJECTIVE: This study aimed to describe an adaptive intervention that integrates community mental health workers, diabetes nurse educators, family members, and patients as partners in care while promoting diabetes self-management for Mexican American individuals with T2DM. The project incorporates four evidence-based, culturally tailored treatments to determine what sequence of intervention strategies work most efficiently and for whom. Given the increasing prevalence of T2DM, achieving better control of diabetes and lowering the associated medical complications experienced disproportionally by Mexican American individuals is a public health priority. METHODS: Funded by the National Institute of Nursing Research (National Institutes of Health grant R01 NR015809), this project used a sequential multiple assignment randomized trial and included 330 Spanish-speaking Latinx patients with T2DM. In the first phase of the study, subjects were randomly assigned to an evidence-based diabetes self-management educational program called Tomando Control delivered in a group format for 6, biweekly 1.5-hour sessions, led either by a community health worker or a diabetes nurse educator. In the second phase of the study, those subjects who did not improve their diabetes self-management behaviors were rerandomized to receive either an augmented version of Tomando Control or a multifamily group treatment focused on problem-solving. The primary outcome measure was the "Summary of Diabetes Self-Care Activities." Evaluations were made at baseline and at 3, 6, and 12 months. RESULTS: This study was funded in June 2016 for a period of 5 years. Institutional review board approval was obtained in November 2016. Between March 2017 and September 2020, a total of 330 patients were recruited from the outpatient primary care clinics of Olive View-UCLA Medical Center, with a brief hiatus between May 2020 and July 2020 due to COVID-19 restrictions. The study interventions were completed in December 2020. Data collection began in March 2017 and was completed in December 2021. Data analysis is expected to be completed in Spring 2023, and results will be published in Fall 2023. CONCLUSIONS: The results of this trial should help practitioners in selecting the optimal approach for improving diabetes self-management in Spanish-speaking, Latinx patients with T2DM. TRIAL REGISTRATION: ClinicalTrials.gov NCT03092063; https://clinicaltrials.gov/ct2/show/NCT03092063. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): DERR1-10.2196/44793. CI - (c)Alex Kopelowicz, Karabi Nandy, Maria Elena Ruiz, Rhonda Polzin, Kevin Kurator, Soma Wali. Originally published in JMIR Research Protocols (https://www.researchprotocols.org), 16.01.2023. FAU - Kopelowicz, Alex AU - Kopelowicz A AUID- ORCID: 0000-0002-1728-4105 AD - Department of Psychiatry & Biobehavioral Sciences, David Geffen School of Medicine at UCLA, Los Angeles, CA, United States. FAU - Nandy, Karabi AU - Nandy K AUID- ORCID: 0000-0001-9071-6835 AD - Department of Population & Data Sciences, University of Texas Southwestern Medical Center, Dallas, TX, United States. FAU - Ruiz, Maria Elena AU - Ruiz ME AUID- ORCID: 0000-0002-9534-4062 AD - University of California, Los Angeles School of Nursing, Los Angeles, CA, United States. FAU - Polzin, Rhonda AU - Polzin R AUID- ORCID: 0000-0002-8348-5925 AD - Department of Nursing, Olive View-UCLA Medical Center, Sylmar, CA, United States. FAU - Kurator, Kevin AU - Kurator K AUID- ORCID: 0000-0003-1342-6337 AD - Department of Medicine, Olive View-UCLA Medical Center, Sylmar, CA, United States. FAU - Wali, Soma AU - Wali S AUID- ORCID: 0000-0002-5285-2876 AD - Department of Medicine, Olive View-UCLA Medical Center, Sylmar, CA, United States. LA - eng SI - ClinicalTrials.gov/NCT03092063 GR - R01 NR015809/NR/NINR NIH HHS/United States PT - Journal Article DEP - 20230116 PL - Canada TA - JMIR Res Protoc JT - JMIR research protocols JID - 101599504 PMC - PMC9887518 OTO - NOTNLM OT - Latinx OT - community health workers OT - diabetes education OT - nurses OT - promotores OT - type 2 diabetes COIS- Conflicts of Interest: None declared. EDAT- 2023/01/17 06:00 MHDA- 2023/01/17 06:01 PMCR- 2023/01/16 CRDT- 2023/01/16 11:53 PHST- 2022/12/03 00:00 [received] PHST- 2022/12/25 00:00 [accepted] PHST- 2022/12/24 00:00 [revised] PHST- 2023/01/16 11:53 [entrez] PHST- 2023/01/17 06:00 [pubmed] PHST- 2023/01/17 06:01 [medline] PHST- 2023/01/16 00:00 [pmc-release] AID - v12i1e44793 [pii] AID - 10.2196/44793 [doi] PST - epublish SO - JMIR Res Protoc. 2023 Jan 16;12:e44793. doi: 10.2196/44793. PMID- 36638130 OWN - NLM STAT- MEDLINE DCOM- 20230117 LR - 20250103 IS - 1932-6203 (Electronic) IS - 1932-6203 (Linking) VI - 18 IP - 1 DP - 2023 TI - "Tell us what's going on": Exploring the information needs of pregnant and post-partum women in Australia during the pandemic with 'Tweets', 'Threads', and women's views. PG - e0279990 LID - 10.1371/journal.pone.0279990 [doi] LID - e0279990 AB - INTRODUCTION: The provision of maternity services in Australia has been significantly disrupted in response to the COVID-19 pandemic. Many changes were initiated quickly, often with rapid dissemination of information to women. The aim of this study was to better understand what information and messages were circulating regarding COVID-19 and pregnancy in Australia and potential information gaps. METHODS: This study adopted a qualitative approach using social media and interviews. A data analytics tool (TIGER-C19) was used to extract data from social media platforms Reddit and Twitter from June to July 2021 (in the middle of the third COVID-19 wave in Australia). A total of 21 individual semi-structured interviews were conducted with those who were, or had been, pregnant in Australia since March 2020. Social media data were analysis via inductive content analysis and interview data were thematically analysed. RESULTS: Social media provided a critical platform for sharing and seeking information, as well as highlighting attitudes of the community towards COVID-19 vaccines in pregnancy. Women interviewed described wanting further information on the risks COVID-19 posed to themselves and their babies, and greater familiarity with the health service during pregnancy, in which they would labour and give birth. Health providers were a trusted source of information. Communication strategies that allowed participants to engage in real-time interactive discussions were preferred. A real or perceived lack of information led participants to turn to informal sources, increasing the potential for exposure to misinformation. CONCLUSION: It is vital that health services communicate effectively with pregnant women, early and often throughout public health crises, such as the COVID-19 pandemic. This was particularly important during periods of increased restrictions on accessing hospital services. Information and communication strategies need to be clear, consistent, timely and accessible to reduce reliance on informal and potentially inaccurate sources. CI - Copyright: (c) 2023 Caddy et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. FAU - Caddy, Cassandra AU - Caddy C AUID- ORCID: 0000-0001-5874-5505 AD - Burnet Institute, Melbourne, VIC, Australia. FAU - Cheong, Marc AU - Cheong M AD - Burnet Institute, Melbourne, VIC, Australia. AD - School of Computing and Information Systems, University of Melbourne, Parkville, VIC, Australia. FAU - Lim, Megan S C AU - Lim MSC AD - Burnet Institute, Melbourne, VIC, Australia. FAU - Power, Robert AU - Power R AD - Burnet Institute, Melbourne, VIC, Australia. FAU - Vogel, Joshua P AU - Vogel JP AD - Burnet Institute, Melbourne, VIC, Australia. AD - School of Population and Global Health, University of Melbourne, Parkville, VIC, Australia. FAU - Bradfield, Zoe AU - Bradfield Z AD - Burnet Institute, Melbourne, VIC, Australia. AD - Curtin University, Bentley, WA, Australia. AD - King Edward Memorial Hospital, Subiaco, WA, Australia. FAU - Coghlan, Benjamin AU - Coghlan B AD - Burnet Institute, Melbourne, VIC, Australia. FAU - Homer, Caroline S E AU - Homer CSE AD - Burnet Institute, Melbourne, VIC, Australia. AD - School of Population and Global Health, University of Melbourne, Parkville, VIC, Australia. FAU - Wilson, Alyce N AU - Wilson AN AD - Burnet Institute, Melbourne, VIC, Australia. AD - School of Population and Global Health, University of Melbourne, Parkville, VIC, Australia. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20230113 PL - United States TA - PLoS One JT - PloS one JID - 101285081 RN - 0 (COVID-19 Vaccines) SB - IM MH - Female MH - Pregnancy MH - Humans MH - *Pandemics MH - COVID-19 Vaccines MH - *COVID-19/epidemiology MH - Qualitative Research MH - Pregnant People MH - Postpartum Period MH - Parturition PMC - PMC9838848 COIS- The authors have declared no competing interests exist. EDAT- 2023/01/14 06:00 MHDA- 2023/01/18 06:00 PMCR- 2023/01/13 CRDT- 2023/01/13 13:34 PHST- 2022/02/08 00:00 [received] PHST- 2022/12/19 00:00 [accepted] PHST- 2023/01/13 13:34 [entrez] PHST- 2023/01/14 06:00 [pubmed] PHST- 2023/01/18 06:00 [medline] PHST- 2023/01/13 00:00 [pmc-release] AID - PONE-D-22-03875 [pii] AID - 10.1371/journal.pone.0279990 [doi] PST - epublish SO - PLoS One. 2023 Jan 13;18(1):e0279990. doi: 10.1371/journal.pone.0279990. eCollection 2023. PMID- 36601076 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230111 IS - 2296-861X (Print) IS - 2296-861X (Electronic) IS - 2296-861X (Linking) VI - 9 DP - 2022 TI - The effects of antioxidants on knee osteoarthritis: A systematic review and meta-analysis. PG - 1026450 LID - 10.3389/fnut.2022.1026450 [doi] LID - 1026450 AB - OBJECTIVE: Knee osteoarthritis (KOA) is one of the growing health problems with a considerable burden. With recent research on the possible effectiveness of antioxidants in the remission of KOA symptoms, a systematic review and meta-analysis was required to confirm this hypothesis. DESIGN: Literature studies were searched on the most comprehensive databases such as PubMed, International Scientific Indexing, and Scopus, with no language and time restrictions. On 17 July 2021, a search strategy was developed based on the roots of "osteoarthritis (OA)" and "antioxidants," with no time or language limitations. As the primary outcome, pain was evaluated based on all indicators for evaluating pain [e.g., Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain scores, the visual analog scale (VAS), and the numerical rating scale (NRS)]. The symptoms and functions of KOA and quality of life (QOL) were also considered as secondary outcomes, each of which was measured and reported by the corresponding instrument in the studies. To measure the changes in pain, symptoms, and functions of participants, we included randomized controlled trials with a placebo control or other medical therapeutic interventions. Publication bias was assessed using Begg's funnel plot and Egger's regression test, which was deemed to be statistically significant at 0.1, and the results were checked by the trim-and-fill test. RESULTS: After refinement, data were extracted from 31 documents from 7,698 primary searched papers. Using the VAS as a reliable psychometric measuring instrument, the present study revealed that a significant difference in the characteristics of disease-related symptoms of patients with KOA was reached after antioxidant therapy (standardized mean difference (SMD): 0.467, 95% confidence interval (CI): 0.303-0.632, p < 0.0001). The results reported by WOMAC confirmed no significant difference in the combined score, difficulty score, pain score, and stiffness score. CONCLUSION: As the first comprehensive systematic review of the association between antioxidant supplementation and KOA, this study showed that antioxidants can decrease disease-related symptoms in patients with KOA. The results can be useful for health policy decisions and future related studies. SYSTEMATIC REVIEW REGISTRATION: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42022351060, identifier: CRD42022351060. CI - Copyright (c) 2022 Nejadhosseinian, Djalalinia, Haerian, Alikhani, Mansour, Mousavian, Mardani-Fard, Kasaeian and Faezi. FAU - Nejadhosseinian, Mohammad AU - Nejadhosseinian M AD - Joint Reconstruction Research Center, Tehran University of Medical Science, Tehran, Iran. AD - Rheumatology Research Center, Tehran University of Medical Sciences, Tehran, Iran. FAU - Djalalinia, Shirin AU - Djalalinia S AD - Development of Research and Technology Center, Deputy of Research and Technology, Ministry of Health and Medical Education, Tehran, Iran. AD - Non-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran. FAU - Haerian, Hoda AU - Haerian H AD - Rheumatology Research Center, Tehran University of Medical Sciences, Tehran, Iran. FAU - Alikhani, Majid AU - Alikhani M AD - Rheumatology Research Center, Tehran University of Medical Sciences, Tehran, Iran. FAU - Mansour, Asieh AU - Mansour A AD - Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran. FAU - Mousavian, Amir-Hossein AU - Mousavian AH AD - Hematology, Oncology and Stem Cell Transplantation Research Center, Research Institute for Oncology, Hematology and Cell Therapy, Tehran University of Medical Sciences, Tehran, Iran. AD - Digestive Diseases Research Center, Digestive Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran. FAU - Mardani-Fard, Heydar Ali AU - Mardani-Fard HA AD - Department of Mathematics, Yasouj University, Yasouj, Iran. FAU - Kasaeian, Amir AU - Kasaeian A AD - Hematology, Oncology and Stem Cell Transplantation Research Center, Research Institute for Oncology, Hematology and Cell Therapy, Tehran University of Medical Sciences, Tehran, Iran. AD - Digestive Diseases Research Center, Digestive Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran. AD - Inflammation Research Center, Tehran University of Medical Sciences, Tehran, Iran. FAU - Faezi, Seyedeh Tahereh AU - Faezi ST AD - Rheumatology Research Center, Tehran University of Medical Sciences, Tehran, Iran. LA - eng PT - Journal Article PT - Systematic Review DEP - 20221219 PL - Switzerland TA - Front Nutr JT - Frontiers in nutrition JID - 101642264 PMC - PMC9806224 OTO - NOTNLM OT - antioxidant OT - cartilage damage OT - knee osteoarthritis (KOA) OT - meta-analysis OT - osteoarthritis OT - systematic reviews COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2023/01/06 06:00 MHDA- 2023/01/06 06:01 PMCR- 2022/01/01 CRDT- 2023/01/05 02:23 PHST- 2022/08/23 00:00 [received] PHST- 2022/11/10 00:00 [accepted] PHST- 2023/01/05 02:23 [entrez] PHST- 2023/01/06 06:00 [pubmed] PHST- 2023/01/06 06:01 [medline] PHST- 2022/01/01 00:00 [pmc-release] AID - 10.3389/fnut.2022.1026450 [doi] PST - epublish SO - Front Nutr. 2022 Dec 19;9:1026450. doi: 10.3389/fnut.2022.1026450. eCollection 2022. PMID- 36600205 OWN - NLM STAT- MEDLINE DCOM- 20230106 LR - 20230203 IS - 1471-2458 (Electronic) IS - 1471-2458 (Linking) VI - 23 IP - 1 DP - 2023 Jan 4 TI - Impact of easing COVID-19 lockdown restrictions on traumatic injuries in Riyadh, Saudi Arabia: one-year experience at a major trauma centre. PG - 22 LID - 10.1186/s12889-023-14981-9 [doi] LID - 22 AB - INTRODUCTION: Lockdown restrictions due to the COVID-19 pandemic have reduced the number of injuries recorded. However, little is known about the impact of easing COVID-19 lockdown restrictions on the nature and outcome of injuries. This study aims to compare injury patterns prior to and after the easing of COVID-19 lockdown restrictions in Saudi Arabia. METHOD: Data were collected retrospectively from the Saudi TraumA Registry for the period between March 25, 2019, and June 21, 2021. These data corresponded to three periods: March 2019-February 2020 (pre-restrictions, period 1), March 2020-June 2020 (lockdown, period 2), and July 2020-June 2021 (post easing of restrictions, period 3). Data related to patients' demographics, mechanism and severity of injury, and in-hospital mortality were collected and analysed. RESULTS: A total of 5,147 traumatic injury patients were included in the analysis (pre-restrictions n = 2593; lockdown n = 218; post easing of lockdown restrictions n = 2336). An increase in trauma cases (by 7.6%) was seen in the 30-44 age group after easing restrictions (n = 648 vs. 762, p < 0.01). Motor vehicle crashes (MVC) were the leading cause of injury, followed by falls in all the three periods. MVC-related injuries decreased by 3.1% (n = 1068 vs. 890, p = 0.03) and pedestrian-related injuries decreased by 2.7% (n = 227 vs. 143, p < 0.01); however, burn injuries increased by 2.2% (n = 134 vs. 174, p < 0.01) and violence-related injuries increased by 0.9% (n = 45 vs. 60, p = 0.05) post easing of lockdown restrictions. We observed an increase in in-hospital mortality during the period of 12 months after easing of lockdown restrictions-4.9% (114/2336) compared to 12 months of pre-lockdown period-4.3% (113/2593). CONCLUSION: This is one of the first studies to document trauma trends over a one-year period after easing lockdown restrictions. MVC continues to be the leading cause of injuries despite a slight decrease; overall injury cases rebounded towards pre-lockdown levels in Saudi Arabia. Injury prevention needs robust legislation with respect to road safety measures and law enforcement that can decrease the burden of traumatic injuries. CI - (c) 2023. The Author(s). FAU - Alharbi, Rayan Jafnan AU - Alharbi RJ AUID- ORCID: 0000-0002-0504-3240 AD - Department of Emergency Medical Service, College of Applied Medical Sciences, Jazan University, 45142, Al Maarefah Rd, Jazan, Saudi Arabia. rjalharbi@jazanu.edu.sa. FAU - Al-Jafar, Rami AU - Al-Jafar R AD - Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK. AD - Department of Data Services, Lean Business Services, Riyadh, Saudi Arabia. FAU - Chowdhury, Sharfuddin AU - Chowdhury S AD - Trauma Center, King Saud Medical City, Riyadh, Saudi Arabia. FAU - Rahman, Muhammad Aziz AU - Rahman MA AD - School of Health, Federation University Australia, Berwick, VIC, Australia. FAU - Almuwallad, Ateeq AU - Almuwallad A AD - Department of Emergency Medical Service, College of Applied Medical Sciences, Jazan University, 45142, Al Maarefah Rd, Jazan, Saudi Arabia. AD - Centre for Trauma Science, Blizard Institute Queen Mary University, London, UK. FAU - Alshibani, Abdullah AU - Alshibani A AD - Department of Emergency Medical Services, College of Applied Medical Sciences, King Saud bin, Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia. AD - King Abdullah International Medical Research Center, Riyadh, Saudi Arabia. FAU - Lewis, Virginia AU - Lewis V AUID- ORCID: 0000-0001-7802-625X AD - Australia Institute for Primary Care and Ageing (AIPCA), La Trobe University, Melbourne, VIC, Australia. LA - eng GR - KSRG-2022-069/King Salman Center for Disability Research/ PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20230104 PL - England TA - BMC Public Health JT - BMC public health JID - 100968562 SB - IM MH - Humans MH - *Trauma Centers MH - *COVID-19/epidemiology/prevention & control MH - Saudi Arabia/epidemiology MH - Retrospective Studies MH - Pandemics/prevention & control MH - Communicable Disease Control PMC - PMC9812537 OTO - NOTNLM OT - Covid-19 OT - Easing restrictions OT - Injury OT - Major trauma OT - Motor Vehicle Crashes OT - Pandemic COIS- The authors declare that they have no competing interests. EDAT- 2023/01/05 06:00 MHDA- 2023/01/07 06:00 PMCR- 2023/01/04 CRDT- 2023/01/04 23:33 PHST- 2022/08/08 00:00 [received] PHST- 2023/01/03 00:00 [accepted] PHST- 2023/01/04 23:33 [entrez] PHST- 2023/01/05 06:00 [pubmed] PHST- 2023/01/07 06:00 [medline] PHST- 2023/01/04 00:00 [pmc-release] AID - 10.1186/s12889-023-14981-9 [pii] AID - 14981 [pii] AID - 10.1186/s12889-023-14981-9 [doi] PST - epublish SO - BMC Public Health. 2023 Jan 4;23(1):22. doi: 10.1186/s12889-023-14981-9. PMID- 36590788 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240928 IS - 2589-5370 (Electronic) IS - 2589-5370 (Linking) VI - 56 DP - 2023 Feb TI - SARS-CoV-2 seroprevalence in children worldwide: A systematic review and meta-analysis. PG - 101786 LID - 10.1016/j.eclinm.2022.101786 [doi] LID - 101786 AB - BACKGROUND: The higher hospitalisation rates of those aged 0-19 years (referred to herein as 'children') observed since the emergence of the immune-evasive SARS-CoV-2 Omicron variant and subvariants, along with the persisting vaccination disparities highlighted a need for in-depth knowledge of SARS-CoV-2 sero-epidemiology in children. Here, we conducted this systematic review to assess SARS-CoV-2 seroprevalence and determinants in children worldwide. METHODS: In this systematic review and meta-analysis study, we searched international and preprinted scientific databases from December 1, 2019 to July 10, 2022. Pooled seroprevalences were estimated according to World Health Organization (WHO) regions (at 95% confidence intervals, CIs) using random-effects meta-analyses. Associations with SARS-CoV-2 seroprevalence and sources of heterogeneity were investigated using sub-group and meta-regression analyses. The protocol used in this study has been registered in PROSPERO (CRD42022350833). FINDINGS: We included 247 studies involving 757,075 children from 70 countries. Seroprevalence estimates varied from 7.3% (5.8-9.1%) in the first wave of the COVID-19 pandemic to 37.6% (18.1-59.4%) in the fifth wave and 56.6% (52.8-60.5%) in the sixth wave. The highest seroprevalences in different pandemic waves were estimated for South-East Asia (17.9-81.8%) and African (17.2-66.1%) regions; while the lowest seroprevalence was estimated for the Western Pacific region (0.01-1.01%). Seroprevalence estimates were higher in children at older ages, in those living in underprivileged countries or regions, and in those of minority ethnic backgrounds. INTERPRETATION: Our findings indicate that, by the end of 2021 and before the Omicron wave, around 50-70% of children globally were still susceptible to SARS-CoV-2 infection, clearly emphasising the need for more effective vaccines and better vaccination coverage among children and adolescents, particularly in developing countries and minority ethnic groups. FUNDING: None. CI - (c) 2022 The Author(s). FAU - Naeimi, Reza AU - Naeimi R AD - Infectious Diseases and Tropical Medicine Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran. FAU - Sepidarkish, Mahdi AU - Sepidarkish M AD - Department of Biostatistics and Epidemiology, School of Public Health, Babol University of Medical Sciences, Babol, Iran. FAU - Mollalo, Abolfazl AU - Mollalo A AD - Department of Public Health and Prevention Science, School of Health Sciences, Baldwin Wallace University, Berea, OH, USA. FAU - Parsa, Hamid AU - Parsa H AD - Department of Neurology, University of Visayas, Gullas College of Medicine, Cebu City, 600 Cebu, Philippines. FAU - Mahjour, Sanaz AU - Mahjour S AD - Department of Psychiatry and Behavioral Sciences, Northwestern Feinberg School of Medicine, Chicago, IL, 60611, USA. FAU - Safarpour, Fatemeh AU - Safarpour F AD - Infectious Diseases and Tropical Medicine Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran. FAU - Almukhtar, Mustafa AU - Almukhtar M AD - Harlem Medical Center, IL, USA. FAU - Mechaal, Amal AU - Mechaal A AD - Division of Hematology/Oncology, Department of Medicine, University of Illinois College of Medicine, Chicago, USA. FAU - Chemaitelly, Hiam AU - Chemaitelly H AD - Infectious Disease Epidemiology Group, Weill Cornell Medicine-Qatar, Cornell University, Doha, Qatar. AD - World Health Organization Collaborating Centre for Disease Epidemiology Analytics on HIV/AIDS, Sexually Transmitted Infections and Viral Hepatitis, Weill Cornell Medicine-Qatar, Qatar-Foundation-Education City, Cornell University, Doha, Qatar. AD - Department of Population Health Sciences, Weill Cornell Medicine, Cornell University, New York, USA. FAU - Sartip, Behnam AU - Sartip B AD - Department of Psychiatry and Behavioral Sciences, Northwestern Feinberg School of Medicine, Chicago, IL, 60611, USA. FAU - Marhoommirzabak, Elika AU - Marhoommirzabak E AD - Department of Neurology, University of Visayas, Gullas College of Medicine, Cebu City, 600 Cebu, Philippines. FAU - Ardekani, Ali AU - Ardekani A AD - Health Policy Research Center, Institute of Health, Shiraz University of Medical Sciences, Shiraz, Iran. FAU - Hotez, Peter J AU - Hotez PJ AD - Texas Children's Hospital Center for Vaccine Development, Department of Pediatrics and Molecular Virology and Microbiology, National School of Tropical Medicine, Baylor College of Medicine, Houston, TX, USA. FAU - Gasser, Robin B AU - Gasser RB AD - Department of Veterinary Biosciences, Melbourne Veterinary School, The University of Melbourne, Parkville, Victoria, Australia. FAU - Rostami, Ali AU - Rostami A AD - Infectious Diseases and Tropical Medicine Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran. LA - eng PT - Journal Article DEP - 20221228 PL - England TA - EClinicalMedicine JT - EClinicalMedicine JID - 101733727 PMC - PMC9795163 OTO - NOTNLM OT - COVID-19 OT - Children OT - Meta-analysis OT - SARS-CoV-2 OT - Seroprevalence OT - Serum antibodies COIS- All authors declare no competing interests. Prof. Hotez is a co-inventor of a COVID-19 recombinant protein vaccine technology owned by Baylor College of Medicine (BCM) that was recently licensed by Baylor Ventures non-exclusively and with no patent restrictions to several companies committed to advance vaccines for low- and middle-income countries. These include Biological E (India-CORBEVAX) and BioFarma (Indonesia-INDOVAC), Incepta (Bangladesh). He has no involvement in license negotiations conducted by BCM. Similar to other research universities, a long-standing BCM policy provides its faculty and staff, who make discoveries and that result in a commercial license, a share of any royalty income. To date, BCM has not distributed any royalty income to the co-inventors on the COVID-19 recombinant protein vaccine technology. EDAT- 2023/01/03 06:00 MHDA- 2023/01/03 06:01 PMCR- 2022/12/28 CRDT- 2023/01/02 04:35 PHST- 2022/09/30 00:00 [received] PHST- 2022/11/28 00:00 [revised] PHST- 2022/11/29 00:00 [accepted] PHST- 2023/01/02 04:35 [entrez] PHST- 2023/01/03 06:00 [pubmed] PHST- 2023/01/03 06:01 [medline] PHST- 2022/12/28 00:00 [pmc-release] AID - S2589-5370(22)00515-6 [pii] AID - 101786 [pii] AID - 10.1016/j.eclinm.2022.101786 [doi] PST - ppublish SO - EClinicalMedicine. 2023 Feb;56:101786. doi: 10.1016/j.eclinm.2022.101786. Epub 2022 Dec 28. PMID- 36585149 OWN - NLM STAT- MEDLINE DCOM- 20230103 LR - 20240910 IS - 2044-6055 (Electronic) IS - 2044-6055 (Linking) VI - 12 IP - 12 DP - 2022 Dec 30 TI - Availability and prioritisation of COVID-19 vaccines among patients with advanced chronic kidney disease and kidney failure during the height of the pandemic: a global survey by the International Society of Nephrology. PG - e065112 LID - 10.1136/bmjopen-2022-065112 [doi] LID - e065112 AB - OBJECTIVE: Patients with advanced chronic kidney disease (CKD) or kidney failure receiving replacement therapy (KFRT) are highly vulnerable to COVID-19 infection, morbidity and mortality. Vaccination is effective, but access differs around the world. We aimed to ascertain the availability, readiness and prioritisation of COVID-19 vaccines for this group of patients globally. SETTING AND PARTICIPANTS: Collaborators from the International Society of Nephrology (ISN), Dialysis Outcomes and Practice Patterns Study and ISN-Global Kidney Health Atlas developed an online survey that was administered electronically to key nephrology leaders in 174 countries between 2 July and 4 August 2021. RESULTS: Survey responses were received from 99 of 174 countries from all 10 ISN regions, among which 88/174 (50%) were complete. At least one vaccine was available in 96/99 (97%) countries. In 71% of the countries surveyed, patients on dialysis were prioritised for vaccination, followed by patients living with a kidney transplant (KT) (62%) and stage 4/5 CKD (51%). Healthcare workers were the most common high priority group for vaccination. At least 50% of patients receiving in-centre haemodialysis, peritoneal dialysis or KT were estimated to have completed vaccination at the time of the survey in 55%, 64% and 51% of countries, respectively. At least 50% of patients in all three patient groups had been vaccinated in >70% of high-income countries and in 100% of respondent countries in Western Europe.The most common barriers to vaccination of patients were vaccine hesitancy (74%), vaccine shortages (61%) and mass vaccine distribution challenges (48%). These were reported more in low-income and lower middle-income countries compared with high-income countries. CONCLUSION: Patients with advanced CKD or KFRT were prioritised in COVID-19 vaccination in most countries. Multiple barriers led to substantial variability in the successful achievement of COVID-19 vaccination across the world, with high-income countries achieving the most access and success. CI - (c) Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. FAU - Wijewickrama, Eranga S AU - Wijewickrama ES AD - Faculty of Medicine, University of Colombo, Colombo, Sri Lanka. FAU - Abdul Hafidz, Muhammad Iqbal AU - Abdul Hafidz MI AD - Nephrology Unit, Universiti Teknologi MARA (UiTM), Selangor, Malaysia. FAU - Robinson, Bruce M AU - Robinson BM AD - University of Michigan, Ann Arbor, Michigan, USA. FAU - Johnson, David W AU - Johnson DW AD - Department of Kidney and Transplant Services, Princess Alexandra Hospital, Woolloongabba, Queensland, Australia. FAU - Liew, Adrian AU - Liew A AD - Mount Elizabeth Novena Hospital, Singapore. FAU - Dreyer, Gavin AU - Dreyer G AD - Renal Medicine, Barts Health NHS Trust, London, UK. FAU - Caskey, Fergus J AU - Caskey FJ AD - Population Health Sciences, University of Bristol, Bristol, UK. FAU - Bello, Aminu K AU - Bello AK AD - Nephrology, University of Alberta, Edmonton, Alberta, Canada. FAU - Zaidi, Deenaz AU - Zaidi D AD - Medicine, University of Alberta, Edmonton, Alberta, Canada. FAU - Damster, Sandrine AU - Damster S AD - International Society of Nephrology, Brussels, Belgium. FAU - Salaro, Silvia AU - Salaro S AD - International Society of Nephrology, Brussels, Belgium. FAU - Luyckx, Valerie Ann AU - Luyckx VA AUID- ORCID: 0000-0001-7066-8135 AD - Nephrology, University Children's Hospital, Zurich, Switzerland. AD - Department of Paediatrics and Child Heath, University of Cape Town, Cape Town, South Africa. AD - Renal Division, Brigham and Women's Hospital, Harvard medical School, Boston, MA, USA. FAU - Bajpai, Divya AU - Bajpai D AUID- ORCID: 0000-0003-2294-0506 AD - Nephrology, Seth GS Medical College and KEM Hospital, Mumbai, Maharashtra, India divyaa24@gmail.com. LA - eng PT - Journal Article DEP - 20221230 PL - England TA - BMJ Open JT - BMJ open JID - 101552874 RN - 0 (COVID-19 Vaccines) SB - IM MH - Humans MH - *Nephrology MH - Renal Dialysis MH - COVID-19 Vaccines MH - Pandemics MH - *COVID-19/epidemiology/prevention & control MH - *Renal Insufficiency, Chronic/epidemiology/therapy MH - *Kidney Failure, Chronic/therapy MH - Surveys and Questionnaires PMC - PMC9808761 OTO - NOTNLM OT - COVID-19 OT - dialysis OT - epidemiology OT - health policy OT - renal transplantation COIS- Competing interests: EW, MIAH, AL, GD, FC, AKB, SD, SS, DZ, VAL and DB have no disclosures. Global support for the ongoing DOPPS programme is provided without restriction on publications by a variety of funders. For details see, https://www.dopps.org/AboutUs/Support.aspx. BMR has received consultancy fees or travel reimbursement since 2019 from AstraZeneca, GlaxoSmithKline and Kyowa Kirin Co, all paid directly to his institution of employment. DJ has received consultancy fees, research grants, speaker's honoraria and travel sponsorships from Baxter Healthcare and Fresenius Medical Care, consultancy fees from AstraZeneca, Bayer and AWAK, speaker's honoraria from Ono and BI & Lilly, and travel sponsorships from Ono and Amgen. He is a current recipient of an Australian National Health and Medical Research Council Leadership Investigator Grant. EDAT- 2022/12/31 06:00 MHDA- 2023/01/04 06:00 PMCR- 2022/12/30 CRDT- 2022/12/30 21:03 PHST- 2022/12/30 21:03 [entrez] PHST- 2022/12/31 06:00 [pubmed] PHST- 2023/01/04 06:00 [medline] PHST- 2022/12/30 00:00 [pmc-release] AID - bmjopen-2022-065112 [pii] AID - 10.1136/bmjopen-2022-065112 [doi] PST - epublish SO - BMJ Open. 2022 Dec 30;12(12):e065112. doi: 10.1136/bmjopen-2022-065112. PMID- 36584747 OWN - NLM STAT- MEDLINE DCOM- 20230131 LR - 20230301 IS - 1095-8541 (Electronic) IS - 0022-5193 (Print) IS - 0022-5193 (Linking) VI - 561 DP - 2023 Mar 21 TI - Pandemic modelling for regions implementing an elimination strategy. PG - 111378 LID - S0022-5193(22)00369-1 [pii] LID - 10.1016/j.jtbi.2022.111378 [doi] AB - During the COVID-19 pandemic, some countries, such as Australia, China, Iceland, New Zealand, Thailand, and Vietnam successfully implemented an elimination strategy, enacting strict border control and periods of lockdowns to end community transmission. Atlantic Canada and Canada's territories implemented similar policies, and reported long periods with no community cases. In Newfoundland and Labrador (NL), Nova Scotia, and Prince Edward Island a median of 80% or more of daily reported cases were travel-related from July 1, 2020 to May 31, 2021. With increasing vaccination coverage, it may be appropriate to exit an elimination strategy, but most existing epidemiological frameworks are applicable only to situations where most cases occur in the community, and are not appropriate for regions that have implemented an elimination strategy. To inform the pandemic response in regions that are implementing an elimination strategy, we extend importation modelling to consider post-arrival travel restrictions, and pharmaceutical and non-pharmaceutical interventions in the local community. We find that shortly after the Omicron variant had begun spreading in Canada, the expected daily number of spillovers, infections spread to NL community members from travellers and their close contacts, was higher than any time previously in the pandemic. By December 24, 2021, the expected number of spillovers was 44% higher than the previous high, which occurred in late July 2021 shortly after travel restrictions were first relaxed. We develop a method to assess the characteristics of potential future community outbreaks in regions that are implementing an elimination strategy. We apply this method to predict the effect of variant and vaccination coverage on the size of hypothetical community outbreaks in Mount Pearl, a suburb of the St. John's metropolitan area in NL. Our methodology can be used to evaluate alternative plans to relax public health restrictions when vaccine coverage is high in regions that have implemented an elimination strategy. This manuscript was submitted as part of a theme issue on "Modelling COVID-19 and Preparedness for Future Pandemics". CI - Copyright (c) 2022 The Author(s). Published by Elsevier Ltd.. All rights reserved. FAU - Hurford, Amy AU - Hurford A AD - Memorial University of Newfoundland, Department of Biology, St. John's, NL A1C 5S7, Canada; Memorial University of Newfoundland, Mathematics and Statistics Department, St. John's, NL A1C 5S7, Canada. Electronic address: ahurford@mun.ca. FAU - Martignoni, Maria M AU - Martignoni MM AD - Memorial University of Newfoundland, Mathematics and Statistics Department, St. John's, NL A1C 5S7, Canada. FAU - Loredo-Osti, J Concepcion AU - Loredo-Osti JC AD - Memorial University of Newfoundland, Mathematics and Statistics Department, St. John's, NL A1C 5S7, Canada. FAU - Anokye, Francis AU - Anokye F AD - Memorial University of Newfoundland, Department of Biology, St. John's, NL A1C 5S7, Canada. FAU - Arino, Julien AU - Arino J AD - University of Manitoba, Department of Mathematics and Data Science Nexus, Winnipeg, MB R3B 2E9, Canada. FAU - Husain, Bilal Saleh AU - Husain BS AD - University of New Brunswick, Department of Mathematics and Statistics, Fredericton, NB E3B 5A3, Canada. FAU - Gaas, Brian AU - Gaas B AD - Government of Yukon, Department of Health and Social Services, Whitehorse, YT Y1A 3T8, Canada. FAU - Watmough, James AU - Watmough J AD - University of New Brunswick, Department of Mathematics and Statistics, Fredericton, NB E3B 5A3, Canada. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20221228 PL - England TA - J Theor Biol JT - Journal of theoretical biology JID - 0376342 RN - SARS-CoV-2 variants SB - IM MH - Humans MH - *COVID-19/epidemiology/prevention & control MH - SARS-CoV-2 MH - Pandemics/prevention & control MH - Travel MH - Communicable Disease Control MH - Travel-Related Illness PMC - PMC9794400 OTO - NOTNLM OT - Atlantic Canada OT - COVID-19 OT - COVID-zero OT - Elimination OT - Importations OT - Pandemic preparedness OT - Reopening OT - SARS-CoV-2 OT - Travel-related EDAT- 2022/12/31 06:00 MHDA- 2023/02/01 06:00 PMCR- 2022/12/28 CRDT- 2022/12/30 19:12 PHST- 2022/07/15 00:00 [received] PHST- 2022/11/15 00:00 [revised] PHST- 2022/11/30 00:00 [accepted] PHST- 2022/12/31 06:00 [pubmed] PHST- 2023/02/01 06:00 [medline] PHST- 2022/12/30 19:12 [entrez] PHST- 2022/12/28 00:00 [pmc-release] AID - S0022-5193(22)00369-1 [pii] AID - 111378 [pii] AID - 10.1016/j.jtbi.2022.111378 [doi] PST - ppublish SO - J Theor Biol. 2023 Mar 21;561:111378. doi: 10.1016/j.jtbi.2022.111378. Epub 2022 Dec 28. PMID- 36577708 OWN - NLM STAT- MEDLINE DCOM- 20230407 LR - 20240929 IS - 2054-1058 (Electronic) IS - 2054-1058 (Linking) VI - 10 IP - 5 DP - 2023 May TI - The lived experiences of health care professionals regarding visiting restrictions in the emergency department during the COVID-19 pandemic: A multi-perspective qualitative study. PG - 3243-3252 LID - 10.1002/nop2.1576 [doi] AB - AIMS: To explore the lived experiences of emergency department (ED) healthcare professionals regarding visiting restrictions during the COVID-19 pandemic. DESIGN: A qualitative phenomenology study. METHODS: Semi-structured interviews were undertaken. Participants consisted of 10 physicians, 20 clinical nurses, and three managers, who were purposefully selected from two EDs in China between April and July 2021. Colaizzi's approach guided data analysis. RESULTS: Four themes arose: (i) burden moral injury, (ii) higher workload to provide and support patient- and family-centered care, (iii) dissatisfied and unsafe healthcare service for patients and families, and (iv) tailoring strategies to provide family-centered care. PATIENT OR PUBLIC CONTRIBUTION: This study explored the lived experiences of ED health care professionals regarding visiting restrictions during the COVID-19 pandemic. Noted challenges included communicating with families and ethical decision making. Strategies that support ED clinician welfare, and communication with families are warranted if visiting policy restrictions are continued or re-introduced. CI - (c) 2022 The Authors. Nursing Open published by John Wiley & Sons Ltd. FAU - Lyu, Yang AU - Lyu Y AUID- ORCID: 0000-0002-3560-4061 AD - Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. FAU - Yu, Han AU - Yu H AD - Department of Emergency Medicine, Beijing Chao-Yang Hospital, Beijing, China. FAU - Gao, Fengli AU - Gao F AD - Department of Nursing, Beijing Chao-Yang Hospital, Beijing, China. FAU - He, Xinhua AU - He X AD - Department of Emergency Medicine, Beijing Chao-Yang Hospital, Beijing, China. FAU - Crilly, Julia AU - Crilly J AD - Department of Emergency Medicine, Gold Coast Health, Gold Coast, Queensland, Australia. AD - School of Nursing and Midwifery, Menzies Health Institute Queensland, Griffith University, Gold Coast, Queensland, Australia. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20221228 PL - United States TA - Nurs Open JT - Nursing open JID - 101675107 SB - IM MH - Humans MH - *COVID-19 MH - Pandemics MH - Health Personnel MH - Emergency Service, Hospital MH - *Physicians PMC - PMC9880717 OTO - NOTNLM OT - COVID-19 OT - emergency departments OT - moral injury OT - nurses OT - pandemic OT - qualitative study OT - visiting restrictions COIS- The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. EDAT- 2022/12/29 06:00 MHDA- 2023/04/07 06:42 PMCR- 2022/12/28 CRDT- 2022/12/28 22:23 PHST- 2022/12/02 00:00 [revised] PHST- 2022/06/30 00:00 [received] PHST- 2022/12/10 00:00 [accepted] PHST- 2023/04/07 06:42 [medline] PHST- 2022/12/29 06:00 [pubmed] PHST- 2022/12/28 22:23 [entrez] PHST- 2022/12/28 00:00 [pmc-release] AID - NOP21576 [pii] AID - 10.1002/nop2.1576 [doi] PST - ppublish SO - Nurs Open. 2023 May;10(5):3243-3252. doi: 10.1002/nop2.1576. Epub 2022 Dec 28. PMID- 36572604 OWN - NLM STAT- MEDLINE DCOM- 20230306 LR - 20240912 IS - 1873-2518 (Electronic) IS - 0264-410X (Print) IS - 0264-410X (Linking) VI - 41 IP - 11 DP - 2023 Mar 10 TI - Transmission potential of vaccinated and unvaccinated persons infected with the SARS-CoV-2 Delta variant in a federal prison, July-August 2021. PG - 1808-1818 LID - S0264-410X(22)01458-X [pii] LID - 10.1016/j.vaccine.2022.11.045 [doi] AB - BACKGROUND: The extent to which vaccinated persons who become infected with SARS-CoV-2 contribute to transmission is unclear. During a SARS-CoV-2 Delta variant outbreak among incarcerated persons with high vaccination rates in a federal prison, we assessed markers of viral shedding in vaccinated and unvaccinated persons. METHODS: Consenting incarcerated persons with confirmed SARS-CoV-2 infection provided mid-turbinate nasal specimens daily for 10 consecutive days and reported symptom data via questionnaire. Real-time reverse transcription-polymerase chain reaction (RT-PCR), viral whole genome sequencing, and viral culture was performed on these nasal specimens. Duration of RT-PCR positivity and viral culture positivity was assessed using survival analysis. RESULTS: A total of 957 specimens were provided by 93 participants, of whom 78 (84 %) were vaccinated and 17 (16 %) were unvaccinated. No significant differences were detected in duration of RT-PCR positivity among vaccinated participants (median: 13 days) versus those unvaccinated (median: 13 days; p = 0.50), or in duration of culture positivity (medians: 5 days and 5 days; p = 0.29). Among vaccinated participants, overall duration of culture positivity was shorter among Moderna vaccine recipients versus Pfizer (p = 0.048) or Janssen (p = 0.003) vaccine recipients. In post-hoc analyses, Moderna vaccine recipients demonstrated significantly shorter duration of culture positivity compared to unvaccinated participants (p = 0.02). When restricted to participants without reported prior infection, the difference between Moderna vaccine recipients and unvaccinated participants was more pronounced (medians: 3 days and 6 days, p = 0.002). CONCLUSIONS: Infectious periods for vaccinated and unvaccinated persons who become infected with SARS-CoV-2 are similar and can be highly variable, though some vaccinated persons are likely infectious for shorter durations. These findings are critically important, especially in congregate settings where viral transmission can lead to large outbreaks. In such settings, clinicians and public health practitioners should consider vaccinated, infected persons to be no less infectious than unvaccinated, infected persons. CI - Published by Elsevier Ltd. FAU - Salvatore, Phillip P AU - Salvatore PP AD - COVID-19 Pandemic Response Team, Centers for Disease Control and Prevention, Atlanta, GA, United States; United States Public Health Service, Rockville, MD, United States. Electronic address: pgx5@cdc.gov. FAU - Lee, Christine C AU - Lee CC AD - COVID-19 Pandemic Response Team, Centers for Disease Control and Prevention, Atlanta, GA, United States; Laboratory Leadership Service, Centers for Disease Control and Prevention, Atlanta, GA, United States. FAU - Sleweon, Sadia AU - Sleweon S AD - COVID-19 Pandemic Response Team, Centers for Disease Control and Prevention, Atlanta, GA, United States. FAU - McCormick, David W AU - McCormick DW AD - COVID-19 Pandemic Response Team, Centers for Disease Control and Prevention, Atlanta, GA, United States; United States Public Health Service, Rockville, MD, United States; Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, GA, United States. FAU - Nicolae, Lavinia AU - Nicolae L AD - COVID-19 Pandemic Response Team, Centers for Disease Control and Prevention, Atlanta, GA, United States. FAU - Knipe, Kristen AU - Knipe K AD - COVID-19 Pandemic Response Team, Centers for Disease Control and Prevention, Atlanta, GA, United States. FAU - Dixon, Tom AU - Dixon T AD - Bureau of Prisons, U.S. Department of Justice, Washington, DC, United States. FAU - Banta, Robert AU - Banta R AD - United States Public Health Service, Rockville, MD, United States; Bureau of Prisons, U.S. Department of Justice, Washington, DC, United States. FAU - Ogle, Isaac AU - Ogle I AD - United States Public Health Service, Rockville, MD, United States; Bureau of Prisons, U.S. Department of Justice, Washington, DC, United States. FAU - Young, Cristen AU - Young C AD - Bureau of Prisons, U.S. Department of Justice, Washington, DC, United States. FAU - Dusseau, Charles AU - Dusseau C AD - United States Public Health Service, Rockville, MD, United States; Bureau of Prisons, U.S. Department of Justice, Washington, DC, United States. FAU - Salmonson, Shawn AU - Salmonson S AD - Bureau of Prisons, U.S. Department of Justice, Washington, DC, United States. FAU - Ogden, Charles AU - Ogden C AD - United States Public Health Service, Rockville, MD, United States; Bureau of Prisons, U.S. Department of Justice, Washington, DC, United States. FAU - Godwin, Eric AU - Godwin E AD - Bureau of Prisons, U.S. Department of Justice, Washington, DC, United States. FAU - Ballom, TeCora AU - Ballom T AD - United States Public Health Service, Rockville, MD, United States; Bureau of Prisons, U.S. Department of Justice, Washington, DC, United States. FAU - Rhodes, Tara AU - Rhodes T AD - United States Public Health Service, Rockville, MD, United States; Bureau of Prisons, U.S. Department of Justice, Washington, DC, United States. FAU - Wynn, Nhien Tran AU - Wynn NT AD - COVID-19 Pandemic Response Team, Centers for Disease Control and Prevention, Atlanta, GA, United States. FAU - David, Ebenezer AU - David E AD - COVID-19 Pandemic Response Team, Centers for Disease Control and Prevention, Atlanta, GA, United States. FAU - Bessey, Theresa K AU - Bessey TK AD - COVID-19 Pandemic Response Team, Centers for Disease Control and Prevention, Atlanta, GA, United States. FAU - Kim, Gimin AU - Kim G AD - COVID-19 Pandemic Response Team, Centers for Disease Control and Prevention, Atlanta, GA, United States. FAU - Suppiah, Suganthi AU - Suppiah S AD - COVID-19 Pandemic Response Team, Centers for Disease Control and Prevention, Atlanta, GA, United States. FAU - Tamin, Azaibi AU - Tamin A AD - COVID-19 Pandemic Response Team, Centers for Disease Control and Prevention, Atlanta, GA, United States. FAU - Harcourt, Jennifer L AU - Harcourt JL AD - COVID-19 Pandemic Response Team, Centers for Disease Control and Prevention, Atlanta, GA, United States. FAU - Sheth, Mili AU - Sheth M AD - COVID-19 Pandemic Response Team, Centers for Disease Control and Prevention, Atlanta, GA, United States. FAU - Lowe, Luis AU - Lowe L AD - COVID-19 Pandemic Response Team, Centers for Disease Control and Prevention, Atlanta, GA, United States. FAU - Browne, Hannah AU - Browne H AD - COVID-19 Pandemic Response Team, Centers for Disease Control and Prevention, Atlanta, GA, United States. FAU - Tate, Jacqueline E AU - Tate JE AD - COVID-19 Pandemic Response Team, Centers for Disease Control and Prevention, Atlanta, GA, United States; United States Public Health Service, Rockville, MD, United States. FAU - Kirking, Hannah L AU - Kirking HL AD - COVID-19 Pandemic Response Team, Centers for Disease Control and Prevention, Atlanta, GA, United States; United States Public Health Service, Rockville, MD, United States. FAU - Hagan, Liesl M AU - Hagan LM AD - COVID-19 Pandemic Response Team, Centers for Disease Control and Prevention, Atlanta, GA, United States. LA - eng PT - Journal Article DEP - 20221213 PL - Netherlands TA - Vaccine JT - Vaccine JID - 8406899 RN - SARS-CoV-2 variants SB - IM MH - Humans MH - *Prisons MH - SARS-CoV-2 MH - *COVID-19/epidemiology/prevention & control MH - Disease Outbreaks PMC - PMC9744684 OTO - NOTNLM OT - COVID-19 transmission OT - Correctional facilities OT - Infectious disease outbreaks OT - Vaccination OT - Virus shedding COIS- Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2022/12/27 06:00 MHDA- 2023/03/07 06:00 PMCR- 2022/12/13 CRDT- 2022/12/26 21:54 PHST- 2022/09/27 00:00 [received] PHST- 2022/11/19 00:00 [accepted] PHST- 2022/12/27 06:00 [pubmed] PHST- 2023/03/07 06:00 [medline] PHST- 2022/12/26 21:54 [entrez] PHST- 2022/12/13 00:00 [pmc-release] AID - S0264-410X(22)01458-X [pii] AID - 10.1016/j.vaccine.2022.11.045 [doi] PST - ppublish SO - Vaccine. 2023 Mar 10;41(11):1808-1818. doi: 10.1016/j.vaccine.2022.11.045. Epub 2022 Dec 13. PMID- 36567660 OWN - NLM STAT- MEDLINE DCOM- 20230224 LR - 20230308 IS - 1326-5377 (Electronic) IS - 0025-729X (Print) IS - 0025-729X (Linking) VI - 218 IP - 3 DP - 2023 Feb 20 TI - Emergency department presentations during the COVID-19 pandemic in Queensland (to June 2021): interrupted time series analysis. PG - 120-125 LID - 10.5694/mja2.51819 [doi] AB - OBJECTIVES: To assess emergency department (ED) presentation numbers in Queensland during the coronavirus disease 2019 (COVID-19) pandemic to mid-2021, a period of relatively low COVID-19 case numbers. DESIGN: Interrupted time series analysis. SETTING: All 105 Queensland public hospital EDs. MAIN OUTCOME MEASURES: Numbers of ED presentations during the COVID-19 lockdown period (11 March 2020 - 30 June 2020) and the period of easing restrictions (1 July 2020 - 30 June 2021), compared with pre-pandemic period (1 January 2018 - 10 March 2020), overall (daily numbers) and by Australasian Triage Scale (ATS; daily numbers) and selected diagnostic categories (cardiac, respiratory, mental health, injury-related conditions) and conditions (stroke, sepsis) (weekly numbers). RESULTS: During the lockdown period, the mean number of ED presentations was 19.4% lower (95% confidence interval, -20.9% to -17.9%) than during the pre-pandemic period (predicted mean number: 5935; actual number: 4786 presentations). The magnitudes of the decline and the time to return to predicted levels varied by ATS category and diagnostic group; changes in presentation numbers were least marked for ATS 1 and 2 (most urgent) presentations, and for presentations with cardiac conditions or stroke. Numbers remained below predicted levels during the 12-month post-lockdown period for ATS 5 (least urgent) presentations and presentations with mental health problems, respiratory conditions, or sepsis. CONCLUSIONS: The COVID-19 pandemic and related public restrictions were associated with profound changes in health care use. Pandemic plans should include advice about continuing to seek care for serious health conditions and health emergencies, and support alternative sources of care for less urgent health care needs. CI - (c) 2022 The Authors. Medical Journal of Australia published by John Wiley & Sons Australia, Ltd on behalf of AMPCo Pty Ltd. FAU - Sweeny, Amy L AU - Sweeny AL AUID- ORCID: 0000-0001-8392-5612 AD - Griffith University, Gold Coast, QLD. AD - Gold Coast Hospital and Health Service, Gold Coast, QLD. FAU - Keijzers, Gerben AU - Keijzers G AD - Gold Coast Hospital and Health Service, Gold Coast, QLD. AD - Bond University, Gold Coast, QLD. FAU - Marshall, Andrea AU - Marshall A AD - Gold Coast Hospital and Health Service, Gold Coast, QLD. AD - Menzies Health Institute Queensland, Griffith University, Gold Coast, QLD. FAU - Hall, Emma J AU - Hall EJ AD - Gold Coast Hospital and Health Service, Gold Coast, QLD. FAU - Ranse, Jamie AU - Ranse J AD - Gold Coast Hospital and Health Service, Gold Coast, QLD. AD - Menzies Health Institute Queensland, Griffith University, Gold Coast, QLD. FAU - Zhang, Ping AU - Zhang P AD - Menzies Health Institute Queensland, Griffith University, Gold Coast, QLD. FAU - Grant, Gary AU - Grant G AD - Menzies Health Institute Queensland, Griffith University, Gold Coast, QLD. FAU - Huang, Ya-Ling AU - Huang YL AD - Gold Coast Hospital and Health Service, Gold Coast, QLD. AD - Southern Cross University Faculty of Health, Gold Coast, QLD. FAU - Palipana, Dinesh AU - Palipana D AD - Griffith University, Gold Coast, QLD. AD - Gold Coast Hospital and Health Service, Gold Coast, QLD. FAU - Teng, Yang D AU - Teng YD AD - Harvard Medical School, Boston, MA, United States of America. FAU - Gerhardy, Benjamin AU - Gerhardy B AD - Nepean Hospital, Penrith, NSW. FAU - Greenslade, Jaimi H AU - Greenslade JH AD - Royal Brisbane and Women's Hospital, Brisbane, QLD. AD - Australian Centre for Health Services Innovation, Centre for Healthcare Transformation, Queensland University of Technology, Brisbane, QLD. FAU - Jones, Philip AU - Jones P AD - Gold Coast Hospital and Health Service, Gold Coast, QLD. FAU - Crilly, Julia L AU - Crilly JL AD - Gold Coast Hospital and Health Service, Gold Coast, QLD. AD - Menzies Health Institute Queensland, Griffith University, Gold Coast, QLD. LA - eng GR - Emergency Medicine Foundation/ PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20221226 PL - Australia TA - Med J Aust JT - The Medical journal of Australia JID - 0400714 SB - IM MH - Humans MH - *COVID-19 MH - Pandemics MH - Queensland MH - Interrupted Time Series Analysis MH - Communicable Disease Control MH - Emergency Service, Hospital MH - *Stroke/epidemiology MH - Retrospective Studies PMC - PMC9880727 OTO - NOTNLM OT - COVID-19 OT - Disease transmission OT - Emergency services OT - Forecasting OT - Public health OT - infectious OT - medical COIS- No relevant disclosures. EDAT- 2022/12/27 06:00 MHDA- 2023/02/25 06:00 PMCR- 2022/12/26 CRDT- 2022/12/26 03:22 PHST- 2022/10/12 00:00 [revised] PHST- 2022/06/20 00:00 [received] PHST- 2022/10/13 00:00 [accepted] PHST- 2022/12/27 06:00 [pubmed] PHST- 2023/02/25 06:00 [medline] PHST- 2022/12/26 03:22 [entrez] PHST- 2022/12/26 00:00 [pmc-release] AID - MJA251819 [pii] AID - 10.5694/mja2.51819 [doi] PST - ppublish SO - Med J Aust. 2023 Feb 20;218(3):120-125. doi: 10.5694/mja2.51819. Epub 2022 Dec 26. PMID- 36538348 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230723 IS - 2561-326X (Electronic) IS - 2561-326X (Linking) VI - 6 IP - 12 DP - 2022 Dec 20 TI - Preferences of Older Adult Veterans With Heart Failure for Engaging With Mobile Health Technology to Support Self-care: Qualitative Interview Study Among Patients With Heart Failure and Content Analysis. PG - e41317 LID - 10.2196/41317 [doi] LID - e41317 AB - BACKGROUND: Heart failure (HF) affects approximately 6.5 million adults in the United States, disproportionately afflicting older adults. Mobile health (mHealth) has emerged as a promising tool to empower older adults in HF self-care. However, little is known about the use of this approach among older adult veterans. OBJECTIVE: The goal of this study was to explore which features of an app were prioritized for older adult veterans with HF. METHODS: Between January and July 2021, we conducted semistructured interviews with patients with heart failure aged 65 years and older at a single facility in an integrated health care system (the Veterans Health Administration). We performed content analysis and derived themes based on the middle-range theory of chronic illness, generating findings both deductively and inductively. The qualitative questions captured data on the 3 key themes of the theory: self-care maintenance, self-care monitoring, and self-care management. Qualitative responses were analyzed using a qualitative data management platform, and descriptive statistics were used to analyze demographic data. RESULTS: Among patients interviewed (n=9), most agreed that a smartphone app for supporting HF self-care was desirable. In addition to 3 a priori themes, we identified 7 subthemes: education on daily HF care, how often to get education on HF, support of medication adherence, dietary restriction support, goal setting for exercises, stress reduction strategies, and prompts of when to call a provider. In addition, we identified 3 inductive themes related to veteran preferences for app components: simplicity, ability to share data with caregivers, and positive framing of HF language. CONCLUSIONS: We identified educational and tracking app features that can guide the development of HF self-care for an older adult veteran population. Future research needs to be done to extend these findings and assess the feasibility of and test an app with these features. CI - (c)Marva Foster, Wei Xiong, Lisa Quintiliani, Christine W Hartmann, Stephan Gaehde. Originally published in JMIR Formative Research (https://formative.jmir.org), 20.12.2022. FAU - Foster, Marva AU - Foster M AUID- ORCID: 0000-0002-2265-0413 AD - VA Boston Healthcare System, Center for Healthcare Organization and Implementation Research, Boston, MA, United States. AD - Department of General Internal Medicine, School of Medicine, Boston University, Boston, MA, United States. FAU - Xiong, Wei AU - Xiong W AUID- ORCID: 0000-0002-7214-4404 AD - Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States. FAU - Quintiliani, Lisa AU - Quintiliani L AUID- ORCID: 0000-0002-3328-6768 AD - Department of General Internal Medicine, School of Medicine, Boston University, Boston, MA, United States. FAU - Hartmann, Christine W AU - Hartmann CW AUID- ORCID: 0000-0003-0983-0601 AD - VA Bedford Healthcare System, Center for Healthcare Organization and Implementation Research, Bedford, MA, United States. AD - Department of Public Health, Zuckerberg College of Health Sciences, University of Massachusetts, Lowell, MA, United States. FAU - Gaehde, Stephan AU - Gaehde S AUID- ORCID: 0000-0002-8536-4465 AD - VA Boston Healthcare System, Department of Medicine, Section of Emergency Services, Boston, MA, United States. AD - Department of Medicine, School of Medicine, Boston University, Boston, MA, United States. LA - eng GR - IK6 HX003398/HX/HSRD VA/United States PT - Journal Article DEP - 20221220 PL - Canada TA - JMIR Form Res JT - JMIR formative research JID - 101726394 PMC - PMC9812271 OTO - NOTNLM OT - elderly OT - elderly health care OT - elderly self-care OT - heart failure OT - mHealth technology OT - mhealth intervention OT - mobile health OT - mobile health technology OT - older adults OT - perceptions OT - qualitative research OT - self-care OT - veteran health COIS- Conflicts of Interest: None declared. EDAT- 2022/12/21 06:00 MHDA- 2022/12/21 06:01 PMCR- 2022/12/20 CRDT- 2022/12/20 11:52 PHST- 2022/07/21 00:00 [received] PHST- 2022/11/14 00:00 [accepted] PHST- 2022/11/09 00:00 [revised] PHST- 2022/12/20 11:52 [entrez] PHST- 2022/12/21 06:00 [pubmed] PHST- 2022/12/21 06:01 [medline] PHST- 2022/12/20 00:00 [pmc-release] AID - v6i12e41317 [pii] AID - 10.2196/41317 [doi] PST - epublish SO - JMIR Form Res. 2022 Dec 20;6(12):e41317. doi: 10.2196/41317. PMID- 36510241 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240526 IS - 1752-1505 (Print) IS - 1752-1505 (Electronic) IS - 1752-1505 (Linking) VI - 16 IP - 1 DP - 2022 Dec 12 TI - Adult mortality before and during the first wave of COVID-19 pandemic in nine communities of Yemen: a key informant study. PG - 63 LID - 10.1186/s13031-022-00497-3 [doi] LID - 63 AB - INTRODUCTION: Widespread armed conflict has affected Yemen since 2014. To date, the mortality toll of seven years of crisis, and any excess due to the COVID-19 pandemic, are not well quantified. We attempted to estimate population mortality during the pre-pandemic and pandemic periods in nine purposively selected urban and rural communities of southern and central Yemen (Aden and Ta'iz governorates), totalling > 100,000 people. METHODS: Within each study site, we collected lists of decedents between January 2014-March 2021 by interviewing different categories of key community informants, including community leaders, imams, healthcare workers, senior citizens and others. After linking records across lists based on key variables, we applied two-, three- or four-list capture-recapture analysis to estimate total death tolls. We also computed death rates by combining these estimates with population denominators, themselves subject to estimation. RESULTS: After interviewing 138 disproportionately (74.6%) male informants, we identified 2445 unique decedents. While informants recalled deaths throughout the study period, reported deaths among children were sparse: we thus restricted analysis to persons aged >/= 15 years old. We noted a peak in reported deaths during May-July 2020, plausibly coinciding with the first COVID-19 wave. Death rate estimates featured uninformatively large confidence intervals, but appeared elevated compared to the non-crisis baseline, particularly in two sites where a large proportion of deaths were attributed to war injuries. There was no clear-cut evidence of excess mortality during the pandemic period. CONCLUSIONS: We found some evidence of a peak in mortality during the early phase of the pandemic, but death rate estimates were otherwise too imprecise to enable strong inference on trends. Estimates suggested substantial mortality elevations from baseline during the crisis period, but are subject to serious potential biases. The study highlighted challenges of data collection in this insecure, politically contested environment. CI - (c) 2022. The Author(s). FAU - Alhaffar, Mervat AU - Alhaffar M AD - Department of Infectious Disease Epidemiology, Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, UK. Mervat.Alhaffar1@lshtm.ac.uk. FAU - Basaleem, Huda AU - Basaleem H AD - Department of Community Medicine and Public Health, Faculty of Medicine and Health Science, University of Aden, Aden, Yemen. FAU - Othman, Fouad AU - Othman F AD - Faculty of Medicine and Health Science, Ta'iz University, Ta'iz, Yemen. FAU - Alsakkaf, Khaled AU - Alsakkaf K AD - Department of Community Medicine and Public Health, Faculty of Medicine and Health Science, University of Aden, Aden, Yemen. FAU - Naji, Sena Mohammed Mohsen AU - Naji SMM AD - Epidemiology Surveillance Office, Ta'iz Governorate Health Office, Ta'iz, Yemen. FAU - Kolaise, Hussein AU - Kolaise H AD - Department of Internal Medicine, Faculty of Medicine and Health Science, University of Aden, Aden, Yemen. FAU - Babattah, Abdullah K AU - Babattah AK AD - Primary Health Care Program, Health Sector, HUMAN ACCESS for Partnership and Development, Aden, Yemen. FAU - Salem, Yassin Abdulmalik Mahyoub AU - Salem YAM AD - Epidemiology Surveillance Office, Ta'iz Governorate Health Office, Ta'iz, Yemen. FAU - Brindle, Hannah AU - Brindle H AD - Department of Infectious Disease Epidemiology, Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, UK. FAU - Yahya, Najwa AU - Yahya N AD - Yemen Public Health Network, Aden, Yemen. FAU - Pepe, Pasquale AU - Pepe P AD - Department of Infectious Disease Epidemiology, Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, UK. FAU - Checchi, Francesco AU - Checchi F AD - Department of Infectious Disease Epidemiology, Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, UK. LA - eng GR - 300708-139/Foreign, Commonwealth and Development Office/ PT - Journal Article DEP - 20221212 PL - England TA - Confl Health JT - Conflict and health JID - 101286573 PMC - PMC9743127 OTO - NOTNLM OT - Armed conflict OT - COVID-19 OT - Capture recapture OT - Crisis OT - Humanitarian OT - Key informant OT - Mortality OT - Multiple systems estimation OT - SARS-CoV-2 OT - Yemen COIS- The authors declare that they have no competing interests. EDAT- 2022/12/13 06:00 MHDA- 2022/12/13 06:01 PMCR- 2022/12/12 CRDT- 2022/12/12 23:50 PHST- 2022/05/15 00:00 [received] PHST- 2022/12/05 00:00 [accepted] PHST- 2022/12/12 23:50 [entrez] PHST- 2022/12/13 06:00 [pubmed] PHST- 2022/12/13 06:01 [medline] PHST- 2022/12/12 00:00 [pmc-release] AID - 10.1186/s13031-022-00497-3 [pii] AID - 497 [pii] AID - 10.1186/s13031-022-00497-3 [doi] PST - epublish SO - Confl Health. 2022 Dec 12;16(1):63. doi: 10.1186/s13031-022-00497-3. PMID- 36466214 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20221224 IS - 2772-7076 (Electronic) IS - 2772-7076 (Linking) VI - 6 DP - 2023 Mar TI - High anti-SARS-CoV-2 seroprevalence among unvaccinated mother-child pairs from a rural setting in north-eastern Tanzania during the second wave of COVID-19. PG - 48-57 LID - 10.1016/j.ijregi.2022.11.011 [doi] AB - BACKGROUND: The reported infection rates and burden of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in low- and middle-income countries, including those in sub-Saharan Africa, are relatively low compared to the rates and burden in Europe and America, partly due to limited testing capability. Unlike many countries, Tanzania has implemented neither mass screening nor restrictive measures such as lockdowns to date. The prevalence of SARS-CoV-2 infection in rural mainland Tanzania is largely unknown. METHODS: A cross-sectional study was conducted between April and October 2021 to assess the anti-SARS-CoV-2 seroprevalence among mother-child pairs (n = 634 children, n = 518 mothers) in a rural setting in north-eastern Tanzania. RESULTS: A very high prevalence of anti-SARS-CoV-2 antibody titres was found, with seroprevalence rates ranging from 29% among mothers and 40% among children, with a dynamic peak in seropositivity incidence at the end of July/early August being revealed. Significant differences in age, socioeconomic status, and body composition were associated with seropositivity in mothers and children. No significant associations were observed between seropositivity and comorbidities, including anaemia, diabetes, malaria, and HIV. CONCLUSIONS: The transmission of SARS-CoV-2 in a rural region of Tanzania during 2021 was high, indicating a much higher infection rate in rural Tanzania compared to that reported in the UK and USA during the same period. Ongoing immune surveillance may be vital to monitoring the burden of viral infection in rural settings without access to molecular genotyping, where the load of communicable diseases may mask COVID-19. Surveillance could be implemented in tandem with the intensification of vaccination strategies. CI - (c) 2022 The Authors. FAU - Msemo, Omari Abdul AU - Msemo OA AD - National Institute for Medical Research, Tanga Centre, Tanga, Tanzania. FAU - Perez-Alos, Laura AU - Perez-Alos L AD - Laboratory of Molecular Medicine, Department of Clinical Immunology, Section 7631, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark. FAU - Minja, Daniel T R AU - Minja DTR AD - National Institute for Medical Research, Tanga Centre, Tanga, Tanzania. FAU - Hansen, Cecilie Bo AU - Hansen CB AD - Laboratory of Molecular Medicine, Department of Clinical Immunology, Section 7631, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark. FAU - Gesase, Samwel AU - Gesase S AD - National Institute for Medical Research, Tanga Centre, Tanga, Tanzania. FAU - Mtove, George AU - Mtove G AD - National Institute for Medical Research, Tanga Centre, Tanga, Tanzania. FAU - Mbwana, Joyce AU - Mbwana J AD - National Institute for Medical Research, Tanga Centre, Tanga, Tanzania. FAU - Larsen, Victoria Marie Linderod AU - Larsen VML AD - Laboratory of Molecular Medicine, Department of Clinical Immunology, Section 7631, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark. AD - Department of Technology, Faculty of Health, University College Copenhagen, Copenhagen, Denmark. FAU - Bogestad, Emilie Caroline Skuladottir AU - Bogestad ECS AD - Laboratory of Molecular Medicine, Department of Clinical Immunology, Section 7631, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark. AD - Department of Technology, Faculty of Health, University College Copenhagen, Copenhagen, Denmark. FAU - Grunnet, Louise Groth AU - Grunnet LG AD - Steno Diabetes Center Copenhagen, Herlev, Denmark. FAU - Christensen, Dirk Lund AU - Christensen DL AD - Global Health Section, Department of Public Health, University of Copenhagen, Copenhagen, Denmark. FAU - Bygbjerg, Ib Christian AU - Bygbjerg IC AD - Global Health Section, Department of Public Health, University of Copenhagen, Copenhagen, Denmark. FAU - Burgner, David AU - Burgner D AD - Murdoch Children's Research Institute, Melbourne, Victoria, Australia. AD - Department of Paediatrics, Melbourne University, Melbourne, Victoria, Australia. FAU - Schmiegelow, Christentze AU - Schmiegelow C AD - Centre for Medical Parasitology, Department of Immunology and Microbiology, University of Copenhagen and Department of Infectious Diseases, Copenhagen University Hospital, Copenhagen, Denmark. AD - Department of Obstetrics, Copenhagen University Hospital, Copenhagen, Denmark. FAU - Garred, Peter AU - Garred P AD - Laboratory of Molecular Medicine, Department of Clinical Immunology, Section 7631, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark. FAU - Hjort, Line AU - Hjort L AD - Novo Nordisk Foundation Centre for Basic Metabolic Research, Metabolic Epigenetics Group, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. AD - Novo Nordisk Foundation Centre for Basic Metabolic Research, Metabolic Epigenetics Group, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. LA - eng PT - Journal Article DEP - 20221128 PL - England TA - IJID Reg JT - IJID regions JID - 9918418183106676 PMC - PMC9709504 OTO - NOTNLM OT - Anti-SARS-CoV-2 OT - Immune surveillance OT - Low- and middle-income countries OT - Rural OT - Seroprevalence OT - Sub-Saharan Africa OT - Tanzania OT - Vaccination EDAT- 2022/12/06 06:00 MHDA- 2022/12/06 06:01 PMCR- 2022/11/28 CRDT- 2022/12/05 03:58 PHST- 2022/10/04 00:00 [received] PHST- 2022/11/23 00:00 [revised] PHST- 2022/11/24 00:00 [accepted] PHST- 2022/12/06 06:00 [pubmed] PHST- 2022/12/06 06:01 [medline] PHST- 2022/12/05 03:58 [entrez] PHST- 2022/11/28 00:00 [pmc-release] AID - S2772-7076(22)00144-8 [pii] AID - 10.1016/j.ijregi.2022.11.011 [doi] PST - ppublish SO - IJID Reg. 2023 Mar;6:48-57. doi: 10.1016/j.ijregi.2022.11.011. Epub 2022 Nov 28. PMID- 36449326 OWN - NLM STAT- MEDLINE DCOM- 20221202 LR - 20260503 IS - 1438-8871 (Electronic) IS - 1439-4456 (Print) IS - 1438-8871 (Linking) VI - 24 IP - 11 DP - 2022 Nov 30 TI - Ice Flavor-Related Discussions on Twitter: Content Analysis. PG - e41785 LID - 10.2196/41785 [doi] LID - e41785 AB - BACKGROUND: The US Food and Drug Administration (FDA) recently restricted characterizing flavors in tobacco products. As a result, ice hybrid-flavored e-cigarettes, which combine a cooling flavor with fruit or other flavors (eg, banana ice), emerged on the market. Like menthol, ice-flavored e-cigarettes produce a cooling sensory experience. It is unclear if ice hybrid-flavored e-cigarettes should be considered characterizing flavors or menthol, limiting regulatory action. Monitoring the public's conversations about ice-flavored e-cigarettes on Twitter may help inform the tobacco control community about these products and contribute to the US FDA policy targets in the future. OBJECTIVE: This study documented the themes pertaining to vaping and ice flavor-related conversations on Twitter. Our goal was to identify key conversation trends and ascertain users' recent experiences with ice-flavored e-cigarette products. METHODS: Posts containing vaping-related (eg, "vape," "ecig," "e-juice," or "e-cigarette") and ice-related (ie, "Ice," "Cool," "Frost," and "Arctic") terms were collected from Twitter's streaming application programming interface from January 1 to July 21, 2021. After removing retweets, a random sample of posts (N=2001) was selected, with 590 posts included in the content analysis. Themes were developed through an inductive approach. Theme co-occurrence was also examined. RESULTS: Many of the 590 posts were marked as (or consisted of) marketing material (n=306, 51.9%), contained positive personal testimonials (n=180, 30.5%), and mentioned disposable pods (n=117, 19.8%). Other themes had relatively low prevalence in the sample: neutral personal testimonials (n=45, 7.6%), cannabidiol products (n=41, 7%), negative personal testimonials (n=41, 7%), "official" flavor description (n=37, 6.3%), ice-flavored JUUL (n=19, 3.2%), information seeking (n=14, 2.4%), and comparison to combustible tobacco (n=10, 1.7%). The most common co-occurring themes in a single tweet were related to marketing and disposable pods (n=73, 12.4%). CONCLUSIONS: Our findings offer insight into the public's experience with and understanding of ice-flavored e-cigarette products. Ice-flavored e-cigarette products are actively marketed on Twitter, and the messages about them are positive. Public health education campaigns on the harms of flavored e-cigarettes may help to reduce positive social norms about ice-flavored products. Future studies should evaluate the relationship between exposure to personal testimonials of ice-flavored vaping products and curiosity, harm perceptions, and experimentation with these products among priority populations. CI - (c)Artur Galimov, Julia Vassey, Ellen Galstyan, Jennifer B Unger, Matthew G Kirkpatrick, Jon-Patrick Allem. Originally published in the Journal of Medical Internet Research (https://www.jmir.org), 30.11.2022. FAU - Galimov, Artur AU - Galimov A AUID- ORCID: 0000-0002-9718-439X AD - Department of Population and Public Health Sciences, Keck School of Medicine of University of Southern California, Los Angeles, CA, United States. FAU - Vassey, Julia AU - Vassey J AUID- ORCID: 0000-0003-3002-2000 AD - Department of Population and Public Health Sciences, Keck School of Medicine of University of Southern California, Los Angeles, CA, United States. FAU - Galstyan, Ellen AU - Galstyan E AUID- ORCID: 0000-0003-1350-5983 AD - Department of Population and Public Health Sciences, Keck School of Medicine of University of Southern California, Los Angeles, CA, United States. FAU - Unger, Jennifer B AU - Unger JB AUID- ORCID: 0000-0001-9064-6603 AD - Department of Population and Public Health Sciences, Keck School of Medicine of University of Southern California, Los Angeles, CA, United States. FAU - Kirkpatrick, Matthew G AU - Kirkpatrick MG AUID- ORCID: 0000-0003-2586-9514 AD - Department of Population and Public Health Sciences, Keck School of Medicine of University of Southern California, Los Angeles, CA, United States. FAU - Allem, Jon-Patrick AU - Allem JP AUID- ORCID: 0000-0001-9135-8689 AD - Department of Population and Public Health Sciences, Keck School of Medicine of University of Southern California, Los Angeles, CA, United States. LA - eng GR - U54 CA180905/CA/NCI NIH HHS/United States PT - Journal Article PT - Research Support, U.S. Gov't, P.H.S. DEP - 20221130 PL - Canada TA - J Med Internet Res JT - Journal of medical Internet research JID - 100959882 RN - 1490-04-6 (Menthol) RN - 0 (Ice) SB - IM MH - United States MH - Humans MH - *Electronic Nicotine Delivery Systems MH - Menthol MH - Ice MH - *Social Media MH - *Vaping MH - Nicotiana PMC - PMC9752452 OTO - NOTNLM OT - FDA OT - Twitter OT - e-cigarette OT - electronic cigarettes OT - ice flavors OT - infodemiology OT - public OT - public health OT - smoking OT - social media OT - tobacco OT - tobacco policy OT - vaping COIS- Conflicts of Interest: J-PA has received fees for consulting services in court cases pertaining to the content on social media platforms. He reports no other conflicts of interest. All other authors declare no competing interests. EDAT- 2022/12/01 06:00 MHDA- 2022/12/03 06:00 PMCR- 2022/11/30 CRDT- 2022/11/30 11:52 PHST- 2022/08/08 00:00 [received] PHST- 2022/11/09 00:00 [accepted] PHST- 2022/10/26 00:00 [revised] PHST- 2022/11/30 11:52 [entrez] PHST- 2022/12/01 06:00 [pubmed] PHST- 2022/12/03 06:00 [medline] PHST- 2022/11/30 00:00 [pmc-release] AID - v24i11e41785 [pii] AID - 10.2196/41785 [doi] PST - epublish SO - J Med Internet Res. 2022 Nov 30;24(11):e41785. doi: 10.2196/41785. PMID- 36417468 OWN - NLM STAT- MEDLINE DCOM- 20221215 LR - 20260930 IS - 1553-7358 (Electronic) IS - 1553-734X (Print) IS - 1553-734X (Linking) VI - 18 IP - 11 DP - 2022 Nov TI - Trends in SARS-CoV-2 infection prevalence during England's roadmap out of lockdown, January to July 2021. PG - e1010724 LID - 10.1371/journal.pcbi.1010724 [doi] LID - e1010724 AB - BACKGROUND: Following rapidly rising COVID-19 case numbers, England entered a national lockdown on 6 January 2021, with staged relaxations of restrictions from 8 March 2021 onwards. AIM: We characterise how the lockdown and subsequent easing of restrictions affected trends in SARS-CoV-2 infection prevalence. METHODS: On average, risk of infection is proportional to infection prevalence. The REal-time Assessment of Community Transmission-1 (REACT-1) study is a repeat cross-sectional study of over 98,000 people every round (rounds approximately monthly) that estimates infection prevalence in England. We used Bayesian P-splines to estimate prevalence and the time-varying reproduction number (Rt) nationally, regionally and by age group from round 8 (beginning 6 January 2021) to round 13 (ending 12 July 2021) of REACT-1. As a comparator, a separate segmented-exponential model was used to quantify the impact on Rt of each relaxation of restrictions. RESULTS: Following an initial plateau of 1.54% until mid-January, infection prevalence decreased until 13 May when it reached a minimum of 0.09%, before increasing until the end of the study to 0.76%. Following the first easing of restrictions, which included schools reopening, the reproduction number Rt increased by 82% (55%, 108%), but then decreased by 61% (82%, 53%) at the second easing of restrictions, which was timed to match the Easter school holidays. Following further relaxations of restrictions, the observed Rt increased steadily, though the increase due to these restrictions being relaxed was offset by the effects of vaccination and also affected by the rapid rise of Delta. There was a high degree of synchrony in the temporal patterns of prevalence between regions and age groups. CONCLUSION: High-resolution prevalence data fitted to P-splines allowed us to show that the lockdown was effective at reducing risk of infection with school holidays/closures playing a significant part. CI - Copyright: (c) 2022 Eales et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. FAU - Eales, Oliver AU - Eales O AUID- ORCID: 0000-0002-8086-4495 AD - School of Public Health, Imperial College London, London, United Kingdom. AD - MRC Centre for Global infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergency Analytics, Imperial College London, London, United Kingdom. FAU - Wang, Haowei AU - Wang H AD - School of Public Health, Imperial College London, London, United Kingdom. AD - MRC Centre for Global infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergency Analytics, Imperial College London, London, United Kingdom. FAU - Haw, David AU - Haw D AD - School of Public Health, Imperial College London, London, United Kingdom. AD - MRC Centre for Global infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergency Analytics, Imperial College London, London, United Kingdom. FAU - Ainslie, Kylie E C AU - Ainslie KEC AD - School of Public Health, Imperial College London, London, United Kingdom. AD - MRC Centre for Global infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergency Analytics, Imperial College London, London, United Kingdom. AD - Centre for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, The Netherlands. FAU - Walters, Caroline E AU - Walters CE AD - School of Public Health, Imperial College London, London, United Kingdom. AD - MRC Centre for Global infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergency Analytics, Imperial College London, London, United Kingdom. FAU - Atchison, Christina AU - Atchison C AD - School of Public Health, Imperial College London, London, United Kingdom. FAU - Cooke, Graham AU - Cooke G AD - Department of Infectious Disease, Imperial College London, London, United Kingdom. AD - Imperial College Healthcare NHS Trust, London, United Kingdom. AD - National Institute for Health Research Imperial Biomedical Research Centre, London. FAU - Barclay, Wendy AU - Barclay W AD - Department of Infectious Disease, Imperial College London, London, United Kingdom. FAU - Ward, Helen AU - Ward H AD - School of Public Health, Imperial College London, London, United Kingdom. AD - Imperial College Healthcare NHS Trust, London, United Kingdom. AD - National Institute for Health Research Imperial Biomedical Research Centre, London. FAU - Darzi, Ara AU - Darzi A AUID- ORCID: 0000-0001-7815-7989 AD - Imperial College Healthcare NHS Trust, London, United Kingdom. AD - National Institute for Health Research Imperial Biomedical Research Centre, London. AD - Institute of Global Health Innovation at Imperial College London, London, United Kingdom. FAU - Ashby, Deborah AU - Ashby D AD - School of Public Health, Imperial College London, London, United Kingdom. FAU - Donnelly, Christl A AU - Donnelly CA AD - School of Public Health, Imperial College London, London, United Kingdom. AD - MRC Centre for Global infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergency Analytics, Imperial College London, London, United Kingdom. AD - Department of Statistics, University of Oxford, Oxford, United Kingdom. FAU - Elliott, Paul AU - Elliott P AD - School of Public Health, Imperial College London, London, United Kingdom. AD - Imperial College Healthcare NHS Trust, London, United Kingdom. AD - National Institute for Health Research Imperial Biomedical Research Centre, London. AD - MRC Centre for Environment and Health, School of Public Health, Imperial College London, London, United Kingdom. AD - Health Data Research (HDR) UK London at Imperial College, London, United Kingdom. AD - UK Dementia Research Institute at Imperial College, London, United Kingdom. FAU - Riley, Steven AU - Riley S AD - School of Public Health, Imperial College London, London, United Kingdom. AD - MRC Centre for Global infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergency Analytics, Imperial College London, London, United Kingdom. LA - eng GR - MR/L01341X/1/MRC_/Medical Research Council/United Kingdom GR - MC_PC_19012/MRC_/Medical Research Council/United Kingdom GR - 200861/Z/16/Z/WT_/Wellcome Trust/United Kingdom GR - MC_PC_17114/MRC_/Medical Research Council/United Kingdom GR - MR/J008761/1/MRC_/Medical Research Council/United Kingdom GR - 200187/Z/15/Z/WT_/Wellcome Trust/United Kingdom GR - MR/R015600/1/MRC_/Medical Research Council/United Kingdom GR - MR/S019669/1/MRC_/Medical Research Council/United Kingdom GR - 205456/Z/16/Z/WT_/Wellcome Trust/United Kingdom GR - RE/18/4/34215/BHF_/British Heart Foundation/United Kingdom PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Research Support, U.S. Gov't, P.H.S. DEP - 20221123 PL - United States TA - PLoS Comput Biol JT - PLoS computational biology JID - 101238922 SB - IM MH - Humans MH - *COVID-19/epidemiology/prevention & control MH - Cross-Sectional Studies MH - Bayes Theorem MH - Communicable Disease Control MH - SARS-CoV-2 PMC - PMC9728904 COIS- The authors have declared that no competing interests exist. EDAT- 2022/11/24 06:00 MHDA- 2022/12/15 06:00 PMCR- 2022/11/23 CRDT- 2022/11/23 13:53 PHST- 2022/06/28 00:00 [received] PHST- 2022/11/07 00:00 [accepted] PHST- 2022/12/07 00:00 [revised] PHST- 2022/11/24 06:00 [pubmed] PHST- 2022/12/15 06:00 [medline] PHST- 2022/11/23 13:53 [entrez] PHST- 2022/11/23 00:00 [pmc-release] AID - PCOMPBIOL-D-22-00962 [pii] AID - 10.1371/journal.pcbi.1010724 [doi] PST - epublish SO - PLoS Comput Biol. 2022 Nov 23;18(11):e1010724. doi: 10.1371/journal.pcbi.1010724. eCollection 2022 Nov. PMID- 36416209 OWN - NLM STAT- MEDLINE DCOM- 20230504 LR - 20240603 IS - 1475-6773 (Electronic) IS - 0017-9124 (Print) IS - 0017-9124 (Linking) VI - 58 IP - 3 DP - 2023 Jun TI - Perspectives of nursing home administrators across the United States during the COVID-19 pandemic. PG - 686-696 LID - 10.1111/1475-6773.14104 [doi] AB - OBJECTIVE: To characterize the experiences of nursing home administrators as they manage facilities across the United States during the COVID-19 pandemic. DATA SOURCES AND STUDY SETTING: We conducted 156 interviews, consisting of four repeated interviews with administrators from 40 nursing homes in eight health care markets across the country from July 2020 through December 2021. STUDY DESIGN: We subjected the interview transcripts to a rigorous qualitative analysis to identify overarching themes using a modified grounded theory approach to applied thematic analysis. DATA COLLECTION METHODS: In-depth, semi-structured qualitative interviews were conducted virtually or by phone, and audio-recorded, with participants' consent. Audio recordings were transcribed. PRINCIPAL FINDINGS: Interviews with nursing home administrators revealed a number of important cross-cutting themes. In interviewing each facility's administrator four times over the course of the pandemic, we heard perspectives regarding the stages of the pandemic, and how they varied by the facility and changed over time. We also heard how policies implemented by federal, state, and local governments to respond to COVID-19 were frequently changing, confusing, and conflicting. Administrators described the effect of COVID-19 and efforts to mitigate it on residents, including how restrictions on activities, communal dining, and visitation resulted in cognitive decline, depression, and weight loss. Administrators also discussed the impact of COVID-19 on staff and staffing levels, reporting widespread challenges in keeping facilities staffed as well as strategies used to hire and retain staff. Administrators described concerns for the sustainability of the nursing home industry resulting from the substantial costs and pressures associated with responding to COVID-19, the reductions in revenue, and the negative impact of how nursing homes appeared in the media. CONCLUSIONS: Findings from our research reflect nursing home administrator perspectives regarding challenges operating during COVID-19 and have substantial implications for policy and practice. CI - (c) 2022 Health Research and Educational Trust. FAU - Gadbois, Emily A AU - Gadbois EA AUID- ORCID: 0000-0003-1643-2732 AD - Brown University School of Public Health, Center for Gerontology and Healthcare Research, Providence, Rhode Island, USA. FAU - Brazier, Joan F AU - Brazier JF AD - Brown University School of Public Health, Center for Gerontology and Healthcare Research, Providence, Rhode Island, USA. FAU - Meehan, Amy AU - Meehan A AD - Brown University School of Public Health, Center for Gerontology and Healthcare Research, Providence, Rhode Island, USA. FAU - Rafat, Aseel AU - Rafat A AD - Brown University School of Public Health, Center for Gerontology and Healthcare Research, Providence, Rhode Island, USA. FAU - Rahman, Momotazur AU - Rahman M AUID- ORCID: 0000-0002-8592-3511 AD - Brown University School of Public Health, Center for Gerontology and Healthcare Research, Providence, Rhode Island, USA. FAU - Grabowski, David C AU - Grabowski DC AD - Department of Health Care Policy, Harvard Medical School, Boston, Massachusetts, USA. FAU - Shield, Renee AU - Shield R AD - Center for Gerontology and Healthcare Research, Brown University School of Public Health, Seekonk, Massachusetts, USA. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20221201 PL - United States TA - Health Serv Res JT - Health services research JID - 0053006 SB - IM MH - United States MH - Humans MH - *COVID-19/epidemiology MH - Pandemics MH - Nursing Homes MH - Skilled Nursing Facilities MH - Administrative Personnel PMC - PMC10154166 OTO - NOTNLM OT - COVID-19 OT - nursing homes OT - pandemic OT - qualitative OT - residents OT - skilled nursing facilities OT - staffing EDAT- 2022/11/24 06:00 MHDA- 2023/05/04 12:42 PMCR- 2024/06/01 CRDT- 2022/11/23 05:43 PHST- 2023/05/04 12:42 [medline] PHST- 2022/11/24 06:00 [pubmed] PHST- 2022/11/23 05:43 [entrez] PHST- 2024/06/01 00:00 [pmc-release] AID - HESR14104 [pii] AID - 10.1111/1475-6773.14104 [doi] PST - ppublish SO - Health Serv Res. 2023 Jun;58(3):686-696. doi: 10.1111/1475-6773.14104. Epub 2022 Dec 1. PMID- 36407792 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20221205 IS - 2352-3409 (Electronic) IS - 2352-3409 (Linking) VI - 45 DP - 2022 Dec TI - COVID-19 behavior determinants dataset. PG - 108732 LID - 10.1016/j.dib.2022.108732 [doi] LID - 108732 AB - The COVID-19 Behavior Determinants Database (http://covid19-database.com) is a research project that examined the sociodemographic and psychological determinants of COVID-19 related attitudes and behaviors. It is a comprehensive web-based survey that was administered to adults ages 18 or older (total n=8070) from the United States of America (n = 5326), including the four most populous states, specifically New York, California, Florida, and Texas, and Canada (n = 2744), including all provinces, except Quebec. The survey was collected at three timepoints, May 2020 (n=1019), July 2020 (n=4027), and March 2021 (n=3024). Participants provided detailed sociodemographic information and completed a battery of psychological assessments. Participants also provided information about prior testing for COVID-19 and perceived seriousness of COVID-19 and the need for current physical (social) distancing restrictions. The database is helpful to researchers and public health policy decision-makers who are interested in investigating and identifying the determinants of COVID-19 related attitudes and behaviors in North America. CI - (c) 2022 The Author(s). FAU - Song, Jianmeng AU - Song J AD - Institute of Medical Science, University of Toronto, Toronto, Canada. AD - Multimodal Imaging Group, Centre for Addiction and Mental Health (CAMH), Toronto, Canada. FAU - Kim, Julia AU - Kim J AD - Institute of Medical Science, University of Toronto, Toronto, Canada. AD - Multimodal Imaging Group, Centre for Addiction and Mental Health (CAMH), Toronto, Canada. FAU - Graff-Guerrero, Ariel AU - Graff-Guerrero A AD - Institute of Medical Science, University of Toronto, Toronto, Canada. AD - Multimodal Imaging Group, Centre for Addiction and Mental Health (CAMH), Toronto, Canada. AD - Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health (CAMH) , Toronto, Canada. AD - Department of Psychiatry, University of Toronto, Toronto, Canada. FAU - Quilty, Lena AU - Quilty L AD - Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health (CAMH) , Toronto, Canada. AD - Department of Psychiatry, University of Toronto, Toronto, Canada. FAU - Sanches, Marcos AU - Sanches M AD - Krembil Centre for Neuroinformatics, CAMH, Toronto, Canada. FAU - Wells, Samantha AU - Wells S AD - Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health (CAMH) , Toronto, Canada. AD - Department of Psychiatry, University of Toronto, Toronto, Canada. AD - Institute for Mental Health Policy Research, CAMH, Toronto, Canada. AD - Dalla Lana School of Public Health, University of Toronto, Toronto, Canada. FAU - Brown, Eric E AU - Brown EE AD - Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health (CAMH) , Toronto, Canada. AD - Department of Psychiatry, University of Toronto, Toronto, Canada. FAU - Agic, Branka AU - Agic B AD - Dalla Lana School of Public Health, University of Toronto, Toronto, Canada. AD - Provincial System Support Program (PSSP), CAMH, Toronto, Canada. FAU - Pollock, Bruce G AU - Pollock BG AD - Institute of Medical Science, University of Toronto, Toronto, Canada. AD - Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health (CAMH) , Toronto, Canada. AD - Department of Psychiatry, University of Toronto, Toronto, Canada. FAU - Gerretsen, Philip AU - Gerretsen P AD - Institute of Medical Science, University of Toronto, Toronto, Canada. AD - Multimodal Imaging Group, Centre for Addiction and Mental Health (CAMH), Toronto, Canada. AD - Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health (CAMH) , Toronto, Canada. AD - Department of Psychiatry, University of Toronto, Toronto, Canada. LA - eng PT - Journal Article DEP - 20221108 PL - Netherlands TA - Data Brief JT - Data in brief JID - 101654995 PMC - PMC9640375 OTO - NOTNLM OT - COVID-19 OT - COVID-19 related attitudes OT - COVID-19 related behaviours OT - Survey COIS- The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2022/11/22 06:00 MHDA- 2022/11/22 06:01 PMCR- 2022/11/08 CRDT- 2022/11/21 04:39 PHST- 2022/07/17 00:00 [received] PHST- 2022/09/07 00:00 [revised] PHST- 2022/11/02 00:00 [accepted] PHST- 2022/11/22 06:00 [pubmed] PHST- 2022/11/22 06:01 [medline] PHST- 2022/11/21 04:39 [entrez] PHST- 2022/11/08 00:00 [pmc-release] AID - S2352-3409(22)00936-2 [pii] AID - 108732 [pii] AID - 10.1016/j.dib.2022.108732 [doi] PST - ppublish SO - Data Brief. 2022 Dec;45:108732. doi: 10.1016/j.dib.2022.108732. Epub 2022 Nov 8. PMID- 36407655 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20260929 IS - 2211-6753 (Print) IS - 2211-6753 (Electronic) VI - 49 DP - 2022 Jun TI - Spatio-temporal modelling of COVID-19 incident cases using Richards' curve: An application to the Italian regions. PG - 100544 LID - 10.1016/j.spasta.2021.100544 [doi] AB - We introduce an extended generalised logistic growth model for discrete outcomes, in which spatial and temporal dependence are dealt with the specification of a network structure within an Auto-Regressive approach. A major challenge concerns the specification of the network structure, crucial to consistently estimate the canonical parameters of the generalised logistic curve, e.g. peak time and height. We compared a network based on geographic proximity and one built on historical data of transport exchanges between regions. Parameters are estimated under the Bayesian framework, using Stan probabilistic programming language. The proposed approach is motivated by the analysis of both the first and the second wave of COVID-19 in Italy, i.e. from February 2020 to July 2020 and from July 2020 to December 2020, respectively. We analyse data at the regional level and, interestingly enough, prove that substantial spatial and temporal dependence occurred in both waves, although strong restrictive measures were implemented during the first wave. Accurate predictions are obtained, improving those of the model where independence across regions is assumed. CI - (c) 2021 Elsevier B.V. All rights reserved. FAU - Mingione, Marco AU - Mingione M AD - University of Rome "La Sapienza", Dpt. of Statistical Sciences, Rome, Italy. AD - Institute of Applied Computing "M. Picone" (IAC - CNR), Italy. FAU - Alaimo Di Loro, Pierfrancesco AU - Alaimo Di Loro P AD - University of Rome "La Sapienza", Dpt. of Statistical Sciences, Rome, Italy. FAU - Farcomeni, Alessio AU - Farcomeni A AD - University of Rome "Tor Vergata", Dpt. of Economics and Finance, Italy. FAU - Divino, Fabio AU - Divino F AD - University of Molise, Dpt. of Bio-Sciences, Italy. FAU - Lovison, Gianfranco AU - Lovison G AD - University of Palermo, Dpt. of Economics, Management and Statistics, Italy. AD - Swiss TPH, Dpt. of Epidemiology and Public Health, Switzerland. FAU - Maruotti, Antonello AU - Maruotti A AD - Libera Universita Maria Ss Assunta, Dpt. GEPLI, Italy. AD - University of Bergen, Dpt. of Mathematics, Norway. FAU - Lasinio, Giovanna Jona AU - Lasinio GJ AD - University of Rome "La Sapienza", Dpt. of Statistical Sciences, Rome, Italy. LA - eng PT - Journal Article DEP - 20211009 PL - Netherlands TA - Spat Stat JT - Spatial statistics JID - 101612400 PMC - PMC9643104 OTO - NOTNLM OT - COVID-19 OT - Conditional Auto-Regressive OT - Generalised logistic growth OT - Stan EDAT- 2022/11/22 06:00 MHDA- 2022/11/22 06:01 PMCR- 2021/10/09 CRDT- 2022/11/21 04:37 PHST- 2021/04/15 00:00 [received] PHST- 2021/08/06 00:00 [revised] PHST- 2021/09/23 00:00 [accepted] PHST- 2022/11/21 04:37 [entrez] PHST- 2022/11/22 06:00 [pubmed] PHST- 2022/11/22 06:01 [medline] PHST- 2021/10/09 00:00 [pmc-release] AID - S2211-6753(21)00054-3 [pii] AID - 100544 [pii] AID - 10.1016/j.spasta.2021.100544 [doi] PST - ppublish SO - Spat Stat. 2022 Jun;49:100544. doi: 10.1016/j.spasta.2021.100544. Epub 2021 Oct 9. PMID- 36406146 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230427 IS - 2564-1891 (Electronic) IS - 2564-1891 (Linking) VI - 2 IP - 1 DP - 2022 Jan-Jun TI - Using Natural Language Processing to Explore Mental Health Insights From UK Tweets During the COVID-19 Pandemic: Infodemiology Study. PG - e32449 LID - 10.2196/32449 [doi] LID - e32449 AB - BACKGROUND: There is need to consider the value of soft intelligence, leveraged using accessible natural language processing (NLP) tools, as a source of analyzed evidence to support public health research outputs and decision-making. OBJECTIVE: The aim of this study was to explore the value of soft intelligence analyzed using NLP. As a case study, we selected and used a commercially available NLP platform to identify, collect, and interrogate a large collection of UK tweets relating to mental health during the COVID-19 pandemic. METHODS: A search strategy comprised of a list of terms related to mental health, COVID-19, and lockdown restrictions was developed to prospectively collate relevant tweets via Twitter's advanced search application programming interface over a 24-week period. We deployed a readily and commercially available NLP platform to explore tweet frequency and sentiment across the United Kingdom and identify key topics of discussion. A series of keyword filters were used to clean the initial data retrieved and also set up to track specific mental health problems. All collated tweets were anonymized. RESULTS: We identified and analyzed 286,902 tweets posted from UK user accounts from July 23, 2020 to January 6, 2021. The average sentiment score was 50%, suggesting overall neutral sentiment across all tweets over the study period. Major fluctuations in volume (between 12,622 and 51,340) and sentiment (between 25% and 49%) appeared to coincide with key changes to any local and/or national social distancing measures. Tweets around mental health were polarizing, discussed with both positive and negative sentiment. Key topics of consistent discussion over the study period included the impact of the pandemic on people's mental health (both positively and negatively), fear and anxiety over lockdowns, and anger and mistrust toward the government. CONCLUSIONS: Using an NLP platform, we were able to rapidly mine and analyze emerging health-related insights from UK tweets into how the pandemic may be impacting people's mental health and well-being. This type of real-time analyzed evidence could act as a useful intelligence source that agencies, local leaders, and health care decision makers can potentially draw from, particularly during a health crisis. CI - (c)Christopher Marshall, Kate Lanyi, Rhiannon Green, Georgina C Wilkins, Fiona Pearson, Dawn Craig. Originally published in JMIR Infodemiology (https://infodemiology.jmir.org), 31.03.2022. FAU - Marshall, Christopher AU - Marshall C AUID- ORCID: 0000-0002-7970-681X AD - National Institute for Health Research Innovation Observatory Newcastle University Newcastle United Kingdom. FAU - Lanyi, Kate AU - Lanyi K AUID- ORCID: 0000-0002-3258-7286 AD - National Institute for Health Research Innovation Observatory Newcastle University Newcastle United Kingdom. FAU - Green, Rhiannon AU - Green R AUID- ORCID: 0000-0001-6113-0675 AD - National Institute for Health Research Innovation Observatory Newcastle University Newcastle United Kingdom. FAU - Wilkins, Georgina C AU - Wilkins GC AUID- ORCID: 0000-0001-8800-3596 AD - National Institute for Health Research Innovation Observatory Newcastle University Newcastle United Kingdom. FAU - Pearson, Fiona AU - Pearson F AUID- ORCID: 0000-0003-1626-0862 AD - National Institute for Health Research Innovation Observatory Newcastle University Newcastle United Kingdom. FAU - Craig, Dawn AU - Craig D AUID- ORCID: 0000-0002-5808-0096 AD - National Institute for Health Research Innovation Observatory Newcastle University Newcastle United Kingdom. LA - eng PT - Journal Article DEP - 20220331 PL - Canada TA - JMIR Infodemiology JT - JMIR infodemiology JID - 9918249014806676 PMC - PMC9642841 OTO - NOTNLM OT - COVID-19 OT - Twitter OT - artificial intelligence OT - lockdown OT - machine learning OT - mental health OT - natural language processing OT - sentiment OT - soft intelligence COIS- Conflicts of Interest: The National Institute for Health Research (NIHR) Innovation Observatory purchased a license to use and evaluate the natural language processing (NLP) platform, Wordnerds. However, as independent users, the authors have no vested interest in the tool. EDAT- 2022/11/22 06:00 MHDA- 2022/11/22 06:01 PMCR- 2022/03/31 CRDT- 2022/11/21 04:12 PHST- 2021/07/28 00:00 [received] PHST- 2021/10/15 00:00 [revised] PHST- 2022/01/12 00:00 [accepted] PHST- 2022/11/21 04:12 [entrez] PHST- 2022/11/22 06:00 [pubmed] PHST- 2022/11/22 06:01 [medline] PHST- 2022/03/31 00:00 [pmc-release] AID - v2i1e32449 [pii] AID - 10.2196/32449 [doi] PST - epublish SO - JMIR Infodemiology. 2022 Mar 31;2(1):e32449. doi: 10.2196/32449. eCollection 2022 Jan-Jun. PMID- 36367583 OWN - NLM STAT- MEDLINE DCOM- 20221117 LR - 20260930 IS - 1537-4521 (Electronic) IS - 0148-5717 (Print) IS - 0148-5717 (Linking) VI - 49 IP - 12 DP - 2022 Dec 1 TI - Changes in Sexual Behavior Over the COVID-19 Pandemic Among a Community-Based Cohort of Men Who Have Sex With Men in Columbus, Ohio. PG - 844-850 LID - 10.1097/OLQ.0000000000001719 [doi] AB - BACKGROUND: The purpose was to assess COVID-19 beliefs and attitudes and examine COVID-19-related changes in sexual behavior of men who have sex with men during 3 time periods: April-July 2020 (T1), August-December 2020 (T2), January-May 2021 (T3). METHODS: Data were analyzed from 157 men who have sex with men in Ohio recruited to participate in a longitudinal multisite network study of syphilis epidemiology in 3 US cities: Columbus, Ohio; Baltimore, Maryland; and Chicago, Illinois. In April 2020, a COVID-19 module was appended to existing baseline and follow-up surveys to assess beliefs, attitudes, and changes in sexual behavior. Sample characteristics were summarized. Correlations between demographic variables (age, racial identity) and COVID-19 outcomes were examined. RESULTS: In response to COVID-19 social distancing restrictions and self-reported anxiety, some men limited sexual activity at T1, but the majority (n = 105 [67%]) continued to engage in sex. The number of men engaging in sex increased over time (T2: n = 124 [79%]; T3: n = 121 [77%]). At T1, men not in a relationship more frequently reported having less sex compared with prepandemic (n = 39 [57%]). By T3, men in a relationship more frequently reported less sex (n = 32 [54%]). Increased anxiety about sex and condom use was positively correlated with identifying as a man of color (P < 0.001). Most of the sample reported either starting or increasing online sexual activity during each time period. CONCLUSIONS: Future efforts to target sexual health during a pandemic or other health emergencies should prioritize men of color and address the unique perspective of both single and partnered men. CI - Copyright (c) 2022 American Sexually Transmitted Diseases Association. All rights reserved. FAU - Ricks, JaNelle M AU - Ricks JM AD - From the College of Public Health, Ohio State University, Columbus, OH. FAU - Spahnie, Morgan AU - Spahnie M AD - From the College of Public Health, Ohio State University, Columbus, OH. FAU - Matthews, Amiah AU - Matthews A AD - From the College of Public Health, Ohio State University, Columbus, OH. FAU - Copen, Casey E AU - Copen CE AD - Division of STD Prevention, Centers for Disease Control and Prevention, Atlanta, GA. FAU - Rushmore, Julie AU - Rushmore J AD - Division of STD Prevention, Centers for Disease Control and Prevention, Atlanta, GA. FAU - Bernstein, Kyle T AU - Bernstein KT AD - Division of STD Prevention, Centers for Disease Control and Prevention, Atlanta, GA. FAU - Miller, William C AU - Miller WC AD - From the College of Public Health, Ohio State University, Columbus, OH. FAU - Turner, Abigail N AU - Turner AN AD - College of Medicine, Ohio State University, Columbus, OH. LA - eng GR - U01 PS005170/PS/NCHHSTP CDC HHS/United States GR - U01PS005170/ACL/ACL HHS/United States PT - Journal Article PT - Research Support, U.S. Gov't, P.H.S. DEP - 20220930 PL - United States TA - Sex Transm Dis JT - Sexually transmitted diseases JID - 7705941 SB - IM MH - Humans MH - Male MH - *COVID-19/epidemiology MH - Homosexuality, Male MH - Ohio/epidemiology MH - Pandemics MH - *Sexual and Gender Minorities MH - *Sexual Behavior PMC - PMC9668357 COIS- Conflict of Interest and Sources of Funding: The author(s) declare no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. EDAT- 2022/11/12 06:00 MHDA- 2022/11/16 06:00 PMCR- 2022/09/30 CRDT- 2022/11/11 11:14 PHST- 2022/11/11 11:14 [entrez] PHST- 2022/11/12 06:00 [pubmed] PHST- 2022/11/16 06:00 [medline] PHST- 2022/09/30 00:00 [pmc-release] AID - 00007435-202212000-00009 [pii] AID - STD_220381 [pii] AID - 10.1097/OLQ.0000000000001719 [doi] PST - ppublish SO - Sex Transm Dis. 2022 Dec 1;49(12):844-850. doi: 10.1097/OLQ.0000000000001719. Epub 2022 Sep 30. PMID- 36361120 OWN - NLM STAT- MEDLINE DCOM- 20221114 LR - 20240907 IS - 1660-4601 (Electronic) IS - 1661-7827 (Print) IS - 1660-4601 (Linking) VI - 19 IP - 21 DP - 2022 Oct 31 TI - The Long-Term Impact of COVID-19 Lockdowns in Istanbul. LID - 10.3390/ijerph192114235 [doi] LID - 14235 AB - The World Health Organization (WHO) have set sustainability development goals to reduce diseases, deaths, and the environmental impact of cities due to air pollution. In Istanbul, although average pollutant concentrations have been on a downward trend in recent years, extreme values and their annual exceedance numbers are high based on the air quality standards of WHO and the EU. Due to COVID-19 lockdowns, statistically significant reductions in emissions were observed for short periods. However, how long the effect of the lockdowns will last is unknown. For this reason, this study aims to investigate the impact of long-term lockdowns on Istanbul's air quality. The restriction period is approximated to the same periods of the previous years to eliminate seasonal effects. A series of paired t-tests (p-value < 0.05) were applied to hourly data from 12 March 2016, until 1 July 2021, when quarantines were completed at 36 air quality monitoring stations in Istanbul. The findings reveal that the average air quality of Istanbul was approximately 17% improved during the long-term lockdowns. Therefore, the restriction-related changes in emission distributions continued in the long-term period of 476 days. However, it is unknown how long this effect will continue, which will be the subject of future studies. Moreover, it was observed that the emission probability density functions changed considerably during the lockdowns compared to the years before. Accordingly, notable decreases were detected in air quality limit exceedances in terms of both excessive pollutant concentrations and frequency of occurrence, respectively, for PM(10) (-13% and -13%), PM(2.5) (-16% and -30%), and NO(2) (-3% and -8%), but not for O(3) (+200% and +540%) and SO(2) (-10% and +2.5%). FAU - Tan, Elcin AU - Tan E AUID- ORCID: 0000-0001-7677-6073 AD - Department of Meteorological Engineering, Aeronautics and Astronautics Faculty, Istanbul Technical University, Maslak, 34469 Istanbul, Turkey. LA - eng PT - Journal Article DEP - 20221031 PL - Switzerland TA - Int J Environ Res Public Health JT - International journal of environmental research and public health JID - 101238455 RN - 0 (Air Pollutants) RN - 0 (Particulate Matter) RN - S7G510RUBH (Nitrogen Dioxide) SB - IM MH - Humans MH - *Air Pollutants/analysis MH - Particulate Matter/analysis MH - *COVID-19/epidemiology/prevention & control MH - Communicable Disease Control MH - *Air Pollution/analysis MH - Environmental Monitoring MH - Nitrogen Dioxide/analysis PMC - PMC9654864 OTO - NOTNLM OT - COVID-19 lockdown OT - nitrogen dioxide OT - ozone OT - particulate matter OT - sulfur dioxide COIS- The author declares no conflict of interest. EDAT- 2022/11/12 06:00 MHDA- 2022/11/15 06:00 PMCR- 2022/10/31 CRDT- 2022/11/11 01:20 PHST- 2022/09/17 00:00 [received] PHST- 2022/10/19 00:00 [revised] PHST- 2022/10/28 00:00 [accepted] PHST- 2022/11/11 01:20 [entrez] PHST- 2022/11/12 06:00 [pubmed] PHST- 2022/11/15 06:00 [medline] PHST- 2022/10/31 00:00 [pmc-release] AID - ijerph192114235 [pii] AID - ijerph-19-14235 [pii] AID - 10.3390/ijerph192114235 [doi] PST - epublish SO - Int J Environ Res Public Health. 2022 Oct 31;19(21):14235. doi: 10.3390/ijerph192114235. PMID- 36347786 OWN - NLM STAT- MEDLINE DCOM- 20221212 LR - 20221221 IS - 1808-8686 (Electronic) IS - 1808-8694 (Print) IS - 1808-8686 (Linking) VI - 88 Suppl 3 IP - Suppl 3 DP - 2022 Nov-Dec TI - Vestibular assessment in children aged zero to twelve years: an integrative review. PG - S212-S224 LID - S1808-8694(22)00122-7 [pii] LID - 10.1016/j.bjorl.2022.09.006 [doi] AB - OBJECTIVE: To describe the main vestibular assessment tests performed in children aged zero to twelve years and the main causes of referral for vestibular assessment. METHODS: The review was guided by the following question: What are the main vestibular assessment tests performed in children aged zero to twelve years and the main causes of referral for vestibular assessment? The PVO strategy was used, being defined as: Population (P) - newborns and children; study Variable (V) - causes of referral for vestibular assessment; study Outcome (O): the main vestibular assessment tests and the main findings. This study was carried out using the main available databases in the months of July, August and September 2021, with no restrictions regarding language and publication date, namely: PubMed, Web of Science, Scientific Electronic Library Online (SciELO), Latin-American and Caribbean Literature in Health Sciences (LILACS), ScienceDirect, Cochrane Library and Embase. The descriptors were obtained from the MeSH database: newborn, infant, child, children, vestibular screening, vestibular infant screening, vestibular newborn screening, test, vestibular function, vestibular function test. RESULTS: A total of 7,078 studies were identified. After reading the titles and abstracts, 107 of them were selected, with 101 remaining after the exclusion of duplicates. After the full-text reading, 31 articles were included. It was observed that the most frequently used tests were: rotational tests, caloric stimulation and cervical vestibular evoked myogenic potential and the main causes of referral for vestibular evaluation were hearing loss and vestibular screening. CONCLUSION: The main tests for vestibular screening and/or assessment of children aged zero to twelve years are the rotary chair testing, caloric stimulation and cervical-vestibular evoked myogenic potential. Consequently, performing these procedures is extremely important, since the presence of vestibular dysfunction is quite common in the studied population. CI - Copyright (c) 2022 Associacao Brasileira de Otorrinolaringologia e Cirurgia Cervico-Facial. Published by Elsevier Editora Ltda. All rights reserved. FAU - Duarte, Danielle Samara Bandeira AU - Duarte DSB AD - Universidade Federal de Pernambuco (UFPE), Recife, PE, Brazil. Electronic address: daniellesamaraduarte@hotmail.com. FAU - Cabral, Anna Marial de Lira AU - Cabral AML AD - Universidade Federal de Pernambuco (UFPE), Curso de Fonoaudiologia, Recife, PE, Brazil. FAU - Britto, Diana Babini Lapa de Albuquerque AU - Britto DBLA AD - Universidade Federal de Pernambuco (UFPE), Departamento de Fonoaudiologia, Recife, PE, Brazil. LA - eng PT - Journal Article PT - Review DEP - 20221014 PL - Brazil TA - Braz J Otorhinolaryngol JT - Brazilian journal of otorhinolaryngology JID - 101207337 SB - IM MH - Child MH - Humans MH - Infant MH - Infant, Newborn MH - *Deafness MH - *Vestibular Evoked Myogenic Potentials/physiology MH - Vestibular Function Tests MH - *Vestibule, Labyrinth MH - Child, Preschool PMC - PMC9761112 OTO - NOTNLM OT - Children OT - Infants OT - Vertigo OT - Vestibular alterations OT - Vestibular evaluation EDAT- 2022/11/09 06:00 MHDA- 2022/12/15 06:00 PMCR- 2022/10/14 CRDT- 2022/11/08 22:07 PHST- 2022/04/08 00:00 [received] PHST- 2022/08/10 00:00 [revised] PHST- 2022/09/23 00:00 [accepted] PHST- 2022/11/09 06:00 [pubmed] PHST- 2022/12/15 06:00 [medline] PHST- 2022/11/08 22:07 [entrez] PHST- 2022/10/14 00:00 [pmc-release] AID - S1808-8694(22)00122-7 [pii] AID - 10.1016/j.bjorl.2022.09.006 [doi] PST - ppublish SO - Braz J Otorhinolaryngol. 2022 Nov-Dec;88 Suppl 3(Suppl 3):S212-S224. doi: 10.1016/j.bjorl.2022.09.006. Epub 2022 Oct 14. PMID- 36347597 OWN - NLM STAT- Publisher LR - 20240216 IS - 1470-2738 (Electronic) IS - 0143-005X (Print) IS - 0143-005X (Linking) VI - 77 IP - 1 DP - 2022 Nov 8 TI - Epidemiology of SARS-CoV-2 during the first three waves in Scotland: a national record linkage study. PG - 1-8 LID - jech-2022-219367 [pii] LID - 10.1136/jech-2022-219367 [doi] AB - BACKGROUND: The early COVID-19 pandemic in Scotland-defined as the era before widespread access to vaccination and monoclonal antibody treatment-can be characterised into three distinct waves: March-July 2020, July 2020-April 2021 and May-August 2021. Each wave was met with various societal restrictions in an effort to reduce disease transmission and associated morbidity and mortality. Understanding the epidemiology of infections during these waves can provide valuable insights into future pandemic planning. METHODS: Scottish RT-PCR testing data reported up until 8 August 2021, the day prior to most restrictions being lifted in Scotland, were included. Demographic characteristics including age, sex and social deprivation associated with transmission, morbidity and mortality were compared across waves. A case-control analysis for each wave was then modelled to further compare risk factors associated with death over time. RESULTS: Of the 349 904 reported cases, there were 18 099, 197 251 and 134 554 in waves 1, 2 and 3, respectively. Hospitalisations, intensive care unit admissions and deaths appeared highest in wave 2, though risk factors associated with COVID-19 death remained similar across the waves. Higher deprivation and certain comorbidities were associated with higher deaths in all waves. CONCLUSIONS: Despite the higher number of cases reported in waves 2 and 3, case fatality rates were lower: likely a combination of improved detection of infections in younger age groups, introduction of social measures and vaccination. Higher social deprivation and comorbidities resulted in higher deaths for all waves. CI - (c) Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. FAU - Leslie, Kirstin AU - Leslie K AUID- ORCID: 0000-0001-5103-425X AD - Clinical and Protecting Health, Public Health Scotland Glasgow Office, Glasgow, UK kirstin.leslie@phs.scot. FAU - Findlay, Beth AU - Findlay B AD - Clinical and Protecting Health, Public Health Scotland Glasgow Office, Glasgow, UK. FAU - Ryan, Theresa AU - Ryan T AD - Data Driven Innovation, Public Health Scotland Glasgow Office, Glasgow, UK. FAU - Green, Leonardo I AU - Green LI AD - Clinical and Protecting Health, Public Health Scotland Glasgow Office, Glasgow, UK. FAU - Harvey, Ciaran AU - Harvey C AD - Data Driven Innovation, Public Health Scotland Glasgow Office, Glasgow, UK. FAU - Whettlock, Alice E AU - Whettlock AE AD - Clinical and Protecting Health, Public Health Scotland Glasgow Office, Glasgow, UK. FAU - Bishop, Jen AU - Bishop J AD - Data Driven Innovation, Public Health Scotland Glasgow Office, Glasgow, UK. FAU - Ponce Hardy, Vicki AU - Ponce Hardy V AUID- ORCID: 0000-0003-0837-5862 AD - Place and Wellbeing, Public Health Scotland, Edinburgh, UK. FAU - Went, April AU - Went A AD - Data Driven Innovation, Public Health Scotland Glasgow Office, Glasgow, UK. FAU - Wallace, Lesley AU - Wallace L AD - Clinical and Protecting Health, Public Health Scotland Glasgow Office, Glasgow, UK. FAU - McLeod, Allan AU - McLeod A AD - Clinical and Protecting Health, Public Health Scotland Glasgow Office, Glasgow, UK. FAU - Weir, Amanda AU - Weir A AD - Clinical and Protecting Health, Public Health Scotland Glasgow Office, Glasgow, UK. FAU - Marsh, Kimberly AU - Marsh K AD - Clinical and Protecting Health, Public Health Scotland Glasgow Office, Glasgow, UK. LA - eng PT - Journal Article DEP - 20221108 PL - England TA - J Epidemiol Community Health JT - Journal of epidemiology and community health JID - 7909766 SB - IM PMC - PMC9763220 OTO - NOTNLM OT - COVID-19 OT - DEATH OT - EPIDEMIOLOGIC MEASUREMENTS OT - HEALTH POLICY OT - PUBLIC HEALTH COIS- Competing interests: None declared. EDAT- 2022/11/09 06:00 MHDA- 2022/11/09 06:00 PMCR- 2022/11/08 CRDT- 2022/11/08 21:03 PHST- 2022/06/07 00:00 [received] PHST- 2022/10/14 00:00 [accepted] PHST- 2022/11/08 21:03 [entrez] PHST- 2022/11/09 06:00 [pubmed] PHST- 2022/11/09 06:00 [medline] PHST- 2022/11/08 00:00 [pmc-release] AID - jech-2022-219367 [pii] AID - 10.1136/jech-2022-219367 [doi] PST - aheadofprint SO - J Epidemiol Community Health. 2022 Nov 8;77(1):1-8. doi: 10.1136/jech-2022-219367. PMID- 36347109 OWN - NLM STAT- MEDLINE DCOM- 20221215 LR - 20230220 IS - 1879-1379 (Electronic) IS - 0022-3956 (Print) IS - 0022-3956 (Linking) VI - 156 DP - 2022 Dec TI - The trajectory of mental health problems for UK emerging adults during COVID-19. PG - 491-497 LID - S0022-3956(22)00620-3 [pii] LID - 10.1016/j.jpsychires.2022.10.068 [doi] AB - Initial COVID-19 restrictions were associated with declining mental health, particularly in UK emerging adults. Prior research has yet to examine changes in mental health in this demographic over the entire course of the three UK national lockdowns. Drawing upon the Understanding Society COVID-19 Survey, this study examined the trajectory of mental health problems for emerging adults (18-29-year-olds) from April 2020-September 2021. Mental health problems were assessed at nine time-points using the General Health Questionnaire. The analytic sample included 1018 participants (304 males, 714 females). Growth curve modelling was used to examine the trajectory of mental health problems and the associated sociodemographic and health covariates. Females and those with fewer household members, lower income, no private garden, and pre-existing mental or physical health diagnoses reported more mental health problems. Gender differences were evident in the rate of change. Females' mental health problems declined from the first lockdown until just after the relaxation of initial restrictive measures (September 2020), increased until April 2021 (constituting lockdowns two and three), and then slightly decreased until September 2021 during the phased exit from restrictions. Males' mental health problems followed a similar trajectory, with a greater rate of increase in mental health problems from July 2020-April 2021, and a greater rate of decline from April-September 2021. Females reported more mental health problems throughout the three national lockdowns than males. These findings can inform public health policies targeted toward young adult populations and highlight sub-populations at greater risk of worsening mental health. CI - Copyright (c) 2022 The Authors. Published by Elsevier Ltd.. All rights reserved. FAU - Thorpe, William John Robert AU - Thorpe WJR AD - Department of Clinical, Educational and Health Psychology, University College London, 1-19 Torrington Place, London, WC1E 7HB, United Kingdom. Electronic address: william.thorpe.19@alumni.ucl.ac.uk. FAU - Gutman, Leslie Morrison AU - Gutman LM AD - Department of Clinical, Educational and Health Psychology, University College London, 1-19 Torrington Place, London, WC1E 7HB, United Kingdom. Electronic address: l.gutman@ucl.ac.uk. LA - eng PT - Journal Article DEP - 20221102 PL - England TA - J Psychiatr Res JT - Journal of psychiatric research JID - 0376331 SB - IM MH - Female MH - Male MH - Young Adult MH - Humans MH - *Mental Health MH - *COVID-19/epidemiology MH - Communicable Disease Control MH - Sex Characteristics MH - United Kingdom/epidemiology PMC - PMC9628646 OTO - NOTNLM OT - COVID-19 OT - Gender OT - Longitudinal OT - Mental health OT - Socio-demographic OT - Young adults OT - pandemic COIS- Declaration of competing interest None. EDAT- 2022/11/09 06:00 MHDA- 2022/12/15 06:00 PMCR- 2022/11/02 CRDT- 2022/11/08 18:18 PHST- 2022/04/07 00:00 [received] PHST- 2022/10/16 00:00 [revised] PHST- 2022/10/28 00:00 [accepted] PHST- 2022/11/09 06:00 [pubmed] PHST- 2022/12/15 06:00 [medline] PHST- 2022/11/08 18:18 [entrez] PHST- 2022/11/02 00:00 [pmc-release] AID - S0022-3956(22)00620-3 [pii] AID - 10.1016/j.jpsychires.2022.10.068 [doi] PST - ppublish SO - J Psychiatr Res. 2022 Dec;156:491-497. doi: 10.1016/j.jpsychires.2022.10.068. Epub 2022 Nov 2. PMID- 36339201 OWN - NLM STAT- MEDLINE DCOM- 20221108 LR - 20230918 IS - 2296-2565 (Electronic) IS - 2296-2565 (Linking) VI - 10 DP - 2022 TI - A qualitative study of nursing practitioners' experiences with COVID-19 patients dying alone in Greece. PG - 981780 LID - 10.3389/fpubh.2022.981780 [doi] LID - 981780 AB - BACKGROUND: In Greece, there is still limited research on death in isolation due to COVID-19. This deserves attention because of the recent financial crisis, which profoundly impacted public health, and the high relevance of the Hippocratic tradition to the moral values of clinical practice. METHODS: A prospective qualitative study using in-depth interviews with 15 frontline nursing practitioners working in a COVID-19 ward or intensive care unit (ICU) was conducted from July 2021 to December 2021. RESULTS: The inability of family members to say a final goodbye before, during, or after death by performing proper mourning rituals is extremely inhuman and profoundly impacts the mental health status of patients, family members, and nursing practitioners. Patients and their family members strongly desire to see each other. Epidemiology, liability, and proper nursing performance emerged as reasons for the enforced strict visitation restrictions. Participants emphasized that visitations should be allowed on an individual basis and highlighted the need for the effective use of remote communication technology, which, however, does not substitute for in-person contact. Importantly, physicians allowed "clandestine" visits on an individual basis. Nursing practitioners had a strong empathic attitude toward both patients and their families, and a strong willingness to provide holistic care and pay respect to dead bodies. However, they also experienced moral distress. Witnessing heartbreaking scenes with patients and/or their families causes nursing practitioners to experience intense psychological distress, which affects their family life rather than nursing performance. Ultimately, there was a shift from a patient-centered care model to a population-centered care model. Furthermore, we identified a range of policy- and culture-related factors that exaggerate the negative consequences of dying alone of COVID-19. CONCLUSION: These results reinforce the existing literature on several fronts. However, we identified some nuances related to political decisions and, most importantly, convictions that are deeply rooted in Greek culture. These findings are of great importance in planning tailored interventions to mitigate the problem of interest and have implications for other similar national contexts. CI - Copyright (c) 2022 Voultsos, Tsompanian, Deligianni, Tsamadou and Tsaroucha. FAU - Voultsos, Polychronis AU - Voultsos P AD - Laboratory of Forensic Medicine & Toxicology, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece. FAU - Tsompanian, Anna AU - Tsompanian A AD - Postgraduate Program on Bioethics, Laboratory of Bioethics and Laboratory of Experimental Surgery and Surgical Research, School of Medicine, Democritus University of Thrace, Alexandroupolis, Greece. FAU - Deligianni, Maria AU - Deligianni M AD - Laboratory of Forensic Medicine & Toxicology, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece. FAU - Tsamadou, Eftychia AU - Tsamadou E AD - Laboratory of Forensic Medicine & Toxicology, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece. FAU - Tsaroucha, Alexandra K AU - Tsaroucha AK AD - Postgraduate Program on Bioethics, Laboratory of Bioethics and Laboratory of Experimental Surgery and Surgical Research, School of Medicine, Democritus University of Thrace, Alexandroupolis, Greece. LA - eng PT - Journal Article DEP - 20221021 PL - Switzerland TA - Front Public Health JT - Frontiers in public health JID - 101616579 SB - IM MH - Humans MH - *COVID-19/epidemiology MH - Greece/epidemiology MH - Prospective Studies MH - Qualitative Research MH - Family/psychology PMC - PMC9634155 OTO - NOTNLM OT - COVID-19 pandemic OT - death in isolation OT - dying alone OT - hospitalized COVID-19 patients OT - nursing practitioners/professionals COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2022/11/08 06:00 MHDA- 2022/11/09 06:00 PMCR- 2022/10/21 CRDT- 2022/11/07 04:41 PHST- 2022/08/19 00:00 [received] PHST- 2022/10/10 00:00 [accepted] PHST- 2022/11/07 04:41 [entrez] PHST- 2022/11/08 06:00 [pubmed] PHST- 2022/11/09 06:00 [medline] PHST- 2022/10/21 00:00 [pmc-release] AID - 10.3389/fpubh.2022.981780 [doi] PST - epublish SO - Front Public Health. 2022 Oct 21;10:981780. doi: 10.3389/fpubh.2022.981780. eCollection 2022. PMID- 36338548 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20221108 IS - 2564-1891 (Electronic) IS - 2564-1891 (Linking) VI - 2 IP - 2 DP - 2022 Jul-Dec TI - Investigating COVID-19 Vaccine Communication and Misinformation on TikTok: Cross-sectional Study. PG - e38316 LID - 10.2196/38316 [doi] LID - e38316 AB - BACKGROUND: The COVID-19 pandemic has highlighted the need for reliable information, especially around vaccines. Vaccine hesitancy is a growing concern and a great threat to broader public health. The prevalence of social media within our daily lives emphasizes the importance of accurately analyzing how health information is being disseminated to the public. TikTok is of particular interest, as it is an emerging social media platform that young adults may be increasingly using to access health information. OBJECTIVE: The objective of this study was to examine and describe the content within the top 100 TikToks trending with the hashtag #covidvaccine. METHODS: The top 250 most viewed TikToks with the hashtag #covidvaccine were batch downloaded on July 1, 2021, with their respective metadata. Each TikTok was subsequently viewed and encoded by 2 independent reviewers. Coding continued until 100 TikToks could be included based on language and content. Descriptive features were recorded including health care professional (HCP) status of creator, verification of HCP status, genre, and misinformation addressed. Primary inclusion criteria were any TikToks in English with discussion of a COVID-19 vaccine. RESULTS: Of 102 videos included, the median number of plays was 1,700,000, with median shares of 9224 and 62,200 followers. Upon analysis, 14.7% (15/102) of TikToks included HCPs, of which 80% (12/102) could be verified via social media or regulatory body search; 100% (15/15) of HCP-created TikToks supported vaccine use, and overall, 81.3% (83/102) of all TikToks (created by either a layperson or an HCP) supported vaccine use. CONCLUSIONS: As the pandemic continues, vaccine hesitancy poses a threat to lifting restrictions, and discovering reasons for this hesitancy is important to public health measures. This study summarizes the discourse around vaccine use on TikTok. Importantly, it opens a frank discussion about the necessity to incorporate new social media platforms into medical education, so we might ensure our trainees are ready to engage with patients on novel platforms. CI - (c)Katherine van Kampen, Jeremi Laski, Gabrielle Herman, Teresa M Chan. Originally published in JMIR Infodemiology (https://infodemiology.jmir.org), 25.10.2022. FAU - van Kampen, Katherine AU - van Kampen K AUID- ORCID: 0000-0001-7415-3243 AD - Michael G DeGroote School of Medicine Faculty of Health Sciences McMaster University Hamilton, ON Canada. FAU - Laski, Jeremi AU - Laski J AUID- ORCID: 0000-0001-9737-8293 AD - College of Medicine Central Michigan University Mount Pleasant, MI United States. FAU - Herman, Gabrielle AU - Herman G AUID- ORCID: 0000-0003-4695-5251 AD - Michael G DeGroote School of Medicine Faculty of Health Sciences McMaster University Hamilton, ON Canada. FAU - Chan, Teresa M AU - Chan TM AUID- ORCID: 0000-0001-6104-462X AD - Division of Emergency Medicine, Department of Medicine Faculty of Health Sciences McMaster University Hamilton, ON Canada. AD - Office of Continuing Professional Development Faculty of Health Sciences McMaster University Hamilton, ON Canada. AD - McMaster Education Research, Innovation, and Theory Faculty of Health Sciences McMaster University Hamilton, ON Canada. AD - Division of Education & Innovation Department of Medicine, Faculty of Health Sciences McMaster University Hamilton, ON Canada. LA - eng PT - Journal Article DEP - 20221025 PL - Canada TA - JMIR Infodemiology JT - JMIR infodemiology JID - 9918249014806676 PMC - PMC9620417 OTO - NOTNLM OT - COVID-19 OT - COVID-19 vaccines OT - Infodemiology OT - TikTok OT - content analysis OT - health information OT - misinformation OT - public health OT - social media OT - vaccinations OT - vaccine hesitancy OT - web-based health information COIS- Conflicts of Interest: None declared. EDAT- 2022/11/08 06:00 MHDA- 2022/11/08 06:01 PMCR- 2022/10/25 CRDT- 2022/11/07 04:29 PHST- 2022/03/28 00:00 [received] PHST- 2022/08/30 00:00 [revised] PHST- 2022/10/01 00:00 [accepted] PHST- 2022/11/07 04:29 [entrez] PHST- 2022/11/08 06:00 [pubmed] PHST- 2022/11/08 06:01 [medline] PHST- 2022/10/25 00:00 [pmc-release] AID - v2i2e38316 [pii] AID - 10.2196/38316 [doi] PST - epublish SO - JMIR Infodemiology. 2022 Oct 25;2(2):e38316. doi: 10.2196/38316. eCollection 2022 Jul-Dec. PMID- 36336084 OWN - NLM STAT- MEDLINE DCOM- 20230501 LR - 20230502 IS - 1097-6868 (Electronic) IS - 0002-9378 (Print) IS - 0002-9378 (Linking) VI - 228 IP - 5 DP - 2023 May TI - Reductions in stillbirths and preterm birth in COVID-19-vaccinated women: a multicenter cohort study of vaccination uptake and perinatal outcomes. PG - 585.e1-585.e16 LID - S0002-9378(22)00882-1 [pii] LID - 10.1016/j.ajog.2022.10.040 [doi] AB - BACKGROUND: COVID-19 infection in pregnancy is associated with a higher risk of progression to severe disease, but vaccine uptake by pregnant women is hindered by persistent safety concerns. COVID-19 vaccination in pregnancy has been shown to reduce stillbirth, but its relationship with preterm birth is uncertain. OBJECTIVE: This study aimed to measure the rate of COVID-19 vaccine uptake among women giving birth in Melbourne, Australia, and to compare perinatal outcomes by vaccination status. STUDY DESIGN: This was a retrospective multicenter cohort study conducted after the June 2021 government recommendations for messenger RNA COVID-19 vaccination during pregnancy. Routinely collected data from all 12 public maternity hospitals in Melbourne were extracted on births at >/=20 weeks' gestation from July 1, 2021 to March 31, 2022. Maternal sociodemographic characteristics were analyzed from the total birth cohort. Perinatal outcomes were compared between vaccinated and unvaccinated women for whom weeks 20 to 43 of gestation fell entirely within the 9-month data collection period. The primary outcomes were the rates of stillbirth and preterm birth (spontaneous and iatrogenic) in singleton pregnancies of at least 24 weeks' gestation, after exclusion of congenital anomalies. Secondary perinatal outcomes included the rate of congenital anomalies among infants born at >/=20 weeks' gestation and birthweight /=24 weeks' gestation. We calculated the adjusted odds ratio of perinatal outcomes among vaccinated vs unvaccinated women using inverse propensity score-weighting regression adjustment with multiple covariates; P<.05 was considered statistically significant. RESULTS: Births from 32,536 women were analyzed: 17,365 (53.4%) were vaccinated and 15,171 (47.6%) were unvaccinated. Vaccinated women were more likely to be older, nulliparous, nonsmoking, not requiring an interpreter, of higher socioeconomic status, and vaccinated against pertussis and influenza. Vaccination status also varied by region of birth. Vaccinated women had a significantly lower rate of stillbirth compared with unvaccinated women (0.2% vs 0.8%; adjusted odds ratio, 0.18; 95% confidence interval, 0.09-0.37; P<.001). Vaccination was associated with a significant reduction in total preterm births at <37 weeks (5.1% vs 9.2%; adjusted odds ratio, 0.60; 95% confidence interval, 0.51-0.71; P<.001), spontaneous preterm birth (2.4% vs 4.0%; adjusted odds ratio, 0.73; 95% confidence interval, 0.56-0.96; P=.02), and iatrogenic preterm birth (2.7% vs 5.2%; adjusted odds ratio, 0.52; 95% confidence interval, 0.41-0.65; P<.001). Infants born to vaccinated mothers also had lower rates of admission to the neonatal intensive care unit. There was no significant increase in the rate of congenital anomalies or birthweight 0.05). The Cobbs angle of scoliosis also improved significantly (8.0 degrees (0 degrees , 13.0 degrees ) vs. 10.0 degrees (0 degrees , 18.5 degrees ), Z=-3.01, P=0.003). The Hammersmith functional motor scale expanded scores of children with SMA type 2 and type 3 both showed significant elevation (11.0 (8.0, 18.0) vs. 11.0 (5.0, 18.5) scores, 44.0 (36.5, 53.0) vs. 44.0 (34.0, 51.5) scores, Z=2.44, 3.11, P=0.015, 0.002). Conclusion: Multidisciplinary management is beneficial for delaying the progression of the multi-system impairments of SMA patients, such as malnutrition, restrictive ventilation dysfunction and scoliosis. FAU - Xia, Y AU - Xia Y AD - Department of Neurology, the Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou 310052, China. FAU - Feng, Y J AU - Feng YJ AD - Department of Neurology, the Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou 310052, China. FAU - Yao, M AU - Yao M AD - Department of Neurology, the Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou 310052, China. FAU - Jin, J N AU - Jin JN AD - Department of Neurology, the Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou 310052, China. FAU - Wei, J AU - Wei J AD - Department of Neurology, the Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou 310052, China. FAU - Cui, Y Q AU - Cui YQ AD - Department of Neurology, the Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou 310052, China. FAU - Wang, L S AU - Wang LS AD - Department of Neurology, the Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou 310052, China. FAU - Chen, T T AU - Chen TT AD - Department of Developmental Behavior, the Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou 310052, China. FAU - Chen, X Y AU - Chen XY AD - Department of Developmental Behavior, the Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou 310052, China. FAU - Li, H B AU - Li HB AD - Department of Orthopedics, the Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou 310052, China. FAU - Xu, J F AU - Xu JF AD - Department of Orthopedics, the Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou 310052, China. FAU - Long, Q AU - Long Q AD - Department of Clinial Nutrition, the Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou 310052, China. FAU - Jiang, Y AU - Jiang Y AD - Department of Respiratory, the Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou 310052, China. FAU - Liu, J L AU - Liu JL AD - Department of Respiratory, the Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou 310052, China. FAU - Lou, J G AU - Lou JG AD - Department of Gastroenterology, the Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou 310052, China. FAU - Gao, F AU - Gao F AD - Department of Neurology, the Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou 310052, China. FAU - Mao, S S AU - Mao SS AD - Department of Neurology, the Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou 310052, China. LA - chi GR - 2022C03167/Key R&D Program of Zhejiang Province/ GR - 2021C03099/Key Technologies Research and Development Program of Zhejiang Province/ GR - LGC21H090001/Zhejiang Province Public Welfare Technology Application Research Project/ PT - English Abstract PT - Journal Article PL - China TA - Zhonghua Er Ke Za Zhi JT - Zhonghua er ke za zhi = Chinese journal of pediatrics JID - 0417427 SB - IM MH - Child MH - Male MH - Female MH - Humans MH - Child, Preschool MH - *Scoliosis MH - Retrospective Studies MH - Follow-Up Studies MH - *Muscular Atrophy, Spinal MH - *Malnutrition EDAT- 2022/11/02 06:00 MHDA- 2022/11/04 06:00 CRDT- 2022/11/01 21:29 PHST- 2022/11/01 21:29 [entrez] PHST- 2022/11/02 06:00 [pubmed] PHST- 2022/11/04 06:00 [medline] AID - 10.3760/cma.j.cn112140-20220221-00138 [doi] PST - ppublish SO - Zhonghua Er Ke Za Zhi. 2022 Nov 2;60(11):1134-1139. doi: 10.3760/cma.j.cn112140-20220221-00138. PMID- 36292334 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20221030 IS - 2227-9032 (Print) IS - 2227-9032 (Electronic) IS - 2227-9032 (Linking) VI - 10 IP - 10 DP - 2022 Sep 27 TI - Profile of Patients with Cardiovascular Diseases during the Pandemic in a Cardiology Clinic of a COVID-19 Support Hospital. LID - 10.3390/healthcare10101887 [doi] LID - 1887 AB - BACKGROUND: During the pandemic, our hospital became a COVID support hospital and consequently the cardiology clinic had restricted activity; thus, it received only suspect and/or patients confirmed positive with the various COVID-19 strains that were associated with a chronic/flaring cardiovascular pathology. METHODS: Two batches of patients admitted during a one-year period were compared in the cardiology clinic over two different periods of time: BATCH I (1 April 2019 to 31 March 2020), in a non-COVID context (BATCH I N-COV) and BATCH II (1 July 2020 to 30 June 2021) comprising patients that presented with respiratory infection of SARS-CoV-2 (BATCH II COV-2), associated with chronic and/or acute cardiovascular condition. To determine the profile of the patients admitted in our clinic, we observed the following parameters: age, type of cardiac condition, and admission mode (for the N-COV group). RESULTS: The data obtained as absolute numbers and as percentages in relation to the total number of admissions were presented in separate tables and graphs for both of the studied groups. CONCLUSIONS: The SARS-CoV-2 pandemic, in its almost two years of evolution, has divided the medical world in two main categories: COVID and non-COVID. Admission of the patients with chronic, but non-COVID cardiac conditions, in our case, dropped to almost one-quarter when we compared the two absolute admission numbers: 1382 in the year prior to pandemic compared with only 356 in the pandemic year. We believe that the number of deaths due to SARS-CoV-2 infection was infinitely higher than the reported ones and uncountable, in as much as COVID-19 did not kill only the infected patients, but it has also yielded a very large number of collateral victims among chronic patients who had no contact with the disease, but were unable to be admitted and treated for chronic heart disease. FAU - Carstea, Andrei AU - Carstea A AD - Doctoral School, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania. AD - Department of Cardiology, Clinical Municipal Hospital "Philanthropy" of Craiova, 200143 Craiova, Romania. FAU - Mita, Adrian AU - Mita A AD - Department of Medical Semiology, Faculty of Medicine, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania. AD - Department of Internal Medicine 2-Gastroenterology Compartment, Clinical Municipal Hospital "Philanthropy" of Craiova, 200143 Craiova, Romania. FAU - Fortofoiu, Mircea-Catalin AU - Fortofoiu MC AUID- ORCID: 0000-0002-3341-1442 AD - Department of Medical Semiology, Faculty of Medicine, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania. AD - Department of Internal Medicine 2-Gastroenterology Compartment, Clinical Municipal Hospital "Philanthropy" of Craiova, 200143 Craiova, Romania. FAU - Doica, Irina Paula AU - Doica IP AD - Doctoral School, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania. FAU - Carstea, Doina AU - Carstea D AD - Doctoral School, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania. AD - Department of Cardiology, Clinical Municipal Hospital "Philanthropy" of Craiova, 200143 Craiova, Romania. FAU - Diaconu, Ileana-Diana AU - Diaconu ID AD - Doctoral School, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania. AD - Department of Pediatric Pneumology, National Institute of Pneumology "Marius Nasta", 050159 Bucharest, Romania. FAU - Abu Alhija Barau, Anca AU - Abu Alhija Barau A AD - Department of Medical Semiology, Faculty of Medicine, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania. AD - Department of Internal Medicine 2-Gastroenterology Compartment, Clinical Municipal Hospital "Philanthropy" of Craiova, 200143 Craiova, Romania. FAU - Martin, Liviu AU - Martin L AD - Targu Jiu Branch, Faculty of General Nursing, (AMG), University of "Titu Maiorescu" Bucharest, 040441 Bucharest, Romania. AD - Department of Surgery, Emergency Clinical Hospital "Dr. Stefan Odobleja" Craiova, 200349 Craiova, Romania. FAU - Filip, Maria Monalisa AU - Filip MM AD - Department of Internal Medicine 2-Gastroenterology Compartment, Clinical Municipal Hospital "Philanthropy" of Craiova, 200143 Craiova, Romania. AD - Department of Medical Semiology, Faculty of Midwife and Nursing, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania. FAU - Golli, Andreea Loredana AU - Golli AL AUID- ORCID: 0000-0002-1802-3601 AD - Department of Public Health and Management, Faculty of Medicine, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania. AD - Department of Public Health-Epidemiology, Clinical County Emergency Hospital of Craiova, 200642 Craiova, Romania. FAU - Fortofoiu, Maria AU - Fortofoiu M AUID- ORCID: 0000-0002-2056-6779 AD - Department of Emergency Medicine, Faculty of Medicine, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania. AD - Department of Emergency Medicine, Clinical Municipal Hospital "Philanthropy" of Craiova, 200143 Craiova, Romania. LA - eng GR - 26/40C/06.10.2021/Didactica Association/ PT - Journal Article DEP - 20220927 PL - Switzerland TA - Healthcare (Basel) JT - Healthcare (Basel, Switzerland) JID - 101666525 PMC - PMC9601427 OTO - NOTNLM OT - COVID-19 virus OT - SARS-CoV-2 OT - cardiovascular diseases OT - pandemic infection COIS- The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results. EDAT- 2022/10/28 06:00 MHDA- 2022/10/28 06:01 PMCR- 2022/09/27 CRDT- 2022/10/27 01:17 PHST- 2022/08/04 00:00 [received] PHST- 2022/09/09 00:00 [revised] PHST- 2022/09/22 00:00 [accepted] PHST- 2022/10/27 01:17 [entrez] PHST- 2022/10/28 06:00 [pubmed] PHST- 2022/10/28 06:01 [medline] PHST- 2022/09/27 00:00 [pmc-release] AID - healthcare10101887 [pii] AID - healthcare-10-01887 [pii] AID - 10.3390/healthcare10101887 [doi] PST - epublish SO - Healthcare (Basel). 2022 Sep 27;10(10):1887. doi: 10.3390/healthcare10101887. PMID- 36285872 OWN - NLM STAT- MEDLINE DCOM- 20230122 LR - 20230327 IS - 1522-9645 (Electronic) IS - 0195-668X (Linking) VI - 44 IP - 3 DP - 2023 Jan 14 TI - Association between basic life support and survival in sports-related sudden cardiac arrest: a meta-analysis. PG - 180-192 LID - 10.1093/eurheartj/ehac586 [doi] AB - AIMS: To evaluate the association of basic life support with survival after sports-related sudden cardiac arrest (SR-SCA). METHODS AND RESULTS: In this systematic review and meta-analysis, a search of several databases from each database inception to 31 July 2021 without language restrictions was conducted. Studies were considered eligible if they evaluated one of three scenarios in patients with SR-SCA: (i) bystander presence, (ii) bystander cardiopulmonary resuscitation (CPR), or (iii) bystander automated external defibrillator (AED) use and provided information on survival. Risk of bias was evaluated using Risk of Bias in Non-randomized Studies of Interventions. The primary outcome was survival at the longest follow up. The meta-analysis was conducted using the random-effects model. The Grading of Recommendations Assessment, Development, and Evaluations (GRADE) approach was used to rate certainty in the evidence. In total, 28 non-randomized studies were included. The meta-analysis showed significant benefit on survival in all three groups: bystander presence [odds ratio (OR) 2.55, 95% confidence interval (CI) 1.48-4.37; I2 = 25%; 9 studies-988 patients], bystander CPR (OR 3.84, 95% CI 2.36-6.25; I2 = 54%; 23 studies-2523 patients), and bystander AED use (OR 5.25, 95% CI 3.58-7.70; I2 = 16%; 19 studies-1227 patients). The GRADE certainty of evidence was judged to be moderate. CONCLUSION: In patients with SR-SCA, bystander presence, bystander CPR, and bystander AED use were significantly associated with survival. These results highlight the importance of witness intervention and encourage countries to develop their first aid training policy and AED installation in sport settings. CI - (c) The Author(s) 2022. Published by Oxford University Press on behalf of the European Society of Cardiology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. FAU - Michelland, Laurianne AU - Michelland L AD - Department of Emergency, Service Mobile d'Urgence et Reanimation (SMUR), Groupe Hospitalier Intercommunal Le Raincy-Montfermeil, Montfermeil, France. AD - Universite Paris Cite, INSERM, UMR-S970, Paris Cardiovascular Research Center, Team "Integrative Epidemiology of Cardiovascular Diseases", Paris, France. FAU - Murad, Mohammad H AU - Murad MH AD - Division of Public Health, Infectious Diseases and Occupational Medicine, Mayo Clinic, Rochester, MN, USA. FAU - Bougouin, Wulfran AU - Bougouin W AD - Universite Paris Cite, INSERM, UMR-S970, Paris Cardiovascular Research Center, Team "Integrative Epidemiology of Cardiovascular Diseases", Paris, France. AD - Medical-Surgical Intensive Care Unit, Ramsay Generale de Sante, Hopital Prive Jacques Cartier, 6 Avenue du Noyer Lambert, 91300 Massy, France. FAU - Van Der Broek, Mark AU - Van Der Broek M AD - Department of Research, Streem Energy, 75011 Paris, France. FAU - Prokop, Larry J AU - Prokop LJ AD - Mayo Clinic Libraries, Mayo Clinic, Rochester, MN, USA. FAU - Anys, Soraya AU - Anys S AD - Universite Paris Cite, INSERM, UMR-S970, Paris Cardiovascular Research Center, Team "Integrative Epidemiology of Cardiovascular Diseases", Paris, France. AD - Cardiology Department, Georges Pompidou European Hospital, AP-HP, 20 Rue Leblanc, 75015 Paris, France. FAU - Perier, Marie-Cecile AU - Perier MC AD - Universite Paris Cite, INSERM, UMR-S970, Paris Cardiovascular Research Center, Team "Integrative Epidemiology of Cardiovascular Diseases", Paris, France. FAU - Cariou, Alain AU - Cariou A AD - Universite Paris Cite, INSERM, UMR-S970, Paris Cardiovascular Research Center, Team "Integrative Epidemiology of Cardiovascular Diseases", Paris, France. AD - Medical Intensive Care Unit, Cochin Hospital, AP-HP, 27 Rue du Faubourg Saint-Jacques, 75014 Paris, France. FAU - Empana, Jean Philippe AU - Empana JP AUID- ORCID: 0000-0002-1469-7772 AD - Universite Paris Cite, INSERM, UMR-S970, Paris Cardiovascular Research Center, Team "Integrative Epidemiology of Cardiovascular Diseases", Paris, France. FAU - Marijon, Eloi AU - Marijon E AUID- ORCID: 0000-0001-7227-3428 AD - Universite Paris Cite, INSERM, UMR-S970, Paris Cardiovascular Research Center, Team "Integrative Epidemiology of Cardiovascular Diseases", Paris, France. AD - Cardiology Department, Georges Pompidou European Hospital, AP-HP, 20 Rue Leblanc, 75015 Paris, France. FAU - Jouven, Xavier AU - Jouven X AD - Universite Paris Cite, INSERM, UMR-S970, Paris Cardiovascular Research Center, Team "Integrative Epidemiology of Cardiovascular Diseases", Paris, France. AD - Cardiology Department, Georges Pompidou European Hospital, AP-HP, 20 Rue Leblanc, 75015 Paris, France. FAU - Jabre, Patricia AU - Jabre P AUID- ORCID: 0000-0002-5950-6669 AD - Universite Paris Cite, INSERM, UMR-S970, Paris Cardiovascular Research Center, Team "Integrative Epidemiology of Cardiovascular Diseases", Paris, France. AD - Service d'Aide Medicale d'Urgence-SAMU de Paris, Necker-Enfants malades Hospital, AP-HP, 149 Rue de Sevres, 75015 Paris, France. LA - eng PT - Journal Article PT - Meta-Analysis PT - Systematic Review PL - England TA - Eur Heart J JT - European heart journal JID - 8006263 SB - IM CIN - Eur Heart J. 2023 Jan 14;44(3):193-195. doi: 10.1093/eurheartj/ehac659. PMID: 36419208 MH - Humans MH - *Cardiopulmonary Resuscitation/methods MH - *Death, Sudden, Cardiac/epidemiology/prevention & control MH - Defibrillators MH - *Electric Countershock/instrumentation/methods MH - *Emergency Medical Services/methods MH - *Out-of-Hospital Cardiac Arrest/therapy OTO - NOTNLM OT - Automated external defibrillators OT - Bystander OT - Cardiopulmonary resuscitation OT - Sports-related sudden cardiac arrest COIS- Conflict of interest: W.B. has received consulting fees from Withings. All other authors have no conflict of interest to declare. EDAT- 2022/10/27 06:00 MHDA- 2023/01/18 06:00 CRDT- 2022/10/26 07:02 PHST- 2021/12/10 00:00 [received] PHST- 2022/08/12 00:00 [revised] PHST- 2022/10/04 00:00 [accepted] PHST- 2022/10/27 06:00 [pubmed] PHST- 2023/01/18 06:00 [medline] PHST- 2022/10/26 07:02 [entrez] AID - 6774392 [pii] AID - 10.1093/eurheartj/ehac586 [doi] PST - ppublish SO - Eur Heart J. 2023 Jan 14;44(3):180-192. doi: 10.1093/eurheartj/ehac586. PMID- 36285602 OWN - NLM STAT- MEDLINE DCOM- 20221027 LR - 20260514 IS - 1758-2652 (Electronic) IS - 1758-2652 (Linking) VI - 25 IP - 10 DP - 2022 Oct TI - Impact of the COVID-19 pandemic on TB services at ART programmes in low- and middle-income countries: a multi-cohort survey. PG - e26018 LID - 10.1002/jia2.26018 [doi] LID - e26018 AB - INTRODUCTION: COVID-19 stretched healthcare systems to their limits, particularly in settings with a pre-existing high burden of infectious diseases, including HIV and tuberculosis (TB). We studied the impact of COVID-19 on TB services at antiretroviral therapy (ART) clinics in low- and middle-income countries. METHODS: We surveyed ART clinics providing TB services in the International Epidemiology Databases to Evaluate AIDS (IeDEA) consortium in Africa and the Asia-Pacific until July 2021 (TB diagnoses until the end of 2021). We collected site-level data using standardized questionnaires. RESULTS: Of 46 participating ART clinics, 32 (70%) were in Africa and 14 (30%) in the Asia-Pacific; 52% provided tertiary care. Most clinics (85%) reported disrupted routine HIV care services during the pandemic, both in Africa (84%) and the Asia-Pacific (86%). The most frequently reported impacts were on staff (52%) and resource shortages (37%; protective clothing, face masks and disinfectants). Restrictions in TB health services were observed in 12 clinics (26%), mainly reduced access to TB diagnosis and postponed follow-up visits (6/12, 50% each), and restrictions in TB laboratory services (22%). Restrictions of TB services were addressed by dispensing TB drugs for longer periods than usual (7/12, 58%), providing telehealth services (3/12, 25%) and with changes in directly observed therapy (DOT) (e.g. virtual DOT, 3/12). The number of TB diagnoses at participating clinics decreased by 21% in 2020 compared to 2019; the decline was more pronounced in tertiary than primary/secondary clinics (24% vs. 12%) and in sites from the Asia-Pacific compared to Africa (46% vs. 14%). In 2021, TB diagnoses continued to decline in Africa (-8%) but not in the Asia-Pacific (+62%) compared to 2020. During the pandemic, new infection control measures were introduced or intensified at the clinics, including wearing face masks, hand sanitation and patient triage. CONCLUSIONS: The COVID-19 pandemic led to staff shortages, reduced access to TB care and delays in follow-up visits for people with TB across IeDEA sites in Africa and the Asia-Pacific. Increased efforts are needed to restore and secure ongoing access to essential TB services in these contexts. CI - (c) 2022 The Authors. Journal of the International AIDS Society published by John Wiley & Sons Ltd on behalf of the International AIDS Society. FAU - Marti, Mariana AU - Marti M AD - Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland. FAU - Zurcher, Kathrin AU - Zurcher K AUID- ORCID: 0000-0002-7915-3194 AD - Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland. FAU - Enane, Leslie A AU - Enane LA AUID- ORCID: 0000-0001-8390-5881 AD - The Ryan White Center for Pediatric Infectious Disease and Global Health, Department of Pediatrics, Indiana University School of Medicine, Indianapolis, Indiana, USA. FAU - Diero, Lameck AU - Diero L AD - Department of Medicine, Moi University School of Medicine, Eldoret, Kenya. AD - Department of Medicine, Moi Teaching and Referral Hospital, Eldoret, Kenya. FAU - Marcy, Olivier AU - Marcy O AUID- ORCID: 0000-0003-3350-112X AD - University of Bordeaux, Inserm U1219, IRD EMR271, Bordeaux, France. FAU - Tiendrebeogo, Thierry AU - Tiendrebeogo T AUID- ORCID: 0000-0002-9393-9732 AD - University of Bordeaux, Inserm U1219, IRD EMR271, Bordeaux, France. FAU - Yotebieng, Marcel AU - Yotebieng M AD - Division of General Internal Medicine, Department of Medicine, Albert Einstein College of Medicine, Bronx, New York, USA. FAU - Twizere, Christelle AU - Twizere C AUID- ORCID: 0000-0003-1102-5564 AD - Centre National de Reference en matiere de VIH/SIDA Burundi (CNR), Bujumbura, Burundi. FAU - Khusuwan, Suwimon AU - Khusuwan S AUID- ORCID: 0000-0001-6975-057X AD - Chiangrai Prachanukroh Hospital, Chiang Rai, Thailand. FAU - Yunihastuti, Evy AU - Yunihastuti E AUID- ORCID: 0000-0001-6650-0559 AD - Faculty of Medicine Universitas Indonesia, Dr. Cipto Mangunkusumo General Hospital, Jakarta, Indonesia. FAU - Reubenson, Gary AU - Reubenson G AD - Rahima Moosa Mother and Child Hospital, Department of Paediatrics and Child Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. FAU - Shah, N Sarita AU - Shah NS AD - Emory Rollins School of Public Health, Emory University, Atlanta, Georgia, USA. FAU - Egger, Matthias AU - Egger M AUID- ORCID: 0000-0001-7462-5132 AD - Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland. AD - Centre for Infectious Disease Epidemiology and Research, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa. AD - Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK. FAU - Ballif, Marie AU - Ballif M AUID- ORCID: 0000-0003-3133-3011 AD - Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland. FAU - Fenner, Lukas AU - Fenner L AUID- ORCID: 0000-0003-3309-4835 AD - Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland. CN - IeDEA global consortium AD - Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland. LA - eng GR - L40 HD103261/HD/NICHD NIH HHS/United States GR - U54 AG062334/AG/NIA NIH HHS/United States GR - K23 HD095778/HD/NICHD NIH HHS/United States GR - R24 AI124872/AI/NIAID NIH HHS/United States GR - U01 AI069911/AI/NIAID NIH HHS/United States GR - U01 AI069919/AI/NIAID NIH HHS/United States GR - P30 AI168386/AI/NIAID NIH HHS/United States GR - U01 AI069924/AI/NIAID NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't PL - Switzerland TA - J Int AIDS Soc JT - Journal of the International AIDS Society JID - 101478566 RN - 0 (Disinfectants) SB - IM MH - Humans MH - *HIV Infections/diagnosis/drug therapy/epidemiology MH - *COVID-19/epidemiology MH - Pandemics MH - Developing Countries MH - *Tuberculosis/diagnosis/drug therapy/epidemiology MH - Surveys and Questionnaires MH - *Disinfectants/therapeutic use PMC - PMC9597377 OTO - NOTNLM OT - COVID-19 OT - HIV clinic OT - antiretroviral therapy OT - differentiated service delivery OT - low- and middle-income countries OT - tuberculosis COIS- None to declare. EDAT- 2022/10/27 06:00 MHDA- 2022/10/28 06:00 PMCR- 2022/10/26 CRDT- 2022/10/26 04:53 PHST- 2022/06/13 00:00 [received] PHST- 2022/09/21 00:00 [accepted] PHST- 2022/10/26 04:53 [entrez] PHST- 2022/10/27 06:00 [pubmed] PHST- 2022/10/28 06:00 [medline] PHST- 2022/10/26 00:00 [pmc-release] AID - JIA226018 [pii] AID - 10.1002/jia2.26018 [doi] PST - ppublish SO - J Int AIDS Soc. 2022 Oct;25(10):e26018. doi: 10.1002/jia2.26018. PMID- 36270449 OWN - NLM STAT- MEDLINE DCOM- 20221201 LR - 20250623 IS - 1879-0461 (Electronic) IS - 1040-8428 (Linking) VI - 180 DP - 2022 Dec TI - P16 gene promoter methylation is associated with oncogenesis and progression of gastric carcinomas: A systematic review and meta-analysis. PG - 103843 LID - S1040-8428(22)00267-0 [pii] LID - 10.1016/j.critrevonc.2022.103843 [doi] AB - INTRODUCTION: Gastric cancer is the fourth leading cause of neoplastic morbidity worldwide, and its pathogenesis has been related to genetic and epigenetic alterations in cell cycle regulatory genes, such as p16. OBJECTIVES: This systematic review was developed to investigate the association of the p16 gene promoter methylation with oncogenesis and the progression of gastric carcinomas. METHODOLOGY: MEDLINE and Scopus databases were searched for relevant subsidiary studies, with the publication until July 2021 and without language restriction. The complete protocol was registered in the PROSPERO platform under the identification 308218. The Newcastle-Ottawa scale (NOS) was used to assess the methodological quality of the included manuscripts. The meta-analysis was conducted using RevMan 5.4 (R) software. The random effects model was used, Odds Ratio (OR) was calculated with 95% confidence intervals (95% CI). Heterogeneity and inferential significance were measured. RESULTS: 48 articles were aggregated in the qualitative synthesis and 47 in the meta-analysis, totaling 6599 gastric specimens evaluated. Associations of p16 methylation with the following outcomes were observed: gastric oncogenesis (p < 0.00001); intestinal metaplasia (p = 0.002); poor histological differentiation (p = 0.03); local invasion (p = 0.001); lymph node dissemination (p = 0.03); more advanced TNM staging (p = 0.01); and Epstein Barr virus infection (p < 0.00001). In contrast, no association of p16 methylation was found with Lauren's histological classification (p = 0.62); distant metastasis (p = 0.71); or Helicobacter pylori infection (p = 0.79). CONCLUSIONS: the findings described provide empirical evidence for the categorization of p16 methylation as a substantial biomolecular step in gastric carcinogenesis, and reveal a crucial role of Epstein Barr virus in triggering this epigenetic alteration. CI - Copyright (c) 2022 Elsevier B.V. All rights reserved. FAU - Spagnol, Luigi Wolkmer AU - Spagnol LW AD - Medical Department, Federal University of Fronteira Sul (UFFS), Passo Fundo Campus, Rio Grande do Sul, Brazil. Electronic address: wolkmerspagnol@gmail.com. FAU - Polettini, Jossimara AU - Polettini J AD - Medical Department, Federal University of Fronteira Sul (UFFS), Passo Fundo Campus, Rio Grande do Sul, Brazil. FAU - Silveira, Daniela Augustin AU - Silveira DA AD - Medical Department, Federal University of Fronteira Sul (UFFS), Passo Fundo Campus, Rio Grande do Sul, Brazil. FAU - Wegner, Gustavo Roberto Minetto AU - Wegner GRM AD - Medical Department, Federal University of Fronteira Sul (UFFS), Passo Fundo Campus, Rio Grande do Sul, Brazil. FAU - Paiva, Daniel Felipe Fernandes AU - Paiva DFF AD - Dentistry Department, Campinas State University (UNICAMP), Campinas, Sao Paulo, Brazil. LA - eng PT - Journal Article PT - Meta-Analysis PT - Systematic Review DEP - 20221019 PL - Netherlands TA - Crit Rev Oncol Hematol JT - Critical reviews in oncology/hematology JID - 8916049 SB - IM MH - Humans MH - Carcinogenesis/genetics MH - *Carcinoma MH - Cell Transformation, Neoplastic/genetics MH - *DNA Methylation MH - *Epstein-Barr Virus Infections/complications MH - Genes, p16 MH - *Helicobacter Infections/complications MH - *Stomach Neoplasms/genetics/complications MH - Promoter Regions, Genetic OTO - NOTNLM OT - Carcinogenesis OT - DNA methylation OT - Epigenomics OT - Gastric cancer OT - Genes, p16 COIS- Conflict of interest statement The authors Luigi Wolkmer Spagnol, Jossimara Polettini, Daniela Augustin Silveira, Gustavo Roberto Minetto Wegner, and Daniel Fernandes Paiva declare the absence of any conflicts of interest in the present study. EDAT- 2022/10/22 06:00 MHDA- 2022/11/30 06:00 CRDT- 2022/10/21 19:25 PHST- 2022/08/30 00:00 [received] PHST- 2022/10/02 00:00 [revised] PHST- 2022/10/11 00:00 [accepted] PHST- 2022/10/22 06:00 [pubmed] PHST- 2022/11/30 06:00 [medline] PHST- 2022/10/21 19:25 [entrez] AID - S1040-8428(22)00267-0 [pii] AID - 10.1016/j.critrevonc.2022.103843 [doi] PST - ppublish SO - Crit Rev Oncol Hematol. 2022 Dec;180:103843. doi: 10.1016/j.critrevonc.2022.103843. Epub 2022 Oct 19. PMID- 36264578 OWN - NLM STAT- MEDLINE DCOM- 20221026 LR - 20250530 IS - 2574-3805 (Electronic) IS - 2574-3805 (Linking) VI - 5 IP - 10 DP - 2022 Oct 3 TI - Longitudinal Household Assessment of Respiratory Illness in Children and Parents During the COVID-19 Pandemic. PG - e2237522 LID - 10.1001/jamanetworkopen.2022.37522 [doi] LID - e2237522 AB - IMPORTANCE: In the early COVID-19 pandemic, SARS-CoV-2 testing was only accessible and recommended for symptomatic persons or adults. This restriction hampered assessment of the true incidence of SARS-CoV-2 infection in children as well as detailed characterization of the SARS-CoV-2 disease spectrum and how this spectrum compared with that of other common respiratory illnesses. OBJECTIVE: To estimate the community incidence of SARS-CoV-2 infection in children and parents and to assess the symptoms and symptom severity of respiratory illness episodes involving SARS-CoV-2-positive test results relative to those with SARS-CoV-2-negative test results. DESIGN, SETTING, AND PARTICIPANTS: This cohort study randomly selected Dutch households with at least 1 child younger than 18 years. A total of 1209 children and adults from 307 households were prospectively followed up between August 25, 2020, and July 29, 2021, covering the second and third waves of the COVID-19 pandemic. Participation included SARS-CoV-2 screening at 4- to 6-week intervals during the first 23 weeks of participation (core study period; August 25, 2020, to July 29, 2021). Participants in all households finishing the core study before July 1, 2021, were invited to participate in the extended follow-up and to actively report respiratory symptoms using an interactive app until July 1, 2021. At new onset of respiratory symptoms or a SARS-CoV-2 positive test result, a household outbreak study was initiated, which included daily symptom recording, repeated polymerase chain reaction testing (nose-throat swabs and saliva and fecal samples), and SARS-CoV-2 antibody measurement (paired dried blood spots) in all household members. Outbreaks, households, and episodes of respiratory illness were described as positive or negative depending on SARS-CoV-2 test results. Data on participant race and ethnicity were not reported because they were not uniformly collected in the original cohorts and were therefore not representative or informative. EXPOSURES: SARS-CoV-2-positive and SARS-CoV-2-negative respiratory illness episodes. MAIN OUTCOMES AND MEASURES: Age-stratified incidence rates, symptoms, and symptom severity for SARS-CoV-2-positive and SARS-CoV-2-negative respiratory illness episodes. RESULTS: Among 307 households including 1209 participants (638 female [52.8%]; 403 [33.3%] aged <12 years, 179 [14.8%] aged 12-17 years, and 627 [51.9%] aged >/=18 years), 183 household outbreaks of respiratory illness were observed during the core study and extended follow-up period, of which 63 (34.4%) were SARS-CoV-2 positive (59 outbreaks [32.2%] during the core study and 4 outbreaks [2.2%] during follow-up). SARS-CoV-2 incidence was similar across all ages (0.24/person-year [PY]; 95% CI, 0.21-0.28/PY). Overall, 33 of 134 confirmed SARS-CoV-2 episodes (24.6%) were asymptomatic. The incidence of SARS-CoV-2-negative respiratory illness episodes was highest in children younger than 12 years (0.94/PY; 95% CI, 0.89-0.97/PY). When comparing SARS-CoV-2-positive vs SARS-CoV-2-negative respiratory illness episodes in children younger than 12 years, no differences were observed in number of symptoms (median [IQR], 2 [2-4] for both groups), symptom severity (median [IQR] maximum symptom severity score, 6 [4-9] vs 7 [6-13]), or symptom duration (median [IQR], 6 [5-12] days vs 8 [4-13] days). However, among adults, SARS-CoV-2-positive episodes had a significantly higher number (median [IQR], 6 [4-8] vs 3 [2-4]), severity (median [IQR] maximum symptom severity score, 15 [9-19] vs 7 [6-11]), and duration (median [IQR] 13 [8-29] days vs 5 [3-11] days; P < .001 for all comparisons) of symptoms vs SARS-CoV-2-negative episodes. CONCLUSIONS AND RELEVANCE: In this cohort study, during the first pandemic year when mostly partial or full in-person learning occurred, the SARS-CoV-2 incidence rate in children was substantially higher than estimated from routine testing or seroprevalence data and was similar to that of adult household members. Unlike in unvaccinated adults, SARS-CoV-2 symptoms and symptom severity in children were similar to other common respiratory illnesses. These findings may prove useful when developing pediatric COVID-19 vaccine recommendations. FAU - de Hoog, Marieke L A AU - de Hoog MLA AD - Julius Centre for Health Sciences and Primary Care, Department of Epidemiology, University Medical Centre Utrecht, Utrecht, the Netherlands. FAU - Sluiter-Post, Judith G C AU - Sluiter-Post JGC AD - Spaarne Gasthuis Academy, Spaarne Gasthuis, Hoofddorp, the Netherlands. FAU - Westerhof, Ilse AU - Westerhof I AD - Julius Centre for Health Sciences and Primary Care, Department of Epidemiology, University Medical Centre Utrecht, Utrecht, the Netherlands. FAU - Fourie, Elandri AU - Fourie E AD - Spaarne Gasthuis Academy, Spaarne Gasthuis, Hoofddorp, the Netherlands. FAU - Heuvelman, Valerie D AU - Heuvelman VD AD - Department of Pediatrics, Erasmus MC-Sophia Children's Hospital, Erasmus University Medical Center, Rotterdam, the Netherlands. FAU - Boom, Trisja T AU - Boom TT AD - Julius Centre for Health Sciences and Primary Care, Department of Epidemiology, University Medical Centre Utrecht, Utrecht, the Netherlands. FAU - Euser, Sjoerd M AU - Euser SM AD - Regional Public Health Laboratory Kennemerland, Haarlem, the Netherlands. FAU - Badoux, Paul AU - Badoux P AD - Regional Public Health Laboratory Kennemerland, Haarlem, the Netherlands. FAU - Reusken, Chantal AU - Reusken C AD - Centre for Infectious Disease Control, World Health Organization COVID-19 Reference Laboratory, National Institute for Public Health and the Environment, Bilthoven, the Netherlands. FAU - Bont, Louis J AU - Bont LJ AD - Department of Pediatric Infectious Diseases and Immunology, Wilhelmina Children's Hospital University Medical Center Utrecht, Utrecht, the Netherlands. FAU - Sanders, Elisabeth A M AU - Sanders EAM AD - Centre for Infectious Disease Control, World Health Organization COVID-19 Reference Laboratory, National Institute for Public Health and the Environment, Bilthoven, the Netherlands. AD - Department of Pediatric Infectious Diseases and Immunology, Wilhelmina Children's Hospital University Medical Center Utrecht, Utrecht, the Netherlands. FAU - Jaddoe, Vincent W V AU - Jaddoe VWV AD - Department of Pediatrics, Erasmus MC-Sophia Children's Hospital, Erasmus University Medical Center, Rotterdam, the Netherlands. FAU - Herpers, Bjorn L AU - Herpers BL AD - Regional Public Health Laboratory Kennemerland, Haarlem, the Netherlands. FAU - Eggink, Dirk AU - Eggink D AD - Centre for Infectious Disease Control, World Health Organization COVID-19 Reference Laboratory, National Institute for Public Health and the Environment, Bilthoven, the Netherlands. FAU - Wildenbeest, Joanne G AU - Wildenbeest JG AD - Department of Pediatric Infectious Diseases and Immunology, Wilhelmina Children's Hospital University Medical Center Utrecht, Utrecht, the Netherlands. FAU - Duijts, Liesbeth AU - Duijts L AD - Department of Pediatrics, Erasmus MC-Sophia Children's Hospital, Erasmus University Medical Center, Rotterdam, the Netherlands. FAU - van Houten, Marlies A AU - van Houten MA AD - Spaarne Gasthuis Academy, Spaarne Gasthuis, Hoofddorp, the Netherlands. AD - Department of Pediatrics, Spaarne Gasthuis, Haarlem and Hoofddorp, the Netherlands. FAU - Bruijning-Verhagen, Patricia C J L AU - Bruijning-Verhagen PCJL AD - Julius Centre for Health Sciences and Primary Care, Department of Epidemiology, University Medical Centre Utrecht, Utrecht, the Netherlands. LA - eng GR - 001/WHO_/World Health Organization/International PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20221003 PL - United States TA - JAMA Netw Open JT - JAMA network open JID - 101729235 RN - 0 (COVID-19 Vaccines) SB - IM MH - Adolescent MH - Adult MH - Child MH - Female MH - Humans MH - Cohort Studies MH - *COVID-19/diagnosis/epidemiology MH - COVID-19 Testing MH - COVID-19 Vaccines MH - Pandemics MH - Parents MH - SARS-CoV-2 MH - Seroepidemiologic Studies MH - Male PMC - PMC9585428 COIS- Conflict of Interest Disclosures: Dr Bont reported being the founding chairman of the Respiratory Syncytial Virus Network (ReSViNET) Foundation outside the submitted work. Dr Duijts reported receiving grants from Stichting Vrienden van het Sophia during the conduct of the study and grants from ATHLETE (Advancing Tools for Human Early Lifecourse Exposome Research and Translation), EUCAN-Connect, and the European Union Horizon 2020 LifeCycle Research and Innovation Programme outside the submitted work. Dr Bruijning-Verhagen reported serving as an external advisor to the Dutch Health Council on the topic of COVID-19 vaccination in children aged 5 to 11 years outside the submitted work. No other disclosures were reported. EDAT- 2022/10/21 06:00 MHDA- 2022/10/25 06:00 PMCR- 2022/10/20 CRDT- 2022/10/20 11:34 PHST- 2022/10/20 11:34 [entrez] PHST- 2022/10/21 06:00 [pubmed] PHST- 2022/10/25 06:00 [medline] PHST- 2022/10/20 00:00 [pmc-release] AID - 2797502 [pii] AID - zoi221057 [pii] AID - 10.1001/jamanetworkopen.2022.37522 [doi] PST - epublish SO - JAMA Netw Open. 2022 Oct 3;5(10):e2237522. doi: 10.1001/jamanetworkopen.2022.37522. PMID- 36264576 OWN - NLM STAT- MEDLINE DCOM- 20221024 LR - 20221105 IS - 2574-3805 (Electronic) IS - 2574-3805 (Linking) VI - 5 IP - 10 DP - 2022 Oct 3 TI - Racial and Ethnic Differences in the Association of Low-Carbohydrate Diet With Mortality in the Multi-Ethnic Study of Atherosclerosis. PG - e2237552 LID - 10.1001/jamanetworkopen.2022.37552 [doi] LID - e2237552 AB - IMPORTANCE: Evidence linking low-carbohydrate diets (LCDs) to mortality is limited among multiethnic populations. OBJECTIVE: To evaluate the association between LCDs and mortality by race and ethnicity. DESIGN, SETTING, AND PARTICIPANTS: The Multi-Ethnic Study of Atherosclerosis is a large, population-based prospective cohort study of adults aged 45 to 84 years recruited from 6 US communities. A total of 6109 participants without baseline cardiovascular disease were included in this analysis. Baseline data were collected from July 2000 to August 2002, with follow-up completed by December 2017. The data were analyzed between May 2021 and April 2022. EXPOSURES: Food frequency questionnaires were used to assess dietary intake. From these data, overall LCD scores were calculated from the percentages of energy intake from carbohydrates, fats, and proteins. Animal-based (emphasizing saturated fat and animal protein) and vegetable-based (emphasizing monounsaturated fat and vegetable protein) LCD scores were also calculated. MAIN OUTCOMES AND MEASURES: All-cause and cause-specific mortality over a median follow-up of 15.9 years (IQR, 14.3-16.6 years). RESULTS: Among the 6109 participants (mean [SD] age, 62.3 [10.3] years; 3190 women [52.2%]; 1623 African American [26.6%], 701 Chinese American [11.5%], 1350 Hispanic [22.1%], and 2435 non-Hispanic White [39.8%]), there were 1391 deaths. Overall, LCD scores were not associated with mortality, but when analyses were stratified by race and ethnicity, a lower risk of all-cause and non-CV mortality was observed among Hispanic participants with moderate carbohydrate intake. Specifically, the hazard ratios for total mortality for overall LCD scores were 0.58 (95% CI, 0.40-0.84) for quintile 2, 0.67 (95% CI, 0.45-0.98) for quintile 3, 0.60 (95% CI, 0.41-0.87) for quintile 4, and 0.83 (95% CI, 0.57-1.21) for quintile 5, with quintile 1 as the reference group. A similar association was observed for animal-based (but not vegetable-based) LCD scores. In contrast, no significant associations were found between LCD scores and mortality risk in the other racial and ethnic groups. CONCLUSIONS AND RELEVANCE: In this cohort study of multiethnic US adults, LCD score was not associated with mortality in the whole population. However, moderate carbohydrate intake was associated with a lower risk of mortality among Hispanic participants. These findings suggest that the association between carbohydrate intake and mortality may differ according to race and ethnicity. Dietary guidelines considering these differences may be necessary. FAU - Oh, Seung-Won AU - Oh SW AD - Department of Family Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea. AD - Healthcare System Gangnam Center, Seoul National University Hospital, Seoul, Republic of Korea. FAU - Wood, Alexis C AU - Wood AC AD - Department of Pediatrics, US Department of Agriculture/Agricultural Research Service Children's Nutrition Research Center, Baylor College of Medicine, Houston, Texas. FAU - Hwang, Seung-Sik AU - Hwang SS AD - Department of Public Health Sciences, Graduate School of Public Health, Seoul National University, Seoul, Republic of Korea. FAU - Allison, Matthew AU - Allison M AD - Department of Family Medicine, University of California, San Diego. LA - eng PT - Journal Article PT - Research Support, N.I.H., Extramural DEP - 20221003 PL - United States TA - JAMA Netw Open JT - JAMA network open JID - 101729235 RN - 0 (Plant Proteins, Dietary) RN - 0 (Carbohydrates) SB - IM MH - Humans MH - Cohort Studies MH - *Ethnicity MH - Prospective Studies MH - Diet, Carbohydrate-Restricted MH - *Atherosclerosis MH - Plant Proteins, Dietary MH - Carbohydrates PMC - PMC9585425 COIS- Conflict of Interest Disclosures: Dr Wood reported receiving grants from the National Cattlemen's Beef Association and Hass Avocado Board during the conduct of the study. No other disclosures were reported. EDAT- 2022/10/21 06:00 MHDA- 2022/10/25 06:00 PMCR- 2022/10/20 CRDT- 2022/10/20 11:34 PHST- 2022/10/20 11:34 [entrez] PHST- 2022/10/21 06:00 [pubmed] PHST- 2022/10/25 06:00 [medline] PHST- 2022/10/20 00:00 [pmc-release] AID - 2797500 [pii] AID - zoi221059 [pii] AID - 10.1001/jamanetworkopen.2022.37552 [doi] PST - epublish SO - JAMA Netw Open. 2022 Oct 3;5(10):e2237552. doi: 10.1001/jamanetworkopen.2022.37552. PMID- 36204710 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20260928 IS - 2515-4826 (Electronic) IS - 2515-4826 (Linking) VI - 4 DP - 2021 TI - Changes in the utilisation of acute hospital care in Ireland during the first wave of the COVID-19 pandemic in 2020. PG - 67 LID - 10.12688/hrbopenres.13307.3 [doi] LID - 67 AB - BACKGROUND: Reduced and delayed presentations for non-COVID-19 illness during the COVID-19 pandemic have implications for population health and health systems. The aim of this study is to quantify and characterise changes in acute hospital healthcare utilisation in Ireland during the first wave of COVID-19 to inform healthcare system planning and recovery. METHODS: A retrospective, population-based, observational study was conducted using two national datasets, Patient Experience Time (PET) and Hospital In-Patient Enquiry (HIPE). The study period was 6th January to 5th July 2020. RESULTS: Comparison between time periods pre- and post-onset of the COVID-19 pandemic within 2020 showed there were 81,712 fewer Emergency Department (ED) presentations (-18.8%), 19,692 fewer admissions from ED (-17.4%) and 210,357 fewer non-COVID-19 hospital admissions (-35.0%) than expected based on pre-COVID-19 activity. Reductions were greatest at the peak of population-level restrictions, at extremes of age and for elective admissions. In the period immediately following the first wave, acute hospital healthcare utilisation remained below pre-COVID-19 levels, however, there were increases in emergency alcohol-related admissions (Rate Ratio 1.22, 95% CI 1.03, 1.43, p-value 0.016), admissions with self-harm (Rate Ratio 1.39, 95% CI 1.01, 1.91, p-value 0.043) and mental health admissions (Rate Ratio 1.28, 95% CI 1.03, 1.60, p-value 0.028). DISCUSSION: While public health implications of delayed and lost care will only become fully apparent over time, recovery planning must begin immediately. In the short-term, backlogs in care need to be managed and population health impacts of COVID-19 and associated restrictions, particularly in relation to mental health and alcohol, need to be addressed through strong public health and health system responses. In the long-term, COVID-19 highlights health system weakness and is an opportunity to progress health system reform to deliver a universal, high-quality, sustainable and resilient health system, capable of meeting population health needs and responding to future pandemics. CI - Copyright: (c) 2022 Marron L et al. FAU - Marron, Louise AU - Marron L AUID- ORCID: 0000-0002-3206-7758 AD - Department of Public Health HSE East, Dr Steevens' Hospital, Dublin 8, Ireland. FAU - Burke, Sara AU - Burke S AUID- ORCID: 0000-0001-9419-1642 AD - Centre for Health Policy and Management, Trinity College Dublin, Dublin 2, Ireland. FAU - Kavanagh, Paul AU - Kavanagh P AUID- ORCID: 0000-0001-8576-2247 AD - Health Intelligence Unit, Strategic Planning and Transformation, Jervis House, Jervis St, Dublin 1, Ireland. AD - Department of Epidemiology and Public Health, Royal College of Surgeons, Dublin 2, Ireland. LA - eng PT - Journal Article DEP - 20221012 PL - Ireland TA - HRB Open Res JT - HRB open research JID - 101754913 PMC - PMC9513415 OTO - NOTNLM OT - COVID-19 OT - alcohol OT - health services OT - health systems OT - healthcare utilisation OT - mental health OT - public health OT - secondary care COIS- No competing interests were disclosed. EDAT- 2022/10/21 06:00 MHDA- 2022/10/21 06:01 PMCR- 2022/10/12 CRDT- 2022/10/20 03:02 PHST- 2022/10/05 00:00 [accepted] PHST- 2022/10/20 03:02 [entrez] PHST- 2022/10/21 06:00 [pubmed] PHST- 2022/10/21 06:01 [medline] PHST- 2022/10/12 00:00 [pmc-release] AID - 10.12688/hrbopenres.13307.3 [doi] PST - epublish SO - HRB Open Res. 2022 Oct 12;4:67. doi: 10.12688/hrbopenres.13307.3. eCollection 2021. PMID- 36253037 OWN - NLM STAT- MEDLINE DCOM- 20221019 LR - 20221116 IS - 2044-6055 (Electronic) IS - 2044-6055 (Linking) VI - 12 IP - 10 DP - 2022 Oct 17 TI - Effect of social prescribing link workers on health outcomes and costs for adults in primary care and community settings: a systematic review. PG - e062951 LID - 10.1136/bmjopen-2022-062951 [doi] LID - e062951 AB - OBJECTIVES: To establish the evidence base for the effects on health outcomes and costs of social prescribing link workers (non-health or social care professionals who connect people to community resources) for people in community settings focusing on people experiencing multimorbidity and social deprivation. DESIGN: Systematic review and narrative synthesis using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach. DATA SOURCES: Cochrane Database, Cochrane Central Register of Controlled Trials, ClinicalTrials.gov, EU Clinical Trials Register, CINAHL, Embase, Global Health, PubMed/MEDLINE, PsycInfo, LILACS, Web of Science and grey literature were searched up to 31 July 2021. A forward citation search was completed on 9 June 2022. ELIGIBILITY CRITERIA: Controlled trials meeting the Cochrane Effectiveness of Practice and Organisation of Care (EPOC) guidance on eligible study designs assessing the effect of social prescribing link workers for adults in community settings on any outcomes. No language restrictions were applied. DATA EXTRACTION AND SYNTHESIS: Two independent reviewers extracted data, evaluated study quality using the Cochrane EPOC risk of bias tool and judged certainty of the evidence. Results were synthesised narratively. RESULTS: Eight studies (n=6500 participants), with five randomised controlled trials at low risk of bias and three controlled before-after studies at high risk of bias, were included. Four included participants experiencing multimorbidity and social deprivation. Four (n=2186) reported no impact on health-related quality of life (HRQoL). Four (n=1924) reported mental health outcomes with three reporting no impact. Two US studies found improved ratings of high-quality care and reduced hospitalisations for people with multimorbidity experiencing deprivation. No cost-effectiveness analyses were identified. The certainty of the evidence was low or very low. CONCLUSIONS: There is an absence of evidence for social prescribing link workers. Policymakers should note this and support evaluation of current programmes before mainstreaming. PROSPERO REGISTRATION NUMBER: CRD42019134737. CI - (c) Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. FAU - Kiely, Bridget AU - Kiely B AUID- ORCID: 0000-0002-5752-0432 AD - Department of General Practice, RCSI University of Medicine and Health Sciences, Dublin, Ireland bridgetkiely@rcsi.com. FAU - Croke, Aisling AU - Croke A AD - Department of General Practice, RCSI University of Medicine and Health Sciences, Dublin, Ireland. FAU - O'Shea, Muireann AU - O'Shea M AD - Department of General Practice, RCSI University of Medicine and Health Sciences, Dublin, Ireland. FAU - Boland, Fiona AU - Boland F AUID- ORCID: 0000-0003-3228-0046 AD - Data Science Centre, RCSI University of Medicine and Health Sciences, Dublin, Ireland. FAU - O'Shea, Eamon AU - O'Shea E AD - School of Business and Economics, National University of Ireland Galway, Galway, Ireland. FAU - Connolly, Deirdre AU - Connolly D AD - Discipline of Occupational Therapy, Trinity College, Dublin, Ireland. FAU - Smith, Susan M AU - Smith SM AD - Department of General Practice, RCSI University of Medicine and Health Sciences, Dublin, Ireland. AD - Discipline of Public Health and Primary Care, Trinity College Dublin, Dublin, Ireland. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Systematic Review DEP - 20221017 PL - England TA - BMJ Open JT - BMJ open JID - 101552874 SB - IM MH - Adult MH - Controlled Before-After Studies MH - Humans MH - Outcome Assessment, Health Care MH - Primary Health Care MH - *Quality of Life MH - *Social Workers PMC - PMC9644316 OTO - NOTNLM OT - health policy OT - primary care OT - social medicine COIS- Competing interests: None declared. EDAT- 2022/10/18 06:00 MHDA- 2022/10/20 06:00 PMCR- 2022/09/14 CRDT- 2022/10/17 21:03 PHST- 2022/10/17 21:03 [entrez] PHST- 2022/10/18 06:00 [pubmed] PHST- 2022/10/20 06:00 [medline] PHST- 2022/09/14 00:00 [pmc-release] AID - bmjopen-2022-062951 [pii] AID - 10.1136/bmjopen-2022-062951 [doi] PST - epublish SO - BMJ Open. 2022 Oct 17;12(10):e062951. doi: 10.1136/bmjopen-2022-062951. PMID- 36247075 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20221019 IS - 2364-3722 (Print) IS - 2196-9736 (Electronic) IS - 2196-9736 (Linking) VI - 10 IP - 8 DP - 2022 Aug TI - Thermal ablation of mucosal defect margins to prevent local recurrence of large colorectal polyps: a systematic review and meta-analysis. PG - E1127-E1135 LID - 10.1055/a-1869-2446 [doi] AB - Background and study aims Endoscopic mucosal resection of large non-pedunculated colorectal polyps is characterized by a high risk of recurrence. Thermal ablation of the mucosal defect margins may reduce recurrence in these lesions, but a systematic overview of the current evidence is lacking. Methods We searched PubMed, Embase and Cochrane until July 2021, for studies on thermal ablation of mucosal defect margins of large non-pedunculated colorectal polyps. Main goal of this meta-analysis was to identify pooled risk difference of recurrence between thermal ablation vs. no adjuvant treatment. Secondary goal was to identify pooled recurrence rate after snare tip soft coagulation (STSC) and argon plasma coagulation (APC). Results Ten studies on thermal ablation of mucosal defect margins were included, with three studies on argon plasma coagulation, six studies on snare tip soft coagulation and one study comparing both treatment modalities, representing a total of 316 APC cases and 1598 STSC cases. Overall pooled risk difference of recurrence was -0.17 (95 % confidence interval [CI] -0.22 to -0.12) as compared to no adjuvant treatment. Pooled risk difference was -0.16 (95 % CI -0.19 to -0.14) for STSC and -0.26 (95 % CI -0.80 to 0.28) for APC. Pooled recurrence rate was 4 % (95 % CI 2 % to 8 %) for STSC and 9 % (95 % CI 4 % to 19 %) for APC. Conclusions Thermal ablation of mucosal defect margins significantly reduces recurrence rate in large non-pedunculated colorectal lesions compared to no adjuvant treatment. While no evidence for superiority exists, STSC may be preferred over APC, because this method is the most evidence-based, and cost-effective modality. CI - The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/). FAU - Meulen, Lonne W T AU - Meulen LWT AD - Department of Internal Medicine, Division of Gastroenterology and Hepatology, Maastricht University Medical Center, Maastricht, The Netherlands. AD - GROW, School for Oncology and Reproduction, Maastricht University, Maastricht, The Netherlands. FAU - Bogie, Roel M M AU - Bogie RMM AD - Department of Internal Medicine, Division of Gastroenterology and Hepatology, Maastricht University Medical Center, Maastricht, The Netherlands. AD - GROW, School for Oncology and Reproduction, Maastricht University, Maastricht, The Netherlands. FAU - Winkens, Bjorn AU - Winkens B AD - Department of Methodology and Statistics, Maastricht University, Maastricht, The Netherlands. AD - CAPHRI, Care and Public Health Research Institute, Maastricht University, Maastricht, The Netherlands. FAU - Masclee, Ad A M AU - Masclee AAM AD - Department of Internal Medicine, Division of Gastroenterology and Hepatology, Maastricht University Medical Center, Maastricht, The Netherlands. AD - NUTRIM, School for Nutrition and Translational Research in Metabolism, Maastricht University, Maastricht, The Netherlands. FAU - Moons, Leon M G AU - Moons LMG AD - Department of Gastroenterology and Hepatology, University Medical Center Utrecht, Utrecht, The Netherlands. LA - eng PT - Journal Article PT - Review DEP - 20220815 PL - Germany TA - Endosc Int Open JT - Endoscopy international open JID - 101639919 PMC - PMC9554920 COIS- Competing interests Dr. Bogie was supported by an unrestricted educational grant from Pentax Medical B.V. Dr. Masclee was supported by a health care efficiency grant from ZON MW (Organization for Health Research and Development, The Netherlands), an unrestricted research grant from Will Pharma S.A., a restricted educational grant from Ferring B.V., research funding from Allegan and Grunenthal, gave scientific advice to Bayer, Kyowa Kirin, and Takeda, and received a research grant from Pentax Europe GmBH and the Dutch Cancer Society. Dr. Moons declares consultancy for Boston Scientific. EDAT- 2022/10/18 06:00 MHDA- 2022/10/18 06:01 PMCR- 2022/08/01 CRDT- 2022/10/17 04:42 PHST- 2022/01/04 00:00 [received] PHST- 2022/05/31 00:00 [accepted] PHST- 2022/10/17 04:42 [entrez] PHST- 2022/10/18 06:00 [pubmed] PHST- 2022/10/18 06:01 [medline] PHST- 2022/08/01 00:00 [pmc-release] AID - 10.1055/a-1869-2446 [doi] PST - epublish SO - Endosc Int Open. 2022 Aug 15;10(8):E1127-E1135. doi: 10.1055/a-1869-2446. eCollection 2022 Aug. PMID- 36216375 OWN - NLM STAT- MEDLINE DCOM- 20221012 LR - 20221025 IS - 2399-6641 (Electronic) IS - 2399-6641 (Linking) VI - 11 IP - 4 DP - 2022 Oct TI - Development, implementation and evaluation of high-quality virtual preoperative anaesthetic assessment during COVID-19 and beyond: a quality improvement report. LID - 10.1136/bmjoq-2022-001959 [doi] LID - e001959 AB - BACKGROUND: Preoperative risk factor identification and optimisation are widely accepted as the gold standard of care for elective surgery and are essential for reducing morbidity and mortality. COVID-19 public health restrictions required a careful balance between ensuring best medical practices and maintaining safety by minimising patient face-to-face attendance in the hospital. Based on the successful implementation of telemedicine (TM) in other medical specialties and its feasibility in the preoperative context, this study aimed to develop, implement and evaluate a high-quality virtual preoperative anaesthetic assessment process. METHODS: The three-step model for improvement was used. The specific, measurable, actionable, relevant, time aim (step 1) and measures for improvement (step 2) were defined at the onset of the project. The plan-do-study-act tool was used for the structured implementation of improvement interventions (step 3) in three phases. Data relating to virtual and in-person referrals, assessments, did-not-attend (DNA) rate, consultation time, day of surgery delays and cancellations, and service-user and provider experience surveys were recorded prospectively. RESULTS: A total of 2805 patients were assessed in the preoperative anaesthetic assessment clinic between July 2020 and March 2021. The mean rate of virtual preoperative assessments was 50% (SD +/-10) (1390/2805). 0.1% (30/2805) were inappropriately referred on the alternative pathway. The DNA rate was 0.4% (8/1398) and 3% (43/1458) for virtual and in-person pathways, respectively. The mean consultation times for virtual and in-person attendance were 19 (SD +/-7) and 31 (SD +/-13) min, respectively. There were five same-day surgery cancellations and one delay due to medical reasons. When asked about their experience with the virtual assessment, both service users and providers reported high satisfaction, minimal technical difficulties and shared concerns about limited opportunities for physical examination. CONCLUSION: This is one of the first implementational studies to comprehensively outline the feasibility of TM in preoperative anaesthetic assessment during COVID-19. CI - (c) Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. FAU - Popivanov, Petar AU - Popivanov P AUID- ORCID: 0000-0001-7840-3860 AD - Department of Perioperative Medicine, Coombe Women and Infants University Hospital, Dublin, Ireland ppopivanov@coombe.ie. FAU - Bampoe, Sohail AU - Bampoe S AD - University College London Hospitals NHS Foundation Trust, London, UK. FAU - Tan, Terry AU - Tan T AD - Department of Perioperative Medicine, Coombe Women and Infants University Hospital, Dublin, Ireland. FAU - Rafferty, Paul AU - Rafferty P AD - Faculty of Leadership and Quality in Healthcare, Royal College of Physicians of Ireland, Dublin, Ireland. LA - eng PT - Journal Article PL - England TA - BMJ Open Qual JT - BMJ open quality JID - 101710381 RN - 0 (Anesthetics) SB - IM MH - Ambulatory Care Facilities MH - *Anesthetics MH - *COVID-19 MH - Humans MH - Quality Improvement MH - *Telemedicine PMC - PMC9556744 OTO - NOTNLM OT - Anaesthesia OT - COVID-19 OT - Quality improvement OT - Quality improvement methodologies OT - Telemedicine COIS- Competing interests: None declared. EDAT- 2022/10/11 06:00 MHDA- 2022/10/13 06:00 PMCR- 2022/10/10 CRDT- 2022/10/10 20:42 PHST- 2022/04/25 00:00 [received] PHST- 2022/09/27 00:00 [accepted] PHST- 2022/10/10 20:42 [entrez] PHST- 2022/10/11 06:00 [pubmed] PHST- 2022/10/13 06:00 [medline] PHST- 2022/10/10 00:00 [pmc-release] AID - bmjoq-2022-001959 [pii] AID - 10.1136/bmjoq-2022-001959 [doi] PST - ppublish SO - BMJ Open Qual. 2022 Oct;11(4):e001959. doi: 10.1136/bmjoq-2022-001959. PMID- 36207217 OWN - NLM STAT- MEDLINE DCOM- 20230131 LR - 20230202 IS - 0929-6646 (Print) IS - 0929-6646 (Electronic) IS - 0929-6646 (Linking) VI - 122 IP - 2 DP - 2023 Feb TI - The impact of the coronavirus disease 2019 epidemic and national public restrictions on Pediatric Intensive Care Units in Taiwan. PG - 113-120 LID - S0929-6646(22)00361-8 [pii] LID - 10.1016/j.jfma.2022.09.011 [doi] AB - BACKGROUND/PURPOSE: Coronavirus disease 2019 (COVID-19) pandemic challenges pediatric health globally by limited medical accessibility. In response to COVID-19 epidemic in Taiwan, public restrictions were applied and the Level 3 alert was announced from May to July in 2021 for local outbreak. This study aims to analyze patients' clinical features and outcomes in the pediatric intensive care unit (PICU) during the COVID-19 epidemic with the Level 3 alert in Taiwan. METHODS: Medical records were retrospectively collected in patients admitted to the PICU of National Taiwan University Children's Hospital from May to July 2021 (Level 3 alert) and May to July 2019 and 2020 (control periods). Clinical characteristics and outcomes were compared between patients in the period with the Level 3 alert and control periods. RESULTS: During the study period, PICU monthly admissions significantly decreased in the Level 3 alert period and were negatively correlated with monthly newly confirmed COVID-19 cases. Patients admitted during the Level 3 alert were older, had higher disease severity, lower proportion of cardiovascular disease, and higher proportion of hematology-oncology diseases than those in the control group. After adjusting for the above factors, admission during Level 3 alert was an independent factor for higher mortality rate and prolonged length of stay (>14 days) in the PICU. CONCLUSION: During the COVID-19 epidemic with strict public restrictions, critically ill patients admitted to the PICU decreased but had increased disease severity, prolonged length of stay in the PICU, and higher mortality, reflecting the impact of quarantine and limited medical access. CI - Copyright (c) 2022. Published by Elsevier B.V. FAU - Wu, Jeng-Hung AU - Wu JH AD - Department of Pediatrics, National Taiwan University Children's Hospital and College of Medicine, National Taiwan University, Taipei, Taiwan. FAU - Wang, Ching-Chia AU - Wang CC AD - Department of Pediatrics, National Taiwan University Children's Hospital and College of Medicine, National Taiwan University, Taipei, Taiwan. FAU - Lu, Frank Leigh AU - Lu FL AD - Department of Pediatrics, National Taiwan University Children's Hospital and College of Medicine, National Taiwan University, Taipei, Taiwan. FAU - Huang, Shu-Chien AU - Huang SC AD - Department of Surgery, National Taiwan University Children's Hospital and National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei, Taiwan. FAU - Liu, Yueh-Ping AU - Liu YP AD - Department of Medical Affairs, Ministry of Health and Welfare, Taipei, Taiwan. FAU - Lu, Chun-Yi AU - Lu CY AD - Department of Pediatrics, National Taiwan University Children's Hospital and College of Medicine, National Taiwan University, Taipei, Taiwan. FAU - Chang, Luan-Yin AU - Chang LY AD - Department of Pediatrics, National Taiwan University Children's Hospital and College of Medicine, National Taiwan University, Taipei, Taiwan. FAU - Wu, En-Ting AU - Wu ET AD - Department of Pediatrics, National Taiwan University Children's Hospital and College of Medicine, National Taiwan University, Taipei, Taiwan. Electronic address: 008745@ntuh.gov.tw. LA - eng PT - Journal Article DEP - 20220923 PL - Singapore TA - J Formos Med Assoc JT - Journal of the Formosan Medical Association = Taiwan yi zhi JID - 9214933 SB - IM MH - Child MH - Humans MH - Infant MH - *COVID-19/epidemiology MH - Taiwan/epidemiology MH - Retrospective Studies MH - Hospitalization MH - Intensive Care Units, Pediatric MH - Length of Stay PMC - PMC9500089 OTO - NOTNLM OT - Coronavirus disease 2019 OT - Length of stay OT - Mortality OT - Outcomes OT - Pediatric intensive care unit COIS- Conflict of Interest The authors declare no conflicts of interest related to the subject matter or materials discussed in this article. EDAT- 2022/10/08 06:00 MHDA- 2023/02/01 06:00 PMCR- 2022/09/23 CRDT- 2022/10/07 22:05 PHST- 2022/05/16 00:00 [received] PHST- 2022/09/13 00:00 [revised] PHST- 2022/09/18 00:00 [accepted] PHST- 2022/10/08 06:00 [pubmed] PHST- 2023/02/01 06:00 [medline] PHST- 2022/10/07 22:05 [entrez] PHST- 2022/09/23 00:00 [pmc-release] AID - S0929-6646(22)00361-8 [pii] AID - 10.1016/j.jfma.2022.09.011 [doi] PST - ppublish SO - J Formos Med Assoc. 2023 Feb;122(2):113-120. doi: 10.1016/j.jfma.2022.09.011. Epub 2022 Sep 23. PMID- 36202429 OWN - NLM STAT- MEDLINE DCOM- 20221010 LR - 20250530 IS - 2059-7908 (Print) IS - 2059-7908 (Electronic) IS - 2059-7908 (Linking) VI - 7 IP - 10 DP - 2022 Oct TI - Impact of the COVID-19 pandemic on access to and utilisation of services for sexual and reproductive health: a scoping review. LID - 10.1136/bmjgh-2022-009594 [doi] LID - e009594 AB - INTRODUCTION: The COVID-19 pandemic has negatively impacted health systems globally and widened preexisting disparities. We conducted a scoping review on the impact of the COVID-19 pandemic on women and girls' access to and utilisation of sexual and reproductive health (SRH) services for contraception, abortion, gender-based and intimate partner violence (GBV/IPV) and sexually transmitted infections (STIs). METHODS: We systematically searched peer reviewed literature and quantitative reports, published between December 2019 and July 2021, focused on women and girls' (15-49 years old) access to and utilisation of selected SRH services during the COVID-19 pandemic. Included studies were grouped based on setting, SRH service area, study design, population and reported impact. Qualitative data were coded, organised thematically and grouped by major findings. RESULTS: We included 83 of 3067 identified studies and found that access to contraception, in-person safe abortion services, in-person services for GBV/IPV and STI/HIV testing, prevention and treatment decreased. The geographical distribution of this body of research was uneven and significantly less representative of countries where COVID-19 restrictions were very strict. Access was limited by demand and supply side barriers including transportation disruptions, financial hardships, limited resources and legal restrictions. Few studies focused on marginalised groups with distinct SRH needs. CONCLUSION: Reports indicated negative impacts on access to and utilisation of SRH services globally, especially for marginalised populations during the pandemic. Our findings call for strengthening of health systems preparedness and resilience to safeguard global access to essential SRH services in ongoing and future emergencies. CI - (c) Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. FAU - VanBenschoten, Hannah AU - VanBenschoten H AUID- ORCID: 0000-0002-2629-150X AD - Department of Bioengineering, University of Washington, Seattle, Washington, USA. FAU - Kuganantham, Hamsadvani AU - Kuganantham H AD - Department of Sexual and Reproductive Health, WHO, Geneve, Switzerland. FAU - Larsson, Elin C AU - Larsson EC AD - Department of Women's and Children's Health, Karolinska Institute, Stockholm, Sweden. AD - WHO Collaborating Center for Human Reproduction, Karolinska University Hospital, Stockholm, Sweden. FAU - Endler, Margit AU - Endler M AUID- ORCID: 0000-0003-0164-6455 AD - Department of Women and Children's Health, Karolinska Institutet, Stockholm, Sweden. AD - Department of Obsetrics and Gynecology, Stockholm South General Hospital, Stockholm, Sweden. FAU - Thorson, Anna AU - Thorson A AD - Department of Sexual and Reproductive Health and Research, WHO, Geneve, Switzerland. AD - Department of Global Public Health, Karolinska Institute, Stockholm, Sweden. FAU - Gemzell-Danielsson, Kristina AU - Gemzell-Danielsson K AD - Department of Women's and Children's Health, Karolinska Institute, Stockholm, Sweden. AD - WHO Collaborating Center for Human Reproduction, Karolinska University Hospital, Stockholm, Sweden. FAU - Hanson, Claudia AU - Hanson C AUID- ORCID: 0000-0001-8066-7873 AD - Department of Global Public Health, Karolinska Institute, Stockholm, Sweden. AD - Department of Disease Control, London School of Hygiene & Tropical Medicine Faculty of Infectious and Tropical Diseases, London, UK. FAU - Ganatra, Bela AU - Ganatra B AD - Department of Sexual and Reproductive Health and Research, WHO, Geneve, Switzerland. FAU - Ali, Moazzam AU - Ali M AUID- ORCID: 0000-0001-6949-8976 AD - Department of Sexual and Reproductive Health and Research, WHO, Geneve, Switzerland. FAU - Cleeve, Amanda AU - Cleeve A AUID- ORCID: 0000-0001-8115-5503 AD - Department of Women's and Children's Health, Karolinska Institute, Stockholm, Sweden Amanda.cleeve@ki.se. AD - Department of Obsetrics and Gynecology, Stockholm South General Hospital, Stockholm, Sweden. LA - eng GR - 001/WHO_/World Health Organization/International PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Scoping Review PL - England TA - BMJ Glob Health JT - BMJ global health JID - 101685275 SB - IM MH - Adolescent MH - Adult MH - *COVID-19 MH - Female MH - Humans MH - Middle Aged MH - Pandemics MH - Pregnancy MH - Reproductive Health MH - *Reproductive Health Services MH - *Sexual Health MH - *Sexually Transmitted Diseases/prevention & control MH - Young Adult PMC - PMC9539651 OTO - NOTNLM OT - COVID-19 OT - HIV OT - Health systems OT - Systematic review COIS- Competing interests: None declared. EDAT- 2022/10/07 06:00 MHDA- 2022/10/12 06:00 PMCR- 2022/10/06 CRDT- 2022/10/06 20:52 PHST- 2022/05/11 00:00 [received] PHST- 2022/08/13 00:00 [accepted] PHST- 2022/10/06 20:52 [entrez] PHST- 2022/10/07 06:00 [pubmed] PHST- 2022/10/12 06:00 [medline] PHST- 2022/10/06 00:00 [pmc-release] AID - bmjgh-2022-009594 [pii] AID - 10.1136/bmjgh-2022-009594 [doi] PST - ppublish SO - BMJ Glob Health. 2022 Oct;7(10):e009594. doi: 10.1136/bmjgh-2022-009594. PMID- 36196435 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20221007 IS - 2639-8028 (Electronic) IS - 2639-8028 (Linking) VI - 4 IP - 10 DP - 2022 Oct TI - Screening for Social Risk Factors in the ICU During the Pandemic. PG - e0761 LID - 10.1097/CCE.0000000000000761 [doi] LID - e0761 AB - Due to limitations in data collected through electronic health records, the social risk factors (SRFs) that predate severe illness and restrict access to critical care services are poorly understood. OBJECTIVES: This study explored the feasibility and utility of directly eliciting SRFs in the ICU by implementing a screening program. DESIGN SETTING AND PARTICIPANTS: Five hundred sixty-six critically ill patients at the medical ICU of Robert Wood Johnson University Hospital from July 1, 2019, to September 31, 2021, were interviewed for SRFs using an adapted version of the American Academy of Family Physicians' Social Needs Screening Tool. MAIN OUTCOMES AND MEASURES: For each SRFs, we compared basic demographic factors, proxies of socioeconomic status, and severity score between those with and without the SRFs through chi-square tests and Wilcoxon rank-sum tests. Furthermore, we determined the prevalence of SRFs overall, before, and during the COVID-19 pandemic. RESULTS: Of critically ill patients, 39.58% reported at least one SRF. Age, zip-code matched median household income, and insurance type differed depending on the SRFs. Notably, patients with SRFs were admitted with a lower average severity score, indicating reduced risk in mortality. Since March 2020, the prevalence of SRFs in the ICU overall fell from 54.47% to 35.44%. Conversely, the proportion of patients unable to afford healthcare increased statistically significantly from 7.32% to 18.06%. CONCLUSIONS AND RELEVANCE: Screening for SRFs in the ICU detected the presence of disproportionally low-risk patients whose access to critical care services became restricted throughout the pandemic. CI - Copyright (c) 2022 The Authors. Published by Wolters Kluwer Health, Inc. on behalf of the Society of Critical Care Medicine. FAU - Ge, Derek AU - Ge D AD - Department of Medicine, Robert Wood Johnson Medical School, Rutgers University, New Brunswick, NJ. FAU - Weber, Alec M AU - Weber AM AD - Department of Medicine, Robert Wood Johnson Medical School, Rutgers University, New Brunswick, NJ. AD - Department of Medicine, Westchester Medical Center, Valhalla, NY. FAU - Vatson, Jayanth AU - Vatson J AD - Department of Medicine, Robert Wood Johnson Medical School, Rutgers University, New Brunswick, NJ. FAU - Andrews, Tracy AU - Andrews T AD - Department of Biostatistics and Epidemiology, School of Public Health, Rutgers University, Piscataway, NJ. FAU - Levytska, Natalia AU - Levytska N AD - Department of Medicine, Robert Wood Johnson Medical School, Rutgers University, New Brunswick, NJ. FAU - Shu, Carol AU - Shu C AD - Department of Medicine, Robert Wood Johnson Medical School, Rutgers University, New Brunswick, NJ. FAU - Hussain, Sabiha AU - Hussain S AD - Department of Medicine, Robert Wood Johnson Medical School, Rutgers University, New Brunswick, NJ. LA - eng PT - Journal Article DEP - 20220929 PL - United States TA - Crit Care Explor JT - Critical care explorations JID - 101746347 PMC - PMC9524932 COIS- The authors have disclosed that they do not have any potential conflicts of interest. EDAT- 2022/10/06 06:00 MHDA- 2022/10/06 06:01 PMCR- 2022/09/29 CRDT- 2022/10/05 01:50 PHST- 2022/10/05 01:50 [entrez] PHST- 2022/10/06 06:00 [pubmed] PHST- 2022/10/06 06:01 [medline] PHST- 2022/09/29 00:00 [pmc-release] AID - 10.1097/CCE.0000000000000761 [doi] PST - epublish SO - Crit Care Explor. 2022 Sep 29;4(10):e0761. doi: 10.1097/CCE.0000000000000761. eCollection 2022 Oct. PMID- 36282939 STAT- Publisher PB - Agency for Healthcare Research and Quality (US) CTI - U.S. Preventive Services Task Force Evidence Syntheses, formerly Systematic Evidence Reviews DP - 2022 Oct BTI - Screening for Depression, Anxiety, and Suicide Risk in Children and Adolescents: An Evidence Review for the U.S. Preventive Services Task Force AB - PURPOSE: To review the evidence on screening (benefits and harms of screening, accuracy of screening, benefits and harms of treatment) for suicide risk, anxiety, and depression in children and adolescents in settings relevant to primary care in the United States for the U.S. Preventive Services Task Force. DATA SOURCES: PubMed, the Cochrane Library, PsycINFO, CINAHL and trial registries through July 19, 2021; bibliographies from retrieved articles, outside experts, and surveillance of the literature through June 1, 2022. STUDY SELECTION: Two investigators independently selected English-language studies using a priori defined criteria. We included trials that evaluated the benefits or harms of screening for suicide risk, anxiety, or depression compared with no screening or usual care. We included studies of screening with instruments feasible in primary care settings. For treatment benefits and harms, we included drugs approved for pediatric use by the Food and Drug Administration. For suicide and depression treatment studies, we included any eligible psychotherapy or collaborative care interventions. For anxiety, we restricted nonpharmacological interventions to cognitive behavioral therapy (CBT). Eligible outcomes included test accuracy, symptoms, response, remission, loss of diagnosis, all-cause mortality, functioning, suicide-related symptoms or events, withdrawal due to adverse events, serious adverse events, and harms from screening. We also included systematic reviews reporting on harms of treatment. We excluded studies with poor methodological quality. DATA EXTRACTION AND ANALYSIS: One investigator extracted data and a second checked accuracy. Two reviewers independently rated methodological quality for all included studies. When at least three similar studies were available, we conducted meta-analyses. DATA SYNTHESIS: We included 80 studies (in 106 publications). No studies evaluated the direct benefits of screening compared with no screening or usual care. Seventeen studies reported on accuracy of screening instruments for one or more conditions; of these, one reported on suicide (N=580), 10 on anxiety (N=3,260), seven on depression (N=3,316), and two on anxiety or depression (N=695). Studies reported a wide range for sensitivity and specificity across a variety of instruments, with no more than one or two studies on each instrument. For suicide, sensitivity ranged from 0.87 to 0.91, and specificity was 0.60. For anxiety, sensitivity generally ranged from 0.34 to 1.00, and specificity from 0.47 to 0.98. For depression, sensitivity ranged from 0.59 to 0.94, and specificity from 0.38 to 0.96. Two RCTs (N=2,675) compared short-term distress from screening for suicide risk and reported no significant differences between those screened and those who were not screened. Sixty randomized, controlled trials (RCTs) addressed benefits of treatment; of these, 16 reported on suicide risk interventions (N=3,034), 29 on anxiety treatment (N=2,970), 13 on depression treatment (N=2,156), and two on depression or anxiety treatment (N=236). Interventions addressing suicide risk or self-harm reported lower scores for the Beck Hopelessness Scale (pooled mean difference: -2.35 [95% confidence interval [CI], -4.06 to -0.65]; N=644; k=4) for intervention arms when compared with control arms. Findings for other measures were mixed or not statistically significantly different. Of the 29 RCTs on anxiety treatment, 22 were on CBT; six were on pharmacotherapy; and one had multiple arms evaluating CBT, sertraline, and CBT plus sertraline. The evidence suggests CBT was associated with gains on several pooled measures of symptom improvement (magnitude of change varies by outcome measure), response (pooled relative risk [RR]: 1.89 [95% CI, 1.17 to 3.05]; N=606; k=6; I2=64%), remission (RR: 2.68 [95% CI, 1.48 to 4.88]; N=321; k=4), and loss of diagnosis (RRs range from 3.02 to 3.09), when compared with usual care or wait-list. The evidence on functioning for CBT was mixed. The evidence suggests pharmacotherapy, when compared with placebo, was associated with gains on two pooled measures of symptom improvement (mean difference Pediatric Anxiety Rating Scale: -4.0 [95% CI, -5.5 to -2.5], N=726, k=5 and mean difference Clinical Global Impressions-Severity: -0.84 [95% CI, -1.13 to -0.55]; N=550, k=4) and response (RR: 2.11 [95% CI, 1.58 to 2.98]; N=370; k=5) but was mixed on measures of functioning. Of the 13 RCTs on depression treatment, eight were on psychotherapy; two on pharmacotherapy; one on CBT, fluoxetine, and their combination; and one on collaborative care. Results for psychotherapy varied by measure. Two pooled estimates suggested that psychotherapy is associated with improved symptoms (Beck Depression Inventory [BDI] or BDI-II standardized mean difference: -0.58 [95% CI, -0.83 to -0.34]; N=471; k=4 and Hamilton Depression Scale mean difference: -2.25 [95% CI,-4.09 to -0.41]; N=262; k=3), clinical response (3 studies with statistically significant results using varying thresholds), and loss of diagnosis (RR: 1.73 [95% CI, 1.00 to 3.00; N=395; k=4) but no statistically significant differences for other measures. The evidence suggested statistically pharmacotherapy was associated with improvement for one measure of symptoms (Children's Depression Rating Scale-Revised [CDRS-R] mean difference -3.76 [95% CI, -5.95 to -1.57, N=793; k=3), and pharmacotherapy was associated with improvement for remission, but the pooled differences were not statistically significant. The single collaborative care trial (N=101) found that collaborative care was associated with improved symptoms at 6 months (CDRS-R change: 8.5 [95% CI, 13.4 to -3.6]), response by 12 months (odds ratio [OR] for >/=50% reduction in CDRS-R score: 3.3 [95% CI, 1.4 to 8.2], and remission (OR for Patient Health Questionnaire-9 <5 at 6 months: 5.2 [95% CI, 1.6 to 17.3]). The study reported no statistically significant benefits on measures of functioning. Twenty studies (19 randomized controlled trials and 1 meta-analysis) addressed harms. Of these, two reported on suicide risk interventions (N=885), 11 on anxiety treatment (N=1,293), and seven on depression treatment (N=1,352). Two RCTs of interventions to reduce suicide risk or self-harm reported no statistically significant differences in adverse events. Of the 11 RCTs reporting harms of anxiety treatments, four evaluated CBT; six evaluated pharmacotherapy; and one evaluated CBT, sertraline, and their combination. The evidence from CBT studies yielded inconsistent results on suicide-related events; these studies also suggested lower rates of withdrawal due to adverse events and serious adverse events in the CBT arms. Suicide-related events and withdrawals due to adverse events in pharmacotherapy studies were rare and not statistically significant; however, they were more commonly reported in pharmacotherapy arms when compared with placebo arms. Of the seven studies reporting harms of depression treatment, three evaluated pharmacotherapy; two evaluated psychotherapy; one evaluated CBT, fluoxetine, and their combination; and one evaluated collaborative care (1,276 from trials). Suicide-related outcomes, withdrawal as a result of adverse events, and serious adverse events were not statistically significant between study arms but were more frequent for pharmacotherapy when compared with placebo; inconsistencies in the evidence further reduced certainty. The evidence from the collaborative care study was inconsistent. LIMITATIONS: No studies were available that reported benefits of screening compared with no screening. Limited evidence was available on harms of screening, long-term outcomes, test accuracy, and suicide risk and depression treatment in children. Treatment-as-usual comparators for suicide risk interventions included active treatments. The review was limited to drugs approved for pediatric use by the Food and Drug Administration (FDA). For anxiety, psychotherapy was limited to CBT. CONCLUSIONS: We found no eligible studies that reported on benefits directly arising from screening when compared with usual care or no screening. Limited direct evidence suggests no short-term harms from screening for suicide risk. The evidence for screening for suicide risk, anxiety, and depression in children and adolescents relied on indirect evidence on the accuracy of screening and the benefits and harms of treatment. The evidence suggests that some screening instruments are reasonably accurate for anxiety and depression, but the evidence is limited for suicide risk screening instruments. Both pharmacotherapy and psychotherapy treatments have some benefit for some depression and anxiety outcomes (specifically, CBT for anxiety alone was reviewed); the evidence is limited for suicide risk interventions. Harms are rare in treatment studies but more frequent in pharmacotherapy arms when compared with placebo. Evidence gaps persist in children younger than age 11 years for test accuracy; depression and suicide risk interventions; and screening and treatment differences by sex, race/ethnicity, sexual orientation, and gender identity. FAU - Viswanathan, Meera AU - Viswanathan M FAU - Wallace, Ina AU - Wallace I FAU - Middleton, Jennifer Cook AU - Middleton JC FAU - Kennedy, Sara M AU - Kennedy SM FAU - McKeeman, Joni AU - McKeeman J FAU - Hudson, Kesha AU - Hudson K FAU - Rains, Caroline AU - Rains C FAU - Vander Schaaf, Emily B AU - Vander Schaaf EB FAU - Kahwati, Leila AU - Kahwati L LA - eng PT - Review PT - Book PL - Rockville (MD) EDAT- 2022/10/01 00:00 CRDT- 2022/10/01 00:00 AID - NBK585407 [bookaccession] PMID- 35633845 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240904 IS - 2515-4826 (Electronic) IS - 2515-4826 (Linking) VI - 4 DP - 2021 TI - Mental health following an initial period of COVID-19 restrictions: findings from a cross-sectional survey in the Republic of Ireland. PG - 130 LID - 10.12688/hrbopenres.13400.2 [doi] LID - 130 AB - Background: We assessed the mental health of individuals in the general population, during an initial period of easing of COVID-19 restrictions in the Republic of Ireland (RoI). Methods: Data were collected through a nationally representative cross-sectional telephone survey, during the first period of easing of restrictions during the COVID-19 pandemic between May and July 2020. Mental health was examined using the Patient Health Questionnaire Anxiety Depression Scale. Poisson regression analyses were conducted to estimate risk ratios with robust variance estimation of the association between selected demographic factors and the risk of having depression and anxiety symptoms. Results: Of the 1,983 participants, 27.7% (n = 549; 95% CI: 0.26 - 0.30) reported depression and anxiety symptoms, while 74 (3.8%; 95% CI: 0.03 - 0.05) disclosed self-harm and/or suicidal thoughts. Females (RR: 1.60, 95% CI: 1.37 - 1.87, p < 0.0005), employed individuals who experienced a change in work status (RR: 1.50, 95% CI: 1.24 - 1.82, p < 0.0005), participants cocooning due to a health condition (RR: 1.34, 95% CI: 1.08 - 1.66, p< 0.01), participants who were self-isolating (RR: 1.25, 95% CI: 1.03 - 1.51, p=0.025) and moderate-heavy drinkers (RR: 1.27, 95% CI: 1.09 - 1.47, p<0.01) were at increased risk of depression and anxiety. Young people aged 18-29 years and those in the two lowest income categories were most likely to report self-harm and/or suicidal thoughts. Conclusion: As the COVID-19 pandemic continues, with further waves and associated restrictions, the impact on mental health in the population as a whole and in specific subgroups must be considered. Study protocol registration: doi.org/10.12688/hrbopenres.13103.2. CI - Copyright: (c) 2022 Troya MI et al. FAU - Troya, Maria Isabela AU - Troya MI AUID- ORCID: 0000-0003-0474-3832 AD - School of Public Health, University College Cork, Cork, Ireland. FAU - Joyce, Mary AU - Joyce M AUID- ORCID: 0000-0003-0560-4260 AD - National Suicide Research Foundation, Cork, Ireland. FAU - Khashan, Ali AU - Khashan A AUID- ORCID: 0000-0002-7499-9406 AD - School of Public Health, University College Cork, Cork, Ireland. FAU - Buckley, Claire AU - Buckley C AUID- ORCID: 0000-0002-3174-7022 AD - School of Public Health, University College Cork, Cork, Ireland. FAU - Chakraborti, Kasturi AU - Chakraborti K AD - School of Public Health, University College Cork, Cork, Ireland. FAU - Hoevel, Philipp AU - Hoevel P AUID- ORCID: 0000-0002-1370-4272 AD - School of Mathematical Sciences, University College Cork, Cork, Ireland. FAU - Humphries, Rory AU - Humphries R AD - School of Mathematical Sciences, University College Cork, Cork, Ireland. FAU - Kearney, Patricia M AU - Kearney PM AUID- ORCID: 0000-0001-9599-3540 AD - School of Public Health, University College Cork, Cork, Ireland. FAU - Kiely, Elizabeth AU - Kiely E AUID- ORCID: 0000-0003-4228-1739 AD - School of Applied Social Studies, University College Cork, Cork, Ireland. FAU - Murphy, Mike AU - Murphy M AD - School of Applied Psychology, University College Cork, Cork, Ireland. FAU - Perry, Ivan AU - Perry I AD - School of Public Health, University College Cork, Cork, Ireland. FAU - Arensman, Ella AU - Arensman E AUID- ORCID: 0000-0003-0376-1203 AD - School of Public Health, University College Cork, Cork, Ireland. AD - National Suicide Research Foundation, Cork, Ireland. AD - Australian Institute for Suicide Research and Prevention, Griffith University, Brisbane, Australia. LA - eng PT - Journal Article DEP - 20220922 PL - Ireland TA - HRB Open Res JT - HRB open research JID - 101754913 PMC - PMC9120930 OTO - NOTNLM OT - Virus diseases; COVID-19; public health; public mental health; epidemiology; mental health COIS- No competing interests were disclosed. EDAT- 2022/09/30 06:00 MHDA- 2022/09/30 06:01 PMCR- 2022/09/22 CRDT- 2022/09/29 02:03 PHST- 2022/09/05 00:00 [accepted] PHST- 2022/09/29 02:03 [entrez] PHST- 2022/09/30 06:00 [pubmed] PHST- 2022/09/30 06:01 [medline] PHST- 2022/09/22 00:00 [pmc-release] AID - 10.12688/hrbopenres.13400.2 [doi] PST - epublish SO - HRB Open Res. 2022 Sep 22;4:130. doi: 10.12688/hrbopenres.13400.2. eCollection 2021. PMID- 36141964 OWN - NLM STAT- MEDLINE DCOM- 20220926 LR - 20230113 IS - 1660-4601 (Electronic) IS - 1661-7827 (Print) IS - 1660-4601 (Linking) VI - 19 IP - 18 DP - 2022 Sep 16 TI - Social Media Sentiments on Suicides at the New York City Landmark, Vessel: A Twitter Study. LID - 10.3390/ijerph191811694 [doi] LID - 11694 AB - Vessel is a landmark created by Heatherwick Studio where visitors can enjoy views of New York City from different heights and perspectives. However, between February 2020 and July 2021, four individuals jumped to their deaths from the landmark. Effective preventive solutions have yet to be identified, and the site is currently closed. In this study, we examined the trajectory of public sentiment on the suicide-related activity at Vessel on Twitter by investigating the engagement patterns and identifying themes about the four suicides from February 2020 to August 2021 (n = 3058 tweets). The results show increased levels of discussion about each successive suicide case in the first 14 days following each incident (from 6 daily tweets for the first case to 104 for the fourth case). It also took longer for relevant discussions to dissipate (4 days for the first and 14 days for the fourth case, KS statistic = 0.71, p < 0.001). Thematic analysis shows a shift from expressions of emotion to urging suicide prevention actions in the third and fourth cases; additionally, we detected growing support for restricting means. We suggest that, prior to the reopening of Vessel, collective efforts should be made to install safety protections and reduce further suicide risks. FAU - Yip, Paul AU - Yip P AUID- ORCID: 0000-0003-1596-4120 AD - The HKJC Centre for Suicide Research and Prevention, The University of Hong Kong, Hong Kong, China. FAU - Xiao, Yunyu AU - Xiao Y AUID- ORCID: 0000-0002-0479-1781 AD - Department of Population Health Sciences, Weill Cornell Medicine, NewYork-Presbyterian, New York, NY 10065, USA. FAU - Xu, Yucan AU - Xu Y AUID- ORCID: 0000-0003-0247-0404 AD - The HKJC Centre for Suicide Research and Prevention, The University of Hong Kong, Hong Kong, China. FAU - Chan, Evangeline AU - Chan E AD - The HKJC Centre for Suicide Research and Prevention, The University of Hong Kong, Hong Kong, China. FAU - Cheung, Florence AU - Cheung F AD - The HKJC Centre for Suicide Research and Prevention, The University of Hong Kong, Hong Kong, China. FAU - Chan, Christian S AU - Chan CS AD - Department of Psychology, The University of Hong Kong, Hong Kong, China. FAU - Pirkis, Jane AU - Pirkis J AUID- ORCID: 0000-0002-2538-4472 AD - Centre for Mental Health, Melbourne School of Population and Global Health, Carlton VIC 3053, Australia. LA - eng PT - Journal Article DEP - 20220916 PL - Switzerland TA - Int J Environ Res Public Health JT - International journal of environmental research and public health JID - 101238455 SB - IM MH - Attitude MH - Humans MH - New York City/epidemiology MH - *Social Media MH - *Suicide PMC - PMC9517673 OTO - NOTNLM OT - Twitter OT - public sentiment OT - restriction of means OT - social media OT - suicide prevention COIS- The authors declare no conflict of interest. EDAT- 2022/09/24 06:00 MHDA- 2022/09/28 06:00 PMCR- 2022/09/16 CRDT- 2022/09/23 01:20 PHST- 2022/08/26 00:00 [received] PHST- 2022/09/13 00:00 [revised] PHST- 2022/09/15 00:00 [accepted] PHST- 2022/09/23 01:20 [entrez] PHST- 2022/09/24 06:00 [pubmed] PHST- 2022/09/28 06:00 [medline] PHST- 2022/09/16 00:00 [pmc-release] AID - ijerph191811694 [pii] AID - ijerph-19-11694 [pii] AID - 10.3390/ijerph191811694 [doi] PST - epublish SO - Int J Environ Res Public Health. 2022 Sep 16;19(18):11694. doi: 10.3390/ijerph191811694. PMID- 36138365 OWN - NLM STAT- MEDLINE DCOM- 20220926 LR - 20221013 IS - 1471-2458 (Electronic) IS - 1471-2458 (Linking) VI - 22 IP - 1 DP - 2022 Sep 23 TI - Quarantine preparedness - the missing factor in COVID-19 behaviour change? Qualitative insights from Australia. PG - 1806 LID - 10.1186/s12889-022-14185-7 [doi] LID - 1806 AB - BACKGROUND: A key feature of the global public health response to contain and slow the spread of COVID-19 has been community-based quarantine and self-isolation. As part of The Optimise Study, this research sought to understand the factors that influence people's ability to undertake home-based quarantine and isolation to contain the spread of COVID-19. METHODS: Semi-structured qualitative phone interviews (n = 25) were conducted by telephone with people who participated in community-based quarantine in Australia before 31 March 2020. The Capability Opportunity Motivation Behaviour model was used to conduct a thematic analysis. RESULTS: Participants required clear, accessible and trusted information to guide them in home-based quarantine and isolation. A sense of social responsibility and belief in the efficacy of the restrictions to reduce viral transmission aided their motivation. Access to essential needs, supportive living environments, and emotional support were required to adhere to restrictions, but few were prepared. CONCLUSIONS: Findings demonstrate that in addition to having the capability and motivation to adhere to restrictions, it is vital that people are also encouraged to prepare for the challenge to ensure access to physical, social and emotional support. Findings also illustrate the importance of engaging communities in planning and preparedness for quarantine and self-isolation public health responses. CI - (c) 2022. The Author(s). FAU - Davis, Angela AU - Davis A AD - Behaviours and Health Risks, Burnet Institute, Melbourne, VIC, Australia. FAU - Munari, Stephanie AU - Munari S AUID- ORCID: 0000-0002-2296-7787 AD - Disease Elimination, Burnet Institute, Melbourne, VIC, Australia. stephanie.munari@burnet.edu.au. FAU - Doyle, Joseph AU - Doyle J AD - Disease Elimination, Burnet Institute, Melbourne, VIC, Australia. AD - Department of Infectious Diseases, The Alfred Hospital, Melbourne, VIC, Australia. FAU - Sutton, Brett AU - Sutton B AD - Communicable Disease Prevention and Control, Victorian Department of Health, Melbourne, VIC, Australia. FAU - Cheng, Allen AU - Cheng A AD - Department of Infectious Diseases, The Alfred Hospital, Melbourne, VIC, Australia. FAU - Hellard, Margaret AU - Hellard M AD - Disease Elimination, Burnet Institute, Melbourne, VIC, Australia. AD - Department of Infectious Diseases, The Alfred Hospital, Melbourne, VIC, Australia. AD - School of Public Health and Preventative Medicine, Monash University, Melbourne, VIC, Australia. AD - Doherty Institute and School of Population and Global Health, University of Melbourne, Melbourne, VIC, Australia. FAU - Gibbs, Lisa AU - Gibbs L AD - Melbourne School of Population and Global Health, University of Melbourne, Melbourne, VIC, Australia. AD - Centre for Disaster Management and Public Safety, University of Melbourne, Melbourne, VIC, Australia. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20220923 PL - England TA - BMC Public Health JT - BMC public health JID - 100968562 SB - IM MH - Australia MH - *COVID-19/prevention & control MH - Humans MH - Motivation MH - Public Health MH - *Quarantine/psychology PMC - PMC9502922 OTO - NOTNLM OT - COM-B model OT - COVID-19 OT - Health behaviours OT - Isolation OT - Planning OT - Preparedness OT - Quarantine COIS- MH receives funding from Gilead Sciences and Abbvie for investigator initiated research. JD declares funding to his institution from Gilead Sciences and Abbvie for investigator initiated research and speaking fees. AC was previously Deputy Victorian Chief Health Officer (July 2020-June 2021) and was involved in quarantine policy during that time. The remaining authors declare that they have no competing interests. EDAT- 2022/09/23 06:00 MHDA- 2022/09/28 06:00 PMCR- 2022/09/23 CRDT- 2022/09/22 23:38 PHST- 2022/03/25 00:00 [received] PHST- 2022/09/14 00:00 [accepted] PHST- 2022/09/22 23:38 [entrez] PHST- 2022/09/23 06:00 [pubmed] PHST- 2022/09/28 06:00 [medline] PHST- 2022/09/23 00:00 [pmc-release] AID - 10.1186/s12889-022-14185-7 [pii] AID - 14185 [pii] AID - 10.1186/s12889-022-14185-7 [doi] PST - epublish SO - BMC Public Health. 2022 Sep 23;22(1):1806. doi: 10.1186/s12889-022-14185-7. PMID- 36127354 OWN - NLM STAT- MEDLINE DCOM- 20220923 LR - 20220927 IS - 2055-1010 (Electronic) IS - 2055-1010 (Linking) VI - 32 IP - 1 DP - 2022 Sep 21 TI - The use of non-steroidal anti-inflammatory drugs (NSAIDs) in COVID-19. PG - 35 LID - 10.1038/s41533-022-00300-z [doi] LID - 35 AB - Early in the COVID-19 pandemic, anecdotal reports emerged suggesting non-steroidal anti-inflammatory drugs (NSAIDs) may increase susceptibility to infection and adversely impact clinical outcomes. This narrative literature review (March 2020-July 2021) attempted to clarify the relationship between NSAID use and COVID-19 outcomes related to disease susceptibility or severity. Twenty-four relevant publications (covering 25 studies) reporting original research data were identified; all were observational cohort studies, and eight were described as retrospective. Overall, these studies are consistent in showing that NSAIDs neither increase the likelihood of SARS-CoV-2 infection nor worsen outcomes in patients with COVID-19. This is reflected in current recommendations from major public health authorities across the world, which support NSAID use for analgesic or antipyretic treatment during COVID-19. Thus, there is no basis on which to restrict or prohibit use of these drugs by consumers or patients to manage their health conditions and symptoms during the pandemic. CI - (c) 2022. The Author(s). FAU - Kushner, Pamela AU - Kushner P AUID- ORCID: 0000-0002-5871-1265 AD - Kushner Wellness Center, Los Angeles, CA, USA. pamkushner@hotmail.com. AD - Department of Family Medicine, University of California, Irvine, CA, USA. pamkushner@hotmail.com. FAU - McCarberg, Bill H AU - McCarberg BH AD - Department of Family Medicine, University of California at San Diego School of Medicine, San Diego, CA, USA. FAU - Grange, Laurent AU - Grange L AD - Rheumatology Department, Grenoble-Alpes University Hospital, Echirolles, France. AD - President of the French League Against Rheumatism (AFLAR), Paris, France. FAU - Kolosov, Anton AU - Kolosov A AD - Medical Affairs, GSK Consumer Healthcare, Rochester Park, Singapore, Singapore. FAU - Haveric, Anela Lihic AU - Haveric AL AD - Consumer Safety, GSK Consumer Healthcare, Nyon, Switzerland. FAU - Zucal, Vincent AU - Zucal V AD - Consumer Safety, GSK Consumer Healthcare, Warren, NJ, USA. FAU - Petruschke, Richard AU - Petruschke R AD - Medical Affairs, GSK Consumer Healthcare, Warren, NJ, USA. FAU - Bissonnette, Stephane AU - Bissonnette S AD - Medical Affairs, GSK Consumer Healthcare, Warren, NJ, USA. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review DEP - 20220921 PL - England TA - NPJ Prim Care Respir Med JT - NPJ primary care respiratory medicine JID - 101631999 RN - 0 (Anti-Inflammatory Agents, Non-Steroidal) RN - 0 (Antipyretics) SB - IM MH - Anti-Inflammatory Agents, Non-Steroidal/therapeutic use MH - *Antipyretics/therapeutic use MH - *COVID-19 MH - Humans MH - Pandemics MH - Retrospective Studies MH - SARS-CoV-2 PMC - PMC9489480 COIS- P.K. is a speaker and an advisory board member for GSK. B.H.M. is an advisor to Lilly, Scilex, and Averitas, a member of the Speaker's Bureau for Adapt and Scilex, and holds stocks in Johnson & Johnson. L.G. is a member of the French board of GRAINS, which is supported by GSK. A.K., A.L.H., V.Z., R.P., and S.B. are current or former employees of GSK Consumer Healthcare. EDAT- 2022/09/21 06:00 MHDA- 2022/09/24 06:00 PMCR- 2022/09/21 CRDT- 2022/09/20 23:18 PHST- 2021/10/06 00:00 [received] PHST- 2022/07/26 00:00 [accepted] PHST- 2022/09/20 23:18 [entrez] PHST- 2022/09/21 06:00 [pubmed] PHST- 2022/09/24 06:00 [medline] PHST- 2022/09/21 00:00 [pmc-release] AID - 10.1038/s41533-022-00300-z [pii] AID - 300 [pii] AID - 10.1038/s41533-022-00300-z [doi] PST - epublish SO - NPJ Prim Care Respir Med. 2022 Sep 21;32(1):35. doi: 10.1038/s41533-022-00300-z. PMID- 36112372 OWN - NLM STAT- MEDLINE DCOM- 20220920 LR - 20221002 IS - 2574-3805 (Electronic) IS - 2574-3805 (Linking) VI - 5 IP - 9 DP - 2022 Sep 1 TI - Changes in Emergency Department Visits for Cannabis Hyperemesis Syndrome Following Recreational Cannabis Legalization and Subsequent Commercialization in Ontario, Canada. PG - e2231937 LID - 10.1001/jamanetworkopen.2022.31937 [doi] LID - e2231937 AB - IMPORTANCE: Prior research suggests that the legalization of recreational cannabis is associated with increases in cannabis hyperemesis syndrome (CHS), but it is unclear how cannabis commercialization (ie, greater retail store access as well as increased variety and potency of cannabis products) may be associated with these changes. OBJECTIVES: To examine changes in the number and characteristics of CHS emergency department (ED) visits from before to after legalization of cannabis in Ontario, Canada. DESIGN, SETTING, AND PARTICIPANTS: This repeated cross-sectional study used interrupted time-series analyses to examine immediate and gradual changes in ED visits for CHS in Ontario, Canada, during 3 time periods: prelegalization (January 2014-September 2018), legalization with product and retail store restrictions (October 2018-February 2020), and commercialization with new products and expanded stores, which coincided with the COVID-19 pandemic (March 2020-June 2021). Data were obtained from routinely collected and linked health administrative databases. All individuals aged at least 15 years and who were eligible for Ontario's Universal Health Coverage were included. Data were analyzed between March and July 2022. MAIN OUTCOMES AND MEASURES: Monthly counts of ED visits for CHS per capita. RESULTS: There were 12 866 ED visits for CHS from 8140 individuals during the study. Overall, the mean (SD) age was 27.4 (10.5) years, with 2834 individuals (34.8%) aged 19 to 24 years, 4163 (51.5%) females, and 1353 individuals (16.6%) with a mental health ED visit or hospitalization in the 2 years before their first CHS ED visit. Nearly 10% of visits (1135 visits [8.8%]) led to hospital admissions. Monthly rates of CHS ED visits increased 13-fold during the 7.5-year study period, from 0.26 visits per 100 000 population in January 2014 to 3.43 visits per 100 000 population in June 2021. Legalization was not associated with an immediate or gradual change in rates of ED visits for CHS; however, commercialization during the COVID-19 pandemic period was associated with an immediate increase in rates of CHS ED visits (incidence rate ratio [IRR], 1.49; 95% CI, 1.31-1.70). During commercialization, rates of CHS ED visits increased more in women (IRR, 1.49; 95% CI, 1.16-1.92) and individuals older than the legal age of cannabis purchase (eg, age 19-24 years: IRR, 1.60; 95% CI, 1.19-2.16) than men (IRR, 1.08; 95% CI, 0.85-1.37) and individuals younger than the legal age of purchase (IRR, 0.78; 95% CI, 0.42-1.45). CONCLUSIONS AND RELEVANCE: This cross-sectional study found large increases in CHS ED visits during the period of time when the market commercialized and the COVID-19 pandemic occurred. Greater awareness of CHS symptoms by ED staff in regions where legal commercialized cannabis markets exist is indicated. FAU - Myran, Daniel Thomas AU - Myran DT AD - Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada. AD - Department of Family Medicine, University of Ottawa, Ottawa, Ontario, Canada. AD - ICES Ottawa, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada. FAU - Roberts, Rhiannon AU - Roberts R AD - Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada. FAU - Pugliese, Michael AU - Pugliese M AD - ICES Ottawa, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada. FAU - Taljaard, Monica AU - Taljaard M AD - Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada. AD - School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada. FAU - Tanuseputro, Peter AU - Tanuseputro P AD - Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada. AD - ICES Ottawa, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada. AD - Bruyere Research Institute, Ottawa, Ontario, Canada. AD - Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada. FAU - Pacula, Rosalie Liccardo AU - Pacula RL AD - Sol Price School of Public Policy, Schaeffer Center for Health Policy & Economics, University of Southern California, Los Angeles. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20220901 PL - United States TA - JAMA Netw Open JT - JAMA network open JID - 101729235 RN - 0 (Hallucinogens) SB - IM MH - *COVID-19/epidemiology MH - *Cannabis/adverse effects MH - Cross-Sectional Studies MH - Emergency Service, Hospital MH - Female MH - *Hallucinogens MH - Humans MH - Male MH - Ontario/epidemiology MH - Pandemics MH - Syndrome MH - Vomiting PMC - PMC9482056 COIS- Conflict of Interest Disclosures: Dr Pacula reported receiving grants from the National Institute on Drug Abuse and National Institute on Alcohol Abuse and Alcoholism, personal fees from the Centers for Disease Control and Prevention, and serving as a consultant for the National Academies of Sciences, Engineering, and Medicine outside the submitted work. No other disclosures were reported. EDAT- 2022/09/17 06:00 MHDA- 2022/09/21 06:00 PMCR- 2022/09/16 CRDT- 2022/09/16 11:33 PHST- 2022/09/16 11:33 [entrez] PHST- 2022/09/17 06:00 [pubmed] PHST- 2022/09/21 06:00 [medline] PHST- 2022/09/16 00:00 [pmc-release] AID - 2796355 [pii] AID - zoi220912 [pii] AID - 10.1001/jamanetworkopen.2022.31937 [doi] PST - epublish SO - JAMA Netw Open. 2022 Sep 1;5(9):e2231937. doi: 10.1001/jamanetworkopen.2022.31937. PMID- 36078412 OWN - NLM STAT- MEDLINE DCOM- 20220913 LR - 20260127 IS - 1660-4601 (Electronic) IS - 1661-7827 (Print) IS - 1660-4601 (Linking) VI - 19 IP - 17 DP - 2022 Aug 27 TI - A CAST-Based Analysis of the Metro Accident That Was Triggered by the Zhengzhou Heavy Rainstorm Disaster. LID - 10.3390/ijerph191710696 [doi] LID - 10696 AB - Emergency management research is used to deal with the increasing number of extreme weather threats in urban areas. This paper uses causal analysis based on systems theory (CAST) to review the subway water ingress accident and the government's emergency management actions in Zhengzhou, Henan Province, during the heavy rainstorm disaster on 20 July 2021. The aims of this article are to establish safety control structures at both the enterprise level and the government level, and to systematically analyze the problems in emergency management in Zhengzhou City. Our analysis found that the construction of disaster prevention facilities restricted emergency management. Therefore, we suggest that enterprises and governments not only pay attention to emergency management, but also to the construction of disaster prevention facilities. This article also points out that the system of chief executive responsibility that is implemented in China is becoming a double-edged sword in emergency management. Our study makes recommendations for enhancing the capacities of emergency management, points out the shortcomings of the existing emergency management structure, and provides knowledge gained for future emergency management research. FAU - Zhao, Jiale AU - Zhao J AD - College of Environment and Safety Engineering, Fuzhou University, Fuzhou 350116, China. FAU - Yang, Fuqiang AU - Yang F AD - College of Environment and Safety Engineering, Fuzhou University, Fuzhou 350116, China. FAU - Guo, Yong AU - Guo Y AD - College of Environment and Safety Engineering, Fuzhou University, Fuzhou 350116, China. FAU - Ren, Xin AU - Ren X AD - Safety and Security Science Group, Faculty of Technology, Policy and Management, Delft University of Technology, 2628 BX Delft, The Netherlands. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20220827 PL - Switzerland TA - Int J Environ Res Public Health JT - International journal of environmental research and public health JID - 101238455 SB - IM MH - Accidents MH - China MH - Cities MH - *Disasters MH - *Railroads PMC - PMC9518579 OTO - NOTNLM OT - CAST OT - China OT - emergency management OT - extreme weather OT - urban waterlogging COIS- The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results. EDAT- 2022/09/10 06:00 MHDA- 2022/09/14 06:00 PMCR- 2022/08/27 CRDT- 2022/09/09 01:15 PHST- 2022/06/29 00:00 [received] PHST- 2022/08/14 00:00 [revised] PHST- 2022/08/24 00:00 [accepted] PHST- 2022/09/09 01:15 [entrez] PHST- 2022/09/10 06:00 [pubmed] PHST- 2022/09/14 06:00 [medline] PHST- 2022/08/27 00:00 [pmc-release] AID - ijerph191710696 [pii] AID - ijerph-19-10696 [pii] AID - 10.3390/ijerph191710696 [doi] PST - epublish SO - Int J Environ Res Public Health. 2022 Aug 27;19(17):10696. doi: 10.3390/ijerph191710696. PMID- 36047406 OWN - NLM STAT- MEDLINE DCOM- 20230502 LR - 20230515 IS - 1552-7573 (Electronic) IS - 0164-0275 (Print) IS - 0164-0275 (Linking) VI - 45 IP - 5-6 DP - 2023 May-Jun TI - Coping Strategies Used by Older Cancer Survivors During the COVID-19 Pandemic: A Longitudinal Qualitative Study. PG - 448-457 LID - 10.1177/01640275221120102 [doi] AB - Objectives: The objective of this study is to longitudinally examine the coping strategies used by older cancer survivors (>/=60 years of age) during COVID-19. Methods: An interpretive descriptive approach was used to collect and analyse qualitative data collected via 1:1 telephone interviews at three timepoints: June/July 2020, January 2021, and March 2021. Main Findings: Coping strategies used by older adults reflected the resources available to them, and their agency in self-triaging and deciding on resources to support their coping. These decisions were impacted by pandemic-imposed restrictions and necessitated readjustment over time. Three themes were developed to describe coping strategies (including any changes): adapting means and methods to connect with others; being intentional about outlook; and taking actions toward a brighter future. Conclusion: Older adults used a variety of coping strategies, though their reliance on resources beyond themselves (e.g., family/friends) indicates a need to add tailored resources to existing professional services. FAU - Galica, Jacqueline AU - Galica J AUID- ORCID: 0000-0002-3072-2472 AD - School of Nursing, Division of Cancer Care & Epidemiology, Queen's Cancer Research Institute, Queen's University, Kingston, ON, Canada. RINGGOLD: 4257 FAU - Kilgour, Heather M AU - Kilgour HM AD - School of Nursing, Faculty of Applied Science, The University of British Columbia, Vancouver, BC, Canada. RINGGOLD: 8166 FAU - Oliffe, John L AU - Oliffe JL AD - School of Nursing, Faculty of Applied Science, The University of British Columbia, Vancouver, BC, Canada. RINGGOLD: 8166 FAU - Haase, Kristen R AU - Haase KR AD - School of Nursing, Faculty of Applied Science, The University of British Columbia, Vancouver, BC, Canada. RINGGOLD: 8166 LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20220901 PL - United States TA - Res Aging JT - Research on aging JID - 7908221 SB - IM MH - Humans MH - Aged MH - *COVID-19 MH - *Cancer Survivors MH - Pandemics MH - *Neoplasms/therapy MH - Adaptation, Psychological PMC - PMC10130934 OTO - NOTNLM OT - COVID-19 OT - cancer OT - coping behaviors OT - coping skills OT - older adults OT - qualitative COIS- The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. EDAT- 2022/09/02 06:00 MHDA- 2023/05/02 06:42 PMCR- 2022/09/01 CRDT- 2022/09/01 05:03 PHST- 2023/05/02 06:42 [medline] PHST- 2022/09/02 06:00 [pubmed] PHST- 2022/09/01 05:03 [entrez] PHST- 2022/09/01 00:00 [pmc-release] AID - 10.1177_01640275221120102 [pii] AID - 10.1177/01640275221120102 [doi] PST - ppublish SO - Res Aging. 2023 May-Jun;45(5-6):448-457. doi: 10.1177/01640275221120102. Epub 2022 Sep 1. PMID- 36041833 OWN - NLM STAT- MEDLINE DCOM- 20220902 LR - 20250728 IS - 2169-575X (Electronic) IS - 2169-575X (Linking) VI - 10 IP - 4 DP - 2022 Aug 30 TI - Adapting High Impact Practices in Family Planning During the COVID-19 Pandemic: Experiences From Kenya, Nigeria, and Zimbabwe. LID - 10.9745/GHSP-D-22-00064 [doi] LID - e2200064 AB - BACKGROUND: We describe how High Impact Practices (HIPs) in family planning (FP) were adapted across Kenya, Nigeria, and Zimbabwe to maintain access to services in response to the coronavirus disease (COVID-19) pandemic. METHODS: Using a qualitative data collection tool structured around 3 HIP categories (service delivery, demand creation, and enabling environment), adaptations in FP programs during the pandemic were documented. We describe adaptations made to 3 specific HIPs: mobile outreach, community health workers, and digital health for social and behavior change. PROGRAM EXPERIENCES: In Zimbabwe, the Mhuri/Imuli project adapted its mobile outreach model integrating community-based outreach with facility-based outreach. The number of outreach clients served per week peaked at 1,759 (July 2020) from a low of 203 (May 2020). Clients choosing long-acting reversible methods increased from 22% to 59% during the 3 months before and after lockdown, respectively.In Kenya, a program addressed youth's hesitation to visit health facilities through youth community health volunteers, who provided counseling, community dialogues, contraceptive pills, and condoms. Over 6 months, the program reached 1,048 youth with community dialogues, and 4,656 youth received FP services. In Nigeria, peer mobilizers provided services through a socially distanced community-based program to help adolescent girls access contraceptive self-injection when movement restrictions limited youth's ability to travel to facilities.In Nigeria, Adolescents 360 adapted sexual and reproductive health information programs for virtual delivery through WhatsApp. A contraceptive education Facebook campaign gained more than 80,000 followers, reached 5.9 million adolescents, and linked 330 adolescents to program-supported facilities from January to March 2021. In Kenya, the Kibera-based project used WhatsApp to reach youth with discussion groups and health workers with skills strengthening. CONCLUSION: Monitoring how projects adapt HIPs to ensure continuity of care during the COVID-19 pandemic can help inform the implementation of successful adaptations in the face of present and future challenges. CI - (c) Malkin et al. FAU - Malkin, Morrisa AU - Malkin M AD - FHI 360, Durham, NC, USA. FAU - Mickler, Alexandria K AU - Mickler AK AD - U.S. Agency for International Development/Public Health Institute, Washington, DC, USA. FAU - Ajibade, Theophilus O AU - Ajibade TO AD - Society for Family Health, Abuja, Nigeria. FAU - Coppola, Alexis AU - Coppola A AD - Population Services International, Washington, DC, USA. FAU - Demise, Eden AU - Demise E AD - Population Services International, Washington, DC, USA. FAU - Derera, Esinath AU - Derera E AD - FHI 360, Harare, Zimbabwe. FAU - Ede, Joy Otsanya AU - Ede JO AD - Society for Family Health, Abuja, Nigeria. FAU - Gallagher, Meghan AU - Gallagher M AD - Save the Children, Washington, DC, USA. FAU - Gumbo, Lucia AU - Gumbo L AD - U.S. Agency for International Development, Harare, Zimbabwe. FAU - Jakopo, Zorodzai AU - Jakopo Z AD - FHI 360, Mutare, Zimbabwe. FAU - Little, Kristen AU - Little K AD - Population Services International, Washington, DC, USA. FAU - Mbinda, Absolom AU - Mbinda A AD - FHI 360, Mutare, Zimbabwe. FAU - Muchena, Gladwin AU - Muchena G AD - FHI 360, Mutare, Zimbabwe. FAU - Muhonde, Nyaradzo Debra AU - Muhonde ND AD - FHI 360, Mutare, Zimbabwe. FAU - Ncube, Khesiwe AU - Ncube K AD - FHI 360, Bulawayo, Zimbabwe. FAU - Ogbondeminu, Fifi Oluwatoyin AU - Ogbondeminu FO AD - Society for Family Health, Abuja, Nigeria. FAU - Pryor, Shannon AU - Pryor S AD - Save the Children, Washington, DC, USA. FAU - Sang, Elsie Nzale AU - Sang EN AD - Save the Children International, Nairobi, Kenya. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Research Support, U.S. Gov't, Non-P.H.S. DEP - 20220830 PL - United States TA - Glob Health Sci Pract JT - Global health, science and practice JID - 101624414 RN - 0 (Contraceptive Agents) SB - IM MH - Adolescent MH - *COVID-19/epidemiology/prevention & control MH - Communicable Disease Control MH - Contraceptive Agents MH - *Family Planning Services/methods MH - Female MH - Humans MH - Kenya/epidemiology MH - Nigeria/epidemiology MH - Pandemics MH - Zimbabwe/epidemiology PMC - PMC9426984 EDAT- 2022/08/31 06:00 MHDA- 2022/09/03 06:00 PMCR- 2022/08/30 CRDT- 2022/08/30 21:23 PHST- 2022/02/17 00:00 [received] PHST- 2022/07/20 00:00 [accepted] PHST- 2022/08/30 21:23 [entrez] PHST- 2022/08/31 06:00 [pubmed] PHST- 2022/09/03 06:00 [medline] PHST- 2022/08/30 00:00 [pmc-release] AID - GHSP-D-22-00064 [pii] AID - 10.9745/GHSP-D-22-00064 [doi] PST - epublish SO - Glob Health Sci Pract. 2022 Aug 30;10(4):e2200064. doi: 10.9745/GHSP-D-22-00064. Print 2022 Aug 30. PMID- 36032185 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220830 IS - 2279-9028 (Print) IS - 2279-9036 (Electronic) IS - 2279-9028 (Linking) VI - 11 IP - 3 DP - 2022 Jul TI - Factors influencing stress during the second imposed of COVID-19 social restrictions in Indonesia. PG - 22799036221115771 LID - 10.1177/22799036221115771 [doi] LID - 22799036221115771 AB - BACKGROUND: The spread of the COVID-19 virus has had a significant impact on the governmental and social aspects, as well as to the psychological status of the population. In Indonesia, social restriction was a strategy to limit people's mobility to reduce virus transmission. As social beings, the imposition of social restriction makes them fall into stress due to feeling lonely, and some cannot earn money. The aim of the study was to assess the factor association of stress level and resilience of the Indonesian people during the imposition of the second social restriction due to the COVID-19 pandemic. DESIGN AND METHOD: A cross-sectional study was performed on respondents aged at least 18 years on 29 July-16 August 2021, when the social restriction was enforced for the second time. The online survey was conducted through several social media platforms (Facebook, Instagram, Twitter, and WhatsApp) to 256 respondents. The analysis was carried out descriptively and analytically using the chi-square and binary logistic regression. RESULTS: This study shows that there is a significant relationship between age (p < 0.001), marital status (p < 0.001), occupation (p < 0.001), income before and during the pandemic (p < 0.001) and resilience level to stress level among Indonesian. Resilience level is the only protective factor for people to not get stressed. Being normal resilience put them at 0.05 times (95% CI 0.01-0.76) more likely to have low perceived stress than low resilience. CONCLUSION: Resilience level is the only factor that influence stress level among people in Indonesia during the second imposed social restriction in Indonesia. CI - (c) The Author(s) 2022. FAU - Sulistyawati, Sulistyawati AU - Sulistyawati S AD - Department of Public Health, Faculty of Public Health, Universitas Ahmad Dahlan, Yogyakarta, Indonesia. FAU - Aji, Budi AU - Aji B AD - Department of Public Health, Faculty of Health Sciences, Jenderal Soedirman University, Purwokerto, Indonesia. FAU - Rokhmayanti, Rokhmayanti AU - Rokhmayanti R AD - Department of Public Health, Faculty of Public Health, Universitas Ahmad Dahlan, Yogyakarta, Indonesia. FAU - Wijayanti, Siwi Pramatama Mars AU - Wijayanti SPM AD - Department of Public Health, Faculty of Health Sciences, Jenderal Soedirman University, Purwokerto, Indonesia. LA - eng PT - Journal Article DEP - 20220822 PL - United States TA - J Public Health Res JT - Journal of public health research JID - 101580775 PMC - PMC9403475 OTO - NOTNLM OT - COVID-19 OT - Indonesia OT - Stress OT - resilience OT - social restriction COIS- Declaration of conflicting interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. EDAT- 2022/08/30 06:00 MHDA- 2022/08/30 06:01 PMCR- 2022/08/22 CRDT- 2022/08/29 04:37 PHST- 2022/07/09 00:00 [received] PHST- 2022/07/09 00:00 [accepted] PHST- 2022/08/29 04:37 [entrez] PHST- 2022/08/30 06:00 [pubmed] PHST- 2022/08/30 06:01 [medline] PHST- 2022/08/22 00:00 [pmc-release] AID - 10.1177_22799036221115771 [pii] AID - 10.1177/22799036221115771 [doi] PST - epublish SO - J Public Health Res. 2022 Aug 22;11(3):22799036221115771. doi: 10.1177/22799036221115771. eCollection 2022 Jul. PMID- 35994315 OWN - NLM STAT- MEDLINE DCOM- 20220824 LR - 20260728 IS - 2291-5222 (Electronic) IS - 2291-5222 (Linking) VI - 10 IP - 8 DP - 2022 Aug 22 TI - Wearables for Measuring the Physical Activity and Sedentary Behavior of Patients With Axial Spondyloarthritis: Systematic Review. PG - e34734 LID - 10.2196/34734 [doi] LID - e34734 AB - BACKGROUND: Axial spondyloarthritis (axSpA) is an inflammatory rheumatic disease associated with chronic back pain and restricted mobility and physical function. Increasing physical activity is a viable strategy for improving the health and quality of life of patients with axSpA. Thus, quantifying physical activity and sedentary behavior in this population is relevant to clinical outcomes and disease management. However, to the best of our knowledge, no systematic review to date has identified and synthesized the available evidence on the use of wearable devices to objectively measure the physical activity or sedentary behavior of patients with axSpA. OBJECTIVE: This study aimed to review the literature on the use of wearable activity trackers as outcome measures for physical activity and sedentary behavior in patients with axSpA. METHODS: PubMed, PEDro, and Cochrane electronic databases were searched in July 2021 for relevant original articles, with no limits on publication dates. Studies were included if they were original articles, targeted adults with a diagnosis of axSpA, and reported wearable device-measured physical activity or sedentary behavior among patients with axSpA. Data regarding the study's characteristics, the sample description, the methods used for measuring physical activity and sedentary behavior (eg, wearable devices, assessment methods, and outcomes), and the main results of the physical activity and sedentary behavior assessments were extracted. RESULTS: A total of 31 studies were initially identified; 13 (13/31, 42%) met the inclusion criteria, including 819 patients with axSpA. All the studies used accelerometer-based wearable devices to assess physical activity. Of the 13 studies, 4 (4/31, 31%) studies also reported outcomes related to sedentary behavior. Wearable devices were secured on the wrists (3/13 studies, 23%), lower back (3/13, 23%), right hip (3/13, 23%), waist (2/13, 15%), anterior thigh (1/13, 8%), or right arm (1/13, 8%). The methods for reporting physical activity and sedentary behavior were heterogeneous. Approximately 77% (10/13) of studies had a monitoring period of 1 week, including weekend days. CONCLUSIONS: To date, few studies have used wearable devices to quantify the physical activity and sedentary behavior of patients with axSpA. The methodologies and results were heterogeneous, and none of these studies assessed the psychometric properties of these wearables in this specific population. Further investigation in this direction is needed before using wearable device-measured physical activity and sedentary behavior as outcome measures in intervention studies in patients with axSpA. TRIAL REGISTRATION: PROSPERO CRD42020182398; https://tinyurl.com/ec22jzkt. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): RR2-10.2196/23359. CI - (c)Julie Soulard, Thomas Carlin, Johannes Knitza, Nicolas Vuillerme. Originally published in JMIR mHealth and uHealth (https://mhealth.jmir.org), 22.08.2022. FAU - Soulard, Julie AU - Soulard J AUID- ORCID: 0000-0001-8138-1447 AD - Universite Grenoble Alpes, AGEIS, La Tronche, France. AD - LabCom Telecom4Health, Orange Labs & Universite Grenoble Alpes, CNRS, Inria, Grenoble INP-UGA, Grenoble, France. AD - Grenoble Alpes University Hospital, Grenoble, France. FAU - Carlin, Thomas AU - Carlin T AUID- ORCID: 0000-0001-9058-1723 AD - Universite Grenoble Alpes, AGEIS, La Tronche, France. AD - LabCom Telecom4Health, Orange Labs & Universite Grenoble Alpes, CNRS, Inria, Grenoble INP-UGA, Grenoble, France. FAU - Knitza, Johannes AU - Knitza J AUID- ORCID: 0000-0001-9695-0657 AD - Universite Grenoble Alpes, AGEIS, La Tronche, France. AD - LabCom Telecom4Health, Orange Labs & Universite Grenoble Alpes, CNRS, Inria, Grenoble INP-UGA, Grenoble, France. AD - Department of Internal Medicine 3-Rheumatology and Immunology, Friedrich-Alexander University, Erlangen-Nurnberg, and Universitatsklinikum Erlangen, Erlangen, Germany. AD - Deutsches Zentrum fur Immuntherapie, Friedrich-Alexander University Erlangen-Nurnberg and Universitatsklinikum Erlangen, Erlangen, Germany. FAU - Vuillerme, Nicolas AU - Vuillerme N AUID- ORCID: 0000-0003-3773-393X AD - Universite Grenoble Alpes, AGEIS, La Tronche, France. AD - LabCom Telecom4Health, Orange Labs & Universite Grenoble Alpes, CNRS, Inria, Grenoble INP-UGA, Grenoble, France. AD - Institut Universitaire de France, Paris, France. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Systematic Review DEP - 20220822 PL - Canada TA - JMIR Mhealth Uhealth JT - JMIR mHealth and uHealth JID - 101624439 SB - IM MH - Adult MH - *Axial Spondyloarthritis MH - Exercise MH - Humans MH - Quality of Life MH - Sedentary Behavior MH - *Wearable Electronic Devices PMC - PMC9446133 OTO - NOTNLM OT - axial spondyloarthritis OT - eHealth OT - mHealth OT - mobile health OT - mobile phone OT - objective measures OT - physical activity OT - rheumatology OT - sedentary behavior OT - systematic review OT - wearable COIS- Conflicts of Interest: None declared. EDAT- 2022/08/23 06:00 MHDA- 2022/08/25 06:00 PMCR- 2022/08/22 CRDT- 2022/08/22 11:52 PHST- 2021/11/05 00:00 [received] PHST- 2022/03/21 00:00 [accepted] PHST- 2022/02/02 00:00 [revised] PHST- 2022/08/22 11:52 [entrez] PHST- 2022/08/23 06:00 [pubmed] PHST- 2022/08/25 06:00 [medline] PHST- 2022/08/22 00:00 [pmc-release] AID - v10i8e34734 [pii] AID - 10.2196/34734 [doi] PST - epublish SO - JMIR Mhealth Uhealth. 2022 Aug 22;10(8):e34734. doi: 10.2196/34734. PMID- 35981079 OWN - NLM STAT- MEDLINE DCOM- 20220822 LR - 20251031 IS - 1932-6203 (Electronic) IS - 1932-6203 (Linking) VI - 17 IP - 8 DP - 2022 TI - A systematic review of evidence on employment transitions and weight change by gender in ageing populations. PG - e0273218 LID - 10.1371/journal.pone.0273218 [doi] LID - e0273218 AB - BACKGROUND: Becoming unemployed is associated with poorer health, including weight gain. Middle- and older-age adults are a growing segment of workforces globally, but they are also more vulnerable to changes to employment status, especially during economic shocks. Expected workforce exits over the next decade may exacerbate both the obesity epidemic and the economic burden of obesity. This review extends current knowledge on economic correlates of health to assess whether employment transitions impact body weight by sex/gender among middle-aged and older adults. METHODS: Eight bibliometric databases were searched between June and July 2021, supplemented by hand-searches, with no restriction on publication date or country. Longitudinal studies, or reviews, were eligible when examining body weight as a function of employment status change in adults >/=50 years. Data extraction and quality appraisal used predefined criteria; reported findings were analysed by narrative synthesis. RESULTS: We screened 6,001 unique abstracts and identified 12 articles that met inclusion criteria. All studies examined retirement; of which two also examined job-loss. Overall, studies showed that retirement led to weight gain or no difference in weight change compared to non-retirees; however, reported effects were not consistent for either women or men across studies or for both women and men within a study. Reported effects also differed by occupation: weight gain was more commonly observed among retirees from physical occupations but not among retirees from sedentary occupations. Few studies assessed the role of health behaviours; sleep was the least studied. Most studies were medium quality. CONCLUSIONS: Existing studies do not provide a clear enough picture of how employment transitions affect body weight. Firm conclusions on the impact of employment transitions on weight cannot be made without further high-quality evidence that considers the role of gender, job-type, other health behaviours, and other transitions, like job-loss. FAU - Tam, Alexander C T AU - Tam ACT AUID- ORCID: 0000-0002-3359-5552 AD - Faculty of Medicine, School of Population and Public Health, University of British Columbia, Vancouver, British Columbia, Canada. FAU - Steck, Veronica A AU - Steck VA AUID- ORCID: 0000-0002-6278-9567 AD - Faculty of Science, Department of Life Sciences, McGill University, Montreal, Quebec, Canada. FAU - Janjua, Sahib AU - Janjua S AD - Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia, Canada. FAU - Liu, Ting Yu AU - Liu TY AUID- ORCID: 0000-0002-5056-8978 AD - Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia, Canada. FAU - Murphy, Rachel A AU - Murphy RA AD - Faculty of Medicine, School of Population and Public Health, University of British Columbia, Vancouver, British Columbia, Canada. AD - Cancer Control Research, BC Cancer Research Institute, Vancouver, British Columbia, Canada. FAU - Zhang, Wei AU - Zhang W AUID- ORCID: 0000-0001-7988-1979 AD - Faculty of Medicine, School of Population and Public Health, University of British Columbia, Vancouver, British Columbia, Canada. AD - Centre for Health Evaluation and Outcome Sciences (CHEOS), Providence Research, Vancouver, British Columbia, Canada. FAU - Conklin, Annalijn I AU - Conklin AI AUID- ORCID: 0000-0002-6532-8790 AD - Centre for Health Evaluation and Outcome Sciences (CHEOS), Providence Research, Vancouver, British Columbia, Canada. AD - Faculty of Pharmaceutical Sciences, Collaboration for Outcomes Research and Evaluation (CORE), University of British Columbia, Vancouver, British Columbia, Canada. LA - eng PT - Journal Article PT - Systematic Review DEP - 20220818 PL - United States TA - PLoS One JT - PloS one JID - 101285081 SB - IM MH - *Body Weight MH - *Employment/statistics & numerical data MH - Female MH - Humans MH - Male MH - Middle Aged MH - Obesity MH - *Retirement MH - Sex Factors MH - Weight Gain PMC - PMC9387864 COIS- The authors have declared that no competing interests exist. EDAT- 2022/08/19 06:00 MHDA- 2022/08/23 06:00 PMCR- 2022/08/18 CRDT- 2022/08/18 14:05 PHST- 2021/12/11 00:00 [received] PHST- 2022/08/04 00:00 [accepted] PHST- 2022/08/18 14:05 [entrez] PHST- 2022/08/19 06:00 [pubmed] PHST- 2022/08/23 06:00 [medline] PHST- 2022/08/18 00:00 [pmc-release] AID - PONE-D-21-39118 [pii] AID - 10.1371/journal.pone.0273218 [doi] PST - epublish SO - PLoS One. 2022 Aug 18;17(8):e0273218. doi: 10.1371/journal.pone.0273218. eCollection 2022. PMID- 35977192 OWN - NLM STAT- MEDLINE DCOM- 20220905 LR - 20261003 IS - 2689-0186 (Electronic) IS - 2689-0186 (Linking) VI - 2 IP - 8 DP - 2021 Aug TI - Medicaid Subscription-Based Payment Models and Implications for Access to Hepatitis C Medications. PG - e212291 LID - 10.1001/jamahealthforum.2021.2291 [doi] LID - e212291 AB - IMPORTANCE: Hepatitis C virus (HCV) can be cured with direct-acting antiviral medications, but state Medicaid programs often restrict access to these lifesaving medications owing to their high costs. Subscription-based payment models (SBPMs), wherein states contract with a single manufacturer to supply prescriptions at a reduced price, may offer a solution that increases access. Whether SBPMs are associated with changes in HCV medication use is unknown. OBJECTIVE: To estimate changes in Medicaid-covered HCV prescription fills after Louisiana and Washington implemented SBPMs on July 1, 2019. DESIGN SETTING AND PARTICIPANTS: This cross-sectional study examined trends in prescription fills of Medicaid-covered direct-acting antiviral HCV medications in Louisiana and Washington after implementation of SBPMs. A synthetic control approach was used to compare changes in HCV prescription fills between states that did and did not implement SBPMs. The unit of analysis was state-quarter. Outpatient direct-acting antiviral HCV prescription fills from the Medicaid State Drug Utilization Data files were obtained from all 50 US states and the District of Columbia from January 1, 2017, to June 30, 2020. EXPOSURES: Implementation of SBPMs for Medicaid-covered direct-acting antiviral HCV medications. MAIN OUTCOMES AND MEASURES: Direct-acting antiviral HCV prescriptions filled per 100 000 Medicaid enrollees. RESULTS: In the year preceding SBPM implementation, the mean (SD) rate of quarterly HCV prescription fills per 100 000 Medicaid enrollees was 43.1 (8.6) prescriptions in Louisiana and 50.1 (4.1) in Washington. After SBPM implementation, the mean (SD) rate of quarterly HCV prescription fills per 100 000 enrollees was 206.0 (51.2) prescriptions in Louisiana and 53.9 (11.0) in Washington. In synthetic control models, SBPM implementation in Louisiana was associated with an increase of 173.5 (95% CI, 74.3-265.3) quarterly prescription fills per 100 000 Medicaid enrollees during the following year, a relative increase of 534.5% (95% CI, 228.7%-1125.0%). Washington did not experience a significant change in prescription fills following SBPM implementation. CONCLUSIONS AND RELEVANCE: In this cross-sectional study, Louisiana experienced substantial increases in HCV medication use among its Medicaid-enrolled population following SBPM implementation, whereas Washington did not. These differences may partially be explained by state-level variation in SBPM implementation, historical restrictions on access to HCV medications, and responses to the COVID-19 pandemic. CI - Copyright 2021 Auty SG et al. JAMA Health Forum. FAU - Auty, Samantha G AU - Auty SG AD - Department of Health Law, Policy, and Management, Boston University School of Public Health, Boston, Massachusetts. FAU - Shafer, Paul R AU - Shafer PR AD - Department of Health Law, Policy, and Management, Boston University School of Public Health, Boston, Massachusetts. FAU - Griffith, Kevin N AU - Griffith KN AD - Department of Health Policy, Vanderbilt University School of Medicine, Nashville, Tennessee. LA - eng GR - K12 HS026395/HS/AHRQ HHS/United States GR - T32 DA041898/DA/NIDA NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't PT - Research Support, U.S. Gov't, P.H.S. DEP - 20210827 PL - United States TA - JAMA Health Forum JT - JAMA health forum JID - 101769500 RN - 0 (Antiviral Agents) CIN - doi: 10.1001/jamahealthforum.2021.2412 CIN - doi: 10.1001/jamahealthforum.2021.2285 MH - Antiviral Agents/therapeutic use MH - *COVID-19 MH - Cross-Sectional Studies MH - Hepacivirus MH - *Hepatitis C/drug therapy MH - *Hepatitis C, Chronic/drug therapy MH - Humans MH - Medicaid MH - Pandemics MH - United States/epidemiology PMC - PMC8796990 MID - NIHMS1761375 COIS- Conflict of Interest Disclosures: Ms Auty reported receiving support for unrelated work from the National Institute of Drug Abuse (T32-DA041898-03). Dr Shafer reported receiving research support for unrelated work from the Robert Wood Johnson Foundation, the Commonwealth Fund, Renova Health, and the Department of Veterans Affairs (through a contract with the Boston University School of Public Health) and serving as a consultant to Patient Funding Alternatives for unrelated work. Dr Griffith reported receiving support for unrelated work from the Agency for Healthcare Research and Quality (K12-HS026395). EDAT- 2022/08/18 06:00 MHDA- 2022/08/18 06:01 PMCR- 2021/08/27 CRDT- 2022/08/17 15:53 PHST- 2021/05/01 00:00 [received] PHST- 2021/06/28 00:00 [accepted] PHST- 2022/08/17 15:53 [entrez] PHST- 2022/08/18 06:00 [pubmed] PHST- 2022/08/18 06:01 [medline] PHST- 2021/08/27 00:00 [pmc-release] AID - aoi210037 [pii] AID - 10.1001/jamahealthforum.2021.2291 [doi] PST - epublish SO - JAMA Health Forum. 2021 Aug 27;2(8):e212291. doi: 10.1001/jamahealthforum.2021.2291. eCollection 2021 Aug. PMID- 35974420 OWN - NLM STAT- MEDLINE DCOM- 20220818 LR - 20250728 IS - 2397-0642 (Electronic) IS - 2397-0642 (Linking) VI - 7 IP - 1 DP - 2022 Aug 17 TI - Evaluation of the effectiveness of surveillance policies to control the COVID-19 pandemic in Sao Paulo, Brazil. PG - 27 LID - 10.1186/s41256-022-00260-4 [doi] LID - 27 AB - BACKGROUND: Surveillance efforts are essential to pandemic control, especially where the state is the primary health provider, such as Brazil. When public health testing guidelines limit molecular tests, there are reductions in detection efforts aimed at early recognition, isolation, and treatment of those infected with the virus. This study evaluates the effectiveness of surveillance policies to control the COVID-19 pandemic in Sao Paulo. METHODS: We conducted an interrupted time series analysis with a segmented regression model to analyze if changes in the state's guidelines improved RT-PCR testing outcomes in Brazil's most affluent and largest state, Sao Paulo. Anonymized daily data on the RT-PCR tests conducted in public laboratories belonging to the state-wide network from March 1, 2020 to June 5, 2021 were extracted from the Sao Paulo State open-source database, while the data on the genomic sequences were obtained from GISAID. We then aggregated these data for the 17 regional health departments in the state to evaluate regional-level outcomes. RESULTS: The public health system restricted RT-PCR testing to hospitalized cases in the first months. Testing was expanded to permit symptomatic testing of non-hospitalized persons only in July 2020, but a statistically significant increase in surveillance efforts was not observed. Case definition was expanded to allow case confirmation based on clinical, laboratory and image data criteria other than an RT-PCR test without increasing the testing effort for asymptomatic suspicious cases in September 2020. There was an increase in the mean volume of testing in each RHD, but the test positivity rate increased due to insufficient testing expansion. Results also show an uneven improvement in testing outcomes following these changes across the state's regional health departments. CONCLUSIONS: Evidence suggests that lower RT-PCR testing and genomic surveillance efforts are associated with areas characterized by a higher population concentration and a greater population reliance on the public health system. Our results highlight the need to structure health surveillance and information systems for disease control and prevention in emergency settings considering local demographics and vulnerabilities. In high prevalence settings, efforts at identifying and including vulnerable populations in routine and enhanced surveillance programs during COVID-19 must be significantly improved. CI - (c) 2022. The Author(s). FAU - Barberia, Lorena G AU - Barberia LG AUID- ORCID: 0000-0001-6319-543X AD - Department of Political Science, University of Sao Paulo, Avenida Professor Luciano Gualberto, 315 - Sala 2067 - Cidade Universitaria, Sao Paulo, SP, 05508-900, Brazil. lorenabarberia@usp.br. FAU - de P Moreira, Natalia AU - de P Moreira N AUID- ORCID: 0000-0002-8544-1133 AD - Department of Political Science, University of Sao Paulo, Avenida Professor Luciano Gualberto, 315 - Sala 2067 - Cidade Universitaria, Sao Paulo, SP, 05508-900, Brazil. FAU - Kemp, Brigina AU - Kemp B AUID- ORCID: 0000-0002-9948-5284 AD - Conselho de Secretarios Municipais de Saude - SP, Avenida Angelica, 2466, - 17 degrees floor - Consolacao, Sao Paulo, SP, 01228200, Brazil. FAU - de Sousa Mascena Veras, Maria Amelia AU - de Sousa Mascena Veras MA AUID- ORCID: 0000-0002-1159-5762 AD - Departamento de Saude Coletiva, Faculdade de Ciencias Medicas da Santa Casa de Sao Paulo, Dr Cesario Mota Jr St. 61, Sao Paulo, SP, 01221-020, Brazil. FAU - Zamudio, Marcela AU - Zamudio M AUID- ORCID: 0000-0001-9474-8383 AD - Department of Political Science, University of Sao Paulo, Avenida Professor Luciano Gualberto, 315 - Sala 2067 - Cidade Universitaria, Sao Paulo, SP, 05508-900, Brazil. FAU - Rosa, Isabel Seelaender Costa AU - Rosa ISC AUID- ORCID: 0000-0001-8480-5196 AD - Department of Political Science, University of Sao Paulo, Avenida Professor Luciano Gualberto, 315 - Sala 2067 - Cidade Universitaria, Sao Paulo, SP, 05508-900, Brazil. FAU - de J Carvalho, Rebeca AU - de J Carvalho R AUID- ORCID: 0000-0003-4654-804X AD - Department of Public Administration and Government, FGV EAESP Business Administration School of Sao Paulo, Avenida 9 de julho, 2029, Bela Vista, Sao Paulo, SP, 01313-902, Brazil. FAU - Sousa, Tatiane C M AU - Sousa TCM AUID- ORCID: 0000-0002-4359-465X AD - Department of Political Science, University of Sao Paulo, Avenida Professor Luciano Gualberto, 315 - Sala 2067 - Cidade Universitaria, Sao Paulo, SP, 05508-900, Brazil. AD - Fundacao Oswaldo Cruz, ENSP, Rio de Janeiro, RJ, Brazil. LA - eng PT - Journal Article DEP - 20220817 PL - Netherlands TA - Glob Health Res Policy JT - Global health research and policy JID - 101705789 SB - IM MH - Brazil/epidemiology MH - *COVID-19/diagnosis/epidemiology/prevention & control MH - Humans MH - Pandemics/prevention & control MH - Policy MH - Public Health PMC - PMC9381395 OTO - NOTNLM OT - COVID-19 OT - RT-PCR public health testing policies OT - Surveillance COIS- The authors declare no competing interests. EDAT- 2022/08/17 06:00 MHDA- 2022/08/19 06:00 PMCR- 2022/08/17 CRDT- 2022/08/16 23:44 PHST- 2021/11/19 00:00 [received] PHST- 2022/08/06 00:00 [accepted] PHST- 2022/08/16 23:44 [entrez] PHST- 2022/08/17 06:00 [pubmed] PHST- 2022/08/19 06:00 [medline] PHST- 2022/08/17 00:00 [pmc-release] AID - 10.1186/s41256-022-00260-4 [pii] AID - 260 [pii] AID - 10.1186/s41256-022-00260-4 [doi] PST - epublish SO - Glob Health Res Policy. 2022 Aug 17;7(1):27. doi: 10.1186/s41256-022-00260-4. PMID- 35967191 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220830 IS - 2589-5559 (Electronic) IS - 2589-5559 (Linking) VI - 4 IP - 9 DP - 2022 Sep TI - Impact of the COVID-19 pandemic on hepatitis B and C elimination: An EASL survey. PG - 100531 LID - 10.1016/j.jhepr.2022.100531 [doi] LID - 100531 AB - BACKGROUND & AIMS: The World Health Organization (WHO) HBV and HCV elimination targets, set in 2016 and based on projections to 2030, were unable to consider the impact of intervening factors. To evaluate the impact of the COVID-19 pandemic on viral hepatitis elimination programs, the European Association for the Study of the Liver (EASL) conducted a survey in liver centers worldwide in 2021. METHODS: A web-based questionnaire was distributed (May-July 2021) to all EASL members representing clinical units providing HBV and HCV hepatitis care. Results are expressed as absolute numbers and reduction rates for each care activity. RESULTS: Data were collected from 32 European and 12 non-European clinical centers. Between January 2019 (pre-pandemic) and December 2020 (during the pandemic), chronic HBV consultations decreased by 32% and 26%, new referrals by 38% and 39%, HBV testing rates by 39% and 21% (for HBsAg detection) and 30% and 22% (for HBV DNA detection), and new HBV treatments by 20% and 44% (p = 0.328) in European and non-European centers, respectively. With regard to HCV during the same time frame, the overall reductions were 39% and 50% for consultations, 49% and 49% for new referrals, 11% and 38% for HCV RNA detection, and 51% and 54% for new HCV antiviral treatments for European and non-European Centers, respectively (p = 0.071). CONCLUSIONS: All steps in the viral hepatitis care cascade have been hampered by the COVID-19 pandemic, with a comparable impact across different centers. These data reaffirm the pandemic's major effect on global viral hepatitis elimination programs and suggest that actions to achieve the WHO 2030 targets should be reconsidered and revised to account for each country's progress relative to pre-pandemic values. LAY SUMMARY: The EASL multinational survey conclusively shows that viral hepatitis elimination programs, expected to provide control of hepatitis B and hepatitis C worldwide by 2030, have been held back by the COVID-19 pandemic in clinical centers from several European and non-European countries, with a comparable impact across centers. Limitations in the cascade of care for both HBV and HCV were linked to limited access to screening, consultations, specific testing, and actual treatment. As restrictions for COVID-19 begin to lift, efforts to diagnose and provide treatment for viral hepatitis should remain high on the list of priorities for public health officials to maintain the WHO elimination efforts. Measures that have been put in place to control the COVID-19 pandemic could be transferred to increasing the diagnosis and linkage to care of people with hepatitis. CI - (c) 2022 Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL). FAU - Kondili, Loreta A AU - Kondili LA AD - Center for Global Health, Istituto Superiore di Sanita, Rome, Italy. FAU - Buti, Maria AU - Buti M AD - Liver Unit, Hospital Universitario Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain. AD - Centro de Investigacion Biomedica en Red de Enfermedades Hepaticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain. FAU - Riveiro-Barciela, Mar AU - Riveiro-Barciela M AD - Liver Unit, Hospital Universitario Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain. AD - Centro de Investigacion Biomedica en Red de Enfermedades Hepaticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain. FAU - Maticic, Mojca AU - Maticic M AD - Clinic for Infectious Diseases, University Medical Centre Ljubljana, Slovenia. AD - Faculty of Medicine, University of Ljubljana, Slovenia. FAU - Negro, Francesco AU - Negro F AD - Divisions of Gastroenterology and Hepatology and of Clinical Pathology, University Hospitals, Geneva, Switzerland. FAU - Berg, Thomas AU - Berg T AD - Division of Hepatology, Department of Medicine II, Leipzig, University Medical Leipzig, Leipzig, Germany. FAU - Craxi, Antonio AU - Craxi A AD - Gastroenterology and Hepatology Unit, Department of Internal Medicine and Medical Specialties "PROMISE", University of Palermo, Palermo, Italy. LA - eng PT - Journal Article DEP - 20220727 PL - Netherlands TA - JHEP Rep JT - JHEP reports : innovation in hepatology JID - 101761237 PMC - PMC9364666 OTO - NOTNLM OT - COVID-19 pandemic OT - EASL, European Association for the Study of the Liver OT - EU Centers, European centers OT - Hepatitis B virus OT - Hepatitis C virus OT - Non-EU Centers, Non-European centers OT - SARS-CoV-2, severe acute respiratory syndrome coronavirus-2 OT - WHO elimination targets OT - WHO, World Health Organization COIS- LK: Received speaker fees from Gilead and Abbvie and consultancy fees from Abbvie. MB: Received grants/research support from Abbvie, BMS, and Gilead. Received honoraria/consultation fees or participated in an advisory board for Abbvie, Gilead, GSK, Janssen, MSD, and Roche. Participated in a company-sponsored speaker's bureau for Abbvie, Gilead, and Janssen. MRB: Received research funding from Gilead and served as a speaker for Gilead and AbbVie. MM: Nothing to declare. TB: Received grants/research support from Abbvie, BMS, Gilead, MSD/Merck, Humedics, Intercept, Merz, Norgine, Novartis, Orphalan, and Sequana Medical. Received honoraria/consultation fees or served on the advisory board for Abbvie, Alexion, Bayer, Gilead, GSK, Eisai, Enyo Pharma, Falk Foundation, HepaRegeniX GmbH, Humedics, Intercept, Ipsen, Janssen, MSD/Merck, Novartis, Orphalan, Roche, Sequana Medical, SIRTEX, SOBI, and Shionogi. Participated in a company-sponsored speaker's bureau for Abbvie, Alexion, Bayer, Gilead, Eisai, Intercept, Ipsen, Janssen, MedUpdate GmbH, MSD/Merck, Novartis, Orphalan, Sequana Medica, SIRTEX, and SOBI. FN: Advisor for Gilead and AbbVie, and received speaker fees from Roche Diagnostics. AC: Received grants and research support from AbbVie, Alfasigma, Bayer, BMS, Gilead Sciences, Intercept, MSD, and Roche. Served on advisory committees for AbbVie, Alfasigma, Bayer, BMS, Gilead Sciences, Intercept, MSD, and Roche. Participated in speaking and teaching activities for AbbVie, Alfasigma, Bayer, BMS, and Gilead Sc. Please refer to the accompanying ICMJE disclosure forms for further details. EDAT- 2022/08/16 06:00 MHDA- 2022/08/16 06:01 PMCR- 2022/07/27 CRDT- 2022/08/15 03:54 PHST- 2022/02/16 00:00 [received] PHST- 2022/06/08 00:00 [revised] PHST- 2022/06/11 00:00 [accepted] PHST- 2022/08/16 06:00 [pubmed] PHST- 2022/08/16 06:01 [medline] PHST- 2022/08/15 03:54 [entrez] PHST- 2022/07/27 00:00 [pmc-release] AID - S2589-5559(22)00103-3 [pii] AID - 100531 [pii] AID - 10.1016/j.jhepr.2022.100531 [doi] PST - ppublish SO - JHEP Rep. 2022 Sep;4(9):100531. doi: 10.1016/j.jhepr.2022.100531. Epub 2022 Jul 27. PMID- 35966132 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230523 IS - 0033-5177 (Print) IS - 1573-7845 (Electronic) IS - 0033-5177 (Linking) VI - 57 IP - 3 DP - 2023 TI - Considering the temporal interdependence of human mobility and COVID-19 concerning Indonesia's large-scale social distancing policies. PG - 2791-2810 LID - 10.1007/s11135-022-01497-4 [doi] AB - The year 2020 has marked the beginning of a new life in which humans must struggle and adapt to coexist with a new coronavirus, known as COVID-19. Population density is one of the most significant factors affecting the speed of COVID-19's spread, and it is closely related to human activity and movement. Therefore, many countries have implemented policies that restrict human movement to reduce the risk of transmission. This study aims to identify the temporal dependence between human mobility and virus transmission, indicated by the number of active cases, in the context of large-scale social restriction policies implemented by the Indonesian government. This analysis helps identify which government policies can significantly reduce the number of active COVID-19 cases in Indonesia. We conducted a temporal interdependency analysis using a time-varying Gaussian copula, where the parameter fluctuates throughout the observation. We use the percentage change in human mobility data and the number of active COVID-19 cases in Indonesia from March 28, 2020, to July 9, 2021. The results show that human mobility in public areas significantly influenced the number of active COVID-19 cases. Moreover, the temporal interdependencies between the two variables behaved differently according to the implementation period of large-scale social distancing policies. Among the five types of policies implemented in Indonesia, the policy that had the most significant influence on the number of active COVID-19 cases was several restrictions during the Implementation of Restrictions on Community Activities (Pelaksanaan Pembatasan Kegiatan Masyarakat/PPKM) period. We conclude that the strictness of rules restricting social activities generally affected the number of active COVID-19 cases, especially in the early days of the pandemic. Finally, the government can implement policies that are at least equivalent to the rules in PPKM if, in the future, cases of COVID-19 spike again. CI - (c) The Author(s), under exclusive licence to Springer Nature B.V. 2022, Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. FAU - Ahdika, Atina AU - Ahdika A AUID- ORCID: 0000-0001-9161-227X AD - Jalan Kaliurang Km 14.5, Sleman Yogyakarta, 55584 Indonesia Department of Statistics, Universitas Islam Indonesia. GRID: grid.444633.2. ISNI: 0000 0000 9879 6211 FAU - Primandari, Arum Handini AU - Primandari AH AD - Jalan Kaliurang Km 14.5, Sleman Yogyakarta, 55584 Indonesia Department of Statistics, Universitas Islam Indonesia. GRID: grid.444633.2. ISNI: 0000 0000 9879 6211 FAU - Adlin, Falah Novayanda AU - Adlin FN AD - Jalan Kaliurang Km 14.5, Sleman Yogyakarta, 55584 Indonesia Department of Statistics, Universitas Islam Indonesia. GRID: grid.444633.2. ISNI: 0000 0000 9879 6211 LA - eng PT - Journal Article DEP - 20220809 PL - Switzerland TA - Qual Quant JT - Quality & quantity JID - 1245762 PMC - PMC9362535 OTO - NOTNLM OT - COVID-19 OT - Human mobility OT - Large-scale social distancing OT - Temporal interdependence OT - Time-varying copula COIS- Conflict of interestWe declare that we have no conflict of interest to disclose. EDAT- 2022/08/16 06:00 MHDA- 2022/08/16 06:01 PMCR- 2022/08/09 CRDT- 2022/08/15 03:35 PHST- 2022/06/23 00:00 [accepted] PHST- 2022/08/16 06:01 [medline] PHST- 2022/08/16 06:00 [pubmed] PHST- 2022/08/15 03:35 [entrez] PHST- 2022/08/09 00:00 [pmc-release] AID - 1497 [pii] AID - 10.1007/s11135-022-01497-4 [doi] PST - ppublish SO - Qual Quant. 2023;57(3):2791-2810. doi: 10.1007/s11135-022-01497-4. Epub 2022 Aug 9. PMID- 35929997 OWN - NLM STAT- MEDLINE DCOM- 20220908 LR - 20250728 IS - 2472-1727 (Electronic) VI - 114 IP - 15 DP - 2022 Sep 1 TI - First trimester COVID-19 and the risk of major congenital malformations-International Registry of Coronavirus Exposure in Pregnancy. PG - 906-914 LID - 10.1002/bdr2.2070 [doi] AB - There is limited information about the effects of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection during the first trimester of pregnancy on the risk of major congenital malformations (MCMs). The International Registry of Coronavirus Exposure in Pregnancy (IRCEP) was designed to estimate the relative risk of adverse perinatal outcomes among women with Coronavirus Disease 2019 (COVID-19) at specific times during gestation. Adult women were eligible to enroll if they had a SARS-CoV-2 test, regardless of the results, or clinically confirmed COVID-19 during pregnancy. Self-administered questionnaires collected data on SARS-CoV-2 infection, pregnancy outcomes (including detailed questions on MCMs), and potential confounders. The analysis of MCMs includes women with either a positive SARS-CoV-2 PCR test or a clinical diagnosis of COVID-19 during the first trimester (exposed group) or a negative SARS-CoV-2 test (reference) that enrolled while pregnant. Sensitivity analyses were restricted to participants who enrolled before the availability of informative prenatal screening tests and extended to those enrolled after end of pregnancy. Generalized linear models were used to estimate relative risks (RR) and 95% confidence intervals (CI). Of 17,163 participants enrolled between June 2020 and July 2021, 1727 had a SARS-CoV-2 infection during the first trimester, of whom 1,675 enrolled during pregnancy. Of 10,235 controls with a negative test during pregnancy, 4,172 enrolled during pregnancy. Restriction to participants with complete follow-up reduced the sample size to 92 exposed and 292 unexposed reference pregnancies. MCMs were reported in 3 (3.3%) exposed and 8 (2.7%) unexposed (RR 1.2; 95% CI 0.32-4.2) newborns. The RR was 2.5 (95%CI 0.23-27) among those enrolled before prenatal screening, and 2.2 (95%CI 0.89-5.3) in the overall study population including those enrolled post-pregnancy. No specific pattern of malformations was observed. Although results are compatible with no major teratogenic effects associated with maternal SARS-CoV-2 infection, RR estimates were imprecise and larger studies are warranted. CI - (c) 2022 Wiley Periodicals LLC. FAU - Hernandez-Diaz, Sonia AU - Hernandez-Diaz S AUID- ORCID: 0000-0003-1458-7642 AD - Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA. FAU - Smith, Louisa H AU - Smith LH AD - Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA. FAU - Wyszynski, Diego F AU - Wyszynski DF AD - Pregistry, California, Los Angeles, USA. FAU - Rasmussen, Sonja A AU - Rasmussen SA AUID- ORCID: 0000-0002-0574-4928 AD - Departments of Pediatrics, Obstetrics and Gynecology, & Epidemiology, University of Florida, USA. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20220805 PL - United States TA - Birth Defects Res JT - Birth defects research JID - 101701004 SB - IM MH - Adult MH - *COVID-19 MH - Female MH - Humans MH - Infant, Newborn MH - Pregnancy MH - Pregnancy Outcome MH - Pregnancy Trimester, First MH - Registries MH - SARS-CoV-2 PMC - PMC9538886 OTO - NOTNLM OT - COVID-19 OT - cohort OT - malformations OT - pregnancy OT - registry COIS- None. EDAT- 2022/08/06 06:00 MHDA- 2022/09/09 06:00 PMCR- 2022/08/05 CRDT- 2022/08/05 11:02 PHST- 2022/06/26 00:00 [revised] PHST- 2022/02/24 00:00 [received] PHST- 2022/06/28 00:00 [accepted] PHST- 2022/08/06 06:00 [pubmed] PHST- 2022/09/09 06:00 [medline] PHST- 2022/08/05 11:02 [entrez] PHST- 2022/08/05 00:00 [pmc-release] AID - BDR22070 [pii] AID - 10.1002/bdr2.2070 [doi] PST - ppublish SO - Birth Defects Res. 2022 Sep 1;114(15):906-914. doi: 10.1002/bdr2.2070. Epub 2022 Aug 5. PMID- 35921047 OWN - NLM STAT- MEDLINE DCOM- 20220805 LR - 20251031 IS - 1469-493X (Electronic) IS - 1361-6137 (Linking) VI - 8 IP - 8 DP - 2022 Aug 3 TI - Impact of low-dose computed tomography (LDCT) screening on lung cancer-related mortality. PG - CD013829 LID - 10.1002/14651858.CD013829.pub2 [doi] LID - CD013829 AB - BACKGROUND: Lung cancer is the most common cause of cancer-related death in the world, however lung cancer screening has not been implemented in most countries at a population level. A previous Cochrane Review found limited evidence for the effectiveness of lung cancer screening with chest radiography (CXR) or sputum cytology in reducing lung cancer-related mortality, however there has been increasing evidence supporting screening with low-dose computed tomography (LDCT). OBJECTIVES: To determine whether screening for lung cancer using LDCT of the chest reduces lung cancer-related mortality and to evaluate the possible harms of LDCT screening. SEARCH METHODS: We performed the search in collaboration with the Information Specialist of the Cochrane Lung Cancer Group and included the Cochrane Lung Cancer Group Trial Register, Cochrane Central Register of Controlled Trials (CENTRAL, the Cochrane Library, current issue), MEDLINE (accessed via PubMed) and Embase in our search. We also searched the clinical trial registries to identify unpublished and ongoing trials. We did not impose any restriction on language of publication. The search was performed up to 31 July 2021. SELECTION CRITERIA: Randomised controlled trials (RCTs) of lung cancer screening using LDCT and reporting mortality or harm outcomes. DATA COLLECTION AND ANALYSIS: Two review authors were involved in independently assessing trials for eligibility, extraction of trial data and characteristics, and assessing risk of bias of the included trials using the Cochrane RoB 1 tool. We assessed the certainty of evidence using GRADE. Primary outcomes were lung cancer-related mortality and harms of screening. We performed a meta-analysis, where appropriate, for all outcomes using a random-effects model. We only included trials in the analysis of mortality outcomes if they had at least 5 years of follow-up. We reported risk ratios (RRs) and hazard ratios (HRs), with 95% confidence intervals (CIs) and used the I(2) statistic to investigate heterogeneity. MAIN RESULTS: We included 11 trials in this review with a total of 94,445 participants. Trials were conducted in Europe and the USA in people aged 40 years or older, with most trials having an entry requirement of >/= 20 pack-year smoking history (e.g. 1 pack of cigarettes/day for 20 years or 2 packs/day for 10 years etc.). One trial included male participants only. Eight trials were phase three RCTs, with two feasibility RCTs and one pilot RCT. Seven of the included trials had no screening as a comparison, and four trials had CXR screening as a comparator. Screening frequency included annual, biennial and incrementing intervals. The duration of screening ranged from 1 year to 10 years. Mortality follow-up was from 5 years to approximately 12 years. None of the included trials were at low risk of bias across all domains. The certainty of evidence was moderate to low across different outcomes, as assessed by GRADE. In the meta-analysis of trials assessing lung cancer-related mortality, we included eight trials (91,122 participants), and there was a reduction in mortality of 21% with LDCT screening compared to control groups of no screening or CXR screening (RR 0.79, 95% CI 0.72 to 0.87; 8 trials, 91,122 participants; moderate-certainty evidence). There were probably no differences in subgroups for analyses by control type, sex, geographical region, and nodule management algorithm. Females appeared to have a larger lung cancer-related mortality benefit compared to males with LDCT screening. There was also a reduction in all-cause mortality (including lung cancer-related) of 5% (RR 0.95, 95% CI 0.91 to 0.99; 8 trials, 91,107 participants; moderate-certainty evidence). Invasive tests occurred more frequently in the LDCT group (RR 2.60, 95% CI 2.41 to 2.80; 3 trials, 60,003 participants; moderate-certainty evidence). However, analysis of 60-day postoperative mortality was not significant between groups (RR 0.68, 95% CI 0.24 to 1.94; 2 trials, 409 participants; moderate-certainty evidence). False-positive results and recall rates were higher with LDCT screening compared to screening with CXR, however there was low-certainty evidence in the meta-analyses due to heterogeneity and risk of bias concerns. Estimated overdiagnosis with LDCT screening was 18%, however the 95% CI was 0 to 36% (risk difference (RD) 0.18, 95% CI -0.00 to 0.36; 5 trials, 28,656 participants; low-certainty evidence). Four trials compared different aspects of health-related quality of life (HRQoL) using various measures. Anxiety was pooled from three trials, with participants in LDCT screening reporting lower anxiety scores than in the control group (standardised mean difference (SMD) -0.43, 95% CI -0.59 to -0.27; 3 trials, 8153 participants; low-certainty evidence). There were insufficient data to comment on the impact of LDCT screening on smoking behaviour. AUTHORS' CONCLUSIONS: The current evidence supports a reduction in lung cancer-related mortality with the use of LDCT for lung cancer screening in high-risk populations (those over the age of 40 with a significant smoking exposure). However, there are limited data on harms and further trials are required to determine participant selection and optimal frequency and duration of screening, with potential for significant overdiagnosis of lung cancer. Trials are ongoing for lung cancer screening in non-smokers. CI - Copyright (c) 2022 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. FAU - Bonney, Asha AU - Bonney A AD - Department of Respiratory and Sleep Medicine, Royal Melbourne Hospital, Parkville, Australia. AD - Department of Medicine, University of Melbourne, Melbourne, Australia. FAU - Malouf, Reem AU - Malouf R AD - National Perinatal Epidemiology Unit (NPEU), University of Oxford, Oxford, UK. FAU - Marchal, Corynne AU - Marchal C AD - University of Franche-Comte, Besancon, France. FAU - Manners, David AU - Manners D AD - Respiratory Medicine, Midland St John of God Public and Private Hospital, Midland, Australia. FAU - Fong, Kwun M AU - Fong KM AD - Thoracic Medicine Program, The Prince Charles Hospital, Brisbane, Australia. AD - UQ Thoracic Research Centre, School of Medicine, The University of Queensland, Brisbane, Australia. FAU - Marshall, Henry M AU - Marshall HM AD - School of Medicine, The University of Queensland, Brisbane, Australia. FAU - Irving, Louis B AU - Irving LB AD - Department of Respiratory and Sleep Medicine, Royal Melbourne Hospital, Parkville, Australia. FAU - Manser, Renee AU - Manser R AD - Department of Respiratory and Sleep Medicine, Royal Melbourne Hospital, Parkville, Australia. AD - Department of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia. LA - eng PT - Journal Article PT - Meta-Analysis PT - Systematic Review DEP - 20220803 PL - England TA - Cochrane Database Syst Rev JT - The Cochrane database of systematic reviews JID - 100909747 SB - IM UOF - doi: 10.1002/14651858.CD013829 MH - Adult MH - Bias MH - *Early Detection of Cancer/methods MH - Female MH - Humans MH - *Lung Neoplasms/diagnostic imaging/mortality MH - Male MH - Randomized Controlled Trials as Topic MH - Tomography, X-Ray Computed/methods PMC - PMC9347663 COIS- Asha Bonney has a Postgraduate Scholarship from the Australian National Health and Medical Research Council. Reem Malouf: none known Corynne Marchal: none known David Manners has received speaking honoraria from Astra Zeneca and research grant funding from Curtin Medical School, Curtin University. Kwun M Fong: Co-investigator on the International Lung Screening Trial. This is an international, multicentre, investigator initiated study, funded in Australia by a National Health and Medical Research Grant. The study is an observational cohort study examining low-dose screening for lung cancer in high-risk former and current smokers. KF also undertook the QLCSS lung cancer screening trial, a pilot one-armed study which is not eligible as it is not a RCT - Queensland Smart State Grant.
Chair of the Lung Cancer Consultative Group for NGO Lung Foundation Australia (no payment).
KF declares occasional speaking on lung cancer at conferences and meetings where industry may be the organiser or a sponsor.
KF has an Australian Medical Research Future Fund Fellowship. KF received in-kind support with software licences for MeVis Veolity Computer Aided Diagnosis for the ILST clinical trial. KF is a reviewer for UpToDate (not related to CT screening). KF is Editor for the Cochrane Lung Cancer Group. Henry M Marshall is an investigator on the International Lung Screen Trial. He has received honoraria to speak on the subjects of smoking cessation, lung cancer screening and COPD. Louis B Irving: none known Renee Manser: none known. Co-editor, Cochrane Lung Cancer Review Group
Co-investigator on the International Lung Screening Trial. This is an international, multicentre, investigator initiated trial, funded in Australia by a National Health and Medical Research Grant. The study is an observational cohort study examining low-dose screening for lung cancer in high-risk former and current smokers. EDAT- 2022/08/04 06:00 MHDA- 2022/08/06 06:00 PMCR- 2023/08/03 CRDT- 2022/08/03 11:23 PHST- 2022/08/03 11:23 [entrez] PHST- 2022/08/04 06:00 [pubmed] PHST- 2022/08/06 06:00 [medline] PHST- 2023/08/03 00:00 [pmc-release] AID - CD013829.pub2 [pii] AID - 10.1002/14651858.CD013829.pub2 [doi] PST - epublish SO - Cochrane Database Syst Rev. 2022 Aug 3;8(8):CD013829. doi: 10.1002/14651858.CD013829.pub2. PMID- 35895062 OWN - NLM STAT- MEDLINE DCOM- 20220729 LR - 20251031 IS - 2574-3805 (Electronic) IS - 2574-3805 (Linking) VI - 5 IP - 7 DP - 2022 Jul 1 TI - Analysis of Epigenetic Age Acceleration and Healthy Longevity Among Older US Women. PG - e2223285 LID - 10.1001/jamanetworkopen.2022.23285 [doi] LID - e2223285 AB - IMPORTANCE: Accelerated biological aging is associated with decreased physical capability and cognitive functioning, which are associated with increased risk of morbidity and mortality. OBJECTIVE: We investigated associations between epigenetic age acceleration (EAA), a biomarker associated with aging, and healthy longevity among older women. DESIGN, SETTING, AND PARTICIPANTS: This cohort study was a secondary analysis of participants in the Women's Health Initiative (WHI) who were eligible to survive to age 90 years by September 30, 2020. Participants were located in multiple centers. This study was restricted to women with genome-wide DNA methylation data, generated from baseline blood samples within 3 WHI ancillary studies. Median (IQR) follow-up times from baseline were 21.6 (19.6-22.9) years and 21.4 (19.8-22.7) years for women who survived to age 90 years with and without intact mobility, respectively, and 13.2 (8.8-16.7) for women who did not survive to age 90 years. Data were analyzed from December 2020 to July 2021. EXPOSURES: EAA was estimated using 4 established "clocks": Horvath pantissue, Hannum, Pheno, and Grim. MAIN OUTCOMES AND MEASURES: Using multinomial logistic regression, odds ratios (ORs) and 95% CIs were estimated for 3 healthy longevity outcomes for each clock: survival to age 90 years with intact mobility, survival to age 90 years without intact mobility, and no survival to age 90 years. RESULTS: Among 1813 women, there were 464 women (mean [SD] age at baseline, 71.6 [3.5] years) who survived to age 90 years with intact mobility and cognitive functioning, 420 women (mean [SD] age at baseline, 71.3 [3.2] years) who survived to age 90 years without intact mobility and cognitive functioning, and 929 women (mean [SD] age at baseline, 70.2 [3.4] years) who did not survive to age 90 years. Women who survived to age 90 years with intact mobility and cognitive function were healthier at baseline compared with women who survived without those outcomes or who did not survive to age 90 years (eg, 143 women [30.8%] vs 101 women [24.0%] and 202 women [21.7%] with 0 chronic conditions). The odds of surviving to age 90 years with intact mobility were lower for every 1 SD increase in EAA compared with those who did not survive to age 90 years as measured by AgeAccelHorvath (OR, 0.82; 95% CI, 0.69-0.96; P = .01), AgeAccelHannum (OR, 0.67; 95% CI, 0.56-0.80; P < .001), AgeAccelPheno (OR, 0.60; 95% CI, 0.51-0.72; P < .001), and AgeAccelGrim (OR, 0.68; 95% CI, 0.55-0.84; P < .001). ORs were similar for women who survived to age 90 years with intact mobility and cognitive function (eg, AgeAccelHorvath: OR per 1 SD increase in EAA, 0.83; 95% CI, 0.71-0.98; P = .03) compared with women who did not survive to age 90 years. CONCLUSIONS AND RELEVANCE: These findings suggest that EAA may be a valid biomarker associated with healthy longevity among older women and may be used for risk stratification and risk estimation of future functional and cognitive aging. Outcomes suggest that future studies may focus on the potential for public health interventions to counteract EAA and its association with poor health outcomes to lower disease burden while increasing longevity. FAU - Jain, Purva AU - Jain P AD - Herbert Wertheim School of Public Health and Human Longevity Science, University of California San Diego, La Jolla. FAU - Binder, Alexandra M AU - Binder AM AD - Cancer Epidemiology Program, University of Hawaii Cancer Center, Honolulu. AD - Department of Epidemiology, Fielding School of Public Health, University of California, Los Angeles. FAU - Chen, Brian AU - Chen B AD - Herbert Wertheim School of Public Health and Human Longevity Science, University of California San Diego, La Jolla. FAU - Parada, Humberto Jr AU - Parada H Jr AD - Division of Epidemiology and Biostatistics, School of Public Health, San Diego State University. AD - Moores Cancer Center, University of California, San Diego, La Jolla. FAU - Gallo, Linda C AU - Gallo LC AD - Division of Epidemiology and Biostatistics, School of Public Health, San Diego State University. FAU - Alcaraz, John AU - Alcaraz J AD - Moores Cancer Center, University of California, San Diego, La Jolla. FAU - Horvath, Steve AU - Horvath S AD - Department of Human Genetics, David Geffen School of Medicine, University of California, Los Angeles. AD - Department of Biostatistics, School of Public Health, University of California, Los Angeles. FAU - Bhatti, Parveen AU - Bhatti P AD - Cancer Control Research, BC Cancer, Vancouver, British Columbia, Canada. FAU - Whitsel, Eric A AU - Whitsel EA AD - Department of Epidemiology, Gillings School of Public Health, Chapel Hill, North Carolina. AD - Department of Medicine, School of Medicine, University of North Carolina at Chapel Hill. FAU - Jordahl, Kristina AU - Jordahl K AD - Department of Epidemiology, School of Public Health, University of Washington, Seattle. FAU - Baccarelli, Andrea A AU - Baccarelli AA AD - Department of Environmental Health Sciences, Mailman School of Public Health, Columbia University Irving Medical Center, New York, New York. FAU - Hou, Lifang AU - Hou L AD - Institute for Public Health and Medicine, Northwestern University, Chicago, Illinois. FAU - Stewart, James D AU - Stewart JD AD - Department of Epidemiology, Gillings School of Public Health, Chapel Hill, North Carolina. AD - Department of Medicine, School of Medicine, University of North Carolina at Chapel Hill. FAU - Li, Yun AU - Li Y AD - Department of Genetics, University of North Carolina at Chapel Hill. AD - Department of Biostatistics, University of North Carolina at Chapel Hill. AD - Department of Computer Science, University of North Carolina at Chapel Hill. FAU - Justice, Jamie N AU - Justice JN AD - Sticht Center for Healthy Aging and Alzheimer's Prevention, Section of Gerontology and Geriatric Medicine, Department of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, North Carolina. FAU - LaCroix, Andrea Z AU - LaCroix AZ AD - Herbert Wertheim School of Public Health and Human Longevity Science, University of California San Diego, La Jolla. LA - eng GR - T32 AG058529/AG/NIA NIH HHS/United States GR - R01 ES020836/ES/NIEHS NIH HHS/United States GR - HHSN268201600018C/HL/NHLBI NIH HHS/United States GR - HHSN268201600001C/HL/NHLBI NIH HHS/United States GR - HHSN268201600002C/HL/NHLBI NIH HHS/United States GR - HHSN268201600003C/HL/NHLBI NIH HHS/United States GR - HHSN268201600004C/HL/NHLBI NIH HHS/United States GR - HHSN268201300006C/HL/NHLBI NIH HHS/United States GR - U54 CA132384/CA/NCI NIH HHS/United States GR - U54 CA132379/CA/NCI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20220701 PL - United States TA - JAMA Netw Open JT - JAMA network open JID - 101729235 SB - IM MH - Aged, 80 and over MH - *Aging/genetics/physiology MH - Cohort Studies MH - *Epigenesis, Genetic/physiology MH - Female MH - Humans MH - *Longevity/genetics/physiology MH - United States PMC - PMC9331104 COIS- Conflict of Interest Disclosures: Dr Binder reported receiving grants from the National Cancer Institute (NCI) of the National Institutes of Health (NIH) during the conduct of the study and scientific advisory fees from the Epigenetic Clock Development Foundation. Dr Chen reported being a full-time employee and having a patent pending for Foxo Technologies outside the submitted work and owning common stock in Illumina. Dr Horvath reported receiving grants from the National Institute on Aging during the conduct of the study, receiving personal fees from Epigenetic Clock Development Foundation outside the submitted work, and having a patent pending for Epigenetic Clock Development Foundation. Dr Jordahl reported receiving grants from the NCI during the conduct of the study and personal fees from Bristol Myers Squibb outside the submitted work. No other disclosures were reported. EDAT- 2022/07/28 06:00 MHDA- 2022/07/30 06:00 PMCR- 2022/07/27 CRDT- 2022/07/27 11:34 PHST- 2022/07/27 11:34 [entrez] PHST- 2022/07/28 06:00 [pubmed] PHST- 2022/07/30 06:00 [medline] PHST- 2022/07/27 00:00 [pmc-release] AID - 2794706 [pii] AID - zoi220662 [pii] AID - 10.1001/jamanetworkopen.2022.23285 [doi] PST - epublish SO - JAMA Netw Open. 2022 Jul 1;5(7):e2223285. doi: 10.1001/jamanetworkopen.2022.23285. PMID- 35879058 OWN - NLM STAT- MEDLINE DCOM- 20220727 LR - 20251204 IS - 2233-6869 (Electronic) IS - 1598-9992 (Print) IS - 1598-9992 (Linking) VI - 80 IP - 1 DP - 2022 Jul 25 TI - Efficacy of a Restrictive Diet in Irritable Bowel Syndrome: A Systematic Review and Network Meta-analysis. PG - 6-16 LID - 10.4166/kjg.2022.014 [doi] AB - BACKGROUND/AIMS: Dietary factors can aggravate the symptoms of irritable bowel syndrome (IBS). Many IBS patients try restrictive diets to relieve their symptoms, but the types of diets with an exacerbating factor are unknown. Therefore, this paper reports the results of a systematic review and network meta-analysis of randomized-controlled trials (RCTs) reviewing the efficacy of food restriction diets in IBS. METHODS: The MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, and Clinicaltrials.gov databases were searched until July 21, 2021, to retrieve RCTs assessing the efficacy of restriction diets in adults with IBS. Two independent reviewers performed the eligibility assessment and data abstraction. RCTs that evaluated a restriction diet versus a control diet and assessed the improvement in global IBS symptoms were included. These trials reported a dichotomous assessment of the overall response to therapy. RESULTS: A total of 1,949 citations were identified. After full-text screening, 14 RCTs were considered eligible for the systematic review and network meta-analysis. A starch- and sucrose-reduced diet and a diet with low-fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (FODMAPs) showed significantly better results than a usual diet. Symptom flare-ups in patients on a gluten- free diet were also significantly lower than in those on high-gluten diets. CONCLUSIONS: These findings showed that the starch- and sucrose-reduced, low FODMAP, and gluten-free diets had superior effects in reducing IBS symptoms. Further studies, including head-to-head trials will be needed to establish the effectiveness of dietary restrictions on IBS symptoms. FAU - Yu, Seung Jung AU - Yu SJ AD - Department of Internal Medicine, Inje University Busan Paik Hospital, Busan, Korea. FAU - Lee, Hong Sub AU - Lee HS AUID- ORCID: 0000-0002-2962-0209 AD - Department of Internal Medicine, Inje University Busan Paik Hospital, Busan, Korea. FAU - Gung, Hyeon Jeong AU - Gung HJ AD - Department of Internal Medicine, Soonchunhyang University Hospital Bucheon, Bucheon, Korea. FAU - Kim, Ju Seok AU - Kim JS AD - Department of Internal Medicine, Chungnam National University College of Medicine, Daejeon, Korea. FAU - Kim, Ki Bae AU - Kim KB AD - Department of Internal Medicine, Chungbuk National University Hospital, Cheongju, Korea. FAU - Kwon, Yong Hwan AU - Kwon YH AD - Department of Internal Medicine, Kyungpook National University Hospital, Daegu, Korea. FAU - Kim, Jae Hak AU - Kim JH AD - Department of Internal Medicine, Dongguk University College of Medicine, Goyang, Korea. FAU - Koo, Hoon Sup AU - Koo HS AD - Department of Internal Medicine, Konyang University Hospital, Daejeon, Korea. FAU - Shin, Hyun-Deok AU - Shin HD AD - Department of Internal Medicine, Dankook University Hospital, Cheonan, Korea. FAU - Jee, Sam Ryong AU - Jee SR AD - Department of Internal Medicine, Inje University Busan Paik Hospital, Busan, Korea. FAU - Lee, Han Byul AU - Lee HB AD - Department of Public Health, Ajou University Graduate School of Public Health, Suwon, Korea. FAU - Kim, Jeehyoung AU - Kim J AD - Department of Orthopedic Surgery, Seoul Sacred Heart General Hospital, Seoul, Korea. FAU - Park, Hye-Won AU - Park HW AD - Inje University Medical Library, Busan, Korea. CN - IBS Research Study Group of the Korean Society of Neurogastroenterology and Motility LA - eng PT - Journal Article PT - Network Meta-Analysis PT - Research Support, Non-U.S. Gov't PT - Systematic Review PL - Korea (South) TA - Korean J Gastroenterol JT - The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi JID - 101189416 RN - 0 (Monosaccharides) RN - 0 (Oligosaccharides) RN - 57-50-1 (Sucrose) RN - 9005-25-8 (Starch) SB - IM MH - Adult MH - Diet MH - Diet, Carbohydrate-Restricted MH - Diet, Gluten-Free MH - Fermentation MH - Humans MH - *Irritable Bowel Syndrome/therapy MH - Monosaccharides MH - Oligosaccharides MH - Starch MH - Sucrose PMC - PMC12285310 OTO - NOTNLM OT - Irritable bowel syndrome OT - Network meta-analysis OT - Restrictive diet therapy OT - Systematic review COIS- Conflict of interest None. EDAT- 2022/07/26 06:00 MHDA- 2022/07/28 06:00 PMCR- 2022/07/25 CRDT- 2022/07/25 21:41 PHST- 2022/01/17 00:00 [received] PHST- 2022/04/12 00:00 [revised] PHST- 2022/04/18 00:00 [accepted] PHST- 2022/07/25 21:41 [entrez] PHST- 2022/07/26 06:00 [pubmed] PHST- 2022/07/28 06:00 [medline] PHST- 2022/07/25 00:00 [pmc-release] AID - kjg.2022.014 [pii] AID - kjg-80-1-6 [pii] AID - 10.4166/kjg.2022.014 [doi] PST - ppublish SO - Korean J Gastroenterol. 2022 Jul 25;80(1):6-16. doi: 10.4166/kjg.2022.014. PMID- 35876490 OWN - NLM STAT- MEDLINE DCOM- 20220727 LR - 20250728 IS - 2057-5858 (Electronic) IS - 2057-5858 (Linking) VI - 8 IP - 7 DP - 2022 Jul TI - Replacement of the Alpha variant of SARS-CoV-2 by the Delta variant in Lebanon between April and June 2021. LID - 10.1099/mgen.0.000838 [doi] LID - mgen000838 AB - The COVID-19 pandemic continues to expand globally, with case numbers rising in many areas of the world, including the Eastern Mediterranean Region. Lebanon experienced its largest wave of COVID-19 infections from January to April 2021. Limited genomic surveillance was undertaken, with just 26 SARS-CoV-2 genomes available for this period, nine of which were from travellers from Lebanon detected by other countries. Additional genome sequencing is thus needed to allow surveillance of variants in circulation. In total, 905 SARS-CoV-2 genomes were sequenced using the ARTIC protocol. The genomes were derived from SARS-CoV-2-positive samples, selected retrospectively from the sentinel COVID-19 surveillance network, to capture diversity of location, sampling time, sex, nationality and age. Although 16 PANGO lineages were circulating in Lebanon in January 2021, by February there were just four, with the Alpha variant accounting for 97 % of samples. In the following 2 months, all samples contained the Alpha variant. However, this had changed dramatically by June and July 2021, when all samples belonged to the Delta variant. This study documents a ten-fold increase in the number of SARS-CoV-2 genomes available from Lebanon. The Alpha variant, first detected in the UK, rapidly swept through Lebanon, causing the country's largest wave to date, which peaked in January 2021. The Alpha variant was introduced to Lebanon multiple times despite travel restrictions, but the source of these introductions remains uncertain. The Delta variant was detected in Gambia in travellers from Lebanon in mid-May, suggesting community transmission in Lebanon several weeks before this variant was detected in the country. Prospective sequencing in June/July 2021 showed that the Delta variant had completely replaced the Alpha variant in under 6 weeks. FAU - Merhi, Georgi AU - Merhi G AD - Department of Natural Sciences, Lebanese American University, School of Arts and Sciences, Byblos, Lebanon. FAU - Trotter, Alexander J AU - Trotter AJ AD - Quadram Institute Bioscience, Norwich Research Park, Norwich, Norfolk, UK. FAU - de Oliveira Martins, Leonardo AU - de Oliveira Martins L AD - Quadram Institute Bioscience, Norwich Research Park, Norwich, Norfolk, UK. FAU - Koweyes, Jad AU - Koweyes J AD - Department of Natural Sciences, Lebanese American University, School of Arts and Sciences, Byblos, Lebanon. FAU - Le-Viet, Thanh AU - Le-Viet T AD - Quadram Institute Bioscience, Norwich Research Park, Norwich, Norfolk, UK. FAU - Abou Naja, Hala AU - Abou Naja H AD - Ministry of Public Health, Epidemiological Surveillance Program, Museum Square, Beirut, Lebanon. FAU - Al Buaini, Mona AU - Al Buaini M AD - National Influenza Centre Research Laboratory, Rafic Hariri University Hospital, Beirut, Lebanon. FAU - Prosolek, Sophie J AU - Prosolek SJ AD - Quadram Institute Bioscience, Norwich Research Park, Norwich, Norfolk, UK. FAU - Alikhan, Nabil-Fareed AU - Alikhan NF AD - Quadram Institute Bioscience, Norwich Research Park, Norwich, Norfolk, UK. FAU - Lott, Martin AU - Lott M AD - Quadram Institute Bioscience, Norwich Research Park, Norwich, Norfolk, UK. FAU - Tohmeh, Tatiana AU - Tohmeh T AD - Ministry of Public Health, Epidemiological Surveillance Program, Museum Square, Beirut, Lebanon. FAU - Badran, Bassam AU - Badran B AD - Laboratory of Molecular Biology and Cancer Immunology, Faculty of Sciences, Lebanese University, Lebanon. FAU - Jupp, Orla J AU - Jupp OJ AD - University of East Anglia, Norwich, Norfolk, UK. FAU - Gardner, Sarah AU - Gardner S AD - University of East Anglia, Norwich, Norfolk, UK. FAU - Felgate, Matthew W AU - Felgate MW AD - University of East Anglia, Norwich, Norfolk, UK. FAU - Makin, Kate A AU - Makin KA AD - University of East Anglia, Norwich, Norfolk, UK. FAU - Wilkinson, Janine M AU - Wilkinson JM AD - University of East Anglia, Norwich, Norfolk, UK. FAU - Stanley, Rachael AU - Stanley R AD - Norfolk and Norwich University Hospital, Norwich, Norfolk, UK. FAU - Sesay, Abdul K AU - Sesay AK AD - MRC Unit The Gambia at LHSTM, Fajara, Gambia. FAU - Webber, Mark A AU - Webber MA AD - Quadram Institute Bioscience, Norwich Research Park, Norwich, Norfolk, UK. AD - University of East Anglia, Norwich, Norfolk, UK. FAU - Davidson, Rose K AU - Davidson RK AD - University of East Anglia, Norwich, Norfolk, UK. FAU - Ghosn, Nada AU - Ghosn N AD - Ministry of Public Health, Epidemiological Surveillance Program, Museum Square, Beirut, Lebanon. FAU - Pallen, Mark AU - Pallen M AD - Quadram Institute Bioscience, Norwich Research Park, Norwich, Norfolk, UK. AD - University of East Anglia, Norwich, Norfolk, UK. FAU - Hasan, Hamad AU - Hasan H AD - Ministry of Public Health, Beirut, Lebanon. FAU - Page, Andrew J AU - Page AJ AD - Quadram Institute Bioscience, Norwich Research Park, Norwich, Norfolk, UK. FAU - Tokajian, Sima AU - Tokajian S AD - Department of Natural Sciences, Lebanese American University, School of Arts and Sciences, Byblos, Lebanon. LA - eng GR - BB/R012504/1/BB_/Biotechnology and Biological Sciences Research Council/United Kingdom GR - BBS/E/F/000PR10352/BB_/Biotechnology and Biological Sciences Research Council/United Kingdom GR - BB/CCG1860/1/BB_/Biotechnology and Biological Sciences Research Council/United Kingdom PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - England TA - Microb Genom JT - Microbial genomics JID - 101671820 RN - SARS-CoV-2 variants SB - IM MH - *COVID-19/epidemiology MH - Genome, Viral/genetics MH - Humans MH - Lebanon/epidemiology MH - Pandemics MH - Phylogeny MH - Prospective Studies MH - Retrospective Studies MH - *SARS-CoV-2/genetics PMC - PMC9455693 OTO - NOTNLM OT - SARS-CoV-2 OT - bioinformatics OT - genomic epidemiology OT - sequencing COIS- The study funders had no role in the design of the study, analysis or the interpretation of the data, or the decision to submit the paper for publication. The only direct funder involvement was the World Health Organisation who provided a grant towards the sequencing costs incurred by LAU and assisted with sample logistics. EDAT- 2022/07/26 06:00 MHDA- 2022/07/28 06:00 PMCR- 2022/07/25 CRDT- 2022/07/25 08:53 PHST- 2022/07/25 08:53 [entrez] PHST- 2022/07/26 06:00 [pubmed] PHST- 2022/07/28 06:00 [medline] PHST- 2022/07/25 00:00 [pmc-release] AID - 000838 [pii] AID - 10.1099/mgen.0.000838 [doi] PST - ppublish SO - Microb Genom. 2022 Jul;8(7):mgen000838. doi: 10.1099/mgen.0.000838. PMID- 35872871 OWN - NLM STAT- MEDLINE DCOM- 20220726 LR - 20260728 IS - 2314-6141 (Electronic) IS - 2314-6133 (Print) VI - 2022 DP - 2022 TI - Comparison of Transnasal Humidified Rapid-Insufflation Ventilatory Exchange and Facemasks in Preoxygenation: A Systematic Review and Meta-Analysis. PG - 9858820 LID - 10.1155/2022/9858820 [doi] LID - 9858820 AB - BACKGROUND: Transnasal Humidified Rapid-Insufflation Ventilatory Exchange (THRIVE) has received increasing attention and application as an effective noninvasive mode of ventilation in the treatment of clinical anesthesia and critically ill patients. The conclusions reached in clinical studies of THRIVE and facemask oxygenation are still controversial, and the main objective of this systematic review is to determine the advantages of THRIVE over facemask oxygenation in intensive care units, respiratory medicine, and perioperative preoxygenation. METHODS: PubMed, Embase, Web of Science, and Cochrane Library have search restrictions. The search library was full of English language articles from the first publication to 15 July 2021. Eligible randomized controlled study designs were included. 245 records were screened, and 5 studies met the inclusion criteria, enrolling a total of 235 patients. RESULTS: Studying the THRIVE group compared to the facemask group, three studies analyzing intubation time showed that there is no difference in the effect of THRIVE and facemasks (MD -1.22, 95% CI -7.23 to 4.78, and P = 0.69 > 0.05). Three studies analyzing apnea showed that there was no difference between the two groups (SMD 1, 95% CI -0.76 to 2.76, and P = 0.27 > 0.05). Three studies analyzing PaO(2) after preoxygenation showed that THRIVE is more effective than facemasks (MD 72.58, 95% CI 31.25 to 113.90, Z = 3.44, and P < 0.001). Two studies analyzing oxygen saturation SpO(2) after successful intubation showed that there was no difference in the effectiveness (MD 0.09, 95% CI -1.03 to 1.22, and P = 0.87 > 0.05). Two studies analyzing PCO(2) after complete paralysis or intubation preoxygenation showed that there was no difference between the two groups (MD 2.76, 95% CI -1.74 to 7.26, and P = 0.23 > 0.05). CONCLUSIONS: THRIVE does not have a greater advantage over a facemask in improving apnea time, oxygenation time, PCO(2), and SpO(2), but it has an advantage in improving arterial partial pressure of oxygen (PaO(2)) after preoxygenation, which can improve PaO(2) well. This trial is registered with the protocol registration number CRD42021268143. CI - Copyright (c) 2022 Yongkai Li and Jianzhong Yang. FAU - Li, Yongkai AU - Li Y AUID- ORCID: 0000-0002-2881-7632 AD - Emergency Trauma Center, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, China. FAU - Yang, Jianzhong AU - Yang J AUID- ORCID: 0000-0002-7308-0123 AD - Emergency Trauma Center, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, China. LA - eng PT - Journal Article PT - Meta-Analysis PT - Systematic Review DEP - 20220713 PL - United States TA - Biomed Res Int JT - BioMed research international JID - 101600173 RN - S88TT14065 (Oxygen) SB - IM MH - Apnea MH - Humans MH - *Insufflation/methods MH - Masks MH - Oxygen MH - Oxygen Inhalation Therapy MH - Partial Pressure PMC - PMC9300319 COIS- The authors declare no conflicts of interest. EDAT- 2022/07/26 06:00 MHDA- 2022/07/27 06:00 PMCR- 2022/07/13 CRDT- 2022/07/25 03:26 PHST- 2022/03/22 00:00 [received] PHST- 2022/06/21 00:00 [revised] PHST- 2022/06/29 00:00 [accepted] PHST- 2022/07/25 03:26 [entrez] PHST- 2022/07/26 06:00 [pubmed] PHST- 2022/07/27 06:00 [medline] PHST- 2022/07/13 00:00 [pmc-release] AID - 10.1155/2022/9858820 [doi] PST - epublish SO - Biomed Res Int. 2022 Jul 13;2022:9858820. doi: 10.1155/2022/9858820. eCollection 2022. PMID- 35871429 OWN - NLM STAT- MEDLINE DCOM- 20220726 LR - 20260414 IS - 2047-2986 (Electronic) IS - 2047-2978 (Print) IS - 2047-2978 (Linking) VI - 12 DP - 2022 Jul 25 TI - To what extent is alcohol consumption in social gatherings associated with observance of COVID-19 restrictions? A rapid review. PG - 13001 LID - 10.7189/jogh.12.13001 [doi] LID - 13001 AB - BACKGROUND: Pre-pandemic research found a connection between alcohol consumption and reduced physical distancing among strangers. Understanding the association between alcohol consumption at social gatherings and observance of COVID-19 restrictions can help inform policy related to the safe operation of public spaces where alcohol is typically consumed, as well as guidance related to the safe conduct of social events in private spaces. METHODS: We conducted a rapid review using adapted systematic review methods to explore the association between alcohol consumption in social gatherings and compliance with COVID-19 public health measures and produced a narrative synthesis of our findings. We ran searches in eleven health-related databases (MEDLINE, PubMed, CINAHL, Scopus, Embase (Ovid), ProQuest Public Health, ProQuest Coronavirus, Global Health (Ovid), WHO COVID-19 literature database, PsycInfo (Ovid) and ASSIA) between July 9, 2021, and July 31, 2021. We assessed methodological quality using the relevant Joanna Briggs Institute (JBI) checklists. This review was conducted and reported in accordance with PRISMA-P guidelines. RESULTS: We identified 7936 studies from the searches. After title, abstract and full-text review, three cross-sectional studies were eligible for inclusion. One study found that people who adhered strongly to physical distancing rules were engaged in about 40% fewer weekly drinks and 60% fewer heavy episodic drinking occasions in a week than people who adhered poorly to physical distancing rules (P < 0.01). One study found that people who reported low-risk alcohol consumption patterns had a higher chance of adhering to hand hygiene measures than those who reported high-risk alcohol consumption (odds ratio (OR) = 4.24, 95% confidence interval (CI) = 1.08-16.64). No other statistically significant results on patterns of alcohol consumption and compliance with individual public health measures or with non-pharmaceutical interventions (NPIs) were found. The direction of effect between alcohol consumption and non-adherence to NPIs and the effect of confounding factors has not been established. The quality of studies found was low to moderate, with risk of recall bias and selection bias due to study design; and the extent to which those studies can be generalised beyond their original settings may be limited. CONCLUSIONS: Despite existing evidence suggesting an association between alcohol consumption, reduced physical distancing, and increased social interaction, we found few studies of variable quality exploring the relationship between alcohol consumption and compliance with public health measures. A possible association between higher-risk alcohol behaviours and lower compliance with certain NPIs was suggested, but the direction of effect is unknown, and further studies are required to confirm this finding. CI - Copyright (c) 2022 by the Journal of Global Health. All rights reserved. FAU - Kulkarni, Durga AU - Kulkarni D AD - Usher Network for COVID-19 Evidence Reviews (UNCOVER) group, Usher Institute, University of Edinburgh, Edinburgh, UK. FAU - Nundy, Madhurima AU - Nundy M AD - Usher Network for COVID-19 Evidence Reviews (UNCOVER) group, Usher Institute, University of Edinburgh, Edinburgh, UK. FAU - McSwiggan, Emilie AU - McSwiggan E AD - Usher Network for COVID-19 Evidence Reviews (UNCOVER) group, Usher Institute, University of Edinburgh, Edinburgh, UK. FAU - Adams, Emily AU - Adams E AD - Usher Network for COVID-19 Evidence Reviews (UNCOVER) group, Usher Institute, University of Edinburgh, Edinburgh, UK. FAU - Dozier, Marshall AU - Dozier M AD - Usher Network for COVID-19 Evidence Reviews (UNCOVER) group, Usher Institute, University of Edinburgh, Edinburgh, UK. FAU - Hartnup, Karen AU - Hartnup K AD - Usher Network for COVID-19 Evidence Reviews (UNCOVER) group, Usher Institute, University of Edinburgh, Edinburgh, UK. FAU - Leow, Amanda AU - Leow A AD - Usher Network for COVID-19 Evidence Reviews (UNCOVER) group, Usher Institute, University of Edinburgh, Edinburgh, UK. FAU - Mureyi, Dudzai AU - Mureyi D AD - Usher Network for COVID-19 Evidence Reviews (UNCOVER) group, Usher Institute, University of Edinburgh, Edinburgh, UK. FAU - Nelson, Sarah AU - Nelson S AD - Usher Network for COVID-19 Evidence Reviews (UNCOVER) group, Usher Institute, University of Edinburgh, Edinburgh, UK. FAU - McQuillan, Ruth AU - McQuillan R AD - Usher Network for COVID-19 Evidence Reviews (UNCOVER) group, Usher Institute, University of Edinburgh, Edinburgh, UK. FAU - Theodoratou, Evropi AU - Theodoratou E AD - Usher Network for COVID-19 Evidence Reviews (UNCOVER) group, Usher Institute, University of Edinburgh, Edinburgh, UK. AD - Centre for Global Health, Usher Institute, University of Edinburgh, Edinburgh, UK. LA - eng GR - WT_/Wellcome Trust/United Kingdom PT - Journal Article PT - Systematic Review DEP - 20220725 PL - Scotland TA - J Glob Health JT - Journal of global health JID - 101578780 SB - IM MH - Humans MH - Alcohol Drinking/epidemiology MH - *COVID-19/epidemiology MH - Cross-Sectional Studies PMC - PMC9308983 COIS- Disclosure of interest: The authors have completed the ICMJE Disclosure of Interest Form (available on request from the corresponding author) and declare no conflicts of interest. EDAT- 2022/07/25 06:00 MHDA- 2022/07/27 06:00 PMCR- 2022/07/25 CRDT- 2022/07/24 14:15 PHST- 2022/07/24 14:15 [entrez] PHST- 2022/07/25 06:00 [pubmed] PHST- 2022/07/27 06:00 [medline] PHST- 2022/07/25 00:00 [pmc-release] AID - jogh-12-13001 [pii] AID - 10.7189/jogh.12.13001 [doi] PST - epublish SO - J Glob Health. 2022 Jul 25;12:13001. doi: 10.7189/jogh.12.13001. PMID- 35863887 OWN - NLM STAT- Publisher LR - 20240921 IS - 1472-3263 (Electronic) IS - 1368-4973 (Print) IS - 1368-4973 (Linking) VI - 99 IP - 4 DP - 2022 Jul 21 TI - Changes in STI and HIV testing and testing need among men who have sex with men during the UK's COVID-19 pandemic response. PG - 226-38 LID - sextrans-2022-055429 [pii] LID - 10.1136/sextrans-2022-055429 [doi] AB - OBJECTIVES: We examined the impact of COVID-19-related restrictions on sexual behaviours, STI and HIV testing and testing need among men who have sex with men (MSM) in the UK. METHODS: We used social media and dating applications to recruit to three cross-sectional surveys (S1-S3) during the UK's pandemic response (S1: 23 June-14 July 2020; S2: 23 November-12 December 2020; S3: 23 March-14 April 2021). Surveys included lookback periods of around 3-4 months (P1-P3, respectively). Eligible participants were UK resident men (cisgender/transgender) and gender-diverse people assigned male at birth (low numbers of trans and gender-diverse participants meant restricting these analyses to cisgender men), aged >/=16 years who reported sex with men (cisgender/transgender) in the last year (S1: N=1950; S2: N=1463; S3: N=1487). Outcomes were: recent STI/HIV testing and unmet testing need (new male and/or multiple condomless anal sex partners without a recent STI/HIV test). Crude and adjusted associations with each outcome were assessed using logistic regression. RESULTS: Participants' sociodemographic characteristics were similar across surveys. The proportion reporting a recent STI and/or HIV test increased between P1 and P2 (25.0% to 37.2% (p<0.001) and 29.7% to 39.4% (p<0.001), respectively), then stabilised in P3 (40.5% reporting HIV testing). Unmet STI testing need increased across P1 and P2 (26.0% to 32.4%; p<0.001), but trends differed between groups, for example, unmet STI testing need was higher in bisexually-identifying (vs gay-identifying) MSM across periods (adjusted OR (aOR): P1=1.64; P2=1.42), but declined in HIV-positive (vs HIV-negative/unknown) MSM (aOR: P1=2.06; P2=0.68). Unmet HIV testing need increased across P1 and P2 (22.9% to 31.0%; p<0.001) and declined in P3 (25.1%; p=0.001). During P3, MSM reporting a low life-satisfaction level (vs medium-very high) had greater unmet need (aOR: 1.44), while from P2 onwards HIV pre-exposure prophylaxis users (vs non-users) had lower unmet need (aOR: P2=0.32; P3=0.50). CONCLUSION: Considerable unmet STI/HIV testing need occurred among MSM during COVID-19-related restrictions, especially in bisexually-identifying men and those reporting low life satisfaction. Improving access to STI/HIV testing in MSM is essential to prevent inequalities being exacerbated. CI - (c) Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ. FAU - Brown, Jack Rg AU - Brown JR AUID- ORCID: 0000-0003-1334-8658 AD - UCL Institute for Global Health, University College London, London, UK jack.brown@ucl.ac.uk. AD - The National Institute for Health Research Health Protection Research Unit in Blood Borne and Sexually Transmitted Infections at University College London in partnership with the UK Health Security Agency, London, UK. FAU - Reid, David AU - Reid D AUID- ORCID: 0000-0001-6832-2418 AD - UCL Institute for Global Health, University College London, London, UK. AD - The National Institute for Health Research Health Protection Research Unit in Blood Borne and Sexually Transmitted Infections at University College London in partnership with the UK Health Security Agency, London, UK. FAU - Howarth, Alison R AU - Howarth AR AUID- ORCID: 0000-0002-0597-6614 AD - UCL Institute for Global Health, University College London, London, UK. AD - The National Institute for Health Research Health Protection Research Unit in Blood Borne and Sexually Transmitted Infections at University College London in partnership with the UK Health Security Agency, London, UK. FAU - Mohammed, Hamish AU - Mohammed H AUID- ORCID: 0000-0002-2060-7286 AD - UCL Institute for Global Health, University College London, London, UK. AD - The National Institute for Health Research Health Protection Research Unit in Blood Borne and Sexually Transmitted Infections at University College London in partnership with the UK Health Security Agency, London, UK. AD - Blood Safety, Hepatitis, STIs and HIV Division, UK Health Security Agency, London, UK. FAU - Saunders, John AU - Saunders J AUID- ORCID: 0000-0001-9658-7798 AD - UCL Institute for Global Health, University College London, London, UK. AD - The National Institute for Health Research Health Protection Research Unit in Blood Borne and Sexually Transmitted Infections at University College London in partnership with the UK Health Security Agency, London, UK. AD - Blood Safety, Hepatitis, STIs and HIV Division, UK Health Security Agency, London, UK. FAU - Pulford, Caisey V AU - Pulford CV AUID- ORCID: 0000-0003-2500-9119 AD - The National Institute for Health Research Health Protection Research Unit in Blood Borne and Sexually Transmitted Infections at University College London in partnership with the UK Health Security Agency, London, UK. AD - Blood Safety, Hepatitis, STIs and HIV Division, UK Health Security Agency, London, UK. FAU - Hughes, Gwenda AU - Hughes G AUID- ORCID: 0000-0003-2090-7702 AD - The National Institute for Health Research Health Protection Research Unit in Blood Borne and Sexually Transmitted Infections at University College London in partnership with the UK Health Security Agency, London, UK. AD - UK Public Health Rapid Support Team, London School of Hygiene and Tropical Medicine Department of Infectious Disease Epidemiology, London, UK. FAU - Mercer, Catherine H AU - Mercer CH AUID- ORCID: 0000-0002-4220-5034 AD - UCL Institute for Global Health, University College London, London, UK. AD - The National Institute for Health Research Health Protection Research Unit in Blood Borne and Sexually Transmitted Infections at University College London in partnership with the UK Health Security Agency, London, UK. LA - eng PT - Journal Article DEP - 20220721 PL - England TA - Sex Transm Infect JT - Sexually transmitted infections JID - 9805554 SB - IM PMC - PMC10313956 OTO - NOTNLM OT - COVID-19 OT - HIV OT - sexual behaviour OT - sexual health COIS- Competing interests: None declared. EDAT- 2022/07/22 06:00 MHDA- 2022/07/22 06:00 PMCR- 2022/07/21 CRDT- 2022/07/21 21:42 PHST- 2022/01/21 00:00 [received] PHST- 2022/06/25 00:00 [accepted] PHST- 2022/07/21 21:42 [entrez] PHST- 2022/07/22 06:00 [pubmed] PHST- 2022/07/22 06:00 [medline] PHST- 2022/07/21 00:00 [pmc-release] AID - sextrans-2022-055429 [pii] AID - 10.1136/sextrans-2022-055429 [doi] PST - aheadofprint SO - Sex Transm Infect. 2022 Jul 21;99(4):226-38. doi: 10.1136/sextrans-2022-055429. PMID- 35850742 OWN - NLM STAT- MEDLINE DCOM- 20220721 LR - 20240901 IS - 1471-2458 (Electronic) IS - 1471-2458 (Linking) VI - 22 IP - 1 DP - 2022 Jul 18 TI - A qualitative process analysis of daily contact testing as an alternative to self-isolation following close contact with a confirmed carrier of SARS-CoV-2. PG - 1373 LID - 10.1186/s12889-022-13800-x [doi] LID - 1373 AB - BACKGROUND: In July 2021, a randomised controlled trial was conducted to compare the effect on SARS-CoV-2 transmission of seven days of Daily Contact Testing (DCT) using Lateral Flow Test (LFT) and two Polymerase Chain Reaction (PCR) tests as an alternative to 10 days of standard self-isolation with one PCR, following close contact with a SARS-CoV-2 carrier. In this qualitative study, we used a nested process evaluation to aid interpretation of the trial and provide insight into factors influencing use of tests, understanding of test results, and how tests were used to inform behavioural decisions. METHODS: Interviews were conducted with 60 participants (42 randomised to DCT and 18 randomised to self-isolation) who had been in close contact with a confirmed SARS-CoV-2 carrier and had consented to take part in the trial. RESULTS: Data were organised into three overarching themes: (1) assessing the risks and benefits of DCT (2) use of testing during the study period and (3) future use of testing. Attitudes toward DCT as an alternative to self-isolation and behaviour during the testing period appeared to be informed by an assessment of the associated risks and benefits. Participants reported how important it was for them to avoid isolation, how necessary self-isolation was considered to be, and the ability of LFTs to detect infection. Behaviour during the testing period was modified to reduce risks and harms as much as possible. Testing was considered a potential compromise, reducing both risk of transmission and the negative impact of self-isolation, and was regarded as a way to return to normal. CONCLUSION: Participants in this study viewed DCT as a sensible, feasible, and welcome means of avoiding unnecessary self-isolation. Although negative LFTs provided reassurance, most people still restricted their activity as recommended. DCT was also highly valued by those in vulnerable households as a means of providing reassurance of the absence of infection and as an important means of detecting infection and prompting self-isolation when necessary. CI - (c) 2022. The Author(s). FAU - Denford, Sarah AU - Denford S AD - Health Protection Research Unit in Behavioural Science and Evaluation at the University of Bristol in Collaboration With UK Health Security Agency, Bristol, UK. sarah.denford@bristol.ac.uk. AD - Population Health Sciences, Bristol Medical School, University of Bristol, Priory Road Complex, BS8 1TU, Bristol, UK. sarah.denford@bristol.ac.uk. AD - School of Psychological Science, University of Bristol, Bristol, UK. sarah.denford@bristol.ac.uk. FAU - Martin, Alex F AU - Martin AF AD - Health Protection Research Unit in Emergency Preparedness and Response at King's College London in Collaboration With UK Health Security Agency, London, UK. FAU - Towler, Lauren AU - Towler L AD - School of Psychological Science, University of Bristol, Bristol, UK. AD - School of Psychology, University of Southampton, Southampton, UK. FAU - Mowbray, Fiona AU - Mowbray F AD - Health Protection Research Unit in Emergency Preparedness and Response at King's College London in Collaboration With UK Health Security Agency, London, UK. FAU - Essery, Rosie AU - Essery R AD - Health Protection Research Unit in Behavioural Science and Evaluation at the University of Bristol in Collaboration With UK Health Security Agency, Bristol, UK. AD - Population Health Sciences, Bristol Medical School, University of Bristol, Priory Road Complex, BS8 1TU, Bristol, UK. AD - School of Psychological Science, University of Bristol, Bristol, UK. AD - School of Psychology, University of Southampton, Southampton, UK. FAU - Bloomer, Rachael AU - Bloomer R AD - Population Health Sciences, Bristol Medical School, University of Bristol, Priory Road Complex, BS8 1TU, Bristol, UK. FAU - Ready, Derren AU - Ready D AD - Health Protection Research Unit in Behavioural Science and Evaluation at the University of Bristol in Collaboration With UK Health Security Agency, Bristol, UK. AD - UK Health Security Agency, London, England, UK. FAU - Love, Nicola AU - Love N AD - Health Protection Research Unit in Behavioural Science and Evaluation at the University of Bristol in Collaboration With UK Health Security Agency, Bristol, UK. AD - UK Health Security Agency, London, England, UK. FAU - Amlot, Richard AU - Amlot R AD - Health Protection Research Unit in Behavioural Science and Evaluation at the University of Bristol in Collaboration With UK Health Security Agency, Bristol, UK. AD - Health Protection Research Unit in Emergency Preparedness and Response at King's College London in Collaboration With UK Health Security Agency, London, UK. AD - UK Health Security Agency, London, England, UK. FAU - Oliver, Isabel AU - Oliver I AD - Health Protection Research Unit in Behavioural Science and Evaluation at the University of Bristol in Collaboration With UK Health Security Agency, Bristol, UK. AD - UK Health Security Agency, London, England, UK. FAU - Rubin, G James AU - Rubin GJ AD - Health Protection Research Unit in Emergency Preparedness and Response at King's College London in Collaboration With UK Health Security Agency, London, UK. FAU - Yardley, Lucy AU - Yardley L AD - Health Protection Research Unit in Behavioural Science and Evaluation at the University of Bristol in Collaboration With UK Health Security Agency, Bristol, UK. AD - Population Health Sciences, Bristol Medical School, University of Bristol, Priory Road Complex, BS8 1TU, Bristol, UK. AD - School of Psychological Science, University of Bristol, Bristol, UK. AD - School of Psychology, University of Southampton, Southampton, UK. LA - eng GR - DH_/Department of Health/United Kingdom PT - Journal Article PT - Randomized Controlled Trial PT - Research Support, Non-U.S. Gov't DEP - 20220718 PL - England TA - BMC Public Health JT - BMC public health JID - 100968562 SB - IM MH - *COVID-19/diagnosis/prevention & control MH - Humans MH - *SARS-CoV-2/genetics PMC - PMC9294818 OTO - NOTNLM OT - Covid-19 OT - Lateral flow device OT - Process evaluation OT - Qualitative OT - Testing COIS- None declared. EDAT- 2022/07/20 06:00 MHDA- 2022/07/22 06:00 PMCR- 2022/07/18 CRDT- 2022/07/19 07:45 PHST- 2021/12/13 00:00 [received] PHST- 2022/07/12 00:00 [accepted] PHST- 2022/07/19 07:45 [entrez] PHST- 2022/07/20 06:00 [pubmed] PHST- 2022/07/22 06:00 [medline] PHST- 2022/07/18 00:00 [pmc-release] AID - 10.1186/s12889-022-13800-x [pii] AID - 13800 [pii] AID - 10.1186/s12889-022-13800-x [doi] PST - epublish SO - BMC Public Health. 2022 Jul 18;22(1):1373. doi: 10.1186/s12889-022-13800-x. PMID- 35832718 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220716 IS - 1734-1922 (Print) IS - 1896-9151 (Electronic) IS - 1734-1922 (Linking) VI - 18 IP - 4 DP - 2022 TI - Hypertensive urgencies during the first wave of the COVID-19 pandemic in a tertiary hospital setting: a U-shaped alarming curve. PG - 982-990 LID - 10.5114/aoms/141243 [doi] AB - INTRODUCTION: The coronavirus disease 2019 (COVID-19) pandemic provoked unprecedented disturbance in hypertension care, while alarming concerns arose about its long-term consequences. We investigated the trends of emergency visits and admissions regarding uncontrolled hypertension in order to assess the impact of COVID-19 spread on population behavior towards hypertension urgencies during its first wave. MATERIAL AND METHODS: Data from daily unscheduled visits and admission counts in the Cardiology sector were collected from the Emergency Department database of a tertiary General Hospital in Athens, Greece for the period January 15(th) to July 15(th) 2020. These data were compared with those from the previous year. Cases of patients who presented with hypertensive urgency or who were admitted due to uncontrolled hypertension were separately analyzed. RESULTS: A total of 7,373 patient records were analyzed. Hypertension urgency cases demonstrated a U-shaped distribution in 2020, showing a declining trend during the rapid virus spread, an image that was reversed after the transmission rate's decline. COVID-19 incidence in Greece was inversely associated with uncontrolled hypertension admissions during its declining phase (r = -0.64, p = 0.009), whereas total attendance exhibited a similar correlation during the first and the following months of the pandemic (r = 0.677, p = 0.031, r = -0.789, p = 0.001). Uncontrolled hypertension rate on admission was positively related to the national incidence of COVID-19 cases during the first months of 2020 (r = 0.82, p = 0.045). CONCLUSIONS: Hypertensive urgency-related visits followed a U-shape distribution during the pandemic's first wave with the attendance nadir coinciding with the virus spread peak. This is a complex phenomenon, closely related to increased levels of public stress, disruptions in health care services and to a lesser extent to the imposed restrictions in transportation. The initial relative increase in uncontrolled hypertension-related admissions rate, combined with the later increase of hypertensive urgencies may be indicative of blood pressure deregulation among the studied population, which is multifactorial and potentially detrimental. CI - Copyright: (c) 2022 Termedia & Banach. FAU - Leontsinis, Ioannis AU - Leontsinis I AD - First Cardiology Clinic, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece. FAU - Papademetriou, Vasilios AU - Papademetriou V AD - Cardiology Department, Georgetown University and Veterans Affairs Medical Center, Washington, District of Columbia, USA. FAU - Chrysohoou, Christina AU - Chrysohoou C AD - First Cardiology Clinic, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece. FAU - Kariori, Maria AU - Kariori M AD - First Cardiology Clinic, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece. FAU - Dalakouras, Ioannis AU - Dalakouras I AD - First Cardiology Clinic, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece. FAU - Tolis, Panayotis AU - Tolis P AD - First Cardiology Clinic, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece. FAU - Fragoulis, Christos AU - Fragoulis C AD - First Cardiology Clinic, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece. FAU - Kalos, Theodoros AU - Kalos T AD - First Cardiology Clinic, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece. FAU - Tatakis, Fotios-Panagiotis AU - Tatakis FP AD - First Cardiology Clinic, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece. FAU - Dimitriadis, Kyriakos AU - Dimitriadis K AD - First Cardiology Clinic, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece. FAU - Doumas, Michael AU - Doumas M AD - Second Propedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, Hippokration Hospital, Thessaloniki, Greece. FAU - Sambatakou, Helen AU - Sambatakou H AD - Second Department of Internal Medicine, HIV Unit, Hippokration General Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece. FAU - Pirounaki, Maria AU - Pirounaki M AD - Department of Internal Medicine, Hippokration General Hospital, Athens, Greece. FAU - Mihas, Constantinos AU - Mihas C AD - First Cardiology Clinic, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece. FAU - Katsiki, Niki AU - Katsiki N AD - Department of Nutritional Sciences and Dietetics, International Hellenic University, Athens, Greece. AD - School of Medicine, European University Cyprus, Nicosia, Cyprus. FAU - Bhaskar, Sonu AU - Bhaskar S AD - Department of Neurology, Liverpool Hospital and South Western Sydney Local Health District, Sydney, NSW, Australia. FAU - Tsivgoulis, Georgios AU - Tsivgoulis G AD - Second Department of Neurology, Attikon Hospital, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece. FAU - Tousoulis, Dimitrios AU - Tousoulis D AD - First Cardiology Clinic, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece. FAU - Banach, Maciej AU - Banach M AD - Department of Hypertension, Medical University of Lodz (MUL), Lodz, Poland. AD - Polish Mother's Memorial Hospital Research Institute (PMMHRI), Lodz, Poland. AD - Cardiovascular Research Centre, University of Zielona Gora, Zielona Gora, Poland. FAU - Tsioufis, Konstantinos AU - Tsioufis K AD - First Cardiology Clinic, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece. LA - eng PT - Journal Article DEP - 20210923 PL - Poland TA - Arch Med Sci JT - Archives of medical science : AMS JID - 101258257 PMC - PMC9266735 OTO - NOTNLM OT - blood pressure OT - coronavirus disease 2019 OT - hypertension urgency OT - uncontrolled hypertension COIS- The authors declare no conflict of interest. EDAT- 2022/07/15 06:00 MHDA- 2022/07/15 06:01 PMCR- 2021/09/23 CRDT- 2022/07/14 02:28 PHST- 2021/03/11 00:00 [received] PHST- 2021/08/13 00:00 [accepted] PHST- 2022/07/14 02:28 [entrez] PHST- 2022/07/15 06:00 [pubmed] PHST- 2022/07/15 06:01 [medline] PHST- 2021/09/23 00:00 [pmc-release] AID - 141243 [pii] AID - 10.5114/aoms/141243 [doi] PST - epublish SO - Arch Med Sci. 2021 Sep 23;18(4):982-990. doi: 10.5114/aoms/141243. eCollection 2022. PMID- 35830382 OWN - NLM STAT- MEDLINE DCOM- 20220715 LR - 20220722 IS - 1932-6203 (Electronic) IS - 1932-6203 (Linking) VI - 17 IP - 7 DP - 2022 TI - To Zoom or not to Zoom: A longitudinal study of UK population's activities during the COVID-19 pandemic. PG - e0270207 LID - 10.1371/journal.pone.0270207 [doi] LID - e0270207 AB - This longitudinal study determines the frequency and way of people doing activities from Spring 2020 to Summer 2021 during different phases of the COVID-19 pandemic in the UK. Six online surveys were carried out between April 2020 and July 2021. 4,992 participants were engaged in the cross-sectional study and 203 participants who provided repeat responses were included in the subset sample of prospective cohort analysis. Primary outcomes measured were the frequency and the mode of doing the activities (online or in-person) across sixteen selected activity groups, as defined by the UK National Time Use Survey. The results show that cultural activities, spending time with others, and travelling, were the activities with the largest proportions of frequency and mode changes. The most significant changes occurred from March to June 2020, a period that included the first lockdown. Survey results from this period show a significant decrease among most of the sixteen measured activities. From March to October 2020, a period which spans the first lockdown and its subsequent ease of restrictions, showed the most significant shift from accessing activities in-person to online. Despite 'Freedom Day', the July 19th 2021 date in which all restrictions were abolished, it was found that people do cultural activities and group activities at a significantly lower frequency than before the pandemic. In addition, despite a lack of restrictions after this date, more than half of participants access many activities, such as spending time with others, shopping, work and studying, online or hybrid. This study provides an invaluable insight into understanding how people in the UK changed their lifestyle, including what activities they do, and how they accessed those activities in light of the COVID-19 pandemic and related public health policy implemented to address the pandemic. These results may serve as unique evidence for policymakers. FAU - Li, Lan AU - Li L AUID- ORCID: 0000-0002-5532-5764 AD - Centre for Digital Public Health in Emergencies, Institute for Risk and Disaster Reduction, University College London, London, United Kingdom. FAU - Sullivan, Ava AU - Sullivan A AD - Centre for Digital Public Health in Emergencies, Institute for Risk and Disaster Reduction, University College London, London, United Kingdom. AD - EcoHealth Alliance, New York, New York, United States of America. FAU - Musah, Anwar AU - Musah A AD - Centre for Digital Public Health in Emergencies, Institute for Risk and Disaster Reduction, University College London, London, United Kingdom. AD - Department of Geography, University College London, London, United Kingdom. FAU - Stavrianaki, Katerina AU - Stavrianaki K AUID- ORCID: 0000-0001-9413-1842 AD - Centre for Digital Public Health in Emergencies, Institute for Risk and Disaster Reduction, University College London, London, United Kingdom. AD - Department of Statistical Science, University College London, London, United Kingdom. FAU - Wood, Caroline E AU - Wood CE AD - Centre for Digital Public Health in Emergencies, Institute for Risk and Disaster Reduction, University College London, London, United Kingdom. FAU - Baker, Philip AU - Baker P AD - Centre for Digital Public Health in Emergencies, Institute for Risk and Disaster Reduction, University College London, London, United Kingdom. AD - Crisis Response, British Red Cross, London, United Kingdom. FAU - Kostkova, Patty AU - Kostkova P AD - Centre for Digital Public Health in Emergencies, Institute for Risk and Disaster Reduction, University College London, London, United Kingdom. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20220713 PL - United States TA - PLoS One JT - PloS one JID - 101285081 SB - IM MH - *COVID-19/epidemiology MH - Communicable Disease Control MH - Cross-Sectional Studies MH - Humans MH - Longitudinal Studies MH - Pandemics MH - Prospective Studies MH - United Kingdom/epidemiology PMC - PMC9278744 COIS- The authors have declared that no competing interests exist. EDAT- 2022/07/14 06:00 MHDA- 2022/07/16 06:00 PMCR- 2022/07/13 CRDT- 2022/07/13 13:33 PHST- 2022/03/23 00:00 [received] PHST- 2022/06/06 00:00 [accepted] PHST- 2022/07/13 13:33 [entrez] PHST- 2022/07/14 06:00 [pubmed] PHST- 2022/07/16 06:00 [medline] PHST- 2022/07/13 00:00 [pmc-release] AID - PONE-D-22-08632 [pii] AID - 10.1371/journal.pone.0270207 [doi] PST - epublish SO - PLoS One. 2022 Jul 13;17(7):e0270207. doi: 10.1371/journal.pone.0270207. eCollection 2022. PMID- 35820879 OWN - NLM STAT- MEDLINE DCOM- 20220714 LR - 20240831 IS - 1471-2458 (Electronic) IS - 1471-2458 (Linking) VI - 22 IP - 1 DP - 2022 Jul 12 TI - "COVID knocked me straight into the dirt": perspectives from people experiencing homelessness on the impacts of the COVID-19 pandemic. PG - 1327 LID - 10.1186/s12889-022-13748-y [doi] LID - 1327 AB - BACKGROUND: People experiencing homelessness are uniquely susceptible and disproportionately affected by the impacts of the COVID-19 pandemic. Understanding context-specific challenges, responses, and perspectives of people experiencing homelessness is essential to improving pandemic response and mitigating the long-term consequences of the pandemic on this vulnerable population. METHODS: As part of an ongoing community-based participatory research study in partnership with a homeless service organization in Indiana, semi-structured interviews were conducted with a total of 34 individuals experiencing homelessness between January and July 2021. Guided by the NIMHD Health Disparities Research Framework, which builds on the socio-ecological model, data was thematically coded using Nvivo12 qualitative coding software and themes were organized by levels of influence (individual, interpersonal, community, societal) and domains of influence (biological, behavioral, physical/built environment, sociocultural environment, health care system). RESULTS: Narratives revealed numerous and compounding factors affecting COVID-19 risks and health outcomes among people experiencing homelessness across all levels and domains of influence. At the individual level, people experiencing homelessness face unique challenges that heightened their susceptibility to COVID-19, including pre-existing physical and mental health conditions, substance use and behavioral health risks, socioeconomic precarity, and low health literacy and COVID-related knowledge. At the interpersonal level, poor communication between people experiencing homelessness and service providers led to limited understanding of and poor compliance with COVID safety measures. At the community level, closures and service disruptions restricted access to usual spaces and resources to meet basic needs. At a policy level, people experiencing homelessness were disregarded in ways that made pandemic relief resources largely inaccessible to them. CONCLUSIONS: Our findings reveal important and mitigable issues with ongoing pandemic response efforts in homeless populations through direct, first-hand accounts of their experiences during COVID-19. These insights offer opportunities for multilevel interventions to improve outreach, communication, and impact mitigation strategies for people experiencing homelessness. This study highlights the importance of centering the voices of vulnerable communities to inform future pandemic response for homeless and other underserved and marginalized populations. CI - (c) 2022. The Author(s). FAU - Rodriguez, Natalia M AU - Rodriguez NM AD - Department of Public Health, College of Health and Human Sciences, Purdue University, West Lafayette, IN, USA. natalia@purdue.edu. AD - Regenstrief Center for Healthcare Engineering, Purdue University, West Lafayette, IN, USA. natalia@purdue.edu. FAU - Martinez, Rebecca G AU - Martinez RG AD - Department of Anthropology, College of Liberal Arts, Purdue University, West Lafayette, Indiana, USA. FAU - Ziolkowski, Rebecca AU - Ziolkowski R AD - Department of Public Health, College of Health and Human Sciences, Purdue University, West Lafayette, IN, USA. FAU - Tolliver, Cealia AU - Tolliver C AD - Department of Pharmacy Practice, College of Pharmacy, Purdue University, West Lafayette, Indiana, USA. FAU - Young, Hope AU - Young H AD - Department of Public Health, College of Health and Human Sciences, Purdue University, West Lafayette, IN, USA. FAU - Ruiz, Yumary AU - Ruiz Y AD - Department of Public Health, College of Health and Human Sciences, Purdue University, West Lafayette, IN, USA. LA - eng GR - K01 CA241073/CA/NCI NIH HHS/United States GR - UL1 TR002529/TR/NCATS NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural DEP - 20220712 PL - England TA - BMC Public Health JT - BMC public health JID - 100968562 SB - IM MH - *COVID-19/epidemiology MH - *Ill-Housed Persons/psychology MH - Humans MH - Pandemics MH - Qualitative Research MH - Social Problems PMC - PMC9275174 OTO - NOTNLM OT - COVID-19 OT - Community-based participatory research OT - Disaster response OT - Health disparities OT - Homelessness OT - Pandemic response OT - Socio-ecological model COIS- NMR is a member of the board of directors of a non-profit homelessness service organization in Indiana. RGM, RZ, CT, HY, and YR declare no competing interests. EDAT- 2022/07/13 06:00 MHDA- 2022/07/15 06:00 PMCR- 2022/07/12 CRDT- 2022/07/12 23:37 PHST- 2022/03/11 00:00 [received] PHST- 2022/07/06 00:00 [accepted] PHST- 2022/07/12 23:37 [entrez] PHST- 2022/07/13 06:00 [pubmed] PHST- 2022/07/15 06:00 [medline] PHST- 2022/07/12 00:00 [pmc-release] AID - 10.1186/s12889-022-13748-y [pii] AID - 13748 [pii] AID - 10.1186/s12889-022-13748-y [doi] PST - epublish SO - BMC Public Health. 2022 Jul 12;22(1):1327. doi: 10.1186/s12889-022-13748-y. PMID- 35809115 OWN - NLM STAT- MEDLINE DCOM- 20220916 LR - 20261010 IS - 1436-3771 (Electronic) IS - 1432-6981 (Linking) VI - 26 IP - 9 DP - 2022 Sep TI - Unusual complications at the recipient site following periodontal plastic surgery procedures: a systematic review. PG - 5595-5609 LID - 10.1007/s00784-022-04596-6 [doi] AB - OBJECTIVE: To identify and describe unusual soft tissue complications of periodontal plastic surgery procedures at the recipient site after periodontal grafts. MATERIALS AND METHODS: Two independent reviewers performed a comprehensive search in MEDLINE, Cochrane, periodontics journals, reference lists, and grey literature for articles dated up to July 2021. Publications related to surgical interventions only around the teeth with an unusual complication at the recipient site were selected. No restrictions were made in the number of cases, follow-up period, or language. The Cochrane Collaboration's tool for assessing risk of bias, the Newcastle-Ottawa Scale (NOS), and two validated case report/series checklists were used to critically appraise the studies. RESULTS: A total of 1434 articles were examined, of which 28 met the inclusion criteria: one RCT, two cohort studies, and twenty-five case reports/series. The periodontal plastic surgery procedures described in these articles were conducted to treat lack of attached gingiva and gingival recessions. The following unusual complications were found: bone exostosis, epithelial inclusion, root resorption, abscess, overgrowth, "liver clot" formation, and oroantral communication. CONCLUSION: Bone exostosis and epithelial inclusions were the most prevalent unusual complications following treatment with subepithelial connective tissue graft, free gingival graft, and acellular dermal matrix allograft. Due to the nature of the reports, the clinical recommendations for diagnosis and treatment cannot be homogenized. Clinical studies reporting complications are required to develop management protocols (PROSPERO CRD42021230875). CLINICAL RELEVANCE: Clinicians need to know the main complications that can occur in mucogingival surgeries as well as their clinical management to provide a successful and predictable treatment. CI - (c) 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. FAU - Alarcon, Marco Antonio AU - Alarcon MA AD - PerioImplant Research Group UPCH, Academic Department of Clinical Stomatology, Cayetano Heredia Peruvian University, 2475 Salaverry Avenue, San Isidro District, Lima, Peru. FAU - Moses, Ana Ximena AU - Moses AX AUID- ORCID: 0000-0001-8423-6587 AD - PerioImplant Research Group UPCH, Academic Department of Clinical Stomatology, Cayetano Heredia Peruvian University, 2475 Salaverry Avenue, San Isidro District, Lima, Peru. ana.moses.a@upch.pe. FAU - Palma, Daniella AU - Palma D AD - PerioImplant Research Group UPCH, Academic Department of Clinical Stomatology, Cayetano Heredia Peruvian University, 2475 Salaverry Avenue, San Isidro District, Lima, Peru. FAU - Garcia-Roncero, Herminio AU - Garcia-Roncero H AD - Department of Prosthodontics, School of Dentistry, Universitat Internacional de Catalunya, Barcelona, Spain. FAU - de Carvalho, Paulo F Mesquita AU - de Carvalho PFM AD - Implanteperio Institute - Research and Advanced Training in Dentistry, Sao Paulo, Brazil. LA - eng PT - Journal Article PT - Systematic Review DEP - 20220709 PL - Germany TA - Clin Oral Investig JT - Clinical oral investigations JID - 9707115 MH - Connective Tissue/transplantation MH - *Exostoses MH - Gingiva/transplantation MH - *Gingival Recession/etiology/surgery MH - Humans MH - Postoperative Complications MH - *Plastic Surgery Procedures/methods MH - *Surgery, Plastic MH - Surgical Flaps/surgery MH - Tooth Root/surgery OTO - NOTNLM OT - Gingival recession OT - Grafts OT - Periodontics OT - Postoperative complications OT - Systematic review EDAT- 2022/07/10 06:00 MHDA- 2022/09/17 06:00 CRDT- 2022/07/09 11:13 PHST- 2022/01/23 00:00 [received] PHST- 2022/06/20 00:00 [accepted] PHST- 2022/07/10 06:00 [pubmed] PHST- 2022/09/17 06:00 [medline] PHST- 2022/07/09 11:13 [entrez] AID - 10.1007/s00784-022-04596-6 [pii] AID - 10.1007/s00784-022-04596-6 [doi] PST - ppublish SO - Clin Oral Investig. 2022 Sep;26(9):5595-5609. doi: 10.1007/s00784-022-04596-6. Epub 2022 Jul 9. PMID- 35802350 OWN - NLM STAT- MEDLINE DCOM- 20220712 LR - 20250623 IS - 1469-493X (Electronic) IS - 1361-6137 (Linking) VI - 7 IP - 7 DP - 2022 Jul 8 TI - Interventions for interpersonal communication about end of life care between health practitioners and affected people. PG - CD013116 LID - 10.1002/14651858.CD013116.pub2 [doi] LID - CD013116 AB - BACKGROUND: Communication about end of life (EoL) and EoL care is critically important for providing quality care as people approach death. Such communication is often complex and involves many people (patients, family members, carers, health professionals). How best to communicate with people in the period approaching death is not known, but is an important question for quality of care at EoL worldwide. This review fills a gap in the evidence on interpersonal communication (between people and health professionals) in the last year of life, focusing on interventions to improve interpersonal communication and patient, family member and carer outcomes. OBJECTIVES: To assess the effects of interventions designed to improve verbal interpersonal communication about EoL care between health practitioners and people affected by EoL. SEARCH METHODS: We searched CENTRAL, MEDLINE, Embase, PsycINFO, and CINAHL from inception to July 2018, without language or date restrictions. We contacted authors of included studies and experts and searched reference lists to identify relevant papers. We searched grey literature sources, conference proceedings, and clinical trials registries in September 2019. Database searches were re-run in June 2021 and potentially relevant studies listed as awaiting classification or ongoing. SELECTION CRITERIA: This review assessed the effects of interventions, evaluated in randomised and quasi-randomised trials, intended to enhance interpersonal communication about EoL care between patients expected to die within 12 months, their family members and carers, and health practitioners involved in their care. Patients of any age from birth, in any setting or care context (e.g. acute catastrophic injury, chronic illness), and all health professionals involved in their care were eligible. All communication interventions were eligible, as long as they included interpersonal interaction(s) between patients and family members or carers and health professionals. Interventions could be simple or complex, with one or more communication aims (e.g. to inform, skill, engage, support). Effects were sought on outcomes for patients, family and carers, health professionals and health systems, including adverse (unintended) effects. To ensure this review's focus was maintained on interpersonal communication in the last 12 months of life, we excluded studies that addressed specific decisions, shared or otherwise, and the tools involved in such decision-making. We also excluded studies focused on advance care planning (ACP) reporting ACP uptake or completion as the primary outcome. Finally, we excluded studies of communication skills training for health professionals unless patient outcomes were reported as primary outcomes. DATA COLLECTION AND ANALYSIS: Standard Cochrane methods were used, including dual review author study selection, data extraction and quality assessment of the included studies. MAIN RESULTS: Eight trials were included. All assessed intervention effects compared with usual care. Certainty of the evidence was low or very low. All outcomes were downgraded for indirectness based on the review's purpose, and many were downgraded for imprecision and/or inconsistency. Certainty was not commonly downgraded for methodological limitations. A summary of the review's findings is as follows. Knowledge and understanding (four studies, low-certainty evidence; one study without usable data): interventions to improve communication (e.g. question prompt list, with or without patient and physician training) may have little or no effect on knowledge of illness and prognosis, or information needs and preferences, although studies were small and measures used varied across trials. Evaluation of the communication (six studies measuring several constructs (communication quality, patient-centredness, involvement preferences, doctor-patient relationship, satisfaction with consultation), most low-certainty evidence): across constructs there may be minimal or no effects of interventions to improve EoL communication, and there is uncertainty about effects of interventions such as a patient-specific feedback sheet on quality of communication. Discussions of EoL or EoL care (six studies measuring selected outcomes, low- or very low-certainty evidence): a family conference intervention may increase duration of EoL discussions in an intensive care unit (ICU) setting, while use of a structured serious illness conversation guide may lead to earlier discussions of EoL and EoL care (each assessed by one study). We are uncertain about effects on occurrence of discussions and question asking in consultations, and there may be little or no effect on content of communication in consultations. Adverse outcomes or unintended effects (limited evidence): there is insufficient evidence to determine whether there are adverse outcomes associated with communication interventions (e.g. question prompt list, family conference, structured discussions) for EoL and EoL care. Patient and/or carer anxiety was reported by three studies, but judged as confounded. No other unintended consequences, or worsening of desired outcomes, were reported. Patient/carer quality of life (four studies, low-certainty evidence; two without useable data): interventions to improve communication may have little or no effect on quality of life. Health practitioner outcomes (three studies, low-certainty evidence; two without usable data): interventions to improve communication may have little or no effect on health practitioner outcomes (satisfaction with communication during consultation; one study); effects on other outcomes (knowledge, preparedness to communicate) are unknown. Health systems impacts: communication interventions (e.g. structured EoL conversations) may have little or no effect on carer or clinician ratings of quality of EoL care (satisfaction with care, symptom management, comfort assessment, quality of care) (three studies, low-certainty evidence), or on patients' self-rated care and illness, or numbers of care goals met (one study, low-certainty evidence). Communication interventions (e.g. question prompt list alone or with nurse-led communication skills training) may slightly increase mean consultation length (two studies), but other health service impacts (e.g. hospital admissions) are unclear. AUTHORS' CONCLUSIONS: Findings of this review are inconclusive for practice. Future research might contribute meaningfully by seeking to fill gaps for populations not yet studied in trials; and to develop responsive outcome measures with which to better assess the effects of communication on the range of people involved in EoL communication episodes. Mixed methods and/or qualitative research may contribute usefully to better understand the complex interplay between different parties involved in communication, and to inform development of more effective interventions and appropriate outcome measures. Co-design of such interventions and outcomes, involving the full range of people affected by EoL communication and care, should be a key underpinning principle for future research in this area. CI - Copyright (c) 2022 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. FAU - Ryan, Rebecca E AU - Ryan RE AD - Centre for Health Communication and Participation, School of Psychology and Public Health, La Trobe University, Bundoora, Australia. FAU - Connolly, Michael AU - Connolly M AD - School of Nursing, Midwifery and Health Systems, University College Dublin and Our Lady's Hospice and Care Services, Dublin, Ireland. FAU - Bradford, Natalie K AU - Bradford NK AD - Centre for Children's Health Research, Cancer and Palliative Care Outcomes at Centre for Children's Health Research, Queensland University of Technology (QUT), South Brisbane, Australia. FAU - Henderson, Simon AU - Henderson S AD - Department of Aviation, The University of New South Wales, Sydney, Australia. FAU - Herbert, Anthony AU - Herbert A AD - Paediatric Palliative Care Service, Children's Health Queensland, Hospital and Health Service, South Brisbane, Australia. AD - Centre for Children's Health Research, Queensland University of Technology, South Brisbane, Australia. FAU - Schonfeld, Lina AU - Schonfeld L AD - Centre for Health Communication and Participation, School of Psychology and Public Health, La Trobe University, Bundoora, Australia. FAU - Young, Jeanine AU - Young J AD - School of Nursing, Midwifery and Paramedicine, University of the Sunshine Coast, Sippy Downs, Australia. FAU - Bothroyd, Josephine I AU - Bothroyd JI AD - Self-employed, Health Care Consumers' Association of the ACT, Duffy, Australia. FAU - Henderson, Amanda AU - Henderson A AD - School of Nursing, Midwifery and Paramedicine, University of the Sunshine Coast, Sippy Downs, Australia. LA - eng SI - ClinicalTrials.gov/NCT00331877 SI - ClinicalTrials.gov/NCT00325611 SI - ClinicalTrials.gov/NCT01245621 SI - ClinicalTrials.gov/NCT01990742 SI - ClinicalTrials.gov/NCT02261935 SI - ClinicalTrials.gov/NCT02606149 SI - ClinicalTrials.gov/NCT02723799 SI - ClinicalTrials.gov/NCT02730858 SI - ClinicalTrials.gov/NCT02944344 SI - ClinicalTrials.gov/NCT03099746 SI - ClinicalTrials.gov/NCT03548142 SI - ClinicalTrials.gov/NCT03626402 SI - ClinicalTrials.gov/NCT03770481 PT - Journal Article PT - Systematic Review DEP - 20220708 PL - England TA - Cochrane Database Syst Rev JT - The Cochrane database of systematic reviews JID - 100909747 SB - IM UOF - doi: 10.1002/14651858.CD013116 MH - Anxiety MH - *Communication MH - Humans MH - *Physician-Patient Relations MH - Quality of Life MH - Randomized Controlled Trials as Topic MH - *Terminal Care PMC - PMC9266997 COIS- Rebecca Ryan: completed this work as part of her role as Joint Co-ordinating Editor with the Cochrane Consumers and Communication Group. Her position is funded by a Cochrane Infrastructure Grant provided by the National Health and Medical Research Council (NHMRC). Michael Connolly: completed this work as part of his Evidence Synthesis Ireland Fellowship. Natalie Bradford: none to declare. Simon Henderson: none to declare. Anthony Herbert: received funding from Australia Research Council (2018 to 2020) and Gilead Sciences (2016). Lina Schonfeld: none to declare. Jeanine Young: none to declare. Josephine Bothroyd: none to declare. Amanda Henderson: none to declare. EDAT- 2022/07/09 06:00 MHDA- 2022/07/14 06:00 PMCR- 2023/07/08 CRDT- 2022/07/08 11:21 PHST- 2022/07/08 11:21 [entrez] PHST- 2022/07/09 06:00 [pubmed] PHST- 2022/07/14 06:00 [medline] PHST- 2023/07/08 00:00 [pmc-release] AID - CD013116.pub2 [pii] AID - 10.1002/14651858.CD013116.pub2 [doi] PST - epublish SO - Cochrane Database Syst Rev. 2022 Jul 8;7(7):CD013116. doi: 10.1002/14651858.CD013116.pub2. PMID- 35791335 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250530 IS - 2666-7762 (Electronic) IS - 2666-7762 (Linking) VI - 20 DP - 2022 Sep TI - Observed protection against SARS-CoV-2 reinfection following a primary infection: A Danish cohort study among unvaccinated using two years of nationwide PCR-test data. PG - 100452 LID - 10.1016/j.lanepe.2022.100452 [doi] LID - 100452 AB - BACKGROUND: The level of protection after a SARS-CoV-2 infection against reinfection and COVID-19 disease remains important with much of the world still unvaccinated. METHODS: Analysing nationwide, individually referable, Danish register data including RT-PCR-test results, we conducted a cohort study using Cox regression to compare SARS-CoV-2 infection rates before and after a primary infection among still unvaccinated individuals, adjusting for sex, age, comorbidity and residency region. Estimates of protection against infection were calculated as 1 minus the hazard ratio. Estimates of protection against symptomatic infections and infections leading to hospitalisation were also calculated. The prevalence of infections classified as symptomatic or asymptomatic was compared for primary infections and reinfections. The study also assessed protection against each of the main viral variants after a primary infection with an earlier variant by restricting follow-up time to distinct, mutually exclusive periods during which each variant dominated. FINDINGS: Until 1 July 2021 the estimated protection against reinfection was 83.4% (95%CI: 82.2-84.6%); but lower for the 65+ year-olds (72.2%; 95%CI: 53.2-81.0%). Moderately higher estimates were found for protection against symptomatic disease, 88.3% overall (95%CI: 85.9-90.3%). First-time cases who reported no symptoms were more likely to experience a reinfection (odds ratio: 1.48; 95%CI: 1.35-1.62). By autumn 2021, when infections were almost exclusively caused by the Delta variant, the estimated protection following a recent first infection was 91.3% (95%CI: 89.7-92.7%) compared to 71.4% (95%CI: 66.9-75.3%) after a first infection over a year earlier. With Omicron, a first infection with an earlier variant in the past 3-6 months gave an estimated 51.0% (95%CI: 50.1-52.0%) protection, whereas a first infection longer than 12 months earlier provided only 19.0% (95%CI: 17.2-20.5%) protection. Protection by an earlier variant-infection against hospitalisation due to a new infection was estimated at: 86.6% (95%CI: 46.3-96.7%) for Alpha, 97.2% (95%CI: 89.0-99.3%) for Delta, and 69.8% (95%CI: 51.5-81.2%) for the Omicron variant. INTERPRETATION: SARS-CoV-2 infection offered a high level of sustained protection against reinfection, comparable with that offered by vaccines, but decreased with the introduction of new main virus variants; dramatically so when Omicron appeared. Protection was lower among the elderly but appeared more pronounced following symptomatic compared to asymptomatic infections. The level of estimated protection against serious disease was somewhat higher than that against infection and possibly longer lasting. Decreases in protection against reinfection, seemed primarily to be driven by viral evolution. FUNDING: None. CI - (c) 2022 The Authors. FAU - Michlmayr, Daniela AU - Michlmayr D AD - Department of Bacteria, Parasites and Fungi, Statens Serum Institut, 5 Artillerivej, 2300 Copenhagen S, Denmark. AD - European Programme for Public Health Microbiology Training (EUPHEM), European Centre for Disease Prevention and Control (ECDC), Gustav III:s Boulevard 40, 16973 Solna, Sweden. FAU - Hansen, Christian Holm AU - Hansen CH AD - Department of Infectious Disease Epidemiology and Prevention, Statens Serum Institut, 5 Artillerivej, 2300 Copenhagen S, Denmark. AD - MRC International Statistics and Epidemiology Group, Department of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK. FAU - Gubbels, Sophie Madeleine AU - Gubbels SM AD - Division of Infectious Disease Preparedness, Statens Serum Institut, 5 Artillerivej, 2300 Copenhagen S, Denmark. FAU - Valentiner-Branth, Palle AU - Valentiner-Branth P AD - Department of Infectious Disease Epidemiology and Prevention, Statens Serum Institut, 5 Artillerivej, 2300 Copenhagen S, Denmark. FAU - Bager, Peter AU - Bager P AD - Division of Infectious Disease Preparedness, Statens Serum Institut, 5 Artillerivej, 2300 Copenhagen S, Denmark. FAU - Obel, Niels AU - Obel N AD - Department of Infectious Disease Epidemiology and Prevention, Statens Serum Institut, 5 Artillerivej, 2300 Copenhagen S, Denmark. AD - Department of Infectious Diseases, Rigshospitalet, Copenhagen, Denmark. FAU - Drewes, Birgitte AU - Drewes B AD - Danish Patient Safety Authority, Copenhagen, Denmark. FAU - Moller, Camilla Holten AU - Moller CH AD - Division of Infectious Disease Preparedness, Statens Serum Institut, 5 Artillerivej, 2300 Copenhagen S, Denmark. FAU - Moller, Frederik Trier AU - Moller FT AD - Department of Infectious Disease Epidemiology and Prevention, Statens Serum Institut, 5 Artillerivej, 2300 Copenhagen S, Denmark. FAU - Legarth, Rebecca AU - Legarth R AD - Division of Infectious Disease Preparedness, Statens Serum Institut, 5 Artillerivej, 2300 Copenhagen S, Denmark. FAU - Molbak, Kare AU - Molbak K AD - Division of Infectious Disease Preparedness, Statens Serum Institut, 5 Artillerivej, 2300 Copenhagen S, Denmark. AD - Department of Veterinary and Animal Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Gronnegardsvej 15, 1870 Frederiksberg C, Denmark. FAU - Ethelberg, Steen AU - Ethelberg S AD - Department of Infectious Disease Epidemiology and Prevention, Statens Serum Institut, 5 Artillerivej, 2300 Copenhagen S, Denmark. AD - Department of Public Health, Global Health Section, University of Copenhagen, Oster Farimagsgade 5, 1014 Kobenhavn K, Denmark. LA - eng GR - MR/R010161/1/MRC_/Medical Research Council/United Kingdom PT - Journal Article DEP - 20220630 PL - England TA - Lancet Reg Health Eur JT - The Lancet regional health. Europe JID - 101777707 PMC - PMC9245510 OTO - NOTNLM OT - COVID-19 OT - Cohort studies OT - Epidemic OT - Herd immunity OT - Immunity OT - Reinfection OT - SARS-CoV-2 variants COIS- All authors declare no competing interests. EDAT- 2022/07/07 06:00 MHDA- 2022/07/07 06:01 PMCR- 2022/06/30 CRDT- 2022/07/06 01:53 PHST- 2022/07/06 01:53 [entrez] PHST- 2022/07/07 06:00 [pubmed] PHST- 2022/07/07 06:01 [medline] PHST- 2022/06/30 00:00 [pmc-release] AID - S2666-7762(22)00146-6 [pii] AID - 100452 [pii] AID - 10.1016/j.lanepe.2022.100452 [doi] PST - ppublish SO - Lancet Reg Health Eur. 2022 Sep;20:100452. doi: 10.1016/j.lanepe.2022.100452. Epub 2022 Jun 30. PMID- 35787706 OWN - NLM STAT- MEDLINE DCOM- 20231023 LR - 20260921 IS - 1757-9147 (Electronic) IS - 1757-9139 (Print) IS - 1757-9147 (Linking) VI - 143 IP - 5 DP - 2023 Sep TI - Mental health and wellbeing among people with informal caring responsibilities across different time points during the COVID-19 pandemic: a population-based propensity score matching analysis. PG - 275-284 LID - 10.1177/17579139221104973 [doi] AB - AIMS: Due to a prolonged period of national and regional lockdown measures during the coronavirus (COVID-19) pandemic, there has been an increase reliance on informal care for informal carers. In light of this, the current study compared the experiences of carers and non-carers on various mental health and wellbeing measures across six key time points during the pandemic. METHODS: Data analysed were from the University College London (UCL) COVID -19 Social Study. Our study focused on six time points in England: (1) the first national lockdown (March-April 2020); (2) the beginning of first lockdown rules easing (May 2020); (3) the second national lockdown (November 2020); (4) the third national lockdown (January 2021); (5) the easing of the third lockdown (March 2021); and (6) the end of restrictions (July-August 2021). We considered five mental health and wellbeing measures: depressive symptoms, anxiety symptoms, loneliness, life satisfaction, and sense of being worthwhile. Propensity score matching was applied for the analyses. RESULTS: We found that informal carers experienced higher levels of depressive and anxiety symptoms than non-carers across much of the pandemic. During the first national lockdown, carers also experienced a higher sense of life being worthwhile. No association was found between informal caring responsibilities and levels of loneliness and life satisfaction. CONCLUSION: Given that carers are an essential national healthcare support, especially during a pandemic, it is crucial to integrate carers' needs into healthcare planning and delivery. These results highlight that there is a pressing need to provide adequate and targeted mental health support for carers during and following this pandemic. FAU - Mak, Hei Wan AU - Mak HW AUID- ORCID: 0000-0002-2013-1644 AD - Department of Behavioural Science and Health, University College London, London, UK. FAU - Bu, Feifei AU - Bu F AUID- ORCID: 0000-0003-2060-3768 AD - Department of Behavioural Science and Health, University College London, London, UK. FAU - Fancourt, Daisy AU - Fancourt D AD - Department of Behavioural Science and Health, University College London, 1-19 Torrington Place, London WC1E 7HB, UK. LA - eng GR - 205407/Z/16/Z/WT_/Wellcome Trust/United Kingdom PT - Journal Article PT - Review DEP - 20220705 PL - United States TA - Perspect Public Health JT - Perspectives in public health JID - 101499631 SB - IM MH - Humans MH - *Mental Health MH - *COVID-19/epidemiology MH - Pandemics MH - Propensity Score MH - Communicable Disease Control MH - Caregivers/psychology PMC - PMC10576404 OTO - NOTNLM OT - COVID-19 OT - informal carers OT - mental health OT - mental wellbeing COIS- Conflict Of InterestThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. EDAT- 2022/07/06 06:00 MHDA- 2023/10/23 00:42 PMCR- 2023/10/14 CRDT- 2022/07/05 17:46 PHST- 2023/10/23 00:42 [medline] PHST- 2022/07/06 06:00 [pubmed] PHST- 2022/07/05 17:46 [entrez] PHST- 2023/10/14 00:00 [pmc-release] AID - 10.1177_17579139221104973 [pii] AID - 10.1177/17579139221104973 [doi] PST - ppublish SO - Perspect Public Health. 2023 Sep;143(5):275-284. doi: 10.1177/17579139221104973. Epub 2022 Jul 5. PMID- 35774562 OWN - NLM STAT- MEDLINE DCOM- 20220704 LR - 20240903 IS - 2296-2565 (Electronic) IS - 2296-2565 (Linking) VI - 10 DP - 2022 TI - COVID-19 Preventive Measures in Northern California Jails: Perceived Deficiencies, Barriers, and Unintended Harms. PG - 854343 LID - 10.3389/fpubh.2022.854343 [doi] LID - 854343 AB - BACKGROUND: Carceral facilities are high-risk settings for COVID-19 transmission. Little is known about the hidden burden of infection or practical barriers to infection control in these settings, especially in jails. There is also limited research on the mental health impacts of the pandemic among people living and working in carceral facilities. METHODS: Between July 8, 2020 and April 30, 2021, we performed SARS-CoV-2 rapid antibody testing and administered a questionnaire among residents and staff of four Northern California jails. We utilized multivariable logistic regression, adjusting for demographic and carceral characteristics, to analyze factors associated with prior infection, including perceived likelihood of prior infection and access to new masks. We additionally assessed the implementation of, perceptions toward, and impacts of COVID-19 policies in practice. We engaged stakeholder representatives, including incarcerated individuals, to guide study design, procedures, and results interpretation. RESULTS: We enrolled 788 jail residents and 380 jail staff. Nearly half of residents and two-thirds of staff who were antibody-positive had not previously tested positive for COVID-19. Among residents without a prior COVID-19 diagnosis, antibody positivity was significantly associated with perceived likelihood of prior infection (adjusted OR = 8.9; 95% CI, 3.6-22.0). Residents who had flu-like illness in jail cited inadequate responses to reported illness and deterrents to symptom reporting, including fears of medical isolation and perceptions of medical neglect. Residents also disclosed deficient access to face masks, which was associated with antibody positivity (adjusted OR = 13.8, 95% CI, 1.8-107.0). Worsened mental health was pervasive among residents, attributed not only to fear of COVID-19 and unsanitary jail conditions but also to intensified isolation and deprivation due to pandemic restrictions on in-person visitation, programs, and recreation time. CONCLUSION: Carceral settings present significant challenges to maintaining infection control and human rights. Custody officials should work diligently to transform the conditions of medical isolation, which could mitigate deterrents to symptom reporting. Furthermore, they should minimize use of restrictive measures like lockdowns and suspension of visitation that exacerbate the mental health harms of incarceration. Instead, custody officials should ensure comprehensive implementation of other preventive strategies like masking, testing, and vaccination, in conjunction with multisector efforts to advance decarceration. CI - Copyright (c) 2022 Liu, LeBoa, Rodriguez, Sherif, Trinidad, del Rosario, Allen, Clifford, Redding, Chen, Rosas, Morales, Chyorny and Andrews. FAU - Liu, Yiran E AU - Liu YE AD - Division of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford, CA, United States. AD - Cancer Biology Graduate Program, Stanford University School of Medicine, Stanford, CA, United States. FAU - LeBoa, Christopher AU - LeBoa C AD - Division of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford, CA, United States. FAU - Rodriguez, Marcela AU - Rodriguez M AD - Stanford Center for Clinical Research, Stanford University School of Medicine, Stanford, CA, United States. FAU - Sherif, Beruk AU - Sherif B AD - Stanford Center for Clinical Research, Stanford University School of Medicine, Stanford, CA, United States. FAU - Trinidad, Chrisele AU - Trinidad C AD - Stanford Center for Clinical Research, Stanford University School of Medicine, Stanford, CA, United States. FAU - Del Rosario, Michael AU - Del Rosario M AD - Division of Correctional Health Services, San Mateo County Health, Redwood City, CA, United States. FAU - Allen, Sophie AU - Allen S AD - Stanford Law School, Stanford, CA, United States. AD - Department of Sociology, Stanford School of Humanities and Sciences, Stanford, CA, United States. FAU - Clifford, Christine AU - Clifford C AD - Silicon Valley De-Bug, San Jose, CA, United States. FAU - Redding, Jennifer AU - Redding J AD - Santa Clara County Office of the Public Defender, San Jose, CA, United States. FAU - Chen, Wei-Ting AU - Chen WT AD - Office of Community Engagement, Stanford University School of Medicine, Stanford, CA, United States. FAU - Rosas, Lisa G AU - Rosas LG AD - Office of Community Engagement, Stanford University School of Medicine, Stanford, CA, United States. FAU - Morales, Carlos AU - Morales C AD - Division of Correctional Health Services, San Mateo County Health, Redwood City, CA, United States. FAU - Chyorny, Alexander AU - Chyorny A AD - Division of Custody Health, Department of Medicine, Santa Clara Valley Health and Hospital System, San Jose, CA, United States. FAU - Andrews, Jason R AU - Andrews JR AD - Division of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford, CA, United States. LA - eng GR - UL1 TR003142/TR/NCATS NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20220614 PL - Switzerland TA - Front Public Health JT - Frontiers in public health JID - 101616579 RN - 0 (Antibodies, Viral) SB - IM EIN - Front Public Health. 2022 Aug 16;10:1002199. doi: 10.3389/fpubh.2022.1002199. PMID: 36052012 MH - Antibodies, Viral MH - *COVID-19/epidemiology/prevention & control MH - COVID-19 Testing MH - Humans MH - Infection Control MH - Jails MH - SARS-CoV-2 PMC - PMC9237366 OTO - NOTNLM OT - COVID-19 OT - community-based research OT - incarceration OT - infection control OT - jails OT - mental health OT - seroprevalence OT - stakeholder engagement COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2022/07/02 06:00 MHDA- 2022/07/06 06:00 PMCR- 2022/06/14 CRDT- 2022/07/01 02:38 PHST- 2022/01/13 00:00 [received] PHST- 2022/05/16 00:00 [accepted] PHST- 2022/07/01 02:38 [entrez] PHST- 2022/07/02 06:00 [pubmed] PHST- 2022/07/06 06:00 [medline] PHST- 2022/06/14 00:00 [pmc-release] AID - 10.3389/fpubh.2022.854343 [doi] PST - epublish SO - Front Public Health. 2022 Jun 14;10:854343. doi: 10.3389/fpubh.2022.854343. eCollection 2022. PMID- 35772295 OWN - NLM STAT- MEDLINE DCOM- 20220919 LR - 20230120 IS - 1878-0067 (Electronic) IS - 1755-4365 (Print) IS - 1878-0067 (Linking) VI - 40 DP - 2022 Sep TI - Investigating the relationship between interventions, contact patterns, and SARS-CoV-2 transmissibility. PG - 100601 LID - S1755-4365(22)00046-9 [pii] LID - 10.1016/j.epidem.2022.100601 [doi] AB - BACKGROUND: After a rapid upsurge of COVID-19 cases in Italy during the fall of 2020, the government introduced a three-tiered restriction system aimed at increasing physical distancing. The Ministry of Health, after periodic epidemiological risk assessments, assigned a tier to each of the 21 Italian regions and autonomous provinces. It is still unclear to what extent these different sets of measures altered the number of daily interactions and the social mixing patterns. METHODS AND FINDINGS: We conducted a survey between July 2020 and March 2021 to monitor changes in social contact patterns among individuals in the metropolitan city of Milan, Italy, which was hardly hit by the second wave of the COVID-19 pandemic. The number of daily contacts during periods characterized by different levels of restrictions was analyzed through negative binomial regression models and age-specific contact matrices were estimated under the different tiers of restrictions. By relying on the empirically estimated mixing patterns, we quantified relative changes in SARS-CoV-2 transmission potential associated with the different tiers. As tighter restrictions were implemented during the fall of 2020, a progressive reduction in the mean number of daily contacts recorded by study participants was observed: from 15.9 % under mild restrictions (yellow tier), to 41.8 % under strong restrictions (red tier). Higher restrictions levels were also found to increase the relative contribution of contacts occurring within the household. The SARS-CoV-2 reproduction number was estimated to decrease by 17.1 % (95 %CI: 1.5-30.1), 25.1 % (95 %CI: 13.0-36.0) and 44.7 % (95 %CI: 33.9-53.0) under the yellow, orange, and red tiers, respectively. CONCLUSIONS: Our results give an important quantification of the expected contribution of different restriction levels in shaping social contacts and decreasing the transmission potential of SARS-CoV-2. These estimates can find an operational use in anticipating the effect that the implementation of these tiered restriction can have on SARS-CoV-2 reproduction number under an evolving epidemiological situation. CI - Copyright (c) 2022 The Authors. Published by Elsevier B.V. All rights reserved. FAU - Trentini, Filippo AU - Trentini F AD - Dondena Centre for Research on Social Dynamics and Public Policy, Bocconi University, Milan, Italy; Covid Crisis Lab, Bocconi University, Italy; Center for Health Emergencies, Bruno Kessler Foundation, Trento, Italy. Electronic address: filippo.trentini@unibocconi.it. FAU - Manna, Adriana AU - Manna A AD - Dondena Centre for Research on Social Dynamics and Public Policy, Bocconi University, Milan, Italy; Department of Network and Data Science, Central European University, Wien, Austria. FAU - Balbo, Nicoletta AU - Balbo N AD - Dondena Centre for Research on Social Dynamics and Public Policy, Bocconi University, Milan, Italy; Department of Social and Political Sciences, Bocconi University, Milan, Italy. FAU - Marziano, Valentina AU - Marziano V AD - Center for Health Emergencies, Bruno Kessler Foundation, Trento, Italy. FAU - Guzzetta, Giorgio AU - Guzzetta G AD - Center for Health Emergencies, Bruno Kessler Foundation, Trento, Italy. FAU - O'Dell, Samantha AU - O'Dell S AD - Laboratory for Computational Epidemiology and Public Health, Department of Epidemiology and Biostatistics, Indiana University School of Public Health, Bloomington, IN, USA. FAU - Kummer, Allisandra G AU - Kummer AG AD - Laboratory for Computational Epidemiology and Public Health, Department of Epidemiology and Biostatistics, Indiana University School of Public Health, Bloomington, IN, USA. FAU - Litvinova, Maria AU - Litvinova M AD - Laboratory for Computational Epidemiology and Public Health, Department of Epidemiology and Biostatistics, Indiana University School of Public Health, Bloomington, IN, USA. FAU - Merler, Stefano AU - Merler S AD - Center for Health Emergencies, Bruno Kessler Foundation, Trento, Italy. FAU - Ajelli, Marco AU - Ajelli M AD - Laboratory for Computational Epidemiology and Public Health, Department of Epidemiology and Biostatistics, Indiana University School of Public Health, Bloomington, IN, USA. FAU - Poletti, Piero AU - Poletti P AD - Center for Health Emergencies, Bruno Kessler Foundation, Trento, Italy. FAU - Melegaro, Alessia AU - Melegaro A AD - Dondena Centre for Research on Social Dynamics and Public Policy, Bocconi University, Milan, Italy; Covid Crisis Lab, Bocconi University, Italy; Department of Social and Political Sciences, Bocconi University, Milan, Italy. Electronic address: alessia.melegaro@unibocconi.it. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20220617 PL - Netherlands TA - Epidemics JT - Epidemics JID - 101484711 SB - IM MH - *COVID-19/epidemiology MH - Family Characteristics MH - Humans MH - Pandemics MH - *SARS-CoV-2 MH - Surveys and Questionnaires PMC - PMC9212945 OTO - NOTNLM OT - COVID-19 OT - Human behavior OT - Mixing patterns OT - Non-pharmaceutical interventions OT - Reproduction number OT - SARS-CoV-2 OT - Social contacts OT - Tiers OT - Transmissibility COIS- Competing interests M.A. has received research funding from Seqirus. The funding is not related to COVID-19 and to this study. The contents of this publication are the sole responsibility of the authors and don't necessarily reflect the views of the funders. All other authors declare no competing interest. EDAT- 2022/07/01 06:00 MHDA- 2022/09/20 06:00 PMCR- 2022/06/17 CRDT- 2022/06/30 18:21 PHST- 2022/01/12 00:00 [received] PHST- 2022/06/10 00:00 [revised] PHST- 2022/06/14 00:00 [accepted] PHST- 2022/07/01 06:00 [pubmed] PHST- 2022/09/20 06:00 [medline] PHST- 2022/06/30 18:21 [entrez] PHST- 2022/06/17 00:00 [pmc-release] AID - S1755-4365(22)00046-9 [pii] AID - 100601 [pii] AID - 10.1016/j.epidem.2022.100601 [doi] PST - ppublish SO - Epidemics. 2022 Sep;40:100601. doi: 10.1016/j.epidem.2022.100601. Epub 2022 Jun 17. PMID- 35759292 OWN - NLM STAT- MEDLINE DCOM- 20220629 LR - 20260127 IS - 1365-2346 (Electronic) IS - 0265-0215 (Linking) VI - 39 IP - 7 DP - 2022 Jul 1 TI - Single-injection regional analgesia techniques for mastectomy surgery: A network meta-analysis. PG - 591-601 LID - 10.1097/EJA.0000000000001644 [doi] AB - BACKGROUND: Patients undergoing mastectomy surgery experience severe postoperative pain. Several regional techniques have been developed to reduce pain intensity but it is unclear, which of these techniques is most effective. OBJECTIVES: To synthesise direct and indirect comparisons for the relative efficacy of different regional and local analgesia techniques in the setting of unilateral mastectomy. Postoperative opioid consumption at 24 h, postoperative pain at extubation, 1, 12 and 24 h, postoperative nausea and vomiting were collected. DESIGN: Systematic review with network meta-analysis (PROSPERO:CRD42021250651). DATA SOURCE: PubMed, Scopus, the Cochrane Central Register of Controlled Trials (from inception until 7 July 2021). ELIGIBILITY CRITERIA: All randomised controlled trials investigating single-injection regional and local analgesia techniques in adult patients undergoing unilateral mastectomy were included in our study without any language or publication date restriction. RESULTS: Sixty-two included studies randomising 4074 patients and investigating nine techniques entered the analysis. All techniques were associated with less opioid consumption compared with controls The greatest mean difference [95% confidence interval (CI)] was associated with deep serratus anterior plane block: mean difference -16.1 mg (95% CI, -20.7 to -11.6). The greatest reduction in pain score was associated with the interpectoral-pecto-serratus plane block (mean difference -1.3, 95% CI, -1.6 to - 1) at 12 h postoperatively, and with superficial serratus anterior plane block (mean difference -1.4, 95% CI, -2.4 to -0.5) at 24 h. Interpectoral-pectoserratus plane block resulted in the greatest statistically significant reduction in postoperative nausea/vomiting when compared with placebo/no intervention with an OR of 0.23 (95% CI, 0.13 to 0.40). CONCLUSION: All techniques were associated with superior analgesia and less opioid consumption compared with controls. No single technique was identified as superior to others. In comparison, local anaesthetic infiltration does not offer advantages over multimodal analgesia alone. TRIAL REGISTRATION: PROSPERO (CRD4202125065). CI - Copyright (c) 2021 European Society of Anaesthesiology and Intensive Care. Unauthorized reproduction of this article is prohibited. FAU - De Cassai, Alessandro AU - De Cassai A AD - From the UOC Anesthesia and Intensive Care Unit, University Hospital of Padua (ADC, FZ, FG, AB, LP, TP, PN), UOC Anesthesia and Intensive Care Unit, Department of Medicine-DIMED, University of Padua, Padua, Italy (SDP, GL, FB, LD, NS, PN), Department of Anesthesiology, Perioperative and Pain Medicine, Stanford University School of Medicine, Stanford (ERM) and Anesthesiology and Perioperative Care Service, Veterans Affairs Palo Alto Healthcare System, Palo Alto, California, USA (ERM). FAU - Zarantonello, Francesco AU - Zarantonello F FAU - Geraldini, Federico AU - Geraldini F FAU - Boscolo, Annalisa AU - Boscolo A FAU - Pasin, Laura AU - Pasin L FAU - De Pinto, Silvia AU - De Pinto S FAU - Leardini, Giovanni AU - Leardini G FAU - Basile, Francesca AU - Basile F FAU - Disaro, Laura AU - Disaro L FAU - Sella, Nicolo AU - Sella N FAU - Mariano, Edward R AU - Mariano ER FAU - Pettenuzzo, Tommaso AU - Pettenuzzo T FAU - Navalesi, Paolo AU - Navalesi P LA - eng PT - Journal Article PT - Network Meta-Analysis PT - Systematic Review DEP - 20211207 PL - England TA - Eur J Anaesthesiol JT - European journal of anaesthesiology JID - 8411711 RN - 0 (Analgesics, Opioid) RN - 0 (Anesthetics, Local) SB - IM CIN - Eur J Anaesthesiol. 2023 Sep 1;40(9):709. doi: 10.1097/EJA.0000000000001766. PMID: 37530715 MH - Adult MH - *Analgesia/methods MH - Analgesics, Opioid MH - Anesthetics, Local MH - *Breast Neoplasms MH - Female MH - Humans MH - Mastectomy/adverse effects MH - Postoperative Pain/diagnosis/etiology/prevention & control MH - Postoperative Nausea and Vomiting/epidemiology/etiology/prevention & control MH - Randomized Controlled Trials as Topic EDAT- 2022/06/28 06:00 MHDA- 2022/06/30 06:00 CRDT- 2022/06/27 11:43 PHST- 2022/06/27 11:43 [entrez] PHST- 2022/06/28 06:00 [pubmed] PHST- 2022/06/30 06:00 [medline] AID - 00003643-202207000-00004 [pii] AID - 10.1097/EJA.0000000000001644 [doi] PST - ppublish SO - Eur J Anaesthesiol. 2022 Jul 1;39(7):591-601. doi: 10.1097/EJA.0000000000001644. Epub 2021 Dec 7. PMID- 35752784 OWN - NLM STAT- MEDLINE DCOM- 20220628 LR - 20220716 IS - 1472-6963 (Electronic) IS - 1472-6963 (Linking) VI - 22 IP - 1 DP - 2022 Jun 25 TI - Quality of life among health care workers with and without prior COVID-19 infection in Bangladesh. PG - 823 LID - 10.1186/s12913-022-08174-0 [doi] LID - 823 AB - BACKGROUND: Health care workers have been facing difficulties in coping with the COVID-19 infection from the beginning. The study aimed to compare Quality of Life (QOL) among health care workers (HCWs) with and without prior COVID-19 disease. METHODS: This study was conducted from July 2020 to January 2021 among 444 HCWs. We randomly interviewed 3244 participants for our earlier nationwide survey from a list of COVID-19 positive cases after their recovery, and we found 222 HCWs among the respondents. We randomly chose 222 HCWs unaffected by COVID as a comparison group from our selected hospitals. We measured QOL using World Health Organization's WHOQOL-BREF tool. Physical, psychological, environmental, and social ties were the four areas assessed on a 5-point Likert scale where a higher score suggests better QOL. Due to pandemic restrictions, we used telephonic interviews for data collection. RESULTS: A higher QOL score was observed in HCWs with prior COVID-19 infection in all four domains than HCWs without previous COVID-19 conditions. Comorbidity was negatively associated with QOL scores of the physical (p = 0.001) and (p < 0.001) and psychological (p = 0.05, and (p < 0.05) domains for non-COVID and COVID-affected groups, respectively. Current smoking was significantly associated with lower psychological (p = 0.019) and environmental (p = 0.007) QOL scores among HCWs with prior COVID-19 infection. Hospitalization history due to COVID infection was a contributing factor for lower physical QOL scores (p = 0.048). Environmental (p = 0.016) QOL scores were significantly associated with the monthly income in the prior COVID-19 infection group, and physical scores were significantly associated (p = 0.05) with a monthly income in the non-COVID group. CONCLUSION: Governmental and non-governmental stakeholders should focus on potentially modifiable factors to improve health care workers' quality of life. CI - (c) 2022. The Author(s). FAU - Rahman, Mahfil Ara AU - Rahman MA AD - Department of Public Health, North South University, Dhaka, 1229, Bangladesh. AD - Department of Reproductive and Child Health, Centre for Injury Prevention & Research Bangladesh, Mohakhali, Dhaka, 1206, Bangladesh. FAU - Sagar, Soumik Kha AU - Sagar SK AD - Nutrition and Clinical Services Division (NCSD), International Centre for Diarrheal Disease Research (icddr,b), Mohakhali, Dhaka, 1212, Bangladesh. FAU - Dalal, Koustuv AU - Dalal K AUID- ORCID: 0000-0001-7393-796X AD - Division of Public Health Science, School of Health Sciences, Mid Sweden University, Sundsvall, Sweden. Koustuv.dalal@miun.se. FAU - Barsha, Sabrina Yesmin AU - Barsha SY AD - Ibn Sina Medical College Hospital, Kallyanpur, Dhaka, 1216, Bangladesh. FAU - Ara, Tasnim AU - Ara T AD - Institute of Statistical Research and Training (ISRT), University of Dhaka, Dhaka, 1000, Bangladesh. FAU - Khan, Md Abdullah Saeed AU - Khan MAS AD - Department of Public Health, North South University, Dhaka, 1229, Bangladesh. AD - Infectious Disease Hospital, Mohakhali, Dhaka, 1212, Bangladesh. FAU - Saha, Shuvajit AU - Saha S AD - Department of Maternal and Child Health, Projahnmo Research Foundation, Dhaka, Bangladesh. FAU - Sarmin, Tanjina AU - Sarmin T AD - National Institute of Preventive and Social Medicine (NIPSOM), Mohakhali, Dhaka, 1212, Bangladesh. FAU - Hossian, Mosharop AU - Hossian M AD - Department of Epidemiology, Public Health Professional Development Society (PPDS), Dhaka, 1205, Bangladesh. FAU - Nabi, Mohammad Hayatun AU - Nabi MH AD - Department of Public Health, North South University, Dhaka, 1229, Bangladesh. FAU - Rahman, Mohammad Lutfor AU - Rahman ML AD - Institute of Statistical Research and Training (ISRT), University of Dhaka, Dhaka, 1000, Bangladesh. FAU - Hawlader, Mohammad Delwer Hossain AU - Hawlader MDH AD - Department of Public Health, North South University, Dhaka, 1229, Bangladesh. LA - eng PT - Journal Article DEP - 20220625 PL - England TA - BMC Health Serv Res JT - BMC health services research JID - 101088677 SB - IM MH - Bangladesh/epidemiology MH - *COVID-19/epidemiology MH - Health Personnel/psychology MH - Humans MH - Pandemics MH - Quality of Life PMC - PMC9233781 OTO - NOTNLM OT - Bangladesh OT - COVID-19 OT - Health care workers (HCWs) OT - Quality of life (QOL) COIS- Declared none. EDAT- 2022/06/26 06:00 MHDA- 2022/06/29 06:00 PMCR- 2022/06/25 CRDT- 2022/06/25 23:29 PHST- 2021/11/11 00:00 [received] PHST- 2022/06/10 00:00 [accepted] PHST- 2022/06/25 23:29 [entrez] PHST- 2022/06/26 06:00 [pubmed] PHST- 2022/06/29 06:00 [medline] PHST- 2022/06/25 00:00 [pmc-release] AID - 10.1186/s12913-022-08174-0 [pii] AID - 8174 [pii] AID - 10.1186/s12913-022-08174-0 [doi] PST - epublish SO - BMC Health Serv Res. 2022 Jun 25;22(1):823. doi: 10.1186/s12913-022-08174-0. PMID- 35722739 OWN - NLM STAT- MEDLINE DCOM- 20220913 LR - 20250728 IS - 1365-2893 (Electronic) IS - 1352-0504 (Print) IS - 1352-0504 (Linking) VI - 29 IP - 10 DP - 2022 Oct TI - Impact of COVID-19 lockdown restrictions on hepatitis C testing in Australian primary care services providing care for people who inject drugs. PG - 908-918 LID - 10.1111/jvh.13723 [doi] AB - In 2020, the Australian state of Victoria experienced the longest COVID-19 lockdowns of any jurisdiction, with two lockdowns starting in March and July, respectively. Lockdowns may impact progress towards eliminating hepatitis C through reductions in hepatitis C testing. To examine the impact of lockdowns on hepatitis C testing in Victoria, de-identified data were extracted from a network of 11 services that specialize in the care of people who inject drugs (PWID). Interrupted time-series analyses estimated weekly changes in hepatitis C antibody and RNA testing from 1 January 2019 to 14 May 2021 and described temporal changes in testing associated with lockdowns. Interruptions were defined at the weeks corresponding to the start of the first lockdown (week 14) and the start (week 80) and end (week 95) of the second lockdown. Pre-COVID, an average of 80.6 antibody and 25.7 RNA tests were performed each week. Following the first lockdown in Victoria, there was an immediate drop of 23.2 antibody tests and 8.6 RNA tests per week (equivalent to a 31% and 46% drop, respectively). Following the second lockdown, there was an immediate drop of 17.2 antibody tests and 4.6 RNA tests per week (equivalent to a 26% and 33% drop, respectively). With testing and case finding identified as a key challenge to Australia achieving hepatitis C elimination targets, the cumulative number of testing opportunities missed during lockdowns may prolong efforts to find, diagnose and engage or reengage in care of the remaining population of PWID living with hepatitis C. CI - (c) 2022 The Authors. Journal of Viral Hepatitis published by John Wiley & Sons Ltd. FAU - Traeger, Michael W AU - Traeger MW AUID- ORCID: 0000-0002-3452-350X AD - Burnet Institute, Melbourne, Victoria, Australia. AD - School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia. FAU - van Santen, Daniela K AU - van Santen DK AUID- ORCID: 0000-0002-9890-4694 AD - Burnet Institute, Melbourne, Victoria, Australia. AD - School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia. AD - Department of Infectious Disease, Research and Prevention, Public Health Service of Amsterdam, Amsterdam, the Netherlands. FAU - Sacks-Davis, Rachel AU - Sacks-Davis R AD - Burnet Institute, Melbourne, Victoria, Australia. AD - School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia. FAU - Asselin, Jason AU - Asselin J AD - Burnet Institute, Melbourne, Victoria, Australia. FAU - Carter, Allison AU - Carter A AD - Kirby Institute, UNSW Sydney, Sydney, New South Wales, Australia. AD - Faculty of Health Sciences, Simon Fraser University, Vancouver, British Columbia, Canada. AD - Australian Human Rights Institute, UNSW Sydney, Sydney, New South Wales, Australia. FAU - Doyle, Joseph S AU - Doyle JS AD - Burnet Institute, Melbourne, Victoria, Australia. AD - Department of Infectious Diseases, The Alfred and Monash University, Melbourne, Victoria, Australia. FAU - Pedrana, Alisa AU - Pedrana A AD - Burnet Institute, Melbourne, Victoria, Australia. AD - School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia. FAU - Wilkinson, Anna L AU - Wilkinson AL AUID- ORCID: 0000-0002-4475-5224 AD - Burnet Institute, Melbourne, Victoria, Australia. AD - School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia. FAU - Howell, Jessica AU - Howell J AD - Burnet Institute, Melbourne, Victoria, Australia. AD - Department of Gastroenterology, St Vincent's Hospital, Melbourne, Victoria, Australia. AD - Department of Medicine, University of Melbourne, Melbourne, Victoria, Australia. FAU - Thatcher, Rebecca AU - Thatcher R AD - Access Health, Melbourne, Victoria, Australia. FAU - Didlick, John AU - Didlick J AD - Hepatitis Australia, Canberra, Australian Capital Territory, Australia. FAU - Donovan, Basil AU - Donovan B AD - Kirby Institute, UNSW Sydney, Sydney, New South Wales, Australia. AD - Sydney Sexual Health Centre, Sydney, New South Wales, Australia. FAU - Guy, Rebecca AU - Guy R AD - Kirby Institute, UNSW Sydney, Sydney, New South Wales, Australia. FAU - Hellard, Margaret E AU - Hellard ME AUID- ORCID: 0000-0002-5055-3266 AD - Burnet Institute, Melbourne, Victoria, Australia. AD - Department of Infectious Diseases, The Alfred and Monash University, Melbourne, Victoria, Australia. AD - Peter Doherty Institute, Melbourne, Victoria, Australia. FAU - Stoove, Mark A AU - Stoove MA AD - Burnet Institute, Melbourne, Victoria, Australia. AD - School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia. CN - Australia Collaboration for Coordinated Enhanced Sentinel Surveillance of Sexually Transmissible Infections and Blood Borne Viruses (ACCESS) LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20220705 PL - England TA - J Viral Hepat JT - Journal of viral hepatitis JID - 9435672 RN - 63231-63-0 (RNA) SB - IM MH - Australia/epidemiology MH - *COVID-19/epidemiology/prevention & control MH - Communicable Disease Control MH - *Drug Users MH - Hepacivirus/genetics MH - *Hepatitis C/diagnosis/epidemiology/prevention & control MH - Humans MH - Primary Health Care MH - RNA MH - *Substance Abuse, Intravenous/complications PMC - PMC9350356 OTO - NOTNLM OT - COVID-19 OT - hepatitis C OT - lockdowns OT - people who inject drugs COIS- MWT has received speaker's fees and investigator-initiated funding from Gilead Sciences. JSD declares payments to his institution for investigator-initiated research from AbbVie and Gilead and consultancies from AbbVie, Gilead and Merck. AP declares investigator-initiated research from AbbVie, Gilead, Merck and consultancies fees from Gilead. JH declares investigator-initiated funding from Gilead Sciences and Eisai and advisory board fees from Gilead Sciences. MEH received funding for investigator-initiated research from Gilead Sciences and Abbvie. All other authors declare no conflicts of interest. ACCESS is funded by the Australian Department of Health. EDAT- 2022/06/21 06:00 MHDA- 2022/09/14 06:00 PMCR- 2022/07/05 CRDT- 2022/06/20 04:16 PHST- 2022/03/31 00:00 [revised] PHST- 2021/11/19 00:00 [received] PHST- 2022/05/26 00:00 [accepted] PHST- 2022/06/21 06:00 [pubmed] PHST- 2022/09/14 06:00 [medline] PHST- 2022/06/20 04:16 [entrez] PHST- 2022/07/05 00:00 [pmc-release] AID - JVH13723 [pii] AID - 10.1111/jvh.13723 [doi] PST - ppublish SO - J Viral Hepat. 2022 Oct;29(10):908-918. doi: 10.1111/jvh.13723. Epub 2022 Jul 5. PMID- 35710243 OWN - NLM STAT- MEDLINE DCOM- 20220620 LR - 20220716 IS - 2044-6055 (Electronic) IS - 2044-6055 (Linking) VI - 12 IP - 6 DP - 2022 Jun 16 TI - COVID-19 vaccine hesitancy and vaccine passports: a cross-sectional conjoint experiment in Japan. PG - e060829 LID - 10.1136/bmjopen-2022-060829 [doi] LID - e060829 AB - OBJECTIVES: While the development of vaccines against the Novel Coronavirus (COVID-19) brought hope of establishing herd immunity and ending the global pandemic, vaccine hesitancy can hinder the progress towards herd immunity. In this study, by analysing the data collected when citizens undergo public health restrictions due to the pandemic, we assess the determinants of vaccine hesitancy, reasons for hesitation and potential effectiveness of vaccine passports used to relax public health restrictions on mitigating vaccine hesitancy. DESIGN: Cross-sectional study, longitudinal study and conjoint experimental design. SETTING: An online survey conducted in Japan in July 2021. PARTICIPANTS: A demographically representative sample of 5000 Japanese adults aged 20-74. PRIMARY OUTCOME MEASURES: COVID-19 vaccination intention RESULTS: We found that about 30% of respondents did not intend to get vaccinated or had not yet decided, with major reasons for vaccine hesitancy relating to concerns about the safety and side effects of the vaccine. In line with previous findings, younger age, lower socioeconomic status, and psychological and behavioural factors such as weaker COVID-19 fear were associated with vaccine hesitancy. Easing of public health restrictions such as travel, wearing face masks and dining out at night was associated with an increase in vaccine acceptance by 4%-10%. Moreover, we found that more than 90% of respondents who intended to get vaccinated actually received it while smaller proportions among those undecided and unwilling to get vaccinated did so. CONCLUSION: With a major concern about vaccine safety and side effects, interventions to mitigate against these may help to reduce vaccine hesitancy. Moreover, when citizens are imposed with restrictions, vaccine passports that increase their freedom may be helpful to increase vaccination rates. CI - (c) Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. FAU - Okamoto, Shohei AU - Okamoto S AUID- ORCID: 0000-0002-8580-5291 AD - Research Team for Social Participation and Community Health, Tokyo Metropolitan Institute of Gerontology, Itabashi-ku, Tokyo, Japan shohei@z2.keio.jp. AD - Institute for Global Health Policy Research, National Center for Global Health and Medicine, Shinjuku-ku, Tokyo, Japan. AD - Research Center for Financial Gerontology, Keio University, Minato-ku, Tokyo, Japan. FAU - Kamimura, Kazuki AU - Kamimura K AUID- ORCID: 0000-0002-4404-799X AD - Research Center for Financial Gerontology, Keio University, Minato-ku, Tokyo, Japan. AD - Hirao School of Management, Konan University, Nishinomiya, Hyogo, Japan. FAU - Komamura, Kohei AU - Komamura K AD - Research Center for Financial Gerontology, Keio University, Minato-ku, Tokyo, Japan. AD - Faculty of Economics, Keio University, Minato-ku, Tokyo, Japan. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20220616 PL - England TA - BMJ Open JT - BMJ open JID - 101552874 RN - 0 (COVID-19 Vaccines) RN - 0 (Vaccines) SB - IM MH - Adult MH - *COVID-19/epidemiology/prevention & control MH - COVID-19 Vaccines MH - Cross-Sectional Studies MH - Humans MH - Japan MH - Longitudinal Studies MH - Vaccination MH - Vaccination Hesitancy MH - *Vaccines PMC - PMC9207577 OTO - NOTNLM OT - COVID-19 OT - health economics OT - health policy OT - infection control OT - public health COIS- Competing interests: None declared. EDAT- 2022/06/17 06:00 MHDA- 2022/06/22 06:00 PMCR- 2022/06/16 CRDT- 2022/06/16 21:07 PHST- 2022/06/16 21:07 [entrez] PHST- 2022/06/17 06:00 [pubmed] PHST- 2022/06/22 06:00 [medline] PHST- 2022/06/16 00:00 [pmc-release] AID - bmjopen-2022-060829 [pii] AID - 10.1136/bmjopen-2022-060829 [doi] PST - epublish SO - BMJ Open. 2022 Jun 16;12(6):e060829. doi: 10.1136/bmjopen-2022-060829. PMID- 35699343 OWN - NLM STAT- MEDLINE DCOM- 20221205 LR - 20250623 IS - 1365-2982 (Electronic) IS - 1350-1925 (Print) IS - 1350-1925 (Linking) VI - 34 IP - 12 DP - 2022 Dec TI - Post-operative colonic manometry in children with anorectal malformations: A systematic review. PG - e14415 LID - 10.1111/nmo.14415 [doi] LID - e14415 AB - BACKGROUND: Children with anorectal malformations may experience constipation and fecal incontinence following repair. The contribution of altered anorectal function to these persistent symptoms is relatively intuitive; however, colonic motility in this cohort is less well understood. Manometry may be used to directly assess colonic motility. PURPOSE: The purpose of this systematic review was to synthesize the available evidence regarding post-operative colonic motility in children with anorectal malformations and evaluate the reported equipment and protocols used to perform colonic manometry in this cohort. This systematic review was conducted in compliance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). We conducted a systematic review of four databases: Embase, MEDLINE, PubMed, and the Cochrane Library (1(st) January 1985-22(nd) July 2021). Studies reporting colonic manometry performed in children following anorectal malformation repair were assessed for eligibility. Data were extracted independently by two authors. Four studies were eligible for inclusion. Of the combined total cohort of 151 children, post-operative colonic manometry was conducted in 35. Insufficient reporting of medical characteristics, bowel function, and manometric outcomes restricted comparison between studies, and limited clinical applicability. No results from high-resolution colonic manometry were identified. Despite the prevalence of post-operative bowel dysfunction in children with repaired anorectal malformations, this systematic review highlighted the markedly limited evidence regarding post-operative colonic motility. This cohort may benefit from assessment with high-resolution techniques; however, future work must emphasize adherence to standardized manometry protocols, and include robust reporting of surgical characteristics, bowel function, and manometric outcomes. CI - (c) 2022 The Authors. Neurogastroenterology & Motility published by John Wiley & Sons Ltd. FAU - Evans-Barns, Hannah M E AU - Evans-Barns HME AUID- ORCID: 0000-0003-0970-1746 AD - Department of Paediatric Surgery, The Royal Children's Hospital, Melbourne, Victoria, Australia. AD - Surgical Research Group, Murdoch Children's Research Institute, Melbourne, Victoria, Australia. AD - Department of Paediatrics, University of Melbourne, Melbourne, Victoria, Australia. FAU - Tien, Melissa Y AU - Tien MY AD - Department of Paediatrics, University of Melbourne, Melbourne, Victoria, Australia. FAU - Trajanovska, Misel AU - Trajanovska M AD - Department of Paediatric Surgery, The Royal Children's Hospital, Melbourne, Victoria, Australia. AD - Surgical Research Group, Murdoch Children's Research Institute, Melbourne, Victoria, Australia. AD - Department of Paediatrics, University of Melbourne, Melbourne, Victoria, Australia. FAU - Safe, Mark AU - Safe M AD - Department of Gastroenterology and Clinical Nutrition, The Royal Children's Hospital, Melbourne, Victoria, Australia. FAU - Hutson, John M AU - Hutson JM AD - Surgical Research Group, Murdoch Children's Research Institute, Melbourne, Victoria, Australia. AD - Department of Paediatrics, University of Melbourne, Melbourne, Victoria, Australia. AD - Department of Urology, The Royal Children's Hospital, Melbourne, Victoria, Australia. FAU - Dinning, Phil G AU - Dinning PG AUID- ORCID: 0000-0001-8910-2801 AD - Department of Surgery, College of Medicine and Public Health, The Flinders University and Flinders Medical Centre, Bedford Park, South Australia, Australia. FAU - King, Sebastian K AU - King SK AD - Department of Paediatric Surgery, The Royal Children's Hospital, Melbourne, Victoria, Australia. AD - Surgical Research Group, Murdoch Children's Research Institute, Melbourne, Victoria, Australia. AD - Department of Paediatrics, University of Melbourne, Melbourne, Victoria, Australia. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Systematic Review DEP - 20220614 PL - England TA - Neurogastroenterol Motil JT - Neurogastroenterology and motility JID - 9432572 SB - IM MH - Child MH - Humans MH - *Anorectal Malformations MH - Rectum MH - Anal Canal/surgery MH - Manometry/methods MH - Colon MH - Constipation MH - *Fecal Incontinence/diagnosis PMC - PMC10078517 OTO - NOTNLM OT - anorectal malformation OT - colon OT - gastrointestinal motility OT - manometry COIS- None of the authors have any conflicts of interest to disclose. Financial Disclosure: None of the authors have any financial relationships relevant to this article to disclose. EDAT- 2022/06/15 06:00 MHDA- 2022/12/06 06:00 PMCR- 2023/04/06 CRDT- 2022/06/14 08:22 PHST- 2022/03/07 00:00 [revised] PHST- 2021/11/28 00:00 [received] PHST- 2022/04/20 00:00 [accepted] PHST- 2022/06/15 06:00 [pubmed] PHST- 2022/12/06 06:00 [medline] PHST- 2022/06/14 08:22 [entrez] PHST- 2023/04/06 00:00 [pmc-release] AID - NMO14415 [pii] AID - 10.1111/nmo.14415 [doi] PST - ppublish SO - Neurogastroenterol Motil. 2022 Dec;34(12):e14415. doi: 10.1111/nmo.14415. Epub 2022 Jun 14. PMID- 35698839 OWN - NLM STAT- MEDLINE DCOM- 20220615 LR - 20231106 IS - 1598-6357 (Electronic) IS - 1011-8934 (Print) IS - 1011-8934 (Linking) VI - 37 IP - 23 DP - 2022 Jun 13 TI - Optimal Social Distancing Policy for COVID-19 Control in Korea: A Model-Based Analysis. PG - e189 LID - 10.3346/jkms.2022.37.e189 [doi] LID - e189 AB - BACKGROUND: Since March 2020, when coronavirus disease 2019 (COVID-19) was declared a pandemic, many countries have applied unprecedented restrictive measures to contain the spread of the virus. This study aimed to explore the optimal social distancing policy for COVID-19 control in South Korea to safely reopen the society. METHODS: We developed an age-specific, deterministic compartment epidemic model to examine the COVID-19 control decision-making process, including the epidemiology of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) between 1 July 2021 and 30 December 2022. The model consists of the natural history of COVID-19, testing performance, vaccinations, and social distancing enforcement measures to detect and control SARS-CoV-2. We modelled potential intervention scenarios with three distinct components: 1) social distancing duration and level; 2) testing intensity; and 3) vaccination uptake rate. The primary and secondary outcomes were COVID-19 incidence and prevalence of severe patients requiring intensive care unit (ICU) care. RESULTS: Four (or more) months of social distancing (that can reduce 40-60% transmission) may mitigate epidemic resurgence and ICU demand in the future and keep the cases below the capacity limit if the testing intensity and vaccination rate remain constant or increase by 20% (with respect to the current level). In contrast, two months of strict social distancing enforcement may also successfully mitigate future epidemic surge and ICU demand as long as testing intensity and vaccination rates are increased by 20%. CONCLUSION: In South Korea, given the relatively high vaccination coverage and low incidence, four or more months of social distancing enforcement can effectively mitigate epidemic resurgence after lifting the social distancing measures. In addition, increasing the testing intensity and vaccination rate may help reduce necessary social distancing levels and duration to prevent a future epidemic resurgence and mitigate social and economic damage. CI - (c) 2022 The Korean Academy of Medical Sciences. FAU - Jo, Youngji AU - Jo Y AUID- ORCID: 0000-0002-1440-2786 AD - Section of Infectious Disease, Department of Medicine, Boston Medical Center, Boston, MA, USA. FAU - Shrestha, Sourya AU - Shrestha S AUID- ORCID: 0000-0002-6106-6834 AD - Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. FAU - Radnaabaatar, Munkhzul AU - Radnaabaatar M AUID- ORCID: 0000-0003-4968-5031 AD - Artificial Intelligence and Big-Data Convergence Center, Gil Medical Center, Gachon University College of Medicine, Incheon, Korea. FAU - Park, Hojun AU - Park H AUID- ORCID: 0000-0003-4965-872X AD - Artificial Intelligence and Big-Data Convergence Center, Gil Medical Center, Gachon University College of Medicine, Incheon, Korea. AD - Department of Preventive Medicine, Gachon University College of Medicine, Incheon, Korea. FAU - Jung, Jaehun AU - Jung J AUID- ORCID: 0000-0002-4856-3668 AD - Artificial Intelligence and Big-Data Convergence Center, Gil Medical Center, Gachon University College of Medicine, Incheon, Korea. AD - Department of Preventive Medicine, Gachon University College of Medicine, Incheon, Korea. eastside1st@gmail.com. LA - eng GR - F32 MH128120/MH/NIMH NIH HHS/United States PT - Journal Article DEP - 20220613 PL - Korea (South) TA - J Korean Med Sci JT - Journal of Korean medical science JID - 8703518 SB - IM MH - *COVID-19/epidemiology/prevention & control MH - Humans MH - Pandemics/prevention & control MH - Physical Distancing MH - Policy MH - SARS-CoV-2 PMC - PMC9194485 OTO - NOTNLM OT - COVID-19 OT - ICU OT - Pandemic OT - SARS-CoV-2 OT - Social Distancing Policy COIS- The authors have no potential conflicts of interest to declare. EDAT- 2022/06/15 06:00 MHDA- 2022/06/16 06:00 PMCR- 2022/06/13 CRDT- 2022/06/14 03:32 PHST- 2022/01/16 00:00 [received] PHST- 2022/05/16 00:00 [accepted] PHST- 2022/06/14 03:32 [entrez] PHST- 2022/06/15 06:00 [pubmed] PHST- 2022/06/16 06:00 [medline] PHST- 2022/06/13 00:00 [pmc-release] AID - 37.e189 [pii] AID - 10.3346/jkms.2022.37.e189 [doi] PST - epublish SO - J Korean Med Sci. 2022 Jun 13;37(23):e189. doi: 10.3346/jkms.2022.37.e189. PMID- 35682122 OWN - NLM STAT- MEDLINE DCOM- 20220613 LR - 20240829 IS - 1660-4601 (Electronic) IS - 1661-7827 (Print) IS - 1660-4601 (Linking) VI - 19 IP - 11 DP - 2022 May 27 TI - Utilization of Postnatal Care Services among Thai Women during the COVID-19 Pandemic: Results of a Web-Based Survey. LID - 10.3390/ijerph19116536 [doi] LID - 6536 AB - The postnatal period is an underserved aspect of maternity care, potentially worsened by the COVID-19 pandemic. This study aims to identify postnatal care (PNC) use by health personnel within the 42 days of childbirth among postpartum mothers in Thailand. This web-based, cross-sectional study was conducted from July to October 2021 (n = 840). Multiple binary and ordinal logistic regressions were conducted to predict three outcome variables (>/=2 times, >/=3 times, or level of PNC use). Women who received PNC were in low numbers (>/=2: 30.7% and (>/=3: 12.9%), while 54.4% of women reported no barriers to access PNC, and 31.9% reported barriers, including worries over COVID-19 infection, followed by movement restrictions imposed by the government (11.7%) and the closure of healthcare centers (10%). Women working in a self-employed capacity, living in urban areas, and undergoing a Caesarean section with no/less worry about COVID-19 infection were more likely to utilize postnatal care (>/=2 or number of PNC). This study provides timely information, revealing that a relatively low percentage of postpartum women received PNC, particularly among the socially deprived group. Since the fear of COVID infection is listed as a major barrier, the provision of PNC services, including a telehealth program should be considered. FAU - Aye, Yin Min AU - Aye YM AUID- ORCID: 0000-0002-7419-0818 AD - ASEAN Institute for Health Development, Mahidol University, Nakhon Pathom 73170, Thailand. FAU - Kim, Soo Jung AU - Kim SJ AD - Department of Health Sciences, Hamburg University of Applied Sciences, 20099 Hamburg, Germany. FAU - Suriyawongpaisal, Wichukorn AU - Suriyawongpaisal W AD - ASEAN Institute for Health Development, Mahidol University, Nakhon Pathom 73170, Thailand. FAU - Hong, Seo Ah AU - Hong SA AUID- ORCID: 0000-0002-6702-8038 AD - ASEAN Institute for Health Development, Mahidol University, Nakhon Pathom 73170, Thailand. FAU - Chang, Yan-Shing AU - Chang YS AUID- ORCID: 0000-0002-9086-4472 AD - Florence Nightingale Faculty of Nursing, Midwifery & Palliative Care, King's College London, London SE1 8WA, UK. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20220527 PL - Switzerland TA - Int J Environ Res Public Health JT - International journal of environmental research and public health JID - 101238455 SB - IM MH - *COVID-19/epidemiology MH - Cesarean Section MH - Cross-Sectional Studies MH - Female MH - Humans MH - Internet MH - *Maternal Health Services MH - Pandemics MH - Postnatal Care MH - Pregnancy MH - Thailand/epidemiology PMC - PMC9179996 OTO - NOTNLM OT - COVID-19 OT - Thailand OT - barriers OT - postnatal care service OT - women COIS- The authors declare no conflict of interest. EDAT- 2022/06/11 06:00 MHDA- 2022/06/14 06:00 PMCR- 2022/05/27 CRDT- 2022/06/10 01:11 PHST- 2022/04/27 00:00 [received] PHST- 2022/05/23 00:00 [revised] PHST- 2022/05/25 00:00 [accepted] PHST- 2022/06/10 01:11 [entrez] PHST- 2022/06/11 06:00 [pubmed] PHST- 2022/06/14 06:00 [medline] PHST- 2022/05/27 00:00 [pmc-release] AID - ijerph19116536 [pii] AID - ijerph-19-06536 [pii] AID - 10.3390/ijerph19116536 [doi] PST - epublish SO - Int J Environ Res Public Health. 2022 May 27;19(11):6536. doi: 10.3390/ijerph19116536. PMID- 35681962 OWN - NLM STAT- MEDLINE DCOM- 20220613 LR - 20220716 IS - 1660-4601 (Electronic) IS - 1661-7827 (Print) IS - 1660-4601 (Linking) VI - 19 IP - 11 DP - 2022 May 24 TI - Predictors of Loss to Follow-Up in an HIV Vaccine Preparedness Study in Masaka, Uganda. LID - 10.3390/ijerph19116377 [doi] LID - 6377 AB - BACKGROUND: High participant retention is essential to achieve adequate statistical power for clinical trials. We assessed participant retention and predictors of loss to follow-up (LTFU) in an HIV vaccine-preparedness study in Masaka, Uganda. METHODS: Between July 2018 and March 2021, HIV sero-negative adults (18-45 years) at high risk of HIV infection were identified through HIV counselling and testing (HCT) from sex-work hotspots along the trans-African highway and fishing communities along the shores of Lake Victoria. Study procedures included collection of baseline socio-demographic data, quarterly HCT, and 6-monthly collection of sexual risk behaviour data. Retention strategies included collection of detailed locator data, short clinic visits (1-2 h), flexible reimbursement for transport costs, immediate (/=2 sequential study visits. Poisson regression models were used to identify baseline factors associated with LTFU. RESULTS: 672 participants were included in this analysis. Of these, 336 (50%) were female and 390 (58%) were /=2 underlying medical conditions was associated with severe illness in patients aged <1 (PR 1.82), 5 to 11 (PR 3.72), and 12 to 17 years (PR 3.19). CONCLUSIONS: Among patients hospitalized for COVID-19, factors associated with severe illness included RSV coinfection in those aged <5 years, obesity in those aged 5 to 17 years, and other underlying conditions for all age groups <18 years. These findings can inform pediatric practice, risk communication, and prevention strategies, including vaccination against COVID-19. CI - Copyright (c) 2022 by the American Academy of Pediatrics. FAU - Choudhary, Rewa AU - Choudhary R AD - COVID-19 Emergency Response Team. AD - Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia. FAU - Webber, Bryant J AU - Webber BJ AD - COVID-19 Emergency Response Team. AD - Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia. AD - Air Force Institute of Technology, Wright-Patterson AFB, Ohio. FAU - Womack, Lindsay S AU - Womack LS AD - COVID-19 Emergency Response Team. AD - United States Public Health Service, Commissioned Corps, Rockville, Maryland. FAU - Dupont, Hannah K AU - Dupont HK AD - COVID-19 Emergency Response Team. AD - United States Public Health Service, Commissioned Corps, Rockville, Maryland. FAU - Chiu, Sophia K AU - Chiu SK AD - COVID-19 Emergency Response Team. FAU - Wanga, Valentine AU - Wanga V AD - COVID-19 Emergency Response Team. AD - Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia. FAU - Gerdes, Megan E AU - Gerdes ME AD - COVID-19 Emergency Response Team. FAU - Hsu, Sophia AU - Hsu S AD - COVID-19 Emergency Response Team. AD - United States Public Health Service, Commissioned Corps, Rockville, Maryland. FAU - Shi, Dallas S AU - Shi DS AD - COVID-19 Emergency Response Team. AD - Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia. FAU - Dulski, Theresa M AU - Dulski TM AD - COVID-19 Emergency Response Team. AD - Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia. FAU - Idubor, Osatohamwen I AU - Idubor OI AD - COVID-19 Emergency Response Team. AD - United States Public Health Service, Commissioned Corps, Rockville, Maryland. FAU - Wendel, Arthur M AU - Wendel AM AD - COVID-19 Emergency Response Team. AD - United States Public Health Service, Commissioned Corps, Rockville, Maryland. FAU - Agathis, Nickolas T AU - Agathis NT AD - COVID-19 Emergency Response Team. AD - Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia. FAU - Anderson, Kristi AU - Anderson K AD - COVID-19 Emergency Response Team. FAU - Boyles, Tricia AU - Boyles T AD - COVID-19 Emergency Response Team. FAU - Click, Eleanor S AU - Click ES AD - COVID-19 Emergency Response Team. FAU - Da Silva, Juliana AU - Da Silva J AD - COVID-19 Emergency Response Team. FAU - Evans, Mary E AU - Evans ME AD - COVID-19 Emergency Response Team. FAU - Gold, Jeremy A W AU - Gold JAW AD - COVID-19 Emergency Response Team. FAU - Haston, Julia C AU - Haston JC AD - COVID-19 Emergency Response Team. AD - Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia. FAU - Logan, Pamela AU - Logan P AD - COVID-19 Emergency Response Team. FAU - Maloney, Susan A AU - Maloney SA AD - COVID-19 Emergency Response Team. FAU - Martinez, Marisol AU - Martinez M AD - COVID-19 Emergency Response Team. FAU - Natarajan, Pavithra AU - Natarajan P AD - COVID-19 Emergency Response Team. FAU - Spicer, Kevin B AU - Spicer KB AD - COVID-19 Emergency Response Team. FAU - Swancutt, Mark AU - Swancutt M AD - COVID-19 Emergency Response Team. FAU - Stevens, Valerie A AU - Stevens VA AD - COVID-19 Emergency Response Team. FAU - Rogers-Brown, Jessica AU - Rogers-Brown J AD - COVID-19 Emergency Response Team. FAU - Chandra, Gyan AU - Chandra G AD - COVID-19 Emergency Response Team. FAU - Light, Megan AU - Light M AD - COVID-19 Emergency Response Team. FAU - Barr, Frederick E AU - Barr FE AD - Arkansas Children's, Little Rock, Arkansas. FAU - Snowden, Jessica AU - Snowden J AD - Arkansas Children's, Little Rock, Arkansas. FAU - Kociolek, Larry K AU - Kociolek LK AD - Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois. FAU - McHugh, Matthew AU - McHugh M AD - Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois. FAU - Wessel, David L AU - Wessel DL AD - Children's National Hospital, Washington, DC. FAU - Simpson, Joelle N AU - Simpson JN AD - Children's National Hospital, Washington, DC. FAU - Gorman, Kathleen C AU - Gorman KC AD - Children's National Hospital, Washington, DC. FAU - Breslin, Kristen A AU - Breslin KA AD - Children's National Hospital, Washington, DC. FAU - DeBiasi, Roberta L AU - DeBiasi RL AD - Children's National Hospital, Washington, DC. FAU - Thompson, Aaron AU - Thompson A AD - Children's Hospital New Orleans, New Orleans, Louisiana. AD - Tulane University School of Medicine and LSU Health, New Orleans, Louisiana. FAU - Kline, Mark W AU - Kline MW AD - Children's Hospital New Orleans, New Orleans, Louisiana. AD - Tulane University School of Medicine and LSU Health, New Orleans, Louisiana. FAU - Boom, Julie A AU - Boom JA AD - Department of Pediatrics, Baylor College of Medicine, Houston, Texas. AD - Texas Children's Hospital, Houston, Texas. FAU - Singh, Ila R AU - Singh IR AD - Texas Children's Hospital, Houston, Texas. AD - Department of Pathology and Immunology, Baylor College of Medicine, Houston, Texas. FAU - Dowlin, Michael AU - Dowlin M AD - Department of Pathology and Immunology, Baylor College of Medicine, Houston, Texas. FAU - Wietecha, Mark AU - Wietecha M AD - Children's Hospital Association, Washington, DC. FAU - Schweitzer, Beth AU - Schweitzer B AD - COVID-19 Emergency Response Team. FAU - Morris, Sapna Bamrah AU - Morris SB AD - COVID-19 Emergency Response Team. FAU - Koumans, Emilia H AU - Koumans EH AD - COVID-19 Emergency Response Team. FAU - Ko, Jean Y AU - Ko JY AD - COVID-19 Emergency Response Team. AD - United States Public Health Service, Commissioned Corps, Rockville, Maryland. FAU - Siegel, David A AU - Siegel DA AD - COVID-19 Emergency Response Team. AD - United States Public Health Service, Commissioned Corps, Rockville, Maryland. FAU - Kimball, Anne A AU - Kimball AA AD - COVID-19 Emergency Response Team. LA - eng GR - CC999999/ImCDC/Intramural CDC HHS/United States GR - R61 HD105593/HD/NICHD NIH HHS/United States PT - Journal Article PT - Research Support, U.S. Gov't, P.H.S. PL - United States TA - Hosp Pediatr JT - Hospital pediatrics JID - 101585349 RN - SARS-CoV-2 variants SB - IM MH - *COVID-19/epidemiology/therapy MH - Child MH - *Coinfection MH - Cross-Sectional Studies MH - Hospitalization MH - Humans MH - Infant MH - Obesity MH - *Respiratory Syncytial Virus Infections/epidemiology MH - SARS-CoV-2 MH - United States/epidemiology PMC - PMC9773098 MID - NIHMS1857223 COIS- CONFLICT OF INTEREST DISCLOSURES: All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. Dr Singh reports funding from the National Institutes of Health (NIH) as a coinvestigator for grant R61HD105593 to characterize pediatric coronavirus disease 2019 (COVID-19). Dr DeBiasi reports grant support and contracts for COVID-19 and multisystem inflammatory syndrome in children, unrelated to the current work; consulting fees from I-ACT for Children; honoraria from the Infectious Diseases in Children Conference (NYC) and Children's Hospital Colorado Infectious Diseases Conference (Denver); and unpaid membership on the board of the Pediatric Infectious Diseases Society. Dr Kociolek reports a grant from the Walder Foundation Chicago Coronavirus Assessment Network Initiative, institutional support from Merck and NIH and National Institute of Allergy and Infectious Diseases; and honoraria for educational events at Northwest Community Hospital and Nemours and DuPont Children's Hospital. Dr Snowden reports institutional support from NIH Office of the Director-Environmental influences on Child Health Outcomes program and NIH or National Heart, Lung, and Blood Institute RECOVER program, unrelated to the current work. Dr Barr reports application of patent 17364280 with Asklepion Pharmaceuticals for L-citrulline to prevent or treat endothelial dysfunction. Dr Morris reports membership on a data safety monitoring board in a study of ivermectin for treatment of severe COVID-19 in Ghana. Ms Hsu reports ownership of 5 shares of Moderna stock and 7 shares of Novavax stock, and ownership within the past 36 months (but no current ownership) of stock in BioNTech, Gilead Sciences, and Pfizer. Dr Dulski reports that her husband receives restricted stock units as part of his compensation from his employer, a cancer diagnostics company that also performs COVID-19 testing. No other potential conflicts of interest relevant to this article were disclosed. EDAT- 2022/06/08 06:00 MHDA- 2022/09/09 06:00 PMCR- 2023/09/01 CRDT- 2022/06/07 09:13 PHST- 2022/06/08 06:00 [pubmed] PHST- 2022/09/09 06:00 [medline] PHST- 2022/06/07 09:13 [entrez] PHST- 2023/09/01 00:00 [pmc-release] AID - 188252 [pii] AID - 10.1542/hpeds.2022-006613 [doi] PST - ppublish SO - Hosp Pediatr. 2022 Sep 1;12(9):760-783. doi: 10.1542/hpeds.2022-006613. PMID- 35667736 OWN - NLM STAT- MEDLINE DCOM- 20220608 LR - 20250530 IS - 2044-6055 (Electronic) IS - 2044-6055 (Linking) VI - 12 IP - 6 DP - 2022 Jun 6 TI - COVID-19 in the context of pregnancy, infancy and parenting (CoCoPIP) study: protocol for a longitudinal study of parental mental health, social interactions, physical growth and cognitive development of infants during the pandemic. PG - e053800 LID - 10.1136/bmjopen-2021-053800 [doi] LID - e053800 AB - INTRODUCTION: While the secondary impact of the COVID-19 pandemic on the psychological well-being of pregnant women and parents has become apparent over the past year, the impact of these changes on early social interactions, physical growth and cognitive development of their infants is unknown, as is the way in which a range of COVID-19-related changes have mediated this impact. This study (CoCoPIP) will investigate: (1) how parent's experiences of the social, medical and financial changes during the pandemic have impacted prenatal and postnatal parental mental health and parent-infant social interaction; and (2) the extent to which these COVID-19-related changes in parental prenatal and postnatal mental health and social interaction are associated with fetal and infant development. METHODS AND ANALYSIS: The CoCoPIP study is a national online survey initiated in July 2020. This ongoing study (n=1700 families currently enrolled as of 6 May 2021) involves both quantitative and qualitative data being collected across pregnancy and infancy. It is designed to identify the longitudinal impact of the pandemic from pregnancy to 2 years of age as assessed using a range of parent- and self-report measures, with the aim of identifying if stress-associated moderators (ie, loss of income, COVID-19 illness, access to ante/postnatal support) appear to impact parental mental health, and in turn, infant development. In addition, we aim to document individual differences in social and cognitive development in toddlers who were born during restrictions intended to mitigate COVID-19 spread (eg, social distancing, national lockdowns). ETHICS AND DISSEMINATION: Ethical approval was given by the University of Cambridge, Psychology Research Ethics Committee (PRE.2020.077). Findings will be made available via community engagement, public forums (eg, social media,) and to national (eg, NHS England) and local (Cambridge Universities Hospitals NHS Foundation Trust) healthcare partners. Results will be submitted for publication in peer-reviews journals. CI - (c) Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ. FAU - Aydin, Ezra AU - Aydin E AUID- ORCID: 0000-0003-4845-053X AD - Department of Psychology, University of Cambridge, Cambridge, UK ea420@cam.ac.uk. AD - Department of Psychiatry, Columbia University, New York City, NY, USA. FAU - Weiss, Staci M AU - Weiss SM AD - Department of Psychology, University of Cambridge, Cambridge, UK. FAU - Glasgow, Kevin A AU - Glasgow KA AD - Department of Education, University of Cambridge, Cambridge, UK. FAU - Barlow, Jane AU - Barlow J AD - Department of Social Policy, University of Oxford, Oxford, Oxfordshire, UK. FAU - Austin, Topun AU - Austin T AD - Rosie Hospital, Cambridge, Cambridgeshire, UK. AD - NIHR Cambridge Biomedical Research Centre, Cambridge, Cambridgeshire, UK. FAU - Johnson, Mark H AU - Johnson MH AD - Department of Psychology, University of Cambridge, Cambridge, UK. FAU - Lloyd-Fox, Sarah AU - Lloyd-Fox S AD - Department of Psychology, University of Cambridge, Cambridge, UK. LA - eng GR - MR/S018425/1/MRC_/Medical Research Council/United Kingdom GR - MR/T003057/1/MRC_/Medical Research Council/United Kingdom GR - DH_/Department of Health/United Kingdom PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20220606 PL - England TA - BMJ Open JT - BMJ open JID - 101552874 SB - IM MH - *COVID-19/epidemiology MH - Cognition MH - Communicable Disease Control MH - Female MH - Humans MH - Infant MH - Longitudinal Studies MH - Mental Health MH - Pandemics MH - Parenting MH - Parents/psychology MH - Parturition MH - Pregnancy MH - Social Interaction PMC - PMC9170803 OTO - NOTNLM OT - COVID-19 OT - Fetal medicine OT - QUALITATIVE RESEARCH COIS- Competing interests: None declared. EDAT- 2022/06/07 06:00 MHDA- 2022/06/09 06:00 PMCR- 2022/06/06 CRDT- 2022/06/06 20:53 PHST- 2022/06/06 20:53 [entrez] PHST- 2022/06/07 06:00 [pubmed] PHST- 2022/06/09 06:00 [medline] PHST- 2022/06/06 00:00 [pmc-release] AID - bmjopen-2021-053800 [pii] AID - 10.1136/bmjopen-2021-053800 [doi] PST - epublish SO - BMJ Open. 2022 Jun 6;12(6):e053800. doi: 10.1136/bmjopen-2021-053800. PMID- 35649585 OWN - NLM STAT- MEDLINE DCOM- 20220603 LR - 20231101 IS - 2044-6055 (Electronic) IS - 2044-6055 (Linking) VI - 12 IP - 6 DP - 2022 Jun 1 TI - Cohort profile: maternal and child health and parenting practices during the COVID-19 pandemic in Ceara, Brazil: birth cohort study (Iracema-COVID). PG - e060824 LID - 10.1136/bmjopen-2022-060824 [doi] LID - e060824 AB - PURPOSE: Maternal and child health and parenting practices during the COVID-19 pandemic in Ceara (Iracema-COVID) is a longitudinal, prospective population-based birth cohort designed to understand the effects of the pandemic and social withdrawal in maternal mental health, child development and parenting practices of mothers and families. PARTICIPANTS: A sample of mothers who gave birth in July and August 2020 (n=351) was enrolled in the study in January 2021. Interviews were conducted by telephone. Data were collected through standardised questionnaires that, in addition to sociodemographic and economic data, collected information on breast feeding, mental health status and COVID-19. FINDINGS TO DATE: Results from the first wave show that the majority of participants have 9-11 years of schooling (54.4%; 95% CI 61.0 to 70.9) and are of mixed race (71.5%; 95% CI 66.5 to 76.0). At the time of the survey, 27.9% of the participants were out of the labor force (95% CI 23.5 to 32.9) and 78.6% reported a decrease in family income after restrictions imposed due to the pandemic (95% CI 74.0 to 82.6). The prevalence of maternal common mental disorder symptoms was 32.5% (95% CI 27.8 to 37.6). FUTURE PLANS: Follow-up visits are planned to occur every 6 months for the next five years (2021-2025). Additional topics will be included in future waves (eg, food insecurity and parenting practices). Communication strategies for bonding, such as picture cards, pictures of mothers with their children and phone calls to the participants, will be used to minimise attrition. Results of this prospective cohort will generate novel knowledge on the impact of the COVID-19 pandemic on maternal and child health and parenting practices in a population of women and children living in fifth largest city of Brazil. CI - (c) Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. FAU - Castro, Marcia C AU - Castro MC AUID- ORCID: 0000-0003-4606-2795 AD - Department of Global Health and Population, Harvard University T H Chan School of Public Health, Boston, Massachusetts, USA mcastro@hsph.harvard.edu. FAU - Farias-Antunez, Simone AU - Farias-Antunez S AUID- ORCID: 0000-0002-1546-4217 AD - Department of Community Health, Federal University of Ceara, Fortaleza, Ceara, Brazil. FAU - Araujo, David Augusto Batista Sa AU - Araujo DABS AD - Department of Community Health, Federal University of Ceara, Fortaleza, Ceara, Brazil. FAU - Penna, Ana Luiza AU - Penna AL AD - Department of Global Health and Population, Harvard University T H Chan School of Public Health, Boston, Massachusetts, USA. FAU - Oliveira, Francisco Ariclene AU - Oliveira FA AD - Department of Community Health, Federal University of Ceara, Fortaleza, Ceara, Brazil. FAU - de Aquino, Camila Machado AU - de Aquino CM AD - Department of Maternal and Child Health, Faculty of Medicine, Federal University of Ceara, Fortaleza, CE, Brazil. FAU - Lima Neto, Antonio Silva AU - Lima Neto AS AD - Fortaleza Municipal Health Secretariat, Fortaleza, Ceara, Brazil. AD - University of Fortaleza, Fortaleza, Ceara, Brazil. FAU - de Sousa, Geziel Dos Santos AU - de Sousa GDS AD - Fortaleza Municipal Health Secretariat, Fortaleza, Ceara, Brazil. FAU - Tavares Machado, Marcia Maria AU - Tavares Machado MM AD - Department of Community Health, Federal University of Ceara, Fortaleza, Ceara, Brazil. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20220601 PL - England TA - BMJ Open JT - BMJ open JID - 101552874 SB - IM MH - Birth Cohort MH - Brazil/epidemiology MH - *COVID-19/epidemiology MH - Child MH - Child Health MH - Cohort Studies MH - Female MH - Humans MH - Pandemics MH - Parenting/psychology MH - Prospective Studies PMC - PMC9160586 OTO - NOTNLM OT - covid-19 OT - epidemiology OT - public health COIS- Competing interests: None declared. EDAT- 2022/06/02 06:00 MHDA- 2022/06/07 06:00 PMCR- 2022/06/01 CRDT- 2022/06/01 20:52 PHST- 2022/06/01 20:52 [entrez] PHST- 2022/06/02 06:00 [pubmed] PHST- 2022/06/07 06:00 [medline] PHST- 2022/06/01 00:00 [pmc-release] AID - bmjopen-2022-060824 [pii] AID - 10.1136/bmjopen-2022-060824 [doi] PST - epublish SO - BMJ Open. 2022 Jun 1;12(6):e060824. doi: 10.1136/bmjopen-2022-060824. PMID- 35642377 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250530 IS - 2056-4724 (Print) IS - 2056-4724 (Electronic) IS - 2056-4724 (Linking) VI - 8 IP - 4 DP - 2022 Jun 1 TI - Mental health and well-being during the second wave of COVID-19: longitudinal analyses of the UK COVID-19 Mental Health and Wellbeing study (UK COVID-MH). PG - e103 LID - 10.1192/bjo.2022.58 [doi] LID - e103 AB - BACKGROUND: Waves 1 to 3 (March 2020 to May 2020) of the UK COVID-19 Mental Health and Wellbeing study suggested an improvement in some indicators of mental health across the first 6 weeks of the UK lockdown; however, suicidal ideation increased. AIMS: To report the prevalence of mental health and well-being of adults in the UK from March/April 2020 to February 2021. METHOD: Quota sampling was employed at wave 1 (March/April 2020), and online surveys were conducted at seven time points. Primary analyses cover waves 4 (May/June 2020), 5 (July/August 2020), 6 (October 2020) and 7 (February 2021), including a period of increased restrictions in the UK. Mental health indicators were suicidal ideation, self-harm, suicide attempt, depression, anxiety, defeat, entrapment, loneliness and well-being. RESULTS: A total of 2691 (87.5% of wave 1) individuals participated in at least one survey between waves 4 and 7. Depressive symptoms and loneliness increased from October 2020 to February 2021. Defeat and entrapment increased from July/August 2020 to October 2020, and remained elevated in February 2021. Well-being decreased from July/August 2020 to October 2020. Anxiety symptoms and suicidal ideation did not change. Young adults, women, those who were socially disadvantaged and those with a pre-existing mental health condition reported worse mental health. CONCLUSIONS: The mental health and well-being of the UK population deteriorated from July/August 2020 to October 2020 and February 2021, which coincided with the second wave of COVID-19. Suicidal thoughts did not decrease significantly, suggesting a need for continued vigilance as we recover from the pandemic. FAU - Wetherall, Karen AU - Wetherall K AUID- ORCID: 0000-0002-4000-8969 AD - Suicidal Behaviour Research Laboratory, Institute of Health & Wellbeing, University of Glasgow, UK. FAU - Cleare, Seonaid AU - Cleare S AD - Suicidal Behaviour Research Laboratory, Institute of Health & Wellbeing, University of Glasgow, UK. FAU - McClelland, Heather AU - McClelland H AD - Suicidal Behaviour Research Laboratory, Institute of Health & Wellbeing, University of Glasgow, UK. FAU - Melson, Ambrose J AU - Melson AJ AUID- ORCID: 0000-0003-1415-3801 AD - Suicidal Behaviour Research Laboratory, Institute of Health & Wellbeing, University of Glasgow, UK. FAU - Niedzwiedz, Claire L AU - Niedzwiedz CL AUID- ORCID: 0000-0001-6133-4168 AD - Institute of Health & Wellbeing, University of Glasgow, UK. FAU - O'Carroll, Ronan E AU - O'Carroll RE AD - Division of Psychology, University of Stirling, UK. FAU - O'Connor, Daryl B AU - O'Connor DB AD - School of Psychology, University of Leeds, UK. FAU - Platt, Steve AU - Platt S AD - Usher Institute, University of Edinburgh, UK. FAU - Scowcroft, Elizabeth AU - Scowcroft E AD - Samaritans, UK. FAU - Watson, Billy AU - Watson B AD - Scottish Association for Mental Health, UK. FAU - Zortea, Tiago AU - Zortea T AUID- ORCID: 0000-0002-8451-0555 AD - Oxford Institute of Clinical Psychology Training and Research, University of Oxford, UK. FAU - Ferguson, Eamonn AU - Ferguson E AD - School of Psychology, Nottingham University, UK. FAU - Robb, Kathryn A AU - Robb KA AD - Institute of Health & Wellbeing, University of Glasgow, UK. FAU - O'Connor, Rory C AU - O'Connor RC AUID- ORCID: 0000-0002-3650-4994 AD - Suicidal Behaviour Research Laboratory, Institute of Health & Wellbeing, University of Glasgow, UK. LA - eng GR - MR/R024774/1/MRC_/Medical Research Council/United Kingdom PT - Journal Article DEP - 20220601 PL - England TA - BJPsych Open JT - BJPsych open JID - 101667931 PMC - PMC9171032 OTO - NOTNLM OT - COVID-19 OT - depression OT - general population OT - mental health OT - suicidal ideation COIS- During the conduct of the study, R.C.O. reports grants from the Scottish Association for Mental Health, Samaritans, Mindstep Foundation, National Institute for Health Research, Medical Research Foundation, Scottish Government and NHS Health Scotland/Public Health Scotland. R.C.O. is co-chair of the Academic Advisory Group to the Scottish Government's National Suicide Prevention Leadership Group, and is a member of the National Institute for Health and Care Excellence guideline development group for their new self-harm guidelines. C.L.N. reports grants from Medical Research Council outside of this work. S.P. reports personal fees from Health Service Executive, Dublin, Ireland, and NHS Health Scotland, Edinburgh, Scotland, outside of the submitted work. T.Z. reports being employed by the Scottish Government Scotland National Suicide Prevention Leadership Group during the conduct of the study, grants from NHS Scotland Endowment Funds outside of this work and is a co-chair of the Early Career Group of the International Association for Suicide Prevention. E.F. reports grants from Pfizer Limited, Versus Arthritis, the Football Association, Medical Research Foundation and U.S. Army Medical Research and Materiel Command, outside of the submitted work. E.S. (Samaritans) and B.W. (Scottish Association for Mental Health) are employees of two of the funders of this research. K.W., S.C., H.M., A.J.M., R.E.O., D.B.O. and K.A.R. have nothing to disclose. EDAT- 2022/06/02 06:00 MHDA- 2022/06/02 06:01 PMCR- 2022/06/01 CRDT- 2022/06/01 03:13 PHST- 2022/06/01 03:13 [entrez] PHST- 2022/06/02 06:00 [pubmed] PHST- 2022/06/02 06:01 [medline] PHST- 2022/06/01 00:00 [pmc-release] AID - S2056472422000588 [pii] AID - 10.1192/bjo.2022.58 [doi] PST - epublish SO - BJPsych Open. 2022 Jun 1;8(4):e103. doi: 10.1192/bjo.2022.58. PMID- 38603061 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240829 IS - 2515-9372 (Electronic) IS - 1035-719X (Print) IS - 1035-719X (Linking) VI - 22 IP - 2 DP - 2022 Jun TI - Evaluating a peer-led wellbeing programme for doctors-in-training during the COVID-19 pandemic in Victoria, Australia, using the Most Significant Change technique. PG - 90-107 LID - 10.1177/1035719X221080576 [doi] AB - This article discusses the use of the Most Significant Change (MSC) technique in a mixed-methods evaluation of a pilot wellbeing programme for obstetrics and gynaecology doctors-in-training introduced at a large public hospital during Melbourne, Australia's second coronavirus (COVID-19) lockdown, which occurred from 7 July to 26 October 2020. The evaluation was conducted remotely using videoconferencing technology, to conform with pandemic restrictions. MSC complemented the program's participatory principles and was chosen because it seeks to learn about participants' perceptions of programme impacts by evaluating their stories of significant change. Stakeholders select one story exemplifying the most significant change resulting from the evaluated program. Inductive thematic analysis of all stories is combined with reasons for making the selection, to inform learnings (Dart & Davies, 2003; Tonkin et al., 2021). Nine stories of change were included in the selection. The most significant change was a more supportive workplace culture brought about by enabling basic needs to be met and breaking down hierarchical barriers. This was linked to five interconnected themes - connection, caring, communication, confidence and cooperation. The evaluation learnings are explored and reflections on remotely conducting MSC evaluation are shared. CI - (c) The Author(s) 2022. FAU - Crinall, Karen AU - Crinall K AUID- ORCID: 0000-0002-3643-9969 AD - Crinall Consulting, VIC, Australia. FAU - Ward, Madeleine AU - Ward M AD - Monash Health, Clayton, VIC, Australia; Monash University, Clayton, VIC, Australia. RINGGOLD: 2538. RINGGOLD: 22457 FAU - McDonald, Rebecca AU - McDonald R AD - Monash Health, Clayton, VIC, Australia; Monash University, Clayton, VIC, Australia. RINGGOLD: 2538. RINGGOLD: 22457 FAU - Crinall, William AU - Crinall W AUID- ORCID: 0000-0002-5199-9606 AD - Federation University Australia, Cowes, VIC, Australia. RINGGOLD: 72534 FAU - Aridas, James AU - Aridas J AD - Monash Health, Clayton, VIC, Australia; The Ritchie Centre, Hudson Institute of Medical Research, Clayton, VIC, Australia. RINGGOLD: 2538 FAU - Rolnik, Daniel L AU - Rolnik DL AD - Monash Health, Clayton, VIC, Australia; Monash University, Clayton, VIC, Australia. RINGGOLD: 2538. RINGGOLD: 22457 LA - eng PT - Journal Article PL - England TA - Eval J Australas JT - Evaluation journal of Australasia JID - 101768517 PMC - PMC8961201 OTO - NOTNLM OT - COVID-19 pandemic OT - Most Significant Change technique OT - Zoom OT - doctors-in-training OT - healthcare programme evaluation OT - pandemic kindness movement OT - workplace wellbeing programmes COIS- Declaration of conflicting interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. EDAT- 2022/06/01 00:00 MHDA- 2022/06/01 00:01 PMCR- 2022/06/01 CRDT- 2024/04/11 13:51 PHST- 2022/06/01 00:01 [medline] PHST- 2022/06/01 00:00 [pubmed] PHST- 2024/04/11 13:51 [entrez] PHST- 2022/06/01 00:00 [pmc-release] AID - 10.1177_1035719X221080576 [pii] AID - 10.1177/1035719X221080576 [doi] PST - ppublish SO - Eval J Australas. 2022 Jun;22(2):90-107. doi: 10.1177/1035719X221080576. PMID- 35633577 OWN - NLM STAT- MEDLINE DCOM- 20220531 LR - 20220531 IS - 2795-4552 (Electronic) IS - 2795-4552 (Linking) VI - 1 IP - 1 DP - 2022 Jan-Mar TI - The 2021 Portuguese Society of Ophthalmology joint guidelines with Paediatric Rheumatology on the screening, monitoring and medical treatment of juvenile idiopathic arthritis-associated uveitis. PG - 49-62 AB - AIM: To develop the first Ophthalmology joint guidelines with Paediatric Rheumatology with recommendations on the screening, monitoring and medical treatment of juvenile idiopathic arthritis-associated uveitis (JIA-U), endorsed by the Portuguese Society of Ophthalmology (SPO). METHODS: A systematic literature review was conducted to include publications up to July 14th 2020, with no language restrictions, in order to include all the international position papers/guidelines concerning the medical management of JIA-U and randomised clinical trials assessing the efficacy and safety of medical treatment in this field. We searched through MEDLINE (PubMed), Scopus, Web of Science and Cochrane Library. The Delphi modified technique to generate consensus was used. Preliminary evidence statements were subject to an anonymous agreement assessment and discussion process using an online survey, followed by further discussion and update at a national meeting. A draft of the manuscript with all recommendations was then circulated among all participants and suggestions were incorporated. The final version was again circulated before publication. RESULTS: Twenty-six recommendations were developed focusing on the following topics: general management (3), screening and follow-up of uveitis (4), treatment (17) and health education in JIA-U among patients and families (2). CONCLUSION: These guidelines were designed to support the shared medical management of patients with JIA-U and emphasize the need for a multidisciplinary approach between Ophthalmology and Paediatric Rheumatology regarding the comprehensive care of JIA-U. We acknowledge that updating these recommendations will be warranted in the future, as more evidence becomes available. KEY-WORDS: juvenile idiopathic arthritis, uveitis, biological treatment, conventional immunosuppressive treatment, multidisciplinary management, guidelines, consensus, review, Delphi Technique. FAU - Leal, Ines AU - Leal I AD - Ophthalmology Department, Hospital de Santa Maria, Centro Hospitalar Universitario Lisboa Norte, Centro Academico de Medicina de Lisboa, Portugal; Centro de Estudos das Ciencias da Visao, Clinica Universitaria de Oftalmologia, FMUL, Portugal. FAU - Miranda, Vasco AU - Miranda V AD - Ophthalmology Department, Centro Hospitalar Universitario do Porto, Porto, Portugal. FAU - Fonseca, Cristina AU - Fonseca C AD - Centro de Responsabilidade Integrado de Oftalmologia, Centro Hospitalar e Universitario de Coimbra. FAU - Barbosa-Breda, Joao AU - Barbosa-Breda J AD - Ophthalmology Department, Centro Hospitalar Universitario do Porto, Portugal; UnIC@RISE, Department of Surgery and Physiology, Faculty of Medicine of the University of Porto, Portugal; KULeuven, Research Group Ophthalmology, Department of Neurosciences. FAU - Cordeiro Sousa, David AU - Cordeiro Sousa D AD - Ophthalmology Department, Hospital de Santa Maria, Centro Hospitalar Universitario Lisboa Norte, Centro Academico de Medicina de Lisboa, Portugal; Centro de Estudos das Ciencias da Visao, Clinica Universitaria de Oftalmologia, Faculdade de Medicina. FAU - Mesquita-Marques, Paulo AU - Mesquita-Marques P AD - Ophthalmology Department, Hospital de Braga, Braga, Portugal; Ophthalmology Department, Instituto CUF Porto, Porto, Portugal. FAU - Araujo, Joana AU - Araujo J AD - Ophthalmology Department, Centro Hospitalar Universitario Sao Joao, Porto, Portugal. FAU - Silva, Marta Ines AU - Silva MI AD - Ophthalmology Department, Centro Hospitalar Universitario Sao Joao, Porto, Portugal. FAU - Pedrosa, Ana Catarina AU - Pedrosa AC AD - Ophthalmology Department, Centro Hospitalar Universitario Sao Joao, Porto, Portugal; Faculdade de Medicina da Universidade do Porto, Porto, Portugal. FAU - Palmares, Jorge AU - Palmares J AD - Hospital Lusiadas Porto, Porto Portugal. FAU - Furtado, Maria Joao AU - Furtado MJ AD - Ophthalmology Department, Centro Hospitalar Universitario do Porto, Porto, Portugal; Instituto de Ciencias Biomedicas Abel Salazar, Universidade do Porto, Porto, Portugal. FAU - Macedo, Mafalda AU - Macedo M AD - Ophthalmology Department, Centro Hospitalar Universitario do Porto, Porto, Portugal; Instituto de Ciencias Biomedicas Abel Salazar, Universidade do Porto, Porto, Portugal. FAU - Lages, Vania AU - Lages V AD - Ophthalmology Department, Hospital da Senhora da Oliveira, Guimaraes, Portugal. FAU - Fonseca, Sofia AU - Fonseca S AD - Ophthalmology Department, Centro Hospitalar de Vila Nova de Gaia/Espinho, Portugal. FAU - Goncalves, Rita AU - Goncalves R AD - Ophthalmology Department, Hospital Pedro Hispano, ULS Matosinhos, Portugal. FAU - Ruao, Miguel AU - Ruao M AD - Ophthalmology Department, Centro Hospitalar Entre o Douro e Vouga, Santa Maria da Feira, Portugal. FAU - Gomes Rodrigues, Filipa AU - Gomes Rodrigues F AD - Ophthalmology Department, Hospital de Vila Franca de Xira, Vila Franca de Xira, Portugal. FAU - Ribeiro, Miguel AU - Ribeiro M AD - Ophthalmology Department, Centro Hospitalar Tondela-Viseu, Portugal. FAU - Proenca, Rui AU - Proenca R AD - Centro de Responsabilidade Integrado de Oftalmologia, Centro Hospitalar e Universitario de Coimbra; Faculdade de Medicina, Universidade de Coimbra, Centro Academico Clinico de Coimbra, Portugal. FAU - Almeida, Mariana AU - Almeida M AD - Ophthalmology Department, Centro Hospitalar do Oeste, Caldas da Rainha, Portugal. FAU - Liverani, Marco AU - Liverani M AD - Ophthalmology Department, Hospital de Vila Franca de Xira, Vila Franca de Xira, Portugal. FAU - Morais Pina, Susana AU - Morais Pina S AD - Ophthalmology Department, Hospital Beatriz Angelo, Loures, Portugal. FAU - Bernardo, Manuela AU - Bernardo M AD - Ophthalmology Department, Hospital Prof Dr Fernando Fonseca EPE, Portugal. FAU - Nogueira, Vanda AU - Nogueira V AD - Instituto de Oftalmologia Dr. Gama Pinto, Lisbon, Portugal. FAU - Guerra Pinto, Rita AU - Guerra Pinto R AD - Instituto de Oftalmologia Dr. Gama Pinto, Lisbon, Portugal. FAU - Pinto Ferreira, Fernando AU - Pinto Ferreira F AD - Ophthalmology Department, Centro Hospitalar Universitario Lisboa Central, Lisbon, Portugal. FAU - Pinto Proenca, Rita AU - Pinto Proenca R AD - Ophthalmology Department, Centro Hospitalar Universitario Lisboa Central, Lisbon, Portugal. FAU - Domingues, Isabel AU - Domingues I AD - Ophthalmology Department, Hospital Lusiadas Lisboa, Portugal. FAU - Guedes, Marta AU - Guedes M AD - Ophthalmology Department, Hospital Egas Moniz, Centro Hospitalar de Lisboa Ocidental, Lisboa, Portugal. FAU - Cordeiro, Miguel AU - Cordeiro M AD - Ophthalmology Department, Hospital Egas Moniz, Centro Hospitalar de Lisboa Ocidental, Lisboa, Portugal. FAU - Fraga, Filipe AU - Fraga F AD - Ophthalmology Department, Hospital Garcia de Orta, Almada, Portugal. FAU - Berens, Olga AU - Berens O AD - Ophthalmology Department, Hospital do Espirito Santo, Evora, Portugal. FAU - Gregorio, Tatiana AU - Gregorio T AD - Ophthalmology Department, Hospital Dr. Nelio Mendonca, SESARAM, Funchal, Portugal. FAU - Brito, Iva AU - Brito I AD - Paediatric Rheumatology and Young Adult Unit,Centro Hospitalar Universitario S. Joao, Porto, Portugal; 11Faculdade de Medicina da Universidade do Porto, Portugal. FAU - Oliveira-Ramos, Filipa AU - Oliveira-Ramos F AD - Paediatric Rheumatology Unit, Hospital Santa Maria, Centro Hospitalar Universitario Lisboa Norte, Centro Academico de Medicina de Lisboa, Portugal; Rheumatology Research Unit, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade Lisboa. FAU - Fonseca, Joao Eurico AU - Fonseca JE AD - Rheumatology Research Unit, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa; Rheumatology Department, Hospital de Santa Maria, Centro Hospitalar Universitario Lisboa Norte, Centro Academico de Medicina de Lisboa, Portugal. FAU - Figueira, Luis AU - Figueira L AD - Ophthalmology Department, Centro Hospitalar Universitario Sao Joao, Porto, Portugal; Center for Drug Discovery and Innovative Medicines (MedInUP) of the University of Porto, Portugal. LA - eng PT - Journal Article PT - Systematic Review TT - The 2021 Portuguese Society of Ophthalmology joint guidelines with Paediatric Rheumatology on the screening, monitoring and medical treatment of juvenile idiopathic arthritis-associated uveitis. PL - Portugal TA - ARP Rheumatol JT - ARP rheumatology JID - 9918402287906676 SB - IM MH - *Arthritis, Juvenile/complications MH - Child MH - Humans MH - *Ophthalmology MH - Portugal MH - *Rheumatology MH - *Uveitis/diagnosis EDAT- 2022/05/29 06:00 MHDA- 2022/06/01 06:00 CRDT- 2022/05/28 17:32 PHST- 2022/05/28 17:32 [entrez] PHST- 2022/05/29 06:00 [pubmed] PHST- 2022/06/01 06:00 [medline] AID - PC210181 [pii] PST - ppublish SO - ARP Rheumatol. 2022 Jan-Mar;1(1):49-62. PMID- 35632506 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220716 IS - 2076-393X (Print) IS - 2076-393X (Electronic) IS - 2076-393X (Linking) VI - 10 IP - 5 DP - 2022 May 10 TI - A Social Network Analysis of Tweets Related to Mandatory COVID-19 Vaccination in Poland. LID - 10.3390/vaccines10050750 [doi] LID - 750 AB - Poland's efforts to combat COVID-19 were hindered by endemic vaccination hesitancy and the prevalence of opponents to pandemic restrictions. In this environment, the policy of a COVID-19 vaccination mandate faces strong resistance in the public debate. Exploring the discourse around this resistance could help uncover the motives and develop an understanding of vaccination hesitancy in Poland. This paper aims to conduct a social network analysis and content analysis of Twitter discussions around the intention of the Polish Ministry of Health to introduce mandatory vaccinations for COVID-19. Twitter was chosen as a platform to study because of the critical role it played during the global health crisis. Twitter data were retrieved from 26 July to 9 December 2021 through the API v2 for Academic Research, and analysed using NodeXL and Gephi. When conducting social network analysis, nodes were ranked by their betweenness centrality. Clustering analysis with the Clauset-Newman-Moore algorithm revealed two important groups of users: advocates and opponents of mandatory vaccination. The temporal trends of tweets, the most used hashtags, the sentiment expressed in the most popular tweets, and correlations with epidemiological data were also studied. The results reveal a substantial degree of polarisation, a high intensity of the discussion, and a high degree of involvement of Twitter users. Vaccination mandate advocates were consistently more numerous, but less engaged and less mobilised to "preach" their own stances. Vaccination mandate opponents were vocal and more mobilised to participate: either as original authors or as information diffusers. Our research leads to the conclusion that systematic monitoring of the public debate on vaccines is essential not only in counteracting misinformation, but also in crafting evidence-based as well as emotionally motivating narratives. FAU - Olszowski, Rafal AU - Olszowski R AUID- ORCID: 0000-0002-4494-3890 AD - Faculty of Humanities, AGH University of Science and Technology, Gramatyka 8a, 30-071 Krakow, Poland. AD - Center for Collective Intelligence, Massachusetts Institute of Technology, 245 First Street, E94, Cambridge, MA 02142, USA. FAU - Zabdyr-Jamroz, Michal AU - Zabdyr-Jamroz M AD - Faculty of Health Sciences, Institute of Public Health, Jagiellonian University Medical College, Skawinska 8 Street, 31-066 Krakow, Poland. FAU - Baran, Sebastian AU - Baran S AD - Department of Mathematics, Cracow University of Economics, Rakowicka 27, 31-510 Krakow, Poland. FAU - Pieta, Piotr AU - Pieta P AUID- ORCID: 0000-0001-8490-7117 AD - Faculty of Humanities, AGH University of Science and Technology, Gramatyka 8a, 30-071 Krakow, Poland. FAU - Ahmed, Wasim AU - Ahmed W AUID- ORCID: 0000-0001-8923-1865 AD - Stirling University Management School, University of Stirling, Stirling FK9 4LA, UK. LA - eng PT - Journal Article DEP - 20220510 PL - Switzerland TA - Vaccines (Basel) JT - Vaccines JID - 101629355 PMC - PMC9145409 OTO - NOTNLM OT - COVID-19 OT - Poland OT - Twitter debate OT - mandatory vaccination OT - social media OT - social network analysis OT - vaccination hesitancy COIS- The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results. EDAT- 2022/05/29 06:00 MHDA- 2022/05/29 06:01 PMCR- 2022/05/10 CRDT- 2022/05/28 01:44 PHST- 2021/12/31 00:00 [received] PHST- 2022/04/30 00:00 [revised] PHST- 2022/05/06 00:00 [accepted] PHST- 2022/05/28 01:44 [entrez] PHST- 2022/05/29 06:00 [pubmed] PHST- 2022/05/29 06:01 [medline] PHST- 2022/05/10 00:00 [pmc-release] AID - vaccines10050750 [pii] AID - vaccines-10-00750 [pii] AID - 10.3390/vaccines10050750 [doi] PST - epublish SO - Vaccines (Basel). 2022 May 10;10(5):750. doi: 10.3390/vaccines10050750. PMID- 35617363 OWN - NLM STAT- MEDLINE DCOM- 20220530 LR - 20240829 IS - 1549-1676 (Electronic) IS - 1549-1277 (Print) IS - 1549-1277 (Linking) VI - 19 IP - 5 DP - 2022 May TI - Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-2 infections: Update of a living systematic review and meta-analysis. PG - e1003987 LID - 10.1371/journal.pmed.1003987 [doi] LID - e1003987 AB - BACKGROUND: Debate about the level of asymptomatic Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection continues. The amount of evidence is increasing and study designs have changed over time. We updated a living systematic review to address 3 questions: (1) Among people who become infected with SARS-CoV-2, what proportion does not experience symptoms at all during their infection? (2) What is the infectiousness of asymptomatic and presymptomatic, compared with symptomatic, SARS-CoV-2 infection? (3) What proportion of SARS-CoV-2 transmission in a population is accounted for by people who are asymptomatic or presymptomatic? METHODS AND FINDINGS: The protocol was first published on 1 April 2020 and last updated on 18 June 2021. We searched PubMed, Embase, bioRxiv, and medRxiv, aggregated in a database of SARS-CoV-2 literature, most recently on 6 July 2021. Studies of people with PCR-diagnosed SARS-CoV-2, which documented symptom status at the beginning and end of follow-up, or mathematical modelling studies were included. Studies restricted to people already diagnosed, of single individuals or families, or without sufficient follow-up were excluded. One reviewer extracted data and a second verified the extraction, with disagreement resolved by discussion or a third reviewer. Risk of bias in empirical studies was assessed with a bespoke checklist and modelling studies with a published checklist. All data syntheses were done using random effects models. Review question (1): We included 130 studies. Heterogeneity was high so we did not estimate a mean proportion of asymptomatic infections overall (interquartile range (IQR) 14% to 50%, prediction interval 2% to 90%), or in 84 studies based on screening of defined populations (IQR 20% to 65%, prediction interval 4% to 94%). In 46 studies based on contact or outbreak investigations, the summary proportion asymptomatic was 19% (95% confidence interval (CI) 15% to 25%, prediction interval 2% to 70%). (2) The secondary attack rate in contacts of people with asymptomatic infection compared with symptomatic infection was 0.32 (95% CI 0.16 to 0.64, prediction interval 0.11 to 0.95, 8 studies). (3) In 13 modelling studies fit to data, the proportion of all SARS-CoV-2 transmission from presymptomatic individuals was higher than from asymptomatic individuals. Limitations of the evidence include high heterogeneity and high risks of selection and information bias in studies that were not designed to measure persistently asymptomatic infection, and limited information about variants of concern or in people who have been vaccinated. CONCLUSIONS: Based on studies published up to July 2021, most SARS-CoV-2 infections were not persistently asymptomatic, and asymptomatic infections were less infectious than symptomatic infections. Summary estimates from meta-analysis may be misleading when variability between studies is extreme and prediction intervals should be presented. Future studies should determine the asymptomatic proportion of SARS-CoV-2 infections caused by variants of concern and in people with immunity following vaccination or previous infection. Without prospective longitudinal studies with methods that minimise selection and measurement biases, further updates with the study types included in this living systematic review are unlikely to be able to provide a reliable summary estimate of the proportion of asymptomatic infections caused by SARS-CoV-2. REVIEW PROTOCOL: Open Science Framework (https://osf.io/9ewys/). FAU - Buitrago-Garcia, Diana AU - Buitrago-Garcia D AUID- ORCID: 0000-0001-9761-206X AD - Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland. AD - Graduate School of Health Sciences, University of Bern, Bern, Switzerland. FAU - Ipekci, Aziz Mert AU - Ipekci AM AUID- ORCID: 0000-0002-0260-9691 AD - Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland. FAU - Heron, Leonie AU - Heron L AUID- ORCID: 0000-0002-3820-3343 AD - Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland. FAU - Imeri, Hira AU - Imeri H AUID- ORCID: 0000-0002-0412-1649 AD - Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland. FAU - Araujo-Chaveron, Lucia AU - Araujo-Chaveron L AUID- ORCID: 0000-0002-2110-6088 AD - EHESP French School of Public Health, Paris and Rennes, France. AD - Institut Pasteur, Paris, France. FAU - Arevalo-Rodriguez, Ingrid AU - Arevalo-Rodriguez I AUID- ORCID: 0000-0002-7326-4504 AD - Clinical Biostatistics Unit, Hospital Universitario Ramon y Cajal, IRYCIS, CIBER of Epidemiology and Public Health, Madrid, Spain. FAU - Ciapponi, Agustin AU - Ciapponi A AUID- ORCID: 0000-0001-5142-6122 AD - Instituto de Efectividad Clinica y Sanitaria (IECS-CONICET), Buenos Aires, Argentina. FAU - Cevik, Muge AU - Cevik M AUID- ORCID: 0000-0003-1133-3874 AD - Division of Infection and Global Health Research, School of Medicine, University of St. Andrews, Fife, Scotland, United Kingdom. FAU - Hauser, Anthony AU - Hauser A AUID- ORCID: 0000-0002-7221-1929 AD - Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland. FAU - Alam, Muhammad Irfanul AU - Alam MI AUID- ORCID: 0000-0002-8759-6585 AD - EHESP French School of Public Health, Paris and Rennes, France. FAU - Meili, Kaspar AU - Meili K AUID- ORCID: 0000-0002-9889-4406 AD - Department of Epidemiology and Global Health, Umea University, Umea, Sweden. FAU - Meyerowitz, Eric A AU - Meyerowitz EA AUID- ORCID: 0000-0001-7954-6548 AD - Division of Infectious Diseases, Montefiore Medical Center, Bronx, New York, New York, United States of America. FAU - Prajapati, Nirmala AU - Prajapati N AUID- ORCID: 0000-0001-7518-5968 AD - Universite Paris-Saclay, Paris, France. FAU - Qiu, Xueting AU - Qiu X AUID- ORCID: 0000-0001-6810-7304 AD - Center for Communicable Disease Dynamics, Department of Epidemiology, Harvard TH Chan School of Public Health, Boston, Massachusetts, United States of America. FAU - Richterman, Aaron AU - Richterman A AUID- ORCID: 0000-0001-7920-7191 AD - Division of Infectious Diseases, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America. FAU - Robles-Rodriguez, William Gildardo AU - Robles-Rodriguez WG AUID- ORCID: 0000-0002-8383-6844 AD - Fundacion Universitaria de Ciencias de la Salud, Bogota, Colombia. FAU - Thapa, Shabnam AU - Thapa S AD - Manchester Centre for Health Economics, University of Manchester, Manchester, United Kingdom. FAU - Zhelyazkov, Ivan AU - Zhelyazkov I AUID- ORCID: 0000-0001-6320-7517 AD - University of Sheffield, Sheffield, United Kingdom. FAU - Salanti, Georgia AU - Salanti G AUID- ORCID: 0000-0002-3830-8508 AD - Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland. FAU - Low, Nicola AU - Low N AUID- ORCID: 0000-0003-4817-8986 AD - Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland. LA - eng PT - Journal Article PT - Meta-Analysis PT - Research Support, Non-U.S. Gov't PT - Systematic Review DEP - 20220526 PL - United States TA - PLoS Med JT - PLoS medicine JID - 101231360 SB - IM MH - Asymptomatic Infections/epidemiology MH - *COVID-19/epidemiology MH - Humans MH - Mass Screening MH - Prospective Studies MH - SARS-CoV-2 PMC - PMC9135333 COIS- I have read the journal's policy and the authors of this manuscript have the following competing interests: NL is an academic editor at PLOS Medicine, received the grant funding from the organisations declared above, is a member of the Swiss National COVID-19 Science Task Force, and is on the scientific board of Sefunda, a start-up company that develops point-of-care diagnostics for sexually transmitted infections. DBG receives funding from the organisations declared above. AMI, LH, HI receive salary support from the grants to NL from the Swiss National Science Foundation 320030_176233, and/or European Union H2020 101003688 EDAT- 2022/05/27 06:00 MHDA- 2022/05/31 06:00 PMCR- 2022/05/26 CRDT- 2022/05/26 14:03 PHST- 2022/01/24 00:00 [received] PHST- 2022/04/13 00:00 [accepted] PHST- 2022/05/26 14:03 [entrez] PHST- 2022/05/27 06:00 [pubmed] PHST- 2022/05/31 06:00 [medline] PHST- 2022/05/26 00:00 [pmc-release] AID - PMEDICINE-D-22-00260 [pii] AID - 10.1371/journal.pmed.1003987 [doi] PST - epublish SO - PLoS Med. 2022 May 26;19(5):e1003987. doi: 10.1371/journal.pmed.1003987. eCollection 2022 May. PMID- 35615972 OWN - NLM STAT- MEDLINE DCOM- 20220708 LR - 20260612 IS - 1365-2222 (Electronic) IS - 0954-7894 (Linking) VI - 52 IP - 7 DP - 2022 Jul TI - Detection and management of milk allergy: Delphi consensus study. PG - 848-858 LID - 10.1111/cea.14179 [doi] AB - BACKGROUND: There is significant overdiagnosis of milk allergy in young children in some countries, leading to unnecessary use of specialized formula. This guidance, developed by experts without commercial ties to the formula industry, aims to reduce milk allergy overdiagnosis and support carers of children with suspected milk allergy. METHODS: Delphi study involving two rounds of anonymous consensus building and an open meeting between January and July 2021. Seventeen experts in general practice, nutrition, midwifery, health visiting, lactation support and relevant areas of paediatrics participated, located in Europe, North America, Middle East, Africa, Australia and Asia. Five authors of previous milk allergy guidelines and seven parents provided feedback. FINDINGS: Participants agreed on 38 essential recommendations through consensus. Recommendations highlighted the importance of reproducibility and specificity for diagnosing milk allergy in children with acute or delayed symptoms temporally related to milk protein ingestion; and distinguished between children directly consuming milk protein and exclusively breastfed infants. Consensus was reached that maternal dietary restriction is not usually necessary to manage milk allergy, and that for exclusively breastfed infants with chronic symptoms, milk allergy diagnosis should only be considered in specific, rare circumstances. Consensus was reached that milk allergy diagnosis does not need to be considered for stool changes, aversive feeding or occasional spots of blood in stool, if there is no temporal relationship with milk protein ingestion. When compared with previous guidelines, these consensus recommendations resulted in more restrictive criteria for detecting milk allergy and a more limited role for maternal dietary exclusions and specialized formula. INTERPRETATION: These new milk allergy recommendations from non-conflicted, multidisciplinary experts advise narrower criteria, more prominent support for breastfeeding and less use of specialized formula, compared with current guidelines. CI - (c) 2022 The Authors. Clinical & Experimental Allergy published by John Wiley & Sons Ltd. FAU - Allen, Hilary I AU - Allen HI AD - National Heart and Lung Institute, Imperial College London, London, UK. FAU - Pendower, Ursula AU - Pendower U AD - National Heart and Lung Institute, Imperial College London, London, UK. FAU - Santer, Miriam AU - Santer M AD - Primary Care Research Centre, University of Southampton, Southampton, UK. FAU - Groetch, Marion AU - Groetch M AD - Department of Pediatrics, Jaffe Food Allergy Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA. FAU - Cohen, Mitchell AU - Cohen M AD - Department of Paediatrics, University of Alabama at Birmingham & Children's of Alabama, Birmingham, Alabama, USA. FAU - Murch, Simon H AU - Murch SH AD - University of Warwick, Coventry, UK. FAU - Williams, Hywel C AU - Williams HC AD - Centre of Evidence Based Dermatology, School of Medicine, University of Nottingham, Nottingham, UK. FAU - Munblit, Daniel AU - Munblit D AUID- ORCID: 0000-0001-9652-6856 AD - Department of Paediatrics and Paediatric Infectious Diseases, Institute of Child's Health, Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia. FAU - Katz, Yitzhak AU - Katz Y AD - Allergy and Immunology Institute, Assaf Harofeh Medical Center, Department of Paediatrics, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. FAU - Gupta, Neeraj AU - Gupta N AD - Division of Paediatric Allergy, Department of Paediatrics, Institute of Child Health, Sir Ganga Ram Hospital, Rajinder Nagar, New Delhi, India. FAU - Adil, Sabeen AU - Adil S AD - International Lactation Consultant Association, Raleigh, North Carolina, USA. FAU - Baines, Justine AU - Baines J AD - Manchester Children's Community Centre, Manchester, UK. FAU - de Bont, Eefje G P M AU - de Bont EGPM AD - Department of Family Medicine, CAPHRI School for Public Health and Primary Care, Maastricht University, Maastricht, The Netherlands. FAU - Ridd, Matthew AU - Ridd M AUID- ORCID: 0000-0002-7954-8823 AD - Population Health Sciences, University of Bristol, Bristol, UK. FAU - Sibson, Victoria L AU - Sibson VL AD - First Steps Nutrition Trust, London, UK. FAU - McFadden, Alison AU - McFadden A AD - Mother and Infant Research Unit, University of Dundee, Dundee, UK. FAU - Koplin, Jennifer J AU - Koplin JJ AUID- ORCID: 0000-0002-7576-5142 AD - Murdoch Children's Research Institute, Parkville, Victoria, Australia. FAU - Munene, Josephine AU - Munene J AD - Certified Lactation Educator, Kenya Association for Breastfeeding and La Leche League South Africa, Nairobi, Kenya. FAU - Perkin, Michael R AU - Perkin MR AUID- ORCID: 0000-0001-9272-2585 AD - Population Health Research Institute, St George's University of London, London, UK. FAU - Sicherer, Scott H AU - Sicherer SH AD - Department of Paediatrics, University of Alabama at Birmingham & Children's of Alabama, Birmingham, Alabama, USA. FAU - Boyle, Robert J AU - Boyle RJ AUID- ORCID: 0000-0002-4913-7580 AD - National Heart and Lung Institute, Imperial College London, London, UK. LA - eng PT - Consensus Statement PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20220610 PL - England TA - Clin Exp Allergy JT - Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology JID - 8906443 RN - 0 (Allergens) RN - 0 (Milk Proteins) SB - IM MH - Allergens MH - Child MH - Child, Preschool MH - Delphi Technique MH - Female MH - Humans MH - Infant MH - Infant Formula MH - *Milk Hypersensitivity/diagnosis MH - Milk Proteins MH - Reproducibility of Results OTO - NOTNLM OT - Cow's milk allergy OT - Delphi consensus OT - breastfeeding OT - overdiagnosis EDAT- 2022/05/27 06:00 MHDA- 2022/07/09 06:00 CRDT- 2022/05/26 04:43 PHST- 2022/05/17 00:00 [revised] PHST- 2022/03/08 00:00 [received] PHST- 2022/05/19 00:00 [accepted] PHST- 2022/05/27 06:00 [pubmed] PHST- 2022/07/09 06:00 [medline] PHST- 2022/05/26 04:43 [entrez] AID - 10.1111/cea.14179 [doi] PST - ppublish SO - Clin Exp Allergy. 2022 Jul;52(7):848-858. doi: 10.1111/cea.14179. Epub 2022 Jun 10. PMID- 35605636 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260410 LR - 20260410 IS - 1476-1645 (Electronic) IS - 0002-9637 (Print) IS - 0002-9637 (Linking) VI - 107 IP - 1 DP - 2022 Jul 13 TI - Transmission Dynamics of COVID-19 in Ghana and the Impact of Public Health Interventions. PG - 175-179 LID - 10.4269/ajtmh.21-0718 [doi] AB - This study characterized COVID-19 transmission in Ghana in 2020 and 2021 by estimating the time-varying reproduction number (Rt) and exploring its association with various public health interventions at the national and regional levels. Ghana experienced four pandemic waves, with epidemic peaks in July 2020 and January, August, and December 2021. The epidemic peak was the highest nationwide in December 2021 with Rt >/= 2. Throughout 2020 and 2021, per-capita cumulative case count by region increased with population size. Mobility data suggested a negative correlation between Rt and staying home during the first 90 days of the pandemic. The relaxation of movement restrictions and religious gatherings was not associated with increased Rt in the regions with fewer case burdens. Rt decreased from > 1 when schools reopened in January 2021 to < 1 after vaccination rollout in March 2021. Findings indicated most public health interventions were associated with Rt reduction at the national and regional levels. FAU - Ofori, Sylvia K AU - Ofori SK AD - Department of Biostatistics, Epidemiology and Environmental Health Sciences, Jiann-Ping Hsu College of Public Health, Georgia Southern University, Statesboro, Georgia. FAU - Schwind, Jessica S AU - Schwind JS AD - Department of Biostatistics, Epidemiology and Environmental Health Sciences, Jiann-Ping Hsu College of Public Health, Georgia Southern University, Statesboro, Georgia. FAU - Sullivan, Kelly L AU - Sullivan KL AD - Department of Biostatistics, Epidemiology and Environmental Health Sciences, Jiann-Ping Hsu College of Public Health, Georgia Southern University, Statesboro, Georgia. FAU - Cowling, Benjamin J AU - Cowling BJ AD - WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region. FAU - Chowell, Gerardo AU - Chowell G AD - Department of Population Health Sciences, School of Public Health, Georgia State University, Atlanta, Georgia. FAU - Fung, Isaac Chun-Hai AU - Fung IC AD - Department of Biostatistics, Epidemiology and Environmental Health Sciences, Jiann-Ping Hsu College of Public Health, Georgia Southern University, Statesboro, Georgia. LA - eng PT - Journal Article DEP - 20220523 PL - United States TA - Am J Trop Med Hyg JT - The American journal of tropical medicine and hygiene JID - 0370507 SB - IM PMC - PMC9294683 EDAT- 2022/05/24 06:00 MHDA- 2022/05/24 06:01 PMCR- 2022/05/23 CRDT- 2022/05/23 19:03 PHST- 2021/06/24 00:00 [received] PHST- 2022/04/05 00:00 [accepted] PHST- 2022/05/24 06:01 [medline] PHST- 2022/05/24 06:00 [pubmed] PHST- 2022/05/23 19:03 [entrez] PHST- 2022/05/23 00:00 [pmc-release] AID - tpmd210718 [pii] AID - 10.4269/ajtmh.21-0718 [doi] PST - epublish SO - Am J Trop Med Hyg. 2022 May 23;107(1):175-179. doi: 10.4269/ajtmh.21-0718. Print 2022 Jul 13. PMID- 35589348 OWN - NLM STAT- MEDLINE DCOM- 20220523 LR - 20220716 IS - 2044-6055 (Electronic) IS - 2044-6055 (Linking) VI - 12 IP - 5 DP - 2022 May 19 TI - Examining the psychological and financial impact of travel restrictions on citizens and permanent residents stranded abroad during the COVID-19 pandemic: international cross-sectional study. PG - e059922 LID - 10.1136/bmjopen-2021-059922 [doi] LID - e059922 AB - OBJECTIVES: This study aimed to evaluate the psychological and financial distress reported by citizens and permanent residents stranded abroad due to international travel restrictions introduced in response to the COVID-19 pandemic. DESIGN: An international cross-sectional study. SETTING: A primary analysis of data collected between July and September 2021 through an online survey targeting individuals stranded abroad and unable to return to their country of residence due to international travel restrictions. RESPONDENTS: A total of 1054 individuals aged 18-84 years. DATA ANALYSIS: Multivariable logistic regression models were used to explore the relationship between higher levels of depression, anxiety and stress and participant variables. OUTCOME MEASURES: The survey answered questions regarding COVID-19 travel restriction-related impacts: personal stress, anxiety and depression (using the validated 21-item Depression, Anxiety and Stress Scale (DASS-21) tool), as well as impacts on housing and financial security and demographic data. RESULTS: A total of 75.4% of respondents reported wanting to return to the Oceania region (75.4%), with 45% stranded in Europe. 64.2% reported financial distress while stranded abroad. 64.4% (x̄=9.43, SD=5.81) reported moderate-to-extremely severe (based on the DASS-21 classification) levels of depression, 41.7% for anxiety (x̄=5.46, SD=4.74), and 58.1% for stress (x̄=10.64, SD=5.26). Multivariable analysis indicated that financial stress, an employment change, being <30 years, having a high perceived risk of contracting COVID-19 abroad and being stranded for >2 months were significantly related to scores of moderate-to-extremely severe depression, anxiety and stress. CONCLUSION: The study is among the first to explore the psychological and financial distress-related impacts associated with being stranded abroad due to COVID-19 travel restrictions. It highlights a range of unintended consequences that arise from pandemic-related travel restrictions, identifies the health and social needs of a particularly vulnerable population, and provides clues as to the types of support that may be adopted to best support them. CI - (c) Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. FAU - McDermid, Pippa AU - McDermid P AUID- ORCID: 0000-0001-6393-4271 AD - School of Population Health, University of New South Wales, Sydney, New South Wales, Australia. FAU - Craig, Adam AU - Craig A AD - School of Population Health, University of New South Wales, Sydney, New South Wales, Australia. FAU - Sheel, Meru AU - Sheel M AUID- ORCID: 0000-0001-5453-070X AD - Sydney School of Public Health, The University of Sydney, Sydney, New South Wales, Australia. FAU - Blazek, Katrina AU - Blazek K AD - School of Population Health, University of New South Wales, Sydney, New South Wales, Australia. FAU - Talty, Siobhan AU - Talty S AD - The Me AL/TA, Madrid, Spain. FAU - Seale, Holly AU - Seale H AUID- ORCID: 0000-0002-1877-5395 AD - School of Population Health, University of New South Wales, Sydney, New South Wales, Australia h.seale@unsw.edu.au. LA - eng PT - Journal Article DEP - 20220519 PL - England TA - BMJ Open JT - BMJ open JID - 101552874 SB - IM MH - Anxiety/epidemiology/psychology MH - *COVID-19/epidemiology MH - Cross-Sectional Studies MH - Depression/epidemiology/psychology MH - Humans MH - Pandemics MH - SARS-CoV-2 MH - Stress, Psychological/epidemiology MH - Surveys and Questionnaires PMC - PMC9121108 OTO - NOTNLM OT - COVID-19 OT - INFECTIOUS DISEASES OT - MENTAL HEALTH OT - Public health COIS- Competing interests: None declared. EDAT- 2022/05/20 06:00 MHDA- 2022/05/24 06:00 PMCR- 2022/05/19 CRDT- 2022/05/19 21:12 PHST- 2022/05/19 21:12 [entrez] PHST- 2022/05/20 06:00 [pubmed] PHST- 2022/05/24 06:00 [medline] PHST- 2022/05/19 00:00 [pmc-release] AID - bmjopen-2021-059922 [pii] AID - 10.1136/bmjopen-2021-059922 [doi] PST - epublish SO - BMJ Open. 2022 May 19;12(5):e059922. doi: 10.1136/bmjopen-2021-059922. PMID- 35586200 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220716 IS - 1179-1462 (Electronic) IS - 1179-1462 (Linking) VI - 14 DP - 2022 TI - Distal and/or Proximal Joint Stiffness Among Post-Fracture Patients Treated in University of Gondar Comprehensive Specialized Hospital, Gondar, Ethiopia. PG - 157-167 LID - 10.2147/ORR.S365011 [doi] AB - BACKGROUND: Stiffness, or more precisely, a restriction in the range of motion, is a potential complication following any intra- or extra-articular injury. The passive or active range of motion of the physiological joint is an important factor in determining the significance of joint stiffness. The goals of this study were to assess the incidence of joint stiffness following a fracture, using a standard goniometer, and to identify potential predictors of joint stiffness among post-fracture patients. METHODS: A prospective hospital-based cross-sectional study was conducted from July 1, 2021 to September 13, 2021, at University of Gondar Comprehensive Specialized Hospital. A total of 230 study participants participated in the study, and systematic sampling methods were used to recruit the study participants. Bivariate and multivariable binary logistic regression model analyses were conducted, with SPSS version 23, to identify factors associated with post-fracture joint stiffness. RESULTS: The overall prevalence of post-fracture stiffness was 25.7% (n=59). Having a left-side fracture (AOR=10.83; 95% CI 1.71-17.74), patients having no physiotherapy follow-up (AOR=6.72; 95% CI 1.79-25.13), and patients using assistive devices (AOR=11.95; 95% CI 3.63-39.35) were significantly associated with post-fracture stiffness, with p-values of less than 0.05. CONCLUSION: The study found that one-quarter of the study participants experienced post-fracture joint stiffness. A fracture on the left side, individuals with no physiotherapy follow-up, and the use of assistive devices were found to be independent predictors of joint stiffness. Early referral of fracture patients to the rehabilitation center is recommended to prevent post-fracture complications and joint stiffness. CI - (c) 2022 Gashaw et al. FAU - Gashaw, Moges AU - Gashaw M AUID- ORCID: 0000-0002-4532-1786 AD - Department of Physiotherapy, School of Medicine, College of Medicine and Health Sciences, University of Gondar Comprehensive Specialized Hospital, Gondar, Ethiopia. FAU - Aragaw, Fantu Mamo AU - Aragaw FM AUID- ORCID: 0000-0002-4128-077X AD - Department of Epidemiology and Biostatistics, Institute of Public Health, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia. FAU - Zemed, Ashenafi AU - Zemed A AUID- ORCID: 0000-0002-5565-1420 AD - Department of Physiotherapy, School of Medicine, College of Medicine and Health Sciences, University of Gondar Comprehensive Specialized Hospital, Gondar, Ethiopia. FAU - Endalew, Mastewal AU - Endalew M AD - Department of Environmental and Occupational Health and Safety, Institute of Public Health, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia. FAU - Tsega, Nuhamin Tesfa AU - Tsega NT AUID- ORCID: 0000-0002-8194-9896 AD - Department of Women's and Family Health, School of Midwifery, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia. FAU - Asratie, Melaku Hunie AU - Asratie MH AUID- ORCID: 0000-0002-2281-7519 AD - Department of Women's and Family Health, School of Midwifery, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia. FAU - Belay, Daniel Gashaneh AU - Belay DG AUID- ORCID: 0000-0002-5724-6234 AD - Department of Epidemiology and Biostatistics, Institute of Public Health, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia. AD - Department of Human Anatomy, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia. LA - eng PT - Journal Article DEP - 20220512 PL - New Zealand TA - Orthop Res Rev JT - Orthopedic research and reviews JID - 101531415 PMC - PMC9109725 OTO - NOTNLM OT - fracture OT - joint OT - physiotherapy OT - range of motion OT - stiffness COIS- All authors declare that they have no financial or personal conflicts of interest as a result of this work. EDAT- 2022/05/20 06:00 MHDA- 2022/05/20 06:01 PMCR- 2022/05/12 CRDT- 2022/05/19 02:20 PHST- 2022/03/04 00:00 [received] PHST- 2022/04/26 00:00 [accepted] PHST- 2022/05/19 02:20 [entrez] PHST- 2022/05/20 06:00 [pubmed] PHST- 2022/05/20 06:01 [medline] PHST- 2022/05/12 00:00 [pmc-release] AID - 365011 [pii] AID - 10.2147/ORR.S365011 [doi] PST - epublish SO - Orthop Res Rev. 2022 May 12;14:157-167. doi: 10.2147/ORR.S365011. eCollection 2022. PMID- 35579382 OWN - NLM STAT- MEDLINE DCOM- 20220519 LR - 20260927 IS - 1469-493X (Electronic) IS - 1361-6137 (Linking) VI - 5 IP - 5 DP - 2022 May 17 TI - Physiotherapy for pain and disability in adults with complex regional pain syndrome (CRPS) types I and II. PG - CD010853 LID - 10.1002/14651858.CD010853.pub3 [doi] LID - CD010853 AB - BACKGROUND: Complex regional pain syndrome (CRPS) is a painful and disabling condition that usually manifests in response to trauma or surgery and is associated with significant pain and disability. CRPS can be classified into two types: type I (CRPS I) in which a specific nerve lesion has not been identified and type II (CRPS II) where there is an identifiable nerve lesion. Guidelines recommend the inclusion of a variety of physiotherapy interventions as part of the multimodal treatment of people with CRPS. This is the first update of the review originally published in Issue 2, 2016. OBJECTIVES: To determine the effectiveness of physiotherapy interventions for treating pain and disability associated with CRPS types I and II in adults. SEARCH METHODS: For this update we searched CENTRAL (the Cochrane Library), MEDLINE, Embase, CINAHL, PsycINFO, LILACS, PEDro, Web of Science, DARE and Health Technology Assessments from February 2015 to July 2021 without language restrictions, we searched the reference lists of included studies and we contacted an expert in the field. We also searched additional online sources for unpublished trials and trials in progress. SELECTION CRITERIA: We included randomised controlled trials (RCTs) of physiotherapy interventions compared with placebo, no treatment, another intervention or usual care, or other physiotherapy interventions in adults with CRPS I and II. Primary outcomes were pain intensity and disability. Secondary outcomes were composite scores for CRPS symptoms, health-related quality of life (HRQoL), patient global impression of change (PGIC) scales and adverse effects. DATA COLLECTION AND ANALYSIS: Two review authors independently screened database searches for eligibility, extracted data, evaluated risk of bias and assessed the certainty of evidence using the GRADE system. MAIN RESULTS: We included 16 new trials (600 participants) along with the 18 trials from the original review totalling 34 RCTs (1339 participants). Thirty-three trials included participants with CRPS I and one trial included participants with CRPS II. Included trials compared a diverse range of interventions including physical rehabilitation, electrotherapy modalities, cortically directed rehabilitation, electroacupuncture and exposure-based approaches. Most interventions were tested in small, single trials. Most were at high risk of bias overall (27 trials) and the remainder were at 'unclear' risk of bias (seven trials). For all comparisons and outcomes where we found evidence, we graded the certainty of the evidence as very low, downgraded due to serious study limitations, imprecision and inconsistency. Included trials rarely reported adverse effects. Physiotherapy compared with minimal care for adults with CRPS I One trial (135 participants) of multimodal physiotherapy, for which pain data were unavailable, found no between-group differences in pain intensity at 12-month follow-up. Multimodal physiotherapy demonstrated a small between-group improvement in disability at 12 months follow-up compared to an attention control (Impairment Level Sum score, 5 to 50 scale; mean difference (MD) -3.7, 95% confidence interval (CI) -7.13 to -0.27) (very low-certainty evidence). Equivalent data for pain were not available. Details regarding adverse events were not reported. Physiotherapy compared with minimal care for adults with CRPS II We did not find any trials of physiotherapy compared with minimal care for adults with CRPS II. AUTHORS' CONCLUSIONS: The evidence is very uncertain about the effects of physiotherapy interventions on pain and disability in CRPS. This conclusion is similar to our 2016 review. Large-scale, high-quality RCTs with longer-term follow-up are required to test the effectiveness of physiotherapy-based interventions for treating pain and disability in adults with CRPS I and II. CI - Copyright (c) 2022 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. FAU - Smart, Keith M AU - Smart KM AD - UCD School of Public Health, Physiotherapy and Sports Science, University College Dublin, Dublin, Ireland. AD - Physiotherapy Department, St Vincent's University Hospital, Dublin, Ireland. FAU - Ferraro, Michael C AU - Ferraro MC AD - Centre for Pain IMPACT, Neuroscience Research Australia, Sydney, Australia. AD - School of Health Sciences, Faculty of Medicine, University of New South Wales, Sydney, Australia. FAU - Wand, Benedict M AU - Wand BM AD - School of Physiotherapy, The University of Notre Dame Australia, Fremantle, Australia. FAU - O'Connell, Neil E AU - O'Connell NE AD - Department of Health Sciences, Centre for Health and Wellbeing Across the Lifecourse, Brunel University London, Uxbridge, UK. LA - eng SI - ClinicalTrials.gov/NCT01944150 SI - ClinicalTrials.gov/NCT02753335 PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Systematic Review DEP - 20220517 PL - England TA - Cochrane Database Syst Rev JT - The Cochrane database of systematic reviews JID - 100909747 SB - IM UOF - Cochrane Database Syst Rev. 2016 Feb 24;2:CD010853. doi: 10.1002/14651858.CD010853.pub2. PMID: 26905470 MH - Adult MH - *Complex Regional Pain Syndromes/therapy MH - *Electric Stimulation Therapy MH - Humans MH - Pain MH - Pain Measurement MH - Physical Therapy Modalities PMC - PMC9112661 COIS- KMS: none known. KMS maintains a small clinical caseload as a clinical specialist physiotherapist and manages patients with CRPS. MCF: none known. BMW: none known. NOC: none known. NOC is an author as well as PaPaS Co-ordinating Editor but had no input into the editorial decisions or processes for this review. KMS, BMW and NOC are qualified physiotherapists, and MCF is a health scientist, although none currently practice in private health care or for a 'for profit' organisation. Since NOC is an author and PaPaS Co-ordinating Editor, we acknowledge the input of Christopher Eccleston, who acted as Sign-off Editor for this review. NOC had no input into the editorial decisions or processes for this review. EDAT- 2022/05/18 06:00 MHDA- 2022/05/20 06:00 PMCR- 2023/05/17 CRDT- 2022/05/17 08:23 PHST- 2022/05/17 08:23 [entrez] PHST- 2022/05/18 06:00 [pubmed] PHST- 2022/05/20 06:00 [medline] PHST- 2023/05/17 00:00 [pmc-release] AID - CD010853.pub3 [pii] AID - 10.1002/14651858.CD010853.pub3 [doi] PST - epublish SO - Cochrane Database Syst Rev. 2022 May 17;5(5):CD010853. doi: 10.1002/14651858.CD010853.pub3. PMID- 35576000 OWN - NLM STAT- MEDLINE DCOM- 20220707 LR - 20250728 IS - 2168-6211 (Electronic) IS - 2168-6203 (Print) IS - 2168-6203 (Linking) VI - 176 IP - 7 DP - 2022 Jul 1 TI - Association Between High-Need Education-Based Funding and School Suspension Rates for Autistic Students in New Zealand. PG - 664-671 LID - 10.1001/jamapediatrics.2022.1296 [doi] AB - IMPORTANCE: Autistic students often experience poor educational outcomes that have implications for later life, including unemployment, interactions with the criminal justice system, increased risk for substance abuse, and low socioeconomic status. Improving educational outcomes is critical for ensuring that autistic young people can reach their potential. OBJECTIVE: To quantify differences in suspension rates between autistic and nonautistic students and to assess whether high-need education-based funding for autistic students is associated with reduced rates of school suspension. DESIGN, SETTING, AND PARTICIPANTS: This national cohort study used linked health and education data from New Zealand's Integrated Data Infrastructure. Data were obtained for students aged 5 to 16 years from January 1 to December 31, 2018, and analyzed July 7, 2021, to January 1, 2022. A novel case identification method was used to identify autistic students. EXPOSURES: High-need education-based funding (Ongoing Resourcing Scheme [ORS]) obtained before 2019. MAIN OUTCOMES AND MEASURES: Rates of suspension from school. Crude and adjusted analyses of the association between suspension rates and autism among the full population with adjustment made for sociodemographic characteristics (sex, age, ethnicity, deprivation, and urban or rural profile of residence) were conducted using complete-case, 2-level random intercept logistic multivariable regressions. To assess the association between ORS funding and suspension, analysis was restricted to autistic students. RESULTS: Of the 736 911 students in the study population, 9741 (1.3%) were identified as autistic (median [SD] age, 10 [3.2] years; 7710 [79.1%] boys), and 727 170 (98.7%) as nonautistic (median [SD] age, 10 [3.4] years; 369 777 [50.9%] boys). School suspension was experienced by 504 autistic students (5.2%) and 13 845 nonautistic students (1.9%). After adjustment for demographic characteristics, autistic students had significantly higher odds of suspension than their nonautistic peers (adjusted odds ratio, 2.81; 95% CI, 2.55-3.11). Of the 9741 autistic students, 2895 (29.7%) received high-need education-based (ORS) funding. Suspensions were experienced by 57 autistic students (2.0%) with high-need funding and 447 autistic students (6.5%) without high-need funding. After adjustment for demographic characteristics, co-occurring conditions, and level of disability support need, autistic students with high-need funding had significantly lower odds of suspension than autistic students without high-need funding (adjusted odds ratio, 0.29; 95% CI, 0.21-0.40). CONCLUSIONS AND RELEVANCE: In this cohort study, the findings of disparities in suspension rates between autistic and nonautistic students underscore the challenges faced in providing inclusive education for all young people, regardless of disability status. This study found that high-need funding was associated with reduced suspension rates among autistic students, suggesting that if appropriate supports are afforded to autistic students, a more inclusive education can be provided. FAU - Bowden, Nicholas AU - Bowden N AD - A Better Start National Science Challenge, Auckland, New Zealand. AD - Department of Women's and Children's Health, University of Otago, Dunedin, New Zealand. FAU - Gibb, Sheree AU - Gibb S AD - A Better Start National Science Challenge, Auckland, New Zealand. AD - Department of Public Health, University of Otago Wellington, Wellington, New Zealand. FAU - Audas, Richard AU - Audas R AD - A Better Start National Science Challenge, Auckland, New Zealand. AD - Department of Women's and Children's Health, University of Otago, Dunedin, New Zealand. FAU - Clendon, Sally AU - Clendon S AD - Institute of Education, Massey University, Auckland, New Zealand. FAU - Dacombe, Joanne AU - Dacombe J AD - Department of Women's and Children's Health, University of Otago, Dunedin, New Zealand. AD - Autism New Zealand, Wellington, New Zealand. FAU - Kokaua, Jesse AU - Kokaua J AD - A Better Start National Science Challenge, Auckland, New Zealand. AD - Va'a O Tautai, Centre for Pacific Health, Division of Health Sciences, University of Otago, Dunedin, New Zealand. FAU - Milne, Barry J AU - Milne BJ AD - A Better Start National Science Challenge, Auckland, New Zealand. AD - Centre of Methods and Policy Application in the Social Sciences, Faculty of Arts, University of Auckland, Auckland, New Zealand. AD - School of Social Sciences, Faculty of Arts, University of Auckland, Auckland, New Zealand. FAU - Mujoo, Himang AU - Mujoo H AD - Department of Women's and Children's Health, University of Otago, Dunedin, New Zealand. FAU - Murray, Samuel William AU - Murray SW AD - CCS Disability Action, Dunedin, New Zealand. FAU - Smiler, Kirsten AU - Smiler K AD - School of Health, Victoria University of Wellington, Wellington, New Zealand. FAU - Stace, Hilary AU - Stace H AD - Health Services Research Centre, Victoria University of Wellington, Wellington, New Zealand. FAU - van der Meer, Larah AU - van der Meer L AD - Autism New Zealand, Wellington, New Zealand. AD - Faculty of Education, Victoria University of Wellington, Wellington, New Zealand. FAU - Taylor, Barry James AU - Taylor BJ AD - A Better Start National Science Challenge, Auckland, New Zealand. AD - Department of Women's and Children's Health, University of Otago, Dunedin, New Zealand. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - JAMA Pediatr JT - JAMA pediatrics JID - 101589544 SB - IM MH - Adolescent MH - *Autistic Disorder/epidemiology MH - Child MH - Cohort Studies MH - Female MH - Humans MH - Male MH - New Zealand/epidemiology MH - Schools MH - Students PMC - PMC9112133 COIS- Conflict of Interest Disclosures: Dr Gibb reported receiving grants from the New Zealand Ministry of Business, Innovation, and Employment during the conduct of the study and from Janssen-Cilag Pty Ltd outside the submitted work. Mrs Dacombe reported performing paid advisory work for the New Zealand Ministry of Education outside the submitted work. Dr Kokaua reported receiving grants from the Health Research Council of New Zealand during the conduct of the study. Dr Milne reported receiving grants from the New Zealand Ministry of Business, Innovation, and Employment during the conduct of the study. Prof Taylor reported receiving grants from the University of Auckland under the Better Start National Science Challenge during the conduct of the study. No other disclosures were reported. EDAT- 2022/05/17 06:00 MHDA- 2022/07/08 06:00 PMCR- 2023/05/16 CRDT- 2022/05/16 13:20 PHST- 2022/05/17 06:00 [pubmed] PHST- 2022/07/08 06:00 [medline] PHST- 2022/05/16 13:20 [entrez] PHST- 2023/05/16 00:00 [pmc-release] AID - 2792410 [pii] AID - poi220021 [pii] AID - 10.1001/jamapediatrics.2022.1296 [doi] PST - ppublish SO - JAMA Pediatr. 2022 Jul 1;176(7):664-671. doi: 10.1001/jamapediatrics.2022.1296. PMID- 35570577 OWN - NLM STAT- MEDLINE DCOM- 20231116 LR - 20231116 IS - 1558-691X (Electronic) IS - 0033-2941 (Print) IS - 0033-2941 (Linking) VI - 126 IP - 6 DP - 2023 Dec TI - A Longitudinal Study of the Psychological State of Teachers Before and During the COVID-19 Outbreak in Mexico. PG - 2789-2820 LID - 10.1177/00332941221100458 [doi] LID - 00332941221100458 AB - The COVID-19 outbreak significantly impacted people's lives. Within the education system, the teaching mode drastically changed to adapt to the social distancing restrictions due to the pandemic. Consequently, teachers have been facing challenges associated with remote learning in addition to those of the pandemic. The aim of the present study was to assess the psychological state among teachers at two stages: pre-pandemic (November 2019) and during the pandemic (June-July 2020 and June-July 2021). Information regarding demographic data, depression, anxiety, and stress (DASS-21), and burnout syndrome (MBI-ES) was collected using validated questionnaires. Results showed a significantly higher scores as well as a higher prevalence in the DASS-21 and the MBI-ES scales, on the second measurement taken during the pandemic compared to the pre-pandemic period and the first evaluation during the pandemic. During the second evaluation on pandemic stage, female teachers of >/=45 years of age with a college-level of education, 11 years of teaching experience, and currently teaching at preschools and primary schools were significantly associated with higher anxiety, stress, EE, and burnout scores. In addition, female teachers aged >/=45 years reported higher PD and PA scores. Finally, an association between burnout syndrome and depression was identified in the evaluations carried out during the pandemic considering both the total sample and the analysis per gender. The study shows that teachers' mental health has been negatively affected by the pandemic. Efforts from the education system and health authorities are crucial to design and implement strategies to improve teachers' mental health during the fight against COVID-19. FAU - Cortes-Alvarez, Nadia Yanet AU - Cortes-Alvarez NY AUID- ORCID: 0000-0002-0596-9107 AD - Department of Nursing and Midwifery, Division of Natural and Exact Sciences, University of Guanajuato, Mexico. FAU - Garduno, Alicia Saldivar AU - Garduno AS AD - Autonomous Metropolitan, University-Iztapalapa, Mexico. FAU - Sanchez-Vidana, Dalinda Isabel AU - Sanchez-Vidana DI AD - Department of Rehabilitation Sciences, The Hong Kong Polytechnic University, Hong Kong. FAU - Marmolejo-Murillo, Leticia Gabriela AU - Marmolejo-Murillo LG AD - Department of Medicine and Nutrition, Division of Health Sciences, University of Guanajuato, Mexico. FAU - Vuelvas-Olmos, Cesar Ruben AU - Vuelvas-Olmos CR AUID- ORCID: 0000-0003-3212-4166 AD - PhD Medical Sciences Program, School of Medicine, University of Colima, Mexico. RINGGOLD: 27800 LA - eng PT - Journal Article DEP - 20220514 PL - United States TA - Psychol Rep JT - Psychological reports JID - 0376475 SB - IM MH - Child, Preschool MH - Female MH - Humans MH - Middle Aged MH - Longitudinal Studies MH - Mexico/epidemiology MH - *COVID-19 MH - Educational Status MH - Disease Outbreaks PMC - PMC9111914 OTO - NOTNLM OT - COVID-19 OT - academic staff OT - anxiety OT - burnout OT - depression OT - pandemic OT - stress COIS- Declaration of Conflicting InterestsThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. EDAT- 2022/05/17 06:00 MHDA- 2023/11/16 06:44 PMCR- 2022/05/14 CRDT- 2022/05/16 03:16 PHST- 2023/11/16 06:44 [medline] PHST- 2022/05/17 06:00 [pubmed] PHST- 2022/05/16 03:16 [entrez] PHST- 2022/05/14 00:00 [pmc-release] AID - 10.1177_00332941221100458 [pii] AID - 10.1177/00332941221100458 [doi] PST - ppublish SO - Psychol Rep. 2023 Dec;126(6):2789-2820. doi: 10.1177/00332941221100458. Epub 2022 May 14. PMID- 35564927 OWN - NLM STAT- MEDLINE DCOM- 20220517 LR - 20220716 IS - 1660-4601 (Electronic) IS - 1661-7827 (Print) IS - 1660-4601 (Linking) VI - 19 IP - 9 DP - 2022 May 2 TI - Age-Related Differences in Psychological Distress during the COVID-19 Pandemic. LID - 10.3390/ijerph19095532 [doi] LID - 5532 AB - While the negative impact of COVID-19 total lockdown on mental health in youth has been extensively studied, findings collected during subsequent waves of the pandemic, in which restrictive rules were more eased, are very sparse. Here, we explore perceived psychological distress during the partial lockdown of the third wave in Southern Italy in a large sample of students, focusing on age and gender differences. Also, we assessed whether attending the type of education could have a protective role on students' psychological well-being. An online survey was completed by 1064 southern Italian students (age range: 8-19 years; males = 368) from March to July 2021. The survey consists of a set of questions regarding general sociodemographic information as well as several aspects of students' psychological well-being. Psychological distress was higher in high school students compared to both elementary and middle ones. In addition, we found gender differences, but only in high school students, with females reporting higher psychological distress than males. Finally, our mediation analysis showed a mediated role of face-to-face schooling in the relationship between age and psychological distress. In conclusion, this study highlights age-related differences in psychological distress during the pandemic and the protective role of school in presence for mental health in Italian students. FAU - Rega, Angelo AU - Rega A AUID- ORCID: 0000-0002-0641-7347 AD - Department of Humanistic Studies, University of Naples Federico II, 80138 Napoli, Italy. AD - Neapolisanit s.r.l. Rehabilitation Center, 80044 Ottaviano, Italy. FAU - Nappo, Raffaele AU - Nappo R AD - Neapolisanit s.r.l. Rehabilitation Center, 80044 Ottaviano, Italy. FAU - Simeoli, Roberta AU - Simeoli R AUID- ORCID: 0000-0001-7564-6816 AD - Department of Humanistic Studies, University of Naples Federico II, 80138 Napoli, Italy. AD - Neapolisanit s.r.l. Rehabilitation Center, 80044 Ottaviano, Italy. FAU - Cerasuolo, Mariangela AU - Cerasuolo M AUID- ORCID: 0000-0002-4178-4695 AD - Associazione Italiana Per L'Assistenza Spastici Onlus Sez Di Cicciano, 80033 Cicciano, Italy. AD - Faculty of Medicine, University of Ostrava, 70103 Ostrava, Czech Republic. AD - Department of Psychology, University of Campania L. Vanvitelli, 81100 Caserta, Italy. LA - eng PT - Journal Article DEP - 20220502 PL - Switzerland TA - Int J Environ Res Public Health JT - International journal of environmental research and public health JID - 101238455 SB - IM MH - Adolescent MH - Adult MH - *COVID-19/epidemiology MH - Child MH - Communicable Disease Control MH - Cross-Sectional Studies MH - Depression/psychology MH - Female MH - Humans MH - Male MH - Pandemics MH - *Psychological Distress MH - SARS-CoV-2 MH - Young Adult PMC - PMC9101009 OTO - NOTNLM OT - COVID-19 pandemic OT - psychological distress OT - students COIS- The authors declare no conflict of interest. EDAT- 2022/05/15 06:00 MHDA- 2022/05/18 06:00 PMCR- 2022/05/02 CRDT- 2022/05/14 01:15 PHST- 2022/03/31 00:00 [received] PHST- 2022/04/28 00:00 [revised] PHST- 2022/04/29 00:00 [accepted] PHST- 2022/05/14 01:15 [entrez] PHST- 2022/05/15 06:00 [pubmed] PHST- 2022/05/18 06:00 [medline] PHST- 2022/05/02 00:00 [pmc-release] AID - ijerph19095532 [pii] AID - ijerph-19-05532 [pii] AID - 10.3390/ijerph19095532 [doi] PST - epublish SO - Int J Environ Res Public Health. 2022 May 2;19(9):5532. doi: 10.3390/ijerph19095532. PMID- 35538498 OWN - NLM STAT- MEDLINE DCOM- 20220512 LR - 20220716 IS - 1756-0500 (Electronic) IS - 1756-0500 (Linking) VI - 15 IP - 1 DP - 2022 May 10 TI - Trends of COVID-19 incidence in Manitoba and public health measures: March 2020 to February 2022. PG - 162 LID - 10.1186/s13104-022-06049-5 [doi] LID - 162 AB - OBJECTIVES: The increasing spread of severe acute respiratory syndrome coronavirus-2 has prompted Canada to take unprecedented measures. The objective of this study was to examine the impact of the implemented public health measures on the incidence of COVID-19 in Manitoba. RESULTS: Using the COVID-19 dataset, we examined the temporal trends of daily reported COVID-19 cases and the coinciding public health measures implemented from March 12, 2020 to February 28, 2022. We calculated the 7-day moving average and crude COVID-19 infection rate/100,000 Manitobans. Due to the restrictions applied, the infection rate decreased from 2.4 (April 1) to 0.07 infections (May 1, 2020). Between May 4 and July 17, 2020, the reported cases stabilized, and some restrictions were lifted. However, in November, the cases peaked with infection rate of 29. Additional restrictions were implemented, and the rate dropped to 3.6 infections on March 31, 2021. As of August 2021, 62.8% of eligible Manitobans received two vaccine doses. The infection rate increased to 128.3 infections on December 31, 2021 and mitigation measures were implemented. This study describes how physical distancing in conjunction with other containment measures can reduce the COVID-19 burden. Future studies into the extent of the implementation of the restrictions are necessary. CI - (c) 2022. The Author(s). FAU - Aboulatta, Laila AU - Aboulatta L AD - College of Pharmacy, Rady Faculty of Health Sciences, University of Manitoba, 750 McDermot Avenue, Winnipeg, MB, R3E 0T5, Canada. FAU - Kowalec, Kaarina AU - Kowalec K AD - College of Pharmacy, Rady Faculty of Health Sciences, University of Manitoba, 750 McDermot Avenue, Winnipeg, MB, R3E 0T5, Canada. AD - Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden. FAU - Delaney, Joseph AU - Delaney J AD - College of Pharmacy, Rady Faculty of Health Sciences, University of Manitoba, 750 McDermot Avenue, Winnipeg, MB, R3E 0T5, Canada. AD - Department of Epidemiology, University of Washington, Seattle, USA. FAU - Alessi-Severini, Silvia AU - Alessi-Severini S AD - College of Pharmacy, Rady Faculty of Health Sciences, University of Manitoba, 750 McDermot Avenue, Winnipeg, MB, R3E 0T5, Canada. AD - Manitoba Center for Health Policy, Winnipeg, MB, Canada. FAU - Leong, Christine AU - Leong C AD - College of Pharmacy, Rady Faculty of Health Sciences, University of Manitoba, 750 McDermot Avenue, Winnipeg, MB, R3E 0T5, Canada. AD - Deptarment of Psychiatry, College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Canada. FAU - Falk, Jamie AU - Falk J AD - College of Pharmacy, Rady Faculty of Health Sciences, University of Manitoba, 750 McDermot Avenue, Winnipeg, MB, R3E 0T5, Canada. FAU - Eltonsy, Sherif AU - Eltonsy S AUID- ORCID: 0000-0002-0520-5406 AD - College of Pharmacy, Rady Faculty of Health Sciences, University of Manitoba, 750 McDermot Avenue, Winnipeg, MB, R3E 0T5, Canada. sherif.eltonsy@umanitoba.ca. AD - The Children's Hospital Research Institute of Manitoba, Winnipeg, Canada. sherif.eltonsy@umanitoba.ca. LA - eng GR - #4443/Research Manitoba/ PT - Journal Article DEP - 20220510 PL - England TA - BMC Res Notes JT - BMC research notes JID - 101462768 SB - IM MH - *COVID-19/epidemiology MH - Humans MH - Incidence MH - Manitoba/epidemiology MH - Public Health MH - SARS-CoV-2 PMC - PMC9088149 OTO - NOTNLM OT - COVID-19 OT - Incidence OT - Masks OT - Mitigation measures OT - Physical distancing COIS- The authors declare that they have no competing interests. EDAT- 2022/05/11 06:00 MHDA- 2022/05/14 06:00 PMCR- 2022/05/10 CRDT- 2022/05/10 23:39 PHST- 2022/01/31 00:00 [received] PHST- 2022/04/24 00:00 [accepted] PHST- 2022/05/10 23:39 [entrez] PHST- 2022/05/11 06:00 [pubmed] PHST- 2022/05/14 06:00 [medline] PHST- 2022/05/10 00:00 [pmc-release] AID - 10.1186/s13104-022-06049-5 [pii] AID - 6049 [pii] AID - 10.1186/s13104-022-06049-5 [doi] PST - epublish SO - BMC Res Notes. 2022 May 10;15(1):162. doi: 10.1186/s13104-022-06049-5. PMID- 35525226 OWN - NLM STAT- MEDLINE DCOM- 20220902 LR - 20260518 IS - 1557-8615 (Electronic) IS - 0883-9441 (Print) IS - 0883-9441 (Linking) VI - 71 DP - 2022 Oct TI - Variation in communication and family visiting policies in intensive care within and between countries during the Covid-19 pandemic: The COVISIT international survey. PG - 154050 LID - S0883-9441(22)00079-X [pii] LID - 10.1016/j.jcrc.2022.154050 [doi] AB - BACKGROUND: During the COVID-19 pandemic, intensive care units (ICU) introduced restrictions to in-person family visiting to safeguard patients, healthcare personnel, and visitors. METHODS: We conducted a web-based survey (March-July 2021) investigating ICU visiting practices before the pandemic, at peak COVID-19 ICU admissions, and at the time of survey response. We sought data on visiting policies and communication modes including use of virtual visiting (videoconferencing). RESULTS: We obtained 667 valid responses representing ICUs in all continents. Before the pandemic, 20% (106/525) had unrestricted visiting hours; 6% (30/525) did not allow in-person visiting. At peak, 84% (558/667) did not allow in-person visiting for patients with COVID-19; 66% for patients without COVID-19. This proportion had decreased to 55% (369/667) at time of survey reporting. A government mandate to restrict hospital visiting was reported by 53% (354/646). Most ICUs (55%, 353/615) used regular telephone updates; 50% (306/667) used telephone for formal meetings and discussions regarding prognosis or end-of-life. Virtual visiting was available in 63% (418/667) at time of survey. CONCLUSIONS: Highly restrictive visiting policies were introduced at the initial pandemic peaks, were subsequently liberalized, but without returning to pre-pandemic practices. Telephone became the primary communication mode in most ICUs, supplemented with virtual visits. CI - Copyright (c) 2022 Elsevier Inc. All rights reserved. FAU - Tabah, Alexis AU - Tabah A AD - Intensive Care Unit, Redcliffe Hospital, Metro North Hospital and Health services, Queensland, Australia; Queensland University of Technology, Brisbane, Queensland, Australia; Faculty of Medicine, University of Queensland, Brisbane, Queensland, Australia. Electronic address: a.tabah@uq.edu.au. FAU - Elhadi, Muhammed AU - Elhadi M AD - Faculty of Medicine, University of Tripoli, Tripoli, Libya. FAU - Ballard, Emma AU - Ballard E AD - QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia. FAU - Cortegiani, Andrea AU - Cortegiani A AD - Department of Surgical, Oncological and Oral Sciences (Di.Chir.On.S.), University of Palermo, Italy; Department of Anesthesia, Intensive Care and Emergency, Policlinico Paolo Giaccone, Palermo, Italy. FAU - Cecconi, Maurizio AU - Cecconi M AD - Anaesthesia and Intensive Care Units, Humanitas Research Hospital, Milan, Italy; Humanitas University, Milan, Italy. FAU - Unoki, Takeshi AU - Unoki T AD - Department of Acute and Critical Care Nursing, School of Nursing, Sapporo City University, Sapporo, Japan. FAU - Galarza, Laura AU - Galarza L AD - Department of Intensive Care, Hospital General Universitario de Castellon, Castellon de la Plana, Spain. FAU - Rosa, Regis Goulart AU - Rosa RG AD - Intensive Care Unit, Hospital Moinhos de Vento, Porto Alegre, Rio Grande do Sul, Brazil. FAU - Barbier, Francois AU - Barbier F AD - Medecine Intensive - Reanimation Hopital de la Source - CHR Orleans, Orleans, France. FAU - Azoulay, Elie AU - Azoulay E AD - Medecine Intensive et Reanimation, Groupe FAMIREA, Hopital Saint-Louis, Universite de Paris, Paris, France. FAU - Laupland, Kevin B AU - Laupland KB AD - Department of Intensive Care Services, Royal Brisbane and Women's Hospital, Brisbane, Australia; Queensland University of Technology, Brisbane, Queensland, Australia. FAU - Kai, Nathalie Ssi Yan AU - Kai NSY AD - Queensland University of Technology, Brisbane, Queensland, Australia. FAU - Ostermann, Marlies AU - Ostermann M AD - Department of Critical Care & Nephrology, King's College London, Guy's & St. Thomas' NHS Foundation Trust, London, United Kingdom. FAU - Francois, Guy AU - Francois G AD - Division of Scientific Affairs, Research, European Society of Intensive Care Medicine, Brussels, Belgium. FAU - De Waele, Jan J AU - De Waele JJ AD - Department of Critical Care Medicine, Ghent University Hospital, Ghent, Belgium; Division of Internal Medicine and Pediatrics, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium. FAU - Fiest, Kirsten AU - Fiest K AD - Departments of Critical Care Medicine, Community Health Sciences, Psychiatry, O'Brien Institute for Public Health, University of Calgary, Calgary, Canada. FAU - Spronk, Peter AU - Spronk P AD - Departments of Intensive Care Medicine, Gelre Hospitals, Albert Schweitzerlaan, Apeldoorn, the Netherlands. FAU - Benbenishty, Julie AU - Benbenishty J AD - Intensive Care Trauma, Hadassah Medical Center, Jerusalem, Israel. FAU - Pellegrini, Mariangela AU - Pellegrini M AD - Intensive Care Unit, AnOpIVA, Akademiska sjukhuset, Uppsala, Sweden; Hedenstierna Laboratory, Department of Surgical Science, Uppsala University, Uppsala, Sweden. FAU - Rose, Louise AU - Rose L AD - Florence Nightingale Faculty of Nursing, Midwifery and Palliative Care, King's College London, London, UK; Critical Care and Lane Fox Clinical Respiratory Physiology Research Centre, Guy's and St. Thomas' NHS Foundation Trust, London, UK. CN - COVISIT contributors LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20220504 PL - United States TA - J Crit Care JT - Journal of critical care JID - 8610642 SB - IM MH - *COVID-19 MH - Communication MH - Critical Care MH - Family MH - Humans MH - Intensive Care Units MH - Organizational Policy MH - Pandemics MH - Policy MH - *Visitors to Patients PMC - PMC9067300 OTO - NOTNLM OT - COVID-19 OT - Family OT - Intensive care OT - Restriction OT - Visiting FIR - Ramanan, Mahesh IR - Ramanan M IRAD- Intensive Care Units, Caboolture and Prince Charles Hospitals, Queensland, Australia; School of Medicine, University of Queensland, Australia; The George Institute for Global Health, Sydney, Australia; University of New South Wales, Sydney, Australia. FIR - Bailey, Rachel IR - Bailey R IRAD- Intensive Care Outreach, Caboolture Hospital, Caboolture, QLD, Australia. FIR - Kronberger, Irmgard E IR - Kronberger IE IRAD- Medical University Innsbruck, Department of Visceral, Transplant and Thoracic Surgery, Anichstrasse 35, A-6020 Innsbruck, Austria. FIR - Cerovac, Anis IR - Cerovac A IRAD- General Hospital Tesanj, Department for Gynecology and Obstetrics, Bosnia and Herzegovina; School of Medicine, Department for Anatomy, University of Tuzla, Bosnia and Herzegovina. FIR - Sligl, Wendy IR - Sligl W IRAD- Critical Care Medicine and Infectious Diseases, Adjunct Appointment, School of Public Health, University of Alberta, Canada. FIR - Persec, Jasminka IR - Persec J IRAD- Clinical Department of Anesthesiology, Reanimatology and Intensive Care Medicine, University Hospital Dubrava, Zagreb, Croatia; Croatian Society of Intensive Care Medicine, Croatia. FIR - Lincango-Naranjo, Eddy IR - Lincango-Naranjo E IRAD- Hospital Vozandes Quito, Quito, Ecuador. FIR - Osman, Nermin IR - Osman N IRAD- Medical Statistics, Medical Research Institute, Alexandria University, Egypt; United Nations System Staff College Intern-UNITAR, Egypt; Member of the Royal Statistical Association, Egypt. FIR - Tanas, Yousef IR - Tanas Y IRAD- Alexandria University Main Hospital, Egypt. FIR - Dean, Yomna IR - Dean Y IRAD- Alexandria University Main Hospital, Egypt. FIR - Abbas, Ahmed Mohamed IR - Abbas AM IRAD- Assiut University, Egypt; Faculty of Medicine, Assiut University, Assiut, Egypt. FIR - Elbahnasawy, Mohamed Gamal IR - Elbahnasawy MG IRAD- Tanta University Faculty of Medicine, Egypt. FIR - Elshennawy, Eslam Mohamed IR - Elshennawy EM IRAD- Kafr Elshikh University Hospital, Egypt. FIR - Elmandouh, Omar IR - Elmandouh O IRAD- Alexandria University Hospital, Egypt. FIR - Ahmed, Fatima Hamed IR - Ahmed FH IRAD- Faculty of Medicine Alkasr Alainy, Cairo University, Cairo, Egypt. FIR - Koulenti, Despoina IR - Koulenti D IRAD- 2nd Critical Care Department, Attikon University Hospital, Athens, Greece. FIR - Tsakiridis, Ioannis IR - Tsakiridis I IRAD- Third Department of Obstetrics and Gynecology, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Greece. FIR - Gurjar, Mohan IR - Gurjar M IRAD- Department of Critical Care Medicine, Sanjay Gandhi Post Graduate Institute of Medical Sciences (SGPGIMS), Rae Bareli Road, Lucknow, UP 226014, India. FIR - Cindryani, Marilaeta IR - Cindryani M IRAD- ICU IRD Sanglah, Indonesia. FIR - Mahmoodpoor, Ata IR - Mahmoodpoor A IRAD- Anesthesiology, Iran; Research Deputy of Faculty of Medicine, Tabriz University of Medical Sciences, Iran; Director of ICU Program, Iran. FIR - Aldawoody, Hogir Imad Rasheed IR - Aldawoody HIR IRAD- Khanaqin General Hospital, Iraq. FIR - Zuccaro, Francesco IR - Zuccaro F IRAD- Medico Chirurgo - Anestesia e Rianimazione, Responsabile U.O.S. Coordinamento Aziendale Trapianti d'Organo E Tessuti, Italy. FIR - Iozzo, Pasquale IR - Iozzo P IRAD- Department of Anesthesia Intensive Care and Emergency, Policlinico Paolo Giaccone, Palermo, Italy. FIR - Ippolito, Mariachiara IR - Ippolito M IRAD- Department of Surgical Oncological and Oral Science (Di.Chir.On.S.), University of Palermo, Italy; Department of Anesthesia Intensive Care and Emergency, Policlinico Paolo Giaccone, Palermo, Italy. FIR - Katayama, Yukiko IR - Katayama Y IRAD- Nursing Department, Sakakibara Memorial Hospital, Fuchu, Japan. FIR - Kuribara, Tomoki IR - Kuribara T IRAD- School of Nursing, Sapporo City University, Sapporo, Japan. FIR - Miyazaki, Satoko IR - Miyazaki S IRAD- Nursing Department, Tokai University Hospital, Isehara, Japan. FIR - Nakayama, Asami IR - Nakayama A IRAD- Nursing Department, Dokkyo Medical University Hospital, Mibu, Japan. FIR - Ouchi, Akira IR - Ouchi A IRAD- College of Nursing, Ibaraki Christian University, Omika, Japan. FIR - Sakuramoto, Hideaki IR - Sakuramoto H IRAD- School of Nursing, Japanese Red Cross Kyushu International College of Nursing, Munakata, Japan. FIR - Tamoto, Mitsuhiro IR - Tamoto M IRAD- Nursing Department, University of Kyoto Hospital, Kyoto, Japan. FIR - Yamada, Toru IR - Yamada T IRAD- Nursing Department, Toho University Omori Hospital, Tokyo, Japan. FIR - Serhan, Hashem Abdulaziz Abu IR - Serhan HAA IRAD- Jordan Hospitals, Jordan. FIR - Alsakarneh, Saqr Ghaleb Ghassab IR - Alsakarneh SGG IRAD- Al-Balqa' Applied University, Jordan. FIR - Kaligozhin, Zhannur IR - Kaligozhin Z IRAD- National Research Center for Oncology and Transplantation, Astana, Kazakhstan. FIR - Viderman, Dmitriy IR - Viderman D IRAD- Nazarbayev University School of Medicine, National Research Oncology Center, Department of Anesthesiology and Intensive Care, Nur-Sultan, Kazakhstan. FIR - Karout, Lina IR - Karout L IRAD- American University of Beirut Medical Center, Lebanon. FIR - Hasan, Mohd Shahnaz IR - Hasan MS IRAD- UMMC, Kuala Lumpur, Malaysia. FIR - Zakaria, Andee Dzulkarnaen IR - Zakaria AD IRAD- School of Medical Sciences & Hospital, Universiti Sains, Malaysia. FIR - Namendys-Silva, Silvio A IR - Namendys-Silva SA IRAD- Division of Pulmonary, Anesthesia and Critical Care Medicine, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico. FIR - Rai, Lajpat IR - Rai L IRAD- Dow University of Health Sciences Karachi, Pakistan. FIR - Abello, Antonio Thaddeus R IR - Abello ATR IRAD- The Medical City Clark, Mabalacat, Pampanga, Philippines. FIR - Povoa, Pedro IR - Povoa P IRAD- NOVA Medical School, New University of Lisbon, Portugal. FIR - Tomescu, Dana IR - Tomescu D IRAD- Anesthesia and Intensive Care, "Carol Davila "University of Medicine and Pharmacy, Romania; Anesthesiology & Intensive Care Dept 3, Fundeni Clinical Institute, Sos Fundeni 258 sect 2 zip, 22328, Bucharest, ROMANIA. FIR - Drozdov, Evgeniy IR - Drozdov E IRAD- Siberian State Medical University, Tomsk, Russia. FIR - Gallego, Alberto Orejas IR - Gallego AO IRAD- Hospital Universitario Severo Ochoa, Leganes, Madrid, Spain. FIR - Jariod-Ferrer, Ursula M IR - Jariod-Ferrer UM IRAD- Miguel Servet University Hospital, Zaragoza, Spain. FIR - Nunez-Garcia, Bernardo IR - Nunez-Garcia B IRAD- University Hospital Parc Tauli de Sabadell, Spain. FIR - Mohamed, Ahmed Mohamed Ibrahim IR - Mohamed AMI IRAD- Gadarif Teaching Hospital, Sudan. FIR - George, Abram Raymon Moneer IR - George ARM IRAD- Soba University Hospital, Sudan. FIR - Jeitziner, Marie-Madlen IR - Jeitziner MM IRAD- Department of Intensive Care Medicine, University Hospital Bern (Inselspital), University of Bern, Freiburgstrasse 4, 3010 Bern, Switzerland. FIR - Saracoglu, Kemal Tolga IR - Saracoglu KT IRAD- Department of Anesthesiology and Intensive Care, Health Sciences University, Kartal Dr Lutfi Kirdar City Hospital, Istanbul, Turkey. FIR - Isik, Arda IR - Isik A IRAD- General Surgery, Division of General Surgery,School of Medicine, Istanbul Medeniyet University, Kadikoy/Istanbul, Turkey. FIR - Aslan, Abdullah Tarik IR - Aslan AT IRAD- Department of Internal Medicine, Hacettepe University School of Medicine, Ankara, Turkey. FIR - Torlinski, Tomasz IR - Torlinski T IRAD- Anaesthetics - University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Hospital Birmingham, Mindelsohn Way, Edgbaston, UK. EDAT- 2022/05/08 06:00 MHDA- 2022/09/03 06:00 PMCR- 2022/05/04 CRDT- 2022/05/07 18:27 PHST- 2022/02/22 00:00 [received] PHST- 2022/04/12 00:00 [revised] PHST- 2022/04/20 00:00 [accepted] PHST- 2022/05/08 06:00 [pubmed] PHST- 2022/09/03 06:00 [medline] PHST- 2022/05/07 18:27 [entrez] PHST- 2022/05/04 00:00 [pmc-release] AID - S0883-9441(22)00079-X [pii] AID - 154050 [pii] AID - 10.1016/j.jcrc.2022.154050 [doi] PST - ppublish SO - J Crit Care. 2022 Oct;71:154050. doi: 10.1016/j.jcrc.2022.154050. Epub 2022 May 4. PMID- 35471566 OWN - NLM STAT- MEDLINE DCOM- 20220428 LR - 20220716 IS - 2574-3805 (Electronic) IS - 2574-3805 (Linking) VI - 5 IP - 4 DP - 2022 Apr 1 TI - Analysis of Race and Sex Bias in the Autism Diagnostic Observation Schedule (ADOS-2). PG - e229498 LID - 10.1001/jamanetworkopen.2022.9498 [doi] LID - e229498 AB - IMPORTANCE: There are long-standing disparities in the prevalence of autism spectrum disorder (ASD) across race and sex. Surprisingly, few studies have examined whether these disparities arise partially out of systematic biases in the Autism Diagnostic Observation Schedule, Second Edition (ADOS-2), the reference standard measure of ASD. OBJECTIVE: To examine differential item functioning (DIF) of ADOS-2 items across sex and race. DESIGN, SETTING, AND PARTICIPANTS: This is a cross-sectional study of children who were evaluated for ASD between 2014 and 2020 at a specialty outpatient clinic located in the Mid-Atlantic region of the US. Data were analyzed from July 2021 to February 2022. EXPOSURES: Child race (Black/African American vs White) and sex (female vs male). MAIN OUTCOMES AND MEASURES: Item-level biases across ADOS-2 harmonized algorithm items, including social affect (SA; 10 items) and repetitive/restricted behaviors (RRBs; 4 items), were evaluated across 3 modules. Measurement bias was identified by examining DIF and differential test functioning (DTF), within a graded response, item response theory framework. Statistical significance was determined by a likelihood ratio chi2 test, and a series of metrics was used to examine the magnitude of DIF and DTF. RESULTS: A total of 6269 children (mean [SD] age, 6.77 [3.27] years; 1619 Black/African American [25.9%], 3151 White [50.3%], and 4970 male [79.4%]), were included in this study. Overall, 16 of 140 ADOS-2 diagnostic items (11%) had a significant DIF. For race, 8 items had a significant DIF, 6 of which involved SA. No single item showed DIF consistently across all modules. Most items with DIF had greater difficulty and poorer discrimination in Black/African American children compared with White children. For sex, 5 items showed significant DIF. DIF was split across SA and RRB. However, hand mannerisms evidenced DIF across all 5 algorithms, with generally greater difficulty. The magnitude of DIF was only moderate to large for 2 items: hand mannerisms (among female children) and repetitive interests (among Black/African American children). The overall estimated effect of DIF on total DTF was not large. CONCLUSIONS AND RELEVANCE: These findings suggest that the ADOS-2 does not have widespread systematic measurement bias across race or sex. However, the findings raise some concerns around underdetection that warrant further research. FAU - Kalb, Luther G AU - Kalb LG AD - Center for Autism and Related Disorders, Kennedy Krieger Institute, Baltimore, Maryland. AD - Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland. AD - Department of Neuropsychology, Kennedy Krieger Institute, Baltimore, Maryland. FAU - Singh, Vini AU - Singh V AD - Center for Autism and Related Disorders, Kennedy Krieger Institute, Baltimore, Maryland. FAU - Hong, Ji Su AU - Hong JS AD - Center for Autism and Related Disorders, Kennedy Krieger Institute, Baltimore, Maryland. AD - Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland. FAU - Holingue, Calliope AU - Holingue C AD - Center for Autism and Related Disorders, Kennedy Krieger Institute, Baltimore, Maryland. AD - Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland. AD - Department of Neuropsychology, Kennedy Krieger Institute, Baltimore, Maryland. FAU - Ludwig, Natasha N AU - Ludwig NN AD - Department of Neuropsychology, Kennedy Krieger Institute, Baltimore, Maryland. AD - Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland. FAU - Pfeiffer, Danika AU - Pfeiffer D AD - Center for Autism and Related Disorders, Kennedy Krieger Institute, Baltimore, Maryland. AD - Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland. FAU - Reetzke, Rachel AU - Reetzke R AD - Center for Autism and Related Disorders, Kennedy Krieger Institute, Baltimore, Maryland. AD - Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland. FAU - Gross, Alden L AU - Gross AL AD - Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland. AD - Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland. AD - Center on Aging and Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland. FAU - Landa, Rebecca AU - Landa R AD - Center for Autism and Related Disorders, Kennedy Krieger Institute, Baltimore, Maryland. AD - Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland. LA - eng PT - Journal Article PT - Research Support, N.I.H., Extramural DEP - 20220401 PL - United States TA - JAMA Netw Open JT - JAMA network open JID - 101729235 SB - IM CIN - JAMA Netw Open. 2022 Apr 1;5(4):e229503. doi: 10.1001/jamanetworkopen.2022.9503. PMID: 35471575 MH - *Autism Spectrum Disorder/diagnosis/epidemiology MH - *Autistic Disorder MH - Child MH - Cross-Sectional Studies MH - Female MH - Humans MH - Male MH - Racial Groups MH - Sexism PMC - PMC9044110 COIS- Conflict of Interest Disclosures: None reported. EDAT- 2022/04/27 06:00 MHDA- 2022/04/29 06:00 PMCR- 2022/04/26 CRDT- 2022/04/26 12:53 PHST- 2022/04/26 12:53 [entrez] PHST- 2022/04/27 06:00 [pubmed] PHST- 2022/04/29 06:00 [medline] PHST- 2022/04/26 00:00 [pmc-release] AID - 2791527 [pii] AID - zoi220286 [pii] AID - 10.1001/jamanetworkopen.2022.9498 [doi] PST - epublish SO - JAMA Netw Open. 2022 Apr 1;5(4):e229498. doi: 10.1001/jamanetworkopen.2022.9498. PMID- 35459950 OWN - NLM STAT- MEDLINE DCOM- 20220519 LR - 20220519 IS - 1464-3677 (Electronic) IS - 1353-4505 (Linking) VI - 34 IP - 2 DP - 2022 May 13 TI - Modelling the effect of COVID-19 mass vaccination on acute hospital admissions. LID - mzac031 [pii] LID - 10.1093/intqhc/mzac031 [doi] AB - BACKGROUND: Managing high levels of acute COVID-19 bed occupancy can affect the quality of care provided to both affected patients and those requiring other hospital services. Mass vaccination has offered a route to reduce societal restrictions while protecting hospitals from being overwhelmed. Yet, early in the mass vaccination effort, the possible impact on future bed pressures remained subject to considerable uncertainty. OBJECTIVE: The aim of this study was to model the effect of vaccination on projections of acute and intensive care bed demand within a 1 million resident healthcare system located in South West England. METHODS: An age-structured epidemiological model of the susceptible-exposed-infectious-recovered type was fitted to local data up to the time of the study, in early March 2021. Model parameters and vaccination scenarios were calibrated through a system-wide multidisciplinary working group, comprising public health intelligence specialists, healthcare planners, epidemiologists and academics. Scenarios assumed incremental relaxations to societal restrictions according to the envisaged UK Government timeline, with all restrictions to be removed by 21 June 2021. RESULTS: Achieving 95% vaccine uptake in adults by 31 July 2021 would not avert the third wave in autumn 2021 but would produce a median peak bed requirement approximately 6% (IQR: 1-24%) of that experienced during the second wave (January 2021). A 2-month delay in vaccine rollout would lead to significantly higher peak bed occupancy, at 66% (11-146%) of that of the second wave. If only 75% uptake was achieved (the amount typically associated with vaccination campaigns), then the second wave peak for acute and intensive care beds would be exceeded by 4% and 19%, respectively, an amount which would seriously pressure hospital capacity. CONCLUSION: Modelling influenced decision-making among senior managers in setting COVID-19 bed capacity levels, as well as highlighting the importance of public health in promoting high vaccine uptake among the population. Forecast accuracy has since been supported by actual data collected following the analysis, with observed peak bed occupancy falling comfortably within the inter-quartile range of modelled projections. CI - (c) The Author(s) 2022. Published by Oxford University Press on behalf of International Society for Quality in Health Care. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. FAU - Booton, Ross D AU - Booton RD AD - Bristol Medical School, University of Bristol, 5 Tyndall Avenue, Bristol, BS8 1UD, UK. FAU - Powell, Anna L AU - Powell AL AD - Modelling and Analytics, UK National Health Service (BNSSG CCG), 360 Bristol, Marlborough Street, BS3 1NX, UK. FAU - Turner, Katy M E AU - Turner KME AD - Bristol Medical School, University of Bristol, 5 Tyndall Avenue, Bristol, BS8 1UD, UK. AD - Health Data Research UK South West Better Care Partnership, Bristol, BS, UK. FAU - Wood, Richard M AU - Wood RM AUID- ORCID: 0000-0002-3476-395X AD - Modelling and Analytics, UK National Health Service (BNSSG CCG), 360 Bristol, Marlborough Street, BS3 1NX, UK. AD - Health Data Research UK South West Better Care Partnership, Bristol, BS, UK. AD - School of Management, University of Bath, Claverton Down, Bath, BA2 7AY, UK. LA - eng GR - NIHR200877/NIHR Health Protection Research Unit in Behavioural Science and Evaluation/ GR - CFC0129/Health Data Research UK/ PT - Journal Article PL - England TA - Int J Qual Health Care JT - International journal for quality in health care : journal of the International Society for Quality in Health Care JID - 9434628 SB - IM MH - Adult MH - *COVID-19/epidemiology/prevention & control MH - Hospitals MH - Humans MH - Mass Vaccination MH - SARS-CoV-2 MH - Vaccination OTO - NOTNLM OT - COVID-19 OT - bed management OT - coronavirus OT - hospital capacity OT - mathematical modelling OT - vaccination EDAT- 2022/04/24 06:00 MHDA- 2022/05/20 06:00 CRDT- 2022/04/23 05:24 PHST- 2021/10/10 00:00 [received] PHST- 2022/03/14 00:00 [revised] PHST- 2022/04/21 00:00 [accepted] PHST- 2022/04/24 06:00 [pubmed] PHST- 2022/05/20 06:00 [medline] PHST- 2022/04/23 05:24 [entrez] AID - 6572765 [pii] AID - 10.1093/intqhc/mzac031 [doi] PST - ppublish SO - Int J Qual Health Care. 2022 May 13;34(2):mzac031. doi: 10.1093/intqhc/mzac031. PMID- 35454301 OWN - NLM STAT- MEDLINE DCOM- 20220426 LR - 20250623 IS - 1648-9144 (Electronic) IS - 1010-660X (Print) IS - 1010-660X (Linking) VI - 58 IP - 4 DP - 2022 Mar 22 TI - The Morphology of Impacted Maxillary Central Incisors: A Systematic Review. LID - 10.3390/medicina58040462 [doi] LID - 462 AB - Background and Objectives: The knowledge of the morphology of impacted maxillary central incisors may lead to more effective treatment. Therefore, this systematic review aimed to evaluate the morphology of impacted maxillary central incisors and compare them with contralateral teeth. Material and methods: This systematic review adhered to the PRISMA statement. The literature search was carried out using PubMed (Medline database), Cochrane Library, ProQuest, Web of Science and Science Direct electronic databases with no publication date restrictions up to July 2021. Data assessing the morphology of unilaterally impacted maxillary central incisors (ICI) evaluated with CBCT were extracted, and the quality of the studies was evaluated. Crown length, root length, and root dilaceration of impacted maxillary central incisors were compared with contralateral unimpacted teeth. Results: The initial database search identified a total number of 287 studies. After applying the selection criteria, 21 articles were selected for a full-text analysis, and four retrospective studies involving 205 patients were included in the systematic review. According to the Newcastle-Ottawa Scale (NOS), two of included articles were graded as "Good" and the remaining two as "Fair" quality. The results showed no difference between impacted teeth and their contralateral crowns, or a minor decrease in ICI crown length (from 0.15 to 0.56 mm). The root lengths of impacted maxillary central incisors were considerably shorter than contralateral incisors (from 2.13 to 3.22 mm) and, as dental age increased, root growth decreased and the incidence of root dilaceration was more frequent. Conclusions: The root lengths of impacted maxillary central incisors were considerably shorter compared to the contralateral incisors. Root dilacerations frequency and severity increased as dental age increased. FAU - Mockute, Guoda AU - Mockute G AUID- ORCID: 0000-0001-6519-350X AD - Faculty of Odontology, Medical Academy, Lithuanian University of Health Sciences, J. Luksos-Daumanto 2, LT-50106 Kaunas, Lithuania. FAU - Klimaite, Guste AU - Klimaite G AUID- ORCID: 0000-0002-5130-0105 AD - Faculty of Odontology, Medical Academy, Lithuanian University of Health Sciences, J. Luksos-Daumanto 2, LT-50106 Kaunas, Lithuania. FAU - Smailiene, Dalia AU - Smailiene D AD - Department of Orthodontics, Medical Academy, Lithuanian University of Health Sciences, J. Luksos-Daumanto 6, LT-50106 Kaunas, Lithuania. LA - eng PT - Journal Article PT - Systematic Review DEP - 20220322 PL - Switzerland TA - Medicina (Kaunas) JT - Medicina (Kaunas, Lithuania) JID - 9425208 SB - IM MH - Cone-Beam Computed Tomography/methods MH - Humans MH - *Incisor MH - Maxilla MH - Retrospective Studies MH - *Tooth, Impacted PMC - PMC9026335 OTO - NOTNLM OT - crown length OT - impacted OT - maxillary central incisors OT - root dilaceration OT - root length OT - root morphology COIS- The authors declare no conflict of interest. EDAT- 2022/04/24 06:00 MHDA- 2022/04/27 06:00 PMCR- 2022/03/22 CRDT- 2022/04/23 01:03 PHST- 2022/02/17 00:00 [received] PHST- 2022/03/20 00:00 [revised] PHST- 2022/03/21 00:00 [accepted] PHST- 2022/04/23 01:03 [entrez] PHST- 2022/04/24 06:00 [pubmed] PHST- 2022/04/27 06:00 [medline] PHST- 2022/03/22 00:00 [pmc-release] AID - medicina58040462 [pii] AID - medicina-58-00462 [pii] AID - 10.3390/medicina58040462 [doi] PST - epublish SO - Medicina (Kaunas). 2022 Mar 22;58(4):462. doi: 10.3390/medicina58040462. PMID- 35452109 OWN - NLM STAT- MEDLINE DCOM- 20220426 LR - 20250530 IS - 2574-3805 (Electronic) IS - 2574-3805 (Linking) VI - 5 IP - 4 DP - 2022 Apr 1 TI - Psychological Distress Before and During the COVID-19 Pandemic Among Adults in the United Kingdom Based on Coordinated Analyses of 11 Longitudinal Studies. PG - e227629 LID - 10.1001/jamanetworkopen.2022.7629 [doi] LID - e227629 AB - IMPORTANCE: How population mental health has evolved across the COVID-19 pandemic under varied lockdown measures is poorly understood, and the consequences for health inequalities are unclear. OBJECTIVE: To investigate changes in mental health and sociodemographic inequalities from before and across the first year of the COVID-19 pandemic in 11 longitudinal studies. DESIGN, SETTING, AND PARTICIPANTS: This cohort study included adult participants from 11 UK longitudinal population-based studies with prepandemic measures of psychological distress. Analyses were coordinated across these studies, and estimates were pooled. Data were collected from 2006 to 2021. EXPOSURES: Trends in the prevalence of poor mental health were assessed in the prepandemic period (time period 0 [TP 0]) and at 3 pandemic TPs: 1, initial lockdown (March to June 2020); 2, easing of restrictions (July to October 2020); and 3, a subsequent lockdown (November 2020 to March 2021). Analyses were stratified by sex, race and ethnicity, education, age, and UK country. MAIN OUTCOMES AND MEASURES: Multilevel regression was used to examine changes in psychological distress from the prepandemic period across the first year of the COVID-19 pandemic. Psychological distress was assessed using the 12-item General Health Questionnaire, the Kessler 6, the 9-item Malaise Inventory, the Short Mood and Feelings Questionnaire, the 8-item or 9-item Patient Health Questionnaire, the Hospital Anxiety and Depression Scale, and the Centre for Epidemiological Studies-Depression across different studies. RESULTS: In total, 49 993 adult participants (12 323 [24.6%] aged 55-64 years; 32 741 [61.2%] women; 4960 [8.7%] racial and ethnic minority) were analyzed. Across the 11 studies, mental health deteriorated from prepandemic scores across all 3 pandemic periods, but there was considerable heterogeneity across the study-specific estimated effect sizes (pooled estimate for TP 1: standardized mean difference [SMD], 0.15; 95% CI, 0.06-0.25; TP 2: SMD, 0.18; 95% CI, 0.09-0.27; TP 3: SMD, 0.21; 95% CI, 0.10-0.32). Changes in psychological distress across the pandemic were higher in women (TP 3: SMD, 0.23; 95% CI, 0.11, 0.35) than men (TP 3: SMD, 0.16; 95% CI, 0.06-0.26) and lower in individuals with below-degree level education at TP 3 (SMD, 0.18; 95% CI, 0.06-0.30) compared with those who held degrees (SMD, 0.26; 95% CI, 0.14-0.38). Increased psychological distress was most prominent among adults aged 25 to 34 years (SMD, 0.49; 95% CI, 0.14-0.84) and 35 to 44 years (SMD, 0.35; 95% CI, 0.10-0.60) compared with other age groups. No evidence of changes in distress differing by race and ethnicity or UK country were observed. CONCLUSIONS AND RELEVANCE: In this study, the substantial deterioration in mental health seen in the UK during the first lockdown did not reverse when lockdown lifted, and a sustained worsening was observed across the pandemic period. Mental health declines have been unequal across the population, with women, those with higher degrees, and those aged 25 to 44 years more affected than other groups. FAU - Patel, Kishan AU - Patel K AD - MRC Unit for Lifelong Health and Ageing, University College London, London, England, United Kingdom. FAU - Robertson, Elaine AU - Robertson E AD - MRC/CSO Social & Public Health Sciences Unit, University of Glasgow, Glasgow, Scotland. FAU - Kwong, Alex S F AU - Kwong ASF AD - Division of Psychiatry, University of Edinburgh, Edinburgh, Scotland. AD - MRC Integrative Epidemiology Unit, University of Bristol, Bristol, England. FAU - Griffith, Gareth J AU - Griffith GJ AD - MRC Integrative Epidemiology Unit, University of Bristol, Bristol, England. AD - Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, England. FAU - Willan, Kathryn AU - Willan K AD - Bradford Institute for Health Research, United Kingdom. FAU - Green, Michael J AU - Green MJ AD - MRC/CSO Social & Public Health Sciences Unit, University of Glasgow, Glasgow, Scotland. FAU - Di Gessa, Giorgio AU - Di Gessa G AD - Department of Epidemiology and Public Health, University College London, London, England, United Kingdom. FAU - Huggins, Charlotte F AU - Huggins CF AD - Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, Scotland. FAU - McElroy, Eoin AU - McElroy E AD - Department of Neuroscience, Psychology and Behaviour, University of Leicester, Leicester, England. FAU - Thompson, Ellen J AU - Thompson EJ AD - Department of Twin Research and Genetic Epidemiology, School of Life Course & Population Sciences, King's College London, London, England. FAU - Maddock, Jane AU - Maddock J AD - MRC Unit for Lifelong Health and Ageing, University College London, London, England, United Kingdom. FAU - Niedzwiedz, Claire L AU - Niedzwiedz CL AD - Institute of Health & Wellbeing, University of Glasgow, Glasgow, Scotland. FAU - Henderson, Morag AU - Henderson M AD - Centre for Longitudinal Studies, University College London, London, England, United Kingdom. FAU - Richards, Marcus AU - Richards M AD - MRC Unit for Lifelong Health and Ageing, University College London, London, England, United Kingdom. FAU - Steptoe, Andrew AU - Steptoe A AD - Department of Epidemiology and Public Health, University College London, London, England, United Kingdom. FAU - Ploubidis, George B AU - Ploubidis GB AD - Centre for Longitudinal Studies, University College London, London, England, United Kingdom. FAU - Moltrecht, Bettina AU - Moltrecht B AD - Centre for Longitudinal Studies, University College London, London, England, United Kingdom. FAU - Booth, Charlotte AU - Booth C AD - Centre for Longitudinal Studies, University College London, London, England, United Kingdom. FAU - Fitzsimons, Emla AU - Fitzsimons E AD - Centre for Longitudinal Studies, University College London, London, England, United Kingdom. FAU - Silverwood, Richard AU - Silverwood R AD - Centre for Longitudinal Studies, University College London, London, England, United Kingdom. FAU - Patalay, Praveetha AU - Patalay P AD - MRC Unit for Lifelong Health and Ageing, University College London, London, England, United Kingdom. AD - Centre for Longitudinal Studies, University College London, London, England, United Kingdom. FAU - Porteous, David AU - Porteous D AD - Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, Scotland. AD - Centre for Medical Information, University of Edinburgh, Edinburgh, Scotland. FAU - Katikireddi, Srinivasa Vittal AU - Katikireddi SV AD - MRC/CSO Social & Public Health Sciences Unit, University of Glasgow, Glasgow, Scotland. LA - eng GR - MC_PC_19009/MRC_/Medical Research Council/United Kingdom GR - MR/R024774/1/MRC_/Medical Research Council/United Kingdom GR - SPHSU17/CSO_/Chief Scientist Office/United Kingdom GR - MC_UU_00019/1/MRC_/Medical Research Council/United Kingdom GR - MC_PC_20030/MRC_/Medical Research Council/United Kingdom GR - MC_PC_15018/MRC_/Medical Research Council/United Kingdom GR - SCAF/15/02/CSO_/Chief Scientist Office/United Kingdom GR - R01 AG017644/AG/NIA NIH HHS/United States GR - MC_UU_00022/2/MRC_/Medical Research Council/United Kingdom GR - MC_PC_20059/MRC_/Medical Research Council/United Kingdom GR - MC_UU_00019/3/MRC_/Medical Research Council/United Kingdom GR - G9815508/MRC_/Medical Research Council/United Kingdom PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20220401 PL - United States TA - JAMA Netw Open JT - JAMA network open JID - 101729235 SB - IM MH - Adult MH - *COVID-19/epidemiology MH - Cohort Studies MH - Communicable Disease Control MH - Depression/epidemiology MH - Ethnicity MH - Female MH - Humans MH - Longitudinal Studies MH - Male MH - Minority Groups MH - Pandemics MH - *Psychological Distress MH - United Kingdom/epidemiology PMC - PMC9034408 COIS- Conflict of Interest Disclosures: Ms Robertson reported receiving grants from the Medical Research Council (MRC) and the Scottish Government Chief Scientist Office during the conduct of the study. Dr Griffith reports holding a postdoctoral post funded by the MRC and receiving a postdoctoral fellowship from grants from the Economic and Social Research Council (ESRC) during the conduct of the study. Dr Green reported receiving grants from the MRC during the conduct of the study. Dr Huggins reported receiving grants from the Wellcome Trust during the conduct of the study. Dr Niedzwiedz reported receiving grants from the MRC during the conduct of the study and outside the submitted work. Dr Henderson reported grants from ESRC during the conduct of the study. Dr Katikireddi reported receiving grants from the MRC and the Scottish Government Chief Scientist Office during the conduct of the study; serving as cochair of the Scottish Government's Expert Reference Group on Ethnicity and COVID-19; being a member of the UK Government's Scientific Advisory Group on Emergencies subgroup on ethnicity; and being a member of the UK Cabinet Office's International Best Practice Advisory Group. No other disclosures were reported. EDAT- 2022/04/23 06:00 MHDA- 2022/04/27 06:00 PMCR- 2022/04/22 CRDT- 2022/04/22 12:13 PHST- 2022/04/22 12:13 [entrez] PHST- 2022/04/23 06:00 [pubmed] PHST- 2022/04/27 06:00 [medline] PHST- 2022/04/22 00:00 [pmc-release] AID - 2791456 [pii] AID - zoi220240 [pii] AID - 10.1001/jamanetworkopen.2022.7629 [doi] PST - epublish SO - JAMA Netw Open. 2022 Apr 1;5(4):e227629. doi: 10.1001/jamanetworkopen.2022.7629. PMID- 35442911 OWN - NLM STAT- MEDLINE DCOM- 20220804 LR - 20250728 IS - 1938-808X (Electronic) IS - 1040-2446 (Linking) VI - 97 IP - 8 DP - 2022 Aug 1 TI - Revisiting Retake Policy: Analyzing the Success Rates of Examinees With Multiple Attempts on the United States Medical Licensing Examination. PG - 1219-1225 LID - 10.1097/ACM.0000000000004713 [doi] AB - PURPOSE: A testing program's decision making on retake policy considers a number of factors, including fairness to examinees, examination security, examination purpose, and classification accuracy. For high-stakes licensure and certification examinations charged with protection of the public, this includes balancing fairness issues inherent in the potential for false negatives with the public protection need to minimize false positives. Since 2012, the United States Medical Licensing Examination (USMLE) has maintained a policy of /= 5 attempts showed a significant effect of gender, race, and medical school status, although the associated sample sizes are small. Misclassification analyses showed that, as attempts increased, the percentage of false passers increased and percentage of false failers decreased. CONCLUSIONS: These considerations led to the USMLE's decision to reduce its attempt limit from 6 to 4 on any Step or Step component effective July 2021. This change balances the competing interests of fairness and examination access to the examinee population, while simultaneously maintaining a minimum standard consistent with the mission of the USMLE program to protect the public. CI - Copyright (c) 2022 by the Association of American Medical Colleges. FAU - Rubright, Jonathan D AU - Rubright JD AD - J.D. Rubright is vice president, Office of Research, National Board of Medical Examiners, Philadelphia, Pennsylvania. FAU - Ong, Thai Q AU - Ong TQ AD - T.Q. Ong is psychometrician, Psychometrics and Data Analysis, National Board of Medical Examiners, Philadelphia, Pennsylvania. FAU - Jodoin, Michael G AU - Jodoin MG AD - M.G. Jodoin is senior vice president, Customer and Portfolio Management, National Board of Medical Examiners, Philadelphia, Pennsylvania. FAU - Johnson, David A AU - Johnson DA AD - D.A. Johnson is chief assessment officer, Federation of State Medical Boards, Euless, Texas. FAU - Barone, Michael A AU - Barone MA AD - M.A. Barone is vice president, Competency Based Assessment, National Board of Medical Examiners, Philadelphia, Pennsylvania. LA - eng PT - Journal Article DEP - 20220721 PL - England TA - Acad Med JT - Academic medicine : journal of the Association of American Medical Colleges JID - 8904605 SB - IM MH - *Certification MH - Clinical Competence MH - Educational Measurement MH - Humans MH - *Licensure MH - Licensure, Medical MH - Physical Examination MH - Policy MH - United States EDAT- 2022/04/21 06:00 MHDA- 2022/08/05 06:00 CRDT- 2022/04/20 17:12 PHST- 2022/04/21 06:00 [pubmed] PHST- 2022/08/05 06:00 [medline] PHST- 2022/04/20 17:12 [entrez] AID - 00001888-202208000-00050 [pii] AID - 10.1097/ACM.0000000000004713 [doi] PST - ppublish SO - Acad Med. 2022 Aug 1;97(8):1219-1225. doi: 10.1097/ACM.0000000000004713. Epub 2022 Jul 21. PMID- 35442384 OWN - NLM STAT- MEDLINE DCOM- 20220422 LR - 20220422 IS - 1807-3107 (Electronic) IS - 1806-8324 (Linking) VI - 36 DP - 2022 TI - Irisin effects on bone: systematic review with meta-analysis of preclinical studies and prospects for oral health. PG - e055 LID - S1806-83242022000100951 [pii] LID - 10.1590/1807-3107bor-2022.vol36.0055 [doi] AB - Bone quality is an important issue in dentistry. Low bone density may be associated with more severe periodontitis, and may influence implant therapy success. Recent evidence suggests that physical activity can improve alveolar bone quality. Irisin is an exercise-mediated peptide that might be involved in this process. We assessed the effect of exercise and that of intra-peritoneal irisin administration on bone quality in healthy and osteoporosis-induced rodents. This study was registered at PROSPERO (CRD42020184140), and followed PRISMA guidelines. A search by two independent examiners was conducted in five databases and gray literature up to July 2021, without restrictions regarding language or date of publication. Initially, they analyzed retrieved titles and abstracts (n=3,844) based on eligibility criteria. Of this total, 19 studies remained for full-text reading, and 16 proceeded to the data extraction and quality assessment phases. Meta-analyses were conducted (n= 6 studies) to establish the effects of irisin administration on cancellous bone mineral density (BMD). Exercise or irisin administration enhanced bone quality, but the meta-analysis showed that BMD increased only slightly in osteoporotic rodents (BMD: mean difference 0.03 mg/cm3 - 95% CI 0.01-0.05). This indicates that they had no significant benefits on the bones of healthy animals. Implications of key findings evidence the potential of irisin as an agent able to mitigate bone loss caused by osteoporosis, an outcome that could favor dental rehabilitation. More studies investigating the effect of irisin on alveolar bone are needed to elucidate its therapeutic viability and implications. FAU - Pereira, Luciano Jose AU - Pereira LJ AUID- ORCID: 0000-0002-0502-2554 AD - Universidade Federal de Lavras - UFLA, Department of Health Sciences, Lavras, MG, Brazil. FAU - Andrade, Eric Francelino AU - Andrade EF AUID- ORCID: 0000-0002-9253-3108 AD - Universidade Federal dos Vales do Jequitinhonha e Mucuri - UFVJM, Department of Physiology, Unai, MG, Brazil. FAU - Barroso, Livia Correa AU - Barroso LC AUID- ORCID: 0000-0001-8422-5538 AD - Universidade Federal de Minas Gerais - UFMG, School of Dentistry, Department of Oral Pathology and Surgery, Belo Horizonte, MG, Brazil. FAU - Lima, Renato Ribeiro de AU - Lima RR AUID- ORCID: 0000-0003-4607-4964 AD - Universidade Federal de Lavras - UFLA, Department of Exact Sciences, Lavras, MG, Brazil. FAU - Macari, Soraia AU - Macari S AUID- ORCID: 0000-0001-7643-6589 AD - Universidade Federal de Minas Gerais - UFMG, School of Dentistry, Department of Restortaive Dentistry, Belo Horizonte, MG, Brazil. FAU - Paiva, Saul Martins AU - Paiva SM AUID- ORCID: 0000-0002-3968-1638 AD - Universidade Federal de Minas Gerais - UFMG, School of Dentistry, Department of Paediatric Dentistry and Orthodontics, Belo Horizonte, MG, Brazil. FAU - Silva, Tarcilia Aparecida AU - Silva TA AUID- ORCID: 0000-0001-9623-7835 AD - Universidade Federal de Minas Gerais - UFMG, School of Dentistry, Department of Oral Pathology and Surgery, Belo Horizonte, MG, Brazil. LA - eng PT - Journal Article PT - Meta-Analysis PT - Systematic Review DEP - 20220415 PL - Brazil TA - Braz Oral Res JT - Brazilian oral research JID - 101307187 SB - IM MH - Animals MH - Bone Density MH - Bone and Bones MH - Exercise MH - *Oral Health MH - *Osteoporosis/prevention & control EDAT- 2022/04/21 06:00 MHDA- 2022/04/23 06:00 CRDT- 2022/04/20 12:15 PHST- 2020/12/04 00:00 [received] PHST- 2022/01/26 00:00 [accepted] PHST- 2022/04/20 12:15 [entrez] PHST- 2022/04/21 06:00 [pubmed] PHST- 2022/04/23 06:00 [medline] AID - S1806-83242022000100951 [pii] AID - 10.1590/1807-3107bor-2022.vol36.0055 [doi] PST - epublish SO - Braz Oral Res. 2022 Apr 15;36:e055. doi: 10.1590/1807-3107bor-2022.vol36.0055. eCollection 2022. PMID- 35399252 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240826 IS - 1177-889X (Print) IS - 1177-889X (Electronic) IS - 1177-889X (Linking) VI - 16 DP - 2022 TI - Acceptance of COVID-19 Vaccine and Associated Factors Among Pregnant Women in Saudi Arabia. PG - 861-873 LID - 10.2147/PPA.S357653 [doi] AB - BACKGROUND: Coronavirus disease 19 (COVID-19) vaccination has been established as preventing severe and mortal COVID-19. Vaccination is critical strategy in controlling the COVID-19 pandemic, to restrict infections and reduce disease severity. Vaccination coverage will be more extensive if we can better identify vaccination barriers in the population, especially among vulnerable groups, of which one is pregnant women. The aim of this study was to determine the level of acceptance of COVID-19 vaccination and detect the factors that influence vaccine acceptance among pregnant women in Saudi Arabia. METHODS: This was a cross-sectional, web-based study conducted in Western, Eastern, North, South, and Central Regions in Saudi Arabia between July and September 2021 among pregnant women, using multi-stage sampling. All pregnant women above 18 years were invited to participate in the study. Pregnant under 18 years of age and those with a contraindication to receiving COVID-19 vaccination were excluded. Binomial logistic regression (univariate and multivariate) was used to identify the influencing factors on vaccination acceptance. RESULTS: Among the 5307 pregnant women, the acceptance level of COVID-19 vaccine was 68%. In the multivariate regression model analysis, the most common predictors of acceptance were living in North Region (P = 0.001, OR = 1.9), living in South Region (P = 0.000, OR = 3.06), and living in Central Region (P = 0.035, OR = 1.42) in comparison to living in Western Region. Gestational week (P = 0.018, OR=0.98), income more than 8000 SR (P = 0.000, OR = 0.51), education level (primary, secondary, and university; P = 0.002, 0.008, and 0.010, respectively), having had gestational diabetes mellitus (P = 0.013, OR = 1.86), being vaccinated with influenza vaccine during present pregnancy (P = 0.000, OR = 4.55, OR = 1.81), being vaccinated with tetanus vaccine during present pregnancy (P = 0.039), and believing that the COVID-19 vaccine could harm their baby (P = 0.000, OR = 0.12). CONCLUSION: Our study reported high acceptance of COVID-19 vaccination. The major two reasons for refusal were concerns about a lack of data on COVID-19 vaccination safety and the possibility of harming the fetus. Continued public health efforts, such as educational television programs and awareness campaigns about the safety of the COVID-19 vaccine for pregnant women, are required to raise awareness. More studies of COVID-19 vaccine safety in pregnant women would assist in overcoming these obstacles and encourage pregnant women to be vaccinated. CI - (c) 2022 Ghamri et al. FAU - Ghamri, Ranya A AU - Ghamri RA AUID- ORCID: 0000-0002-8622-4042 AD - Department of Family Medicine, Faculty of Medicine, King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia. FAU - Othman, Sahar S AU - Othman SS AD - Department of Family Medicine, Faculty of Medicine, King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia. FAU - Alhiniah, Mudhawi H AU - Alhiniah MH AD - Faculty of Medicine, King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia. FAU - Alelyani, Rakan H AU - Alelyani RH AD - Faculty of Medicine, King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia. FAU - Badawi, Atheer M AU - Badawi AM AD - Faculty of Medicine, King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia. FAU - Alshahrani, Asma A AU - Alshahrani AA AD - Faculty of Medicine, King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia. LA - eng PT - Journal Article DEP - 20220402 PL - New Zealand TA - Patient Prefer Adherence JT - Patient preference and adherence JID - 101475748 PMC - PMC8986189 OTO - NOTNLM OT - COVID-19 OT - Saudi Arabia OT - acceptance OT - pregnancy OT - pregnant women OT - vaccine COIS- The authors report no conflicts of interest for this work. EDAT- 2022/04/12 06:00 MHDA- 2022/04/12 06:01 PMCR- 2022/04/02 CRDT- 2022/04/11 05:11 PHST- 2022/01/09 00:00 [received] PHST- 2022/03/04 00:00 [accepted] PHST- 2022/04/11 05:11 [entrez] PHST- 2022/04/12 06:00 [pubmed] PHST- 2022/04/12 06:01 [medline] PHST- 2022/04/02 00:00 [pmc-release] AID - 357653 [pii] AID - 10.2147/PPA.S357653 [doi] PST - epublish SO - Patient Prefer Adherence. 2022 Apr 2;16:861-873. doi: 10.2147/PPA.S357653. eCollection 2022. PMID- 35395204 OWN - NLM STAT- MEDLINE DCOM- 20220419 LR - 20260518 IS - 2215-0374 (Electronic) IS - 2215-0366 (Print) IS - 2215-0366 (Linking) VI - 9 IP - 5 DP - 2022 May TI - Automated virtual reality therapy to treat agoraphobic avoidance and distress in patients with psychosis (gameChange): a multicentre, parallel-group, single-blind, randomised, controlled trial in England with mediation and moderation analyses. PG - 375-388 LID - S2215-0366(22)00060-8 [pii] LID - 10.1016/S2215-0366(22)00060-8 [doi] AB - BACKGROUND: Automated delivery of psychological therapy using immersive technologies such as virtual reality (VR) might greatly increase the availability of effective help for patients. We aimed to evaluate the efficacy of an automated VR cognitive therapy (gameChange) to treat avoidance and distress in patients with psychosis, and to analyse how and in whom it might work. METHODS: We did a parallel-group, single-blind, randomised, controlled trial across nine National Health Service trusts in England. Eligible patients were aged 16 years or older, with a clinical diagnosis of a schizophrenia spectrum disorder or an affective diagnosis with psychotic symptoms, and had self-reported difficulties going outside due to anxiety. Patients were randomly assigned (1:1) to either gameChange VR therapy plus usual care or usual care alone, using a permuted blocks algorithm with randomly varying block size, stratified by study site and service type. gameChange VR therapy was provided in approximately six sessions over 6 weeks. Trial assessors were masked to group allocation. Outcomes were assessed at 0, 6 (primary endpoint), and 26 weeks after randomisation. The primary outcome was avoidance of, and distress in, everyday situations, assessed using the self-reported Oxford Agoraphobic Avoidance Scale (O-AS). Outcome analyses were done in the intention-to-treat population (ie, all participants who were assigned to a study group for whom data were available). We performed planned mediation and moderation analyses to test the effects of gameChange VR therapy when added to usual care. This trial is registered with the ISRCTN registry, 17308399. FINDINGS: Between July 25, 2019, and May 7, 2021 (with a pause in recruitment from March 16, 2020, to Sept 14, 2020, due to COVID-19 pandemic restrictions), 551 patients were assessed for eligibility and 346 were enrolled. 231 (67%) patients were men and 111 (32%) were women, 294 (85%) were White, and the mean age was 37.2 years (SD 12.5). 174 patients were randomly assigned to the gameChange VR therapy group and 172 to the usual care alone group. Compared with the usual care alone group, the gameChange VR therapy group had significant reductions in agoraphobic avoidance (O-AS adjusted mean difference -0.47, 95% CI -0.88 to -0.06; n=320; Cohen's d -0.18; p=0.026) and distress (-4.33, -7.78 to -0.87; n=322; -0.26; p=0.014) at 6 weeks. Reductions in threat cognitions and within-situation defence behaviours mediated treatment outcomes. The greater the severity of anxious fears and avoidance, the greater the treatment benefits. There was no significant difference in the occurrence of serious adverse events between the gameChange VR therapy group (12 events in nine patients) and the usual care alone group (eight events in seven patients; p=0.37). INTERPRETATION: Automated VR therapy led to significant reductions in anxious avoidance of, and distress in, everyday situations compared with usual care alone. The mediation analysis indicated that the VR therapy worked in accordance with the cognitive model by reducing anxious thoughts and associated protective behaviours. The moderation analysis indicated that the VR therapy particularly benefited patients with severe agoraphobic avoidance, such as not being able to leave the home unaccompanied. gameChange VR therapy has the potential to increase the provision of effective psychological therapy for psychosis, particularly for patients who find it difficult to leave their home, visit local amenities, or use public transport. FUNDING: National Institute of Health Research Invention for Innovation programme, National Institute of Health Research Oxford Health Biomedical Research Centre. CI - Copyright (c) 2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved. FAU - Freeman, Daniel AU - Freeman D AD - Department of Psychiatry, University of Oxford, Oxford, UK; Oxford Health NHS Foundation Trust, Oxford, UK. Electronic address: daniel.freeman@psych.ox.ac.uk. FAU - Lambe, Sinead AU - Lambe S AD - Department of Psychiatry, University of Oxford, Oxford, UK; Oxford Health NHS Foundation Trust, Oxford, UK. FAU - Kabir, Thomas AU - Kabir T AD - McPin Foundation, London, UK. FAU - Petit, Ariane AU - Petit A AD - Department of Psychiatry, University of Oxford, Oxford, UK. FAU - Rosebrock, Laina AU - Rosebrock L AD - Department of Psychiatry, University of Oxford, Oxford, UK; Oxford Health NHS Foundation Trust, Oxford, UK. FAU - Yu, Ly-Mee AU - Yu LM AD - Oxford Primary Care Clinical Trials Unit, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK. FAU - Dudley, Robert AU - Dudley R AD - Cumbria, Northumberland, Tyne, and Wear NHS Foundation Trust, Newcastle upon Tyne, UK; Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, UK. FAU - Chapman, Kate AU - Chapman K AD - Avon and Wiltshire Mental Health Partnership NHS Trust, Bath, UK. FAU - Morrison, Anthony AU - Morrison A AD - Greater Manchester Mental Health Foundation Trust, Manchester, UK; Division of Psychology and Mental Health, University of Manchester, Manchester, UK. FAU - O'Regan, Eileen AU - O'Regan E AD - Nottinghamshire Healthcare NHS Foundation Trust, Nottingham, UK. FAU - Aynsworth, Charlotte AU - Aynsworth C AD - Cumbria, Northumberland, Tyne, and Wear NHS Foundation Trust, Newcastle upon Tyne, UK. FAU - Jones, Julia AU - Jones J AD - Nottinghamshire Healthcare NHS Foundation Trust, Nottingham, UK. FAU - Murphy, Elizabeth AU - Murphy E AD - Greater Manchester Mental Health Foundation Trust, Manchester, UK. FAU - Powling, Rosie AU - Powling R AD - Avon and Wiltshire Mental Health Partnership NHS Trust, Bath, UK. FAU - Galal, Ushma AU - Galal U AD - Oxford Primary Care Clinical Trials Unit, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK. FAU - Grabey, Jenna AU - Grabey J AD - Oxford Primary Care Clinical Trials Unit, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK. FAU - Rovira, Aitor AU - Rovira A AD - Department of Psychiatry, University of Oxford, Oxford, UK; Oxford Health NHS Foundation Trust, Oxford, UK. FAU - Martin, Jennifer AU - Martin J AD - National Institute for Health Research MindTech MedTech Co-operative, Nottingham, UK; Mental Health and Clinical Neurosciences, School of Medicine, Institute of Mental Health, University of Nottingham, Nottingham, UK; National Institute for Health Research Nottingham Biomedical Research Centre, Mental Health & Technology Theme, Nottingham, UK. FAU - Hollis, Chris AU - Hollis C AD - Nottinghamshire Healthcare NHS Foundation Trust, Nottingham, UK; National Institute for Health Research MindTech MedTech Co-operative, Nottingham, UK; Mental Health and Clinical Neurosciences, School of Medicine, Institute of Mental Health, University of Nottingham, Nottingham, UK; National Institute for Health Research Nottingham Biomedical Research Centre, Mental Health & Technology Theme, Nottingham, UK. FAU - Clark, David M AU - Clark DM AD - Department of Experimental Psychology, University of Oxford, Oxford, UK; Oxford Health NHS Foundation Trust, Oxford, UK. FAU - Waite, Felicity AU - Waite F AD - Department of Psychiatry, University of Oxford, Oxford, UK; Oxford Health NHS Foundation Trust, Oxford, UK. CN - gameChange Trial Group LA - eng GR - WT_/Wellcome Trust/United Kingdom PT - Journal Article PT - Multicenter Study PT - Randomized Controlled Trial PT - Research Support, Non-U.S. Gov't DEP - 20220405 PL - England TA - Lancet Psychiatry JT - The lancet. Psychiatry JID - 101638123 SB - IM MH - Adult MH - *COVID-19 MH - England MH - Female MH - Humans MH - Male MH - Pandemics MH - *Psychotic Disorders/psychology/therapy MH - Single-Blind Method MH - State Medicine MH - Treatment Outcome MH - *Virtual Reality Exposure Therapy PMC - PMC9010306 COIS- Declaration of interests DF is a founder and a non-executive director of Oxford VR, which will commercialise the therapy; holds equity in and receives personal payments from Oxford VR; holds a contract for his university team to advise Oxford VR on treatment development; and reports grants from National Institute for Health Research (NIHR), Medical Research Council (MRC), and International Foundation. CH reports grants from NIHR and MRC; and was chair of the National Institute for Health and Care Excellence Guideline for psychosis and schizophrenia in children and young people (CG155). The University of Oxford, Oxford Health NHS Foundation Trust, McPin Foundation, NIHR MindTech MedTech Co-operative, and the Royal College of Art received a share of the licencing fee from Oxford VR for the gameChange software. DMC reports a Senior Investigator Award from the Wellcome Trust and is National Clinical and Informatic Advisor for the NHS Improving Access to Psychological Therapy (IAPT) programme. RD reports a grant from the NIHR, is a clinician working in the NHS delivering cognitive therapy, and receives payments for workshops of cognitive behavioural therapy and royalties from books on cognitive behavioural therapy. SL reports consultancy work and fees from Oxford VR. AP reports a grant from the NIHR. All other authors declare no competing interests. FIR - Altunkaya, James IR - Altunkaya J FIR - Andleeb, Humma IR - Andleeb H FIR - Bergin, Aislinn IR - Bergin A FIR - Bold, Emily IR - Bold E FIR - Bond, Jessica IR - Bond J FIR - Bransby-Adams, Kate IR - Bransby-Adams K FIR - Brown, Susan IR - Brown S FIR - Chan, Cindy IR - Chan C FIR - Chauhan, Nisha IR - Chauhan N FIR - Craven, Michael IR - Craven M FIR - Freeman, Jason IR - Freeman J FIR - Geddes, John IR - Geddes J FIR - Goodsell, Andrew IR - Goodsell A FIR - Jenner, Lucy IR - Jenner L FIR - Kenny, Alex IR - Kenny A FIR - Leal, Jose IR - Leal J FIR - Mitchell, Joanna IR - Mitchell J FIR - Peel, Heather IR - Peel H FIR - Pervez, Maryam IR - Pervez M FIR - Prouten, Eloise IR - Prouten E FIR - Roberts, Eva IR - Roberts E FIR - Robotham, Dan IR - Robotham D FIR - Walker, Harry IR - Walker H FIR - West, Jonathan IR - West J EDAT- 2022/04/09 06:00 MHDA- 2022/04/20 06:00 PMCR- 2022/05/01 CRDT- 2022/04/08 20:09 PHST- 2021/12/07 00:00 [received] PHST- 2022/02/16 00:00 [revised] PHST- 2022/02/16 00:00 [accepted] PHST- 2022/04/09 06:00 [pubmed] PHST- 2022/04/20 06:00 [medline] PHST- 2022/04/08 20:09 [entrez] PHST- 2022/05/01 00:00 [pmc-release] AID - S2215-0366(22)00060-8 [pii] AID - 10.1016/S2215-0366(22)00060-8 [doi] PST - ppublish SO - Lancet Psychiatry. 2022 May;9(5):375-388. doi: 10.1016/S2215-0366(22)00060-8. Epub 2022 Apr 5. PMID- 35369783 OWN - NLM STAT- MEDLINE DCOM- 20220721 LR - 20220721 IS - 1724-6016 (Electronic) IS - 1120-6721 (Linking) VI - 32 IP - 4 DP - 2022 Jul TI - Low-vision rehabilitation in Italy: Cross-sectional data from the Device and Aids Registry (D.A.Re). PG - 1942-1946 LID - 10.1177/11206721221091367 [doi] AB - OBJECTIVES: We are reporting on the characteristics of low-vision adults attending large rehabilitation services which provide data to D.A.Re (Devices & Aids REgister) in Italy. D.A.Re aims to gather information about low-vision aids owned by Italian patients with visual impairment. METHODS: We included consecutive patients attending low-vision rehabilitation centres providing data to D.A.Re from 2019 to July 2021. Demographic features, self-reported use of technology and aids, vision performance, and the Instrumental Activity of Daily Living (IADL) score were collected. RESULTS: 720 patients were included in the D.A.Re. About half of the patients were affected by Age-related Macular Degeneration (389, 54.9%). Patients reported a long interval between onset of vision disability and access to low-vision rehabilitation, which was over two years in almost 30% of cases. Blindness registration status was almost complete when reported, but almost 40% were unable to report on this. IADL scores were higher for younger people and those with better visual acuity and critical print size (CPS), and lower for visual field restriction (p < 0.01 for all predictors). Of interest, better IADL scores were recorded for those with computer knowledge who used optical aids and software in univariate analyses and multivariate analyses, adjusting for level of visual disability and employment status (p < 0.01 for all predictors). CONCLUSIONS: We report on the profile of low-vision patients using rehabilitation services in Italy. Longitudinal data during and after vision rehabilitation were collected. Our results support the validity of the D.A.Re to monitor the use of low-vision devices in Italy. FAU - Bartolomei, Federico AU - Bartolomei F AUID- ORCID: 0000-0001-6007-5096 AD - Istituto Cavazza, Bologna, Italy. FAU - Biagini, Ilaria AU - Biagini I AUID- ORCID: 0000-0003-1263-7183 AD - Department of Neurosciences, Psychology, Drug Research and Child Health (NEUROFARBA), University of Florence and AOU Careggi, Firenze, Italy. FAU - Sato, Giovanni AU - Sato G AUID- ORCID: 0000-0003-1492-5306 AD - Centro Oculistico S. Paolo Hospital, S. Antonio Padova, Italy. FAU - Falchini, Elisabetta AU - Falchini E AD - Centro integrato per la Riabilitazione Visiva 'Carlo Monti', AOU Careggi, Firenze, Italy. FAU - Di Simone, Alessia AU - Di Simone A AD - C.E.R.Vi UICI, Enna, Italy. FAU - Mastrantuono, Chiara AU - Mastrantuono C AD - Centro Officina dei Sensi, Ascoli Piceno, Italy. FAU - Micarelli, Silvia AU - Micarelli S AD - Azienda Servizi alla Persona disabile visiva S. Alessio - Margherita di Savoia, Rome, Italy. FAU - Virgili, Gianni AU - Virgili G AD - Department of Neurosciences, Psychology, Drug Research and Child Health (NEUROFARBA), University of Florence and AOU Careggi, Firenze, Italy. AD - Centre for Public Health, Queen's University of Belfast, Belfast, Northern Ireland (UK). LA - eng PT - Journal Article DEP - 20220404 PL - United States TA - Eur J Ophthalmol JT - European journal of ophthalmology JID - 9110772 SB - IM MH - Adult MH - Blindness/epidemiology MH - Cross-Sectional Studies MH - Humans MH - *Macular Degeneration MH - Registries MH - *Vision, Low/epidemiology/rehabilitation OTO - NOTNLM OT - Retina OT - age-related macular degeneration OT - genetics OT - glaucoma OT - optics/refraction/instruments OT - retina OT - retinal pathology/research EDAT- 2022/04/05 06:00 MHDA- 2022/07/22 06:00 CRDT- 2022/04/04 05:23 PHST- 2022/04/05 06:00 [pubmed] PHST- 2022/07/22 06:00 [medline] PHST- 2022/04/04 05:23 [entrez] AID - 10.1177/11206721221091367 [doi] PST - ppublish SO - Eur J Ophthalmol. 2022 Jul;32(4):1942-1946. doi: 10.1177/11206721221091367. Epub 2022 Apr 4. PMID- 35358214 OWN - NLM STAT- MEDLINE DCOM- 20220414 LR - 20230721 IS - 1932-6203 (Electronic) IS - 1932-6203 (Linking) VI - 17 IP - 3 DP - 2022 TI - Antibody seroprevalence against SARS-CoV-2 within the Canton of Sarajevo, Bosnia and Herzegovina-One year later. PG - e0265431 LID - 10.1371/journal.pone.0265431 [doi] LID - e0265431 AB - BACKGROUND: Serostudies are important resources when following pandemics and predicting their further spread, as well as determining the length of protection against reinfection and vaccine development. The aim of this study was to update data on the prevalence of seropositive individuals in Canton Sarajevo, Bosnia and Herzegovina (B&H) from September 2020 to May 2021. METHODS: Anti-SARS-CoV-2 antibodies were quantified using an electrochemiluminescence immunoassay. RESULTS: Compared to the period April-July 2020, when anti-SARS-CoV-2 antibodies were detected in 3.77% of samples, one year later (May 2021) the estimated percentage within the same population of the urban Canton Sarajevo was 29.9% (5,406/18,066). Of all anti-SARS-CoV-2 Ig-positive individuals, 53.27% were men, and 69.00% were of 50 years of age or younger. Also, the current update found the individuals 50 years of age or younger to be more frequently anti-SARS-CoV-2 Ig positive compared to older individuals. On the other hand, higher median anti-SARS-CoV-2 Ig levels were found in individuals > 50 years old than in younger individuals, as well as in men compared to women. Seropositivity gradually increased from September 2020 to May 2021, with the lowest frequency of positive cases (3.5%) observed in September 2020, and the highest frequency (77.7%) in January 2021. CONCLUSION: Our results provided important seroprevalence data that could help in planning restrictive local public health measures to protect the population of Sarajevo Canton, especially considering that at the time of the study the vaccines were virtually inaccessible to the general population not belonging to any of the high-priority groups for vaccination. FAU - Prguda-Mujic, Jasminka AU - Prguda-Mujic J AUID- ORCID: 0000-0002-3969-7373 AD - Eurofarm Molecular Diagnostics Laboratory, Eurofarm Centre, Sarajevo, Bosnia and Herzegovina. FAU - Hasanic, Osman AU - Hasanic O AUID- ORCID: 0000-0002-8881-1769 AD - Department of Genetics and Bioengineering, International Burch University, Sarajevo, Bosnia and Herzegovina. FAU - Besic, Larisa AU - Besic L AD - Department of Genetics and Bioengineering, International Burch University, Sarajevo, Bosnia and Herzegovina. FAU - Asic, Adna AU - Asic A AUID- ORCID: 0000-0001-6197-9572 AD - Department of Genetics and Bioengineering, International Burch University, Sarajevo, Bosnia and Herzegovina. FAU - Halilovic, Sabina AU - Halilovic S AD - Department of Genetics and Bioengineering, International Burch University, Sarajevo, Bosnia and Herzegovina. FAU - Cesic, Aida Kulo AU - Cesic AK AD - Department of Pharmacology, Clinical Pharmacology and Toxicology, Medical Faculty, University of Sarajevo, Bosnia and Herzegovina. FAU - Ljevakovic, Neira AU - Ljevakovic N AD - Department of Genetics and Bioengineering, International Burch University, Sarajevo, Bosnia and Herzegovina. FAU - Muminovic, Fildesa AU - Muminovic F AD - Department of Genetics and Bioengineering, International Burch University, Sarajevo, Bosnia and Herzegovina. FAU - Huseinovic, Sukrija AU - Huseinovic S AD - Department of Genetics and Bioengineering, International Burch University, Sarajevo, Bosnia and Herzegovina. FAU - Ler, Daria AU - Ler D AD - Department of Genetics and Bioengineering, International Burch University, Sarajevo, Bosnia and Herzegovina. FAU - Salihefendic, Lana AU - Salihefendic L AD - Alea Genetic Centre, Health Institute Alea Dr. Kandic, Sarajevo, Bosnia and Herzegovina. FAU - Konjhodzic, Rijad AU - Konjhodzic R AD - Alea Genetic Centre, Health Institute Alea Dr. Kandic, Sarajevo, Bosnia and Herzegovina. FAU - Primorac, Dragan AU - Primorac D AD - St. Catherine Specialty Hospital, Zagreb/Zabok, Croatia. AD - Eberly College of Science, The Pennsylvania State University, University Park, State College, Pennsylvania, United States of America. AD - The Henry C. Lee College of Criminal Justice and Forensic Sciences, University of New Haven, West Haven, Connecticut, United States of America. AD - Medical School, University of Split, Split, Croatia. AD - School of Medicine, Faculty of Dental Medicine and Health, Josip Juraj Strossmayer University Osijek, Osijek, Croatia. AD - School of Medicine, Josip Juraj Strossmayer University Osijek, Osijek, Croatia. AD - Faculty of Medicine, University of Rijeka, Rijeka, Croatia. AD - Medical School REGIOMED, Coburg, Germany. FAU - Marjanovic, Damir AU - Marjanovic D AD - Department of Genetics and Bioengineering, International Burch University, Sarajevo, Bosnia and Herzegovina. AD - Institute for Anthropological Research, University of Zagreb, Zagreb, Croatia. LA - eng PT - Journal Article DEP - 20220331 PL - United States TA - PLoS One JT - PloS one JID - 101285081 RN - 0 (Antibodies, Viral) SB - IM MH - Antibodies, Viral MH - Bosnia and Herzegovina/epidemiology MH - *COVID-19/epidemiology MH - Female MH - Humans MH - Male MH - Middle Aged MH - *SARS-CoV-2 MH - Seroepidemiologic Studies PMC - PMC8970370 COIS- The authors have declared that no competing interests exist. EDAT- 2022/04/01 06:00 MHDA- 2022/04/15 06:00 PMCR- 2022/03/31 CRDT- 2022/03/31 17:14 PHST- 2021/08/04 00:00 [received] PHST- 2022/03/02 00:00 [accepted] PHST- 2022/03/31 17:14 [entrez] PHST- 2022/04/01 06:00 [pubmed] PHST- 2022/04/15 06:00 [medline] PHST- 2022/03/31 00:00 [pmc-release] AID - PONE-D-21-25253 [pii] AID - 10.1371/journal.pone.0265431 [doi] PST - epublish SO - PLoS One. 2022 Mar 31;17(3):e0265431. doi: 10.1371/journal.pone.0265431. eCollection 2022. PMID- 35352217 OWN - NLM STAT- MEDLINE DCOM- 20220614 LR - 20220614 IS - 1434-9949 (Electronic) IS - 0770-3198 (Print) IS - 0770-3198 (Linking) VI - 41 IP - 7 DP - 2022 Jul TI - Prevalence and risk of COVID-19 in patients with rheumatic diseases: a systematic review and meta-analysis. PG - 2213-2223 LID - 10.1007/s10067-022-06087-1 [doi] AB - OBJECTIVES: COVID-19 pandemic has already had a tremendous impact on the process of human society; the survival of mankind and the healthy living environment deterioration with the influence will last for many years. This meta-analysis aims to assess the risk of COVID-19 in patients with rheumatic diseases. METHODS: PubMed, Web of Science, Embase, China National Knowledge Infrastructure (CNKI), and Chinese Biomedical Database (CBM) were systematically searched with no language restriction up to July 5, 2021. The pooled rates were synthesized by fixed effect model or random effect model depending on heterogeneity. RESULTS: A total of 83 articles were included in this meta-analysis. The incidence of COVID-19 in patient with rheumatic diseases was 0.0190 (95% CI: 0.0136-0.0252), and the hospitalization rate, intensive care unit admission rate, mechanical ventilation rate, and case fatality rate of patients with rheumatic diseases infected with COVID-19 were 0.4396 (95% CI: 0.3899-0.4898), 0.0635 (95% CI: 0.0453-0.0836), 0.0461 (95% CI: 0.0330-0.0609), and 0.0346 (95% CI: 0.0218-0.0493), respectively. CONCLUSIONS: Our research shows that patients with rheumatic diseases have great risk of COVID-19. Differences in COVID-19 incidence, hospitalization rates, and mortality rates in regions were statistically significant. We still need to pay attention to the risk of COVID-19 in patients with rheumatic diseases. KEY POINTS: * Although the risk of COVID-19 in patients with rheumatic diseases has been discussed in previous meta-analysis, their research directions were inconsistent, and few studies focus on prevalence or serious outcomes of COVID-19 in patient with rheumatic diseases, while the quality of these articles was variable. * The incidence of COVID-19 and serious clinical outcomes in patients with rheumatic diseases were still high along with differential risks in most regions. * The use of glucocorticoids and conventional synthetic disease-modifying antirheumatic drugs did not affect the hospitalization rate and mortality in rheumatism patients with COVID-19. CI - (c) 2022. International League of Associations for Rheumatology (ILAR). FAU - Wang, Feier AU - Wang F AD - Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, 81 Meishan Road, Hefei, 230032, Anhui, China. AD - The Key Laboratory of Major Autoimmune Diseases, Anhui Medical University, 81 Meishan Road, Hefei, 230032, Anhui, China. FAU - Ma, Yubo AU - Ma Y AD - Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, 81 Meishan Road, Hefei, 230032, Anhui, China. AD - The Key Laboratory of Major Autoimmune Diseases, Anhui Medical University, 81 Meishan Road, Hefei, 230032, Anhui, China. FAU - Xu, Shanshan AU - Xu S AD - Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, 81 Meishan Road, Hefei, 230032, Anhui, China. AD - The Key Laboratory of Major Autoimmune Diseases, Anhui Medical University, 81 Meishan Road, Hefei, 230032, Anhui, China. FAU - Liu, Huanhuan AU - Liu H AD - Department of Clinical Laboratory, the Second Hospital of Anhui Medical University, 678 Furong Road, Hefei, Anhui, China. FAU - Chen, Yuting AU - Chen Y AD - Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, 81 Meishan Road, Hefei, 230032, Anhui, China. AD - The Key Laboratory of Major Autoimmune Diseases, Anhui Medical University, 81 Meishan Road, Hefei, 230032, Anhui, China. FAU - Yang, Hui AU - Yang H AD - Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, 81 Meishan Road, Hefei, 230032, Anhui, China. AD - The Key Laboratory of Major Autoimmune Diseases, Anhui Medical University, 81 Meishan Road, Hefei, 230032, Anhui, China. FAU - Shao, Ming AU - Shao M AD - Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, 81 Meishan Road, Hefei, 230032, Anhui, China. AD - The Key Laboratory of Major Autoimmune Diseases, Anhui Medical University, 81 Meishan Road, Hefei, 230032, Anhui, China. FAU - Xu, Wei AU - Xu W AD - Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, 81 Meishan Road, Hefei, 230032, Anhui, China. AD - The Key Laboratory of Major Autoimmune Diseases, Anhui Medical University, 81 Meishan Road, Hefei, 230032, Anhui, China. FAU - Kong, Jiangping AU - Kong J AD - Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, 81 Meishan Road, Hefei, 230032, Anhui, China. AD - The Key Laboratory of Major Autoimmune Diseases, Anhui Medical University, 81 Meishan Road, Hefei, 230032, Anhui, China. FAU - Chen, Liwen AU - Chen L AD - Department of Clinical Laboratory, the Second Hospital of Anhui Medical University, 678 Furong Road, Hefei, Anhui, China. FAU - Xu, Shengqian AU - Xu S AD - Department of Rheumatism and Immunity, the First Affiliated Hospital of Anhui Medical University, Hefei, 230022, Anhui, China. FAU - Shuai, Zongwen AU - Shuai Z AD - Department of Rheumatism and Immunity, the First Affiliated Hospital of Anhui Medical University, Hefei, 230022, Anhui, China. FAU - Pan, Faming AU - Pan F AUID- ORCID: 0000-0003-4242-1025 AD - Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, 81 Meishan Road, Hefei, 230032, Anhui, China. famingpan@ahmu.edu.cn. AD - The Key Laboratory of Major Autoimmune Diseases, Anhui Medical University, 81 Meishan Road, Hefei, 230032, Anhui, China. famingpan@ahmu.edu.cn. LA - eng PT - Journal Article PT - Meta-Analysis PT - Systematic Review DEP - 20220330 PL - Germany TA - Clin Rheumatol JT - Clinical rheumatology JID - 8211469 SB - IM MH - *COVID-19/epidemiology MH - Humans MH - Pandemics MH - Prevalence MH - *Rheumatic Diseases/complications/epidemiology MH - SARS-CoV-2 PMC - PMC8964246 OTO - NOTNLM OT - COVID-19 OT - Meta-analysis OT - Prevalence OT - Rheumatic disease EDAT- 2022/03/31 06:00 MHDA- 2022/06/15 06:00 PMCR- 2022/03/29 CRDT- 2022/03/30 05:43 PHST- 2021/08/17 00:00 [received] PHST- 2022/01/29 00:00 [accepted] PHST- 2022/01/03 00:00 [revised] PHST- 2022/03/31 06:00 [pubmed] PHST- 2022/06/15 06:00 [medline] PHST- 2022/03/30 05:43 [entrez] PHST- 2022/03/29 00:00 [pmc-release] AID - 10.1007/s10067-022-06087-1 [pii] AID - 6087 [pii] AID - 10.1007/s10067-022-06087-1 [doi] PST - ppublish SO - Clin Rheumatol. 2022 Jul;41(7):2213-2223. doi: 10.1007/s10067-022-06087-1. Epub 2022 Mar 30. PMID- 35342952 OWN - NLM STAT- MEDLINE DCOM- 20220713 LR - 20220713 IS - 1365-2362 (Electronic) IS - 0014-2972 (Linking) VI - 52 IP - 8 DP - 2022 Aug TI - Risk of ischaemic heart diseases and stroke in behcet disease: A systematic review and meta-analysis. PG - e13778 LID - 10.1111/eci.13778 [doi] AB - BACKGROUND: Behcet disease (BD) is a systemic vasculitis. In addition to the mucocutaneous lesions, the vascular injury of pathophysiology in BD is theoretically correlated with cardiovascular diseases. This study aimed to elucidate the association of BD with ischaemic heart diseases (IHDs) and stroke. METHODS: A systematic search of PubMed, Embase, Web of Science and Cochrane Library databases was performed for all relevant observational studies from database inception until 10 July 2021. No language restriction was applied. A random-effects model was used for meta-analysis. RESULTS: A total of six observational studies consisting of three cohort studies, two cross-sectional studies and one study with both study designs were adopted in the meta-analysis. The numbers of patients with BD and healthy controls were 9,813 and 41,802, respectively. The pooled analysis demonstrated no significant association between BD and IHD. By contrast, we found that patients with BD had a significantly higher risk of stroke (adjusted hazard ratio, 2.083; 95% confidence interval, 1.339-3.240; p = 0.001) than healthy controls. We observed substantial heterogeneity across studies in few meta-analyses, but no significant publication bias was detected in any of the meta-analyses. CONCLUSIONS: BD was significantly associated with stroke but not IHD. Physicians should be aware of possible vascular and neurological complications during care of patients with BD. CI - (c) 2022 Stichting European Society for Clinical Investigation Journal Foundation. Published by John Wiley & Sons Ltd. FAU - Chuang, Kai-Wen AU - Chuang KW AD - School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan. FAU - Chang, Hua-Ching AU - Chang HC AUID- ORCID: 0000-0003-3608-1394 AD - Department of Dermatology, Taipei Medical University Hospital, Taipei, Taiwan. AD - Department of Dermatology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan. AD - Research Center of Big Data and Meta-Analysis, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan. LA - eng PT - Journal Article PT - Meta-Analysis PT - Systematic Review DEP - 20220405 PL - England TA - Eur J Clin Invest JT - European journal of clinical investigation JID - 0245331 SB - IM MH - *Behcet Syndrome/complications/epidemiology MH - Cross-Sectional Studies MH - Humans MH - *Myocardial Ischemia/epidemiology/etiology MH - Risk Factors MH - *Stroke/complications/etiology OTO - NOTNLM OT - Behcet disease OT - cerebrovascular accident OT - ischaemic heart diseases OT - stroke EDAT- 2022/03/29 06:00 MHDA- 2022/07/14 06:00 CRDT- 2022/03/28 05:32 PHST- 2022/03/02 00:00 [revised] PHST- 2022/01/06 00:00 [received] PHST- 2022/03/26 00:00 [accepted] PHST- 2022/03/29 06:00 [pubmed] PHST- 2022/07/14 06:00 [medline] PHST- 2022/03/28 05:32 [entrez] AID - 10.1111/eci.13778 [doi] PST - ppublish SO - Eur J Clin Invest. 2022 Aug;52(8):e13778. doi: 10.1111/eci.13778. Epub 2022 Apr 5. PMID- 35331539 OWN - NLM STAT- MEDLINE DCOM- 20220330 LR - 20220401 IS - 2405-4577 (Electronic) IS - 2405-4577 (Linking) VI - 48 DP - 2022 Apr TI - Effect of Paleolithic-based low-carbohydrate vs. moderate-carbohydrate diets with portion-control and calorie-counting on CTRP6, asprosin and metabolic markers in adults with metabolic syndrome: A randomized clinical trial. PG - 87-98 LID - S2405-4577(21)01117-7 [pii] LID - 10.1016/j.clnesp.2021.11.013 [doi] AB - OBJECTIVE: Several recent studies have been undertaken into carbohydrate-restricted diets. it has not been clearly demonstrated whether diets with different proportions of energy from carbohydrate exert distinct effects on metabolism and inflammation or not. The current randomized clinical trial (RCT) has been conducted to further elucidate the effects of severe and mild carbohydrate restriction on inflammation and cardiometabolic status in adults with metabolic syndrome (MetS). METHODS: Eighty adults with metabolic syndrome were randomized to one of the four carbohydrate restricted diets: Paleolithic-based low-carbohydrate diet with calorie-counting method (PLCD-CC) (n = 20), Paleolithic-based low-carbohydrate diet with portion-control method (PLCD-PC) (n = 20), moderate-carbohydrate diet with calorie-counting method (MCD-CC) (n = 20) and moderate-carbohydrate diet with portion-control method (MCD-PC) (n = 20) for 10 weeks. PLCD is defined as a diet consisting of 25-30% of energy from carbohydrate, 30% of energy from protein and 40-45% of energy from fat and encourages consumption of fruits, vegetables and lean meat. MCD is characterized as 40-45% carbohydrate, 30% protein and 30-35% fat. Body weight and composition, adipokines such as Asprosin, chemerin, leptin, hepatokines namely CTRP-6, FGF-21 and cardiovascular disease (CVD) risk factors were tested at baseline and at the end of 10 weeks. RESULTS: A total of 69 participants aged 42.95 (9.27) with metabolic syndrome completed the trial. At the end of current 10-week dietary intervention trial, significant reduction in weight, waist circumference, body fat, visceral fat and waist-hip ratio (WHR) was observed in all four intervention arms (P < 0.001). Also, the observed differences among groups did not reach statistical significance (P > 0.05). Moreover, we found significant reduction in CTRP6 and leptin in all intervention groups (P < 0.001). Reduction of Asprosin level was also marginally significant between intervention groups (P < 0.05). All four intervention groups were found to improve cardiometabolic markers such as FBS, TG, total cholesterol and LDL cholesterol compared to baseline. However, despite clinically significant difference, the within- and between-group changes were not statistically significant at the end of trial. CONCLUSIONS: The current RCT in Iranian adults with metabolic syndrome revealed that both moderate and Paleolithic-based low carbohydrate diets with both delivery approaches have comparable beneficial effects in terms of body weight and composition, cardiometabolic factors and metabolism-related adipokines and hepatokines. TRIAL REGISTRATION: Available at: https://en.irct.ir/trial/21157, identifier: (IRCT2016121925267N4), Registered on 26 July 2017. CI - Copyright (c) 2021 European Society for Clinical Nutrition and Metabolism. Published by Elsevier Ltd. All rights reserved. FAU - Shemirani, Farnoosh AU - Shemirani F AD - Department of Cellular and Molecular Nutrition, School of Nutritional Science and Dietetics, Tehran University of Medical Sciences, Tehran, Iran. FAU - Djafarian, Kurosh AU - Djafarian K AD - Department of Clinical Nutrition, School of Nutritional Science and Dietetics, Tehran University of Medical Sciences, Tehran, Iran. FAU - Fotouhi, Akbar AU - Fotouhi A AD - Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran. FAU - Azadbakht, Leila AU - Azadbakht L AD - Department of Community Nutrition, School of Nutritional Science and Dietetics, Tehran University of Medical Sciences, Tehran, Iran; Diabetes Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran; Department of Community Nutrition, School of Nutrition and Food Science, Isfahan University of Medical Sciences, Isfahan, Iran. FAU - Rezaei, Nima AU - Rezaei N AD - Research Center for Immunodeficiencies, Pediatrics Center of Excellence, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran. FAU - Chamari, Maryam AU - Chamari M AD - Department of Community Nutrition, School of Nutritional Science and Dietetics, Tehran University of Medical Sciences, Tehran, Iran. FAU - Shabani, Samaneh AU - Shabani S AD - Department of Cellular and Molecular Nutrition, School of Nutritional Science and Dietetics, Tehran University of Medical Sciences, Tehran, Iran. FAU - Mahmoudi, Maryam AU - Mahmoudi M AD - Department of Cellular and Molecular Nutrition, School of Nutritional Science and Dietetics, Tehran University of Medical Sciences, Tehran, Iran. Electronic address: maryam.mahmoudi73@gmail.com. LA - eng SI - IRCT/IRCT2016121925267N4 PT - Journal Article PT - Randomized Controlled Trial PT - Research Support, Non-U.S. Gov't DEP - 20211129 PL - England TA - Clin Nutr ESPEN JT - Clinical nutrition ESPEN JID - 101654592 RN - 0 (Carbohydrates) SB - IM MH - Adult MH - Carbohydrates MH - Diet, Carbohydrate-Restricted MH - Energy Intake MH - Humans MH - *Metabolic Syndrome MH - Waist Circumference OTO - NOTNLM OT - Adipokines OT - Low-carbohydrate diet OT - Metabolic syndrome OT - Paleolithic diet OT - Randomized clinical trial COIS- Conflicts of interest Authors declare that there is no conflict of interest. EDAT- 2022/03/26 06:00 MHDA- 2022/03/31 06:00 CRDT- 2022/03/25 05:32 PHST- 2021/07/24 00:00 [received] PHST- 2021/10/29 00:00 [revised] PHST- 2021/11/07 00:00 [accepted] PHST- 2022/03/25 05:32 [entrez] PHST- 2022/03/26 06:00 [pubmed] PHST- 2022/03/31 06:00 [medline] AID - S2405-4577(21)01117-7 [pii] AID - 10.1016/j.clnesp.2021.11.013 [doi] PST - ppublish SO - Clin Nutr ESPEN. 2022 Apr;48:87-98. doi: 10.1016/j.clnesp.2021.11.013. Epub 2021 Nov 29. PMID- 35317884 OWN - NLM STAT- MEDLINE DCOM- 20220704 LR - 20220726 IS - 1469-4409 (Electronic) IS - 0950-2688 (Print) IS - 0950-2688 (Linking) VI - 150 DP - 2022 Mar 23 TI - Increased transmission of SARS-CoV-2 in Denmark during UEFA European championships. PG - e123 LID - 10.1017/S095026882200019X [doi] LID - e123 AB - Denmark hosted four games during the 2020 UEFA European championships (EC2020). After declining positive SARS-CoV-2 test rates in Denmark, a rise occurred during and after the tournament, concomitant with the replacement of the dominant Alpha lineage (B.1.1.7) by the Delta lineage (B.1.617.2), increasing vaccination rates and cessation of several restrictions. A cohort study including 33 227 cases was conducted from 30 May to 25 July 2021, 14 days before and after the EC2020. Included was a nested cohort with event information from big-screen events and matches at the Danish national stadium, Parken (DNSP) in Copenhagen, held from 12 June to 28 June 2021. Information from whole-genome sequencing, contact tracing and Danish registries was collected. Case-case connections were used to establish transmission trees. Cases infected on match days were compared to cases not infected on match days as a reference. The crude incidence rate ratio (IRR) of transmissions was 1.55, corresponding to 584 (1.76%) cases attributable to EC2020 celebrations. The IRR adjusted for covariates was lower (IRR 1.41) but still significant, and also pointed to a reduced number of transmissions from fully vaccinated cases (IRR 0.59). These data support the hypothesis that the EC2020 celebrations contributed to the rise of cases in Denmark in the early summer of 2021. FAU - Bennedbaek, Marc AU - Bennedbaek M AD - Virus and Microbiological Special Diagnostics, Statens Serum Institut, Copenhagen, Denmark. FAU - Button, Mia Sarah Fischer AU - Button MSF AD - Division of Infectious Disease Preparedness, Statens Serum Institut, Copenhagen, Denmark. FAU - Nielsen, Lise Birk AU - Nielsen LB AD - Division of Infectious Disease Preparedness, Statens Serum Institut, Copenhagen, Denmark. FAU - Bybjerg-Grauholm, Jonas AU - Bybjerg-Grauholm J AUID- ORCID: 0000-0003-1705-4008 AD - Department for Congenital Disorders, Statens Serum Institut, Copenhagen, Denmark. FAU - Wiid Svarrer, Christina AU - Wiid Svarrer C AD - Department of Bacteria, Parasites and Fungi, Statens Serum Institut, Copenhagen, Denmark. FAU - Moller, Karina Lauenborg AU - Moller KL AD - Division of Infectious Disease Preparedness, Statens Serum Institut, Copenhagen, Denmark. FAU - Kristensen, Brian AU - Kristensen B AD - Division of Infectious Disease Preparedness, Statens Serum Institut, Copenhagen, Denmark. FAU - Legarth, Rebecca AU - Legarth R AD - Division of Infectious Disease Preparedness, Statens Serum Institut, Copenhagen, Denmark. FAU - Gunalan, Vithiagaran AU - Gunalan V AD - Virus and Microbiological Special Diagnostics, Statens Serum Institut, Copenhagen, Denmark. FAU - Zenas, Ditte Rechter AU - Zenas DR AD - Division of Infectious Disease Preparedness, Statens Serum Institut, Copenhagen, Denmark. FAU - Irshad, Irfatha AU - Irshad I AD - Division of Infectious Disease Preparedness, Statens Serum Institut, Copenhagen, Denmark. FAU - Gubbels, Sophie AU - Gubbels S AD - Division of Infectious Disease Preparedness, Statens Serum Institut, Copenhagen, Denmark. FAU - Sieber, Raphael N AU - Sieber RN AD - Department of Bacteria, Parasites and Fungi, Statens Serum Institut, Copenhagen, Denmark. FAU - Stegger, Marc AU - Stegger M AD - Department of Bacteria, Parasites and Fungi, Statens Serum Institut, Copenhagen, Denmark. FAU - Valentiner-Branth, Palle AU - Valentiner-Branth P AD - Division of Infectious Disease Preparedness, Statens Serum Institut, Copenhagen, Denmark. FAU - Rasmussen, Morten AU - Rasmussen M AD - Virus and Microbiological Special Diagnostics, Statens Serum Institut, Copenhagen, Denmark. FAU - Moller, Camilla Holten AU - Moller CH AD - Division of Infectious Disease Preparedness, Statens Serum Institut, Copenhagen, Denmark. FAU - Fonager, Jannik AU - Fonager J AD - Virus and Microbiological Special Diagnostics, Statens Serum Institut, Copenhagen, Denmark. FAU - Moller, Frederik Trier AU - Moller FT AUID- ORCID: 0000-0002-1059-4661 AD - Division of Infectious Disease Preparedness, Statens Serum Institut, Copenhagen, Denmark. LA - eng PT - Journal Article DEP - 20220323 PL - England TA - Epidemiol Infect JT - Epidemiology and infection JID - 8703737 RN - SARS-CoV-2 variants SB - IM MH - *COVID-19/epidemiology MH - Cohort Studies MH - Denmark/epidemiology MH - Humans MH - *SARS-CoV-2 PMC - PMC9254153 OTO - NOTNLM OT - Epidemiology OT - SARS-CoV-2 OT - mass events OT - public health OT - transmission COIS- None. EDAT- 2022/03/24 06:00 MHDA- 2022/07/06 06:00 PMCR- 2022/03/23 CRDT- 2022/03/23 05:36 PHST- 2022/03/24 06:00 [pubmed] PHST- 2022/07/06 06:00 [medline] PHST- 2022/03/23 05:36 [entrez] PHST- 2022/03/23 00:00 [pmc-release] AID - S095026882200019X [pii] AID - 10.1017/S095026882200019X [doi] PST - epublish SO - Epidemiol Infect. 2022 Mar 23;150:e123. doi: 10.1017/S095026882200019X. PMID- 35317773 OWN - NLM STAT- MEDLINE DCOM- 20220325 LR - 20220326 IS - 1471-2458 (Electronic) IS - 1471-2458 (Linking) VI - 22 IP - 1 DP - 2022 Mar 23 TI - Exploring the impact of COVID-19 on substance use patterns and service access of street involved individuals in Kingston, Ontario: a qualitative study. PG - 571 LID - 10.1186/s12889-022-12976-6 [doi] LID - 571 AB - This study aims to understand the experiences of street-involved individuals during the COVID-19 pandemic regarding substance use patterns and service access. With the collision of the COVID-19 pandemic and Canadian opioid epidemic came an increase in opioid related overdoses and increased barriers in accessing essential services since March 2020. Semi-structured interviews were conducted in June and July 2021, with 30 street-involved individuals in Kingston, Ontario. Analysis followed a phenomenological approach to qualitative research. Themes were coded by two independent researchers using NVIVO12. COVID-19 had detrimental effects on the lives of street-involved folks who use substances. Increased substance use to combat feelings of isolation and hopelessness related to loss of income and housing was commonly described. Increased fentanyl usage was considered the major contributor to the rise in overdoses over the pandemic. Restrictions on public access to businesses and services disproportionately impacted individuals with limited means. Harm reduction services and mental health support were considered extremely important throughout the pandemic. The coinciding COVID-19 pandemic and opioid epidemic place street-involved individuals who use substances in a uniquely dangerous position. As such, it is imperative that public policy decision-makers consider the differential needs of street-involved community members to provide safe, relevant, and compassionate solutions in future public health emergencies. CI - (c) 2022. The Author(s). FAU - McCann, Victoria AU - McCann V AD - Queen's University School of Medicine, Kingston, ON, K7L 3N6, Canada. FAU - Allen, Rachael AU - Allen R AD - Queen's University School of Medicine, Kingston, ON, K7L 3N6, Canada. rachael.allen@queensu.ca. FAU - Purkey, Eva AU - Purkey E AD - Department of Family Medicine, Queen's University, Kingston, ON, K7L3G2, Canada. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20220323 PL - England TA - BMC Public Health JT - BMC public health JID - 100968562 SB - IM MH - *COVID-19/epidemiology MH - Humans MH - Ontario/epidemiology MH - Pandemics MH - Qualitative Research MH - *Substance-Related Disorders/epidemiology PMC - PMC8940590 OTO - NOTNLM OT - COVID-19 OT - Harm reduction OT - Opioid epidemic OT - Public health OT - Qualitative research OT - Service access OT - Street involved OT - Substance use COIS- The authors declare no conflict of interest. EDAT- 2022/03/24 06:00 MHDA- 2022/03/26 06:00 PMCR- 2022/03/23 CRDT- 2022/03/23 05:35 PHST- 2021/12/03 00:00 [received] PHST- 2022/03/09 00:00 [accepted] PHST- 2022/03/23 05:35 [entrez] PHST- 2022/03/24 06:00 [pubmed] PHST- 2022/03/26 06:00 [medline] PHST- 2022/03/23 00:00 [pmc-release] AID - 10.1186/s12889-022-12976-6 [pii] AID - 12976 [pii] AID - 10.1186/s12889-022-12976-6 [doi] PST - epublish SO - BMC Public Health. 2022 Mar 23;22(1):571. doi: 10.1186/s12889-022-12976-6. PMID- 35317492 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230107 IS - 2214-7519 (Print) IS - 2214-7519 (Electronic) IS - 2214-7519 (Linking) VI - 29 DP - 2022 Sep TI - The impact of reduced operating room capacity on the time delay of urgent surgical care for neurosurgical patients during the COVID-19 pandemic. PG - 101544 LID - 10.1016/j.inat.2022.101544 [doi] AB - BACKGROUND: The COVID-19 pandemic raised major challenges to the management of patient flows and medical staff resource allocation. To prevent the collapse of medical facilities, elective diagnostic and surgical procedures were drastically reduced, canceled or rescheduled. METHODS: We recorded all in-hospital treated patients and outpatient clinics visits of our neurosurgical department from March 2017 to February 2021. Changes of OR capacity, in-hospital neurosurgical treatments and outpatient clinics visits during the pandemic episode was compared on a monthly bases to the previous years. RESULTS: A total of 3'214 data points from in-house treated patients and 11'400 outpatient clinics visits were collected. The ratio of elective (73.5% +/- 1.5) to emergency surgeries (26.5% +/- 1.5) remained unchanged from 2017 to 2021. Significantly less neurosurgical interventions were performed in April 2020 (-42%), significantly more in July 2020 (+36%). Number of outpatient clinics visits remained in the expected monthly range (mean n = 211 +/- 67). Total OR capacity was reduced to 30% in April 2020 and 55% in January 2021. No significant delay of urgent surgical treatments was detected during restricted (<85%) OR capacity. On average, the delay of rescheduled consultations was 58 days (range 3 - 183 days), three (6.5%) were referred as emergencies. CONCLUSIONS: Dynamic monitoring and adjustment of resources is essential to maintain surgical care. The sharp restrictions of surgical activities resulted in significant fluctuations and 5% decrease of treated neurosurgical patients during the COVID-19 pandemic. However, urgent neurosurgical care was assured without significant time delay during periods of reduced OR capacity. CI - (c) 2022 Published by Elsevier B.V. FAU - Schoni, Daniel AU - Schoni D AD - Neurosurgery, Cantonal Hospital of Winterthur, Winterthur, Switzerland. FAU - Halatsch, Marc-Eric AU - Halatsch ME AD - Neurosurgery, Cantonal Hospital of Winterthur, Winterthur, Switzerland. FAU - Alfieri, Alex AU - Alfieri A AD - Neurosurgery, Cantonal Hospital of Winterthur, Winterthur, Switzerland. AD - Neurocenter of Southern Switzerland EOC, Faculty of Biomedical Sciences, USI, Lugano, Switzerland. LA - eng PT - Journal Article DEP - 20220317 PL - Netherlands TA - Interdiscip Neurosurg JT - Interdisciplinary neurosurgery : Advanced techniques and case management JID - 101648481 PMC - PMC8926944 OTO - NOTNLM OT - FOPH, federal office of public health OT - HRA, Human Research Act OT - Hospital outpatient clinics OT - ICU, Intensive Care Unit OT - Neurosurgery OT - Non-COVID-19 patients OT - OR, operating room OT - Operating room capacity OT - Pandemic care management COIS- The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2022/03/24 06:00 MHDA- 2022/03/24 06:01 PMCR- 2022/03/17 CRDT- 2022/03/23 05:15 PHST- 2022/03/08 00:00 [received] PHST- 2022/03/15 00:00 [accepted] PHST- 2022/03/23 05:15 [entrez] PHST- 2022/03/24 06:00 [pubmed] PHST- 2022/03/24 06:01 [medline] PHST- 2022/03/17 00:00 [pmc-release] AID - S2214-7519(22)00058-5 [pii] AID - 101544 [pii] AID - 10.1016/j.inat.2022.101544 [doi] PST - ppublish SO - Interdiscip Neurosurg. 2022 Sep;29:101544. doi: 10.1016/j.inat.2022.101544. Epub 2022 Mar 17. PMID- 35315920 OWN - NLM STAT- MEDLINE DCOM- 20220414 LR - 20220507 IS - 2574-3805 (Electronic) IS - 2574-3805 (Linking) VI - 5 IP - 3 DP - 2022 Mar 1 TI - Association of Music Interventions With Health-Related Quality of Life: A Systematic Review and Meta-analysis. PG - e223236 LID - 10.1001/jamanetworkopen.2022.3236 [doi] LID - e223236 AB - IMPORTANCE: Increasing evidence supports the ability of music to broadly promote well-being and health-related quality of life (HRQOL). However, the magnitude of music's positive association with HRQOL is still unclear, particularly relative to established interventions, limiting inclusion of music interventions in health policy and care. OBJECTIVE: To synthesize results of studies investigating outcomes of music interventions in terms of HRQOL, as assessed by the 36- and 12-Item Health Survey Short Forms (SF-36 and SF-12). DATA SOURCES: MEDLINE, Embase, Web of Science, PsycINFO, ClinicalTrials.gov, and International Clinical Trials Registry Platform (searched July 30, 2021, with no restrictions). STUDY SELECTION: Inclusion criteria were randomized and single-group studies of music interventions reporting SF-36 data at time points before and after the intervention. Observational studies were excluded. Studies were reviewed independently by 2 authors. DATA EXTRACTION AND SYNTHESIS: Data were independently extracted and appraised using GRADE criteria (Grading of Recommendations, Assessment, Development, and Evaluations) by multiple authors. Inverse-variance random-effects meta-analyses quantified changes in SF-36 mental and physical component summary (respectively, MCS and PCS) scores from preintervention to postintervention and vs common control groups. MAIN OUTCOMES AND MEASURES: SF-36 or SF-12 MCS and PCS scores, defined a priori. RESULTS: Analyses included 779 participants from 26 studies (mean [SD] age, 60 [11] years). Music interventions (music listening, 10 studies; music therapy, 7 studies; singing, 8 studies; gospel music, 1 study) were associated with significant improvements in MCS scores (total mean difference, 2.95 points; 95% CI, 1.39-4.51 points; P < .001) and PCS scores (total mean difference, 1.09 points; 95% CI, 0.15-2.03 points; P = .02). In subgroup analysis (8 studies), the addition of music to standard treatment for a range of conditions was associated with significant improvements in MCS scores vs standard treatment alone (mean difference, 3.72 points; 95% CI, 0.40-7.05 points; P = .03). Effect sizes did not vary between music intervention types or doses; no evidence of small study or publication biases was present in any analysis. Mean difference in MCS scores met SF-36 minimum important difference thresholds (mean difference 3 or greater). CONCLUSIONS AND RELEVANCE: In this systematic review and meta-analysis, music interventions were associated with clinically meaningful improvements in HRQOL; however, substantial individual variation in intervention outcomes precluded conclusions regarding optimal music interventions and doses for distinct clinical and public health scenarios. FAU - McCrary, J Matt AU - McCrary JM AD - Institute of Music Physiology and Musicians' Medicine, Hannover University of Music, Drama and Media, Hannover, Germany. AD - Prince of Wales Clinical School, University of New South Wales, Sydney, New South Wales, Australia. FAU - Altenmuller, Eckart AU - Altenmuller E AD - Institute of Music Physiology and Musicians' Medicine, Hannover University of Music, Drama and Media, Hannover, Germany. FAU - Kretschmer, Clara AU - Kretschmer C AD - Institute of Music Physiology and Musicians' Medicine, Hannover University of Music, Drama and Media, Hannover, Germany. FAU - Scholz, Daniel S AU - Scholz DS AD - Institute of Music Physiology and Musicians' Medicine, Hannover University of Music, Drama and Media, Hannover, Germany. LA - eng PT - Journal Article PT - Meta-Analysis PT - Research Support, Non-U.S. Gov't PT - Systematic Review DEP - 20220301 PL - United States TA - JAMA Netw Open JT - JAMA network open JID - 101729235 SB - IM MH - Health Surveys MH - Humans MH - Middle Aged MH - *Music MH - *Quality of Life PMC - PMC8941357 COIS- Conflict of Interest Disclosures: None reported. EDAT- 2022/03/23 06:00 MHDA- 2022/04/15 06:00 PMCR- 2022/03/22 CRDT- 2022/03/22 12:11 PHST- 2022/03/22 12:11 [entrez] PHST- 2022/03/23 06:00 [pubmed] PHST- 2022/04/15 06:00 [medline] PHST- 2022/03/22 00:00 [pmc-release] AID - 2790186 [pii] AID - zoi220125 [pii] AID - 10.1001/jamanetworkopen.2022.3236 [doi] PST - epublish SO - JAMA Netw Open. 2022 Mar 1;5(3):e223236. doi: 10.1001/jamanetworkopen.2022.3236. PMID- 35302509 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240829 IS - 2561-326X (Electronic) IS - 2561-326X (Linking) VI - 6 IP - 4 DP - 2022 Apr 4 TI - Effects of COVID-19 on Physical Activity and Its Relationship With Mental Health in a US Community Sample: Cross-sectional, Convenience Sampling-based Online Survey. PG - e32387 LID - 10.2196/32387 [doi] LID - e32387 AB - BACKGROUND: COVID-19 restrictions may make it difficult for people to engage in the recommended amounts of physical activity (PA). OBJECTIVE: The influence of the COVID-19 pandemic on PA, as well as the links between PA and mental health, was investigated in this study. METHODS: Participants were recruited using convenience sampling and responded to an online survey between April 15 and July 1, 2021, with ages ranging from 18 to 24 years (n=156, 40.9% of the sample) to >/=55 years (n=28, 7.4% of the sample). To assess general psychological distress, depression, anxiety, and pandemic anxiety, a battery of mental health assessments was used. The International Physical Activity Questionnaire - Short Form was used to collect PA data from participants, who were then classified as inactive, minimally active, or highly active. Participants also indicated the locations where they performed PA before and during COVID-19. RESULTS: A sample of 381 individuals was included in this research. The logistic regression analysis results were interpreted as odds ratios (ORs), where an OR higher than 1 indicated a greater chance of an event occurring and an OR less than 1 implied a lower likelihood of an event occurring. Logistic regression results revealed that inactive individuals were more likely to develop psychological distress (OR 2.17, 95% CI 1.27-3.69, P=.004), depression (OR 3.81, 95% CI 1.92-7.57, P<.001), and anxiety (OR 1.86, 95% CI 0.99-3.47, P=.05) as compared to highly active individuals. Furthermore, when compared to highly active people, those who were only minimally active had a higher risk of depression (OR 2.14, 95% CI 1.05-4.33, P=.04). Wilcoxon signed-rank tests revealed that COVID-19 has a greater impact on reducing the chances of less active individuals engaging in PA outside and in public spaces. Highly active people's physical exercise locations had changed less, and their exercise frequency at home increased. CONCLUSIONS: Programmatic and policy interventions geared particularly toward enhancing PA among those less active may be a helpful strategy for addressing the worldwide pandemic's mental health crisis. CI - (c)Wei Zhang, Dominick Velez. Originally published in JMIR Formative Research (https://formative.jmir.org), 04.04.2022. FAU - Zhang, Wei AU - Zhang W AUID- ORCID: 0000-0002-9192-9549 AD - Department of Psychology, New Jersey City University, Jersey City, NJ, United States. FAU - Velez, Dominick AU - Velez D AUID- ORCID: 0000-0003-1499-2445 AD - Department of Psychology, New Jersey City University, Jersey City, NJ, United States. LA - eng PT - Journal Article DEP - 20220404 PL - Canada TA - JMIR Form Res JT - JMIR formative research JID - 101726394 PMC - PMC8982649 OTO - NOTNLM OT - COVID-19 OT - United States OT - anxiety OT - cross-sectional OT - depression OT - distress OT - mental health OT - physical activity OT - risk OT - survey COIS- Conflicts of Interest: None declared. EDAT- 2022/03/19 06:00 MHDA- 2022/03/19 06:01 PMCR- 2022/04/04 CRDT- 2022/03/18 12:11 PHST- 2021/07/25 00:00 [received] PHST- 2022/03/17 00:00 [accepted] PHST- 2022/01/31 00:00 [revised] PHST- 2022/03/19 06:00 [pubmed] PHST- 2022/03/19 06:01 [medline] PHST- 2022/03/18 12:11 [entrez] PHST- 2022/04/04 00:00 [pmc-release] AID - v6i4e32387 [pii] AID - 10.2196/32387 [doi] PST - epublish SO - JMIR Form Res. 2022 Apr 4;6(4):e32387. doi: 10.2196/32387. PMID- 35289000 OWN - NLM STAT- MEDLINE DCOM- 20220425 LR - 20220716 IS - 1439-0507 (Electronic) IS - 0933-7407 (Print) IS - 0933-7407 (Linking) VI - 65 IP - 5 DP - 2022 May TI - As the virus sowed, the fungus reaped! A comparative analysis of the clinico-epidemiological characteristics of rhino-orbital mucormycosis before and during COVID-19 pandemic. PG - 567-576 LID - 10.1111/myc.13437 [doi] AB - BACKGROUND: The sudden surge of mucormycosis cases which happened during the second wave of COVID-19 pandemic was a significant public health problem in India. OBJECTIVES: The aim of this study was to analyse the clinico-epidemicological characteristics of the mucormycosis cases to determine the changes that had occurred due to COVID-19 pandemic. METHODOLOGY: A retrospective cross-sectional study was conducted at the Department of Otolaryngology Head and Neck Surgery, PGIMER, Chandigarh, India. Patients diagnosed with rhino-orbital mucormycosis were categorised into the following groups: Pre-pandemic(May 2019 to April 2020), Pandemic Pre-epidemic (May 2020 to April 2021) and Epidemic (1 May 2021 to 12 July 2021). The epidemiological, clinical and surgical data of all the patients were retrieved from the hospital records and analysed. RESULTS: The epidemic period had 370 cases, compared with 65 during pandemic period and 42 in the pre-pandemic period. Diabetes mellitus was seen in 87% of cases during epidemic period, 92.9% in the pre-pandemic period and 90.8% in the pre-pandemic pre-epidemic period. The proportion of patients suffering from vision loss, restricted extra-ocular movements, palatal ulcer and nasal obstruction was higher in the pre-epidemic groups, and the difference was significant (p, <.01). There was no history of oxygen use in 85.9% of patients and no steroid use in 76.5%. The death rates were the lowest during epidemic (10%). CONCLUSION: COVID-19 has caused a statistically significant increase in the number of mucormycosis infections. The mortality and morbidity which showed an increase during the first wave of COVID-19 decreased significantly during the epidemic period. CI - (c) 2022 Wiley-VCH GmbH. FAU - Muraleedharan, Manjul AU - Muraleedharan M AD - Department of Otolaryngology Head and Neck Surgery, Postgraduate Institute of Medical Education and Research, Chandigarh, India. FAU - Panda, Naresh Kumar AU - Panda NK AUID- ORCID: 0000-0002-1767-7013 AD - Department of Otolaryngology Head and Neck Surgery, Postgraduate Institute of Medical Education and Research, Chandigarh, India. FAU - Angrish, Prerna AU - Angrish P AD - Department of Otolaryngology Head and Neck Surgery, Postgraduate Institute of Medical Education and Research, Chandigarh, India. FAU - Arora, Kanika AU - Arora K AD - Department of Otolaryngology Head and Neck Surgery, Postgraduate Institute of Medical Education and Research, Chandigarh, India. FAU - Patro, Sourabha Kumar AU - Patro SK AUID- ORCID: 0000-0002-4819-7928 AD - Department of Otolaryngology Head and Neck Surgery, Postgraduate Institute of Medical Education and Research, Chandigarh, India. FAU - Bansal, Sandeep AU - Bansal S AD - Department of Otolaryngology Head and Neck Surgery, Postgraduate Institute of Medical Education and Research, Chandigarh, India. FAU - Chakrabarti, Arunaloke AU - Chakrabarti A AD - Department of Medical Microbiology, Postgraduate Institute of Medical Education and Research, Chandigarh, India. FAU - Rudramurthy, Shivaprakash Mandya AU - Rudramurthy SM AUID- ORCID: 0000-0002-9097-9253 AD - Department of Medical Microbiology, Postgraduate Institute of Medical Education and Research, Chandigarh, India. FAU - Bakshi, Jaimanti AU - Bakshi J AD - Department of Otolaryngology Head and Neck Surgery, Postgraduate Institute of Medical Education and Research, Chandigarh, India. FAU - Mohindra, Satyawati AU - Mohindra S AD - Department of Otolaryngology Head and Neck Surgery, Postgraduate Institute of Medical Education and Research, Chandigarh, India. FAU - Gupta, Rijuneeta AU - Gupta R AD - Department of Otolaryngology Head and Neck Surgery, Postgraduate Institute of Medical Education and Research, Chandigarh, India. FAU - Virk, Ramandeep Singh AU - Virk RS AD - Department of Otolaryngology Head and Neck Surgery, Postgraduate Institute of Medical Education and Research, Chandigarh, India. FAU - Verma, Roshan Kumar AU - Verma RK AD - Department of Otolaryngology Head and Neck Surgery, Postgraduate Institute of Medical Education and Research, Chandigarh, India. FAU - Ramavat, Anurag Snehi AU - Ramavat AS AD - Department of Otolaryngology Head and Neck Surgery, Postgraduate Institute of Medical Education and Research, Chandigarh, India. FAU - Nayak, Gyanaranjan AU - Nayak G AD - Department of Otolaryngology Head and Neck Surgery, Postgraduate Institute of Medical Education and Research, Chandigarh, India. LA - eng PT - Journal Article DEP - 20220408 PL - Germany TA - Mycoses JT - Mycoses JID - 8805008 SB - IM MH - *COVID-19/epidemiology MH - Cross-Sectional Studies MH - Fungi MH - Humans MH - *Mucormycosis/diagnosis MH - Pandemics MH - Retrospective Studies PMC - PMC9115264 OTO - NOTNLM OT - COVID-19 OT - epidemic OT - invasive fungal infection OT - long COVID OT - mucorales OT - mucormycosis OT - pandemic OT - steroid COIS- The authors do not have any conflict of interest to declare. EDAT- 2022/03/16 06:00 MHDA- 2022/04/26 06:00 PMCR- 2022/04/08 CRDT- 2022/03/15 05:47 PHST- 2022/03/08 00:00 [revised] PHST- 2022/02/04 00:00 [received] PHST- 2022/03/08 00:00 [accepted] PHST- 2022/03/16 06:00 [pubmed] PHST- 2022/04/26 06:00 [medline] PHST- 2022/03/15 05:47 [entrez] PHST- 2022/04/08 00:00 [pmc-release] AID - MYC13437 [pii] AID - 10.1111/myc.13437 [doi] PST - ppublish SO - Mycoses. 2022 May;65(5):567-576. doi: 10.1111/myc.13437. Epub 2022 Apr 8. PMID- 35287942 OWN - NLM STAT- MEDLINE DCOM- 20220531 LR - 20250623 IS - 1943-4723 (Electronic) IS - 0002-8177 (Linking) VI - 153 IP - 6 DP - 2022 Jun TI - Comparison of orthodontic root resorption of root-filled and vital teeth: A meta-analysis. PG - 532-541.e7 LID - S0002-8177(22)00021-6 [pii] LID - 10.1016/j.adaj.2021.11.012 [doi] AB - BACKGROUND: In this systematic review, the authors aimed to answer the following question: Do vital teeth differ in the level of external root resorption induced by means of orthodontic treatment compared with root-filled teeth? TYPES OF STUDIES REVIEWED: The search strategy was performed in 6 electronic databases and in gray literature for articles published until July 29, 2021. Two reviewers independently assessed potentially eligible studies according to the following criteria: studies that evaluated patients undergoing fixed orthodontic therapy and compared the mean difference in millimeters of orthodontically induced external root resorption in endodontically treated teeth with the vital contralateral tooth. Only randomized, quasi-randomized, nonrandomized, cohort, case-control, or cross-sectional studies were considered eligible. There were no restrictions on language or publication time. Two reviewers also independently extracted data on the characteristics of the included studies, methods, and results, and performed risk-of-bias analysis using the Meta-Analysis of Statistics Assessment and Review instrument. Estimates of interest were calculated using random-effects meta-analyses. The certainty of the evidence was assessed using the Grading of Recommendations Assessment, Development and Evaluation tool. RESULTS: Eleven studies were included in the quantitative synthesis. Endodontically treated teeth had a lower level of root resorption (mean difference, 0.45 mm; 95% CI, -0.69 to -0.21 mm). However, the level of certainty of the evidence was considered very low owing to confounding factors. CONCLUSIONS AND PRACTICAL IMPLICATIONS: Endodontically treated teeth may have a lower level of orthodontically induced root resorption than vital teeth, but the evidence is still uncertain about this outcome. Furthermore, owing to the small effect size, this difference might not be clinically significant (up to 1 mm). CI - Copyright (c) 2022 American Dental Association. Published by Elsevier Inc. All rights reserved. FAU - Alves Otelakoski, Bruna AU - Alves Otelakoski B FAU - Magno Goncalves, Flavio AU - Magno Goncalves F FAU - Marques de Mattos de Araujo, Bianca AU - Marques de Mattos de Araujo B FAU - Zeigelboim, Bianca Simone AU - Zeigelboim BS FAU - Verissimo Meira Taveira, Karinna AU - Verissimo Meira Taveira K FAU - Sampaio Santos, Rosane AU - Sampaio Santos R FAU - Guariza-Filho, Odilon AU - Guariza-Filho O FAU - Stechman-Neto, Jose AU - Stechman-Neto J FAU - Miranda de Araujo, Cristiano AU - Miranda de Araujo C LA - eng PT - Journal Article PT - Meta-Analysis PT - Systematic Review DEP - 20220311 PL - England TA - J Am Dent Assoc JT - Journal of the American Dental Association (1939) JID - 7503060 SB - IM MH - Case-Control Studies MH - Cross-Sectional Studies MH - Humans MH - *Root Resorption/etiology MH - Tooth Root MH - *Tooth, Nonvital OTO - NOTNLM OT - Orthodontic treatment OT - nonvital tooth OT - root canal treatment OT - root resorption EDAT- 2022/03/16 06:00 MHDA- 2022/06/01 06:00 CRDT- 2022/03/15 05:39 PHST- 2021/10/02 00:00 [received] PHST- 2021/11/09 00:00 [revised] PHST- 2021/11/15 00:00 [accepted] PHST- 2022/03/16 06:00 [pubmed] PHST- 2022/06/01 06:00 [medline] PHST- 2022/03/15 05:39 [entrez] AID - S0002-8177(22)00021-6 [pii] AID - 10.1016/j.adaj.2021.11.012 [doi] PST - ppublish SO - J Am Dent Assoc. 2022 Jun;153(6):532-541.e7. doi: 10.1016/j.adaj.2021.11.012. Epub 2022 Mar 11. PMID- 35273465 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220314 IS - 1188-4169 (Print) IS - 1481-8531 (Electronic) IS - 1188-4169 (Linking) VI - 48 IP - 1 DP - 2022 Jan 26 TI - The Yukon's experience with COVID-19: Travel restrictions, variants and spread among the unvaccinated. PG - 17-21 LID - 10.14745/ccdr.v48i01a03 [doi] AB - The Yukon's experience with coronavirus disease 2019 (COVID-19) has been an interesting one; the territory successfully implemented travel restrictions to limit importing the virus and rolled out vaccines quickly compared to most Canadian jurisdictions. However, the Yukon's first wave of COVID-19 in June and July 2021 overwhelmed the healthcare system due to widespread transmission in unvaccinated children, youth and adults, despite high vaccination uptake overall and mandatory masking. This experience highlights the importance of continued support for public vaccination programs, widespread vaccine uptake in paediatric populations, and the judicious relaxation of non-pharmaceutical interventions in all Canadian jurisdictions as they reopen while more contagious variants emerge. FAU - McPhee-Knowles, Sara AU - McPhee-Knowles S AD - Yukon University, Whitehorse, YT. FAU - Hoffman, Bryn AU - Hoffman B AD - Queen's School of Medicine, Queen's University, Kingston, ON. FAU - Kanary, Lisa AU - Kanary L AD - Yukon University, Whitehorse, YT. LA - eng PT - Journal Article DEP - 20220126 PL - Canada TA - Can Commun Dis Rep JT - Canada communicable disease report = Releve des maladies transmissibles au Canada JID - 9303729 PMC - PMC8856720 OTO - NOTNLM OT - COVID-19 OT - Yukon Territory OT - northern Canada OT - outbreak OT - pandemic response OT - travel restrictions OT - vaccination COIS- Competing interests: None. EDAT- 2022/03/12 06:00 MHDA- 2022/03/12 06:01 PMCR- 2022/01/26 CRDT- 2022/03/11 05:39 PHST- 2022/03/11 05:39 [entrez] PHST- 2022/03/12 06:00 [pubmed] PHST- 2022/03/12 06:01 [medline] PHST- 2022/01/26 00:00 [pmc-release] AID - 480103 [pii] AID - 10.14745/ccdr.v48i01a03 [doi] PST - epublish SO - Can Commun Dis Rep. 2022 Jan 26;48(1):17-21. doi: 10.14745/ccdr.v48i01a03. eCollection 2022 Jan 26. PMID- 35263350 OWN - NLM STAT- MEDLINE DCOM- 20220317 LR - 20240824 IS - 1932-6203 (Electronic) IS - 1932-6203 (Linking) VI - 17 IP - 3 DP - 2022 TI - Reasons for COVID-19 vaccine refusal among people incarcerated in Canadian federal prisons. PG - e0264145 LID - 10.1371/journal.pone.0264145 [doi] LID - e0264145 AB - BACKGROUND: Vaccine uptake rates have been historically low in correctional settings. To better understand vaccine hesitancy in these high-risk settings, we explored reasons for COVID-19 vaccine refusal among people in federal prisons. METHODS: Three maximum security all-male federal prisons in British Columbia, Alberta, and Ontario (Canada) were chosen, representing prisons with the highest proportions of COVID-19 vaccine refusal. Using a qualitative descriptive design and purposive sampling, individual semi-structured interviews were conducted with incarcerated people who had previously refused at least one COVID-19 vaccine until data saturation was achieved. An inductive-deductive thematic analysis of audio-recorded interview transcripts was conducted using the Conceptual Model of Vaccine Hesitancy. RESULTS: Between May 19-July 8, 2021, 14 participants were interviewed (median age: 30 years; n = 7 Indigenous, n = 4 visible minority, n = 3 White). Individual-, interpersonal-, and system-level factors were identified. Three were particularly relevant to the correctional setting: 1) Risk perception: participants perceived that they were at lower risk of COVID-19 due to restricted visits and interactions; 2) Health care services in prison: participants reported feeling "punished" and stigmatized due to strict COVID-19 restrictions, and failed to identify personal benefits of vaccination due to the lack of incentives; 3) Universal distrust: participants expressed distrust in prison employees, including health care providers. INTERPRETATION: Reasons for vaccine refusal among people in prison are multifaceted. Educational interventions could seek to address COVID-19 risk misconceptions in prison settings. However, impact may be limited if trust is not fostered and if incentives are not considered in vaccine promotion. FAU - Ortiz-Paredes, David AU - Ortiz-Paredes D AUID- ORCID: 0000-0002-0431-4889 AD - Centre for Outcomes Research and Evaluation, Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada. FAU - Varsaneux, Olivia AU - Varsaneux O AD - Correctional Service Canada (CSC), Ottawa, Ontario, Canada. FAU - Worthington, James AU - Worthington J AD - Correctional Service Canada (CSC), Ottawa, Ontario, Canada. FAU - Park, Hyejin AU - Park H AUID- ORCID: 0000-0002-5355-5187 AD - Centre for Outcomes Research and Evaluation, Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada. FAU - MacDonald, Shannon E AU - MacDonald SE AD - Faculty of Nursing, University of Alberta, Edmonton, Alberta, Canada. AD - School of Public Health, University of Alberta, Edmonton, Alberta, Canada. FAU - Basta, Nicole E AU - Basta NE AUID- ORCID: 0000-0002-4951-6353 AD - Department of Epidemiology, Biostatistics and Occupational Health, School of Population and Global Health, McGill University, Montreal, Quebec, Canada. FAU - Lebouche, Bertrand AU - Lebouche B AUID- ORCID: 0000-0002-1273-9393 AD - Centre for Outcomes Research and Evaluation, Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada. AD - Department of Family Medicine, Faculty of Medicine and Health Sciences, McGill University, Montreal, Quebec, Canada. AD - Division of Infectious Diseases and Chronic Viral Illness Service, Department of Medicine, McGill University Health Centre, Montreal, Quebec, Canada. FAU - Cox, Joseph AU - Cox J AUID- ORCID: 0000-0002-7041-1556 AD - Centre for Outcomes Research and Evaluation, Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada. AD - Department of Epidemiology, Biostatistics and Occupational Health, School of Population and Global Health, McGill University, Montreal, Quebec, Canada. AD - Division of Infectious Diseases and Chronic Viral Illness Service, Department of Medicine, McGill University Health Centre, Montreal, Quebec, Canada. FAU - Ismail, Shainoor J AU - Ismail SJ AD - Division of Immunization Programs and Pandemic Preparedness, Centre for Immunization and Respiratory Infectious Diseases, Public Health Agency of Canada, Ottawa, Ontario, Canada. AD - Metro City Medical Clinic, Edmonton, Alberta, Canada. FAU - Kronfli, Nadine AU - Kronfli N AD - Centre for Outcomes Research and Evaluation, Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada. AD - Department of Epidemiology, Biostatistics and Occupational Health, School of Population and Global Health, McGill University, Montreal, Quebec, Canada. AD - Division of Infectious Diseases and Chronic Viral Illness Service, Department of Medicine, McGill University Health Centre, Montreal, Quebec, Canada. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20220309 PL - United States TA - PLoS One JT - PloS one JID - 101285081 SB - IM MH - Adult MH - Alberta MH - Attitude MH - British Columbia MH - COVID-19/epidemiology/*prevention & control/virology MH - Delivery of Health Care MH - Humans MH - Interviews as Topic MH - Male MH - Middle Aged MH - Ontario MH - Prisoners/*psychology MH - Risk MH - SARS-CoV-2/isolation & purification MH - Social Norms MH - Social Responsibility MH - Vaccination Refusal/*statistics & numerical data MH - Young Adult PMC - PMC8906611 COIS- I have read the journal's policy and the authors of this manuscript have the following competing interests: NEB is supported by a Canada Research Chair (Tier 2) in Infectious Disease Prevention. BL holds a Canadian Institutes for Health Research, Strategy for Patient-Oriented Research Mentorship Chair in Innovative Clinical Trials for HIV Care and also supported by a career award, LE 250, from the Quebec's Ministry of Health for researchers in Family Medicine. BL reports research funding from Gilead Sciences, Merck and ViiV Health care, advisory fees from Gilead Sciences, ViiV Health care, Merck, and speaker fees from Gilead Sciences, ViiV Health care and Merck. JC has research funding from ViiV Health care and Gilead Sciences, and reports remuneration for advisory work (ViiV Health care, Gilead Sciences and Merck Canada). NK is supported by a career award from the Fonds de Recherche Quebec - Sante (FRQ-S; Junior 1). NK reports research funding from Gilead Sciences, advisory fees from Gilead Sciences, ViiV Health care, Merck and Abbvie, and speaker fees from Gilead Sciences and Merck. DOP, OV, JW, HP, SEM, NEB, and SJI have declared no competing interests. EDAT- 2022/03/10 06:00 MHDA- 2022/03/18 06:00 PMCR- 2022/03/09 CRDT- 2022/03/09 17:12 PHST- 2021/10/14 00:00 [received] PHST- 2022/02/03 00:00 [accepted] PHST- 2022/03/09 17:12 [entrez] PHST- 2022/03/10 06:00 [pubmed] PHST- 2022/03/18 06:00 [medline] PHST- 2022/03/09 00:00 [pmc-release] AID - PONE-D-21-33012 [pii] AID - 10.1371/journal.pone.0264145 [doi] PST - epublish SO - PLoS One. 2022 Mar 9;17(3):e0264145. doi: 10.1371/journal.pone.0264145. eCollection 2022. PMID- 35241472 OWN - NLM STAT- MEDLINE DCOM- 20220308 LR - 20220309 IS - 2044-6055 (Electronic) IS - 2044-6055 (Linking) VI - 12 IP - 3 DP - 2022 Mar 3 TI - Association of frailty and cognitive function disorders in old patients with COVID-19: a protocol of systematic review and meta-analysis. PG - e056190 LID - 10.1136/bmjopen-2021-056190 [doi] LID - e056190 AB - INTRODUCTION: COVID-19 infections have become an urgent worldwide public health concern. Although it is primarily a respiratory disease, up to two-thirds of hospitalised COVID-19 patients exhibit nervous system damage and an increased risk of frailty. In this study,we aim to investigate the relationship between frailty and cognitive function disorders in patients with COVID-19 with a systematic review and meta-analysis approach. METHODS AND ANALYSIS: This meta-analysis has been registered by the International Prospective Register of Systematic Reviews. We will search for relevant studies from PubMed, Embase, Chinese Biological Medical Database, China National Knowledge Infrastructure, Wanfang Database, the Cochrane Central Register of Controlled Trials databases, from their inception to 5 July 2021. We will also search reference lists of selected articles for additional studies. Our search strategy will have no language restrictions. We will employ a fi xed or random-effects model to calculate OR and 95% CIs for pooled data, and assess heterogeneity using Cochrane's Q and I(2) tests. The primary outcome will be the rate of cognitive disorders related to frailty in old patients with COVID-19. ETHICS AND DISSEMINATION: Ethical approval is not essential since data will be extracted from previously published studies. The results of this meta-analysis will be published in a peer-reviewed journal. PROSPERO REGISTRATION NUMBER: CRD42021257148. CI - (c) Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. FAU - Jiao, Bo AU - Jiao B AD - Department of Anesthesiology, West China Hospital, Sichuan University, Chengdu, China. FAU - Chen, Mingyuan AU - Chen M AD - Department of Pathology, Sichuan University West China Second University Hospital, Chengdu, Sichuan, China. FAU - Fan, Minmin AU - Fan M AD - Department of Anesthesiology, West China Hospital, Sichuan University, Chengdu, Sichuan, China. FAU - Luo, Xi AU - Luo X AD - Department of Anesthesiology, West China Hospital,Sichuan University, Chengdu, Sichuan, China. FAU - Chen, Chan AU - Chen C AUID- ORCID: 0000-0001-5823-8247 AD - Department of Anesthesiology, Sichuan University West China Hospital, Chengdu, China xychenchan@gmail.com. FAU - Liu, Jin AU - Liu J AD - Department of Anesthesiology, West China Hospital,Sichuan University, Chengdu, Sichuan, China. LA - eng PT - Journal Article DEP - 20220303 PL - England TA - BMJ Open JT - BMJ open JID - 101552874 SB - IM MH - *COVID-19/complications MH - China MH - Cognition MH - *Frailty/complications MH - Humans MH - Meta-Analysis as Topic MH - Research Design MH - SARS-CoV-2 MH - Systematic Reviews as Topic PMC - PMC8895415 OTO - NOTNLM OT - COVID-19 OT - delirium & cognitive disorders OT - geriatric medicine OT - mental health OT - old age psychiatry COIS- Competing interests: None declared. EDAT- 2022/03/05 06:00 MHDA- 2022/03/09 06:00 PMCR- 2022/03/03 CRDT- 2022/03/04 05:37 PHST- 2022/03/04 05:37 [entrez] PHST- 2022/03/05 06:00 [pubmed] PHST- 2022/03/09 06:00 [medline] PHST- 2022/03/03 00:00 [pmc-release] AID - bmjopen-2021-056190 [pii] AID - 10.1136/bmjopen-2021-056190 [doi] PST - epublish SO - BMJ Open. 2022 Mar 3;12(3):e056190. doi: 10.1136/bmjopen-2021-056190. PMID- 35231023 OWN - NLM STAT- MEDLINE DCOM- 20220311 LR - 20260602 IS - 1549-1676 (Electronic) IS - 1549-1277 (Print) IS - 1549-1277 (Linking) VI - 19 IP - 3 DP - 2022 Mar TI - Changes in social contacts in England during the COVID-19 pandemic between March 2020 and March 2021 as measured by the CoMix survey: A repeated cross-sectional study. PG - e1003907 LID - 10.1371/journal.pmed.1003907 [doi] LID - e1003907 AB - BACKGROUND: During the Coronavirus Disease 2019 (COVID-19) pandemic, the United Kingdom government imposed public health policies in England to reduce social contacts in hopes of curbing virus transmission. We conducted a repeated cross-sectional study to measure contact patterns weekly from March 2020 to March 2021 to estimate the impact of these policies, covering 3 national lockdowns interspersed by periods of less restrictive policies. METHODS AND FINDINGS: The repeated cross-sectional survey data were collected using online surveys of representative samples of the UK population by age and gender. Survey participants were recruited by the online market research company Ipsos MORI through internet-based banner and social media ads and email campaigns. The participant data used for this analysis are restricted to those who reported living in England. We calculated the mean daily contacts reported using a (clustered) bootstrap and fitted a censored negative binomial model to estimate age-stratified contact matrices and estimate proportional changes to the basic reproduction number under controlled conditions using the change in contacts as a scaling factor. To put the findings in perspective, we discuss contact rates recorded throughout the year in terms of previously recorded rates from the POLYMOD study social contact study. The survey recorded 101,350 observations from 19,914 participants who reported 466,710 contacts over 53 weeks. We observed changes in social contact patterns in England over time and by participants' age, personal risk factors, and perception of risk. The mean reported contacts for adults 18 to 59 years old ranged between 2.39 (95% confidence interval [CI] 2.20 to 2.60) contacts and 4.93 (95% CI 4.65 to 5.19) contacts during the study period. The mean contacts for school-age children (5 to 17 years old) ranged from 3.07 (95% CI 2.89 to 3.27) to 15.11 (95% CI 13.87 to 16.41). This demonstrates a sustained decrease in social contacts compared to a mean of 11.08 (95% CI 10.54 to 11.57) contacts per participant in all age groups combined as measured by the POLYMOD social contact study in 2005 to 2006. Contacts measured during periods of lockdowns were lower than in periods of eased social restrictions. The use of face coverings outside the home has remained high since the government mandated use in some settings in July 2020. The main limitations of this analysis are the potential for selection bias, as participants are recruited through internet-based campaigns, and recall bias, in which participants may under- or overreport the number of contacts they have made. CONCLUSIONS: In this study, we observed that recorded contacts reduced dramatically compared to prepandemic levels (as measured in the POLYMOD study), with changes in reported contacts correlated with government interventions throughout the pandemic. Despite easing of restrictions in the summer of 2020, the mean number of reported contacts only returned to about half of that observed prepandemic at its highest recorded level. The CoMix survey provides a unique repeated cross-sectional data set for a full year in England, from the first day of the first lockdown, for use in statistical analyses and mathematical modelling of COVID-19 and other diseases. FAU - Gimma, Amy AU - Gimma A AUID- ORCID: 0000-0003-2645-7212 AD - Centre for Mathematical Modelling of Infectious Diseases, Department of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, United Kingdom. FAU - Munday, James D AU - Munday JD AUID- ORCID: 0000-0002-6206-7134 AD - Centre for Mathematical Modelling of Infectious Diseases, Department of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, United Kingdom. FAU - Wong, Kerry L M AU - Wong KLM AUID- ORCID: 0000-0002-4400-2257 AD - Centre for Mathematical Modelling of Infectious Diseases, Department of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, United Kingdom. FAU - Coletti, Pietro AU - Coletti P AUID- ORCID: 0000-0001-9935-1692 AD - UHasselt, Data Science Institute and I-BioStat, Hasselt, Belgium. FAU - van Zandvoort, Kevin AU - van Zandvoort K AUID- ORCID: 0000-0002-7770-0537 AD - Centre for Mathematical Modelling of Infectious Diseases, Department of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, United Kingdom. FAU - Prem, Kiesha AU - Prem K AUID- ORCID: 0000-0003-0528-798X AD - Centre for Mathematical Modelling of Infectious Diseases, Department of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, United Kingdom. CN - CMMID COVID-19 working group FAU - Klepac, Petra AU - Klepac P AUID- ORCID: 0000-0003-4132-3933 AD - Centre for Mathematical Modelling of Infectious Diseases, Department of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, United Kingdom. FAU - Rubin, G James AU - Rubin GJ AUID- ORCID: 0000-0002-4440-0570 AD - Department of Psychological Medicine, King's College London, Denmark Hill, London, United Kingdom. FAU - Funk, Sebastian AU - Funk S AUID- ORCID: 0000-0002-2842-3406 AD - Centre for Mathematical Modelling of Infectious Diseases, Department of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, United Kingdom. FAU - Edmunds, W John AU - Edmunds WJ AUID- ORCID: 0000-0002-9179-2917 AD - Centre for Mathematical Modelling of Infectious Diseases, Department of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, United Kingdom. FAU - Jarvis, Christopher I AU - Jarvis CI AUID- ORCID: 0000-0002-0812-2446 AD - Centre for Mathematical Modelling of Infectious Diseases, Department of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, United Kingdom. LA - eng GR - INV-016832/GATES/Gates Foundation/United States GR - 210758/Z/18/Z/WT_/Wellcome Trust/United Kingdom GR - R01 AI141534/AI/NIAID NIH HHS/United States GR - R01 NS110424/NS/NINDS NIH HHS/United States GR - INV-001754/GATES/Gates Foundation/United States GR - 221303/Z/20/Z/WT_/Wellcome Trust/United Kingdom GR - MC_PC_19065/MRC_/Medical Research Council/United Kingdom GR - INV-003174/GATES/Gates Foundation/United States PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20220301 PL - United States TA - PLoS Med JT - PLoS medicine JID - 101231360 SB - IM MH - Adolescent MH - Adult MH - Aged MH - Attitude to Health MH - COVID-19/*psychology MH - Cross-Sectional Studies MH - England MH - Female MH - Humans MH - Male MH - Middle Aged MH - Models, Psychological MH - Pandemics MH - *Social Interaction MH - Surveys and Questionnaires MH - Young Adult PMC - PMC8887739 COIS- The authors have declared that no competing interests exist. EDAT- 2022/03/02 06:00 MHDA- 2022/03/12 06:00 PMCR- 2022/03/01 CRDT- 2022/03/01 17:12 PHST- 2021/05/28 00:00 [received] PHST- 2022/01/06 00:00 [accepted] PHST- 2022/03/01 17:12 [entrez] PHST- 2022/03/02 06:00 [pubmed] PHST- 2022/03/12 06:00 [medline] PHST- 2022/03/01 00:00 [pmc-release] AID - PMEDICINE-D-21-02365 [pii] AID - 10.1371/journal.pmed.1003907 [doi] PST - epublish SO - PLoS Med. 2022 Mar 1;19(3):e1003907. doi: 10.1371/journal.pmed.1003907. eCollection 2022 Mar. PMID- 35227416 OWN - NLM STAT- MEDLINE DCOM- 20220608 LR - 20231213 IS - 2213-2619 (Electronic) IS - 2213-2600 (Print) IS - 2213-2600 (Linking) VI - 10 IP - 6 DP - 2022 Jun TI - Vaccine efficacy against severe COVID-19 in relation to delta variant (B.1.617.2) and time since second dose in patients in Scotland (REACT-SCOT): a case-control study. PG - 566-572 LID - S2213-2600(22)00045-5 [pii] LID - 10.1016/S2213-2600(22)00045-5 [doi] AB - BACKGROUND: Reports have suggested that the efficacy of vaccines against COVID-19 might have fallen since the delta (B.1.617.2) SARS-CoV-2 variant replaced the alpha (B.1.1.7) variant as the predominant variant. We aimed to investigate, for the two main classes of vaccine, whether efficacy against severe COVID-19 has decreased since delta became the predominant variant and whether the efficacy of two doses of vaccine against severe COVID-19 wanes with time since second dose. METHODS: In the REACT-SCOT case-control study, vaccine efficacy was estimated using a matched case-control design that includes all diagnosed cases of COVID-19 in Scotland up to Sept 8, 2021. For every incident case of COVID-19 in the Scottish population, ten controls matched for age rounded to the nearest year, sex, and primary care practice, and alive on the day of presentation of the case that they were matched to were selected using the Community Health Index database. To minimise ascertainment bias we prespecified the primary outcome measure to assess vaccine efficacy as severe COVID-19, defined as diagnosed patients with entry to critical care within 21 days of first positive test, death within 28 days of first positive test, or any death for which COVID-19 was coded as underlying cause. Although the data extracted for this study included cases presenting up to Sept 22, 2021, the analyses reported here are restricted to cases and controls presenting from Dec 1, 2020, to Sept 8, 2021, ensuring follow-up for at least 14 days after presentation date to allow classification of hospitalisation and (for most cases) severity based on entry to critical care or fatal outcome. FINDINGS: During the study period, a total of 5645 severe cases of COVID-19 were recorded; these were matched to 50 096 controls. Of the severe cases, 4495 (80%) were not vaccinated, and of the controls, 36 879 (74%) were not vaccinated. Of the severe cases of COVID-19 who had been vaccinated, 389 had received an mRNA vaccine and 759 had received the ChAdOx1 vaccine. The efficacy of vaccination against severe COVID-19 decreased in May, 2021, coinciding with the replacement of the alpha SARS-CoV-2 variant by the delta variant in Scotland, but this decrease was reversed over the following month. In the most recent time window centred on July 29, 2021, the efficacy of two doses was 91% (95% CI 87-94) for the ChAdOx1 vaccine and 92% (88-95) for mRNA (Pfizer or Moderna) vaccines. The efficacy of the ChAdOx1 vaccine against severe COVID-19 declined with time since second dose to 69% (95% CI 52-80) at 20 weeks from second dose. The efficacy of mRNA vaccines declined in the first ten weeks from second dose but more slowly thereafter to 93% (88-96) at 20 weeks from second dose. INTERPRETATION: Our results are reassuring with respect to concerns that vaccine efficacy against severe COVID-19 might have fallen since the delta variant became predominant, or that efficacy of mRNA vaccines wanes within the first 5-6 months after second dose. However, the efficacy of the ChAdOx1 vaccine against severe COVID-19 wanes substantially by 20 weeks from second dose. Efficacy of mRNA vaccines after 20 weeks and against newer variants remains to be established. Our findings support the case for additional protective measures for those at risk of severe disease, including, but not limited to, booster doses, at times when transmission rates are high or expected to rise. FUNDING: None. CI - Copyright (c) 2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved. FAU - McKeigue, Paul M AU - McKeigue PM AD - Usher Institute, College of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh, UK; Public Health Scotland, Glasgow, UK. Electronic address: paul.mckeigue@ed.ac.uk. FAU - McAllister, David A AU - McAllister DA AD - Institute of Health and Wellbeing, University of Glasgow, Glasgow, UK; Public Health Scotland, Glasgow, UK. FAU - Hutchinson, Sharon J AU - Hutchinson SJ AD - School of Health and Life Sciences, Glasgow Caledonian University, Glasgow, UK; Public Health Scotland, Glasgow, UK. FAU - Robertson, Chris AU - Robertson C AD - Department of Mathematics and Statistics, University of Strathclyde, Glasgow, UK; Institute of Genetics and Cancer, College of Medicine and Veterinary Medicine, University of Edinburgh, Western General Hospital Campus, Edinburgh, UK; Public Health Scotland, Glasgow, UK. FAU - Stockton, Diane AU - Stockton D AD - Public Health Scotland, Glasgow, UK. FAU - Colhoun, Helen M AU - Colhoun HM AD - Public Health Scotland, Glasgow, UK. LA - eng GR - 201492/Z/16/Z/WT_/Wellcome Trust/United Kingdom PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20220225 PL - England TA - Lancet Respir Med JT - The Lancet. Respiratory medicine JID - 101605555 RN - 0 (COVID-19 Vaccines) RN - 0 (Vaccines, Synthetic) RN - 0 (mRNA Vaccines) RN - SARS-CoV-2 variants SB - IM EIN - Lancet Respir Med. 2022 Jun;10(6):e60. doi: 10.1016/S2213-2600(22)00139-4. PMID: 35427532 MH - *COVID-19/epidemiology/prevention & control MH - COVID-19 Vaccines MH - Case-Control Studies MH - Humans MH - *SARS-CoV-2/genetics MH - Scotland/epidemiology MH - Vaccine Efficacy MH - Vaccines, Synthetic MH - mRNA Vaccines PMC - PMC8880999 COIS- Declaration of interests HMC receives research support and honoraria and is a member of advisory panels or speaker bureaus for Sanofi Aventis, Regeneron, Novartis, Novo-Nordisk, and Eli Lilly. HMC receives or has recently received non-binding research support from ChAdOx1 and Novo-Nordisk. SJH received honoraria from Gilead. All other authors declare no competing interests. EDAT- 2022/03/02 06:00 MHDA- 2022/06/09 06:00 PMCR- 2022/02/25 CRDT- 2022/03/01 05:43 PHST- 2021/10/08 00:00 [received] PHST- 2022/01/10 00:00 [revised] PHST- 2022/01/18 00:00 [accepted] PHST- 2022/03/02 06:00 [pubmed] PHST- 2022/06/09 06:00 [medline] PHST- 2022/03/01 05:43 [entrez] PHST- 2022/02/25 00:00 [pmc-release] AID - S2213-2600(22)00045-5 [pii] AID - 10.1016/S2213-2600(22)00045-5 [doi] PST - ppublish SO - Lancet Respir Med. 2022 Jun;10(6):566-572. doi: 10.1016/S2213-2600(22)00045-5. Epub 2022 Feb 25. PMID- 35227353 OWN - NLM STAT- MEDLINE DCOM- 20220307 LR - 20220307 IS - 2078-5135 (Electronic) VI - 111 IP - 8 DP - 2021 May 21 TI - Tracking mortality in near to real time provides essential information about the impact of the COVID-19 pandemic in South Africa in 2020. PG - 732-740 LID - 10.7196/SAMJ.2021.v111i8.15809 [doi] AB - Producing timely and accurate estimates of the impact of COVID-19 on mortality is challenging for most countries, but impossible for South Africa (SA) from cause-of-death statistics. Objectives. To quantify the excess deaths and likely magnitude of COVID-19 in SA in 2020 and draw conclusions on monitoring the epidemic in 2021. Methods. Basic details of deaths registered on the National Population Register by the Department of Home Affairs (DoHA) are provided to the South African Medical Research Council weekly. Adjustments are made to the numbers of weekly deaths to account for non-registration on the population register, as well as late registration of death with the DoHA. The weekly number of deaths is compared with the number predicted based on the Holt-Winters time-series analysis of past deaths for provinces and metropolitan areas. Excess deaths were calculated for all-causes deaths and natural deaths, using the predicted deaths as a baseline. In addition, an adjustment was made to the baseline for natural deaths to account for the drop in natural deaths due to lockdown. Results. We estimated that just over 550 000 deaths occurred among persons aged >/=1 year during 2020, 13% higher than the 485 000 predicted before the pandemic. A pronounced increase in weekly deaths from natural causes peaked in the middle of July across all ages except <20 years, and across all provinces with slightly different timing. During December, it became clear that SA was experiencing a second wave of COVID-19 that would exceed the death toll of the first wave. In 2020, there were 70 000 - 76 000 excess deaths from natural causes, depending on the base. Using the adjusted base, the excess death rate from natural causes was 122 per 100 000 population, with a male-to-female ratio of 0.78. Deaths from unnatural causes halved for both males and females during the stringent lockdown level 5. The numbers reverted towards the predicted number with some fluctuations as lockdown restrictions varied. Just under 5 000 unnatural deaths were averted. Conclusions. Tracking the weekly numbers of deaths in near to real time has provided important information about the spatiotemporal impact of the pandemic and highlights that the ~28 000 reported COVID-19 deaths during 2020 substantially understate the death toll from COVID-19. There is an urgent need to re-engineer the system of collecting and processing cause-of-death information so that it can be accessed in a timely way to inform public health actions. FAU - Bradshaw, D AU - Bradshaw D AD - Burden of Disease Research Unit, South African Medical Research Council, Cape Town, South Africa; School of Public Health and Family Medicine, Faculty of Health Sciences, University of Cape Town, South Africa. debbie.bradshaw@mrc.ac.za. FAU - Dorrington, R E AU - Dorrington RE FAU - Laubscher, R AU - Laubscher R FAU - Moultrie, T A AU - Moultrie TA FAU - Groenewald, P AU - Groenewald P LA - eng PT - Journal Article DEP - 20210521 PL - South Africa TA - S Afr Med J JT - South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde JID - 0404520 SB - IM MH - Adolescent MH - Adult MH - Aged MH - Aged, 80 and over MH - COVID-19/epidemiology/*mortality MH - Cause of Death/trends MH - Child MH - Child, Preschool MH - Communicable Disease Control/methods/statistics & numerical data MH - Female MH - Humans MH - Infant MH - Male MH - Middle Aged MH - Mortality/*trends MH - Population Surveillance/*methods MH - South Africa/epidemiology EDAT- 2022/03/02 06:00 MHDA- 2022/03/08 06:00 CRDT- 2022/03/01 05:43 PHST- 2021/05/21 00:00 [received] PHST- 2021/05/21 00:00 [accepted] PHST- 2022/03/01 05:43 [entrez] PHST- 2022/03/02 06:00 [pubmed] PHST- 2022/03/08 06:00 [medline] AID - 10.7196/SAMJ.2021.v111i8.15809 [doi] PST - epublish SO - S Afr Med J. 2021 May 21;111(8):732-740. doi: 10.7196/SAMJ.2021.v111i8.15809. PMID- 35220973 OWN - NLM STAT- MEDLINE DCOM- 20220302 LR - 20240824 IS - 1471-2458 (Electronic) IS - 1471-2458 (Linking) VI - 22 IP - 1 DP - 2022 Feb 28 TI - Impact of the COVID-19 pandemic on Bordetella pertussis infections in England. PG - 405 LID - 10.1186/s12889-022-12830-9 [doi] LID - 405 AB - BACKGROUND: In March 2020, England went into its first lockdown in response to the COVID-19 pandemic. Restrictions eased temporarily, followed by second and third waves in October 2020 and January 2021. Recent data showed that the COVID-19 pandemic resulted in reduced transmission of some invasive diseases. We assess the impact of the COVID-19 pandemic on pertussis incidence and on the immunisation programme in England. METHODS: We assessed trends in pertussis cases from 2012 to 2020 by age group and month. Incidence from the time that England eased its initial lockdown measures in July 2020 through to summer 2021 was calculated and the incidence rate ratios of pertussis cases from five years prior to the pandemic (July 2014 - June 2019) compared to the same time period during the pandemic (July 2020 - June 2021). Vaccine coverage estimates for pertussis containing vaccines were reviewed for the maternal and childhood programmes. RESULTS: A substantial decline in pertussis cases was observed from April 2020 onwards, marking the lowest number of cases in the last decade. Pertussis incidence dropped in all age groups, particularly among infants less than one year old (0.50 / 100,000 during July 2020 to June 2021 compared to 24.49/ 100,000 from July 2014 to June 2019). The incidence rate ratio was 0.02 (95% CI 0.01 to 0.02) for July 2014 to June 2019 (pre-pandemic) compared to the pandemic period of July 2020 to June 2021. None of the cases had a co-infection with SARS-CoV-2. Vaccine coverage for infants born between January to March 2020 with three doses of pertussis vaccine by 12 months of age decreased by 1.1% points compared to infants born between January to March 2019 (91.6% and 92.7%, respectively). Prenatal pertussis coverage for the 2020 to 2021 financial year was 2.7% points lower than the year prior to the pandemic (70.5% and 76.8%, respectively). CONCLUSIONS: Lockdown measures due to the COVID-19 pandemic have had a significant impact on pertussis transmission. With the easing of restrictions it is important to continue monitoring pertussis cases in England alongside coverage of the maternal and childhood immunisation programmes. CI - (c) 2022. The Author(s). FAU - Tessier, Elise AU - Tessier E AD - Immunisations and Countermeasures Division, UK Health Security Agency, 61 Colindale Avenue, NW9 5EQ, London, England. Elise.Tessier@phe.gov.uk. FAU - Campbell, Helen AU - Campbell H AD - Immunisations and Countermeasures Division, UK Health Security Agency, 61 Colindale Avenue, NW9 5EQ, London, England. FAU - Ribeiro, Sonia AU - Ribeiro S AD - Immunisations and Countermeasures Division, UK Health Security Agency, 61 Colindale Avenue, NW9 5EQ, London, England. FAU - Rai, Yuma AU - Rai Y AD - Immunisations and Countermeasures Division, UK Health Security Agency, 61 Colindale Avenue, NW9 5EQ, London, England. FAU - Burton, Simon AU - Burton S AD - Immunisations and Countermeasures Division, UK Health Security Agency, 61 Colindale Avenue, NW9 5EQ, London, England. FAU - Roy, Partho AU - Roy P AD - Immunisations and Countermeasures Division, UK Health Security Agency, 61 Colindale Avenue, NW9 5EQ, London, England. FAU - Fry, Norman K AU - Fry NK AD - Respiratory and Vaccine Preventable Bacteria Reference Unit, UK Health Security Agency, 61 Colindale Avenue, NW9 5EQ, London, England. FAU - Litt, David AU - Litt D AD - Respiratory and Vaccine Preventable Bacteria Reference Unit, UK Health Security Agency, 61 Colindale Avenue, NW9 5EQ, London, England. FAU - Amirthalingam, Gayatri AU - Amirthalingam G AD - Immunisations and Countermeasures Division, UK Health Security Agency, 61 Colindale Avenue, NW9 5EQ, London, England. LA - eng PT - Journal Article DEP - 20220228 PL - England TA - BMC Public Health JT - BMC public health JID - 100968562 RN - 0 (Pertussis Vaccine) SB - IM MH - Bordetella pertussis MH - *COVID-19/epidemiology/prevention & control MH - Child MH - Communicable Disease Control MH - England/epidemiology MH - Female MH - Humans MH - Infant MH - Pandemics/prevention & control MH - Pertussis Vaccine MH - Pregnancy MH - SARS-CoV-2 MH - *Whooping Cough/epidemiology/prevention & control PMC - PMC8882439 COIS- The authors have no competing interests to declare that are relevant for the content of this article. EDAT- 2022/03/01 06:00 MHDA- 2022/03/03 06:00 PMCR- 2022/02/28 CRDT- 2022/02/28 05:27 PHST- 2021/09/24 00:00 [received] PHST- 2022/02/14 00:00 [accepted] PHST- 2022/02/28 05:27 [entrez] PHST- 2022/03/01 06:00 [pubmed] PHST- 2022/03/03 06:00 [medline] PHST- 2022/02/28 00:00 [pmc-release] AID - 10.1186/s12889-022-12830-9 [pii] AID - 12830 [pii] AID - 10.1186/s12889-022-12830-9 [doi] PST - epublish SO - BMC Public Health. 2022 Feb 28;22(1):405. doi: 10.1186/s12889-022-12830-9. PMID- 35216575 OWN - NLM STAT- MEDLINE DCOM- 20220302 LR - 20240320 IS - 1471-2458 (Electronic) IS - 1471-2458 (Linking) VI - 22 IP - 1 DP - 2022 Feb 25 TI - Changing sexual behaviours amongst MSM during the COVID-19 restrictions in Wales: a mixed methods study. PG - 396 LID - 10.1186/s12889-022-12821-w [doi] LID - 396 AB - BACKGROUND: The COVID-19 pandemic and its associated restrictions stopped people freely engaging in sexual behaviour. We explored sexual behaviour amongst men who have sex with men (MSM) using mixed methods during the multiple lockdowns in Wales. METHODS: An online survey was advertised on social media platforms (focusing on Welsh LGBT groups), from June 2020 to July 2020. MSM over 16 years were invited to take part if they were resident in Wales. Qualitative interviews were undertaken as part of a study examining knowledge and awareness of sexual health. Interviews were conducted between September 2020 and February 2021 via Zoom(c). Interview data was analysed thematically and integrated with survey data. RESULTS: The survey received 70 responses, 60% (n = 42) reported not having sexual activity during lockdown. Restrictions altered the number of new sexual partners per week with over 80% (n = 56) not having any new sexual partners for the 12 weeks of the first lockdown. However, as the weeks progressed following the first lockdown there was an increase in the number of new sexual partners. Interview data indicated that the COVID-19 pandemic had a large impact on reducing sexual behaviour with other MSM in Wales. 'Lockdown fatigue' was viewed to result in different levels of adherence to the lockdown rules depending on the lockdown being discussed. Of those engaging in sex outside the rules, 'shame' was commonly reported. The restrictions were believed to have a positive impact on reducing the spread of sexually transmitted infections. CONCLUSIONS: The COVID-19 pandemic and associated restrictions had a significant impact on sexual behaviours among MSM in Wales, with the majority fully adhering to the lockdown rules. Although the population were largely compliant with the lockdown restrictions, lockdown fatigue may suggest that any future lockdowns might not have the same effect. CI - (c) 2022. The Author(s). FAU - Williams, Adam AU - Williams A AD - Centre for Trials Research, School of Medicine, College of Biomedical & Life Sciences, Cardiff University, Wales, UK. WilliamsAD7@cardiff.ac.uk. FAU - Gillespie, David AU - Gillespie D AD - Centre for Trials Research, School of Medicine, College of Biomedical & Life Sciences, Cardiff University, Wales, UK. FAU - Couzens, Zoe AU - Couzens Z AD - Public Health Wales NHS Trust, Wales, UK. FAU - Wood, Fiona AU - Wood F AD - PRIME Centre Wales, Division of Population Medicine, School of Medicine, College of Biomedical & Life Sciences, Cardiff University, Wales, UK. FAU - Hughes, Kathryn AU - Hughes K AD - PRIME Centre Wales, Division of Population Medicine, School of Medicine, College of Biomedical & Life Sciences, Cardiff University, Wales, UK. FAU - Hood, Kerenza AU - Hood K AD - Centre for Trials Research, School of Medicine, College of Biomedical & Life Sciences, Cardiff University, Wales, UK. LA - eng GR - 517019/European Social Fund/ PT - Journal Article DEP - 20220225 PL - England TA - BMC Public Health JT - BMC public health JID - 100968562 SB - IM MH - *COVID-19/epidemiology/prevention & control MH - Communicable Disease Control MH - Homosexuality, Male MH - Humans MH - Male MH - Pandemics/prevention & control MH - SARS-CoV-2 MH - Sexual Behavior MH - Sexual Partners MH - *Sexual and Gender Minorities MH - Wales/epidemiology PMC - PMC8874301 OTO - NOTNLM OT - Behaviour Change OT - COVID-19 OT - Mixed methods OT - Sexual and gender minorities OT - Sexual health COIS- The authors declare that they have no competing interests. EDAT- 2022/02/27 06:00 MHDA- 2022/03/03 06:00 PMCR- 2022/02/25 CRDT- 2022/02/26 05:29 PHST- 2021/09/22 00:00 [received] PHST- 2022/02/16 00:00 [accepted] PHST- 2022/02/26 05:29 [entrez] PHST- 2022/02/27 06:00 [pubmed] PHST- 2022/03/03 06:00 [medline] PHST- 2022/02/25 00:00 [pmc-release] AID - 10.1186/s12889-022-12821-w [pii] AID - 12821 [pii] AID - 10.1186/s12889-022-12821-w [doi] PST - epublish SO - BMC Public Health. 2022 Feb 25;22(1):396. doi: 10.1186/s12889-022-12821-w. PMID- 35206374 OWN - NLM STAT- MEDLINE DCOM- 20220301 LR - 20250623 IS - 1660-4601 (Electronic) IS - 1661-7827 (Print) IS - 1660-4601 (Linking) VI - 19 IP - 4 DP - 2022 Feb 15 TI - Anxiety Linked to COVID-19: A Systematic Review Comparing Anxiety Rates in Different Populations. LID - 10.3390/ijerph19042189 [doi] LID - 2189 AB - The COVID-19 pandemic has incited a rise in anxiety, with uncertainty regarding the specific impacts and risk factors across multiple populations. A qualitative systematic review was conducted to investigate the prevalence and associations of anxiety in different sample populations in relation to the COVID-19 pandemic. Four databases were utilised in the search (Medline, EMBASE, CINAHL, and PsycINFO). The review period commenced in April 2021 and was finalised on 5 July 2021. A total of 3537 studies were identified of which 87 were included in the review (sample size: 755,180). Healthcare workers had the highest prevalence of anxiety (36%), followed by university students (34.7%), the general population (34%), teachers (27.2%), parents (23.3%), pregnant women (19.5%), and police (8.79%). Risk factors such as being female, having pre-existing mental conditions, lower socioeconomic status, increased exposure to infection, and being younger all contributed to worsened anxiety. The review included studies published before July 2021; due to the ongoing nature of the COVID-19 pandemic, this may have excluded relevant papers. Restriction to only English papers and a sample size > 1000 may have also limited the range of papers included. These findings identify groups who are most vulnerable to developing anxiety in a pandemic and what specific risk factors are most common across multiple populations. FAU - Saeed, Hafsah AU - Saeed H AD - Neuroscience Research Unit, School of Life Sciences, University of Technology Sydney, Sydney, NSW 2007, Australia. FAU - Eslami, Ardalan AU - Eslami A AD - Neuroscience Research Unit, School of Life Sciences, University of Technology Sydney, Sydney, NSW 2007, Australia. FAU - Nassif, Najah T AU - Nassif NT AUID- ORCID: 0000-0003-2675-8322 AD - School of Life Sciences, University of Technology Sydney, Sydney, NSW 2007, Australia. FAU - Simpson, Ann M AU - Simpson AM AD - School of Life Sciences, University of Technology Sydney, Sydney, NSW 2007, Australia. FAU - Lal, Sara AU - Lal S AD - Neuroscience Research Unit, School of Life Sciences, University of Technology Sydney, Sydney, NSW 2007, Australia. LA - eng PT - Journal Article PT - Systematic Review DEP - 20220215 PL - Switzerland TA - Int J Environ Res Public Health JT - International journal of environmental research and public health JID - 101238455 SB - IM MH - Anxiety/epidemiology MH - *COVID-19/epidemiology MH - Depression/epidemiology MH - Female MH - Humans MH - Mental Health MH - Pandemics MH - Pregnancy MH - SARS-CoV-2 PMC - PMC8871867 OTO - NOTNLM OT - COVID-19 OT - anxiety OT - mental health OT - qualitative systematic review COIS- All authors declare no conflict of interest. EDAT- 2022/02/26 06:00 MHDA- 2022/03/03 06:00 PMCR- 2022/02/15 CRDT- 2022/02/25 01:09 PHST- 2022/01/23 00:00 [received] PHST- 2022/02/09 00:00 [revised] PHST- 2022/02/10 00:00 [accepted] PHST- 2022/02/25 01:09 [entrez] PHST- 2022/02/26 06:00 [pubmed] PHST- 2022/03/03 06:00 [medline] PHST- 2022/02/15 00:00 [pmc-release] AID - ijerph19042189 [pii] AID - ijerph-19-02189 [pii] AID - 10.3390/ijerph19042189 [doi] PST - epublish SO - Int J Environ Res Public Health. 2022 Feb 15;19(4):2189. doi: 10.3390/ijerph19042189. PMID- 35201544 OWN - NLM STAT- MEDLINE DCOM- 20220603 LR - 20250623 IS - 1573-3610 (Electronic) IS - 0094-5145 (Print) IS - 0094-5145 (Linking) VI - 47 IP - 3 DP - 2022 Jun TI - Barriers and Factors Associated with HPV Vaccination Among American Indians and Alaska Natives: A Systematic Review. PG - 563-575 LID - 10.1007/s10900-022-01079-3 [doi] AB - American Indian and Alaska Native (AI/AN) persons bear a disproportionate burden of human papillomavirus (HPV)-associated cancers and face unique challenges to HPV vaccination. We undertook a systematic review to synthesize the available evidence on HPV vaccination barriers and factors among AI/AN persons in the United States. We searched fourteen bibliographic databases, four citation indexes, and six gray literature sources from July 2006 to January 2021. We did not restrict our search by study design, setting, or publication type. Two reviewers independently screened the titles and abstracts (stage 1) and full-text (stage 2) of studies for selection. Both reviewers then independently extracted data using a data extraction form and undertook quality appraisal and bias assessment using the modified Mixed Methods Appraisal Tool. We conducted thematic synthesis to generate descriptive themes. We included a total of 15 records after identifying 3017, screening 1415, retrieving 203, and assessing 41 records. A total of 21 unique barriers to HPV vaccination were reported across 15 themes at the individual (n = 12) and clinic or provider (n = 3) levels. At the individual level, the most common barriers to vaccination-safety and lack of knowledge about the HPV vaccine-were each reported in the highest number of studies (n = 9; 60%). The findings from this review signal the need to develop interventions that target AI/AN populations to increase the adoption and coverage of HPV vaccination. Failure to do so may widen disparities. CI - (c) 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. FAU - Gopalani, Sameer V AU - Gopalani SV AUID- ORCID: 0000-0003-0611-305X AD - Department of Biostatistics and Epidemiology, Hudson College of Public Health, University of Oklahoma Health Sciences Center, 801 N.E. 13th Street, Oklahoma City, OK, 73104, USA. sameer-gopalani@ouhsc.edu. FAU - Sedani, Ami E AU - Sedani AE AD - Department of Biostatistics and Epidemiology, Hudson College of Public Health, University of Oklahoma Health Sciences Center, 801 N.E. 13th Street, Oklahoma City, OK, 73104, USA. FAU - Janitz, Amanda E AU - Janitz AE AD - Department of Biostatistics and Epidemiology, Hudson College of Public Health, University of Oklahoma Health Sciences Center, 801 N.E. 13th Street, Oklahoma City, OK, 73104, USA. FAU - Clifton, Shari C AU - Clifton SC AD - Robert M. Bird Health Sciences Library, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 73104, USA. FAU - Peck, Jennifer D AU - Peck JD AD - Department of Biostatistics and Epidemiology, Hudson College of Public Health, University of Oklahoma Health Sciences Center, 801 N.E. 13th Street, Oklahoma City, OK, 73104, USA. FAU - Comiford, Ashley AU - Comiford A AD - Cherokee Nation Public Health, Cherokee Nation, Tahlequah, OK, 74464, USA. FAU - Campbell, Janis E AU - Campbell JE AD - Department of Biostatistics and Epidemiology, Hudson College of Public Health, University of Oklahoma Health Sciences Center, 801 N.E. 13th Street, Oklahoma City, OK, 73104, USA. LA - eng GR - P30 CA225520/CA/NCI NIH HHS/United States GR - U54 GM104938/GM/NIGMS NIH HHS/United States GR - U54GM104938/GM/NIGMS NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't PT - Systematic Review DEP - 20220224 PL - Netherlands TA - J Community Health JT - Journal of community health JID - 7600747 RN - 0 (Papillomavirus Vaccines) SB - IM MH - *Alaska Natives MH - Humans MH - *Indians, North American MH - *Papillomavirus Infections/prevention & control MH - *Papillomavirus Vaccines/therapeutic use MH - United States MH - Vaccination MH - American Indian or Alaska Native PMC - PMC9167249 MID - NIHMS1783793 OTO - NOTNLM OT - Alaska Native OT - American Indian OT - Cancer prevention OT - HPV vaccination OT - Native American OT - Systematic review COIS- Conflicts of Interest None. EDAT- 2022/02/25 06:00 MHDA- 2022/06/07 06:00 PMCR- 2023/06/01 CRDT- 2022/02/24 12:24 PHST- 2022/02/11 00:00 [accepted] PHST- 2022/02/25 06:00 [pubmed] PHST- 2022/06/07 06:00 [medline] PHST- 2022/02/24 12:24 [entrez] PHST- 2023/06/01 00:00 [pmc-release] AID - 10.1007/s10900-022-01079-3 [pii] AID - 10.1007/s10900-022-01079-3 [doi] PST - ppublish SO - J Community Health. 2022 Jun;47(3):563-575. doi: 10.1007/s10900-022-01079-3. Epub 2022 Feb 24. PMID- 35199848 OWN - NLM STAT- MEDLINE DCOM- 20220301 LR - 20250623 IS - 1469-493X (Electronic) IS - 1361-6137 (Linking) VI - 2 IP - 2 DP - 2022 Feb 24 TI - Interventions for the management of transient tachypnoea of the newborn - an overview of systematic reviews. PG - CD013563 LID - 10.1002/14651858.CD013563.pub2 [doi] LID - CD013563 AB - BACKGROUND: Transient tachypnoea of the newborn (TTN) is characterised by tachypnoea and signs of respiratory distress. It is caused by delayed clearance of lung fluid at birth. TTN typically appears within the first two hours of life in term and late preterm newborns. Although it is usually a self-limited condition, admission to a neonatal unit is frequently required for monitoring, the provision of respiratory support, and drugs administration. These interventions might reduce respiratory distress during TTN and enhance the clearance of lung liquid. The goals are reducing the effort required to breathe, improving respiratory distress, and potentially shortening the duration of tachypnoea. However, these interventions might be associated with harm in the infant. OBJECTIVES: The aim of this overview was to evaluate the benefits and harms of different interventions used in the management of TTN. METHODS: We searched the Cochrane Database of Systematic Reviews on 14 July 2021 for ongoing and published Cochrane Reviews on the management of TTN in term (> 37 weeks' gestation) or late preterm (34 to 36 weeks' gestation) infants. We included all published Cochrane Reviews assessing the following categories of interventions administered within the first 48 hours of life: beta-agonists (e.g. salbutamol and epinephrine), corticosteroids, diuretics, fluid restriction, and non-invasive respiratory support. The reviews compared the above-mentioned interventions to placebo, no treatment, or other interventions for the management of TTN. The primary outcomes of this overview were duration of tachypnoea and the need for mechanical ventilation. Two overview authors independently checked the eligibility of the reviews retrieved by the search and extracted data from the included reviews using a predefined data extraction form. Any disagreements were resolved by discussion with a third overview author. Two overview authors independently assessed the methodological quality of the included reviews using the AMSTAR 2 (A MeaSurement Tool to Assess systematic Reviews) tool. We used the GRADE approach to assess the certainty of evidence for effects of interventions for TTN management. As all of the included reviews reported summary of findings tables, we extracted the information already available and re-graded the certainty of evidence of the two primary outcomes to ensure a homogeneous assessment. We provided a narrative summary of the methods and results of each of the included reviews and summarised this information using tables and figures. MAIN RESULTS: We included six Cochrane Reviews, corresponding to 1134 infants enrolled in 18 trials, on the management of TTN in term and late preterm infants, assessing salbutamol (seven trials), epinephrine (one trial), budesonide (one trial), diuretics (two trials), fluid restriction (four trials), and non-invasive respiratory support (three trials). The quality of the included reviews was high, with all of them fulfilling the critical domains of the AMSTAR 2. The certainty of the evidence was very low for the primary outcomes, due to the imprecision of the estimates (few, small included studies) and unclear or high risk of bias. Salbutamol may reduce the duration of tachypnoea compared to placebo (mean difference (MD) -16.83 hours, 95% confidence interval (CI) -22.42 to -11.23, 2 studies, 120 infants, low certainty evidence). We did not identify any review that compared epinephrine or corticosteroids to placebo and reported on the duration of tachypnoea. However, one review reported on "trend of normalisation of respiratory rate", a similar outcome, and found no differences between epinephrine and placebo (effect size not reported). The evidence is very uncertain regarding the effect of diuretics compared to placebo (MD -1.28 hours, 95% CI -13.0 to 10.45, 2 studies, 100 infants, very low certainty evidence). We did not identify any review that compared fluid restriction to standard fluid rates and reported on the duration of tachypnoea. The evidence is very uncertain regarding the effect of continuous positive airway pressure (CPAP) compared to free-flow oxygen therapy (MD -21.1 hours, 95% CI -22.9 to -19.3, 1 study, 64 infants, very low certainty evidence); the effect of nasal high-frequency (oscillation) ventilation (NHFV) compared to CPAP (MD -4.53 hours, 95% CI -5.64 to -3.42, 1 study, 40 infants, very low certainty evidence); and the effect of nasal intermittent positive pressure ventilation (NIPPV) compared to CPAP on duration of tachypnoea (MD 4.30 hours, 95% CI -19.14 to 27.74, 1 study, 40 infants, very low certainty evidence). Regarding the need for mechanical ventilation, the evidence is very uncertain for the effect of salbutamol compared to placebo (risk ratio (RR) 0.60, 95% CI 0.13 to 2.86, risk difference (RD) 10 fewer, 95% CI 50 fewer to 30 more per 1000, 3 studies, 254 infants, very low certainty evidence); the effect of epinephrine compared to placebo (RR 0.67, 95% CI 0.08 to 5.88, RD 70 fewer, 95% CI 460 fewer to 320 more per 1000, 1 study, 20 infants, very low certainty evidence); and the effect of corticosteroids compared to placebo (RR 0.52, 95% CI 0.05 to 5.38, RD 40 fewer, 95% CI 170 fewer to 90 more per 1000, 1 study, 49 infants, very low certainty evidence). We did not identify a review that compared diuretics to placebo and reported on the need for mechanical ventilation. The evidence is very uncertain regarding the effect of fluid restriction compared to standard fluid administration (RR 0.73, 95% CI 0.24 to 2.23, RD 20 fewer, 95% CI 70 fewer to 40 more per 1000, 3 studies, 242 infants, very low certainty evidence); the effect of CPAP compared to free-flow oxygen (RR 0.30, 95% CI 0.01 to 6.99, RD 30 fewer, 95% CI 120 fewer to 50 more per 1000, 1 study, 64 infants, very low certainty evidence); the effect of NIPPV compared to CPAP (RR 4.00, 95% CI 0.49 to 32.72, RD 150 more, 95% CI 50 fewer to 350 more per 1000, 1 study, 40 infants, very low certainty evidence); and the effect of NHFV versus CPAP (effect not estimable, 1 study, 40 infants, very low certainty evidence). Regarding our secondary outcomes, duration of hospital stay was the only outcome reported in all of the included reviews. One trial on fluid restriction reported a lower duration of hospitalisation in the restricted-fluids group, but with very low certainty of evidence. The evidence was very uncertain for the effects on secondary outcomes for the other five reviews. Data on potential harms were scarce, as all of the trials were underpowered to detect possible increases in adverse events such as pneumothorax, arrhythmias, and electrolyte imbalances. No adverse effects were reported for salbutamol; however, this medication is known to carry a risk of tachycardia, tremor, and hypokalaemia in other settings. AUTHORS' CONCLUSIONS: This overview summarises the evidence from six Cochrane Reviews of randomised trials regarding the effects of postnatal interventions in the management of TTN. Salbutamol may reduce the duration of tachypnoea slightly. We are uncertain as to whether salbutamol reduces the need for mechanical ventilation. We are uncertain whether epinephrine, corticosteroids, diuretics, fluid restriction, or non-invasive respiratory support reduces the duration of tachypnoea and the need for mechanical ventilation, due to the extremely limited evidence available. Data on harms were lacking. CI - Copyright (c) 2022 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. FAU - Bruschettini, Matteo AU - Bruschettini M AD - Department of Clinical Sciences Lund, Paediatrics, Lund University, Skane University Hospital, Lund, Sweden. AD - Cochrane Sweden, Lund University, Skane University Hospital, Lund, Sweden. FAU - Hassan, Karl-Omar AU - Hassan KO AD - Medical Clinic, Hudiksvall Hospital, Hudiksvall, Sweden. FAU - Romantsik, Olga AU - Romantsik O AD - Department of Clinical Sciences Lund, Paediatrics, Lund University, Skane University Hospital, Lund, Sweden. FAU - Banzi, Rita AU - Banzi R AD - Center for Health Regulatory Policies, Mario Negri Institute for Pharmacological Research IRCCS, Milan, Italy. FAU - Calevo, Maria Grazia AU - Calevo MG AD - Epidemiology, Biostatistics Unit, IRCCS, Istituto Giannina Gaslini, Genoa, Italy. FAU - Moresco, Luca AU - Moresco L AD - Pediatric and Neonatology Unit, Ospedale San Paolo, Savona, Italy. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Systematic Review DEP - 20220224 PL - England TA - Cochrane Database Syst Rev JT - The Cochrane database of systematic reviews JID - 100909747 SB - IM UOF - doi: 10.1002/14651858.CD013563 MH - Humans MH - Infant MH - Infant, Newborn MH - Infant, Premature MH - Intermittent Positive-Pressure Ventilation MH - Oxygen Inhalation Therapy MH - Systematic Reviews as Topic MH - *Transient Tachypnea of the Newborn/therapy PMC - PMC8867535 COIS- Four overview authors are authors of several of the included reviews: MB of five reviews (Bruschettini 2020; Gupta 2021; Moresco 2016; Moresco 2020; Moresco 2021); MGC and LM of five reviews (Bruschettini 2020; Moresco 2016; Moresco 2020; Moresco 2021); and OR of two reviews (Bruschettini 2020; Moresco 2020). As prespecified in our protocol, two other overview authors (KOH and RB) carried out data extraction and quality assessment for these reviews in order to minimise intellectual bias. MB has no other interests to declare. KOH has no interests to declare. OR has no other interests to declare. RB has no interests to declare. MGC has no other interests to declare. LM has no other interests to declare. EDAT- 2022/02/25 06:00 MHDA- 2022/03/03 06:00 PMCR- 2023/02/24 CRDT- 2022/02/24 08:43 PHST- 2022/02/24 08:43 [entrez] PHST- 2022/02/25 06:00 [pubmed] PHST- 2022/03/03 06:00 [medline] PHST- 2023/02/24 00:00 [pmc-release] AID - CD013563.pub2 [pii] AID - 10.1002/14651858.CD013563.pub2 [doi] PST - epublish SO - Cochrane Database Syst Rev. 2022 Feb 24;2(2):CD013563. doi: 10.1002/14651858.CD013563.pub2. PMID- 35187524 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240912 IS - 2667-193X (Electronic) IS - 2667-193X (Linking) VI - 9 DP - 2022 May TI - Public health guideline compliance and perceived government effectiveness during the COVID-19 pandemic in Canada: Findings from a longitudinal cohort study. PG - 100185 LID - 10.1016/j.lana.2022.100185 [doi] LID - 100185 AB - BACKGROUND: The coronavirus disease 2019 (COVID-19) pandemic has imposed enormous adversity worldwide. Public health guidelines have been a first line of defense but rely on compliance with evolving recommendations and restrictions. This study sought to characterize adherence to and perceptions of public health guidelines over a one-year timeframe during the pandemic. METHODS: Participants were 1435 community adults in Ontario who completed assessments at five time points (April 2020, July 2020, October 2020, January 2021, and April 2021; 92% retention). Participants were assessed for self-reported adherence to government protocols and perceptions of government response (importance, compliance, and effectiveness). Analyses used general linear mixed-effects modelling of overall changes by time and examined differences based on age and sex. FINDINGS: Over time, participants reported high or increasing behavioural engagement in public health guidelines, including physical distancing, restricting activity, and masking. In contrast, participants exhibited significant reductions in perceived importance and compliance, with evidence of more negative changes in younger participants. The largest changes were a substantial reduction in perceived government effectiveness, from predominantly positive perceptions to predominantly negative perceptions. INTERPRETATION: These results illuminate evolving trends in public health compliance and perceptions over the course of the pandemic in Canada, revealing the malleability of public perceptions of public health recommendations and government effectiveness. FUNDING: This research was funded by a grant from the Canadian Institutes of Health Research (CIHR). CIHR had no role in study design, data collection, data analysis, interpretation, or writing of the report. CI - (c) 2022 Published by Elsevier Ltd. FAU - Levitt, Emily E AU - Levitt EE AD - Peter Boris Centre for Addictions Research, McMaster University & St. Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada. FAU - Gohari, Mahmood R AU - Gohari MR AD - Peter Boris Centre for Addictions Research, McMaster University & St. Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada. FAU - Syan, Sabrina K AU - Syan SK AD - Peter Boris Centre for Addictions Research, McMaster University & St. Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada. FAU - Belisario, Kyla AU - Belisario K AD - Peter Boris Centre for Addictions Research, McMaster University & St. Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada. FAU - Gillard, Jessica AU - Gillard J AD - Peter Boris Centre for Addictions Research, McMaster University & St. Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada. FAU - DeJesus, Jane AU - DeJesus J AD - Peter Boris Centre for Addictions Research, McMaster University & St. Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada. FAU - Levitt, Anthony AU - Levitt A AD - Department of Psychiatry, Sunnybrook Health Sciences Centre & Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada. FAU - MacKillop, James AU - MacKillop J AD - Peter Boris Centre for Addictions Research, McMaster University & St. Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada. AD - Homewood Research Institute, Guelph, Ontario, Canada. LA - eng PT - Journal Article DEP - 20220214 PL - England TA - Lancet Reg Health Am JT - Lancet regional health. Americas JID - 9918232503006676 PMC - PMC8841140 OTO - NOTNLM OT - COVID-19 OT - Government adherence OT - Government perceptions OT - Government response OT - Government trust OT - Pandemic COIS- No authors declare any competing interests associated with this study. JM is a principal and senior scientist in BEAM Diagnostics, Inc. and a consultant to ClairvoyantRx, Inc. but no associated products or services were used in this study. EDAT- 2022/02/22 06:00 MHDA- 2022/02/22 06:01 PMCR- 2022/02/14 CRDT- 2022/02/21 06:07 PHST- 2022/02/21 06:07 [entrez] PHST- 2022/02/22 06:00 [pubmed] PHST- 2022/02/22 06:01 [medline] PHST- 2022/02/14 00:00 [pmc-release] AID - S2667-193X(22)00002-3 [pii] AID - 100185 [pii] AID - 10.1016/j.lana.2022.100185 [doi] PST - ppublish SO - Lancet Reg Health Am. 2022 May;9:100185. doi: 10.1016/j.lana.2022.100185. Epub 2022 Feb 14. PMID- 35179502 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220716 IS - 1929-0748 (Print) IS - 1929-0748 (Electronic) IS - 1929-0748 (Linking) VI - 11 IP - 2 DP - 2022 Feb 18 TI - Testing an mHealth System for Individuals With Mild to Moderate Alcohol Use Disorders: Protocol for a Type 1 Hybrid Effectiveness-Implementation Trial. PG - e31109 LID - 10.2196/31109 [doi] LID - e31109 AB - BACKGROUND: The extent of human interaction needed to achieve effective and cost-effective use of mobile health (mHealth) apps for individuals with mild to moderate alcohol use disorder (AUD) remains largely unexamined. This study seeks to understand how varying levels of human interaction affect the ways in which an mHealth intervention for the prevention and treatment of AUDs works or does not work, for whom, and under what circumstances. OBJECTIVE: The primary aim is to detect the effectiveness of an mHealth intervention by assessing differences in self-reported risky drinking patterns and quality of life between participants in three study groups (self-monitored, peer-supported, and clinically integrated). The cost-effectiveness of each approach will also be assessed. METHODS: This hybrid type 1 study is an unblinded patient-level randomized clinical trial testing the effects of using an evidence-based mHealth system on participants' drinking patterns and quality of life. There are two groups of participants for this study: individuals receiving the intervention and health care professionals practicing in the broader health care environment. The intervention is a smartphone app that encourages users to reduce their alcohol consumption within the context of integrative medicine using techniques to build healthy habits. The primary outcomes for quantitative analysis will be participant data on their risky drinking days and quality of life as well as app use from weekly and quarterly surveys. Cost measures include intervention and implementation costs. The cost per participant will be determined for each study arm, with intervention and implementation costs separated within each group. There will also be a qualitative assessment of health care professionals' engagement with the app as well as their thoughts on participant experience with the app. RESULTS: This protocol was approved by the Health Sciences Minimal Risk Institutional Review Board on November 18, 2019, with subsequent annual reviews. Recruitment began on March 6, 2020, but was suspended on March 13, 2020, due to the COVID-19 pandemic restrictions. Limited recruitment resumed on July 6, 2020. Trial status as of November 17, 2021, is as follows: 357 participants were enrolled in the study for a planned enrollment of 546 participants. CONCLUSIONS: The new knowledge gained from this study could have wide and lasting benefits related to the integration of mHealth systems for individuals with mild to moderate AUDs. The results of this study will guide policy makers and providers toward cost-effective ways to incorporate technology in health care and community settings. TRIAL REGISTRATION: ClinicalTrials.gov NCT04011644; https://clinicaltrials.gov/ct2/show/NCT04011644. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): DERR1-10.2196/31109. CI - (c)Linda S Park, Ming-Yuan Chih, Christine Stephenson, Nicholas Schumacher, Randall Brown, David Gustafson, Bruce Barrett, Andrew Quanbeck. Originally published in JMIR Research Protocols (https://www.researchprotocols.org), 18.02.2022. FAU - Park, Linda S AU - Park LS AUID- ORCID: 0000-0001-8008-343X AD - Department of Family Medicine and Community Health, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, United States. FAU - Chih, Ming-Yuan AU - Chih MY AUID- ORCID: 0000-0001-7130-1415 AD - Department of Health and Clinical Sciences, College of Health Sciences, University of Kentucky, Lexington, KY, United States. FAU - Stephenson, Christine AU - Stephenson C AUID- ORCID: 0000-0002-7922-4749 AD - Center for Health Disparities Research, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, United States. FAU - Schumacher, Nicholas AU - Schumacher N AUID- ORCID: 0000-0002-0081-4069 AD - Department of Family Medicine and Community Health, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, United States. FAU - Brown, Randall AU - Brown R AUID- ORCID: 0000-0002-5445-8119 AD - Department of Family Medicine and Community Health, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, United States. FAU - Gustafson, David AU - Gustafson D AUID- ORCID: 0000-0002-0660-1902 AD - Department of Industrial and Systems Engineering, College of Engineering, University of Wisconsin-Madison, Madison, WI, United States. FAU - Barrett, Bruce AU - Barrett B AUID- ORCID: 0000-0002-3953-4718 AD - Department of Family Medicine and Community Health, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, United States. FAU - Quanbeck, Andrew AU - Quanbeck A AUID- ORCID: 0000-0003-0762-4804 AD - Department of Family Medicine and Community Health, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, United States. LA - eng SI - ClinicalTrials.gov/NCT04011644 GR - R01 AA024150/AA/NIAAA NIH HHS/United States PT - Journal Article DEP - 20220218 PL - Canada TA - JMIR Res Protoc JT - JMIR research protocols JID - 101599504 PMC - PMC8900897 OTO - NOTNLM OT - alcohol reduction OT - alcohol use disorder OT - mHealth OT - mobile health OT - protocol OT - quality of life OT - risky drinking OT - wellness COIS- Conflicts of Interest: AQ has a shareholder interest in CHESS Health, a public benefit corporation that disseminates technology to the specialty addiction treatment system. The relationship between the author and CHESS Mobile Health is managed the University of Wisconsin-Madison's Conflict of Interest Committee. EDAT- 2022/02/19 06:00 MHDA- 2022/02/19 06:01 PMCR- 2022/02/18 CRDT- 2022/02/18 12:13 PHST- 2021/06/10 00:00 [received] PHST- 2021/12/20 00:00 [accepted] PHST- 2021/12/02 00:00 [revised] PHST- 2022/02/18 12:13 [entrez] PHST- 2022/02/19 06:00 [pubmed] PHST- 2022/02/19 06:01 [medline] PHST- 2022/02/18 00:00 [pmc-release] AID - v11i2e31109 [pii] AID - 10.2196/31109 [doi] PST - epublish SO - JMIR Res Protoc. 2022 Feb 18;11(2):e31109. doi: 10.2196/31109. PMID- 35178372 OWN - NLM STAT- MEDLINE DCOM- 20220223 LR - 20240930 IS - 2296-2565 (Electronic) IS - 2296-2565 (Linking) VI - 9 DP - 2021 TI - Changes in Alcohol Consumption and Determinants of Excessive Drinking During the COVID-19 Lockdown in the Slovak Republic. PG - 791077 LID - 10.3389/fpubh.2021.791077 [doi] LID - 791077 AB - As a result of the coronavirus disease 2019 (COVID-19) pandemic, countries have been forced to adopt strong restrictions, such as lockdown, which can lead to serious consequences for public health, including the problematic use of addictive substances. The aim of this cross-sectional study was to examine changes in alcohol consumption and to identify determinants against the background of excessive drinking during the COVID-19 lockdown in the Slovak Republic. The research included 445 respondents (33% males and 67% females), and the data collection through the questionnaire took place from April 29, 2020 to July 1, 2020. Measures such as drinking frequency, amount of alcohol and excessive drinking were used to examine alcohol consumption. Descriptive analysis and binary logistic regression were used to meet the main aim. The findings provide a closer look at the situation in the Slovak Republic and contribute to comprehensive international knowledge. The frequency of excessive drinking did not change in about half of respondents (53% of males and 69% of females). More respondents decreased their excessive drinking than increased, both among males (31 and 16%, respectively) and females (25 and 6%, respectively). Similar results were found for drinking frequency and amount of alcohol. Amongst Slovak respondents, an increase in excessive drinking was more common among males, younger people, smokers, and smokers who increased smoking during the lockdown. Especially in the case of vulnerable populations, public policies should consider a response to impending problems. The findings of this study encourage the implementation of effective and evidence-based prevention programs, which are more than necessary in the Slovak Republic. CI - Copyright (c) 2022 Gavurova, Khouri, Ivankova and Kubak. FAU - Gavurova, Beata AU - Gavurova B AD - Institute of Earth Resources, Faculty of Mining, Ecology, Process Control and Geotechnologies, Technical University of Kosice, Kosice, Slovakia. FAU - Khouri, Samer AU - Khouri S AD - Institute of Earth Resources, Faculty of Mining, Ecology, Process Control and Geotechnologies, Technical University of Kosice, Kosice, Slovakia. FAU - Ivankova, Viera AU - Ivankova V AD - Institute of Earth Resources, Faculty of Mining, Ecology, Process Control and Geotechnologies, Technical University of Kosice, Kosice, Slovakia. FAU - Kubak, Matus AU - Kubak M AD - Department of Regional Sciences and Management, Faculty of Economics, Technical University of Kosice, Kosice, Slovakia. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20220201 PL - Switzerland TA - Front Public Health JT - Frontiers in public health JID - 101616579 SB - IM MH - Alcohol Drinking/epidemiology MH - *COVID-19 MH - Communicable Disease Control MH - Cross-Sectional Studies MH - Female MH - Humans MH - Male MH - SARS-CoV-2 MH - Slovakia/epidemiology PMC - PMC8843933 OTO - NOTNLM OT - COVID-19 lockdown OT - Slovakia OT - alcohol consumption OT - determinants OT - drinking OT - individual characteristics OT - substance use OT - unhealthy behavior COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2022/02/19 06:00 MHDA- 2022/02/24 06:00 PMCR- 2022/02/01 CRDT- 2022/02/18 05:50 PHST- 2021/10/07 00:00 [received] PHST- 2021/12/22 00:00 [accepted] PHST- 2022/02/18 05:50 [entrez] PHST- 2022/02/19 06:00 [pubmed] PHST- 2022/02/24 06:00 [medline] PHST- 2022/02/01 00:00 [pmc-release] AID - 10.3389/fpubh.2021.791077 [doi] PST - epublish SO - Front Public Health. 2022 Feb 1;9:791077. doi: 10.3389/fpubh.2021.791077. eCollection 2021. PMID- 35174030 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220219 IS - 2168-8184 (Print) IS - 2168-8184 (Electronic) IS - 2168-8184 (Linking) VI - 14 IP - 1 DP - 2022 Jan TI - Significantly Increased Public Interest in Major Depressive Disorder During the COVID-19 Pandemic: Insights From a Google Trends Analysis. PG - e21228 LID - 10.7759/cureus.21228 [doi] LID - e21228 AB - Background As early as before the coronavirus disease 2019 (COVID-19) pandemic, nearly one billion people worldwide suffered from mental health problems. Of all the mental health conditions, major depressive disorder (MDD) is the leading cause of global health-related burden. During the COVID-19 pandemic, many uncertain factors affecting mental health accumulated, such as virus transmission, blockade and ban, public transport restrictions, closure of schools and enterprises, and reduction of social interaction, which led to an increase in the potential risk of MDD, further increasing the global health-related burden. Methodology To better clarify the public interest in major depressive disorder during the COVID-19 pandemic, a Google Trends analysis was employed with data from December 2019 to December 2021, taking the cumulative diagnosis rate and cumulative mortality rate of COVID-19 as the reference standard, The changes in public interest and behavior in online searching for major depressive disorder in the three countries most affected by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus (i.e. the United States, Brazil, and India) were evaluated. Results We observed that during the COVID-19 pandemic, public interest in major depressive disorder increased significantly on the Internet. At the same time, compared with the United States, this upward trend is more prominent in India and Brazil. The study found that the major depressive disorder search index of the United States reached the maximum at the end of September 2021, the major depressive disorder search index of Brazil reached the maximum at the beginning of July 2021, and the major depressive disorder search index of India reached the maximum at the beginning of June 2021. The above time nodes are the first turning point of decline after the continuous surge of COVID-19 confirmed cases in the United States, Brazil, and India, indicating that there is an important time correlation between the surge of COVID-19 cases and the public online search term major depressive disorder. Conclusion The Google Trends analysis shows that public interest in major depressive disorder is on the rise under the COVID-19 pandemic and that COVID-19 may be associated with MDD. These findings deserve further exploration, especially as a growing body of research reports suggests that the COVID-19 pandemic has led to a surge in the prevalence of MDD. The epidemic alerts the vast majority of countries to urgently strengthen mental health systems and provide patients with the necessary interventions based on the determinants of poor mental health. CI - Copyright (c) 2022, Li et al. FAU - Li, Chencheng AU - Li C AD - Center for Studies of Education and Psychology of Ethnic Minorities in Southwest China, Southwest University, Chongqing, CHN. FAU - Tan, Qinyi AU - Tan Q AD - Center for Studies of Education and Psychology of Ethnic Minorities in Southwest China, Southwest University, Chongqing, CHN. FAU - Zou, Manxing AU - Zou M AD - Department of Natural Medicinal Chemistry, China Pharmaceutical University, Nanjing, CHN. FAU - Zeng, Liang AU - Zeng L AD - Office of Medical Education Research, Chongqing Medical University, Chongqing, CHN. FAU - Kang, Muyun AU - Kang M AD - Academic Affairs Office, Southwest Medical University, Luzhou, CHN. FAU - Chen, Lisha AU - Chen L AD - Traditional Chinese Medicine, Affiliated Traditional Chinese Medicine Hospital of Southwest Medical University, Luzhou, CHN. LA - eng PT - Journal Article DEP - 20220114 PL - United States TA - Cureus JT - Cureus JID - 101596737 PMC - PMC8841016 OTO - NOTNLM OT - covid-19 OT - google trends OT - major depressive disorder (mdd) OT - mental illness OT - pandemic OT - psychology health COIS- The authors have declared that no competing interests exist. EDAT- 2022/02/18 06:00 MHDA- 2022/02/18 06:01 PMCR- 2022/01/14 CRDT- 2022/02/17 05:36 PHST- 2022/01/14 00:00 [accepted] PHST- 2022/02/17 05:36 [entrez] PHST- 2022/02/18 06:00 [pubmed] PHST- 2022/02/18 06:01 [medline] PHST- 2022/01/14 00:00 [pmc-release] AID - 10.7759/cureus.21228 [doi] PST - epublish SO - Cureus. 2022 Jan 14;14(1):e21228. doi: 10.7759/cureus.21228. eCollection 2022 Jan. PMID- 35173022 OWN - NLM STAT- MEDLINE DCOM- 20220224 LR - 20240824 IS - 2059-7908 (Print) IS - 2059-7908 (Electronic) IS - 2059-7908 (Linking) VI - 7 IP - 2 DP - 2022 Feb TI - A mixed-methods study of maternal health care utilisation in six referral hospitals in four sub-Saharan African countries before and during the COVID-19 pandemic. LID - 10.1136/bmjgh-2021-008064 [doi] LID - e008064 AB - INTRODUCTION: In sub-Saharan Africa, referral hospitals are important sources of key maternal health services, especially during a crisis such as the COVID-19 pandemic. This study prospectively assessed the effect of the COVID-19 pandemic on maternal health service utilisation in six large referral hospitals in Guinea, Nigeria, Tanzania and Uganda during the first year of the pandemic. METHODS: Mixed-methods design combining three data sources: (1) quantitative data based on routine antenatal, childbirth and postnatal care data collected March 2019-February 2021, (2) qualitative data from recurring rounds of semi-structured interviews conducted July 2020-February 2021 with 22 maternity skilled heath personnel exploring their perceptions of service utilisation and (3) timeline data of COVID-19 epidemiology, global, national and hospital-level events. Qualitative and quantitative data were analysed separately, framed based on the timeline analysis and triangulated when reporting. RESULTS: Three periods including a first wave, slow period and second wave were identified. Maternal health service utilisation was lower during the pandemic compared with the prepandemic year in all but one selected referral hospital. During the pandemic, service utilisation was particularly lower during the waves and higher or stable during the slow period. Fear of being infected in hospitals, lack of transportation, and even when available, high cost of transportation and service closures were key reasons affecting utilisation during the waves. However, community perception that the pandemic was over or insinuation by Government of the same appeared to stabilise use of referral hospitals for childbirth. CONCLUSION: Utilisation of maternal health services across the continuum of care varied through the different periods and across countries. In crisis situations such as COVID-19, restrictions and service closures need to be implemented with consideration given to alternative options for women to access and use services. Information on measures put in place for safe hospital use should be communicated to women. CI - (c) Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. FAU - Banke-Thomas, Aduragbemi AU - Banke-Thomas A AUID- ORCID: 0000-0002-4449-0131 AD - School of Human Sciences, University of Greenwich, London, UK a.bankethomas@gre.ac.uk. AD - LSE Health, London School of Economics and Political Science, London, UK. FAU - Semaan, Aline AU - Semaan A AD - Department of Public Health, Institute of Tropical Medicine, Antwerpen, Belgium. FAU - Amongin, Dinah AU - Amongin D AUID- ORCID: 0000-0002-1420-005X AD - Department of Obstetrics and Gynaecology, School of Medicine, College of Health Sciences, Makerere University, Kampala, Uganda. AD - Department of Health Policy Planning and Management, Makerere University School of Public Health, Kampala, Uganda. FAU - Babah, Ochuwa AU - Babah O AD - Department of Obstetrics and Gynaecology, College of Medicine, University of Lagos, Idi-Araba, Lagos, Nigeria. FAU - Dioubate, Nafissatou AU - Dioubate N AD - Centre National de Formation et de Recherche en Sante Rurale de Maferinyah, Forecariah, Guinea. FAU - Kikula, Amani AU - Kikula A AD - Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania, United Republic of. FAU - Nakubulwa, Sarah AU - Nakubulwa S AD - Department of Obstetrics and Gynaecology, School of Medicine, College of Health Sciences, Makerere University, Kampala, Uganda. AD - Kawempe National Referral Hospital, Kampala, Uganda. FAU - Ogein, Olubunmi AU - Ogein O AD - Department of Obstetrics and Gynaecology, College of Medicine, University of Lagos, Idi-Araba, Lagos, Nigeria. FAU - Adroma, Moses AU - Adroma M AD - Department of Obstetrics and Gynaecology, School of Medicine, College of Health Sciences, Makerere University, Kampala, Uganda. FAU - Anzo Adiga, William AU - Anzo Adiga W AD - Mulago Specialized Women and Neonatal Hospital, Kampala, Uganda. FAU - Diallo, Abdourahmane AU - Diallo A AD - Maternite de l'Hopital National Ignace Deen de Conakry, Conakry, Guinea. FAU - Diallo, Lamine AU - Diallo L AD - Maternite de l'Hopital Regional de Mamou, Mamou, Guinea. FAU - Cellou Diallo, Mamadou AU - Cellou Diallo M AD - Maternite de l'Hopital National Ignace Deen de Conakry, Conakry, Guinea. FAU - Maomou, Cece AU - Maomou C AD - Maternite de l'Hopital Regional de Mamou, Mamou, Guinea. FAU - Mtinangi, Nathanael AU - Mtinangi N AD - Department of Obstetrics and Gynaecology, Muhimbili National Hospital, Dar es Salaam, Dar es Salaam, Tanzania, United Republic of. FAU - Sy, Telly AU - Sy T AD - Maternite de l'Hopital National Ignace Deen de Conakry, Conakry, Guinea. FAU - Delvaux, Therese AU - Delvaux T AD - Department of Public Health, Institute of Tropical Medicine, Antwerpen, Belgium. FAU - Afolabi, Bosede Bukola AU - Afolabi BB AUID- ORCID: 0000-0002-7511-7567 AD - Department of Obstetrics and Gynaecology, College of Medicine, University of Lagos, Idi-Araba, Lagos, Nigeria. FAU - Delamou, Alexandre AU - Delamou A AUID- ORCID: 0000-0002-9397-7106 AD - Centre National de Formation et de Recherche en Sante Rurale de Maferinyah, Forecariah, Guinea. AD - Centre d'Excellence Africain pour la Prevention et le Controle des Maladies Transmissibles, Universite Gamal Abdel Nasser de Conakry, Conakry, Guinea. FAU - Nakimuli, Annettee AU - Nakimuli A AD - Department of Obstetrics and Gynaecology, School of Medicine, College of Health Sciences, Makerere University, Kampala, Uganda. FAU - Pembe, Andrea Barnabas AU - Pembe AB AD - Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania, United Republic of. FAU - Benova, Lenka AU - Benova L AD - Department of Public Health, Institute of Tropical Medicine, Antwerpen, Belgium. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - England TA - BMJ Glob Health JT - BMJ global health JID - 101685275 SB - IM MH - *COVID-19 MH - Female MH - Hospitals MH - Humans MH - *Maternal Health Services MH - Pandemics MH - Patient Acceptance of Health Care MH - Pregnancy MH - Referral and Consultation MH - SARS-CoV-2 MH - Tanzania PMC - PMC8852239 OTO - NOTNLM OT - COVID-19 OT - descriptive study OT - health services research OT - maternal health OT - obstetrics COIS- Competing interests: None declared. EDAT- 2022/02/18 06:00 MHDA- 2022/02/25 06:00 PMCR- 2022/02/16 CRDT- 2022/02/17 05:30 PHST- 2021/11/20 00:00 [received] PHST- 2022/01/20 00:00 [accepted] PHST- 2022/02/17 05:30 [entrez] PHST- 2022/02/18 06:00 [pubmed] PHST- 2022/02/25 06:00 [medline] PHST- 2022/02/16 00:00 [pmc-release] AID - bmjgh-2021-008064 [pii] AID - 10.1136/bmjgh-2021-008064 [doi] PST - ppublish SO - BMJ Glob Health. 2022 Feb;7(2):e008064. doi: 10.1136/bmjgh-2021-008064. PMID- 35162443 OWN - NLM STAT- MEDLINE DCOM- 20220217 LR - 20220219 IS - 1660-4601 (Electronic) IS - 1661-7827 (Print) IS - 1660-4601 (Linking) VI - 19 IP - 3 DP - 2022 Jan 27 TI - Rapid Control of a SARS-CoV-2 B.1.617.2 (Delta) Variant COVID-19 Community Outbreak: The Successful Experience in Pingtung County of Taiwan. LID - 10.3390/ijerph19031421 [doi] LID - 1421 AB - The Severe Acute Respiratory Syndrome-associated Coronavirus 2 (SARS-CoV-2) was an outbreak in December, 2019 and rapidly spread to the world. All variants of SARS-CoV-2, including the globally and currently dominant Delta variant (Delta-SARS-CoV-2), caused severe disease and mortality. Among all variants, Delta-SARS-CoV-2 had the highest transmissibility, growth rate, and secondary attack rate than other variants except for the new variant of Omicron that still exists with many unknown effects. In Taiwan, the pandemic Delta-SARS-CoV-2 began in Pingtung from 14 June 2021 and ceased at 11 July 2021. Seventeen patients were infected by Delta-SARS-CoV-2 and 1 person died during the Pingtung outbreak. The Public Health Bureau of Pingtung County Government stopped the Delta-SARS-CoV-2 outbreak within 1 month through measures such as epidemic investigation, rapid gene sequencing, rapidly expanding isolation, expanded screening of the Delta-SARS-CoV-2 antigen for people who lived in regional villages, and indirect intervention, including rapid vaccination, short lockdown period, and travel restrictions. Indirect environmental factors, such as low levels of air pollution, tropic weather in the summer season, and rural areas might have accelerated the ability to control the Delta-SARS-CoV-2 spread. This successful experience might be recommended as a successful formula for the unvaccinated or insufficiently vaccinated regions. FAU - Shy, Cherng-Gueih AU - Shy CG AD - Public Health Bureau, Pingtung County Government, Pingtung, Pingtung County 900, Taiwan. AD - Department of Radiology, Pingtung Christian Hospital, Pingtung, Pingtung County 900, Taiwan. FAU - Lu, Jian-He AU - Lu JH AD - Emerging Compounds Research Center, General Research Service Center, National Pingtung University of Science and Technology, Neipu, Pingtung County 912, Taiwan. FAU - Lin, Hui-Chen AU - Lin HC AD - Kaohsiung-Pingtung Regional Center, Taiwan Centers for Disease Control, Ministry of Health and Welfare, Executive Yuan, Taipei City 10050, Taiwan. FAU - Hung, Min-Nan AU - Hung MN AD - Kaohsiung-Pingtung Regional Center, Taiwan Centers for Disease Control, Ministry of Health and Welfare, Executive Yuan, Taipei City 10050, Taiwan. FAU - Chang, Hsiu-Chun AU - Chang HC AD - Public Health Bureau, Pingtung County Government, Pingtung, Pingtung County 900, Taiwan. FAU - Lu, Meng-Lun AU - Lu ML AD - Public Health Bureau, Pingtung County Government, Pingtung, Pingtung County 900, Taiwan. FAU - Chao, How-Ran AU - Chao HR AUID- ORCID: 0000-0001-6492-6417 AD - Emerging Compounds Research Center, General Research Service Center, National Pingtung University of Science and Technology, Neipu, Pingtung County 912, Taiwan. AD - Department of Environmental Science and Engineering, College of Engineering, National Pingtung University of Science and Technology, Neipu, Pingtung County 912, Taiwan. AD - Institute of Food Safety Management, College of Agriculture, National Pingtung University of Science and Technology, Neipu, Pingtung County 912, Taiwan. AD - School of Dentistry, College of Dental Medicine, Kaohsiung Medical University, Kaohsiung City 807, Taiwan. FAU - Chen, Yao-Shen AU - Chen YS AD - Department of Administration, Kaohsiung Veterans General Hospital, Kaohsiung 813, Taiwan. AD - School of Medicine, National Yang Ming Chiao Tung University, Taipei 112, Taiwan. FAU - Wang, Pi-Sheng AU - Wang PS AD - Hospital and Social Welfare Organizations Administration Commission, Ministry of Health and Welfare, Nangang, Taipei City 11558, Taiwan. LA - eng GR - MOST 109-2221-E-202-MY3/Pingtung County Government/ GR - MOST 110-2222-E-020-001-/The Ministry of Science and Technology, Taiwan/ PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20220127 PL - Switzerland TA - Int J Environ Res Public Health JT - International journal of environmental research and public health JID - 101238455 RN - SARS-CoV-2 variants SB - IM MH - *COVID-19 MH - Communicable Disease Control MH - Disease Outbreaks MH - Humans MH - SARS-CoV-2 MH - Taiwan/epidemiology PMC - PMC8834902 OTO - NOTNLM OT - Delta-variant OT - PCR fast screening OT - Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) OT - quarantine OT - rapid control OT - vaccination COIS- The authors declare no conflict of interest. EDAT- 2022/02/16 06:00 MHDA- 2022/02/19 06:00 PMCR- 2022/01/27 CRDT- 2022/02/15 01:14 PHST- 2021/12/23 00:00 [received] PHST- 2022/01/17 00:00 [revised] PHST- 2022/01/25 00:00 [accepted] PHST- 2022/02/15 01:14 [entrez] PHST- 2022/02/16 06:00 [pubmed] PHST- 2022/02/19 06:00 [medline] PHST- 2022/01/27 00:00 [pmc-release] AID - ijerph19031421 [pii] AID - ijerph-19-01421 [pii] AID - 10.3390/ijerph19031421 [doi] PST - epublish SO - Int J Environ Res Public Health. 2022 Jan 27;19(3):1421. doi: 10.3390/ijerph19031421. PMID- 35156086 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220501 IS - 2673-5059 (Electronic) IS - 2673-5059 (Linking) VI - 2 DP - 2021 TI - Impact of COVID-19 on Gender-Based Violence Prevention and Response Services in Kenya, Uganda, Nigeria, and South Africa: A Cross-Sectional Survey. PG - 780771 LID - 10.3389/fgwh.2021.780771 [doi] LID - 780771 AB - BACKGROUND: Epidemics and other complex emergencies historically have had a disproportionate impact on women and girls, increasing their vulnerability to gender-based violence (GBV). The COVID-19 pandemic has been no different, with reports of rising cases of GBV emerging worldwide. Already a significant problem in Kenya, Uganda, Nigeria, and South Africa, GBV in these countries has been exacerbated by government restrictions intended to contain the spread of COVID-19. The purpose of this study was to understand how the COVID-19 pandemic affected the availability of GBV prevention and response services from the perspective of the organizations that provide them. METHODS: A cross-sectional online survey of people who work in GBV prevention and response in Kenya, Uganda, Nigeria, and South Africa was administered from July to October 2020. A convenience sample was identified through web search, contacts of in-country consultants, and relevant listservs and technical working groups. Descriptive analyses were completed using SPSS. RESULTS: A total of 187 respondents completed the survey. Nearly all (98.9%) survey respondents reported that COVID-19 impacted their work. The majority (77.9%) stated that work decreased due to government restrictions or GBV services being deemed non-essential. The types of service most impacted were community-based prevention, shelters, and legal services. Survey respondents overwhelmingly agreed (99.3%) that COVID-19 impacted GBV prevalence and identified adolescents and women with disabilities as particularly vulnerable groups. CONCLUSIONS: GBV prevention and response services in Kenya, Uganda, Nigeria, and South Africa were highly impacted by the COVID-19 pandemic, largely due to government restrictions and the failure of governments to deem GBV services as essential. Preparedness for future crises should ensure that GBV is adequately prioritized in the initial response in order to maintain service availability with special attention paid to at-risk populations. CI - Copyright (c) 2022 Roy, Bukuluki, Casey, Jagun, John, Mabhena, Mwangi and McGovern. FAU - Roy, Charlotte M AU - Roy CM AD - Global Health Justice and Governance Program, Heilbrunn Department of Population and Family Health, Columbia University Mailman School of Public Health, New York, NY, United States. AD - Department of Emergency Medicine, Columbia University Irving Medical Center, New York, NY, United States. FAU - Bukuluki, Paul AU - Bukuluki P AD - Department of Social Work and Social Administration, School of Social Sciences, Makerere University, Kampala, Uganda. FAU - Casey, Sara E AU - Casey SE AD - Global Health Justice and Governance Program, Heilbrunn Department of Population and Family Health, Columbia University Mailman School of Public Health, New York, NY, United States. FAU - Jagun, Moriam O AU - Jagun MO AD - Center for Bridging Health Gaps, Lagos, Nigeria. FAU - John, Neetu A AU - John NA AD - Global Health Justice and Governance Program, Heilbrunn Department of Population and Family Health, Columbia University Mailman School of Public Health, New York, NY, United States. FAU - Mabhena, Nicoletta AU - Mabhena N AD - ResearchLinkME, Johannesburg, South Africa. FAU - Mwangi, Mary AU - Mwangi M AD - Independent Consultant, Nairobi, Kenya. FAU - McGovern, Terry AU - McGovern T AD - Global Health Justice and Governance Program, Heilbrunn Department of Population and Family Health, Columbia University Mailman School of Public Health, New York, NY, United States. LA - eng PT - Journal Article DEP - 20220127 PL - Switzerland TA - Front Glob Womens Health JT - Frontiers in global women's health JID - 101776281 PMC - PMC8829509 OTO - NOTNLM OT - COVID- 19 OT - emergency preparedness OT - gender equity OT - gender-based violence (GBV) OT - intimate partner violence (IPV) OT - sub-Saharan Africa COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2022/02/15 06:00 MHDA- 2022/02/15 06:01 PMCR- 2022/01/27 CRDT- 2022/02/14 05:37 PHST- 2021/09/21 00:00 [received] PHST- 2021/12/22 00:00 [accepted] PHST- 2022/02/14 05:37 [entrez] PHST- 2022/02/15 06:00 [pubmed] PHST- 2022/02/15 06:01 [medline] PHST- 2022/01/27 00:00 [pmc-release] AID - 10.3389/fgwh.2021.780771 [doi] PST - epublish SO - Front Glob Womens Health. 2022 Jan 27;2:780771. doi: 10.3389/fgwh.2021.780771. eCollection 2021. PMID- 35155994 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220501 IS - 2564-1891 (Electronic) IS - 2564-1891 (Linking) VI - 2 IP - 1 DP - 2022 Jan-Jun TI - Misinformation About and Interest in Chlorine Dioxide During the COVID-19 Pandemic in Mexico Identified Using Google Trends Data: Infodemiology Study. PG - e29894 LID - 10.2196/29894 [doi] LID - e29894 AB - BACKGROUND: The COVID-19 pandemic has prompted the increasing popularity of several emerging therapies or preventives that lack scientific evidence or go against medical directives. One such therapy involves the consumption of chlorine dioxide, which is commonly used in the cleaning industry and is available commercially as a mineral solution. This substance has been promoted as a preventive or treatment agent for several diseases, including SARS-CoV-2 infection. As interest in chlorine dioxide has grown since the start of the pandemic, health agencies, institutions, and organizations worldwide have tried to discourage and restrict the consumption of this substance. OBJECTIVE: The aim of this study is to analyze search engine trends in Mexico to evaluate changes in public interest in chlorine dioxide since the beginning of the COVID-19 pandemic. METHODS: We retrieved public query data for the Spanish equivalent of the term "chlorine dioxide" from the Google Trends platform. The location was set to Mexico, and the time frame was from March 3, 2019, to February 21, 2021. A descriptive analysis was performed. The Kruskal-Wallis and Dunn tests were used to identify significant changes in search volumes for this term between four consecutive time periods, each of 13 weeks, from March 1, 2020, to February 27, 2021. RESULTS: From the start of the pandemic in Mexico (February 2020), an upward trend was observed in the number of searches compared with that in 2019. Maximum volume trends were recorded during the week of July 19-25, 2020. The search volumes declined between September and November 2020, but another peak was registered in December 2020 through February 2021, which reached a maximum value on January 10. Percentage change from the first to the fourth time periods was +312.85, -71.35, and +228.18, respectively. Pairwise comparisons using the Kruskal-Wallis and Dunn tests showed significant differences between the four periods (P<.001). CONCLUSIONS: Misinformation is a public health risk because it can lower compliance with the recommended measures and encourage the use of therapies that have not been proven safe. The ingestion of chlorine dioxide presents a danger to the population, and several adverse reactions have been reported. Programs should be implemented to direct those interested in this substance to accurate medical information. CI - (c)Jonathan Matias Chejfec-Ciociano, Juan Pablo Martinez-Herrera, Alexa Darianna Parra-Guerra, Ricardo Chejfec, Francisco Jose Barbosa-Camacho, Juan Carlos Ibarrola-Pena, Gabino Cervantes-Guevara, Guillermo Alonso Cervantes-Cardona, Clotilde Fuentes-Orozco, Enrique Cervantes-Perez, Benjamin Garcia-Reyna, Alejandro Gonzalez-Ojeda. Originally published in JMIR Infodemiology (https://infodemiology.jmir.org), 27.01.2022. FAU - Chejfec-Ciociano, Jonathan Matias AU - Chejfec-Ciociano JM AUID- ORCID: 0000-0003-0205-6844 AD - Unidad de Investigacion Biomedica 02 Hospital de Especialidades del Centro Medico Nacional de Occidente Instituto Mexicano del Seguro Social Guadalajara Mexico. FAU - Martinez-Herrera, Juan Pablo AU - Martinez-Herrera JP AUID- ORCID: 0000-0003-2243-9391 AD - Unidad de Investigacion Biomedica 02 Hospital de Especialidades del Centro Medico Nacional de Occidente Instituto Mexicano del Seguro Social Guadalajara Mexico. FAU - Parra-Guerra, Alexa Darianna AU - Parra-Guerra AD AUID- ORCID: 0000-0001-5833-9849 AD - Unidad de Investigacion Biomedica 02 Hospital de Especialidades del Centro Medico Nacional de Occidente Instituto Mexicano del Seguro Social Guadalajara Mexico. FAU - Chejfec, Ricardo AU - Chejfec R AUID- ORCID: 0000-0002-9477-1943 AD - Max Bell School of Public Policy McGill University Montreal, QC Canada. FAU - Barbosa-Camacho, Francisco Jose AU - Barbosa-Camacho FJ AUID- ORCID: 0000-0002-3897-2767 AD - Unidad de Investigacion Biomedica 02 Hospital de Especialidades del Centro Medico Nacional de Occidente Instituto Mexicano del Seguro Social Guadalajara Mexico. FAU - Ibarrola-Pena, Juan Carlos AU - Ibarrola-Pena JC AUID- ORCID: 0000-0003-4271-7512 AD - Unidad de Investigacion Biomedica 02 Hospital de Especialidades del Centro Medico Nacional de Occidente Instituto Mexicano del Seguro Social Guadalajara Mexico. FAU - Cervantes-Guevara, Gabino AU - Cervantes-Guevara G AUID- ORCID: 0000-0001-6249-4737 AD - Hospital Civil de Guadalajara "Fray Antonio Alcalde" Universidad de Guadalajara Guadalajara Mexico. AD - Departamento de Bienestar y Desarrollo Sustentable Centro Universitario del Norte Universidad de Guadalajara Colotlan Mexico. FAU - Cervantes-Cardona, Guillermo Alonso AU - Cervantes-Cardona GA AUID- ORCID: 0000-0003-0180-6201 AD - Departamento de Disciplinas Filosofico, Metodologicas e Instrumentales Centro Universitario de Ciencias de la Salud Universidad de Guadalajara Guadalajara Mexico. FAU - Fuentes-Orozco, Clotilde AU - Fuentes-Orozco C AUID- ORCID: 0000-0001-6230-8359 AD - Unidad de Investigacion Biomedica 02 Hospital de Especialidades del Centro Medico Nacional de Occidente Instituto Mexicano del Seguro Social Guadalajara Mexico. FAU - Cervantes-Perez, Enrique AU - Cervantes-Perez E AUID- ORCID: 0000-0002-6333-9082 AD - Departamento de Nutriologia Clinica Instituto Nacional de Ciencias Medicas y Nutricion "Salvador Zubiran" Ciudad de Mexico Mexico. FAU - Garcia-Reyna, Benjamin AU - Garcia-Reyna B AUID- ORCID: 0000-0001-8649-9831 AD - Centro Universitario del Norte Universidad de Guadalajara Colotlan Mexico. FAU - Gonzalez-Ojeda, Alejandro AU - Gonzalez-Ojeda A AUID- ORCID: 0000-0003-2935-8703 AD - Unidad de Investigacion Biomedica 02 Hospital de Especialidades del Centro Medico Nacional de Occidente Instituto Mexicano del Seguro Social Guadalajara Mexico. LA - eng PT - Journal Article DEP - 20220127 PL - Canada TA - JMIR Infodemiology JT - JMIR infodemiology JID - 9918249014806676 PMC - PMC8805460 OTO - NOTNLM OT - COVID-19 OT - COVID-19 misinformation OT - Google Trends OT - chlorine dioxide OT - coronavirus OT - digital epidemiology OT - infodemiology OT - internet OT - internet behavior OT - mHealth OT - mobile health OT - pandemic OT - public health surveillance OT - tele-epidemiology COIS- Conflicts of Interest: None declared. EDAT- 2022/02/15 06:00 MHDA- 2022/02/15 06:01 PMCR- 2022/01/27 CRDT- 2022/02/14 05:37 PHST- 2021/04/24 00:00 [received] PHST- 2021/06/01 00:00 [revised] PHST- 2021/12/07 00:00 [accepted] PHST- 2022/02/14 05:37 [entrez] PHST- 2022/02/15 06:00 [pubmed] PHST- 2022/02/15 06:01 [medline] PHST- 2022/01/27 00:00 [pmc-release] AID - v2i1e29894 [pii] AID - 10.2196/29894 [doi] PST - epublish SO - JMIR Infodemiology. 2022 Jan 27;2(1):e29894. doi: 10.2196/29894. eCollection 2022 Jan-Jun. PMID- 35155844 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230612 IS - 2452-0918 (Print) IS - 2213-3984 (Electronic) IS - 2213-3984 (Linking) VI - 14 DP - 2022 Mar-Apr TI - Incidence and severity of SARS-CoV-2 virus post COVID-19 vaccination: A cross-sectional study in India. PG - 100983 LID - 10.1016/j.cegh.2022.100983 [doi] AB - INTRODUCTION: Several sociodemographic variables, including ethnic inequality, have been identified as potentially influencing the uptake of COVID-19 vaccinations. To develop herd immunity against COVID-19, at least 70-85% of the population must be vaccinated. As the situation with COVID-19 changes, the public's perception keeps fluctuating. We designed a survey to determine the prevalence of vaccinated individuals and the rate of infectivity post-vaccination. We also aimed to study the clinical manifestations and infectivity of the SARS-CoV-2 virus post-vaccination. MATERIALS AND METHODS: A cross-sectional study was conducted from May 10, 2021 to July 10, 2021 across India through a pre-tested validated semi-structured self-administered electronic questionnaire, to the study subjects with objectives explained and the confidentiality of the data and results had been assured. The questionnaires were prepared using Google forms and the link was sent across social media platforms such as WhatsApp, Facebook, and various social platforms where people are actively engaged following the restrictions and protocols of social distancing. General demographic data, followed by their lifestyle and comorbid conditions, and data on their vaccination, infectivity, and side effects were collected. RESULTS: We included 2334 participants in the study, of which the majority of the study participants were in the age group of 25-34 years (38.6%). 1729 were vaccinated individuals of which 80.7% had received Covishield and 17.8% had received Covaxin. Around 61.1% have received both doses among 1729 vaccinated individuals and 38.9% had received only one dose of vaccine. The majority of the fully vaccinated individuals had a gap of 4-5 weeks for the second dose (37.1%) followed by 5-6 weeks (11.2%). Post-vaccination 50.8% had experienced muscle pain, 46% had experienced fatigue, 36.5% weakness, and 12.3% back pain. Among vaccinated 26% turned out to be COVID-19 positive and 44.5% non-vaccinated got infected. The odds of infection among non -vaccinated individuals was 2.27 times higher than vaccinated individuals. Individuals who encountered the viral antigen for the second time experienced either through vaccination or infection demonstrated exaggerated inflammatory response which is explained by the antibody-dependent enhancement phenomenon without life-threatening complications. CONCLUSION: Although more than 50% of the vaccinated individuals experienced some form of musculoskeletal side effects, we noted a high acceptance rate (74%) of vaccination among the participants. The vaccinated individuals were two times safer from infection compared to the non-vaccinated individuals. CI - (c) 2022 The Authors. FAU - Selvaraj, Preethi AU - Selvaraj P AD - Research Associate, Orthopaedic Research Group, Coimbatore, Tamil Nadu, India. AD - Department of Community Medicine, SRM Medical College Hospital and Research Centre, SRM Institute of Science and Technology, Chengalpattu, Tamil Nadu, India. FAU - Muthu, Sathish AU - Muthu S AD - Research Associate, Orthopaedic Research Group, Coimbatore, Tamil Nadu, India. AD - Department of Orthopaedics, Government Medical College and Hospital, Dindigul, Tamil Nadu, India. FAU - Jeyaraman, Naveen AU - Jeyaraman N AD - Research Associate, Orthopaedic Research Group, Coimbatore, Tamil Nadu, India. AD - Fellow in Arthroplasty, Department of Orthopaedics, Atlas Hospitals, Tiruchirappalli, Tamil Nadu, India. FAU - Prajwal, Gollahalli Shivashankar AU - Prajwal GS AD - Research Associate, Orthopaedic Research Group, Coimbatore, Tamil Nadu, India. AD - Fellow in Spine Surgery, Department of Orthopaedics, Mallika Spine Centre, Guntur, Andhra Pradesh, India. FAU - Jeyaraman, Madhan AU - Jeyaraman M AD - Research Associate, Orthopaedic Research Group, Coimbatore, Tamil Nadu, India. AD - Department of Orthopaedics, Faculty of Medicine - Sri Lalithambigai Medical College and Hospital, Dr MGR Educational and Research Institute, Chennai, Tamil Nadu, India. LA - eng PT - Journal Article DEP - 20220209 PL - India TA - Clin Epidemiol Glob Health JT - Clinical epidemiology and global health JID - 101608821 PMC - PMC8824716 OTO - NOTNLM OT - COVID-19 OT - Infectivity OT - SARS-CoV-2 virus OT - Side-effects OT - Vaccination COIS- Nil. EDAT- 2022/02/15 06:00 MHDA- 2022/02/15 06:01 PMCR- 2022/02/09 CRDT- 2022/02/14 05:36 PHST- 2021/12/17 00:00 [received] PHST- 2022/01/28 00:00 [revised] PHST- 2022/02/03 00:00 [accepted] PHST- 2022/02/15 06:00 [pubmed] PHST- 2022/02/15 06:01 [medline] PHST- 2022/02/14 05:36 [entrez] PHST- 2022/02/09 00:00 [pmc-release] AID - S2213-3984(22)00023-9 [pii] AID - 100983 [pii] AID - 10.1016/j.cegh.2022.100983 [doi] PST - ppublish SO - Clin Epidemiol Glob Health. 2022 Mar-Apr;14:100983. doi: 10.1016/j.cegh.2022.100983. Epub 2022 Feb 9. PMID- 35154584 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220501 IS - 2008-126X (Print) IS - 2228-7442 (Electronic) IS - 2008-126X (Linking) VI - 12 IP - 4 DP - 2021 Jul-Aug TI - Infectious Agents and Stroke: A Systematic Review. PG - 427-440 LID - 10.32598/bcn.2021.1324.2 [doi] AB - INTRODUCTION: A major cause of injury and the second cause of death worldwide is stroke. Among several infectious agents considered as the risk factor of stroke, some pathogens demonstrated stronger robust associations with stroke. Proposing an accurate correlation between infectious microorganisms and stroke provides valuable information for early intervention and control of the infections. METHODS: In this study, we searched the literature using the Web of Science, PMC/Medline via PubMed, and Scopus databases up to July 2018 without time and language restrictions. After quality assessment, 16 articles were included in the study. The whole data extraction process was independently conducted by two reviewers. RESULTS: Based on the results of the studies, viruses, such as Hepatitis C virus (HCV), Hepatitis B virus (HBV), Human Immunodeficiency Virus (HIV), Herpes Simplex Virus Type-1, 2 (HSV-1, 2), Varicella-Zoster Virus (VZV or Chickenpox), and West Nile virus (WNV) seem to be common causes of ischemic stroke. Moreover, the association of other microbial categories, such as Streptococcus mutans (in bacteria), Toxocara spp. and Toxoplasma gondii (in parasites), and Rhizopus sp. (in fungi) with stroke was reported. CONCLUSION: Considering the adverse role of the above-mentioned microorganisms, it is necessary to implement some preventive measures for stroke treatment. CI - Copyright(c) 2021 Iranian Neuroscience Society. FAU - Saberi, Alia AU - Saberi A AUID- ORCID: 0000-0002-7665-5199 AD - Department of Neurology, Neuroscience Research Center, Poursina Hospital, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran. FAU - Akhondzadeh, Shahin AU - Akhondzadeh S AUID- ORCID: 0000-0002-2277-5101 AD - Psychiatric Research Center, Roozbeh Hospital, Tehran University of Medical Sciences, Tehran, Iran. FAU - Kazemi, Samira AU - Kazemi S AUID- ORCID: 0000-0002-8457-3679 AD - Department of Epidemiology, School of Public Health, Iran University of Medical Sciences, Tehran, Iran. FAU - Kazemi, Samaneh AU - Kazemi S AUID- ORCID: 0000-0002-0663-8764 AD - Deputy of Research and Technology, Guilan University of Medical Sciences, Rasht, Iran. LA - eng PT - Journal Article PT - Review DEP - 20210701 PL - Iran TA - Basic Clin Neurosci JT - Basic and clinical neuroscience JID - 101575211 PMC - PMC8817172 OTO - NOTNLM OT - Bacteria OT - Fungi OT - Infection OT - Stroke OT - Viruses COIS- Conflict of interest The authors declared no conflicts of interest. EDAT- 2022/02/15 06:00 MHDA- 2022/02/15 06:01 PMCR- 2021/07/01 CRDT- 2022/02/14 05:32 PHST- 2019/06/09 00:00 [received] PHST- 2020/04/25 00:00 [revised] PHST- 2021/05/30 00:00 [accepted] PHST- 2022/02/14 05:32 [entrez] PHST- 2022/02/15 06:00 [pubmed] PHST- 2022/02/15 06:01 [medline] PHST- 2021/07/01 00:00 [pmc-release] AID - BCN-12-427 [pii] AID - 10.32598/bcn.2021.1324.2 [doi] PST - ppublish SO - Basic Clin Neurosci. 2021 Jul-Aug;12(4):427-440. doi: 10.32598/bcn.2021.1324.2. Epub 2021 Jul 1. PMID- 35147688 OWN - NLM STAT- MEDLINE DCOM- 20220221 LR - 20221207 IS - 2574-3805 (Electronic) IS - 2574-3805 (Linking) VI - 5 IP - 2 DP - 2022 Feb 1 TI - Analysis of COVID-19 Risk Following a Ring Vaccination Intervention to Address SARS-CoV-2 Alpha Variant Transmission in Montreal, Canada. PG - e2147042 LID - 10.1001/jamanetworkopen.2021.47042 [doi] LID - e2147042 AB - IMPORTANCE: Given limited COVID-19 vaccine availability early in the pandemic, optimizing immunization strategies was of paramount importance. Ring vaccination has been used successfully to control transmission of other airborne respiratory viruses. OBJECTIVE: To assess the association of a ring vaccination intervention on COVID-19 spread in the initial epicenter of SARS-CoV-2 Alpha variant transmission in Montreal, Canada. DESIGN, SETTING, AND PARTICIPANTS: This cohort study compared COVID-19 daily disease risk in 3 population-based groups of neighborhoods in Montreal, Canada, defined by their intervention-specific vaccine coverage at the neighborhood level: the primary intervention group (500 or more vaccinated persons per 10 000 persons), secondary intervention group (95 to 499), and control group (0 to 50). The groups were compared within each of 3 time periods: before intervention (December 1, 2020, to March 16, 2021), during and immediately after intervention (March 17 to April 17, 2021), and 3 weeks after the intervention midpoint (April 18 to July 18, 2021). Data were analyzed between June 2021 and November 2021. EXPOSURES: Vaccination targeted parents and teachers of children attending the 32 schools and 48 childcare centers in 2 adjacent neighborhoods with highest local transmission (case counts) of Alpha variant shortly after its introduction. Participants were invited to receive 1 dose of mRNA vaccine between March 22 and April 9, 2021 (before vaccine was available to these age groups). MAIN OUTCOMES AND MEASURES: COVID-19 risk in 3 groups of neighborhoods based on intervention-specific vaccine coverage. RESULTS: A total of 11 794 residents were immunized, with a mean (SD) age of 43 (8) years (range, 16-93 years); 5766 participants (48.9%) lived in a targeted neighborhood, and 9784 (83.0%) were parents. COVID-19 risk in the primary intervention group was significantly higher than in the control group before (unadjusted risk ratio [RR], 1.58; 95% CI 1.52-1.65) and during (RR, 1.63; 95% CI, 1.52-1.76) intervention, and reached a level similar to the other groups in the weeks following the intervention (RR, 1.03; 95% CI, 0.94-1.12). A similar trend was observed when restricting to SARS-CoV-2 variants and persons aged 30 to 59 years (before: RR, 1.72; 95% CI, 1.63-1.83 vs after: RR, 1.01; 95% CI, 0.88-1.17). CONCLUSIONS AND RELEVANCE: Our findings show that ring vaccination was associated with a reduction in COVID-19 risk in areas with high local transmission of Alpha variant shortly after its introduction. Ring vaccination may be considered as an adjunct to mass immunization to control transmission in specific areas, based on local epidemiology. FAU - Perinet, Simone AU - Perinet S AD - Direction regionale de sante publique de Montreal, Montreal, Quebec, Canada. AD - Canadian Field Epidemiology Program, Public Health Agency of Canada, Canada. FAU - Cadieux, Genevieve AU - Cadieux G AD - Direction regionale de sante publique de Montreal, Montreal, Quebec, Canada. AD - Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Quebec, Canada. FAU - Mercure, Sarah-Amelie AU - Mercure SA AD - Direction regionale de sante publique de Montreal, Montreal, Quebec, Canada. FAU - Drouin, Mylene AU - Drouin M AD - Direction regionale de sante publique de Montreal, Montreal, Quebec, Canada. AD - Ecole de sante publique, Universite de Montreal, Montreal, Quebec, Canada. FAU - Allard, Robert AU - Allard R AD - Direction regionale de sante publique de Montreal, Montreal, Quebec, Canada. AD - Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Quebec, Canada. LA - eng PT - Journal Article DEP - 20220201 PL - United States TA - JAMA Netw Open JT - JAMA network open JID - 101729235 RN - SARS-CoV-2 variants SB - IM MH - Adolescent MH - Adult MH - Aged MH - Aged, 80 and over MH - COVID-19/epidemiology/*transmission MH - Child MH - Cohort Studies MH - Female MH - Humans MH - Male MH - Mass Vaccination/methods/standards/statistics & numerical data MH - Middle Aged MH - Odds Ratio MH - Population Surveillance/methods MH - Quebec/epidemiology MH - Risk Assessment/*methods/statistics & numerical data MH - SARS-CoV-2/drug effects/pathogenicity MH - Vaccination/methods/*standards/statistics & numerical data MH - *COVID-19 Drug Treatment PMC - PMC8837915 COIS- Conflict of Interest Disclosures: Drs Cadieux, Mercure, Allard, and Drouin are employees of the Direction regionale de sante publique (DRSP) de Montreal. Ms Perinet is a Canadian Field Epidemiology Program fellow who was completing her 2-year training program at the Montreal DRSP at the time of publication. EDAT- 2022/02/12 06:00 MHDA- 2022/02/22 06:00 PMCR- 2022/02/11 CRDT- 2022/02/11 12:12 PHST- 2022/02/11 12:12 [entrez] PHST- 2022/02/12 06:00 [pubmed] PHST- 2022/02/22 06:00 [medline] PHST- 2022/02/11 00:00 [pmc-release] AID - 2788978 [pii] AID - zoi211296 [pii] AID - 10.1001/jamanetworkopen.2021.47042 [doi] PST - epublish SO - JAMA Netw Open. 2022 Feb 1;5(2):e2147042. doi: 10.1001/jamanetworkopen.2021.47042. PMID- 35142619 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220329 IS - 2368-7959 (Print) IS - 2368-7959 (Electronic) IS - 2368-7959 (Linking) VI - 9 IP - 2 DP - 2022 Feb 10 TI - Depressive Symptoms and Anxiety During the COVID-19 Pandemic: Large, Longitudinal, Cross-sectional Survey. PG - e33585 LID - 10.2196/33585 [doi] LID - e33585 AB - BACKGROUND: The COVID-19 pandemic has influenced the mental health of millions across the globe. Understanding factors associated with depressive symptoms and anxiety across 12 months of the pandemic can help identify groups at higher risk and psychological processes that can be targeted to mitigate the long-term mental health impact of the pandemic. OBJECTIVE: This study aims to determine sociodemographic features, COVID-19-specific factors, and general psychological variables associated with depressive symptoms and anxiety over 12 months of the pandemic. METHODS: Nationwide, cross-sectional electronic surveys were implemented in May (n=14,636), July (n=14,936), October (n=14,946), and December (n=15,265) 2020 and March/April 2021 (n=14,557) in the United States. Survey results were weighted to be representative of the US population. The samples were drawn from a market research platform, with a 69% cooperation rate. Surveys assessed depressive symptoms in the past 2 weeks and anxiety in the past week, as well as sociodemographic features; COVID-19 restriction stress, worry, perceived risk, coping strategies, and exposure; intolerance of uncertainty; and loneliness. RESULTS: Across 12 months, an average of 24% of respondents reported moderate-to-severe depressive symptoms and 32% reported moderate-to-severe anxiety. Of the sociodemographic variables, age was most consistently associated with depressive symptoms and anxiety, with younger adults more likely to report higher levels of those outcomes. Intolerance of uncertainty and loneliness were consistently and strongly associated with the outcomes. Of the COVID-19-specific variables, stress from COVID-19 restrictions, worry about COVID-19, coping behaviors, and having COVID-19 were associated with a higher likelihood of depressive symptoms and anxiety. CONCLUSIONS: Depressive symptoms and anxiety were high in younger adults, adults who reported restriction stress or worry about COVID-19 or who had had COVID-19, and those with intolerance of uncertainty and loneliness. Symptom monitoring as well as early and accessible intervention are recommended. CI - (c)James J MacDonald, Ryan Baxter-King, Lynn Vavreck, Arash Naeim, Neil Wenger, Karen Sepucha, Annette L Stanton. Originally published in JMIR Mental Health (https://mental.jmir.org), 10.02.2022. FAU - MacDonald, James J AU - MacDonald JJ AUID- ORCID: 0000-0003-3939-2307 AD - Department of Psychology, University of California, Los Angeles, Los Angeles, CA, United States. FAU - Baxter-King, Ryan AU - Baxter-King R AUID- ORCID: 0000-0002-2772-7301 AD - Department of Political Science, College of Letters and Sciences, University of California, Los Angeles, Los Angeles, CA, United States. FAU - Vavreck, Lynn AU - Vavreck L AUID- ORCID: 0000-0003-4582-7960 AD - Department of Political Science, College of Letters and Sciences, University of California, Los Angeles, Los Angeles, CA, United States. AD - Department of Communication, College of Letters and Sciences, University of California, Los Angeles, Los Angeles, CA, United States. FAU - Naeim, Arash AU - Naeim A AUID- ORCID: 0000-0001-6830-5933 AD - Center for SMART Health, Clinical and Translational Science Institute, University of California, Los Angeles, Los Angeles, CA, United States. FAU - Wenger, Neil AU - Wenger N AUID- ORCID: 0000-0002-9884-3967 AD - Division of General Internal Medicine and Health Sciences Research, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, United States. FAU - Sepucha, Karen AU - Sepucha K AUID- ORCID: 0000-0002-3762-3880 AD - Health Decision Sciences Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States. FAU - Stanton, Annette L AU - Stanton AL AUID- ORCID: 0000-0001-9021-2549 AD - Department of Psychology, University of California, Los Angeles, Los Angeles, CA, United States. AD - Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, Los Angeles, CA, United States. LA - eng PT - Journal Article DEP - 20220210 PL - Canada TA - JMIR Ment Health JT - JMIR mental health JID - 101658926 PMC - PMC8834874 OTO - NOTNLM OT - COVID-19 OT - anxiety OT - depression OT - health intervention OT - mental health OT - pandemic OT - psychological variables OT - public health OT - symptom monitoring OT - younger adults COIS- Conflicts of Interest: None declared. EDAT- 2022/02/11 06:00 MHDA- 2022/02/11 06:01 PMCR- 2022/02/10 CRDT- 2022/02/10 12:13 PHST- 2021/09/14 00:00 [received] PHST- 2021/12/24 00:00 [accepted] PHST- 2021/11/26 00:00 [revised] PHST- 2022/02/10 12:13 [entrez] PHST- 2022/02/11 06:00 [pubmed] PHST- 2022/02/11 06:01 [medline] PHST- 2022/02/10 00:00 [pmc-release] AID - v9i2e33585 [pii] AID - 10.2196/33585 [doi] PST - epublish SO - JMIR Ment Health. 2022 Feb 10;9(2):e33585. doi: 10.2196/33585. PMID- 35138402 OWN - NLM STAT- MEDLINE DCOM- 20220221 LR - 20221207 IS - 2574-3805 (Electronic) IS - 2574-3805 (Linking) VI - 5 IP - 2 DP - 2022 Feb 1 TI - Efficacy of Niclosamide vs Placebo in SARS-CoV-2 Respiratory Viral Clearance, Viral Shedding, and Duration of Symptoms Among Patients With Mild to Moderate COVID-19: A Phase 2 Randomized Clinical Trial. PG - e2144942 LID - 10.1001/jamanetworkopen.2021.44942 [doi] LID - e2144942 AB - IMPORTANCE: Oral anthelmintic niclosamide has potent in vitro antiviral activity against SARS-CoV-2. Repurposed niclosamide could be a safe and efficacious COVID-19 therapy. OBJECTIVE: To investigate whether niclosamide decreased SARS-CoV-2 shedding and duration of symptoms among patients with mild to moderate COVID-19. DESIGN, SETTING, AND PARTICIPANTS: This randomized, placebo-controlled clinical trial enrolled individuals testing positive for SARS-CoV-2 by polymerase chain reaction with mild to moderate symptoms of COVID. All trial participants, investigators, staff, and laboratory personnel were kept blind to participant assignments. Enrollment was among individuals reporting at Tufts Medical Center and Wellforce Network in Massachusetts for outpatient COVID-19 testing. The trial opened to accrual on October 1, 2020; the last participant enrolled on April 20, 2021. Trial exclusion criteria included hospitalization at time of enrollment or use of any experimental treatment for COVID-19, including vaccination. Enrollment was stopped before attaining the planned sample size when COVID-19 diagnoses decreased precipitously in Massachusetts. Data were analyzed from July through September 2021. INTERVENTIONS: In addition to receiving current standard of care, participants were randomly assigned on a 1:1 basis to receive niclosamide 2 g by mouth daily for 7 days or identically labeled placebo at the same dosing schedule. MAIN OUTCOMES AND MEASURES: Oropharyngeal and fecal samples were self-collected for viral shedding measured by reverse-transcriptase-polymerase-chain-reaction on days 3, 7, 10, and 14, and an additional fecal sample was collected on day 21. A telehealth platform was developed to conduct remote study visits, monitor symptoms, and coordinate sample collection via couriers. The primary end point was the proportion of participants with viral clearance in respiratory samples at day 3 based on the intention-to-treat sample. Mean times to viral clearance and symptom resolution were calculated as restricted mean survival times and accounted for censored observations. RESULTS: Among 73 participants, 36 individuals were enrolled and randomized to niclosamide and 37 individuals to placebo. Participant characteristics were similar across treatment groups; among 34 patients receiving placebo and 33 patients receiving niclosamide in the intention-to-treat sample, mean (SD) age was 36.0 (13.3) years vs 36.8 (12.9) years and there were 21 (61.8%) men vs 20 (60.6%) men. The overall mean (SD) age was 36.4 (13.0) years. For the primary end point, 66.67% (95% CI, 50.74% to 81.81%) of participants receiving niclosamide and 55.88% (95% CI, 40.27% to 72.73%) of participants receiving placebo had oropharyngeal SARS-CoV-2 clearance at day 3 (P = .37). Among 63 participants with symptoms, niclosamide did not significantly shorten symptom duration, which was 12.01 (95% CI, 8.82 to 15.2) days in the niclosamide group vs 14.61 (95% CI, 11.25 to 17.96) days in the placebo group (mean difference, -2.6 [95% CI, -7.23 to 2.03] days). Niclosamide was well-tolerated; the most commonly reported adverse events in the placebo and niclosamide groups were headaches (11 patients [32.4%] vs 7 patients [21.2%]; P = .31) and cough (8 patients [23.5%] vs 7 patients [21.2%]; P = .82). CONCLUSIONS AND RELEVANCE: In this randomized clinical trial, there was no significant difference in oropharyngeal clearance of SARS-CoV-2 at day 3 between placebo and niclosamide groups. Confirmation in larger studies is warranted. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04399356. FAU - Cairns, Dana M AU - Cairns DM AD - Department of Biomedical Engineering, Tufts University, Medford, Massachusetts. FAU - Dulko, Dorothy AU - Dulko D AD - Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, Massachusetts. AD - Tufts Clinical and Translational Science Institute, Tufts University, Boston, Massachusetts. FAU - Griffiths, Jeffrey K AU - Griffiths JK AD - Department of Public Health and Community Medicine, Tufts University School of Medicine, Boston, Massachusetts. AD - Division of Geographic Medicine and Infectious Diseases, Tufts Medical Center, Boston, Massachusetts. FAU - Golan, Yoav AU - Golan Y AD - Tufts Clinical and Translational Science Institute, Tufts University, Boston, Massachusetts. AD - Division of Geographic Medicine and Infectious Diseases, Tufts Medical Center, Boston, Massachusetts. FAU - Cohen, Theodora AU - Cohen T AD - Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, Massachusetts. FAU - Trinquart, Ludovic AU - Trinquart L AD - Tufts Clinical and Translational Science Institute, Tufts University, Boston, Massachusetts. FAU - Price, Lori Lyn AU - Price LL AD - Tufts Clinical and Translational Science Institute, Tufts University, Boston, Massachusetts. FAU - Beaulac, Kirthana R AU - Beaulac KR AD - Department of Pharmacy, Emerson Hospital, Concord, Massachusetts. FAU - Selker, Harry P AU - Selker HP AD - Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, Massachusetts. AD - Tufts Clinical and Translational Science Institute, Tufts University, Boston, Massachusetts. LA - eng SI - ClinicalTrials.gov/NCT04399356 GR - UL1 TR002544/TR/NCATS NIH HHS/United States PT - Journal Article PT - Randomized Controlled Trial PT - Research Support, N.I.H., Extramural DEP - 20220201 PL - United States TA - JAMA Netw Open JT - JAMA network open JID - 101729235 RN - 0 (Antiviral Agents) RN - 8KK8CQ2K8G (Niclosamide) SB - IM MH - Adult MH - Antiviral Agents/*therapeutic use MH - *Drug Repositioning MH - Female MH - Humans MH - Male MH - Massachusetts MH - Middle Aged MH - Niclosamide/*therapeutic use MH - SARS-CoV-2/*drug effects MH - Symptom Assessment MH - Treatment Outcome MH - Virus Shedding/*drug effects MH - *COVID-19 Drug Treatment PMC - PMC8829666 COIS- Conflict of Interest Disclosures: Dr Golan reported receiving personal fees from Pfizer, Merck, and Appili Therapeutics outside the submitted work. Dr Beaulac reported receiving personal fees from Astellas Pharma and Allergan-AbbVie and grants from Diatherix outside the submitted work. No other disclosures were reported. EDAT- 2022/02/10 06:00 MHDA- 2022/02/22 06:00 PMCR- 2022/02/09 CRDT- 2022/02/09 12:17 PHST- 2022/02/09 12:17 [entrez] PHST- 2022/02/10 06:00 [pubmed] PHST- 2022/02/22 06:00 [medline] PHST- 2022/02/09 00:00 [pmc-release] AID - 2788857 [pii] AID - zoi211243 [pii] AID - 10.1001/jamanetworkopen.2021.44942 [doi] PST - epublish SO - JAMA Netw Open. 2022 Feb 1;5(2):e2144942. doi: 10.1001/jamanetworkopen.2021.44942. PMID- 35131019 OWN - NLM STAT- MEDLINE DCOM- 20220209 LR - 20260127 IS - 2095-4352 (Print) VI - 33 IP - 12 DP - 2021 Dec TI - [Field investigation of standardized construction of intensive care unit in county-level public hospitals in Dizhou City, Guizhou Province]. PG - 1497-1503 LID - 10.3760/cma.j.cn121430-20210830-01294 [doi] AB - OBJECTIVE: To investigate the standardized construction of critical care departments in different cities and counties of Guizhou province to promote the homogenization development of critical care medicine in Guizhou Province. METHODS: Using research methods such as field investigation and data collection, the public hospitals of 88 counties and urban areas in 9 prefectures and cities of Guizhou province were divided into five routes: southeast, northeast, northwest, southwest, and Guiyang. To design the survey form for the standardized construction of ICU, the e-form was sent to the director of ICU or his/her designated personnel by email or wechat 2-3 days in advance. Check the authenticity of data item by item on site, and leave the hospital after checking the receipt form. RESULTS: From April to July 2021, the survey and research data collection was completed for 146 public hospitals (excluding provincial hospitals) with intensive care departments in 88 counties and cities of 9 dizhou cities in Guizhou Province, including 24 Grade-III Level A hospitals. 122 Grade-II and above hospitals (including 8 Grade-III Level B hospitals, 11 Grade-III comprehensive hospitals, 97 Level-II A hospitals, 3 Level-II B hospitals, and 3 Level-II comprehensive hospitals). 146 public hospitals have a total of 80 983 beds and 104 017 open beds. The department of Critical Care has 2 035 beds. The ratio of actual beds in ICU to total beds in hospital was 2.51%. From 1999 to 2010, 18 (12.33%) established departments, and from 2011 to 2021, 128 (87.67%) established departments. The total area of the discipline is 113 355.48 m(2), with an average bed area of 55.70 m(2). There were 97 hospitals with 1.5-2.0 m bed spacing, accounting for 66.44%, and 49 hospitals with 2.1- > 2.5 m spacing, accounting for 33.56%. The number of negative pressure wards: 1 in each of 43 hospitals, accounting for 29.45%; 103 hospitals did not have, accounting for 70.55%. The number of single rooms: 288 in 140 hospitals, accounting for 95.89%; 6 hospitals did not have, accounting for 4.11%. Central oxygen supply: 138 hospitals have (94.52%); 8 hospitals did not have, accounting for 5.48%. Natural ventilation: in 129 hospitals with 88.36%; 17 hospitals did not have, accounting for 11.64%. Specialized ICU construction: 66 hospitals, accounting for 45.21%; none in 80 hospitals, accounting for 54.79%. There are 3 712 doctors and nurses in 146 public hospitals. The total number of doctors was 1 041, and the ratio of doctors to beds was 0.51:1. The total number of nurses was 2 675, and the ratio of nurses to beds was 1.31:1. CONCLUSIONS: All 88 counties and districts in 9 prefectures and cities of Guizhou province have established intensive care medicine departments. The standardization of the discipline construction has been significantly improved. Lack of talents is still an important factor restricting the rapid development of the discipline. FAU - Wang, Difen AU - Wang D AD - Department of Critical Care Medicine, Affiliated Hospital of Guizhou Medical University, Guizhou Quality Control Center of Critical Care Medicine, Guiyang 550004,Guizhou, China. FAU - Liu, Di AU - Liu D AD - School of Journalism and Communication, National Digital Health Research Center, China Institute of Education and Social Development, Beijing Normal University, Beijing 100875, China. Corresponding author: Wang Difen, Email: 1078666485@qq.com. FAU - Liu, Xu AU - Liu X AD - Department of Critical Care Medicine, Affiliated Hospital of Guizhou Medical University, Guizhou Quality Control Center of Critical Care Medicine, Guiyang 550004,Guizhou, China. FAU - Liu, Ying AU - Liu Y AD - Department of Critical Care Medicine, Affiliated Hospital of Guizhou Medical University, Guizhou Quality Control Center of Critical Care Medicine, Guiyang 550004,Guizhou, China. FAU - Fu, Jiangquan AU - Fu J AD - Department of Critical Care Medicine, Affiliated Hospital of Guizhou Medical University, Guizhou Quality Control Center of Critical Care Medicine, Guiyang 550004,Guizhou, China. FAU - Shen, Feng AU - Shen F AD - Department of Critical Care Medicine, Affiliated Hospital of Guizhou Medical University, Guizhou Quality Control Center of Critical Care Medicine, Guiyang 550004,Guizhou, China. FAU - Tang, Yan AU - Tang Y AD - Department of Critical Care Medicine, Affiliated Hospital of Guizhou Medical University, Guizhou Quality Control Center of Critical Care Medicine, Guiyang 550004,Guizhou, China. FAU - Liu, Yuanyi AU - Liu Y AD - Department of Critical Care Medicine, Affiliated Hospital of Guizhou Medical University, Guizhou Quality Control Center of Critical Care Medicine, Guiyang 550004,Guizhou, China. FAU - Li, Liang AU - Li L AD - Department of Critical Care Medicine, Affiliated Hospital of Guizhou Medical University, Guizhou Quality Control Center of Critical Care Medicine, Guiyang 550004,Guizhou, China. FAU - Liu, Ming AU - Liu M AD - Department of Critical Care Medicine, Affiliated Hospital of Guizhou Medical University, Guizhou Quality Control Center of Critical Care Medicine, Guiyang 550004,Guizhou, China. LA - chi PT - Journal Article PL - China TA - Zhonghua Wei Zhong Bing Ji Jiu Yi Xue JT - Zhonghua wei zhong bing ji jiu yi xue JID - 101604552 SB - IM MH - China MH - Cities MH - *Critical Care MH - Female MH - Hospitals, Public MH - Humans MH - *Intensive Care Units MH - Male EDAT- 2022/02/09 06:00 MHDA- 2022/02/10 06:00 CRDT- 2022/02/08 05:38 PHST- 2022/02/08 05:38 [entrez] PHST- 2022/02/09 06:00 [pubmed] PHST- 2022/02/10 06:00 [medline] AID - 10.3760/cma.j.cn121430-20210830-01294 [doi] PST - ppublish SO - Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2021 Dec;33(12):1497-1503. doi: 10.3760/cma.j.cn121430-20210830-01294. PMID- 35129484 OWN - NLM STAT- MEDLINE DCOM- 20230313 LR - 20230321 IS - 1528-1140 (Electronic) IS - 0003-4932 (Linking) VI - 277 IP - 4 DP - 2023 Apr 1 TI - Impact of Body Mass Index on Major Complications, Multiple Complications, In-hospital Mortality, and Failure to Rescue After Esophagectomy for Esophageal Cancer: A Nationwide Inpatient Database Study in Japan. PG - e785-e792 LID - 10.1097/SLA.0000000000005321 [doi] AB - OBJECTIVE: To examine the association of BMI with mortality and related outcomes after oncologic esophagectomy. SUMMARY BACKGROUND DATA: Previous studies showed that high BMI was a risk factor for anastomotic leakage and low BMI was a risk factor for respiratory complications after esophagectomy. However, the association between BMI and in-hospital mortality after oncologic esophagectomy remains unclear. METHODS: Data for patients who underwent esophagectomy for esophageal cancer between July 2010 and March 2019 were extracted from a Japanese nationwide inpatient database. Multivariate regression analyses and restricted cubic spline analyses were used to investigate the associations between BMI and short-term outcomes, adjusting for potential confounders. RESULTS: Among 39,406 eligible patients, in-hospital mortality, major complications, and multiple complications (>/=2 major complications) occurred in 1069 (2.7%), 14,824 (37.6%), and 3621 (9.2%), respectively. Compared with normal weight (18.5-22.9 kg/m 2 ), severe underweight (<16.0 kg/m 2 ), mild/moderate underweight (16.0-18.4 kg/m 2 ), and obese (>/=27.5 kg/m 2 )were significantly associated with higher in-hospital mortality [odds ratio 2.20 (95% confidence interval 1.65-2.94), 1.25 (1.01-1.49), and 1.48 (1.05-2.09), respectively]. BMI showed U-shaped dose-response associations with mortality, major complications, and multiple complications. BMI also showed a reverse J-shaped association with failure to rescue (death after major complications). CONCLUSIONS: Both high BMI and low BMI were associated with mortality, major complications and multiple complications after esophagectomy for esophageal cancer. Patients with low BMI were more likely to die once a major complication occurred. The present results can assist with risk stratification in patients undergoing oncologic esophagectomy. CI - Copyright (c) 2021 Wolters Kluwer Health, Inc. All rights reserved. FAU - Hirano, Yuki AU - Hirano Y AD - Department of Hepatobiliary-Pancreatic and Gastrointestinal Surgery, International University of Health and Welfare School of Medicine, Chiba, Japan. FAU - Kaneko, Hidehiro AU - Kaneko H AD - Department of cardiovascular Medicine, The University of Tokyo, Tokyo, Japan. FAU - Konishi, Takaaki AU - Konishi T AD - Department of Clinical Epidemiology and Health Economics, School of Public Health, The University of Tokyo, Tokyo, Japan. FAU - Itoh, Hidetaka AU - Itoh H AD - Department of cardiovascular Medicine, The University of Tokyo, Tokyo, Japan. FAU - Matsuda, Satoru AU - Matsuda S AD - Department of Surgery, Keio University School of Medicine, Tokyo, Japan. FAU - Kawakubo, Hirofumi AU - Kawakubo H AD - Department of Surgery, Keio University School of Medicine, Tokyo, Japan. FAU - Uda, Kazuaki AU - Uda K AD - Department of Clinical Epidemiology and Health Economics, School of Public Health, The University of Tokyo, Tokyo, Japan. FAU - Matsui, Hiroki AU - Matsui H AD - Department of Clinical Epidemiology and Health Economics, School of Public Health, The University of Tokyo, Tokyo, Japan. FAU - Fushimi, Kiyohide AU - Fushimi K AD - Department of Health Policy and Informatics, Tokyo Medical and Dental University Graduate School, Tokyo, Japan. FAU - Itano, Osamu AU - Itano O AD - Department of Hepatobiliary-Pancreatic and Gastrointestinal Surgery, International University of Health and Welfare School of Medicine, Chiba, Japan. FAU - Yasunaga, Hideo AU - Yasunaga H AD - Department of Clinical Epidemiology and Health Economics, School of Public Health, The University of Tokyo, Tokyo, Japan. FAU - Kitagawa, Yuko AU - Kitagawa Y AD - Department of Surgery, Keio University School of Medicine, Tokyo, Japan. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20211123 PL - United States TA - Ann Surg JT - Annals of surgery JID - 0372354 SB - IM MH - Humans MH - Body Mass Index MH - *Overweight/complications/surgery MH - Thinness/complications/surgery MH - Hospital Mortality MH - Inpatients MH - Esophagectomy/adverse effects MH - Japan/epidemiology MH - Postoperative Complications/etiology MH - *Esophageal Neoplasms MH - Retrospective Studies COIS- The authors report no conflicts of interest. EDAT- 2022/02/08 06:00 MHDA- 2023/03/14 06:00 CRDT- 2022/02/07 12:13 PHST- 2022/02/08 06:00 [pubmed] PHST- 2023/03/14 06:00 [medline] PHST- 2022/02/07 12:13 [entrez] AID - 00000658-202304000-00033 [pii] AID - 10.1097/SLA.0000000000005321 [doi] PST - ppublish SO - Ann Surg. 2023 Apr 1;277(4):e785-e792. doi: 10.1097/SLA.0000000000005321. Epub 2021 Nov 23. PMID- 35111317 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230202 IS - 2049-4637 (Print) IS - 2049-4645 (Electronic) IS - 2049-4637 (Linking) VI - 16 IP - 1 DP - 2022 Feb TI - What is the content of virtually delivered pain management programmes for people with persistent musculoskeletal pain? A systematic review. PG - 84-95 LID - 10.1177/20494637211023074 [doi] AB - INTRODUCTION: Virtual consultations (VC) have been embraced by healthcare organisations during the COVID-19 pandemic. VC allows continuation of patient care while adhering to government advised restrictions and social distancing measures. Multidisciplinary pain management programmes (PMPs) are a core element of many pain services and utilising virtual methods to deliver PMPs has allowed them to continue to provide care. This systematic review aimed to explore the content of existing virtually delivered PMPs and discuss if and how these findings can be used to guide clinical delivery. METHODS: Eligible studies included adults (aged ⩾18 years) with persistent musculoskeletal pain and any virtually delivered intervention that was described as a PMP or that had components of PMPs. Databases were searched from inception until July 2020. We performed a content analysis comparing existing interventions with established evidence-based clinical guidelines published by the British Pain Society (BPS). Intervention reporting quality was assessed using the Template for Intervention Description and Replication (TIDieR) checklist: an established checklist developed to improve the completeness of the reporting of interventions. RESULTS: Eight studies were included. One intervention included six of the seven components recommended by the BPS; none included all seven. 'Skills training and activity management' was present in all eight interventions; 'education' and 'cognitive therapy methods' were present in six interventions; 'graded activation' and 'methods to enhance acceptance, mindfulness and psychological flexibility' were present in four interventions; 'physical exercise' was present in two interventions and 'graded exposure' was present in one intervention. None of the studies described all 12 items of the TIDieR checklist adequately enough for replication. CONCLUSION: Published virtual PMPs partially meet established clinical guidelines. Future virtual PMPs should be based on evidence-based clinical guidelines, and more research is needed to explore the effectiveness of virtually delivered PMPs and each recommended component. CI - (c) The British Pain Society 2021. FAU - Booth, Gregory AU - Booth G AUID- ORCID: 0000-0003-3332-1890 AD - Therapies Department, Royal National Orthopaedic Hospital NHS Trust, Stanmore, UK. FAU - Williams, Deborah AU - Williams D AUID- ORCID: 0000-0003-2935-0621 AD - Therapies Department, Royal National Orthopaedic Hospital NHS Trust, Stanmore, UK. FAU - Patel, Hasina AU - Patel H AD - Therapies Department, Royal National Orthopaedic Hospital NHS Trust, Stanmore, UK. FAU - Gilbert, Anthony W AU - Gilbert AW AD - Therapies Department, Royal National Orthopaedic Hospital NHS Trust, Stanmore, UK. AD - School of Health Sciences, University of Southampton, Southampton, UK. LA - eng PT - Journal Article DEP - 20210613 PL - England TA - Br J Pain JT - British journal of pain JID - 101583844 PMC - PMC8801687 OTO - NOTNLM OT - COVID-19 OT - chronic pain OT - pain management programme OT - persistent pain OT - rehabilitation OT - virtual consultations COIS- Conflict of interest: The author(s) declared no potential conflicts of interest with respect to the research, authorship and/or publication of this article. EDAT- 2022/02/04 06:00 MHDA- 2022/02/04 06:01 PMCR- 2023/02/01 CRDT- 2022/02/03 05:33 PHST- 2022/02/03 05:33 [entrez] PHST- 2022/02/04 06:00 [pubmed] PHST- 2022/02/04 06:01 [medline] PHST- 2023/02/01 00:00 [pmc-release] AID - 10.1177_20494637211023074 [pii] AID - 10.1177/20494637211023074 [doi] PST - ppublish SO - Br J Pain. 2022 Feb;16(1):84-95. doi: 10.1177/20494637211023074. Epub 2021 Jun 13. PMID- 35104291 OWN - NLM STAT- MEDLINE DCOM- 20220301 LR - 20250729 IS - 1932-6203 (Electronic) IS - 1932-6203 (Linking) VI - 17 IP - 2 DP - 2022 TI - Silver diamine fluoride and oral health-related quality of life: A review and network meta-analysis. PG - e0261627 LID - 10.1371/journal.pone.0261627 [doi] LID - e0261627 AB - OBJECTIVE: Silver diamine fluoride (SDF) is an effective non-surgical treatment for dental caries which may also impact oral health-related quality of life (OHRQoL). The objective of this study was to conduct a network meta-analysis of SDF versus other standard of care therapies on OHRQoL. DATA SOURCES: Studies published in PubMed/MEDLINE, Scopus, or Web of Science through July 2021 with no date or language restrictions. STUDY SELECTION: Any randomized controlled trial, cohort, or case-control study that included silver diamine fluoride as either a single or combinative treatment for dental caries and a quantitatively measured outcome for oral health-related quality of life was included. DATA EXTRACTION AND SYNTHESIS: Potentially eligible studies were screened by two independent reviewers trained in conducting systematic reviews. Studies meeting inclusion criteria underwent a full-text review with data being extracted using a standardized form, including publication details, study methodology, outcomes, assessors, and sample information. Studies underwent a risk of bias assessment. Quantitative synthesis was performed using fixed effects meta-analysis and individual comparisons were assessed via network meta-analysis. MAIN OUTCOME(S) AND MEASURE(S): Oral health-related quality of life. RESULTS: 19 articles were returned following search strategies. Following screening, ten studies were evaluated for full-text eligibility and five were retained for meta-analyses. Results across all treatments indicate no differences in OHRQoL when compared to SDF (SMD = -0.06, 95% CI = -0.20, 0.08). Direct and indirect estimates from network meta-analysis indicated that OHRQoL in children was not significantly different when treated with SDF versus atraumatic restorations (d = 0.02, 95% CI = -0.32, 0.36) or placebo (d = 0.03, 95% CI = -0.16, 0.22). CONCLUSIONS: Evidence from the literature consistently shows no discernible impact on OHRQoL across various non-surgical treatments for dental caries. Overall oral health-related quality of life may increase regardless of treatment protocol due to treatment of the underlying disease. Concerns over the staining of dental decay and oral mucosa resulting from treatment with silver diamine fluoride do not seem to affect OHRQoL. FAU - Ruff, Ryan Richard AU - Ruff RR AUID- ORCID: 0000-0003-0731-5614 AD - Department of Epidemiology & Health Promotion, New York College of Dentistry, New York, New York, United States of America. FAU - Whittemore, Rachel AU - Whittemore R AD - Department of Epidemiology & Health Promotion, New York College of Dentistry, New York, New York, United States of America. FAU - Grochecki, Martyna AU - Grochecki M AD - Department of Epidemiology & Health Promotion, New York College of Dentistry, New York, New York, United States of America. FAU - Bateson, Jillian AU - Bateson J AD - Department of Epidemiology & Health Promotion, New York College of Dentistry, New York, New York, United States of America. FAU - Barry Godin, Tamarinda J AU - Barry Godin TJ AD - Department of Epidemiology & Health Promotion, New York College of Dentistry, New York, New York, United States of America. LA - eng PT - Journal Article PT - Network Meta-Analysis PT - Review DEP - 20220201 PL - United States TA - PLoS One JT - PloS one JID - 101285081 RN - 0 (Cariostatic Agents) RN - 0 (Fluorides, Topical) RN - 0 (Quaternary Ammonium Compounds) RN - 0 (Silver Compounds) RN - DDU19UEV1Y (silver diamine fluoride) SB - IM MH - Cariostatic Agents/*therapeutic use MH - Databases, Factual MH - Dental Caries/prevention & control MH - Fluorides, Topical/therapeutic use MH - Humans MH - Oral Health MH - *Quality of Life MH - Quaternary Ammonium Compounds/*therapeutic use MH - Silver Compounds/*therapeutic use PMC - PMC8806055 COIS- The authors have declared that no competing interests exist. EDAT- 2022/02/02 06:00 MHDA- 2022/03/03 06:00 PMCR- 2022/02/01 CRDT- 2022/02/01 17:10 PHST- 2021/07/22 00:00 [received] PHST- 2021/12/06 00:00 [accepted] PHST- 2022/02/01 17:10 [entrez] PHST- 2022/02/02 06:00 [pubmed] PHST- 2022/03/03 06:00 [medline] PHST- 2022/02/01 00:00 [pmc-release] AID - PONE-D-21-23753 [pii] AID - 10.1371/journal.pone.0261627 [doi] PST - epublish SO - PLoS One. 2022 Feb 1;17(2):e0261627. doi: 10.1371/journal.pone.0261627. eCollection 2022. PMID- 35091134 OWN - NLM STAT- MEDLINE DCOM- 20220411 LR - 20250623 IS - 1879-0593 (Electronic) IS - 1368-8375 (Linking) VI - 126 DP - 2022 Mar TI - Significance of p53 overexpression in the prediction of the malignant transformation risk of oral potentially malignant disorders: A systematic review and meta-analysis. PG - 105734 LID - S1368-8375(22)00023-9 [pii] LID - 10.1016/j.oraloncology.2022.105734 [doi] AB - OBJECTIVES: To evaluate the current evidence in relation to the predictive value of p53 overexpression as a biomarker of the malignant transformation risk in oral potentially malignant disorders (OPMD). MATERIAL AND METHODS: We searched PubMed, Embase, Web of Science and Scopus for studies published before July-2021, not restricted by date or publication language, with longitudinal design and assessing p53 overexpression by immunohistochemistry. We evaluated the quality of primary-level studies using QUIPS tool. We carried out meta-analyses, examined inter-study heterogeneity through subgroup and meta-regression analyses, and performed sensitivity and small-study effects analyses to test the stability and reliability of results. RESULTS: Twenty four studies (1,210 patients) met inclusion criteria. P53 overexpression was associated with a statistically significant about 2 fold risk (RR = 1.88, 95 %CI = 1.39-2.56, p < 0.001). Leukoplakia maintained this significant relationship after subgroup meta-analysis (p = 0.002). Regarding the immunohistochemical technique, better results were obtained by the subgroups using anti-p53 DO7 antibody (p = 0.001), at high concentration (dilution < 1: 100, p < 0.001), incubated for long periods (overnight, p = 0.02), and at low temperature (4 degrees C, p = 0.007). Furthermore, meta-regression analysis showed that the association between p53 overexpression and higher oral cancer risk was independent of the presence and/or severity of epithelial dysplasia (p > 0.05). CONCLUSION: Our systematic review and meta-analysis supports the assessment of p53 overexpression in the prediction of the malignant transformation risk of OPMD. CI - Copyright (c) 2022 Elsevier Ltd. All rights reserved. FAU - Ramos-Garcia, Pablo AU - Ramos-Garcia P AD - School of Dentistry, University of Granada, Granada, Spain; Biohealth Research Institute IBS, Granada, Spain. Electronic address: pramos@correo.ugr.es. FAU - Gonzalez-Moles, Miguel Angel AU - Gonzalez-Moles MA AD - School of Dentistry, University of Granada, Granada, Spain; Biohealth Research Institute IBS, Granada, Spain; WHO Collaborating Centre for Oral Cancer, London, UK. Electronic address: magonzal@ugr.es. FAU - Warnakulasuriya, Saman AU - Warnakulasuriya S AD - WHO Collaborating Centre for Oral Cancer, London, UK; Oral Medicine Department, King's College London, London, UK. Electronic address: saman.warne@kcl.ac.uk. LA - eng PT - Journal Article PT - Meta-Analysis PT - Systematic Review DEP - 20220125 PL - England TA - Oral Oncol JT - Oral oncology JID - 9709118 RN - 0 (Tumor Suppressor Protein p53) SB - IM MH - Cell Transformation, Neoplastic/genetics/pathology MH - Humans MH - Leukoplakia, Oral/genetics MH - *Mouth Diseases MH - *Mouth Neoplasms/genetics/pathology MH - *Precancerous Conditions MH - Reproducibility of Results MH - Tumor Suppressor Protein p53 OTO - NOTNLM OT - Dysplasia OT - Leukoplakia OT - Malignant transformation OT - Meta-analysis OT - Oral cancer OT - Oral lichen planus OT - Oral potentially malignant disorders OT - P53 OT - Systematic review OT - TP53 EDAT- 2022/01/30 06:00 MHDA- 2022/04/12 06:00 CRDT- 2022/01/29 05:36 PHST- 2021/10/27 00:00 [received] PHST- 2022/01/10 00:00 [revised] PHST- 2022/01/19 00:00 [accepted] PHST- 2022/01/30 06:00 [pubmed] PHST- 2022/04/12 06:00 [medline] PHST- 2022/01/29 05:36 [entrez] AID - S1368-8375(22)00023-9 [pii] AID - 10.1016/j.oraloncology.2022.105734 [doi] PST - ppublish SO - Oral Oncol. 2022 Mar;126:105734. doi: 10.1016/j.oraloncology.2022.105734. Epub 2022 Jan 25. PMID- 35083471 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20241207 IS - 2806-6073 (Electronic) IS - 2806-6073 (Linking) VI - 1 DP - 2021 TI - The impact of long-term care insurance in China on beneficiaries and caregivers: A systematic review. LID - e2021014 [pii] LID - 10.52872/001c.29559 [doi] AB - BACKGROUND: China's long-term care insurance (LTCI) policy has been minimally evaluated. This systematic review aimed to assess the impact of China's LTCI pilot on beneficiaries and their caregivers. METHODS: This review is based on a search of peer-reviewed studies in English (Embase, MEDLINE, Web of Science) and Chinese (China National Knowledge Infrastructure [CNKI], VIP, Wanfang) databases from January 2016 through July 2020, with all studies published in English or Chinese included. We included quantitative analyses of beneficiary-level data that assessed the impact of LTCI on beneficiaries and their caregivers, with no restriction placed on the outcomes studied. RESULTS: Nine studies met our inclusion criteria. One study was a randomised trial and two used quasi-experimental approaches. Four studies examined LTCI's effect on beneficiaries' quality of life, physical pain, and health service utilisation; one study reported the effect on beneficiaries' healthcare expenditures; and one study evaluated the impact on caregivers' care tasks. These studies generally found LTCI to be associated with an improvement in patients' quality of life (including decreased physical pain), a reduction in the number of outpatient visits and hospitalisations, decreased patient-level health expenditures (e.g. one study reported a reduction in the length of stay, inpatient expenditures, and health insurance expenditures in tertiary hospitals by 41.0%, 17.7%, and 11.4%, respectively), and reduced informal care tasks for caregivers. In addition, four out of four studies that evaluated this outcome found that beneficiaries' overall satisfaction with LTCI was high. CONCLUSION: The current evidence base for the effects of LTCI in China on beneficiaries and their caregivers is sparse. Nonetheless, the existing studies suggest that LTCI has positive effects on beneficiaries and their caregivers. Further rigorous research on the impacts of LTCI in China is needed to inform the future expansion of the program. FAU - Chen, Simiao AU - Chen S AUID- ORCID: 0000-0003-0555-2157 AD - Heidelberg Institute of Global Health (HIGH), Faculty of Medicine and University Hospital, Heidelberg University; Chinese Academy of Medical Sciences and Peking Union Medical College. FAU - Li, Linye AU - Li L AUID- ORCID: 0000-0002-8158-1980 AD - Chinese Academy of Social Sciences. FAU - Yang, Juntao AU - Yang J AUID- ORCID: 0000-0003-1180-391X AD - State Key Laboratory of Medical Molecular Biology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences & Peking Union Medical College. FAU - Jiao, Lirui AU - Jiao L AUID- ORCID: 0000-0002-2505-7447 AD - Columbia University. FAU - Golden, Todd AU - Golden T AD - Division of Cancer Control and Population Sciences, National Cancer Institute. FAU - Wang, Zhuoran AU - Wang Z AUID- ORCID: 0000-0001-5175-8645 AD - Chinese Academy of Medical Sciences and Peking Union Medical College. FAU - Liu, Haitao AU - Liu H AUID- ORCID: 0000-0002-6184-1466 AD - Chinese Academy of Medical Sciences and Peking Union Medical College. FAU - Wu, Peixin AU - Wu P AUID- ORCID: 0000-0002-1288-0610 AD - Chinese Academy of Medical Sciences and Peking Union Medical College. FAU - Barnighausen, Till AU - Barnighausen T AUID- ORCID: 0000-0002-4182-4212 AD - Heidelberg Institute of Global Health (HIGH), Faculty of Medicine and University Hospital, Heidelberg University; Chinese Academy of Medical Sciences and Peking Union Medical College; Department of Global Health and Population, Harvard School of Public Health. FAU - Geldsetzer, Pascal AU - Geldsetzer P AUID- ORCID: 0000-0002-8878-5505 AD - Heidelberg Institute of Global Health (HIGH), Faculty of Medicine and University Hospital, Heidelberg University; Division of Primary Care and Population Health, Department of Medicine, Stanford University. FAU - Wang, Chen AU - Wang C AUID- ORCID: 0000-0001-7857-5435 AD - Chinese Academy of Medical Sciences and Peking Union Medical College; National Clinical Research Center for Respiratory Diseases, Beijing, China; Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, China-Japan Friendship Hospital. LA - eng GR - KL2 TR003143/TR/NCATS NIH HHS/United States PT - Journal Article DEP - 20211116 PL - Scotland TA - J Glob Health Econ Policy JT - Journal of global health economics and policy JID - 9918284149406676 PMC - PMC8788994 MID - NIHMS1757325 OTO - NOTNLM OT - China OT - beneficiaries and caregivers OT - long-term care insurance OT - systematic review COIS- CONFLICT OF INTEREST DISCLOSURES The authors completed the ICMJE Unified Competing Interest form at (available upon request from the corresponding author), and declare no conflicts of interest. EDAT- 2022/01/28 06:00 MHDA- 2022/01/28 06:01 PMCR- 2022/01/25 CRDT- 2022/01/27 05:51 PHST- 2022/01/27 05:51 [entrez] PHST- 2022/01/28 06:00 [pubmed] PHST- 2022/01/28 06:01 [medline] PHST- 2022/01/25 00:00 [pmc-release] AID - e2021014 [pii] AID - 10.52872/001c.29559 [doi] PST - ppublish SO - J Glob Health Econ Policy. 2021;1:e2021014. doi: 10.52872/001c.29559. Epub 2021 Nov 16. PMID- 35075716 OWN - NLM STAT- MEDLINE DCOM- 20221108 LR - 20250623 IS - 1365-2702 (Electronic) IS - 0962-1067 (Print) IS - 0962-1067 (Linking) VI - 31 IP - 23-24 DP - 2022 Dec TI - Effect of a game-based intervention on preoperative pain and anxiety in children: A systematic review and meta-analysis. PG - 3350-3367 LID - 10.1111/jocn.16227 [doi] AB - BACKGROUND: Games are increasingly being used as a means of alleviating pain and anxiety in paediatric patients, in the view that this form of distraction is effective, non-invasive and non-pharmacological. AIMS: To determine whether a game-based intervention (via gamification or virtual reality) during the induction of anaesthesia reduces preoperative pain and anxiety in paediatric patients. METHODS: A systematic review with meta-analysis of randomised controlled trials was performed in accordance with the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines and using RevMan software. The review was based on a search of the EMBASE, CINAHL, Medline, SciELO and Scopus databases, conducted in July 2021. No restriction was placed on the year of publication. RESULTS: 26 studies were found, with a total study population of 2525 children. Regarding pain reduction, no significant differences were reported. For anxiety during anaesthesia induction, however, a mean difference of -10.62 (95% CI -13.85, -7.39) on the Modified Yale Preoperative Anxiety Scale, in favour of game-based intervention, was recorded. CONCLUSIONS: Game-based interventions alleviate preoperative anxiety during the induction of anaesthesia in children. This innovative and pleasurable approach can be helpful in the care of paediatric surgical patients. RELEVANCE TO CLINICAL PRACTICE: In children, preoperative management is a challenging task for healthcare professionals, and game-based strategies could enhance results, improving patients' emotional health and boosting post-surgery recovery. Distractive games-based procedures should be considered for incorporation in the pre-surgery clinical workflow in order to optimise healthcare. CI - (c) 2022 The Authors. Journal of Clinical Nursing published by John Wiley & Sons Ltd. FAU - Suleiman-Martos, Nora AU - Suleiman-Martos N AUID- ORCID: 0000-0003-4133-0092 AD - Nursing Department, Faculty of Health Sciences, University of Granada, Ceuta, Spain. FAU - Garcia-Lara, Ruben A AU - Garcia-Lara RA AD - Granada-Northeast Health Management Area, Andalusian Health Service, Granada, Spain. FAU - Membrive-Jimenez, Maria J AU - Membrive-Jimenez MJ AUID- ORCID: 0000-0003-1074-1462 AD - National Institute of Health Management, Ceuta University Hospital, Ceuta, Spain. FAU - Pradas-Hernandez, Laura AU - Pradas-Hernandez L AD - Andalusian Health Service, San Cecilio Clinical University Hospital, Granada, Spain. FAU - Romero-Bejar, Jose L AU - Romero-Bejar JL AUID- ORCID: 0000-0002-5310-9638 AD - Statistics and Operational Research Department, University of Granada, Granada, Spain. FAU - Dominguez-Vias, German AU - Dominguez-Vias G AD - Physiology Department, Faculty of Health Sciences, University of Granada, Ceuta, Spain. FAU - Gomez-Urquiza, Jose L AU - Gomez-Urquiza JL AUID- ORCID: 0000-0002-8684-1817 AD - Nursing Department, Faculty of Health Sciences, University of Granada, Granada, Spain. LA - eng PT - Journal Article PT - Meta-Analysis PT - Systematic Review DEP - 20220124 PL - England TA - J Clin Nurs JT - Journal of clinical nursing JID - 9207302 CIN - J Clin Nurs. 2023 Nov;32(21-22):7924-7925. doi: 10.1111/jocn.16764. PMID: 37264503 MH - Humans MH - Child MH - *Anxiety/prevention & control/psychology MH - *Anesthesia, General/psychology MH - Anxiety Disorders MH - Emotions MH - Pain PMC - PMC9787560 OTO - NOTNLM OT - anxiety OT - children OT - game OT - pain OT - perioperative care OT - virtual reality COIS- The authors declare that there is no conflict of interest. EDAT- 2022/01/26 06:00 MHDA- 2022/11/09 06:00 PMCR- 2022/12/23 CRDT- 2022/01/25 05:52 PHST- 2021/12/27 00:00 [revised] PHST- 2021/08/13 00:00 [received] PHST- 2022/01/02 00:00 [accepted] PHST- 2022/01/26 06:00 [pubmed] PHST- 2022/11/09 06:00 [medline] PHST- 2022/01/25 05:52 [entrez] PHST- 2022/12/23 00:00 [pmc-release] AID - JOCN16227 [pii] AID - 10.1111/jocn.16227 [doi] PST - ppublish SO - J Clin Nurs. 2022 Dec;31(23-24):3350-3367. doi: 10.1111/jocn.16227. Epub 2022 Jan 24. PMID- 35070782 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250530 IS - 2220-3206 (Print) IS - 2220-3206 (Electronic) IS - 2220-3206 (Linking) VI - 11 IP - 12 DP - 2021 Dec 19 TI - Impact of lockdown relaxation and implementation of the face-covering policy on mental health: A United Kingdom COVID-19 study. PG - 1346-1365 LID - 10.5498/wjp.v11.i12.1346 [doi] AB - BACKGROUND: Pandemic mitigation policies, such as lockdown, are known to impact on mental health of individuals. Compulsory face covering under relaxed lockdown restrictions gives assurance of less transmission of airborne infection and has the potential to improve mental health of individuals affected by restrictions. AIM: To examine the association of the lockdown relaxation and the implementation of the face covering policy on the mental health of the general population and sub-groups in the United Kingdom using interrupted time series model. METHODS: Using a web-based cross-sectional survey of 28890 United Kingdom adults carried out during May 1, 2020 to July 31, 2020, changes in mental health status using generalised anxiety disorder (GAD-7), and impact of events scale-revised (IES-R) scales are examined, at the dates of the first lockdown relaxation (July 4, 2020) and the subsequent introduction of face covering (July 24, 2020) in United Kingdom. A sharp regression discontinuity design is used to check discontinuities in mental health outcomes at policy-change dates. RESULTS: Average GAD-7 scores of participants were 5.6, 5.6 and 4.3 during the lockdown period, the lockdown relaxation phase and the phase of compulsory face covering, respectively, with lower scores indicating lower anxiety levels. Corresponding scores for IES-R were 17.3, 16.8 and 13.4, with lower scores indicating less distress. Easing lockdown measures and subsequent introduction of face covering, on average, reduced GAD-7 by 0.513 (95%CI: 0.913-0.112) and 1.148 (95%CI: 1.800-0.496), respectively. Corresponding reductions in IES-R were 2.620 (95%CI: 4.279-0.961) and 3.449 (95%CI: 5.725-1.172). These imply that both lockdown relaxation and compulsory face-covering have a positive association with mental health scores (GAD-7 and IES-R). CONCLUSION: The differential impact of lockdown and relaxation on the mental health of population sub-groups is evident in this study with future implications for policy. Introduction of face covering in public places had a stronger positive association with mental health than lockdown relaxation. CI - (c)The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. FAU - Rathod, Shanaya AU - Rathod S AD - Department of Research and Development, Southern Health NHS Foundation Trust, Southampton SO30 3JB, Hampshire, United Kingdom. FAU - Pallikadavath, Saseendran AU - Pallikadavath S AD - School of Health and Care Professions, University of Portsmouth, Portsmouth PO1 2DT, Hampshire, United Kingdom. FAU - Graves, Elizabeth AU - Graves E AD - Department of Research and Development, Southern Health NHS Foundation Trust, Southampton SO30 3JB, Hampshire, United Kingdom. FAU - Rahman, Mohammad Mahbubur AU - Rahman MM AD - School of Health and Care Professions, University of Portsmouth, Portsmouth PO1 2DT, Hampshire, United Kingdom. FAU - Brooks, Ashlea AU - Brooks A AD - Department of Research and Development, Southern Health NHS Foundation Trust, Southampton SO30 3JB, Hampshire, United Kingdom. FAU - Soomro, Mustafa G AU - Soomro MG AD - Mental Health, Solent NHS Trust, Portsmouth P03 6AD, United Kingdom. FAU - Rathod, Pranay AU - Rathod P AD - PPI, PPI Representative, London SO30 3JB, United Kingdom. FAU - Phiri, Peter AU - Phiri P AD - Department of Research and Development, Southern Health NHS Foundation Trust, Southampton SO30 3JB, Hampshire, United Kingdom. LA - eng GR - MR/N006267/1/MRC_/Medical Research Council/United Kingdom PT - Journal Article DEP - 20211219 PL - United States TA - World J Psychiatry JT - World journal of psychiatry JID - 101610480 PMC - PMC8717029 OTO - NOTNLM OT - Anxiety OT - COVID-19 OT - Face-covering OT - Lockdown OT - Mental health OT - Psychological impact COIS- Conflict-of-interest statement: Dr Rathod reports others from Janssen, other from Otsuka, other from Lundbeck, outside the submitted work. Dr Phiri reports other from Queen Mary University London, other from Stanford University School of Medicine, other from John Wiley and Blackwell, outside the submitted work. All other authors report no conflict of interest. EDAT- 2022/01/25 06:00 MHDA- 2022/01/25 06:01 PMCR- 2021/12/19 CRDT- 2022/01/24 08:53 PHST- 2021/06/17 00:00 [received] PHST- 2021/08/04 00:00 [revised] PHST- 2021/10/20 00:00 [accepted] PHST- 2022/01/24 08:53 [entrez] PHST- 2022/01/25 06:00 [pubmed] PHST- 2022/01/25 06:01 [medline] PHST- 2021/12/19 00:00 [pmc-release] AID - 10.5498/wjp.v11.i12.1346 [doi] PST - epublish SO - World J Psychiatry. 2021 Dec 19;11(12):1346-1365. doi: 10.5498/wjp.v11.i12.1346. eCollection 2021 Dec 19. PMID- 35066525 OWN - NLM STAT- MEDLINE DCOM- 20220207 LR - 20240124 IS - 2162-0989 (Electronic) IS - 2162-0989 (Linking) VI - 11 IP - 1 DP - 2022 Jan 20 TI - The Impact of Hyperopia on Academic Performance Among Children: A Systematic Review. PG - 36-51 LID - 10.1097/APO.0000000000000492 [doi] AB - PURPOSE: To assess the impact of uncorrected hyperopia and hyperopic spectacle correction on children's academic performance. DESIGN: Systematic review and meta-analysis. METHODS: We searched 9 electronic databases from inception to July 26, 2021, for studies assessing associations between hyperopia and academic performance. There were no restrictions on language, publication date, or geographic location. A quality checklist was applied. Random-effects models estimated pooled effect size as a standardized mean difference (SMD) in 4 outcome domains: cognitive skills, educational performance, reading skills, and reading speed. (PROSPERO registration: CRD-42021268972). RESULTS: Twenty-five studies (21 observational and 4 interventional) out of 3415 met the inclusion criteria. No full-scale randomized trials were identified. Meta-analyses of the 5 studies revealed a small but significant adverse effect on educational performance in uncorrected hyperopic compared to emmetropic children SMD -0.18 [95% confidence interval (CI), -0.27 to -0.09]; P < 0.001, 4 studies and a moderate negative effect on reading skills in uncorrected hyperopic compared to emmetropic children [SMD -0.46 (95% CI, -0.90 to -0.03); P = 0.036, 3 studies]. Reading skills were significantly worse in hyperopic than myopic children [SMD -0.29 (95% CI, -0.43 to -0.15); P < 0.001, 1 study]. Qualitative analysis on 10 (52.6%) of 19 studies excluded from meta-analysis found a significant (P < 0.05) association between uncorrected hyperopia and impaired academic performance. Two interventional studies found hyperopic spectacle correction significantly improved reading speed (P < 0.05). CONCLUSIONS: Evidence indicates that uncorrected hyperopia is associated with poor academic performance. Given the limitations of current methodologies, further research is needed to evaluate the impact on academic performance of providing hyperopic correction. CI - Copyright (c) 2022 Asia-Pacific Academy of Ophthalmology. Published by Wolters Kluwer Health, Inc. on behalf of the Asia-Pacific Academy of Ophthalmology. FAU - Mavi, Sonia AU - Mavi S AD - Centre for Public Health, School of Medicine Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, UK. FAU - Chan, Ving Fai AU - Chan VF AD - Centre for Public Health, School of Medicine Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, UK. FAU - Virgili, Gianni AU - Virgili G AD - Centre for Public Health, School of Medicine Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, UK. AD - Department NEUROFARBA, University of Florence, Florence, Italy. FAU - Biagini, Ilaria AU - Biagini I AD - Department NEUROFARBA, University of Florence, Florence, Italy. FAU - Congdon, Nathan AU - Congdon N AD - Centre for Public Health, School of Medicine Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, UK. AD - Orbis International, New York, NY, US. AD - Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, China. FAU - Piyasena, Prabhath AU - Piyasena P AD - Centre for Public Health, School of Medicine Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, UK. FAU - Yong, Ai Chee AU - Yong AC AD - Centre for Public Health, School of Medicine Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, UK. FAU - Ciner, Elise B AU - Ciner EB AD - Pennsylvania College of Optometry, Salus University, Elkins Park, PA, US. FAU - Kulp, Marjean Taylor AU - Kulp MT AD - The Ohio State University College of Optometry, Columbus, OH, US. FAU - Candy, T Rowan AU - Candy TR AD - School of Optometry, Indiana University, Bloomington, IN, US. FAU - Collins, Megan AU - Collins M AD - Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, US. FAU - Bastawrous, Andrew AU - Bastawrous A AD - International Centre for Eye Health, Clinical Research Department, London School of Hygiene and Tropical Medicine, London, UK. AD - Peek Vision, London, UK. FAU - Morjaria, Priya AU - Morjaria P AD - International Centre for Eye Health, Clinical Research Department, London School of Hygiene and Tropical Medicine, London, UK. AD - Peek Vision, London, UK. FAU - Watts, Elanor AU - Watts E AD - Tennent Institute of Ophthalmology, Gartnavel General Hospital, Glasgow, UK. FAU - Masiwa, Lynett Erita AU - Masiwa LE AD - Optometry Unit, Department of Primary Health Care, Faculty of Medicine and Health Sciences, University of Zimbabwe, Harare, Zimbabwe. FAU - Kumora, Christopher AU - Kumora C AD - Zimbabwe Optometric Association, Harare, Zimbabwe. FAU - Moore, Bruce AU - Moore B AD - New England College of Optometry, Boston, MA, US. FAU - Little, Julie-Anne AU - Little JA AD - Centre for Optometry and Vision Science, School of Biomedical Sciences, Biomedical Sciences Research Institute, Ulster University, Coleraine, UK. LA - eng PT - Journal Article PT - Meta-Analysis PT - Systematic Review DEP - 20220120 PL - United States TA - Asia Pac J Ophthalmol (Phila) JT - Asia-Pacific journal of ophthalmology (Philadelphia, Pa.) JID - 101583622 SB - IM MH - *Academic Performance MH - Child MH - Emmetropia MH - Eyeglasses MH - Humans MH - *Hyperopia/therapy MH - Visual Acuity COIS- The authors have no conflicts of interest to declare. EDAT- 2022/01/24 06:00 MHDA- 2022/02/08 06:00 CRDT- 2022/01/23 20:37 PHST- 2022/01/24 06:00 [pubmed] PHST- 2022/02/08 06:00 [medline] PHST- 2022/01/23 20:37 [entrez] AID - S2162-0989(23)00675-8 [pii] AID - 10.1097/APO.0000000000000492 [doi] PST - epublish SO - Asia Pac J Ophthalmol (Phila). 2022 Jan 20;11(1):36-51. doi: 10.1097/APO.0000000000000492. PMID- 35058151 OWN - NLM STAT- MEDLINE DCOM- 20220202 LR - 20230320 IS - 1743-6109 (Electronic) IS - 1743-6095 (Print) IS - 1743-6095 (Linking) VI - 19 IP - 2 DP - 2022 Feb TI - Changes in Frequency and Patterns of Marital Sexual Activity During COVID-19: Evidence From Longitudinal Data Prior to, During and After Lockdown in Singapore. PG - 188-200 LID - S1743-6095(21)00821-3 [pii] LID - 10.1016/j.jsxm.2021.12.004 [doi] AB - BACKGROUND: The literature suggests that the pandemic has affected sexual activity and sexual desire around the world, potentially due to increased levels of stress, movement restrictions under lockdown conditions, and changes in relationship quality. AIM: To investigate changes in frequency and patterns of marital sexual activity and the role of potential factors underlying these changes, during and after COVID-19 lockdown. METHODS: This longitudinal study followed 409 heterosexual married female participants who completed a baseline survey in April-July 2018 and biweekly online surveys over the next 14 weeks; an online survey in May 2020 during the lockdown in Singapore; and an online survey in June 2020 after the lockdown was lifted. Participants were recruited in 2018 using street intercept and screened for inclusion and exclusion criteria. Logistic fixed-effects models were used to test for changes in frequency and patterns of marital sexual activity and assess underlying factors. Pseudo-design-based sample weights were applied. OUTCOMES: The 2018 in-person baseline survey collected information on demographic characteristics and ideal frequency of marital sex, while follow-up online questionnaires in May-June 2020 included items on exact dates of marital sexual activity of previous weeks; stress and fatigue levels; both spouses' stay-at-home statuses during lockdown; and marital satisfaction. RESULTS: 409 heterosexual married women were included in this study. Compared to pre-pandemic levels, the proportion of participants not having marital sex within a week remained stable while weekly sexual frequency increased, with more evenly distributed sexual activity on weekdays and weekends. Stress, fatigue, and marital satisfaction levels predicted probability of non-activity and sexual frequency. CLINICAL TRANSLATION: The increase in weekly sexual frequency has implications for sexual and reproductive health, including sexual satisfaction and prevalence of infertility and low birth weight associated with waiting time to pregnancy. STRENGTHS & LIMITATIONS: The longitudinal nature of the dataset provides unique insights into differences in frequency of marital sexual activity during compared to before the pandemic. Unlike previous studies, detailed data on exact dates of sexual activity allow for detection of differences in sexual activity by day of the week. However, dates of sexual activity were recorded retrospectively and may contain recall errors. Data were collected only from wives and hence dates of marital sexual activities were not cross-validated with husbands. CONCLUSION: Results point to more active and flexible marital sex lives during the pandemic, with effects that persisted after the lockdown ended. Tan PL. Changes in Frequency and Patterns of Marital Sexual Activity During COVID-19: Evidence From Longitudinal Data Prior to, During and After Lockdown in Singapore. J Sex Med 2022;19:188-200. CI - Copyright (c) 2021 International Society for Sexual Medicine. Published by Elsevier Inc. All rights reserved. FAU - Tan, Poh Lin AU - Tan PL AD - Lee Kuan Yew School of Public Policy, National University of Singapore, Singapore. Electronic address: spptplj@nus.edu.sg. LA - eng PT - Journal Article DEP - 20211213 PL - Netherlands TA - J Sex Med JT - The journal of sexual medicine JID - 101230693 SB - IM MH - *COVID-19 MH - Communicable Disease Control MH - Female MH - Humans MH - Longitudinal Studies MH - Retrospective Studies MH - SARS-CoV-2 MH - Sexual Behavior MH - Singapore/epidemiology PMC - PMC8763353 OTO - NOTNLM OT - COVID-19 OT - Lockdown OT - Relationship Satisfaction OT - Sexual Behavior OT - Sexual Frequency OT - Stress EDAT- 2022/01/22 06:00 MHDA- 2022/02/03 06:00 PMCR- 2021/12/13 CRDT- 2022/01/21 05:56 PHST- 2021/08/15 00:00 [received] PHST- 2021/11/29 00:00 [revised] PHST- 2021/12/02 00:00 [accepted] PHST- 2022/01/22 06:00 [pubmed] PHST- 2022/02/03 06:00 [medline] PHST- 2022/01/21 05:56 [entrez] PHST- 2021/12/13 00:00 [pmc-release] AID - S1743-6095(21)00821-3 [pii] AID - 10.1016/j.jsxm.2021.12.004 [doi] PST - ppublish SO - J Sex Med. 2022 Feb;19(2):188-200. doi: 10.1016/j.jsxm.2021.12.004. Epub 2021 Dec 13. PMID- 35039293 OWN - NLM STAT- MEDLINE DCOM- 20220121 LR - 20241004 IS - 2044-6055 (Electronic) IS - 2044-6055 (Linking) VI - 12 IP - 1 DP - 2022 Jan 17 TI - Adoption and continued use of mobile contact tracing technology: multilevel explanations from a three-wave panel survey and linked data. PG - e053327 LID - 10.1136/bmjopen-2021-053327 [doi] LID - e053327 AB - OBJECTIVE: To identify the key individual-level (demographics, attitudes, mobility) and contextual (COVID-19 case numbers, tiers of mobility restrictions, urban districts) determinants of adopting the NHS COVID-19 contact tracing app and continued use overtime. DESIGN AND SETTING: A three-wave panel survey conducted in England in July 2020 (background survey), November 2020 (first measure of app adoption) and March 2021 (continued use of app and new adopters) linked with official data. PARTICIPANTS: N=2500 adults living in England, representative of England's population in terms of regional distribution, age and gender (2011 census). PRIMARY OUTCOME: Repeated measures of self-reported app usage. ANALYTICAL APPROACH: Multilevel logistic regression linking a range of individual level (from survey) and contextual (from linked data) determinants to app usage. RESULTS: We observe initial app uptake at 41%, 95% CI (0.39% to 0.43%), and a 12% drop-out rate by March 2021, 95% CI (0.10% to 0.14%). We also found that 7% of nonusers as of wave 2 became new adopters by wave 3, 95% CI (0.05% to 0.08%). Initial uptake (or failure to use) of the app associated with social norms, privacy concerns and misinformation about third-party data access, with those living in postal districts with restrictions on mobility less likely to use the app. Perceived lack of transparent evidence of effectiveness was associated with drop-out of use. In addition, those who trusted the government were more likely to adopt in wave 3 as new adopters. CONCLUSIONS: Successful uptake of the contact tracing app should be evaluated within the wider context of the UK Government's response to the crisis. Trust in government is key to adoption of the app in wave 3 while continued use is linked to perceptions of transparent evidence. Providing clear information to address privacy concerns could increase uptake, however, the disparities in continued use among ethnic minority participants needs further investigation. CI - (c) Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ. FAU - Horvath, Laszlo AU - Horvath L AUID- ORCID: 0000-0003-0606-1050 AD - Politics, Birkbeck College, University of London, London, UK L.Horvath@bbk.ac.uk. AD - Politics, University of Exeter, Exeter, UK. FAU - Banducci, Susan AU - Banducci S AD - Politics, University of Exeter, Exeter, UK. FAU - Blamire, Joshua AU - Blamire J AD - Institute for Community Research and Development, University of Wolverhampton, Wolverhampton, UK. FAU - Degnen, Cathrine AU - Degnen C AD - School of Geography, Politics and Sociology, Newcastle University, Newcastle upon Tyne, UK. FAU - James, Oliver AU - James O AD - Politics, University of Exeter, Exeter, UK. FAU - Jones, Andrew AU - Jones A AD - Faculty of Laws, UCL, London, UK. FAU - Stevens, Daniel AU - Stevens D AD - Politics, University of Exeter, Exeter, UK. FAU - Tyler, Katharine AU - Tyler K AD - Sociology, Philosophy and Anthropology, University of Exeter, Exeter, UK. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20220117 PL - England TA - BMJ Open JT - BMJ open JID - 101552874 SB - IM MH - Adult MH - *COVID-19 MH - Contact Tracing MH - Ethnic and Racial Minorities MH - Ethnicity MH - Humans MH - Minority Groups MH - *Mobile Applications MH - SARS-CoV-2 MH - Semantic Web PMC - PMC8764714 OTO - NOTNLM OT - COVID-19 OT - health informatics OT - information technology OT - public health COIS- Competing interests: None declared. EDAT- 2022/01/19 06:00 MHDA- 2022/01/22 06:00 PMCR- 2022/01/17 CRDT- 2022/01/18 05:44 PHST- 2022/01/18 05:44 [entrez] PHST- 2022/01/19 06:00 [pubmed] PHST- 2022/01/22 06:00 [medline] PHST- 2022/01/17 00:00 [pmc-release] AID - bmjopen-2021-053327 [pii] AID - 10.1136/bmjopen-2021-053327 [doi] PST - epublish SO - BMJ Open. 2022 Jan 17;12(1):e053327. doi: 10.1136/bmjopen-2021-053327. PMID- 35029174 OWN - NLM STAT- MEDLINE DCOM- 20220124 LR - 20230103 IS - 1536-5964 (Electronic) IS - 0025-7974 (Print) IS - 0025-7974 (Linking) VI - 101 IP - 2 DP - 2022 Jan 14 TI - Clinical study on acupuncture treatment of COVID-19: A protocol for a systematic review and meta-analysis. PG - e28296 LID - 10.1097/MD.0000000000028296 [doi] LID - e28296 AB - BACKGROUND: COVID-19 is an acute respiratory infectious disease, which makes people difficult to breathe; in addition, it is often accompanied by headache, olfaction, and taste disorders of the neurological manifestations. Acupuncture has been proved to have a therapeutic effect on various neurologic manifestations. This study is designed to evaluate the effectiveness and safety of acupuncture for the neurologic manifestations in COVID-19. METHODS: Randomized controlled trials from December 2019 to July 2021 will be included without restrictions on language or publication date. PubMed, EMBASE, Cochrane Library, Web of Science, Chinese Biomedical Databases (CBM), China National Knowledge Infrastructure (CNKI), Wanfang database, and VIP database will be searched. Two researchers will independently select studies, extract data, and evaluate study quality. Cochrane risk of bias tool for randomized trials will be used to assess the risk of bias of included studies. Statistical analyses will be performed using the Review Manager V.5.3 and stata 14.0. ETHICS AND DISSEMINATION: This study will not involve personal information. Ethical approval will not be required. We will publish the results in a peer-reviewed journal. PROSPERO TRIAL REGISTRATION NUMBER: CRD42021265699. CI - Copyright (c) 2022 the Author(s). Published by Wolters Kluwer Health, Inc. FAU - Luo, Wenjun AU - Luo W AD - Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China. FAU - Zhai, Yan AU - Zhai Y AD - Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China. FAU - Sun, Mi AU - Sun M AD - Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China. FAU - Guo, Dong AU - Guo D AD - Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China. FAU - Xie, Fang AU - Xie F AD - Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China. FAU - Yu, Zhou AU - Yu Z AD - Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China. FAU - Tang, Zunhao AU - Tang Z AD - Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China. LA - eng GR - XLSP-2013-35/The Second round construction project of national TCM academic genre inheritance studio/ PT - Journal Article PL - United States TA - Medicine (Baltimore) JT - Medicine JID - 2985248R SB - IM MH - *Acupuncture Therapy MH - *COVID-19/therapy MH - Humans MH - Meta-Analysis as Topic MH - Research Design MH - SARS-CoV-2 MH - Systematic Reviews as Topic MH - Treatment Outcome PMC - PMC8757955 COIS- The authors report no conflicts of interest. EDAT- 2022/01/15 06:00 MHDA- 2022/01/27 06:00 PMCR- 2022/01/14 CRDT- 2022/01/14 08:39 PHST- 2021/11/26 00:00 [received] PHST- 2021/11/29 00:00 [accepted] PHST- 2022/01/14 08:39 [entrez] PHST- 2022/01/15 06:00 [pubmed] PHST- 2022/01/27 06:00 [medline] PHST- 2022/01/14 00:00 [pmc-release] AID - 00005792-202201140-00004 [pii] AID - MD-D-21-07857 [pii] AID - 10.1097/MD.0000000000028296 [doi] PST - ppublish SO - Medicine (Baltimore). 2022 Jan 14;101(2):e28296. doi: 10.1097/MD.0000000000028296. PMID- 35015761 OWN - NLM STAT- MEDLINE DCOM- 20220125 LR - 20260924 IS - 1932-6203 (Electronic) IS - 1932-6203 (Linking) VI - 17 IP - 1 DP - 2022 TI - A systematic review of methodological approaches for evaluating real-world effectiveness of COVID-19 vaccines: Advising resource-constrained settings. PG - e0261930 LID - 10.1371/journal.pone.0261930 [doi] LID - e0261930 AB - Real-world effectiveness studies are important for monitoring performance of COVID-19 vaccination programmes and informing COVID-19 prevention and control policies. We aimed to synthesise methodological approaches used in COVID-19 vaccine effectiveness studies, in order to evaluate which approaches are most appropriate to implement in low- and middle-income countries (LMICs). For this rapid systematic review, we searched PubMed and Scopus for articles published from inception to July 7, 2021, without language restrictions. We included any type of peer-reviewed observational study measuring COVID-19 vaccine effectiveness, for any population. We excluded randomised control trials and modelling studies. All data used in the analysis were extracted from included papers. We used a standardised data extraction form, modified from STrengthening the Reporting of OBservational studies in Epidemiology (STROBE). Study quality was assessed using the REal Life EVidence AssessmeNt Tool (RELEVANT) tool. This study is registered with PROSPERO, CRD42021264658. Our search identified 3,327 studies, of which 42 were eligible for analysis. Most studies (97.5%) were conducted in high-income countries and the majority assessed mRNA vaccines (78% mRNA only, 17% mRNA and viral vector, 2.5% viral vector, 2.5% inactivated vaccine). Thirty-five of the studies (83%) used a cohort study design. Across studies, short follow-up time and limited assessment and mitigation of potential confounders, including previous SARS-CoV-2 infection and healthcare seeking behaviour, were major limitations. This review summarises methodological approaches for evaluating real-world effectiveness of COVID-19 vaccines and highlights the lack of such studies in LMICs, as well as the importance of context-specific vaccine effectiveness data. Further research in LMICs will refine guidance for conducting real-world COVID-19 vaccine effectiveness studies in resource-constrained settings. FAU - Teerawattananon, Yot AU - Teerawattananon Y AD - Health Intervention and Technology Assessment Program, Ministry of Public Health, Nonthaburi, Thailand. AD - Saw Swee Hock School of Public Health, National University of Singapore, Singapore, Singapore. FAU - Anothaisintawee, Thunyarat AU - Anothaisintawee T AD - Department of Family Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand. FAU - Pheerapanyawaranun, Chatkamol AU - Pheerapanyawaranun C AD - Health Intervention and Technology Assessment Program, Ministry of Public Health, Nonthaburi, Thailand. FAU - Botwright, Siobhan AU - Botwright S AUID- ORCID: 0000-0002-8204-2065 AD - Health Intervention and Technology Assessment Program, Ministry of Public Health, Nonthaburi, Thailand. FAU - Akksilp, Katika AU - Akksilp K AUID- ORCID: 0000-0002-7270-8820 AD - Health Intervention and Technology Assessment Program, Ministry of Public Health, Nonthaburi, Thailand. FAU - Sirichumroonwit, Natchalaikorn AU - Sirichumroonwit N AD - Health Intervention and Technology Assessment Program, Ministry of Public Health, Nonthaburi, Thailand. FAU - Budtarad, Nuttakarn AU - Budtarad N AD - Health Intervention and Technology Assessment Program, Ministry of Public Health, Nonthaburi, Thailand. FAU - Isaranuwatchai, Wanrudee AU - Isaranuwatchai W AD - Health Intervention and Technology Assessment Program, Ministry of Public Health, Nonthaburi, Thailand. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Systematic Review DEP - 20220111 PL - United States TA - PLoS One JT - PloS one JID - 101285081 RN - 0 (COVID-19 Vaccines) SB - IM MH - Humans MH - *COVID-19/prevention & control/virology MH - *COVID-19 Vaccines/administration & dosage MH - Databases, Factual MH - SARS-CoV-2/isolation & purification MH - Treatment Outcome MH - *Vaccination/methods MH - Vaccine Efficacy MH - Observational Studies as Topic PMC - PMC8752025 COIS- This study was funded by the Health Systems Research Institute (https://hsri.or.th/researcher), grant number 64134002RM011L0. The authors declare that no other competing interests exist. EDAT- 2022/01/12 06:00 MHDA- 2022/01/27 06:00 PMCR- 2022/01/11 CRDT- 2022/01/11 17:36 PHST- 2021/08/23 00:00 [received] PHST- 2021/12/13 00:00 [accepted] PHST- 2022/01/11 17:36 [entrez] PHST- 2022/01/12 06:00 [pubmed] PHST- 2022/01/27 06:00 [medline] PHST- 2022/01/11 00:00 [pmc-release] AID - PONE-D-21-26919 [pii] AID - 10.1371/journal.pone.0261930 [doi] PST - epublish SO - PLoS One. 2022 Jan 11;17(1):e0261930. doi: 10.1371/journal.pone.0261930. eCollection 2022. PMID- 35014692 OWN - NLM STAT- MEDLINE DCOM- 20220207 LR - 20250623 IS - 1469-493X (Electronic) IS - 1361-6137 (Linking) VI - 1 IP - 1 DP - 2022 Jan 11 TI - Antecolic versus retrocolic reconstruction after partial pancreaticoduodenectomy. PG - CD011862 LID - 10.1002/14651858.CD011862.pub3 [doi] LID - CD011862 AB - BACKGROUND: Pancreatic cancer remains one of the five leading causes of cancer deaths in industrialised nations. For adenocarcinomas in the head of the gland and premalignant lesions, partial pancreaticoduodenectomy represents the standard treatment for resectable tumours. The gastro- or duodenojejunostomy after partial pancreaticoduodenectomy can be reestablished via either an antecolic or retrocolic route. The debate about the more favourable technique for bowel reconstruction is ongoing. OBJECTIVES: To compare the effectiveness and safety of antecolic and retrocolic gastro- or duodenojejunostomy after partial pancreaticoduodenectomy. SEARCH METHODS: In this updated version, we conducted a systematic literature search up to 6 July 2021 to identify all randomised controlled trials (RCTs) in the Cochrane Central Register of Controlled Trials (CENTRAL), the Cochrane Library 2021, Issue 6, MEDLINE (1946 to 6 July 2021), and Embase (1974 to 6 July 2021). We applied no language restrictions. We handsearched reference lists of identified trials to identify further relevant trials, and searched the trial registries clinicaltrials.govand World Health Organization International Clinical Trials Registry Platform for ongoing trials. SELECTION CRITERIA: We considered all RCTs comparing antecolic with retrocolic reconstruction of bowel continuity after partial pancreaticoduodenectomy for any given indication to be eligible. DATA COLLECTION AND ANALYSIS: Two review authors independently screened the identified references and extracted data from the included trials. The same two review authors independently assessed risk of bias of included trials, according to standard Cochrane methodology. We used a random-effects model to pool the results of the individual trials in a meta-analysis. We used odds ratios (OR) to compare binary outcomes and mean differences (MD) for continuous outcomes. MAIN RESULTS: Of a total of 287 citations identified by the systematic literature search, we included eight randomised controlled trials (reported in 11 publications), with a total of 818 participants. There was high risk of bias in all of the trials in regard to blinding of participants and/or outcome assessors and unclear risk for selective reporting in six of the trials. There was little or no difference in the frequency of delayed gastric emptying (OR 0.67; 95% confidence interval (CI) 0.41 to 1.09; eight trials, 818 participants, low-certainty evidence) with relevant heterogeneity between trials (I(2)=40%). There was little or no difference in postoperative mortality (risk difference (RD) -0.00; 95% CI -0.02 to 0.01; eight trials, 818 participants, high-certainty evidence); postoperative pancreatic fistula (OR 1.01; 95% CI 0.73 to 1.40; eight trials, 818 participants, low-certainty evidence); postoperative haemorrhage (OR 0.87; 95% CI 0.47 to 1.59; six trials, 742 participants, low-certainty evidence); intra-abdominal abscess (OR 1.11; 95% CI 0.71 to 1.74; seven trials, 788 participants, low-certainty evidence); bile leakage (OR 0.82; 95% CI 0.35 to 1.91; seven trials, 606 participants, low-certainty evidence); reoperation rate (OR 0.68; 95% CI 0.34 to 1.36; five trials, 682 participants, low-certainty evidence); and length of hospital stay (MD -0.21; 95% CI -1.41 to 0.99; eight trials, 818 participants, low-certainty evidence). Only one trial reported quality of life, on a subgroup of 73 participants, also without a relevant difference between the two groups at any time point. The overall certainty of the evidence was low to moderate, due to some degree of heterogeneity, inconsistency and risk of bias in the included trials. AUTHORS' CONCLUSIONS: There was low- to moderate-certainty evidence suggesting that antecolic reconstruction after partial pancreaticoduodenectomy results in little to no difference in morbidity, mortality, length of hospital stay, or quality of life. Due to heterogeneity in definitions of the endpoints between trials, and differences in postoperative management, future research should be based on clearly defined endpoints and standardised perioperative management, to potentially elucidate differences between these two procedures. Novel strategies should be evaluated for prophylaxis and treatment of common complications, such as delayed gastric emptying. CI - Copyright (c) 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. FAU - Huttner, Felix J AU - Huttner FJ AD - Department of General and Visceral Surgery, Ulm University Hospital , Ulm , Germany. FAU - Klotz, Rosa AU - Klotz R AD - Department of General, Visceral and Transplant Surgery, University of Heidelberg, Heidelberg, Germany. FAU - Ulrich, Alexis AU - Ulrich A AD - Department of General, Visceral, Thoracic and Vascular Surgery , Lukas Hospital Neuss , Neuss , Germany. FAU - Buchler, Markus W AU - Buchler MW AD - Department of General, Visceral and Transplant Surgery, University of Heidelberg, Heidelberg, Germany. FAU - Probst, Pascal AU - Probst P AD - Department of General, Visceral and Transplant Surgery, University of Heidelberg, Heidelberg, Germany. AD - Department of Surgery , Cantonal Hospital Thurgau , Frauenfeld , Switzerland. FAU - Diener, Markus K AU - Diener MK AD - Department of General and Visceral Surgery , Medical Center, University of Freiburg , Freiburg , Germany. LA - eng PT - Journal Article PT - Meta-Analysis PT - Research Support, Non-U.S. Gov't PT - Systematic Review DEP - 20220111 PL - England TA - Cochrane Database Syst Rev JT - The Cochrane database of systematic reviews JID - 100909747 SB - IM UOF - Cochrane Database Syst Rev. 2016 Sep 30;9:CD011862. doi: 10.1002/14651858.CD011862.pub2. PMID: 27689801 MH - Humans MH - Length of Stay MH - *Pancreatectomy MH - Pancreatic Fistula MH - *Pancreaticoduodenectomy/adverse effects MH - Postoperative Complications PMC - PMC8750387 COIS- FH: none known.
RK: none known.
MKD: none known.
MWB: none known.
AU: none known.
PP: none known. EDAT- 2022/01/12 06:00 MHDA- 2022/02/08 06:00 PMCR- 2023/01/11 CRDT- 2022/01/11 08:49 PHST- 2022/01/11 08:49 [entrez] PHST- 2022/01/12 06:00 [pubmed] PHST- 2022/02/08 06:00 [medline] PHST- 2023/01/11 00:00 [pmc-release] AID - CD011862.pub3 [pii] AID - 10.1002/14651858.CD011862.pub3 [doi] PST - epublish SO - Cochrane Database Syst Rev. 2022 Jan 11;1(1):CD011862. doi: 10.1002/14651858.CD011862.pub3. PMID- 34993617 OWN - NLM STAT- MEDLINE DCOM- 20220308 LR - 20261010 IS - 1436-3771 (Electronic) IS - 1432-6981 (Linking) VI - 26 IP - 3 DP - 2022 Mar TI - Clinical effectiveness of clear aligner treatment compared to fixed appliance treatment: an overview of systematic reviews. PG - 2353-2370 LID - 10.1007/s00784-021-04361-1 [doi] AB - OBJECTIVE: To evaluate the available evidence regarding clinical effectiveness of clear aligner treatment (CAT). MATERIALS AND METHODS: A comprehensive literature search was conducted for systematic reviews investigating effectiveness of CAT published up to July 15, 2021. This was accomplished using different electronic databases. No language restriction was applied. Screening, quality assessment, and data extraction were performed by two authors independently. Information was categorized and narratively synthesized for the key findings from moderate and high-quality reviews. RESULTS: A total of 361 potentially eligible reviews were identified. After excluding the non-relevant/low-quality reviews, 18 systematic reviews were included. CAT was found to be effective for mild to moderate malocclusions, and was associated with inferior outcomes when treating severe cases or with achieving specific tooth movements. There were conflicting results regarding treatment duration; however, CAT may be associated with shorter treatment in mild to moderate cases. Relapse was greater with CAT, while periodontal health was better. The risk of root resorption tended to be lower with CAT. Regarding pain, the results were unclear, although CAT was found to be more comfortable and associated with a reduced impact on eating and chewing. CONCLUSIONS: The level of evidence regarding CAT is moderate; hence, further high-quality randomized clinical trials are required. Evidence supports use of aligners as an alternate to fixed appliances in patients with mild-to-moderate malocclusion but not in severe cases. Advancement in technology could enhance the accuracy of CAT in delivering planned outcomes. CLINICAL RELEVANCE: CAT can be used effectively for selected cases with mild to moderate malocclusion. REGISTRATION: PROSPERO registration number: CRD42021246855. CI - (c) 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. FAU - Yassir, Yassir A AU - Yassir YA AUID- ORCID: 0000-0001-9577-8947 AD - Orthodontic Department, College of Dentistry, University of Baghdad, Baghdad, Iraq. yassirkyassir@gmail.com. AD - School of Dentistry, University of Dundee, Dundee, UK. yassirkyassir@gmail.com. FAU - Nabbat, Sarah A AU - Nabbat SA AD - Ministry of Health, Baghdad, Iraq. FAU - McIntyre, Grant T AU - McIntyre GT AD - School of Dentistry, University of Dundee, Dundee, UK. FAU - Bearn, David R AU - Bearn DR AD - School of Dentistry, University of Dundee, Dundee, UK. LA - eng PT - Journal Article PT - Review DEP - 20220106 PL - Germany TA - Clin Oral Investig JT - Clinical oral investigations JID - 9707115 MH - Humans MH - *Malocclusion/therapy MH - Orthodontic Appliances, Fixed MH - *Orthodontic Appliances, Removable MH - Systematic Reviews as Topic MH - Treatment Outcome OTO - NOTNLM OT - Clear aligner OT - Orthodontic appliances OT - Overview of systematic reviews OT - Removable appliance EDAT- 2022/01/08 06:00 MHDA- 2022/03/09 06:00 CRDT- 2022/01/07 06:38 PHST- 2021/09/24 00:00 [received] PHST- 2021/12/29 00:00 [accepted] PHST- 2022/01/08 06:00 [pubmed] PHST- 2022/03/09 06:00 [medline] PHST- 2022/01/07 06:38 [entrez] AID - 10.1007/s00784-021-04361-1 [pii] AID - 10.1007/s00784-021-04361-1 [doi] PST - ppublish SO - Clin Oral Investig. 2022 Mar;26(3):2353-2370. doi: 10.1007/s00784-021-04361-1. Epub 2022 Jan 6. PMID- 34986503 OWN - NLM STAT- MEDLINE DCOM- 20220222 LR - 20250623 IS - 2046-0260 (Electronic) IS - 2046-0252 (Linking) VI - 11 IP - 1 DP - 2022 Feb TI - Prevalence and factors associated with mental health problems in Saudi general population during the coronavirus disease 2019 pandemic: A systematic review and meta-analysis. PG - 18-29 LID - 10.1002/pchj.516 [doi] AB - This systematic review and meta-analysis generates evidence of the prevalence and associated factors of common mental disorders (i.e., depression, anxiety, and stress) related to the pandemic among the Saudi general population. Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, a comprehensive literature search was performed in the respective databases (e.g., PubMed, Scopus, Web of Science), from 22 July to 17 August 2021, and identified a total of 220 articles. Adhering to the inclusion criteria (i.e., original research concerning the prevalence and/or associated factors of depression and/or anxiety and/or stress disorders among the general Saudi population, published in English peer-reviewed journals), 15 studies were included in this review which consisted of a total of 262,656 participants. The overall prevalence of depression, anxiety, and stress was 30% (95% confidence interval [CI]: 22% to 38%, I(2) = 99.58%), 20% (95% CI: 16% to 24%, I(2) = 99.32%), and 29% (95% CI: 11% to 47%, I(2) = 99.76%), respectively. Risk factors of mental health problems were found to be female sex, younger age group, single/divorced marital status, lower education, lower income, non-Saudis, unemployment status, students, being in a small family and living with elderly of the sociodemographic factors. Smokers, less physical activities, lower resilience, reduced immune status, chronic health problems, and psychiatric illness history were associated with a higher degree of mental health problems. In addition, coronavirus disease 2019 (COVID-19)-related risk factors of mental illness included lack of knowledge, fear, worry and concern, family member or friends' infection or death, lockdown restrictions, quarantine, confirmed or suspected of COVID-19 infection, and even pandemic effects. In conclusion, appropriate mental health preventive approaches for the Saudi general people are highly needed, where this review can be worthy of help by providing in detailed information to the respective authorities. CI - (c) 2022 Institute of Psychology, Chinese Academy of Sciences and John Wiley & Sons Australia, Ltd. FAU - Alzahrani, Faris AU - Alzahrani F AUID- ORCID: 0000-0001-6306-8342 AD - Joint Program for Postgraduate Studies in Preventive Medicine, Abha, Saudi Arabia. AD - Department of Public Health, General Directorate of Health Affairs in Aseer Region, Ministry of Health, Abha, Saudi Arabia. FAU - Alshahrani, Najim Z AU - Alshahrani NZ AUID- ORCID: 0000-0002-2163-004X AD - Department of Family and Community Medicine, College of Medicine, University of Jeddah, Jeddah, Saudi Arabia. FAU - Abu Sabah, Abdulelah AU - Abu Sabah A AD - Joint Program for Postgraduate Studies in Preventive Medicine, Abha, Saudi Arabia. AD - Department of Public Health, General Directorate of Health Affairs in Aseer Region, Ministry of Health, Abha, Saudi Arabia. FAU - Zarbah, Abdulmajid AU - Zarbah A AD - Psychiatry Department, College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia. FAU - Abu Sabah, Saeed AU - Abu Sabah S AD - College of Medicine, King Khalid University, Abha, Saudi Arabia. FAU - Mamun, Mohammed A AU - Mamun MA AUID- ORCID: 0000-0002-1728-8966 AD - CHINTA Research Bangladesh, Dhaka, Bangladesh. AD - Department of Public Health and Informatics, Jahangirnagar University, Dhaka, Bangladesh. AD - Department of Public Health, Daffodil International University, Dhaka, Bangladesh. LA - eng PT - Journal Article PT - Meta-Analysis PT - Systematic Review DEP - 20220105 PL - Australia TA - Psych J JT - PsyCh journal JID - 101598595 SB - IM MH - Aged MH - Anxiety/epidemiology MH - *COVID-19 MH - Communicable Disease Control MH - Depression/epidemiology/psychology MH - Female MH - Humans MH - Mental Health MH - *Pandemics MH - Prevalence MH - SARS-CoV-2 MH - Saudi Arabia/epidemiology OTO - NOTNLM OT - COVID-19 OT - Saudi Arabia OT - anxiety OT - depression OT - mental disorders OT - stress EDAT- 2022/01/06 06:00 MHDA- 2022/02/23 06:00 CRDT- 2022/01/05 20:13 PHST- 2021/11/04 00:00 [revised] PHST- 2021/09/16 00:00 [received] PHST- 2021/11/25 00:00 [accepted] PHST- 2022/01/06 06:00 [pubmed] PHST- 2022/02/23 06:00 [medline] PHST- 2022/01/05 20:13 [entrez] AID - 10.1002/pchj.516 [doi] PST - ppublish SO - Psych J. 2022 Feb;11(1):18-29. doi: 10.1002/pchj.516. Epub 2022 Jan 5. PMID- 34986271 OWN - NLM STAT- MEDLINE DCOM- 20220207 LR - 20250623 IS - 1469-493X (Electronic) IS - 1361-6137 (Linking) VI - 1 IP - 1 DP - 2022 Jan 5 TI - High versus low-added sugar consumption for the primary prevention of cardiovascular disease. PG - CD013320 LID - 10.1002/14651858.CD013320.pub2 [doi] LID - CD013320 AB - BACKGROUND: High intake of added sugar have been suggested to impact the risk for cardiovascular disease (CVD). Knowledge on the subject can contribute to preventing CVD. OBJECTIVES: To assess the effects of a high versus low-added sugar consumption for primary prevention of CVD in the general population. SEARCH METHODS: We searched Cochrane Central Register of Controlled Trials (CENTRAL) in the Cochrane Library, MEDLINE, Embase, Conference Proceedings Citation Index-Science (CPCI-S) on 2 July 2021. We also conducted a search of ClinicalTrials.gov and the WHO International Clinical Trials Registry Platform (ICTRP) Search Portal for ongoing or unpublished trials. The search was performed together with reference checking, citation searching and contact with study authors to identify additional studies. We imposed no restriction on language of publication or publication status. SELECTION CRITERIA: We included randomised controlled trials (RCTs), including cross-over trials, that compared different levels of added sugar intake. Exclusion criteria were: participants aged below 18 years; diabetes mellitus (type 1 and 2); and previous CVD. Primary outcomes were incident cardiovascular events (coronary, carotid, cerebral and peripheral arterial disease) and all-cause mortality. Secondary outcomes were changes in systolic and diastolic blood pressure, total cholesterol, LDL-cholesterol, HDL-cholesterol, triglycerides, fasting plasma glucose and adverse events (gastrointestinal symptoms and impaired dental health). DATA COLLECTION AND ANALYSIS: We used the standard methodological procedures expected by Cochrane. MAIN RESULTS: We included 21 RCTs (1110 participants completing the interventions) examining the effects of different levels of added sugar intake with a mean duration of 14 weeks. The study participants were generally described as healthy and the mean age ranged from 22 to 57 years. No studies reported on cardiovascular events or all-cause mortality. There was minimal effect of low intake of added sugar on total cholesterol levels (MD 0.11, 95% CI 0.01 to 0.21; I(2) = 0%; 16 studies; 763 participants; low certainty of evidence) and triglycerides (MD 0.10, 95% CI 0.03 to 0.17; I(2) = 3%; 14 studies; 725 participants) but no evidence of effect on LDL-cholesterol and HDL-cholesterol. There was minimal effect on diastolic blood pressure (MD 1.52, 95% CI 0.67 to 2.37; I(2) = 0%; 13 studies; 873 participants) and on systolic blood pressure (MD 1.44, 95% 0.08 to 2.80; I(2) = 27%, 14 studies; 873 participants; low certainty of evidence), but no evidence of effect on fasting plasma glucose. Only one study reported on dental health, with no events. No other trials reported adverse events (impaired dental health or gastrointestinal symptoms). All results were judged as low-quality evidence according to GRADE. The risk of bias was generally unclear, five studies were classified at an overall low risk of bias (low risk in at least four domains, not including other bias). AUTHORS' CONCLUSIONS: No trials investigating the effect of added sugar on cardiovascular events or all-cause mortality were identified in our searches. Evidence is uncertain whether low intake of added sugar has an effect on risk factors for CVD; the effect was small and the clinical relevance is, therefore, uncertain. Practical ways to achieve reductions in dietary added sugar includes following current dietary recommendations. Future trials should have longer follow-up time and report on all-cause mortality and cardiovascular events in order to clarify the effect of added sugar on these outcomes. Future trials should also aim for more direct interventions and preferably be more independent of industry funding. CI - Copyright (c) 2022 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. FAU - Bergwall, Sara AU - Bergwall S AD - Department of Clinical Sciences Malmo, Vascular Diseases, Lund University, Malmo, Sweden. FAU - Johansson, Anna AU - Johansson A AD - Department of Clinical Sciences Malmo, Vascular Diseases, Lund University, Malmo, Sweden. FAU - Sonestedt, Emily AU - Sonestedt E AD - Department of Clinical Sciences Malmo, Nutritional Epidemiology, Lund University, Malmo, Sweden. FAU - Acosta, Stefan AU - Acosta S AD - Department of Vascular Diseases, Malmo University Hospital, Malmo, Sweden. LA - eng SI - ClinicalTrials.gov/NCT03679689 SI - ClinicalTrials.gov/NCT03574987 SI - ClinicalTrials.gov/NCT02548767 SI - ClinicalTrials.gov/NCT03543644 SI - ClinicalTrials.gov/NCT03259685 GR - BB/G009899/1/BB_/Biotechnology and Biological Sciences Research Council/United Kingdom PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Systematic Review DEP - 20220105 PL - England TA - Cochrane Database Syst Rev JT - The Cochrane database of systematic reviews JID - 100909747 RN - 0 (Dietary Sugars) RN - 0 (Sugars) RN - 97C5T2UQ7J (Cholesterol) SB - IM UOF - doi: 10.1002/14651858.CD013320 MH - Adult MH - Aged MH - *Cardiovascular Diseases/epidemiology/prevention & control MH - Cholesterol MH - Dietary Sugars/adverse effects MH - Humans MH - Middle Aged MH - Primary Prevention MH - Sugars MH - Young Adult PMC - PMC8730703 COIS- Sara Bergwall has declared that she has no conflicts of interest. Anna Johansson reports to work as a health professional related to the topic area of this review. Emily Sonestedt has declared that she has no conflicts of interest. Stefan Acosta has declared that he has no conflicts of interest. EDAT- 2022/01/06 06:00 MHDA- 2022/02/08 06:00 PMCR- 2023/01/05 CRDT- 2022/01/05 17:27 PHST- 2022/01/05 17:27 [entrez] PHST- 2022/01/06 06:00 [pubmed] PHST- 2022/02/08 06:00 [medline] PHST- 2023/01/05 00:00 [pmc-release] AID - CD013320.pub2 [pii] AID - 10.1002/14651858.CD013320.pub2 [doi] PST - epublish SO - Cochrane Database Syst Rev. 2022 Jan 5;1(1):CD013320. doi: 10.1002/14651858.CD013320.pub2. PMID- 34979235 OWN - NLM STAT- MEDLINE DCOM- 20220217 LR - 20260730 IS - 1096-1186 (Electronic) IS - 1043-6618 (Print) IS - 1043-6618 (Linking) VI - 176 DP - 2022 Feb TI - Systemic administration of glucocorticoids, cardiovascular complications and mortality in patients hospitalised with COVID-19, SARS, MERS or influenza: A systematic review and meta-analysis of randomised trials. PG - 106053 LID - S1043-6618(21)00637-X [pii] LID - 10.1016/j.phrs.2021.106053 [doi] LID - 106053 AB - BACKGROUND: Administration of glucocorticoids might reduce mortality in patients with severe COVID-19 but have adverse cardiometabolic effects. OBJECTIVES: to investigate the effect of systemic administration of glucocorticoids on cardiovascular complications and all-cause mortality in patients hospitalised with respiratory viral infections, including COVID-19, SARS, MERS and influenza. METHODS: We identified randomised trials published prior to July 28th, 2021. The Mantel-Haenszel random effects method and the Hartung and Knapp adjustment were used to obtain pooled estimates of treatment effect with 95% confidence intervals. RESULTS: No randomised trials of glucocorticoids for SARS, MERS or influenza reported relevant outcomes. We included eleven COVID-19 randomised trials (8109 patients). Overall, compared to placebo or standard care, glucocorticoids were not associated with a reduction of in-hospital mortality (p = 0.09). In a pre-specified sub-analysis, in-hospital mortality was reduced by 19% when follow-up was restricted to 14 days from randomisation (5/11 trials, 1329 patients, p = 0.02). With longer follow-up (9/11 trials, 7874 patients), administration of glucocorticoids was associated with a trend to benefit for those requiring mechanical ventilation (RR 0.86; 95% CI 0.57-1.27) but possible harm for those not receiving oxygen at randomisation (RR 1.27; 95% CI 1.00 - 1.61), an effect that was significantly different amongst subgroups (p = 0.0359). Glucocorticoids reduced the risk of worsening renal function by 37% (4/11 trials); reported rate of other cardiovascular complications was low. CONCLUSIONS: Administration of systemic glucocorticoids to patients hospitalised with COVID-19 does not lower mortality overall but may reduce it in those requiring respiratory support and increase it in those who do not. CI - Copyright (c) 2022 The Authors. Published by Elsevier Ltd.. All rights reserved. FAU - Caiazzo, Elisabetta AU - Caiazzo E AD - Centre for Immunobiology, Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, UK; Department of Pharmacy, School of Medicine and Surgery, University of Naples Federico II, Naples, Italy. FAU - Rezig, Asma O M AU - Rezig AOM AD - Centre for Immunobiology, Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, UK. FAU - Bruzzese, Dario AU - Bruzzese D AD - Department of Public health, University of Naples Federico II, Naples, Italy. FAU - Ialenti, Armando AU - Ialenti A AD - Department of Pharmacy, School of Medicine and Surgery, University of Naples Federico II, Naples, Italy. FAU - Cicala, Carla AU - Cicala C AD - Department of Pharmacy, School of Medicine and Surgery, University of Naples Federico II, Naples, Italy. FAU - Cleland, John G F AU - Cleland JGF AD - Robertson Centre for Biostatistics, and Glasgow Clinical Trials Unit, Institute of Health and Wellbeing, University of Glasgow, UK; National Heart & Lung Institute, Imperial College London, UK. FAU - Guzik, Tomasz J AU - Guzik TJ AD - Institute of Cardiovascular and Medical Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, UK; Department of Internal and Agricultural Medicine, Jagiellonian University Medical College, Krakow, Poland. FAU - Maffia, Pasquale AU - Maffia P AD - Centre for Immunobiology, Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, UK; Department of Pharmacy, School of Medicine and Surgery, University of Naples Federico II, Naples, Italy; Institute of Cardiovascular and Medical Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, UK. Electronic address: Pasquale.Maffia@glasgow.ac.uk. FAU - Pellicori, Pierpaolo AU - Pellicori P AD - Robertson Centre for Biostatistics, and Glasgow Clinical Trials Unit, Institute of Health and Wellbeing, University of Glasgow, UK. Electronic address: pierpaolo.pellicori@glasgow.ac.uk. LA - eng GR - PG/19/84/34771/BHF_/British Heart Foundation/United Kingdom GR - PG/21/10541/BHF_/British Heart Foundation/United Kingdom GR - PG/21/10634/BHF_/British Heart Foundation/United Kingdom GR - ERC_/European Research Council/International PT - Journal Article PT - Meta-Analysis PT - Research Support, Non-U.S. Gov't PT - Systematic Review DEP - 20211231 PL - Netherlands TA - Pharmacol Res JT - Pharmacological research JID - 8907422 RN - 0 (Glucocorticoids) SB - IM MH - COVID-19/mortality MH - Cardiovascular Diseases/*etiology/mortality MH - Glucocorticoids/*therapeutic use MH - Hospitalization MH - Humans MH - Influenza, Human/*drug therapy/mortality MH - Randomized Controlled Trials as Topic MH - SARS-CoV-2/drug effects MH - Severe Acute Respiratory Syndrome/*drug therapy MH - *COVID-19 Drug Treatment PMC - PMC8719379 OTO - NOTNLM OT - COVID-19 OT - Dexamethasone OT - Glucocorticoids OT - Meta-analysis OT - Mortality OT - Steroids COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2022/01/04 06:00 MHDA- 2022/02/19 06:00 PMCR- 2022/02/01 CRDT- 2022/01/03 20:13 PHST- 2021/12/02 00:00 [received] PHST- 2021/12/28 00:00 [revised] PHST- 2021/12/29 00:00 [accepted] PHST- 2022/01/04 06:00 [pubmed] PHST- 2022/02/19 06:00 [medline] PHST- 2022/01/03 20:13 [entrez] PHST- 2022/02/01 00:00 [pmc-release] AID - S1043-6618(21)00637-X [pii] AID - 106053 [pii] AID - 10.1016/j.phrs.2021.106053 [doi] PST - ppublish SO - Pharmacol Res. 2022 Feb;176:106053. doi: 10.1016/j.phrs.2021.106053. Epub 2021 Dec 31. PMID- 34976621 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240404 IS - 2211-3355 (Print) IS - 2211-3355 (Electronic) IS - 2211-3355 (Linking) VI - 24 DP - 2021 Dec TI - Factors associated with changes in movement behaviors in toddlers and preschoolers during the COVID-19 pandemic: A national cross-sectional study in Mexico. PG - 101552 LID - 10.1016/j.pmedr.2021.101552 [doi] LID - 101552 AB - Little is known about physical activity, screen time and sleep among Mexican toddlers and preschoolers. The COVID-19 pandemic led to the closure of childcare education centers and restrictions to spend time outdoors. This study aimed to investigate the correlates of changes in movement behaviors from before to during the early stages of the COVID-19 lockdown in a national sample of toddlers and preschoolers in Mexico. A cross-sectional study was conducted using an open online survey completed by caretakers of children aged 1-5 years from April to July 2020. The questionnaire enquired about the time spent in each movement behavior during a regular week before and during lockdown, and family and household characteristics. Factors associated with changes in movement behaviors were explored using adjusted linear regression models. A total of 631 children (3.3y, 95% CI: 3.1, 3.4) were included in the study. During lockdown, physical activity decreased by 25%, screen time doubled, and sleep quality declined in 17% (p < 0.001). Toddlers and preschoolers of older age, attending a childcare education center before the lockdown, with a screen in their bedroom, higher access to electronic devices, and lower socioeconomic level experienced greater changes during this period. Those with limits on the use of electronic devices, who had someone available to play with them, and availability of toys experienced less pronounced changes. Pandemic restrictions have impacted movement behaviors of toddlers and preschoolers, with disproportionate effects among lower socioeconomic levels. Interventions with a multi-level equity-oriented approach are urgently needed to mitigate these effects. CI - (c) 2021 The Authors. FAU - Jauregui, Alejandra AU - Jauregui A AD - Health and Nutrition Research Center, National Institute of Public Health, Cuernavaca, Mexico. FAU - Argumedo, Gabriela AU - Argumedo G AD - Health and Nutrition Research Center, National Institute of Public Health, Cuernavaca, Mexico. FAU - Medina, Catalina AU - Medina C AD - Health and Nutrition Research Center, National Institute of Public Health, Cuernavaca, Mexico. FAU - Bonvecchio-Arenas, Anabelle AU - Bonvecchio-Arenas A AD - Health and Nutrition Research Center, National Institute of Public Health, Cuernavaca, Mexico. FAU - Romero-Martinez, Martin AU - Romero-Martinez M AD - Population Health Research Center, National Institute of Public Health, Cuernavaca, Mexico. FAU - Okely, Anthony D AU - Okely AD AD - Early Start and Illawarra Health & Medical Research Institute, University of Wollongong, Wollongong, NSW, Australia. LA - eng PT - Journal Article DEP - 20210908 PL - United States TA - Prev Med Rep JT - Preventive medicine reports JID - 101643766 PMC - PMC8683886 OTO - NOTNLM OT - COVID-19 OT - Children OT - Physical activity OT - Sedentary behavior OT - Sleep COIS- The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2022/01/04 06:00 MHDA- 2022/01/04 06:01 PMCR- 2021/09/08 CRDT- 2022/01/03 05:45 PHST- 2021/02/26 00:00 [received] PHST- 2021/07/12 00:00 [revised] PHST- 2021/09/04 00:00 [accepted] PHST- 2022/01/03 05:45 [entrez] PHST- 2022/01/04 06:00 [pubmed] PHST- 2022/01/04 06:01 [medline] PHST- 2021/09/08 00:00 [pmc-release] AID - S2211-3355(21)00242-4 [pii] AID - 101552 [pii] AID - 10.1016/j.pmedr.2021.101552 [doi] PST - epublish SO - Prev Med Rep. 2021 Sep 8;24:101552. doi: 10.1016/j.pmedr.2021.101552. eCollection 2021 Dec. PMID- 40478081 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250607 IS - 1865-2654 (Electronic) IS - 1865-2646 (Print) IS - 1865-2646 (Linking) VI - 16 IP - 4 DP - 2022 TI - Limitations of democratic rights during the Covid-19 pandemic-exploring the citizens' perception and discussions on dangers to democracy in Germany. PG - 635-661 LID - 10.1007/s12286-023-00556-w [doi] AB - The governments' mitigation measures to fight the COVID-19 pandemic are unprecedented in our post-war history. For overcoming this crisis, citizens were expected to act in compliance with these measures in order to control the spread of the virus and keep public health systems functional. This call for protecting the public health at the same time confronted citizens with several and severe limitations of their democratic freedoms and rights: confinement, restriction on freedoms of movement, religion, specific provisions for public protest and finally also limitations to the right of education by school closures. This paper analyzes how citizens perceive the threat the COVID-19 pandemic and especially the mitigation measures posed for democracy. We assume that pandemic waves and pandemic fatigue have an impact on the perception of threat. To see the overall societal picture, we exploit a large-scale archive of online discourse on Twitter out of which we extract democracy-related discourse with the same temporal and geospatial coverage for our investigation. From that data source, we apply computational methods to extract time series data reflecting aggregated opinions and their evolution over time concerned with the correlation of attitudes towards democracy. We them move deeper using a longitudinal panel survey we conducted in November/December 2020, March/April 2021, and July/August 2021. to have a view of the relationship between citizens' socio-economic status and basic political attitudes. Our multi-method analysis bases on the German case and covers the period from December 2020 to August 2021. CI - (c) The Author(s) 2023. FAU - Katsanidou, Alexia AU - Katsanidou A AUID- ORCID: 0000-0001-5187-5171 AD - GESIS-Leibniz Institute for the Social Sciences, Unter Sachsenhausen 6-8, 50667 Cologne, Germany. GRID: grid.425053.5. ISNI: 0000 0001 1013 1176 AD - Institute for Sociology and Social Psychology, University of Cologne, Cologne, Germany. GRID: grid.6190.e. ISNI: 0000 0000 8580 3777 FAU - Kneuer, Marianne AU - Kneuer M AD - Institute of Political Science, Technical University Dresden, Dresden, Germany. GRID: grid.4488.0. ISNI: 0000 0001 2111 7257 FAU - Bensmann, Felix AU - Bensmann F AD - GESIS-Leibniz Institute for the Social Sciences, Unter Sachsenhausen 6-8, 50667 Cologne, Germany. GRID: grid.425053.5. ISNI: 0000 0001 1013 1176 FAU - Dimitrov, Dimitar AU - Dimitrov D AD - GESIS-Leibniz Institute for the Social Sciences, Unter Sachsenhausen 6-8, 50667 Cologne, Germany. GRID: grid.425053.5. ISNI: 0000 0001 1013 1176 FAU - Dietze, Stefan AU - Dietze S AD - GESIS-Leibniz Institute for the Social Sciences, Unter Sachsenhausen 6-8, 50667 Cologne, Germany. GRID: grid.425053.5. ISNI: 0000 0001 1013 1176 AD - Heinrich Heine University Dusseldorf, Dusseldorf, Germany. GRID: grid.411327.2. ISNI: 0000 0001 2176 9917 LA - eng PT - Journal Article DEP - 20230214 PL - Germany TA - Z Vgl Polit JT - Zeitschrift fur vergleichende politikwissenschaft JID - 9918989296006676 PMC - PMC9927050 OTO - NOTNLM OT - COVID-19 OT - Democracy OT - Democratic rights OT - Panel Survey OT - Twitter COIS- Conflict of interestA. Katsanidou, M. Kneuer, F. Bensmann, D. Dimitrov and S. Dietze declare that they have no competing interests. EDAT- 2022/01/01 00:00 MHDA- 2022/01/01 00:01 PMCR- 2023/02/14 CRDT- 2025/06/06 10:45 PHST- 2022/07/28 00:00 [received] PHST- 2023/01/05 00:00 [revised] PHST- 2023/01/17 00:00 [accepted] PHST- 2022/01/01 00:01 [medline] PHST- 2022/01/01 00:00 [pubmed] PHST- 2025/06/06 10:45 [entrez] PHST- 2023/02/14 00:00 [pmc-release] AID - 556 [pii] AID - 10.1007/s12286-023-00556-w [doi] PST - ppublish SO - Z Vgl Polit. 2022;16(4):635-661. doi: 10.1007/s12286-023-00556-w. Epub 2023 Feb 14. PMID- 34971109 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220416 IS - 1552-5279 (Electronic) IS - 1552-5260 (Print) IS - 1552-5260 (Linking) VI - 17 Suppl 12 IP - Suppl 12 DP - 2021 Dec TI - Feasibility and evaluation of the Dementia Engagement Modelling Program (DEMP): a novel model of aged care during COVID-19. PG - e057991 LID - 10.1002/alz.057991 [doi] LID - e057991 AB - BACKGROUND: The COVID-19 pandemic has a significant impact on the quality of life of aged care residents living with dementia (RLWD). Lockdown measures necessary to protect RLWD and caring staff from COVID-19 have resulted in increased social isolation, loneliness, and behaviors and psychological symptoms of dementia (BPSD). In response, the Australian Government funded a pilot program, the Dementia Engagement Modelling Program (DEMP) as part of the Aged Care COVID-19 Grief and Trauma support package for RLWD, their families and aged care staff. Operated by the Dementia Centre of HammondCare, the DEMP provides first-line multimodal external support for RLWD at a greater risk of developing BPSD due to COVID-19 restrictions. This study aims to describe the DEMP and evaluate its feasibility and outcomes for Australian RLWD. METHODS: A team of 10 trained DEMP consultants was involved in delivering a consultancy service that modelled best practice and person-centred activities of engagement to support staff in providing residents with meaningful purpose, comfort, and reassurance. Consultants also provided coaching and development opportunities for staff to enhance their knowledge regarding communication and engagement. Outcome measures included the regular administration of the Engagement in Preferred ActivitieS Scale (EPASS; >/=4-9 moderate-to-high engagement). A phone evaluation survey for supported residential aged care homes (RACHs) was conducted to determine the feasibility of DEMP. RESULTS: A total of 60 residents (86.0 +/- 7.8 y; 68% female) across 10 RACHs from three Australian states (VIC, NSW, QLD) was supported by DEMP between May and July 2021. More than half of the residents had Alzheimer's disease (n = 24, 40%) and vascular dementia (n = 7, 12%). Completed EPASS assessments (n = 389) demonstrated that the vast majority (64%-72%) of residents scored moderate-to-high engagement. All supported RACHs highly recommended the DEMP to other colleagues and rated the program highly for implementation feasibility including the recommended engagement activities/brokered items. CONCLUSIONS: The DEMP is a novel, feasible and effective dementia-specific engagement modelling program for Australian RLWD in the era of COVID-19 pandemic. CI - (c) 2021 the Alzheimer's Association. FAU - Atee, Mustafa AU - Atee M AD - The Dementia Centre, HammondCare, Wembley, WA, Australia. AD - Curtin Medical School, Faculty of Health Sciences, Curtin University, Bentley, WA, Australia. FAU - Morris, Thomas AU - Morris T AD - The Dementia Centre, HammondCare, St Leonards, NSW, Australia. FAU - Cunningham, Colm AU - Cunningham C AD - The Dementia Centre, HammondCare, St Leonards, NSW, Australia. AD - School of Public Health & Community Medicine, University of New South Wales, Sydney, NSW, Australia. LA - eng PT - Journal Article PL - United States TA - Alzheimers Dement JT - Alzheimer's & dementia : the journal of the Alzheimer's Association JID - 101231978 SB - IM PMC - PMC9011648 EDAT- 2022/01/01 06:00 MHDA- 2022/01/01 06:01 PMCR- 2021/12/31 CRDT- 2021/12/31 08:41 PHST- 2021/12/31 08:41 [entrez] PHST- 2022/01/01 06:00 [pubmed] PHST- 2022/01/01 06:01 [medline] PHST- 2021/12/31 00:00 [pmc-release] AID - ALZ057991 [pii] AID - 10.1002/alz.057991 [doi] PST - ppublish SO - Alzheimers Dement. 2021 Dec;17 Suppl 12(Suppl 12):e057991. doi: 10.1002/alz.057991. PMID- 34971088 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220416 IS - 1552-5279 (Electronic) IS - 1552-5260 (Print) IS - 1552-5260 (Linking) VI - 17 Suppl 12 IP - Suppl 12 DP - 2021 Dec TI - Effect of COVID-19 on BPSD severity and caregiver distress: Trend data from national dementia-specific behavior support programs in Australia. PG - e058454 LID - 10.1002/alz.058454 [doi] LID - e058454 AB - BACKGROUND: Globally, Coronavirus disease 2019 (COVID-19) caused a significant disruption to the physical and mental well-being of all individuals, including those living with dementia. Social restrictions and lockdown measures due to COVID-19 have worsened the feelings of loneliness and behaviours and psychological symptoms of dementia (BPSD). National BPSD support programs in Australia are offered by Dementia Support Australia (DSA) through the Dementia Behavior Management Advisory Service (DBMAS) and the Severe Behavior Response Teams (SBRT). This study aims to investigate the impact of COVID-19 on BPSD severity and related caregiver distress among referrals to DSA programs. METHODS: A retrospective comparative analysis was conducted on the intake data of referrals to DSA between two periods: Pre-COVID-19 Period (January 2018-Decmeber 2019) and COVID-19 Period (January 2020-July 2021). Referrals were compared on demographic characteristics (e.g., age), and BPSD severity (i.e., neuropsychiatric symptoms such as agitation) and caregiver distress as measured by the Neuropsychiatric Inventory (NPI). NPI scores were compared on a month-to-month basis between the specified periods. RESULTS: Across the two periods, there were a total of 23,180 referrals eligible for the analysis. While no differences were noted in age, sex, or dementia subtype, there were elevated levels of NPI severity and caregiver distress scores during COVID-19 Period compared to the Pre-COVID-19 Period. The month-to-month trends of these differences (Figure 1, Figure 2) reflect the timing of outbreaks across Australia. Specifically, there were no significant differences at the start of 2020 prior to the declaration of the pandemic, with an initial rise in NPI severity and distress through April after initial measures were implemented nationally in March 2020. These levels of severity and distress continued to rise through the remainder of 2020, alongside outbreaks in specific regions within Australia, such as Victoria (June-October), and New South Wales (December/January). NPI severity and caregiver distress then began to return to Pre-COVID levels from February-May before elevating again with the outbreak of the Delta variant in Australia. CONCLUSIONS: COVID-19 has a significant impact on the severity levels of BPSD and related caregiver distress. CI - (c) 2021 the Alzheimer's Association. FAU - Whiting, Daniel AU - Whiting D AD - The Dementia Centre, HammondCare, St Leonards, NSW, Australia. FAU - Atee, Mustafa AU - Atee M AD - The Dementia Centre, HammondCare, Wembley, WA, Australia. AD - Curtin Medical School, Faculty of Health Sciences, Curtin University, Bentley, WA, Australia. FAU - Morris, Thomas AU - Morris T AD - The Dementia Centre, HammondCare, St Leonards, NSW, Australia. FAU - Cunningham, Colm AU - Cunningham C AD - The Dementia Centre, HammondCare, St Leonards, NSW, Australia. AD - School of Public Health & Community Medicine, University of New South Wales, Sydney, NSW, Australia. LA - eng PT - Journal Article PL - United States TA - Alzheimers Dement JT - Alzheimer's & dementia : the journal of the Alzheimer's Association JID - 101231978 SB - IM PMC - PMC9011483 EDAT- 2022/01/01 06:00 MHDA- 2022/01/01 06:01 PMCR- 2021/12/31 CRDT- 2021/12/31 08:41 PHST- 2021/12/31 08:41 [entrez] PHST- 2022/01/01 06:00 [pubmed] PHST- 2022/01/01 06:01 [medline] PHST- 2021/12/31 00:00 [pmc-release] AID - ALZ058454 [pii] AID - 10.1002/alz.058454 [doi] PST - ppublish SO - Alzheimers Dement. 2021 Dec;17 Suppl 12(Suppl 12):e058454. doi: 10.1002/alz.058454. PMID- 37427400 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250604 IS - 2689-0216 (Electronic) IS - 2690-3830 (Print) IS - 2689-0216 (Linking) VI - 2 IP - 6 DP - 2021 TI - Primary Care Practices in Western North Carolina: Adaptation to the COVID-19 Pandemic and Ongoing Challenges. PG - 433-440 LID - 10.36518/2689-0216.1331 [doi] AB - INTRODUCTION: The COVID-19 pandemic has created unique challenges for primary care practices while also highlighting their importance in the pandemic response. To understand primary care practice needs, a survey was conducted of practices in Western North Carolina. METHODS: Phase 2 of a primary care needs assessment was administered to 63 practices in Western North Carolina over the course of six weeks, from July 23 to August 31, 2021. RESULTS: Most practices were operating with normal hours, though some still operated with reduced hours. Many practices reported insufficient personal protective equipment (PPE) supplies. While most practices provided at least some care via telehealth, practices cited different barriers to providing telehealth, with patient technology challenges being the most frequently cited. DISCUSSION: Practices have adapted to the restrictions of the pandemic, but many are still vulnerable, and the patients they serve may face reduced access to care due to practice limitations or barriers to telehealth. Practices play a critical role in providing care to patients throughout the pandemic and continue to assist in pandemic response by providing COVID-19 testing and other services. CONCLUSION: Primary care practices in Western North Carolina continue to provide care to patients and support the overall pandemic response. The pandemic has highlighted the need to include primary care in emergency response efforts. Ongoing work will allow North Carolina to reach practices more effectively in future crises via the newly created NC Responds system, which allows primary care practices to be contacted in the event of a public health emergency. CI - (c) 2021 HCA Physician Services, Inc. d/b/a Emerald Medical Education. FAU - Friedman, Hannah R AU - Friedman HR AD - University of North Carolina, Chapel Hill, NC. FAU - Konstanzer, Joseph AU - Konstanzer J AD - University of North Carolina, Chapel Hill, NC. FAU - Richman, Erica AU - Richman E AD - Cecil G. Sheps Center for Health Services Research, Chapel Hill, NC. FAU - Cass, Brian AU - Cass B AD - Cecil G. Sheps Center for Health Services Research, Chapel Hill, NC. FAU - Hodge, Bryan AU - Hodge B AD - UNC Health Sciences at the Mountain Area Health Education Center, Asheville, NC. FAU - Denslow, Sheri AU - Denslow S AD - UNC Health Sciences at the Mountain Area Health Education Center, Asheville, NC. FAU - Halladay, Jacqueline AU - Halladay J AD - University of North Carolina, Chapel Hill, NC. LA - eng GR - T32 HS000032/HS/AHRQ HHS/United States PT - Journal Article DEP - 20211229 PL - United States TA - HCA Healthc J Med JT - HCA healthcare journal of medicine JID - 9918316187606676 PMC - PMC10324795 OTO - NOTNLM OT - COVID-19 OT - SARS-CoV-2 OT - coronavirus infections OT - delivery of health care OT - needs assessment OT - pandemics OT - primary care physicians OT - primary health care COIS- Conflicts of Interest The authors declare that they have no conflicts of interest. EDAT- 2021/12/29 00:00 MHDA- 2021/12/29 00:01 PMCR- 2021/12/29 CRDT- 2023/07/10 05:24 PHST- 2021/12/29 00:01 [medline] PHST- 2021/12/29 00:00 [pubmed] PHST- 2023/07/10 05:24 [entrez] PHST- 2021/12/29 00:00 [pmc-release] AID - 26890216_vol2_iss6_433 [pii] AID - 10.36518/2689-0216.1331 [doi] PST - epublish SO - HCA Healthc J Med. 2021 Dec 29;2(6):433-440. doi: 10.36518/2689-0216.1331. eCollection 2021. PMID- 34955074 OWN - NLM STAT- MEDLINE DCOM- 20220321 LR - 20260127 IS - 1365-2060 (Electronic) IS - 0785-3890 (Print) IS - 0785-3890 (Linking) VI - 54 IP - 1 DP - 2022 Dec TI - Use of serotonin reuptake inhibitor antidepressants and the risk of bleeding complications in patients on anticoagulant or antiplatelet agents: a systematic review and meta-analysis. PG - 80-97 LID - 10.1080/07853890.2021.2017474 [doi] AB - BACKGROUND: Serotonin reuptake inhibitor (SRI) antidepressants are implicated in increasing the risk of bleeding among users; however, the comparative increase in bleeding risk with concurrent antithrombotic therapy (anticoagulant or antiplatelet) remains unclear. As such, we performed a systematic review and meta-analysis of all available evidence to evaluate the effects of SRI and the risk of bleeding complications among patients receiving antithrombotic therapy. METHODS: We searched Medline, Embase, PubMed, PsycINFO, Cochrane Library, Web of Science, Scopus, CINAHL, and grey literature (Google Scholar and preprint reports) up to 26 November, 2020, with no language restrictions (updated on 31 July 2021). The primary outcome of interest was major bleeding. Secondary outcomes included intracranial haemorrhage, gastrointestinal bleeding, and any bleeding events. We used a random-effects model meta-analysis to estimate the odds ratios (ORs) and 95% confidence intervals (CIs). RESULTS: We did not identify any randomised studies but found 32 non-randomized studies (cohort or case-control) with 1,848,285 patients that fulfilled the study selection criteria and were included in the meta-analysis. Among individuals receiving anticoagulants (13 studies), SRI users experienced a statistically higher risk of major bleeding compared to non-SRI users: pooled OR was 1.39 (95% CI, 1.23-1.58; p < .001; moderate heterogeneity). Among individuals receiving antiplatelet therapy (2 studies), SRI users were associated with an increased risk of major bleeding: pooled OR was 1.45 (95% CI, 1.17-1.80; p = .001; low heterogeneity). For secondary outcomes, the use of SRI among individuals treated with antithrombotic therapy revealed a higher risk of gastrointestinal bleeding or any bleeding events, whereas only anticoagulant use was illustrated an increased risk of intracranial haemorrhage. CONCLUSIONS: The use of SRI antidepressants among patients treated with antithrombotic therapy (either anticoagulant or antiplatelet) is associated with a higher risk of bleeding complications, suggesting that caution is warranted in co-prescription. PROSPERO REGISTRATION: CRD42018083917KEY MESSAGESIn this meta-analysis of 32 non-randomized studies, SRI users were associated with the risk of bleeding complications compared to non-SRI users, with concurrent antithrombotic use (either anticoagulant or antiplatelet).The risk was consistently elevated across types of bleeding events (major bleeding, gastrointestinal bleeding, or any bleeding events), whereas only anticoagulant use was associated with intracranial haemorrhage.To promote the rational use of medicines, our findings suggest that the risk-benefit ratio must account for the clear efficacy of SRI against safety concerns in terms of bleeding risks. FAU - Nochaiwong, Surapon AU - Nochaiwong S AD - Department of Pharmaceutical Care, Faculty of Pharmacy, Chiang Mai University, Chiang Mai, Thailand. AD - Pharmacoepidemiology and Statistics Research Center (PESRC), Faculty of Pharmacy, Chiang Mai University, Chiang Mai, Thailand. FAU - Ruengorn, Chidchanok AU - Ruengorn C AD - Department of Pharmaceutical Care, Faculty of Pharmacy, Chiang Mai University, Chiang Mai, Thailand. AD - Pharmacoepidemiology and Statistics Research Center (PESRC), Faculty of Pharmacy, Chiang Mai University, Chiang Mai, Thailand. FAU - Awiphan, Ratanaporn AU - Awiphan R AD - Department of Pharmaceutical Care, Faculty of Pharmacy, Chiang Mai University, Chiang Mai, Thailand. AD - Pharmacoepidemiology and Statistics Research Center (PESRC), Faculty of Pharmacy, Chiang Mai University, Chiang Mai, Thailand. FAU - Chai-Adisaksopha, Chatree AU - Chai-Adisaksopha C AD - Division of Hematology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand. FAU - Tantraworasin, Apichat AU - Tantraworasin A AD - Pharmacoepidemiology and Statistics Research Center (PESRC), Faculty of Pharmacy, Chiang Mai University, Chiang Mai, Thailand. AD - Department of Surgery, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand. FAU - Phosuya, Chabaphai AU - Phosuya C AD - Department of Pharmaceutical Care, Faculty of Pharmacy, Chiang Mai University, Chiang Mai, Thailand. FAU - Kanjanarat, Penkarn AU - Kanjanarat P AD - Department of Pharmaceutical Care, Faculty of Pharmacy, Chiang Mai University, Chiang Mai, Thailand. AD - Pharmacoepidemiology and Statistics Research Center (PESRC), Faculty of Pharmacy, Chiang Mai University, Chiang Mai, Thailand. FAU - Chongruksut, Wilaiwan AU - Chongruksut W AD - Pharmacoepidemiology and Statistics Research Center (PESRC), Faculty of Pharmacy, Chiang Mai University, Chiang Mai, Thailand. AD - Department of Surgery, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand. FAU - Sood, Manish M AU - Sood MM AD - Ottawa Hospital Research Institute, Ottawa Hospital, Ottawa, Canada. AD - Division of Nephrology, Department of Medicine, University of Ottawa, Ottawa, Canada. FAU - Thavorn, Kednapa AU - Thavorn K AD - Pharmacoepidemiology and Statistics Research Center (PESRC), Faculty of Pharmacy, Chiang Mai University, Chiang Mai, Thailand. AD - Ottawa Hospital Research Institute, Ottawa Hospital, Ottawa, Canada. AD - School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, Ottawa, Canada. LA - eng PT - Journal Article PT - Meta-Analysis PT - Research Support, Non-U.S. Gov't PT - Systematic Review PL - England TA - Ann Med JT - Annals of medicine JID - 8906388 RN - 0 (Anticoagulants) RN - 0 (Antidepressive Agents) RN - 0 (Platelet Aggregation Inhibitors) RN - 0 (Selective Serotonin Reuptake Inhibitors) SB - IM MH - Anticoagulants/adverse effects MH - Antidepressive Agents/adverse effects MH - Hemorrhage/chemically induced/epidemiology MH - Humans MH - *Platelet Aggregation Inhibitors/adverse effects MH - *Selective Serotonin Reuptake Inhibitors/adverse effects PMC - PMC8725830 OTO - NOTNLM OT - *Anticoagulation OT - *antidepressant OT - *antiplatelet OT - *bleeding complications OT - *meta-analysis OT - *serotonin-reuptake inhibitors COIS- All authors declare no competing interests. All the researchers involved performed this study in the context of their research. EDAT- 2021/12/28 06:00 MHDA- 2022/03/22 06:00 PMCR- 2021/12/27 CRDT- 2021/12/27 05:30 PHST- 2021/12/27 05:30 [entrez] PHST- 2021/12/28 06:00 [pubmed] PHST- 2022/03/22 06:00 [medline] PHST- 2021/12/27 00:00 [pmc-release] AID - 2017474 [pii] AID - 10.1080/07853890.2021.2017474 [doi] PST - ppublish SO - Ann Med. 2022 Dec;54(1):80-97. doi: 10.1080/07853890.2021.2017474. PMID- 34952279 OWN - NLM STAT- MEDLINE DCOM- 20220408 LR - 20240923 IS - 1873-4758 (Electronic) IS - 0955-3959 (Print) IS - 0955-3959 (Linking) VI - 101 DP - 2022 Mar TI - Public interest in ∆(8)-Tetrahydrocannabinol (delta-8-THC) increased in US states that restricted ∆(9)-Tetrahydrocannabinol (delta-9-THC) use. PG - 103557 LID - S0955-3959(21)00475-8 [pii] LID - 10.1016/j.drugpo.2021.103557 [doi] AB - BACKGROUND: There is an expanding unregulated market for a psychotropic compound called ∆(8)-Tetrahydrocannabinol (delta-8-THC) that is being derived from hemp, but there are no empirical estimates of public interest in this compound. METHODS: To measure public interest, we obtained yearly Google query fractions (QFs) that mentioned delta-8-THC (i.e., "delta 8," "delta-8," or "Delta8") for the past decade (from January 2011 through August 2021) for every country and territory in the world and every state in the United States (US) from Google Trends. We also obtained the same trends for the last complete month of data for all US states (July 2021) to compare across cannabis use policies. We summarized QFs across years, countries, US states and cannabis policies in US states using linear regression, means and ratios. We estimated raw search counts for the US using comscore.com. RESULTS: The global rate of delta-8-THC searches was stable between 2011 and 2019 before increasing by 257.0% from 2019 to 2020 and 705.0% from 2020 to 2021. In 2021, the rate of delta-8-THC searches in the US was at least 10 times higher than the rates in other countries or territories. In absolute terms, there were 22.3 million delta-8-THC searches in the US in the first 8 months of 2021 alone. Increases in delta-8-THC searches from 2020 to 2021 occurred in all 50 US states and the District of Columbia (Mean 854.2%; range = 256.4% - 2831.2%) but continued to vary substantially between states in 2021. In July 2021, the legal status of delta-9-THC use across US states explained 49.0% of the variance in delta-8-THC QFs between US states (R(2) = 0.490; p < 0.001) and was inversely associated, where delta-8-THC QFs were higher in jurisdictions with stricter cannabis use policies. CONCLUSION: Public interest in delta-8-THC increased rapidly in 2020 and 2021 and was particularly high in US states that restricted delta-9-THC use. Jurisdictions should clarify whether delta-8-THC can be sold as a hemp product. CI - Copyright (c) 2021 Elsevier B.V. All rights reserved. FAU - Leas, Eric C AU - Leas EC AD - Herbert Wertheim School of Public Health and Human Longevity Science, University of California San Diego, La Jolla, CA, USA. Electronic address: ecleas@ucsd.edu. FAU - Nobles, Alicia L AU - Nobles AL AD - Division of Infectious Diseases and Global Public Health, Department of Medicine, University of California San Diego, La Jolla, CA, USA. FAU - Shi, Yuyan AU - Shi Y AD - Herbert Wertheim School of Public Health and Human Longevity Science, University of California San Diego, La Jolla, CA, USA. FAU - Hendrickson, Erik AU - Hendrickson E AD - Herbert Wertheim School of Public Health and Human Longevity Science, University of California San Diego, La Jolla, CA, USA. LA - eng GR - K25 DA049944/DA/NIDA NIH HHS/United States GR - R01 DA049730/DA/NIDA NIH HHS/United States GR - R21 DA051356/DA/NIDA NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural DEP - 20211221 PL - Netherlands TA - Int J Drug Policy JT - The International journal on drug policy JID - 9014759 RN - 0 (Analgesics) RN - 0 (Cannabinoid Receptor Agonists) RN - 0 (Hallucinogens) RN - 19GBJ60SN5 (Cannabidiol) RN - 7J8897W37S (Dronabinol) SB - IM MH - Analgesics MH - *Cannabidiol MH - Cannabinoid Receptor Agonists MH - *Cannabis MH - Dronabinol MH - *Hallucinogens MH - Humans MH - United States PMC - PMC9126323 MID - NIHMS1788441 OTO - NOTNLM OT - CBD OT - Cannabidiol OT - Cannabinoid OT - Cannabis OT - Google OT - Hemp OT - Marijuana COIS- Declarations of Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2021/12/25 06:00 MHDA- 2022/04/09 06:00 PMCR- 2022/05/23 CRDT- 2021/12/24 20:14 PHST- 2021/09/08 00:00 [received] PHST- 2021/11/19 00:00 [revised] PHST- 2021/11/28 00:00 [accepted] PHST- 2021/12/25 06:00 [pubmed] PHST- 2022/04/09 06:00 [medline] PHST- 2021/12/24 20:14 [entrez] PHST- 2022/05/23 00:00 [pmc-release] AID - S0955-3959(21)00475-8 [pii] AID - 10.1016/j.drugpo.2021.103557 [doi] PST - ppublish SO - Int J Drug Policy. 2022 Mar;101:103557. doi: 10.1016/j.drugpo.2021.103557. Epub 2021 Dec 21. PMID- 34949034 OWN - NLM STAT- MEDLINE DCOM- 20211230 LR - 20211230 IS - 1660-4601 (Electronic) IS - 1661-7827 (Print) IS - 1660-4601 (Linking) VI - 18 IP - 24 DP - 2021 Dec 20 TI - Experiencing the Unprecedented COVID-19 Lockdown: Abu Dhabi Older Adults' Challenges and Concerns. LID - 10.3390/ijerph182413427 [doi] LID - 13427 AB - This study focused on older adults (60+ years old) of both genders in Abu Dhabi during the COVID-19 pandemic before vaccines were made available (age ranged from 60 years to 75 years). They faced more strict rules of movement restriction and isolation that might have resulted in certain psychological feelings and social reactions. The main objective was to understand Abu Dhabi older adults' psychological feelings during the pandemic and to identify their main concerns and challenges considering the various COVID-19-related policies and restrictions. The psychological feelings focused on fear, loneliness, sadness, irritability, emotional exhaustion, depressive symptoms, sleeping disorders, overeating, and excessive screen use. The objectives also included the changes in the psychological feelings concerning time. Other objectives covered better understanding the differences in (some activities) compared to the other age categories. Data were gathered through an online survey of community members from February to July 2020 as part of government initiatives (Department of Community Development). Responses were collected from 574 older adults in Abu Dhabi (60.1% male and 39.9% female). The analysis mainly used descriptive analysis, t-tests, analysis of variance (ANOVA), and simple trend analysis. For all tests, a p-value less than 0.05 was used for significance. The results pointed to the significant rise in feelings related to excessive screen use, fear, loneliness, and stress. The most significant concerns were related to more restrictions being imposed and not being able to see the grandchildren.The impact of new technologies on their quality of life was significantly reflected by respondents. The influence of the pandemic on older adults' health and weight was also investigated. Analysis of variance, t-tests, and regression analysis with relevant tests were employed. The relevant results showed that some negative psychological feelings were common among older adults during the pandemic. However, the psychological feelings did not portray significant changes with time, except for sleeping disorders and overeating. Overall, older adults scored significantly different from other age groups on many challenges, concerns, and views regarding new technologies during the pandemic. No significant differences were observed regarding gender and marital status for the challenges and concerns. The research summarizes some policy guidance while noting some limitations of this study and future research directions. FAU - Badri, Masood A AU - Badri MA AD - Department of Community Development, Ministries Complex, Abu Dhabi CFJ7+2P, United Arab Emirates. AD - Department of Business Administration, United Arab Emirates University, Abu Dhabi 6M2H+44, United Arab Emirates. FAU - Alkhaili, Mugheer A AU - Alkhaili MA AD - Department of Community Development, Ministries Complex, Abu Dhabi CFJ7+2P, United Arab Emirates. FAU - Aldhaheri, Hamad AU - Aldhaheri H AD - Department of Community Development, Ministries Complex, Abu Dhabi CFJ7+2P, United Arab Emirates. FAU - Yang, Guang AU - Yang G AD - Department of Community Development, Ministries Complex, Abu Dhabi CFJ7+2P, United Arab Emirates. FAU - Albahar, Muna AU - Albahar M AD - Department of Community Development, Ministries Complex, Abu Dhabi CFJ7+2P, United Arab Emirates. AD - Department of Business Administration, United Arab Emirates University, Abu Dhabi 6M2H+44, United Arab Emirates. FAU - Alrashdi, Asma AU - Alrashdi A AD - Department of Community Development, Ministries Complex, Abu Dhabi CFJ7+2P, United Arab Emirates. FAU - Almulla, Bushra AU - Almulla B AD - Department of Community Development, Ministries Complex, Abu Dhabi CFJ7+2P, United Arab Emirates. FAU - Alhyas, Layla AU - Alhyas L AD - Department of Community Development, Ministries Complex, Abu Dhabi CFJ7+2P, United Arab Emirates. LA - eng PT - Journal Article DEP - 20211220 PL - Switzerland TA - Int J Environ Res Public Health JT - International journal of environmental research and public health JID - 101238455 SB - IM MH - Aged MH - *COVID-19 MH - Communicable Disease Control MH - Female MH - Humans MH - Male MH - Middle Aged MH - *Pandemics MH - Quality of Life MH - SARS-CoV-2 MH - United Arab Emirates PMC - PMC8705884 OTO - NOTNLM OT - Abu Dhabi OT - COVID-19 OT - older adults OT - social isolation OT - technological challenges COIS- The authors declare that there has been no conflict of interest. EDAT- 2021/12/25 06:00 MHDA- 2021/12/31 06:00 PMCR- 2021/12/20 CRDT- 2021/12/24 01:20 PHST- 2021/11/15 00:00 [received] PHST- 2021/12/14 00:00 [revised] PHST- 2021/12/14 00:00 [accepted] PHST- 2021/12/24 01:20 [entrez] PHST- 2021/12/25 06:00 [pubmed] PHST- 2021/12/31 06:00 [medline] PHST- 2021/12/20 00:00 [pmc-release] AID - ijerph182413427 [pii] AID - ijerph-18-13427 [pii] AID - 10.3390/ijerph182413427 [doi] PST - epublish SO - Int J Environ Res Public Health. 2021 Dec 20;18(24):13427. doi: 10.3390/ijerph182413427. PMID- 34933205 OWN - NLM STAT- MEDLINE DCOM- 20220112 LR - 20250530 IS - 1476-5616 (Electronic) IS - 0033-3506 (Print) IS - 0033-3506 (Linking) VI - 202 DP - 2022 Jan TI - COVID-19 and tobacco cessation: lessons from India. PG - 93-99 LID - S0033-3506(21)00441-8 [pii] LID - 10.1016/j.puhe.2021.11.010 [doi] AB - OBJECTIVES: The Government of India prohibited the sale of tobacco products during the COVID-19 lockdown to prevent the spread of the SARS-CoV-2 virus. This study assessed the tobacco cessation behaviour and its predictors among adult tobacco users during the initial COVID-19 lockdown period in India. METHODS: A cross-sectional study was conducted with 801 adult tobacco users (both smoking and smokeless tobacco) in two urban metropolitan cities of India over a 2-month period (July to August 2020). The study assessed complete tobacco cessation and quit attempts during the lockdown period. Logistic and negative binomial regression models were used to study the correlates of tobacco cessation and quit attempts, respectively. RESULTS: In total, 90 (11.3%) tobacco users reported that they had quit using tobacco after the COVID-19 lockdown period. Overall, a median of two quit attempts (interquartile range 0-6) was made by tobacco users. Participants with good knowledge on the harmful effects of tobacco use and COVID-19 were significantly more likely to quit tobacco use (odds ratio [OR] 2.2; 95% confidence interval [CI] 1.2-4.0) and reported more quit attempts (incidence risk ratio 5.7; 95% CI 2.8-11.8) compared to those with poor knowledge. Participants who had access to tobacco products were less likely to quit tobacco use compared to those who had no access (OR 0.3; 95% CI 0.2-0.5]. CONCLUSIONS: Access restrictions and correct knowledge on the harmful effects of tobacco use and COVID-19 can play an important role in creating a conducive environment for tobacco cessation among users. CI - Copyright (c) 2021 The Authors. Published by Elsevier Ltd.. All rights reserved. FAU - Arora, M AU - Arora M AD - HRIDAY, New Delhi, India; Public Health Foundation of India, Haryana, New Delhi, India. Electronic address: monika@hriday-shan.org. FAU - Nazar, G P AU - Nazar GP AD - HRIDAY, New Delhi, India; Public Health Foundation of India, Haryana, New Delhi, India. FAU - Sharma, N AU - Sharma N AD - HRIDAY, New Delhi, India. FAU - Jain, N AU - Jain N AD - Public Health Foundation of India, Haryana, New Delhi, India. FAU - Davidson, F AU - Davidson F AD - Usher Institute and SPECTRUM Consortium, University of Edinburgh, Edinburgh, United Kingdom. FAU - Mohan, S AU - Mohan S AD - Public Health Foundation of India, Haryana, New Delhi, India; Centre for Chronic Disease Control, New Delhi, India. FAU - Mohan, D AU - Mohan D AD - Madras Diabetes Research Foundation, Chennai, India. FAU - Ali, M K AU - Ali MK AD - Rollins School of Public Health, Emory University, Atlanta, USA. FAU - Mohan, V AU - Mohan V AD - Madras Diabetes Research Foundation, Chennai, India. FAU - Tandon, N AU - Tandon N AD - All India Institute of Medical Sciences, New Delhi, India. FAU - Narayan, K M Venkat AU - Narayan KMV AD - Rollins School of Public Health, Emory University, Atlanta, USA. FAU - Prabhakaran, D AU - Prabhakaran D AD - Public Health Foundation of India, Haryana, New Delhi, India; Centre for Chronic Disease Control, New Delhi, India. FAU - Bauld, L AU - Bauld L AD - Usher Institute and SPECTRUM Consortium, University of Edinburgh, Edinburgh, United Kingdom. FAU - Srinath Reddy, K AU - Srinath Reddy K AD - Public Health Foundation of India, Haryana, New Delhi, India. LA - eng GR - MR/P027946/1/MRC_/Medical Research Council/United Kingdom GR - MR/P027946/2/MRC_/Medical Research Council/United Kingdom PT - Journal Article DEP - 20211116 PL - Netherlands TA - Public Health JT - Public health JID - 0376507 SB - IM MH - Adult MH - *COVID-19 MH - Communicable Disease Control MH - Cross-Sectional Studies MH - Humans MH - India MH - SARS-CoV-2 MH - *Smoking Cessation MH - *Tobacco Use Cessation PMC - PMC8633921 OTO - NOTNLM OT - COVID-19 OT - Cessation OT - India OT - Smoking OT - Tobacco EDAT- 2021/12/22 06:00 MHDA- 2022/01/13 06:00 PMCR- 2021/11/16 CRDT- 2021/12/21 20:21 PHST- 2021/08/12 00:00 [received] PHST- 2021/10/20 00:00 [revised] PHST- 2021/11/11 00:00 [accepted] PHST- 2021/12/22 06:00 [pubmed] PHST- 2022/01/13 06:00 [medline] PHST- 2021/12/21 20:21 [entrez] PHST- 2021/11/16 00:00 [pmc-release] AID - S0033-3506(21)00441-8 [pii] AID - 10.1016/j.puhe.2021.11.010 [doi] PST - ppublish SO - Public Health. 2022 Jan;202:93-99. doi: 10.1016/j.puhe.2021.11.010. Epub 2021 Nov 16. PMID- 34924001 OWN - NLM STAT- MEDLINE DCOM- 20211221 LR - 20211223 IS - 1745-6215 (Electronic) IS - 1745-6215 (Linking) VI - 22 IP - 1 DP - 2021 Dec 19 TI - A survey of knowledge, perceptions and use of core outcome sets among clinical trialists. PG - 937 LID - 10.1186/s13063-021-05891-5 [doi] LID - 937 AB - BACKGROUND: Core outcome sets (COS) are standardised sets of outcomes, which represent the minimum outcomes that should be measured and reported in clinical trials. COS can enhance comparability across health trials by reducing heterogeneity of outcome measurement and reporting and potentially minimising selective outcome reporting. Examining what researchers involved in trials know and think about COS is essential to increase awareness and promote COS uptake. The aim of this study is therefore to examine clinical trialists' knowledge, perceptions and experiences of COS. METHODS: An online survey design was used. Participants were clinical trialists, operationalised for the current study as researchers named as the contact person on a trial registered on the International Standard Randomised Controlled Trial Number (ISRCTN) Trial repository between 1 January 2019 and 21 July 2020. Survey items assessed clinical trialists' familiarity with and understanding of COS, along with experiences of COS use and development. RESULTS: Of 1913 clinical trialists contacted to participate, 62 (3%) completed the survey. Forty (65%) participants were familiar with COS and, of those familiar with COS, 21 (55%) had been involved in a trial that used a COS. Of clinical trialists who used COS in a trial(s), less than half (n = 9, 41%) reported that all COS outcomes were used. The main barriers to using COS are poor knowledge about COS (n = 43, 69%) and difficulties identifying relevant COS (n = 42, 68%). Clinical trialists also reported perceptions of COS as restrictive and often containing too many outcomes. The main enablers to using COS are clear understanding (n = 51, 82%) and perceived importance of COS (n = 44, 71%). CONCLUSIONS: Enhancing clinical trialists' use of all COS outcomes is needed to reduce outcome heterogeneity and enhance comparability across trial findings. Enhancing awareness of COS importance among researchers and funders is needed to ensure that COS are developed and used by clinical trialists. Education and training may further promote awareness and understanding of COS. CI - (c) 2021. The Author(s). FAU - Bellucci, Chiara AU - Bellucci C AD - School of Public Health, University College Cork, Cork, Ireland. FAU - Hughes, Karen AU - Hughes K AD - MRC Hub for Trials Methodology Research Network, Department of Biostatistics, University of Liverpool, Liverpool, UK. FAU - Toomey, Elaine AU - Toomey E AD - School of Allied Health, University of Limerick, Limerick, Ireland. FAU - Williamson, Paula R AU - Williamson PR AD - MRC/NIHR Trials Methodology Research Partnership, Department of Biostatistics, University of Liverpool, Liverpool, UK. FAU - Matvienko-Sikar, Karen AU - Matvienko-Sikar K AUID- ORCID: 0000-0003-2777-6581 AD - School of Public Health, University College Cork, Cork, Ireland. Karen.msikar@ucc.ie. LA - eng GR - Student Summer Scholarship 2020/Health Research Board Trial Methodology Research Network/ GR - HRB ARPP-2018- A 011/HRBI_/Health Research Board/Ireland PT - Journal Article PT - Randomized Controlled Trial DEP - 20211219 PL - England TA - Trials JT - Trials JID - 101263253 SB - IM MH - Humans MH - *Outcome Assessment, Health Care PMC - PMC8684586 OTO - NOTNLM OT - Attitudes OT - Core outcome sets OT - Knowledge OT - Trials OT - Uptake COIS- The authors declare that they have no competing interests. EDAT- 2021/12/21 06:00 MHDA- 2021/12/22 06:00 PMCR- 2021/12/19 CRDT- 2021/12/20 05:33 PHST- 2020/11/04 00:00 [received] PHST- 2021/11/28 00:00 [accepted] PHST- 2021/12/20 05:33 [entrez] PHST- 2021/12/21 06:00 [pubmed] PHST- 2021/12/22 06:00 [medline] PHST- 2021/12/19 00:00 [pmc-release] AID - 10.1186/s13063-021-05891-5 [pii] AID - 5891 [pii] AID - 10.1186/s13063-021-05891-5 [doi] PST - epublish SO - Trials. 2021 Dec 19;22(1):937. doi: 10.1186/s13063-021-05891-5. PMID- 34919291 OWN - NLM STAT- MEDLINE DCOM- 20220427 LR - 20220427 IS - 1365-2230 (Electronic) IS - 0307-6938 (Linking) VI - 47 IP - 5 DP - 2022 May TI - Clinical features of chronic bullous dermatosis of childhood. PG - 873-881 LID - 10.1111/ced.15059 [doi] AB - BACKGROUND: Chronic bullous dermatosis of childhood (CBDC) is a rare autoimmune subepidermal blistering disease, which can develop following vaccination or medication, or with an autoimmune condition or illness, among other causes. AIM: To identify and better understand the clinical features of CBDC by performing a systematic review, in line with the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines. METHODS: Eligible studies included publication since 1980, CBDC diagnosis, case studies, subjects aged < 18 years, clinical features and no language restriction. A database search was conducted including Embase, MEDLINE and Scopus on 14 July 2021 (see Appendix for search terms). Data were assessed for risk of bias. Jamovi was used for statistical analysis. Age and sex were compared with mucocutaneous involvement, cutaneous involvement, other symptoms, human leucocyte antigen type and lesion descriptions. RESULTS: After removing duplicate references using Endnote, 351 papers were identified, of which 91 met the inclusion criteria. These papers included 130 cases of CBDC: 110 children and 20 neonates. The ratio of male : female patients was 19 : 1 for neonates and 74:55 for children. chi(2) analysis with 1 degree of freedom showed that CBDC in neonates was associated with facial (chi(2)((1)) = 9.67, P < 0.01), mouth (chi(2)((1)) = 31.0, P < 0.001), upper airway (chi(2)((1)) = 52.7, P < 0.001), oesophageal (chi(2)((1)) = 34.6, P < 0.001), ophthalmic (chi(2)((1)) = 6.27, P = 0.01) involvement and with respiratory distress (chi(2)((1)) = 22.7 P < 0.001). CBDC in children was associated with genital (chi(2)((1)) = 3.96, P < 0.05), arm (chi(2)((1)) = 6.99, P < 0.01) and leg (chi(2)((1)) = 7.03, P < 0.01) involvement. CBDC in male patients was associated with facial (chi(2)((1)) = 7.01, P < 0.01), scalp (chi(2)((1)) = 5.96, P < 0.02) and perianal (chi(2)((1)) = 7.22, P < 0.01) involvement. CONCLUSION: Neonates with CBDC are more likely to have a mucocutaneous distribution of lesions, whereas children are more likely to have cutaneous lesions. The limitations of this study include selection bias, and the small neonate sample size makes the study unrepresentative of the population. The review highlights the need for further research into the clinical features of CBDC in neonates. CI - (c) 2021 British Association of Dermatologists. FAU - Wilson, Anna AU - Wilson A AUID- ORCID: 0000-0001-5596-2109 AD - Department of Dermatology, St George Hospital, Sydney, NSW, Australia. AD - Faculty of Medicine, University of NSW, Sydney, NSW, Australia. FAU - Murrell, Dedee F AU - Murrell DF AUID- ORCID: 0000-0003-2971-0199 AD - Department of Dermatology, St George Hospital, Sydney, NSW, Australia. AD - Faculty of Medicine, University of NSW, Sydney, NSW, Australia. LA - eng PT - Journal Article PT - Systematic Review DEP - 20220102 PL - England TA - Clin Exp Dermatol JT - Clinical and experimental dermatology JID - 7606847 RN - 0 (Immunoglobulin A) SB - IM MH - *Autoimmune Diseases MH - Child MH - Chronic Disease MH - Female MH - *Graft vs Host Disease MH - Humans MH - Immunoglobulin A/analysis MH - Infant, Newborn MH - Male MH - *Skin Diseases, Vesiculobullous/drug therapy EDAT- 2021/12/18 06:00 MHDA- 2022/04/28 06:00 CRDT- 2021/12/17 12:27 PHST- 2021/11/26 00:00 [received] PHST- 2021/12/07 00:00 [accepted] PHST- 2021/12/18 06:00 [pubmed] PHST- 2022/04/28 06:00 [medline] PHST- 2021/12/17 12:27 [entrez] AID - 10.1111/ced.15059 [doi] PST - ppublish SO - Clin Exp Dermatol. 2022 May;47(5):873-881. doi: 10.1111/ced.15059. Epub 2022 Jan 2. PMID- 34919135 OWN - NLM STAT- MEDLINE DCOM- 20220113 LR - 20241108 IS - 2574-3805 (Electronic) IS - 2574-3805 (Linking) VI - 4 IP - 12 DP - 2021 Dec 1 TI - Intermittent Fasting and Obesity-Related Health Outcomes: An Umbrella Review of Meta-analyses of Randomized Clinical Trials. PG - e2139558 LID - 10.1001/jamanetworkopen.2021.39558 [doi] LID - e2139558 AB - IMPORTANCE: Several meta-analyses of randomized clinical trials (RCTs) have demonstrated the many health benefits of intermittent fasting (IF). However, there has been little synthesis of the strength and quality of this evidence in aggregate to date. OBJECTIVE: To grade the evidence from published meta-analyses of RCTs that assessed the associations of IF (zero-calorie alternate-day fasting, modified alternate-day fasting, the 5:2 diet, and time-restricted eating) with obesity-related health outcomes. EVIDENCE REVIEW: PubMed, Embase, and Cochrane database of systematic reviews were searched from database inception to January 12, 2021. Data analysis was conducted from April 2021 through July 2021. Meta-analyses of RCTs investigating effects of IF in adults were included. The effect sizes of IF were recalculated using a random-effects model. We assessed the quality of evidence per association by applying the GRADE criteria (Grading of Recommendations, Assessment, Development, and Evaluations) as high, moderate, low, and very low. FINDINGS: A total of 11 meta-analyses comprising 130 RCTs (median [IQR] sample size, 38 [24-69] participants; median [IQR] follow-up period, 3 [2-5] months) were included describing 104 unique associations of different types of IF with obesity-related health outcomes (median [IQR] studies per association, 4 [3-5]). There were 28 statistically significant associations (27%) that demonstrated the beneficial outcomes for body mass index, body weight, fat mass, low-density lipoprotein cholesterol, total cholesterol, triglycerides, fasting plasma glucose, fasting insulin, homeostatic model assessment of insulin resistance, and blood pressure. IF was found to be associated with reduced fat-free mass. One significant association (1%) supported by high-quality evidence was modified alternate-day fasting for 1 to 2 months, which was associated with moderate reduction in body mass index in healthy adults and adults with overweight, obesity, or nonalcoholic fatty liver disease compared with regular diet. Six associations (6%) were supported by moderate quality evidence. The remaining associations found to be significant were supported by very low (75 associations [72%]) to low (22 associations [21%]) quality evidence. CONCLUSIONS AND RELEVANCE: In this umbrella review, we found beneficial associations of IF with anthropometric and cardiometabolic outcomes supported by moderate to high quality of evidence, which supports the role of IF, especially modified alternate-day fasting, as a weight loss approach for adults with overweight or obesity. More clinical trials with long-term follow-up are needed to investigate the effects of IF on clinical outcomes such as cardiovascular events and mortality. FAU - Patikorn, Chanthawat AU - Patikorn C AD - Department of Social and Administrative Pharmacy, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, Thailand. FAU - Roubal, Kiera AU - Roubal K AD - School of Pharmacy, University of Wisconsin-Madison. FAU - Veettil, Sajesh K AU - Veettil SK AD - Department of Pharmacotherapy, College of Pharmacy, University of Utah, Salt Lake City. FAU - Chandran, Viji AU - Chandran V AD - Department of Pharmacy Practice, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, Udupi, Karnataka, India. FAU - Pham, Tuan AU - Pham T AD - Division of Gastroenterology, Hepatology & Nutrition, Department of Internal Medicine, University of Utah, Salt Lake City. FAU - Lee, Yeong Yeh AU - Lee YY AD - School of Medical Sciences, Universiti Sains Malaysia, Kota Bharu, Malaysia. FAU - Giovannucci, Edward L AU - Giovannucci EL AD - Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, Massachusetts. AD - Department of Nutrition, Harvard T. H. Chan School of Public Health, Boston, Massachusetts. FAU - Varady, Krista A AU - Varady KA AD - Department of Kinesiology and Nutrition, University of Illinois at Chicago. FAU - Chaiyakunapruk, Nathorn AU - Chaiyakunapruk N AD - Department of Pharmacotherapy, College of Pharmacy, University of Utah, Salt Lake City. LA - eng PT - Journal Article PT - Systematic Review DEP - 20211201 PL - United States TA - JAMA Netw Open JT - JAMA network open JID - 101729235 SB - IM MH - Fasting/*physiology MH - Heart Disease Risk Factors MH - Humans MH - Meta-Analysis as Topic MH - Models, Statistical MH - Non-alcoholic Fatty Liver Disease/diet therapy/metabolism/physiopathology MH - Obesity/*diet therapy/metabolism/physiopathology MH - Randomized Controlled Trials as Topic MH - Treatment Outcome MH - Weight Loss PMC - PMC8683964 COIS- Conflict of Interest Disclosures: Dr Pham reported receiving personal fees for the Southwest Obesity Symposium outside the submitted work. Dr Varady reported receiving author fees from Hachette Book Group for the book, The Every Other Day Diet. No other conflicts were reported. EDAT- 2021/12/18 06:00 MHDA- 2022/01/14 06:00 PMCR- 2021/12/17 CRDT- 2021/12/17 12:21 PHST- 2021/12/17 12:21 [entrez] PHST- 2021/12/18 06:00 [pubmed] PHST- 2022/01/14 06:00 [medline] PHST- 2021/12/17 00:00 [pmc-release] AID - 2787246 [pii] AID - zoi211110 [pii] AID - 10.1001/jamanetworkopen.2021.39558 [doi] PST - epublish SO - JAMA Netw Open. 2021 Dec 1;4(12):e2139558. doi: 10.1001/jamanetworkopen.2021.39558. PMID- 34916335 OWN - NLM STAT- MEDLINE DCOM- 20221025 LR - 20250530 IS - 1472-3263 (Electronic) IS - 1368-4973 (Print) IS - 1368-4973 (Linking) VI - 98 IP - 7 DP - 2022 Nov TI - Impacts of COVID-19 on sexual behaviour in Britain: findings from a large, quasi-representative survey (Natsal-COVID). PG - 469-477 LID - 10.1136/sextrans-2021-055210 [doi] AB - OBJECTIVES: Physical restrictions imposed to combat COVID-19 dramatically altered sexual lifestyles but the specific impacts on sexual behaviour are still emerging. We investigated physical and virtual sexual activities, sexual frequency and satisfaction in the 4 months following lockdown in Britain in March 2020 and compared with pre-lockdown. METHODS: Weighted analyses of web panel survey data collected July/August 2020 from a quota-based sample of 6654 people aged 18-59 years in Britain. Multivariable regression took account of participants' opportunity for partnered sex, gender and age, to examine their independent associations with perceived changes in sexual frequency and satisfaction. RESULTS: Most participants (86.7%) reported some form of sex following lockdown with physical activities more commonly reported than virtual activities (83.7% vs 52.6%). Altogether, 63.2% reported sex with someone ('partnered sex') since lockdown, three-quarters of whom were in steady cohabiting relationships. With decreasing relationship formality, partnered sex was less frequently reported, while masturbation, sex toy use and virtual activities were more frequently reported. Around half of all participants perceived no change in partnered sex frequency compared with the 3 months pre-lockdown, but this was only one-third among those not cohabiting, who were more likely to report increases in non-partnered activities than those cohabiting. Two-thirds of participants perceived no change in sexual satisfaction; declines were more common among those not cohabiting. Relationship informality and younger age were independently associated with perceiving change, often declines, in sexual frequency and satisfaction. CONCLUSIONS: Our quasi-representative study of the British population found a substantial minority reported significant shifts in sexual repertoires, frequency and satisfaction following the introduction of COVID-19 restrictions. However, these negative changes were perceived by some more than others; predominantly those not cohabiting and the young. As these groups are most likely to experience adverse sexual health, it is important to monitor behaviour as restrictions ease to understand the longer term consequences, including for health services. CI - (c) Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ. FAU - Mercer, Catherine H AU - Mercer CH AUID- ORCID: 0000-0002-4220-5034 AD - Institute for Global Health, University College London, London, UK c.mercer@ucl.ac.uk. FAU - Clifton, Soazig AU - Clifton S AUID- ORCID: 0000-0002-4171-0805 AD - Institute for Global Health, University College London, London, UK. AD - NatCen Social Research, London, UK. FAU - Riddell, Julie AU - Riddell J AUID- ORCID: 0000-0002-8084-4566 AD - MRC/CSO Social and Public Health Sciences Unit, University of Glasgow, Glasgow, UK. FAU - Tanton, Clare AU - Tanton C AUID- ORCID: 0000-0002-4612-1858 AD - Faculty of Public Health and Policy, London School of Hygiene and Tropical Medicine, London, UK. FAU - Freeman, Lily AU - Freeman L AD - Institute for Global Health, University College London, London, UK. FAU - Copas, Andrew J AU - Copas AJ AUID- ORCID: 0000-0001-8968-5963 AD - Institute for Global Health, University College London, London, UK. FAU - Dema, Emily AU - Dema E AUID- ORCID: 0000-0002-7254-2023 AD - Institute for Global Health, University College London, London, UK. FAU - Boso Perez, Raquel AU - Boso Perez R AUID- ORCID: 0000-0001-7342-4566 AD - MRC/CSO Social and Public Health Sciences Unit, University of Glasgow, Glasgow, UK. FAU - Gibbs, Jo AU - Gibbs J AUID- ORCID: 0000-0001-5696-0260 AD - Institute for Global Health, University College London, London, UK. FAU - Macdowall, Wendy AU - Macdowall W AUID- ORCID: 0000-0001-5868-8336 AD - Faculty of Public Health and Policy, London School of Hygiene and Tropical Medicine, London, UK. FAU - Menezes, Dee AU - Menezes D AUID- ORCID: 0000-0002-1628-1228 AD - Institute for Health Informatics, University College London, London, UK. FAU - Ridge, Mary-Clare AU - Ridge MC AUID- ORCID: 0000-0001-9621-4529 AD - Institute for Global Health, University College London, London, UK. FAU - Bonell, Chris AU - Bonell C AUID- ORCID: 0000-0002-6253-6498 AD - Faculty of Public Health and Policy, London School of Hygiene and Tropical Medicine, London, UK. FAU - Sonnenberg, Pam AU - Sonnenberg P AUID- ORCID: 0000-0002-1067-1583 AD - Institute for Global Health, University College London, London, UK. FAU - Field, Nigel AU - Field N AUID- ORCID: 0000-0002-2825-6652 AD - Institute for Global Health, University College London, London, UK. FAU - Mitchell, Kirstin R AU - Mitchell KR AUID- ORCID: 0000-0002-4409-6601 AD - MRC/CSO Social and Public Health Sciences Unit, University of Glasgow, Glasgow, UK. LA - eng GR - MC_UU_00022/3/MRC_/Medical Research Council/United Kingdom GR - SPHSU18/CSO_/Chief Scientist Office/United Kingdom GR - 212931/Z/18/Z/WT_/Wellcome Trust/United Kingdom GR - DH_/Department of Health/United Kingdom PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20211216 PL - England TA - Sex Transm Infect JT - Sexually transmitted infections JID - 9805554 SB - IM MH - Humans MH - United Kingdom/epidemiology MH - *COVID-19/epidemiology/prevention & control MH - Communicable Disease Control MH - Sexual Behavior MH - Sexual Partners PMC - PMC8687784 OTO - NOTNLM OT - COVID-19 OT - sexual behaviour OT - sexual health OT - sexual partners COIS- Competing interests: None declared. EDAT- 2021/12/18 06:00 MHDA- 2022/10/26 06:00 PMCR- 2021/12/16 CRDT- 2021/12/17 06:13 PHST- 2021/07/07 00:00 [received] PHST- 2021/11/08 00:00 [accepted] PHST- 2021/12/18 06:00 [pubmed] PHST- 2022/10/26 06:00 [medline] PHST- 2021/12/17 06:13 [entrez] PHST- 2021/12/16 00:00 [pmc-release] AID - sextrans-2021-055210 [pii] AID - 10.1136/sextrans-2021-055210 [doi] PST - ppublish SO - Sex Transm Infect. 2022 Nov;98(7):469-477. doi: 10.1136/sextrans-2021-055210. Epub 2021 Dec 16. PMID- 34910151 OWN - NLM STAT- MEDLINE DCOM- 20220113 LR - 20260518 IS - 2574-3805 (Electronic) IS - 2574-3805 (Linking) VI - 4 IP - 12 DP - 2021 Dec 1 TI - Evaluation of Clinical Practice Guidelines on Fall Prevention and Management for Older Adults: A Systematic Review. PG - e2138911 LID - 10.1001/jamanetworkopen.2021.38911 [doi] LID - e2138911 AB - IMPORTANCE: With the global population aging, falls and fall-related injuries are ubiquitous, and several clinical practice guidelines for falls prevention and management for individuals 60 years or older have been developed. A systematic evaluation of the recommendations and agreement level is lacking. OBJECTIVES: To perform a systematic review of clinical practice guidelines for falls prevention and management for adults 60 years or older in all settings (eg, community, acute care, and nursing homes), evaluate agreement in recommendations, and identify potential gaps. EVIDENCE REVIEW: A systematic review following Preferred Reporting Items for Systematic Reviews and Meta-analyses statement methods for clinical practice guidelines on fall prevention and management for older adults was conducted (updated July 1, 2021) using MEDLINE, PubMed, PsycINFO, Embase, CINAHL, the Cochrane Library, PEDro, and Epistemonikos databases. Medical Subject Headings search terms were related to falls, clinical practice guidelines, management and prevention, and older adults, with no restrictions on date, language, or setting for inclusion. Three independent reviewers selected records for full-text examination if they followed evidence- and consensus-based processes and assessed the quality of the guidelines using Appraisal of Guidelines for Research & Evaluation II (AGREE-II) criteria. The strength of the recommendations was evaluated using Grades of Recommendation, Assessment, Development, and Evaluation scores, and agreement across topic areas was assessed using the Fleiss kappa statistic. FINDINGS: Of 11 414 records identified, 159 were fully reviewed and assessed for eligibility, and 15 were included. All 15 selected guidelines had high-quality AGREE-II total scores (mean [SD], 80.1% [5.6%]), although individual quality domain scores for clinical applicability (mean [SD], 63.4% [11.4%]) and stakeholder (clinicians, patients, or caregivers) involvement (mean [SD], 76.3% [9.0%]) were lower. A total of 198 recommendations covering 16 topic areas in 15 guidelines were identified after screening 4767 abstracts that proceeded to 159 full texts. Most (>/=11) guidelines strongly recommended performing risk stratification, assessment tests for gait and balance, fracture and osteoporosis management, multifactorial interventions, medication review, exercise promotion, environment modification, vision and footwear correction, referral to physiotherapy, and cardiovascular interventions. The strengths of the recommendations were inconsistent for vitamin D supplementation, addressing cognitive factors, and falls prevention education. Recommendations on use of hip protectors and digital technology or wearables were often missing. None of the examined guidelines included a patient or caregiver panel in their deliberations. CONCLUSIONS AND RELEVANCE: This systematic review found that current clinical practice guidelines on fall prevention and management for older adults showed a high degree of agreement in several areas in which strong recommendations were made, whereas other topic areas did not achieve this level of consensus or coverage. Future guidelines should address clinical applicability of their recommendations and include perspectives of patients and other stakeholders. FAU - Montero-Odasso, Manuel M AU - Montero-Odasso MM AD - Schulich School of Medicine and Dentistry, Division of Geriatric Medicine, Department of Medicine, The University of Western Ontario, London, Ontario, Canada. AD - Gait and Brain Lab, Parkwood Institute, Lawson Health Research Institute, London, Ontario, Canada. AD - Department of Epidemiology and Biostatistics, The University of Western Ontario, London, Ontario, Canada. FAU - Kamkar, Nellie AU - Kamkar N AD - Gait and Brain Lab, Parkwood Institute, Lawson Health Research Institute, London, Ontario, Canada. FAU - Pieruccini-Faria, Frederico AU - Pieruccini-Faria F AD - Gait and Brain Lab, Parkwood Institute, Lawson Health Research Institute, London, Ontario, Canada. AD - Department of Epidemiology and Biostatistics, The University of Western Ontario, London, Ontario, Canada. FAU - Osman, Abdelhady AU - Osman A AD - Department of Epidemiology and Biostatistics, The University of Western Ontario, London, Ontario, Canada. FAU - Sarquis-Adamson, Yanina AU - Sarquis-Adamson Y AD - Gait and Brain Lab, Parkwood Institute, Lawson Health Research Institute, London, Ontario, Canada. FAU - Close, Jacqueline AU - Close J AD - Falls, Balance and Injury Research Centre, Neuroscience Research Australia, University of New South Wales, Sydney, Australia. AD - Prince of Wales Clinical School, Medicine, University of New South Wales, Sydney, Australia. FAU - Hogan, David B AU - Hogan DB AD - Division of Geriatric Medicine, Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada. FAU - Hunter, Susan Winifred AU - Hunter SW AD - Faculty of Health Sciences, University of Western Ontario, London, Ontario, Canada. AD - School of Physical Therapy, University of Western Ontario, London, Ontario, Canada. FAU - Kenny, Rose Anne AU - Kenny RA AD - Department of Medical Gerontology, Mercers Institute for Ageing, St James Hospital, Dublin, Ireland. FAU - Lipsitz, Lewis A AU - Lipsitz LA AD - Hinda and Arthur Marcus Institute for Aging Research, Hebrew SeniorLife, Harvard Medical School, Boston, Massachusetts. FAU - Lord, Stephen R AU - Lord SR AD - Falls, Balance and Injury Research Centre, Neuroscience Research Australia, Sydney, New South Wales, Australia. AD - School of Public Health and Community Medicine, University of New South Wales, Sydney, New South Wales, Australia. FAU - Madden, Kenneth M AU - Madden KM AD - Division of Geriatric Medicine, Department of Medicine, Department of Internal Medicine, Section of Geriatric Medicine, University of British Columbia, Vancouver, British Columbia, Canada. AD - Division of Geriatric Medicine, Department of Medicine, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada. FAU - Petrovic, Mirko AU - Petrovic M AD - Section of Geriatrics, Department of Internal Medicine and Paediatrics, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium. FAU - Ryg, Jesper AU - Ryg J AD - Department of Geriatric Medicine, Odense University Hospital, Odense, Denmark. AD - Geriatric Research Unit, Department of Clinical Research, University of Southern Denmark, Odense, Denmark. FAU - Speechley, Mark AU - Speechley M AD - Department of Epidemiology and Biostatistics, The University of Western Ontario, London, Ontario, Canada. AD - Schulich Interfaculty Program in Public Health, Schulich School of Medicine & Dentistry, University of Western Ontario, London, Ontario, Canada. FAU - Sultana, Munira AU - Sultana M AD - Gait and Brain Lab, Parkwood Institute, Lawson Health Research Institute, London, Ontario, Canada. FAU - Tan, Maw Pin AU - Tan MP AD - Centre for Innovation in Medical Engineering, Faculty of Engineering, University of Malaysia, Kuala Lumpur, Malaysia. AD - Department of Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia. FAU - van der Velde, N AU - van der Velde N AD - Section of Geriatric Medicine, Department of Internal Medicine, Amsterdam Public Health, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands. FAU - Verghese, Joe AU - Verghese J AD - Institute for Aging Research, Department of Medicine, Albert Einstein College of Medicine, Bronx, New York. AD - Department of Neurology, Albert Einstein College of Medicine, Bronx, New York. FAU - Masud, Tahir AU - Masud T AD - Department of Geriatric Medicine, Odense University Hospital, Odense, Denmark. AD - Geriatric Research Unit, Department of Clinical Research, University of Southern Denmark, Odense, Denmark. AD - Department of Geriatric Medicine, Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom. CN - Task Force on Global Guidelines for Falls in Older Adults LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Systematic Review DEP - 20211201 PL - United States TA - JAMA Netw Open JT - JAMA network open JID - 101729235 SB - IM EIN - JAMA Netw Open. 2023 Aug 1;6(8):e2332257. doi: 10.1001/jamanetworkopen.2023.32257. PMID: 37639275 MH - Accidental Falls/*prevention & control MH - Aged MH - Aged, 80 and over MH - Combined Modality Therapy MH - Consensus MH - Environment Design MH - Health Promotion/methods/standards MH - Health Services for the Aged/*standards MH - Humans MH - Medication Review MH - Middle Aged MH - Osteoporosis/complications/therapy MH - Physical Therapy Modalities/standards MH - Practice Guidelines as Topic MH - Wounds and Injuries/etiology/therapy PMC - PMC8674747 COIS- Conflict of Interest Disclosures: Dr Montero-Odasso reported receiving support through grants for his program in Gait and Brain Health from the Canadian Institutes of Health Research, the Ontario Ministry of Research and Innovation, the Ontario Neurodegenerative Diseases Research Initiative, the Canadian Consortium on Neurodegeneration in Aging, the Weston Family Foundation, and the Department of Medicine Program of Experimental Medicine Research Award, University of Western Ontario; and being the first recipient of the Schulich Clinician-Scientist Award. Dr Tan reported receiving grants from the University of Malaya Impactful Interdisciplinary, and a fundamental research grant and a long-term research grant from the Ministry of Higher Education Malaysia; and personal fees from Astella, Merck, Mylan-UpJohn, Novartis, Pfizer, and Sanofi outside the submitted work. No other disclosures were reported. FIR - Petrovic, Mirko IR - Petrovic M FIR - Nieuwboer, Alice IR - Nieuwboer A FIR - Vlaeyen, Ellen IR - Vlaeyen E FIR - Milisen, Koen IR - Milisen K FIR - Ryg, Jesper IR - Ryg J FIR - Kenny, Rose Anne IR - Kenny RA FIR - Bourke, Robert IR - Bourke R FIR - Hartikainen, Sirpa IR - Hartikainen S FIR - Van der Cammen, Tischa IR - Van der Cammen T FIR - Van der Velde, Nathalie IR - Van der Velde N FIR - Masud, Tahir IR - Masud T FIR - Todd, Chris IR - Todd C FIR - Martin, Finbarr C IR - Martin FC FIR - Marsh, David R IR - Marsh DR FIR - Lamb, Sallie IR - Lamb S FIR - Frith, James IR - Frith J FIR - Logan, Pip IR - Logan P FIR - Skelton, Dawn IR - Skelton D FIR - Blain, Hubert IR - Blain H FIR - Anweiller, Cedric IR - Anweiller C FIR - Freiberger, Ellen IR - Freiberger E FIR - Becker, Clemens IR - Becker C FIR - Cesari, Matteo IR - Cesari M FIR - Casas-Herrero, Alvaro IR - Casas-Herrero A FIR - Jara, Javier Perez IR - Jara JP FIR - Bouzon, Christina Alonzo IR - Bouzon CA FIR - Welmer, Ana-Karim IR - Welmer AK FIR - Birnghebuam, Stephanie IR - Birnghebuam S FIR - Kressig, Reto IR - Kressig R FIR - Montero-Odasso, Manuel IR - Montero-Odasso M FIR - Speechley, Mark IR - Speechley M FIR - McIlroy, Bill IR - McIlroy B FIR - Hunter, Susan IR - Hunter S FIR - Camicioli, Richard IR - Camicioli R FIR - Madden, Kenneth IR - Madden K FIR - Norris, Mireille IR - Norris M FIR - Watt, Jennifer IR - Watt J FIR - Mallet, Louise IR - Mallet L FIR - Hogan, David B IR - Hogan DB FIR - Verghese, Joe IR - Verghese J FIR - Sejdic, Ervin IR - Sejdic E FIR - Ferruci, Luigi IR - Ferruci L FIR - Lipsitz, Lewis IR - Lipsitz L FIR - Ganz, David A IR - Ganz DA FIR - Alexander, Neil B IR - Alexander NB FIR - Giber, Fabiana IR - Giber F FIR - Schapira, Marcelo IR - Schapira M FIR - Jauregui, Ricardo IR - Jauregui R FIR - Melgar-Cuellar, Felipe IR - Melgar-Cuellar F FIR - Carvalho de Abreu, Daniela Cristina IR - Carvalho de Abreu DC FIR - Lourenco, Roberto Alves IR - Lourenco RA FIR - Pierrucini, Monica IR - Pierrucini M FIR - Ceriani, Alejandro IR - Ceriani A FIR - Marin-Larrain, Pedro IR - Marin-Larrain P FIR - Gac Espinola, Homero IR - Gac Espinola H FIR - Gomez-Montes, Jose Fernando IR - Gomez-Montes JF FIR - Cano-Gutierrez, Carlos Alberto IR - Cano-Gutierrez CA FIR - Ramirez Ulate, Xinia IR - Ramirez Ulate X FIR - Picado Ovares, Jose Ernesto IR - Picado Ovares JE FIR - Buendia, Patricio Gabriel IR - Buendia PG FIR - Tito, Susana Lucia IR - Tito SL FIR - Martinez Padilla, Diego IR - Martinez Padilla D FIR - Aguilar-Navarro, Sara G IR - Aguilar-Navarro SG FIR - Mimenza, Alberto IR - Mimenza A FIR - Moctezum, Rogelio IR - Moctezum R FIR - Avila-Funes, Alberto IR - Avila-Funes A FIR - Gutierrez-Robledo, Luis Miguel IR - Gutierrez-Robledo LM FIR - Cornejo Aleman, Luis Manuel IR - Cornejo Aleman LM FIR - Aguilera Caona, Edgar IR - Aguilera Caona E FIR - Carbajal, Juan Carlos IR - Carbajal JC FIR - Parodi, Jose F IR - Parodi JF FIR - Sgaravatti, Aldo IR - Sgaravatti A FIR - Lord, Stephen IR - Lord S FIR - Sherrington, Cathie IR - Sherrington C FIR - Said, Cathy IR - Said C FIR - Cameron, Ian IR - Cameron I FIR - Morris, Meg IR - Morris M FIR - Duque, Gustavo IR - Duque G FIR - Close, Jacqueline IR - Close J FIR - Kerse, Ngaire IR - Kerse N FIR - Tan, Maw Pin IR - Tan MP FIR - Duan, Leilei IR - Duan L FIR - Sakurai, Ryota IR - Sakurai R FIR - Hooi Wong, Chek IR - Hooi Wong C FIR - Negahban, Hossein IR - Negahban H FIR - Won Won, Chang IR - Won Won C FIR - Hausdorff, Jeffrey IR - Hausdorff J FIR - Kalula, Sebastiana IR - Kalula S FIR - Kobusingye, Olive IR - Kobusingye O EDAT- 2021/12/16 06:00 MHDA- 2022/01/14 06:00 PMCR- 2021/12/15 CRDT- 2021/12/15 12:42 PHST- 2021/12/15 12:42 [entrez] PHST- 2021/12/16 06:00 [pubmed] PHST- 2022/01/14 06:00 [medline] PHST- 2021/12/15 00:00 [pmc-release] AID - 2787179 [pii] AID - zoi211099 [pii] AID - 10.1001/jamanetworkopen.2021.38911 [doi] PST - epublish SO - JAMA Netw Open. 2021 Dec 1;4(12):e2138911. doi: 10.1001/jamanetworkopen.2021.38911. PMID- 34901209 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20211215 IS - 2297-055X (Print) IS - 2297-055X (Electronic) IS - 2297-055X (Linking) VI - 8 DP - 2021 TI - The Associations of Lipid Profiles With Cardiovascular Diseases and Death in a 10-Year Prospective Cohort Study. PG - 745539 LID - 10.3389/fcvm.2021.745539 [doi] LID - 745539 AB - Background: Dyslipidemia is one of the modifiable risk factors for cardiovascular diseases (CVD). Identifying subjects with lipid abnormality facilitates preventative interventions. Objectives: To evaluate the effects of lipid indices on the risks of ischemic stroke (IS), coronary heart disease (CHD), CVD, all-cause death, and CVD death. Methods: The cohort study of 4,128 subjects started in May 2009 and followed up to July 2020. Restricted cubic spline (RCS) regression analysis was used to explore the dose-response relationship between lipid indices with outcomes. Cox proportional hazard regression analysis was used to estimate the association with a hazard ratio (HR) and 95% CI. Results: RCS analysis showed that there were significant linear associations of TG with IS, non-high-density lipoprotein cholesterol (HDL-C), apolipoprotein B (ApoB), and total cholesterol (TC)/HDL-C ratio with all-cause death, non-HDL-C and RC with CVD death, and significant non-linear associations of ApoB with IS and CVD, TC, LDL-C, ApoAI, and TC/HDL-C ratio with CHD, and TC with all-cause death (all P <0.1). Cox regression analysis revealed that subjects with TC <155 mg/dl (vs. 155-184 mg/dl), > 185 mg/dl (vs. 155-184 mg/dl), and ApoB <0.7 g/l (vs. >/=0.7 g/l) had higher risks of CHD (P < 0.05), the adjusted HRs (95% CIs) were 1.933 (1.248-2.993), 1.561 (1.077-2.261), and 1.502 (1.01-2.234), respectively. Subjects with ApoAI > 2.1 g/l (vs. 1.6-2.1 g/l) and TG <80 mg/dl (vs. 80-177 mg/dl) had higher risks of CVD and all-cause death (P < 0.05), the adjusted HRs (95% CIs) were 1.476 (1.031-2.115) and 1.234 (1.002-1.519), respectively. Conclusions: Lower or higher levels of TC, higher level of ApoAI, and lower level of ApoB were associated with increased risks of CVD, and lower level of TG was associated with increased all-cause death. Maintaining optimal lipid levels would help to prevent CVD and reduce mortality. CI - Copyright (c) 2021 Dong, Yang, Zhuang, Sun, Wei, Zhao, Chen, Chen, Li, Wei, Chen, Fan and Shen. FAU - Dong, Jiayi AU - Dong J AD - Department of Epidemiology, School of Public Health, Nanjing Medical University, Nanjing, China. FAU - Yang, Song AU - Yang S AD - Department of Cardiology, Affiliated Yixing People's Hospital of Jiangsu University, People's Hospital of Yixing City, Yixing, China. FAU - Zhuang, Qian AU - Zhuang Q AD - Department of Cardiology, Affiliated Yixing People's Hospital of Jiangsu University, People's Hospital of Yixing City, Yixing, China. FAU - Sun, Junxiang AU - Sun J AD - Department of Cardiology, Affiliated Yixing People's Hospital of Jiangsu University, People's Hospital of Yixing City, Yixing, China. FAU - Wei, Pengfei AU - Wei P AD - Department of Cardiology, Affiliated Yixing People's Hospital of Jiangsu University, People's Hospital of Yixing City, Yixing, China. FAU - Zhao, Xianghai AU - Zhao X AD - Department of Cardiology, Affiliated Yixing People's Hospital of Jiangsu University, People's Hospital of Yixing City, Yixing, China. FAU - Chen, Yanchun AU - Chen Y AD - Department of Cardiology, Affiliated Yixing People's Hospital of Jiangsu University, People's Hospital of Yixing City, Yixing, China. FAU - Chen, Xiaotian AU - Chen X AD - Department of Epidemiology, School of Public Health, Nanjing Medical University, Nanjing, China. FAU - Li, Mengxia AU - Li M AD - Department of Epidemiology, School of Public Health, Nanjing Medical University, Nanjing, China. FAU - Wei, Lai AU - Wei L AD - Department of Epidemiology, School of Public Health, Nanjing Medical University, Nanjing, China. FAU - Chen, Changying AU - Chen C AD - Department of Epidemiology, School of Public Health, Nanjing Medical University, Nanjing, China. FAU - Fan, Yao AU - Fan Y AD - Department of Clinical Epidemiology, Geriatric Hospital of Nanjing Medical University, Nanjing, China. FAU - Shen, Chong AU - Shen C AD - Department of Epidemiology, School of Public Health, Nanjing Medical University, Nanjing, China. AD - Department of Clinical Epidemiology, Geriatric Hospital of Nanjing Medical University, Nanjing, China. LA - eng PT - Journal Article DEP - 20211125 PL - Switzerland TA - Front Cardiovasc Med JT - Frontiers in cardiovascular medicine JID - 101653388 PMC - PMC8655628 OTO - NOTNLM OT - apolipoprotein OT - cardiovascular diseases OT - cohort study OT - death OT - derived lipid indices OT - lipids COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2021/12/14 06:00 MHDA- 2021/12/14 06:01 PMCR- 2021/01/01 CRDT- 2021/12/13 18:10 PHST- 2021/07/22 00:00 [received] PHST- 2021/10/25 00:00 [accepted] PHST- 2021/12/13 18:10 [entrez] PHST- 2021/12/14 06:00 [pubmed] PHST- 2021/12/14 06:01 [medline] PHST- 2021/01/01 00:00 [pmc-release] AID - 10.3389/fcvm.2021.745539 [doi] PST - epublish SO - Front Cardiovasc Med. 2021 Nov 25;8:745539. doi: 10.3389/fcvm.2021.745539. eCollection 2021. PMID- 34898835 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220805 IS - 0734-7324 (Print) IS - 0734-7324 (Linking) VI - 39 IP - 4 DP - 2021 TI - Alcohol Use Cravings as a Mediator Between Associated Risk Factors on Increased Alcohol Use among Youth Adults in New York During the COVID-19 Pandemic. PG - 415-429 LID - 10.1080/07347324.2021.1950091 [doi] AB - The sudden increase in alcohol use in the young adult population during the COVID-19 pandemic may be partially explained by social isolation and stress due to restricted stay-at-home orders. The goal of this study was to assess specific psychological factors (e.g., anxiety, depressive symptoms, sleep disturbances, and alcohol cravings) and COVID-19 diagnoses and their association with increased alcohol use and misuse during the COVID-19 pandemic among New York residents 18-35 years of age. Survey data were collected via Qualtrics between July 2020-October 2020. Path analyses tests were employed to test alcohol use cravings as a mediator. Among the total sample (N=575), mean age was 27.94+/-4.12; a majority were White non-Hispanic (66%), female (55%) and had completed a 4-year college or university degree (n = 249; 43.5%). Results revealed that alcohol use cravings was a significant mediator between sleep disturbances, having a COVID-19 diagnoses, and having mental health symptoms on increased alcohol use. Our findings underscore the importance of providing alcohol use prevention and treatment resources in this unprecedented COVID-19 era. Policymakers, public health professionals, and clinicians have a significant role in curbing the COVID-19-induced substance use epidemic. FAU - Opara, Ijeoma AU - Opara I AD - Department of Social & Behavioral Sciences, School of Public Health, Yale University. AD - Center for Interdisciplinary Research on AIDS, School of Public Health, Yale University. FAU - Malik, Sana AU - Malik S AD - School of Social Welfare, Stony Brook University. FAU - Lardier, David T Jr AU - Lardier DT Jr AD - Department of Individual, Family, and Community Education, University of New Mexico. AD - Department of Psychiatry and Behavioral Sciences, University of New Mexico. FAU - Gamble-George, Joyonna AU - Gamble-George J AD - Rory Meyers College of Nursing, New York University. FAU - Kelly, Ryan J AU - Kelly RJ AD - Department of Individual, Family, and Community Education, University of New Mexico. FAU - Okafor, Chukwuemeka N AU - Okafor CN AD - College of Public Health, Baylor University. FAU - Greene, R Neil AU - Greene RN AD - Department of Individual, Family, and Community Education, University of New Mexico. FAU - Parisi, Deanna AU - Parisi D AD - Program of Public Health, Stony Brook University. LA - eng GR - DP5 OD029636/OD/NIH HHS/United States GR - R25 MH087217/MH/NIMH NIH HHS/United States GR - R25 MH118935/MH/NIMH NIH HHS/United States GR - T32 DA007233/DA/NIDA NIH HHS/United States PT - Journal Article DEP - 20210804 PL - United States TA - Alcohol Treat Q JT - Alcoholism treatment quarterly JID - 8411865 PMC - PMC8664084 MID - NIHMS1722316 OTO - NOTNLM OT - COVID-19 OT - alcohol use OT - mental health OT - sleep OT - young adults EDAT- 2021/12/14 06:00 MHDA- 2021/12/14 06:01 PMCR- 2022/08/04 CRDT- 2021/12/13 17:46 PHST- 2021/12/13 17:46 [entrez] PHST- 2021/12/14 06:00 [pubmed] PHST- 2021/12/14 06:01 [medline] PHST- 2022/08/04 00:00 [pmc-release] AID - 10.1080/07347324.2021.1950091 [doi] PST - ppublish SO - Alcohol Treat Q. 2021;39(4):415-429. doi: 10.1080/07347324.2021.1950091. Epub 2021 Aug 4. PMID- 34896386 OWN - NLM STAT- MEDLINE DCOM- 20220324 LR - 20230202 IS - 1095-8304 (Electronic) IS - 0195-6663 (Print) IS - 0195-6663 (Linking) VI - 169 DP - 2022 Feb 1 TI - Food insecurity, food parenting practices, and child eating behaviors among low-income Hispanic families of young children. PG - 105857 LID - S0195-6663(21)00764-9 [pii] LID - 10.1016/j.appet.2021.105857 [doi] AB - Food insecurity is associated with negative food parenting practices that may promote child obesity, including pressure to eat and food restriction. Less is known about the relationship between food insecurity and positive food parenting practices, including exposing the child to new foods and involving the child in food preparation. Further, few studies have investigated the associations between food insecurity and child eating behaviors that have been linked to poor dietary outcomes. Using baseline data collected as part of a larger pilot intervention, we examined the relationships between food security status, food parenting practices, and child eating behaviors in a predominately Hispanic, low-income sample of parents and their preschool aged children (n = 66). Between July of 2019 and 2020, caregivers recruited from 4 urban communities in Rhode Island completed assessments of household food security, food parenting practices, and four child eating behaviors: food responsiveness, emotional overeating, enjoyment of food, and satiety responsiveness. Although 46% of caregivers reported food insecurity, food insecurity was not directly associated with any food parenting practice. Children in food insecure households were rated as higher in levels of food responsiveness and enjoyment of food as compared to children in food secure households. Children in food insecure households were rated as lower in satiety responsiveness as compared to children in food secure households. Child emotional overeating did not vary by food security status. Future interventions to reduce child obesity among low-income Hispanic families should assess food security status and consider any level of food insecurity as a potential signal of unhealthy child eating behaviors. CI - Copyright (c) 2021 Elsevier Ltd. All rights reserved. FAU - McCurdy, Karen AU - McCurdy K AD - Department of Human Development & Family Science, University of Rhode Island, Kingston, RI, 02881, USA. Electronic address: kmccurdy@uri.edu. FAU - Gans, Kim M AU - Gans KM AD - Department of Human Development & Family Sciences, University of Connecticut, Storrs, CT, 06269, USA. FAU - Risica, Patricia Markham AU - Risica PM AD - Department of Behavioral and Social Sciences, Brown School of Public Health, Providence, RI, 02912, USA. FAU - Fox, Katelyn AU - Fox K AD - Department of Nutrition and Food Sciences, University of Rhode Island, Kingston, RI, 02881, USA. FAU - Tovar, Alison AU - Tovar A AD - Department of Nutrition and Food Sciences, University of Rhode Island, Kingston, RI, 02881, USA. LA - eng GR - R34 HL140229/HL/NHLBI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural DEP - 20211210 PL - England TA - Appetite JT - Appetite JID - 8006808 SB - IM MH - Child MH - Child, Preschool MH - Feeding Behavior/psychology MH - Food Insecurity MH - *Food Supply MH - Hispanic or Latino MH - Humans MH - *Parenting PMC - PMC8748423 MID - NIHMS1765008 OTO - NOTNLM OT - Child eating behaviors OT - Food insecurity OT - Food parenting OT - Hispanic OT - Low-income OT - Preschoolers COIS- Declarations of competing interest None. EDAT- 2021/12/14 06:00 MHDA- 2022/03/25 06:00 PMCR- 2023/02/01 CRDT- 2021/12/13 12:19 PHST- 2021/08/20 00:00 [received] PHST- 2021/11/22 00:00 [revised] PHST- 2021/12/08 00:00 [accepted] PHST- 2021/12/14 06:00 [pubmed] PHST- 2022/03/25 06:00 [medline] PHST- 2021/12/13 12:19 [entrez] PHST- 2023/02/01 00:00 [pmc-release] AID - S0195-6663(21)00764-9 [pii] AID - 10.1016/j.appet.2021.105857 [doi] PST - ppublish SO - Appetite. 2022 Feb 1;169:105857. doi: 10.1016/j.appet.2021.105857. Epub 2021 Dec 10. PMID- 34896200 OWN - NLM STAT- MEDLINE DCOM- 20220531 LR - 20250728 IS - 1527-3296 (Electronic) IS - 0196-6553 (Print) IS - 0196-6553 (Linking) VI - 50 IP - 6 DP - 2022 Jun TI - Retrospective evaluation of the symptom-based work restriction strategy of healthcare providers in the first epidemic of COVID-19 at a tertiary care hospital in Tokyo, Japan. PG - 645-650 LID - S0196-6553(21)00797-5 [pii] LID - 10.1016/j.ajic.2021.11.029 [doi] AB - BACKGROUND: Effectiveness of restricting healthcare providers (HCPs) from working based on the coronavirus disease 2019 (COVID-19)-like symptoms should be evaluated. METHODS: A total of 495 HCPs in a tertiary care hospital in Tokyo, Japan, participated in this study between June and July in 2020. Analysis of serum anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody to identify infected HCPs, questionnaire surveys, and medical record reviews were conducted to evaluate the appropriateness of symptom-based work restriction for 10 days. RESULTS: Five participants (1.0%) were identified as infected. Forty-six participants (9.3%) experienced work restriction and all 5 infected participants (10.8%) restricted working, even though the real-time reverse transcription-polymerase chain reaction was positive only in 4 participants (80.0%). There were no unexpectedly infected participants among those who did not experience work restriction. However, only 46 of 110 HCPs with COVID-19-like symptoms (41.8%) restricted themselves from working. DISCUSSION: Symptom-based work restriction strategy successfully prevented infected HCPs to work, but showed low specificity to identify truly infected HCPs, and their low adherence to the strategy was revealed. CONCLUSIONS: HCPs with COVID-19-like symptoms should restrict working as the first step of infection prevention, but the strategy to identify truly infected HCPs is necessary. CI - Copyright (c) 2021 The Authors. Published by Elsevier Inc. All rights reserved. FAU - Shikano, Hiroki AU - Shikano H AD - Department of Clinical Laboratory, St. Luke's International Hospital, Chuo-ku, Tokyo, Japan. FAU - Uehara, Yuki AU - Uehara Y AD - Department of Clinical Laboratory, St. Luke's International Hospital, Chuo-ku, Tokyo, Japan; Department of Infectious Diseases, St. Luke's International Hospital, Chuo-ku, Tokyo, Japan; Department of Microbiology, Juntendo University Faculty of Medicine, Bunkyo-ku, Tokyo, Japan. Electronic address: yukiue@luke.ac.jp. FAU - Kuboki, Rino AU - Kuboki R AD - Department of Clinical Laboratory, St. Luke's International Hospital, Chuo-ku, Tokyo, Japan. FAU - Tashino, Erika AU - Tashino E AD - Department of Clinical Laboratory, St. Luke's International Hospital, Chuo-ku, Tokyo, Japan. FAU - Nakahara, Fumiko AU - Nakahara F AD - Department of Clinical Laboratory, St. Luke's International Hospital, Chuo-ku, Tokyo, Japan. FAU - Matsumoto, Yumi AU - Matsumoto Y AD - Department of Clinical Laboratory, St. Luke's International Hospital, Chuo-ku, Tokyo, Japan. FAU - Kusakabe, Satomi AU - Kusakabe S AD - Department of Clinical Laboratory, St. Luke's International Hospital, Chuo-ku, Tokyo, Japan. FAU - Fukazawa, Chizumi AU - Fukazawa C AD - Department of Clinical Laboratory, St. Luke's International Hospital, Chuo-ku, Tokyo, Japan. FAU - Matsuo, Takahiro AU - Matsuo T AD - Department of Infectious Diseases, St. Luke's International Hospital, Chuo-ku, Tokyo, Japan. FAU - Mori, Nobuyoshi AU - Mori N AD - Department of Infectious Diseases, St. Luke's International Hospital, Chuo-ku, Tokyo, Japan. FAU - Ayabe, Akiko AU - Ayabe A AD - Division of Health Care Administration, St. Luke's International Hospital, Chuo-ku, Tokyo, Japan. FAU - Jinta, Torahiko AU - Jinta T AD - Division of Health Care Administration, St. Luke's International Hospital, Chuo-ku, Tokyo, Japan; Department of Respiratory Medicine, St. Luke's International Hospital, Chuo-ku, Tokyo, Japan. FAU - Taki, Fumika AU - Taki F AD - Division of Health Care Administration, St. Luke's International Hospital, Chuo-ku, Tokyo, Japan; Department of Nephrology, St. Luke's International Hospital, Chuo-ku, Tokyo, Japan. FAU - Sakamoto, Fumie AU - Sakamoto F AD - Quality Improvement Center, St. Luke's International Hospital, Chuo-ku, Tokyo, Japan. FAU - Takahashi, Osamu AU - Takahashi O AD - Graduate School of Public Health, St. Luke's International University, Chuo-ku, Tokyo, Japan; Department of General Internal Medicine, St. Luke's International Hospital, Chuo-ku, Tokyo, Japan. FAU - Fukui, Tsuguya AU - Fukui T AD - Graduate School of Public Health, St. Luke's International University, Chuo-ku, Tokyo, Japan; Department of General Internal Medicine, St. Luke's International Hospital, Chuo-ku, Tokyo, Japan. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20211208 PL - United States TA - Am J Infect Control JT - American journal of infection control JID - 8004854 SB - IM MH - *COVID-19 MH - Health Personnel MH - Humans MH - Japan/epidemiology MH - Retrospective Studies MH - SARS-CoV-2 MH - Tertiary Care Centers MH - Tokyo/epidemiology PMC - PMC8653401 OTO - NOTNLM OT - Adherence to infection control strategy OT - Allergic rhinitis OT - Anti-severe acute respiratory syndrome coronavirus 2 antibody OT - Severe acute respiratory syndrome coronavirus 2 EDAT- 2021/12/14 06:00 MHDA- 2022/06/01 06:00 PMCR- 2021/12/08 CRDT- 2021/12/13 12:15 PHST- 2021/10/08 00:00 [received] PHST- 2021/11/19 00:00 [revised] PHST- 2021/11/19 00:00 [accepted] PHST- 2021/12/14 06:00 [pubmed] PHST- 2022/06/01 06:00 [medline] PHST- 2021/12/13 12:15 [entrez] PHST- 2021/12/08 00:00 [pmc-release] AID - S0196-6553(21)00797-5 [pii] AID - 10.1016/j.ajic.2021.11.029 [doi] PST - ppublish SO - Am J Infect Control. 2022 Jun;50(6):645-650. doi: 10.1016/j.ajic.2021.11.029. Epub 2021 Dec 8. PMID- 34894172 OWN - NLM STAT- MEDLINE DCOM- 20211223 LR - 20231108 IS - 1348-9585 (Electronic) IS - 1341-9145 (Print) IS - 1341-9145 (Linking) VI - 63 IP - 1 DP - 2021 Jan TI - Does working at home compromise mental health? A study on European mature adults in COVID times. PG - e12299 LID - 10.1002/1348-9585.12299 [doi] LID - e12299 AB - INTRODUCTION: The COVID-19 pandemic has transformed working at home (WAH) into the exclusive mode of working for many European workers. Although WAH will likely remain after COVID-19, its consequences on workers' health are unclear. This study examines the association of WAH and the change of four mental health (MH) domains. METHODS: We used data from the last wave of the Survey on Health, Aging, and Retirement in Europe, collected in June and July 2020 on European people aged 50 and older. We restricted our analysis to people aged 50-65 who were working before COVID-19 (N = 7065). We modeled the risk of worsening of depression and anxiety feelings, sleeping trouble, and feelings of loneliness as a function of the working situation (usual setting, at home and usual setting, at home only), using logistic regressions. A first model adjusted for sociodemographic variables, a second one adding country fixed effects, and the last one adding the stringency of COVID-19-related restrictions. RESULTS: WAH was significantly associated with a worsening of all MH symptoms. Nevertheless, when the stringency index was factored in, no significant association of WAH was found with any of the health outcomes except for anxiety feelings (+4.3% points). However, the increased anxiety feelings among people in WAH were not greater than the one observed among nonworkers. DISCUSSION: Our findings show that WAH was not a major cause of mental health deterioration among European mature adults during the first month of the pandemic. Further evidence is needed on WAH under post-COVID-19 "normal" circumstances. CI - (c) 2021 The Authors. Journal of Occupational Health published by John Wiley & Sons Australia, Ltd on behalf of The Japan Society for Occupational Health. FAU - Perelman, Julian AU - Perelman J AUID- ORCID: 0000-0001-6634-9000 AD - NOVA National School of Public Health, Public Health Research Centre, Universidade NOVA de Lisboa, Lisbon, Portugal. AD - Comprehensive Health Research Centre, Universidade NOVA de Lisboa, Lisbon, Portugal. FAU - Serranheira, Florentino AU - Serranheira F AD - NOVA National School of Public Health, Public Health Research Centre, Universidade NOVA de Lisboa, Lisbon, Portugal. AD - Comprehensive Health Research Centre, Universidade NOVA de Lisboa, Lisbon, Portugal. FAU - Pita Barros, Pedro AU - Pita Barros P AD - Nova School of Business and Economics, Universidade NOVA de Lisboa, Carcavelos, Portugal. FAU - Laires, Pedro AU - Laires P AD - NOVA National School of Public Health, Public Health Research Centre, Universidade NOVA de Lisboa, Lisbon, Portugal. AD - Comprehensive Health Research Centre, Universidade NOVA de Lisboa, Lisbon, Portugal. AD - Novartis, Basel, Switzerland. LA - eng PT - Journal Article PL - Australia TA - J Occup Health JT - Journal of occupational health JID - 9616320 SB - IM MH - Aged MH - *COVID-19/epidemiology MH - Europe/epidemiology MH - Humans MH - *Mental Health/statistics & numerical data MH - Middle Aged MH - *Teleworking PMC - PMC8665463 OTO - NOTNLM OT - COVID-19 OT - Europe OT - mental health OT - teleworking OT - working at home EDAT- 2021/12/12 06:00 MHDA- 2021/12/24 06:00 PMCR- 2021/12/11 CRDT- 2021/12/11 08:37 PHST- 2021/11/08 00:00 [revised] PHST- 2021/06/18 00:00 [received] PHST- 2021/11/17 00:00 [accepted] PHST- 2021/12/11 08:37 [entrez] PHST- 2021/12/12 06:00 [pubmed] PHST- 2021/12/24 06:00 [medline] PHST- 2021/12/11 00:00 [pmc-release] AID - JOH212299 [pii] AID - 10.1002/1348-9585.12299 [doi] PST - ppublish SO - J Occup Health. 2021 Jan;63(1):e12299. doi: 10.1002/1348-9585.12299. PMID- 34889314 OWN - NLM STAT- MEDLINE DCOM- 20211216 LR - 20220301 IS - 2531-6745 (Electronic) IS - 0392-4203 (Print) IS - 0392-4203 (Linking) VI - 92 IP - S6 DP - 2021 Dec 10 TI - Impact of the COVID-19 pandemic on physical activity among university students in Pavia, Northern Italy. PG - e2021443 LID - 10.23750/abm.v92iS6.12232 [doi] LID - e2021443 AB - AIM: To evaluate the University of Pavia students about physical activity (PA) changes before, during and after the COVID-19 pandemic. METHODS: The International Physical Activity Questionnaires (IPAQ) survey was employed to evaluate the PA in three periods: the pre-pandemic period, during national stay-at-home order (March 9th - May 4th 2020), current PA. Exercise intensity for each period was defined using the Metabolic Equivalent of Task (Met) as unit of measurement. The questionnaire was administered online to university students from June 9th to July 4th 2021, structured in four sections, also collecting demographic data. RESULTS: 55,6% of the study population reported a significant decrease in PA during lockdown. The number of active/very active subjects dropped from 72.2% in pre-pandemic period to 29.6% during containment measures. 50% reported a substantial increase in moving out of the lockdown. Stay-at-home order was associated with an increase in sedentary lifestyle (68.5%), which sharply decreased moving out from lockdown (two-third of study population). Average time in minutes spent sitting was 612 before pandemic, 844 during the pandemic and 670 after social restrictions. CONCLUSIONS: Lockdown had a negative impact on PA among the university students leading to an increase in sedentary behaviours. Following the gradual relaxation of the restrictive measures, situation has improved, without however returning to pre-pandemic level. It is of fundamental importance to study new strategies to promote healthy lifestyles while coping with the on-going pandemic. FAU - Bertocchi, Lucia AU - Bertocchi L AD - Exercise and Sports Sciences, University of Pavia, Pavia, Italy. lucia.bertocchi01@universitadipavia.it. FAU - Vecchio, Riccardo AU - Vecchio R AD - Department of Public Health, Experimental and Forensic Medicine, University of Pavia, Pavia, Italy. riccardo.vecchio03@universitadipavia.it. FAU - Sorbello, Sebastiano AU - Sorbello S AD - Department of Public Health, Experimental and Forensic Medicine, University of Pavia, Pavia, Italy. sebastiano.sor11@gmail.com. FAU - Correale, Luca AU - Correale L AD - Department of Public Health, Experimental and Forensic Medicine, University of Pavia, Pavia, Italy. anna.odone@unipv.it. FAU - Gentile, Leandro AU - Gentile L AD - Department of Public Health, Experimental and Forensic Medicine, University of Pavia, Pavia, Italy. leandro.gentile01@universitadipavia.it. FAU - Buzzachera, Cosme AU - Buzzachera C AD - Department of Public Health, Experimental and Forensic Medicine, University of Pavia, Pavia, Italy. anna.odone@unipv.it. FAU - Gaeta, Maddalena AU - Gaeta M AD - Department of Public Health, Experimental and Forensic Medicine, University of Pavia, Pavia, Italy. maddalena.gaeta@unipv.it. FAU - Odone, Anna AU - Odone A AD - Department of Public Health, Experimental and Forensic Medicine, University of Pavia, Pavia, Italy. anna.odone@unipv.it. LA - eng PT - Journal Article DEP - 20211210 PL - Italy TA - Acta Biomed JT - Acta bio-medica : Atenei Parmensis JID - 101295064 SB - IM MH - *COVID-19 MH - Communicable Disease Control MH - Exercise MH - Humans MH - Italy/epidemiology MH - *Pandemics MH - SARS-CoV-2 MH - Students MH - Universities PMC - PMC8851014 COIS- Each author declares that he or she has no commercial associations (e.g. consultancies, stock ownership, equity interest, patent/licensing arrangement etc.) that might pose a conflict of interest in connection with the submitted article. EDAT- 2021/12/11 06:00 MHDA- 2021/12/17 06:00 PMCR- 2021/01/01 CRDT- 2021/12/10 08:43 PHST- 2021/09/03 00:00 [received] PHST- 2021/09/23 00:00 [accepted] PHST- 2021/12/10 08:43 [entrez] PHST- 2021/12/11 06:00 [pubmed] PHST- 2021/12/17 06:00 [medline] PHST- 2021/01/01 00:00 [pmc-release] AID - ACTA-92-443 [pii] AID - 10.23750/abm.v92iS6.12232 [doi] PST - epublish SO - Acta Biomed. 2021 Dec 10;92(S6):e2021443. doi: 10.23750/abm.v92iS6.12232. PMID- 34889294 OWN - NLM STAT- MEDLINE DCOM- 20211214 LR - 20220429 IS - 1536-5964 (Electronic) IS - 0025-7974 (Print) IS - 0025-7974 (Linking) VI - 100 IP - 49 DP - 2021 Dec 10 TI - Acupuncture for headache in COVID-19: A protocol for systematic review and meta-analysis. PG - e28174 LID - 10.1097/MD.0000000000028174 [doi] LID - e28174 AB - BACKGROUND: Coronavirus disease 2019 (COVID-19) is an acute respiratory infectious disease which making people difficult to breathe and often accompanied with headache. Acupuncture have been proved the therapeutic effect on headache, but there has been no high-quality evidence on acupuncture for the headache in COVID-19. This study is designed to evaluate the effectiveness and safety of acupuncture for headache in COVID-19. METHODS: Randomized controlled trials from December 2019 to July 2021 will be included without restrictions on language or publication date. PubMed, EMBASE, Cochrane Library, Web of Science, Chinese Biomedical Databases, China National Knowledge Infrastructure, Wanfang database, and VIP database will be searched. Two researchers will independently select studies, extract data and evaluate study quality. Cochrane risk of bias tool for randomized trials will be used to assess the risk of bias of included studies. Statistical analyses will be performed using the Review Manager V.5.3 and stata 14.0. ETHICS AND DISSEMINATION: This study will not involve personal information. Ethical approval will not be required. We will publish the results in a peer-reviewed journal. PROSPERO TRIAL REGISTRATION NUMBER: CRD42021270722. CI - Copyright (c) 2021 the Author(s). Published by Wolters Kluwer Health, Inc. FAU - Sun, Mi AU - Sun M AD - Department of Acupuncture and Moxibustion, Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China. FAU - Jin, Xian AU - Jin X AD - Department of Acupuncture and Moxibustion, Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China. AD - Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China. FAU - Zang, Mingxiao AU - Zang M AD - Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China. FAU - Jiang, Weijia AU - Jiang W AD - Department of Acupuncture and Moxibustion, Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China. FAU - Zhao, Chunxiao AU - Zhao C AD - Department of Acupuncture and Moxibustion, Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China. FAU - Bi, Jieyu AU - Bi J AD - Department of Acupuncture and Moxibustion, Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China. FAU - Yu, Huijuan AU - Yu H AD - Department of Acupuncture and Moxibustion, Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China. FAU - Tan, Qiwen AU - Tan Q AUID- ORCID: 0000-0001-6527-9012 AD - Department of Acupuncture and Moxibustion, Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China. LA - eng GR - NO.220318/TCM "Zhi Wei Bing" Scientific Research Innovation Team of Shandong University of Traditional Chinese Medicine/ PT - Journal Article PL - United States TA - Medicine (Baltimore) JT - Medicine JID - 2985248R SB - IM MH - *Acupuncture Therapy MH - COVID-19/*complications MH - Headache/*complications/*therapy MH - Humans MH - *Meta-Analysis as Topic MH - SARS-CoV-2 MH - Systematic Reviews as Topic/*methods PMC - PMC8663821 COIS- The authors have no conflicts of interest to disclose. EDAT- 2021/12/11 06:00 MHDA- 2021/12/15 06:00 PMCR- 2021/12/10 CRDT- 2021/12/10 08:43 PHST- 2021/11/11 00:00 [received] PHST- 2021/11/19 00:00 [accepted] PHST- 2021/12/10 08:43 [entrez] PHST- 2021/12/11 06:00 [pubmed] PHST- 2021/12/15 06:00 [medline] PHST- 2021/12/10 00:00 [pmc-release] AID - 00005792-202112100-00075 [pii] AID - MD-D-21-07620 [pii] AID - 10.1097/MD.0000000000028174 [doi] PST - ppublish SO - Medicine (Baltimore). 2021 Dec 10;100(49):e28174. doi: 10.1097/MD.0000000000028174. PMID- 34882918 OWN - NLM STAT- MEDLINE DCOM- 20230228 LR - 20230306 IS - 1478-5153 (Electronic) IS - 1362-1017 (Linking) VI - 28 IP - 2 DP - 2023 Mar TI - The relationship between practice environment, job satisfaction and intention to leave in critical care nurses. PG - 167-176 LID - 10.1111/nicc.12737 [doi] AB - BACKGROUND: Recent studies in the Kingdom of Saudi Arabia (KSA) have shown that the increasing nursing turnover in the health care industry has become a great source of concern. The overdependence on the supply of expatriate nurses (74%) and coronavirus disease 2019 (COVID-19) travel restrictions have exacerbated this staffing issue. AIMS: To examine the relationship between perception of nursing practice environment (NPE), job satisfaction and intention to leave (ITL) among critical care nurses working in the state of Ha'il in KSA. DESIGN: Cross-sectional correlational (observational) design. METHODS: Data were collected via electronic online survey distributed to registered critical care nurses working in King Khalid Hospital (KKH), Ha'il, KSA, between July and August 2020. Participant demographics and key variables data related to NPE, job satisfaction and ITL respectively were collected from the participants using existing and validated questionnaires. Descriptive statistics and correlational analysis and multivariable analyses were conducted. RESULTS: A response rate of 98% was achieved (152/160) for the study. Findings showed that the NPE was largely favourable (M = 2.89, SD = 0.44); however, nurse participation in hospital affairs (M = 2.83, SD = 0.47) and staffing and resource adequacy (M = 2.88, SD = 0.47) scored lowest. NPE was found to be significantly correlated with job satisfaction (rs = .287, P < .01). A significant negative relationship was found between NPE and ITL (rs = -0.277**, P < .01). However, job satisfaction was associated with ITL (rs = -.007, P = .930). CONCLUSIONS: Maintaining a healthy work environment and job satisfaction levels in critical care units is key to improving, recruitment and retention of nursing staff. RELEVANCE TO CLINICAL PRACTICE: Critical care and hospital leaders should implement programs that enhance the quality of the practice environment. This will improve nurse participation in unit and hospital affairs, job satisfaction and intention to stay. CI - (c) 2021 British Association of Critical Care Nurses. FAU - Alenazy, Faisal S AU - Alenazy FS AUID- ORCID: 0000-0002-8251-0412 AD - School of Nursing and Centre for Healthcare Transformation, Queensland University of Technology, Brisbane, Queensland, Australia. AD - School of Nursing, ICU/Critical Care, University of Ha'il, Ha'il, Kingdom of Saudi Arabia. FAU - Dettrick, Zoe AU - Dettrick Z AUID- ORCID: 0000-0003-1091-1820 AD - School of Public Health and Social Work, Queensland University of Technology, Brisbane, Queensland, Australia. FAU - Keogh, Samantha AU - Keogh S AUID- ORCID: 0000-0002-2797-4388 AD - School of Nursing and Centre for Healthcare Transformation, Queensland University of Technology, Brisbane, Queensland, Australia. LA - eng GR - Saudi Ministry of Health (SMOH)/ GR - UOH0/University of Ha'il/ PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20211209 PL - England TA - Nurs Crit Care JT - Nursing in critical care JID - 9808649 MH - Humans MH - Job Satisfaction MH - *Nursing Staff, Hospital MH - Intention MH - Cross-Sectional Studies MH - *COVID-19 MH - Surveys and Questionnaires MH - *Nurses MH - Critical Care OTO - NOTNLM OT - Saudi Arabia OT - critical care nursing OT - intention to leave OT - job satisfaction OT - nurses' practice environments EDAT- 2021/12/10 06:00 MHDA- 2023/03/03 06:00 CRDT- 2021/12/09 17:45 PHST- 2021/11/23 00:00 [revised] PHST- 2021/07/20 00:00 [received] PHST- 2021/11/25 00:00 [accepted] PHST- 2021/12/10 06:00 [pubmed] PHST- 2023/03/03 06:00 [medline] PHST- 2021/12/09 17:45 [entrez] AID - 10.1111/nicc.12737 [doi] PST - ppublish SO - Nurs Crit Care. 2023 Mar;28(2):167-176. doi: 10.1111/nicc.12737. Epub 2021 Dec 9. PMID- 34882569 OWN - NLM STAT- MEDLINE DCOM- 20220301 LR - 20220716 IS - 2369-2960 (Electronic) IS - 2369-2960 (Linking) VI - 8 IP - 2 DP - 2022 Feb 24 TI - COVID-19 Surveillance Updates in US Metropolitan Areas: Dynamic Panel Data Modeling. PG - e28737 LID - 10.2196/28737 [doi] LID - e28737 AB - BACKGROUND: Despite the availability of vaccines, the US incidence of new COVID-19 cases per day nearly doubled from the beginning of July to the end of August 2021, fueled largely by the rapid spread of the Delta variant. While the "Delta wave" appears to have peaked nationally, some states and municipalities continue to see elevated numbers of new cases. Vigilant surveillance including at a metropolitan level can help identify any reignition and validate continued and strong public health policy responses in problem localities. OBJECTIVE: This surveillance report aimed to provide up-to-date information for the 25 largest US metropolitan areas about the rapidity of descent in the number of new cases following the Delta wave peak, as well as any potential reignition of the pandemic associated with declining vaccine effectiveness over time, new variants, or other factors. METHODS: COVID-19 pandemic dynamics for the 25 largest US metropolitan areas were analyzed through September 19, 2021, using novel metrics of speed, acceleration, jerk, and 7-day persistence, calculated from the observed data on the cumulative number of cases as reported by USAFacts. Statistical analysis was conducted using dynamic panel data models estimated with the Arellano-Bond regression techniques. The results are presented in tabular and graphic forms for visual interpretation. RESULTS: On average, speed in the 25 largest US metropolitan areas declined from 34 new cases per day per 100,000 population, during the week ending August 15, 2021, to 29 new cases per day per 100,000 population, during the week ending September 19, 2021. This average masks important differences across metropolitan areas. For example, Miami's speed decreased from 105 for the week ending August 15, 2021, to 40 for the week ending September 19, 2021. Los Angeles, San Francisco, Riverside, and San Diego had decreasing speed over the sample period and ended with single-digit speeds for the week ending September 19, 2021. However, Boston, Washington DC, Detroit, Minneapolis, Denver, and Charlotte all had their highest speed of the sample during the week ending September 19, 2021. These cities, as well as Houston and Baltimore, had positive acceleration for the week ending September 19, 2021. CONCLUSIONS: There is great variation in epidemiological curves across US metropolitan areas, including increasing numbers of new cases in 8 of the largest 25 metropolitan areas for the week ending September 19, 2021. These trends, including the possibility of waning vaccine effectiveness and the emergence of resistant variants, strongly indicate the need for continued surveillance and perhaps a return to more restrictive public health guidelines for some areas. CI - (c)Theresa B Oehmke, Charles B Moss, James F Oehmke. Originally published in JMIR Public Health and Surveillance (https://publichealth.jmir.org), 24.02.2022. FAU - Oehmke, Theresa B AU - Oehmke TB AUID- ORCID: 0000-0002-8738-8735 AD - Department of Civil and Environmental Engineering, University of California, Berkeley, Berkeley, CA, United States. FAU - Moss, Charles B AU - Moss CB AUID- ORCID: 0000-0002-1172-7112 AD - Institute of Food and Agricultural Sciences, University of Florida, Gainesville, FL, United States. FAU - Oehmke, James F AU - Oehmke JF AUID- ORCID: 0000-0003-2003-3443 AD - Department of Emergency Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, United States. LA - eng PT - Journal Article DEP - 20220224 PL - Canada TA - JMIR Public Health Surveill JT - JMIR public health and surveillance JID - 101669345 RN - SARS-CoV-2 variants SB - IM MH - *COVID-19/epidemiology MH - Humans MH - Longitudinal Studies MH - *Pandemics/prevention & control MH - Public Health Surveillance/methods MH - SARS-CoV-2 PMC - PMC8914733 OTO - NOTNLM OT - 7-Day persistence OT - COVID-19 OT - Houston OT - Sars-CoV-2 OT - United States OT - acceleration OT - coronavirus OT - data OT - dynamic panel data model OT - jerk OT - modeling OT - monitoring OT - public health OT - response OT - speed OT - surveillance OT - surveillance system OT - transmission COIS- Conflicts of Interest: None declared. EDAT- 2021/12/10 06:00 MHDA- 2022/03/03 06:00 PMCR- 2022/02/24 CRDT- 2021/12/09 17:23 PHST- 2021/03/15 00:00 [received] PHST- 2021/11/30 00:00 [accepted] PHST- 2021/09/30 00:00 [revised] PHST- 2021/12/10 06:00 [pubmed] PHST- 2022/03/03 06:00 [medline] PHST- 2021/12/09 17:23 [entrez] PHST- 2022/02/24 00:00 [pmc-release] AID - v8i2e28737 [pii] AID - 10.2196/28737 [doi] PST - epublish SO - JMIR Public Health Surveill. 2022 Feb 24;8(2):e28737. doi: 10.2196/28737. PMID- 34878549 OWN - NLM STAT- MEDLINE DCOM- 20220117 LR - 20220117 IS - 2574-3805 (Electronic) IS - 2574-3805 (Linking) VI - 4 IP - 12 DP - 2021 Dec 1 TI - Factors Associated With the Use of a Salt Substitute in Rural China. PG - e2137745 LID - 10.1001/jamanetworkopen.2021.37745 [doi] LID - e2137745 AB - IMPORTANCE: Lowering sodium intake reduces blood pressure and may reduce the risk of cardiovascular diseases. The use of reduced-sodium salt (a salt substitute) may achieve sodium reduction, but its effectiveness may be associated with the context of its use. OBJECTIVE: To identify factors associated with the use of salt substitutes in rural populations in China within the Salt Substitute and Stroke Study, a large-scale cluster randomized trial. DESIGN, SETTING, AND PARTICIPANTS: This sequential mixed-methods qualitative evaluation, conducted from July 2 to August 28, 2018, in rural communities across 3 provinces in China, included a quantitative survey, collection of 24-hour urine samples, and face-to-face interviews. A random subsample of trial participants, selected from the 3 provinces, completed the quantitative survey (n = 1170) and provided urine samples (n = 1025). Interview respondents were purposively selected from the intervention group based on their different ranges of urinary sodium excretion levels. Statistical analysis was performed from September 18, 2018, to February 22, 2019. EXPOSURES: The intervention group of the Salt Substitute and Stroke Study was provided with the free salt substitute while the control group continued to use regular salt. MAIN OUTCOMES AND MEASURES: Knowledge, attitudes, and behaviors regarding the use of the salt substitute were measured using quantitative surveys, and urinary sodium levels were measured using 24-hour urine samples. Contextual factors were explored through semistructured interviews and integrated findings from surveys and interviews. RESULTS: A total of 1170 individuals participated in the quantitative survey. Among the 1025 participants with successful urine samples, the mean (SD) age was 67.4 (7.5) years, and 502 (49.0%) were female. The estimated salt intake of participants who believed that high salt intake was good for health was higher; however, it was not significantly different (0.84 g/d [95% CI, -0.04 to 1.72 g/d]) from those who believed that high salt intake was bad for health. Thirty individuals participated in the qualitative interviews (18 women [60.0%]; mean [SD] age, 70.3 [6.0] years). Quantitative and qualitative data indicated high acceptability of and adherence to the salt substitute. Contextual factors negatively associated with the use of the salt substitute included a lack of knowledge about the benefits associated with salt reduction and consumption of high-sodium pickled foods. In addition, reduced antihypertensive medication was reported by a few participants using the salt substitute. CONCLUSIONS AND RELEVANCE: This study suggests that lack of comprehensive understanding of sodium reduction and salt substitutes and habitual consumption of high-sodium foods (such as pickled foods) were the main barriers to the use of salt substitutes to reduce sodium intake. These factors should be considered in future population-based, sodium-reduction interventions. FAU - Liu, Yishu AU - Liu Y AD - The George Institute for Global Health, University of New South Wales, Sydney, Australia. FAU - Chu, Hongling AU - Chu H AD - Research Center of Clinical Epidemiology, Peking University Third Hospital, Beijing, China. FAU - Peng, Ke AU - Peng K AD - The George Institute for Global Health, University of New South Wales, Sydney, Australia. AD - National Clinical Research Center for Cardiovascular Diseases, Fuwai Hospital Chinese Academy of Medical Sciences, Shenzhen, Shenzhen, China. FAU - Yin, Xuejun AU - Yin X AD - The George Institute for Global Health, University of New South Wales, Sydney, Australia. FAU - Huang, Liping AU - Huang L AD - The George Institute for Global Health, University of New South Wales, Sydney, Australia. FAU - Wu, Yangfeng AU - Wu Y AD - The George Institute for Global Health at Peking University Health Science Center, Beijing, China. AD - Peking University Clinical Research Institute, Peking University, Beijing, China. FAU - Pearson, Sallie-Anne AU - Pearson SA AD - Centre for Big Data Research in Health, University of New South Wales, Sydney, Australia. FAU - Li, Nicole AU - Li N AD - The George Institute for Global Health, University of New South Wales, Sydney, Australia. FAU - Elliott, Paul AU - Elliott P AD - School of Public Health, Imperial College London, London, United Kingdom. FAU - Yan, Lijing L AU - Yan LL AD - The George Institute for Global Health at Peking University Health Science Center, Beijing, China. AD - Duke Global Health Institute, and Global Health Research Centre, Duke Kunshan, University, Kunshan, China. FAU - Labarthe, Darwin R AU - Labarthe DR AD - Feinberg School of Medicine, Northwestern University, Chicago, Illinois. FAU - Hao, Zhixin AU - Hao Z AD - The George Institute for Global Health at Peking University Health Science Center, Beijing, China. FAU - Feng, Xiangxian AU - Feng X AD - School of Public Health, Changzhi Medical College, Changzhi, China. FAU - Zhang, Jianxin AU - Zhang J AD - Department of Noncommunicable Disease Prevention and Control, Center for Disease Control of Hebei Province, Shijizhuang, China. FAU - Zhang, Yuhong AU - Zhang Y AD - School of Public Health and Management, Ningxia Medical University, Yinchuan, China. FAU - Zhang, Ruijuan AU - Zhang R AD - School of Public Health, Xi'an Jiaotong University School of Medicine, Xi'an, China. FAU - Zhou, Bo AU - Zhou B AD - Department of Evidence-based Medicine, First Hospital of China Medical University, Shenyang, China. FAU - Li, Zhifang AU - Li Z AD - School of Public Health, Changzhi Medical College, Changzhi, China. FAU - Sun, Jixin AU - Sun J AD - Department of Noncommunicable Disease Prevention and Control, Center for Disease Control of Hebei Province, Shijizhuang, China. FAU - Zhao, Yi AU - Zhao Y AD - School of Public Health and Management, Ningxia Medical University, Yinchuan, China. FAU - Yu, Yan AU - Yu Y AD - School of Public Health, Xi'an Jiaotong University School of Medicine, Xi'an, China. FAU - Tian, Maoyi AU - Tian M AD - The George Institute for Global Health, University of New South Wales, Sydney, Australia. AD - The George Institute for Global Health at Peking University Health Science Center, Beijing, China. AD - School of Public Health, Harbin Medical University, Harbin, China. FAU - Neal, Bruce AU - Neal B AD - The George Institute for Global Health, University of New South Wales, Sydney, Australia. AD - School of Public Health, Imperial College London, London, United Kingdom. FAU - Liu, Hueiming AU - Liu H AD - The George Institute for Global Health, University of New South Wales, Sydney, Australia. AD - Sydney Institute for Women, Children and Their Families, Sydney Local Health District, Sydney, Australia. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20211201 PL - United States TA - JAMA Netw Open JT - JAMA network open JID - 101729235 RN - 0 (Flavoring Agents) RN - 0 (Sodium Chloride, Dietary) SB - IM CIN - JAMA Netw Open. 2021 Dec 1;4(12):e2138651. doi: 10.1001/jamanetworkopen.2021.38651. PMID: 34878555 MH - Aged MH - China MH - Diet, Sodium-Restricted/*psychology MH - Female MH - Flavoring Agents/*adverse effects MH - *Health Knowledge, Attitudes, Practice MH - Humans MH - Hypertension/*chemically induced/*diet therapy MH - Male MH - Middle Aged MH - Rural Population/statistics & numerical data MH - Sodium Chloride, Dietary/*adverse effects/*urine PMC - PMC8655604 COIS- Conflict of Interest Disclosures: Drs Huang, Wu, N. Li, and Neal reported receiving grants from the National Health and Medical Research Council of Australia during the conduct of the study. Dr H. Liu reported receiving grants from The George Institute for Global Health during the conduct of the study. No other disclosures were reported. EDAT- 2021/12/09 06:00 MHDA- 2022/01/18 06:00 PMCR- 2021/12/08 CRDT- 2021/12/08 12:25 PHST- 2021/12/08 12:25 [entrez] PHST- 2021/12/09 06:00 [pubmed] PHST- 2022/01/18 06:00 [medline] PHST- 2021/12/08 00:00 [pmc-release] AID - 2786938 [pii] AID - zoi211070 [pii] AID - 10.1001/jamanetworkopen.2021.37745 [doi] PST - epublish SO - JAMA Netw Open. 2021 Dec 1;4(12):e2137745. doi: 10.1001/jamanetworkopen.2021.37745. PMID- 34876436 OWN - NLM STAT- MEDLINE DCOM- 20220307 LR - 20260127 IS - 2044-6055 (Electronic) IS - 2044-6055 (Linking) VI - 11 IP - 12 DP - 2021 Dec 7 TI - Observing time effect of SSRIs on suicide risk and suicide-related behaviour: a network meta-analysis protocol. PG - e054479 LID - 10.1136/bmjopen-2021-054479 [doi] LID - e054479 AB - INTRODUCTION: Suicide is a serious problem worldwide and 90% cases are associated with pre-existing or underlying mental illness. As a common treatment for depressive symptoms that suicidal people may receive, selective serotonin reuptake inhibitors (SSRIs) have been linked to a possible increase in suicide rates. Studies focusing on SSRIs and suicide have produced inconsistent results, suggesting that use of SSRIs decreases, increases, has no effect on suicide rates, or that the effect of SSRIs on suicide is age-dependent. This protocol of network meta-analysis aims to precisely evaluate the time effects of SSRIs by observing weekly changes of suicidality in the first 2 months of the treatment, and consequently, to explore whether the effect of the SSRIs on suicide varies depending on the stages of the treatment; if so, we will identify the turning point. METHODS AND ANALYSIS: We will search in the following databases: PubMed, Web of science, China National Knowledge Infrastructure and Wanfang Data, from dates of inception to 9 July 2021, with language restricted to English and Chinese. Studies focusing on the time effect of SSRIs on suicide will be retrieved. Then, the study selection process will follow the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guideline, and the quality assessment will be conducted with Cochrane Collaboration's tool. Two researchers will work independently on data extraction using a standardised data extraction spreadsheet. Any disagreement between two researchers will be discussed and determined by a third researcher. ETHICS AND DISSEMINATION: This work does not require ethics approval as it will be based on published studies. This review will be published in peer-reviewed journals. PROSPERO REGISTRATION NUMBER: CRD42021244779. CI - (c) Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. FAU - Chen, Qing-Hua AU - Chen QH AD - Affiliated Brain Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China. FAU - Li, Yu-Ling AU - Li YL AD - Affiliated Brain Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China. FAU - Hu, Yi-Ru AU - Hu YR AD - Affiliated Brain Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China. FAU - Liang, Wan-Yuan AU - Liang WY AD - Affiliated Brain Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China. FAU - Zhang, Bin AU - Zhang B AUID- ORCID: 0000-0002-9280-8247 AD - Affiliated Brain Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China zhang.bin845@foxmail.com. LA - eng PT - Clinical Trial Protocol PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20211207 PL - England TA - BMJ Open JT - BMJ open JID - 101552874 RN - 0 (Selective Serotonin Reuptake Inhibitors) SB - IM MH - Disease Susceptibility MH - Humans MH - Review Literature as Topic MH - *Selective Serotonin Reuptake Inhibitors/adverse effects MH - Suicidal Ideation MH - *Suicide Prevention MH - Network Meta-Analysis as Topic PMC - PMC8655524 OTO - NOTNLM OT - depression & mood disorders OT - protocols & guidelines OT - suicide & self-harm COIS- Competing interests: None declared. EDAT- 2021/12/09 06:00 MHDA- 2022/03/08 06:00 PMCR- 2021/12/06 CRDT- 2021/12/08 05:51 PHST- 2021/12/08 05:51 [entrez] PHST- 2021/12/09 06:00 [pubmed] PHST- 2022/03/08 06:00 [medline] PHST- 2021/12/06 00:00 [pmc-release] AID - bmjopen-2021-054479 [pii] AID - 10.1136/bmjopen-2021-054479 [doi] PST - epublish SO - BMJ Open. 2021 Dec 7;11(12):e054479. doi: 10.1136/bmjopen-2021-054479. PMID- 34873595 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240923 IS - 2693-5015 (Electronic) IS - 2693-5015 (Linking) DP - 2021 Nov 30 TI - Tracking SARS-COV-2 Variants Using Nanopore Sequencing in Ukraine in Summer 2021. LID - rs.3.rs-1044446 [pii] LID - 10.21203/rs.3.rs-1044446/v1 [doi] AB - Since spring 2020, Ukraine has experienced at least two COVID-19 waves and has just entered a third wave in autumn 2021. The use of real-time genomic epidemiology has enabled the tracking of SARS-CoV-2 circulation patterns worldwide, thus informing evidence-based public health decision making, including implementation of travel restrictions and vaccine rollout strategies. However, insufficient capacity for local genetic sequencing in Ukraine and other Lower and Middle-Income countries limit opportunities for similar analyses. Herein, we report local sequencing of 24 SARS-CoV-2 genomes from patient samples collected in Kyiv in July 2021 using Oxford Nanopore MinION technology. Together with other published Ukrainian SARS-COV-2 genomes sequenced mostly abroad, our data suggest that the second wave of the epidemic in Ukraine (February-April 2021) was dominated by the Alpha variant of concern (VOC), while the beginning of the third wave has been dominated by the Delta VOC. Furthermore, our phylogeographic analysis revealed that the Delta variant was introduced into Ukraine in summer 2021 from multiple locations worldwide, with most introductions coming from Central and Eastern European countries. This study highlights the need to urgently integrate affordable and easily-scaled pathogen sequencing technologies in locations with less developed genomic infrastructure, in order to support local public health decision making. FAU - Yakovleva, Anna AU - Yakovleva A AD - University of Oxford. FAU - Kovalenko, Ganna AU - Kovalenko G AD - University of Cambridge. FAU - Redlinger, Matthew AU - Redlinger M AD - University of Alaska Anchorage. FAU - Liulchuk, Mariia G AU - Liulchuk MG AD - State Institution "L.V. Gromashevsky Institute of Epidemiology and Infectious Diseases of National Academy of Medical Sciences of Ukraine". FAU - Bortz, Eric AU - Bortz E AD - University of Alaska Anchorage. FAU - Zadorozhna, Viktoria I AU - Zadorozhna VI AD - State Institution "L.V. Gromashevsky Institute of Epidemiology and Infectious Diseases of National Academy of Medical Sciences of Ukraine". FAU - Scherbinska, Alla M AU - Scherbinska AM AD - State Institution "L.V. Gromashevsky Institute of Epidemiology and Infectious Diseases of National Academy of Medical Sciences of Ukraine". FAU - Wertheim, Joel O AU - Wertheim JO AD - University of California San Diego. FAU - Goodfellow, Ian AU - Goodfellow I AD - University of Cambridge. FAU - Meredith, Luke AU - Meredith L AD - University of Cambridge. FAU - Vasylyeva, Tetyana I AU - Vasylyeva TI AD - University of California San Diego. LA - eng GR - WT_/Wellcome Trust/United Kingdom GR - P20 GM103395/GM/NIGMS NIH HHS/United States GR - R01 AI135992/AI/NIAID NIH HHS/United States PT - Journal Article PT - Preprint DEP - 20211130 PL - United States TA - Res Sq JT - Research square JID - 101768035 UIN - Sci Rep. 2022 Sep 21;12(1):15749. doi: 10.1038/s41598-022-19414-y. PMID: 36131001 PMC - PMC8647652 COIS- Competing interests The authors declare no competing interests. EDAT- 2021/12/08 06:00 MHDA- 2021/12/08 06:01 PMCR- 2021/12/06 CRDT- 2021/12/07 06:46 PHST- 2021/12/07 06:46 [entrez] PHST- 2021/12/08 06:00 [pubmed] PHST- 2021/12/08 06:01 [medline] PHST- 2021/12/06 00:00 [pmc-release] AID - rs.3.rs-1044446 [pii] AID - 10.21203/rs.3.rs-1044446/v1 [doi] PST - epublish SO - Res Sq [Preprint]. 2021 Nov 30:rs.3.rs-1044446. doi: 10.21203/rs.3.rs-1044446/v1. PMID- 34864193 OWN - NLM STAT- MEDLINE DCOM- 20220118 LR - 20220928 IS - 1878-3511 (Electronic) IS - 1201-9712 (Print) IS - 1201-9712 (Linking) VI - 115 DP - 2022 Feb TI - Contrasting SARS-CoV-2 epidemics in Singapore: cohort studies in migrant workers and the general population. PG - 72-78 LID - S1201-9712(21)00891-2 [pii] LID - 10.1016/j.ijid.2021.11.043 [doi] AB - IMPORTANCE: Since January 2020, Singapore has implemented comprehensive measures to suppress SARS-CoV-2. Despite this, the country has experienced contrasting epidemics, with limited transmission in the community and explosive outbreaks in migrant worker dormitories. OBJECTIVE: To estimate SARS-CoV-2 infection incidence among migrant workers and the general population in Singapore. DESIGN: Prospective serological cohort studies. SETTING: Two cohort studies - in a migrant worker dormitory and in the general population in Singapore. PARTICIPANTS: 478 residents of a SARS-CoV-2-affected migrant worker dormitory were followed up between May and July 2020, with blood samples collected on recruitment and after 2 and 6 weeks. In addition, 937 community-dwelling adult Singapore residents, for whom pre-pandemic sera were available, were recruited. These individuals also provided a serum sample on recruitment in November/December 2020. EXPOSURE: Exposure to SARS-CoV-2 in a densely populated migrant worker dormitory and in the general population. MAIN OUTCOMES AND MEASURES: The main outcome measures were the incidences of SARS-CoV-2 infection in migrant workers and in the general population, as determined by the detection of neutralizing antibodies against SARS-CoV-2, and adjusting for assay sensitivity and specificity using a Bayesian modeling framework. RESULTS: No evidence of community SARS-CoV-2 exposure was found in Singapore prior to September 2019. It was estimated that < 2 per 1000 adult residents in the community were infected with SARS-CoV-2 in 2020 (cumulative seroprevalence: 0.16%; 95% CrI: 0.008-0.72%). Comparison with comprehensive national case notification data suggested that around 1 in 4 infections in the general population were associated with symptoms. In contrast, in the migrant worker cohort, almost two-thirds had been infected by July 2020 (cumulative seroprevalence: 63.8%; 95% CrI: 57.9-70.3%); no symptoms were reported in almost all of these infections. CONCLUSIONS AND RELEVANCE: Our findings demonstrate that SARS-CoV-2 suppression is possible with strict and rapid implementation of border restrictions, case isolation, contact tracing, quarantining, and social-distancing measures. However, the risk of large-scale epidemics in densely populated environments requires specific consideration in preparedness planning. Prioritization of these settings in vaccination strategies should minimize the risk of future resurgences and potential spillover of transmission to the wider community. CI - Copyright (c) 2021 The Authors. Published by Elsevier Ltd.. All rights reserved. FAU - Clapham, Hannah E AU - Clapham HE AD - Saw Swee Hock School of Public Health, National University of Singapore and National University Health System, Singapore. FAU - Chia, Wan Ni AU - Chia WN AD - Programme in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore. FAU - Tan, Linda Wei Lin AU - Tan LWL AD - Saw Swee Hock School of Public Health, National University of Singapore and National University Health System, Singapore. FAU - Kumar, Vishakha AU - Kumar V AD - Saw Swee Hock School of Public Health, National University of Singapore and National University Health System, Singapore. FAU - Lim, Jane M AU - Lim JM AD - Saw Swee Hock School of Public Health, National University of Singapore and National University Health System, Singapore. FAU - Shankar, Nivedita AU - Shankar N AD - Saw Swee Hock School of Public Health, National University of Singapore and National University Health System, Singapore. FAU - Tun, Zaw Myo AU - Tun ZM AD - Saw Swee Hock School of Public Health, National University of Singapore and National University Health System, Singapore. FAU - Zahari, Marina AU - Zahari M AD - Saw Swee Hock School of Public Health, National University of Singapore and National University Health System, Singapore. FAU - Hsu, Li Yang AU - Hsu LY AD - Saw Swee Hock School of Public Health, National University of Singapore and National University Health System, Singapore. FAU - Sun, Louisa Jin AU - Sun LJ AD - Infectious Diseases, Alexandra Hospital, National University Health System, Singapore. FAU - Wang, Lin Fa AU - Wang LF AD - Programme in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore. FAU - Tam, Clarence C AU - Tam CC AD - Saw Swee Hock School of Public Health, National University of Singapore and National University Health System, Singapore; London School of Hygiene and Tropical Medicine, London, United Kingdom. Electronic address: clarence.tam@nus.edu.sg. LA - eng GR - WT_/Wellcome Trust/United Kingdom PT - Journal Article DEP - 20211202 PL - Canada TA - Int J Infect Dis JT - International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases JID - 9610933 SB - IM MH - Adult MH - Bayes Theorem MH - *COVID-19 MH - Humans MH - Pandemics MH - Prospective Studies MH - SARS-CoV-2 MH - Seroepidemiologic Studies MH - Singapore/epidemiology MH - *Transients and Migrants PMC - PMC8636323 EDAT- 2021/12/06 06:00 MHDA- 2022/01/19 06:00 PMCR- 2021/12/02 CRDT- 2021/12/05 21:06 PHST- 2021/07/25 00:00 [received] PHST- 2021/11/22 00:00 [revised] PHST- 2021/11/28 00:00 [accepted] PHST- 2021/12/06 06:00 [pubmed] PHST- 2022/01/19 06:00 [medline] PHST- 2021/12/05 21:06 [entrez] PHST- 2021/12/02 00:00 [pmc-release] AID - S1201-9712(21)00891-2 [pii] AID - 10.1016/j.ijid.2021.11.043 [doi] PST - ppublish SO - Int J Infect Dis. 2022 Feb;115:72-78. doi: 10.1016/j.ijid.2021.11.043. Epub 2021 Dec 2. PMID- 34863621 OWN - NLM STAT- MEDLINE DCOM- 20211220 LR - 20221221 IS - 1873-2518 (Electronic) IS - 0264-410X (Print) IS - 0264-410X (Linking) VI - 40 IP - 1 DP - 2022 Jan 3 TI - Individual factors influencing COVID-19 vaccine acceptance in between and during pandemic waves (July-December 2020). PG - 151-161 LID - S0264-410X(21)01414-6 [pii] LID - 10.1016/j.vaccine.2021.10.073 [doi] AB - BACKGROUND: A year after the start of the COVID-19 outbreak, the global rollout of vaccines gives us hope of ending the pandemic. Lack of vaccine confidence, however, poses a threat to vaccination campaigns. This study aims at identifying individuals' characteristics that explain vaccine willingness in Flanders (Belgium), while also describing trends over time (July-December 2020). METHODS: The analysis included data of 10 survey waves of the Great Corona Survey, a large-scale online survey that was open to the general public and had 17,722-32,219 respondents per wave. Uni- and multivariable general additive models were fitted to associate vaccine willingness with socio-demographic and behavioral variables, while correcting for temporal and geographical variability. RESULTS: We found 84.2% of the respondents willing to be vaccinated, i.e., respondents answering that they were definitely (61.2%) or probably (23.0%) willing to get a COVID-19 vaccine, while 9.8% indicated maybe, 3.9% probably not and 2.2% definitely not. In Flanders, vaccine willingness was highest in July 2020 (90.0%), decreased over the summer period to 80.2% and started to increase again from late September, reaching 85.9% at the end of December 2020. Vaccine willingness was significantly associated with respondents' characteristics: previous survey participation, age, gender, province, educational attainment, household size, financial situation, employment sector, underlying medical conditions, mental well-being, government trust, knowing someone with severe COVID-19 symptoms and compliance with restrictive measures. These variables could explain much, but not all, variation in vaccine willingness. CONCLUSIONS: Both the timing and location of data collection influence vaccine willingness results, emphasizing that comparing data from different regions, countries and/or timepoints should be done with caution. To maximize COVID-19 vaccination coverage, vaccination campaigns should focus on (a combination of) subpopulations: aged 31-50, females, low educational attainment, large households, difficult financial situation, low mental well-being and labourers, unemployed and self-employed citizens. CI - Copyright (c) 2021 Elsevier Ltd. All rights reserved. FAU - Valckx, Sara AU - Valckx S AD - Centre for the Evaluation of Vaccination, VAXINFECTIO, Faculty of Medicine and Health Sciences, University of Antwerp, 2000 Antwerpen, Belgium. Electronic address: sara.valckx@uantwerpen.be. FAU - Crevecoeur, Jonas AU - Crevecoeur J AD - Leuven Biostatistics and statistical Bioinformatics Centre (L-BioStat), Faculty of Medicine, KU Leuven, Kapucijnenvoer 35, building D, box 7001, 3000 Leuven, Belgium; Interuniversity Institute for Biostatistics and statistical Bioinformatics (I-BioStat), Data Science Institute, Hasselt University, Martelarenlaan 42, 3500 Hasselt, Belgium. Electronic address: jonas.crevecoeur@kuleuven.be. FAU - Verelst, Frederik AU - Verelst F AD - Centre for Health Economics Research and Modelling Infectious Diseases, VAXINFECTIO, Faculty of Medicine and Health Sciences, University of Antwerp, 2000 Antwerpen, Belgium. Electronic address: frederik.Verelst@uantwerpen.be. FAU - Vranckx, Maren AU - Vranckx M AD - Interuniversity Institute for Biostatistics and statistical Bioinformatics (I-BioStat), Data Science Institute, Hasselt University, Martelarenlaan 42, 3500 Hasselt, Belgium. Electronic address: maren.vranckx@uhasselt.be. FAU - Hendrickx, Greet AU - Hendrickx G AD - Centre for the Evaluation of Vaccination, VAXINFECTIO, Faculty of Medicine and Health Sciences, University of Antwerp, 2000 Antwerpen, Belgium. Electronic address: greet.hendrickx@uantwerpen.be. FAU - Hens, Niel AU - Hens N AD - Centre for Health Economics Research and Modelling Infectious Diseases, VAXINFECTIO, Faculty of Medicine and Health Sciences, University of Antwerp, 2000 Antwerpen, Belgium; Interuniversity Institute for Biostatistics and statistical Bioinformatics (I-BioStat), Data Science Institute, Hasselt University, Martelarenlaan 42, 3500 Hasselt, Belgium. Electronic address: niel.hens@uantwerpen.be. FAU - Van Damme, Pierre AU - Van Damme P AD - Centre for the Evaluation of Vaccination, VAXINFECTIO, Faculty of Medicine and Health Sciences, University of Antwerp, 2000 Antwerpen, Belgium. Electronic address: pierre.vandamme@uantwerpen.be. FAU - Pepermans, Koen AU - Pepermans K AD - Faculty of Social Sciences, University of Antwerp, Sint-Jacobstraat 2, 2000 Antwerpen, Belgium. Electronic address: koen.pepermans@uantwerpen.be. FAU - Beutels, Philippe AU - Beutels P AD - Centre for Health Economics Research and Modelling Infectious Diseases, VAXINFECTIO, Faculty of Medicine and Health Sciences, University of Antwerp, 2000 Antwerpen, Belgium. Electronic address: philippe.beutels@uantwerpen.be. FAU - Neyens, Thomas AU - Neyens T AD - Leuven Biostatistics and statistical Bioinformatics Centre (L-BioStat), Faculty of Medicine, KU Leuven, Kapucijnenvoer 35, building D, box 7001, 3000 Leuven, Belgium; Interuniversity Institute for Biostatistics and statistical Bioinformatics (I-BioStat), Data Science Institute, Hasselt University, Martelarenlaan 42, 3500 Hasselt, Belgium. Electronic address: thomas.neyens@uhasselt.be. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20211201 PL - Netherlands TA - Vaccine JT - Vaccine JID - 8406899 RN - 0 (COVID-19 Vaccines) RN - 0 (Vaccines) SB - IM MH - *COVID-19 MH - COVID-19 Vaccines MH - Female MH - Humans MH - Pandemics/prevention & control MH - SARS-CoV-2 MH - *Vaccines PMC - PMC8634074 OTO - NOTNLM OT - COVID-19 OT - Online survey OT - Socio-demographics OT - Trust OT - Vaccine hesitancy OT - Vaccine willingness COIS- Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Unrelated to the work reported here, the University of Antwerp has received unrestricted grants and compensation for meeting attendance with GSK and Pfizer. The University of Antwerp obtains research grants from vaccine manufacturers for the conduct of vaccine trials for which PVD is principal investigator. The authors have no other competing interest to declare. EDAT- 2021/12/06 06:00 MHDA- 2021/12/21 06:00 PMCR- 2021/12/01 CRDT- 2021/12/05 20:54 PHST- 2021/02/16 00:00 [received] PHST- 2021/08/01 00:00 [revised] PHST- 2021/10/27 00:00 [accepted] PHST- 2021/12/06 06:00 [pubmed] PHST- 2021/12/21 06:00 [medline] PHST- 2021/12/05 20:54 [entrez] PHST- 2021/12/01 00:00 [pmc-release] AID - S0264-410X(21)01414-6 [pii] AID - 10.1016/j.vaccine.2021.10.073 [doi] PST - ppublish SO - Vaccine. 2022 Jan 3;40(1):151-161. doi: 10.1016/j.vaccine.2021.10.073. Epub 2021 Dec 1. PMID- 34856969 OWN - NLM STAT- MEDLINE DCOM- 20211206 LR - 20211214 IS - 1471-2458 (Electronic) IS - 1471-2458 (Linking) VI - 21 IP - 1 DP - 2021 Dec 2 TI - A national population-based study of patients, bystanders and contextual factors associated with resuscitation in witnessed cardiac arrest: insight from the french ReAC registry. PG - 2202 LID - 10.1186/s12889-021-12269-4 [doi] LID - 2202 AB - BACKGROUND: In out-of-hospital cardiac arrest (OHCA), bystander initiated cardiopulmonary resuscitation (CPR) increases the chance of return of spontaneous circulation and survival with a favourable neurological status. Socioeconomic disparities have been highlighted in OHCA field. In areas with the lowest average socioeconomic status, OHCA incidence increased, and bystander CPR decreased. Evaluations were performed on restricted geographical area, and European evaluation is lacking. We aimed to analyse, at a national level, the impact of area-level social deprivation on the initiation of CPR in case of a witnessed OHCA. METHODS: We included all witnessed OHCA cases with age over 18 years from July 2011 to July 2018 form the OHCA French national registry. We excluded OHCA occurred in front of rescue teams or in nursing home, and patients with incomplete address or partial geocoding. We collected data from context, bystander and patient. The area-level social deprivation was estimated by the French version of the European Deprivation Index (in quintile) associated with the place where OHCA occurred. We assessed the associations between Utstein variables and social deprivation level using a mixed-effect logit model with bystander-initiated CPR. RESULTS: We included 23,979 witnessed OHCA of which 12,299 (51%) had a bystander-initiated CPR. More than one third of the OHCA (8,326 (35%)) occurred in an area from the highest quintile of social deprivation. The higher the area-level deprivation, the less the proportion of bystander-initiated CPR (56% in Quintile 1 versus 48% in Quintile 5). The In the multivariable analysis, bystander less often began CPR in areas with the highest deprivation level, compared to those with the lowest deprivation level (OR=0.69, IC95%: 0.63-0.75). CONCLUSIONS: The level of social deprivation of the area where OHCA occurred was associated with bystander-initiated CPR. It decreased in the more deprived areas although these areas also concentrate more younger patients. CI - (c) 2021. The Author(s). FAU - Reuter, Paul-Georges AU - Reuter PG AD - Emergency Department, Toulouse University Hospital, 31000, Toulouse, France. paul-georges.reuter@aphp.fr. AD - UMR 1027, Paul Sabatier University Toulouse III, Inserm, Toulouse, France. paul-georges.reuter@aphp.fr. AD - AP-HP, SAMU 92, Hopital Raymond Poincare, 104, Boulevard Raymond Poincare , 92380, Garches, France. paul-georges.reuter@aphp.fr. FAU - Baert, Valentine AU - Baert V AD - Evaluation des technologies de sante et des pratiques medicales, Univ. Lille, CHU Lille, 2694, F-59000, Lille, ULR, France. AD - French National Out-of-Hospital Cardiac Arrest Registry, ReAC, Lille, France. FAU - Colineaux, Helene AU - Colineaux H AD - UMR 1027, Paul Sabatier University Toulouse III, Inserm, Toulouse, France. FAU - Escutnaire, Josephine AU - Escutnaire J AD - Evaluation des technologies de sante et des pratiques medicales, Univ. Lille, CHU Lille, 2694, F-59000, Lille, ULR, France. FAU - Javaud, Nicolas AU - Javaud N AD - AP-HP, Urgences, Centre de Reference sur les Angioedemes a Kinines, Hopital Louis Mourier, Universite de Paris, 92700, Colombes, France. FAU - Delpierre, Cyrille AU - Delpierre C AD - UMR 1027, Paul Sabatier University Toulouse III, Inserm, Toulouse, France. FAU - Adnet, Frederic AU - Adnet F AD - UF Recherche-Enseignement-Qualite, hopital Avicenne, AP-HP, Universite Paris, Urgences - Samu 93, 13, Inserm U942, 93000, Bobigny, France. FAU - Loeb, Thomas AU - Loeb T AD - AP-HP, SAMU 92, Hopital Raymond Poincare, 104, Boulevard Raymond Poincare , 92380, Garches, France. FAU - Charpentier, Sandrine AU - Charpentier S AD - Emergency Department, Toulouse University Hospital, 31000, Toulouse, France. AD - UMR 1027, Paul Sabatier University Toulouse III, Inserm, Toulouse, France. FAU - Lapostolle, Frederic AU - Lapostolle F AD - UF Recherche-Enseignement-Qualite, hopital Avicenne, AP-HP, Universite Paris, Urgences - Samu 93, 13, Inserm U942, 93000, Bobigny, France. FAU - Hubert, Herve AU - Hubert H AD - Evaluation des technologies de sante et des pratiques medicales, Univ. Lille, CHU Lille, 2694, F-59000, Lille, ULR, France. AD - French National Out-of-Hospital Cardiac Arrest Registry, ReAC, Lille, France. FAU - Lamy, Sebastien AU - Lamy S AD - UMR 1027, Paul Sabatier University Toulouse III, Inserm, Toulouse, France. AD - Group for Research and Analysis in Population Health (GAP), Claudius Regaud Institute, IUCT-O, Toulouse, France. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20211202 PL - England TA - BMC Public Health JT - BMC public health JID - 100968562 SB - IM MH - Adolescent MH - *Cardiopulmonary Resuscitation MH - *Emergency Medical Services MH - Humans MH - Logistic Models MH - *Out-of-Hospital Cardiac Arrest/epidemiology/therapy MH - Registries MH - Social Deprivation PMC - PMC8638114 OTO - NOTNLM OT - Bystander OT - Cardiopulmonary resuscitation OT - Deprivation OT - Out-of-hospital cardiac arrest OT - Registry COIS- All authors have completed the Unified Competing Interest Form (available on request from the corresponding author) and declare: no support from any organisation for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work. EDAT- 2021/12/04 06:00 MHDA- 2021/12/15 06:00 PMCR- 2021/12/02 CRDT- 2021/12/03 05:40 PHST- 2020/11/23 00:00 [received] PHST- 2021/11/10 00:00 [accepted] PHST- 2021/12/03 05:40 [entrez] PHST- 2021/12/04 06:00 [pubmed] PHST- 2021/12/15 06:00 [medline] PHST- 2021/12/02 00:00 [pmc-release] AID - 10.1186/s12889-021-12269-4 [pii] AID - 12269 [pii] AID - 10.1186/s12889-021-12269-4 [doi] PST - epublish SO - BMC Public Health. 2021 Dec 2;21(1):2202. doi: 10.1186/s12889-021-12269-4. PMID- 34856116 OWN - NLM STAT- MEDLINE DCOM- 20220131 LR - 20220131 IS - 1545-1151 (Electronic) IS - 1545-1151 (Linking) VI - 18 DP - 2021 Dec 2 TI - A Market Basket Assessment: Prices and Availability of Healthy Foods Across SNAP-Authorized Food Outlets in Counties With High Obesity Rates in Mississippi. PG - E99 LID - 10.5888/pcd18.210173 [doi] LID - E99 AB - INTRODUCTION: The Mississippi Delta is predominantly rural and ranks among the US regions with the highest obesity rates. Throughout the US, rural and low-income communities have limited access to healthy foods. Given the interrelation between the quality of the food environment and the healthfulness of diets and obesity rates, the food environment is an important public health concern in these communities. METHODS: We conducted a retail assessment in July 2019 in the Delta region of Mississippi and evaluated prices and availability of healthy foods at Supplemental Nutrition Assistance Program-accepting retail establishments using the validated Market Basket Assessment Tool. We used regression analysis to identify differences in prices and availability of healthy foods across food retail formats. RESULTS: The healthy foods availability and quality score for convenience stores, which comprise the highest proportion of store formats in the region, was 70% lower than for supermarkets. Compared with the prices at supermarkets, the prices at convenience stores were 48% higher for grains, 35% higher for fruit and vegetables, 73% higher for meats, and 95% higher for beans, seeds, and nuts. The healthfulness of foods available at dollar stores was also lower than the healthfulness at supermarkets, but prices were generally similar. CONCLUSION: The availability of supermarkets and grocery stores was limited in the study area, but the concentration of convenience stores was high. Overall, access and affordability of healthy foods were restricted in the counties studied; these findings are useful for intervention development. FAU - Canales, Elizabeth AU - Canales E AD - Department of Agricultural Economics, Mississippi State University, PO Box 5187, Mississippi State, MS 39762. Email: Elizabeth.canales@msstate.edu. FAU - Fan, Linlin AU - Fan L AD - Department of Agricultural Economics, Sociology and Education, Pennsylvania State University, State College, Pennsylvania. FAU - Buys, David R AU - Buys DR AD - Department of Food Science, Nutrition and Health Promotion, Mississippi State University, Starkville, Mississippi. FAU - Cantave, Marven D AU - Cantave MD AD - Mississippi State University Extension, Belzoni, Mississippi. AD - Now with Feeding America, Lexington, Mississippi. LA - eng PT - Journal Article PT - Research Support, U.S. Gov't, Non-P.H.S. PT - Research Support, U.S. Gov't, P.H.S. DEP - 20211202 PL - United States TA - Prev Chronic Dis JT - Preventing chronic disease JID - 101205018 SB - IM MH - *Access to Healthy Foods MH - Commerce MH - Food MH - *Food Supply MH - Humans MH - Obesity/epidemiology MH - Vegetables PMC - PMC8673945 EDAT- 2021/12/03 06:00 MHDA- 2022/02/01 06:00 PMCR- 2021/01/01 CRDT- 2021/12/02 20:10 PHST- 2021/12/02 20:10 [entrez] PHST- 2021/12/03 06:00 [pubmed] PHST- 2022/02/01 06:00 [medline] PHST- 2021/01/01 00:00 [pmc-release] AID - E99 [pii] AID - 21_0173 [pii] AID - 10.5888/pcd18.210173 [doi] PST - epublish SO - Prev Chronic Dis. 2021 Dec 2;18:E99. doi: 10.5888/pcd18.210173. PMID- 34851398 OWN - NLM STAT- MEDLINE DCOM- 20220111 LR - 20220327 IS - 2574-3805 (Electronic) IS - 2574-3805 (Linking) VI - 4 IP - 12 DP - 2021 Dec 1 TI - Association of Fluoroquinolone Prescribing Rates With Black Box Warnings from the US Food and Drug Administration. PG - e2136662 LID - 10.1001/jamanetworkopen.2021.36662 [doi] LID - e2136662 AB - IMPORTANCE: In 2013 and 2016, the US Food and Drug Administration (FDA) issued warnings and recommended limited use of fluoroquinolones for patients with certain acute conditions. It is not clear how prescribers have responded to these warnings. OBJECTIVE: To analyze changes in prescribing of fluoroquinolones after the 2013 and 2016 FDA warnings and to examine the physician characteristics associated with these changes. DESIGN, SETTING, AND PARTICIPANTS: This cross-sectional study used Medicare administrative claims data on Medicare fee-for-service beneficiaries and OneKey data on physicians and their organizations from January 1, 2011, to December 31, 2017. The sample was restricted to outpatient visits for sinusitis, bronchitis, and uncomplicated urinary tract infections. An interrupted time series approach was used to analyze the changes in the prescription rate after each FDA warning. Data analysis was performed between January 1, 2011, and December 31, 2017. INTERVENTIONS: Two FDA black box warnings released in August 2013 and July 2016. MAIN OUTCOMES AND MEASURES: The main outcome was an indicator for fluoroquinolone prescriptions in 3 periods: before the 2013 warning (baseline period), after the 2013 warning but before the 2016 warning (postwarning period 1), and after the 2016 warning (postwarning period 2). RESULTS: The sample comprised 1 238 397 unique patients with a total of 2 720 071 outpatient acute care visits. Of this sample, 848 360 were women (68.5%), and the mean (SD) age was 69.7 (12.6) years. The immediate prescribing levels of fluoroquinolones in postwarning period 1 increased by 3.42 percentage points (95% CI, 3.23-3.62; P < .001) and declined by -0.77 percentage points (95% CI, -1.00 to -0.54; P < .001) in postwarning period 2. The prescribing trend increased by 0.08 percentage points per month (95% CI, 0.08-0.10; P < .001) in postwarning period 1 and 0.06 percentage points per month (95% CI, 0.04-0.08; P < .001) in postwarning period 2. In postwarning period 1, the prescribing levels for physicians who were affiliated with hospitals with a top 10th percentile case mix index vs those without such affiliation decreased by -1.13 percentage points (95% CI, -1.92 to -0.34; P = .005), whereas the levels for primary care physicians declined by -1.34 percentage points (95% CI, -1.78 to -0.88; P < .001) compared with non-primary care physicians in postwarning period 2. Physicians at teaching hospitals were the only ones who showed a decline in prescribing trend in postwarning period 1. CONCLUSIONS AND RELEVANCE: This cross-sectional study found an overall decline in prescribing of fluoroquinolones after the release of FDA warnings. Understanding the association of physician and organizational characteristics with fluoroquinolone prescribing behavior may ultimately help to identify mechanisms to improve de-adoption. FAU - Sankar, Ashwini AU - Sankar A AD - Carlson School of Management, Department of Finance, University of Minnesota, Minneapolis. AD - Department of Economics, Macalester College, St Paul, Minnesota. FAU - Swanson, Kristi M AU - Swanson KM AD - Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, Minnesota. FAU - Zhou, Jiani AU - Zhou J AD - School of Public Health, University of Minnesota, Minneapolis. FAU - Jena, Anupam Bapu AU - Jena AB AD - Department of Health Care Policy, Harvard Medical School, Harvard University, Boston, Massachusetts. FAU - Ross, Joseph S AU - Ross JS AD - Yale University, Yale School of Medicine, New Haven, Connecticut. FAU - Shah, Nilay D AU - Shah ND AD - Division of Health Care Policy and Research, Mayo Clinic, Rochester, Minnesota. FAU - Karaca-Mandic, Pinar AU - Karaca-Mandic P AD - Carlson School of Management, Department of Finance, University of Minnesota, Minneapolis. LA - eng GR - UL1 TR001863/TR/NCATS NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20211201 PL - United States TA - JAMA Netw Open JT - JAMA network open JID - 101729235 RN - 0 (Anti-Bacterial Agents) RN - 0 (Fluoroquinolones) SB - IM MH - Aged MH - Aged, 80 and over MH - Ambulatory Care/*statistics & numerical data MH - Anti-Bacterial Agents/*therapeutic use MH - Bronchitis/drug therapy MH - Cross-Sectional Studies MH - Drug Labeling/legislation & jurisprudence MH - Drug Prescriptions/*statistics & numerical data MH - Female MH - Fluoroquinolones/*therapeutic use MH - Health Plan Implementation MH - Humans MH - Interrupted Time Series Analysis MH - Male MH - Medicare MH - Middle Aged MH - Practice Patterns, Physicians'/*statistics & numerical data MH - Sinusitis/drug therapy MH - United States MH - United States Food and Drug Administration MH - Urinary Tract Infections/drug therapy PMC - PMC8637256 COIS- Conflict of Interest Disclosures: Ms Zhou reported being a research fellow at Medtronic outside the submitted work. Dr Jena reported receiving personal fees from Pfizer, Hill Rom Services, Bristol Myers Squibb, Eli Lilly, Vertex Pharmaceuticals, Tesaro, AstraZeneca, Bioverativ, Merck, Janssen, Edwards Life Sciences, Novartis, Amgen, Eisai, Otsuka, Celgene, Sanofi Aventis, Biogen, Precision Health Economics, and the Analysis Group outside the submitted work. Dr Ross reported receiving grants from the US Food and Drug Administration (FDA), Johnson & Johnson, the Medical Devices Innovation Consortium, and the Laura and John Arnold Foundation outside the submitted work. Dr Shah reported receiving grants from the FDA, the Center for Medicare and Medicaid Innovation, and the Patient Centered Outcomes Research Institute outside the submitted work. Dr Karaca-Mandic reported receiving grants from the American Cancer Society; receiving personal fees from Tactile Medical, Sempre Health, and Precision Health Economics; and holding an executive position at XanthosHealth LLC outside the submitted work. No other disclosures were reported. EDAT- 2021/12/02 06:00 MHDA- 2022/01/12 06:00 PMCR- 2021/12/01 CRDT- 2021/12/01 12:29 PHST- 2021/12/01 12:29 [entrez] PHST- 2021/12/02 06:00 [pubmed] PHST- 2022/01/12 06:00 [medline] PHST- 2021/12/01 00:00 [pmc-release] AID - 2786698 [pii] AID - zoi211037 [pii] AID - 10.1001/jamanetworkopen.2021.36662 [doi] PST - epublish SO - JAMA Netw Open. 2021 Dec 1;4(12):e2136662. doi: 10.1001/jamanetworkopen.2021.36662. PMID- 34844180 OWN - NLM STAT- MEDLINE DCOM- 20220324 LR - 20231116 IS - 2059-7029 (Electronic) IS - 2059-7029 (Linking) VI - 6 IP - 6 DP - 2021 Dec TI - Pan-Asian adaptation of the EHNS-ESMO-ESTRO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with squamous cell carcinoma of the head and neck. PG - 100309 LID - S2059-7029(21)00271-4 [pii] LID - 10.1016/j.esmoop.2021.100309 [doi] LID - 100309 AB - The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of squamous cell carcinoma (SCC) of the oral cavity, larynx, oropharynx and hypopharynx was published in 2020. It was therefore decided by both the ESMO and the Korean Society of Medical Oncology (KSMO) to convene a special, virtual guidelines meeting in July 2021 to adapt the ESMO 2020 guidelines to consider the potential ethnic differences associated with the treatment of SCCs of the head and neck (SCCHN) in Asian patients. These guidelines represent the consensus opinions reached by experts in the treatment of patients with SCCHN (excluding nasopharyngeal carcinomas) representing the oncological societies of Korea (KSMO), China (CSCO), India (ISMPO), Japan (JSMO), Malaysia (MOS), Singapore (SSO) and Taiwan (TOS). The voting was based on scientific evidence and was independent of the current treatment practices and drug access restrictions in the different Asian countries. The latter was discussed when appropriate. This manuscript provides a series of expert recommendations (Clinical Practice Guidelines) which can be used to provide guidance to health care providers and clinicians for the optimisation of the diagnosis, treatment and management of patients with SCC of the oral cavity, larynx, oropharynx and hypopharynx across Asia. CI - Copyright (c) 2021 The Authors. Published by Elsevier Ltd.. All rights reserved. FAU - Keam, B AU - Keam B AD - Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea. Electronic address: bhumsuk@snu.ac.kr. FAU - Machiels, J-P AU - Machiels JP AD - Service d'Oncologie Medicale, Institut Roi Albert II, Cliniques Universitaires Saint-Luc, Brussels, Belgium. FAU - Kim, H R AU - Kim HR AD - Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea. FAU - Licitra, L AU - Licitra L AD - Head and Neck Cancer Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori and University of Milan, Milan, Italy. FAU - Golusinski, W AU - Golusinski W AD - Department of Head and Neck Surgery, Poznan University of Medical Sciences, The Greater Poland Cancer Centre, Poznan, Poland. FAU - Gregoire, V AU - Gregoire V AD - Department of Radiation Oncology, Centre Leon Berard, Lyon, France. FAU - Lee, Y G AU - Lee YG AD - Division of Hematology and Medical Oncology, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea. FAU - Belka, C AU - Belka C AD - Department of Radiation Oncology, LMU Hospital, Munich, Germany. FAU - Guo, Y AU - Guo Y AD - Department of Medical Oncology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China. FAU - Rajappa, S J AU - Rajappa SJ AD - Medical Oncology, Basavatarakam Indo American Cancer Hospital and Research Institute, Hyderabad, India. FAU - Tahara, M AU - Tahara M AD - Department of Head and Neck Medical Oncology, National Cancer Center Hospital East, Chiba, Japan. FAU - Azrif, M AU - Azrif M AD - Clinical Oncology, Prince Court Medical Centre, Kuala Lumpur, Malaysia. FAU - Ang, M K AU - Ang MK AD - Department of Medical Oncology, National Cancer Centre, Singapore, Singapore. FAU - Yang, M-H AU - Yang MH AD - Institute of Clinical Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan. FAU - Wang, C-H AU - Wang CH AD - Division of Hemato-oncology, Department of Internal Medicine, Keelung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Taoyuan, Taiwan. FAU - Ng, Q S AU - Ng QS AD - Division of Medical Oncology, National Cancer Centre, Singapore, Singapore. FAU - Wan Zamaniah, W I AU - Wan Zamaniah WI AD - Clinical Oncology Unit, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia. FAU - Kiyota, N AU - Kiyota N AD - Oncology/Hematology, Cancer Center, Kobe University Hospital, Kobe, Japan. FAU - Babu, S AU - Babu S AD - Department of Medical Oncology, Kidwai Memorial Institute of Oncology, Bangalore, India. FAU - Yang, K AU - Yang K AD - Department of Clinical Oncology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. FAU - Curigliano, G AU - Curigliano G AD - Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy; Istituto Europeo di Oncologia, IRCCS, Milano, Italy. FAU - Peters, S AU - Peters S AD - Department of Oncology, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland. FAU - Kim, T W AU - Kim TW AD - Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. FAU - Yoshino, T AU - Yoshino T AD - Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center East, Chiba, Japan. FAU - Pentheroudakis, G AU - Pentheroudakis G AD - ESMO, Lugano, Switzerland. LA - eng PT - Journal Article PT - Practice Guideline PT - Research Support, Non-U.S. Gov't DEP - 20211126 PL - England TA - ESMO Open JT - ESMO open JID - 101690685 SB - IM MH - *Carcinoma, Squamous Cell/diagnosis/therapy MH - Follow-Up Studies MH - *Head and Neck Neoplasms/diagnosis/therapy MH - Humans MH - Medical Oncology MH - Squamous Cell Carcinoma of Head and Neck/diagnosis/therapy PMC - PMC8710460 OTO - NOTNLM OT - ESMO OT - Pan-Asian OT - guidelines OT - head and neck OT - squamous cell carcinoma OT - treatment COIS- Disclosure BK declares grants or contracts from Merck Sharp & Dohme (MSD) Oncology, Ono Pharmaceutical and AstraZeneca, consulting fees from AstraZeneca, MSD Oncology, ABL Bio, Genexine, Cellid, Handok, Celid, Trial Informatics and CBS Bio, payment or honoraria from MSD Oncology and Merck. J-PM declares consulting fees/honoraria from Pfizer, Roche, AstraZeneca, Bayer, Innate, Merck Serono, Boehringer, Bristol Myers Squibb (BMS), Novartis, Janssen, Incyte, Cue Biopharma, ALX Oncology, iTEOS, TheRNA and NEKTAR, support for attending meetings and/or travel from Amgen, Pfizer and MSD and participation at a Safety or Advisory Board for PsiOxus. LL declares institutional grants or contracts from AstraZeneca, BMS, Boehringer Ingelheim, Celgene International, Eisai, Exelixis Inc, Debiopharm International SA, Hoffman-La Roche Ltd., IRX Therapeutics Inc., Medpace Inc., Merck-Serono, MSD, Novartis, Pfizer, Roche Spa and Buran and receipt of honoraria or fees (for public speaking/teaching in medical meetings and/or for providing expert opinion in Advisory Boards) for AstraZeneca, Bayer, BMS, Eisai, MSD, Merck-Serono, Boehringer Ingelheim, Hoffman La Roche Ltd., Novartis, Roche, Debiopharm International SA, Sobi, Incyte Biosciences Italy SRL, Doxa Pharma, Amgen, Nanobiotics and GlaxoSmithKline (GSK). CB declares payment or honoraria from Merck KGaA, BMS and Roche. MT declares consulting fees from Ono Pharmaceuticals, MSD, BMS and Merck Biopharma, and honoraria from Eisai, Ono Pharmaceuticals, BMS and Merck Biopharma. MA declares consulting fees from MSD, AstraZeneca, Eli Lilly, DKSH, Eisai, Roche, Novartis and Merck, payment or honoraria from MSD, AstraZeneca, Eli Lilly, DKSH, Eisai, Roche, Novartis and Merck, support for attending meetings and/or travel from MSD, Roche, Elekta/Abex and AstraZeneca, and is the president of the Malaysian Oncological Society. MKA declares honoraria for presentations from Pfizer and Boehringer Ingelheim, sponsorship for meetings from AstraZeneca, Boehringer Ingelheim and DKSH. QSNg declares support for attending meetings and or travel from BMS, Boehringer Ingelheim, MSD and Astellas, and participation in Safety or Advisory Boards for MSD and Boehringer Ingelheim. WIWZ declares honoraria for lectures from Amgen Malaysia, DKSH Malaysia, Eisai Malaysia, Eli Lilly Malaysia, Ipsen Malaysia, MSD Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, Merck Serono Malaysia, Pfizer Malaysia and Roche Malaysia, travel grants from Amgen Malaysia, Celgene Malaysia, Eisai Malaysia, Eli Lilly Malaysia, MSD Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, and Roche Malaysia, participation on an Advisory Board for Celgene Malaysia, Roche Malaysia, Eli Lilly Malaysia, Eisai Malaysia and MSD Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, and is a member of ASCO AP Regional Council and Greater Petaling Cancer City Challenge UICC. NK declares institutional grants or contracts from Ono Pharmaceutical, BMS, AstraZeneca, Pfizer, Chugai Pharmaceutical, Rakuten Medical, Bayer and Adlai Nortye, payment or honoraria from Ono Pharmaceutical, BMS, Merck Biopharma, MSD, Eisai and Bayer, participation on a Data Safety Monitoring Board or Advisory Board for Bayer and Adlai Nortye. GC declares institutional grants from Merck, consulting fees from BMS, Pfizer, MSD, AstraZeneca, Daichii Sankyo, Lilly, Novartis and Seattle Genetics, payment or honoraria from AstraZeneca, Roche and Daichii Sankyo. SP declares fees for consultancy/advisory roles from AbbVie, Amgen, AstraZeneca, Bayer, Beigene, Biocartis, Boehringer Ingelheim, BMS, Clovis, Daiichi Sankyo, Debiopharm, ecancer, Eli Lilly, Elsevier, Foundation Medicine, Illumina, Imedex, Incyte, Janssen, Medscape, MSD, Merck Serono, Merrimack, Novartis, PharmaMar, Phosplatin Therapeutics, PER, Pfizer, PRIME, Regeneron, Roche/Genentech, RTP, Sanofi, Seattle Genetics, Takeda, speaker roles for AstraZeneca, Boehringer Ingelheim, BMS, ecancer, Eli Lilly, Illumina, Imedex, Medscape, MSD, Novartis, PER, Pfizer, Prime, Roche/Genentech, RTP, Sanofi, Takeda and the receipt of grants/research support: (Sub) investigator in trials (institutional financial support for trials) sponsored by Amgen, AstraZeneca, Biodesix, Boehringer Ingelheim, BMS, Clovis, GSK, Illumina, Lilly, MSD, Merck Serono, Mirati, Novartis, and Pfizer, Phosplatin Therapeutics, Roche/Genentech. TWK declares institutional grants or contracts from Roche, and sanofi-aventis. TY declares institutional grants or contracts from Taiho Pharmaceutical, Sumitomo Dainippon, Ono Pharmaceutical, Chugai Pharmaceutical, Amgen, Parexel International, MSD, Daiichi-Sankyo and Sanofi. All other authors have declared no conflicts of interest. EDAT- 2021/11/30 06:00 MHDA- 2022/03/25 06:00 PMCR- 2021/11/26 CRDT- 2021/11/29 20:27 PHST- 2021/09/27 00:00 [received] PHST- 2021/10/26 00:00 [revised] PHST- 2021/10/27 00:00 [accepted] PHST- 2021/11/30 06:00 [pubmed] PHST- 2022/03/25 06:00 [medline] PHST- 2021/11/29 20:27 [entrez] PHST- 2021/11/26 00:00 [pmc-release] AID - S2059-7029(21)00271-4 [pii] AID - 100309 [pii] AID - 10.1016/j.esmoop.2021.100309 [doi] PST - ppublish SO - ESMO Open. 2021 Dec;6(6):100309. doi: 10.1016/j.esmoop.2021.100309. Epub 2021 Nov 26. PMID- 34843382 OWN - NLM STAT- MEDLINE DCOM- 20220214 LR - 20260930 IS - 1539-3704 (Electronic) IS - 0003-4819 (Print) IS - 0003-4819 (Linking) VI - 175 IP - 1 DP - 2022 Jan TI - Disparities in Dolutegravir Uptake Affecting Females of Reproductive Age With HIV in Low- and Middle-Income Countries After Initial Concerns About Teratogenicity : An Observational Study. PG - 84-94 LID - 10.7326/M21-3037 [doi] AB - BACKGROUND: The transition to dolutegravir-containing antiretroviral therapy (ART) in low- and middle-income countries (LMICs) was complicated by an initial safety signal in May 2018 suggesting that exposure to dolutegravir at conception was possibly associated with infant neural tube defects. On the basis of additional evidence, in July 2019, the World Health Organization recommended dolutegravir for all adults and adolescents living with HIV. OBJECTIVE: To describe dolutegravir uptake and disparities by sex and age group in LMICs. DESIGN: Observational cohort study. SETTING: 87 sites that began using dolutegravir in 11 LMICs in the Asia-Pacific; Caribbean, Central and South America network for HIV epidemiology (CCASAnet); and sub-Saharan African regions of the International epidemiology Databases to Evaluate AIDS (IeDEA) consortium. PATIENTS: 134 672 patients aged 16 years or older who received HIV care from January 2017 through March 2020. MEASUREMENTS: Sex, age group, and dolutegravir uptake (that is, newly initiating ART with dolutegravir or switching to dolutegravir from another regimen). RESULTS: Differences in dolutegravir uptake among females of reproductive age (16 to 49 years) emerged after the safety signal. By the end of follow-up, the cumulative incidence of dolutegravir uptake among females 16 to 49 years old was 29.4% (95% CI, 29.0% to 29.7%) compared with 57.7% (CI, 57.2% to 58.3%) among males 16 to 49 years old. This disparity was greater in countries that began implementing dolutegravir before the safety signal and initially had highly restrictive policies versus countries with a later rollout. Dolutegravir uptake was similar among females and males aged 50 years or older. LIMITATION: Follow-up was limited to 6 to 8 months after international guidelines recommended expanding access to dolutegravir. CONCLUSION: Substantial disparities in dolutegravir uptake affecting females of reproductive age through early 2020 are documented. Although this disparity was anticipated because of country-level restrictions on access, the results highlight its extent and initial persistence. PRIMARY FUNDING SOURCE: National Institutes of Health. FAU - Romo, Matthew L AU - Romo ML AUID- ORCID: 0000-0002-3038-0644 AD - Department of Epidemiology and Biostatistics, CUNY Graduate School of Public Health and Health Policy, City University of New York, and CUNY Institute for Implementation Science in Population Health, New York, New York (M.L.R., E.B., E.A.K., D.N.). FAU - Patel, Rena C AU - Patel RC AUID- ORCID: 0000-0001-9893-5856 AD - Department of Medicine and Department of Global Health, University of Washington, Seattle, Washington (R.C.P.). FAU - Edwards, Jessie K AU - Edwards JK AUID- ORCID: 0000-0002-1741-335X AD - Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina (J.K.E.). FAU - Humphrey, John M AU - Humphrey JM AD - Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana (J.M.H., K.K.W.). FAU - Musick, Beverly S AU - Musick BS AUID- ORCID: 0000-0003-0334-6798 AD - Department of Biostatistics and Health Data Science, Indiana University School of Medicine, Indianapolis, Indiana (B.S.M.). FAU - Bernard, Caitlin AU - Bernard C AUID- ORCID: 0000-0002-6753-1098 AD - Department of Obstetrics & Gynecology, Indiana University School of Medicine, Indianapolis, Indiana (C.B.). FAU - Maina, Mercy W AU - Maina MW AD - Department of Pharmacy, Moi Teaching and Referral Hospital, Eldoret, Kenya (M.W.M.). FAU - Brazier, Ellen AU - Brazier E AUID- ORCID: 0000-0002-8514-1958 AD - Department of Epidemiology and Biostatistics, CUNY Graduate School of Public Health and Health Policy, City University of New York, and CUNY Institute for Implementation Science in Population Health, New York, New York (M.L.R., E.B., E.A.K., D.N.). FAU - Castelnuovo, Barbara AU - Castelnuovo B AUID- ORCID: 0000-0001-7756-5032 AD - Infectious Diseases Institute, Makerere University College of Health Sciences, Kampala, Uganda (B.C.). FAU - Penner, Jeremy AU - Penner J AUID- ORCID: 0000-0001-6443-1748 AD - Family AIDS Care & Education Services, Kisumu, Kenya, and Department of Family Practice, University of British Columbia, Vancouver, British Columbia, Canada (J.P.). FAU - Wyka, Katarzyna AU - Wyka K AD - Department of Epidemiology and Biostatistics, CUNY Graduate School of Public Health and Health Policy, City University of New York, New York, New York (K.W.). FAU - Cardoso, Sandra Wagner AU - Cardoso SW AUID- ORCID: 0000-0001-5230-0003 AD - Instituto Nacional de Infectologia, Laboratorio de Pesquisa Clinica em HIV/AIDS, Fundacao Oswaldo Cruz, Rio de Janeiro, Brazil (S.W.C.). FAU - Ly, Penh Sun AU - Ly PS AD - National Center for HIV/AIDS, Dermatology and STDs, Ministry of Health, Phnom Penh, Cambodia (P.S.L.). FAU - Kunzekwenyika, Cordelia AU - Kunzekwenyika C AUID- ORCID: 0000-0002-1687-3397 AD - SolidarMed, Masvingo, Zimbabwe (C.K.). FAU - Cortes, Claudia P AU - Cortes CP AUID- ORCID: 0000-0001-9101-9783 AD - Departamento de Medicina, Universidad de Chile & Fundacion Arriaran, Santiago, Chile (C.P.C.). FAU - Panczak, Radoslaw AU - Panczak R AUID- ORCID: 0000-0001-5141-683X AD - Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland (R.P.). FAU - Kelvin, Elizabeth A AU - Kelvin EA AUID- ORCID: 0000-0002-0566-8697 AD - Department of Epidemiology and Biostatistics, CUNY Graduate School of Public Health and Health Policy, City University of New York, and CUNY Institute for Implementation Science in Population Health, New York, New York (M.L.R., E.B., E.A.K., D.N.). FAU - Wools-Kaloustian, Kara K AU - Wools-Kaloustian KK AD - Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana (J.M.H., K.K.W.). FAU - Nash, Denis AU - Nash D AUID- ORCID: 0000-0002-3280-5386 AD - Department of Epidemiology and Biostatistics, CUNY Graduate School of Public Health and Health Policy, City University of New York, and CUNY Institute for Implementation Science in Population Health, New York, New York (M.L.R., E.B., E.A.K., D.N.). CN - International epidemiology Databases to Evaluate AIDS (IeDEA) LA - eng GR - U01 AI096299/AI/NIAID NIH HHS/United States GR - U01 AI069476/AI/NIAID NIH HHS/United States GR - U01 AI069911/AI/NIAID NIH HHS/United States GR - K23 HD105495/HD/NICHD NIH HHS/United States GR - U01 AI069923/AI/NIAID NIH HHS/United States GR - R24 AI124872/AI/NIAID NIH HHS/United States GR - U01 AI069907/AI/NIAID NIH HHS/United States GR - K01 AI125087/AI/NIAID NIH HHS/United States GR - K23 AI120855/AI/NIAID NIH HHS/United States GR - U01 AI069924/AI/NIAID NIH HHS/United States PT - Journal Article PT - Observational Study PT - Research Support, N.I.H., Extramural PT - Video-Audio Media DEP - 20211130 PL - United States TA - Ann Intern Med JT - Annals of internal medicine JID - 0372351 RN - 0 (HIV Integrase Inhibitors) RN - 0 (Heterocyclic Compounds, 3-Ring) RN - 0 (Oxazines) RN - 0 (Piperazines) RN - 0 (Pyridones) RN - DKO1W9H7M1 (Dolutegravir) SB - IM CIN - Ann Intern Med. 2022 Jan;175(1):133-134. doi: 10.7326/M21-4338. PMID: 34843381 MH - Adolescent MH - Adult MH - *Developing Countries MH - Female MH - HIV Infections/*drug therapy MH - HIV Integrase Inhibitors/*administration & dosage/*adverse effects MH - Heterocyclic Compounds, 3-Ring/*administration & dosage/*adverse effects MH - Humans MH - Middle Aged MH - Oxazines/*administration & dosage/*adverse effects MH - Piperazines/*administration & dosage/*adverse effects MH - Pyridones/*administration & dosage/*adverse effects MH - Dolutegravir PMC - PMC8808594 MID - NIHMS1772077 FIR - Khol, V IR - Khol V FIR - Zhang, F J IR - Zhang FJ FIR - Zhao, H X IR - Zhao HX FIR - Han, N IR - Han N FIR - Lee, M P IR - Lee MP FIR - Li, P C K IR - Li PCK FIR - Lam, W IR - Lam W FIR - Wong, H Y IR - Wong HY FIR - Kumarasamy, N IR - Kumarasamy N FIR - Ezhilarasi, C IR - Ezhilarasi C FIR - Pujari, S IR - Pujari S FIR - Joshi, K IR - Joshi K FIR - Gaikwad, S IR - Gaikwad S FIR - Chitalikar, A IR - Chitalikar A FIR - Merati, T P IR - Merati TP FIR - Wirawan, D N IR - Wirawan DN FIR - Yuliana, F IR - Yuliana F FIR - Yunihastuti, E IR - Yunihastuti E FIR - Imran, D IR - Imran D FIR - Widhani, A IR - Widhani A FIR - Tanuma, J IR - Tanuma J FIR - Oka, S IR - Oka S FIR - Nishijima, T IR - Nishijima T FIR - Choi, J Y IR - Choi JY FIR - Na, S IR - Na S FIR - Kim, J M IR - Kim JM FIR - Gani, Y M IR - Gani YM FIR - Rudi, N B IR - Rudi NB FIR - Azwa, I IR - Azwa I FIR - Kamarulzaman, A IR - Kamarulzaman A FIR - Omar, S F Syed IR - Omar SFS FIR - Ponnampalavanar, S IR - Ponnampalavanar S FIR - Ditangco, R IR - Ditangco R FIR - Pasayan, M K IR - Pasayan MK FIR - Mationg, M L IR - Mationg ML FIR - Chan, Y J IR - Chan YJ FIR - Ku, W W IR - Ku WW FIR - Ke, E IR - Ke E FIR - Wu, P C IR - Wu PC FIR - Ng, O T IR - Ng OT FIR - Lim, P L IR - Lim PL FIR - Lee, L S IR - Lee LS FIR - Ya, J K IR - Ya JK FIR - Avihingsanon, A IR - Avihingsanon A FIR - Gatechompol, S IR - Gatechompol S FIR - Phanuphak, P IR - Phanuphak P FIR - Phadungphon, C IR - Phadungphon C FIR - Kiertiburanakul, S IR - Kiertiburanakul S FIR - Phuphuakrat, A IR - Phuphuakrat A FIR - Chumla, L IR - Chumla L FIR - Sanmeema, N IR - Sanmeema N FIR - Chaiwarith, R IR - Chaiwarith R FIR - Sirisanthana, T IR - Sirisanthana T FIR - Praparattanapan, J IR - Praparattanapan J FIR - Nuket, K IR - Nuket K FIR - Khuwuwan, S IR - Khuwuwan S FIR - Kantipong, P IR - Kantipong P FIR - Kambua, P IR - Kambua P FIR - Nguyen, K V IR - Nguyen KV FIR - Bui, H V IR - Bui HV FIR - Nguyen, D T H IR - Nguyen DTH FIR - Nguyen, D T IR - Nguyen DT FIR - Do, C D IR - Do CD FIR - Ngo, A V IR - Ngo AV FIR - Nguyen, L T IR - Nguyen LT FIR - Sohn, A H IR - Sohn AH FIR - Ross, J L IR - Ross JL FIR - Petersen, B IR - Petersen B FIR - Law, M G IR - Law MG FIR - Jiamsakul, A IR - Jiamsakul A FIR - Bijker, R IR - Bijker R FIR - Rupasinghe, D IR - Rupasinghe D FIR - Cahn, Pedro IR - Cahn P FIR - Cesar, Carina IR - Cesar C FIR - Fink, Valeria IR - Fink V FIR - Sued, Omar IR - Sued O FIR - Dell'Isola, Emanuel IR - Dell'Isola E FIR - Perez, Hector IR - Perez H FIR - Valiente, Jose IR - Valiente J FIR - Yamamoto, Cleyton IR - Yamamoto C FIR - Grinsztejn, Beatriz IR - Grinsztejn B FIR - Veloso, Valdilea IR - Veloso V FIR - Luz, Paula IR - Luz P FIR - de Boni, Raquel IR - de Boni R FIR - Friedman, Ruth IR - Friedman R FIR - Moreira, Ronaldo IR - Moreira R FIR - Pinto, Jorge IR - Pinto J FIR - Ferreira, Flavia IR - Ferreira F FIR - Maia, Marcelle IR - Maia M FIR - de Menezes Succi, Regina Celia IR - de Menezes Succi RC FIR - Machado, Daisy Maria IR - Machado DM FIR - de Fatima Barbosa Gouvea, Aida IR - de Fatima Barbosa Gouvea A FIR - Wolff, Marcelo IR - Wolff M FIR - Rodriguez, Maria Fernanda IR - Rodriguez MF FIR - Allendes, Gladys IR - Allendes G FIR - Pape, Jean William IR - Pape JW FIR - Rouzier, Vanessa IR - Rouzier V FIR - Marcelin, Adias IR - Marcelin A FIR - Perodin, Christian IR - Perodin C FIR - Luque, Marco Tulio IR - Luque MT FIR - Padgett, Denis IR - Padgett D FIR - Madero, Juan Sierra IR - Madero JS FIR - Ramirez, Brenda Crabtree IR - Ramirez BC FIR - Belaunzaran, Paco IR - Belaunzaran P FIR - Vega, Yanink Caro IR - Vega YC FIR - Gotuzzo, Eduardo IR - Gotuzzo E FIR - Mejia, Fernando IR - Mejia F FIR - Carriquiry, Gabriela IR - Carriquiry G FIR - McGowan, Catherine C IR - McGowan CC FIR - Shepherd, Bryan E IR - Shepherd BE FIR - Sterling, Timothy IR - Sterling T FIR - Jayathilake, Karu IR - Jayathilake K FIR - Person, Anna K IR - Person AK FIR - Rebeiro, Peter F IR - Rebeiro PF FIR - Castilho, Jessica IR - Castilho J FIR - Duda, Stephany N IR - Duda SN FIR - Maruri, Fernanda IR - Maruri F FIR - Vansell, Hilary IR - Vansell H FIR - Jenkins, Cathy IR - Jenkins C FIR - Kim, Ahra IR - Kim A FIR - Lotspeich, Sarah IR - Lotspeich S FIR - Pelagie, Nimbona IR - Pelagie N FIR - Gateretse, Patrick IR - Gateretse P FIR - Munezero, Jeanine IR - Munezero J FIR - Nitereka, Valentin IR - Nitereka V FIR - Niyongabo, Theodore IR - Niyongabo T FIR - Twizere, Christelle IR - Twizere C FIR - Bukuru, Helene IR - Bukuru H FIR - Nahimana, Thierry IR - Nahimana T FIR - Baransaka, Elysee IR - Baransaka E FIR - Barasukana, Patrice IR - Barasukana P FIR - Kabanda, Eugene IR - Kabanda E FIR - Manirakiza, Martin IR - Manirakiza M FIR - Ndikumwenayo, Francois IR - Ndikumwenayo F FIR - Biziragusenyuka, Jeremie IR - Biziragusenyuka J FIR - Michelline Munezero, Ange Marie IR - Michelline Munezero AM FIR - Nforniwe, Denis Nsame IR - Nforniwe DN FIR - Ajeh, Rogers IR - Ajeh R FIR - Ngamani, Marc Lionel IR - Ngamani ML FIR - Dzudie, Anastase IR - Dzudie A FIR - Mbuh, Akindeh IR - Mbuh A FIR - Amadou, Djenabou IR - Amadou D FIR - Pefura Yone, Eric Walter IR - Pefura Yone EW FIR - Kendowo, Ernestine IR - Kendowo E FIR - Akele, Catherine IR - Akele C FIR - Clever, Akili IR - Clever A FIR - Kitetele, Faustin IR - Kitetele F FIR - Lelo, Patricia IR - Lelo P FIR - Tabala, Martine IR - Tabala M FIR - Ekembe, Cherubin IR - Ekembe C FIR - Kaba, Didine IR - Kaba D FIR - Diafouka, Merlin IR - Diafouka M FIR - Ekat, Martin Herbas IR - Ekat MH FIR - Nsonde, Dominique Mahambou IR - Nsonde DM FIR - Mafoua, Adolphe IR - Mafoua A FIR - Christ, Massamba Ndala IR - Christ MN FIR - Igirimbabazi, Jules IR - Igirimbabazi J FIR - Ayinkamiye, Nicole IR - Ayinkamiye N FIR - Uwineza, Providance IR - Uwineza P FIR - Ndamijimana, Emmanuel IR - Ndamijimana E FIR - Habarurema, Emmanuel IR - Habarurema E FIR - Nyiraneza, Marie Luise IR - Nyiraneza ML FIR - Nyiransabimana, Marie Louise IR - Nyiransabimana ML FIR - Tuyisenge, Liliane IR - Tuyisenge L FIR - Shyaka, Christian IR - Shyaka C FIR - Kankindi, Catherine IR - Kankindi C FIR - Uwakijijwe, Bonheur IR - Uwakijijwe B FIR - Ingabire, Marie Grace IR - Ingabire MG FIR - Ndumuhire, Jules IR - Ndumuhire J FIR - Nyirabahutu, Marie Goretti IR - Nyirabahutu MG FIR - Muyango, Fred IR - Muyango F FIR - Bihibindi, Jean Christophe IR - Bihibindi JC FIR - Uwamahoro, Oliver IR - Uwamahoro O FIR - Ndoli, Yvette IR - Ndoli Y FIR - Nsanzimana, Sabin IR - Nsanzimana S FIR - Mugwaneza, Placidie IR - Mugwaneza P FIR - Remera, Eric IR - Remera E FIR - Umumararungu, Esperance IR - Umumararungu E FIR - Rwibasira, Gallican Nshogoza IR - Rwibasira GN FIR - Habimana, Dominique Savio IR - Habimana DS FIR - Gasana, Josephine IR - Gasana J FIR - Kanyabwisha, Faustin IR - Kanyabwisha F FIR - Kubwimana, Gallican IR - Kubwimana G FIR - Muhoza, Benjamin IR - Muhoza B FIR - Munyaneza, Athanase IR - Munyaneza A FIR - Murenzi, Gad IR - Murenzi G FIR - Musabyimana, Francoise IR - Musabyimana F FIR - Umwiza, Francine IR - Umwiza F FIR - Ingabire, Charles IR - Ingabire C FIR - Tuyisenge, Patrick IR - Tuyisenge P FIR - Butera, Alex M IR - Butera AM FIR - Kabahizi, Jules IR - Kabahizi J FIR - Rurangwa, Ephrem IR - Rurangwa E FIR - Feza, Rosine IR - Feza R FIR - Mukashyaka, Eugenie IR - Mukashyaka E FIR - Benekigeri, Chantal IR - Benekigeri C FIR - Musaninyange, Jacqueline IR - Musaninyange J FIR - Adedimeji, Adebola IR - Adedimeji A FIR - Anastos, Kathryn IR - Anastos K FIR - Dilorenzo, Madeline IR - Dilorenzo M FIR - Murchison, Lynn IR - Murchison L FIR - Ross, Jonathan IR - Ross J FIR - Yotebieng, Marcel IR - Yotebieng M FIR - Addison, Diane IR - Addison D FIR - Jones, Heidi IR - Jones H FIR - Kulkarni, Sarah IR - Kulkarni S FIR - Tymejczyk, Olga IR - Tymejczyk O FIR - Elul, Batya IR - Elul B FIR - Cai, Xiatao IR - Cai X FIR - Dong, Allan IR - Dong A FIR - Hoover, Don IR - Hoover D FIR - Kim, Hae-Young IR - Kim HY FIR - Li, Chunshan IR - Li C FIR - Shi, Qiuhu IR - Shi Q FIR - Lancaster, Kathryn IR - Lancaster K FIR - Kuniholm, Mark IR - Kuniholm M FIR - Edmonds, Andrew IR - Edmonds A FIR - Parcesepe, Angela IR - Parcesepe A FIR - Keiser, Olivia IR - Keiser O FIR - Duda, Stephany IR - Duda S FIR - Kimmel, April IR - Kimmel A FIR - Diero, L IR - Diero L FIR - Ayaya, S IR - Ayaya S FIR - Sang, E IR - Sang E FIR - Bukusi, E IR - Bukusi E FIR - Mulwa, Edwin IR - Mulwa E FIR - Nyanaro, George IR - Nyanaro G FIR - Kasozi, Charles IR - Kasozi C FIR - Ssemakadde, Mathew IR - Ssemakadde M FIR - Bwana, Mwebesa Bosco IR - Bwana MB FIR - Muyindike, Winnie IR - Muyindike W FIR - Byakwaga, Helen IR - Byakwaga H FIR - Kanyesigye, Michael IR - Kanyesigye M FIR - Semeere, Aggrey IR - Semeere A FIR - Matovu, John Michael IR - Matovu JM FIR - Nalugoda, Fred IR - Nalugoda F FIR - Wasswa, Francis X IR - Wasswa FX FIR - Kazyoba, Paul IR - Kazyoba P FIR - Mayige, Mary IR - Mayige M FIR - Lyamuya, Rita Elias IR - Lyamuya RE FIR - Mayanga, Francis IR - Mayanga F FIR - Ngonyani, Kapella IR - Ngonyani K FIR - Lwali, Jerome IR - Lwali J FIR - Urassa, Mark IR - Urassa M FIR - Nyaga, Charles IR - Nyaga C FIR - Machemba, Richard IR - Machemba R FIR - Yiannoutsos, Constantin IR - Yiannoutsos C FIR - Elul, Batya IR - Elul B FIR - Vreeman, Rachel IR - Vreeman R FIR - Syvertsen, Jennifer IR - Syvertsen J FIR - Kantor, Rami IR - Kantor R FIR - Martin, Jeffrey IR - Martin J FIR - Wenger, Megan IR - Wenger M FIR - Cohen, Craig IR - Cohen C FIR - Kulzer, Jayne IR - Kulzer J FIR - Maartens, Gary IR - Maartens G FIR - Bolton, Carolyn IR - Bolton C FIR - Wood, Robin IR - Wood R FIR - Sipambo, Nosisa IR - Sipambo N FIR - Tanser, Frank IR - Tanser F FIR - Boulle, Andrew IR - Boulle A FIR - Fatti, Geoffrey IR - Fatti G FIR - Mbewe, Safari IR - Mbewe S FIR - Singh, Elvira IR - Singh E FIR - Chimbetete, Cleophas IR - Chimbetete C FIR - Technau, Karl IR - Technau K FIR - Eley, Brian IR - Eley B FIR - Muhairwe, Josephine IR - Muhairwe J FIR - Rafael, Idivino IR - Rafael I FIR - Fox, Matthew P IR - Fox MP FIR - Prozesky, Hans IR - Prozesky H FIR - Anderegg, Nina IR - Anderegg N FIR - Ballif, Marie IR - Ballif M FIR - Dao Ostinelli, Cam Ha IR - Dao Ostinelli CH FIR - Egger, Matthias IR - Egger M FIR - Fenner, Lukas IR - Fenner L FIR - Haas, Andreas IR - Haas A FIR - Hossmann, Stefanie IR - Hossmann S FIR - Rohner, Eliane IR - Rohner E FIR - Riou, Julien IR - Riou J FIR - Skrivankova, Veronika IR - Skrivankova V FIR - Smith, Lilian IR - Smith L FIR - Taghavi, Katayoun IR - Taghavi K FIR - von Groote, Per IR - von Groote P FIR - Wandeler, Gilles IR - Wandeler G FIR - Zaniewski, Elizabeth IR - Zaniewski E FIR - Zurcher, Kathrin IR - Zurcher K FIR - Anderson, Kim IR - Anderson K FIR - Boulle, Andrew IR - Boulle A FIR - Cornell, Morna IR - Cornell M FIR - Davies, Mary-Ann IR - Davies MA FIR - Iyun, Victoria IR - Iyun V FIR - Johnson, Leigh IR - Johnson L FIR - Kassanjee, Reshma IR - Kassanjee R FIR - Kehoe, Kathleen IR - Kehoe K FIR - Kubjane, Mmamapudi IR - Kubjane M FIR - Maxwell, Nicola IR - Maxwell N FIR - Nyakato, Patience IR - Nyakato P FIR - Patten, Gem IR - Patten G FIR - Tlali, Mpho IR - Tlali M FIR - Tsondai, Priscilla IR - Tsondai P FIR - de Waal, Renee IR - de Waal R EDAT- 2021/11/30 06:00 MHDA- 2022/02/15 06:00 PMCR- 2022/07/01 CRDT- 2021/11/29 17:14 PHST- 2021/11/30 06:00 [pubmed] PHST- 2022/02/15 06:00 [medline] PHST- 2021/11/29 17:14 [entrez] PHST- 2022/07/01 00:00 [pmc-release] AID - 10.7326/M21-3037 [doi] PST - ppublish SO - Ann Intern Med. 2022 Jan;175(1):84-94. doi: 10.7326/M21-3037. Epub 2021 Nov 30. PMID- 34832542 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20211130 IS - 2076-0817 (Print) IS - 2076-0817 (Electronic) IS - 2076-0817 (Linking) VI - 10 IP - 11 DP - 2021 Oct 27 TI - Halved Incidence of Scrub Typhus after Travel Restrictions to Confine a Surge of COVID-19 in Taiwan. LID - 10.3390/pathogens10111386 [doi] LID - 1386 AB - Scrub typhus is a rickettsial disease that is usually transmitted by mite exposure. Infected patients may present with a fever, fatigue, headache, and muscle pain. A blackish skin lesion, called eschar, is pathognomic. The mortality rate in untreated cases is high. The first case of scrub typhus in Taiwan was reported in 1908 during the Japanese colonization. In this article, using the National Infectious Disease Statistics System (NIDSS) from the Taiwan CDC, we analyzed the dynamic incidence of scrub typhus from 2016 to 2021, both seasonally and geographically. In addition, we asked whether the recent travel restrictions and social distancing policy in Taiwan (19 May to 27 July 2021), implemented due to the COVID-19 outbreak, would change the incidence of scrub typhus. The results showed that scrub typhus was most common in summer, with an incidence almost twofold greater than that in winter or spring. Most cases were identified in rural regions. Interestingly, there was a significant 52% reduction in the summer incidence in 2021, compared to the average summer incidence of the past 5 years. This reduction coincided with the countrywide lockdown measures and travel restrictions. The restricted measures for outdoor activities may have contributed to the reduced incidence of scrub typhus. FAU - Lin, En-Cheng AU - Lin EC AUID- ORCID: 0000-0003-4317-5524 AD - Department of Dermatology, Kaohsiung Veterans General Hospital, Kaohsiung 813, Taiwan. FAU - Tu, Hung-Pin AU - Tu HP AUID- ORCID: 0000-0003-1044-2673 AD - Department of Public Health and Environmental Medicine, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan. FAU - Hong, Chien-Hui AU - Hong CH AUID- ORCID: 0000-0002-5118-620X AD - Department of Dermatology, Kaohsiung Veterans General Hospital, Kaohsiung 813, Taiwan. AD - Department of Dermatology, School of Medicine, National Yang Ming Chiao Tung University, Taipei 112, Taiwan. LA - eng PT - Journal Article DEP - 20211027 PL - Switzerland TA - Pathogens JT - Pathogens (Basel, Switzerland) JID - 101596317 PMC - PMC8623167 OTO - NOTNLM OT - COVID-19 OT - Orientia tsutsugamushi OT - rickettsial disease OT - scrub typhus COIS- The authors declare no conflict of interest. EDAT- 2021/11/28 06:00 MHDA- 2021/11/28 06:01 PMCR- 2021/10/27 CRDT- 2021/11/27 01:19 PHST- 2021/09/05 00:00 [received] PHST- 2021/10/20 00:00 [revised] PHST- 2021/10/26 00:00 [accepted] PHST- 2021/11/27 01:19 [entrez] PHST- 2021/11/28 06:00 [pubmed] PHST- 2021/11/28 06:01 [medline] PHST- 2021/10/27 00:00 [pmc-release] AID - pathogens10111386 [pii] AID - pathogens-10-01386 [pii] AID - 10.3390/pathogens10111386 [doi] PST - epublish SO - Pathogens. 2021 Oct 27;10(11):1386. doi: 10.3390/pathogens10111386. PMID- 34831876 OWN - NLM STAT- MEDLINE DCOM- 20211203 LR - 20260901 IS - 1660-4601 (Electronic) IS - 1661-7827 (Print) IS - 1660-4601 (Linking) VI - 18 IP - 22 DP - 2021 Nov 18 TI - Knowledge Update on the Economic Evaluation of Pacemaker Telemonitoring Systems. LID - 10.3390/ijerph182212120 [doi] LID - 12120 AB - (1) Introduction: In the last two decades, telemedicine has been increasingly applied to telemonitoring (TM) of patients with pacemakers; however, presently, its growth has significantly accelerated because of the COVID-19 pandemic, which has pushed patients and healthcare workers alike to seek new ways to stay healthy with minimal physical contact. Therefore, the main objective of this study was to update the current knowledge on the differences in the medium-and long-term effectiveness of TM and conventional monitoring (CM) in relation to costs and health outcomes. (2) Methods: Three databases and one scientific registry were searched (PubMed, EMBASE, Scopus, and Google Scholar), with no restrictions on language or year of publication. Studies published until July 2021 were included. The inclusion criteria were: (a) experimental or observational design, (b) complete economic evaluation, (c) patients with implanted pacemakers, and (d) comparison of TM with CM. Measurements of study characteristics (author, study duration, sample size, age, sex, major indication for implantation, and pacemaker used), analysis, significant results of the variables (analysis performed, primary endpoints, secondary endpoints, health outcomes, and cost outcomes), and further miscellaneous measurements (methodological quality, variables coded, instrument development, coder training, and intercoder reliability, etc.) were included. (3) Results: 11 studies met the inclusion criteria, consisting of 3372 enrolled patients; 1773 (52.58%) of them were part of randomized clinical trials. The mean age was 72 years, and the atrioventricular block was established as the main indication for device implantation. TM was significantly effective in detecting the presence or absence of pacemaker problems, leading to a reduction in the number of unscheduled hospital visits (8.34-55.55%). The cost of TM was up to 87% lower than that of CM. There were no significant differences in health-related quality of life (HRQoL) and the number of cardiovascular events. (4) Conclusions: Most of the studies included in this systematic review confirm that in the TM group of patients with pacemakers, cardiovascular events are detected and treated earlier, and the number of unscheduled visits to the hospital is significantly reduced, without affecting the HRQoL of patients. In addition, with TM modality, both formal and informal costs are significantly reduced in the medium and long term. FAU - Lopez-Villegas, Antonio AU - Lopez-Villegas A AUID- ORCID: 0000-0003-0815-5421 AD - Social Involvement of Critical and Emergency Medicine, CTS-609 Research Group, Poniente Hospital, 04700 El Ejido-Almeria, Spain. FAU - Leal-Costa, Cesar AU - Leal-Costa C AUID- ORCID: 0000-0002-7711-3877 AD - Nursing Department, University of Murcia, 30120 Murcia, Spain. FAU - Perez-Heredia, Mercedes AU - Perez-Heredia M AUID- ORCID: 0000-0003-3973-3634 AD - Research Management Department, Primary Care District Poniente of Almeria, 04700 El Ejido-Almeria, Spain. FAU - Villegas-Tripiana, Irene AU - Villegas-Tripiana I AUID- ORCID: 0000-0002-4488-2717 AD - Research Support Unit and Library, Poniente Hospital, 04700 El Ejido-Almeria, Spain. FAU - Catalan-Matamoros, Daniel AU - Catalan-Matamoros D AUID- ORCID: 0000-0001-7783-4984 AD - UC3M MediaLab, Department of Communication and Media Studies, Madrid University Carlos III, 28903 Madrid, Spain. AD - Health Sciences Research Institute, University of Almeria, 04120 Almeria, Spain. LA - eng GR - PI17/02056/Instituto de Salud Carlos III/ PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Systematic Review DEP - 20211118 PL - Switzerland TA - Int J Environ Res Public Health JT - International journal of environmental research and public health JID - 101238455 SB - IM MH - Aged MH - *COVID-19 MH - Cost-Benefit Analysis MH - Humans MH - *Pacemaker, Artificial MH - Pandemics MH - Quality of Life MH - Reproducibility of Results PMC - PMC8624333 OTO - NOTNLM OT - cost-benefit analysis OT - follow-up studies OT - health-related quality of life OT - pacemakers OT - remote telemonitoring OT - telemedicine COIS- The authors declare no conflict of interest. EDAT- 2021/11/28 06:00 MHDA- 2021/12/15 06:00 PMCR- 2021/11/18 CRDT- 2021/11/27 01:16 PHST- 2021/10/16 00:00 [received] PHST- 2021/11/15 00:00 [revised] PHST- 2021/11/16 00:00 [accepted] PHST- 2021/11/27 01:16 [entrez] PHST- 2021/11/28 06:00 [pubmed] PHST- 2021/12/15 06:00 [medline] PHST- 2021/11/18 00:00 [pmc-release] AID - ijerph182212120 [pii] AID - ijerph-18-12120 [pii] AID - 10.3390/ijerph182212120 [doi] PST - epublish SO - Int J Environ Res Public Health. 2021 Nov 18;18(22):12120. doi: 10.3390/ijerph182212120. PMID- 36896392 OWN - NLM STAT- MEDLINE DCOM- 20230314 LR - 20230327 IS - 2046-1402 (Electronic) IS - 2046-1402 (Linking) VI - 10 DP - 2021 TI - The perceived impact of the COVID-19 pandemic on medical students' future careers. PG - 1211 LID - 10.12688/f1000research.73249.2 [doi] LID - 1211 AB - Background: The COVID-19 pandemic disrupted medical education on multiple levels, and medical students have been forced to adjust to distance learning, altered clinical opportunities, and standardized testing inconsistencies. We sought to identify the effects of these dramatic deviations on medical students' career plans. Methods: We conducted a cross-sectional online survey of medical students between July 13, 2020, and September 9, 2020 in order to assess the implications of the COVID-19 pandemic on students' career decisions. Descriptive statistics were calculated for all variables. Results: Of the 585 eligible medical students, we had a final sample of 76 responses (n=76) (13% response rate). Students felt neutral regarding having more time to explore research projects (Mean +/- SD; 3.06 +/- 1.18) and hobbies (3.43 +/- 1.28). Most survey respondents somewhat disagreed that they considered quitting medical school during the pandemic (1.55 +/- 1.10). Students somewhat agreed that they view the field of medicine more positively since the onset of the COVID-19 pandemic (3.60 +/- 1.09). Respondents somewhat agreed that they would be unable to explore other specialties and find their best fit (3.55 +/- 1.32). We found that the minority (4/66, 6%) of students had considered changing their specialty. Students felt neutral in terms of their Step 1 (3.25 +/- 1.05) or Step 2 (2.81 +/- 1.02) score deterring them from future career opportunities. Conclusions: Most medical students have experienced barriers in their career pathway as a direct cause of COVID-19 restrictions on medical education, including the ability to explore different specialties to discover their best fit or find a chance to network with mentors. However, despite these obstacles, most students remain committed to medicine. CI - Copyright: (c) 2023 Mahjoub H et al. FAU - Mahjoub, Heba AU - Mahjoub H AD - Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, 21205, USA. AD - Department of Opthamology, New England Eye Center, Tufts Medical Center, Tufts University School of Medicine, Boston, Massachusetts, USA. FAU - Vasavda, Chirag AU - Vasavda C AD - Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, 21205, USA. AD - The Solomon H. Snyder Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, Maryland,  21205, USA. FAU - Bertram, Amanda AU - Bertram A AD - Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, 21205, USA. FAU - Davison, Ashwini AU - Davison A AD - Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, 21205, USA. AD - Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, 21205, USA. FAU - Sozio, Stephen AU - Sozio S AUID- ORCID: 0000-0002-0099-0484 AD - Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, 21205, USA. AD - Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, 21205, USA. LA - eng SI - figshare/10.6084/m9.figshare.16879090.v1 PT - Journal Article DEP - 20211126 PL - England TA - F1000Res JT - F1000Research JID - 101594320 SB - IM MH - Humans MH - *Students, Medical MH - *COVID-19 MH - Pandemics MH - Cross-Sectional Studies MH - Career Choice MH - Surveys and Questionnaires PMC - PMC9989541 OTO - NOTNLM OT - COVID-19 pandemic OT - career planning OT - medical education OT - medical students COIS- No competing interests were disclosed. EDAT- 2021/11/26 00:00 MHDA- 2023/03/15 06:00 PMCR- 2023/02/24 CRDT- 2023/03/13 04:10 PHST- 2023/02/16 00:00 [accepted] PHST- 2023/03/13 04:10 [entrez] PHST- 2021/11/26 00:00 [pubmed] PHST- 2023/03/15 06:00 [medline] PHST- 2023/02/24 00:00 [pmc-release] AID - 10.12688/f1000research.73249.2 [doi] PST - epublish SO - F1000Res. 2021 Nov 26;10:1211. doi: 10.12688/f1000research.73249.2. eCollection 2021. PMID- 34815483 OWN - NLM STAT- Publisher LR - 20250530 IS - 1476-5373 (Electronic) IS - 0007-0610 (Print) IS - 0007-0610 (Linking) DP - 2021 Nov 23 TI - 'You had to do something': prescribing antibiotics in Scotland during the COVID-19 pandemic restrictions and remobilisation. PG - 1-6 LID - 10.1038/s41415-021-3621-8 [doi] AB - Introduction The COVID-19 pandemic brought about seismic change for dentistry including the direction to provide remote advice and prescribe analgesia and antimicrobials. The possibilities for care have widened, but the impact of both restrictions and remobilisation on antibiotic prescribing is not known.Aims To report the impact of COVID-19 restrictions and remobilisation on dental antibiotic prescriptions and explore dentists' intentions and attitudes towards antibiotic prescribing.Design and setting Public Health Scotland national prescribing and claims data are reported alongside an online survey of Scottish general and public health service dentists including closed and open-ended questions.Results Antibiotic prescribing rose by 49% following the suspension of routine dental care, to a peak of 34,993 antibiotics (July 2020). The data also show that since the remobilisation of NHS dental care, antibiotic prescribing remains raised at levels around 28% higher than pre-pandemic. The survey highlights dentists' frustrations and concerns about this increased use of antibiotics. Most dentists intend to reduce their prescribing; however, significant challenges to this being realised were raised.Conclusions The previous success within dentistry to protect against the development of antimicrobial resistance has suffered a knock-back during the pandemic. A renewed focus on reducing unnecessary antibiotics within dentistry is required but, crucially, needs to be approached sensitively alongside the current backdrop of challenges within the service. CI - (c) 2021. The Author(s). FAU - Duncan, Eilidh M AU - Duncan EM AD - Health Services Research Unit, Institute of Applied Health Sciences, University of Aberdeen, Aberdeen, UK. e.duncan@abdn.ac.uk. FAU - Goulao, Beatriz AU - Goulao B AD - Health Services Research Unit, Institute of Applied Health Sciences, University of Aberdeen, Aberdeen, UK. FAU - Clarkson, Janet AU - Clarkson J AD - NHS Education for Scotland, Edinburgh, UK; Dental Health Services Research Unit, School of Dentistry, University of Dundee, Dundee, UK. FAU - Young, Linda AU - Young L AD - NHS Education for Scotland, Edinburgh, UK. FAU - Ramsay, Craig R AU - Ramsay CR AD - Health Services Research Unit, Institute of Applied Health Sciences, University of Aberdeen, Aberdeen, UK. LA - eng GR - HSRU2/CSO_/Chief Scientist Office/United Kingdom PT - Journal Article DEP - 20211123 PL - England TA - Br Dent J JT - British dental journal JID - 7513219 SB - IM EIN - Br Dent J. 2021 Dec;231(11):695. doi: 10.1038/s41415-021-3774-5. PMID: 34893753 PMC - PMC8609985 EDAT- 2021/11/25 06:00 MHDA- 2021/11/25 06:00 PMCR- 2021/11/23 CRDT- 2021/11/24 06:16 PHST- 2021/08/26 00:00 [received] PHST- 2021/10/18 00:00 [accepted] PHST- 2021/11/25 06:00 [pubmed] PHST- 2021/11/25 06:00 [medline] PHST- 2021/11/24 06:16 [entrez] PHST- 2021/11/23 00:00 [pmc-release] AID - 10.1038/s41415-021-3621-8 [pii] AID - 3621 [pii] AID - 10.1038/s41415-021-3621-8 [doi] PST - aheadofprint SO - Br Dent J. 2021 Nov 23:1-6. doi: 10.1038/s41415-021-3621-8. PMID- 34804220 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220510 IS - 1793-9453 (Electronic) IS - 1793-8759 (Print) IS - 1793-9453 (Linking) VI - 14 IP - 2 DP - 2022 Apr TI - Ethical and Social Issues for Health Care Providers in the Intensive Care Unit during the Early Stages of the COVID-19 Pandemic in Japan: a Questionnaire Survey. PG - 115-131 LID - 10.1007/s41649-021-00194-y [doi] AB - This questionnaire-based observational study was conducted in July 2020 with the aim of understanding the ethical and social issues faced by health care providers (HCPs) registered with the Japanese Society of Intensive Care Medicine in intensive care units (ICUs) during the coronavirus disease (COVID-19) pandemic. There were 200 questionnaire respondents, and we analyzed the responses of 189 members who had been involved in COVID-19 treatment in ICUs. The ethical and social issues that HCPs recognized during the pandemic were difficulties in the decision-making process with patients' families, limitations of life-sustaining treatment, lack of palliative care, and inadequate mental support for patients' families and HCPs. Regarding decision-making on issues of clinical ethics during the pandemic, more than half of the respondents thought they had failed to provide sufficient palliative care to patients and responded that they experienced moral distress. The free-text responses on moral distress revealed issues such as unusual treatment and care, restricted visits, challenging situations for HCPs, and psychological burden. Additionally, 38.1% of respondents experienced episodes of social prejudice or discrimination and 4.7% experienced a shortage of medical resources. Our study result shows that the moral distress of HCPs was caused by difficulties in patient-centered decision-making and insufficient medical care to patients and their families. These were caused mainly by a lack of communication due to the stronger implementation of infection control measures. We believe that it is important to address ethical and social issues during a pandemic in order to provide appropriate medical care and prevent burnout among HCPs. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s41649-021-00194-y. CI - (c) The Author(s) 2021. FAU - Seino, Yusuke AU - Seino Y AD - Department of Biomedical Ethics and Public Policy, Graduate School of Medicine, Osaka University, Suita, Osaka Japan. GRID: grid.136593.b. ISNI: 0000 0004 0373 3971 FAU - Aizawa, Yayoi AU - Aizawa Y AD - Department of Biomedical Ethics and Public Policy, Graduate School of Medicine, Osaka University, Suita, Osaka Japan. GRID: grid.136593.b. ISNI: 0000 0004 0373 3971 FAU - Kogetsu, Atsushi AU - Kogetsu A AD - Department of Biomedical Ethics and Public Policy, Graduate School of Medicine, Osaka University, Suita, Osaka Japan. GRID: grid.136593.b. ISNI: 0000 0004 0373 3971 FAU - Kato, Kazuto AU - Kato K AUID- ORCID: 0000-0001-9006-9551 AD - Department of Biomedical Ethics and Public Policy, Graduate School of Medicine, Osaka University, Suita, Osaka Japan. GRID: grid.136593.b. ISNI: 0000 0004 0373 3971 LA - eng PT - Journal Article DEP - 20211115 PL - England TA - Asian Bioeth Rev JT - Asian bioethics review JID - 101608807 PMC - PMC8590925 OTO - NOTNLM OT - COVID-19 OT - Clinical ethics OT - Ethical issues OT - Intensive care unit OT - Japan OT - Moral distress OT - Social issues COIS- Conflict of InterestThe authors declare no competing interests. EDAT- 2021/11/23 06:00 MHDA- 2021/11/23 06:01 PMCR- 2021/11/15 CRDT- 2021/11/22 06:43 PHST- 2021/08/11 00:00 [received] PHST- 2021/10/09 00:00 [revised] PHST- 2021/10/12 00:00 [accepted] PHST- 2021/11/23 06:00 [pubmed] PHST- 2021/11/23 06:01 [medline] PHST- 2021/11/22 06:43 [entrez] PHST- 2021/11/15 00:00 [pmc-release] AID - 194 [pii] AID - 10.1007/s41649-021-00194-y [doi] PST - epublish SO - Asian Bioeth Rev. 2021 Nov 15;14(2):115-131. doi: 10.1007/s41649-021-00194-y. eCollection 2022 Apr. PMID- 34800245 OWN - NLM STAT- MEDLINE DCOM- 20220628 LR - 20261028 IS - 1573-3688 (Electronic) IS - 1053-0487 (Linking) VI - 32 IP - 2 DP - 2022 Jun TI - Variation in General Practice Services Provided to Australian Workers with Low Back Pain: A Cross-Jurisdictional Comparative Study. PG - 203-214 LID - 10.1007/s10926-021-10013-8 [doi] AB - PURPOSE: To compare the frequency of General Practitioner (GP) services and the time between first and last GP services (service duration) provided to workers with low back pain (LBP) between four Australian workers' compensation jurisdictions. METHODS: Retrospective cohort study using service level data collated from the Australian states of Western Australia, South Australia, Victoria and Queensland. Negative binomial regression was used to compare GP service volume between jurisdictions in workers with accepted LBP compensation claims. Quantile regression was used to compare GP service duration. Models were adjusted for sociodemographic factors and occupation. Analyses were repeated in four cohorts with progressively more restrictive cohort definitions to account for the influence of jurisdictional policy variation in employer excess, service delivery and maximum time-loss benefit duration. RESULTS: The study sample included 47,185 time-loss claims accepted between July 2010 and June 2015, that were linked with 452,391 GP services. Workers with LBP in Queensland recorded significantly fewer GP services funded and recorded significantly shorter average service duration than in other states. This pattern of jurisdictional variation was evident in all four cohorts, but was attenuated when cohorts excluded short- and long duration claims. In the final, most restricted cohort statistically significant adjusted incidence rate ratios of 1.47-1.60 were observed in Victoria, South Australia and Western Australia, while these states recorded additional service duration of 4.3-20.7 weeks at the median. CONCLUSION: There is significant variation in provision of GP services to injured workers with LBP between four Australian workers' compensation jurisdictions. Administrative requirements for time-based provision of work capacity certificates by medical practitioners may be contributing to service variation. CI - (c) 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. FAU - Collie, Alex AU - Collie A AUID- ORCID: 0000-0003-2617-9339 AD - School of Public Health and Preventive Medicine, Monash University, 553 St Kilda Road, Melbourne, 3004, Australia. alex.collie@monash.edu. FAU - Sheehan, Luke AU - Sheehan L AD - School of Public Health and Preventive Medicine, Monash University, 553 St Kilda Road, Melbourne, 3004, Australia. FAU - Di Donato, Michael AU - Di Donato M AD - School of Public Health and Preventive Medicine, Monash University, 553 St Kilda Road, Melbourne, 3004, Australia. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20211120 PL - Netherlands TA - J Occup Rehabil JT - Journal of occupational rehabilitation JID - 9202814 SB - IM MH - *General Practice MH - Humans MH - *Low Back Pain/therapy MH - *Occupational Injuries/epidemiology/therapy MH - Retrospective Studies MH - Victoria MH - Workers' Compensation OTO - NOTNLM OT - Comparative study OT - General practice OT - Health service use OT - Low back pain OT - Workers' compensation EDAT- 2021/11/21 06:00 MHDA- 2022/06/29 06:00 CRDT- 2021/11/20 12:08 PHST- 2021/11/08 00:00 [accepted] PHST- 2021/11/21 06:00 [pubmed] PHST- 2022/06/29 06:00 [medline] PHST- 2021/11/20 12:08 [entrez] AID - 10.1007/s10926-021-10013-8 [pii] AID - 10.1007/s10926-021-10013-8 [doi] PST - ppublish SO - J Occup Rehabil. 2022 Jun;32(2):203-214. doi: 10.1007/s10926-021-10013-8. Epub 2021 Nov 20. PMID- 34794401 OWN - NLM STAT- MEDLINE DCOM- 20211206 LR - 20241108 IS - 1471-2458 (Electronic) IS - 1471-2458 (Linking) VI - 21 IP - 1 DP - 2021 Nov 18 TI - National or population level interventions addressing the social determinants of mental health - an umbrella review. PG - 2118 LID - 10.1186/s12889-021-12145-1 [doi] LID - 2118 AB - BACKGROUND: Social circumstances in which people live and work impact the population's mental health. We aimed to synthesise evidence identifying effective interventions and policies that influence the social determinants of mental health at national or scaled population level. We searched five databases (Cochrane Library, Global Health, MEDLINE, EMBASE and PsycINFO) between Jan 1st 2000 and July 23rd 2019 to identify systematic reviews of population-level interventions or policies addressing a recognised social determinant of mental health and collected mental health outcomes. There were no restrictions on country, sub-population or age. A narrative overview of results is provided. Quality assessment was conducted using Assessment of Multiple Systematic Reviews (AMSTAR 2). This study was registered on PROSPERO (CRD42019140198). RESULTS: We identified 20 reviews for inclusion. Most reviews were of low or critically low quality. Primary studies were mostly observational and from higher income settings. Higher quality evidence indicates more generous welfare benefits may reduce socioeconomic inequalities in mental health outcomes. Lower quality evidence suggests unemployment insurance, warm housing interventions, neighbourhood renewal, paid parental leave, gender equality policies, community-based parenting programmes, and less restrictive migration policies are associated with improved mental health outcomes. Low quality evidence suggests restriction of access to lethal means and multi-component suicide prevention programmes are associated with reduced suicide risk. CONCLUSION: This umbrella review has identified a small and overall low-quality evidence base for population level interventions addressing the social determinants of mental health. There are significant gaps in the evidence base for key policy areas, which limit ability of national policymakers to understand how to effectively improve population mental health. CI - (c) 2021. The Author(s). FAU - Shah, Neha AU - Shah N AD - City University London, Northampton Square, EC1V 0HB, London, UK. neha.shah@phe.gov.uk. FAU - Walker, Ian F AU - Walker IF AD - Hull York Medical School, University of York, Heslington, York, YO10 5DD, England. FAU - Naik, Yannish AU - Naik Y AD - Leeds Teaching Hospitals NHS Trust, Great St George Street, Leeds, LS1 3EX, England. FAU - Rajan, Selina AU - Rajan S AD - Department of Health Services Research and Policy, The London School of Hygiene and Tropical Medicine, London, WC1E 7H, UK. FAU - O'Hagan, Kate AU - O'Hagan K AD - Public Health England, Wellington House, 133-155 Waterloo Road, London, SE1 8UG, UK. FAU - Black, Michelle AU - Black M AD - School of Health and Related Research, The University of Sheffield, Regent Court, 30 Regent, Sheffield, S1 4DA, England. FAU - Cartwright, Christopher AU - Cartwright C AD - Bradford Institute for Health Research, Bradford Royal Infirmary, Bradford Teaching Hospitals NHS Foundation Trust, Duckworth Lane, Bradford, BD9 6RJ, England. FAU - Tillmann, Taavi AU - Tillmann T AD - Centre for Global Non-Communicable Disease, Institute for Global Health, UCL, 30 Guilford, London, WC1N 1EH, UK. FAU - Pearce-Smith, Nicola AU - Pearce-Smith N AD - Public Health England, Wellington House, 133-155 Waterloo Road, London, SE1 8UG, UK. FAU - Stansfield, Jude AU - Stansfield J AD - School of Health and Community Studies, Leeds Beckett University, Portland Building, PD519, Portland Place, Leeds, LS1 3HE, UK. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Systematic Review DEP - 20211118 PL - England TA - BMC Public Health JT - BMC public health JID - 100968562 SB - IM MH - Housing MH - Humans MH - Income MH - Mental Health MH - *Population Health MH - *Social Determinants of Health MH - Systematic Reviews as Topic PMC - PMC8599417 OTO - NOTNLM OT - Health policy OT - Intervention OT - Mental health OT - Population health OT - Public health OT - Public mental health OT - Social determinants COIS- NS, IW, JS, KOH, TT and NPS are currently employed or affiliated with Public Health England. YN, SR, TT MB and CC do not declare any competing interests. EDAT- 2021/11/20 06:00 MHDA- 2021/12/15 06:00 PMCR- 2021/11/18 CRDT- 2021/11/19 05:33 PHST- 2021/04/22 00:00 [received] PHST- 2021/09/15 00:00 [accepted] PHST- 2021/11/19 05:33 [entrez] PHST- 2021/11/20 06:00 [pubmed] PHST- 2021/12/15 06:00 [medline] PHST- 2021/11/18 00:00 [pmc-release] AID - 10.1186/s12889-021-12145-1 [pii] AID - 12145 [pii] AID - 10.1186/s12889-021-12145-1 [doi] PST - epublish SO - BMC Public Health. 2021 Nov 18;21(1):2118. doi: 10.1186/s12889-021-12145-1. PMID- 34789541 OWN - NLM STAT- MEDLINE DCOM- 20230321 LR - 20250530 IS - 1468-3318 (Electronic) IS - 0964-4563 (Print) IS - 0964-4563 (Linking) VI - 32 IP - e1 DP - 2023 Apr TI - Profile of menthol cigarette smokers in the months following the removal of these products from the market: a cross-sectional population survey in England. PG - e121-e124 LID - 10.1136/tobaccocontrol-2021-057005 [doi] AB - INTRODUCTION: In May 2020, the EU Tobacco Products Directive ban on the sale of menthol cigarettes was implemented in England. This study examined the prevalence of menthol cigarette smoking after the ban, according to sociodemographic and smoking characteristics. METHODS: Cross-sectional data came from a representative survey of current smokers (18+) in England (unweighted n=2681) between July 2020 and June 2021. The weighted prevalence of menthol cigarette smoking as a proportion of total cigarette smoking was calculated, log-binomial regression explored trends over time, and chi(2) statistics assessed the relationship between menthol smoking, sociodemographic and smoking characteristics. Sources of purchase of menthol cigarettes were explored. RESULTS: Between July 2020 and June 2021, 15.7% (95% CI 14.5 to 17.1) of smokers reported smoking menthol cigarettes. The fitted non-linear trend supported no initial change followed by a possible reduction across April-June 2021 and fit the data better than linear and null (no change) models (chi(2)(2)=2519.7, p=0.06; chi(2)(3)=2519.7, p=0.006). Menthol cigarette smoking was more common among younger groups (16-24=25.2%; 25-34=19.9%) and women (19.4%). Menthol cigarette smokers showed lower cigarette dependence compared with other smokers. Past-6-month purchases of menthol cigarettes from any illicit or cross-border source declined from 30.1% in the last 6 months of 2020 to 17.5% in the first 6 months of 2021. CONCLUSIONS: A substantial minority of current smokers in England reported menthol cigarette smoking between July 2020 and June 2021, despite the ban, possibly reflecting mitigation of restrictions by a variety of licit means, such as legal menthol accessories. The reduction in menthol smoking across April-June 2021 warrants further monitoring. CI - (c) Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ. FAU - Kock, Loren AU - Kock L AUID- ORCID: 0000-0002-2961-8838 AD - Department of Behavioural Science and Health, University College London, London, UK l.kock@ucl.ac.uk. AD - SPECTRUM Research Consortium, Edinburgh, UK. FAU - Shahab, Lion AU - Shahab L AUID- ORCID: 0000-0003-4033-442X AD - Department of Behavioural Science and Health, University College London, London, UK. AD - SPECTRUM Research Consortium, Edinburgh, UK. FAU - Bogdanovica, Ilze AU - Bogdanovica I AUID- ORCID: 0000-0002-2662-6293 AD - SPECTRUM Research Consortium, Edinburgh, UK. AD - Division of Epidemiology and Public Health, University of Nottingham, Nottingham, UK. FAU - Brown, Jamie AU - Brown J AD - Department of Behavioural Science and Health, University College London, London, UK. AD - SPECTRUM Research Consortium, Edinburgh, UK. LA - eng GR - 22962/CRUK_/Cancer Research UK/United Kingdom GR - MC_PC_18003/MRC_/Medical Research Council/United Kingdom GR - MR/S037519/1/MRC_/Medical Research Council/United Kingdom GR - 20606/CRUK_/Cancer Research UK/United Kingdom GR - C1417/A22962/CRUK_/Cancer Research UK/United Kingdom GR - A22962/CRUK_/Cancer Research UK/United Kingdom PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20211117 PL - England TA - Tob Control JT - Tobacco control JID - 9209612 RN - 1490-04-6 (Menthol) SB - IM MH - Humans MH - Female MH - Smokers MH - Menthol MH - Cross-Sectional Studies MH - *Tobacco Products MH - *Cigarette Smoking/epidemiology PMC - PMC7614336 MID - EMS140494 OTO - NOTNLM OT - illegal tobacco products OT - public policy OT - surveillance and monitoring COIS- Competing interests: Authors are members of the UK Prevention Research Partnership, an initiative funded by UK Research and Innovation Councils, the Department of Health and Social Care (England), and the UK devolved administrations and leading health research charities. JB reports receiving grants from Cancer Research UK during the conduct of the study and receiving unrestricted research funding from pharmaceutical companies who manufacture smoking cessation medications to study smoking cessation outside the submitted work. LS reports receiving honoraria for talks, receiving an unrestricted research grant and travel expenses to attend meetings and workshops by pharmaceutical companies that make smoking cessation products (Pfizer and Johnson & Johnson), and acting as a paid reviewer for grant-awarding bodies and as a paid consultant for health care companies. LK and IB have no competing interests to declare. EDAT- 2021/11/19 06:00 MHDA- 2023/03/22 06:00 PMCR- 2023/04/01 CRDT- 2021/11/18 06:10 PHST- 2021/08/23 00:00 [received] PHST- 2021/11/02 00:00 [accepted] PHST- 2021/11/19 06:00 [pubmed] PHST- 2023/03/22 06:00 [medline] PHST- 2021/11/18 06:10 [entrez] PHST- 2023/04/01 00:00 [pmc-release] AID - tobaccocontrol-2021-057005 [pii] AID - 10.1136/tobaccocontrol-2021-057005 [doi] PST - ppublish SO - Tob Control. 2023 Apr;32(e1):e121-e124. doi: 10.1136/tobaccocontrol-2021-057005. Epub 2021 Nov 17. PMID- 34789023 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20251016 LR - 20251016 IS - 1724-6032 (Electronic) IS - 1129-7298 (Linking) VI - 24 IP - 5 DP - 2023 Sep TI - Defining difficult intravenous access (DIVA): A systematic review. PG - 904 - 910 LID - 10.1177/11297298211059648 [doi] AB - BACKGROUND: The term "difficult intravenous access" (DIVA) is commonly used but not clearly defined. Repeated attempts at peripheral intravenous catheter (PIVC) insertion can be a traumatic experience for patients, leading to sub-optimal clinical and economic outcomes. We conducted a systematic literature review (SLR) to collate literature definitions of DIVA, with the aim of arriving at an evidence-driven definition. METHODS: The SLR was designed to identify clinical, cost, and quality of life publications in patients requiring the insertion of a PIVC in any setting, including studies on US-guidance and/or guidewire, and studies with no specific intervention. The search was restricted to English language studies published between 1st January 2010 and 30th July 2020, and the Ovid platform was used to search several electronic databases, in addition to hand searching of clinical trial registries. RESULTS: About 121 studies were included in the SLR, of which 64 reported on the objectives relevant to this manuscript. Prevalence estimates varied widely from 6% to 87.7% across 19 publications, reflecting differences in definitions used. Of 43 publications which provided a definition of DIVA, six key themes emerged. Of these, themes 1-3 (failed attempts at PIV access using traditional technique; based on physical examination findings for example no visible or palpable veins; and personal history of DIVA) were covered by all but one publication. Following a failed insertion attempt, the most common number of subsequent attempts was 3, and it was frequently reported that a more experienced clinician would attempt to gain access after multiple failed attempts. CONCLUSIONS: Considering the themes identified, an evidence-driven definition of DIVA is proposed: "when a clinician has two or more failed attempts at PIV access using traditional techniques, physical examination findings are suggestive of DIVA (e.g. no visible or palpable veins) or the patient has a stated or documented history of DIVA." FAU - Bahl, Amit AU - Bahl A AUID- ORCID: 0000-0001-9495-1293 AD - Emergency Medicine, Beaumont Hospital, Royal Oak, MI, USA. FAU - Johnson, Steven AU - Johnson S AUID- ORCID: 0000-0001-7858-178X AD - Emergency Medicine, Beaumont Hospital, Royal Oak, MI, USA. FAU - Alsbrooks, Kimberly AU - Alsbrooks K AUID- ORCID: 0000-0002-8684-7100 AD - Becton Dickinson and Co, Franklin Lakes, NJ, USA. FAU - Mares, Alicia AU - Mares A AD - Becton Dickinson and Co, Franklin Lakes, NJ, USA. FAU - Gala, Smeet AU - Gala S AD - Becton Dickinson and Co, Franklin Lakes, NJ, USA. FAU - Hoerauf, Klaus AU - Hoerauf K AD - Becton Dickinson and Co, Franklin Lakes, NJ, USA. AD - Department of Anesthesiology and Intensive Care, Medical University of Vienna, Vienna, Austria. LA - eng PT - Journal Article DEP - 20211117 PL - United States TA - J Vasc Access JT - The journal of vascular access JID - 100940729 SB - IM OTO - NOTNLM OT - DIVA OT - DVA OT - difficult venous access OT - hard stick OT - venous access EDAT- 2021/11/19 06:00 MHDA- 2021/11/19 06:01 CRDT- 2021/11/18 05:40 PHST- 2021/11/19 06:01 [medline] PHST- 2021/11/18 05:40 [entrez] PHST- 2021/11/19 06:00 [pubmed] AID - 10.1177/11297298211059648 [doi] PST - epublish SO - J Vasc Access. 2021 Nov 17;24(5):904 - 910. doi: 10.1177/11297298211059648. Print 2023 Sep. PMID- 34788918 OWN - NLM STAT- MEDLINE DCOM- 20211119 LR - 20240818 IS - 0253-2727 (Print) IS - 2707-9740 (Electronic) IS - 0253-2727 (Linking) VI - 42 IP - 10 DP - 2021 Oct 14 TI - [Clinical prognostic analysis of 124 adult patients with hemophagocytic lymphohistiocytosis: a multicenter retrospective study of the Huaihai Lymphoma Working Group]. PG - 800-806 LID - 10.3760/cma.j.issn.0253-2727.2021.10.002 [doi] AB - Objective: Factors influencing the prognosis of hemophagocytic lymphohistiocytosis (HLH) in adults were analyzed based on multicentric data. Methods: Clinical data of 124 adult patients with HLH diagnosed in eight medical centers in the Huaihai Lymphoma Working Group from March 2014 to July 2020 were collected. The optimal truncation value of continuous variables was obtained based on the Maxstat algorithm, X-Tile software, and restricted cubic spline. Cox proportional risk regression model was used to construct the adult HLH risk prediction model, and the visualization of the model was realized through the histogram. The bootstrap resampling method was used to verify the model, C-index and calibration curve was used to verify the histogram, and the prediction accuracy was checked. Kaplan-Meier analysis was used to calculate the survival rate and draw the survival curve. Furthermore, the differences between groups were tested by log-rank. Results: The median age of the 124 patients was 55 (18-84) years, including 61 (49.19%) males. The most common etiology was infection. Serum ferritin increased in 110 cases (88.71%) , hepatosplenomegaly in 57 cases (45.97%) . Of the 124 patients, 77 (62.10%) died, and the median survival time of the patients was 7.07 months. Univariate results showed that the prognosis of adult HLH was influenced by sex, age, fibrinogen, serum creatinine, alanine aminotransferase, and albumin (P<0.05) . The results of multivariate analysis showed that gender, platelet, albumin, alanine aminotransferase, and treatment regimens were independent influencing factors for prognosis. Based on the above five risk factors, the prediction model of the histogram was established, and the C-index of the model was 0.739. Finally, the calibration chart showed good consistency between the observed and predicted values of HLH. Conclusion: The prognosis of the adult hemophagocytic syndrome is influenced by many factors. Gender, platelet, albumin, alanine aminotransferase, and treatment regimens are independent risk factors. Therefore, the established histogram provides a visual tool for clinicians to evaluate the prognosis of adult HLH. FAU - Shen, Z Y AU - Shen ZY AD - Department of Epidemiology and Health Statistics, School of Public Health, Xuzhou Medical University, Xuzhou 221004, China. FAU - He, C L AU - He CL AD - Department of Epidemiology and Health Statistics, School of Public Health, Xuzhou Medical University, Xuzhou 221004, China. FAU - Sun, Q AU - Sun Q AD - Department of Hematology, Affiliated Hospital of Xuzhou Medical University, Xuzhou 221002, China. FAU - Zhang, S AU - Zhang S AD - Department of Hematology, Affiliated Hospital of Xuzhou Medical University, Xuzhou 221002, China. FAU - Hu, L L AU - Hu LL AD - Department of Hematology, Affiliated Hospital of Xuzhou Medical University, Xuzhou 221002, China. FAU - Liu, Q H AU - Liu QH AD - Department of Hematology, The First Affiliated Hospital of Anhui Medical University, Hefei 230022, China. FAU - Zhang, H AU - Zhang H AD - Department of Hematology, The Affiliated Hospital of Jining Medical University, Jining 272000, China. FAU - Liu, X AU - Liu X AD - Department of Hematology, The Affiliated Hospital of Jining Medical University, Jining 272000, China. FAU - Miao, Y Q AU - Miao YQ AD - Department of Hematology, Yancheng First People's Hospital, Yancheng 224001, China. FAU - Gu, W Y AU - Gu WY AD - Department of Hematology, The First People's Hospital of Changzhou, Changzhou 213003, China. FAU - Wang, F AU - Wang F AD - Department of Hematology, The First People's Hospital of Changzhou, Changzhou 213003, China. FAU - Wang, C L AU - Wang CL AD - Department of Hematology, The First People's Hospital of Huaian, Huaian 223300, China. FAU - Shi, Y Y AU - Shi YY AD - Department of Hematology, The First People's Hospital of Huaian, Huaian 223300, China. FAU - Wang, L AU - Wang L AD - Department of Hematology, Taian Central Hospital, Taian 271000, China. FAU - Jiao, J AU - Jiao J AD - Department of Hematology, Taian Central Hospital, Taian 271000, China. FAU - Ye, J J AU - Ye JJ AD - Department ofHematology, Qilu Hospital of Shandong University, Jinan 250012, China. FAU - Xu, L Y AU - Xu LY AD - Department of Hematology, Affiliated Hospital of Xuzhou Medical University, Xuzhou 221002, China. FAU - Yan, D M AU - Yan DM AD - Department of Hematology, Affiliated Hospital of Xuzhou Medical University, Xuzhou 221002, China. FAU - Li, Z Y AU - Li ZY AD - Department of Hematology, Affiliated Hospital of Xuzhou Medical University, Xuzhou 221002, China. FAU - Jin, Y L AU - Jin YL AD - Department of Epidemiology and Health Statistics, School of Public Health, Xuzhou Medical University, Xuzhou 221004, China. FAU - Huang, S P AU - Huang SP AD - Department of Epidemiology and Health Statistics, School of Public Health, Xuzhou Medical University, Xuzhou 221004, China. FAU - Xu, K L AU - Xu KL AD - Department of Hematology, Affiliated Hospital of Xuzhou Medical University, Xuzhou 221002, China. FAU - Sang, W AU - Sang W AD - Department of Hematology, Affiliated Hospital of Xuzhou Medical University, Xuzhou 221002, China. LA - chi GR - QNRC2016791/Key Young Medical Talents of Jiangsu Province/ GR - BK20171181, BK20170257/Natural Science Foundation of Jiangsu Province/ GR - BE2019638/Key Social Development Project of Jiangsu Science and Technology Department/ PT - Journal Article PT - Multicenter Study PL - China TA - Zhonghua Xue Ye Xue Za Zhi JT - Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi JID - 8212398 SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Humans MH - *Lymphohistiocytosis, Hemophagocytic MH - *Lymphoma MH - Male MH - Middle Aged MH - Prognosis MH - Proportional Hazards Models MH - Retrospective Studies PMC - PMC8607015 OTO - NOTNLM OT - Adult OT - Hemophagocytic lymphohistiocytosis OT - Prognostic analysis EDAT- 2021/11/18 06:00 MHDA- 2021/11/20 06:00 PMCR- 2021/10/01 CRDT- 2021/11/17 21:14 PHST- 2021/11/17 21:14 [entrez] PHST- 2021/11/18 06:00 [pubmed] PHST- 2021/11/20 06:00 [medline] PHST- 2021/10/01 00:00 [pmc-release] AID - cjh-42-10-800 [pii] AID - 10.3760/cma.j.issn.0253-2727.2021.10.002 [doi] PST - ppublish SO - Zhonghua Xue Ye Xue Za Zhi. 2021 Oct 14;42(10):800-806. doi: 10.3760/cma.j.issn.0253-2727.2021.10.002. PMID- 34772259 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240404 IS - 1996-1944 (Print) IS - 1996-1944 (Electronic) IS - 1996-1944 (Linking) VI - 14 IP - 21 DP - 2021 Nov 8 TI - Treatment Prognosis of Restored Teeth with Crown Lengthening vs. Deep Margin Elevation: A Systematic Review. LID - 10.3390/ma14216733 [doi] LID - 6733 AB - Crown lengthening surgery and deep margin elevation are two distinct approaches used to manage decayed teeth. This systematic review examined the survival rate of badly decayed teeth when restored using the crown lengthening technique and compared it to the deep margin elevation technique. The search was conducted during July 2020 and then again updated at the end of July 2021, and no restriction concerning publication status and time was applied during the search. Cochrane Database, EBSCO, Scopus, and Medline databases were searched electronically for relevant literature. Google Scholar was used as a secondary source. Predefined inclusion and exclusion criteria were used to select the relevant articles. PRISMA guidelines were followed. The focused PICO question was: 'Does the crown lengthening technique (I) provide a better survival rate (O) than deep margin elevation technique (C) following the restoration of badly decayed teeth (P).' A total of six articles were included after performing screening based on the eligibility criteria. Four studies focused on crown lengthening while two focused on deep margin elevation technique. A majority of the studies showed a high risk of bias owing to methodological insufficiencies. Crown lengthening (CL) treated cases showed a change in the free gingival margin at six months post-surgery. A tissue rebound was seen that was correlated to the periodontal biotype. Teeth treated with the deep margin elevation (DME) technique showed high survivability. There is a lack of high-quality trials examining surgical comparisons between CL and DME with long-term follow-up. Patient- and dentist-reported outcomes have not been given adequate consideration in the literature. Based on the limited evidence, it can be concluded that for restorative purposes, crown lengthening surgery can be successful in long-term retention of restored teeth. However, the deep margin elevation technique has a better survival ratio. Future well-designed and executed research will have an effect on the evidence and level of certainty for the best approach to treating severely decayed teeth. FAU - Mugri, Maryam H AU - Mugri MH AUID- ORCID: 0000-0002-5613-9760 AD - Department of Maxillofacial Surgery and Diagnostic Sciences, College of Dentistry, Jazan University, Jazan 45142, Saudi Arabia. FAU - Sayed, Mohammed E AU - Sayed ME AUID- ORCID: 0000-0001-8667-8987 AD - Department of Prosthetic Dental Sciences, College of Dentistry, Jazan University, Jazan 45142, Saudi Arabia. FAU - Nedumgottil, Binoy Mathews AU - Nedumgottil BM AD - Department of Prosthodontics and Dental Implantology, College of Dentistry, King Faisal University, Al-Ahsa 31982, Saudi Arabia. FAU - Bhandi, Shilpa AU - Bhandi S AD - Department of Restorative Dental Science, Division of Operative Dentistry, College of Dentistry, Jazan University, Jazan 45142, Saudi Arabia. FAU - Raj, A Thirumal AU - Raj AT AUID- ORCID: 0000-0002-1079-1024 AD - Department of Oral Pathology and Microbiology, Sri Venkateswara Dental College and Hospital, Chennai 600130, India. FAU - Testarelli, Luca AU - Testarelli L AUID- ORCID: 0000-0003-3904-3000 AD - Department of Oral and Maxillo-Facial Sciences, Universita di Roma La Sapienza, 00185 Roma, Italy. FAU - Khurshid, Zohaib AU - Khurshid Z AUID- ORCID: 0000-0001-7998-7335 AD - Department of Prosthodontics and Dental Implantology, College of Dentistry, King Faisal University, Al-Ahsa 31982, Saudi Arabia. FAU - Jain, Saurabh AU - Jain S AUID- ORCID: 0000-0002-0071-4068 AD - Department of Prosthetic Dental Sciences, College of Dentistry, Jazan University, Jazan 45142, Saudi Arabia. FAU - Patil, Shankargouda AU - Patil S AUID- ORCID: 0000-0001-7246-5497 AD - Department of Maxillofacial Surgery and Diagnostic Science, Division of Oral Pathology, College of Dentistry, Jazan University, Jazan 45142, Saudi Arabia. LA - eng PT - Journal Article PT - Review DEP - 20211108 PL - Switzerland TA - Materials (Basel) JT - Materials (Basel, Switzerland) JID - 101555929 PMC - PMC8587366 OTO - NOTNLM OT - crown lengthening OT - deep margin elevation OT - restoration OT - systematic review OT - tooth decay COIS- The authors declare no conflict of interest. EDAT- 2021/11/14 06:00 MHDA- 2021/11/14 06:01 PMCR- 2021/11/08 CRDT- 2021/11/13 01:17 PHST- 2021/09/25 00:00 [received] PHST- 2021/11/03 00:00 [revised] PHST- 2021/11/04 00:00 [accepted] PHST- 2021/11/13 01:17 [entrez] PHST- 2021/11/14 06:00 [pubmed] PHST- 2021/11/14 06:01 [medline] PHST- 2021/11/08 00:00 [pmc-release] AID - ma14216733 [pii] AID - materials-14-06733 [pii] AID - 10.3390/ma14216733 [doi] PST - epublish SO - Materials (Basel). 2021 Nov 8;14(21):6733. doi: 10.3390/ma14216733. PMID- 34769952 OWN - NLM STAT- MEDLINE DCOM- 20211118 LR - 20240818 IS - 1660-4601 (Electronic) IS - 1661-7827 (Print) IS - 1660-4601 (Linking) VI - 18 IP - 21 DP - 2021 Oct 30 TI - Behavioral Correlates of COVID-19 Worry: Stigma, Knowledge, and News Source. LID - 10.3390/ijerph182111436 [doi] LID - 11436 AB - Non-adherence to COVID-19 guidelines may be attributable to low levels of worry. This study assessed whether endorsing COVID-19-stigmatizing restrictions, COVID-19 knowledge, and preferred news source were associated with being 'very worried' versus 'not at all' or 'somewhat' worried about contracting COVID-19. Survey data were collected in July-August 2020 from N = 547 New York State (NYS) and N = 504 national Amazon MTurk workers. Respondents who endorsed COVID-19 stigmatizing restrictions (NYS OR 1.96; 95% CI 1.31, 2.92; national OR 1.80; 95% CI 1.06, 3.08) and consumed commercial news (NYS OR 1.89; 95% CI 1.21, 2.96; national OR 1.93; 95% CI 1.24, 3.00) were more likely to be very worried. National respondents who consumed The New York Times (OR 1.52; 95% CI 1.00, 2.29) were more likely to be very worried, while those with little knowledge (OR 0.24; 95% CI 0.13, 0.43) were less likely to be very worried. NYS (OR 2.66; 95% CI 1.77, 4.00) and national (OR 3.17; 95% CI 1.95, 5.16) respondents with probable depression were also more likely to be very worried. These characteristics can help identify those requiring intervention to maximize perceived threat to COVID-19 and encourage uptake of protective behaviors while protecting psychological wellbeing. FAU - Meltzer, Gabriella Y AU - Meltzer GY AUID- ORCID: 0000-0002-6885-9730 AD - Department of Social and Behavioral Sciences, School of Global Public Health, New York University, New York, NY 10003, USA. FAU - Chang, Virginia W AU - Chang VW AD - Department of Social and Behavioral Sciences, School of Global Public Health, New York University, New York, NY 10003, USA. AD - Department of Population Health, Grossman School of Medicine, New York University, New York, NY 10003, USA. FAU - Lieff, Sarah A AU - Lieff SA AD - Department of Social and Behavioral Sciences, School of Global Public Health, New York University, New York, NY 10003, USA. FAU - Grivel, Margaux M AU - Grivel MM AUID- ORCID: 0000-0002-8856-143X AD - Department of Social and Behavioral Sciences, School of Global Public Health, New York University, New York, NY 10003, USA. FAU - Yang, Lawrence H AU - Yang LH AD - Department of Social and Behavioral Sciences, School of Global Public Health, New York University, New York, NY 10003, USA. AD - Department of Epidemiology, School of Global Public Health, New York University, New York, NY 10003, USA. AD - Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY 10032, USA. FAU - Des Jarlais, Don C AU - Des Jarlais DC AD - Department of Epidemiology, School of Global Public Health, New York University, New York, NY 10003, USA. LA - eng GR - N/A/New York University School of Global Public Health/ PT - Journal Article DEP - 20211030 PL - Switzerland TA - Int J Environ Res Public Health JT - International journal of environmental research and public health JID - 101238455 SB - IM MH - Anxiety MH - *COVID-19 MH - Cross-Sectional Studies MH - Humans MH - SARS-CoV-2 MH - Surveys and Questionnaires PMC - PMC8583421 OTO - NOTNLM OT - COVID-19 OT - Health Belief Model OT - depression OT - knowledge OT - news media OT - stigma OT - worry COIS- The authors declare no conflict of interest. EDAT- 2021/11/14 06:00 MHDA- 2021/11/19 06:00 PMCR- 2021/10/30 CRDT- 2021/11/13 01:08 PHST- 2021/10/10 00:00 [received] PHST- 2021/10/29 00:00 [revised] PHST- 2021/10/29 00:00 [accepted] PHST- 2021/11/13 01:08 [entrez] PHST- 2021/11/14 06:00 [pubmed] PHST- 2021/11/19 06:00 [medline] PHST- 2021/10/30 00:00 [pmc-release] AID - ijerph182111436 [pii] AID - ijerph-18-11436 [pii] AID - 10.3390/ijerph182111436 [doi] PST - epublish SO - Int J Environ Res Public Health. 2021 Oct 30;18(21):11436. doi: 10.3390/ijerph182111436. PMID- 34769654 OWN - NLM STAT- MEDLINE DCOM- 20211118 LR - 20240404 IS - 1660-4601 (Electronic) IS - 1661-7827 (Print) IS - 1660-4601 (Linking) VI - 18 IP - 21 DP - 2021 Oct 23 TI - Family Function and Child Adjustment Difficulties in the COVID-19 Pandemic: An International Study. LID - 10.3390/ijerph182111136 [doi] LID - 11136 AB - To estimate specific proximal and distal effects of COVID-19-related restrictions on families on children's adjustment problems, we conducted a six-site international study. In total, 2516 parents from Australia, China, Italy, Sweden, the United Kingdom, and the United States of America living with a young child (M(age) = 5.77, SD = 1.10, range = 3 to 8 years, 47.9% female) completed an online survey between April and July 2020. The survey included the Strengths and Difficulties Questionnaire and family risk factors (parent distress, parent-child conflict, couple conflict, and household chaos) as well as a scale to index COVID-19-related family disruption. Our analyses also included public data on the stringency of national restrictions. Across the six sites, parental responses indicated elevated levels of hyperactivity, conduct, and emotion problems in children from families characterized by heightened levels of parent distress, parent-child conflict, and household chaos. In contrast, increased peer problems were more strongly related to COVID-19-related social disruption and stringency measures. Mediation models demonstrated that associations between COVID-19 social disruption and child difficulties could be explained by parental distress. Taken together, these results suggest that although the experience of the pandemic differed across countries, associations between COVID-19-related family experiences and child adjustment difficulties were similar in their nature and magnitude across six different contexts. Programs to support family resilience could help buffer the impact of the pandemic for two generations. FAU - Foley, Sarah AU - Foley S AD - Moray House School of Education and Sport, University of Edinburgh, Edinburgh EH8 8AQ, UK. FAU - Badinlou, Farzaneh AU - Badinlou F AD - Department of Psychology, Uppsala University, 751 42 Uppsala, Sweden. AD - Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet, 117 63 Stockholm, Sweden. FAU - Brocki, Karin C AU - Brocki KC AD - Department of Psychology, Uppsala University, 751 42 Uppsala, Sweden. FAU - Frick, Matilda A AU - Frick MA AD - Department of Psychology, Uppsala University, 751 42 Uppsala, Sweden. FAU - Ronchi, Luca AU - Ronchi L AUID- ORCID: 0000-0001-7723-9376 AD - Department of Brain and Behavioural Sciences, University of Pavia, 27100 Pavia, Italy. FAU - Hughes, Claire AU - Hughes C AD - Centre for Family Research, University of Cambridge, Cambridge CB2 3RQ, UK. LA - eng GR - ES/T008989/1/Economic and Social Research Council/ GR - Newnham College, University of Cambridge/ GR - F32 HD102106/HD/NICHD NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, U.S. Gov't, Non-P.H.S. DEP - 20211023 PL - Switzerland TA - Int J Environ Res Public Health JT - International journal of environmental research and public health JID - 101238455 SB - IM MH - *COVID-19 MH - Child MH - Child, Preschool MH - Family Health MH - Female MH - Humans MH - Male MH - Pandemics MH - *Resilience, Psychological MH - SARS-CoV-2 MH - United States PMC - PMC8582895 OTO - NOTNLM OT - COVID-19 OT - child adjustment OT - distress OT - family OT - international OT - risk COIS- The authors report no conflict of interest. EDAT- 2021/11/14 06:00 MHDA- 2021/11/19 06:00 PMCR- 2021/10/23 CRDT- 2021/11/13 01:07 PHST- 2021/09/20 00:00 [received] PHST- 2021/10/15 00:00 [revised] PHST- 2021/10/20 00:00 [accepted] PHST- 2021/11/13 01:07 [entrez] PHST- 2021/11/14 06:00 [pubmed] PHST- 2021/11/19 06:00 [medline] PHST- 2021/10/23 00:00 [pmc-release] AID - ijerph182111136 [pii] AID - ijerph-18-11136 [pii] AID - 10.3390/ijerph182111136 [doi] PST - epublish SO - Int J Environ Res Public Health. 2021 Oct 23;18(21):11136. doi: 10.3390/ijerph182111136. PMID- 34757239 OWN - NLM STAT- MEDLINE DCOM- 20220103 LR - 20220103 IS - 1873-5347 (Electronic) IS - 0277-9536 (Linking) VI - 291 DP - 2021 Dec TI - "We have to respect that option": The abortion aversion complex in safety-net healthcare organizations. PG - 114468 LID - S0277-9536(21)00800-5 [pii] LID - 10.1016/j.socscimed.2021.114468 [doi] AB - In July 2019, the Trump administration began implementing its domestic gag rule to ban discussion of abortion in pregnancy options counseling and ensure physical separation of contraceptive and abortion services at clinical sites funded by the federal government's Title X Family Planning program. In this paper, we examine how organizational policy utilization correlated with organization-level protocols for discussing abortion in options counseling interactions while the domestic gag rule policy was under legal contest. From April 2018 to July 2019, we conducted in-depth interviews with 50 administrators in charge of setting clinical protocols regarding options counseling after a positive pregnancy test at 20 Title X-covered and 14 non-Title X-covered safety-net healthcare organizations in Ohio. We found that organizational characteristics and Title X policy utilization did not explain the heterogeneity in approaches to abortion referral that administrators reported. Administrators from 2 of 20 organizations covered by Title X policy requirements pre-emptively restricted discussion of abortion in their facilities in advance of policy enactment. Meanwhile, administrators from 10 of 14 non-Title X-covered organizations did not restrict discussion of abortion. Our analysis demonstrates how safety-net healthcare organizations' response to federal policy is shaped by administrators' institutional entrepreneurship within the abortion aversion complex: a pattern of policy miscomprehension and endorsed abortion stigma that facilitates the structural stigmatization of abortion within safety-net healthcare organizations. We conclude that current efforts to reverse the domestic gag rule will fail unless local abortion aversion complexes are targeted with intervention. CI - Copyright (c) 2021 Elsevier Ltd. All rights reserved. FAU - Kim, Emily AU - Kim E AD - University of Cincinnati College of Medicine, 3230 Eden Ave, Cincinnati, OH, 45267, USA. FAU - Singh, Sachika AU - Singh S AD - University of Cincinnati, Department of Sociology, 1014 Crosley Tower, P.O. Box 210378, Cincinnati, OH, 45221-0378, USA. FAU - Bommaraju, Aalap AU - Bommaraju A AD - University of Cincinnati, Department of Sociology, 1014 Crosley Tower, P.O. Box 210378, Cincinnati, OH, 45221-0378, USA. FAU - Norris, Alison H AU - Norris AH AD - Ohio State University, College of Public Health, 250 Cunz Hall, 1841 Neil Ave, Columbus, OH, 43210, USA. FAU - Bessett, Danielle AU - Bessett D AD - University of Cincinnati, Department of Sociology, 1014 Crosley Tower, P.O. Box 210378, Cincinnati, OH, 45221-0378, USA. Electronic address: danielle.bessett@uc.edu. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20211009 PL - England TA - Soc Sci Med JT - Social science & medicine (1982) JID - 8303205 SB - IM MH - *Abortion, Induced MH - Delivery of Health Care MH - Family Planning Services MH - Female MH - Humans MH - Organizations MH - Pregnancy MH - *Respect MH - United States OTO - NOTNLM OT - Abortion stigma OT - Healthcare administrators OT - Ohio OT - Pregnancy options counseling OT - Safety-net clinics OT - Title X EDAT- 2021/11/11 06:00 MHDA- 2022/01/04 06:00 CRDT- 2021/11/10 15:27 PHST- 2021/02/19 00:00 [received] PHST- 2021/09/18 00:00 [revised] PHST- 2021/10/07 00:00 [accepted] PHST- 2021/11/11 06:00 [pubmed] PHST- 2022/01/04 06:00 [medline] PHST- 2021/11/10 15:27 [entrez] AID - S0277-9536(21)00800-5 [pii] AID - 10.1016/j.socscimed.2021.114468 [doi] PST - ppublish SO - Soc Sci Med. 2021 Dec;291:114468. doi: 10.1016/j.socscimed.2021.114468. Epub 2021 Oct 9. PMID- 34754650 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20211111 IS - 2168-8184 (Print) IS - 2168-8184 (Electronic) IS - 2168-8184 (Linking) VI - 13 IP - 10 DP - 2021 Oct TI - Effect of Lockdown on Diabetes Care During the COVID-19 Pandemic: Result of a Telephone-Based Survey Among Patients Attending a Diabetic Clinic in Northern India. PG - e18489 LID - 10.7759/cureus.18489 [doi] LID - e18489 AB - Background The coronavirus disease 2019 (COVID-19) pandemic has aggravated the demand for diabetes care due to restrictive measures like the lockdown affecting access to healthcare services. The current study was conducted to assess the changes in medication compliance, dietary pattern, and glucose monitoring during the lockdown period as compared to the pre-lockdown period among patients living with type 2 diabetes mellitus (T2DM) attending a diabetes clinic in northern India. Methods This cross-sectional study was conducted between May and July 2020. Information regarding the sociodemographic and clinical profiles of the patients like age, sex, income, qualification, family history of diabetes, history of smoking and alcohol, type of treatment, co-morbidities, drug adherence for T2DM, changes in the pattern of diet, physical activity, blood glucose monitoring, and drug usage during and before the lockdown was collected through telephonic interviews using a structured tool. Descriptive analysis was performed, and the chi-square and Wilcoxon sign ranks tests were used to see the association between variables. Results A total of 260 patients were enrolled in the study. A higher proportion of males reported a decrease in the consumption of cereals (13.9%), eggs (56.5%), and meat and fish (92.7%) and an increase in water intake (25.8%) while a higher proportion of females reported no change in physical activity levels (77.2%) during the lockdown against pre-COVID times. There was a significant improvement in medication adherence and glycemic control during the lockdown period as compared to the pre-lockdown times. Conclusion More time for self-care, adequate counseling about glycemic goals, and knowledge of self-monitoring of blood glucose levels helped the majority of patients in adopting a healthy lifestyle and achieve better glycemic control during the COVID-19 lockdown. CI - Copyright (c) 2021, Verma et al. FAU - Verma, Madhur AU - Verma M AD - Department of Community and Family Medicine, All India Institute of Medical Sciences, Bathinda, IND. FAU - Sharma, Priyanka AU - Sharma P AD - Department of Community Medicine, Vardhaman Mahavir Medical College (VMMC) & Safdarjung Hospital, New Delhi, IND. FAU - Chaudhari, Atul AU - Chaudhari A AD - School of Public Health, Post Graduate Institute of Medical Education and Research, Chandigarh, IND. FAU - Sharma, Meenakshi AU - Sharma M AD - School of Public Health, Post Graduate Institute of Medical Education and Research, Chandigarh, IND. FAU - Kalra, Sanjay AU - Kalra S AD - Endocrinology, Bharti Hospital, Karnal, IND. LA - eng PT - Journal Article DEP - 20211005 PL - United States TA - Cureus JT - Cureus JID - 101596737 PMC - PMC8567109 OTO - NOTNLM OT - diabetes care OT - dietary pattern OT - lockdown OT - medication adherence OT - pandemic COIS- The authors have declared that no competing interests exist. EDAT- 2021/11/11 06:00 MHDA- 2021/11/11 06:01 PMCR- 2021/10/05 CRDT- 2021/11/10 06:43 PHST- 2021/10/05 00:00 [accepted] PHST- 2021/11/10 06:43 [entrez] PHST- 2021/11/11 06:00 [pubmed] PHST- 2021/11/11 06:01 [medline] PHST- 2021/10/05 00:00 [pmc-release] AID - 10.7759/cureus.18489 [doi] PST - epublish SO - Cureus. 2021 Oct 5;13(10):e18489. doi: 10.7759/cureus.18489. eCollection 2021 Oct. PMID- 34742265 OWN - NLM STAT- MEDLINE DCOM- 20211206 LR - 20211214 IS - 1472-6874 (Electronic) IS - 1472-6874 (Linking) VI - 21 IP - 1 DP - 2021 Nov 6 TI - Barriers to seeking post-abortion care in Paktika Province, Afghanistan: a qualitative study of clients and community members. PG - 390 LID - 10.1186/s12905-021-01529-5 [doi] LID - 390 AB - BACKGROUND: Unsafe abortion is a leading cause of maternal mortality. In Afghanistan, which has experienced decades of armed conflict and where abortion is highly restricted, maternal mortality is high at 638 maternal deaths per 100,000 live births. Post-abortion care (PAC) is a lifesaving package of interventions to reduce morbidity and mortality related to induced or spontaneous abortion, but is rarely provided and often of poor quality, particularly in humanitarian settings. In July 2018, we conducted a study to identify the factors that influence access to and use of PAC services at Sharana Provincial Hospital. METHODS: In-depth interviews (IDIs) were conducted with ten women who had received PAC services at Sharana Hospital, and eight focus group discussions (FGDs) were conducted with 40 married women and 40 married men aged 18-45 from four villages surrounding Sharana Hospital. RESULTS: PAC clients and community participants discussed similar barriers to seeking PAC, including cost, distance to the health facility, the need for male accompaniment to seek care, perceived and actual quality of care, stigma and shame. Despite the mentioned stigma around abortion, community members expressed willingness to help women to receive PAC. CONCLUSIONS: Our results suggest that while some barriers are not unique to PAC, others, especially those related to stigma around abortion, may be specific to PAC. It is important for the Ministry of Public Health and its partners to prioritize addressing these barriers to ensure that women have access to this critical life-saving care. CI - (c) 2021. The Author(s). FAU - Perera, Shiromi M AU - Perera SM AD - International Medical Corps, 1313 L St. NW, Suite 110, Washington, DC, 20005, USA. FAU - Achakzai, Haroon AU - Achakzai H AD - International Medical Corps Afghanistan, House # 11, Street-6, District -10, Qala-e-Fatullah, Kabul, Afghanistan. FAU - Giuffrida, Monica M AU - Giuffrida MM AD - RAISE Initiative, Heilbrunn Department of Population and Family Health, Mailman School of Public Health, Columbia University, 60 Haven Ave, New York, NY, B210032, USA. FAU - Kulkarni, Meghana Jayne AU - Kulkarni MJ AD - RAISE Initiative, Heilbrunn Department of Population and Family Health, Mailman School of Public Health, Columbia University, 60 Haven Ave, New York, NY, B210032, USA. FAU - Nagle, Devin C AU - Nagle DC AD - RAISE Initiative, Heilbrunn Department of Population and Family Health, Mailman School of Public Health, Columbia University, 60 Haven Ave, New York, NY, B210032, USA. FAU - Wali, Mohammad Kameen AU - Wali MK AD - International Medical Corps Afghanistan, House # 11, Street-6, District -10, Qala-e-Fatullah, Kabul, Afghanistan. FAU - Casey, Sara E AU - Casey SE AUID- ORCID: 0000-0002-8476-0327 AD - RAISE Initiative, Heilbrunn Department of Population and Family Health, Mailman School of Public Health, Columbia University, 60 Haven Ave, New York, NY, B210032, USA. sec42@columbia.edu. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20211106 PL - England TA - BMC Womens Health JT - BMC women's health JID - 101088690 SB - IM MH - *Abortion, Induced MH - *Abortion, Spontaneous MH - Afghanistan MH - Female MH - Health Facilities MH - Humans MH - Male MH - Pregnancy MH - Qualitative Research PMC - PMC8571834 OTO - NOTNLM OT - Afghanistan OT - Barriers OT - Post-abortion care OT - Reproductive health COIS- The authors declare that they have no competing interests. EDAT- 2021/11/08 06:00 MHDA- 2021/12/15 06:00 PMCR- 2021/11/06 CRDT- 2021/11/07 20:19 PHST- 2020/05/13 00:00 [received] PHST- 2021/10/28 00:00 [accepted] PHST- 2021/11/07 20:19 [entrez] PHST- 2021/11/08 06:00 [pubmed] PHST- 2021/12/15 06:00 [medline] PHST- 2021/11/06 00:00 [pmc-release] AID - 10.1186/s12905-021-01529-5 [pii] AID - 1529 [pii] AID - 10.1186/s12905-021-01529-5 [doi] PST - epublish SO - BMC Womens Health. 2021 Nov 6;21(1):390. doi: 10.1186/s12905-021-01529-5. PMID- 34741828 OWN - NLM STAT- MEDLINE DCOM- 20211217 LR - 20221221 IS - 1528-3984 (Electronic) IS - 0197-4572 (Print) IS - 0197-4572 (Linking) VI - 42 IP - 6 DP - 2021 Nov-Dec TI - Experiences of long-term care and supportive living residents and families during the COVID-19 pandemic: "It's a lot different for us than it is for the average Joe". PG - 1547-1555 LID - S0197-4572(21)00332-3 [pii] LID - 10.1016/j.gerinurse.2021.10.012 [doi] AB - Long-term care and supportive living (LTC/SL) residents are among the most at risk for severe outcomes of COVID-19. As such, early public health measures focused on this population. This study examined the experiences and perspectives of residents and family members of residents living in LTC/SL centres in Alberta, Canada during the COVID-19 pandemic. Between July and October 2020, we conducted semi-structured interviews with 14 residents and 18 family members of residents from 10 centres. Interviews were audio-recorded and analyzed using qualitative content analysis. Analysis revealed 5 categories from resident interviews (Living with Rules and Restrictions; COVID-19 Knowledge and Information; Wellbeing; Centre Operational Response; Criticisms and Suggestions for Improvement) and 6 categories from family interviews (Family Role; Navigating the New Normal; COVID-19 Knowledge and Information; Policy Limitations; Policy Impact; Centre Response). The results highlight the importance of engaging residents and families during pandemic preparation, response, and follow-up evaluation. CI - Copyright (c) 2021 Elsevier Inc. All rights reserved. FAU - Ickert, Carla AU - Ickert C AD - CapitalCare, 6th floor, 10909 - Jasper Ave, Edmonton, Alberta T5J 3M9, Canada. Electronic address: research@capitalcare.net. FAU - Stefaniuk, Rachel AU - Stefaniuk R AD - CapitalCare, 6th floor, 10909 - Jasper Ave, Edmonton, Alberta T5J 3M9, Canada. FAU - Leask, James AU - Leask J AD - CapitalCare, 6th floor, 10909 - Jasper Ave, Edmonton, Alberta T5J 3M9, Canada. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20211022 PL - United States TA - Geriatr Nurs JT - Geriatric nursing (New York, N.Y.) JID - 8309633 MH - *COVID-19 MH - Family MH - Humans MH - Long-Term Care MH - *Pandemics/prevention & control MH - SARS-CoV-2 PMC - PMC8531259 OTO - NOTNLM OT - COVID-19 pandemic OT - Long-term care OT - Public health policies OT - Supportive living COIS- Declaration of Competing Interest None. EDAT- 2021/11/07 06:00 MHDA- 2021/12/18 06:00 PMCR- 2021/10/22 CRDT- 2021/11/06 20:06 PHST- 2021/07/05 00:00 [received] PHST- 2021/10/08 00:00 [revised] PHST- 2021/10/12 00:00 [accepted] PHST- 2021/11/07 06:00 [pubmed] PHST- 2021/12/18 06:00 [medline] PHST- 2021/11/06 20:06 [entrez] PHST- 2021/10/22 00:00 [pmc-release] AID - S0197-4572(21)00332-3 [pii] AID - 10.1016/j.gerinurse.2021.10.012 [doi] PST - ppublish SO - Geriatr Nurs. 2021 Nov-Dec;42(6):1547-1555. doi: 10.1016/j.gerinurse.2021.10.012. Epub 2021 Oct 22. PMID- 34731488 OWN - NLM STAT- MEDLINE DCOM- 20211213 LR - 20261002 IS - 1920-7476 (Electronic) IS - 0008-4263 (Print) IS - 0008-4263 (Linking) VI - 112 IP - 6 DP - 2021 Dec TI - Partner number and use of COVID-19 risk reduction strategies during initial phases of the pandemic in British Columbia, Canada: a survey of sexual health service clients. PG - 973-983 LID - 10.17269/s41997-021-00566-9 [doi] AB - OBJECTIVES: Initial public health guidance related to sex and COVID-19 infection focused on reducing partner number. We characterized individuals having a higher partner number during the initial phases of the pandemic. METHODS: In British Columbia, the initial wave of COVID-19 cases was from March 14 to May 19, 2020, followed by gradual lifting of public health restrictions. We conducted an e-mail survey of existing sexual health service clients during the period of July 23 to August 4, 2020. We used bivariate logistic regression to examine the association between the reported number of sexual partners since the start of the pandemic and key variables (level of significance p < 0.01). RESULTS: Of the 1196 clients in our final sample, 42% reported 2+ partners since the start of the pandemic, with higher odds among participants who were men who have sex with men, and single or in open relationships prior to the pandemic. This group was more likely to perceive stigma associated with having sex during the pandemic, and had the highest use of strategies to reduce risk of COVID-19 infection during sexual encounters (mainly focused on reducing/avoiding partners, such as masturbation, limiting sex to a "bubble", and not having sex). CONCLUSION: Sexual health service clients in BC with 2+ partners during the initial phases of BC's pandemic used strategies to reduce their risk of COVID-19 infection during sex. Our study provides support for a harm reduction approach to guidance on COVID-19 risk during sex, and highlights the need for further research on stigma related to having sex during the COVID-19 pandemic. CI - (c) 2021. The Author(s). FAU - Gilbert, Mark AU - Gilbert M AUID- ORCID: 0000-0001-5978-6843 AD - Clinical Prevention Services, British Columbia Centre for Disease Control, 655 West 12th, Vancouver, British Columbia, V5Z 4R4, Canada. mark.gilbert@bccdc.ca. AD - School of Population and Public Health, University of British Columbia, Vancouver, British Columbia, Canada. mark.gilbert@bccdc.ca. FAU - Chang, Hsiu-Ju AU - Chang HJ AD - Clinical Prevention Services, British Columbia Centre for Disease Control, 655 West 12th, Vancouver, British Columbia, V5Z 4R4, Canada. FAU - Ablona, Aidan AU - Ablona A AD - Clinical Prevention Services, British Columbia Centre for Disease Control, 655 West 12th, Vancouver, British Columbia, V5Z 4R4, Canada. FAU - Salway, Travis AU - Salway T AD - Faculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia, Canada. FAU - Ogilvie, Gina AU - Ogilvie G AD - School of Population and Public Health, University of British Columbia, Vancouver, British Columbia, Canada. AD - Women's Health Research Institute, BC Women's, Vancouver, British Columbia, Canada. FAU - Wong, Jason AU - Wong J AD - Clinical Prevention Services, British Columbia Centre for Disease Control, 655 West 12th, Vancouver, British Columbia, V5Z 4R4, Canada. AD - School of Population and Public Health, University of British Columbia, Vancouver, British Columbia, Canada. FAU - Campeau, Laurence AU - Campeau L AD - Vancouver Island Health Authority, Victoria, British Columbia, Canada. FAU - Worthington, Catherine AU - Worthington C AD - School of Public Health and Social Policy, University of Victoria, Victoria, British Columbia, Canada. FAU - Grace, Daniel AU - Grace D AD - Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada. FAU - Grennan, Troy AU - Grennan T AD - Clinical Prevention Services, British Columbia Centre for Disease Control, 655 West 12th, Vancouver, British Columbia, V5Z 4R4, Canada. AD - Division of Infectious Diseases, University of British Columbia, Vancouver, British Columbia, Canada. LA - eng GR - CTW-155387/CIHR/Canada PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20211103 PL - Switzerland TA - Can J Public Health JT - Canadian journal of public health = Revue canadienne de sante publique JID - 0372714 SB - IM MH - British Columbia/epidemiology MH - *COVID-19 MH - Health Services MH - Homosexuality, Male MH - Humans MH - Male MH - Pandemics/prevention & control MH - Risk Reduction Behavior MH - SARS-CoV-2 MH - Sexual Behavior MH - Sexual Partners MH - *Sexual and Gender Minorities PMC - PMC8565172 OTO - NOTNLM OT - COVID-19 OT - Health promotion OT - Public health OT - Sexual behaviour COIS- The authors declare no competing interests. EDAT- 2021/11/04 06:00 MHDA- 2021/12/15 06:00 PMCR- 2021/11/03 CRDT- 2021/11/03 17:32 PHST- 2020/12/23 00:00 [received] PHST- 2021/07/30 00:00 [accepted] PHST- 2021/11/04 06:00 [pubmed] PHST- 2021/12/15 06:00 [medline] PHST- 2021/11/03 17:32 [entrez] PHST- 2021/11/03 00:00 [pmc-release] AID - 10.17269/s41997-021-00566-9 [pii] AID - 566 [pii] AID - 10.17269/s41997-021-00566-9 [doi] PST - ppublish SO - Can J Public Health. 2021 Dec;112(6):973-983. doi: 10.17269/s41997-021-00566-9. Epub 2021 Nov 3. PMID- 34717829 OWN - NLM STAT- MEDLINE DCOM- 20211119 LR - 20250530 IS - 1474-547X (Electronic) IS - 0140-6736 (Print) IS - 0140-6736 (Linking) VI - 398 IP - 10313 DP - 2021 Nov 13 TI - Non-pharmaceutical interventions, vaccination, and the SARS-CoV-2 delta variant in England: a mathematical modelling study. PG - 1825-1835 LID - S0140-6736(21)02276-5 [pii] LID - 10.1016/S0140-6736(21)02276-5 [doi] AB - BACKGROUND: England's COVID-19 roadmap out of lockdown policy set out the timeline and conditions for the stepwise lifting of non-pharmaceutical interventions (NPIs) as vaccination roll-out continued, with step one starting on March 8, 2021. In this study, we assess the roadmap, the impact of the delta (B.1.617.2) variant of SARS-CoV-2, and potential future epidemic trajectories. METHODS: This mathematical modelling study was done to assess the UK Government's four-step process to easing lockdown restrictions in England, UK. We extended a previously described model of SARS-CoV-2 transmission to incorporate vaccination and multi-strain dynamics to explicitly capture the emergence of the delta variant. We calibrated the model to English surveillance data, including hospital admissions, hospital occupancy, seroprevalence data, and population-level PCR testing data using a Bayesian evidence synthesis framework, then modelled the potential trajectory of the epidemic for a range of different schedules for relaxing NPIs. We estimated the resulting number of daily infections and hospital admissions, and daily and cumulative deaths. Three scenarios spanning a range of optimistic to pessimistic vaccine effectiveness, waning natural immunity, and cross-protection from previous infections were investigated. We also considered three levels of mixing after the lifting of restrictions. FINDINGS: The roadmap policy was successful in offsetting the increased transmission resulting from lifting NPIs starting on March 8, 2021, with increasing population immunity through vaccination. However, because of the emergence of the delta variant, with an estimated transmission advantage of 76% (95% credible interval [95% CrI] 69-83) over alpha, fully lifting NPIs on June 21, 2021, as originally planned might have led to 3900 (95% CrI 1500-5700) peak daily hospital admissions under our central parameter scenario. Delaying until July 19, 2021, reduced peak hospital admissions by three fold to 1400 (95% CrI 700-1700) per day. There was substantial uncertainty in the epidemic trajectory, with particular sensitivity to the transmissibility of delta, level of mixing, and estimates of vaccine effectiveness. INTERPRETATION: Our findings show that the risk of a large wave of COVID-19 hospital admissions resulting from lifting NPIs can be substantially mitigated if the timing of NPI relaxation is carefully balanced against vaccination coverage. However, with the delta variant, it might not be possible to fully lift NPIs without a third wave of hospital admissions and deaths, even if vaccination coverage is high. Variants of concern, their transmissibility, vaccine uptake, and vaccine effectiveness must be carefully monitored as countries relax pandemic control measures. FUNDING: National Institute for Health Research, UK Medical Research Council, Wellcome Trust, and UK Foreign, Commonwealth and Development Office. CI - Copyright (c) 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved. FAU - Sonabend, Raphael AU - Sonabend R AD - MRC Centre for Global Infectious Disease Analysis, Jameel Institute, School of Public Health, Imperial College London, London, UK. FAU - Whittles, Lilith K AU - Whittles LK AD - MRC Centre for Global Infectious Disease Analysis, Jameel Institute, School of Public Health, Imperial College London, London, UK; National Institute for Health Research Health Protection Research Unit in Modelling Methodology, Imperial College London, Public Health England, London School of Hygiene & Tropical Medicine, London, UK; Modelling and Economics Unit, National Infection Service, Public Health England, London, UK. FAU - Imai, Natsuko AU - Imai N AD - MRC Centre for Global Infectious Disease Analysis, Jameel Institute, School of Public Health, Imperial College London, London, UK. FAU - Perez-Guzman, Pablo N AU - Perez-Guzman PN AD - MRC Centre for Global Infectious Disease Analysis, Jameel Institute, School of Public Health, Imperial College London, London, UK. FAU - Knock, Edward S AU - Knock ES AD - MRC Centre for Global Infectious Disease Analysis, Jameel Institute, School of Public Health, Imperial College London, London, UK; National Institute for Health Research Health Protection Research Unit in Modelling Methodology, Imperial College London, Public Health England, London School of Hygiene & Tropical Medicine, London, UK. FAU - Rawson, Thomas AU - Rawson T AD - MRC Centre for Global Infectious Disease Analysis, Jameel Institute, School of Public Health, Imperial College London, London, UK. FAU - Gaythorpe, Katy A M AU - Gaythorpe KAM AD - MRC Centre for Global Infectious Disease Analysis, Jameel Institute, School of Public Health, Imperial College London, London, UK. FAU - Djaafara, Bimandra A AU - Djaafara BA AD - MRC Centre for Global Infectious Disease Analysis, Jameel Institute, School of Public Health, Imperial College London, London, UK. FAU - Hinsley, Wes AU - Hinsley W AD - MRC Centre for Global Infectious Disease Analysis, Jameel Institute, School of Public Health, Imperial College London, London, UK. FAU - FitzJohn, Richard G AU - FitzJohn RG AD - MRC Centre for Global Infectious Disease Analysis, Jameel Institute, School of Public Health, Imperial College London, London, UK. FAU - Lees, John A AU - Lees JA AD - MRC Centre for Global Infectious Disease Analysis, Jameel Institute, School of Public Health, Imperial College London, London, UK. FAU - Kanapram, Divya Thekke AU - Kanapram DT AD - MRC Centre for Global Infectious Disease Analysis, Jameel Institute, School of Public Health, Imperial College London, London, UK. FAU - Volz, Erik M AU - Volz EM AD - MRC Centre for Global Infectious Disease Analysis, Jameel Institute, School of Public Health, Imperial College London, London, UK. FAU - Ghani, Azra C AU - Ghani AC AD - MRC Centre for Global Infectious Disease Analysis, Jameel Institute, School of Public Health, Imperial College London, London, UK. FAU - Ferguson, Neil M AU - Ferguson NM AD - MRC Centre for Global Infectious Disease Analysis, Jameel Institute, School of Public Health, Imperial College London, London, UK; National Institute for Health Research Health Protection Research Unit in Modelling Methodology, Imperial College London, Public Health England, London School of Hygiene & Tropical Medicine, London, UK. Electronic address: neil.ferguson@imperial.ac.uk. FAU - Baguelin, Marc AU - Baguelin M AD - MRC Centre for Global Infectious Disease Analysis, Jameel Institute, School of Public Health, Imperial College London, London, UK; National Institute for Health Research Health Protection Research Unit in Modelling Methodology, Imperial College London, Public Health England, London School of Hygiene & Tropical Medicine, London, UK; Department of Infectious Disease Epidemiology, Faculty of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, London, UK. FAU - Cori, Anne AU - Cori A AD - MRC Centre for Global Infectious Disease Analysis, Jameel Institute, School of Public Health, Imperial College London, London, UK; National Institute for Health Research Health Protection Research Unit in Modelling Methodology, Imperial College London, Public Health England, London School of Hygiene & Tropical Medicine, London, UK. Electronic address: a.cori@imperial.ac.uk. LA - eng GR - WT_/Wellcome Trust/United Kingdom GR - MC_PC_19012/MRC_/Medical Research Council/United Kingdom GR - MR/R015600/1/MRC_/Medical Research Council/United Kingdom GR - MR/V038109/1/MRC_/Medical Research Council/United Kingdom PT - Journal Article DEP - 20211028 PL - England TA - Lancet JT - Lancet (London, England) JID - 2985213R RN - 0 (COVID-19 Vaccines) SB - IM CIN - Lancet. 2021 Nov 13;398(10313):1781-1783. doi: 10.1016/S0140-6736(21)02386-2. PMID: 34717830 MH - COVID-19/epidemiology/mortality/*prevention & control/*transmission MH - COVID-19 Vaccines/*administration & dosage MH - Communicable Disease Control/*organization & administration MH - England/epidemiology MH - Hospital Mortality/trends MH - Hospitalization/statistics & numerical data MH - Humans MH - Models, Theoretical MH - Patient Admission/statistics & numerical data MH - *SARS-CoV-2 MH - Vaccination Coverage/*organization & administration PMC - PMC8550916 COIS- Declaration of interests AC has received payment from Pfizer for teaching of mathematical modelling of infectious diseases. KAMG has received honoraria from Wellcome Genome Campus for lectures and salary support from the Bill & Melinda Gates Foundation and Gavi, the Vaccine Alliance, through Imperial College London for work outside this study. All other authors declare no competing interests. EDAT- 2021/11/01 06:00 MHDA- 2021/11/20 06:00 PMCR- 2021/11/13 CRDT- 2021/10/31 20:42 PHST- 2021/08/17 00:00 [received] PHST- 2021/09/28 00:00 [revised] PHST- 2021/10/07 00:00 [accepted] PHST- 2021/11/01 06:00 [pubmed] PHST- 2021/11/20 06:00 [medline] PHST- 2021/10/31 20:42 [entrez] PHST- 2021/11/13 00:00 [pmc-release] AID - S0140-6736(21)02276-5 [pii] AID - 10.1016/S0140-6736(21)02276-5 [doi] PST - ppublish SO - Lancet. 2021 Nov 13;398(10313):1825-1835. doi: 10.1016/S0140-6736(21)02276-5. Epub 2021 Oct 28. PMID- 34713613 OWN - NLM STAT- MEDLINE DCOM- 20211101 LR - 20221005 IS - 1758-2652 (Electronic) IS - 1758-2652 (Linking) VI - 24 Suppl 6 IP - Suppl 6 DP - 2021 Oct TI - "It went through the roof": an observation study exploring the rise in PrEP uptake among Zimbabwean female sex workers in response to adaptations during Covid-19. PG - e25813 LID - 10.1002/jia2.25813 [doi] LID - e25813 AB - INTRODUCTION: Sisters with a Voice (Sisters), a programme providing community-led differentiated HIV prevention and treatment services, including condoms, HIV testing, pre-exposure prophylaxis (PrEP) and antiretroviral therapy linkage for sex workers, reached over 26,000 female sex workers (FSW) across Zimbabwe in 2020. Zimbabwe's initial Covid "lockdown" in March 2020 and associated movement restrictions interrupted clinical service provision for 6 weeks, particularly in mobile clinics, triggering the adaptation of services for the Covid-19 context and a scale up of differentiated service delivery (DSD) models. PrEP service delivery decentralized with shifts from clinical settings towards community/home-based, peer-led PrEP services to expand and maintain access. We hypothesize that peer-led community-based provision of PrEP services influenced both demand and supply-side determinants of PrEP uptake. We observed the effect of these adaptations on PrEP uptake among FSW accessing services in Sisters in 2020. METHODS: New FSW PrEP initiations throughout 2020 were tracked by analysing routine Sisters programme data and comparing it with national PrEP initiation data for 2020. We mapped PrEP uptake among all negative FSW attending services in Sisters alongside Covid-19 adaptations and shifts in the operating environment throughout 2020: prior to lockdown (January-March 2020), during severe restrictions (April-June 2020), subsequent easing (July-September 2020) and during drug stockouts that followed (October-December 2020). RESULTS AND DISCUSSION: PrEP uptake in 2020 occurred at rates <25% (315 initiations or fewer) per month prior to the emergence of Covid-19. In response to Covid-19 restrictions, DSD models were scaled up in April 2020, including peer demand creation, community-based delivery, multi-month dispensing and the use of virtual platforms for appointment scheduling and post-PrEP initiation support. Beginning May 2020, PrEP uptake increased monthly, peaking at an initiation rate of 51% (n = 1360) in September 2020. Unexpected rise in demand coincided with national commodity shortages between October and December 2020, resulting in restriction of new initiations with sites prioritizing refills. CONCLUSIONS: Despite the impact of Covid-19 on the Sisters Programme and FSW mobility, DSD adaptations led to a large increase in PrEP initiations compared to pre-Covid levels demonstrating that a peer-led, community-based PrEP service delivery model is effective and can be adopted for long-term use. CI - (c) 2021 The Authors. Journal of the International AIDS Society published by John Wiley & Sons Ltd on behalf of the International AIDS Society. FAU - Matambanadzo, Primrose AU - Matambanadzo P AD - Centre for Sexual Health and HIV/AIDS Research Zimbabwe, Harare, Zimbabwe. FAU - Busza, Joanna AU - Busza J AUID- ORCID: 0000-0001-6334-0318 AD - Centre for Evaluation, London School of Hygiene and Tropical Medicine, London, UK. FAU - Mafaune, Haurovi AU - Mafaune H AD - Centre for Sexual Health and HIV/AIDS Research Zimbabwe, Harare, Zimbabwe. FAU - Chinyanganya, Lillian AU - Chinyanganya L AD - Centre for Sexual Health and HIV/AIDS Research Zimbabwe, Harare, Zimbabwe. FAU - Machingura, Fortunate AU - Machingura F AD - Centre for Sexual Health and HIV/AIDS Research Zimbabwe, Harare, Zimbabwe. FAU - Ncube, Getrude AU - Ncube G AD - AIDS and TB Unit, Ministry of Health and Child Care, Harare, Zimbabwe. FAU - Steen, Richard AU - Steen R AUID- ORCID: 0000-0002-0798-022X AD - Department of Public Health, Erasmus Medical Centre, Rotterdam, The Netherlands. FAU - Phillips, Andrew AU - Phillips A AUID- ORCID: 0000-0003-2384-4807 AD - Institute for Global Health, University College London, London, UK. FAU - Cowan, Frances Mary AU - Cowan FM AUID- ORCID: 0000-0003-3087-4422 AD - Centre for Sexual Health and HIV/AIDS Research Zimbabwe, Harare, Zimbabwe. AD - Department of International Public Health, Liverpool School of Tropical Medicine, Liverpool, UK. LA - eng GR - WT_/Wellcome Trust/United Kingdom PT - Journal Article PT - Observational Study PT - Research Support, Non-U.S. Gov't PT - Research Support, U.S. Gov't, Non-P.H.S. PL - Switzerland TA - J Int AIDS Soc JT - Journal of the International AIDS Society JID - 101478566 RN - 0 (Anti-HIV Agents) SB - IM MH - *Anti-HIV Agents/therapeutic use MH - *COVID-19 MH - Communicable Disease Control MH - Female MH - *HIV Infections/drug therapy/prevention & control MH - Humans MH - *Pre-Exposure Prophylaxis MH - SARS-CoV-2 MH - *Sex Workers PMC - PMC8554216 OTO - NOTNLM OT - HIV prevention OT - PrEP OT - Sars-Cov2 OT - Zimbabwe OT - differentiated care OT - sex workers COIS- The authors declare that they have no competing interests. EDAT- 2021/10/30 06:00 MHDA- 2021/11/03 06:00 PMCR- 2021/10/28 CRDT- 2021/10/29 06:53 PHST- 2021/03/16 00:00 [received] PHST- 2021/08/19 00:00 [accepted] PHST- 2021/10/29 06:53 [entrez] PHST- 2021/10/30 06:00 [pubmed] PHST- 2021/11/03 06:00 [medline] PHST- 2021/10/28 00:00 [pmc-release] AID - JIA225813 [pii] AID - 10.1002/jia2.25813 [doi] PST - ppublish SO - J Int AIDS Soc. 2021 Oct;24 Suppl 6(Suppl 6):e25813. doi: 10.1002/jia2.25813. PMID- 34710304 OWN - NLM STAT- MEDLINE DCOM- 20211101 LR - 20211101 IS - 2379-3961 (Electronic) IS - 1098-1861 (Linking) VI - 120 IP - 3 DP - 2021 Oct TI - Rapid Transition to Telemedicine During the COVID-19 Pandemic: Medical Genetics Experience. PG - 218-221 AB - BACKGROUND: The coronavirus SARS-CoV-2 (COVID-19) pandemic interrupted delivery of outpatient health care to minimize risk of exposure. This pandemic threatened to increase longstanding national concerns about access to both initial and follow-up genetics clinics services. The Medical Genetics Clinic at the University of Wisconsin-Madison Waisman Center (WCMGC) rapidly transitioned to offering appointments using telemedicine in March 2020 when the public health emergency for COVID-19 pandemic was declared. METHODS: Datasets were reviewed for the periods April - July 2019 (pre-COVID baseline) and April - July 2020 (COVID project data). Patient schedules were accessed to determine the number of appointments kept, no-shows, and late cancellations. A telephone survey was utilized to assess patient satisfaction with telemedicine. RESULTS: Fewer appointments were missed and providers completed more clinic visits after transitioning to telemedicine. Patients and their families were equally satisfied with care received and were amenable to telemedicine use in the future. Telemedicine allowed WCMGC to continue serving patients during a period of restricted on-site services, suggesting its continuation would improve access to genetic services. CI - Copyright(c) Board of Regents of the University of Wisconsin System and The Medical College of Wisconsin, Inc. FAU - Zoran, Sara AU - Zoran S AD - Waisman Center, University of Wisconsin, Madison, Wisconsin. FAU - Turcott, Christie AU - Turcott C AD - Waisman Center, University of Wisconsin, Madison, Wisconsin. FAU - Whitehead, Amy AU - Whitehead A AD - Waisman Center, University of Wisconsin, Madison, Wisconsin. FAU - Hrabik, Lynn AU - Hrabik L AD - Waisman Center, University of Wisconsin, Madison, Wisconsin. FAU - Harris, Anne AU - Harris A AD - Waisman Center, University of Wisconsin, Madison, Wisconsin. FAU - Scott Schwoerer, Jessica AU - Scott Schwoerer J AD - Department of Pediatrics, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, jscottschwoerer@pediatrics.wisc.edu. LA - eng PT - Journal Article PL - United States TA - WMJ JT - WMJ : official publication of the State Medical Society of Wisconsin JID - 9716054 SB - IM MH - *COVID-19 MH - *Genetics, Medical MH - Humans MH - Pandemics MH - SARS-CoV-2 MH - *Telemedicine EDAT- 2021/10/29 06:00 MHDA- 2021/11/03 06:00 CRDT- 2021/10/28 17:33 PHST- 2021/10/28 17:33 [entrez] PHST- 2021/10/29 06:00 [pubmed] PHST- 2021/11/03 06:00 [medline] PST - ppublish SO - WMJ. 2021 Oct;120(3):218-221. PMID- 34704102 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220223 DP - 2021 Oct 20 TI - Evidence of transmission from fully vaccinated individuals in a large outbreak of the SARS-CoV-2 Delta variant in Provincetown, Massachusetts. LID - 2021.10.20.21265137 [pii] LID - 10.1101/2021.10.20.21265137 [doi] AB - Multiple summer events, including large indoor gatherings, in Provincetown, Massachusetts (MA), in July 2021 contributed to an outbreak of over one thousand COVID-19 cases among residents and visitors. Most cases were fully vaccinated, many of whom were also symptomatic, prompting a comprehensive public health response, motivating changes to national masking recommendations, and raising questions about infection and transmission among vaccinated individuals. To characterize the outbreak and the viral population underlying it, we combined genomic and epidemiological data from 467 individuals, including 40% of known outbreak-associated cases. The Delta variant accounted for 99% of sequenced outbreak-associated cases. Phylogenetic analysis suggests over 40 sources of Delta in the dataset, with one responsible for a single cluster containing 83% of outbreak-associated genomes. This cluster was likely not the result of extensive spread at a single site, but rather transmission from a common source across multiple settings over a short time. Genomic and epidemiological data combined provide strong support for 25 transmission events from, including many between, fully vaccinated individuals; genomic data alone provides evidence for an additional 64. Together, genomic epidemiology provides a high-resolution picture of the Provincetown outbreak, revealing multiple cases of transmission of Delta from fully vaccinated individuals. However, despite its magnitude, the outbreak was restricted in its onward impact in MA and the US, likely due to high vaccination rates and a robust public health response. FAU - Siddle, Katherine J AU - Siddle KJ FAU - Krasilnikova, Lydia A AU - Krasilnikova LA FAU - Moreno, Gage K AU - Moreno GK FAU - Schaffner, Stephen F AU - Schaffner SF FAU - Vostok, Johanna AU - Vostok J FAU - Fitzgerald, Nicholas A AU - Fitzgerald NA FAU - Lemieux, Jacob E AU - Lemieux JE FAU - Barkas, Nikolaos AU - Barkas N FAU - Loreth, Christine AU - Loreth C FAU - Specht, Ivan AU - Specht I FAU - Tomkins-Tinch, Christopher H AU - Tomkins-Tinch CH FAU - Silbert, Jillian AU - Silbert J FAU - Schaeffer, Beau AU - Schaeffer B FAU - Taylor, Bradford P AU - Taylor BP FAU - Loftness, Bryn AU - Loftness B FAU - Johnson, Hillary AU - Johnson H FAU - Schubert, Petra L AU - Schubert PL FAU - Shephard, Hanna M AU - Shephard HM FAU - Doucette, Matthew AU - Doucette M FAU - Fink, Timelia AU - Fink T FAU - Lang, Andrew S AU - Lang AS FAU - Baez, Stephanie AU - Baez S FAU - Beauchamp, John AU - Beauchamp J FAU - Hennigan, Scott AU - Hennigan S FAU - Buzby, Erika AU - Buzby E FAU - Ash, Stephanie AU - Ash S FAU - Brown, Jessica AU - Brown J FAU - Clancy, Selina AU - Clancy S FAU - Cofsky, Seana AU - Cofsky S FAU - Gagne, Luc AU - Gagne L FAU - Hall, Joshua AU - Hall J FAU - Harrington, Rachel AU - Harrington R FAU - Gionet, Gabrielle L AU - Gionet GL FAU - DeRuff, Katherine C AU - DeRuff KC FAU - Vodzak, Megan E AU - Vodzak ME FAU - Adams, Gordon C AU - Adams GC FAU - Dobbins, Sabrina T AU - Dobbins ST FAU - Slack, Sarah D AU - Slack SD FAU - Reilly, Steven K AU - Reilly SK FAU - Anderson, Lisa M AU - Anderson LM FAU - Cipicchio, Michelle C AU - Cipicchio MC FAU - DeFelice, Matthew T AU - DeFelice MT FAU - Grimsby, Jonna L AU - Grimsby JL FAU - Anderson, Scott E AU - Anderson SE FAU - Blumenstiel, Brendan S AU - Blumenstiel BS FAU - Meldrim, James C AU - Meldrim JC FAU - Rooke, Heather M AU - Rooke HM FAU - Vicente, Gina AU - Vicente G FAU - Smith, Natasha L AU - Smith NL FAU - Messer, Katelyn S AU - Messer KS FAU - Reagan, Faye L AU - Reagan FL FAU - Mandese, Zoe M AU - Mandese ZM FAU - Lee, Matthew D AU - Lee MD FAU - Ray, Marianne C AU - Ray MC FAU - Fisher, Marissa E AU - Fisher ME FAU - Ulcena, Maesha A AU - Ulcena MA FAU - Nolet, Corey M AU - Nolet CM FAU - English, Sean E AU - English SE FAU - Larkin, Katie L AU - Larkin KL FAU - Vernest, Kyle AU - Vernest K FAU - Chaluvadi, Sushma AU - Chaluvadi S FAU - Arvidson, Deirdre AU - Arvidson D FAU - Melchiono, Maurice AU - Melchiono M FAU - Covell, Theresa AU - Covell T FAU - Harik, Vaira AU - Harik V FAU - Brock-Fisher, Taylor AU - Brock-Fisher T FAU - Dunn, Molly AU - Dunn M FAU - Kearns, Amanda AU - Kearns A FAU - Hanage, William P AU - Hanage WP FAU - Bernard, Clare AU - Bernard C FAU - Philippakis, Anthony AU - Philippakis A FAU - Lennon, Niall J AU - Lennon NJ FAU - Gabriel, Stacey B AU - Gabriel SB FAU - Gallagher, Glen R AU - Gallagher GR FAU - Smole, Sandra AU - Smole S FAU - Madoff, Lawrence C AU - Madoff LC FAU - Brown, Catherine M AU - Brown CM FAU - Park, Daniel J AU - Park DJ FAU - MacInnis, Bronwyn L AU - MacInnis BL FAU - Sabeti, Pardis C AU - Sabeti PC LA - eng PT - Journal Article PT - Preprint DEP - 20211020 PL - United States TA - medRxiv JT - medRxiv : the preprint server for health sciences JID - 101767986 UIN - Cell. 2022 Feb 3;185(3):485-492.e10. doi: 10.1016/j.cell.2021.12.027. PMID: 35051367 PMC - PMC8547534 EDAT- 2021/10/28 06:00 MHDA- 2021/10/28 06:01 PMCR- 2021/10/26 CRDT- 2021/10/27 07:15 PHST- 2021/10/27 07:15 [entrez] PHST- 2021/10/28 06:00 [pubmed] PHST- 2021/10/28 06:01 [medline] PHST- 2021/10/26 00:00 [pmc-release] AID - 2021.10.20.21265137 [pii] AID - 10.1101/2021.10.20.21265137 [doi] PST - epublish SO - medRxiv [Preprint]. 2021 Oct 20:2021.10.20.21265137. doi: 10.1101/2021.10.20.21265137. PMID- 34693584 OWN - NLM STAT- MEDLINE DCOM- 20220808 LR - 20251112 IS - 1365-2702 (Electronic) IS - 0962-1067 (Linking) VI - 31 IP - 17-18 DP - 2022 Sep TI - Dose-response association between nurse staffing and patient outcomes following major cancer surgeries using a nationwide inpatient database in Japan. PG - 2562-2573 LID - 10.1111/jocn.16075 [doi] AB - AIMS AND OBJECTIVES: To examine the non-linear dose-response associations between nurse staffing levels and patient outcomes using a nationwide inpatient database in Japan. BACKGROUND: Previous studies showed that higher nurse staffing levels were associated with better patient outcomes. However, it remains unclear whether there are thresholds for the associations between higher nurse staffing levels and improved patient outcomes. DESIGNS: Retrospective observational study design following the STROBE guideline. METHODS: We identified all patients aged >/=20 years who underwent one of six major cancer surgeries between July 2010 and March 2018 using data from the Diagnosis Procedure Combination database, a nationwide database for acute-care inpatients in Japan. Restricted cubic spline regression analyses, the statistical method that allows non-linear functional form, were performed with several scenarios of cut-off points to examine the dose-response associations between patient-to-nurse ratio per shift and failure to rescue, 30-day in-hospital mortality and postoperative complications. RESULTS: Among 645,687 patients, restricted cubic spline regression analyses showed insignificant associations of patient-to-nurse ratio with failure to rescue and 30-day in-hospital mortality with no threshold, but a reverse J-shaped association with postoperative complications with a threshold of patient-to-nurse ratio per shift of 5.4. CONCLUSIONS: In terms of postoperative complications, additional registered nurses were associated with decreased postoperative complications. However, this incremental benefit of additional registered nurses may disappear if hospitals allocate five to six number of registered nurses in general wards. RELEVANCE TO CLINICAL PRACTICE: This study suggested that additional registered nurses over one per five to six patients may not bring the incremental benefit to decrease postoperative complications. CI - (c) 2021 John Wiley & Sons Ltd. FAU - Hirose, Naoki AU - Hirose N AUID- ORCID: 0000-0002-4914-0763 AD - Department of Clinical Epidemiology and Health Economics, School of Public Health, The University of Tokyo, Tokyo, Japan. AD - Global Health Nursing, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan. FAU - Morita, Kojiro AU - Morita K AD - Global Nursing Research Center, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. FAU - Matsui, Hiroki AU - Matsui H AD - Department of Clinical Epidemiology and Health Economics, School of Public Health, The University of Tokyo, Tokyo, Japan. FAU - Fushimi, Kiyohide AU - Fushimi K AD - Department of Health Policy and Informatics, Tokyo Medical and Dental University Graduate School of Medicine, Tokyo, Japan. FAU - Yasunaga, Hideo AU - Yasunaga H AD - Department of Clinical Epidemiology and Health Economics, School of Public Health, The University of Tokyo, Tokyo, Japan. LA - eng GR - 20H03907/Ministry of Education, Culture, Sports, Science and Technology/ GR - 19AA2007/Ministry of Health, Labour and Welfare/ GR - 20AA2005/Ministry of Health, Labour and Welfare/ PT - Journal Article PT - Observational Study DEP - 20211024 PL - England TA - J Clin Nurs JT - Journal of clinical nursing JID - 9207302 MH - Humans MH - Inpatients MH - Japan MH - *Neoplasms/surgery MH - *Nursing Staff, Hospital MH - Outcome Assessment, Health Care MH - Personnel Staffing and Scheduling MH - Postoperative Complications/epidemiology MH - Retrospective Studies MH - Workforce OTO - NOTNLM OT - cancer surgeries OT - failure to rescue OT - in-hospital mortality OT - nurse staffing OT - postoperative complications EDAT- 2021/10/26 06:00 MHDA- 2022/08/09 06:00 CRDT- 2021/10/25 07:00 PHST- 2021/08/18 00:00 [revised] PHST- 2021/03/24 00:00 [received] PHST- 2021/09/21 00:00 [accepted] PHST- 2021/10/26 06:00 [pubmed] PHST- 2022/08/09 06:00 [medline] PHST- 2021/10/25 07:00 [entrez] AID - 10.1111/jocn.16075 [doi] PST - ppublish SO - J Clin Nurs. 2022 Sep;31(17-18):2562-2573. doi: 10.1111/jocn.16075. Epub 2021 Oct 24. PMID- 34693515 OWN - NLM STAT- MEDLINE DCOM- 20211124 LR - 20250623 IS - 1469-493X (Electronic) IS - 1361-6137 (Linking) VI - 10 IP - 10 DP - 2021 Oct 25 TI - Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis. PG - CD013650 LID - 10.1002/14651858.CD013650.pub2 [doi] LID - CD013650 AB - BACKGROUND: Cardiovascular disease (CVD) is a leading cause of death globally. Recently, dipeptidyl peptidase-4 inhibitors (DPP4i), glucagon-like peptide-1 receptor agonists (GLP-1RA) and sodium-glucose co-transporter-2 inhibitors (SGLT2i) were approved for treating people with type 2 diabetes mellitus. Although metformin remains the first-line pharmacotherapy for people with type 2 diabetes mellitus, a body of evidence has recently emerged indicating that DPP4i, GLP-1RA and SGLT2i may exert positive effects on patients with known CVD. OBJECTIVES: To systematically review the available evidence on the benefits and harms of DPP4i, GLP-1RA, and SGLT2i in people with established CVD, using network meta-analysis. SEARCH METHODS: We searched CENTRAL, MEDLINE, Embase, and the Conference Proceedings Citation Index on 16 July 2020. We also searched clinical trials registers on 22 August 2020. We did not restrict by language or publication status. SELECTION CRITERIA: We searched for randomised controlled trials (RCTs) investigating DPP4i, GLP-1RA, or SGLT2i that included participants with established CVD. Outcome measures of interest were CVD mortality, fatal and non-fatal myocardial infarction, fatal and non-fatal stroke, all-cause mortality, hospitalisation for heart failure (HF), and safety outcomes. DATA COLLECTION AND ANALYSIS: Three review authors independently screened the results of searches to identify eligible studies and extracted study data. We used the GRADE approach to assess the certainty of the evidence. We conducted standard pairwise meta-analyses and network meta-analyses by pooling studies that we assessed to be of substantial homogeneity; subgroup and sensitivity analyses were also pursued to explore how study characteristics and potential effect modifiers could affect the robustness of our review findings. We analysed study data using the odds ratios (ORs) and log odds ratios (LORs) with their respective 95% confidence intervals (CIs) and credible intervals (Crls), where appropriate. We also performed narrative synthesis for included studies that were of substantial heterogeneity and that did not report quantitative data in a usable format, in order to discuss their individual findings and relevance to our review scope. MAIN RESULTS: We included 31 studies (287 records), of which we pooled data from 20 studies (129,465 participants) for our meta-analysis. The majority of the included studies were at low risk of bias, using Cochrane's tool for assessing risk of bias. Among the 20 pooled studies, six investigated DPP4i, seven studied GLP-1RA, and the remaining seven trials evaluated SGLT2i. All outcome data described below were reported at the longest follow-up duration. 1. DPP4i versus placebo Our review suggests that DPP4i do not reduce any risk of efficacy outcomes: CVD mortality (OR 1.00, 95% CI 0.91 to 1.09; high-certainty evidence), myocardial infarction (OR 0.97, 95% CI 0.88 to 1.08; high-certainty evidence), stroke (OR 1.00, 95% CI 0.87 to 1.14; high-certainty evidence), and all-cause mortality (OR 1.03, 95% CI 0.96 to 1.11; high-certainty evidence). DPP4i probably do not reduce hospitalisation for HF (OR 0.99, 95% CI 0.80 to 1.23; moderate-certainty evidence). DPP4i may not increase the likelihood of worsening renal function (OR 1.08, 95% CI 0.88 to 1.33; low-certainty evidence) and probably do not increase the risk of bone fracture (OR 1.00, 95% CI 0.83 to 1.19; moderate-certainty evidence) or hypoglycaemia (OR 1.11, 95% CI 0.95 to 1.29; moderate-certainty evidence). They are likely to increase the risk of pancreatitis (OR 1.63, 95% CI 1.12 to 2.37; moderate-certainty evidence). 2. GLP-1RA versus placebo Our findings indicate that GLP-1RA reduce the risk of CV mortality (OR 0.87, 95% CI 0.79 to 0.95; high-certainty evidence), all-cause mortality (OR 0.88, 95% CI 0.82 to 0.95; high-certainty evidence), and stroke (OR 0.87, 95% CI 0.77 to 0.98; high-certainty evidence). GLP-1RA probably do not reduce the risk of myocardial infarction (OR 0.89, 95% CI 0.78 to 1.01; moderate-certainty evidence), and hospitalisation for HF (OR 0.95, 95% CI 0.85 to 1.06; high-certainty evidence). GLP-1RA may reduce the risk of worsening renal function (OR 0.61, 95% CI 0.44 to 0.84; low-certainty evidence), but may have no impact on pancreatitis (OR 0.96, 95% CI 0.68 to 1.35; low-certainty evidence). We are uncertain about the effect of GLP-1RA on hypoglycaemia and bone fractures. 3. SGLT2i versus placebo This review shows that SGLT2i probably reduce the risk of CV mortality (OR 0.82, 95% CI 0.70 to 0.95; moderate-certainty evidence), all-cause mortality (OR 0.84, 95% CI 0.74 to 0.96; moderate-certainty evidence), and reduce the risk of HF hospitalisation (OR 0.65, 95% CI 0.59 to 0.71; high-certainty evidence); they do not reduce the risk of myocardial infarction (OR 0.97, 95% CI 0.84 to 1.12; high-certainty evidence) and probably do not reduce the risk of stroke (OR 1.12, 95% CI 0.92 to 1.36; moderate-certainty evidence). In terms of treatment safety, SGLT2i probably reduce the incidence of worsening renal function (OR 0.59, 95% CI 0.43 to 0.82; moderate-certainty evidence), and probably have no effect on hypoglycaemia (OR 0.90, 95% CI 0.75 to 1.07; moderate-certainty evidence) or bone fracture (OR 1.02, 95% CI 0.88 to 1.18; high-certainty evidence), and may have no impact on pancreatitis (OR 0.85, 95% CI 0.39 to 1.86; low-certainty evidence). 4. Network meta-analysis Because we failed to identify direct comparisons between each class of the agents, findings from our network meta-analysis provided limited novel insights. Almost all findings from our network meta-analysis agree with those from the standard meta-analysis. GLP-1RA may not reduce the risk of stroke compared with placebo (OR 0.87, 95% CrI 0.75 to 1.0; moderate-certainty evidence), which showed similar odds estimates and wider 95% Crl compared with standard pairwise meta-analysis. Indirect estimates also supported comparison across all three classes. SGLT2i was ranked the best for CVD and all-cause mortality. AUTHORS' CONCLUSIONS: Findings from both standard and network meta-analyses of moderate- to high-certainty evidence suggest that GLP-1RA and SGLT2i are likely to reduce the risk of CVD mortality and all-cause mortality in people with established CVD; high-certainty evidence demonstrates that treatment with SGLT2i reduce the risk of hospitalisation for HF, while moderate-certainty evidence likely supports the use of GLP-1RA to reduce fatal and non-fatal stroke. Future studies conducted in the non-diabetic CVD population will reveal the mechanisms behind how these agents improve clinical outcomes irrespective of their glucose-lowering effects. CI - Copyright (c) 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. FAU - Kanie, Takayoshi AU - Kanie T AD - Department of Cardiology, St. Luke's International Hospital, Tokyo, Japan. FAU - Mizuno, Atsushi AU - Mizuno A AD - Department of Cardiology, St. Luke's International Hospital, Tokyo, Japan. AD - Penn Medicine Nudge Unit, University of Pennsylvania Philadelphia, Philadelphia, PA, USA. AD - Leonard Davis Institute for Health Economics, University of Pennsylvania, Philadelphia, PA, USA. AD - Division of Cardiovascular Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, USA. FAU - Takaoka, Yoshimitsu AU - Takaoka Y AD - Department of Cardiology, St. Luke's International Hospital, Tokyo, Japan. FAU - Suzuki, Takahiro AU - Suzuki T AD - Department of Cardiology, St. Luke's International Hospital, Tokyo, Japan. FAU - Yoneoka, Daisuke AU - Yoneoka D AD - Division of Biostatistics and Bioinformatics, Graduate School of Public Health, St. Luke's International University, Tokyo, Japan. FAU - Nishikawa, Yuri AU - Nishikawa Y AD - Department of Gerontological Nursing and Healthcare Systems Management, Graduate School of Health Care Sciences, Tokyo Medical and Dental University, Tokyo, Japan. AD - Department of Gerontological Nursing, Kyorin University, Tokyo, Japan. FAU - Tam, Wilson Wai San AU - Tam WWS AD - Alice Lee Center for Nursing Studies, NUS Yong Loo Lin School of Medicine, Singapore, Singapore. FAU - Morze, Jakub AU - Morze J AD - Department of Human Nutrition, University of Warmia and Mazury, Olsztyn, Poland. FAU - Rynkiewicz, Andrzej AU - Rynkiewicz A AD - Department of Cardiology and Cardiosurgery, School of Medicine, University of Warmia and Mazury, Olsztyn, Poland. FAU - Xin, Yiqiao AU - Xin Y AD - Health Economics and Health Technology Assessment (HEHTA), Institute of Health and Wellbeing, University of Glasgow, Glasgow, UK. FAU - Wu, Olivia AU - Wu O AD - Health Economics and Health Technology Assessment (HEHTA), Institute of Health and Wellbeing, University of Glasgow, Glasgow, UK. FAU - Providencia, Rui AU - Providencia R AD - Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK. FAU - Kwong, Joey Sw AU - Kwong JS AD - Global Health Nursing, Graduate School of Nursing Science, St. Luke's International University, Tokyo, Japan. LA - eng SI - ClinicalTrials.gov/NCT03619213 SI - ClinicalTrials.gov/NCT03087773 SI - ClinicalTrials.gov/NCT03485222 SI - ClinicalTrials.gov/NCT03057951 SI - ClinicalTrials.gov/NCT04146155 SI - ClinicalTrials.gov/NCT02917031 SI - ClinicalTrials.gov/NCT02397421 SI - ClinicalTrials.gov/NCT03574597 SI - ClinicalTrials.gov/NCT03485092 PT - Journal Article PT - Network Meta-Analysis PT - Research Support, Non-U.S. Gov't PT - Systematic Review DEP - 20211025 PL - England TA - Cochrane Database Syst Rev JT - The Cochrane database of systematic reviews JID - 100909747 RN - 0 (Dipeptidyl-Peptidase IV Inhibitors) RN - 0 (Sodium-Glucose Transporter 2 Inhibitors) RN - 0 (Symporters) RN - 89750-14-1 (Glucagon-Like Peptide 1) RN - 9NEZ333N27 (Sodium) RN - EC 3.4.14.- (Dipeptidyl-Peptidases and Tripeptidyl-Peptidases) RN - IY9XDZ35W2 (Glucose) SB - IM CIN - Ann Intern Med. 2022 Mar;175(3):JC26. doi: 10.7326/J22-0003. PMID: 35226528 CIN - Am Fam Physician. 2022 Jul;106(1):24-25. PMID: 35839371 MH - *Cardiovascular Diseases MH - *Dipeptidyl-Peptidase IV Inhibitors/adverse effects MH - Dipeptidyl-Peptidases and Tripeptidyl-Peptidases MH - Glucagon-Like Peptide 1 MH - Glucose MH - Humans MH - Sodium MH - *Sodium-Glucose Transporter 2 Inhibitors/adverse effects MH - *Symporters PMC - PMC8812344 COIS- TK declares having no conflicts of interest. AM declares having no conflicts of interest. YT declares having no conflicts of interest. TS declares having no conflicts of interest. DY declares having no conflicts of interest. YN declares having no conflicts of interest. WWST declares having no conflicts of interest. JM declares having no conflicts of interest. AR has previously received honoraria for speaking and consultancy from Boehringer Ingelheim in Poland. YX declares having no conflicts of interest. OW: The CRSU is a support unit funded by NIHR to provide methodological advice to NIHR-funded evidence synthesis research. It is within the CRSU's remit to support Cochrane Reviews with research questions that are relevant to UK NHS patients. OW is the Director of the CRSU. OW also declares a research grant from Novo Nordisk (2017-2018), received via their institution, for a study to estimate the incidence and the economic burden of cardiovascular events in type 2 diabetes mellitus in Scotland, using routine linked health data. RP declares having no conflicts of interest. JSWK declares having no conflicts of interest. EDAT- 2021/10/26 06:00 MHDA- 2021/11/25 06:00 PMCR- 2022/10/25 CRDT- 2021/10/25 06:54 PHST- 2021/10/25 06:54 [entrez] PHST- 2021/10/26 06:00 [pubmed] PHST- 2021/11/25 06:00 [medline] PHST- 2022/10/25 00:00 [pmc-release] AID - CD013650.pub2 [pii] AID - 10.1002/14651858.CD013650.pub2 [doi] PST - epublish SO - Cochrane Database Syst Rev. 2021 Oct 25;10(10):CD013650. doi: 10.1002/14651858.CD013650.pub2. PMID- 34682423 OWN - NLM STAT- MEDLINE DCOM- 20211028 LR - 20240403 IS - 1660-4601 (Electronic) IS - 1661-7827 (Print) IS - 1660-4601 (Linking) VI - 18 IP - 20 DP - 2021 Oct 12 TI - Are Sleep Problems Related to Psychological Distress in Healthy Aging during the COVID-19 Pandemic? A Review. LID - 10.3390/ijerph182010676 [doi] LID - 10676 AB - The SARS-CoV-2 pandemic, characterized by home confinement and other restrictive measures to reduce the spread of the infection, led to significant changes in people's habits and lifestyle. One of the most common problems is the worsening of sleep quality or quantity, which could have negative effects on psychological wellbeing, particularly in older adults. The purposes of the present literature review considering healthy aging subjects are (a) to examine the existing research on sleep alterations during the current pandemic and (b) to highlight possible relationships between sleep problems and psychological distress. A systematic search strategy was implemented according to PRISMA guidelines in the international literature online databases, up to 1 July 2021. After identification and screening phases, 11 articles were included in this review. The studies found possible associations between sleep problems and mood changes-particularly in terms of depression and anxiety. In addition, altered sleep patterns seemed to be related to changes in individual aspects, lifestyle, and attitudes adopted by older adults during the COVID-19 lockdown. Thus, the pandemic could affect the sleep and psychological wellbeing of the older population, even in healthy aging. FAU - Cipriani, Giuseppina Elena AU - Cipriani GE AD - Department of Psychology, University of Turin, 10124 Turin, Italy. FAU - Bartoli, Massimo AU - Bartoli M AD - Department of Psychology, University of Turin, 10124 Turin, Italy. FAU - Amanzio, Martina AU - Amanzio M AD - Department of Psychology, University of Turin, 10124 Turin, Italy. LA - eng GR - 66346/The Fondazione CRT - Cassa di Risparmio di Torino, IT, "GAIA-MENTE" 2019/ PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review DEP - 20211012 PL - Switzerland TA - Int J Environ Res Public Health JT - International journal of environmental research and public health JID - 101238455 SB - IM MH - Aged MH - Anxiety MH - *COVID-19 MH - Communicable Disease Control MH - Depression/epidemiology MH - *Healthy Aging MH - Humans MH - Pandemics MH - *Psychological Distress MH - SARS-CoV-2 MH - Sleep MH - *Sleep Wake Disorders/epidemiology PMC - PMC8536178 OTO - NOTNLM OT - COVID-19 pandemic OT - SARS-CoV-2 OT - anxiety OT - cognitive decline OT - depressive symptoms OT - healthy aging OT - psychological distress OT - sleep problems COIS- The authors declare no conflict of interest. EDAT- 2021/10/24 06:00 MHDA- 2021/10/29 06:00 PMCR- 2021/10/12 CRDT- 2021/10/23 01:11 PHST- 2021/09/21 00:00 [received] PHST- 2021/10/06 00:00 [accepted] PHST- 2021/10/23 01:11 [entrez] PHST- 2021/10/24 06:00 [pubmed] PHST- 2021/10/29 06:00 [medline] PHST- 2021/10/12 00:00 [pmc-release] AID - ijerph182010676 [pii] AID - ijerph-18-10676 [pii] AID - 10.3390/ijerph182010676 [doi] PST - epublish SO - Int J Environ Res Public Health. 2021 Oct 12;18(20):10676. doi: 10.3390/ijerph182010676. PMID- 34678576 OWN - NLM STAT- MEDLINE DCOM- 20220308 LR - 20220308 IS - 1878-0334 (Electronic) IS - 1871-4021 (Linking) VI - 15 IP - 6 DP - 2021 Nov-Dec TI - Effect of saffron supplementation on liver enzymes: A systematic review and meta-analysis of randomized controlled trials. PG - 102311 LID - S1871-4021(21)00331-3 [pii] LID - 10.1016/j.dsx.2021.102311 [doi] AB - BACKGROUND AND AIMS: Possible protective effects of saffron (Crocus sativus L) have been reported in several randomized clinical trials (RCTs). Current systematic review was performed to summarize the efficacy of saffron intake on liver enzymes. METHODS: An electronic database search was conducted on PubMed/Medline, Scopus, Web of Science, and Cochrane for RCTs comparing effect of saffron and placebo on liver enzymes from inception to July 2021. There was no restriction in language of included studies and we calculated the standardized mean difference (SMD) and 95% Confidence Intervals (CI) for each variable. Random-effect model was used to calculate effect size. RESULTS: Eight studies (n = 463 participants) were included in the systematic review. The saffron intake was associated with a statistically significant decrease in aspartate aminotransferase (AST) (SMD: -0.18; 95% CI: -0.34, -0.02; I(2) = 0%) in comparison to placebo intake. Our results also indicated that saffron consumption did not have a significant effect on alanine aminotransferase (ALT) (SMD: -0.14; 95% CI: -0.36, 0.09; I(2) = 47.0%) and alkaline phosphatase (ALP) levels (SMD: 0.14; 95% CI: -0.18, 0.46; I(2) = 42.9%) compared to placebo. CONCLUSIONS: Saffron intake showed beneficial impacts on circulating AST levels. However, larger well-designed RCTs are still needed to clarify the effect of saffron intake on these and other liver enzymes. CI - Copyright (c) 2021 Diabetes India. Published by Elsevier Ltd. All rights reserved. FAU - Hasani, Motahareh AU - Hasani M AD - Department of Nutrition, School of Public Health, Iran University of Medical Sciences, Tehran, Iran. FAU - Malekahmadi, Mahsa AU - Malekahmadi M AD - Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran; Department of Clinical Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran, Iran. FAU - Rezamand, Gholamreza AU - Rezamand G AD - Colorectal Research Center, Iran University of Medical Sciences, Tehran, Iran. FAU - Estevao, M Dulce AU - Estevao MD AD - Universidade do Algarve, Escola Superior de Saude, Campus de Gambelas, Faro, Portugal. Electronic address: mestevao@ualg.pt. FAU - Pizarro, Ana Beatriz AU - Pizarro AB AD - Clinical Research Center, Fundacion Valle del Lili, Cali, Colombia. Electronic address: a.pizarro@javeriana.edu.co. FAU - Heydari, Hafez AU - Heydari H AD - Cellular and Molecular Research Center, Sabzevar University of Medical Sciences, Sabzevar, Iran. Electronic address: Hafez1362@gmail.com. FAU - Hoong, Wong Chun AU - Hoong WC AD - Department of Pharmacy, Sultanah Aminah Hospital, Johor Bahru, Johor, Malaysia. Electronic address: ljun3251@hotmail.com. FAU - Arafah, Omar Ahnaf AU - Arafah OA AD - College of Medicine, Alfaisal University, Riyadh, Saudi Arabia. Electronic address: o_arafah@hotmail.com. FAU - Barakeh, Abdul Rahman Riad AU - Barakeh ARR AD - College of Medicine, Alfaisal University, Riyadh, Saudi Arabia. Electronic address: A.R.R.Barakeh@gmail.com. FAU - Rahman, Areej AU - Rahman A AD - College of Medicine, Alfaisal University, Riyadh, Saudi Arabia. Electronic address: Reej2121994@gmail.com. FAU - Alrashidi, Mona Saud K AU - Alrashidi MSK AD - Department of Family Medicine, National Guard Hospital, Jeddah, Saudi Arabia. FAU - Abu-Zaid, Ahmed AU - Abu-Zaid A AD - College of Medicine, Alfaisal University, Riyadh, Saudi Arabia; Department of Pharmacology, College of Graduate Health Sciences, University of Tennessee Health Science Center, Memphis, TN, United States. Electronic address: aabuzaid@live.com. LA - eng PT - Journal Article PT - Meta-Analysis PT - Systematic Review DEP - 20211012 PL - Netherlands TA - Diabetes Metab Syndr JT - Diabetes & metabolic syndrome JID - 101462250 RN - 0 (Anti-Inflammatory Agents) RN - 0 (Antioxidants) RN - EC 2.6.1.1 (Aspartate Aminotransferases) RN - EC 2.6.1.2 (Alanine Transaminase) SB - IM MH - Alanine Transaminase/antagonists & inhibitors/blood MH - Anti-Inflammatory Agents/administration & dosage MH - Antioxidants/administration & dosage MH - Aspartate Aminotransferases/*antagonists & inhibitors/blood MH - *Crocus MH - *Dietary Supplements MH - Humans MH - Liver/*drug effects/*enzymology MH - Randomized Controlled Trials as Topic/*methods OTO - NOTNLM OT - Alanine aminotransferase OT - Alkaline phosphatase OT - Aspartate aminotransferase OT - Crocus OT - Saffron COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2021/10/23 06:00 MHDA- 2022/03/09 06:00 CRDT- 2021/10/22 20:39 PHST- 2021/06/15 00:00 [received] PHST- 2021/09/13 00:00 [revised] PHST- 2021/10/08 00:00 [accepted] PHST- 2021/10/23 06:00 [pubmed] PHST- 2022/03/09 06:00 [medline] PHST- 2021/10/22 20:39 [entrez] AID - S1871-4021(21)00331-3 [pii] AID - 10.1016/j.dsx.2021.102311 [doi] PST - ppublish SO - Diabetes Metab Syndr. 2021 Nov-Dec;15(6):102311. doi: 10.1016/j.dsx.2021.102311. Epub 2021 Oct 12. PMID- 34674741 OWN - NLM STAT- MEDLINE DCOM- 20211025 LR - 20220224 IS - 1745-6215 (Electronic) IS - 1745-6215 (Linking) VI - 22 IP - 1 DP - 2021 Oct 21 TI - The 4MOTHERS trial of the impact of a mobile money-based intervention on maternal and neonatal health outcomes in Madagascar: study protocol of a cluster-randomized hybrid effectiveness-implementation trial. PG - 725 LID - 10.1186/s13063-021-05694-8 [doi] LID - 725 AB - BACKGROUND: Mobile money-a service enabling users to receive, store, and send electronic money using mobile phones-has been widely adopted across low- and middle-income economies to pay for a variety of services, including healthcare. However, evidence on its effects on healthcare access and health outcomes are scarce and the possible implications of using mobile money for financing and payment of maternal healthcare services-which generally require large one-time out-of-pocket payments-have not yet been systematically assessed in low-resource settings. The aim of this study is to determine the impact on health outcomes, cost-effectiveness, feasibility, acceptability, and usefulness of mobile phone-based savings and payment service, the Mobile Maternal Health Wallet (MMHW), for skilled healthcare during pregnancy and delivery among women in Madagascar. METHODS: This is a hybrid effectiveness-implementation type-1 trial, determining the effectiveness of the intervention while evaluating the context of its implementation in Madagascar's Analamanga region, containing the capital, Antananarivo. Using a stratified cluster randomized design, 61 public-sector primary-care health facilities were randomized within 6 strata to either receive the intervention or not (29 intervention vs. 32 control facilities). The strata were defined by a health facility's antenatal care visit volume and its capacity to offer facility-based deliveries. The registered pre-specified primary outcomes are (i) delivery at a health facility, (ii) antenatal care visits, and (iii) total healthcare expenditure during pregnancy, delivery, and neonatal period. The registered pre-specified secondary outcomes include additional health outcomes, economic outcomes, and measurements of user experience and satisfaction. Our estimated enrolment number is 4600 women, who completed their pregnancy between July 1, 2020, and December 31, 2021. A series of nested mixed-methods studies will elucidate client and provider perceptions on feasibility, acceptability, and usefulness of the intervention to inform future implementation efforts. DISCUSSION: A cluster-randomized, hybrid effectiveness-implementation design allows for a robust approach to determine whether the MMHW is a feasible and beneficial intervention in a resource-restricted public healthcare environment. We expect the results of our study to guide future initiatives and health policy decisions related to maternal and neonatal health and universal healthcare coverage through technology in Madagascar and other countries in sub-Saharan Africa. TRIAL REGISTRATION: This trial was registered on March 12, 2021: Deutsches Register Klinischer Studien (German Clinical Trials Register), identifier: DRKS00014928 . For World Health Organization Trial Registration Data Set see Additional file 1. CI - (c) 2021. The Author(s). FAU - Lacroze, Etienne AU - Lacroze E AD - Heidelberg Institute of Global Health, Medical Faculty and University Hospital, University of Heidelberg, Heidelberg, Germany. AD - Global Digital Health Lab, Charite - Universitatsmedizin Berlin, Berlin, Germany. FAU - Barnighausen, Till AU - Barnighausen T AD - Heidelberg Institute of Global Health, Medical Faculty and University Hospital, University of Heidelberg, Heidelberg, Germany. AD - Department of Global Health and Population, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA. AD - Africa Health Research Institute (AHRI), Mtubatuba, KwaZulu-Natal, South Africa. FAU - De Neve, Jan Walter AU - De Neve JW AD - Heidelberg Institute of Global Health, Medical Faculty and University Hospital, University of Heidelberg, Heidelberg, Germany. FAU - Vollmer, Sebastian AU - Vollmer S AD - Department of Global Health and Population, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA. AD - Department of Economics and Centre for Modern Indian Studies, University of Gottingen, Gottingen, Germany. FAU - Ratsimbazafy, Rolland Marie AU - Ratsimbazafy RM AD - National Institute of Public and Community Health, Antananarivo, Madagascar. FAU - Emmrich, Peter Martin Ferdinand AU - Emmrich PMF AD - John Innes Centre, Norwich, UK. FAU - Muller, Nadine AU - Muller N AD - Heidelberg Institute of Global Health, Medical Faculty and University Hospital, University of Heidelberg, Heidelberg, Germany. AD - Department of Infectious Diseases and Respiratory Medicine, Charite - Universitatsmedizin Berlin, Berlin, Germany. FAU - Rajemison, Elsa AU - Rajemison E AD - Heidelberg Institute of Global Health, Medical Faculty and University Hospital, University of Heidelberg, Heidelberg, Germany. AD - Global Digital Health Lab, Charite - Universitatsmedizin Berlin, Berlin, Germany. FAU - Rampanjato, Zavaniarivo AU - Rampanjato Z AD - Heidelberg Institute of Global Health, Medical Faculty and University Hospital, University of Heidelberg, Heidelberg, Germany. AD - Ministry of Public Health of the Republic of Madagascar, Antananarivo, Madagascar. FAU - Ratsiambakaina, Diana AU - Ratsiambakaina D AD - Ministry of Public Health of the Republic of Madagascar, Antananarivo, Madagascar. FAU - Knauss, Samuel AU - Knauss S AD - Heidelberg Institute of Global Health, Medical Faculty and University Hospital, University of Heidelberg, Heidelberg, Germany. AD - Global Digital Health Lab, Charite - Universitatsmedizin Berlin, Berlin, Germany. AD - Charite Global Health and Department of Experimental Neurology and Center for Stroke Research, Charite - Universitatsmedizin Berlin, Chariteplatz 1, 10117, Berlin, Germany. AD - Berlin Institute of Health, Berlin, Germany. FAU - Emmrich, Julius Valentin AU - Emmrich JV AUID- ORCID: 0000-0002-3393-0840 AD - Heidelberg Institute of Global Health, Medical Faculty and University Hospital, University of Heidelberg, Heidelberg, Germany. julius.emmrich@charite.de. AD - Global Digital Health Lab, Charite - Universitatsmedizin Berlin, Berlin, Germany. julius.emmrich@charite.de. AD - Charite Global Health and Department of Experimental Neurology and Center for Stroke Research, Charite - Universitatsmedizin Berlin, Chariteplatz 1, 10117, Berlin, Germany. julius.emmrich@charite.de. AD - Berlin Institute of Health, Berlin, Germany. julius.emmrich@charite.de. LA - eng GR - Afresi-016/Bundesministerium fur Bildung und Forschung/ PT - Journal Article DEP - 20211021 PL - England TA - Trials JT - Trials JID - 101263253 SB - IM MH - *Cell Phone MH - Female MH - Humans MH - Infant, Newborn MH - Madagascar MH - *Maternal Health Services MH - Outcome Assessment, Health Care MH - Pregnancy MH - Prenatal Care PMC - PMC8529568 OTO - NOTNLM OT - Digital health OT - Maternal OT - Mobile payment OT - Out-of-pocket payments OT - Randomized trial OT - Sub-Saharan Africa OT - Universal health coverage COIS- The authors declare that they have no competing interests. EDAT- 2021/10/23 06:00 MHDA- 2021/10/26 06:00 PMCR- 2021/10/21 CRDT- 2021/10/22 05:35 PHST- 2021/03/22 00:00 [received] PHST- 2021/10/07 00:00 [accepted] PHST- 2021/10/22 05:35 [entrez] PHST- 2021/10/23 06:00 [pubmed] PHST- 2021/10/26 06:00 [medline] PHST- 2021/10/21 00:00 [pmc-release] AID - 10.1186/s13063-021-05694-8 [pii] AID - 5694 [pii] AID - 10.1186/s13063-021-05694-8 [doi] PST - epublish SO - Trials. 2021 Oct 21;22(1):725. doi: 10.1186/s13063-021-05694-8. PMID- 34663652 OWN - NLM STAT- MEDLINE DCOM- 20211029 LR - 20250623 IS - 2044-6055 (Electronic) IS - 2044-6055 (Linking) VI - 11 IP - 10 DP - 2021 Oct 18 TI - A rapid systematic review of measures to protect older people in long-term care facilities from COVID-19. PG - e047012 LID - 10.1136/bmjopen-2020-047012 [doi] LID - e047012 AB - OBJECTIVES: The global COVID-19 pandemic produced large-scale health and economic complications. Older people and those with comorbidities are particularly vulnerable to this virus, with nursing homes and long term care facilities (LTCF) experiencing significant morbidity and mortality associated with COVID-19 outbreaks. The aim of this rapid systematic review was to investigate measures implemented in LTCF to reduce transmission of COVID-19 and their effect on morbidity and mortality of residents, staff and visitors. SETTING: Long-term care facilities. PARTICIPANTS: Residents, staff and visitors of facilities. PRIMARY AND SECONDARY OUTCOME MEASURES: Databases (PubMed, EMBASE, CINAHL, Cochrane Databases and repositories and MedRXiv prepublished database) were systematically searched from inception to 27 July 2020 to identify studies reporting assessment of interventions to reduce transmission of COVID-19 in nursing homes among residents, staff or visitors. Outcome measures include facility characteristics, morbidity data, case fatalities and transmission rates. Due to study quality and heterogeneity, no meta-analysis was conducted. RESULTS: The search yielded 1414 articles, with 38 studies included. Reported interventions include mass testing, use of personal protective equipment, symptom screening, visitor restrictions, hand hygiene and droplet/contact precautions, and resident cohorting. Prevalence rates ranged from 1.2% to 85.4% in residents and 0.6% to 62.6% in staff. Mortality rates ranged from 5.3% to 55.3% in residents. CONCLUSIONS: Novel evidence in this review details the impact of facility size, availability of staff and practices of operating between multiple facilities, and for-profit status of facilities as factors contributing to the size and number of COVID-19 outbreaks. No causative relationships can be determined; however, this review provides evidence of interventions that reduce transmission of COVID-19 in LTCF. PROSPERO REGISTRATION NUMBER: CRD42020191569. CI - (c) Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. FAU - Frazer, Kate AU - Frazer K AUID- ORCID: 0000-0002-6703-266X AD - School of Nursing, Midwifery and Health Systems, University College Dublin, Dublin, Ireland. FAU - Mitchell, Lachlan AU - Mitchell L AUID- ORCID: 0000-0003-1316-3688 AD - National Nutrition Surveillance Centre, University College Dublin, Dublin, Ireland lachlan.mitchell@ucd.ie. AD - School of Public Health, Physiotherapy and Sport Science, University College Dublin, Dublin, Ireland. FAU - Stokes, Diarmuid AU - Stokes D AD - Health Sciences Library, University College Dublin, Dublin, Ireland. FAU - Lacey, Ella AU - Lacey E AD - School of Medicine, University College Dublin, Dublin, Ireland. FAU - Crowley, Eibhlin AU - Crowley E AD - Office for Health Affairs, College of Health and Agricultural Science, University College Dublin, Dublin, Ireland. FAU - Kelleher, Cecily C AU - Kelleher CC AD - National Nutrition Surveillance Centre, University College Dublin, Dublin, Ireland. AD - School of Public Health, Physiotherapy and Sport Science, University College Dublin, Dublin, Ireland. LA - eng PT - Journal Article PT - Systematic Review DEP - 20211018 PL - England TA - BMJ Open JT - BMJ open JID - 101552874 SB - IM MH - Aged MH - *COVID-19 MH - Humans MH - Long-Term Care MH - Nursing Homes MH - Pandemics MH - SARS-CoV-2 PMC - PMC8523961 OTO - NOTNLM OT - COVID-19 OT - geriatric medicine OT - public health COIS- Competing interests: CCK was a member of an expert panel investigating COVID-19 in nursing homes in Ireland. EDAT- 2021/10/20 06:00 MHDA- 2021/10/30 06:00 PMCR- 2021/10/17 CRDT- 2021/10/19 05:54 PHST- 2021/10/19 05:54 [entrez] PHST- 2021/10/20 06:00 [pubmed] PHST- 2021/10/30 06:00 [medline] PHST- 2021/10/17 00:00 [pmc-release] AID - bmjopen-2020-047012 [pii] AID - 10.1136/bmjopen-2020-047012 [doi] PST - epublish SO - BMJ Open. 2021 Oct 18;11(10):e047012. doi: 10.1136/bmjopen-2020-047012. PMID- 34635077 OWN - NLM STAT- MEDLINE DCOM- 20211015 LR - 20211015 IS - 1471-2458 (Electronic) IS - 1471-2458 (Linking) VI - 21 IP - 1 DP - 2021 Oct 12 TI - A multicenter study of short-term changes in mental health emergency services use during lockdown in Kitchener-Waterloo, Ontario during the COVID-19 pandemic. PG - 1840 LID - 10.1186/s12889-021-11807-4 [doi] LID - 1840 AB - BACKGROUND: The COVID-19 pandemic and subsequent lockdown measures have led to increasing mental health concerns in the general population. We aimed to assess the short-term impact of the pandemic lockdown on mental health emergency services use in the Kitchener-Waterloo region of Ontario, Canada. METHODS: We conducted an observational study during the 6-month period between March 5 and September 5, 2020 using National Ambulatory Care Reporting System metadata from mental health visits to three regional Emergency Departments (ED); mental health and substance related police calls; and calls to a regional mental health crisis telephone line, comparing volumes during the pandemic lockdown with the same period in 2019. Quasi-Poisson regressions were used to determine significant differences between numbers of each visit or call type during the lockdown period versus the previous year. Significant changes in ED visits, mental health diagnoses, police responses, and calls to the crisis line from March 5 to September 5, 2020 were examined using changepoint analyses. RESULTS: Involuntary admissions, substance related visits, mood related visits, situational crisis visits, and self-harm related mental health visits to the EDs were significantly reduced during the lockdown period compared to the year before. Psychosis-related and alcohol-related visits were not significantly reduced. Among police calls, suicide attempts were significantly decreased during the period of lockdown, but intoxication, assault, and domestic disputes were not significantly different. Mental health crisis telephone calls were significantly decreased during the lockdown period. There was a significant increase in weekly mental health diagnoses starting in the week of July 12 - July 18. There was a significant increase in crisis calls starting in the week of May 31 - June 6, the same week that many guidelines, such as gathering restrictions, were eased. There was a significant increase in weekly police responses starting in the week of June 14 - June 20. CONCLUSIONS: Contrary to our hypothesis, the decrease in most types of mental health ED visits, mental health and substance-related police calls, and mental health crisis calls largely mirrored the overall decline in emergency services usage during the lockdown period. This finding is unexpected in the context of increased attention to acutely deteriorating mental health during the COVID-19 pandemic. CI - (c) 2021. The Author(s). FAU - Dainton, Christopher AU - Dainton C AD - McMaster University, 1280 Main Street W., Hamilton, Ontario, 835 King St. West, Kitchener, ON, Canada. Christopher.dainton@gmail.com. AD - Grand River Hospital, 835 King St. West, Kitchener, Ontario, N2G 1G3, Canada. Christopher.dainton@gmail.com. FAU - Donato-Woodger, Simon AU - Donato-Woodger S AD - Grand River Hospital, 835 King St. West, Kitchener, Ontario, N2G 1G3, Canada. FAU - Chu, Charlene H AU - Chu CH AD - Lawrence S. Bloomberg Faculty of Nursing, University of Toronto, 155 College Street Suite 130, Toronto, ON, M5T 1P8, Canada. AD - Toronto Rehabilitation Institute, University Health Network, 550 University Ave, Toronto, Ontario, M5G 2A2, Canada. LA - eng PT - Journal Article PT - Multicenter Study PT - Observational Study DEP - 20211012 PL - England TA - BMC Public Health JT - BMC public health JID - 100968562 SB - IM MH - *COVID-19 MH - Communicable Disease Control MH - Emergency Service, Hospital MH - Humans MH - Mental Health MH - Ontario/epidemiology MH - *Pandemics MH - SARS-CoV-2 PMC - PMC8505015 OTO - NOTNLM OT - COVID-19 OT - Lockdown OT - Pandemic OT - Psychiatric emergency COIS- The authors declare that they have no competing interests. EDAT- 2021/10/13 06:00 MHDA- 2021/10/16 06:00 PMCR- 2021/10/12 CRDT- 2021/10/12 05:34 PHST- 2021/09/07 00:00 [received] PHST- 2021/09/15 00:00 [accepted] PHST- 2021/10/12 05:34 [entrez] PHST- 2021/10/13 06:00 [pubmed] PHST- 2021/10/16 06:00 [medline] PHST- 2021/10/12 00:00 [pmc-release] AID - 10.1186/s12889-021-11807-4 [pii] AID - 11807 [pii] AID - 10.1186/s12889-021-11807-4 [doi] PST - epublish SO - BMC Public Health. 2021 Oct 12;21(1):1840. doi: 10.1186/s12889-021-11807-4. PMID- 34625992 OWN - NLM STAT- MEDLINE DCOM- 20220818 LR - 20250728 IS - 1471-6712 (Electronic) IS - 0283-9318 (Print) IS - 0283-9318 (Linking) VI - 36 IP - 3 DP - 2022 Sep TI - Dignity reflections based on experiences of end-of-life care during the first wave of the COVID-19 pandemic: A qualitative inquiry among bereaved relatives in the Netherlands (the CO-LIVE study). PG - 769-781 LID - 10.1111/scs.13038 [doi] AB - BACKGROUND: The COVID-19 pandemic affects care practices for critically ill patients, with or without a COVID-19 infection, and may have affected the experience of dying for patients and their relatives in the physical, psychological, social and spiritual domains. AIM: To give insight into aspects of end-of-life care practices that might have jeopardised or supported the dignity of the patients and their family members during the first wave of the COVID-19 pandemic in the Netherlands. METHODOLOGY: A qualitative study involving 25 in-depth interviews with purposively sampled bereaved relatives of patients who died during the COVID-19 pandemic between March and July 2020 in the Netherlands. We created a dignity-inspired framework for analysis, and used the models of Chochinov et al. and Van Gennip et al. as sensitising concepts. These focus on illness-related aspects and the individual, relational and societal/organisational level of dignity. RESULTS: Four themes concerning aspects of end-of-life care practices were identified as possibly jeopardising the dignity of patients or relatives: 'Dealing with an unknown illness', 'Being isolated', 'Restricted farewells' and 'Lack of attentiveness and communication'. The analysis showed that 'Meaningful end-of-life moments' and 'Compassionate professional support' contributed to the dignity of patients and their relatives. CONCLUSION: This study illuminates possible aspects of end-of-life care practices that jeopardised or supported dignity. Experienced dignity of bereaved relatives was associated with the unfamiliarity of the virus and issues associated with preventive measures. However, most aspects that had an impact on the dignity experiences of relatives were based in human action and relationships. Relatives experienced that preventive measures could be mitigated by health care professionals to make them less devastating. CI - (c) 2021 The Authors. Scandinavian Journal of Caring Sciences published by John Wiley & Sons Ltd on behalf of Nordic College of Caring Science. FAU - Becque, Yvonne N AU - Becque YN AUID- ORCID: 0000-0002-9188-9911 AD - Research Centre Innovations in Care, Rotterdam University of Applied Sciences, Rotterdam, The Netherlands. AD - Department of Public Health, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands. FAU - van der Geugten, Wendy AU - van der Geugten W AUID- ORCID: 0000-0002-5011-0676 AD - University of Humanistic Studies, Utrecht, The Netherlands. FAU - van der Heide, Agnes AU - van der Heide A AD - Department of Public Health, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands. FAU - Korfage, Ida J AU - Korfage IJ AD - Department of Public Health, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands. FAU - Pasman, H Roeline W AU - Pasman HRW AD - Department of Public and Occupational Health, Expertise Center for Palliative Care, Amsterdam UMC, VU University, Amsterdam, The Netherlands. FAU - Onwuteaka-Philipsen, Bregje D AU - Onwuteaka-Philipsen BD AD - Department of Public and Occupational Health, Expertise Center for Palliative Care, Amsterdam UMC, VU University, Amsterdam, The Netherlands. FAU - Zee, Masha AU - Zee M AD - Department of Public and Occupational Health, Expertise Center for Palliative Care, Amsterdam UMC, VU University, Amsterdam, The Netherlands. FAU - Witkamp, Erica AU - Witkamp E AD - Research Centre Innovations in Care, Rotterdam University of Applied Sciences, Rotterdam, The Netherlands. AD - Department of Public Health, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands. FAU - Goossensen, Anne AU - Goossensen A AD - University of Humanistic Studies, Utrecht, The Netherlands. LA - eng GR - 844001803/Netherlands Organisation for Health Research and Development (ZonMw)/ PT - Journal Article DEP - 20211009 PL - Sweden TA - Scand J Caring Sci JT - Scandinavian journal of caring sciences JID - 8804206 MH - *COVID-19 MH - Humans MH - Netherlands MH - Palliative Care/psychology MH - Pandemics MH - Qualitative Research MH - *Terminal Care/psychology PMC - PMC8661881 OTO - NOTNLM OT - COVID-19 OT - dignity OT - end of life OT - palliative care OT - quality of care COIS- The authors declare no conflicts of interest. EDAT- 2021/10/10 06:00 MHDA- 2022/08/19 06:00 PMCR- 2021/10/09 CRDT- 2021/10/09 06:32 PHST- 2021/05/23 00:00 [received] PHST- 2021/09/26 00:00 [accepted] PHST- 2021/10/10 06:00 [pubmed] PHST- 2022/08/19 06:00 [medline] PHST- 2021/10/09 06:32 [entrez] PHST- 2021/10/09 00:00 [pmc-release] AID - SCS13038 [pii] AID - 10.1111/scs.13038 [doi] PST - ppublish SO - Scand J Caring Sci. 2022 Sep;36(3):769-781. doi: 10.1111/scs.13038. Epub 2021 Oct 9. PMID- 34623633 OWN - NLM STAT- MEDLINE DCOM- 20211124 LR - 20250623 IS - 1469-493X (Electronic) IS - 1361-6137 (Linking) VI - 10 IP - 10 DP - 2021 Oct 8 TI - Ketamine and other glutamate receptor modulators for depression in adults with bipolar disorder. PG - CD011611 LID - 10.1002/14651858.CD011611.pub3 [doi] LID - CD011611 AB - BACKGROUND: Glutamergic system dysfunction has been implicated in the pathophysiology of bipolar depression. This is an update of the 2015 Cochrane Review for the use of glutamate receptor modulators for depression in bipolar disorder. OBJECTIVES: 1. To assess the effects of ketamine and other glutamate receptor modulators in alleviating the acute symptoms of depression in people with bipolar disorder. 2. To review the acceptability of ketamine and other glutamate receptor modulators in people with bipolar disorder who are experiencing depressive symptoms. SEARCH METHODS: We searched the Cochrane Central Register of Controlled Trials (CENTRAL), Ovid MEDLINE, Embase and PsycINFO all years to July 2020. We did not apply any restrictions to date, language or publication status. SELECTION CRITERIA: RCTs comparing ketamine or other glutamate receptor modulators with other active psychotropic drugs or saline placebo in adults with bipolar depression. DATA COLLECTION AND ANALYSIS: Two review authors independently selected studies for inclusion, assessed trial quality and extracted data. Primary outcomes were response rate and adverse events. Secondary outcomes included remission rate, depression severity change scores, suicidality, cognition, quality of life, and dropout rate. The GRADE framework was used to assess the certainty of the evidence. MAIN RESULTS: Ten studies (647 participants) were included in this review (an additional five studies compared to the 2015 review). There were no additional studies added to the comparisons identified in the 2015 Cochrane review on ketamine, memantine and cytidine versus placebo. However, three new comparisons were found: ketamine versus midazolam, N-acetylcysteine versus placebo, and riluzole versus placebo. The glutamate receptor modulators studied were ketamine (three trials), memantine (two), cytidine (one), N-acetylcysteine (three), and riluzole (one). Eight of these studies were placebo-controlled and two-armed. In seven trials the glutamate receptor modulators had been used as add-on drugs to mood stabilisers. Only one trial compared ketamine with an active comparator, midazolam. The treatment period ranged from a single intravenous administration (all ketamine studies), to repeated administration for riluzole, memantine, cytidine, and N-acetylcysteine (with a follow-up of eight weeks, 8 to 12 weeks, 12 weeks, and 16 to 20 weeks, respectively). Six of the studies included sites in the USA, one in Taiwan, one in Denmark, one in Australia, and in one study the location was unclear. All participants had a primary diagnosis of bipolar disorder and were experiencing an acute bipolar depressive episode, diagnosed according to the Diagnostic and Statistical Manual of Mental Disorders fourth edition (IV) or fourth edition text revision (IV-TR). Among all glutamate receptor modulators included in this review, only ketamine appeared to be more efficacious than placebo 24 hours after infusion for response rate (odds ratio (OR) 11.61, 95% confidence interval (CI) 1.25 to 107.74; P = 0.03; participants = 33; studies = 2; I(2) = 0%, low-certainty evidence). Ketamine seemed to be more effective in reducing depression rating scale scores (MD -11.81, 95% CI -20.01 to -3.61; P = 0.005; participants = 32; studies = 2; I(2) = 0%, very low-certainty evidence). There was no evidence of ketamine's efficacy in producing remission over placebo at 24 hours (OR 5.16, 95% CI 0.51 to 52.30; P = 0.72; participants = 33; studies = 2; I(2) = 0%, very low-certainty evidence). Evidence on response, remission or depression rating scale scores between ketamine and midazolam was uncertain at 24 hours due to very low-certainty evidence (OR 3.20, 95% CI 0.23 to 45.19). In the one trial assessing ketamine and midazolam, there were no dropouts due to adverse effects or for any reason (very low-certainty evidence). Placebo may have been more effective than N-acetylcysteine in reducing depression rating scale scores at three months, although this was based on very low-certainty evidence (MD 1.28, 95% CI 0.24 to 2.31; participants = 58; studies = 2). Very uncertain evidence found no difference in response at three months (OR 0.82, 95% CI 0.32 to 2.14; participants = 69; studies = 2; very low-certainty evidence). No data were available for remission or acceptability. Extremely limited data were available for riluzole vs placebo, finding only very-low certainty evidence of no difference in dropout rates (OR 2.00, 95% CI 0.31 to 12.84; P = 0.46; participants = 19; studies = 1; I(2) = 0%). AUTHORS' CONCLUSIONS: It is difficult to draw reliable conclusions from this review due to the certainty of the evidence being low to very low, and the relatively small amount of data usable for analysis in bipolar disorder, which is considerably less than the information available for unipolar depression. Nevertheless, we found uncertain evidence in favour of a single intravenous dose of ketamine (as add-on therapy to mood stabilisers) over placebo in terms of response rate up to 24 hours, however ketamine did not show any better efficacy for remission in bipolar depression. Even though ketamine has the potential to have a rapid and transient antidepressant effect, the efficacy of a single intravenous dose may be limited. We did not find conclusive evidence on adverse events with ketamine, and there was insufficient evidence to draw meaningful conclusions for the remaining glutamate receptor modulators. However, ketamine's psychotomimetic effects (such as delusions or delirium) may have compromised study blinding in some studies, and so we cannot rule out the potential bias introduced by inadequate blinding procedures. To draw more robust conclusions, further methodologically sound RCTs (with adequate blinding) are needed to explore different modes of administration of ketamine, and to study different methods of sustaining antidepressant response, such as repeated administrations. CI - Copyright (c) 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. FAU - Dean, Rebecca L AU - Dean RL AD - Oxford, UK. FAU - Marquardt, Tahnee AU - Marquardt T AD - Oxford, UK. FAU - Hurducas, Claudia AU - Hurducas C AD - Oxford, UK. FAU - Spyridi, Styliani AU - Spyridi S AD - Department of Rehabilitation Sciences, Faculty of Health Sciences, Cyprus University of Technology, Lemesos, Cyprus. FAU - Barnes, Annabelle AU - Barnes A AD - Oxford Health NHS Foundation Trust, Oxford, UK. FAU - Smith, Rebecca AU - Smith R AD - UK. FAU - Cowen, Philip J AU - Cowen PJ AD - Department of Psychiatry, University of Oxford, Oxford, UK. FAU - McShane, Rupert AU - McShane R AD - Department of Psychiatry, University of Oxford, Oxford, UK. FAU - Hawton, Keith AU - Hawton K AD - Centre for Suicide Research, University Department of Psychiatry, Warneford Hospital, Oxford, UK. FAU - Malhi, Gin S AU - Malhi GS AD - Discipline of Psychiatry, Northern Clinical School, University of Sydney, Sydney, Australia. FAU - Geddes, John AU - Geddes J AD - UK. FAU - Cipriani, Andrea AU - Cipriani A AD - Department of Psychiatry, University of Oxford, Oxford, UK. LA - eng SI - ClinicalTrials.gov/NCT01797575 SI - ClinicalTrials.gov/NCT00088699 SI - ClinicalTrials.gov/NCT00088699 SI - ClinicalTrials.gov/NCT01881763 GR - MR/S003037/1/MRC_/Medical Research Council/United Kingdom PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Systematic Review DEP - 20211008 PL - England TA - Cochrane Database Syst Rev JT - The Cochrane database of systematic reviews JID - 100909747 RN - 0 (Receptors, Glutamate) RN - 690G0D6V8H (Ketamine) SB - IM UOF - Cochrane Database Syst Rev. 2015 Sep 29;(9):CD011611. doi: 10.1002/14651858.CD011611.pub2. PMID: 26415966 MH - Adult MH - *Bipolar Disorder/drug therapy MH - Depression/drug therapy MH - Humans MH - *Ketamine/therapeutic use MH - Quality of Life MH - Receptors, Glutamate PMC - PMC8499740 COIS- RD, TM, CH, SS, AB, RS, PJC, KH and JG report no competing interests. RM runs NHS and self-pay ketamine clinics for Oxford Health NHS Foundation Trust. RM has undertaken educational and scientific advisory board work for Janssen Pharmaceuticals to support educational and research activity, no funds are received personally. Janssen supported RM's attendance at the APA conference in New York in 2018. RM has undertaken scientific advisory board work for Sage pharmaceuticals, no funds are directly received. RM is supported by the NIHR Oxford Health Biomedical Research Centre. GSM has received grant or research support from National Health and Medical Research Council, Australian Rotary Health, NSW Health, American Foundation for Suicide Prevention, Ramsay Research and Teaching Fund, Elsevier, AstraZeneca, Janssen-Cilag, Lundbeck, Otsuka and Servier; and has been a consultant for AstraZeneca, Janssen-Cilag, Lundbeck, Otsuka and Servier. AC has received research and consultancy fees from INCiPiT (Italian Network for Paediatric Trials), CARIPLO Foundation and Angelini Pharma. EDAT- 2021/10/09 06:00 MHDA- 2021/11/25 06:00 PMCR- 2022/10/08 CRDT- 2021/10/08 12:28 PHST- 2021/10/08 12:28 [entrez] PHST- 2021/10/09 06:00 [pubmed] PHST- 2021/11/25 06:00 [medline] PHST- 2022/10/08 00:00 [pmc-release] AID - CD011611.pub3 [pii] AID - 10.1002/14651858.CD011611.pub3 [doi] PST - epublish SO - Cochrane Database Syst Rev. 2021 Oct 8;10(10):CD011611. doi: 10.1002/14651858.CD011611.pub3. PMID- 34620666 OWN - NLM STAT- MEDLINE DCOM- 20211015 LR - 20260901 IS - 2044-6055 (Electronic) IS - 2044-6055 (Linking) VI - 11 IP - 10 DP - 2021 Oct 7 TI - Multifaceted antibiotic stewardship intervention using a participatory-action-research approach to improve antibiotic prescribing for urinary tract infections in frail elderly (ImpresU): study protocol for a European qualitative study followed by a pragmatic cluster randomised controlled trial. PG - e052552 LID - 10.1136/bmjopen-2021-052552 [doi] LID - e052552 AB - INTRODUCTION: Almost 60% of antibiotics in frail elderly are prescribed for alleged urinary tract infections (UTIs). A substantial part of this comprises prescriptions in case of non-specific symptoms or asymptomatic bacteriuria, for which the latest guidelines promote restrictiveness with antibiotics. We aim to reduce inappropriate antibiotic use for UTIs through an antibiotic stewardship intervention (ASI) that encourages to prescribe according to these guidelines. To develop an effective ASI, we first need a better understanding of the complex decision-making process concerning suspected UTIs in frail elderly. Moreover, the implementation approach requires tailoring to the heterogeneous elderly care setting. METHODS AND ANALYSIS: First, we conduct a qualitative study to explore factors contributing to antibiotic prescribing for UTIs in frail elderly, using semi-structured interviews with general practitioners, nursing staff, patients and informal caregivers. Next, we perform a pragmatic cluster randomised controlled trial in elderly care organisations. A multifaceted ASI is implemented in the intervention group; the control group receives care as usual. The ASI is centred around a decision tool that promotes restrictive antibiotic use, supported by a toolbox with educational materials. For the implementation, we use a modified participatory-action-research approach, guided by the results of the qualitative study. The primary outcome is the number of antibiotic prescriptions for suspected UTIs. We aim to recruit 34 clusters with in total 680 frail elderly residents >/=70 years. Data collection takes place during a 5-month baseline period and a 7-month follow-up period. Finally, we perform a process evaluation. The study has been delayed for 6 months due to COVID-19 and is expected to end in July 2021. ETHICS AND DISSEMINATION: Ethical approvals and/or waivers were obtained from the ethical committees in Poland, the Netherlands, Norway and Sweden. The results will be disseminated through publication in peer-reviewed journals and conference presentations. TRIAL REGISTRATION NUMBER: NCT03970356. CI - (c) Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY. Published by BMJ. FAU - Hartman, Esther A R AU - Hartman EAR AUID- ORCID: 0000-0003-0907-2476 AD - Department of Medicine for Older People, Amsterdam Public Health Research Institute, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands e.hartman1@amsterdamumc.nl. AD - Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands. FAU - Groen, Wim G AU - Groen WG AD - Department of Medicine for Older People, Amsterdam Public Health Research Institute, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands. FAU - Heltveit-Olsen, Silje Rebekka AU - Heltveit-Olsen SR AD - The Antibiotic Centre for Primary Care, Department of General Practice, Institute of Health and Society, University of Oslo, Oslo, Norway. FAU - Lindbaek, Morten AU - Lindbaek M AD - The Antibiotic Centre for Primary Care, Department of General Practice, Institute of Health and Society, University of Oslo, Oslo, Norway. FAU - Hoye, Sigurd AU - Hoye S AD - The Antibiotic Centre for Primary Care, Department of General Practice, Institute of Health and Society, University of Oslo, Oslo, Norway. FAU - Sundvall, Par-Daniel AU - Sundvall PD AD - General Practice/Family Medicine, School of Public Health and Community Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden. AD - Research, Education, Development & Innovation, Primary Health Care, Region Vastra Gotaland, Sweden. FAU - Gunnarsson, Ronny AU - Gunnarsson R AD - General Practice/Family Medicine, School of Public Health and Community Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden. AD - Research, Education, Development & Innovation, Primary Health Care, Region Vastra Gotaland, Sweden. FAU - Skoglund, Ingmarie AU - Skoglund I AD - General Practice/Family Medicine, School of Public Health and Community Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden. AD - Research, Education, Development & Innovation, Primary Health Care, Region Vastra Gotaland, Sweden. FAU - Snaebjornsson Arnljots, Egill AU - Snaebjornsson Arnljots E AD - General Practice/Family Medicine, School of Public Health and Community Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden. AD - Research, Education, Development & Innovation, Primary Health Care, Region Vastra Gotaland, Sweden. FAU - Godycki-Cwirko, Maciej AU - Godycki-Cwirko M AD - Centre for Family and Community Medicine, Faculty of Health Sciences, Medical University of Lodz, Lodz, Poland. FAU - Kowalczyk, Anna AU - Kowalczyk A AD - Centre for Family and Community Medicine, Faculty of Health Sciences, Medical University of Lodz, Lodz, Poland. FAU - Platteel, Tamara N AU - Platteel TN AD - Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands. FAU - Zuithoff, Nicolaas P A AU - Zuithoff NPA AD - Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands. FAU - Monnier, Annelie A AU - Monnier AA AUID- ORCID: 0000-0002-5844-286X AD - Department of Medicine for Older People, Amsterdam Public Health Research Institute, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands. FAU - Verheij, Theo J M AU - Verheij TJM AD - Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands. FAU - Hertogh, Cees M P M AU - Hertogh CMPM AD - Department of Medicine for Older People, Amsterdam Public Health Research Institute, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands. FAU - van de Pol, Alma C AU - van de Pol AC AD - Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands. LA - eng SI - ClinicalTrials.gov/NCT03970356 PT - Clinical Trial Protocol PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20211007 PL - England TA - BMJ Open JT - BMJ open JID - 101552874 RN - 0 (Anti-Bacterial Agents) SB - IM MH - Aged MH - Anti-Bacterial Agents/therapeutic use MH - *Antimicrobial Stewardship MH - *COVID-19 MH - Frail Elderly MH - Humans MH - Inappropriate Prescribing/prevention & control MH - Randomized Controlled Trials as Topic MH - *Respiratory Tract Infections/drug therapy MH - *Urinary Tract Infections/drug therapy MH - Pragmatic Clinical Trials as Topic PMC - PMC8499316 OTO - NOTNLM OT - medical education & training OT - primary care OT - urinary tract infections COIS- Competing interests: None declared. EDAT- 2021/10/09 06:00 MHDA- 2021/10/16 06:00 PMCR- 2021/10/07 CRDT- 2021/10/08 06:10 PHST- 2021/10/08 06:10 [entrez] PHST- 2021/10/09 06:00 [pubmed] PHST- 2021/10/16 06:00 [medline] PHST- 2021/10/07 00:00 [pmc-release] AID - bmjopen-2021-052552 [pii] AID - 10.1136/bmjopen-2021-052552 [doi] PST - epublish SO - BMJ Open. 2021 Oct 7;11(10):e052552. doi: 10.1136/bmjopen-2021-052552. PMID- 34615342 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220311 IS - 2279-9028 (Print) IS - 2279-9036 (Electronic) IS - 2279-9028 (Linking) VI - 11 IP - 1 DP - 2021 Oct 6 TI - The first year of COVID-19 in Italy: incidence, lethality, and health policies. LID - 10.4081/jphr.2021.2201 [doi] LID - 2201 AB - BACKGROUND: The novel coronavirus disease is an ongoing pandemic that started in China in December 2019. This paper is aimed at estimating the first two infections waves in Italy in relation to adopted health policies. DESIGN AND METHODS: We moved deaths of the Italian COVID-19 registry from recorded to infection date by the weighted moving average. We considered two infection fatality ratios related to the effective or saturated health system, we estimated the likely incidence curve from the resulting deaths and evaluated the curve shape before and after the national health policies. RESULTS: From the 24th of February 2020 to the 7th of February 2021, we estimated 6,664,655 (4,639,221-9,325,138) cases distributed on two waves. Suitable daily infection fatality rates were 2.53% within the first wave and 1.15% within the second one. The first wave (February-July 2020) had its peak on the 14th of March 2020 (26,575). The second wave (August 2020-February 2021) was fatter with the peak on the 12th of November (60,425) and a hump in December before decreasing to 26,288 at the end. Adopted health policies were followed by changes in the curve rate. CONCLUSIONS: Tracing infection contacts and quarantining asymptomatic people reduced virus lethality in the second wave. Restriction on population mobility is effective within a suppression strategy, distance learning reduces contacts among families. Removal of restrictions should be implemented by sequential steps for avoiding a quick rising of incident cases. A reasonable public health daily goal to control both virus spread and lethality could be to find at least 87 cases for each death. FAU - Ferrante, Pierpaolo AU - Ferrante P AD - Department of Occupational and Environmental Medicine, Epidemiology and Hygiene, Italian National Workers' Compensation Authority (INAIL). p.ferrante@inail.it. LA - eng PT - Journal Article DEP - 20211006 PL - United States TA - J Public Health Res JT - Journal of public health research JID - 101580775 PMC - PMC8883532 EDAT- 2021/10/08 06:00 MHDA- 2021/10/08 06:01 PMCR- 2021/10/06 CRDT- 2021/10/07 03:21 PHST- 2021/02/24 00:00 [received] PHST- 2021/08/05 00:00 [accepted] PHST- 2021/10/08 06:00 [pubmed] PHST- 2021/10/08 06:01 [medline] PHST- 2021/10/07 03:21 [entrez] PHST- 2021/10/06 00:00 [pmc-release] AID - 10.4081/jphr.2021.2201 [doi] PST - epublish SO - J Public Health Res. 2021 Oct 6;11(1):2201. doi: 10.4081/jphr.2021.2201. PMID- 34610937 OWN - NLM STAT- MEDLINE DCOM- 20211102 LR - 20220216 IS - 2044-6055 (Electronic) IS - 2044-6055 (Linking) VI - 11 IP - 10 DP - 2021 Oct 5 TI - Prevalence of disposable pod use and consumer preference for e-cigarette product characteristics among vape shop customers in Southern California: a cross-sectional study. PG - e049604 LID - 10.1136/bmjopen-2021-049604 [doi] LID - e049604 AB - OBJECTIVES: In February 2020, the US Food and Drug Administration issued a guidance restricting the sales and distribution of cartridge-based e-cigarettes with flavours other than tobacco and menthol. Disposable devices were exempt from this guidance. This study examined the prevalence of disposable pod use and flavour preference compared with refillable pod and other e-cigarette users among vape shop customers. DESIGN: Cross-sectional study. SETTING: In July 2019-March 2020, trained data collectors visited 44 vape shops in California with permission to recruit customers from shop owners. PARTICIPANTS: Intercept interviews with 276 customers were conducted. OUTCOMES AND PROCEDURES: Customers were grouped based on self-reported device type used most often (disposable pod, refillable pod and other e-cigarettes). Groups were compared on self-reported demographics, flavours preferred, daily e-cigarette use, preferred nicotine concentration levels and cigarette use. RESULTS: Of the 276 customers surveyed, 11.2% used disposable pods in the past 30 days. Among disposable pod users, fruit/candy (80.7%), mint (77.4%) and menthol (67.7%) were common preferred flavours, while tobacco flavours were less commonly preferred (19.4%). When compared with refillable pod and other non-pod e-cigarette device users, disposable pod users were younger, used higher nicotine concentration levels, were more likely to prefer mint and menthol flavours and use e-cigarettes as their first product, while less likely to ever use cigarettes and use e-cigarettes daily. DISCUSSION: Despite using higher nicotine levels and preferred menthol/mint flavours more often than users of other devices, disposable pod users reported lower prevalence of lifetime smoking and daily vaping and were younger. Given the current findings, regulations addressing non-tobacco flavours and nicotine concentration in disposable pod devices merit consideration in efforts to reduce vaping in younger adult never smokers. CI - (c) Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. FAU - Galimov, Artur AU - Galimov A AUID- ORCID: 0000-0002-9718-439X AD - Department of Population and Public Health Sciences, University of Southern California Keck School of Medicine, Los Angeles, California, USA galimov@usc.edu. FAU - Leventhal, Adam AU - Leventhal A AD - Department of Population and Public Health Sciences, University of Southern California Keck School of Medicine, Los Angeles, California, USA. AD - Institute for Addiction Science, University of Southern California, Los Angeles, CA, USA. FAU - Meza, Leah AU - Meza L AD - Department of Population and Public Health Sciences, University of Southern California Keck School of Medicine, Los Angeles, California, USA. FAU - Unger, Jennifer B AU - Unger JB AD - Department of Population and Public Health Sciences, University of Southern California Keck School of Medicine, Los Angeles, California, USA. FAU - Huh, Jimi AU - Huh J AD - Department of Population and Public Health Sciences, University of Southern California Keck School of Medicine, Los Angeles, California, USA. FAU - Baezconde-Garbanati, Lourdes AU - Baezconde-Garbanati L AD - Department of Population and Public Health Sciences, University of Southern California Keck School of Medicine, Los Angeles, California, USA. FAU - Sussman, Steven Y AU - Sussman SY AD - Department of Population and Public Health Sciences, University of Southern California Keck School of Medicine, Los Angeles, California, USA. AD - Department of Psychology, University of Southern California, Los Angeles, CA, USA. AD - School of Social Work, University of Southern California, Los Angeles, CA, USA. LA - eng GR - K24 DA048160/DA/NIDA NIH HHS/United States GR - U54 CA180905/CA/NCI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20211005 PL - England TA - BMJ Open JT - BMJ open JID - 101552874 SB - IM MH - Adult MH - California/epidemiology MH - Consumer Behavior MH - Cross-Sectional Studies MH - *Electronic Nicotine Delivery Systems MH - Humans MH - Prevalence MH - *Tobacco Products MH - *Vaping PMC - PMC8493914 OTO - NOTNLM OT - health policy OT - public health OT - substance misuse COIS- Competing interests: None declared. EDAT- 2021/10/07 06:00 MHDA- 2021/11/03 06:00 PMCR- 2021/10/05 CRDT- 2021/10/06 05:53 PHST- 2021/10/06 05:53 [entrez] PHST- 2021/10/07 06:00 [pubmed] PHST- 2021/11/03 06:00 [medline] PHST- 2021/10/05 00:00 [pmc-release] AID - bmjopen-2021-049604 [pii] AID - 10.1136/bmjopen-2021-049604 [doi] PST - epublish SO - BMJ Open. 2021 Oct 5;11(10):e049604. doi: 10.1136/bmjopen-2021-049604. PMID- 34604601 OWN - NLM STAT- MEDLINE DCOM- 20211110 LR - 20261001 IS - 2421-4248 (Electronic) IS - 1121-2233 (Print) IS - 1121-2233 (Linking) VI - 62 IP - 2 DP - 2021 Jun TI - Bacterial lysates (OM-85 BV): a cost-effective proposal in order to contrast antibiotic resistance. PG - E564-E573 LID - 10.15167/2421-4248/jpmh2021.62.2.1734 [doi] AB - BACKGROUND: Chronic Obstructive Pulmonary Disease (COPD) is one of the most frequent pathologies in which antibiotics are used because 50% of the exacerbations are attributable to a bacterial infection. The aims of our study were: i) to perform a meta-analysis on the efficacy of the bacterial lysate OM-85 BV in preventing acute exacerbations in patients with COPD; ii) to evaluate whether this preventive treatment can lead to significant savings for the National Health Service (NHS). METHODS: A systematic research was conducted in the electronic database MEDLINE (PubMed) in June 2017-July 2020, collecting evidences without time restrictions. Only randomized controlled trials (RCTs) were included. The keywords used were "OM 85 BV AND chronic bronchitis" and "OM 85 BV AND COPD". A cost-effectiveness analysis (CEA) was performed considering the costs for a treatment with OM-8BV, the costs for the treatment of an acute exacerbation and the number of prevented exacerbations. RESULTS: 59 publications were found, but the meta-analysis was conducted on 13 studies that met the inclusion criteria. OM-85 BV is responsible of a statistically significant reduction in the mean number of COPD exacerbations (p < 0.01; WMD = -0.86; CI 95%: -1.38, -0.34) and in the days of antibiotic therapy (p < 0.01; WMD = -9.49; CI 95%: -11.93, -7.05). The cost-effectiveness ratio with a negative value is in favor to treatment. CONCLUSIONS: OM-85 BV is effective in reducing exacerbations, and could lead to significant savings for the NHS. Moreover, reducing the number of exacerbations it could avoid an over-use of antibiotics and the consequent antibiotic resistance. CI - (c)2021 Pacini Editore SRL, Pisa, Italy. FAU - Troiano, Gianmarco AU - Troiano G AD - Post Graduate School of Public Health, University of Siena. FAU - Messina, Gabriele AU - Messina G AD - Department of molecular and developmental medicine, University of Siena. FAU - Nante, Nicola AU - Nante N AD - Department of molecular and developmental medicine, University of Siena. LA - eng PT - Journal Article PT - Meta-Analysis DEP - 20210730 PL - Italy TA - J Prev Med Hyg JT - Journal of preventive medicine and hygiene JID - 9214440 RN - 0 (Cell Extracts) RN - 0 (Broncho-Vaxom) RN - 0 (Bacterial Lysates) SB - IM EIN - J Prev Med Hyg. 2021 Sep 15;62(3):E790-E792. doi: 10.15167/2421-4248/jpmh2021.62.3.1734. PMID: 34909511 MH - Cell Extracts/*therapeutic use MH - Cost-Benefit Analysis MH - *Drug Resistance, Bacterial MH - Humans MH - *Pulmonary Disease, Chronic Obstructive/drug therapy/microbiology MH - Bacterial Lysates PMC - PMC8451348 OTO - NOTNLM OT - Adults OT - Antibiotic resistance OT - Bacterial lysates OT - General practice COIS- Conflict of interest statement The authors declare no conflict of interest. EDAT- 2021/10/05 06:00 MHDA- 2021/11/11 06:00 PMCR- 2021/07/30 CRDT- 2021/10/04 06:12 PHST- 2020/08/25 00:00 [received] PHST- 2021/03/22 00:00 [accepted] PHST- 2021/10/04 06:12 [entrez] PHST- 2021/10/05 06:00 [pubmed] PHST- 2021/11/11 06:00 [medline] PHST- 2021/07/30 00:00 [pmc-release] AID - 10.15167/2421-4248/jpmh2021.62.2.1734 [doi] PST - epublish SO - J Prev Med Hyg. 2021 Jul 30;62(2):E564-E573. doi: 10.15167/2421-4248/jpmh2021.62.2.1734. eCollection 2021 Jun. PMID- 34602095 OWN - NLM STAT- MEDLINE DCOM- 20211021 LR - 20211021 IS - 1742-4682 (Electronic) IS - 1742-4682 (Linking) VI - 18 IP - 1 DP - 2021 Oct 3 TI - Analysis of international traveler mobility patterns in Tokyo to identify geographic foci of dengue fever risk. PG - 17 LID - 10.1186/s12976-021-00149-8 [doi] LID - 17 AB - Travelers play a role in triggering epidemics of imported dengue fever because they can carry the virus to other countries during the incubation period. If a traveler carrying dengue virus visits open green space and is bitten by mosquitoes, a local outbreak can ensue. In the present study, we aimed to understand the movement patterns of international travelers in Tokyo using mobile phone data, with the goal of identifying geographical foci of dengue transmission. We analyzed datasets based on mobile phone access to WiFi systems and measured the spatial distribution of international visitors in Tokyo on two specific dates (one weekday in July 2017 and another weekday in August 2017). Mobile phone users were classified by nationality into three groups according to risk of dengue transmission. Sixteen national parks were selected based on their involvement in a 2014 dengue outbreak and abundance of Aedes mosquitoes. We found that not all national parks were visited by international travelers and that visits to cemeteries were very infrequent. We also found that travelers from countries with high dengue prevalence were less likely to visit national parks compared with travelers from dengue-free countries. Travelers from countries with sporadic dengue cases and countries with regional transmission tended to visit common destinations. By contrast, the travel footprints of visitors from countries with continuous dengue transmission were focused on non-green spaces. Entomological surveillance in Tokyo has been restricted to national parks since the 2014 dengue outbreak. However, our results indicate that areas subject to surveillance should include both public and private green spaces near tourist sites. CI - (c) 2021. The Author(s). FAU - Yuan, Baoyin AU - Yuan B AD - Graduate School of Medicine, Hokkaido University, Kita 15 Jo Nishi 7 Chome, Kita-ku, Sapporo-shi, Hokkaido, 060-8638, Japan. AD - CREST, Japan Science and Technology Agency, Honcho 4-1-8, Kawaguchi, Saitama, 332-0012, Japan. AD - School of Mathematics, South China University of Technology, 381 Wushan Rd, Tianhe District, Guangzhou, China. FAU - Lee, Hyojung AU - Lee H AD - Graduate School of Medicine, Hokkaido University, Kita 15 Jo Nishi 7 Chome, Kita-ku, Sapporo-shi, Hokkaido, 060-8638, Japan. AD - CREST, Japan Science and Technology Agency, Honcho 4-1-8, Kawaguchi, Saitama, 332-0012, Japan. AD - Department of Statistics, Kyungpook National University, Daegu, 41566, South Korea. FAU - Nishiura, Hiroshi AU - Nishiura H AUID- ORCID: 0000-0003-0941-8537 AD - Graduate School of Medicine, Hokkaido University, Kita 15 Jo Nishi 7 Chome, Kita-ku, Sapporo-shi, Hokkaido, 060-8638, Japan. nishiura.hiroshi.5r@kyoto-u.ac.jp. AD - CREST, Japan Science and Technology Agency, Honcho 4-1-8, Kawaguchi, Saitama, 332-0012, Japan. nishiura.hiroshi.5r@kyoto-u.ac.jp. AD - Kyoto University School of Public Health, Yoshidakonoecho, Sakyoku, Kyoto, 6068501, Japan. nishiura.hiroshi.5r@kyoto-u.ac.jp. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20211003 PL - England TA - Theor Biol Med Model JT - Theoretical biology & medical modelling JID - 101224383 SB - IM MH - Animals MH - *Dengue/epidemiology MH - Disease Outbreaks MH - Prevalence MH - Tokyo/epidemiology MH - Travel PMC - PMC8487561 OTO - NOTNLM OT - Coherence OT - Dengue OT - Imported case OT - Sightseeing OT - Tourism OT - Transmission COIS- The authors declare that co-author H. Nishiura is the Editor-in-Chief of Theoretical Biology and Medical Modelling. This does not alter the authors' adherence to all the Theoretical Biology and Medical Modelling policies on sharing data and materials. EDAT- 2021/10/05 06:00 MHDA- 2023/02/25 06:00 PMCR- 2021/10/03 CRDT- 2021/10/04 05:30 PHST- 2021/06/23 00:00 [received] PHST- 2021/09/21 00:00 [accepted] PHST- 2021/10/04 05:30 [entrez] PHST- 2021/10/05 06:00 [pubmed] PHST- 2023/02/25 06:00 [medline] PHST- 2021/10/03 00:00 [pmc-release] AID - 10.1186/s12976-021-00149-8 [pii] AID - 149 [pii] AID - 10.1186/s12976-021-00149-8 [doi] PST - epublish SO - Theor Biol Med Model. 2021 Oct 3;18(1):17. doi: 10.1186/s12976-021-00149-8. PMID- 34597741 OWN - NLM STAT- MEDLINE DCOM- 20211220 LR - 20221221 IS - 1095-8304 (Electronic) IS - 0195-6663 (Print) IS - 0195-6663 (Linking) VI - 168 DP - 2022 Jan 1 TI - Exploring impact on eating behaviour, exercise and well-being during COVID-19 restrictions in the Netherlands. PG - 105720 LID - S0195-6663(21)00627-9 [pii] LID - 10.1016/j.appet.2021.105720 [doi] AB - Many studies address the effect of the COVID-19 restrictions on food consumption and health, focusing on one or two measurements. Whether or not any effects are permanent or change over a longer period of restrictions has not been assessed in such studies. This study presented a survey containing questions on food consumption, exercise and self-assessed physical and mental health, repeatedly for six times over a 20-week period (July to November 2020) to a representative sample of 258 Dutch consumers. The majority of consumers reported no change in food consumption compared to before the COVID-19 restrictions, two smaller groups report a change to a more, or a less, healthy choice. This trend appears stable over the course of the measurements. The 'healthy changers' seem to couple a healthy and more diverse diet to healthy exercise habits, in contrast to the 'unhealthy changers'. No change was observed in self-assessed physical health over the measurements. Overall a decline in time spent exercising showed, as well as a decline in self-assessed mental health. Clearly a lockdown situation affects food choice, exercise habits and (self-assessed) mental health. The fact that habits are able to suddenly change, for better or for worse, and that a decrease in mental health was reported, suggests that such insights need to be further explored to help individual consumers retain a healthy diet and lifestyle, and governments devise effective public health recommendations. CI - Copyright (c) 2021. Published by Elsevier Ltd. FAU - Dijksterhuis, Garmt B AU - Dijksterhuis GB AD - Wageningen Food & Biobased Research, Wageningen University & Research, PO Box 17, NL 6700 AA, Wageningen, the Netherlands. Electronic address: garmt.dijksterhuis@wur.nl. FAU - van Bergen, Geertje AU - van Bergen G AD - Wageningen Food & Biobased Research, Wageningen University & Research, PO Box 17, NL 6700 AA, Wageningen, the Netherlands. Electronic address: geertje.vanbergen@wur.nl. FAU - de Wijk, Rene A AU - de Wijk RA AD - Wageningen Food & Biobased Research, Wageningen University & Research, PO Box 17, NL 6700 AA, Wageningen, the Netherlands. Electronic address: rene.dewijk@wur.nl. FAU - Zandstra, Elizabeth H AU - Zandstra EH AD - Human Nutrition & Health, Wageningen University & Research, Stippeneng 4, 6708 WE, Wageningen, the Netherlands; Unilever Foods Innovation Centre Wageningen, Bronland 14, 6708 WH, Wageningen, the Netherlands. Electronic address: liesbeth.zandstra@wur.nl. FAU - Kaneko, Daisuke AU - Kaneko D AD - Kikkoman Europe R&D Laboratory B.V., Nieuwe Kanaal 7G, 6709 PA, Wageningen, the Netherlands. Electronic address: d.kaneko@kikkoman.nl. FAU - Vingerhoeds, Monique AU - Vingerhoeds M AD - Wageningen Food & Biobased Research, Wageningen University & Research, PO Box 17, NL 6700 AA, Wageningen, the Netherlands. Electronic address: monique.vingerhoeds@wur.nl. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20210929 PL - England TA - Appetite JT - Appetite JID - 8006808 SB - IM MH - *COVID-19 MH - Communicable Disease Control MH - Feeding Behavior MH - Humans MH - Netherlands MH - SARS-CoV-2 PMC - PMC8479541 OTO - NOTNLM OT - COVID-19 lockdown OT - Eating behavior OT - Exercise OT - Health OT - Mental well-being EDAT- 2021/10/02 06:00 MHDA- 2021/12/21 06:00 PMCR- 2021/09/29 CRDT- 2021/10/01 20:15 PHST- 2021/02/04 00:00 [received] PHST- 2021/09/13 00:00 [revised] PHST- 2021/09/27 00:00 [accepted] PHST- 2021/10/02 06:00 [pubmed] PHST- 2021/12/21 06:00 [medline] PHST- 2021/10/01 20:15 [entrez] PHST- 2021/09/29 00:00 [pmc-release] AID - S0195-6663(21)00627-9 [pii] AID - 105720 [pii] AID - 10.1016/j.appet.2021.105720 [doi] PST - ppublish SO - Appetite. 2022 Jan 1;168:105720. doi: 10.1016/j.appet.2021.105720. Epub 2021 Sep 29. PMID- 34593030 OWN - NLM STAT- MEDLINE DCOM- 20211004 LR - 20211004 IS - 1745-6215 (Electronic) IS - 1745-6215 (Linking) VI - 22 IP - 1 DP - 2021 Sep 30 TI - Effects of modified-Paleo and moderate-carbohydrate diets on body composition, serum levels of hepatokines and adipocytokines, and flow cytometric analysis of endothelial microparticles in adults with metabolic syndrome: a study protocol for a randomized clinical trial. PG - 673 LID - 10.1186/s13063-021-05612-y [doi] LID - 673 AB - BACKGROUND: Metabolic syndrome is a combination of metabolic risk factors causing a pathological condition that increases the risk of non-communicable diseases, such as diabetes and cardiovascular diseases. A variety of dietary approaches have been examined to halt this rapid trend; however, the effects of modified-Paleo diet and medium-carbohydrate diet on inflammation, adipokines, hepatokines, and the profile of endothelial microparticles in individuals with metabolic syndrome have not been investigated in detail. The present study is designed to examine the effect of modified-Paleo and moderate-carbohydrate diet with two delivery modes: "fixed diet plan" vs "calorie counting" on weight, body composition, serum levels of some hepatokines and adipocytokines, and flow cytometric analysis of endothelial microparticles in adults with metabolic syndrome. METHODS: Eighty metabolic syndrome patients will be recruited in this study. They will be randomly allocated to one of the following 4 groups: (1) receiving a modified-Paleo diet with calorie counting, (2) receiving a modified-Paleo diet with a fixed diet plan, (3) receiving a medium-carbohydrate diet with calorie counting, and (4) receiving a medium-carbohydrate diet with a fixed diet plan for 10 weeks. Weight, height, waist circumference, and body composition will be assessed at the study baseline and at the end of the trial. Serum insulin, asprosin, chemerin, FGF-21, CTRP-1, PYY, ghrelin, plasma EMPs (CD31+/CD42b- and CD144+/CD42b-), lipid profile, glycemic indices, hs-CRP, leptin, vitamin C, creatinine and satiety, hunger, fullness, and desire to eat (via visual analog scales) will be measured at the study baseline and at the end of the trial. Insulin resistance and insulin sensitivity will be determined using the HOMA-IR and QUICKI equations. DISCUSSION: To the best of our knowledge, this is the first randomized controlled trial that will determine the effect of modified-Paleo and moderate-carbohydrate diet on weight, body composition, serum levels of some hepatokines and adipocytokines, and the profile of EMPs in adults with metabolic syndrome. Moreover, the effects of different diet delivery modes, including "fixed diet plan" and "calorie counting" will also be analyzed. The results of this trial can provide clinical witnesses on the effectiveness of carbohydrate-restricted diets in ameliorating metabolic status and prevent the development of chronic diseases. TRIAL REGISTRATION: Iranian Registry of Clinical Trials IRCT2016121925267N4 . Registered on 26 July 2017. CI - (c) 2021. The Author(s). FAU - Shemirani, Farnoosh AU - Shemirani F AD - Department of Cellular and Molecular Nutrition, School of Nutritional Science and Dietetics, Tehran University of Medical Sciences, Tehran, 14155-6447, Iran. FAU - Fotouhi, Akbar AU - Fotouhi A AD - Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran. FAU - Djafarian, Kurosh AU - Djafarian K AD - Department of Clinical Nutrition, School of Nutritional Science and Dietetics, Tehran University of Medical Sciences, Tehran, Iran. FAU - Azadbakht, Leila AU - Azadbakht L AD - Department of Community Nutrition, School of Nutritional Science and Dietetics, Tehran University of Medical Sciences, Tehran, Iran. AD - Diabetes Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran. AD - Department of Community Nutrition, School of Nutrition and Food Science, Isfahan University of Medical Sciences, Isfahan, Iran. FAU - Rezaei, Nima AU - Rezaei N AD - Research Center for Immunodeficiencies, Pediatrics Center of Excellence, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran. FAU - Mahmoudi, Maryam AU - Mahmoudi M AD - Department of Cellular and Molecular Nutrition, School of Nutritional Science and Dietetics, Tehran University of Medical Sciences, Tehran, 14155-6447, Iran. maryam.mahmoudi73@gmail.com. LA - eng GR - 95-04-161-33886/Tehran University of Medical Sciences and Health Services/ PT - Clinical Trial Protocol PT - Journal Article DEP - 20210930 PL - England TA - Trials JT - Trials JID - 101263253 RN - 0 (Adipokines) RN - 0 (Carbohydrates) RN - 0 (Chemokines) RN - 0 (FBN1 protein, human) RN - 0 (Fibrillin-1) RN - 0 (Microfilament Proteins) RN - 0 (Peptide Fragments) RN - 0 (Peptide Hormones) RN - 0 (RARRES2 protein, human) SB - IM MH - Adipokines MH - Adult MH - Body Composition MH - Carbohydrates MH - Chemokines MH - Diet, Carbohydrate-Restricted MH - Fibrillin-1 MH - Humans MH - Iran MH - *Metabolic Syndrome/diagnosis MH - Microfilament Proteins MH - Peptide Fragments MH - *Peptide Hormones MH - Randomized Controlled Trials as Topic PMC - PMC8483422 OTO - NOTNLM OT - Low-carbohydrate diet OT - Metabolic syndrome OT - Randomized control trial COIS- The authors declare that they have no competing interests. EDAT- 2021/10/02 06:00 MHDA- 2021/10/05 06:00 PMCR- 2021/09/30 CRDT- 2021/10/01 05:45 PHST- 2020/05/11 00:00 [received] PHST- 2021/09/08 00:00 [accepted] PHST- 2021/10/01 05:45 [entrez] PHST- 2021/10/02 06:00 [pubmed] PHST- 2021/10/05 06:00 [medline] PHST- 2021/09/30 00:00 [pmc-release] AID - 10.1186/s13063-021-05612-y [pii] AID - 5612 [pii] AID - 10.1186/s13063-021-05612-y [doi] PST - epublish SO - Trials. 2021 Sep 30;22(1):673. doi: 10.1186/s13063-021-05612-y. PMID- 34590313 OWN - NLM STAT- MEDLINE DCOM- 20220105 LR - 20221005 IS - 1530-0277 (Electronic) IS - 0145-6008 (Print) IS - 0145-6008 (Linking) VI - 45 IP - 12 DP - 2021 Dec TI - Is talk cheap? Correspondence between self-attributions about changes in drinking and longitudinal changes in drinking during the 2019 coronavirus pandemic. PG - 2560-2568 LID - 10.1111/acer.14724 [doi] AB - BACKGROUND: There are concerns that the coronavirus disease 2019 (COVID-19) pandemic may increase drinking, but most accounts to date are cross-sectional studies of self-attributions about alcohol-related impacts and the accuracy of those perceptions has not been investigated. The current study examined the correspondence between self-attributions of pandemic-related changes in drinking and longitudinally-measured changes in drinking and alcohol-related consequences in a sample of emerging adults. METHODS: In an existing ongoing longitudinal study on alcohol misuse (>/=1 heavy episodic drinking day/month) in emerging adults, 473 individuals (M(age) = 23.8; 41.7% male) received a supplemental assessment from June 17th to July 1st, 2020, during public health restrictions in Ontario, Canada. These intrapandemic data were matched to the most recent assessment prior to the pandemic (~8 months earlier). Self-attributions about changes in drinking were assessed globally (i.e., increases/decreases/no change) and with higher resolution questions clarifying the magnitude of changes. RESULTS: Global self-attributions about changes in drinking substantively paralleled longitudinal changes in weekly drinking days (DD). In the longitudinal data, individuals' who self-reported increases in drinking exhibited significant increases; individuals' who self-reported decreases exhibited significant decreases; and individuals who self-reported no change exhibited nonsignificant changes. Higher resolution items likewise revealed longitudinal patterns of weekly drinking that were substantively consistent with self-attributions. Heavy DD and alcohol-related consequences exhibited similar patterns, but only individuals who self-reported large increases in drinking exhibited increases on these outcomes. Individuals who reported large increases in drinking also exhibited significant increases in depression and posttraumatic stress disorder symptoms. CONCLUSIONS: Self-attributions about drinking closely corresponded to longitudinal changes in drinking, supporting the validity of self-attributions in population-level surveys, particularly in young adults. Notably, a subgroup was identified that exhibited pronounced increases for all alcohol-related outcomes and concurrent increases in internalizing psychopathology. CI - (c) 2021 by the Research Society on Alcoholism. FAU - Minhas, Meenu AU - Minhas M AUID- ORCID: 0000-0001-6741-3940 AD - Peter Boris Centre for Addictions Research, St. Joseph's Healthcare Hamilton, McMaster University, Hamilton, Ontario, Canada. FAU - Belisario, Kyla AU - Belisario K AUID- ORCID: 0000-0001-5403-9531 AD - Peter Boris Centre for Addictions Research, St. Joseph's Healthcare Hamilton, McMaster University, Hamilton, Ontario, Canada. FAU - Gonzalez-Roz, Alba AU - Gonzalez-Roz A AD - Peter Boris Centre for Addictions Research, St. Joseph's Healthcare Hamilton, McMaster University, Hamilton, Ontario, Canada. AD - Department of Psychology/IUNICS, University of the Balearic Islands, Majorca, Spain. FAU - Halladay, Jillian AU - Halladay J AD - Peter Boris Centre for Addictions Research, St. Joseph's Healthcare Hamilton, McMaster University, Hamilton, Ontario, Canada. AD - Department of Health Evidence and Impact, McMaster University, Hamilton, Ontario, Canada. FAU - Morris, Vanessa AU - Morris V AUID- ORCID: 0000-0002-0077-428X AD - Department of Psychology, York University, Toronto, Ontario, Canada. FAU - Keough, Matthew AU - Keough M AD - Department of Psychology, York University, Toronto, Ontario, Canada. FAU - Murphy, James AU - Murphy J AUID- ORCID: 0000-0001-9378-8754 AD - University of Memphis, Memphis, Tennessee, USA. FAU - MacKillop, James AU - MacKillop J AUID- ORCID: 0000-0002-8695-1071 AD - Peter Boris Centre for Addictions Research, St. Joseph's Healthcare Hamilton, McMaster University, Hamilton, Ontario, Canada. AD - Homewood Research Institute, Guelph, Ontario, Canada. LA - eng GR - CIHR/Canada GR - CIHR/Canada PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20211021 PL - England TA - Alcohol Clin Exp Res JT - Alcoholism, clinical and experimental research JID - 7707242 SB - IM MH - Adult MH - Alcohol Drinking/*epidemiology/psychology MH - Alcoholism/epidemiology/psychology MH - Anxiety/epidemiology MH - COVID-19/*epidemiology/psychology MH - Cross-Sectional Studies MH - Depression/epidemiology MH - Female MH - Humans MH - Longitudinal Studies MH - Male MH - Ontario/epidemiology MH - Psychopathology MH - *SARS-CoV-2 MH - Self Report MH - Stress Disorders, Post-Traumatic/epidemiology MH - Surveys and Questionnaires MH - Young Adult PMC - PMC8653375 OTO - NOTNLM OT - COVID-19 OT - alcohol OT - emerging adults OT - self-report OT - validity COIS- JM is a principal and senior scientist in BEAM Diagnostics, Inc., and a member of the Scientific Advisory Board of Clairvoyant Therapeutics, Inc. No other authors have disclosures. EDAT- 2021/10/01 06:00 MHDA- 2022/01/06 06:00 PMCR- 2021/10/21 CRDT- 2021/09/30 07:30 PHST- 2021/09/22 00:00 [revised] PHST- 2021/08/06 00:00 [received] PHST- 2021/09/23 00:00 [accepted] PHST- 2021/10/01 06:00 [pubmed] PHST- 2022/01/06 06:00 [medline] PHST- 2021/09/30 07:30 [entrez] PHST- 2021/10/21 00:00 [pmc-release] AID - ACER14724 [pii] AID - 10.1111/acer.14724 [doi] PST - ppublish SO - Alcohol Clin Exp Res. 2021 Dec;45(12):2560-2568. doi: 10.1111/acer.14724. Epub 2021 Oct 21. PMID- 34588227 OWN - NLM STAT- MEDLINE DCOM- 20211004 LR - 20211004 IS - 2044-6055 (Electronic) IS - 2044-6055 (Linking) VI - 11 IP - 9 DP - 2021 Sep 28 TI - Impact of COVID-19 social distancing measures on future incidence of invasive pneumococcal disease in England and Wales: a mathematical modelling study. PG - e045380 LID - 10.1136/bmjopen-2020-045380 [doi] LID - e045380 AB - OBJECTIVES: In January 2020, the UK moved to a 1+1 schedule for the 13-valent pneumococcal conjugate vaccine (PCV13) with a single priming dose at 3-month and a 12-month booster. We modelled the impact on invasive pneumococcal disease (IPD) out to 2030/2031 of reductions in PCV13 coverage and population mixing associated with restrictions on non-essential healthcare visits and social distancing measures introduced in 2020/2021 to reduce SARS-CoV-2 transmission. DESIGN: Using an existing model of pneumococcal transmission in England and Wales, we simulated the impact of a 40% reduction in coverage and a 40% reduction in mixing between and within age groups during two lockdowns in spring 2020 and autumn/winter 2020/2021. More and less extreme reductions in coverage and mixing were explored in a sensitivity analysis. MAIN OUTCOME MEASURES: Predicted annual numbers of IPD cases under different coverage and mixing reduction scenarios with uncertainty intervals (UIs) generated from minimum and maximum values of the model predictions using 500 parameter sets. RESULTS: The model predicted that any increase in IPD cases resulting from a reduction in PCV13 coverage would be more than offset by a reduction in pneumococcal transmission due to social distancing measures and that overall reductions in IPD cases will persist for a few years after resumption of normal mixing. The net reduction in cumulative IPD cases over the five epidemiological years from July 2019 was predicted to be 13 494 (UI 12 211, 14 676) all ages. Similar results were obtained in the sensitivity analysis. CONCLUSION: COVID-19 lockdowns are predicted to have had a profound effect on pneumococcal transmission resulting in a reduction in pneumococcal carriage prevalence and IPD incidence for up to 5 years after the end of the lockdown period. Carriage studies will be informative in confirming the predicted impact of the lockdown measures after they have been lifted. CI - (c) Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY. Published by BMJ. FAU - Choi, Yoon Hong AU - Choi YH AUID- ORCID: 0000-0001-5561-4366 AD - Statistics, Modelling and Economics Department, Public Health England, London, UK yoon.choi@phe.gov.uk. FAU - Miller, Elizabeth AU - Miller E AD - Department of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK. LA - eng PT - Journal Article DEP - 20210928 PL - England TA - BMJ Open JT - BMJ open JID - 101552874 RN - 0 (Pneumococcal Vaccines) SB - IM MH - *COVID-19 MH - Communicable Disease Control MH - England/epidemiology MH - Humans MH - Incidence MH - Infant MH - Physical Distancing MH - *Pneumococcal Infections/epidemiology/prevention & control MH - Pneumococcal Vaccines MH - SARS-CoV-2 MH - Wales/epidemiology PMC - PMC8479589 OTO - NOTNLM OT - COVID-19 OT - epidemiology OT - infectious diseases OT - public health COIS- Competing interests: None declared. EDAT- 2021/10/01 06:00 MHDA- 2021/10/05 06:00 PMCR- 2021/09/28 CRDT- 2021/09/30 06:02 PHST- 2021/09/30 06:02 [entrez] PHST- 2021/10/01 06:00 [pubmed] PHST- 2021/10/05 06:00 [medline] PHST- 2021/09/28 00:00 [pmc-release] AID - bmjopen-2020-045380 [pii] AID - 10.1136/bmjopen-2020-045380 [doi] PST - epublish SO - BMJ Open. 2021 Sep 28;11(9):e045380. doi: 10.1136/bmjopen-2020-045380. PMID- 34583661 OWN - NLM STAT- MEDLINE DCOM- 20211001 LR - 20261001 IS - 1471-2458 (Electronic) IS - 1471-2458 (Linking) VI - 21 IP - 1 DP - 2021 Sep 28 TI - Associations of physical activity and sedentary behaviors with child mental well-being during the COVID-19 pandemic. PG - 1770 LID - 10.1186/s12889-021-11805-6 [doi] LID - 1770 AB - BACKGROUND: The COVID-19 pandemic resulted in public health and policy measures to reduce in-person contact and the transmission of the virus. These measures impacted daily life and mental well-being (MWB). The aims of this study were to explore the MWB impacts of COVID-19 on children and assess the associations among perceived changes in physical activity (PA) and sedentary behaviors (SB), with perceived MWB changes, using a mixed-methods approach. METHODS: A convergent parallel mixed-methods design consisting of an online survey with a convenience sample and interviews was conducted from May through July 2020 with parents/caregivers of kindergarten through 5th graders in the St. Louis region. Survey domains assessed included child MWB, PA, and SB. Interviews were recorded, transcribed, and qualitatively analyzed using a code book developed to elicit themes. Survey data was analyzed with chi-squared tests and logistic regressions. The dependent variable was perceived change in child MWB due to the impact of COVID-19. Independent variables included perceived changes in PA, SB, and child concerns about COVID-19. RESULTS: Sample size consisted of 144 surveys and 16 interviews. Most parents reported a perceived decrease in child MWB (74%), a decrease in child PA (61%), and an increase in child SB (91%). Discontentment with stay-at-home orders and concern about COVID-19 were associated with a perceived decrease in MWB. Children whose PA decreased were 53% less likely to have the same or better MWB (OR 0.47) and children whose outside PA decreased were 72% less likely to have the same or better MWB (OR 0.28). Common qualitative themes included difficulty in adjusting to COVID-19 restrictions due to school closures and lack of socializing, child concerns about family getting sick, and PA benefits for improving MWB. CONCLUSIONS: Based on parent perceptions, MWB decreased with COVID-19. Maintained or increased child PA improved the chances MWB would remain the same or improve. Parent interviews provide context to these findings by showing how COVID-19 impacted MWB and the associations between PA and MWB. Understanding protective factors for child MWB during COVID-19 is important to offset negative long-term health outcomes from this ongoing pandemic. CI - (c) 2021. The Author(s). FAU - Gilbert, Amanda S AU - Gilbert AS AUID- ORCID: 0000-0001-6948-0127 AD - Prevention Research Center in St. Louis, Brown School at Washington University in St. Louis, St. Louis, MO, USA. a.s.gilbert@wustl.edu. FAU - Schmidt, Laurel AU - Schmidt L AD - Prevention Research Center in St. Louis, Brown School at Washington University in St. Louis, St. Louis, MO, USA. FAU - Beck, Alan AU - Beck A AD - Prevention Research Center in St. Louis, Brown School at Washington University in St. Louis, St. Louis, MO, USA. FAU - Kepper, Maura M AU - Kepper MM AD - Prevention Research Center in St. Louis, Brown School at Washington University in St. Louis, St. Louis, MO, USA. FAU - Mazzucca, Stephanie AU - Mazzucca S AD - Prevention Research Center in St. Louis, Brown School at Washington University in St. Louis, St. Louis, MO, USA. FAU - Eyler, Amy AU - Eyler A AD - Prevention Research Center in St. Louis, Brown School at Washington University in St. Louis, St. Louis, MO, USA. LA - eng GR - T32 HL130357/HL/NHLBI NIH HHS/United States GR - P30 DK092950/DK/NIDDK NIH HHS/United States GR - U48DP006395/ACL/ACL HHS/United States GR - P30 DK056341/DK/NIDDK NIH HHS/United States GR - U48 DP006395/DP/NCCDPHP CDC HHS/United States GR - U48DP006395/CC/CDC HHS/United States PT - Journal Article PT - Research Support, U.S. Gov't, P.H.S. DEP - 20210928 PL - England TA - BMC Public Health JT - BMC public health JID - 100968562 SB - IM MH - *COVID-19 MH - Child MH - Exercise MH - Humans MH - *Pandemics MH - SARS-CoV-2 MH - Sedentary Behavior PMC - PMC8478004 OTO - NOTNLM OT - COVID-19 OT - Child OT - Mental well-being OT - Mixed-methods OT - Physical activity OT - Sedentary behavior COIS- The authors declare that they have no competing interests. EDAT- 2021/09/30 06:00 MHDA- 2021/10/02 06:00 PMCR- 2021/09/28 CRDT- 2021/09/29 05:37 PHST- 2020/11/04 00:00 [received] PHST- 2021/09/15 00:00 [accepted] PHST- 2021/09/29 05:37 [entrez] PHST- 2021/09/30 06:00 [pubmed] PHST- 2021/10/02 06:00 [medline] PHST- 2021/09/28 00:00 [pmc-release] AID - 10.1186/s12889-021-11805-6 [pii] AID - 11805 [pii] AID - 10.1186/s12889-021-11805-6 [doi] PST - epublish SO - BMC Public Health. 2021 Sep 28;21(1):1770. doi: 10.1186/s12889-021-11805-6. PMID- 34569701 OWN - NLM STAT- MEDLINE DCOM- 20211103 LR - 20211211 IS - 1447-0594 (Electronic) IS - 1444-1586 (Print) IS - 1447-0594 (Linking) VI - 21 IP - 11 DP - 2021 Nov TI - Change in subjective health status among frail older Japanese people owing to the coronavirus disease pandemic and characteristics of their responses. PG - 1053-1059 LID - 10.1111/ggi.14276 [doi] AB - AIM: The coronavirus disease 2019 (COVID-19) pandemic remains a major global public health issue, and it has led to restrictions in physical and social activities among community-dwelling people, including frail older adults. This study aimed to determine the impact of the pandemic on the subjective health status and characteristics of community-dwelling frail older adults by assessing their knowledge of infection, behaviors and negative psychological response. METHODS: During October 2019, 720 older adults participated in "The Otassha Study." A year after the COVID-19 outbreak, between June 29 and July 31, 2020, a health status questionnaire, comprising questions concerning knowledge about infection, behaviors and psychological responses during the pandemic, was sent to all participants of the health examination in 2019. Respondents were divided into the robust and frail groups, and their responses were compared. RESULTS: Although the self-reported health status of the older adults in both groups was worse in 2020 than in 2019, differences were not observed in the degree of deterioration between the groups. Those in the frail group had fewer resources of information related to COVID-19 and had fewer coping behaviors for health maintenance compared with the robust group. CONCLUSION: Information gathering and actions aimed at health maintenance tended to be weaker among older adults with frailty, although the influence of COVID-19 on subjective health status did not differ significantly between robust and frail adults. Therefore, robust and frail older adults may need to adopt different countermeasures to prevent worse health during this pandemic. Geriatr Gerontol Int 2021; 21: 1053-1059. CI - (c) 2021 Japan Geriatrics Society. FAU - Kera, Takeshi AU - Kera T AUID- ORCID: 0000-0002-2356-0188 AD - Department of Physical Therapy, Takasaki University of Health and Welfare, Takasaki, Japan. AD - Research Team for Human Care, Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan. FAU - Kawai, Hisashi AU - Kawai H AUID- ORCID: 0000-0003-3015-6041 AD - Research Team for Human Care, Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan. FAU - Ejiri, Manami AU - Ejiri M AUID- ORCID: 0000-0003-3544-4587 AD - Research Team for Human Care, Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan. FAU - Takahashi, Junta AU - Takahashi J AUID- ORCID: 0000-0001-8599-6107 AD - The Tokyo Metropolitan Support Center for Promotion of Preventive Care, Tokyo, Japan. FAU - Nishida, Kazumasa AU - Nishida K AD - Health Promotion Management Office, Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan. FAU - Harai, Akihiro AU - Harai A AD - Health Promotion Management Office, Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan. FAU - Hirano, Hirohiko AU - Hirano H AD - Research Team for Promoting Independence and Mental Health, Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan. FAU - Watanabe, Yutaka AU - Watanabe Y AUID- ORCID: 0000-0002-4983-2399 AD - Gerodontology, Department of Oral Health Science, Faculty of Dental Medicine, Hokkaido University, Sapporo, Japan. FAU - Fujiwara, Yoshinori AU - Fujiwara Y AD - Research Team for Social Participation and Community Health, Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan. FAU - Ihara, Kazushige AU - Ihara K AD - Department of Social Medicine, Hirosaki University School of Medicine, Aomori, Japan. FAU - Kim, Hunkyung AU - Kim H AD - Research Team for Promoting Independence and Mental Health, Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan. FAU - Obuchi, Shuichi AU - Obuchi S AUID- ORCID: 0000-0003-0187-9275 AD - Research Team for Human Care, Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan. LA - eng GR - 29-42/2019 Research Funding for Longevity Sciences/ GR - 16K01853/Japan Society for the Promotion of Science/ GR - 18K18462/Japan Society for the Promotion of Science/ PT - Journal Article DEP - 20210927 PL - Japan TA - Geriatr Gerontol Int JT - Geriatrics & gerontology international JID - 101135738 SB - IM MH - Aged MH - *COVID-19 MH - Cross-Sectional Studies MH - Diagnostic Self Evaluation MH - *Frail Elderly MH - Geriatric Assessment MH - Health Status MH - Humans MH - Japan/epidemiology MH - Pandemics MH - SARS-CoV-2 PMC - PMC8652671 OTO - NOTNLM OT - COVID-19 OT - behaviors OT - frail OT - questionnaire OT - self-reported health status EDAT- 2021/09/28 06:00 MHDA- 2021/11/04 06:00 PMCR- 2021/09/27 CRDT- 2021/09/27 09:04 PHST- 2021/08/20 00:00 [revised] PHST- 2021/05/11 00:00 [received] PHST- 2021/08/24 00:00 [accepted] PHST- 2021/09/28 06:00 [pubmed] PHST- 2021/11/04 06:00 [medline] PHST- 2021/09/27 09:04 [entrez] PHST- 2021/09/27 00:00 [pmc-release] AID - GGI14276 [pii] AID - 10.1111/ggi.14276 [doi] PST - ppublish SO - Geriatr Gerontol Int. 2021 Nov;21(11):1053-1059. doi: 10.1111/ggi.14276. Epub 2021 Sep 27. PMID- 34563867 OWN - NLM STAT- MEDLINE DCOM- 20211115 LR - 20221221 IS - 1873-5347 (Electronic) IS - 0277-9536 (Print) IS - 0277-9536 (Linking) VI - 289 DP - 2021 Nov TI - Area level deprivation and monthly COVID-19 cases: The impact of government policy in England. PG - 114413 LID - S0277-9536(21)00745-0 [pii] LID - 10.1016/j.socscimed.2021.114413 [doi] AB - This paper aims to understand the relationship between area level deprivation and monthly COVID-19 cases in England in response to government policy throughout 2020. The response variable is monthly reported COVID-19 cases at the Middle Super Output Area (MSOA) level by Public Health England, with Index of Multiple Deprivation (IMD), ethnicity (percentage of the population across 5 ethnicity categories) and the percentage of the population older than 70 years old and time as predictors. A GEE population-averaged panel-data model was employed to model trends in monthly COVID-19 cases with the population of each MSOA included as the exposure variable. Area level deprivation is significantly associated with COVID-19 cases from March 2020; however, this relationship is reversed in December 2020. Follow up analysis found that this reversal was maintained when controlling for the novel COVID-19 variant outbreak in the South East of England. This analysis indicates that changes in the role of deprivation and monthly reported COVID-19 over time cases may be linked to two government policies: (1) the premature easing of national restrictions in July 2020 when cases were still high in the most deprived areas in England and (2) the introduction of a regional tiered system in October predominantly in the North of England. The analysis adds to the evidence showing that deprivation is a key driver of COVID-19 outcomes and highlights the unintended negative impact of government policy. CI - Copyright (c) 2021 The Authors. Published by Elsevier Ltd.. All rights reserved. FAU - Morrissey, Karyn AU - Morrissey K AD - DTU Management, Department of Technology, Management and Economics, Technical University of Denmark, Demark; European Centre for Environment and Human Health, University of Exeter, UK; Alan Turing Institute, London, UK. Electronic address: kamorr@dtu.dk. FAU - Spooner, Fiona AU - Spooner F AD - European Centre for Environment and Human Health, University of Exeter, UK. Electronic address: F.Spooner@exeter.ac.uk. FAU - Salter, James AU - Salter J AD - Mathematics, School of Engineering, Mathematics and Physical Sciences, University of Exeter, UK; Joint Centre for Excellence in Environmental Intelligence, Exeter, UK. Electronic address: J.M.Salter@exeter.ac.uk. FAU - Shaddick, Gavin AU - Shaddick G AD - Mathematics, School of Engineering, Mathematics and Physical Sciences, University of Exeter, UK; Joint Centre for Excellence in Environmental Intelligence, Exeter, UK; Alan Turing Institute, London, UK. Electronic address: g.shaddick@exeter.ac.uk. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20210923 PL - England TA - Soc Sci Med JT - Social science & medicine (1982) JID - 8303205 SB - IM MH - Aged MH - *COVID-19 MH - England/epidemiology MH - Government MH - Humans MH - Policy MH - SARS-CoV-2 PMC - PMC8459718 OTO - NOTNLM OT - COVID-19 cases OT - Deprivation OT - England OT - Government policy OT - Panel data analysis EDAT- 2021/09/27 06:00 MHDA- 2021/11/16 06:00 PMCR- 2021/09/23 CRDT- 2021/09/26 20:50 PHST- 2021/04/21 00:00 [received] PHST- 2021/08/25 00:00 [revised] PHST- 2021/09/17 00:00 [accepted] PHST- 2021/09/27 06:00 [pubmed] PHST- 2021/11/16 06:00 [medline] PHST- 2021/09/26 20:50 [entrez] PHST- 2021/09/23 00:00 [pmc-release] AID - S0277-9536(21)00745-0 [pii] AID - 114413 [pii] AID - 10.1016/j.socscimed.2021.114413 [doi] PST - ppublish SO - Soc Sci Med. 2021 Nov;289:114413. doi: 10.1016/j.socscimed.2021.114413. Epub 2021 Sep 23. PMID- 34557193 OWN - NLM STAT- MEDLINE DCOM- 20211217 LR - 20231107 IS - 1664-3224 (Electronic) IS - 1664-3224 (Linking) VI - 12 DP - 2021 TI - Associations Between Maternal Immunisation and Reduced Rates of Preterm Birth and Stillbirth: A Population Based Retrospective Cohort Study. PG - 704254 LID - 10.3389/fimmu.2021.704254 [doi] LID - 704254 AB - Stillbirth and preterm birth (PTB) remain two of the most important, unresolved challenges in modern pregnancy care. Approximately 10% of all births are preterm with nearly one million children dying each year due to PTB. It remains the most common cause of death among children under five years of age. The numbers for stillbirth are no less shocking with 2.6 million babies stillborn each year. With minimal impact on the rate of these adverse birth outcomes over the past decade there is an urgent need to identify more effective interventions to tackle these problems. In this retrospective cohort study, we used whole-of-population data, to determine if maternal immunization during pregnancy against influenza and/or pertussis, is associated with a lower risk of PTB, delivering a small-for-gestational age (SGA) infant, developing preeclampsia or stillbirth. Women with a singleton pregnancy at 28 or more weeks' gestation delivering in Victoria, Australia from July 2015 to December 2018 were included in the analysis. Log-binomial regression was used to measure the relationship between vaccination during pregnancy against influenza and against pertussis, with preterm birth, SGA, preeclampsia and stillbirth. Variables included in the adjusted model were maternal age, body mass index, first or subsequent birth, maternal Indigenous status, socio-economic quintile, smoking, public or private maternity care and metropolitan or rural location of the hospital. Women who received influenza vaccine were 75% less likely to have a stillbirth (aRR 025; 95% CI 0.20, 0.31), and 31% less likely to birth <37 weeks (aRR 0.69; 95% CI 0.66, 0.72). Women who received pertussis vaccine were 77% less likely to have a stillbirth (aOR 0.23; 95% CI 0.18, 0.28) and 32% less likely to birth <37 weeks gestation (aRR 0.68; 95% CI 0.66, 0.71). Vaccination also reduced the odds of small for gestational age by 13% and reduced the odds of pre-eclampsia when restricted to primiparous women. This association was seen over four different influenza seasons and independent of the time of year suggesting that any protective effect on obstetric outcomes afforded by maternal vaccination may not be due to a pathogen-specific response but rather due to pathogen-agnostic immune-modulatory effects. CI - Copyright (c) 2021 Giles, Davey and Wallace. FAU - Giles, Michelle L AU - Giles ML AD - The Ritchie Centre, Department of Obstetrics and Gynaecology, Monash University, Clayton, VIC, Australia. FAU - Davey, Mary-Ann AU - Davey MA AD - The Ritchie Centre, Department of Obstetrics and Gynaecology, Monash University, Clayton, VIC, Australia. FAU - Wallace, Euan M AU - Wallace EM AD - The Ritchie Centre, Department of Obstetrics and Gynaecology, Monash University, Clayton, VIC, Australia. LA - eng PT - Journal Article DEP - 20210907 PL - Switzerland TA - Front Immunol JT - Frontiers in immunology JID - 101560960 RN - 0 (Influenza Vaccines) RN - 0 (Pertussis Vaccine) SB - IM MH - Female MH - Humans MH - Influenza Vaccines/*administration & dosage MH - *Maternal Health Services MH - Pertussis Vaccine/*administration & dosage MH - Pregnancy MH - Pregnancy Complications, Infectious/epidemiology/*prevention & control MH - Premature Birth/*epidemiology MH - Retrospective Studies MH - Stillbirth/*epidemiology MH - *Vaccination MH - Victoria/epidemiology PMC - PMC8454544 OTO - NOTNLM OT - immunisation OT - influenza OT - pertussis OT - pregnancy OT - preterm birth COIS- EW is a recipient of a National Health and Medical Research Council (NHMRC) Program Grant (APP1113902) and is a chief investigator on the NHMRC Stillbirth Centre for Research Excellence (APP1116640). The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2021/09/25 06:00 MHDA- 2021/12/18 06:00 PMCR- 2021/01/01 CRDT- 2021/09/24 07:06 PHST- 2021/05/02 00:00 [received] PHST- 2021/07/26 00:00 [accepted] PHST- 2021/09/24 07:06 [entrez] PHST- 2021/09/25 06:00 [pubmed] PHST- 2021/12/18 06:00 [medline] PHST- 2021/01/01 00:00 [pmc-release] AID - 10.3389/fimmu.2021.704254 [doi] PST - epublish SO - Front Immunol. 2021 Sep 7;12:704254. doi: 10.3389/fimmu.2021.704254. eCollection 2021. PMID- 34547483 OWN - NLM STAT- MEDLINE DCOM- 20220127 LR - 20220127 IS - 2213-2961 (Electronic) IS - 2095-2546 (Print) IS - 2213-2961 (Linking) VI - 10 IP - 6 DP - 2021 Dec TI - The relationships between step count and all-cause mortality and cardiovascular events: A dose-response meta-analysis. PG - 620-628 LID - S2095-2546(21)00101-0 [pii] LID - 10.1016/j.jshs.2021.09.004 [doi] AB - BACKGROUND: A goal of 10,000 steps per day is widely advocated, but there is little evidence to support that goal. Our purpose was to examine the dose-response relationships between step count and all-cause mortality and cardiovascular disease risk. METHODS: Cochrane Central Register of Controlled Trials, EMBASE, OVID, PubMed, Scopus, and Web of Science databases were systematically searched for studies published before July 9, 2021, that evaluated the association between daily steps and at least 1 outcome. RESULTS: Sixteen publications (12 related to all-cause mortality, 5 related to cardiovascular disease; and 1 article contained 2 outcomes: both all-cause death and cardiovascular events) were eligible for inclusion in the meta-analysis. There was evidence of a nonlinear dose-response relationship between step count and risk of all-cause mortality or cardiovascular disease (p = 0.002 and p = 0.014 for nonlinearity, respectively). When we restricted the analyses to accelerometer-based studies, the third quartile had a 40.36% lower risk of all-cause mortality and a 35.05% lower risk of cardiovascular event than the first quartile (all-cause mortality: Q1 = 4183 steps/day, Q3 = 8959 steps/day; cardiovascular event: Q1 = 3500 steps/day, Q3 = 9500 steps/day; respectively). CONCLUSION: Our meta-analysis suggests inverse associations between higher step count and risk of premature death and cardiovascular events in middle-aged and older adults, with nonlinear dose-response patterns. CI - Copyright (c) 2021. Production and hosting by Elsevier B.V. FAU - Sheng, Mingxin AU - Sheng M AD - Key Laboratory of Environmental Medicine Engineering of Ministry of Education, Department of Epidemiology and Biostatistics, School of Public Health, Southeast University, Nanjing 210009, China. FAU - Yang, Junyue AU - Yang J AD - Key Laboratory of Environmental Medicine Engineering of Ministry of Education, Department of Epidemiology and Biostatistics, School of Public Health, Southeast University, Nanjing 210009, China. FAU - Bao, Min AU - Bao M AD - Key Laboratory of Environmental Medicine Engineering of Ministry of Education, Department of Epidemiology and Biostatistics, School of Public Health, Southeast University, Nanjing 210009, China. FAU - Chen, Tianzhi AU - Chen T AD - Department of Health Policy and Management, School of Public Health, Peking University, Beijing 100191, China. FAU - Cai, Ruixue AU - Cai R AD - Key Laboratory of Environmental Medicine Engineering of Ministry of Education, Department of Epidemiology and Biostatistics, School of Public Health, Southeast University, Nanjing 210009, China. FAU - Zhang, Na AU - Zhang N AD - Key Laboratory of Environmental Medicine Engineering of Ministry of Education, Department of Epidemiology and Biostatistics, School of Public Health, Southeast University, Nanjing 210009, China. FAU - Chen, Hongling AU - Chen H AD - Key Laboratory of Environmental Medicine Engineering of Ministry of Education, Department of Epidemiology and Biostatistics, School of Public Health, Southeast University, Nanjing 210009, China. FAU - Liu, Minqi AU - Liu M AD - Key Laboratory of Environmental Medicine Engineering of Ministry of Education, Department of Epidemiology and Biostatistics, School of Public Health, Southeast University, Nanjing 210009, China. FAU - Wu, Xueyu AU - Wu X AD - Key Laboratory of Environmental Medicine Engineering of Ministry of Education, Department of Epidemiology and Biostatistics, School of Public Health, Southeast University, Nanjing 210009, China. FAU - Zhang, Bowen AU - Zhang B AD - Key Laboratory of Environmental Medicine Engineering of Ministry of Education, Department of Epidemiology and Biostatistics, School of Public Health, Southeast University, Nanjing 210009, China. FAU - Liu, Yiting AU - Liu Y AD - Key Laboratory of Environmental Medicine Engineering of Ministry of Education, Department of Epidemiology and Biostatistics, School of Public Health, Southeast University, Nanjing 210009, China. FAU - Chao, Jianqian AU - Chao J AD - Key Laboratory of Environmental Medicine Engineering of Ministry of Education, Department of Epidemiology and Biostatistics, School of Public Health, Southeast University, Nanjing 210009, China. Electronic address: chaoseu@163.com. LA - eng PT - Journal Article PT - Meta-Analysis PT - Research Support, Non-U.S. Gov't PT - Review DEP - 20210920 PL - China TA - J Sport Health Sci JT - Journal of sport and health science JID - 101606001 SB - IM MH - Aged MH - *Cardiovascular Diseases/epidemiology MH - Humans MH - Middle Aged PMC - PMC8724621 OTO - NOTNLM OT - All-cause death OT - Cardiovascular disease OT - Daily steps OT - Dose-response OT - Healthy lifestyle OT - Primary prevention COIS- Competing interests The authors declare that they have no competing interests. EDAT- 2021/09/22 06:00 MHDA- 2022/01/28 06:00 PMCR- 2021/09/20 CRDT- 2021/09/21 20:17 PHST- 2021/04/01 00:00 [received] PHST- 2021/06/01 00:00 [revised] PHST- 2021/07/21 00:00 [accepted] PHST- 2021/09/22 06:00 [pubmed] PHST- 2022/01/28 06:00 [medline] PHST- 2021/09/21 20:17 [entrez] PHST- 2021/09/20 00:00 [pmc-release] AID - S2095-2546(21)00101-0 [pii] AID - 10.1016/j.jshs.2021.09.004 [doi] PST - ppublish SO - J Sport Health Sci. 2021 Dec;10(6):620-628. doi: 10.1016/j.jshs.2021.09.004. Epub 2021 Sep 20. PMID- 34544389 OWN - NLM STAT- MEDLINE DCOM- 20210924 LR - 20210924 IS - 1471-2334 (Electronic) IS - 1471-2334 (Linking) VI - 21 IP - 1 DP - 2021 Sep 20 TI - COVID-19 may exacerbate the clinical, structural and psychological barriers to retention in care among women living with HIV in rural and peri-urban settings in Uganda. PG - 980 LID - 10.1186/s12879-021-06684-6 [doi] LID - 980 AB - BACKGROUND: Retention of pregnant and breastfeeding women and their infants in HIV care still remains low in Uganda. Recent literature has shown that the effects of COVID-19 mitigation measures may increase disease burden of common illnesses including HIV, Tuberculosis, Malaria and other key public health outcomes such as maternal mortality. A research program was undertaken to locate disengaged HIV positive women on option B+ and supported them to reengage in care. A 1 year follow up done following the tracing revealed that some women still disengaged from care. We aimed to establish the barriers to and facilitators for reengagement in care among previously traced women on option B+, and how these could have been impacted by the COVID-19 pandemic. METHODS: This was a cross sectional qualitative study using individual interviews conducted in June and July, 2020, a period when the COVID-19 response measures such as lockdown and restrictions on transport were being observed in Uganda. Study participants were drawn from nine peri-urban and rural public healthcare facilities. Purposive sampling was used to select women still engaged in and those who disengaged from care approximately after 1 year since they were last contacted. Seventeen participants were included. Data was analysed using the content analysis approach. RESULTS: Women reported various barriers that affected their reengagement and retention in care during the COVID-19 pandemic. These included structural barriers such as transport difficulties and financial constraints; clinical barriers which included unsupportive healthcare workers, short supply of drugs, clinic delays, lack of privacy and medicine side effects; and psychosocial barriers such as perceived or experienced stigma and non-disclosure of HIV sero-status. Supportive structures such as family, community-based medicine distribution models, and a friendly healthcare environment were key facilitators to retention in care among this group. The COVID-19 pandemic was reported to exacerbate the barriers to retention in care. CONCLUSIONS: COVID-19 may exacerbate barriers to retention in HIV care among those who have experienced previous disengagement. We recommend community-based models such as drop out centres, peer facilitated distribution and community outreaches as alternative measures for access to ART during the COVID-19 pandemic. CI - (c) 2021. The Author(s). FAU - Nalubega, Sylivia AU - Nalubega S AUID- ORCID: 0000-0002-0756-5819 AD - Department of Nursing, School of Health Sciences, Soroti University, Po Box, 211, Soroti, Uganda. syliviaogwang@yahoo.com. FAU - Kyenkya, Joshua AU - Kyenkya J AD - Research Department, Infectious Diseases Institute, College of Health Sciences, Makerere University, Kampala, Uganda. FAU - Bagaya, Irene AU - Bagaya I AD - Research Department, Infectious Diseases Institute, College of Health Sciences, Makerere University, Kampala, Uganda. FAU - Nabukenya, Sylvia AU - Nabukenya S AD - Research Department, Infectious Diseases Institute, College of Health Sciences, Makerere University, Kampala, Uganda. FAU - Ssewankambo, Nelson AU - Ssewankambo N AD - Department of Medicine, School of Medicine, College of Health Sciences, Makerere University, Kampala, Uganda. FAU - Nakanjako, Damalie AU - Nakanjako D AD - Department of Medicine, School of Medicine, College of Health Sciences, Makerere University, Kampala, Uganda. FAU - Kiragga, Agnes N AU - Kiragga AN AD - Research Department, Infectious Diseases Institute, College of Health Sciences, Makerere University, Kampala, Uganda. LA - eng GR - U91 HA06801/Afya Bora Consortium/ GR - 100448 LOCATOR TMA 2015 CDF - 1036/European Commission/ PT - Journal Article DEP - 20210920 PL - England TA - BMC Infect Dis JT - BMC infectious diseases JID - 100968551 SB - IM MH - *COVID-19 MH - Communicable Disease Control MH - Cross-Sectional Studies MH - Female MH - *HIV Infections/epidemiology MH - Humans MH - Infant MH - Pandemics MH - Pregnancy MH - Qualitative Research MH - *Retention in Care MH - SARS-CoV-2 MH - Uganda/epidemiology PMC - PMC8451386 OTO - NOTNLM OT - Barriers OT - COVID-19 OT - HIV care OT - Retention OT - Uganda OT - Women COIS- The authors declare that there is no competing interests regarding this study. EDAT- 2021/09/22 06:00 MHDA- 2021/09/25 06:00 PMCR- 2021/09/20 CRDT- 2021/09/21 05:34 PHST- 2020/10/14 00:00 [received] PHST- 2021/09/13 00:00 [accepted] PHST- 2021/09/21 05:34 [entrez] PHST- 2021/09/22 06:00 [pubmed] PHST- 2021/09/25 06:00 [medline] PHST- 2021/09/20 00:00 [pmc-release] AID - 10.1186/s12879-021-06684-6 [pii] AID - 6684 [pii] AID - 10.1186/s12879-021-06684-6 [doi] PST - epublish SO - BMC Infect Dis. 2021 Sep 20;21(1):980. doi: 10.1186/s12879-021-06684-6. PMID- 34539457 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20261001 IS - 1664-0640 (Print) IS - 1664-0640 (Electronic) IS - 1664-0640 (Linking) VI - 12 DP - 2021 TI - Global Financial Crisis, Smart Lockdown Strategies, and the COVID-19 Spillover Impacts: A Global Perspective Implications From Southeast Asia. PG - 643783 LID - 10.3389/fpsyt.2021.643783 [doi] LID - 643783 AB - This present study primarily emphasizes to seek the COVID-19 adverse impacts posing health challenges and global economic crisis. The pandemic (COVID-19) continues to hit the global economies adversely. Pakistan is the 5th-most-populous nation, and recorded positive cases with the third-highest positivity ratio in South Asia, and 26th-highest deaths toll of 21,450 and 29th number of most COVID-19 positive cases with 933,750 worldwide, as of June 6, 2021. The first wave appeared at the end of May 2020, and mid of June reported its peak, which ended by mid-July 2020. Early November 2020 witnessed the second wave with low intensity reached the climax by mid-December. The COVID-19's third wave severely affected the country during mid-March 2021. It exhibited the highest positivity rate, around 20%. New positive patients and deaths toll commenced to skyrocket and reported peak by April 15, 2021. Then situation gradually improved with effective measures and restrictions. The pandemic coronavirus (COVID-19) has affected 220 territories, regions, and countries and resulted in more than 174.116 million infections, deaths, 3.75 million, and 157.157 million positive cases fully recovered from this infectious disease, as of June 7, 2021. The pandemic has caused a severe crisis of healthcare facilities and economic challenges worldwide. Pakistani economy reported GPD's negative growth (-0.05) for the first time over the last 60 years in 2020, which caused a massive financial crisis. The Government's relief package intervened to reduce public mental stress and improve the quality of their lives. IMF reported that Pakistan's GPD bounced back at 4% growth by June 2021. This article determines that economic instability and health burden happened in Pakistan for a longer time than financial disequilibrium that occurred globally. Pakistan encountered this crisis due to its feeble healthcare systems and fragile economy. This study explores adverse health issues and spillover consequences on the economic crisis in Pakistan with global implications. It recommends smart lockdown restrictions in most affected areas to reopen the economic cycle with strict preventive measures to minimize the COVD-19 adverse consequences. CI - Copyright (c) 2021 Wang, Wang, Abbas, Duan and Mubeen. FAU - Wang, Chunlei AU - Wang C AD - School of International Economics and Trade, Shanghai Lixin University of Accounting and Finance, Shanghai, China. FAU - Wang, Dake AU - Wang D AD - School of Media and Communication, Shanghai Jiao Tong University, Shanghai, China. FAU - Abbas, Jaffar AU - Abbas J AD - School of Media and Communication, Shanghai Jiao Tong University, Shanghai, China. AD - Antai College of Economics and Management, Shanghai Jiao Tong University, Shanghai, China. FAU - Duan, Kaifeng AU - Duan K AD - School of Economics and Management, Tongji University, Shanghai, China. FAU - Mubeen, Riaqa AU - Mubeen R AD - School of Management, Harbin Institute of Technology, Harbin, China. LA - eng PT - Journal Article DEP - 20210903 PL - Switzerland TA - Front Psychiatry JT - Frontiers in psychiatry JID - 101545006 PMC - PMC8446391 OTO - NOTNLM OT - COVID-19 OT - economic crisis OT - public health OT - smart lockdown strategy OT - social factors OT - spillover impacts COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2021/09/21 06:00 MHDA- 2021/09/21 06:01 PMCR- 2021/09/03 CRDT- 2021/09/20 06:01 PHST- 2020/12/18 00:00 [received] PHST- 2021/06/09 00:00 [accepted] PHST- 2021/09/20 06:01 [entrez] PHST- 2021/09/21 06:00 [pubmed] PHST- 2021/09/21 06:01 [medline] PHST- 2021/09/03 00:00 [pmc-release] AID - 10.3389/fpsyt.2021.643783 [doi] PST - epublish SO - Front Psychiatry. 2021 Sep 3;12:643783. doi: 10.3389/fpsyt.2021.643783. eCollection 2021. PMID- 34538265 OWN - NLM STAT- MEDLINE DCOM- 20210924 LR - 20260705 IS - 1756-3305 (Electronic) IS - 1756-3305 (Linking) VI - 14 IP - 1 DP - 2021 Sep 19 TI - Impact of interventions on the incidence of natural focal diseases during the outbreak of COVID-19 in Jiangsu Province, China. PG - 483 LID - 10.1186/s13071-021-04986-x [doi] LID - 483 AB - BACKGROUND: During the period of the coronavirus disease 2019 (COVID-19) outbreak, strong intervention measures, such as lockdown, travel restriction, and suspension of work and production, may have curbed the spread of other infectious diseases, including natural focal diseases. In this study, we aimed to study the impact of COVID-19 prevention and control measures on the reported incidence of natural focal diseases (brucellosis, malaria, hemorrhagic fever with renal syndrome [HFRS], dengue, severe fever with thrombocytopenia syndrome [SFTS], rabies, tsutsugamushi and Japanese encephalitis [JE]). METHODS: The data on daily COVID-19 confirmed cases and natural focal disease cases were collected from Jiangsu Provincial Center for Disease Control and Prevention (Jiangsu Provincial CDC). We described and compared the difference between the incidence in 2020 and the incidence in 2015-2019 in four aspects: trend in reported incidence, age, sex, and urban and rural distribution. An autoregressive integrated moving average (ARIMA) (p, d, q) x (P, D, Q)(s) model was adopted for natural focal diseases, malaria and severe fever with thrombocytopenia syndrome (SFTS), and an ARIMA (p, d, q) model was adopted for dengue. Nonparametric tests were used to compare the reported and the predicted incidence in 2020, the incidence in 2020 and the previous 4 years, and the difference between the duration from illness onset date to diagnosed date (DID) in 2020 and in the previous 4 years. The determination coefficient (R(2)) was used to evaluate the goodness of fit of the model simulation. RESULTS: Natural focal diseases in Jiangsu Province showed a long-term seasonal trend. The reported incidence of natural focal diseases, malaria and dengue in 2020 was lower than the predicted incidence, and the difference was statistically significant (P < 0.05). The reported incidence of brucellosis in July, August, October and November 2020, and SFTS in May to November 2020 was higher than that in the same period in the previous 4 years (P < 0.05). The reported incidence of malaria in April to December 2020, HFRS in March, May and December 2020, and dengue in July to November 2020 was lower than that in the same period in the previous 4 years (P < 0.05). In males, the reported incidence of malaria in 2020 was lower than that in the previous 4 years, and the reported incidence of dengue in 2020 was lower than that in 2017-2019. The reported incidence of malaria in the 20-60-year age group was lower than that in the previous 4 years; the reported incidence of dengue in the 40-60-year age group was lower than that in 2016-2018. The reported cases of malaria in both urban and rural areas were lower than in the previous 4 years. The DID of brucellosis and SFTS in 2020 was shorter than that in 2015-2018; the DID of tsutsugamushi in 2020 was shorter than that in the previous 4 years. CONCLUSIONS: Interventions for COVID-19 may help control the epidemics of natural focal diseases in Jiangsu Province. The reported incidence of natural focal diseases, especially malaria and dengue, decreased during the outbreak of COVID-19 in 2020. COVID-19 prevention and control measures had the greatest impact on the reported incidence of natural focal diseases in males and people in the 20-60-year age group. CI - (c) 2021. The Author(s). FAU - Cheng, Xiaoqing AU - Cheng X AD - Jiangsu Provincial Center for Disease Control and Prevention (Jiangsu Institution of Public Health), Nanjing, 210009, Jiangsu, People's Republic of China. FAU - Hu, Jianli AU - Hu J AD - Jiangsu Provincial Center for Disease Control and Prevention (Jiangsu Institution of Public Health), Nanjing, 210009, Jiangsu, People's Republic of China. FAU - Luo, Li AU - Luo L AD - State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University, Xiamen, 361102, Fujian, People's Republic of China. FAU - Zhao, Zeyu AU - Zhao Z AD - State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University, Xiamen, 361102, Fujian, People's Republic of China. FAU - Zhang, Nan AU - Zhang N AD - Jiangsu Provincial Center for Disease Control and Prevention (Jiangsu Institution of Public Health), Nanjing, 210009, Jiangsu, People's Republic of China. FAU - Hannah, Mikah Ngwanguong AU - Hannah MN AD - Medical College, Xiamen University, Xiamen, 361102, Fujian, People's Republic of China. FAU - Rui, Jia AU - Rui J AD - State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University, Xiamen, 361102, Fujian, People's Republic of China. FAU - Lin, Shengnan AU - Lin S AD - State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University, Xiamen, 361102, Fujian, People's Republic of China. FAU - Zhu, Yuanzhao AU - Zhu Y AD - State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University, Xiamen, 361102, Fujian, People's Republic of China. FAU - Wang, Yao AU - Wang Y AD - State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University, Xiamen, 361102, Fujian, People's Republic of China. FAU - Yang, Meng AU - Yang M AD - State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University, Xiamen, 361102, Fujian, People's Republic of China. FAU - Xu, Jingwen AU - Xu J AD - State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University, Xiamen, 361102, Fujian, People's Republic of China. FAU - Liu, Xingchun AU - Liu X AD - State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University, Xiamen, 361102, Fujian, People's Republic of China. FAU - Yang, Tianlong AU - Yang T AD - State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University, Xiamen, 361102, Fujian, People's Republic of China. FAU - Liu, Weikang AU - Liu W AD - State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University, Xiamen, 361102, Fujian, People's Republic of China. FAU - Li, Peihua AU - Li P AD - State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University, Xiamen, 361102, Fujian, People's Republic of China. FAU - Deng, Bin AU - Deng B AD - State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University, Xiamen, 361102, Fujian, People's Republic of China. FAU - Li, Zhuoyang AU - Li Z AD - State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University, Xiamen, 361102, Fujian, People's Republic of China. FAU - Liu, Chan AU - Liu C AD - State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University, Xiamen, 361102, Fujian, People's Republic of China. FAU - Huang, Jiefeng AU - Huang J AD - State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University, Xiamen, 361102, Fujian, People's Republic of China. FAU - Peng, Zhihang AU - Peng Z AD - School of Public Health, Nanjing Medical University, Nanjing, 211166, Jiangsu, People's Republic of China. zhihangpeng@njmu.edu.cn. FAU - Bao, Changjun AU - Bao C AD - Jiangsu Provincial Center for Disease Control and Prevention (Jiangsu Institution of Public Health), Nanjing, 210009, Jiangsu, People's Republic of China. bao2000_cn@163.com. FAU - Chen, Tianmu AU - Chen T AUID- ORCID: 0000-0003-0710-5086 AD - State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University, Xiamen, 361102, Fujian, People's Republic of China. chentianmu@xmu.edu.cn. LA - eng GR - No: BE2015714/Jiangsu Province Science & Technology Demonstration Project for Emerging Infectious Diseases Control and Prevention/ GR - No: ZDXKA2016008/Key Medical Discipline of Epidemiology/ GR - INV-005834/GATES/Gates Foundation/United States GR - No: 2020Y0002/Fujian Provincial Department of Science and Technology (CN)/ GR - No: 3502Z2020YJ03/Xiamen New Coronavirus Prevention and Control Emergency Tackling Special Topic Program/ PT - Journal Article DEP - 20210919 PL - England TA - Parasit Vectors JT - Parasites & vectors JID - 101462774 SB - IM MH - Adult MH - Age Distribution MH - Aged MH - Brucellosis/*epidemiology MH - COVID-19/epidemiology/*prevention & control MH - China/epidemiology MH - Dengue/*epidemiology MH - Disease Outbreaks MH - Female MH - Humans MH - Incidence MH - Malaria/*epidemiology MH - Male MH - Middle Aged MH - Physical Distancing MH - Severe Fever with Thrombocytopenia Syndrome/epidemiology MH - Travel/statistics & numerical data MH - Young Adult PMC - PMC8449989 OTO - NOTNLM OT - COVID-19 OT - Impact OT - Intervention OT - Natural focal diseases COIS- The authors declare that they have no competing interests. EDAT- 2021/09/21 06:00 MHDA- 2021/09/25 06:00 PMCR- 2021/09/19 CRDT- 2021/09/20 05:32 PHST- 2021/04/28 00:00 [received] PHST- 2021/08/31 00:00 [accepted] PHST- 2021/09/20 05:32 [entrez] PHST- 2021/09/21 06:00 [pubmed] PHST- 2021/09/25 06:00 [medline] PHST- 2021/09/19 00:00 [pmc-release] AID - 10.1186/s13071-021-04986-x [pii] AID - 4986 [pii] AID - 10.1186/s13071-021-04986-x [doi] PST - epublish SO - Parasit Vectors. 2021 Sep 19;14(1):483. doi: 10.1186/s13071-021-04986-x. PMID- 34532334 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20210918 IS - 2296-858X (Print) IS - 2296-858X (Electronic) IS - 2296-858X (Linking) VI - 8 DP - 2021 TI - Baseline Neutrophil-to-Lymphocyte Ratio Is Independently Associated With 90-Day Transplant-Free Mortality in Patients With Cirrhosis. PG - 726950 LID - 10.3389/fmed.2021.726950 [doi] LID - 726950 AB - Background: Patients with cirrhosis have an increased risk of short-term mortality, however, few studies quantify the association between neutrophil-to-lymphocyte ratio (NLR) and 90-day transplant-free mortality in cirrhotic patients. Methods: We prospectively analyzed 3,970 patients with chronic liver diseases from two multicenter cohorts in China (January 2015 to December 2016 and July 2018 to January 2019). Restricted cubic splines (RCS) were used to analyze the relation of NLR and all-causes 90-day transplant-free mortality in cirrhosis. Results: A total of 2,583 cirrhotic patients were enrolled in our study. Restricted cubic splines showed that the odds ratio (OR) of all causes 90-day transplant-free mortality started to increase rapidly until around NLR 6.5, and then was relatively flat (p for non-linearity <0.001). The risk of 90-day transplant-free mortality in cirrhotic patients with NLR < 6.5 increased with an increment of 23% for every unit increase in NLR (p < 0.001). The patients with NLR < 4.5 had the highest risk (OR: 2.34, 95% CI 1.66-3.28). In multivariable-adjusted stratified analyses, the increase in the incidence of 90-day transplant-free mortality with NLR increasing was consistent (OR >1.0) across all major prespecified subgroups, including infection group (OR: 1.04, 95% CI 1.00-1.09) and non-infection (OR: 1.06, 95% CI 1.02-1.11) group. The trends for NLR and numbers of patients with organ failure varied synchronously and were significantly increased with time from day 7 to day 28. Conclusions: We found a non-linear association between baseline NLR and the adjusted probability of 90-day transplant-free mortality. A certain range of NLR is closely associated with poor short-term prognosis in patients with cirrhosis. CI - Copyright (c) 2021 Liu, Li, Xia, Wang, Huang, Li, Meng, Gao, Qian, Liu, Lu, Liu, Deng, Zheng, Yan, Qiao, Xiang, Zhang, Chen, Chen, Luo, Gao, Ji, Li, Zhou, Ren, Lu, Li, Zhang and Zheng. FAU - Liu, Jing AU - Liu J AD - Department of Infectious Diseases, Institute of Infection and Immunology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. AD - Chinese Chronic Liver Failure Consortium, Shanghai, China. FAU - Li, Hai AU - Li H AD - Chinese Chronic Liver Failure Consortium, Shanghai, China. AD - Department of Gastroenterology, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China. FAU - Xia, Jie AU - Xia J AD - Chinese Chronic Liver Failure Consortium, Shanghai, China. AD - Department of Infectious Diseases, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing, China. FAU - Wang, Xianbo AU - Wang X AD - Chinese Chronic Liver Failure Consortium, Shanghai, China. AD - Center of Integrative Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing, China. FAU - Huang, Yan AU - Huang Y AD - Chinese Chronic Liver Failure Consortium, Shanghai, China. AD - Department of Infectious Disease, Hunan Key Laboratory of Viral Hepatitis, Xiangya Hospital, Central South University, Hunan, China. FAU - Li, Beiling AU - Li B AD - Chinese Chronic Liver Failure Consortium, Shanghai, China. AD - Hepatology Unit, Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China. FAU - Meng, Zhongji AU - Meng Z AD - Chinese Chronic Liver Failure Consortium, Shanghai, China. AD - Department of Infectious Diseases, Hubei Clinical Research Center for Precise Diagnosis and Treatment of Liver Cancer, Taihe Hospital, Hubei University of Medicine, Shiyan, China. FAU - Gao, Yanhang AU - Gao Y AD - Chinese Chronic Liver Failure Consortium, Shanghai, China. AD - Department of Hepatology, First Hospital of Jilin University, Jilin, China. FAU - Qian, Zhiping AU - Qian Z AD - Chinese Chronic Liver Failure Consortium, Shanghai, China. AD - Department of Liver Intensive Care Unit, Shanghai Public Health Clinical Centre, Fudan University, Shanghai, China. FAU - Liu, Feng AU - Liu F AD - Chinese Chronic Liver Failure Consortium, Shanghai, China. AD - Department of Infectious Diseases and Hepatology, The Second Hospital of Shandong University, Shandong, China. FAU - Lu, Xiaobo AU - Lu X AD - Chinese Chronic Liver Failure Consortium, Shanghai, China. AD - Liver Disease Center, First Affiliated Hospital of Xinjiang Medical University, Xinjiang, China. FAU - Liu, Junping AU - Liu J AD - Chinese Chronic Liver Failure Consortium, Shanghai, China. AD - Department of Infectious Diseases, Henan Provincial People's Hospital, Henan, China. FAU - Deng, Guohong AU - Deng G AD - Chinese Chronic Liver Failure Consortium, Shanghai, China. AD - Department of Infectious Diseases, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing, China. FAU - Zheng, Yubao AU - Zheng Y AD - Chinese Chronic Liver Failure Consortium, Shanghai, China. AD - Department of Infectious Diseases, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, China. FAU - Yan, Huadong AU - Yan H AD - Chinese Chronic Liver Failure Consortium, Shanghai, China. AD - Department of Hepatology, Ningbo No. 2 Hospital, Ningbo, China. FAU - Qiao, Liang AU - Qiao L AD - Chinese Chronic Liver Failure Consortium, Shanghai, China. AD - Department of Gastroenterology, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China. FAU - Xiang, Xiaomei AU - Xiang X AD - Chinese Chronic Liver Failure Consortium, Shanghai, China. AD - Department of Infectious Diseases, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing, China. FAU - Zhang, Qun AU - Zhang Q AD - Chinese Chronic Liver Failure Consortium, Shanghai, China. AD - Center of Integrative Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing, China. FAU - Chen, Ruochan AU - Chen R AD - Chinese Chronic Liver Failure Consortium, Shanghai, China. AD - Department of Infectious Disease, Hunan Key Laboratory of Viral Hepatitis, Xiangya Hospital, Central South University, Hunan, China. FAU - Chen, Jinjun AU - Chen J AD - Chinese Chronic Liver Failure Consortium, Shanghai, China. AD - Hepatology Unit, Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China. FAU - Luo, Sen AU - Luo S AD - Chinese Chronic Liver Failure Consortium, Shanghai, China. AD - Department of Infectious Diseases, Hubei Clinical Research Center for Precise Diagnosis and Treatment of Liver Cancer, Taihe Hospital, Hubei University of Medicine, Shiyan, China. FAU - Gao, La AU - Gao L AD - Chinese Chronic Liver Failure Consortium, Shanghai, China. AD - Department of Hepatology, First Hospital of Jilin University, Jilin, China. FAU - Ji, Liujuan AU - Ji L AD - Chinese Chronic Liver Failure Consortium, Shanghai, China. AD - Department of Liver Intensive Care Unit, Shanghai Public Health Clinical Centre, Fudan University, Shanghai, China. FAU - Li, Jing AU - Li J AD - Chinese Chronic Liver Failure Consortium, Shanghai, China. AD - Department of Infectious Diseases and Hepatology, The Second Hospital of Shandong University, Shandong, China. FAU - Zhou, Xinyi AU - Zhou X AD - Chinese Chronic Liver Failure Consortium, Shanghai, China. AD - Liver Disease Center, First Affiliated Hospital of Xinjiang Medical University, Xinjiang, China. FAU - Ren, Haotang AU - Ren H AD - Chinese Chronic Liver Failure Consortium, Shanghai, China. AD - State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Disease, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. FAU - Lu, Sihong AU - Lu S AD - Department of Infectious Diseases, Institute of Infection and Immunology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. AD - Chinese Chronic Liver Failure Consortium, Shanghai, China. FAU - Li, Sumeng AU - Li S AD - Department of Infectious Diseases, Institute of Infection and Immunology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. AD - Chinese Chronic Liver Failure Consortium, Shanghai, China. FAU - Zhang, Weituo AU - Zhang W AD - Clinical Research Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China. FAU - Zheng, Xin AU - Zheng X AD - Department of Infectious Diseases, Institute of Infection and Immunology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. AD - Chinese Chronic Liver Failure Consortium, Shanghai, China. LA - eng PT - Journal Article DEP - 20210831 PL - Switzerland TA - Front Med (Lausanne) JT - Frontiers in medicine JID - 101648047 PMC - PMC8438214 OTO - NOTNLM OT - acute decompensation OT - acute-on-chronic liver failure OT - cirrhosis OT - neutrophil-to-lymphocyte ratio OT - short-term mortality COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2021/09/18 06:00 MHDA- 2021/09/18 06:01 PMCR- 2021/08/31 CRDT- 2021/09/17 07:18 PHST- 2021/06/17 00:00 [received] PHST- 2021/08/04 00:00 [accepted] PHST- 2021/09/17 07:18 [entrez] PHST- 2021/09/18 06:00 [pubmed] PHST- 2021/09/18 06:01 [medline] PHST- 2021/08/31 00:00 [pmc-release] AID - 10.3389/fmed.2021.726950 [doi] PST - epublish SO - Front Med (Lausanne). 2021 Aug 31;8:726950. doi: 10.3389/fmed.2021.726950. eCollection 2021. PMID- 34531332 OWN - NLM STAT- MEDLINE DCOM- 20211015 LR - 20260127 IS - 1945-4589 (Electronic) IS - 1945-4589 (Linking) VI - 13 IP - 18 DP - 2021 Sep 16 TI - Efficacy and safety of current medications for treating severe and non-severe COVID-19 patients: an updated network meta-analysis of randomized placebo-controlled trials. PG - 21866-21902 LID - 10.18632/aging.203522 [doi] AB - BACKGROUND: Many recent studies have investigated the role of drug interventions for coronavirus disease 2019 (COVID-19) infection. However, an important question has been raised about how to select the effective and secure medications for COVID-19 patients. The aim of this analysis was to assess the efficacy and safety of the various medications available for severe and non-severe COVID-19 patients based on randomized placebo-controlled trials (RPCTs). METHODS: We did an updated network meta-analysis. We searched the databases from inception until July 31, 2021, with no language restrictions. We included RPCTs comparing 49 medications and placebo in the treatment of severe and non-severe patients (aged 18 years or older) with COVID-19 infection. We extracted data on the trial and patient characteristics, and the following primary outcomes: all-cause mortality, the ratios of virological cure, and treatment-emergent adverse events. Odds ratio (OR) and their 95% confidence interval (CI) were used as effect estimates. RESULTS: From 3,869 publications, we included 61 articles related to 73 RPCTs (57 in non-severe COVID-19 patients and 16 in severe COVID-19 patients), comprising 20,680 patients. The mean sample size was 160 (interquartile range 96-393) in this study. The median duration of follow-up drugs intervention was 28 days (interquartile range 21-30). For increase in virological cure, we only found that proxalutamide (OR 9.16, 95% CI 3.15-18.30), ivermectin (OR 6.33, 95% CI 1.22-32.86), and low dosage bamlanivimab (OR 5.29, 95% CI 1.12-24.99) seemed to be associated with non-severe COVID-19 patients when compared with placebo, in which proxalutamide seemed to be better than low dosage bamlanivimab (OR 5.69, 95% CI 2.43-17.65). For decrease in all-cause mortality, we found that proxalutamide (OR 0.13, 95% CI 0.09-0.19), imatinib (OR 0.49, 95% CI 0.25-0.96), and baricitinib (OR 0.58, 95% CI 0.42-0.82) seemed to be associated with non-severe COVID-19 patients; however, we only found that immunoglobulin gamma (OR 0.27, 95% CI 0.08-0.89) was related to severe COVID-19 patients when compared with placebo. For change in treatment-emergent adverse events, we only found that sotrovimab (OR 0.21, 95% CI 0.13-0.34) was associated with non-severe COVID-19 patients; however, we did not find any medications that presented a statistical difference when compared with placebo among severe COVID-19 patients. CONCLUSION: We conclude that marked variations exist in the efficacy and safety of medications between severe and non-severe patients with COVID-19. It seems that monoclonal antibodies (e.g., low dosage bamlanivimab, baricitinib, imatinib, and sotrovimab) are a better choice for treating severe or non-severe COVID-19 patients. Clinical decisions to use preferentially medications should carefully consider the risk-benefit profile based on efficacy and safety of all active interventions in patients with COVID-19 at different levels of infection. FAU - Cheng, Qinglin AU - Cheng Q AD - Hangzhou Center for Disease Control and Prevention, Hangzhou 310021, China. AD - School of Medicine, Hangzhou Normal University, Hangzhou 310021, China. FAU - Chen, Junfang AU - Chen J AD - Hangzhou Center for Disease Control and Prevention, Hangzhou 310021, China. FAU - Jia, Qingjun AU - Jia Q AD - Hangzhou Center for Disease Control and Prevention, Hangzhou 310021, China. FAU - Fang, Zijian AU - Fang Z AD - Hangzhou Center for Disease Control and Prevention, Hangzhou 310021, China. FAU - Zhao, Gang AU - Zhao G AD - Hangzhou Center for Disease Control and Prevention, Hangzhou 310021, China. LA - eng PT - Journal Article PT - Network Meta-Analysis PT - Research Support, Non-U.S. Gov't PT - Systematic Review DEP - 20210916 PL - United States TA - Aging (Albany NY) JT - Aging JID - 101508617 RN - 0 (Antibodies, Monoclonal) RN - 0 (Antibodies, Monoclonal, Humanized) RN - 0 (Azetidines) RN - 8A1O1M485B (Imatinib Mesylate) RN - 0 (Immunologic Factors) RN - 0 (Oxazoles) RN - 0 (Purines) RN - 0 (Pyrazoles) RN - 0 (Sulfonamides) RN - 0 (Thiohydantoins) RN - 1MTK0BPN8V (sotrovimab) RN - 0 (Antibodies, Neutralizing) RN - 45I6OFJ8QH (bamlanivimab) RN - ISP4442I3Y (baricitinib) RN - QX6O64GP40 (proxalutamide) SB - IM MH - Antibodies, Monoclonal/*therapeutic use MH - Antibodies, Monoclonal, Humanized/therapeutic use MH - Azetidines/therapeutic use MH - COVID-19/mortality MH - Humans MH - Imatinib Mesylate/therapeutic use MH - Immunologic Factors/*therapeutic use MH - Oxazoles/therapeutic use MH - Purines/therapeutic use MH - Pyrazoles/therapeutic use MH - SARS-CoV-2 MH - Severity of Illness Index MH - Sulfonamides/therapeutic use MH - Thiohydantoins/therapeutic use MH - Treatment Outcome MH - *COVID-19 Drug Treatment MH - Antibodies, Neutralizing PMC - PMC8507270 OTO - NOTNLM OT - COVID-19 OT - efficacy OT - network meta-analysis OT - randomized placebo-controlled trials OT - safety COIS- CONFLICTS OF INTEREST: The authors declare no conflicts of interest related to this study. EDAT- 2021/09/18 06:00 MHDA- 2021/10/16 06:00 PMCR- 2021/09/30 CRDT- 2021/09/17 06:17 PHST- 2021/05/05 00:00 [received] PHST- 2021/08/31 00:00 [accepted] PHST- 2021/09/18 06:00 [pubmed] PHST- 2021/10/16 06:00 [medline] PHST- 2021/09/17 06:17 [entrez] PHST- 2021/09/30 00:00 [pmc-release] AID - 203522 [pii] AID - 10.18632/aging.203522 [doi] PST - ppublish SO - Aging (Albany NY). 2021 Sep 16;13(18):21866-21902. doi: 10.18632/aging.203522. Epub 2021 Sep 16. PMID- 34530357 OWN - NLM STAT- MEDLINE DCOM- 20211112 LR - 20211112 IS - 1873-4499 (Electronic) IS - 0899-7071 (Linking) VI - 80 DP - 2021 Dec TI - Opportunistic CT screening of osteoporosis on thoracic and lumbar spine: a meta-analysis. PG - 382-390 LID - S0899-7071(21)00337-5 [pii] LID - 10.1016/j.clinimag.2021.08.005 [doi] AB - BACKGROUND: Osteoporotic fractures are a major contributor to late life morbidity and mortality, and impose a substantial societal cost, yet osteoporosis remains substantially underdiagnosed and undertreated. The purpose of this meta-analysis was to assess the pooled diagnostic sensitivity and specificity of computed tomography (CT) images for diagnosing osteoporosis in patients who meet WHO dual X-ray absorptiometry (DXA) osteoporosis criteria using specific Hounsfield unit (HU) values as a threshold. METHODS: Systematic literature searches in PubMed, Embase, Web of Science and Google Scholar were performed from the earliest available date through 1 July 2018, restricted to publications in English. Participants in all studies underwent CT scans that included the lumbar and/or thoracic spine for different indications and HU measurements were used to identify osteoporosis. DXA scans served as the reference standard. RESULTS: Ten eligible studies were identified. The mean area under the hierarchical summary receiver operating characteristic (ROC) curve for diagnosis osteoporosis was 0.84 (95% CI: 0.81, 0.87). The pooled diagnostic sensitivity and specificity of CT images to identify osteoporosis were 0.83 (95% CI: 0.73, 0.90) and 0.74 (95% CI: 0.69, 0.79). The positive likelihood ratio (LR+), negative likelihood ratio (LR-), and diagnostic odds ratio were 3.4 (95% CI: 2.7, 4.5), 0.21 (95% CI: 0.12, 0.36), and 16.4 (95% CI: 7.8, 34.3), respectively. The bias-adjusted sensitivity and specificity of CT were 0.73 and 0.71. Meta-regression demonstrated that country of study, DXA criteria and scanner manufacturer were significant factors associated with the sensitivity of CT in detecting osteoporosis while scanner manufacturer was the only factor associated with specificity of CT. CONCLUSIONS: This meta-analysis showed reasonable pooled sensitivity and specificity for using threshold values measured on CT scans to identify osteoporosis opportunistically. CI - Copyright (c) 2021 Elsevier Inc. All rights reserved. FAU - Zhu, Yeqing AU - Zhu Y AD - Department of Radiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Radiology, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China. FAU - Triphuridet, Natthaya AU - Triphuridet N AD - Department of Radiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Pulmonary Medicine, Faculty of Medicine and Public Health, HRH Princess Chulabhorn College of Medical Science, Chulabhorn Royal Academy, Bangkok, Thailand. FAU - Yip, Rowena AU - Yip R AD - Department of Radiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. FAU - Becker, Betsy J AU - Becker BJ AD - Department of Educational Psychology and Learning Systems, College of Education, Florida State University, Tallahassee, FL, USA. FAU - Wang, Yong AU - Wang Y AD - Department of Radiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Radiology, Zhongshan Hospital, Xiamen University, Xiamen, Fujian, China. FAU - Yankelevitz, David F AU - Yankelevitz DF AD - Department of Radiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. FAU - Henschke, Claudia I AU - Henschke CI AD - Department of Radiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Electronic address: Claudia.Henschke@mountsinai.org. LA - eng PT - Journal Article PT - Meta-Analysis DEP - 20210810 PL - United States TA - Clin Imaging JT - Clinical imaging JID - 8911831 SB - IM MH - Absorptiometry, Photon MH - *Bone Density MH - Humans MH - Lumbar Vertebrae/diagnostic imaging MH - *Osteoporosis/diagnostic imaging/epidemiology MH - Retrospective Studies MH - Tomography, X-Ray Computed OTO - NOTNLM OT - Bone density OT - CT attenuation OT - Meta-analysis OT - Opportunistic screening OT - Osteoporosis EDAT- 2021/09/17 06:00 MHDA- 2021/11/16 06:00 CRDT- 2021/09/16 20:27 PHST- 2020/11/16 00:00 [received] PHST- 2021/07/27 00:00 [revised] PHST- 2021/08/04 00:00 [accepted] PHST- 2021/09/17 06:00 [pubmed] PHST- 2021/11/16 06:00 [medline] PHST- 2021/09/16 20:27 [entrez] AID - S0899-7071(21)00337-5 [pii] AID - 10.1016/j.clinimag.2021.08.005 [doi] PST - ppublish SO - Clin Imaging. 2021 Dec;80:382-390. doi: 10.1016/j.clinimag.2021.08.005. Epub 2021 Aug 10. PMID- 34530058 OWN - NLM STAT- MEDLINE DCOM- 20211209 LR - 20250623 IS - 1879-176X (Electronic) IS - 0300-5712 (Linking) VI - 114 DP - 2021 Nov TI - Influence of remaining axial walls on of root filled teeth restored with a single crown and adhesively bonded fibre post: A systematic review and meta-analysis. PG - 103813 LID - S0300-5712(21)00236-0 [pii] LID - 10.1016/j.jdent.2021.103813 [doi] AB - OBJECTIVES: To synthesise evidence on structural failures and prevalence of post-treatment endodontic disease (PTD) in anterior and posterior root filled teeth with a single crown and adhesively bonded fibre post with regards to the number of axial walls. DATA: An electronic search was performed, no language constraints or restriction on the year of publication were applied. SOURCES: PubMed, Medline, Cochrane and Scopus on 13th of July 2021. STUDY SELECTION: Clinical studies that reported the remaining number of axial walls for permanent anterior and posterior root filled teeth (RFT) restored with single crowns and adhesively bonded fibre posts with a minimum of 1 year follow-up were included. Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines [1] were used. The number of axial walls and the success/failures were analysed as follows: fibre post and/or core decementation, post and/or core fracture and post treatment endodontic disease, and root fracture. CONCLUSIONS: A total of 811 studies were identified with 5 meeting the inclusion criteria. The two randomized controlled trials included had 'some concerns' as determined by the Cochrane risk-of-bias 2 tool while the Newcastle-Ottawa scale found low risk of bias for the remaining three studies. The random effects model for subgroup meta-analysis revealed failures for posterior RFT increased with decreasing numbers of remaining walls. Failures for 0 remaining walls were 23% (95% CI = 10% - 36%) and for one remaining wall 15% (CI: 3% -26%), irrespective of follow-up times. Fibre post debonding and PTD increased with decreasing numbers of walls. Relative & catastrophic failure of posterior teeth restored with a fibre post and single crown after root canal treatment increased with decreasing numbers of remaining axial walls. CLINICAL SIGNIFICANCE: This synthesis is unique as it minimizes the presence of confounding factors by reviewing evidence of failures and post-treatment endodontic disease associated with teeth restored with single crowns. Therefore, it provides valuable predictive evidence of potential coronal restoration catastrophes and post-treatment endodontic disease associated with root filled teeth. CI - Copyright (c) 2021 Elsevier Ltd. All rights reserved. FAU - AlSaleh, E AU - AlSaleh E AD - School of Dentistry, College of Biomedical and Lifesciences, Cardiff University, Cardiff CF14 4XY, United Kingdom. FAU - Dutta, A AU - Dutta A AD - School of Dentistry, College of Biomedical and Lifesciences, Cardiff University, Cardiff CF14 4XY, United Kingdom. FAU - Dummer, P M H AU - Dummer PMH AD - School of Dentistry, College of Biomedical and Lifesciences, Cardiff University, Cardiff CF14 4XY, United Kingdom. FAU - Farnell, D J J AU - Farnell DJJ AD - School of Dentistry, College of Biomedical and Lifesciences, Cardiff University, Cardiff CF14 4XY, United Kingdom. FAU - Vianna, M E AU - Vianna ME AD - School of Dentistry, College of Biomedical and Lifesciences, Cardiff University, Cardiff CF14 4XY, United Kingdom. Electronic address: viannam@cardiff.ac.uk. LA - eng PT - Journal Article PT - Meta-Analysis PT - Systematic Review DEP - 20210914 PL - England TA - J Dent JT - Journal of dentistry JID - 0354422 SB - IM MH - Crowns MH - Dental Restoration Failure MH - Humans MH - *Post and Core Technique MH - Root Canal Obturation MH - Tooth Crown MH - *Tooth, Nonvital OTO - NOTNLM OT - Axial walls OT - Failure mode OT - Fibre posts OT - Meta-analysis OT - Single crown OT - Systematic review EDAT- 2021/09/17 06:00 MHDA- 2021/12/15 06:00 CRDT- 2021/09/16 20:13 PHST- 2021/05/31 00:00 [received] PHST- 2021/08/31 00:00 [revised] PHST- 2021/09/04 00:00 [accepted] PHST- 2021/09/17 06:00 [pubmed] PHST- 2021/12/15 06:00 [medline] PHST- 2021/09/16 20:13 [entrez] AID - S0300-5712(21)00236-0 [pii] AID - 10.1016/j.jdent.2021.103813 [doi] PST - ppublish SO - J Dent. 2021 Nov;114:103813. doi: 10.1016/j.jdent.2021.103813. Epub 2021 Sep 14. PMID- 34526005 OWN - NLM STAT- MEDLINE DCOM- 20210922 LR - 20231107 IS - 1471-2458 (Electronic) IS - 1471-2458 (Linking) VI - 21 IP - 1 DP - 2021 Sep 15 TI - Ontario adults' health behaviors, mental health, and overall well-being during the COVID-19 pandemic. PG - 1679 LID - 10.1186/s12889-021-11732-6 [doi] LID - 1679 AB - BACKGROUND: Public health measures such as physical distancing and work-from-home initiatives have been implemented to slow the spread of COVID-19. These measures may also be associated with unhealthy lifestyle behaviors, which could be particularly problematic for those already at highest risk for losing years of healthy life due to chronic disease (i.e., 30-59-year-olds). The purpose of this paper is two-fold: (1) to provide an overview of Ontario adults' health behaviors (i.e., physical activity, sedentary behaviors, and dietary intake), mental health, and well-being during the first few months of the COVID-19 pandemic (April-July 2020); and (2) to explore the difference between physical activity and various health behaviors (i.e., well-being, mental health, and dietary intake). METHODS: As a part of a larger, longitudinal study, participants completed an online survey that included demographic information, the Global Physical Activity Questionnaire, Starting the Conversation, the Mental Health Inventory, and the Personal Wellbeing Index-Adult. Data analyses involved computing measures of central tendency and dispersion for demographic characteristics and tools followed by descriptive statistics. Separate independent t-tests were conducted to investigate the difference between physical activity status and well-being, mental health, and dietary intake. RESULTS: A total of 2157 Ontarians completed an online survey. Descriptive statistics indicated that respondents met physical activity and sedentary behavior guidelines, reported double the amount of recommended recreational screen time, practiced moderately healthy dietary behaviors, experienced mental health problems, and scored below "normal" in some well-being domains. CONCLUSION: As the end of the COVID-19 pandemic is currently unknown, its associated restrictions and society changes may influence adults' behaviors in both the short- and longer-term. As such, our findings might provide immediate insight into the development of timely and evidence-informed health promotion and disease prevention strategies for Canadians, which could support adults' health behaviors, mental health, and well-being during the COVID-19 pandemic and other, future pandemics. CI - (c) 2021. The Author(s). FAU - Shillington, Katie J AU - Shillington KJ AUID- ORCID: 0000-0003-1363-8778 AD - Health and Rehabilitation Sciences Program, Faculty of Health Sciences, University of Western Ontario, London, Ontario, Canada. FAU - Vanderloo, Leigh M AU - Vanderloo LM AUID- ORCID: 0000-0003-4621-3717 AD - School of Occupational Therapy, Faculty of Health Sciences, University of Western Ontario, London, Ontario, Canada. FAU - Burke, Shauna M AU - Burke SM AUID- ORCID: 0000-0003-2749-1631 AD - Health and Rehabilitation Sciences Program, Faculty of Health Sciences, University of Western Ontario, London, Ontario, Canada. AD - School of Health Studies, Faculty of Health Sciences, University of Western Ontario, London, Ontario, Canada. FAU - Ng, Victor AU - Ng V AUID- ORCID: 0000-0001-6613-4835 AD - Schulich School of Medicine and Dentistry, University of Western Ontario, London, Ontario, Canada. AD - Department of Family and Community Medicine, University of Toronto, Toronto, Ontario, Canada. AD - Division of Professional and Practice Support, College of Family Physicians of Canada, Mississauga, Ontario, Canada. FAU - Tucker, Patricia AU - Tucker P AUID- ORCID: 0000-0002-8392-9418 AD - Health and Rehabilitation Sciences Program, Faculty of Health Sciences, University of Western Ontario, London, Ontario, Canada. AD - School of Occupational Therapy, Faculty of Health Sciences, University of Western Ontario, London, Ontario, Canada. FAU - Irwin, Jennifer D AU - Irwin JD AUID- ORCID: 0000-0003-0219-4075 AD - Health and Rehabilitation Sciences Program, Faculty of Health Sciences, University of Western Ontario, London, Ontario, Canada. jenirwin@uwo.ca. AD - School of Health Studies, Faculty of Health Sciences, University of Western Ontario, London, Ontario, Canada. jenirwin@uwo.ca. LA - eng PT - Journal Article DEP - 20210915 PL - England TA - BMC Public Health JT - BMC public health JID - 100968562 SB - IM MH - Adult MH - *COVID-19 MH - Health Behavior MH - Humans MH - Longitudinal Studies MH - Mental Health MH - Middle Aged MH - Ontario/epidemiology MH - *Pandemics MH - SARS-CoV-2 PMC - PMC8441954 OTO - NOTNLM OT - COVID-19 OT - Diet OT - Mental health OT - Physical activity OT - Sedentary behavior OT - Well-being COIS- The authors declare that they have no competing interests. EDAT- 2021/09/17 06:00 MHDA- 2021/09/23 06:00 PMCR- 2021/09/15 CRDT- 2021/09/16 05:43 PHST- 2021/01/26 00:00 [received] PHST- 2021/08/31 00:00 [accepted] PHST- 2021/09/16 05:43 [entrez] PHST- 2021/09/17 06:00 [pubmed] PHST- 2021/09/23 06:00 [medline] PHST- 2021/09/15 00:00 [pmc-release] AID - 10.1186/s12889-021-11732-6 [pii] AID - 11732 [pii] AID - 10.1186/s12889-021-11732-6 [doi] PST - epublish SO - BMC Public Health. 2021 Sep 15;21(1):1679. doi: 10.1186/s12889-021-11732-6. PMID- 34521372 OWN - NLM STAT- MEDLINE DCOM- 20210920 LR - 20240403 IS - 1471-2458 (Electronic) IS - 1471-2458 (Linking) VI - 21 IP - 1 DP - 2021 Sep 14 TI - Exploring the relationship between mobility and COVID- 19 infection rates for the second peak in the United States using phase-wise association. PG - 1669 LID - 10.1186/s12889-021-11657-0 [doi] LID - 1669 AB - Human mobility plays an important role in the dynamics of infectious disease spread. Evidence from the initial nationwide lockdowns for COVID- 19 indicates that restricting human mobility is an effective strategy to contain the spread. While a direct correlation was observed early on, it is not known how mobility impacted COVID- 19 infection growth rates once lockdowns are lifted, primarily due to modulation by other factors such as face masks, social distancing, and the non-linear patterns of both mobility and infection growth. This paper introduces a piece-wise approach to better explore the phase-wise association between state-level COVID- 19 incidence data and anonymized mobile phone data for various states in the United States. Prior literature analyzed the linear correlation between mobility and the number of cases during the early stages of the pandemic. However, it is important to capture the non-linear dynamics of case growth and mobility to be usable for both tracking and forecasting COVID- 19 infections, which is accomplished by the piece-wise approach. The associations between mobility and case growth rate varied widely for various phases of the epidemic curve when the stay-at-home orders were lifted. The mobility growth patterns had a strong positive association of 0.7 with the growth in the number of cases, with a lag of 5 to 7 weeks, for the fast-growth phase of the pandemic, for only 20 states that had a peak between July 1st and September 30, 2020. Overall though, mobility cannot be used to predict the rise in the number of cases after initial lockdowns have been lifted. Our analysis explores the gradual diminishing value of mobility associations in the later stage of the outbreak. Our analysis indicates that the relationship between mobility and the increase in the number of cases, once lockdowns have been lifted, is tenuous at best and there is no strong relationship between these signals. But we identify the remnants of the last associations in specific phases of the growth curve. CI - (c) 2021. The Author(s). FAU - Gottumukkala, Raju AU - Gottumukkala R AD - Informatics Research Institute, University of Louisiana at Lafayette, Lafayette, USA. gnraju@ieee.org. AD - Mechanical Engineering Department, University of Louisiana at Lafayette, Lafayette, USA. gnraju@ieee.org. FAU - Katragadda, Satya AU - Katragadda S AD - Informatics Research Institute, University of Louisiana at Lafayette, Lafayette, USA. FAU - Bhupatiraju, Ravi Teja AU - Bhupatiraju RT AD - Informatics Research Institute, University of Louisiana at Lafayette, Lafayette, USA. FAU - Kamal, Azmyin Md AU - Kamal AM AD - Informatics Research Institute, University of Louisiana at Lafayette, Lafayette, USA. FAU - Raghavan, Vijay AU - Raghavan V AD - Informatics Research Institute, University of Louisiana at Lafayette, Lafayette, USA. FAU - Chu, Henry AU - Chu H AD - Informatics Research Institute, University of Louisiana at Lafayette, Lafayette, USA. FAU - Kolluru, Ramesh AU - Kolluru R AD - Informatics Research Institute, University of Louisiana at Lafayette, Lafayette, USA. FAU - Ashkar, Ziad AU - Ashkar Z AD - Informatics Research Institute, University of Louisiana at Lafayette, Lafayette, USA. LA - eng PT - Journal Article PT - Research Support, U.S. Gov't, Non-P.H.S. DEP - 20210914 PL - England TA - BMC Public Health JT - BMC public health JID - 100968562 SB - IM EIN - BMC Public Health. 2021 Oct 26;21(1):1942. doi: 10.1186/s12889-021-11904-4. PMID: 34702244 MH - *COVID-19 MH - *Cell Phone MH - Communicable Disease Control MH - Humans MH - Pandemics MH - SARS-CoV-2 MH - United States/epidemiology PMC - PMC8438287 COIS- The authors declare that they have no competing interests. EDAT- 2021/09/16 06:00 MHDA- 2021/09/21 06:00 PMCR- 2021/09/14 CRDT- 2021/09/15 05:43 PHST- 2021/04/15 00:00 [received] PHST- 2021/08/09 00:00 [accepted] PHST- 2021/09/15 05:43 [entrez] PHST- 2021/09/16 06:00 [pubmed] PHST- 2021/09/21 06:00 [medline] PHST- 2021/09/14 00:00 [pmc-release] AID - 10.1186/s12889-021-11657-0 [pii] AID - 11657 [pii] AID - 10.1186/s12889-021-11657-0 [doi] PST - epublish SO - BMC Public Health. 2021 Sep 14;21(1):1669. doi: 10.1186/s12889-021-11657-0. PMID- 34512309 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20210914 IS - 1663-4365 (Print) IS - 1663-4365 (Electronic) IS - 1663-4365 (Linking) VI - 13 DP - 2021 TI - The Effect and Mechanism of Cholesterol and Vitamin B(12) on Multi-Domain Cognitive Function: A Prospective Study on Chinese Middle-Aged and Older Adults. PG - 707958 LID - 10.3389/fnagi.2021.707958 [doi] LID - 707958 AB - Background: Nutrients are associated with cognitive function, but limited research studies have systematically evaluated on multi-domain cognitive function. The aim of this study was to investigate the effect and mechanism of specific nutrient on multi-domain cognitive function, and provide nutrition guidance for improving cognitive function. Methods: Participants were selected based on a multicenter prospective study on middle-aged and older adults in China. Global cognitive function was evaluated by the Mini-Mental State Examination (MMSE). Nutrients intake was assessed according to food frequency questionnaire and China Food Composition Database, and principal component analysis was performed to extract nutrient patterns. Associations between specific nutrients and cognitive function were assessed using log-binomial regression. Restricted cubic spline was used to illustrate the dose-response relationship of nutrients with multi-domain cognitive function. Mediation analysis was used to determine the mechanism of nutrients in cognitive function. Results: Four nutrient patterns were identified (vitamin-mineral, protein-carbohydrate, fatty acid-vitamin E, and cholesterol-vitamin B(12)), and only a nutrient pattern rich in cholesterol and vitamin B(12) was found associated with cognitive function (RR = 0.891, 95%CI = 0.794-0.999). In multi-domain cognitive function, dietary cholesterol and vitamin B(12) were related to better performance of visual memory function (P = 0.034, P = 0.02). In dose-response relationship, it suggested a U-shaped association between vitamin B(12) and MMSE (P = 0.02) within a certain range. Conclusions: Dietary intake rich in cholesterol and vitamin B(12) was associated with better cognitive function, and vitamin B(12) had a U-shaped dose-response relation with MMSE. Thus, ensuring moderate cholesterol and vitamin B(12)intake may be an advisable strategy to improve cognitive function in middle-aged and older adults. Clinical Trial Registration: EMCOA, ChiCTR-OOC-17011882, Registered 5th, July 2017-Retrospectively registered, http://www.medresman.org/uc/project/projectedit.aspx?proj=2610. CI - Copyright (c) 2021 Wang, Liu, Zhang, Wang, Liu, Wang, Hao, Ju and Xiao. FAU - Wang, Lijing AU - Wang L AD - School of Public Health, Capital Medical University, Beijing, China. FAU - Liu, Kuo AU - Liu K AD - School of Public Health, Capital Medical University, Beijing, China. FAU - Zhang, Xiaona AU - Zhang X AD - School of Public Health, Capital Medical University, Beijing, China. FAU - Wang, Yushan AU - Wang Y AD - School of Public Health, Capital Medical University, Beijing, China. FAU - Liu, Wen AU - Liu W AD - School of Public Health, Capital Medical University, Beijing, China. FAU - Wang, Tao AU - Wang T AD - School of Public Health, Capital Medical University, Beijing, China. FAU - Hao, Ling AU - Hao L AD - School of Public Health, Capital Medical University, Beijing, China. FAU - Ju, Mengwei AU - Ju M AD - School of Public Health, Capital Medical University, Beijing, China. FAU - Xiao, Rong AU - Xiao R AD - School of Public Health, Capital Medical University, Beijing, China. LA - eng PT - Journal Article DEP - 20210827 PL - Switzerland TA - Front Aging Neurosci JT - Frontiers in aging neuroscience JID - 101525824 PMC - PMC8430239 OTO - NOTNLM OT - cholesterol OT - dose-response relation OT - mediation analysis OT - mild cognitive impairment OT - vitamin B12 COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2021/09/14 06:00 MHDA- 2021/09/14 06:01 PMCR- 2021/01/01 CRDT- 2021/09/13 06:42 PHST- 2021/05/11 00:00 [received] PHST- 2021/07/20 00:00 [accepted] PHST- 2021/09/13 06:42 [entrez] PHST- 2021/09/14 06:00 [pubmed] PHST- 2021/09/14 06:01 [medline] PHST- 2021/01/01 00:00 [pmc-release] AID - 10.3389/fnagi.2021.707958 [doi] PST - epublish SO - Front Aging Neurosci. 2021 Aug 27;13:707958. doi: 10.3389/fnagi.2021.707958. eCollection 2021. PMID- 34510411 OWN - NLM STAT- MEDLINE DCOM- 20211124 LR - 20260127 IS - 1469-493X (Electronic) IS - 1361-6137 (Linking) VI - 9 IP - 9 DP - 2021 Sep 12 TI - Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder. PG - CD011612 LID - 10.1002/14651858.CD011612.pub3 [doi] LID - CD011612 AB - BACKGROUND: Many studies have recently been conducted to assess the antidepressant efficacy of glutamate modification in mood disorders. This is an update of a review first published in 2015 focusing on the use of glutamate receptor modulators in unipolar depression. OBJECTIVES: To assess the effects - and review the acceptability and tolerability - of ketamine and other glutamate receptor modulators in alleviating the acute symptoms of depression in people with unipolar major depressive disorder. SEARCH METHODS: We searched the Cochrane Central Register of Controlled Trials (CENTRAL), Ovid MEDLINE, Embase and PsycINFO all years to July 2020. We did not apply any restrictions to date, language or publication status. SELECTION CRITERIA: Double- or single-blinded randomised controlled trials (RCTs) comparing ketamine, memantine, esketamine or other glutamate receptor modulators with placebo (pill or saline infusion), other active psychotropic drugs, or electroconvulsive therapy (ECT) in adults with unipolar major depression. DATA COLLECTION AND ANALYSIS: Three review authors independently identified studies, assessed trial quality and extracted data. The primary outcomes were response rate (50% reduction on a standardised rating scale) and adverse events. We decided a priori to measure the efficacy outcomes at different time points and run sensitivity/subgroup analyses. Risk of bias was assessed using the Cochrane tool, and certainty of the evidence was assessed using GRADE. MAIN RESULTS: Thirty-one new studies were identified for inclusion in this updated review. Overall, we included 64 studies (5299 participants) on ketamine (31 trials), esketamine (9), memantine (5), lanicemine (4), D-cycloserine (2), Org26576 (2), riluzole (2), atomoxetine (1), basimglurant (1), citicoline (1), CP-101,606 (1), decoglurant (1), MK-0657 (1), N-acetylcysteine (1), rapastinel (1), and sarcosine (1). Forty-eight studies were placebo-controlled, and 48 were two-arm studies. The majority of trials defined an inclusion criterion for the severity of depressive symptoms at baseline: 29 at least moderate depression; 17 severe depression; and five mild-to-moderate depression. Nineteen studies recruited only patients with treatment-resistant depression, defined as inadequate response to at least two antidepressants. The majority of studies investigating ketamine administered as a single dose, whilst all of the included esketamine studies used a multiple dose regimen (most frequently twice a week for four weeks). Most studies looking at ketamine used intravenous administration, whilst the majority of esketamine trials used intranasal routes. The evidence suggests that ketamine may result in an increase in response and remission compared with placebo at 24 hours odds ratio (OR) 3.94, 95% confidence interval (CI) 1.54 to 10.10; n = 185, studies = 7, very low-certainty evidence). Ketamine may reduce depression rating scale scores over placebo at 24 hours, but the evidence is very uncertain (standardised mean difference (SMD) -0.87, 95% CI -1.26 to -0.48; n = 231, studies = 8, very low-certainty evidence). There was no difference in the number of participants assigned to ketamine or placebo who dropped out for any reason (OR 1.25, 95% CI 0.19 to 8.28; n = 201, studies = 6, very low-certainty evidence). When compared with midazolam, the evidence showed that ketamine increases remission rates at 24 hours (OR 2.21, 95% CI 0.67 to 7.32; n = 122,studies = 2, low-certainty evidence). The evidence is very uncertain about the response efficacy of ketamine at 24 hours in comparison with midazolam, and its ability to reduce depression rating scale scores at the same time point (OR 2.48, 95% CI 1.00 to 6.18; n = 296, studies = 4,very low-certainty evidence). There was no difference in the number of participants who dropped out of studies for any reason between ketamine and placebo (OR 0.33, 95% CI 0.05 to 2.09; n = 72, studies = 1, low-certainty evidence). Esketamine treatment likely results in a large increase in participants achieving remission at 24 hours compared with placebo (OR 2.74, 95% CI 1.71 to 4.40; n = 894, studies = 5, moderate-certainty evidence). Esketamine probably results in decreases in depression rating scale scores at 24 hours compared with placebo (SMD -0.31, 95% CI -0.45 to -0.17; n = 824, studies = 4, moderate-certainty evidence). Our findings show that esketamine increased response rates, although this evidence is uncertain (OR 2.11, 95% CI 1.20 to 3.68; n = 1071, studies = 5, low-certainty evidence). There was no evidence that participants assigned to esketamine treatment dropped out of trials more frequently than those assigned to placebo for any reason (OR 1.58, 95% CI 0.92 to 2.73; n = 773, studies = 4,moderate-certainty evidence). We found very little evidence for the remaining glutamate receptor modulators. We rated the risk of bias as low or unclear for most domains, though lack of detail regarding masking of treatment in the studies reduced our certainty in the effect for all outcomes. AUTHORS' CONCLUSIONS: Our findings show that ketamine and esketamine may be more efficacious than placebo at 24 hours. How these findings translate into clinical practice, however, is not entirely clear. The evidence for use of the remaining glutamate receptor modulators is limited as very few trials were included in the meta-analyses for each comparison and the majority of comparisons included only one study. Long term non-inferiority RCTs comparing repeated ketamine and esketamine, and rigorous real-world monitoring are needed to establish comprehensive data on safety and efficacy. CI - Copyright (c) 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. FAU - Dean, Rebecca L AU - Dean RL AD - Oxford Health NHS Foundation Trust, Oxford, UK. FAU - Hurducas, Claudia AU - Hurducas C AD - Oxford Health NHS Foundation Trust, Oxford, UK. FAU - Hawton, Keith AU - Hawton K AD - Centre for Suicide Research, Department of Psychiatry, University of Oxford, Oxford, UK. FAU - Spyridi, Styliani AU - Spyridi S AD - Department of Rehabilitation Sciences, Faculty of Health Sciences, Cyprus University of Technology, Lemesos, Cyprus. FAU - Cowen, Philip J AU - Cowen PJ AD - Department of Psychiatry, University of Oxford, Oxford, UK. FAU - Hollingsworth, Sarah AU - Hollingsworth S AD - Oxford Health NHS Foundation Trust, Oxford, UK. FAU - Marquardt, Tahnee AU - Marquardt T AD - Oxford Health NHS Foundation Trust, Oxford, UK. FAU - Barnes, Annabelle AU - Barnes A AD - Oxford Health NHS Foundation Trust, Oxford, UK. FAU - Smith, Rebecca AU - Smith R AD - Oxford Health NHS Foundation Trust, Oxford, UK. FAU - McShane, Rupert AU - McShane R AD - Oxford Health NHS Foundation Trust, Oxford, UK. AD - Department of Psychiatry, University of Oxford, Oxford, UK. FAU - Turner, Erick H AU - Turner EH AD - Portland Veterans Affairs Medical Center, P3MHDC, Portland, USA. AD - Department of Psychiatry, Oregon Health & Science University, Portland, Oregon, USA. FAU - Cipriani, Andrea AU - Cipriani A AD - Oxford Health NHS Foundation Trust, Oxford, UK. AD - Department of Psychiatry, University of Oxford, Oxford, UK. LA - eng SI - ClinicalTrials.gov/NCT02417064 SI - ClinicalTrials.gov/NCT03039192 SI - ClinicalTrials.gov/NCT00408031 SI - ClinicalTrials.gov/NCT00977353 SI - ClinicalTrials.gov/NCT03097133 SI - ClinicalTrials.gov/NCT01304147 SI - ClinicalTrials.gov/NCT00680433 SI - ClinicalTrials.gov/NCT00610649 SI - ClinicalTrials.gov/NCT02418585 SI - ClinicalTrials.gov/NCT00491686 SI - ClinicalTrials.gov/NCT00781742 SI - ClinicalTrials.gov/NCT00344682 SI - ClinicalTrials.gov/NCT01457677 SI - ClinicalTrials.gov/NCT00986479 SI - ClinicalTrials.gov/NCT03965871 SI - ClinicalTrials.gov/NCT04019704 SI - ClinicalTrials.gov/NCT04210804 GR - MR/S003037/1/MRC_/Medical Research Council/United Kingdom PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Systematic Review DEP - 20210912 PL - England TA - Cochrane Database Syst Rev JT - The Cochrane database of systematic reviews JID - 100909747 RN - 0 (Antidepressive Agents) RN - 0 (Receptors, Glutamate) RN - 690G0D6V8H (Ketamine) SB - IM UOF - Cochrane Database Syst Rev. 2015 Sep 23;(9):CD011612. doi: 10.1002/14651858.CD011612.pub2. PMID: 26395901 CIN - J Psychopharmacol. 2023 Aug;37(8):836-844. doi: 10.1177/02698811221123046. PMID: 36218274 MH - Adult MH - Antidepressive Agents/therapeutic use MH - Depression MH - *Major Depressive Disorder/drug therapy MH - Humans MH - *Ketamine/therapeutic use MH - Receptors, Glutamate/therapeutic use PMC - PMC8434915 COIS- Rebecca Dean: none known. Claudia Hurducas: none known. Sarah Hollingsworth: none known. Tahnee Marquardt: none known. Stella Spyridi: none known. Phil Cowen: PJC has a patent with the University of Oxford on the use of ebselen in treatment-resistant depression Keith Hawton: none known. Rupert McShane: Rupert McShane runs NHS and self-pay ketamine clinics for Oxford Health NHS Foundation Trust. Rupert has undertaken educational and scientific advisory board work for Janssen Pharmaceuticals to support educational and research activity, no funds are received personally. Janssen supported Rupert's attendance at the APA conference in New York in 2018. Rupert has undertaken scientific advisory board work for Sage pharmaceuticals, no funds are directly received. Erick Turner: Erick Turner has no financial interest in esketamine, ketamine or competing treatments. Erick previously worked as a Medical Officer for the US Food and Drug Administration (FDA), charged with reviewing applications submitted by pharmaceutical companies and determining whether the evidence on drug efficacy and safety met the FDA's criteria for US marketing approval. Erick is a former member of the Psychopharmacologic Drugs Advisory Committee which, together with the Drug Safety and Risk Management Advisory Committee, convened in Feb 2019, to advise the FDA on whether to approve esketamine, although Erick did not take part in that particular meeting due to matters related to the government shutdown. Andrea Cipriani: Andrea Cipriani has received research and consultancy fees from INCiPiT (Italian Network for Paediatric Trials), CARIPLO Foundation and Angelini Pharma. EDAT- 2021/09/13 06:00 MHDA- 2021/11/25 06:00 PMCR- 2022/09/12 CRDT- 2021/09/12 21:14 PHST- 2021/09/12 21:14 [entrez] PHST- 2021/09/13 06:00 [pubmed] PHST- 2021/11/25 06:00 [medline] PHST- 2022/09/12 00:00 [pmc-release] AID - CD011612.pub3 [pii] AID - 10.1002/14651858.CD011612.pub3 [doi] PST - epublish SO - Cochrane Database Syst Rev. 2021 Sep 12;9(9):CD011612. doi: 10.1002/14651858.CD011612.pub3. PMID- 34507923 OWN - NLM STAT- MEDLINE DCOM- 20220120 LR - 20220120 IS - 2468-0869 (Electronic) IS - 2468-0451 (Print) IS - 2468-0451 (Linking) VI - 27 IP - 1 DP - 2022 Feb TI - Unexpected benefit of COVID-19 hospital restrictions: Reduction in patients isolating with multidrug resistant organisms after restrictions were lifted. PG - 10-14 LID - S2468-0451(21)00043-2 [pii] LID - 10.1016/j.idh.2021.08.001 [doi] AB - BACKGROUND: During the COVID-19 pandemic, measures to prevent microorganism transmission were implemented across hospitals, including wearing compulsory surgical masks, minimising non-urgent procedures and restricting visitors. Previously, concerns have been raised that MRO-associated deaths could rise during a future pandemic through superimposed bacterial infections, inappropriate antibiotic use and reduced focus on preventing MRO infections. METHODS: In the state of Queensland, Australia with a population of 5 million, only a short first wave of coronavirus cases occurred and restrictions were quickly scaled back. This presented a natural experiment of pre-, during and post-COVID-19 restriction timings to evaluate the effectiveness of heightened prevention measures on multidrug resistant organism (MRO) infections. Patient isolation days and MRO types were collected weekly from routine infection control reports, at a large public hospital, from 28th January 2020 to 24th July 2020. In this interrupted time series design, we employed Poisson mixed effect regression modelling to evaluate the difference in incidence of patient isolation days between time periods. RESULTS: Compared to pre-COVID, patient isolation days reduced during COVID restrictions (incidence rate ratio 0.65, 95%CI: 0.59, 0.70; p < 0.001) and increased again post-COVID restrictions, but did not return to pre-COVID levels (0.87, 95%CI: 0.80, 0.95; p = 0.001). The efficiency of isolating patients improved after COVID-19 with fewer bed closures required. CONCLUSION: Heightened infection control awareness, hand sanitation and mask wearing after COVID-19 restrictions were lifted appear to effectively prevent common hospital-acquired MRO infections. CI - Copyright (c) 2021 Australasian College for Infection Prevention and Control. Published by Elsevier B.V. All rights reserved. FAU - Elliott, Thomas M AU - Elliott TM AD - QIMR Berghofer Medical Research Institute, 300 Herston Rd, Herston, Brisbane, QLD 4006, Australia. Electronic address: thomas.elliott@qimrberghofer.edu.au. FAU - Hurst, Cameron AU - Hurst C AD - QIMR Berghofer Medical Research Institute, 300 Herston Rd, Herston, Brisbane, QLD 4006, Australia. FAU - Doidge, Michelle AU - Doidge M AD - Infectious Diseases Unit, Royal Brisbane and Womens' Hospital, Herston, Brisbane, QLD 4029, Australia. FAU - Hurst, Trish AU - Hurst T AD - Infectious Diseases Unit, Royal Brisbane and Womens' Hospital, Herston, Brisbane, QLD 4029, Australia; The University of Queensland, Centre for Clinical Research, Herston, Brisbane, QLD 4006, Australia. FAU - Harris, Patrick Na AU - Harris PN AD - The University of Queensland, Centre for Clinical Research, Herston, Brisbane, QLD 4006, Australia; Central Microbiology, Pathology Queensland, Royal Brisbane and Women's Hospital, Herston, Brisbane, QLD 4029, Australia. FAU - Gordon, Louisa G AU - Gordon LG AD - QIMR Berghofer Medical Research Institute, 300 Herston Rd, Herston, Brisbane, QLD 4006, Australia; The University of Queensland, School of Public Health, Brisbane, QLD 4006, Australia; Queensland University of Technology, School of Nursing, Kelvin Grove, Brisbane, QLD 4059, Australia. Electronic address: https://twitter.com/@louisagord. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20210818 PL - Netherlands TA - Infect Dis Health JT - Infection, disease & health JID - 101689703 SB - IM MH - *COVID-19 MH - Drug Resistance, Multiple, Bacterial MH - Hospitals MH - Humans MH - Pandemics MH - SARS-CoV-2 PMC - PMC8372517 OTO - NOTNLM OT - COVID-19 OT - Interrupted time series analysis OT - Multidrug resistant organism EDAT- 2021/09/12 06:00 MHDA- 2022/01/21 06:00 PMCR- 2021/08/18 CRDT- 2021/09/11 05:32 PHST- 2021/05/20 00:00 [received] PHST- 2021/08/01 00:00 [revised] PHST- 2021/08/03 00:00 [accepted] PHST- 2021/09/12 06:00 [pubmed] PHST- 2022/01/21 06:00 [medline] PHST- 2021/09/11 05:32 [entrez] PHST- 2021/08/18 00:00 [pmc-release] AID - S2468-0451(21)00043-2 [pii] AID - 10.1016/j.idh.2021.08.001 [doi] PST - ppublish SO - Infect Dis Health. 2022 Feb;27(1):10-14. doi: 10.1016/j.idh.2021.08.001. Epub 2021 Aug 18. PMID- 34502010 OWN - NLM STAT- MEDLINE DCOM- 20210914 LR - 20250623 IS - 1660-4601 (Electronic) IS - 1661-7827 (Print) IS - 1660-4601 (Linking) VI - 18 IP - 17 DP - 2021 Sep 6 TI - Impact of the SARS-CoV-2 Coronavirus Pandemic on Physical Activity, Mental Health and Quality of Life in Professional Athletes-A Systematic Review. LID - 10.3390/ijerph18179423 [doi] LID - 9423 AB - Due to the rapid rate of spread of the SARS-CoV-2 coronavirus, a number of restrictions have been introduced into public spaces, including those related to the operation of sports facilities, compounding the difficulty for athletes to conduct appropriate forms of training. The aim of this study was to review current scientific reports assessing the impact of the pandemic on the physical activity, mental state, and quality of life of professional athletes. Popular scientific databases-PubMed, Scopus, and Embase-were systematically searched from the beginning of the pandemic until 12 July 2021. According to the adopted criteria, 14 articles were included in the review. Ten of the qualified studies determined the impact of the pandemic on the physical activity of athletes. The authors of 11 papers assessed the mental state and quality of life of athletes during the pandemic. The studies showed negative effects of the pandemic: a decrease in overall physical fitness and number of days and hours of training, as well as an increase in the occurrence of negative emotions (stress, fatigue, and depression) and a decrease in sleep quality. Changes in physical activity had an impact on overall well-being ratings, which depended on the sex of the subjects. Women were more likely to experience negative emotions compared to men. The mental state of the athletes affected the quality of sleep. This review summarises the negative effects of the SARS-CoV-2 coronavirus pandemic on the physical and mental health of professional athletes. FAU - Jurecka, Alicja AU - Jurecka A AUID- ORCID: 0000-0001-8761-5638 AD - Department of Orthopedics and Physiotherapy, Faculty of Health Sciences, Jagiellonian University Medical College, 30-688 Krakow, Poland. FAU - Skucinska, Paulina AU - Skucinska P AD - Students' Scientific Society, Faculty of Health Sciences, Jagiellonian University Medical College, 31-007 Krakow, Poland. FAU - Gadek, Artur AU - Gadek A AD - Department of Orthopedics and Physiotherapy, Faculty of Health Sciences, Jagiellonian University Medical College, 30-688 Krakow, Poland. LA - eng PT - Journal Article PT - Systematic Review DEP - 20210906 PL - Switzerland TA - Int J Environ Res Public Health JT - International journal of environmental research and public health JID - 101238455 SB - IM MH - Athletes MH - *COVID-19 MH - Exercise MH - Female MH - Humans MH - Male MH - Mental Health MH - Pandemics MH - Quality of Life MH - *SARS-CoV-2 PMC - PMC8431129 OTO - NOTNLM OT - COVID-19 OT - exercise OT - health-related quality of life OT - mental condition OT - sportsmen OT - training COIS- The authors declare no conflict of interest. EDAT- 2021/09/11 06:00 MHDA- 2021/09/15 06:00 PMCR- 2021/09/06 CRDT- 2021/09/10 01:06 PHST- 2021/07/31 00:00 [received] PHST- 2021/08/28 00:00 [revised] PHST- 2021/09/02 00:00 [accepted] PHST- 2021/09/10 01:06 [entrez] PHST- 2021/09/11 06:00 [pubmed] PHST- 2021/09/15 06:00 [medline] PHST- 2021/09/06 00:00 [pmc-release] AID - ijerph18179423 [pii] AID - ijerph-18-09423 [pii] AID - 10.3390/ijerph18179423 [doi] PST - epublish SO - Int J Environ Res Public Health. 2021 Sep 6;18(17):9423. doi: 10.3390/ijerph18179423. PMID- 34501661 OWN - NLM STAT- MEDLINE DCOM- 20210914 LR - 20210914 IS - 1660-4601 (Electronic) IS - 1661-7827 (Print) IS - 1660-4601 (Linking) VI - 18 IP - 17 DP - 2021 Aug 27 TI - Longitudinal Distress among Brazilian University Workers during Pandemics. LID - 10.3390/ijerph18179072 [doi] LID - 9072 AB - The present study aimed to examine changes in mental distress in Brazilian university workers during the pandemic. All workers (n approximately 1850) of an institution were invited to respond to a survey that took place in three stages, with collections in May (n = 407), June/July (n = 258), and August (n = 207) 2020, and included questions on demographic, health, general and psychological support, and psychometric assessment of mental distress (Clinical Outcome Routine Evaluation- CORE-OM) combined with an open question about major concerns. The results of the Multilevel Modeling analysis pointed to the absence of significant differences across the repeated measures of distress. The only variable associated with increased psychological distress over time was a lower level of support for household chores. Qualitative analysis of the reported major concerns was carried out with a sub-sample who showed reliable deterioration in CORE-OM across time (n = 17). The diversity of concerns reported by this group reinforced that work-life imbalance contributes to mental distress of university workers during the pandemic. Low response rate, although not unexpected due to the circumstances, limits the generalization of findings. The present data suggest that in addition to issues related to contagion and specific restricted measures to contain the spread of the disease, the personal reorganization of life required to maintain activities at home and work can be an important contributor to pandemic-related psychological distress. FAU - Zibetti, Murilo Ricardo AU - Zibetti MR AUID- ORCID: 0000-0002-8934-5640 AD - Post Graduate Program in Psychology, Universidade do Vale do Rio dos Sinos-UNISINOS, Sao Leopoldo 93022-970, Brazil. FAU - Serralta, Fernanda Barcellos AU - Serralta FB AUID- ORCID: 0000-0003-4602-6495 AD - Post Graduate Program in Psychology, Universidade do Vale do Rio dos Sinos-UNISINOS, Sao Leopoldo 93022-970, Brazil. FAU - Evans, Chris AU - Evans C AUID- ORCID: 0000-0002-4197-4202 AD - Department of Psychology, The University of Sheffield, Sheffield S1 1HD, UK. LA - eng PT - Journal Article DEP - 20210827 PL - Switzerland TA - Int J Environ Res Public Health JT - International journal of environmental research and public health JID - 101238455 SB - IM MH - *COVID-19 MH - Humans MH - Pandemics MH - *Psychological Distress MH - SARS-CoV-2 MH - Universities PMC - PMC8430478 OTO - NOTNLM OT - COVID-19 OT - longitudinal studies OT - pandemics OT - psychological distress OT - quarantine COIS- The authors declare no conflict of interest. EDAT- 2021/09/11 06:00 MHDA- 2021/09/15 06:00 PMCR- 2021/08/27 CRDT- 2021/09/10 01:04 PHST- 2021/07/24 00:00 [received] PHST- 2021/08/21 00:00 [revised] PHST- 2021/08/23 00:00 [accepted] PHST- 2021/09/10 01:04 [entrez] PHST- 2021/09/11 06:00 [pubmed] PHST- 2021/09/15 06:00 [medline] PHST- 2021/08/27 00:00 [pmc-release] AID - ijerph18179072 [pii] AID - ijerph-18-09072 [pii] AID - 10.3390/ijerph18179072 [doi] PST - epublish SO - Int J Environ Res Public Health. 2021 Aug 27;18(17):9072. doi: 10.3390/ijerph18179072. PMID- 34501568 OWN - NLM STAT- MEDLINE DCOM- 20210914 LR - 20261001 IS - 1660-4601 (Electronic) IS - 1661-7827 (Print) IS - 1660-4601 (Linking) VI - 18 IP - 17 DP - 2021 Aug 26 TI - "One of My Basic Necessities of Life Is Work. That's Just Broken Away."-Explorative Triangulation of Personal and Work-Related Impacts for Supervisors and Disabled Employees in German Social Firms during the COVID-19 Pandemic. LID - 10.3390/ijerph18178979 [doi] LID - 8979 AB - Social firms are located on the general labor market and employ 30-50% of severely disabled people. Findings on personal and work-related impacts for employees and supervisors during the COVID-19 pandemic are not yet available and will be investigated in the present study. Using the approach of a method triangulation, focus groups with employees and individual interviews with supervisors of several social firms from the North of Germany were combined and collected in parallel. Between July and November 2020, 16 semi-structured telephone interviews with supervisors and three focus groups with 3-6 employees each working within the same team (14 employees in total) were conducted. Both formats were recorded, transcribed, anonymized, and analyzed by using Mayring's qualitative content analysis. Because a large proportion of the employees and supervisors interviewed worked in the gastronomy sector, they were particularly affected by the "restriction of social contacts" beginning in March 2020. Hygiene and distance regulations were implemented and personnel planning and distribution of work were adapted. Challenges were raised for employees with disabilities due to the implementation of hygiene and distance regulations, a sudden loss of work, lacking routines, additional work, a lack of movement, social contacts and financial challenges. Both employees and supervisors reported fears of infection, conflicts, additional work and fears of job loss. Additionally, supervisors dealt with less staffing, challenges in detaching from work and a strained economic situation. Overall, new insights were gained into the work-related impacts for employees and supervisors in inclusive workplaces during the current COVID-19 pandemic but further research on health-promoting structures is needed. FAU - Kordsmeyer, Ann-Christin AU - Kordsmeyer AC AUID- ORCID: 0000-0002-9998-5027 AD - Institute for Occupational and Maritime Medicine (ZfAM), University Medical Center Hamburg-Eppendorf (UKE), Seewartenstr. 10, 20459 Hamburg, Germany. FAU - Efimov, Ilona AU - Efimov I AUID- ORCID: 0000-0002-7578-4765 AD - Institute for Occupational and Maritime Medicine (ZfAM), University Medical Center Hamburg-Eppendorf (UKE), Seewartenstr. 10, 20459 Hamburg, Germany. FAU - Lengen, Julia Christine AU - Lengen JC AD - Institute for Occupational and Maritime Medicine (ZfAM), University Medical Center Hamburg-Eppendorf (UKE), Seewartenstr. 10, 20459 Hamburg, Germany. FAU - Harth, Volker AU - Harth V AD - Institute for Occupational and Maritime Medicine (ZfAM), University Medical Center Hamburg-Eppendorf (UKE), Seewartenstr. 10, 20459 Hamburg, Germany. FAU - Mache, Stefanie AU - Mache S AUID- ORCID: 0000-0003-4979-0587 AD - Institute for Occupational and Maritime Medicine (ZfAM), University Medical Center Hamburg-Eppendorf (UKE), Seewartenstr. 10, 20459 Hamburg, Germany. LA - eng GR - 54401/Bundesministerium fur Gesundheit/ PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20210826 PL - Switzerland TA - Int J Environ Res Public Health JT - International journal of environmental research and public health JID - 101238455 SB - IM MH - *COVID-19 MH - Germany/epidemiology MH - Humans MH - *Pandemics MH - SARS-CoV-2 MH - Workplace PMC - PMC8431327 OTO - NOTNLM OT - COVID-19 OT - SARS-CoV-2 OT - occupational health OT - social enterprises OT - social firms OT - working conditions COIS- The authors declare no conflict of interest. EDAT- 2021/09/11 06:00 MHDA- 2021/09/15 06:00 PMCR- 2021/08/26 CRDT- 2021/09/10 01:04 PHST- 2021/07/27 00:00 [received] PHST- 2021/08/20 00:00 [revised] PHST- 2021/08/21 00:00 [accepted] PHST- 2021/09/10 01:04 [entrez] PHST- 2021/09/11 06:00 [pubmed] PHST- 2021/09/15 06:00 [medline] PHST- 2021/08/26 00:00 [pmc-release] AID - ijerph18178979 [pii] AID - ijerph-18-08979 [pii] AID - 10.3390/ijerph18178979 [doi] PST - epublish SO - Int J Environ Res Public Health. 2021 Aug 26;18(17):8979. doi: 10.3390/ijerph18178979. PMID- 34497138 OWN - NLM STAT- MEDLINE DCOM- 20220617 LR - 20250728 IS - 1468-3296 (Electronic) IS - 0040-6376 (Linking) VI - 77 IP - 7 DP - 2022 Jul TI - Diagnostic accuracy of focused deep venous, lung, cardiac and multiorgan ultrasound in suspected pulmonary embolism: a systematic review and meta-analysis. PG - 679-689 LID - 10.1136/thoraxjnl-2021-216838 [doi] AB - OBJECTIVE: To determine the diagnostic accuracy of point-of-care ultrasound in suspected pulmonary embolism. DESIGN: Systematic review and meta-analysis. DATA SOURCES: MEDLINE, Embase, CINAHL and Cochrane library were searched on 2 July 2020 with no restrictions on the date of publication. Subject headings or subheadings combined with text words for the concepts of pulmonary embolism, ultrasound and diagnosis were used. ELIGIBILITY CRITERIA AND DATA ANALYSIS: Eligible studies reported sensitivity and specificity of deep venous, lung, cardiac or multiorgan ultrasound in patients with suspected pulmonary embolism, using an adequate reference-test. Prospective, cross-sectional and retrospective studies were considered for eligibility. No restrictions were made on language. Studies were excluded if a control group consisted of healthy volunteers or if transesophageal or endobronchial ultrasound was used. Risk of bias was assessed using quality assessment of diagnostic accuracy studies-2. Meta-analysis of sensitivity and specificity was performed by construction of hierarchical summary receiver operator curves. I(2) was used to assess the study heterogeneity. MAIN OUTCOME MEASURES: The primary outcome was overall sensitivity and specificity of reported ultrasound signs, stratified by organ approach (deep venous, lung, cardiac and multiorgan). Secondary outcomes were stratum-specific sensitivity and specificity within subgroups defined by pretest probability of pulmonary embolism. RESULTS: 6378 references were identified, and 70 studies included. The study population comprised 9664 patients with a prevalence of pulmonary embolism of 39.9% (3852/9664). Risk of bias in at least one domain was found in 98.6% (69/70) of included studies. Most frequently, 72.8% (51/70) of studies reported >24 hours between ultrasound examination and reference test or did not disclose time interval at all. Level of heterogeneity ranged from 0% to 100%. Most notable ultrasound signs were bilateral compression of femoral and popliteal veins (22 studies; 4708 patients; sensitivity 43.7% (36.3% to 51.4%); specificity 96.7% (95.4% to 97.6%)), presence of at least one hypoechoic pleural-based lesion (19 studies; 2134 patients; sensitivity 81.4% (73.2% to 87.5%); specificity 87.4% (80.9% to 91.9%)), D-sign (13 studies; 1579 patients; sensitivity 29.7% (24.6% to 35.4%); specificity 96.2% (93.1% to 98.0%)), visible right ventricular thrombus (5 studies; 995 patients; sensitivity 4.7% (2.7% to 8.1%); specificity 100% (99.0% to 100%)) and McConnell's sign (11 studies; 1480 patients; sensitivity 29.1% (20.0% to 40.1%); specificity 98.6% (96.7% to 99.4%)). CONCLUSION: Several ultrasound signs exhibit a high specificity for pulmonary embolism, suggesting that implementation of ultrasound in the initial assessment of patients with suspected pulmonary embolism may improve the selection of patients for radiation imaging. PROSPERO REGISTRATION NUMBER: CRD42020184313. CI - (c) Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ. FAU - Falster, Casper AU - Falster C AUID- ORCID: 0000-0002-0389-5386 AD - Department of Respiratory Medicine, Odense University Hospital, Odense, Denmark Casper.falster@rsyd.dk. AD - Odense Respiratory Research Unit (ODIN), Department of Clinical Research, University of Southern Denmark, Odense, Denmark. FAU - Jacobsen, Niels AU - Jacobsen N AUID- ORCID: 0000-0001-6189-2290 AD - Department of Respiratory Medicine, Odense University Hospital, Odense, Denmark. AD - Odense Respiratory Research Unit (ODIN), Department of Clinical Research, University of Southern Denmark, Odense, Denmark. FAU - Coman, Karen Ehlers AU - Coman KE AD - Department of Oncology, Odense University Hospital, Odense, Denmark. FAU - Hojlund, Mikkel AU - Hojlund M AUID- ORCID: 0000-0002-5786-5203 AD - Department of Public Health, Clinical Pharmacology, Pharmacy and Environmental Medicine, University of Southern Denmark, Odense, Denmark. FAU - Gaist, Thomas Agerbo AU - Gaist TA AD - Department of Neurology, Odense University Hospital, Odense, Denmark. FAU - Posth, Stefan AU - Posth S AUID- ORCID: 0000-0002-4325-038X AD - Department of Emergency Medicine, Odense University Hospital, Odense, Denmark. FAU - Moller, Jacob Eifer AU - Moller JE AUID- ORCID: 0000-0003-2873-5845 AD - Department of Cardiology, Odense University Hospital, Odense, Denmark. FAU - Brabrand, Mikkel AU - Brabrand M AUID- ORCID: 0000-0002-3340-8251 AD - Department of Emergency Medicine, Odense University Hospital, Odense, Denmark. AD - Department of Regional Health Research, University of Southern Denmark, Esbjerg, Denmark. FAU - Laursen, Christian B AU - Laursen CB AUID- ORCID: 0000-0001-6382-9906 AD - Department of Respiratory Medicine, Odense University Hospital, Odense, Denmark. AD - Odense Respiratory Research Unit (ODIN), Department of Clinical Research, University of Southern Denmark, Odense, Denmark. LA - eng PT - Journal Article PT - Meta-Analysis PT - Research Support, Non-U.S. Gov't PT - Systematic Review DEP - 20210908 PL - England TA - Thorax JT - Thorax JID - 0417353 SB - IM MH - Cross-Sectional Studies MH - Humans MH - *Lung/diagnostic imaging MH - Prospective Studies MH - *Pulmonary Embolism/diagnostic imaging MH - Retrospective Studies MH - Sensitivity and Specificity OTO - NOTNLM OT - emergency medicine OT - pulmonary embolism COIS- Competing interests: JEM has received grants and personal fees from Abiomed, personal fees from Novartis, personal fees from Orion Pharma and personal fees from Boeinger Ingleheim outside the submitted work. EDAT- 2021/09/10 06:00 MHDA- 2022/06/18 06:00 CRDT- 2021/09/09 06:08 PHST- 2021/01/04 00:00 [received] PHST- 2021/08/12 00:00 [accepted] PHST- 2021/09/10 06:00 [pubmed] PHST- 2022/06/18 06:00 [medline] PHST- 2021/09/09 06:08 [entrez] AID - thoraxjnl-2021-216838 [pii] AID - 10.1136/thoraxjnl-2021-216838 [doi] PST - ppublish SO - Thorax. 2022 Jul;77(7):679-689. doi: 10.1136/thoraxjnl-2021-216838. Epub 2021 Sep 8. PMID- 34495568 OWN - NLM STAT- MEDLINE DCOM- 20211203 LR - 20211214 IS - 1369-7625 (Electronic) IS - 1369-6513 (Print) IS - 1369-6513 (Linking) VI - 24 IP - 6 DP - 2021 Dec TI - Children's perspectives and experiences of the COVID-19 pandemic and UK public health measures. PG - 2057-2064 LID - 10.1111/hex.13350 [doi] AB - BACKGROUND: The COVID-19 pandemic has had profound impacts on how we live our lives; yet, the implications for children and the effects on children's everyday lives have been relatively underacknowledged. Understanding children's views on COVID-19 and related restrictions on their lives provides an important opportunity to understand how children have responded to the pandemic, including the impacts on their social and emotional well-being. OBJECTIVE: This study explored the experiences and perspectives of children in relation to the COVID-19 pandemic and related restrictions on everyday life. METHOD: A qualitative study using semistructured online interviews with participatory drawings was undertaken between May and July 2020. Eighteen children from England and Wales, aged 7-11 years, participated in interviews. FINDINGS: Themes included children's reflections on (1) COVID-19 as a deadly contagion; (2) fears and sadness and (3) social responsibility and opportunities to respond positively. CONCLUSIONS: Young children offer insightful reflections on their experiences during the first wave of the COVID-19 pandemic in the United Kingdom. Children and young people's perspectives must be considered in future public health discourse. PATIENT OR PUBLIC CONTRIBUTION: This work was informed by conversations with my own three primary school-aged children and the children of friends. A formal Patient and Public Involvement (PPI) group was not established due to the speed with which the project was undertaken. Any future research in this area would benefit from formal PPI in the design, methods and questions. CI - (c) 2021 The Authors. Health Expectations published by John Wiley & Sons Ltd. FAU - Thompson, Jill AU - Thompson J AUID- ORCID: 0000-0001-9256-1208 AD - Health Sciences School, Division of Nursing and Midwifery, The University of Sheffield, Sheffield, UK. FAU - Spencer, Grace AU - Spencer G AUID- ORCID: 0000-0002-6160-7776 AD - School of Education and Social Care, Anglia Ruskin University, Cambridge, UK. FAU - Curtis, Penny AU - Curtis P AD - Health Sciences School, Division of Nursing and Midwifery, The University of Sheffield, Sheffield, UK. LA - eng GR - No funding was received to undertake this study/ PT - Journal Article DEP - 20210908 PL - England TA - Health Expect JT - Health expectations : an international journal of public participation in health care and health policy JID - 9815926 SB - IM MH - Adolescent MH - *COVID-19 MH - Child MH - Child, Preschool MH - Humans MH - Pandemics/prevention & control MH - Public Health MH - Qualitative Research MH - SARS-CoV-2 PMC - PMC8628584 OTO - NOTNLM OT - COVID-19 OT - children OT - public health OT - qualitative research EDAT- 2021/09/09 06:00 MHDA- 2021/12/15 06:00 PMCR- 2021/12/01 CRDT- 2021/09/08 12:35 PHST- 2021/07/15 00:00 [revised] PHST- 2021/05/20 00:00 [received] PHST- 2021/08/06 00:00 [accepted] PHST- 2021/09/09 06:00 [pubmed] PHST- 2021/12/15 06:00 [medline] PHST- 2021/09/08 12:35 [entrez] PHST- 2021/12/01 00:00 [pmc-release] AID - HEX13350 [pii] AID - 10.1111/hex.13350 [doi] PST - ppublish SO - Health Expect. 2021 Dec;24(6):2057-2064. doi: 10.1111/hex.13350. Epub 2021 Sep 8. PMID- 34494077 OWN - NLM STAT- MEDLINE DCOM- 20210915 LR - 20211129 IS - 2204-2091 (Electronic) IS - 2204-2091 (Linking) VI - 31 IP - 3 DP - 2021 Sep 8 TI - Bondi and beyond. Lessons from three waves of COVID-19 from 2020. LID - 3132112 [pii] LID - 10.17061/phrp3132112 [doi] AB - OBJECTIVES: To describe local operational aspects of the coronavirus disease 2019 (COVID-19) response during the first three waves of outbreaks in New South Wales (NSW), Australia, which began in January, July and December 2020. Type of program or service: Public health outbreak response. METHODS: Narrative with epidemiological linking and genomic testing. RESULTS: Epidemiological linking and genomic testing found that during the first wave of COVID-19 in NSW, a large number of community transmissions went undetected because of limited testing for the virus and limited contact tracing of cases. The second wave of COVID-19 in NSW emerged following reintroduction from the second wave in Victoria, Australia in July 2020, and the third wave followed undetected introduction from overseas. By the second and third waves, cases could be more effectively detected and isolated through an increased ability to test and contact trace, and to rapidly genomic sequence severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) isolates, allowing most cases to be identified and epidemiologically linked. This greater certainty in understanding chains of transmission resulted in control of the outbreaks despite less stringent restrictions on the community, by using a refined strategy of targeted shutdown, restrictions on cases, their close contacts, identified hotspots and venues of concern rather than a whole of community lockdown. Risk assessments of potential transmission sites were constantly updated through our evolving experience with transmission events. However, this refined strategy did leave the potential for large point source outbreaks should any cases go undetected. [Addendum] A fourth wave that began in Sydney in June 2021 challenged this strategy due to the more transmissible nature of the Delta variant of SARS-CoV-2. LESSONS LEARNT: A wave of COVID-19 infections can develop quickly from one infected person. The community needs to remain vigilant, adhering to physical distancing measures, signing in to venues they visit, and getting tested if they have any symptoms. Signing out of venues on exit allows public health resources to be used more efficiently to respond to outbreaks. FAU - Capon, Adam AU - Capon A AD - Public Health Unit, South Eastern Sydney Local Health District, NSW, Australia; School of Public Health, University of Sydney, NSW, Australia; adam.capon@health.nsw.gov.au. FAU - Sheppeard, Vicky AU - Sheppeard V AD - Public Health Unit, South Eastern Sydney Local Health District, NSW, Australia; School of Public Health, University of Sydney, NSW, Australia. FAU - Gonzalez, Nicolas AU - Gonzalez N AD - Public Health Unit, South Eastern Sydney Local Health District, NSW, Australia. FAU - Draper, Jenny AU - Draper J AD - Centre for Infectious Diseases and Microbiology Laboratory Services, NSW Health Pathology - Institute of Clinical Pathology and Medical Research, Sydney, NSW, Australia. FAU - Zhu, Alice AU - Zhu A AD - Public Health Unit, South Eastern Sydney Local Health District, NSW, Australia. FAU - Browne, Maria AU - Browne M AD - Public Health Unit, South Eastern Sydney Local Health District, NSW, Australia. FAU - Sullivan, Eleanor AU - Sullivan E AD - Public Health Unit, South Eastern Sydney Local Health District, NSW, Australia. FAU - Mihajlovic, Milica AU - Mihajlovic M AD - Public Health Unit, South Eastern Sydney Local Health District, NSW, Australia. FAU - Rockett, Rebecca AU - Rockett R AD - Centre for Infectious Diseases and Microbiology - Public Health, Westmead Hospital, Sydney, NSW, Australia; Marie Bashir Institute for Infectious Diseases and Biosecurity, University of Sydney, NSW, Australia. FAU - Ferson, Mark J AU - Ferson MJ AD - Public Health Unit, South Eastern Sydney Local Health District, NSW, Australia; School of Population Health, UNSW Sydney, Australia. LA - eng PT - Journal Article DEP - 20210908 PL - Australia TA - Public Health Res Pract JT - Public health research & practice JID - 101648133 SB - IM CIN - Public Health Res Pract. 2021 Sep 8;31(3):3132114. doi: 10.17061/phrp3132114. PMID: 34494069 MH - Adolescent MH - Adult MH - Aged MH - Aged, 80 and over MH - COVID-19/diagnosis/*epidemiology/*prevention & control MH - COVID-19 Testing/methods MH - Child MH - Child, Preschool MH - Communicable Disease Control/*methods/organization & administration MH - Contact Tracing/methods MH - Disease Outbreaks/prevention & control/*statistics & numerical data MH - Female MH - Humans MH - Infant MH - Infant, Newborn MH - Male MH - Middle Aged MH - New South Wales/epidemiology MH - Physical Distancing MH - Public Health MH - Quarantine/methods MH - SARS-CoV-2/isolation & purification MH - Victoria/epidemiology MH - Young Adult COIS- None declared. EDAT- 2021/09/09 06:00 MHDA- 2021/09/16 06:00 CRDT- 2021/09/08 06:55 PHST- 2021/09/08 06:55 [entrez] PHST- 2021/09/09 06:00 [pubmed] PHST- 2021/09/16 06:00 [medline] AID - 3132112 [pii] AID - 10.17061/phrp3132112 [doi] PST - epublish SO - Public Health Res Pract. 2021 Sep 8;31(3):3132112. doi: 10.17061/phrp3132112. PMID- 34485813 OWN - NLM STAT- MEDLINE DCOM- 20210907 LR - 20240229 IS - 2515-5091 (Electronic) IS - 2515-5091 (Linking) VI - 5 IP - 5 DP - 2021 Oct TI - Ethnic Differences in Survival Among Lung Cancer Patients: A Systematic Review. LID - 10.1093/jncics/pkab062 [doi] LID - pkab062 AB - BACKGROUND: Despite a substantially worse risk factor profile, Hispanics in the United States experience lower incidence of many diseases and longer survival than non-Hispanic Whites (NHWs), an epidemiological phenomenon known as the Hispanic Health Paradox (HHP). This systematic review evaluated the published longitudinal literature to address whether this pattern extends to lung cancer survival. METHODS: Searches of Medline, PubMed, Embase, Web of Science, and the Cochrane Library were conducted for publications dated from January 1, 2000, to July 18, 2018. Records were restricted to articles written in English, employing a longitudinal design, and reporting a direct survival comparison (overall survival [OS], cancer-specific survival [CSS]) between NHW and Hispanic lung cancer patients. RESULTS: A final sample of 29 full-text articles were included, with 28 fully adjusted models of OS and 21 of CSS included. Overall, 26 (92.9%) OS models and 20 (95.2%) CSS models documented either no difference (OS = 16, CSS = 11) or a Hispanic survival advantage (OS = 10, CSS = 9). Both larger studies and those including foreign-born Hispanics were more likely to show a Hispanic survival advantage, and 2 studies of exclusively no-smokers showed a survival disadvantage. A number of reporting gaps were identified including Hispanic background and sociodemographic characteristics. CONCLUSIONS: Hispanics exhibit similar or better survival in the context of lung cancer relative to NHWs despite a considerably worse risk factor profile. These findings support the HHP in the context of lung cancer. Further research is needed to understand the potential mechanisms of the HHP as it relates to lung cancer. CI - (c) The Author(s) 2021. Published by Oxford University Press. FAU - Price, Sarah N AU - Price SN AUID- ORCID: 0000-0002-1622-1700 AD - Department of Psychology, University of Arizona, Tucson, AZ, USA. FAU - Flores, Melissa AU - Flores M AUID- ORCID: 0000-0002-9436-6665 AD - Department of Psychology, University of Arizona, Tucson, AZ, USA. AD - Center for Border Health Disparities, University of Arizona Health Sciences, Tucson, AZ, USA. FAU - Hamann, Heidi A AU - Hamann HA AUID- ORCID: 0000-0002-3207-0949 AD - Department of Psychology, University of Arizona, Tucson, AZ, USA. AD - Department of Family and Community Medicine, University of Arizona, Tucson, AZ, USA. FAU - Ruiz, John M AU - Ruiz JM AUID- ORCID: 0000-0002-3398-7054 AD - Department of Psychology, University of Arizona, Tucson, AZ, USA. LA - eng GR - R01 CA262719/CA/NCI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Systematic Review DEP - 20210707 PL - England TA - JNCI Cancer Spectr JT - JNCI cancer spectrum JID - 101721827 MH - Humans MH - Cause of Death MH - *Hispanic or Latino/statistics & numerical data MH - Longitudinal Studies MH - *Lung Neoplasms/ethnology/mortality MH - Risk Factors MH - Survival Analysis MH - United States MH - White PMC - PMC8410140 EDAT- 2021/09/07 06:00 MHDA- 2021/09/07 06:01 PMCR- 2021/07/07 CRDT- 2021/09/06 06:14 PHST- 2021/01/22 00:00 [received] PHST- 2021/03/29 00:00 [revised] PHST- 2021/05/20 00:00 [accepted] PHST- 2021/09/06 06:14 [entrez] PHST- 2021/09/07 06:00 [pubmed] PHST- 2021/09/07 06:01 [medline] PHST- 2021/07/07 00:00 [pmc-release] AID - pkab062 [pii] AID - 10.1093/jncics/pkab062 [doi] PST - epublish SO - JNCI Cancer Spectr. 2021 Jul 7;5(5):pkab062. doi: 10.1093/jncics/pkab062. eCollection 2021 Oct. PMID- 34483571 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240907 IS - 0975-5950 (Print) IS - 2229-3418 (Electronic) IS - 0975-5950 (Linking) VI - 12 IP - 2 DP - 2021 May-Aug TI - Evidence mapping and quality analysis of published dental literature on COVID-19 - A systematic review. PG - 139-161 LID - 10.4103/njms.NJMS_237_20 [doi] AB - A large number of scientific articles have been published regarding impact of COVID-19 infection on dental practice, dental professionals, and the mode of spread of infection via dental procedures. The present systematic review was planned with an aim of evidence mapping and quality analysis of published research on the dental aspects of COVID-19 infection. The protocol was registered at https://share.osf.io/registration/46221-C87-BA8. The search was performed in Scopus, PubMed, Cochrane, and Embase databases till 15th July 2020. There was no restriction of year of publication and language. All types of published articles related to Dentistry, Dentist, Dental practice, and Oral health education on COVID-19 were included. The Joanna Briggs Institute's (JBI) Critical Appraisal Tools were used for the risk of bias analysis of included studies. A total of 393 articles were short-listed and were checked for eligibility and finally, 380 articles were included. Among the 380 research articles published (till July 15, 2020), the majority of the included articles belonged to the lowermost strata of the evidence pyramid. There were 54 original research articles with no randomized clinical trial, systematic review or, meta-analysis pertaining to the dental perspective of COVID-19 infection. The level of available evidence about dentistry and COVID-19 infection is very low with a lack of researches of highest quality. The guidelines/recommendations for dental professionals, proposed by the different scientific organizations/societies regarding COVID-19 infection are only consensus-based necessitating the need to formulate evidence-based guidelines. There is a need to identify essential research questions and strengthen the study designs in most of the aspects related to the dentistry and COVID-19 pandemic. CI - Copyright: (c) 2021 National Journal of Maxillofacial Surgery. FAU - Rahul, Morankar AU - Rahul M AD - Division of Pedodontics and Preventive Dentistry, Centre for Dental Education and Research, AIIMS, New Delhi, India. FAU - Tewari, Nitesh AU - Tewari N AD - Division of Pedodontics and Preventive Dentistry, Centre for Dental Education and Research, AIIMS, New Delhi, India. FAU - Mathur, Vijay AU - Mathur V AD - Division of Pedodontics and Preventive Dentistry, Centre for Dental Education and Research, AIIMS, New Delhi, India. FAU - Goel, Shubhi AU - Goel S AD - Division of Pedodontics and Preventive Dentistry, Centre for Dental Education and Research, AIIMS, New Delhi, India. FAU - Jain, Gunjar AU - Jain G AD - Department of Orthopaedics, AIIMS, New Delhi, India. LA - eng PT - Journal Article PT - Review DEP - 20210715 PL - India TA - Natl J Maxillofac Surg JT - National journal of maxillofacial surgery JID - 101578767 PMC - PMC8386272 OTO - NOTNLM OT - COVID-19 OT - dental professionals OT - dentistry OT - evidence mapping OT - oral health OT - quality analysis COIS- There are no conflicts of interest. EDAT- 2021/09/07 06:00 MHDA- 2021/09/07 06:01 PMCR- 2021/05/01 CRDT- 2021/09/06 05:48 PHST- 2020/10/27 00:00 [received] PHST- 2021/02/12 00:00 [accepted] PHST- 2021/09/06 05:48 [entrez] PHST- 2021/09/07 06:00 [pubmed] PHST- 2021/09/07 06:01 [medline] PHST- 2021/05/01 00:00 [pmc-release] AID - NJMS-12-139 [pii] AID - 10.4103/njms.NJMS_237_20 [doi] PST - ppublish SO - Natl J Maxillofac Surg. 2021 May-Aug;12(2):139-161. doi: 10.4103/njms.NJMS_237_20. Epub 2021 Jul 15. PMID- 34463025 OWN - NLM STAT- MEDLINE DCOM- 20211111 LR - 20211207 IS - 1533-2500 (Electronic) IS - 1530-7085 (Print) IS - 1530-7085 (Linking) VI - 21 IP - 8 DP - 2021 Nov TI - Telemedicine for chronic pain treatment during the COVID-19 pandemic: Do pain intensity and anxiousness correlate with patient acceptance? PG - 934-942 LID - 10.1111/papr.13071 [doi] AB - INTRODUCTION: Recent recommendations for the treatment of chronic pain patients during the coronavirus disease 2019 (COVID-19) pandemic suggest using telemedicine instead of in-person consultations. Knowing whether patients with chronic pain are receptive to the use of telemedicine during a pandemic might improve tailored care. OBJECTIVE: The aims of the present study were to assess patients' acceptance of telemedicine during the COVID-19 pandemic in Switzerland and to examine the correlation of acceptance with pain intensity and anxiousness. METHODS: An anonymous survey was conducted from March 31, 2020, to July 30, 2020, with 61 patients referred to the Pain Center at the Bern University Hospital Inselspital in Bern, Switzerland. Collected data were analyzed descriptively, and correlations were calculated between acceptance of telemedicine and mean levels of current pain, psychological distress, and fear of COVID-19. RESULTS: Our main finding was an average level of acceptance of telemedicine, with a mean of 6.25 on a scale from 0 (not at all) to 10 (completely), with substantial variability and range (SD = 3.56). The acceptance of telemedicine correlated negatively with current mean pain level (r = -0.44), worries (r = -0.42), and fear of COVID-19 (r = -0.4), as well as positively with the general condition (r = 0.46). CONCLUSIONS: Using telemedicine for chronic pain treatment during the COVID-19 crisis was accepted to a sufficient degree by a considerable proportion of patients. However, the higher the mean levels of pain and anxiousness, the lower the acceptance, indicating that these severely burdened patients may suffer most from treatment restrictions. For this subgroup, telemedicine might not suffice and in-person visits should be considered. CI - (c) 2021 World Institute of Pain. FAU - Harnik, Michael Alexander AU - Harnik MA AUID- ORCID: 0000-0002-0191-5742 AD - Department of Anaesthesiology and Pain Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland. FAU - Blattler, Larissa AU - Blattler L AD - Division of Psychosomatic Medicine, Department of Neurology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland. FAU - Limacher, Andreas AU - Limacher A AD - CTU Bern, University of Bern, Bern, Switzerland. FAU - Reisig, Florian AU - Reisig F AD - Department of Anaesthesiology and Pain Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland. FAU - Grosse Holtforth, Martin AU - Grosse Holtforth M AD - Department of Clinical Psychology and Psychotherapy, University of Bern, Bern, Switzerland. AD - Department of Clinical Psychology and Psychotherapy, Department of Psychology, University of Bern, Bern, Switzerland. AD - Division of Psychosomatic Medicine, Department of Neurology, Inselspital, Bern University Hospital, Bern, Switzerland. FAU - Streitberger, Konrad AU - Streitberger K AD - Department of Anaesthesiology and Pain Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland. LA - eng PT - Journal Article DEP - 20210914 PL - United States TA - Pain Pract JT - Pain practice : the official journal of World Institute of Pain JID - 101130835 SB - IM MH - Anxiety/epidemiology MH - *COVID-19 MH - *Chronic Pain/epidemiology/therapy MH - Humans MH - Pandemics MH - SARS-CoV-2 MH - *Telemedicine PMC - PMC8646884 OTO - NOTNLM OT - acceptance OT - chronic pain OT - eHealth OT - remote care OT - telemedicine COIS- The authors have no conflicts of interest to declare. All co-authors have seen and agree with the contents of the manuscript and there are no financial interests to report. We certify that the submission is original work and is not under review by any other publication. EDAT- 2021/09/01 06:00 MHDA- 2021/11/12 06:00 PMCR- 2021/09/14 CRDT- 2021/08/31 06:58 PHST- 2021/06/04 00:00 [revised] PHST- 2021/03/13 00:00 [received] PHST- 2021/08/19 00:00 [accepted] PHST- 2021/09/01 06:00 [pubmed] PHST- 2021/11/12 06:00 [medline] PHST- 2021/08/31 06:58 [entrez] PHST- 2021/09/14 00:00 [pmc-release] AID - PAPR13071 [pii] AID - 10.1111/papr.13071 [doi] PST - ppublish SO - Pain Pract. 2021 Nov;21(8):934-942. doi: 10.1111/papr.13071. Epub 2021 Sep 14. PMID- 34452941 OWN - NLM STAT- MEDLINE DCOM- 20210902 LR - 20240830 IS - 2059-7908 (Print) IS - 2059-7908 (Electronic) IS - 2059-7908 (Linking) VI - 6 IP - 8 DP - 2021 Aug TI - Indirect effects of COVID-19 on maternal, neonatal, child, sexual and reproductive health services in Kampala, Uganda. LID - 10.1136/bmjgh-2021-006102 [doi] LID - e006102 AB - BACKGROUND: COVID-19 impacted global maternal, neonatal and child health outcomes. We hypothesised that the early, strict lockdown that restricted individuals' movements in Uganda limited access to services. METHODS: An observational study, using routinely collected data from Electronic Medical Records, was carried out, in Kawempe district, Kampala. An interrupted time series analysis assessed the impact on maternal, neonatal, child, sexual and reproductive health services from July 2019 to December 2020. Descriptive statistics summarised the main outcomes before (July 2019-March 2020), during (April 2020-June 2020) and after the national lockdown (July 2020-December 2020). RESULTS: Between 1 July 2019 and 31 December 2020, there were 14 401 antenatal clinic, 33 499 deliveries, 111 658 childhood service and 57 174 sexual health attendances. All antenatal and vaccination services ceased in lockdown for 4 weeks.During the 3-month lockdown, the number of antenatal attendances significantly decreased and remain below pre-COVID levels (370 fewer/month). Attendances for prevention of mother-to-child transmission of HIV dropped then stabilised. Increases during lockdown and immediately postlockdown included the number of women treated for high blood pressure, eclampsia and pre-eclampsia (218 more/month), adverse pregnancy outcomes (stillbirths, low-birth-weight and premature infant births), the rate of neonatal unit admissions, neonatal deaths and abortions. Maternal mortality remained stable. Immunisation clinic attendance declined while neonatal death rate rose (from 39 to 49/1000 livebirths). The number of children treated for pneumonia, diarrhoea and malaria decreased during lockdown. CONCLUSION: The Ugandan response to COVID-19 negatively impacted maternal, child and neonatal health, with an increase seen in pregnancy complications and fetal and infant outcomes, likely due to delayed care-seeking behaviour. Decreased vaccination clinic attendance leaves a cohort of infants unprotected, affecting all vaccine-preventable diseases. Future pandemic responses must consider impacts of movement restrictions and access to preventative services to protect maternal and child health. CI - (c) Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. FAU - Burt, Jessica Florence AU - Burt JF AD - School of Medicine, University of Leeds, Leeds, UK. AD - Makerere University Johns Hopkins University, Kampala, Uganda. FAU - Ouma, Joseph AU - Ouma J AD - Makerere University Johns Hopkins University, Kampala, Uganda. FAU - Lubyayi, Lawrence AU - Lubyayi L AD - MRC/UVRI and LSHTM Uganda Research Unit, Entebbe, Wakiso, Uganda. FAU - Amone, Alexander AU - Amone A AD - Makerere University Johns Hopkins University, Kampala, Uganda. FAU - Aol, Lorna AU - Aol L AD - Makerere University Johns Hopkins University, Kampala, Uganda. FAU - Sekikubo, Musa AU - Sekikubo M AD - Obstetrics and Gynecology, Makerere University and Mulago National Referral Hospital, Kampala, Uganda. FAU - Nakimuli, Annettee AU - Nakimuli A AD - Obstetrics and Gynecology, Makerere University and Mulago National Referral Hospital, Kampala, Uganda. FAU - Nakabembe, Eve AU - Nakabembe E AD - Obstetrics and Gynecology, Makerere University and Mulago National Referral Hospital, Kampala, Uganda. FAU - Mboizi, Robert AU - Mboizi R AD - Makerere University Johns Hopkins University, Kampala, Uganda. FAU - Musoke, Philippa AU - Musoke P AD - Makerere University Johns Hopkins University, Kampala, Uganda. FAU - Kyohere, Mary AU - Kyohere M AD - Makerere University Johns Hopkins University, Kampala, Uganda. FAU - Namara Lugolobi, Emily AU - Namara Lugolobi E AD - Makerere University Johns Hopkins University, Kampala, Uganda. FAU - Khalil, Asma AU - Khalil A AD - Infection and Immunity, St. George's, University of London, London, UK. FAU - Le Doare, Kirsty AU - Le Doare K AD - MRC/UVRI and LSHTM Uganda Research Unit, Entebbe, Wakiso, Uganda kiledoar@sgul.ac.uk. AD - Infection and Immunity, St. George's, University of London, London, UK. LA - eng PT - Journal Article PT - Observational Study PT - Research Support, Non-U.S. Gov't PL - England TA - BMJ Glob Health JT - BMJ global health JID - 101685275 SB - IM MH - *COVID-19 MH - Child MH - Communicable Disease Control MH - Female MH - Humans MH - Infant MH - Infant, Newborn MH - Infectious Disease Transmission, Vertical MH - Pregnancy MH - *Reproductive Health Services MH - SARS-CoV-2 MH - Uganda/epidemiology PMC - PMC8406460 OTO - NOTNLM OT - COVID-19 OT - child health OT - maternal health OT - public health OT - vaccines COIS- Competing interests: None declared. EDAT- 2021/08/29 06:00 MHDA- 2021/09/03 06:00 PMCR- 2021/08/26 CRDT- 2021/08/28 05:31 PHST- 2021/04/23 00:00 [received] PHST- 2021/08/08 00:00 [accepted] PHST- 2021/08/28 05:31 [entrez] PHST- 2021/08/29 06:00 [pubmed] PHST- 2021/09/03 06:00 [medline] PHST- 2021/08/26 00:00 [pmc-release] AID - bmjgh-2021-006102 [pii] AID - 10.1136/bmjgh-2021-006102 [doi] PST - ppublish SO - BMJ Glob Health. 2021 Aug;6(8):e006102. doi: 10.1136/bmjgh-2021-006102. PMID- 34452871 OWN - NLM STAT- MEDLINE DCOM- 20211012 LR - 20240817 IS - 1876-035X (Electronic) IS - 1876-0341 (Print) IS - 1876-0341 (Linking) VI - 14 IP - 10 DP - 2021 Oct TI - Non-linear spatial linkage between COVID-19 pandemic and mobility in ten countries: A lesson for future wave. PG - 1411-1426 LID - S1876-0341(21)00226-4 [pii] LID - 10.1016/j.jiph.2021.08.008 [doi] AB - BACKGROUND: Restrictive measures enacted in response to the COVID-19 pandemic have resulted in dramatic and substantial variations in people's travel habits and behaviors worldwide. This paper empirically examines the asymmetric inter-linkages between transportation mobility and COVID-19. METHODS: Using daily data from 1st March 2020 to 15th July 2020, this study draws the dynamic and causal relationships between transportation mobility and COVID-19 in ten selected countries (i.e., USA, Brazil, Mexico, UK, Spain, Italy, France, Germany, Canada, and Belgium). To systematically analyze how the quantiles of COVID-19 (transportation mobility) affect the quantiles of transportation mobility (COVID-19), a complete set of non-linear modeling including the quantile-on-quantile (QQ) regression and quantile Granger causality in mean is applied. RESULTS: Our preliminary findings strictly reject the preposition of data normality and highlight that the observed relationship is highly correlated and quantile-dependent. The empirical results demonstrate the heterogeneous dependence between COVID-19 and transportation mobility across quantiles. The findings acclaim the presence of a significant positive association between COVID-19 and transportation mobility in the USA, UK, Spain, Italy, Canada, France, Germany and Belgium, predominantly at upper quantiles, but results are contrasting in the case of Brazil and Mexico. In addition, either lower or upper quantiles of both variables indicate a declining negative effect of transportation mobility on COVID-19. Furthermore, the outcomes of quantile Granger causality in mean conclude a bidirectional causal link between COVID-19 and transportation mobility for almost all sample countries. Unlike them, France has found unidirectional causality that extends from COVID-19 to transportation mobility. CONCLUSIONS: We may conclude that COVID-19 leads to a reduction in transportation mobility. On the other hand, the empirical results quantify that excessive transportation mobility levels stimulate pandemic cases, and social distancing is one of the primary measures to encounter infection transmission. Imperative country-specific policy implications pertaining to public health, potential virus spread, transportation, and the environment may be drawn from these findings. CI - Copyright (c) 2021 The Author(s). Published by Elsevier Ltd.. All rights reserved. FAU - Habib, Yasir AU - Habib Y AD - School of Management and Economics, Beijing Institute of Technology, Beijing 100081, China. Electronic address: yasirhabib.ch@outlook.com. FAU - Xia, Enjun AU - Xia E AD - School of Management and Economics, Beijing Institute of Technology, Beijing 100081, China. Electronic address: enjunxia@bit.edu.cn. FAU - Hashmi, Shujahat Haider AU - Hashmi SH AD - School of Economics, Huazhong University of Science and Technology, Wuhan, China; Research Associate, MUSLIM Institute, Islamabad, Pakistan. Electronic address: shujahat_hashmi@hotmail.com. FAU - Fareed, Zeeshan AU - Fareed Z AD - School of Economics and Management, Huzhou University, Huzhou, Zhejiang, China. Electronic address: zeeshanfareed@hotmail.com. LA - eng PT - Journal Article DEP - 20210813 PL - England TA - J Infect Public Health JT - Journal of infection and public health JID - 101487384 SB - IM MH - *COVID-19 MH - Humans MH - *Pandemics MH - SARS-CoV-2 MH - Transportation MH - Travel PMC - PMC8529856 OTO - NOTNLM OT - COVID-19 OT - Quantile-on quantile (QQ) approach OT - Transportation mobility EDAT- 2021/08/29 06:00 MHDA- 2021/10/13 06:00 PMCR- 2021/08/13 CRDT- 2021/08/28 05:30 PHST- 2021/04/30 00:00 [received] PHST- 2021/08/06 00:00 [revised] PHST- 2021/08/08 00:00 [accepted] PHST- 2021/08/29 06:00 [pubmed] PHST- 2021/10/13 06:00 [medline] PHST- 2021/08/28 05:30 [entrez] PHST- 2021/08/13 00:00 [pmc-release] AID - S1876-0341(21)00226-4 [pii] AID - 10.1016/j.jiph.2021.08.008 [doi] PST - ppublish SO - J Infect Public Health. 2021 Oct;14(10):1411-1426. doi: 10.1016/j.jiph.2021.08.008. Epub 2021 Aug 13. PMID- 34448865 OWN - NLM STAT- MEDLINE DCOM- 20210909 LR - 20261001 IS - 2574-3805 (Electronic) IS - 2574-3805 (Linking) VI - 4 IP - 8 DP - 2021 Aug 2 TI - Factors Associated With Household Transmission of SARS-CoV-2: An Updated Systematic Review and Meta-analysis. PG - e2122240 LID - 10.1001/jamanetworkopen.2021.22240 [doi] LID - e2122240 AB - IMPORTANCE: A previous systematic review and meta-analysis of household transmission of SARS-CoV-2 that summarized 54 published studies through October 19, 2020, found an overall secondary attack rate (SAR) of 16.6% (95% CI, 14.0%-19.3%). However, the understanding of household secondary attack rates for SARS-CoV-2 is still evolving, and updated analysis is needed. OBJECTIVE: To use newly published data to further the understanding of SARS-CoV-2 transmission in the household. DATA SOURCES: PubMed and reference lists of eligible articles were used to search for records published between October 20, 2020, and June 17, 2021. No restrictions on language, study design, time, or place of publication were applied. Studies published as preprints were included. STUDY SELECTION: Articles with original data that reported at least 2 of the following factors were included: number of household contacts with infection, total number of household contacts, and secondary attack rates among household contacts. Studies that reported household infection prevalence (which includes index cases), that tested contacts using antibody tests only, and that included populations overlapping with another included study were excluded. Search terms were SARS-CoV-2 or COVID-19 with secondary attack rate, household, close contacts, contact transmission, contact attack rate, or family transmission. DATA EXTRACTION AND SYNTHESIS: Meta-analyses were performed using generalized linear mixed models to obtain SAR estimates and 95% CIs. The Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) reporting guideline was followed. MAIN OUTCOMES AND MEASURES: Overall household SAR for SARS-CoV-2, SAR by covariates (contact age, sex, ethnicity, comorbidities, and relationship; index case age, sex, symptom status, presence of fever, and presence of cough; number of contacts; study location; and variant), and SAR by index case identification period. RESULTS: A total of 2722 records (2710 records from database searches and 12 records from the reference lists of eligible articles) published between October 20, 2020, and June 17, 2021, were identified. Of those, 93 full-text articles reporting household transmission of SARS-CoV-2 were assessed for eligibility, and 37 studies were included. These 37 new studies were combined with 50 of the 54 studies (published through October 19, 2020) from our previous review (4 studies from Wuhan, China, were excluded because their study populations overlapped with another recent study), resulting in a total of 87 studies representing 1 249 163 household contacts from 30 countries. The estimated household SAR for all 87 studies was 18.9% (95% CI, 16.2%-22.0%). Compared with studies from January to February 2020, the SAR for studies from July 2020 to March 2021 was higher (13.4% [95% CI, 10.7%-16.7%] vs 31.1% [95% CI, 22.6%-41.1%], respectively). Results from subgroup analyses were similar to those reported in a previous systematic review and meta-analysis; however, the SAR was higher to contacts with comorbidities (3 studies; 50.0% [95% CI, 41.4%-58.6%]) compared with previous findings, and the estimated household SAR for the B.1.1.7 (alpha) variant was 24.5% (3 studies; 95% CI, 10.9%-46.2%). CONCLUSIONS AND RELEVANCE: The findings of this study suggest that the household remains an important site of SARS-CoV-2 transmission, and recent studies have higher household SAR estimates compared with the earliest reports. More transmissible variants and vaccines may be associated with further changes. FAU - Madewell, Zachary J AU - Madewell ZJ AD - Department of Biostatistics, University of Florida, Gainesville. FAU - Yang, Yang AU - Yang Y AD - Department of Biostatistics, University of Florida, Gainesville. FAU - Longini, Ira M Jr AU - Longini IM Jr AD - Department of Biostatistics, University of Florida, Gainesville. FAU - Halloran, M Elizabeth AU - Halloran ME AD - Fred Hutchinson Cancer Research Center, Seattle, Washington. AD - Department of Biostatistics, University of Washington, Seattle. FAU - Dean, Natalie E AU - Dean NE AD - Department of Biostatistics, University of Florida, Gainesville. LA - eng GR - R01 AI139761/AI/NIAID NIH HHS/United States PT - Journal Article PT - Meta-Analysis PT - Research Support, N.I.H., Extramural PT - Systematic Review DEP - 20210802 PL - United States TA - JAMA Netw Open JT - JAMA network open JID - 101729235 SB - IM MH - Adolescent MH - Adult MH - COVID-19/epidemiology/etiology/*transmission MH - Child MH - Child, Preschool MH - China/epidemiology MH - *Family Characteristics MH - Female MH - Humans MH - Incidence MH - Infant MH - Male MH - Risk Factors MH - SARS-CoV-2 MH - Young Adult PMC - PMC8397928 COIS- Conflict of Interest Disclosures: Dr Halloran reported receiving grants from the National Institute of Allergy and Infectious Diseases during the conduct of the study. No other disclosures were reported. EDAT- 2021/08/28 06:00 MHDA- 2021/09/10 06:00 PMCR- 2021/08/27 CRDT- 2021/08/27 12:24 PHST- 2021/08/27 12:24 [entrez] PHST- 2021/08/28 06:00 [pubmed] PHST- 2021/09/10 06:00 [medline] PHST- 2021/08/27 00:00 [pmc-release] AID - 2783544 [pii] AID - zoi210658 [pii] AID - 10.1001/jamanetworkopen.2021.22240 [doi] PST - epublish SO - JAMA Netw Open. 2021 Aug 2;4(8):e2122240. doi: 10.1001/jamanetworkopen.2021.22240. PMID- 34448482 OWN - NLM STAT- MEDLINE DCOM- 20210902 LR - 20251219 IS - 1460-2229 (Electronic) IS - 0263-2136 (Print) IS - 0263-2136 (Linking) VI - 38 IP - Suppl 1 DP - 2021 Aug 27 TI - The perspective of Canadian health care professionals on abortion service during the COVID-19 pandemic. PG - i30-i36 LID - 10.1093/fampra/cmab083 [doi] AB - BACKGROUND: The COVID-19 pandemic and pandemic response created novel challenges for abortion services. Canada was uniquely positioned to transition to telemedicine because internationally common restrictions on abortion medication were removed before the pandemic. OBJECTIVE: We sought to characterize the experiences of abortion health care professionals in Canada during the COVID-19 pandemic and the impact of the pandemic response on abortion services. METHODS: We conducted a sequential mixed methods study between July 2020 and January 2021. We invited physicians, nurse practitioners and administrators to participate in a cross-sectional survey containing an open-ended question about the impact of the pandemic response on abortion care. We employed an inductive codebook thematic analysis, which informed the development of a second, primarily quantitative survey. RESULTS: Our initial survey had 307 respondents and our second had 78. Fifty-three percent were family physicians. Our first survey found respondents considered abortion access essential. We identified three key topicss: access to abortion care was often maintained despite pandemic-related challenges (e.g. difficulty obtaining tests, additional costs); change of practice to low-touch medication abortion care and provider perceptions of patient experience, including shifting demand, telemedicine acceptability and increased rural access. The second survey indicated uptake of telemedicine medication abortion among 89% of participants except in Quebec, where regulations meant procedures were nearly exclusively surgical. Restrictions did not delay care according to 76% of participants. CONCLUSIONS: Canadian health care professionals report their facilities deemed abortion an essential service. Provinces and territories, except Quebec, described a robust pandemic transition to telemedicine to ensure access to services. PODCAST: An accompanying podcast is available in the Supplementary Data, in which the authors Dr Madeleine Ennis and Kate Wahl discuss their research on how family planning care and access to abortion services have changed during the COVID-19 pandemic. CI - (c) The Author(s) 2021. Published by Oxford University Press. FAU - Ennis, Madeleine AU - Ennis M AD - Department of Obstetrics and Gynaecology, University of British Columbia, Vancouver, Canada. FAU - Wahl, Kate AU - Wahl K AD - Department of Obstetrics and Gynaecology, University of British Columbia, Vancouver, Canada. FAU - Jeong, Dahn AU - Jeong D AD - The School of Population and Public Health, University of British Columbia, Vancouver, Canada. FAU - Knight, Kira AU - Knight K AD - Department of Family Practice, University of British Columbia, Vancouver, Canada. FAU - Renner, Regina AU - Renner R AD - Department of Obstetrics and Gynaecology, University of British Columbia, Vancouver, Canada. FAU - Munro, Sarah AU - Munro S AD - Department of Obstetrics and Gynaecology, University of British Columbia, Vancouver, Canada. FAU - Dunn, Sheila AU - Dunn S AD - Department of Family and Community Medicine, University of Toronto, Toronto, ON, Canada. FAU - Guilbert, Edith AU - Guilbert E AD - Department of Obstetrics and Gynaecology, Laval University, Quebec City, QC, Canada. FAU - Norman, Wendy V AU - Norman WV AUID- ORCID: 0000-0003-4340-7882 AD - Department of Family Practice, University of British Columbia, Vancouver, Canada. AD - Department of Public Health, Environments and Society, Faculty of Public Health & Policy, London School of Hygiene & Tropical Medicine, London, UK. LA - eng GR - The Canadian Institutes of Health Research/ GR - PHE148161/CIHR/Canada GR - The Michael Smith Foundation for Health Research/ GR - CPP-329455-107837/Public Health Agency of Canada Chair in Applied Public Health Research/ PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - England TA - Fam Pract JT - Family practice JID - 8500875 SB - IM MH - Abortion, Induced/*statistics & numerical data MH - Adult MH - *Attitude of Health Personnel MH - COVID-19/*epidemiology MH - Canada/epidemiology MH - Cross-Sectional Studies MH - Female MH - Health Services Accessibility MH - Humans MH - Male MH - Pandemics MH - SARS-CoV-2 MH - Surveys and Questionnaires MH - Telemedicine MH - Pregnancy PMC - PMC8414916 OAB - Access to abortion care was challenged by the response to COVID-19. Canada had fewer restrictions on medical abortion than many other countries when the pandemic began. The goal of this study was to describe the experiences of health care practitioners providing abortion in Canada and the impact of the pandemic and the pandemic response measures on abortion services. We conducted two surveys of physicians, nurse practitioners and administrators between July 2020 and January 2021. Most of the health care practitioners who participated reported that medical and surgical abortion care were essential and that, except in the province of Quebec, there was a rapid transition to virtual telemedicine care for first trimester abortions. Several practitioners said that virtual care made abortion more accessible. Other practitioners reported that it was challenging to order certain tests, access operating room facilities or make referrals for late second trimester cases. Practitioners felt that patients had strong fears about COVID-19 exposure and reported that limited contraception access was increasingly a reason for seeking abortion care. The results of the study suggested that abortion was considered essential and that the pandemic instigated a transition to virtual care in all provinces and territories except Quebec. OABL- eng OTO - NOTNLM OT - Access to health care OT - COVID-19 OT - Canada OT - induced abortion OT - surveys and questionnaires OT - transition care EDAT- 2021/08/28 06:00 MHDA- 2021/09/03 06:00 PMCR- 2021/08/23 CRDT- 2021/08/27 08:40 PHST- 2021/08/27 08:40 [entrez] PHST- 2021/08/28 06:00 [pubmed] PHST- 2021/09/03 06:00 [medline] PHST- 2021/08/23 00:00 [pmc-release] AID - 6358430 [pii] AID - cmab083 [pii] AID - 10.1093/fampra/cmab083 [doi] PST - ppublish SO - Fam Pract. 2021 Aug 27;38(Suppl 1):i30-i36. doi: 10.1093/fampra/cmab083. PMID- 34444479 OWN - NLM STAT- MEDLINE DCOM- 20210906 LR - 20210906 IS - 1660-4601 (Electronic) IS - 1661-7827 (Print) IS - 1660-4601 (Linking) VI - 18 IP - 16 DP - 2021 Aug 18 TI - Factors Affecting Breastfeeding Practices under Lockdown during the COVID-19 Pandemic in Thailand: A Cross-Sectional Survey. LID - 10.3390/ijerph18168729 [doi] LID - 8729 AB - A COVID-19 lockdown and restrictive order has had a large impact on the lives of people. This cross-sectional study was conducted to identify factors affecting breastfeeding among mothers living in Thailand during the lockdown. Data were collected from 903 mothers with infants ages 0-12 months from 17 July 2020 to 17 October 2020 after the first nationwide COVID-19 lockdown period by an online platform and interview questionnaire survey. Multivariable logistic regression analysis was used to investigate the association between the effect of lockdown and breastfeeding practices with potential confounder adjustment including maternal age, ethnicity, newborn age <6 months, family income below $16,130 per annum, education below undergraduate level, and working status. Mothers changed breastfeeding practices in this period (n = 39, 4.32%) including having changed from exclusive breastfeeding to combined breastfeeding with formula milk (n = 22, 2.44%), and having reduced the frequency when compared to before the pandemic (n = 13, 1.44%). The associated factors of changing breastfeeding practices were "contact with healthcare services" (aOR = 0.46, 95% CI 0.22 to 0.96, p = 0.04), "infant feeding support from health personnel" (aOR = 0.39, 95% CI 0.16 to 1.94, p = 0.035), and "lack family support and help with feeding your baby after lockdown" (aOR = 7.04, 95% CI 1.92 to 25.84, p = 0.003). In conclusion, this study showed a slight decrease in breastfeeding in the sampled mothers during the COVID-19 lockdown in Thailand. A long-term national surveillance system for maintenance of breastfeeding should be established. Health care service interventions and additional information are needed to support mothers and families for breastfeeding during pandemics. FAU - Piankusol, Chanodom AU - Piankusol C AUID- ORCID: 0000-0003-1616-5988 AD - Department of Community Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand. FAU - Sirikul, Wachiranun AU - Sirikul W AD - Department of Community Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand. FAU - Ongprasert, Krongporn AU - Ongprasert K AUID- ORCID: 0000-0002-2766-7046 AD - Department of Community Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand. FAU - Siviroj, Penprapa AU - Siviroj P AUID- ORCID: 0000-0003-4781-4119 AD - Department of Community Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand. LA - eng PT - Journal Article DEP - 20210818 PL - Switzerland TA - Int J Environ Res Public Health JT - International journal of environmental research and public health JID - 101238455 SB - IM MH - Breast Feeding MH - *COVID-19 MH - Communicable Disease Control MH - Cross-Sectional Studies MH - Female MH - Humans MH - Infant MH - Infant, Newborn MH - Mothers MH - *Pandemics MH - SARS-CoV-2 MH - Thailand/epidemiology PMC - PMC8391455 OTO - NOTNLM OT - COVID-19 OT - Thailand OT - breastfeeding OT - health care service contact OT - infant feeding support OT - lockdown COIS- The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses or interpretation of data; in the writing of manuscript, or in the decision to publish results EDAT- 2021/08/28 06:00 MHDA- 2021/09/07 06:00 PMCR- 2021/08/18 CRDT- 2021/08/27 01:20 PHST- 2021/08/03 00:00 [received] PHST- 2021/08/15 00:00 [revised] PHST- 2021/08/17 00:00 [accepted] PHST- 2021/08/27 01:20 [entrez] PHST- 2021/08/28 06:00 [pubmed] PHST- 2021/09/07 06:00 [medline] PHST- 2021/08/18 00:00 [pmc-release] AID - ijerph18168729 [pii] AID - ijerph-18-08729 [pii] AID - 10.3390/ijerph18168729 [doi] PST - epublish SO - Int J Environ Res Public Health. 2021 Aug 18;18(16):8729. doi: 10.3390/ijerph18168729. PMID- 34444249 OWN - NLM STAT- MEDLINE DCOM- 20210902 LR - 20250623 IS - 1660-4601 (Electronic) IS - 1661-7827 (Print) IS - 1660-4601 (Linking) VI - 18 IP - 16 DP - 2021 Aug 11 TI - Impact of Sexual Activity on the Risk of Male Genital Tumors: A Systematic Review of the Literature. LID - 10.3390/ijerph18168500 [doi] LID - 8500 AB - Most cancers are related to lifestyle and environmental risk factors, including smoking, alcohol consumption, dietary habits, and environment (occupational exposures). A growing interest in the association between sexual activity (SA) and the development of different types of tumors in both men and women has been recorded in recent years. The aim of the present systematic review is to describe and critically discuss the current evidence regarding the association between SA and male genital cancers (prostatic, penile, and testicular), and to analyze the different theories and biological mechanisms reported in the literature. A comprehensive bibliographic search in the MEDLINE, Scopus, and Web of Science databases was performed in July 2021. Papers in the English language without chronological restrictions were selected. Retrospective and prospective primary clinical studies, in addition to previous systematic reviews and meta-analyses, were included. A total of 19 studies, including 953,704 patients were selected. Case reports, conference abstracts, and editorial comments were excluded. Men with more than 20 sexual partners in their lifetime, and those reporting more than 21 ejaculations per month, reported a decreased risk of overall and less aggressive prostate cancer (PCa). About 40% of penile cancers (PCs) were HPV-associated, with HPV 16 being the dominant genotype. Data regarding the risk of HPV in circumcised patients are conflicting, although circumcision appears to have a protective role against PC. Viral infections and epididymo-orchitis are among the main sex-related risk factors studied for testicular cancer (TC); however, data in the literature are limited. Testicular trauma can allow the identification of pre-existing TC. SA is closely associated with the development of PC through high-risk HPV transmission; in this context, phimosis appears to be a favoring factor. Sexual behaviors appear to play a significant role in PCa pathogenesis, probably through inflammatory mechanisms; however, protective sexual habits have also been described. A direct correlation between SA and TC has not yet been proven, although infections remain the most studied sex-related factor. FAU - Crocetto, Felice AU - Crocetto F AUID- ORCID: 0000-0002-4315-7660 AD - Urology Unit, Department of Neurosciences, Reproductive Sciences and Odontostomatology, University of Naples "Federico II", 80121 Naples, Italy. FAU - Arcaniolo, Davide AU - Arcaniolo D AUID- ORCID: 0000-0002-5282-2335 AD - Urology Unit, Department of Woman Child and of General and Specialist Surgery, University of Campania "Luigi Vanvitelli", 80121 Naples, Italy. FAU - Napolitano, Luigi AU - Napolitano L AUID- ORCID: 0000-0003-2036-0356 AD - Urology Unit, Department of Neurosciences, Reproductive Sciences and Odontostomatology, University of Naples "Federico II", 80121 Naples, Italy. FAU - Barone, Biagio AU - Barone B AUID- ORCID: 0000-0003-4884-132X AD - Urology Unit, Department of Neurosciences, Reproductive Sciences and Odontostomatology, University of Naples "Federico II", 80121 Naples, Italy. FAU - La Rocca, Roberto AU - La Rocca R AD - Urology Unit, Department of Neurosciences, Reproductive Sciences and Odontostomatology, University of Naples "Federico II", 80121 Naples, Italy. FAU - Capece, Marco AU - Capece M AUID- ORCID: 0000-0002-1951-404X AD - Urology Unit, Department of Neurosciences, Reproductive Sciences and Odontostomatology, University of Naples "Federico II", 80121 Naples, Italy. FAU - Caputo, Vincenzo Francesco AU - Caputo VF AD - Urology Unit, Department of Neurosciences, Reproductive Sciences and Odontostomatology, University of Naples "Federico II", 80121 Naples, Italy. FAU - Imbimbo, Ciro AU - Imbimbo C AD - Urology Unit, Department of Neurosciences, Reproductive Sciences and Odontostomatology, University of Naples "Federico II", 80121 Naples, Italy. FAU - De Sio, Marco AU - De Sio M AUID- ORCID: 0000-0003-0820-6030 AD - Urology Unit, Department of Woman Child and of General and Specialist Surgery, University of Campania "Luigi Vanvitelli", 80121 Naples, Italy. FAU - Calace, Francesco Paolo AU - Calace FP AD - Urology Unit, Department of Neurosciences, Reproductive Sciences and Odontostomatology, University of Naples "Federico II", 80121 Naples, Italy. AD - Urology Unit, Department of Woman Child and of General and Specialist Surgery, University of Campania "Luigi Vanvitelli", 80121 Naples, Italy. FAU - Manfredi, Celeste AU - Manfredi C AUID- ORCID: 0000-0002-9706-8516 AD - Urology Unit, Department of Neurosciences, Reproductive Sciences and Odontostomatology, University of Naples "Federico II", 80121 Naples, Italy. AD - Urology Unit, Department of Woman Child and of General and Specialist Surgery, University of Campania "Luigi Vanvitelli", 80121 Naples, Italy. LA - eng PT - Journal Article PT - Systematic Review DEP - 20210811 PL - Switzerland TA - Int J Environ Res Public Health JT - International journal of environmental research and public health JID - 101238455 SB - IM MH - Female MH - Humans MH - Male MH - Prospective Studies MH - Retrospective Studies MH - Risk Factors MH - Sexual Behavior MH - Sexual Partners MH - *Testicular Neoplasms/epidemiology/etiology PMC - PMC8392571 OTO - NOTNLM OT - penile cancer OT - prostate cancer OT - sex OT - sexual activity OT - testicular cancer COIS- The authors declare no conflict of interest. EDAT- 2021/08/28 06:00 MHDA- 2021/09/03 06:00 PMCR- 2021/08/11 CRDT- 2021/08/27 01:19 PHST- 2021/07/07 00:00 [received] PHST- 2021/08/01 00:00 [revised] PHST- 2021/08/09 00:00 [accepted] PHST- 2021/08/27 01:19 [entrez] PHST- 2021/08/28 06:00 [pubmed] PHST- 2021/09/03 06:00 [medline] PHST- 2021/08/11 00:00 [pmc-release] AID - ijerph18168500 [pii] AID - ijerph-18-08500 [pii] AID - 10.3390/ijerph18168500 [doi] PST - epublish SO - Int J Environ Res Public Health. 2021 Aug 11;18(16):8500. doi: 10.3390/ijerph18168500. PMID- 34444077 OWN - NLM STAT- MEDLINE DCOM- 20210903 LR - 20250530 IS - 1660-4601 (Electronic) IS - 1661-7827 (Print) IS - 1660-4601 (Linking) VI - 18 IP - 16 DP - 2021 Aug 6 TI - An Assessment of Government Capacity Building to Restrict the Marketing of Unhealthy Food and Non-Alcoholic Beverage Products to Children in the Region of the Americas. LID - 10.3390/ijerph18168324 [doi] LID - 8324 AB - The Pan American Health Organization (PAHO) Strategic Plan 2020-2025 committed to reduce children's consumption of energy-dense nutrient-poor food and beverage products high in fat, sugar and salt (HFSS) and promote healthy eating patterns to reduce malnutrition in all forms. This paper describes the capacity-building needs in PAHO's Member States to restrict the marketing of HFSS food and beverages to children. We asked Ministries of Health officials or national institutes/departmental representatives (n = 35) to complete a 28-item web-based survey (January to July 2020). Capacity-building needs were assessed using an adapted version of the World Health Organization's government capacity-building framework with three modules: public health infrastructure, policies and information systems. Notable achievements for the PAHO's Plan of Action were identified. State representatives reported strong infrastructure and information systems; however, policy improvements are needed to increase comprehensive national responses. These include using a constitutional health and human rights approach within the policies, policies that document conflict of interest from non-state actors, and strengthening regulatory oversight for digital media platforms. These findings provide baseline data and we suggest priorities for further action to strengthen national governments' capacity-building and to accelerate the development, implementation, and monitoring systems to restrict the marketing of HFSS food and non-alcoholic beverages to children in the region of the Americas. FAU - Patino, Sofia Rincon-Gallardo AU - Patino SR AUID- ORCID: 0000-0002-7997-1971 AD - Department of Non-Communicable Diseases and Mental Health, Pan American Health Organization, World Health Organization, Washington, DC 20037, USA. FAU - Da Silva Gomes, Fabio AU - Da Silva Gomes F AUID- ORCID: 0000-0003-4997-4642 AD - Department of Non-Communicable Diseases and Mental Health, Pan American Health Organization, World Health Organization, Washington, DC 20037, USA. FAU - Constantinou, Steven AU - Constantinou S AD - Department of Non-Communicable Diseases and Mental Health, Pan American Health Organization, World Health Organization, Washington, DC 20037, USA. FAU - Lemaire, Robin AU - Lemaire R AUID- ORCID: 0000-0002-5191-6364 AD - Center for Public Administration and Policy, School of Public and International Affairs, Virginia Polytechnic Institute and State University, Blacksburg, VA 24061, USA. FAU - Hedrick, Valisa E AU - Hedrick VE AUID- ORCID: 0000-0002-1534-9198 AD - Department of Human Nutrition, Foods, and Exercise, College of Agriculture and Life Sciences, Virginia Polytechnic Institute and State University, Blacksburg, VA 24061, USA. FAU - Serrano, Elena L AU - Serrano EL AD - Department of Human Nutrition, Foods, and Exercise, College of Agriculture and Life Sciences, Virginia Polytechnic Institute and State University, Blacksburg, VA 24061, USA. FAU - Kraak, Vivica I AU - Kraak VI AUID- ORCID: 0000-0002-9303-5530 AD - Department of Human Nutrition, Foods, and Exercise, College of Agriculture and Life Sciences, Virginia Polytechnic Institute and State University, Blacksburg, VA 24061, USA. LA - eng GR - 001/WHO_/World Health Organization/International PT - Journal Article DEP - 20210806 PL - Switzerland TA - Int J Environ Res Public Health JT - International journal of environmental research and public health JID - 101238455 SB - IM MH - Beverages MH - *Capacity Building MH - Child MH - Food MH - Government MH - Humans MH - *Internet MH - Marketing PMC - PMC8394636 OTO - NOTNLM OT - capacity-building OT - children OT - food marketing OT - government regulation OT - nutrition policy OT - obesity OT - region of the Americas COIS- The authors declare no conflict of interest. EDAT- 2021/08/28 06:00 MHDA- 2021/09/04 06:00 PMCR- 2021/08/06 CRDT- 2021/08/27 01:18 PHST- 2021/06/29 00:00 [received] PHST- 2021/07/26 00:00 [revised] PHST- 2021/07/30 00:00 [accepted] PHST- 2021/08/27 01:18 [entrez] PHST- 2021/08/28 06:00 [pubmed] PHST- 2021/09/04 06:00 [medline] PHST- 2021/08/06 00:00 [pmc-release] AID - ijerph18168324 [pii] AID - ijerph-18-08324 [pii] AID - 10.3390/ijerph18168324 [doi] PST - epublish SO - Int J Environ Res Public Health. 2021 Aug 6;18(16):8324. doi: 10.3390/ijerph18168324. PMID- 34435661 OWN - NLM STAT- MEDLINE DCOM- 20211124 LR - 20250623 IS - 1469-493X (Electronic) IS - 1361-6137 (Linking) VI - 8 IP - 8 DP - 2021 Aug 26 TI - Image-guided glucocorticoid injection versus injection without image guidance for shoulder pain. PG - CD009147 LID - 10.1002/14651858.CD009147.pub3 [doi] LID - CD009147 AB - BACKGROUND: Despite widespread use, our 2012 Cochrane review did not confirm that use of imaging to guide glucocorticoid injection for people with shoulder pain improves its efficacy. OBJECTIVES: To update our review and assess the benefits and harms of image-guided glucocorticoid injection compared to non-image-guided injection for patients with shoulder pain. SEARCH METHODS: We updated the search of the Cochrane Central Register of Controlled Trials (CENTRAL, via Ovid), MEDLINE (Ovid), Embase (Ovid) and clinicaltrials.gov to 15 Feb 2021, and the World Health Organisation International Clinical Trials Registry Platform (http://www.who.int/trialsearch/Default.aspx) to 06 July 2020. We also screened reference lists of retrieved review articles and trials to identify potentially relevant studies. SELECTION CRITERIA: We included randomised or quasi-randomised controlled trials that compared image-guided glucocorticoid injection to injection without image guidance (either landmark-guided or intramuscular) injection in patients with shoulder pain (rotator cuff disease, adhesive capsulitis or mixed or undefined shoulder pain). Major outcomes were pain, function, proportion of participants with treatment success, quality of life, adverse events, serious adverse events and withdrawals due to adverse events. Minor outcomes were shoulder range of motion and proportion of participants requiring surgery or additional injections. There were no restrictions on language or date of publication. DATA COLLECTION AND ANALYSIS: We used standard methodologic procedures expected by Cochrane. MAIN RESULTS: Nineteen trials were included (1035 participants). Fourteen trials included participants with rotator cuff disease, four with adhesive capsulitis, and one with mixed or undefined shoulder pain. Trial size varied from 28 to 256 participants, most participants were female, mean age ranged between 31 and 60 years, and mean symptom duration varied from 2 to 23 months. Two trials were at low risk of bias for all criteria. The most notable sources of bias in the remaining trials included performance bias and detection bias. Moderate-certainty evidence (downgraded for bias) indicates that ultrasound-guided injection probably provides little or no clinically important benefits compared with injection without guidance with respect to pain (15 trials) or function (14 trials) at three to six weeks follow-up. It may not improve quality of life (2 trials, low-certainty evidence, downgraded due to potential for bias and imprecision) and we are uncertain about the effect of ultrasound-guided injection on participant-rated treatment success due to very low-certainty evidence (downgraded for bias, inconsistency and imprecision). Mean pain (scale range 0 to 10, higher scores indicate more pain) was 3.1 points with injection without image guidance and 0.5 points better (0.2 points better to 0.8 points better; 1003 participants, 15 trials) with an ultrasound-guided injection. This represents a slight difference for pain (0.5 to 1.0 points on a 0 to 10 scale). Mean function (scale range 0 to 100, higher scores indicate better function) was 68 points with injection without image guidance and 2.4 points better (0.2 points worse to 5.1 points better; 895 participants, 14 trials) with an ultrasound-guided injection. Mean quality of life (scale range 0 to 100, higher scores indicate better quality of life) was 65 with injection without image guidance and 2.8 points better (0.7 worse to 6.4 better; 220 participants, 2 trials) with an ultrasound-guided injection. In five trials (350 participants), 101/175 (or 606 per 1000) people in the ultrasound-guided group reported treatment success compared with 68/175 (or 389 per 1000) people in the group injected without image guidance (RR 1.56 (95% CI 0.89 to 2.75)), an absolute difference of 22% more reported success (4% fewer to 62% more). Low-certainty evidence (downgraded for bias and imprecision) indicates that ultrasound-guided injections may not reduce the risk of adverse events compared to injections without image guidance. In five trials (402 participants), 38/200 (or 181 per 1000) people in the ultrasound-guided group reported adverse events compared with 51/202 (or 252 per 1000) in the non-image-guided injection group (RR 0.72 (95% CI 0.4 to 1.28)), an absolute difference of 7% fewer adverse events (15% fewer to 7% more). Five trials reported that there were no serious adverse events. The remaining trials did not report serious adverse events. One trial reported that 1/53 (or 19 per 1000) in the injection without image guidance group and 0/53 in the ultrasound-guided group withdrew due to adverse events. Sensitivity analyses indicate that the effects for pain and function may have been influenced by selection bias, and the effects for function may have been influenced by detection bias. The test for subgroup differences indicated there were unlikely to be differences in pain and function across different shoulder conditions. AUTHORS' CONCLUSIONS: Our updated review does not support use of image guidance for injections in the shoulder. Moderate-certainty evidence indicates that ultrasound-guided injection in the treatment of shoulder pain probably provides little or no benefit over injection without imaging in terms of pain or function and low-certainty evidence indicates there may be no difference in quality of life. We are uncertain if ultrasound-guided injection improves participant-rated treatment success, due to very low-certainty evidence. Low-certainty evidence also suggests ultrasound-guided injection may not reduce the risk of adverse events compared with non-image-guided injection. No serious adverse events were reported in any trial. The lack of significant benefit of image guidance over injection without image guidance to improve patient-relevant outcomes or reduce harms, suggests that any added cost of image guidance appears unjustified. CI - Copyright (c) 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. FAU - Zadro, Joshua AU - Zadro J AD - Faculty of Medicine and Health, The University of Sydney, Sydney, Australia. FAU - Rischin, Adam AU - Rischin A AD - Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University; Monash-Cabrini Department of Musculoskeletal Health and Clinical Epidemiology, Cabrini Health, Melbourne, Australia. FAU - Johnston, Renea V AU - Johnston RV AD - Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University; Monash-Cabrini Department of Musculoskeletal Health and Clinical Epidemiology, Cabrini Health, Melbourne, Australia. FAU - Buchbinder, Rachelle AU - Buchbinder R AD - Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University; Monash-Cabrini Department of Musculoskeletal Health and Clinical Epidemiology, Cabrini Health, Melbourne, Australia. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Systematic Review DEP - 20210826 PL - England TA - Cochrane Database Syst Rev JT - The Cochrane database of systematic reviews JID - 100909747 RN - 0 (Glucocorticoids) SB - IM UOF - Cochrane Database Syst Rev. 2012 Aug 15;(8):CD009147. doi: 10.1002/14651858.CD009147.pub2. PMID: 22895984 CIN - Ugeskr Laeger. 2022 Apr 18;184(16):V205098. PMID: 35485781 MH - Child, Preschool MH - Female MH - *Glucocorticoids MH - Humans MH - Pain Measurement MH - Quality of Life MH - Rotator Cuff MH - *Shoulder Pain/drug therapy PMC - PMC8407470 COIS- JZ: none known. AR: none known. RB is the Co-ordinating Editor of Cochrane Musculoskeletal, but was not involved in editorial decisions regarding this review. She is a recipient of a National Health and Medical Research Council (NHMRC) Cochrane Collaboration Round 7 Funding Program Grant, which supports the activities of the Cochrane Musculoskeletal Editorial base, but the funders do not participate in the conduct of reviews. RJ is the Managing Editor of Cochrane Musculoskeletal, but was not involved in editorial decisions regarding this review. She is a recipient of an NHMRC (Australia) Cochrane Collaboration Round 7 Funding Program Grant, which supports the Cochrane Musculoskeletal Editorial base, but the funders do not participate in the conduct of this review. EDAT- 2021/08/27 06:00 MHDA- 2021/11/25 06:00 PMCR- 2022/08/26 CRDT- 2021/08/26 09:02 PHST- 2021/08/26 09:02 [entrez] PHST- 2021/08/27 06:00 [pubmed] PHST- 2021/11/25 06:00 [medline] PHST- 2022/08/26 00:00 [pmc-release] AID - CD009147.pub3 [pii] AID - 10.1002/14651858.CD009147.pub3 [doi] PST - epublish SO - Cochrane Database Syst Rev. 2021 Aug 26;8(8):CD009147. doi: 10.1002/14651858.CD009147.pub3. PMID- 34433606 OWN - NLM STAT- MEDLINE DCOM- 20210906 LR - 20240403 IS - 2044-6055 (Electronic) IS - 2044-6055 (Linking) VI - 11 IP - 8 DP - 2021 Aug 25 TI - Impact of social restrictions during the COVID-19 pandemic on the physical activity levels of adults aged 50-92 years: a baseline survey of the CHARIOT COVID-19 Rapid Response prospective cohort study. PG - e050680 LID - 10.1136/bmjopen-2021-050680 [doi] LID - e050680 AB - OBJECTIVES: Physical inactivity is more common in older adults, is associated with social isolation and loneliness and contributes to increased morbidity and mortality. We examined the effect of social restrictions to reduce COVID-19 transmission in the UK (lockdown), on physical activity (PA) levels of older adults and the social predictors of any change. DESIGN: Baseline analysis of a survey-based prospective cohort study. SETTING: Adults enrolled in the Cognitive Health in Ageing Register for Investigational and Observational Trials cohort from general practitioner practices in North West London were invited to participate from April to July 2020. PARTICIPANTS: 6219 cognitively healthy adults aged 50-92 years completed the survey. MAIN OUTCOME MEASURES: Self-reported PA before and after the introduction of lockdown, as measured by metabolic equivalent of task (MET) minutes. Associations of PA with demographic, lifestyle and social factors, mood and frailty. RESULTS: Mean PA was significantly lower following the introduction of lockdown from 3519 to 3185 MET min/week (p<0.001). After adjustment for confounders and prelockdown PA, lower levels of PA after the introduction of lockdown were found in those who were over 85 years old (640 (95% CI 246 to 1034) MET min/week less); were divorced or single (240 (95% CI 120 to 360) MET min/week less); living alone (277 (95% CI 152 to 402) MET min/week less); reported feeling lonely often (306 (95% CI 60 to 552) MET min/week less); and showed symptoms of depression (1007 (95% CI 612 to 1401) MET min/week less) compared with those aged 50-64 years, married, cohabiting and not reporting loneliness or depression, respectively. CONCLUSIONS AND IMPLICATIONS: Markers of social isolation, loneliness and depression were associated with lower PA following the introduction of lockdown in the UK. Targeted interventions to increase PA in these groups should be considered. CI - (c) Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY. Published by BMJ. FAU - Salman, David AU - Salman D AUID- ORCID: 0000-0002-1481-8829 AD - Department of Primary Care and Public Health, Imperial College London, London, UK d.salman11@imperial.ac.uk thomas.beaney@imperial.ac.uk. AD - MSk Lab, Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, London, UK. FAU - Beaney, Thomas AU - Beaney T AD - Department of Primary Care and Public Health, Imperial College London, London, UK d.salman11@imperial.ac.uk thomas.beaney@imperial.ac.uk. FAU - E Robb, Catherine AU - E Robb C AD - Ageing Epidemiology Research Unit (AGE), Faculty of Medicine, School of Public Health, Imperial College London, London, UK. FAU - de Jager Loots, Celeste A AU - de Jager Loots CA AUID- ORCID: 0000-0003-0789-3297 AD - Ageing Epidemiology Research Unit (AGE), Faculty of Medicine, School of Public Health, Imperial College London, London, UK. FAU - Giannakopoulou, Parthenia AU - Giannakopoulou P AD - Ageing Epidemiology Research Unit (AGE), Faculty of Medicine, School of Public Health, Imperial College London, London, UK. FAU - Udeh-Momoh, Chinedu T AU - Udeh-Momoh CT AD - Ageing Epidemiology Research Unit (AGE), Faculty of Medicine, School of Public Health, Imperial College London, London, UK. FAU - Ahmadi-Abhari, Sara AU - Ahmadi-Abhari S AD - Ageing Epidemiology Research Unit (AGE), Faculty of Medicine, School of Public Health, Imperial College London, London, UK. FAU - Majeed, Azeem AU - Majeed A AD - Department of Primary Care and Public Health, Imperial College London, London, UK. AD - Public Health Directorate, Imperial College Healthcare NHS Trust, London, UK. FAU - Middleton, Lefkos T AU - Middleton LT AD - Ageing Epidemiology Research Unit (AGE), Faculty of Medicine, School of Public Health, Imperial College London, London, UK. AD - Public Health Directorate, Imperial College Healthcare NHS Trust, London, UK. FAU - McGregor, Alison H AU - McGregor AH AD - MSk Lab, Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, London, UK. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20210825 PL - England TA - BMJ Open JT - BMJ open JID - 101552874 SB - IM MH - Aged MH - Aged, 80 and over MH - *COVID-19 MH - *Communicable Disease Control MH - *Exercise MH - Humans MH - Middle Aged MH - Pandemics MH - Prospective Studies MH - Surveys and Questionnaires MH - United Kingdom PMC - PMC8390149 OTO - NOTNLM OT - COVID-19 OT - geriatric medicine OT - preventive medicine OT - public health OT - sports medicine COIS- Competing interests: LTM reports research funding from Janssen, Novartis, Merck and Takeda, outside the submitted work. EDAT- 2021/08/27 06:00 MHDA- 2021/09/07 06:00 PMCR- 2021/08/25 CRDT- 2021/08/26 05:36 PHST- 2021/08/26 05:36 [entrez] PHST- 2021/08/27 06:00 [pubmed] PHST- 2021/09/07 06:00 [medline] PHST- 2021/08/25 00:00 [pmc-release] AID - bmjopen-2021-050680 [pii] AID - 10.1136/bmjopen-2021-050680 [doi] PST - epublish SO - BMJ Open. 2021 Aug 25;11(8):e050680. doi: 10.1136/bmjopen-2021-050680. PMID- 34429263 OWN - NLM STAT- MEDLINE DCOM- 20220830 LR - 20251112 IS - 1878-7541 (Electronic) IS - 1550-8307 (Linking) VI - 18 IP - 5 DP - 2022 Sep-Oct TI - Burnout and spirituality among nurses: A scoping review. PG - 612-620 LID - S1550-8307(21)00174-9 [pii] LID - 10.1016/j.explore.2021.08.001 [doi] AB - OBJECTIVE: To investigate the relationship between spirituality / religiousness and Burnout Syndrome in nurses, as well as to examine the current evidence for spiritual/religious interventions to alleviate their symptoms. DATA SOURCES: A scoping review was conducted using CINAHL, SCOPUS, Web of Science, Pubmed databases, and grey literature, between January and July 2020. STUDY SELECTION: Two researchers performed the searches with a 95% agreement rate for the inclusion and exclusion of the studies. Both quantitative and qualitative studies published in peer-reviewed journals, using Spanish, Portuguese or English language were included. Restriction on publication date was not applied. DATA EXTRACTION: A total of 1143 articles were identified and 18 were included in the final analysis. Quality assessment was performed, following CONSORT, STROBE, PRISMA and COREQ guidelines. Finally, the following data were extracted: authors, year, country, study design and sample characteristics, purpose of the study, and major findings. DATA SYNTHESIS: The results of the present review show that spirituality / religiousness is a common strategy used by nurses when coping with stress and burnout. Most studies reveal that spiritual and religious beliefs are correlated with lower levels of burnout, exhaustion and depersonalization in different settings. Nevertheless, two studies have not found any relationship and one study has found worse outcomes. CONCLUSIONS: There is a lack of experimental studies trying to examine if spiritual interventions could modify burnout levels in clinical practice. Health managers should be aware of the spirituality / religiousness of their nurses and provide the appropriate spiritual support. CI - Copyright (c) 2021 The Authors. Published by Elsevier Inc. All rights reserved. FAU - De Diego-Cordero, Rocio AU - De Diego-Cordero R AD - Department of Nursing, Faculty of Nursing, Physiotherapy, and Podiatry, Universidad de Sevilla, Research Group under the Andalusian Research CTS 969 Innovation in HealthCare and Social Determinants of Health. Seville, Spain. Electronic address: rdediego2@us.es. FAU - Iglesias-Romo, Marta AU - Iglesias-Romo M AD - Department of Nursing, Faculty of Nursing, Physiotherapy, and Podiatry, Universidad de Sevilla. FAU - Badanta, Barbara AU - Badanta B AD - Department of Nursing, Faculty of Nursing, Physiotherapy, and Podiatry, Universidad de Sevilla, Spain; Research Group under the Andalusian Research CTS 1050 Complex Care, Chronic and Health Outcomes Seville, Seville, Spain. Electronic address: bbadanta@us.es. FAU - Lucchetti, Giancarlo AU - Lucchetti G AD - School of Medicine. Federal University of Juiz de Fora, Brazil. Electronic address: g.lucchetti@yahoo.com.br. FAU - Vega-Escano, Juan AU - Vega-Escano J AD - Spanish Red Cross Nursing School. University of Seville, Avda. Cruz Roja 1, 41009 Seville, Spain. LA - eng PT - Journal Article PT - Scoping Review DEP - 20210812 PL - United States TA - Explore (NY) JT - Explore (New York, N.Y.) JID - 101233160 SB - IM MH - Adaptation, Psychological MH - *Burnout, Professional MH - Humans MH - Religion MH - *Spiritual Therapies MH - Spirituality OTO - NOTNLM OT - Burnout syndrome OT - Global occupational health OT - Nurses OT - Religion OT - Spirituality EDAT- 2021/08/26 06:00 MHDA- 2022/08/31 06:00 CRDT- 2021/08/25 05:43 PHST- 2021/05/04 00:00 [received] PHST- 2021/08/02 00:00 [revised] PHST- 2021/08/04 00:00 [accepted] PHST- 2021/08/26 06:00 [pubmed] PHST- 2022/08/31 06:00 [medline] PHST- 2021/08/25 05:43 [entrez] AID - S1550-8307(21)00174-9 [pii] AID - 10.1016/j.explore.2021.08.001 [doi] PST - ppublish SO - Explore (NY). 2022 Sep-Oct;18(5):612-620. doi: 10.1016/j.explore.2021.08.001. Epub 2021 Aug 12. PMID- 34426470 OWN - NLM STAT- MEDLINE DCOM- 20210827 LR - 20210910 IS - 2044-6055 (Electronic) IS - 2044-6055 (Linking) VI - 11 IP - 8 DP - 2021 Aug 23 TI - Development and validation of a risk-adjustment model for mortality and hospital length of stay for trauma patients: a prospective registry-based study in Australia. PG - e050795 LID - 10.1136/bmjopen-2021-050795 [doi] LID - e050795 AB - OBJECTIVES: Adequate risk adjustment for factors beyond the control of the healthcare system contributes to the process of transparent and equitable benchmarking of trauma outcomes. Current risk adjustment models are not optimal in terms of the number and nature of predictor variables included in the model and the treatment of missing data. We propose a statistically robust and parsimonious risk adjustment model for the purpose of benchmarking. SETTING: This study analysed data from the multicentre Australia New Zealand Trauma Registry from 1 July 2016 to 30 June 2018 consisting of 31 trauma centres. OUTCOME MEASURES: The primary endpoints were inpatient mortality and length of hospital stay. Firth logistic regression and robust linear regression models were used to study the endpoints, respectively. Restricted cubic splines were used to model non-linear relationships with age. Model validation was performed on a subset of the dataset. RESULTS: Of the 9509 patients in the model development cohort, 72% were male and approximately half (51%) aged over 50 years . For mortality, cubic splines in age, injury cause, arrival Glasgow Coma Scale motor score, highest and second-highest Abbreviated Injury Scale scores and shock index were significant predictors. The model performed well in the validation sample with an area under the curve of 0.93. For length of stay, the identified predictor variables were similar. Compared with low falls, motor vehicle occupants stayed on average 2.6 days longer (95% CI: 2.0 to 3.1), p<0.001. Sensitivity analyses did not demonstrate any marked differences in the performance of the models. CONCLUSION: Our risk adjustment model of six variables is efficient and can be reliably collected from registries to enhance the process of benchmarking. CI - (c) Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. FAU - Earnest, Arul AU - Earnest A AUID- ORCID: 0000-0003-2693-5034 AD - Department of Epidemiology and Preventive Medicine, Monash University School of Public Health and Preventive Medicine, Melbourne, Victoria, Australia arul.earnest@monash.edu. FAU - Palmer, Cameron AU - Palmer C AD - Trauma Service, Royal Children's Hospital Melbourne, Parkville, Victoria, Australia. FAU - O'Reilly, Gerard AU - O'Reilly G AD - Department of Epidemiology and Preventive Medicine, Monash University School of Public Health and Preventive Medicine, Melbourne, Victoria, Australia. AD - Emergency and Trauma Centre, The Alfred, Melbourne, Victoria, Australia. AD - National Trauma Research Institute, The Alfred, Melbourne, Victoria, Australia. FAU - Burrell, Maxine AU - Burrell M AD - State Trauma Unit, Royal Perth Hospital, Perth, Western Australia, Australia. FAU - McKie, Emily AU - McKie E AD - Department of Epidemiology and Preventive Medicine, Monash University School of Public Health and Preventive Medicine, Melbourne, Victoria, Australia. FAU - Rao, Sudhakar AU - Rao S AD - State Trauma Unit, Royal Perth Hospital, Perth, Western Australia, Australia. FAU - Curtis, Kate AU - Curtis K AUID- ORCID: 0000-0002-3746-0348 AD - Sydney Nursing School, University of Sydney, Sydney, New South Wales, Australia. AD - Illawarra Shoalhaven, Local Health District, Sydney, New South Wales, Australia. FAU - Cameron, Peter AU - Cameron P AD - Department of Epidemiology and Preventive Medicine, Monash University School of Public Health and Preventive Medicine, Melbourne, Victoria, Australia. AD - Emergency and Trauma Centre, The Alfred, Melbourne, Victoria, Australia. LA - eng PT - Journal Article DEP - 20210823 PL - England TA - BMJ Open JT - BMJ open JID - 101552874 SB - IM MH - Aged MH - Australia/epidemiology MH - *Hospitals MH - Humans MH - Length of Stay MH - Male MH - Registries MH - *Risk Adjustment PMC - PMC8383878 OTO - NOTNLM OT - epidemiology OT - orthopaedic & trauma surgery OT - public health COIS- Competing interests: Associate Professor GO'R is currently a NHMRC Research Fellow at the National Trauma Research Institute, Alfred Hospital, Melbourne, Australia, leading the project titled Maximising the usefulness and timeliness of trauma and emergency registry data for improving patient outcomes. Professor PC is funded by the Medical Research Futures Fund as a Practitioner Fellow. EDAT- 2021/08/25 06:00 MHDA- 2021/08/28 06:00 PMCR- 2021/08/23 CRDT- 2021/08/24 05:47 PHST- 2021/08/24 05:47 [entrez] PHST- 2021/08/25 06:00 [pubmed] PHST- 2021/08/28 06:00 [medline] PHST- 2021/08/23 00:00 [pmc-release] AID - bmjopen-2021-050795 [pii] AID - 10.1136/bmjopen-2021-050795 [doi] PST - epublish SO - BMJ Open. 2021 Aug 23;11(8):e050795. doi: 10.1136/bmjopen-2021-050795. PMID- 34420493 OWN - NLM STAT- MEDLINE DCOM- 20221123 LR - 20221123 IS - 1476-4954 (Electronic) IS - 1476-4954 (Linking) VI - 35 IP - 25 DP - 2022 Dec TI - Fetal growth restriction: underdiagnosed condition with non-optimal screening. PG - 8237-8244 LID - 10.1080/14767058.2021.1967924 [doi] AB - BACKGROUND: Fetal Growth restriction (FGR) is the pathological failure of a fetus to reach its biologically determined growth potential. Detection of FGR fetuses is a universally agreed key objective of antenatal care. Antenatal detection of FGR has undeniable benefits, juggling between intensive fetal surveillance and optimized timing of delivery; it reduces adverse perinatal outcomes by up to four-fold. However, FGR is still widely underdiagnosed. We aimed to identify the prevalence of FGR diagnosis in our wards and study the impact of the 2013 published French guidelines on the detection rate of FGR. The secondary objective aimed to highlight the factors of suboptimal screening in the population of non-diagnosed FGR fetuses and emphasize the screening method that led to antenatal diagnosis of FGR. MATERIALS AND METHODS: We conducted a retrospective study at a single tertiary maternity center in Lyon-France, the Femme Mere Enfant Hospital, including the exhaustive population of FGR born after 24 + 0 weeks of gestation from 1 January 2011 to 31 December 2017. FGR was defined combining the neonatal and antenatal consensus-based definitions for early and late FGR in absence of congenital anomalies, excluding small for gestational age fetuses. For all FGR fetuses, we compared the antenatal detection rate of FGR during 2011-2013 to 2015-2017, since the French guidelines were published in December 2013. When FGR fetuses underwent an antenatal diagnosis of FGR, we retrospectively collected the characteristics that led to the diagnosis. When fetuses were not diagnosed as FGR, we retrospectively reviewed the implementation of the recommended screening method, enabling to evaluate whether screening was optimal or not. Statistical analysis was performed in July 2018, and statistical significance was regarded as a p-value <.05. RESULTS: Over the seven-year period, and among 31,052 newborns, 1020 (3.3%) infants were identified as FGR and met the inclusion criteria. The detection rate of FGR was similar before and after publication of the French Guidelines related to FGR in 2013. Indeed, 50.8% (201/395) FGR were diagnosed between 2011 and 2013 versus 52.6% (245/465) between 2015 and 2017 (p = .59). In the population of non-diagnosed FGR infants, screening was suboptimal in 80%. Symphysis-fundal height (SFH) was not measured in 10.7%, with no difference before and after 2014 (7.3 versus 11.8% p = .11). Ultrasound examination for fetal biometry had not been prescribed in spite of abnormal SFH in 47.7% of undiagnosed FGR infants. Diagnosis has been missed in 11.5% of infants because of misinterpretation of the estimated fetal weight's centile. CONCLUSION: FGR is widely underdiagnosed. However, the limited performances can partially be explained by the regular misuse of screening method in clinical practice. Despite the systematic third trimester ultrasound screening, the detection rate of FGR was similar to the one reported in the medical literature. The timing of routine third trimester ultrasound in low-risk women may be rethought. FAU - Atallah, Anthony AU - Atallah A AUID- ORCID: 0000-0002-4805-2083 AD - Department of Obstetrics and Gynecology, Femme Mere Enfant Hospital, Hospices Civils de Lyon, University Hospital Center, Bron, France. AD - University of Lyon, University Claude Bernard Lyon 1, University of Saint-Etienne, Saint-Etienne, France. AD - University Hospital Centre Sainte Justine, Department of Maternal Fetal Medicine, University of Montreal, Canada. FAU - Butin, Marine AU - Butin M AD - Department of Neonatalogy, Femme Mere Enfant Hospital, Hospices Civils de Lyon, University Hospital Center, Bron, France. AD - International Center for Research in Infectiology, INSERM U1111, CNRS UMR5308, University of Lyon 1, Lyon, France. FAU - Moret, Stephanie AU - Moret S AD - Department of Obstetrics and Gynecology, Femme Mere Enfant Hospital, Hospices Civils de Lyon, University Hospital Center, Bron, France. FAU - Claris, Olivier AU - Claris O AD - University Hospital Centre Sainte Justine, Department of Maternal Fetal Medicine, University of Montreal, Canada. AD - University of Lyon, Lyon, EA, France. FAU - Gaucherand, Pascal AU - Gaucherand P AD - Department of Obstetrics and Gynecology, Femme Mere Enfant Hospital, Hospices Civils de Lyon, University Hospital Center, Bron, France. AD - University of Lyon, University Claude Bernard Lyon 1, University of Saint-Etienne, Saint-Etienne, France. FAU - Doret-Dion, Muriel AU - Doret-Dion M AD - Department of Obstetrics and Gynecology, Femme Mere Enfant Hospital, Hospices Civils de Lyon, University Hospital Center, Bron, France. AD - University of Lyon, University Claude Bernard Lyon 1, University of Saint-Etienne, Saint-Etienne, France. LA - eng PT - Journal Article DEP - 20210822 PL - England TA - J Matern Fetal Neonatal Med JT - The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians JID - 101136916 SB - IM MH - Female MH - Infant, Newborn MH - Pregnancy MH - Humans MH - *Fetal Growth Retardation/diagnostic imaging/epidemiology MH - Retrospective Studies MH - Pregnancy Trimester, Third MH - *Prenatal Diagnosis/methods MH - Prenatal Care/methods MH - Ultrasonography, Prenatal MH - Gestational Age MH - Infant, Small for Gestational Age OTO - NOTNLM OT - Growth restriction OT - antenatal management OT - evidence based care OT - fetal growth restriction OT - prenatal care OT - symphysis-fundal height OT - ultrasound screening EDAT- 2021/08/24 06:00 MHDA- 2022/11/24 06:00 CRDT- 2021/08/23 05:30 PHST- 2021/08/24 06:00 [pubmed] PHST- 2022/11/24 06:00 [medline] PHST- 2021/08/23 05:30 [entrez] AID - 10.1080/14767058.2021.1967924 [doi] PST - ppublish SO - J Matern Fetal Neonatal Med. 2022 Dec;35(25):8237-8244. doi: 10.1080/14767058.2021.1967924. Epub 2021 Aug 22. PMID- 34414999 OWN - NLM STAT- MEDLINE DCOM- 20211102 LR - 20250103 IS - 1698-6946 (Electronic) IS - 1698-4447 (Print) IS - 1698-4447 (Linking) VI - 26 IP - 6 DP - 2021 Nov 1 TI - The impact of COVID-19 on access to dental care for people with disabilities: a global survey during the COVID-19 first wave lockdown. PG - e770-e777 LID - 10.4317/medoral.24742 [doi] AB - BACKGROUND: It is unclear what immediate impact the COVID-19 pandemic has had on delivery of oral healthcare to people with disabilities worldwide. AIM: To report the international impact of COVID-19 lockdown on oral healthcare provision for people with disabilities before, during and after the first lockdown (March to July 2020). MATERIAL AND METHODS: Cross-sectional online self-administered survey of dentists who treat people with disabilities completed 10th to 31st of July 2020. Responses allowed comparison from before, during and immediately after the first wave lockdowns of the COVID-19 pandemic. Data were analysed using McNemar's test to compare reported practice before to during lockdown, and before to after lockdown. RESULTS: Four-hundred-thirty-six respondents from across global regions reported a significant reduction from before to during and from before to after lockdown regarding: the proportion of dentists treating people with all types of disability (p <0.001) and the number of patients with disabilities seen per week (p<0.0001). The proportion reporting no availability of any pharmacological supports rose from 22% pre-lockdown to 61% during lockdown (p < 0.001) and a persistent 44% after lockdown (p < 0.001). An increase in teledentistry was observed. CONCLUSIONS: During the first COVID-19 lockdown, there was a significant negative impact on the delivery of dental care to people with disabilities. Oral healthcare access was significantly restricted for people with disabilities with access to sedation and general anaesthesia particularly affected. There is now an increased need to ensure that no-one is left behind in new and existing services as they emerge post-pandemic. FAU - Mac Giolla Phadraig, C AU - Mac Giolla Phadraig C AD - Department of Child and Public Dental Health Dublin Dental University Hospital Trinity College Dublin, Dublin 2, Ireland macgiolla@dental.tcd.ie. FAU - van Harten, M-T AU - van Harten MT FAU - Diniz-Freitas, M AU - Diniz-Freitas M FAU - Limeres Posse, J AU - Limeres Posse J FAU - Faulks, D AU - Faulks D FAU - Dougall, A AU - Dougall A FAU - Diz Dios, P AU - Diz Dios P FAU - Daly, B AU - Daly B LA - eng PT - Journal Article DEP - 20211101 PL - Spain TA - Med Oral Patol Oral Cir Bucal JT - Medicina oral, patologia oral y cirugia bucal JID - 101231694 SB - IM MH - *COVID-19 MH - Communicable Disease Control MH - Cross-Sectional Studies MH - Dental Care MH - *Persons with Disabilities MH - Humans MH - Pandemics MH - SARS-CoV-2 MH - Surveys and Questionnaires PMC - PMC8601643 COIS- Conflicts of interest The authors confirm no conflict of interest. EDAT- 2021/08/21 06:00 MHDA- 2021/11/03 06:00 PMCR- 2021/11/01 CRDT- 2021/08/20 09:06 PHST- 2021/03/16 00:00 [received] PHST- 2021/07/16 00:00 [accepted] PHST- 2021/08/21 06:00 [pubmed] PHST- 2021/11/03 06:00 [medline] PHST- 2021/08/20 09:06 [entrez] PHST- 2021/11/01 00:00 [pmc-release] AID - 24742 [pii] AID - 10.4317/medoral.24742 [doi] PST - epublish SO - Med Oral Patol Oral Cir Bucal. 2021 Nov 1;26(6):e770-e777. doi: 10.4317/medoral.24742. PMID- 34407785 OWN - NLM STAT- MEDLINE DCOM- 20210820 LR - 20231107 IS - 1471-2474 (Electronic) IS - 1471-2474 (Linking) VI - 22 IP - 1 DP - 2021 Aug 18 TI - Utilisation of outpatient physiotherapy in patients following total knee arthroplasty - a systematic review. PG - 711 LID - 10.1186/s12891-021-04600-2 [doi] LID - 711 AB - OBJECTIVE: Data on the utilisation of outpatient physiotherapy (PT) in patients following total knee arthroplasty (TKA) are scarce, and available studies have not been systematically synthesised. This study aims to summarise the existing literature on outpatient PT following TKA as well as to identify factors associated with its use. METHODS: A systematic literature search in MEDLINE (via PubMed), CINAHL, Scopus and PEDro was conducted in July 2020 without language restrictions. Two authors independently selected studies, extracted data and assessed study quality. The primary outcome was the proportion being treated with at least one session of outpatient PT (land- or water-based treatments supervised/provided by a qualified physiotherapist) during any defined period within 12 months following TKA. Furthermore, predictors for the use of PT were assessed. Studies including only revision surgeries or bilateral TKA were excluded. RESULTS: After screening 1934 titles/abstracts and 56 full text articles, 5 studies were included. Proportions of PT utilisation ranged from 16.7 to 84.5%. There were large variations in the time periods after hospital discharge (4 weeks to 12 months) and in the reporting of PT definitions. Female sex was associated with higher PT utilisation, and compared to patients after total hip arthroplasty, utilisation was higher among those following TKA. CONCLUSION: Despite using a broad search strategy, we found only 5 studies assessing the utilisation of PT after hospital discharge in patients with TKA. These studies showed large heterogeneity in PT utilisation, assessed time periods and PT definitions. Clearly, more studies from different countries with uniform PT definitions are needed to address this relevant public health question. CI - (c) 2021. The Author(s). FAU - Jacobs, Hannes AU - Jacobs H AD - Department of Health Services Research, Carl von Ossietzky University Oldenburg, Ammerlander Heerstr. 114-118, 26129, Oldenburg, Germany. Hannes.Jacobs@uol.de. FAU - Seeber, Gesine H AU - Seeber GH AD - University Hospital for Orthopaedics and Trauma Surgery Pius-Hospital, Medical Campus University of Oldenburg, Oldenburg, Germany. AD - Department of Orthopedics, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. FAU - Allers, Katharina AU - Allers K AD - Department of Health Services Research, Carl von Ossietzky University Oldenburg, Ammerlander Heerstr. 114-118, 26129, Oldenburg, Germany. FAU - Hoffmann, Falk AU - Hoffmann F AD - Department of Health Services Research, Carl von Ossietzky University Oldenburg, Ammerlander Heerstr. 114-118, 26129, Oldenburg, Germany. LA - eng PT - Journal Article PT - Systematic Review DEP - 20210818 PL - England TA - BMC Musculoskelet Disord JT - BMC musculoskeletal disorders JID - 100968565 SB - IM MH - *Arthroplasty, Replacement, Hip MH - *Arthroplasty, Replacement, Knee/adverse effects MH - Female MH - Humans MH - *Osteoarthritis, Knee/surgery MH - Outpatients MH - Patient Discharge MH - Physical Therapy Modalities PMC - PMC8375073 OTO - NOTNLM OT - Arthroplasty OT - Health services research OT - Osteoarthritis OT - Physical therapy OT - Rehabilitation COIS- The authors declare that they have no competing interests. EDAT- 2021/08/20 06:00 MHDA- 2021/08/21 06:00 PMCR- 2021/08/18 CRDT- 2021/08/19 05:35 PHST- 2021/05/27 00:00 [received] PHST- 2021/08/03 00:00 [accepted] PHST- 2021/08/19 05:35 [entrez] PHST- 2021/08/20 06:00 [pubmed] PHST- 2021/08/21 06:00 [medline] PHST- 2021/08/18 00:00 [pmc-release] AID - 10.1186/s12891-021-04600-2 [pii] AID - 4600 [pii] AID - 10.1186/s12891-021-04600-2 [doi] PST - epublish SO - BMC Musculoskelet Disord. 2021 Aug 18;22(1):711. doi: 10.1186/s12891-021-04600-2. PMID- 34406258 OWN - NLM STAT- MEDLINE DCOM- 20210820 LR - 20210820 IS - 1806-9282 (Electronic) IS - 0104-4230 (Linking) VI - 67 IP - 2 DP - 2021 Feb TI - Effectiveness of early therapeutic intervention in phases one and two after COVID-19 infection: systematic review. PG - 302-312 LID - S0104-42302021000300302 [pii] LID - 10.1590/1806-9282.67.02.20200594 [doi] AB - OBJECTIVES: Although research in relation to new vaccines for the coronavirus, SARS-CoV-2 (COVID-19), is ongoing, it has been reported that medical teams are also considering the use of antiviral drugs in patients in order to verify their effectiveness when infection signs and symptoms present, mainly in stages one and two of the disease. METHODS: For the selection of studies, the combination based on the Medical Subject Heading Terms (MeSH) was used, and the databases Medline (Pubmed), LILACS, SciELO, SCOPUS, Web of Science, and BIREME were searched. The search period for articles consisted of manuscripts published between January 2010 and July 2020 without language and localization restrictions. RESULTS: Initially, 20 articles were selected and then reduced to 19 after exclusion based on repetititve articles. Titles and abstracts were analyzed, and 14 articles were excluded because they did not meet the inclusion criteria and did not answer the guiding question. Studies show that patients receiving certain medications in the initial stages (one and two) indicate a reversal of complications during hospitalization or often do not require hospitalization in addition to being discharged in a shorter period of time. CONCLUSION: Studies have reported that effective drugs for treating COVID-19 exist. In addition, this study emphasizes the importance of performing therapeutic interventions in the initial stages of infection aimed at reversing the disease and minimizing public health costs. FAU - Goncalves, Laura Faustino AU - Goncalves LF AUID- ORCID: 0000-0002-0043-4349 AD - Universidade Federal de Santa Catarina, Faculdade de Fonoaudiologia - Florianopolis (SC), Brazil. FAU - Cipriano, Guilherme de Souza AU - Cipriano GS AUID- ORCID: 0000-0002-3884-9945 AD - Universidade Federal de Santa Catarina, Faculdade de Fonoaudiologia - Florianopolis (SC), Brazil. FAU - Paiva, Karina Mary AU - Paiva KM AUID- ORCID: 0000-0001-7086-534X AD - Universidade Federal de Santa Catarina, Faculdade de Fonoaudiologia - Florianopolis (SC), Brazil. FAU - Gonzales, Ana Ines AU - Gonzales AI AUID- ORCID: 0000-0001-7475-9114 AD - Universidade do Estado de Santa Catarina, Centro de Ciencias da Saude e do Esporte - Florianopolis (SC), Brazil. FAU - Haas, Patricia AU - Haas P AUID- ORCID: 0000-0001-9797-7755 AD - Universidade Federal de Santa Catarina, Faculdade de Fonoaudiologia - Florianopolis (SC), Brazil. LA - eng PT - Journal Article PT - Systematic Review PL - Brazil TA - Rev Assoc Med Bras (1992) JT - Revista da Associacao Medica Brasileira (1992) JID - 9308586 RN - 0 (Antiviral Agents) SB - IM MH - Antiviral Agents MH - *COVID-19 MH - Hospitalization MH - Humans MH - SARS-CoV-2 EDAT- 2021/08/19 06:00 MHDA- 2021/08/21 06:00 CRDT- 2021/08/18 12:24 PHST- 2020/09/20 00:00 [received] PHST- 2020/12/10 00:00 [accepted] PHST- 2021/08/18 12:24 [entrez] PHST- 2021/08/19 06:00 [pubmed] PHST- 2021/08/21 06:00 [medline] AID - S0104-42302021000300302 [pii] AID - 10.1590/1806-9282.67.02.20200594 [doi] PST - ppublish SO - Rev Assoc Med Bras (1992). 2021 Feb;67(2):302-312. doi: 10.1590/1806-9282.67.02.20200594. PMID- 34389291 OWN - NLM STAT- MEDLINE DCOM- 20220203 LR - 20260127 IS - 1097-6868 (Electronic) IS - 0002-9378 (Print) IS - 0002-9378 (Linking) VI - 226 IP - 2 DP - 2022 Feb TI - COVID-19 vaccination during pregnancy: coverage and safety. PG - 236.e1-236.e14 LID - S0002-9378(21)00873-5 [pii] LID - 10.1016/j.ajog.2021.08.007 [doi] AB - BACKGROUND: Concerns have been raised regarding a potential surge of COVID-19 in pregnancy, secondary to the rising numbers of COVID-19 in the community, easing of societal restrictions, and vaccine hesitancy. Although COVID-19 vaccination is now offered to all pregnant women in the United Kingdom; limited data exist on its uptake and safety. OBJECTIVE: This study aimed to investigate the uptake and safety of COVID-19 vaccination among pregnant women. STUDY DESIGN: This was a cohort study of pregnant women who gave birth at St George's University Hospitals National Health Service Foundation Trust, London, United Kingdom, between March 1, 2020, and July 4, 2021. The primary outcome was uptake of COVID-19 vaccination and its determinants. The secondary outcomes were perinatal safety outcomes. Data were collected on COVID-19 vaccination uptake, vaccination type, gestational age at vaccination, and maternal characteristics, including age, parity, ethnicity, index of multiple deprivation score, and comorbidities. Further data were collected on perinatal outcomes, including stillbirth (fetal death at >/=24 weeks' gestation), preterm birth, fetal and congenital abnormalities, and intrapartum complications. Pregnancy and neonatal outcomes of women who received the vaccine were compared with that of a matched cohort of women with balanced propensity scores. Effect magnitudes of vaccination on perinatal outcomes were reported as mean differences or odds ratios with 95% confidence intervals. Factors associated with antenatal vaccination were assessed with logistic regression analysis. RESULTS: Data were available for 1328 pregnant women of whom 140 received at least 1 dose of the COVID-19 vaccine before giving birth and 1188 women who did not; 85.7% of those vaccinated received their vaccine in the third trimester of pregnancy and 14.3% in the second trimester of pregnancy. Of those vaccinated, 127 (90.7%) received a messenger RNA vaccine and 13 (9.3%) a viral vector vaccine. There was evidence of reduced vaccine uptake in younger women (P=.001), women with high levels of deprivation (ie, fifth quintile of the index of multiple deprivation; P=.008), and women of Afro-Caribbean or Asian ethnicity compared with women of White ethnicity (P<.001). Women with prepregnancy diabetes mellitus had increased vaccine uptake (P=.008). In the multivariable model the fifth deprivation quintile (most deprived) (adjusted odds ratio, 0.10; 95% confidence interval, 0.02-0.10; P=.003) and Afro-Caribbean ethnicity (adjusted odds ratio, 0.27; 95% confidence interval, 0.06-0.85; P=.044) were significantly associated with lower antenatal vaccine uptake, whereas prepregnancy diabetes mellitus was significantly associated with higher antenatal vaccine uptake (adjusted odds ratio, 10.5; 95% confidence interval, 1.74-83.2; P=.014). In a propensity score-matched cohort, the rates of adverse pregnancy outcomes of 133 women who received at least 1 dose of the COVID-19 vaccine in pregnancy were similar to that of unvaccinated pregnant women (P>.05 for all): stillbirth (0.0% vs 0.2%), fetal abnormalities (2.2% vs 2.5%), postpartum hemorrhage (9.8% vs 9.0%), cesarean delivery (30.8% vs 34.1%), small for gestational age (12.0% vs 12.8%), maternal high-dependency unit or intensive care admission (6.0% vs 4.0%), or neonatal intensive care unit admission (5.3% vs 5.0%). Intrapartum pyrexia (3.7% vs 1.0%; P=.046) was significantly increased but the borderline statistical significance was lost after excluding women with antenatal COVID-19 infection (P=.079). Mixed-effects Cox regression showed that vaccination was not significantly associated with birth at <40 weeks' gestation (hazard ratio, 0.93; 95% confidence interval, 0.71-1.23; P=.624). CONCLUSION: Of pregnant women eligible for COVID-19 vaccination, less than one-third accepted COVID-19 vaccination during pregnancy, and they experienced similar pregnancy outcomes with unvaccinated pregnant women. There was lower uptake among younger women, non-White ethnicity, and lower socioeconomic background. This study has contributed to the body of evidence that having COVID-19 vaccination in pregnancy does not alter perinatal outcomes. Clear communication to improve awareness among pregnant women and healthcare professionals on vaccine safety is needed, alongside strategies to address vaccine hesitancy. These strategies include postvaccination surveillance to gather further data on pregnancy outcomes, particularly after first-trimester vaccination, and long-term infant follow-up. CI - Copyright (c) 2021 Elsevier Inc. All rights reserved. FAU - Blakeway, Helena AU - Blakeway H AD - Fetal Medicine Unit, St George's Hospital, St George's University of London, London, United Kingdom. FAU - Prasad, Smriti AU - Prasad S AD - Fetal Medicine Unit, St George's Hospital, St George's University of London, London, United Kingdom. FAU - Kalafat, Erkan AU - Kalafat E AD - Department of Obstetrics and Gynecology, School of Medicine, Koc University, Istanbul, Turkey; Faculty of Arts and Sciences, Department of Statistics, Middle East Technical University, Ankara, Turkey. FAU - Heath, Paul T AU - Heath PT AD - Paediatric Infectious Diseases Research Group and Vaccine Institute, Institute of Infection and Immunity, St George's University of London, London, United Kingdom. FAU - Ladhani, Shamez N AU - Ladhani SN AD - National Infection Service, Public Health England, London, United Kingdom; Paediatric Infectious Diseases Research Group, St George's University of London, London, United Kingdom. FAU - Le Doare, Kirsty AU - Le Doare K AD - Paediatric Infectious Diseases Research Group and Vaccine Institute, Institute of Infection and Immunity, St George's University of London, London, United Kingdom. FAU - Magee, Laura A AU - Magee LA AD - Department of Women and Children's Health, School of Life Course Sciences, King's College London, London, United Kingdom. FAU - O'Brien, Pat AU - O'Brien P AD - Institute for Women's Health, University College London Hospital, London, United Kingdom; Royal College of Obstetricians and Gynaecologists, London, United Kingdom; University College London Hospitals National Health Service Foundation Trust, London, United Kingdom. FAU - Rezvani, Arezou AU - Rezvani A AD - Fetal Medicine Unit, St George's Hospital, St George's University of London, London, United Kingdom. FAU - von Dadelszen, Peter AU - von Dadelszen P AD - Department of Women and Children's Health, School of Life Course Sciences, King's College London, London, United Kingdom. FAU - Khalil, Asma AU - Khalil A AD - Fetal Medicine Unit, St George's Hospital, St George's University of London, London, United Kingdom; Vascular Biology Research Centre, Molecular and Clinical Sciences Research Institute, St George's University of London, London, United Kingdom. Electronic address: akhalil@sgul.ac.uk. LA - eng PT - Journal Article DEP - 20210810 PL - United States TA - Am J Obstet Gynecol JT - American journal of obstetrics and gynecology JID - 0370476 RN - EPK39PL4R4 (2019-nCoV Vaccine mRNA-1273) RN - 0 (BNT162 Vaccine) RN - 0 (COVID-19 Vaccines) RN - B5S3K2V0G8 (ChAdOx1 nCoV-19) SB - IM CIN - Am J Obstet Gynecol. 2022 Mar;226(3):448-449. doi: 10.1016/j.ajog.2021.10.027. PMID: 34699750 CIN - Am J Obstet Gynecol. 2022 Aug;227(2):370. doi: 10.1016/j.ajog.2022.04.027. PMID: 35469814 MH - 2019-nCoV Vaccine mRNA-1273/therapeutic use MH - Adult MH - Age Factors MH - Asian People MH - BNT162 Vaccine/therapeutic use MH - Black People MH - COVID-19/*prevention & control MH - COVID-19 Vaccines/*therapeutic use MH - Caribbean Region MH - Case-Control Studies MH - Cesarean Section/statistics & numerical data MH - ChAdOx1 nCoV-19/therapeutic use MH - Congenital Abnormalities/epidemiology MH - Ethnicity MH - Female MH - Fever/epidemiology MH - Humans MH - Infant, Small for Gestational Age MH - Intensive Care Units MH - Intensive Care Units, Neonatal MH - Logistic Models MH - Obstetric Labor Complications/epidemiology MH - Postpartum Hemorrhage/epidemiology MH - Pregnancy MH - Pregnancy Complications, Infectious/*prevention & control MH - Premature Birth/epidemiology MH - Propensity Score MH - Proportional Hazards Models MH - SARS-CoV-2 MH - Social Deprivation MH - Social Determinants of Health MH - Stillbirth/epidemiology MH - United Kingdom/epidemiology MH - Vaccination Coverage/*statistics & numerical data PMC - PMC8352848 OTO - NOTNLM OT - COVID-19 OT - SARS-CoV-2 OT - coverage OT - immunization OT - mRNA OT - pregnancy OT - safety vaccine uptake OT - vaccination OT - viral vector EDAT- 2021/08/15 06:00 MHDA- 2022/02/04 06:00 PMCR- 2021/08/10 CRDT- 2021/08/14 05:42 PHST- 2021/07/21 00:00 [received] PHST- 2021/08/01 00:00 [accepted] PHST- 2021/08/15 06:00 [pubmed] PHST- 2022/02/04 06:00 [medline] PHST- 2021/08/14 05:42 [entrez] PHST- 2021/08/10 00:00 [pmc-release] AID - S0002-9378(21)00873-5 [pii] AID - 10.1016/j.ajog.2021.08.007 [doi] PST - ppublish SO - Am J Obstet Gynecol. 2022 Feb;226(2):236.e1-236.e14. doi: 10.1016/j.ajog.2021.08.007. Epub 2021 Aug 10. PMID- 34385230 OWN - NLM STAT- MEDLINE DCOM- 20210816 LR - 20231107 IS - 2044-6055 (Electronic) IS - 2044-6055 (Linking) VI - 11 IP - 8 DP - 2021 Aug 12 TI - Suicidal behaviour in adults during the COVID-19 pandemic: protocol for systematic review of observational studies. PG - e045313 LID - 10.1136/bmjopen-2020-045313 [doi] LID - e045313 AB - INTRODUCTION: COVID-19 pandemic has an impact on mortality indicators worldwide. Mitigation and repression actions to reduce the morbidity and mortality associated with the disease are necessary. However, they are criticised in the economic, social and psychological spheres. This social isolation, increased unemployment, routine changes, news of health complications and deaths related to COVID-19 can cause psychological repercussions that will certainly intensify in the coming months, and suicidal behaviour presents itself as a fatal outcome. It is necessary to know factors associated with suicidal behaviour in adults during the pandemic. Although there are studies, there is no systematic review to assess these factors, specifically in adults. The objective is to critically synthesise the scientific evidence on the factors associated with suicidal behaviour in adults in the COVID-19 pandemic. METHODS AND ANALYSES: A systematic review will be carried out, recommended by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) protocol, in seven databases: Medical Literature Analysis and Retrieval System Online (MEDLINE), ISI of Knowledge, Excerpta Medica Database (EMBASE), SCOPUS, Latin American and Caribbean Health Sciences Literature (LILACS), Chinese National Knowledge Infrastructure (PsycINFO), Chinese National Knowledge Infrastructure (CNKI) and ScienceDirect. Preliminary search was carried out on 30 July 2020 and will be updated in March 2021. No restrictions on publication date, study location or languages will be considered in this review. The preliminary research strategies were carried out on 30 July 2020 and will be updated in February 2021. To measure the agreement between reviewers at each screening stage, Cohen's Kappa will be calculated. Primary outcome will be factors related to suicidal behaviour in adults during COVID-19 pandemic. Grouped standardised mean differences and 95% CIs will be calculated. The risk of bias in observational studies will be assessed using the Methodological Index for Non-Randomised Studies (MINORS). Statistical heterogeneity will be assessed with the I2 statistic. ETHICS AND DISCLOSURE: Ethical approval is not required, as primary data will not be collected. The findings will be disseminated through peer-reviewed publications. PROSPERO REGISTRATION NUMBER: CRD42020208816. CI - (c) Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. FAU - Silva Junior, Fernando Jose Guedes da AU - Silva Junior FJGD AUID- ORCID: 0000-0001-5731-632X AD - Nursing Department, Universidade Federal do Piaui, Teresina, Piaui, Brazil fernandoguedes@ufpi.edu.br. FAU - Miranda, Priscilla Ingrid Gomes AU - Miranda PIG AUID- ORCID: 0000-0001-8948-7158 AD - Nursing Department, Universidade Federal do Piaui, Teresina, Piaui, Brazil. FAU - Sales, Jaqueline Carvalho E Silva AU - Sales JCES AD - Nursing Department, Universidade Federal do Piaui, Teresina, Piaui, Brazil. FAU - Parente, Adriana da Cunha Menezes AU - Parente ADCM AD - Nursing Department, Universidade Federal do Piaui, Teresina, Piaui, Brazil. FAU - Monteiro, Claudete Ferreira de Souza AU - Monteiro CFS AD - Nursing Department, Universidade Federal do Piaui, Teresina, Piaui, Brazil. FAU - Costa, Ana Paula Cardoso AU - Costa APC AD - Nursing Department, Universidade Federal do Piaui, Teresina, Piaui, Brazil. FAU - Campos, Luana Ruth Braga AU - Campos LRB AD - Nursing Department, Universidade Federal do Piaui, Teresina, Piaui, Brazil. FAU - Lima, Larissa Alves de Araujo AU - Lima LAA AD - Nursing Department, Universidade Federal do Piaui, Teresina, Piaui, Brazil. FAU - Ibiapina, Aline Raquel de Sousa AU - Ibiapina ARS AD - Nursing Department, Universidade Federal do Piaui, Teresina, Piaui, Brazil. FAU - Pillon, Sandra Cristina AU - Pillon SC AD - Nursing Department, USP, Ribeirao Preto, Sao Paulo, Brazil. FAU - Goncalves, Angelica Martins de Souza AU - Goncalves AMS AD - Nursing Department, UFSCar, Sao Carlos, Sao Paulo, Brazil. FAU - Vieira, Chrystiany Placido de Brito AU - Vieira CPB AD - Nursing Department, Universidade Federal do Piaui, Teresina, Piaui, Brazil. FAU - Galiza, Francisca Tereza de AU - Galiza FT AD - Nursing Department, Universidade Federal do Piaui, Teresina, Piaui, Brazil. LA - eng PT - Journal Article DEP - 20210812 PL - England TA - BMJ Open JT - BMJ open JID - 101552874 SB - IM MH - Adult MH - *COVID-19 MH - Humans MH - *Pandemics MH - Research Design MH - SARS-CoV-2 MH - Social Isolation MH - Suicidal Ideation MH - Systematic Reviews as Topic PMC - PMC8361698 OTO - NOTNLM OT - COVID-19 OT - adult psychiatry OT - suicide & self-harm COIS- Competing interests: None declared. EDAT- 2021/08/14 06:00 MHDA- 2021/08/17 06:00 PMCR- 2021/08/12 CRDT- 2021/08/13 06:13 PHST- 2021/08/13 06:13 [entrez] PHST- 2021/08/14 06:00 [pubmed] PHST- 2021/08/17 06:00 [medline] PHST- 2021/08/12 00:00 [pmc-release] AID - bmjopen-2020-045313 [pii] AID - 10.1136/bmjopen-2020-045313 [doi] PST - epublish SO - BMJ Open. 2021 Aug 12;11(8):e045313. doi: 10.1136/bmjopen-2020-045313. PMID- 34380961 OWN - NLM STAT- MEDLINE DCOM- 20211125 LR - 20211125 IS - 1538-9804 (Electronic) IS - 0162-220X (Linking) VI - 44 IP - 6 DP - 2021 Nov-Dec 01 TI - The Effect of Acupressure on Relieving Cancer-Related Fatigue: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. PG - E578-E588 LID - 10.1097/NCC.0000000000000997 [doi] AB - BACKGROUND: Fatigue, a common complaint reported by patients with cancer or in survivorship, has been negatively associated with quality of life, emotional health, and cognitive functions. Acupressure, a traditional Chinese medicine, has been increasingly practiced in clinical and community settings. However, little evidence supports the beneficial effects of acupressure on the reduction of general, physical, and mental fatigue in cancer survivors. OBJECTIVE: The aim of this study was to examine the effect of acupressure on fatigue in cancer survivors and the moderators of the effect of acupressure on cancer-related fatigue relief. METHODS: Databases, namely, PubMed, Embase, CINAHL, and ProQuest, were searched from their inception to July 17, 2020. No language and publication period restrictions were applied. Only randomized controlled trials that examined the effects of acupressure on cancer-related fatigue were included. A random-effects model was used for data analyses. RESULTS: Fourteen articles involving 776 participants with cancers were included. Acupressure considerably alleviated cancer-related general, physical, and mental fatigue (g = -0.87, -0.87, and -0.37) compared with controls. Increasing female percentage of participants significantly reduced the effects of acupressure on fatigue (B = -0.01, P < .001). The executor and operation approach as well as treatment period during chemotherapy did not moderate the effects of acupressure on fatigue relief. CONCLUSION: Acupressure is effective at alleviating cancer-related fatigue. IMPLICATIONS FOR PRACTICE: Health professionals and patients can use acupressure to alleviate fatigue during and after chemotherapy. Nursing personnel could incorporate acupressure into clinical practice as part of a multimodal approach to alleviating fatigue in cancer survivors. CI - Copyright (c) 2021 Wolters Kluwer Health, Inc. All rights reserved. FAU - Hsieh, Shu-Hua AU - Hsieh SH AD - Author Affiliations: Department of Nursing, Far Eastern Memorial Hospital (Mrs Hsieh and Ms Wu), New Taipei; School of Nursing, College of Nursing, Taipei Medical University (Mrs Hsieh, Ms Wu, Mr Romadlon, Mr Hasan, and Dr Chiu), Taiwan; Neurosurgical Department, Chang Gung Memorial Hospital (Dr Chen), Keelung; School of Medicine, Chang-Gung University (Dr Chen), Taoyuan; and Research Center of Sleep Medicine, College of Medicine, Taipei Medical University (Dr Chiu), Taiwan. FAU - Wu, Chia-Rung AU - Wu CR FAU - Romadlon, Debby Syahru AU - Romadlon DS FAU - Hasan, Faizul AU - Hasan F FAU - Chen, Pin-Yuan AU - Chen PY FAU - Chiu, Hsiao-Yean AU - Chiu HY LA - eng PT - Journal Article PT - Meta-Analysis PT - Systematic Review PL - United States TA - Cancer Nurs JT - Cancer nursing JID - 7805358 SB - IM MH - *Acupressure MH - Fatigue/etiology/therapy MH - Female MH - Humans MH - *Neoplasms/complications/therapy MH - Quality of Life MH - Randomized Controlled Trials as Topic COIS- The authors have no conflicts of interest to disclose. EDAT- 2021/08/13 06:00 MHDA- 2021/11/26 06:00 CRDT- 2021/08/12 05:45 PHST- 2021/08/13 06:00 [pubmed] PHST- 2021/11/26 06:00 [medline] PHST- 2021/08/12 05:45 [entrez] AID - 00002820-900000000-98814 [pii] AID - 10.1097/NCC.0000000000000997 [doi] PST - ppublish SO - Cancer Nurs. 2021 Nov-Dec 01;44(6):E578-E588. doi: 10.1097/NCC.0000000000000997. PMID- 34364236 OWN - NLM STAT- MEDLINE DCOM- 20211227 LR - 20211227 IS - 1532-1983 (Electronic) IS - 0261-5614 (Linking) VI - 40 IP - 8 DP - 2021 Aug TI - Validity of the energy-restricted Mediterranean Diet Adherence Screener. PG - 4971-4979 LID - S0261-5614(21)00326-5 [pii] LID - 10.1016/j.clnu.2021.06.030 [doi] AB - BACKGROUND: Short dietary assessment tools can be useful to estimate food intake and diet quality in large-scale epidemiological studies with time constraints. OBJECTIVE: To determine the concurrent validity of the 17-item energy-restricted Mediterranean Adherence Screener (er-MEDAS) used in the PREDIMED (PREvencion con DIeta MEDiterranea)-Plus trial and to analyse its capacity to detect 1-year changes in diet and cardiometabolic risk factors. METHODS: Validation study nested in the PREDIMED-Plus (n = 6760, 55-75 years). Dietary data were collected by the 17-item er-MEDAS and a 143-item validated semiquantitative food frequency questionnaire (FFQ) at baseline and after 1-year intervention. Cardiometabolic risk markers were measured at both time points. A Mediterranean diet (MedDiet) score was derived from both instruments. Concurrent validity was evaluated by Pearson and intra-class correlation coefficients (ICC) and Bland and Altman limits of agreement. Construct validity was evaluated by assessing 1-year changes in FFQ-reported dietary intake and cardiometabolic profile changes in relation to changes in er-MEDAS. RESULTS: A moderate to good correlation between the MedDiet score calculated by both measurement instruments was found: r = 0.61 and ICC = 0.60 (both p < 0.001). Agreement of each of the er-MEDAS items ranged from 55.4% to 85.0% with a moderate mean concordance (kappa = 0.41). Between baseline and 1-year follow-up, energy intake measured by the FFQ decreased by 242 kcal, while Mediterranean food consumption increased in participants with the highest increase in the er-MEDAS MedDiet score. An increase in the er-MEDAS MedDiet score ratings was associated with a decrease in BMI, waist circumference, triglycerides, fasting glucose, diastolic blood pressure, and triglycerides/HDL-cholesterol ratio (p < 0.001 for all), and with an increase in HDL-cholesterol (p = 0.006). CONCLUSION: The er-MEDAS shows a modest to good concurrent validity compared with FFQ data. It shows acceptable construct validity, as a greater er-MEDAS score was associated with more favourable dietary and cardiometabolic profiles over time. TRIAL REGISTRY: ISRCTN89898870; registration date, 24 July 2014. https://www.isrctn.com/ISRCTN89898870. CI - Copyright (c) 2021 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved. FAU - Schroder, Helmut AU - Schroder H AD - Cardiovascular Risk and Nutrition Research Group, Hospital Del Mar Medical Research Institute (IMIM), Barcelona, Spain; CIBER Epidemiologia y Salud Publica (CIBERESP), Instituto de Salud Carlos III (ISCIII), Madrid, Spain. Electronic address: hschroeder@imim.es. FAU - Zomeno, Maria Dolors AU - Zomeno MD AD - Cardiovascular Risk and Nutrition Research Group, Hospital Del Mar Medical Research Institute (IMIM), Barcelona, Spain; Programa de Doctorado en Alimentacion y Nutricion, Facultad de Farmacia, Universidad de Barcelona, Barcelona, Spain. FAU - Martinez-Gonzalez, Miguel Angel AU - Martinez-Gonzalez MA AD - CIBER Fisiopatologia de La Obesidad y Nutricion (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain; University of Navarra, Department of Preventive Medicine and Public Health, IDISNA, Pamplona, Spain; Department of Nutrition, Harvard T. H. Chan School of Public Health, Boston, USA. FAU - Salas-Salvado, Jordi AU - Salas-Salvado J AD - CIBER Fisiopatologia de La Obesidad y Nutricion (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain; Universitat Rovira i Virgili, Departament de Bioquimica i Biotecnologia, Unitat de Nutricio Humana, IISPV, Hospital Universitari de Sant Joan de Reus, 43201, Reus, Spain. FAU - Corella, Dolores AU - Corella D AD - CIBER Fisiopatologia de La Obesidad y Nutricion (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain; Department of Preventive Medicine, University of Valencia, Valencia, Spain. FAU - Vioque, Jesus AU - Vioque J AD - CIBER Epidemiologia y Salud Publica (CIBERESP), Instituto de Salud Carlos III (ISCIII), Madrid, Spain; Miguel Hernandez University, Instituto de Investigacion Sanitaria y Biomedica de Alicante, ISABIAL-UMH, Alicante, Spain. FAU - Romaguera, Dora AU - Romaguera D AD - CIBER Fisiopatologia de La Obesidad y Nutricion (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain; Health Research Institute of the Balearic Islands (IdISBa), Palma de Mallorca, Spain. FAU - Martinez, J Alfredo AU - Martinez JA AD - CIBER Fisiopatologia de La Obesidad y Nutricion (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain; Cardiometabolic Nutrition Program, IMDEA Food, CEI UAM + CSIC, Madrid, Spain; Department of Nutrition, Food Sciences, and Physiology, Center for Nutrition Research, University of Navarra, Pamplona, Spain. FAU - Tinahones, Francisco J AU - Tinahones FJ AD - CIBER Fisiopatologia de La Obesidad y Nutricion (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain; Virgen de La Victoria Hospital, Department of Endocrinology, University of Malaga, Malaga, Spain. FAU - Miranda, Jose Lopez AU - Miranda JL AD - CIBER Fisiopatologia de La Obesidad y Nutricion (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain; Lipids and Atherosclerosis Unit, Department of Internal Medicine, Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, Cordoba, Spain. FAU - Estruch, Ramon AU - Estruch R AD - CIBER Fisiopatologia de La Obesidad y Nutricion (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain; Department of Internal Medicine, IDIBAPS, Hospital Clinic, University of Barcelona, Barcelona, Spain. FAU - Bueno-Cavanillas, Aurora AU - Bueno-Cavanillas A AD - CIBER Epidemiologia y Salud Publica (CIBERESP), Instituto de Salud Carlos III (ISCIII), Madrid, Spain; Department of Preventive Medicine and Public Health, University of Granada, Granada. FAU - Alonso Gomez, Angel M AU - Alonso Gomez AM AD - CIBER Fisiopatologia de La Obesidad y Nutricion (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain; Bioaraba Health Research Institute, Osakidetza Basque Health Service, Araba University Hospital, University of the Basque Country UPV/EHU, Vitoria-Gasteiz, Spain. FAU - Tur, Josep A AU - Tur JA AD - CIBER Fisiopatologia de La Obesidad y Nutricion (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain; Health Research Institute of the Balearic Islands (IdISBa), Palma de Mallorca, Spain; Research Group on Community Nutrition & Oxidative Stress, University of Balearic Islands, Palma de Mallorca, Spain. FAU - Warnberg, Julia AU - Warnberg J AD - CIBER Fisiopatologia de La Obesidad y Nutricion (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain; Department of Nursing, School of Health Sciences, University of Malaga-IBIMA, Malaga, Spain. FAU - Serra-Majem, Lluis AU - Serra-Majem L AD - CIBER Fisiopatologia de La Obesidad y Nutricion (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain; Institute for Biomedical Research, University of Las Palmas de Gran Canarias, 35016, Las Palmas, Spain. FAU - Martin, Vicente AU - Martin V AD - CIBER Epidemiologia y Salud Publica (CIBERESP), Instituto de Salud Carlos III (ISCIII), Madrid, Spain; Instituto de Biomedicina (IBIOMED), Universidad de Leon, Leon, Spain. FAU - Vazquez, Clotilde AU - Vazquez C AD - CIBER Fisiopatologia de La Obesidad y Nutricion (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain; Department of Endocrinology and Nutrition, Hospital Fundacion Jimenez Diaz, Instituto de Investigaciones Biomedicas IISFJD. University Autonoma, Madrid, Spain. FAU - Lapetra, Jose AU - Lapetra J AD - CIBER Fisiopatologia de La Obesidad y Nutricion (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain; Department of Family Medicine, Research Unit, Distrito Sanitario Atencion Primaria Sevilla, Sevilla, Spain. FAU - Pinto, Xavier AU - Pinto X AD - CIBER Fisiopatologia de La Obesidad y Nutricion (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain; Lipids and Vascular Risk Unit, Internal Medicine, Hospital Universitario de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain. FAU - Vidal, Josep AU - Vidal J AD - CIBER Diabetes y Enfermedades Metabolicas (CIBERDEM), Instituto de Salud Carlos III (ISCIII), Madrid, Spain; Department of Endocrinology, Institut D'Investigacions Biomediques August Pi Sunyer (IDIBAPS), Hospital Clinic, University of Barcelona, Barcelona, Spain. FAU - Daimiel, Lidia AU - Daimiel L AD - Nutritional Control of the Epigenome Group, Precision Nutrition and Obesity Program, IMDEA Food, CEI UAM + CSIC, Madrid, Spain. FAU - Gaforio, Jose Juan AU - Gaforio JJ AD - CIBER Epidemiologia y Salud Publica (CIBERESP), Instituto de Salud Carlos III (ISCIII), Madrid, Spain; Department of Health Sciences, Center for Advanced Studies in Olive Grove and Olive Oils, University of Jaen, Jaen, Spain. FAU - Matia-Martin, Pilar AU - Matia-Martin P AD - Department of Endocrinology and Nutrition, Instituto de Investigacion Sanitaria Hospital Clinico San Carlos (IdISSC), Madrid, Spain. FAU - Ros, Emilio AU - Ros E AD - CIBER Fisiopatologia de La Obesidad y Nutricion (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain; Lipid Clinic, Department of Endocrinology and Nutrition, Institut D'Investigacions Biomediques August Pi Sunyer (IDIBAPS), Hospital Clinic, Barcelona, Spain. FAU - Lassale, Camille AU - Lassale C AD - Cardiovascular Risk and Nutrition Research Group, Hospital Del Mar Medical Research Institute (IMIM), Barcelona, Spain. FAU - Ruiz-Canela, Miguel AU - Ruiz-Canela M AD - CIBER Fisiopatologia de La Obesidad y Nutricion (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain; University of Navarra, Department of Preventive Medicine and Public Health, IDISNA, Pamplona, Spain. FAU - Babio, Nancy AU - Babio N AD - CIBER Fisiopatologia de La Obesidad y Nutricion (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain; Universitat Rovira i Virgili, Departament de Bioquimica i Biotecnologia, Unitat de Nutricio Humana, IISPV, Hospital Universitari de Sant Joan de Reus, 43201, Reus, Spain. FAU - Sorli, Jose V AU - Sorli JV AD - CIBER Fisiopatologia de La Obesidad y Nutricion (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain; Department of Preventive Medicine, University of Valencia, Valencia, Spain. FAU - Garcia-Arellano, Ana AU - Garcia-Arellano A AD - CIBER Fisiopatologia de La Obesidad y Nutricion (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain; University of Navarra, Department of Preventive Medicine and Public Health, IDISNA, Pamplona, Spain; Emergency Department, Complejo Hospitalario de Navarra, Servicio Navarro de Salud-Osaunbidea, Spain. FAU - Diaz-Lopez, Andres AU - Diaz-Lopez A AD - CIBER Fisiopatologia de La Obesidad y Nutricion (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain; Serra Hunter Fellow, Universitat Rovira I Virgili, Departament de Ciencies Mediques Basiques, Nutrition and Mental Health Research Group (NUTRISAM), Reus, Spain; Institut D'Investigacio Sanitaria Pere Virgili (IISPV), Reus, Spain. FAU - Fito, Montserrat AU - Fito M AD - Cardiovascular Risk and Nutrition Research Group, Hospital Del Mar Medical Research Institute (IMIM), Barcelona, Spain; CIBER Fisiopatologia de La Obesidad y Nutricion (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain. FAU - Castaner, Olga AU - Castaner O AD - Cardiovascular Risk and Nutrition Research Group, Hospital Del Mar Medical Research Institute (IMIM), Barcelona, Spain; CIBER Fisiopatologia de La Obesidad y Nutricion (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain. CN - PREDIMED-Plus investigators LA - eng SI - ISRCTN/ISRCTN89898870 PT - Journal Article PT - Multicenter Study PT - Research Support, Non-U.S. Gov't PT - Validation Study DEP - 20210706 PL - England TA - Clin Nutr JT - Clinical nutrition (Edinburgh, Scotland) JID - 8309603 RN - 0 (Biomarkers) RN - 0 (Blood Glucose) RN - 0 (Triglycerides) SB - IM MH - Aged MH - Biomarkers/analysis MH - Blood Glucose/analysis MH - Blood Pressure MH - Body Mass Index MH - *Caloric Restriction MH - Diet Surveys/*standards MH - Diet, Healthy/*statistics & numerical data MH - *Diet, Mediterranean MH - Female MH - Guideline Adherence/statistics & numerical data MH - Humans MH - Male MH - Mass Screening MH - Middle Aged MH - Nutrition Policy MH - Randomized Controlled Trials as Topic MH - Reproducibility of Results MH - Surveys and Questionnaires/*standards MH - Triglycerides/blood MH - Waist Circumference OTO - NOTNLM OT - Diet OT - Energy restriction OT - Mediterranean diet OT - Short screener OT - Validation OT - Validity COIS- Conflict of Interest Dr Salas-Salvado reports serving on the board of and receiving grant support (through his institution) from the International Nut and Dried Fruit Council and the Eroski Foundation, and serving on the Executive Committee of the Instituto Danone Spain and on the Scientific Committee of the Danone International Institute. He has received research support from Patrimonio Comunal Olivarero and Borges S.A., Spain. He reports receiving consulting fees or travel expenses from Danone; Eroski Foundation, Instituto Danone-Spain, and Abbot Laboratories. Dr Ros reports grants, non-financial support, and other fees from California Walnut Commission and Alexion, and non-financial support from the International Nut and Dried Fruit Council, all outside of the submitted work. Dr Pinto reports serving on the board of and receiving personal consulting fees from Sanofi Aventis, Amgen, and Abbott Laboratories, as well as personal lecture fees from Esteve, Lacer, and Rubio laboratories. Victor Mico reports grants from Fundacion Cerveza y Salud. Dr Corella reported receiving grants from ISCIII during the conduct of the study. Dr Romaguera reported receiving grants from ISCIII during the conduct of the study and grants from Fundacion AstraZeneca outside the submitted work. Dr Estruch reported receiving grants from ISCIII and olive oil for the trial from Fundacion Patrimonio Comunal Olivarero during the conduct of the study and personal fees from Brewers of Europe, Fundacion Cerveza y Salud, Interprofesional del Aceite de Oliva, Instituto Cervantes, Pernaud Richar, Fundacion Dieta Mediterranea, and Wine and Culinary International Forum; also nonfinancial support from Sociedad Espanola de Nutricion and Fundacion Bosch y Gimpera and grants from Uriach Laboratories outside the submitted work. Dr Lopez-Miranda reported receiving grants from Fondo de Investigaciones Sanitarias, ISCIII, during the conduct of the study. Dr Matia-Martin reported receiving grants from ISCIII during the conduct of the study and personal fees from Organizacion Interprofesional Lactea outside the submitted work. Dr Vidal reported receiving grants from ISCIII during the conduct of the study. EDAT- 2021/08/08 06:00 MHDA- 2021/12/28 06:00 CRDT- 2021/08/07 20:28 PHST- 2021/03/12 00:00 [received] PHST- 2021/06/11 00:00 [revised] PHST- 2021/06/27 00:00 [accepted] PHST- 2021/08/08 06:00 [pubmed] PHST- 2021/12/28 06:00 [medline] PHST- 2021/08/07 20:28 [entrez] AID - S0261-5614(21)00326-5 [pii] AID - 10.1016/j.clnu.2021.06.030 [doi] PST - ppublish SO - Clin Nutr. 2021 Aug;40(8):4971-4979. doi: 10.1016/j.clnu.2021.06.030. Epub 2021 Jul 6. PMID- 34364199 OWN - NLM STAT- MEDLINE DCOM- 20211217 LR - 20211217 IS - 1873-4758 (Electronic) IS - 0955-3959 (Linking) VI - 98 DP - 2021 Dec TI - 'We're in this together': A content analysis of marketing by alcohol brands on Facebook and Instagram during the first UK Lockdown, 2020. PG - 103376 LID - S0955-3959(21)00281-4 [pii] LID - 10.1016/j.drugpo.2021.103376 [doi] AB - BACKGROUND: The closure of on-licence premises and the restrictions placed on citizen's movements and leisure to address the COVID-19 pandemic in 2020, created an unprecedented situation for the alcohol industry. With the availability and supply of alcohol being restricted, and the social context of alcohol use transformed, alcohol corporations were required to adapt their marketing materials and actions in response. METHODS: A content analysis of alcohol marketing by 18 alcohol brands on Facebook and Instagram during the first UK national lockdown (from 17th March- 4th July 2020) was conducted. Comments left by social media followers on posts advertising what could be defined as brand COVID-19 Corporate Social Responsibility (CSR) initiatives (i.e. monetary donations, production of hand sanitiser) were thematically analysed. FINDINGS: Alcohol brands quickly adapted to the changing social, economic and health context of the global pandemic. Changes to the availability and sale of alcohol were evident, with brands encouraging the stockpiling of alcohol as an essential item through predominantly online sales and delivery services. Brands also adapted to the changing social and physical context of alcohol use and intensified encouragement of home drinking. Messages of togetherness underpinned the promotion of virtual interactions, for which alcohol use was presented as a key component. Consumers were encouraged to contribute to pandemic responses by 'staying at home', and consuming alcohol. Importantly, COVID-19 provided a useful marketing opportunity for alcohol producers to present themselves as private partners to a primarily public sector response, through innovative CSR initiatives such as philanthropic donations to help prevent the transmission of COVID-19. An inductive thematic analysis of online comments on CSR posts found that such activities were interpreted by consumers as ethical actions, and that they reinforced positive brand image and loyalty amongst existing and new consumers. CONCLUSION: Alcohol corporations are highly resilient in times of crises and the brands analysed were able to quickly adapt their marketing to the COVID-19 pandemic. Future research is required to examine whether these profitable strategies are maintained post pandemic. CI - Copyright (c) 2021 Elsevier B.V. All rights reserved. FAU - Atkinson, Amanda Marie AU - Atkinson AM AD - Public Health Institute, Liverpool John Moores University Liverpool, United Kingdom. Electronic address: a.m.atkinson@ljmu.ac.uk. FAU - Sumnall, Harry AU - Sumnall H AD - Public Health Institute, Liverpool John Moores University Liverpool, United Kingdom. FAU - Meadows, Beth AU - Meadows B AD - Public Health Institute, Liverpool John Moores University Liverpool, United Kingdom. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20210804 PL - Netherlands TA - Int J Drug Policy JT - The International journal on drug policy JID - 9014759 SB - IM MH - *COVID-19 MH - Communicable Disease Control MH - Humans MH - Marketing MH - Pandemics MH - SARS-CoV-2 MH - *Social Media MH - United Kingdom OTO - NOTNLM OT - Alcohol marketing OT - Corporate social responsibility OT - Covid-19 OT - Public Health OT - Social media EDAT- 2021/08/08 06:00 MHDA- 2021/12/18 06:00 CRDT- 2021/08/07 20:27 PHST- 2021/03/09 00:00 [received] PHST- 2021/06/22 00:00 [revised] PHST- 2021/07/01 00:00 [accepted] PHST- 2021/08/08 06:00 [pubmed] PHST- 2021/12/18 06:00 [medline] PHST- 2021/08/07 20:27 [entrez] AID - S0955-3959(21)00281-4 [pii] AID - 10.1016/j.drugpo.2021.103376 [doi] PST - ppublish SO - Int J Drug Policy. 2021 Dec;98:103376. doi: 10.1016/j.drugpo.2021.103376. Epub 2021 Aug 4. PMID- 34327541 OWN - NLM STAT- MEDLINE DCOM- 20210907 LR - 20260518 IS - 1437-1588 (Electronic) IS - 1436-9990 (Print) IS - 1436-9990 (Linking) VI - 64 IP - 9 DP - 2021 Sep TI - [Loneliness during the first wave of the SARS-CoV-2 pandemic-results of the German National Cohort (NAKO)]. PG - 1157-1164 LID - 10.1007/s00103-021-03393-y [doi] AB - BACKGROUND: Early during the pandemic and the following protective countermeasures, an interest in the consequences of the enacted restriction of social contacts for the mental health of the population arose. Loneliness describes the perceived quality of one's own contacts and relationships with other individuals. Several prior studies reported associations of loneliness with different somatic and psychiatric disorders. AIM: To analyse the frequency of loneliness and its association with depression and anxiety symptoms in the first wave of the pandemic in Germany in May 2020. METHODS: The German National Cohort (NAKO) had recruited and examined 205,000 individuals aged 20 to 69 years in 18 study centres across Germany between 2014 and 2019. The follow-up examination was temporarily stopped due to the pandemic between March and July 2020. In this period a COVID-related questionnaire was developed and sent to all participants. We analysed the first 113,928 questionnaires that were sent back within four weeks in May 2020. Loneliness was assessed with the three-item UCLA Loneliness Scale and anxiety and depression symptoms were collected using the PHQ‑9 and GAD‑7 scales from the Patient Health Questionnaire. RESULTS: Among the NAKO participants, 31.7% reported to be lonely in May 2020. Women and young adults reported more loneliness than men and older adults. With increasing scores of loneliness, the severity of depression and anxiety symptoms also steadily increased. Individuals who were lonely during the pandemic had already reported higher PHQ‑9 and GAD‑7 scores during the baseline examination on average 2.5 years earlier, compared to those who did not feel lonely. CONCLUSIONS: Among participants of the German National Cohort, we observed an increase in loneliness during the first wave of the SARS-CoV‑2 pandemic in spring 2020 and a strong relationship of increasing loneliness with decreasing mental health. CI - (c) 2021. The Author(s). FAU - Berger, Klaus AU - Berger K AD - Institut fur Epidemiologie und Sozialmedizin, Universitat Munster, Domagkstr. 3, 48149, Munster, Deutschland. bergerk@uni-muenster.de. FAU - Riedel-Heller, Steffi AU - Riedel-Heller S AD - Institut fur Sozialmedizin, Arbeitsmedizin und Public Health (ISAP), Medizinische Fakultat, Universitat Leipzig, Leipzig, Deutschland. FAU - Pabst, Alexander AU - Pabst A AD - Institut fur Sozialmedizin, Arbeitsmedizin und Public Health (ISAP), Medizinische Fakultat, Universitat Leipzig, Leipzig, Deutschland. FAU - Rietschel, Marcella AU - Rietschel M AD - Abteilung Genetische Epidemiologie in der Psychiatrie, Zentralinstitut fur seelische Gesundheit, Mannheim, Deutschland. FAU - Richter, Dirk AU - Richter D AD - Zentrum Psychiatrische Rehabilitation, Universitare Psychiatrische Dienste Bern, Bern, Schweiz. AD - Universitatsklinik fur Psychiatrie und Psychotherapie, Universitat Bern, Bern, Schweiz. AD - Departement Gesundheit, Berner Fachhochschule, Bern, Schweiz. CN - NAKO-Konsortium LA - ger PT - Journal Article TT - Einsamkeit wahrend der ersten Welle der SARS-CoV-2-Pandemie - Ergebnisse der NAKO-Gesundheitsstudie. DEP - 20210729 PL - Germany TA - Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz JT - Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz JID - 101181368 SB - IM MH - Aged MH - Anxiety Disorders/epidemiology MH - *COVID-19/psychology MH - Depression/epidemiology MH - Female MH - Germany/epidemiology MH - Humans MH - *Loneliness MH - Male MH - *Pandemics MH - Young Adult PMC - PMC8320420 OTO - NOTNLM OT - Anxiety OT - Cohort study OT - Depression OT - Loneliness OT - Mental health FIR - Lieb, Wolfgang IR - Lieb W FIR - Hermes, Anne IR - Hermes A FIR - Becher, Heiko IR - Becher H FIR - Obi, Nadia IR - Obi N FIR - Gunther, Kathrin IR - Gunther K FIR - Ahrens, Wolfgang IR - Ahrens W FIR - Castell, Stefanie IR - Castell S FIR - Kemmling, Yvonne IR - Kemmling Y FIR - Karch, Andre IR - Karch A FIR - Legath, Nicole IR - Legath N FIR - Schmidt, Borge IR - Schmidt B FIR - Emmel, Carina IR - Emmel C FIR - Kuss, Oliver IR - Kuss O FIR - Schikowski, Tamara IR - Schikowski T FIR - Koch-Gallenkamp, Lena IR - Koch-Gallenkamp L FIR - Holleczek, Bernd IR - Holleczek B FIR - Damms-Machado, Antje IR - Damms-Machado A FIR - Halina Greiser, Karin IR - Halina Greiser K FIR - Michels, Karin B IR - Michels KB FIR - Franzke, Claus-Werner IR - Franzke CW FIR - Peters, Annette IR - Peters A FIR - Thierry, Sigrid IR - Thierry S FIR - Fischer, Beate IR - Fischer B FIR - Leitzmann, Michael IR - Leitzmann M FIR - Loffler, Markus IR - Loffler M FIR - Wirkner, Kerstin IR - Wirkner K FIR - Mikolajczyk, Rafael IR - Mikolajczyk R FIR - Rujescu, Dan IR - Rujescu D FIR - Gastell, Sylvia IR - Gastell S FIR - Schulze, Matthias B IR - Schulze MB FIR - Krist, Lilian IR - Krist L FIR - Fricke, Julia IR - Fricke J FIR - Jaeschke, Lina IR - Jaeschke L FIR - Pischon, Tobias IR - Pischon T FIR - Meinke-Franze, Claudia IR - Meinke-Franze C FIR - Volzke, Henry IR - Volzke H EDAT- 2021/07/31 06:00 MHDA- 2021/09/08 06:00 PMCR- 2021/07/29 CRDT- 2021/07/30 06:54 PHST- 2021/03/09 00:00 [received] PHST- 2021/07/05 00:00 [accepted] PHST- 2021/07/31 06:00 [pubmed] PHST- 2021/09/08 06:00 [medline] PHST- 2021/07/30 06:54 [entrez] PHST- 2021/07/29 00:00 [pmc-release] AID - 10.1007/s00103-021-03393-y [pii] AID - 3393 [pii] AID - 10.1007/s00103-021-03393-y [doi] PST - ppublish SO - Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2021 Sep;64(9):1157-1164. doi: 10.1007/s00103-021-03393-y. Epub 2021 Jul 29. PMID- 34315251 OWN - NLM STAT- MEDLINE DCOM- 20220107 LR - 20260127 IS - 1524-4628 (Electronic) IS - 0039-2499 (Linking) VI - 52 IP - 11 DP - 2021 Nov TI - Greater Adherence to Secondary Prevention Medications Improves Survival After Stroke or Transient Ischemic Attack: A Linked Registry Study. PG - 3569-3577 LID - 10.1161/STROKEAHA.120.033133 [doi] AB - BACKGROUND AND PURPOSE: Although a target of 80% medication adherence is commonly cited, it is unclear whether greater adherence improves survival after stroke or transient ischemic attack (TIA). We investigated associations between medication adherence during the first year postdischarge, and mortality up to 3 years, to provide evidence-based targets for medication adherence. METHODS: Retrospective cohort study of 1-year survivors of first-ever stroke or TIA, aged >/=18 years, from the Australian Stroke Clinical Registry (July 2010-June 2014) linked with nationwide prescription refill and mortality data (until August 2017). Adherence to antihypertensive agents, statins, and nonaspirin antithrombotic medications was based on the proportion of days covered from discharge until 1 year. Cox regression with restricted cubic splines was used to investigate nonlinear relationships between medication adherence and all-cause mortality (to 3 years postdischarge). Models were adjusted for age, sex, socioeconomic position, stroke factors, primary care factors, and concomitant medication use. RESULTS: Among 8363 one-year survivors of first-ever stroke or TIA (44% aged >/=75 years, 44% female, 18% TIA), 75% were supplied antihypertensive agents. In patients without intracerebral hemorrhage (N=7446), 84% were supplied statins, and 65% were supplied nonaspirin antithrombotic medications. Median adherence was approximately 90% for each medication group. Between 1% and 100% adherence, greater adherence to statins or antihypertensive agents, but not nonaspirin antithrombotic agents, was associated with improved survival. When restricted to linear regions above 60% adherence, each 10% increase in adherence was associated with a reduction in all-cause mortality of 13% for antihypertensive agents (hazard ratio, 0.87 [95% CI, 0.81-0.95]), 13% for statins (hazard ratio, 0.87 [95% CI, 0.80-0.95]), and 15% for nonaspirin antithrombotic agents (hazard ratio, 0.85 [95% CI, 0.79-0.93]). CONCLUSIONS: Greater levels of medication adherence after stroke or TIA are associated with improved survival, even among patients with near-perfect adherence. Interventions to improve medication adherence are needed to maximize survival poststroke. FAU - Dalli, Lachlan L AU - Dalli LL AUID- ORCID: 0000-0003-1449-9132 AD - Stroke and Ageing Research, Department of Medicine, School of Clinical Sciences at Monash Health (L.L.D., J.K., D.A.C., A.G.T., R.G., M.F.K.), Central Clinical School, Monash University, VIC, Australia. FAU - Kim, Joosup AU - Kim J AUID- ORCID: 0000-0002-4079-0428 AD - Stroke and Ageing Research, Department of Medicine, School of Clinical Sciences at Monash Health (L.L.D., J.K., D.A.C., A.G.T., R.G., M.F.K.), Central Clinical School, Monash University, VIC, Australia. AD - The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Heidelberg, VIC, Australia (J.K., D.A.C., M.F.K.). FAU - Cadilhac, Dominique A AU - Cadilhac DA AUID- ORCID: 0000-0001-8162-682X AD - Stroke and Ageing Research, Department of Medicine, School of Clinical Sciences at Monash Health (L.L.D., J.K., D.A.C., A.G.T., R.G., M.F.K.), Central Clinical School, Monash University, VIC, Australia. AD - The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Heidelberg, VIC, Australia (J.K., D.A.C., M.F.K.). FAU - Greenland, Melanie AU - Greenland M AUID- ORCID: 0000-0001-9363-8844 AD - Oxford Vaccine Group, Department of Paediatrics, Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, United Kingdom (M.G.). AD - Nuffield Department of Population Health, Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, University of Oxford, United Kingdom (M.G.). FAU - Sanfilippo, Frank M AU - Sanfilippo FM AUID- ORCID: 0000-0003-3639-0787 AD - School of Population and Global Health, The University of Western Australia, Perth (F.M.S.). FAU - Andrew, Nadine E AU - Andrew NE AUID- ORCID: 0000-0002-4846-2840 AD - Peninsula Clinical School (N.E.A.), Central Clinical School, Monash University, VIC, Australia. FAU - Thrift, Amanda G AU - Thrift AG AUID- ORCID: 0000-0001-8533-4170 AD - Stroke and Ageing Research, Department of Medicine, School of Clinical Sciences at Monash Health (L.L.D., J.K., D.A.C., A.G.T., R.G., M.F.K.), Central Clinical School, Monash University, VIC, Australia. FAU - Grimley, Rohan AU - Grimley R AUID- ORCID: 0000-0002-7006-6908 AD - Stroke and Ageing Research, Department of Medicine, School of Clinical Sciences at Monash Health (L.L.D., J.K., D.A.C., A.G.T., R.G., M.F.K.), Central Clinical School, Monash University, VIC, Australia. AD - Sunshine Coast Clinical School, School of Medicine, Griffith University, Birtinya, QLD, Australia (R.G.). FAU - Lindley, Richard I AU - Lindley RI AUID- ORCID: 0000-0002-0104-5679 AD - Faculty of Medicine and Health, The University of Sydney, NSW, Australia (R.I.L.). FAU - Sundararajan, Vijaya AU - Sundararajan V AUID- ORCID: 0000-0001-9387-1865 AD - Department of Public Health, La Trobe University, Bundoora, VIC, Australia (V.S.). FAU - Crompton, Douglas E AU - Crompton DE AUID- ORCID: 0000-0002-0776-1203 AD - Department of Neurology, Northern Health, Epping, VIC, Australia (D.E.C.). FAU - Lannin, Natasha A AU - Lannin NA AUID- ORCID: 0000-0002-2066-8345 AD - Department of Neuroscience (N.A.L.), Central Clinical School, Monash University, VIC, Australia. AD - Alfred Health, Melbourne, VIC, Australia (N.A.L.). FAU - Anderson, Craig S AU - Anderson CS AUID- ORCID: 0000-0002-7248-4863 AD - The George Institute for Global Health, Sydney, NSW, Australia (C.S.A.). AD - The George Institute for Global Health, Peking University Health Science Center, China (C.S.A.). FAU - Whiley, Leanne AU - Whiley L AD - Rockhampton Hospital, QLD, Australia (L.W.). FAU - Kilkenny, Monique F AU - Kilkenny MF AUID- ORCID: 0000-0002-3375-287X AD - Stroke and Ageing Research, Department of Medicine, School of Clinical Sciences at Monash Health (L.L.D., J.K., D.A.C., A.G.T., R.G., M.F.K.), Central Clinical School, Monash University, VIC, Australia. AD - The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Heidelberg, VIC, Australia (J.K., D.A.C., M.F.K.). LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20210728 PL - United States TA - Stroke JT - Stroke JID - 0235266 RN - 0 (Antihypertensive Agents) RN - 0 (Fibrinolytic Agents) RN - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors) SB - IM MH - Aged MH - Antihypertensive Agents/therapeutic use MH - Cohort Studies MH - Female MH - Fibrinolytic Agents/therapeutic use MH - Humans MH - Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use MH - Ischemic Attack, Transient/drug therapy/mortality MH - Ischemic Stroke/*drug therapy/*mortality MH - Male MH - Middle Aged MH - Registries MH - Retrospective Studies MH - Secondary Prevention/*methods MH - *Drug Monitoring OTO - NOTNLM OT - antihypertensive agents OT - cerebral hemorrhage OT - medication adherence OT - mortality OT - secondary prevention OT - survival EDAT- 2021/07/29 06:00 MHDA- 2022/01/08 06:00 CRDT- 2021/07/28 05:27 PHST- 2021/07/29 06:00 [pubmed] PHST- 2022/01/08 06:00 [medline] PHST- 2021/07/28 05:27 [entrez] AID - 10.1161/STROKEAHA.120.033133 [doi] PST - ppublish SO - Stroke. 2021 Nov;52(11):3569-3577. doi: 10.1161/STROKEAHA.120.033133. Epub 2021 Jul 28. PMID- 34311275 OWN - NLM STAT- MEDLINE DCOM- 20210929 LR - 20210929 IS - 1879-3363 (Electronic) IS - 0025-326X (Linking) VI - 171 DP - 2021 Oct TI - What remains on the beach after tourists leave? The case of Abais beach (Sergipe, Brazil). PG - 112700 LID - S0025-326X(21)00734-7 [pii] LID - 10.1016/j.marpolbul.2021.112700 [doi] AB - The study evaluated the characteristics of marine litter disposed of by tourists on the Abais beach (state of Sergipe, Brazil), during the dry (December/2017, January/2018, and February/2018) and rainy (May/2018, June/2018, and July/2018) months. Litter was collected on a Sunday of each month after the tourists left. The values of abundance (9.71 +/- 2.03 items/m), weight (21.07 +/- 16.04 g/m), volume (0.58 +/- 0.25 L/m), richness (33 litter groups) and plastic percentage (75.07 +/- 4.81%) were higher in the dry months compared to the rainy ones (2.01 +/- 2.80 items/m; 5.08 +/- 6.01 g/m; 0.17 +/- 0.16 L/m; 22 litter groups; and 68.62 +/- 5.98% of plastic, respectively). Considering the tourist importance of the Abais beach to Sergipe state, it is crucial to develop effective cleaning actions, environmental awareness campaigns for tourists, residents and traders, as well as to establish restrictive public legal instruments to promote reduction, reuse, and recycling of the marine litter. CI - Copyright (c) 2021 Elsevier Ltd. All rights reserved. FAU - de Melo Nobre, Fernanda Silva AU - de Melo Nobre FS AD - Programa de Pos-Graduacao em Engenharia e Ciencias Ambientais, Universidade Federal de Sergipe, Av. Marechal Rondon s/n, CEP 49.100-000 Sao Cristovao, Sergipe, Brazil. FAU - Santos, Ana Alice AU - Santos AA AD - Departamento de Ecologia, Universidade Federal de Sergipe, Av. Marechal Rondon s/n, CEP 49.100-000 Sao Cristovao, Sergipe, Brazil. FAU - Nilin, Jeamylle AU - Nilin J AD - Instituto de Biologia, Universidade Federal de Uberlandia, Campus Umuarama, rua Ceara s/n Bloco 2D, sala 28, CEP 38405-302 Uberlandia, Minas Gerais, Brazil. Electronic address: jeamylle@gmail.com. LA - eng PT - Journal Article DEP - 20210723 PL - England TA - Mar Pollut Bull JT - Marine pollution bulletin JID - 0260231 RN - 0 (Plastics) RN - 0 (Waste Products) SB - IM MH - *Bathing Beaches MH - Brazil MH - Environmental Monitoring MH - Plastics MH - *Waste Products/analysis OTO - NOTNLM OT - Beach litter OT - Coastal management OT - Marine pollution OT - Plastic OT - Tourism EDAT- 2021/07/27 06:00 MHDA- 2021/09/30 06:00 CRDT- 2021/07/26 20:22 PHST- 2021/02/14 00:00 [received] PHST- 2021/06/28 00:00 [revised] PHST- 2021/07/01 00:00 [accepted] PHST- 2021/07/27 06:00 [pubmed] PHST- 2021/09/30 06:00 [medline] PHST- 2021/07/26 20:22 [entrez] AID - S0025-326X(21)00734-7 [pii] AID - 10.1016/j.marpolbul.2021.112700 [doi] PST - ppublish SO - Mar Pollut Bull. 2021 Oct;171:112700. doi: 10.1016/j.marpolbul.2021.112700. Epub 2021 Jul 23. PMID- 34307958 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240402 IS - 2451-8654 (Electronic) IS - 2451-8654 (Linking) VI - 23 DP - 2021 Sep TI - Clinical trials proposed for the VA Cooperative Studies Program: Success rates and factors impacting approval. PG - 100811 LID - 10.1016/j.conctc.2021.100811 [doi] LID - 100811 AB - The process by which funding organizations select among the myriad number of proposals they receive is a matter of significant concern for researchers and the public alike. Despite an extensive literature on the topic of peer review and publications on criteria by which clinical investigations are reviewed, publications analyzing peer review and other processes leading to government funding decisions on large multi-site clinical trials proposals are sparse. To partially address this gap, we reviewed the outcomes of scientific and programmatic evaluation for all letters of intent (LOIs) received by the Department of Veterans Affairs (VA) Cooperative Studies Program (CSP) between July 4, 2008, and November 28, 2016. If accepted, these LOIs represented initial steps towards later full proposals that also underwent scientific peer review. Twenty-two of 87 LOIs were ultimately funded and executed as CSP projects, for an overall success rate of 25%. Most proposals which received a negative decision did so prior to submission of a full proposal. Common reasons for negative scientific review of LOIs included investigator inexperience, perceived lack of major scientific impact, lack of preliminary data and flawed or confused experimental design, while the most common reasons for negative reviews of final proposals included questions of scientific impact and issues of study design, including outcome measures, randomization, and stratification. Completed projects have been published in high impact clinical journals. Findings highlight several factors leading to successfully obtaining funding support for clinical trials. While our analysis is restricted to trials proposed for CSP, the similarities in review processes with those employed by the National Institutes of Health and the Patient Centered Outcomes Research Institute suggest the possibility that they may also be important in a broader context. FAU - Burnaska, David R AU - Burnaska DR AD - Cooperative Studies Program, Office of Research and Development, Veterans Health Administration, Washington DC, 20420, USA. FAU - Huang, Grant D AU - Huang GD AD - Cooperative Studies Program, Office of Research and Development, Veterans Health Administration, Washington DC, 20420, USA. FAU - O'Leary, Timothy J AU - O'Leary TJ AD - Cooperative Studies Program, Office of Research and Development, Veterans Health Administration, Washington DC, 20420, USA. AD - Department of Pathology, University of Maryland School of Medicine, Baltimore, MD, USA. LA - eng PT - Journal Article DEP - 20210709 PL - Netherlands TA - Contemp Clin Trials Commun JT - Contemporary clinical trials communications JID - 101671157 PMC - PMC8287148 OTO - NOTNLM OT - Clinical trials OT - Letters of intent OT - Peer review OT - Success rates OT - Veterans COIS- The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2021/07/27 06:00 MHDA- 2021/07/27 06:01 PMCR- 2021/07/09 CRDT- 2021/07/26 06:44 PHST- 2020/08/23 00:00 [received] PHST- 2021/04/26 00:00 [revised] PHST- 2021/06/21 00:00 [accepted] PHST- 2021/07/26 06:44 [entrez] PHST- 2021/07/27 06:00 [pubmed] PHST- 2021/07/27 06:01 [medline] PHST- 2021/07/09 00:00 [pmc-release] AID - S2451-8654(21)00112-5 [pii] AID - 100811 [pii] AID - 10.1016/j.conctc.2021.100811 [doi] PST - epublish SO - Contemp Clin Trials Commun. 2021 Jul 9;23:100811. doi: 10.1016/j.conctc.2021.100811. eCollection 2021 Sep. PMID- 34300110 OWN - NLM STAT- MEDLINE DCOM- 20210729 LR - 20240402 IS - 1660-4601 (Electronic) IS - 1661-7827 (Print) IS - 1660-4601 (Linking) VI - 18 IP - 14 DP - 2021 Jul 19 TI - Perceived Access to Health Care Services and Relevance of Telemedicine during the COVID-19 Pandemic in Germany. LID - 10.3390/ijerph18147661 [doi] LID - 7661 AB - During the COVID-19 pandemic in Germany, non-pharmaceutical interventions were imposed to contain the spread of the virus. Based on cross-sectional waves in March, July and December 2020 of the COVID-19 Snapshot Monitoring (COSMO), the present study investigated the impact of the introduced measures on the perceived access to health care. Additionally, for the wave in December, treatment occasion as well as utilization and satisfaction regarding telemedicine were analysed. For 18-74-year-old participants requiring medical care, descriptive and logistic regression analyses were performed. During the less strict second lockdown in December, participants reported more frequently ensured access to health care (91.2%) compared to the first lockdown in March (86.8%), but less frequently compared to July (94.2%) during a period with only mild restrictions. In December, main treatment occasions of required medical appointments were check-up visits at the general practitioner (55.2%) and dentist (36.2%), followed by acute treatments at the general practitioner (25.6%) and dentist (19.0%), treatments at the physio-, ergo- or speech therapist (13.1%), psychotherapist (11.9%), and scheduled hospital admissions or surgeries (10.0%). Of the participants, 20.0% indicated utilization of telemedical (15.4% telephone, 7.6% video) consultations. Of them, 43.7% were satisfied with the service. In conclusion, for the majority of participants, access to medical care was ensured during the COVID-19 pandemic; however, access slightly decreased during phases of lockdown. Telemedicine complemented the access to medical appointments. FAU - Reitzle, Lukas AU - Reitzle L AD - Department of Epidemiology and Health Monitoring, Robert Koch Institute, 12101 Berlin, Germany. FAU - Schmidt, Christian AU - Schmidt C AD - Department of Epidemiology and Health Monitoring, Robert Koch Institute, 12101 Berlin, Germany. FAU - Farber, Francesca AU - Farber F AD - Department of Epidemiology and Health Monitoring, Robert Koch Institute, 12101 Berlin, Germany. FAU - Huebl, Lena AU - Huebl L AUID- ORCID: 0000-0002-2822-7202 AD - Department of Tropical Medicine, Bernhard Nocht Institute for Tropical Medicine, University Medical Center Hamburg-Eppendorf, 20359 Hamburg, Germany. AD - I. Department of Medicine, University Medical Center Hamburg-Eppendorf, 20251 Hamburg, Germany. FAU - Wieler, Lothar Heinz AU - Wieler LH AD - Robert Koch Institute, 13353 Berlin, Germany. FAU - Ziese, Thomas AU - Ziese T AD - Department of Epidemiology and Health Monitoring, Robert Koch Institute, 12101 Berlin, Germany. FAU - Heidemann, Christin AU - Heidemann C AD - Department of Epidemiology and Health Monitoring, Robert Koch Institute, 12101 Berlin, Germany. LA - eng GR - GE20150323 and GE20190305/Bundesministerium fur Gesundheit/ PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20210719 PL - Switzerland TA - Int J Environ Res Public Health JT - International journal of environmental research and public health JID - 101238455 SB - IM MH - Adolescent MH - Adult MH - Aged MH - Ambulatory Care MH - *COVID-19 MH - Communicable Disease Control MH - Cross-Sectional Studies MH - Germany/epidemiology MH - Health Services Accessibility MH - Humans MH - Middle Aged MH - Pandemics MH - SARS-CoV-2 MH - *Telemedicine MH - Young Adult PMC - PMC8303178 OTO - NOTNLM OT - COVID-19 OT - SARS-CoV-2 OT - access to health care OT - health care utilization OT - telemedicine COIS- The authors declare no conflict of interest. EDAT- 2021/07/25 06:00 MHDA- 2021/07/30 06:00 PMCR- 2021/07/19 CRDT- 2021/07/24 01:06 PHST- 2021/06/04 00:00 [received] PHST- 2021/07/14 00:00 [revised] PHST- 2021/07/15 00:00 [accepted] PHST- 2021/07/24 01:06 [entrez] PHST- 2021/07/25 06:00 [pubmed] PHST- 2021/07/30 06:00 [medline] PHST- 2021/07/19 00:00 [pmc-release] AID - ijerph18147661 [pii] AID - ijerph-18-07661 [pii] AID - 10.3390/ijerph18147661 [doi] PST - epublish SO - Int J Environ Res Public Health. 2021 Jul 19;18(14):7661. doi: 10.3390/ijerph18147661. PMID- 34297070 OWN - NLM STAT- MEDLINE DCOM- 20210805 LR - 20260726 IS - 2574-3805 (Electronic) IS - 2574-3805 (Linking) VI - 4 IP - 7 DP - 2021 Jul 1 TI - Methadone Access for Opioid Use Disorder During the COVID-19 Pandemic Within the United States and Canada. PG - e2118223 LID - 10.1001/jamanetworkopen.2021.18223 [doi] LID - e2118223 AB - IMPORTANCE: Methadone access may be uniquely vulnerable to disruption during COVID-19, and even short delays in access are associated with decreased medication initiation and increased illicit opioid use and overdose death. Relative to Canada, US methadone provision is more restricted and limited to specialized opioid treatment programs. OBJECTIVE: To compare timely access to methadone initiation in the US and Canada during COVID-19. DESIGN, SETTING, AND PARTICIPANTS: This cross-sectional study was conducted from May to June 2020. Participating clinics provided methadone for opioid use disorder in 14 US states and territories and 3 Canadian provinces with the highest opioid overdose death rates. Statistical analysis was performed from July 2020 to January 2021. EXPOSURES: Nation and type of health insurance (US Medicaid and US self-pay vs Canadian provincial). MAIN OUTCOMES AND MEASURES: Proportion of clinics accepting new patients and days to first appointment. RESULTS: Among 268 of 298 US clinics contacted as a patient with Medicaid (90%), 271 of 301 US clinics contacted as a self-pay patient (90%), and 237 of 288 Canadian clinics contacted as a patient with provincial insurance (82%), new patients were accepted for methadone at 231 clinics (86%) during US Medicaid contacts, 230 clinics (85%) during US self-pay contacts, and at 210 clinics (89%) during Canadian contacts. Among clinics not accepting new patients, at least 44% of 27 clinics reported that the COVID-19 pandemic was the reason. The mean wait for first appointment was greater among US Medicaid contacts (3.5 days [95% CI, 2.9-4.2 days]) and US self-pay contacts (4.1 days [95% CI, 3.4-4.8 days]) than Canadian contacts (1.9 days [95% CI, 1.7-2.1 days]) (P < .001). Open-access model (walk-in hours for new patients without an appointment) utilization was reported by 57 Medicaid (30%), 57 self-pay (30%), and 115 Canadian (59%) contacts offering an appointment. CONCLUSIONS AND RELEVANCE: In this cross-sectional study of 2 nations, more than 1 in 10 methadone clinics were not accepting new patients. Canadian clinics offered more timely methadone access than US opioid treatment programs. These results suggest that the methadone access shortage was exacerbated by COVID-19 and that changes to the US opioid treatment program model are needed to improve the timeliness of access. Increased open-access model adoption may increase timely access. FAU - Joudrey, Paul J AU - Joudrey PJ AD - Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut. FAU - Adams, Zoe M AU - Adams ZM AD - Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut. FAU - Bach, Paxton AU - Bach P AD - British Columbia Center on Substance Use, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada. FAU - Van Buren, Sarah AU - Van Buren S AD - Yale School of Nursing, Orange, Connecticut. FAU - Chaiton, Jessica A AU - Chaiton JA AD - British Columbia Center on Substance Use, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada. FAU - Ehrenfeld, Lucy AU - Ehrenfeld L AD - Yale School of Nursing, Orange, Connecticut. FAU - Guerra, Mary Elizabeth AU - Guerra ME AD - Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut. FAU - Gleeson, Brynna AU - Gleeson B AD - Vassar College, Poughkeepsie, New York. FAU - Kimmel, Simeon D AU - Kimmel SD AD - Sections of General Internal Medicine and Infectious Diseases, Department of Medicine, Boston University School of Medicine and Boston Medical Center, Boston, Massachusetts. FAU - Medley, Ashley AU - Medley A AD - Yale School of Nursing, Orange, Connecticut. FAU - Mekideche, Wassim AU - Mekideche W AD - Faculty of Pharmacy, Universite de Montreal, Montreal, Canada. FAU - Paquet, Maxime AU - Paquet M AD - Faculty of Pharmacy, Universite de Montreal, Montreal, Canada. FAU - Sung, Minhee AU - Sung M AD - Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut. AD - VA Connecticut Healthcare System, West Haven. FAU - Wang, Melinda AU - Wang M AD - Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut. FAU - You Kheang, R O Olivier AU - You Kheang ROO AD - Faculty of Pharmacy, Universite de Montreal, Montreal, Canada. FAU - Zhang, Jingxian AU - Zhang J AD - Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut. FAU - Wang, Emily A AU - Wang EA AD - Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut. FAU - Edelman, E Jennifer AU - Edelman EJ AD - Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut. AD - Center for Interdisciplinary Research on AIDS, Yale School of Public Health, New Haven, Connecticut. LA - eng GR - L30 DA052056/DA/NIDA NIH HHS/United States GR - UL1 TR001863/TR/NCATS NIH HHS/United States GR - UM1 DA049412/DA/NIDA NIH HHS/United States GR - K12 DA033312/DA/NIDA NIH HHS/United States GR - R25 DA037756/DA/NIDA NIH HHS/United States PT - Comparative Study PT - Journal Article PT - Research Support, N.I.H., Extramural DEP - 20210701 PL - United States TA - JAMA Netw Open JT - JAMA network open JID - 101729235 RN - 0 (Analgesics, Opioid) RN - UC6VBE7V1Z (Methadone) SB - IM MH - Ambulatory Care Facilities MH - Analgesics, Opioid MH - *COVID-19 MH - Canada MH - Cross-Sectional Studies MH - Financing, Personal MH - Health Services MH - *Health Services Accessibility MH - Insurance, Health MH - Medicaid MH - Methadone/*therapeutic use MH - *Opiate Substitution Treatment MH - Opioid-Related Disorders/*therapy MH - *Pandemics MH - United States MH - *Waiting Lists PMC - PMC8303098 COIS- Conflict of Interest Disclosures: Dr Bach reported grants from the Michael Smith Foundation for Health Research and grants from the Canadian Institutes of Health Research outside the submitted work. Dr Kimmel reported personal fees from Abt Associates for work as a consultant on access to medications for opioid use disorder in nursing facilities and personal fees from the American Academy of Addiction Psychiatry Fees for lecturing about medications for opioid use disorder and harm reduction as part of the opioid response network outside the submitted work. No other disclosures were reported. EDAT- 2021/07/24 06:00 MHDA- 2021/08/06 06:00 PMCR- 2021/07/23 CRDT- 2021/07/23 12:22 PHST- 2021/07/23 12:22 [entrez] PHST- 2021/07/24 06:00 [pubmed] PHST- 2021/08/06 06:00 [medline] PHST- 2021/07/23 00:00 [pmc-release] AID - 2782211 [pii] AID - zoi210537 [pii] AID - 10.1001/jamanetworkopen.2021.18223 [doi] PST - epublish SO - JAMA Netw Open. 2021 Jul 1;4(7):e2118223. doi: 10.1001/jamanetworkopen.2021.18223. PMID- 34292866 OWN - NLM STAT- MEDLINE DCOM- 20210929 LR - 20240403 IS - 1438-8871 (Electronic) IS - 1439-4456 (Print) IS - 1438-8871 (Linking) VI - 23 IP - 8 DP - 2021 Aug 13 TI - Digital Surveillance Through an Online Decision Support Tool for COVID-19 Over One Year of the Pandemic in Italy: Observational Study. PG - e29556 LID - 10.2196/29556 [doi] LID - e29556 AB - BACKGROUND: Italy has experienced severe consequences (ie, hospitalizations and deaths) during the COVID-19 pandemic. Online decision support systems (DSS) and self-triage applications have been used in several settings to supplement health authority recommendations to prevent and manage COVID-19. A digital Italian health tech startup, Paginemediche, developed a noncommercial, online DSS with a chat user interface to assist individuals in Italy manage their potential exposure to COVID-19 and interpret their symptoms since early in the pandemic. OBJECTIVE: This study aimed to compare the trend in online DSS sessions with that of COVID-19 cases reported by the national health surveillance system in Italy, from February 2020 to March 2021. METHODS: We compared the number of sessions by users with a COVID-19-positive contact and users with COVID-19-compatible symptoms with the number of cases reported by the national surveillance system. To calculate the distance between the time series, we used the dynamic time warping algorithm. We applied Symbolic Aggregate approXimation (SAX) encoding to the time series in 1-week periods. We calculated the Hamming distance between the SAX strings. We shifted time series of online DSS sessions 1 week ahead. We measured the improvement in Hamming distance to verify the hypothesis that online DSS sessions anticipate the trends in cases reported to the official surveillance system. RESULTS: We analyzed 75,557 sessions in the online DSS; 65,207 were sessions by symptomatic users, while 19,062 were by contacts of individuals with COVID-19. The highest number of online DSS sessions was recorded early in the pandemic. Second and third peaks were observed in October 2020 and March 2021, respectively, preceding the surge in notified COVID-19 cases by approximately 1 week. The distance between sessions by users with COVID-19 contacts and reported cases calculated by dynamic time warping was 61.23; the distance between sessions by symptomatic users was 93.72. The time series of users with a COVID-19 contact was more consistent with the trend in confirmed cases. With the 1-week shift, the Hamming distance between the time series of sessions by users with a COVID-19 contact and reported cases improved from 0.49 to 0.46. We repeated the analysis, restricting the time window to between July 2020 and December 2020. The corresponding Hamming distance was 0.16 before and improved to 0.08 after the time shift. CONCLUSIONS: Temporal trends in the number of online COVID-19 DSS sessions may precede the trend in reported COVID-19 cases through traditional surveillance. The trends in sessions by users with a contact with COVID-19 may better predict reported cases of COVID-19 than sessions by symptomatic users. Data from online DSS may represent a useful supplement to traditional surveillance and support the identification of early warning signals in the COVID-19 pandemic. CI - (c)Alberto Eugenio Tozzi, Francesco Gesualdo, Emanuele Urbani, Alessandro Sbenaglia, Roberto Ascione, Nicola Procopio, Ileana Croci, Caterina Rizzo. Originally published in the Journal of Medical Internet Research (https://www.jmir.org), 13.08.2021. FAU - Tozzi, Alberto Eugenio AU - Tozzi AE AUID- ORCID: 0000-0002-6884-984X AD - Multifactorial and Complex Diseases Research Area, Bambino Gesu Children's Hospital IRCCS, Rome, Italy. FAU - Gesualdo, Francesco AU - Gesualdo F AUID- ORCID: 0000-0002-9087-4398 AD - Multifactorial and Complex Diseases Research Area, Bambino Gesu Children's Hospital IRCCS, Rome, Italy. FAU - Urbani, Emanuele AU - Urbani E AUID- ORCID: 0000-0001-7326-7943 AD - Paginemediche, Salerno, Italy. FAU - Sbenaglia, Alessandro AU - Sbenaglia A AUID- ORCID: 0000-0001-7181-8609 AD - Paginemediche, Salerno, Italy. FAU - Ascione, Roberto AU - Ascione R AUID- ORCID: 0000-0003-2620-5576 AD - Healthware Group, Salerno, Italy. FAU - Procopio, Nicola AU - Procopio N AUID- ORCID: 0000-0001-7277-8880 AD - Healthware Group, Salerno, Italy. FAU - Croci, Ileana AU - Croci I AUID- ORCID: 0000-0002-3448-6059 AD - Multifactorial and Complex Diseases Research Area, Bambino Gesu Children's Hospital IRCCS, Rome, Italy. FAU - Rizzo, Caterina AU - Rizzo C AUID- ORCID: 0000-0002-5583-7508 AD - Clinical Pathways and Epidemiology Unit, Bambino Gesu Children's Hospital IRCCS, Rome, Italy. LA - eng PT - Journal Article PT - Observational Study DEP - 20210813 PL - Canada TA - J Med Internet Res JT - Journal of medical Internet research JID - 100959882 SB - IM MH - *COVID-19 MH - Humans MH - Italy/epidemiology MH - *Pandemics/prevention & control MH - SARS-CoV-2 MH - Triage PMC - PMC8366755 OTO - NOTNLM OT - COVID-19 OT - Italy OT - decision support OT - digital surveillance OT - internet OT - observational OT - online decision support system OT - online tool OT - public health OT - support OT - surveillance COIS- Conflicts of Interest: EU, AS, RA, and NP work for Paginemediche and Healthware Group, which were involved in the development of the online DSS included on the Paginemediche website. CR received grants for participating in Advisory Boards. The other authors declare no conflicts of interest. EDAT- 2021/07/23 06:00 MHDA- 2021/09/30 06:00 PMCR- 2021/08/13 CRDT- 2021/07/22 17:18 PHST- 2021/04/16 00:00 [received] PHST- 2021/07/18 00:00 [accepted] PHST- 2021/07/14 00:00 [revised] PHST- 2021/07/23 06:00 [pubmed] PHST- 2021/09/30 06:00 [medline] PHST- 2021/07/22 17:18 [entrez] PHST- 2021/08/13 00:00 [pmc-release] AID - v23i8e29556 [pii] AID - 10.2196/29556 [doi] PST - epublish SO - J Med Internet Res. 2021 Aug 13;23(8):e29556. doi: 10.2196/29556. PMID- 34289524 OWN - NLM STAT- MEDLINE DCOM- 20251103 LR - 20260612 IS - 1365-2702 (Electronic) IS - 0962-1067 (Print) IS - 0962-1067 (Linking) VI - 34 IP - 12 DP - 2025 Dec TI - Otago exercise programme for physical function and mental health among older adults with cognitive frailty during COVID-19: A randomised controlled trial. PG - 5130-5143 LID - 10.1111/jocn.15964 [doi] AB - AIMS AND OBJECTIVES: Quarantine during the COVID-19 pandemic resulted in longer-term sedentary behaviours and mental health problems. Our study aimed to evaluate the impact of the Otago exercise programme (OEP) on physical function and mental health among elderly with cognitive frailty during COVID-19. BACKGROUND: Lockdowns and restrictions during the COVID-19 pandemic result in longer-term sedentary behaviours related disease and mental problem. Older people with cognitive frailty are more vulnerable to be influenced. Timely intervention may achieve better outcomes, OEP exercise was designed as a balance and muscle-strengthening programme for elderly people. DESIGN: A parallel-group, assessor-blinded randomised controlled trial was performed according to CONSORT guidelines. METHODS: This study was conducted from July 2020 to October 2020 among 62 elderly people with cognitive frailty from a nursing home. Participants were randomly divided into an OEP group (n = 31) or a control group (n = 31). Both groups received sleep- and diet-related health education. The OEP group also received a 12-week group exercise programme. The Five Times Sit to Stand Test (FTSST), Berg Balance Scale (BBS), and Timed Up and Go Test (TUGT) were used to assess physical function. The Geriatric Depression Scale-15 (GDS-15) and the 12-Item Short Form Health Survey Mental Component Summary (SF-12 MCS) were used to assess mental health. Outcomes were measured at 6 and 12 weeks. RESULTS: Physical function and mental health were similar in the two groups at baseline. At 12 weeks, the OEP group (difference in change from baseline: FTSST, -2.78; TUGT, -3.73; BBS, 2.17; GDS-15, -0.72; SF-12 MCS, 2.58; all p < .001) exhibited significantly greater improvements than the control group (difference in change from baseline: FTSST, 1.55; TUGT, 1.66; BBS, -0.10; GDS-15, 1.07; SF-12 MCS, -5.95; all p < .001). CONCLUSION: Our findings showed the OEP group had better physical function and mental health outcomes than the control group. OEP can be used to improve the physical and mental function among elderly people with cognitive frailty during the COVID-19 pandemic. RELEVANCE TO CLINICAL PRACTICE: Otago exercise program intervention programmes should be implemented to improve physical function for cognitive frailty elderly to reduce the harm of longer-term sedentary behaviours, and to ruduce depression symptom and improve mental health, particularly during COVID-19 pandemic period. CI - (c) 2021 John Wiley & Sons Ltd. FAU - Chen, Xi AU - Chen X AUID- ORCID: 0000-0002-8129-755X AD - The Second Xiangya Hospital, Central South University, Changsha, China. FAU - Zhao, Liping AU - Zhao L AUID- ORCID: 0000-0002-7682-9339 AD - The Second Xiangya Hospital, Central South University, Changsha, China. FAU - Liu, Youshuo AU - Liu Y AD - The Second Xiangya Hospital, Central South University, Changsha, China. FAU - Zhou, Zhiming AU - Zhou Z AD - Geriatric Rehabilitation Hospital of Changsha, Changsha, China. FAU - Zhang, Hua AU - Zhang H AD - Changsha NO.1 Social Welfare Institution, Changsha, China. FAU - Wei, Dongli AU - Wei D AD - Geriatric Rehabilitation Hospital of Changsha, Changsha, China. FAU - Chen, Jianliang AU - Chen J AD - Shenzhen Hostal of Integrated Traditional Chinese and Western Medicine, Shenzhen, China. FAU - Li, Yan AU - Li Y AD - The Second Xiangya Hospital, Central South University, Changsha, China. FAU - Ou, Jinnan AU - Ou J AD - The Second Xiangya Hospital, Central South University, Changsha, China. FAU - Huang, Jin AU - Huang J AUID- ORCID: 0000-0002-9303-671X AD - The Second Xiangya Hospital, Central South University, Changsha, China. FAU - Yang, Xiaomei AU - Yang X AD - Guangzhou Development District Hospital, Guangzhou, China. FAU - Ma, Caili AU - Ma C AD - The Second Xiangya Hospital, Central South University, Changsha, China. LA - eng GR - 2020SK3003/Natural Science Foundation of Hunan province/ GR - 2019-HLKY-32/Health commission Foundation Hunan Province of and the Nursing Research Project of the Second Xiangya Hospital, Central South University/ GR - 81770833/National Natural Science Foundation of China/ GR - 81974223/National Natural Science Foundation of China/ GR - 82071593/National Natural Science Foundation of China/ GR - B2019153/Health and Family Planning Commission of Hunan Province/ PT - Journal Article PT - Randomized Controlled Trial PT - Research Support, Non-U.S. Gov't DEP - 20210721 PL - England TA - J Clin Nurs JT - Journal of clinical nursing JID - 9207302 SB - IM MH - Humans MH - *COVID-19/epidemiology MH - Aged MH - Male MH - Female MH - *Mental Health MH - *Exercise Therapy/methods MH - Aged, 80 and over MH - *Frail Elderly/psychology MH - SARS-CoV-2 MH - *Exercise MH - *Cognitive Dysfunction PMC - PMC8447213 OTO - NOTNLM OT - advanced nursing practice OT - health promotion OT - mental health OT - older people OT - quality of life OT - randomised controlled trial COIS- The author(s) declared no potential conflicts of interest with respect to the research, authorship and/or publication of this article. EDAT- 2021/07/22 06:00 MHDA- 2025/11/03 16:06 PMCR- 2021/07/21 CRDT- 2021/07/21 20:13 PHST- 2021/06/09 00:00 [revised] PHST- 2021/04/04 00:00 [received] PHST- 2021/06/21 00:00 [accepted] PHST- 2025/11/03 16:06 [medline] PHST- 2021/07/22 06:00 [pubmed] PHST- 2021/07/21 20:13 [entrez] PHST- 2021/07/21 00:00 [pmc-release] AID - JOCN15964 [pii] AID - 10.1111/jocn.15964 [doi] PST - ppublish SO - J Clin Nurs. 2025 Dec;34(12):5130-5143. doi: 10.1111/jocn.15964. Epub 2021 Jul 21. PMID- 34288910 OWN - NLM STAT- MEDLINE DCOM- 20210728 LR - 20260127 IS - 1932-6203 (Electronic) IS - 1932-6203 (Linking) VI - 16 IP - 7 DP - 2021 TI - The introduction of a mandatory mask policy was associated with significantly reduced COVID-19 cases in a major metropolitan city. PG - e0253510 LID - 10.1371/journal.pone.0253510 [doi] LID - e0253510 AB - BACKGROUND: Whilst evidence of use of face masks in reducing COVID-19 cases is increasing, the impact of mandatory use across a large population has been difficult to assess. Introduction of mandatory mask use on July 22, 2020 during a resurgence of COVID-19 in Melbourne, Australia created a situation that facilitated an assessment of the impact of the policy on the epidemic growth rate as its introduction occurred in the absence of other changes to restrictions. METHODS AND FINDINGS: Exponential epidemic growth or decay rates in daily COVID-19 diagnoses were estimated using a non-weighted linear regression of the natural logarithm of the daily cases against time, using a linear spline model with one knot (lspline package in R v 3.6.3). The model's two linear segments pivot around the hinge day, on which the mask policy began to take effect, 8 days following the introduction of the policy. We used two forms of data to assess change in mask usage: images of people wearing masks in public places obtained from a major media outlet and population-based survey data. Potential confounding factors (including daily COVID-19 tests, number of COVID-19 cases among population subsets affected differentially by the mask policy-e.g., healthcare workers) were examined for their impact on the results. Daily cases fitted an exponential growth in the first log-linear segment (k = +0.042, s.e. = 0.007), and fitted an exponential decay in the second (k = -0.023, s.e. = 0.017) log-linear segment. Over a range of reported serial intervals for SARS-CoV-2 infection, these growth rates correspond to a 22-33% reduction in an effective reproduction ratio before and after mandatory mask use. Analysis of images of people in public spaces showed mask usage rose from approximately 43% to 97%. Analysis of survey data found that on the third day before policy introduction, 44% of participants reported "often" or "always" wearing a mask; on the fourth day after, 100% reported "always" doing so. No potentially confounding factors were associated with the observed change in growth rates. CONCLUSIONS: The mandatory mask use policy substantially increased public use of masks and was associated with a significant decline in new COVID-19 cases after introduction of the policy. This study strongly supports the use of masks for controlling epidemics in the broader community. FAU - Scott, Nick AU - Scott N AD - The Burnet Institute, Melbourne, Australia. AD - Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia. FAU - Saul, Allan AU - Saul A AUID- ORCID: 0000-0003-0665-4091 AD - The Burnet Institute, Melbourne, Australia. FAU - Spelman, Tim AU - Spelman T AD - The Burnet Institute, Melbourne, Australia. FAU - Stoove, Mark AU - Stoove M AD - The Burnet Institute, Melbourne, Australia. AD - Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia. FAU - Pedrana, Alisa AU - Pedrana A AD - The Burnet Institute, Melbourne, Australia. AD - Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia. FAU - Saeri, Alexander AU - Saeri A AD - BehaviourWorks Australia, Monash Sustainable Development Institute, Monash University, Melbourne, Australia. FAU - Grundy, Emily AU - Grundy E AD - BehaviourWorks Australia, Monash Sustainable Development Institute, Monash University, Melbourne, Australia. FAU - Smith, Liam AU - Smith L AD - BehaviourWorks Australia, Monash Sustainable Development Institute, Monash University, Melbourne, Australia. FAU - Toole, Michael AU - Toole M AD - The Burnet Institute, Melbourne, Australia. FAU - McIntyre, Chandini Raina AU - McIntyre CR AD - Biosecurity Program, The Kirby Institute, University of New South Wales, Sydney, Australia. FAU - Crabb, Brendan S AU - Crabb BS AD - The Burnet Institute, Melbourne, Australia. AD - Department of Immunology and Pathology, Monash University, Melbourne, Australia. AD - Doherty Institute and School of Population and Global Health, University of Melbourne, Parkville, Australia. FAU - Hellard, Margaret AU - Hellard M AUID- ORCID: 0000-0002-5055-3266 AD - The Burnet Institute, Melbourne, Australia. AD - Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia. AD - Doherty Institute and School of Population and Global Health, University of Melbourne, Parkville, Australia. AD - Department of Infectious Diseases, The Alfred Hospital, Melbourne, Australia. LA - eng PT - Journal Article DEP - 20210721 PL - United States TA - PLoS One JT - PloS one JID - 101285081 SB - IM ECI - PLoS One. 2023 Apr 21;18(4):e0284939. doi: 10.1371/journal.pone.0284939. PMID: 37083861 MH - Australia/epidemiology MH - COVID-19/*epidemiology/*prevention & control MH - Cities/epidemiology MH - Health Behavior MH - Humans MH - Masks/*statistics & numerical data MH - Multivariate Analysis MH - Pandemics/prevention & control MH - *Policy PMC - PMC8294480 COIS- BC serves on the National COVID-19 Health Research Advisory Committee that provides guidance to the Federal Government's COVID-19 response. NS, MH, A Saeri, EG and LS provide guidance to the Victorian Government's COVID-19 response. MH and NS receive funding from the Victorian Government for the Optimise Study and COVID-19 modelling work. A Saeri and EG receive funding from the Victorian Government for the SCRUB project. CRM serves on the National COVID-19 Health Research Advisory Committee that provides guidance to the Federal Government's COVID-19 response. She currently receives funding from the National Health and Medical Research Council and Medical Research Futures Fund, Office of Health Protection, Department of Health, Sanofi and from the Defence Intelligence Organisation. This does not alter our adherence to PLOS ONE policies on sharing data and materials. EDAT- 2021/07/22 06:00 MHDA- 2021/07/29 06:00 PMCR- 2021/07/21 CRDT- 2021/07/21 17:23 PHST- 2021/02/10 00:00 [received] PHST- 2021/06/05 00:00 [accepted] PHST- 2021/07/21 17:23 [entrez] PHST- 2021/07/22 06:00 [pubmed] PHST- 2021/07/29 06:00 [medline] PHST- 2021/07/21 00:00 [pmc-release] AID - PONE-D-21-04565 [pii] AID - 10.1371/journal.pone.0253510 [doi] PST - epublish SO - PLoS One. 2021 Jul 21;16(7):e0253510. doi: 10.1371/journal.pone.0253510. eCollection 2021. PMID- 34284302 OWN - NLM STAT- MEDLINE DCOM- 20210913 LR - 20210913 IS - 1532-2688 (Electronic) IS - 1059-1311 (Linking) VI - 91 DP - 2021 Oct TI - Efficacy and safety of levetiracetam versus (fos)phenytoin for second-line treatment of epilepticus: a meta-analysis of latest randomized controlled trials. PG - 339-345 LID - S1059-1311(21)00242-9 [pii] LID - 10.1016/j.seizure.2021.07.012 [doi] AB - OBJECTIVES: To assess the efficiency and safety profiles of levetiracetam and (fos)phenytoin (phenytoin or fosphenytoin) for second-line treatment of seizures by performing a meta-analysis of RCTs. METHODS: We systematically searched PubMed, Embase, Cochrane, FDA.gov, and ClinicalTrials.gov for RCTs (published before July 31, 2020; no language restrictions). Two independent reviewers screened abstracts and titles against inclusion and exclusion criteria published previously in the PROSPERO: CRD42020202736. Eleven studies fulfilled the established criteria. We assessed pooled data by using a random-effects model. Quality analysis was performed by using version 2 of the Cochrane risk-of-bias tool (RoB 2). RevMan v.5.3 was used to perform statistical analyses, and publication bias (egger's test) was assessed with Stata MP v.14.0. RESULTS: Levetiracetam was similar to (fos)phenytoin in seizure termination rate (risk ratio [RR] 0.94; 95% CI 0.87 to 1.01), time of seizure termination (mean difference [MD] 0.44; -0.60 to 1.49), and drug resistance ([RR] 1.12, 0.86 to 1.45). The safety outcome showed a significant statistical difference between fosphenytoin group and levetiracetam group ([RR] 1.44, 1.14 to 1.81), while there was no significant difference observed between phenytoin treatment and levetiracetam treatment ([RR] 1.26, 0.99 to 1.60). CONCLUSION: Levetiracetam was similar to (fos)phenytoin in cessation rate convulsive status epilepticus, and drug resistance, while it was superior (fos)phenytoin in pooled safety outcome. Further exploration is still needed as to whether it is the first choice for second-line drugs. CI - Copyright (c) 2021 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved. FAU - Feng, Yuyi AU - Feng Y AD - School of Life and Pharmaceutical Sciences, Dalian University of Technology, Panjin 124221, China. FAU - Chen, Yueyue AU - Chen Y AD - Translational Medicine Research Institute, College of Medicine, Yangzhou University, Yangzhou 225001, China. FAU - Jia, Yaqin AU - Jia Y AD - School of Life and Pharmaceutical Sciences, Dalian University of Technology, Panjin 124221, China. FAU - Wang, Zhe AU - Wang Z AD - School of Life and Pharmaceutical Sciences, Dalian University of Technology, Panjin 124221, China. FAU - Wang, Xiaoyu AU - Wang X AD - School of Life and Pharmaceutical Sciences, Dalian University of Technology, Panjin 124221, China. FAU - Jiang, Lili AU - Jiang L AD - School of Life and Pharmaceutical Sciences, Dalian University of Technology, Panjin 124221, China. FAU - Ai, Chunzhi AU - Ai C AD - State Key Laboratory for the Chemistry and Molecular Engineering of Medicinal Resources, School of Chemistry and Pharmaceutical Sciences, Guangxi Normal University, Guilin 541004, China. FAU - Li, Wei AU - Li W AD - Translational Medicine Research Institute, College of Medicine, Yangzhou University, Yangzhou 225001, China; Jiangsu Co-innovation Center for Prevention and Control of Important Animal Infectious Diseases and Zoonoses, College of Veterinary Medicine, Yangzhou University, Yangzhou 225009, China. Electronic address: weili@yzu.edu.cn. FAU - Liu, Yong AU - Liu Y AD - School of Life and Pharmaceutical Sciences, Dalian University of Technology, Panjin 124221, China. Electronic address: yliu@dlut.edu.cn. LA - eng PT - Journal Article PT - Meta-Analysis PT - Review DEP - 20210713 PL - England TA - Seizure JT - Seizure JID - 9306979 RN - 0 (Anticonvulsants) RN - 44YRR34555 (Levetiracetam) RN - 6158TKW0C5 (Phenytoin) SB - IM MH - Anticonvulsants/therapeutic use MH - Humans MH - Levetiracetam/therapeutic use MH - *Phenytoin/therapeutic use MH - Randomized Controlled Trials as Topic MH - *Status Epilepticus/drug therapy OTO - NOTNLM OT - Fosphenytoin OT - Levetiracetam OT - Meta-analysis OT - Phenytoin OT - Status epilepticus EDAT- 2021/07/21 06:00 MHDA- 2021/09/14 06:00 CRDT- 2021/07/20 20:20 PHST- 2021/02/07 00:00 [received] PHST- 2021/07/06 00:00 [revised] PHST- 2021/07/09 00:00 [accepted] PHST- 2021/07/21 06:00 [pubmed] PHST- 2021/09/14 06:00 [medline] PHST- 2021/07/20 20:20 [entrez] AID - S1059-1311(21)00242-9 [pii] AID - 10.1016/j.seizure.2021.07.012 [doi] PST - ppublish SO - Seizure. 2021 Oct;91:339-345. doi: 10.1016/j.seizure.2021.07.012. Epub 2021 Jul 13. PMID- 34279648 OWN - NLM STAT- MEDLINE DCOM- 20210726 LR - 20220305 IS - 2574-3805 (Electronic) IS - 2574-3805 (Linking) VI - 4 IP - 7 DP - 2021 Jul 1 TI - Assessment of COVID-19-Related Immigration Concerns Among Latinx Immigrants in the US. PG - e2117049 LID - 10.1001/jamanetworkopen.2021.17049 [doi] LID - e2117049 AB - IMPORTANCE: Despite the contentious immigration environment and disproportionate rates of COVID-19 infection among Latinx individuals in the US, immigrants' concerns about engaging in COVID-19-related testing, treatment, and contact tracing have been largely unexplored. OBJECTIVE: To examine the proportions of Latinx immigrants who endorse statements about the potential negative immigration ramifications of seeking and using COVID-19-related testing and treatment services and engaging in contact tracing. DESIGN, SETTING, AND PARTICIPANTS: In this cross-sectional survey study, 25 COVID-19-related items were incorporated into the online Spanish-language survey of an ongoing study. Data were collected between July 15 and October 9, 2020, in Chicago, Illinois; Los Angeles, California; and Phoenix, Arizona. A nonrandom sample of 379 adult, Spanish-speaking, noncitizen Latinx immigrants (with either documented or undocumented immigration status) were sent surveys. Of those, 336 individuals (88.7% participation rate) returned surveys, and 43 individuals did not. An additional 213 individuals were screened but ineligible. Descriptive statistics were computed, and mean comparisons and bivariate correlations between sociodemographic variables, indices of immigration risk, and COVID-19-related survey items were conducted. MAIN OUTCOMES AND MEASURES: Items elicited agreement or disagreement with statements about immigrants' access to COVID-19-related testing and treatment services and the potential immigration ramifications of using these services. Willingness to identify an undocumented person during contact tracing was also assessed. RESULTS: A total of 336 Latinx immigrants completed surveys. The mean (SD) age of participants was 39.7 (8.9) years; 210 participants (62.5%) identified as female, and 216 participants (64.3%) had undocumented immigration status. In total, 89 participants (26.5%) agreed that hospital emergency departments were the only source of COVID-19 testing or treatment for uninsured immigrants, and 106 participants (31.6%) agreed that using public testing and health care services for COVID-19 could jeopardize one's immigration prospects. A total of 96 participants (28.6%) and 114 participants (33.9%), respectively, would not identify an undocumented household member or coworker during contact tracing. Reluctance to identify an undocumented household member or coworker was associated with having had deportation experiences (r = -0.17; 95% CI, -0.06 to 0.27; P = .003) but not with the number of years lived in the US (r = 0.07; 95% CI, -0.16 to 0.17; P = .15) or immigration status (r = 0.03; 95% CI, -0.07 to 0.13; P = .56). CONCLUSIONS AND RELEVANCE: In this cross-sectional survey study, a substantial number of immigrants endorsed statements about immigrants' restricted access to COVID-19-related testing and treatment services and the potential negative immigration ramifications of using these services. These results suggest that programs for COVID-19-related testing, contact tracing, and vaccine administration that are designed to allay immigration concerns are needed. FAU - Galletly, Carol L AU - Galletly CL AD - Center for AIDS Intervention Research, Department of Psychiatry and Behavioral Medicine, Medical College of Wisconsin, Milwaukee. FAU - Lechuga, Julia AU - Lechuga J AD - Department of Public Health Sciences, College of Health Sciences, University of Texas-El Paso, El Paso. FAU - Dickson-Gomez, Julia B AU - Dickson-Gomez JB AD - Center for AIDS Intervention Research, Department of Psychiatry and Behavioral Medicine, Medical College of Wisconsin, Milwaukee. AD - Institute for Health Equity, Medical College of Wisconsin, Milwaukee. FAU - Glasman, Laura R AU - Glasman LR AD - Center for AIDS Intervention Research, Department of Psychiatry and Behavioral Medicine, Medical College of Wisconsin, Milwaukee. FAU - McAuliffe, Timothy L AU - McAuliffe TL AD - Center for AIDS Intervention Research, Department of Psychiatry and Behavioral Medicine, Medical College of Wisconsin, Milwaukee. FAU - Espinoza-Madrigal, Ivan AU - Espinoza-Madrigal I AD - Lawyers for Civil Rights, Boston, Massachusetts. LA - eng GR - R25 DA028567/DA/NIDA NIH HHS/United States GR - P30 MH052776/MH/NIMH NIH HHS/United States GR - R01 MD011573/MD/NIMHD NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural DEP - 20210701 PL - United States TA - JAMA Netw Open JT - JAMA network open JID - 101729235 SB - IM MH - Adult MH - Arizona/epidemiology MH - COVID-19/epidemiology/*prevention & control MH - COVID-19 Testing/methods/statistics & numerical data MH - Chicago/epidemiology MH - Cross-Sectional Studies MH - Emigration and Immigration/statistics & numerical data/*trends MH - Female MH - Hispanic or Latino/*statistics & numerical data MH - Humans MH - Los Angeles/epidemiology MH - Male MH - Mass Screening/methods MH - Middle Aged MH - Qualitative Research MH - Surveys and Questionnaires PMC - PMC8290301 COIS- Conflict of Interest Disclosures: Dr Galletly reported receiving grants from the National Institute of Mental Health (NIMH) and the National Institute on Minority Health and Health Disparities (NIMHD) during the conduct of the study. Dr Lechuga reported receiving grants from the National Institute on Drug Abuse (NIDA) and the NIMHD during the conduct of the study. Dr Dickson-Gomez reported receiving grants from the NIDA, the NIMH, and the NIMHD during the conduct of the study. Dr Glasman reported receiving grants from the NIMH and the NIMHD during the conduct of the study. Dr McAuliffe reported receiving grants from the NIMH and the NIMHD during the conduct of the study. No other disclosures were reported. EDAT- 2021/07/20 06:00 MHDA- 2021/07/27 06:00 PMCR- 2021/07/19 CRDT- 2021/07/19 12:58 PHST- 2021/07/19 12:58 [entrez] PHST- 2021/07/20 06:00 [pubmed] PHST- 2021/07/27 06:00 [medline] PHST- 2021/07/19 00:00 [pmc-release] AID - 2782051 [pii] AID - zoi210508 [pii] AID - 10.1001/jamanetworkopen.2021.17049 [doi] PST - epublish SO - JAMA Netw Open. 2021 Jul 1;4(7):e2117049. doi: 10.1001/jamanetworkopen.2021.17049. PMID- 34279236 OWN - NLM STAT- MEDLINE DCOM- 20211025 LR - 20211025 IS - 1438-8871 (Electronic) IS - 1439-4456 (Print) IS - 1438-8871 (Linking) VI - 23 IP - 7 DP - 2021 Jul 19 TI - Leading Topics in Twitter Discourse on JUUL and Puff Bar Products: Content Analysis. PG - e26510 LID - 10.2196/26510 [doi] LID - e26510 AB - BACKGROUND: In response to the recent government restrictions, flavored JUUL products, which are rechargeable closed-system electronic cigarettes (e-cigarettes), are no longer available for sale. However, disposable closed-system products such as the flavored Puff Bar e-cigarette continues to be available. If e-cigarette consumers simply switch between products during the current government restrictions limited to 1 type of product over another, then such restrictions would be less effective. A step forward in this line of research is to understand how the public discusses these products by examining discourse referencing both Puff Bar and JUUL in the same conversation. Twitter data provide ample opportunity to capture such early trends that could be used to help public health researchers stay abreast of the rapidly changing e-cigarette marketplace. OBJECTIVE: The goal of this study was to examine public discourse referencing both Puff Bar and JUUL products in the same conversation on Twitter. METHODS: We collected data from Twitter's streaming application programming interface between July 16, 2019, and August 29, 2020, which included both "Puff Bar" and "JUUL" (n=2632). We then used an inductive approach to become familiar with the data and generate a codebook to identify common themes. Saturation was determined to be reached with 10 themes. RESULTS: Posts often mentioned flavors, dual use, design features, youth use, health risks, switching 1 product for the other, price, confusion over the differences between products, longevity of the products, and nicotine concentration. CONCLUSIONS: On examining the public's conversations about Puff Bar and JUUL products on Twitter, having described themes in posts, this study aimed to help the tobacco control community stay informed about 2 popular e-cigarette products with different device features, which can be potentially substituted for one another. Future health communication campaigns may consider targeting the health consequences of using multiple e-cigarette products or dual use to reduce exposure to high levels of nicotine among younger populations. CI - (c)Jon-Patrick Allem, Allison Dormanesh, Anuja Majmundar, Vanessa Rivera, Maya Chu, Jennifer B Unger, Tess Boley Cruz. Originally published in the Journal of Medical Internet Research (https://www.jmir.org), 19.07.2021. FAU - Allem, Jon-Patrick AU - Allem JP AUID- ORCID: 0000-0001-9135-8689 AD - Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States. FAU - Dormanesh, Allison AU - Dormanesh A AUID- ORCID: 0000-0001-9060-7356 AD - Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States. FAU - Majmundar, Anuja AU - Majmundar A AUID- ORCID: 0000-0002-7785-3357 AD - Department of Surveillance and Health Equity Science, American Cancer Society, Washington, DC, United States. FAU - Rivera, Vanessa AU - Rivera V AUID- ORCID: 0000-0002-5046-1185 AD - Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States. FAU - Chu, Maya AU - Chu M AUID- ORCID: 0000-0001-8674-6740 AD - Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States. FAU - Unger, Jennifer B AU - Unger JB AUID- ORCID: 0000-0001-9064-6603 AD - Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States. FAU - Cruz, Tess Boley AU - Cruz TB AUID- ORCID: 0000-0002-5894-1802 AD - Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States. LA - eng GR - U54 CA180905/CA/NCI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20210719 PL - Canada TA - J Med Internet Res JT - Journal of medical Internet research JID - 100959882 SB - IM MH - Adolescent MH - *Electronic Nicotine Delivery Systems MH - Humans MH - Public Health MH - *Social Media MH - *Tobacco Products MH - Tobacco Use PMC - PMC8329759 OTO - NOTNLM OT - JUUL OT - Puff Bar OT - Twitter OT - electronic cigarettes OT - infodemiology OT - public health OT - social media COIS- Conflicts of Interest: None declared. EDAT- 2021/07/20 06:00 MHDA- 2021/10/26 06:00 PMCR- 2021/07/19 CRDT- 2021/07/19 12:49 PHST- 2020/12/14 00:00 [received] PHST- 2021/06/14 00:00 [accepted] PHST- 2021/02/10 00:00 [revised] PHST- 2021/07/19 12:49 [entrez] PHST- 2021/07/20 06:00 [pubmed] PHST- 2021/10/26 06:00 [medline] PHST- 2021/07/19 00:00 [pmc-release] AID - v23i7e26510 [pii] AID - 10.2196/26510 [doi] PST - epublish SO - J Med Internet Res. 2021 Jul 19;23(7):e26510. doi: 10.2196/26510. PMID- 34277533 OWN - NLM STAT- MEDLINE DCOM- 20210721 LR - 20210721 IS - 2296-2565 (Electronic) IS - 2296-2565 (Linking) VI - 9 DP - 2021 TI - COVID-19, Alcohol Consumption and Stockpiling Practises in Midlife Women: Repeat Surveys During Lockdown in Australia and the United Kingdom. PG - 642950 LID - 10.3389/fpubh.2021.642950 [doi] LID - 642950 AB - Introduction: This project examined the impact of COVID-19 and associated restrictions on alcohol practises (consumption and stockpiling), and perceptions of health risk among women in midlife (those aged 45-64 years). Methods: We collected online survey data from 2,437 midlife women in the United Kingdom (UK) and Australia in May 2020, recruited using a commercial panel, in the early days of mandated COVID-19 related restrictions in both countries. Participants were surveyed again (N = 1,377) in July 2020, at a time when COVID-19 restrictions were beginning to ease. The surveys included the Alcohol Use Disorder Identification Test-Consumption (AUDIT-C) and questions alcohol stockpiling. Analysis involved a range of univariate and multivariate techniques examining the impact of demographic variables and negative affect on consumption and acquisition outcomes. Results: In both surveys (May and July), UK women scored higher than Australian women on the AUDIT-C, and residence in the UK was found to independently predict stockpiling of alcohol (RR: 1.51; 95% CI: 1.20, 1.91). Developing depression between surveys (RR: 1.53; 95% CI: 1.14, 2.04) and reporting pessimism (RR: 1.42; 95% CI: 1.11, 1.81), and fear/anxiety (RR: 1.33; 95% CI: 1.05, 1.70) at the beginning of the study period also predicted stockpiling by the end of the lockdown. Having a tertiary education was protective for alcohol stockpiling at each time point (RR: 0.69; 95% CI: 0.54, 0.87). Conclusions: COVID-19 was associated with increases in risky alcohol practises that were predicted by negative emotional responses to the pandemic. Anxiety, pessimism and depression predicted stockpiling behaviour in UK and Australian women despite the many demographic and contextual differences between the two cohorts. Given our findings and the findings of others that mental health issues developed or were exacerbated during lockdown and may continue long after that time, urgent action is required to address a potential future pandemic of alcohol-related harms. CI - Copyright (c) 2021 Miller, Olver, Wilson, Lunnay, Meyer, Foley, Thomas, Toson and Ward. FAU - Miller, Emma R AU - Miller ER AD - College of Medicine and Public Health, Flinders University, Adelaide, SA, Australia. FAU - Olver, Ian N AU - Olver IN AD - School of Psychology, The University of Adelaide, Adelaide, SA, Australia. FAU - Wilson, Carlene J AU - Wilson CJ AD - College of Medicine and Public Health, Flinders University, Adelaide, SA, Australia. AD - School of Psychology and Public Health, La Trobe University, Melbourne, VIC, Australia. AD - Olivia Newton-John Cancer Wellness and Research Centre, Austin Health, Melbourne, VIC, Australia. FAU - Lunnay, Belinda AU - Lunnay B AD - College of Medicine and Public Health, Flinders University, Adelaide, SA, Australia. FAU - Meyer, Samantha B AU - Meyer SB AD - School of Public Health and Health Systems, University of Waterloo, Ontario, ON, Canada. FAU - Foley, Kristen AU - Foley K AD - College of Medicine and Public Health, Flinders University, Adelaide, SA, Australia. FAU - Thomas, Jessica A AU - Thomas JA AD - College of Medicine and Public Health, Flinders University, Adelaide, SA, Australia. FAU - Toson, Barbara AU - Toson B AD - College of Medicine and Public Health, Flinders University, Adelaide, SA, Australia. FAU - Ward, Paul R AU - Ward PR AD - College of Medicine and Public Health, Flinders University, Adelaide, SA, Australia. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20210630 PL - Switzerland TA - Front Public Health JT - Frontiers in public health JID - 101616579 SB - IM MH - Alcohol Drinking/epidemiology MH - Australia/epidemiology MH - *COVID-19 MH - Communicable Disease Control MH - Cross-Sectional Studies MH - Female MH - Humans MH - SARS-CoV-2 MH - United Kingdom/epidemiology PMC - PMC8278199 OTO - NOTNLM OT - COVID-19 OT - alcohol OT - health perception OT - midlife women OT - survey COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2021/07/20 06:00 MHDA- 2021/07/22 06:00 PMCR- 2021/06/30 CRDT- 2021/07/19 06:00 PHST- 2020/12/17 00:00 [received] PHST- 2021/06/03 00:00 [accepted] PHST- 2021/07/19 06:00 [entrez] PHST- 2021/07/20 06:00 [pubmed] PHST- 2021/07/22 06:00 [medline] PHST- 2021/06/30 00:00 [pmc-release] AID - 10.3389/fpubh.2021.642950 [doi] PST - epublish SO - Front Public Health. 2021 Jun 30;9:642950. doi: 10.3389/fpubh.2021.642950. eCollection 2021. PMID- 34272224 OWN - NLM STAT- MEDLINE DCOM- 20210722 LR - 20260518 IS - 2044-6055 (Electronic) IS - 2044-6055 (Linking) VI - 11 IP - 7 DP - 2021 Jul 16 TI - COVID-19-related attitudes, risk perceptions, preventive behaviours and economic impact in sub-Saharan African countries: implementing a longitudinal phone-based survey protocol in rural Senegalese households. PG - e050090 LID - 10.1136/bmjopen-2021-050090 [doi] LID - e050090 AB - INTRODUCTION: Rural areas are considered safe havens against the increased spread of COVID-19 and associated restrictive measures, especially in contexts where public authorities are not in a position to systematically and substantially ease COVID-19-induced economic shocks. In the current sub-Saharan Africa context, still marked by uncertainty surrounding the spread of COVID-19, we present the protocol of an ongoing longitudinal study aimed at investigating COVID-19-related attitudes, risks perceptions, preventive behaviours and economic impact in rural areas in Senegal. METHODS AND ANALYSIS: A prospective randomised longitudinal study of 600 households located in three semiurban villages and nine randomly selected rural villages in the Niakhar area (located 135 km East of Dakar). Three ad hoc phone surveys are administered to 600 heads of households, their housewives in charge of managing the household and a relative living temporarily in the household, respectively. In addition to sharing identical sets of questions on several topics (risks perceptions, attitudes to curfew, attitudes to vaccines, beliefs about COVID-19 infection), the three separate survey questionnaires also include other topics (economic impact, local preventive strategies) whose related questions differ between questionnaires. As analysing evolutions is the study's primary focus, data on all the topics covered will be collected in three waves unless the spread of COVID-19 by mid-2021 justifies extending data collection. The present article presents the study protocol and details about the implementation of the first wave of data collection which started in July 2020. The decision to wait before presenting the protocol was based on the unprecedented context the COVID-19 pandemic. ETHICS AND DISSEMINATION: The survey's protocol was approved by the Senegalese National Ethical Committee for Research in Health (131/MSAS/CNERS/Sec) and received authorisation from both the Senegalese Ministry of Health (619/MSAS/DPRS/DR) and the French Commission on Information Technology and Liberties (CNIL 2220771). CI - (c) Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. FAU - Seror, Valerie AU - Seror V AUID- ORCID: 0000-0001-8002-435X AD - Aix Marseille Univ, IRD, AP-HM, SSA, VITROME, Marseille, France valerie.seror@inserm.fr. AD - IHU, Mediterranee Infection, Marseille, France. FAU - Maradan, Gwenaelle AU - Maradan G AD - ORS PACA, Southeastern Health Regional Observatory, Marseille, France. FAU - Ba, El-Hadj AU - Ba EH AD - VITROME, Campus Universitaire de l'IRD, Hann, Senegal. FAU - Cortaredona, Sebastien AU - Cortaredona S AD - Aix Marseille Univ, IRD, AP-HM, SSA, VITROME, Marseille, France. AD - IHU, Mediterranee Infection, Marseille, France. FAU - Berenger, Cyril AU - Berenger C AD - ORS PACA, Southeastern Health Regional Observatory, Marseille, France. FAU - L'Haridon, Olivier AU - L'Haridon O AD - Univ Rennes, CNRS, CREM UMR 6211, Rennes, France. AD - Faculty of Economics, University of Rennes 1, Rennes, France. FAU - Sokhna, Cheikh AU - Sokhna C AD - Aix Marseille Univ, IRD, AP-HM, SSA, VITROME, Marseille, France. AD - IHU, Mediterranee Infection, Marseille, France. AD - VITROME, Campus Universitaire de l'IRD, Hann, Senegal. CN - CO3ELSER group LA - eng PT - Clinical Trial Protocol PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20210716 PL - England TA - BMJ Open JT - BMJ open JID - 101552874 SB - IM MH - Africa South of the Sahara MH - Attitude MH - *COVID-19 MH - Humans MH - Longitudinal Studies MH - Pandemics MH - Perception MH - Prospective Studies MH - Randomized Controlled Trials as Topic MH - SARS-CoV-2 MH - Senegal PMC - PMC8288240 OTO - NOTNLM OT - COVID-19 OT - health economics OT - public health OT - tropical medicine COIS- Competing interests: None declared. FIR - Ba, Elhadji IR - Ba E FIR - Ndiaye, Assane IR - Ndiaye A FIR - Sokhna, Cheikh IR - Sokhna C FIR - Berenger, Cyril IR - Berenger C FIR - Maradan, Gwenaelle IR - Maradan G FIR - Seror, Valerie IR - Seror V FIR - Cortaredona, Sebastien IR - Cortaredona S FIR - Peretti-Watel, Patrick IR - Peretti-Watel P FIR - L'Haridon, Olivier IR - L'Haridon O FIR - Raude, Jocelyn IR - Raude J EDAT- 2021/07/18 06:00 MHDA- 2021/07/23 06:00 PMCR- 2021/07/16 CRDT- 2021/07/17 05:43 PHST- 2021/07/17 05:43 [entrez] PHST- 2021/07/18 06:00 [pubmed] PHST- 2021/07/23 06:00 [medline] PHST- 2021/07/16 00:00 [pmc-release] AID - bmjopen-2021-050090 [pii] AID - 10.1136/bmjopen-2021-050090 [doi] PST - epublish SO - BMJ Open. 2021 Jul 16;11(7):e050090. doi: 10.1136/bmjopen-2021-050090. PMID- 34271458 OWN - NLM STAT- MEDLINE DCOM- 20210818 LR - 20260815 IS - 1879-1379 (Electronic) IS - 0022-3956 (Print) IS - 0022-3956 (Linking) VI - 141 DP - 2021 Sep TI - Facing the "new normal": How adjusting to the easing of COVID-19 lockdown restrictions exposes mental health inequalities. PG - 276-286 LID - S0022-3956(21)00420-9 [pii] LID - 10.1016/j.jpsychires.2021.07.001 [doi] AB - BACKGROUND: Re-establishing societal norms in the wake of the COVID-19 pandemic will be important for restoring public mental health and psychosocial wellbeing as well as economic recovery. We investigated the impact on post-pandemic adjustment of a history of mental disorder, with particular reference to obsessive-compulsive (OC) symptoms or traits. METHODS: The study was pre-registered (Open Science Framework; https://osf.io/gs8j2/). Adult members of the public (n = 514) were surveyed between July and November 2020, to identify the extent to which they reported difficulties re-adjusting as lockdown conditions eased. All were assessed using validated scales to determine which demographic and mental health-related factors impacted adjustment. An exploratory analysis of a subgroup on an objective online test of cognitive inflexibility was also performed. RESULTS: Adjustment was related to a history of mental disorder and the presence of OC symptoms and traits, all acting indirectly and statistically-mediated via depression, anxiety and stress; and in the case of OC symptoms, also via COVID-related anxiety (all p < 0.001). One hundred and twenty-eight (25%) participants reported significant adjustment difficulties and were compared with those self-identifying as "good adjusters" (n = 231). This comparison revealed over-representation of those with a history or family history of mental disorder in the poor adjustment category (all p < 0.05). 'Poor-adjusters' additionally reported higher COVID-related anxiety, depression, anxiety and stress and OC symptoms and traits (all p < 0.05). Furthermore, history of mental disorder directly statistically mediated adjustment status (p < 0.01), whereas OC symptoms (not OC traits) acted indirectly via COVID-related anxiety (p < 0.001). Poor-adjusters also showed evidence of greater cognitive inflexibility on the intra-extra-dimensional set-shift task. CONCLUSION: Individuals with a history of mental disorder, OC symptoms and OC traits experienced greater difficulties adjusting after lockdown-release, largely statistically mediated by increased depression, anxiety, including COVID-related anxiety, and stress. The implications for clinical and public health policies and interventions are discussed. CI - Copyright (c) 2021 Elsevier Ltd. All rights reserved. FAU - Fineberg, Naomi A AU - Fineberg NA AD - School of Life and Medical Sciences, University of Hertfordshire, Hatfield, United Kingdom; Hertfordshire Partnership University NHS Foundation Trust, Welwyn Garden City, United Kingdom; University of Cambridge School of Clinical Medicine, Cambridge, United Kingdom. FAU - Pellegrini, Luca AU - Pellegrini L AD - School of Life and Medical Sciences, University of Hertfordshire, Hatfield, United Kingdom; Hertfordshire Partnership University NHS Foundation Trust, Welwyn Garden City, United Kingdom; Department of Biomedical and Neuromotor Sciences, University of Bologna, Italy. Electronic address: luca.pellegrini@nhs.net. FAU - Wellsted, David AU - Wellsted D AD - School of Life and Medical Sciences, University of Hertfordshire, Hatfield, United Kingdom. FAU - Hall, Natalie AU - Hall N AD - School of Life and Medical Sciences, University of Hertfordshire, Hatfield, United Kingdom. FAU - Corazza, Ornella AU - Corazza O AD - School of Life and Medical Sciences, University of Hertfordshire, Hatfield, United Kingdom. FAU - Giorgetti, Valentina AU - Giorgetti V AD - School of Life and Medical Sciences, University of Hertfordshire, Hatfield, United Kingdom. FAU - Cicconcelli, Dorotea AU - Cicconcelli D AD - School of Life and Medical Sciences, University of Hertfordshire, Hatfield, United Kingdom. FAU - Theofanous, Elena AU - Theofanous E AD - School of Life and Medical Sciences, University of Hertfordshire, Hatfield, United Kingdom. FAU - Sireau, Nick AU - Sireau N AD - School of Life and Medical Sciences, University of Hertfordshire, Hatfield, United Kingdom. FAU - Adam, David AU - Adam D AD - School of Life and Medical Sciences, University of Hertfordshire, Hatfield, United Kingdom. FAU - Chamberlain, Samuel R AU - Chamberlain SR AD - University of Southampton, Department of Psychiatry, Faculty of Medicine, Southampton, United Kingdom; Southern Health NHS Foundation Trust, Southampton, United Kingdom. FAU - Laws, Keith R AU - Laws KR AD - School of Life and Medical Sciences, University of Hertfordshire, Hatfield, United Kingdom. LA - eng GR - 110049/WT_/Wellcome Trust/United Kingdom PT - Journal Article DEP - 20210706 PL - England TA - J Psychiatr Res JT - Journal of psychiatric research JID - 0376331 SB - IM MH - Adult MH - Anxiety/epidemiology MH - *COVID-19 MH - Communicable Disease Control MH - Depression/epidemiology MH - Health Status Disparities MH - Humans MH - *Mental Health MH - Pandemics MH - SARS-CoV-2 PMC - PMC7611491 MID - EMS132031 OTO - NOTNLM OT - COVID-19 OT - Cognitive inflexibility OT - Lockdown release OT - Mental-health OT - Obsessive-compulsive OT - Pandemic COIS- Prof. Naomi A. Fineberg declares that in the past 3 years she has held research or networking grants from the ECNP, UK NIHR, EU H2020, MRC, University of Hertfordshire, Wellcome Trust; she has accepted travel and/or hospitality expenses from the BAP, ECNP, RCPsych, CINP, International Forum of Mood and Anxiety Disorders, World Psychiatric Association, Indian Association for Biological Psychiatry, Sun; she has received payment from Taylor and Francis and Elsevier for editorial duties. In the past 3 years, she has accepted a paid speaking engagement in a webinar sponsored by Abbott. Previously, she has accepted paid speaking engagements in various industry supported symposia and has recruited patients for various industry-sponsored studies in the field of OCD treatment. She leads an NHS treatment service for OCD. She holds Board membership for various registered charities linked to OCD. She gives expert advice on psychopharmacology to the UK MHRA. Prof. Samuel R. Chamberlain declares that his role in this research was funded by a Wellcome Trust Clinical Fellowship (110049/Z/15/Z & 110049/Z/15/A). Prof. Chamberlain previously consulted for Promentis (past 3 years) and receives a stipend from Elsevier for editorial work. Dr. Luca Pellegrini, Dr. David Wellsted, Natalie Hall, Prof. Ornella Corazza, Valentina Giorgetti, Dorotea Cicconcelli, Elena Theofanous, Nick Sireau, David Adam, Prof. Keith R. Laws report no financial relationships with commercial interests. EDAT- 2021/07/17 06:00 MHDA- 2021/08/19 06:00 PMCR- 2021/07/06 CRDT- 2021/07/16 20:31 PHST- 2021/04/02 00:00 [received] PHST- 2021/06/24 00:00 [revised] PHST- 2021/07/04 00:00 [accepted] PHST- 2021/07/17 06:00 [pubmed] PHST- 2021/08/19 06:00 [medline] PHST- 2021/07/16 20:31 [entrez] PHST- 2021/07/06 00:00 [pmc-release] AID - S0022-3956(21)00420-9 [pii] AID - 10.1016/j.jpsychires.2021.07.001 [doi] PST - ppublish SO - J Psychiatr Res. 2021 Sep;141:276-286. doi: 10.1016/j.jpsychires.2021.07.001. Epub 2021 Jul 6. PMID- 34264164 OWN - NLM STAT- MEDLINE DCOM- 20210722 LR - 20210722 IS - 1727-9445 (Electronic) IS - 1608-5906 (Linking) VI - 20 IP - 2 DP - 2021 Jul TI - Integration of family planning services into HIV services in Nigeria: Evidence from the Performance Monitoring and Accountability 2020 survey in seven states. PG - 181-188 LID - 10.2989/16085906.2021.1925312 [doi] AB - Despite global calls for stronger linkages between family planning and HIV, a growing body of evidence in sub-Saharan Africa suggests that the integration of family planning and HIV service delivery is suboptimal in some countries. In this study, we assess the integration and quality of family planning services in health facilities that provide HIV-related services in Nigeria. This study analysed secondary data from the Performance Monitoring and Accountability 2020 cross-sectional survey conducted between May and July 2016 in seven states in Nigeria. Our study sample was restricted to 290 health facilities providing HIV services. We performed descriptive statistics and binary logistic regression analyses. Ninety-five per cent of the health facilities reported offering family planning counselling, provision of family planning methods, and/or referral for family planning methods to clients accessing HIV services. About 84% of these health facilities with integrated family planning and HIV services reported that they discussed the preferred method, dual methods, instructions and side effects of the chosen method, and the reproductive intentions with clients during an HIV consultation. None of the health facilities' characteristics was significantly associated with the integration of family planning services into HIV services. Private health facilities (aOR 0.3, 95% CI 0.07-0.92), urban health facilities (aOR 3.8, 95% CI 1.64-8.76), and provision of postnatal care (aOR 3.9, 95% CI 1.10-13.74) were statistically associated with the quality of family planning services provided to clients accessing HIV services. Family planning services were integrated into HIV services in a majority of the health facilities in our study. However, our findings indicate the need for improvement in the quality of family planning services provided to clients accessing HIV services. FAU - Olakunde, Babayemi O AU - Olakunde BO AUID- ORCID: 0000-0002-0864-6901 AD - Department of Community Prevention and Care Services, National Agency for the Control of AIDS, Abuja, Nigeria. AD - Center for Translation and Implementation Research, University of Nigeria Nsukka, Enugu, Nigeria. FAU - Adeyinka, Daniel A AU - Adeyinka DA AUID- ORCID: 0000-0003-1855-6878 AD - Department of Public Health, National AIDS and STI Control Programme, Federal Ministry of Health, Abuja, Nigeria. AD - Department of Community Health and Epidemiology, University of Saskatchewan, Saskatoon, Canada. FAU - OlaOlorun, Funmilola M AU - OlaOlorun FM AUID- ORCID: 0000-0001-5544-2875 AD - Department of Community Medicine, College of Medicine, University of Ibadan, Ibadan, Nigeria. FAU - Oladele, Tolulope T AU - Oladele TT AUID- ORCID: 0000-0002-8149-3585 AD - Department of Community Prevention and Care Services, National Agency for the Control of AIDS, Abuja, Nigeria. FAU - Yahaya, Hidayat AU - Yahaya H AD - Department of Community Prevention and Care Services, National Agency for the Control of AIDS, Abuja, Nigeria. FAU - Ndukwe, Chinwendu D AU - Ndukwe CD AD - Department of Community Prevention and Care Services, National Agency for the Control of AIDS, Abuja, Nigeria. LA - eng PT - Journal Article PL - South Africa TA - Afr J AIDS Res JT - African journal of AIDS research : AJAR JID - 101146510 SB - IM MH - Cross-Sectional Studies MH - Delivery of Health Care, Integrated/methods/*statistics & numerical data MH - Family Planning Services/methods/*statistics & numerical data MH - HIV Infections/epidemiology/*therapy MH - Health Care Surveys/*statistics & numerical data MH - Health Facilities/statistics & numerical data MH - Humans MH - Nigeria/epidemiology MH - Referral and Consultation/statistics & numerical data MH - Sex Education/statistics & numerical data OTO - NOTNLM OT - HIV OT - contraception OT - linkage EDAT- 2021/07/16 06:00 MHDA- 2021/07/23 06:00 CRDT- 2021/07/15 12:13 PHST- 2021/07/15 12:13 [entrez] PHST- 2021/07/16 06:00 [pubmed] PHST- 2021/07/23 06:00 [medline] AID - 10.2989/16085906.2021.1925312 [doi] PST - ppublish SO - Afr J AIDS Res. 2021 Jul;20(2):181-188. doi: 10.2989/16085906.2021.1925312. PMID- 34263056 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20210716 IS - 2382-1205 (Print) IS - 2382-1205 (Electronic) IS - 2382-1205 (Linking) VI - 8 DP - 2021 Jan-Dec TI - Lessons Learnt from the COVID-19 Pandemic: Starting Residency in a Foster Institution. PG - 23821205211024055 LID - 10.1177/23821205211024055 [doi] LID - 23821205211024055 AB - In Singapore, the Ministry of Health (MOH) raised the public health response level from DORSCON (Disease Outbreak Response System Condition) 'Yellow' to 'Orange' on 7 February 2020. This instituted strict movement restrictions for all healthcare workers to minimise cross-institutional transmission of COVID-19, creating a unique scenario where many residents physically located in different healthcare institutions at the start of DORSCON Orange were unable to return to their matched Sponsoring Institutions (SIs) to begin residency training in July 2020. Residents faced multiple administrative and emotional challenges as a result of freezing of cross-institutional movement. These challenges included concerns with regards to meeting training requirements (due to different modes of assessment, and posting structures between the 3 SIs) and concerns with regards to emotional support (due to starting residency in an unfamiliar environment where the resident may have less pre-existing connections/support). These challenges were swiftly addressed by the strong support of foster and parent institutions, and close communication between the leadership of the 3 SIs. Lessons learnt from the current pandemic include the need for a common online platform across the 3 SIs with regards to assessment forms, importance of sharing teaching materials between the different SIs and the need for close collaboration between parent and foster SIs with regards to balancing training requirements versus the needs posed by a pandemic situation on the healthcare structure. CI - (c) The Author(s) 2021. FAU - Tan, Jiekai AU - Tan J AUID- ORCID: 0000-0001-5646-9076 AD - National Healthcare Group Residency, Singapore, Singapore. FAU - Wee, Lin AU - Wee L AD - National Healthcare Group Residency, Singapore, Singapore. FAU - Li-Ann Chia, Faith AU - Li-Ann Chia F AD - National Healthcare Group Residency, Singapore, Singapore. AD - Department of Rheumatology, Allergy and Immunology, Tan Tock Seng Hospital, Singapore, Singapore. FAU - Khoon Ng, Wee AU - Khoon Ng W AUID- ORCID: 0000-0001-6278-4419 AD - National Healthcare Group Residency, Singapore, Singapore. AD - Department of Gastroenterology and Hepatology, Tan Tock Seng Hospital, Singapore, Singapore. LA - eng PT - Journal Article DEP - 20210628 PL - United States TA - J Med Educ Curric Dev JT - Journal of medical education and curricular development JID - 101690298 PMC - PMC8243090 OTO - NOTNLM OT - Coronavirus OT - Singapore OT - education OT - graduate OT - internship and residency OT - medical OT - public health COIS- Declaration of conflicting interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. EDAT- 2021/07/16 06:00 MHDA- 2021/07/16 06:01 PMCR- 2021/06/28 CRDT- 2021/07/15 06:25 PHST- 2020/12/26 00:00 [received] PHST- 2021/05/11 00:00 [accepted] PHST- 2021/07/15 06:25 [entrez] PHST- 2021/07/16 06:00 [pubmed] PHST- 2021/07/16 06:01 [medline] PHST- 2021/06/28 00:00 [pmc-release] AID - 10.1177_23821205211024055 [pii] AID - 10.1177/23821205211024055 [doi] PST - epublish SO - J Med Educ Curric Dev. 2021 Jun 28;8:23821205211024055. doi: 10.1177/23821205211024055. eCollection 2021 Jan-Dec. PMID- 34259640 OWN - NLM STAT- MEDLINE DCOM- 20211025 LR - 20261016 IS - 1438-8871 (Electronic) IS - 1439-4456 (Print) IS - 1438-8871 (Linking) VI - 23 IP - 7 DP - 2021 Jul 14 TI - Acceptability of an mHealth App That Provides Harm Reduction Services Among People Who Inject Drugs: Survey Study. PG - e25428 LID - 10.2196/25428 [doi] LID - e25428 AB - BACKGROUND: Harm reduction services reduce the negative consequences of drug injection and are often embedded within syringe service programs (SSPs). However, people who inject drugs (PWID) suboptimally engage with such services because of stigma, fear, transportation restrictions, and limited hours of operation. Mobile health (mHealth) apps may provide an opportunity to overcome these barriers and extend the reach of SSPs beyond that of the traditional brick-and-mortar models. OBJECTIVE: This study aims to assess the prevalence of smartphone ownership, the level of comfort in providing the personal information required to use mHealth apps, and interest in using an mHealth app to access harm reduction services among PWID to guide the development of an app. METHODS: We administered a survey to 115 PWID who were enrolled via respondent-driven sampling from July 2018 to July 2019. We examined the extent to which PWID had access to smartphones; were comfortable in providing personal information such as name, email, and address; and expressed interest in various app-based services. We measured participant characteristics (demographics, health status, and behaviors) and used binary logistic and Poisson regressions to identify independent correlates of mHealth-related variables. The primary regression outcomes included summary scores for access, comfort, and interest. The secondary outcomes included binary survey responses for individual comfort or interest components. RESULTS: Most participants were White (74/105, 70.5%), male (78/115, 67.8%), and middle-aged (mean=41.7 years), and 67.9% (74/109) owned a smartphone. Participants reported high levels of comfort in providing personal information to use an mHealth app, including name (96/109, 88.1%), phone number (92/109, 84.4%), email (85/109, 77.9%), physical address (85/109, 77.9%), and linkage to medical records (72/109, 66.1%). Participants also reported strong interest in app-based services, including medication or sterile syringe delivery (100/110, 90.9%), lab or appointment scheduling (90/110, 81.8%), medication reminders (77/110, 70%), educational material (65/110, 59.1%), and group communication forums (64/110, 58.2%). Most participants were comfortable with the idea of home delivery of syringes (93/109, 85.3%). Homeless participants had lower access to smartphones (adjusted odds ratio [AOR] 0.15, 95% CI 0.05-0.46; P=.001), but no other participant characteristics were associated with primary outcomes. Among secondary outcomes, recent SSP use was positively associated with comfort with the home delivery of syringes (AOR 3.29, 95% CI 1.04-10.3 P=.04), and being older than 50 years was associated with an increased interest in educational materials (AOR 4.64, 95% CI 1.31-16.5; P=.02) and group communication forums (AOR 3.69, 95% CI 1.10-12.4; P=.04). CONCLUSIONS: Our findings suggest that aside from those experiencing homelessness or unstable housing, PWID broadly have access to smartphones, are comfortable with sharing personal information, and express interest in a wide array of services within an app. Given the suboptimal access to and use of SSPs among PWID, an mHealth app has a high potential to address the harm reduction needs of this vulnerable population. CI - (c)Tyler Shelby, Xin Zhou, Douglas Barber, Frederick Altice. Originally published in the Journal of Medical Internet Research (https://www.jmir.org), 14.07.2021. FAU - Shelby, Tyler AU - Shelby T AUID- ORCID: 0000-0003-0581-4399 AD - Yale University School of Medicine, New Haven, CT, United States. AD - Department of Epidemiology of Microbial Diseases, Yale University School of Public Health, New Haven, CT, United States. FAU - Zhou, Xin AU - Zhou X AUID- ORCID: 0000-0003-2852-1468 AD - Section of Infectious Diseases, Yale University School of Medicine, New Haven, CT, United States. FAU - Barber, Douglas AU - Barber D AUID- ORCID: 0000-0001-6830-2484 AD - Yale University School of Medicine, New Haven, CT, United States. FAU - Altice, Frederick AU - Altice F AUID- ORCID: 0000-0002-7860-693X AD - Department of Epidemiology of Microbial Diseases, Yale University School of Public Health, New Haven, CT, United States. AD - Section of Infectious Diseases, Yale University School of Medicine, New Haven, CT, United States. AD - Centre of Excellence on Research on AIDS, University of Malaya, Kuala Lumpur, Malaysia. LA - eng GR - R01 DA033679/DA/NIDA NIH HHS/United States GR - R21 DA039842/DA/NIDA NIH HHS/United States GR - UL1 TR001863/TR/NCATS NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20210714 PL - Canada TA - J Med Internet Res JT - Journal of medical Internet research JID - 100959882 RN - 0 (Pharmaceutical Preparations) SB - IM MH - *HIV Infections MH - Harm Reduction MH - Humans MH - Male MH - Middle Aged MH - *Mobile Applications MH - *Pharmaceutical Preparations MH - *Substance Abuse, Intravenous MH - Surveys and Questionnaires MH - *Telemedicine PMC - PMC8319773 OTO - NOTNLM OT - mHealth OT - mobile phone OT - patient preferences OT - people who inject drugs OT - service access OT - syringe services programs COIS- Conflicts of Interest: None declared. EDAT- 2021/07/15 06:00 MHDA- 2021/10/26 06:00 PMCR- 2021/07/14 CRDT- 2021/07/14 12:19 PHST- 2020/11/01 00:00 [received] PHST- 2021/05/24 00:00 [accepted] PHST- 2021/01/27 00:00 [revised] PHST- 2021/07/14 12:19 [entrez] PHST- 2021/07/15 06:00 [pubmed] PHST- 2021/10/26 06:00 [medline] PHST- 2021/07/14 00:00 [pmc-release] AID - v23i7e25428 [pii] AID - 10.2196/25428 [doi] PST - epublish SO - J Med Internet Res. 2021 Jul 14;23(7):e25428. doi: 10.2196/25428. PMID- 34246949 OWN - NLM STAT- MEDLINE DCOM- 20210810 LR - 20221217 IS - 1573-2517 (Electronic) IS - 0165-0327 (Print) IS - 0165-0327 (Linking) VI - 293 DP - 2021 Oct 1 TI - Quantifying the mental health burden of the most severe covid-19 restrictions: A natural experiment. PG - 406-414 LID - S0165-0327(21)00646-7 [pii] LID - 10.1016/j.jad.2021.06.060 [doi] AB - BACKGROUND: The COVID-19 pandemic, and the restrictions required to halt spread of the infection, are associated with increased population burden of moderate to severe symptoms of depression and anxiety. The aim was to quantify the mental health burden of the most severe COVID-19 related restrictions. METHODS: A natural experiment in which differences between Australian states and territories in the severity of restrictions for pandemic control, divided the population. People in Victoria experienced the most severe, and people in all other states and territories less severe or negligible restrictions. Data were collected in national, anonymously completed, online surveys (in April and in July / August 2020) of adults in Australia. Outcomes were, in the previous fortnight, experiencing clinically significant depressive symptoms (Patient Health Questionnaire 9 score >/=10); or symptoms of generalised anxiety (Generalised Anxiety Disorder Scale 7 score >/=10). RESULTS: In total, 23,749 eligible respondents contributed complete data. There were no differences in the population burden of mental health problems between Victoria and the other states and territories at Survey One. By Survey Two prevalence rates of clinically significant depressive (Adjusted Odds Ratio (aOR) 1.96; 95% CI 1.62; 2.37) and anxiety (aOR 1.87; 95%CI 1.53; 2.29) symptoms were substantially and significantly higher in Victoria than in other states and territories. LIMITATIONS: Online surveys are less accessible to some groups of people. The data are self-report and not diagnostic. CONCLUSIONS: The most severe COVID-19 restrictions are associated with near double the population prevalence of moderate to severe depressive and generalised anxiety symptoms. CI - Copyright (c) 2021. Published by Elsevier B.V. FAU - Fisher, Jane AU - Fisher J AD - School of Public Health and Preventive Medicine, Monash University. Electronic address: jane.fisher@monash.edu. FAU - Tran, Thach AU - Tran T AD - School of Public Health and Preventive Medicine, Monash University. FAU - Hammarberg, Karin AU - Hammarberg K AD - School of Public Health and Preventive Medicine, Monash University. FAU - Nguyen, Hau AU - Nguyen H AD - School of Public Health and Preventive Medicine, Monash University. FAU - Stocker, Ruby AU - Stocker R AD - School of Public Health and Preventive Medicine, Monash University. FAU - Rowe, Heather AU - Rowe H AD - School of Public Health and Preventive Medicine, Monash University. FAU - Sastri, Jayagowri AU - Sastri J AD - School of Public Health and Preventive Medicine, Monash University. FAU - Popplestone, Sally AU - Popplestone S AD - School of Public Health and Preventive Medicine, Monash University. FAU - Kirkman, Maggie AU - Kirkman M AD - School of Public Health and Preventive Medicine, Monash University. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20210702 PL - Netherlands TA - J Affect Disord JT - Journal of affective disorders JID - 7906073 SB - IM MH - Adult MH - Anxiety/epidemiology MH - *COVID-19 MH - Cross-Sectional Studies MH - Depression MH - Humans MH - Mental Health MH - *Pandemics MH - SARS-CoV-2 MH - Victoria/epidemiology PMC - PMC8264352 OTO - NOTNLM OT - Mental health OT - Population burden OT - Severe COVID-19 restrictions COIS- All authors declare that they have no conflicts of interest. EDAT- 2021/07/12 06:00 MHDA- 2021/08/11 06:00 PMCR- 2021/07/02 CRDT- 2021/07/11 20:46 PHST- 2021/01/26 00:00 [received] PHST- 2021/06/21 00:00 [revised] PHST- 2021/06/27 00:00 [accepted] PHST- 2021/07/12 06:00 [pubmed] PHST- 2021/08/11 06:00 [medline] PHST- 2021/07/11 20:46 [entrez] PHST- 2021/07/02 00:00 [pmc-release] AID - S0165-0327(21)00646-7 [pii] AID - 10.1016/j.jad.2021.06.060 [doi] PST - ppublish SO - J Affect Disord. 2021 Oct 1;293:406-414. doi: 10.1016/j.jad.2021.06.060. Epub 2021 Jul 2. PMID- 34244286 OWN - NLM STAT- MEDLINE DCOM- 20210714 LR - 20240812 IS - 2044-6055 (Electronic) IS - 2044-6055 (Linking) VI - 11 IP - 7 DP - 2021 Jul 9 TI - Clinical efficacy and security of glycyrrhizic acid preparation in the treatment of anti-SARS-CoV-2 drug-induced liver injury: a protocol of systematic review and meta-analysis. PG - e051484 LID - 10.1136/bmjopen-2021-051484 [doi] LID - e051484 AB - INTRODUCTION: COVID-19 is a highly infectious acute pneumonia. Glycyrrhizic acid preparation (GAP) has been found to have hepatoprotective and antiviral effects, but there is no supporting evidence on its efficacy and security for patients with COVID-19. METHODS AND ANALYSIS: The systematic review methods will be defined by Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. This study will start on 1 July 2021 and end on 31 October 2021. A comprehensive electronic search will be conducted with the search of Web of Science, PubMed, Ovid web, China National Knowledge Infrastructure, Chinese Scientific and Journal Database, Wanfang Database and grey literature, and manual search will be conducted to search literature of randomised controlled trials, single-arm trials and retrospective studies about GAP in the treatment of anti-SARS-CoV-2 drug-induced liver injury from 1 December 2019 to 1 July 2021. There is no time limitations of publication and language will be restricted to Chinese and English. Retrieved studies will be independently screened by two researchers and relevant data will be extracted from studies. Interstudy heterogeneity will be assessed using the I(2) statistic and explored through meta-regressions and subgroup analyses. Depending on data availability, we plan to conduct subgroup analyses by study population, geographical region and other selected clinical variables of interest. Quality assessment of the studies will be performed. Cochrane Handbook for Systematic Reviews of Interventions will be used to assess the risk of bias, and Grading of Recommendations Assessment, Development and Evaluation will be used to access the confidence in cumulative evidence. ETHICS AND DISSEMINATION: Ethical approval will not be required for no primary data of individual patients will be collected. The final report will be shared with the scientific community through publication in a peer-reviewed journal, as well as with key stakeholders, including patients, healthcare professionals and those working on COVID-19 research. PROSPERO REGISTRATION NUMBER: CRD42021234647. CI - (c) Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. FAU - Tian, Xia AU - Tian X AUID- ORCID: 0000-0002-4845-3602 AD - Department of Respiratory Medicine, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, People's Republic of China. FAU - Gan, Wenfan AU - Gan W AD - Department of Respiratory Medicine, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, People's Republic of China. FAU - Nie, Yisen AU - Nie Y AD - Department of Respiratory Medicine, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, People's Republic of China. FAU - Ying, Rongtao AU - Ying R AD - Department of Respiratory Medicine, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, People's Republic of China. FAU - Tan, Yongji AU - Tan Y AD - College of Clinical Medicine, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, People's Republic of China. FAU - Chen, Junli AU - Chen J AD - College of Clinical Medicine, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, People's Republic of China. FAU - Chen, Mei AU - Chen M AD - Department of Respiratory Medicine, Chengdu Fifth People's Hospital, Chengdu, People's Republic of China. FAU - Zhang, Chuantao AU - Zhang C AD - Department of Respiratory Medicine, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, People's Republic of China zhangchuantao@cdutcm.edu.cn. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20210709 PL - England TA - BMJ Open JT - BMJ open JID - 101552874 RN - 6FO62043WK (Glycyrrhizic Acid) SB - IM MH - *COVID-19 MH - *Chemical and Drug Induced Liver Injury/drug therapy/etiology MH - China MH - Glycyrrhizic Acid MH - Humans MH - Meta-Analysis as Topic MH - Research Design MH - Retrospective Studies MH - SARS-CoV-2 MH - Systematic Reviews as Topic MH - Treatment Outcome PMC - PMC8275357 OTO - NOTNLM OT - COVID-19 OT - infectious diseases & infestations OT - protocols & guidelines OT - public health COIS- Competing interests: None declared. EDAT- 2021/07/11 06:00 MHDA- 2021/07/15 06:00 PMCR- 2021/07/09 CRDT- 2021/07/10 05:40 PHST- 2021/07/10 05:40 [entrez] PHST- 2021/07/11 06:00 [pubmed] PHST- 2021/07/15 06:00 [medline] PHST- 2021/07/09 00:00 [pmc-release] AID - bmjopen-2021-051484 [pii] AID - 10.1136/bmjopen-2021-051484 [doi] PST - epublish SO - BMJ Open. 2021 Jul 9;11(7):e051484. doi: 10.1136/bmjopen-2021-051484. PMID- 34242268 OWN - NLM STAT- MEDLINE DCOM- 20210719 LR - 20210722 IS - 1932-6203 (Electronic) IS - 1932-6203 (Linking) VI - 16 IP - 7 DP - 2021 TI - Regional variation in COVID-19 positive hospitalisation across Scotland during the first wave of the pandemic and its relation to population density: A cross-sectional observation study. PG - e0253636 LID - 10.1371/journal.pone.0253636 [doi] LID - e0253636 AB - BACKGROUND: There have been large regional differences in COVID-19 virus activity across the UK with many commentators suggesting that these are related to age, ethnicity and social class. There has also been a focus on cases, hospitalisations and deaths rather than on hospitalisation rates expressed per 100,000 population. The purpose of our study was to examine regional variation in COVID-19 positive hospitalisation rates in Scotland during the first wave of the pandemic and the possibility that these might be related to population density. METHODS AND FINDINGS: This was a repeated point prevalence study. The number of COVID-19 positive patients hospitalised in the eleven Scottish mainland health boards peaked at 1517 on 19th April, then fell to a low of 243 on 16th August before rising slightly to 262 on 15th September. In July, August and September only four boards had more than 5 hospitalised patients. There was a statistically significant relationship between hospitalisation rates and population density on 97.7% of individual days during the first wave of the pandemic (Pearson's r 0.62-0.93, with 123 of a possible 174 days having p values <0.001). Multiple linear regression analyses performed on data from the 11 mainland boards across six time points suggest that population density accounted for 70.2% of the variation in hospitalisation rate in April, 72.3% in May, 81.2% in June, 91.0% in July, 91.0% in August, and 88.1% in September. Neither population median age nor median social deprivation score at health board level were statistically significant in the final model for hospitalisation. CONCLUSION: There were large differences in crude COVID-19 hospitalisation rates across the 11 mainland Scottish health boards, that were significantly related to population density. Given that lockdown was originally introduced to prevent the NHS from being overwhelmed, we believe our results support a regional rather than a national approach to lifting or reimposing more restrictive measures, and that hospitalisation rates should be part of the decision making process. FAU - Rideout, Andrew AU - Rideout A AD - Department of Public Health, Dumfries and Galloway Royal Infirmary, Dumfries, Scotland. FAU - Murray, Calum AU - Murray C AD - Education Centre, Dumfries and Galloway Royal Infirmary, Dumfries, Scotland. FAU - Isles, Chris AU - Isles C AUID- ORCID: 0000-0001-7830-7561 AD - Medical Unit, Dumfries and Galloway Royal Infirmary, Dumfries, Scotland. LA - eng PT - Journal Article PT - Observational Study DEP - 20210709 PL - United States TA - PLoS One JT - PloS one JID - 101285081 SB - IM MH - Adult MH - COVID-19/*epidemiology/*therapy/*transmission MH - Cross-Sectional Studies MH - Female MH - *Hospitalization MH - Humans MH - Male MH - Middle Aged MH - *Pandemics MH - Population Density MH - *SARS-CoV-2 MH - Scotland/epidemiology PMC - PMC8270435 COIS- The authors have declared that no competing interests exist. EDAT- 2021/07/10 06:00 MHDA- 2021/07/20 06:00 PMCR- 2021/07/09 CRDT- 2021/07/09 17:22 PHST- 2021/03/07 00:00 [received] PHST- 2021/06/10 00:00 [accepted] PHST- 2021/07/09 17:22 [entrez] PHST- 2021/07/10 06:00 [pubmed] PHST- 2021/07/20 06:00 [medline] PHST- 2021/07/09 00:00 [pmc-release] AID - PONE-D-20-38210 [pii] AID - 10.1371/journal.pone.0253636 [doi] PST - epublish SO - PLoS One. 2021 Jul 9;16(7):e0253636. doi: 10.1371/journal.pone.0253636. eCollection 2021. PMID- 34233987 OWN - NLM STAT- MEDLINE DCOM- 20210804 LR - 20260127 IS - 2044-6055 (Electronic) IS - 2044-6055 (Linking) VI - 11 IP - 7 DP - 2021 Jul 7 TI - Is there a correlation between children's outdoor active mobility behaviour and neighbourhood safety? A systematic review of the evidence. PG - e047062 LID - 10.1136/bmjopen-2020-047062 [doi] LID - e047062 AB - OBJECTIVE: To identify, summarise and evaluate evidence on the correlation between perceived and actual neighbourhood safety (personal and road danger) and diverse forms of outdoor active mobility behaviour (ie, active play, exercise, and travel) among primary-school-aged children. DESIGN: A systematic review of evidence from observational studies exploring children's active mobility behaviour and safety. DATA SOURCES: Six electronic databases were searched: Google Scholar, PubMed, Scopus, Science Direct, ProQuest and Web of Science from study inception until July 2020. DATA EXTRACTION AND SYNTHESIS: Study selection and quality assessment were conducted independently by two reviewers. We expanded on a quality assessment tool and adopted a vote-counting technique to determine strength of evidence. The outcomes were categorised by individual, family and neighbourhood levels. RESULTS: A total of 29 studies were included, with a majority of cross-sectional design. Higher parental perceived personal safety correlated with increased children's active mobility behaviour, but most commonly in active travel (eg, independent walking or cycling to a local destination). Increased concerns regarding road danger correlated with a decrease in each type of children's active behaviour; active travel, play and exercise. However, these correlations were influenced by child's sex/gender, age, car ownership, neighbourhood types, across time, and proximity to destination. Limited or inconclusive evidence was found on correlate of children's outdoor active mobility behaviour to 'stranger danger', children's perceived personal safety, race/ethnicity, socioeconomic status or measured safety. CONCLUSION: Children are restricted by perception of safety. Encouraging children's active travel may require future strategies to address characteristics relevant to types of the neighbourhood that promote a high sense of personal safety. Children and parents may embrace other types of active mobility behaviour if road danger is mitigated. Sex/gender and age-specific interventions and redesign of public places could lead to child-friendly cities. Future studies may benefit from adopting validated measurement methods and fill existing research gaps. CI - (c) Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. FAU - Zougheibe, Roula AU - Zougheibe R AUID- ORCID: 0000-0002-3649-583X AD - School of Earth and Planetary Sciences, Curtin University, Perth, Western Australia, Australia roula.zougheibe@postgrad.curtin.edu.au. FAU - Jepson, Beverly AU - Jepson B AD - School of Allied Health, Curtin University, Perth, Western Australia, Australia. FAU - Norman, Richard AU - Norman R AD - School of Public Health, Curtin University, Perth, Western Australia, Australia. FAU - Gudes, Ori AU - Gudes O AD - School of Population Health, UNSW, Sydney, New South Wales, Australia. FAU - Dewan, Ashraf AU - Dewan A AD - School of Earth and Planetary Sciences, Curtin University, Perth, Western Australia, Australia. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Systematic Review DEP - 20210707 PL - England TA - BMJ Open JT - BMJ open JID - 101552874 SB - IM MH - Child MH - Cities MH - Cross-Sectional Studies MH - *Exercise MH - Humans MH - Parents MH - *Residence Characteristics MH - Schools PMC - PMC8264888 OTO - NOTNLM OT - epidemiology OT - public health OT - sports medicine COIS- Competing interests: None declared. EDAT- 2021/07/09 06:00 MHDA- 2021/08/05 06:00 PMCR- 2021/07/07 CRDT- 2021/07/08 05:50 PHST- 2021/07/08 05:50 [entrez] PHST- 2021/07/09 06:00 [pubmed] PHST- 2021/08/05 06:00 [medline] PHST- 2021/07/07 00:00 [pmc-release] AID - bmjopen-2020-047062 [pii] AID - 10.1136/bmjopen-2020-047062 [doi] PST - epublish SO - BMJ Open. 2021 Jul 7;11(7):e047062. doi: 10.1136/bmjopen-2020-047062. PMID- 34232178 OWN - NLM STAT- MEDLINE DCOM- 20210713 LR - 20250604 IS - 1536-5964 (Electronic) IS - 0025-7974 (Print) IS - 0025-7974 (Linking) VI - 100 IP - 27 DP - 2021 Jul 9 TI - Efficacy of ultrasound-accelerated versus traditional catheter-directed thrombolysis in treatment of lower extremity deep venous thrombosis: A protocol for systematic review and meta-analysis. PG - e26454 LID - 10.1097/MD.0000000000026454 [doi] LID - e26454 AB - BACKGROUND: There is no meta-analysis or review in the literature to compare and evaluate the difference and effectiveness of ultrasonic-accelerated thrombolysis (UAT) and catheter directed thrombolysis (CDT) in lower extremity deep vein thrombosis (DVT) patients. Therefore, we conducted this protocol of systematic review and meta-analysis to evaluate the efficacy between UAT and CDT for patients with lower extremity DVT. METHODS: We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols reporting guidelines to conduct this study. Reviewers will search the PubMed, Cochrane Library, Web of Science, and EMBASE online databases using the key phrases "deep venous thrombosis," "thrombolysis," and "ultrasound-accelerated" for all cohort studies published up to July 22, 2021. There is no restriction in the dates of publication or language in the search for the current review. The primary outcome is major bleeding. Secondary outcomes include health-related quality of life and complications such as recurrent venous thromboembolism, pulmonary embolism, in-stent thrombosis, and death. Review Manager software (v 5.4; Cochrane Collaboration) will be used for the meta-analysis. A P value of < .05 is considered to be statistically significant. RESULTS: We hypothesized that these two methods would provide similar therapeutic benefits. OSF REGISTRATION NUMBER: 10.17605/OSF.IO/YZB3H. CI - Copyright (c) 2021 the Author(s). Published by Wolters Kluwer Health, Inc. FAU - Ma, Shan AU - Ma S AD - Department of Interventional Medicine, Zhangye Second People's Hospital, Zhangye City, Gansu, China. FAU - Zhao, Zhizhen AU - Zhao Z AD - Department of Pharmacy, Zhangye Second People's Hospital, Zhangye City, Gansu, China. FAU - Song, Zhijun AU - Song Z AD - Department of Interventional Medicine, Zhangye Second People's Hospital, Zhangye City, Gansu, China. FAU - Wang, Li AU - Wang L AUID- ORCID: 0000-0003-3367-8320 AD - Department of Five Sense Organs, Zhang Ye People's Hospital Affiliated To Hexi University, Zhangye City, Gansu, China. LA - eng GR - No: 2014-J2-04/Zhangye City Science and Technology Project/ PT - Journal Article PL - United States TA - Medicine (Baltimore) JT - Medicine JID - 2985248R RN - 0 (Fibrinolytic Agents) SB - IM MH - Fibrinolytic Agents/*therapeutic use MH - Humans MH - Lower Extremity/*blood supply MH - Thrombolytic Therapy/*methods MH - Treatment Outcome MH - Ultrasonography MH - Venous Thrombosis/diagnosis/*drug therapy MH - Meta-Analysis as Topic MH - Systematic Reviews as Topic PMC - PMC8270574 COIS- The authors have no conflicts of interest to disclose. EDAT- 2021/07/08 06:00 MHDA- 2021/07/14 06:00 PMCR- 2021/07/09 CRDT- 2021/07/07 12:16 PHST- 2021/06/04 00:00 [received] PHST- 2021/06/07 00:00 [accepted] PHST- 2021/07/07 12:16 [entrez] PHST- 2021/07/08 06:00 [pubmed] PHST- 2021/07/14 06:00 [medline] PHST- 2021/07/09 00:00 [pmc-release] AID - 00005792-202107090-00016 [pii] AID - MD-D-21-04086 [pii] AID - 10.1097/MD.0000000000026454 [doi] PST - ppublish SO - Medicine (Baltimore). 2021 Jul 9;100(27):e26454. doi: 10.1097/MD.0000000000026454. PMID- 34211412 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20210703 IS - 1664-0640 (Print) IS - 1664-0640 (Electronic) IS - 1664-0640 (Linking) VI - 12 DP - 2021 TI - Dynamics of Perceived Positive Changes and Indicators of Well-Being Within Different Phases of the COVID-19 Pandemic. PG - 685975 LID - 10.3389/fpsyt.2021.685975 [doi] LID - 685975 AB - Background: During the COVID-19 pandemic, people reported about fears, depressive states, and phases of loneliness. However, there have also been positively experienced changes in terms of awareness of nature, reflection of life, more intensive relationships, meaningful digital media usage to connect with others, and interest in spirituality. We were interested in the dynamics of these indicators directly after the first lockdown, the summer months and during the second wave of the pandemic with its second lockdown, and how they relate to the perceived restrictions, fears, and worries. Method: Survey with standardized questionnaires, i.e., Perceived Changes Questionnaire, WHO-Five Well-being Index, Brief Multidimensional Life Satisfaction Scale, Awe/Gratitude scale. Participants were categorized as cohort 1 (June 2020; n = 1,333), cohort 2 (July to September 2020, n = 823), and cohort three (October 2020 to January 2021, n = 625). Results: Participants perceived changes in specific attitudes and behaviors, which have impacted their well-being and life satisfaction. Compared to their experiences directly after the first wave of the pandemic (cohort 1), well-being (Hedge's g = 0.83) and life satisfaction (g = 0.63) decreased during the second wave (cohort 3) and participants' stressors increased (g = -0.94). At the same time, positive perceptions such as Nature/Silence/Contemplation (g = 0.67), Spirituality (g = 0.62), Relationships (g = 0.55), and Digital media usage declined (g = 0.31), but not Reflections on life (g = -0.03). In cohort 3, the proportion of persons relying on their faith as a strong hold was declining also in nominally religious persons. Awe/Gratitude was among the best predictors of perceived positive changes, indicating a resource which is nevertheless declining during the second wave of the pandemic (g = 0.60). Conclusions: Several perceptions, attitudes, and behaviors have changed, particularly during the second wave of the pandemic, which had a strong influence on psychological health. Although Awe/Gratitude was confirmed as the best predictor of perceived positive changes, this resource may not buffer against the negative outcomes of the pandemic but helps to recognize the still positive aspects in life. There is a need for new and not yet defined public health communities that could focus on persons which are affected in their physical, mental, social, and spiritual health and well-being due to the pandemic. CI - Copyright (c) 2021 Bussing, Rodrigues Recchia, Dienberg, Surzykiewicz and Baumann. FAU - Bussing, Arndt AU - Bussing A AD - Professorship Quality of Life, Spirituality and Coping, Faculty of Health, Witten/Herdecke University, Herdecke, Germany. AD - IUNCTUS-Competence Center for Christian Spirituality, Philosophical-Theological Academy, Munster, Germany. FAU - Rodrigues Recchia, Daniela AU - Rodrigues Recchia D AD - Chair of Research Methods and Statistics in Psychology, Faculty of Health, Witten/Herdecke University, Witten, Germany. FAU - Dienberg, Thomas AU - Dienberg T AD - IUNCTUS-Competence Center for Christian Spirituality, Philosophical-Theological Academy, Munster, Germany. FAU - Surzykiewicz, Janusz AU - Surzykiewicz J AD - Chair of Social Pedagogy, Catholic University Eichstatt-Ingolstadt, Eichstatt, Germany. FAU - Baumann, Klaus AU - Baumann K AD - IUNCTUS-Competence Center for Christian Spirituality, Philosophical-Theological Academy, Munster, Germany. AD - Caritas Science and Christian Social Work, Faculty of Theology, Albert-Ludwig-University, Freiburg im Breisgau, Germany. LA - eng PT - Journal Article DEP - 20210615 PL - Switzerland TA - Front Psychiatry JT - Frontiers in psychiatry JID - 101545006 PMC - PMC8239218 OTO - NOTNLM OT - COVID-19 pandemic OT - coping with pandemic stress OT - perceived changes OT - spirituality OT - well-being COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2021/07/03 06:00 MHDA- 2021/07/03 06:01 PMCR- 2021/06/15 CRDT- 2021/07/02 06:36 PHST- 2021/03/26 00:00 [received] PHST- 2021/04/26 00:00 [accepted] PHST- 2021/07/02 06:36 [entrez] PHST- 2021/07/03 06:00 [pubmed] PHST- 2021/07/03 06:01 [medline] PHST- 2021/06/15 00:00 [pmc-release] AID - 10.3389/fpsyt.2021.685975 [doi] PST - epublish SO - Front Psychiatry. 2021 Jun 15;12:685975. doi: 10.3389/fpsyt.2021.685975. eCollection 2021. PMID- 34209708 OWN - NLM STAT- MEDLINE DCOM- 20210708 LR - 20210724 IS - 1660-4601 (Electronic) IS - 1661-7827 (Print) IS - 1660-4601 (Linking) VI - 18 IP - 13 DP - 2021 Jun 29 TI - Using the Food Stress Index for Emergency Food Assistance: An Australian Case Series Analysis during the COVID-19 Pandemic and Natural Disasters. LID - 10.3390/ijerph18136960 [doi] LID - 6960 AB - Food insecurity increases with human and natural disasters. Two tools were developed to assist effective food relief in Western Australia: the Food Stress Index (similar to rental stress, predicts the likelihood of household food insecurity by geographic location) and a basic and nutritious Food Basket Recommendation (that quantifies the types and amounts of food to meet dietary recommendations for different family types). This study aims to understand and compare the processes and impact of using these tools for organisations and their clients involved in emergency food assistance and/or disaster preparedness. A multiple case-study design analysed organisation's use of the tools to assist the response to COVID-19 pandemic restrictions and the catastrophic bushfires in Australia. Qualitative interviews were conducted by telephone and Zoom (a cloud-based video conferencing service) in July-August 2020. A purposeful sample of eight interviewees representing seven cases (government, food relief and community organisations involved in emergency food assistance and/or disaster preparedness). Three themes emerged from the analysis, (1) organisations are confident users of the tools; (2) Collaborations were "Ready to Go" and (3) Food Stress Index is a "game changer". Findings demonstrate the intrinsic value of the tools in the provision of emergency food relief under both normal circumstances and in times of increased need, i.e., COVID-19 pandemic. The study highlights the value and importance of ongoing intersectoral collaborations for food relief and food security (e.g., the Western Australian Food Relief Framework) and suggests that upscaling of the Food Stress Index and food baskets will increase the effectiveness of measures to address food insecurity in Australia. FAU - Pollard, Christina Mary AU - Pollard CM AUID- ORCID: 0000-0003-4261-4601 AD - Faculty of Health Sciences, School of Population Health, Curtin University, Bentley, WA 6102, Australia. AD - East Metropolitan Health Service, Perth, WA 6000, Australia. FAU - Landrigan, Timothy John AU - Landrigan TJ AUID- ORCID: 0000-0002-2103-8820 AD - Faculty of Health Sciences, School of Population Health, Curtin University, Bentley, WA 6102, Australia. FAU - Gray, Jennie Margaret AU - Gray JM AD - Western Australian Council of Social Service, East Victoria Park, WA 6101, Australia. FAU - McDonald, Lockie AU - McDonald L AD - Independent Consultant, Fullsky Consulting, Mount Lawley, WA 6050, Australia. FAU - Creed, Helen AU - Creed H AD - Western Australian Council of Social Service, East Victoria Park, WA 6101, Australia. FAU - Booth, Sue AU - Booth S AUID- ORCID: 0000-0002-7834-1732 AD - College of Medicine and Public Health, Flinders University, Adelaide, SA 5000, Australia. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20210629 PL - Switzerland TA - Int J Environ Res Public Health JT - International journal of environmental research and public health JID - 101238455 SB - IM MH - Australia MH - *COVID-19 MH - *Food Assistance MH - Humans MH - *Natural Disasters MH - Pandemics MH - SARS-CoV-2 MH - Western Australia PMC - PMC8297278 OTO - NOTNLM OT - COVID-19 OT - Food Stress Index OT - disaster management OT - emergency food assistance OT - food insecurity COIS- The authors declare no conflict of interest. EDAT- 2021/07/03 06:00 MHDA- 2021/07/09 06:00 PMCR- 2021/06/29 CRDT- 2021/07/02 01:39 PHST- 2021/05/26 00:00 [received] PHST- 2021/06/22 00:00 [revised] PHST- 2021/06/24 00:00 [accepted] PHST- 2021/07/02 01:39 [entrez] PHST- 2021/07/03 06:00 [pubmed] PHST- 2021/07/09 06:00 [medline] PHST- 2021/06/29 00:00 [pmc-release] AID - ijerph18136960 [pii] AID - ijerph-18-06960 [pii] AID - 10.3390/ijerph18136960 [doi] PST - epublish SO - Int J Environ Res Public Health. 2021 Jun 29;18(13):6960. doi: 10.3390/ijerph18136960. PMID- 36540159 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20221222 IS - 0169-2046 (Print) IS - 0169-2046 (Electronic) IS - 0169-2046 (Linking) VI - 211 DP - 2021 Jul TI - The role of perceived public and private green space in subjective health and wellbeing during and after the first peak of the COVID-19 outbreak. PG - 104092 LID - 10.1016/j.landurbplan.2021.104092 [doi] AB - Research has consistently shown that access to parks and gardens is beneficial to people's health and wellbeing. In this paper, we explore the role of both public and private green space in subjective health and wellbeing during and after the first peak of the COVID-19 outbreak that took place in the UK in the first half of 2020. It makes use of the longitudinal COVID-19 Public Experiences (COPE) study, with baseline data collected in March/April 2020 (during the first peak) and follow-up data collected in June/July 2020 (after the first peak) which included an optional module that asked respondents about their home and neighbourhood (n = 5,566). Regression analyses revealed that both perceived access to public green space (e.g. a park or woodland) and reported access to a private green space (a private garden) were associated with better subjective wellbeing and self-rated health. In line with the health compensation hypothesis for green space, private gardens had a greater protective effect where the nearest green space was perceived to be more than a 10-minute walk away. This interaction was however only present during the first COVID-19 peak when severe lockdown restrictions came into place, but not in the post-peak period when restrictions were being eased. The study found few differences across demographic groups. A private garden was relatively more beneficial for men than for women during but not after the first peak. The results suggest that both public and private green space are an important resource for health and wellbeing in times of crisis. CI - (c) 2021 The Authors. FAU - Poortinga, Wouter AU - Poortinga W AD - Welsh School of Architecture, Cardiff University, Cardiff, Wales, UK. AD - School of Psychology, Cardiff University, Cardiff, Wales, UK. FAU - Bird, Natasha AU - Bird N AD - School of Psychology, Cardiff University, Cardiff, Wales, UK. FAU - Hallingberg, Britt AU - Hallingberg B AD - Cardiff School of Sport & Health Science, Cardiff Metropolitan University, Cardiff, Wales, UK. FAU - Phillips, Rhiannon AU - Phillips R AD - Cardiff School of Sport & Health Science, Cardiff Metropolitan University, Cardiff, Wales, UK. FAU - Williams, Denitza AU - Williams D AD - Cardiff School of Sport & Health Science, Cardiff Metropolitan University, Cardiff, Wales, UK. LA - eng PT - Journal Article DEP - 20210403 PL - Netherlands TA - Landsc Urban Plan JT - Landscape and urban planning JID - 101087690 PMC - PMC9754643 OTO - NOTNLM OT - COVID-19 OT - Gardens OT - Green space OT - Self-rated health OT - Subjective wellbeing EDAT- 2021/07/01 00:00 MHDA- 2021/07/01 00:01 PMCR- 2021/04/03 CRDT- 2022/12/21 02:05 PHST- 2020/12/10 00:00 [received] PHST- 2021/03/04 00:00 [revised] PHST- 2021/03/17 00:00 [accepted] PHST- 2022/12/21 02:05 [entrez] PHST- 2021/07/01 00:00 [pubmed] PHST- 2021/07/01 00:01 [medline] PHST- 2021/04/03 00:00 [pmc-release] AID - S0169-2046(21)00055-4 [pii] AID - 104092 [pii] AID - 10.1016/j.landurbplan.2021.104092 [doi] PST - ppublish SO - Landsc Urban Plan. 2021 Jul;211:104092. doi: 10.1016/j.landurbplan.2021.104092. Epub 2021 Apr 3. PMID- 34191957 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20210630 IS - 1867-299X (Print) IS - 2190-8249 (Electronic) IS - 1867-299X (Linking) VI - 12 IP - 1 DP - 2021 Mar TI - Soft Law Governance in Times of Coronavirus in Spain. PG - 111-126 LID - 10.1017/err.2020.117 [doi] AB - Early in the COVID-19 pandemic, between March and July 2020, Spanish national and regional authorities made extensive use of soft law mechanisms to fight the spread of the virus and to tackle the consequences of the crisis. Soft law was used either as an instrument in and of itself, or as a justification for hard law instruments, with more than 200 non-binding measures being enacted by the state and by the Autonomous Communities. Spanish courts also used soft law as a tool to interpret existing hard law instruments, Such uses give rise to concerns about the transparency of administrative action and the principle of legal certainty. Moreover, the widespread use of soft law to justify the adoption of binding measures restricting fundamental rights might have consequences for democratic accountability and judicial control of executive action. This article indicates the need to reconsider the current system of constitutional and legal constraints attached to this form of regulation, by introducing some binding procedural rules relating to its adoption and its publication, and by clarifying its legal effects and the mechanism through which it can be enforced by courts. CI - (c) The Author(s) 2021. FAU - Utrilla Fernandez-Bermejo, Dolores AU - Utrilla Fernandez-Bermejo D AD - Universidad de Castilla - La Mancha, Spain; email: MDolores.Utrilla@uclm.es. LA - eng PT - Journal Article PL - Germany TA - Eur J Risk Regul JT - European journal of risk regulation : EJRR JID - 101617321 PMC - PMC8060621 EDAT- 2021/07/01 06:00 MHDA- 2021/07/01 06:01 PMCR- 2021/04/22 CRDT- 2021/06/30 17:29 PHST- 2021/06/30 17:29 [entrez] PHST- 2021/07/01 06:00 [pubmed] PHST- 2021/07/01 06:01 [medline] PHST- 2021/04/22 00:00 [pmc-release] AID - S1867299X20001178 [pii] AID - 10.1017/err.2020.117 [doi] PST - ppublish SO - Eur J Risk Regul. 2021 Mar;12(1):111-126. doi: 10.1017/err.2020.117. PMID- 34190583 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20250725 LR - 20250725 IS - 2379-5042 (Electronic) IS - 2379-5042 (Linking) VI - 6 IP - 3 DP - 2021 Jun 30 TI - Molecular Epidemiology of SARS-CoV-2 in Greece Reveals Low Rates of Onward Virus Transmission after Lifting of Travel Restrictions Based on Risk Assessment during Summer 2020. PG - 101128msphere0018021 LID - 10.1128/mSphere.00180-21 [doi] LID - e00180-21 AB - The novel coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spread rapidly during the first months of 2020 and continues to expand in multiple areas across the globe. Molecular epidemiology has provided an added value to traditional public health tools by identifying SARS-CoV-2 clusters or providing evidence that clusters based on virus sequences and contact tracing are highly concordant. Our aim was to infer the levels of virus importation and to estimate the impact of public health measures related to travel restrictions to local transmission in Greece. Our phylogenetic and phylogeographic analyses included 389 full-genome SARS-CoV-2 sequences collected during the first 7 months of the pandemic in Greece and a random collection in five replicates of 3,000 sequences sampled globally, as well as the best hits to our data set identified by BLAST. Phylogenetic trees were reconstructed by the maximum likelihood method, and the putative source of SARS-CoV-2 infections was inferred by phylogeographic analysis. Phylogenetic analyses revealed the presence of 89 genetically distinct viruses identified as independent introductions into Greece. The proportion of imported strains was 41%, 11.5%, and 8.8% during the three periods of sampling, namely, March (no travel restrictions), April to June (strict travel restrictions), and July to September (lifting of travel restrictions based on thorough risk assessment), respectively. The results of phylogeographic analysis were confirmed by a Bayesian approach. Our findings reveal low levels of onward transmission from imported cases during summer and underscore the importance of targeted public health measures that can increase the safety of international travel during a pandemic. IMPORTANCE Our study based on current state-of-the-art molecular epidemiology methods suggests that virus screening and public health measures after the lifting of travel restrictions prevented SARS-CoV-2 onward transmission from imported cases during summer 2020 in Greece. These findings provide important data on the efficacy of targeted public health measures and have important implications regarding the safety of international travel during a pandemic. Our results can provide a roadmap about prevention policy in the future regarding the reopening of borders in the presence of differences in vaccination coverage, the circulation of the virus, and the presence of newly emergent variants across the globe. FAU - Kostaki, Evangelia Georgia AU - Kostaki EG AUID- ORCID: 0000-0002-3346-0930 AD - Department of Hygiene, Epidemiology and Medical Statistics, Medical School, National and Kapodistrian University of Athens, Athens, Greece. GRID: grid.5216.0 FAU - Pavlopoulos, Georgios A AU - Pavlopoulos GA AD - Center of New Biotechnologies & Precision Medicine, Medical School, National and Kapodistrian University of Athens, Athens, Greece. GRID: grid.5216.0 AD - Institute for Fundamental Biomedical Research, Biomedical Sciences Research Center "Alexander Fleming," Vari, Greece. FAU - Verrou, Kleio-Maria AU - Verrou KM AD - Center of New Biotechnologies & Precision Medicine, Medical School, National and Kapodistrian University of Athens, Athens, Greece. GRID: grid.5216.0 FAU - Ampatziadis-Michailidis, Giannis AU - Ampatziadis-Michailidis G AD - Center of New Biotechnologies & Precision Medicine, Medical School, National and Kapodistrian University of Athens, Athens, Greece. GRID: grid.5216.0 FAU - Harokopos, Vaggelis AU - Harokopos V AD - Institute for Fundamental Biomedical Research, Biomedical Sciences Research Center "Alexander Fleming," Vari, Greece. FAU - Hatzis, Pantelis AU - Hatzis P AD - Center of New Biotechnologies & Precision Medicine, Medical School, National and Kapodistrian University of Athens, Athens, Greece. GRID: grid.5216.0 AD - Institute for Fundamental Biomedical Research, Biomedical Sciences Research Center "Alexander Fleming," Vari, Greece. FAU - Moulos, Panagiotis AU - Moulos P AD - Center of New Biotechnologies & Precision Medicine, Medical School, National and Kapodistrian University of Athens, Athens, Greece. GRID: grid.5216.0 AD - Institute for Fundamental Biomedical Research, Biomedical Sciences Research Center "Alexander Fleming," Vari, Greece. FAU - Siafakas, Nikolaos AU - Siafakas N AD - Laboratory of Clinical Microbiology, ATTIKON University Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece. GRID: grid.5216.0 FAU - Pournaras, Spyridon AU - Pournaras S AD - Laboratory of Clinical Microbiology, ATTIKON University Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece. GRID: grid.5216.0 FAU - Hadjichristodoulou, Christos AU - Hadjichristodoulou C AD - Laboratory of Hygiene and Epidemiology, Faculty of Medicine, Larisa, Greece. FAU - Chatzopoulou, Fani AU - Chatzopoulou F AD - Labnet, Laboratories, Thessaloniki, Greece. FAU - Chatzidimitriou, Dimitrios AU - Chatzidimitriou D AD - Labnet, Laboratories, Thessaloniki, Greece. AD - Department of Microbiology, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece. FAU - Panagopoulos, Periklis AU - Panagopoulos P AD - 2nd Department of Internal Medicine, General Hospital of Alexandroupoli, Democritus University of Thrace, Alexandroupoli, Greece. FAU - Lourida, Panagiota AU - Lourida P AD - Infectious Diseases Clinic A, Thoracic Diseases General Hospital Sotiria, Athens, Greece. FAU - Argyraki, Aikaterini AU - Argyraki A AD - Infectious Diseases Clinic A, Thoracic Diseases General Hospital Sotiria, Athens, Greece. FAU - Lytras, Theodoros AU - Lytras T AD - School of Medicine, European University Cyprus, Nicosia, Cyprus. FAU - Sapounas, Spyros AU - Sapounas S AD - National Public Health Organization, Athens, Greece. FAU - Gerolymatos, Gerasimos AU - Gerolymatos G AD - National Public Health Organization, Athens, Greece. FAU - Panagiotakopoulos, Georgios AU - Panagiotakopoulos G AD - National Public Health Organization, Athens, Greece. FAU - Prezerakos, Panagiotis AU - Prezerakos P AD - Department of Nursing, University of Peloponnese, Tripoli, Greece. FAU - Tsiodras, Sotirios AU - Tsiodras S AD - 4th Department of Internal Medicine, Attikon University Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece. GRID: grid.5216.0 FAU - Sypsa, Vana AU - Sypsa V AD - Department of Hygiene, Epidemiology and Medical Statistics, Medical School, National and Kapodistrian University of Athens, Athens, Greece. GRID: grid.5216.0 FAU - Hatzakis, Angelos AU - Hatzakis A AD - Department of Hygiene, Epidemiology and Medical Statistics, Medical School, National and Kapodistrian University of Athens, Athens, Greece. GRID: grid.5216.0 FAU - Anastassopoulou, Cleo AU - Anastassopoulou C AD - Department of Microbiology, Medical School, National and Kapodistrian University of Athens, Athens, Greece. GRID: grid.5216.0 FAU - Spanakis, Nikolaos AU - Spanakis N AD - Department of Microbiology, Medical School, National and Kapodistrian University of Athens, Athens, Greece. GRID: grid.5216.0 FAU - Tsakris, Athanasios AU - Tsakris A AD - Department of Microbiology, Medical School, National and Kapodistrian University of Athens, Athens, Greece. GRID: grid.5216.0 FAU - Dimopoulos, Meletios Athanasios AU - Dimopoulos MA AD - Center of New Biotechnologies & Precision Medicine, Medical School, National and Kapodistrian University of Athens, Athens, Greece. GRID: grid.5216.0 AD - Department of Therapeutics, Medical School, National and Kapodistrian University of Athens, Athens, Greece. GRID: grid.5216.0 FAU - Kotanidou, Anastasia AU - Kotanidou A AD - 1st Intensive Care Unit, General Hospital Evangelismos, National and Kapodistrian University of Athens, Athens, Greece. GRID: grid.5216.0 FAU - Sfikakis, Petros AU - Sfikakis P AD - Center of New Biotechnologies & Precision Medicine, Medical School, National and Kapodistrian University of Athens, Athens, Greece. GRID: grid.5216.0 AD - 1st Department of Propaedeutic Internal Medicine, Medical School, National and Kapodistrian University of Athens, Athens, Greece. GRID: grid.5216.0 FAU - Kollias, Georgios AU - Kollias G AD - Center of New Biotechnologies & Precision Medicine, Medical School, National and Kapodistrian University of Athens, Athens, Greece. GRID: grid.5216.0 AD - Institute for Bioinnovation, Biomedical Sciences Research Center "Alexander Fleming," Vari, Greece. AD - Department of Physiology, Medical School, National and Kapodistrian University of Athens, Athens, Greece. GRID: grid.5216.0 FAU - Magiorkinis, Gkikas AU - Magiorkinis G AD - Department of Hygiene, Epidemiology and Medical Statistics, Medical School, National and Kapodistrian University of Athens, Athens, Greece. GRID: grid.5216.0 FAU - Paraskevis, Dimitrios AU - Paraskevis D AUID- ORCID: 0000-0001-6167-7152 AD - Department of Hygiene, Epidemiology and Medical Statistics, Medical School, National and Kapodistrian University of Athens, Athens, Greece. GRID: grid.5216.0 LA - eng PT - Journal Article DEP - 20210630 PL - United States TA - mSphere JT - mSphere JID - 101674533 SB - IM PMC - PMC8265632 OTO - NOTNLM OT - SARS-CoV-2 OT - molecular epidemiology OT - phylogeography OT - public health OT - travel restrictions EDAT- 2021/07/01 06:00 MHDA- 2021/07/01 06:01 PMCR- 2021/06/30 CRDT- 2021/06/30 12:15 PHST- 2021/07/01 06:01 [medline] PHST- 2021/07/01 06:00 [pubmed] PHST- 2021/06/30 12:15 [entrez] PHST- 2021/06/30 00:00 [pmc-release] AID - mSphere00180-21 [pii] AID - 10.1128/mSphere.00180-21 [doi] PST - ppublish SO - mSphere. 2021 Jun 30;6(3):101128msphere0018021. doi: 10.1128/mSphere.00180-21. Epub 2021 Jun 30. PMID- 34185816 OWN - NLM STAT- MEDLINE DCOM- 20210712 LR - 20230920 IS - 1932-6203 (Electronic) IS - 1932-6203 (Linking) VI - 16 IP - 6 DP - 2021 TI - Contextualising COVID-19 prevention behaviour over time in Australia: Patterns and long-term predictors from April to July 2020 in an online social media sample. PG - e0253930 LID - 10.1371/journal.pone.0253930 [doi] LID - e0253930 AB - BACKGROUND: In Australia in March 2020 a national public health directive required that non-essential workers stay at home, except for essential activities. These restrictions began easing in May 2020 as community transmission slowed. OBJECTIVES: This study investigated changes in COVID prevention behaviours from April-July 2020, and psychosocial predictors of these behaviours. METHODS: An Australia-wide (national) survey was conducted in April, with monthly follow-up over four months. Participants who were adults (18+ years), currently residing in Australia and who could read and understand English were eligible. Recruitment was via online social media. Analysis sample included those who provided responses to the baseline survey (April) and at least one subsequent follow-up survey (N = 1834 out of a possible 3216 who completed the April survey). 71.7% of the sample was female (n = 1,322). Principal components analysis (PCA) combined self-reported adherence across seven prevention behaviours. PCA identified two behaviour types: 'distancing' (e.g. staying 1.5m away) and 'hygiene' (e.g. washing hands), explaining 28.3% and 24.2% of variance, respectively. Distancing and hygiene behaviours were analysed individually using multivariable regression models. RESULTS: On average, participants agreed with statements of adherence for all behaviours (means all above 4 out of 7). Distancing behaviours declined each month (p's < .001), whereas hygiene behaviours remained relatively stable. For distancing, stronger perceptions of societal risk, self-efficacy to maintain distancing, and greater perceived social obligation at baseline were associated with adherence in June and July (p's<0.05). For hygiene, the only significant correlate of adherence in June and July was belief that one's actions could prevent infection of family members (p < .001). CONCLUSION: High adherence to COVID prevention behaviours were reported in this social media sample; however, distancing behaviours tended to decrease over time. Belief in social responsibility may be an important aspect to consider in encouraging distancing behaviours. These findings have implications for managing a shift from government-imposed restrictions to individual responsibility. FAU - Ayre, Julie AU - Ayre J AUID- ORCID: 0000-0002-5279-5189 AD - Sydney Health Literacy Lab, School of Public Health, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia. FAU - Cvejic, Erin AU - Cvejic E AUID- ORCID: 0000-0002-6043-6071 AD - Sydney Health Literacy Lab, School of Public Health, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia. FAU - McCaffery, Kirsten AU - McCaffery K AUID- ORCID: 0000-0003-2696-5006 AD - Sydney Health Literacy Lab, School of Public Health, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia. FAU - Copp, Tessa AU - Copp T AD - Sydney Health Literacy Lab, School of Public Health, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia. FAU - Cornell, Samuel AU - Cornell S AD - Sydney Health Literacy Lab, School of Public Health, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia. FAU - Dodd, Rachael H AU - Dodd RH AUID- ORCID: 0000-0002-8080-6359 AD - Sydney Health Literacy Lab, School of Public Health, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia. FAU - Pickles, Kristen AU - Pickles K AD - Sydney Health Literacy Lab, School of Public Health, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia. FAU - Batcup, Carys AU - Batcup C AD - Sydney Health Literacy Lab, School of Public Health, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia. FAU - Isautier, Jennifer M J AU - Isautier JMJ AD - Sydney Health Literacy Lab, School of Public Health, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia. FAU - Nickel, Brooke AU - Nickel B AUID- ORCID: 0000-0002-8100-4278 AD - Sydney Health Literacy Lab, School of Public Health, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia. FAU - Dakin, Thomas AU - Dakin T AD - Sydney Health Literacy Lab, School of Public Health, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia. FAU - Bonner, Carissa AU - Bonner C AD - Sydney Health Literacy Lab, School of Public Health, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia. LA - eng PT - Journal Article DEP - 20210629 PL - United States TA - PLoS One JT - PloS one JID - 101285081 SB - IM MH - Adolescent MH - Adult MH - Aged MH - Aged, 80 and over MH - Australia/epidemiology MH - COVID-19/epidemiology/*prevention & control/virology MH - Female MH - *Health Behavior MH - Health Knowledge, Attitudes, Practice MH - Humans MH - Hygiene MH - Male MH - Middle Aged MH - Physical Distancing MH - Principal Component Analysis MH - SARS-CoV-2 MH - Self Efficacy MH - *Social Media MH - Surveys and Questionnaires MH - Young Adult PMC - PMC8241082 COIS- The authors have declared that no competing interests exist. EDAT- 2021/06/30 06:00 MHDA- 2021/07/13 06:00 PMCR- 2021/06/29 CRDT- 2021/06/29 17:19 PHST- 2021/03/08 00:00 [received] PHST- 2021/06/15 00:00 [accepted] PHST- 2021/06/29 17:19 [entrez] PHST- 2021/06/30 06:00 [pubmed] PHST- 2021/07/13 06:00 [medline] PHST- 2021/06/29 00:00 [pmc-release] AID - PONE-D-21-07536 [pii] AID - 10.1371/journal.pone.0253930 [doi] PST - epublish SO - PLoS One. 2021 Jun 29;16(6):e0253930. doi: 10.1371/journal.pone.0253930. eCollection 2021. PMID- 34175001 OWN - NLM STAT- MEDLINE DCOM- 20210705 LR - 20210723 IS - 2468-2667 (Electronic) VI - 6 IP - 7 DP - 2021 Jul TI - Targeted smoking cessation for dual users of combustible and electronic cigarettes: a randomised controlled trial. PG - e500-e509 LID - S2468-2667(20)30307-8 [pii] LID - 10.1016/S2468-2667(20)30307-8 [doi] AB - BACKGROUND: Although many smokers use electronic cigarettes (e-cigarettes) to quit smoking, most continue to smoke while vaping. This dual use might delay cessation and increase toxicant exposure. We aimed to test the efficacy of a self-help intervention designed to help dual users to quit smoking. METHODS: In this three-arm randomised controlled trial we recruited individuals in the USA using Facebook and multimedia advertisements. Included participants were 18 years or older, smoked at least weekly in the preceding year, and vaped at least weekly in the preceding month. We used computer generated randomisation with balanced-permuted blocks (block size 10, with 2-4-4 ratio) to allocate participants to assessment only (ASSESS group), generic smoking cessation self-help booklets (GENERIC group), or booklets targeting dual users (eTARGET group). Individuals in the generic or targeted intervention groups received monthly cessation materials for 18 months, with assessments every 3 months for 24 months. The main outcome was self-reported 7-day point-prevalence smoking abstinence at each assessment point. All randomly allocated participants were included in primary analyses using generalised estimating equations for each of 20 datasets created by multiple imputation. Analysis of the chi(2)s produced an F test. The trial is registered with ClinicalTrials.gov, NCT02416011, and is now closed. FINDINGS: Between July 12, 2016, and June 30, 2017, we randomly assigned 2896 dual users (575 to assessment, 1154 to generic intervention, and 1167 to targeted self-help). 7-day point-prevalence smoking abstinence increased from 14% at 3 months to 42% at 24 months (F(7,541.7)=67.1, p<0.0001) in the overall sample. Targeted self-help resulted in higher smoking abstinence than did assessment alone throughout the treatment period (F(1,973.8)=10.20, p=0.0014 [alpha=0.017]). The generic intervention group had abstinence rates between those of the assessment and targeted groups, but did not significantly differ from either when adjusted for multiple comparisons (GENERIC vs eTARGET F(1,1102.5)=1.79, p=0.18 [alpha=0.05]; GENERIC vs ASSESS F(1,676.7)=4.29, p=0.039 [alpha=0.025]). Differences between study groups attenuated after the interventions ended. INTERPRETATION: A targeted self-help intervention with high potential for dissemination could be efficacious in promoting smoking cessation among dual users of combustible cigarettes and e-cigarettes. FUNDING: National Institute on Drug Abuse, National Cancer Institute. CI - Copyright (c) 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license. Published by Elsevier Ltd.. All rights reserved. FAU - Martinez, Ursula AU - Martinez U AD - Department of Health Outcomes and Behavior, H Lee Moffitt Cancer Center, Tampa, FL, USA; Department of Oncologic Sciences, University of South Florida, Tampa, FL, USA. FAU - Simmons, Vani N AU - Simmons VN AD - Department of Health Outcomes and Behavior, H Lee Moffitt Cancer Center, Tampa, FL, USA; Department of Oncologic Sciences, University of South Florida, Tampa, FL, USA; Department of Psychology, University of South Florida, Tampa, FL, USA. FAU - Sutton, Steven K AU - Sutton SK AD - Department of Biostatistics and Bioinformatics, H Lee Moffitt Cancer Center, Tampa, FL, USA; Department of Oncologic Sciences, University of South Florida, Tampa, FL, USA; Department of Psychology, University of South Florida, Tampa, FL, USA. FAU - Drobes, David J AU - Drobes DJ AD - Department of Health Outcomes and Behavior, H Lee Moffitt Cancer Center, Tampa, FL, USA; Department of Oncologic Sciences, University of South Florida, Tampa, FL, USA; Department of Psychology, University of South Florida, Tampa, FL, USA. FAU - Meltzer, Lauren R AU - Meltzer LR AD - Department of Health Outcomes and Behavior, H Lee Moffitt Cancer Center, Tampa, FL, USA. FAU - Brandon, Karen O AU - Brandon KO AD - Department of Health Outcomes and Behavior, H Lee Moffitt Cancer Center, Tampa, FL, USA. FAU - Byrne, Margaret M AU - Byrne MM AD - Department of Health Outcomes and Behavior, H Lee Moffitt Cancer Center, Tampa, FL, USA; Department of Oncologic Sciences, University of South Florida, Tampa, FL, USA. FAU - Harrell, Paul T AU - Harrell PT AD - Department of Pediatrics, Eastern Virginia Medical School, Norfolk, VA, USA. FAU - Eissenberg, Thomas AU - Eissenberg T AD - Center for the Study of Tobacco Products, Department of Psychology, Virginia Commonwealth University, Richmond, VA, USA. FAU - Bullen, Christopher R AU - Bullen CR AD - School of Population Health, Faculty of Medical and Health Science, University of Auckland, Auckland, New Zealand. FAU - Brandon, Thomas H AU - Brandon TH AD - Department of Health Outcomes and Behavior, H Lee Moffitt Cancer Center, Tampa, FL, USA; Department of Oncologic Sciences, University of South Florida, Tampa, FL, USA; Department of Psychology, University of South Florida, Tampa, FL, USA. Electronic address: thomas.brandon@moffitt.org. LA - eng SI - ClinicalTrials.gov/NCT02416011 GR - P30 CA076292/CA/NCI NIH HHS/United States GR - R01 DA037961/DA/NIDA NIH HHS/United States PT - Journal Article PT - Randomized Controlled Trial PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't PL - England TA - Lancet Public Health JT - The Lancet. Public health JID - 101699003 SB - IM CIN - Lancet Public Health. 2021 Jul;6(7):e441-e442. doi: 10.1016/S2468-2667(21)00034-7. PMID: 34174995 MH - Adolescent MH - Adult MH - Cost-Benefit Analysis MH - *Electronic Nicotine Delivery Systems MH - Female MH - Health Behavior MH - Health Promotion/*methods MH - Humans MH - Male MH - *Smoking MH - Smoking Cessation/*methods MH - Surveys and Questionnaires MH - Vaping MH - Young Adult PMC - PMC8281505 MID - NIHMS1718704 COIS- Declaration of interests THB has received research support from the US National Institutes of Health (NIH), the American Cancer Society, the Florida Department of Health, and Pfizer; has collaborated on funded research with Voxiva, Optum, and the University of East Anglia (Norwich, UK); spent a sabbatical period at the Trimbos Institute and Utrecht University (Utrecht, Netherlands); is on the advisory board of, and holds restricted stock in, Hava Health, which is developing a pharmaceutical grade electronic nicotine delivery system for smoking cessation; participated in a Best Brains Exchange for Health Canada, providing advice on e-cigarette policy; and consulted for the Australian Government Solicitor regarding plain tobacco packaging. UM has received research support from the NIH and the Galician Plan of Research, Innovation, and Growth (Spain); and has received funding from the Barrie Foundation to receive predoctoral training at the University of Newcastle (Callaghan, NSW, Australia). VNS has received research support from the NIH and the Florida Department of Health. SKS has received research support from the NIH, the American Cancer Society, the Florida Department of Health, and Pfizer. DJD has received research support from the NIH, the American Cancer Society, and the Florida Department of Health; and has provided paid expert testimony in litigation against tobacco companies. MMB has received funding from the NIH, the Florida Department of Health, the US Department of Veterans Affairs, the US Centers for Disease Control and Prevention, the National Science Foundation, and the US Department of Housing & Urban Development; and has received research support from Gilead Sciences, Florida Blue Foundation, Bristol Myers Squibb Foundation, Merck Foundation, Maine Cancer Foundation, and Pfizer. PTH has received research support from the NIH, US Food and Drug Administration (FDA), and Virginia Foundation for Healthy Youth. TE conducts research supported by the National Institute on Drug Abuse of the NIH and the Center for Tobacco Products of the FDA; is a paid consultant in litigation against the tobacco industry and the electronic cigarette industry; is named on one patent for a device that measures the puffing behaviour of electronic cigarette users and on another patent for a smartphone app that determines electronic cigarette device and liquid characteristics; owns shares in a variety of mutual funds, the exact stock makeup of which he has no control, and owns shares in three publicly traded companies, none of which are in any way related to the tobacco industry, the electronic cigarette industry, or any other aspect of this work; and has served as a special government employee of the US Government in the context of his service on the FDA's Tobacco Products Scientific Advisory Committee and the Department of Health and Human Services Secretary's Advisory Committee on Human Research Protection. CRB has received research support from the New Zealand Ministry of Health, the Health Research Council of New Zealand, CureKids Foundation, Heart Foundation, Health Promotion Agency, and Auckland Council and Sanitarium; collaborates on funded research with Newcastle University (Australia) through a grant from the Australian National Health and Medical Research Council, with Zhejiang University (Hangzhou, China) and Kunming University (Yunnan, China) on an Education New Zealand Tripartite grant, and with the University of Malaya (Kuala Lumpur, Malaysia) on a University of Malaya Grand Challenges grant; received funding from Pfizer Australasia for a survey of the impact of COVID-19 on health workers in low-income and middle-income countries and from Johnson & Johnson Japan for consultancy on smoking cessation medication; and was a consultant to Moffit Cancer Center on this study through an NIH grant. The employees of Moffitt Cancer Center-UM, VNS, SKS, DJD, LRM, KOB, MMB, and THB-are eligible for sharing of any revenue that might be generated by products developed during their employment, including the intervention used in this study. LRM and KOB declare no additional competing interests. EDAT- 2021/06/28 06:00 MHDA- 2021/07/06 06:00 PMCR- 2021/07/15 CRDT- 2021/06/27 20:29 PHST- 2020/07/17 00:00 [received] PHST- 2020/12/10 00:00 [revised] PHST- 2020/12/18 00:00 [accepted] PHST- 2021/06/27 20:29 [entrez] PHST- 2021/06/28 06:00 [pubmed] PHST- 2021/07/06 06:00 [medline] PHST- 2021/07/15 00:00 [pmc-release] AID - S2468-2667(20)30307-8 [pii] AID - 10.1016/S2468-2667(20)30307-8 [doi] PST - ppublish SO - Lancet Public Health. 2021 Jul;6(7):e500-e509. doi: 10.1016/S2468-2667(20)30307-8. PMID- 34173998 OWN - NLM STAT- MEDLINE DCOM- 20210928 LR - 20260518 IS - 1471-0528 (Electronic) IS - 1470-0328 (Linking) VI - 128 IP - 11 DP - 2021 Oct TI - Preventable stillbirths in India and Pakistan: a prospective, observational study. PG - 1762-1773 LID - 10.1111/1471-0528.16820 [doi] AB - OBJECTIVE: Stillbirths occur 10-20 times more frequently in low-income settings compared with high-income settings. We created a methodology to define the proportion of stillbirths that are potentially preventable in low-income settings and applied it to stillbirths in sites in India and Pakistan. DESIGN: Prospective observational study. SETTING: Three maternity hospitals in Davangere, India and a large public hospital in Karachi, Pakistan. POPULATION: All cases of stillbirth at >/=20 weeks of gestation occurring from July 2018 to February 2020 were screened for participation; 872 stillbirths were included in this analysis. METHODS: We prospectively defined the conditions and gestational ages that defined the stillbirth cases considered potentially preventable. Informed consent was sought from the parent(s) once the stillbirth was identified, either before or soon after delivery. All information available, including obstetric and medical history, clinical course, fetal heart sounds on admission, the presence of maceration as well as examination of the stillbirth after delivery, histology, and polymerase chain reaction for infectious pathogens of the placenta and various fetal tissues, was used to assess whether a stillbirth was potentially preventable. MAIN OUTCOME MEASURES: Whether a stillbirth was determined to be potentially preventable and the criteria for assignment to those categories. RESULTS: Of 984 enrolled, 872 stillbirths at >/=20 weeks of gestation met the inclusion criteria and were included; of these, 55.5% were deemed to be potentially preventable. Of the 649 stillbirths at >/=28 weeks of gestation and >/=1000 g birthweight, 73.5% were considered potentially preventable. The most common conditions associated with a potentially preventable stillbirth at >/=28 weeks of gestation and >/=1000 g birthweight were small for gestational age (SGA) (52.8%), maternal hypertension (50.2%), antepartum haemorrhage (31.4%) and death that occurred after hospital admission (15.7%). CONCLUSIONS: Most stillbirths in these sites were deemed preventable and were often associated with maternal hypertension, antepartum haemorrhage, SGA and intrapartum demise. TWEETABLE ABSTRACT: Most stillbirths are preventable by better care for women with hypertension, growth restriction and antepartum haemorrhage. CI - (c) 2021 John Wiley & Sons Ltd. FAU - Goldenberg, R L AU - Goldenberg RL AD - Columbia University, New York, NY, USA. FAU - Saleem, S AU - Saleem S AD - Aga Khan University, Karachi, Pakistan. FAU - Goudar, S S AU - Goudar SS AD - KLE Academy of Higher Education and Research's JN Medical College, Belagavi, India. FAU - Silver, R M AU - Silver RM AD - University of Utah, Salt Lake City, UT, USA. FAU - Tikmani, S S AU - Tikmani SS AD - Aga Khan University, Karachi, Pakistan. FAU - Guruprasad, G AU - Guruprasad G AD - J.J.M. Medical College, Davangere, India. FAU - Dhaded, S M AU - Dhaded SM AD - KLE Academy of Higher Education and Research's JN Medical College, Belagavi, India. FAU - Yasmin, H AU - Yasmin H AD - Jinnah Postgraduate Medical Centre, Karachi, Pakistan. FAU - Bano, K AU - Bano K AD - Jinnah Postgraduate Medical Centre, Karachi, Pakistan. FAU - Somannavar, M S AU - Somannavar MS AUID- ORCID: 0000-0002-8871-5072 AD - KLE Academy of Higher Education and Research's JN Medical College, Belagavi, India. FAU - Yogeshkumar, S AU - Yogeshkumar S AD - KLE Academy of Higher Education and Research's JN Medical College, Belagavi, India. FAU - Hwang, K AU - Hwang K AD - RTI International, Durham, NC, USA. FAU - Aceituno, A AU - Aceituno A AD - RTI International, Durham, NC, USA. FAU - Parlberg, L AU - Parlberg L AD - RTI International, Durham, NC, USA. FAU - McClure, E M AU - McClure EM AUID- ORCID: 0000-0001-8659-5444 AD - RTI International, Durham, NC, USA. CN - PURPOSE Study Group LA - eng GR - OPP1169824/Bill and Melinda Gates Foundation/ PT - Journal Article PT - Multicenter Study PT - Observational Study PT - Research Support, Non-U.S. Gov't DEP - 20210719 PL - England TA - BJOG JT - BJOG : an international journal of obstetrics and gynaecology JID - 100935741 SB - IM CIN - BJOG. 2021 Oct;128(11):1774. doi: 10.1111/1471-0528.16822. PMID: 34216093 CIN - BJOG. 2022 Jan;129(1):172-173. doi: 10.1111/1471-0528.16881. PMID: 34519159 MH - Adult MH - Female MH - Fetal Death/*prevention & control MH - Gestational Age MH - Humans MH - India/epidemiology MH - Infant, Newborn MH - Infant, Small for Gestational Age MH - Obstetric Labor Complications/epidemiology MH - Pakistan/epidemiology MH - Pregnancy MH - Prenatal Care/standards/*statistics & numerical data MH - Prospective Studies MH - Quality of Health Care/*statistics & numerical data MH - Stillbirth/*epidemiology OTO - NOTNLM OT - Antepartum haemorrhage OT - hypertension OT - preventability OT - small for gestational age OT - stillbirth FIR - Goudar, Shivaprasad S IR - Goudar SS FIR - Dhaded, Sangappa M IR - Dhaded SM FIR - Nagmoti, Mahantesh B IR - Nagmoti MB FIR - Harakuni, Sheetal U IR - Harakuni SU FIR - Somannavar, Manjunath S IR - Somannavar MS FIR - Yogeshkumar, S IR - Yogeshkumar S FIR - Guruprasad, Gowdar IR - Guruprasad G FIR - Raghoji, Chaitali R IR - Raghoji CR FIR - Nadig, Naveen G IR - Nadig NG FIR - Aradhya, Gayathri H IR - Aradhya GH FIR - Kusagur, Varun B IR - Kusagur VB FIR - Patil, Lingaraja Gowda C IR - Patil LGC FIR - Siddartha, E S IR - Siddartha ES FIR - Dhananjaya, Shobha IR - Dhananjaya S FIR - Sarvamangala, B IR - Sarvamangala B FIR - Veena, G R IR - Veena GR FIR - Kulkarni, Vardendra G IR - Kulkarni VG FIR - Rajashekar, K S IR - Rajashekar KS FIR - Sunilkumar, K Byranahalli IR - Sunilkumar KB FIR - Nagaraj, T S IR - Nagaraj TS FIR - Jeevika, M U IR - Jeevika MU FIR - Harikiran, Reddy R IR - Harikiran RR FIR - Joish, Upendra Kumar IR - Joish UK FIR - Mangala, G K IR - Mangala GK FIR - Pujar, Sneharoopa IR - Pujar S FIR - Saleem, Sarah IR - Saleem S FIR - Tikmani, Shiyam Sunder IR - Tikmani SS FIR - Ariff, Shabina IR - Ariff S FIR - Shaikh, Lumaan IR - Shaikh L FIR - Uddin, Zeeshan IR - Uddin Z FIR - Ghanchi, Najia IR - Ghanchi N FIR - Ahmed, Imran IR - Ahmed I FIR - Feroz, Anam IR - Feroz A FIR - Reza, Sayyeda IR - Reza S FIR - Roujani, Sana IR - Roujani S FIR - Masheer, Shazia IR - Masheer S FIR - Nausheen, Sidrah IR - Nausheen S FIR - Yasmin, Haleema IR - Yasmin H FIR - Bano, Khadija IR - Bano K FIR - Tanveer, Saba IR - Tanveer S FIR - Haider, Maharukh IR - Haider M FIR - Raza, Jamal IR - Raza J FIR - Shaikh, Mehmood IR - Shaikh M FIR - Hanif, Muhammad IR - Hanif M FIR - Aceituna, Anna IR - Aceituna A FIR - Bann, Carla IR - Bann C FIR - Hwang, Kay IR - Hwang K FIR - Kim, Jean IR - Kim J FIR - McClure, Elizabeth IR - McClure E FIR - Moore, Janet IR - Moore J FIR - Parlberg, Lindsay IR - Parlberg L FIR - Parepelli, Suchetia IR - Parepelli S FIR - Goldenberg, Robert L IR - Goldenberg RL EDAT- 2021/06/27 06:00 MHDA- 2021/09/29 06:00 CRDT- 2021/06/26 12:13 PHST- 2021/05/06 00:00 [accepted] PHST- 2021/06/27 06:00 [pubmed] PHST- 2021/09/29 06:00 [medline] PHST- 2021/06/26 12:13 [entrez] AID - 10.1111/1471-0528.16820 [doi] PST - ppublish SO - BJOG. 2021 Oct;128(11):1762-1773. doi: 10.1111/1471-0528.16820. Epub 2021 Jul 19. PMID- 34173887 OWN - NLM STAT- MEDLINE DCOM- 20220128 LR - 20220726 IS - 1436-3771 (Electronic) IS - 1432-6981 (Print) IS - 1432-6981 (Linking) VI - 26 IP - 1 DP - 2022 Jan TI - The impact of the COVID-19 pandemic on the dental-maxillofacial emergency service of a German university hospital in the year 2020. PG - 385-395 LID - 10.1007/s00784-021-04010-7 [doi] AB - OBJECTIVES: COVID-19 is considered one of the most serious pandemic in history and has posed major challenges to the world's health care. Dentistry and oral and maxillofacial surgery (CMFS) are particularly affected due to direct exposure to the respiratory tract, as the reservoir of SARS-CoV-2. In this study, the impact of the COVID-19-pandemic on a dental and CMFS emergency services in Germany in 2020 was first time investigated and correlated with governmental restriction measures in public life. MATERIALS AND METHODS: Epidemiological data of a German University Hospital were analysed from a total of 8386 patients in 2019 and 2020. Parameters included information on demographics, time, weekday and reason for presentation, as well as diagnosis and therapy performed. Data from 2020 were compared with those from 2019, taking into account the nationwide periods of public life restrictions. RESULTS: In 2020, 22% fewer patients presented via dental and CMFS emergency service. In a monthly comparison, there were negative peaks of up to - 41% in November, but also a plus of 26% in July. The largest decreases were recorded during the lockdown periods in spring (- 33%) and winter (- 39%). Further, a threefold increase in actual emergencies and inpatient admissions revealed during these time periods (p < 0.001). CONCLUSIONS: COVID-19 pandemic had a significant impact on the dental and CMFS emergency service in 2020 resulting in more severe cases. CLINICAL RELEVANCE: This study underlines the importance of maintaining an emergency service system and basic outpatient care in these specialities, which requires uniform recommendations from the medical-dental societies and politics. CI - (c) 2021. The Author(s). FAU - Thiem, D G E AU - Thiem DGE AD - Department of Oral and Maxillofacial Surgery, Facial Plastic Surgery, University Medical Centre Mainz, Augustusplatz 2, 55131, Mainz, Germany. daniel.thiem@uni-mainz.de. FAU - Polsak, M AU - Polsak M AD - Department of Oral and Maxillofacial Surgery, Facial Plastic Surgery, University Medical Centre Mainz, Augustusplatz 2, 55131, Mainz, Germany. FAU - Romer, P AU - Romer P AD - Department of Oral and Maxillofacial Surgery, Facial Plastic Surgery, University Medical Centre Mainz, Augustusplatz 2, 55131, Mainz, Germany. FAU - Gielisch, M AU - Gielisch M AD - Department of Oral and Maxillofacial Surgery, Facial Plastic Surgery, University Medical Centre Mainz, Augustusplatz 2, 55131, Mainz, Germany. FAU - Blatt, S AU - Blatt S AD - Department of Oral and Maxillofacial Surgery, Facial Plastic Surgery, University Medical Centre Mainz, Augustusplatz 2, 55131, Mainz, Germany. FAU - Al-Nawas, B AU - Al-Nawas B AD - Department of Oral and Maxillofacial Surgery, School of Dentistry, Kyung Hee University, Seoul, Korea. FAU - Kammerer, P W AU - Kammerer PW AD - Department of Oral and Maxillofacial Surgery, Facial Plastic Surgery, University Medical Centre Mainz, Augustusplatz 2, 55131, Mainz, Germany. LA - eng PT - Journal Article DEP - 20210626 PL - Germany TA - Clin Oral Investig JT - Clinical oral investigations JID - 9707115 MH - *COVID-19 MH - Communicable Disease Control MH - Hospitals, University MH - Humans MH - *Pandemics MH - SARS-CoV-2 PMC - PMC8233631 OTO - NOTNLM OT - CMFS OT - Government guidelines OT - Healthcare system OT - Primary care OT - SARS-CoV-2 COIS- The authors declare that they have no competing interests. EDAT- 2021/06/27 06:00 MHDA- 2022/01/29 06:00 PMCR- 2021/06/26 CRDT- 2021/06/26 12:08 PHST- 2021/03/21 00:00 [received] PHST- 2021/04/23 00:00 [accepted] PHST- 2021/06/27 06:00 [pubmed] PHST- 2022/01/29 06:00 [medline] PHST- 2021/06/26 12:08 [entrez] PHST- 2021/06/26 00:00 [pmc-release] AID - 10.1007/s00784-021-04010-7 [pii] AID - 4010 [pii] AID - 10.1007/s00784-021-04010-7 [doi] PST - ppublish SO - Clin Oral Investig. 2022 Jan;26(1):385-395. doi: 10.1007/s00784-021-04010-7. Epub 2021 Jun 26. PMID- 34171517 OWN - NLM STAT- MEDLINE DCOM- 20211208 LR - 20240923 IS - 1532-8449 (Electronic) IS - 0882-5963 (Print) IS - 0882-5963 (Linking) VI - 61 DP - 2021 Nov-Dec TI - Impact of COVID-19 on Pediatric Clinical Research. PG - 240-244 LID - S0882-5963(21)00176-7 [pii] LID - 10.1016/j.pedn.2021.06.005 [doi] AB - PURPOSE: Many public institutions and settings have taken action to limit exposure to and slow the spread of the novel coronavirus (COVID-19). We sought to characterize the impact of stay-at-home orders on our study of cerebral autoregulation and its association with developmental delays in infants with congenital heart disease compared with healthy controls. DESIGN AND METHODS: We calculated the number of participants recruited (i.e., not enrolled in the study) and assessed (i.e., currently enrolled) before March 2020 (pre-COVID-19) and the number of participants that we could not recruit or assess between March and July 2020 (missed due to COVID-19), separately for congenital heart disease and healthy control infants, in reference to the impacts of COVID-19. We used negative binomial regressions to determine incidence rate ratios which compared participants recruited and assessed pre-COVID-19 and missed due to COVID-19. RESULTS: Recruitment and assessments significantly decreased following the pandemic, i.e., participants were more likely to be recruited or be assessed pre-COVID-19 compared to during the pandemic. Study participants were 3.3 times as likely to have assessments performed pre-COVID-19 compared to during the COVID-19 pandemic (p < 0.001). CLINICAL IMPLICATIONS: Clinical research teams may consider making protocol modifications such as virtual visits or video recordings explaining the study, for example, to adjust to the restrictions caused by COVID-19. CONCLUSION: The COVID-19 pandemic drastically reduced recruitment and assessments completed in our study. Study teams will need to continue to modify procedures for recruitment and assessments that align with COVID-19 regulations to facilitate research progress during the pandemic. CI - Copyright (c) 2021 Elsevier Inc. All rights reserved. FAU - Tran, Nhu N AU - Tran NN AD - Keck School of Medicine of University of Southern California (KSOM USC), Department of Surgery and Children's Hospital, Los Angeles (CHLA), United States of America. Electronic address: ntran@chla.usc.edu. FAU - Tran, Michelle AU - Tran M AD - Department of Preventive Medicine, KSOM USC and Division of Research on Children, Youth, and Families, The Saban Research Institute, CHLA, United States of America. FAU - Lopez, Jeraldine AU - Lopez J AD - Division of Research on Children, Youth, and Families, The Saban Research Institute, CHLA, United States of America. FAU - Woon, Jessica AU - Woon J AD - Department of Biological Sciences, USC Dornsife College of Letters, Arts, and Sciences and Division of Research on Children, Youth, and Families, The Saban Research Institute, CHLA, United States of America. FAU - Nguyen, Jennifer AU - Nguyen J AD - Department of Biological Sciences, USC Dornsife College of Letters, Arts, and Sciences and Division of Research on Children, Youth, and Families, The Saban Research Institute, CHLA, United States of America. FAU - Brecht, Mary-Lynn AU - Brecht ML AD - University of California, Los Angeles, School of Nursing, United States of America. LA - eng GR - UL1 TR001855/TR/NCATS NIH HHS/United States PT - Journal Article DEP - 20210615 PL - United States TA - J Pediatr Nurs JT - Journal of pediatric nursing JID - 8607529 SB - IM MH - *COVID-19 MH - Child MH - Humans MH - Pandemics MH - SARS-CoV-2 PMC - PMC8205280 OTO - NOTNLM OT - COVID-19 OT - Clinical research OT - Congenital heart disease OT - Pediatrics OT - Stay-at-home order EDAT- 2021/06/26 06:00 MHDA- 2021/12/15 06:00 PMCR- 2021/06/15 CRDT- 2021/06/25 20:16 PHST- 2020/12/13 00:00 [received] PHST- 2021/06/10 00:00 [revised] PHST- 2021/06/11 00:00 [accepted] PHST- 2021/06/26 06:00 [pubmed] PHST- 2021/12/15 06:00 [medline] PHST- 2021/06/25 20:16 [entrez] PHST- 2021/06/15 00:00 [pmc-release] AID - S0882-5963(21)00176-7 [pii] AID - 10.1016/j.pedn.2021.06.005 [doi] PST - ppublish SO - J Pediatr Nurs. 2021 Nov-Dec;61:240-244. doi: 10.1016/j.pedn.2021.06.005. Epub 2021 Jun 15. PMID- 34168460 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220424 IS - 1178-2390 (Print) IS - 1178-2390 (Electronic) IS - 1178-2390 (Linking) VI - 14 DP - 2021 TI - Psychological Effects of Lockdown Measures for the COVID-19 Outbreak in Patients with Systemic Lupus Erythematosus. PG - 1475-1488 LID - 10.2147/JMDH.S311325 [doi] AB - OBJECTIVE: To compare the psychological impact of the lockdown measures contrasting the COVID-19 outbreak between systemic lupus erythematosus (SLE) and general population. PATIENTS AND METHODS: From July 15th to August 15th 2020, a retrospective survey referring to the period March 9th to May 18th 2020 was administered to SLE patients and the results of the survey, called LEPRE (Lupus Erythematosus PREsto) study, were compared with those from the PRESTO (imPact of quaRantine mEasures againST cOvid19) project, the same survey provided to the general population. Consecutive patients >18 years old affected by SLE and regularly followed in a single rheumatologic centre were involved. Primary outcome was to compare the scores of the Impact of Events Scale-Revised (IES-R), the General Health Questionnaire 12 (GHQ-12) and the Center for Epidemiological Depression Scale (CES-D) between patients and general population. RESULTS: A total of 64 patients completed the survey. After a propensity score matching, they were compared to 128 people from PRESTO project. The median age among patients was 43 years (I-III interquartile range 35-54.5), 88% were female and 100% Caucasian. IES-R [(score>23: 57% (34) vs 49% (58)], GHQ-12 [(score>13: 85% (52) vs 88% (106)], and CES-D [(score>15: 45% (28) vs 40% (46)] scores were not statistically different between patients and controls (p>0.05). CONCLUSION: Restrictive measures for COVID-19 pandemic had no greater impact on patients with SLE than in the general population. Strategy for coping to the SLE might be useful during lockdown measures and may be helpful for other chronic conditions. CI - (c) 2021 Quartuccio et al. FAU - Quartuccio, Luca AU - Quartuccio L AUID- ORCID: 0000-0002-0134-6439 AD - Rheumatology Clinic, Department of Specialist Medicine, ASUFC, Udine, Italy. AD - Department of Medicine (DAME), University of Udine, Udine, Italy. FAU - De Marchi, Ginevra AU - De Marchi G AD - Rheumatology Clinic, Department of Specialist Medicine, ASUFC, Udine, Italy. FAU - Azzolina, Danila AU - Azzolina D AD - Unit of Biostatistics, Epidemiology and Public Health, Department of Cardiology, Thoracic and Vascular Sciences, University of Padova, Padova, Italy. FAU - Maresio, Elisabetta AU - Maresio E AD - Prochild Onlus, Unit of Psychotherapy and Psychology, Trieste, Italy. FAU - Colatutto, Donatella AU - Colatutto D AD - Rheumatology Clinic, Department of Specialist Medicine, ASUFC, Udine, Italy. AD - Department of Medicine (DAME), University of Udine, Udine, Italy. FAU - Binutti, Marco AU - Binutti M AD - Rheumatology Clinic, Department of Specialist Medicine, ASUFC, Udine, Italy. AD - Department of Medicine (DAME), University of Udine, Udine, Italy. FAU - Monte, Marinella AU - Monte M AD - Associazione Malati Reumatici (A.Ma.Re.), Udine, Italy. FAU - Gallipoli, Silvia AU - Gallipoli S AUID- ORCID: 0000-0003-2635-1936 AD - Zeta Research s.r.l., Trieste, Italy. FAU - Zobec, Federica AU - Zobec F AD - Zeta Research s.r.l., Trieste, Italy. FAU - Lanera, Corrado AU - Lanera C AD - Unit of Biostatistics, Epidemiology and Public Health, Department of Cardiology, Thoracic and Vascular Sciences, University of Padova, Padova, Italy. FAU - Lorenzoni, Giulia AU - Lorenzoni G AD - Unit of Biostatistics, Epidemiology and Public Health, Department of Cardiology, Thoracic and Vascular Sciences, University of Padova, Padova, Italy. FAU - Palese, Alvisa AU - Palese A AD - Department of Medicine (DAME), University of Udine, Udine, Italy. AD - School of Nursing, Department of Medicine, University of Udine, Udine, Italy. FAU - Silano, Marco AU - Silano M AD - Unit of Human Nutrition and Health, Department of Food Safety Nutrition and Veterinary Public Health, Istituto Superiore di Sanita, Rome, 00161, Italy. FAU - De Vita, Salvatore AU - De Vita S AD - Rheumatology Clinic, Department of Specialist Medicine, ASUFC, Udine, Italy. AD - Department of Medicine (DAME), University of Udine, Udine, Italy. FAU - Gregori, Dario AU - Gregori D AUID- ORCID: 0000-0001-7906-0580 AD - Unit of Biostatistics, Epidemiology and Public Health, Department of Cardiology, Thoracic and Vascular Sciences, University of Padova, Padova, Italy. LA - eng PT - Journal Article DEP - 20210617 PL - New Zealand TA - J Multidiscip Healthc JT - Journal of multidisciplinary healthcare JID - 101512691 PMC - PMC8216740 OTO - NOTNLM OT - COVID-19 OT - psychological distress OT - systemic lupus erythematosus COIS- No authors have any financial support or other benefits from commercial sources for the work reported on in the manuscript, or any other financial interests which could create a potential conflict of interest or the appearance of a conflict of interest concerning the work. The authors reported no conflicts of interest for this work. EDAT- 2021/06/26 06:00 MHDA- 2021/06/26 06:01 PMCR- 2021/06/17 CRDT- 2021/06/25 06:48 PHST- 2021/03/18 00:00 [received] PHST- 2021/05/05 00:00 [accepted] PHST- 2021/06/25 06:48 [entrez] PHST- 2021/06/26 06:00 [pubmed] PHST- 2021/06/26 06:01 [medline] PHST- 2021/06/17 00:00 [pmc-release] AID - 311325 [pii] AID - 10.2147/JMDH.S311325 [doi] PST - epublish SO - J Multidiscip Healthc. 2021 Jun 17;14:1475-1488. doi: 10.2147/JMDH.S311325. eCollection 2021. PMID- 34162652 OWN - NLM STAT- MEDLINE DCOM- 20210628 LR - 20220531 IS - 2044-6055 (Electronic) IS - 2044-6055 (Linking) VI - 11 IP - 6 DP - 2021 Jun 23 TI - Prevalence and risk factors of depression symptoms among Chinese seafarers during the COVID-19 pandemic: a cross-sectional study. PG - e048660 LID - 10.1136/bmjopen-2021-048660 [doi] LID - e048660 AB - BACKGROUND: To curb the spread of COVID-19, most countries have adopted measures such as banning shore leave at ports and placed restrictions on crew change. Seafarers may bear an excess pressure during the COVID-19 pandemic. This study aimed to investigate the prevalence and risk factors associated with depression symptoms among Chinese seafarers during the COVID-19 pandemic. DESIGN: Cross-sectional study. METHODS: This field survey-based study was conducted at Rongcheng Port, Shandong Province, China, from 10 June 2020 to 25 July 2020. Sociodemographic and occupational characteristics and health-related behaviours were collected through a face-to-face questionnaire. The Self-Rating Depression Scale was used to evaluate depression status during the preceding week. Logistic regression models were used to explore factors related to depression. RESULTS: 441 male Chinese seafarers were enrolled. Overall, the proportions of seafarers with low, moderate and severe depression symptoms were 23.35%, 9.30% and 9.07%, respectively. Compared with those with good self-rated health (SRH), seafarers with poor SRH had higher odds of depression (OR, 2.24, 95% CI 1.22 to 4.11). Less leisure time or physical exercise was associated with more severe self-reported depression symptoms (1-3 per week vs >/=4 per week: OR, 1.72, 95% CI 0.71 to 4.14; none vs >/=4 per week: OR, 3.93, 95% CI 1.67 to 9.26). Poor sleep quality was associated with higher likelihood of reporting severe depression (fair vs good: OR, 2.78, 95% CI 1.54 to 5.01; poor vs good: OR, 4.30, 95% CI 1.65 to 11.24). The more frequent seafarers worked overtime a week, the higher the likelihood of reporting severe depression symptoms (1-2 per week vs none: OR, 1.82, 95% CI 1.04 to 3.18; >/=3 per week vs none: OR, 2.49, 95% CI 1.05 to 5.92). Also, high perceived work stress was linked to higher odds of being depressed (intermediate vs low: OR, 2.06, 95% CI 0.78 to 5.46; high vs low: OR, 3.83, 95% CI 1.35 to 10.90). CONCLUSIONS: There is a high burden of depression associated with COVID-19 among seafarers. Special interventions that protect the mental health of seafarers are more critical than ever in the context of the pandemic. CI - (c) Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. FAU - Qin, Wenzhe AU - Qin W AUID- ORCID: 0000-0002-2891-4221 AD - Centre for Health Management and Policy Research, School of Public Health, Cheeloo College of Medicine, Shandong University, Jinan, China. FAU - Li, Lei AU - Li L AD - Department of Health Quarantine, Jinan Airport Customs, Jinan, China. FAU - Zhu, Dongshan AU - Zhu D AUID- ORCID: 0000-0002-0697-7432 AD - Centre for Health Management and Policy Research, School of Public Health, Cheeloo College of Medicine, Shandong University, Jinan, China. FAU - Ju, Chengfei AU - Ju C AD - Department of Health Quarantine, Rongcheng Customs, Rongcheng, China. FAU - Bi, Pengfei AU - Bi P AD - Department of Health Quarantine, Rongcheng Customs, Rongcheng, China. FAU - Li, Shixue AU - Li S AD - Centre for Health Management and Policy Research, School of Public Health, Cheeloo College of Medicine, Shandong University, Jinan, China shixueli@sdu.edu.cn. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20210623 PL - England TA - BMJ Open JT - BMJ open JID - 101552874 SB - IM MH - Anxiety MH - *COVID-19/psychology MH - China/epidemiology MH - Cross-Sectional Studies MH - *Depression/epidemiology MH - Humans MH - Male MH - Naval Medicine MH - Pandemics MH - Prevalence MH - Risk Factors MH - Surveys and Questionnaires PMC - PMC8230921 OTO - NOTNLM OT - COVID-19 OT - depression & mood disorders OT - epidemiology COIS- Competing interests: None declared. EDAT- 2021/06/25 06:00 MHDA- 2021/06/29 06:00 PMCR- 2021/06/23 CRDT- 2021/06/24 05:41 PHST- 2021/06/24 05:41 [entrez] PHST- 2021/06/25 06:00 [pubmed] PHST- 2021/06/29 06:00 [medline] PHST- 2021/06/23 00:00 [pmc-release] AID - bmjopen-2021-048660 [pii] AID - 10.1136/bmjopen-2021-048660 [doi] PST - epublish SO - BMJ Open. 2021 Jun 23;11(6):e048660. doi: 10.1136/bmjopen-2021-048660. PMID- 34159050 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240402 IS - 2211-3355 (Print) IS - 2211-3355 (Electronic) IS - 2211-3355 (Linking) VI - 23 DP - 2021 Sep TI - Turning over a new leaf: Vape shop closings, openings and transitions in six U.S. Metropolitan statistical areas. PG - 101428 LID - 10.1016/j.pmedr.2021.101428 [doi] LID - 101428 AB - This study characterizes vape shop closings, openings, and changes in product mix in six U.S. metropolitan statistical areas with different tobacco and marijuana policies. With concern for higher rates of marijuana use among those who vape nicotine, the presence of marijuana-related terms in store names was also assessed. A census of stores that were classified online as vape shops/stores or vaporizer stores were telephoned in April-May 2018 (n = 739) and July-September 2019 (n = 919) to verify whether vape products and other tobacco products (OTP) were sold. We computed the percent of stores that closed, opened, and started/stopped selling OTP. Multilevel models tested whether these events varied by store type and by neighborhood demographics. Within 16 months, 11.5% of 739 stores had closed and 29.8% of 919 stores at follow-up had opened. Closings were more likely among vape-only than vape + OTP stores (AOR = 2.51, 95% CI = 1.47,4.29); vape-only stores were less likely to open (AOR = 0.46, 95% CI = 0.34,0.62). Regardless of store type, the odds of a store opening increased as the proportion of non-Hispanic/Latino White residents in the census tract increased (AOR = 1.47, 95% CI = 1.18,1.85). Overall, 2.0% of stores (vape-only and vape + OTP) had marijuana-related names at baseline and 3.5% at follow-up. The observed change (1.6% to 5.8%) was greatest in Oklahoma City, where the state legalized medical marijuana between baseline and follow-up. More stores were opening than closing in six U.S. metropolitan statistical areas before statewide sales restrictions on flavored tobacco and COVID-19. Uniform licensing is recommended to define vape shops and track their location and sales practices. CI - (c) 2021 Published by Elsevier Inc. FAU - Barker, Dianne C AU - Barker DC AD - Barker Bi-Coastal Health Consultants, Inc., 20 Ellery Rd, Newport, RI 02840, USA. FAU - Henriksen, Lisa AU - Henriksen L AD - Stanford Prevention Research Center, Stanford University School of Medicine, 1070 Arastradero Road, Suite 100, Palo Alto, CA 94304, USA. FAU - Voelker, David H AU - Voelker DH AD - Stanford Prevention Research Center, Stanford University School of Medicine, 1070 Arastradero Road, Suite 100, Palo Alto, CA 94304, USA. FAU - Ali, Amna AU - Ali A AD - Stanford Prevention Research Center, Stanford University School of Medicine, 1070 Arastradero Road, Suite 100, Palo Alto, CA 94304, USA. FAU - Raskind, Ilana G AU - Raskind IG AD - Stanford Prevention Research Center, Stanford University School of Medicine, 1070 Arastradero Road, Suite 100, Palo Alto, CA 94304, USA. FAU - Schleicher, Nina C AU - Schleicher NC AD - Stanford Prevention Research Center, Stanford University School of Medicine, 1070 Arastradero Road, Suite 100, Palo Alto, CA 94304, USA. FAU - Johnson, Trent O AU - Johnson TO AD - Stanford Prevention Research Center, Stanford University School of Medicine, 1070 Arastradero Road, Suite 100, Palo Alto, CA 94304, USA. FAU - Berg, Carla J AU - Berg CJ AD - Department of Prevention and Community Health, Milken Institute School of Public Health, George Washington Cancer Center, George Washington University, 800 22nd St NW, #7000C, Washington, DC 20052, USA. LA - eng GR - R01 CA215155/CA/NCI NIH HHS/United States GR - R01 CA217165/CA/NCI NIH HHS/United States GR - T32 HL007034/HL/NHLBI NIH HHS/United States PT - Journal Article DEP - 20210530 PL - United States TA - Prev Med Rep JT - Preventive medicine reports JID - 101643766 PMC - PMC8193612 OTO - NOTNLM OT - Census tract demographics OT - Licensure OT - Longitudinal OT - Marijuana OT - Other tobacco products OT - Policy OT - Retail environment OT - Tobacco control OT - Vape Shops COIS- The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2021/06/24 06:00 MHDA- 2021/06/24 06:01 PMCR- 2021/05/30 CRDT- 2021/06/23 07:21 PHST- 2020/11/25 00:00 [received] PHST- 2021/05/13 00:00 [revised] PHST- 2021/05/25 00:00 [accepted] PHST- 2021/06/23 07:21 [entrez] PHST- 2021/06/24 06:00 [pubmed] PHST- 2021/06/24 06:01 [medline] PHST- 2021/05/30 00:00 [pmc-release] AID - S2211-3355(21)00118-2 [pii] AID - 101428 [pii] AID - 10.1016/j.pmedr.2021.101428 [doi] PST - epublish SO - Prev Med Rep. 2021 May 30;23:101428. doi: 10.1016/j.pmedr.2021.101428. eCollection 2021 Sep. PMID- 34155237 OWN - NLM STAT- MEDLINE DCOM- 20210707 LR - 20260127 IS - 2045-2322 (Electronic) IS - 2045-2322 (Linking) VI - 11 IP - 1 DP - 2021 Jun 21 TI - The effect of COVID19 pandemic restrictions on an urban rodent population. PG - 12957 LID - 10.1038/s41598-021-92301-0 [doi] LID - 12957 AB - Shortly after the enactment of restrictions aimed at limiting the spread of COVID-19, various local government and public health authorities around the world reported an increased sighting of rats. Such reports have yet to be empirically validated. Here we combined data from multi-catch rodent stations (providing data on rodent captures), rodent bait stations (providing data on rodent activity) and residents' complaints to explore the effects of a six week lockdown period on rodent populations within the City of Sydney, Australia. The sampling interval encompassed October 2019 to July 2020 with lockdown defined as the interval from April 1st to May 15th, 2020. Rodent captures and activity (visits to bait stations) were stable prior to lockdown. Captures showed a rapid increase and then decline during the lockdown, while rodent visits to bait stations declined throughout this period. There were no changes in the frequency of complaints during lockdown relative to before and after lockdown. There was a non-directional change in the geographical distribution of indices of rodent abundance suggesting that rodents redistributed in response to resource scarcity. We hypothesize that lockdown measures initially resulted in increased rodent captures due to sudden shortage of human-derived food resources. Rodent visits to bait stations might not show this pattern due to the nature of the binary data collected, namely the presence or absence of a visit. Relocation of bait stations driven by pest management goals may also have affected the detection of any directional spatial effect. We conclude that the onset of COVID-19 may have disrupted commensal rodent populations, with possible implications for the future management of these ubiquitous urban indicator species. FAU - Bedoya-Perez, Miguel A AU - Bedoya-Perez MA AUID- ORCID: 0000-0003-2081-4485 AD - Brain and Mind Centre, The University of Sydney, Sydney, NSW, 2050, Australia. miguel.bedoyaperez@sydney.edu.au. AD - School of Psychology, The University of Sydney, Faculty of Science, Sydney, NSW, 2006, Australia. miguel.bedoyaperez@sydney.edu.au. AD - School of Life and Environmental Sciences, The University of Sydney, Faculty of Science, Sydney, NSW, 2006, Australia. miguel.bedoyaperez@sydney.edu.au. FAU - Ward, Michael P AU - Ward MP AUID- ORCID: 0000-0002-9921-4986 AD - Sydney School of Veterinary Science, The University of Sydney, Faculty of Science, Sydney, NSW, 2570, Australia. FAU - Loomes, Max AU - Loomes M AUID- ORCID: 0000-0003-1042-0968 AD - Brain and Mind Centre, The University of Sydney, Sydney, NSW, 2050, Australia. AD - School of Psychology, The University of Sydney, Faculty of Science, Sydney, NSW, 2006, Australia. FAU - McGregor, Iain S AU - McGregor IS AUID- ORCID: 0000-0002-9307-7159 AD - Brain and Mind Centre, The University of Sydney, Sydney, NSW, 2050, Australia. AD - School of Psychology, The University of Sydney, Faculty of Science, Sydney, NSW, 2006, Australia. AD - Lambert Initiative for Cannabinoid Therapeutics, The University of Sydney, Sydney, NSW, 2050, Australia. FAU - Crowther, Mathew S AU - Crowther MS AUID- ORCID: 0000-0001-8968-1161 AD - School of Life and Environmental Sciences, The University of Sydney, Faculty of Science, Sydney, NSW, 2006, Australia. LA - eng GR - 2019/609066/The Council of the City of Sydney/ PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20210621 PL - England TA - Sci Rep JT - Scientific reports JID - 101563288 SB - IM MH - Animals MH - Australia/epidemiology MH - COVID-19/*epidemiology/*prevention & control/virology MH - Cities/epidemiology MH - Food MH - Humans MH - Pandemics/*prevention & control MH - Pest Control/*methods MH - Quarantine/*methods MH - Rats MH - *SARS-CoV-2 MH - Urban Population PMC - PMC8217515 COIS- The authors declare no competing interests. EDAT- 2021/06/23 06:00 MHDA- 2021/07/08 06:00 PMCR- 2021/06/21 CRDT- 2021/06/22 06:07 PHST- 2020/11/18 00:00 [received] PHST- 2021/06/03 00:00 [accepted] PHST- 2021/06/22 06:07 [entrez] PHST- 2021/06/23 06:00 [pubmed] PHST- 2021/07/08 06:00 [medline] PHST- 2021/06/21 00:00 [pmc-release] AID - 10.1038/s41598-021-92301-0 [pii] AID - 92301 [pii] AID - 10.1038/s41598-021-92301-0 [doi] PST - epublish SO - Sci Rep. 2021 Jun 21;11(1):12957. doi: 10.1038/s41598-021-92301-0. PMID- 34155072 OWN - NLM STAT- MEDLINE DCOM- 20210624 LR - 20220531 IS - 2044-6055 (Electronic) IS - 2044-6055 (Linking) VI - 11 IP - 6 DP - 2021 Jun 21 TI - Policy implementation analysis on access to healthcare among undocumented immigrants in seven autonomous communities of Spain, 2012-2018. PG - e045626 LID - 10.1136/bmjopen-2020-045626 [doi] LID - e045626 AB - BACKGROUND: In 2012, the Government of Spain enacted Royal Decree-Law (RDL) 16/2012 and Royal Decree (RD) 1192/2012 excluding undocumented immigrants from publicly funded healthcare services. We conducted a policy implementation analysis to describe and evaluate the legal and regulatory actions taken at the autonomous community (AC) level after enactment of 2012 RDL and RD and their impact on access to general healthcare and HIV services among undocumented immigrants. METHODS: We reviewed documents published by the governments of seven ACs (Andalucia, Aragon, Euskadi (Basque Country), Castilla-La Mancha, Galicia, Madrid, Valencia) from April 2012 to July 2018, describing circumstances under which undocumented immigrants would be able to access free healthcare services. We developed indicators according to the main systemic barriers presented in official documents to analyse access to free healthcare across the participating ACs. ACs were grouped under five access categories: high, medium-high, medium, medium-low and low. RESULTS: Andalucia provided the highest access to free healthcare for undocumented immigrants in both general care and HIV treatment. Medium-high access was provided by Euskadi and medium access by Aragon, Madrid and Valencia. Castilla-La Mancha provided medium-low access. Galicia had low access. Only Madrid and Galicia provided different and higher level of access to undocumented migrants in HIV care compared with general healthcare. CONCLUSIONS: Implementation of 2012 RDL and RD across the ACs varied significantly, in part due to the decentralisation of the Spanish healthcare system. The challenge of healthcare access among undocumented immigrants included persistent systemic restrictions, frequent and unclear rule changes, and the need to navigate differences across ACs of Spain. CI - (c) Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. FAU - Gogishvili, Megi AU - Gogishvili M AUID- ORCID: 0000-0001-6452-109X AD - Center of Systems and Community Design, City University of New York School of Public Health, New York, New York, USA. FAU - Costa, Sergio A AU - Costa SA AD - Center of Systems and Community Design, City University of New York School of Public Health, New York, New York, USA. FAU - Florez, Karen AU - Florez K AD - Center of Systems and Community Design, City University of New York School of Public Health, New York, New York, USA. FAU - Huang, Terry T AU - Huang TT AUID- ORCID: 0000-0001-5544-5187 AD - Center of Systems and Community Design, City University of New York School of Public Health, New York, New York, USA terry.huang@sph.cuny.edu. LA - eng PT - Journal Article PT - Review DEP - 20210621 PL - England TA - BMJ Open JT - BMJ open JID - 101552874 SB - IM MH - *Emigrants and Immigrants MH - Health Services Accessibility MH - Humans MH - Policy MH - Policy Making MH - Spain MH - *Undocumented Immigrants PMC - PMC8217913 OTO - NOTNLM OT - HIV & AIDS OT - health policy OT - public health COIS- Competing interests: None declared. EDAT- 2021/06/23 06:00 MHDA- 2021/06/25 06:00 PMCR- 2021/06/21 CRDT- 2021/06/22 05:53 PHST- 2021/06/22 05:53 [entrez] PHST- 2021/06/23 06:00 [pubmed] PHST- 2021/06/25 06:00 [medline] PHST- 2021/06/21 00:00 [pmc-release] AID - bmjopen-2020-045626 [pii] AID - 10.1136/bmjopen-2020-045626 [doi] PST - epublish SO - BMJ Open. 2021 Jun 21;11(6):e045626. doi: 10.1136/bmjopen-2020-045626. PMID- 34153317 OWN - NLM STAT- MEDLINE DCOM- 20220620 LR - 20260728 IS - 1879-0518 (Electronic) IS - 0010-7824 (Print) IS - 0010-7824 (Linking) VI - 111 DP - 2022 Jul TI - A systematic review exploring the contraception values and preferences of sex workers, transmasculine individuals, people who inject drugs, and those living in humanitarian contexts. PG - 32-38 LID - S0010-7824(21)00191-8 [pii] LID - 10.1016/j.contraception.2021.06.008 [doi] AB - OBJECTIVE: We sought to systematically review the literature on values and preferences regarding contraception among individuals within selected key populations. STUDY DESIGN: As part of a larger set of reviews on patients' and providers' values and preferences related to contraception globally, we searched ten electronic databases for articles from January 1, 2005 to July 27, 2020. No language restrictions were applied. Data was independently abstracted by two authors and study rigor was assessed using an 8-item measure developed by the Evidence Project for quantitative studies and an adapted CASP checklist for qualitative studies. RESULTS: We identified 12 studies that met our inclusion criteria examining selected key populations, including sex workers, transmasculine individuals, people who inject drugs, or those living in humanitarian contexts. Seven key themes that spoke to values and preferences emerged related to: autonomy, perceived effectiveness and safety, birth spacing and family outcomes, impacts on sexual experience, hormonal effects (e.g. desire for non-hormonal method or perception that the method is more natural as compared to hormonal methods), physical attributes (e.g. appearance and/or ease of use), and stigma. Six studies were of high rigor, five were of moderate rigor, and one was of low rigor. One study described the values and preferences of two of the selected key populations. The research available on the values and preferences of sex workers regarding methods of contraception was limited to female condoms. CONCLUSION: Consideration of the values and preferences of individuals within selected key populations can inform providers, programme managers and policy makers participating in the delivery of contraceptive care. Contraceptive research among sex workers, transmasculine individuals, people who inject drugs, or those living in humanitarian contexts is quite limited; further research is needed to better understand the values and preferences of these populations. CI - Copyright (c) 2021. Published by Elsevier Inc. FAU - Lavelanet, Antonella F AU - Lavelanet AF AD - UNDP-UNFPA-UNICEF-WHO-World Bank Special Programme of Research, Development and Research Training in Human Reproduction (HRP), Department of Sexual and Reproductive Health and Research, World Health Organization, Geneva, Switzerland. Electronic address: lavelaneta@who.int. FAU - Ralph, Jessika A AU - Ralph JA AD - Department of Obstetrics, Gynecology and Women's Health, University of Minnesota, MN, United States. FAU - Ti, Angeline AU - Ti A AD - Departments of Gynecology and Obstetrics, and Family and Preventive Medicine, Emory University School of Medicine, Atlanta, GA, United States. FAU - Duggaraju, Avani AU - Duggaraju A AD - Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States. FAU - Yeh, Ping Teresa AU - Yeh PT AD - Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States. LA - eng GR - 001/WHO_/World Health Organization/International PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't PT - Systematic Review DEP - 20210618 PL - United States TA - Contraception JT - Contraception JID - 0234361 RN - 0 (Contraceptive Agents) RN - 0 (Pharmaceutical Preparations) SB - IM MH - Contraception/methods MH - Contraceptive Agents MH - *Drug Users MH - Female MH - Humans MH - Pharmaceutical Preparations MH - *Sex Workers PMC - PMC9233148 OTO - NOTNLM OT - Contraception OT - Family planning OT - Humanitarian OT - Injection drug use OT - Sex worker OT - Transmasculine OT - Values and preferences EDAT- 2021/06/22 06:00 MHDA- 2022/06/22 06:00 PMCR- 2022/07/01 CRDT- 2021/06/21 20:13 PHST- 2020/12/15 00:00 [received] PHST- 2021/05/14 00:00 [revised] PHST- 2021/06/13 00:00 [accepted] PHST- 2021/06/22 06:00 [pubmed] PHST- 2022/06/22 06:00 [medline] PHST- 2021/06/21 20:13 [entrez] PHST- 2022/07/01 00:00 [pmc-release] AID - S0010-7824(21)00191-8 [pii] AID - 10.1016/j.contraception.2021.06.008 [doi] PST - ppublish SO - Contraception. 2022 Jul;111:32-38. doi: 10.1016/j.contraception.2021.06.008. Epub 2021 Jun 18. PMID- 34114722 OWN - NLM STAT- MEDLINE DCOM- 20210818 LR - 20210818 IS - 1099-1050 (Electronic) IS - 1057-9230 (Linking) VI - 30 IP - 9 DP - 2021 Sep TI - Weather, mental health, and mobility during the first wave of the COVID-19 pandemic. PG - 2296-2306 LID - 10.1002/hec.4371 [doi] AB - During the first United Kingdom wave of the COVID-19 outbreak, the first lockdown was announced on March 23, 2020, with a final easing of the restrictions on July 4, 2020. Among the most important public health costs of lockdown restrictions are the potential adverse effects on mental health and physical activity. Using data from the UK Household Longitudinal Study and Google COVID-19 Mobility Reports we find evidence of reduced park mobility during the initial period of the first UK lockdown and confirm existing evidence of worsening mental health. Linkage with weather data shows that contrary to popular belief, daily or weekly weather conditions do not exacerbate the mental health consequences of the pandemic, as we found no systematic associations during the first lockdown period; on the other hand, we find systematic links between park mobility and weather over the same period. CI - (c) 2021 The Authors. Health Economics published by John Wiley & Sons Ltd. FAU - Burdett, Ashley AU - Burdett A AD - Department of Economics, University of Essex, UK. FAU - Davillas, Apostolos AU - Davillas A AUID- ORCID: 0000-0002-6607-274X AD - Health Economics Group, Norwich Medical School, University of East Anglia, UK. AD - IZA, Bonn, Germany. AD - Global Labor Organization (GLO). FAU - Etheridge, Ben AU - Etheridge B AD - Department of Economics, University of Essex, UK. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20210611 PL - England TA - Health Econ JT - Health economics JID - 9306780 SB - IM MH - *COVID-19 MH - Communicable Disease Control MH - Humans MH - Longitudinal Studies MH - Mental Health MH - *Pandemics MH - SARS-CoV-2 MH - Weather OTO - NOTNLM OT - COVID-19 OT - mental health OT - mobility OT - weather conditions EDAT- 2021/06/12 06:00 MHDA- 2021/08/19 06:00 CRDT- 2021/06/11 08:52 PHST- 2021/04/12 00:00 [revised] PHST- 2021/02/16 00:00 [received] PHST- 2021/05/27 00:00 [accepted] PHST- 2021/06/12 06:00 [pubmed] PHST- 2021/08/19 06:00 [medline] PHST- 2021/06/11 08:52 [entrez] AID - 10.1002/hec.4371 [doi] PST - ppublish SO - Health Econ. 2021 Sep;30(9):2296-2306. doi: 10.1002/hec.4371. Epub 2021 Jun 11. PMID- 34111117 OWN - NLM STAT- MEDLINE DCOM- 20210621 LR - 20231111 IS - 1935-2735 (Electronic) IS - 1935-2727 (Print) IS - 1935-2727 (Linking) VI - 15 IP - 6 DP - 2021 Jun TI - The impact of COVID-19 lockdown on dengue transmission in Sri Lanka; A natural experiment for understanding the influence of human mobility. PG - e0009420 LID - 10.1371/journal.pntd.0009420 [doi] LID - e0009420 AB - BACKGROUND: Dengue is one of the major public health problems in Sri Lanka. Its outbreak pattern depends on a multitude of drivers, including human mobility. Here we evaluate the impact of COVID-19 related mobility restriction (lockdown) on the risk of dengue in Sri Lanka. METHODOLOGY: Two-stage hierarchical models were fitted using an interrupted time-series design based on the notified dengue cases, January 2015 to July 2020. In the first stage model, the district level impact was estimated using quasi-Poisson regression models while accounting for temporal trends. Estimates were pooled at zonal and national levels in the second stage model using meta-analysis. The influence of the extended period of school closure on dengue in children in the western province was compared to adults. FINDINGS: Statistically significant and homogeneous reduction of dengue risk was observed at all levels during the lockdown. Overall an 88% reduction in risk (RR 0.12; 95% CI from 0.08 to 0.17) was observed at the national level. The highest impact was observed among children aged less than 19 years showing a 92% reduction (RR 0.8; 95% CI from 0.03 to 0.25). We observed higher impact in the dry zone having 91% reduction (RR 0.09; 95% CI from 0.05 to 0.15) compared to wet zone showing 83% reduction (RR 0.17; 95% CI from 0.09 to 0.30). There was no indication that the overall health-seeking behaviour for dengue had a substantial influence on these estimates. SIGNIFICANCE: This study offers a broad understanding of the change in risk of dengue during the COVID-19 pandemic and associated mobility restrictions in Sri Lanka. The analysis using the mobility restrictions as a natural experiment suggests mobility patterns to be a very important driver of dengue transmission. FAU - Liyanage, Prasad AU - Liyanage P AUID- ORCID: 0000-0002-5174-7644 AD - Department of Epidemiology and Global Health, Umea University, Umea, Sweden. AD - Ministry of Health, Colombo, 01000, Sri Lanka. FAU - Rocklov, Joacim AU - Rocklov J AUID- ORCID: 0000-0003-4030-0449 AD - Department of Public Health and Clinical Medicine, Section of Sustainable Health, Umea University, Umea, Sweden. FAU - Tissera, Hasitha Aravinda AU - Tissera HA AUID- ORCID: 0000-0002-9379-1002 AD - Ministry of Health, Colombo, 01000, Sri Lanka. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20210610 PL - United States TA - PLoS Negl Trop Dis JT - PLoS neglected tropical diseases JID - 101291488 SB - IM MH - Adult MH - COVID-19/*prevention & control MH - Child MH - Climate MH - Communicable Disease Control MH - Dengue/*epidemiology/*transmission MH - Humans MH - Interrupted Time Series Analysis MH - Physical Distancing MH - Schools/statistics & numerical data MH - Sri Lanka/epidemiology PMC - PMC8192006 COIS- The authors have declared that no competing interests exist. EDAT- 2021/06/11 06:00 MHDA- 2021/06/22 06:00 PMCR- 2021/06/10 CRDT- 2021/06/10 17:21 PHST- 2020/12/11 00:00 [received] PHST- 2021/04/28 00:00 [accepted] PHST- 2021/06/10 17:21 [entrez] PHST- 2021/06/11 06:00 [pubmed] PHST- 2021/06/22 06:00 [medline] PHST- 2021/06/10 00:00 [pmc-release] AID - PNTD-D-20-02142 [pii] AID - 10.1371/journal.pntd.0009420 [doi] PST - epublish SO - PLoS Negl Trop Dis. 2021 Jun 10;15(6):e0009420. doi: 10.1371/journal.pntd.0009420. eCollection 2021 Jun. PMID- 34105838 OWN - NLM STAT- MEDLINE DCOM- 20211111 LR - 20220716 IS - 1360-0443 (Electronic) IS - 0965-2140 (Print) IS - 0965-2140 (Linking) VI - 116 IP - 12 DP - 2021 Dec TI - Alcohol use among young Australian adults in May-June 2020 during the COVID-19 pandemic: a prospective cohort study. PG - 3398-3407 LID - 10.1111/add.15599 [doi] AB - AIMS: To estimate change in young people's alcohol consumption during COVID-19 restrictions in Australia in early-mid 2020, and test whether those changes were consistent by gender and level of consumption prior to the pandemic. DESIGN: Prospective longitudinal cohort. SETTING: Secondary schools in New South Wales, Tasmania and Western Australia. PARTICIPANTS: Subsample of a cohort (n = 443) recruited in the first year of secondary school in 2010-11. Analysis data included three waves collected in September 2017-July 2018, September 2018-May 2019 and August 2019-January 2020), and in May-June 2020. MEASUREMENTS: The primary predictors were time, gender and level of consumption prior to the pandemic. Outcome variables, analysed by mixed-effects models, included frequency and typical quantity of alcohol consumption, binge drinking, peak consumption, alcohol-related harm and drinking contexts. FINDINGS: Overall consumption (frequency x quantity) during the restrictions declined by 17% [incidence rate ratio (IRR) = 0.83; 95% confidence interval (CI) = 0.73, 0.95] compared to February 2020, and there was a 35% decline in the rate of alcohol-related harms in the same period (IRR = 0.66; 95% CI = 0.54, 0.79). Changes in alcohol consumption were largely consistent by gender. CONCLUSIONS: From a survey of secondary school students in Australia, there is evidence for a reduction in overall consumption and related harms during the COVID-19 restrictions. CI - (c) 2021 Society for the Study of Addiction. FAU - Clare, Philip J AU - Clare PJ AUID- ORCID: 0000-0002-2009-7386 AD - Prevention Research Collaboration, University of Sydney, Camperdown, NSW, Australia. AD - National Drug and Alcohol Research Centre, University of New South Wales, Sydney, NSW, Australia. FAU - Aiken, Alexandra AU - Aiken A AD - National Drug and Alcohol Research Centre, University of New South Wales, Sydney, NSW, Australia. FAU - Yuen, Wing See AU - Yuen WS AUID- ORCID: 0000-0002-2791-6858 AD - National Drug and Alcohol Research Centre, University of New South Wales, Sydney, NSW, Australia. FAU - Upton, Emily AU - Upton E AD - National Drug and Alcohol Research Centre, University of New South Wales, Sydney, NSW, Australia. FAU - Kypri, Kypros AU - Kypri K AUID- ORCID: 0000-0002-9657-9904 AD - School of Medicine and Public Health, University of Newcastle, Callaghan, NSW, Australia. FAU - Degenhardt, Louisa AU - Degenhardt L AUID- ORCID: 0000-0002-8513-2218 AD - National Drug and Alcohol Research Centre, University of New South Wales, Sydney, NSW, Australia. FAU - Bruno, Raimondo AU - Bruno R AD - School of Psychological Sciences, University of Tasmania, Hobart, Tasmania, Australia. FAU - McCambridge, Jim AU - McCambridge J AUID- ORCID: 0000-0002-5461-7001 AD - Department of Health Sciences, University of York, York, UK. FAU - McBride, Nyanda AU - McBride N AUID- ORCID: 0000-0003-1714-6631 AD - National Drug Research Institute, Curtin University, Perth, WA, Australia. FAU - Hutchinson, Delyse AU - Hutchinson D AUID- ORCID: 0000-0003-3221-7143 AD - National Drug and Alcohol Research Centre, University of New South Wales, Sydney, NSW, Australia. AD - Centre for Social and Early Emotional Development, Deakin University, Melbourne, VIC, Australia. AD - Department of Paediatrics, University of Melbourne, Melbourne, VIC, Australia. AD - Murdoch Children's Research Institute, Royal Children's Hospital, University of Melbourne, Melbourne, VIC, Australia. FAU - Slade, Tim AU - Slade T AUID- ORCID: 0000-0002-1725-9188 AD - The Matilda Centre for Research in Mental Health and Substance Use, University of Sydney, Sydney, NSW, Australia. FAU - Mattick, Richard AU - Mattick R AD - National Drug and Alcohol Research Centre, University of New South Wales, Sydney, NSW, Australia. FAU - Peacock, Amy AU - Peacock A AUID- ORCID: 0000-0002-5705-2026 AD - National Drug and Alcohol Research Centre, University of New South Wales, Sydney, NSW, Australia. LA - eng GR - Australian Foundation for Alcohol Research and Education/ GR - Australian Government/ GR - 1096668/Australian Research Council/ GR - Australian Rotary Health/ GR - APP1041867/National Health and Medical Research Council/ GR - APP1045318/National Health and Medical Research Council/ GR - APP1109366/National Health and Medical Research Council/ GR - APP1146634/National Health and Medical Research Council/ GR - APP1174630/National Health and Medical Research Council/ GR - APP1197488/National Health and Medical Research Council/ GR - GNT0188568/National Health and Medical Research Council/ GR - GNT1009381/National Health and Medical Research Council/ GR - GNT1064893/National Health and Medical Research Council/ PT - Journal Article DEP - 20210624 PL - England TA - Addiction JT - Addiction (Abingdon, England) JID - 9304118 SB - IM MH - Adolescent MH - Adult MH - Alcohol Drinking/epidemiology MH - Australia/epidemiology MH - *COVID-19 MH - Cohort Studies MH - Humans MH - *Pandemics MH - Prospective Studies MH - SARS-CoV-2 PMC - PMC8212116 OTO - NOTNLM OT - Alcohol OT - COVID-19 OT - epidemiology, prospective cohort OT - public health, young adults EDAT- 2021/06/10 06:00 MHDA- 2021/11/12 06:00 PMCR- 2021/06/24 CRDT- 2021/06/09 08:55 PHST- 2021/01/20 00:00 [revised] PHST- 2020/10/04 00:00 [received] PHST- 2021/05/26 00:00 [accepted] PHST- 2021/06/10 06:00 [pubmed] PHST- 2021/11/12 06:00 [medline] PHST- 2021/06/09 08:55 [entrez] PHST- 2021/06/24 00:00 [pmc-release] AID - ADD15599 [pii] AID - 10.1111/add.15599 [doi] PST - ppublish SO - Addiction. 2021 Dec;116(12):3398-3407. doi: 10.1111/add.15599. Epub 2021 Jun 24. PMID- 34098303 OWN - NLM STAT- MEDLINE DCOM- 20211213 LR - 20240918 IS - 1873-6483 (Electronic) IS - 0740-5472 (Print) IS - 0740-5472 (Linking) VI - 131 DP - 2021 Dec TI - Changes in methadone program practices and fatal methadone overdose rates in Connecticut during COVID-19. PG - 108449 LID - S0740-5472(21)00175-6 [pii] LID - 10.1016/j.jsat.2021.108449 [doi] AB - BACKGROUND: Due to the COVID-19 pandemic, the Substance Abuse and Mental Health Services Administration (SAMHSA) has relaxed restrictions on methadone treatment in the United States. There is concern that the relaxation may increase fatal overdose rates. This study examines opioid treatment program (OTP) changes to methadone treatment during COVID-19 and changes in fatal methadone-involved overdose rates in Connecticut. METHODS: From July 8th to August 18th, 2020, we conducted a comprehensive state-wide survey of all eight OTPs that dispense methadone in Connecticut to examine programmatic changes during COVID-19. We also analyzed state-level data on confirmed accidental opioid-involved deaths to assess if relaxation of take-home dosing restrictions and in-person attendance requirements correlated with increased methadone-involved fatal overdose rates. RESULTS: OTPs reported implementing multiple changes to methadone treatment in response to the COVID-19 pandemic. The percent of patients receiving 28-day take-home doses increased from 0.1% to 16.8%, 14-day take-home doses increased from 14.2% to 26.8%, and the percent receiving one or no take-home doses decreased from 37.5% to 9.6%. Monthly or more frequent drug testing decreased from 15% to 4.6% and 75.2% of individual counseling for methadone patients transitioned to telehealth. However, changes to methadone treatment varied considerably by program. OTP providers said restrictions on methadone should be relaxed and increases in take-home dosing as well as telehealth should be continued in non-pandemic situations. Methadone-involved fatalities relative to other opioid-involved fatalities did not increase in Connecticut following changes in OTP practices. CONCLUSIONS: Connecticut OTPs relaxed methadone treatment requirements during COVID-19. Since relaxing restrictions on methadone treatment has not increased fatal overdoses, we recommend that the reductions in-person dosing and attendance requirements implemented during the COVID-19 pandemic should be continued and made permanent. CI - Copyright (c) 2021 Elsevier Inc. All rights reserved. FAU - Brothers, Sarah AU - Brothers S AD - Department of Sociology, Yale University, New Haven, CT 06520-8265, United States of America. Electronic address: Sarah.brothers@yale.edu. FAU - Viera, Adam AU - Viera A AD - Department of Social and Behavioral Sciences, Yale School of Public Health, New Haven, CT 06510-8034, United States of America. FAU - Heimer, Robert AU - Heimer R AD - Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT 06510-8034, United States of America. LA - eng PT - Journal Article DEP - 20210429 PL - United States TA - J Subst Abuse Treat JT - Journal of substance abuse treatment JID - 8500909 RN - 0 (Analgesics, Opioid) RN - UC6VBE7V1Z (Methadone) SB - IM MH - Analgesics, Opioid/therapeutic use MH - *COVID-19 MH - Connecticut/epidemiology MH - *Drug Overdose/drug therapy/epidemiology MH - Humans MH - Methadone/therapeutic use MH - Opiate Substitution Treatment MH - *Opioid-Related Disorders/drug therapy/epidemiology MH - Pandemics MH - SARS-CoV-2 MH - United States PMC - PMC9758251 OTO - NOTNLM OT - COVID-19 OT - Medication-based treatment OT - Methadone OT - Opioid use disorder OT - Overdose OT - Telehealth COIS- The authors have no conflicts to report. EDAT- 2021/06/08 06:00 MHDA- 2021/12/15 06:00 PMCR- 2021/04/29 CRDT- 2021/06/07 20:22 PHST- 2020/11/08 00:00 [received] PHST- 2021/04/16 00:00 [revised] PHST- 2021/04/22 00:00 [accepted] PHST- 2021/06/08 06:00 [pubmed] PHST- 2021/12/15 06:00 [medline] PHST- 2021/06/07 20:22 [entrez] PHST- 2021/04/29 00:00 [pmc-release] AID - S0740-5472(21)00175-6 [pii] AID - 108449 [pii] AID - 10.1016/j.jsat.2021.108449 [doi] PST - ppublish SO - J Subst Abuse Treat. 2021 Dec;131:108449. doi: 10.1016/j.jsat.2021.108449. Epub 2021 Apr 29. PMID- 34097769 OWN - NLM STAT- MEDLINE DCOM- 20210618 LR - 20211207 IS - 1469-493X (Electronic) IS - 1361-6137 (Linking) VI - 5 IP - 5 DP - 2021 May 6 TI - Impact of the diagnostic test Xpert MTB/RIF on patient outcomes for tuberculosis. PG - CD012972 LID - 10.1002/14651858.CD012972.pub2 [doi] LID - CD012972 AB - BACKGROUND: The World Health Organization (WHO) recommends Xpert MTB/RIF in place of smear microscopy to diagnose tuberculosis (TB), and many countries have adopted it into their diagnostic algorithms. However, it is not clear whether the greater accuracy of the test translates into improved health outcomes. OBJECTIVES: To assess the impact of Xpert MTB/RIF on patient outcomes in people being investigated for tuberculosis. SEARCH METHODS: We searched the following databases, without language restriction, from 2007 to 24 July 2020: Cochrane Infectious Disease Group (CIDG) Specialized Register; CENTRAL; MEDLINE OVID; Embase OVID; CINAHL EBSCO; LILACS BIREME; Science Citation Index Expanded (Web of Science), Social Sciences citation index (Web of Science), and Conference Proceedings Citation Index - Social Science & Humanities (Web of Science). We also searched the WHO International Clinical Trials Registry Platform, ClinicalTrials.gov, and the Pan African Clinical Trials Registry for ongoing trials. SELECTION CRITERIA: We included individual- and cluster-randomized trials, and before-after studies, in participants being investigated for tuberculosis. We analysed the randomized and non-randomized studies separately. DATA COLLECTION AND ANALYSIS: For each study, two review authors independently extracted data, using a piloted data extraction tool. We assessed the risk of bias using Cochrane and Effective Practice and Organisation of Care (EPOC) tools. We used random effects meta-analysis to allow for heterogeneity between studies in setting and design. The certainty of the evidence in the randomized trials was assessed by GRADE. MAIN RESULTS: We included 12 studies: eight were randomized controlled trials (RCTs), and four were before-and-after studies. Most included RCTs had a low risk of bias in most domains of the Cochrane 'Risk of bias' tool. There was inconclusive evidence of an effect of Xpert MTB/RIF on all-cause mortality, both overall (risk ratio (RR) 0.89, 95% confidence interval (CI) 0.75 to 1.05; 5 RCTs, 9932 participants, moderate-certainty evidence), and restricted to studies with six-month follow-up (RR 0.98, 95% CI 0.78 to 1.22; 3 RCTs, 8143 participants; moderate-certainty evidence). There was probably a reduction in mortality in participants known to be infected with HIV (odds ratio (OR) 0.80, 95% CI 0.67 to 0.96; 5 RCTs, 5855 participants; moderate-certainty evidence). It is uncertain whether Xpert MTB/RIF has no or a modest effect on the proportion of participants starting tuberculosis treatment who had a successful treatment outcome (OR) 1.10, 95% CI 0.96 to 1.26; 3RCTs, 4802 participants; moderate-certainty evidence). There was also inconclusive evidence of an effect on the proportion of participants who were treated for tuberculosis (RR 1.10, 95% CI 0.98 to 1.23; 5 RCTs, 8793 participants; moderate-certainty evidence). The proportion of participants treated for tuberculosis who had bacteriological confirmation was probably higher in the Xpert MTB/RIF group (RR 1.44, 95% CI 1.29 to 1.61; 6 RCTs, 2068 participants; moderate-certainty evidence). The proportion of participants with bacteriological confirmation who were lost to follow-up pre-treatment was probably reduced (RR 0.59, 95% CI 0.41 to 0.85; 3 RCTs, 1217 participants; moderate-certainty evidence). AUTHORS' CONCLUSIONS: We were unable to confidently rule in or rule out the effect on all-cause mortality of using Xpert MTB/RIF rather than smear microscopy. Xpert MTB/RIF probably reduces mortality among participants known to be infected with HIV. We are uncertain whether Xpert MTB/RIF has a modest effect or not on the proportion treated or, among those treated, on the proportion with a successful outcome. It probably does not have a substantial effect on these outcomes. Xpert MTB/RIF probably increases both the proportion of treated participants who had bacteriological confirmation, and the proportion with a laboratory-confirmed diagnosis who were treated. These findings may inform decisions about uptake alongside evidence on cost-effectiveness and implementation. CI - Copyright (c) 2021 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration. FAU - Haraka, Frederick AU - Haraka F AD - Elizabeth Glaser Pediatric AIDS Foundation, Dar es Salaam, Tanzania. AD - Ifakara Health Institute, Bagamoyo, Tanzania. AD - University of Basel, Basel, Switzerland. AD - Swiss Tropical and Public Health Institute, Basel, Switzerland. FAU - Kakolwa, Mwaka AU - Kakolwa M AD - Ifakara Health Institute, Dodoma, Tanzania. FAU - Schumacher, Samuel G AU - Schumacher SG AD - FIND, Geneva, Switzerland. FAU - Nathavitharana, Ruvandhi R AU - Nathavitharana RR AD - Division of Infectious Diseases, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, USA. FAU - Denkinger, Claudia M AU - Denkinger CM AD - FIND, Geneva, Switzerland. AD - Division of Tropical Medicine, Centre for Infectious Diseases, University Hospital Heidelberg, Heidelberg, Germany. FAU - Gagneux, Sebastien AU - Gagneux S AD - University of Basel, Basel, Switzerland. AD - Swiss Tropical and Public Health Institute, Basel, Switzerland. FAU - Reither, Klaus AU - Reither K AD - Ifakara Health Institute, Bagamoyo, Tanzania. AD - University of Basel, Basel, Switzerland. AD - Swiss Tropical and Public Health Institute, Basel, Switzerland. FAU - Ross, Amanda AU - Ross A AD - University of Basel, Basel, Switzerland. AD - Swiss Tropical and Public Health Institute, Basel, Switzerland. LA - eng GR - K23 AI132648/AI/NIAID NIH HHS/United States PT - Journal Article PT - Meta-Analysis PT - Research Support, Non-U.S. Gov't PT - Systematic Review DEP - 20210506 PL - England TA - Cochrane Database Syst Rev JT - The Cochrane database of systematic reviews JID - 100909747 RN - 0 (Antibiotics, Antitubercular) RN - 0 (Reagent Kits, Diagnostic) RN - VJT6J7R4TR (Rifampin) SB - IM UOF - doi: 10.1002/14651858.CD012972 MH - Antibiotics, Antitubercular/*pharmacology MH - Bias MH - Confidence Intervals MH - Controlled Before-After Studies MH - Drug Resistance, Bacterial MH - HIV Infections/mortality MH - Humans MH - Mycobacterium tuberculosis/*drug effects/genetics/*isolation & purification MH - Nucleic Acid Amplification Techniques/methods MH - Odds Ratio MH - Randomized Controlled Trials as Topic MH - Reagent Kits, Diagnostic MH - Real-Time Polymerase Chain Reaction/*methods MH - Rifampin/*pharmacology MH - Tuberculosis, Pulmonary/*diagnosis/drug therapy/microbiology/mortality PMC - PMC8208889 COIS- FH has no known conflict of interest. RRN has no known conflict of interest. SGS is employed by the Foundation for Innovative New Diagnostics (FIND). FIND has conducted studies and published on Xpert MTB/RIF as part of a collaborative project between FIND, a Swiss non-pro fi t, Cepheid, a US company, and academic partners. The product developed through this partnership was developed under a contract that obligated FIND to pay for development costs and trial costs, and Cepheid to make the test available at preferential pricing to the public sector in developing countries. In addition, FIND conducted studies for the Xpert MTB/RIF Ultra assay, which have also been published. MK has no known conflict of interest. CMD was also employed by FIND during this review. SG has no known conflict of interest. KR is a board member of the Trial Safety Board, iM4TB, Lausanne, CH for a tuberculosis drug trial unrelated to the submitted work. AR has no known conflict of interest. EDAT- 2021/06/08 06:00 MHDA- 2021/06/22 06:00 PMCR- 2021/05/06 CRDT- 2021/06/07 17:22 PHST- 2021/06/07 17:22 [entrez] PHST- 2021/06/08 06:00 [pubmed] PHST- 2021/06/22 06:00 [medline] PHST- 2021/05/06 00:00 [pmc-release] AID - CD012972.pub2 [pii] AID - 10.1002/14651858.CD012972.pub2 [doi] PST - epublish SO - Cochrane Database Syst Rev. 2021 May 6;5(5):CD012972. doi: 10.1002/14651858.CD012972.pub2. PMID- 34090684 OWN - NLM STAT- MEDLINE DCOM- 20220322 LR - 20260901 IS - 1875-595X (Electronic) IS - 0020-6539 (Print) IS - 0020-6539 (Linking) VI - 72 IP - 2 DP - 2022 Apr TI - A Review of Aerosol Generation Mitigation in International Dental Guidance. PG - 203-210 LID - S0020-6539(21)00071-X [pii] LID - 10.1016/j.identj.2021.04.002 [doi] AB - INTRODUCTION: The coronavirus disease 2019 (COVID-19) led to the worldwide closure of dental practices or reduction of dental services. By the end of April 2020, governments and professional organisations were publishing recommendations or guidance for the reopening/restructuring of dental services. The aim of this study was to assess how dental aerosol-generating procedures (AGPs) were defined in international dental guidelines, what mitigation processes were advised, and whether they were linked to COVID-19 epidemiology. METHODS: Electronic searches of a broad range of databases, along with grey literature searches, without language restriction were conducted up to 13 July 2020. Recommendations for the use of face masks and fallow times with patients without COVID-19 were assessed against the deaths per 1 million population in the included countries and country income level using Pearson Chi-squared statistics. RESULTS: Sixty-three guidance documents were included. Most (98%) indicated that AGPs can be performed with patients without COVID-19 with caveats, including advice to restrict AGPs where possible, with 21% only recommending AGPs for dental emergencies. Face masks were recommended by most documents (94%), with 91% also specifying the use of goggles or face shields. Fallow periods for patients without COVID-19 were mentioned in 48% of documents, ranging from 2 to 180 minutes. There were no significant differences in recommendations for face masks or fallow time in patients without COVID-19 by country death rate (P = .463 and P = .901) or World Bank status (P = .504 and P = .835). Most documents recommended procedural or environmental mitigations such as preprocedural mouthwash (82%) and general ventilation (52%). Few documents provided underpinning evidence for their recommendations. CONCLUSIONS: While the amount of high-quality direct evidence related to dentistry and COVID-19 remains limited, it is important to be explicit about the considered judgements for recommendations as well as generate new evidence to face this challenge. CI - Copyright (c) 2021 The Authors. Published by Elsevier Inc. All rights reserved. FAU - Robertson, Clare AU - Robertson C AD - Health Services Research Unit, University of Aberdeen, Aberdeen, UK. Electronic address: c.robertson@abdn.ac.uk. FAU - Clarkson, Jan E AU - Clarkson JE AD - School of Dentistry, University of Dundee, Dundee, UK. FAU - Aceves-Martins, Magaly AU - Aceves-Martins M AD - Health Services Research Unit, University of Aberdeen, Aberdeen, UK. FAU - Ramsay, Craig R AU - Ramsay CR AD - Health Services Research Unit, University of Aberdeen, Aberdeen, UK. FAU - Richards, Derek AU - Richards D AD - School of Dentistry, University of Dundee, Dundee, UK. FAU - Colloc, Thibault AU - Colloc T AD - Aberdeen Royal Infirmary, NHS Grampian, Aberdeen, UK. CN - CoDER Working Group LA - eng GR - HSRU1/CSO_/Chief Scientist Office/United Kingdom PT - Journal Article PT - Review DEP - 20210603 PL - England TA - Int Dent J JT - International dental journal JID - 0374714 RN - 0 (Aerosols) SB - IM MH - Aerosols MH - *COVID-19/prevention & control MH - Humans PMC - PMC8172569 OTO - NOTNLM OT - Aerosol-generating procedures OT - COVID-19 OT - Dental OT - Guidelines OT - International OT - Rapid review COIS- Conflicts of interest None disclosed. EDAT- 2021/06/07 06:00 MHDA- 2022/03/23 06:00 PMCR- 2021/06/03 CRDT- 2021/06/06 20:39 PHST- 2021/01/11 00:00 [received] PHST- 2021/03/17 00:00 [revised] PHST- 2021/04/08 00:00 [accepted] PHST- 2021/06/07 06:00 [pubmed] PHST- 2022/03/23 06:00 [medline] PHST- 2021/06/06 20:39 [entrez] PHST- 2021/06/03 00:00 [pmc-release] AID - S0020-6539(21)00071-X [pii] AID - 10.1016/j.identj.2021.04.002 [doi] PST - ppublish SO - Int Dent J. 2022 Apr;72(2):203-210. doi: 10.1016/j.identj.2021.04.002. Epub 2021 Jun 3. PMID- 34089927 OWN - NLM STAT- MEDLINE DCOM- 20211028 LR - 20221003 IS - 2213-2201 (Electronic) IS - 2213-2198 (Print) VI - 9 IP - 10 DP - 2021 Oct TI - Improvement in Health-Related Quality of Life in Food-Allergic Patients: A Meta-Analysis. PG - 3705-3714 LID - S2213-2198(21)00607-3 [pii] LID - 10.1016/j.jaip.2021.05.020 [doi] AB - BACKGROUND: Food allergy (FA) is a growing global problem that can affect patients' health-related quality of life (HRQoL) owing to increased anxiety as well as social and economic restrictions. Interventions such as oral food challenges (OFCs) and oral immunotherapy (OIT) have been shown to improve HRQoL. However, meta-analyses and systematic synthesis of these data are lacking. OBJECTIVE: To review and quantitatively synthesize potential benefits of interventions (OIT and OFC) systematically to address FA to a variety of foods. METHODS: We conducted a systematic search through PubMed and Cochrane Medical Library databases and performed a meta-analysis focusing on studies assessing changes in HRQoL after OIT and/or OFCs in FA participants and caregivers from 2010 to July 2020. Random effects model and I(2) statistics were used to assess overall intervention effects and heterogeneity across studies. RESULTS: We included 13 publications in this meta-analysis (OIT = 7; OFCs = 6). Mean change in HRQoL scores after OIT and OFCs was -1.25 (P < .001) and -0.78 (P = .052), with a significant I(2) of 87% (P < .001) and 90% (P < .001), respectively. Five OIT studies found significant improvements in HRQoL in the OIT group compared with the placebo group, with an overall standardized mean difference of -0.56 (P = .007; I(2) = 42%, P = .099). CONCLUSIONS: This meta-analysis showed that in FA patients, both OIT and OFCs are associated with an improvement in HRQoL. Well-designed and long-term HRQoL studies are necessary to ascertain sustained benefits of OIT and OFCs. CI - Copyright (c) 2021 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved. FAU - Cao, Shu AU - Cao S AD - Sean N. Parker Center for Allergy and Asthma Research at Stanford University, Stanford University, Stanford, Calif. FAU - Borro, Matteo AU - Borro M AD - Sean N. Parker Center for Allergy and Asthma Research at Stanford University, Stanford University, Stanford, Calif; Clinical Immunology Unit, Department of Internal Medicine, University of Genoa and Ospedale Policlinico San Martino, Genoa, Italy; Department of Internal Medicine, San Paolo Hospital, Savona, Italy. FAU - Alonzi, Sarah AU - Alonzi S AD - Sean N. Parker Center for Allergy and Asthma Research at Stanford University, Stanford University, Stanford, Calif; Department of Psychology, Loyola University, New Orleans, La. FAU - Sindher, Sayantani AU - Sindher S AD - Sean N. Parker Center for Allergy and Asthma Research at Stanford University, Stanford University, Stanford, Calif; Division of Pulmonary and Critical Care Medicine, Stanford University, Stanford, Calif. FAU - Nadeau, Kari AU - Nadeau K AD - Sean N. Parker Center for Allergy and Asthma Research at Stanford University, Stanford University, Stanford, Calif; Division of Pulmonary and Critical Care Medicine, Stanford University, Stanford, Calif. FAU - Chinthrajah, R Sharon AU - Chinthrajah RS AD - Sean N. Parker Center for Allergy and Asthma Research at Stanford University, Stanford University, Stanford, Calif; Division of Pulmonary and Critical Care Medicine, Stanford University, Stanford, Calif. Electronic address: schinths@stanford.edu. LA - eng GR - U01 AI147462/AI/NIAID NIH HHS/United States GR - U19 AI104209/AI/NIAID NIH HHS/United States GR - UM1 AI130839/AI/NIAID NIH HHS/United States GR - UM2 AI130836/AI/NIAID NIH HHS/United States PT - Journal Article PT - Meta-Analysis PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20210602 PL - United States TA - J Allergy Clin Immunol Pract JT - The journal of allergy and clinical immunology. In practice JID - 101597220 RN - 0 (Allergens) SB - IM CIN - J Allergy Clin Immunol Pract. 2021 Oct;9(10):3715-3716. doi: 10.1016/j.jaip.2021.07.003. PMID: 34627537 MH - Administration, Oral MH - Allergens MH - Desensitization, Immunologic MH - *Food Hypersensitivity MH - Humans MH - *Quality of Life PMC - PMC8511199 MID - NIHMS1715174 OTO - NOTNLM OT - Food allergy OT - Meta-analysis OT - Oral food challenge OT - Oral immunotherapy OT - Quality of life questionnaires EDAT- 2021/06/06 06:00 MHDA- 2021/10/29 06:00 PMCR- 2022/10/01 CRDT- 2021/06/05 20:14 PHST- 2020/10/18 00:00 [received] PHST- 2021/05/20 00:00 [revised] PHST- 2021/05/22 00:00 [accepted] PHST- 2021/06/06 06:00 [pubmed] PHST- 2021/10/29 06:00 [medline] PHST- 2021/06/05 20:14 [entrez] PHST- 2022/10/01 00:00 [pmc-release] AID - S2213-2198(21)00607-3 [pii] AID - 10.1016/j.jaip.2021.05.020 [doi] PST - ppublish SO - J Allergy Clin Immunol Pract. 2021 Oct;9(10):3705-3714. doi: 10.1016/j.jaip.2021.05.020. Epub 2021 Jun 2. PMID- 34088881 OWN - NLM STAT- Publisher LR - 20240222 IS - 1468-3318 (Electronic) IS - 0964-4563 (Linking) DP - 2021 Jun 4 TI - Implementation of a comprehensive flavoured tobacco product sales restriction and retail tobacco sales. LID - tobaccocontrol-2021-056494 [pii] LID - 10.1136/tobaccocontrol-2021-056494 [doi] AB - OBJECTIVE: San Francisco's comprehensive restriction on flavoured tobacco sales applies to all flavours (including menthol), all products and all retailers (without exemptions). This study evaluates associations of policy implementation with changes in tobacco sales in San Francisco and in two California cities without any sales restriction. METHODS: Using weekly retail sales data (July 2015 through December 2019), we computed sales volume in equivalent units within product categories and the proportion of flavoured tobacco. An interrupted time series analysis estimated within-city changes associated with the policy's effective and enforcement dates, separately by product category for San Francisco and comparison cities, San Jose and San Diego. RESULTS: Predicted average weekly flavoured tobacco sales decreased by 96% from before the policy to after enforcement (p<0.05), and to very low levels across all products, including cigars with concept-flavour names (eg, Jazz). Average weekly flavoured tobacco sales did not change in San Jose and decreased by 10% in San Diego (p<0.05). Total tobacco sales decreased by 25% in San Francisco, 8% in San Jose and 17% in San Diego (each, p<0.05). CONCLUSIONS: San Francisco's comprehensive restriction virtually eliminated flavoured tobacco sales and decreased total tobacco sales in mainstream retailers. Unlike other US flavoured tobacco policy evaluations, there was no evidence of substitution to concept-flavour named products. Results may be attributed to San Francisco Department of Health's self-education and rigorous retailer education, as well as the law's rebuttable presumption of a product as flavoured based on manufacturer communication. CI - (c) Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ. FAU - Gammon, Doris G AU - Gammon DG AUID- ORCID: 0000-0002-5879-7986 AD - Center for Health Analytics, Media, and Policy, RTI International, Research Triangle Park, North Carolina, USA dgammon@rti.org. FAU - Rogers, Todd AU - Rogers T AUID- ORCID: 0000-0002-1592-2150 AD - Center for Health Analytics, Media, and Policy, RTI International, Research Triangle Park, North Carolina, USA. FAU - Gaber, Jennifer AU - Gaber J AUID- ORCID: 0000-0002-1467-0115 AD - Center for Health Analytics, Media, and Policy, RTI International, Research Triangle Park, North Carolina, USA. FAU - Nonnemaker, James M AU - Nonnemaker JM AUID- ORCID: 0000-0003-1044-7482 AD - Center for Health Analytics, Media, and Policy, RTI International, Research Triangle Park, North Carolina, USA. FAU - Feld, Ashley L AU - Feld AL AD - Center for Health Analytics, Media, and Policy, RTI International, Research Triangle Park, North Carolina, USA. FAU - Henriksen, Lisa AU - Henriksen L AUID- ORCID: 0000-0002-9288-3562 AD - Stanford Prevention Research Center, Stanford University School of Medicine, Stanford, California, USA. FAU - Johnson, Trent O AU - Johnson TO AD - Stanford Prevention Research Center, Stanford University School of Medicine, Stanford, California, USA. FAU - Kelley, Terence AU - Kelley T AD - California Tobacco Control Program, California Department of Public Health, Sacramento, California, USA. FAU - Andersen-Rodgers, Elizabeth AU - Andersen-Rodgers E AUID- ORCID: 0000-0002-4126-6564 AD - California Tobacco Control Program, California Department of Public Health, Sacramento, California, USA. LA - eng PT - Journal Article DEP - 20210604 PL - England TA - Tob Control JT - Tobacco control JID - 9209612 SB - IM OTO - NOTNLM OT - economics OT - public policy OT - surveillance and monitoring COIS- Competing interests: The California Department of Public Health was involved in the study design, data collection, analysis, interpretation and writing. CDPH reviewed the text prior to submission and did not influence whether and where to submit for publication. EDAT- 2021/06/06 06:00 MHDA- 2021/06/06 06:00 CRDT- 2021/06/05 05:37 PHST- 2021/01/20 00:00 [received] PHST- 2021/04/26 00:00 [revised] PHST- 2021/05/03 00:00 [accepted] PHST- 2021/06/05 05:37 [entrez] PHST- 2021/06/06 06:00 [pubmed] PHST- 2021/06/06 06:00 [medline] AID - tobaccocontrol-2021-056494 [pii] AID - 10.1136/tobaccocontrol-2021-056494 [doi] PST - aheadofprint SO - Tob Control. 2021 Jun 4:tobaccocontrol-2021-056494. doi: 10.1136/tobaccocontrol-2021-056494. PMID- 34081349 OWN - NLM STAT- MEDLINE DCOM- 20210804 LR - 20221005 IS - 1530-0277 (Electronic) IS - 0145-6008 (Print) IS - 0145-6008 (Linking) VI - 45 IP - 7 DP - 2021 Jul TI - COVID-19 impacts on drinking and mental health in emerging adults: Longitudinal changes and moderation by economic disruption and sex. PG - 1448-1457 LID - 10.1111/acer.14624 [doi] AB - BACKGROUND: There are significant concerns that the COVID-19 pandemic may have negative effects on substance use and mental health, but most studies to date are cross-sectional. In a sample of emerging adults, over a two-week period during the pandemic, the current study examined: (1) changes in drinking-related outcomes, depression, anxiety, and posttraumatic stress disorder and (2) differences in changes by sex and income loss. The intra-pandemic measures were compared to pre-pandemic measures. METHODS: Participants were 473 emerging adults (M(age) = 23.84; 41.7% male) in an existing longitudinal study on alcohol misuse who were assessed from June 17 to July 1, 2020, during acute public health restrictions in Ontario, Canada. These intra-pandemic data were matched to participant pre-pandemic reports, collected an average of 5 months earlier. Assessments included validated measures of drinking, alcohol-related consequences, and mental health indicators. RESULTS: Longitudinal analyses revealed significant decreases in heavy drinking and adverse alcohol consequences, with no moderation by sex or income loss, but with substantial heterogeneity in changes. Significant increases in continuous measures of depression and anxiety were present, both of which were moderated by sex. Females reported significantly larger increases in depression and anxiety. Income loss >50% was significantly associated with increases in depression. CONCLUSIONS: During the initial phase of the pandemic, reductions in heavy drinking and alcohol consequences were present in this sample of emerging adults, perhaps due to restrictions on socializing. In contrast, there was an increase in internalizing symptoms , especially in females, highlighting disparities in the mental health impacts of the pandemic. CI - (c) 2021 by the Research Society on Alcoholism. FAU - Minhas, Meenu AU - Minhas M AUID- ORCID: 0000-0001-6741-3940 AD - Peter Boris Centre for Addictions Research, St Joseph's Healthcare Hamilton, McMaster University, Hamilton, ON, Canada. FAU - Belisario, Kyla AU - Belisario K AUID- ORCID: 0000-0001-5403-9531 AD - Peter Boris Centre for Addictions Research, St Joseph's Healthcare Hamilton, McMaster University, Hamilton, ON, Canada. FAU - Gonzalez-Roz, Alba AU - Gonzalez-Roz A AD - Department of Psychology/IUNICS, University of the Balearic Islands, Majorca, Spain. FAU - Halladay, Jillian AU - Halladay J AD - Peter Boris Centre for Addictions Research, St Joseph's Healthcare Hamilton, McMaster University, Hamilton, ON, Canada. AD - Department of Health Evidence and Impact, McMaster University, Hamilton, ON, Canada. FAU - Murphy, James G AU - Murphy JG AUID- ORCID: 0000-0001-9378-8754 AD - Department of Psychology, University of Memphis, Memphis, TN, USA. FAU - MacKillop, James AU - MacKillop J AUID- ORCID: 0000-0002-8695-1071 AD - Peter Boris Centre for Addictions Research, St Joseph's Healthcare Hamilton, McMaster University, Hamilton, ON, Canada. AD - Homewood Research Institute, Guelph, ON, Canada. LA - eng GR - CIHR/Canada GR - CIHR/Canada PT - Journal Article PT - Observational Study DEP - 20210603 PL - England TA - Alcohol Clin Exp Res JT - Alcoholism, clinical and experimental research JID - 7707242 SB - IM MH - Alcohol Drinking/economics/epidemiology/*psychology MH - Alcoholism/economics/epidemiology/*psychology MH - COVID-19/economics/epidemiology/*psychology MH - Cohort Studies MH - Cross-Sectional Studies/methods MH - Female MH - Humans MH - Longitudinal Studies MH - Male MH - Mental Disorders/economics/epidemiology/psychology MH - Mental Health/economics/*trends MH - Ontario/epidemiology MH - *Sex Characteristics MH - *Social Class MH - Young Adult PMC - PMC8212111 OTO - NOTNLM OT - COVID-19 OT - alcohol OT - anxiety OT - depression OT - emerging adults OT - sex differences COIS- James MacKillop is a principal in BEAM Diagnostics, Inc., but no BEAM products were used in the study reported. No other authors have declarations. EDAT- 2021/06/04 06:00 MHDA- 2021/08/05 06:00 PMCR- 2021/06/03 CRDT- 2021/06/03 12:36 PHST- 2021/04/20 00:00 [revised] PHST- 2021/02/21 00:00 [received] PHST- 2021/04/21 00:00 [accepted] PHST- 2021/06/04 06:00 [pubmed] PHST- 2021/08/05 06:00 [medline] PHST- 2021/06/03 12:36 [entrez] PHST- 2021/06/03 00:00 [pmc-release] AID - ACER14624 [pii] AID - 10.1111/acer.14624 [doi] PST - ppublish SO - Alcohol Clin Exp Res. 2021 Jul;45(7):1448-1457. doi: 10.1111/acer.14624. Epub 2021 Jun 3. PMID- 34075361 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220423 IS - 2666-142X (Electronic) IS - 2666-142X (Linking) VI - 3 DP - 2021 Nov TI - Experiences of cancer care during COVID-19: Phase 1 results of a longitudinal qualitative study. PG - 100030 LID - 10.1016/j.ijnsa.2021.100030 [doi] LID - 100030 AB - BACKGROUND: Healthcare services have responded to the challenges of service delivery during COVID-19 with telehealth and hybrid models of care. However, there is limited understanding of the experiences of care amongst people affected by cancer and how their experiences may change and evolve against the shifting landscape of COVID-19 incidence, mortality, vaccination and refinements in service delivery. OBJECTIVES: This study explores the experiences of cancer care amongst people affected by cancer in Ireland during the COVID-19 pandemic. This paper presents the results of the initial cross-sectional semi-structured interviews and the longitudinal qualitative research design which will be employed in this study. DESIGN: A longitudinal descriptive qualitative study. SETTING: Ireland. PARTICIPANTS: People living with and after cancer or caring for someone with cancer during the COVID-19 pandemic. METHODS: Participants were recruited to the study via social media advertisements and consented to participate in up to three semi-structured interviews between January and July 2021. Initial semi-structured interviews were conducted with 16 participants in January 2021. Participants completed measures of resilience (2-item Connor-Davidson Resilience Scale) and distress (The National Comprehensive Cancer Network Distress Thermometer). Interviews were recorded, transcribed and analysed thematically. RESULTS: Participants reported low levels of distress and moderate to high levels of resilience on average. Three themes were generated from analysis of the first phase of cross-sectional interviews. Participants described a counterbalance of being cautious of infection and keeping safe through prevention and shielding strategies. Although hospitals felt safe and were working efficiently, some participants felt COVID-19 had compromised person-centredness and empathy in care. While participants valued the measures taken to minimize infection risk, substitution of face-to-face appointments with telehealth services and attending essential face-to-face appointments alone restricted participants' access to professional and social support. Despite this, many participants felt public health measures to reduce transmission of COVID-19 had created a sense of not missing out, feeling safe and reduced difficult social interactions requiring explanation of their diagnosis. CONCLUSIONS: There is an opportunity to learn from the experiences of healthcare delivery from the perspectives of people affected by cancer during the COVID-19 pandemic. The results highlight the complexities and dualities of living with, after or caring for someone with cancer during the COVID-19 pandemic. Opportunities for longitudinal qualitative research to explore the evolving experiences, concerns and persistent and emerging unmet information and clinical needs within the rapidly changing socio-political, socio-cultural and healthcare contexts of the COVID-19 pandemic are highlighted. CI - (c) 2021 The Author(s). Published by Elsevier Ltd. FAU - Drury, Amanda AU - Drury A AD - School of Nursing, Midwifery and Health Systems, University College Dublin, Belfield, Dublin 4, Ireland. FAU - Eicher, Manuela AU - Eicher M AD - Department of Oncology, Lausanne University Hospital (CHUV), Lausanne, Switzerland. AD - Institute of Higher Education and Research in Healthcare (IUFRS), Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland. FAU - Dowling, Maura AU - Dowling M AD - School of Nursing and Midwifery, National University of Ireland, Galway, Ireland. LA - eng PT - Journal Article DEP - 20210527 PL - England TA - Int J Nurs Stud Adv JT - International journal of nursing studies advances JID - 101769252 PMC - PMC8158401 OTO - NOTNLM OT - COVID-19 OT - Cancer OT - Cancer care OT - Distress OT - Ehealth OT - Experiences of care OT - Models of care OT - Resilience OT - Telemedicine OT - Unmet needs COIS- AD, ME and MD report no conflict of interest. The authors alone are responsible for the content and writing of this paper. EDAT- 2021/06/03 06:00 MHDA- 2021/06/03 06:01 PMCR- 2021/05/27 CRDT- 2021/06/02 06:46 PHST- 2021/04/09 00:00 [received] PHST- 2021/05/11 00:00 [revised] PHST- 2021/05/13 00:00 [accepted] PHST- 2021/06/03 06:00 [pubmed] PHST- 2021/06/03 06:01 [medline] PHST- 2021/06/02 06:46 [entrez] PHST- 2021/05/27 00:00 [pmc-release] AID - S2666-142X(21)00012-6 [pii] AID - 100030 [pii] AID - 10.1016/j.ijnsa.2021.100030 [doi] PST - ppublish SO - Int J Nurs Stud Adv. 2021 Nov;3:100030. doi: 10.1016/j.ijnsa.2021.100030. Epub 2021 May 27. PMID- 34067341 OWN - NLM STAT- MEDLINE DCOM- 20210702 LR - 20250108 IS - 1660-4601 (Electronic) IS - 1661-7827 (Print) IS - 1660-4601 (Linking) VI - 18 IP - 11 DP - 2021 May 22 TI - Tobacco Control as an LGBTQ+ Issue: Knowledge, Attitudes, and Recommendations from LGBTQ+ Community Leaders. LID - 10.3390/ijerph18115546 [doi] LID - 5546 AB - Tobacco companies use price discounts, including coupons and rebates, to market their products. Lesbian, gay, bisexual, transgender, and queer (LGBTQ+) communities are targeted by these marketing strategies, contributing to inequitably high tobacco use. Some localities have adopted policies restricting tobacco price discounts; for successful implementation, community buy-in is crucial. From July-October 2018, Equality California staff conducted semi-structured interviews with seven participants in Los Angeles, CA. Themes included familiarity with tobacco price discounts, their perceived impact on tobacco use in LGBTQ+ communities, and attitudes toward potential policy restrictions. Interview notes were analyzed using a deductive approach to qualitative analysis. Awareness of tobacco price discounts varied; some interviewees were familiar, while others expressed surprise at their ubiquity. Price discounts were seen to disproportionately impact LGBTQ+ individuals, especially those who additionally identify with other vulnerable groups, including young people and communities of color. Support for policy restrictions was unanimous; however, interviewees expressed concern over political opposition and emphasized a need for culturally competent outreach to LGBTQ+ communities. Community organizations are essential in mobilizing support for policy reform. Understanding the perceptions and recommendations of community leaders provides tools for policy action, likely improving outcomes to reduce LGBTQ+ tobacco use through restricting tobacco price discounts. FAU - Acosta-Deprez, Veronica AU - Acosta-Deprez V AD - Department of Health Science, California State University, Long Beach, CA 90802, USA. FAU - Jou, Judy AU - Jou J AD - Department of Health Science, California State University, Long Beach, CA 90802, USA. FAU - London, Marisa AU - London M AD - OUT Against Big Tobacco Program, Equality California, Los Angeles, CA 90010, USA. FAU - Ai, Mike AU - Ai M AD - OUT Against Big Tobacco Program, Equality California, Los Angeles, CA 90010, USA. FAU - Chu, Carolyn AU - Chu C AD - Urban and Regional Planning Masters Program, University of California, Los Angeles, CA 90095, USA. FAU - Cermak, Nhi AU - Cermak N AD - Department of Health Science, California State University, Long Beach, CA 90802, USA. FAU - Kozlovich, Shannon AU - Kozlovich S AUID- ORCID: 0000-0002-8900-6382 AD - Programs Department, Equality California, Los Angeles, CA 90010, USA. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20210522 PL - Switzerland TA - Int J Environ Res Public Health JT - International journal of environmental research and public health JID - 101238455 SB - IM MH - Adolescent MH - Female MH - Health Knowledge, Attitudes, Practice MH - Humans MH - Los Angeles MH - *Sexual and Gender Minorities MH - Tobacco Use MH - Tobacco Products PMC - PMC8196887 OTO - NOTNLM OT - LGBTQ+ OT - policy OT - tobacco COIS- The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results. EDAT- 2021/06/03 06:00 MHDA- 2021/07/03 06:00 PMCR- 2021/05/22 CRDT- 2021/06/02 01:19 PHST- 2021/04/01 00:00 [received] PHST- 2021/05/13 00:00 [revised] PHST- 2021/05/17 00:00 [accepted] PHST- 2021/06/02 01:19 [entrez] PHST- 2021/06/03 06:00 [pubmed] PHST- 2021/07/03 06:00 [medline] PHST- 2021/05/22 00:00 [pmc-release] AID - ijerph18115546 [pii] AID - ijerph-18-05546 [pii] AID - 10.3390/ijerph18115546 [doi] PST - epublish SO - Int J Environ Res Public Health. 2021 May 22;18(11):5546. doi: 10.3390/ijerph18115546. PMID- 34048478 OWN - NLM STAT- MEDLINE DCOM- 20210607 LR - 20250530 IS - 1932-6203 (Electronic) IS - 1932-6203 (Linking) VI - 16 IP - 5 DP - 2021 TI - COVID-19 impacts equine welfare: Policy implications for laminitis and obesity. PG - e0252340 LID - 10.1371/journal.pone.0252340 [doi] LID - e0252340 AB - The COVID-19 pandemic continues to impact human health and welfare on a global level. In March 2020, stringent national restrictions were enforced in the UK to protect public health and slow the spread of the SARS-CoV-2 virus. Restrictions were likely to have resulted in collateral consequences for the health and welfare of horses and ponies, especially those at risk of obesity and laminitis and this issue warranted more detailed exploration. The current study utilised qualitative methodology to investigate the implications of COVID-19 related policies upon equine management and welfare with a focus on horses and ponies at risk of laminitis and obesity. Twenty-four interviews with five sub-groups of key equestrian welfare stakeholders in the UK were conducted between May and July of 2020 to understand the challenges facing equine welfare in the context of laminitis and obesity susceptible animals. Thematic analysis revealed lockdown-associated factors with the potential to compromise welfare of horses and ponies at risk of obesity and laminitis. These included: disparate information and guidance, difficulties enacting public health measures in yard environments, and horses having reduced exercise during the pandemic. Positive examples of clear and consistent information sharing by farriers were reported to have improved horse owner understanding of routine hoof care during lockdown. Analysis suggested that the recommendations for supporting the management-based needs of horses under reduced supervision were not clearly defined, or were not sufficiently disseminated, across the equine industry. These findings support the development of guidelines specific to the care of horses and ponies at risk of obesity and laminitis through collaborative input from veterinary and welfare experts, to reduce the negative impacts of future lockdown events in the UK. FAU - Ward, Ashley B AU - Ward AB AD - Scotland's Rural College, Aberdeen, United Kingdom. AD - The Rowett Institute, University of Aberdeen, Foresterhill, Aberdeen, United Kingdom. FAU - Stephen, Kate AU - Stephen K AUID- ORCID: 0000-0003-3258-7355 AD - Scotland's Rural College, Aberdeen, United Kingdom. FAU - Argo, Caroline McGregor AU - Argo CM AD - Scotland's Rural College, Aberdeen, United Kingdom. FAU - Harris, Patricia A AU - Harris PA AD - Equine Studies Group, WALTHAM Petcare Science Institute, Leicestershire, United Kingdom. FAU - Watson, Christine A AU - Watson CA AD - Scotland's Rural College, Aberdeen, United Kingdom. FAU - Neacsu, Madalina AU - Neacsu M AD - The Rowett Institute, University of Aberdeen, Foresterhill, Aberdeen, United Kingdom. FAU - Russell, Wendy AU - Russell W AD - The Rowett Institute, University of Aberdeen, Foresterhill, Aberdeen, United Kingdom. FAU - Grove-White, Dai H AU - Grove-White DH AD - Faculty of Health and Life Sciences, University of Liverpool, Wirral, United Kingdom. FAU - Morrison, Philippa K AU - Morrison PK AUID- ORCID: 0000-0003-4187-0371 AD - Scotland's Rural College, Aberdeen, United Kingdom. LA - eng GR - HIPS/19/51/CSO_/Chief Scientist Office/United Kingdom PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20210528 PL - United States TA - PLoS One JT - PloS one JID - 101285081 SB - IM MH - *Animal Welfare MH - Animals MH - *COVID-19 MH - Horse Diseases/*epidemiology/prevention & control MH - Horses MH - Humans MH - Obesity/*epidemiology/prevention & control MH - *SARS-CoV-2 PMC - PMC8162578 COIS- Co-author PH is employed by the funding organization. This does not alter our adherence to PLOS ONE policies on sharing data and materials. All other authors declare that they have no competing interests. EDAT- 2021/05/29 06:00 MHDA- 2021/06/08 06:00 PMCR- 2021/05/28 CRDT- 2021/05/28 17:24 PHST- 2020/12/04 00:00 [received] PHST- 2021/05/12 00:00 [accepted] PHST- 2021/05/28 17:24 [entrez] PHST- 2021/05/29 06:00 [pubmed] PHST- 2021/06/08 06:00 [medline] PHST- 2021/05/28 00:00 [pmc-release] AID - PONE-D-20-38153 [pii] AID - 10.1371/journal.pone.0252340 [doi] PST - epublish SO - PLoS One. 2021 May 28;16(5):e0252340. doi: 10.1371/journal.pone.0252340. eCollection 2021. PMID- 34032730 OWN - NLM STAT- MEDLINE DCOM- 20210603 LR - 20231111 IS - 1536-5964 (Electronic) IS - 0025-7974 (Print) IS - 0025-7974 (Linking) VI - 100 IP - 21 DP - 2021 May 28 TI - Acupuncture for type 2 diabetes mellitus with nonalcoholic fatty liver disease: A protocol for systematic review and meta-analysis. PG - e26043 LID - 10.1097/MD.0000000000026043 [doi] LID - e26043 AB - BACKGROUND: T2DM with NAFLD is a common disorder of glucose and lipid metabolism affecting the quality of life of patients. Due to the limitations and adverse reactions of drug treatment, acupuncture has been proved to be an effective method for the treatment of T2DM with NAFLD. This study aims to evaluate the efficacy and safety of acupuncture in the treatment of NAFLD in T2DM class, and to provide high-quality evidence for acupuncture in the treatment of this disease. METHODS: From establishment of the database to 31 July 2021, We will search the Cochrane Central Register of controlled trials, PubMed, MEDLINE, EMBASE, Web of science. Five Chinese databases, including China National Knowledge Infrastructure (CNKI), WanFang database, VIP, Chinese Biomedical Literature Database (CBM) and the Chinese clinical trial registry. There are no restrictions on language or publication, and they are independently screened and collected by two reviewers. Review Manager 5.3 software will be used for meta analysis. If necessary, heterogeneity testing, data synthesis, and subgroup analysis will be performed. RESULTS: The effectiveness and safety of acupuncture in the treatment of T2DM with NAFLD will be assessed by the outcomes of test's, including: imaging indicators, biomarkers of hepatic steatosis, serological indicators of hepatic fibrosis, improvement of serum NAFLD liver fat score, BMI, blood glucose indexes, blood lipid indexes, insulin level and safety indicators. CONCLUSION: This meta-analysis will further determine the beneficial efficacy and safety of acupuncture for T2DM combined with NAFLD. CI - Copyright (c) 2021 the Author(s). Published by Wolters Kluwer Health, Inc. FAU - Li, Mengyuan AU - Li M AUID- ORCID: 0000-0002-0039-6661 AD - Changchun University of Chinese Medicine, Nanguan District, Changchun, Jilin, China. FAU - Yao, Lin AU - Yao L FAU - Huang, Haipeng AU - Huang H FAU - Wang, Guan AU - Wang G FAU - Yu, Bin AU - Yu B FAU - Zheng, Haizhu AU - Zheng H FAU - Wang, Hongfeng AU - Wang H LA - eng GR - 81874502/National Natural Science Foundation of China/ GR - 82074548/National Natural Science Foundation of China/ GR - 2020043/Jilin Scientific and Technological of Traditional Chinese Medicine Program/ PT - Journal Article PL - United States TA - Medicine (Baltimore) JT - Medicine JID - 2985248R RN - 0 (Biomarkers) RN - 0 (Blood Glucose) SB - IM MH - Acupuncture Therapy/adverse effects/*methods MH - Biomarkers/blood MH - Blood Glucose/analysis MH - Diabetes Mellitus, Type 2/blood/complications/metabolism/*therapy MH - Humans MH - Meta-Analysis as Topic MH - Non-alcoholic Fatty Liver Disease/diagnosis/etiology/metabolism/*therapy MH - Quality of Life MH - Randomized Controlled Trials as Topic MH - Systematic Reviews as Topic MH - Treatment Outcome PMC - PMC8154503 COIS- The authors have no conflicts of interests to disclose. EDAT- 2021/05/26 06:00 MHDA- 2021/06/04 06:00 PMCR- 2021/05/28 CRDT- 2021/05/25 13:55 PHST- 2021/04/29 00:00 [received] PHST- 2021/05/04 00:00 [accepted] PHST- 2021/05/25 13:55 [entrez] PHST- 2021/05/26 06:00 [pubmed] PHST- 2021/06/04 06:00 [medline] PHST- 2021/05/28 00:00 [pmc-release] AID - 00005792-202105280-00040 [pii] AID - MD-D-21-03210 [pii] AID - 10.1097/MD.0000000000026043 [doi] PST - ppublish SO - Medicine (Baltimore). 2021 May 28;100(21):e26043. doi: 10.1097/MD.0000000000026043. PMID- 34030469 OWN - NLM STAT- MEDLINE DCOM- 20210621 LR - 20240402 IS - 2326-5108 (Electronic) IS - 2326-5094 (Print) IS - 2326-5094 (Linking) VI - 19 IP - 3 DP - 2021 May-Jun TI - Experiences and Views of Domestic Summer Travelers During the COVID-19 Pandemic: Findings from a National Survey. PG - 338-348 LID - 10.1089/hs.2020.0212 [doi] AB - Domestic travel creates a serious risk of spreading COVID-19, including novel strains of the virus. Motivating potential travelers to take precautions is critical, especially for those at higher risk for severe illness. To provide an evidence base for communication efforts, we examined the experiences and views of travelers during the summer of 2020 through a telephone survey of 1,968 US adults, conducted in English and Spanish, July 2 through July 16, 2020. The survey found that more than one-quarter (28%) of adults had traveled domestically in the prior 30 days, most commonly for "vacation" (43%), and less than half wore masks (46%) or practiced social distancing (47%) "all of the time." Although high-risk adults were significantly less likely to travel than non-high-risk adults (23% vs 31%; P < .001), they were no more likely to take precautions. Many travelers did not wear a mask or practice social distancing because they felt such actions were unnecessary (eg, they were outside or with friends and family). Although a substantial share of travelers (43% to 53%) trusted public health agencies "a great deal" for information about reducing risks while traveling, more travelers (73%) trusted their own healthcare providers. Findings suggest that outreach may be improved by partnering with providers to emphasize the benefits of layering precautions and provide targeted education to high-risk individuals. Messages that are empathetic to the need to reduce stress and convey how precautions can protect loved ones may be particularly resonant after more than a year of pandemic-related restrictions. FAU - SteelFisher, Gillian K AU - SteelFisher GK AD - Gillian K. SteelFisher, PhD, MSc, is a Senior Research Scientist and Deputy Director; Caitlin L. McMurtry, SM, is a Research Fellow; and Hannah L. Caporello is Program Manager; all at the Harvard Opinion Research Program, Department of Health Policy and Management, Harvard T.H. Chan School of Public Health (HSPH), Boston, MA. Caitlin L. McMurtry is also a PhD Candidate, PhD Program in Health Policy, Harvard University, Cambridge, MA. Ericka McGowan, MS, is Senior Director, Immunization and Infectious Disease Team, Association of State and Territorial Health Officials (ASTHO), Arlington, VA. Thomas J. Schafer is Project Director, National Public Health Information Coalition, Canton, GA. Keri M. Lubell, PhD, is a Behavioral Scientist, Division of Emergency Operations, Center for Preparedness and Response, Centers for Disease Control and Prevention (CDC), Atlanta, GA. Allison L. Friedman, MS, is a Health Communications Specialist; Jessica Allen, MPH, MSW, is a Health Communications Specialist, Travelers' Health Branch; and Caitlin Shockey, JD, is Associate Director for Communication; all in the Division of Global Migration and Quarantine, National Center for Emerging and Zoonotic Infectious Diseases, CDC, Atlanta, GA. Alison Grady, MPH, is a Health Communications Strategist, Kapili Services, LLC, Atlanta, GA. Eran N. Ben-Porath, PhD, is Executive Vice President, SSRS, Glen Mills, PA. All authors acted in a personal capacity. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the CDC, any other portion of the Government of the United States, ASTHO, National Public Health Information Coalition, HSPH, Harvard University, or SSRS. The study was conducted through a cooperative agreement between CDC and ASTHO, who subsequently subcontracted to HSPH. FAU - McMurtry, Caitlin L AU - McMurtry CL AD - Gillian K. SteelFisher, PhD, MSc, is a Senior Research Scientist and Deputy Director; Caitlin L. McMurtry, SM, is a Research Fellow; and Hannah L. Caporello is Program Manager; all at the Harvard Opinion Research Program, Department of Health Policy and Management, Harvard T.H. Chan School of Public Health (HSPH), Boston, MA. Caitlin L. McMurtry is also a PhD Candidate, PhD Program in Health Policy, Harvard University, Cambridge, MA. Ericka McGowan, MS, is Senior Director, Immunization and Infectious Disease Team, Association of State and Territorial Health Officials (ASTHO), Arlington, VA. Thomas J. Schafer is Project Director, National Public Health Information Coalition, Canton, GA. Keri M. Lubell, PhD, is a Behavioral Scientist, Division of Emergency Operations, Center for Preparedness and Response, Centers for Disease Control and Prevention (CDC), Atlanta, GA. Allison L. Friedman, MS, is a Health Communications Specialist; Jessica Allen, MPH, MSW, is a Health Communications Specialist, Travelers' Health Branch; and Caitlin Shockey, JD, is Associate Director for Communication; all in the Division of Global Migration and Quarantine, National Center for Emerging and Zoonotic Infectious Diseases, CDC, Atlanta, GA. Alison Grady, MPH, is a Health Communications Strategist, Kapili Services, LLC, Atlanta, GA. Eran N. Ben-Porath, PhD, is Executive Vice President, SSRS, Glen Mills, PA. All authors acted in a personal capacity. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the CDC, any other portion of the Government of the United States, ASTHO, National Public Health Information Coalition, HSPH, Harvard University, or SSRS. The study was conducted through a cooperative agreement between CDC and ASTHO, who subsequently subcontracted to HSPH. FAU - Caporello, Hannah L AU - Caporello HL AD - Gillian K. SteelFisher, PhD, MSc, is a Senior Research Scientist and Deputy Director; Caitlin L. McMurtry, SM, is a Research Fellow; and Hannah L. Caporello is Program Manager; all at the Harvard Opinion Research Program, Department of Health Policy and Management, Harvard T.H. Chan School of Public Health (HSPH), Boston, MA. Caitlin L. McMurtry is also a PhD Candidate, PhD Program in Health Policy, Harvard University, Cambridge, MA. Ericka McGowan, MS, is Senior Director, Immunization and Infectious Disease Team, Association of State and Territorial Health Officials (ASTHO), Arlington, VA. Thomas J. Schafer is Project Director, National Public Health Information Coalition, Canton, GA. Keri M. Lubell, PhD, is a Behavioral Scientist, Division of Emergency Operations, Center for Preparedness and Response, Centers for Disease Control and Prevention (CDC), Atlanta, GA. Allison L. Friedman, MS, is a Health Communications Specialist; Jessica Allen, MPH, MSW, is a Health Communications Specialist, Travelers' Health Branch; and Caitlin Shockey, JD, is Associate Director for Communication; all in the Division of Global Migration and Quarantine, National Center for Emerging and Zoonotic Infectious Diseases, CDC, Atlanta, GA. Alison Grady, MPH, is a Health Communications Strategist, Kapili Services, LLC, Atlanta, GA. Eran N. Ben-Porath, PhD, is Executive Vice President, SSRS, Glen Mills, PA. All authors acted in a personal capacity. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the CDC, any other portion of the Government of the United States, ASTHO, National Public Health Information Coalition, HSPH, Harvard University, or SSRS. The study was conducted through a cooperative agreement between CDC and ASTHO, who subsequently subcontracted to HSPH. FAU - McGowan, Ericka AU - McGowan E AD - Gillian K. SteelFisher, PhD, MSc, is a Senior Research Scientist and Deputy Director; Caitlin L. McMurtry, SM, is a Research Fellow; and Hannah L. Caporello is Program Manager; all at the Harvard Opinion Research Program, Department of Health Policy and Management, Harvard T.H. Chan School of Public Health (HSPH), Boston, MA. Caitlin L. McMurtry is also a PhD Candidate, PhD Program in Health Policy, Harvard University, Cambridge, MA. Ericka McGowan, MS, is Senior Director, Immunization and Infectious Disease Team, Association of State and Territorial Health Officials (ASTHO), Arlington, VA. Thomas J. Schafer is Project Director, National Public Health Information Coalition, Canton, GA. Keri M. Lubell, PhD, is a Behavioral Scientist, Division of Emergency Operations, Center for Preparedness and Response, Centers for Disease Control and Prevention (CDC), Atlanta, GA. Allison L. Friedman, MS, is a Health Communications Specialist; Jessica Allen, MPH, MSW, is a Health Communications Specialist, Travelers' Health Branch; and Caitlin Shockey, JD, is Associate Director for Communication; all in the Division of Global Migration and Quarantine, National Center for Emerging and Zoonotic Infectious Diseases, CDC, Atlanta, GA. Alison Grady, MPH, is a Health Communications Strategist, Kapili Services, LLC, Atlanta, GA. Eran N. Ben-Porath, PhD, is Executive Vice President, SSRS, Glen Mills, PA. All authors acted in a personal capacity. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the CDC, any other portion of the Government of the United States, ASTHO, National Public Health Information Coalition, HSPH, Harvard University, or SSRS. The study was conducted through a cooperative agreement between CDC and ASTHO, who subsequently subcontracted to HSPH. FAU - Schafer, Thomas J AU - Schafer TJ AD - Gillian K. SteelFisher, PhD, MSc, is a Senior Research Scientist and Deputy Director; Caitlin L. McMurtry, SM, is a Research Fellow; and Hannah L. Caporello is Program Manager; all at the Harvard Opinion Research Program, Department of Health Policy and Management, Harvard T.H. Chan School of Public Health (HSPH), Boston, MA. Caitlin L. McMurtry is also a PhD Candidate, PhD Program in Health Policy, Harvard University, Cambridge, MA. Ericka McGowan, MS, is Senior Director, Immunization and Infectious Disease Team, Association of State and Territorial Health Officials (ASTHO), Arlington, VA. Thomas J. Schafer is Project Director, National Public Health Information Coalition, Canton, GA. Keri M. Lubell, PhD, is a Behavioral Scientist, Division of Emergency Operations, Center for Preparedness and Response, Centers for Disease Control and Prevention (CDC), Atlanta, GA. Allison L. Friedman, MS, is a Health Communications Specialist; Jessica Allen, MPH, MSW, is a Health Communications Specialist, Travelers' Health Branch; and Caitlin Shockey, JD, is Associate Director for Communication; all in the Division of Global Migration and Quarantine, National Center for Emerging and Zoonotic Infectious Diseases, CDC, Atlanta, GA. Alison Grady, MPH, is a Health Communications Strategist, Kapili Services, LLC, Atlanta, GA. Eran N. Ben-Porath, PhD, is Executive Vice President, SSRS, Glen Mills, PA. All authors acted in a personal capacity. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the CDC, any other portion of the Government of the United States, ASTHO, National Public Health Information Coalition, HSPH, Harvard University, or SSRS. The study was conducted through a cooperative agreement between CDC and ASTHO, who subsequently subcontracted to HSPH. FAU - Lubell, Keri M AU - Lubell KM AD - Gillian K. SteelFisher, PhD, MSc, is a Senior Research Scientist and Deputy Director; Caitlin L. McMurtry, SM, is a Research Fellow; and Hannah L. Caporello is Program Manager; all at the Harvard Opinion Research Program, Department of Health Policy and Management, Harvard T.H. Chan School of Public Health (HSPH), Boston, MA. Caitlin L. McMurtry is also a PhD Candidate, PhD Program in Health Policy, Harvard University, Cambridge, MA. Ericka McGowan, MS, is Senior Director, Immunization and Infectious Disease Team, Association of State and Territorial Health Officials (ASTHO), Arlington, VA. Thomas J. Schafer is Project Director, National Public Health Information Coalition, Canton, GA. Keri M. Lubell, PhD, is a Behavioral Scientist, Division of Emergency Operations, Center for Preparedness and Response, Centers for Disease Control and Prevention (CDC), Atlanta, GA. Allison L. Friedman, MS, is a Health Communications Specialist; Jessica Allen, MPH, MSW, is a Health Communications Specialist, Travelers' Health Branch; and Caitlin Shockey, JD, is Associate Director for Communication; all in the Division of Global Migration and Quarantine, National Center for Emerging and Zoonotic Infectious Diseases, CDC, Atlanta, GA. Alison Grady, MPH, is a Health Communications Strategist, Kapili Services, LLC, Atlanta, GA. Eran N. Ben-Porath, PhD, is Executive Vice President, SSRS, Glen Mills, PA. All authors acted in a personal capacity. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the CDC, any other portion of the Government of the United States, ASTHO, National Public Health Information Coalition, HSPH, Harvard University, or SSRS. The study was conducted through a cooperative agreement between CDC and ASTHO, who subsequently subcontracted to HSPH. FAU - Friedman, Allison L AU - Friedman AL AD - Gillian K. SteelFisher, PhD, MSc, is a Senior Research Scientist and Deputy Director; Caitlin L. McMurtry, SM, is a Research Fellow; and Hannah L. Caporello is Program Manager; all at the Harvard Opinion Research Program, Department of Health Policy and Management, Harvard T.H. Chan School of Public Health (HSPH), Boston, MA. Caitlin L. McMurtry is also a PhD Candidate, PhD Program in Health Policy, Harvard University, Cambridge, MA. Ericka McGowan, MS, is Senior Director, Immunization and Infectious Disease Team, Association of State and Territorial Health Officials (ASTHO), Arlington, VA. Thomas J. Schafer is Project Director, National Public Health Information Coalition, Canton, GA. Keri M. Lubell, PhD, is a Behavioral Scientist, Division of Emergency Operations, Center for Preparedness and Response, Centers for Disease Control and Prevention (CDC), Atlanta, GA. Allison L. Friedman, MS, is a Health Communications Specialist; Jessica Allen, MPH, MSW, is a Health Communications Specialist, Travelers' Health Branch; and Caitlin Shockey, JD, is Associate Director for Communication; all in the Division of Global Migration and Quarantine, National Center for Emerging and Zoonotic Infectious Diseases, CDC, Atlanta, GA. Alison Grady, MPH, is a Health Communications Strategist, Kapili Services, LLC, Atlanta, GA. Eran N. Ben-Porath, PhD, is Executive Vice President, SSRS, Glen Mills, PA. All authors acted in a personal capacity. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the CDC, any other portion of the Government of the United States, ASTHO, National Public Health Information Coalition, HSPH, Harvard University, or SSRS. The study was conducted through a cooperative agreement between CDC and ASTHO, who subsequently subcontracted to HSPH. FAU - Allen, Jessica AU - Allen J AD - Gillian K. SteelFisher, PhD, MSc, is a Senior Research Scientist and Deputy Director; Caitlin L. McMurtry, SM, is a Research Fellow; and Hannah L. Caporello is Program Manager; all at the Harvard Opinion Research Program, Department of Health Policy and Management, Harvard T.H. Chan School of Public Health (HSPH), Boston, MA. Caitlin L. McMurtry is also a PhD Candidate, PhD Program in Health Policy, Harvard University, Cambridge, MA. Ericka McGowan, MS, is Senior Director, Immunization and Infectious Disease Team, Association of State and Territorial Health Officials (ASTHO), Arlington, VA. Thomas J. Schafer is Project Director, National Public Health Information Coalition, Canton, GA. Keri M. Lubell, PhD, is a Behavioral Scientist, Division of Emergency Operations, Center for Preparedness and Response, Centers for Disease Control and Prevention (CDC), Atlanta, GA. Allison L. Friedman, MS, is a Health Communications Specialist; Jessica Allen, MPH, MSW, is a Health Communications Specialist, Travelers' Health Branch; and Caitlin Shockey, JD, is Associate Director for Communication; all in the Division of Global Migration and Quarantine, National Center for Emerging and Zoonotic Infectious Diseases, CDC, Atlanta, GA. Alison Grady, MPH, is a Health Communications Strategist, Kapili Services, LLC, Atlanta, GA. Eran N. Ben-Porath, PhD, is Executive Vice President, SSRS, Glen Mills, PA. All authors acted in a personal capacity. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the CDC, any other portion of the Government of the United States, ASTHO, National Public Health Information Coalition, HSPH, Harvard University, or SSRS. The study was conducted through a cooperative agreement between CDC and ASTHO, who subsequently subcontracted to HSPH. FAU - Shockey, Caitlin AU - Shockey C AD - Gillian K. SteelFisher, PhD, MSc, is a Senior Research Scientist and Deputy Director; Caitlin L. McMurtry, SM, is a Research Fellow; and Hannah L. Caporello is Program Manager; all at the Harvard Opinion Research Program, Department of Health Policy and Management, Harvard T.H. Chan School of Public Health (HSPH), Boston, MA. Caitlin L. McMurtry is also a PhD Candidate, PhD Program in Health Policy, Harvard University, Cambridge, MA. Ericka McGowan, MS, is Senior Director, Immunization and Infectious Disease Team, Association of State and Territorial Health Officials (ASTHO), Arlington, VA. Thomas J. Schafer is Project Director, National Public Health Information Coalition, Canton, GA. Keri M. Lubell, PhD, is a Behavioral Scientist, Division of Emergency Operations, Center for Preparedness and Response, Centers for Disease Control and Prevention (CDC), Atlanta, GA. Allison L. Friedman, MS, is a Health Communications Specialist; Jessica Allen, MPH, MSW, is a Health Communications Specialist, Travelers' Health Branch; and Caitlin Shockey, JD, is Associate Director for Communication; all in the Division of Global Migration and Quarantine, National Center for Emerging and Zoonotic Infectious Diseases, CDC, Atlanta, GA. Alison Grady, MPH, is a Health Communications Strategist, Kapili Services, LLC, Atlanta, GA. Eran N. Ben-Porath, PhD, is Executive Vice President, SSRS, Glen Mills, PA. All authors acted in a personal capacity. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the CDC, any other portion of the Government of the United States, ASTHO, National Public Health Information Coalition, HSPH, Harvard University, or SSRS. The study was conducted through a cooperative agreement between CDC and ASTHO, who subsequently subcontracted to HSPH. FAU - Grady, Alison AU - Grady A AD - Gillian K. SteelFisher, PhD, MSc, is a Senior Research Scientist and Deputy Director; Caitlin L. McMurtry, SM, is a Research Fellow; and Hannah L. Caporello is Program Manager; all at the Harvard Opinion Research Program, Department of Health Policy and Management, Harvard T.H. Chan School of Public Health (HSPH), Boston, MA. Caitlin L. McMurtry is also a PhD Candidate, PhD Program in Health Policy, Harvard University, Cambridge, MA. Ericka McGowan, MS, is Senior Director, Immunization and Infectious Disease Team, Association of State and Territorial Health Officials (ASTHO), Arlington, VA. Thomas J. Schafer is Project Director, National Public Health Information Coalition, Canton, GA. Keri M. Lubell, PhD, is a Behavioral Scientist, Division of Emergency Operations, Center for Preparedness and Response, Centers for Disease Control and Prevention (CDC), Atlanta, GA. Allison L. Friedman, MS, is a Health Communications Specialist; Jessica Allen, MPH, MSW, is a Health Communications Specialist, Travelers' Health Branch; and Caitlin Shockey, JD, is Associate Director for Communication; all in the Division of Global Migration and Quarantine, National Center for Emerging and Zoonotic Infectious Diseases, CDC, Atlanta, GA. Alison Grady, MPH, is a Health Communications Strategist, Kapili Services, LLC, Atlanta, GA. Eran N. Ben-Porath, PhD, is Executive Vice President, SSRS, Glen Mills, PA. All authors acted in a personal capacity. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the CDC, any other portion of the Government of the United States, ASTHO, National Public Health Information Coalition, HSPH, Harvard University, or SSRS. The study was conducted through a cooperative agreement between CDC and ASTHO, who subsequently subcontracted to HSPH. FAU - Ben-Porath, Eran N AU - Ben-Porath EN AD - Gillian K. SteelFisher, PhD, MSc, is a Senior Research Scientist and Deputy Director; Caitlin L. McMurtry, SM, is a Research Fellow; and Hannah L. Caporello is Program Manager; all at the Harvard Opinion Research Program, Department of Health Policy and Management, Harvard T.H. Chan School of Public Health (HSPH), Boston, MA. Caitlin L. McMurtry is also a PhD Candidate, PhD Program in Health Policy, Harvard University, Cambridge, MA. Ericka McGowan, MS, is Senior Director, Immunization and Infectious Disease Team, Association of State and Territorial Health Officials (ASTHO), Arlington, VA. Thomas J. Schafer is Project Director, National Public Health Information Coalition, Canton, GA. Keri M. Lubell, PhD, is a Behavioral Scientist, Division of Emergency Operations, Center for Preparedness and Response, Centers for Disease Control and Prevention (CDC), Atlanta, GA. Allison L. Friedman, MS, is a Health Communications Specialist; Jessica Allen, MPH, MSW, is a Health Communications Specialist, Travelers' Health Branch; and Caitlin Shockey, JD, is Associate Director for Communication; all in the Division of Global Migration and Quarantine, National Center for Emerging and Zoonotic Infectious Diseases, CDC, Atlanta, GA. Alison Grady, MPH, is a Health Communications Strategist, Kapili Services, LLC, Atlanta, GA. Eran N. Ben-Porath, PhD, is Executive Vice President, SSRS, Glen Mills, PA. All authors acted in a personal capacity. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the CDC, any other portion of the Government of the United States, ASTHO, National Public Health Information Coalition, HSPH, Harvard University, or SSRS. The study was conducted through a cooperative agreement between CDC and ASTHO, who subsequently subcontracted to HSPH. LA - eng PT - Journal Article DEP - 20210524 PL - United States TA - Health Secur JT - Health security JID - 101654694 SB - IM MH - Adult MH - COVID-19/epidemiology/*prevention & control MH - *Health Behavior MH - Humans MH - Male MH - Middle Aged MH - Physical Distancing MH - Safety Management/*methods MH - Seasons MH - Self Care/psychology/*statistics & numerical data MH - Surveys and Questionnaires MH - Travel/psychology/*statistics & numerical data PMC - PMC8217589 OTO - NOTNLM OT - COVID-19 OT - Epidemic management/response OT - Mask wearing OT - Risk communication OT - Social distancing OT - Travel EDAT- 2021/05/26 06:00 MHDA- 2021/06/22 06:00 PMCR- 2021/06/07 CRDT- 2021/05/25 05:31 PHST- 2021/05/26 06:00 [pubmed] PHST- 2021/06/22 06:00 [medline] PHST- 2021/05/25 05:31 [entrez] PHST- 2021/06/07 00:00 [pmc-release] AID - 10.1089/hs.2020.0212 [pii] AID - 10.1089/hs.2020.0212 [doi] PST - ppublish SO - Health Secur. 2021 May-Jun;19(3):338-348. doi: 10.1089/hs.2020.0212. Epub 2021 May 24. PMID- 34019835 OWN - NLM STAT- MEDLINE DCOM- 20210527 LR - 20210604 IS - 2214-109X (Electronic) IS - 2214-109X (Linking) VI - 9 IP - 6 DP - 2021 Jun TI - Need for and use of contraception by women before and during COVID-19 in four sub-Saharan African geographies: results from population-based national or regional cohort surveys. PG - e793-e801 LID - S2214-109X(21)00105-4 [pii] LID - 10.1016/S2214-109X(21)00105-4 [doi] AB - BACKGROUND: Although hindrances to the sexual and reproductive health of women are expected because of COVID-19, the actual effect of the pandemic on contraceptive use and unintended pregnancy risk in women, particularly in sub-Saharan Africa, remains largely unknown. We aimed to examine population-level changes in the need for and use of contraception by women during the COVID-19 pandemic, determine if these changes differed by sociodemographic characteristics, and compare observed changes during the COVID-19 pandemic with trends in the 2 preceding years. METHODS: In this study, we used four rounds of Performance Monitoring for Action (PMA) population-based survey data collected in four geographies: two at the country level (Burkina Faso and Kenya) and two at the subnational level (Kinshasa, Democratic Republic of the Congo and Lagos, Nigeria). These geographies were selected for this study as they completed surveys immediately before the onset of COVID-19 and implemented a follow-up specific to COVID-19. The first round comprised the baseline PMA panel survey implemented between November, 2019, and February, 2020 (referred to as baseline). The second round comprised telephone-based follow-up surveys between May 28 and July 20, 2020 (referred to as COVID-19 follow-up). The third and fourth rounds comprised two previous cross-sectional survey rounds implemented in the same geographies between 2017 and 2019. FINDINGS: Our analyses were restricted to 7245 women in union (married or living with a partner, as if married) who were interviewed at baseline and COVID-19 follow-up. The proportion of women in need of contraception significantly increased in Lagos only, by 5.81 percentage points (from 74.5% to 80.3%). Contraceptive use among women in need increased significantly in the two rural geographies, with a 17.37 percentage point increase in rural Burkina Faso (30.7% to 48.1%) and a 7.35 percentage point increase in rural Kenya (71.6% to 78.9%). These overall trends mask several distinct patterns by sociodemographic group. Specifically, there was an increase in the need for contraception among nulliparous women across all geographies investigated. INTERPRETATION: Our findings do not support the anticipated deleterious effect of COVID-19 on access to and use of contraceptive services by women in the earliest stages of the pandemic. Although these results are largely encouraging, we warn that these trends might not be sustainable throughout prolonged economic hardship and service disruptions. FUNDING: Bill & Melinda Gates Foundation. TRANSLATION: For the French translation of the abstract see Supplementary Materials section. CI - Copyright (c) 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved. FAU - Wood, Shannon N AU - Wood SN AD - Department of Population, Family and Reproductive Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. Electronic address: swood@jhu.edu. FAU - Karp, Celia AU - Karp C AD - Department of Population, Family and Reproductive Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. FAU - OlaOlorun, Funmilola AU - OlaOlorun F AD - College of Medicine, University of Ibadan, Ibadan, Nigeria. FAU - Pierre, Akilimali Z AU - Pierre AZ AD - Kinshasa School of Public Health, Kinshasa, DR Congo. FAU - Guiella, Georges AU - Guiella G AD - Institut Superieur des Sciences de la Population, Ouagadougou, Burkina Faso. FAU - Gichangi, Peter AU - Gichangi P AD - International Centre for Reproductive Health-Kenya, Nairobi, Kenya. FAU - Zimmerman, Linnea A AU - Zimmerman LA AD - Department of Population, Family and Reproductive Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. FAU - Anglewicz, Philip AU - Anglewicz P AD - Department of Population, Family and Reproductive Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. FAU - Larson, Elizabeth AU - Larson E AD - Department of Population, Family and Reproductive Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. FAU - Moreau, Caroline AU - Moreau C AD - Department of Population, Family and Reproductive Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA; Soins et Sante Primaire, CESP Centre for Research in Epidemiology and Population Health U1018, Inserm, Paris, France. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - England TA - Lancet Glob Health JT - The Lancet. Global health JID - 101613665 SB - IM CIN - Lancet Glob Health. 2021 Jun;9(6):e728-e729. doi: 10.1016/S2214-109X(21)00231-X. PMID: 34019825 MH - Adolescent MH - Adult MH - Africa South of the Sahara/epidemiology MH - COVID-19/*epidemiology MH - Cohort Studies MH - Contraception/*statistics & numerical data MH - Female MH - Health Care Surveys MH - *Health Services Needs and Demand MH - Humans MH - Middle Aged MH - Young Adult PMC - PMC8149322 COIS- Declaration of interests All authors report grants from the Bill & Melinda Gates Foundation during the conduct of the study. EDAT- 2021/05/22 06:00 MHDA- 2021/05/28 06:00 PMCR- 2021/05/18 CRDT- 2021/05/21 20:13 PHST- 2020/10/21 00:00 [received] PHST- 2021/02/22 00:00 [revised] PHST- 2021/02/25 00:00 [accepted] PHST- 2021/05/22 06:00 [pubmed] PHST- 2021/05/28 06:00 [medline] PHST- 2021/05/21 20:13 [entrez] PHST- 2021/05/18 00:00 [pmc-release] AID - S2214-109X(21)00105-4 [pii] AID - 10.1016/S2214-109X(21)00105-4 [doi] PST - ppublish SO - Lancet Glob Health. 2021 Jun;9(6):e793-e801. doi: 10.1016/S2214-109X(21)00105-4. PMID- 34016134 OWN - NLM STAT- MEDLINE DCOM- 20210617 LR - 20260221 IS - 1745-6215 (Electronic) IS - 1745-6215 (Linking) VI - 22 IP - 1 DP - 2021 May 20 TI - Heterogeneity in design and analysis of ICU delirium randomized trials: a systematic review. PG - 354 LID - 10.1186/s13063-021-05299-1 [doi] LID - 354 AB - BACKGROUND: There is a growing number of randomized controlled trials (RCTs) evaluating interventions to prevent or treat delirium in the intensive care unit (ICU). Efforts to improve the conduct of delirium RCTs are underway, but none address issues related to statistical analysis. The purpose of this review is to evaluate heterogeneity in the design and analysis of delirium outcomes and advance methodological recommendations for delirium RCTs in the ICU. METHODS: Relevant databases, including PubMed and Embase, were searched with no restrictions on language or publication date; the search was conducted on July 8, 2019. RCTs conducted on adult ICU patients with delirium as the primary outcome were included where trial results were available. Data on frequency and duration of delirium assessments, delirium outcome definitions, and statistical methods were independently extracted in duplicate. The review was registered with PROSPERO (CRD42020141204). RESULTS: Among 65 eligible RCTs, 44 (68%) targeted the prevention of delirium. The duration of follow-up varied, with 31 (48%) RCTs having /=15 years) eligible for HIVST. The primary outcome compared lifetime HIV testing among adolescents (15 to 19 years) between arms. Secondary outcomes compared: recent HIV testing (in the last 3 months) among older adults (>/=40 years) and men; cumulative 6-month incidence of ART initiation per 100,000 population; knowledge of the preventive benefits of HIV treatment; and HIV testing stigma. Outcomes were measured through a post-intervention survey and at neighboring health facilities. Analysis used intention-to-treat for cluster-level outcomes. Community health groups delivered 24,316 oral fluid-based HIVST kits. The survey included 90.2% (3,960/4,388) of listed participants in the 15 community-led HIVST clusters and 89.2% (3,920/4,394) of listed participants in the 15 SOC clusters. Overall, the proportion of men was 39.0% (3,072/7,880). Most participants obtained primary-level education or below, were married, and reported a sexual partner. Lifetime HIV testing among adolescents was higher in the community-led HIVST arm (84.6%, 770/910) than the SOC arm (67.1%, 582/867; adjusted risk difference [RD] 15.2%, 95% CI 7.5% to 22.9%; p < 0.001), especially among 15 to 17 year olds and boys. Recent testing among older adults was also higher in the community-led HIVST arm (74.5%, 869/1,166) than the SOC arm (31.5%, 350/1,111; adjusted RD 42.1%, 95% CI 34.9% to 49.4%; p < 0.001). Similarly, the proportions of recently tested men were 74.6% (1,177/1,577) and 33.9% (507/1,495) in the community-led HIVST and SOC arms, respectively (adjusted RD 40.2%, 95% CI 32.9% to 47.4%; p < 0.001). Knowledge of HIV treatment benefits and HIV testing stigma showed no differences between arms. Cumulative incidence of ART initiation was respectively 305.3 and 226.1 per 100,000 population in the community-led HIVST and SOC arms (RD 72.3, 95% CI -36.2 to 180.8; p = 0.18). In post hoc analysis, ART initiations in the 3-month post-intervention period were higher in the community-led HIVST arm than the SOC arm (RD 97.7, 95% CI 33.4 to 162.1; p = 0.004). HIVST uptake was 74.7% (2,956/3,960), with few adverse events (0.6%, 18/2,955) and at US$5.70 per HIVST kit distributed. The main limitations include the use of self-reported HIV testing outcomes and lack of baseline measurement for the primary outcome. CONCLUSIONS: In this study, we found that community-led HIVST was effective, safe, and affordable, with population impact and coverage rapidly realised at low cost. This approach could enable community HIV testing in high HIV prevalence settings and demonstrates potential for economies of scale and scope. TRIAL REGISTRATION: Clinicaltrials.gov NCT03541382. FAU - Indravudh, Pitchaya P AU - Indravudh PP AUID- ORCID: 0000-0003-4013-7645 AD - Department of Global Health and Development, London School of Hygiene & Tropical Medicine, London, United Kingdom. AD - Malawi-Liverpool-Wellcome Trust Clinical Research Programme, Blantyre, Malawi. FAU - Fielding, Katherine AU - Fielding K AUID- ORCID: 0000-0002-6524-3754 AD - Department of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, United Kingdom. AD - School of Public Health, University of the Witwatersrand, Johannesburg, South Africa. FAU - Kumwenda, Moses K AU - Kumwenda MK AUID- ORCID: 0000-0003-3091-7330 AD - Malawi-Liverpool-Wellcome Trust Clinical Research Programme, Blantyre, Malawi. FAU - Nzawa, Rebecca AU - Nzawa R AD - Malawi-Liverpool-Wellcome Trust Clinical Research Programme, Blantyre, Malawi. FAU - Chilongosi, Richard AU - Chilongosi R AD - Population Services International Malawi, Lilongwe, Malawi. FAU - Desmond, Nicola AU - Desmond N AUID- ORCID: 0000-0002-2874-8569 AD - Malawi-Liverpool-Wellcome Trust Clinical Research Programme, Blantyre, Malawi. AD - Department of International Public Health, Liverpool School of Tropical Medicine, Liverpool, United Kingdom. FAU - Nyirenda, Rose AU - Nyirenda R AD - Department of HIV and AIDS, Ministry of Health, Lilongwe, Malawi. FAU - Neuman, Melissa AU - Neuman M AUID- ORCID: 0000-0002-8870-6504 AD - Department of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, United Kingdom. FAU - Johnson, Cheryl C AU - Johnson CC AUID- ORCID: 0000-0001-5499-5523 AD - Global HIV, Hepatitis and Sexually Transmitted Infections Programmes, World Health Organisation, Geneva, Switzerland. AD - Department of Clinical Research, London School of Hygiene & Tropical Medicine, London, United Kingdom. FAU - Baggaley, Rachel AU - Baggaley R AD - Global HIV, Hepatitis and Sexually Transmitted Infections Programmes, World Health Organisation, Geneva, Switzerland. FAU - Hatzold, Karin AU - Hatzold K AUID- ORCID: 0000-0002-5117-3732 AD - Population Services International, Washington, District of Columbia, United States of America. FAU - Terris-Prestholt, Fern AU - Terris-Prestholt F AUID- ORCID: 0000-0003-1693-5196 AD - Department of Global Health and Development, London School of Hygiene & Tropical Medicine, London, United Kingdom. FAU - Corbett, Elizabeth L AU - Corbett EL AD - Malawi-Liverpool-Wellcome Trust Clinical Research Programme, Blantyre, Malawi. AD - Department of Clinical Research, London School of Hygiene & Tropical Medicine, London, United Kingdom. LA - eng SI - ClinicalTrials.gov/NCT03541382 GR - 001/WHO_/World Health Organization/International GR - 200901/Z/16/Z/WT_/Wellcome Trust/United Kingdom GR - MR/R010161/1/MRC_/Medical Research Council/United Kingdom GR - WT091769/WT_/Wellcome Trust/United Kingdom PT - Journal Article PT - Randomized Controlled Trial PT - Research Support, Non-U.S. Gov't DEP - 20210511 PL - United States TA - PLoS Med JT - PLoS medicine JID - 101231360 RN - 0 (Anti-Retroviral Agents) SB - IM MH - *Anti-Retroviral Agents/administration & dosage MH - *Community Participation/statistics & numerical data MH - *Diagnostic Tests, Routine/statistics & numerical data MH - *HIV Testing/statistics & numerical data MH - Malawi MH - *Mass Screening/statistics & numerical data MH - *Public Health/statistics & numerical data MH - Humans MH - Male MH - Female MH - Adolescent MH - Young Adult MH - Adult PMC - PMC8112698 COIS- The authors have declared that no competing interests exist. EDAT- 2021/05/12 06:00 MHDA- 2021/08/26 06:00 PMCR- 2021/05/11 CRDT- 2021/05/11 17:22 PHST- 2020/08/03 00:00 [received] PHST- 2021/04/04 00:00 [accepted] PHST- 2021/05/11 17:22 [entrez] PHST- 2021/05/12 06:00 [pubmed] PHST- 2021/08/26 06:00 [medline] PHST- 2021/05/11 00:00 [pmc-release] AID - PMEDICINE-D-20-03726 [pii] AID - 10.1371/journal.pmed.1003608 [doi] PST - epublish SO - PLoS Med. 2021 May 11;18(5):e1003608. doi: 10.1371/journal.pmed.1003608. eCollection 2021 May. PMID- 33968879 OWN - NLM STAT- MEDLINE DCOM- 20210512 LR - 20240402 IS - 2296-2565 (Electronic) IS - 2296-2565 (Linking) VI - 9 DP - 2021 TI - The Impact of Universal Mask Use on SARS-COV-2 in Victoria, Australia on the Epidemic Trajectory of COVID-19. PG - 625499 LID - 10.3389/fpubh.2021.625499 [doi] LID - 625499 AB - Objective(s): To estimate the impact of universal community face mask use in Victoria, Australia along with other routine disease control measures in place. Methods: A mathematical modeling study using an age structured deterministic model for Victoria, was simulated for 123 days between 1 June 2020 and 1 October 2020, incorporating lockdown, contact tracing, and case findings with and without mask use in varied scenarios. The model tested the impact of differing scenarios of the universal use of face masks in Victoria, by timing, varying mask effectiveness, and uptake. Results: A six-week lockdown with standard control measures, but no masks, would have resulted in a large resurgence by September, following the lifting of restrictions. Mask use can substantially reduce the epidemic size, with a greater impact if at least 50% of people wear a mask which has an effectiveness of at least 40%. Early mask use averts more cases than mask usage that is only implemented closer to the peak. No mask use, with a 6-week lockdown, results in 67,636 cases and 120 deaths by 1 October 2020 if no further lockdowns are used. If mask use at 70% uptake commences on 23 July 2020, this is reduced to 7,961 cases and 42 deaths. We estimated community mask effectiveness to be 11%. Conclusion(s): Lockdown and standard control measures may not have controlled the epidemic in Victoria. Mask use can substantially improve epidemic control if its uptake is higher than 50% and if moderately effective masks are used. Early mask use should be considered in other states if community transmission is present, as this has a greater effect than later mask wearing mandates. CI - Copyright (c) 2021 Costantino and Raina MacIntyre. FAU - Costantino, Valentina AU - Costantino V AD - The Biosecurity Program, The Kirby Institute, University of New South Wales, Kensington, NSW, Australia. FAU - Raina MacIntyre, Chandini AU - Raina MacIntyre C AD - The Biosecurity Program, The Kirby Institute, University of New South Wales, Kensington, NSW, Australia. AD - College of Health Solutions, Arizona State University, Tempe, AZ, United States. AD - College of Public Affairs and Community Solutions, Arizona State University, Tempe, AZ, United States. LA - eng PT - Journal Article DEP - 20210421 PL - Switzerland TA - Front Public Health JT - Frontiers in public health JID - 101616579 SB - IM MH - *COVID-19 MH - Communicable Disease Control MH - *Epidemics MH - Humans MH - SARS-CoV-2 MH - Victoria/epidemiology PMC - PMC8096905 OTO - NOTNLM OT - Coronavirus - COVID-19 OT - mask effectiveness OT - modeling study OT - outbreak control OT - universal masks use COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2021/05/11 06:00 MHDA- 2021/05/13 06:00 PMCR- 2021/04/21 CRDT- 2021/05/10 06:28 PHST- 2020/11/03 00:00 [received] PHST- 2021/03/10 00:00 [accepted] PHST- 2021/05/10 06:28 [entrez] PHST- 2021/05/11 06:00 [pubmed] PHST- 2021/05/13 06:00 [medline] PHST- 2021/04/21 00:00 [pmc-release] AID - 10.3389/fpubh.2021.625499 [doi] PST - epublish SO - Front Public Health. 2021 Apr 21;9:625499. doi: 10.3389/fpubh.2021.625499. eCollection 2021. PMID- 33959581 OWN - NLM STAT- MEDLINE DCOM- 20210528 LR - 20220531 IS - 2296-2565 (Electronic) IS - 2296-2565 (Linking) VI - 9 DP - 2021 TI - An Overview of Systematic Reviews of Acupuncture for Infertile Women Undergoing in vitro Fertilization and Embryo Transfer. PG - 651811 LID - 10.3389/fpubh.2021.651811 [doi] LID - 651811 AB - Background: Currently, more and more subfertility couples are opting for combined acupuncture to improve the success rate of in vitro fertilization and embryo transfer (IVF-ET). However, the efficacy and safety of acupuncture in IVF-ET is still highly controversial. Objectives: The purpose of this overview is to summarize evidence of essential outcomes of systematic reviews (SRs) of acupuncture in IVF-ET and evaluate their methodological quality. Methods: We conducted a comprehensive literature search for relevant SRs in eight databases from inception to July 31, 2020, without language restriction. We evaluated the methodological quality of the included SRs by using A Measurement Tool to Assess Systematic Reviews 2 (AMSTAR-2), which was the latest available assessment tool. The Risk of Bias in Systematic Review (ROBIS) tool was used to assess the risk of bias in SRs. We assessed the Grades of Recommendation, Assessment, Development, and Evaluation (GRADE) score to determine the strength of evidence. We excluded the overlapping randomized controlled trials (RCTs) and performed a re-meta-analysis of the primary RCTs. Results: This review included 312 original RCT studies and 65,388 participants. By using AMSTAR-2, we found that the methodological quality of 16 SRs was critically low, because they had more than one critical weakness. Our reviews showed that although the GRADE for quality of evidence profile was suboptimal, acupuncture seemed to be beneficial in increasing the pregnancy rate. Our re-meta-analysis suggested that acupuncture was superior to sham acupuncture in improving the clinical pregnancy rate (CPR) of IVF-ET with substantial heterogeneity (RR = 1.31, 95% CI: 1.13-1.52, p = 0.0004, I(2) = 66%). No statistical difference was observed regarding the outcomes of live birth rate (LBR), ongoing pregnancy rate (OPR), biochemical pregnancy rate (BPR), and miscarriage rate (MR) between two groups. When compared with no adjunctive treatment groups, acupuncture improved CPR (RR = 1. 25, 95% CI: 1.11-1.42, p = 0.0003) and OPR (RR = 1. 38, 95% CI: 1.04-1.83, p = 0.03). Acupuncture was more superior than no adjunctive treatment in reducing MR (OR = 1.42, 95% CI: 1.03-1.95, p = 0.03) and BPR (RR = 1.19, 95% CI: 1.02-1.37, p = 0.02). Conclusions: Although the evidence of acupuncture in IVF-ET is insufficient, acupuncture appears to be beneficial to increase the clinical pregnancy rate in women undergoing IVF-ET. However, there are severe heterogeneity and methodological quality defects, which limit the reliability of results. Further, high-quality primary studies are still needed. CI - Copyright (c) 2021 Wang, Wang, Wei, He, Cao, Zhang and Li. FAU - Wang, Xia AU - Wang X AD - Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China. FAU - Wang, Yan AU - Wang Y AD - Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China. FAU - Wei, Shaobin AU - Wei S AD - Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China. FAU - He, Bisong AU - He B AD - Department of Clinical Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, China. FAU - Cao, Yihong AU - Cao Y AD - Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China. FAU - Zhang, Nannan AU - Zhang N AD - Department of Clinical Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, China. FAU - Li, Maoya AU - Li M AD - Department of Clinical Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, China. LA - eng PT - Journal Article PT - Meta-Analysis PT - Research Support, Non-U.S. Gov't PT - Review DEP - 20210420 PL - Switzerland TA - Front Public Health JT - Frontiers in public health JID - 101616579 SB - IM MH - *Acupuncture Therapy MH - Embryo Transfer MH - Female MH - Fertilization in Vitro MH - Humans MH - *Infertility, Female/therapy MH - Pregnancy MH - Systematic Reviews as Topic PMC - PMC8096176 OTO - NOTNLM OT - acupuncture OT - in vitro fertilization OT - methodological quality OT - overview OT - systematic reviews COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2021/05/08 06:00 MHDA- 2021/05/29 06:00 PMCR- 2021/04/20 CRDT- 2021/05/07 07:15 PHST- 2021/01/11 00:00 [received] PHST- 2021/03/19 00:00 [accepted] PHST- 2021/05/07 07:15 [entrez] PHST- 2021/05/08 06:00 [pubmed] PHST- 2021/05/29 06:00 [medline] PHST- 2021/04/20 00:00 [pmc-release] AID - 10.3389/fpubh.2021.651811 [doi] PST - epublish SO - Front Public Health. 2021 Apr 20;9:651811. doi: 10.3389/fpubh.2021.651811. eCollection 2021. PMID- 33956832 OWN - NLM STAT- MEDLINE DCOM- 20210517 LR - 20210525 IS - 1932-6203 (Electronic) IS - 1932-6203 (Linking) VI - 16 IP - 5 DP - 2021 TI - The ongoing indirect effect of the COVID-19 pandemic on a pediatric emergency department. PG - e0251003 LID - 10.1371/journal.pone.0251003 [doi] LID - e0251003 AB - INTRODUCTION: The SARS-CoV-2 coronavirus pandemic may cause significant morbidity and mortality in adults, yet severe cases are rare among children. The indirect impact of the pandemic on health care delivery in general and pediatric emergency department (PED) visits in particular has been widely reported. AIMS: To assess the impact of the pandemic and the social restrictions imposed in its wake on PED visits and hospitalization rates in our Israeli medical center. We also sought to track these data in relation to the variation in pandemic severity and social restrictions over time. A comparison of this data with that of the adult emergency department was also performed. METHODS: Data for this study were drawn from the Shaare Zedek Medical Center (SZMC), Jerusalem, Israel computerized databank. The daily number of PED and adult ER visits as well as hospitalizations resulting from these visits during the months January-July during the years 2018, 2019, 2020 were recorded. We compared the risk ratio for hospitalization in 2019 and 2020, as well as the incidence rate ratio. RESULTS: During March and April there was a decrease in PED visits from 4,588 visits in 2019 to 2,527 visits in 2020 (ratio = .551, 95%CI [.52,.58]. Despite the drop in PED visits, the rate of hospitalizations rose with respect to 2019 (Risk Ratio = 1.31, p < .001, 95%CI [1.17,1.47]). Similar but more moderate trends were seen in the adult ED. From May-July 2020, after the lockdown was lifted, PED visits remained 30% below the same time period from 2018 and 2019, while the hospitalization rate returned to its pre-pandemic level. CONCLUSIONS: A significant drop in PED visits is seen to extend well beyond the peak of the pandemic and the lockdown period. This highlights the potential risk of children with serious emergencies becoming casualties of the pandemic by their not being brought to medical attention. Efforts should be made to raise public awareness among parents and other caretakers of children regarding this matter. FAU - Erlichman, Matti AU - Erlichman M AD - Shaare Zedek Medical Center and the Faculty of Medicine at the Hebrew University in Jerusalem, Pediatric Emergency Department, Jerusalem, Israel. FAU - Zalut, Todd AU - Zalut T AD - Emergency Department, Shaare Zedek Medical Center, Jerusalem, Israel. FAU - Schwartz, Shepard AU - Schwartz S AD - Shaare Zedek Medical Center and the Faculty of Medicine at the Hebrew University in Jerusalem, Pediatric Emergency Department, Jerusalem, Israel. FAU - Weiser, Giora AU - Weiser G AUID- ORCID: 0000-0001-8743-5469 AD - Shaare Zedek Medical Center and the Faculty of Medicine at the Hebrew University in Jerusalem, Pediatric Emergency Department, Jerusalem, Israel. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20210506 PL - United States TA - PLoS One JT - PloS one JID - 101285081 SB - IM MH - *COVID-19/epidemiology/prevention & control MH - Child MH - Communicable Disease Control MH - *Emergency Service, Hospital/statistics & numerical data MH - Hospitalization/statistics & numerical data MH - Hospitals, Pediatric/statistics & numerical data MH - Humans MH - Israel/epidemiology MH - Pandemics MH - SARS-CoV-2/isolation & purification PMC - PMC8117792 COIS- The authors have declared that no competing interests exist. EDAT- 2021/05/07 06:00 MHDA- 2021/05/18 06:00 PMCR- 2021/05/06 CRDT- 2021/05/06 18:04 PHST- 2020/12/09 00:00 [received] PHST- 2021/04/16 00:00 [accepted] PHST- 2021/05/06 18:04 [entrez] PHST- 2021/05/07 06:00 [pubmed] PHST- 2021/05/18 06:00 [medline] PHST- 2021/05/06 00:00 [pmc-release] AID - PONE-D-20-38694 [pii] AID - 10.1371/journal.pone.0251003 [doi] PST - epublish SO - PLoS One. 2021 May 6;16(5):e0251003. doi: 10.1371/journal.pone.0251003. eCollection 2021. PMID- 33956330 OWN - NLM STAT- MEDLINE DCOM- 20211022 LR - 20230920 IS - 1179-2027 (Electronic) IS - 1170-7690 (Print) IS - 1170-7690 (Linking) VI - 39 IP - 7 DP - 2021 Jul TI - Economic Burden of Multiple Sclerosis in Low- and Middle-Income Countries: A Systematic Review. PG - 789-807 LID - 10.1007/s40273-021-01032-7 [doi] AB - BACKGROUND: Although the economic burden of multiple sclerosis (MS) in high-income countries (HICs) has been extensively studied, information on the costs of MS in low- and middle-income countries (LMICs) remains scarce. Moreover, no review synthesizing and assessing the costs of MS in LMICs has yet been undertaken. OBJECTIVE: Our objective was to systematically identify and review the cost of illness (COI) of MS in LMICs to critically appraise the methodologies used, compare cost estimates across countries and by level of disease severity, and examine cost drivers. METHODS: We conducted a systematic literature search for original studies in English, French, and Dutch containing prevalence or incidence-based cost data of MS in LMICs. The search was conducted in MEDLINE (Ovid), PubMed, Embase (Ovid), Cochrane Library, National Health Service Economic Evaluation Database (NHS EED), Econlit, and CINAHL (EBSCO) on July 2020 without restrictions on publication date. Recommended and validated methods were used for data extraction and analysis to make the results of the COI studies comparable. Costs were adjusted to $US, year 2019 values, using the World Bank purchasing power parity and inflated using the consumer price index. RESULTS: A total of 14 studies were identified, all of which were conducted in upper-middle-income economies. Eight studies used a bottom-up approach for costing, and six used a top-down approach. Four studies used a societal perspective. The total annual cost per patient ranged between $US463 and 58,616. Costs varied across studies and countries, mainly because of differences regarding the inclusion of costs of disease-modifying therapies (DMTs), the range of cost items included, the methodological choices such as approaches used to estimate healthcare resource consumption, and the inclusion of informal care and productivity losses. Characteristics and methodologies of the included studies varied considerably, especially regarding the perspective adopted, cost data specification, and reporting of costs per severity levels. The total costs increased with greater disease severity. The cost ratios between different levels of MS severity within studies were relatively stable; costs were around 1-1.5 times higher for moderate versus mild MS and about two times higher for severe versus mild MS. MS drug costs were the main cost driver for less severe MS, whereas the proportion of direct non-medical costs and indirect costs increased with greater disease severity. CONCLUSION: MS places a huge economic burden on healthcare systems and societies in LMICs. Methodological differences and substantial variations in terms of absolute costs were found between studies, which made comparison of studies challenging. However, the cost ratios across different levels of MS severity were similar, making comparisons between studies by disease severity feasible. Cost drivers were mainly DMTs and relapse treatments, and this was consistent across studies. Yet, the distribution of cost components varied with disease severity. FAU - Dahham, Jalal AU - Dahham J AUID- ORCID: 0000-0002-2875-124X AD - Department of Health Services Research, Care and Public Health Research Institute (CAPHRI), Faculty of Health Medicine and Life Sciences, Maastricht University, 6200 MD, Maastricht, The Netherlands. j.dahham@maastrichtuniversity.nl. FAU - Rizk, Rana AU - Rizk R AUID- ORCID: 0000-0002-8850-6502 AD - Institut National de Sante Publique, d'Epidemiologie Clinique et de Toxicologie (INSPECT-Lb), Beirut, Lebanon. FAU - Kremer, Ingrid AU - Kremer I AUID- ORCID: 0000-0003-2784-8207 AD - Department of Health Services Research, Care and Public Health Research Institute (CAPHRI), Faculty of Health Medicine and Life Sciences, Maastricht University, 6200 MD, Maastricht, The Netherlands. FAU - Evers, Silvia M A A AU - Evers SMAA AUID- ORCID: 0000-0003-1026-570X AD - Department of Health Services Research, Care and Public Health Research Institute (CAPHRI), Faculty of Health Medicine and Life Sciences, Maastricht University, 6200 MD, Maastricht, The Netherlands. AD - Centre for Economic Evaluations and Machine Learning, Trimbos Institute, Utrecht, The Netherlands. FAU - Hiligsmann, Mickael AU - Hiligsmann M AUID- ORCID: 0000-0003-4274-9258 AD - Department of Health Services Research, Care and Public Health Research Institute (CAPHRI), Faculty of Health Medicine and Life Sciences, Maastricht University, 6200 MD, Maastricht, The Netherlands. LA - eng PT - Journal Article PT - Systematic Review DEP - 20210506 PL - New Zealand TA - Pharmacoeconomics JT - PharmacoEconomics JID - 9212404 MH - *Cost of Illness MH - Developing Countries MH - Drug Costs MH - Health Care Costs MH - Humans MH - *Multiple Sclerosis MH - State Medicine PMC - PMC8200340 COIS- Jalal Dahham, Rana Rizk, Ingrid Kremer, Silvia M.A.A. Evers, and Mickael Hiligsmann have no conflicts of interest that are directly relevant to the content of this article. EDAT- 2021/05/07 06:00 MHDA- 2021/10/28 06:00 PMCR- 2021/05/06 CRDT- 2021/05/06 13:12 PHST- 2021/03/19 00:00 [accepted] PHST- 2021/05/07 06:00 [pubmed] PHST- 2021/10/28 06:00 [medline] PHST- 2021/05/06 13:12 [entrez] PHST- 2021/05/06 00:00 [pmc-release] AID - 10.1007/s40273-021-01032-7 [pii] AID - 1032 [pii] AID - 10.1007/s40273-021-01032-7 [doi] PST - ppublish SO - Pharmacoeconomics. 2021 Jul;39(7):789-807. doi: 10.1007/s40273-021-01032-7. Epub 2021 May 6. PMID- 33942117 OWN - NLM STAT- MEDLINE DCOM- 20210517 LR - 20210517 IS - 1541-8243 (Electronic) IS - 0038-4348 (Linking) VI - 114 IP - 5 DP - 2021 May TI - COVID-19 Impact on Orthopedic Surgeons: Elective Procedures, Telehealth, and Income. PG - 311-316 LID - 10.14423/SMJ.0000000000001249 [doi] AB - OBJECTIVES: The purpose of this study was to investigate the response in orthopedic surgery to the coronavirus disease 2019 (COVID-19) pandemic across the United States by surveying surgeons about their care setting, timing of restrictions on elective surgery, use of telehealth, and estimated economic impact. METHODS: A survey was distributed via REDCap through state orthopedic organizations between April and July 2020. The 22-question digital survey collected information regarding restrictions on elective procedures, location of care, utilization of telehealth, and estimated reductions in annual income. RESULTS: In this study, 192 participants responded to the survey (average age 49.9 +/- 11.0 years, 92.7% male). Responses primarily originated from Alabama (30.2%), Georgia (30.2%), and Missouri (16.1%). The remainder of the responses were grouped into the category "other." Respondents did not vary significantly by state in operative setting or income type (salary, work relative value units, or collections). Most of the participants documented elective procedure restrictions in hospital and ambulatory settings. The highest frequency of closures occurred between March 18 and 20 (47% in hospital, 51% in ambulatory). Of the participants, financial loss estimates varied across states (P = 0.005), with 50% of physicians claiming >50% losses of income in Alabama (24% Georgia, 10% Missouri, 31% other). Regarding telehealth, practices set up for these services before 2020 varied across states. None of the orthopedic practices in Alabama had telehealth before the COVID-19 pandemic (Missouri 25%, Georgia 9%, other 8%, P = 0.06); however, respondents generally were split when considering the anticipation of implementing telehealth into routine practice. CONCLUSIONS: Most practices did implement restrictions for elective clinic visits and procedures early during the pandemic. COVID-19 ultimately will result in a large revenue loss for elective orthopedic practices. Services such as telehealth may help offset these losses and help deliver orthopedic care to patients remotely. FAU - Paul, Kyle D AU - Paul KD AD - From the Department of Orthopaedic Surgery, the University of Alabama at Birmingham, and the Department of Epidemiology, School of Public Health, the University of Alabama at Birmingham, Birmingham. FAU - Levitt, Eli AU - Levitt E AD - From the Department of Orthopaedic Surgery, the University of Alabama at Birmingham, and the Department of Epidemiology, School of Public Health, the University of Alabama at Birmingham, Birmingham. FAU - McGwin, Gerald AU - McGwin G AD - From the Department of Orthopaedic Surgery, the University of Alabama at Birmingham, and the Department of Epidemiology, School of Public Health, the University of Alabama at Birmingham, Birmingham. FAU - Brabston, Eugene W 3rd AU - Brabston EW 3rd AD - From the Department of Orthopaedic Surgery, the University of Alabama at Birmingham, and the Department of Epidemiology, School of Public Health, the University of Alabama at Birmingham, Birmingham. FAU - Gilbert, Shawn R AU - Gilbert SR AD - From the Department of Orthopaedic Surgery, the University of Alabama at Birmingham, and the Department of Epidemiology, School of Public Health, the University of Alabama at Birmingham, Birmingham. FAU - Ponce, Brent A AU - Ponce BA AD - From the Department of Orthopaedic Surgery, the University of Alabama at Birmingham, and the Department of Epidemiology, School of Public Health, the University of Alabama at Birmingham, Birmingham. FAU - Momaya, Amit M AU - Momaya AM AD - From the Department of Orthopaedic Surgery, the University of Alabama at Birmingham, and the Department of Epidemiology, School of Public Health, the University of Alabama at Birmingham, Birmingham. LA - eng PT - Journal Article PL - United States TA - South Med J JT - Southern medical journal JID - 0404522 SB - IM MH - Adult MH - COVID-19/*prevention & control MH - Elective Surgical Procedures/*trends MH - Female MH - Health Care Surveys MH - Health Services Accessibility/trends MH - Humans MH - Income/*trends MH - Male MH - Middle Aged MH - Orthopedic Procedures/*trends MH - Orthopedic Surgeons/economics/*trends MH - Telemedicine/*trends MH - United States EDAT- 2021/05/05 06:00 MHDA- 2021/05/18 06:00 CRDT- 2021/05/04 06:57 PHST- 2021/05/04 06:57 [entrez] PHST- 2021/05/05 06:00 [pubmed] PHST- 2021/05/18 06:00 [medline] AID - SMJ_210050 [pii] AID - 10.14423/SMJ.0000000000001249 [doi] PST - ppublish SO - South Med J. 2021 May;114(5):311-316. doi: 10.14423/SMJ.0000000000001249. PMID- 33938076 OWN - NLM STAT- MEDLINE DCOM- 20210910 LR - 20210910 IS - 1099-1611 (Electronic) IS - 1057-9249 (Linking) VI - 30 IP - 9 DP - 2021 Sep TI - Neuro-oncological patients' and caregivers' psychosocial burden during the COVID-19 pandemic-A prospective study with qualitative content analysis. PG - 1502-1513 LID - 10.1002/pon.5713 [doi] AB - OBJECTIVE: The COVID-19 pandemic may reinforce psychosocial distress of neuro-oncological patients. We aimed to (1) differentiate the burden caused by the pandemic versus the tumor and (2) establish topics relevant for brain tumor patients (BTPs) and caregivers. METHODS: Patients and caregivers were prospectively assessed from April 2020-July 2020 by a 10-item comprising interview over the phone, including qualitative and quantitative questions. They were quantitatively evaluated i.a. by the distress thermometer (DT, score 1-10). The qualitative questions were analyzed using structured content analysis: The interview questions defined the main categories. Subcategories were derived by an inductive approach assessing the frequency of patients' and caregivers' answers. RESULTS: A total of 69 patients and 20 caregivers were interviewed; n = 36 were female (49%), mean age was 53 years (range 32-81). Patients' disease-related DT scores were higher than the COVID-19-related DT scores: the median of the disease-related DT score was 7 (range 2-10) versus median of COVID-19-related distress: 5.0 (range 2-7). Caregivers perceived a higher burden due to the disease (DT median disease: 8; range 2-10 vs. DT pandemic: 3, range 0-10). A total of five main and 21 subcategories were elaborated, most frequently mentioned were "restrictions in public and private affairs" (28%), "changes in the psychological well-being" (23%), "limited social interaction by contact restriction" (25%). Subcategories relevant for caregivers were similar to those of BTPs. CONCLUSION: A considerable proportion of patients and caregivers still perceived the brain tumor disease as more burdensome than the pandemic. We established main and subcategories of interview items possibly of great relevance to patients during these difficult times, which could be implemented in the content-related adaption of the psychosocial assessment. CI - (c) 2021 The Authors. Psycho-Oncology published by John Wiley & Sons Ltd. FAU - Binswanger, Julia AU - Binswanger J AD - Department of Neurology and Interdisciplinary Neuro-Oncology, University Hospital Tubingen, Hertie Institute for Clinical Brain Research, Eberhard-Karls-University Tubingen, Tubingen, Germany. FAU - Kohl, Carolin AU - Kohl C AD - Department of Neurology and Interdisciplinary Neuro-Oncology, University Hospital Tubingen, Hertie Institute for Clinical Brain Research, Eberhard-Karls-University Tubingen, Tubingen, Germany. FAU - Behling, Felix AU - Behling F AD - Center for Neuro-Oncology, Comprehensive Cancer Center Tubingen-Stuttgart, University Hospital Tubingen, Eberhard-Karls-University Tubingen, Tubingen, Germany. AD - Department of Neurosurgery, University Hospital Tubingen, Eberhard-Karls-University Tubingen, Tubingen, Germany. FAU - Noell, Susan AU - Noell S AD - Center for Neuro-Oncology, Comprehensive Cancer Center Tubingen-Stuttgart, University Hospital Tubingen, Eberhard-Karls-University Tubingen, Tubingen, Germany. AD - Department of Neurosurgery, University Hospital Tubingen, Eberhard-Karls-University Tubingen, Tubingen, Germany. FAU - Hirsch, Sophie AU - Hirsch S AD - Department of Neurology and Interdisciplinary Neuro-Oncology, University Hospital Tubingen, Hertie Institute for Clinical Brain Research, Eberhard-Karls-University Tubingen, Tubingen, Germany. AD - Center for Neuro-Oncology, Comprehensive Cancer Center Tubingen-Stuttgart, University Hospital Tubingen, Eberhard-Karls-University Tubingen, Tubingen, Germany. FAU - Hickmann, Anne-Katrin AU - Hickmann AK AD - Department of Neurosurgery, Universitat St Gallen Bibliothek, St. Gallen, Switzerland. FAU - Tatagiba, Marcos Soares AU - Tatagiba MS AD - Center for Neuro-Oncology, Comprehensive Cancer Center Tubingen-Stuttgart, University Hospital Tubingen, Eberhard-Karls-University Tubingen, Tubingen, Germany. AD - Department of Neurosurgery, University Hospital Tubingen, Eberhard-Karls-University Tubingen, Tubingen, Germany. FAU - Tabatabai, Ghazaleh AU - Tabatabai G AD - Department of Neurology and Interdisciplinary Neuro-Oncology, University Hospital Tubingen, Hertie Institute for Clinical Brain Research, Eberhard-Karls-University Tubingen, Tubingen, Germany. AD - Center for Neuro-Oncology, Comprehensive Cancer Center Tubingen-Stuttgart, University Hospital Tubingen, Eberhard-Karls-University Tubingen, Tubingen, Germany. FAU - Hippler, Melina AU - Hippler M AD - Department of Neurology and Interdisciplinary Neuro-Oncology, University Hospital Tubingen, Hertie Institute for Clinical Brain Research, Eberhard-Karls-University Tubingen, Tubingen, Germany. AD - Center for Neuro-Oncology, Comprehensive Cancer Center Tubingen-Stuttgart, University Hospital Tubingen, Eberhard-Karls-University Tubingen, Tubingen, Germany. FAU - Renovanz, Mirjam AU - Renovanz M AUID- ORCID: 0000-0002-2824-3720 AD - Department of Neurology and Interdisciplinary Neuro-Oncology, University Hospital Tubingen, Hertie Institute for Clinical Brain Research, Eberhard-Karls-University Tubingen, Tubingen, Germany. AD - Center for Neuro-Oncology, Comprehensive Cancer Center Tubingen-Stuttgart, University Hospital Tubingen, Eberhard-Karls-University Tubingen, Tubingen, Germany. AD - Department of Neurosurgery, University Hospital Tubingen, Eberhard-Karls-University Tubingen, Tubingen, Germany. LA - eng GR - Unassigned/Bayer/ GR - Unassigned/Medac/ PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20210505 PL - England TA - Psychooncology JT - Psycho-oncology JID - 9214524 SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - *Brain Neoplasms/epidemiology MH - *COVID-19 MH - Caregivers MH - Female MH - Humans MH - Middle Aged MH - Pandemics MH - Prospective Studies MH - SARS-CoV-2 OTO - NOTNLM OT - COVID-19 OT - brain tumor OT - caregivers OT - interview OT - patients OT - psycho-oncology OT - qualitative content analysis EDAT- 2021/05/04 06:00 MHDA- 2021/09/11 06:00 CRDT- 2021/05/03 06:40 PHST- 2021/04/11 00:00 [revised] PHST- 2021/01/25 00:00 [received] PHST- 2021/04/12 00:00 [accepted] PHST- 2021/05/04 06:00 [pubmed] PHST- 2021/09/11 06:00 [medline] PHST- 2021/05/03 06:40 [entrez] AID - 10.1002/pon.5713 [doi] PST - ppublish SO - Psychooncology. 2021 Sep;30(9):1502-1513. doi: 10.1002/pon.5713. Epub 2021 May 5. PMID- 33937547 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240809 IS - 2410-8219 (Electronic) IS - 0379-6175 (Print) IS - 0379-6175 (Linking) VI - 77 IP - 1 DP - 2021 TI - Experiences of secondary health conditions amongst people with spinal cord injury in South Africa: A qualitative study. PG - 1530 LID - 10.4102/sajp.v77i1.1530 [doi] LID - 1530 AB - BACKGROUND: Secondary health conditions (SHCs) such as pain, pressure sores, sexual problems, bowel and bladder problems are prevalent throughout the lifespan of people with spinal cord injury (SCI). Studies have reported that SHCs decrease life expectancy and increase health care costs. Studies on the lived experience of SHCs are, however, limited. OBJECTIVES: To explore the experiences of SHCs amongst people with SCI in a public rehabilitation hospital in South Africa. METHOD: Face-to-face semi-structured interviews were conducted with people with SCI from August 2018 to July 2019. All interviews were transcribed verbatim and analysed using a content analysis approach. RESULTS: Seventeen people with SCI were interviewed. Participants experienced a range of SHCs. The most common experienced SHC was pain (94%). The main theme that emerged from the analysis was 'the impact of secondary health conditions on health and well-being'. The categories linked to the impact were SHCs co-occurrence and how SHCs limit function, restrict participation, affect mental health and disrupt lives. CONCLUSION: We found that SHCs were enormously impactful on our participants' lives and health, as illustrated by their stories of fear, embarrassment and shame. Understanding people with SCI experiences of SHCs can enhance communication between people with SCI and health professionals and may help develop prevention strategies. CLINICAL IMPLICATIONS: To enhance patient-centred care, health professionals are encouraged to actively listen to patients' experiences of illness and the impact on health and wellbeing. CI - (c) 2021. The Authors. FAU - Pilusa, Sonti I AU - Pilusa SI AUID- ORCID: 0000-0003-0606-9669 AD - Department of Physiotherapy, School of Therapeutic Sciences, Faculty of Health Sciences, University of the Witwatersrand, Parktown, South Africa. FAU - Myezwa, Hellen AU - Myezwa H AUID- ORCID: 0000-0003-4562-6413 AD - Department of Physiotherapy, School of Therapeutic Sciences, Faculty of Health Sciences, University of the Witwatersrand, Parktown, South Africa. FAU - Potterton, Joanne AU - Potterton J AUID- ORCID: 0000-0002-8020-274X AD - Department of Physiotherapy, School of Therapeutic Sciences, Faculty of Health Sciences, University of the Witwatersrand, Parktown, South Africa. LA - eng GR - WT_/Wellcome Trust/United Kingdom PT - Journal Article DEP - 20210406 PL - South Africa TA - S Afr J Physiother JT - The South African journal of physiotherapy JID - 9816433 PMC - PMC8063775 OTO - NOTNLM OT - health OT - secondary complications OT - secondary health conditions OT - spinal cord injury OT - wellbeing COIS- The authors declare that they have no financial or personal relationships that may have inappropriately influenced them in writing this article. EDAT- 2021/05/04 06:00 MHDA- 2021/05/04 06:01 PMCR- 2021/04/06 CRDT- 2021/05/03 06:24 PHST- 2020/09/07 00:00 [received] PHST- 2021/01/26 00:00 [accepted] PHST- 2021/05/03 06:24 [entrez] PHST- 2021/05/04 06:00 [pubmed] PHST- 2021/05/04 06:01 [medline] PHST- 2021/04/06 00:00 [pmc-release] AID - SAJP-77-1530 [pii] AID - 10.4102/sajp.v77i1.1530 [doi] PST - epublish SO - S Afr J Physiother. 2021 Apr 6;77(1):1530. doi: 10.4102/sajp.v77i1.1530. eCollection 2021. PMID- 33926000 OWN - NLM STAT- MEDLINE DCOM- 20210505 LR - 20240402 IS - 1660-4601 (Electronic) IS - 1661-7827 (Print) IS - 1660-4601 (Linking) VI - 18 IP - 9 DP - 2021 Apr 26 TI - Physical Activity Supporting Connection to Nature, and Helping to Maintain Wellbeing during the Covid-19 Restrictions in England. LID - 10.3390/ijerph18094585 [doi] LID - 4585 AB - The Covid-19 pandemic and the restrictions put in place to prevent or reduce the spread of the disease led to anxiety, concern and stress for many people. In England restrictions varied at different times of the year, and throughout this time there was a lot of attention focused on the importance of exercise and on engaging with nature to maintain wellbeing. We undertook an online survey that ran for six weeks in June/July 2020 and gained a response from 2115 people, of which 25% were male and 74% female, with 35% aged 16-44 and 65% aged 45+. This survey focused on people who were already interested or engaged with nature. We explored whether being physically activity changed or not, if being active impacted people's wellbeing and whether those who were active benefited from connecting to nature. We found that those meeting the government recommended levels of physical activity in the previous week, of 150 min, were more likely to maintain their overall wellbeing through feeling that the things they did in their life were worthwhile (p < 0.0001) and reported an increase in feelings of connection to nature (p < 0.0001). While those who did less than 30 min of physical activity in the previous week were less happy (p < 0.0001) and more anxious than usual (p < 0.0001). The research highlights the importance of physical activity and contact with nature and how these can play important roles in maintaining people's everyday wellbeing under extremely difficult national circumstances. FAU - O'Brien, Liz AU - O'Brien L AUID- ORCID: 0000-0001-7976-9987 AD - Forest Research, Social and Economic Research Group, Farnham GU10 4LH, UK. FAU - Forster, Jack AU - Forster J AD - Forest Research, Social and Economic Research Group, Farnham GU10 4LH, UK. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20210426 PL - Switzerland TA - Int J Environ Res Public Health JT - International journal of environmental research and public health JID - 101238455 SB - IM MH - *COVID-19 MH - England MH - Exercise MH - Female MH - Humans MH - Male MH - Middle Aged MH - Pandemics MH - SARS-CoV-2 PMC - PMC8123673 OTO - NOTNLM OT - motivations OT - nature OT - nature connection OT - physical activity OT - trees and woodlands OT - wellbeing COIS- Sport England provided the Short Active Lives Survey for use in this study. Members of Sport England and Forestry England made a small number of suggestions to the questions developed in the questionnaire. They were not involved in data collection, analyses or interpretation of the data; or in the writing of the manuscript, or in the decision to publish the results. EDAT- 2021/05/01 06:00 MHDA- 2021/05/06 06:00 PMCR- 2021/04/26 CRDT- 2021/04/30 01:33 PHST- 2021/03/02 00:00 [received] PHST- 2021/04/16 00:00 [revised] PHST- 2021/04/19 00:00 [accepted] PHST- 2021/04/30 01:33 [entrez] PHST- 2021/05/01 06:00 [pubmed] PHST- 2021/05/06 06:00 [medline] PHST- 2021/04/26 00:00 [pmc-release] AID - ijerph18094585 [pii] AID - ijerph-18-04585 [pii] AID - 10.3390/ijerph18094585 [doi] PST - epublish SO - Int J Environ Res Public Health. 2021 Apr 26;18(9):4585. doi: 10.3390/ijerph18094585. PMID- 33917800 OWN - NLM STAT- MEDLINE DCOM- 20210524 LR - 20240401 IS - 1660-4601 (Electronic) IS - 1661-7827 (Print) IS - 1660-4601 (Linking) VI - 18 IP - 8 DP - 2021 Apr 8 TI - Physical Activity Behaviors and Barriers in Multifetal Pregnancy: What to Expect When You're Expecting More. LID - 10.3390/ijerph18083907 [doi] LID - 3907 AB - The health benefits of prenatal physical activity (PA) are established for singleton pregnancies. In contrast, individuals with multifetal pregnancies (twins, triplets or more) are recommended to restrict or cease PA. The objectives of the current study were to determine behaviors and barriers to PA in multifetal pregnancies. Between 29 May and 24 July 2020, individuals with multifetal pregnancies participated in an online survey. Of the 415 respondents, there were 366 (88%) twin, 45 (11%) triplet and 4 (1%) quadruplet pregnancies. Twenty-seven percent (n = 104/388) of respondents completed no PA at all during pregnancy, 57% (n = 220/388) completed PA below current recommendations, and 16% (n = 64/388) achieved current recommendations (150-min per week of moderate-intensity activity). Most respondents (n = 314/363 [87%]) perceived barriers to PA during multifetal pregnancy. The most prominent were physical symptoms (n = 204/363 [56%]) and concerns about risks to fetal wellbeing (n = 128/363 [35%]). Sixty percent (n = 92/153) felt that these barriers could be overcome but expressed the need for evidence-based information regarding PA in multifetal pregnancy. Individuals with multifetal pregnancies have low engagement with current PA recommendations but remain physically active in some capacity. There are physical and psychosocial barriers to PA in multifetal pregnancy and future research should focus on how these can be removed. FAU - Meah, Victoria L AU - Meah VL AUID- ORCID: 0000-0003-3312-4010 AD - Program for Pregnancy and Postpartum Health, Physical Activity and Diabetes Laboratory, Faculty of Kinesiology, Sport, and Recreation, Women and Children's Health Research Institute, Alberta Diabetes Institute, University of Alberta, Edmonton, AB T6G 2E1, Canada. FAU - Strynadka, Morgan C AU - Strynadka MC AUID- ORCID: 0000-0002-6720-9154 AD - Program for Pregnancy and Postpartum Health, Physical Activity and Diabetes Laboratory, Faculty of Kinesiology, Sport, and Recreation, Women and Children's Health Research Institute, Alberta Diabetes Institute, University of Alberta, Edmonton, AB T6G 2E1, Canada. FAU - Khurana, Rshmi AU - Khurana R AUID- ORCID: 0000-0003-0929-9347 AD - Departments of Medicine and Obstetrics & Gynecology, Women and Children's Health Research Institute, University of Alberta, Edmonton, AB T6G 2G3, Canada. FAU - Davenport, Margie H AU - Davenport MH AUID- ORCID: 0000-0001-5627-5773 AD - Program for Pregnancy and Postpartum Health, Physical Activity and Diabetes Laboratory, Faculty of Kinesiology, Sport, and Recreation, Women and Children's Health Research Institute, Alberta Diabetes Institute, University of Alberta, Edmonton, AB T6G 2E1, Canada. LA - eng GR - CIHR/Canada PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20210408 PL - Switzerland TA - Int J Environ Res Public Health JT - International journal of environmental research and public health JID - 101238455 SB - IM MH - Exercise MH - Female MH - Humans MH - Pregnancy MH - *Pregnancy Outcome MH - *Pregnancy Reduction, Multifetal MH - Triplets MH - Twins PMC - PMC8068193 OTO - NOTNLM OT - activity restriction OT - exercise OT - healthcare provider advice OT - multiple pregnancy COIS- The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results. EDAT- 2021/05/01 06:00 MHDA- 2021/05/25 06:00 PMCR- 2021/04/08 CRDT- 2021/04/30 01:07 PHST- 2021/03/10 00:00 [received] PHST- 2021/04/01 00:00 [revised] PHST- 2021/04/04 00:00 [accepted] PHST- 2021/04/30 01:07 [entrez] PHST- 2021/05/01 06:00 [pubmed] PHST- 2021/05/25 06:00 [medline] PHST- 2021/04/08 00:00 [pmc-release] AID - ijerph18083907 [pii] AID - ijerph-18-03907 [pii] AID - 10.3390/ijerph18083907 [doi] PST - epublish SO - Int J Environ Res Public Health. 2021 Apr 8;18(8):3907. doi: 10.3390/ijerph18083907. PMID- 33917682 OWN - NLM STAT- MEDLINE DCOM- 20210505 LR - 20240401 IS - 1660-4601 (Electronic) IS - 1661-7827 (Print) IS - 1660-4601 (Linking) VI - 18 IP - 8 DP - 2021 Apr 8 TI - Impact of COVID-19 on Healthcare Labor Market in the United States: Lower Paid Workers Experienced Higher Vulnerability and Slower Recovery. LID - 10.3390/ijerph18083894 [doi] LID - 3894 AB - The resilience of the healthcare industry, often considered recession-proof, is being tested by the COVID-19 induced reductions in physical mobility and restrictions on elective and non-emergent medical procedures. We assess early COVID-19 effects on the dynamics of decline and recovery in healthcare labor markets in the United States. Descriptive analyses with monthly cross-sectional data on unemployment rates, employment, labor market entry/exit, and weekly work hours among healthcare workers in each healthcare industry and occupation, using the Current Population Survey from July 2019-2020 were performed. We found that unemployment rates increased dramatically for all healthcare industries, with the strongest early impacts on dentists' offices (41.3%), outpatient centers (10.5%), physician offices (9.5%), and home health (7.8%). Lower paid workers such as technologists/technicians (10.5%) and healthcare aides (12.6%) were hit hardest and faced persistently high unemployment, while nurses (4%), physicians/surgeons (1.4%), and pharmacists (0.7%) were spared major disruptions. Unique economic vulnerabilities faced by low-income healthcare workers may need to be addressed to avoid serious disruptions from future events similar to COVID-19. FAU - Bhandari, Neeraj AU - Bhandari N AD - Department of Healthcare Administration and Policy, School of Public Health, University of Nevada, Las Vegas, NV 89119, USA. FAU - Batra, Kavita AU - Batra K AUID- ORCID: 0000-0002-0722-0191 AD - Office of Research, School of Medicine, University of Nevada, Las Vegas, NV 89102, USA. FAU - Upadhyay, Soumya AU - Upadhyay S AUID- ORCID: 0000-0002-4651-0925 AD - Department of Healthcare Administration and Policy, School of Public Health, University of Nevada, Las Vegas, NV 89119, USA. FAU - Cochran, Christopher AU - Cochran C AUID- ORCID: 0000-0002-6138-623X AD - Department of Healthcare Administration and Policy, School of Public Health, University of Nevada, Las Vegas, NV 89119, USA. LA - eng PT - Journal Article DEP - 20210408 PL - Switzerland TA - Int J Environ Res Public Health JT - International journal of environmental research and public health JID - 101238455 SB - IM MH - *COVID-19 MH - Cross-Sectional Studies MH - Delivery of Health Care MH - Economics MH - *Health Care Sector MH - Humans MH - Occupations MH - SARS-CoV-2 MH - Socioeconomic Factors MH - Unemployment MH - United States PMC - PMC8067982 OTO - NOTNLM OT - COVID-19 OT - current population survey OT - healthcare employment OT - labor market COIS- The authors declare no conflict of interest. EDAT- 2021/05/01 06:00 MHDA- 2021/05/06 06:00 PMCR- 2021/04/08 CRDT- 2021/04/30 01:07 PHST- 2021/02/27 00:00 [received] PHST- 2021/03/30 00:00 [revised] PHST- 2021/04/01 00:00 [accepted] PHST- 2021/04/30 01:07 [entrez] PHST- 2021/05/01 06:00 [pubmed] PHST- 2021/05/06 06:00 [medline] PHST- 2021/04/08 00:00 [pmc-release] AID - ijerph18083894 [pii] AID - ijerph-18-03894 [pii] AID - 10.3390/ijerph18083894 [doi] PST - epublish SO - Int J Environ Res Public Health. 2021 Apr 8;18(8):3894. doi: 10.3390/ijerph18083894. PMID- 33916365 OWN - NLM STAT- MEDLINE DCOM- 20210505 LR - 20220716 IS - 1660-4601 (Electronic) IS - 1661-7827 (Print) IS - 1660-4601 (Linking) VI - 18 IP - 7 DP - 2021 Apr 5 TI - Pregnancy Outcome during the First COVID 19 Lockdown in Vienna, Austria. LID - 10.3390/ijerph18073782 [doi] LID - 3782 AB - The COVID 19 pandemic represents a major stress factor for non-infected pregnant women. Although maternal stress during pregnancy increases the risk of preterm birth and intrauterine growth restriction, an increasing number of studies yielded no negative effects of COVID 19 lockdowns on pregnancy outcome. The present study focused on pregnancy outcome during the first COVID 19 lockdown phase in Austria. In particular, it was hypothesized that the national lockdown had no negative effects on birth weight, low birth weight rate and preterm birth rate. In a retrospective medical record-based single center study, the outcome of 669 singleton live births in Vienna Austria during the lockdown phase between March and July 2020 was compared with the pregnancy outcome of 277 live births at the same hospital during the pre-lockdown months of January and February 2020 and, in addition, with the outcome of 28,807 live births between 2005 and 2019. The rate of very low gestational age was significantly lower during the lockdown phase than during the pre-lockdown phase. The rate of low gestational age, however, was slightly higher during the lockdown phase. Mean birth weight was significantly higher during the lockdown phase; the rates of low birth weight, very low birth weight and extremely low birth weight were significantly lower during the lockdown phase. In contrast, maternal gestational weight gain was significantly higher during the lockdown phase. The stressful lockdown phase in Austria seems to have no negative affect on gestational length and newborn weight among non-infected mothers. FAU - Kirchengast, Sylvia AU - Kirchengast S AD - Department of Evolutionary Anthropology, University of Vienna, A-1090 Vienna, Austria. FAU - Hartmann, Beda AU - Hartmann B AD - Danube Hospital, A-1220 Vienna, Austria. LA - eng PT - Journal Article DEP - 20210405 PL - Switzerland TA - Int J Environ Res Public Health JT - International journal of environmental research and public health JID - 101238455 SB - IM MH - Austria MH - *COVID-19 MH - Communicable Disease Control MH - Female MH - Humans MH - Infant, Newborn MH - Pregnancy MH - Pregnancy Outcome/epidemiology MH - *Premature Birth/epidemiology MH - Retrospective Studies MH - SARS-CoV-2 PMC - PMC8038559 OTO - NOTNLM OT - COVID 19 pandemic in Austria OT - birth weight OT - maternal gestational weight gain OT - preterm birth COIS- The authors declare no conflict of interest. EDAT- 2021/05/01 06:00 MHDA- 2021/05/06 06:00 PMCR- 2021/04/05 CRDT- 2021/04/30 01:03 PHST- 2021/02/15 00:00 [received] PHST- 2021/03/23 00:00 [revised] PHST- 2021/03/31 00:00 [accepted] PHST- 2021/04/30 01:03 [entrez] PHST- 2021/05/01 06:00 [pubmed] PHST- 2021/05/06 06:00 [medline] PHST- 2021/04/05 00:00 [pmc-release] AID - ijerph18073782 [pii] AID - ijerph-18-03782 [pii] AID - 10.3390/ijerph18073782 [doi] PST - epublish SO - Int J Environ Res Public Health. 2021 Apr 5;18(7):3782. doi: 10.3390/ijerph18073782. PMID- 33914025 OWN - NLM STAT- MEDLINE DCOM- 20210702 LR - 20240824 IS - 2374-2445 (Electronic) IS - 2374-2437 (Print) IS - 2374-2437 (Linking) VI - 7 IP - 6 DP - 2021 Jun 1 TI - Modeling Strategies to Optimize Cancer Screening in USPSTF Guideline-Noncompliant Women. PG - 885-894 LID - 10.1001/jamaoncol.2021.0952 [doi] AB - IMPORTANCE: In 2018, only half of US women obtained all evidence-based cancer screenings. This proportion may have declined during the COVID-19 pandemic because of social distancing, high-risk factors, and fear. OBJECTIVE: To evaluate optimal screening strategies in women who obtain some, but not all, US Preventive Services Task Force (USPSTF)-recommended cancer screenings. DESIGN, SETTING, AND PARTICIPANTS: This modeling study was conducted from January 31, 2017, to July 20, 2020, and used 4 validated mathematical models from the National Cancer Institute's Cancer Intervention and Surveillance Modeling Network using data from 20 million simulated women born in 1965 in the US. INTERVENTIONS: Forty-five screening strategies were modeled that combined breast, cervical, colorectal, and/or lung cancer (LC) screenings; restricted to 1, 2, 3 or 4 screenings per year; or all eligible screenings once every 5 years. MAIN OUTCOMES AND MEASURES: Modeled life-years gained from restricted cancer screenings as a fraction of those attainable from full compliance with USPSTF recommendations (maximum benefits). Results were stratified by LC screening eligibility (LC-eligible/ineligible). We repeated the analysis with 2018 adherence rates, evaluating the increase in adherence required for restricted screenings to have the same population benefit as USPSTF recommendations. RESULTS: This modeling study of 20 million simulated US women found that it was possible to reduce screening intensity to 1 carefully chosen test per year in women who were ineligible for LC screening and 2 tests per year in eligible women while maintaining 94% or more of the maximum benefits. Highly ranked strategies screened for various cancers, but less often than recommended by the USPSTF. For example, among LC-ineligible women who obtained just 1 screening per year, the optimal strategy frequently delayed breast and cervical cancer screenings by 1 year and skipped 3 mammograms entirely. Among LC-eligible women, LC screening was essential; strategies omitting it provided 25% or less of the maximum benefits. The top-ranked strategy restricted to 2 screenings per year was annual LC screening and alternating fecal immunochemical test with mammography (skipping mammograms when due for cervical cancer screening, 97% of maximum benefits). If adherence in a population of LC-eligible women obtaining 2 screenings per year were to increase by 1% to 2% (depending on the screening test), this model suggests that it would achieve the same benefit as USPSTF recommendations at 2018 adherence rates. CONCLUSIONS AND RELEVANCE: This modeling study of 45 cancer screening strategies suggests that women who are noncompliant with cancer screening guidelines may be able to reduce USPSTF-recommended screening intensity with minimal reduction in overall benefits. FAU - Taksler, Glen B AU - Taksler GB AD - Cleveland Clinic Community Care, Cleveland Clinic, Cleveland, Ohio. AD - Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio. AD - Population Health Research Institute, Case Western Reserve University at The MetroHealth System, Cleveland, Ohio. FAU - Peterse, Elisabeth F P AU - Peterse EFP AD - Department of Public Health, Erasmus University Medical Center, Rotterdam, the Netherlands. FAU - Willems, Isarah AU - Willems I AD - Department of Public Health, Erasmus University Medical Center, Rotterdam, the Netherlands. FAU - Ten Haaf, Kevin AU - Ten Haaf K AD - Department of Public Health, Erasmus University Medical Center, Rotterdam, the Netherlands. FAU - Jansen, Erik E L AU - Jansen EEL AD - Department of Public Health, Erasmus University Medical Center, Rotterdam, the Netherlands. FAU - de Kok, Inge M C M AU - de Kok IMCM AD - Department of Public Health, Erasmus University Medical Center, Rotterdam, the Netherlands. FAU - van Ravesteyn, Nicolien T AU - van Ravesteyn NT AD - Department of Public Health, Erasmus University Medical Center, Rotterdam, the Netherlands. FAU - de Koning, Harry J AU - de Koning HJ AD - Department of Public Health, Erasmus University Medical Center, Rotterdam, the Netherlands. FAU - Lansdorp-Vogelaar, Iris AU - Lansdorp-Vogelaar I AD - Department of Public Health, Erasmus University Medical Center, Rotterdam, the Netherlands. LA - eng GR - U01 CA199284/CA/NCI NIH HHS/United States GR - U01 CA199218/CA/NCI NIH HHS/United States GR - U01 CA199334/CA/NCI NIH HHS/United States GR - R01 AG059979/AG/NIA NIH HHS/United States GR - U01 CA199335/CA/NCI NIH HHS/United States GR - KL2 TR000440/TR/NCATS NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PL - United States TA - JAMA Oncol JT - JAMA oncology JID - 101652861 SB - IM MH - Breast Neoplasms/diagnosis/diagnostic imaging/epidemiology/virology MH - COVID-19/*complications/diagnostic imaging/epidemiology/virology MH - Colorectal Neoplasms/diagnosis/epidemiology/virology MH - *Early Detection of Cancer MH - Female MH - Guidelines as Topic MH - Humans MH - Lung Neoplasms/diagnosis/epidemiology/virology MH - Mammography MH - *Models, Theoretical MH - Patient Compliance MH - SARS-CoV-2/pathogenicity MH - Uterine Cervical Neoplasms/diagnosis/epidemiology/virology PMC - PMC8085765 COIS- Conflict of Interest Disclosures: Dr Taksler reported grants from the National Institute on Aging and National Center for Advancing Translational Sciences during the conduct of the study and personal fees from the University of Michigan outside the submitted work. Ms Willems reported grants from the National Cancer Institute during the conduct of the study. Dr ten Haaf reported grants from the National Institutes of Health/National Cancer Institute during the conduct of the study and grants from the European Union, University of Zurich, Cancer Research UK; nonfinancial support from the International Association for the Study of Lung Cancer, Russian Society of Clinical Oncology, and NELSON-Netherland-Leuven Lung Cancer Screening; travel expenses from the IASLC, RUSSCO, and Biomedical Research in Endstage and Obstructive Lung Disease; speaking fees Tagung Thorakale Tumore and Erasmus University Medical Center; and receipt from Siemens Germany of 4 digital workstations and LungCARE for the performance of 3-dimensional measurements outside the submitted work. Mr Jansen and Dr de Kok reported grants from the National Cancer Institute during the conduct of the study. Dr van Ravesteyn reported grants from the National Institutes of Health/National Cancer Institute during the conduct of the study. Dr de Koning reported grants from the National Institutes of Health, National Institute for Public Health and the Environment, and Horizon2020\European Union during the conduct of the study as well as personal fees from MSD, Teva, Menarini, and IPSOS outside the submitted work. Dr Lansdorp-Vogelaar reported grants the from National Cancer Institute during the conduct of the study. No other disclosures were reported. EDAT- 2021/04/30 06:00 MHDA- 2021/07/03 06:00 PMCR- 2022/04/29 CRDT- 2021/04/29 12:26 PHST- 2021/04/30 06:00 [pubmed] PHST- 2021/07/03 06:00 [medline] PHST- 2021/04/29 12:26 [entrez] PHST- 2022/04/29 00:00 [pmc-release] AID - 2778915 [pii] AID - coi210011 [pii] AID - 10.1001/jamaoncol.2021.0952 [doi] PST - ppublish SO - JAMA Oncol. 2021 Jun 1;7(6):885-894. doi: 10.1001/jamaoncol.2021.0952. PMID- 33909803 OWN - NLM STAT- MEDLINE DCOM- 20210430 LR - 20210430 IS - 1678-4219 (Electronic) IS - 0004-2803 (Linking) VI - 58 IP - 1 DP - 2021 Jan-Mar TI - LONG TERM MANAGEMENT OF GLYCOGEN STORAGE DISEASE TYPE 1B: A BRAZILIAN TERTIARY CENTER EXPERIENCE. PG - 87-92 LID - S0004-28032021000100087 [pii] LID - 10.1590/S0004-2803.202100000-15 [doi] AB - BACKGROUND: Glycogen storage disease (GSD) type 1b is a multisystemic disease in which immune and infectious complications are present, in addition to the well-known metabolic manifestations of GSD. Treatment with granulocyte-colony stimulating factor (G-CSF) is often indicated in the management of neutropenia and inflammatory bowel disease. OBJECTIVE: To report on the demographics, genotype, clinical presentation, management, and complications of pediatric patients with glycogen storage disease type 1b (GSD 1b), with special attention to immune-related complications. METHODS: Retrospective case series of seven patients with GSD 1b diagnosed and followed at a tertiary university hospital in Brazil, from July/2000 until July/2016. RESULTS: Mean age at referral was fourteen months. Diagnosis of GSD 1b was based on clinical and laboratory findings and supported by genetic studies in five cases. All patients presented suffered from neutropenia, managed with G-CSF - specifically Filgrastim. Hospitalizations for infections were frequent. Two patients developed inflammatory bowel disease. Six patients remained alive, one died at age 14 years and 9 months. The mean age at the end of the follow-up was 11.5 years. Compliance to treatment was suboptimal: poor compliance to medications, starch and dietetic management of GSD were documented, and outpatient appointments were frequently missed. CONCLUSION: Managing GSD 1b is challenging not only for the chronic and multisystemic nature of this disease, but also for the additional demands related dietary restrictions, use of multiple medications and the need for frequent follow-up visits; furthermore in Brazil, the difficulties are increased in a scenario where we frequently care for patients with unfavorable socioeconomic status and with irregular supply of medications in the public health system. FAU - Takao, Marina Mayumi Vendrame AU - Takao MMV AUID- ORCID: 0000-0002-9430-7817 AD - Universidade Estadual de Campinas (Unicamp), Faculdade de Ciencias Medicas, Departamento de Pediatria, Campinas, SP, Brasil. FAU - Sandy, Natascha Silva AU - Sandy NS AUID- ORCID: 0000-0002-7744-8984 AD - Division of Gastroenterology, Hepatology and Nutrition - Department of Pediatrics - Hospital for Sick Children, University of Toronto. Toronto, ON, Canada. FAU - Riccetto, Adriana Gut Lopes AU - Riccetto AGL AUID- ORCID: 0000-0002-1330-3591 AD - Universidade Estadual de Campinas (Unicamp), Faculdade de Ciencias Medicas, Departamento de Pediatria, Campinas, SP, Brasil. FAU - Tommaso, Adriana Maria Alves DE AU - Tommaso AMA AUID- ORCID: 0000-0001-7077-9804 AD - Universidade Estadual de Campinas (Unicamp), Faculdade de Ciencias Medicas, Departamento de Pediatria, Campinas, SP, Brasil. LA - eng PT - Journal Article PL - Brazil TA - Arq Gastroenterol JT - Arquivos de gastroenterologia JID - 15310600R RN - 143011-72-7 (Granulocyte Colony-Stimulating Factor) SB - IM MH - Adolescent MH - Brazil MH - Child MH - *Glycogen Storage Disease Type I/complications/therapy MH - Granulocyte Colony-Stimulating Factor MH - Humans MH - *Neutropenia MH - Retrospective Studies EDAT- 2021/04/29 06:00 MHDA- 2021/05/01 06:00 CRDT- 2021/04/28 17:37 PHST- 2020/09/05 00:00 [received] PHST- 2020/11/03 00:00 [accepted] PHST- 2021/04/28 17:37 [entrez] PHST- 2021/04/29 06:00 [pubmed] PHST- 2021/05/01 06:00 [medline] AID - S0004-28032021000100087 [pii] AID - 10.1590/S0004-2803.202100000-15 [doi] PST - ppublish SO - Arq Gastroenterol. 2021 Jan-Mar;58(1):87-92. doi: 10.1590/S0004-2803.202100000-15. PMID- 33898371 OWN - NLM STAT- MEDLINE DCOM- 20210430 LR - 20240401 IS - 2296-2565 (Electronic) IS - 2296-2565 (Linking) VI - 9 DP - 2021 TI - Assessment of COVID-19 Pandemic in Nepal: A Lockdown Scenario Analysis. PG - 599280 LID - 10.3389/fpubh.2021.599280 [doi] LID - 599280 AB - The Government of Nepal issued a nationwide lockdown from 24 March to 21 July 2020, prohibiting domestic and international travels, closure of the border and non-essential services. There were only two confirmed cases from 610 Reverse Transcription Polymerase Chain Reaction (RT-PCR) tests and no fatalities when the government introduced nationwide lockdown. This study aimed to explore the overall scenario of COVID-19 including spatial distribution of cases; government efforts, and impact on public health, socio-economy, and education during the lockdown in Nepal. We collated and analyzed data using official figures from the Nepalese Ministry of Health and Population. Nepal had performed 7,791 RT-PCR tests for COVID-19, the highest number of tests during the lockdown. It has recorded its highest daily rise in coronavirus infections with a total of 740 new cases from the total of 4,483 RT-PCR tests performed on a single day. Nepal had reported a total of 17,994 positive cases and 40 deaths at the end of lockdown. The spatial distribution clearly shows that the cases were rapidly spreading from the southern part of the country where most points of entry and exit from India are located. To contain the spread of the virus, the government has also initiated various preventive measures and strategies during the lockdown. The Government of Nepal needs to allocate more resources, increase its capacity to test and trace, establish dedicated isolation and quarantine facility and impose local restrictions such as a local lockdown based on risk assessment rather than a nationwide lockdown. CI - Copyright (c) 2021 Sharma, Banstola and Parajuli. FAU - Sharma, Kusum AU - Sharma K AD - Research and Innovation Department, Science Hub, Kathmandu, Nepal. FAU - Banstola, Amrit AU - Banstola A AD - Department of Research and Training, Public Health Perspective Nepal, Pokhara, Nepal. AD - Faculty of Health and Applied Sciences, University of the West of England, Bristol, United Kingdom. FAU - Parajuli, Rishi Ram AU - Parajuli RR AD - Department of Civil Engineering, University of Bristol, Bristol, United Kingdom. LA - eng PT - Journal Article DEP - 20210408 PL - Switzerland TA - Front Public Health JT - Frontiers in public health JID - 101616579 SB - IM MH - COVID-19/diagnosis/*epidemiology MH - COVID-19 Nucleic Acid Testing MH - *Communicable Disease Control MH - Humans MH - India MH - Nepal/epidemiology MH - *Pandemics MH - Quarantine MH - Reverse Transcriptase Polymerase Chain Reaction MH - Travel PMC - PMC8060478 OTO - NOTNLM OT - COVID-19 OT - Nepal OT - challenges OT - coronavirus OT - impacts OT - lockdown OT - public health OT - spatial distribution analysis COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2021/04/27 06:00 MHDA- 2021/05/01 06:00 PMCR- 2021/04/08 CRDT- 2021/04/26 05:57 PHST- 2020/08/26 00:00 [received] PHST- 2021/03/09 00:00 [accepted] PHST- 2021/04/26 05:57 [entrez] PHST- 2021/04/27 06:00 [pubmed] PHST- 2021/05/01 06:00 [medline] PHST- 2021/04/08 00:00 [pmc-release] AID - 10.3389/fpubh.2021.599280 [doi] PST - epublish SO - Front Public Health. 2021 Apr 8;9:599280. doi: 10.3389/fpubh.2021.599280. eCollection 2021. PMID- 33879117 OWN - NLM STAT- MEDLINE DCOM- 20210504 LR - 20210504 IS - 1471-2458 (Electronic) IS - 1471-2458 (Linking) VI - 21 IP - 1 DP - 2021 Apr 20 TI - The potential dangers of not understanding COVID-19 public health restrictions in dementia: "It's a groundhog day - every single day she does not understand why she can't go out for a walk". PG - 762 LID - 10.1186/s12889-021-10815-8 [doi] LID - 762 AB - BACKGROUND: Sudden public health restrictions can be difficult to comprehend for people with cognitive deficits. However, these are even more important for them to adhere to due to their increased levels of vulnerability, particularly to COVID-19. With a lack of previous evidence, we explored the understanding and changes in adherence to COVID-19 public health restrictions over time in people living with dementia (PLWD). METHODS: Unpaid carers and PLWD were interviewed over the phone in April 2020, shortly after the nationwide UK lockdown, with a proportion followed up from 24th June to 10th July. Participants were recruited via social care and third sector organisations across the UK, and via social media. FINDINGS: A total of 70 interviews (50 baseline, 20 follow-up) were completed with unpaid carers and PLWD. Five themes emerged: Confusion and limited comprehension; Frustration and burden; Putting oneself in danger; Adherence to restrictions in wider society; (Un) changed perceptions. Most carers reported limited to no understanding of the public health measures in PLWD, causing distress and frustration for both the carer and the PLWD. Due to the lack of understanding, some PLWD put themselves in dangerous situations without adhering to the restrictions. PLWD with cognitive capacity who participated understood the measures and adhered to these. DISCUSSION: In light of the new second wave of the pandemic, public health measures need to be simpler for PLWD to avoid unwilful non-adherence. Society also needs to be more adaptive to the needs of people with cognitive disabilities more widely, as blanket rules cause distress to the lives of those affected by dementia. FAU - Giebel, Clarissa AU - Giebel C AUID- ORCID: 0000-0002-0746-0566 AD - Department of Primary Care & Mental Health, University of Liverpool, Brownlow Street, Liverpool, L69 3GL, UK. Clarissa.giebel@liverpool.ac.uk. AD - NIHR ARC NWC, Liverpool, UK. Clarissa.giebel@liverpool.ac.uk. FAU - Hanna, Kerry AU - Hanna K AD - Department of Primary Care & Mental Health, University of Liverpool, Brownlow Street, Liverpool, L69 3GL, UK. FAU - Rajagopal, Manoj AU - Rajagopal M AD - Lancashire and South Cumbria NHS Trust, Preston, UK. FAU - Komuravelli, Aravind AU - Komuravelli A AD - North West Boroughs NHS Trust, Warrington, UK. FAU - Cannon, Jacqueline AU - Cannon J AD - Lewy Body Society, Wigan, UK. FAU - Shenton, Justine AU - Shenton J AD - Sefton Older People's Forum, Liverpool, UK. FAU - Eley, Ruth AU - Eley R AD - Liverpool Dementia Action Alliance, Liverpool, UK. FAU - Gaughan, Anna AU - Gaughan A AD - Together In Dementia Everyday (TIDE), Liverpool, UK. FAU - Callaghan, Steve AU - Callaghan S AD - EQE Health, Liverpool, UK. FAU - Tetlow, Hilary AU - Tetlow H AD - SURF Liverpool, Liverpool, UK. FAU - Limbert, Stan AU - Limbert S AD - NIHR ARC NWC, Liverpool, UK. FAU - Whittington, Rosie AU - Whittington R AD - Me2U Day Care Centre, Liverpool, UK. FAU - Rogers, Carol AU - Rogers C AD - National Museums Liverpool, Liverpool, UK. FAU - Ward, Kym AU - Ward K AD - The Brain Charity, Liverpool, UK. FAU - Shaw, Lisa AU - Shaw L AD - Department of Modern Languages and Cultures, University of Liverpool, Liverpool, UK. FAU - Butchard, Sarah AU - Butchard S AD - Department of Primary Care & Mental Health, University of Liverpool, Brownlow Street, Liverpool, L69 3GL, UK. AD - NIHR ARC NWC, Liverpool, UK. FAU - Gabbay, Mark AU - Gabbay M AD - Department of Primary Care & Mental Health, University of Liverpool, Brownlow Street, Liverpool, L69 3GL, UK. AD - NIHR ARC NWC, Liverpool, UK. LA - eng GR - ARC NWC/National Institute for Health Research/ PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20210420 PL - England TA - BMC Public Health JT - BMC public health JID - 100968562 SB - IM MH - COVID-19/*prevention & control MH - Caregivers MH - *Communicable Disease Control MH - *Comprehension MH - *Dementia MH - Female MH - Humans MH - Interviews as Topic MH - Public Health MH - United Kingdom PMC - PMC8057664 COIS- N/a EDAT- 2021/04/22 06:00 MHDA- 2021/05/05 06:00 PMCR- 2021/04/20 CRDT- 2021/04/21 05:39 PHST- 2020/10/28 00:00 [received] PHST- 2021/04/12 00:00 [accepted] PHST- 2021/04/21 05:39 [entrez] PHST- 2021/04/22 06:00 [pubmed] PHST- 2021/05/05 06:00 [medline] PHST- 2021/04/20 00:00 [pmc-release] AID - 10.1186/s12889-021-10815-8 [pii] AID - 10815 [pii] AID - 10.1186/s12889-021-10815-8 [doi] PST - epublish SO - BMC Public Health. 2021 Apr 20;21(1):762. doi: 10.1186/s12889-021-10815-8. PMID- 33871297 OWN - NLM STAT- MEDLINE DCOM- 20220519 LR - 20240923 IS - 1559-8519 (Electronic) IS - 0022-4499 (Print) IS - 0022-4499 (Linking) VI - 59 IP - 5 DP - 2022 May-Jun TI - "They Want You to Kill Your Inner Queer but Somehow Leave the Human Alive": Delineating the Impacts of Sexual Orientation and Gender Identity and Expression Change Efforts. PG - 599-609 LID - 10.1080/00224499.2021.1910616 [doi] AB - Sexual orientation and gender identity and expression change efforts (SOGIECE) aim to suppress the sexual and gender identities of Two-Spirit, lesbian, gay, bisexual, trans, and other queer (2SLGBTQ+) people. Exposure to SOGIECE is associated with significant psychosocial morbidity. Yet, there is a dearth of knowledge specifying the ways in which these psychosocial impacts are produced and experienced. This qualitative interpretive description study aimed to delineate the impacts of SOGIECE. To do so, we thematically analyzed data from in-depth interviews, conducted between January and July 2020, with 22 people with lived experience of SOGIECE. Study participants indicated that feelings of shame and brokenness related to their sexual and gender identities were deeply implicated in and shaped by experiences with SOGIECE. SOGIECE also had socially isolating effects, which had restricted participants' opportunities for meaningful connection with others, including romantic partners and 2SLGBTQ+ communities. Further, SOGIECE had contributed to experiences of profound emotional distress, mental illness (e.g., anxiety, depression), and suicidality. These findings underscore the need for several responsive policy and programmatic interventions, including legislation to prevent SOGIECE, enhanced sexuality- and gender-related educational efforts with the families and support persons of 2SLGBTQ+ people, and targeted mental health screening and supports for SOGIECE survivors. FAU - Goodyear, Trevor AU - Goodyear T AUID- ORCID: 0000-0002-7068-575X AD - School of Nursing, University of British Columbia. AD - British Columbia Centre on Substance Use. FAU - Kinitz, David J AU - Kinitz DJ AD - Dalla Lana School of Public Health, University of Toronto. FAU - Dromer, Elisabeth AU - Dromer E AD - Ecole de Sante Publique de l'Universite de Montreal. AD - Centre de Recherche en Sante Publique, Universite de Montreal et CIUSS du Centre-Sud-de-l'Ile-de-Montreal. FAU - Gesink, Dionne AU - Gesink D AD - Dalla Lana School of Public Health, University of Toronto. FAU - Ferlatte, Olivier AU - Ferlatte O AUID- ORCID: 0000-0003-2721-4757 AD - Ecole de Sante Publique de l'Universite de Montreal. AD - Centre de Recherche en Sante Publique, Universite de Montreal et CIUSS du Centre-Sud-de-l'Ile-de-Montreal. FAU - Knight, Rod AU - Knight R AUID- ORCID: 0000-0002-1464-1584 AD - British Columbia Centre on Substance Use. AD - Department of Medicine, University of British Columbia. FAU - Salway, Travis AU - Salway T AUID- ORCID: 0000-0002-5699-5444 AD - British Columbia Centre for Disease Control. AD - Centre for Gender and Sexual Health Equity. AD - Faculty of Health Sciences, Simon Fraser University. LA - eng GR - F32 DA033756/DA/NIDA NIH HHS/United States GR - R25 DA037756/DA/NIDA NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20210419 PL - United States TA - J Sex Res JT - Journal of sex research JID - 0062647 SB - IM MH - Bisexuality MH - Female MH - *Gender Identity MH - Humans MH - Male MH - Sexual Behavior MH - *Sexual and Gender Minorities MH - Sexuality PMC - PMC8557955 MID - NIHMS1691829 COIS- Disclosure statement We declare no conflicts of interest. EDAT- 2021/04/20 06:00 MHDA- 2022/05/20 06:00 PMCR- 2023/05/01 CRDT- 2021/04/19 12:12 PHST- 2021/04/20 06:00 [pubmed] PHST- 2022/05/20 06:00 [medline] PHST- 2021/04/19 12:12 [entrez] PHST- 2023/05/01 00:00 [pmc-release] AID - 10.1080/00224499.2021.1910616 [doi] PST - ppublish SO - J Sex Res. 2022 May-Jun;59(5):599-609. doi: 10.1080/00224499.2021.1910616. Epub 2021 Apr 19. PMID- 33869566 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20231111 IS - 2297-7775 (Electronic) IS - 2297-7775 (Linking) VI - 6 DP - 2021 TI - On the Outside Looking In: A Global Doula Response to COVID-19. PG - 613978 LID - 10.3389/fsoc.2021.613978 [doi] LID - 613978 AB - From around the world, doulas report the impact of new COVID-19 restrictions on their ability to provide continuous emotional, physical, and informational support to pregnant people and their families. In a qualitative survey conducted in March and April 2020, we heard from over 500 doulas in 24 countries. Doulas practicing across the world revealed rapid changes to hospital policies. Even accounting for different public health responses across countries, the doulas in our study pointed to one common theme - their absence at births and the subsequent need to support birthing people virtually. In a follow-up survey and in interviews we conducted in July, we reconnected with doulas from our initial study to track their access to institutional birthing spaces. As countries experienced the effects of "flattening the curve," we found that doulas were still not considered "essential" workers and the majority could not attend births. Our research shows that doulas have ambiguous feelings about the efficacy of virtual support, that they raise concerns about the long-term impact of COVID on their profession and that they are concerned about mistreatment and obstetric violence as birthing people enter hospitals alone. CI - Copyright (c) 2021 Searcy and Castaneda. FAU - Searcy, Julie Johnson AU - Searcy JJ AD - Department of History and Anthropology, Butler University, Indianapolis, IN, United States. FAU - Castaneda, Angela N AU - Castaneda AN AD - Department of Sociology and Anthropology, DePauw University, Greencastle, IN, United States. LA - eng PT - Journal Article DEP - 20210219 PL - Switzerland TA - Front Sociol JT - Frontiers in sociology JID - 101777459 PMC - PMC8022595 OTO - NOTNLM OT - COVID-19 OT - birth OT - doulas OT - pandemic OT - reproduction COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2021/04/20 06:00 MHDA- 2021/04/20 06:01 PMCR- 2021/02/19 CRDT- 2021/04/19 06:34 PHST- 2020/10/04 00:00 [received] PHST- 2021/01/19 00:00 [accepted] PHST- 2021/04/19 06:34 [entrez] PHST- 2021/04/20 06:00 [pubmed] PHST- 2021/04/20 06:01 [medline] PHST- 2021/02/19 00:00 [pmc-release] AID - 613978 [pii] AID - 10.3389/fsoc.2021.613978 [doi] PST - epublish SO - Front Sociol. 2021 Feb 19;6:613978. doi: 10.3389/fsoc.2021.613978. eCollection 2021. PMID- 33866675 OWN - NLM STAT- MEDLINE DCOM- 20211018 LR - 20230124 IS - 1600-6143 (Electronic) IS - 1600-6135 (Linking) VI - 21 IP - 10 DP - 2021 Oct TI - Perspectives of solid organ transplant recipients on medicine-taking: Systematic review of qualitative studies. PG - 3369-3387 LID - 10.1111/ajt.16613 [doi] AB - Medicine-taking among transplant recipients is a complex and ubiquitous task with significant impacts on outcomes. This study aimed to describe the perspectives and experiences of medicine-taking in adult solid organ transplant recipients. Electronic databases were searched to July 2020, and thematic synthesis was used to analyze the data. From 119 studies (n = 2901), we identified six themes: threats to identity and ambitions (impaired self-image, restricting goals and roles, loss of financial independence); navigating through uncertainty and distrust (lacking tangible/perceptible benefits, unprepared for side effects, isolation in decision-making); alleviating treatment burdens (establishing and mastering routines, counteracting side effects, preparing for the unexpected); gaining and seeking confidence (clarity with knowledge, reassurance through collective experiences, focusing on the future outlook); recalibrating to a new normal posttransplant (adjusting to ongoing dependence on medications, in both states of illness and health, unfulfilled expectations); and preserving graft survival (maintaining the ability to participate in life, avoiding rejection, enacting a social responsibility of giving back). Transplant recipients take medications to preserve graft function, but dependence on medications jeopardizes their sense of normality. Interventions supporting the adaptation to medicine-taking and addressing treatment burdens may improve patient satisfaction and capacities to take medications for improved outcomes. CI - (c) 2021 The American Society of Transplantation and the American Society of Transplant Surgeons. FAU - Tang, James AU - Tang J AUID- ORCID: 0000-0002-7004-9315 AD - Sydney School of Public Health, The University of Sydney, Sydney, NSW, Australia. AD - Centre for Kidney Research, The Children's Hospital at Westmead, Westmead, NSW, Australia. FAU - Kerklaan, Jasmijn AU - Kerklaan J AUID- ORCID: 0000-0001-9145-9914 AD - Centre for Kidney Research, The Children's Hospital at Westmead, Westmead, NSW, Australia. AD - Department of Pediatric Nephrology, Academic Medical Center, Emma Children's Hospital, Amsterdam, the Netherlands. FAU - Wong, Germaine AU - Wong G AUID- ORCID: 0000-0001-8422-7269 AD - Sydney School of Public Health, The University of Sydney, Sydney, NSW, Australia. AD - Centre for Kidney Research, The Children's Hospital at Westmead, Westmead, NSW, Australia. AD - Centre for Transplant and Renal Research, Westmead Hospital, Westmead, NSW, Australia. FAU - Howell, Martin AU - Howell M AUID- ORCID: 0000-0001-9740-712X AD - Sydney School of Public Health, The University of Sydney, Sydney, NSW, Australia. AD - Centre for Kidney Research, The Children's Hospital at Westmead, Westmead, NSW, Australia. FAU - Scholes-Robertson, Nicole AU - Scholes-Robertson N AUID- ORCID: 0000-0001-8260-0453 AD - Sydney School of Public Health, The University of Sydney, Sydney, NSW, Australia. AD - Centre for Kidney Research, The Children's Hospital at Westmead, Westmead, NSW, Australia. FAU - Guha, Chandana AU - Guha C AUID- ORCID: 0000-0002-0767-4185 AD - Sydney School of Public Health, The University of Sydney, Sydney, NSW, Australia. AD - Centre for Kidney Research, The Children's Hospital at Westmead, Westmead, NSW, Australia. FAU - Kelly, Ayano AU - Kelly A AUID- ORCID: 0000-0003-3325-3840 AD - Centre for Kidney Research, The Children's Hospital at Westmead, Westmead, NSW, Australia. FAU - Tong, Allison AU - Tong A AUID- ORCID: 0000-0001-8973-9538 AD - Sydney School of Public Health, The University of Sydney, Sydney, NSW, Australia. AD - Centre for Kidney Research, The Children's Hospital at Westmead, Westmead, NSW, Australia. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Systematic Review DEP - 20210615 PL - United States TA - Am J Transplant JT - American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons JID - 100968638 SB - IM CIN - Am J Transplant. 2021 Oct;21(10):3221-3222. doi: 10.1111/ajt.16620. PMID: 33891800 MH - Adult MH - Graft Survival MH - Humans MH - Interpersonal Relations MH - *Organ Transplantation MH - Qualitative Research MH - *Transplant Recipients OTO - NOTNLM OT - clinical research/practice OT - immunosuppressant OT - organ transplantation in general OT - qualitative research EDAT- 2021/04/19 06:00 MHDA- 2021/10/21 06:00 CRDT- 2021/04/18 21:11 PHST- 2021/03/16 00:00 [revised] PHST- 2021/01/18 00:00 [received] PHST- 2021/04/02 00:00 [accepted] PHST- 2021/04/19 06:00 [pubmed] PHST- 2021/10/21 06:00 [medline] PHST- 2021/04/18 21:11 [entrez] AID - S1600-6135(22)08756-1 [pii] AID - 10.1111/ajt.16613 [doi] PST - ppublish SO - Am J Transplant. 2021 Oct;21(10):3369-3387. doi: 10.1111/ajt.16613. Epub 2021 Jun 15. PMID- 33862647 OWN - NLM STAT- MEDLINE DCOM- 20210514 LR - 20220423 IS - 1439-4421 (Electronic) IS - 0941-3790 (Linking) VI - 83 IP - 5 DP - 2021 May TI - Retracing the COVID-19 Pandemic in Germany from a Public Perspective using Google Search Queries Related to "coronavirus". PG - e9-e14 LID - 10.1055/a-1398-5417 [doi] AB - AIM OF THE STUDY: During pandemics, the whole population is simultaneously confronted with the same health threat, resulting in enormous public interest. The current COVID-19 pandemic has left the world in a unique state of crisis. The aim of this analysis was to explore whether Google searches can be used to retrospectively retrace the COVID-19 pandemic in Germany and to detect local outbreaks by reflecting public interest in the virus. METHODS: Google Trends was used to explore the relative search volume (RSV) related to "coronavirus" from January 2020 to July 2020 in Germany. The RSV ranging between 0-100 was compared to new SARS-CoV-2 infections per day on a national level and to the cumulative infection numbers on a state level, as well as to important infectiological and political events. RESULTS: The most striking search peaks occurred after the first reported SARS-CoV-2 infection in Germany (January 27), during a major local outbreak in Heinsberg (February 25), after school closings (March 13) and the largest peak after nationwide contact restrictions (March 22) were announced. On a state level, peaks in RSV were observed after the first reported infection in each respective state. In addition, a higher RSV was recorded in states with higher numbers of infections (r=0,6, p=0,014) such as in Bavaria (RSV=96, 391 infections/100,000 inhabitants) and Baden-Wurttemberg (RSV=98, 340 infections/100,000 inhabitants). The lowest RSV (n=83) and lowest number of infections (50 infections/100,000 inhabitants) was observed in Mecklenburg-Western Pomerania. Since the end of May, SARS-CoV-2 related RSV remained at low level even when numbers of infections were temporarily rising due to local outbreaks such as the outbreak in Gutersloh, North Rhine-Westphalia. CONCLUSION: RSV related to "coronavirus" precisely reflected public interest during the beginning of the COVID-19 pandemic. As public interest has strongly declined, information distribution regarding the newest developments over the entire course of the pandemic will be a major public health challenge. ZIEL DER STUDIE: Wahrend Pandemien ist die gesamte Gesellschaft zur gleichen Zeit mit derselben Erkrankung konfrontiert, was zu grossem offentlichen Interesse fuhrt. Die aktuelle COVID-19 Pandemie hat die ganze Welt in einen einmaligen Ausnahmezustand versetzt. Ziel dieser Studie war es zu untersuchen ob das Pandemiegeschehen in Deutschland anhand von Google Suchanfragen retrospektiv rekonstruiert werden kann und ob lokale Ausbruche mithilfe von Google Daten detektiert werden konnen. METHODIK: Das relative Google Suchvolumen (RSV) zum Thema "Coronavirus" wurde fur den Zeitraum von Januar bis Juli 2020 mit Google Trends analysiert. Das RSV, das zwischen 0 und 100 betragen kann, wurde auf Bundesebene mit den taglich neu gemeldeten SARS-CoV-2 Infektionszahlen und auf Landerebene mit den kumulativen Infektionszahlen pro Bundesland sowie wichtigen infektiologischen und politischen Ereignissen verglichen. ERGEBNISSE: Hochstwerte im Google Suchvolumen nach der ersten gemeldeten SARS-CoV-2-Infektion in Deutschland (27. Januar), wahrend des lokalen Ausbruchs in Heinsberg (25. Februar), nach den Schulschliessungen (13. Marz) sowie, der absolute Hochstwert, nach Verkundung der bundesweiten Kontaktbeschrankungen (22. Marz) verzeichnet worden. Auf Bundeslanderebene wurde immer dann ein Anstieg im Suchvolumen beobachtet, wenn die erste SARS-CoV-2 Infektion im jeweiligen Bundesland gemeldet wurde. Zudem wurde ein hoheres RSV in Bundeslandern mit mehr gemeldeten SARS-CoV-2-Infektionen registriert (r=0,6, p=0,014), wie z. B. in Bayern (RSV=96, 391 Infektionen/100 000 Einwohner) und Baden-Wurttemberg (RSV=98, 340 Infektionen/100 000 Einwohner). Das niedrigste RSV (n=83) und die niedrigste Anzahl an Infektionen (50 Infektionen/100 000 Einwohner) wurde in Mecklenburg-Vorpommern beobachtet. Seit Ende Mai ist das RSV bezuglich SARS-CoV-2 konstant gering, obwohl die Zahl an Neuinfektionen zwischenzeitlich aufgrund lokaler Ausbruche gestiegen war wie z. B. der lokale Ausbruch in Gutersloh, Nordrhein-Westfalen. SCHLUssFOLGERUNG: Das RSV zum Thema "Coronavirus" bildeten das offentliche Interesse wahrend der ersten Monate der COVID-19 Pandemie prazise ab. Da das offentliche Interesse jedoch stark nachgelassen hat, konnte es eine zentrale Herausforderung im weiteren Verlauf der Pandemie darstellen, die Bevolkerung weiterhin uber neueste Entwicklungen und Massnahmen informiert zu halten. CI - Thieme. All rights reserved. FAU - Schuster, Barbara AU - Schuster B AUID- ORCID: 0000-0001-6411-6318 AD - Technical University of Munich, School of Medicine, Department of Dermatology and Allergy, Munich, Germany. FAU - Tizek, Linda AU - Tizek L AD - Technical University of Munich, School of Medicine, Department of Dermatology and Allergy, Munich, Germany. FAU - Schielein, Maximilian C AU - Schielein MC AUID- ORCID: 0000-0003-3767-1337 AD - Technical University of Munich, School of Medicine, Department of Dermatology and Allergy, Munich, Germany. FAU - Ziehfreund, Stefanie AU - Ziehfreund S AD - Technical University of Munich, School of Medicine, Department of Dermatology and Allergy, Munich, Germany. AD - Technical University of Munich, School of Medicine, Institute of General Practice, Munich, Germany. FAU - Rothe, Kathrin AU - Rothe K AD - Technical University of Munich, School of Medicine, Institute for Medical Microbiology, Immunology and Hygiene, Munich, Germany. FAU - Spinner, Christoph D AU - Spinner CD AUID- ORCID: 0000-0002-3875-5367 AD - Technical University of Munich, School of Medicine, Department of Internal Medicine II, Munich, Germany. FAU - Biedermann, Tilo AU - Biedermann T AD - Technical University of Munich, School of Medicine, Department of Dermatology and Allergy, Munich, Germany. FAU - Zink, Alexander AU - Zink A AD - Technical University of Munich, School of Medicine, Department of Dermatology and Allergy, Munich, Germany. LA - eng PT - Journal Article TT - Aufarbeitung der COVID-19-Pandemie in Deutschland aus Bevolkerungssicht mithilfe von Google Suchanfragen zum Thema "Coronavirus". DEP - 20210416 PL - Germany TA - Gesundheitswesen JT - Gesundheitswesen (Bundesverband der Arzte des Offentlichen Gesundheitsdienstes (Germany)) JID - 9204210 SB - IM MH - *COVID-19 MH - Germany/epidemiology MH - Humans MH - *Pandemics MH - Retrospective Studies MH - SARS-CoV-2 COIS- The authors declare that they have no conflict of interest. EDAT- 2021/04/17 06:00 MHDA- 2021/05/15 06:00 CRDT- 2021/04/16 20:32 PHST- 2021/04/17 06:00 [pubmed] PHST- 2021/05/15 06:00 [medline] PHST- 2021/04/16 20:32 [entrez] AID - 10.1055/a-1398-5417 [doi] PST - ppublish SO - Gesundheitswesen. 2021 May;83(5):e9-e14. doi: 10.1055/a-1398-5417. Epub 2021 Apr 16. PMID- 33862016 OWN - NLM STAT- MEDLINE DCOM- 20210628 LR - 20250530 IS - 2215-0374 (Electronic) IS - 2215-0366 (Print) IS - 2215-0366 (Linking) VI - 8 IP - 7 DP - 2021 Jul TI - Suicide trends in the early months of the COVID-19 pandemic: an interrupted time-series analysis of preliminary data from 21 countries. PG - 579-588 LID - S2215-0366(21)00091-2 [pii] LID - 10.1016/S2215-0366(21)00091-2 [doi] AB - BACKGROUND: The COVID-19 pandemic is having profound mental health consequences for many people. Concerns have been expressed that, at their most extreme, these consequences could manifest as increased suicide rates. We aimed to assess the early effect of the COVID-19 pandemic on suicide rates around the world. METHODS: We sourced real-time suicide data from countries or areas within countries through a systematic internet search and recourse to our networks and the published literature. Between Sept 1 and Nov 1, 2020, we searched the official websites of these countries' ministries of health, police agencies, and government-run statistics agencies or equivalents, using the translated search terms "suicide" and "cause of death", before broadening the search in an attempt to identify data through other public sources. Data were included from a given country or area if they came from an official government source and were available at a monthly level from at least Jan 1, 2019, to July 31, 2020. Our internet searches were restricted to countries with more than 3 million residents for pragmatic reasons, but we relaxed this rule for countries identified through the literature and our networks. Areas within countries could also be included with populations of less than 3 million. We used an interrupted time-series analysis to model the trend in monthly suicides before COVID-19 (from at least Jan 1, 2019, to March 31, 2020) in each country or area within a country, comparing the expected number of suicides derived from the model with the observed number of suicides in the early months of the pandemic (from April 1 to July 31, 2020, in the primary analysis). FINDINGS: We sourced data from 21 countries (16 high-income and five upper-middle-income countries), including whole-country data in ten countries and data for various areas in 11 countries). Rate ratios (RRs) and 95% CIs based on the observed versus expected numbers of suicides showed no evidence of a significant increase in risk of suicide since the pandemic began in any country or area. There was statistical evidence of a decrease in suicide compared with the expected number in 12 countries or areas: New South Wales, Australia (RR 0.81 [95% CI 0.72-0.91]); Alberta, Canada (0.80 [0.68-0.93]); British Columbia, Canada (0.76 [0.66-0.87]); Chile (0.85 [0.78-0.94]); Leipzig, Germany (0.49 [0.32-0.74]); Japan (0.94 [0.91-0.96]); New Zealand (0.79 [0.68-0.91]); South Korea (0.94 [0.92-0.97]); California, USA (0.90 [0.85-0.95]); Illinois (Cook County), USA (0.79 [0.67-0.93]); Texas (four counties), USA (0.82 [0.68-0.98]); and Ecuador (0.74 [0.67-0.82]). INTERPRETATION: This is the first study to examine suicides occurring in the context of the COVID-19 pandemic in multiple countries. In high-income and upper-middle-income countries, suicide numbers have remained largely unchanged or declined in the early months of the pandemic compared with the expected levels based on the pre-pandemic period. We need to remain vigilant and be poised to respond if the situation changes as the longer-term mental health and economic effects of the pandemic unfold. FUNDING: None. CI - Copyright (c) 2021 Elsevier Ltd. All rights reserved. FAU - Pirkis, Jane AU - Pirkis J AD - Centre for Mental Health, Melbourne School of Population and Global Health, University of Melbourne, Melbourne, VIC, Australia. Electronic address: j.pirkis@unimelb.edu.au. FAU - John, Ann AU - John A AD - Swansea University Medical School, Swansea, UK. FAU - Shin, Sangsoo AU - Shin S AD - Centre for Mental Health, Melbourne School of Population and Global Health, University of Melbourne, Melbourne, VIC, Australia. FAU - DelPozo-Banos, Marcos AU - DelPozo-Banos M AD - Swansea University Medical School, Swansea, UK. FAU - Arya, Vikas AU - Arya V AD - Centre for Mental Health, Melbourne School of Population and Global Health, University of Melbourne, Melbourne, VIC, Australia; Translational Health Research Institute, Western Sydney University, Campbelltown, NSW, Australia. FAU - Analuisa-Aguilar, Pablo AU - Analuisa-Aguilar P AD - Ministry of Public Health, Department of Health Promotion, Quito, Ecuador. FAU - Appleby, Louis AU - Appleby L AD - National Confidential Inquiry into Suicide and Safety in Mental Health, University of Manchester, Manchester, UK. FAU - Arensman, Ella AU - Arensman E AD - School of Public Health, National Suicide Research Foundation, University College Cork, Cork, Ireland; Australian Institute for Suicide Research and Prevention, School of Applied Psychology, Griffith University, Brisbane, QLD, Australia. FAU - Bantjes, Jason AU - Bantjes J AD - Institute for Life Course Health Research, Department of Global Health, Stellenbosch University, Stellenbosch, South Africa. FAU - Baran, Anna AU - Baran A AD - Working Group on Prevention of Suicide and Depression at Public Health Council, Warsaw, Poland; Department of Psychiatry, Blekinge Hospital, Karlshamn, Sweden. FAU - Bertolote, Jose M AU - Bertolote JM AD - Botucatu Medical School, Universidade Estadual Paulista, Sao Paulo, Brazil. FAU - Borges, Guilherme AU - Borges G AD - Instituto Nacional de Psiquiatria Ramon de la Fuente Muniz, Mexico City, Mexico. FAU - Brecic, Petrana AU - Brecic P AD - Department for Medical Ethics, University Psychiatric Hospital Vrapce, School of Medicine, University of Zagreb, Zagreb, Croatia; Department for Psychiatry, University Psychiatric Hospital Vrapce, School of Medicine, University of Zagreb, Zagreb, Croatia. FAU - Caine, Eric AU - Caine E AD - University of Rochester Medical Center, Rochester, NY, USA. FAU - Castelpietra, Giulio AU - Castelpietra G AD - Region Friuli Venezia Giulia, Central Health Directorate, Outpatient and Inpatient Care Service, Trieste, Italy; Department of Medicine, University of Udine, Trieste, Italy. FAU - Chang, Shu-Sen AU - Chang SS AD - Institute of Health Behaviors and Community Sciences, College of Public Health, National Taiwan University, Taipei, Taiwan. FAU - Colchester, David AU - Colchester D AD - Thames Valley Local Criminal Justice Board, Bicester, UK. FAU - Crompton, David AU - Crompton D AD - Australian Institute for Suicide Research and Prevention, School of Applied Psychology, Griffith University, Brisbane, QLD, Australia. FAU - Curkovic, Marko AU - Curkovic M AD - Department for Medical Ethics, University Psychiatric Hospital Vrapce, School of Medicine, University of Zagreb, Zagreb, Croatia. FAU - Deisenhammer, Eberhard A AU - Deisenhammer EA AD - Department of Psychiatry, Psychotherapy and Psychosomatics, Medical University of Innsbruck, Innsbruck, Austria. FAU - Du, Chengan AU - Du C AD - Center for Outcomes Research and Evaluation, Yale School of Medicine, New Haven, CT, USA. FAU - Dwyer, Jeremy AU - Dwyer J AD - Centre for Mental Health, Melbourne School of Population and Global Health, University of Melbourne, Melbourne, VIC, Australia; Coroners Court of Victoria, Melbourne, VIC, Australia. FAU - Erlangsen, Annette AU - Erlangsen A AD - Danish Research Institute for Suicide Prevention, Copenhagen, Denmark; Department of Mental Health, Johns Hopkins School of Public Health, Baltimore, MD, USA; Centre for Mental Health Research, Australian National University, Canberra, ACT, Australia. FAU - Faust, Jeremy S AU - Faust JS AD - Brigham and Women's Hospital Department of Emergency Medicine, Boston, MA, USA. FAU - Fortune, Sarah AU - Fortune S AD - School of Population Health, University of Auckland, Auckland, New Zealand. FAU - Garrett, Andrew AU - Garrett A AD - Magistrates Court of Tasmania (Coronial Division), Hobart, TAS, Australia. FAU - George, Devin AU - George D AD - Bureau of Vital Records and Statistics, Louisiana Office of Public Health, Baton Rouge, LA, USA. FAU - Gerstner, Rebekka AU - Gerstner R AD - Ministry of Public Health, Undersecretary of Health Services, Quito, Ecuador. FAU - Gilissen, Renske AU - Gilissen R AD - Research Department, 113 Suicide Prevention, Amsterdam, Netherlands. FAU - Gould, Madelyn AU - Gould M AD - Departments of Psychiatry and Epidemiology, Columbia University Medical Center/New York State Psychiatric Institute, New York, NY, USA. FAU - Hawton, Keith AU - Hawton K AD - Centre for Suicide Research, University of Oxford, Oxford, UK. FAU - Kanter, Joseph AU - Kanter J AD - Louisiana Department of Health, Baton Rouge, LA, USA. FAU - Kapur, Navneet AU - Kapur N AD - Centre for Mental Health and Safety and National Institute for Health Research Patient Safety Translational Research Centre, University of Manchester, Manchester, UK; Greater Manchester Mental Health NHS Foundation Trust, Manchester, UK. FAU - Khan, Murad AU - Khan M AD - Department of Psychiatry, Aga Khan University, Karachi, Pakistan. FAU - Kirtley, Olivia J AU - Kirtley OJ AD - KU Leuven, Center for Contextual Psychiatry, Leuven, Belgium. FAU - Knipe, Duleeka AU - Knipe D AD - Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK; South Asian Clinical Toxicology Research Collaboration, Faculty of Medicine, University of Peradeniya, Peradeniya, Sri Lanka. FAU - Kolves, Kairi AU - Kolves K AD - Australian Institute for Suicide Research and Prevention, School of Applied Psychology, Griffith University, Brisbane, QLD, Australia. FAU - Leske, Stuart AU - Leske S AD - Australian Institute for Suicide Research and Prevention, School of Applied Psychology, Griffith University, Brisbane, QLD, Australia. FAU - Marahatta, Kedar AU - Marahatta K AD - World Health Organization, Country Office for Nepal, Kathmandu, Nepal. FAU - Mittendorfer-Rutz, Ellenor AU - Mittendorfer-Rutz E AD - Karolinska Institutet, Stockholm, Sweden. FAU - Neznanov, Nikolay AU - Neznanov N AD - Bekhterev National Medical Research Center of Psychiatry and Neurology, Pavlov First Saint Petersburg State Medical University, Saint Petersburg, Russia. FAU - Niederkrotenthaler, Thomas AU - Niederkrotenthaler T AD - Unit Suicide Research and Mental Health Promotion, Department of Social and Preventive Medicine, Center for Public Health, Medical University of Vienna, Vienna, Austria. FAU - Nielsen, Emma AU - Nielsen E AD - School of Psychology, University of Nottingham, Nottingham, UK. FAU - Nordentoft, Merete AU - Nordentoft M AD - Mental Health Centre Copenhagen, Copenhagen, Denmark. FAU - Oberlerchner, Herwig AU - Oberlerchner H AD - Department of Psychiatry and Psychotherapy, Klinikum Klagenfurt am Worthersee, Klagenfurt, Austria. FAU - O'Connor, Rory C AU - O'Connor RC AD - Suicidal Behaviour Research Lab, University of Glasgow, Glasgow, UK. FAU - Pearson, Melissa AU - Pearson M AD - Preventing Deaths from Poisoning Research Group, University of Edinburgh, Edinburgh, UK. FAU - Phillips, Michael R AU - Phillips MR AD - Suicide Research and Prevention Center, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China; Departments of Psychiatry and Epidemiology, Columbia University, New York, NY, USA. FAU - Platt, Steve AU - Platt S AD - Usher Institute, University of Edinburgh, Edinburgh, UK. FAU - Plener, Paul L AU - Plener PL AD - Department of Child and Adolescent Psychiatry, Medical University of Vienna, Vienna, Austria; Department of Child and Adolescent Psychiatry and Psychotherapy, University of Ulm, Ulm, Germany. FAU - Psota, Georg AU - Psota G AD - Psychosocial Services in Vienna, Vienna, Austria. FAU - Qin, Ping AU - Qin P AD - National Centre for Suicide Research and Prevention, Institute of Clinical Medicine, University of Oslo, Oslo, Norway. FAU - Radeloff, Daniel AU - Radeloff D AD - Department of Child and Adolescent Psychiatry, Psychotherapy and Psychosomatics, University Hospital Leipzig, Leipzig, Germany. FAU - Rados, Christa AU - Rados C AD - Department of Psychiatry and Psychotherapeutic Medicine, Landeskrankenhaus Villach, Villach, Austria. FAU - Reif, Andreas AU - Reif A AD - Department of Psychiatry, Psychosomatic Medicine and Psychotherapy, University Hospital Frankfurt, Frankfurt am Main, Germany. FAU - Reif-Leonhard, Christine AU - Reif-Leonhard C AD - Department of Psychiatry, Psychosomatic Medicine and Psychotherapy, University Hospital Frankfurt, Frankfurt am Main, Germany. FAU - Rozanov, Vsevolod AU - Rozanov V AD - Department of Borderline Disorders and Psychotherapy, Bekhterev National Medical Research Center of Psychiatry and Neurology, Saint Petersburg State University, Saint Petersburg, Russia. FAU - Schlang, Christiane AU - Schlang C AD - Department of Psychiatry, Health Authority Frankfurt am Main, Frankfurt, Germany. FAU - Schneider, Barbara AU - Schneider B AD - Department of Addictive Disorders, Psychiatry and Psychotherapy, LVR-Klinik Koln, Cologne, Germany; Department of Psychiatry, Psychosomatic Medicine and Psychotherapy, Goethe-University, Frankfurt am Main, Germany. FAU - Semenova, Natalia AU - Semenova N AD - Organizational-Scientific Department, Bekhterev National Medical Research Center of Psychiatry and Neurology, Saint Petersburg, Russia. FAU - Sinyor, Mark AU - Sinyor M AD - Department of Psychiatry, University of Toronto, Toronto, ON, Canada; Department of Psychiatry, Sunnybrook Health Sciences Centre, Toronto, ON, Canada. FAU - Townsend, Ellen AU - Townsend E AD - Self-Harm Research Group, School of Psychology, University of Nottingham, Nottingham, UK. FAU - Ueda, Michiko AU - Ueda M AD - Waseda University, Faculty of Political Science and Economics, Tokyo, Japan. FAU - Vijayakumar, Lakshmi AU - Vijayakumar L AD - Sneha-Suicide Prevention Centre, Voluntary Health Services, Chennai, India. FAU - Webb, Roger T AU - Webb RT AD - Centre for Mental Health and Safety and National Institute for Health Research Patient Safety Translational Research Centre, University of Manchester, Manchester, UK. FAU - Weerasinghe, Manjula AU - Weerasinghe M AD - Department of Community Medicine, Faculty of Medicine and Allied Sciences, Rajarata University of Sri Lanka, Anuradhapura, Sri Lanka. FAU - Zalsman, Gil AU - Zalsman G AD - Department of Psychiatry, Sackler School of Medicine, Tel Aviv University and Geha Mental Health Center, Tel Aviv, Israel; Division of Molecular Imaging and Neuropathology, New York State Psychiatric Institute and Department of Psychiatry, Columbia University, New York, USA. FAU - Gunnell, David AU - Gunnell D AD - National Institute of Health Research Biomedical Research Centre, University Hospitals Bristol and Weston NHS Foundation Trust, University of Bristol, Bristol, UK. FAU - Spittal, Matthew J AU - Spittal MJ AD - Centre for Mental Health, Melbourne School of Population and Global Health, University of Melbourne, Melbourne, VIC, Australia. LA - eng GR - 001/WHO_/World Health Organization/International GR - MC_PC_17211/MRC_/Medical Research Council/United Kingdom PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20210413 PL - England TA - Lancet Psychiatry JT - The lancet. Psychiatry JID - 101638123 SB - IM CIN - Lancet Psychiatry. 2021 Jul;8(7):552-553. doi: 10.1016/S2215-0366(21)00117-6. PMID: 33862017 EIN - Lancet Psychiatry. 2021 Aug;8(8):e18. doi: 10.1016/S2215-0366(21)00213-3. PMID: 34097871 CIN - Tijdschr Psychiatr. 2021;63(6):487-488. PMID: 34231870 EIN - Lancet Psychiatry. 2021 Nov;8(11):e21. doi: 10.1016/S2215-0366(21)00358-8. PMID: 34461047 CIN - Prim Care Companion CNS Disord. 2021 Nov 18;23(6):21com03088. doi: 10.4088/PCC.21com03088. PMID: 34797964 CIN - Dtsch Arztebl Int. 2022 Jul 25;119(29-30):502-503. doi: 10.3238/arztebl.m2022.0198. PMID: 36345581 MH - COVID-19/*complications MH - Developed Countries/statistics & numerical data MH - *Global Health MH - Humans MH - *Models, Statistical MH - Suicide/*statistics & numerical data PMC - PMC9188435 COIS- Declaration of interests We declare no competing interests. EDAT- 2021/04/17 06:00 MHDA- 2021/06/29 06:00 PMCR- 2021/04/13 CRDT- 2021/04/16 20:10 PHST- 2020/12/22 00:00 [received] PHST- 2021/02/12 00:00 [revised] PHST- 2021/02/24 00:00 [accepted] PHST- 2021/04/17 06:00 [pubmed] PHST- 2021/06/29 06:00 [medline] PHST- 2021/04/16 20:10 [entrez] PHST- 2021/04/13 00:00 [pmc-release] AID - S2215-0366(21)00091-2 [pii] AID - 10.1016/S2215-0366(21)00091-2 [doi] PST - ppublish SO - Lancet Psychiatry. 2021 Jul;8(7):579-588. doi: 10.1016/S2215-0366(21)00091-2. Epub 2021 Apr 13. PMID- 33849993 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20231219 IS - 1526-632X (Electronic) IS - 0028-3878 (Linking) VI - 96 IP - 22 DP - 2021 May 31 TI - Vagus Nerve Stimulation and Seizure Outcomes in Pediatric Refractory Epilepsy: Systematic Review and Meta-analysis. PG - 1041-1051 LID - 10.1212/WNL.0000000000012030 [doi] AB - OBJECTIVE: We synthesized evidence for effectiveness of vagus nerve stimulation (VNS) as adjuvant therapy in pediatric drug-resistant epilepsy (DRE) by obtaining pooled estimates for seizure outcomes and analyzing their determinants. METHODS: MEDLINE, EMBASE, and Cochrane databases were searched up to July 2019 for original research on VNS in pediatric (/=50% seizure reduction, at the last reported follow-up. Other outcomes included a 50% RR and proportion of seizure-free patients at additional reported time points. A random-effects meta-analysis with restricted maximum likelihood estimation was performed to obtain pooled effect estimates. Meta-regression using multiple linear models was performed to obtain determinants of seizure outcomes and sources of heterogeneity. RESULTS: A total of 101 studies were included. The pooled prevalence estimates for a 50% RR and seizure freedom at last follow-up (mean 2.54 years) were 56.4% (95% confidence intervals [CIs] 52.4, 60.4) and 11.6% (95% CI 9.6, 13.9), respectively. Fewer antiseizure medications (ASMs) tried before VNS and later age at onset of seizures were associated with better seizure outcomes following VNS implantation. An effect of sex distribution of studies on long-term outcomes and a potential publication bias for short-term outcomes were also observed. CONCLUSION: Pooled evidence supports possible effectiveness of VNS in pediatric DRE, although complete seizure freedom is less common. Early referral (fewer trials of ASMs) may be a modifiable factor for desirable seizure outcomes with VNS from a clinical perspective. CI - (c) 2021 American Academy of Neurology. FAU - Jain, Puneet AU - Jain P AUID- ORCID: 0000-0002-6009-0859 AD - From the Epilepsy Program (P.J.), Division of Neurology, Department of Pediatrics, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada; Division of Pediatric Neurology (P.J.), Department of Pediatrics, Danat Al Emarat Hospital for Women and Children, Abu Dhabi, United Arab Emirates; Comprehensive Epilepsy Center (R.A.), Division of Neurology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH; and Department of Pediatrics (R.A.), University of Cincinnati College of Medicine, Cincinnati, OH. FAU - Arya, Ravindra AU - Arya R AUID- ORCID: 0000-0003-0873-9718 AD - From the Epilepsy Program (P.J.), Division of Neurology, Department of Pediatrics, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada; Division of Pediatric Neurology (P.J.), Department of Pediatrics, Danat Al Emarat Hospital for Women and Children, Abu Dhabi, United Arab Emirates; Comprehensive Epilepsy Center (R.A.), Division of Neurology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH; and Department of Pediatrics (R.A.), University of Cincinnati College of Medicine, Cincinnati, OH. ravindra.arya@cchmc.org. LA - eng PT - Journal Article PT - Review DEP - 20210531 PL - United States TA - Neurology JT - Neurology JID - 0401060 SB - IM EDAT- 2021/04/15 06:00 MHDA- 2021/04/15 06:01 CRDT- 2021/04/14 05:53 PHST- 2020/07/23 00:00 [received] PHST- 2021/02/18 00:00 [accepted] PHST- 2021/04/15 06:01 [medline] PHST- 2021/04/15 06:00 [pubmed] PHST- 2021/04/14 05:53 [entrez] AID - WNL.0000000000012030 [pii] AID - 10.1212/WNL.0000000000012030 [doi] PST - epublish SO - Neurology. 2021 May 31;96(22):1041-1051. doi: 10.1212/WNL.0000000000012030. PMID- 33849611 OWN - NLM STAT- MEDLINE DCOM- 20210617 LR - 20210617 IS - 1745-6215 (Electronic) IS - 1745-6215 (Linking) VI - 22 IP - 1 DP - 2021 Apr 13 TI - Impact of a shared decision-making mHealth tool on caregivers' team situational awareness, communication effectiveness, and performance during pediatric cardiopulmonary resuscitation: study protocol of a cluster randomized controlled trial. PG - 277 LID - 10.1186/s13063-021-05170-3 [doi] LID - 277 AB - BACKGROUND: Effective team communication, coordination, and situational awareness (SA) by team members are critical components to deliver optimal cardiopulmonary resuscitation (CPR). Complexity of care during CPR, involvement of numerous providers, miscommunication, and other exogenous factors can all contribute to negatively influencing patient care, thus jeopardizing survival. We aim to investigate whether an mHealth supportive tool (the Interconnected and Focused Mobile Apps on patient Care Environment [InterFACE]) developed as a collaborative platform to support CPR providers in real-time and share patient-centered information would increase SA during pediatric CPR. METHODS: We will conduct a prospective, cluster randomized controlled trial by groups of 6 participants in a tertiary pediatric emergency department (33,000 consultations/year) with pediatric physicians and nurses. We will compare the impact of the InterFACE tool with conventional communication methods on SA and effective team communication during a standardized pediatric in-hospital cardiac arrest and a polytrauma high-fidelity simulations. Forty-eight participants will be randomized (1:1) to consecutively perform two 20-min video-recorded scenarios using either the mHealth tool or conventional methods. The primary endpoint is the SA score, measured with the Situation Awareness Global Assessment Technique (SAGAT) instrument. Enrollment will start in late 2020 and data analysis in early 2021. We anticipate that the intervention will be completed by early 2021 and study results will be submitted in mid 2021 for publication. DISCUSSION: This clinical trial will assess the impact of a collaborative mHealth tool on increasing situational awareness and effective team communication during in-hospital pediatric resuscitation. As research in this area is scarce, the results generated by this study may become of paramount importance in improving the care of children receiving in-hospital CPR, in the era of increasing communication technology. TRIAL REGISTRATION: ClinicalTrials.gov NCT04464603 . Registered on 9 July 2020. FAU - Ehrler, Frederic AU - Ehrler F AD - Department of Diagnostic, Geneva University Hospitals, Geneva, Switzerland. FAU - Sahyoun, Cyril AU - Sahyoun C AD - Department of Pediatric Emergency Medicine, Children's Hospital, Geneva University Hospitals, 47 Avenue de la Roseraie, 1211, Geneva 14, Switzerland. FAU - Manzano, Sergio AU - Manzano S AD - Department of Pediatric Emergency Medicine, Children's Hospital, Geneva University Hospitals, 47 Avenue de la Roseraie, 1211, Geneva 14, Switzerland. FAU - Sanchez, Oliver AU - Sanchez O AD - Division of Pediatric Surgery, University Center of Pediatric Surgery of Western Switzerland, Geneva University Hospitals, Geneva, Switzerland. FAU - Gervaix, Alain AU - Gervaix A AD - Department of Pediatric Emergency Medicine, Children's Hospital, Geneva University Hospitals, 47 Avenue de la Roseraie, 1211, Geneva 14, Switzerland. FAU - Lovis, Christian AU - Lovis C AD - Department of Radiology and Medical Informatics, Division of Medical Information Sciences, Geneva University Hospitals, Geneva, Switzerland. FAU - Courvoisier, Delphine S AU - Courvoisier DS AD - Quality of Care Unit, Geneva University Hospitals, Geneva, Switzerland. FAU - Lacroix, Laurence AU - Lacroix L AD - Department of Pediatric Emergency Medicine, Children's Hospital, Geneva University Hospitals, 47 Avenue de la Roseraie, 1211, Geneva 14, Switzerland. FAU - Siebert, Johan N AU - Siebert JN AUID- ORCID: 0000-0002-2871-3382 AD - Department of Pediatric Emergency Medicine, Children's Hospital, Geneva University Hospitals, 47 Avenue de la Roseraie, 1211, Geneva 14, Switzerland. Johan.Siebert@hcuge.ch. AD - University of Geneva, Geneva, Switzerland. Johan.Siebert@hcuge.ch. LA - eng SI - ClinicalTrials.gov/NCT04464603 GR - QS2-25/Hopitaux Universitaires de Geneve/ PT - Clinical Trial Protocol PT - Journal Article DEP - 20210413 PL - England TA - Trials JT - Trials JID - 101263253 SB - IM MH - Awareness MH - *Cardiopulmonary Resuscitation MH - Caregivers MH - Child MH - Communication MH - Humans MH - Prospective Studies MH - Randomized Controlled Trials as Topic MH - *Telemedicine PMC - PMC8042906 OTO - NOTNLM OT - Cardiopulmonary resuscitation OT - Information technology OT - Leadership OT - Mobile device OT - Pediatrics OT - Situation awareness OT - Taskwork OT - Teamwork COIS- JNS and FE are the owners of the InterFACE solution. InterFACE is currently restricted to research purposes only and it is not intended for commercial use at the time of the writing of this study protocol. Further marketing is not excluded. All other authors declare no competing interests. EDAT- 2021/04/15 06:00 MHDA- 2021/06/22 06:00 PMCR- 2021/04/13 CRDT- 2021/04/14 05:40 PHST- 2020/10/16 00:00 [received] PHST- 2021/03/05 00:00 [accepted] PHST- 2021/04/14 05:40 [entrez] PHST- 2021/04/15 06:00 [pubmed] PHST- 2021/06/22 06:00 [medline] PHST- 2021/04/13 00:00 [pmc-release] AID - 10.1186/s13063-021-05170-3 [pii] AID - 5170 [pii] AID - 10.1186/s13063-021-05170-3 [doi] PST - epublish SO - Trials. 2021 Apr 13;22(1):277. doi: 10.1186/s13063-021-05170-3. PMID- 33842205 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240331 IS - 2213-6258 (Electronic) IS - 2213-624X (Print) IS - 2213-624X (Linking) VI - 9 IP - 2 DP - 2021 Jun TI - Analyzing the ultimate impact of COVID-19 in Africa. PG - 796-804 LID - 10.1016/j.cstp.2021.03.016 [doi] AB - The Covid-19 pandemic has spread quickly across the globe in late 2019 and this has continued into 2020, causing a complete closure of daily routines, depleting global resources and, in extreme cases, causing loss of life. In Africa, with its hot climate, decision makers try to get people to their work as health care professionals or sometimes access health care facilities. For the peak four months; April, May, June, and July, the virus appeared, spread, and began to decrease. This study aims at analyzing the direct impact of Covid-19 in Africa according to the available data until July 2020. It provides statistics and policies prepared by African countries for this pandemic with the aid of other developed countries' experiences. From studying such applicable policies, it can be seen in a number of cases that lockdown restrictions, school and workplace closures, and limitations to the internal movement have the chief effect of reducing virus spread. Change in travel behavior and number of visitors appear in response to such a crisis. Regarding the potential economic repercussions in the studied period, GDP shows a sharp drop of 3.4%, appearing as a reduction of 6% on the price of oil, reducing the number of tourists by 46%, and causing fluctuations in currency. These suggest a mutual influence between the crisis and the transport sector. CI - (c) 2021 Published by Elsevier Ltd on behalf of World Conference on Transport Research Society. FAU - Elbany, M AU - Elbany M AD - Civil Engineering Department, Transportation and Traffic Engineering, Faculty of Engineering, Port-Said University, Egypt. FAU - Elhenawy, Y AU - Elhenawy Y AD - Mechanical Power Engineering Department, Faculty of Engineering, Port-Said University, Egypt. LA - eng PT - Journal Article DEP - 20210406 PL - Netherlands TA - Case Stud Transp Policy JT - Case studies on transport policy JID - 101766458 PMC - PMC8021502 OTO - NOTNLM OT - Covid-19 OT - Mobility OT - Pandemic impact OT - Potential economic OT - Precautionary restrictions OT - Public transport EDAT- 2021/04/13 06:00 MHDA- 2021/04/13 06:01 PMCR- 2021/04/06 CRDT- 2021/04/12 06:23 PHST- 2020/09/06 00:00 [received] PHST- 2021/02/13 00:00 [revised] PHST- 2021/03/29 00:00 [accepted] PHST- 2021/04/13 06:00 [pubmed] PHST- 2021/04/13 06:01 [medline] PHST- 2021/04/12 06:23 [entrez] PHST- 2021/04/06 00:00 [pmc-release] AID - S2213-624X(21)00052-3 [pii] AID - 10.1016/j.cstp.2021.03.016 [doi] PST - ppublish SO - Case Stud Transp Policy. 2021 Jun;9(2):796-804. doi: 10.1016/j.cstp.2021.03.016. Epub 2021 Apr 6. PMID- 33839730 OWN - NLM STAT- MEDLINE DCOM- 20210803 LR - 20210803 IS - 1421-9891 (Electronic) IS - 1022-6877 (Print) IS - 1022-6877 (Linking) VI - 27 IP - 4 DP - 2021 TI - Alcohol Use during the COVID-19 Pandemic: Self-Reported Changes and Motives for Change. PG - 257-262 LID - 10.1159/000515102 [doi] AB - BACKGROUND: In Europe, the COVID-19 pandemic triggered a range of restrictive measures, which may have impacted alcohol consumption. OBJECTIVES: We explored perceived changes in alcohol consumption, their association with sociodemographic characteristics and past year alcohol consumption, and self-reported reasons for change after CO-VID-19 restrictions in Norway. METHOD: A web-based survey was sent to Norwegians aged 18 years and older in June-July 2020. Respondents reporting any past year alcohol use (n = 1,200) were asked whether they drank less, approximately the same, or more after the COVID-19 restrictions compared to before and reasons for drinking less or more. RESULTS: Almost a third (29.9%) reported they drank less, whereas 13.3% reported they drank more. Females, younger respondents, and Oslo residents were more likely to report both less and more drinking (p values between 0.001 and 0.029). Past year alcohol use was associated with less drinking (OR = 0.93; p < 0.001) and more drinking (OR = 1.07; p < 0.001). More drinking was also associated with living with child(ren) (p = 0.023) and high educational level (p = 0.029). The most frequently reported reasons for drinking less pertained to fewer social occasions and less on-premise drinking, whereas reasons for drinking more pertained to treating oneself to something good and fewer consequences of drinking more. CONCLUSIONS: After the COVID-19 restrictions were implemented, a substantial proportion of Norwegians changed their drinking behaviour. CI - (c) 2021 S. Karger AG, Basel. FAU - Bramness, Jorgen G AU - Bramness JG AD - Department of Drug and Tobacco Research, Norwegian Institute of Public Health, Oslo, Norway. AD - Institute of Clinical Medicine, UiT - The Arctic University of Norway, Tromso, Norway. FAU - Bye, Elin K AU - Bye EK AD - Department of Drug and Tobacco Research, Norwegian Institute of Public Health, Oslo, Norway. FAU - Moan, Inger Synnove AU - Moan IS AD - Department of Drug and Tobacco Research, Norwegian Institute of Public Health, Oslo, Norway. FAU - Rossow, Ingeborg AU - Rossow I AD - Department of Drug and Tobacco Research, Norwegian Institute of Public Health, Oslo, Norway. LA - eng PT - News DEP - 20210409 PL - Switzerland TA - Eur Addict Res JT - European addiction research JID - 9502920 SB - IM MH - Adult MH - Alcohol Drinking/*epidemiology/*psychology MH - COVID-19/*epidemiology MH - Child MH - Female MH - Humans MH - Internet MH - Male MH - *Motivation MH - Norway/epidemiology MH - Pandemics MH - *Self Report MH - Social Change MH - Surveys and Questionnaires PMC - PMC8089433 OTO - NOTNLM OT - Alcohol use OT - COVID-19 OT - Changes OT - Norway OT - Pandemic COIS- The authors have no conflicts of interest to declare. EDAT- 2021/04/12 06:00 MHDA- 2021/08/04 06:00 PMCR- 2021/05/03 CRDT- 2021/04/11 20:49 PHST- 2020/09/21 00:00 [received] PHST- 2021/02/05 00:00 [accepted] PHST- 2021/04/12 06:00 [pubmed] PHST- 2021/08/04 06:00 [medline] PHST- 2021/04/11 20:49 [entrez] PHST- 2021/05/03 00:00 [pmc-release] AID - 000515102 [pii] AID - ear-0001 [pii] AID - 10.1159/000515102 [doi] PST - ppublish SO - Eur Addict Res. 2021;27(4):257-262. doi: 10.1159/000515102. Epub 2021 Apr 9. PMID- 33825836 OWN - NLM STAT- MEDLINE DCOM- 20210420 LR - 20240331 IS - 2574-3805 (Electronic) IS - 2574-3805 (Linking) VI - 4 IP - 4 DP - 2021 Apr 1 TI - Association of Human Mobility Restrictions and Race/Ethnicity-Based, Sex-Based, and Income-Based Factors With Inequities in Well-being During the COVID-19 Pandemic in the United States. PG - e217373 LID - 10.1001/jamanetworkopen.2021.7373 [doi] LID - e217373 AB - IMPORTANCE: An accurate understanding of the distributional implications of public health policies is critical for ensuring equitable responses to the COVID-19 pandemic and future public health threats. OBJECTIVE: To identify and quantify the association of race/ethnicity-based, sex-based, and income-based inequities of state-specific lockdowns with 6 well-being dimensions in the United States. DESIGN, SETTING, AND PARTICIPANTS: This pooled, repeated cross-sectional study used data from 14 187 762 households who participated in phase 1 of the population-representative US 2020 Household Pulse Survey (HPS). Households were invited to participate by email, text message, and/or telephone as many as 3 times. Data were collected via an online questionnaire from April 23 to July 21, 2020, and participants lived in all 50 US states and the District of Columbia. EXPOSURES: Indicators of race/ethnicity, sex, and income and their intersections. MAIN OUTCOMES AND MEASURES: Unemployment; food insufficiency; mental health problems; no medical care received for health problems; default on last month's rent or mortgage; and class cancellations with no distance learning. Race/ethnicity, sex, income, and their intersections were used to measure distributional implications across historically marginalized populations; state-specific, time-varying population mobility was used to measure lockdown intensity. Logistic regression models with pooled repeated cross-sections were used to estimate risk of dichotomous outcomes by social group, adjusted for confounding variables. RESULTS: The 1 088 314 respondents (561 570 [51.6%; 95% CI, 51.4%-51.9%] women) were aged 18 to 88 years (mean [SD], 51.55 [15.74] years), and 826 039 (62.8%; 95% CI, 62.5%-63.1%) were non-Hispanic White individuals; 86 958 (12.5%; 95% CI, 12.4%-12.7%), African American individuals; 86 062 (15.2%; 95% CI, 15.0%-15.4%), Hispanic individuals; and 50 227 (5.6%; 95% CI, 5.5%-5.7%), Asian individuals. On average, every 10% reduction in mobility was associated with higher odds of unemployment (odds ratio [OR], 1.3; 95% CI, 1.2-1.4), food insufficiency (OR, 1.1; 95% CI, 1.1-1.2), mental health problems (OR, 1.04; 95% CI, 1.0-1.1), and class cancellations (OR, 1.1; 95% CI, 1.1-1.2). Across most dimensions compared with White men with high income, African American individuals with low income experienced the highest risks (eg, food insufficiency, men: OR, 3.3; 95% CI, 2.8-3.7; mental health problems, women: OR, 1.9; 95% CI, 1.8-2.1; medical care inaccessibility, women: OR, 1.7; 95% CI, 1.6-1.9; unemployment, men: OR, 2.8; 95% CI, 2.5-3.2; rent/mortgage defaults, men: OR, 5.7; 95% CI, 4.7-7.1). Other high-risk groups were Hispanic individuals (eg, unemployment, Hispanic men with low income: OR, 2.9; 95% CI, 2.5-3.4) and women with low income across all races/ethnicities (eg, medical care inaccessibility, non-Hispanic White women: OR, 1.8; 95% CI, 1.7-2.0). CONCLUSIONS AND RELEVANCE: In this cross-sectional study, African American and Hispanic individuals, women, and households with low income had higher odds of experiencing adverse outcomes associated with the COVID-19 pandemic and stay-at-home orders. Blanket public health policies ignoring existing distributions of risk to well-being may be associated with increased race/ethnicity-based, sex-based, and income-based inequities. FAU - Chakrabarti, Suman AU - Chakrabarti S AD - Department of Global Health, University of Washington Schools of Public Health and Medicine, Seattle. FAU - Hamlet, Leigh C AU - Hamlet LC AD - Department of Civil and Environmental Engineering, University of Washington College of Engineering, Seattle. FAU - Kaminsky, Jessica AU - Kaminsky J AD - Department of Civil and Environmental Engineering, University of Washington College of Engineering, Seattle. FAU - Subramanian, S V AU - Subramanian SV AD - Harvard Center for Population and Development Studies, Department of Social and Behavioral Sciences, Harvard T.H. Chan School of Public Health, Boston, Massachusetts. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20210401 PL - United States TA - JAMA Netw Open JT - JAMA network open JID - 101729235 SB - IM MH - Adolescent MH - Adult MH - Aged MH - Aged, 80 and over MH - *COVID-19 MH - Communicable Disease Control/*statistics & numerical data MH - Cross-Sectional Studies MH - Ethnicity/*statistics & numerical data MH - Family Characteristics MH - Female MH - Food Security/statistics & numerical data MH - Health Status Disparities MH - Humans MH - Income/*statistics & numerical data MH - Male MH - Middle Aged MH - Racial Groups/*statistics & numerical data MH - SARS-CoV-2 MH - *Sex Factors MH - Unemployment/statistics & numerical data MH - United States MH - Young Adult PMC - PMC8027913 COIS- Conflict of Interest Disclosures: None reported. EDAT- 2021/04/08 06:00 MHDA- 2021/04/21 06:00 PMCR- 2021/04/07 CRDT- 2021/04/07 12:24 PHST- 2021/04/07 12:24 [entrez] PHST- 2021/04/08 06:00 [pubmed] PHST- 2021/04/21 06:00 [medline] PHST- 2021/04/07 00:00 [pmc-release] AID - 2778200 [pii] AID - zoi210239 [pii] AID - 10.1001/jamanetworkopen.2021.7373 [doi] PST - epublish SO - JAMA Netw Open. 2021 Apr 1;4(4):e217373. doi: 10.1001/jamanetworkopen.2021.7373. PMID- 33825567 OWN - NLM STAT- MEDLINE DCOM- 20210514 LR - 20210525 IS - 1477-030X (Electronic) IS - 0269-2163 (Print) IS - 0269-2163 (Linking) VI - 35 IP - 5 DP - 2021 May TI - Dying in times of the coronavirus: An online survey among healthcare professionals about end-of-life care for patients dying with and without COVID-19 (the CO-LIVE study). PG - 830-842 LID - 10.1177/02692163211003778 [doi] AB - BACKGROUND: During the COVID-19 outbreak restricting measures may have affected the provision of good end-of-life care for patients with and without COVID-19. AIM: To describe characteristics of patients who died and the care they received, and to examine how patient characteristics, setting and visiting restrictions are related to provided care and evaluation of the dying process. DESIGN: An open observational online survey among healthcare professionals about their experience of end-of-life care that was provided to a patient with or without COVID-19 who died between March and July 2020. SETTING/PARTICIPANTS: Healthcare professionals (nurses, physicians and others) in the Netherlands from all settings: home (n = 163), hospital (n = 249), nursing home (n = 192), hospice (n = 89) or elsewhere (n = 68). RESULTS: Of patients reported on, 56% had COVID-19. Among these patients, 358 (84.4%) also had a serious chronic illness. Having COVID-19 was negatively, and having a serious chronic illness was positively associated with healthcare staff's favourable appreciation of end-of-life care. Often there had been visiting restrictions in the last 2 days of life (75.8%). This was negatively associated with appreciation of care at the end of life and the dying process. Finally, care at the end of life was less favourably appreciated in hospitals and especially nursing homes, and more favourably in home settings and especially hospices. CONCLUSIONS: Our study suggests that end-of-life care during the COVID-19 pandemic may be further optimised, especially in nursing homes and hospitals. Allowing at least some level of visits of relatives seems a key component. FAU - Onwuteaka-Philipsen, Bregje D AU - Onwuteaka-Philipsen BD AUID- ORCID: 0000-0002-9440-1248 AD - Department of Public and Occupational Health, Amsterdam Public Health Research Institute, Expertise Center for Palliative Care, Amsterdam UMC, VU University, Amsterdam, The Netherlands. FAU - Pasman, H Roeline W AU - Pasman HRW AD - Department of Public and Occupational Health, Amsterdam Public Health Research Institute, Expertise Center for Palliative Care, Amsterdam UMC, VU University, Amsterdam, The Netherlands. FAU - Korfage, Ida J AU - Korfage IJ AD - Department of Public Health, Erasmus MC University Medical Center, Rotterdam, The Netherlands. FAU - Witkamp, Erica AU - Witkamp E AD - Department of Public Health, Erasmus MC University Medical Center, Rotterdam, The Netherlands. AD - Research Center Innovations in Care, Rotterdam University of Applied Sciences, Rotterdam, The Netherlands. FAU - Zee, Masha AU - Zee M AD - Department of Public and Occupational Health, Amsterdam Public Health Research Institute, Expertise Center for Palliative Care, Amsterdam UMC, VU University, Amsterdam, The Netherlands. FAU - van Lent, Liza Gg AU - van Lent LG AUID- ORCID: 0000-0002-4979-3051 AD - Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands. FAU - Goossensen, Anne AU - Goossensen A AD - University of Humanistic Studies, Utrecht, The Netherlands. FAU - van der Heide, Agnes AU - van der Heide A AD - Department of Public Health, Erasmus MC University Medical Center, Rotterdam, The Netherlands. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20210407 PL - England TA - Palliat Med JT - Palliative medicine JID - 8704926 SB - IM MH - *COVID-19 MH - Delivery of Health Care MH - Humans MH - Netherlands MH - Pandemics MH - SARS-CoV-2 MH - *Terminal Care PMC - PMC8114455 OTO - NOTNLM OT - COVID-19 OT - end of life OT - palliative care OT - quality of care OT - quality of dying COIS- Declaration of conflicting interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. EDAT- 2021/04/08 06:00 MHDA- 2021/05/15 06:00 PMCR- 2021/05/12 CRDT- 2021/04/07 12:16 PHST- 2021/04/08 06:00 [pubmed] PHST- 2021/05/15 06:00 [medline] PHST- 2021/04/07 12:16 [entrez] PHST- 2021/05/12 00:00 [pmc-release] AID - 10.1177_02692163211003778 [pii] AID - 10.1177/02692163211003778 [doi] PST - ppublish SO - Palliat Med. 2021 May;35(5):830-842. doi: 10.1177/02692163211003778. Epub 2021 Apr 7. PMID- 33821083 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220731 IS - 1467-9701 (Electronic) IS - 0378-5920 (Print) IS - 0378-5920 (Linking) VI - 45 IP - 2 DP - 2022 Feb TI - COVID-19, public procurement regimes and trade policy. PG - 409-429 LID - 10.1111/twec.13118 [doi] AB - This paper analyses a prominent dimension of the initial policy response to the COVID-19 pandemic observed in many countries: the imposition of export restrictions and actions to facilitate imports. Using weekly data on the use of trade policy instruments during the first seven months of the COVID-19 pandemic (January-July, 2020), we assess the relationship between the use of trade policy instruments and attributes of pre-crisis public procurement regulation. Controlling for country size, government effectiveness and economic factors, we find that use of export restrictions targeting medical products is strongly positively correlated with the total number of steps and average time required to complete procurement processes in the pre-crisis period. Membership of trade agreements encompassing public procurement disciplines is associated with actions to facilitate trade in medical products. These findings suggest future empirical assessments of the drivers of trade policy during the pandemic should consider public procurement systems. CI - (c) 2021 John Wiley & Sons Ltd. FAU - Hoekman, Bernard AU - Hoekman B AUID- ORCID: 0000-0002-6839-7142 AD - Robert Schuman Centre for Advanced Studies European University Institute Florence Italy. AD - CEPR London UK. FAU - Shingal, Anirudh AU - Shingal A AUID- ORCID: 0000-0001-8007-7531 AD - Robert Schuman Centre for Advanced Studies European University Institute Florence Italy. AD - S.P. Jain Institute of Management & Research, Mumbai, India and Robert Schuman Centre for Advanced Studies European University Institute Florence Italy. FAU - Eknath, Varun AU - Eknath V AD - World Bank Group Washington DC USA. FAU - Ereshchenko, Viktoriya AU - Ereshchenko V AD - World Bank Group Washington DC USA. LA - eng PT - Journal Article DEP - 20210306 PL - England TA - World Econ JT - The World economy JID - 101742003 PMC - PMC8013529 OTO - NOTNLM OT - COVID-19 OT - export controls OT - public procurement OT - trade agreements OT - trade facilitation OT - trade policy EDAT- 2021/04/07 06:00 MHDA- 2021/04/07 06:01 PMCR- 2021/03/06 CRDT- 2021/04/06 05:51 PHST- 2020/11/12 00:00 [received] PHST- 2021/02/13 00:00 [revised] PHST- 2021/02/15 00:00 [accepted] PHST- 2021/04/07 06:00 [pubmed] PHST- 2021/04/07 06:01 [medline] PHST- 2021/04/06 05:51 [entrez] PHST- 2021/03/06 00:00 [pmc-release] AID - TWEC13118 [pii] AID - 10.1111/twec.13118 [doi] PST - ppublish SO - World Econ. 2022 Feb;45(2):409-429. doi: 10.1111/twec.13118. Epub 2021 Mar 6. PMID- 33816420 OWN - NLM STAT- MEDLINE DCOM- 20210528 LR - 20250130 IS - 2296-2565 (Electronic) IS - 2296-2565 (Linking) VI - 9 DP - 2021 TI - Physician-Patient Language Discordance and Poor Health Outcomes: A Systematic Scoping Review. PG - 629041 LID - 10.3389/fpubh.2021.629041 [doi] LID - 629041 AB - Objective: This systematic review assessed whether physician-patient language concordance, compared with discordance, is associated with better health outcomes. Methods: A systematic literature search was conducted, without language restrictions, using PubMed, EMBASE, Web of Science, and PsycINFO, from inception to July 2020. We included studies that evaluated the effects of physician-patient language concordance on health outcomes. Articles were screened, selected, and data-extracted in duplicate. Review protocol was prospectively registered (PROSPERO, CRD42020157229). Results: There were 541 citations identified through databases and eight citations through reverse search and Google Scholar. A total of 15 articles (84,750 participants) were included reporting outcomes within five domains: diabetes care (four studies), inpatient care (five studies), cancer screening (three studies), healthcare counseling (two studies), and mental health care (one study). Ten studies were of good quality, four were fair, and one was poor, according to the modified Newcastle-Ottawa Scale. Eight studies (53%) showed a significant negative association between language discordance and at least one clinical outcome. Five studies (33%) found no association. Conclusion: Over half the evidence collated showed that physician-patient language concordance was associated with better health clinical outcomes. CI - Copyright (c) 2021 Cano-Ibanez, Zolfaghari, Amezcua-Prieto and Khan. FAU - Cano-Ibanez, Naomi AU - Cano-Ibanez N AD - Department of Preventive Medicine and Public Health, Faculty of Medicine, University of Granada, Granada, Spain. AD - Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Granada, Spain. AD - Instituto de Investigacion Biosanitaria ibs. GRANADA, Granada, Spain. FAU - Zolfaghari, Yasmin AU - Zolfaghari Y AD - Women's Health Research Unit, Barts and the London School of Medicine and Dentistry, London, United Kingdom. FAU - Amezcua-Prieto, Carmen AU - Amezcua-Prieto C AD - Department of Preventive Medicine and Public Health, Faculty of Medicine, University of Granada, Granada, Spain. AD - Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Granada, Spain. AD - Instituto de Investigacion Biosanitaria ibs. GRANADA, Granada, Spain. FAU - Khan, Khalid Saeed AU - Khan KS AD - Department of Preventive Medicine and Public Health, Faculty of Medicine, University of Granada, Granada, Spain. AD - Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Granada, Spain. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Scoping Review DEP - 20210319 PL - Switzerland TA - Front Public Health JT - Frontiers in public health JID - 101616579 SB - IM MH - Data Management MH - Humans MH - *Language MH - Physician-Patient Relations MH - *Physicians PMC - PMC8017287 OTO - NOTNLM OT - health outcomes OT - language concordance OT - migrants OT - patient OT - physician COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2021/04/06 06:00 MHDA- 2021/05/29 06:00 PMCR- 2021/03/19 CRDT- 2021/04/05 06:09 PHST- 2020/11/25 00:00 [received] PHST- 2021/02/08 00:00 [accepted] PHST- 2021/04/05 06:09 [entrez] PHST- 2021/04/06 06:00 [pubmed] PHST- 2021/05/29 06:00 [medline] PHST- 2021/03/19 00:00 [pmc-release] AID - 10.3389/fpubh.2021.629041 [doi] PST - epublish SO - Front Public Health. 2021 Mar 19;9:629041. doi: 10.3389/fpubh.2021.629041. eCollection 2021. PMID- 33810875 OWN - NLM STAT- MEDLINE DCOM- 20210804 LR - 20210804 IS - 1872-6054 (Electronic) IS - 0168-8510 (Linking) VI - 125 IP - 5 DP - 2021 May TI - Consumer directed care aged care reforms in Australia since 2009: A retrospective policy analysis. PG - 577-581 LID - S0168-8510(21)00084-1 [pii] LID - 10.1016/j.healthpol.2021.03.012 [doi] AB - In 2009, the Australian federal government used the projected rise in aged care expenditure and changing societal attitudes to justify the decision to overhaul the funding for aged healthcare services. A major feature of the reforms was the introduction of a consumer directed care (CDC) model. This followed the UK, Sweden, Canada and the USA who had already implemented CDC to some degree. The CDC model transferred aged care decisions from providers to consumers. This promised to create a competitive market system, resulting in decreased costs, increased quality and increased consumer satisfaction of aged healthcare services. Advocacy services were also reformed to address market failures. These changes were achieved by engaging key actors throughout the policy cycle, giving perceived legitimacy and transparency; and commissioning reviews with restricted scope and at calculated times, limiting their ability to produce negative criticism. In July 2018, the federal government gained full funding and responsibility for aged care with the support of key stakeholders and multiple reviews, yet with little objective data on the benefit of the reforms. This analysis highlights the power of the policymaking process in creating policies. CI - Copyright (c) 2021 Elsevier B.V. All rights reserved. FAU - Moore, Corey B AU - Moore CB AD - School of Public Health and Community Medicine, University of New South Wales, Sydney, NSW, Australia. Electronic address: coreybmoore@hotmail.com. LA - eng PT - Journal Article DEP - 20210325 PL - Ireland TA - Health Policy JT - Health policy (Amsterdam, Netherlands) JID - 8409431 MH - Aged MH - Australia MH - Canada MH - Humans MH - *Policy Making MH - Retrospective Studies MH - Sweden OTO - NOTNLM OT - Aged people OT - Australia OT - Consumer Directed Car OT - Healthcare OT - Policy analysis triangle COIS- Declaration of Competing Interest I have no conflict of interest to disclose. EDAT- 2021/04/04 06:00 MHDA- 2021/08/05 06:00 CRDT- 2021/04/03 05:27 PHST- 2019/09/23 00:00 [received] PHST- 2020/11/07 00:00 [revised] PHST- 2021/03/05 00:00 [accepted] PHST- 2021/04/04 06:00 [pubmed] PHST- 2021/08/05 06:00 [medline] PHST- 2021/04/03 05:27 [entrez] AID - S0168-8510(21)00084-1 [pii] AID - 10.1016/j.healthpol.2021.03.012 [doi] PST - ppublish SO - Health Policy. 2021 May;125(5):577-581. doi: 10.1016/j.healthpol.2021.03.012. Epub 2021 Mar 25. PMID- 33809221 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20210413 IS - 2227-9067 (Print) IS - 2227-9067 (Electronic) IS - 2227-9067 (Linking) VI - 8 IP - 3 DP - 2021 Mar 12 TI - "You Can't Go to the Park, You Can't Go Here, You Can't Go There": Exploring Parental Experiences of COVID-19 and Its Impact on Their Children's Movement Behaviours. LID - 10.3390/children8030219 [doi] LID - 219 AB - The COVID-19 outbreak and related public health guidelines have changed the daily lives of Canadians and restricted opportunities for healthy movement behaviours for children. The purpose of this study was to explore how parents experienced the pandemic-related restrictions and how they impacted their children's movement behaviours. Methods: Twenty-nine semi-structured one-on-one interviews were conducted (June-July 2020) with parents of children (5-11 years old) in Ontario and British Columbia. Interviews lasted between 24-104 min, were audio-recorded, transcribed verbatim, and thematically analyzed. Results: Findings emphasized various individual (e.g., motivation), interpersonal (e.g., parent work schedule), built (e.g., closure of parks) and natural environment (e.g., weather) factors related to children's movement behaviours. The findings highlighted the loss of structured activities and destinations for children's physical activity, and restricted opportunities for outdoor play exacerbated by shrinking childhood independent mobility. Conclusion: Families are adapting to many pandemic-related challenges including adhering to public health restrictions, parents juggling multiple roles, conducting work and school from home, as well as exacerbating factors like weather. It will be important to continue to encourage outdoor time, support policies and practice that facilitate independent mobility, and develop centralized resources that help families in the maintenance of healthy movement behaviours. FAU - Riazi, Negin A AU - Riazi NA AUID- ORCID: 0000-0002-0674-177X AD - School of Kinesiology, The University of British Columbia, 210-6081 University Boulevard, Vancouver, BC V6T 1Z1, Canada. FAU - Wunderlich, Kelly AU - Wunderlich K AD - School of Kinesiology, The University of British Columbia, 210-6081 University Boulevard, Vancouver, BC V6T 1Z1, Canada. FAU - Gierc, Madelaine AU - Gierc M AD - School of Kinesiology, The University of British Columbia, 210-6081 University Boulevard, Vancouver, BC V6T 1Z1, Canada. FAU - Brussoni, Mariana AU - Brussoni M AUID- ORCID: 0000-0002-1495-816X AD - Department of Pediatrics, The University of British Columbia, Rm 2D19, 4480 Oak Street, Vancouver, BC V6H 3V4, Canada. FAU - Moore, Sarah A AU - Moore SA AD - School of Health and Human Performance, Dalhousie University, Stairs House, 6230 South Street, Halifax, NS B3H 1T8, Canada. FAU - Tremblay, Mark S AU - Tremblay MS AD - Healthy Active Living and Obesity Research Group, Children's Hospital of Eastern Ontario Research Institute, 401 Smyth Road, Research Building 1, Ottawa, ON K1H 8L1, Canada. FAU - Faulkner, Guy AU - Faulkner G AUID- ORCID: 0000-0001-8898-2536 AD - School of Kinesiology, The University of British Columbia, 210-6081 University Boulevard, Vancouver, BC V6T 1Z1, Canada. LA - eng GR - University of British Columbia/ PT - Journal Article DEP - 20210312 PL - Switzerland TA - Children (Basel) JT - Children (Basel, Switzerland) JID - 101648936 PMC - PMC8000735 OTO - NOTNLM OT - interview OT - outdoor play OT - physical activity OT - qualitative OT - screen time COIS- The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results. EDAT- 2021/04/04 06:00 MHDA- 2021/04/04 06:01 PMCR- 2021/03/12 CRDT- 2021/04/03 01:32 PHST- 2021/01/31 00:00 [received] PHST- 2021/03/10 00:00 [revised] PHST- 2021/03/11 00:00 [accepted] PHST- 2021/04/03 01:32 [entrez] PHST- 2021/04/04 06:00 [pubmed] PHST- 2021/04/04 06:01 [medline] PHST- 2021/03/12 00:00 [pmc-release] AID - children8030219 [pii] AID - children-08-00219 [pii] AID - 10.3390/children8030219 [doi] PST - epublish SO - Children (Basel). 2021 Mar 12;8(3):219. doi: 10.3390/children8030219. PMID- 33807607 OWN - NLM STAT- MEDLINE DCOM- 20210412 LR - 20260127 IS - 1648-9144 (Electronic) IS - 1010-660X (Print) IS - 1010-660X (Linking) VI - 57 IP - 3 DP - 2021 Mar 5 TI - SARS-CoV-2 in Pregnancy-The First Wave. LID - 10.3390/medicina57030241 [doi] LID - 241 AB - Background and Objectives: COVID-19, a disease caused by SARS-CoV-2, is a public health emergency. Data on the effect of the virus on pregnancy are limited. Materials and Methods: We carried out a retrospective descriptive study, in order to evaluate the obstetric results on pregnant women in which SARS-CoV-2 was detected through RT-PCR of the nasopharyngeal swab, at admission to the maternity hospital. Results: From 16 March to 31 July 2020, 12 SARS-CoV-2 positive pregnant women have been hospitalized. Eleven were hospitalized for initiation or induction of labor, corresponding to 0.64% of deliveries in the maternity hospital. One pregnant woman was hospitalized for threatened abortion, culminating in a stillbirth at 20 weeks of gestation. Regarding the severity of the disease, nine women were asymptomatic and three had mild illness (two had associated cough and one headache). Three had relevant environmental exposure and a history of contact with infected persons. None had severe or critical illness due to SARS-CoV-2. There were no maternal deaths. The following gestational complications were observed: one stillbirth, one preterm labor, one preterm prelabor rupture of membranes, and one fetal growth restriction. Four deliveries were eutocic, two vacuum-assisted deliveries and five were cesarean sections. The indications for cesarean section were obstetric. Conclusions: SARS-CoV-2 infection was found in a minority of hospitalized pregnant women in this sample. Most are asymptomatic or have mild illness, from gestational complications to highlight stillbirth and preterm birth. There were no cases of vertical transmission by coronavirus. FAU - de Vasconcelos Gaspar, Andreia AU - de Vasconcelos Gaspar A AUID- ORCID: 0000-0003-3071-1236 AD - Bissaya Barreto Maternity-Obstetrics Service B, Coimbra Hospital and University Center, 3000 Coimbra, Portugal. FAU - Santos Silva, Isabel AU - Santos Silva I AD - Bissaya Barreto Maternity-Obstetrics Service B, Coimbra Hospital and University Center, 3000 Coimbra, Portugal. LA - eng PT - Journal Article DEP - 20210305 PL - Switzerland TA - Medicina (Kaunas) JT - Medicina (Kaunas, Lithuania) JID - 9425208 SB - IM MH - Adult MH - COVID-19/*epidemiology/physiopathology MH - Cesarean Section MH - Cough/physiopathology MH - Female MH - Fetal Growth Retardation/epidemiology MH - Premature Rupture of Fetal Membranes/epidemiology MH - Headache/physiopathology MH - Hospitalization MH - Hospitals, Maternity MH - Humans MH - Labor, Induced MH - Obstetric Labor, Premature/epidemiology MH - Portugal/epidemiology MH - Postpartum Hemorrhage/epidemiology MH - Pregnancy MH - Pregnancy Complications, Infectious/*epidemiology MH - Pregnancy Outcome MH - Premature Birth/epidemiology MH - Retrospective Studies MH - SARS-CoV-2 MH - Severity of Illness Index MH - Stillbirth/epidemiology MH - Vacuum Extraction, Obstetrical PMC - PMC7999825 OTO - NOTNLM OT - SARS virus OT - coronavirus infections OT - infectious OT - pregnancy OT - pregnancy complications OT - pregnancy outcome COIS- The authors declare no conflict of interest. EDAT- 2021/04/04 06:00 MHDA- 2021/04/13 06:00 PMCR- 2021/03/05 CRDT- 2021/04/03 01:27 PHST- 2020/12/15 00:00 [received] PHST- 2021/02/24 00:00 [revised] PHST- 2021/03/02 00:00 [accepted] PHST- 2021/04/03 01:27 [entrez] PHST- 2021/04/04 06:00 [pubmed] PHST- 2021/04/13 06:00 [medline] PHST- 2021/03/05 00:00 [pmc-release] AID - medicina57030241 [pii] AID - medicina-57-00241 [pii] AID - 10.3390/medicina57030241 [doi] PST - epublish SO - Medicina (Kaunas). 2021 Mar 5;57(3):241. doi: 10.3390/medicina57030241. PMID- 33799698 OWN - NLM STAT- MEDLINE DCOM- 20210408 LR - 20210408 IS - 1660-4601 (Electronic) IS - 1661-7827 (Print) IS - 1660-4601 (Linking) VI - 18 IP - 6 DP - 2021 Mar 11 TI - Experience of the COVID-19 Pandemic in Rural Odisha, India: Knowledge, Preventative Actions, and Impacts on Daily Life. LID - 10.3390/ijerph18062863 [doi] LID - 2863 AB - We conducted 131 semi-structured phone interviews with householders in rural Odisha, India to explore participants' COVID-19 related knowledge, perceptions, and preventative actions, as well as how the pandemic affected their daily life, economic and food security, and the village-level response. Interviews were conducted with 73 heads of household, 37 primary caregivers, and 21 members of village water and sanitation committees from 43 rural villages in Ganjam and Gajapati districts in Odisha state. The study took place between May-July 2020 throughout various lockdown restrictions and at a time when many migrant workers were returning to their villages and cases were rising. Most respondents could name at least one correct symptom of COVID-19 (75%), but there was lower knowledge about causes of the disease and high-risk groups, and overall COVID-19 knowledge was lowest among caregivers. Respondents reported high compliance with important preventative measures, including staying home as much as possible (94%), social distancing (91%), washing hands frequently (96%), and wearing a facial mask (95%). Additionally, many respondents reported job loss (31%), financial challenges (93%), challenges related to staying home whether as a preventative measure or due to lockdowns (57%), changes in types and/or amount of food consumed (61%), and adverse emotional effects as a result of the pandemic and lockdown. We also provide detailed summaries of qualitative responses to allow for deeper insights into the lived experience of villagers during this pandemic. Although the research revealed high compliance with preventative measures, the pandemic and associated lockdowns also led to many challenges and hardships faced in daily life particularly around job loss, economic security, food security, and emotional wellbeing. The results underscore the vulnerability of marginalized populations to the pandemic and the need for measures that increase resilience to large-scale shocks. FAU - Bauza, Valerie AU - Bauza V AUID- ORCID: 0000-0003-1919-0767 AD - Department of Environmental Health, Rollins School of Public Health, Emory University, Atlanta, GA 30322, USA. FAU - Sclar, Gloria D AU - Sclar GD AUID- ORCID: 0000-0002-5996-167X AD - Department of Environmental Health, Rollins School of Public Health, Emory University, Atlanta, GA 30322, USA. AD - Department of Psychology, University of Zurich, 8006 Zurich, Switzerland. FAU - Bisoyi, Alokananda AU - Bisoyi A AD - Independent Consultant, Berhampur, Odisha 760001, India. FAU - Owens, Ajile AU - Owens A AD - Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA 30322, USA. FAU - Ghugey, Apurva AU - Ghugey A AD - Gram Vikas, Bhubaneswar, Odisha 751009, India. FAU - Clasen, Thomas AU - Clasen T AUID- ORCID: 0000-0003-4062-5788 AD - Department of Environmental Health, Rollins School of Public Health, Emory University, Atlanta, GA 30322, USA. LA - eng GR - OPP1125067/Bill and Melinda Gates Foundation/ GR - T32ES012870/ES/NIEHS NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20210311 PL - Switzerland TA - Int J Environ Res Public Health JT - International journal of environmental research and public health JID - 101238455 SB - IM MH - *COVID-19 MH - Communicable Disease Control MH - Humans MH - India/epidemiology MH - *Pandemics/prevention & control MH - SARS-CoV-2 PMC - PMC7998707 OTO - NOTNLM OT - COVID-19 OT - SARS-CoV-2 OT - crisis response OT - novel coronavirus OT - pandemic COIS- The authors declare no conflict of Interest. EDAT- 2021/04/04 06:00 MHDA- 2021/04/10 06:00 PMCR- 2021/03/11 CRDT- 2021/04/03 01:03 PHST- 2021/01/15 00:00 [received] PHST- 2021/02/26 00:00 [revised] PHST- 2021/03/05 00:00 [accepted] PHST- 2021/04/03 01:03 [entrez] PHST- 2021/04/04 06:00 [pubmed] PHST- 2021/04/10 06:00 [medline] PHST- 2021/03/11 00:00 [pmc-release] AID - ijerph18062863 [pii] AID - ijerph-18-02863 [pii] AID - 10.3390/ijerph18062863 [doi] PST - epublish SO - Int J Environ Res Public Health. 2021 Mar 11;18(6):2863. doi: 10.3390/ijerph18062863. PMID- 33778914 OWN - NLM STAT- MEDLINE DCOM- 20210614 LR - 20250130 IS - 1433-9285 (Electronic) IS - 0933-7954 (Print) IS - 0933-7954 (Linking) VI - 56 IP - 6 DP - 2021 Jun TI - Interventions to increase migrants' care-seeking behaviour for stigmatised conditions: a scoping review. PG - 913-930 LID - 10.1007/s00127-021-02065-1 [doi] AB - BACKGROUND: Despite availability of effective treatments, migrants in high-income countries seek care for conditions associated with stigma to a lower extent than the rest of the population. We conducted a scoping review to map the literature on interventions to increase migrants' care-seeking behaviour in high-income countries for stigmatised conditions. Main body of the abstract: We searched 15 electronic databases and journals, hand-searched references and citations, to identify studies on interventions to increase migrants' care-seeking in high-income countries for stigmatised conditions. We applied language restrictions for English and Swedish, and searched the full time period up to 5 July 2019. Our primary outcome of interest was care utilisation. RESULTS: 5447 records were identified in the literature searches. We identified 16 eligible studies, all from North America, that reported interventions to increase migrants' care-seeking behaviour for hepatitis B (n = 1) and mental health (n = 15). Three approaches were identified: health communication (n = 10), support groups (n = 2), and primary care-based approaches (n = 4). There was a general trend towards community-based interventions tailored to individual migrant groups. Significant gaps were identified in the literature, including studies conducted in Europe and studies including men or children. Furthermore, the choice of study designs introduced significant bias that prevented accurate conclusions on intervention effectiveness. CONCLUSION: The available evidence on interventions to increase migrants' in high-income countries care-seeking behaviour for stigmatised conditions is limited in scope and quality. Future research, using reliable study designs, is needed to fill the remaining gaps and to boost the scope and reliability of the evidence. FAU - Place, Vanessa AU - Place V AD - Karolinska Institutet, Stockholm, Sweden. FAU - Nabb, Benjamin AU - Nabb B AD - Karolinska Institutet, Stockholm, Sweden. FAU - Viksten Assel, Karima AU - Viksten Assel K AD - Karolinska Institutet, Stockholm, Sweden. AD - Transkulturellt Centrum, Stockholm, Sweden. FAU - Baarnhielm, Sofie AU - Baarnhielm S AD - Karolinska Institutet, Stockholm, Sweden. AD - Transkulturellt Centrum, Stockholm, Sweden. FAU - Dalman, Christina AU - Dalman C AD - Karolinska Institutet, Stockholm, Sweden. AD - Centre for Epidemiology and Community Medicine, Stockholm, Sweden. FAU - Hollander, Anna-Clara AU - Hollander AC AUID- ORCID: 0000-0002-1246-5804 AD - Karolinska Institutet, Stockholm, Sweden. anna-clara.hollander@ki.se. AD - Research Group Epidemiology of Psychiatric Conditions, Substance Use and Social Environment (EPICSS), Department of Public Health Sciences, Karolinska Institutet, Solnavagen 1E, SE-171 77, Stockholm, Sweden. anna-clara.hollander@ki.se. LA - eng GR - 2018-05763/Vetenskapsradet/ GR - Forte 2016-00870/Forskningsradet om Halsa, Arbetsliv och Valfard/ PT - Journal Article PT - Scoping Review DEP - 20210329 PL - Germany TA - Soc Psychiatry Psychiatr Epidemiol JT - Social psychiatry and psychiatric epidemiology JID - 8804358 SB - IM MH - Child MH - Europe MH - Humans MH - Male MH - Mental Health MH - Patient Acceptance of Health Care MH - Reproducibility of Results MH - *Transients and Migrants PMC - PMC8192321 OTO - NOTNLM OT - Care-seeking OT - HIV OT - Hepatitis OT - High-income countries OT - Interventions to increase care-seeking behaviour OT - Mental health OT - Migrants OT - Scoping review OT - Stigma OT - TB COIS- The authors declare that they have no conflict of interest. EDAT- 2021/03/30 06:00 MHDA- 2021/06/16 06:00 PMCR- 2021/03/29 CRDT- 2021/03/29 06:50 PHST- 2020/08/21 00:00 [received] PHST- 2021/03/10 00:00 [accepted] PHST- 2021/03/30 06:00 [pubmed] PHST- 2021/06/16 06:00 [medline] PHST- 2021/03/29 06:50 [entrez] PHST- 2021/03/29 00:00 [pmc-release] AID - 10.1007/s00127-021-02065-1 [pii] AID - 2065 [pii] AID - 10.1007/s00127-021-02065-1 [doi] PST - ppublish SO - Soc Psychiatry Psychiatr Epidemiol. 2021 Jun;56(6):913-930. doi: 10.1007/s00127-021-02065-1. Epub 2021 Mar 29. PMID- 33764197 OWN - NLM STAT- MEDLINE DCOM- 20211224 LR - 20240404 IS - 1477-0970 (Electronic) IS - 1352-4585 (Print) IS - 1352-4585 (Linking) VI - 28 IP - 1 DP - 2022 Jan TI - Impact of COVID-19 on multiple sclerosis care and management: Results from the European Committee for Treatment and Research in Multiple Sclerosis survey. PG - 132-138 LID - 10.1177/13524585211005339 [doi] AB - BACKGROUND: The spread of Coronavirus disease-19 (COVID-19) poses unique challenges in the management of people with multiple sclerosis (PwMS). OBJECTIVES: To collect data about the impact of COVID-19 emergency on access to care for PwMS and on MS treatment practices. METHODS: Between March and July 2020, the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) promoted an online survey covering patient access to care, management of relapses and visits, disease-modifying therapy (DMT) and experience with COVID-19. RESULTS: Three-hundred and sixty neurologists from 52 countries (68% from Europe) completed the survey. 98% reported COVID-19-related restrictions. Telemedicine was adopted to overcome the limited access to care and was newly activated (73%) or widely implemented (17%). 70% reported changes in DMT management. Interferons and glatiramer were considered safe. Dimethyl fumarate, teriflunomide and fingolimod were considered safe except for patients developing lymphopenia. No modifications were considered for natalizumab in 64%, cladribine in 24%, anti-CD20 in 22% and alemtuzumab in 17%; 18% (for alemtuzumab and cladribine) and 43% (for anti-CD20) considered postponing treatment. CONCLUSION: The ECTRIMS survey highlighted the challenges in keeping standards of care in clinical practice. Telemedicine clearly needs to be implemented. Gathering data on DMT safety will remain crucial to inform treatment decisions. FAU - Portaccio, Emilio AU - Portaccio E AD - University Hospital Careggi, Florence, Italy. FAU - Fonderico, Mattia AU - Fonderico M AUID- ORCID: 0000-0002-1716-5579 AD - Department of Neurofarba, University of Florence, Florence, Italy. FAU - Hemmer, Bernhard AU - Hemmer B AUID- ORCID: 0000-0001-5985-6784 AD - Neurology Department, Klinikum rechts der Isar TU Munchen, Munich, Germany/Munich Cluster of Systems Neurology (SyNergy), Munich, Germany. FAU - Derfuss, Tobias AU - Derfuss T AUID- ORCID: 0000-0001-8431-8769 AD - Departments of Neurology and Biomedicine, University Hospital of Basel, Basel, Switzerland. FAU - Stankoff, Bruno AU - Stankoff B AD - Department of Neurology, ICM, Hopital Pitie Salpetriere, Paris, France. FAU - Selmaj, Krzysztof AU - Selmaj K AD - Department of Neurology, University of Warmia and Mazury in Olsztyn, Olsztyn, Poland. FAU - Tintore, Mar AU - Tintore M AUID- ORCID: 0000-0001-9999-5359 AD - Department of the Neurology/Neuroimmunology and Research Institute Barcelona, Multiple Sclerosis Centre of Catalonia (Cemcat), Barcelona, Spain. FAU - Amato, Maria Pia AU - Amato MP AD - Department of Neurofarba, University of Florence, Florence, Italy/IRCCS Fondazione Don Carlo Gnocchi, Florence, Italy. LA - eng PT - Journal Article DEP - 20210325 PL - England TA - Mult Scler JT - Multiple sclerosis (Houndmills, Basingstoke, England) JID - 9509185 RN - 0 (Immunosuppressive Agents) RN - G926EC510T (Fingolimod Hydrochloride) SB - IM MH - *COVID-19 MH - Fingolimod Hydrochloride/therapeutic use MH - Humans MH - Immunosuppressive Agents MH - *Multiple Sclerosis/drug therapy MH - *Multiple Sclerosis, Relapsing-Remitting MH - SARS-CoV-2 PMC - PMC8689421 OTO - NOTNLM OT - Coronavirus disease-19 OT - Multiple sclerosis OT - access to care OT - disease-modifying treatment OT - telemedicine COIS- Declaration of Conflicting Interests: The author(s) declared the following potential conflicts of interest with respect to the research, authorship and/or publication of this article: E.P. received compensation for travel grants, participation in advisory board and/or speaking activities from Biogen, Merck Serono, Sanofi, Teva and Novartis; serves on the editorial board of Frontiers in Neurology. M.F. has no conflicts of interest. B.H. has served on scientific advisory boards for Novartis; he has served as DMSC member for AllergyCare, Polpharma and TG therapeutics; he or his institution have received speaker honoraria from Desitin and his institution received research grants from Regeneron for MS research. He holds part of two patents: one for the detection of antibodies against KIR4.1 in a subpopulation of patients with MS and one for genetic determinants of neutralising antibodies to interferon. T.D. serves on scientific advisory boards for Novartis, Merck, Biogen, Genzyme, GeNeuro, Mitsubishi Pharma, Actelion, Roche, Alexion and Celgene; has received funding for travel and/or speaker honoraria from Biogen, Genzyme, Novartis, Merck and Roche, and received research support from Biogen, Novartis, Roche, the European Union, the Swiss National Science Foundation and the Swiss MS Society. B.S. reports grants and personal fees from Roche, Sanofi Genzyme and Merck Serono, and personal fees from Novartis, Biogen and Teva, outside the submitted work. K.S. received honoraria for speaking, consulting and serving for advisory boards for Merck, Novartis, Roche, Biogen, Celgene and TG therapeutics. M.T. has received compensation for consulting services and speaking honoraria from Almirall, Bayer Schering Pharma, Biogen Idec, Genzyme, Merck Serono, Novartis, Roche, Sanofi-Aventis Viela-Bio and Teva Pharmaceuticals. She is co-editor of Multiple Sclerosis Journal - Experimental, Translational and Clinical. M.P.A. received compensation for consulting services and/or speaking activities from Bayer, Biogen Idec, Merck Serono, Novartis, Roche, Sanofi Genzyme and Teva Pharmaceutical Industries and received research support from Biogen Idec, Merck Serono, Roche, Pharmaceutical Industries and Fondazione Italiana Sclerosi Multipla. All conflicts are not relevant to the topic of the study. EDAT- 2021/03/26 06:00 MHDA- 2021/12/25 06:00 PMCR- 2021/12/21 CRDT- 2021/03/25 12:22 PHST- 2021/03/26 06:00 [pubmed] PHST- 2021/12/25 06:00 [medline] PHST- 2021/03/25 12:22 [entrez] PHST- 2021/12/21 00:00 [pmc-release] AID - 10.1177_13524585211005339 [pii] AID - 10.1177/13524585211005339 [doi] PST - ppublish SO - Mult Scler. 2022 Jan;28(1):132-138. doi: 10.1177/13524585211005339. Epub 2021 Mar 25. PMID- 33760882 OWN - NLM STAT- MEDLINE DCOM- 20210421 LR - 20210421 IS - 1932-6203 (Electronic) IS - 1932-6203 (Linking) VI - 16 IP - 3 DP - 2021 TI - Use of face masks to limit the spread of the COVID-19 among western Ugandans: Knowledge, attitude and practices. PG - e0248706 LID - 10.1371/journal.pone.0248706 [doi] LID - e0248706 AB - BACKGROUND: The world is grappling with an ever-changing COVID-19 pandemic using preventive measures such as personal hygiene, face masks, restrictions on travel and gatherings in communities, in addition to a race to find a vaccine. The purpose of this study was to evaluate the knowledge, attitudes and practices of the western Uganda community on the proper use of face masks to mitigate the spread of COVID-19. METHODS: A cross-sectional study using a structured questionnaire was carried out from 1st July to 10th July 2020 among western Ugandans of consent age of 18 years and above. Data was analysed using Stata version 14.2. RESULTS: Among the respondents (n = 1114), the mean age was 30.7 (SD 11.1), 51% were males, 53.9% married and 43% had attained secondary education. Most participants (60.1%, n = 670) had satisfactory knowledge on the use of face masks and participants at a tertiary education level [AOR 2.6 (95% CI: 1.42-4.67; p = 0.002)] were likely to have satisfactory knowledge than participants who had not education. On attitude, most respondents (69.4%) were confident enough to correctly put on a face mask; 83.4% believed that a face mask can protect against COVID-19 and 75.9% of respondents had never shared their face mask. The majority of respondents (95.2%) agreed wearing face masks in public places was important to protect themselves against COVID-19; 60.3% reported washing their hands before wearing and after removing the face mask. Unfortunately, 51.5% reported removing the face mask if they needed to talk to someone. CONCLUSION: Despite the satisfactory knowledge, good attitude and practices, there is still much more to be done in terms of knowledge, attitude and practices among participants. Government, non-governmental organizations and civil society should improve sensitization of populations on how to behave with face masks while talking to avoid the spread of the COVID-19 among western Ugandans. FAU - Sikakulya, Franck Katembo AU - Sikakulya FK AUID- ORCID: 0000-0001-8101-273X AD - Faculty of Clinical Medicine and Dentistry, Department of Surgery, Kampala International University Western Campus, Ishaka-Bushenyi, Uganda. AD - Faculty of Medicine, Universite Catholique du Graben, Butembo, Democratic Republic of the Congo. FAU - Ssebuufu, Robinson AU - Ssebuufu R AUID- ORCID: 0000-0003-2053-1696 AD - Faculty of Clinical Medicine and Dentistry, Department of Surgery, Kampala International University Western Campus, Ishaka-Bushenyi, Uganda. FAU - Mambo, Simon Binezero AU - Mambo SB AD - Youth Alliance for Reproductive Health, Goma, Democratic Republic of the Congo. FAU - Pius, Theophilus AU - Pius T AD - Department of Medical Laboratory Sciences, Kampala International University Western Campus, Ishaka-Bushenyi, Uganda. FAU - Kabanyoro, Annet AU - Kabanyoro A AD - School of Nursing Sciences, Kampala International University Western Campus, Ishaka-Bushenyi, Uganda. FAU - Kamahoro, Elizabeth AU - Kamahoro E AD - School of Nursing Sciences, Kampala International University Western Campus, Ishaka-Bushenyi, Uganda. FAU - Mulumba, Yusuf AU - Mulumba Y AUID- ORCID: 0000-0002-3456-8919 AD - Biostatistics, Cancer Institute, Makerere University, Kampala, Uganda. FAU - Muhongya, Jean Kakule AU - Muhongya JK AD - Allied Health Sciences Department, Kampala International University Western Campus, Ishaka-Bushenyi, Uganda. FAU - Kyamanywa, Patrick AU - Kyamanywa P AD - Faculty of Clinical Medicine and Dentistry, Department of Surgery, Kampala International University Western Campus, Ishaka-Bushenyi, Uganda. LA - eng PT - Journal Article DEP - 20210324 PL - United States TA - PLoS One JT - PloS one JID - 101285081 SB - IM MH - Adolescent MH - Adult MH - Aged MH - Aged, 80 and over MH - COVID-19/*prevention & control/transmission MH - Cross-Sectional Studies MH - Female MH - Health Knowledge, Attitudes, Practice/ethnology MH - Humans MH - Knowledge MH - Male MH - Masks/*statistics & numerical data/*trends/virology MH - Middle Aged MH - Pandemics/prevention & control MH - SARS-CoV-2/pathogenicity MH - Surveys and Questionnaires MH - Uganda/epidemiology PMC - PMC7990295 COIS- The authors have declared that no competing interests exist. EDAT- 2021/03/25 06:00 MHDA- 2021/04/22 06:00 PMCR- 2021/03/24 CRDT- 2021/03/24 17:28 PHST- 2020/12/14 00:00 [received] PHST- 2021/03/03 00:00 [accepted] PHST- 2021/03/24 17:28 [entrez] PHST- 2021/03/25 06:00 [pubmed] PHST- 2021/04/22 06:00 [medline] PHST- 2021/03/24 00:00 [pmc-release] AID - PONE-D-20-39306 [pii] AID - 10.1371/journal.pone.0248706 [doi] PST - epublish SO - PLoS One. 2021 Mar 24;16(3):e0248706. doi: 10.1371/journal.pone.0248706. eCollection 2021. PMID- 33751026 OWN - NLM STAT- MEDLINE DCOM- 20211122 LR - 20240818 IS - 1537-6591 (Electronic) IS - 1058-4838 (Print) IS - 1058-4838 (Linking) VI - 73 IP - 10 DP - 2021 Nov 16 TI - Characteristics Associated With Household Transmission of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in Ontario, Canada: A Cohort Study. PG - 1840-1848 LID - 10.1093/cid/ciab186 [doi] AB - BACKGROUND: Within-household transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has been identified as one of the main sources of spread of coronavirus disease 2019 (COVID-19) after lockdown restrictions and self-isolation guidelines are implemented. Secondary attack rates among household contacts are estimated to be 5-10 times higher than among non-household contacts, but it is unclear which individuals are more prone to transmit infection within their households. METHODS: Using address matching, a cohort was assembled of all individuals with laboratory-confirmed COVID-19 residing in private households in Ontario, Canada. Descriptive analyses were performed to compare characteristics of cases in households that experienced secondary transmission versus those that did not. Logistic regression models were fit to determine index case characteristics and neighborhood characteristics associated with transmission. RESULTS: Between January and July 2020, there were 26 714 individuals with COVID-19 residing in 21 226 households. Longer testing delays (>/=5 vs 0 days; odds ratio [OR], 3.02; 95% confidence interval [CI], 2.53-3.60) and male gender (OR, 1.28; 95% CI, 1.18-1.38) were associated with greater odds of household secondary transmission, while being a healthcare worker (OR, .56; 95% CI, .50-.62) was associated with lower odds of transmission. Neighborhoods with larger average family size and a higher proportion of households with multiple persons per room were also associated with greater odds of transmission. CONCLUSIONS: It is important for individuals to get tested for SARS-CoV-2 infection as soon as symptoms appear, and to isolate away from household contacts; this is particularly important in neighborhoods with large family sizes and/or crowded households. CI - (c) The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. FAU - Paul, Lauren A AU - Paul LA AD - Health Protection, Public Health Ontario, Toronto, Ontario, Canada. FAU - Daneman, Nick AU - Daneman N AD - Health Protection, Public Health Ontario, Toronto, Ontario, Canada. AD - Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada. AD - ICES, Toronto, Ontario, Canada. AD - Division of Infectious Diseases, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada. AD - Department of Medicine, University of Toronto, Toronto, Ontario, Canada. AD - Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, Ontario, Canada. FAU - Brown, Kevin A AU - Brown KA AD - Health Protection, Public Health Ontario, Toronto, Ontario, Canada. AD - ICES, Toronto, Ontario, Canada. AD - Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada. FAU - Johnson, James AU - Johnson J AD - Environmental and Occupational Health, Public Health Ontario, Toronto, Ontario, Canada. FAU - van Ingen, Trevor AU - van Ingen T AD - Knowledge Services, Public Health Ontario, Toronto, Ontario, Canada. FAU - Joh, Eugene AU - Joh E AD - Health Protection, Public Health Ontario, Toronto, Ontario, Canada. FAU - Wilson, Sarah E AU - Wilson SE AD - Health Protection, Public Health Ontario, Toronto, Ontario, Canada. AD - ICES, Toronto, Ontario, Canada. AD - Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada. FAU - Buchan, Sarah A AU - Buchan SA AD - Health Protection, Public Health Ontario, Toronto, Ontario, Canada. AD - ICES, Toronto, Ontario, Canada. AD - Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada. LA - eng GR - Public Health Ontario/ PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - Clin Infect Dis JT - Clinical infectious diseases : an official publication of the Infectious Diseases Society of America JID - 9203213 SB - IM MH - *COVID-19 MH - Cohort Studies MH - Communicable Disease Control MH - Family Characteristics MH - Humans MH - Male MH - Ontario/epidemiology MH - *SARS-CoV-2 PMC - PMC7989533 OTO - NOTNLM OT - COVID-19 OT - SARS-CoV-2 OT - household OT - transmission EDAT- 2021/03/23 06:00 MHDA- 2021/11/23 06:00 PMCR- 2021/03/05 CRDT- 2021/03/22 18:56 PHST- 2020/12/03 00:00 [received] PHST- 2021/03/23 06:00 [pubmed] PHST- 2021/11/23 06:00 [medline] PHST- 2021/03/22 18:56 [entrez] PHST- 2021/03/05 00:00 [pmc-release] AID - 6159706 [pii] AID - ciab186 [pii] AID - 10.1093/cid/ciab186 [doi] PST - ppublish SO - Clin Infect Dis. 2021 Nov 16;73(10):1840-1848. doi: 10.1093/cid/ciab186. PMID- 33747987 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250130 IS - 2251-6093 (Electronic) IS - 2251-6085 (Print) IS - 2251-6085 (Linking) VI - 50 IP - 2 DP - 2021 Feb TI - Basics of Developing a COVID-19 Reopening Roadmap: A Systematic Scoping Review. PG - 232-244 LID - 10.18502/ijph.v50i2.5336 [doi] AB - BACKGROUND: The necessity of easing pandemic restrictions is explicit. Due to the harsh consequences of lockdowns, governments are willing to find reasonable pathways to reopen their activities. METHODS: To find out the basics of developing a reopening roadmap, on 6(th)-10(th) July 2020, we conducted a systematic search on PubMed, Scopus, and Web of Science to review the databases; and Google by manual to review the grey literature. Two independent authors extracted the data, and the senior author solved the discrepancies. RESULTS: Sixteen documents were included. Data categorized into four sections: principals, general recommendations for individuals, health key metrics, and in-phases strategy. The number of phases or stages differed from three to six, with a minimum of two weeks considered for each one. Health key metrics were categorized into four subsets: sufficient preventive capacities, appropriate diagnostic capacity, appropriate epidemiological monitoring, and sufficient health system capacity. These metrics were used as the criteria for progressing or returning over the roadmap, which guarantees a roadmap's dynamicity. Noticeably, few roadmaps did not mention the criteria that may alter the dynamicity of their roadmap. When some areas face new surges, the roadmap's dynamicity is essential, and it is vital to describe the criteria to stop the reopening process and implement the restrictions again. CONCLUSION: Providing evidence for policymaking about lifting the COVID-19 restrictions seems to be missed in the literature should be addressed more, and further studies are recommended. CI - Copyright (c) 2021 Askarian et al. Published by Tehran University of Medical Sciences. FAU - Askarian, Mehrdad AU - Askarian M AD - Department of Community Medicine, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran. AD - Health Behavior Science Research Center, Shiraz University of Medical Sciences, Shiraz, Iran. FAU - Groot, Gary AU - Groot G AD - Department of Community Health and Epidemiology, College of Medicine, University of Saskatchewan, Saskatoon, Canada. FAU - Taherifard, Ehsan AU - Taherifard E AD - Department of Internal Medicine, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran. FAU - Taherifard, Erfan AU - Taherifard E AD - Department of Internal Medicine, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran. FAU - Akbarialiabad, Hossein AU - Akbarialiabad H AD - Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran. FAU - Borazjani, Roham AU - Borazjani R AD - Trauma Research Center, Shahid Rajaee (Emtiaz) Trauma Hospital, Shiraz University of Medical Sciences, Shiraz, Iran. FAU - Askarian, Ardalan AU - Askarian A AD - College of Arts & Science, University of Saskatchewan, Saskatoon, Canada. FAU - Taghrir, Mohammad Hossein AU - Taghrir MH AD - Department of Community Medicine, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran. LA - eng PT - Journal Article PT - Scoping Review PL - Iran TA - Iran J Public Health JT - Iranian journal of public health JID - 7505531 PMC - PMC7956085 OTO - NOTNLM OT - COVID-19 OT - Global health OT - Health policy OT - Public health COIS- Conflict of interest The authors declare that there is no conflict of interests. EDAT- 2021/03/23 06:00 MHDA- 2021/03/23 06:01 PMCR- 2021/02/01 CRDT- 2021/03/22 08:20 PHST- 2021/03/22 08:20 [entrez] PHST- 2021/03/23 06:00 [pubmed] PHST- 2021/03/23 06:01 [medline] PHST- 2021/02/01 00:00 [pmc-release] AID - IJPH-50-232 [pii] AID - 10.18502/ijph.v50i2.5336 [doi] PST - ppublish SO - Iran J Public Health. 2021 Feb;50(2):232-244. doi: 10.18502/ijph.v50i2.5336. PMID- 33739987 OWN - NLM STAT- MEDLINE DCOM- 20210402 LR - 20231111 IS - 1932-6203 (Electronic) IS - 1932-6203 (Linking) VI - 16 IP - 3 DP - 2021 TI - Understanding the clinical and demographic characteristics of second coronavirus spike in 192 patients in Tehran, Iran: A retrospective study. PG - e0246314 LID - 10.1371/journal.pone.0246314 [doi] LID - e0246314 AB - During the last months of the coronavirus pandemic, with all those public restrictions and health interventions, the transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) appears now to have been raised in some countries around the world. Iran was one of those first countries facing the second wave of coronavirus, due to the lack of appropriate public restrictions because of economic problems the country is facing. The clinical and demographic characteristics of severe cases and non-severe cases of Coronavirus Disease (COVID-19) in 192 patients in Tehran, Iran, between June 16 and July 11, 2020, were investigated. The patients were divided into severe cases (n = 82) and non-severe cases (n = 110). Demographic and clinical characteristics were compared between the two study clusters. The mean age was 54.6 +/- 17.2 years, and the most common presenting symptom was persistent cough (81.8%) and fever (79.7%). The logistic regression model revealed that age, BMI, and affected family members were statistically associated with severity. Patients with complicated conditions of disorders faced more hospitalization days and medical care than the average statistical data. As the coronavirus spike in the case and death reports from June 2020, we observed the rise in the incidence of severe cases, where 42.7% (82/192) of cases have resulted in severe conditions. Our findings also suggested that the effect of IFB (Betamethasone) was more valid than the other alternative drugs such as LPV/r and IVIg. FAU - Zaferani Arani, Hamid AU - Zaferani Arani H AD - Young Researchers and Elite Club, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran. FAU - Dehghan Manshadi, Giti AU - Dehghan Manshadi G AD - Department of Anesthesiology and Critical Care, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran. FAU - Atashi, Hesam Adin AU - Atashi HA AUID- ORCID: 0000-0003-3558-204X AD - Young Researchers and Elite Club, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran. FAU - Rezaei Nejad, Aida AU - Rezaei Nejad A AUID- ORCID: 0000-0001-7737-7824 AD - Stem Cell and Regenerative Medicine Center of Excellence, Tehran University of Medical Sciences, Tehran, Iran. FAU - Ghorani, Seyyed Mojtaba AU - Ghorani SM AUID- ORCID: 0000-0002-1683-1816 AD - Young Researchers and Elite Club, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran. FAU - Abolghasemi, Soheila AU - Abolghasemi S AD - Department of Infectious Diseases, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran. FAU - Bahrani, Maryam AU - Bahrani M AUID- ORCID: 0000-0001-5570-3246 AD - Department of Emergency Medicine, Faculty of Medicine, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran. FAU - Khaledian, Homayoon AU - Khaledian H AD - Young Researchers and Elite Club, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran. FAU - Bozorg Savodji, Pantea AU - Bozorg Savodji P AD - Young Researchers and Elite Club, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran. FAU - Hoseinian, Mohammad AU - Hoseinian M AUID- ORCID: 0000-0001-7752-2681 AD - Young Researchers and Elite Club, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran. FAU - Kazemzade Bejandi, Atefe AU - Kazemzade Bejandi A AUID- ORCID: 0000-0001-5382-0086 AD - Young Researchers and Elite Club, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran. FAU - Abolghasemi, Shahla AU - Abolghasemi S AUID- ORCID: 0000-0002-4355-5271 AD - Tehran Medical Sciences, Islamic Azad University, Tehran, Iran. LA - eng PT - Journal Article DEP - 20210319 PL - United States TA - PLoS One JT - PloS one JID - 101285081 RN - 0 (Immunoglobulins, Intravenous) RN - 9842X06Q6M (Betamethasone) SB - IM MH - Adult MH - Aged MH - Betamethasone/therapeutic use MH - Body Mass Index MH - COVID-19/epidemiology/*pathology/virology MH - Cough/etiology MH - Female MH - Fever/etiology MH - Humans MH - Immunoglobulins, Intravenous/therapeutic use MH - Iran/epidemiology MH - Logistic Models MH - Male MH - Middle Aged MH - Pandemics MH - Retrospective Studies MH - SARS-CoV-2/isolation & purification MH - Severity of Illness Index MH - COVID-19 Drug Treatment PMC - PMC7979149 COIS- The authors have declared that no competing interests exist. EDAT- 2021/03/20 06:00 MHDA- 2021/04/07 06:00 PMCR- 2021/03/19 CRDT- 2021/03/19 17:21 PHST- 2020/08/05 00:00 [received] PHST- 2021/01/17 00:00 [accepted] PHST- 2021/03/19 17:21 [entrez] PHST- 2021/03/20 06:00 [pubmed] PHST- 2021/04/07 06:00 [medline] PHST- 2021/03/19 00:00 [pmc-release] AID - PONE-D-20-24382 [pii] AID - 10.1371/journal.pone.0246314 [doi] PST - epublish SO - PLoS One. 2021 Mar 19;16(3):e0246314. doi: 10.1371/journal.pone.0246314. eCollection 2021. PMID- 33737299 OWN - NLM STAT- MEDLINE DCOM- 20220124 LR - 20231111 IS - 1538-7755 (Electronic) IS - 1055-9965 (Print) IS - 1055-9965 (Linking) VI - 30 IP - 6 DP - 2021 Jun TI - Effects of Diet and Exercise-Induced Weight Loss on Biomarkers of Inflammation in Breast Cancer Survivors: A Systematic Review and Meta-analysis. PG - 1048-1062 LID - 10.1158/1055-9965.EPI-20-1029 [doi] AB - BACKGROUND: Adiponectin, leptin, and pro- and anti-inflammatory cytokines are implicated in breast cancer risk and recurrence. Weight loss, via the dynamic interplay of energy balance through exercise and/or caloric restriction, decreases risk of breast cancer recurrence. METHODS: We investigated the effects of lifestyle modifications (exercise only, or combined caloric restriction and exercise) on adipokines, IL2, IL6, IL8, IL10, C-reactive protein (CRP), and TNFalpha biomarkers in breast cancer survivors. Searches were completed in June and July of 2019 to identify randomized controlled trials that met inclusion criteria. Weighted mean difference was calculated using random- or fixed-effects models based on the heterogeneity of the studies. RESULTS: 2501 records were identified, with 30 ultimately meeting inclusion criteria of the systematic review; 21 studies provided data suitable for meta-analysis. We observed leptin levels were significantly reduced in the exercise-only group compared with sedentary control [WMD -5.66; 95% confidence interval (CI), -11.0 to -0.33; P = 0.04]. CONCLUSIONS: Leptin may be a primary mediator of exercise-induced improvements in breast cancer recurrence. IMPACT: This is the first review and meta-analysis to examine combined exercise and caloric restriction programs in breast cancer survivors. Future studies should further examine combined programs and their efficacy for altering leptin. CI - (c)2021 American Association for Cancer Research. FAU - Bruinsma, Tyler J AU - Bruinsma TJ AD - College of Medicine, Penn State University, Hershey, Pennsylvania. FAU - Dyer, Anne-Marie AU - Dyer AM AD - College of Medicine, Penn State University, Hershey, Pennsylvania. AD - Department of Public Health Sciences, Penn State University, Hershey, Pennsylvania. FAU - Rogers, Connie J AU - Rogers CJ AUID- ORCID: 0000-0003-4072-2721 AD - Department of Nutritional Sciences, College of Health and Human Development, Penn State University, University Park, Pennsylvania. AD - Cancer Institute, Penn State University, Hershey, Pennsylvania. AD - Center for Molecular Immunology and Infectious Disease, Huck Institutes of the Life Sciences, Penn State University, University Park, Pennsylvania. FAU - Schmitz, Kathryn H AU - Schmitz KH AUID- ORCID: 0000-0003-2400-2935 AD - College of Medicine, Penn State University, Hershey, Pennsylvania. AD - Department of Public Health Sciences, Penn State University, Hershey, Pennsylvania. AD - Cancer Institute, Penn State University, Hershey, Pennsylvania. FAU - Sturgeon, Kathleen M AU - Sturgeon KM AUID- ORCID: 0000-0001-9602-7897 AD - College of Medicine, Penn State University, Hershey, Pennsylvania. kms99@psu.edu. AD - Department of Public Health Sciences, Penn State University, Hershey, Pennsylvania. AD - Cancer Institute, Penn State University, Hershey, Pennsylvania. LA - eng GR - KL2 TR002015/TR/NCATS NIH HHS/United States GR - UL1 TR002014/TR/NCATS NIH HHS/United States PT - Journal Article PT - Meta-Analysis PT - Research Support, N.I.H., Extramural PT - Systematic Review DEP - 20210318 PL - United States TA - Cancer Epidemiol Biomarkers Prev JT - Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology JID - 9200608 RN - 0 (Biomarkers) RN - 0 (Biomarkers, Tumor) RN - 0 (LEP protein, human) RN - 0 (Leptin) SB - IM MH - Biomarkers/blood MH - Biomarkers, Tumor/blood/*metabolism MH - Body Mass Index MH - Breast Neoplasms/blood/*immunology/therapy MH - Cancer Survivors/*psychology MH - Diet, Healthy MH - Exercise/*immunology MH - Female MH - Humans MH - Inflammation/blood/diagnosis/immunology MH - Leptin/blood/metabolism MH - Neoplasm Recurrence, Local/blood/epidemiology/immunology/*prevention & control MH - Weight Loss/immunology PMC - PMC8172485 MID - NIHMS1685788 COIS- Conflict of Interest: The authors declare no potential conflicts of interest. EDAT- 2021/03/20 06:00 MHDA- 2022/01/27 06:00 PMCR- 2021/12/01 CRDT- 2021/03/19 06:33 PHST- 2020/09/18 00:00 [received] PHST- 2020/12/02 00:00 [revised] PHST- 2021/03/10 00:00 [accepted] PHST- 2021/03/20 06:00 [pubmed] PHST- 2022/01/27 06:00 [medline] PHST- 2021/03/19 06:33 [entrez] PHST- 2021/12/01 00:00 [pmc-release] AID - 1055-9965.EPI-20-1029 [pii] AID - 10.1158/1055-9965.EPI-20-1029 [doi] PST - ppublish SO - Cancer Epidemiol Biomarkers Prev. 2021 Jun;30(6):1048-1062. doi: 10.1158/1055-9965.EPI-20-1029. Epub 2021 Mar 18. PMID- 33733255 OWN - NLM STAT- MEDLINE DCOM- 20210325 LR - 20210325 IS - 2972-4066 (Electronic) IS - 0304-4602 (Linking) VI - 50 IP - 2 DP - 2021 Feb TI - Paediatric emergency department attendances during COVID-19 and SARS in Singapore. PG - 126-134 LID - 10.47102/annals-acadmedsg.2020500 [doi] AB - INTRODUCTION: We evaluated the impact of public health measures on paediatric emergency department attendances during the COVID-19 and severe acute respiratory syndrome (SARS) outbreaks in Singapore. METHODS: Between 1 January 2020 and 31 July 2020, we retrospectively reviewed paediatric emergency department attendances and admissions in a tertiary paediatric hospital in Singapore before and after a national lockdown to combat the spread of COVID-19 in Singapore. Hospital attendances and admissions were compared with data from a corresponding period in 2019 (1 January 2019 to 31 July 2019), as well as during and after the SARS outbreak (1 January 2003 to 31 December 2004). RESULTS: Compared with a corresponding non-outbreak period, emergency department attendances decreased in line with nationwide public health measures during the COVID-19 and SARS outbreaks (2020 and 2003 respectively), before increasing gradually following lifting of restrictions, albeit not to recorded levels before these outbreaks. During the COVID-19 outbreak, mean daily attendances decreased by 40%, from 458 per day in January-July 2019, to 274 per day in January-July 2020. The absolute number of hospital inpatient admissions decreased by 37% from January-July 2019 (19,629) to January-July 2020 (12,304). The proportion of emergency department attendances requiring admission remained similar: 20% in January-July 2019 and 21% in January-July 2020. CONCLUSION: Nationwide public health measures in Singapore have had an impact on paediatric emergency department attendances and hospital inpatient admissions. Data from this study could inform planning and resource allocation for emergency departments in Singapore and internationally. FAU - Tan, Ronald M R AU - Tan RMR AD - Department of Emergency Medicine, KK Women's and Children's Hospital, Singapore. FAU - Ganapathy, Sashikumar AU - Ganapathy S FAU - Tyebally, Arif AU - Tyebally A FAU - Lee, Khai Pin AU - Lee KP FAU - Chong, Shu Ling AU - Chong SL FAU - Soo, Jenifer S L AU - Soo JSL FAU - Thoon, Koh Cheng AU - Thoon KC FAU - Chan, Yoke Hwee AU - Chan YH FAU - Ng, Kee Chong AU - Ng KC LA - eng PT - Journal Article PL - Singapore TA - Ann Acad Med Singap JT - Annals of the Academy of Medicine, Singapore JID - 7503289 SB - IM MH - Adolescent MH - *COVID-19/epidemiology/prevention & control MH - Child MH - Child, Preschool MH - Disease Outbreaks MH - Emergency Service, Hospital/*trends MH - Facilities and Services Utilization/*trends MH - Female MH - Health Policy MH - Humans MH - Infant MH - Infant, Newborn MH - Male MH - Patient Acceptance of Health Care/*statistics & numerical data MH - Patient Admission/trends MH - Pediatrics MH - Retrospective Studies MH - *Severe Acute Respiratory Syndrome/epidemiology MH - Singapore/epidemiology EDAT- 2021/03/19 06:00 MHDA- 2021/03/26 06:00 CRDT- 2021/03/18 06:58 PHST- 2021/03/18 06:58 [entrez] PHST- 2021/03/19 06:00 [pubmed] PHST- 2021/03/26 06:00 [medline] AID - 10.47102/annals-acadmedsg.2020500 [doi] PST - ppublish SO - Ann Acad Med Singap. 2021 Feb;50(2):126-134. doi: 10.47102/annals-acadmedsg.2020500. PMID- 33729915 OWN - NLM STAT- MEDLINE DCOM- 20210401 LR - 20250530 IS - 1474-4457 (Electronic) IS - 1473-3099 (Print) IS - 1473-3099 (Linking) VI - 21 IP - 2 DP - 2021 Feb TI - The temporal association of introducing and lifting non-pharmaceutical interventions with the time-varying reproduction number (R) of SARS-CoV-2: a modelling study across 131 countries. PG - 193-202 LID - S1473-3099(20)30785-4 [pii] LID - 10.1016/S1473-3099(20)30785-4 [doi] AB - BACKGROUND: Non-pharmaceutical interventions (NPIs) were implemented by many countries to reduce the transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causal agent of COVID-19. A resurgence in COVID-19 cases has been reported in some countries that lifted some of these NPIs. We aimed to understand the association of introducing and lifting NPIs with the level of transmission of SARS-CoV-2, as measured by the time-varying reproduction number (R), from a broad perspective across 131 countries. METHODS: In this modelling study, we linked data on daily country-level estimates of R from the London School of Hygiene & Tropical Medicine (London, UK) with data on country-specific policies on NPIs from the Oxford COVID-19 Government Response Tracker, available between Jan 1 and July 20, 2020. We defined a phase as a time period when all NPIs remained the same, and we divided the timeline of each country into individual phases based on the status of NPIs. We calculated the R ratio as the ratio between the daily R of each phase and the R from the last day of the previous phase (ie, before the NPI status changed) as a measure of the association between NPI status and transmission of SARS-CoV-2. We then modelled the R ratio using a log-linear regression with introduction and relaxation of each NPI as independent variables for each day of the first 28 days after the change in the corresponding NPI. In an ad-hoc analysis, we estimated the effect of reintroducing multiple NPIs with the greatest effects, and in the observed sequence, to tackle the possible resurgence of SARS-CoV-2. FINDINGS: 790 phases from 131 countries were included in the analysis. A decreasing trend over time in the R ratio was found following the introduction of school closure, workplace closure, public events ban, requirements to stay at home, and internal movement limits; the reduction in R ranged from 3% to 24% on day 28 following the introduction compared with the last day before introduction, although the reduction was significant only for public events ban (R ratio 0.76, 95% CI 0.58-1.00); for all other NPIs, the upper bound of the 95% CI was above 1. An increasing trend over time in the R ratio was found following the relaxation of school closure, bans on public events, bans on public gatherings of more than ten people, requirements to stay at home, and internal movement limits; the increase in R ranged from 11% to 25% on day 28 following the relaxation compared with the last day before relaxation, although the increase was significant only for school reopening (R ratio 1.24, 95% CI 1.00-1.52) and lifting bans on public gatherings of more than ten people (1.25, 1.03-1.51); for all other NPIs, the lower bound of the 95% CI was below 1. It took a median of 8 days (IQR 6-9) following the introduction of an NPI to observe 60% of the maximum reduction in R and even longer (17 days [14-20]) following relaxation to observe 60% of the maximum increase in R. In response to a possible resurgence of COVID-19, a control strategy of banning public events and public gatherings of more than ten people was estimated to reduce R, with an R ratio of 0.71 (95% CI 0.55-0.93) on day 28, decreasing to 0.62 (0.47-0.82) on day 28 if measures to close workplaces were added, 0.58 (0.41-0.81) if measures to close workplaces and internal movement restrictions were added, and 0.48 (0.32-0.71) if measures to close workplaces, internal movement restrictions, and requirements to stay at home were added. INTERPRETATION: Individual NPIs, including school closure, workplace closure, public events ban, ban on gatherings of more than ten people, requirements to stay at home, and internal movement limits, are associated with reduced transmission of SARS-CoV-2, but the effect of introducing and lifting these NPIs is delayed by 1-3 weeks, with this delay being longer when lifting NPIs. These findings provide additional evidence that can inform policy-maker decisions on the timing of introducing and lifting different NPIs, although R should be interpreted in the context of its known limitations. FUNDING: Wellcome Trust Institutional Strategic Support Fund and Data-Driven Innovation initiative. CI - Copyright (c) 2021 Elsevier Ltd. All rights reserved. FAU - Li, You AU - Li Y AD - Usher Institute, University of Edinburgh, Edinburgh, UK. FAU - Campbell, Harry AU - Campbell H AD - Usher Institute, University of Edinburgh, Edinburgh, UK. FAU - Kulkarni, Durga AU - Kulkarni D AD - Usher Institute, University of Edinburgh, Edinburgh, UK. FAU - Harpur, Alice AU - Harpur A AD - Usher Institute, University of Edinburgh, Edinburgh, UK. FAU - Nundy, Madhurima AU - Nundy M AD - Usher Institute, University of Edinburgh, Edinburgh, UK. FAU - Wang, Xin AU - Wang X AD - Usher Institute, University of Edinburgh, Edinburgh, UK. FAU - Nair, Harish AU - Nair H AD - Usher Institute, University of Edinburgh, Edinburgh, UK. Electronic address: harish.nair@ed.ac.uk. CN - Usher Network for COVID-19 Evidence Reviews (UNCOVER) group LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20201022 PL - United States TA - Lancet Infect Dis JT - The Lancet. Infectious diseases JID - 101130150 SB - IM CIN - Lancet Infect Dis. 2021 Apr;21(4):458. doi: 10.1016/S1473-3099(20)30935-X. PMID: 33421365 MH - *Basic Reproduction Number MH - *COVID-19/prevention & control/transmission MH - Communicable Diseases, Emerging/prevention & control MH - Global Health MH - Humans MH - *Models, Theoretical MH - *Quarantine MH - *SARS-CoV-2 MH - Time Factors PMC - PMC7581351 EDAT- 2021/03/18 06:00 MHDA- 2021/04/02 06:00 PMCR- 2020/10/22 CRDT- 2021/03/17 17:21 PHST- 2020/08/06 00:00 [received] PHST- 2020/09/01 00:00 [revised] PHST- 2020/09/21 00:00 [accepted] PHST- 2021/03/17 17:21 [entrez] PHST- 2021/03/18 06:00 [pubmed] PHST- 2021/04/02 06:00 [medline] PHST- 2020/10/22 00:00 [pmc-release] AID - S1473-3099(20)30785-4 [pii] AID - 10.1016/S1473-3099(20)30785-4 [doi] PST - ppublish SO - Lancet Infect Dis. 2021 Feb;21(2):193-202. doi: 10.1016/S1473-3099(20)30785-4. Epub 2020 Oct 22. PMID- 33725821 OWN - NLM STAT- MEDLINE DCOM- 20210329 LR - 20230103 IS - 1536-5964 (Electronic) IS - 0025-7974 (Print) IS - 0025-7974 (Linking) VI - 100 IP - 10 DP - 2021 Mar 12 TI - Liberal blood transfusion strategies and associated infection in orthopedic patients: A meta-analysis. PG - e24430 LID - 10.1097/MD.0000000000024430 [doi] LID - e24430 AB - OBJECTIVE: It remains unclear whether transfusion strategies during orthopedic surgery and infection are related. The purpose of this study is to evaluate whether liberal blood transfusion strategies contribute to infection risk in orthopedic patients by analyzing randomized controlled trials (RCTs). METHODS: RCTs with liberal versus restrictive red blood cell (RBC) transfusion strategies were identified by searching PubMed, Embase, the Cochrane Central Register of Controlled Trials from their inception to July 2019. Ten studies with infections as outcomes were included in the final analysis. According to the Jadad scale, all studies were considered to be of high quality. RESULTS: Ten trials involving 3938 participants were included in this study. The pooled risk ratio (RR) for the association between liberal transfusion strategy and infection was 1.34 (95% confidence intervals [CI], 0.94-1.90; P = .106). The sensitivity analysis indicated unstable results, and no significant publication bias was observed. CONCLUSION: This pooled analysis of RCTs demonstrates that liberal transfusion strategies in orthopedic patients result in a nonsignificant increase in infections compared with more restrictive strategies. The conclusions are mainly based on retrospective studies and should not be considered as recommendation before they are supported by larger scale and well-designed RCTs. CI - Copyright (c) 2021 the Author(s). Published by Wolters Kluwer Health, Inc. FAU - Wang, Ying AU - Wang Y AD - Department of Pharmacology, Medical College of Hebei University of Engineering. FAU - Chen, Junli AU - Chen J AD - Department of Orthopedics, Affiliated Hospital of Hebei University of Engineering. FAU - Yang, Zhitang AU - Yang Z AD - Department of Neurology Department, Affiliated Hospital of Hebei University of Engineering, Handan, Hebei, PR China. FAU - Liu, Yugang AU - Liu Y AUID- ORCID: 0000-0002-4355-9352 AD - Department of Orthopedics, Affiliated Hospital of Hebei University of Engineering. LA - eng GR - QN2019077/Youth Fund Research Project of Science and Technology of Hebei Colleges and Universities/ GR - 1723208067-1/Handan Municipal Science and Technology Project/ PT - Journal Article PT - Meta-Analysis PL - United States TA - Medicine (Baltimore) JT - Medicine JID - 2985248R SB - IM MH - Blood Loss, Surgical/prevention & control MH - Blood Transfusion/*statistics & numerical data MH - Humans MH - Infections/*epidemiology/etiology MH - Intraoperative Care/*adverse effects/methods/statistics & numerical data MH - Orthopedic Procedures/*adverse effects MH - Postoperative Complications/*epidemiology/etiology MH - Randomized Controlled Trials as Topic MH - Risk Assessment/statistics & numerical data MH - Risk Factors PMC - PMC7969247 COIS- The authors have no conflicts of interests to disclose. EDAT- 2021/03/18 06:00 MHDA- 2021/03/30 06:00 PMCR- 2021/03/12 CRDT- 2021/03/17 01:08 PHST- 2020/08/03 00:00 [received] PHST- 2020/12/30 00:00 [accepted] PHST- 2021/03/17 01:08 [entrez] PHST- 2021/03/18 06:00 [pubmed] PHST- 2021/03/30 06:00 [medline] PHST- 2021/03/12 00:00 [pmc-release] AID - 00005792-202103120-00015 [pii] AID - MD-D-20-07626 [pii] AID - 10.1097/MD.0000000000024430 [doi] PST - ppublish SO - Medicine (Baltimore). 2021 Mar 12;100(10):e24430. doi: 10.1097/MD.0000000000024430. PMID- 33707178 OWN - NLM STAT- MEDLINE DCOM- 20211025 LR - 20250530 IS - 2515-2009 (Electronic) IS - 2515-1991 (Print) IS - 2515-1991 (Linking) VI - 47 IP - 4 DP - 2021 Oct TI - Disrupted prevention: condom and contraception access and use among young adults during the initial months of the COVID-19 pandemic. An online survey. PG - 269-276 LID - 10.1136/bmjsrh-2020-200975 [doi] AB - BACKGROUND: The initial response to COVID-19 in the UK involved a rapid contraction of face-to-face sexual and reproductive health (SRH) services and widespread use of remote workarounds. This study sought to illuminate young people's experiences of accessing and using condoms and contraception in the early months of the pandemic. METHODS: We analysed data, including open-text responses, from an online survey conducted in June-July 2020 with a convenience sample of 2005 16-24-year-olds living in Scotland. RESULTS: Among those who used condoms and contraception, one quarter reported that COVID-19 mitigation measures had made a difference to their access or use. Open-text responses revealed a landscape of disrupted prevention, including changes to sexual risk-taking and preventive practices, unwanted contraceptive pathways, unmet need for sexually transmitted infection (STI) testing, and switches from freely provided to commercially sold condoms and contraception. Pandemic-related barriers to accessing free condoms and contraception included: (1) uncertainty about the legitimacy of accessing SRH care and self-censorship of need; (2) confusion about differences between SRH care and advice received from healthcare professionals during the pandemic compared with routine practice; and (3) exacerbation of existing access barriers, alongside reduced social support and resources to navigate SRH care. CONCLUSIONS: Emerging barriers to STI and pregnancy prevention within the context of COVID-19 have the potential to undermine positive SRH practices, and widen inequalities, among young people. As SRH services are restored amid evolving pandemic restrictions, messaging to support navigation of condom and contraception services should be co-created with young people. CI - (c) Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY. Published by BMJ. FAU - Lewis, Ruth AU - Lewis R AUID- ORCID: 0000-0002-6768-6188 AD - MRC/CSO Social and Public Health Sciences Unit, University of Glasgow, Glasgow, UK ruth.lewis@glasgow.ac.uk. FAU - Blake, Carolyn AU - Blake C AUID- ORCID: 0000-0002-7231-4290 AD - MRC/CSO Social and Public Health Sciences Unit, University of Glasgow, Glasgow, UK. FAU - Shimonovich, Michal AU - Shimonovich M AD - MRC/CSO Social and Public Health Sciences Unit, University of Glasgow, Glasgow, UK. FAU - Coia, Nicky AU - Coia N AD - Sandyford Sexual Health Service, NHS Greater Glasgow and Clyde, Glasgow, UK. FAU - Duffy, Johann AU - Duffy J AD - Health Improvement Department, NHS Lanarkshire, Bothwell, South Lanarkshire, UK. FAU - Kerr, Yvonne AU - Kerr Y AD - Public Health, NHS Lothian, Edinburgh, UK. FAU - Wilson, Jill AU - Wilson J AD - Sandyford Sexual Health Service, NHS Greater Glasgow and Clyde, Glasgow, UK. FAU - Graham, Cynthia Ann AU - Graham CA AUID- ORCID: 0000-0002-7884-599X AD - Department of Psychology, University of Southampton, Southampton, UK. FAU - Mitchell, Kirstin R AU - Mitchell KR AUID- ORCID: 0000-0002-4409-6601 AD - MRC/CSO Social and Public Health Sciences Unit, University of Glasgow, Glasgow, UK. LA - eng GR - SPHSU17/CSO_/Chief Scientist Office/United Kingdom GR - SPHSU18/CSO_/Chief Scientist Office/United Kingdom GR - MC_UU_12017/11/MRC_/Medical Research Council/United Kingdom GR - MC_UU_00022/3/MRC_/Medical Research Council/United Kingdom GR - MC_UU_00022/2/MRC_/Medical Research Council/United Kingdom GR - SPHSU11/CSO_/Chief Scientist Office/United Kingdom PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20210311 PL - England TA - BMJ Sex Reprod Health JT - BMJ sexual & reproductive health JID - 101715577 SB - IM MH - Adolescent MH - *COVID-19 MH - *Condoms MH - Female MH - Health Services Accessibility MH - Humans MH - Pandemics MH - Pregnancy MH - SARS-CoV-2 MH - Young Adult PMC - PMC7956735 OTO - NOTNLM OT - COVID-19 OT - contraception behavior OT - health services accessibility OT - reproductive health OT - sexual health OT - sexually transmitted diseases COIS- Competing interests: None declared. EDAT- 2021/03/13 06:00 MHDA- 2021/10/26 06:00 PMCR- 2021/03/11 CRDT- 2021/03/12 06:24 PHST- 2020/11/25 00:00 [received] PHST- 2021/02/08 00:00 [revised] PHST- 2021/02/15 00:00 [accepted] PHST- 2021/03/13 06:00 [pubmed] PHST- 2021/10/26 06:00 [medline] PHST- 2021/03/12 06:24 [entrez] PHST- 2021/03/11 00:00 [pmc-release] AID - bmjsrh-2020-200975 [pii] AID - 10.1136/bmjsrh-2020-200975 [doi] PST - ppublish SO - BMJ Sex Reprod Health. 2021 Oct;47(4):269-276. doi: 10.1136/bmjsrh-2020-200975. Epub 2021 Mar 11. PMID- 33706844 OWN - NLM STAT- MEDLINE DCOM- 20220314 LR - 20231105 IS - 1475-2662 (Electronic) IS - 0007-1145 (Print) IS - 0007-1145 (Linking) VI - 127 IP - 2 DP - 2022 Jan 28 TI - Systematic review of the effects of pandemic confinements on body weight and their determinants. PG - 298-317 LID - 10.1017/S0007114521000921 [doi] AB - Pandemics and subsequent lifestyle restrictions such as 'lockdowns' may have unintended consequences, including alterations in body weight. This systematic review assesses the impact of pandemic confinement on body weight and identifies contributory factors. A comprehensive literature search was performed in seven electronic databases and in grey sources from their inception until 1 July 2020 with an update in PubMed and Scopus on 1 February 2021. In total, 2361 unique records were retrieved, of which forty-one studies were identified eligible: one case-control study, fourteen cohort and twenty-six cross-sectional studies (469, 362 total participants). The participants ranged in age from 6 to 86 years. The proportion of female participants ranged from 37 % to 100 %. Pandemic confinements were associated with weight gain in 7.2-72.4 % of participants and weight loss in 11.1-32.0 % of participants. Weight gain ranged from 0.6 (sd 1.3) to 3.0 (sd 2.4) kg, and weight loss ranged from 2.0 (sd 1.4) to 2.9 (sd 1.5) kg. Weight gain occurred predominantly in participants who were already overweight or obese. Associated factors included increased consumption of unhealthy food with changes in physical activity and altered sleep patterns. Weight loss during the pandemic was observed in individuals with previous low weight, and those who ate less and were more physically active before lockdown. Maintaining a stable weight was more difficult in populations with reduced income, particularly in individuals with lower educational attainment. The findings of this systematic review highlight the short-term effects of pandemic confinements. FAU - Khan, Moien Ab AU - Khan MA AUID- ORCID: 0000-0003-4970-4618 AD - Nutrition Studies Research Group, Department of Family Medicine, College of Medicine and Health Sciences, United Arab Emirates University, Al-Ain, United Arab Emirates. AD - Primary Care, NHS North West London, LondonTW3 3EB, UK. FAU - Menon, Preetha AU - Menon P AD - Institute of Public Health, College of Medicine and Health Sciences, United Arab Emirates University, Al-Ain, United Arab Emirates. FAU - Govender, Romona AU - Govender R AD - Nutrition Studies Research Group, Department of Family Medicine, College of Medicine and Health Sciences, United Arab Emirates University, Al-Ain, United Arab Emirates. FAU - Abu Samra, Amal Mb AU - Abu Samra AM AD - Nutrition Studies Research Group, Department of Family Medicine, College of Medicine and Health Sciences, United Arab Emirates University, Al-Ain, United Arab Emirates. FAU - Allaham, Kholoud K AU - Allaham KK AD - Nutrition Studies Research Group, Department of Family Medicine, College of Medicine and Health Sciences, United Arab Emirates University, Al-Ain, United Arab Emirates. FAU - Nauman, Javaid AU - Nauman J AD - Institute of Public Health, College of Medicine and Health Sciences, United Arab Emirates University, Al-Ain, United Arab Emirates. AD - Department of Circulation and Medical Imaging, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway. AD - Healthy Living for Pandemic Event Protection (HL - PIVOT) Network, Chicago, IL, USA. FAU - Ostlundh, Linda AU - Ostlundh L AD - National Medical Library, College of Medicine and Health Sciences, United Arab Emirates University, Al-Ain, United Arab Emirates. FAU - Mustafa, Halla AU - Mustafa H AD - Nutrition Studies Research Group, Department of Family Medicine, College of Medicine and Health Sciences, United Arab Emirates University, Al-Ain, United Arab Emirates. FAU - Smith, Jane E M AU - Smith JEM AD - Bodreinallt Surgery, NHS Wales, Conwy, LL32 8AT, UK. FAU - AlKaabi, Juma M AU - AlKaabi JM AD - Department of Internal Medicine, College of Medicine and Health Sciences, United Arab Emirates University, Al-Ain, United Arab Emirates. LA - eng PT - Journal Article PT - Systematic Review DEP - 20210312 PL - England TA - Br J Nutr JT - The British journal of nutrition JID - 0372547 SB - IM MH - Adolescent MH - Adult MH - Aged MH - Aged, 80 and over MH - Body Weight MH - *COVID-19/epidemiology MH - Case-Control Studies MH - Child MH - Cross-Sectional Studies MH - Female MH - Humans MH - Middle Aged MH - *Pandemics MH - Young Adult PMC - PMC8376925 OTO - NOTNLM OT - Body weight OT - Lockdown OT - Obesity OT - Pandemic OT - Quarantine OT - Weight determinants EDAT- 2021/03/13 06:00 MHDA- 2022/03/15 06:00 PMCR- 2022/01/13 CRDT- 2021/03/12 05:53 PHST- 2021/03/13 06:00 [pubmed] PHST- 2022/03/15 06:00 [medline] PHST- 2021/03/12 05:53 [entrez] PHST- 2022/01/13 00:00 [pmc-release] AID - S0007114521000921 [pii] AID - 10.1017/S0007114521000921 [doi] PST - ppublish SO - Br J Nutr. 2022 Jan 28;127(2):298-317. doi: 10.1017/S0007114521000921. Epub 2021 Mar 12. PMID- 33690812 OWN - NLM STAT- MEDLINE DCOM- 20220105 LR - 20220309 IS - 1741-3850 (Electronic) IS - 1741-3842 (Print) IS - 1741-3842 (Linking) VI - 43 IP - 4 DP - 2021 Dec 10 TI - Epidemiology of COVID-19 and public health restrictions during the first wave of the pandemic in Ireland in 2020. PG - 714-722 LID - 10.1093/pubmed/fdab049 [doi] LID - fdab049 AB - BACKGROUND: We describe the epidemiological trends and report and review the public health restrictions implemented during the first wave of the COVID-19 pandemic in Ireland. METHODS: The study reviewed confirmed cases of COVID-19 notified from 1 March to 18 July 2020. Data were obtained from the national COVID-19 Data Hub, the National Health Protection Surveillance Centre, the National Contact Management Programme and the European Centre for Disease Prevention and Control. RESULTS: A total of 25 617 cases were notified during the study period. Weekly cases and deaths peaked in mid-April 2020 at 5701 and 316, respectively. Mean number of close contacts per case was lowest at 0.7 in April, rising to 6.6 by July. Outbreak settings shifted from travel and workplace in March, to healthcare in April. Restrictions implemented on 12 March extended to full lockdown on 27 March. Phased relaxation of restrictions commenced 18 May. Effective suppression of community transmission of COVID-19 was achieved by June 2020. CONCLUSION: Lockdown is a crude population-level restriction effective in controlling COVID-19. Phased relaxation of restrictions in Ireland, however, led to an immediate increase in mean number of contacts per case, which facilitates viral transmission unless individual-level restrictions are adhered to. This demonstrates a limitation of lockdown as a long-term mechanism of pandemic control. CI - (c) The Author(s) 2021. Published by Oxford University Press on behalf of Faculty of Public Health. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. FAU - Conway, Robert AU - Conway R AD - Health Protection Surveillance Centre, Dublin D01 A4A3, Ireland. FAU - Kelly, David M AU - Kelly DM AD - Department of Public Health, Health Service Executive East, D08 W2A8 Dublin, Ireland. FAU - Mullane, Paul AU - Mullane P AD - Department of Public Health, Health Service Executive East, D08 W2A8 Dublin, Ireland. FAU - Ni Bhuachalla, Cliodhna AU - Ni Bhuachalla C AD - Department of Public Health, Health Service Executive South, T12 XH60 Cork, Ireland. FAU - O'Connor, Lois AU - O'Connor L AD - Health Protection Surveillance Centre, Dublin D01 A4A3, Ireland. FAU - Buckley, Claire AU - Buckley C AD - School of Public Health, University College Cork, T12 XF62 Cork, Ireland. FAU - Kearney, Patricia M AU - Kearney PM AD - School of Public Health, University College Cork, T12 XF62 Cork, Ireland. FAU - Doyle, Sarah AU - Doyle S AD - Health Service Executive Contact Management Programme, Dr Steevens' Hospital, D08 W2A8 Dublin, Ireland. LA - eng PT - Journal Article PL - England TA - J Public Health (Oxf) JT - Journal of public health (Oxford, England) JID - 101188638 SB - IM EIN - J Public Health (Oxf). 2022 Mar 7;44(1):e170. doi: 10.1093/pubmed/fdab097. PMID: 33729537 MH - *COVID-19 MH - Communicable Disease Control MH - Humans MH - Ireland/epidemiology MH - *Pandemics/prevention & control MH - Public Health MH - SARS-CoV-2 PMC - PMC7989427 OTO - NOTNLM OT - COVID-19 OT - contact tracing OT - epidemiology OT - lockdown OT - non-pharmaceutical interventions OT - surveillance EDAT- 2021/03/11 06:00 MHDA- 2022/01/06 06:00 PMCR- 2021/03/24 CRDT- 2021/03/10 18:20 PHST- 2021/01/29 00:00 [received] PHST- 2021/02/06 00:00 [revised] PHST- 2021/02/14 00:00 [accepted] PHST- 2021/03/11 06:00 [pubmed] PHST- 2022/01/06 06:00 [medline] PHST- 2021/03/10 18:20 [entrez] PHST- 2021/03/24 00:00 [pmc-release] AID - 6159021 [pii] AID - fdab049 [pii] AID - 10.1093/pubmed/fdab049 [doi] PST - ppublish SO - J Public Health (Oxf). 2021 Dec 10;43(4):714-722. doi: 10.1093/pubmed/fdab049. PMID- 33690148 OWN - NLM STAT- MEDLINE DCOM- 20211021 LR - 20250530 IS - 1478-5242 (Electronic) IS - 0960-1643 (Print) IS - 0960-1643 (Linking) VI - 71 IP - 710 DP - 2021 Sep TI - Effectiveness and perceptions of using templates in long-term condition reviews: a systematic synthesis of quantitative and qualitative studies. PG - e652-e659 LID - 10.3399/BJGP.2020.0963 [doi] AB - BACKGROUND: Review templates are commonly used in long-term condition (LTC) consultations to standardise care for patients and promote consistent data recording. However, templates may affect interactions during the review and, potentially, inhibit patient-centred care. AIM: To systematically review the literature about the impact that LTC review templates have on process and health outcomes, and the views of health professionals and patients on using review templates in consultations. DESIGN AND SETTING: Parallel qualitative and quantitative systematic reviews. METHOD: Following Cochrane methodology, nine databases were searched (1995-2019; updated July 2020) for clinical trials and qualitative studies of LTC templates in healthcare settings. Duplicate selection, risk-of-bias assessment, and data extraction were performed. The quantitative and qualitative analyses were conducted in parallel, and findings synthesised narratively. RESULTS: In total, 12 qualitative and 14 quantitative studies were included (two studies reported both qualitative and quantitative data, and were included in both analyses). Review templates were well used, but the only study to assess health outcomes showed no effect. Templates can improve documentation of key measures and act as a reminder tool; however, they can restrict the review process, and risk health professionals' agendas being prioritised over those of patients. Templates may also limit opportunities to discuss individuals' concerns about living with their condition and act as a barrier to providing patient-centred care. CONCLUSION: Future research should evaluate health, as well as process, outcomes. The potential benefits of templates in improving documentation should be balanced against concerns that 'tick boxes' may override patient agendas, unless templates are designed to promote patient-centred care. CI - (c) The Authors. FAU - Morrissey, Mary AU - Morrissey M AD - Health Protection Team, Public Health NHS Lothian, Edinburgh, UK. FAU - Shepherd, Elizabeth AU - Shepherd E AD - Sioux Lookout First Nations Health Authority, Sioux Lookout, Canada. FAU - Kinley, Emma AU - Kinley E AD - Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, UK. FAU - McClatchey, Kirstie AU - McClatchey K AD - Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, UK. FAU - Pinnock, Hilary AU - Pinnock H AD - Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, UK. LA - eng GR - AUKCAR/19/01/CSO_/Chief Scientist Office/United Kingdom PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review DEP - 20210826 PL - England TA - Br J Gen Pract JT - The British journal of general practice : the journal of the Royal College of General Practitioners JID - 9005323 SB - IM EIN - Br J Gen Pract. 2022 Mar 31;72(717):158. doi: 10.3399/bjgp22X718949. PMID: 35361609 MH - Bias MH - *Health Personnel MH - Humans MH - *Patient-Centered Care MH - Perception MH - Qualitative Research PMC - PMC8321439 OTO - NOTNLM OT - chronic conditions OT - delivery of health care OT - long-term conditions OT - patient-centred care OT - primary care OT - review templates EDAT- 2021/03/11 06:00 MHDA- 2021/10/27 06:00 PMCR- 2021/07/27 CRDT- 2021/03/10 17:57 PHST- 2020/10/27 00:00 [received] PHST- 2021/03/02 00:00 [accepted] PHST- 2021/03/11 06:00 [pubmed] PHST- 2021/10/27 06:00 [medline] PHST- 2021/03/10 17:57 [entrez] PHST- 2021/07/27 00:00 [pmc-release] AID - BJGP.2020.0963 [pii] AID - 10.3399/BJGP.2020.0963 [doi] PST - epublish SO - Br J Gen Pract. 2021 Aug 26;71(710):e652-e659. doi: 10.3399/BJGP.2020.0963. Print 2021 Sep. PMID- 33686870 OWN - NLM STAT- MEDLINE DCOM- 20211018 LR - 20211018 IS - 2047-9980 (Electronic) IS - 2047-9980 (Linking) VI - 10 IP - 6 DP - 2021 Mar 16 TI - Reoperative Mitral Surgery Versus Transcatheter Mitral Valve Replacement: A Systematic Review. PG - e019854 LID - 10.1161/JAHA.120.019854 [doi] LID - e019854 AB - Bioprosthetic mitral structural valve degeneration and failed mitral valve repair (MVr) have traditionally been treated with reoperative mitral valve surgery. Transcatheter mitral valve-in-valve (MVIV) and valve-in-ring (MVIR) replacement are now feasible, but data comparing these approaches are lacking. We sought to compare the outcomes of (1) reoperative mitral valve replacement (redo-MVR) and MVIV for structural valve degeneration, and (2) reoperative mitral valve repair (redo-MVr) or MVR and MVIR for failed MVr. A literature search of PubMed, Embase, and the Cochrane Library was conducted up to July 31, 2020. Thirty-two studies involving 25 832 patients were included. Redo-MVR was required in approximately 35% of patients after index surgery at 10 years, with 5% to 15% 30-day mortality. MVIV resulted in >95% procedural success with 30-day and 1-year mortality of 0% to 8% and 11% to 16%, respectively. Recognized complications included left ventricular outflow tract obstruction (0%-6%), valve migration (0%-9%), and residual regurgitation (0%-6%). Comparisons of redo-MVR and MVIV showed no statistically significant differences in mortality (11.3% versus 11.9% at 1 year, P=0.92), albeit higher rates of major bleeding and arrhythmias with redo-MVR. MVIR resulted in 0% to 34% mortality at 1 year, whereas both redo-MVr and MVR for failed repairs were performed with minimal mortality and durable long-term results. MVIV is therefore a viable alternative to redo-MVR for structural valve degeneration, whereas redo-MVr or redo-MVR is preferred for failed MVr given the suboptimal results with MVIR. However, not all patients will be candidates for MVIV/MVIR because anatomical restrictions may preclude transcatheter options from adequately addressing the underlying pathology. FAU - Sengupta, Aditya AU - Sengupta A AD - Department of Cardiovascular Surgery Mount Sinai Hospital New York NY. FAU - Yazdchi, Farhang AU - Yazdchi F AD - Division of Cardiac Surgery Brigham and Women's Hospital Boston MA. FAU - Alexis, Sophia L AU - Alexis SL AD - Department of Cardiovascular Surgery Mount Sinai Hospital New York NY. FAU - Percy, Edward AU - Percy E AD - Division of Cardiac Surgery Brigham and Women's Hospital Boston MA. FAU - Premkumar, Akash AU - Premkumar A AD - Division of Cardiac Surgery Brigham and Women's Hospital Boston MA. FAU - Hirji, Sameer AU - Hirji S AD - Division of Cardiac Surgery Brigham and Women's Hospital Boston MA. FAU - Bapat, Vinayak N AU - Bapat VN AD - Minneapolis Heart Institute Foundation Minneapolis MN. FAU - Bhatt, Deepak L AU - Bhatt DL AD - Brigham and Women's Heart & Vascular CenterHarvard Medical School Boston MA. FAU - Kaneko, Tsuyoshi AU - Kaneko T AD - Division of Cardiac Surgery Brigham and Women's Hospital Boston MA. FAU - Tang, Gilbert H L AU - Tang GHL AD - Department of Cardiovascular Surgery Mount Sinai Hospital New York NY. LA - eng PT - Journal Article PT - Systematic Review DEP - 20210309 PL - England TA - J Am Heart Assoc JT - Journal of the American Heart Association JID - 101580524 SB - IM MH - Cardiac Catheterization/*methods MH - Heart Valve Diseases/*surgery MH - *Heart Valve Prosthesis MH - Heart Valve Prosthesis Implantation/*methods MH - Humans MH - Mitral Valve/*surgery MH - Reoperation PMC - PMC8174229 OTO - NOTNLM OT - redo mitral valve repair OT - reoperative mitral valve replacement OT - transcatheter mitral valve replacement OT - valve-in-ring OT - valve-in-valve COIS- Dr Tang is a physician proctor for Medtronic and a consultant for Abbott Structural Heart, Medtronic and W.L. Gore & Associates. Dr Kaneko is a speaker for Abbott Structural Heart and Baylis Medical, a consultant for 4C Medical, and has served as a proctor and educator for Edwards Lifesciences and Medtronic. Dr Bapat has served as a consultant for Medtronic, Edwards Lifesciences, 4C Medical, and Boston Scientific. Dr Bhatt discloses the following relationships-Advisory Board: Cardax, Cereno Scientific, Elsevier Practice Update Cardiology, Medscape Cardiology, PhaseBio, Regado Biosciences; Board of Directors: Boston VA Research Institute, Society of Cardiovascular Patient Care, TobeSoft; Chair: American Heart Association Quality Oversight Committee; Data Monitoring Committees: Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute, for the PORTICO trial, funded by St. Jude Medical, now Abbott), Cleveland Clinic (including for the ExCEED trial, funded by Edwards), Duke Clinical Research Institute, Mayo Clinic, Mount Sinai School of Medicine (for the ENVISAGE trial, funded by Daiichi Sankyo), Population Health Research Institute; Honoraria: American College of Cardiology (Senior Associate Editor, Clinical Trials and News, ACC.org; Vice-Chair, ACC Accreditation Committee), Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute; RE-DUAL PCI clinical trial steering committee funded by Boehringer Ingelheim; AEGIS-II executive committee funded by CSL Behring), Belvoir Publications (Editor-in-Chief, Harvard Heart Letter), Duke Clinical Research Institute (clinical trial steering committees, including for the PRONOUNCE trial, funded by Ferring Pharmaceuticals), HMP Global (Editor-in-Chief, Journal of Invasive Cardiology), Journal of the American College of Cardiology (Guest Editor; Associate Editor), Medtelligence/ReachMD (CME steering committees), Population Health Research Institute (for the COMPASS operations committee, publications committee, steering committee, and USA national co-leader, funded by Bayer), Slack Publications (Chief Medical Editor, Cardiology Today's Intervention), Society of Cardiovascular Patient Care (Secretary/Treasurer), WebMD (CME steering committees); Other: Clinical Cardiology (Deputy Editor), NCDR-ACTION Registry Steering Committee (Chair), VA CART Research and Publications Committee (Chair); Research Funding: Abbott, Afimmune, Amarin, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Chiesi, CSL Behring, Eisai, Ethicon, Ferring Pharmaceuticals, Forest Laboratories, Fractyl, Idorsia, Ironwood, Ischemix, Lilly, Medtronic, PhaseBio, Pfizer, PLx Pharma, Regeneron, Roche, Sanofi Aventis, Synaptic, The Medicines Company; Royalties: Elsevier (Editor, Cardiovascular Intervention: A Companion to Braunwald's Heart Disease); Site Co-Investigator: Biotronik, Boston Scientific, CSI, St. Jude Medical (now Abbott), Svelte; Trustee: American College of Cardiology; Unfunded Research: FlowCo, Merck, Novo Nordisk, Takeda. The remaining authors have no disclosures to report. EDAT- 2021/03/10 06:00 MHDA- 2021/10/21 06:00 PMCR- 2021/03/16 CRDT- 2021/03/09 08:38 PHST- 2021/03/10 06:00 [pubmed] PHST- 2021/10/21 06:00 [medline] PHST- 2021/03/09 08:38 [entrez] PHST- 2021/03/16 00:00 [pmc-release] AID - JAH36031 [pii] AID - 10.1161/JAHA.120.019854 [doi] PST - ppublish SO - J Am Heart Assoc. 2021 Mar 16;10(6):e019854. doi: 10.1161/JAHA.120.019854. Epub 2021 Mar 9. PMID- 33675583 OWN - NLM STAT- MEDLINE DCOM- 20220112 LR - 20220112 IS - 2047-2927 (Electronic) IS - 2047-2919 (Linking) VI - 9 IP - 4 DP - 2021 Jul TI - Evaluating the quality of reported outcomes for microsurgical TESE in men with non-obstructive azoospermia: A methodological analysis. PG - 1108-1118 LID - 10.1111/andr.12997 [doi] AB - BACKGROUND: Publications of microsurgical testicular sperm extraction (mTESE) techniques and outcomes are heterogeneous, which may limit creation of best surgical practices. OBJECTIVE: To study the quality and heterogeneity of published mTESE outcomes via a methodological analysis. MATERIALS/METHODS: A systematic methodological analysis of all published literature on the use of mTESE in men with non-obstructive azoospermia from 1999 to the July 2020 was performed. PubMed and MEDLINE searches were performed using the search terms "microdissection TESE OR microsurgical TESE." Publications were evaluated on their reporting of pre-operative factors, intraoperative techniques, surgical and clinical outcomes, and adverse events. RESULTS: Fifty-five studies met inclusion criteria. Surgical technique and sperm retrieval rates were the most reported criteria. Reporting on the presence of an embryologist intraoperatively was observed in approximately 30% of articles, while other procedural details including method of sperm quantification, quantity retrieved, and number of cryopreserved vials were observed in fewer than 10% of articles. Clinical outcomes, including pregnancy rates and live birth rates, were reported in fewer than 40% of the articles. Fetal outcomes including fetal and neonatal anomalies were rarely reported. Fetal growth restriction, preterm delivery, small or large for gestational age, and NICU admissions were never reported. CONCLUSION: There are inconsistencies in reporting quality of mTESE outcomes, specifically a lack of information on the quantity and quality of sperm retrieved, the role of embryology intraoperatively, and clinical outcomes, such as live birth rate and fetal anomalies. These gaps may guide development of standardized reporting guidelines to better assess and compare clinical outcomes across institutions and maintain focus on couples-centric fertility outcomes in future mTESE studies. CI - (c) 2021 American Society of Andrology and European Academy of Andrology. FAU - Ernandez, John AU - Ernandez J AD - Harvard Medical School, Boston, MA, USA. FAU - Berk, Brittany AU - Berk B AD - Division of Urology, Brigham and Women's Hospital, Boston, MA, USA. FAU - Han, Tracy AU - Han T AD - Division of Urology, Brigham and Women's Hospital, Boston, MA, USA. FAU - Abou Ghayda, Ramy AU - Abou Ghayda R AD - Department of Urology, Case Western Reserve University, Cleveland, OH, USA. FAU - Kathrins, Martin AU - Kathrins M AUID- ORCID: 0000-0002-2251-0461 AD - Division of Urology, Brigham and Women's Hospital, Boston, MA, USA. LA - eng PT - Journal Article PT - Systematic Review DEP - 20210315 PL - England TA - Andrology JT - Andrology JID - 101585129 RN - Azoospermia, Nonobstructive SB - IM MH - Azoospermia/*surgery MH - Humans MH - Male MH - Microsurgery/methods MH - Research Design/*standards MH - *Sperm Retrieval MH - *Treatment Outcome OTO - NOTNLM OT - Surgical sperm extraction azoospermia methodological analysis EDAT- 2021/03/07 06:00 MHDA- 2022/01/13 06:00 CRDT- 2021/03/06 12:08 PHST- 2021/02/22 00:00 [revised] PHST- 2020/12/14 00:00 [received] PHST- 2021/02/25 00:00 [accepted] PHST- 2021/03/07 06:00 [pubmed] PHST- 2022/01/13 06:00 [medline] PHST- 2021/03/06 12:08 [entrez] AID - 10.1111/andr.12997 [doi] PST - ppublish SO - Andrology. 2021 Jul;9(4):1108-1118. doi: 10.1111/andr.12997. Epub 2021 Mar 15. PMID- 33671203 OWN - NLM STAT- MEDLINE DCOM- 20210311 LR - 20210311 IS - 1660-4601 (Electronic) IS - 1661-7827 (Print) IS - 1660-4601 (Linking) VI - 18 IP - 4 DP - 2021 Feb 17 TI - Changes in Smoking Behaviour and Home-Smoking Rules during the Initial COVID-19 Lockdown Period in Israel. LID - 10.3390/ijerph18041931 [doi] LID - 1931 AB - The COVID-19 pandemic has caused devastating impacts globally. To mitigate virus spread, Israel imposed severe restrictions during March-April 2020. An online cross-sectional survey was conducted in April 2020 among current and ex-smokers to explore changes in smoking behaviour and home-smoking rules during this period. Bivariate analysis and multivariate logistic regression examined associations between sociodemographic characteristics and perceived risk of infection and quitting smoking during the initial COVID-19 period. Current smoking was reported by 437 (66.2%) of the 660 participants, 46 (7%) quit during the initial restriction period, and 177 (26.8%) were ex-smokers. Nearly half (44.4%) of current smokers intensified their smoking, and 16% attempted to quit. Quitting during the COVID-19 period was significantly associated with higher education (adjusted odds ratio (aOR): 1.97, 95% CI: 1.0-3.8), not living with a smoker (aOR: 2.18, 95% CI: 1.0-4.4), and having an underlying chronic condition that increases risk for COVID-19 complications (aOR: 2.32, 95% CI: 1.1-4.6). Both an increase in smoking behaviour and in attempts to quit smoking during the initial COVID-19 pandemic were evident in this sample of adult Israeli smokers. Governments need to use this opportunity to encourage smokers to attempt quitting and create smoke-free homes, especially during lockdown conditions, while providing mental and social support to all smokers. FAU - Bar-Zeev, Yael AU - Bar-Zeev Y AUID- ORCID: 0000-0002-1916-836X AD - Braun School of Public Health and Community Medicine, Hebrew University-Hadassah Medical Centre, Jerusalem 9112102, Israel. FAU - Shauly, Michal AU - Shauly M AD - Braun School of Public Health and Community Medicine, Hebrew University-Hadassah Medical Centre, Jerusalem 9112102, Israel. FAU - Lee, Hannah AU - Lee H AD - Braun School of Public Health and Community Medicine, Hebrew University-Hadassah Medical Centre, Jerusalem 9112102, Israel. FAU - Neumark, Yehuda AU - Neumark Y AD - Braun School of Public Health and Community Medicine, Hebrew University-Hadassah Medical Centre, Jerusalem 9112102, Israel. LA - eng PT - Journal Article DEP - 20210217 PL - Switzerland TA - Int J Environ Res Public Health JT - International journal of environmental research and public health JID - 101238455 SB - IM MH - Adult MH - *COVID-19 MH - Communicable Disease Control MH - Cross-Sectional Studies MH - Humans MH - Israel/epidemiology MH - Pandemics MH - Smoking/*epidemiology MH - Smoking Cessation/*statistics & numerical data PMC - PMC7922914 OTO - NOTNLM OT - COVID-19 OT - home-smoking-rules OT - smoking OT - smoking cessation COIS- Y.B.-Z. has received fees for lectures from Pfizer Ltd., Novartis NCH, and GSK Consumer Health (distributors of smoking cessation pharmacotherapy in Israel) in the past (2012-July 2019). All other authors declare no conflict of interest. EDAT- 2021/03/07 06:00 MHDA- 2021/03/12 06:00 PMCR- 2021/02/01 CRDT- 2021/03/06 01:09 PHST- 2020/12/29 00:00 [received] PHST- 2021/01/29 00:00 [revised] PHST- 2021/02/11 00:00 [accepted] PHST- 2021/03/06 01:09 [entrez] PHST- 2021/03/07 06:00 [pubmed] PHST- 2021/03/12 06:00 [medline] PHST- 2021/02/01 00:00 [pmc-release] AID - ijerph18041931 [pii] AID - ijerph-18-01931 [pii] AID - 10.3390/ijerph18041931 [doi] PST - epublish SO - Int J Environ Res Public Health. 2021 Feb 17;18(4):1931. doi: 10.3390/ijerph18041931. PMID- 33649696 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230429 IS - 0964-5691 (Print) IS - 1873-524X (Electronic) IS - 0964-5691 (Linking) VI - 206 DP - 2021 Jun 1 TI - Beachgoer perceptions on health regulations of COVID-19 in two popular beaches on the Brazilian Amazon. PG - 105576 LID - 10.1016/j.ocecoaman.2021.105576 [doi] AB - The sandy beaches of the Brazilian Amazon coast have enormous touristic potential and attract thousands of visitors each year, principally in July, at the beginning of the summer vacation period. In 2020, beach going was affected worldwide by the Covid-19 pandemic, but how did the pandemic affect recreational beach use on the Amazon coast in the Brazilian state of Para? Given this, the objective of this work is to identify public perception in compliance with health safety established by authorities due to COVID-19 pandemic in two popular beaches on the Brazilian Amazon. Recreational patterns on the beaches of this region were analyzed from the user's perspective in July, through semi-structured interviews and direct observations. Recreational activities were prohibited on the beaches located within protected areas. At other locations, however, including Ajuruteua and Atalaia, the beaches were reopened on July 1 st, and both sites received thousands of visitors in July, despite the fact that interviewees believed the pandemic to be dangerous, and considered the situation in Para state to be at least as bad or worse than in previous months. Agglomerations were verified on both study beaches and social distancing and other protective measures were limited. The increase in the new cases recorded in August was due to the relaxation of restrictions on social, recreational, and economic activities by the local authorities in July 2020, including the reopening of public access to beaches. As Para state has been hard-hit by the pandemic, prohibitions on recreational beach use should clearly not have been lifted during this period. A number of management measures were presented in this study. These measures should contribute to the prevention of the spread of the virus during the upcoming public holidays, as long as the pandemic continues. CI - (c) 2021 Elsevier Ltd. All rights reserved. FAU - Pereira, Luci Cajueiro Carneiro AU - Pereira LCC AD - Instituto de Estudos Costeiros, Universidade Federal do Para, Alameda Leandro Ribeiro, s/n, Aldeia, 68600-000, Braganca, Para, Brazil. FAU - Sousa Felix, Rosigleyse Correa de AU - Sousa Felix RC AD - Instituto de Estudos Costeiros, Universidade Federal do Para, Alameda Leandro Ribeiro, s/n, Aldeia, 68600-000, Braganca, Para, Brazil. FAU - Brito Dias, Ana Beatriz AU - Brito Dias AB AD - Instituto de Estudos Costeiros, Universidade Federal do Para, Alameda Leandro Ribeiro, s/n, Aldeia, 68600-000, Braganca, Para, Brazil. FAU - Pessoa, Rubem Manoel Coelho AU - Pessoa RMC AD - Instituto de Estudos Costeiros, Universidade Federal do Para, Alameda Leandro Ribeiro, s/n, Aldeia, 68600-000, Braganca, Para, Brazil. FAU - da Silva, Brenda Ribeiro Padilha AU - da Silva BRP AD - Instituto de Estudos Costeiros, Universidade Federal do Para, Alameda Leandro Ribeiro, s/n, Aldeia, 68600-000, Braganca, Para, Brazil. FAU - da Costa Baldez, Carlos Alessandro AU - da Costa Baldez CA AD - Faculdade de Matematica, Universidade Federal do Para, Alameda Leandro Ribeiro, s/n, Aldeia, 68600-000, Braganca, Para, Brazil. FAU - Costa, Rauquirio Marinho da AU - Costa RMD AD - Instituto de Estudos Costeiros, Universidade Federal do Para, Alameda Leandro Ribeiro, s/n, Aldeia, 68600-000, Braganca, Para, Brazil. FAU - Silva, Taynara Sousa da AU - Silva TSD AD - Instituto de Estudos Costeiros, Universidade Federal do Para, Alameda Leandro Ribeiro, s/n, Aldeia, 68600-000, Braganca, Para, Brazil. FAU - Silva Assis, Luciane Ferreira da AU - Silva Assis LFD AD - Instituto de Estudos Costeiros, Universidade Federal do Para, Alameda Leandro Ribeiro, s/n, Aldeia, 68600-000, Braganca, Para, Brazil. FAU - Jimenez, Jose A AU - Jimenez JA AD - Laboratori d'Enginyeria Maritima, Universitat Politecnica de Catalunya.BarcelonaTech, c/Jordi Girona 1-3, Campus Nord ed D1, 08034, Barcelona, Spain. LA - eng PT - Journal Article DEP - 20210225 PL - England TA - Ocean Coast Manag JT - Ocean & coastal management JID - 101518802 PMC - PMC7904457 OTO - NOTNLM OT - Amazon coast OT - Beach activities OT - Pandemic OT - Summer peak COIS- The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2021/03/03 06:00 MHDA- 2021/03/03 06:01 PMCR- 2021/02/25 CRDT- 2021/03/02 06:20 PHST- 2020/11/15 00:00 [received] PHST- 2021/02/14 00:00 [revised] PHST- 2021/02/17 00:00 [accepted] PHST- 2021/03/03 06:00 [pubmed] PHST- 2021/03/03 06:01 [medline] PHST- 2021/03/02 06:20 [entrez] PHST- 2021/02/25 00:00 [pmc-release] AID - S0964-5691(21)00061-2 [pii] AID - 105576 [pii] AID - 10.1016/j.ocecoaman.2021.105576 [doi] PST - ppublish SO - Ocean Coast Manag. 2021 Jun 1;206:105576. doi: 10.1016/j.ocecoaman.2021.105576. Epub 2021 Feb 25. PMID- 33647707 OWN - NLM STAT- MEDLINE DCOM- 20210426 LR - 20250530 IS - 1873-6327 (Electronic) IS - 0306-4603 (Print) IS - 0306-4603 (Linking) VI - 118 DP - 2021 Jul TI - The impact of the initial Covid-19 lockdown upon regular sports bettors in Britain: Findings from a cross-sectional online study. PG - 106876 LID - S0306-4603(21)00061-7 [pii] LID - 10.1016/j.addbeh.2021.106876 [doi] AB - BACKGROUND: In Britain, unprecedented restrictions on daily life associated with the Covid-19 pandemic included the suspension of professional sports events during the initial 'lockdown'. This provides opportunities to observe changes in sports bettors' behaviour when their primary form of activity is removed and assess the impact of Covid-19 related circumstances upon gambling. METHODS: In July 2020, we conducted an online cross-sectional survey of people who bet regularly (at least monthly) on sports before Covid-19 (n = 3866). Bi-variate analyses compared changes in gambling behaviours before and during the initial lockdown. Multi-variate logistic regression models explored associations between problem gambling (men) and moderate risk or problem gambling (MRPG) (women) with changes in Covid-19 related circumstances and changing gambling behaviours during Britain's initial 'lockdown' (March-June 2020). RESULTS: 29.8% of male sports bettors and 33.4% of female sports bettors stopped gambling altogether during the initial Covid-19 lockdown, though 17.3% of men and 16.5% of women started a new form of gambling during lockdown. Among men, adjusted odds ratios of problem gambling were higher among those starting a new gambling activity during lockdown (OR = 2.50 [95% CI 1.38-4.53]). Among women, adjusted odds ratios of MRPG were higher among those whose frequency of gambling on any activity increased during lockdown (OR = 4.21 [1.99-8.92] and among those shielding for health reasons. Poorer wellbeing was associated with problem gambling for men and MRPG for women. CONCLUSIONS: Those changing gambling behaviours during the initial Covid-19 lockdown (e.g. increasing gambling frequency or starting a new gambling activity) are potentially vulnerable to gambling harms. CI - Copyright (c) 2021 The Author(s). Published by Elsevier Ltd.. All rights reserved. FAU - Wardle, Heather AU - Wardle H AD - School of Social and Political Sciences, University of Glasgow, Adam Smith Building, Bute Gardens, Glasgow G12 8RT, UK; Faculty of Public Health and Policy, London School of Hygiene and Tropical Medicine, 15-17 Tavistock Place, London WC1H 9SH, UK. Electronic address: Heather.wardle@glasgow.ac.uk. FAU - Donnachie, Craig AU - Donnachie C AD - School of Social and Political Sciences, University of Glasgow, Adam Smith Building, Bute Gardens, Glasgow G12 8RT, UK. FAU - Critchlow, Nathan AU - Critchlow N AD - Institute of Social Marketing, University of Stirling, Stirling FK9 4LA, UK. FAU - Brown, Ashley AU - Brown A AD - Institute of Social Marketing, University of Stirling, Stirling FK9 4LA, UK. FAU - Bunn, Christopher AU - Bunn C AD - School of Social and Political Sciences, University of Glasgow, Adam Smith Building, Bute Gardens, Glasgow G12 8RT, UK. FAU - Dobbie, Fiona AU - Dobbie F AD - Usher Institute, University of Edinburgh, Doorway 1, Old Medical School, Teviot Place, Edinburgh EH8 9AG, UK. FAU - Gray, Cindy AU - Gray C AD - Institute of Health and Wellbeing, Room 230, 25-29 Bute Gardens, Glasgow G12 8RS, UK. FAU - Mitchell, Danielle AU - Mitchell D AD - Institute of Social Marketing, University of Stirling, Stirling FK9 4LA, UK. FAU - Purves, Richard AU - Purves R AD - Institute of Social Marketing, University of Stirling, Stirling FK9 4LA, UK. FAU - Reith, Gerda AU - Reith G AD - School of Social and Political Sciences, University of Glasgow, Adam Smith Building, Bute Gardens, Glasgow G12 8RT, UK. FAU - Stead, Martine AU - Stead M AD - Institute of Social Marketing, University of Stirling, Stirling FK9 4LA, UK. FAU - Hunt, Kate AU - Hunt K AD - Institute of Social Marketing, University of Stirling, Stirling FK9 4LA, UK. LA - eng GR - MR/S019200/1/MRC_/Medical Research Council/United Kingdom PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20210223 PL - England TA - Addict Behav JT - Addictive behaviors JID - 7603486 SB - IM MH - *COVID-19 MH - Communicable Disease Control MH - Cross-Sectional Studies MH - Female MH - *Gambling/epidemiology MH - Humans MH - Male MH - Pandemics MH - *Sports MH - United Kingdom/epidemiology PMC - PMC9757982 OTO - NOTNLM OT - Covid-19 OT - Gambling OT - Gambling harms OT - Sports betting EDAT- 2021/03/02 06:00 MHDA- 2021/04/27 06:00 PMCR- 2021/02/23 CRDT- 2021/03/01 20:16 PHST- 2020/11/10 00:00 [received] PHST- 2021/02/04 00:00 [revised] PHST- 2021/02/08 00:00 [accepted] PHST- 2021/03/02 06:00 [pubmed] PHST- 2021/04/27 06:00 [medline] PHST- 2021/03/01 20:16 [entrez] PHST- 2021/02/23 00:00 [pmc-release] AID - S0306-4603(21)00061-7 [pii] AID - 106876 [pii] AID - 10.1016/j.addbeh.2021.106876 [doi] PST - ppublish SO - Addict Behav. 2021 Jul;118:106876. doi: 10.1016/j.addbeh.2021.106876. Epub 2021 Feb 23. PMID- 33639028 OWN - NLM STAT- MEDLINE DCOM- 20211210 LR - 20231107 IS - 1365-277X (Electronic) IS - 0952-3871 (Print) IS - 0952-3871 (Linking) VI - 34 IP - 5 DP - 2021 Oct TI - Caregivers' feeding behaviour, children's eating behaviour and weight status among children of preschool age in China. PG - 807-818 LID - 10.1111/jhn.12869 [doi] AB - BACKGROUND: Childhood overweight and obesity have become significant public health challenges worldwide. The present study aimed to investigate whether caregivers' feeding behaviour and children's eating behaviour were associated with the weight status of preschool children in China. METHODS: A cross-sectional questionnaire was administered to 912 caregivers of preschool children from April to July 2016. Caregivers' feeding behaviours were assessed by the Chinese Preschooler's Caregiver Feeding Behaviour Scale. Children's eating behaviours were evaluated using the Chinese Preschooler's Eating Behaviour Questionnaire. After controlling for demographic characteristics, multiple linear regression and logistic regression analyses were performed to evaluate the relationship between caregivers' feeding behaviour, children's eating behaviour and children's body mass index (BMI). RESULTS: The results showed that weight concerns on the part of caregivers (beta = 0.53) and food responsiveness on the part of children (beta = 0.93) were positively correlated with children's BMI, whereas caregivers' responsibility for feeding (beta = -0.68) and children's external eating (beta = -0.53) were negatively correlated with BMI. Among caregiver feeding behaviours, weight concerns [odds ratio (OR) =4.54, p < 0.001] and behaviour-restricted feeding (OR =0.29, p < 0.001) were positively correlated with children's BMI. A child's food responsiveness (OR =4.04, p < 0.001) was also positively correlated with his/her BMI, whereas the child's satiety responsiveness (OR =0.42, p < 0.001) and emotional eating habits (OR =0.56, p < 0.001) were negatively correlated with overweight/obesity status. CONCLUSIONS: Our study demonstrated that children's eating behaviour and caregivers' feeding behaviour were associated with weight status among preschool children in China. Behaviour interventions on caregivers and their children may prevent or reduce weight problems in preschool children. CI - (c) 2021 The Authors. Journal of Human Nutrition and Dietetics published by John Wiley & Sons Ltd on behalf of British Dietetic Association. FAU - Yuan, Jing AU - Yuan J AD - Department of Health Statistics, School of Public Health, Fourth Military Medical University, Xi'an, China. AD - Department of Medical Information, PLA 960th Hospital, Jinan, China. FAU - Jiang, Xun AU - Jiang X AD - Tangdu Hospital, Fourth Military Medical University, Xi'an, China. FAU - Zhu, Tongyu AU - Zhu T AD - Department of Obstetrics and Gynecology, PLA 960th Hospital, Jinan, China. FAU - Zhang, Yuhai AU - Zhang Y AD - Department of Health Statistics, School of Public Health, Fourth Military Medical University, Xi'an, China. FAU - Wang, Yue AU - Wang Y AD - Department of Health Statistics, School of Public Health, Fourth Military Medical University, Xi'an, China. FAU - Yang, Xianjun AU - Yang X AD - Prevention and Control Centre for Disease, Chengdu Military Command, Chengdu, China. FAU - Shang, Lei AU - Shang L AUID- ORCID: 0000-0003-0470-0066 AD - Department of Health Statistics, School of Public Health, Fourth Military Medical University, Xi'an, China. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20210227 PL - England TA - J Hum Nutr Diet JT - Journal of human nutrition and dietetics : the official journal of the British Dietetic Association JID - 8904840 SB - IM MH - Body Mass Index MH - *Caregivers MH - Child MH - Child Behavior MH - Child, Preschool MH - Cross-Sectional Studies MH - *Feeding Behavior MH - Female MH - Humans MH - Male MH - Overweight/epidemiology MH - Surveys and Questionnaires PMC - PMC8518084 OTO - NOTNLM OT - BMI OT - eating behaviour OT - feeding behaviour OT - overweight/obesity OT - preschool children COIS- The authors have no conflicts of interest. EDAT- 2021/02/28 06:00 MHDA- 2021/12/15 06:00 PMCR- 2021/10/15 CRDT- 2021/02/27 17:04 PHST- 2020/10/30 00:00 [revised] PHST- 2020/08/13 00:00 [received] PHST- 2020/12/07 00:00 [accepted] PHST- 2021/02/28 06:00 [pubmed] PHST- 2021/12/15 06:00 [medline] PHST- 2021/02/27 17:04 [entrez] PHST- 2021/10/15 00:00 [pmc-release] AID - JHN12869 [pii] AID - 10.1111/jhn.12869 [doi] PST - ppublish SO - J Hum Nutr Diet. 2021 Oct;34(5):807-818. doi: 10.1111/jhn.12869. Epub 2021 Feb 27. PMID- 33626977 OWN - NLM STAT- MEDLINE DCOM- 20220411 LR - 20220705 IS - 1552-5708 (Electronic) IS - 0891-9887 (Print) IS - 0891-9887 (Linking) VI - 35 IP - 3 DP - 2022 May TI - Emotional and Mental Wellbeing Following COVID-19 Public Health Measures on People Living With Dementia and Carers. PG - 344-352 LID - 10.1177/0891988721996816 [doi] AB - BACKGROUND: To date, there appears to be no evidence on the longer-term impacts caused by COVID-19 and its related public health restrictions on some of the most vulnerable in our societies. The aim of this research was to explore the change in impact of COVID-19 public health measures on the mental wellbeing of people living with dementia (PLWD) and unpaid carers. METHOD: Semi-structured, follow-up telephone interviews were conducted with PLWD and unpaid carers between June and July 2020. Participants were asked about their experiences of accessing social support services during the pandemic, and the impact of restrictions on their daily lives. RESULTS: 20 interviews were conducted and thematically analyzed, which produced 3 primary themes concerning emotional responses and impact to mental health and wellbeing during the course of the pandemic: 1) Impact on mental health during lockdown, 2) Changes to mental health following easing of public health, and 3) The long-term effect of public health measures. CONCLUSIONS: The findings from this research shed light on the longer-term psychological impacts of the UK Government's public health measures on PLWD and their carers. The loss of social support services was key in impacting this cohort mentally and emotionally, displaying a need for better psychological support, for both carers and PLWD. FAU - Hanna, Kerry AU - Hanna K AUID- ORCID: 0000-0001-7357-7749 AD - Department of Primary Care & Mental Health, 4591University of Liverpool, Liverpool, UK. AD - Kerry Hanna and Clarissa Giebel are joint first authors. FAU - Giebel, Clarissa AU - Giebel C AD - Department of Primary Care & Mental Health, 4591University of Liverpool, Liverpool, UK. AD - NIHR ARC NWC, Liverpool, UK. AD - Kerry Hanna and Clarissa Giebel are joint first authors. FAU - Tetlow, Hilary AU - Tetlow H AD - SURF Liverpool, Liverpool, UK. FAU - Ward, Kym AU - Ward K AD - 130122The Brain Charity, Liverpool, UK. FAU - Shenton, Justine AU - Shenton J AD - Sefton Older People's Forum, Liverpool, UK. FAU - Cannon, Jacqueline AU - Cannon J AD - Wigan Dementia Action Alliance, Liverpool, UK. AD - Lewy Body Society, Liverpool, UK. FAU - Komuravelli, Aravind AU - Komuravelli A AD - 8255North West Boroughs NHS Trust, Warrington, UK. FAU - Gaughan, Anna AU - Gaughan A AD - Together In Dementia Everyday (TIDE), Liverpool, UK. FAU - Eley, Ruth AU - Eley R AD - Liverpool Dementia Action Alliance, Liverpool, UK. FAU - Rogers, Carol AU - Rogers C AD - 71283National Museums Liverpool, Liverpool, UK. FAU - Rajagopal, Manoj AU - Rajagopal M AD - Lancashire and South Cumbria NHS Trust, Liverpool, UK. FAU - Limbert, Stan AU - Limbert S AD - NIHR ARC NWC, Liverpool, UK. FAU - Callaghan, Steve AU - Callaghan S AD - EQE Health, Liverpool, UK. FAU - Whittington, Rosie AU - Whittington R AD - Me2U Day Care Centre, Liverpool, UK. FAU - Butchard, Sarah AU - Butchard S AD - Department of Primary Care & Mental Health, 4591University of Liverpool, Liverpool, UK. AD - NIHR ARC NWC, Liverpool, UK. FAU - Shaw, Lisa AU - Shaw L AD - Department of Modern Languages and Cultures, 4591University of Liverpool, Liverpool, UK. FAU - Gabbay, Mark AU - Gabbay M AD - Department of Primary Care & Mental Health, 4591University of Liverpool, Liverpool, UK. AD - NIHR ARC NWC, Liverpool, UK. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20210225 PL - United States TA - J Geriatr Psychiatry Neurol JT - Journal of geriatric psychiatry and neurology JID - 8805645 SB - IM MH - *COVID-19 MH - Caregivers/psychology MH - Communicable Disease Control MH - *Dementia MH - Emotions MH - Humans MH - Public Health MH - SARS-CoV-2 PMC - PMC8996307 OTO - NOTNLM OT - alzheimer's disease OT - anxiety OT - caregiver burden OT - dementia OT - elderly OT - health services research COIS- Declaration of Conflicting Interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. EDAT- 2021/02/26 06:00 MHDA- 2022/04/12 06:00 PMCR- 2022/04/11 CRDT- 2021/02/25 05:30 PHST- 2021/02/26 06:00 [pubmed] PHST- 2022/04/12 06:00 [medline] PHST- 2021/02/25 05:30 [entrez] PHST- 2022/04/11 00:00 [pmc-release] AID - 10.1177_0891988721996816 [pii] AID - 10.1177/0891988721996816 [doi] PST - ppublish SO - J Geriatr Psychiatry Neurol. 2022 May;35(3):344-352. doi: 10.1177/0891988721996816. Epub 2021 Feb 25. PMID- 33625499 OWN - NLM STAT- MEDLINE DCOM- 20220117 LR - 20240824 IS - 2168-6238 (Electronic) IS - 2168-622X (Print) IS - 2168-622X (Linking) VI - 78 IP - 5 DP - 2021 May 1 TI - Association of Attention-Deficit/Hyperactivity Disorder in Childhood and Adolescence With the Risk of Subsequent Psychotic Disorder: A Systematic Review and Meta-analysis. PG - 519-529 LID - 10.1001/jamapsychiatry.2020.4799 [doi] AB - IMPORTANCE: Growing evidence supports an association between attention-deficit/hyperactivity disorder (ADHD) in childhood and subsequent psychotic disorders. Both disorders share physiopathological features such as attention deficits, dopaminergic imbalance, and genetic susceptibility. However, the results of epidemiologic studies have been conflicting. OBJECTIVE: To provide a quantitative synthesis of studies exploring the association between ADHD and the risk of subsequent psychotic disorder. DATA SOURCES: A systematic literature search of the MEDLINE, Scopus, PsycInfo, and Web of Science databases was performed from inception until the final analysis on July 7, 2020. No restriction of language was applied. STUDY SELECTION: Cohort and case-control studies examining the relative risk of developing a psychotic disorder in people diagnosed with ADHD at younger than 18 years compared with control individuals without ADHD. DATA EXTRACTION AND SYNTHESIS: Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) and Meta-analysis of Observational Studies in Epidemiology (MOOSE) guidelines were followed in reporting results. Two independent reviewers extracted the data and assessed the risk of bias of individual studies using the Newcastle-Ottawa Scale. Preferably adjusted odds ratios (aORs) or hazard ratios from the identified studies were extracted, and ORs were computed when they were not adjusted. A random-effects model was used to calculate the pooled relative effect using the meta package in R. MAIN OUTCOMES AND MEASURES: An association between ADHD (exposure) and psychotic disorder (outcomes); both diagnoses were based on international classification. RESULTS: A total of 15 studies were included in the review. Twelve studies were pooled in the meta-analysis, representing 1.85 million participants. A diagnosis of ADHD in childhood was associated with a significant increase in the risk of subsequent psychotic disorder, with a pooled relative effect of 4.74 (95% CI, 4.11-5.46; I2 = 43% [95% CI, 0%-70%]). No significant between-group differences were found for subgroup analyses according to psychotic disorder (odds ratio [OR], 5.04; 95% CI, 4.36-5.83) or schizophrenia (OR, 4.59; 95% CI, 3.83-5.50) outcomes, cohort (OR, 4.64; 95% CI, 4.04-5.34) or case-control (OR, 6.81; 95% CI, 4.21-11.03) study design, and adjusted (OR, 4.72; 95% CI, 4.11-5.46) or unadjusted (OR, 3.81; 95% CI, 1.39-10.49) estimates. Meta-regressions were not significant when sex and bias score were used as covariates. No evidence of publication bias was found. CONCLUSIONS AND RELEVANCE: These findings suggest that childhood ADHD is associated with an increased risk of a subsequent psychotic disorder. Further studies are required to determine the mechanisms linking these common conditions and whether early intervention for ADHD might reduce the risk of subsequent psychotic disorder. FAU - Nourredine, Mikail AU - Nourredine M AD - Service Hospitalo-Universitaire de Pharmacotoxicologie de Lyon, Hospices Civils de Lyon, Lyon, France. AD - Service Universitaire d'Addictologie de Lyon, Centre Hospitalier Le Vinatier, Bron, France. FAU - Gering, Adrien AU - Gering A AD - Centre d'Evaluation et de Diagnostic de l'Autisme et Autres Troubles du Neurodeveloppement, Centre Hospitalier Le Vinatier, Bron, France. FAU - Fourneret, Pierre AU - Fourneret P AD - Service de Psychopathologie de l'Enfant et du Developpement, Hospices Civils de Lyon, Lyon, France. FAU - Rolland, Benjamin AU - Rolland B AD - Service Universitaire d'Addictologie de Lyon, Centre Hospitalier Le Vinatier, Bron, France. AD - Universite de Lyon, Universite Claude Bernard Lyon, Centre de Recherche en Neurosciences de Lyon, Institut National de la Sante et de la Recherche Medicale (INSERM) U1028, Centre National de la Recherche Scientifique (CNRS) Unite Mixte de Recherche (UMR) 5292, Psychiatric Disorders: Neuroscience Research And Clinical Research 2, Lyon, France. FAU - Falissard, Bruno AU - Falissard B AD - Centre de Recherche en Epidemiologie et en Sante des Populations, INSERM U1018, Universite Paris-Saclay, Paris, France. FAU - Cucherat, Michel AU - Cucherat M AD - Laboratoire de Biometrie et Biologie Evolutive, Service de Pharmacologie Clinique, UMR CNRS 5558, Lyon, France. FAU - Geoffray, Marie-Maude AU - Geoffray MM AD - Centre d'Evaluation et de Diagnostic de l'Autisme et Autres Troubles du Neurodeveloppement, Centre Hospitalier Le Vinatier, Bron, France. AD - Health Services and Performance Research EA7425, Universite Lyon 1, Lyon, France. FAU - Jurek, Lucie AU - Jurek L AD - Centre d'Evaluation et de Diagnostic de l'Autisme et Autres Troubles du Neurodeveloppement, Centre Hospitalier Le Vinatier, Bron, France. AD - Health Services and Performance Research EA7425, Universite Lyon 1, Lyon, France. LA - eng PT - Journal Article PT - Meta-Analysis PT - Systematic Review PL - United States TA - JAMA Psychiatry JT - JAMA psychiatry JID - 101589550 SB - IM MH - Adolescent MH - Adult MH - Attention Deficit Disorder with Hyperactivity/*epidemiology MH - Child MH - *Comorbidity MH - Humans MH - Psychotic Disorders/*epidemiology MH - Risk PMC - PMC7905700 COIS- Conflict of Interest Disclosures: Dr Nourredine reported receiving nonfinancial support from HAC Pharma and Janssen-Cilag Ltd outside the submitted work. Dr Rolland reported receiving personal fees from Shire plc and nonfinancial support from HAC Pharma during the conduct of the study and personal fees from Indivior plc, Ethypharm, Grunenthal, Jansen Global Services, LLC, Otsuka Pharmaceutical Co, Ltd, Gilead Sciences, Inc, and AbbVie, grants from Camurus AB, Gilead Sciences, Inc, and Merck Sharp & Dohme, and nonfinancial support from Recordati SpA outside the submitted work. Dr Falissard reported receiving personal fees from Eli Lilly and Company, Bristol Myers Squibb, Servier Laboratories, GlaxoSmithKline, HRA Pharma, F. Hoffmann-La Roche AG, Boehringer Ingelheim, Bayer AG, Almirall, SA, Allergan Plc, Stallergenes Greer, Sanofi Genzyme, Pierre Fabre Group, AstraZeneca, Novartis AG, Janssen Global Services, LLC, Astellas Pharma US, Inc, Biotronik, Daiichi Sankyo Company Limited, Gilead Sciences, Inc, Merck Sharp & Dohme, H Lundbeck A/S, Actelion Pharmaceuticals US, Inc, AbbVie, Alnylam Pharmaceuticals, Inc, Amgen, Inc, Biocodex, Biogen, BioSpec, Bioprojet, Biotronik, Celgene Corporation, Chiesi USA, Inc, D&A Pharma, Eisai Co, Ltd, Ethypharm, Laboratoires Genevrier, Grunenthal, IDM Pharma Inc, Idorsia Pharmaceuticals Ltd, Indivior PLC, LEO Pharma A/S, The Menarini Group, Novo Nordisk A/S, Otsuka Pharmaceutical Co, Ltd, Pfizer, Inc, Recordati SpA, Takeda Pharmaceutical Company Limited, and UCB SA outside the submitted work. Dr Jurek reported receiving personal fees from Servier Laboratories outside the submitted work. No other disclosures were reported. EDAT- 2021/02/25 06:00 MHDA- 2022/01/18 06:00 PMCR- 2022/02/24 CRDT- 2021/02/24 12:11 PHST- 2021/02/25 06:00 [pubmed] PHST- 2022/01/18 06:00 [medline] PHST- 2021/02/24 12:11 [entrez] PHST- 2022/02/24 00:00 [pmc-release] AID - 2776916 [pii] AID - yoi200092 [pii] AID - 10.1001/jamapsychiatry.2020.4799 [doi] PST - ppublish SO - JAMA Psychiatry. 2021 May 1;78(5):519-529. doi: 10.1001/jamapsychiatry.2020.4799. PMID- 33621720 OWN - NLM STAT- MEDLINE DCOM- 20210728 LR - 20240908 IS - 1873-491X (Electronic) IS - 0020-7489 (Print) IS - 0020-7489 (Linking) VI - 117 DP - 2021 May TI - Strict isolation requires a different approach to the family of hospitalised patients with COVID-19: A rapid qualitative study. PG - 103858 LID - S0020-7489(20)30349-7 [pii] LID - 10.1016/j.ijnurstu.2020.103858 [doi] AB - BACKGROUND: The outbreak of the COVID-19 pandemic influenced family-centred care dramatically due to restricting visiting policies. In this new situation, nurses were challenged to develop new approaches to involve family members in patient care. A better understanding of these changes and the experiences of nurses is essential to make an adaptation of procedures, and to secure a family-centred approach in care as much as possible. OBJECTIVES: The aim of this study was to investigate how family involvement had taken place, and to explore the experiences of nurses with family involvement during the COVID-19 outbreak. In addition, we aimed to formulate recommendations for the involvement of family. METHODS: We conducted a qualitative study using patient record review and focus-group interviews between April and July 2020. We reviewed records of patients with confirmed COVID-19, who were admitted to the COVID-19 wards at two affiliated university hospitals in the Netherlands. All records were searched for notations referring to family involvement. In two focus-groups, nurses who worked at the COVID-19 wards were invited to share their experiences. The Rigorous and Accelerated Data Reduction (RADaR) method was used to collect, reduce and analyse the data. RESULTS: In total, 189 patient records were reviewed and nine nurses participated in the focus-group meetings. Patient records revealed infrequent and often unstructured communication with focus on physical condition. Nurses confirmed that communication with family was far less than before and that the physical condition of the patient was predominant. The involvement of family in care was limited to practicalities, although more involvement was described in end-of-life situations. Nurses experienced moral distress due to the visiting restrictions, though some acknowledged that they had experienced the direct patient care so intense and burdensome, that family contact simply felt too much. CONCLUSION: The communication with and involvement of family in hospital care changed enormously during the COVID-19 outbreak. Based on the identified themes, we formulated recommendations that may be helpful for family-centered care in hospitals during periods of restricted visiting policy. CI - Copyright (c) 2021 The Authors. Published by Elsevier Ltd.. All rights reserved. FAU - Maaskant, J M AU - Maaskant JM AD - Emma Children's Hospital, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands. Electronic address: j.m.maaskant@amsterdamumc.nl. FAU - Jongerden, I P AU - Jongerden IP AD - Department of Public and Occupational Health, Amsterdam Public Health research institute, Amsterdam UMC, VU University, Amsterdam, the Netherlands. FAU - Bik, J AU - Bik J AD - Department of Internal Medicine, Amsterdam UMC, VU University, Amsterdam, the Netherlands. FAU - Joosten, M AU - Joosten M AD - Department of Internal Medicine, Amsterdam UMC, VU University, Amsterdam, the Netherlands. FAU - Musters, S AU - Musters S AD - Department of Surgery, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands. FAU - Storm-Versloot, M N AU - Storm-Versloot MN AD - Department of Surgery, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands. FAU - Wielenga, J AU - Wielenga J AD - Emma Children's Hospital, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands. FAU - Eskes, A M AU - Eskes AM AD - Department of Surgery, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands; Menzies Health Institute Queensland and School of Nursing and Midwifery, Griffith University, Gold Coast, Australia. CN - FAM-Corona Group LA - eng PT - Journal Article DEP - 20201224 PL - England TA - Int J Nurs Stud JT - International journal of nursing studies JID - 0400675 SB - IM MH - *COVID-19 MH - Humans MH - Netherlands MH - *Pandemics MH - Qualitative Research MH - SARS-CoV-2 PMC - PMC7834466 OTO - NOTNLM OT - COVID-19 OT - Communication OT - Family involvement OT - Family-centred care OT - Nursing care EDAT- 2021/02/24 06:00 MHDA- 2021/07/29 06:00 PMCR- 2020/12/24 CRDT- 2021/02/23 20:09 PHST- 2020/10/24 00:00 [received] PHST- 2020/12/12 00:00 [revised] PHST- 2020/12/16 00:00 [accepted] PHST- 2021/02/24 06:00 [pubmed] PHST- 2021/07/29 06:00 [medline] PHST- 2021/02/23 20:09 [entrez] PHST- 2020/12/24 00:00 [pmc-release] AID - S0020-7489(20)30349-7 [pii] AID - 103858 [pii] AID - 10.1016/j.ijnurstu.2020.103858 [doi] PST - ppublish SO - Int J Nurs Stud. 2021 May;117:103858. doi: 10.1016/j.ijnurstu.2020.103858. Epub 2020 Dec 24. PMID- 33620086 OWN - NLM STAT- MEDLINE DCOM- 20210304 LR - 20231107 IS - 1469-493X (Electronic) IS - 1361-6137 (Linking) VI - 2 IP - 2 DP - 2021 Feb 23 TI - Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19. PG - CD013665 LID - 10.1002/14651858.CD013665.pub2 [doi] LID - CD013665 AB - BACKGROUND: The clinical implications of SARS-CoV-2 infection are highly variable. Some people with SARS-CoV-2 infection remain asymptomatic, whilst the infection can cause mild to moderate COVID-19 and COVID-19 pneumonia in others. This can lead to some people requiring intensive care support and, in some cases, to death, especially in older adults. Symptoms such as fever, cough, or loss of smell or taste, and signs such as oxygen saturation are the first and most readily available diagnostic information. Such information could be used to either rule out COVID-19, or select patients for further testing. This is an update of this review, the first version of which published in July 2020. OBJECTIVES: To assess the diagnostic accuracy of signs and symptoms to determine if a person presenting in primary care or to hospital outpatient settings, such as the emergency department or dedicated COVID-19 clinics, has COVID-19. SEARCH METHODS: For this review iteration we undertook electronic searches up to 15 July 2020 in the Cochrane COVID-19 Study Register and the University of Bern living search database. In addition, we checked repositories of COVID-19 publications. We did not apply any language restrictions. SELECTION CRITERIA: Studies were eligible if they included patients with clinically suspected COVID-19, or if they recruited known cases with COVID-19 and controls without COVID-19. Studies were eligible when they recruited patients presenting to primary care or hospital outpatient settings. Studies in hospitalised patients were only included if symptoms and signs were recorded on admission or at presentation. Studies including patients who contracted SARS-CoV-2 infection while admitted to hospital were not eligible. The minimum eligible sample size of studies was 10 participants. All signs and symptoms were eligible for this review, including individual signs and symptoms or combinations. We accepted a range of reference standards. DATA COLLECTION AND ANALYSIS: Pairs of review authors independently selected all studies, at both title and abstract stage and full-text stage. They resolved any disagreements by discussion with a third review author. Two review authors independently extracted data and resolved disagreements by discussion with a third review author. Two review authors independently assessed risk of bias using the Quality Assessment tool for Diagnostic Accuracy Studies (QUADAS-2) checklist. We presented sensitivity and specificity in paired forest plots, in receiver operating characteristic space and in dumbbell plots. We estimated summary parameters using a bivariate random-effects meta-analysis whenever five or more primary studies were available, and whenever heterogeneity across studies was deemed acceptable. MAIN RESULTS: We identified 44 studies including 26,884 participants in total. Prevalence of COVID-19 varied from 3% to 71% with a median of 21%. There were three studies from primary care settings (1824 participants), nine studies from outpatient testing centres (10,717 participants), 12 studies performed in hospital outpatient wards (5061 participants), seven studies in hospitalised patients (1048 participants), 10 studies in the emergency department (3173 participants), and three studies in which the setting was not specified (5061 participants). The studies did not clearly distinguish mild from severe COVID-19, so we present the results for all disease severities together. Fifteen studies had a high risk of bias for selection of participants because inclusion in the studies depended on the applicable testing and referral protocols, which included many of the signs and symptoms under study in this review. This may have especially influenced the sensitivity of those features used in referral protocols, such as fever and cough. Five studies only included participants with pneumonia on imaging, suggesting that this is a highly selected population. In an additional 12 studies, we were unable to assess the risk for selection bias. This makes it very difficult to judge the validity of the diagnostic accuracy of the signs and symptoms from these included studies. The applicability of the results of this review update improved in comparison with the original review. A greater proportion of studies included participants who presented to outpatient settings, which is where the majority of clinical assessments for COVID-19 take place. However, still none of the studies presented any data on children separately, and only one focused specifically on older adults. We found data on 84 signs and symptoms. Results were highly variable across studies. Most had very low sensitivity and high specificity. Only cough (25 studies) and fever (7 studies) had a pooled sensitivity of at least 50% but specificities were moderate to low. Cough had a sensitivity of 67.4% (95% confidence interval (CI) 59.8% to 74.1%) and specificity of 35.0% (95% CI 28.7% to 41.9%). Fever had a sensitivity of 53.8% (95% CI 35.0% to 71.7%) and a specificity of 67.4% (95% CI 53.3% to 78.9%). The pooled positive likelihood ratio of cough was only 1.04 (95% CI 0.97 to 1.11) and that of fever 1.65 (95% CI 1.41 to 1.93). Anosmia alone (11 studies), ageusia alone (6 studies), and anosmia or ageusia (6 studies) had sensitivities below 50% but specificities over 90%. Anosmia had a pooled sensitivity of 28.0% (95% CI 17.7% to 41.3%) and a specificity of 93.4% (95% CI 88.3% to 96.4%). Ageusia had a pooled sensitivity of 24.8% (95% CI 12.4% to 43.5%) and a specificity of 91.4% (95% CI 81.3% to 96.3%). Anosmia or ageusia had a pooled sensitivity of 41.0% (95% CI 27.0% to 56.6%) and a specificity of 90.5% (95% CI 81.2% to 95.4%). The pooled positive likelihood ratios of anosmia alone and anosmia or ageusia were 4.25 (95% CI 3.17 to 5.71) and 4.31 (95% CI 3.00 to 6.18) respectively, which is just below our arbitrary definition of a 'red flag', that is, a positive likelihood ratio of at least 5. The pooled positive likelihood ratio of ageusia alone was only 2.88 (95% CI 2.02 to 4.09). Only two studies assessed combinations of different signs and symptoms, mostly combining fever and cough with other symptoms. These combinations had a specificity above 80%, but at the cost of very low sensitivity (< 30%). AUTHORS' CONCLUSIONS: The majority of individual signs and symptoms included in this review appear to have very poor diagnostic accuracy, although this should be interpreted in the context of selection bias and heterogeneity between studies. Based on currently available data, neither absence nor presence of signs or symptoms are accurate enough to rule in or rule out COVID-19. The presence of anosmia or ageusia may be useful as a red flag for COVID-19. The presence of fever or cough, given their high sensitivities, may also be useful to identify people for further testing. Prospective studies in an unselected population presenting to primary care or hospital outpatient settings, examining combinations of signs and symptoms to evaluate the syndromic presentation of COVID-19, are still urgently needed. Results from such studies could inform subsequent management decisions. CI - Copyright (c) 2021 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration. FAU - Struyf, Thomas AU - Struyf T AD - Department of Public Health and Primary Care, KU Leuven, Leuven, Belgium. FAU - Deeks, Jonathan J AU - Deeks JJ AD - Test Evaluation Research Group, Institute of Applied Health Research, University of Birmingham, Birmingham, UK. AD - NIHR Birmingham Biomedical Research Centre, University Hospitals Birmingham NHS Foundation Trust and University of Birmingham, Birmingham, UK. FAU - Dinnes, Jacqueline AU - Dinnes J AD - Test Evaluation Research Group, Institute of Applied Health Research, University of Birmingham, Birmingham , UK. AD - NIHR Birmingham Biomedical Research Centre, University Hospitals Birmingham NHS Foundation Trust and University of Birmingham, Birmingham, UK. FAU - Takwoingi, Yemisi AU - Takwoingi Y AD - Test Evaluation Research Group, Institute of Applied Health Research, University of Birmingham, Birmingham, UK. AD - NIHR Birmingham Biomedical Research Centre, University Hospitals Birmingham NHS Foundation Trust and University of Birmingham, Birmingham, UK. FAU - Davenport, Clare AU - Davenport C AD - Test Evaluation Research Group, Institute of Applied Health Research, University of Birmingham, Birmingham, UK. AD - NIHR Birmingham Biomedical Research Centre, University Hospitals Birmingham NHS Foundation Trust and University of Birmingham, Birmingham, UK. FAU - Leeflang, Mariska Mg AU - Leeflang MM AD - Epidemiology and Data Science, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands. AD - Biomarker and Test Evaluation Programme (BiTE) , Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands. FAU - Spijker, Rene AU - Spijker R AD - Medical Library, Amsterdam UMC, University of Amsterdam, Amsterdam Public Health, Amsterdam, Netherlands. AD - Cochrane Netherlands, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands. FAU - Hooft, Lotty AU - Hooft L AD - Cochrane Netherlands, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht , Netherlands. FAU - Emperador, Devy AU - Emperador D AD - FIND, Geneva, Switzerland. FAU - Domen, Julie AU - Domen J AD - Department of Public Health and Primary Care, KU Leuven, Leuven, Belgium. FAU - Horn, Sebastiaan R A AU - Horn SRA AD - De Wijkpraktijk, Antwerp, Belgium. FAU - Van den Bruel, Ann AU - Van den Bruel A AD - Department of Public Health and Primary Care, KU Leuven, Leuven, Belgium. CN - Cochrane COVID-19 Diagnostic Test Accuracy Group AD - NIHR Birmingham Biomedical Research Centre, University Hospitals Birmingham NHS Foundation Trust and University of Birmingham, Birmingham, UK. LA - eng PT - Journal Article PT - Meta-Analysis PT - Systematic Review DEP - 20210223 PL - England TA - Cochrane Database Syst Rev JT - The Cochrane database of systematic reviews JID - 100909747 SB - IM UOF - Cochrane Database Syst Rev. 2020 Jul 7;7:CD013665. doi: 10.1002/14651858.CD013665. PMID: 32633856 UIN - Cochrane Database Syst Rev. 2022 May 20;5:CD013665. doi: 10.1002/14651858.CD013665.pub3. PMID: 35593186 MH - Ageusia/diagnosis/etiology MH - *Ambulatory Care MH - Anosmia/diagnosis/etiology MH - Arthralgia/diagnosis/etiology MH - Bias MH - COVID-19/complications/*diagnosis/epidemiology MH - Cough/diagnosis/etiology MH - Diarrhea/diagnosis/etiology MH - Dyspnea/diagnosis/etiology MH - Fatigue/diagnosis/etiology MH - Fever/diagnosis/etiology MH - Headache/diagnosis/etiology MH - Humans MH - Myalgia/diagnosis/etiology MH - Outpatient Clinics, Hospital/statistics & numerical data MH - Pandemics MH - Physical Examination MH - *Primary Health Care MH - *SARS-CoV-2 MH - Selection Bias MH - *Symptom Assessment/classification/statistics & numerical data PMC - PMC8407425 COIS- Thomas Struyf: none known Jonathan J Deeks: none known Jacqueline Dinnes: none known Yemisi Takwoingi: none known Clare Davenport: none known Mariska MG Leeflang: none known Rene Spijker: the Dutch Cochrane Centre (DCC) has received grants for performing commissioned systematic reviews. In no situation did the commissioner have any influence on the results of the work. Lotty Hooft: none known Devy Emperador: is employed by FIND. FIND is a global non-for profit product development partnership and WHO Diagnostic Collaboration Centre. It is FIND's role to accelerate access to high quality diagnostic tools for low resource settings and this is achieved by supporting both R&D and access activities for a wide range of diseases, including COVID-19. FIND has several clinical research projects to evaluate multiple new diagnostic tests against published Target Product Profiles that have been defined through consensus processes. These studies are for diagnostic products developed by private sector companies who provide access to know-how, equipment/reagents, and contribute through unrestricted donations as per FIND policy and external SAC review. Julie Domen: none known Sebastiaan Horn: none known Ann Van den Bruel: none known EDAT- 2021/02/24 06:00 MHDA- 2021/03/05 06:00 PMCR- 2021/02/23 CRDT- 2021/02/23 08:38 PHST- 2021/02/23 08:38 [entrez] PHST- 2021/02/24 06:00 [pubmed] PHST- 2021/03/05 06:00 [medline] PHST- 2021/02/23 00:00 [pmc-release] AID - CD013665.pub2 [pii] AID - 10.1002/14651858.CD013665.pub2 [doi] PST - epublish SO - Cochrane Database Syst Rev. 2021 Feb 23;2(2):CD013665. doi: 10.1002/14651858.CD013665.pub2. PMID- 33619195 OWN - NLM STAT- MEDLINE DCOM- 20210225 LR - 20210226 IS - 2044-6055 (Electronic) IS - 2044-6055 (Linking) VI - 11 IP - 2 DP - 2021 Feb 22 TI - Multidimensional dynamic healthcare personnel (HCP)-centric model from a low-income and middle-income country to support and protect COVID-19 warriors: a large prospective cohort study. PG - e043837 LID - 10.1136/bmjopen-2020-043837 [doi] LID - e043837 AB - OBJECTIVES: Healthcare personnel (HCP) are at an increased risk of acquiring COVID-19 infection especially in resource-restricted healthcare settings, and return to homes unfit for self-isolation, making them apprehensive about COVID-19 duty and transmission risk to their families. We aimed at implementing a novel multidimensional HCP-centric evidence-based, dynamic policy with the objectives to reduce risk of HCP infection, ensure welfare and safety of the HCP and to improve willingness to accept and return to duty. SETTING: Our tertiary care university hospital, with 12 600 HCP, was divided into high-risk, medium-risk and low-risk zones. In the high-risk and medium-risk zones, we organised training, logistic support, postduty HCP welfare and collected feedback, and sent them home after they tested negative for COVID-19. We supervised use of appropriate personal protective equipment (PPE) and kept communication paperless. PARTICIPANTS: We recruited willing low-risk HCP, aged <50 years, with no comorbidities to work in COVID-19 zones. Social distancing, hand hygiene and universal masking were advocated in the low-risk zone. RESULTS: Between 31 March and 20 July 2020, we clinically screened 5553 outpatients, of whom 3012 (54.2%) were COVID-19 suspects managed in the medium-risk zone. Among them, 346 (11.4%) tested COVID-19 positive (57.2% male) and were managed in the high-risk zone with 19 (5.4%) deaths. One (0.08%) of the 1224 HCP in high-risk zone, 6 (0.62%) of 960 HCP in medium-risk zone and 23 (0.18%) of the 12 600 HCP in the low-risk zone tested positive at the end of shift. All the 30 COVID-19-positive HCP have since recovered. This HCP-centric policy resulted in low transmission rates (<1%), ensured satisfaction with training (92%), PPE (90.8%), medical and psychosocial support (79%) and improved acceptance of COVID-19 duty with 54.7% volunteering for re-deployment. CONCLUSION: A multidimensional HCP-centric policy was effective in ensuring safety, satisfaction and welfare of HCP in a resource-poor setting and resulted in a willing workforce to fight the pandemic. CI - (c) Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. FAU - Dutta, Usha AU - Dutta U AD - Department of Gastroenterology, PGIMER, Chandigarh, India ushadutta@gmail.com. FAU - Sachan, Anurag AU - Sachan A AD - Department of Gastroenterology, PGIMER, Chandigarh, India. FAU - Premkumar, Madhumita AU - Premkumar M AUID- ORCID: 0000-0003-2961-4148 AD - Department of Gastroenterology, PGIMER, Chandigarh, India. AD - Department of Hepatology, PGIMER, Chandigarh, India. FAU - Gupta, Tulika AU - Gupta T AD - Department of Anatomy, PGIMER, Chandigarh, India. FAU - Sahoo, Swapnajeet AU - Sahoo S AD - Department of Psychiatry, PGIMER, Chandigarh, India. FAU - Grover, Sandeep AU - Grover S AD - Department of Psychiatry, PGIMER, Chandigarh, India. FAU - Sharma, Sugandhi AU - Sharma S AUID- ORCID: 0000-0001-7828-3547 AD - Department of Community Medicine and School of Public Health, PGIMER, Chandigarh, India. FAU - Lakshmi, P V M AU - Lakshmi PVM AD - Department of Community Medicine and School of Public Health, PGIMER, Chandigarh, India. FAU - Talati, Shweta AU - Talati S AD - Department of Hospital Administration, PGIMER, Chandigarh, India. FAU - Biswal, Manisha AU - Biswal M AD - Department of Microbiology, PGIMER, Chandigarh, India. FAU - Suri, Vikas AU - Suri V AD - Department of Internal Medicine, PGIMER, Chandigarh, India. FAU - Singh, Mini P AU - Singh MP AD - Department of Virology, PGIMER, Chandigarh, India. FAU - Ghai, Babita AU - Ghai B AD - Department of Anesthesia, PGIMER, Chandigarh, India. FAU - Chhabra, Rajesh AU - Chhabra R AD - Department of Neurosurgery, PGIMER, Chandigarh, India. FAU - Bharti, Bhavneet AU - Bharti B AD - Department of Pediatrics, PGIMER, Chandigarh, India. FAU - Samanta, Jayanta AU - Samanta J AD - Department of Gastroenterology, PGIMER, Chandigarh, India. FAU - Arora, Pankaj AU - Arora P AD - Department of Hospital Administration, PGIMER, Chandigarh, India. AD - Department of Internal Medicine, PGIMER, Chandigarh, India. FAU - Mohindra, Ritin AU - Mohindra R AD - Department of Internal Medicine, PGIMER, Chandigarh, India. FAU - Malhotra, Sunita AU - Malhotra S AD - Department of Dietetics, PGIMER, Chandigarh, India. FAU - Singh, Gurmeet AU - Singh G AD - Department of Community Medicine and School of Public Health, PGIMER, Chandigarh, India. FAU - Guru, Rashmi Ranjan AU - Guru RR AD - Department of Hospital Administration, PGIMER, Chandigarh, India. FAU - Pandey, Navin AU - Pandey N AD - Department of Hospital Administration, PGIMER, Chandigarh, India. FAU - Koushal, Vipin AU - Koushal V AD - Department of Hospital Administration, PGIMER, Chandigarh, India. FAU - Kumar, Ashok AU - Kumar A AD - Department of Hospital Administration, PGIMER, Chandigarh, India. FAU - Bhogal, Ranjitpal Singh AU - Bhogal RS AD - Department of Hospital Administration, PGIMER, Chandigarh, India. FAU - Aggarwal, Arun K AU - Aggarwal AK AD - Department of Community Medicine and School of Public Health, PGIMER, Chandigarh, India. FAU - Goel, Kapil AU - Goel K AD - Department of Community Medicine and School of Public Health, PGIMER, Chandigarh, India. FAU - Malhotra, Pankaj AU - Malhotra P AD - Department of Internal Medicine, PGIMER, Chandigarh, India. FAU - Yaddanapudi, Narayana AU - Yaddanapudi N AD - Department of Anesthesia, PGIMER, Chandigarh, India. FAU - Mahajan, Pranay AU - Mahajan P AD - Department of Hospital Administration, PGIMER, Chandigarh, India. FAU - Thakur, J S AU - Thakur JS AUID- ORCID: 0000-0003-1339-1429 AD - Department of Community Medicine and School of Public Health, PGIMER, Chandigarh, India. FAU - Sehgal, Rakesh AU - Sehgal R AD - Department of Parasitology, PGIMER, Chandigarh, India. FAU - Ghosh, Arnab AU - Ghosh A AD - Department of Virology, PGIMER, Chandigarh, India. FAU - Sehgal, Inderpaul Singh AU - Sehgal IS AUID- ORCID: 0000-0002-6505-6019 AD - Department of Pulmonology, PGIMER, Chandigarh, India. FAU - Agarwal, Ritesh AU - Agarwal R AD - Department of Pulmonology, PGIMER, Chandigarh, India. FAU - Jayashree, Muralidharan AU - Jayashree M AD - Department of Pediatrics, PGIMER, Chandigarh, India. FAU - Bhalla, Ashish AU - Bhalla A AD - Department of Internal Medicine, PGIMER, Chandigarh, India. FAU - Jain, Sanjay AU - Jain S AD - Department of Internal Medicine, PGIMER, Chandigarh, India. FAU - Kochhar, Rakesh AU - Kochhar R AUID- ORCID: 0000-0002-4077-6474 AD - Department of Gastroenterology, PGIMER, Chandigarh, India. FAU - Chakrabarti, Arunaloke AU - Chakrabarti A AD - Department of Microbiology, PGIMER, Chandigarh, India. FAU - Puri, Goverdhan Dutt AU - Puri GD AD - Department of Anesthesia, PGIMER, Chandigarh, India. FAU - Ram, Jagat AU - Ram J AD - Department of Ophthalmology, PGIMER, Chandigarh, India. LA - eng PT - Journal Article DEP - 20210222 PL - England TA - BMJ Open JT - BMJ open JID - 101552874 SB - IM MH - Adult MH - *COVID-19/epidemiology/prevention & control/therapy/transmission MH - Developing Countries MH - Female MH - Hospitals, University/organization & administration MH - Humans MH - *Infectious Disease Transmission, Patient-to-Professional/prevention & control MH - Male MH - *Medical Staff, Hospital/statistics & numerical data MH - Models, Organizational MH - *Occupational Diseases/epidemiology/prevention & control MH - Organizational Policy MH - Personal Protective Equipment MH - Prospective Studies MH - Risk Assessment MH - Tertiary Care Centers/organization & administration PMC - PMC7902325 OTO - NOTNLM OT - clinical governance OT - health & safety OT - health policy OT - human resource management OT - international health services OT - organisation of health services COIS- Competing interests: None declared. EDAT- 2021/02/24 06:00 MHDA- 2021/02/26 06:00 PMCR- 2021/02/24 CRDT- 2021/02/23 06:09 PHST- 2021/02/23 06:09 [entrez] PHST- 2021/02/24 06:00 [pubmed] PHST- 2021/02/26 06:00 [medline] PHST- 2021/02/24 00:00 [pmc-release] AID - bmjopen-2020-043837 [pii] AID - 10.1136/bmjopen-2020-043837 [doi] PST - epublish SO - BMJ Open. 2021 Feb 22;11(2):e043837. doi: 10.1136/bmjopen-2020-043837. PMID- 33612430 OWN - NLM STAT- MEDLINE DCOM- 20210405 LR - 20260929 IS - 2589-7500 (Electronic) IS - 2589-7500 (Linking) VI - 3 IP - 4 DP - 2021 Apr TI - Indirect acute effects of the COVID-19 pandemic on physical and mental health in the UK: a population-based study. PG - e217-e230 LID - S2589-7500(21)00017-0 [pii] LID - 10.1016/S2589-7500(21)00017-0 [doi] AB - BACKGROUND: There are concerns that the response to the COVID-19 pandemic in the UK might have worsened physical and mental health, and reduced use of health services. However, the scale of the problem is unquantified, impeding development of effective mitigations. We aimed to ascertain what has happened to general practice contacts for acute physical and mental health outcomes during the pandemic. METHODS: Using de-identified electronic health records from the Clinical Research Practice Datalink (CPRD) Aurum (covering 13% of the UK population), between 2017 and 2020, we calculated weekly primary care contacts for selected acute physical and mental health conditions: anxiety, depression, self-harm (fatal and non-fatal), severe mental illness, eating disorder, obsessive-compulsive disorder, acute alcohol-related events, asthma exacerbation, chronic obstructive pulmonary disease exacerbation, acute cardiovascular events (cerebrovascular accident, heart failure, myocardial infarction, transient ischaemic attacks, unstable angina, and venous thromboembolism), and diabetic emergency. Primary care contacts included remote and face-to-face consultations, diagnoses from hospital discharge letters, and secondary care referrals, and conditions were identified through primary care records for diagnoses, symptoms, and prescribing. Our overall study population included individuals aged 11 years or older who had at least 1 year of registration with practices contributing to CPRD Aurum in the specified period, but denominator populations varied depending on the condition being analysed. We used an interrupted time-series analysis to formally quantify changes in conditions after the introduction of population-wide restrictions (defined as March 29, 2020) compared with the period before their introduction (defined as Jan 1, 2017 to March 7, 2020), with data excluded for an adjustment-to-restrictions period (March 8-28). FINDINGS: The overall population included 9 863 903 individuals on Jan 1, 2017, and increased to 10 226 939 by Jan 1, 2020. Primary care contacts for almost all conditions dropped considerably after the introduction of population-wide restrictions. The largest reductions were observed for contacts for diabetic emergencies (odds ratio 0.35 [95% CI 0.25-0.50]), depression (0.53 [0.52-0.53]), and self-harm (0.56 [0.54-0.58]). In the interrupted time-series analysis, with the exception of acute alcohol-related events (0.98 [0.89-1.10]), there was evidence of a reduction in contacts for all conditions (anxiety 0.67 [0.66-0.67], eating disorders 0.62 [0.59-0.66], obsessive-compulsive disorder [0.69 [0.64-0.74]], self-harm 0.56 [0.54-0.58], severe mental illness 0.80 [0.78-0.83], stroke 0.59 [0.56-0.62], transient ischaemic attack 0.63 [0.58-0.67], heart failure 0.62 [0.60-0.64], myocardial infarction 0.72 [0.68-0.77], unstable angina 0.72 [0.60-0.87], venous thromboembolism 0.94 [0.90-0.99], and asthma exacerbation 0.88 [0.86-0.90]). By July, 2020, except for unstable angina and acute alcohol-related events, contacts for all conditions had not recovered to pre-lockdown levels. INTERPRETATION: There were substantial reductions in primary care contacts for acute physical and mental conditions following the introduction of restrictions, with limited recovery by July, 2020. Further research is needed to ascertain whether these reductions reflect changes in disease frequency or missed opportunities for care. Maintaining health-care access should be a key priority in future public health planning, including further restrictions. The conditions we studied are sufficiently severe that any unmet need will have substantial ramifications for the people with the conditions as well as health-care provision. FUNDING: Wellcome Trust Senior Fellowship, Health Data Research UK. CI - Copyright (c) 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved. FAU - Mansfield, Kathryn E AU - Mansfield KE AD - Department of Non-Communicable Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK. Electronic address: kathryn.mansfield@lshtm.ac.uk. FAU - Mathur, Rohini AU - Mathur R AD - Department of Non-Communicable Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK. FAU - Tazare, John AU - Tazare J AD - Department of Non-Communicable Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK. FAU - Henderson, Alasdair D AU - Henderson AD AD - Department of Non-Communicable Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK. FAU - Mulick, Amy R AU - Mulick AR AD - Department of Non-Communicable Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK. FAU - Carreira, Helena AU - Carreira H AD - Department of Non-Communicable Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK. FAU - Matthews, Anthony A AU - Matthews AA AD - Unit of Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden. FAU - Bidulka, Patrick AU - Bidulka P AD - Department of Non-Communicable Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK. FAU - Gayle, Alicia AU - Gayle A AD - National Heart and Lung Institute, Imperial College London, London, UK. FAU - Forbes, Harriet AU - Forbes H AD - Department of Non-Communicable Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK; Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK. FAU - Cook, Sarah AU - Cook S AD - Department of Non-Communicable Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK; Department of Community Medicine, University of Tromso-The Arctic University of Norway, Tromso, Norway. FAU - Wong, Angel Y S AU - Wong AYS AD - Department of Non-Communicable Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK. FAU - Strongman, Helen AU - Strongman H AD - Department of Non-Communicable Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK. FAU - Wing, Kevin AU - Wing K AD - Department of Non-Communicable Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK. FAU - Warren-Gash, Charlotte AU - Warren-Gash C AD - Department of Non-Communicable Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK. FAU - Cadogan, Sharon L AU - Cadogan SL AD - Department of Non-Communicable Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK. FAU - Smeeth, Liam AU - Smeeth L AD - Department of Non-Communicable Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK. FAU - Hayes, Joseph F AU - Hayes JF AD - Division of Psychiatry, University College London, London, UK. FAU - Quint, Jennifer K AU - Quint JK AD - National Heart and Lung Institute, Imperial College London, London, UK. FAU - McKee, Martin AU - McKee M AD - Department of Health Services Research and Policy, London School of Hygiene & Tropical Medicine, London, UK. FAU - Langan, Sinead M AU - Langan SM AD - Department of Non-Communicable Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK; Health Data Research UK, London, UK. LA - eng GR - 211085/Z/18/Z/WT_/Wellcome Trust/United Kingdom GR - 201375/Z/16/Z/WT_/Wellcome Trust/United Kingdom GR - 201440/WT_/Wellcome Trust/United Kingdom GR - 205039/WT_/Wellcome Trust/United Kingdom GR - 211085/WT_/Wellcome Trust/United Kingdom GR - MR/S019669/1/MRC_/Medical Research Council/United Kingdom GR - 205039/Z/16/Z/WT_/Wellcome Trust/United Kingdom GR - 201440/Z/16/Z/WT_/Wellcome Trust/United Kingdom GR - 201375/WT_/Wellcome Trust/United Kingdom GR - MR/S003940/1/MRC_/Medical Research Council/United Kingdom PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20210218 PL - England TA - Lancet Digit Health JT - The Lancet. Digital health JID - 101751302 SB - IM CIN - Lancet Digit Health. 2021 Apr;3(4):e205-e206. doi: 10.1016/S2589-7500(21)00024-8. PMID: 33612431 MH - Adolescent MH - Adult MH - Aged MH - Aged, 80 and over MH - *COVID-19/psychology MH - Child MH - Electronic Health Records MH - Female MH - *Health Status MH - Hospitalization/trends MH - Humans MH - Interrupted Time Series Analysis MH - Male MH - Mental Disorders/*epidemiology MH - Mental Health MH - Middle Aged MH - Patient Acceptance of Health Care/*statistics & numerical data MH - Primary Health Care/*statistics & numerical data/trends MH - United Kingdom/epidemiology MH - Young Adult PMC - PMC7985613 MID - EMS120708 EDAT- 2021/02/23 06:00 MHDA- 2021/04/07 06:00 PMCR- 2021/02/18 CRDT- 2021/02/22 05:49 PHST- 2020/12/19 00:00 [received] PHST- 2021/01/13 00:00 [revised] PHST- 2021/01/19 00:00 [accepted] PHST- 2021/02/23 06:00 [pubmed] PHST- 2021/04/07 06:00 [medline] PHST- 2021/02/22 05:49 [entrez] PHST- 2021/02/18 00:00 [pmc-release] AID - S2589-7500(21)00017-0 [pii] AID - 10.1016/S2589-7500(21)00017-0 [doi] PST - ppublish SO - Lancet Digit Health. 2021 Apr;3(4):e217-e230. doi: 10.1016/S2589-7500(21)00017-0. Epub 2021 Feb 18. PMID- 33608960 OWN - NLM STAT- MEDLINE DCOM- 20211029 LR - 20220802 IS - 1520-6629 (Electronic) IS - 0090-4392 (Print) IS - 0090-4392 (Linking) VI - 49 IP - 6 DP - 2021 Aug TI - Expectations and beliefs: How single young gay, bisexual and other men who have sex with men envision romantic relationships. PG - 1732-1747 LID - 10.1002/jcop.22522 [doi] AB - We developed measures of relational beliefs and expectations among single young gay and bisexual men (YGBM). Data come from an online cross-sectional study YGBM, which ran from July 2012 until January 2013. There were 50 items on relational beliefs and 25 items on relational expectations. We used random split samples and a priori analysis to group items together and applied principal axis factoring with varimax orthogonal rotation. We had a total N = 1582 in our analytical sample and identified six constructs of relational expectations (restrictions, negative break up, masculine and gender norms, optimism, cheating, immediacy) and two constructs of relational beliefs (sex beliefs, equality). Our findings highlight specific relational cognitions among YGBM and offer insight into the beliefs and expectations that may inform their relationships. Findings may be useful for health professionals to help YGBM reflect and understand the health implications of their beliefs and expectations about same-sex relationships to promote healthy decision-making as they seek future partners. CI - (c) 2021 Wiley Periodicals LLC. FAU - Sang, Jordan M AU - Sang JM AUID- ORCID: 0000-0001-5649-0326 AD - Department of Behavioral and Community Health Sciences, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania, USA. AD - Center for LGBT Health Research, University of Pittsburgh, Pittsburgh, Pennsylvania, USA. FAU - Egan, James E AU - Egan JE AUID- ORCID: 0000-0003-3888-7148 AD - Department of Behavioral and Community Health Sciences, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania, USA. AD - Center for LGBT Health Research, University of Pittsburgh, Pittsburgh, Pennsylvania, USA. FAU - Meanley, Steven P AU - Meanley SP AUID- ORCID: 0000-0002-6098-9733 AD - School of Nursing, University of Pennsylvania, Pittsburgh, Pennsylvania, USA. AD - Program on Sexuality, Technology & Action Research, University of Pennsylvania, Philadelphia, Pennsylvania, USA. FAU - Hawk, Mary E AU - Hawk ME AUID- ORCID: 0000-0001-9753-4356 AD - Department of Behavioral and Community Health Sciences, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania, USA. AD - Center for LGBT Health Research, University of Pittsburgh, Pittsburgh, Pennsylvania, USA. FAU - Markovic, Nina AU - Markovic N AD - Center for LGBT Health Research, University of Pittsburgh, Pittsburgh, Pennsylvania, USA. AD - School of Dental Medicine, University of Pittsburgh, Philadelphia, Pennsylvania, USA. FAU - Bear, Todd M AU - Bear TM AUID- ORCID: 0000-0001-5252-6926 AD - Department of Behavioral and Community Health Sciences, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania, USA. FAU - Matthews, Derrick D AU - Matthews DD AUID- ORCID: 0000-0002-3579-3608 AD - Department of Health Behavior, Gillings School of Public Health, University of North Carolina, Chapel Hill, North Carolina, USA. FAU - Bauermeister, Jose A AU - Bauermeister JA AUID- ORCID: 0000-0002-9276-2306 AD - School of Nursing, University of Pennsylvania, Pittsburgh, Pennsylvania, USA. AD - Program on Sexuality, Technology & Action Research, University of Pennsylvania, Philadelphia, Pennsylvania, USA. LA - eng GR - K01 MH087242/MH/NIMH NIH HHS/United States GR - R34 MH101997/MH/NIMH NIH HHS/United States GR - K01-MH087242/NH/NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20210219 PL - United States TA - J Community Psychol JT - Journal of community psychology JID - 0367033 SB - IM MH - Cross-Sectional Studies MH - *HIV Infections MH - Homosexuality, Male MH - Humans MH - Male MH - Motivation MH - Sexual Partners MH - *Sexual and Gender Minorities PMC - PMC8316259 MID - NIHMS1674334 OTO - NOTNLM OT - cognition OT - dating OT - factor analysis OT - relationships OT - sexual minority COIS- CONFLICT OF INTERESTS The authors declare that there are no conflict of interests. EDAT- 2021/02/21 06:00 MHDA- 2021/10/30 06:00 PMCR- 2022/08/01 CRDT- 2021/02/20 05:39 PHST- 2021/01/11 00:00 [revised] PHST- 2020/10/06 00:00 [received] PHST- 2021/01/12 00:00 [accepted] PHST- 2021/02/21 06:00 [pubmed] PHST- 2021/10/30 06:00 [medline] PHST- 2021/02/20 05:39 [entrez] PHST- 2022/08/01 00:00 [pmc-release] AID - 10.1002/jcop.22522 [doi] PST - ppublish SO - J Community Psychol. 2021 Aug;49(6):1732-1747. doi: 10.1002/jcop.22522. Epub 2021 Feb 19. PMID- 33606607 OWN - NLM STAT- MEDLINE DCOM- 20230419 LR - 20230613 IS - 2045-7723 (Electronic) IS - 1079-0268 (Print) IS - 1079-0268 (Linking) VI - 46 IP - 3 DP - 2023 May TI - Association between sleep quality and participation in people with spinal cord injury: A preliminary study. PG - 477-484 LID - 10.1080/10790268.2021.1876818 [doi] AB - Objective: To explore the association between perceived sleep quality and participation in people with spinal cord injury (SCI).Design: Cross-sectional study.Setting: Spinal unit at the Citta della Salute e della Scienza University Hospital of Turin, Italy.Participants: From May to July 2019, 55 consecutive outpatients were recruited.Outcome measures: A set of structured questionnaires was administered. It included sociodemographic data, the Pittsburgh Sleep Quality Index, the Utrecht Scale for Evaluation of Rehabilitation-Participation, the Spinal Cord Independence Measure Self-Report, the Short Form version 12.2, and the Hospital Anxiety and Depression Scale. T-tests were used to highlight differences between participation and participant characteristics. Bivariate analyses and linear regressions were performed to identify associations between sleep quality and participation.Results: Differences in participation occurred mainly in individuals with a higher level of injury, caregiver dependency, and lower functional level. Participants reporting better sleep quality had more frequent (r = -0.36, P < 0.01), less restricted (r = -0.32, P < 0.05), and more satisfactory participation (r = -0.33, P < 0.01). Linear regression analyses showed that poor sleep quality was significantly associated with reduced participation frequency (beta = -0.30, P = 0.03) and less satisfaction with participation (beta = -0.49, P < 0.001). Moreover, age, number of hours slept at night, and time since injury were associated with satisfaction with participation.Conclusions: An association was found between sleep quality and participation in people with SCI. Given the high prevalence of sleep problems and their association with all dimensions of participation, the promotion of sleep quality should be encouraged because it may positively affect participation. FAU - Conti, Alessio AU - Conti A AD - Department of Public Health and Paediatric Sciences, University of Torino, Torino, Italy. FAU - Sperlinga, Riccardo AU - Sperlinga R AD - School of Nursing, Catholic University of the Sacred Heart, Torino, Italy. FAU - Luciani, Michela AU - Luciani M AD - Department of Public Health and Paediatric Sciences, University of Torino, Torino, Italy. FAU - Crenna, Maria Francesca AU - Crenna MF AD - School of Nursing, Catholic University of the Sacred Heart, Torino, Italy. FAU - Piovan, Chiara AU - Piovan C AD - Department of Physical Medicine and Rehabilitation, Spinal Unit, A.O.U. Citta della Salute e della Scienza University Hospital, Torino, Italy. FAU - Scavino, Enrica AU - Scavino E AD - School of Nursing, Catholic University of the Sacred Heart, Torino, Italy. FAU - Campagna, Sara AU - Campagna S AD - Department of Public Health and Paediatric Sciences, University of Torino, Torino, Italy. LA - eng PT - Journal Article DEP - 20210219 PL - England TA - J Spinal Cord Med JT - The journal of spinal cord medicine JID - 9504452 SB - IM CIN - J Spinal Cord Med. 2022 Jan;45(1):7. doi: 10.1080/10790268.2021.2015217. PMID: 34982658 CIN - J Spinal Cord Med. 2022 Jan;45(1):8-9. doi: 10.1080/10790268.2021.2015218. PMID: 34982957 MH - Humans MH - *Spinal Cord Injuries/complications/epidemiology/rehabilitation MH - Quality of Life MH - Cross-Sectional Studies MH - Sleep Quality MH - Surveys and Questionnaires PMC - PMC10114967 OTO - NOTNLM OT - Participation OT - Sleep quality OT - Spinal cord injuries EDAT- 2021/02/20 06:00 MHDA- 2023/04/19 06:41 PMCR- 2022/02/19 CRDT- 2021/02/19 17:10 PHST- 2023/04/19 06:41 [medline] PHST- 2021/02/20 06:00 [pubmed] PHST- 2021/02/19 17:10 [entrez] PHST- 2022/02/19 00:00 [pmc-release] AID - 1876818 [pii] AID - 10.1080/10790268.2021.1876818 [doi] PST - ppublish SO - J Spinal Cord Med. 2023 May;46(3):477-484. doi: 10.1080/10790268.2021.1876818. Epub 2021 Feb 19. PMID- 33602533 OWN - NLM STAT- MEDLINE DCOM- 20210623 LR - 20241127 IS - 1873-2607 (Electronic) IS - 0749-3797 (Linking) VI - 60 IP - 5 DP - 2021 May TI - Tobacco 21 Policies in the U.S.: The Importance of Local Control With Federal Policy. PG - 639-647 LID - S0749-3797(21)00062-3 [pii] LID - 10.1016/j.amepre.2020.12.009 [doi] AB - INTRODUCTION: In December 2019, the U.S. raised the minimum legal sales age of tobacco to 21 years, a law commonly known as Tobacco 21. This study examines local Tobacco 21 policies for the inclusion of model policy components: comprehensive tobacco definition, age verification and tobacco access, enforcement measures, tobacco retail license, and violation penalties. METHODS: A document analysis of Tobacco 21 local policies passed in the U.S. before July 1, 2019 (N=477) was conducted in May 2020 using a Tobacco 21 policy assessment tool. Policies were coded by 2 independent coders for the inclusion of components. RESULTS: Many localities included model component: comprehensive tobacco definition (65%), appearance age (70.9%), local tobacco retail license (72%), a graduated monetary penalty structure (93%), and tobacco retail license suspensions or revocations (74%) for repeated violations. However, only 17.4% of policies included an appearance age in compliance with federal law (30 years). Furthermore, few policies included enforcement components, such as a mandatory number of inspections (5.9%) or compliance checks (6.7%) per year, or a minimum age for the underage purchasers used during compliance checks (8.4%). CONCLUSIONS: Local policies can play an important role in tobacco control by providing an added layer to ensure adequate enforcement of age-restriction policies and allow an avenue to introduce strict measures that may diffuse into higher branches of government for policy adoption. Although many local Tobacco 21 policies fill regulatory gaps within the state and federal laws, often there is a lack of model components to ensure that policies are implemented as intended. CI - Copyright (c) 2021 American Journal of Preventive Medicine. Published by Elsevier Inc. All rights reserved. FAU - Dobbs, Page D AU - Dobbs PD AD - Health, Human Performance and Recreation Department, University of Arkansas, Fayetteville, Arkansas. Electronic address: pdobbs@uark.edu. FAU - Chadwick, Ginny AU - Chadwick G AD - Family and Community Medicine, University of Missouri, Columbia, Missouri. FAU - Dunlap, Chris M AU - Dunlap CM AD - Department of Health and Exercise Science, The University of Oklahoma, Norman, Oklahoma. FAU - White, Katherine A AU - White KA AD - Department of Health and Exercise Science, The University of Oklahoma, Norman, Oklahoma. FAU - Cheney, Marshall K AU - Cheney MK AD - Department of Health and Exercise Science, The University of Oklahoma, Norman, Oklahoma. LA - eng PT - Journal Article DEP - 20210216 PL - Netherlands TA - Am J Prev Med JT - American journal of preventive medicine JID - 8704773 SB - IM MH - Adult MH - Commerce MH - Humans MH - Public Policy MH - *Tobacco Products MH - Tobacco Use EDAT- 2021/02/20 06:00 MHDA- 2021/06/24 06:00 CRDT- 2021/02/19 05:46 PHST- 2020/07/29 00:00 [received] PHST- 2020/11/13 00:00 [revised] PHST- 2020/12/03 00:00 [accepted] PHST- 2021/02/20 06:00 [pubmed] PHST- 2021/06/24 06:00 [medline] PHST- 2021/02/19 05:46 [entrez] AID - S0749-3797(21)00062-3 [pii] AID - 10.1016/j.amepre.2020.12.009 [doi] PST - ppublish SO - Am J Prev Med. 2021 May;60(5):639-647. doi: 10.1016/j.amepre.2020.12.009. Epub 2021 Feb 16. PMID- 33602380 OWN - NLM STAT- MEDLINE DCOM- 20220121 LR - 20240807 IS - 1559-6834 (Electronic) IS - 0899-823X (Print) IS - 0899-823X (Linking) VI - 43 IP - 1 DP - 2022 Jan TI - Impact of coronavirus disease 2019 (COVID-19) on US Hospitals and Patients, April-July 2020. PG - 32-39 LID - 10.1017/ice.2021.69 [doi] AB - OBJECTIVE: The rapid spread of severe acute respiratory coronavirus virus 2 (SARS-CoV-2) throughout key regions of the United States in early 2020 placed a premium on timely, national surveillance of hospital patient censuses. To meet that need, the Centers for Disease Control and Prevention's National Healthcare Safety Network (NHSN), the nation's largest hospital surveillance system, launched a module for collecting hospital coronavirus disease 2019 (COVID-19) data. We present time-series estimates of the critical hospital capacity indicators from April 1 to July 14, 2020. DESIGN: From March 27 to July 14, 2020, the NHSN collected daily data on hospital bed occupancy, number of hospitalized patients with COVID-19, and the availability and/or use of mechanical ventilators. Time series were constructed using multiple imputation and survey weighting to allow near-real-time daily national and state estimates to be computed. RESULTS: During the pandemic's April peak in the United States, among an estimated 431,000 total inpatients, 84,000 (19%) had COVID-19. Although the number of inpatients with COVID-19 decreased from April to July, the proportion of occupied inpatient beds increased steadily. COVID-19 hospitalizations increased from mid-June in the South and Southwest regions after stay-at-home restrictions were eased. The proportion of inpatients with COVID-19 on ventilators decreased from April to July. CONCLUSIONS: The NHSN hospital capacity estimates served as important, near-real-time indicators of the pandemic's magnitude, spread, and impact, providing quantitative guidance for the public health response. Use of the estimates detected the rise of hospitalizations in specific geographic regions in June after they declined from a peak in April. Patient outcomes appeared to improve from early April to mid-July. FAU - Sapiano, Mathew R P AU - Sapiano MRP AUID- ORCID: 0000-0001-6938-6683 AD - Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia. AD - Lantana Consulting Group, Thetford, Vermont. FAU - Dudeck, Margaret A AU - Dudeck MA AD - Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia. FAU - Soe, Minn AU - Soe M AD - Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia. FAU - Edwards, Jonathan R AU - Edwards JR AD - Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia. FAU - O'Leary, Erin N AU - O'Leary EN AD - Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia. AD - Lantana Consulting Group, Thetford, Vermont. FAU - Wu, Hsiu AU - Wu H AD - Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia. FAU - Allen-Bridson, Katherine AU - Allen-Bridson K AD - Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia. FAU - Amor, Agasha AU - Amor A AD - Lantana Consulting Group, Thetford, Vermont. FAU - Arcement, Rashad AU - Arcement R AD - Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia. AD - CACI, Atlanta, Georgia. FAU - Chernetsky Tejedor, Sheri AU - Chernetsky Tejedor S AD - Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia. AD - Division of Hospital Medicine, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia. AD - Department of Biomedical Informatics, Emory University School of Medicine, Atlanta, Georgia. FAU - Dantes, Ray AU - Dantes R AD - Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia. AD - Division of Hospital Medicine, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia. FAU - Gross, Cindy AU - Gross C AD - Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia. AD - CACI, Atlanta, Georgia. FAU - Haass, Kathryn AU - Haass K AD - Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia. FAU - Konnor, Rebecca AU - Konnor R AD - Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia. AD - CACI, Atlanta, Georgia. FAU - Kroop, Seth R AU - Kroop SR AD - COVID-19 Response, Centers for Disease Control and Prevention, Atlanta, Georgia. FAU - Leaptrot, Denise AU - Leaptrot D AD - Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia. AD - CACI, Atlanta, Georgia. FAU - Lemoine, Kent AU - Lemoine K AD - Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia. FAU - Nkwata, Allan AU - Nkwata A AD - Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia. AD - Leidos, Atlanta, Georgia. FAU - Peterson, Kelly AU - Peterson K AD - Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia. FAU - Wattenmaker, Lauren AU - Wattenmaker L AD - Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia. FAU - Weiner-Lastinger, Lindsey M AU - Weiner-Lastinger LM AD - Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia. FAU - Pollock, Daniel AU - Pollock D AD - Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia. FAU - Benin, Andrea L AU - Benin AL AD - Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia. CN - NHSN Hospital COVID-19 Team LA - eng PT - Journal Article DEP - 20210219 PL - United States TA - Infect Control Hosp Epidemiol JT - Infection control and hospital epidemiology JID - 8804099 SB - IM MH - Bed Occupancy MH - *COVID-19 MH - Hospitalization MH - Hospitals MH - Humans MH - SARS-CoV-2 MH - United States/epidemiology PMC - PMC7943952 EDAT- 2021/02/20 06:00 MHDA- 2022/01/22 06:00 PMCR- 2021/03/10 CRDT- 2021/02/19 05:42 PHST- 2021/02/20 06:00 [pubmed] PHST- 2022/01/22 06:00 [medline] PHST- 2021/02/19 05:42 [entrez] PHST- 2021/03/10 00:00 [pmc-release] AID - S0899823X21000696 [pii] AID - 10.1017/ice.2021.69 [doi] PST - ppublish SO - Infect Control Hosp Epidemiol. 2022 Jan;43(1):32-39. doi: 10.1017/ice.2021.69. Epub 2021 Feb 19. PMID- 33589283 OWN - NLM STAT- MEDLINE DCOM- 20211124 LR - 20250103 IS - 0013-7006 (Print) IS - 0013-7006 (Linking) VI - 47 IP - 5 DP - 2021 Oct TI - [Evaluation of the use of care programs provided for under the law of 5 July 2011]. PG - 420-425 LID - S0013-7006(21)00025-7 [pii] LID - 10.1016/j.encep.2020.09.012 [doi] AB - OBJECTIVES: The law of 5 July 2011 introduced the possibility of outpatient care without consent in the context of care programs (CP). Despite major ethical and legal issues and frequent recourse in France, few studies are available on the use of this mechanism. An in-depth review of practices involving a large sample of CP was essential. The main objective of this study was to look at their content, the clinical profile of the patients involved, and the progress of these CP. METHODS: We carried out a retrospective, observational study, including all the CP set up between January 1st, 2016 and December 31st, 2018 in the Sarthe department. Data strictly related to the CP (content, justification, duration, patient compliance, re-hospitalizations, etc.), and patient-related variables (socio-demographic characteristics, diagnosis, antecedents, etc.) were studied. RESULTS: We studied 559 CP, 70 % of which (n=391) in the context of "care by decision of the hospital director", with a wide disparity of recourse by psychiatric sector. One third of the hospitalizations without consent ended with a CP. They involved men (68.5 %, n=383), with a psychotic disorder (77.8 %, n=435), with a history of hospitalization (90 %, n=503), and with poor adherence to care (83.2 %, n=465). Cannabis use accounted for 41.3 % (n=231) of cases. Certificates initiating CP did not have a clear justification (34.6 %, n=251) or state a goal of adherence to treatment (16.5 %, n=120). The content of the different CP was homogeneous: 65.6% of medical consultations and 47.6 % with a nurse, 100 % mentioned treatment used. Their average duration was 3.4 months. Even though the CP were followed (69.9 %, n=391), 52.8% (n=295) ended with reintegration, mainly justified by symptomatic relapse (34.8 %, n=147), and new CP were put in place almost systematically (90.6 %, n=260). However, reintegrations were shorter than first-time admissions (26 vs. 95 days). When a decision was lifted (n=174), it was based on the criteria of clinical stability (35.7 %, n=120) and compliance with the CP (27.6 %, n=93). Half of hospitalizations in "care at the decision of the State representative" ended with a CP. These CP were longer (4.5 months) and with a higher rate of reintegration (62.2 %) than for those in "care at the decision of the hospital director". There was no significant difference of CP compliance according to the mode of psychiatric care. CONCLUSIONS: Our study allows a precise vision of patients concerned by CP: men with risk factors for psychiatric dangerousness, with a severe clinical profile. It also found a high rate of re-hospitalization despite good adherence with the CP which is in line with a device allowing the work of an alliance to care and interventions at the beginning of relapse. CP have poorly personalized content and are poorly justified by psychiatrists although it is a freedom-restricting measure, highlighting the need for increased awareness amongst psychiatrists of the legal framework of their practice regarding care without consent. CI - Copyright (c) 2021 L'Encephale, Paris. Published by Elsevier Masson SAS. All rights reserved. FAU - Jamet, L AU - Jamet L AD - Etablissement public de sante mentale de la Sarthe, 72703 Allonnes cedex, France. Electronic address: laeti.jamet@gmail.com. FAU - Neveux, P AU - Neveux P AD - HealthEcon AG, Basel, 4051, CH. FAU - Gohier, B AU - Gohier B AD - Service de psychiatrie et d'addictologie, centre hospitalier universitaire, 49100 Angers, France; UPRES EA 4638, University of Angers, 49100 Angers, France. FAU - Orsat, M AU - Orsat M AD - Clinique du Pole Sante Sud, 72000 Le Mans, France; Section psychiatrie legale de l'AFPBN, 75014 Paris, France. LA - fre PT - Journal Article PT - Observational Study TT - Evaluation du recours au programme de soins prevu par la loi du 5 juillet 2011. DEP - 20210212 PL - France TA - Encephale JT - L'Encephale JID - 7505643 SB - IM MH - Commitment of Persons with Psychiatric Disorders MH - Dangerous Behavior MH - Female MH - Humans MH - Male MH - *Psychiatry MH - *Psychotic Disorders/epidemiology/therapy MH - Retrospective Studies OTO - NOTNLM OT - Care programs OT - Care without consent OT - Compulsory community treatment OT - Loi du 5 juillet 2011 OT - Outpatient care OT - Programme de soins OT - Psychiatrie OT - Psychiatry OT - Soin ambulatoire OT - Soins psychiatriques sans consentement EDAT- 2021/02/17 06:00 MHDA- 2021/11/25 06:00 CRDT- 2021/02/16 05:48 PHST- 2020/03/02 00:00 [received] PHST- 2020/09/10 00:00 [revised] PHST- 2020/09/28 00:00 [accepted] PHST- 2021/02/17 06:00 [pubmed] PHST- 2021/11/25 06:00 [medline] PHST- 2021/02/16 05:48 [entrez] AID - S0013-7006(21)00025-7 [pii] AID - 10.1016/j.encep.2020.09.012 [doi] PST - ppublish SO - Encephale. 2021 Oct;47(5):420-425. doi: 10.1016/j.encep.2020.09.012. Epub 2021 Feb 12. PMID- 33585726 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220622 IS - 2452-1094 (Print) IS - 2452-1094 (Electronic) IS - 2452-1094 (Linking) VI - 7 IP - 5 DP - 2022 Sep-Oct TI - Impact of the COVID-19 Pandemic on Radiation Oncology Departments in Brazil. PG - 100667 LID - 10.1016/j.adro.2021.100667 [doi] LID - 100667 AB - PURPOSE: The COVID-19 pandemic brought several challenges to cancer practice, especially in ensuring continuity of treatment during this period while minimizing the risks of transmission to a vulnerable population. For radiation oncology departments in Brazil, this contingency has become even more complex owing to the significant effect observed in different sectors of society and the large number of COVID-19 cases and deaths. This study estimated the effect of the COVID-19 pandemic on Brazilian radiation oncology departments and the coping measures used in the country. METHODS AND MATERIALS: The Brazilian Radiotherapy Society developed a questionnaire, with 14 questions, that were sent to all heads of radiation oncology departments in the country between May and June 2020. These data were evaluated regarding cases confirmed and deaths by COVID-19 in epidemiologic week 28, on July 11, 2020. RESULTS: One hundred twenty-six questionnaires from different regions were answered, representing 44% of the country's services. A drop in the number of patients was observed in 61% of services. This drop was observed both in patients from the public and supplementary private health insurance systems. Regarding patients and employees with COVID-19, we observed that services that primarily treat Unified Health System patients reported significantly fewer cases of the disease. About half of the services had collaborators and patients during radiation therapy with a positive diagnosis of COVID-19. Among the coping measures, the services used intensified hygiene and cleanliness practices, interpersonal distancing, restrictions on access to companions, and other changes in daily practice. CONCLUSIONS: Thus, there was an important drop in the number of radiation therapy patients in the country during the pandemic, and this effect was similar among the services, regardless of the characteristics of the patients and the departments' coping measures adopted during the pandemic. CI - (c) 2021 The Authors. FAU - Oliveira, Harley F AU - Oliveira HF AD - Radiotherapy Department of the Centro de Tratamento em Radio-Oncologia (CTR), Ribeirao Preto/SP; Marcio Cunha Hospital - Fundacao Sao Francisco Xavier, Ipatinga, MG, Brazil. FAU - Yoshinari, Gerson H Jr AU - Yoshinari GH Jr AD - Faculty of Medicine of Itajuba - Afya group, Itajuba, MG, Brazil; Radiotherapy Department of the Oncominas, Pouso Alegre, MG, Brazil. FAU - Veras, Igor M AU - Veras IM AD - Radiotherapy Department of the Regional Integrated Oncology Center, Fortaleza, CE, Brazil. FAU - de Almeida, Wilson J Jr AU - de Almeida WJ Jr AD - Radiotherapy Department of the Moinhos dos Ventos Hospital, Porto Alegre, RS, Brazil. FAU - Freitas, Nilceana M A AU - Freitas NMA AD - Radiotherapy Department of the Araujo Jorge Hospital of the Goias State Association Against Cancer, Goiania, GO, Brazil. FAU - Castilho, Marcus S AU - Castilho MS AD - Radiotherapy Department of the Felicio Rocho Hospital, Belo Horizonte, MG, Brazil. FAU - Pellizzon, Antonio C de A AU - Pellizzon ACA AD - Radiotherapy Department of the AC Camargo Hospital, Sao Paulo, SP, Brazil. FAU - Erlich, Felipe AU - Erlich F AD - Radiotherapy Department of the Jose Alencar Gomes da Silva National Cancer Institute (INCA), Rio de Janeiro, RJ, Brazil. FAU - Affonso, Renato J Jr AU - Affonso RJ Jr AD - Radiotherapy Department of the Barretos Cancer Hospital, Barretos, SP, Brazil. FAU - de Carvalho, Icaro T AU - de Carvalho IT AD - Radiotherapy Department of the Albert Einstein Hospital, Sao Paulo, SP, Brazil. FAU - Leite, Andre C C AU - Leite ACC AD - Radiotherapy Department of the Dom Pedro de Alcantara Hospital, Feira de Santana, BA, Brazil. FAU - Kuhnen, Felipe Q AU - Kuhnen FQ AD - Radiotherapy Department of the Charity Hospital of Florianopolis, Florianopolis, SC, Brazil. FAU - Najas, Rosa M X F AU - Najas RMXF AD - Radiotherapy Department of the Rio Grande do Norte State League Against Cancer, Natal, RN, Brazil. FAU - Rosa, Arthur Accioly AU - Rosa AA AD - Radiotherapy Department of the Santa Izabel Hospital and Portugues da Bahia Hospital, Salvador, BA, Brazil. LA - eng PT - Journal Article DEP - 20210206 PL - United States TA - Adv Radiat Oncol JT - Advances in radiation oncology JID - 101677247 PMC - PMC7866893 EDAT- 2021/02/16 06:00 MHDA- 2021/02/16 06:01 PMCR- 2021/02/06 CRDT- 2021/02/15 06:12 PHST- 2020/10/16 00:00 [received] PHST- 2021/01/27 00:00 [accepted] PHST- 2021/02/16 06:00 [pubmed] PHST- 2021/02/16 06:01 [medline] PHST- 2021/02/15 06:12 [entrez] PHST- 2021/02/06 00:00 [pmc-release] AID - S2452-1094(21)00025-7 [pii] AID - 100667 [pii] AID - 10.1016/j.adro.2021.100667 [doi] PST - ppublish SO - Adv Radiat Oncol. 2022 Sep-Oct;7(5):100667. doi: 10.1016/j.adro.2021.100667. Epub 2021 Feb 6. PMID- 33577763 OWN - NLM STAT- MEDLINE DCOM- 20210722 LR - 20240908 IS - 1097-6868 (Electronic) IS - 0002-9378 (Print) IS - 0002-9378 (Linking) VI - 225 IP - 1 DP - 2021 Jul TI - Passage of abortion ban and women's accurate understanding of abortion legality. PG - 63.e1-63.e8 LID - S0002-9378(21)00096-X [pii] LID - 10.1016/j.ajog.2021.02.009 [doi] AB - BACKGROUND: Legislative and judicial procedures related to banning abortion after 6 weeks of gestation in Ohio occurred from November 2018 to July 2019. These activities could have increased the belief that abortion has become illegal even though the 6-week abortion ban has never been in effect to date. OBJECTIVE: We sought to determine the prevalence and correlates of holding the belief that abortion is illegal in Ohio and to evaluate whether this belief increased over the time in which the 6-week abortion ban was introduced, passed twice, and then blocked in Ohio. STUDY DESIGN: We analyzed data from the first wave of the Ohio Survey of Women, a population-based survey of adult, reproductive-aged Ohioan women conducted from October 2018 to June 2019. During each of the 8 survey months, a median of 240 women (range, 70-761) completed the survey, including the survey question "Based on what you know or have heard, is it legal to get an abortion in your state?" We used multivariable logistic regression to assess the prevalence and correlates of believing that abortion is illegal in the state of Ohio. In addition, we used multinomial logistic regression to evaluate whether this belief increased over the interval during which women completed the survey, which roughly corresponded to the interval marked by legislative and judicial activities surrounding the 6-week abortion ban. RESULTS: Most of the 2359 participants understood that abortion is legal in the state of Ohio (64.0%) with the remainder believing it to be illegal (9.8%) or being unsure (26.2%). Correlates of believing abortion to be illegal included younger age, lower socioeconomic status, never married or married status, and Black, non-Hispanic race and ethnicity. Being unsure about legality did not change over time; however, the proportion of women who believed that abortion is illegal increased from the first month (4.5%) to the last month (15.9%) of the study period. Each additional study month was associated with a 17% increase in the odds of believing abortion to be illegal, in both unadjusted and adjusted models (odds ratio, 1.17; 95% confidence interval, 1.08-1.27). CONCLUSION: Attempts to restrict abortion access could contribute to women mistakenly believing that abortion is illegal despite it being unsuccessful. CI - Copyright (c) 2021 The Author(s). Published by Elsevier Inc. All rights reserved. FAU - Gallo, Maria F AU - Gallo MF AD - Division of Epidemiology, College of Public Health, The Ohio State University, Columbus, OH. Electronic address: gallo.86@osu.edu. FAU - Casterline, John B AU - Casterline JB AD - Department of Sociology, College of Arts and Sciences, The Ohio State University, Columbus, OH. FAU - Chakraborty, Payal AU - Chakraborty P AD - Division of Epidemiology, College of Public Health, The Ohio State University, Columbus, OH. FAU - Norris, Alison AU - Norris A AD - Division of Epidemiology, College of Public Health, The Ohio State University, Columbus, OH. FAU - Bessett, Danielle AU - Bessett D AD - Department of Sociology, College of Arts and Sciences, University of Cincinnati, Cincinnati, OH. FAU - Turner, Abigail Norris AU - Turner AN AD - Division of Infectious Diseases, College of Medicine, The Ohio State University, Columbus, OH. LA - eng GR - P2C HD058484/HD/NICHD NIH HHS/United States PT - Journal Article DEP - 20210210 PL - United States TA - Am J Obstet Gynecol JT - American journal of obstetrics and gynecology JID - 0370476 SB - IM MH - Abortion, Induced/*legislation & jurisprudence MH - Abortion, Legal/*legislation & jurisprudence MH - Adolescent MH - Adult MH - Female MH - Gestational Age MH - *Health Knowledge, Attitudes, Practice MH - Humans MH - Ohio MH - Pregnancy MH - Social Class MH - Surveys and Questionnaires MH - Young Adult PMC - PMC9723984 MID - NIHMS1850276 OTO - NOTNLM OT - abortion OT - knowledge OT - legality OT - women COIS- The authors report no conflict of interest. EDAT- 2021/02/13 06:00 MHDA- 2021/07/23 06:00 PMCR- 2022/12/06 CRDT- 2021/02/12 20:11 PHST- 2020/11/19 00:00 [received] PHST- 2021/02/02 00:00 [revised] PHST- 2021/02/07 00:00 [accepted] PHST- 2021/02/13 06:00 [pubmed] PHST- 2021/07/23 06:00 [medline] PHST- 2021/02/12 20:11 [entrez] PHST- 2022/12/06 00:00 [pmc-release] AID - S0002-9378(21)00096-X [pii] AID - 10.1016/j.ajog.2021.02.009 [doi] PST - ppublish SO - Am J Obstet Gynecol. 2021 Jul;225(1):63.e1-63.e8. doi: 10.1016/j.ajog.2021.02.009. Epub 2021 Feb 10. PMID- 33559651 OWN - NLM STAT- MEDLINE DCOM- 20211025 LR - 20211025 IS - 1896-494X (Electronic) IS - 1232-1087 (Linking) VI - 34 IP - 3 DP - 2021 Jun 28 TI - An association between cumulative exposure to light at night and the prevalence of hyperuricemia in steel workers. PG - 385-401 LID - 128747 [pii] LID - 10.13075/ijomeh.1896.01648 [doi] AB - OBJECTIVES: Exposure to light at night (LAN) can disturb circadian endocrine and metabolic rhythms. Hyperuricemia (HUA) is an early-onset metabolic disorder. However, it is still not clear whether LAN exposure increases the prevalence of HUA. MATERIAL AND METHODS: The authors used crosssectional data on the Beijing-Tianjin-Hebei occupational populations cohort from March-July 2017. A total of 7664 steel workers were finally selected to investigate the relationship between LAN exposure and the prevalence of HUA among steel workers. The authors collected demographic and socio-economic data, as well as information on lifestyle factors, anthropometric measures, and laboratory tests. The restricted cubic spline method was used to analyze the dose-response relationship between cumulative LAN exposure and the prevalence of HUA. Logistic regression analyses were used to fit the relationship between them. RESULTS: The average age of the participants was 43.5+/-8.6 years; 7051 (91.7%) of them were males, 2749 (35.9%) reported to suffer from HUA, and 1241 (16.2%) were not exposed to LAN. There was a significant non-linear dose-response relationship between them. After adjustment for the confounding factors, including demographic data, lifestyle factors, etc., the lower LAN exposure was significantly associated with HUA (0-1931.7 days, OR = 1.180, and the 95% CI: 1.000-1.394; 1931.7-4343 days, OR = 1.215, 95% CI: 1.035-1.426). CONCLUSIONS: This study revealed that a certain amount of exposure to LAN is independently related to the prevalence of HUA in steel workers in China. Int J Occup Med Environ Health. 2021;34(3):385-401. CI - This work is available in Open Access model and licensed under a CC BY-NC 3.0 PL license. FAU - Li, Xiaoming AU - Li X AD - North China University of Science and Technology, Tangshan, China (School of Public Health). FAU - Xu, Xianghui AU - Xu X AD - North China University of Science and Technology, Tangshan, China (Hospital). FAU - Song, Yang AU - Song Y AD - North China University of Science and Technology, Tangshan, China (School of Public Health). FAU - Cui, Shiyue AU - Cui S AD - North China University of Science and Technology, Tangshan, China (School of Public Health). FAU - Xue, Chao AU - Xue C AD - North China University of Science and Technology, Tangshan, China (School of Public Health). FAU - Wang, Lihua AU - Wang L AD - North China University of Science and Technology, Tangshan, China (School of Public Health). FAU - Wu, Jianhui AU - Wu J AD - North China University of Science and Technology, Tangshan, China (School of Public Health). FAU - Yuan, Juxiang AU - Yuan J AD - North China University of Science and Technology, Tangshan, China (School of Public Health). LA - eng PT - Journal Article DEP - 20210204 PL - Poland TA - Int J Occup Med Environ Health JT - International journal of occupational medicine and environmental health JID - 9437093 SB - IM MH - Adult MH - Cohort Studies MH - Cross-Sectional Studies MH - Humans MH - *Hyperuricemia/epidemiology MH - Male MH - Metal Workers MH - Middle Aged MH - Prevalence MH - Risk Factors OTO - NOTNLM OT - circadian rhythms OT - hyperuricemia OT - light at night OT - restricted cubic spline OT - steel workers OT - uric acid EDAT- 2021/02/10 06:00 MHDA- 2021/10/26 06:00 CRDT- 2021/02/09 08:44 PHST- 2021/02/10 06:00 [pubmed] PHST- 2021/10/26 06:00 [medline] PHST- 2021/02/09 08:44 [entrez] AID - 128747 [pii] AID - 10.13075/ijomeh.1896.01648 [doi] PST - ppublish SO - Int J Occup Med Environ Health. 2021 Jun 28;34(3):385-401. doi: 10.13075/ijomeh.1896.01648. Epub 2021 Feb 4. PMID- 33551299 OWN - NLM STAT- MEDLINE DCOM- 20210521 LR - 20220805 IS - 1873-2518 (Electronic) IS - 0264-410X (Print) IS - 0264-410X (Linking) VI - 39 IP - 9 DP - 2021 Mar 1 TI - Parent support for social media standards combatting vaccine misinformation. PG - 1364-1369 LID - S0264-410X(21)00005-0 [pii] LID - 10.1016/j.vaccine.2021.01.005 [doi] AB - We sought to assess parental support for varying standards that social media sites can employ to combat vaccine misinformation. Between July and August 2019, we conducted a web-based survey with a national sample of 1073 parents of adolescents and who use social media. The survey assessed support for ten standards about vaccine misinformation. Multivariable logistic regression assessed correlates of support. Overall, 61% of parents supported at least one standard. Support for each standard varied greatly (12-51%), with higher support for less restrictive standards. Parents more often supported standards if their child had already initiated human papillomavirus (HPV) vaccination, if they were non-Hispanic black or Hispanic, if they agreed that vaccine misinformation is harmful, or if they saw information on social media in favor of HPV vaccine (all p < .05). Our findings suggest favorable support for standards that social media sites can implement to combat vaccine misinformation. CI - Copyright (c) 2021 Elsevier Ltd. All rights reserved. FAU - Spanos, Katherine E AU - Spanos KE AD - Department of Public Health Sciences, Penn State College of Medicine, Hershey, PA, USA. FAU - Kraschnewski, Jennifer L AU - Kraschnewski JL AD - Department of Public Health Sciences, Penn State College of Medicine, Hershey, PA, USA; Department of Medicine, Penn State College of Medicine, Hershey, PA, USA. FAU - Moss, Jennifer L AU - Moss JL AD - Department of Public Health Sciences, Penn State College of Medicine, Hershey, PA, USA; Department of Family and Community Medicine, Penn State College of Medicine, Hershey, PA, USA. FAU - Wong, Ashley AU - Wong A AD - Department of Public Health Sciences, Penn State College of Medicine, Hershey, PA, USA. FAU - Calo, William A AU - Calo WA AD - Department of Public Health Sciences, Penn State College of Medicine, Hershey, PA, USA; Penn State Cancer Institute, Hershey, PA, USA. Electronic address: wcalo@phs.psu.edu. LA - eng GR - R37 CA253279/CA/NCI NIH HHS/United States PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20210204 PL - Netherlands TA - Vaccine JT - Vaccine JID - 8406899 RN - 0 (Papillomavirus Vaccines) SB - IM MH - Adolescent MH - Child MH - Communication MH - Health Knowledge, Attitudes, Practice MH - Humans MH - *Papillomavirus Infections MH - *Papillomavirus Vaccines MH - Parents MH - Patient Acceptance of Health Care MH - *Social Media MH - Vaccination PMC - PMC9348833 MID - NIHMS1825398 OTO - NOTNLM OT - Anti-vaccine OT - Human papillomavirus OT - Misinformation OT - Social media OT - Social media users OT - Vaccines COIS- Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Kraschnewski was Principal Investigator of a Penn State University College of Medicine research grant awarded by Merck. The other authors have no financial disclosures or potential conflicts of interest to report. EDAT- 2021/02/09 06:00 MHDA- 2021/05/22 06:00 PMCR- 2022/08/03 CRDT- 2021/02/08 05:30 PHST- 2020/09/30 00:00 [received] PHST- 2020/12/30 00:00 [revised] PHST- 2021/01/03 00:00 [accepted] PHST- 2021/02/09 06:00 [pubmed] PHST- 2021/05/22 06:00 [medline] PHST- 2021/02/08 05:30 [entrez] PHST- 2022/08/03 00:00 [pmc-release] AID - S0264-410X(21)00005-0 [pii] AID - 10.1016/j.vaccine.2021.01.005 [doi] PST - ppublish SO - Vaccine. 2021 Mar 1;39(9):1364-1369. doi: 10.1016/j.vaccine.2021.01.005. Epub 2021 Feb 4. PMID- 33549166 OWN - NLM STAT- MEDLINE DCOM- 20210311 LR - 20250530 IS - 2352-3018 (Electronic) IS - 2405-4704 (Print) IS - 2352-3018 (Linking) VI - 8 IP - 3 DP - 2021 Mar TI - The impact of the COVID-19 lockdown on HIV care in 65 South African primary care clinics: an interrupted time series analysis. PG - e158-e165 LID - S2352-3018(20)30359-3 [pii] LID - 10.1016/S2352-3018(20)30359-3 [doi] AB - BACKGROUND: The effect of the COVID-19 pandemic on HIV outcomes in low-income and middle-income countries is poorly described. We aimed to measure the impact of the 2020 national COVID-19 lockdown on HIV testing and treatment in KwaZulu-Natal, South Africa, where 1.7 million people are living with HIV. METHODS: In this interrupted time series analysis, we analysed anonymised programmatic data from 65 primary care clinics in KwaZulu-Natal province, South Africa. We included data from people testing for HIV, initiating antiretroviral therapy (ART), and collecting ART at participating clinics during the study period, with no age restrictions. We used descriptive statistics to summarise demographic and clinical data, and present crude summaries of the main outcomes of numbers of HIV tests per month, ART initiations per week, and ART collection visits per week, before and after the national lockdown that began on March 27, 2020. We used Poisson segmented regression models to estimate the immediate impact of the lockdown on these outcomes, as well as post-lockdown trends. FINDINGS: Between Jan 1, 2018, and July 31, 2020, we recorded 1 315 439 HIV tests. Between Jan 1, 2018, and June 15, 2020, we recorded 71 142 ART initiations and 2 319 992 ART collection visits. We recorded a median of 41 926 HIV tests per month before lockdown (January, 2018, to March, 2020; IQR 37 838-51 069) and a median of 38 911 HIV tests per month after lockdown (April, 2020, to July, 2020; IQR 32 699-42 756). In the Poisson regression model, taking into account long-term trends, lockdown was associated with an estimated 47.6% decrease in HIV testing in April, 2020 (incidence rate ratio [IRR] 0.524, 95% CI 0.446-0.615). ART initiations decreased from a median of 571 per week before lockdown (IQR 498-678), to 375 per week after lockdown (331-399), with an estimated 46.2% decrease in the Poisson regression model in the first week of lockdown (March 30, 2020, to April 5, 2020; IRR 0.538, 0.459-0.630). There was no marked change in the number of ART collection visits (median 18 519 visits per week before lockdown [IQR 17 074-19 922] vs 17 863 visits per week after lockdown [17 509-18 995]; estimated effect in the first week of lockdown IRR 0.932, 95% CI 0.794-1.093). As restrictions eased, HIV testing and ART initiations gradually improved towards pre-lockdown levels (slope change 1.183/month, 95% CI 1.113-1.256 for HIV testing; 1.156/month, 1.085-1.230 for ART initiations). INTERPRETATION: ART provision was generally maintained during the 2020 COVID-19 lockdown, but HIV testing and ART initiations were heavily impacted. Strategies to increase testing and treatment initiation should be implemented. FUNDING: Wellcome Trust, Africa Oxford Initiative. CI - Copyright (c) 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved. FAU - Dorward, Jienchi AU - Dorward J AD - Centre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu-Natal, Durban, KwaZulu-Natal, South Africa; Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, Oxfordshire, UK. Electronic address: jienchi.dorward@phc.ox.ac.uk. FAU - Khubone, Thokozani AU - Khubone T AD - eThekwini Municipality Health Unit, eThekwini Municipality, Durban KwaZulu-Natal, South Africa. FAU - Gate, Kelly AU - Gate K AD - Department of Family Medicine, University of KwaZulu-Natal, Durban, KwaZulu-Natal, South Africa; Bethesda Hospital, uMkhanyakude District, KwaZulu-Natal, South Africa. FAU - Ngobese, Hope AU - Ngobese H AD - eThekwini Municipality Health Unit, eThekwini Municipality, Durban KwaZulu-Natal, South Africa. FAU - Sookrajh, Yukteshwar AU - Sookrajh Y AD - eThekwini Municipality Health Unit, eThekwini Municipality, Durban KwaZulu-Natal, South Africa. FAU - Mkhize, Siyabonga AU - Mkhize S AD - Bethesda Hospital, uMkhanyakude District, KwaZulu-Natal, South Africa. FAU - Jeewa, Aslam AU - Jeewa A AD - Centre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu-Natal, Durban, KwaZulu-Natal, South Africa. FAU - Bottomley, Christian AU - Bottomley C AD - London School of Hygiene & Tropical Medicine, London, UK. FAU - Lewis, Lara AU - Lewis L AD - Centre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu-Natal, Durban, KwaZulu-Natal, South Africa. FAU - Baisley, Kathy AU - Baisley K AD - London School of Hygiene & Tropical Medicine, London, UK. FAU - Butler, Christopher C AU - Butler CC AD - Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, Oxfordshire, UK. FAU - Gxagxisa, Nomakhosi AU - Gxagxisa N AD - eThekwini Municipality Health Unit, eThekwini Municipality, Durban KwaZulu-Natal, South Africa. FAU - Garrett, Nigel AU - Garrett N AD - Centre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu-Natal, Durban, KwaZulu-Natal, South Africa; Discipline of Public Health Medicine, School of Nursing and Public Health, University of KwaZulu-Natal, Durban, KwaZulu-Natal, South Africa. LA - eng GR - MR/R010161/1/MRC_/Medical Research Council/United Kingdom GR - WT_/Wellcome Trust/United Kingdom PT - Journal Article PT - Multicenter Study PT - Research Support, Non-U.S. Gov't DEP - 20210204 PL - Netherlands TA - Lancet HIV JT - The lancet. HIV JID - 101645355 RN - 0 (Anti-HIV Agents) SB - IM MH - Adolescent MH - Adult MH - Ambulatory Care Facilities MH - Anti-HIV Agents/*therapeutic use MH - Antiretroviral Therapy, Highly Active MH - COVID-19/*prevention & control MH - Child MH - Child, Preschool MH - Female MH - HIV Infections/*diagnosis/*drug therapy MH - Humans MH - Infant MH - Infant, Newborn MH - Interrupted Time Series Analysis MH - Male MH - Mass Screening/*statistics & numerical data MH - Middle Aged MH - Primary Health Care/*statistics & numerical data MH - Public Health Surveillance MH - SARS-CoV-2 MH - South Africa MH - Young Adult PMC - PMC8011055 EDAT- 2021/02/08 06:00 MHDA- 2021/03/12 06:00 PMCR- 2021/02/04 CRDT- 2021/02/07 20:27 PHST- 2020/10/20 00:00 [received] PHST- 2020/12/11 00:00 [revised] PHST- 2020/12/17 00:00 [accepted] PHST- 2021/02/08 06:00 [pubmed] PHST- 2021/03/12 06:00 [medline] PHST- 2021/02/07 20:27 [entrez] PHST- 2021/02/04 00:00 [pmc-release] AID - S2352-3018(20)30359-3 [pii] AID - 10.1016/S2352-3018(20)30359-3 [doi] PST - ppublish SO - Lancet HIV. 2021 Mar;8(3):e158-e165. doi: 10.1016/S2352-3018(20)30359-3. Epub 2021 Feb 4. PMID- 33542617 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220420 IS - 1177-5467 (Print) IS - 1177-5483 (Electronic) IS - 1177-5467 (Linking) VI - 15 DP - 2021 TI - Reduction in Ophthalmic Presentations to Australian Emergency Departments During the COVID-19 Period: Are We Seeing the Full Picture? PG - 341-346 LID - 10.2147/OPTH.S289467 [doi] AB - PURPOSE: To examine changing patterns of ophthalmic presentations to emergency departments (EDs) during the lockdowns associated with the first wave of the COVID-19 pandemic in Australia and the two months immediately following lockdown relaxation. PATIENTS AND METHODS: This was a retrospective audit of triage coding and ICD-10-AM coding for all patient presentations to four Australian EDs from March 29 to May 31 in 2019 and 2020 (the COVID-19 lockdown period and the corresponding period in 2019), and from June 1 to July 31 in 2019 and 2020 (the post-lockdown period and the corresponding period in 2019). Number of ophthalmic presentations triaged per day and number of seven common and/or time-sensitive, vision threatening ophthalmic diagnoses were examined. Differences in mean daily presentation numbers were assessed with non-paired Student's t-test with Bonferroni correction. RESULTS: Total ophthalmic presentations per day during COVID-19 lockdowns fell by 16% compared to the corresponding period in 2019 (13.0 +/- 4.0 in 2019 vs 10.8 +/- 3.3 in 2020, mean +/- standard deviation; p=0.01). There was also a significant decrease in presentations of atraumatic retinal detachment, conjunctivitis, and eye pain. In the two months following easing of lockdown restrictions, total ophthalmic presentations per day returned to the same level as that of the corresponding period in 2019 (12.2 +/- 4.3 in 2019 vs 12.3 +/- 4.1 in 2020, p=0.97). CONCLUSION: Total ophthalmic presentations and presentations of atraumatic retinal detachment, conjunctivitis and, eye pain to EDs fell during the lockdowns associated with the first wave of COVID-19 in Australia. These may represent delays in patients seeking appropriate medical attention and may have implications on patient morbidity long after the COVID-19 pandemic. CI - (c) 2021 Kam et al. FAU - Kam, Andrew W AU - Kam AW AUID- ORCID: 0000-0003-3676-4101 AD - Department of Ophthalmology, Westmead Hospital, Westmead, New South Wales, Australia. AD - Executive Unit, Westmead Hospital, Westmead, New South Wales, Australia. AD - Westmead and Central Clinical Schools, Discipline of Clinical Ophthalmology and Eye Health, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia. FAU - Gunasekaran, Nathan AU - Gunasekaran N AD - Department of Ophthalmology, Westmead Hospital, Westmead, New South Wales, Australia. FAU - Chaudhry, Sarah G AU - Chaudhry SG AD - Department of Ophthalmology, Westmead Hospital, Westmead, New South Wales, Australia. FAU - Vukasovic, Matthew AU - Vukasovic M AD - Department of Emergency Medicine, Westmead Hospital, Westmead, New South Wales, Australia. FAU - White, Andrew J R AU - White AJR AD - Department of Ophthalmology, Westmead Hospital, Westmead, New South Wales, Australia. AD - Westmead and Central Clinical Schools, Discipline of Clinical Ophthalmology and Eye Health, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia. AD - The Westmead Institute for Medical Research, Westmead Hospital, Westmead, New South Wales, Australia. FAU - Fung, Adrian T AU - Fung AT AUID- ORCID: 0000-0002-1117-3893 AD - Department of Ophthalmology, Westmead Hospital, Westmead, New South Wales, Australia. AD - Westmead and Central Clinical Schools, Discipline of Clinical Ophthalmology and Eye Health, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia. AD - The Westmead Institute for Medical Research, Westmead Hospital, Westmead, New South Wales, Australia. AD - Department of Ophthalmology, Faculty of Medicine, Health and Human Sciences, Macquarie University, Macquarie Park, New South Wales, Australia. LA - eng PT - Journal Article DEP - 20210129 PL - New Zealand TA - Clin Ophthalmol JT - Clinical ophthalmology (Auckland, N.Z.) JID - 101321512 PMC - PMC7853628 OTO - NOTNLM OT - COVID-19 OT - emergency medicine OT - ophthalmic epidemiology OT - public health OT - retinal detachment COIS- The authors report no conflicts of interest in this work. EDAT- 2021/02/06 06:00 MHDA- 2021/02/06 06:01 PMCR- 2021/01/29 CRDT- 2021/02/05 05:58 PHST- 2020/10/29 00:00 [received] PHST- 2020/11/19 00:00 [accepted] PHST- 2021/02/05 05:58 [entrez] PHST- 2021/02/06 06:00 [pubmed] PHST- 2021/02/06 06:01 [medline] PHST- 2021/01/29 00:00 [pmc-release] AID - 289467 [pii] AID - 10.2147/OPTH.S289467 [doi] PST - epublish SO - Clin Ophthalmol. 2021 Jan 29;15:341-346. doi: 10.2147/OPTH.S289467. eCollection 2021. PMID- 33538617 OWN - NLM STAT- MEDLINE DCOM- 20220124 LR - 20220124 IS - 1744-8395 (Electronic) IS - 1476-0584 (Linking) VI - 20 IP - 3 DP - 2021 Mar TI - Immunization coverage among asplenic patients and strategies to increase vaccination compliance: a systematic review and meta-analysis. PG - 297-308 LID - 10.1080/14760584.2021.1886085 [doi] AB - BACKGROUND: Asplenic or splenectomized patients have a higher risk (ranging from 10 to 50-fold) than the general population of developing an overwhelming post-splenectomy infection (OPSI). Thus, they should receive specific vaccinations to prevent bacterial infections and influenza. The aim of this meta-analysis was to estimate vaccination coverage (VC) with the recommended vaccines among splenectomized patients; strategies recommended in those studies to improve VC worldwide are considered as well. RESEARCH DESIGN AND METHODS: Scopus, MEDLINE/PubMed, Google Scholar and ISI Web of Knowledge databases were searched. Research papers, short reports, reviews, and meta-analyses published between January 1, 2010 and July 18, 2020 were included; no geographic restrictions were included. Twenty-four studies were included in the meta-analysis. RESULTS: For anti-pneumococcal vaccination, coverage was 55.1% (95%CI = 41.0-69.2%), for anti-Hib 48.3% (95%CI = 34.3-52.3%), for anti-meningococcal C/ACYW135 33.7% (95%CI = 23.6-43.9%), for anti-meningococcal B 13.3% (95%CI = 7.0-19.5%) and for anti-influenza 53.2% (95%CI = 22.0-84.4%). Most studies determined a lack of adherence to international guidelines by healthcare workers and suggested the need to better educate health professionals in the management of post-splenectomy patients. CONCLUSIONS: The meta-analysis showed the suboptimal immunization coverage for the vaccines recommended for asplenic patients. Greater efforts must be made by public health professionals to increase VC in this group of patients at risk. Introducing specific prophylaxis protocols in the clinical routine seems to guarantee better immunization compliance in those patients. FAU - Bianchi, Francesco Paolo AU - Bianchi FP AD - Department of Biomedical Science and Human Oncology, Aldo Moro University of Bari, Bari, Italy. FAU - Stefanizzi, Pasquale AU - Stefanizzi P AD - Department of Biomedical Science and Human Oncology, Aldo Moro University of Bari, Bari, Italy. FAU - Spinelli, Giuseppe AU - Spinelli G AD - Department of Biomedical Science and Human Oncology, Aldo Moro University of Bari, Bari, Italy. FAU - Mascipinto, Simona AU - Mascipinto S AD - Department of Biomedical Science and Human Oncology, Aldo Moro University of Bari, Bari, Italy. FAU - Tafuri, Silvio AU - Tafuri S AD - Department of Biomedical Science and Human Oncology, Aldo Moro University of Bari, Bari, Italy. LA - eng PT - Journal Article PT - Meta-Analysis PT - Systematic Review DEP - 20210214 PL - England TA - Expert Rev Vaccines JT - Expert review of vaccines JID - 101155475 RN - 0 (Bacterial Vaccines) RN - 0 (Influenza Vaccines) SB - IM MH - Bacterial Infections/prevention & control MH - Bacterial Vaccines/*administration & dosage MH - Humans MH - Influenza Vaccines/*administration & dosage MH - Influenza, Human/prevention & control MH - *Splenectomy MH - Vaccination/*psychology/*statistics & numerical data MH - Vaccination Coverage/*statistics & numerical data MH - Vaccination Hesitancy/*psychology/*statistics & numerical data OTO - NOTNLM OT - Splenectomy OT - opsi OT - prevention OT - vaccine coverage EDAT- 2021/02/05 06:00 MHDA- 2022/01/27 06:00 CRDT- 2021/02/04 12:10 PHST- 2021/02/05 06:00 [pubmed] PHST- 2022/01/27 06:00 [medline] PHST- 2021/02/04 12:10 [entrez] AID - 10.1080/14760584.2021.1886085 [doi] PST - ppublish SO - Expert Rev Vaccines. 2021 Mar;20(3):297-308. doi: 10.1080/14760584.2021.1886085. Epub 2021 Feb 14. PMID- 35608922 OWN - NLM STAT- MEDLINE DCOM- 20220526 LR - 20251025 IS - 1469-493X (Electronic) IS - 1361-6137 (Linking) VI - (2) IP - 2 DP - 2021 Feb 3 TI - Coenzyme Q10 for heart failure. PG - CD008684 LID - 10.1002/14651858.CD008684.pub3 [doi] LID - CD008684 AB - BACKGROUND: Coenzyme Q10, or ubiquinone, is a non-prescription nutritional supplement. It is a fat-soluble molecule that acts as an electron carrier in mitochondria, and as a coenzyme for mitochondrial enzymes. Coenzyme Q10 deficiency may be associated with a multitude of diseases, including heart failure. The severity of heart failure correlates with the severity of coenzyme Q10 deficiency. Emerging data suggest that the harmful effects of reactive oxygen species are increased in people with heart failure, and coenzyme Q10 may help to reduce these toxic effects because of its antioxidant activity. Coenzyme Q10 may also have a role in stabilising myocardial calcium-dependent ion channels, and in preventing the consumption of metabolites essential for adenosine-5'-triphosphate (ATP) synthesis. Coenzyme Q10, although not a primary recommended treatment, could be beneficial to people with heart failure. Several randomised controlled trials have compared coenzyme Q10 to other therapeutic modalities, but no systematic review of existing randomised trials was conducted prior to the original version of this Cochrane Review, in 2014. OBJECTIVES: To review the safety and efficacy of coenzyme Q10 in heart failure. SEARCH METHODS: We searched CENTRAL, MEDLINE, Embase, Web of Science, CINAHL Plus, and AMED on 16 October 2020; ClinicalTrials.gov on 16 July 2020, and the ISRCTN Registry on 11 November 2019. We applied no language restrictions. SELECTION CRITERIA: We included randomised controlled trials of either parallel or cross-over design that assessed the beneficial and harmful effects of coenzyme Q10 in people with heart failure. When we identified cross-over studies, we considered data only from the first phase. DATA COLLECTION AND ANALYSIS: We used standard Cochrane methods, assessed study risk of bias using the Cochrane 'Risk of bias' tool, and GRADE methods to assess the quality of the evidence. For dichotomous data, we calculated the risk ratio (RR); for continuous data, the mean difference (MD), both with 95% confidence intervals (CI). Where appropriate data were available, we conducted meta-analysis. When meta-analysis was not possible, we wrote a narrative synthesis. We provided a PRISMA flow chart to show the flow of study selection. MAIN RESULTS: We included eleven studies, with 1573 participants, comparing coenzyme Q10 to placebo or conventional therapy (control). In the majority of the studies, sample size was relatively small. There were important differences among studies in daily coenzyme Q10 dose, follow-up period, and the measures of treatment effect. All studies had unclear, or high risk of bias, or both, in one or more bias domains. We were only able to conduct meta-analysis for some of the outcomes. None of the included trials considered quality of life, measured on a validated scale, exercise variables (exercise haemodynamics), or cost-effectiveness. Coenzyme Q10 probably reduces the risk of all-cause mortality more than control (RR 0.58, 95% CI 0.35 to 0.95; 1 study, 420 participants; number needed to treat for an additional beneficial outcome (NNTB) 13.3; moderate-quality evidence). There was low-quality evidence of inconclusive results between the coenzyme Q10 and control groups for the risk of myocardial infarction (RR 1.62, 95% CI 0.27 to 9.59; 1 study, 420 participants), and stroke (RR 0.18, 95% CI 0.02 to 1.48; 1 study, 420 participants). Coenzyme Q10 probably reduces hospitalisation related to heart failure (RR 0.62, 95% CI 0.49 to 0.78; 2 studies, 1061 participants; NNTB 9.7; moderate-quality evidence). Very low-quality evidence suggests that coenzyme Q10 may improve the left ventricular ejection fraction (MD 1.77, 95% CI 0.09 to 3.44; 7 studies, 650 participants), but the results are inconclusive for exercise capacity (MD 48.23, 95% CI -24.75 to 121.20; 3 studies, 91 participants); and the risk of developing adverse events (RR 0.70, 95% CI 0.45 to 1.10; 2 studies, 568 participants). We downgraded the quality of the evidence mainly due to high risk of bias and imprecision. AUTHORS' CONCLUSIONS: The included studies provide moderate-quality evidence that coenzyme Q10 probably reduces all-cause mortality and hospitalisation for heart failure. There is low-quality evidence of inconclusive results as to whether coenzyme Q10 has an effect on the risk of myocardial infarction, or stroke. Because of very low-quality evidence, it is very uncertain whether coenzyme Q10 has an effect on either left ventricular ejection fraction or exercise capacity. There is low-quality evidence that coenzyme Q10 may increase the risk of adverse effects, or have little to no difference. There is currently no convincing evidence to support or refute the use of coenzyme Q10 for heart failure. Future trials are needed to confirm our findings. CI - Copyright (c) 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. FAU - Al Saadi, Tareq AU - Al Saadi T AD - Department of Internal Medicine, University of Illinois at Chicago/Advocate Christ Medical Center, Oak Lawn, Illinois, USA. FAU - Assaf, Yazan AU - Assaf Y AD - Department of Cardiovascular Diseases, Mayo Clinic, Rochester, USA. AD - Department of Medicine, University of Florida, Gainesville, USA. FAU - Farwati, Medhat AU - Farwati M AD - Department of Cardiovascular Diseases, Mayo Clinic, Rochester, USA. AD - Department of Internal Medicine, Cleveland Clinic Foundation, Cleveland, USA. FAU - Turkmani, Khaled AU - Turkmani K AD - Department of Surgery, AlKalamoon General Hospital, AlNabek, Syrian Arab Republic. AD - Faculty of Medicine, Syrian Private University, Damascus, Syrian Arab Republic. FAU - Al-Mouakeh, Ahmed AU - Al-Mouakeh A AD - Faculty of Medicine, University of Aleppo, Aleppo, Syrian Arab Republic. FAU - Shebli, Baraa AU - Shebli B AD - Faculty of Medicine, University of Aleppo, Aleppo, Syrian Arab Republic. FAU - Khoja, Mohammed AU - Khoja M AD - ENT Department, Al Razi Public Hospital, Aleppo, Syrian Arab Republic. AD - Medical Education Program, Syrian Virtual University, Damascus, Syrian Arab Republic. FAU - Essali, Adib AU - Essali A AD - Community Mental Health, Counties Manukau Health, Manukau, New Zealand. FAU - Madmani, Mohammed E AU - Madmani ME AD - Department of Medicine, Cardiology Division, University of Arkansas for Medical Sciences, Little Rock, USA. LA - eng PT - Journal Article PT - Meta-Analysis PT - Research Support, Non-U.S. Gov't PT - Systematic Review DEP - 20210203 PL - England TA - Cochrane Database Syst Rev JT - The Cochrane database of systematic reviews JID - 100909747 RN - 1339-63-5 (Ubiquinone) RN - EJ27X76M46 (coenzyme Q10) RN - Coenzyme Q10 Deficiency SB - IM UOF - Cochrane Database Syst Rev. 2014 Jun 02;(6):CD008684. doi: 10.1002/14651858.CD008684.pub2. PMID: 24049047 MH - Ataxia MH - *Heart Failure/drug therapy MH - Humans MH - Mitochondrial Diseases MH - Muscle Weakness MH - *Myocardial Infarction/drug therapy MH - Quality of Life MH - *Stroke MH - Stroke Volume MH - Ubiquinone/adverse effects/analogs & derivatives/deficiency MH - Ventricular Function, Left PMC - PMC8092430 COIS- TA has no conflicts of interest to declare YA has no conflicts of interest to declare MF has no conflicts of interest to declare KT has no conflicts of interest to declare AM has no conflicts of interest to declare BS has no conflicts of interest to declare MK has no conflicts of interest to declare AE has no conflicts of interest to declare MM has no conflicts of interest to declare EDAT- 2021/02/03 00:00 MHDA- 2022/05/27 06:00 PMCR- 2022/02/03 CRDT- 2022/05/24 12:11 PHST- 2022/05/24 12:11 [entrez] PHST- 2021/02/03 00:00 [pubmed] PHST- 2022/05/27 06:00 [medline] PHST- 2022/02/03 00:00 [pmc-release] AID - CD008684.pub3 [pii] AID - 10.1002/14651858.CD008684.pub3 [doi] PST - epublish SO - Cochrane Database Syst Rev. 2021 Feb 3;(2)(2):CD008684. doi: 10.1002/14651858.CD008684.pub3. PMID- 33528551 OWN - NLM STAT- MEDLINE DCOM- 20210412 LR - 20231110 IS - 2574-3805 (Electronic) IS - 2574-3805 (Linking) VI - 4 IP - 2 DP - 2021 Feb 1 TI - Association of Combat Experiences With Suicide Attempts Among Active-Duty US Service Members. PG - e2036065 LID - 10.1001/jamanetworkopen.2020.36065 [doi] LID - e2036065 AB - IMPORTANCE: There is uncertainty about the role that military deployment experiences play in suicide-related outcomes. Most previous research has defined combat experiences broadly, and a limited number of cross-sectional studies have examined the association between specific combat exposure (eg, killing) and suicide-related outcomes. OBJECTIVE: To prospectively examine combat exposures associated with suicide attempts among active-duty US service members while accounting for demographic, military-specific, and mental health factors. DESIGN, SETTING, AND PARTICIPANTS: This cohort study analyzed data from the Millennium Cohort Study, an ongoing prospective longitudinal study of US service members from all military branches. Participants were enrolled in 4 phases from July 1, 2001, to April 4, 2013, and completed a self-administered survey at enrollment and every 3 to 5 years thereafter. The population for the present study was restricted to active-duty service members from the first 4 enrollment phases who deployed in support of the wars in Iraq and Afghanistan. Questionnaire data were linked with medical encounter data through September 30, 2015. Data analyses were conducted from January 10, 2017, to December 14, 2020. EXPOSURES: Combat exposure was examined in 3 ways (any combat experience, overall combat severity, and 13 individual combat experiences) using a 13-item self-reported combat measure. MAIN OUTCOMES AND MEASURES: Suicide attempts were identified from military electronic hospitalization and ambulatory medical encounter data using the International Classification of Diseases, Ninth Revision codes. RESULTS: Among 57 841 participants, 44 062 were men (76.2%) and 42 095 were non-Hispanic White individuals (72.8%), and the mean (SD) age was 26.9 (5.3) years. During a mean (SD) follow-up period of 5.6 (4.0) years, 235 participants had a suicide attempt (0.4%). Combat exposure, defined broadly, was not associated with suicide attempts in Cox proportional hazards time-to-event regression models after adjustments for demographic and military-specific factors; high combat severity and certain individual combat experiences were associated with an increased risk for suicide attempts. However, these associations were mostly accounted for by mental disorders, especially posttraumatic stress disorder. After adjustment for mental disorders, combat experiences with significant association with suicide attempts included being attacked or ambushed (hazard ratio [HR], 1.55; 95% CI, 1.16-2.06), seeing dead bodies or human remains (HR, 1.34; 95% CI, 1.01-1.78), and being directly responsible for the death of a noncombatant (HR, 1.81; 95% CI, 1.04-3.16). CONCLUSIONS AND RELEVANCE: This study suggests that deployed service members who experience high levels of combat or are exposed to certain types of combat experiences (involving unexpected events or those that challenge moral or ethical norms) may be at an increased risk of a suicide attempt, either directly or mediated through a mental disorder. FAU - LeardMann, Cynthia A AU - LeardMann CA AD - Deployment Health Research Department, Naval Health Research Center, San Diego, California. AD - Leidos, San Diego, California. FAU - Matsuno, Rayna K AU - Matsuno RK AD - Deployment Health Research Department, Naval Health Research Center, San Diego, California. AD - Leidos, San Diego, California. FAU - Boyko, Edward J AU - Boyko EJ AD - Seattle Epidemiologic Research and Information Center, Department of Veterans Affairs Puget Sound Health Care System, Seattle, Washington. AD - Department of Epidemiology, University of Washington School of Public Health, Seattle. AD - Department of Medicine, University of Washington School of Medicine, Seattle. FAU - Powell, Teresa M AU - Powell TM AD - Deployment Health Research Department, Naval Health Research Center, San Diego, California. AD - Leidos, San Diego, California. FAU - Reger, Mark A AU - Reger MA AD - Veterans Affairs Puget Sound Healthcare System, Seattle, Washington. AD - Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle. FAU - Hoge, Charles W AU - Hoge CW AD - Center for Psychiatry and Neuroscience, Walter Reed Army Institute of Research, Silver Spring, Maryland. AD - Psychiatry Division, Office of the Army Surgeon General, Falls Church, Virginia. CN - Millennium Cohort Study LA - eng PT - Journal Article PT - Research Support, U.S. Gov't, Non-P.H.S. DEP - 20210201 PL - United States TA - JAMA Netw Open JT - JAMA network open JID - 101729235 SB - IM MH - Adult MH - Afghan Campaign 2001- MH - Depressive Disorder/*epidemiology/psychology MH - Female MH - Homicide/psychology/*statistics & numerical data MH - Humans MH - Iraq War, 2003-2011 MH - Male MH - Mediation Analysis MH - Military Deployment MH - Military Personnel/psychology/*statistics & numerical data MH - Patient Health Questionnaire MH - Proportional Hazards Models MH - Stress Disorders, Post-Traumatic/*epidemiology/psychology MH - Suicide, Attempted/psychology/*statistics & numerical data MH - United States/epidemiology MH - War Exposure/*statistics & numerical data MH - War-Related Injuries/epidemiology/psychology MH - Young Adult PMC - PMC7856539 COIS- Conflict of Interest Disclosures: Dr Boyko reported serving on the Bayer AG advisory board. No other disclosures were reported. EDAT- 2021/02/03 06:00 MHDA- 2021/04/13 06:00 PMCR- 2021/02/02 CRDT- 2021/02/02 12:13 PHST- 2021/02/02 12:13 [entrez] PHST- 2021/02/03 06:00 [pubmed] PHST- 2021/04/13 06:00 [medline] PHST- 2021/02/02 00:00 [pmc-release] AID - 2775737 [pii] AID - zoi201077 [pii] AID - 10.1001/jamanetworkopen.2020.36065 [doi] PST - epublish SO - JAMA Netw Open. 2021 Feb 1;4(2):e2036065. doi: 10.1001/jamanetworkopen.2020.36065. PMID- 33525441 OWN - NLM STAT- MEDLINE DCOM- 20210204 LR - 20210227 IS - 1660-4601 (Electronic) IS - 1661-7827 (Print) IS - 1660-4601 (Linking) VI - 18 IP - 3 DP - 2021 Jan 28 TI - Change of Use in Community Services among Disabled Older Adults during COVID-19 in Japan. LID - 10.3390/ijerph18031148 [doi] LID - 1148 AB - During the COVID-19 pandemic, social interactions were restricted, including community services for disabled older adults. This study aimed to describe the change of use in community services related to long-term care insurance (LTCI) during the pandemic in Japan. A retrospective descriptive study was conducted using data collected via a cloud-based management support platform for older adult care provider "Kaipoke", by a private-sector company "SMS Co., Ltd.", in which care-managers of LTCI manage their office work. Data collection occurred from July 2019 to June 2020. Study subjects were LTCI service users aged 65 years and above. Subjects were living at home. We examined changes in the number of users of LTCI services before and after the COVID-19 pandemic began, using an interrupted time-series analysis. Results indicated that the use of outpatient services was reduced; however, home-visit services were maintained. The decrease in use was significant in the seven prefectures where the infection initially spread. There are concerns that older adults or surrounding caregivers can be affected by such changes in LTC service use. It is therefore necessary to implement sustainable measures from a long-term perspective and investigate their influence as part of future studies. FAU - Ito, Tomoko AU - Ito T AD - Department of Health Services Research, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki 305-8577, Japan. AD - Health Services Research and Development Center, University of Tsukuba, Tsukuba, Ibaraki 305-8577, Japan. FAU - Hirata-Mogi, Sachiko AU - Hirata-Mogi S AD - Health Services Research and Development Center, University of Tsukuba, Tsukuba, Ibaraki 305-8577, Japan. AD - Analytics & Innovation Department, Research & Development Group, SMS Co., Ltd., Tokyo 105-0011, Japan. FAU - Watanabe, Taeko AU - Watanabe T AD - Health Services Research and Development Center, University of Tsukuba, Tsukuba, Ibaraki 305-8577, Japan. FAU - Sugiyama, Takehiro AU - Sugiyama T AUID- ORCID: 0000-0001-5391-682X AD - Department of Health Services Research, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki 305-8577, Japan. AD - Health Services Research and Development Center, University of Tsukuba, Tsukuba, Ibaraki 305-8577, Japan. AD - Diabetes and Metabolism Information Center, Research Institute, National Center for Global Health and Medicine, Tokyo 162-8655, Japan. FAU - Jin, Xueying AU - Jin X AD - Department of Health Services Research, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki 305-8577, Japan. AD - Health Services Research and Development Center, University of Tsukuba, Tsukuba, Ibaraki 305-8577, Japan. FAU - Kobayashi, Shu AU - Kobayashi S AD - Analytics & Innovation Department, Research & Development Group, SMS Co., Ltd., Tokyo 105-0011, Japan. FAU - Tamiya, Nanako AU - Tamiya N AD - Department of Health Services Research, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki 305-8577, Japan. AD - Health Services Research and Development Center, University of Tsukuba, Tsukuba, Ibaraki 305-8577, Japan. LA - eng GR - CRE30018 in University of Tsukuba/SMS Co., Ltd./International PT - Journal Article DEP - 20210128 PL - Switzerland TA - Int J Environ Res Public Health JT - International journal of environmental research and public health JID - 101238455 SB - IM MH - Aged MH - *COVID-19 MH - Community Health Services/*statistics & numerical data MH - Home Care Services/*statistics & numerical data MH - Humans MH - *Insurance, Long-Term Care MH - Interrupted Time Series Analysis MH - Japan/epidemiology MH - *Pandemics MH - Retrospective Studies MH - Social Welfare PMC - PMC7908432 OTO - NOTNLM OT - COVID-19 OT - community services OT - home-visit services OT - older adults OT - outpatient services COIS- This study was funded by SMS Co., Ltd. SH was a researcher at the University of Tsukuba for joint research with SMS Co., Ltd. in the 2020 financial year (i.e., April 2020 to the present). The research project was supported by SMS Co., Ltd. SH and SK were employed by SMS Co., Ltd. SH, SK, and SMS Co., Ltd. had not played any role in the conduct of this study, except for data collection. The funders had no role in the design of the study; in the analyses or interpretation of data; in the writing of the manuscript, or in the decision to publish the results. T.S. was hired by University of Tsukuba using the fund from SMS Co. for joint research. EDAT- 2021/02/03 06:00 MHDA- 2021/02/05 06:00 PMCR- 2021/02/01 CRDT- 2021/02/02 01:03 PHST- 2020/12/09 00:00 [received] PHST- 2021/01/23 00:00 [revised] PHST- 2021/01/24 00:00 [accepted] PHST- 2021/02/02 01:03 [entrez] PHST- 2021/02/03 06:00 [pubmed] PHST- 2021/02/05 06:00 [medline] PHST- 2021/02/01 00:00 [pmc-release] AID - ijerph18031148 [pii] AID - ijerph-18-01148 [pii] AID - 10.3390/ijerph18031148 [doi] PST - epublish SO - Int J Environ Res Public Health. 2021 Jan 28;18(3):1148. doi: 10.3390/ijerph18031148. PMID- 33516189 OWN - NLM STAT- MEDLINE DCOM- 20210614 LR - 20210614 IS - 1471-2261 (Electronic) IS - 1471-2261 (Linking) VI - 21 IP - 1 DP - 2021 Jan 30 TI - Assessment of chronic disease self-management in patients with chronic heart failure based on the MCID of patient-reported outcomes by the multilevel model. PG - 58 LID - 10.1186/s12872-021-01872-3 [doi] LID - 58 AB - PURPOSE: The minimal clinically important difference (MCID) of a patient-reported outcome (PRO) represents the threshold value of the change in the score for that PRO. It is deemed to have an important implication in clinical management. This study was performed to evaluate the clinical significance of chronic disease self-management (CDSM) for patients with chronic heart failure based on the MCID of the chronic heart failure-PRO measure (CHF-PROM). METHODS: A multicenter, prospective cohort study of 555 patients with heart failure were enrolled from July 2018. Advice of CDSM was provided in written form at discharge to all patients. Information regarding CHF-PROM and CDSM were collected during follow-up. Multilevel models were applied to dynamically evaluate the effects of CDSM for CHF-PROM scores, as well as its physical and psychological domains. MCID changes of the PRO were introduced and compared with beta values of CDSM obtained from the multi-level models to further evaluate the clinical significance. The STROBE checklist is shown in Additional file 1. RESULTS: Scores for CHF-PROM improved significantly after discharge. The multilevel models showed that a regular schedule, avoidance of over-eating, a low-sodium diet and exercise increased scores on CHF-PROM. Compared with the MCID, avoidance of over-eating (12.39 vs. 9.75) and maintenance of a regular schedule often (10.98 vs. 9.75), and exercise almost every day (11.36 vs. 9.75) reached clinical significance for the overall summary. Avoidance of over-eating (5.88 vs. 4.79) and a regular schedule almost every day (4.96 vs. 4.79) reached clinical significance for the physical scores. Avoidance of over-eating half of the time (5.26 vs. 4.87) and a regular schedule almost every day (5.84 vs. 4.87) demonstrated clinical significance for the psychological scores. CONCLUSIONS: This study observed an association of avoidance of over-eating and maintenance of a regular schedule with the improvement of CHF-PROM. It provides further evidence for management of heart failure. TRIAL REGISTRATION: Current Prospective Trials NCT02878811; registered August 25, 2016; https://clinicaltrials.gov/ct2/show/NCT02878811?term=NCT02878811&draw=2&rank=1 . FAU - Tian, Jing AU - Tian J AD - Department of Cardiology, The 1St Hospital of Shanxi Medical University, 85 South Jiefang Road, Taiyuan, 030001, Shanxi Province, China. AD - Shanxi Provincial Key Laboratory of Major Diseases Risk Assessment, 56 South XinJian Road, Taiyuan, 030001, Shanxi Province, China. FAU - Zhao, Jinghua AU - Zhao J AD - Department of Health Statistics, School of Public Health, Shanxi Medical University, 56 South XinJian Road, Taiyuan, 030001, Shanxi Province, China. FAU - Zhang, Qing AU - Zhang Q AD - Department of Cardiology, The 1St Hospital of Shanxi Medical University, 85 South Jiefang Road, Taiyuan, 030001, Shanxi Province, China. FAU - Ren, Jia AU - Ren J AD - Department of Cardiology, The 1St Hospital of Shanxi Medical University, 85 South Jiefang Road, Taiyuan, 030001, Shanxi Province, China. FAU - Han, Linai AU - Han L AD - Department of Cardiology, The 1St Hospital of Shanxi Medical University, 85 South Jiefang Road, Taiyuan, 030001, Shanxi Province, China. FAU - Li, Jing AU - Li J AD - Department of Health Statistics, School of Public Health, Shanxi Medical University, 56 South XinJian Road, Taiyuan, 030001, Shanxi Province, China. FAU - Zhang, Yanbo AU - Zhang Y AUID- ORCID: 0000-0002-9461-4163 AD - Department of Health Statistics, School of Public Health, Shanxi Medical University, 56 South XinJian Road, Taiyuan, 030001, Shanxi Province, China. sxmuzyb@126.com. AD - Shanxi Provincial Key Laboratory of Major Diseases Risk Assessment, 56 South XinJian Road, Taiyuan, 030001, Shanxi Province, China. sxmuzyb@126.com. FAU - Han, Qinghua AU - Han Q AD - Department of Cardiology, The 1St Hospital of Shanxi Medical University, 85 South Jiefang Road, Taiyuan, 030001, Shanxi Province, China. syhqn@sohu.com. LA - eng SI - ClinicalTrials.gov/NCT02878811 GR - 81872714/Innovative Research Group Project of the National Natural Science Foundation of China/ GR - 201801D221423/Natural Science Foundation of Shanxi Province/ GR - 2016YFC090310/Natural Science Foundation of Shanxi Province/ GR - YDZX20191400004850/Natural Science Foundation of Shanxi Province/ PT - Journal Article PT - Multicenter Study PT - Observational Study PT - Research Support, Non-U.S. Gov't DEP - 20210130 PL - England TA - BMC Cardiovasc Disord JT - BMC cardiovascular disorders JID - 100968539 SB - IM MH - Aged MH - Aged, 80 and over MH - China MH - Chronic Disease MH - Diet, Sodium-Restricted MH - Exercise MH - Feeding Behavior MH - Female MH - *Healthy Lifestyle MH - Heart Failure/diagnosis/physiopathology/psychology/*therapy MH - Humans MH - Hyperphagia/physiopathology/prevention & control/psychology MH - Male MH - Middle Aged MH - *Minimal Clinically Important Difference MH - Patient Discharge MH - *Patient Reported Outcome Measures MH - Prospective Studies MH - *Risk Reduction Behavior MH - *Self-Management MH - Time Factors MH - Treatment Outcome PMC - PMC7847136 OTO - NOTNLM OT - Chronic disease self-management OT - Chronic heart failure OT - Minimal clinically important difference OT - Multilevel model OT - Patient-reported outcome COIS- The authors declare that they have no competing interests. EDAT- 2021/02/01 06:00 MHDA- 2021/06/16 06:00 PMCR- 2021/01/30 CRDT- 2021/01/31 20:20 PHST- 2020/07/04 00:00 [received] PHST- 2021/01/18 00:00 [accepted] PHST- 2021/01/31 20:20 [entrez] PHST- 2021/02/01 06:00 [pubmed] PHST- 2021/06/16 06:00 [medline] PHST- 2021/01/30 00:00 [pmc-release] AID - 10.1186/s12872-021-01872-3 [pii] AID - 1872 [pii] AID - 10.1186/s12872-021-01872-3 [doi] PST - epublish SO - BMC Cardiovasc Disord. 2021 Jan 30;21(1):58. doi: 10.1186/s12872-021-01872-3. PMID- 33515746 OWN - NLM STAT- MEDLINE DCOM- 20210917 LR - 20250623 IS - 1553-4669 (Electronic) IS - 1553-4650 (Linking) VI - 28 IP - 6 DP - 2021 Jun TI - Surgical Management of Adnexal Masses in Pregnancy: A Systematic Review and Meta-analysis. PG - 1171-1182.e2 LID - S1553-4650(21)00053-4 [pii] LID - 10.1016/j.jmig.2021.01.020 [doi] AB - OBJECTIVE: The incidence of adnexal masses in pregnancy is 1% to 6%. Although surgery is often indicated, there are no definitive management guidelines. We aimed to investigate the optimal approach to surgical management of adnexal masses in pregnancy on the basis of a meta-analysis of previous studies. DATA SOURCES: We performed a systematic review using MEDLINE, Embase, Cochrane Library, and Clinicaltrials.gov from inception to July 17, 2020. METHODS OF STUDY SELECTION: There were no restrictions on study type, language, or publication date. Comparative and noncomparative retrospective studies that reviewed operative techniques used in surgery of adnexal masses in pregnancy were included. Meta-analyses were performed to assess outcomes. This study was registered in the International Prospective Register of Systematic Reviews (CRD42019129709). TABULATION, INTEGRATION, AND RESULTS: Comparative studies were identified for laparoscopy vs laparotomy and elective vs emergent surgery (11 and 4, respectively). Elective surgery is defined as a scheduled antepartum procedure. For laparoscopy vs laparotomy, the mean maternal ages and gestational ages at time of surgery were similar (27.8 years vs 27.7 years, p = .85; 16.2 weeks in laparoscopy vs 15.4 weeks in laparotomy, p = .59). Mass size was larger in those undergoing laparotomy (mean 8.8 cm vs 7.8 cm, p = .03). The most common pathologic condition was dermoid cyst (36%), and the risk of discovering a malignant tumor was 1%. Laparoscopy was not associated with a statistically increased risk of spontaneous abortion (SAB) or preterm delivery (PTD) (odds ratio [OR] 1.53; 95% confidence interval [CI], 0.67-3.52; p = .31 and OR 0.95; 95% CI, 0.47-1.89; p = .88, respectively). The mean length of hospital stay was 2.5 days after laparoscopy vs 5.3 days after laparotomy (p <.001). The decrease in estimated blood loss in laparoscopy was not statistically significant (94.0 mL in laparotomy vs 54.0 mL in laparoscopy, p = .06). Operative times were similar in laparoscopy and laparotomy (80.0 minutes vs 72.5 minutes, p = .09). Elective surgery was associated with a decreased risk of PTD (OR 0.13; 95% CI, 0.04-0.48; p = .05). Noncomparative studies were identified for laparoscopy and laparotomy. Laparotomy had more SABs and PTDs than laparoscopy (pooled proportion = 0.02 vs 0.07 and pooled proportion = 0.02 vs 0.14, respectively). CONCLUSION: Laparoscopy for the surgical management of adnexal masses in pregnancy is associated with shorter length of hospital stay and similar risk of SAB or PTD. Elective surgery is associated with a decreased risk of PTD. CI - Copyright (c) 2021 AAGL. Published by Elsevier Inc. All rights reserved. FAU - Cagino, Kristen AU - Cagino K AD - Department of Obstetrics and Gynecology (Drs. Cagino, Li, and Acholonu, Jr). Electronic address: kac9239@nyp.org. FAU - Li, Xuan AU - Li X AD - Department of Obstetrics and Gynecology (Drs. Cagino, Li, and Acholonu, Jr). FAU - Thomas, Charlene AU - Thomas C AD - Department of Population Health Sciences (Dr. Christos and Ms. Thomas). FAU - Delgado, Diana AU - Delgado D AD - Samuel J. Wood Library and C.V. Starr Biomedical Information Center (Ms. Delgado), NewYork-Presbyterian Weill Cornell Medical Center, New York, New York. FAU - Christos, Paul AU - Christos P AD - Department of Population Health Sciences (Dr. Christos and Ms. Thomas). FAU - Acholonu, Uchenna Jr AU - Acholonu U Jr AD - Department of Obstetrics and Gynecology (Drs. Cagino, Li, and Acholonu, Jr). LA - eng GR - UL1 TR002384/TR/NCATS NIH HHS/United States PT - Journal Article PT - Meta-Analysis PT - Research Support, N.I.H., Extramural PT - Systematic Review DEP - 20210128 PL - United States TA - J Minim Invasive Gynecol JT - Journal of minimally invasive gynecology JID - 101235322 SB - IM MH - *Adnexal Diseases/surgery MH - Female MH - Humans MH - Infant, Newborn MH - *Laparoscopy MH - Laparotomy MH - Pregnancy MH - Retrospective Studies MH - Treatment Outcome OTO - NOTNLM OT - Operative techniques OT - Ovarian cyst OT - Ovarian mass OT - Perinatal complications EDAT- 2021/01/31 06:00 MHDA- 2021/09/18 06:00 CRDT- 2021/01/30 20:09 PHST- 2020/11/11 00:00 [received] PHST- 2021/01/20 00:00 [revised] PHST- 2021/01/22 00:00 [accepted] PHST- 2021/01/31 06:00 [pubmed] PHST- 2021/09/18 06:00 [medline] PHST- 2021/01/30 20:09 [entrez] AID - S1553-4650(21)00053-4 [pii] AID - 10.1016/j.jmig.2021.01.020 [doi] PST - ppublish SO - J Minim Invasive Gynecol. 2021 Jun;28(6):1171-1182.e2. doi: 10.1016/j.jmig.2021.01.020. Epub 2021 Jan 28. PMID- 33507564 OWN - NLM STAT- MEDLINE DCOM- 20220111 LR - 20230202 IS - 1879-3479 (Electronic) IS - 0020-7292 (Print) IS - 0020-7292 (Linking) VI - 156 IP - 2 DP - 2022 Feb TI - Food insecurity and adverse pregnancy outcomes among rural Malawian women. PG - 309-315 LID - 10.1002/ijgo.13630 [doi] AB - OBJECTIVE: To investigate whether food insecurity is associated with adverse pregnancy outcomes such as miscarriage, stillbirth, and neonatal mortality among women in rural Malawi. METHODS: We analyzed data from the baseline (July 2014 to February 2015) and follow-up (January 2018 to May 2018) waves of a longitudinal study of reproductive-age women in rural Malawi. We sampled women from villages from the catchment area of a community hospital in rural Lilongwe district of Malawi using stratified cluster sampling. We classified women as food secure or insecure at baseline. Using unadjusted and adjusted log-binomial models, we used baseline data to examine the cross-sectional association between food insecurity and ever experiencing an adverse pregnancy outcome. We used baseline and follow-up data to assess the longitudinal association between food insecurity and experiencing a new adverse pregnancy outcome during follow-up. In a subgroup analysis, we repeated the longitudinal analysis after restricting the sample to women who had no adverse pregnancy outcomes at baseline. RESULTS: We observed no significant cross-sectional association between baseline food insecurity and ever experiencing an adverse pregnancy outcome (adjusted prevalence ratio: 1.09; 95% confidence interval [CI]: 0.78-1.53). Baseline food insecurity was not associated with experiencing a new adverse pregnancy outcome during follow-up (adjusted risk ratio [aRR]: 1.14, 95% CI: 0.60-2.20) or in the subgroup analysis (aRR: 1.52, 95% CI: 0.78-2.96). CONCLUSIONS: While food insecurity is a critical issue, in this cohort of rural Malawian women, food insecurity was not associated with adverse pregnancy outcomes. CI - (c) 2021 International Federation of Gynecology and Obstetrics. FAU - Hood, Robert B AU - Hood RB AD - The Ohio State University College of Public Health, Columbus, OH, USA. FAU - Norris, Alison H AU - Norris AH AD - The Ohio State University College of Public Health, Columbus, OH, USA. AD - The Ohio State University College of Medicine, Columbus, OH, USA. FAU - Huber-Krum, Sarah AU - Huber-Krum S AD - Harvard T.H. Chan School of Public Health, Boston, MA, USA. FAU - Garver, Sarah AU - Garver S AD - The University of Chicago, Chicago, IL, USA. FAU - Chapotera, Gertrude AU - Chapotera G AD - University of Malawi College of Medicine, Blantyre, Malawi. FAU - Turner, Abigail N AU - Turner AN AD - The Ohio State University College of Public Health, Columbus, OH, USA. AD - The Ohio State University College of Medicine, Columbus, OH, USA. LA - eng GR - UL1 TR001070/TR/NCATS NIH HHS/United States GR - KL2TR001068/OSU Center for Clinical and Translational Science/ GR - Bill & Melinda Gates Foundation's/ GR - NICHD P2C-HD058484/Ohio State University/ GR - OSU Public Health Preparedness for Infectious Diseases program/ GR - KL2 TR001068/TR/NCATS NIH HHS/United States GR - TL1TR001069/OSU Center for Clinical and Translational Science/ GR - NCATS UL1TR001070/OSU Center for Clinical and Translational Science/ GR - P2C HD058484/HD/NICHD NIH HHS/United States GR - TL1 TR001069/TR/NCATS NIH HHS/United States PT - Journal Article DEP - 20210217 PL - United States TA - Int J Gynaecol Obstet JT - International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics JID - 0210174 SB - IM MH - Cross-Sectional Studies MH - Female MH - Food Insecurity MH - Humans MH - Infant, Newborn MH - Longitudinal Studies MH - Pregnancy MH - *Pregnancy Outcome/epidemiology MH - *Rural Population PMC - PMC9808894 MID - NIHMS1856323 OTO - NOTNLM OT - Malawi OT - adverse pregnancy outcomes OT - cross-sectional OT - food insecurity OT - longitudinal OT - rural COIS- CONFLICTS OF INTEREST None to disclose. EDAT- 2021/01/29 06:00 MHDA- 2022/01/12 06:00 PMCR- 2023/02/01 CRDT- 2021/01/28 12:18 PHST- 2020/11/09 00:00 [revised] PHST- 2020/07/27 00:00 [received] PHST- 2021/01/25 00:00 [accepted] PHST- 2021/01/29 06:00 [pubmed] PHST- 2022/01/12 06:00 [medline] PHST- 2021/01/28 12:18 [entrez] PHST- 2023/02/01 00:00 [pmc-release] AID - 10.1002/ijgo.13630 [doi] PST - ppublish SO - Int J Gynaecol Obstet. 2022 Feb;156(2):309-315. doi: 10.1002/ijgo.13630. Epub 2021 Feb 17. PMID- 33492377 OWN - NLM STAT- MEDLINE DCOM- 20210201 LR - 20220323 IS - 2574-3805 (Electronic) IS - 2574-3805 (Linking) VI - 4 IP - 1 DP - 2021 Jan 4 TI - Evaluation of Seasonal Respiratory Virus Activity Before and After the Statewide COVID-19 Shelter-in-Place Order in Northern California. PG - e2035281 LID - 10.1001/jamanetworkopen.2020.35281 [doi] LID - e2035281 AB - IMPORTANCE: Public health initiatives that include shelter-in-place orders are expensive and unpopular. Demonstrating the success of these initiatives is essential to justify their systemic or individual cost. OBJECTIVE: To examine the association of a shelter-in-place order with lower rates of seasonal respiratory viral activity. DESIGN, SETTING, AND PARTICIPANTS: This cohort study with interrupted time series analysis obtained monthly counts of respiratory virus testing results at UC Davis Health from August 1, 2014, to July 31, 2020. Patients of all ages underwent testing conducted by the laboratory at UC Davis Health, a referral center for a 65 000-square-mile area that includes 33 counties and more than 6 million Northern California residents. EXPOSURES: A statewide shelter-in-place order was instituted on March 19, 2020, restricting residents to their homes except for traveling for essential activities. Large social gatherings were prohibited, schools were closed, and nonessential personnel worked remotely. Those who had to leave their homes were mandated to wear face masks, engage in frequent handwashing, and maintain physical distancing. MAIN OUTCOMES AND MEASURES: Positivity rates of common respiratory viruses within the community served by UC Davis Health. RESULTS: A total of 46 128 tests for viral respiratory pathogens over a 6-year period were included in the analysis. For the postexposure period (March 25-July 31), approximately 168 positive test results occurred for the studied organisms in the 2020 virus year, a positivity rate of 9.88 positive results per 100 tests that was much lower than the positivity rate of 29.90 positive results per 100 tests observed for this date range in the previous 5 virus years. In contrast, the positivity rates were similar for the preexposure time frame (August 1-March 24) in the 2020 virus year and for the same time periods in the 5 previous years (30.40 vs 33.68 positive results per 100 tests). In the regression analyses, statistically significant decreases in viral activity were observed in the postexposure period for influenza (93% decrease; incidence rate ratio [IRR], 0.07; 95% CI, 0.02-0.33) and for rhinovirus or enterovirus (81% decrease; IRR, 0.19; 95% CI, 0.09-0.39) infections. Lower rates of postexposure viral activity were seen for respiratory syncytial virus, parainfluenzavirus, coronaviruses, and adenoviruses; however, these associations were not statistically significant. CONCLUSIONS AND RELEVANCE: Using interrupted time series analysis of testing for viral respiratory pathogens, this study found that statistically significant lower rates of common community respiratory viruses appeared to be associated with a shelter-in-place order during the coronavirus disease 2019 pandemic. FAU - Partridge, Elizabeth AU - Partridge E AD - Department of Pediatrics, University of California at Davis School of Medicine, Sacramento. FAU - McCleery, Ellen AU - McCleery E AD - Department of Pediatrics, University of California at Davis School of Medicine, Sacramento. FAU - Cheema, Ritu AU - Cheema R AD - Department of Pediatrics, University of California at Davis School of Medicine, Sacramento. FAU - Nakra, Natasha AU - Nakra N AD - Department of Pediatrics, University of California at Davis School of Medicine, Sacramento. FAU - Lakshminrusimha, Satyan AU - Lakshminrusimha S AD - Department of Pediatrics, University of California at Davis School of Medicine, Sacramento. FAU - Tancredi, Daniel J AU - Tancredi DJ AD - Department of Pediatrics, University of California at Davis School of Medicine, Sacramento. FAU - Blumberg, Dean A AU - Blumberg DA AD - Department of Pediatrics, University of California at Davis School of Medicine, Sacramento. LA - eng GR - UL1 TR001860/TR/NCATS NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural DEP - 20210104 PL - United States TA - JAMA Netw Open JT - JAMA network open JID - 101729235 SB - IM MH - Adolescent MH - Adult MH - COVID-19/*prevention & control/transmission MH - California/epidemiology MH - Female MH - Humans MH - Male MH - Middle Aged MH - Quarantine/methods/*standards/statistics & numerical data MH - Respiratory Tract Infections/epidemiology/*virology MH - *Seasons PMC - PMC7835714 COIS- Conflict of Interest Disclosures: None reported. EDAT- 2021/01/26 06:00 MHDA- 2021/02/02 06:00 PMCR- 2021/01/25 CRDT- 2021/01/25 12:15 PHST- 2021/01/25 12:15 [entrez] PHST- 2021/01/26 06:00 [pubmed] PHST- 2021/02/02 06:00 [medline] PHST- 2021/01/25 00:00 [pmc-release] AID - 2775607 [pii] AID - zoi201063 [pii] AID - 10.1001/jamanetworkopen.2020.35281 [doi] PST - epublish SO - JAMA Netw Open. 2021 Jan 4;4(1):e2035281. doi: 10.1001/jamanetworkopen.2020.35281. PMID- 33488426 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20231110 IS - 1664-0640 (Print) IS - 1664-0640 (Electronic) IS - 1664-0640 (Linking) VI - 11 DP - 2020 TI - Mental Distress and Human Rights Violations During COVID-19: A Rapid Review of the Evidence Informing Rights, Mental Health Needs, and Public Policy Around Vulnerable Populations. PG - 603875 LID - 10.3389/fpsyt.2020.603875 [doi] LID - 603875 AB - Background: COVID-19 prevention and mitigation efforts were abrupt and challenging for most countries with the protracted lockdown straining socioeconomic activities. Marginalized groups and individuals are particularly vulnerable to adverse effects of the pandemic such as human rights abuses and violations which can lead to psychological distress. In this review, we focus on mental distress and disturbances that have emanated due to human rights restrictions and violations amidst the pandemic. We underscore how mental health is both directly impacted by the force of pandemic and by prevention and mitigation structures put in place to combat the disease. Methods: We conducted a review of relevant studies examining human rights violations in COVID-19 response, with a focus on vulnerable populations, and its association with mental health and psychological well-being. We searched PubMed and Embase databases for studies between December 2019 to July 2020. Three reviewers evaluated the eligibility criteria and extracted data. Results: Twenty-four studies were included in the systematic inquiry reporting on distress due to human rights violations. Unanimously, the studies found vulnerable populations to be at a high risk for mental distress. Limited mobility rights disproportionately harmed psychiatric patients, low-income individuals, and minorities who were at higher risk for self-harm and worsening mental health. Healthcare workers suffered negative mental health consequences due to stigma and lack of personal protective equipment and stigma. Other vulnerable groups such as the elderly, children, and refugees also experienced negative consequences. Conclusions: This review emphasizes the need to uphold human rights and address long term mental health needs of populations that have suffered disproportionately during the pandemic. Countries can embed a proactive psychosocial response to medical management as well as in existing prevention strategies. International human rights guidelines are useful in this direction but an emphasis should be placed on strengthening rights informed psychosocial response with specific strategies to enhance mental health in the long-term. We underscore that various fundamental human rights are interdependent and therefore undermining one leads to a poor impact on the others. We strongly recommend global efforts toward focusing both on minimizing fatalities, protecting human rights, and promoting long term mental well-being. CI - Copyright (c) 2021 Rahman, Ahmed, Moitra, Damschroder, Brownson, Chorpita, Idele, Gohar, Huang, Saxena, Lai, Peterson, Harper, McKay, Amugune, Esho, Ronen, Othieno and Kumar. FAU - Rahman, Muhammad AU - Rahman M AD - University of Washington, Seattle, WA, United States. FAU - Ahmed, Rabab AU - Ahmed R AD - Washington University, St. Louis, MO, United States. FAU - Moitra, Modhurima AU - Moitra M AD - University of Washington, Seattle, WA, United States. AD - Department of Health Metrics Sciences, University of Washington, Seattle, WA, United States. FAU - Damschroder, Laura AU - Damschroder L AD - VA Ann Arbor Healthcare System, Ann Arbor, MI, United States. FAU - Brownson, Ross AU - Brownson R AD - Washington University, St. Louis, MO, United States. FAU - Chorpita, Bruce AU - Chorpita B AD - Department of Psychology, University of California Los Angeles Life Sciences, Los Angeles, CA, United States. FAU - Idele, Priscilla AU - Idele P AD - United Nations International Children's Emergency Fund (UNICEF), New York, NY, United States. FAU - Gohar, Fatima AU - Gohar F AD - United Nations International Children's Emergency Fund (UNICEF), New York, NY, United States. FAU - Huang, Keng Yen AU - Huang KY AD - New York University, New York, NY, United States. FAU - Saxena, Shekhar AU - Saxena S AD - Harvard T.H Chan School of Public Health, Harvard University, Cambridge, MA, United States. FAU - Lai, Joanna AU - Lai J AD - United Nations International Children's Emergency Fund (UNICEF), New York, NY, United States. FAU - Peterson, Stefan Swartling AU - Peterson SS AD - Uppsala University, Uppsala, Sweden. FAU - Harper, Gary AU - Harper G AD - University of Michigan, Ann Arbor, MI, United States. FAU - McKay, Mary AU - McKay M AD - Washington University, St. Louis, MO, United States. FAU - Amugune, Beatrice AU - Amugune B AD - University of Nairobi, Nairobi, Kenya. FAU - Esho, Tammary AU - Esho T AD - Amref Health Africa, Nairobi, Kenya. FAU - Ronen, Keshet AU - Ronen K AD - University of Washington, Seattle, WA, United States. FAU - Othieno, Caleb AU - Othieno C AD - University of Botswana, Gaborone, Botswana. FAU - Kumar, Manasi AU - Kumar M AD - University of Washington, Seattle, WA, United States. AD - University of Nairobi, Nairobi, Kenya. LA - eng PT - Journal Article DEP - 20210108 PL - Switzerland TA - Front Psychiatry JT - Frontiers in psychiatry JID - 101545006 PMC - PMC7820171 OTO - NOTNLM OT - LMICs (low and middle income countries) OT - health care worker [non-MESH] OT - human rights OT - lockdown OT - mental and behavioral health OT - stigma and discrimination OT - vulnerable populations COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2021/01/26 06:00 MHDA- 2021/01/26 06:01 PMCR- 2021/01/08 CRDT- 2021/01/25 05:38 PHST- 2020/09/08 00:00 [received] PHST- 2020/11/23 00:00 [accepted] PHST- 2021/01/25 05:38 [entrez] PHST- 2021/01/26 06:00 [pubmed] PHST- 2021/01/26 06:01 [medline] PHST- 2021/01/08 00:00 [pmc-release] AID - 10.3389/fpsyt.2020.603875 [doi] PST - epublish SO - Front Psychiatry. 2021 Jan 8;11:603875. doi: 10.3389/fpsyt.2020.603875. eCollection 2020. PMID- 33481804 OWN - NLM STAT- MEDLINE DCOM- 20210211 LR - 20240330 IS - 1935-2735 (Electronic) IS - 1935-2727 (Print) IS - 1935-2727 (Linking) VI - 15 IP - 1 DP - 2021 Jan TI - Transmission dynamics and control of COVID-19 in Chile, March-October, 2020. PG - e0009070 LID - 10.1371/journal.pntd.0009070 [doi] LID - e0009070 AB - Since the detection of the first case of COVID-19 in Chile on March 3rd, 2020, a total of 513,188 cases, including ~14,302 deaths have been reported in Chile as of November 2nd, 2020. Here, we estimate the reproduction number throughout the epidemic in Chile and study the effectiveness of control interventions especially the effectiveness of lockdowns by conducting short-term forecasts based on the early transmission dynamics of COVID-19. Chile's incidence curve displays early sub-exponential growth dynamics with the deceleration of growth parameter, p, estimated at 0.8 (95% CI: 0.7, 0.8) and the reproduction number, R, estimated at 1.8 (95% CI: 1.6, 1.9). Our findings indicate that the control measures at the start of the epidemic significantly slowed down the spread of the virus. However, the relaxation of restrictions and spread of the virus in low-income neighborhoods in May led to a new surge of infections, followed by the reimposition of lockdowns in Greater Santiago and other municipalities. These measures have decelerated the virus spread with R estimated at ~0.96 (95% CI: 0.95, 0.98) as of November 2nd, 2020. The early sub-exponential growth trend (p ~0.8) of the COVID-19 epidemic transformed into a linear growth trend (p ~0.5) as of July 7th, 2020, after the reimposition of lockdowns. While the broad scale social distancing interventions have slowed the virus spread, the number of new COVID-19 cases continue to accrue, underscoring the need for persistent social distancing and active case detection and isolation efforts to maintain the epidemic under control. FAU - Tariq, Amna AU - Tariq A AUID- ORCID: 0000-0003-2344-5398 AD - Department of Population Health Sciences, School of Public Health, Georgia State University, Atlanta, Georgia, United States of America. FAU - Undurraga, Eduardo A AU - Undurraga EA AUID- ORCID: 0000-0002-4425-1253 AD - Escuela de Gobierno, Pontificia Universidad Catolica de Chile, Santiago, Region Metropolitana, Chile. AD - Millennium Initiative for Collaborative Research in Bacterial Resistance (MICROB-R), Santiago, Region Metropolitana, Chile. AD - Research Center for Integrated Disaster Risk Management (CIGIDEN), Santiago, Region Metropolitana, Chile. FAU - Laborde, Carla Castillo AU - Laborde CC AUID- ORCID: 0000-0001-6004-5882 AD - Centro de Epidemiologia y Politicas de Salud, Facultad de Medicina, Clinica Alemana Universidad del Desarrollo, Santiago, Region Metropolitana, Chile. FAU - Vogt-Geisse, Katia AU - Vogt-Geisse K AUID- ORCID: 0000-0001-6661-5938 AD - Facultad de Ingenieria y Ciencias, Universidad Adolfo Ibanez, Santiago, Region Metropolitana, Chile. FAU - Luo, Ruiyan AU - Luo R AUID- ORCID: 0000-0003-4365-1148 AD - Department of Population Health Sciences, School of Public Health, Georgia State University, Atlanta, Georgia, United States of America. FAU - Rothenberg, Richard AU - Rothenberg R AUID- ORCID: 0000-0002-4968-6248 AD - Department of Population Health Sciences, School of Public Health, Georgia State University, Atlanta, Georgia, United States of America. FAU - Chowell, Gerardo AU - Chowell G AD - Department of Population Health Sciences, School of Public Health, Georgia State University, Atlanta, Georgia, United States of America. LA - eng GR - R01 GM130900/GM/NIGMS NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't PT - Research Support, U.S. Gov't, Non-P.H.S. DEP - 20210122 PL - United States TA - PLoS Negl Trop Dis JT - PLoS neglected tropical diseases JID - 101291488 SB - IM UOF - medRxiv. 2020 Dec 15:2020.05.15.20103069. doi: 10.1101/2020.05.15.20103069. PMID: 33354684 MH - Basic Reproduction Number MH - COVID-19/diagnosis/epidemiology/*prevention & control/*transmission MH - Chile/epidemiology MH - Epidemics/prevention & control MH - Humans MH - Incidence MH - Models, Biological MH - Physical Distancing PMC - PMC7857594 COIS- The authors have declared that no competing interests exist. EDAT- 2021/01/23 06:00 MHDA- 2021/02/12 06:00 PMCR- 2021/01/22 CRDT- 2021/01/22 17:13 PHST- 2020/07/17 00:00 [received] PHST- 2020/12/13 00:00 [accepted] PHST- 2021/02/03 00:00 [revised] PHST- 2021/01/23 06:00 [pubmed] PHST- 2021/02/12 06:00 [medline] PHST- 2021/01/22 17:13 [entrez] PHST- 2021/01/22 00:00 [pmc-release] AID - PNTD-D-20-01299 [pii] AID - 10.1371/journal.pntd.0009070 [doi] PST - epublish SO - PLoS Negl Trop Dis. 2021 Jan 22;15(1):e0009070. doi: 10.1371/journal.pntd.0009070. eCollection 2021 Jan. PMID- 33475972 OWN - NLM STAT- MEDLINE DCOM- 20211102 LR - 20250919 IS - 1970-9366 (Electronic) IS - 1828-0447 (Print) IS - 1828-0447 (Linking) VI - 16 IP - 5 DP - 2021 Aug TI - Comparison of treatments for the prevention of fetal growth restriction in obstetric antiphospholipid syndrome: a systematic review and network meta-analysis. PG - 1357-1367 LID - 10.1007/s11739-020-02609-4 [doi] AB - Women with criteria and non-criteria obstetric antiphospholipid syndrome (APS) carry an increased risk of pregnancy complications, including fetal growth restriction (FGR). The management of obstetric APS traditionally involves clinicians, obstetricians and gynaecologists; however, the most appropriate prophylactic treatment strategy for FGR prevention in APS is still debated. We performed a systematic review and network meta-analysis (NetMA) to summarize current evidence on pharmacological treatments for the prevention of FGR in APS. We searched PubMed and Embase from inception until July 2020, for randomized controlled trials and prospective studies on pregnant women with criteria or non-criteria obstetric APS. NetMA using a frequentist framework were conducted for the primary outcome (FGR) and for secondary outcomes (fetal or neonatal death and preterm birth). Adverse events were narratively summarised. Out of 1124 citations, we included eight studies on 395 pregnant patients with obstetric APS treated with low-dose aspirin (LDA) + unfractionated heparin (UFH) (n = 132 patients), LDA (n = 115), LDA + low molecular weight heparin (n = 100), LDA + corticosteroids (n = 29), LDA + UFH + intravenous immunoglobulin (n = 7), or untreated (n = 12). No difference among treatments emerged in terms of FGR prevention, but estimates were largely imprecise, and most studies were at high/unclear risk of bias. An increased risk of fetal or neonatal death was found for LDA monotherapy as compared to LDA + heparin, and for no treatment as compared to LDA + corticosteroids. The risk of preterm birth was higher for LDA + UFH + IVIg as compared to LDA or LDA + heparin, and for LDA + corticosteroids as compared to LDA or LDA + LMWH. No treatment was associated with an increased risk of bleeding, thrombocytopenia or osteopenia. CI - (c) 2021. The Author(s). FAU - Urban, Maria Letizia AU - Urban ML AD - Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy. FAU - Bettiol, Alessandra AU - Bettiol A AD - Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy. FAU - Mattioli, Irene AU - Mattioli I AD - Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy. FAU - Emmi, Giacomo AU - Emmi G AD - Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy. giacomo.emmi@unifi.it. FAU - Di Scala, Gerardo AU - Di Scala G AD - Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy. FAU - Avagliano, Laura AU - Avagliano L AD - Department of Health Sciences, San Paolo Hospital Medical School, University of Milan, Milan, Italy. FAU - Lombardi, Niccolo AU - Lombardi N AD - Department of Neurosciences, Psychology, Drug Research and Child Health, University of Florence, Florence, Italy. FAU - Crescioli, Giada AU - Crescioli G AD - Department of Neurosciences, Psychology, Drug Research and Child Health, University of Florence, Florence, Italy. AD - PeaRL Perinatal Research Laboratory, University of Florence, CiaoLapo Foundation for Perinatal Health, Prato, Italy. FAU - Virgili, Gianni AU - Virgili G AD - Department of Neurosciences, Psychology, Drug Research and Child Health, University of Florence, Florence, Italy. AD - Centre for Public Health, Queen's University Belfast, Belfast, Northern Ireland. FAU - Serena, Caterina AU - Serena C AD - Division of Obstetrics and Gynaecology, Department of Biomedical, Experimental and Clinical Sciences, University of Florence, Florence, Italy. FAU - Mecacci, Federico AU - Mecacci F AD - Division of Obstetrics and Gynaecology, Department of Biomedical, Experimental and Clinical Sciences, University of Florence, Florence, Italy. FAU - Ravaldi, Claudia AU - Ravaldi C AD - PeaRL Perinatal Research Laboratory, University of Florence, CiaoLapo Foundation for Perinatal Health, Prato, Italy. AD - Department of Health Sciences, University of Florence, Florence, Italy. FAU - Vannacci, Alfredo AU - Vannacci A AD - Department of Neurosciences, Psychology, Drug Research and Child Health, University of Florence, Florence, Italy. AD - PeaRL Perinatal Research Laboratory, University of Florence, CiaoLapo Foundation for Perinatal Health, Prato, Italy. FAU - Silvestri, Elena AU - Silvestri E AD - Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy. FAU - Prisco, Domenico AU - Prisco D AD - Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy. LA - eng PT - Journal Article PT - Network Meta-Analysis PT - Systematic Review DEP - 20210121 PL - Italy TA - Intern Emerg Med JT - Internal and emergency medicine JID - 101263418 SB - IM MH - Adult MH - Antiphospholipid Syndrome/prevention & control/*therapy MH - Female MH - Fetal Growth Retardation/prevention & control/*therapy MH - Humans MH - Pregnancy MH - Pregnancy Complications/prevention & control MH - Randomized Controlled Trials as Topic/statistics & numerical data PMC - PMC8310508 OTO - NOTNLM OT - Antiphospholipid syndrome OT - Aspirin OT - Fetal growth restriction OT - Heparin OT - Network meta-analysis COIS- The authors declare no conflicts of interest. EDAT- 2021/01/22 06:00 MHDA- 2021/11/03 06:00 PMCR- 2021/01/21 CRDT- 2021/01/21 12:21 PHST- 2020/10/05 00:00 [received] PHST- 2020/12/14 00:00 [accepted] PHST- 2021/01/22 06:00 [pubmed] PHST- 2021/11/03 06:00 [medline] PHST- 2021/01/21 12:21 [entrez] PHST- 2021/01/21 00:00 [pmc-release] AID - 10.1007/s11739-020-02609-4 [pii] AID - 2609 [pii] AID - 10.1007/s11739-020-02609-4 [doi] PST - ppublish SO - Intern Emerg Med. 2021 Aug;16(5):1357-1367. doi: 10.1007/s11739-020-02609-4. Epub 2021 Jan 21. PMID- 33474517 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250530 IS - 2459-3087 (Electronic) IS - 2459-3087 (Linking) VI - 7 DP - 2021 TI - Adherence to smoke-free policies in Ghana: Findings from a cross-sectional survey of hospitality venue owners and staff. PG - 4 LID - 10.18332/tpc/131058 [doi] LID - 4 AB - INTRODUCTION: Implementation of and compliance with smoke-free policies (SFPs) can be problematic in many low- and middle-income countries (LMICs) due to limited resources. This study evaluated knowledge, opinions and compliance related to Ghana's SFPs among owners and staff of hospitality venues by city, staff designation, and venue type. METHODS: A cross-sectional study design was used in venue types including hotels, bars, pubs and restaurants in the three cities of Kumasi, Accra, and Tamale, in Ghana.Data were collected between July and September 2019. Interviewer administered face-to-face surveys were conducted with owners and staff (n=142) recruited from randomly selected hospitality venues (n=154) in these three large cities of Ghana. The relationship between knowledge, opinions, and compliance items on SFPs, and city, venue type and staff designation was first studied using chi(2) or a Fisher's exact test, and then with univariate logistic regression model analysis. RESULTS: Of the 142 respondents, some had heard of Ghana's 2012 Tobacco Control Act (27.5%), smoking restriction in public places (29%), smoke-free places (22%), and display of 'no smoking' signage (6.3%). Knowledge levels were higher in Accra compared to Tamale (OR=3.08; 95% CI: 1.10-8.60). Staff designation and type of venue did not have any relationship with knowledge levels. Support for SFPs was over 80%, but opinions in support of SFPs were lower in Accra than Tamale (OR=0.25; 95% CI: 0.08-0.71). Compliance with SFPs was similar in the three cities. Hotels were three times more compliant compared to bars and pubs (OR=3.16; 95% CI: 1.48-6.71). CONCLUSIONS: The study highlights the strong support for restriction of smoking in public places including hospitality venues despite poor knowledge and low compliance levels with the current SFPs. A review of the current SFP in Ghana together with education of hospitality staff on the benefits and requirements of SFPs is recommended. CI - (c) 2021 Singh A. FAU - Singh, Arti AU - Singh A AD - School of Public Health, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana. FAU - Dobbie, Fiona AU - Dobbie F AD - Usher Institute, University of Edinburgh, Edinburgh, United Kingdom. FAU - Kinnunen, Tarja I AU - Kinnunen TI AD - Faculty of Social Sciences (Health Sciences), Tampere University, Tampere, Finland. FAU - Okello, Gabriel AU - Okello G AD - African Centre for Clean Air, Kampala, Uganda. FAU - Semple, Sean AU - Semple S AD - Institute for Social Marketing and Health, University of Stirling, Stirling, United Kingdom. FAU - Okyere, Portia Boakye AU - Okyere PB AD - School of Public Health, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana. FAU - Logo, Divine Darlington AU - Logo DD AD - Ghana Health Service, Research and Development Division, Accra, Ghana. FAU - Lartey, Kwabena Fosu AU - Lartey KF AD - School of Public Health, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana. FAU - McNeil, Ann AU - McNeil A AD - King's College London, London, United Kingdom. FAU - Britton, John AU - Britton J AD - University of Nottingham, Nottingham, United Kingdom. FAU - Bauld, Linda AU - Bauld L AD - Usher Institute, University of Edinburgh, Edinburgh, United Kingdom. FAU - Owusu-Dabo, Ellis AU - Owusu-Dabo E AD - School of Public Health, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana. LA - eng GR - MR/P027946/2/MRC_/Medical Research Council/United Kingdom PT - Journal Article DEP - 20210116 PL - Greece TA - Tob Prev Cessat JT - Tobacco prevention & cessation JID - 101693412 PMC - PMC7811357 OTO - NOTNLM OT - Ghana OT - compliance OT - hospitality staff OT - knowledge OT - smoke-free policy COIS- The authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest and none was reported. EDAT- 2021/01/22 06:00 MHDA- 2021/01/22 06:01 PMCR- 2021/01/16 CRDT- 2021/01/21 05:37 PHST- 2020/10/07 00:00 [received] PHST- 2020/11/25 00:00 [revised] PHST- 2020/11/30 00:00 [accepted] PHST- 2021/01/21 05:37 [entrez] PHST- 2021/01/22 06:00 [pubmed] PHST- 2021/01/22 06:01 [medline] PHST- 2021/01/16 00:00 [pmc-release] AID - 4 [pii] AID - 10.18332/tpc/131058 [doi] PST - epublish SO - Tob Prev Cessat. 2021 Jan 16;7:4. doi: 10.18332/tpc/131058. eCollection 2021. PMID- 33471117 OWN - NLM STAT- MEDLINE DCOM- 20210127 LR - 20240330 IS - 2574-3805 (Electronic) IS - 2574-3805 (Linking) VI - 4 IP - 1 DP - 2021 Jan 4 TI - Associations of Government-Mandated Closures and Restrictions With Aggregate Mobility Trends and SARS-CoV-2 Infections in Nigeria. PG - e2032101 LID - 10.1001/jamanetworkopen.2020.32101 [doi] LID - e2032101 AB - IMPORTANCE: To prepare for future coronavirus disease 2019 (COVID-19) waves, Nigerian policy makers need insights into community spread of COVID-19 and changes in rates of infection associated with government-mandated closures and restrictions. OBJECTIVES: To measure the association of closures and restrictions with aggregate mobility and the association of mobility with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections and to characterize community spread of COVID-19. DESIGN, SETTING, AND PARTICIPANTS: This cross-sectional study used aggregated anonymized mobility data from smartphone users in Nigeria who opted to provide location history (from a pool of up to 40 million individuals) collected between February 27 and July 21, 2020. The analyzed data included daily counts of confirmed SARS-CoV-2 infections and daily changes in aggregate mobility across 6 categories: retail and recreation, grocery and pharmacy, parks, transit stations, workplaces, and residential. Closures and restrictions were initiated on March 30, 2020, and partially eased on May 4, 2020. MAIN OUTCOMES AND MEASURES: Interrupted time series were used to measure associations of closures and restrictions with aggregate mobility. Negative binomial regression was used to evaluate associations between confirmed SARS-CoV-2 infections and mobility categories. Averted infections were estimated by subtracting cumulative confirmed infections from estimated infections assuming no closures and restrictions. RESULTS: Closures and restrictions had negative associations with mean change in daily aggregate mobility in retail and recreation (-46.87 [95% CI, -55.98 to -37.76] percentage points; P < .001), grocery and pharmacy (-28.95 [95% CI, -40.12 to -17.77] percentage points; P < .001), parks (-43.59 [95% CI, -49.89 to -37.30] percentage points; P < .001), transit stations (-47.44 [95% CI, -56.70 to -38.19] percentage points; P < .001), and workplaces (-53.07 [95% CI, -67.75 to -38.39] percentage points; P < .001) and a positive association with mobility in residential areas (24.10 [95% CI, 19.14 to 29.05] percentage points; P < .001). Most of these changes reversed after closures and restrictions were partially eased (retail and recreation: 14.63 [95% CI, 10.95 to 18.30] percentage points; P < .001; grocery and pharmacy: 15.29 [95% CI, 10.90 to 19.67] percentage points; P < .001; parks: 6.48 [95% CI, 3.98 to 8.99] percentage points; P < .001; transit stations: 17.93 [95% CI, 14.03 to 21.83] percentage points; P < .001; residential: -5.59 [95% CI, -9.08 to -2.09] percentage points; P = .002). Additionally, every percentage point increase in aggregate mobility was associated with higher incidences of SARS-CoV-2 infection in residential areas (incidence rate ratio [IRR], 1.03 [95% CI, 1.00 to 1.07]; P = .04), transit stations (IRR, 1.02 [95% CI, 1.00 to 1.03]; P = .008), and workplaces (IRR, 1.01 [95% CI, 1.00 to 1.02]; P = .04). Lastly, closures and restrictions may have been associated with averting up to 5.8 million SARS-CoV-2 infections over the study period. CONCLUSIONS AND RELEVANCE: In this cross-sectional study, closures and restrictions had significant associations with aggregate mobility and were associated with decreased SARS-CoV-2 infections. These findings suggest that future anticontagion measures need better infection control and contact tracing in residential areas, transit stations, and workplaces. FAU - Erim, Daniel O AU - Erim DO AD - Parexel International, Durham, North Carolina. FAU - Oke, Gbemisola A AU - Oke GA AD - Department of Periodontology and Community Dentistry, University of Ibadan, Nigeria. FAU - Adisa, Akinyele O AU - Adisa AO AD - Department of Oral Pathology, University of Ibadan, Nigeria. FAU - Odukoya, Oluwakemi AU - Odukoya O AD - Department of Community Health and Primary Care, University of Lagos, Nigeria. FAU - Ayo-Yusuf, Olalekan A AU - Ayo-Yusuf OA AD - Sefako Makgatho Health Sciences University, Ga-Rankuwa, South Africa. FAU - Erim, Theodora Nawa AU - Erim TN AD - Holly Hill Hospital, Raleigh, North Carolina. FAU - Tsafa, Tina N AU - Tsafa TN AD - Benue State University, Makurdi, Nigeria. FAU - Meremikwu, Martin M AU - Meremikwu MM AD - Department of Paediatrics, University of Calabar Teaching Hospital, Calabar, Nigeria. FAU - Agaku, Israel T AU - Agaku IT AD - Department of Oral Epidemiology, Harvard Dental School, Boston, Massachusetts. LA - eng GR - K43 TW010704/TW/FIC NIH HHS/United States PT - Journal Article DEP - 20210104 PL - United States TA - JAMA Netw Open JT - JAMA network open JID - 101729235 SB - IM MH - Adult MH - COVID-19/*epidemiology/prevention & control MH - Cross-Sectional Studies MH - *Epidemiological Monitoring MH - Female MH - Humans MH - Incidence MH - Male MH - Mandatory Programs/*organization & administration MH - Middle Aged MH - Nigeria MH - Public Health MH - Quarantine/*statistics & numerical data MH - SARS-CoV-2 MH - Travel PMC - PMC7818105 COIS- Conflict of Interest Disclosures: None reported. EDAT- 2021/01/21 06:00 MHDA- 2021/01/28 06:00 PMCR- 2021/01/20 CRDT- 2021/01/20 12:22 PHST- 2021/01/20 12:22 [entrez] PHST- 2021/01/21 06:00 [pubmed] PHST- 2021/01/28 06:00 [medline] PHST- 2021/01/20 00:00 [pmc-release] AID - 2775300 [pii] AID - zoi200995 [pii] AID - 10.1001/jamanetworkopen.2020.32101 [doi] PST - epublish SO - JAMA Netw Open. 2021 Jan 4;4(1):e2032101. doi: 10.1001/jamanetworkopen.2020.32101. PMID- 33461375 OWN - NLM STAT- MEDLINE DCOM- 20220707 LR - 20250728 IS - 1552-6518 (Electronic) IS - 0886-2605 (Linking) VI - 37 IP - 13-14 DP - 2022 Jul TI - Alcohol Accessibility and Family Violence-related Ambulance Attendances. PG - NP10661-NP10682 LID - 10.1177/0886260520986262 [doi] AB - There is substantial evidence supporting the association between alcohol license density and violent crime. However, the impact of different types of alcohol licenses on intimate partner and family violence is sparse. We explored the associations between access to alcohol outlets, and family and intimate partner violence using paramedic clinical records, given this service is often the first to respond to acute crises. Coded ambulance attendance data from 694 postcodes in Victoria, Australia, from July 1, 2016 to June 30, 2018 where alcohol or another drug, mental health or self-harm associated with family or intimate partner violence was indicated were examined. A hybrid model of spatial autoregressive and negative binomial zero-inflated Poisson-based count regression models was used to examine associations with alcohol outlet density and socioeconomic factors. We found that access to a liquor license outlet was significantly associated with family violence-related attendances across all types of outlets, including on-premise (late night) licenses (beta = 1.73, SE: 0.18), restaurant licenses (beta = 0.83, SE: 0.28), and packaged liquor licenses (beta = 0.62, SE: 0.06). Our results demonstrate a significant relationship between alcohol-related harms in the context of family violence and provides evidence of the relationship between alcohol-related family violence in both victims and perpetrators. The findings of this study highlight the need for public health interventions such as licensing policy and town planning changes to reduce these harms by restricting alcohol availability. FAU - Scott, Debbie AU - Scott D AUID- ORCID: 0000-0002-4530-584X AD - Monash University, Box Hill, Australia. AD - Turning Point, Richmond, Australia. FAU - Ogeil, Rowan P AU - Ogeil RP AD - Monash University, Box Hill, Australia. AD - Turning Point, Richmond, Australia. FAU - Maoyeri, Foruhar AU - Maoyeri F AD - Monash University, Box Hill, Australia. AD - Turning Point, Richmond, Australia. FAU - Heilbronn, Cherie AU - Heilbronn C AD - Turning Point, Richmond, Australia. FAU - Coomber, Kerri AU - Coomber K AUID- ORCID: 0000-0001-6160-0235 AD - Deakin University, Geelong, Australia. FAU - Smith, Karen AU - Smith K AD - Ambulance Victoria, Doncaster, Australia. AD - Monash University, Frankston, Australia. AD - Monash University, Melbourne, Australia. FAU - Miller, Peter G AU - Miller PG AD - Deakin University, Geelong, Australia. AD - Centre for Addiction and Mental Health, London, Canada. AD - Curtin University of Technology, Perth, Australia. FAU - Lubman, Dan I AU - Lubman DI AD - Monash University, Box Hill, Australia. AD - Turning Point, Richmond, Australia. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20210118 PL - United States TA - J Interpers Violence JT - Journal of interpersonal violence JID - 8700910 SB - IM MH - *Alcohol Drinking/epidemiology MH - Alcoholic Beverages MH - Ambulances MH - *Domestic Violence MH - Humans MH - Victoria/epidemiology OTO - NOTNLM OT - alcohol outlet density OT - family violence OT - intimate partner violence OT - negative binomial zero-inflated Poisson OT - spatial autoregressive OT - spatial slipover effects EDAT- 2021/01/20 06:00 MHDA- 2022/07/08 06:00 CRDT- 2021/01/19 05:36 PHST- 2021/01/20 06:00 [pubmed] PHST- 2022/07/08 06:00 [medline] PHST- 2021/01/19 05:36 [entrez] AID - 10.1177/0886260520986262 [doi] PST - ppublish SO - J Interpers Violence. 2022 Jul;37(13-14):NP10661-NP10682. doi: 10.1177/0886260520986262. Epub 2021 Jan 18. PMID- 33460434 OWN - NLM STAT- MEDLINE DCOM- 20211222 LR - 20211222 IS - 1537-6591 (Electronic) IS - 1058-4838 (Print) IS - 1058-4838 (Linking) VI - 73 IP - 12 DP - 2021 Dec 16 TI - Reopening Schools and the Dynamics of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infections in Israel: A Nationwide Study. PG - 2265-2275 LID - 10.1093/cid/ciab035 [doi] LID - ciab035 AB - BACKGROUND: Benefits of school reopening must be weighed against the morbidity and mortality risks and the impact of enhancing spread of coronavirus disease 2019 (COVID-19). We investigated the effects of school reopening and easing of social-distancing restrictions on dynamics of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections in Israel between March and July 2020. METHODS: We examined the nationwide age-wise weekly incidence, prevalence, SARS-CoV-2 polymerase chain reaction tests, their positivity, COVID-19 hospitalizations, and associated mortality. Temporal differences in these parameters following school reopening, school ending, and following easing of restrictions such as permission of large-scale gatherings were examined. RESULTS: Incidence of SARS-CoV-2 infections gradually increased following school reopening in all age groups, with a significantly higher increase in adults than children. Higher rate ratios (RRs) of sample positivity rates 21-27 days following school reopening relative to positivity rates prior to openings were found for the age groups 40-59 (RR, 4.72; 95% CI, 3.26-6.83) and 20-39 (RR, 3.37 [2.51-4.53]) years, but not for children aged 0-9 (RR, 1.46 [.85-2.51]) and 10-19 (RR, .93 [.65-1.34]) years. No increase was observed in COVID-19-associated hospitalizations and deaths following school reopening. In contrast, permission of large-scale gatherings was accompanied by increases in incidence and positivity rates of samples for all age groups, and increased hospitalizations and mortality. CONCLUSIONS: This analysis does not support a major role of school reopening in the resurgence of COVID-19 in Israel. Easing restrictions on large-scale gatherings was the major influence on this resurgence. CI - (c) The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com. FAU - Somekh, Ido AU - Somekh I AD - Department of Pediatric Hematology Oncology, Schneider Children's Medical Center of Israel, Petah Tikva, Israel. AD - Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. FAU - Shohat, Tamy AU - Shohat T AD - Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. FAU - Boker, Lital Keinan AU - Boker LK AD - Israel Center for Disease Control, Israel Ministry of Health, Ramat Gan, Israel. AD - School of Public Health, University of Haifa, Haifa, Israel. FAU - Simoes, Eric A F AU - Simoes EAF AD - University of Colorado School of Medicine, Aurora, Colorado, USA. FAU - Somekh, Eli AU - Somekh E AD - Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. AD - Department of Pediatrics, Mayanei Hayeshuah Medical Center, Bnei Brak, Israel. LA - eng GR - 3-16983/Ministry of Science and Technology/ PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - Clin Infect Dis JT - Clinical infectious diseases : an official publication of the Infectious Diseases Society of America JID - 9203213 SB - IM MH - *COVID-19 MH - Child MH - Child, Preschool MH - Humans MH - Israel/epidemiology MH - *SARS-CoV-2 MH - Schools PMC - PMC7929073 OTO - NOTNLM OT - COVID-19 OT - SARS-CoV-2 OT - children OT - reopening OT - schools EDAT- 2021/01/19 06:00 MHDA- 2021/12/24 06:00 PMCR- 2021/03/03 CRDT- 2021/01/18 17:05 PHST- 2020/10/26 00:00 [received] PHST- 2021/01/14 00:00 [accepted] PHST- 2021/01/19 06:00 [pubmed] PHST- 2021/12/24 06:00 [medline] PHST- 2021/01/18 17:05 [entrez] PHST- 2021/03/03 00:00 [pmc-release] AID - 6103916 [pii] AID - ciab035 [pii] AID - 10.1093/cid/ciab035 [doi] PST - ppublish SO - Clin Infect Dis. 2021 Dec 16;73(12):2265-2275. doi: 10.1093/cid/ciab035. PMID- 33452193 OWN - NLM STAT- MEDLINE DCOM- 20210514 LR - 20210514 IS - 2044-6055 (Electronic) IS - 2044-6055 (Linking) VI - 11 IP - 1 DP - 2021 Jan 15 TI - Incidence of HIV and HCV in people who inject drugs: a systematic and meta-analysis review protocol. PG - e041482 LID - 10.1136/bmjopen-2020-041482 [doi] LID - e041482 AB - INTRODUCTION: HIV and hepatitis C virus (HCV) are major health concerns globally. This systematic review and meta-analysis protocol study aims to estimate the incidence of HIV and HCV among people who inject drugs (PWIDs) by reviewing studies that have applied mathematical modelling. The primary purpose of this systematic review is to identify and review mathematical modelling studies of HIV and HCV incidence in PWIDs.Methods and analysis cohort, cross-sectional and clinical trial studies conducted to estimate the incidence of HIV and HCV based on mathematical models or have evaluated the effectiveness of mathematical models will be considered for inclusion in the review. A comprehensive search applying a Cochrane approach will be used to identify relevant primary studies, published between January 2000 and July 2020, and indexed in PubMed, EMBASE, Opengrey, WOS, SCOPUS and Cochrane Library with no restriction on language. This protocol was prepared according to the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P). Study selection and data extraction will be performed by two independent reviewers. Assessment of risk of bias will be implemented using forms of the Critical Appraisal Skills Programme. Publication bias will be assessed by funnel plots, Begg's and Egger's tests. A meta-analysis will be conducted to answer the first research question, 'What is the incidence of HIV and HCV when applying mathematical model in PWID?'. Clinical heterogeneity will be assessed by looking at the characteristics of participants, method of diagnosis and case definitions in the included primary studies. In addition, subgroup analyses will be conducted for population and secondary outcomes. ETHICS AND DISSEMINATION: There are no ethical issues related to this study. The findings will be published in peer-reviewed scientific journals and presented at international and national conferences. PROSPERO REGISTRATION NUMBER: CRD42019126476. CI - (c) Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. FAU - Sharhani, Asaad AU - Sharhani A AD - Department of Epidemiology and Biostatistics, Public Health Faculty, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. FAU - Jorjoran Shushtari, Zahra AU - Jorjoran Shushtari Z AD - Social Determinants of Health Research Center, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran. FAU - Rahmani, Azam AU - Rahmani A AD - Nursing and Midwifery Care Research Center, School of Nursing and Midwifery, Tehran University of Medical Sciences, Tehran, Iran. FAU - Armoon, Bahram AU - Armoon B AUID- ORCID: 0000-0001-5467-9889 AD - Social Determinants of Health Research Center, Saveh University of Medical Sciences, Saveh, Iran. FAU - Noroozi, Mehdi AU - Noroozi M AD - Social Determinants of Health Research Center, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran. FAU - Ahounbar, Elaheh AU - Ahounbar E AD - Substance Abuse and Dependence Research Center, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran. FAU - Karimi, Salah Eddin AU - Karimi SE AUID- ORCID: 0000-0002-1542-0214 AD - Social Determinants of Health Research Center, Health Management and Safety Promotion Research Institute, Tabriz University of Medical Sciences, Tabriz, Iran salahkarimi2009@gmail.com. FAU - Higgs, Peter AU - Higgs P AD - Department of Public Health, La Trobe University, Plenty Rd & Kingsbury Dr, Bundoora, VIC 3086, La Trobe University, Melbourne, Victoria, Australia. AD - Behaviours and Health Risks Program, Burnet Institute, 85 Commercial Road, Melbourne, VIC 3004, Burnet Institute, Melbourne, Victoria, Australia. LA - eng PT - Journal Article DEP - 20210115 PL - England TA - BMJ Open JT - BMJ open JID - 101552874 RN - 0 (Pharmaceutical Preparations) SB - IM MH - Cross-Sectional Studies MH - *HIV Infections/epidemiology MH - Hepacivirus MH - *Hepatitis C/epidemiology MH - Humans MH - Incidence MH - Meta-Analysis as Topic MH - *Pharmaceutical Preparations MH - Prevalence MH - Research Design MH - Systematic Reviews as Topic PMC - PMC7813328 OTO - NOTNLM OT - HIV & AIDS OT - epidemiology OT - infectious diseases COIS- Competing interests: None declared. EDAT- 2021/01/17 06:00 MHDA- 2021/05/15 06:00 PMCR- 2021/01/15 CRDT- 2021/01/16 05:33 PHST- 2021/01/16 05:33 [entrez] PHST- 2021/01/17 06:00 [pubmed] PHST- 2021/05/15 06:00 [medline] PHST- 2021/01/15 00:00 [pmc-release] AID - bmjopen-2020-041482 [pii] AID - 10.1136/bmjopen-2020-041482 [doi] PST - epublish SO - BMJ Open. 2021 Jan 15;11(1):e041482. doi: 10.1136/bmjopen-2020-041482. PMID- 33441669 OWN - NLM STAT- MEDLINE DCOM- 20210817 LR - 20231110 IS - 2045-2322 (Electronic) IS - 2045-2322 (Linking) VI - 11 IP - 1 DP - 2021 Jan 13 TI - Comparative analysis of visit and home blood pressure in a pilot trial on the effect of 18% sodium substitute salt on blood pressure. PG - 907 LID - 10.1038/s41598-020-79282-2 [doi] LID - 907 AB - Aim to compare the home blood pressure monitoring (HBPM) and visit blood pressure monitoring in a clinical phase I single-arm pilot trial. The 18% sodium substitute salt was used in 43 hypertensives for 8 weeks, and visited once a week, while weekly visit blood (VBP) pressure, daily home blood pressure (HBP) and urine test results before and after intervention were collected. 43 hypertensive patients were recruited, 4 were lost. And enrolled 39 patients for analysis. The VBP were lower than morning HBP and night HBP (P < 0.05). And VBP was good correlated with morning BP (SBP: r = 0.692, P < 0.001, DBP: r = 0.789, P < 0.001) and night BP (SBP: r = 0.571, P < 0.001, DBP: r = 0.738, P < 0.001). The results of mixed linear model analysis showed that patients' visit SBP (- 11.4 mmHg, 95% CI: - 17.0 to - 5.7, P < 0.001), morning home SBP (- 10.0 mmHg, 95% CI: - 16.4 to - 3.6, P = 0.003) and night home SBP (- 10.2 mmHg, 95% CI: - 15.8 to - 4.6, P = 0.001) decreased significantly, after intervention. Both HBP and VBP showed that 18% substitute salt intervention could decrease the blood pressure of hypertensives. Medication led to VBP lower than HBP, but the two still had a good correlation.Trial registration: NCT03226327. Registered 21 July 2017-Retrospectively registered, http://www.clinicaltrials.gov . FAU - Liu, Ting AU - Liu T AD - Department of Epidemiology, School of Public Health and Management, Research Center for Medicine and Social Development, Innovation Center for Social Risk Governance in Health, Chongqing Medical University, Chongqing, 400016, China. FAU - Rao, Huakun AU - Rao H AD - Department of Epidemiology, School of Public Health and Management, Research Center for Medicine and Social Development, Innovation Center for Social Risk Governance in Health, Chongqing Medical University, Chongqing, 400016, China. FAU - Wang, Meixian AU - Wang M AD - Department of Epidemiology, School of Public Health and Management, Research Center for Medicine and Social Development, Innovation Center for Social Risk Governance in Health, Chongqing Medical University, Chongqing, 400016, China. FAU - Xu, Huini AU - Xu H AD - Chongqing Nan'an District People's Hospital, Chongqing, China. FAU - Wang, Wen AU - Wang W AD - Chongqing Nan'an District People's Hospital, Chongqing, China. FAU - Li, Ge AU - Li G AD - Department of Epidemiology, School of Public Health and Management, Research Center for Medicine and Social Development, Innovation Center for Social Risk Governance in Health, Chongqing Medical University, Chongqing, 400016, China. FAU - Wang, Hao AU - Wang H AD - Chongqing Nan'an District People's Hospital, Chongqing, China. FAU - Mu, Lihong AU - Mu L AD - Department of Epidemiology, School of Public Health and Management, Research Center for Medicine and Social Development, Innovation Center for Social Risk Governance in Health, Chongqing Medical University, Chongqing, 400016, China. 1097123703@qq.com. LA - eng SI - ClinicalTrials.gov/NCT03226327 PT - Clinical Trial, Phase I PT - Journal Article DEP - 20210113 PL - England TA - Sci Rep JT - Scientific reports JID - 101563288 RN - 9NEZ333N27 (Sodium) SB - IM MH - Aged MH - Blood Pressure/*drug effects/physiology MH - Blood Pressure Determination/*methods MH - Blood Pressure Monitoring, Ambulatory/*methods MH - Diet, Sodium-Restricted/methods MH - Female MH - Humans MH - Hypertension/*drug therapy/physiopathology MH - Male MH - Middle Aged MH - Pilot Projects MH - Sodium/*administration & dosage PMC - PMC7806920 COIS- This study received funding from the Health Source (Chongqing) Cardiovascular Health Technology Co., Ltd, but the company did not participate in the design, implementation, data collection, analysis and article writing process of the study. All authors declare there are no other conflicts. EDAT- 2021/01/15 06:00 MHDA- 2021/08/18 06:00 PMCR- 2021/01/13 CRDT- 2021/01/14 05:38 PHST- 2020/01/15 00:00 [received] PHST- 2020/12/04 00:00 [accepted] PHST- 2021/01/14 05:38 [entrez] PHST- 2021/01/15 06:00 [pubmed] PHST- 2021/08/18 06:00 [medline] PHST- 2021/01/13 00:00 [pmc-release] AID - 10.1038/s41598-020-79282-2 [pii] AID - 79282 [pii] AID - 10.1038/s41598-020-79282-2 [doi] PST - epublish SO - Sci Rep. 2021 Jan 13;11(1):907. doi: 10.1038/s41598-020-79282-2. PMID- 33435462 OWN - NLM STAT- MEDLINE DCOM- 20210115 LR - 20230310 IS - 1660-4601 (Electronic) IS - 1661-7827 (Print) IS - 1660-4601 (Linking) VI - 18 IP - 2 DP - 2021 Jan 9 TI - The Perceived Impact of COVID-19 among Treatment-Seeking Smokers: A Mixed Methods Approach. LID - 10.3390/ijerph18020505 [doi] LID - 505 AB - The consequences of the COVID-19 pandemic on behavioral health, including tobacco use, are not fully known. The current study sought to measure the perceived impact of COVID-19 and the resulting stay-at-home orders in Philadelphia, Pennsylvania and Buffalo, New York on smokers enrolled in four smoking cessation trials between March 2020 and July 2020. The survey collected quantitative data regarding life changes due to COVID-19, health/exposure status, and the impact on their cessation attempt (e.g., motivation to quit, change in triggers). The questionnaire collected qualitative data to better understand how such changes could explain changes in smoking behavior. Of the 42 participants surveyed, approximately half indicated that COVID-19 changed their motivation and ability to quit or remain quit. Among those who reported that it was easier to quit following the stay-at-home orders (n = 24), most attributed this to concerns regarding the severity of COVID-19 among smokers. Among those who reported more difficulty quitting (n = 15), most attributed this to their increased stress due to the pandemic and the inability to access activities, places, or people that could help them manage triggers. Given public health warnings of continued surges in COVID-19, these data provide insight into who may benefit from further smoking cessation support should existing restrictions or new stay-at-home orders be enacted. FAU - Rosoff-Verbit, Zoe AU - Rosoff-Verbit Z AUID- ORCID: 0000-0002-4976-6221 AD - Department of Psychiatry, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA. FAU - Logue-Chamberlain, Erin AU - Logue-Chamberlain E AD - Department of Psychiatry, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA. FAU - Fishman, Jessica AU - Fishman J AD - Department of Psychiatry, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA. AD - Annenberg School for Communication, University of Pennsylvania, Philadelphia, PA 19104, USA. FAU - Audrain-McGovern, Janet AU - Audrain-McGovern J AD - Department of Psychiatry, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA. FAU - Hawk, Larry AU - Hawk L AUID- ORCID: 0000-0001-6593-9746 AD - Department of Psychology, State University of New York at Buffalo, Buffalo, NY 14260, USA. FAU - Mahoney, Martin AU - Mahoney M AUID- ORCID: 0000-0002-5069-1140 AD - Department of Internal Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263, USA. FAU - Mazur, Alexa AU - Mazur A AD - Department of Psychiatry, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA. FAU - Ashare, Rebecca AU - Ashare R AD - Department of Psychiatry, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA. LA - eng GR - R01-CA206058/CA/NCI NIH HHS/United States GR - Investigator Initiated Grant/Novo Nordisk/International GR - R01 CA206193/CA/NCI NIH HHS/United States GR - R01-CA206193/CA/NCI NIH HHS/United States GR - R01-DA042682/DA/NIDA NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20210109 PL - Switzerland TA - Int J Environ Res Public Health JT - International journal of environmental research and public health JID - 101238455 SB - IM MH - *COVID-19 MH - Humans MH - *Motivation MH - New York/epidemiology MH - Pandemics MH - Patient Acceptance of Health Care/*statistics & numerical data MH - Philadelphia/epidemiology MH - *Smokers MH - Smoking Cessation/*statistics & numerical data MH - Surveys and Questionnaires PMC - PMC7826630 OTO - NOTNLM OT - COVID-19 OT - coronavirus OT - smoking cessation OT - theory of planned behavior OT - tobacco use COIS- Rebecca Ashare has an investigator-initiated sponsored award from Novo Nordisk, Inc. Martin Mahoney has received study medications from Pfizer in support of randomized clinical trials and has previously served as a consultant to and speaker for Pfizer on the topic of smoking cessation. All other authors declare no conflicts of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results. EDAT- 2021/01/14 06:00 MHDA- 2021/01/16 06:00 PMCR- 2021/01/01 CRDT- 2021/01/13 01:02 PHST- 2020/10/30 00:00 [received] PHST- 2021/01/04 00:00 [revised] PHST- 2021/01/06 00:00 [accepted] PHST- 2021/01/13 01:02 [entrez] PHST- 2021/01/14 06:00 [pubmed] PHST- 2021/01/16 06:00 [medline] PHST- 2021/01/01 00:00 [pmc-release] AID - ijerph18020505 [pii] AID - ijerph-18-00505 [pii] AID - 10.3390/ijerph18020505 [doi] PST - epublish SO - Int J Environ Res Public Health. 2021 Jan 9;18(2):505. doi: 10.3390/ijerph18020505. PMID- 33431077 OWN - NLM STAT- MEDLINE DCOM- 20211029 LR - 20240512 IS - 1475-2727 (Electronic) IS - 1368-9800 (Print) IS - 1368-9800 (Linking) VI - 24 IP - 15 DP - 2021 Oct TI - Food neophobia in Lebanese children: scale validation and correlates. PG - 5015-5023 LID - 10.1017/S1368980021000082 [doi] AB - OBJECTIVE: To validate the Food Neophobia Scale (FNS) and determine factors associated with the presence of food neophobia (FN) in a sample of Lebanese children. DESIGN: Cross-sectional study conducted between July and December 2019. SETTING: All Lebanese governorates. PARTICIPANTS: Parents of Lebanese children aged 2 to 10 years. RESULTS: Out of 850 questionnaires, 194 were excluded. The mean age of children was 5.34 +/- 2.20 years (50.8 % females); 238 (36.4 %) had low neophobia scores (/=42). All items of the FNS were extracted except item 8 and yielded a two-factor solution with Eigenvalues > 1 (variance explained = 51.64 %; Kaiser-Meyer-Olkin (KMO) test = 0.746; Bartlett's sphericity test P < 0.001; alphaCronbach = 0.739). Children who refused initially to eat vegetables (beta = 5.51), fish (beta = 4.57), fruits (beta = 4.75) or eggs (beta = 2.99) and higher parents' instrumental feeding scores (beta = 0.3) were significantly associated with higher neophobia scores, whereas higher parents' encouragement scores (beta = -0.21) were significantly associated with lower neophobia scores in children. CONCLUSION: FN is common in children. Neophobic children tend to have lower variety in their diets. One of the ways to lower the levels of neophobia is the use of encouragement by the parents. In contrast, offering a reward to children for them to eat a certain food was associated with more signs of avoidance. More studies should be conducted to evaluate awareness levels concerning FN. FAU - El Mouallem, Rayane AU - El Mouallem R AD - Faculty of Medicine and Medical Sciences, Holy Spirit University of Kaslik (USEK), Jounieh, Lebanon. FAU - Malaeb, Diana AU - Malaeb D AD - School of Pharmacy, Lebanese International University, Mseitbeh, Beirut, Lebanon. AD - Life Sciences and Health Department, Paris-Est University, Paris, France. FAU - Akel, Marwan AU - Akel M AD - School of Pharmacy, Lebanese International University, Mseitbeh, Beirut, Lebanon. AD - INSPECT-LB: Institut National de Sante Publique, Epidemiologie Clinique et Toxicologie-Liban, Beirut, Lebanon. FAU - Hallit, Souheil AU - Hallit S AUID- ORCID: 0000-0001-6918-5689 AD - Faculty of Medicine and Medical Sciences, Holy Spirit University of Kaslik (USEK), Jounieh, Lebanon. AD - INSPECT-LB: Institut National de Sante Publique, Epidemiologie Clinique et Toxicologie-Liban, Beirut, Lebanon. FAU - Fadous Khalife, Marie-Claude AU - Fadous Khalife MC AD - Faculty of Medicine and Medical Sciences, Holy Spirit University of Kaslik (USEK), Jounieh, Lebanon. AD - Pediatrics and Neonatology Department, Notre Dame des Secours University Hospital, Byblos, Lebanon. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20210112 PL - England TA - Public Health Nutr JT - Public health nutrition JID - 9808463 SB - IM MH - *Avoidant Restrictive Food Intake Disorder MH - Child MH - Child, Preschool MH - Cross-Sectional Studies MH - Diet MH - Food Preferences MH - Humans MH - Surveys and Questionnaires MH - Vegetables PMC - PMC11082810 OTO - NOTNLM OT - Awareness OT - Encouragement OT - Food neophobia OT - Lebanese children OT - Parental feeding styles EDAT- 2021/01/13 06:00 MHDA- 2021/10/30 06:00 PMCR- 2021/01/12 CRDT- 2021/01/12 05:45 PHST- 2021/01/13 06:00 [pubmed] PHST- 2021/10/30 06:00 [medline] PHST- 2021/01/12 05:45 [entrez] PHST- 2021/01/12 00:00 [pmc-release] AID - S1368980021000082 [pii] AID - 10.1017/S1368980021000082 [doi] PST - ppublish SO - Public Health Nutr. 2021 Oct;24(15):5015-5023. doi: 10.1017/S1368980021000082. Epub 2021 Jan 12. PMID- 33430924 OWN - NLM STAT- MEDLINE DCOM- 20210118 LR - 20221207 IS - 1745-6215 (Electronic) IS - 1745-6215 (Linking) VI - 22 IP - 1 DP - 2021 Jan 11 TI - Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial. PG - 42 LID - 10.1186/s13063-020-04998-5 [doi] LID - 42 AB - OBJECTIVES: As of December, 1(st), 2020, coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2, resulted in more than 1 472 917 deaths worldwide and death toll is still increasing exponentially. Many COVID-19 infected people are asymptomatic or experience moderate symptoms and recover without medical intervention. However, older people and those with comorbid hypertension, diabetes, obesity, or heart disease are at higher risk of mortality. Because current therapeutic options for COVID-19 patients are limited specifically for this elderly population at risk, Biophytis is developing BIO101 (20-hydroxyecdysone, a Mas receptor activator) as a new treatment option for managing patients with SARS-CoV-2 infection at the severe stage. The angiotensin converting enzyme 2 (ACE2) serves as a receptor for SARS-CoV-2. Interaction between ACE2 and SARS-CoV2 spike protein seems to alter the function of ACE2, a key player in the renin-angiotensin system (RAS). The clinical picture of COVID-19 includes acute respiratory distress syndrome (ARDS), cardiomyopathy, multiorgan dysfunction and shock, all of which might result from an imbalance of the RAS. We propose that RAS balance could be restored in COVID-19 patients through MasR activation downstream of ACE2 activity, with 20-hydroxyecdysone (BIO101) a non-peptidic Mas receptor (MasR) activator. Indeed, MasR activation by 20-hydroxyecdysone harbours anti-inflammatory, anti-thrombotic, and anti-fibrotic properties. BIO101, a 97% pharmaceutical grade 20-hydroxyecdysone could then offer a new therapeutic option by improving the respiratory function and ultimately promoting survival in COVID-19 patients that develop severe forms of this devastating disease. Therefore, the objective of this COVA study is to evaluate the safety and efficacy of BIO101, whose active principle is 20-hydroxyecdysone, in COVID-19 patients with severe pneumonia. TRIAL DESIGN: Randomized, double-blind, placebo-controlled, multi-centre, group sequential and adaptive which will be conducted in 2 parts. Part 1: Ascertain the safety and tolerability of BIO101 and obtain preliminary indication of the activity of BIO101, in preventing respiratory deterioration in the target population Part 2: Re-assessment of the sample size needed for the confirmatory part 2 and confirmation of the effect of BIO101 observed in part 1 in the target population. The study is designed as group sequential to allow an efficient run-through, from obtaining an early indication of activity to a final confirmation. And adaptive - to allow accumulation of early data and adapt sample size in part 2 in order to inform the final design of the confirmatory part of the trial. PARTICIPANTS: Inclusion criteria 1. Age: 45 and above 2. A confirmed diagnosis of COVID-19 infection, within the last 14 days, prior to randomization, as determined by PCR or other approved commercial or public health assay, in a specimen as specified by the test used. 3. Hospitalized, in observation or planned to be hospitalized due to COVID-19 infection symptoms with anticipated hospitalization duration >/=3 days 4. With evidence of pneumonia based on all of the following: a. Clinical findings on a physical examination b. Respiratory symptoms developed within the past 7 days 5. With evidence of respiratory decompensation that started not more than 4 days before start of study medication and present at screening, meeting one of the following criteria, as assessed by healthcare staff: a. Tachypnea: >/=25 breaths per minute b. Arterial oxygen saturation 7 days - due to other and non-COVID-19 related conditions 3. Participant on invasive mechanical ventilation via an endotracheal tube, or extracorporeal membrane oxygenation (ECMO), or high-flow Oxygen (delivery of oxygen at a flow of >/=16 L/min.). 4. Participant is not able to take medications by mouth (as capsules or as a powder, mixed in water). 5. Disallowed concomitant medication: Consumption of any herbal products containing 20-hydroxyecdysone and derived from Leuzea carthamoides; Cyanotis vaga or Cyanotis arachnoidea is not allowed (e.g. performance enhancing agents). 6. Any known hypersensitivity to any of the ingredients, or excipients of the study medication, BIO101. 7. Renal disease requiring dialysis, or known renal insufficiency (eGFR/=16 L/min. Only if the primary endpoint is significant at the primary final analysis the following Key secondary endpoints will be tested in that order: Proportion of participants with events of respiratory failure at Day 28 Proportion of participants with 'positive' events at Day 28. Proportion of participants with events of all-cause mortality at Day 28 A 'positive' event is defined as the official discharge from hospital care by the department due to improvement in participant condition. Secondary and exploratory endpoints: In addition, a variety of functional measures and biomarkers (including the SpO2 / FiO2 ratio, viral load and markers related to inflammation, muscles, tissue and the RAS / MAS pathways) will also be collected. RANDOMIZATION: Randomization is performed using an IBM clinical development IWRS system during the baseline visit. Block-permuted randomization will be used to assign eligible participants in a 1:1 ratio. In part 1, randomization will be stratified by RAS pathway modulator use (yes/no) and co-morbidities (none vs. 1 and above). In Part 2, randomization will be stratified by centre, gender, RAS pathway modulator use (yes/no), co-morbidities (none vs. 1 and above), receiving Continuous Positive Airway Pressure/Bi-level Positive Airway Pressure (CPAP/BiPAP) at study entry (Yes/No) and suspicion of COVID-19 related myocarditis or pericarditis (present or not). BLINDING (MASKING): Participants, caregivers, and the study team assessing the outcomes are blinded to group assignment. All therapeutic units (TU), BIO101 b.i.d. or placebo b.i.d., cannot be distinguished in compliance with the double-blind process. An independent data-monitoring committee (DMC) will conduct 2 interim analyses. A first one based on the data from part 1 and a second from the data from parts 1 and 2. The first will inform about BIO101 safety, to allow the start of recruitment into part 2 followed by an analysis of the efficacy data, to obtain an indication of activity. The second interim analysis will inform about the sample size that will be required for part 2, in order to achieve adequate statistical power. Numbers to be randomised (sample size) Number of participants randomized: up to 465, in total Part 1: 50 (to obtain the proof of concept in COVID-19 patients). Part 2: 310, potentially increased by 50% (up to 465, based on interim analysis 2) (to confirm the effects of BIO101 observed in part 1). TRIAL STATUS: The current protocol Version is V 10.0, dated on 24.09.2020. The recruitment that started on September 1(st) 2020 is ongoing and is anticipated to finish for the whole study by March2021. TRIAL REGISTRATION: The trial was registered before trial start in trial registries: EudraCT , No. 2020-001498-63, registered May 18, 2020; and Clinicaltrials.gov, identifier NCT04472728 , registered July 15, 2020. FULL PROTOCOL: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol. FAU - Dioh, W AU - Dioh W AD - Biophytis SA, Sorbonne Universite - BC9, 4 place Jussieu, 75005, Paris, France. FAU - Chabane, M AU - Chabane M AD - Biophytis SA, Sorbonne Universite - BC9, 4 place Jussieu, 75005, Paris, France. FAU - Tourette, C AU - Tourette C AD - Biophytis SA, Sorbonne Universite - BC9, 4 place Jussieu, 75005, Paris, France. FAU - Azbekyan, A AU - Azbekyan A AD - Biophytis, Inc, 210 Broadway, Suite #201, Cambridge, MA, 02139, USA. FAU - Morelot-Panzini, C AU - Morelot-Panzini C AD - Service de Pneumologie, Medecine Intensive et Reanimation - R3S (SPMIR-R3S), Hopital Pitie-Salpetriere - APHP, Paris, France. FAU - Hajjar, L A AU - Hajjar LA AD - Universidade de Sao Paulo Instituto do Coracao, Sao Paulo, SP, Brasil. FAU - Lins, M AU - Lins M AD - General Hospital Sint-Maarten, Mechelen, Belgium. FAU - Nair, G B AU - Nair GB AD - Oakland University William Beaumont School of Medicine, Royal Oak, MI, USA. FAU - Whitehouse, T AU - Whitehouse T AD - Queen Elizabeth Hospital Birmingham, Birmingham, B15 2GW, UK. FAU - Mariani, J AU - Mariani J AD - Sorbonne Universite, CNRS - Institut de Biologie Paris Seine (B2A), 75005, Paris, France. FAU - Latil, M AU - Latil M AD - Biophytis SA, Sorbonne Universite - BC9, 4 place Jussieu, 75005, Paris, France. FAU - Camelo, S AU - Camelo S AD - Biophytis SA, Sorbonne Universite - BC9, 4 place Jussieu, 75005, Paris, France. FAU - Lafont, R AU - Lafont R AD - Sorbonne Universite, CNRS - Institut de Biologie Paris Seine (BIOSIPE), 75005, Paris, France. FAU - Dilda, P J AU - Dilda PJ AD - Biophytis SA, Sorbonne Universite - BC9, 4 place Jussieu, 75005, Paris, France. FAU - Veillet, S AU - Veillet S AD - Biophytis SA, Sorbonne Universite - BC9, 4 place Jussieu, 75005, Paris, France. FAU - Agus, S AU - Agus S AD - Biophytis, Inc, 210 Broadway, Suite #201, Cambridge, MA, 02139, USA. sam.agus@biophytis.com. LA - eng SI - ClinicalTrials.gov/NCT04472728 PT - Clinical Trial Protocol PT - Letter DEP - 20210111 PL - England TA - Trials JT - Trials JID - 101263253 RN - 0 (MAS1 protein, human) RN - 0 (Proto-Oncogene Mas) RN - 0 (Proto-Oncogene Proteins) RN - 0 (Receptors, Coronavirus) RN - 0 (Receptors, G-Protein-Coupled) RN - 0 (Spike Glycoprotein, Coronavirus) RN - 0 (spike protein, SARS-CoV-2) RN - 5289-74-7 (Ecdysterone) RN - EC 3.4.17.23 (Angiotensin-Converting Enzyme 2) SB - IM MH - Aged MH - Aged, 80 and over MH - Angiotensin-Converting Enzyme 2/metabolism MH - COVID-19/physiopathology MH - Disease Progression MH - Double-Blind Method MH - Ecdysterone/*therapeutic use MH - Extracorporeal Membrane Oxygenation/statistics & numerical data MH - Hospitalization MH - Humans MH - Hypoxia/physiopathology MH - Middle Aged MH - Mortality MH - Oxygen Inhalation Therapy/statistics & numerical data MH - Proto-Oncogene Mas MH - Proto-Oncogene Proteins/metabolism MH - Randomized Controlled Trials as Topic MH - Receptors, Coronavirus/metabolism MH - Receptors, G-Protein-Coupled/metabolism MH - Renin-Angiotensin System MH - Respiration, Artificial/statistics & numerical data MH - Respiratory Insufficiency/*drug therapy/physiopathology MH - SARS-CoV-2 MH - Spike Glycoprotein, Coronavirus/metabolism MH - Tachypnea/physiopathology MH - Treatment Outcome MH - *COVID-19 Drug Treatment PMC - PMC7797700 OTO - NOTNLM OT - 20-hydroxyecdysone OT - Acute respiratory Distress Syndrome OT - BIO101 OT - COVID-19 OT - Inflammation OT - Mas receptor OT - Renin Angiotensin System OT - SARS-CoV2 OT - angiotensin converting enzyme-2 OT - randomised controlled trial COIS- We declare non-competing interest that all authors apart from CMP, LAH, ML, TW and GBN are employees of BIOPHYTIS SA. We believe, however, that the company's potential commercial interests had no impact on the scientific rationale or conduct of the trial. CMP, LAH, ML, TW and GBN are members of the COVA steering committee and country clinical investigators and declare no-competing interests. EDAT- 2021/01/13 06:00 MHDA- 2021/01/20 06:00 PMCR- 2021/01/11 CRDT- 2021/01/12 05:43 PHST- 2020/12/17 00:00 [received] PHST- 2020/12/23 00:00 [accepted] PHST- 2021/01/12 05:43 [entrez] PHST- 2021/01/13 06:00 [pubmed] PHST- 2021/01/20 06:00 [medline] PHST- 2021/01/11 00:00 [pmc-release] AID - 10.1186/s13063-020-04998-5 [pii] AID - 4998 [pii] AID - 10.1186/s13063-020-04998-5 [doi] PST - epublish SO - Trials. 2021 Jan 11;22(1):42. doi: 10.1186/s13063-020-04998-5. PMID- 33416886 OWN - NLM STAT- MEDLINE DCOM- 20210315 LR - 20240229 IS - 2574-3805 (Electronic) IS - 2574-3805 (Linking) VI - 4 IP - 1 DP - 2021 Jan 4 TI - Assessment of Mortality Among Durable Left Ventricular Assist Device Recipients Ineligible for Clinical Trials. PG - e2032865 LID - 10.1001/jamanetworkopen.2020.32865 [doi] LID - e2032865 AB - IMPORTANCE: While wide-scale adoption of durable left ventricular assist devices (LVADs) can be attributed to favorable randomized clinical trial outcomes, restrictive selection criteria may be associated with a lack of generalizability to real-world experience. OBJECTIVE: To estimate the proportion of LVAD recipients who are eligible for clinical trials and to assess whether an association exists between trial eligibility and mortality. DESIGN, SETTING, AND PARTICIPANTS: This cohort study examined 14 679 patients undergoing primary, intracorporeal continuous-flow LVAD implantation (with or without a right ventricular assist device) in 181 North American centers from January 1, 2012, to June 30, 2017, identified in the Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS). To simulate a trial population, trial criteria from the Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Therapy With HeartMate 3 (MOMENTUM 3) were mapped to INTERMACS variables. Patients were categorized as eligible for trial inclusion or ineligible for trial inclusion and by number of ineligibility criteria met. Follow-up in INTERMACS was complete for all patients through October 31, 2017. Data were analyzed from July 2019 through November 2020. EXPOSURES: Undergoing durable LVAD implantation. MAIN OUTCOMES AND MEASURES: Trial eligibility and postimplant mortality were analyzed using Kaplan-Meier estimates and Cox proportional hazards models. RESULTS: Among 14 679 recipients, mean (SD) age was 57 (13) years, 11 503 individuals (78.4%) were men, and 11 406 individuals (77.7%) presented with New York Heart Association class IV heart failure. A total of 6429 recipients (43.8%) were ineligible for trial inclusion, of whom 4226 individuals (65.7%) met 1 ineligibility criterion, 1442 individuals (22.4%) met 2 criteria, and 761 individuals (11.8%) met 3 or more criteria. Estimated mortality for recipients who were trial-ineligible was higher than for recipients who were trial-eligible (1-year mortality: 25.3% [95% CI, 24.2%-26.5%] vs 16.2% [95% CI, 15.4%-17.1%]; 3-year mortality: 42.8% [95% CI, 41.3%-44.4%] vs 36.4% [95% CI, 35.0%-37.8%]; log-rank P < .001 for both). Patients who were trial-ineligible had increased risk of mortality compared with patients who were trial-eligible if they met 1 trial ineligibility criterion (hazard ratio [HR], 1.16 [95% CI, 1.08-1.24]; P < .001), 2 trial ineligibility criteria (HR, 1.51 [95% CI, 1.36-1.67]; P < .001), or 3 or more trial ineligibility criteria (HR, 2.09 [95% CI, 1.84-2.39]; P < .001). Among patients meeting only 1 ineligibility criterion, 4 criteria were independently associated with mortality: prior or ongoing mechanical circulatory support (HR, 1.63 [95% CI, 1.23-2.16]; P = .001), elevated creatinine level (HR, 1.42 [95% CI, 1.17-1.72]; P < .001), elevated bilirubin level (HR, 1.39 [95% CI, 1.17-1.66]; P < .001), and low albumin or prealbumin level (HR, 1.18 [95% CI, 1.05-1.33]; P = .007). CONCLUSIONS AND RELEVANCE: These findings suggest that while treatment for patients who are ineligible for LVAD trial inclusion should be weighed against medical management, more consideration could be given to designing trials with eligibility criteria that reflect real-world experience. FAU - Brescia, Alexander A AU - Brescia AA AD - Department of Cardiac Surgery, Michigan Medicine, University of Michigan, Ann Arbor. AD - Center for Healthcare Outcomes and Policy, University of Michigan, Ann Arbor. FAU - Watt, Tessa M F AU - Watt TMF AD - Department of Cardiac Surgery, Michigan Medicine, University of Michigan, Ann Arbor. AD - Center for Healthcare Outcomes and Policy, University of Michigan, Ann Arbor. FAU - Pagani, Francis D AU - Pagani FD AD - Department of Cardiac Surgery, Michigan Medicine, University of Michigan, Ann Arbor. AD - Center for Healthcare Outcomes and Policy, University of Michigan, Ann Arbor. FAU - Cascino, Thomas M AU - Cascino TM AD - Center for Healthcare Outcomes and Policy, University of Michigan, Ann Arbor. AD - Division of Cardiovascular Medicine, Department of Internal Medicine, Michigan Medicine, University of Michigan, Ann Arbor. FAU - Zhang, Min AU - Zhang M AD - Department of Biostatistics, School of Public Health, University of Michigan, Ann Arbor. FAU - McCullough, Jeffrey S AU - McCullough JS AD - Department of Health Management and Policy, School of Public Health, University of Michigan, Ann Arbor. FAU - Shore, Supriya AU - Shore S AD - Division of Cardiovascular Medicine, Department of Internal Medicine, Michigan Medicine, University of Michigan, Ann Arbor. FAU - Likosky, Donald S AU - Likosky DS AD - Department of Cardiac Surgery, Michigan Medicine, University of Michigan, Ann Arbor. AD - Center for Healthcare Outcomes and Policy, University of Michigan, Ann Arbor. FAU - Aaronson, Keith D AU - Aaronson KD AD - Division of Cardiovascular Medicine, Department of Internal Medicine, Michigan Medicine, University of Michigan, Ann Arbor. FAU - Thompson, Michael P AU - Thompson MP AD - Department of Cardiac Surgery, Michigan Medicine, University of Michigan, Ann Arbor. AD - Center for Healthcare Outcomes and Policy, University of Michigan, Ann Arbor. CN - Michigan Congestive Heart Failure Investigators LA - eng GR - T32 HL076123/HL/NHLBI NIH HHS/United States PT - Journal Article PT - Multicenter Study PT - Research Support, N.I.H., Extramural PT - Research Support, U.S. Gov't, P.H.S. DEP - 20210104 PL - United States TA - JAMA Netw Open JT - JAMA network open JID - 101729235 SB - IM CIN - Ann Thorac Surg. 2022 Jan;113(1):381. doi: 10.1016/j.athoracsur.2021.02.069. PMID: 33711301 EIN - JAMA Netw Open. 2021 Jun 1;4(6):e2118963. doi: 10.1001/jamanetworkopen.2021.18963. PMID: 34152423 MH - *Clinical Trials as Topic MH - Female MH - Heart Failure/*mortality/*therapy MH - *Heart-Assist Devices MH - Humans MH - Male MH - Middle Aged MH - North America MH - *Patient Selection MH - Prognosis MH - Research Design PMC - PMC7794668 COIS- Conflict of Interest Disclosures: Dr Pagani reported receiving personal fees from FineHeart outside the submitted work and serving as chair of The Society of Thoracic Surgeons Interagency Registry for Mechanically Assisted Circulatory Support National Database Task Force. Dr Likosky reported receiving a grant from the National Institutes of Health and personal fees from the American Society of Extracorporeal Technology outside the submitted work. Dr Aaronson reported receiving grants from Abbott and HeartWare and personal fees from Medtronic outside the submitted work. Dr Thompson reported receiving partial salary support from Blue Cross Blue Shield of Michigan outside the submitted work. No other disclosures were reported. EDAT- 2021/01/09 06:00 MHDA- 2021/03/16 06:00 PMCR- 2021/01/08 CRDT- 2021/01/08 12:13 PHST- 2021/01/08 12:13 [entrez] PHST- 2021/01/09 06:00 [pubmed] PHST- 2021/03/16 06:00 [medline] PHST- 2021/01/08 00:00 [pmc-release] AID - 2774719 [pii] AID - zoi201011 [pii] AID - 10.1001/jamanetworkopen.2020.32865 [doi] PST - epublish SO - JAMA Netw Open. 2021 Jan 4;4(1):e2032865. doi: 10.1001/jamanetworkopen.2020.32865. PMID- 33413051 OWN - NLM STAT- MEDLINE DCOM- 20210205 LR - 20240330 IS - 1651-1905 (Electronic) IS - 1403-4948 (Print) IS - 1403-4948 (Linking) VI - 49 IP - 1 DP - 2021 Feb TI - A comparison of COVID-19 epidemiological indicators in Sweden, Norway, Denmark, and Finland. PG - 69-78 LID - 10.1177/1403494820980264 [doi] AB - Aims: To compare the early impact of COVID-19 infections and mortality from February to July 2020 across the Nordic nations of Sweden, Norway, Denmark, and Finland through available public data sources and conduct a descriptive analysis of the potential factors that drove different epidemiological outcomes, with a focus on Sweden's response. Methods: COVID-19 cases, deaths, tests, case age distribution, and the difference between 2020 all-cause mortality and the average mortality of the previous 5 years were compared across nations. Patterns in cell phone mobility data, testing strategies, and seniors' care home deaths were also compared. Data for each nation were based on publicly available sources as of July 31, 2020. Results: Compared with its Nordic peers, Sweden had a higher incidence rate across all ages, a higher COVID-19-related death rate only partially explained by population demographics, a higher death rate in seniors' care, and higher all-cause mortality. Sweden had approximately half as much mobility change as its Nordic neighbours until April and followed similar rates as its neighbours from April to July. Denmark led its Nordic peers in testing rates, while Sweden had the highest cumulative test-positivity rate continuously from mid-March. Conclusions: COVID-19 pushed Sweden's health system to its capacity, exposed systemic weaknesses in the seniors' care system, and revealed challenges with implementing effective contact tracing and testing strategies while experiencing a high case burden. Looser government restrictions at the beginning of the outbreak are likely to have played a role in the impact of COVID-19 in Sweden. In an effort to improve epidemic control, Sweden has increased testing rates, implemented more restrictive prevention measures, and increased their intensive care unit bed capacity. FAU - Yarmol-Matusiak, Erica A AU - Yarmol-Matusiak EA AD - Ivey Business School, Western University, London, ON, Canada. AD - Department of Epidemiology and Biostatistics, Schulich School of Medicine & Dentistry, Western University, London, ON, Canada. FAU - Cipriano, Lauren E AU - Cipriano LE AUID- ORCID: 0000-0001-5568-4516 AD - Ivey Business School, Western University, London, ON, Canada. AD - Department of Epidemiology and Biostatistics, Schulich School of Medicine & Dentistry, Western University, London, ON, Canada. FAU - Stranges, Saverio AU - Stranges S AD - Department of Epidemiology and Biostatistics, Schulich School of Medicine & Dentistry, Western University, London, ON, Canada. AD - Department of Family Medicine, Schulich School of Medicine & Dentistry, Western University, London, ON, Canada. AD - Department of Population Health, Luxembourg Institute of Health, Strassen, Luxembourg. LA - eng PT - Comparative Study PT - Journal Article DEP - 20210107 PL - Sweden TA - Scand J Public Health JT - Scandinavian journal of public health JID - 100883503 SB - IM MH - Adolescent MH - Adult MH - Age Distribution MH - Aged MH - Aged, 80 and over MH - COVID-19/diagnosis/*epidemiology/mortality MH - COVID-19 Testing/statistics & numerical data MH - Cause of Death/trends MH - Child MH - Child, Preschool MH - Denmark/epidemiology MH - Finland/epidemiology MH - Humans MH - Infant MH - Infant, Newborn MH - Middle Aged MH - Mortality/trends MH - Norway/epidemiology MH - Sweden/epidemiology MH - Young Adult PMC - PMC7797349 OTO - NOTNLM OT - COVID-19 OT - COVID-19 mortality OT - Nordic OT - infectious disease prevention OT - infectious disease transmission OT - policy analysis OT - public health strategy COIS- Declaration of conflicting interests: The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. EDAT- 2021/01/09 06:00 MHDA- 2021/02/07 06:00 PMCR- 2021/02/04 CRDT- 2021/01/08 05:41 PHST- 2021/01/09 06:00 [pubmed] PHST- 2021/02/07 06:00 [medline] PHST- 2021/01/08 05:41 [entrez] PHST- 2021/02/04 00:00 [pmc-release] AID - 10.1177_1403494820980264 [pii] AID - 10.1177/1403494820980264 [doi] PST - ppublish SO - Scand J Public Health. 2021 Feb;49(1):69-78. doi: 10.1177/1403494820980264. Epub 2021 Jan 7. PMID- 33411669 OWN - NLM STAT- MEDLINE DCOM- 20210118 LR - 20210206 IS - 1545-1151 (Electronic) IS - 1545-1151 (Linking) VI - 18 DP - 2021 Jan 7 TI - Very Low Food Security Among Low-Income Households With Children in California Before and Shortly After the Economic Downturn From COVID-19. PG - E01 LID - 10.5888/pcd18.200517 [doi] LID - E01 AB - We examined levels of very low food security (VLFS) among low-income households with children in California before and shortly after the economic downturn from coronavirus disease 2019 (COVID-19). Households were randomly sampled in 2018, 2019, and 2020; 11,653 mothers were administered the US Department of Agriculture 6-item Food Security Survey Module. Post-COVID-19 (April 27 to July 21, 2020, a period when stay-at-home restrictions were eased in the state), 14.0% of mothers reported VLFS versus 19.3% pre-COVID-19 (November 21, 2019, to March 14, 2020) (P = .003), 22.2% in 2019 (P < .001), and 19.0% in 2018 (P = .004). Existing systems to quickly obtain food assistance benefits in California and new federal benefits available in response to COVID-19 may have reduced VLFS. FAU - Molitor, Fred AU - Molitor F AD - California State University Sacramento, Department of Communication Studies, Sacramento, California. AD - 1881 Dormity Rd, Rescue, CA 95672. Email: fred.molitor@csus.edu. FAU - Doerr, Celeste AU - Doerr C AD - Public Health Institute, Center for Wellness and Nutrition, Sacramento, California. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20210107 PL - United States TA - Prev Chronic Dis JT - Preventing chronic disease JID - 101205018 SB - IM MH - *COVID-19/epidemiology/prevention & control MH - California/epidemiology MH - Child MH - *Child Welfare/economics/ethnology/statistics & numerical data MH - *Chronic Disease/epidemiology/prevention & control MH - Communicable Disease Control/organization & administration MH - Family Characteristics MH - Female MH - *Food Security/methods/standards/statistics & numerical data MH - Humans MH - Male MH - Mothers MH - Poverty/*statistics & numerical data MH - SARS-CoV-2 MH - Self Report PMC - PMC7845548 EDAT- 2021/01/08 06:00 MHDA- 2021/01/20 06:00 PMCR- 2021/01/01 CRDT- 2021/01/07 17:13 PHST- 2021/01/07 17:13 [entrez] PHST- 2021/01/08 06:00 [pubmed] PHST- 2021/01/20 06:00 [medline] PHST- 2021/01/01 00:00 [pmc-release] AID - E01 [pii] AID - 20_0517 [pii] AID - 10.5888/pcd18.200517 [doi] PST - epublish SO - Prev Chronic Dis. 2021 Jan 7;18:E01. doi: 10.5888/pcd18.200517. PMID- 33410596 OWN - NLM STAT- MEDLINE DCOM- 20210621 LR - 20210621 IS - 2054-1058 (Electronic) IS - 2054-1058 (Linking) VI - 8 IP - 2 DP - 2021 Mar TI - Experience of aggressive behaviour of health professionals in home care services and the role of persons with dementia. PG - 833-843 LID - 10.1002/nop2.689 [doi] AB - AIMS: To explore the view of health professionals on the form and frequency of aggressive behaviour of clients against health professionals in home care services. DESIGN: An explorative cross-sectional survey was conducted. METHODS: We conducted a survey using the Survey of Violence Experienced by Staff German version Revised (SOVES-G-R) and the Impact of Patient Aggression on Carers Scale (IMPACS). A convenience sample of 852 healthcare professionals from German-speaking Switzerland participated. Data collection was conducted between July-October 2019. Data were analysed descriptively using IBM SPSS Statistics. RESULTS: Of the health professionals, 78.9% (N = 672) experienced aggressive behaviour since they worked in home care services. The most frequent aggressive behaviour was verbal aggression (75.6%, N = 644), while the most common predisposing factor was restriction in cognitive ability (71.3%, N = 67). Fear, burden and impairment of nursing relationship were common consequences of aggressive behaviour. CI - (c) 2021 The Authors. Nursing Open published by John Wiley & Sons Ltd. FAU - Schnelli, Angela AU - Schnelli A AUID- ORCID: 0000-0003-0805-6247 AD - Department of Nursing Science, University of Vienna, Vienna, Austria. AD - Center for Dementia Care, Institute of Applied Nursing Sciences, Department of Health, University of Applied Sciences of Eastern Switzerland, St. Gallen, Switzerland. FAU - Mayer, Hanna AU - Mayer H AD - Department of Nursing Science, University of Vienna, Vienna, Austria. FAU - Ott, Stefan AU - Ott S AD - Department of Economy, University of Applied Sciences of Eastern Switzerland, St. Gallen, Switzerland. FAU - Zeller, Adelheid AU - Zeller A AD - Center for Dementia Care, Institute of Applied Nursing Sciences, Department of Health, University of Applied Sciences of Eastern Switzerland, St. Gallen, Switzerland. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20210107 PL - United States TA - Nurs Open JT - Nursing open JID - 101675107 SB - IM MH - Aggression MH - Cross-Sectional Studies MH - *Dementia/epidemiology MH - *Home Care Services MH - Humans MH - Switzerland/epidemiology PMC - PMC7877137 OTO - NOTNLM OT - aggression management OT - community care OT - dementia OT - nursing home care OT - survey designs COIS- The authors declared no potential conflicts of interest concerning the research, authorship, and publication of this article. EDAT- 2021/01/08 06:00 MHDA- 2021/06/22 06:00 PMCR- 2021/01/07 CRDT- 2021/01/07 08:41 PHST- 2020/07/02 00:00 [received] PHST- 2020/10/30 00:00 [accepted] PHST- 2021/01/08 06:00 [pubmed] PHST- 2021/06/22 06:00 [medline] PHST- 2021/01/07 08:41 [entrez] PHST- 2021/01/07 00:00 [pmc-release] AID - NOP2689 [pii] AID - 10.1002/nop2.689 [doi] PST - ppublish SO - Nurs Open. 2021 Mar;8(2):833-843. doi: 10.1002/nop2.689. Epub 2021 Jan 7. PMID- 33408034 OWN - NLM STAT- MEDLINE DCOM- 20210419 LR - 20250522 IS - 2212-4411 (Electronic) VI - 131 IP - 4 DP - 2021 Apr TI - Is medication-related osteonecrosis of the jaw associated with tumor necrosis factor-alpha inhibition? PG - 422-427 LID - S2212-4403(20)31402-4 [pii] LID - 10.1016/j.oooo.2020.12.001 [doi] AB - OBJECTIVE: This article reviews the literature and evidence of the association of medication-related osteonecrosis of the jaw with tumor necrosis factor-alpha inhibition. METHODS: A systematic review was performed using electronic databases (PubMed, MEDLINE, and Embase) using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Key terms were used in the search. No restrictions were placed on publication status. Selection criteria comprised all levels of available evidence. Articles in the English language were selected up to and including July 2020. Reference lists of relevant studies were searched for additional articles. Articles were selected on the basis of inclusion and exclusion criteria. Findings from eligible studies were extracted by one reviewer and confirmed by a second. Disagreements were settled through discussion. RESULTS: The initial search of the key terms yielded 2107 articles. There were 1192 articles remaining after removal of duplicates and addition of 6 articles that were hand-selected from among reference lists of relevant studies. There were 12 eligible articles after screening. The full texts were read, and 5 articles were included on the basis of inclusion and exclusion criteria. CONCLUSIONS: Further research is required to determine an association of medication-related osteonecrosis of the jaw and tumor necrosis factor-alpha inhibition. CI - Copyright (c) 2020 Elsevier Inc. All rights reserved. FAU - Rosenberg, Stacy A AU - Rosenberg SA AD - Department of Periodontology, School of Dental Medicine, Stony Brook University, Stony Brook, NY, USA. FAU - Migliorati, Cesar AU - Migliorati C AD - College of Dentistry, University of Florida, Gainesville, FL, USA. FAU - Romanos, Georgios E AU - Romanos GE AD - Department of Periodontology, School of Dental Medicine, Stony Brook University, Stony Brook, NY, USA. Electronic address: georgios.romanos@stonybrook.edu. LA - eng PT - Journal Article PT - Systematic Review DEP - 20201216 PL - United States TA - Oral Surg Oral Med Oral Pathol Oral Radiol JT - Oral surgery, oral medicine, oral pathology and oral radiology JID - 101576782 RN - 0 (Tumor Necrosis Factor-alpha) SB - IM MH - Humans MH - *Osteonecrosis MH - *Tumor Necrosis Factor-alpha EDAT- 2021/01/08 06:00 MHDA- 2021/04/20 06:00 CRDT- 2021/01/07 05:53 PHST- 2020/08/08 00:00 [received] PHST- 2020/12/05 00:00 [revised] PHST- 2020/12/10 00:00 [accepted] PHST- 2021/01/08 06:00 [pubmed] PHST- 2021/04/20 06:00 [medline] PHST- 2021/01/07 05:53 [entrez] AID - S2212-4403(20)31402-4 [pii] AID - 10.1016/j.oooo.2020.12.001 [doi] PST - ppublish SO - Oral Surg Oral Med Oral Pathol Oral Radiol. 2021 Apr;131(4):422-427. doi: 10.1016/j.oooo.2020.12.001. Epub 2020 Dec 16. PMID- 33399859 OWN - NLM STAT- MEDLINE DCOM- 20210315 LR - 20220827 IS - 2574-3805 (Electronic) IS - 2574-3805 (Linking) VI - 4 IP - 1 DP - 2021 Jan 4 TI - Comparison of Utilization, Costs, and Quality of Medicaid vs Subsidized Private Health Insurance for Low-Income Adults. PG - e2032669 LID - 10.1001/jamanetworkopen.2020.32669 [doi] LID - e2032669 AB - IMPORTANCE: There has been little rigorous evidence to date comparing public vs private health insurance. With policy makers considering a range of policies to expand coverage, understanding the trade-offs between these coverage types is critical. OBJECTIVE: To compare months of coverage, utilization, quality, and costs between low-income adults with Medicaid vs those with subsidized private (Marketplace) insurance. DESIGN, SETTING, AND PARTICIPANTS: This cross-sectional study used a propensity score-matched sample of adults enrolled in either Medicaid or Marketplace plans at any point between January 1, 2014, and December 31, 2015. The sample was restricted to individuals with incomes narrowly above and below 138% of the federal poverty level (FPL), which represented the eligibility cutoff between the programs. Data were obtained from 3 state agencies merging comprehensive insurance claims with income eligibility data for Colorado Medicaid expansion and Marketplace enrollees. Income data were linked with an all-payer claims database, and generalized linear models were used to adjust for clinical and demographic confounders. Participants included 8182 low-income nonpregnant adults aged 19 to 64 years enrolled in Medicaid or Marketplace coverage during the 2014 to 2015 period, with incomes between 134% and 143% of the FPL. EXPOSURES: Health insurance through Colorado Medicaid or Colorado's state-based Marketplace. MAIN OUTCOMES AND MEASURES: The primary analytical approach was a multivariate regression analysis of the propensity score-matched sample. Primary outcomes were months of coverage in Medicaid or Marketplace insurance, office and emergency department (ED) visits, ambulatory care-sensitive hospitalizations, and total costs. For secondary quality outcomes, the propensity score-matched sample was widened to 129% to 148% of the FPL to ensure adequate sample size. Secondary outcomes included prescription drug utilization, types of ED visits, hospitalizations, out-of-pocket costs, and clinical quality measures. Primary data analysis was between September 2018 to July 2019, with revisions finalized in November 2020. RESULTS: The propensity score-matched narrow-income sample included a total of 8182 participants (4091 Medicaid eligible [50%]: mean [SD] age, 42.8 [13.6] years; 2230 women [54.5%]; 4091 Marketplace eligible [50%]: mean [SD] age, 42.7 [13.9] years; 2229 women [54.5%]). Demographic differences across the 2 groups were well balanced, with all standardized mean differences less than 0.10. Marketplace coverage was associated with fewer ED visits (mean, 0.36 [95% CI, 0.32-0.40] visits vs 0.56 [95% CI, 0.50-0.62] visits; P < .001) and more office (outpatient) visits than Medicaid (mean, 2.22 [95% CI, 2.11-2.32] visits vs 1.73 [95% CI, 1.64-1.81] visits; P < .001). No differences in ambulatory care-sensitive hospitalizations were found (0.004 [95% CI, 0.001-0.006] vs 0.007 [95% CI, 0.002-0.011]; P = .15). Total costs were 83% higher in Marketplace coverage (mean, $4553 [95% CI, $3368-$5738] vs $2484 [95% CI, $1760-$3209]; P < .001) owing almost entirely to higher prices, and out-of-pocket costs were 10 times higher (mean, $569 [95% CI, $337-$801] vs $45 [95% CI, $26-$65]; P < .001). Five of 12 secondary quality measures favored private insurance, and 1 favored Medicaid. CONCLUSIONS AND RELEVANCE: In this cross-sectional propensity score-matched study, Medicaid and Marketplace coverage differed in important ways. Public coverage through Medicaid was associated with more ED visits and fewer office visits than private Marketplace coverage, which may reflect barriers to outpatient care or lower cost-sharing barriers to ED care in Medicaid. Results suggest that Medicaid coverage was substantially less costly to beneficiaries and society than private coverage, with mixed results on health care quality. FAU - Allen, Heidi AU - Allen H AD - Columbia University School of Social Work, New York, New York. FAU - Gordon, Sarah H AU - Gordon SH AD - Department of Health Law, Policy, and Management, Boston University School of Public Health, Boston, Massachusetts. FAU - Lee, Dennis AU - Lee D AD - Department of Health Policy and Management, Harvard T. H. Chan School of Public Health, Boston, Massachusetts. FAU - Bhanja, Aditi AU - Bhanja A AD - Department of Health Policy and Management, Harvard T. H. Chan School of Public Health, Boston, Massachusetts. FAU - Sommers, Benjamin D AU - Sommers BD AD - Department of Health Policy and Management, Harvard T. H. Chan School of Public Health, Boston, Massachusetts. AD - Department of Medicine, Brigham & Women's Hospital, Boston, Massachusetts. LA - eng PT - Comparative Study PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20210104 PL - United States TA - JAMA Netw Open JT - JAMA network open JID - 101729235 SB - IM MH - Adult MH - Aged MH - Colorado MH - Cross-Sectional Studies MH - Female MH - Humans MH - Insurance Coverage/*economics MH - Insurance, Health/*economics MH - Male MH - Medicaid/*economics MH - Middle Aged MH - *Poverty MH - Propensity Score MH - United States PMC - PMC9377505 COIS- Conflict of Interest Disclosures: Dr Allen reported receiving grants from Robert Wood Johnson Foundation and the National Institutes of Health; and personal fees from Health Resources and Services Administration, the Society for Social Work Research, the Milbank Memorial Fund, and Redscout outside the submitted work. Dr Sommers reported receiving grants from Robert Wood Johnson Foundation's Polices for Action Program, Baylor Scott & White, and the Commonwealth Fund during the conduct of the study; personal fees from Health Research & Educational Trust Stipend for an editor's position at Health Services Research, a Massachusetts Medical Society honorarium for a lecture, an Urban Institute honorarium for grant review, an AcademyHealth honorarium for grant review, an American Economic Journal honorarium for journal review; and consulting for the Illinois Department of Healthcare and Family Services Consulting outside the submitted work. No other disclosures were reported. EDAT- 2021/01/06 06:00 MHDA- 2021/03/16 06:00 PMCR- 2021/01/05 CRDT- 2021/01/05 12:13 PHST- 2021/01/05 12:13 [entrez] PHST- 2021/01/06 06:00 [pubmed] PHST- 2021/03/16 06:00 [medline] PHST- 2021/01/05 00:00 [pmc-release] AID - 2774583 [pii] AID - zoi201005 [pii] AID - 10.1001/jamanetworkopen.2020.32669 [doi] PST - epublish SO - JAMA Netw Open. 2021 Jan 4;4(1):e2032669. doi: 10.1001/jamanetworkopen.2020.32669. PMID- 33399074 OWN - NLM STAT- MEDLINE DCOM- 20211029 LR - 20211029 IS - 2059-7029 (Electronic) IS - 2059-7029 (Linking) VI - 6 IP - 1 DP - 2021 Feb TI - The European Medicines Agency review of the initial application of atezolizumab and the role of PD-L1 expression as biomarker for checkpoint inhibitors. PG - 100008 LID - S2059-7029(20)32870-2 [pii] LID - 10.1016/j.esmoop.2020.100008 [doi] LID - 100008 AB - Immune checkpoint inhibitors have revolutionised cancer therapeutics. Translational research evaluating the role of biomarkers is essential to identify the ideal target population for these drugs. From a regulatory perspective, the identification of biomarkers and diagnostic assays is strongly encouraged by the European Medicines Agency (EMA). The aim of this article is to analyse the role of programmed death-ligand 1 (PD-L1) expression as a predictive biomarker in relation to the data submitted for the initial assessment of atezolizumab, a monoclonal antibody targeting human PD-L1. On 20 July 2017, atezolizumab was granted a marketing authorisation valid throughout the European Union (EU) for adult patients with (i) locally advanced or metastatic non-small-cell lung cancer (NSCLC) after chemotherapy and (ii) locally advanced or metastatic urothelial carcinoma (UC) after chemotherapy or cisplatin-ineligibility. Initially, these indications were not restricted by the level of PD-L1 expression, but preliminary data from an ongoing phase III trial in patients with UC led to a restriction in the UC indication to cisplatin-ineligible patients whose tumours have >/=5% PD-L1 expression. Still, the role of PD-L1 expression as predictive biomarker for atezolizumab therapy remains inconclusive and further research is needed. Data in this paper came from the scientific review leading to the initial regulatory approval of atezolizumab in the EU and its complementary application for indication (EMEA/H/C/004143/II/0010). The full scientific assessment report and product information are available on the EMA website (www.ema.europa.eu). CI - Copyright (c) 2020 The Authors. Published by Elsevier Ltd.. All rights reserved. FAU - Araujo-Fernandez, I AU - Araujo-Fernandez I AD - Oncology and Haematology Office, European Medicines Agency, Amsterdam, The Netherlands; Agence Nationale de Securite du Medicament et des Produits de Sante, Saint-Denis, France. FAU - Delgado, J AU - Delgado J AD - Oncology and Haematology Office, European Medicines Agency, Amsterdam, The Netherlands; Department of Haematology, Hospital Clinic, Barcelona, Spain. Electronic address: julio.delgado@ema.europa.eu. FAU - Moscetti, L AU - Moscetti L AD - Oncology and Haematology Office, European Medicines Agency, Amsterdam, The Netherlands; Department of Oncology, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy. FAU - Sarac, S B AU - Sarac SB AD - Danish Medicines Agency, Copenhagen, Denmark; Committee for Medicinal Products for Human Use, EMA, Amsterdam, The Netherlands. FAU - Zander, H AU - Zander H AD - Paul Ehrlich Institut, Langen, Germany. FAU - Mueller-Egert, S AU - Mueller-Egert S AD - Paul Ehrlich Institut, Langen, Germany. FAU - Dunder, K AU - Dunder K AD - Committee for Medicinal Products for Human Use, EMA, Amsterdam, The Netherlands; Lakemedelsverket, Uppsala, Sweden. FAU - Pean, E AU - Pean E AD - Oncology and Haematology Office, European Medicines Agency, Amsterdam, The Netherlands. FAU - Bergmann, L AU - Bergmann L AD - Universitatsklinikum Frankfurt, Frankfurt, Germany. FAU - Enzmann, H AU - Enzmann H AD - Committee for Medicinal Products for Human Use, EMA, Amsterdam, The Netherlands; Bundesinstitut fur Arzneimittel und Medizinprodukte, Bonn, Germany. FAU - Pignatti, F AU - Pignatti F AD - Oncology and Haematology Office, European Medicines Agency, Amsterdam, The Netherlands. LA - eng PT - Journal Article PT - Review DEP - 20201216 PL - England TA - ESMO Open JT - ESMO open JID - 101690685 RN - 0 (Antibodies, Monoclonal, Humanized) RN - 0 (B7-H1 Antigen) RN - 0 (Biomarkers) RN - 52CMI0WC3Y (atezolizumab) SB - IM MH - Antibodies, Monoclonal, Humanized MH - B7-H1 Antigen MH - Biomarkers MH - *Carcinoma, Non-Small-Cell Lung/drug therapy MH - *Carcinoma, Transitional Cell MH - Humans MH - *Lung Neoplasms/drug therapy MH - *Urinary Bladder Neoplasms PMC - PMC7910722 OTO - NOTNLM OT - EMA OT - PD-L1 expression OT - TECENTRIQ OT - atezolizumab OT - biomarkers OT - bladder cancer OT - lung cancer COIS- Disclosure The authors declare no conflict of interest. Disclaimer This publication is based on the European Public Assessment Report of TECENTRIQ, the summary of product characteristics, and other product information as published on the EMA website (www.ema.europa.eu). For the most current information on this marketing authorisation, please refer to the EMA website. The views expressed in this article are the personal views of the author(s) and may not be understood or quoted as being made on behalf of or reflecting the position of the regulatory agency/agencies or organisations with which the author(s) is/are employed/affiliated. EDAT- 2021/01/06 06:00 MHDA- 2021/10/30 06:00 PMCR- 2020/12/16 CRDT- 2021/01/05 08:37 PHST- 2020/10/09 00:00 [received] PHST- 2020/11/12 00:00 [revised] PHST- 2020/11/14 00:00 [accepted] PHST- 2021/01/06 06:00 [pubmed] PHST- 2021/10/30 06:00 [medline] PHST- 2021/01/05 08:37 [entrez] PHST- 2020/12/16 00:00 [pmc-release] AID - S2059-7029(20)32870-2 [pii] AID - 100008 [pii] AID - 10.1016/j.esmoop.2020.100008 [doi] PST - ppublish SO - ESMO Open. 2021 Feb;6(1):100008. doi: 10.1016/j.esmoop.2020.100008. Epub 2020 Dec 16. PMID- 33387848 OWN - NLM STAT- MEDLINE DCOM- 20210202 LR - 20240809 IS - 1476-5616 (Electronic) IS - 0033-3506 (Print) IS - 0033-3506 (Linking) VI - 190 DP - 2021 Jan TI - Sharp increase in depression and anxiety among Brazilian adults during the COVID-19 pandemic: findings from the PAMPA cohort. PG - 101-107 LID - S0033-3506(20)30501-1 [pii] LID - 10.1016/j.puhe.2020.11.013 [doi] AB - OBJECTIVES: We aimed to compare the prevalence of depression and anxiety symptoms before and during the pandemic and identify factors associated with aggravated mental health symptoms. STUDY DESIGN: Retrospective cohort study. METHODS: We identified the proportion of normal, mild, moderate, and severe symptoms of depression and anxiety before and during the social distancing restrictions in adults from southern Brazil. An online, self-administered questionnaire was delivered for residents within the state of Rio Grande do Sul. Depressive and anxiety symptoms were examined by the Hospital Anxiety and Depression Scale. RESULTS: Most of the participants (n = 2314) aged between 31 and 59 years (54.2%), were women (76.6%), White (90.6%) with a university degree (66.6%). Moderate-to-severe symptoms of depression and anxiety were reported in 3.9% and 4.5% of participants, respectively, before COVID-19. During the pandemic (June-July, 2020), these proportions increased to 29.1% (6.6-fold increase) and 37.8% (7.4-fold increase), respectively. Higher rates of depressive and anxiety symptoms were observed among women, those aged 18-30 years, diagnosed with chronic disease and participants who had their income negatively affected by social restrictions. Remaining active or becoming physically active during social distancing restrictions reduced the probability of aggravated mental health disorders. CONCLUSIONS: Depressive and anxiety symptoms had a 6.6- and 7.4-fold increase since the COVID-19 pandemic. Public policies such as physical activity promotion and strategies to reduce the economic strain caused by this pandemic are urgently needed to mitigate the impact of the pandemic on mental health. CI - Copyright (c) 2020 The Royal Society for Public Health. Published by Elsevier Ltd. All rights reserved. FAU - Feter, N AU - Feter N AD - Postgraduate Program in Physical Education, Federal University of Pelotas, Rua Luis de Camoes, 625, 96055630, Pelotas, Brazil; GEEAF - Physical Activity Epidemiology Research Group, Rua Luis de Camoes, 625, 96055630, Pelotas, Brazil; School of Human Movement and Nutrition Sciences, The University of Queensland, St Lucia, QLD, 4067, Australia; Neuroscience and Physical Activity Research Group, Rua Luis de Camoes, 625, 96055630, Pelotas, Brazil. Electronic address: n.feter@uq.edu.au. FAU - Caputo, E L AU - Caputo EL AD - Postgraduate Program in Physical Education, Federal University of Pelotas, Rua Luis de Camoes, 625, 96055630, Pelotas, Brazil; GEEAF - Physical Activity Epidemiology Research Group, Rua Luis de Camoes, 625, 96055630, Pelotas, Brazil; Neuroscience and Physical Activity Research Group, Rua Luis de Camoes, 625, 96055630, Pelotas, Brazil. FAU - Doring, I R AU - Doring IR AD - GEEAF - Physical Activity Epidemiology Research Group, Rua Luis de Camoes, 625, 96055630, Pelotas, Brazil. FAU - Leite, J S AU - Leite JS AD - Neuroscience and Physical Activity Research Group, Rua Luis de Camoes, 625, 96055630, Pelotas, Brazil; Postgraduate Program in Cardiology, Federal University of Rio Grande Do Sul, Rua Ramiro Barcelos, 2400, 90035003, Porto Alegre, Brazil. FAU - Cassuriaga, J AU - Cassuriaga J AD - Postgraduate Program in Physical Education, Federal University of Pelotas, Rua Luis de Camoes, 625, 96055630, Pelotas, Brazil; Neuroscience and Physical Activity Research Group, Rua Luis de Camoes, 625, 96055630, Pelotas, Brazil. FAU - Reichert, F F AU - Reichert FF AD - Postgraduate Program in Physical Education, Federal University of Pelotas, Rua Luis de Camoes, 625, 96055630, Pelotas, Brazil; GEEAF - Physical Activity Epidemiology Research Group, Rua Luis de Camoes, 625, 96055630, Pelotas, Brazil. FAU - da Silva, M C AU - da Silva MC AD - Postgraduate Program in Physical Education, Federal University of Pelotas, Rua Luis de Camoes, 625, 96055630, Pelotas, Brazil; GEEAF - Physical Activity Epidemiology Research Group, Rua Luis de Camoes, 625, 96055630, Pelotas, Brazil. FAU - Coombes, J S AU - Coombes JS AD - School of Human Movement and Nutrition Sciences, The University of Queensland, St Lucia, QLD, 4067, Australia. FAU - Rombaldi, A J AU - Rombaldi AJ AD - Postgraduate Program in Physical Education, Federal University of Pelotas, Rua Luis de Camoes, 625, 96055630, Pelotas, Brazil; GEEAF - Physical Activity Epidemiology Research Group, Rua Luis de Camoes, 625, 96055630, Pelotas, Brazil; Neuroscience and Physical Activity Research Group, Rua Luis de Camoes, 625, 96055630, Pelotas, Brazil. LA - eng PT - Journal Article DEP - 20201231 PL - Netherlands TA - Public Health JT - Public health JID - 0376507 SB - IM MH - Adolescent MH - Adult MH - Aged MH - Aged, 80 and over MH - Anxiety/*epidemiology/etiology MH - Anxiety Disorders/epidemiology/etiology MH - Brazil/epidemiology MH - COVID-19/complications/epidemiology/prevention & control/*psychology MH - Cohort Studies MH - Depression/*epidemiology/etiology MH - Female MH - Humans MH - Income MH - Longitudinal Studies MH - Male MH - Mental Health/*statistics & numerical data MH - Middle Aged MH - Pandemics MH - Prevalence MH - Retrospective Studies MH - *SARS-CoV-2 MH - Surveys and Questionnaires MH - Young Adult PMC - PMC7773543 OTO - NOTNLM OT - Anxiety OT - COVID-19 OT - Cohort OT - Depressive OT - Longitudinal EDAT- 2021/01/03 06:00 MHDA- 2021/02/03 06:00 PMCR- 2020/12/31 CRDT- 2021/01/02 20:11 PHST- 2020/09/20 00:00 [received] PHST- 2020/11/17 00:00 [revised] PHST- 2020/11/17 00:00 [accepted] PHST- 2021/01/03 06:00 [pubmed] PHST- 2021/02/03 06:00 [medline] PHST- 2021/01/02 20:11 [entrez] PHST- 2020/12/31 00:00 [pmc-release] AID - S0033-3506(20)30501-1 [pii] AID - 10.1016/j.puhe.2020.11.013 [doi] PST - ppublish SO - Public Health. 2021 Jan;190:101-107. doi: 10.1016/j.puhe.2020.11.013. Epub 2020 Dec 31. PMID- 33355637 OWN - NLM STAT- MEDLINE DCOM- 20210426 LR - 20210426 IS - 2168-6173 (Electronic) IS - 2168-6165 (Print) IS - 2168-6165 (Linking) VI - 139 IP - 2 DP - 2021 Feb 1 TI - Random Survival Forests Analysis of Intraoperative Complications as Predictors of Descemet Stripping Automated Endothelial Keratoplasty Graft Failure in the Cornea Preservation Time Study. PG - 191-197 LID - 10.1001/jamaophthalmol.2020.5743 [doi] AB - IMPORTANCE: A new analytic method can evaluate factors of interest associated with graft failure after Descemet stripping automated endothelial keratoplasty (DSAEK) or more generally in any ophthalmic surgical setting with a time-to-event outcome. OBJECTIVE: To reanalyze types of intraoperative complications associated with DSAEK graft failure in the Cornea Preservation Time Study using random survival forests. DESIGN, SETTING, AND PARTICIPANTS: This cohort study, initially conceived in April 2019, used a prediction model to conduct a post hoc secondary analysis of data collected in a multicenter, double-masked, randomized clinical trial. Forty US clinical sites with 70 surgeons participated, with donor corneas provided by 23 US eye banks. The study included 1090 participants, representing 1330 eyes, undergoing DSAEK for Fuchs dystrophy (1255 eyes [94.4%]) or pseudophakic or aphakic corneal edema (75 eyes [5.6%]). Enrollment occurred between April 16, 2012, and February 20, 2014, and follow-up ended June 5, 2017. Statistical analysis was performed from July 10, 2019, to May 29, 2020. INTERVENTION: Descemet stripping automated endothelial keratoplasty with random assignment of a donor cornea with preservation time of 7 days or less or 8 to 14 days. MAIN OUTCOMES AND MEASURES: Ranked variable importance for intraoperative complications among 50 donor, recipient, and eye bank variables and restricted mean survival time through 47 months (1434 days) after DSAEK were examined. Random survival forests, a nonparametric method (with less restrictive model assumptions) that is far more flexible in its ability to model nonlinear effects and interactions, was used to analyze the data. RESULTS: This study included 1090 participants (663 women [60.8%]; median age, 70 years [range, 42-90 years]), representing 1330 eyes. Random survival forests ranked a DSAEK intraoperative complication as the third most predictive factor of graft failure, after surgeon and eye bank, in the final model with 5 predictors. In the first 47 months after DSAEK, the estimated mean difference in restricted mean survival time for grafts that experienced a DSAEK intraoperative complication vs those that did not was -227 days (99% CI, -352 to -70 days) based on the final RSF model. CONCLUSIONS AND RELEVANCE: These findings, while post hoc, support the hypothesis that random survival forests allow for an improved analytic approach for identifying factors predictive of graft failure and for obtaining adjusted graft survival estimates. Random survival forests offer the opportunity to guide the development of future population-based cohort ophthalmic surgical studies, establishing definitive factors for procedural success. FAU - O'Brien, Robert C AU - O'Brien RC AD - Department of Data Science, University of Mississippi Medical Center, Jackson. FAU - Ishwaran, Hemant AU - Ishwaran H AD - Division of Biostatistics, Department of Public Health Sciences, University of Miami, Miami, Florida. FAU - Szczotka-Flynn, Loretta B AU - Szczotka-Flynn LB AD - Department of Ophthalmology and Visual Sciences, Case Western Reserve University, Cleveland, Ohio. AD - University Hospitals Cleveland Medical Center, Cleveland, Ohio. FAU - Lass, Jonathan H AU - Lass JH AD - Department of Ophthalmology and Visual Sciences, Case Western Reserve University, Cleveland, Ohio. AD - University Hospitals Cleveland Medical Center, Cleveland, Ohio. CN - Cornea Preservation Time Study (CPTS) Group LA - eng PT - Journal Article PT - Multicenter Study PT - Randomized Controlled Trial PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't PL - United States TA - JAMA Ophthalmol JT - JAMA ophthalmology JID - 101589539 SB - IM CIN - JAMA Ophthalmol. 2021 Feb 1;139(2):198-199. doi: 10.1001/jamaophthalmol.2020.5741. PMID: 33355603 MH - Adult MH - Aged MH - Aged, 80 and over MH - Corneal Edema/diagnosis/*surgery MH - *Decision Support Techniques MH - Descemet Membrane/*surgery MH - Descemet Stripping Endothelial Keratoplasty/*adverse effects MH - Double-Blind Method MH - Endothelium, Corneal/*transplantation MH - Female MH - Fuchs' Endothelial Dystrophy/diagnosis/*surgery MH - *Graft Survival MH - Humans MH - Intraoperative Complications/*etiology MH - Machine Learning MH - Male MH - Middle Aged MH - Predictive Value of Tests MH - Prospective Studies MH - Risk Assessment MH - Risk Factors MH - Time Factors MH - Treatment Failure MH - United States PMC - PMC7758826 COIS- Conflict of Interest Disclosures: Drs O'Brien, Lass, and Szczotka-Flynn reported receiving grants from the National Institutes of Health (NIH) during the conduct of the study. Dr Szczotka-Flynn reported receiving grants from Alcon and Johnson & Johnson Vision Care outside the submitted work. Dr Lass reported being a voluntary, unpaid board member of the Cleveland Eye Bank Foundation and Eversight. No other disclosures were reported. EDAT- 2020/12/24 06:00 MHDA- 2021/04/27 06:00 PMCR- 2021/12/23 CRDT- 2020/12/23 12:12 PHST- 2020/12/24 06:00 [pubmed] PHST- 2021/04/27 06:00 [medline] PHST- 2020/12/23 12:12 [entrez] PHST- 2021/12/23 00:00 [pmc-release] AID - 2774378 [pii] AID - eoi200103 [pii] AID - 10.1001/jamaophthalmol.2020.5743 [doi] PST - ppublish SO - JAMA Ophthalmol. 2021 Feb 1;139(2):191-197. doi: 10.1001/jamaophthalmol.2020.5743. PMID- 33347842 OWN - NLM STAT- MEDLINE DCOM- 20210618 LR - 20210618 IS - 1097-6868 (Electronic) IS - 0002-9378 (Print) IS - 0002-9378 (Linking) VI - 224 IP - 6 DP - 2021 Jun TI - Modest reduction in adverse birth outcomes following the COVID-19 lockdown. PG - 615.e1-615.e12 LID - S0002-9378(20)32574-6 [pii] LID - 10.1016/j.ajog.2020.12.1198 [doi] AB - BACKGROUND: Widespread lockdowns imposed during the coronavirus disease 2019 crisis may impact birth outcomes. OBJECTIVE: This study aimed to evaluate the association between the COVID-19 lockdown and the risk of adverse birth outcomes in Botswana. STUDY DESIGN: In response to the coronavirus disease 2019 crisis, Botswana enforced a lockdown that restricted movement within the country. We used data from an ongoing nationwide birth outcomes surveillance study to evaluate adverse outcomes (stillbirth, preterm birth, small-for-gestational-age fetuses, and neonatal death) and severe adverse outcomes (stillbirth, very preterm birth, very-small-for-gestational-age fetuses, and neonatal death) recorded prelockdown (January 1, 2020-April 2, 2020), during lockdown (April 3, 2020-May 7, 2020), and postlockdown (May 8, 2020-July 20, 2020). Using difference-in-differences analyses, we compared the net change in each outcome from the prelockdown to lockdown periods in 2020 relative to the same 2 periods in 2017-2019 with the net change in each outcome from the prelockdown to postlockdown periods in 2020 relative to the same 2 periods in 2017-2019. RESULTS: In this study, 68,448 women delivered a singleton infant in 2017-2020 between January 1 and July 20 and were included in our analysis (mean [interquartile range] age of mothers, 26 [22-32] years). Across the included calendar years and periods, the risk of any adverse outcome ranged from 27.92% to 31.70%, and the risk of any severe adverse outcome ranged from 8.40% to 11.38%. The lockdown period was associated with a 0.81 percentage point reduction (95% confidence interval, -2.95% to 1.30%) in the risk of any adverse outcome (3% relative reduction) and a 0.02 percentage point reduction (95% confidence interval, -0.79% to 0.75%) in the risk of any severe adverse outcome (0% relative reduction). The postlockdown period was associated with a 1.72 percentage point reduction (95% confidence, -3.42% to 0.02%) in the risk of any adverse outcome (5% relative reduction) and a 1.62 percentage point reduction (95% confidence interval, -2.69% to -0.55%) in the risk of any severe adverse outcome (14% relative reduction). Reductions in adverse outcomes were largest among women with human immunodeficiency virus and among women delivering at urban delivery sites, driven primarily by reductions in preterm birth and small-for-gestational-age fetuses. CONCLUSION: Adverse birth outcomes decreased from the prelockdown to postlockdown periods in 2020, relative to the change during the same periods in 2017-2019. Our findings may provide insights into associations between mobility and birth outcomes in Botswana and other low- and middle-income countries. CI - Copyright (c) 2020 Elsevier Inc. All rights reserved. FAU - Caniglia, Ellen C AU - Caniglia EC AD - Department of Population Health, New York University Grossman School of Medicine, New York, NY; Harvard T.H. Chan School of Public Health, Boston, MA. Electronic address: ellen.caniglia@nyulangone.org. FAU - Magosi, Lerato E AU - Magosi LE AD - Harvard T.H. Chan School of Public Health, Boston, MA. FAU - Zash, Rebecca AU - Zash R AD - Botswana-Harvard AIDS Institute Partnership, Gaborone, Botswana; Beth Israel Deaconess Medical Center, Boston, MA. FAU - Diseko, Modiegi AU - Diseko M AD - Botswana-Harvard AIDS Institute Partnership, Gaborone, Botswana. FAU - Mayondi, Gloria AU - Mayondi G AD - Botswana-Harvard AIDS Institute Partnership, Gaborone, Botswana. FAU - Mabuta, Judith AU - Mabuta J AD - Botswana-Harvard AIDS Institute Partnership, Gaborone, Botswana. FAU - Powis, Kathleen AU - Powis K AD - Harvard T.H. Chan School of Public Health, Boston, MA; Botswana-Harvard AIDS Institute Partnership, Gaborone, Botswana; Massachusetts General Hospital, Boston, MA. FAU - Dryden-Peterson, Scott AU - Dryden-Peterson S AD - Harvard T.H. Chan School of Public Health, Boston, MA; Botswana-Harvard AIDS Institute Partnership, Gaborone, Botswana; Brigham and Women's Hospital, Boston, MA. FAU - Mosepele, Mosepele AU - Mosepele M AD - University of Botswana, Gaborone, Botswana. FAU - Luckett, Rebecca AU - Luckett R AD - Beth Israel Deaconess Medical Center, Boston, MA; University of Botswana, Gaborone, Botswana. FAU - Makhema, Joseph AU - Makhema J AD - Botswana-Harvard AIDS Institute Partnership, Gaborone, Botswana. FAU - Mmalane, Mompati AU - Mmalane M AD - Botswana-Harvard AIDS Institute Partnership, Gaborone, Botswana. FAU - Lockman, Shahin AU - Lockman S AD - Harvard T.H. Chan School of Public Health, Boston, MA; Botswana-Harvard AIDS Institute Partnership, Gaborone, Botswana; Brigham and Women's Hospital, Boston, MA. FAU - Shapiro, Roger AU - Shapiro R AD - Harvard T.H. Chan School of Public Health, Boston, MA; Botswana-Harvard AIDS Institute Partnership, Gaborone, Botswana. LA - eng GR - K24 AI131928/AI/NIAID NIH HHS/United States GR - K01 HD100222/HD/NICHD NIH HHS/United States GR - R01 HD080471/HD/NICHD NIH HHS/United States GR - D43 TW009610/TW/FIC NIH HHS/United States GR - K24 AI131924/AI/NIAID NIH HHS/United States GR - R01 HD095766/HD/NICHD NIH HHS/United States GR - K23 HD088230/HD/NICHD NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural DEP - 20201224 PL - United States TA - Am J Obstet Gynecol JT - American journal of obstetrics and gynecology JID - 0370476 SB - IM MH - Adult MH - Botswana/epidemiology MH - COVID-19/*prevention & control MH - Communicable Disease Control/methods MH - Female MH - Humans MH - Infant, Small for Gestational Age MH - Perinatal Death MH - Pregnancy MH - Pregnancy Outcome/*epidemiology MH - Premature Birth/epidemiology MH - *Quarantine MH - SARS-CoV-2 MH - Stillbirth/epidemiology MH - Young Adult PMC - PMC7817370 OTO - NOTNLM OT - human immunodeficiency virus OT - mobility OT - neonatal death OT - pregnancy outcomes OT - preterm birth OT - small-for-gestational-age fetuses OT - stillbirth EDAT- 2020/12/22 06:00 MHDA- 2021/06/22 06:00 PMCR- 2020/12/24 CRDT- 2020/12/21 20:10 PHST- 2020/09/16 00:00 [received] PHST- 2020/12/11 00:00 [revised] PHST- 2020/12/14 00:00 [accepted] PHST- 2020/12/22 06:00 [pubmed] PHST- 2021/06/22 06:00 [medline] PHST- 2020/12/21 20:10 [entrez] PHST- 2020/12/24 00:00 [pmc-release] AID - S0002-9378(20)32574-6 [pii] AID - 10.1016/j.ajog.2020.12.1198 [doi] PST - ppublish SO - Am J Obstet Gynecol. 2021 Jun;224(6):615.e1-615.e12. doi: 10.1016/j.ajog.2020.12.1198. Epub 2020 Dec 24. PMID- 33338320 OWN - NLM STAT- MEDLINE DCOM- 20210402 LR - 20221005 IS - 1742-1241 (Electronic) IS - 1368-5031 (Print) IS - 1368-5031 (Linking) VI - 75 IP - 4 DP - 2021 Apr TI - Response to COVID-19 in Cyprus: Policy changes and epidemic trends. PG - e13944 LID - 10.1111/ijcp.13944 [doi] LID - e13944 AB - OBJECTIVES: In late July, Cyprus experienced the second epidemic wave of COVID-19. We present the steps taken by the government and evaluate their effect on epidemic trends. MATERIALS: Cyprus Press and Information Office data were analysed. Using an R-based forecasting program, two models were created to predict cases up to 01/09/2020: Model 1, which utilised data up to 09/06/2020, when airports reopened to foreign travelers with COVID-19 screening; and Model 2, which utilised data until 24/06/2020, when screening for passengers from low-transmission countries was discontinued. RESULTS: PIO data revealed no significant policy changes between 24/06/2020 and 31/07/2020. Prediction models were robust and accurate (Model 1, R(2) = 0.999, P < .001; Model 2, R(2) = 0.998, P < .001). By August 30th, recorded cases exceeded those predicted by Model 1 by 24.47% and by Model 2 by 20.95%, with P values <.001 for both cases. CONCLUSIONS: The significant difference between recorded cases and those projected by Models 1 and 2 suggests that changes in epidemic trends may have been associated with policy changes after their respective dates. Discontinuation of major restrictions such as airport reopening, can destabilise the control of the epidemic, and may concomitantly necessitate a reevaluation of the current epidemic status. In the face of an evolving situation such as the COVID-19 pandemic, states are forced to balance the imposing of restrictions against their impact on the economy. CI - (c) 2020 John Wiley & Sons Ltd. FAU - Kakoullis, Loukas AU - Kakoullis L AUID- ORCID: 0000-0001-6245-1569 AD - Department of Respiratory Medicine, University of Patras General Hospital, Patras, Greece. FAU - Eliades, Elias AU - Eliades E AD - Department of Health Sciences, University of Ulster, Belfast, UK. FAU - Papachristodoulou, Eleni AU - Papachristodoulou E AUID- ORCID: 0000-0002-9726-7144 AD - Department of Respiratory Medicine, University of Patras General Hospital, Patras, Greece. FAU - Parperis, Konstantinos AU - Parperis K AD - Department of Internal Medicine, University of Cyprus Medical School, Nicosia, Cyprus. AD - Department of Medicine, Division of Rheumatology, University of Arizona College of Medicine, Phoenix, AZ, USA. FAU - Chra, Paraskevi AU - Chra P AD - Department of Microbiology, Evangelismos Hospital, Athens, Greece. FAU - Constantinidou, Anastasia AU - Constantinidou A AD - Department of Internal Medicine, University of Cyprus Medical School, Nicosia, Cyprus. FAU - Chatzittofis, Andreas AU - Chatzittofis A AUID- ORCID: 0000-0002-6635-9564 AD - Department of Psychiatry, University of Cyprus Medical School, Nicosia, Cyprus. FAU - Sampsonas, Fotios AU - Sampsonas F AUID- ORCID: 0000-0002-7796-2959 AD - Department of Respiratory Medicine, University of Patras General Hospital, Patras, Greece. FAU - Panos, George AU - Panos G AUID- ORCID: 0000-0002-2712-5909 AD - Department of Internal Medicine, University of Cyprus Medical School, Nicosia, Cyprus. AD - Department of Internal Medicine, Section of Infectious Diseases, University of Patras General Hospital, Patras, Greece. LA - eng PT - Journal Article DEP - 20210103 PL - United States TA - Int J Clin Pract JT - International journal of clinical practice JID - 9712381 SB - IM MH - *COVID-19/epidemiology MH - Cyprus/epidemiology MH - Humans MH - *Pandemics MH - *Public Policy MH - SARS-CoV-2 PMC - PMC7883066 COIS- All authors declare that they have no conflict of interest. EDAT- 2020/12/19 06:00 MHDA- 2021/04/07 06:00 PMCR- 2021/01/03 CRDT- 2020/12/18 17:12 PHST- 2020/09/27 00:00 [received] PHST- 2020/12/14 00:00 [accepted] PHST- 2020/12/19 06:00 [pubmed] PHST- 2021/04/07 06:00 [medline] PHST- 2020/12/18 17:12 [entrez] PHST- 2021/01/03 00:00 [pmc-release] AID - IJCP13944 [pii] AID - 10.1111/ijcp.13944 [doi] PST - ppublish SO - Int J Clin Pract. 2021 Apr;75(4):e13944. doi: 10.1111/ijcp.13944. Epub 2021 Jan 3. PMID- 33337401 OWN - NLM STAT- MEDLINE DCOM- 20210210 LR - 20210210 IS - 1875-9270 (Electronic) IS - 1051-9815 (Linking) VI - 68 IP - 1 DP - 2021 TI - Was a global pandemic needed to adopt the use of telehealth in occupational therapy? PG - 13-20 LID - 10.3233/WOR-205268 [doi] AB - BACKGROUND: An analysis of data from an international survey was undertaken to determine the impact of the COVID-19 pandemic on telehealth practice in occupational therapy worldwide, in addition to facilitators and barriers in utilising this form of service delivery. METHOD: The global online survey was circulated in the occupational therapy community by the World Federation of Occupational Therapists (WFOT) between April and July 2020, collecting responses to closed-ended questions, in addition to free-text comments. Descriptive statistics and bivariate analyses were used to assess relationships between respondent characteristics and the utilisation of telehealth. Thematic statement analysis provided further insight regarding factors impacting telehealth use. RESULTS: Findings revealed a significant increase in the use of telehealth strategies with the onset of the pandemic among survey respondents, with many reported benefits. Bivariate analyses indicated telehealth users were more likely to score higher feelings of safety and positive work morale, as well as perceive employer expectations to be reasonable. Restricted access to technology, limitations of remote practice, funding issues and slow pace of change were identified as barriers for some respondents to utilising telehealth. Facilitators included availability of supportive policy, guidelines and strategies, in addition to education and training. CONCLUSION: This study advances the understanding of the current scope of occupational therapy telehealth practice in the context of the ongoing COVID-19 pandemic. Although results suggest long-term potential for telehealth use as an adjunct to traditional service provision, important considerations were identified regarding factors influencing integration of such strategies. FAU - Hoel, Viktoria AU - Hoel V AD - Institute for Public Health and Nursing Research, University of Bremen, Bremen, Germany. FAU - von Zweck, Claudia AU - von Zweck C AD - World Federation of Occupational Therapists, Geneva, Switzerland. FAU - Ledgerd, Ritchard AU - Ledgerd R AD - World Federation of Occupational Therapists, Geneva, Switzerland. CN - World Federation of Occupational Therapists LA - eng PT - Journal Article PL - United States TA - Work JT - Work (Reading, Mass.) JID - 9204382 SB - IM MH - Global Health/*trends MH - Humans MH - Occupational Therapy/*instrumentation/methods MH - Pandemics/*prevention & control MH - Telemedicine/methods/*trends OTO - NOTNLM OT - COVID-19 OT - health service delivery OT - remote care OT - technology OT - teletherapy EDAT- 2020/12/19 06:00 MHDA- 2021/02/11 06:00 CRDT- 2020/12/18 12:11 PHST- 2020/12/19 06:00 [pubmed] PHST- 2021/02/11 06:00 [medline] PHST- 2020/12/18 12:11 [entrez] AID - WOR205268 [pii] AID - 10.3233/WOR-205268 [doi] PST - ppublish SO - Work. 2021;68(1):13-20. doi: 10.3233/WOR-205268. PMID- 33270109 OWN - NLM STAT- MEDLINE DCOM- 20211124 LR - 20211124 IS - 1469-994X (Electronic) IS - 1462-2203 (Linking) VI - 23 IP - 8 DP - 2021 Aug 4 TI - Going Smokeless: Promotional Features and Reach of US Smokeless Tobacco Direct-Mail Advertising (July 2017-August 2018). PG - 1349-1357 LID - 10.1093/ntr/ntaa255 [doi] AB - INTRODUCTION: Although cigarette use in the United States has declined over time, smokeless tobacco (SLT) use has remained steady. Direct-mail advertising and coupon redemption have been linked to increased tobacco use, and efforts to promote SLT through direct-mail advertising may contribute to sustained SLT use. We examined reach of SLT direct-mail advertisements by recipient demographics and promotional features, including coupons. METHODS: Direct-mail data (n = 418) were acquired from Comperemedia (Mintel) and coded for product type (traditional [eg, chewing tobacco], pouched [eg, moist snuff, snus], or both [traditional SLT and any pouched SLT products]); promotions (eg, coupons); flavors; and themes (eg, masculinity). Using Mintel's volume estimates for number of pieces sent, we calculated the proportion of mail volume sent by recipient demographics (age, income, region) and advertising features across product type. RESULTS: Between July 2017 and August 2018, tobacco companies sent an estimated 249 million pieces of SLT direct-mail to US households; approximately half (49.6%) featured pouched SLT products. Across product types, over 75% of mail volume was sent to 31- to 60-year-old adults and 30-40% was sent to low-income households. The majority (>70%) of pouched SLT product mail contained coupons and flavor promotions. Outdoor and blue-collar-lifestyle themes were prominent in advertisements for all product types, along with less common adventure- and fun-related appeals. CONCLUSIONS: Coupons, flavors, and a combination of blue-collar and fun/adventure message themes were used to promote traditional and pouched SLT products through direct-mail, particularly to low-income households. Results support limits on direct-mail coupon distribution and continued surveillance of marketing appeals. IMPLICATIONS: There is a long history of research into tobacco advertising practices, largely focusing on cigarettes. This study highlights specific direct-mail marketing tactics used by the tobacco industry, including coupons to promote SLT products across the United States. Given the limited success in reducing SLT use and the association between direct-mail promotions and tobacco use, these study results provide support for policies to restrict use of coupons in direct-to-consumer tobacco marketing and indicate the need for continued surveillance of direct-mail advertisements as the SLT market continues to evolve. CI - (c) The Author(s) 2020. Published by Oxford University Press on behalf of the Society for Research on Nicotine and Tobacco. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. FAU - Czaplicki, Lauren AU - Czaplicki L AD - Truth Initiative Schroeder Institute, Washington, DC. AD - Department of Health, Behavior and Society, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD. FAU - Rahman, Basmah AU - Rahman B AUID- ORCID: 0000-0002-3576-2086 AD - Truth Initiative Schroeder Institute, Washington, DC. FAU - Simpson, Randall AU - Simpson R AD - Truth Initiative Schroeder Institute, Washington, DC. FAU - Rose, Shyanika W AU - Rose SW AUID- ORCID: 0000-0002-4200-1197 AD - Center for Health Equity Transformation and Department of Behavioral Science, College of Medicine, University of Kentucky, Lexington, KY. FAU - Liu, Michael AU - Liu M AD - Truth Initiative Schroeder Institute, Washington, DC. FAU - Perks, Siobhan N AU - Perks SN AUID- ORCID: 0000-0002-4982-6327 AD - Truth Initiative Schroeder Institute, Washington, DC. FAU - Moran, Meghan B AU - Moran MB AUID- ORCID: 0000-0001-6745-6668 AD - Department of Health, Behavior and Society, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD. FAU - Schillo, Barbara A AU - Schillo BA AUID- ORCID: 0000-0003-0847-2996 AD - Truth Initiative Schroeder Institute, Washington, DC. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - England TA - Nicotine Tob Res JT - Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco JID - 9815751 SB - IM MH - Adult MH - Advertising MH - Humans MH - Male MH - Middle Aged MH - Postal Service MH - *Tobacco Industry MH - *Tobacco Products MH - Tobacco Use/epidemiology MH - *Tobacco, Smokeless MH - United States EDAT- 2020/12/04 06:00 MHDA- 2021/11/25 06:00 CRDT- 2020/12/03 12:09 PHST- 2020/03/06 00:00 [received] PHST- 2020/12/01 00:00 [accepted] PHST- 2020/12/04 06:00 [pubmed] PHST- 2021/11/25 06:00 [medline] PHST- 2020/12/03 12:09 [entrez] AID - 6017815 [pii] AID - 10.1093/ntr/ntaa255 [doi] PST - ppublish SO - Nicotine Tob Res. 2021 Aug 4;23(8):1349-1357. doi: 10.1093/ntr/ntaa255. PMID- 33217420 OWN - NLM STAT- MEDLINE DCOM- 20210316 LR - 20221215 IS - 1931-3543 (Electronic) IS - 0012-3692 (Print) IS - 0012-3692 (Linking) VI - 159 IP - 3 DP - 2021 Mar TI - Incidence of VTE and Bleeding Among Hospitalized Patients With Coronavirus Disease 2019: A Systematic Review and Meta-analysis. PG - 1182-1196 LID - S0012-3692(20)35146-1 [pii] LID - 10.1016/j.chest.2020.11.005 [doi] AB - BACKGROUND: Individual studies have reported widely variable rates for VTE and bleeding among hospitalized patients with coronavirus disease 2019 (COVID-19). RESEARCH QUESTION: What is the incidence of VTE and bleeding among hospitalized patients with COVID-19? METHODS: In this systematic review and meta-analysis, 15 standard sources and COVID-19-specific sources were searched between January 1, 2020, and July 31, 2020, with no restriction according to language. Incidence estimates were pooled by using random effects meta-analyses. Heterogeneity was evaluated by using the I(2) statistic, and publication bias was assessed by using the Begg and Egger tests. RESULTS: The pooled incidence was 17.0% (95% CI, 13.4-20.9) for VTE, 12.1% (95% CI, 8.4-16.4) for DVT, 7.1% (95% CI, 5.3-9.1) for pulmonary embolism (PE), 7.8% (95% CI, 2.6-15.3) for bleeding, and 3.9% (95% CI, 1.2-7.9) for major bleeding. In subgroup meta-analyses, the incidence of VTE was higher when assessed according to screening (33.1% vs 9.8% by clinical diagnosis), among patients in the ICU (27.9% vs 7.1% in the ward), in prospective studies (25.5% vs 12.4% in retrospective studies), and with the inclusion of catheter-associated thrombosis/isolated distal DVTs and isolated subsegmental PEs. The highest pooled incidence estimate of bleeding was reported for patients receiving intermediate- or full-dose anticoagulation (21.4%) and the lowest in the only prospective study that assessed bleeding events (2.7%). INTERPRETATION: Among hospitalized patients with COVID-19, the overall estimated pooled incidence of VTE was 17.0%, with higher rates with routine screening, inclusion of distal DVT, and subsegmental PE, in critically ill patients and in prospective studies. Bleeding events were observed in 7.8% of patients and were sensitive to use of escalated doses of anticoagulants and nature of data collection. Additional studies are required to ascertain the significance of various thrombotic events and to identify strategies to improve patient outcomes. TRIAL REGISTRY: PROSPERO; No.: CRD42020198864; URL: https://www.crd.york.ac.uk/prospero/. CI - Copyright (c) 2020 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved. FAU - Jimenez, David AU - Jimenez D AD - Respiratory Department, Hospital Ramon y Cajal (IRYCIS), Madrid, Spain; Medicine Department, Universidad de Alcala (IRYCIS), Madrid, Spain; CIBER Enfermedades Respiratorias (CIBERES), Madrid, Spain. Electronic address: djimenez.hrc@gmail.com. FAU - Garcia-Sanchez, Aldara AU - Garcia-Sanchez A AD - Respiratory Department, Hospital Ramon y Cajal (IRYCIS), Madrid, Spain. FAU - Rali, Parth AU - Rali P AD - Department of Thoracic Medicine and Surgery, Lewis Katz School of Medicine, Temple University Hospital, Philadelphia, PA. FAU - Muriel, Alfonso AU - Muriel A AD - Biostatistics Clinic Unit, EA3878-Groupe d'Etude de la Thrombose de Bretagne Occidentale, Hospital Ramon y Cajal (IRYCIS), CIBERESP, Nursing Department Universidad de Alcala, Madrid, Spain. FAU - Bikdeli, Behnood AU - Bikdeli B AD - Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; Center for Outcomes Research and Evaluation, Yale School of Medicine, New Haven, CT; Cardiovascular Research Foundation, New York, NY. FAU - Ruiz-Artacho, Pedro AU - Ruiz-Artacho P AD - CIBER Enfermedades Respiratorias (CIBERES), Madrid, Spain; Department of Internal Medicine, Clinica Universidad de Navarra, Madrid, Spain. FAU - Le Mao, Raphael AU - Le Mao R AD - EA3878-Groupe d'Etude de la Thrombose de Bretagne Occidentale, Universite Europeenne de Bretagne, Brest, France. FAU - Rodriguez, Carmen AU - Rodriguez C AD - Respiratory Department, Hospital Ramon y Cajal (IRYCIS), Madrid, Spain. FAU - Hunt, Beverley J AU - Hunt BJ AD - Thrombosis & Haemophilia Centre, Guys & St Thomas' NHS Foundation Trust, London, United Kingdom. FAU - Monreal, Manuel AU - Monreal M AD - CIBER Enfermedades Respiratorias (CIBERES), Madrid, Spain; Department of Internal Medicine, Hospital Germans Trias i Pujol, Badalona, Barcelona, Universidad Catolica de Murcia, Murcia, Spain. LA - eng PT - Journal Article PT - Meta-Analysis PT - Systematic Review DEP - 20201117 PL - United States TA - Chest JT - Chest JID - 0231335 RN - 0 (Anticoagulants) SB - IM CIN - Chest. 2021 Mar;159(3):908-909. doi: 10.1016/j.chest.2020.12.022. PMID: 33678274 CIN - Chest. 2021 Jun;159(6):2512-2513. doi: 10.1016/j.chest.2021.01.022. PMID: 34099141 CIN - Chest. 2021 Jun;159(6):2513. doi: 10.1016/j.chest.2021.01.024. PMID: 34099142 MH - Anticoagulants/administration & dosage/adverse effects MH - *COVID-19/blood/complications/epidemiology MH - *Hemorrhage/chemically induced/epidemiology MH - Humans MH - Incidence MH - *Pulmonary Embolism/drug therapy/epidemiology/etiology MH - SARS-CoV-2 MH - *Venous Thromboembolism/drug therapy/epidemiology/etiology PMC - PMC7670889 OTO - NOTNLM OT - COVID-19 OT - DVT OT - VTE OT - bleeding OT - pulmonary embolism EDAT- 2020/11/21 06:00 MHDA- 2021/03/17 06:00 PMCR- 2020/11/17 CRDT- 2020/11/20 20:07 PHST- 2020/09/16 00:00 [received] PHST- 2020/10/31 00:00 [revised] PHST- 2020/11/05 00:00 [accepted] PHST- 2020/11/21 06:00 [pubmed] PHST- 2021/03/17 06:00 [medline] PHST- 2020/11/20 20:07 [entrez] PHST- 2020/11/17 00:00 [pmc-release] AID - S0012-3692(20)35146-1 [pii] AID - 10.1016/j.chest.2020.11.005 [doi] PST - ppublish SO - Chest. 2021 Mar;159(3):1182-1196. doi: 10.1016/j.chest.2020.11.005. Epub 2020 Nov 17. PMID- 33217368 OWN - NLM STAT- MEDLINE DCOM- 20211125 LR - 20211125 IS - 1552-6909 (Electronic) IS - 0090-0311 (Linking) VI - 50 IP - 1 DP - 2021 Jan TI - Meta-Synthesis of the Needs of Women Cared for by Midwives During Childbirth in Hospitals. PG - 6-19 LID - S0884-2175(20)30318-X [pii] LID - 10.1016/j.jogn.2020.10.005 [doi] AB - OBJECTIVE: To identify and meta-synthesize results of qualitative studies on the needs of women cared for by midwives during childbirth in hospitals. DATA SOURCES: MEDLINE, Cumulative Index to Nursing and Allied Health Literature (CINAHL), Embase, and the Cochrane Library. STUDY SELECTION: We restricted the bibliographic search to articles published in English to July 31, 2020. The initial search yielded 6,407 articles, and after 2,504 duplicates were removed, we screened the titles and abstracts of 3,903 articles. We conducted a full-text review of 89 articles and included 13 qualitative studies about the needs of women who were hospitalized during childbirth and had midwives as their primary maternity care providers. DATA EXTRACTION: We extracted data (e.g., authors, publication date, type of study, sample size, results, and quotes) from the full text of each article into a standardized table. Two authors reviewed all articles using the Critical Appraisal Skills Programme tool to assess study quality and to independently score each study. DATA SYNTHESIS: We analyzed the findings of each study and synthesized them to develop themes. We found 14 major themes that reflected the needs of women during hospitalization for childbirth: Nutrition, Hygiene, Privacy, Information, Bodily Respect, Respect for Social Role, Family Intimacy, Shelter, Pain Management, Partnership, Movement, Reassurance, Support, and Empowerment. We categorized these themes in Maslow's hierarchy of needs to better understand the phenomenon. CONCLUSION: We identified 14 needs that midwives and nurses can meet when they care for women in hospitals during childbirth. Standardized methods to assess these needs and to link them to specific interventions can be used by midwives and nurses, which will likely affect women's satisfaction with their experience and overall quality of care. CI - Copyright (c) 2020 AWHONN, the Association of Women's Health, Obstetric and Neonatal Nurses. Published by Elsevier Inc. All rights reserved. FAU - Anderson, Gloria AU - Anderson G FAU - Zega, Maurizio AU - Zega M FAU - D'Agostino, Fabio AU - D'Agostino F FAU - Rega, Maria Luisa AU - Rega ML FAU - Colaceci, Sofia AU - Colaceci S FAU - Damiani, Gianfranco AU - Damiani G FAU - Alvaro, Rosaria AU - Alvaro R FAU - Cocchieri, Antonello AU - Cocchieri A LA - eng PT - Journal Article PT - Review DEP - 20201117 PL - United States TA - J Obstet Gynecol Neonatal Nurs JT - Journal of obstetric, gynecologic, and neonatal nursing : JOGNN JID - 8503123 SB - IM MH - Delivery, Obstetric MH - Female MH - Hospitals MH - Humans MH - *Maternal Health Services MH - *Midwifery MH - Parturition MH - Pregnancy MH - Qualitative Research OTO - NOTNLM OT - childbirth OT - labor OT - midwifery OT - need OT - obstetric OT - parturition OT - patient preference OT - personal satisfaction OT - qualitative research EDAT- 2020/11/21 06:00 MHDA- 2021/11/26 06:00 CRDT- 2020/11/20 20:07 PHST- 2020/10/01 00:00 [accepted] PHST- 2020/11/21 06:00 [pubmed] PHST- 2021/11/26 06:00 [medline] PHST- 2020/11/20 20:07 [entrez] AID - S0884-2175(20)30318-X [pii] AID - 10.1016/j.jogn.2020.10.005 [doi] PST - ppublish SO - J Obstet Gynecol Neonatal Nurs. 2021 Jan;50(1):6-19. doi: 10.1016/j.jogn.2020.10.005. Epub 2020 Nov 17. PMID- 33203076 OWN - NLM STAT- MEDLINE DCOM- 20201123 LR - 20250530 IS - 1660-4601 (Electronic) IS - 1661-7827 (Print) IS - 1660-4601 (Linking) VI - 17 IP - 22 DP - 2020 Nov 15 TI - Protocol for a Mixed-Method Investigation of the Impact of the COVID-19 Pandemic and Gambling Practices, Experiences and Marketing in the UK: The "Betting and Gaming COVID-19 Impact Study". LID - 10.3390/ijerph17228449 [doi] LID - 8449 AB - The COVID-19 pandemic led to unprecedented restrictions on people's movements and interactions, as well as the cancellation of major sports events and social activities, directly altering the gambling landscape. There is urgent need to provide regulators, policy makers and treatment providers with evidence on the patterns and context of gambling during COVID-19 and its aftermath. This protocol describes a study addressing the following three questions: (1) How has COVID-19 changed gambling practices and the risk factors for, and experience of, gambling harms? (2) What is the effect of COVID-19 on gambling marketing? (3) How has COVID-19 changed high risk groups' gambling experiences and practices? This mixed-method study focuses on two groups, namely young adults and sports bettors. In workpackage-1, we will extend an existing longitudinal survey of gambling in young adults (aged 16-24 years) (first wave conducted June-August 2019), adding COVID-19-related questions to the second wave (July-August 2020) and extending to a third wave in 2021; and undertake a survey of sports bettors in the UK (baseline n = 4000, ~July-August 2020), with follow-ups in ~October-November 2020 and ~February-March 2021. In workpackage-2, we will examine changes in expenditure on paid-for gambling advertising from January 2019 to July 2021 and undertake a mixed-method content analysis of a random sample of paid-for gambling advertising (n ~ 200) and social media marketing (n ~ 100) during the initial COVID-19 "lockdown". Workpackage-3 will involve qualitative interviews with a purposive sample of (a) young adults (aged 18-24 years) and (b) sports bettors. FAU - Hunt, Kate AU - Hunt K AUID- ORCID: 0000-0002-5873-3632 AD - Institute for Social Marketing and Health, University of Stirling, Stirling FK9 4LA, UK. FAU - Critchlow, Nathan AU - Critchlow N AUID- ORCID: 0000-0001-9145-8874 AD - Institute for Social Marketing and Health, University of Stirling, Stirling FK9 4LA, UK. FAU - Brown, Ashley AU - Brown A AD - Institute for Social Marketing and Health, University of Stirling, Stirling FK9 4LA, UK. FAU - Bunn, Christopher AU - Bunn C AD - School of Social and Political Sciences, University of Glasgow, Glasgow G12 8QQ, UK. FAU - Dobbie, Fiona AU - Dobbie F AUID- ORCID: 0000-0002-8294-8203 AD - Usher Institute, University of Edinburgh, Edinburgh EH8 9YL, UK. FAU - Donnachie, Craig AU - Donnachie C AUID- ORCID: 0000-0003-1637-3138 AD - School of Social and Political Sciences, University of Glasgow, Glasgow G12 8QQ, UK. FAU - Gray, Cindy M AU - Gray CM AD - School of Social and Political Sciences, University of Glasgow, Glasgow G12 8QQ, UK. FAU - Purves, Richard AU - Purves R AUID- ORCID: 0000-0002-6527-0218 AD - Institute for Social Marketing and Health, University of Stirling, Stirling FK9 4LA, UK. FAU - Reith, Gerda AU - Reith G AD - School of Social and Political Sciences, University of Glasgow, Glasgow G12 8QQ, UK. FAU - Stead, Martine AU - Stead M AD - Institute for Social Marketing and Health, University of Stirling, Stirling FK9 4LA, UK. FAU - Mitchell, Danielle AU - Mitchell D AD - Institute for Social Marketing and Health, University of Stirling, Stirling FK9 4LA, UK. FAU - Wardle, Heather AU - Wardle H AUID- ORCID: 0000-0003-1361-3706 AD - School of Social and Political Sciences, University of Glasgow, Glasgow G12 8QQ, UK. LA - eng GR - MR/S019200/1/MRC_/Medical Research Council/United Kingdom GR - ES/V004549/1/UK Research and Innovation/International PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20201115 PL - Switzerland TA - Int J Environ Res Public Health JT - International journal of environmental research and public health JID - 101238455 SB - IM MH - Adolescent MH - Adult MH - Betacoronavirus MH - COVID-19 MH - *Coronavirus Infections MH - *Gambling/epidemiology MH - Humans MH - *Marketing MH - *Pandemics MH - *Pneumonia, Viral MH - Research Design MH - SARS-CoV-2 MH - United Kingdom/epidemiology MH - *Video Games MH - Young Adult PMC - PMC7697159 OTO - NOTNLM OT - COVID-19 OT - commercial determinants of health OT - gambling OT - sports bettors OT - young adults COIS- H.W. was Deputy Chair of the Advisory Board for Safer Gambling between May 2015 and March 2020. She was remunerated by the Gambling Commission (the industry regulator) for this. She is a member of the WHO panel on gambling and in 2019 worked on a study looking at gambling and suicide funded by GambleAware. F.D., N.C., R.P. and M.S. have worked together on one study funded by GambleAware, which examined the impact of gambling marketing/advertising on young people and vulnerable groups. The funders have no role in the design of the study; in the collection, analyses or interpretation of data; in the writing of the manuscript; or in the decision to publish the results. EDAT- 2020/11/19 06:00 MHDA- 2020/11/24 06:00 PMCR- 2020/11/01 CRDT- 2020/11/18 01:02 PHST- 2020/10/07 00:00 [received] PHST- 2020/11/06 00:00 [revised] PHST- 2020/11/12 00:00 [accepted] PHST- 2020/11/18 01:02 [entrez] PHST- 2020/11/19 06:00 [pubmed] PHST- 2020/11/24 06:00 [medline] PHST- 2020/11/01 00:00 [pmc-release] AID - ijerph17228449 [pii] AID - ijerph-17-08449 [pii] AID - 10.3390/ijerph17228449 [doi] PST - epublish SO - Int J Environ Res Public Health. 2020 Nov 15;17(22):8449. doi: 10.3390/ijerph17228449. PMID- 33159356 OWN - NLM STAT- MEDLINE DCOM- 20210511 LR - 20210511 IS - 1742-1241 (Electronic) IS - 1368-5031 (Linking) VI - 75 IP - 3 DP - 2021 Mar TI - Medications disposal and medications storage in Jordan: A cross-sectional study. PG - e13822 LID - 10.1111/ijcp.13822 [doi] AB - AIMS: Many concerns arise from the improper disposal of medications, which is associated with a negative impact on health and wildlife. The majority of the consumers of pharmaceutical products remain unaware of the procedures of disposal of unused or expired medicines. This study aimed to explore the practices of Jordanian individuals regarding the disposal and storage of unused or expired medications. METHODS: A cross-sectional study was conducted in Jordan for the period between July and November 2019 of patients who reported having unused, leftover or expired medications in their homes. The questionnaire tool was constructed based on a number of studies concerning medication recycling and international guidelines about correct and safe disposal of expired, unwanted or unused medication. RESULTS: A total of 1092 participants were included in the study. Their mean age was 32.4 (SD = 13.6) years and 56.8% (n = 620) were males. More than half of the participants (58.1%, n = 634) reported that they had unused, leftover or expired medications in their homes. The bedroom, kitchen and store room were the three most commonly reported places for the storage of unused, leftover or expired medications. The pharmacist was the main source for information regarding the storage of medications. The three most common reasons reported by the participants regarding having unused/leftover medications at home were change or discontinuation by the doctor (29.4%), self-discontinuation as the illness symptoms improved or resolved (28.2%) and forgetfulness (25.1%). CONCLUSION: A high percentage of the Jordanian population improperly handles their unused, leftover or expired medications. More restrictions are needed on the prescribing and dispensing of medications by the authorities concerned and there is a need to establish public guidelines regarding the use and correct disposal of pharmaceuticals. CI - (c) 2020 John Wiley & Sons Ltd. FAU - Naser, Abdallah Y AU - Naser AY AUID- ORCID: 0000-0001-8440-7446 AD - Department of Applied Pharmaceutical Sciences and Clinical Pharmacy, Faculty of Pharmacy, Isra University, Amman, Jordan. FAU - Amara, Noor AU - Amara N AD - Department of Applied Pharmaceutical Sciences and Clinical Pharmacy, Faculty of Pharmacy, Isra University, Amman, Jordan. FAU - Dagash, Ayah AU - Dagash A AD - Department of Applied Pharmaceutical Sciences and Clinical Pharmacy, Faculty of Pharmacy, Isra University, Amman, Jordan. FAU - Naddaf, Ahmad AU - Naddaf A AD - Department of Applied Pharmaceutical Sciences and Clinical Pharmacy, Faculty of Pharmacy, Isra University, Amman, Jordan. LA - eng PT - Journal Article DEP - 20201120 PL - United States TA - Int J Clin Pract JT - International journal of clinical practice JID - 9712381 SB - IM MH - Adult MH - Cross-Sectional Studies MH - Female MH - *Health Knowledge, Attitudes, Practice MH - Humans MH - Jordan MH - Male MH - *Pharmacists MH - Surveys and Questionnaires EDAT- 2020/11/08 06:00 MHDA- 2021/05/12 06:00 CRDT- 2020/11/07 05:35 PHST- 2020/08/10 00:00 [received] PHST- 2020/10/30 00:00 [accepted] PHST- 2020/11/08 06:00 [pubmed] PHST- 2021/05/12 06:00 [medline] PHST- 2020/11/07 05:35 [entrez] AID - 10.1111/ijcp.13822 [doi] PST - ppublish SO - Int J Clin Pract. 2021 Mar;75(3):e13822. doi: 10.1111/ijcp.13822. Epub 2020 Nov 20. PMID- 33150534 OWN - NLM STAT- MEDLINE DCOM- 20210915 LR - 20261010 IS - 1590-1262 (Electronic) IS - 1124-4909 (Linking) VI - 26 IP - 7 DP - 2021 Oct TI - Liver disease in obesity and underweight: the two sides of the coin. A narrative review. PG - 2097-2107 LID - 10.1007/s40519-020-01060-w [doi] AB - PURPOSE: Malnutrition, whether characterized by not enough or too much nutrient intake, is detrimental to the liver. We herein provide a narrative literature revision relative to hepatic disease occurrence in over or undernourished subjects, to shed light on the paradox where both sides of malnutrition lead to similar liver dysfunction and fat accumulation. METHODS: Medline, EMBASE, and Cochrane Library were searched for publications up to July 2020. Articles discussing the association between both chronic and acute liver pathology and malnutrition were evaluated together with studies reporting the dietary intake in subjects affected by malnutrition. RESULTS: The association between overnutrition and non-alcoholic fatty liver disease (NAFLD) is well recognized, as the beneficial effects of calorie restriction and very low carbohydrate diets. Conversely, the link between undernutrition and liver injury is more complex and less understood. In developing countries, early exposure to nutrient deficiency leads to marasmus and kwashiorkor, accompanied by fatty liver, whereas in developed countries anorexia nervosa is a more common form of undernutrition, associated with liver injury. Weight gain in undernutrition is associated with liver function improvement, whereas no study on the impact of macronutrient distribution is available. We hypothesized a role for very low carbohydrate diets in the management of undernutrition derived liver pathology, in addition to the established one in overnutrition-related NAFLD. CONCLUSIONS: Further studies are warranted to update the knowledge regarding undernutrition-related liver disease, and a specific interest should be paid to macronutrient distribution both in the context of refeeding and relative to its role in the development of hepatic complications of anorexia nervosa. LEVEL OF EVIDENCE: Narrative review, Level V. CI - (c) 2020. Springer Nature Switzerland AG. FAU - Risi, Renata AU - Risi R AD - Department of Experimental Medicine, Section of Medical Pathophysiology, Food Science and Endocrinology, Sapienza University of Rome, 00161, Rome, Italy. FAU - Tuccinardi, Dario AU - Tuccinardi D AUID- ORCID: 0000-0002-9139-7159 AD - Department of Endocrinology and Diabetes, Department of Medicine, University Campus Bio-Medico of Rome, Via Alvaro del Portillo, 21, 00128, Rome, Italy. d.tuccinardi@unicampus.it. FAU - Mariani, Stefania AU - Mariani S AD - Department of Experimental Medicine, Section of Medical Pathophysiology, Food Science and Endocrinology, Sapienza University of Rome, 00161, Rome, Italy. FAU - Lubrano, Carla AU - Lubrano C AD - Department of Experimental Medicine, Section of Medical Pathophysiology, Food Science and Endocrinology, Sapienza University of Rome, 00161, Rome, Italy. FAU - Manfrini, Silvia AU - Manfrini S AD - Department of Endocrinology and Diabetes, Department of Medicine, University Campus Bio-Medico of Rome, Via Alvaro del Portillo, 21, 00128, Rome, Italy. FAU - Donini, Lorenzo Maria AU - Donini LM AD - Department of Experimental Medicine, Section of Medical Pathophysiology, Food Science and Endocrinology, Sapienza University of Rome, 00161, Rome, Italy. FAU - Watanabe, Mikiko AU - Watanabe M AD - Department of Experimental Medicine, Section of Medical Pathophysiology, Food Science and Endocrinology, Sapienza University of Rome, 00161, Rome, Italy. LA - eng PT - Journal Article PT - Review DEP - 20201104 PL - Germany TA - Eat Weight Disord JT - Eating and weight disorders : EWD JID - 9707113 SB - IM MH - Energy Intake MH - Humans MH - Liver MH - *Non-alcoholic Fatty Liver Disease/complications MH - Obesity/complications MH - *Thinness OTO - NOTNLM OT - Anorexia nervosa OT - Diet OT - Eating disorder OT - Liver failure OT - Malnutrition OT - NAFLD OT - Treatment OT - Very low carbohydrate diet EDAT- 2020/11/06 06:00 MHDA- 2021/09/16 06:00 CRDT- 2020/11/05 06:10 PHST- 2020/09/12 00:00 [received] PHST- 2020/10/16 00:00 [accepted] PHST- 2020/11/06 06:00 [pubmed] PHST- 2021/09/16 06:00 [medline] PHST- 2020/11/05 06:10 [entrez] AID - 10.1007/s40519-020-01060-w [pii] AID - 10.1007/s40519-020-01060-w [doi] PST - ppublish SO - Eat Weight Disord. 2021 Oct;26(7):2097-2107. doi: 10.1007/s40519-020-01060-w. Epub 2020 Nov 4. PMID- 33115960 OWN - NLM STAT- MEDLINE DCOM- 20211213 LR - 20211214 IS - 1468-3318 (Electronic) IS - 0964-4563 (Linking) VI - 30 IP - 6 DP - 2021 Nov TI - Australian smokers' experiences and perceptions of recessed and firm filter cigarettes. PG - 660-667 LID - 10.1136/tobaccocontrol-2020-055725 [doi] AB - BACKGROUND: While cigarette filter modifications have long been used to increase product appeal and assuage health concerns, tighter marketing restrictions, including plain packaging, have further spurred the growth of filter variants. We explored and assessed experiences and perceptions of smokers who had tried and/or currently use recessed filter cigarettes (RFCs) and firm filter cigarettes (FFCs). METHOD: In November 2018, we undertook eight exploratory focus groups of Australian adult factory-made cigarette smokers (total n=56). In July 2019, we surveyed 999 smokers aged 18-69 years to quantify ever and current use of these products and associated beliefs and sensory experiences. RESULTS: Focus group and survey findings were consistent. Among 988 smokers who had at least tried factory-made cigarettes, 28.9% had tried FFCs and 11.1% currently smoked these, while 36.4% had tried RFCs and 7.5% currently smoked these. Smokers in both studies believed these filters may reduce harm and that FFCs increase appeal. In the survey, 58.9% of RFC triers agreed these hide the filter's brown stain and 48.9% agreed that RFCs keep harmful substances away from the mouth. Similarly, 58.4% of FFC triers agreed these trap more harmful substances than standard filters. Relative to standard filter cigarettes, more smokers experienced FFCs and RFCs as feeling clean (p=0.03) and more current FFC users experienced these as feeling smooth (p=0.01). CONCLUSION: RFCs and FFCs undermine plain packaging legislation, which aims to reduce appeal and minimise misperceptions about the relative harms of different tobacco products. Like other filter modifications, these filter variants should be disallowed. CI - (c) Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ. FAU - Wakefield, Melanie A AU - Wakefield MA AUID- ORCID: 0000-0002-6183-5699 AD - Centre for Behavioural Research in Cancer, Cancer Council Victoria, Melbourne, Victoria, Australia melanie.wakefield@cancervic.org.au. FAU - Dunstone, Kimberley AU - Dunstone K AUID- ORCID: 0000-0001-5362-2805 AD - Centre for Behavioural Research in Cancer, Cancer Council Victoria, Melbourne, Victoria, Australia. FAU - Brennan, Emily AU - Brennan E AUID- ORCID: 0000-0001-9779-0210 AD - Centre for Behavioural Research in Cancer, Cancer Council Victoria, Melbourne, Victoria, Australia. FAU - Vittiglia, Amanda AU - Vittiglia A AD - Centre for Behavioural Research in Cancer, Cancer Council Victoria, Melbourne, Victoria, Australia. FAU - Scollo, Michelle AU - Scollo M AD - Centre for Behavioural Research in Cancer, Cancer Council Victoria, Melbourne, Victoria, Australia. FAU - Durkin, Sarah J AU - Durkin SJ AUID- ORCID: 0000-0002-2795-6454 AD - Centre for Behavioural Research in Cancer, Cancer Council Victoria, Melbourne, Victoria, Australia. FAU - Hoek, Janet AU - Hoek J AUID- ORCID: 0000-0003-4362-1539 AD - Department of Public Health, University of Otago, Wellington, New Zealand. FAU - Thrasher, James AU - Thrasher J AD - University of South Carolina Arnold School of Public Health, Columbia, South Carolina, USA. FAU - Hatsukami, Dorothy AU - Hatsukami D AD - Department of Psychiatry, University of Minnesota, Minneapolis, Minnesota, USA. FAU - Benowitz, Neal AU - Benowitz N AD - School of Medicine, University of California San Francisco, San Francisco, California, USA. FAU - Samet, Jonathan M AU - Samet JM AUID- ORCID: 0000-0001-5676-9175 AD - Colorado School of Public Health, University of Colorado, Denver, Colorado, USA. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20201028 PL - England TA - Tob Control JT - Tobacco control JID - 9209612 SB - IM MH - Adult MH - Australia MH - Humans MH - Marketing MH - Product Packaging MH - *Smokers MH - *Tobacco Products OTO - NOTNLM OT - advertising and promotion OT - packaging and labelling OT - prevention OT - public policy OT - tobacco industry COIS- Competing interests: Outside the submitted work, NB reports personal fees from Pfizer and Achieve Life Sciences as a consultant, and from Tobacco litigation as an expert witness against tobacco companies. MAW, KD, EB, AV, MS and SJD report that they are employed by a non-profit organisation that conducts public health interventions, research and advocacy aimed at reducing the harms of tobacco in the community, especially those pertaining to cancer. JH, JT, DH and JMS have nothing to disclose. EDAT- 2020/10/30 06:00 MHDA- 2021/12/15 06:00 CRDT- 2020/10/29 05:41 PHST- 2020/02/26 00:00 [received] PHST- 2020/07/21 00:00 [revised] PHST- 2020/07/24 00:00 [accepted] PHST- 2020/10/30 06:00 [pubmed] PHST- 2021/12/15 06:00 [medline] PHST- 2020/10/29 05:41 [entrez] AID - tobaccocontrol-2020-055725 [pii] AID - 10.1136/tobaccocontrol-2020-055725 [doi] PST - ppublish SO - Tob Control. 2021 Nov;30(6):660-667. doi: 10.1136/tobaccocontrol-2020-055725. Epub 2020 Oct 28. PMID- 33115327 OWN - NLM STAT- MEDLINE DCOM- 20210217 LR - 20240330 IS - 1758-1095 (Electronic) IS - 0141-0768 (Print) IS - 0141-0768 (Linking) VI - 114 IP - 2 DP - 2021 Feb TI - Anger and confrontation during the COVID-19 pandemic: a national cross-sectional survey in the UK. PG - 77-90 LID - 10.1177/0141076820962068 [doi] AB - OBJECTIVES: To investigate factors associated with anger or confronting others due to COVID-19. DESIGN: Online cross-sectional survey. SETTING: Data were collected between 17 and 20 July 2020. PARTICIPANTS: A total of 2237 participants living in the UK aged 16-75 years. MAIN OUTCOME MEASURES: Reporting having had arguments, felt angry or fallen out with others because of COVID-19. Reporting having confronted or reported someone to the authorities, or that you had been confronted or reported to the authorities, for not wearing a face covering; not keeping your distance from others or being in too large a group; or alternatively following recommended measures too carefully. We used logistic regression analyses to identify factors associated with anger and confrontation. RESULTS: Most participants reported having had arguments, feeling angry or fallen out with others because of COVID-19 (56%, n = 1255). Twenty-two percent (n = 500) of participants reported that they had confronted or reported someone. Fourteen percent (n = 304) of participants reported that they had been confronted or reported by someone. Confronting someone, having been confronted and feeling angry or having had arguments were strongly associated with each other. Anger and confrontation were associated with younger age, greater likelihood of experiencing significant financial difficulties due to the pandemic, greater perceived risk of COVID-19 and getting information about COVID-19 from social media. CONCLUSIONS: Measures put in place to prevent the spread of COVID-19 have caused considerable strain. Increased support, clear messaging on the rationale for easing restrictions and combatting misinformation on social media may all help decrease tension. FAU - Smith, Louise E AU - Smith LE AUID- ORCID: 0000-0002-1277-2564 AD - Institute of Psychiatry, Psychology & Neuroscience, King's College London, London SE5 9RJ, UK. FAU - Duffy, Bobby AU - Duffy B AD - Faculty of Social Science & Public Policy, King's College London, London WC2B 2BG, UK. FAU - Moxham-Hall, Vivienne AU - Moxham-Hall V AD - Faculty of Social Science & Public Policy, King's College London, London WC2B 2BG, UK. FAU - Strang, Lucy AU - Strang L AD - Faculty of Social Science & Public Policy, King's College London, London WC2B 2BG, UK. FAU - Wessely, Simon AU - Wessely S AD - Institute of Psychiatry, Psychology & Neuroscience, King's College London, London SE5 9RJ, UK. FAU - Rubin, G James AU - Rubin GJ AD - Institute of Psychiatry, Psychology & Neuroscience, King's College London, London SE5 9RJ, UK. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20201028 PL - England TA - J R Soc Med JT - Journal of the Royal Society of Medicine JID - 7802879 SB - IM MH - Adolescent MH - Adult MH - Aged MH - *Anger MH - Attitude MH - *COVID-19/prevention & control/psychology MH - *Communicable Disease Control/methods MH - Cross-Sectional Studies MH - Female MH - Humans MH - *Interpersonal Relations MH - Logistic Models MH - Male MH - Middle Aged MH - *Pandemics MH - SARS-CoV-2 MH - Social Media MH - Surveys and Questionnaires MH - United Kingdom/epidemiology MH - Young Adult PMC - PMC7876655 OTO - NOTNLM OT - Government measures OT - community OT - conflict OT - corrosion OT - lockdown OT - tension EDAT- 2020/10/30 06:00 MHDA- 2021/02/18 06:00 PMCR- 2020/10/28 CRDT- 2020/10/29 05:28 PHST- 2020/10/30 06:00 [pubmed] PHST- 2021/02/18 06:00 [medline] PHST- 2020/10/29 05:28 [entrez] PHST- 2020/10/28 00:00 [pmc-release] AID - 10.1177_0141076820962068 [pii] AID - 10.1177/0141076820962068 [doi] PST - ppublish SO - J R Soc Med. 2021 Feb;114(2):77-90. doi: 10.1177/0141076820962068. Epub 2020 Oct 28. PMID- 33104162 OWN - NLM STAT- MEDLINE DCOM- 20220107 LR - 20220107 IS - 2168-6114 (Electronic) IS - 2168-6106 (Print) IS - 2168-6106 (Linking) VI - 181 IP - 1 DP - 2021 Jan 1 TI - Association of Therapies With Reduced Pain and Improved Quality of Life in Patients With Fibromyalgia: A Systematic Review and Meta-analysis. PG - 104-112 LID - 10.1001/jamainternmed.2020.5651 [doi] AB - IMPORTANCE: Fibromyalgia is a chronic condition that results in a significant burden to individuals and society. OBJECTIVE: To investigate the effectiveness of therapies for reducing pain and improving quality of life (QOL) in people with fibromyalgia. DATA SOURCES: Searches were performed in the MEDLINE, Cochrane, Embase, AMED, PsycInfo, and PEDro databases without language or date restrictions on December 11, 2018, and updated on July 15, 2020. STUDY SELECTION: All published randomized or quasi-randomized clinical trials that investigated therapies for individuals with fibromyalgia were screened for inclusion. DATA EXTRACTION AND SYNTHESIS: Two reviewers independently extracted data and assessed risk of bias using the 0 to 10 PEDro scale. Effect sizes for specific therapies were pooled using random-effects models. The quality of evidence was assessed using the Grading of Recommendations Assessment (GRADE) approach. MAIN OUTCOMES AND MEASURES: Pain intensity measured by the visual analog scale, numerical rating scales, and other valid instruments and QOL measured by the Fibromyalgia Impact Questionnaire. RESULTS: A total of 224 trials including 29 962 participants were included. High-quality evidence was found in favor of cognitive behavioral therapy (weighted mean difference [WMD], -0.9; 95% CI, -1.4 to -0.3) for pain in the short term and was found in favor of central nervous system depressants (WMD, -1.2 [95% CI, -1.6 to -0.8]) and antidepressants (WMD, -0.5 [95% CI, -0.7 to -0.4]) for pain in the medium term. There was also high-quality evidence in favor of antidepressants (WMD, -6.8 [95% CI, -8.5 to -5.2]) for QOL in the short term and in favor of central nervous system depressants (WMD, -8.7 [95% CI, -11.3 to -6.0]) and antidepressants (WMD, -3.5 [95% CI, -4.5 to -2.5]) in the medium term. However, these associations were small and did not exceed the minimum clinically important change (2 points on an 11-point scale for pain and 14 points on a 101-point scale for QOL). Evidence for long-term outcomes of interventions was lacking. CONCLUSIONS AND RELEVANCE: This systematic review and meta-analysis suggests that most of the currently available therapies for the management of fibromyalgia are not supported by high-quality evidence. Some therapies may reduce pain and improve QOL in the short to medium term, although the effect size of the associations might not be clinically important to patients. FAU - Mascarenhas, Rodrigo Oliveira AU - Mascarenhas RO AD - Department of Physiotherapy, Universidade Federal dos Vales do Jequitinhonha e Mucuri, Diamantina, Brazil. FAU - Souza, Mateus Bastos AU - Souza MB AD - Postgraduate Program in Rehabilitation and Functional Performance, Universidade Federal dos Vales do Jequitinhonha e Mucuri, Diamantina, Brazil. FAU - Oliveira, Murilo Xavier AU - Oliveira MX AD - Postgraduate Program in Rehabilitation and Functional Performance, Universidade Federal dos Vales do Jequitinhonha e Mucuri, Diamantina, Brazil. FAU - Lacerda, Ana Cristina AU - Lacerda AC AD - Postgraduate Program in Rehabilitation and Functional Performance, Universidade Federal dos Vales do Jequitinhonha e Mucuri, Diamantina, Brazil. FAU - Mendonca, Vanessa Amaral AU - Mendonca VA AD - Postgraduate Program in Rehabilitation and Functional Performance, Universidade Federal dos Vales do Jequitinhonha e Mucuri, Diamantina, Brazil. FAU - Henschke, Nicholas AU - Henschke N AD - Institute for Musculoskeletal Health, The University of Sydney School of Public Health, Sydney, New South Wales, Australia. FAU - Oliveira, Vinicius Cunha AU - Oliveira VC AD - Postgraduate Program in Rehabilitation and Functional Performance, Universidade Federal dos Vales do Jequitinhonha e Mucuri, Diamantina, Brazil. LA - eng PT - Journal Article PT - Meta-Analysis PT - Systematic Review PL - United States TA - JAMA Intern Med JT - JAMA internal medicine JID - 101589534 RN - 0 (Antidepressive Agents) RN - 0 (Central Nervous System Depressants) SB - IM CIN - Ann Intern Med. 2021 Mar;174(3):JC32. doi: 10.7326/ACPJ202103160-032. PMID: 33646839 CIN - JAMA Intern Med. 2021 Jul 1;181(7):1011-1012. doi: 10.1001/jamainternmed.2020.9293. PMID: 33683292 CIN - JAMA Intern Med. 2021 Jul 1;181(7):1011. doi: 10.1001/jamainternmed.2020.9276. PMID: 33683305 CIN - MMW Fortschr Med. 2021 Mar;163(5):32. doi: 10.1007/s15006-021-9728-7. PMID: 33710555 MH - Antidepressive Agents/therapeutic use MH - Central Nervous System Depressants/therapeutic use MH - Cognitive Behavioral Therapy MH - Fibromyalgia/*therapy MH - Humans MH - Quality of Life PMC - PMC7589080 COIS- Conflict of Interest Disclosures: None reported. EDAT- 2020/10/27 06:00 MHDA- 2022/01/08 06:00 PMCR- 2021/10/26 CRDT- 2020/10/26 12:10 PHST- 2020/10/27 06:00 [pubmed] PHST- 2022/01/08 06:00 [medline] PHST- 2020/10/26 12:10 [entrez] PHST- 2021/10/26 00:00 [pmc-release] AID - 2772354 [pii] AID - ioi200082 [pii] AID - 10.1001/jamainternmed.2020.5651 [doi] PST - ppublish SO - JAMA Intern Med. 2021 Jan 1;181(1):104-112. doi: 10.1001/jamainternmed.2020.5651. PMID- 33103608 OWN - NLM STAT- MEDLINE DCOM- 20211004 LR - 20211004 IS - 1545-0848 (Electronic) IS - 1055-0887 (Linking) VI - 39 IP - 2 DP - 2021 Apr-Jun TI - Reactions to the opioid epidemic: A text-mining analysis of tweets. PG - 183-188 LID - 10.1080/10550887.2020.1834812 [doi] AB - This study analyzed public reactions to the opioid epidemic using Twitter discourse. Methods: One month of unique tweets (n = 26,079) from July 23, 2018 to August 22, 2018 were identified using the keyword "opioid" in conjunction with the words "crisis, epidemic, misuse, prescription, and death." Twelve topics, each representing more than 1% of all tweets, together accounted for 17,206 (66%) of identified tweets. Results: The top four tweet topics (representing 38% of the total) addressed lawsuits and public policy, people who use opioids to treat persistent pain, programs to alleviate the opioid epidemic, and one specific initiative, the "#onelesspill" movement. The next seven topics (representing 27% of the total) addressed news articles relating to the opioid epidemic. The 12(th) topic was a book about the opioid crisis (1.7% of the total tweets). Conclusions: These tweets exhibited polarization of opinions with some people calling for tighter restrictions on opioids and others desperate to preserve their daily use of opioids for alleviation of illnesses characterized by persistent pain. Social media posts can help inform efforts to craft public policy and communication strategies to support optimal opioid stewardship. FAU - Rajesh, Kavya AU - Rajesh K AD - Department of Surgery and Perioperative Care, Dell Medical School, The University of Texas at Austin, Austin, TX, USA. FAU - Wilcox, Gary AU - Wilcox G AD - Center for Health Communication and Stan Richards School of Advertising and Public Relations, Moody College of Communication, The University of Texas at Austin, Austin, TX, USA; for Health Communication, Dell Medical School and Moody College of Communication and Stan Richards School of Advertising and Public Relations, The University of Texas at Austin, Austin, TX, USA. FAU - Ring, David AU - Ring D AD - Department of Surgery and Perioperative Care, Dell Medical School, The University of Texas at Austin, Austin, TX, USA. FAU - Mackert, Michael AU - Mackert M AD - Center for Health Communication and Stan Richards School of Advertising and Public Relations, Moody College of Communication, The University of Texas at Austin, Austin, TX, USA; for Health Communication, Dell Medical School and Moody College of Communication and Stan Richards School of Advertising and Public Relations, The University of Texas at Austin, Austin, TX, USA. LA - eng PT - Journal Article DEP - 20201026 PL - England TA - J Addict Dis JT - Journal of addictive diseases JID - 9107051 SB - IM MH - Data Mining/methods MH - Humans MH - *Opioid Epidemic MH - *Public Opinion MH - Social Media/*trends OTO - NOTNLM OT - Opioids OT - Twitter OT - addiction OT - chronic pain OT - social media EDAT- 2020/10/27 06:00 MHDA- 2021/10/05 06:00 CRDT- 2020/10/26 08:42 PHST- 2020/10/27 06:00 [pubmed] PHST- 2021/10/05 06:00 [medline] PHST- 2020/10/26 08:42 [entrez] AID - 10.1080/10550887.2020.1834812 [doi] PST - ppublish SO - J Addict Dis. 2021 Apr-Jun;39(2):183-188. doi: 10.1080/10550887.2020.1834812. Epub 2020 Oct 26. PMID- 33091331 OWN - NLM STAT- MEDLINE DCOM- 20210208 LR - 20210208 IS - 1840-4812 (Electronic) IS - 1512-8601 (Print) IS - 1512-8601 (Linking) VI - 21 IP - 1 DP - 2021 Feb 1 TI - SARS-CoV-2 virus outbreak and the emergency public health measures in Bosnia and Herzegovina: January - July, 2020. PG - 111-116 LID - 10.17305/bjbms.2020.5081 [doi] AB - Between March 5th and July 25th, 2020, the total number of SARS-CoV-2 confirmed cases in Bosnia and Herzegovina (BH) was 10,090, corresponding to a cumulative incidence rate of 285.7/100,000 population. Demographic and clinical information on all the cases along with exposure and contact information were collected using a standardized case report form. In suspected SARS-CoV-2 cases, respiratory specimens were collected and tested by real-time reverse-transcriptase polymerase chain reaction assay. The dynamic of the outbreak was summarized using epidemiological curves, instantaneous reproduction number Rt, and interactive choropleth maps for geographical distribution and spread. The rate of hospitalization was 14.0%(790/5646) in the Federation of Bosnia and Herzegovina (FBH) and 6.2% (267/4299) in the Republic of Srpska (RS). The death rate was 2.2% (122/5646) in FBH and 3.6% in the RS (155/4299). After the authorities lifted mandatory quarantine restrictions, the instantaneous reproduction number increased from 1.13 on May 20th to 1.72 on May 31st. The outbreak concerns both entities, FBH and RS, and it is more pronounced in those aged 20-44 years. It is important to develop the communication and emergency plan for the SARS-CoV-2 outbreak in BH, including the mechanisms to allow the ongoing notification and updates at the national level. FAU - Hukic, Mirsada AU - Hukic M AD - Department of Medical Sciences, Academy of Sciences and Arts of Bosnia and Herzegovina, Sarajevo, Bosnia and Herzegovina; Institute for Biomedical Diagnostic and Research NALAZ, Sarajevo, Bosnia and Herzegovina. FAU - Ponjavic, Mirza AU - Ponjavic M AD - GAUSS Centre for Geospatial Research Sarajevo, Sarajevo, Bosnia and Herzegovina; Faculty of Engineering and Natural Sciences, International Burch University, Sarajevo, Bosnia and Herzegovina. FAU - Tahirovic, Emin AU - Tahirovic E AD - Faculty of Engineering and Natural Sciences, International University of Sarajevo, Sarajevo, Bosnia and Herzegovina; South East European Network for Medical Research (SOVE), Sarajevo, Bosnia and Herzegovina; Epidemic Location Intelligence System (ELIS) Project of Academy of Sciences and Arts of Bosnia and Herzegovina. FAU - Karabegovic, Almir AU - Karabegovic A AD - GAUSS Centre for Geospatial Research Sarajevo, Sarajevo, Bosnia and Herzegovina; Faculty of Electrical Engineering, University of Sarajevo, Sarajevo, Bosnia and Herzegovina. FAU - Ferhatbegovic, Elvir AU - Ferhatbegovic E AD - GAUSS Centre for Geospatial Research Sarajevo, Sarajevo, Bosnia and Herzegovina; Epidemic Location Intelligence System (ELIS), Academy of Sciences and Arts of Bosnia and Herzegovina, Sarajevo, Bosnia and Herzegovina. FAU - Travar, Maja AU - Travar M AD - Epidemic Location Intelligence System (ELIS), Academy of Sciences and Arts of Bosnia and Herzegovina, Sarajevo, Bosnia and Herzegovina; Faculty of Medicine, University of Banja Luka, Banja Luka, Bosnia and Herzegovina; University Clinical Centre of the Republic of Srpska, Banja Luka, Bosnia and Herzegovina. FAU - Serdarevic, Fadila AU - Serdarevic F AD - South East European Network for Medical Research (SOVE), Sarajevo, Bosnia and Herzegovina; Epidemic Location Intelligence System (ELIS), Academy of Sciences and Arts of Bosnia and Herzegovina, Sarajevo, Bosnia and Herzegovina; Erasmus Medical Center, Erasmus University, Rotterdam, Netherlands; Faculty of Medicine, Sarajevo School of Science and Technology, Sarajevo, Bosnia and Herzegovina. LA - eng PT - Journal Article DEP - 20210201 PL - Bosnia and Herzegovina TA - Bosn J Basic Med Sci JT - Bosnian journal of basic medical sciences JID - 101200947 SB - IM MH - Adolescent MH - Adult MH - Aged MH - Aged, 80 and over MH - Basic Reproduction Number MH - Bosnia and Herzegovina/epidemiology MH - COVID-19/*epidemiology MH - Child MH - Child, Preschool MH - Disaster Planning MH - *Disease Outbreaks MH - Female MH - Geography MH - Hospitalization MH - Humans MH - Infant MH - Male MH - Middle Aged MH - Public Health/*methods MH - Quarantine MH - Real-Time Polymerase Chain Reaction MH - Reverse Transcriptase Polymerase Chain Reaction MH - Young Adult PMC - PMC7861623 COIS- Conflict of interests: The authors declare no conflict of interests. EDAT- 2020/10/23 06:00 MHDA- 2021/02/09 06:00 PMCR- 2021/02/01 CRDT- 2020/10/22 20:10 PHST- 2020/08/23 00:00 [received] PHST- 2020/10/16 00:00 [accepted] PHST- 2020/10/23 06:00 [pubmed] PHST- 2021/02/09 06:00 [medline] PHST- 2020/10/22 20:10 [entrez] PHST- 2021/02/01 00:00 [pmc-release] AID - BJBMS-21-111 [pii] AID - 10.17305/bjbms.2020.5081 [doi] PST - epublish SO - Bosn J Basic Med Sci. 2021 Feb 1;21(1):111-116. doi: 10.17305/bjbms.2020.5081. PMID- 33057981 OWN - NLM STAT- MEDLINE DCOM- 20210304 LR - 20240404 IS - 1878-7649 (Print) IS - 1878-7657 (Electronic) IS - 1878-7649 (Linking) VI - 12 IP - 1 DP - 2021 Feb TI - Unmet needs, health policies, and actions during the COVID-19 pandemic: a report from six European countries. PG - 193-204 LID - 10.1007/s41999-020-00415-x [doi] AB - PURPOSE: The United Nations (UN) has published a Policy Brief on the impact of the Coronavirus Disease 2019 (COVID-19) that identifies policies and responses to protect older adults. Our objective was to summarize actions, health policies and clinical guidelines adopted by six European countries (Belgium, France, Italy, Poland, Spain and United Kingdom) during the pandemic, and to assess the impact of national policies on reducing adverse effects of the COVID-19 pandemic in older populations. METHODS: Reports by geriatricians on the measures and actions undertaken by governmental institutions in each country between March and July 2020, as well as the role of primary care during the pandemic, covered three areas: (a) general health strategies related to the pandemic; (b) impact of COVID-19 on health inequity; and (c) initiatives and challenges for the COVID-19 pandemic and beyond. RESULTS: In the six countries, COVID-19 mortality in nursing homes ranged from 26 to 66%. Although all countries endorsed the World Health Organization general recommendations, the reports identified the lack of harmonized European guidelines and policies for nursing homes, with competencies transferred to national (or regional) governments. All countries restricted visits in nursing homes, but no specific action plans were provided. The role of primary care was limited by the centralization of the crisis in hospital settings. CONCLUSIONS: The older population has been greatly affected by COVID-19 and by the policies initiated to control its spread. The right to health and dignity are transgenerational; chronological age should not be the sole criterion in policy decisions. FAU - Miralles, Oriol AU - Miralles O AUID- ORCID: 0000-0002-7094-9153 AD - Geriatrics and Palliative Care Department, Hospital General de L'Hospitalet de Llobregat-Consorci Sanitari Integral, L'Hospitalet de Llobregat, Av. Josep Molins, 29 L'Hospitalet de Llobregat, 08906, Barcelona, Spain. o.mirallesresina@gmail.com. FAU - Sanchez-Rodriguez, Dolores AU - Sanchez-Rodriguez D AD - Clinical Research Unit, CHU Brugmann, Brussels, Belgium. AD - WHO Collaborating Centre for Public Health Aspects of Musculo-Skeletal Health and Aging, Division of Public Health, Epidemiology and Health Economics, University of Liege, Liege, Belgium. AD - Geriatrics Department, Rehabilitation Research Group, Hospital Del Mar Medical Research Institute (IMIM), Universitat Pompeu Fabra, Barcelona, Spain. FAU - Marco, Esther AU - Marco E AD - Physical Medicine and Rehabilitation Departament, Parc de Salut Mar. Hospital del Mar Research Institute (IMIM), Universitat Autonoma de Barcelona, Barcelona, Spain. FAU - Annweiler, Cedric AU - Annweiler C AD - Department of Geriatric Medicine and Memory Clinic, Research Center on Autonomy and Longevity, University Hospital, Angers, France. AD - UPRES EA 4638, University of Angers, Angers, France. AD - Department of Medical Biophysics, Schulich School of Medicine and Dentistry, Robarts Research Institute, The University of Western Ontario, London, ON, Canada. FAU - Baztan, Ainhoa AU - Baztan A AD - Primary Care Center La Florida, Costa Ponent Unit, Institut Catala de La Salut, Catalan Health Institute, L'Hospitalet de Llobregat, Barcelona, Spain. FAU - Betancor, Evora AU - Betancor E AD - Geriatrics and Palliative Care Department, Hospital General de L'Hospitalet de Llobregat-Consorci Sanitari Integral, L'Hospitalet de Llobregat, Av. Josep Molins, 29 L'Hospitalet de Llobregat, 08906, Barcelona, Spain. FAU - Cambra, Alicia AU - Cambra A AD - Geriatrics and Palliative Care Department, Hospital General de L'Hospitalet de Llobregat-Consorci Sanitari Integral, L'Hospitalet de Llobregat, Av. Josep Molins, 29 L'Hospitalet de Llobregat, 08906, Barcelona, Spain. FAU - Cesari, Matteo AU - Cesari M AD - Geriatric Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy. AD - Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy. FAU - Fontecha, Benito J AU - Fontecha BJ AD - Geriatrics and Palliative Care Department, Hospital General de L'Hospitalet de Llobregat-Consorci Sanitari Integral, L'Hospitalet de Llobregat, Av. Josep Molins, 29 L'Hospitalet de Llobregat, 08906, Barcelona, Spain. FAU - Gasowski, Jerzy AU - Gasowski J AD - Department of Internal Medicine and Gerontology, Faculty of Medicine, Medical College, Jagiellonian University, Krakow, Poland. FAU - Gillain, Sophie AU - Gillain S AD - Geriatrics Department, Liege University Hospital, University of Liege, Liege, Belgium. FAU - Hope, Suzy AU - Hope S AD - Department of Healthcare for Older People, Royal Devon & Exeter NHS Foundation Trust, Exeter, UK. AD - College of Medicine and Health, University of Exeter, Exeter, UK. FAU - Phillips, Katie AU - Phillips K AD - Beacon Medical Centre, Sidmouth, Devon, UK. FAU - Piotrowicz, Karolina AU - Piotrowicz K AD - Department of Internal Medicine and Gerontology, Faculty of Medicine, Medical College, Jagiellonian University, Krakow, Poland. FAU - Piro, Niccolo AU - Piro N AD - Geriatric Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy. FAU - Sacco, Guillaume AU - Sacco G AD - Department of Geriatric Medicine and Memory Clinic, Research Center on Autonomy and Longevity, University Hospital, Angers, France. AD - UPRES EA 4638, University of Angers, Angers, France. FAU - Saporiti, Edoardo AU - Saporiti E AD - Geriatric Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy. FAU - Surquin, Murielle AU - Surquin M AD - Beacon Medical Centre, Sidmouth, Devon, UK. AD - Geriatrics Department, CHU Brugmann, Universite Libre de Bruxelles, Brussels, Belgium. FAU - Vall-Llosera, Estel AU - Vall-Llosera E AD - Geriatrics and Palliative Care Department, Hospital General de L'Hospitalet de Llobregat-Consorci Sanitari Integral, L'Hospitalet de Llobregat, Av. Josep Molins, 29 L'Hospitalet de Llobregat, 08906, Barcelona, Spain. LA - eng PT - Journal Article PT - Review DEP - 20201015 PL - Switzerland TA - Eur Geriatr Med JT - European geriatric medicine JID - 101533694 SB - IM EIN - Eur Geriatr Med. 2021 Jun;12(3):667. doi: 10.1007/s41999-021-00476-6. PMID: 33751455 MH - Aged MH - Aged, 80 and over MH - *Ageism MH - *COVID-19/mortality/therapy MH - Europe MH - Geriatrics MH - *Health Policy MH - *Health Services Needs and Demand MH - Humans MH - Nursing Homes MH - Pandemics MH - Practice Guidelines as Topic MH - SARS-CoV-2 PMC - PMC7557304 OTO - NOTNLM OT - Ageism OT - COVID-19 OT - Geriatrics OT - Health policies OT - Older people OT - SARS-CoV-2 COIS- The author declares that they have no cometing of interest. EDAT- 2020/10/16 06:00 MHDA- 2021/03/05 06:00 PMCR- 2020/10/15 CRDT- 2020/10/15 17:39 PHST- 2020/07/15 00:00 [received] PHST- 2020/09/29 00:00 [accepted] PHST- 2020/10/16 06:00 [pubmed] PHST- 2021/03/05 06:00 [medline] PHST- 2020/10/15 17:39 [entrez] PHST- 2020/10/15 00:00 [pmc-release] AID - 10.1007/s41999-020-00415-x [pii] AID - 415 [pii] AID - 10.1007/s41999-020-00415-x [doi] PST - ppublish SO - Eur Geriatr Med. 2021 Feb;12(1):193-204. doi: 10.1007/s41999-020-00415-x. Epub 2020 Oct 15. PMID- 33038555 OWN - NLM STAT- MEDLINE DCOM- 20210111 LR - 20210414 IS - 1878-3511 (Electronic) IS - 1201-9712 (Print) IS - 1201-9712 (Linking) VI - 102 DP - 2021 Jan TI - Spatial variability in reproduction number and doubling time across two waves of the COVID-19 pandemic in South Korea, February to July, 2020. PG - 1-9 LID - S1201-9712(20)32210-4 [pii] LID - 10.1016/j.ijid.2020.10.007 [doi] AB - OBJECTIVES: In South Korea, 13 745 cases of coronavirus disease (COVID-19) had been reported as of 19 July, 2020. To examine spatiotemporal changes in the transmission potential, we aimed to present regional estimates of the doubling time and reproduction number (R(t)) for COVID-19 in the country. METHODS: Daily series of confirmed COVID-19 cases in the most affected regions were extracted from publicly available sources. We employed established mathematical and statistical methods to investigate the time-varying reproduction numbers and doubling time for COVID-19 in Korea. RESULTS: At the regional level, Seoul and Gyeonggi Province experienced the first peak of COVID-19 in early March, followed by a second wave in early June, withR(t) exceeding 3.0 and mean doubling time ranging from 3.6 to 10.1 days. As of 19 July, 2020, Gyeongbuk Province and Daegu had yet to experience a second wave of the disease. During the first wave, mean R(t) for these areas reached 3.5-4.4, and doubling time ranged from 2.8 to 4.6 days. CONCLUSIONS: Our findings support the effectiveness of control measures against COVID-19 in Korea. However, the easing of restrictions that had been imposed by the government in May 2020 facilitated a second wave in the greater Seoul area. CI - Copyright (c) 2020 The Author(s). Published by Elsevier Ltd.. All rights reserved. FAU - Shim, Eunha AU - Shim E AD - Department of Mathematics, Soongsil University, 369 Sangdoro, Dongjak-Gu, Seoul, 06978, Republic of Korea. Electronic address: alicia@ssu.ac.kr. FAU - Tariq, Amna AU - Tariq A AD - Department of Population Health Sciences, School of Public Health, Georgia State University, Atlanta, GA, USA. Electronic address: atariq1@student.gsu.edu. FAU - Chowell, Gerardo AU - Chowell G AD - Department of Population Health Sciences, School of Public Health, Georgia State University, Atlanta, GA, USA. Electronic address: gchowell@gsu.edu. LA - eng PT - Journal Article DEP - 20201008 PL - Canada TA - Int J Infect Dis JT - International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases JID - 9610933 SB - IM MH - Age Factors MH - Basic Reproduction Number MH - COVID-19/*epidemiology/prevention & control/transmission MH - *Communicable Disease Control MH - Female MH - Humans MH - Models, Biological MH - Pandemics/prevention & control MH - Republic of Korea/epidemiology MH - SARS-CoV-2/physiology MH - Seoul/epidemiology MH - Time Factors PMC - PMC7543697 OTO - NOTNLM OT - COVID-19 OT - Coronavirus OT - Reproduction number OT - Republic of Korea OT - Seoul OT - Social distancing EDAT- 2020/10/11 06:00 MHDA- 2021/01/12 06:00 PMCR- 2020/10/08 CRDT- 2020/10/10 20:10 PHST- 2020/08/30 00:00 [received] PHST- 2020/10/01 00:00 [revised] PHST- 2020/10/03 00:00 [accepted] PHST- 2020/10/11 06:00 [pubmed] PHST- 2021/01/12 06:00 [medline] PHST- 2020/10/10 20:10 [entrez] PHST- 2020/10/08 00:00 [pmc-release] AID - S1201-9712(20)32210-4 [pii] AID - 10.1016/j.ijid.2020.10.007 [doi] PST - ppublish SO - Int J Infect Dis. 2021 Jan;102:1-9. doi: 10.1016/j.ijid.2020.10.007. Epub 2020 Oct 8. PMID- 33023714 OWN - NLM STAT- MEDLINE DCOM- 20211025 LR - 20230209 IS - 1475-2727 (Electronic) IS - 1368-9800 (Print) IS - 1368-9800 (Linking) VI - 24 IP - 10 DP - 2021 Jul TI - Low adherence to traditional dietary pattern and food preferences of low-income preschool children with food neophobia. PG - 2859-2866 LID - 10.1017/S1368980020003912 [doi] AB - OBJECTIVE: To associate dietary patterns and food neophobia in low-income preschoolers. DESIGN: This was a cross-sectional study using a semi-structured questionnaire for socio-demographic data, birth conditions and breast-feeding history. Food neophobia was assessed using an adapted version of the Child Food Neophobia Scale. Children's nutritional status was assessed using BMI-for-age and height-for-age Z-scores. Dietary patterns were estimated using a semi-quantitative FFQ through exploratory factor analysis. Multiple linear regression was used to test for an association between food neophobia and dietary pattern adherence. SETTING: Philanthropic childhood education schools in Aracaju, an urban community in northeastern Brazil, between July and December 2017. PARTICIPANTS: Two hundred fourteen children aged 3-6 years and their parents. RESULTS: The percentages of low/medium and high food neophobia among preschoolers were 85.9 % and 11.2 %, respectively. Children with high food neophobia more frequently consumed ultra-processed foods rich in sugars (snacks, filled and unfilled cookies and sweets), as well as protein-rich foods (white meat, cheese and yogurt). Three dietary patterns were identified (traditional, snacks and school snacks). Children with a high level of neophobia had lower adherence to traditional dietary patterns. CONCLUSIONS: A high level of food neophobia among socially vulnerable preschoolers is an eating behaviour related to unhealthy eating and is associated with the poorest diet in typical foods. FAU - Anjos, Lais Andrade Dos AU - Anjos LAD AUID- ORCID: 0000-0002-5065-0111 AD - Federal University of Sergipe (UFS), Department of Nutrition (DNUT), Graduate Program in Nutrition Sciences (PPGCNUT), Avenue Marechal Rondon, s/n, Jardim Rosa Elze, Sao Cristovao, SE49.100-000, Brazil. FAU - Vieira, Diva Aliete Dos Santos AU - Vieira DADS AD - Federal University of Sergipe (UFS), Department of Nutrition (DNUTL), Lagarto, SE, Brazil. FAU - Siqueira, Bruna Nabuco Freire AU - Siqueira BNF AD - Federal University of Sergipe (UFS), Department of Nutrition (DNUT), Graduate Program in Nutrition Sciences (PPGCNUT), Avenue Marechal Rondon, s/n, Jardim Rosa Elze, Sao Cristovao, SE49.100-000, Brazil. FAU - Voci, Silvia Maria AU - Voci SM AD - Federal University of Sergipe (UFS), Department of Nutrition (DNUT), Graduate Program in Nutrition Sciences (PPGCNUT), Avenue Marechal Rondon, s/n, Jardim Rosa Elze, Sao Cristovao, SE49.100-000, Brazil. FAU - Botelho, Anne Jardim AU - Botelho AJ AD - Federal University of Sergipe (UFS), School Hospital, Graduate Program in Health Sciences (PPGCS), Aracaju, SE, Brazil. FAU - Silva, Danielle Goes da AU - Silva DGD AD - Federal University of Sergipe (UFS), Department of Nutrition (DNUT), Graduate Program in Nutrition Sciences (PPGCNUT), Avenue Marechal Rondon, s/n, Jardim Rosa Elze, Sao Cristovao, SE49.100-000, Brazil. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20201007 PL - England TA - Public Health Nutr JT - Public health nutrition JID - 9808463 SB - IM MH - *Avoidant Restrictive Food Intake Disorder MH - Child MH - Child, Preschool MH - Cross-Sectional Studies MH - Diet MH - Feeding Behavior MH - *Food Preferences MH - Humans PMC - PMC9884771 OTO - NOTNLM OT - Dietary patterns OT - Feeding difficulties OT - Food neophobia OT - Preschool children EDAT- 2020/10/08 06:00 MHDA- 2021/10/26 06:00 PMCR- 2020/10/07 CRDT- 2020/10/07 05:34 PHST- 2020/10/08 06:00 [pubmed] PHST- 2021/10/26 06:00 [medline] PHST- 2020/10/07 05:34 [entrez] PHST- 2020/10/07 00:00 [pmc-release] AID - S1368980020003912 [pii] AID - 10.1017/S1368980020003912 [doi] PST - ppublish SO - Public Health Nutr. 2021 Jul;24(10):2859-2866. doi: 10.1017/S1368980020003912. Epub 2020 Oct 7. PMID- 33020970 OWN - NLM STAT- MEDLINE DCOM- 20211124 LR - 20211124 IS - 1099-1557 (Electronic) IS - 1053-8569 (Linking) VI - 30 IP - 2 DP - 2021 Feb TI - Phosphodiesterase type 5 inhibitor use among pregnant and reproductive-age women in the United States. PG - 126-134 LID - 10.1002/pds.5112 [doi] AB - PURPOSE: To assess the prevalence and potential indications of PDE5 inhibitor use among pregnant and reproductive-age women in the United States. METHODS: We identified women 15 to 50 years with a livebirth from January 2001 through March 2018 in Sentinel Database. We assessed the prevalence of PDE5 inhibitor use prior to and during pregnancy by trimester, identified potential on- and off-label indications using predefined diagnosis codes recorded within 90 days before the estimated last menstrual period through delivery. Separately, we used data from IQVIA's National Prescription Audit and Total Patient Tracker to estimate the dispensed prescriptions for PDE5 inhibitors and the number of patients with PDE5 inhibitor prescriptions. RESULTS: We identified approximately 3.3 million pregnancies during 2001 to 2018, 96 of which had PDE5 inhibitor use during pregnancy. Prevalence of PDE5 inhibitor use was 2.61, 0.62, and 0.62 per 100, 000 live-born pregnancies during the first, second, or third trimesters, respectively. Among women exposed to a PDE5 inhibitor from 90 days before conception to the end of pregnancy, 25.0%, 31.1%, and 15.5% had a diagnosis code for fetal growth restriction, preeclampsia, and pulmonary arterial hypertension. In IQVIA data, an estimated 223, 000 prescriptions from July 2015 through June 2018 and 58, 000 women received prescriptions for PDE5 inhibitors in 2017, of whom approximately 15, 000 (26%) were aged 15 to 50 years. CONCLUSION: We found a low prevalence of PDE5 inhibitor use in pregnant and reproductive-age women. Given the very low prevalence of use and the inconsistency of neonatal mortality data across STRIDER centers, the risk to public health is low at present. CI - (c) 2020 John Wiley & Sons Ltd. FAU - Liu, Wei AU - Liu W AUID- ORCID: 0000-0002-0434-4674 AD - Division of Epidemiology, Office of Pharmacovigilance and Epidemiology, Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA. FAU - Menzin, Talia J AU - Menzin TJ AD - Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, Massachusetts, USA. FAU - Woods, Corinne M AU - Woods CM AUID- ORCID: 0000-0002-3385-3881 AD - Division of Epidemiology, Office of Pharmacovigilance and Epidemiology, Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA. FAU - Haug, Nicole R AU - Haug NR AD - Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, Massachusetts, USA. FAU - Li, Jie AU - Li J AD - Division of Epidemiology, Office of Pharmacovigilance and Epidemiology, Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA. FAU - Mathew, Justin A AU - Mathew JA AD - Division of Epidemiology, Office of Pharmacovigilance and Epidemiology, Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA. FAU - Nguyen, Christine P AU - Nguyen CP AD - Division of Bone, Reproductive, and Urologic Products, Office of New Drugs, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA. FAU - Chai, Grace P AU - Chai GP AD - Division of Epidemiology, Office of Pharmacovigilance and Epidemiology, Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA. FAU - Moeny, David G AU - Moeny DG AD - Division of Epidemiology, Office of Pharmacovigilance and Epidemiology, Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA. FAU - Shinde, Mayura AU - Shinde M AD - Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, Massachusetts, USA. LA - eng GR - HHSF2232009100061/FD/FDA HHS/United States PT - Journal Article PT - Research Support, U.S. Gov't, P.H.S. DEP - 20201005 PL - England TA - Pharmacoepidemiol Drug Saf JT - Pharmacoepidemiology and drug safety JID - 9208369 RN - 0 (Phosphodiesterase 5 Inhibitors) SB - IM MH - Databases, Factual MH - Female MH - Fetal Growth Retardation MH - Humans MH - Infant, Newborn MH - *Phosphodiesterase 5 Inhibitors MH - Pregnancy MH - Pregnancy Trimesters MH - *Prescriptions MH - United States/epidemiology OTO - NOTNLM OT - FDA OT - Sentinel OT - drug utilization OT - fetal growth restriction OT - off-label drug use OT - pharmacoepidemiology OT - phosphodiesterase type-5 inhibitor OT - pregnancy EDAT- 2020/10/07 06:00 MHDA- 2021/11/25 06:00 CRDT- 2020/10/06 05:35 PHST- 2019/11/13 00:00 [received] PHST- 2020/08/11 00:00 [revised] PHST- 2020/08/17 00:00 [accepted] PHST- 2020/10/07 06:00 [pubmed] PHST- 2021/11/25 06:00 [medline] PHST- 2020/10/06 05:35 [entrez] AID - 10.1002/pds.5112 [doi] PST - ppublish SO - Pharmacoepidemiol Drug Saf. 2021 Feb;30(2):126-134. doi: 10.1002/pds.5112. Epub 2020 Oct 5. PMID- 32990782 OWN - NLM STAT- MEDLINE DCOM- 20210315 LR - 20210315 IS - 1432-0711 (Electronic) IS - 0932-0067 (Linking) VI - 303 IP - 2 DP - 2021 Feb TI - Comparison of maternal and fetal outcomes between delayed and immediate pushing in the second stage of vaginal delivery: systematic review and meta-analysis of randomized controlled trials. PG - 481-499 LID - 10.1007/s00404-020-05814-w [doi] AB - BACKGROUND: The second stage of labor begins with complete dilatation of the cervix until delivery of the fetus. After the cervix has fully dilated, the caregiver/nurse will provide guidance to the mother regarding the push technique for delivering the fetus (immediate pushing, IP). Because some women receive analgesic medications during labor, they might not be able to push correctly. Therefore, some obstetricians choose to postpone guiding the patient to push until the cervix is fully dilated and the fetal head has begun to descend. At this point, there is an involuntary exertion sensation (delayed pushing, DP) that saves energy and, at the same time, decreases tiredness and fatigue. The best timing for pushing during the second stage of labor is still controversial. The aim of this study was to investigate the different maternal and neonatal outcomes with IP and DP in the second stage of labor. METHODS: The Cochrane Library, EMBASE, PubMed, and Airiti Library (a Chinese database) were searched up to July 2019. Search keywords included: "labor stage, second", "delayed pushing", and "immediate pushing". Gray literature and bibliographies of articles were checked. No language restrictions were applied. Only randomized controlled trials were included. Two independent reviewers identified relevant studies and extracted data. The quality of the studies was assessed using the Cochrane's Risk of Bias tool. A random-effects meta-analysis was used to pool results. Mean differences and risk ratios were calculated with 95% confidence intervals (CIs) using Review Manager 5.3 (The Nordic Cochrane Centre, Copenhagen, Denmark, 2014). The risk of heterogeneity was reported as I(2), and publication bias was visually assessed by funnel plots. RESULTS: In total, 15 studies (n = 6121 participants) were identified. Pooled results demonstrated the following. (1) As to maternal outcomes, in comparison, IP shortened the length of the second stage of labor by 40.9 (95% CI 23.6-58.2) min; however, DP decreased the total length of pushing by 25.4 (95% CI 13.9-37.0) min. The incidence of instrument-assisted vaginal delivery was significantly lower in the DP group in western countries (RR 0.85, 95% CI 0.74-0.97). In addition, the maternal postpartum fatigue score was 0.67 points lower in the DP group (95% CI - 1.09 to - 0.26). There was no statistical significance of the cesarean section rate or blood loss. (2) As to neonatal outcomes (Apgar score at 1 min), the DP group showed a higher score (by 0.19; 95% CI 0.10-0.27 points) than the IP group. CONCLUSIONS: Delayed pushing can decrease the total pushing time and decrease the fatigue score after delivery without significant adverse events compared to the early pushing group. Therefore, we recommend that caregivers instruct the pushing time at the optimal moment, which allows women to have more resting time and save energy during labor. FAU - Szu, Li-Ting AU - Szu LT AD - Center for Nursing and Healthcare Research in Clinical Practice Application, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan. AD - Department of Nursing, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan. FAU - Chou, Pao-Yu AU - Chou PY AD - Center for Nursing and Healthcare Research in Clinical Practice Application, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan. AD - Department of Nursing, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan. FAU - Lin, Pu-Hung AU - Lin PH AD - Center for Nursing and Healthcare Research in Clinical Practice Application, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan. AD - Department of Nursing, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan. FAU - Chen, Chiehfeng AU - Chen C AD - Division of Plastic Surgery, Department of Surgery and Evidence-Based Medicine Center, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan. AD - Department of Public Health, School of Medicine, College of Medicine and Cochrane Taiwan, Taipei Medical University, Taipei, Taiwan. AD - Cochrane Taiwan, Taipei Medical University, Taipei, Taiwan. FAU - Lin, Wei-Lin AU - Lin WL AD - Department of Obstetrics and Gynecology, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan. clin823@gmail.com. FAU - Chen, Kee-Hsin AU - Chen KH AUID- ORCID: 0000-0001-9772-482X AD - Center for Nursing and Healthcare Research in Clinical Practice Application, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan. keehsin@tmu.edu.tw. AD - Department of Nursing, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan. keehsin@tmu.edu.tw. AD - Post-Baccalaureate Program in Nursing, College of Nursing, Taipei Medical University, Taipei, Taiwan. keehsin@tmu.edu.tw. AD - Cochrane Taiwan, Taipei Medical University, Taipei, Taiwan. keehsin@tmu.edu.tw. AD - Evidence-Based Knowledge Translation Center, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan. keehsin@tmu.edu.tw. LA - eng PT - Journal Article PT - Meta-Analysis PT - Research Support, Non-U.S. Gov't PT - Systematic Review DEP - 20200929 PL - Germany TA - Arch Gynecol Obstet JT - Archives of gynecology and obstetrics JID - 8710213 SB - IM MH - Adult MH - Cesarean Section/statistics & numerical data MH - Delivery, Obstetric/*methods/statistics & numerical data MH - Extraction, Obstetrical/statistics & numerical data MH - Female MH - Humans MH - Labor Stage, Second/*physiology MH - Parturition MH - Pregnancy MH - Prenatal Care MH - *Randomized Controlled Trials as Topic MH - Time Factors OTO - NOTNLM OT - Delayed pushing OT - Immediate pushing OT - Second stage of delivery OT - Vaginal delivery EDAT- 2020/09/30 06:00 MHDA- 2021/03/16 06:00 CRDT- 2020/09/29 12:37 PHST- 2020/06/09 00:00 [received] PHST- 2020/09/18 00:00 [accepted] PHST- 2020/09/30 06:00 [pubmed] PHST- 2021/03/16 06:00 [medline] PHST- 2020/09/29 12:37 [entrez] AID - 10.1007/s00404-020-05814-w [pii] AID - 10.1007/s00404-020-05814-w [doi] PST - ppublish SO - Arch Gynecol Obstet. 2021 Feb;303(2):481-499. doi: 10.1007/s00404-020-05814-w. Epub 2020 Sep 29. PMID- 32936428 OWN - NLM STAT- MEDLINE DCOM- 20210520 LR - 20220218 IS - 1573-3610 (Electronic) IS - 0094-5145 (Print) IS - 0094-5145 (Linking) VI - 46 IP - 3 DP - 2021 Jun TI - Mass Events Trigger Malta's Second Peak After Initial Successful Pandemic Suppression. PG - 618-625 LID - 10.1007/s10900-020-00925-6 [doi] AB - The second COVID-19 wave is sweeping the globe as restrictions are lifted. Malta, the 'poster child of Europe's COVID-19 first wave success' also fell victim shortly after it welcomed the first tourists on 1st of July 2020. Only four positive cases were reported over the successive 15 days. Stability was disrupted when two major mass events were organized despite various health professional warnings. In a matter of few just days, daily cases rose to two-digit figures, with high community transmission, a drastic rise in active cases, and a rate per hundred thousand in Europe second only to Spain. Frontliners were swamped with swabbing requests while trying to sustain robust case management, contact tracing and follow-up. Indeed, the number of hospitalizations and the need for intensive ventilation increased. Despite the initial cases were among young adults, within weeks a small spill off on the more elderly population was observed. Restrictions were re-introduced including mandatory mask wearing in specific locations and capping of the total number of people in a single gathering. Malta is an island and the potential for containment would have been relatively simple and effective and permitting mass gatherings was unwise. Protecting the health of the population should take centre stage while carrying out extensive testing, contact tracing and surveillance. Containment and mitigation along with public cooperation is the key to curbing resurgences especially with the influenza season around the corner. FAU - Cuschieri, Sarah AU - Cuschieri S AUID- ORCID: 0000-0003-2012-9234 AD - Department of Anatomy, Faculty of Medicine & Surgery, University of Malta, Rm 425, Biomedical Building, Msida, Malta. sarah.cuschieri@um.edu.mt. FAU - Balzan, Martin AU - Balzan M AD - Department of Respiratory, Mater Dei Hospital, Msida, Malta. FAU - Gauci, Charmaine AU - Gauci C AD - Health Regulations, Office of the Superintendence of Public Health, Pieta, Malta. FAU - Aguis, Steve AU - Aguis S AD - Chief Operating Officer (COO), Mater Dei Hospital, Msida, Malta. FAU - Grech, Victor AU - Grech V AD - Department of Pediatrics, Mater Dei Hospital, Msida, Malta. LA - eng PT - Journal Article DEP - 20200916 PL - Netherlands TA - J Community Health JT - Journal of community health JID - 7600747 SB - IM MH - Adolescent MH - Adult MH - Aged MH - COVID-19/*epidemiology/prevention & control/*transmission MH - Contact Tracing MH - *Crowding MH - Humans MH - Malta/epidemiology MH - *Pandemics/prevention & control MH - Public Health Surveillance MH - Young Adult PMC - PMC7493701 OTO - NOTNLM OT - Coronavirus OT - Economy OT - Malta OT - Pandemics OT - Population health OT - Population surveillance OT - Prevention COIS- Authors declare no conflict of interests. EDAT- 2020/09/17 06:00 MHDA- 2021/05/21 06:00 PMCR- 2020/09/16 CRDT- 2020/09/16 12:16 PHST- 2020/09/10 00:00 [accepted] PHST- 2020/09/17 06:00 [pubmed] PHST- 2021/05/21 06:00 [medline] PHST- 2020/09/16 12:16 [entrez] PHST- 2020/09/16 00:00 [pmc-release] AID - 10.1007/s10900-020-00925-6 [pii] AID - 925 [pii] AID - 10.1007/s10900-020-00925-6 [doi] PST - ppublish SO - J Community Health. 2021 Jun;46(3):618-625. doi: 10.1007/s10900-020-00925-6. Epub 2020 Sep 16. PMID- 32863193 OWN - NLM STAT- MEDLINE DCOM- 20211215 LR - 20211215 IS - 2152-2669 (Electronic) IS - 2152-2669 (Linking) VI - 21 IP - 1 DP - 2021 Jan TI - Effect of Dose Ratio on Mitoxantrone and Daunorubicin in Acute Myeloid Leukemia: A Systematic Review and Meta-analysis of Randomized Controlled Trials. PG - e10-e20 LID - S2152-2650(20)30378-5 [pii] LID - 10.1016/j.clml.2020.08.001 [doi] AB - PURPOSE: To investigate the effects of mitoxantrone and daunorubicin in induced chemotherapy on complete remission (CR), death during induction therapy, overall survival (OS), disease-free survival (DFS), and relapse in patients of all ages with acute myeloid leukemia (AML). METHODS: We searched published reports at the Medline, Embase, and Cochrane Databases as well as other databases from inception through July 2019. There was no restriction on date of publication or language (PROSPERO registration CRD42018095843). RESULTS: We enrolled 12 randomized controlled trials that included data of 4583 AML patients whose disease was untreated or relapsed/refractory, and compared the CR, death during induction therapy, DFS, and OS between mitoxantrone and daunorubicin. Mitoxantrone significantly increased the CR rate (relative risk = 1.07; 95% confidence interval [CI], 1.01, 1.14; P = .03) and DFS (hazard ratio = 0.87; 95% CI, 0.79, 0.96; P = .005) compared to daunorubicin. However, there was no significant difference in death during induction therapy (relative risk = 1.00; 95% CI, 0.81, 1.24; P = .99) and OS (hazard ratio = 0.94; 95% CI, 0.87, 1.01; P = .077) between the two drugs. CONCLUSION: Although more studies are needed to compare mitoxantrone with higher-dose daunorubicin, the results showed that compared to daunorubicin, mitoxantrone can significantly improve CR and DFS in patients of all ages. These findings suggest that mitoxantrone may be a better choice than daunorubicin as an induction chemotherapy agent for AML patients, especially in developing countries. CI - Copyright (c) 2020 Elsevier Inc. All rights reserved. FAU - Deng, Lei AU - Deng L AD - The 960th Hospital of the PLA Joint Logistics Support Force, Jinan, China. FAU - Zhang, Changjian AU - Zhang C AD - The Sixth Medical Center of Chinese PLA General Hospital, Beijing, China. FAU - Ying, Sunyang AU - Ying S AD - University of Chinese Academy of Sciences, Beijing, China. FAU - Cai, Bo AU - Cai B AD - The Fifth Medical Center of Chinese PLA General Hospital, Beijing, China. FAU - Zhou, Fang AU - Zhou F AD - The 960th Hospital of the PLA Joint Logistics Support Force, Jinan, China. Electronic address: zhoufang1@medmail.com.cn. LA - eng PT - Journal Article PT - Meta-Analysis PT - Research Support, Non-U.S. Gov't PT - Systematic Review DEP - 20200806 PL - United States TA - Clin Lymphoma Myeloma Leuk JT - Clinical lymphoma, myeloma & leukemia JID - 101525386 RN - BZ114NVM5P (Mitoxantrone) RN - ZS7284E0ZP (Daunorubicin) SB - IM MH - Adult MH - Antineoplastic Combined Chemotherapy Protocols/pharmacology/*therapeutic use MH - Daunorubicin/pharmacology/*therapeutic use MH - Female MH - Humans MH - Leukemia, Myeloid, Acute/*drug therapy MH - Male MH - Middle Aged MH - Mitoxantrone/pharmacology/*therapeutic use MH - Randomized Controlled Trials as Topic/*methods OTO - NOTNLM OT - Acute myeloid leukemia OT - Daunorubicin OT - Dose Ratio OT - Mitoxantrone OT - Randomized controlled trials EDAT- 2020/08/31 06:00 MHDA- 2021/12/16 06:00 CRDT- 2020/09/01 06:00 PHST- 2020/07/06 00:00 [received] PHST- 2020/08/01 00:00 [revised] PHST- 2020/08/03 00:00 [accepted] PHST- 2020/08/31 06:00 [pubmed] PHST- 2021/12/16 06:00 [medline] PHST- 2020/09/01 06:00 [entrez] AID - S2152-2650(20)30378-5 [pii] AID - 10.1016/j.clml.2020.08.001 [doi] PST - ppublish SO - Clin Lymphoma Myeloma Leuk. 2021 Jan;21(1):e10-e20. doi: 10.1016/j.clml.2020.08.001. Epub 2020 Aug 6. PMID- 32759244 OWN - NLM STAT- MEDLINE DCOM- 20210514 LR - 20250625 IS - 2044-6055 (Electronic) IS - 2044-6055 (Linking) VI - 10 IP - 8 DP - 2020 Aug 5 TI - Comparative efficacy of different exercise interventions in chronic non-specific low back pain: protocol of a systematic review and network meta-analysis. PG - e036050 LID - 10.1136/bmjopen-2019-036050 [doi] LID - e036050 AB - INTRODUCTION: Chronic non-specific low back pain is a major public health problem. Evidence supports the effectiveness of exercise as an intervention. Due to a paucity of direct comparisons of different exercise categories, medical guidelines were unable to make specific recommendations regarding the type of exercise working best in improving chronic low back pain. This network meta-analysis (NMA) of randomised controlled trials aims to investigate the comparative efficacy of different exercise interventions in patients with chronic non-specific low back pain. METHODS AND ANALYSIS: MEDLINE, Scopus, Cochrane Central Register of Controlled Trials, Physiotherapy Evidence Database, SPORTDiscus, Clinicaltrials.gov and the WHO International Clinical Trials Registry Platform search portal were searched on November 2019 and without language restrictions. The search will be updated after data analysis. Studies on adults with non-specific low back pain of at least 12 weeks duration comparing exercise to either no specific intervention (ie, no treatment, wait-list or usual care at the treating physician's discretion) and/or functionally inert interventions (ie, sham or attention control interventions) will be eligible. Pain intensity and back-specific disability are defined as primary outcomes. Secondary outcomes will include health-related physical and mental quality of life, work disability, frequency of analgesic use and adverse events. All outcomes will be analysed short-term, intermediate-term and long-term. Data will be extracted independently by two review authors. Risk of bias will be assessed using the recommendations by the Cochrane Back and Neck Group and be based on an adaptation of the Cochrane Risk of Bias tool. ETHICS AND DISSEMINATION: This NMA will be reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses_NMA checklist. The results will be presented in peer-reviewed journals, implemented in existing national and international guidelines and will be presented to health care providers and decision makers. The planned completion date of the study is 1 July 2021. PROSPERO REGISTRATION NUMBER: CRD42020151472. CI - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. FAU - Anheyer, Dennis AU - Anheyer D AD - Department of Internal and Integrative Medicine, Kliniken Essen-Mitte, University of Duisburg-Essen, Faculty of Medicine, Essen, Germany. FAU - Klose, Petra AU - Klose P AD - Department of Internal and Integrative Medicine, Kliniken Essen-Mitte, University of Duisburg-Essen, Faculty of Medicine, Essen, Germany. FAU - Koch, Anna Katharina AU - Koch AK AUID- ORCID: 0000-0002-2565-8744 AD - Department of Internal and Integrative Medicine, Kliniken Essen-Mitte, University of Duisburg-Essen, Faculty of Medicine, Essen, Germany a.koch@kem-med.com. FAU - Haller, Heidemarie AU - Haller H AUID- ORCID: 0000-0001-7973-4071 AD - Department of Internal and Integrative Medicine, Kliniken Essen-Mitte, University of Duisburg-Essen, Faculty of Medicine, Essen, Germany. FAU - Dobos, Gustav AU - Dobos G AD - Department of Internal and Integrative Medicine, Kliniken Essen-Mitte, University of Duisburg-Essen, Faculty of Medicine, Essen, Germany. FAU - Cramer, Holger AU - Cramer H AD - Department of Internal and Integrative Medicine, Kliniken Essen-Mitte, University of Duisburg-Essen, Faculty of Medicine, Essen, Germany. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20200805 PL - England TA - BMJ Open JT - BMJ open JID - 101552874 SB - IM MH - Adult MH - *Chronic Pain/therapy MH - Exercise Therapy MH - Humans MH - *Low Back Pain/therapy MH - Physical Therapy Modalities MH - Quality of Life MH - Systematic Reviews as Topic MH - Network Meta-Analysis as Topic PMC - PMC7409959 OTO - NOTNLM OT - back pain OT - complementary medicine OT - pain management OT - statistics & research methods COIS- Competing interests: None declared. EDAT- 2020/08/08 06:00 MHDA- 2021/05/15 06:00 PMCR- 2020/08/05 CRDT- 2020/08/08 06:00 PHST- 2020/08/08 06:00 [entrez] PHST- 2020/08/08 06:00 [pubmed] PHST- 2021/05/15 06:00 [medline] PHST- 2020/08/05 00:00 [pmc-release] AID - bmjopen-2019-036050 [pii] AID - 10.1136/bmjopen-2019-036050 [doi] PST - epublish SO - BMJ Open. 2020 Aug 5;10(8):e036050. doi: 10.1136/bmjopen-2019-036050. PMID- 32745350 OWN - NLM STAT- MEDLINE DCOM- 20210426 LR - 20220112 IS - 1464-410X (Electronic) IS - 1464-4096 (Print) IS - 1464-4096 (Linking) VI - 127 IP - 2 DP - 2021 Feb TI - Comparison of the performances of the ADXBLADDER test and urinary cytology in the follow-up of non-muscle-invasive bladder cancer: a blinded prospective multicentric study. PG - 198-204 LID - 10.1111/bju.15194 [doi] AB - OBJECTIVE: To compare directly the performance of the ADXBLADDER test with that of cytology in the detection of non-muscle-invasive bladder cancer (NMIBC) recurrences. BACKGROUND: ADXBLADDER is a urine test based on the detection of MCM5, a DNA licensing factor expressed in all cells capable of dividing. Expression is usually restricted to the basal stem cell compartment; however, in malignancy, MCM5-expressing cells can be found throughout the epithelium. Detection of MCM5 in urine sediment can be indicative of the presence of a bladder tumour. PATIENTS AND METHODS: A multicentre prospective, blinded study was carried out from August 2017 and July 2019 at 21 European Union centres, 14 of which collected matching cytology data. Urine was collected from patients prior to cystoscopy. Urine cytology and ADXBLADDER were performed and compared to the diagnosis obtained by cystoscopy. The performance of cytology and ADXBLADDER were then compared. RESULTS: The overall performance of ADXBLADDER demonstrated a sensitivity of 51.9%, a specificity of 66.4%, and a negative predictive value (NPV) of 92%. The sensitivity of ADXBLADDER for low- and high-grade recurrences was 44.1% and 58.8%, respectively. By contrast, cytology sensitivity was 16.7%, specificity was 98% and NPV was 90.7%. Cytology sensitivity for both low- and high-grade disease was 17.6%. CONCLUSIONS: ADXBLADDER detection of both low- and high-grade NMIBC recurrence is superior to that of cytology, with ADXBLADDER able to exclude the presence of high-grade recurrence in 97.8% of cases compared to 97.1% with cytology. These results show that ADXBLADDER has promise as a more reliable alternative to urine cytology in the follow-up of NMIBC. CI - (c) 2020 The Authors BJU International published by John Wiley & Sons Ltd on behalf of BJU International. FAU - Gontero, Paulo AU - Gontero P AD - Department of Urology, Ospedale Molinette, Turin, Italy. FAU - Montanari, Emanuele AU - Montanari E AD - Department of Urology, Universita' Policlinico Milano, Milan, Italy. FAU - Roupret, Morgan AU - Roupret M AD - Urology Department, GRC n degrees 5, ONCOTYPE-URO, AP-HP, Hopital Pitie-Salpetriere, Sorbonne Universite, Paris, F-75013, France. FAU - Longo, Fabrizio AU - Longo F AD - Department of Urology, Universita' Policlinico Milano, Milan, Italy. FAU - Stockley, Jacqueline AU - Stockley J AUID- ORCID: 0000-0001-6601-5107 AD - Arquer Diagnostics, R&D, Sunderland, UK. FAU - Kennedy, Ashleigh AU - Kennedy A AD - Arquer Diagnostics, R&D, Sunderland, UK. FAU - Rodriguez, Oscar AU - Rodriguez O AUID- ORCID: 0000-0001-6668-4423 AD - Department of Urology, Fundacio Puigvert, Barcelona, Spain. FAU - McCracken, Stuart R C AU - McCracken SRC AD - Sunderland Royal Hospital, Sunderland, UK. FAU - Dudderidge, Tim AU - Dudderidge T AD - University Hospital Southampton, Southampton, UK. FAU - Sieverink, Caroline AU - Sieverink C AD - Department of Urology, Radboud University Medical Centre, Nijmegen, The Netherlands. FAU - Vanie, Felicien AU - Vanie F AD - Urology Department, GRC n degrees 5, ONCOTYPE-URO, AP-HP, Hopital Pitie-Salpetriere, Sorbonne Universite, Paris, F-75013, France. FAU - Allasia, Marco AU - Allasia M AD - Department of Urology, Ospedale Molinette, Turin, Italy. FAU - Witjes, J Alfred AU - Witjes JA AD - Department of Urology, Radboud University Medical Centre, Nijmegen, The Netherlands. FAU - Sylvester, Richard AU - Sylvester R AD - EAU Non-muscle-Invasive Guidelines Panel, EAU Guidelines Office, Brussels, Belgium. FAU - Colombel, Marc AU - Colombel M AD - Department of Urology, Hopital Edouard Herriot, Lyon, France. FAU - Palou, Juan AU - Palou J AD - Department of Urology, Fundacio Puigvert, Barcelona, Spain. LA - eng GR - Arquer DIagnostics Ltd/ PT - Comparative Study PT - Journal Article PT - Multicenter Study PT - Research Support, Non-U.S. Gov't DEP - 20200829 PL - England TA - BJU Int JT - BJU international JID - 100886721 RN - 0 (Biomarkers, Tumor) SB - IM CIN - Nat Rev Urol. 2020 Sep;17(9):486. doi: 10.1038/s41585-020-0368-y. PMID: 32782362 MH - Aged MH - Biomarkers, Tumor/urine MH - Cystoscopy/*methods MH - Female MH - Follow-Up Studies MH - Humans MH - Male MH - Prospective Studies MH - Reproducibility of Results MH - Urinalysis/*methods MH - Urinary Bladder Neoplasms/diagnosis/*urine PMC - PMC7891338 OTO - NOTNLM OT - #BladderCancer OT - #blcsm OT - #uroonc OT - #utuc OT - biomarker OT - bladder cancer OT - cytology MCM5 OT - follow-up OT - non-muscle-invasive bladder cancer OT - surveillance COIS- This was a commercially sponsored study by Arquer Diagnostics Ltd. M. Roupret, P. Gontero, S. R. C. McCracken, T. Dudderidge, M. Colombel, F. Longo, E. Montanari and J. Palou are paid consultants to Arquer Diagnostics. J. A. Witjes has received fees for lecture honorarium for Nucleix. None has any shareholding in Arquer Diagnostics or any related company. J. Stockley and A. Kennedy are employees of Arquer Diagnostics holding share options in the company. The funder of the study assisted the authors in study design, data collection, data analysis, data interpretation, writing of the report, and the decision to submit the paper for publication. P. Gontero, M. Roupret, E. Montanari, F. Longo, T. Dudderidge, J. Palou and S. R. C. McCracken, had access to the raw data. The corresponding author had full access to all the data and had the final responsibility to submit for publication. EDAT- 2020/08/04 06:00 MHDA- 2021/04/27 06:00 PMCR- 2021/02/18 CRDT- 2020/08/04 06:00 PHST- 2020/08/04 06:00 [pubmed] PHST- 2021/04/27 06:00 [medline] PHST- 2020/08/04 06:00 [entrez] PHST- 2021/02/18 00:00 [pmc-release] AID - BJU15194 [pii] AID - 10.1111/bju.15194 [doi] PST - ppublish SO - BJU Int. 2021 Feb;127(2):198-204. doi: 10.1111/bju.15194. Epub 2020 Aug 29. PMID- 32741001 OWN - NLM STAT- MEDLINE DCOM- 20211124 LR - 20211124 IS - 1365-3016 (Electronic) IS - 0269-5022 (Linking) VI - 35 IP - 1 DP - 2021 Jan TI - Proposing a new approach to measuring birth size asymmetry. PG - 65-74 LID - 10.1111/ppe.12684 [doi] AB - BACKGROUND: Existing methods of measuring birth size asymmetry based on ratios of growth parameters are clinically useful but simplistic, and as such may have limited usefulness in studies of aetiology. OBJECTIVES: We aimed to develop a novel method of measuring asymmetric fetal growth at birth and demonstrate its utility in characterising the perturbed growth associated with a number of prenatal exposures and neonatal outcomes. METHODS: Data were drawn from the Queensland (QLD) Perinatal Data Collection, which included all livebirths in the Australian state of QLD between July 2010 and December 2015, with analyses restricted to babies born between 32 and 42 weeks of gestation (n = 280 084). Novel measures of asymmetric birthweight, length, and head circumference were developed using a weighted average, representing "how far" an individual's given birth size measure deviated from the sample average and their other birth size measures. Associations among prenatal exposures and neonatal outcomes with the new asymmetry measures and traditional ratio measures (ie ponderal index, brain-to-body weight ratio, and birth length divided by head circumference) were then compared using log-binomial and multinomial regressions. RESULTS: The new asymmetry measures clearly indicated that prenatal smoking was linked to a disproportionate decrease in all birth size measures and that low birthweight asymmetry and low birth head circumference asymmetry were specifically associated with neonatal respiratory distress and chromosomal abnormalities, respectively. When these same associations were tested using the traditional ratios, the estimates were weak, imprecise, and non-specific. CONCLUSIONS: We developed a new approach to measuring fetal growth asymmetry which provides complimentary insights against the existing ratios approach. Associations with the new asymmetry measures were more precise and easier to interpret than the associations obtained using the ratios, and may better reflect the underlying pathological processes, providing an advantage when investigating the aetiologies of perturbed fetal growth. CI - (c) 2020 John Wiley & Sons Ltd. FAU - Betts, Kim S AU - Betts KS AUID- ORCID: 0000-0001-5855-1911 AD - School of Public Health, Curtin University, Perth, WA, Australia. FAU - Kisely, Steve AU - Kisely S AD - School of Medicine, University of Queensland, Brisbane, QLD, Australia. FAU - Alati, Rosa AU - Alati R AD - School of Public Health, Curtin University, Perth, WA, Australia. LA - eng PT - Journal Article DEP - 20200617 PL - England TA - Paediatr Perinat Epidemiol JT - Paediatric and perinatal epidemiology JID - 8709766 SB - IM MH - Australia/epidemiology MH - Birth Weight MH - Cephalometry MH - Female MH - *Fetal Development MH - *Fetal Growth Retardation MH - Gestational Age MH - Humans MH - Infant, Newborn MH - Pregnancy OTO - NOTNLM OT - asymmetry OT - disproportionate growth OT - fetal growth OT - intrauterine growth restriction OT - neonatal outcomes OT - prenatal exposures EDAT- 2020/08/03 06:00 MHDA- 2021/11/25 06:00 CRDT- 2020/08/03 06:00 PHST- 2019/11/18 00:00 [received] PHST- 2020/03/30 00:00 [revised] PHST- 2020/04/05 00:00 [accepted] PHST- 2020/08/03 06:00 [pubmed] PHST- 2021/11/25 06:00 [medline] PHST- 2020/08/03 06:00 [entrez] AID - 10.1111/ppe.12684 [doi] PST - ppublish SO - Paediatr Perinat Epidemiol. 2021 Jan;35(1):65-74. doi: 10.1111/ppe.12684. Epub 2020 Jun 17. PMID- 32648509 OWN - NLM STAT- MEDLINE DCOM- 20211025 LR - 20220531 IS - 1532-5725 (Electronic) IS - 1078-3903 (Linking) VI - 27 IP - 4 DP - 2021 Jul-Aug TI - Advanced Practice Registered Nurses Using Synchronous Telepsychiatry: An Integrative Systematic Review. PG - 271-282 LID - 10.1177/1078390320939159 [doi] AB - BACKGROUND: Despite wide-spread use, telepsychiatry use among psychiatric mental health advanced practice nurse practitioners (PMH APRNs) has not been systematically explored in the literature. AIMS: Systematically review the PMH APRN usage of live-time, synchronous telepsychiatry including audiovisual teleconferencing technology. METHOD: A comprehensive, systematic search was performed with no publication date restriction across CINAHL, the Cochrane Library, Embase, Google Scholar, PsycINFO, PubMed, Scopus, and Web of Science on July 30, 2019, by a medical librarian. Each citation was blinded and independently reviewed by three reviewers, and consensus was reached for inclusion. Eligible articles were peer-reviewed research or quality improvement articles available in full-text, written in English, including real-time, synchronous, audiovisual telepsychiatry services with PMH APRN providers. Discussion articles and literature reviews were excluded. Article quality and bias were assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) assessment tool. RESULTS: The search yielded a total of 342 articles, and only nine articles met full inclusion criteria. Overall, risk of bias was high in all studies, and the GRADE rating consisted of three "very low," five "low," and one "medium" quality article. However, considering the collectively positive outcomes from PMH APRN telepsychiatry use, the overall GRADE recommendation was to "probably do it" for seven studies and "do it" for two studies. CONCLUSIONS: Though existent literature is low quality and sparse, evidence supports that PMH APRNs can feasibly and successfully provide telepsychiatry services across a wide range of demographic patients and locations. PMH APRNs should contribute more original evidence to guide telepsychiatry implementation and adoption as the service expands. FAU - Finley, Brooke A AU - Finley BA AUID- ORCID: 0000-0002-6179-8381 AD - Brooke A. Finley, MSN, PMHNP-BC, RN-BC, The University of Arizona, Tucson, AZ, USA; The Meadows Behavioral Health, Wickenburg, AZ, USA; FasPsych, LLC, Scottsdale, AZ, USA. FAU - Shea, Kimberly D AU - Shea KD AD - Kimberly D. Shea, PhD, RN-BC, CAPN, The University of Arizona, Tucson, AZ, USA. FAU - Maixner, Roberta AU - Maixner R AD - Roberta Maixner, DNP, JD, GCNE, PMHNP-BC, BSN, RN-BC, Psychiatric Nurse Practitioner, California Men's Colony, Department of Corrections and Rehabilitation Colony. Drive San Luis Obispo, CA, USA. FAU - Slebodnik, Maribeth AU - Slebodnik M AD - Maribeth Slebodnik, MSL, RN, The University of Arizona, Tucson, AZ, USA. LA - eng PT - Journal Article PT - Systematic Review DEP - 20200710 PL - United States TA - J Am Psychiatr Nurses Assoc JT - Journal of the American Psychiatric Nurses Association JID - 9507418 SB - IM MH - *Advanced Practice Nursing MH - Humans MH - *Nurses MH - *Psychiatry MH - Quality Improvement MH - *Telemedicine OTO - NOTNLM OT - advanced practice psychiatric mental health nursing OT - e-psychiatry OT - psychiatric mental health nurse practitioner OT - systematic review OT - telemedicine OT - telemental health OT - telenursing OT - telepsychiatry EDAT- 2020/07/11 06:00 MHDA- 2021/10/26 06:00 CRDT- 2020/07/11 06:00 PHST- 2020/07/11 06:00 [pubmed] PHST- 2021/10/26 06:00 [medline] PHST- 2020/07/11 06:00 [entrez] AID - 10.1177/1078390320939159 [doi] PST - ppublish SO - J Am Psychiatr Nurses Assoc. 2021 Jul-Aug;27(4):271-282. doi: 10.1177/1078390320939159. Epub 2020 Jul 10. PMID- 32533612 OWN - NLM STAT- MEDLINE DCOM- 20210722 LR - 20250721 IS - 1360-0443 (Electronic) IS - 0965-2140 (Print) IS - 0965-2140 (Linking) VI - 116 IP - 2 DP - 2021 Feb TI - Prevalence and correlates of receptive syringe-sharing among people who inject drugs in rural Appalachia. PG - 328-336 LID - 10.1111/add.15151 [doi] AB - BACKGROUND AND AIMS: Syringe-sharing significantly increases the risk of HIV and viral hepatitis acquisition among people who inject drugs (PWID). Clearer understanding of the correlates of receptive syringe-sharing (RSS) is a critical step in preventing bloodborne infectious disease transmission among PWID in rural communities throughout the United States. This study aimed to measure the prevalence and correlates of RSS among PWID in a rural county in Appalachia. DESIGN: Observational, cross-sectional sample from a capture-recapture parent study. SETTING: Cabell County, West Virginia (WV), USA, June-July 2018. PARTICIPANTS: The sample was restricted to people who reported injecting drugs in the past 6 months (n = 420). A total of 180 participants (43%) reported recent (past 6 months) RSS. Participants reported high levels of homelessness (56.0%), food insecurity (64.8%) and unemployment (66.0%). MEASUREMENTS: The main outcome was recent re-use of syringes that participants knew someone else had used before them. Key explanatory variables of interest, selected from the risk environment framework, included: unemployment, arrest and receipt of sterile syringes from a syringe services program (SSP). Logistic regression was used to determine correlates of recent RSS. FINDINGS: PWID reporting recent RSS also reported higher prevalence of homelessness, food insecurity and unemployment than their non-RSS-engaging counterparts. In adjusted analyses, correlates of RSS included: engagement in transactional sex work [adjusted odds ratio (aOR) = 2.27, 95% confidence interval (CI) = 1.26-4.09], unemployment (aOR = 1.67, 95% CI = 1.03-1.72), number of drug types injected (aOR = 1.33, 95% CI = 1.15-1.53) and injection in a public location (aOR = 2.59, 95% CI = 1.64-4.08). Having accessed sterile syringes at an SSP was protective against RSS (aOR = 0.57, 95% CI = 0.35-0.92). CONCLUSION: The prevalence of receptive syringe-sharing among people who inject drugs in a rural US county appears to be high and comparable to urban-based populations. Receptive syringe-sharing among people who inject drugs in a rural setting appears to be associated with several structural and substance use factors, including unemployment and engaging in public injection drug use. Having recently acquired sterile syringes at a syringe services program appears to be protective against receptive syringe sharing. CI - (c) 2020 Society for the Study of Addiction. FAU - White, Rebecca Hamilton AU - White RH AUID- ORCID: 0000-0001-7894-4114 AD - Department of Health, Behavior, and Society, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA. FAU - O'Rourke, Allison AU - O'Rourke A AD - Department of Psychology; DC Center for AIDS Research, George Washington University, Washington, DC, USA. FAU - Kilkenny, Michael E AU - Kilkenny ME AD - Cabell-Huntington Health Department, Huntington, WV, USA. FAU - Schneider, Kristin E AU - Schneider KE AD - Department of Mental Health, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA. FAU - Weir, Brian W AU - Weir BW AD - Department of Health, Behavior, and Society, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA. FAU - Grieb, Suzanne M AU - Grieb SM AD - Department of Health, Behavior, and Society, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA. AD - School of Medicine, Johns Hopkins University, Baltimore, MD, USA. FAU - Sherman, Susan G AU - Sherman SG AD - Department of Health, Behavior, and Society, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA. FAU - Allen, Sean T AU - Allen ST AD - Department of Health, Behavior, and Society, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA. LA - eng GR - R01 DA057552/DA/NIDA NIH HHS/United States GR - P30 AI094189/AI/NIAID NIH HHS/United States GR - K01 DA046234/DA/NIDA NIH HHS/United States GR - T32 DA007292/DA/NIDA NIH HHS/United States GR - P30 AI117970/AI/NIAID NIH HHS/United States PT - Journal Article PT - Observational Study PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20200714 PL - England TA - Addiction JT - Addiction (Abingdon, England) JID - 9304118 SB - IM CIN - Addiction. 2021 Feb;116(2):337-338. doi: 10.1111/add.15301. PMID: 33179307 MH - Adult MH - Appalachian Region/epidemiology MH - Cross-Sectional Studies MH - Female MH - Humans MH - Male MH - Needle Sharing/*statistics & numerical data MH - Prevalence MH - Rural Population/*statistics & numerical data MH - Socioeconomic Factors MH - Substance Abuse, Intravenous/*epidemiology MH - Syringes/statistics & numerical data MH - West Virginia/epidemiology PMC - PMC7736103 MID - NIHMS1617227 OTO - NOTNLM OT - HIV OT - Hepatitis C OT - people who inject drugs OT - polysubstance use OT - receptive syringe sharing OT - rural health EDAT- 2020/06/14 06:00 MHDA- 2021/07/23 06:00 PMCR- 2022/02/01 CRDT- 2020/06/14 06:00 PHST- 2020/01/14 00:00 [received] PHST- 2020/03/26 00:00 [revised] PHST- 2020/06/10 00:00 [accepted] PHST- 2020/06/14 06:00 [pubmed] PHST- 2021/07/23 06:00 [medline] PHST- 2020/06/14 06:00 [entrez] PHST- 2022/02/01 00:00 [pmc-release] AID - 10.1111/add.15151 [doi] PST - ppublish SO - Addiction. 2021 Feb;116(2):328-336. doi: 10.1111/add.15151. Epub 2020 Jul 14. PMID- 32205020 OWN - NLM STAT- MEDLINE DCOM- 20210929 LR - 20210929 IS - 1436-2023 (Electronic) IS - 0949-2658 (Linking) VI - 26 IP - 1 DP - 2021 Jan TI - A systematic review and meta-analysis comparing anterior decompression with fusion and posterior laminoplasty for cervical spondylotic myelopathy. PG - 116-122 LID - S0949-2658(20)30059-2 [pii] LID - 10.1016/j.jos.2020.02.008 [doi] AB - BACKGROUND: The optimal surgical procedure for the treatment of cervical spondylotic myelopathy (CSM) remains controversial because there are few comprehensive studies that have investigated the surgical methods. Therefore, we conducted a systematic review and meta-analysis to evaluate evidence in the literature and to compare the surgical outcomes between anterior decompression with fusion (ADF) and laminoplasty, which are representative procedures for CSM. METHODS: An extensive literature search was performed using PubMed, Embase, and the Cochrane Library to identify comparative studies of ADF and laminoplasty for CSM. The language was restricted to English, and the publication period was from January 2001 to July 2019. We only included studies of CSM and excluded studies that involved patients with ossification of the posterior longitudinal ligament and treatments with posterior instrumented fusion. We extracted outcomes from the studies, such as preoperative and postoperative Japanese Orthopaedic Association (JOA) scores, cervical alignment, surgical complications and reoperation rates. Then, a meta-analysis was performed on these surgical outcomes. RESULTS: Nine studies were obtained, and the quality of the studies was acceptable. In the meta-analysis, the preoperative JOA score was similar between the ADF and laminoplasty groups. The postoperative JOA scores and neurological recovery rates were not different between the ADF and laminoplasty groups. ADF exhibited more favorable results than laminoplasty in terms of postoperative cervical alignment. In contrast, overall complications were more frequently observed in the ADF group than in the laminoplasty group, leading to higher rates of reoperation. However, postoperative neck pain was more frequently observed in the laminoplasty group than in the ADF group. CONCLUSIONS: This systematic review and meta-analysis showed both the merits and shortcomings of ADF and laminoplasty. ADF and laminoplasty showed similar results in terms of neurological recovery. Postoperative cervical lordosis was better preserved with ADF than with laminoplasty. However, ADF was associated with a higher incidence of surgical complications than laminoplasty. CI - Copyright (c) 2020 The Japanese Orthopaedic Association. Published by Elsevier B.V. All rights reserved. FAU - Yoshii, Toshitaka AU - Yoshii T AD - Department of Orthopedic Surgery, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyoku, Tokyo, 113-8511, Japan; Guideline Committee of Ossification of the Spinal Ligament, Japanese Orthopaedic Association, Japan. Electronic address: yoshii.orth@tmd.ac.jp. FAU - Egawa, Satoru AU - Egawa S AD - Department of Orthopedic Surgery, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyoku, Tokyo, 113-8511, Japan. FAU - Chikuda, Hirotaka AU - Chikuda H AD - Department of Orthopedic Surgery, Gunma University School of Medicine, 3-39-22, Showa-machi, Maebashi, Gunma, 371-8513, Japan; Guideline Committee of Ossification of the Spinal Ligament, Japanese Orthopaedic Association, Japan. FAU - Wakao, Norimitsu AU - Wakao N AD - Department of Orthopedic Surgery, National Center for Geriatrics and Gerontology, Moriokacho7-430, Obu City, Aichi, 474-8511, Japan; Guideline Committee of Ossification of the Spinal Ligament, Japanese Orthopaedic Association, Japan. FAU - Furuya, Takeo AU - Furuya T AD - Department of Orthopaedic Surgery, Chiba University Graduate School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba City, Chiba, 260-8670, Japan; Guideline Committee of Ossification of the Spinal Ligament, Japanese Orthopaedic Association, Japan. FAU - Kanchiku, Tsukasa AU - Kanchiku T AD - Department of Orthopedic Surgery, Yamaguchi Rosai Hospital, 1315-4, Oaza-Onoda, Onoda City, Yamaguchi, 756-0095, Japan; Guideline Committee of Ossification of the Spinal Ligament, Japanese Orthopaedic Association, Japan. FAU - Nagoshi, Narihito AU - Nagoshi N AD - Department of Orthopaedic Surgery, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan; Guideline Committee of Ossification of the Spinal Ligament, Japanese Orthopaedic Association, Japan. FAU - Fujiwara, Yasushi AU - Fujiwara Y AD - Department of Orthopedic Surgery, Hiroshima City Asa Citizens Hospital, 2-1-1 Kabeminami2-1-1, Asakitaku, Hiroshima City, 731-0293, Japan; Guideline Committee of Ossification of the Spinal Ligament, Japanese Orthopaedic Association, Japan. FAU - Yoshida, Masahiro AU - Yoshida M AD - Department of Surgery, International University of Health and Welfare Ichikawa Hospital, Konodai 6-1-14, Ichikawashi, Chiba, 272-0827, Japan; Guideline Committee of Ossification of the Spinal Ligament, Japanese Orthopaedic Association, Japan. FAU - Taguchi, Toshihiko AU - Taguchi T AD - Department of Orthopedic Surgery, Yamaguchi Rosai Hospital, 1315-4, Oaza-Onoda, Onoda City, Yamaguchi, 756-0095, Japan; Guideline Committee of Ossification of the Spinal Ligament, Japanese Orthopaedic Association, Japan. FAU - Watanabe, Masahiko AU - Watanabe M AD - Department of Orthopaedic Surgery, Tokai University, 143 Shimokasuya, Isehara City, Kanagawa, 259-1193, Japan; Guideline Committee of Ossification of the Spinal Ligament, Japanese Orthopaedic Association, Japan. LA - eng PT - Journal Article PT - Meta-Analysis PT - Systematic Review DEP - 20200320 PL - Japan TA - J Orthop Sci JT - Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association JID - 9604934 SB - IM MH - Cervical Vertebrae/diagnostic imaging/surgery MH - Decompression, Surgical MH - Humans MH - *Laminoplasty MH - *Spinal Cord Diseases/diagnostic imaging/surgery MH - *Spinal Fusion MH - *Spondylosis/diagnostic imaging/surgery MH - Treatment Outcome COIS- Declaration of Competing Interest The authors have nothing to disclose regarding this study. EDAT- 2020/03/25 06:00 MHDA- 2021/09/30 06:00 CRDT- 2020/03/25 06:00 PHST- 2019/09/26 00:00 [received] PHST- 2019/12/23 00:00 [revised] PHST- 2020/02/09 00:00 [accepted] PHST- 2020/03/25 06:00 [pubmed] PHST- 2021/09/30 06:00 [medline] PHST- 2020/03/25 06:00 [entrez] AID - S0949-2658(20)30059-2 [pii] AID - 10.1016/j.jos.2020.02.008 [doi] PST - ppublish SO - J Orthop Sci. 2021 Jan;26(1):116-122. doi: 10.1016/j.jos.2020.02.008. Epub 2020 Mar 20. PMID- 32133490 OWN - NLM STAT- MEDLINE DCOM- 20210429 LR - 20240922 IS - 1537-6591 (Electronic) IS - 1058-4838 (Print) IS - 1058-4838 (Linking) VI - 72 IP - 7 DP - 2021 Apr 8 TI - Predictive Value of 3 Clinical Criteria for Sepsis (Quick Sequential Organ Failure Assessment, Systemic Inflammatory Response Syndrome, and National Early Warning Score) With Respect to Short-term Mortality in Allogeneic Hematopoietic Cell Transplant Recipients With Suspected Infections. PG - 1220-1229 LID - 10.1093/cid/ciaa214 [doi] AB - BACKGROUND: Sepsis disproportionately affects allogeneic hematopoietic cell transplant (HCT) recipients and is challenging to define. Clinical criteria that predict mortality and intensive care unit end-points in patients with suspected infections (SIs) are used in sepsis definitions, but their predictive value among immunocompromised populations is largely unknown. Here, we evaluate 3 criteria among allogeneic HCT recipients with SIs. METHODS: We evaluated Systemic Inflammatory Response Syndrome (SIRS), quick Sequential Organ Failure Assessment (qSOFA), and National Early Warning Score (NEWS) in relation to short-term mortality among recipients transplanted between September 2010 and July 2017. We used cut-points of >/= 2 for qSOFA/SIRS and >/= 7 for NEWS and restricted to first SI per hospital encounter during patients' first 100 days posttransplant. RESULTS: Of the 880 recipients who experienced >/= 1 SI, 58 (6.6%) died within 28 days and 22 (2.5%) within 10 days of an SI. In relation to 10-day mortality, SIRS was the most sensitive (91.3% [95% confidence interval CI, 72.0%-98.9%]) but least specific (35.0% [95% CI, 32.6%-37.5%]), whereas qSOFA was the most specific (90.5% [95% CI, 88.9%-91.9%]) but least sensitive (47.8% [95% CI, 26.8%-69.4%]). NEWS was moderately sensitive (78.3% [95% CI, 56.3%-92.5%]) and specific (70.2% [95% CI, 67.8%-72.4%]). CONCLUSIONS: NEWS outperformed qSOFA and SIRS, but each criterion had low to moderate predictive accuracy, and the magnitude of the known limitations of qSOFA and SIRS was at least as large as in the general population. Our data suggest that population-specific criteria are needed for immunocompromised patients. CI - (c) The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. FAU - Lind, Margaret L AU - Lind ML AD - Department of Epidemiology, University of Washington School of Public Health, Seattle, Washington, USA. AD - Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA. FAU - Phipps, Amanda I AU - Phipps AI AD - Department of Epidemiology, University of Washington School of Public Health, Seattle, Washington, USA. AD - Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA. FAU - Mooney, Stephen AU - Mooney S AD - Department of Epidemiology, University of Washington School of Public Health, Seattle, Washington, USA. AD - Harborview Injury Prevention and Research Center, Seattle, Washington, USA. FAU - Liu, Catherine AU - Liu C AD - Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA. AD - Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA. AD - Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington School of Medicine, Seattle, Washington, USA. FAU - Fohner, Alison AU - Fohner A AD - Department of Epidemiology, University of Washington School of Public Health, Seattle, Washington, USA. FAU - Patel, Kevin AU - Patel K AD - Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, University of Washington School of Medicine, Seattle, Washington, USA. FAU - Ueda, Masumi AU - Ueda M AD - Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA. AD - Division of Medical Oncology, Department of Medicine, University of Washington School of Medicine, Seattle, Washington, USA. FAU - Pergam, Steven A AU - Pergam SA AD - Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA. AD - Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA. AD - Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington School of Medicine, Seattle, Washington, USA. LA - eng GR - P30 CA015704/CA/NCI NIH HHS/United States GR - P30 CA047904/CA/NCI NIH HHS/United States GR - R00 LM012868/LM/NLM NIH HHS/United States GR - TL1 TR002318/TR/NCATS NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PL - United States TA - Clin Infect Dis JT - Clinical infectious diseases : an official publication of the Infectious Diseases Society of America JID - 9203213 SB - IM CIN - Clin Infect Dis. 2021 Apr 8;72(7):1230-1231. doi: 10.1093/cid/ciaa221. PMID: 32133484 MH - *Early Warning Score MH - *Hematopoietic Stem Cell Transplantation/adverse effects MH - Hospital Mortality MH - Humans MH - Organ Dysfunction Scores MH - Prognosis MH - Retrospective Studies MH - *Sepsis/diagnosis MH - Systemic Inflammatory Response Syndrome/diagnosis MH - Transplant Recipients PMC - PMC8028104 OTO - NOTNLM OT - antibiotic stewardship OT - bacteremia OT - hematopoietic cell transplant OT - mortality OT - sepsis EDAT- 2020/03/07 06:00 MHDA- 2021/04/30 06:00 PMCR- 2020/03/04 CRDT- 2020/03/06 06:00 PHST- 2019/09/25 00:00 [received] PHST- 2020/03/02 00:00 [accepted] PHST- 2020/03/07 06:00 [pubmed] PHST- 2021/04/30 06:00 [medline] PHST- 2020/03/06 06:00 [entrez] PHST- 2020/03/04 00:00 [pmc-release] AID - 5781125 [pii] AID - ciaa214 [pii] AID - 10.1093/cid/ciaa214 [doi] PST - ppublish SO - Clin Infect Dis. 2021 Apr 8;72(7):1220-1229. doi: 10.1093/cid/ciaa214. PMID- 31122971 OWN - NLM STAT- MEDLINE DCOM- 20200602 LR - 20250530 IS - 2044-6055 (Electronic) IS - 2044-6055 (Linking) VI - 9 IP - 5 DP - 2019 May 22 TI - Global epidemiology of Neisseria gonorrhoeae in infertile populations: protocol for a systematic review. PG - e025808 LID - 10.1136/bmjopen-2018-025808 [doi] LID - e025808 AB - INTRODUCTION: A key target of the WHO's 'Global Health Sector Strategy on sexually transmitted infections, 2016-2021' is achieving 90% reduction in Neisseria gonorrhoeae (gonorrhoea for short) incidence globally by 2030. Though untreated, gonorrhoea has been linked to infertility, the epidemiology of this infection in infertile populations remains poorly understood and somewhat a neglected area of reproductive health. Our proposed systematic review aims to fill this gap by characterising comprehensively gonorrhoea infection in infertile populations globally. METHODS AND ANALYSIS: All available studies of gonorrhoea infection in infertile populations, including infertility clinic attendees, will be systematically reviewed informed by Cochrane Collaboration guidelines. Findings will be reported following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Data sources will be searched using broad index terms exploded to cover all subheadings and free text terms with no language or year restriction. Any epidemiological measure in infertile populations based on primary data will be eligible for inclusion. Measures based on different assay types will be extracted as separate studies for different analyses. Only one biospecimen type per assay type will be considered based on a predefined priority order. Samples including fewer than 10 participants or assessing infection in the upper genital tract will be excluded. Quality assessments will be conducted for all measures included in the review. Meta-analyses will be implemented using DerSimonian-Laird random effect models to estimate the mean prevalence of gonorrhoea in infertile populations globally, and stratified by WHO region, assay type, sex, infertility type, infertility diagnosis, among other factors. Detailed heterogeneity assessment will be performed, and potential sources of between-study heterogeneity will be explored using meta-regression. Review will be conducted from 26 March 2018 to 28 July 2019. ETHICS AND DISSEMINATION: An institutional review board clearance is not required as all data are publicly available. The findings will be disseminated through a peer-reviewed publication and international scientific meetings/workshops with key stakeholders. PROSPERO REGISTRATION NUMBER: CRD42018102934. CI - (c) Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. FAU - Chemaitelly, Hiam AU - Chemaitelly H AD - Infectious Disease Epidemiology Group, Weill Cornell Medicine-Qatar, Doha, Qatar. FAU - Harfouche, Manale AU - Harfouche M AD - Infectious Disease Epidemiology Group, Weill Cornell Medicine-Qatar, Doha, Qatar. FAU - Blondeel, Karel AU - Blondeel K AD - Department of Reproductive Health and Research, World Health Organization, Geneva, Switzerland. AD - Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium. FAU - Matsaseng, Thabo Christopher AU - Matsaseng TC AD - Department of Reproductive Health and Research, World Health Organization, Geneva, Switzerland. FAU - Kiarie, James AU - Kiarie J AD - Department of Reproductive Health and Research, World Health Organization, Geneva, Switzerland. FAU - Toskin, Igor AU - Toskin I AD - Department of Reproductive Health and Research, World Health Organization, Geneva, Switzerland. FAU - Abu-Raddad, Laith J AU - Abu-Raddad LJ AUID- ORCID: 0000-0003-0790-0506 AD - Infectious Disease Epidemiology Group, Weill Cornell Medicine-Qatar, Doha, Qatar. AD - Department of Healthcare Policy and Research, Weill Cornell Medicine, New York City, New York, USA. AD - College of Health and Life Sciences, Hamadbin Khalifa University, Doha, Qatar. LA - eng GR - 001/WHO_/World Health Organization/International PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20190522 PL - England TA - BMJ Open JT - BMJ open JID - 101552874 SB - IM MH - Global Health MH - Gonorrhea/*epidemiology MH - Humans MH - Incidence MH - Infertility/*epidemiology MH - Neisseria gonorrhoeae/isolation & purification MH - Prevalence MH - Research Design MH - Systematic Reviews as Topic PMC - PMC6538097 OTO - NOTNLM OT - Neisseria gonorrhoeae OT - Gonorrhea OT - epidemiology OT - infertility OT - prevalence OT - sexually transmitted infections COIS- Competing interests: None declared. EDAT- 2019/05/28 06:00 MHDA- 2020/06/03 06:00 PMCR- 2019/05/22 CRDT- 2019/05/25 06:00 PHST- 2019/05/25 06:00 [entrez] PHST- 2019/05/28 06:00 [pubmed] PHST- 2020/06/03 06:00 [medline] PHST- 2019/05/22 00:00 [pmc-release] AID - bmjopen-2018-025808 [pii] AID - 10.1136/bmjopen-2018-025808 [doi] PST - epublish SO - BMJ Open. 2019 May 22;9(5):e025808. doi: 10.1136/bmjopen-2018-025808.